

# APPROVED DRUG PRODUCTS

## WITH

# THERAPEUTIC EQUIVALENCE EVALUATIONS

## 38th EDITION

**THE PRODUCTS IN THIS LIST HAVE BEEN APPROVED UNDER SECTION 505 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT.**

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
OFFICE OF MEDICAL PRODUCTS AND TOBACCO
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF GENERIC DRUGS
OFFICE OF GENERIC DRUG POLICY

**2018**

# APPROVED DRUG PRODUCTS
# with
# THERAPEUTIC EQUIVALENCE EVALUATIONS

**The products in this list have been approved under section 505 of the Federal Food, Drug, and Cosmetic Act. This volume is current through December 31, 2017.**

# 38th EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
FOOD AND DRUG ADMINISTRATION
OFFICE OF MEDICAL PRODUCTS AND TOBACCO
CENTER FOR DRUG EVALUATION AND RESEARCH
OFFICE OF GENERIC DRUGS
OFFICE OF GENERIC DRUG POLICY

**2018**

# FOOD AND DRUG ADMINISTRATION
# CENTER FOR DRUG EVALUATION AND RESEARCH

## APPROVED DRUG PRODUCTS
## With
## Therapeutic Equivalence Evaluations

## CONTENTS

*PAGE*

# FOOD AND DRUG ADMINISTRATION
# CENTER FOR DRUG EVALUATION AND RESEARCH

## APPROVED DRUG PRODUCTS
## With
## Therapeutic Equivalence Evaluations

## PREFACE TO THIRTY EIGHTH EDITION

The publication, *Approved Drug Products With Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book), identifies drug products approved on the basis of safety and effectiveness by the Food and Drug Administration (FDA) under the Federal Food, Drug, and Cosmetic Act (the FD&C Act). The main criterion for the inclusion of any product is that the product is the subject of an application with an approval that has not been withdrawn for safety or efficacy reasons. Inclusion of products in the Orange Book is independent of any current regulatory action through administrative or judicial means against a drug product. In addition, the Orange Book contains therapeutic equivalence evaluations for approved multisource prescription drug products. These evaluations have been prepared to serve as public information and advice to state health agencies, prescribers, and pharmacists to promote public education in the area of drug product selection and to foster containment of health care costs. Therapeutic equivalence evaluations in this publication are not official FDA actions affecting the legal status of products under the FD&C Act.

***Background of the Publication***. To contain drug costs, virtually every state has adopted laws and/or regulations that encourage the substitution of drug products. These state laws generally require either that substitution be limited to drugs on a specific list (the positive formulary approach) or that it be permitted for all drugs except those prohibited by a particular list (the negative formulary approach). Because of the number of requests in the late 1970s for FDA assistance in preparing both positive and negative formularies, it became apparent that FDA could not serve the needs of each state on an individual basis. The Agency also recognized that providing a single list based on common criteria would be preferable to evaluating drug products on the basis of differing definitions and criteria in various state laws. As a result, on May 31, 1978, the Commissioner of the Food and Drug Administration sent a letter to officials of each state announcing FDA's intent to provide a list of all prescription drug products that are approved by FDA for safety and effectiveness, along with therapeutic equivalence determinations for multisource prescription products.

The Orange Book was distributed as a proposal in January l979. It included only currently marketed prescription drug products approved by FDA through new drug applications (NDAs) and abbreviated new drug applications (ANDAs) under the provisions of Section 505 of the FD&C Act.

The therapeutic equivalence evaluations in the Orange Book reflect FDA's application of specific criteria to the multisource prescription drug products listed in the Orange Book and approved under Section 505 of the FD&C Act. These evaluations are presented in the form of code letters that indicate the basis for the evaluation made. An explanation of the codes appears in the *Introduction*.

A complete discussion of the background and basis of FDA's therapeutic equivalence evaluation policy was published in the *Federal Register* on January 12, 1979 (44 FR 2932). The final rule, which includes FDA's responses to the public comments on the proposal, was published in the *Federal Register* on October 31, 1980 (45 FR 72582). The first publication of the Orange Book in October 1980, concurrent with finalization of the rule, incorporated appropriate corrections and additions. Each subsequent edition has included new approvals and made appropriate changes in data.

On September 24, 1984, the President signed into law the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments). The Hatch-Waxman Amendments require that FDA, among other things, make publicly available a list of approved drug products with monthly supplements. The Orange Book and its monthly Cumulative Supplements satisfy this requirement. The *Addendum* to this publication identifies drugs that qualify under the FD&C Act for periods of exclusivity and provides patent information concerning the listed drugs. The *Addendum* also provides additional information that may be helpful to those submitting an NDA or ANDA to the Agency.

The Agency intends to use this publication to further its objective of obtaining input and comment on the publication itself and related Agency procedures. Therefore, if you have comments on how the publication can be improved, please send them to the Director, Division of Legal and Regulatory Support, Office of Generic Drug Policy, Office of Generic Drugs, Center for Drug Evaluation and Research, 7620 Standish Place, Rockville, MD 20855-2773. Comments received are publicly available to the extent allowable under the Freedom of Information Act and FDA regulations.

# 1.0 INTRODUCTION

## 1.1 Content and Exclusion

The Orange Book is composed of four parts: (1) approved prescription drug products with therapeutic equivalence evaluations; (2) approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; (3) drug products with approval under Section 505 of the FD&C Act administered by the Center for Biologics Evaluation and Research; and (4) a cumulative list of approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing.[1] This publication also includes indices of prescription and OTC drug products by trade name (proprietary name) or established name (if no trade name exists) and by applicant name (holder of the approved application), which have been abbreviated for this publication. Established names for active ingredients generally conform to official compendial names or *United States Adopted Names* (USAN) as described in (21 CFR 299.4(e)). A list of uniform terms is provided in Appendix C.

The *Addendum* contains patent and exclusivity information for the Prescription, OTC, Discontinued Drug Product Lists, and for the Drug Products with Approval under Section 505 of the FD&C Act Administered by the Center for Biologics Evaluation and Research. The publication may include additional information that the Agency deems appropriate to disseminate.

Prior to the 6th Edition, the publication had excluded OTC drug products and drug products with approval under Section 505 of the FD&C Act administered by the Center for Biologics Evaluation and Research. The Hatch-Waxman Amendments required the Agency to begin publishing an up-to-date list of all marketed drug products, OTC as well as prescription, that have been approved for safety and efficacy and for which new drug applications are required.

Under the FD&C Act, some drug products are given tentative approvals. The Agency will not include drug products with tentative approvals in the Orange Book because a drug product that is granted tentative approval is not an approved drug product. Tentative approval lists by month are available on FDA's website Drugs@FDA. When the tentative approval becomes a final approval through a subsequent action letter to the applicant, the Agency will list the drug product and the date of approval in the appropriate approved drug product list.

Distributors or repackagers of products listed in the Orange Book are not identified.

## 1.2 Therapeutic Equivalence-Related Terms

[1] Newly approved products are added to parts 1, 2, or 3, of the Orange Book, depending on the dispensing requirements (prescription or OTC) or approval authority, unless the Orange Book staff is otherwise notified before publication.

***Pharmaceutical Equivalents.*** Drug products are considered pharmaceutical equivalents if they contain the same active ingredients, are of the same dosage form and route of administration, and are formulated to contain the same amount of active ingredient and to meet the same or compendial or other applicable standards (i.e., strength, quality, purity, and identity).[2] They may differ in characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, and, within certain limits, labeling.

***Pharmaceutical Alternatives.*** Drug products are considered pharmaceutical alternatives if they contain the same therapeutic moiety, but are different salts, esters, or complexes of that moiety, or are different dosage forms or strengths (e.g., tetracycline hydrochloride, 250mg capsules vs. tetracycline phosphate complex, 250mg capsules; quinidine sulfate, 200mg tablets vs. quinidine sulfate, 200mg capsules).[3] Different dosage forms and strengths within a product line by a single manufacturer are thus pharmaceutical alternatives, as are extended-release products when compared with immediate-release or standard-release formulations of the same active ingredient.

***Therapeutic Equivalents.*** Drug products are considered to be therapeutic equivalents only if they are pharmaceutical equivalents for which bioequivalence has been demonstrated, and they can be expected to have the same clinical effect and safety profile when administered to patients under the conditions specified in the labeling.[4]

FDA classifies as therapeutically equivalent those products that meet the following general criteria: (1) they are approved as safe and effective; (2) they are pharmaceutical equivalents in that they (a) contain identical amounts of the same active drug ingredient in the same dosage form and route of administration, and (b) meet compendial or other applicable standards of strength, quality, purity, and identity; (3) they are bioequivalent in that (a) they do not present a known or potential bioequivalence problem, and they meet an acceptable *in vitro* standard, or (b) if they do present such a known or potential problem, they are shown to meet an appropriate bioequivalence standard; (4) they are adequately labeled; and (5) they are manufactured in compliance with Current Good Manufacturing Practice regulations. *The concept of therapeutic equivalence, as used to develop the Orange Book, applies only to drug products containing the same active ingredient(s) and does not encompass a comparison of different therapeutic agents used for the same condition (e.g., meperidine hydrochloride vs. morphine sulfate for the treatment of pain).* Any drug product in the Orange Book repackaged and/or distributed by other than the applicant is considered to be therapeutically equivalent to the applicant's drug product even if the applicant's drug product is single source or coded as non-equivalent (e.g., **BN**). Distributors or repackagers of an applicant's drug product are not identified in the Orange Book.

FDA considers drug products to be therapeutically equivalent if they meet the criteria outlined above, even though they may differ in certain other characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time and certain aspects of labeling (e.g., the presence of specific pharmacokinetic information), and storage conditions. When such differences are important in the care of a particular patient, it may be appropriate for the prescribing physician to require that a specific product be dispensed as a medical necessity. With this limitation, however, FDA believes that

2 See generally 21 CFR 314.3(b).
3 See generally 21 CFR 314.3(b).
4 See generally 21 CFR 314.3(b).

products classified as therapeutically equivalent can be substituted with the full expectation that the substituted product will produce the same clinical effect and safety profile as the prescribed product.

***Strength***. Strength refers to the amount of drug substance contained in, delivered, or deliverable from a drug product, which includes: (1)(a) the total quantity of drug substance in mass or units of activity in a dosage unit or container closure (*e.g.*, weight/unit dose, weight/volume or weight/weight in a container closure, or units/volume or units/weight in a container closure); and/or, as applicable, (b) the concentration of the drug substance in mass or units of activity per unit volume or mass (*e.g.*, weight/weight, weight/volume, or units/volume); or (2) such other criteria the Agency establishes for determining the amount of drug substance contained in, delivered, or deliverable from a drug product if the weights and measures described in clause (1)(a) do not apply (*e.g.*, certain drug-device combination products for which the amount of drug substance is emitted per use or unit time).[5] Note that if the criteria the Agency establishes for determining and expressing the amount of drug substance in a product evolves over time, the Agency generally does not intend to revise the expressions of strength for drug products already included in the Orange Book, but rather intends to apply the criteria prospectively to drug products added to the Orange Book.

Although the strength of drug products in the Orange Book is generally expressed in terms of the amount of drug substance (active ingredient) in the drug product, it is sometimes expressed in terms of the amount of the active moiety. For example, certain drug products included in the Orange Book include a designation of "EQ" next to their expression of strength. This "EQ" designation generally is used in connection with salt drug products to indicate that the strength of such drug product is being expressed in terms of the equivalent strength of the active moiety (e.g., "EQ 200MG BASE"), rather than in terms of the strength of the active ingredient.

***Bioavailability***. Bioavailability is the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of drug action. For drug products that are not intended to be absorbed into the bloodstream, bioavailability may be assessed by scientifically valid measurements intended to reflect the rate and extent to which the active ingredient or active moiety becomes available at the site of drug action.

***Bioequivalence***. Bioequivalence is the absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study. Section 505 (j)(8)(B) of the FD&C Act describes one set of conditions under which a test and reference listed drug (see Section 1.4) shall be considered bioequivalent:

> the rate and extent of absorption of the [test] drug do not show a significant difference from the rate and extent of absorption of the [reference] drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses; or
>
> the extent of absorption of the [test] drug does not show a significant difference from the extent of absorption of the [reference] drug when administered at the same molar dose of the therapeutic ingredient under

5 See generally 21 CFR 314.3(b).

> similar experimental conditions in either a single dose or multiple doses and the difference from the [reference] drug in the rate of absorption of the drug is intentional, is reflected in its proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug.

Where these above methods are not applicable (e.g., for drug products that are not intended to be absorbed into the bloodstream), other scientifically valid *in vivo* or *in vitro* test methods to demonstrate bioequivalence may be appropriate.

For example, bioequivalence may sometimes be demonstrated using an *in vitro* bioequivalence standard, especially when such an *in vitro* test has been correlated with human *in vivo* bioavailability data. In other situations, bioequivalence may sometimes be demonstrated through comparative clinical trials or pharmacodynamic studies.

### 1.3 Further Guidance on Bioequivalence

FDA's regulations and guidance documents provide additional information regarding bioequivalence and bioavailability, including methodologies and statistical criteria used to establish the bioequivalence of drug products.[6]

### 1.4 Reference Listed Drug and Reference Standard

A reference listed drug (21 CFR 314.3(b)) means the listed drug identified by FDA as the drug product upon which an applicant relies in seeking approval of its ANDA. Generally, a reference listed drug is a drug product approved in a new drug application under Section 505(c) of the FD&C Act based on full reports of investigations of safety and effectiveness. For an ANDA based on an approved suitability petition (a petitioned ANDA), the reference listed drug generally is the listed drug referenced in the approved suitability petition.[7]

A reference standard is the drug product selected by FDA that an applicant seeking approval of an ANDA must use in conducting an *in vivo* bioequivalence study required for approval. FDA generally selects a single reference standard that ANDA applicants must use in *in vivo* bioequivalence testing. Ordinarily, FDA will select the reference listed drug as the reference standard. However, in some instances (e.g., where the reference listed drug has been withdrawn from sale and FDA has determined it was not withdrawn for reasons of safety or effectiveness, and FDA selects an ANDA as the reference standard), the reference listed drug and the reference standard may be different.

---

6 We note that prior editions of the Preface to the Orange Book included a section entitled "Statistical Criteria for Bioequivalence." Please see FDA's regulations and guidance documents for additional information regarding bioequivalence and bioavailability. See FDA Drugs guidance Web page at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm; FDA Drugs guidance (Product-Specific Recommendations for Generic Drug Development) Web page at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm075207.htm; see generally 21 CFR part 320.

7 21 CFR 314.94(a)(3)(i).

FDA identifies reference listed drugs in the Prescription Drug Product, OTC Drug Product, and Discontinued Drug Product Lists. Listed drugs identified as reference listed drugs represent drug products upon which an applicant can rely in seeking approval of an ANDA. FDA intends to update periodically the reference listed drugs identified in the Prescription Drug Product, OTC Drug Product, and Discontinued Drug Product Lists, as appropriate.

FDA also identifies reference standards in the Prescription Drug Product and OTC Drug Product Lists. Listed drugs identified as reference standards represent the FDA's best judgment at this time as to the appropriate comparator for purposes of conducting any *in vivo* bioequivalence studies required for approval.

In some instances when FDA has not designated a listed drug as a reference listed drug, such listed drug may be shielded from generic competition. If FDA has not designated a reference listed drug for a drug product the applicant intends to duplicate, the potential applicant may ask FDA to designate a reference listed drug for that drug product. Potential applicants should consult agency guidance related to referencing approved drug products in ANDA submissions for information on submitting such a request. Section 1.7, *Therapeutic Equivalence Evaluations Codes* (*products meeting necessary bioequivalence requirements*) explains the character coding system (e.g., ***AB, AB1, AB2, AB3***...) for multisource drug products listed under the same heading with two or more reference listed drugs.

A potential applicant should consult Agency guidance related to referencing approved drug products in ANDA submissions for information on submitting a request for selection of a reference standard. FDA may, on its own initiative, select a new reference standard when doing so will help to ensure that applications for generic drugs may be submitted and evaluated, e.g., in the event that the listed drug currently selected as the reference standard has been withdrawn from sale for other than safety and efficacy reasons.

If an applicant has a question related to the appropriate reference standard, it is recommended that an applicant planning to conduct an *in vivo* bioequivalence study submit a controlled correspondence to the Office of Generic Drugs.

### 1.5 General Policies and Legal Status

The Orange Book contains public information and advice. It does not mandate the drug products that are purchased, prescribed, dispensed, or substituted for one another, nor does it, conversely, mandate the products that should be avoided. To the extent that the Orange Book sets forth FDA's evaluations of the therapeutic equivalence of drug products that have been approved, it contains FDA's advice to the public, to practitioners, and to the states regarding drug product selection. These evaluations do not constitute determinations that any product is in violation of the FD&C Act or that any product is preferable to any other. Therapeutic equivalence evaluations are a scientific judgment based upon evidence, while generic substitution may involve social and economic policy administered by the states, intended to reduce the cost of drugs to consumers. To the extent that the Orange Book identifies drug products approved under Section 505 of the FD&C Act, it sets forth information that the Agency is required to publish and that the public is entitled to under the Freedom of Information Act. Exclusion of a drug product from the Orange Book does not necessarily mean that the drug product is in violation of Section 505 of the FD&C Act, that such a product is not safe or effective, or that such a product is not therapeutically equivalent to other drug products. Rather, the exclusion may

be based on the fact that FDA has not evaluated the safety, effectiveness, and quality of the drug product.

### 1.6 Practitioner/User Responsibilities

***Professional care and judgment should be exercised in using the Orange Book.*** Evaluations of therapeutic equivalence for prescription drugs are based on scientific and medical evaluations by FDA. Products evaluated as therapeutically equivalent can be expected, in the judgment of FDA, to have equivalent clinical effect and no difference in their potential for adverse effects when used under the conditions of their labeling. However, these products may differ in other characteristics such as shape, scoring configuration, release mechanisms, packaging, excipients (including colors, flavors, preservatives), expiration date/time, and, in some instances, labeling. If products with such differences are substituted for each other, there is a potential for patient confusion due to differences in color or shape of tablets, inability to provide a given dose using a partial tablet if the proper scoring configuration is not available, or decreased patient acceptance of certain products because of flavor. For example, there may also be allergic reactions in rare cases due to a coloring or a preservative ingredient, as well as differences in cost to the patient.

FDA evaluation of therapeutic equivalence in no way relieves practitioners of their professional responsibilities in prescribing and dispensing such products with due care and with appropriate information to individual patients. In those circumstances where the characteristics of a specific product, other than its active ingredient, are important in the therapy of a particular patient, the physician's prescribing of that product may be appropriate. Pharmacists must also be familiar with the different characteristics of therapeutically equivalent products, e.g., expiration dates/times and labeling directions for storage of the different products (particularly for reconstituted products), so they can properly advise patients when one product is substituted for another.

***Multisource and single-source drug products.*** In the Orange Book, FDA has evaluated for therapeutic equivalence only multisource prescription drug products approved under Section 505 of the FD&C Act, which in most instances means those pharmaceutical equivalents available from more than one manufacturer. For such products, a therapeutic equivalence code is included and product information is highlighted in bold face and underlined. Those products with approved applications that are single-source (i.e., there is only one approved product available for that active ingredient, dosage form, route of administration, and strength) are also included in the Orange Book, but no therapeutic equivalence code is included with such products. Any drug product in the Orange Book repackaged and/or distributed by other than the applicant (e.g., an authorized generic) is considered to be therapeutically equivalent to the applicant’s drug product even if the applicant’s drug product is single source or coded as non-equivalent (e.g., **BN**). The details of these codes and the policies underlying them are discussed in Section 1.7, *Therapeutic Equivalence Evaluations Codes*. Distributors or repackagers of an applicant’s drug product are not identified in the Orange Book.

***Products in the Orange Book are identified by the names of the holders of approved applications (applicants) who may not necessarily be the manufacturer of the product.*** There are numerous entities other than the applicant that may be involved in the development, manufacturing, and/or marketing of a product. The applicant may have had its product manufactured by a contract manufacturer and may simply be distributing the product for which it has obtained approval. In many instances, however, the manufacturer of the product is also the applicant. The name of the manufacturer is

permitted by regulation to appear on the label, even when the manufacturer is not the applicant or marketer.

Although the products in the Orange Book are identified by the names of the applicants, circumstances, such as changing corporate ownership, have sometimes made identification of the applicant difficult. The Agency believes, based on continuing document review and communication with firms, that the applicant designations in the Orange Book are, in most cases, correct.

To relate firm name information on a product label to that in the Orange Book, the following should be noted: the applicant's name always appears in the Orange Book. This applies whether the applicant (firm name on the Form FDA 356h in the application) is the manufacturer or marketer (firm name in largest letters on the label) or not. However, the applicant's name may not always appear on the label of the product.

If the applicant is the marketer, its name appears in the Orange Book and on the label; if the applicant is not the marketer, and the Agency is aware of a corporate relationship (e.g., parent and subsidiary) between the applicant and the marketer, the name of the applicant appears in the Orange Book and both firm names may appear on the label. Firms with known corporate relationships are displayed in Appendix B. If there is no known corporate relationship between the applicant and the marketer, the applicant's name appears in the Orange Book; however, unless the applicant is the manufacturer, packager, or distributor, the applicant's name may not appear on the label. In this case, the practitioner, from labeling alone, will not be able to relate the marketed product to an applicant cited in the Orange Book, and hence to a specific approved drug product. In such cases, to assure that the product in question is the subject of an approved application, the firm named on the label should be contacted.

To relate trade name (proprietary name) information on a product label to that in the Orange Book, the following should be noted: if the applicant is the marketer, the applicant’s name appears in the Orange Book and on the label; if the Agency is aware of a corporate relationship between the applicant and the marketer, the trade name (proprietary name) of the drug product (established name of the active ingredient, if no trade name exists) appears in the Orange Book. If a corporate relationship exists between an applicant and a marketer and both firms are distributing the drug product, the FDA reserves the right to select the trade name of either the marketer or the applicant to appear in the Orange Book. If there is no known corporate relationship between the applicant and the marketer, the established drug name (i.e., non-proprietary name) appears in the Orange Book.

***Every product in the Orange Book is subject at all times to regulatory action.*** From time to time, approved products may be found in violation of one or more provisions of the FD&C Act. In such circumstances, the Agency may commence appropriate enforcement action to correct the violation, if necessary, by securing removal of the product from the market by voluntary recall, seizure, or other enforcement actions. Such regulatory actions are, however, independent of the inclusion of a product in the Orange Book. The main criterion for inclusion of a product is that it has an application that has been approved and that has not been withdrawn for safety or efficacy reasons. FDA believes that retention of a violative product in the Orange Book will not have any significant adverse health consequences, because other legal mechanisms are available to the Agency to prevent the product's actual marketing. FDA may however, change a product's therapeutic equivalence rating if the circumstances giving rise to the violation change or otherwise call into question the Agency's assessment of whether a product meets the criteria for therapeutic equivalence.

## 1.7 Therapeutic Equivalence Evaluations Codes

Generally, drug products that the Agency considers multisource have been assigned a therapeutic equivalence code. The coding system for therapeutic equivalence evaluations is designed to allow users to determine quickly whether the Agency has evaluated a particular approved product (e.g., a particular strength of an approved drug) as therapeutically equivalent to other pharmaceutically equivalent products (first letter) and to provide additional information on the basis of FDA's evaluations (second letter). With some exceptions (e.g., therapeutic equivalence evaluations for certain 505(b)(2) applications), the therapeutic equivalence evaluation date is the same as the approval date.

The two basic categories into which multisource drugs have been placed are indicated by the first letter of the relevant therapeutic equivalence code as follows:

**A Drug products that FDA considers to be <u>therapeutically equivalent</u> to other pharmaceutically equivalent products, i.e., drug products for which**:

(1) there are no known or suspected bioequivalence problems. These are designated **AA**, **AN**, **AO**, **AP**, or **AT**, depending on the dosage form; or

(2) actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bioequivalence. These are designated **AB**.

**B Drug products that FDA at this time, considers <u>not to be therapeutically equivalent</u> to other pharmaceutically equivalent products, i.e.,**

drug products for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence. Often the problem is with specific dosage forms rather than with the active ingredients. These are designated **BC**, **BD**, **BE**, **BN**, **BP**, **BR**, **BS**, **BT**, **BX,** or **B***.

Individual drug products have been evaluated as therapeutically equivalent to the reference product in accordance with the definitions and policies outlined below:

### "A" CODES

**Drug products that are considered to be therapeutically equivalent to other pharmaceutically equivalent products**.

"**A**" products are those for which there are no known or suspected bioequivalence problems or for which actual or potential bioequivalence problems have been resolved with adequate *in vivo* and/or *in vitro* evidence supporting bioequivalence. Drug products designated with an "**A**" code fall under one of two main policies:

(1) for those active ingredients or dosage forms for which no *in vivo* bioequivalence issue is known or suspected, the information necessary to show bioequivalence between pharmaceutically equivalent products is either presumed and considered self-evident (based on other information in the application for some dosage forms (e.g., solutions)) or satisfied by a showing that an acceptable *in vitro* dissolution standard is met. A

therapeutically equivalent rating is assigned such products so long as they are manufactured in accordance with Current Good Manufacturing Practice regulations and meet the other requirements of their approved applications (these are designated **AA**, **AN**, **AO**, **AP**, or **AT**, depending on the dosage form, as described below); or

(2) for those Drug Efficacy Study Implementation (DESI) drug products containing active ingredients or dosage forms that have been identified by FDA as having actual or potential bioequivalence problems, and for post-1962 drug products in a dosage form presenting a potential bioequivalence problem, an evaluation of therapeutic equivalence is assigned to pharmaceutical equivalents only if the approved application contains adequate scientific evidence establishing through *in vivo* and/or *in vitro* studies the bioequivalence of the product to a selected reference product (these products are designated as **AB**).

There are some general principles that may affect the substitution of pharmaceutically equivalent products in specific cases. Prescribers and dispensers of drugs should be alert to these principles so as to deal appropriately with situations that require professional judgment and discretion.

There may be labeling differences among pharmaceutically equivalent products that require attention on the part of the health professional (e.g., pharmaceutically equivalent powders to be reconstituted for administration as oral or injectable liquids may vary with respect to their expiration time or storage conditions after reconstitution). FDA’s determination that such products are therapeutically equivalent is applicable only when each product is reconstituted, stored, and used under the conditions specified in its labeling.

The Agency may use notes in this publication to point out special situations, such as potential differences between two drug products that have been evaluated as bioequivalent and otherwise therapeutically equivalent, when they should be brought to the attention of health professionals. These notes are contained in Section 1.8, *Description of Certain Special Situations*.

For example, in certain instances, there may be variations among therapeutically equivalent products in their use or in conditions of administration. Such differences may be due to patent or exclusivity rights associated with such use. When such variations may, in the Agency's opinion, affect prescribing or substitution decisions by health professionals, a note may be added to Section 1.8.

Also, occasionally a situation may arise in which changes in a listed drug product after its approval (for example, a change in dosing interval) may have an impact on the substitutability of already approved generic versions of that product that were rated by the Agency as therapeutically equivalent to the listed product. When such changes in the listed drug product are considered by the Agency to have a significant impact on therapeutic equivalence, the Agency will change the therapeutic equivalence ratings for other versions of the drug product unless the manufacturers of those other versions of the product provide additional information to assure equivalence under the changed conditions. Pending receipt of the additional data, the Agency may add a note to Section 1.8, or, in rare cases, may even change the therapeutic equivalence rating.

In some cases (e.g., Isolyte® S w/ Dextrose 5% in Plastic Container and Plasma-Lyte® 148 and Dextrose 5% in Plastic Container), closely related products are listed as containing the same active ingredients, but in

somewhat different amounts. In determining which of these products are pharmaceutically equivalent, generally the Agency has considered products to be pharmaceutically equivalent with labeled strengths of an ingredient that do not vary by more than 1%.

Different salts, esters or other noncovalent derivatives (such as a complex, chelate, or clathrate) of the same active moiety are regarded as different active ingredients. For the purpose of this publication, products containing such different active ingredients are considered pharmaceutical alternatives and, thus, not therapeutically equivalent. Anhydrous and hydrated entities, as well as different polymorphs, are considered to be the same active ingredient and are expected to meet the same standards for identity to be considered pharmaceutical equivalents and therapeutic equivalents.

The codes in this book are not intended to preclude health care professionals from converting pharmaceutically different concentrations into pharmaceutical equivalents using accepted professional practice.

Where package size variations have therapeutic implications, products so packaged have not been considered pharmaceutically equivalent. For example, some oral contraceptives are supplied in 21-tablet and 28-tablet packets; the 28-tablet packets contain 7 placebo or iron tablets. These two packaging configurations are not regarded as pharmaceutically equivalent; thus, they are not designated as therapeutically equivalent.

Preservatives and other inactive ingredients may differ among some therapeutically equivalent drug products. These differences do not affect FDA's evaluation of therapeutic equivalence except in cases where these components may influence bioequivalence or routes of administration.

The specific sub-codes for those drugs evaluated as therapeutically equivalent and the policies underlying these sub-codes follow:

**AA Products in conventional dosage forms not presenting bioequivalence problems**

Multisource drug products coded as **AA** contain active ingredients and are in dosage forms that are not regarded as presenting either actual or potential bioequivalence problems or drug quality or standards issues. However, all oral dosage forms must, nonetheless, meet an appropriate *in vitro* bioequivalence standard that is acceptable to the Agency in order to be approved.

**AB, AB1, AB2, AB3... Products meeting necessary bioequivalence requirements**

Multisource drug products listed under the same heading (i.e., identical active ingredients(s), dosage form, and route(s) of administration) and having the same strength (see Section 1.2, *Therapeutic Equivalence-Related Terms, Strength)* generally will be coded **AB** if data and information are submitted demonstrating bioequivalence.

In certain instances, a number is added to the end of the **AB** code to make a three character code (i.e., **AB1, AB2, AB3, etc.**). Three-character codes generally are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference listed drug products that are not identified as bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code

as the reference listed drug it was compared against. For example, Adalat® CC and Procardia XL®, extended-release tablets, are listed under the active ingredient nifedipine. These drug products, listed under the same heading, are not bioequivalent to each other. Adalat® CC and Procardia XL® have been assigned ratings of **AB1** and **AB2**, respectively. Generic drug products deemed by FDA to be bioequivalent to Adalat® CC and Procardia XL® have been approved. As a result, the generic drug products bioequivalent to Adalat® CC have been assigned a rating of **AB1** and those bioequivalent to Procardia XL® have been assigned a rating of **AB2**. (The assignment of an **AB1** or **AB2** rating to a specific product does not imply product preference.) Even though drug products of distributors and/or repackagers are not included in the Orange Book, they are considered therapeutically equivalent to the applicant's drug product if the applicant's drug product is rated either with an **AB** or three-character code or is single source in the Orange Book. Drugs coded as **AB** under a heading are considered therapeutically equivalent only to other drugs coded as **AB** under that heading. Drugs coded with a three-character code under a heading are considered therapeutically equivalent only to other drugs coded with the same three-character code under that heading.

### AN Solutions and powders for aerosolization

Uncertainty regarding the therapeutic equivalence of aerosolized products arises primarily because of differences in the drug delivery system. Solutions and powders intended for aerosolization that are marketed for use in general-use delivery systems are considered to be pharmaceutically and therapeutically equivalent and are coded **AN**. Those products that are compatible only with a specific delivery system or those products that are packaged in and with a specific delivery system are coded **BN**, unless they have met an appropriate bioequivalence standard and are otherwise determined to be therapeutically equivalent. Solutions or suspensions in a specific delivery system will be coded **AN** if the bioequivalence standard is based upon *in vitro* methodology, if bioequivalence needs to be demonstrated by *in vivo* methodology then the drug products will be coded **AB**.

### AO Injectable oil solutions

The absorption of drugs in injectable (parenteral) oil solutions may vary substantially with the type of oil employed as a vehicle and the concentration of the active ingredient. Injectable oil solutions are therefore considered to be pharmaceutically and therapeutically equivalent only when the active ingredient, its concentration, and the type of oil used as a vehicle are all identical.

### AP Injectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions

It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, historically some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug

products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.

Certain commonly used large volume intravenous products in glass containers are not included in the Orange Book (e.g., dextrose injection 5%, dextrose injection 10%, sodium chloride injection 0.9%) since these products are on the market without FDA approval and the FDA has not published conditions for marketing such parenteral products under approved NDAs. When packaged in plastic containers, however, FDA regulations require approved applications prior to marketing. Approval then depends on, among other things, the extent of the available safety data involving the specific plastic component of the product. All large volume parenteral products are manufactured under similar standards, regardless of whether they are packaged in glass or plastic. Thus, FDA has no reason to believe that the packaging container of large volume parenteral drug products that are pharmaceutically equivalent would have any effect on their therapeutic equivalence.

Consistent with the definition of strength included in Section 1.2, *Therapeutic Equivalence-Related Terms,* the strength of parenteral drug products generally is identified by both the total drug content and the concentration of drug substance in a container approved by FDA.[8] In the past, the strength of liquid parenteral drug products in the Orange Book has not been fully displayed. Rather, the strength of liquid parenteral drug products in the Orange Book has been displayed in terms of concentration, expressed as xmg/mL. Generally, the amount of dry powder or lyophilized powder in a container is identified as the strength, expressed as xmg/vial.

After the enactment of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA), which amended the FD&C Act, it became evident that the format of the Orange Book with respect to parenteral solutions should be changed to reflect that each strength of a drug is considered to be a separate listed drug. The Orange Book now displays the strength of all new approvals of parenteral solutions. Previously, we would have displayed only the concentration of an approved parenteral solution, e.g. 50mg/mL. If this application had a 20 mL and 60 mL container approved, we would now display two product strengths, listing both total drug content and concentration of drug substance in the relevant approved container, e.g. 1gm/20mL (50mg/mL) and 3gm/60mL (50mg/mL).

### AT Topical products

There are a variety of topical dosage forms available for dermatologic, ophthalmic, otic, rectal, and vaginal administration, including creams, gels, lotions, oils, ointments, pastes, solutions, sprays and suppositories. Even though different topical dosage forms may contain the same active ingredient and potency, these dosage forms are not considered pharmaceutically equivalent. Therefore, they are not considered therapeutically equivalent. All solutions and DESI drug products

8 The strengths of certain parenteral drug products, including contrast agents, may be expressed as a percentage.

containing the same active ingredient in the same topical dosage form for which a waiver of *in vivo* bioequivalence has been granted and for which chemistry and manufacturing processes are adequate to demonstrate bioequivalence, are considered therapeutically equivalent and coded **AT**. Pharmaceutically equivalent topical products that raise questions of bioequivalence, including all post-1962 non-solution topical drug products, are coded **AB** when supported by adequate bioequivalence data, and **BT** in the absence of such data.

## "B" CODES

**Drug products that FDA, at this time, considers <u>not to be therapeutically equivalent</u> to other pharmaceutically equivalent products**.

"**B**" products, for which actual or potential bioequivalence problems have not been resolved by adequate evidence of bioequivalence, often have a problem with specific dosage forms rather than with the active ingredients. Drug products designated with a "**B**" code fall under one of three main policies:

(1) the drug products contain active ingredients or are manufactured in dosage forms that have been identified by the Agency as having documented bioequivalence problems or a significant potential for such problems and for which no adequate studies demonstrating bioequivalence have been submitted to FDA; or

(2) the quality standards are inadequate or FDA has an insufficient basis to determine therapeutic equivalence; or

(3) the drug products are under regulatory review.

The specific coding definitions and policies for the "**B**" sub-codes are as follows:

### B* Drug products requiring further FDA investigation and review to determine therapeutic equivalence

The code **B*** is assigned to products previously assigned an **A** or **B** code when FDA receives new information that raises a significant question regarding therapeutic equivalence that can be resolved only through further Agency investigation and/or review of data and information submitted by the applicant. The **B*** code signifies that the Agency will take no position regarding the therapeutic equivalence of the product until the Agency completes its investigation and review.

### BC Extended-release dosage forms (capsules, injectables and tablets)

Extended-release tablets are formulated in such a manner as to make the contained drug substance available over an extended period of time following ingestion.

Although bioavailability studies have been conducted on these dosage forms, they may be subject to bioavailability differences, primarily because applicants developing extended-release products for the same active ingredient rarely employ the same formulation approach. FDA, therefore, does not consider different extended-release dosage forms containing the same active ingredient in equal strength to be therapeutically equivalent unless equivalence between individual products

in both rate and extent has been specifically demonstrated through appropriate bioequivalence studies. Extended-release products for which such bioequivalence data have not been submitted are coded **BC**, while those for which such data are available have been coded **AB**.

### BD Active ingredients and dosage forms with documented bioequivalence problems

The **BD** code denotes products containing active ingredients with known bioequivalence problems and for which adequate studies have not been submitted to FDA demonstrating bioequivalence. Where studies showing bioequivalence have been submitted, the product has been coded **AB**.

### BE Delayed-release oral dosage forms

Where the drug may be destroyed or inactivated by the gastric juice or where it may irritate the gastric mucosa, the use of “enteric” coatings is indicated. Such coatings are intended to delay the release of the medication until the tablet has passed through the stomach. Drug products in delayed-release dosage forms containing the same active ingredients are subject to significant differences in absorption. Unless otherwise specifically noted, the Agency considers different delayed-release products containing the same active ingredients as presenting a potential bioequivalence problem and codes these products **BE** in the absence of *in vivo* studies showing bioequivalence. If adequate *in vivo* studies have demonstrated the bioequivalence of specific delayed-release products, such products are coded **AB**.

### BN Products in aerosol-nebulizer drug delivery systems

This code applies to drug solutions or powders that are marketed only as a component of, or as compatible with, a specific drug delivery system. There may, for example, be significant differences in the dose of drug and particle size delivered by different products of this type. Therefore, the Agency does not consider different metered aerosol dosage forms containing the same active ingredient(s) in equal strengths to be therapeutically equivalent unless the drug products meet an appropriate bioequivalence standard; such products are coded **AB**.

### BP Active ingredients and dosage forms with potential bioequivalence problems

FDA's bioequivalence regulations (21 CFR 320.33) contain criteria and procedures for determining whether a specific active ingredient in a specific dosage form has a potential for causing a bioequivalence problem. It is FDA's policy to consider an ingredient meeting these criteria as having a potential bioequivalence problem even in the absence of positive data demonstrating inequivalence. Pharmaceutically equivalent products containing these ingredients in oral dosage forms are coded **BP** until adequate bioequivalence data are submitted, after which such products are coded **AB**. Injectable suspensions containing an active ingredient suspended in an aqueous or oleaginous vehicle have also been coded **BP**. Injectable suspensions are subject to bioequivalence problems because differences in particle size, polymorphic structure of the suspended active ingredient, or the suspension formulation can significantly affect the rate of release and absorption. FDA does not consider pharmaceutical equivalents of these products bioequivalent without adequate evidence of bioequivalence; such products would be coded **AB**.

### BR Suppositories or enemas that deliver drugs for systemic absorption

The absorption of active ingredients from suppositories or enemas that are intended to have a systemic effect (as distinct from suppositories administered for local effect) can vary significantly from product to product. Therefore, FDA considers pharmaceutically equivalent systemic suppositories or enemas bioequivalent only if *in vivo* evidence of bioequivalence is available. In those cases where *in vivo* evidence is available, the products are coded **AB**. If such evidence is not available, the products are coded **BR**.

### BS Products having drug standard deficiencies

If the drug standards for an active ingredient in a particular dosage form are found by FDA to be deficient so as to prevent an FDA evaluation of either pharmaceutical or therapeutic equivalence, all drug products containing that active ingredient in that dosage form are coded **BS**. For example, if the standards permit a wide variation in pharmacologically active components of the active ingredient such that pharmaceutical equivalence is in question, all products containing that active ingredient in that dosage form are coded **BS**.

### BT Topical products with bioequivalence issues

This code applies mainly to post-1962 dermatologic, ophthalmic, otic, rectal, and vaginal products for topical administration, including creams, ointments, gels, lotions, pastes, and sprays, as well as suppositories not intended for systemic drug absorption. Topical products evaluated as having acceptable clinical performance, but that are not bioequivalent to other pharmaceutically equivalent products or that lack sufficient evidence of bioequivalence, will be coded **BT**.

### BX Drug products for which the data are insufficient to determine therapeutic equivalence

The code **BX** is assigned to specific drug products for which the data that have been reviewed by the Agency are insufficient to determine therapeutic equivalence under the policies stated in this document. In these situations, the drug products are presumed to be therapeutically inequivalent until the Agency has determined that there is adequate information to make a full evaluation of therapeutic equivalence.

## 1.8 Description of Certain Special Situations

Certain drugs listed in the Orange Book present special situations that merit further discussion. The following are descriptions of certain examples of those special situations:

***Amino Acid and Protein Hydrolysate Injections***. These products differ in the amount and kinds of amino acids they contain and, therefore, are not considered pharmaceutical equivalents. For this reason, these products are not considered therapeutically equivalent. At the same time, the Agency believes that it is appropriate to point out that where nitrogen balance is the sole therapeutic objective and individual amino acid content is not a consideration, pharmaceutical alternatives with the same total amount of nitrogen content may be considered therapeutically equivalent.

***Gaviscon*®.** Gaviscon® is an OTC product that has been marketed since September 1970. The active ingredients in this product, aluminum hydroxide and magnesium trisilicate, were reviewed by the Agency's OTC Antacid Panel and were considered to be safe and effective ingredients (Category I) by that Panel. However, the tablet failed to pass the antacid test that is required of all antacid products. The Agency, therefore, placed the tablet in Category III for lack of effectiveness. A full NDA with clinical studies was submitted by Marion Laboratories, Inc., and approved by FDA on December 9, 1983. Gaviscon®'s activity in treating reflux acidity is made possible by the physical-chemical properties of the inactive ingredients, sodium bicarbonate and alginic acid. Therefore, *all ANDAs that cite Gaviscon® tablets as the reference listed drug must contain the inactive ingredients sodium bicarbonate and alginic acid.* A full NDA will be required to support the effectiveness of the drug product if different inactive ingredients are to be substituted for sodium bicarbonate or alginic acid or if different proportions of these ingredients are to be used.

***Levothyroxine Sodium*.** Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium tablet drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (CEDIPROF NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (CEDIPROF NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (CEDIPROF NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Thyro-Tabs (Lloyd NDA 021116) tablets.[9]

The chart outlines TE codes for all 0.025 mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One

9 Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) is currently listed in the Discontinued Drug Product List section of the Orange Book and Mylan's levothyroxine product (ANDA 076187) has been selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

common TE code indicates therapeutic equivalence between products.

| Trade Name | Applicant | Strength | TE Code | Appl No | Product No |
|---|---|---|---|---|---|
| UNITHROID | STEVENS J | 0.025MG | AB1 | 021210 | 001 |
| LEVOTHYROXINE SODIUM | MYLAN | 0.025MG | AB1 | 076187 | 001 |
| LEVOXYL | KING PHARMS | 0.025MG | AB1 | 021301 | 001 |
| SYNTHROID | ABBVIE | 0.025MG | AB1 | 021402 | 001 |
| LEVO-T | CEDIPROF INC | 0.025MG | AB1 | 021342 | 001 |
| | | | | | |
| SYNTHROID | ABBVIE | 0.025MG | AB2 | 021402 | 001 |
| LEVOTHYROXINE SODIUM | MYLAN | 0.025MG | AB2 | 076187 | 001 |
| LEVO-T | CEDIPROF INC | 0.025MG | AB2 | 021342 | 001 |
| UNITHROID | STEVENS J | 0.025MG | AB2 | 021210 | 001 |
| | | | | | |
| LEVOXYL | KING PHARMS | 0.025MG | AB3 | 021301 | 001 |
| LEVO-T | CEDIPROF INC | 0.025MG | AB3 | 021342 | 001 |
| UNITHROID | STEVENS J | 0.025MG | AB3 | 021210 | 001 |
| LEVOTHYROXINE SODIUM | MYLAN | 0.025MG | AB3 | 076187 | 001 |
| | | | | | |
| THYRO-TABS | LLOYD | 0.025MG | N/A[10] | 021116 | 001 |
| LEVOTHYROXINE SODIUM | MYLAN | 0.025MG | AB4 | 076187 | 001 |

***Patent Certification(s) and Reference Standard for ANDAs Duplicating a Drug Product Approved in a Petitioned ANDA.*** To submit an ANDA for a generic drug that is not the same as its reference listed drug because it has one different active ingredient (in a fixed combination drug product), or has a different route of administration, dosage form, or strength than that of the reference listed drug, an applicant first must obtain permission from FDA through what is known as a suitability petition pursuant to section 505(j)(2)(C) of the FD&C Act. A petitioned ANDA relies on the reference listed drug described in the suitability petition. An ANDA for a drug that is the same as a drug product approved in a petitioned ANDA should utilize the drug product approved in the petitioned ANDA as a reference standard. However, the reference listed drug for any such ANDA is generally the listed drug referenced in the approved suitability petition. The ANDA must include appropriate patent certification(s) and an exclusivity statement with respect to the reference listed drug that served as the basis for the approved suitability petition.[11] (This concept also generally applies to an ANDA applicant that utilizes a reference standard that is not a reference listed drug, as such an application must include appropriate patent certification(s) and an exclusivity statement with respect to the reference listed drug.)

***Waived exclusivity.*** If an NDA submitted under Section 505(b) of the FD&C

10 Thyro-Tabs is in the Discontinued Drug Product List and therefore no longer is assigned a TE code.

11 If after approval of a suitability petition and before approval of an ANDA submitted pursuant to the approved petition, a drug product is approved in an NDA for the change described in the petition, the suitability petition and the listed drug identified in the petition can no longer be the basis of submission for such ANDA. Under these circumstances, an applicant seeking approval for a drug product with the change approved in the suitability petition must submit a new ANDA that identifies the drug product approved under such NDA as the RLD and comply with applicable regulatory requirements. See 21 CFR 314.93(f)(2).

Act qualifies for exclusivity under the FD&C Act, the exclusivity is generally listed in the Patent and Exclusivity Section of the Orange Book. If a drug product has received this exclusivity, the FDA will not accept for review and/or will not approve a 505(b)(2) application or an ANDA under Section 505(j) of the FD&C Act, as applicable, in accordance with the relevant exclusivity. If the listed drug is also protected by one or more patents, the approval date for the ANDA or 505(b)(2) application will be determined based on an analysis of the applicant's patent certification(s) or statement(s) for each relevant patent and the effect of relevant exclusivity listed in the Orange Book. However, the holder of the NDA may waive its exclusivity as to any or all ANDAs and 505(b)(2) applications that might otherwise be blocked by such exclusivity. If an NDA sponsor waives its right to the exclusivity protection, qualified ANDAs or 505(b)(2) applications may be accepted for review and/or approved, as applicable, pursuant to the NDA holder's exclusivity being waived. An NDA for which the holder has waived its exclusivity as to all ANDAs and 505(b)(2) applications will be coded with a "W" in the Patent and Exclusivity Section of the Orange Book. The applicant whose product might otherwise be blocked by this exclusivity should indicate in the exclusivity statement in its application that the holder of the listed drug has waived its exclusivity.

### 1.9 Therapeutic Equivalence Code Change for a Category of Multisource Drug Products

The Agency will use the following procedures when, in response to a petition or on its own initiative, it is considering a change in the therapeutic equivalence code for approved multisource drug products. Such changes will generally occur when the Agency becomes aware of new scientific information affecting the therapeutic equivalence of an entire category of multisource drug products in the Orange Book (e.g., information concerning the active ingredient or the dosage form), rather than information concerning a single drug product within the category. These procedures will be used when a change in therapeutic equivalence code is under consideration for all drug products found in the Prescription Drug Product List under a specific drug entity and dosage form. The change may be from the code signifying that the drug does not present a bioequivalence problem (e.g., **AA**) to a code signifying an actual or potential bioequivalence problem (e.g., **BP**), or vice versa. This procedure does not apply to a change of a particular product code (e.g., a change from **BP** to **AB** or from **AB** to **BX**).

Before making a change in a therapeutic equivalence code for an entire category of multisource drug products as described above, the Agency will announce in the *Introduction* to the Cumulative Supplement that it is considering the change and will invite comments. Comments, along with scientific data, may be sent to the Director, Office of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, HFD-650, 7620 Standish Place, Rockville, MD 20855.

The comment period will generally be 60 days in length, and the closing date for comments will be listed in the description of the proposed change for each drug entity.

The most useful type of scientific data submitted to support comments is an *in vivo* bioavailability/bioequivalence study conducted on batches of the subject drug products. Comments including scientific data from an *in vivo* bioavailability/bioequivalence study should present a full description of the analytical procedures and equipment used, a validation of the analytical methodology, including the standard curve, a description of the method of calculating results, and a description of the pharmacokinetic and statistical models used in analyzing the data. Anecdotal or testimonial information is the least useful to the Agency, and submission of comments based on such

information is discouraged. However, when there is supporting published or unpublished scientific literature, copies should be submitted with comments.

### 1.10 Change of the Therapeutic Equivalence Evaluation for a Single Product

The procedure described in Section 1.9 does not apply to a change in a single drug product code. For example, a change in a single drug product's code from **BP** to **AB** as a result of the submission of an acceptable bioequivalence study ordinarily will not be the subject of notice and comment in the Cumulative Supplement. Likewise, a change in a single drug product's code from **AB** to **BX** (e.g., as a result of new information raising a significant question as to bioequivalence) does not require notice and comment. The Agency's responsibility to provide the public with the Agency's most current information related to therapeutic equivalence may require a change in a drug product's code prior to any formal notice and opportunity for the applicant to be heard. The publication in the *Federal Register* of a proposal to withdraw approval of a drug product will ordinarily result in a change in a product's code from **AB** to **BX** if this action has not already been taken.

We recognize that certain drug products approved in 505(b)(2) applications may not have therapeutic equivalence codes, and that FDA may undertake therapeutic equivalence evaluations with respect to such drug products. A person seeking to have a therapeutic equivalence rating for a drug product approved in a 505(b)(2) application may petition the Agency through the citizen petition procedure (see 21 CFR 10.25(a) and 21 CFR 10.30).

### 1.11 Discontinued Section

Those drug products in the discontinued section of the Orange Book (Discontinued Drug Product List) for which a determination has been made that the products were not withdrawn for safety or effectiveness reasons have been annotated with a footnote following the product strength: "**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**". The determinations listed in Orange Book are only reflective of determinations made since 1995 and published in the Federal Register. The identification of these drug products in the Discontinued Drug Product List should avoid the submission of multiple citizen petitions requesting a determination for the same drug product.

Generally, approved products are added to the Discontinued Drug Product List when the applicant notifies the Orange Book staff of the products' not-marketed status. Products may also be added to the Discontinued Drug Product List if annual reports or other submissions to the Agency indicate the product is not being marketed or as a result of other Agency administrative actions.[12] Changes to the Orange Book are not affected by the drug registration and listing requirements of Section 510 of the FD&C Act.

### 1.12 Changes to the Orange Book

Every effort is made to ensure the Annual Edition is current and accurate. Applicants are requested to inform the FDA Orange Book Staff of any changes or corrections, including any change in a product's marketing status that would result in the product being moved to the Discontinued Drug

12 See, e.g., Section 506I(d) of the FD&C Act.

Product List. FDA notes that under Section 506I(a) of the FD&C Act, applicants must notify the Agency in writing 180 days prior to withdrawing a drug product from sale, or if 180 days is not practicable, not later than the date of withdrawal from sale. Furthermore, Section 506I(b) of the FD&C Act requires that applicants notify the Agency in writing within 180 days of approval of a drug product if such drug product will not be available for sale within 180 days of approval. A request to include a newly approved product in the Discontinued Drug Product List, rather than parts 1, 2 or 3 of the Orange Book (as discussed in Section 1.1), must be submitted to the Orange Book staff by the end of the month in which the product is approved to ensure that the product is not included in the "active" portions of the next published Orange Book update.

In addition, FDA Orange Book Staff generally will act on requests to change a proprietary name for a listed drug only after approval of a supplement for the relevant change in proprietary name. To the extent that conventions for describing product identification information (i.e., active ingredients, dosage forms, routes of administration, product names, applicants, strengths) evolve over time, the Agency generally does not intend to revise such information for drug products already included in the Orange Book, but rather intends to apply the change prospectively to drug products added to the Orange Book.

You can contact the Orange Book Staff by email at orangebook@fda.hhs.gov. If you do not have access to email, you can contact the Orange Book Staff by mail at:

FDA/CDER Orange Book Staff
Office of Generic Drug Policy
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

### 1.13 Availability of the Edition

Commencing with the 25th edition, the Annual Edition and current monthly Cumulative Supplement are available in a Portable Document Format (PDF) at the Orange Book home page by clicking on Publications. The PDF annual format duplicates previous paper versions except for the Orphan Products Designations and Approvals List. An annual subscription of the PDF format may be obtained from the U.S. Government Publishing Office, 866-512-1800.

# 2. HOW TO USE THE DRUG PRODUCT LISTS

## 2.1 Key Sections for Using the Drug Product Lists

This publication contains illustrations, along with Drug Product Lists, indices, and lists of abbreviations and terms which facilitate their use.

***Illustrations***. The annotated *Drug Product Illustration*, see Section 2.2, and the *Therapeutic Equivalence Evaluations Illustration*, see Section 2.3, are offered to provide further clarification. These depict the format found in the Prescription Drug Product List (the only list in which therapeutic equivalence evaluation codes are displayed).

***Drug Product Lists***. The Prescription and OTC Drug Product Lists, arranged alphabetically by active ingredient(s), contain product identification information (active ingredients, dosage forms, routes of administration, product names, applicants, strengths) for single and multiple ingredient drug products. Also shown are the application number and drug product number (FDA internal computer data use only) and approval dates for those drug products approved on or after January 1, 1982. The application number preceded by “N” is a New Drug Application (NDA or commonly the innovator). The application number preceded by an “A” is an Abbreviated New Drug Application (ANDA or commonly the generic).

The Discontinued Drug Product List, arranged alphabetically by active ingredient(s), contains product identification information (dosage form, product name, strength, and application number).

If a prescription drug product is available from more than one source (multisource), a therapeutic equivalence code will appear in front of the applicant's name. If a product is therapeutically equivalent to one or more products or to an appropriate reference, it will be designated with a code beginning with "**A**" and the entry will be underlined and printed in bold font for emphasis.

Active ingredient headings for multiple ingredient (combination) drug products are arranged alphabetically. For purposes of this publication, this alphabetical sort takes precedence over United States Pharmacopeia official monograph order (i.e., Reserpine, Hydralazine Hydrochloride, Hydrochlorothiazide). For example, product information labeled as Reserpine, Hydrochlorothiazide and Hydralazine Hydrochloride appears under the active ingredient heading *Hydralazine Hydrochloride; Hydrochlorothiazide; Reserpine*. A cross-reference to the product information (for prescription and OTC products) appears for each additional active ingredient in the product. For combination drug products, the ingredient strengths are separated by semicolons and appear in the same relative sequence as the ingredients in the heading. Available strengths of the dosage form from an applicant appear on separate lines.

To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if necessary. Then, find the ingredient in the applicable Drug Product List. Proceed to the dosage form and route of administration and compare products within that ingredient heading only. Therapeutic equivalence or inequivalence for prescription products is determined on the basis of the therapeutic equivalence codes provided within that specific dosage form and route heading. The OTC Drug Product List, Discontinued Drug Product List, and

Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List have their data arranged similarly.

The Discontinued Drug Product List contains approved products that have never been marketed, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, are for military use, or have had their approvals withdrawn for other than safety or efficacy reasons subsequent to being discontinued from marketing. All products having a "@" in the December Cumulative Supplement of the previous Edition List have been added to the Discontinued Drug Product List appearing in this Edition. In addition, approved drug products that are not in the commercial distribution channel e.g., approved drug products in applications for export only are also listed in the Discontinued Drug Product List.

***Product Name Index*** *(Prescription and OTC Drug Product Lists)*. This is an index of drug products by trade name or established name of the active ingredient, if no trade name exists. The second term of each entry indicates the active ingredient name under which product information can be found in the appropriate Drug Product List. For those drug products with multiple active ingredients, only the first active ingredient (in alphabetical order) will appear. OTC products are so designated.

***Product Name Index Listed by Applicant*** *(Prescription and OTC Drug Product Lists*). This is an index that cross-references applicants to drug products. The bolded and underlined entry represents the applicant name abbreviation used in this publication. Each complete applicant name that is represented by the abbreviated name is marked with an asterisk (*). Listed under each complete applicant name is the first alphabetically arranged ingredient under which product information can be found in the appropriate Drug Product List. OTC products are so designated. To use the Drug Product Lists, determine by alphabetical order the ingredient under which the product information is listed, using the Product Name Index, if appropriate.

***Uniform Terms***. To improve readability, uniform terms are used to designate dosage forms, routes of administration, and abbreviations used to express strengths. These terms are listed in Appendix C. In some cases, the terms used may differ from those used in product labels and other labeling.

## 2.2 DRUG PRODUCT ILLUSTRATION

**SINGLE INGREDIENT**




*NOTE: REFERENCE LISTED DRUG AND REFERENCE STANDARD ARE DISCUSSED IN THE PREFACE SECTION 1.4

**MULTIPLE INGREDIENTS WITH PRODUCT INFORMATION**




THIS EXAMPLE IS FOR PURPOSE OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

## 2.3 THERAPEUTIC EQUIVALENCE EVALUATIONS ILLUSTRATION

DRUG PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN **"A"**) UNDER AN INGREDIENT AND DOSAGE FORM HEADING ARE CONSIDERED THERAPEUTICALLY EQUIVALENT ONLY TO OTHER PRODUCTS CODED **AB** (OR ANY CODE BEGINNING WITH AN **A")** AND **NOT** TO THOSE CODED **BP** (OR ANY CODE BEGINNING WITH **"B"**) AND ANY PRODUCTS NOT LISTED. DRUG PRODUCTS CODED **BP** (OR ANY CODE BEGINNING WITH A **"B"**) ARE **NOT** CONSIDERED THERAPEUTICALLY EQUIVALENT TO ANY OTHER PRODUCT. FOR A COMPLETE EXPLANATION OF THE **TE** CODES REFER TO SECTION 1.7 OF THE *INTRODUCTION.*




NOTE: BOLD FONT AND UNDERLINING DENOTES MULTISOURCE PRODUCTS WHICH ARE CONSIDERED THERAPEUTICALLY EQUIVALENT.

THIS EXAMPLE IS FOR PURPOSES OF ILLUSTRATION ONLY. IT DOES NOT REPRESENT ACTUAL PRODUCTS FROM THE PRESCRIPTION DRUG PRODUCT LIST.

ABACAVIR SULFATE

SOLUTION;ORAL

**ABACAVIR SULFATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | HETERO LABS LTD III | **EQ 20MG BASE/ML** | **A201107** | **001** | Sep 26, 2016 |

**ZIAGEN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **+!** | VIIV HLTHCARE | **EQ 20MG BASE/ML** | **N020978** | **001** | Dec 17, 1998 |

TABLET;ORAL

**ABACAVIR SULFATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | APOTEX INC | **EQ 300MG BASE** | **A201570** | **001** | Dec 17, 2012 |
| **AB** | | AUROBINDO PHARMA LTD | **EQ 300MG BASE** | **A077844** | **001** | Dec 17, 2012 |
| **AB** | | CIPLA LTD | **EQ 300MG BASE** | **A078119** | **001** | Nov 21, 2017 |
| **AB** | | HETERO LABS LTD III | **EQ 300MG BASE** | **A091560** | **001** | Sep 13, 2013 |
| **AB** | | MYLAN PHARMS INC | **EQ 300MG BASE** | **A091294** | **001** | Jun 18, 2012 |
| **AB** | | STRIDES PHARMA | **EQ 300MG BASE** | **A091050** | **001** | Oct 28, 2016 |

**ZIAGEN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | VIIV HLTHCARE | **EQ 300MG BASE** | **N020977** | **001** | Dec 17, 1998 |

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

TABLET;ORAL

TRIUMEQ

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | VIIV HLTHCARE | EQ 600MG BASE;EQ 50MG BASE;300MG | N205551 | 001 | Aug 22, 2014 |

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL

**ABACAVIR SULFATE AND LAMIVUDINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AUROBINDO PHARMA LTD | **EQ 600MG BASE;300MG** | **A206151** | **001** | Mar 28, 2017 |
| **AB** | | CIPLA LTD | **EQ 600MG BASE;300MG** | **A091144** | **001** | Mar 28, 2017 |
| **AB** | | LUPIN LTD | **EQ 600MG BASE;300MG** | **A204990** | **001** | Mar 28, 2017 |
| **AB** | | TEVA PHARMS USA | **EQ 600MG BASE;300MG** | **A079246** | **001** | Sep 29, 2016 |

**EPZICOM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | VIIV HLTHCARE | **EQ 600MG BASE;300MG** | **N021652** | **001** | Aug 02, 2004 |

ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

**ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | LUPIN LTD | **EQ 300MG BASE;150MG;300MG** | **A202912** | **001** | Dec 05, 2013 |

**TRIZIVIR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | VIIV HLTHCARE | **EQ 300MG BASE;150MG;300MG** | **N021205** | **001** | Nov 14, 2000 |

ABALOPARATIDE

SOLUTION;SUBCUTANEOUS

TYMLOS

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | RADIUS HEALTH INC | 3.12MG/1.56ML (2MG/ML) | N208743 | 001 | Apr 28, 2017 |

ABEMACICLIB

TABLET;ORAL

VERZENIO

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | ELI LILLY AND CO | 50MG | N208716 | 001 | Sep 28, 2017 |
| | + | | 100MG | N208716 | 002 | Sep 28, 2017 |
| | + | | 150MG | N208716 | 003 | Sep 28, 2017 |
| | +! | | 200MG | N208716 | 004 | Sep 28, 2017 |

ABIRATERONE ACETATE

TABLET;ORAL

ZYTIGA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | JANSSEN BIOTECH | 250MG | N202379 | 001 | Apr 28, 2011 |
| | + | | 500MG | N202379 | 002 | Apr 14, 2017 |

ACALABRUTINIB

CAPSULE;ORAL

CALQUENCE

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ASTRAZENECA | 100MG | N210259 | 001 | Oct 31, 2017 |

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL

**ACAMPROSATE CALCIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | BARR LABS DIV TEVA | **333MG** | **A200143** | **001** | Nov 18, 2013 |
| **AB** | **!** | GLENMARK GENERICS | **333MG** | **A202229** | **001** | Jul 16, 2013 |
| **AB** | | MYLAN PHARMS INC | **333MG** | **A200142** | **001** | Mar 11, 2014 |
| **AB** | | ZYDUS PHARMS USA INC | **333MG** | **A205995** | **001** | May 26, 2017 |

ACARBOSE

TABLET;ORAL

**ACARBOSE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | EMCURE PHARMS LTD | **25MG** | **A202271** | **001** | Feb 07, 2012 |
| **AB** | | | **50MG** | **A202271** | **002** | Feb 07, 2012 |
| **AB** | | | **100MG** | **A202271** | **003** | Feb 07, 2012 |
| **AB** | | IMPAX LABS | **25MG** | **A078441** | **001** | May 14, 2009 |
| **AB** | | | **50MG** | **A078441** | **002** | May 14, 2009 |
| **AB** | | | **100MG** | **A078441** | **003** | May 14, 2009 |
| **AB** | | MYLAN | **25MG** | **A091053** | **001** | Jan 06, 2011 |
| **AB** | | | **50MG** | **A091053** | **002** | Jan 06, 2011 |
| **AB** | | | **100MG** | **A091053** | **003** | Jan 06, 2011 |
| **AB** | | STRIDES PHARMA | **25MG** | **A090912** | **001** | Jul 27, 2011 |
| **AB** | | | **50MG** | **A090912** | **002** | Jul 27, 2011 |
| **AB** | | | **100MG** | **A090912** | **003** | Jul 27, 2011 |
| **AB** | | VIRTUS PHARM | **25MG** | **A091343** | **001** | Oct 17, 2013 |
| **AB** | | | **50MG** | **A091343** | **002** | Oct 17, 2013 |
| **AB** | | | **100MG** | **A091343** | **003** | Oct 17, 2013 |
| **AB** | | WATSON LABS | **25MG** | **A077532** | **001** | May 07, 2008 |
| **AB** | | | **50MG** | **A077532** | **002** | May 07, 2008 |
| **AB** | | | **100MG** | **A077532** | **003** | May 07, 2008 |
| **AB** | | WEST-WARD PHARMS INT | **25MG** | **A078470** | **001** | May 07, 2008 |
| **AB** | | | **50MG** | **A078470** | **002** | May 07, 2008 |
| **AB** | | | **100MG** | **A078470** | **003** | May 07, 2008 |

**PRECOSE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | BAYER HLTHCARE | **25MG** | **N020482** | **004** | May 29, 1997 |
| **AB** | **+** | | **50MG** | **N020482** | **001** | Sep 06, 1995 |
| **AB** | **+** | | **100MG** | **N020482** | **002** | Sep 06, 1995 |

ACEBUTOLOL HYDROCHLORIDE

CAPSULE;ORAL

**ACEBUTOLOL HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AMNEAL PHARM | **EQ 200MG BASE** | **A075047** | **001** | Dec 30, 1999 |
| **AB** | | | **EQ 400MG BASE** | **A075047** | **002** | Dec 30, 1999 |
| **AB** | | MYLAN | **EQ 200MG BASE** | **A074288** | **001** | Apr 24, 1995 |
| **AB** | | | **EQ 400MG BASE** | **A074288** | **002** | Apr 24, 1995 |

**SECTRAL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | PROMIUS PHARMA | **EQ 200MG BASE** | **N018917** | **001** | Dec 28, 1984 |
| **AB** | **+!** | | **EQ 400MG BASE** | **N018917** | **003** | Dec 28, 1984 |

ACETAMINOPHEN

SOLUTION;IV (INFUSION)

**ACETAMINOPHEN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | CUSTOPHARM INC | **1GM/100ML (10MG/ML)** | **A202605** | **001** | Jun 13, 2016 |
| **AP** | | SANDOZ INC | **1GM/100ML (10MG/ML)** | **A204052** | **001** | Mar 22, 2016 |

**OFIRMEV**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | MALLINCKRODT IP | **1GM/100ML (10MG/ML)** | **N022450** | **001** | Nov 02, 2010 |
| | | ACETAMINOPHEN | | | | |
| | | FRESENIUS KABI USA | 1GM/100ML (10MG/ML) | N204767 | 001 | Oct 28, 2015 |

ACETAMINOPHEN; BUTALBITAL

CAPSULE;ORAL

BUTALBITAL AND ACETAMINOPHEN

| | | | | | | |
|---|---|---|---|---|---|---|
| | | MIKART INC | 300MG;50MG | A207313 | 001 | Dec 27, 2017 |

TABLET;ORAL

**BUTALBITAL AND ACETAMINOPHEN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | CNTY LINE PHARMS | **325MG;50MG** | **A205120** | **001** | Oct 30, 2015 |
| **AA** | | LARKEN LABS INC | **325MG;50MG** | **A203484** | **002** | Dec 04, 2015 |
| **AA** | | MIKART INC | **300MG;50MG** | **A207386** | **001** | Nov 15, 2016 |
| **AA** | **!** | NEXGEN PHARMA | **300MG;50MG** | **A090956** | **001** | Aug 23, 2011 |
| **AA** | | TEDOR PHARMA INC | **300MG;50MG** | **A207635** | **001** | Jun 05, 2017 |

**BUTAPAP**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **!** | MIKART | **325MG;50MG** | **A089987** | **001** | Oct 26, 1992 |
| | | ALLZITAL | | | | |
| | | LARKEN LABS INC | 325MG;25MG | A203484 | 001 | Dec 04, 2015 |

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

**BUTALBITAL, ACETAMINOPHEN AND CAFFEINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **!** | NEXGEN PHARMA | **300MG;50MG;40MG** | **A040885** | **001** | Nov 16, 2009 |
| **AB** | | NUVO PHARM INC | **300MG;50MG;40MG** | **A207118** | **001** | Oct 28, 2016 |
| **AB** | | TEDOR PHARMA INC | **300MG;50MG;40MG** | **A206615** | **001** | Aug 04, 2017 |
| | ! | MAYNE PHARMA INC | 325MG;50MG;40MG | A089007 | 001 | Mar 17, 1986 |

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

SOLUTION;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | MIKART | 325MG/15ML;50MG/15ML;40MG/15ML | A040387 | 001 | Jan 31, 2003 |

TABLET;ORAL

**BUTALBITAL, ACETAMINOPHEN AND CAFFEINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | ACTAVIS LABS UT INC | **325MG;50MG;40MG** | **A088616** | **001** | Nov 09, 1984 |
| **AA** | | CNTY LINE PHARMS | **325MG;50MG;40MG** | **A204984** | **001** | Jan 10, 2017 |
| **AA** | | HIKMA PHARMS | **325MG;50MG;40MG** | **A089718** | **001** | Jun 12, 1995 |
| **AA** | | LANNETT HOLDINGS INC | **325MG;50MG;40MG** | **A200243** | **001** | Sep 13, 2012 |
| **AA** | | MIKART | **325MG;50MG;40MG** | **A089175** | **001** | Jan 21, 1987 |
| **AA** | | SPECGX LLC | **325MG;50MG;40MG** | **A087804** | **001** | Jan 24, 1985 |
| **AA** | **!** | VINTAGE PHARMS | **325MG;50MG;40MG** | **A040511** | **001** | Aug 27, 2003 |

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

**BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | NEXGEN PHARMA INC | **325MG;50MG;40MG;30MG** | **A076560** | **001** | Jun 10, 2004 |
| **AB** | | VINTAGE PHARMS | **325MG;50MG;40MG;30MG** | **A075929** | **001** | Apr 22, 2002 |

**FIORICET W/ CODEINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | ACTAVIS LABS UT INC | **325MG;50MG;40MG;30MG** | **N020232** | **001** | Jul 30, 1992 |

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

| | | | | | | |
|---|---|---|---|---|---|---|
| | | NEXGEN PHARMA INC | 300MG;50MG;40MG;30MG | A076560 | 002 | Jul 19, 2012 |

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE;ORAL

TREZIX

| | | | | | | |
|---|---|---|---|---|---|---|
| | | WRASER PHARMS LLC | 320.5MG;30MG;16MG | A204785 | 001 | Nov 26, 2014 |

TABLET;ORAL

ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE

| | | | | | | |
|---|---|---|---|---|---|---|
| | | LARKEN LABS INC | 325MG;30MG;16MG | A204209 | 001 | Sep 30, 2016 |

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL

**ACETAMINOPHEN AND CODEINE PHOSPHATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | HI TECH PHARMA | **120MG/5ML;12MG/5ML** | **A040119** | **001** | Apr 26, 1996 |
| **AA** | | MIKART | **120MG/5ML;12MG/5ML** | **A089450** | **001** | Oct 27, 1992 |
| **AA** | **!** | PHARM ASSOC | **120MG/5ML;12MG/5ML** | **A087508** | **001** | |
| **AA** | | VINTAGE PHARMS | **120MG/5ML;12MG/5ML** | **A091238** | **001** | Nov 10, 2011 |
| **AA** | | WOCKHARDT BIO AG | **120MG/5ML;12MG/5ML** | **A087006** | **001** | |

TABLET;ORAL

**ACETAMINOPHEN AND CODEINE PHOSPHATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | AMNEAL PHARMS NY | **300MG;30MG** | **A040779** | **001** | May 29, 2008 |
| **AA** | | AUROLIFE PHARMA LLC | **300MG;15MG** | **A202800** | **001** | Apr 15, 2013 |
| **AA** | | | **300MG;30MG** | **A202800** | **002** | Apr 15, 2013 |
| **AA** | | | **300MG;60MG** | **A202800** | **003** | Apr 15, 2013 |
| **AA** | **!** | SPECGX LLC | **300MG;15MG** | **A040419** | **001** | May 31, 2001 |
| **AA** | | | **300MG;30MG** | **A040419** | **002** | May 31, 2001 |
| **AA** | | | **300MG;60MG** | **A040419** | **003** | May 31, 2001 |
| **AA** | | SUN PHARM INDS LTD | **300MG;30MG** | **A085868** | **001** | |
| **AA** | | | **300MG;60MG** | **A087083** | **001** | |
| **AA** | | TEVA | **300MG;15MG** | **A088627** | **001** | Mar 06, 1985 |
| **AA** | | | **300MG;30MG** | **A088628** | **001** | Mar 06, 1985 |
| **AA** | **!** | | **300MG;60MG** | **A088629** | **001** | Mar 06, 1985 |
| **AA** | | VINTAGE | **300MG;15MG** | **A089990** | **001** | Sep 30, 1988 |
| **AA** | | | **300MG;30MG** | **A089805** | **001** | Sep 30, 1988 |
| **AA** | | VINTAGE PHARMS | **300MG;60MG** | **A089828** | **001** | Sep 30, 1988 |

**TYLENOL W/ CODEINE NO. 3**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **!** | JANSSEN PHARMS | **300MG;30MG** | **A085055** | **003** | |

**TYLENOL W/ CODEINE NO. 4**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | JANSSEN PHARMS | **300MG;60MG** | **A085055** | **004** | |

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

**HYDROCODONE BITARTRATE AND ACETAMINOPHEN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **!** | MIKART | **325MG/15ML;7.5MG/15ML** | **A040482** | **001** | Sep 25, 2003 |
| **AA** | | PHARM ASSOC | **325MG/15ML;7.5MG/15ML** | **A040838** | **001** | May 10, 2013 |
| **AA** | | VINTAGE PHARMS | **325MG/15ML;7.5MG/15ML** | **A040894** | **001** | Jul 19, 2011 |
| **AA** | | VISTAPHARM | **325MG/15ML;7.5MG/15ML** | **A200343** | **001** | Jan 25, 2012 |
| | ! | MIKART | 300MG/15ML;10MG/15ML | A040881 | 001 | Feb 25, 2010 |
| | ! | PHARM ASSOC | 325MG/15ML;10MG/15ML | A040834 | 001 | Apr 18, 2008 |

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **ANEXSIA 5/325** | | | | | | | |
| **AA** | | SPECGX LLC | **325MG;5MG** | **A040409** | **001** | Oct 20, 2000 | |
| **ANEXSIA 7.5/325** | | | | | | | |
| **AA** | | SPECGX LLC | **325MG;7.5MG** | **A040405** | **001** | Sep 08, 2000 | |
| **HYDROCODONE BITARTRATE AND ACETAMINOPHEN** | | | | | | | |
| **AA** | | ABHAI LLC | **300MG;5MG** | **A209036** | **001** | Jun 21, 2017 | |
| **AA** | | | **300MG;7.5MG** | **A209036** | **002** | Jun 21, 2017 | |
| **AA** | | | **300MG;10MG** | **A209036** | **003** | Jun 21, 2017 | |
| **AA** | | | **325MG;5MG** | **A209037** | **001** | Jun 21, 2017 | |
| **AA** | | | **325MG;7.5MG** | **A209037** | **002** | Jun 21, 2017 | |
| **AA** | | | **325MG;10MG** | **A209037** | **003** | Jun 21, 2017 | |
| **AA** | | ACTAVIS LABS FL INC | **300MG;5MG** | **A206470** | **001** | Jun 02, 2016 | |
| **AA** | | | **300MG;7.5MG** | **A206470** | **002** | Jun 02, 2016 | |
| **AA** | | | **300MG;10MG** | **A206470** | **003** | Jun 02, 2016 | |
| **AA** | | AMNEAL PHARMS | **300MG;10MG** | **A207137** | **001** | Nov 29, 2016 | |
| **AA** | | AMNEAL PHARMS NY | **300MG;5MG** | **A206869** | **001** | Jun 23, 2017 | |
| **AA** | | | **325MG;5MG** | **A040736** | **001** | Aug 25, 2006 | |
| **AA** | | | **325MG;7.5MG** | **A040746** | **002** | May 10, 2016 | |
| **AA** | | | **325MG;10MG** | **A040746** | **001** | Aug 25, 2006 | |
| **AA** | | AUROLIFE PHARMA LLC | **325MG;5MG** | **A201013** | **001** | Apr 11, 2012 | |
| **AA** | | | **325MG;7.5MG** | **A201013** | **002** | Apr 11, 2012 | |
| **AA** | | | **325MG;10MG** | **A201013** | **003** | Apr 11, 2012 | |
| **AA** | | LANNETT HOLDINGS INC | **300MG;5MG** | **A207171** | **001** | Jun 20, 2017 | |
| **AA** | | | **300MG;7.5MG** | **A207171** | **002** | Jun 20, 2017 | |
| **AA** | | | **300MG;10MG** | **A207171** | **003** | Jun 20, 2017 | |
| **AA** | | | **325MG;5MG** | **A207172** | **001** | Jun 22, 2017 | |
| **AA** | | | **325MG;7.5MG** | **A207172** | **002** | Jun 22, 2017 | |
| **AA** | | | **325MG;10MG** | **A207172** | **003** | Jun 22, 2017 | |
| **AA** | | LARKEN LABS INC | **325MG;5MG** | **A202935** | **002** | Jun 15, 2016 | |
| **AA** | | | **325MG;7.5MG** | **A202935** | **003** | Jun 15, 2016 | |
| **AA** | | | **325MG;10MG** | **A202935** | **004** | Jun 15, 2016 | |
| **AA** | **!** | MIKART | **300MG;5MG** | **A040658** | **001** | Jan 19, 2006 | |
| **AA** | **!** | | **300MG;7.5MG** | **A040658** | **002** | Mar 24, 2006 | |
| **AA** | **!** | | **300MG;10MG** | **A040658** | **003** | Jun 23, 2004 | |
| **AA** | **!** | | **325MG;2.5MG** | **A040846** | **001** | Jun 09, 2010 | |
| **AA** | | | **325MG;7.5MG** | **A040432** | **001** | Jan 22, 2003 | |
| **AA** | | NOVEL LABS INC | **300MG;5MG** | **A206142** | **001** | Nov 14, 2016 | |
| **AA** | | | **300MG;7.5MG** | **A206142** | **002** | Nov 14, 2016 | |
| **AA** | | | **300MG;10MG** | **A206142** | **003** | Nov 14, 2016 | |
| **AA** | | | **325MG;5MG** | **A206245** | **001** | Dec 01, 2016 | |
| **AA** | | | **325MG;7.5MG** | **A206245** | **002** | Dec 01, 2016 | |
| **AA** | | | **325MG;10MG** | **A206245** | **003** | Dec 01, 2016 | |
| **AA** | | PAR PHARM | **300MG;5MG** | **A205001** | **001** | Jul 05, 2016 | |
| **AA** | | | **300MG;7.5MG** | **A205001** | **002** | Jul 05, 2016 | |
| **AA** | | | **300MG;10MG** | **A205001** | **003** | Jul 05, 2016 | |
| **AA** | | RHODES PHARMS | **325MG;5MG** | **A202991** | **001** | Apr 12, 2016 | |
| **AA** | | | **325MG;7.5MG** | **A202991** | **002** | Apr 12, 2016 | |
| **AA** | | | **325MG;10MG** | **A202991** | **003** | Apr 12, 2016 | |
| **AA** | | SPECGX LLC | **300MG;5MG** | **A206718** | **001** | Mar 31, 2017 | |
| **AA** | | | **300MG;7.5MG** | **A206718** | **002** | Mar 31, 2017 | |
| **AA** | | | **300MG;10MG** | **A206718** | **003** | Mar 31, 2017 | |
| **AA** | | | **325MG;10MG** | **A040400** | **001** | Jul 26, 2000 | |
| **AA** | | SUN PHARM INDS INC | **325MG;5MG** | **A090118** | **001** | Dec 23, 2008 | |
| **AA** | | | **325MG;7.5MG** | **A090118** | **002** | Dec 23, 2008 | |
| **AA** | | | **325MG;10MG** | **A090118** | **003** | Dec 23, 2008 | |
| **AA** | | TRIS PHARMA INC | **300MG;5MG** | **A202214** | **004** | Mar 15, 2016 | |
| **AA** | | | **300MG;7.5MG** | **A202214** | **005** | Mar 15, 2016 | |
| **AA** | | | **300MG;10MG** | **A202214** | **006** | Mar 15, 2016 | |
| **AA** | | | **325MG;5MG** | **A202214** | **001** | Mar 27, 2013 | |
| **AA** | | | **325MG;7.5MG** | **A202214** | **002** | Mar 27, 2013 | |
| **AA** | | | **325MG;10MG** | **A202214** | **003** | Mar 27, 2013 | |
| **AA** | | UPSHER-SMITH LABS | **325MG;5MG** | **A206484** | **001** | Mar 24, 2017 | |
| **AA** | | | **325MG;7.5MG** | **A206484** | **002** | Mar 24, 2017 | |
| **AA** | | | **325MG;10MG** | **A206484** | **003** | Mar 24, 2017 | |
| **AA** | | VINTAGE PHARMS | **300MG;5MG** | **A090415** | **001** | Jan 24, 2011 | |
| **AA** | | | **300MG;7.5MG** | **A090415** | **002** | Jan 24, 2011 | |
| **AA** | | | **300MG;10MG** | **A090415** | **003** | Jan 24, 2011 | |
| **AA** | | | **325MG;5MG** | **A040655** | **001** | Jan 19, 2006 | |
| **AA** | | | **325MG;7.5MG** | **A040656** | **001** | Jan 19, 2006 | |
| **AA** | | | **325MG;10MG** | **A040355** | **001** | May 31, 2000 | |

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL

**HYDROCODONE BITARTRATE AND ACETAMINOPHEN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | WES PHARMA INC | **325MG;5MG** | **A210211** | **001** | Oct 30, 2017 |
| **AA** | | | **325MG;7.5MG** | **A210211** | **002** | Oct 30, 2017 |
| **AA** | | | **325MG;10MG** | **A210211** | **003** | Oct 30, 2017 |

**NORCO**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | APIL | **325MG;2.5MG** | **A040148** | **004** | Jul 07, 2014 |
| **AA** | ! | | **325MG;5MG** | **A040099** | **001** | Jun 25, 1997 |
| **AA** | | | **325MG;5MG** | **A040148** | **005** | Jul 07, 2014 |
| **AA** | ! | | **325MG;7.5MG** | **A040148** | **003** | Sep 12, 2000 |
| **AA** | ! | | **325MG;10MG** | **A040148** | **001** | Feb 14, 1997 |

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

**OXYCODONE AND ACETAMINOPHEN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | ! | SPECGX LLC | **325MG/5ML;5MG/5ML** | **A040680** | **001** | Sep 29, 2006 |

**OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | VINTAGE PHARMS | **325MG/5ML;5MG/5ML** | **A203573** | **001** | Dec 18, 2014 |

TABLET;ORAL

**OXYCET**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | SPECGX LLC | **325MG;5MG** | **A087463** | **001** | Dec 07, 1983 |

**OXYCODONE AND ACETAMINOPHEN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | ACTAVIS ELIZABETH | **325MG;2.5MG** | **A201447** | **001** | Apr 12, 2013 |
| **AA** | | | **325MG;5MG** | **A201447** | **002** | Apr 12, 2013 |
| **AA** | | | **325MG;7.5MG** | **A201447** | **003** | Apr 12, 2013 |
| **AA** | | | **325MG;10MG** | **A201447** | **004** | Apr 12, 2013 |
| **AA** | | ALVOGEN MALTA | **325MG;5MG** | **A202677** | **003** | Mar 08, 2016 |
| **AA** | | | **325MG;7.5MG** | **A202677** | **001** | Jul 26, 2012 |
| **AA** | | | **325MG;10MG** | **A202677** | **002** | Jul 26, 2012 |
| **AA** | | AMNEAL PHARMS | **325MG;5MG** | **A040777** | **001** | Nov 27, 2007 |
| **AA** | | AMNEAL PHARMS NY | **325MG;7.5MG** | **A040778** | **002** | Jun 27, 2014 |
| **AA** | | | **325MG;10MG** | **A040778** | **001** | Nov 27, 2007 |
| **AA** | | ASCENT PHARMS INC | **325MG;2.5MG** | **A207419** | **001** | Mar 22, 2017 |
| **AA** | | | **325MG;5MG** | **A207419** | **002** | Mar 22, 2017 |
| **AA** | | | **325MG;7.5MG** | **A207419** | **003** | Mar 22, 2017 |
| **AA** | | | **325MG;10MG** | **A207419** | **004** | Mar 22, 2017 |
| **AA** | | AUROLIFE PHARMA LLC | **325MG;2.5MG** | **A201972** | **001** | Jul 15, 2013 |
| **AA** | | | **325MG;5MG** | **A201972** | **002** | Jul 15, 2013 |
| **AA** | | | **325MG;7.5MG** | **A201972** | **003** | Jul 15, 2013 |
| **AA** | | | **325MG;10MG** | **A201972** | **004** | Jul 15, 2013 |
| **AA** | | CHEMO RESEARCH SL | **325MG;5MG** | **A207574** | **001** | Dec 13, 2016 |
| **AA** | | LANNETT HOLDINGS INC | **325MG;5MG** | **A207333** | **001** | Sep 25, 2017 |
| **AA** | | | **325MG;10MG** | **A207333** | **002** | Sep 25, 2017 |
| **AA** | | MAYNE PHARMA INC | **325MG;2.5MG** | **A090177** | **001** | Oct 20, 2008 |
| **AA** | | | **325MG;5MG** | **A090177** | **002** | Oct 20, 2008 |
| **AA** | | | **325MG;7.5MG** | **A090177** | **003** | Oct 20, 2008 |
| **AA** | | | **325MG;10MG** | **A090177** | **004** | Oct 20, 2008 |
| **AA** | | NESHER PHARMS | **325MG;2.5MG** | **A210079** | **001** | Dec 28, 2017 |
| **AA** | | | **325MG;5MG** | **A210079** | **002** | Dec 28, 2017 |
| **AA** | | | **325MG;7.5MG** | **A210079** | **003** | Dec 28, 2017 |
| **AA** | | | **325MG;10MG** | **A210079** | **004** | Dec 28, 2017 |
| **AA** | | NOVEL LABS INC | **325MG;2.5MG** | **A204407** | **001** | Feb 24, 2017 |
| **AA** | | | **325MG;5MG** | **A204407** | **002** | Feb 24, 2017 |
| **AA** | | | **325MG;7.5MG** | **A204407** | **003** | Feb 24, 2017 |
| **AA** | | | **325MG;10MG** | **A204407** | **004** | Feb 24, 2017 |
| **AA** | | RHODES PHARMS | **325MG;5MG** | **A201278** | **001** | Aug 28, 2014 |
| **AA** | | | **325MG;7.5MG** | **A201278** | **002** | Aug 28, 2014 |
| **AA** | | | **325MG;10MG** | **A201278** | **003** | Aug 28, 2014 |
| **AA** | | SPECGX LLC | **325MG;7.5MG** | **A040545** | **001** | Jun 30, 2004 |
| **AA** | | | **325MG;10MG** | **A040545** | **002** | Jun 30, 2004 |
| **AA** | | SUN PHARM INDS INC | **325MG;2.5MG** | **A090535** | **001** | Dec 26, 2013 |
| **AA** | | | **325MG;5MG** | **A090535** | **002** | Dec 26, 2013 |
| **AA** | | | **325MG;7.5MG** | **A090535** | **003** | Dec 26, 2013 |
| **AA** | | | **325MG;10MG** | **A090535** | **004** | Dec 26, 2013 |
| **AA** | | VINTAGE PHARMS | **325MG;2.5MG** | **A090733** | **001** | Jul 11, 2013 |
| **AA** | | | **325MG;5MG** | **A040105** | **001** | Jul 30, 1996 |
| **AA** | | | **325MG;7.5MG** | **A090734** | **001** | Jul 11, 2013 |
| **AA** | | | **325MG;10MG** | **A090734** | **002** | Jul 11, 2013 |
| **AA** | | WATSON LABS | **325MG;5MG** | **A040171** | **001** | Oct 30, 1997 |
| **AA** | | | **325MG;7.5MG** | **A040535** | **001** | Sep 05, 2003 |
| **AA** | | | **325MG;10MG** | **A040535** | **002** | Sep 05, 2003 |

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

**PERCOCET**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **!** | VINTAGE PHARMS LLC | **325MG;2.5MG** | **A040330** | **001** | Jun 25, 1999 |
| **AA** | **!** | | **325MG;5MG** | **A040330** | **002** | Jun 25, 1999 |
| **AA** | **!** | | **325MG;7.5MG** | **A040330** | **003** | Nov 23, 2001 |
| **AA** | **!** | | **325MG;10MG** | **A040330** | **004** | Nov 23, 2001 |

**ROXICET**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | WEST-WARD PHARMS INT | **325MG;5MG** | **A087003** | **001** | |

OXYCODONE AND ACETAMINOPHEN

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | MIKART | 300MG;2.5MG | A040608 | 001 | Dec 30, 2005 |
| | ! | | 300MG;5MG | A040608 | 002 | Dec 30, 2005 |
| | ! | | 300MG;7.5MG | A040608 | 003 | Dec 30, 2005 |
| | ! | | 300MG;10MG | A040608 | 004 | Dec 30, 2005 |

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET;ORAL

**TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALKEM LABS LTD | **325MG;37.5MG** | **A202076** | **001** | Mar 30, 2012 |
| **AB** | | AMNEAL PHARMS | **325MG;37.5MG** | **A090485** | **001** | Dec 09, 2009 |
| **AB** | | APOTEX INC | **325MG;37.5MG** | **A078778** | **001** | Apr 07, 2014 |
| **AB** | | AUROBINDO PHARMA LTD | **325MG;37.5MG** | **A207152** | **001** | Mar 22, 2017 |
| **AB** | | MACLEODS PHARMS LTD | **325MG;37.5MG** | **A206885** | **001** | May 02, 2017 |
| **AB** | | MICRO LABS LTD INDIA | **325MG;37.5MG** | **A201952** | **001** | Dec 14, 2012 |
| **AB** | | MYLAN | **325MG;37.5MG** | **A077858** | **001** | Sep 26, 2008 |
| **AB** | | PAR PHARM | **325MG;37.5MG** | **A076475** | **001** | Apr 21, 2005 |
| **AB** | | SUN PHARM INDS INC | **325MG;37.5MG** | **A077184** | **001** | Dec 16, 2005 |
| **AB** | | ZYDUS PHARMS USA INC | **325MG;37.5MG** | **A090460** | **001** | Sep 06, 2012 |

**ULTRACET**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | JANSSEN PHARMS | **325MG;37.5MG** | **N021123** | **001** | Aug 15, 2001 |

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL

**ACETAZOLAMIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | HERITAGE PHARMS INC | **500MG** | **A090779** | **001** | Jul 14, 2011 |
| **AB** | | NOSTRUM LABS INC | **500MG** | **A204691** | **001** | Mar 29, 2016 |
| **AB** | | NOVAST LABS LTD | **500MG** | **A203434** | **001** | Sep 30, 2016 |
| **AB** | | ZYDUS PHARMS USA INC | **500MG** | **A040904** | **001** | Dec 10, 2008 |

**DIAMOX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | TEVA BRANDED PHARM | **500MG** | **N012945** | **001** | |

TABLET;ORAL

**ACETAZOLAMIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | HERITAGE PHARMA | **125MG** | **A205530** | **001** | Oct 27, 2016 |
| **AB** | | | **250MG** | **A205530** | **002** | Oct 27, 2016 |
| **AB** | | LANNETT | **250MG** | **A084840** | **001** | |
| **AB** | | STRIDES PHARMA | **125MG** | **A209734** | **001** | Nov 20, 2017 |
| **AB** | | | **250MG** | **A209734** | **002** | Nov 20, 2017 |
| **AB** | | SUN PHARM INDUSTRIES | **125MG** | **A089753** | **002** | Jun 22, 1988 |
| **AB** | | TARO | **125MG** | **A040195** | **001** | May 28, 1997 |
| **AB** | **!** | | **250MG** | **A040195** | **002** | May 28, 1997 |

ACETAZOLAMIDE SODIUM

INJECTABLE;INJECTION

**ACETAZOLAMIDE SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | PAR STERILE PRODUCTS | **EQ 500MG BASE/VIAL** | **A205358** | **001** | Jun 20, 2017 |
| **AP** | | SAGENT AGILA | **EQ 500MG BASE/VIAL** | **A200880** | **001** | May 09, 2012 |
| **AP** | | WEST-WARD PHARMS INT | **EQ 500MG BASE/VIAL** | **A040089** | **001** | Feb 28, 1995 |
| **AP** | **!** | X GEN PHARMS | **EQ 500MG BASE/VIAL** | **A040784** | **001** | Dec 10, 2008 |

**ACETAZOLAMIDE SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | EMCURE PHARMS LTD | **EQ 500MG BASE/VIAL** | **A202693** | **001** | Dec 19, 2014 |

ACETIC ACID, GLACIAL

SOLUTION;IRRIGATION, URETHRAL

**ACETIC ACID 0.25% IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | B BRAUN | **250MG/100ML** | **N018161** | **001** | |
| **AT** | | BAXTER HLTHCARE | **250MG/100ML** | **N018523** | **001** | Feb 19, 1982 |
| **AT** | | ICU MEDICAL INC | **250MG/100ML** | **N017656** | **001** | |

ACETIC ACID, GLACIAL

SOLUTION/DROPS;OTIC

**ACETIC ACID**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | TARO | **2%** | **A088638** | **001** | Sep 06, 1984 |
| **AT** | | VINTAGE | **2%** | **A040607** | **001** | Feb 24, 2005 |
| **AT** | **!** | WOCKHARDT BIO AG | **2%** | **A040166** | **001** | Jul 26, 1996 |

**VOSOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | HI TECH PHARMA | **2%** | **N012179** | **001** | |

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS;OTIC

**ACETASOL HC**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | ACTAVIS MID ATLANTIC | **2%;1%** | **A087143** | **001** | Jan 13, 1982 |

**HYDROCORTISONE AND ACETIC ACID**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | TARO | **2%;1%** | **A088759** | **001** | Mar 04, 1985 |
| **AT** | | VINTAGE | **2%;1%** | **A040609** | **001** | Feb 06, 2006 |

**VOSOL HC**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **+!** | HI TECH PHARMA | **2%;1%** | **N012770** | **001** | |

ACETOHYDROXAMIC ACID

TABLET;ORAL

LITHOSTAT

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | MISSION PHARMA | 250MG | N018749 | 001 | May 31, 1983 |

ACETYLCHOLINE CHLORIDE

FOR SOLUTION;OPHTHALMIC

MIOCHOL-E

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | BAUSCH AND LOMB | 20MG/VIAL | N020213 | 001 | Sep 22, 1993 |

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS

**ACETADOTE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | CUMBERLAND PHARMS | **6GM/30ML (200MG/ML)** | **N021539** | **001** | Jan 23, 2004 |

**ACETYLCYSTEINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AKORN INC | **6GM/30ML (200MG/ML)** | **A203173** | **001** | Mar 24, 2015 |
| **AP** | | AUROBINDO PHARMA LTD | **6GM/30ML (200MG/ML)** | **A207358** | **001** | Feb 29, 2016 |
| **AP** | | FRESENIUS KABI USA | **6GM/30ML (200MG/ML)** | **A200644** | **001** | Nov 07, 2012 |
| **AP** | | MYLAN INSTITUTIONAL | **6GM/30ML (200MG/ML)** | **A203624** | **001** | Jun 19, 2015 |
| **AP** | | SAGENT PHARMS | **6GM/30ML (200MG/ML)** | **A091684** | **001** | Oct 31, 2017 |

SOLUTION;INHALATION, ORAL

**ACETYLCYSTEINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AN** | | ALVOGEN INC | **10%** | **A204674** | **001** | Feb 11, 2014 |
| **AN** | | | **20%** | **A203853** | **001** | Jun 21, 2012 |
| **AN** | | HOSPIRA | **10%** | **A073664** | **001** | Aug 30, 1994 |
| **AN** | | | **20%** | **A074037** | **001** | Aug 30, 1994 |
| **AN** | **!** | LUITPOLD | **10%** | **A072489** | **001** | Jul 28, 1995 |
| **AN** | **!** | | **20%** | **A072547** | **001** | Jul 28, 1995 |

TABLET, EFFERVESCENT;ORAL

CETYLEV

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | ARBOR PHARMS LLC | 500MG | N207916 | 001 | Jan 29, 2016 |
| | +! | | 2.5GM | N207916 | 002 | Jan 29, 2016 |

ACITRETIN

CAPSULE;ORAL

**ACITRETIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | BARR LABS INC | **10MG** | **A091455** | **001** | Apr 04, 2013 |
| **AB** | | | **25MG** | **A091455** | **002** | Apr 04, 2013 |
| **AB** | | IMPAX LABS INC | **10MG** | **A202552** | **001** | Dec 23, 2015 |
| **AB** | | | **17.5MG** | **A202552** | **002** | Dec 23, 2015 |
| **AB** | | | **22.5MG** | **A202552** | **003** | Dec 23, 2015 |
| **AB** | | | **25MG** | **A202552** | **004** | Dec 23, 2015 |
| **AB** | | MYLAN PHARMS INC | **10MG** | **A202148** | **001** | Sep 10, 2015 |
| **AB** | | | **25MG** | **A202148** | **002** | Sep 10, 2015 |
| **AB** | | SIGMAPHARM LABS LLC | **10MG** | **A204633** | **001** | May 22, 2015 |
| **AB** | | | **17.5MG** | **A204633** | **002** | May 22, 2015 |
| **AB** | | | **22.5MG** | **A204633** | **003** | May 22, 2015 |
| **AB** | | | **25MG** | **A204633** | **004** | May 22, 2015 |
| **AB** | | TEVA PHARMS USA | **17.5MG** | **A202897** | **001** | Apr 04, 2013 |
| **AB** | | | **22.5MG** | **A202897** | **002** | Apr 04, 2013 |

**SORIATANE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | STIEFEL LABS INC | **10MG** | **N019821** | **001** | Oct 28, 1996 |
| **AB** | **+** | | **17.5MG** | **N019821** | **003** | Aug 06, 2009 |
| **AB** | **+** | | **22.5MG** | **N019821** | **004** | Aug 06, 2009 |

| | | | | | | |
|---|---|---|---|---|---|---|
| ACITRETIN | | | | | | |
| CAPSULE;ORAL | | | | | | |
| **SORIATANE** | | | | | | |
| **AB** | **+!** | | **25MG** | **N019821** | **002** | Oct 28, 1996 |
| ACLIDINIUM BROMIDE | | | | | | |
| POWDER, METERED;INHALATION | | | | | | |
| TUDORZA PRESSAIR | | | | | | |
| | +! | ASTRAZENECA PHARMS | 0.4MG/INH | N202450 | 001 | Jul 23, 2012 |
| ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE | | | | | | |
| CAPSULE;ORAL | | | | | | |
| SEMPREX-D | | | | | | |
| | +! | AUXILIUM PHARMS LLC | 8MG;60MG | N019806 | 001 | Mar 25, 1994 |
| ACYCLOVIR | | | | | | |
| CAPSULE;ORAL | | | | | | |
| **ACYCLOVIR** | | | | | | |
| **AB** | **!** | APOTEX INC | **200MG** | **A075677** | **001** | Sep 28, 2005 |
| **AB** | | BOSCOGEN | **200MG** | **A075090** | **001** | Jan 26, 1999 |
| **AB** | | CADILA PHARMS LTD | **200MG** | **A201445** | **001** | Mar 06, 2014 |
| **AB** | | CARLSBAD TECHNOLOGY | **200MG** | **A206261** | **001** | Aug 16, 2017 |
| **AB** | | DAVA PHARMS INC | **200MG** | **A074833** | **001** | Apr 22, 1997 |
| **AB** | | TEVA | **200MG** | **A074578** | **001** | Apr 22, 1997 |
| **AB** | | ZYDUS PHARMS USA INC | **200MG** | **A204313** | **001** | Mar 25, 2016 |
| **ZOVIRAX** | | | | | | |
| **AB** | **+** | MYLAN PHARMS INC | **200MG** | **N018828** | **001** | Jan 25, 1985 |
| CREAM;TOPICAL | | | | | | |
| ZOVIRAX | | | | | | |
| | +! | VIB | 5% | N021478 | 001 | Dec 30, 2002 |
| OINTMENT;TOPICAL | | | | | | |
| **ACYCLOVIR** | | | | | | |
| **AB** | | AMNEAL PHARMS | **5%** | **A204605** | **001** | Jun 18, 2014 |
| **AB** | | FOUGERA PHARMS INC | **5%** | **A206633** | **001** | May 11, 2016 |
| **AB** | | G AND W LABS INC | **5%** | **A205591** | **001** | Nov 13, 2017 |
| **AB** | | GLENMARK PHARMS LTD | **5%** | **A205510** | **001** | Jul 31, 2017 |
| **AB** | | MYLAN PHARMS INC | **5%** | **A202459** | **001** | Apr 03, 2013 |
| **AB** | | TARO | **5%** | **A205469** | **001** | Dec 21, 2016 |
| **AB** | | TOLMAR | **5%** | **A206437** | **001** | Jul 31, 2017 |
| **ZOVIRAX** | | | | | | |
| **AB** | **+!** | VALEANT BERMUDA | **5%** | **N018604** | **001** | Mar 29, 1982 |
| SUSPENSION;ORAL | | | | | | |
| **ACYCLOVIR** | | | | | | |
| **AB** | | ACTAVIS MID ATLANTIC | **200MG/5ML** | **A074738** | **001** | Apr 28, 1997 |
| **AB** | | HI TECH PHARMA | **200MG/5ML** | **A077026** | **001** | Jun 07, 2005 |
| **ZOVIRAX** | | | | | | |
| **AB** | **+!** | MYLAN PHARMS INC | **200MG/5ML** | **N019909** | **001** | Dec 22, 1989 |
| TABLET;BUCCAL | | | | | | |
| SITAVIG | | | | | | |
| | +! | EPI HLTH | 50MG | N203791 | 001 | Apr 12, 2013 |
| TABLET;ORAL | | | | | | |
| **ACYCLOVIR** | | | | | | |
| **AB** | | APOTEX INC | **400MG** | **A077309** | **001** | Sep 29, 2005 |
| **AB** | | | **800MG** | **A077309** | **002** | Sep 29, 2005 |
| **AB** | | CADILA PHARMS LTD | **400MG** | **A202168** | **001** | Nov 15, 2013 |
| **AB** | | | **800MG** | **A202168** | **002** | Nov 15, 2013 |
| **AB** | | CARLSBAD | **400MG** | **A075382** | **001** | Apr 30, 1999 |
| **AB** | | | **800MG** | **A075382** | **002** | Apr 30, 1999 |
| **AB** | | DAVA PHARMS INC | **400MG** | **A074946** | **001** | Nov 19, 1997 |
| **AB** | | | **800MG** | **A074946** | **002** | Nov 19, 1997 |
| **AB** | | HERITAGE PHARMS INC | **400MG** | **A074891** | **001** | Oct 31, 1997 |
| **AB** | | | **800MG** | **A074891** | **002** | Oct 31, 1997 |
| **AB** | | HETERO LABS LTD V | **400MG** | **A203834** | **001** | Oct 29, 2013 |
| **AB** | | | **800MG** | **A203834** | **002** | Oct 29, 2013 |
| **AB** | | MYLAN PHARMS INC | **400MG** | **A075211** | **001** | Sep 28, 1998 |
| **AB** | | | **800MG** | **A075211** | **002** | Sep 28, 1998 |
| **AB** | | TEVA | **400MG** | **A074556** | **002** | Apr 22, 1997 |
| **AB** | | | **800MG** | **A074556** | **003** | Apr 22, 1997 |
| **AB** | | ZYDUS PHARMS USA INC | **400MG** | **A204314** | **001** | Aug 19, 2014 |
| **AB** | | | **800MG** | **A204314** | **002** | Aug 19, 2014 |

ACYCLOVIR

TABLET;ORAL

**ZOVIRAX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | MYLAN PHARMS INC | **400MG** | **N020089** | **001** | Apr 30, 1991 |
| **AB** | **+!** | | **800MG** | **N020089** | **002** | Apr 30, 1991 |

ACYCLOVIR SODIUM

INJECTABLE;INJECTION

**ACYCLOVIR SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AUROBINDO PHARMA LTD | **EQ 50MG BASE/ML** | **A203701** | **001** | Oct 11, 2013 |
| **AP** | **!** | FRESENIUS KABI USA | **EQ 50MG BASE/ML** | **A074930** | **001** | May 13, 1998 |
| **AP** | **!** | | **EQ 500MG BASE/VIAL** | **A075015** | **001** | Apr 30, 1998 |
| **AP** | | HIKMA PHARMS | **EQ 500MG BASE/VIAL** | **A205771** | **001** | Feb 29, 2016 |
| **AP** | **!** | | **EQ 1GM BASE/VIAL** | **A205771** | **002** | Feb 29, 2016 |
| **AP** | | ZYDUS PHARMS USA INC | **EQ 500MG BASE/VIAL** | **A206606** | **001** | Jun 13, 2017 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A206606** | **002** | Jun 13, 2017 |

ACYCLOVIR; HYDROCORTISONE

CREAM;TOPICAL

XERESE

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | VALEANT BERMUDA | 5%;1% | N022436 | 001 | Jul 31, 2009 |

ADAPALENE

CREAM;TOPICAL

**ADAPALENE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | FOUGERA PHARMS | **0.1%** | **A090824** | **001** | Jun 30, 2010 |

**DIFFERIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | GALDERMA LABS LP | **0.1%** | **N020748** | **001** | May 26, 2000 |

GEL;TOPICAL

**ADAPALENE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS MID ATLANTIC | **0.3%** | **A201000** | **001** | Oct 27, 2014 |
| **AB** | | GLENMARK GENERICS | **0.1%** | **A091314** | **001** | Jul 01, 2010 |
| **AB** | | PLIVA HRVATSKA DOO | **0.1%** | **A090962** | **001** | Jun 02, 2010 |
| **AB** | | TARO | **0.3%** | **A208322** | **001** | Jun 23, 2016 |
| **AB** | | TOLMAR | **0.3%** | **A200298** | **001** | Jun 14, 2012 |

**DIFFERIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | GALDERMA LABS LP | **0.3%** | **N021753** | **001** | Jun 19, 2007 |

LOTION;TOPICAL

DIFFERIN

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | GALDERMA LABS LP | 0.1% | N022502 | 001 | Mar 17, 2010 |

SOLUTION;TOPICAL

**ADAPALENE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | CALL INC | **0.1%** | **A203981** | **001** | Sep 23, 2016 |
| **AB** | **!** | | **0.1%** | **A204593** | **001** | Jan 05, 2016 |

ADAPALENE; BENZOYL PEROXIDE

GEL;TOPICAL

**ADAPALENE AND BENZOYL PEROXIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS MID ATLANTIC | **0.1%;2.5%** | **A203790** | **001** | Sep 30, 2015 |

**EPIDUO**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | GALDERMA LABS LP | **0.1%;2.5%** | **N022320** | **001** | Dec 08, 2008 |

EPIDUO FORTE

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | GALDERMA LABS | 0.3%;2.5% | N207917 | 001 | Jul 15, 2015 |

ADEFOVIR DIPIVOXIL

TABLET;ORAL

**ADEFOVIR DIPIVOXIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | SIGMAPHARM LABS LLC | **10MG** | **A202051** | **001** | Aug 29, 2013 |

**HEPSERA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | GILEAD | **10MG** | **N021449** | **001** | Sep 20, 2002 |

ADENOSINE

INJECTABLE;INJECTION

**ADENOCARD**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | ASTELLAS | **3MG/ML** | **N019937** | **002** | Oct 30, 1989 |

**ADENOSINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AKORN | **3MG/ML** | **A078076** | **001** | Oct 31, 2008 |
| **AP** | | FRESENIUS KABI USA | **3MG/ML** | **A077133** | **001** | Apr 27, 2005 |
| **AP** | | GLAND PHARMA LTD | **3MG/ML** | **A077283** | **001** | Jun 14, 2007 |
| **AP** | | LUITPOLD | **3MG/ML** | **A090010** | **001** | Apr 28, 2009 |
| **AP** | | MYLAN LABS LTD | **3MG/ML** | **A078640** | **001** | Mar 21, 2014 |
| **AP** | | | **3MG/ML** | **A078686** | **001** | May 13, 2009 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| ADENOSINE | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| **ADENOSINE** | | | | | | | |
| **AP** | | WEST-WARD PHARMS INT | **3MG/ML** | **A076404** | **001** | Jun 16, 2004 |
| **AP** | | | **3MG/ML** | **A076500** | **001** | Jun 16, 2004 |
| SOLUTION;IV (INFUSION) | | | | | | | |
| **ADENOSINE** | | | | | | | |
| **AP** | | AKORN | **60MG/20ML (3MG/ML)** | **A090450** | **001** | Oct 02, 2014 |
| **AP** | | | **90MG/30ML (3MG/ML)** | **A090450** | **002** | Oct 02, 2014 |
| **AP** | | AUROBINDO PHARMA LTD | **60MG/20ML (3MG/ML)** | **A205331** | **001** | Nov 02, 2017 |
| **AP** | | | **90MG/30ML (3MG/ML)** | **A205331** | **002** | Nov 02, 2017 |
| **AP** | | EMCURE PHARMS LTD | **60MG/20ML (3MG/ML)** | **A202313** | **001** | Sep 15, 2014 |
| **AP** | | | **90MG/30ML (3MG/ML)** | **A202313** | **002** | Sep 15, 2014 |
| **AP** | | FRESENIUS KABI USA | **60MG/20ML (3MG/ML)** | **A077897** | **001** | Nov 27, 2017 |
| **AP** | | | **90MG/30ML (3MG/ML)** | **A077897** | **002** | Nov 27, 2017 |
| **AP** | | HOSPIRA INC | **60MG/20ML (3MG/ML)** | **A203883** | **001** | Mar 24, 2014 |
| **AP** | | | **90MG/30ML (3MG/ML)** | **A203883** | **002** | Mar 24, 2014 |
| **AP** | | SAGENT STRIDES | **60MG/20ML (3MG/ML)** | **A090212** | **001** | Mar 28, 2014 |
| **AP** | | | **90MG/30ML (3MG/ML)** | **A090212** | **002** | Mar 28, 2014 |
| **AP** | **!** | TEVA PHARMS USA | **60MG/20ML (3MG/ML)** | **A077425** | **001** | Aug 29, 2013 |
| **AP** | **!** | | **90MG/30ML (3MG/ML)** | **A077425** | **002** | Aug 29, 2013 |
| AFATINIB DIMALEATE | | | | | | | |
| TABLET;ORAL | | | | | | | |
| GILOTRIF | | | | | | | |
| | + | BOEHRINGER INGELHEIM | EQ 20MG BASE | N201292 | 001 | Jul 12, 2013 |
| | + | | EQ 30MG BASE | N201292 | 002 | Jul 12, 2013 |
| | +! | | EQ 40MG BASE | N201292 | 003 | Jul 12, 2013 |
| ALBENDAZOLE | | | | | | | |
| TABLET;ORAL | | | | | | | |
| ALBENZA | | | | | | | |
| | +! | IMPAX LABS INC | 200MG | N020666 | 001 | Jun 11, 1996 |
| ALBUMIN HUMAN | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| OPTISON | | | | | | | |
| | +! | GE HEALTHCARE | 10MG/ML | N020899 | 001 | Dec 31, 1997 |
| ALBUMIN IODINATED I-125 SERUM | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| JEANATOPE | | | | | | | |
| | + | ISO TEX | 100uCi/10ML (10uCi/ML) | N017836 | 003 | Jun 08, 2004 |
| | + | | 500uCi/0.5ML | N017836 | 001 | |
| | +! | | 1,000uCi/ML | N017836 | 002 | |
| ALBUMIN IODINATED I-131 SERUM | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| MEGATOPE | | | | | | | |
| | +! | ISO TEX | 0.5mCi/VIAL | N017837 | 001 | |
| | +! | | 1mCi/VIAL | N017837 | 002 | |
| ALBUTEROL SULFATE | | | | | | | |
| AEROSOL, METERED;INHALATION | | | | | | | |
| PROAIR HFA | | | | | | | |
| BX | +! | TEVA BRANDED PHARM | EQ 0.09MG BASE/INH | N021457 | 001 | Oct 29, 2004 |
| PROVENTIL-HFA | | | | | | | |
| BX | +! | 3M DRUG DELIVERY | EQ 0.09MG BASE/INH | N020503 | 001 | Aug 15, 1996 |
| VENTOLIN HFA | | | | | | | |
| BX | +! | GLAXOSMITHKLINE | EQ 0.09MG BASE/INH | N020983 | 001 | Apr 19, 2001 |
| POWDER, METERED;INHALATION | | | | | | | |
| PROAIR RESPICLICK | | | | | | | |
| | +! | TEVA BRANDED PHARM | EQ 0.090MG BASE/INH | N205636 | 001 | Mar 31, 2015 |
| SOLUTION;INHALATION | | | | | | | |
| **ACCUNEB** | | | | | | | |
| **AN** | **+!** | MYLAN SPECIALITY LP | **EQ 0.021% BASE** | **N020949** | **002** | Apr 30, 2001 |
| **AN** | **+!** | | **EQ 0.042% BASE** | **N020949** | **001** | Apr 30, 2001 |
| **ALBUTEROL SULFATE** | | | | | | | |
| **AN** | | AUROBINDO PHARMA LTD | **EQ 0.083% BASE** | **A206224** | **001** | Oct 17, 2017 |
| **AN** | **!** | BAUSCH AND LOMB | **EQ 0.5% BASE** | **A075050** | **001** | Jun 18, 1998 |
| **AN** | | HI TECH PHARMA | **EQ 0.5% BASE** | **A074543** | **001** | Jan 15, 1998 |
| **AN** | | NEPHRON | **EQ 0.021% BASE** | **A076355** | **002** | Mar 31, 2010 |

ALBUTEROL SULFATE

SOLUTION;INHALATION

**ALBUTEROL SULFATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AN** | | | **EQ 0.042% BASE** | **A076355** | **001** | Jun 28, 2004 |
| **AN** | ! | | **EQ 0.083% BASE** | **A074880** | **001** | Sep 17, 1997 |
| **AN** | | | **EQ 0.5% BASE** | **A075664** | **001** | Jun 26, 2001 |
| **AN** | | RITEDOSE CORP | **EQ 0.083% BASE** | **A077839** | **001** | Dec 16, 2008 |
| **AN** | | SUN PHARMA GLOBAL | **EQ 0.083% BASE** | **A207857** | **001** | Jul 21, 2017 |
| **AN** | | WATSON LABS | **EQ 0.021% BASE** | **A077772** | **001** | Sep 25, 2007 |
| **AN** | | | **EQ 0.042% BASE** | **A077772** | **002** | Sep 25, 2007 |

SYRUP;ORAL

**ALBUTEROL SULFATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | AMNEAL PHARMS | **EQ 2MG BASE/5ML** | **A079241** | **001** | May 12, 2010 |
| **AA** | | G AND W LABS INC | **EQ 2MG BASE/5ML** | **A074454** | **001** | Sep 25, 1995 |
| **AA** | | HI TECH PHARMA | **EQ 2MG BASE/5ML** | **A074749** | **001** | Jan 30, 1998 |
| **AA** | ! | TEVA | **EQ 2MG BASE/5ML** | **A073419** | **001** | Mar 30, 1992 |
| **AA** | | VINTAGE | **EQ 2MG BASE/5ML** | **A078105** | **001** | Dec 27, 2006 |
| **AA** | | VISTAPHARM | **EQ 2MG BASE/5ML** | **A077788** | **001** | Jun 26, 2007 |

TABLET;ORAL

**ALBUTEROL SULFATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | MYLAN | **EQ 2MG BASE** | **A072894** | **002** | Jan 17, 1991 |
| **AB** | ! | | **EQ 4MG BASE** | **A072894** | **001** | Jan 17, 1991 |
| **AB** | | SUN PHARM INDUSTRIES | **EQ 2MG BASE** | **A072637** | **002** | Dec 05, 1989 |
| **AB** | | | **EQ 4MG BASE** | **A072637** | **001** | Dec 05, 1989 |

TABLET, EXTENDED RELEASE;ORAL

**ALBUTEROL SULFATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | MYLAN | **EQ 4MG BASE** | **A078092** | **002** | Jan 29, 2007 |
| **AB** | | | **EQ 8MG BASE** | **A078092** | **001** | Jan 29, 2007 |

**VOSPIRE ER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | DAVA PHARMS INC | **EQ 4MG BASE** | **A076130** | **002** | Sep 26, 2002 |
| **AB** | ! | | **EQ 8MG BASE** | **A076130** | **003** | Sep 26, 2002 |

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION;INHALATION

**ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AN** | | CIPLA LTD | **EQ 0.083% BASE;0.017%** | **A077559** | **001** | Dec 31, 2007 |
| **AN** | | NEPHRON | **EQ 0.083% BASE;0.017%** | **A076749** | **001** | Dec 31, 2007 |
| **AN** | | RITEDOSE CORP | **EQ 0.083% BASE;0.017%** | **A202496** | **001** | Oct 01, 2012 |
| **AN** | | SUN PHARMA GLOBAL | **EQ 0.083% BASE;0.017%** | **A207875** | **001** | Aug 07, 2017 |
| **AN** | | TEVA PHARMS | **EQ 0.083% BASE;0.017%** | **A076724** | **001** | Dec 31, 2007 |
| **AN** | | WATSON LABS TEVA | **EQ 0.083% BASE;0.017%** | **A077063** | **001** | Dec 31, 2007 |

SPRAY, METERED;INHALATION

COMBIVENT RESPIMAT

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | BOEHRINGER INGELHEIM | EQ 0.1MG BASE/INH;0.02MG/INH | N021747 | 001 | Oct 07, 2011 |

ALCAFTADINE

SOLUTION/DROPS;OPHTHALMIC

LASTACAFT

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ALLERGAN | 0.25% | N022134 | 001 | Jul 28, 2010 |

ALCLOMETASONE DIPROPIONATE

CREAM;TOPICAL

**ALCLOMETASONE DIPROPIONATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | ! | FOUGERA PHARMS | **0.05%** | **A076973** | **001** | Jul 12, 2005 |
| **AB** | | GLENMARK GENERICS | **0.05%** | **A079061** | **001** | Jun 23, 2009 |
| **AB** | | TARO | **0.05%** | **A076587** | **001** | Sep 15, 2005 |

OINTMENT;TOPICAL

**ALCLOMETASONE DIPROPIONATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | ! | FOUGERA PHARMS | **0.05%** | **A076884** | **001** | Jul 18, 2005 |
| **AB** | | GLENMARK GENERICS | **0.05%** | **A079227** | **001** | Jul 30, 2009 |
| **AB** | | TARO | **0.05%** | **A076730** | **001** | Jul 29, 2004 |

ALECTINIB HYDROCHLORIDE

CAPSULE;ORAL

ALECENSA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | HOFFMANN-LA ROCHE | EQ 150MG BASE | N208434 | 001 | Dec 11, 2015 |

| | | | | | | |
|---|---|---|---|---|---|---|
| ALENDRONATE SODIUM | | | | | | |
| SOLUTION;ORAL | | | | | | |
| ALENDRONATE SODIUM | | | | | | |
| | ! | WEST-WARD PHARMS INT | EQ 70MG BASE/75ML | A090520 | 001 | Feb 25, 2013 |
| TABLET;ORAL | | | | | | |
| **ALENDRONATE SODIUM** | | | | | | |
| **AB** | | APOTEX | **EQ 5MG BASE** | **A077982** | **001** | Aug 04, 2008 |
| **AB** | | | **EQ 10MG BASE** | **A077982** | **002** | Aug 04, 2008 |
| **AB** | | | **EQ 35MG BASE** | **A077982** | **003** | Aug 04, 2008 |
| **AB** | | | **EQ 70MG BASE** | **A077982** | **004** | Aug 04, 2008 |
| **AB** | | AUROBINDO PHARMA | **EQ 10MG BASE** | **A090124** | **001** | Aug 04, 2008 |
| **AB** | | | **EQ 35MG BASE** | **A090124** | **002** | Aug 04, 2008 |
| **AB** | | | **EQ 70MG BASE** | **A090124** | **003** | Aug 04, 2008 |
| **AB** | | AUSTARPHARMA LLC | **EQ 5MG BASE** | **A090258** | **001** | Sep 24, 2009 |
| **AB** | | | **EQ 10MG BASE** | **A090258** | **002** | Sep 24, 2009 |
| **AB** | | | **EQ 35MG BASE** | **A090258** | **003** | Sep 24, 2009 |
| **AB** | | | **EQ 70MG BASE** | **A090258** | **004** | Sep 24, 2009 |
| **AB** | | CIPLA LTD | **EQ 5MG BASE** | **A076768** | **001** | Aug 04, 2008 |
| **AB** | | | **EQ 10MG BASE** | **A076768** | **002** | Aug 04, 2008 |
| **AB** | | | **EQ 35MG BASE** | **A076768** | **003** | Aug 04, 2008 |
| **AB** | | | **EQ 40MG BASE** | **A076768** | **004** | Aug 04, 2008 |
| **AB** | | | **EQ 70MG BASE** | **A076768** | **005** | Aug 04, 2008 |
| **AB** | | DR REDDYS LABS LTD | **EQ 5MG BASE** | **A079049** | **003** | Aug 04, 2008 |
| **AB** | | | **EQ 10MG BASE** | **A079049** | **004** | Aug 04, 2008 |
| **AB** | | | **EQ 35MG BASE** | **A079049** | **001** | Aug 04, 2008 |
| **AB** | | | **EQ 70MG BASE** | **A079049** | **002** | Aug 04, 2008 |
| **AB** | | IMPAX LABS INC | **EQ 5MG BASE** | **A075710** | **001** | Feb 06, 2008 |
| **AB** | | | **EQ 10MG BASE** | **A075710** | **002** | Feb 06, 2008 |
| **AB** | | | **EQ 35MG BASE** | **A075710** | **003** | Feb 06, 2008 |
| **AB** | | | **EQ 40MG BASE** | **A075710** | **004** | Feb 06, 2008 |
| **AB** | | | **EQ 70MG BASE** | **A075710** | **005** | Feb 06, 2008 |
| **AB** | | JUBILANT CADISTA | **EQ 5MG BASE** | **A090557** | **001** | Feb 18, 2010 |
| **AB** | | | **EQ 10MG BASE** | **A090557** | **002** | Feb 18, 2010 |
| **AB** | | | **EQ 35MG BASE** | **A090557** | **003** | Feb 18, 2010 |
| **AB** | | | **EQ 70MG BASE** | **A090557** | **004** | Feb 18, 2010 |
| **AB** | | MYLAN | **EQ 5MG BASE** | **A076584** | **001** | Aug 04, 2008 |
| **AB** | | | **EQ 10MG BASE** | **A076584** | **002** | Aug 04, 2008 |
| **AB** | | | **EQ 35MG BASE** | **A076584** | **003** | Aug 04, 2008 |
| **AB** | | | **EQ 70MG BASE** | **A076584** | **004** | Aug 04, 2008 |
| **AB** | | SUN PHARMA GLOBAL | **EQ 5MG BASE** | **A090022** | **001** | Sep 10, 2008 |
| **AB** | | | **EQ 10MG BASE** | **A090022** | **002** | Sep 10, 2008 |
| **AB** | | | **EQ 35MG BASE** | **A090022** | **003** | Sep 10, 2008 |
| **AB** | | | **EQ 70MG BASE** | **A090022** | **004** | Sep 10, 2008 |
| **AB** | | WATSON LABS | **EQ 35MG BASE** | **A076984** | **001** | Aug 04, 2008 |
| **AB** | | | **EQ 40MG BASE** | **A076984** | **002** | Aug 04, 2008 |
| **AB** | | | **EQ 70MG BASE** | **A076984** | **003** | Aug 04, 2008 |
| **FOSAMAX** | | | | | | |
| **AB** | **+!** | MERCK AND CO INC | **EQ 70MG BASE** | **N020560** | **005** | Oct 20, 2000 |
| TABLET, EFFERVESCENT;ORAL | | | | | | |
| BINOSTO | | | | | | |
| | +! | MISSION PHARMA | EQ 70MG BASE | N202344 | 001 | Mar 12, 2012 |
| ALENDRONATE SODIUM; CHOLECALCIFEROL | | | | | | |
| TABLET;ORAL | | | | | | |
| FOSAMAX PLUS D | | | | | | |
| | + | MERCK | EQ 70MG BASE;2,800 IU | N021762 | 001 | Apr 07, 2005 |
| | +! | | EQ 70MG BASE;5,600 IU | N021762 | 002 | Apr 26, 2007 |
| ALFENTANIL HYDROCHLORIDE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| **ALFENTA** | | | | | | |
| **AP** | **+!** | AKORN | **EQ 0.5MG BASE/ML** | **N019353** | **001** | Dec 29, 1986 |
| **ALFENTANIL** | | | | | | |
| **AP** | | HOSPIRA | **EQ 0.5MG BASE/ML** | **A075221** | **001** | Oct 28, 1999 |
| ALFUZOSIN HYDROCHLORIDE | | | | | | |
| TABLET, EXTENDED RELEASE;ORAL | | | | | | |
| **ALFUZOSIN HYDROCHLORIDE** | | | | | | |
| **AB** | | APOTEX INC | **10MG** | **A079013** | **001** | Jul 18, 2011 |
| **AB** | | AUROBINDO PHARMA LTD | **10MG** | **A079060** | **001** | Aug 30, 2012 |
| **AB** | | INVAGEN PHARMS | **10MG** | **A090284** | **001** | Jan 17, 2012 |
| **AB** | | MYLAN | **10MG** | **A079014** | **001** | Jul 18, 2011 |

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

**ALFUZOSIN HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | SUN PHARMA GLOBAL | **10MG** | **A079057** | **001** | Jul 18, 2011 |
| **AB** | | TEVA PHARMS | **10MG** | **A079056** | **001** | Jul 18, 2011 |
| **AB** | | TORRENT PHARMS | **10MG** | **A079054** | **001** | Jul 18, 2011 |
| **AB** | | UNICHEM LABS LTD | **10MG** | **A203192** | **001** | Jan 28, 2016 |

**UROXATRAL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | CONCORDIA PHARMS INC | **10MG** | **N021287** | **001** | Jun 12, 2003 |

ALISKIREN HEMIFUMARATE

CAPSULE, PELLET;ORAL

TEKTURNA

| | | | | | |
|---|---|---|---|---|---|
| | +! | NODEN PHARMA | EQ 37.5MG BASE | N210709 | 001 | Nov 14, 2017 |

TABLET;ORAL

TEKTURNA

| | | | | | |
|---|---|---|---|---|---|
| | + | NODEN PHARMA | EQ 150MG BASE | N021985 | 001 | Mar 05, 2007 |
| | +! | | EQ 300MG BASE | N021985 | 002 | Mar 05, 2007 |

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

TEKTURNA HCT

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | NODEN PHARMA | EQ 150MG BASE;12.5MG | N022107 | 001 | Jan 18, 2008 |
| | + | | EQ 150MG BASE;25MG | N022107 | 002 | Jan 18, 2008 |
| | +! | | EQ 300MG BASE;12.5MG | N022107 | 003 | Jan 18, 2008 |
| | +! | | EQ 300MG BASE;25MG | N022107 | 004 | Jan 18, 2008 |

ALITRETINOIN

GEL;TOPICAL

PANRETIN

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | EISAI INC | EQ 0.1% BASE | N020886 | 001 | Feb 02, 1999 |

ALLOPURINOL

TABLET;ORAL

**ALLOPURINOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACCORD HLTHCARE | **100MG** | **A203154** | **001** | May 06, 2013 |
| **AB** | | | **300MG** | **A203154** | **002** | May 06, 2013 |
| **AB** | | APOTEX INC | **100MG** | **A077353** | **001** | Sep 08, 2005 |
| **AB** | | | **300MG** | **A077353** | **002** | Sep 08, 2005 |
| **AB** | | INDOCO REMEDIES | **100MG** | **A204467** | **001** | Jul 28, 2016 |
| **AB** | | | **300MG** | **A204467** | **002** | Jul 28, 2016 |
| **AB** | | IPCA LABS LTD | **100MG** | **A090637** | **001** | Mar 16, 2011 |
| **AB** | | | **300MG** | **A090637** | **002** | Mar 16, 2011 |
| **AB** | | MYLAN | **100MG** | **A018659** | **001** | Oct 24, 1986 |
| **AB** | | | **300MG** | **A018659** | **002** | Oct 24, 1986 |
| **AB** | | NORTHSTAR HLTHCARE | **100MG** | **A078253** | **001** | Sep 11, 2007 |
| **AB** | | | **300MG** | **A078253** | **002** | Sep 11, 2007 |
| **AB** | | SUN PHARM INDS INC | **100MG** | **A078390** | **001** | Aug 30, 2007 |
| **AB** | | | **300MG** | **A078390** | **002** | Aug 30, 2007 |
| **AB** | | SUN PHARM INDUSTRIES | **100MG** | **A071450** | **002** | Jan 09, 1987 |
| **AB** | | | **300MG** | **A071450** | **001** | Jan 09, 1987 |
| **AB** | | VINTAGE PHARMS | **100MG** | **A075798** | **001** | Jun 27, 2003 |
| **AB** | | | **300MG** | **A075798** | **002** | Jun 27, 2003 |
| **AB** | | WATSON LABS | **100MG** | **N018832** | **002** | Sep 28, 1984 |
| **AB** | | | **300MG** | **N018877** | **001** | Sep 28, 1984 |
| **AB** | | ZYDUS PHARMS USA INC | **100MG** | **A210117** | **001** | Oct 12, 2017 |
| **AB** | | | **300MG** | **A210117** | **002** | Oct 12, 2017 |

**LOPURIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | DR REDDYS LA | **100MG** | **A071586** | **001** | Apr 02, 1987 |
| **AB** | | | **300MG** | **A071587** | **001** | Apr 02, 1987 |

**ZYLOPRIM**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | **+** | CASPER PHARMA LLC | **100MG** | **N016084** | **001** |
| **AB** | **+!** | | **300MG** | **N016084** | **002** |

ALLOPURINOL SODIUM

INJECTABLE;INJECTION

**ALLOPURINOL SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | WEST-WARD PHARMS INT | **EQ 500MG BASE/VIAL** | **A076870** | **001** | Aug 26, 2004 |

**ALOPRIM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | MYLAN INSTITUTIONAL | **EQ 500MG BASE/VIAL** | **N020298** | **001** | May 17, 1996 |

ALLOPURINOL; LESINURAD

| | | | | | | |
|---|---|---|---|---|---|---|
| TABLET;ORAL | | | | | | |
| DUZALLO | | | | | | |
| | + | IRONWOOD PHARMS INC | 200MG;200MG | N209203 | 001 | Aug 18, 2017 |
| | +! | | 300MG;200MG | N209203 | 002 | Aug 18, 2017 |

ALMOTRIPTAN MALATE

| | | | | | | |
|---|---|---|---|---|---|---|
| TABLET;ORAL | | | | | | |
| **ALMOTRIPTAN MALATE** | | | | | | |
| **AB** | | AJANTA PHARMA LTD | **EQ 6.25MG BASE** | **A205523** | **001** | Mar 03, 2016 |
| **AB** | | | **EQ 12.5MG BASE** | **A205523** | **002** | Mar 03, 2016 |
| **AB** | | MYLAN PHARMS INC | **EQ 6.25MG BASE** | **A205171** | **001** | Nov 09, 2015 |
| **AB** | | | **EQ 12.5MG BASE** | **A205171** | **002** | Nov 09, 2015 |
| **AB** | | TEVA PHARMS USA | **EQ 6.25MG BASE** | **A078027** | **001** | Jul 07, 2015 |
| **AB** | | | **EQ 12.5MG BASE** | **A078027** | **002** | Jul 07, 2015 |
| **AXERT** | | | | | | |
| **AB** | **+** | JANSSEN PHARMS | **EQ 6.25MG BASE** | **N021001** | **001** | May 07, 2001 |
| **AB** | **+!** | | **EQ 12.5MG BASE** | **N021001** | **002** | May 07, 2001 |

ALOGLIPTIN BENZOATE

| | | | | | | |
|---|---|---|---|---|---|---|
| TABLET;ORAL | | | | | | |
| NESINA | | | | | | |
| | + | TAKEDA PHARMS USA | EQ 6.25MG BASE | N022271 | 001 | Jan 25, 2013 |
| | + | | EQ 12.5MG BASE | N022271 | 002 | Jan 25, 2013 |
| | +! | | EQ 25MG BASE | N022271 | 003 | Jan 25, 2013 |

ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE

| | | | | | | |
|---|---|---|---|---|---|---|
| TABLET;ORAL | | | | | | |
| KAZANO | | | | | | |
| | + | TAKEDA PHARMS USA | EQ 12.5MG BASE;500MG | N203414 | 001 | Jan 25, 2013 |
| | +! | | EQ 12.5MG BASE;1GM | N203414 | 002 | Jan 25, 2013 |

ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE

| | | | | | | |
|---|---|---|---|---|---|---|
| TABLET;ORAL | | | | | | |
| OSENI | | | | | | |
| | + | TAKEDA PHARMS USA | EQ 12.5MG BASE;EQ 15MG BASE | N022426 | 004 | Jan 25, 2013 |
| | + | | EQ 12.5MG BASE;EQ 30MG BASE | N022426 | 005 | Jan 25, 2013 |
| | + | | EQ 12.5MG BASE;EQ 45MG BASE | N022426 | 006 | Jan 25, 2013 |
| | + | | EQ 25MG BASE;EQ 15MG BASE | N022426 | 001 | Jan 25, 2013 |
| | + | | EQ 25MG BASE;EQ 30MG BASE | N022426 | 002 | Jan 25, 2013 |
| | +! | | EQ 25MG BASE;EQ 45MG BASE | N022426 | 003 | Jan 25, 2013 |

ALOSETRON HYDROCHLORIDE

| | | | | | | |
|---|---|---|---|---|---|---|
| TABLET;ORAL | | | | | | |
| **ALOSETRON HYDROCHLORIDE** | | | | | | |
| **AB** | | AMNEAL PHARMS | **EQ 0.5MG BASE** | **A206647** | **001** | Dec 22, 2016 |
| **AB** | | | **EQ 1MG BASE** | **A206647** | **002** | Dec 22, 2016 |
| **AB** | | WEST-WARD PHARMS INT | **EQ 0.5MG BASE** | **A200652** | **001** | May 04, 2015 |
| **AB** | | | **EQ 1MG BASE** | **A200652** | **002** | May 04, 2015 |
| **LOTRONEX** | | | | | | |
| **AB** | **+** | SEBELA IRELAND LTD | **EQ 0.5MG BASE** | **N021107** | **002** | Dec 23, 2003 |
| **AB** | **+!** | | **EQ 1MG BASE** | **N021107** | **001** | Feb 09, 2000 |

ALPHA-TOCOPHEROL ACETATE; ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN K

| | | | | | | |
|---|---|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | | | |
| INFUVITE ADULT | | | | | | |
| | +! | SANDOZ INC | 2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;0.03MG/ML | N021163 | 001 | May 18, 2000 |
| INJECTABLE;IV (INFUSION) | | | | | | |
| INFUVITE ADULT | | | | | | |
| | +! | SANDOZ INC | 2 IU/ML;40MG/ML;12MCG/ML;40 IU/ML;1MCG/ML;3MG/ML;120MCG/ML;8MG/ML;1.2MG/ML;0.72MG/ML;1.2MG/ML;660 IU/ML;30MCG/ML | N021559 | 001 | Jun 16, 2003 |

ALPRAZOLAM

| | | | | | | |
|---|---|---|---|---|---|---|
| CONCENTRATE;ORAL | | | | | | |
| ALPRAZOLAM | | | | | | |
| | ! | WEST-WARD PHARMS INT | 1MG/ML | A074312 | 001 | Oct 31, 1993 |

ALPRAZOLAM

TABLET;ORAL

**ALPRAZOLAM**

| | | | | | | |
|---|---|---|---|---|---|---|
| AB | | ACTAVIS ELIZABETH | 0.25MG | A074342 | 001 | Oct 31, 1993 |
| AB | | | 0.5MG | A074342 | 002 | Oct 31, 1993 |
| AB | | | 1MG | A074342 | 003 | Oct 31, 1993 |
| AB | | | 2MG | A074342 | 004 | Oct 31, 1993 |
| AB | | APOTEX INC | 0.25MG | A077741 | 001 | Jan 19, 2007 |
| AB | | | 0.5MG | A077741 | 002 | Jan 19, 2007 |
| AB | | | 1MG | A077741 | 003 | Jan 19, 2007 |
| AB | | | 2MG | A077741 | 004 | Jan 19, 2007 |
| AB | | AUROBINDO PHARMA LTD | 0.25MG | A203346 | 001 | Jul 31, 2015 |
| AB | | | 0.5MG | A203346 | 002 | Jul 31, 2015 |
| AB | | | 1MG | A203346 | 003 | Jul 31, 2015 |
| AB | | | 2MG | A203346 | 004 | Jul 31, 2015 |
| AB | | DAVA INTL INC | 0.25MG | A074174 | 001 | Oct 19, 1993 |
| AB | | | 0.5MG | A074174 | 002 | Oct 19, 1993 |
| AB | | | 1MG | A074174 | 003 | Oct 19, 1993 |
| AB | | | 2MG | A074174 | 004 | Oct 19, 1993 |
| AB | | MYLAN | 0.25MG | A074215 | 001 | Jan 27, 1994 |
| AB | | | 0.5MG | A074215 | 002 | Jan 27, 1994 |
| AB | | | 1MG | A074215 | 003 | Jan 27, 1994 |
| AB | | | 2MG | A074215 | 004 | Jan 27, 1994 |
| AB | | NATCO PHARMA LTD | 0.25MG | A200739 | 001 | Apr 15, 2015 |
| AB | | | 0.5MG | A200739 | 002 | Apr 15, 2015 |
| AB | | | 1MG | A200739 | 003 | Apr 15, 2015 |
| AB | | | 2MG | A200739 | 004 | Apr 15, 2015 |
| AB | | SANDOZ | 0.25MG | A074112 | 001 | Dec 29, 1995 |
| AB | | | 0.5MG | A074112 | 002 | Dec 29, 1995 |
| AB | | | 1MG | A074112 | 003 | Dec 29, 1995 |
| AB | | | 2MG | A074909 | 001 | Mar 25, 1998 |
| AB | | SUN PHARMA GLOBAL | 0.25MG | A090082 | 001 | Jun 17, 2010 |
| AB | | | 0.5MG | A090082 | 002 | Jun 17, 2010 |
| AB | | | 1MG | A090082 | 003 | Jun 17, 2010 |
| AB | | | 2MG | A090082 | 004 | Jun 17, 2010 |
| AB | | VINTAGE | 0.25MG | A078491 | 001 | Sep 25, 2008 |
| AB | | | 0.5MG | A078491 | 002 | Sep 25, 2008 |
| AB | | | 1MG | A078491 | 003 | Sep 25, 2008 |
| AB | | | 2MG | A078491 | 004 | Dec 12, 2008 |
| AB | | VINTAGE PHARMS | 0.25MG | A090248 | 001 | Sep 17, 2010 |
| AB | | | 0.5MG | A090248 | 002 | Sep 17, 2010 |
| AB | | | 1MG | A090248 | 003 | Sep 17, 2010 |
| AB | | | 2MG | A090248 | 004 | Sep 17, 2010 |

**XANAX**

| | | | | | | |
|---|---|---|---|---|---|---|
| AB | + | PHARMACIA AND UPJOHN | 0.25MG | N018276 | 001 | |
| AB | + | | 0.5MG | N018276 | 002 | |
| AB | +! | | 1MG | N018276 | 003 | |
| AB | + | | 2MG | N018276 | 004 | Nov 27, 1985 |

TABLET, EXTENDED RELEASE;ORAL

**ALPRAZOLAM**

| | | | | | | |
|---|---|---|---|---|---|---|
| AB | | ACTAVIS ELIZABETH | 0.5MG | A078056 | 001 | Feb 13, 2007 |
| AB | | | 1MG | A078056 | 002 | Feb 13, 2007 |
| AB | | | 2MG | A078056 | 003 | Feb 13, 2007 |
| AB | | | 3MG | A078056 | 004 | Feb 13, 2007 |
| AB | | AMNEAL PHARMS NY | 0.5MG | A078387 | 001 | May 30, 2008 |
| AB | | | 1MG | A078387 | 002 | May 30, 2008 |
| AB | | | 2MG | A078387 | 003 | May 30, 2008 |
| AB | | | 3MG | A078387 | 004 | May 30, 2008 |
| AB | | ANCHEN PHARMS | 0.5MG | A078469 | 001 | Sep 29, 2011 |
| AB | | | 1MG | A078469 | 002 | Sep 29, 2011 |
| AB | | | 2MG | A078469 | 003 | Sep 29, 2011 |
| AB | | | 3MG | A078469 | 004 | Sep 29, 2011 |
| AB | | ANI PHARMS INC | 0.5MG | A077725 | 001 | Jul 31, 2006 |
| AB | | | 1MG | A077725 | 002 | Jul 31, 2006 |
| AB | | | 2MG | A077725 | 004 | Jul 31, 2006 |
| AB | | | 3MG | A077725 | 003 | Jul 31, 2006 |
| AB | | APOTEX INC | 0.5MG | A078449 | 001 | Nov 12, 2008 |
| AB | | | 1MG | A078449 | 004 | Dec 23, 2015 |
| AB | | | 2MG | A078449 | 002 | Nov 12, 2008 |
| AB | | | 3MG | A078449 | 003 | Nov 12, 2008 |
| AB | | AUROBINDO PHARMA | 0.5MG | A090871 | 001 | Jun 07, 2011 |

| | | | | | | |
|---|---|---|---|---|---|---|
| ALPRAZOLAM | | | | | | |
| TABLET, EXTENDED RELEASE;ORAL | | | | | | |
| **ALPRAZOLAM** | | | | | | |
| | | LTD | | | | |
| **AB** | | | **1MG** | **A090871** | **002** | Jun 07, 2011 |
| **AB** | | | **2MG** | **A090871** | **003** | Jun 07, 2011 |
| **AB** | | | **3MG** | **A090871** | **004** | Jun 07, 2011 |
| **AB** | | HERITAGE PHARMS INC | **0.5MG** | **A078489** | **001** | Oct 17, 2008 |
| **AB** | | | **1MG** | **A078489** | **002** | Oct 17, 2008 |
| **AB** | | | **2MG** | **A078489** | **003** | Oct 17, 2008 |
| **AB** | | | **3MG** | **A078489** | **004** | Oct 17, 2008 |
| **XANAX XR** | | | | | | |
| **AB** | **+** | PHARMACIA AND UPJOHN | **0.5MG** | **N021434** | **001** | Jan 17, 2003 |
| **AB** | **+** | | **1MG** | **N021434** | **002** | Jan 17, 2003 |
| **AB** | **+** | | **2MG** | **N021434** | **003** | Jan 17, 2003 |
| **AB** | **+!** | | **3MG** | **N021434** | **004** | Jan 17, 2003 |
| TABLET, ORALLY DISINTEGRATING;ORAL | | | | | | |
| **ALPRAZOLAM** | | | | | | |
| **AB** | | ACTAVIS ELIZABETH | **0.25MG** | **A078561** | **001** | Mar 16, 2010 |
| **AB** | | | **0.5MG** | **A078561** | **002** | Mar 16, 2010 |
| **AB** | | | **1MG** | **A078561** | **003** | Mar 16, 2010 |
| **AB** | | | **2MG** | **A078561** | **004** | Mar 16, 2010 |
| **AB** | | PAR PHARM | **0.25MG** | **A078088** | **001** | Jan 09, 2009 |
| **AB** | | | **0.5MG** | **A078088** | **002** | Jan 09, 2009 |
| **AB** | **!** | | **1MG** | **A078088** | **003** | Jan 09, 2009 |
| **AB** | | | **2MG** | **A078088** | **004** | Jan 09, 2009 |
| ALPROSTADIL | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| **ALPROSTADIL** | | | | | | |
| **AP** | | TEVA PHARMS USA | **0.5MG/ML** | **A075196** | **001** | Apr 30, 1999 |
| **AP** | | WEST-WARD PHARMS INT | **0.5MG/ML** | **A074815** | **001** | Jan 20, 1998 |
| **CAVERJECT** | | | | | | |
| **AP** | **+** | PHARMACIA AND UPJOHN | **0.01MG/VIAL** | **N020379** | **001** | Jul 06, 1995 |
| **AP** | **+!** | | **0.02MG/VIAL** | **N020379** | **002** | Jul 06, 1995 |
| **AP** | **+!** | | **0.04MG/VIAL** | **N020379** | **004** | May 19, 1997 |
| **EDEX** | | | | | | |
| **AP** | **+** | AUXILIUM PHARMS LLC | **0.01MG/VIAL** | **N020649** | **002** | Jun 12, 1997 |
| **AP** | **+** | | **0.02MG/VIAL** | **N020649** | **003** | Jun 12, 1997 |
| **AP** | **+!** | | **0.04MG/VIAL** | **N020649** | **004** | Jun 12, 1997 |
| **PROSTIN VR PEDIATRIC** | | | | | | |
| **AP** | **+!** | PHARMACIA AND UPJOHN | **0.5MG/ML** | **N018484** | **001** | |
| CAVERJECT | | | | | | |
| | + | PHARMACIA AND UPJOHN | 0.005MG/VIAL | N020379 | 003 | Jun 27, 1996 |
| CAVERJECT IMPULSE | | | | | | |
| | | PHARMACIA AND UPJOHN | 0.01MG/VIAL | N021212 | 001 | Jun 11, 2002 |
| | | | 0.02MG/VIAL | N021212 | 002 | Jun 11, 2002 |
| EDEX | | | | | | |
| | +! | AUXILIUM PHARMS LLC | 0.01MG/VIAL | N020649 | 005 | Jul 30, 1998 |
| | +! | | 0.02MG/VIAL | N020649 | 006 | Jul 30, 1998 |
| | +! | | 0.04MG/VIAL | N020649 | 007 | Jul 30, 1998 |
| SUPPOSITORY;URETHRAL | | | | | | |
| MUSE | | | | | | |
| | +! | MYLAN SPECIALITY LP | 0.125MG | N020700 | 001 | Nov 19, 1996 |
| | +! | | 0.25MG | N020700 | 002 | Nov 19, 1996 |
| | +! | | 0.5MG | N020700 | 003 | Nov 19, 1996 |
| | +! | | 1MG | N020700 | 004 | Nov 19, 1996 |
| ALTRETAMINE | | | | | | |
| CAPSULE;ORAL | | | | | | |
| HEXALEN | | | | | | |
| | +! | EISAI INC | 50MG | N019926 | 001 | Dec 26, 1990 |

ALVIMOPAN

CAPSULE;ORAL

ENTEREG

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | CUBIST PHARMS | 12MG | N021775 | 001 | May 20, 2008 |

AMANTADINE HYDROCHLORIDE

CAPSULE;ORAL

**AMANTADINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALEMBIC PHARMS LTD | **100MG** | **A208966** | **001** | Jun 21, 2017 |
| **AB** | | BIONPHARMA INC | **100MG** | **A078720** | **001** | May 29, 2008 |
| **AB** | | HERITAGE PHARMA | **100MG** | **A209171** | **001** | Jun 12, 2017 |
| **AB** | | LANNETT HOLDINGS INC | **100MG** | **A209221** | **001** | Jun 15, 2017 |
| **AB** | | NEWGEN PHARMS LLC | **100MG** | **A207570** | **001** | Sep 30, 2016 |
| **AB** | ! | SANDOZ | **100MG** | **A071293** | **001** | Feb 18, 1987 |
| **AB** | | STRIDES PHARMA | **100MG** | **A209047** | **001** | Jun 07, 2017 |
| **AB** | | USL PHARMA | **100MG** | **A070589** | **001** | Aug 05, 1986 |
| **AB** | | WATSON LABS INC | **100MG** | **A208107** | **001** | Dec 06, 2016 |
| **AB** | | ZYDUS PHARMS USA INC | **100MG** | **A208278** | **001** | May 31, 2016 |

CAPSULE, EXTENDED RELEASE;ORAL

GOCOVRI

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | ADAMAS PHARMA | EQ 68.5MG BASE | N208944 | 001 | Aug 24, 2017 |
| | +! | | EQ 137MG BASE | N208944 | 002 | Aug 24, 2017 |

SYRUP;ORAL

**AMANTADINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | ! | CMP PHARMA INC | **50MG/5ML** | **A075819** | **001** | Sep 11, 2002 |
| **AA** | ! | HI TECH PHARMA | **50MG/5ML** | **A074170** | **001** | Oct 28, 1994 |
| **AA** | ! | MIKART | **50MG/5ML** | **A074028** | **001** | Jun 28, 1993 |
| **AA** | ! | PHARM ASSOC | **50MG/5ML** | **A074509** | **001** | Jul 17, 1995 |
| **AA** | ! | WOCKHARDT BIO AG | **50MG/5ML** | **A075060** | **001** | Dec 24, 1998 |

TABLET;ORAL

**AMANTADINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | NEWGEN PHARMS LLC | **100MG** | **A207571** | **001** | Jan 31, 2017 |
| **AB** | | STRIDES PHARMA | **100MG** | **A209035** | **001** | Jun 09, 2017 |
| **AB** | ! | USL PHARMA | **100MG** | **A076186** | **001** | Dec 16, 2002 |
| **AB** | | WATSON LABS INC | **100MG** | **A208096** | **001** | Dec 15, 2016 |

AMBRISENTAN

TABLET;ORAL

LETAIRIS

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | GILEAD | 5MG | N022081 | 001 | Jun 15, 2007 |
| | +! | | 10MG | N022081 | 002 | Jun 15, 2007 |

AMCINONIDE

CREAM;TOPICAL

**AMCINONIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | ! | FOUGERA PHARMS | **0.1%** | **A076065** | **001** | May 15, 2003 |
| **AB** | | TARO PHARM INDS | **0.1%** | **A076229** | **001** | May 31, 2002 |

LOTION;TOPICAL

AMCINONIDE

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | FOUGERA PHARMS | 0.1% | A076329 | 001 | Nov 06, 2002 |

OINTMENT;TOPICAL

**AMCINONIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | ! | FOUGERA PHARMS | **0.1%** | **A076096** | **001** | Nov 19, 2002 |
| **AB** | | TARO PHARM INDS | **0.1%** | **A076367** | **001** | Mar 19, 2003 |

AMIFOSTINE

INJECTABLE;INJECTION

**AMIFOSTINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | MYLAN LABS LTD | **500MG/VIAL** | **A204363** | **001** | Jul 17, 2017 |
| **AP** | | SUN PHARMA GLOBAL | **500MG/VIAL** | **A077126** | **001** | Mar 14, 2008 |

**ETHYOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | CLINIGEN HLTHCARE | **500MG/VIAL** | **N020221** | **001** | Dec 08, 1995 |

AMIKACIN SULFATE

INJECTABLE;INJECTION

**AMIKACIN SULFATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | ! | EMCURE PHARMS LTD | **EQ 250MG BASE/ML** | **A204040** | **001** | Dec 12, 2013 |
| **AP** | | FRESENIUS KABI USA | **EQ 50MG BASE/ML** | **A205605** | **001** | Dec 09, 2015 |
| **AP** | | | **EQ 250MG BASE/ML** | **A205604** | **001** | Dec 09, 2015 |
| **AP** | | SAGENT PHARMS | **EQ 250MG BASE/ML** | **A203323** | **001** | May 12, 2016 |
| **AP** | | TEVA PHARMS USA | **EQ 250MG BASE/ML** | **A064045** | **002** | Sep 28, 1993 |
| **AP** | ! | WEST-WARD PHARMS INT | **EQ 50MG BASE/ML** | **A063313** | **001** | Apr 11, 1994 |

| | | | | | | |
|---|---|---|---|---|---|---|
| AMIKACIN SULFATE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| **AMIKACIN SULFATE** | | | | | | |
| **AP** | | | **EQ 250MG BASE/ML** | **A063315** | **001** | Apr 11, 1994 |
| AMILORIDE HYDROCHLORIDE | | | | | | |
| TABLET;ORAL | | | | | | |
| **AMILORIDE HYDROCHLORIDE** | | | | | | |
| **AB** | **!** | PAR PHARM | **5MG** | **A070346** | **001** | Jan 22, 1986 |
| **AB** | | SIGMAPHARM LABS LLC | **5MG** | **A079133** | **001** | Jan 30, 2009 |
| **AB** | | WINDLAS HLTHCARE | **5MG** | **A204180** | **001** | Aug 07, 2015 |
| **MIDAMOR** | | | | | | |
| **AB** | **+** | PADDOCK LLC | **5MG** | **N018200** | **001** | |
| AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE | | | | | | |
| TABLET;ORAL | | | | | | |
| **AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE** | | | | | | |
| **AB** | | BARR | **EQ 5MG ANHYDROUS;50MG** | **A071111** | **001** | May 10, 1988 |
| **AB** | **!** | MYLAN | **EQ 5MG ANHYDROUS;50MG** | **A073209** | **001** | Oct 31, 1991 |
| AMINO ACIDS | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| AMINO ACIDS | | | | | | |
| | | B BRAUN | 15%(150GM/1000ML) | A091112 | 001 | Apr 13, 2012 |
| | | | 15%(300GM/2000ML) | A091112 | 002 | Apr 13, 2012 |
| AMINOSYN 10% | | | | | | |
| | | ICU MEDICAL INC | 10% (10GM/100ML) | N017673 | 003 | |
| AMINOSYN 10% (PH6) | | | | | | |
| | | ICU MEDICAL INC | 10% (10GM/100ML) | N017673 | 008 | Nov 18, 1985 |
| AMINOSYN 3.5% | | | | | | |
| | | ICU MEDICAL INC | 3.5% (3.5GM/100ML) | N017789 | 004 | |
| AMINOSYN 5% | | | | | | |
| | | ICU MEDICAL INC | 5% (5GM/100ML) | N017673 | 001 | |
| AMINOSYN 7% | | | | | | |
| | | ICU MEDICAL INC | 7% (7GM/100ML) | N017673 | 002 | |
| AMINOSYN 7% (PH6) | | | | | | |
| | | ICU MEDICAL INC | 7% (7GM/100ML) | N017673 | 006 | Nov 18, 1985 |
| AMINOSYN 8.5% | | | | | | |
| | | ICU MEDICAL INC | 8.5% (8.5GM/100ML) | N017673 | 004 | |
| AMINOSYN 8.5% (PH6) | | | | | | |
| | | ICU MEDICAL INC | 8.5% (8.5GM/100ML) | N017673 | 007 | Nov 18, 1985 |
| AMINOSYN II 10% | | | | | | |
| | | ICU MEDICAL INC | 10% (10GM/100ML) | N019438 | 005 | Apr 03, 1986 |
| AMINOSYN II 10% IN PLASTIC CONTAINER | | | | | | |
| | | ICU MEDICAL INC | 10% (10GM/100ML) | N020015 | 001 | Dec 19, 1991 |
| AMINOSYN II 15% IN PLASTIC CONTAINER | | | | | | |
| | | ICU MEDICAL INC | 15% (15GM/100ML) | N020041 | 001 | Dec 19, 1991 |
| AMINOSYN II 7% | | | | | | |
| | | ICU MEDICAL INC | 7% (7GM/100ML) | N019438 | 003 | Apr 03, 1986 |
| AMINOSYN II 8.5% | | | | | | |
| | | ICU MEDICAL INC | 8.5% (8.5GM/100ML) | N019438 | 004 | Apr 03, 1986 |
| AMINOSYN-HBC 7% | | | | | | |
| | | ICU MEDICAL INC | 7% (7GM/100ML) | N019374 | 001 | Jul 12, 1985 |
| AMINOSYN-HF 8% | | | | | | |
| | | ICU MEDICAL INC | 8% (8GM/100ML) | A020345 | 001 | Apr 04, 1996 |
| AMINOSYN-PF 10% | | | | | | |
| | | ICU MEDICAL INC | 10% (10GM/100ML) | N019492 | 002 | Oct 17, 1986 |
| AMINOSYN-PF 7% | | | | | | |
| | | ICU MEDICAL INC | 7% (7GM/100ML) | N019398 | 001 | Sep 06, 1985 |
| AMINOSYN-RF 5.2% | | | | | | |
| | | ICU MEDICAL INC | 5.2% (5.2GM/100ML) | N018429 | 001 | |
| CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER | | | | | | |
| | | BAXTER HLTHCARE | 15% (15GM/100ML) | A020512 | 001 | Aug 30, 1996 |
| FREAMINE HBC 6.9% | | | | | | |
| | | B BRAUN | 6.9% (6.9GM/100ML) | N016822 | 006 | May 17, 1983 |
| FREAMINE III 10% | | | | | | |
| | | B BRAUN | 10% (10GM/100ML) | N016822 | 005 | |
| FREAMINE III 8.5% | | | | | | |
| | | B BRAUN | 8.5% (8.5GM/100ML) | N016822 | 004 | |
| HEPATAMINE 8% | | | | | | |
| | | B BRAUN | 8% (8GM/100ML) | N018676 | 001 | Aug 03, 1982 |
| NEPHRAMINE 5.4% | | | | | | |
| | | B BRAUN | 5.4% (5.4GM/100ML) | N017766 | 001 | |

AMINO ACIDS

INJECTABLE;INJECTION

| | | | | | |
|---|---|---|---|---|---|
| PREMASOL 10% IN PLASTIC CONTAINER | | | | | |
| | BAXTER HLTHCARE | 10% (10GM/100ML) | A075880 | 002 | Jun 19, 2003 |
| PREMASOL 6% IN PLASTIC CONTAINER | | | | | |
| | BAXTER HLTHCARE | 6% (6GM/100ML) | A075880 | 001 | Jun 19, 2003 |
| PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER | | | | | |
| +! | BAXTER HLTHCARE | 20% (20GM/100ML) | N020849 | 001 | Aug 26, 1998 |
| TRAVASOL 10% IN PLASTIC CONTAINER | | | | | |
| | BAXTER HLTHCARE | 10% (10MG/100ML) | N018931 | 003 | Aug 23, 1984 |
| TRAVASOL 5.5% IN PLASTIC CONTAINER | | | | | |
| | BAXTER HLTHCARE | 5.5% (5.5GM/100ML) | N018931 | 001 | Aug 23, 1984 |
| TRAVASOL 8.5% IN PLASTIC CONTAINER | | | | | |
| | BAXTER HLTHCARE | 8.5% (8.5GM/100ML) | N018931 | 002 | Aug 23, 1984 |
| TROPHAMINE | | | | | |
| +! | B BRAUN | 6% (6GM/100ML) | N019018 | 001 | Jul 20, 1984 |
| TROPHAMINE 10% | | | | | |
| +! | B BRAUN | 10% (10GM/100ML) | N019018 | 003 | Sep 07, 1988 |

AMINO ACIDS; CALCIUM ACETATE; GLYCERIN; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

| | | | | | |
|---|---|---|---|---|---|
| PROCALAMINE | | | | | |
| | B BRAUN | 3%;26MG/100ML;3GM/100ML;54MG/100ML;41MG/100ML;150MG/100ML;200MG/100ML;120MG/100ML | N018582 | 001 | May 08, 1982 |

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

| | | | | | |
|---|---|---|---|---|---|
| CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER | | | | | |
| +! | BAXTER HLTHCARE | 2.75%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML | N020678 | 002 | Mar 26, 1997 |
| CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER | | | | | |
| +! | BAXTER HLTHCARE | 2.75%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML | N020678 | 005 | Mar 26, 1997 |
| CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER | | | | | |
| +! | BAXTER HLTHCARE | 2.75%;33MG/100ML;5GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML | N020678 | 001 | Mar 26, 1997 |
| CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER | | | | | |
| +! | BAXTER HLTHCARE | 4.25%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML | N020678 | 009 | Mar 26, 1997 |
| CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER | | | | | |
| +! | BAXTER HLTHCARE | 4.25%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML | N020678 | 011 | Mar 26, 1997 |
| CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER | | | | | |
| +! | BAXTER HLTHCARE | 4.25%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML | N020678 | 012 | Mar 26, 1997 |
| CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER | | | | | |
| +! | BAXTER HLTHCARE | 4.25%;33MG/100ML;5GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML | N020678 | 008 | Mar 26, 1997 |
| CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER | | | | | |
| +! | BAXTER HLTHCARE | 5%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML | N020678 | 016 | Mar 26, 1997 |
| CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER | | | | | |
| +! | BAXTER HLTHCARE | 5%;33MG/100ML;15GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML | N020678 | 017 | Mar 26, 1997 |
| CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER | | | | | |
| +! | BAXTER HLTHCARE | 5%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML | N020678 | 018 | Mar 26, 1997 |
| CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER | | | | | |
| +! | BAXTER HLTHCARE | 5%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML | N020678 | 019 | Mar 26, 1997 |
| CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER | | | | | |
| +! | BAXTER HLTHCARE | 5%;33MG/100ML;35GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML | N020678 | 021 | Mar 26, 1997 |

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL

EMULSION;IV (INFUSION)

| | | | | | |
|---|---|---|---|---|---|
| KABIVEN IN PLASTIC CONTAINER | | | | | |
| + | FRESENIUS KABI USA | 3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (1026ML) | N200656 | 004 | Aug 25, 2014 |
| + | | 3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (1540ML) | N200656 | 005 | Aug 25, 2014 |
| + | | 3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML; | N200656 | 006 | Aug 25, 2014 |

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL

EMULSION;IV (INFUSION)

| | | | | | |
|---|---|---|---|---|---|
| KABIVEN IN PLASTIC CONTAINER | | | | | |
| | | 174MG/100ML;239MG/100ML;147MG/100ML;3.9 GM/100ML (2053ML) | | | |
| +! | | 3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML; 174MG/100ML;239MG/100ML;147MG/100ML;3.9 GM/100ML (2566ML) | N200656 | 007 | Aug 25, 2014 |
| PERIKABIVEN IN PLASTIC CONTAINER | | | | | |
| + | FRESENIUS KABI USA | 2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML; 124MG/100ML;170MG/100ML;105MG/100ML;3.5 GM/100ML (1440ML) | N200656 | 001 | Aug 25, 2014 |
| + | | 2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML; 124MG/100ML;170MG/100ML;105MG/100ML;3.5 GM/100ML (1920ML) | N200656 | 002 | Aug 25, 2014 |
| + | | 2.4%;20MG/100ML;6.8GM/100ML;68MG/100ML; 124MG/100ML;170MG/100ML ;105MG/100ML;3.5GM/100ML (2400ML) | N200656 | 003 | Aug 25, 2014 |

AMINO ACIDS; DEXTROSE

INJECTABLE;INJECTION

| | | | | | |
|---|---|---|---|---|---|
| CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER | | | | | |
| | BAXTER HLTHCARE | 2.75%;10GM/100ML | N020734 | 002 | Sep 29, 1997 |
| CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER | | | | | |
| | BAXTER HLTHCARE | 2.75%;25GM/100ML | N020734 | 005 | Sep 29, 1997 |
| CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | | |
| | BAXTER HLTHCARE | 2.75%;5GM/100ML | N020734 | 001 | Sep 29, 1997 |
| CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER | | | | | |
| | BAXTER HLTHCARE | 4.25%;10GM/100ML | N020734 | 008 | Sep 29, 1997 |
| CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER | | | | | |
| | BAXTER HLTHCARE | 4.25%;20GM/100ML | N020734 | 010 | Sep 29, 1997 |
| CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER | | | | | |
| | BAXTER HLTHCARE | 4.25%;25GM/100ML | N020734 | 011 | Sep 29, 1997 |
| CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | | |
| | BAXTER HLTHCARE | 4.25%;5GM/100ML | N020734 | 007 | Sep 29, 1997 |
| CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER | | | | | |
| | BAXTER HLTHCARE | 5%;10GM/100ML | N020734 | 014 | Sep 29, 1997 |
| CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER | | | | | |
| | BAXTER HLTHCARE | 5%;15GM/100ML | N020734 | 015 | Sep 29, 1997 |
| CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER | | | | | |
| | BAXTER HLTHCARE | 5%;20GM/100ML | N020734 | 016 | Sep 29, 1997 |
| CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER | | | | | |
| | BAXTER HLTHCARE | 5%;25GM/100ML | N020734 | 017 | Sep 29, 1997 |
| CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER | | | | | |
| | BAXTER HLTHCARE | 5%;35GM/100ML | N020734 | 018 | Sep 29, 1997 |

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

INJECTABLE;INJECTION

| | | | | | |
|---|---|---|---|---|---|
| FREAMINE III 8.5% W/ ELECTROLYTES | | | | | |
| | B BRAUN | 8.5%;110MG/100ML;230MG/100ML;10MG/100ML ;440MG/100ML;690MG/100ML | N016822 | 007 | Jul 01, 1988 |

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

| | | | | | |
|---|---|---|---|---|---|
| AMINOSYN 3.5% M | | | | | |
| | ICU MEDICAL INC | 3.5%;21MG/100ML;40MG/100ML;128MG/100ML; 234MG/100ML | N017789 | 003 | |

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

| | | | | | |
|---|---|---|---|---|---|
| FREAMINE III 3% W/ ELECTROLYTES | | | | | |
| | B BRAUN | 3%;54MG/100ML;40MG/100ML;150MG/100ML;20 0MG/100ML;120MG/100ML | N016822 | 003 | |

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION

| | | | | | |
|---|---|---|---|---|---|
| AMINOSYN II 10% W/ ELECTROLYTES | | | | | |
| | ICU MEDICAL INC | 10%;102MG/100ML;45MG/100ML;522MG/100ML; 410MG/100ML | N019437 | 004 | Apr 03, 1986 |
| AMINOSYN II 8.5% W/ ELECTROLYTES | | | | | |
| | ICU MEDICAL INC | 8.5%;102MG/100ML;45MG/100ML;522MG/100ML ;410MG/100ML | N019437 | 005 | Apr 03, 1986 |

| | | | | | | |
|---|---|---|---|---|---|---|
| AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| AMINOSYN 7% W/ ELECTROLYTES | | | | | | |
| | | ICU MEDICAL INC | 7%;102MG/100ML;522MG/100ML;410MG/100ML | N017789 | 002 | |
| AMINOSYN 8.5% W/ ELECTROLYTES | | | | | | |
| | | ICU MEDICAL INC | 8.5%;102MG/100ML;522MG/100ML;410MG/100ML | N017673 | 005 | |
| AMINOCAPROIC ACID | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| **AMINOCAPROIC ACID** | | | | | | |
| **AP** | | LUITPOLD | **250MG/ML** | **A071192** | **001** | Dec 01, 1987 |
| **AMINOCAPROIC ACID IN PLASTIC CONTAINER** | | | | | | |
| **AP** | **!** | HOSPIRA | **250MG/ML** | **A070010** | **001** | Mar 09, 1987 |
| SYRUP;ORAL | | | | | | |
| **AMICAR** | | | | | | |
| **AA** | **+!** | CLOVER PHARMS | **1.25GM/5ML** | **N015230** | **002** | |
| **AMINOCAPROIC ACID** | | | | | | |
| **AA** | | AKORN | **1.25GM/5ML** | **A074759** | **001** | Sep 02, 1998 |
| TABLET;ORAL | | | | | | |
| **AMICAR** | | | | | | |
| **AB** | **+** | CLOVER PHARMS | **500MG** | **N015197** | **001** | |
| **AMINOCAPROIC** | | | | | | |
| **AB** | | AKORN | **500MG** | **A075602** | **001** | May 24, 2001 |
| AMICAR | | | | | | |
| | +! | CLOVER PHARMS | 1GM | N015197 | 002 | Jun 24, 2004 |
| AMINOLEVULINIC ACID HYDROCHLORIDE | | | | | | |
| FOR SOLUTION;ORAL | | | | | | |
| GLEOLAN | | | | | | |
| | +! | NXDC | 1.5GM/VIAL | N208630 | 001 | Jun 06, 2017 |
| GEL;TOPICAL | | | | | | |
| AMELUZ | | | | | | |
| | +! | BIOFRONTERA | 10% | N208081 | 001 | May 10, 2016 |
| SOLUTION;TOPICAL | | | | | | |
| LEVULAN | | | | | | |
| | +! | DUSA | 20% | N020965 | 001 | Dec 03, 1999 |
| AMINOPHYLLINE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| **AMINOPHYLLINE** | | | | | | |
| **AP** | **!** | HOSPIRA | **25MG/ML** | **A087242** | **001** | Oct 26, 1983 |
| **AP** | | LUITPOLD | **25MG/ML** | **A087600** | **001** | |
| AMINOSALICYLIC ACID | | | | | | |
| GRANULE, DELAYED RELEASE;ORAL | | | | | | |
| PASER | | | | | | |
| | ! | JACOBUS | 4GM/PACKET | A074346 | 001 | Jun 30, 1994 |
| AMIODARONE HYDROCHLORIDE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| **AMIODARONE HYDROCHLORIDE** | | | | | | |
| **AP** | **!** | AKORN | **50MG/ML** | **A076232** | **001** | Jul 05, 2006 |
| **AP** | | AUROBINDO PHARMA LTD | **50MG/ML** | **A204550** | **001** | Oct 25, 2017 |
| **AP** | **!** | FRESENIUS KABI USA | **50MG/ML** | **A075761** | **001** | Oct 15, 2002 |
| **AP** | **!** | GLAND PHARMA LTD | **50MG/ML** | **A077161** | **001** | Apr 20, 2005 |
| **AP** | | HIKMA FARMACEUTICA | **50MG/ML** | **A077234** | **001** | Feb 25, 2008 |
| **AP** | **!** | HOSPIRA | **50MG/ML** | **A075955** | **001** | Oct 18, 2002 |
| **AP** | | HOSPIRA INC | **50MG/ML** | **A203884** | **001** | Nov 25, 2013 |
| **AP** | | | **50MG/ML** | **A203885** | **001** | Nov 25, 2013 |
| **AP** | **!** | MYLAN INSTITUTIONAL | **50MG/ML** | **A076217** | **001** | Oct 15, 2002 |
| **AP** | | WOCKHARDT | **50MG/ML** | **A077610** | **001** | Oct 30, 2008 |
| **AP** | | | **50MG/ML** | **A077834** | **001** | Oct 30, 2008 |
| **NEXTERONE** | | | | | | |
| **AP** | **+** | BAXTER HLTHCARE | **50MG/ML** | **N022325** | **001** | Dec 24, 2008 |
| | +! | | 150MG/100ML (1.5MG/ML) | N022325 | 002 | Nov 16, 2010 |
| | +! | | 360MG/200ML (1.8MG/ML) | N022325 | 003 | Nov 16, 2010 |
| TABLET;ORAL | | | | | | |
| **AMIODARONE HYDROCHLORIDE** | | | | | | |
| **AB** | | APOTEX INC | **200MG** | **A078578** | **001** | Nov 06, 2008 |
| **AB** | | AUROBINDO PHARMA LTD | **200MG** | **A204742** | **001** | Jun 03, 2016 |
| **AB** | | MAYNE PHARMA INC | **100MG** | **A075389** | **002** | Dec 28, 2017 |
| **AB** | | | **200MG** | **A075389** | **001** | Jan 25, 2001 |

AMIODARONE HYDROCHLORIDE

TABLET;ORAL

**AMIODARONE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **400MG** | **A075389** | **003** | Dec 28, 2017 |
| **AB** | | MURTY PHARMS | **100MG** | **A077069** | **003** | Oct 04, 2016 |
| **AB** | | | **200MG** | **A077069** | **001** | Apr 08, 2005 |
| **AB** | | | **400MG** | **A077069** | **002** | Apr 08, 2005 |
| **AB** | ! | SANDOZ | **200MG** | **A075315** | **001** | Dec 23, 1998 |
| **AB** | | | **400MG** | **A075315** | **002** | Jun 30, 2000 |
| **AB** | | TARO PHARM | **100MG** | **A075424** | **002** | Dec 18, 2002 |
| **AB** | | | **200MG** | **A075424** | **001** | Mar 30, 2001 |
| **AB** | | | **400MG** | **A076362** | **001** | Nov 29, 2002 |
| **AB** | | TEVA PHARMS | **200MG** | **A074739** | **001** | Nov 30, 1998 |
| **AB** | | ZYDUS PHARMS USA INC | **200MG** | **A079029** | **001** | Sep 16, 2008 |

**PACERONE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | UPSHER-SMITH LABS | **100MG** | **A075135** | **002** | Apr 12, 2005 |
| **AB** | | | **200MG** | **A075135** | **001** | Apr 30, 1998 |

AMIODARONE HYDROCHLORIDE

| | | | | | | |
|---|---|---|---|---|---|---|
| | | TARO PHARM | 300MG | A076362 | 002 | Dec 02, 2003 |

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

**AMITRIPTYLINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACCORD HLTHCARE | **10MG** | **A202446** | **001** | Jun 04, 2014 |
| **AB** | | | **25MG** | **A202446** | **002** | Jun 04, 2014 |
| **AB** | | | **50MG** | **A202446** | **003** | Jun 04, 2014 |
| **AB** | | | **75MG** | **A202446** | **004** | Jun 04, 2014 |
| **AB** | | | **100MG** | **A202446** | **005** | Jun 04, 2014 |
| **AB** | | | **150MG** | **A202446** | **006** | Jun 04, 2014 |
| **AB** | | MYLAN | **10MG** | **A086009** | **002** | |
| **AB** | | | **25MG** | **A086009** | **003** | |
| **AB** | | | **50MG** | **A086009** | **001** | |
| **AB** | | | **75MG** | **A086009** | **004** | |
| **AB** | | | **100MG** | **A086009** | **005** | |
| **AB** | | | **150MG** | **A086009** | **006** | |
| **AB** | | SANDOZ | **10MG** | **A085969** | **001** | |
| **AB** | ! | | **25MG** | **A085966** | **001** | |
| **AB** | | | **50MG** | **A085968** | **001** | |
| **AB** | | | **75MG** | **A085971** | **001** | |
| **AB** | | | **100MG** | **A085967** | **001** | |
| **AB** | | | **150MG** | **A085970** | **001** | |
| **AB** | | VINTAGE PHARMS | **10MG** | **A040218** | **001** | Sep 11, 1997 |
| **AB** | | | **25MG** | **A040218** | **002** | Sep 11, 1997 |
| **AB** | | | **50MG** | **A040218** | **003** | Sep 11, 1997 |
| **AB** | | | **75MG** | **A040218** | **004** | Sep 11, 1997 |
| **AB** | | | **100MG** | **A040218** | **005** | Sep 11, 1997 |
| **AB** | | | **150MG** | **A040218** | **006** | Sep 11, 1997 |
| **AB** | | ZYDUS PHARMS USA INC | **10MG** | **A210086** | **001** | Oct 06, 2017 |
| **AB** | | | **25MG** | **A210086** | **002** | Oct 06, 2017 |
| **AB** | | | **50MG** | **A210086** | **003** | Oct 06, 2017 |
| **AB** | | | **75MG** | **A210086** | **004** | Oct 06, 2017 |
| **AB** | | | **100MG** | **A210086** | **005** | Oct 06, 2017 |
| **AB** | | | **150MG** | **A210086** | **006** | Oct 06, 2017 |

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

| | | | | | |
|---|---|---|---|---|---|
| | MYLAN PHARMS INC | EQ 12.5MG BASE;5MG | A071297 | 002 | Dec 10, 1986 |
| ! | | EQ 25MG BASE;10MG | A071297 | 001 | Dec 10, 1986 |

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET;ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

| | | | | | |
|---|---|---|---|---|---|
| | MYLAN | 10MG;2MG | A071443 | 002 | Nov 10, 1988 |
| | | 10MG;4MG | A071443 | 003 | Nov 10, 1988 |
| ! | | 25MG;2MG | A071443 | 004 | Nov 10, 1988 |
| ! | | 25MG;4MG | A071443 | 005 | Nov 10, 1988 |
| ! | | 50MG;4MG | A071443 | 001 | Nov 10, 1988 |

AMLODIPINE BESYLATE

TABLET;ORAL

**AMLODIPINE BESYLATE**

| | | | | |
|---|---|---|---|---|
| **AB** | ACCORD HLTHCARE | **EQ 2.5MG BASE** | **A202553** | **001** Apr 29, 2013 |
| **AB** | | **EQ 5MG BASE** | **A202553** | **002** Apr 29, 2013 |
| **AB** | | **EQ 10MG BASE** | **A202553** | **003** Apr 29, 2013 |
| **AB** | ALKEM | **EQ 2.5MG BASE** | **A078925** | **001** May 04, 2009 |
| **AB** | | **EQ 5MG BASE** | **A078925** | **002** May 04, 2009 |
| **AB** | | **EQ 10MG BASE** | **A078925** | **003** May 04, 2009 |
| **AB** | AMNEAL PHARMS NY | **EQ 2.5MG BASE** | **A078477** | **001** Jan 16, 2008 |
| **AB** | | **EQ 5MG BASE** | **A078477** | **002** Jan 16, 2008 |
| **AB** | | **EQ 10MG BASE** | **A078477** | **003** Jan 16, 2008 |
| **AB** | APOTEX | **EQ 2.5MG BASE** | **A076719** | **001** May 23, 2007 |
| **AB** | | **EQ 5MG BASE** | **A076719** | **002** May 23, 2007 |
| **AB** | | **EQ 10MG BASE** | **A076719** | **003** May 23, 2007 |
| **AB** | AUROBINDO PHARMA | **EQ 2.5MG BASE** | **A078021** | **001** Jul 17, 2007 |
| **AB** | | **EQ 5MG BASE** | **A078021** | **002** Jul 17, 2007 |
| **AB** | | **EQ 10MG BASE** | **A078021** | **003** Jul 17, 2007 |
| **AB** | CHINA RESOURCES | **EQ 2.5MG BASE** | **A090752** | **003** May 16, 2016 |
| **AB** | | **EQ 5MG BASE** | **A090752** | **001** Apr 15, 2011 |
| **AB** | | **EQ 10MG BASE** | **A090752** | **002** Apr 15, 2011 |
| **AB** | CIPLA LTD | **EQ 2.5MG BASE** | **A077073** | **001** Sep 26, 2007 |
| **AB** | | **EQ 5MG BASE** | **A077073** | **002** Sep 26, 2007 |
| **AB** | | **EQ 10MG BASE** | **A077073** | **003** Sep 26, 2007 |
| **AB** | DR REDDYS LABS LTD | **EQ 2.5MG BASE** | **A076692** | **001** Jul 20, 2007 |
| **AB** | | **EQ 5MG BASE** | **A076692** | **002** Jul 20, 2007 |
| **AB** | | **EQ 10MG BASE** | **A076692** | **003** Jul 20, 2007 |
| **AB** | EPIC PHARMA LLC | **EQ 2.5MG BASE** | **A078552** | **001** Apr 08, 2009 |
| **AB** | | **EQ 5MG BASE** | **A078552** | **002** Apr 08, 2009 |
| **AB** | | **EQ 10MG BASE** | **A078552** | **003** Apr 08, 2009 |
| **AB** | HIKMA PHARMS | **EQ 2.5MG BASE** | **A077771** | **001** Apr 12, 2011 |
| **AB** | | **EQ 5MG BASE** | **A077771** | **002** Apr 12, 2011 |
| **AB** | | **EQ 10MG BASE** | **A077771** | **003** Apr 12, 2011 |
| **AB** | INVAGEN PHARMS | **EQ 2.5MG BASE** | **A077955** | **001** Aug 28, 2007 |
| **AB** | | **EQ 2.5MG BASE** | **A206367** | **001** Dec 10, 2015 |
| **AB** | | **EQ 5MG BASE** | **A077955** | **002** Aug 28, 2007 |
| **AB** | | **EQ 5MG BASE** | **A206367** | **002** Dec 10, 2015 |
| **AB** | | **EQ 10MG BASE** | **A077955** | **003** Aug 28, 2007 |
| **AB** | | **EQ 10MG BASE** | **A206367** | **003** Dec 10, 2015 |
| **AB** | LUPIN | **EQ 2.5MG BASE** | **A078043** | **001** Jul 12, 2007 |
| **AB** | | **EQ 5MG BASE** | **A078043** | **002** Jul 12, 2007 |
| **AB** | | **EQ 10MG BASE** | **A078043** | **003** Jul 12, 2007 |
| **AB** | MACLEODS PHARMS LTD | **EQ 5MG BASE** | **A201380** | **001** Apr 13, 2012 |
| **AB** | | **EQ 10MG BASE** | **A201380** | **002** Apr 13, 2012 |
| **AB** | MYLAN PHARMS INC | **EQ 2.5MG BASE** | **A076418** | **001** Oct 03, 2005 |
| **AB** | | **EQ 5MG BASE** | **A076418** | **002** Oct 03, 2005 |
| **AB** | | **EQ 10MG BASE** | **A076418** | **003** Oct 03, 2005 |
| **AB** | ORCHID HLTHCARE | **EQ 2.5MG BASE** | **A078453** | **001** Jul 02, 2009 |
| **AB** | | **EQ 5MG BASE** | **A078453** | **002** Jul 02, 2009 |
| **AB** | | **EQ 10MG BASE** | **A078453** | **003** Jul 02, 2009 |
| **AB** | POLYGEN PHARMS | **EQ 2.5MG BASE** | **A207821** | **001** Jul 11, 2016 |
| **AB** | | **EQ 5MG BASE** | **A207821** | **002** Jul 11, 2016 |
| **AB** | | **EQ 10MG BASE** | **A207821** | **003** Jul 11, 2016 |
| **AB** | SUN PHARM INDS INC | **EQ 2.5MG BASE** | **A078231** | **001** Nov 30, 2007 |
| **AB** | | **EQ 5MG BASE** | **A078231** | **002** Nov 30, 2007 |
| **AB** | | **EQ 10MG BASE** | **A078231** | **003** Nov 30, 2007 |
| **AB** | SUN PHARM INDS LTD | **EQ 2.5MG BASE** | **A077974** | **001** Jul 09, 2007 |
| **AB** | | **EQ 5MG BASE** | **A077974** | **002** Jul 09, 2007 |
| **AB** | | **EQ 10MG BASE** | **A077974** | **003** Jul 09, 2007 |
| **AB** | TEVA | **EQ 2.5MG BASE** | **A076846** | **001** Jun 28, 2007 |
| **AB** | | **EQ 5MG BASE** | **A076846** | **002** Jun 28, 2007 |
| **AB** | | **EQ 10MG BASE** | **A076846** | **003** Jun 28, 2007 |
| **AB** | TORRENT PHARMS | **EQ 2.5MG BASE** | **A078573** | **001** Sep 22, 2008 |
| **AB** | | **EQ 5MG BASE** | **A078573** | **002** Sep 22, 2008 |
| **AB** | | **EQ 10MG BASE** | **A078573** | **003** Sep 22, 2008 |
| **AB** | UNICHEM LABS LTD | **EQ 2.5MG BASE** | **A203245** | **001** Oct 21, 2013 |
| **AB** | | **EQ 5MG BASE** | **A203245** | **002** Oct 21, 2013 |
| **AB** | | **EQ 10MG BASE** | **A203245** | **003** Oct 21, 2013 |
| **AB** | UPSHER-SMITH LABS | **EQ 2.5MG BASE** | **A077759** | **001** Jul 09, 2007 |
| **AB** | | **EQ 5MG BASE** | **A077759** | **002** Jul 09, 2007 |
| **AB** | | **EQ 10MG BASE** | **A077759** | **003** Jul 09, 2007 |
| **AB** | VINTAGE | **EQ 2.5MG BASE** | **A078414** | **001** Apr 07, 2010 |

AMLODIPINE BESYLATE

TABLET;ORAL

**AMLODIPINE BESYLATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **EQ 5MG BASE** | **A078414** | **002** | Apr 07, 2010 |
| **AB** | | | **EQ 10MG BASE** | **A078414** | **003** | Apr 07, 2010 |
| **AB** | | VIVIMED GLOBAL | **EQ 2.5MG BASE** | **A077516** | **001** | Jul 11, 2007 |
| **AB** | | | **EQ 5MG BASE** | **A077516** | **002** | Jul 11, 2007 |
| **AB** | | | **EQ 10MG BASE** | **A077516** | **003** | Jul 11, 2007 |
| **AB** | | WATSON LABS | **EQ 2.5MG BASE** | **A077671** | **001** | Jul 19, 2007 |
| **AB** | | | **EQ 5MG BASE** | **A077671** | **002** | Jul 19, 2007 |
| **AB** | | | **EQ 10MG BASE** | **A077671** | **003** | Jul 19, 2007 |
| **AB** | | WEST-WARD PHARMS INT | **EQ 2.5MG BASE** | **A077262** | **001** | Jul 09, 2007 |
| **AB** | | | **EQ 5MG BASE** | **A077262** | **002** | Jul 09, 2007 |
| **AB** | | | **EQ 10MG BASE** | **A077262** | **003** | Jul 09, 2007 |
| **AB** | | WOCKHARDT | **EQ 2.5MG BASE** | **A078500** | **001** | Sep 06, 2007 |
| **AB** | | | **EQ 5MG BASE** | **A078500** | **002** | Sep 06, 2007 |
| **AB** | | | **EQ 10MG BASE** | **A078500** | **003** | Sep 06, 2007 |
| **AB** | | ZYDUS PHARMS USA | **EQ 2.5MG BASE** | **A078226** | **001** | Jul 09, 2007 |
| **AB** | | | **EQ 5MG BASE** | **A078226** | **002** | Jul 09, 2007 |
| **AB** | | | **EQ 10MG BASE** | **A078226** | **003** | Jul 09, 2007 |

**NORVASC**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | PFIZER | **EQ 2.5MG BASE** | **N019787** | **001** | Jul 31, 1992 |
| **AB** | + | | **EQ 5MG BASE** | **N019787** | **002** | Jul 31, 1992 |
| **AB** | +! | | **EQ 10MG BASE** | **N019787** | **003** | Jul 31, 1992 |

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET;ORAL

**AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | DR REDDYS LABS LTD | **EQ 2.5MG BASE;EQ 10MG BASE** | **A203874** | **001** | Mar 07, 2014 |
| **AB** | | | **EQ 2.5MG BASE;EQ 20MG BASE** | **A203874** | **002** | Mar 07, 2014 |
| **AB** | | | **EQ 2.5MG BASE;EQ 40MG BASE** | **A203874** | **003** | Mar 07, 2014 |
| **AB** | | | **EQ 5MG BASE;EQ 10MG BASE** | **A203874** | **004** | Mar 07, 2014 |
| **AB** | | | **EQ 5MG BASE;EQ 20MG BASE** | **A203874** | **005** | Mar 07, 2014 |
| **AB** | | | **EQ 5MG BASE;EQ 40MG BASE** | **A203874** | **006** | Mar 07, 2014 |
| **AB** | | | **EQ 5MG BASE;EQ 80MG BASE** | **A203874** | **007** | Mar 07, 2014 |
| **AB** | | | **EQ 10MG BASE;EQ 10MG BASE** | **A203874** | **008** | Mar 07, 2014 |
| **AB** | | | **EQ 10MG BASE;EQ 20MG BASE** | **A203874** | **009** | Mar 07, 2014 |
| **AB** | | | **EQ 10MG BASE;EQ 40MG BASE** | **A203874** | **010** | Mar 07, 2014 |
| **AB** | | | **EQ 10MG BASE;EQ 80MG BASE** | **A203874** | **011** | Mar 07, 2014 |
| **AB** | | MYLAN PHARMS INC | **EQ 2.5MG BASE;EQ 10MG BASE** | **A200465** | **001** | Nov 29, 2013 |
| **AB** | | | **EQ 2.5MG BASE;EQ 20MG BASE** | **A200465** | **002** | Nov 29, 2013 |
| **AB** | | | **EQ 2.5MG BASE;EQ 40MG BASE** | **A200465** | **003** | Nov 29, 2013 |
| **AB** | | | **EQ 5MG BASE;EQ 10MG BASE** | **A200465** | **004** | Nov 29, 2013 |
| **AB** | | | **EQ 5MG BASE;EQ 20MG BASE** | **A200465** | **005** | Nov 29, 2013 |
| **AB** | | | **EQ 5MG BASE;EQ 40MG BASE** | **A200465** | **006** | Nov 29, 2013 |
| **AB** | | | **EQ 5MG BASE;EQ 80MG BASE** | **A200465** | **007** | Nov 29, 2013 |
| **AB** | | | **EQ 10MG BASE;EQ 10MG BASE** | **A200465** | **008** | Nov 29, 2013 |
| **AB** | | | **EQ 10MG BASE;EQ 20MG BASE** | **A200465** | **009** | Nov 29, 2013 |
| **AB** | | | **EQ 10MG BASE;EQ 40MG BASE** | **A200465** | **010** | Nov 29, 2013 |
| **AB** | | | **EQ 10MG BASE;EQ 80MG BASE** | **A200465** | **011** | Nov 29, 2013 |

**CADUET**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | PFIZER | **EQ 2.5MG BASE;EQ 10MG BASE** | **N021540** | **009** | Jul 29, 2004 |
| **AB** | + | | **EQ 2.5MG BASE;EQ 20MG BASE** | **N021540** | **010** | Jul 29, 2004 |
| **AB** | + | | **EQ 2.5MG BASE;EQ 40MG BASE** | **N021540** | **011** | Jul 29, 2004 |
| **AB** | + | | **EQ 5MG BASE;EQ 10MG BASE** | **N021540** | **001** | Jan 30, 2004 |
| **AB** | + | | **EQ 5MG BASE;EQ 20MG BASE** | **N021540** | **002** | Jan 30, 2004 |
| **AB** | + | | **EQ 5MG BASE;EQ 40MG BASE** | **N021540** | **003** | Jan 30, 2004 |
| **AB** | + | | **EQ 5MG BASE;EQ 80MG BASE** | **N021540** | **004** | Jan 30, 2004 |
| **AB** | + | | **EQ 10MG BASE;EQ 10MG BASE** | **N021540** | **005** | Jan 30, 2004 |
| **AB** | + | | **EQ 10MG BASE;EQ 20MG BASE** | **N021540** | **006** | Jan 30, 2004 |
| **AB** | + | | **EQ 10MG BASE;EQ 40MG BASE** | **N021540** | **007** | Jan 30, 2004 |
| **AB** | +! | | **EQ 10MG BASE;EQ 80MG BASE** | **N021540** | **008** | Jan 30, 2004 |

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

**AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | APOTEX INC | **EQ 2.5MG BASE;10MG** | **A091431** | **001** | Dec 30, 2013 |
| **AB** | | | **EQ 5MG BASE;10MG** | **A091431** | **002** | Dec 30, 2013 |
| **AB** | | | **EQ 5MG BASE;20MG** | **A091431** | **003** | Dec 30, 2013 |
| **AB** | | | **EQ 5MG BASE;40MG** | **A091431** | **004** | Dec 30, 2013 |
| **AB** | | | **EQ 10MG BASE;20MG** | **A091431** | **005** | Dec 30, 2013 |
| **AB** | | | **EQ 10MG BASE;40MG** | **A091431** | **006** | Dec 30, 2013 |
| **AB** | | AUROBINDO PHARMA | **EQ 2.5MG BASE;10MG** | **A202239** | **001** | Sep 05, 2012 |

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

**AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| | | LTD | | | | |
| **AB** | | | **EQ 5MG BASE;10MG** | **A202239** | **002** | Sep 05, 2012 |
| **AB** | | | **EQ 5MG BASE;20MG** | **A202239** | **003** | Sep 05, 2012 |
| **AB** | | | **EQ 5MG BASE;40MG** | **A202239** | **004** | Sep 05, 2012 |
| **AB** | | | **EQ 10MG BASE;20MG** | **A202239** | **005** | Sep 05, 2012 |
| **AB** | | | **EQ 10MG BASE;40MG** | **A202239** | **006** | Sep 05, 2012 |
| **AB** | | DR REDDYS LABS INC | **EQ 2.5MG BASE;10MG** | **A077183** | **001** | Apr 15, 2010 |
| **AB** | | | **EQ 5MG BASE;10MG** | **A077183** | **002** | Apr 15, 2010 |
| **AB** | | | **EQ 5MG BASE;20MG** | **A077183** | **003** | Apr 15, 2010 |
| **AB** | | | **EQ 5MG BASE;40MG** | **A090149** | **001** | Jul 05, 2011 |
| **AB** | | | **EQ 10MG BASE;20MG** | **A077183** | **004** | Apr 15, 2010 |
| **AB** | | | **EQ 10MG BASE;40MG** | **A090149** | **002** | Jul 05, 2011 |
| **AB** | | LUPIN PHARMS | **EQ 2.5MG BASE;10MG** | **A078466** | **001** | Feb 05, 2010 |
| **AB** | | | **EQ 5MG BASE;10MG** | **A078466** | **002** | Feb 05, 2010 |
| **AB** | | | **EQ 5MG BASE;20MG** | **A078466** | **003** | Feb 05, 2010 |
| **AB** | | | **EQ 5MG BASE;40MG** | **A078466** | **005** | Jul 05, 2011 |
| **AB** | | | **EQ 10MG BASE;20MG** | **A078466** | **004** | Feb 05, 2010 |
| **AB** | | | **EQ 10MG BASE;40MG** | **A078466** | **006** | Jul 05, 2011 |
| **AB** | | MYLAN | **EQ 2.5MG BASE;10MG** | **A077375** | **001** | May 21, 2010 |
| **AB** | | | **EQ 5MG BASE;10MG** | **A077375** | **002** | May 21, 2010 |
| **AB** | | | **EQ 5MG BASE;20MG** | **A077375** | **003** | May 21, 2010 |
| **AB** | | | **EQ 5MG BASE;40MG** | **A079047** | **001** | Jul 05, 2011 |
| **AB** | | | **EQ 10MG BASE;20MG** | **A077375** | **004** | May 21, 2010 |
| **AB** | | | **EQ 10MG BASE;40MG** | **A079047** | **002** | Jul 05, 2011 |
| **AB** | | PAR PHARM | **EQ 2.5MG BASE;10MG** | **A078381** | **001** | Jul 29, 2010 |
| **AB** | | | **EQ 5MG BASE;10MG** | **A078381** | **002** | Jul 29, 2010 |
| **AB** | | | **EQ 5MG BASE;20MG** | **A078381** | **003** | Jul 29, 2010 |
| **AB** | | | **EQ 5MG BASE;40MG** | **A078381** | **005** | Jul 29, 2010 |
| **AB** | | | **EQ 10MG BASE;20MG** | **A078381** | **004** | Jul 29, 2010 |
| **AB** | | | **EQ 10MG BASE;40MG** | **A078381** | **006** | Jul 29, 2010 |
| **AB** | | TEVA PHARMS | **EQ 2.5MG BASE;10MG** | **A077179** | **001** | May 18, 2007 |
| **AB** | | | **EQ 5MG BASE;10MG** | **A077179** | **002** | May 18, 2007 |
| **AB** | | | **EQ 5MG BASE;20MG** | **A077179** | **003** | May 18, 2007 |
| **AB** | | | **EQ 5MG BASE;40MG** | **A077179** | **005** | Jul 05, 2011 |
| **AB** | | | **EQ 10MG BASE;20MG** | **A077179** | **004** | May 18, 2007 |
| **AB** | | | **EQ 10MG BASE;40MG** | **A077179** | **006** | Jul 05, 2011 |
| **AB** | | WATSON LABS | **EQ 2.5MG BASE;10MG** | **A077890** | **001** | Oct 14, 2010 |
| **AB** | | | **EQ 5MG BASE;10MG** | **A077890** | **002** | Oct 14, 2010 |
| **AB** | | | **EQ 5MG BASE;20MG** | **A077890** | **003** | Oct 14, 2010 |
| **AB** | | | **EQ 10MG BASE;20MG** | **A077890** | **004** | Oct 14, 2010 |
| **AB** | | WATSON LABS INC | **EQ 5MG BASE;40MG** | **A090364** | **001** | Jul 05, 2011 |
| **AB** | | | **EQ 10MG BASE;40MG** | **A090364** | **002** | Jul 05, 2011 |
| | **LOTREL** | | | | | |
| **AB** | **+** | NOVARTIS | **EQ 2.5MG BASE;10MG** | **N020364** | **002** | Mar 03, 1995 |
| **AB** | **+** | | **EQ 5MG BASE;10MG** | **N020364** | **003** | Mar 03, 1995 |
| **AB** | **+** | | **EQ 5MG BASE;20MG** | **N020364** | **004** | Mar 03, 1995 |
| **AB** | **+** | | **EQ 5MG BASE;40MG** | **N020364** | **007** | Apr 11, 2006 |
| **AB** | **+** | | **EQ 10MG BASE;20MG** | **N020364** | **005** | Jun 20, 2002 |
| **AB** | **+!** | | **EQ 10MG BASE;40MG** | **N020364** | **006** | Apr 11, 2006 |

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

**OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | PAR PHARM INC | **EQ 5MG BASE;12.5MG;20MG** | **A206137** | **001** | Oct 26, 2016 |
| **AB** | | | **EQ 5MG BASE;12.5MG;40MG** | **A206137** | **002** | Oct 26, 2016 |
| **AB** | | | **EQ 5MG BASE;25MG;40MG** | **A206137** | **003** | Oct 26, 2016 |
| **AB** | | | **EQ 10MG BASE;12.5MG;40MG** | **A206137** | **004** | Oct 26, 2016 |
| **AB** | | | **EQ 10MG BASE;25MG;40MG** | **A206137** | **005** | Oct 26, 2016 |
| **AB** | | TEVA PHARMS USA | **EQ 5MG BASE;12.5MG;20MG** | **A202491** | **001** | Nov 03, 2016 |
| **AB** | | | **EQ 5MG BASE;12.5MG;40MG** | **A202491** | **002** | Nov 03, 2016 |
| **AB** | | | **EQ 5MG BASE;25MG;40MG** | **A202491** | **003** | Nov 03, 2016 |
| **AB** | | | **EQ 10MG BASE;12.5MG;40MG** | **A202491** | **004** | Nov 03, 2016 |
| **AB** | | | **EQ 10MG BASE;25MG;40MG** | **A202491** | **005** | Nov 03, 2016 |
| **AB** | | TORRENT PHARMS LTD | **EQ 5MG BASE;12.5MG;20MG** | **A203580** | **001** | Oct 26, 2016 |
| **AB** | | | **EQ 5MG BASE;12.5MG;40MG** | **A203580** | **002** | Oct 26, 2016 |
| **AB** | | | **EQ 5MG BASE;25MG;40MG** | **A203580** | **003** | Oct 26, 2016 |
| **AB** | | | **EQ 10MG BASE;12.5MG;40MG** | **A203580** | **004** | Oct 26, 2016 |
| **AB** | | | **EQ 10MG BASE;25MG;40MG** | **A203580** | **005** | Oct 26, 2016 |

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

**TRIBENZOR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | DAIICHI SANKYO | **EQ 5MG BASE;12.5MG;20MG** | **N200175** | **001** | Jul 23, 2010 |
| **AB** | + | | **EQ 5MG BASE;12.5MG;40MG** | **N200175** | **002** | Jul 23, 2010 |
| **AB** | + | | **EQ 5MG BASE;25MG;40MG** | **N200175** | **003** | Jul 23, 2010 |
| **AB** | + | | **EQ 10MG BASE;12.5MG;40MG** | **N200175** | **004** | Jul 23, 2010 |
| **AB** | +! | | **EQ 10MG BASE;25MG;40MG** | **N200175** | **005** | Jul 23, 2010 |

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

**AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AUROBINDO PHARMA LTD | **5MG;12.5MG;160MG** | **A206180** | **001** | Dec 19, 2017 |
| **AB** | | | **5MG;25MG;160MG** | **A206180** | **002** | Dec 19, 2017 |
| **AB** | | | **10MG;12.5MG;160MG** | **A206180** | **003** | Dec 19, 2017 |
| **AB** | | | **10MG;25MG;160MG** | **A206180** | **004** | Dec 19, 2017 |
| **AB** | | | **10MG;25MG;320MG** | **A206180** | **005** | Dec 19, 2017 |
| **AB** | | LUPIN LTD | **5MG;12.5MG;160MG** | **A200797** | **001** | Jun 03, 2015 |
| **AB** | | | **5MG;25MG;160MG** | **A200797** | **002** | Jun 03, 2015 |
| **AB** | | | **10MG;12.5MG;160MG** | **A200797** | **003** | Jun 03, 2015 |
| **AB** | | | **10MG;25MG;160MG** | **A200797** | **004** | Jun 03, 2015 |
| **AB** | | | **10MG;25MG;320MG** | **A200797** | **005** | Jun 03, 2015 |
| **AB** | | PAR PHARM | **5MG;12.5MG;160MG** | **A201087** | **001** | Jun 01, 2015 |
| **AB** | | | **5MG;25MG;160MG** | **A201087** | **002** | Jun 01, 2015 |
| **AB** | | | **10MG;12.5MG;160MG** | **A201087** | **003** | Jun 01, 2015 |
| **AB** | | | **10MG;25MG;160MG** | **A201087** | **004** | Jun 01, 2015 |
| **AB** | | | **10MG;25MG;320MG** | **A201087** | **005** | Jun 01, 2015 |
| **AB** | | TEVA PHARMS | **5MG;12.5MG;160MG** | **A200435** | **001** | Sep 25, 2012 |
| **AB** | | | **5MG;25MG;160MG** | **A200435** | **002** | Sep 25, 2012 |
| **AB** | | | **10MG;12.5MG;160MG** | **A200435** | **005** | Sep 25, 2012 |
| **AB** | | | **10MG;25MG;160MG** | **A200435** | **003** | Sep 25, 2012 |
| **AB** | | | **10MG;25MG;320MG** | **A200435** | **004** | Sep 25, 2012 |
| **AB** | | TORRENT PHARMS LTD | **5MG;12.5MG;160MG** | **A201593** | **001** | Jun 03, 2015 |
| **AB** | | | **5MG;25MG;160MG** | **A201593** | **002** | Jun 03, 2015 |
| **AB** | | | **10MG;12.5MG;160MG** | **A201593** | **003** | Jun 03, 2015 |
| **AB** | | | **10MG;25MG;160MG** | **A201593** | **004** | Jun 03, 2015 |
| **AB** | | | **10MG;25MG;320MG** | **A201593** | **005** | Jun 03, 2015 |

**EXFORGE HCT**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | NOVARTIS | **5MG;12.5MG;160MG** | **N022314** | **001** | Apr 30, 2009 |
| **AB** | + | | **5MG;25MG;160MG** | **N022314** | **002** | Apr 30, 2009 |
| **AB** | + | | **10MG;12.5MG;160MG** | **N022314** | **003** | Apr 30, 2009 |
| **AB** | + | | **10MG;25MG;160MG** | **N022314** | **004** | Apr 30, 2009 |
| **AB** | +! | | **10MG;25MG;320MG** | **N022314** | **005** | Apr 30, 2009 |

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

**AMLODIPINE AND OLMESARTAN MEDOXOMIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AJANTA PHARMA LTD | **EQ 5MG BASE;20MG** | **A207216** | **001** | Oct 28, 2016 |
| **AB** | | | **EQ 5MG BASE;40MG** | **A207216** | **002** | Oct 28, 2016 |
| **AB** | | | **EQ 10MG BASE;20MG** | **A207216** | **003** | Oct 28, 2016 |
| **AB** | | | **EQ 10MG BASE;40MG** | **A207216** | **004** | Oct 28, 2016 |
| **AB** | | ALEMBIC PHARMS LTD | **EQ 5MG BASE;20MG** | **A207073** | **001** | Jul 17, 2017 |
| **AB** | | | **EQ 5MG BASE;40MG** | **A207073** | **002** | Jul 17, 2017 |
| **AB** | | | **EQ 10MG BASE;20MG** | **A207073** | **003** | Jul 17, 2017 |
| **AB** | | | **EQ 10MG BASE;40MG** | **A207073** | **004** | Jul 17, 2017 |
| **AB** | | ALKEM LABS LTD | **EQ 5MG BASE;20MG** | **A209042** | **001** | Aug 14, 2017 |
| **AB** | | | **EQ 5MG BASE;40MG** | **A209042** | **002** | Aug 14, 2017 |
| **AB** | | | **EQ 10MG BASE;20MG** | **A209042** | **003** | Aug 14, 2017 |
| **AB** | | | **EQ 10MG BASE;40MG** | **A209042** | **004** | Aug 14, 2017 |
| **AB** | | AUROBINDO PHARMA LTD | **EQ 5MG BASE;20MG** | **A206906** | **001** | May 15, 2017 |
| **AB** | | | **EQ 5MG BASE;40MG** | **A206906** | **002** | May 15, 2017 |
| **AB** | | | **EQ 10MG BASE;20MG** | **A206906** | **003** | May 15, 2017 |
| **AB** | | | **EQ 10MG BASE;40MG** | **A206906** | **004** | May 15, 2017 |
| **AB** | | GLENMARK PHARMS LTD | **EQ 5MG BASE;20MG** | **A207807** | **001** | Jul 05, 2017 |
| **AB** | | | **EQ 5MG BASE;40MG** | **A207807** | **002** | Jul 05, 2017 |
| **AB** | | | **EQ 10MG BASE;20MG** | **A207807** | **003** | Jul 05, 2017 |
| **AB** | | | **EQ 10MG BASE;40MG** | **A207807** | **004** | Jul 05, 2017 |
| **AB** | | JUBILANT GENERICS | **EQ 5MG BASE;20MG** | **A207450** | **001** | May 15, 2017 |
| **AB** | | | **EQ 5MG BASE;40MG** | **A207450** | **002** | May 15, 2017 |
| **AB** | | | **EQ 10MG BASE;20MG** | **A207450** | **003** | May 15, 2017 |
| **AB** | | | **EQ 10MG BASE;40MG** | **A207450** | **004** | May 15, 2017 |
| **AB** | | MACLEODS PHARMS LTD | **EQ 5MG BASE;20MG** | **A206884** | **001** | Oct 26, 2016 |

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

**AMLODIPINE AND OLMESARTAN MEDOXOMIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **EQ 5MG BASE;40MG** | **A206884** | **003** | Oct 26, 2016 |
| **AB** | | | **EQ 10MG BASE;20MG** | **A206884** | **002** | Oct 26, 2016 |
| **AB** | | | **EQ 10MG BASE;40MG** | **A206884** | **004** | Oct 26, 2016 |
| **AB** | | MICRO LABS | **EQ 5MG BASE;20MG** | **A207435** | **001** | Nov 02, 2017 |
| **AB** | | | **EQ 5MG BASE;40MG** | **A207435** | **002** | Nov 02, 2017 |
| **AB** | | | **EQ 10MG BASE;20MG** | **A207435** | **003** | Nov 02, 2017 |
| **AB** | | | **EQ 10MG BASE;40MG** | **A207435** | **004** | Nov 02, 2017 |
| **AB** | | TEVA PHARMS USA | **EQ 5MG BASE;20MG** | **A091154** | **001** | Oct 26, 2016 |
| **AB** | | | **EQ 5MG BASE;40MG** | **A091154** | **002** | Oct 26, 2016 |
| **AB** | | | **EQ 10MG BASE;20MG** | **A091154** | **003** | Oct 26, 2016 |
| **AB** | | | **EQ 10MG BASE;40MG** | **A091154** | **004** | Oct 26, 2016 |
| **AB** | | TORRENT PHARMS LTD | **EQ 5MG BASE;20MG** | **A202933** | **001** | Nov 25, 2016 |
| **AB** | | | **EQ 5MG BASE;40MG** | **A202933** | **002** | Nov 25, 2016 |
| **AB** | | | **EQ 10MG BASE;20MG** | **A202933** | **003** | Nov 25, 2016 |
| **AB** | | | **EQ 10MG BASE;40MG** | **A202933** | **004** | Nov 25, 2016 |
| **AB** | | ZYDUS PHARMS USA INC | **EQ 5MG BASE;20MG** | **A207771** | **001** | Sep 22, 2017 |
| **AB** | | | **EQ 5MG BASE;40MG** | **A207771** | **002** | Sep 22, 2017 |
| **AB** | | | **EQ 10MG BASE;20MG** | **A207771** | **003** | Sep 22, 2017 |
| **AB** | | | **EQ 10MG BASE;40MG** | **A207771** | **004** | Sep 22, 2017 |

**AZOR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | DAIICHI SANKYO | **EQ 5MG BASE;20MG** | **N022100** | **001** | Sep 26, 2007 |
| **AB** | **+** | | **EQ 5MG BASE;40MG** | **N022100** | **002** | Sep 26, 2007 |
| **AB** | **+** | | **EQ 10MG BASE;20MG** | **N022100** | **003** | Sep 26, 2007 |
| **AB** | **+!** | | **EQ 10MG BASE;40MG** | **N022100** | **004** | Sep 26, 2007 |

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET;ORAL

PRESTALIA

| | | | | | |
|---|---|---|---|---|---|
| + | MARINA BIOTECH | EQ 2.5MG BASE;3.5MG | N205003 | 001 | Jan 21, 2015 |
| + | | EQ 5MG BASE;7MG | N205003 | 002 | Jan 21, 2015 |
| +! | | EQ 10MG BASE;14MG | N205003 | 003 | Jan 21, 2015 |

AMLODIPINE BESYLATE; TELMISARTAN

TABLET;ORAL

**TELMISARTAN AND AMLODIPINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALEMBIC PHARMS LTD | **EQ 5MG BASE;40MG** | **A205234** | **001** | Nov 17, 2016 |
| **AB** | | | **EQ 5MG BASE;80MG** | **A205234** | **003** | Nov 17, 2016 |
| **AB** | | | **EQ 10MG BASE;40MG** | **A205234** | **002** | Nov 17, 2016 |
| **AB** | | | **EQ 10MG BASE;80MG** | **A205234** | **004** | Nov 17, 2016 |
| **AB** | | LUPIN LTD | **EQ 5MG BASE;40MG** | **A201586** | **001** | Jan 08, 2014 |
| **AB** | | | **EQ 5MG BASE;80MG** | **A201586** | **003** | Jan 08, 2014 |
| **AB** | | | **EQ 10MG BASE;40MG** | **A201586** | **002** | Jan 08, 2014 |
| **AB** | | | **EQ 10MG BASE;80MG** | **A201586** | **004** | Jan 08, 2014 |
| **AB** | | MYLAN PHARMS INC | **EQ 5MG BASE;40MG** | **A202516** | **001** | Aug 26, 2014 |
| **AB** | | | **EQ 5MG BASE;80MG** | **A202516** | **003** | Aug 26, 2014 |
| **AB** | | | **EQ 10MG BASE;40MG** | **A202516** | **002** | Aug 26, 2014 |
| **AB** | | | **EQ 10MG BASE;80MG** | **A202516** | **004** | Aug 26, 2014 |
| **AB** | | TORRENT PHARMS LTD | **EQ 5MG BASE;40MG** | **A202517** | **001** | Jan 08, 2014 |
| **AB** | | | **EQ 5MG BASE;80MG** | **A202517** | **003** | Jan 08, 2014 |
| **AB** | | | **EQ 10MG BASE;40MG** | **A202517** | **002** | Jan 08, 2014 |
| **AB** | | | **EQ 10MG BASE;80MG** | **A202517** | **004** | Jan 08, 2014 |

**TWYNSTA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | BOEHRINGER INGELHEIM | **EQ 5MG BASE;40MG** | **N022401** | **001** | Oct 16, 2009 |
| **AB** | **+** | | **EQ 5MG BASE;80MG** | **N022401** | **003** | Oct 16, 2009 |
| **AB** | **+** | | **EQ 10MG BASE;40MG** | **N022401** | **002** | Oct 16, 2009 |
| **AB** | **+!** | | **EQ 10MG BASE;80MG** | **N022401** | **004** | Oct 16, 2009 |

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

**AMLODIPINE BESYLATE AND VALSARTAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALEMBIC PHARMS LTD | **EQ 5MG BASE;160MG** | **A202713** | **001** | Apr 03, 2015 |
| **AB** | | | **EQ 5MG BASE;320MG** | **A202713** | **003** | Apr 03, 2015 |
| **AB** | | | **EQ 10MG BASE;160MG** | **A202713** | **002** | Apr 03, 2015 |
| **AB** | | | **EQ 10MG BASE;320MG** | **A202713** | **004** | Apr 03, 2015 |
| **AB** | | AUROBINDO PHARMA LTD | **EQ 5MG BASE;160MG** | **A206512** | **001** | Apr 22, 2016 |
| **AB** | | | **EQ 5MG BASE;320MG** | **A206512** | **002** | Apr 22, 2016 |
| **AB** | | | **EQ 10MG BASE;160MG** | **A206512** | **003** | Apr 22, 2016 |
| **AB** | | | **EQ 10MG BASE;320MG** | **A206512** | **004** | Apr 22, 2016 |

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

**AMLODIPINE BESYLATE AND VALSARTAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | INVAGEN PHARMS | **EQ 5MG BASE;160MG** | **A205137** | **001** | Sep 16, 2016 |
| **AB** | | | **EQ 5MG BASE;320MG** | **A205137** | **003** | Sep 16, 2016 |
| **AB** | | | **EQ 10MG BASE;160MG** | **A205137** | **002** | Sep 16, 2016 |
| **AB** | | | **EQ 10MG BASE;320MG** | **A205137** | **004** | Sep 16, 2016 |
| **AB** | | LUPIN | **EQ 5MG BASE;160MG** | **A090245** | **001** | Mar 30, 2015 |
| **AB** | | | **EQ 5MG BASE;320MG** | **A090245** | **003** | Mar 30, 2015 |
| **AB** | | | **EQ 10MG BASE;160MG** | **A090245** | **002** | Mar 30, 2015 |
| **AB** | | | **EQ 10MG BASE;320MG** | **A090245** | **004** | Mar 30, 2015 |
| **AB** | | MYLAN PHARMS INC | **EQ 5MG BASE;160MG** | **A090483** | **001** | Mar 30, 2015 |
| **AB** | | | **EQ 5MG BASE;320MG** | **A090483** | **003** | Mar 30, 2015 |
| **AB** | | | **EQ 10MG BASE;160MG** | **A090483** | **002** | Mar 30, 2015 |
| **AB** | | | **EQ 10MG BASE;320MG** | **A090483** | **004** | Mar 30, 2015 |
| **AB** | | NOVEL LABS INC | **EQ 5MG BASE;160MG** | **A202829** | **001** | Mar 30, 2015 |
| **AB** | | | **EQ 5MG BASE;320MG** | **A202829** | **003** | Mar 30, 2015 |
| **AB** | | | **EQ 10MG BASE;160MG** | **A202829** | **002** | Mar 30, 2015 |
| **AB** | | | **EQ 10MG BASE;320MG** | **A202829** | **004** | Mar 30, 2015 |
| **AB** | | PAR PHARM INC | **EQ 5MG BASE;160MG** | **A090011** | **001** | Mar 28, 2013 |
| **AB** | | | **EQ 5MG BASE;320MG** | **A090011** | **003** | Mar 28, 2013 |
| **AB** | | | **EQ 10MG BASE;160MG** | **A090011** | **002** | Mar 28, 2013 |
| **AB** | | | **EQ 10MG BASE;320MG** | **A090011** | **004** | Mar 28, 2013 |
| **AB** | | TEVA PHARMS USA | **EQ 5MG BASE;160MG** | **A091235** | **001** | Mar 30, 2015 |
| **AB** | | | **EQ 5MG BASE;320MG** | **A091235** | **003** | Mar 30, 2015 |
| **AB** | | | **EQ 10MG BASE;160MG** | **A091235** | **002** | Mar 30, 2015 |
| **AB** | | | **EQ 10MG BASE;320MG** | **A091235** | **004** | Mar 30, 2015 |
| **AB** | | TORRENT PHARMS LTD | **EQ 5MG BASE;160MG** | **A202377** | **001** | Mar 30, 2015 |
| **AB** | | | **EQ 5MG BASE;320MG** | **A202377** | **002** | Mar 30, 2015 |
| **AB** | | | **EQ 10MG BASE;160MG** | **A202377** | **003** | Mar 30, 2015 |
| **AB** | | | **EQ 10MG BASE;320MG** | **A202377** | **004** | Mar 30, 2015 |

**EXFORGE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | NOVARTIS | **EQ 5MG BASE;160MG** | **N021990** | **002** | Jun 20, 2007 |
| **AB** | **+** | | **EQ 5MG BASE;320MG** | **N021990** | **004** | Jun 20, 2007 |
| **AB** | **+!** | | **EQ 10MG BASE;160MG** | **N021990** | **003** | Jun 20, 2007 |
| **AB** | **+!** | | **EQ 10MG BASE;320MG** | **N021990** | **005** | Jun 20, 2007 |

AMMONIA N-13

INJECTABLE;INTRAVENOUS

**AMMONIA N 13**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | 3D IMAGING DRUG | **30mCi-300mCi/8ML (3.75-37.5mCi/ML)** | **A203779** | **001** | Oct 19, 2015 |
| **AP** | | BIOMEDCL RES FDN | **48.75mCi-487.5mCi/13ML (3.75-37.5mCi/ML)** | **A204352** | **001** | May 01, 2015 |
| **AP** | | BRIGHAM WOMENS HOSP | **30mCi-300mCi/8ML (3.75-37.5mCi/ML)** | **A203783** | **001** | Oct 30, 2014 |
| **AP** | | CARDINAL HEALTH 414 | **30mCi-300mCi/8ML (3.75-37.5mCi/ML)** | **A203700** | **001** | Feb 25, 2013 |
| **AP** | **+!** | FEINSTEIN | **30mCi-300mCi/8ML (3.75-37.5mCi/ML)** | **N022119** | **001** | Aug 23, 2007 |
| **AP** | | GEN HOSP | **30mCi-300mCi/8ML (3.75-37.5mCi/ML)** | **A207025** | **001** | Feb 03, 2016 |
| **AP** | | GLOBAL ISOTOPES LLC | **30mCi-300mCi/8ML (3.75-37.5mCi/ML)** | **A204465** | **001** | Oct 23, 2014 |
| **AP** | | IBA MOLECULAR N AM | **18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)** | **A204667** | **001** | Apr 22, 2015 |
| **AP** | | JOHNS HOPKINS UNIV | **30mCi-300mCi/8ML (3.75-37.5mCi/ML)** | **A204514** | **001** | Aug 19, 2014 |
| **AP** | | KREITCHMAN PET CTR | **30mCi-300mCi/8ML (3.75-37.5mCi/ML)** | **A203938** | **001** | Dec 09, 2013 |
| **AP** | | MCPRF | **30mCi-300mCi/8ML (3.75-37.5mCi/ML)** | **A203321** | **001** | Feb 25, 2013 |
| **AP** | | MIDWEST MEDCL | **30mCi-300mCi/8ML (3.75-37.5mCi/ML)** | **A204457** | **001** | Nov 18, 2015 |
| **AP** | | MIPS CRF | **30mCi-300mCi/8ML (3.75-37.5mCi/ML)** | **A204535** | **001** | Nov 20, 2014 |
| **AP** | | PETNET | **30mCi-300mCi (3.75-37.5mCi/ML)** | **A204510** | **001** | Nov 02, 2015 |
| **AP** | | SPECTRON MRC LLC | **30mCi-300mCi/8ML (3.75-37.5mCi/ML)** | **A204455** | **001** | Apr 23, 2015 |
| **AP** | | UCLA BIOMEDICAL | **30mCi-300mCi/8ML (3.75-37.5mCi/ML)** | **A203812** | **001** | Jun 27, 2013 |
| **AP** | | UCSF RODIOPHARM | **30mCi-300mCi/8ML (3.75-37.5mCi/ML)** | **A204496** | **001** | Mar 28, 2014 |
| **AP** | | UNIV TX MD ANDERSON | **30mCi-300mCi/8ML (3.75-37.5mCi/ML)** | **A203933** | **001** | Jun 27, 2014 |
| **AP** | | WA UNIV SCH MED | **30mCi-300mCi/8ML (3.75-37.5mCi/ML)** | **A204506** | **001** | Feb 07, 2014 |
| | | ESSENTIAL ISOTOPES | 3.75-260mCi/ML | A205687 | 001 | Dec 17, 2015 |
| | | HOUSTON CYCLOTRON | 3.75-260mCi/ML | A203543 | 001 | Dec 14, 2012 |
| | | NCM USA BRONX LLC | 3.75-260mCi/mL | A204515 | 001 | Feb 04, 2015 |
| | | PRECISION NUCLEAR | 3.75-260mCi/ML | A204547 | 001 | Aug 14, 2015 |
| | | SHERTECH LABS LLC | 3.75-260mCi/ML | A204366 | 001 | Sep 19, 2014 |
| | | WI MEDCL CYCLOTRON | 3.75-260mCi/ML | A204356 | 001 | Dec 18, 2014 |

AMMONIUM CHLORIDE

INJECTABLE;INJECTION

AMMONIUM CHLORIDE IN PLASTIC CONTAINER

| | | | | | | |
|---|---|---|---|---|---|---|
| | **!** | HOSPIRA | 5MEQ/ML | A088366 | 001 | Jun 13, 1984 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AMMONIUM LACTATE | | | | | | | |
| CREAM;TOPICAL | | | | | | | |
| **AMMONIUM LACTATE** | | | | | | | |
| **AB** | ! | PERRIGO NEW YORK | **EQ 12% BASE** | **A075774** | **001** | May 01, 2002 |
| **AB** | | TARO | **EQ 12% BASE** | **A075883** | **001** | Apr 10, 2003 |
| **AB** | | WATSON LABS INC | **EQ 12% BASE** | **A076829** | **001** | Feb 07, 2006 |
| LOTION;TOPICAL | | | | | | | |
| **AMMONIUM LACTATE** | | | | | | | |
| **AB** | ! | PERRIGO NEW YORK | **EQ 12% BASE** | **A075570** | **001** | Jun 23, 2004 |
| **AB** | | TARO | **EQ 12% BASE** | **A076216** | **001** | May 28, 2004 |
| **AB** | | WATSON LABS INC | **EQ 12% BASE** | **A075575** | **001** | Jun 11, 2002 |
| AMOXAPINE | | | | | | | |
| TABLET;ORAL | | | | | | | |
| AMOXAPINE | | | | | | | |
| | | WATSON LABS | 25MG | A072688 | 001 | Aug 28, 1992 |
| | | | 50MG | A072689 | 001 | Aug 28, 1992 |
| | | | 100MG | A072690 | 001 | Aug 28, 1992 |
| | ! | | 150MG | A072691 | 001 | Aug 28, 1992 |
| AMOXICILLIN | | | | | | | |
| CAPSULE;ORAL | | | | | | | |
| **AMOXICILLIN** | | | | | | | |
| **AB** | | AM ANTIBIOTICS | **250MG** | **A062058** | **001** | |
| **AB** | | | **500MG** | **A062058** | **002** | |
| **AB** | | AUROBINDO | **250MG** | **A065271** | **001** | Nov 09, 2005 |
| **AB** | | | **500MG** | **A065271** | **002** | Nov 09, 2005 |
| **AB** | | DAVA PHARMS INC | **250MG** | **A062884** | **001** | Feb 25, 1988 |
| **AB** | | | **500MG** | **A062881** | **001** | Feb 25, 1988 |
| **AB** | | HIKMA PHARMS | **250MG** | **A065291** | **001** | Feb 05, 2007 |
| **AB** | | | **500MG** | **A065291** | **002** | Feb 05, 2007 |
| **AB** | | SANDOZ | **250MG** | **A064076** | **001** | Sep 30, 1994 |
| **AB** | | | **500MG** | **A064076** | **002** | Sep 30, 1994 |
| **AB** | | TEVA | **250MG** | **A061926** | **001** | |
| **AB** | ! | | **500MG** | **A061926** | **003** | |
| **AMOXIL** | | | | | | | |
| **AB** | | DR REDDYS LABS INC | **250MG** | **A062216** | **001** | |
| **AB** | | | **500MG** | **A062216** | **004** | |
| FOR SUSPENSION;ORAL | | | | | | | |
| **AMOXICILLIN** | | | | | | | |
| **AB** | | AUROBINDO | **200MG/5ML** | **A065334** | **001** | Dec 28, 2006 |
| **AB** | | | **400MG/5ML** | **A065334** | **002** | Dec 28, 2006 |
| **AB** | | AUROBINDO PHARMA LTD | **125MG/5ML** | **A204030** | **001** | Sep 15, 2014 |
| **AB** | | | **250MG/5ML** | **A204030** | **002** | Sep 15, 2014 |
| **AB** | | DAVA PHARMS INC | **125MG/5ML** | **A062927** | **001** | Nov 25, 1988 |
| **AB** | | | **250MG/5ML** | **A062927** | **002** | Nov 25, 1988 |
| **AB** | | HIKMA | **125MG/5ML** | **A065322** | **002** | Jun 19, 2006 |
| **AB** | | | **200MG/5ML** | **A065325** | **002** | Jun 19, 2006 |
| **AB** | | | **250MG/5ML** | **A065322** | **001** | Jun 19, 2006 |
| **AB** | | | **400MG/5ML** | **A065325** | **001** | Jun 19, 2006 |
| **AB** | | SANDOZ | **125MG/5ML** | **A065387** | **001** | Mar 26, 2007 |
| **AB** | | | **200MG/5ML** | **A065378** | **001** | Mar 26, 2007 |
| **AB** | | | **250MG/5ML** | **A065387** | **002** | Mar 26, 2007 |
| **AB** | | | **400MG/5ML** | **A065378** | **002** | Mar 26, 2007 |
| **AB** | | TEVA | **125MG/5ML** | **A061931** | **001** | |
| **AB** | | | **200MG/5ML** | **A065119** | **001** | Dec 04, 2002 |
| **AB** | ! | | **250MG/5ML** | **A061931** | **002** | |
| **AB** | ! | | **400MG/5ML** | **A065119** | **002** | Dec 04, 2002 |
| **AB** | | WOCKHARDT BIO AG | **400MG/5ML** | **A065319** | **002** | Jun 18, 2007 |
| **AMOXICILLIN PEDIATRIC** | | | | | | | |
| **AB** | | TEVA | **50MG/ML** | **A061931** | **003** | Dec 01, 1982 |
| **AMOXIL** | | | | | | | |
| **AB** | | DR REDDYS LABS INC | **50MG/ML** | **A062226** | **005** | |
| **AB** | | | **125MG/5ML** | **A062226** | **001** | |
| **AB** | | | **250MG/5ML** | **A062226** | **002** | |
| **LAROTID** | | | | | | | |
| **AB** | | DR REDDYS LABS INC | **125MG/5ML** | **A062226** | **003** | |
| **AB** | | | **250MG/5ML** | **A062226** | **004** | |
| TABLET;ORAL | | | | | | | |
| **AMOXICILLIN** | | | | | | | |
| **AB** | | AUROBINDO | **500MG** | **A065256** | **001** | Nov 09, 2005 |
| **AB** | | | **875MG** | **A065256** | **002** | Nov 09, 2005 |
| **AB** | | HIKMA | **875MG** | **A065255** | **001** | Mar 29, 2006 |

| | | | | | | |
|---|---|---|---|---|---|---|
| AMOXICILLIN | | | | | | |
| TABLET;ORAL | | | | | | |
| **AMOXICILLIN** | | | | | | |
| **AB** | | SANDOZ | **500MG** | **A065228** | **001** | Jul 13, 2005 |
| **AB** | | | **875MG** | **A065228** | **002** | Jul 13, 2005 |
| **AB** | | TEVA | **500MG** | **A065056** | **001** | Sep 18, 2000 |
| **AB** | **!** | | **875MG** | **A065056** | **002** | Sep 18, 2000 |
| TABLET, CHEWABLE;ORAL | | | | | | |
| AMOXICILLIN | | | | | | |
| | | TEVA | 125MG | A064013 | 002 | Sep 11, 1995 |
| | ! | | 250MG | A064013 | 001 | Dec 22, 1992 |
| TABLET, EXTENDED RELEASE;ORAL | | | | | | |
| MOXATAG | | | | | | |
| | +! | VERNALIS R AND D LTD | 775MG | N050813 | 001 | Jan 23, 2008 |
| AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE | | | | | | |
| CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET;ORAL | | | | | | |
| **LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN** | | | | | | |
| **AB** | | RISING PHARMS INC | **500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG** | **A206006** | **001** | Oct 07, 2016 |
| **AB** | | SANDOZ INC | **500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG** | **A202588** | **001** | Mar 04, 2014 |
| **AB** | | TEVA PHARMS USA | **500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG** | **A200218** | **001** | Aug 30, 2013 |
| **PREVPAC** | | | | | | |
| **AB** | **+!** | TAKEDA PHARMS USA | **500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG** | **N050757** | **001** | Dec 02, 1997 |
| AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE | | | | | | |
| CAPSULE, TABLET, CAPSULE, DELAYED RELEASE;ORAL | | | | | | |
| OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN | | | | | | |
| | +! | GASTROENTERO | 500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,20MG | N050824 | 001 | Feb 08, 2011 |
| AMOXICILLIN; CLAVULANATE POTASSIUM | | | | | | |
| FOR SUSPENSION;ORAL | | | | | | |
| **AMOXICILLIN AND CLAVULANATE POTASSIUM** | | | | | | |
| **AB** | | AUROBINDO PHARMA LTD | **200MG/5ML;EQ 28.5MG BASE/5ML** | **A201090** | **001** | Dec 20, 2011 |
| **AB** | | | **400MG/5ML;EQ 57MG BASE/5ML** | **A201090** | **002** | Dec 20, 2011 |
| **AB** | | | **600MG/5ML;EQ 42.9MG BASE/5ML** | **A201091** | **001** | Dec 20, 2011 |
| **AB** | | HIKMA PHARMS | **200MG/5ML;EQ 28.5MG BASE/5ML** | **A065191** | **002** | Jan 25, 2005 |
| **AB** | | | **400MG/5ML;EQ 57MG BASE/5ML** | **A065191** | **001** | Jan 25, 2005 |
| **AB** | | | **600MG/5ML;EQ 42.9MG BASE/5ML** | **A065373** | **001** | Nov 09, 2007 |
| **AB** | | SANDOZ | **200MG/5ML;EQ 28.5MG BASE/5ML** | **A065066** | **001** | Jun 05, 2002 |
| **AB** | | | **400MG/5ML;EQ 57MG BASE/5ML** | **A065066** | **002** | Jun 05, 2002 |
| **AB** | | SANDOZ INC | **200MG/5ML;EQ 28.5MG BASE/5ML** | **A065098** | **001** | Dec 16, 2002 |
| **AB** | | | **400MG/5ML;EQ 57MG BASE/5ML** | **A065098** | **002** | Dec 16, 2002 |
| **AB** | | | **600MG/5ML;EQ 42.9MG BASE/5ML** | **A065358** | **001** | Aug 13, 2007 |
| **AB** | | TEVA | **200MG/5ML;EQ 28.5MG BASE/5ML** | **A065089** | **001** | May 25, 2004 |
| **AB** | **!** | | **400MG/5ML;EQ 57MG BASE/5ML** | **A065089** | **002** | May 25, 2004 |
| **AB** | **!** | | **600MG/5ML;EQ 42.9MG BASE/5ML** | **A065162** | **001** | Mar 12, 2004 |
| **AB** | | WOCKHARDT BIO AG | **250MG/5ML;EQ 62.5MG BASE/5ML** | **A065431** | **001** | Nov 25, 2008 |
| **AB** | | | **600MG/5ML;EQ 42.9MG BASE/5ML** | **A065420** | **001** | Dec 02, 2013 |
| **AUGMENTIN '250'** | | | | | | |
| **AB** | **+!** | DR REDDYS LABS INC | **250MG/5ML;EQ 62.5MG BASE/5ML** | **N050575** | **002** | Aug 06, 1984 |
| AUGMENTIN '125' | | | | | | |
| | + | DR REDDYS LABS INC | 125MG/5ML;EQ 31.25MG BASE/5ML | N050575 | 001 | Aug 06, 1984 |
| TABLET;ORAL | | | | | | |
| **AMOXICILLIN AND CLAVULANATE POTASSIUM** | | | | | | |
| **AB** | | AUROBINDO PHARMA LTD | **250MG;EQ 125MG BASE** | **A091569** | **001** | Jan 20, 2012 |
| **AB** | | | **500MG;EQ 125MG BASE** | **A091569** | **002** | Jan 20, 2012 |
| **AB** | | | **875MG;EQ 125MG BASE** | **A091568** | **001** | Jan 20, 2012 |
| **AB** | | HIKMA PHARMS | **875MG;EQ 125MG BASE** | **A203824** | **001** | Aug 23, 2016 |
| **AB** | | MICRO LABS LTD INDIA | **250MG;EQ 125MG BASE** | **A205707** | **001** | Dec 30, 2016 |
| **AB** | | | **500MG;EQ 125MG BASE** | **A205707** | **002** | Dec 30, 2016 |
| **AB** | | | **875MG;EQ 125MG BASE** | **A204755** | **003** | Dec 30, 2016 |
| **AB** | **!** | SANDOZ | **250MG;EQ 125MG BASE** | **A065189** | **001** | Aug 23, 2005 |
| **AB** | | | **500MG;EQ 125MG BASE** | **A065064** | **001** | Mar 15, 2002 |
| **AB** | **!** | | **875MG;EQ 125MG BASE** | **A065063** | **001** | Mar 14, 2002 |
| **AB** | **!** | SANDOZ INC | **500MG;EQ 125MG BASE** | **A065117** | **001** | Nov 27, 2002 |
| **AB** | | | **875MG;EQ 125MG BASE** | **A065093** | **001** | Nov 21, 2002 |
| **AB** | | TEVA | **500MG;EQ 125MG BASE** | **A065101** | **001** | Oct 30, 2002 |

AMOXICILLIN; CLAVULANATE POTASSIUM

TABLET;ORAL

**AMOXICILLIN AND CLAVULANATE POTASSIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | TEVA PHARMS USA | **875MG;EQ 125MG BASE** | **A065096** | **001** | Oct 29, 2002 |

**AUGMENTIN '875'**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | DR REDDYS LABS INC | **875MG;EQ 125MG BASE** | **N050720** | **001** | Feb 13, 1996 |

TABLET, CHEWABLE;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

| | | | | | |
|---|---|---|---|---|---|
| | TEVA | 200MG;EQ 28.5MG BASE | A065205 | 001 | Feb 09, 2005 |
| ! | | 400MG;EQ 57MG BASE | A065205 | 002 | Feb 09, 2005 |

TABLET, EXTENDED RELEASE;ORAL

**AMOXICILLIN AND CLAVULANATE POTASSIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | SANDOZ | **1GM;EQ 62.5MG BASE** | **A090227** | **001** | Apr 21, 2010 |

**AUGMENTIN XR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | DR REDDYS LABS INC | **1GM;EQ 62.5MG BASE** | **N050785** | **001** | Sep 25, 2002 |

AMPHETAMINE

SUSPENSION, EXTENDED RELEASE;ORAL

ADZENYS ER

| | | | | | |
|---|---|---|---|---|---|
| +! | NEOS THERAPS INC | EQ 1.25MG BASE/ML | N204325 | 001 | Sep 15, 2017 |

DYANAVEL XR

| | | | | | |
|---|---|---|---|---|---|
| +! | TRIS PHARMA INC | EQ 2.5MG BASE/ML | N208147 | 001 | Oct 19, 2015 |

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

ADZENYS XR-ODT

| | | | | | |
|---|---|---|---|---|---|
| + | NEOS THERAPS | EQ 3.1MG BASE | N204326 | 001 | Jan 27, 2016 |
| + | | EQ 6.3MG BASE | N204326 | 002 | Jan 27, 2016 |
| + | | EQ 9.4MG BASE | N204326 | 003 | Jan 27, 2016 |
| + | | EQ 12.5MG BASE | N204326 | 004 | Jan 27, 2016 |
| + | | EQ 15.7MG BASE | N204326 | 005 | Jan 27, 2016 |
| +! | | EQ 18.8MG BASE | N204326 | 006 | Jan 27, 2016 |

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

**ADDERALL XR 10**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | SHIRE | **2.5MG;2.5MG;2.5MG;2.5MG** | **N021303** | **001** | Oct 11, 2001 |

**ADDERALL XR 15**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | SHIRE | **3.75MG;3.75MG;3.75MG;3.75MG** | **N021303** | **006** | May 22, 2002 |

**ADDERALL XR 20**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | SHIRE | **5MG;5MG;5MG;5MG** | **N021303** | **002** | Oct 11, 2001 |

**ADDERALL XR 25**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | SHIRE | **6.25MG;6.25MG;6.25MG;6.25MG** | **N021303** | **004** | May 22, 2002 |

**ADDERALL XR 30**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | SHIRE | **7.5MG;7.5MG;7.5MG;7.5MG** | **N021303** | **003** | Oct 11, 2001 |

**ADDERALL XR 5**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | SHIRE | **1.25MG;1.25MG;1.25MG;1.25MG** | **N021303** | **005** | May 22, 2002 |

**DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | ACTAVIS ELIZABETH | **1.25MG;1.25MG;1.25MG;1.25MG** | **A077302** | **001** | Jun 22, 2012 |
| **AB** | | **2.5MG;2.5MG;2.5MG;2.5MG** | **A077302** | **002** | Jun 22, 2012 |
| **AB** | | **3.75MG;3.75MG;3.75MG;3.75MG** | **A077302** | **003** | Jun 22, 2012 |
| **AB** | | **5MG;5MG;5MG;5MG** | **A077302** | **004** | Jun 22, 2012 |
| **AB** | | **6.25MG;6.25MG;6.25MG;6.25MG** | **A077302** | **005** | Jun 22, 2012 |
| **AB** | | **7.5MG;7.5MG;7.5MG;7.5MG** | **A077302** | **006** | Jun 22, 2012 |
| **AB** | IMPAX LABS | **1.25MG;1.25MG;1.25MG;1.25MG** | **A076852** | **001** | Feb 16, 2016 |
| **AB** | | **2.5MG;2.5MG;2.5MG;2.5MG** | **A076852** | **002** | Feb 16, 2016 |
| **AB** | | **3.75MG;3.75MG;3.75MG;3.75MG** | **A076852** | **003** | Feb 16, 2016 |
| **AB** | | **5MG;5MG;5MG;5MG** | **A076852** | **004** | Feb 16, 2016 |
| **AB** | | **6.25MG;6.25MG;6.25MG;6.25MG** | **A076852** | **005** | Feb 16, 2016 |
| **AB** | | **7.5MG;7.5MG;7.5MG;7.5MG** | **A076852** | **006** | Feb 16, 2016 |
| **AB** | TEVA | **1.25MG;1.25MG;1.25MG;1.25MG** | **A077488** | **001** | Apr 29, 2013 |
| **AB** | | **2.5MG;2.5MG;2.5MG;2.5MG** | **A077488** | **002** | Apr 29, 2013 |
| **AB** | | **3.75MG;3.75MG;3.75MG;3.75MG** | **A077488** | **003** | Apr 29, 2013 |
| **AB** | | **5MG;5MG;5MG;5MG** | **A077488** | **004** | Apr 29, 2013 |
| **AB** | | **6.25MG;6.25MG;6.25MG;6.25MG** | **A077488** | **005** | Apr 29, 2013 |
| **AB** | | **7.5MG;7.5MG;7.5MG;7.5MG** | **A077488** | **006** | Apr 29, 2013 |

**DEXTROAMP SACCHARATE,AMP ASPARTATE,DEXTROAMP SULFATE AND AMP SULFATE**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | BARR LABS INC | **1.25MG;1.25MG;1.25MG;1.25MG** | **A076536** | **001** | Feb 12, 2013 |
| **AB** | | **2.5MG;2.5MG;2.5MG;2.5MG** | **A076536** | **002** | Feb 12, 2013 |
| **AB** | | **3.75MG;3.75MG;3.75MG;3.75MG** | **A076536** | **003** | Feb 12, 2013 |
| **AB** | | **5MG;5MG;5MG;5MG** | **A076536** | **004** | Feb 12, 2013 |
| **AB** | | **6.25MG;6.25MG;6.25MG;6.25MG** | **A076536** | **005** | Feb 12, 2013 |
| **AB** | | **7.5MG;7.5MG;7.5MG;7.5MG** | **A076536** | **006** | Feb 12, 2013 |

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

MYDAYIS

| | | | | | | |
|---|---|---|---|---|---|---|
| + | SHIRE DEV LLC | 3.125MG;3.125MG;3.125MG;3.125MG | N022063 | 001 | Jun 20, 2017 |
| + | | 6.25MG;6.25MG;6.25MG;6.25MG | N022063 | 002 | Jun 20, 2017 |
| + | | 9.375MG;9.375MG;9.375MG;9.375MG | N022063 | 003 | Jun 20, 2017 |
| + | | 12.5MG;12.5MG;12.5MG;12.5MG | N022063 | 004 | Jun 20, 2017 |

TABLET;ORAL

**DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | ACTAVIS ELIZABETH | **1.25MG;1.25MG;1.25MG;1.25MG** | **A040456** | **001** | May 06, 2003 |
| **AB** | | **1.25MG;1.25MG;1.25MG;1.25MG** | **A206340** | **001** | Feb 05, 2016 |
| **AB** | | **1.875MG;1.875MG;1.875MG;1.875MG** | **A206340** | **002** | Feb 05, 2016 |
| **AB** | | **2.5MG;2.5MG;2.5MG;2.5MG** | **A040456** | **002** | May 06, 2003 |
| **AB** | | **2.5MG;2.5MG;2.5MG;2.5MG** | **A206340** | **003** | Feb 05, 2016 |
| **AB** | | **3.125MG;3.125MG;3.125MG;3.125MG** | **A206340** | **004** | Feb 05, 2016 |
| **AB** | | **3.75MG;3.75MG;3.75MG;3.75MG** | **A206340** | **005** | Feb 05, 2016 |
| **AB** | | **5MG;5MG;5MG;5MG** | **A040456** | **003** | May 06, 2003 |
| **AB** | | **5MG;5MG;5MG;5MG** | **A206340** | **006** | Feb 05, 2016 |
| **AB** | | **7.5MG;7.5MG;7.5MG;7.5MG** | **A040456** | **004** | May 06, 2003 |
| **AB** | | **7.5MG;7.5MG;7.5MG;7.5MG** | **A206340** | **007** | Feb 05, 2016 |
| **AB** | ALVOGEN MALTA | **1.25MG;1.25MG;1.25MG;1.25MG** | **A207388** | **001** | Jul 28, 2017 |
| **AB** | | **1.875MG;1.875MG;1.875MG;1.875MG** | **A207388** | **002** | Jul 28, 2017 |
| **AB** | | **2.5MG;2.5MG;2.5MG;2.5MG** | **A207388** | **003** | Jul 28, 2017 |
| **AB** | | **3.125MG;3.125MG;3.125MG;3.125MG** | **A207388** | **004** | Jul 28, 2017 |
| **AB** | | **3.75MG;3.75MG;3.75MG;3.75MG** | **A207388** | **005** | Jul 28, 2017 |
| **AB** | | **5MG;5MG;5MG;5MG** | **A207388** | **006** | Jul 28, 2017 |
| **AB** | | **7.5MG;7.5MG;7.5MG;7.5MG** | **A207388** | **007** | Jul 28, 2017 |
| **AB** | AUROLIFE PHARMA LLC | **1.25MG;1.25MG;1.25MG;1.25MG** | **A202424** | **001** | Nov 27, 2013 |
| **AB** | | **1.875MG;1.875MG;1.875MG;1.875MG** | **A202424** | **002** | Nov 27, 2013 |
| **AB** | | **2.5MG;2.5MG;2.5MG;2.5MG** | **A202424** | **003** | Nov 27, 2013 |
| **AB** | | **3.125MG;3.125MG;3.125MG;3.125MG** | **A202424** | **004** | Nov 27, 2013 |
| **AB** | | **3.75MG;3.75MG;3.75MG;3.75MG** | **A202424** | **005** | Nov 27, 2013 |
| **AB** | | **5MG;5MG;5MG;5MG** | **A202424** | **006** | Nov 27, 2013 |
| **AB** | | **7.5MG;7.5MG;7.5MG;7.5MG** | **A202424** | **007** | Nov 27, 2013 |
| **AB** | BARR | **1.25MG;1.25MG;1.25MG;1.25MG** | **A040422** | **001** | Feb 11, 2002 |
| **AB** | | **1.875MG;1.875MG;1.875MG;1.875MG** | **A040422** | **005** | Mar 19, 2003 |
| **AB** | | **2.5MG;2.5MG;2.5MG;2.5MG** | **A040422** | **002** | Feb 11, 2002 |
| **AB** | | **3.125MG;3.125MG;3.125MG;3.125MG** | **A040422** | **006** | Mar 19, 2003 |
| **AB** | | **3.75MG;3.75MG;3.75MG;3.75MG** | **A040422** | **007** | Mar 19, 2003 |
| **AB** | | **5MG;5MG;5MG;5MG** | **A040422** | **003** | Feb 11, 2002 |
| **AB** | ! | **7.5MG;7.5MG;7.5MG;7.5MG** | **A040422** | **004** | Feb 11, 2002 |
| **AB** | EPIC PHARMA LLC | **1.25MG;1.25MG;1.25MG;1.25MG** | **A040444** | **001** | Jun 19, 2002 |
| **AB** | | **1.875MG;1.875MG;1.875MG;1.875MG** | **A040444** | **005** | Nov 03, 2014 |
| **AB** | | **2.5MG;2.5MG;2.5MG;2.5MG** | **A040444** | **002** | Jun 19, 2002 |
| **AB** | | **3.125MG;3.125MG;3.125MG;3.125MG** | **A040444** | **006** | Nov 03, 2014 |
| **AB** | | **3.75MG;3.75MG;3.75MG;3.75MG** | **A040444** | **007** | Nov 03, 2014 |
| **AB** | | **5MG;5MG;5MG;5MG** | **A040444** | **003** | Jun 19, 2002 |
| **AB** | | **7.5MG;7.5MG;7.5MG;7.5MG** | **A040444** | **004** | Jun 19, 2002 |
| **AB** | MYLAN PHARMS INC | **1.25MG;1.25MG;1.25MG;1.25MG** | **A206721** | **001** | Nov 10, 2015 |
| **AB** | | **1.875MG;1.875MG;1.875MG;1.875MG** | **A206721** | **002** | Nov 10, 2015 |
| **AB** | | **2.5MG;2.5MG;2.5MG;2.5MG** | **A206721** | **003** | Nov 10, 2015 |
| **AB** | | **3.125MG;3.125MG;3.125MG;3.125MG** | **A206721** | **004** | Nov 10, 2015 |
| **AB** | | **3.75MG;3.75MG;3.75MG;3.75MG** | **A206721** | **005** | Nov 10, 2015 |
| **AB** | | **5MG;5MG;5MG;5MG** | **A206721** | **006** | Nov 10, 2015 |
| **AB** | | **7.5MG;7.5MG;7.5MG;7.5MG** | **A206721** | **007** | Nov 10, 2015 |
| **AB** | NESHER PHARMS | **1.25MG;1.25MG;1.25MG;1.25MG** | **A207340** | **001** | Oct 31, 2017 |
| **AB** | | **1.875MG;1.875MG;1.875MG;1.875MG** | **A207340** | **002** | Oct 31, 2017 |
| **AB** | | **2.5MG;2.5MG;2.5MG;2.5MG** | **A207340** | **003** | Oct 31, 2017 |
| **AB** | | **3.125MG;3.125MG;3.125MG;3.125MG** | **A207340** | **004** | Oct 31, 2017 |
| **AB** | | **3.75MG;3.75MG;3.75MG;3.75MG** | **A207340** | **005** | Oct 31, 2017 |
| **AB** | | **5MG;5MG;5MG;5MG** | **A207340** | **006** | Oct 31, 2017 |
| **AB** | | **7.5MG;7.5MG;7.5MG;7.5MG** | **A207340** | **007** | Oct 31, 2017 |
| **AB** | SANDOZ | **1.25MG;1.25MG;1.25MG;1.25MG** | **A040439** | **004** | Sep 27, 2002 |
| **AB** | | **2.5MG;2.5MG;2.5MG;2.5MG** | **A040439** | **001** | Jun 14, 2002 |
| **AB** | | **5MG;5MG;5MG;5MG** | **A040439** | **002** | Jun 14, 2002 |
| **AB** | | **7.5MG;7.5MG;7.5MG;7.5MG** | **A040439** | **003** | Jun 14, 2002 |
| **AB** | SPECGX LLC | **1.25MG;1.25MG;1.25MG;1.25MG** | **A040440** | **001** | Oct 07, 2003 |
| **AB** | | **1.875MG;1.875MG;1.875MG;1.875MG** | **A040440** | **002** | Oct 07, 2003 |
| **AB** | | **2.5MG;2.5MG;2.5MG;2.5MG** | **A040440** | **003** | Oct 07, 2003 |
| **AB** | | **3.125MG;3.125MG;3.125MG;3.125MG** | **A040440** | **004** | Oct 07, 2003 |
| **AB** | | **3.75MG;3.75MG;3.75MG;3.75MG** | **A040440** | **005** | Oct 07, 2003 |
| **AB** | | **5MG;5MG;5MG;5MG** | **A040440** | **006** | Oct 07, 2003 |

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

**DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | | **7.5MG;7.5MG;7.5MG;7.5MG** | **A040440** | **007** | Oct 07, 2003 |
| **AB** | SUN PHARM INDUSTRIES | **1.25MG;1.25MG;1.25MG;1.25MG** | **A040480** | **001** | Sep 09, 2003 |
| **AB** | | **1.875MG;1.875MG;1.875MG;1.875MG** | **A040480** | **002** | Sep 09, 2003 |
| **AB** | | **2.5MG;2.5MG;2.5MG;2.5MG** | **A040480** | **003** | Sep 09, 2003 |
| **AB** | | **3.125MG;3.125MG;3.125MG;3.125MG** | **A040480** | **004** | Sep 09, 2003 |
| **AB** | | **3.75MG;3.75MG;3.75MG;3.75MG** | **A040480** | **005** | Sep 09, 2003 |
| **AB** | | **5MG;5MG;5MG;5MG** | **A040480** | **006** | Sep 09, 2003 |
| **AB** | | **7.5MG;7.5MG;7.5MG;7.5MG** | **A040480** | **007** | Sep 09, 2003 |
| **AB** | SUNRISE PHARM INC | **1.25MG;1.25MG;1.25MG;1.25MG** | **A209799** | **001** | Dec 28, 2017 |
| **AB** | | **1.875MG;1.875MG;1.875MG;1.875MG** | **A209799** | **002** | Dec 28, 2017 |
| **AB** | | **2.5MG;2.5MG;2.5MG;2.5MG** | **A209799** | **003** | Dec 28, 2017 |
| **AB** | | **3.125MG;3.125MG;3.125MG;3.125MG** | **A209799** | **004** | Dec 28, 2017 |
| **AB** | | **3.75MG;3.75MG;3.75MG;3.75MG** | **A209799** | **005** | Dec 28, 2017 |
| **AB** | | **5MG;5MG;5MG;5MG** | **A209799** | **006** | Dec 28, 2017 |
| **AB** | | **7.5MG;7.5MG;7.5MG;7.5MG** | **A209799** | **007** | Dec 28, 2017 |

AMPHETAMINE SULFATE

TABLET;ORAL

EVEKEO

| | | | | | |
|---|---|---|---|---|---|
| | ARBOR PHARMS LLC | 5MG | A200166 | 001 | Aug 09, 2012 |
| ! | | 10MG | A200166 | 002 | Aug 09, 2012 |

AMPHOTERICIN B

INJECTABLE;INJECTION

AMPHOTERICIN B

| | | | | | |
|---|---|---|---|---|---|
| ! | X GEN PHARMS | 50MG/VIAL | A063206 | 001 | Apr 29, 1992 |

INJECTABLE, LIPID COMPLEX;INJECTION

ABELCET

| | | | | | |
|---|---|---|---|---|---|
| +! | LEADIANT BIOSCI INC | 5MG/ML | N050724 | 001 | Nov 20, 1995 |

INJECTABLE, LIPOSOMAL;INJECTION

AMBISOME

| | | | | | |
|---|---|---|---|---|---|
| +! | ASTELLAS | 50MG/VIAL | N050740 | 001 | Aug 11, 1997 |

AMPICILLIN SODIUM

INJECTABLE;INJECTION

**AMPICILLIN SODIUM**

| | | | | | |
|---|---|---|---|---|---|
| **AP** | ACS DOBFAR SPA | **EQ 500MG BASE/VIAL** | **A090884** | **001** | Apr 03, 2013 |
| **AP** | | **EQ 1GM BASE/VIAL** | **A090884** | **002** | Apr 03, 2013 |
| **AP** | | **EQ 2GM BASE/VIAL** | **A090884** | **003** | Apr 03, 2013 |
| **AP** | | **EQ 10GM BASE/VIAL** | **A090889** | **001** | Apr 03, 2013 |
| **AP** | ANTIBIOTICE | **EQ 250MG BASE/VIAL** | **A090354** | **001** | Dec 28, 2009 |
| **AP** | | **EQ 500MG BASE/VIAL** | **A090354** | **002** | Dec 28, 2009 |
| **AP** | | **EQ 1GM BASE/VIAL** | **A090354** | **003** | Dec 28, 2009 |
| **AP** | | **EQ 2GM BASE/VIAL** | **A090354** | **004** | Dec 28, 2009 |
| **AP** | AUROBINDO PHARMA | **EQ 125MG BASE/VIAL** | **A065499** | **001** | Aug 17, 2010 |
| **AP** | | **EQ 250MG BASE/VIAL** | **A065499** | **002** | Aug 17, 2010 |
| **AP** | | **EQ 500MG BASE/VIAL** | **A065499** | **003** | Aug 17, 2010 |
| **AP** | | **EQ 1GM BASE/VIAL** | **A065499** | **004** | Aug 17, 2010 |
| **AP** | | **EQ 2GM BASE/VIAL** | **A065499** | **005** | Aug 17, 2010 |
| **AP** | | **EQ 10GM BASE/VIAL** | **A065493** | **001** | Aug 17, 2010 |
| **AP** | HANFORD GC | **EQ 250MG BASE/VIAL** | **A062772** | **006** | Apr 15, 1993 |
| **AP** | | **EQ 500MG BASE/VIAL** | **A062772** | **007** | Apr 15, 1993 |
| **AP** | | **EQ 1GM BASE/VIAL** | **A062772** | **001** | Apr 15, 1993 |
| **AP** | | **EQ 2GM BASE/VIAL** | **A062772** | **003** | Apr 15, 1993 |
| **AP** | | **EQ 10GM BASE/VIAL** | **A063142** | **001** | Apr 15, 1993 |
| **AP** | HOSPIRA INC | **EQ 250MG BASE/VIAL** | **A202864** | **001** | Sep 04, 2015 |
| **AP** | | **EQ 500MG BASE/VIAL** | **A202864** | **002** | Sep 04, 2015 |
| **AP** | | **EQ 1GM BASE/VIAL** | **A202864** | **003** | Sep 04, 2015 |
| **AP** | | **EQ 2GM BASE/VIAL** | **A202864** | **004** | Sep 04, 2015 |
| **AP** | | **EQ 10GM BASE/VIAL** | **A202865** | **001** | Sep 04, 2015 |
| **AP** | ISTITUTO BIO ITA SPA | **EQ 10GM BASE/VIAL** | **A201404** | **001** | Dec 20, 2013 |
| **AP** | | **EQ 125MG BASE/VIAL** | **A062797** | **001** | Jul 12, 1993 |
| **AP** | | **EQ 250MG BASE/VIAL** | **A062719** | **001** | May 12, 1987 |
| **AP** | | **EQ 500MG BASE/VIAL** | **A062719** | **003** | May 12, 1987 |
| **AP** | | **EQ 1GM BASE/VIAL** | **A062719** | **002** | May 12, 1987 |
| **AP** | | **EQ 2GM BASE/VIAL** | **A062797** | **002** | Jul 12, 1993 |
| **AP** | MYLAN LABS LTD | **EQ 250MG BASE/VIAL** | **A201025** | **001** | Apr 09, 2014 |
| **AP** | | **EQ 500MG BASE/VIAL** | **A201025** | **002** | Apr 09, 2014 |

AMPICILLIN SODIUM

INJECTABLE;INJECTION

**AMPICILLIN SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| AP | | | EQ 1GM BASE/VIAL | A201025 | 003 | Apr 09, 2014 |
| AP | | | EQ 2GM BASE/VIAL | A201025 | 004 | Apr 09, 2014 |
| AP | | | EQ 10GM BASE/VIAL | A202198 | 001 | Apr 07, 2014 |
| AP | | SAGENT PHARMS | EQ 125MG BASE/VIAL | A090583 | 001 | Nov 27, 2015 |
| AP | | | EQ 250MG BASE/VIAL | A090583 | 002 | Nov 27, 2015 |
| AP | | | EQ 500MG BASE/VIAL | A090583 | 003 | Nov 27, 2015 |
| AP | | | EQ 1GM BASE/VIAL | A090583 | 004 | Nov 27, 2015 |
| AP | | | EQ 2GM BASE/VIAL | A090583 | 005 | Nov 27, 2015 |
| AP | | | EQ 10GM BASE/VIAL | A090581 | 001 | Oct 20, 2015 |
| AP | ! | SANDOZ | EQ 125MG BASE/VIAL | A061395 | 001 | |
| AP | ! | | EQ 250MG BASE/VIAL | A061395 | 002 | |
| AP | ! | | EQ 500MG BASE/VIAL | A061395 | 003 | |
| AP | ! | | EQ 1GM BASE/VIAL | A061395 | 004 | |
| AP | ! | | EQ 2GM BASE/VIAL | A061395 | 005 | |
| AP | ! | | EQ 10GM BASE/VIAL | A061395 | 006 | |

POWDER;INTRAVENOUS

**AMPICILLIN SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| AP | ! | SANDOZ | EQ 1GM BASE/VIAL | A062738 | 001 | Feb 19, 1987 |
| AP | ! | | EQ 2GM BASE/VIAL | A062738 | 002 | Feb 19, 1987 |

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

**AMPICILLIN AND SULBACTAM**

| | | | | | | |
|---|---|---|---|---|---|---|
| AP | | ACS DOBFAR | EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL | A065406 | 001 | Dec 22, 2009 |
| AP | | | EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL | A065406 | 002 | Dec 22, 2009 |
| AP | | | EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL | A065403 | 001 | Dec 23, 2009 |
| AP | | ANTIBIOTICE | EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL | A201406 | 001 | Dec 07, 2015 |
| AP | | | EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL | A201406 | 002 | Dec 07, 2015 |
| AP | | AUROBINDO PHARMA | EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL | A090340 | 001 | Sep 20, 2010 |
| AP | | | EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL | A090349 | 001 | Sep 20, 2010 |
| AP | | | EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL | A090340 | 002 | Sep 20, 2010 |
| AP | | | EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL | A090349 | 002 | Sep 20, 2010 |
| AP | | | EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL | A090339 | 001 | Sep 20, 2010 |
| AP | | HANFORD GC | EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL | A065176 | 001 | Nov 30, 2005 |
| AP | | | EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL | A065176 | 002 | Nov 30, 2005 |
| AP | | | EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL | A065188 | 001 | Nov 25, 2005 |
| AP | | HOSPIRA INC | EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL | A090375 | 001 | Dec 21, 2011 |
| AP | | | EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL | A090653 | 001 | Dec 21, 2011 |
| AP | | | EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL | A090375 | 002 | Dec 21, 2011 |
| AP | | | EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL | A090653 | 002 | Dec 21, 2011 |
| AP | | | EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL | A090646 | 001 | Dec 21, 2011 |
| AP | | ISTITUTO BIO ITA SPA | EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL | A065222 | 001 | Nov 29, 2005 |
| AP | | | EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL | A065222 | 002 | Nov 29, 2005 |
| AP | | | EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL | A065314 | 001 | Nov 27, 2006 |
| AP | | MUSTAFA NEVZAT ILAC | EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL | A065316 | 001 | Jun 29, 2007 |
| AP | | | EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL | A065316 | 002 | Jun 29, 2007 |
| AP | | MYLAN LABS LTD | EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL | A201024 | 001 | Apr 07, 2014 |
| AP | | | EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL | A201024 | 002 | Apr 07, 2014 |
| AP | | | EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL | A202197 | 001 | Apr 07, 2014 |
| AP | | SAGENT PHARMS | EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL | A090579 | 001 | Jan 08, 2016 |
| AP | | | EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL | A090579 | 002 | Jan 08, 2016 |
| AP | | | EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL | A090578 | 001 | Jan 11, 2016 |
| AP | | SANDOZ | EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL | A065241 | 001 | Jul 25, 2006 |
| AP | | | EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL | A065310 | 001 | Jul 25, 2006 |
| AP | | | EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL | A065241 | 002 | Jul 25, 2006 |
| AP | | | EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL | A065310 | 002 | Jul 25, 2006 |
| AP | | | EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL | A065240 | 001 | Jul 25, 2006 |
| AP | | WEST-WARD PHARMS INT | EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL | A065074 | 001 | Mar 19, 2002 |
| AP | | | EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL | A065074 | 002 | Mar 19, 2002 |
| AP | | | EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL | A065076 | 001 | Mar 19, 2002 |

**UNASYN**

| | | | | | | |
|---|---|---|---|---|---|---|
| AP | ! | PFIZER | EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL | A062901 | 002 | Feb 27, 1992 |
| AP | ! | | EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL | A062901 | 001 | Nov 23, 1988 |
| AP | +! | | EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL | N050608 | 002 | Dec 31, 1986 |
| AP | +! | | EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL | N050608 | 001 | Dec 31, 1986 |
| AP | +! | | EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL | N050608 | 005 | Dec 10, 1993 |

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE;ORAL

**AMPICILLIN TRIHYDRATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | DAVA PHARMS INC | **EQ 250MG BASE** | **A062883** | **001** | Feb 25, 1988 |
| **AB** | **!** | | **EQ 500MG BASE** | **A062882** | **001** | Feb 25, 1988 |
| **AB** | | SANDOZ | **EQ 250MG BASE** | **A064082** | **001** | Aug 29, 1995 |
| **AB** | | | **EQ 500MG BASE** | **A064082** | **002** | Aug 29, 1995 |

FOR SUSPENSION;ORAL

AMPICILLIN TRIHYDRATE

| | | | | | | |
|---|---|---|---|---|---|---|
| | | DAVA PHARMS INC | EQ 125MG BASE/5ML | A062982 | 001 | Feb 10, 1989 |
| | ! | | EQ 250MG BASE/5ML | A062982 | 002 | Feb 10, 1989 |

ANAGRELIDE HYDROCHLORIDE

CAPSULE;ORAL

**AGRYLIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | SHIRE LLC | **EQ 0.5MG BASE** | **N020333** | **001** | Mar 14, 1997 |

**ANAGRELIDE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | BARR | **EQ 0.5MG BASE** | **A076530** | **001** | Apr 18, 2005 |
| **AB** | | | **EQ 1MG BASE** | **A076530** | **002** | Apr 18, 2005 |
| **AB** | | IMPAX LABS | **EQ 0.5MG BASE** | **A076910** | **001** | Apr 18, 2005 |
| **AB** | | | **EQ 1MG BASE** | **A076910** | **002** | Apr 18, 2005 |
| **AB** | | IVAX SUB TEVA PHARMS | **EQ 0.5MG BASE** | **A076468** | **001** | Apr 18, 2005 |
| **AB** | **!** | | **EQ 1MG BASE** | **A076468** | **002** | Apr 18, 2005 |
| **AB** | | TORRENT PHARMS LTD | **EQ 0.5MG BASE** | **A209151** | **001** | Jun 30, 2017 |
| **AB** | | | **EQ 1MG BASE** | **A209151** | **002** | Jun 30, 2017 |

ANASTROZOLE

TABLET;ORAL

**ANASTROZOLE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACCORD HLTHCARE | **1MG** | **A090568** | **001** | Jun 28, 2010 |
| **AB** | | APOTEX INC | **1MG** | **A200654** | **001** | May 11, 2012 |
| **AB** | | CIPLA LTD | **1MG** | **A091164** | **001** | Jun 28, 2010 |
| **AB** | | DR REDDYS LABS LTD | **1MG** | **A090732** | **001** | Jun 28, 2010 |
| **AB** | | FRESENIUS KABI ONCOL | **1MG** | **A090088** | **001** | Jun 28, 2010 |
| **AB** | | MYLAN | **1MG** | **A091051** | **001** | Jun 28, 2010 |
| **AB** | | NATCO PHARMA LTD | **1MG** | **A079220** | **001** | Jun 28, 2010 |
| **AB** | | SANTOS BIOTECH | **1MG** | **A078944** | **001** | Jun 28, 2010 |
| **AB** | | TEVA PHARMS | **1MG** | **A078058** | **001** | Jun 28, 2010 |
| **AB** | | WEST-WARD PHARMS INT | **1MG** | **A078485** | **001** | Jun 28, 2010 |
| **AB** | | ZYDUS PHARMS USA INC | **1MG** | **A078921** | **001** | Jun 28, 2010 |

**ARIMIDEX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | ASTRAZENECA PHARMS | **1MG** | **N020541** | **001** | Dec 27, 1995 |

ANGIOTENSIN II

SOLUTION;IV (INFUSION)

GIAPREZA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | LA JOLLA PHARM CO | 2.5MG/ML (2.5MG/ML) | N209360 | 001 | Dec 21, 2017 |
| | +! | | 5MG/2ML (2.5MG/ML) | N209360 | 002 | Dec 21, 2017 |

ANIDULAFUNGIN

INJECTABLE;IV (INFUSION)

ERAXIS

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | VICURON | 50MG/VIAL | N021632 | 001 | Feb 17, 2006 |
| | +! | | 100MG/VIAL | N021632 | 002 | Nov 14, 2006 |

APIXABAN

TABLET;ORAL

ELIQUIS

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | BRISTOL MYERS SQUIBB | 2.5MG | N202155 | 001 | Dec 28, 2012 |
| | +! | | 5MG | N202155 | 002 | Dec 28, 2012 |

APOMORPHINE HYDROCHLORIDE

INJECTABLE;SUBCUTANEOUS

APOKYN

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | US WORLDMEDS | 30MG/3ML (10MG/ML) | N021264 | 002 | Apr 20, 2004 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| APRACLONIDINE HYDROCHLORIDE | | | | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | | | | |
| **APRACLONIDINE HYDROCHLORIDE** | | | | | | | |
| **AT** | | AKORN INC | **EQ 0.5% BASE** | **A077764** | **001** | Mar 12, 2009 |
| **IOPIDINE** | | | | | | | |
| **AT** | **+!** | NOVARTIS PHARMS CORP | **EQ 0.5% BASE** | **N020258** | **001** | Jul 30, 1993 |
| | +! | | EQ 1% BASE | N019779 | 001 | Dec 31, 1987 |
| APREMILAST | | | | | | | |
| TABLET;ORAL | | | | | | | |
| OTEZLA | | | | | | | |
| | + | CELGENE CORP | 10MG | N205437 | 001 | Mar 21, 2014 |
| | + | | 20MG | N205437 | 002 | Mar 21, 2014 |
| | +! | | 30MG | N205437 | 003 | Mar 21, 2014 |
| APREPITANT | | | | | | | |
| CAPSULE;ORAL | | | | | | | |
| **APREPITANT** | | | | | | | |
| **AB** | | GLENMARK PHARMS LTD | **40MG** | **A207777** | **001** | Oct 12, 2017 |
| **AB** | | | **80MG** | **A207777** | **002** | Oct 12, 2017 |
| **AB** | | | **125MG** | **A207777** | **003** | Oct 12, 2017 |
| **AB** | | SANDOZ | **40MG** | **A090999** | **001** | Sep 24, 2012 |
| **AB** | | | **80MG** | **A090999** | **002** | Sep 24, 2012 |
| **AB** | | | **125MG** | **A090999** | **003** | Sep 24, 2012 |
| **EMEND** | | | | | | | |
| **AB** | **+** | MERCK | **40MG** | **N021549** | **003** | Jun 30, 2006 |
| **AB** | **+** | | **80MG** | **N021549** | **001** | Mar 26, 2003 |
| **AB** | **+!** | | **125MG** | **N021549** | **002** | Mar 26, 2003 |
| EMULSION;IV (INFUSION) | | | | | | | |
| CINVANTI | | | | | | | |
| | +! | HERON THERAPS INC | 130MG/18ML (7.2MG/ML) | N209296 | 001 | Nov 09, 2017 |
| FOR SUSPENSION;ORAL | | | | | | | |
| EMEND | | | | | | | |
| | +! | MSD MERCK CO | 125MG/KIT | N207865 | 001 | Dec 17, 2015 |
| ARFORMOTEROL TARTRATE | | | | | | | |
| SOLUTION;INHALATION | | | | | | | |
| BROVANA | | | | | | | |
| | +! | SUNOVION | EQ 0.015MG BASE/2ML | N021912 | 001 | Oct 06, 2006 |
| ARGATROBAN | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| **ARGATROBAN** | | | | | | | |
| **AP** | | FRESENIUS KABI USA | **250MG/2.5ML (100MG/ML)** | **N201811** | **001** | Mar 23, 2015 |
| **AP** | | HIKMA PHARM CO LTD | **250MG/2.5ML (100MG/ML)** | **N203049** | **001** | Jan 05, 2012 |
| **AP** | | HOSPIRA INC | **250MG/2.5ML (100MG/ML)** | **A204120** | **001** | Sep 21, 2016 |
| **AP** | | MYLAN INSTITUTIONAL | **250MG/2.5ML (100MG/ML)** | **A202626** | **001** | Jun 30, 2014 |
| **AP** | **+!** | NOVARTIS PHARMS CORP | **250MG/2.5ML (100MG/ML)** | **N020883** | **001** | Jun 30, 2000 |
| **AP** | | PAR STERILE PRODUCTS | **250MG/2.5ML (100MG/ML)** | **A091665** | **001** | Jun 30, 2014 |
| | +! | HIKMA PHARM CO LTD | 50MG/50ML (1MG/ML) | N203049 | 002 | Sep 30, 2016 |
| INJECTABLE;IV (INFUSION) | | | | | | | |
| **ARGATROBAN IN SODIUM CHLORIDE** | | | | | | | |
| **AP** | | GLAND PHARMA LTD | **125MG/125ML (1MG/ML)** | **A205570** | **001** | May 22, 2017 |
| **AP** | **+!** | SANDOZ | **125MG/125ML (1MG/ML)** | **N022485** | **001** | May 09, 2011 |
| ARGATROBAN IN 0.9% SODIUM CHLORIDE | | | | | | | |
| | | TEVA PHARMS USA | 250MG/250ML (1MG/ML) | N206769 | 001 | Dec 15, 2014 |
| ARGATROBAN IN SODIUM CHLORIDE | | | | | | | |
| | +! | EAGLE PHARMS | 50MG/50ML (1MG/ML) | N022434 | 001 | Jun 29, 2011 |
| ARGININE HYDROCHLORIDE | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| R-GENE 10 | | | | | | | |
| | +! | PHARMACIA AND UPJOHN | 10GM/100ML | N016931 | 001 | |
| ARIPIPRAZOLE | | | | | | | |
| FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | | | | | | | |
| ABILIFY MAINTENA KIT | | | | | | | |
| | + | OTSUKA PHARM CO LTD | 300MG/VIAL | N202971 | 001 | Feb 28, 2013 |
| | + | | 300MG | N202971 | 003 | Sep 29, 2014 |
| | +! | | 400MG/VIAL | N202971 | 002 | Feb 28, 2013 |
| | + | | 400MG | N202971 | 004 | Sep 29, 2014 |

ARIPIPRAZOLE

SOLUTION;ORAL

**ARIPIPRAZOLE**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **AA** | **!** | AMNEAL PHARMS | **1MG/ML** | **A203906** | **001** | Aug 14, 2015 |
| **AA** | | APOTEX INC | **1MG/ML** | **A204094** | **001** | Sep 30, 2015 |
| **AA** | | SILARX PHARMS INC | **1MG/ML** | **A204171** | **001** | Aug 14, 2015 |

TABLET;ORAL

**ABILIFY**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | OTSUKA | **2MG** | **N021436** | **006** | Nov 15, 2002 |
| **AB** | **+!** | | **5MG** | **N021436** | **005** | Nov 15, 2002 |
| **AB** | **+!** | | **10MG** | **N021436** | **001** | Nov 15, 2002 |
| **AB** | **+** | | **15MG** | **N021436** | **002** | Nov 15, 2002 |
| **AB** | **+** | | **20MG** | **N021436** | **003** | Nov 15, 2002 |
| **AB** | **+** | | **30MG** | **N021436** | **004** | Nov 15, 2002 |

**ARIPIPRAZOLE**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | ACCORD HLTHCARE | **2MG** | **A206251** | **001** | Dec 07, 2016 |
| **AB** | | **5MG** | **A206251** | **002** | Dec 07, 2016 |
| **AB** | | **10MG** | **A206251** | **003** | Dec 07, 2016 |
| **AB** | | **15MG** | **A206251** | **004** | Dec 07, 2016 |
| **AB** | | **20MG** | **A206251** | **005** | Dec 07, 2016 |
| **AB** | | **30MG** | **A206251** | **006** | Dec 07, 2016 |
| **AB** | AJANTA PHARMA LTD | **2MG** | **A206174** | **001** | Sep 12, 2016 |
| **AB** | | **5MG** | **A206174** | **002** | Sep 12, 2016 |
| **AB** | | **10MG** | **A206174** | **003** | Sep 12, 2016 |
| **AB** | | **15MG** | **A206174** | **004** | Sep 12, 2016 |
| **AB** | | **20MG** | **A206174** | **005** | Sep 12, 2016 |
| **AB** | | **30MG** | **A206174** | **006** | Sep 12, 2016 |
| **AB** | ALEMBIC PHARMS LTD | **2MG** | **A202101** | **001** | Apr 28, 2015 |
| **AB** | | **5MG** | **A202101** | **002** | Apr 28, 2015 |
| **AB** | | **10MG** | **A202101** | **003** | Apr 28, 2015 |
| **AB** | | **15MG** | **A202101** | **004** | Apr 28, 2015 |
| **AB** | | **20MG** | **A202101** | **005** | Apr 28, 2015 |
| **AB** | | **30MG** | **A202101** | **006** | Apr 28, 2015 |
| **AB** | AMNEAL PHARMS | **2MG** | **A204838** | **001** | Jun 17, 2016 |
| **AB** | | **5MG** | **A204838** | **002** | Jun 17, 2016 |
| **AB** | | **10MG** | **A204838** | **003** | Jun 17, 2016 |
| **AB** | | **15MG** | **A204838** | **004** | Jun 17, 2016 |
| **AB** | | **20MG** | **A204838** | **005** | Jun 17, 2016 |
| **AB** | | **30MG** | **A204838** | **006** | Jun 17, 2016 |
| **AB** | APOTEX INC | **2MG** | **A078583** | **001** | Jul 24, 2015 |
| **AB** | | **5MG** | **A078583** | **002** | Jul 24, 2015 |
| **AB** | | **10MG** | **A078583** | **003** | Jul 24, 2015 |
| **AB** | | **15MG** | **A078583** | **004** | Jul 24, 2015 |
| **AB** | | **20MG** | **A078583** | **005** | Jul 24, 2015 |
| **AB** | | **30MG** | **A078583** | **006** | Jul 24, 2015 |
| **AB** | AUROBINDO PHARMA LTD | **2MG** | **A203908** | **001** | Oct 08, 2015 |
| **AB** | | **5MG** | **A203908** | **002** | Oct 08, 2015 |
| **AB** | | **10MG** | **A203908** | **003** | Oct 08, 2015 |
| **AB** | | **15MG** | **A203908** | **004** | Oct 08, 2015 |
| **AB** | | **20MG** | **A203908** | **005** | Oct 08, 2015 |
| **AB** | | **30MG** | **A203908** | **006** | Oct 08, 2015 |
| **AB** | HETERO LABS LTD V | **2MG** | **A205064** | **001** | Apr 28, 2015 |
| **AB** | | **5MG** | **A205064** | **002** | Apr 28, 2015 |
| **AB** | | **10MG** | **A205064** | **003** | Apr 28, 2015 |
| **AB** | | **15MG** | **A205064** | **004** | Apr 28, 2015 |
| **AB** | | **20MG** | **A205064** | **005** | Apr 28, 2015 |
| **AB** | | **30MG** | **A205064** | **006** | Apr 28, 2015 |
| **AB** | MACLEODS PHARMS LTD | **2MG** | **A204111** | **001** | Oct 07, 2016 |
| **AB** | | **5MG** | **A204111** | **002** | Oct 07, 2016 |
| **AB** | | **10MG** | **A204111** | **003** | Oct 07, 2016 |
| **AB** | | **15MG** | **A204111** | **004** | Oct 07, 2016 |
| **AB** | | **20MG** | **A204111** | **005** | Oct 07, 2016 |
| **AB** | | **30MG** | **A204111** | **006** | Oct 07, 2016 |
| **AB** | ORCHID HLTHCARE | **2MG** | **A202683** | **001** | May 23, 2017 |
| **AB** | | **5MG** | **A202683** | **002** | May 23, 2017 |
| **AB** | | **10MG** | **A202683** | **003** | May 23, 2017 |
| **AB** | | **15MG** | **A202683** | **004** | May 23, 2017 |
| **AB** | | **20MG** | **A202683** | **005** | May 23, 2017 |
| **AB** | | **30MG** | **A202683** | **006** | May 23, 2017 |
| **AB** | PRINSTON INC | **2MG** | **A205363** | **001** | Dec 04, 2017 |
| **AB** | | **5MG** | **A205363** | **002** | Dec 04, 2017 |
| **AB** | | **10MG** | **A205363** | **003** | Dec 04, 2017 |

ARIPIPRAZOLE

TABLET;ORAL

**ARIPIPRAZOLE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **15MG** | **A205363** | **004** | Dec 04, 2017 |
| **AB** | | | **20MG** | **A205363** | **005** | Dec 04, 2017 |
| **AB** | | | **30MG** | **A205363** | **006** | Dec 04, 2017 |
| **AB** | | SANTOS BIOTECH | **2MG** | **A091279** | **001** | Jan 09, 2017 |
| **AB** | | | **5MG** | **A091279** | **002** | Jan 09, 2017 |
| **AB** | | | **10MG** | **A091279** | **003** | Jan 09, 2017 |
| **AB** | | | **15MG** | **A091279** | **004** | Jan 09, 2017 |
| **AB** | | | **20MG** | **A091279** | **005** | Jan 09, 2017 |
| **AB** | | | **30MG** | **A091279** | **006** | Jan 09, 2017 |
| **AB** | | SCIEGEN PHARMS INC | **2MG** | **A206383** | **001** | Sep 29, 2016 |
| **AB** | | | **5MG** | **A206383** | **002** | Sep 29, 2016 |
| **AB** | | | **10MG** | **A206383** | **003** | Sep 29, 2016 |
| **AB** | | | **15MG** | **A206383** | **004** | Sep 29, 2016 |
| **AB** | | | **20MG** | **A206383** | **005** | Sep 29, 2016 |
| **AB** | | | **30MG** | **A206383** | **006** | Sep 29, 2016 |
| **AB** | | TEVA PHARMS USA | **2MG** | **A078607** | **001** | Apr 28, 2015 |
| **AB** | | | **5MG** | **A078607** | **002** | Apr 28, 2015 |
| **AB** | | | **10MG** | **A078608** | **001** | Apr 28, 2015 |
| **AB** | | | **15MG** | **A078708** | **001** | Apr 28, 2015 |
| **AB** | | | **20MG** | **A078708** | **002** | Apr 28, 2015 |
| **AB** | | | **30MG** | **A078708** | **003** | Apr 28, 2015 |
| **AB** | | TORRENT PHARMS LTD | **2MG** | **A201519** | **001** | Apr 28, 2015 |
| **AB** | | | **10MG** | **A201519** | **003** | Apr 28, 2015 |
| **AB** | | | **5MG** | **A201519** | **002** | Apr 28, 2015 |
| **AB** | | | **15MG** | **A201519** | **004** | Apr 28, 2015 |
| **AB** | | | **20MG** | **A201519** | **005** | Apr 28, 2015 |
| **AB** | | | **30MG** | **A201519** | **006** | Apr 28, 2015 |

ABILIFY MYCITE KIT

| | | | | | |
|---|---|---|---|---|---|
| + | OTSUKA PHARM CO LTD | 2MG | N207202 | 001 | Nov 13, 2017 |
| +! | | 5MG | N207202 | 002 | Nov 13, 2017 |
| + | | 10MG | N207202 | 003 | Nov 13, 2017 |
| + | | 15MG | N207202 | 004 | Nov 13, 2017 |
| + | | 20MG | N207202 | 005 | Nov 13, 2017 |
| + | | 30MG | N207202 | 006 | Nov 13, 2017 |

TABLET, ORALLY DISINTEGRATING;ORAL

**ARIPIPRAZOLE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **!** | ALEMBIC PHARMS LTD | **10MG** | **A202102** | **001** | Apr 28, 2015 |
| **AB** | | | **15MG** | **A202102** | **002** | Apr 28, 2015 |
| **AB** | | ORCHID HLTHCARE | **10MG** | **A202547** | **001** | Dec 11, 2017 |
| **AB** | | | **15MG** | **A202547** | **002** | Dec 11, 2017 |

ARIPIPRAZOLE LAUROXIL

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

ARISTADA

| | | | | | |
|---|---|---|---|---|---|
| + | ALKERMES INC | 441MG/1.6ML (275.63MG/ML) | N207533 | 001 | Oct 05, 2015 |
| + | | 662MG/2.4ML (275.83MG/ML) | N207533 | 002 | Oct 05, 2015 |
| +! | | 882MG/3.2ML (275.63MG/ML) | N207533 | 003 | Oct 05, 2015 |
| + | | 1064MG/3.9ML (272.82MG/ML) | N207533 | 004 | Jun 05, 2017 |

ARMODAFINIL

TABLET;ORAL

**ARMODAFINIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | LUPIN LTD | **50MG** | **A200751** | **001** | Nov 28, 2016 |
| **AB** | | | **150MG** | **A200751** | **003** | Nov 28, 2016 |
| **AB** | | | **200MG** | **A200751** | **004** | Nov 28, 2016 |
| **AB** | | | **250MG** | **A200751** | **005** | Nov 28, 2016 |
| **AB** | | MYLAN PHARMS INC | **50MG** | **A200043** | **001** | Jun 01, 2012 |
| **AB** | | | **150MG** | **A200043** | **002** | Jun 01, 2012 |
| **AB** | | | **250MG** | **A200043** | **003** | Jun 01, 2012 |
| **AB** | | NATCO PHARMA LTD | **50MG** | **A202768** | **001** | Nov 28, 2016 |
| **AB** | | | **150MG** | **A202768** | **002** | Nov 28, 2016 |
| **AB** | | | **200MG** | **A202768** | **005** | Sep 28, 2017 |
| **AB** | | | **250MG** | **A202768** | **003** | Nov 28, 2016 |

**NUVIGIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | CEPHALON | **50MG** | **N021875** | **001** | Jun 15, 2007 |
| **AB** | **+** | | **150MG** | **N021875** | **003** | Jun 15, 2007 |
| **AB** | **+** | | **200MG** | **N021875** | **005** | Mar 26, 2009 |
| **AB** | **+!** | | **250MG** | **N021875** | **004** | Jun 15, 2007 |

ARMODAFINIL

| | | | | | |
|---|---|---|---|---|---|
| | NATCO PHARMA LTD | 100MG | A202768 | 004 | Sep 28, 2017 |

ARSENIC TRIOXIDE

INJECTABLE;INJECTION

TRISENOX

| | | | | | |
|---|---|---|---|---|---|
| +! | CEPHALON | 1MG/ML | N021248 | 001 | Sep 25, 2000 |
| +! | | 2MG/ML | N021248 | 002 | Oct 13, 2017 |

ARTEMETHER; LUMEFANTRINE

TABLET;ORAL

COARTEM

| | | | | | |
|---|---|---|---|---|---|
| +! | NOVARTIS | 20MG;120MG | N022268 | 001 | Apr 07, 2009 |

ARTICAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

**ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | HOSPIRA | **4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)** | **A079138** | **001** | Jun 18, 2010 |

**SEPTOCAINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | DEPROCO | **4%;EQ 0.0085MG BASE/1.7ML (4%;EQ 0.005MG BASE/ML)** | **N022010** | **001** | Mar 30, 2006 |
| **AP** | **+!** | | **4%;EQ 0.017MG BASE/1.7ML (4%;EQ 0.01MG BASE/ML)** | **N020971** | **001** | Apr 03, 2000 |

**ULTACAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | HANSAMED INC | **4%;EQ 0.0085MG BASE/1.7ML (4%; EQ 0.005MG BASE/ML)** | **A201751** | **001** | Jul 11, 2017 |

**ULTACAN FORTE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | HANSAMED INC | **4%;EQ 0.017MG BASE/1.7ML (4%; EQ 0.01MG BASE/ML)** | **A201750** | **001** | Jul 11, 2017 |

ORABLOC

| | | | | | |
|---|---|---|---|---|---|
| + | PIERREL | 4%;EQ 0.009MG BASE/1.8ML (EQ 0.005MG BASE/ML) | N022466 | 001 | Feb 26, 2010 |
| +! | | 4%;EQ 0.018MG BASE/1.8ML (EQ 0.01MG BASE/ML) | N022466 | 002 | Feb 26, 2010 |

ASCORBIC ACID

SOLUTION;IV (INFUSION)

ASCOR

| | | | | | |
|---|---|---|---|---|---|
| +! | MCGUFF | 25,000MG/50ML (500MG/ML) | N209112 | 001 | Oct 02, 2017 |

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE;IV (INFUSION)

INFUVITE PEDIATRIC

| | | | | | |
|---|---|---|---|---|---|
| +! | SANDOZ INC | 80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL | N021265 | 001 | Feb 21, 2001 |

INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

| | | | | | |
|---|---|---|---|---|---|
| +! | SANDOZ INC | 80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL | N021646 | 001 | Jan 29, 2004 |

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

FOR SOLUTION;IV (INFUSION)

M.V.I. PEDIATRIC

| | | | | | |
|---|---|---|---|---|---|
| +! | HOSPIRA | 80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/VIAL | N018920 | 001 | Sep 21, 2000 |

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E; VITAMIN K

INJECTABLE;IV (INFUSION)

M.V.I. ADULT

| | | | | | |
|---|---|---|---|---|---|
| +! | HOSPIRA | 200MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;0.005MG/VIAL;0.6MG/VIAL;40MG/VIAL;6MG/VIAL;3.6MG/VIAL;6MG/VIAL;1MG/VIAL;10MG/VIAL;0.15MG/VIAL | N021625 | 001 | Jan 30, 2004 |

M.V.I. ADULT (PHARMACY BULK PACKAGE)

| | | | | | |
|---|---|---|---|---|---|
| +! | HOSPIRA | 200MG/5ML;0.06MG/5ML;0.005MG/5ML;15MG/5ML;0.005MG/5ML;0.6MG/5ML;40MG/5ML;6MG/5ML;3.6MG/5ML;6MG/5ML;1MG/5ML;10MG/5ML;0.15MG/5ML | N021643 | 001 | Feb 18, 2004 |

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL

MOVIPREP

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | SALIX PHARMS | 4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM | N021881 | 001 | Aug 02, 2006 |

ASENAPINE MALEATE

TABLET;SUBLINGUAL

SAPHRIS

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | FOREST LABS LLC | EQ 2.5 BASE | N022117 | 003 | Mar 12, 2015 |
| | + | | EQ 5MG BASE | N022117 | 001 | Aug 13, 2009 |
| | +! | | EQ 10MG BASE | N022117 | 002 | Aug 13, 2009 |

ASPIRIN

CAPSULE, EXTENDED RELEASE;ORAL

DURLAZA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | NEW HAVEN PHARMS | 162.5MG | N200671 | 001 | Sep 04, 2015 |

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

**FIORINAL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **+!** | ALLERGAN SALES LLC | **325MG;50MG;40MG** | **N017534** | **005** | Apr 16, 1986 |

**LANORINAL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | LANNETT | **325MG;50MG;40MG** | **A086996** | **002** | Oct 11, 1985 |

TABLET;ORAL

**BUTALBITAL, ASPIRIN AND CAFFEINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **!** | HIKMA INTL PHARMS | **325MG;50MG;40MG** | **A086162** | **002** | Feb 16, 1984 |
| **AA** | | PII | **325MG;50MG;40MG** | **A204195** | **001** | Sep 22, 2016 |

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

**BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | MAYNE PHARMA INC | **325MG;50MG;40MG;30MG** | **A203335** | **001** | Oct 30, 2015 |

**BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | NEXGEN PHARMA INC | **325MG;50MG;40MG;30MG** | **A075231** | **001** | Nov 30, 2001 |
| **AB** | | STEVENS J | **325MG;50MG;40MG;30MG** | **A074951** | **001** | Aug 31, 1998 |

**FIORINAL W/CODEINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | ALLERGAN SALES LLC | **325MG;50MG;40MG;30MG** | **N019429** | **003** | Oct 26, 1990 |

ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE;ORAL

SYNALGOS-DC

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | SUN PHARM INDUSTRIES | 356.4MG;30MG;16MG | N011483 | 004 | Sep 06, 1983 |

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

| | | | | | | |
|---|---|---|---|---|---|---|
| | | SANDOZ | 385MG;30MG;25MG | A074654 | 001 | Dec 31, 1996 |
| | ! | | 770MG;60MG;50MG | A074654 | 002 | Dec 31, 1996 |

ASPIRIN; CARISOPRODOL

TABLET;ORAL

**CARISOPRODOL AND ASPIRIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **!** | HERITAGE PHARMS INC | **325MG;200MG** | **A089594** | **001** | Mar 31, 1989 |
| **AB** | | NOVAST LABS LTD | **325MG;200MG** | **A040832** | **001** | Jan 07, 2010 |
| **AB** | | OXFORD PHARMS | **325MG;200MG** | **A040252** | **001** | Dec 10, 1997 |
| **AB** | | SANDOZ | **325MG;200MG** | **A040116** | **001** | Apr 25, 1996 |

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET;ORAL

**CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | INGENUS PHARMS NJ | **325MG;200MG;16MG** | **A040860** | **001** | Jan 07, 2010 |
| **AB** | **!** | SANDOZ | **325MG;200MG;16MG** | **A040118** | **001** | Apr 16, 1996 |

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE;ORAL

**AGGRENOX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | BOEHRINGER INGELHEIM | **25MG;200MG** | **N020884** | **001** | Nov 22, 1999 |

**ASPIRIN AND DIPYRIDAMOLE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AMNEAL PHARMS | **25MG;200MG** | **A206392** | **001** | Mar 08, 2016 |
| **AB** | | BARR | **25MG;200MG** | **A078804** | **001** | Aug 14, 2009 |
| **AB** | | IMPAX LABS INC | **25MG;200MG** | **A206964** | **001** | Jan 18, 2017 |
| **AB** | | PAR PHARM INC | **25MG;200MG** | **A207944** | **001** | Jan 18, 2017 |
| **AB** | | SANDOZ INC | **25MG;200MG** | **A206739** | **001** | Jan 18, 2017 |
| **AB** | | ZYDUS PHARMS USA INC | **25MG;200MG** | **A206753** | **001** | Aug 29, 2017 |

ASPIRIN; METHOCARBAMOL

TABLET;ORAL

METHOCARBAMOL AND ASPIRIN

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | STEVENS J | 325MG;400MG | A081145 | 001 | Jan 31, 1995 |

ASPIRIN; OMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL

YOSPRALA

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | ARALEZ PHARMS | 81MG;40MG | N205103 | 001 | Sep 14, 2016 |
| | +! | | 325MG;40MG | N205103 | 002 | Sep 14, 2016 |

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

**OXYCODONE AND ASPIRIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | ACTAVIS LABS FL INC | **325MG;4.8355MG** | **A090084** | **001** | Mar 22, 2011 |
| **AA** | | MAYNE PHARMA INC | **325MG;4.8355MG** | **A091670** | **001** | Mar 16, 2011 |

**PERCODAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **+!** | ENDO PHARMS | **325MG;4.8355MG** | **N007337** | **007** | Aug 05, 2005 |

ATAZANAVIR SULFATE

CAPSULE;ORAL

**ATAZANAVIR SULFATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | TEVA PHARMS USA | **EQ 150MG BASE** | **A091673** | **002** | Apr 22, 2014 |
| **AB** | | | **EQ 200MG BASE** | **A091673** | **003** | Apr 22, 2014 |
| **AB** | | | **EQ 300MG BASE** | **A091673** | **004** | Apr 22, 2014 |

**REYATAZ**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | BRISTOL MYERS SQUIBB | **EQ 150MG BASE** | **N021567** | **002** | Jun 20, 2003 |
| **AB** | **+** | | **EQ 200MG BASE** | **N021567** | **003** | Jun 20, 2003 |
| **AB** | **+!** | | **EQ 300MG BASE** | **N021567** | **004** | Oct 16, 2006 |

ATAZANAVIR SULFATE

| | | | | | | |
|---|---|---|---|---|---|---|
| | | TEVA PHARMS USA | EQ 100MG BASE | A091673 | 001 | Apr 22, 2014 |

POWDER;ORAL

REYATAZ

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | BRISTOL MYERS SQUIBB | EQ 50MG BASE/PACKET | N206352 | 001 | Jun 02, 2014 |

ATAZANAVIR SULFATE; COBICISTAT

TABLET;ORAL

EVOTAZ

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | BRISTOL-MYERS SQUIBB | EQ 300MG BASE;150MG | N206353 | 001 | Jan 29, 2015 |

ATENOLOL

TABLET;ORAL

**ATENOLOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALVOGEN MALTA | **25MG** | **A073646** | **001** | Jul 31, 1992 |
| **AB** | | | **50MG** | **A072303** | **001** | Jul 15, 1988 |
| **AB** | | | **100MG** | **A072304** | **001** | Jul 15, 1988 |
| **AB** | | AUROBINDO PHARMA | **25MG** | **A078512** | **001** | Oct 31, 2007 |
| **AB** | | | **50MG** | **A078512** | **002** | Oct 31, 2007 |
| **AB** | | | **100MG** | **A078512** | **003** | Oct 31, 2007 |
| **AB** | | DAVA PHARMS INC | **50MG** | **A073542** | **001** | Dec 19, 1991 |
| **AB** | | | **100MG** | **A073543** | **001** | Dec 19, 1991 |
| **AB** | | IPCA LABS LTD | **25MG** | **A077877** | **001** | Dec 27, 2006 |
| **AB** | | | **50MG** | **A077877** | **002** | Dec 27, 2006 |
| **AB** | | | **100MG** | **A077877** | **003** | Dec 27, 2006 |
| **AB** | | MYLAN | **25MG** | **A073457** | **002** | Apr 26, 1999 |
| **AB** | | | **50MG** | **A073457** | **003** | Jan 24, 1992 |
| **AB** | | | **100MG** | **A073457** | **001** | Jan 24, 1992 |
| **AB** | | SANDOZ | **25MG** | **A074052** | **001** | May 01, 1992 |
| **AB** | | | **50MG** | **A073025** | **001** | Sep 17, 1991 |
| **AB** | | | **100MG** | **A073026** | **001** | Sep 17, 1991 |
| **AB** | | SUN PHARM INDS INC | **25MG** | **A078210** | **001** | Jul 10, 2007 |
| **AB** | | | **50MG** | **A078210** | **002** | Jul 10, 2007 |
| **AB** | | | **100MG** | **A078210** | **003** | Jul 10, 2007 |
| **AB** | | SUN PHARM INDUSTRIES | **25MG** | **A074499** | **001** | Jul 30, 1997 |
| **AB** | | | **50MG** | **A073475** | **001** | Mar 30, 1993 |
| **AB** | | | **100MG** | **A073476** | **001** | Mar 30, 1993 |
| **AB** | | TEVA | **25MG** | **A074056** | **003** | Jul 19, 2004 |
| **AB** | | | **50MG** | **A074056** | **001** | Jan 18, 1995 |
| **AB** | | | **100MG** | **A074056** | **002** | Jan 18, 1995 |
| **AB** | | UNIQUE PHARM LABS | **25MG** | **A077443** | **001** | Sep 13, 2006 |
| **AB** | | | **50MG** | **A077443** | **002** | Sep 13, 2006 |
| **AB** | | | **100MG** | **A077443** | **003** | Sep 13, 2006 |

ATENOLOL

TABLET;ORAL

**ATENOLOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ZYDUS PHARMS USA | **25MG** | **A076900** | **001** | Jan 28, 2005 |
| **AB** | | | **50MG** | **A076900** | **002** | Jan 28, 2005 |
| **AB** | | | **100MG** | **A076900** | **003** | Jan 28, 2005 |

**TENORMIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | ALVOGEN MALTA | **25MG** | **N018240** | **004** | Apr 09, 1990 |
| **AB** | + | | **50MG** | **N018240** | **001** | |
| **AB** | +! | | **100MG** | **N018240** | **002** | |

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

**ATENOLOL AND CHLORTHALIDONE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALVOGEN MALTA | **50MG;25MG** | **A072301** | **001** | May 31, 1990 |
| **AB** | | | **100MG;25MG** | **A072302** | **001** | May 31, 1990 |
| **AB** | | MYLAN | **50MG;25MG** | **A074203** | **001** | Oct 31, 1993 |
| **AB** | | | **100MG;25MG** | **A074203** | **002** | Oct 31, 1993 |
| **AB** | | SUN PHARM INDUSTRIES | **50MG;25MG** | **A073582** | **002** | Apr 29, 1993 |
| **AB** | | | **100MG;25MG** | **A073582** | **001** | Apr 29, 1993 |
| **AB** | | WATSON LABS | **50MG;25MG** | **A073665** | **001** | Jul 02, 1992 |
| **AB** | | | **100MG;25MG** | **A073665** | **002** | Jul 02, 1992 |

**TENORETIC 100**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | +! | ALVOGEN MALTA | **100MG;25MG** | **N018760** | **001** | Jun 08, 1984 |

**TENORETIC 50**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | ALVOGEN MALTA | **50MG;25MG** | **N018760** | **002** | Jun 08, 1984 |

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

**ATOMOXETINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | APOTEX INC | **10MG** | **A078983** | **001** | May 30, 2017 |
| **AB** | | | **18MG** | **A078983** | **002** | May 30, 2017 |
| **AB** | | | **25MG** | **A078983** | **003** | May 30, 2017 |
| **AB** | | | **40MG** | **A078983** | **004** | May 30, 2017 |
| **AB** | | | **60MG** | **A078983** | **005** | May 30, 2017 |
| **AB** | | | **80MG** | **A078983** | **006** | May 30, 2017 |
| **AB** | | | **100MG** | **A078983** | **007** | May 30, 2017 |
| **AB** | | AUROBINDO PHARMA LTD | **10MG** | **A079016** | **001** | May 30, 2017 |
| **AB** | | | **18MG** | **A079016** | **002** | May 30, 2017 |
| **AB** | | | **25MG** | **A079016** | **003** | May 30, 2017 |
| **AB** | | | **40MG** | **A079016** | **004** | May 30, 2017 |
| **AB** | | | **60MG** | **A079016** | **005** | May 30, 2017 |
| **AB** | | | **80MG** | **A079016** | **006** | May 30, 2017 |
| **AB** | | | **100MG** | **A079016** | **007** | May 30, 2017 |
| **AB** | | GLENMARK PHARMS LTD | **10MG** | **A079019** | **001** | May 30, 2017 |
| **AB** | | | **18MG** | **A079019** | **002** | May 30, 2017 |
| **AB** | | | **25MG** | **A079019** | **003** | May 30, 2017 |
| **AB** | | | **40MG** | **A079019** | **004** | May 30, 2017 |
| **AB** | | | **60MG** | **A079019** | **005** | May 30, 2017 |
| **AB** | | | **80MG** | **A079019** | **006** | May 30, 2017 |
| **AB** | | | **100MG** | **A079019** | **007** | May 30, 2017 |
| **AB** | | TEVA PHARMS USA | **10MG** | **A079022** | **001** | May 30, 2017 |
| **AB** | | | **18MG** | **A079022** | **002** | May 30, 2017 |
| **AB** | | | **25MG** | **A079022** | **003** | May 30, 2017 |
| **AB** | | | **40MG** | **A079022** | **004** | May 30, 2017 |
| **AB** | | | **60MG** | **A079022** | **005** | May 30, 2017 |
| **AB** | | | **80MG** | **A079022** | **006** | May 30, 2017 |
| **AB** | | | **100MG** | **A079022** | **007** | May 30, 2017 |

**STRATTERA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | LILLY | **10MG** | **N021411** | **002** | Nov 26, 2002 |
| **AB** | + | | **18MG** | **N021411** | **003** | Nov 26, 2002 |
| **AB** | + | | **25MG** | **N021411** | **004** | Nov 26, 2002 |
| **AB** | + | | **40MG** | **N021411** | **005** | Nov 26, 2002 |
| **AB** | +! | | **60MG** | **N021411** | **006** | Nov 26, 2002 |
| **AB** | + | | **80MG** | **N021411** | **007** | Feb 14, 2005 |
| **AB** | + | | **100MG** | **N021411** | **008** | Feb 14, 2005 |

ATORVASTATIN CALCIUM

TABLET;ORAL

**ATORVASTATIN CALCIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | APOTEX INC | **EQ 10MG BASE** | **A090548** | **001** | May 29, 2012 |
| **AB** | | | **EQ 20MG BASE** | **A090548** | **002** | May 29, 2012 |
| **AB** | | | **EQ 40MG BASE** | **A090548** | **003** | May 29, 2012 |
| **AB** | | | **EQ 80MG BASE** | **A090548** | **004** | May 29, 2012 |
| **AB** | | DR REDDYS LABS LTD | **EQ 10MG BASE** | **A091650** | **001** | Jul 17, 2012 |
| **AB** | | | **EQ 20MG BASE** | **A091650** | **002** | Jul 17, 2012 |
| **AB** | | | **EQ 40MG BASE** | **A091650** | **003** | Jul 17, 2012 |
| **AB** | | | **EQ 80MG BASE** | **A202357** | **001** | Jul 17, 2012 |
| **AB** | | INVAGEN PHARMS | **EQ 10MG BASE** | **A204846** | **001** | Jan 09, 2017 |
| **AB** | | | **EQ 20MG BASE** | **A204846** | **002** | Jan 09, 2017 |
| **AB** | | | **EQ 40MG BASE** | **A204846** | **003** | Jan 09, 2017 |
| **AB** | | | **EQ 80MG BASE** | **A204846** | **004** | Jan 09, 2017 |
| **AB** | | KREMERS URBAN PHARMS | **EQ 10MG BASE** | **A091624** | **001** | Apr 05, 2013 |
| **AB** | | | **EQ 20MG BASE** | **A091624** | **002** | Apr 05, 2013 |
| **AB** | | | **EQ 40MG BASE** | **A091624** | **003** | Apr 05, 2013 |
| **AB** | | | **EQ 80MG BASE** | **A091624** | **004** | Apr 05, 2013 |
| **AB** | | MYLAN PHARMS INC | **EQ 10MG BASE** | **A091226** | **001** | May 29, 2012 |
| **AB** | | | **EQ 20MG BASE** | **A091226** | **002** | May 29, 2012 |
| **AB** | | | **EQ 40MG BASE** | **A091226** | **003** | May 29, 2012 |
| **AB** | | | **EQ 80MG BASE** | **A091226** | **004** | May 29, 2012 |
| **AB** | | SANDOZ INC | **EQ 10MG BASE** | **A077575** | **001** | May 29, 2012 |
| **AB** | | | **EQ 20MG BASE** | **A077575** | **002** | May 29, 2012 |
| **AB** | | | **EQ 40MG BASE** | **A077575** | **003** | May 29, 2012 |
| **AB** | | | **EQ 80MG BASE** | **A077575** | **004** | May 29, 2012 |
| **AB** | | SCIEGEN PHARMS INC | **EQ 10MG BASE** | **A205519** | **001** | May 19, 2016 |
| **AB** | | | **EQ 20MG BASE** | **A205519** | **002** | May 19, 2016 |
| **AB** | | | **EQ 40MG BASE** | **A205519** | **003** | May 19, 2016 |
| **AB** | | | **EQ 80MG BASE** | **A205519** | **004** | May 19, 2016 |
| **AB** | | SUN PHARM INDS LTD | **EQ 10MG BASE** | **A076477** | **001** | Nov 30, 2011 |
| **AB** | | | **EQ 20MG BASE** | **A076477** | **002** | Nov 30, 2011 |
| **AB** | | | **EQ 40MG BASE** | **A076477** | **003** | Nov 30, 2011 |
| **AB** | | | **EQ 80MG BASE** | **A076477** | **004** | Nov 30, 2011 |
| **AB** | | TEVA PHARMS USA | **EQ 10MG BASE** | **A205300** | **001** | Mar 27, 2017 |
| **AB** | | | **EQ 20MG BASE** | **A205300** | **002** | Mar 27, 2017 |
| **AB** | | | **EQ 40MG BASE** | **A205300** | **003** | Mar 27, 2017 |
| **AB** | | | **EQ 80MG BASE** | **A205300** | **004** | Mar 27, 2017 |

**LIPITOR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | PFIZER | **EQ 10MG BASE** | **N020702** | **001** | Dec 17, 1996 |
| **AB** | + | | **EQ 20MG BASE** | **N020702** | **002** | Dec 17, 1996 |
| **AB** | + | | **EQ 40MG BASE** | **N020702** | **003** | Dec 17, 1996 |
| **AB** | +! | | **EQ 80MG BASE** | **N020702** | **004** | Apr 07, 2000 |

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL

EZETIMIBE AND ATORVASTATIN CALCIUM

| | | | | | |
|---|---|---|---|---|---|
| | WATSON LABS TEVA | EQ 10MG BASE;10MG | A206084 | 001 | Apr 26, 2017 |
| | | EQ 20MG BASE;10MG | A206084 | 002 | Apr 26, 2017 |
| | | EQ 40MG BASE;10MG | A206084 | 003 | Apr 26, 2017 |
| ! | | EQ 80MG BASE;10MG | A206084 | 004 | Apr 26, 2017 |

ATOVAQUONE

SUSPENSION;ORAL

**ATOVAQUONE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AMNEAL PHARMS | **750MG/5ML** | **A202960** | **001** | Mar 18, 2014 |
| **AB** | | APOTEX INC | **750MG/5ML** | **A209750** | **001** | Oct 11, 2017 |
| **AB** | | PADDOCK LLC | **750MG/5ML** | **A207833** | **001** | Apr 28, 2017 |

**MEPRON**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | +! | GLAXOSMITHKLINE LLC | **750MG/5ML** | **N020500** | **001** | Feb 08, 1995 |

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET;ORAL

**ATOVAQUONE AND PROGUANIL HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | GLENMARK GENERICS | **62.5MG;25MG** | **A091211** | **002** | Apr 06, 2015 |
| **AB** | | | **250MG;100MG** | **A091211** | **001** | Jan 12, 2011 |
| **AB** | | MYLAN PHARMS INC | **62.5MG;25MG** | **A202362** | **001** | May 27, 2014 |
| **AB** | | | **250MG;100MG** | **A202362** | **002** | May 27, 2014 |

**MALARONE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | +! | GLAXOSMITHKLINE | **250MG;100MG** | **N021078** | **001** | Jul 14, 2000 |

**MALARONE PEDIATRIC**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | GLAXOSMITHKLINE | **62.5MG;25MG** | **N021078** | **002** | Jul 14, 2000 |

ATRACURIUM BESYLATE

INJECTABLE;INJECTION

**ATRACURIUM BESYLATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AUROBINDO PHARMA LTD | **10MG/ML** | **A206011** | **001** | Apr 08, 2015 |
| **AP** | | HOSPIRA INC | **10MG/ML** | **A090761** | **001** | Oct 18, 2012 |
| **AP** | | MYLAN LABS LTD | **10MG/ML** | **A206096** | **001** | Jun 22, 2017 |
| **AP** | | NANJING KING-FRIEND | **10MG/ML** | **A091489** | **001** | Feb 17, 2012 |
| **AP** | **!** | WEST-WARD PHARMS INT | **10MG/ML** | **A074901** | **001** | Jul 18, 1997 |

**ATRACURIUM BESYLATE PRESERVATIVE FREE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AUROBINDO PHARMA LTD | **10MG/ML** | **A206010** | **001** | Apr 08, 2015 |
| **AP** | | HOSPIRA INC | **10MG/ML** | **A090782** | **001** | Oct 18, 2012 |
| **AP** | | MYLAN LABS LTD | **10MG/ML** | **A206001** | **001** | Apr 07, 2017 |
| **AP** | | NANJING KING-FRIEND | **10MG/ML** | **A091488** | **001** | Feb 17, 2012 |
| **AP** | **!** | WEST-WARD PHARMS INT | **10MG/ML** | **A074900** | **001** | Jul 18, 1997 |

ATROPINE

INJECTABLE;INJECTION

ATROPEN

| | | | | | |
|---|---|---|---|---|---|
| +! | MERIDIAN MEDCL TECHN | EQ 0.25MG SULFATE/0.3ML | N017106 | 004 | Sep 17, 2004 |
| +! | | EQ 0.5MG SULFATE/0.7ML | N017106 | 003 | Jun 19, 2003 |
| +! | | EQ 1MG SULFATE/0.7ML | N017106 | 002 | Jun 19, 2003 |
| +! | | EQ 2MG SULFATE/0.7ML | N017106 | 001 | |

ATROPINE SULFATE

SOLUTION;INTRAVENOUS

ATROPINE SULFATE LIFESHIELD ABBOJECT SYRINGE

| | | | | | |
|---|---|---|---|---|---|
| +! | HOSPIRA | 0.5MG/5ML (0.1MG/ML) | N021146 | 004 | Aug 17, 2017 |
| +! | | 1MG/10ML (0.1MG/ML) | N021146 | 005 | Aug 17, 2017 |

SOLUTION;INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, ENDOTRACHEAL

ATROPINE SULFATE ANSYR PLASTIC SYRINGE

| | | | | | |
|---|---|---|---|---|---|
| +! | HOSPIRA | 0.25MG/5ML (0.05MG/ML) | N021146 | 002 | Jul 09, 2001 |
| +! | | 0.5MG/5ML (0.1MG/ML) | N021146 | 001 | Jul 09, 2001 |
| +! | | 1MG/10ML (0.1MG/ML) | N021146 | 003 | Jul 09, 2001 |

SOLUTION/DROPS;OPHTHALMIC

ATROPINE SULFATE

| | | | | | |
|---|---|---|---|---|---|
| +! | AKORN | 1% | N206289 | 001 | Jul 18, 2014 |

ISOPTO ATROPINE

| | | | | | |
|---|---|---|---|---|---|
| | NOVARTIS PHARMS CORP | 1% | N208151 | 001 | Dec 01, 2016 |

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET;ORAL

MOTOFEN

| | | | | | |
|---|---|---|---|---|---|
| +! | SEBELA IRELAND LTD | 0.025MG;1MG | N017744 | 002 | |

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

| | | | | | |
|---|---|---|---|---|---|
| ! | WEST-WARD PHARMS INT | 0.025MG/5ML;2.5MG/5ML | A087708 | 001 | May 03, 1982 |

TABLET;ORAL

**DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | ANI PHARMS INC | **0.025MG;2.5MG** | **A086727** | **001** | |
| **AA** | | LANNETT | **0.025MG;2.5MG** | **A085372** | **001** | |
| **AA** | | MYLAN | **0.025MG;2.5MG** | **A085762** | **001** | |
| **AA** | | PAR PHARM | **0.025MG;2.5MG** | **A040357** | **001** | May 02, 2000 |

**LOMOTIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **+!** | GD SEARLE LLC | **0.025MG;2.5MG** | **N012462** | **001** | |

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE;INTRAMUSCULAR

DUODOTE

| | | | | | |
|---|---|---|---|---|---|
| +! | MERIDIAN MEDCL | 2.1MG/0.7ML;600MG/2ML | N021983 | 001 | Sep 28, 2006 |

AURANOFIN

CAPSULE;ORAL

RIDAURA

| | | | | | |
|---|---|---|---|---|---|
| +! | SEBELA IRELAND LTD | 3MG | N018689 | 001 | May 24, 1985 |

AVANAFIL
TABLET;ORAL
STENDRA

| | | | | | | |
|---|---|---|---|---|---|---|
| + | METUCHEN PHARMS | 50MG | N202276 | 001 | Apr 27, 2012 |
| + | | 100MG | N202276 | 002 | Apr 27, 2012 |
| +! | | 200MG | N202276 | 003 | Apr 27, 2012 |

AVIBACTAM SODIUM; CEFTAZIDIME
POWDER;IV (INFUSION)
AVYCAZ

| | | | | | |
|---|---|---|---|---|---|
| +! | CEREXA | EQ 0.5GM BASE;2GM/VIAL | N206494 | 001 | Feb 25, 2015 |

AXITINIB
TABLET;ORAL
INLYTA

| | | | | | | |
|---|---|---|---|---|---|---|
| + | PF PRISM CV | 1MG | N202324 | 001 | Jan 27, 2012 |
| +! | | 5MG | N202324 | 002 | Jan 27, 2012 |

AZACITIDINE
POWDER;IV (INFUSION), SUBCUTANEOUS
**AZACITIDINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | ACTAVIS LLC | **100MG/VIAL** | **N208216** | **001** | Apr 29, 2016 |
| **AP** | DR REDDYS LABS LTD | **100MG/VIAL** | **A201537** | **001** | Sep 16, 2013 |
| **AP** | MYLAN INSTITUTIONAL | **100MG/VIAL** | **A204949** | **001** | Apr 28, 2016 |
| **AP** | NATCO PHARMA LTD | **100MG/VIAL** | **A207234** | **001** | Jun 23, 2017 |
| **AP** | SHILPA MEDICARE | **100MG/VIAL** | **A207518** | **001** | Sep 29, 2016 |

**VIDAZA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | CELGENE | **100MG/VIAL** | **N050794** | **001** | May 19, 2004 |

AZATHIOPRINE
TABLET;ORAL
**AZASAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | AAIPHARMA LLC | **25MG** | **A075252** | **002** | Feb 03, 2003 |
| **AB** | | **50MG** | **A075252** | **001** | Jun 07, 1999 |
| **AB** | | **75MG** | **A075252** | **003** | Feb 03, 2003 |
| **AB** | | **100MG** | **A075252** | **004** | Feb 03, 2003 |

**AZATHIOPRINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | AMNEAL PHARMS LLC | **50MG** | **A074069** | **001** | Feb 16, 1996 |
| **AB** | MYLAN | **50MG** | **A075568** | **001** | Dec 13, 1999 |
| **AB** | ZYDUS PHARMS USA | **25MG** | **A077621** | **002** | Sep 05, 2008 |
| **AB** | | **50MG** | **A077621** | **001** | Mar 15, 2007 |
| **AB** | | **75MG** | **A077621** | **003** | Sep 05, 2008 |
| **AB** | | **100MG** | **A077621** | **004** | Sep 05, 2008 |

**IMURAN**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | **+!** | SEBELA IRELAND LTD | **50MG** | **N016324** | **001** |

AZATHIOPRINE SODIUM
INJECTABLE;INJECTION
AZATHIOPRINE SODIUM

| | | | | | | |
|---|---|---|---|---|---|---|
| ! | WEST-WARD PHARMS INT | EQ 100MG BASE/VIAL | A074419 | 001 | Mar 31, 1995 |

AZELAIC ACID
AEROSOL, FOAM;TOPICAL
FINACEA

| | | | | | | |
|---|---|---|---|---|---|---|
| +! | BAYER HLTHCARE | 15% | N207071 | 001 | Jul 29, 2015 |

CREAM;TOPICAL
AZELEX

| | | | | | | |
|---|---|---|---|---|---|---|
| +! | ALLERGAN | 20% | N020428 | 001 | Sep 13, 1995 |

GEL;TOPICAL
FINACEA

| | | | | | | |
|---|---|---|---|---|---|---|
| +! | BAYER HLTHCARE | 15% | N021470 | 001 | Dec 24, 2002 |

AZELASTINE HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC
**AZELASTINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | AKORN | **0.05%** | **A203660** | **001** | Nov 08, 2016 |
| **AT** | APOTEX INC | **0.05%** | **A078621** | **001** | Aug 03, 2009 |
| **AT** | **!** SANDOZ INC | **0.05%** | **A202305** | **001** | May 31, 2012 |
| **AT** | SUN PHARMA GLOBAL | **0.05%** | **A078738** | **001** | Jun 21, 2010 |

SPRAY, METERED;NASAL
**ASTELIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | MYLAN SPECIALITY LP | **EQ 0.125MG BASE/SPRAY** | **N020114** | **001** | Nov 01, 1996 |

**ASTEPRO**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | MYLAN SPECIALITY LP | **EQ 0.1876MG BASE/SPRAY** | **N022203** | **002** | Aug 31, 2009 |

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL

**AZELASTINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALKEM LABS LTD | **EQ 0.125MG BASE/SPRAY** | **A208156** | **001** | Aug 18, 2017 |
| **AB** | | AMNEAL PHARMS LLC | **EQ 0.125MG BASE/SPRAY** | **A204660** | **001** | Aug 28, 2017 |
| **AB** | | | **EQ 0.1876MG BASE/SPRAY** | **A208199** | **001** | Dec 15, 2017 |
| **AB** | | APOTEX INC | **EQ 0.125MG BASE/SPRAY** | **A077954** | **001** | Apr 30, 2009 |
| **AB** | | | **EQ 0.1876MG BASE/SPRAY** | **A201846** | **001** | Aug 31, 2012 |
| **AB** | | BRECKENRIDGE PHARM | **EQ 0.125MG BASE/SPRAY** | **A090176** | **001** | Jul 28, 2015 |
| **AB** | | PERRIGO ISRAEL | **EQ 0.1876MG BASE/SPRAY** | **A202743** | **001** | May 08, 2014 |
| **AB** | | SUN PHARMA GLOBAL | **EQ 0.125MG BASE/SPRAY** | **A090423** | **001** | May 23, 2012 |
| **AB** | | UPSHER-SMITH LABS | **EQ 0.125MG BASE/SPRAY** | **A202609** | **001** | Mar 17, 2017 |
| **AB** | | WEST-WARD PHARMS INT | **EQ 0.125MG BASE/SPRAY** | **A091444** | **001** | Oct 24, 2014 |
| **AB** | | | **EQ 0.1876MG BASE/SPRAY** | **A207243** | **001** | Sep 22, 2017 |
| **AB** | | ZYDUS PHARMS USA INC | **EQ 0.125MG BASE/SPRAY** | **A091409** | **001** | Aug 14, 2017 |

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

**AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | APOTEX INC | **EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY** | **A207712** | **001** | Apr 28, 2017 |

**DYMISTA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | MYLAN SPECIALITY LP | **EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY** | **N202236** | **001** | May 01, 2012 |

AZILSARTAN KAMEDOXOMIL

TABLET;ORAL

EDARBI

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | ARBOR PHARMS LLC | EQ 40MG MEDOXOMIL | N200796 | 001 | Feb 25, 2011 |
| | +! | | EQ 80MG MEDOXOMIL | N200796 | 002 | Feb 25, 2011 |

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET;ORAL

EDARBYCLOR

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | ARBOR PHARMS LLC | EQ 40MG MEDOXOMIL;12.5MG | N202331 | 001 | Dec 20, 2011 |
| | +! | | EQ 40MG MEDOXOMIL;25MG | N202331 | 002 | Dec 20, 2011 |

AZITHROMYCIN

FOR SUSPENSION;ORAL

**AZITHROMYCIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | LUPIN LTD | **EQ 100MG BASE/5ML** | **A065488** | **001** | May 15, 2015 |
| **AB** | | | **EQ 200MG BASE/5ML** | **A065488** | **002** | May 15, 2015 |
| **AB** | | PLIVA | **EQ 100MG BASE/5ML** | **A065246** | **002** | Jul 05, 2006 |
| **AB** | | | **EQ 200MG BASE/5ML** | **A065246** | **001** | Jul 05, 2006 |
| **AB** | | TEVA PHARMS | **EQ 100MG BASE/5ML** | **A065419** | **001** | Jun 24, 2008 |
| **AB** | | | **EQ 200MG BASE/5ML** | **A065419** | **002** | Jun 24, 2008 |

**ZITHROMAX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | PFIZER | **EQ 100MG BASE/5ML** | **N050710** | **001** | Oct 19, 1995 |
| **AB** | **+!** | | **EQ 200MG BASE/5ML** | **N050710** | **002** | Oct 19, 1995 |
| | +! | | EQ 1GM BASE/PACKET | N050693 | 001 | Sep 28, 1994 |

FOR SUSPENSION, EXTENDED RELEASE;ORAL

ZMAX

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | PF PRISM CV | EQ 2GM BASE/BOT | N050797 | 001 | Jun 10, 2005 |

INJECTABLE;INJECTION

**AZITHROMYCIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AUROBINDO PHARMA LTD | **EQ 500MG BASE/VIAL** | **A203294** | **001** | Jun 19, 2015 |
| **AP** | | FRESENIUS KABI USA | **EQ 500MG BASE/VIAL** | **A065179** | **001** | Dec 13, 2005 |
| **AP** | | GLAND PHARMA LTD | **EQ 500MG BASE/VIAL** | **A065501** | **001** | Nov 09, 2009 |
| **AP** | | HOSPIRA | **EQ 500MG BASE/VIAL** | **A065500** | **001** | Jun 26, 2009 |
| **AP** | | | **EQ 500MG BASE/VIAL** | **A065511** | **001** | Jun 26, 2009 |
| **AP** | | MYLAN LABS LTD | **EQ 500MG BASE/VIAL** | **A204732** | **001** | Jan 26, 2017 |
| **AP** | | SAGENT STRIDES | **EQ 500MG BASE/VIAL** | **A065506** | **001** | Mar 24, 2009 |
| **AP** | | SUN PHARM INDS LTD | **EQ 500MG BASE/VIAL** | **A090923** | **001** | Apr 02, 2013 |

**ZITHROMAX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | PFIZER | **EQ 500MG BASE/VIAL** | **N050733** | **001** | Jan 30, 1997 |

SOLUTION/DROPS;OPHTHALMIC

AZASITE

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | OAK PHARMS INC | 1% | N050810 | 001 | Apr 27, 2007 |

TABLET;ORAL

**AZITHROMYCIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | APOTEX CORP | **EQ 250MG BASE** | **A065507** | **001** | Jul 13, 2011 |
| **AB** | | | **EQ 500MG BASE** | **A065509** | **001** | Jul 13, 2011 |
| **AB** | | | **EQ 600MG BASE** | **A065508** | **001** | Jul 13, 2011 |
| **AB** | | LUPIN LTD | **EQ 250MG BASE** | **A065398** | **001** | May 15, 2015 |

AZITHROMYCIN

TABLET;ORAL

**AZITHROMYCIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **EQ 500MG BASE** | **A065399** | **001** | May 15, 2015 |
| **AB** | | | **EQ 600MG BASE** | **A065400** | **001** | May 15, 2015 |
| **AB** | | MYLAN | **EQ 600MG BASE** | **A065360** | **001** | Jan 08, 2007 |
| **AB** | | PLIVA | **EQ 250MG BASE** | **A065225** | **001** | Nov 14, 2005 |
| **AB** | | | **EQ 500MG BASE** | **A065223** | **001** | Nov 14, 2005 |
| **AB** | | | **EQ 600MG BASE** | **A065218** | **001** | Nov 14, 2005 |
| **AB** | | SANDOZ | **EQ 250MG BASE** | **A065211** | **001** | Nov 14, 2005 |
| **AB** | | | **EQ 500MG BASE** | **A065212** | **001** | Nov 14, 2005 |
| **AB** | | | **EQ 600MG BASE** | **A065209** | **001** | Nov 14, 2005 |
| **AB** | | TEVA | **EQ 250MG BASE** | **A065153** | **001** | Nov 14, 2005 |
| **AB** | | | **EQ 500MG BASE** | **A065193** | **001** | Nov 14, 2005 |
| **AB** | | | **EQ 600MG BASE** | **A065150** | **001** | Nov 14, 2005 |
| **AB** | | WOCKHARDT | **EQ 250MG BASE** | **A065404** | **001** | Feb 11, 2008 |
| **AB** | | | **EQ 500MG BASE** | **A065405** | **001** | Feb 11, 2008 |
| **AB** | | | **EQ 600MG BASE** | **A065302** | **003** | Feb 11, 2008 |

**ZITHROMAX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | PFIZER | **EQ 250MG BASE** | **N050711** | **001** | Jul 18, 1996 |
| **AB** | **+** | | **EQ 500MG BASE** | **N050784** | **001** | May 24, 2002 |
| **AB** | **+!** | | **EQ 600MG BASE** | **N050730** | **001** | Jun 12, 1996 |

AZTREONAM

FOR SOLUTION;INHALATION

CAYSTON

| | | | | | |
|---|---|---|---|---|---|
| +! | GILEAD | 75MG/VIAL | N050814 | 001 | Feb 22, 2010 |

INJECTABLE;INJECTION

**AZACTAM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | BRISTOL MYERS SQUIBB | **1GM/VIAL** | **N050580** | **002** | Dec 31, 1986 |
| **AP** | **+!** | | **2GM/VIAL** | **N050580** | **003** | Dec 31, 1986 |

**AZTREONAM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | FRESENIUS KABI USA | **1GM/VIAL** | **A065439** | **002** | Jun 18, 2010 |
| **AP** | | | **2GM/VIAL** | **A065439** | **003** | Jun 18, 2010 |

AZACTAM IN PLASTIC CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| +! | BRISTOL MYERS SQUIBB | 20MG/ML | N050632 | 002 | May 24, 1989 |
| +! | | 40MG/ML | N050632 | 001 | May 24, 1989 |

AZTREONAM

| | | | | | |
|---|---|---|---|---|---|
| | FRESENIUS KABI USA | 500MG/VIAL | A065439 | 001 | Jun 18, 2010 |

BACITRACIN

INJECTABLE;INJECTION

**BACIIM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | X GEN PHARMS | **50,000 UNITS/VIAL** | **A064153** | **001** | May 09, 1997 |

**BACITRACIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AKORN | **50,000 UNITS/VIAL** | **A206719** | **001** | Oct 20, 2017 |
| **AP** | | FRESENIUS KABI USA | **50,000 UNITS/VIAL** | **A065116** | **001** | Dec 03, 2002 |
| **AP** | **!** | PHARMACIA AND UPJOHN | **50,000 UNITS/VIAL** | **A060733** | **002** | |
| **AP** | | SAGENT STRIDES | **50,000 UNITS/VIAL** | **A090211** | **001** | May 11, 2010 |
| **AP** | | XELLIA PHARMS APS | **50,000 UNITS/VIAL** | **A203177** | **001** | Aug 25, 2014 |
| | | PHARMACIA AND UPJOHN | 10,000 UNITS/VIAL | A060733 | 001 | |

OINTMENT;OPHTHALMIC

BACITRACIN

| | | | | | |
|---|---|---|---|---|---|
| ! | PERRIGO CO TENNESSEE | 500 UNITS/GM | A061212 | 001 | |

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

**NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | AKORN | **400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM** | **A065213** | **001** | Jul 25, 2012 |
| **AT** | **!** | BAUSCH AND LOMB | **400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM** | **A064068** | **001** | Oct 30, 1995 |

OINTMENT;TOPICAL

CORTISPORIN

| | | | | | |
|---|---|---|---|---|---|
| +! | MONARCH PHARMS | 400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM | N050168 | 002 | May 04, 1984 |

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

**NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | AKORN | **400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM** | **A065088** | **001** | Feb 06, 2004 |
| **AT** | ! | BAUSCH AND LOMB | **400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM** | **A064064** | **001** | Oct 30, 1995 |
| **AT** | | PERRIGO CO TENNESSEE | **400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM** | **A060764** | **002** | |

**NEOSPORIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | + | CASPER PHARMA LLC | **400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM** | **N050417** | **001** | |

BACITRACIN ZINC; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

**BACITRACIN ZINC AND POLYMYXIN B SULFATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | AKORN | **500 UNITS/GM;10,000 UNITS/GM** | **A064028** | **001** | Jan 30, 1995 |
| **AT** | ! | BAUSCH AND LOMB | **500 UNITS/GM;10,000 UNITS/GM** | **A064046** | **001** | Jan 26, 1995 |
| **AT** | | PERRIGO CO TENNESSEE | **500 UNITS/GM;10,000 UNITS/GM** | **A065022** | **001** | Feb 27, 2002 |

BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | PERRIGO CO TENNESSEE | 400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM | A062166 | 002 | |

BACLOFEN

INJECTABLE;INTRATHECAL

**BACLOFEN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | EMERALD INTL LTD | **0.05MG/ML** | **A091193** | **001** | May 03, 2016 |
| **AP** | | | **0.5MG/ML** | **A091193** | **002** | May 03, 2016 |
| **AP** | | | **2MG/ML** | **A091193** | **003** | May 03, 2016 |

**GABLOFEN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | PIRAMAL CRITICAL | **0.05MG/ML** | **N022462** | **001** | Nov 19, 2010 |
| **AP** | | | **0.5MG/ML** | **N022462** | **002** | Nov 19, 2010 |
| **AP** | | | **2MG/ML** | **N022462** | **003** | Nov 19, 2010 |

**LIORESAL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | SAOL THERAPS RES LTD | **0.05MG/ML** | **N020075** | **003** | Nov 07, 1996 |
| **AP** | **+!** | | **0.5MG/ML** | **N020075** | **001** | Jun 17, 1992 |
| **AP** | **+!** | | **2MG/ML** | **N020075** | **002** | Jun 17, 1992 |

GABLOFEN

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | PIRAMAL CRITICAL | 1MG/ML | N022462 | 004 | Jun 22, 2012 |

TABLET;ORAL

**BACLOFEN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | IMPAX LABS | **10MG** | **A077971** | **001** | Oct 26, 2007 |
| **AB** | | | **20MG** | **A077971** | **002** | Oct 26, 2007 |
| **AB** | | IVAX SUB TEVA PHARMS | **10MG** | **A072234** | **001** | Jul 21, 1988 |
| **AB** | ! | | **20MG** | **A072235** | **001** | Jul 21, 1988 |
| **AB** | | LANNETT | **10MG** | **A077241** | **002** | Jul 06, 2007 |
| **AB** | | | **20MG** | **A077241** | **001** | Dec 20, 2005 |
| **AB** | | MYLAN | **20MG** | **A077121** | **002** | Jul 29, 2005 |
| **AB** | | MYLAN PHARMS INC | **10MG** | **A090334** | **001** | Feb 18, 2010 |
| **AB** | | | **20MG** | **A090334** | **002** | Feb 18, 2010 |
| **AB** | | NORTHSTAR HLTHCARE | **10MG** | **A078401** | **002** | Sep 18, 2009 |
| **AB** | | | **20MG** | **A078401** | **001** | Sep 18, 2009 |
| **AB** | | OXFORD PHARMS | **10MG** | **A077088** | **002** | Oct 31, 2007 |
| **AB** | | | **20MG** | **A077088** | **001** | Oct 31, 2007 |
| **AB** | | RUBICON RES PVT LTD | **10MG** | **A209102** | **002** | Nov 28, 2017 |
| **AB** | | | **20MG** | **A209102** | **003** | Nov 28, 2017 |
| **AB** | | SUN PHARM INDS INC | **10MG** | **A077862** | **001** | Aug 14, 2006 |
| **AB** | | | **20MG** | **A077862** | **002** | Aug 14, 2006 |
| **AB** | | USL PHARMA | **10MG** | **A074584** | **001** | Aug 19, 1996 |
| **AB** | | | **20MG** | **A074584** | **002** | Aug 19, 1996 |
| **AB** | | VINTAGE PHARMS | **10MG** | **A077068** | **002** | Aug 30, 2005 |
| **AB** | | | **20MG** | **A077068** | **001** | Aug 30, 2005 |
| | | RUBICON RES PVT LTD | 5MG | A209102 | 001 | Nov 28, 2017 |

| | | | | | | |
|---|---|---|---|---|---|---|
| BALSALAZIDE DISODIUM | | | | | | |
| CAPSULE;ORAL | | | | | | |
| **BALSALAZIDE DISODIUM** | | | | | | |
| **AB** | | APOTEX INC | **750MG** | **A077883** | **001** | Dec 28, 2007 |
| **AB** | | MYLAN | **750MG** | **A077807** | **001** | Dec 28, 2007 |
| **AB** | | WEST-WARD PHARMS INT | **750MG** | **A077806** | **001** | Dec 28, 2007 |
| **COLAZAL** | | | | | | |
| **AB** | **+!** | VALEANT PHARMS INTL | **750MG** | **N020610** | **001** | Jul 18, 2000 |
| TABLET;ORAL | | | | | | |
| **BALSALAZIDE DISODIUM** | | | | | | |
| **AB** | | PAR PHARM INC | **1.1GM** | **A206336** | **001** | Sep 08, 2015 |
| **GIAZO** | | | | | | |
| **AB** | **+!** | VALEANT PHARMS INTL | **1.1GM** | **N022205** | **001** | Feb 03, 2012 |
| BARIUM SULFATE | | | | | | |
| FOR SUSPENSION;ORAL | | | | | | |
| E-Z-HD | | | | | | |
| | +! | BRACCO | 98% (334GM/BOTTLE) | N208036 | 001 | Jan 11, 2016 |
| E-Z-PAQUE | | | | | | |
| | +! | BRACCO | 96% (169GM/BOTTLE) | N208036 | 002 | Apr 07, 2017 |
| PASTE;ORAL | | | | | | |
| VARIBAR | | | | | | |
| | +! | BRACCO | 40% (92GM/230ML) | N208844 | 001 | Oct 14, 2016 |
| SUSPENSION;ORAL | | | | | | |
| LIQUID E-Z-PAQUE | | | | | | |
| | +! | BRACCO | 60% (213GM/355ML) | N208143 | 003 | Mar 01, 2017 |
| READI-CAT 2 | | | | | | |
| | +! | BRACCO | 2% (9GM/450ML) | N208143 | 001 | Jan 15, 2016 |
| READI-CAT 2 SMOOTHIES | | | | | | |
| | +! | BRACCO | 2% (9GM/450ML) | N208143 | 002 | Jan 15, 2016 |
| TAGITOL V | | | | | | |
| | +! | BRACCO | 40% (8GM/20ML) | N208143 | 005 | Aug 04, 2017 |
| VARIBAR NECTAR | | | | | | |
| | +! | BRACCO | 40% (96GM/240ML) | N208143 | 004 | Jul 07, 2017 |
| BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED | | | | | | |
| TABLET;ORAL | | | | | | |
| DUAVEE | | | | | | |
| | +! | WYETH PHARMS PFIZER | EQ 20MG BASE;0.45MG | N022247 | 001 | Oct 03, 2013 |
| BECLOMETHASONE DIPROPIONATE | | | | | | |
| AEROSOL, METERED;INHALATION | | | | | | |
| QVAR 40 | | | | | | |
| | +! | TEVA BRANDED PHARM | 0.04MG/INH | N020911 | 002 | Sep 15, 2000 |
| QVAR 80 | | | | | | |
| | +! | TEVA BRANDED PHARM | 0.08MG/INH | N020911 | 001 | Sep 15, 2000 |
| QVAR REDIHALER | | | | | | |
| | + | NORTON WATERFORD | 0.04MG/INH | N207921 | 001 | Aug 03, 2017 |
| | +! | | 0.08MG/INH | N207921 | 002 | Aug 03, 2017 |
| AEROSOL, METERED;NASAL | | | | | | |
| QNASL | | | | | | |
| | + | TEVA BRANDED PHARM | 0.04MG/ACTUATION | N202813 | 002 | Dec 17, 2014 |
| | +! | | 0.08MG/ACTUATION | N202813 | 001 | Mar 23, 2012 |
| BECLOMETHASONE DIPROPIONATE MONOHYDRATE | | | | | | |
| SPRAY, METERED;NASAL | | | | | | |
| BECONASE AQ | | | | | | |
| | +! | GLAXOSMITHKLINE | EQ 0.042MG DIPROP/SPRAY | N019389 | 001 | Jul 27, 1987 |
| BEDAQUILINE FUMARATE | | | | | | |
| TABLET;ORAL | | | | | | |
| SIRTURO | | | | | | |
| | +! | JANSSEN THERAP | EQ 100MG BASE | N204384 | 001 | Dec 28, 2012 |
| BELINOSTAT | | | | | | |
| POWDER;IV (INFUSION) | | | | | | |
| BELEODAQ | | | | | | |
| | +! | SPECTRUM PHARMS | 500MG/VIAL | N206256 | 001 | Jul 03, 2014 |

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

**BENAZEPRIL HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AMNEAL PHARMS | **5MG** | **A076820** | **001** | Feb 03, 2006 |
| **AB** | | | **10MG** | **A076820** | **002** | Feb 03, 2006 |
| **AB** | | | **20MG** | **A076820** | **003** | Feb 03, 2006 |
| **AB** | | | **40MG** | **A076820** | **004** | Feb 03, 2006 |
| **AB** | | APOTEX INC | **5MG** | **A077128** | **001** | Mar 08, 2006 |
| **AB** | | | **10MG** | **A077128** | **002** | Mar 08, 2006 |
| **AB** | | | **20MG** | **A077128** | **003** | Mar 08, 2006 |
| **AB** | | | **40MG** | **A077128** | **004** | Mar 08, 2006 |
| **AB** | | AUROBINDO PHARMA | **10MG** | **A078212** | **001** | May 22, 2008 |
| **AB** | | | **20MG** | **A078212** | **002** | May 22, 2008 |
| **AB** | | | **40MG** | **A078212** | **003** | May 22, 2008 |
| **AB** | | IVAX SUB TEVA PHARMS | **5MG** | **A076333** | **001** | Feb 11, 2004 |
| **AB** | | | **10MG** | **A076333** | **002** | Feb 11, 2004 |
| **AB** | | | **20MG** | **A076333** | **003** | Feb 11, 2004 |
| **AB** | | | **40MG** | **A076333** | **004** | Feb 11, 2004 |
| **AB** | | MYLAN | **5MG** | **A076430** | **001** | Feb 11, 2004 |
| **AB** | | | **10MG** | **A076430** | **002** | Feb 11, 2004 |
| **AB** | | | **20MG** | **A076430** | **003** | Feb 11, 2004 |
| **AB** | | | **40MG** | **A076430** | **004** | Feb 11, 2004 |
| **AB** | | PRINSTON INC | **5MG** | **A076118** | **001** | Feb 11, 2004 |
| **AB** | | | **10MG** | **A076118** | **002** | Feb 11, 2004 |
| **AB** | | | **20MG** | **A076118** | **003** | Feb 11, 2004 |
| **AB** | | | **40MG** | **A076118** | **004** | Feb 11, 2004 |
| **AB** | | SANDOZ | **5MG** | **A076402** | **001** | Feb 11, 2004 |
| **AB** | | | **10MG** | **A076402** | **002** | Feb 11, 2004 |
| **AB** | | | **20MG** | **A076402** | **003** | Feb 11, 2004 |
| **AB** | | | **40MG** | **A076402** | **004** | Feb 11, 2004 |
| **AB** | | SUN PHARM INDS LTD | **5MG** | **A076344** | **001** | Feb 11, 2004 |
| **AB** | | | **10MG** | **A076344** | **002** | Feb 11, 2004 |
| **AB** | | | **20MG** | **A076344** | **003** | Feb 11, 2004 |
| **AB** | | | **40MG** | **A076344** | **004** | Feb 11, 2004 |
| **AB** | | TEVA | **5MG** | **A076211** | **001** | Feb 11, 2004 |
| **AB** | | | **10MG** | **A076211** | **002** | Feb 11, 2004 |
| **AB** | | | **20MG** | **A076211** | **003** | Feb 11, 2004 |
| **AB** | | | **40MG** | **A076211** | **004** | Feb 11, 2004 |
| **AB** | | ZYDUS PHARMS USA | **5MG** | **A078848** | **001** | May 23, 2008 |
| **AB** | | | **10MG** | **A078848** | **002** | May 23, 2008 |
| **AB** | | | **20MG** | **A078848** | **003** | May 23, 2008 |
| **AB** | | | **40MG** | **A078848** | **004** | May 23, 2008 |

**LOTENSIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | US PHARMS HOLDINGS I | **5MG** | **N019851** | **001** | Jun 25, 1991 |
| **AB** | + | | **10MG** | **N019851** | **002** | Jun 25, 1991 |
| **AB** | + | | **20MG** | **N019851** | **003** | Jun 25, 1991 |
| **AB** | +! | | **40MG** | **N019851** | **004** | Jun 25, 1991 |

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

**BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | APOTEX INC | **5MG;6.25MG** | **A078794** | **001** | Aug 21, 2014 |
| **AB** | | | **10MG;12.5MG** | **A078794** | **002** | Aug 21, 2014 |
| **AB** | | | **20MG;12.5MG** | **A078794** | **003** | Aug 21, 2014 |
| **AB** | | | **20MG;25MG** | **A078794** | **004** | Aug 21, 2014 |
| **AB** | | MYLAN | **5MG;6.25MG** | **A076688** | **001** | Feb 11, 2004 |
| **AB** | | | **10MG;12.5MG** | **A076688** | **002** | Feb 11, 2004 |
| **AB** | | | **20MG;12.5MG** | **A076688** | **003** | Feb 11, 2004 |
| **AB** | | | **20MG;25MG** | **A076688** | **004** | Feb 11, 2004 |
| **AB** | | SANDOZ | **5MG;6.25MG** | **A076631** | **001** | Feb 11, 2004 |
| **AB** | | | **10MG;12.5MG** | **A076631** | **002** | Feb 11, 2004 |
| **AB** | | | **20MG;12.5MG** | **A076631** | **003** | Feb 11, 2004 |
| **AB** | | | **20MG;25MG** | **A076631** | **004** | Feb 11, 2004 |

**LOTENSIN HCT**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | US PHARMS HOLDINGS I | **10MG;12.5MG** | **N020033** | **002** | May 19, 1992 |
| **AB** | + | | **20MG;12.5MG** | **N020033** | **004** | May 19, 1992 |
| **AB** | +! | | **20MG;25MG** | **N020033** | **003** | May 19, 1992 |

BENDAMUSTINE HYDROCHLORIDE

POWDER;IV (INFUSION)

**BENDAMUSTINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | ACCORD HLTHCARE | **25MG/VIAL** | **A205574** | **001** | May 19, 2016 |
| **AP** | | | **100MG/VIAL** | **A205574** | **002** | May 19, 2016 |
| **AP** | | BRECKENRIDGE PHARM | **25MG/VIAL** | **A205447** | **001** | Dec 29, 2016 |
| **AP** | | | **100MG/VIAL** | **A205447** | **002** | Dec 29, 2016 |
| **AP** | | GLENMARK PHARMS LTD | **25MG/VIAL** | **A204771** | **001** | Mar 24, 2016 |
| **AP** | | | **100MG/VIAL** | **A204771** | **002** | Mar 24, 2016 |
| **AP** | | HOSPIRA INC | **25MG/VIAL** | **A204086** | **001** | May 20, 2016 |
| **AP** | | | **100MG/VIAL** | **A204086** | **002** | May 20, 2016 |
| **AP** | | INNOPHARMA LICENSING | **25MG/VIAL** | **A205476** | **001** | Mar 24, 2016 |
| **AP** | | | **100MG/VIAL** | **A205476** | **002** | Mar 24, 2016 |

**TREANDA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | CEPHALON | **25MG/VIAL** | **N022249** | **002** | May 01, 2009 |
| **AP** | **+!** | | **100MG/VIAL** | **N022249** | **001** | Mar 20, 2008 |

SOLUTION;IV (INFUSION)

BENDEKA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | EAGLE PHARMS | 100MG/4ML (25MG/ML) | N208194 | 001 | Dec 07, 2015 |

TREANDA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | CEPHALON | 45MG/0.5ML (90MG/ML) | N022249 | 003 | Sep 13, 2013 |
| | +! | | 180MG/2ML (90MG/ML) | N022249 | 004 | Sep 13, 2013 |

BENDROFLUMETHIAZIDE; NADOLOL

TABLET;ORAL

**CORZIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | KING PHARMS LLC | **5MG;40MG** | **N018647** | **001** | May 25, 1983 |
| **AB** | **+!** | | **5MG;80MG** | **N018647** | **002** | May 25, 1983 |

**NADOLOL AND BENDROFLUMETHIAZIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | IMPAX LABS | **5MG;40MG** | **A077833** | **001** | Mar 30, 2007 |
| **AB** | | | **5MG;80MG** | **A077833** | **002** | Mar 30, 2007 |

BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM

SOLUTION/DROPS;OPHTHALMIC

ALTAFLUOR BENOX

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ALTAIRE PHARMS INC | 0.4%;0.25% | N208582 | 001 | Dec 14, 2017 |

BENZNIDAZOLE

TABLET;ORAL

BENZNIDAZOLE

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | CHEMO RESEARCH SL | 12.5MG | N209570 | 001 | Aug 29, 2017 |
| | +! | | 100MG | N209570 | 002 | Aug 29, 2017 |

BENZONATATE

CAPSULE;ORAL

**BENZONATATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | APOTEX INC | **100MG** | **A091310** | **001** | Jan 16, 2015 |
| **AA** | | | **200MG** | **A091310** | **002** | Jan 16, 2015 |
| **AA** | | BIONPHARMA INC | **100MG** | **A081297** | **001** | Jan 29, 1993 |
| **AA** | | | **200MG** | **A081297** | **002** | Oct 30, 2007 |
| **AA** | | CSPC NBP PHARM CO | **200MG** | **A202765** | **001** | Jul 31, 2015 |
| **AA** | | MIKART | **100MG** | **A040851** | **001** | Nov 09, 2009 |
| **AA** | | | **150MG** | **A040851** | **002** | Nov 09, 2009 |
| **AA** | | | **200MG** | **A040851** | **003** | Nov 09, 2009 |
| **AA** | | ORIT LABS LLC | **100MG** | **A040682** | **001** | Jul 30, 2007 |
| **AA** | | | **200MG** | **A040682** | **002** | Jul 30, 2007 |
| **AA** | | STRIDES PHARMA | **100MG** | **A091133** | **001** | Jul 30, 2015 |
| **AA** | | | **200MG** | **A091133** | **002** | Jul 30, 2015 |
| **AA** | | SUN PHARM INDS INC | **100MG** | **A040587** | **001** | Mar 19, 2008 |
| **AA** | | | **200MG** | **A040587** | **002** | Mar 19, 2008 |
| **AA** | **!** | THE PHARMA NETWORK | **100MG** | **A040627** | **001** | Mar 30, 2007 |
| **AA** | **!** | | **200MG** | **A040749** | **001** | Jul 25, 2007 |
| **AA** | **!** | THEPHARMANETWORK LLC | **150MG** | **A201209** | **001** | Sep 24, 2014 |
| **AA** | | ZYDUS PHARMS USA | **100MG** | **A040597** | **001** | Jun 08, 2007 |
| **AA** | | | **200MG** | **A040597** | **002** | Jun 08, 2007 |

**TESSALON**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **+** | PFIZER | **100MG** | **N011210** | **001** | |

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

**ACANYA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | DOW PHARM | **2.5%;EQ 1.2% BASE** | **N050819** | **001** | Oct 23, 2008 |

**BENZACLIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | VALEANT BERMUDA | **5%;EQ 1% BASE** | **N050756** | **001** | Dec 21, 2000 |

**CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS LABS UT INC | **2.5%;EQ 1.2% BASE** | **A205128** | **001** | Jun 19, 2015 |
| **AB** | | MYLAN PHARMS INC | **5%;EQ 1% BASE** | **A065443** | **001** | Aug 11, 2009 |
| **AB** | | PERRIGO ISRAEL | **5%;EQ 1% BASE** | **A202440** | **001** | Sep 21, 2015 |
| **AB** | | | **5%;1.2%** | **A090979** | **001** | Jun 26, 2012 |
| **AB** | | TARO | **5%;1.2%** | **A206218** | **001** | Dec 15, 2017 |
| **AB** | | TOLMAR | **5%;EQ 1% BASE** | **A204087** | **001** | Jun 27, 2017 |
| **AB** | | | **5%;1.2%** | **A203688** | **001** | Aug 25, 2016 |

**DUAC**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | STIEFEL | **5%;1.2%** | **N050741** | **001** | Aug 26, 2002 |

ONEXTON

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | DOW PHARM | 3.75%;EQ 1.2% BASE | N050819 | 002 | Nov 24, 2014 |

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL;TOPICAL

**BENZAMYCIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | VALEANT INTL | **5%;3%** | **N050557** | **001** | Oct 26, 1984 |

**ERYTHROMYCIN AND BENZOYL PEROXIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | LYNE | **5%;3%** | **A065385** | **001** | Sep 18, 2015 |
| **AB** | | TOLMAR | **5%;3%** | **A065112** | **001** | Mar 29, 2004 |

AKTIPAK

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | CUTANEA | 5%;3% | N050769 | 001 | Nov 27, 2000 |

BENZPHETAMINE HYDROCHLORIDE

TABLET;ORAL

**BENZPHETAMINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | ANDA REPOSITORY | **50MG** | **A040578** | **001** | Apr 17, 2006 |
| **AA** | | EMCURE PHARMS LTD | **50MG** | **A202061** | **001** | Jan 27, 2012 |
| **AA** | | EPIC PHARMA LLC | **50MG** | **A090346** | **001** | Dec 15, 2015 |
| **AA** | **!** | KVK TECH | **50MG** | **A090968** | **001** | Jul 20, 2010 |
| **AA** | | MIKART | **25MG** | **A090473** | **001** | Sep 15, 2010 |
| **AA** | | | **50MG** | **A090473** | **002** | Sep 15, 2010 |
| **AA** | | SPECGX LLC | **50MG** | **A040773** | **001** | Apr 25, 2007 |
| **AA** | | TEDOR PHARM | **25MG** | **A040747** | **002** | Nov 20, 2015 |
| **AA** | | | **50MG** | **A040747** | **001** | Mar 30, 2007 |

BENZTROPINE MESYLATE

INJECTABLE;INJECTION

**BENZTROPINE MESYLATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | FRESENIUS KABI USA | **1MG/ML** | **A090233** | **001** | Jul 28, 2009 |
| **AP** | | HIKMA FARMACEUTICA | **1MG/ML** | **A090287** | **001** | Aug 31, 2009 |
| **AP** | | LUITPOLD | **1MG/ML** | **A091152** | **001** | Mar 29, 2010 |
| **AP** | | NAVINTA LLC | **1MG/ML** | **A091525** | **001** | Feb 05, 2013 |

**COGENTIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | OAK PHARMS AKORN | **1MG/ML** | **N012015** | **001** | |

TABLET;ORAL

**BENZTROPINE MESYLATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | ASPEN GLOBAL INC | **0.5MG** | **A204713** | **001** | Apr 14, 2015 |
| **AA** | | | **1MG** | **A204713** | **002** | Apr 14, 2015 |
| **AA** | | | **2MG** | **A204713** | **003** | Apr 14, 2015 |
| **AA** | | EPIC PHARMA LLC | **0.5MG** | **A072264** | **001** | Feb 27, 1989 |
| **AA** | | | **1MG** | **A072265** | **001** | Feb 27, 1989 |
| **AA** | | | **2MG** | **A072266** | **001** | Feb 27, 1989 |
| **AA** | | INVAGEN PHARMS | **0.5MG** | **A090294** | **001** | Mar 29, 2010 |
| **AA** | | | **1MG** | **A090294** | **002** | Mar 29, 2010 |
| **AA** | | | **2MG** | **A090294** | **003** | Mar 29, 2010 |
| **AA** | | LEADING PHARMA LLC | **0.5MG** | **A090168** | **001** | Nov 28, 2012 |
| **AA** | | | **1MG** | **A090168** | **002** | Nov 28, 2012 |
| **AA** | | | **2MG** | **A090168** | **003** | Nov 28, 2012 |
| **AA** | | PLIVA | **0.5MG** | **A089058** | **001** | Aug 10, 1988 |
| **AA** | | | **1MG** | **A089059** | **001** | Aug 10, 1988 |
| **AA** | | | **2MG** | **A089060** | **001** | Aug 10, 1988 |
| **AA** | **!** | USL PHARMA | **0.5MG** | **A040103** | **001** | Dec 12, 1996 |
| **AA** | **!** | | **1MG** | **A040103** | **002** | Dec 12, 1996 |
| **AA** | **!** | | **2MG** | **A040103** | **003** | Dec 12, 1996 |
| **AA** | | VINTAGE | **0.5MG** | **A040715** | **001** | Aug 27, 2007 |
| **AA** | | | **1MG** | **A040715** | **002** | Aug 27, 2007 |
| **AA** | | | **2MG** | **A040715** | **003** | Aug 27, 2007 |

BENZTROPINE MESYLATE
TABLET;ORAL
BENZTROPINE MESYLATE

| | | | | | |
|---|---|---|---|---|---|
| | OXFORD PHARMS | 0.5MG | A040706 | 002 | Feb 14, 2008 |
| | | 1MG | A040706 | 003 | Feb 14, 2008 |

BENZYL ALCOHOL
LOTION;TOPICAL
ULESFIA

| | | | | | |
|---|---|---|---|---|---|
| +! | SHIONOGI INC | 5% | N022129 | 001 | Apr 09, 2009 |

BENZYLPENICILLOYL POLYLYSINE
INJECTABLE;INJECTION
PRE-PEN

| | | | | | |
|---|---|---|---|---|---|
| +! | ALLERQUEST | 60UMOLAR | N050114 | 001 | |

BEPOTASTINE BESILATE
SOLUTION/DROPS;OPHTHALMIC
BEPREVE

| | | | | | |
|---|---|---|---|---|---|
| +! | BAUSCH AND LOMB INC | 1.5% | N022288 | 001 | Sep 08, 2009 |

BERACTANT
SUSPENSION;INTRATRACHEAL
SURVANTA

| | | | | | |
|---|---|---|---|---|---|
| +! | ABBVIE | 25MG/ML | N020032 | 001 | Jul 01, 1991 |

BESIFLOXACIN HYDROCHLORIDE
SUSPENSION/DROPS;OPHTHALMIC
BESIVANCE

| | | | | | |
|---|---|---|---|---|---|
| +! | BAUSCH AND LOMB | EQ 0.6% BASE | N022308 | 001 | May 28, 2009 |

BETAINE HYDROCHLORIDE
FOR SOLUTION;ORAL
CYSTADANE

| | | | | | |
|---|---|---|---|---|---|
| +! | ORPHAN EUROPE | 1GM/SCOOPFUL | N020576 | 001 | Oct 25, 1996 |

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE
INJECTABLE;INJECTION
**BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | LUITPOLD | **3MG/ML;EQ 3MG BASE/ML** | **A090747** | **001** | Jul 31, 2009 |

**CELESTONE SOLUSPAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | MERCK SHARP DOHME | **3MG/ML;EQ 3MG BASE/ML** | **N014602** | **001** | |

BETAMETHASONE DIPROPIONATE
CREAM;TOPICAL
**BETAMETHASONE DIPROPIONATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS MID ATLANTIC | **EQ 0.05% BASE** | **A070885** | **001** | Feb 03, 1987 |
| **AB** | **+!** | FOUGERA PHARMS | **EQ 0.05% BASE** | **N019137** | **001** | Jun 26, 1984 |
| **AB** | | TARO | **EQ 0.05% BASE** | **A073552** | **001** | Apr 30, 1992 |

CREAM, AUGMENTED;TOPICAL
**BETAMETHASONE DIPROPIONATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | FOUGERA PHARMS | **EQ 0.05% BASE** | **A076215** | **001** | Dec 09, 2003 |
| **AB** | | GLENMARK GENERICS | **EQ 0.05% BASE** | **A078930** | **001** | Sep 23, 2008 |
| **AB** | | PERRIGO NEW YORK | **EQ 0.05% BASE** | **A076592** | **001** | Dec 09, 2003 |
| **AB** | | TARO | **EQ 0.05% BASE** | **A076543** | **001** | Dec 09, 2003 |
| **AB** | | TOLMAR | **EQ 0.05% BASE** | **A076603** | **001** | Jan 23, 2004 |

**DIPROLENE AF**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | MERCK SHARP DOHME | **EQ 0.05% BASE** | **N019555** | **001** | Apr 27, 1987 |

GEL, AUGMENTED;TOPICAL
**BETAMETHASONE DIPROPIONATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **!** | FOUGERA PHARMS | **EQ 0.05% BASE** | **A075276** | **001** | May 13, 2003 |
| **AB** | | TARO | **EQ 0.05% BASE** | **A076508** | **001** | Dec 02, 2003 |

LOTION;TOPICAL
**BETAMETHASONE DIPROPIONATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS MID ATLANTIC | **EQ 0.05% BASE** | **A070281** | **001** | Jul 31, 1985 |
| **AB** | **!** | FOUGERA PHARMS INC | **EQ 0.05% BASE** | **A070275** | **001** | Aug 12, 1985 |
| **AB** | | G AND W LABS INC | **EQ 0.05% BASE** | **A071467** | **001** | Aug 10, 1987 |
| **AB** | | PERRIGO NEW YORK | **EQ 0.05% BASE** | **A072538** | **001** | Jan 31, 1990 |

LOTION, AUGMENTED;TOPICAL
**BETAMETHASONE DIPROPIONATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | FOUGERA PHARMS | **EQ 0.05% BASE** | **A077111** | **001** | May 21, 2007 |
| **AB** | | TARO | **EQ 0.05% BASE** | **A077477** | **001** | May 21, 2007 |

**DIPROLENE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | MERCK SHARP DOHME | **EQ 0.05% BASE** | **N019716** | **001** | Aug 01, 1988 |

BETAMETHASONE DIPROPIONATE

OINTMENT;TOPICAL

**BETAMETHASONE DIPROPIONATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS MID ATLANTIC | **EQ 0.05% BASE** | **A071012** | **001** | Feb 03, 1987 |
| **AB** | **+!** | FOUGERA PHARMS INC | **EQ 0.05% BASE** | **N019141** | **001** | Sep 04, 1984 |
| **AB** | | TARO | **EQ 0.05% BASE** | **A074271** | **001** | Sep 15, 1994 |

OINTMENT, AUGMENTED;TOPICAL

**BETAMETHASONE DIPROPIONATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS MID ATLANTIC | **EQ 0.05% BASE** | **A074304** | **001** | Aug 31, 1995 |
| **AB** | | FOUGERA PHARMS | **EQ 0.05% BASE** | **A075373** | **001** | Jun 22, 1999 |
| **AB** | | TARO | **EQ 0.05% BASE** | **A076753** | **001** | Oct 12, 2004 |
| **AB** | | TELIGENT PHARMA INC | **EQ 0.05% BASE** | **A206118** | **001** | Nov 09, 2017 |

**DIPROLENE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | MERCK SHARP DOHME | **EQ 0.05% BASE** | **N018741** | **001** | Jul 27, 1983 |

SPRAY;TOPICAL

SERNIVO

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | PROMIUS PHARMA LLC | EQ 0.05% BASE/SPRAY | N208079 | 001 | Feb 05, 2016 |

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE

AEROSOL, FOAM;TOPICAL

ENSTILAR

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | LEO PHARMA AS | 0.064%;0.005% | N207589 | 001 | Oct 16, 2015 |

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE

OINTMENT;TOPICAL

**CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | PERRIGO ISRAEL | **0.064%;0.005%** | **A200174** | **001** | Dec 12, 2014 |
| **AB** | | TOLMAR | **0.064%;0.005%** | **A201615** | **001** | Jan 14, 2013 |

**TACLONEX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | LEO PHARMA AS | **0.064%;0.005%** | **N021852** | **001** | Jan 09, 2006 |

SUSPENSION;TOPICAL

TACLONEX

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | LEO PHARMA AS | 0.064%;0.005% | N022185 | 001 | May 09, 2008 |

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM;TOPICAL

**CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS MID ATLANTIC | **EQ 0.05% BASE;1%** | **A076002** | **001** | Aug 02, 2002 |
| **AB** | | FOUGERA PHARMS | **EQ 0.05% BASE;1%** | **A075502** | **001** | Jun 05, 2001 |
| **AB** | | GLENMARK PHARMS | **EQ 0.05% BASE;1%** | **A202894** | **001** | Oct 30, 2015 |
| **AB** | | TARO | **EQ 0.05% BASE;1%** | **A075673** | **001** | May 29, 2001 |

**LOTRISONE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | MERCK SHARP DOHME | **EQ 0.05% BASE;1%** | **N018827** | **001** | Jul 10, 1984 |

LOTION;TOPICAL

**CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | FOUGERA PHARMS | **EQ 0.05% BASE;1%** | **A076516** | **001** | Jun 16, 2005 |
| **AB** | | TARO | **EQ 0.05% BASE;1%** | **A076493** | **001** | Jul 28, 2004 |

**LOTRISONE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | MERCK SHARP DOHME | **EQ 0.05% BASE;1%** | **N020010** | **001** | Dec 08, 2000 |

BETAMETHASONE VALERATE

AEROSOL, FOAM;TOPICAL

**BETAMETHASONE VALERATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | PERRIGO UK FINCO | **0.12%** | **A078337** | **001** | Nov 26, 2012 |
| **AB** | | RICONPHARMA LLC | **0.12%** | **A207144** | **001** | May 24, 2017 |
| **AB** | | TARO PHARM | **0.12%** | **A208204** | **001** | May 24, 2017 |

**LUXIQ**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | MYLAN PHARMS INC | **0.12%** | **N020934** | **001** | Feb 28, 1999 |

CREAM;TOPICAL

**BETA-VAL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | G AND W LABS INC | **EQ 0.1% BASE** | **N018642** | **001** | Mar 24, 1983 |

**BETAMETHASONE VALERATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | FOUGERA PHARMS INC | **EQ 0.1% BASE** | **N018861** | **001** | Aug 31, 1983 |

**DERMABET**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | TARO | **EQ 0.1% BASE** | **A072041** | **001** | Jan 06, 1988 |

**VALNAC**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS MID ATLANTIC | **EQ 0.1% BASE** | **A070050** | **001** | Oct 10, 1984 |

LOTION;TOPICAL

**BETA-VAL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | G AND W LABS INC | **EQ 0.1% BASE** | **A070072** | **001** | Jun 27, 1985 |

| | | | | | | |
|---|---|---|---|---|---|---|
| BETAMETHASONE VALERATE | | | | | | |
| LOTION;TOPICAL | | | | | | |
| **BETAMETHASONE VALERATE** | | | | | | |
| **AB** | **+!** | FOUGERA PHARMS INC | **EQ 0.1% BASE** | **N018866** | **001** | Aug 31, 1983 |
| **AB** | | STI PHARMA LLC | **EQ 0.1% BASE** | **A070052** | **001** | Jul 31, 1985 |
| OINTMENT;TOPICAL | | | | | | |
| **BETA-VAL** | | | | | | |
| **AB** | | G AND W LABS INC | **EQ 0.1% BASE** | **A070069** | **001** | Dec 19, 1985 |
| **BETAMETHASONE VALERATE** | | | | | | |
| **AB** | | ACTAVIS MID ATLANTIC | **EQ 0.1% BASE** | **A070051** | **001** | Oct 10, 1984 |
| **AB** | **+!** | FOUGERA PHARMS INC | **EQ 0.1% BASE** | **N018865** | **001** | Aug 31, 1983 |
| BETAXOLOL HYDROCHLORIDE | | | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | | | |
| **BETAXOLOL HYDROCHLORIDE** | | | | | | |
| **AT** | | AKORN | **EQ 0.5% BASE** | **A075386** | **001** | Jun 30, 2000 |
| **AT** | | MEDIMETRIKS PHARMS | **EQ 0.5% BASE** | **A075630** | **001** | Apr 12, 2001 |
| **AT** | | WOCKHARDT | **EQ 0.5% BASE** | **A078694** | **001** | Nov 16, 2009 |
| **BETOPTIC** | | | | | | |
| **AT** | **+!** | ALCON | **EQ 0.5% BASE** | **N019270** | **001** | Aug 30, 1985 |
| SUSPENSION/DROPS;OPHTHALMIC | | | | | | |
| BETOPTIC S | | | | | | |
| | +! | NOVARTIS PHARMS CORP | EQ 0.25% BASE | N019845 | 001 | Dec 29, 1989 |
| TABLET;ORAL | | | | | | |
| **BETAXOLOL HYDROCHLORIDE** | | | | | | |
| **AB** | | EPIC PHARMA | **10MG** | **A075541** | **001** | Oct 22, 1999 |
| **AB** | **!** | | **20MG** | **A075541** | **002** | Oct 22, 1999 |
| **AB** | | KVK TECH | **10MG** | **A078962** | **001** | Jun 27, 2008 |
| **AB** | | | **20MG** | **A078962** | **002** | Jun 27, 2008 |
| BETHANECHOL CHLORIDE | | | | | | |
| TABLET;ORAL | | | | | | |
| **BETHANECHOL CHLORIDE** | | | | | | |
| **AA** | | AMNEAL PHARM | **5MG** | **A040855** | **001** | Nov 21, 2007 |
| **AA** | | | **10MG** | **A040855** | **002** | Nov 21, 2007 |
| **AA** | | | **25MG** | **A040855** | **003** | Nov 21, 2007 |
| **AA** | | | **50MG** | **A040855** | **004** | Nov 21, 2007 |
| **AA** | | ECI PHARMS LLC | **5MG** | **A040725** | **001** | Oct 26, 2007 |
| **AA** | | | **10MG** | **A040726** | **001** | Oct 26, 2007 |
| **AA** | | | **25MG** | **A040727** | **001** | Oct 26, 2007 |
| **AA** | | | **50MG** | **A040728** | **001** | Oct 26, 2007 |
| **AA** | | HERITAGE PHARMA | **5MG** | **A091256** | **001** | May 04, 2010 |
| **AA** | | | **10MG** | **A091256** | **002** | May 04, 2010 |
| **AA** | | | **25MG** | **A091256** | **003** | May 04, 2010 |
| **AA** | | | **50MG** | **A091256** | **004** | May 04, 2010 |
| **AA** | | LANNETT HOLDINGS INC | **5MG** | **A040677** | **002** | Mar 27, 2008 |
| **AA** | | | **10MG** | **A040677** | **003** | Mar 27, 2008 |
| **AA** | | | **25MG** | **A040677** | **004** | Mar 27, 2008 |
| **AA** | | | **50MG** | **A040677** | **001** | Mar 27, 2008 |
| **AA** | | UPSHER-SMITH LABS | **5MG** | **A040633** | **001** | Jun 01, 2005 |
| **AA** | | | **10MG** | **A040634** | **001** | Jun 01, 2005 |
| **AA** | | | **25MG** | **A040635** | **001** | Jun 01, 2005 |
| **AA** | | | **50MG** | **A040636** | **001** | Jun 01, 2005 |
| **AA** | | WOCKHARDT | **5MG** | **A040532** | **001** | Sep 29, 2003 |
| **AA** | | | **10MG** | **A040533** | **001** | Sep 29, 2003 |
| **AA** | | | **25MG** | **A040534** | **001** | Sep 29, 2003 |
| **AA** | | | **50MG** | **A040518** | **001** | Sep 29, 2003 |
| **DUVOID** | | | | | | |
| **AA** | | BI-COASTAL PHARMA | **10MG** | **A086262** | **001** | |
| **AA** | | | **25MG** | **A086263** | **001** | |
| **AA** | | | **50MG** | **A085882** | **003** | |
| **URECHOLINE** | | | | | | |
| **AA** | **!** | ODYSSEY PHARMS | **5MG** | **A089095** | **001** | Dec 19, 1985 |
| **AA** | **!** | | **10MG** | **A088440** | **001** | May 29, 1984 |
| **AA** | **!** | | **25MG** | **A088441** | **001** | May 29, 1984 |
| **AA** | **!** | | **50MG** | **A089096** | **001** | Dec 19, 1985 |

BETRIXABAN

CAPSULE;ORAL

BEVYXXA

| | | | | | | |
|---|---|---|---|---|---|---|
| + | PORTOLA PHARMS INC | 40MG | | N208383 | 001 | Jun 23, 2017 |
| +! | | 80MG | | N208383 | 002 | Jun 23, 2017 |

BEXAROTENE

CAPSULE;ORAL

**BEXAROTENE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | BIONPHARMA INC | **75MG** | | **A203174** | **001** | Aug 12, 2014 |

**TARGRETIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** **+!** | VALEANT LUXEMBOURG | **75MG** | | **N021055** | **001** | Dec 29, 1999 |

GEL;TOPICAL

TARGRETIN

| | | | | | | |
|---|---|---|---|---|---|---|
| +! | VALEANT LUXEMBOURG | 1% | | N021056 | 001 | Jun 28, 2000 |

BICALUTAMIDE

TABLET;ORAL

**BICALUTAMIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | ACCORD HLTHCARE | **50MG** | | **A078917** | **001** | Jul 06, 2009 |
| **AB** | APOTEX INC | **50MG** | | **A200274** | **001** | May 21, 2015 |
| **AB** | FRESENIUS KABI ONCOL | **50MG** | | **A079045** | **001** | May 13, 2010 |
| **AB** | MYLAN | **50MG** | | **A079185** | **001** | Jul 06, 2009 |
| **AB** | SANDOZ | **50MG** | | **A078575** | **001** | Jul 06, 2009 |
| **AB** | SANTOS BIOTECH | **50MG** | | **A091011** | **001** | Jun 10, 2015 |
| **AB** | SUN PHARMA GLOBAL | **50MG** | | **A079110** | **001** | Jul 06, 2009 |
| **AB** | TEVA | **50MG** | | **A076932** | **001** | Jul 06, 2009 |
| **AB** | WATSON LABS TEVA | **50MG** | | **A078634** | **001** | Aug 28, 2009 |
| **AB** | ZYDUS PHARMS USA INC | **50MG** | | **A079089** | **001** | Jul 06, 2009 |

**CASODEX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** **+!** | ASTRAZENECA PHARMS | **50MG** | | **N020498** | **001** | Oct 04, 1995 |

BIMATOPROST

SOLUTION/DROPS;OPHTHALMIC

**BIMATOPROST**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | APOTEX INC | **0.03%** | | **A090449** | **001** | Jul 20, 2015 |
| **AT** **!** | LUPIN LTD | **0.03%** | | **A203991** | **001** | Feb 20, 2015 |
| **AT** | SANDOZ INC | **0.03%** | | **A202565** | **001** | May 05, 2015 |

LUMIGAN

| | | | | | | |
|---|---|---|---|---|---|---|
| +! | ALLERGAN | 0.01% | | N022184 | 001 | Aug 31, 2010 |

SOLUTION/DROPS;TOPICAL

**BIMATOPROST**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | APOTEX INC | **0.03%** | | **A201894** | **001** | Dec 01, 2014 |
| **AT** | SANDOZ INC | **0.03%** | | **A202719** | **001** | Apr 19, 2016 |

**LATISSE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** **+!** | ALLERGAN | **0.03%** | | **N022369** | **001** | Dec 24, 2008 |

BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION, TABLET, DELAYED RELEASE;ORAL

PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL

| | | | | | | |
|---|---|---|---|---|---|---|
| ! | NOVEL LABS INC | 5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2.86GM;N/A,5.6GM | | A202217 | 001 | Aug 20, 2014 |

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE

CAPSULE;ORAL

PYLERA

| | | | | | | |
|---|---|---|---|---|---|---|
| +! | FOREST LABS LLC | 140MG;125MG;125MG | | N050786 | 001 | Sep 28, 2006 |

BISOPROLOL FUMARATE

TABLET;ORAL

**BISOPROLOL FUMARATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | AUROBINDO PHARMA | **5MG** | | **A077910** | **001** | Dec 27, 2006 |
| **AB** | | **10MG** | | **A077910** | **002** | Dec 27, 2006 |
| **AB** | MYLAN | **5MG** | | **A075831** | **001** | Dec 14, 2005 |
| **AB** **!** | | **10MG** | | **A075831** | **002** | Dec 14, 2005 |
| **AB** | ORIT LABS LLC | **5MG** | | **A204891** | **001** | Jan 11, 2017 |
| **AB** | | **10MG** | | **A204891** | **002** | Jan 11, 2017 |
| **AB** | SANDOZ | **5MG** | | **A075643** | **001** | Nov 16, 2000 |
| **AB** | | **10MG** | | **A075643** | **002** | Nov 16, 2000 |
| **AB** | TEVA PHARMS | **5MG** | | **A075644** | **001** | Jun 26, 2001 |
| **AB** | | **10MG** | | **A075644** | **002** | Jun 26, 2001 |
| **AB** | UNICHEM PHARMS (USA) | **5MG** | | **A078635** | **001** | Aug 18, 2009 |
| **AB** | | **10MG** | | **A078635** | **002** | Aug 18, 2009 |

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

**BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | MYLAN | **2.5MG;6.25MG** | **A075768** | **001** | Sep 25, 2000 |
| **AB** | | | **5MG;6.25MG** | **A075768** | **002** | Sep 25, 2000 |
| **AB** | | | **10MG;6.25MG** | **A075768** | **003** | Sep 25, 2000 |
| **AB** | | SANDOZ | **2.5MG;6.25MG** | **A075579** | **001** | Sep 25, 2000 |
| **AB** | | | **5MG;6.25MG** | **A075579** | **002** | Sep 25, 2000 |
| **AB** | | | **10MG;6.25MG** | **A075579** | **003** | Sep 25, 2000 |
| **AB** | | UNICHEM | **2.5MG;6.25MG** | **A079106** | **001** | Jul 28, 2010 |
| **AB** | | | **5MG;6.25MG** | **A079106** | **002** | Jul 28, 2010 |
| **AB** | | | **10MG;6.25MG** | **A079106** | **003** | Jul 28, 2010 |

**ZIAC**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | TEVA BRANDED PHARM | **2.5MG;6.25MG** | **N020186** | **003** | Mar 26, 1993 |
| **AB** | + | | **5MG;6.25MG** | **N020186** | **001** | Mar 26, 1993 |
| **AB** | +! | | **10MG;6.25MG** | **N020186** | **002** | Mar 26, 1993 |

BIVALIRUDIN

INJECTABLE;INTRAVENOUS

**ANGIOMAX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | +! | THE MEDICINES CO | **250MG/VIAL** | **N020873** | **001** | Dec 15, 2000 |

**BIVALIRUDIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | ACCORD HLTHCARE | **250MG/VIAL** | **A206551** | **001** | Nov 22, 2017 |
| **AP** | | APOTEX INC | **250MG/VIAL** | **A204876** | **001** | Jul 06, 2017 |
| **AP** | | DR REDDYS LABS LTD | **250MG/VIAL** | **A201577** | **001** | May 26, 2017 |
| **AP** | | FRESENIUS KABI USA | **250MG/VIAL** | **A090189** | **001** | Oct 28, 2016 |
| **AP** | | HOSPIRA INC | **250MG/VIAL** | **A090811** | **001** | Jul 14, 2015 |
| **AP** | | | **250MG/VIAL** | **A090816** | **001** | Jul 14, 2015 |

SOLUTION;IV (INFUSION)

BIVALIRUDIN IN 0.9% SODIUM CHLORIDE

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | CELERITY PHARMS | 250MG/50ML (5MG/ML) | N208374 | 001 | Dec 21, 2017 |
| | +! | | 500MG/100ML (5MG/ML) | N208374 | 002 | Dec 21, 2017 |

BLEOMYCIN SULFATE

INJECTABLE;INJECTION

**BLEOMYCIN SULFATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | ! | FRESENIUS KABI USA | **EQ 15 UNITS BASE/VIAL** | **A065185** | **001** | Jan 28, 2008 |
| **AP** | ! | | **EQ 30 UNITS BASE/VIAL** | **A065185** | **002** | Jan 28, 2008 |
| **AP** | | HOSPIRA | **EQ 15 UNITS BASE/VIAL** | **A065031** | **001** | Mar 10, 2000 |
| **AP** | | | **EQ 30 UNITS BASE/VIAL** | **A065031** | **002** | Mar 10, 2000 |
| **AP** | | TEVA PHARMS USA | **EQ 15 UNITS BASE/VIAL** | **A065033** | **001** | Jun 27, 2000 |
| **AP** | | | **EQ 30 UNITS BASE/VIAL** | **A065033** | **002** | Jun 27, 2000 |
| **AP** | | WEST-WARD PHARMS INT | **EQ 15 UNITS BASE/VIAL** | **A065042** | **002** | Oct 17, 2001 |
| **AP** | | | **EQ 30 UNITS BASE/VIAL** | **A065042** | **001** | Oct 17, 2001 |

BORTEZOMIB

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

VELCADE

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | MILLENNIUM PHARMS | 3.5MG/VIAL | N021602 | 001 | May 13, 2003 |

POWDER;INTRAVENOUS

BORTEZOMIB

| | | | | | | |
|---|---|---|---|---|---|---|
| | | FRESENIUS KABI USA | 3.5MG/VIAL | N205004 | 001 | Nov 06, 2017 |

BOSENTAN

TABLET;ORAL

TRACLEER

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | ACTELION PHARMS LTD | 62.5MG | N021290 | 001 | Nov 20, 2001 |
| | +! | | 125MG | N021290 | 002 | Nov 20, 2001 |

TABLET, FOR SUSPENSION;ORAL

TRACLEER

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ACTELION PHARMS | 32MG | N209279 | 001 | Sep 05, 2017 |

BOSUTINIB MONOHYDRATE

TABLET;ORAL

BOSULIF

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | PF PRISM CV | EQ 100MG BASE | N203341 | 001 | Sep 04, 2012 |
| | + | | EQ 400MG BASE | N203341 | 003 | Oct 27, 2017 |
| | + | | EQ 500MG BASE | N203341 | 002 | Sep 04, 2012 |

| | | | | | | |
|---|---|---|---|---|---|---|
| BREXPIPRAZOLE | | | | | | |
| TABLET;ORAL | | | | | | |
| REXULTI | | | | | | |
| + | | OTSUKA PHARM CO LTD | 0.25MG | N205422 | 001 | Jul 10, 2015 |
| + | | | 0.5MG | N205422 | 002 | Jul 10, 2015 |
| + | | | 1MG | N205422 | 003 | Jul 10, 2015 |
| +! | | | 2MG | N205422 | 004 | Jul 10, 2015 |
| + | | | 3MG | N205422 | 005 | Jul 10, 2015 |
| + | | | 4MG | N205422 | 006 | Jul 10, 2015 |
| BRIGATINIB | | | | | | |
| TABLET;ORAL | | | | | | |
| ALUNBRIG | | | | | | |
| + | | ARIAD | 30MG | N208772 | 001 | Apr 28, 2017 |
| +! | | | 90MG | N208772 | 002 | Apr 28, 2017 |
| + | | | 180MG | N208772 | 003 | Oct 02, 2017 |
| BRIMONIDINE TARTRATE | | | | | | |
| GEL;TOPICAL | | | | | | |
| MIRVASO | | | | | | |
| +! | | GALDERMA LABS LP | EQ 0.33% BASE | N204708 | 001 | Aug 23, 2013 |
| SOLUTION/DROPS;OPHTHALMIC | | | | | | |
| **ALPHAGAN P** | | | | | | |
| **AT** | **+!** | ALLERGAN | **0.15%** | **N021262** | **001** | Mar 16, 2001 |
| **BRIMONIDINE TARTRATE** | | | | | | |
| **AT** | | AKORN | **0.2%** | **A076439** | **001** | Mar 14, 2006 |
| **AT** | **!** | BAUSCH AND LOMB | **0.2%** | **A076260** | **001** | May 28, 2003 |
| **AT** | | INDOCO REMEDIES | **0.2%** | **A091691** | **001** | Nov 18, 2014 |
| **AT** | | SANDOZ INC | **0.2%** | **A076254** | **001** | Sep 16, 2003 |
| **AT** | | | **0.2%** | **A078075** | **001** | Jan 30, 2008 |
| **QOLIANA** | | | | | | |
| **AT** | | SANDOZ INC | **0.15%** | **N021764** | **001** | May 22, 2006 |
| ALPHAGAN P | | | | | | |
| +! | | ALLERGAN | 0.1% | N021770 | 001 | Aug 19, 2005 |
| BRIMONIDINE TARTRATE; BRINZOLAMIDE | | | | | | |
| SUSPENSION/DROPS;OPHTHALMIC | | | | | | |
| SIMBRINZA | | | | | | |
| +! | | NOVARTIS PHARMS CORP | 0.2%;1% | N204251 | 001 | Apr 19, 2013 |
| BRIMONIDINE TARTRATE; TIMOLOL MALEATE | | | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | | | |
| COMBIGAN | | | | | | |
| +! | | ALLERGAN | 0.2%;EQ 0.5% BASE | N021398 | 001 | Oct 30, 2007 |
| BRINZOLAMIDE | | | | | | |
| SUSPENSION/DROPS;OPHTHALMIC | | | | | | |
| AZOPT | | | | | | |
| +! | | NOVARTIS PHARMS CORP | 1% | N020816 | 001 | Apr 01, 1998 |
| BRIVARACETAM | | | | | | |
| SOLUTION;INTRAVENOUS | | | | | | |
| BRIVIACT | | | | | | |
| +! | | UCB INC | 50MG/5ML (10MG/ML) | N205837 | 001 | May 12, 2016 |
| SOLUTION;ORAL | | | | | | |
| BRIVIACT | | | | | | |
| +! | | UCB INC | 10MG/ML | N205838 | 001 | May 12, 2016 |
| TABLET;ORAL | | | | | | |
| BRIVIACT | | | | | | |
| + | | UCB INC | 10MG | N205836 | 001 | May 12, 2016 |
| + | | | 25MG | N205836 | 002 | May 12, 2016 |
| + | | | 50MG | N205836 | 003 | May 12, 2016 |
| + | | | 75MG | N205836 | 004 | May 12, 2016 |
| +! | | | 100MG | N205836 | 005 | May 12, 2016 |
| BROMFENAC SODIUM | | | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | | | |
| **BROMFENAC SODIUM** | | | | | | |
| **AT1** | | AMRING PHARMS | **EQ 0.09% ACID** | **A202030** | **001** | Jan 09, 2013 |
| **AT1** | **!** | APOTEX INC | **EQ 0.09% ACID** | **A202435** | **001** | Jun 19, 2014 |
| **AT1** | | PADDOCK LLC | **EQ 0.09% ACID** | **A201941** | **001** | Feb 10, 2015 |
| **AT2** | | APOTEX INC | **EQ 0.09% ACID** | **A202620** | **001** | Jun 23, 2014 |
| **AT2** | **!** | HI-TECH PHARMACAL | **EQ 0.09% ACID** | **A203395** | **001** | Jan 22, 2014 |

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

BROMSITE

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | SUN PHARMA GLOBAL | EQ 0.075% ACID | N206911 | 001 | Apr 08, 2016 |

PROLENSA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | BAUSCH AND LOMB | EQ 0.07% ACID | N203168 | 001 | Apr 05, 2013 |

BROMOCRIPTINE MESYLATE

CAPSULE;ORAL

**BROMOCRIPTINE MESYLATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **!** | MYLAN | **EQ 5MG BASE** | **A077226** | **001** | Apr 04, 2005 |
| **AB** | | ZYDUS PHARMS USA INC | **EQ 5MG BASE** | **A078899** | **001** | Jul 30, 2008 |

**PARLODEL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | US PHARMS HOLDINGS I | **EQ 5MG BASE** | **N017962** | **002** | Mar 01, 1982 |

TABLET;ORAL

**BROMOCRIPTINE MESYLATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | MYLAN | **EQ 2.5MG BASE** | **A076962** | **001** | Sep 24, 2004 |
| **AB** | **!** | PADDOCK LLC | **EQ 2.5MG BASE** | **A077646** | **001** | Oct 01, 2008 |
| **AB** | | SANDOZ INC | **EQ 2.5MG BASE** | **A074631** | **001** | Jan 13, 1998 |

**PARLODEL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | US PHARMS HOLDINGS I | **EQ 2.5MG BASE** | **N017962** | **001** | |

CYCLOSET

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | VEROSCIENCE | EQ 0.8MG BASE | N020866 | 001 | May 05, 2009 |

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

**BROMFED-DM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **!** | WOCKHARDT | **2MG/5ML;10MG/5ML;30MG/5ML** | **A088811** | **001** | Jun 07, 1985 |

**BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | ACELLA PHARMS LLC | **2MG/5ML;10MG/5ML;30MG/5ML** | **A203375** | **001** | Sep 20, 2016 |
| **AA** | | PADDOCK LLC | **2MG/5ML;10MG/5ML;30MG/5ML** | **A205292** | **001** | Jul 15, 2014 |
| **AA** | | TARO PHARM | **2MG/5ML;10MG/5ML;30MG/5ML** | **A205112** | **001** | Feb 27, 2017 |
| **AA** | | VINTAGE PHARMS | **2MG/5ML;10MG/5ML;30MG/5ML** | **A202940** | **001** | Jul 21, 2014 |

BUDESONIDE

AEROSOL, FOAM;RECTAL

UCERIS

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | VALEANT PHARMS INTL | 2MG/ACTUATION | N205613 | 001 | Oct 07, 2014 |

CAPSULE;ORAL

**BUDESONIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALVOGEN MALTA | **3MG** | **A206724** | **001** | Nov 23, 2016 |
| **AB** | | AMNEAL PHARMS | **3MG** | **A206200** | **001** | Jul 31, 2017 |
| **AB** | | APPCO PHARMA LLC | **3MG** | **A207367** | **001** | Apr 07, 2017 |
| **AB** | | BARR LABS DIV TEVA | **3MG** | **A090379** | **001** | Apr 02, 2014 |
| **AB** | | MAYNE PHARMA | **3MG** | **A206623** | **001** | Apr 08, 2016 |
| **AB** | | MYLAN | **3MG** | **A090410** | **001** | May 16, 2011 |
| **AB** | | SCIECURE PHARMA INC | **3MG** | **A209041** | **001** | Sep 28, 2017 |
| **AB** | | ZYDUS PHARMS USA INC | **3MG** | **A206134** | **001** | May 04, 2017 |

**ENTOCORT EC**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | PERRIGO PHARMA INTL | **3MG** | **N021324** | **001** | Oct 02, 2001 |

POWDER, METERED;INHALATION

PULMICORT FLEXHALER

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | ASTRAZENECA | 0.08MG/INH | N021949 | 001 | Jul 12, 2006 |
| | +! | | 0.16MG/INH | N021949 | 002 | Jul 12, 2006 |

SUSPENSION;INHALATION

**BUDESONIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AN** | | APOTEX INC | **0.25MG/2ML** | **A078202** | **001** | Mar 30, 2009 |
| **AN** | | | **0.5MG/2ML** | **A078202** | **002** | Mar 30, 2009 |
| **AN** | | CIPLA LTD | **0.25MG/2ML** | **A205710** | **001** | Nov 16, 2017 |
| **AN** | | | **0.5MG/2ML** | **A205710** | **002** | Nov 16, 2017 |
| **AN** | | | **1MG/2ML** | **A205710** | **003** | Nov 16, 2017 |
| **AN** | | IMPAX LABS INC | **0.25MG/2ML** | **A078404** | **001** | Jul 31, 2012 |
| **AN** | | | **0.5MG/2ML** | **A078404** | **002** | Jul 31, 2012 |
| **AN** | | SANDOZ INC | **0.25MG/2ML** | **A201966** | **003** | Sep 27, 2013 |
| **AN** | | | **0.5MG/2ML** | **A201966** | **002** | Sep 27, 2013 |
| **AN** | | | **1MG/2ML** | **A201966** | **001** | Sep 27, 2013 |
| **AN** | | TEVA PHARMS | **0.25MG/2ML** | **A077519** | **001** | Nov 18, 2008 |
| **AN** | | | **0.5MG/2ML** | **A077519** | **002** | Nov 18, 2008 |
| **AN** | | TEVA PHARMS USA | **1MG/2ML** | **A204548** | **001** | Mar 08, 2016 |

BUDESONIDE

SUSPENSION;INHALATION

**PULMICORT RESPULES**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AN** | **+** | ASTRAZENECA PHARMS | **0.25MG/2ML** | **N020929** | **001** | Aug 08, 2000 |
| **AN** | **+** | | **0.5MG/2ML** | **N020929** | **002** | Aug 08, 2000 |
| **AN** | **+!** | | **1MG/2ML** | **N020929** | **003** | Aug 08, 2000 |

TABLET, EXTENDED RELEASE;ORAL

UCERIS

| | | | | | |
|---|---|---|---|---|---|
| +! | VALEANT PHARMS INTL | 9MG | N203634 | 001 | Jan 14, 2013 |

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE

AEROSOL, METERED;INHALATION

SYMBICORT

| | | | | | |
|---|---|---|---|---|---|
| +! | ASTRAZENECA | 0.08MG/INH;0.0045MG/INH | N021929 | 001 | Jul 21, 2006 |
| +! | | 0.16MG/INH;0.0045MG/INH | N021929 | 002 | Jul 21, 2006 |

BUMETANIDE

INJECTABLE;INJECTION

**BUMETANIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **!** | ATHENEX INC | **0.25MG/ML** | **A074441** | **001** | Jan 27, 1995 |
| **AP** | | HOSPIRA | **0.25MG/ML** | **A074332** | **001** | Oct 31, 1994 |
| **AP** | | WEST-WARD PHARMS INT | **0.25MG/ML** | **A079196** | **001** | Apr 30, 2008 |

TABLET;ORAL

**BUMETANIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AMNEAL PHARMS CO | **0.5MG** | **A209724** | **001** | Oct 18, 2017 |
| **AB** | | | **1MG** | **A209724** | **002** | Oct 18, 2017 |
| **AB** | | | **2MG** | **A209724** | **003** | Oct 18, 2017 |
| **AB** | | IVAX SUB TEVA PHARMS | **0.5MG** | **A074225** | **001** | Apr 24, 1995 |
| **AB** | | | **1MG** | **A074225** | **002** | Apr 24, 1995 |
| **AB** | | | **2MG** | **A074225** | **003** | Apr 24, 1995 |
| **AB** | | SANDOZ | **0.5MG** | **A074700** | **001** | Nov 21, 1996 |
| **AB** | | | **1MG** | **A074700** | **002** | Nov 21, 1996 |
| **AB** | **!** | | **2MG** | **A074700** | **003** | Nov 21, 1996 |

**BUMEX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | VALIDUS PHARMS | **0.5MG** | **N018225** | **002** | Feb 28, 1983 |
| **AB** | **+** | | **1MG** | **N018225** | **001** | Feb 28, 1983 |
| **AB** | **+** | | **2MG** | **N018225** | **003** | Jun 14, 1985 |

BUPIVACAINE

INJECTABLE, LIPOSOMAL;INJECTION

EXPAREL

| | | | | | |
|---|---|---|---|---|---|
| +! | PACIRA PHARMS INC | 133MG/10ML (13.3MG/ML) | N022496 | 001 | Oct 28, 2011 |
| +! | | 266MG/20ML (13.3MG/ML) | N022496 | 002 | Oct 28, 2011 |

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

**BUPIVACAINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AUROBINDO PHARMA LTD | **0.25%** | **A207183** | **001** | May 13, 2016 |
| **AP** | | | **0.5%** | **A207183** | **002** | May 13, 2016 |
| **AP** | | HOSPIRA | **0.25%** | **A070583** | **001** | Feb 17, 1987 |
| **AP** | | | **0.25%** | **A070586** | **001** | Mar 03, 1987 |
| **AP** | | | **0.25%** | **A070590** | **001** | Feb 17, 1987 |
| **AP** | | | **0.25%** | **N018053** | **002** | |
| **AP** | | | **0.5%** | **A070584** | **001** | Feb 17, 1986 |
| **AP** | | | **0.5%** | **A070597** | **001** | Mar 03, 1987 |
| **AP** | | | **0.5%** | **A070609** | **001** | Mar 03, 1987 |
| **AP** | | | **0.5%** | **N018053** | **001** | |
| **AP** | | | **0.75%** | **A070585** | **001** | Mar 03, 1987 |
| **AP** | | | **0.75%** | **N018053** | **003** | |
| **AP** | | SAGENT AGILA | **0.25%** | **A091503** | **001** | Oct 18, 2011 |
| **AP** | | | **0.5%** | **A091503** | **002** | Oct 18, 2011 |

**BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AUROBINDO PHARMA LTD | **0.25%** | **A203895** | **001** | Nov 05, 2013 |
| **AP** | | | **0.5%** | **A203895** | **002** | Nov 05, 2013 |
| **AP** | | | **0.75%** | **A203895** | **003** | Nov 05, 2013 |
| **AP** | | SAGENT AGILA | **0.25%** | **A091487** | **002** | Oct 18, 2011 |
| **AP** | | | **0.5%** | **A091487** | **001** | Oct 18, 2011 |
| **AP** | | | **0.75%** | **A091487** | **003** | Oct 18, 2011 |

**MARCAINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | HOSPIRA | **0.25%** | **N016964** | **001** | |
| **AP** | **+!** | | **0.5%** | **N016964** | **006** | |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| BUPIVACAINE HYDROCHLORIDE | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| **MARCAINE HYDROCHLORIDE PRESERVATIVE FREE** | | | | | | | |
| **AP** | **+!** | HOSPIRA | **0.25%** | **N016964** | **012** | | |
| **AP** | **+!** | | **0.5%** | **N016964** | **005** | | |
| **AP** | **+!** | | **0.75%** | **N016964** | **009** | | |
| **SENSORCAINE** | | | | | | | |
| **AP** | | FRESENIUS KABI USA | **0.25%** | **A070552** | **001** | May 21, 1986 | |
| **AP** | | | **0.25%** | **N018304** | **001** | | |
| **AP** | | | **0.5%** | **A070553** | **001** | May 21, 1986 | |
| **AP** | | | **0.5%** | **N018304** | **002** | | |
| **AP** | | | **0.75%** | **A070554** | **001** | May 21, 1986 | |
| **AP** | | | **0.75%** | **N018304** | **003** | | |
| INJECTABLE;SPINAL | | | | | | | |
| **BUPIVACAINE HYDROCHLORIDE** | | | | | | | |
| **AP** | | BAXTER HLTHCARE CORP | **0.75%** | **A207266** | **001** | Jul 25, 2016 | |
| **AP** | | HOSPIRA | **0.75%** | **A071810** | **001** | Dec 11, 1987 | |
| **MARCAINE** | | | | | | | |
| **AP** | **+!** | HOSPIRA | **0.75%** | **N018692** | **001** | May 04, 1984 | |
| **SENSORCAINE** | | | | | | | |
| **AP** | | FRESENIUS KABI USA | **0.75%** | **A071202** | **001** | Apr 15, 1987 | |
| BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| **BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE** | | | | | | | |
| **AP** | **!** | HOSPIRA | **0.5%;0.005MG/ML** | **A071168** | **001** | Jun 16, 1988 | |
| **AP** | | | **0.5%;0.005MG/ML** | **A071170** | **001** | Jun 16, 1988 | |
| | ! | | 0.25%;0.005MG/ML | A071165 | 001 | Jun 16, 1988 | |
| | | | 0.25%;0.005MG/ML | A071167 | 001 | Jun 16, 1988 | |
| BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| **BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE** | | | | | | | |
| **AP** | | SEPTODONT | **0.5%;0.0091MG/ML** | **A077250** | **001** | Sep 27, 2006 | |
| **BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE** | | | | | | | |
| **AP** | **+!** | HOSPIRA | **0.5%;0.0091MG/ML** | **N022046** | **001** | Jul 13, 1983 | |
| **MARCAINE HYDROCHLORIDE W/ EPINEPHRINE** | | | | | | | |
| **AP** | **+!** | HOSPIRA | **0.25%;0.0091MG/ML** | **N016964** | **004** | | |
| **AP** | **+!** | | **0.5%;0.0091MG/ML** | **N016964** | **008** | | |
| **MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE** | | | | | | | |
| **AP** | **+!** | HOSPIRA | **0.25%;0.0091MG/ML** | **N016964** | **013** | | |
| **AP** | **+!** | | **0.5%;0.0091MG/ML** | **N016964** | **007** | | |
| **AP** | **+!** | | **0.75%;0.0091MG/ML** | **N016964** | **010** | | |
| **SENSORCAINE** | | | | | | | |
| **AP** | | FRESENIUS KABI USA | **0.25%;0.0091MG/ML** | **A070966** | **001** | Oct 13, 1987 | |
| **AP** | | | **0.25%;0.0091MG/ML** | **A070967** | **001** | Oct 13, 1987 | |
| **AP** | | | **0.5%;0.0091MG/ML** | **A070968** | **001** | Oct 13, 1987 | |
| **AP** | | | **0.5%;0.0091MG/ML** | **N018304** | **004** | Sep 02, 1983 | |
| **AP** | | | **0.75%;0.0091MG/ML** | **N018304** | **005** | Sep 02, 1983 | |
| BUPRENORPHINE | | | | | | | |
| FILM, EXTENDED RELEASE;TRANSDERMAL | | | | | | | |
| BUTRANS | | | | | | | |
| | + | PURDUE PHARMA LP | 5MCG/HR | N021306 | 001 | Jun 30, 2010 | |
| | + | | 7.5MCG/HR | N021306 | 005 | Jun 30, 2014 | |
| | + | | 10MCG/HR | N021306 | 002 | Jun 30, 2010 | |
| | + | | 15MCG/HR | N021306 | 004 | Jul 25, 2013 | |
| | +! | | 20MCG/HR | N021306 | 003 | Jun 30, 2010 | |
| SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS | | | | | | | |
| SUBLOCADE | | | | | | | |
| | + | INDIVIOR INC | 100MG/0.5ML (100MG/0.5ML) | N209819 | 001 | Nov 29, 2017 | |
| | +! | | 300MG/1.5ML (200MG/ML) | N209819 | 002 | Nov 29, 2017 | |
| BUPRENORPHINE HYDROCHLORIDE | | | | | | | |
| FILM;BUCCAL | | | | | | | |
| BELBUCA | | | | | | | |
| | + | BDSI | EQ 0.075MG BASE | N207932 | 001 | Oct 23, 2015 | |
| | + | | EQ 0.15MG BASE | N207932 | 002 | Oct 23, 2015 | |
| | + | | EQ 0.3MG BASE | N207932 | 003 | Oct 23, 2015 | |
| | + | | EQ 0.45MG BASE | N207932 | 004 | Oct 23, 2015 | |
| | + | | EQ 0.6MG BASE | N207932 | 005 | Oct 23, 2015 | |
| | + | | EQ 0.75MG BASE | N207932 | 006 | Oct 23, 2015 | |
| | +! | | EQ 0.9MG BASE | N207932 | 007 | Oct 23, 2015 | |

| | | | | | | |
|---|---|---|---|---|---|---|
| BUPRENORPHINE HYDROCHLORIDE | | | | | | |
| IMPLANT;IMPLANTATION | | | | | | |
| PROBUPHINE | | | | | | |
| | +! | BRAEBURN PHARMS INC | EQ 80MG BASE/IMPLANT | N204442 | 001 | May 26, 2016 |
| INJECTABLE;INJECTION | | | | | | |
| **BUPRENEX** | | | | | | |
| **AP** | **+!** | INDIVIOR INC | **EQ 0.3MG BASE/ML** | **N018401** | **001** | |
| **BUPRENORPHINE HYDROCHLORIDE** | | | | | | |
| **AP** | | HOSPIRA | **EQ 0.3MG BASE/ML** | **A074137** | **001** | Jun 03, 1996 |
| **AP** | | LUITPOLD | **EQ 0.3MG BASE/ML** | **A078331** | **001** | Mar 27, 2007 |
| **AP** | | PAR STERILE PRODUCTS | **EQ 0.3MG BASE/ML** | **A206586** | **001** | Jul 28, 2015 |
| **AP** | | WEST-WARD PHARMS INT | **EQ 0.3MG BASE/ML** | **A076931** | **001** | Mar 02, 2005 |
| TABLET;SUBLINGUAL | | | | | | |
| **BUPRENORPHINE HYDROCHLORIDE** | | | | | | |
| **AB** | | ACTAVIS ELIZABETH | **EQ 2MG BASE** | **A090819** | **001** | Feb 19, 2015 |
| **AB** | | | **EQ 8MG BASE** | **A090819** | **002** | Feb 19, 2015 |
| **AB** | | BARR | **EQ 2MG BASE** | **A090360** | **001** | May 07, 2010 |
| **AB** | | | **EQ 8MG BASE** | **A090360** | **002** | May 07, 2010 |
| **AB** | | ETHYPHARM | **EQ 2MG BASE** | **A090622** | **001** | Sep 24, 2010 |
| **AB** | | | **EQ 8MG BASE** | **A090622** | **002** | Sep 24, 2010 |
| **AB** | | MYLAN PHARMS INC | **EQ 2MG BASE** | **A201066** | **001** | Mar 06, 2015 |
| **AB** | | | **EQ 8MG BASE** | **A201066** | **002** | Mar 06, 2015 |
| **AB** | | RHODES PHARMS | **EQ 2MG BASE** | **A207276** | **001** | Mar 27, 2017 |
| **AB** | | | **EQ 8MG BASE** | **A207276** | **002** | Mar 27, 2017 |
| **AB** | | SANDOZ INC | **EQ 2MG BASE** | **A090279** | **001** | Jun 10, 2015 |
| **AB** | | | **EQ 8MG BASE** | **A090279** | **002** | Jun 10, 2015 |
| **AB** | | SUN PHARM INDS LTD | **EQ 2MG BASE** | **A201760** | **001** | Jan 29, 2016 |
| **AB** | | | **EQ 8MG BASE** | **A201760** | **002** | Jan 29, 2016 |
| **AB** | | WEST-WARD PHARMS INT | **EQ 2MG BASE** | **A078633** | **001** | Oct 08, 2009 |
| **AB** | **!** | | **EQ 8MG BASE** | **A078633** | **002** | Oct 08, 2009 |
| BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE | | | | | | |
| FILM;BUCCAL | | | | | | |
| BUNAVAIL | | | | | | |
| | + | BDSI | EQ 2.1MG BASE;EQ 0.3MG BASE | N205637 | 001 | Jun 06, 2014 |
| | + | | EQ 4.2MG BASE;EQ 0.7MG BASE | N205637 | 002 | Jun 06, 2014 |
| | +! | | EQ 6.3MG BASE;EQ 1MG BASE | N205637 | 003 | Jun 06, 2014 |
| FILM;BUCCAL, SUBLINGUAL | | | | | | |
| SUBOXONE | | | | | | |
| | + | INDIVIOR INC | EQ 2MG BASE;EQ 0.5MG BASE | N022410 | 001 | Aug 30, 2010 |
| | + | | EQ 4MG BASE;EQ 1MG BASE | N022410 | 003 | Aug 10, 2012 |
| | + | | EQ 8MG BASE;EQ 2MG BASE | N022410 | 002 | Aug 30, 2010 |
| | +! | | EQ 12MG BASE;EQ 3MG BASE | N022410 | 004 | Aug 10, 2012 |
| TABLET;SUBLINGUAL | | | | | | |
| **BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE** | | | | | | |
| **AB** | | ACTAVIS ELIZABETH | **EQ 2MG BASE;EQ 0.5MG BASE** | **A091422** | **001** | Feb 22, 2013 |
| **AB** | **!** | | **EQ 8MG BASE;EQ 2MG BASE** | **A091422** | **002** | Feb 22, 2013 |
| **AB** | | AMNEAL PHARMS | **EQ 8MG BASE;EQ 2MG BASE** | **A203136** | **002** | Feb 22, 2013 |
| **AB** | | ETHYPHARM USA CORP | **EQ 2MG BASE;EQ 0.5MG BASE** | **A204431** | **001** | Oct 16, 2015 |
| **AB** | | | **EQ 8MG BASE;EQ 2MG BASE** | **A204431** | **002** | Oct 16, 2015 |
| **AB** | | KREMERS URBAN PHARMS | **EQ 2MG BASE;EQ 0.5MG BASE** | **A205022** | **001** | Sep 19, 2016 |
| **AB** | | | **EQ 8MG BASE;EQ 2MG BASE** | **A205022** | **002** | Sep 19, 2016 |
| **AB** | | SPECGX LLC | **EQ 2MG BASE;EQ 0.5MG BASE** | **A207000** | **001** | Dec 13, 2017 |
| **AB** | | | **EQ 8MG BASE;EQ 2MG BASE** | **A207000** | **002** | Dec 13, 2017 |
| **AB** | | SUN PHARM INDS LTD | **EQ 8MG BASE;EQ 2MG BASE** | **A201633** | **002** | Aug 05, 2016 |
| **AB** | | TEVA PHARMS USA | **EQ 2MG BASE;EQ 0.5MG BASE** | **A091149** | **001** | Sep 08, 2014 |
| **AB** | | | **EQ 8MG BASE;EQ 2MG BASE** | **A091149** | **002** | Sep 08, 2014 |
| **AB** | | WEST-WARD PHARMS INT | **EQ 2MG BASE;EQ 0.5MG BASE** | **A203326** | **001** | Jun 27, 2014 |
| **AB** | | | **EQ 8MG BASE;EQ 2MG BASE** | **A203326** | **002** | Jun 27, 2014 |
| **BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE** | | | | | | |
| **AB** | | AMNEAL PHARMS | **EQ 2MG BASE;EQ 0.5MG BASE** | **A203136** | **001** | Feb 22, 2013 |
| **AB** | | SUN PHARM INDS LTD | **EQ 2MG BASE;EQ 0.5MG BASE** | **A201633** | **001** | Aug 05, 2016 |
| ZUBSOLV | | | | | | |
| | + | OREXO US INC | EQ 0.7MG BASE;EQ 0.18MG BASE | N204242 | 006 | Oct 04, 2016 |
| | + | | EQ 1.4MG BASE;EQ 0.36MG BASE | N204242 | 001 | Jul 03, 2013 |
| | + | | EQ 2.9MG BASE;EQ 0.71MG BASE | N204242 | 005 | Jun 04, 2015 |
| | + | | EQ 5.7MG BASE;EQ 1.4MG BASE | N204242 | 002 | Jul 03, 2013 |
| | + | | EQ 8.6MG BASE;EQ 2.1MG BASE | N204242 | 003 | Dec 11, 2014 |
| | +! | | EQ 11.4MG BASE;EQ 2.9MG BASE | N204242 | 004 | Dec 11, 2014 |

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

APLENZIN

| | | | | | | |
|---|---|---|---|---|---|---|
| + | VALEANT PHARMS NORTH | 174MG | N022108 | 001 | Apr 23, 2008 |
| + | | 348MG | N022108 | 002 | Apr 23, 2008 |
| +! | | 522MG | N022108 | 003 | Apr 23, 2008 |

BUPROPION HYDROCHLORIDE

TABLET;ORAL

**BUPROPION HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | APOTEX INC | **75MG** | **A076143** | **001** | Jan 17, 2006 |
| **AB** ! | | **100MG** | **A076143** | **002** | Jan 17, 2006 |
| **AB** | HERITAGE PHARMA | **75MG** | **A206975** | **001** | Aug 19, 2016 |
| **AB** | | **100MG** | **A206975** | **002** | Aug 19, 2016 |
| **AB** | INVAGEN PHARMS | **75MG** | **A207389** | **001** | Sep 18, 2017 |
| **AB** | | **100MG** | **A207389** | **002** | Sep 18, 2017 |
| **AB** | MYLAN | **75MG** | **A075491** | **001** | Apr 17, 2000 |
| **AB** | | **100MG** | **A075491** | **002** | Apr 17, 2000 |
| **AB** | SANDOZ | **75MG** | **A075584** | **001** | Feb 07, 2000 |
| **AB** | | **100MG** | **A075584** | **002** | Feb 07, 2000 |

TABLET, EXTENDED RELEASE;ORAL

**BUPROPION HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB1** | ACTAVIS LABS FL INC | **100MG** | **A079095** | **001** | Mar 24, 2009 |
| **AB1** | | **150MG** | **A079095** | **002** | Mar 24, 2009 |
| **AB1** | | **200MG** | **A079095** | **003** | Mar 24, 2009 |
| **AB1** | ANCHEN PHARMS | **100MG** | **A091459** | **001** | Jun 09, 2011 |
| **AB1** | | **150MG** | **A091459** | **002** | Jun 09, 2011 |
| **AB1** | | **200MG** | **A091459** | **003** | Jun 09, 2011 |
| **AB1** | IMPAX LABS | **100MG** | **A075913** | **001** | Jan 28, 2004 |
| **AB1** | | **150MG** | **A075913** | **002** | Mar 22, 2004 |
| **AB1** | | **200MG** | **A076711** | **001** | Dec 03, 2004 |
| **AB1** | INVAGEN PHARMS | **100MG** | **A206674** | **001** | Feb 09, 2016 |
| **AB1** | | **150MG** | **A206674** | **002** | Feb 09, 2016 |
| **AB1** | | **200MG** | **A206674** | **003** | Feb 09, 2016 |
| **AB1** | JUBILANT GENERICS | **100MG** | **A202774** | **001** | Oct 11, 2013 |
| **AB1** | | **150MG** | **A202774** | **002** | Oct 11, 2013 |
| **AB1** | | **200MG** | **A202774** | **003** | Oct 11, 2013 |
| **AB1** | MYLAN | **100MG** | **A090325** | **001** | Apr 08, 2010 |
| **AB1** | | **150MG** | **A090325** | **002** | Apr 08, 2010 |
| **AB1** | | **200MG** | **A090325** | **003** | Apr 08, 2010 |
| **AB1** | PRINSTON INC | **100MG** | **A202304** | **001** | May 26, 2015 |
| **AB1** | | **150MG** | **A202304** | **002** | May 26, 2015 |
| **AB1** | | **200MG** | **A202304** | **003** | May 26, 2015 |
| **AB1** | SANDOZ | **100MG** | **A075932** | **001** | Nov 25, 2003 |
| **AB1** | | **150MG** | **A075932** | **002** | Mar 22, 2004 |
| **AB1** | | **200MG** | **A075932** | **003** | Jun 22, 2005 |
| **AB1** | SCIEGEN PHARMS INC | **100MG** | **A205794** | **001** | Mar 01, 2016 |
| **AB1** | | **150MG** | **A205794** | **002** | Mar 01, 2016 |
| **AB1** | | **200MG** | **A205794** | **003** | Mar 01, 2016 |
| **AB1** | SUN PHARMA GLOBAL | **100MG** | **A078866** | **001** | Apr 06, 2010 |
| **AB1** | | **150MG** | **A078866** | **002** | Apr 06, 2010 |
| **AB1** | | **200MG** | **A078866** | **003** | Apr 06, 2010 |
| **AB1** | TORRENT PHARMS LTD | **100MG** | **A203969** | **001** | Oct 31, 2014 |
| **AB1** | | **150MG** | **A203969** | **002** | Oct 31, 2014 |
| **AB1** | | **200MG** | **A203969** | **003** | Oct 31, 2014 |
| **AB1** | WATSON LABS INC | **100MG** | **A077455** | **001** | Jul 19, 2010 |
| **AB1** | | **150MG** | **A077455** | **002** | Mar 12, 2008 |
| **AB1** | | **200MG** | **A077455** | **003** | Jul 19, 2010 |

**WELLBUTRIN SR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB1** + | GLAXOSMITHKLINE | **100MG** | **N020358** | **002** | Oct 04, 1996 |
| **AB1** + | | **150MG** | **N020358** | **003** | Oct 04, 1996 |
| **AB1** +! | | **200MG** | **N020358** | **004** | Jun 14, 2002 |

**BUPROPION HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB2** | ACTAVIS LABS FL INC | **150MG** | **A079094** | **001** | Mar 24, 2009 |
| **AB2** | ANCHEN PHARMS | **150MG** | **A091520** | **001** | Jun 09, 2011 |
| **AB2** | IMPAX LABS | **150MG** | **A075914** | **001** | May 27, 2004 |
| **AB2** | JUBILANT GENERICS | **150MG** | **A202775** | **001** | Oct 11, 2013 |
| **AB2** | MYLAN | **150MG** | **A090941** | **001** | May 03, 2010 |
| **AB2** | SANDOZ INC | **150MG** | **A077475** | **001** | Mar 12, 2008 |
| **AB2** | TECH ORGANIZED | **150MG** | **A206122** | **001** | Aug 17, 2016 |

**ZYBAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB2** +! | GLAXOSMITHKLINE | **150MG** | **N020711** | **003** | May 14, 1997 |

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

**BUPROPION HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB3** | | ACTAVIS LABS FL INC | **150MG** | **A077715** | **001** | Nov 26, 2008 |
| **AB3** | | ANBISON LAB CO LTD | **150MG** | **A207224** | **001** | Jun 30, 2017 |
| **AB3** | | | **300MG** | **A207224** | **002** | Jun 30, 2017 |
| **AB3** | | ANCHEN PHARMS | **150MG** | **A077284** | **001** | Dec 14, 2006 |
| **AB3** | | | **300MG** | **A077284** | **002** | Dec 14, 2006 |
| **AB3** | | IMPAX LABS | **150MG** | **A077415** | **001** | Nov 26, 2008 |
| **AB3** | | INVAGEN PHARMS | **150MG** | **A206556** | **001** | Aug 26, 2016 |
| **AB3** | | | **300MG** | **A206556** | **002** | Aug 26, 2016 |
| **AB3** | | JUBILANT GENERICS | **150MG** | **A207459** | **001** | Jun 30, 2017 |
| **AB3** | | | **300MG** | **A207459** | **002** | Jun 30, 2017 |
| **AB3** | | LUPIN LTD | **150MG** | **A090693** | **001** | Apr 06, 2017 |
| **AB3** | | | **300MG** | **A090693** | **002** | Apr 06, 2017 |
| **AB3** | | MYLAN | **150MG** | **A090942** | **001** | Jul 14, 2010 |
| **AB3** | | | **300MG** | **A090942** | **002** | Jul 14, 2010 |
| **AB3** | | SCIEGEN PHARMS INC | **150MG** | **A207479** | **001** | Apr 12, 2017 |
| **AB3** | | | **300MG** | **A207479** | **002** | Apr 12, 2017 |
| **AB3** | | SINOTHERAPEUTICS INC | **150MG** | **A208652** | **001** | Aug 21, 2017 |
| **AB3** | | | **300MG** | **A208652** | **002** | Aug 21, 2017 |
| **AB3** | | SUN PHARMA GLOBAL | **150MG** | **A200695** | **001** | Dec 18, 2014 |
| **AB3** | | TWI PHARMS INC | **150MG** | **A210081** | **001** | Nov 03, 2017 |
| **AB3** | | | **300MG** | **A210081** | **002** | Nov 03, 2017 |
| **AB3** | | WATSON LABS INC | **150MG** | **A077285** | **001** | Nov 26, 2008 |
| **AB3** | | | **300MG** | **A077285** | **002** | Aug 15, 2008 |
| **AB3** | | WOCKHARDT LTD | **150MG** | **A202189** | **001** | Nov 21, 2012 |
| **AB3** | | ZYDUS PHARMS USA INC | **300MG** | **A201567** | **001** | Jan 17, 2014 |

**WELLBUTRIN XL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB3** | **+** | VALEANT INTL | **150MG** | **N021515** | **001** | Aug 28, 2003 |
| **AB3** | **+!** | | **300MG** | **N021515** | **002** | Aug 28, 2003 |

FORFIVO XL

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ALVOGEN | 450MG | N022497 | 001 | Nov 10, 2011 |

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CONTRAVE

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | OREXIGEN | 90MG;8MG | N200063 | 001 | Sep 10, 2014 |

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

**BUSPIRONE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACCORD HLTHCARE | **5MG** | **A202557** | **001** | Dec 30, 2014 |
| **AB** | | | **7.5MG** | **A202557** | **002** | Dec 30, 2014 |
| **AB** | | | **10MG** | **A202557** | **003** | Dec 30, 2014 |
| **AB** | | | **15MG** | **A202557** | **004** | Dec 30, 2014 |
| **AB** | | | **30MG** | **A202557** | **005** | Dec 30, 2014 |
| **AB** | | AMNEAL PHARMS CO | **5MG** | **A208829** | **001** | May 24, 2017 |
| **AB** | | | **7.5MG** | **A208829** | **002** | May 24, 2017 |
| **AB** | | | **10MG** | **A208829** | **003** | May 24, 2017 |
| **AB** | | | **15MG** | **A208829** | **004** | May 24, 2017 |
| **AB** | | | **30MG** | **A208829** | **005** | May 24, 2017 |
| **AB** | | DR REDDYS LABS LTD | **5MG** | **A078246** | **001** | Feb 27, 2009 |
| **AB** | | | **10MG** | **A078246** | **002** | Feb 27, 2009 |
| **AB** | | | **15MG** | **A078246** | **003** | Feb 27, 2009 |
| **AB** | | | **30MG** | **A078246** | **004** | Feb 27, 2009 |
| **AB** | | HERITAGE PHARMA | **5MG** | **A204582** | **001** | Sep 18, 2015 |
| **AB** | | | **10MG** | **A204582** | **002** | Sep 18, 2015 |
| **AB** | | | **15MG** | **A204582** | **003** | Sep 18, 2015 |
| **AB** | | | **30MG** | **A204582** | **004** | Sep 18, 2015 |
| **AB** | | IMPAX LABS INC | **5MG** | **A074253** | **001** | Mar 28, 2001 |
| **AB** | | | **10MG** | **A074253** | **002** | Mar 28, 2001 |
| **AB** | | | **15MG** | **A074253** | **003** | Mar 13, 2002 |
| **AB** | | MYLAN | **5MG** | **A076008** | **003** | Mar 01, 2002 |
| **AB** | | | **7.5MG** | **A075467** | **002** | Mar 28, 2001 |
| **AB** | | | **7.5MG** | **A076008** | **002** | Jul 08, 2013 |
| **AB** | | | **10MG** | **A076008** | **004** | Mar 01, 2002 |
| **AB** | | | **15MG** | **A076008** | **005** | Mar 28, 2001 |
| **AB** | | | **30MG** | **A076008** | **001** | Jun 28, 2001 |
| **AB** | | ORION CORP ORION | **5MG** | **A202087** | **001** | Dec 16, 2015 |
| **AB** | | | **10MG** | **A202087** | **002** | Dec 16, 2015 |
| **AB** | | | **15MG** | **A202087** | **003** | Dec 16, 2015 |

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL

**BUSPIRONE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **30MG** | **A202087** | **004** | Dec 16, 2015 |
| **AB** | | OXFORD PHARMS | **30MG** | **A078302** | **001** | Dec 17, 2007 |
| **AB** | | STRIDES PHARMA | **5MG** | **A202330** | **001** | Aug 25, 2014 |
| **AB** | | | **7.5MG** | **A202330** | **005** | Feb 17, 2017 |
| **AB** | | | **10MG** | **A202330** | **002** | Aug 25, 2014 |
| **AB** | | | **15MG** | **A202330** | **003** | Aug 25, 2014 |
| **AB** | | | **30MG** | **A202330** | **004** | Aug 25, 2014 |
| **AB** | | TEVA | **5MG** | **A075022** | **001** | Feb 28, 2002 |
| **AB** | | | **10MG** | **A075022** | **002** | Feb 28, 2002 |
| **AB** | **!** | | **15MG** | **A075022** | **003** | Feb 28, 2002 |
| **AB** | | | **30MG** | **A075022** | **004** | Mar 25, 2004 |
| **AB** | | ZYDUS PHARMS USA INC | **5MG** | **A078888** | **001** | Feb 07, 2014 |
| **AB** | | | **10MG** | **A078888** | **002** | Feb 07, 2014 |
| **AB** | | | **15MG** | **A078888** | **003** | Feb 07, 2014 |
| **AB** | | | **30MG** | **A078888** | **004** | Feb 07, 2014 |

BUSULFAN

INJECTABLE;INJECTION

**BUSULFAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | ACTAVIS LLC | **6MG/ML** | **A205139** | **001** | Dec 08, 2017 |
| **AP** | | AMNEAL PHARMS CO | **6MG/ML** | **A209580** | **001** | Dec 18, 2017 |
| **AP** | | LUITPOLD PHARMS INC | **6MG/ML** | **A202259** | **001** | Dec 22, 2015 |
| **AP** | | PHARMASCIENCE INC | **6MG/ML** | **A207050** | **001** | Mar 24, 2017 |
| **AP** | | SANDOZ INC | **6MG/ML** | **A205106** | **001** | Jul 07, 2017 |

**BUSULFEX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | OTSUKA PHARM | **6MG/ML** | **N020954** | **001** | Feb 04, 1999 |

**MYLERAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | ASPEN GLOBAL INC | **6MG/ML** | **A208536** | **001** | Nov 20, 2017 |

TABLET;ORAL

MYLERAN

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ASPEN GLOBAL | 2MG | N009386 | 001 | |

BUTABARBITAL SODIUM

TABLET;ORAL

BUTISOL SODIUM

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | MYLAN SPECIALITY LP | 30MG | N000793 | 004 | |

BUTENAFINE HYDROCHLORIDE

CREAM;TOPICAL

MENTAX

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | MYLAN | 1% | N020524 | 001 | Oct 18, 1996 |

BUTOCONAZOLE NITRATE

CREAM;VAGINAL

GYNAZOLE-1

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | PERRIGO ISRAEL | 2% | A200923 | 001 | May 18, 2012 |

BUTORPHANOL TARTRATE

INJECTABLE;INJECTION

**BUTORPHANOL TARTRATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | HIKMA FARMACEUTICA | **1MG/ML** | **A078400** | **001** | May 01, 2009 |
| **AP** | | | **2MG/ML** | **A078400** | **002** | May 01, 2009 |
| **AP** | | WEST-WARD PHARMS INT | **2MG/ML** | **A075046** | **001** | Aug 12, 1998 |

**BUTORPHANOL TARTRATE PRESERVATIVE FREE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | HOSPIRA | **1MG/ML** | **A074626** | **001** | Jan 23, 1997 |
| **AP** | | | **2MG/ML** | **A074626** | **002** | Jan 23, 1997 |
| **AP** | | WEST-WARD PHARMS INT | **1MG/ML** | **A075045** | **001** | Aug 12, 1998 |
| **AP** | | | **2MG/ML** | **A075045** | **002** | Aug 12, 1998 |

SPRAY, METERED;NASAL

**BUTORPHANOL TARTRATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | APOTEX INC | **1MG/SPRAY** | **A075499** | **001** | Dec 04, 2002 |
| **AB** | **!** | MYLAN | **1MG/SPRAY** | **A075759** | **001** | Aug 08, 2001 |
| **AB** | | WEST-WARD PHARMS INT | **1MG/SPRAY** | **A075824** | **001** | Mar 12, 2002 |

CABAZITAXEL

SOLUTION;IV (INFUSION)

JEVTANA KIT

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | SANOFI AVENTIS US | 60MG/1.5ML (40MG/ML) | N201023 | 001 | Jun 17, 2010 |

CABERGOLINE

TABLET;ORAL

**CABERGOLINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS LABS FL INC | **0.5MG** | **A078035** | **001** | Apr 21, 2008 |
| **AB** | | APOTEX CORP | **0.5MG** | **A201503** | **001** | Mar 08, 2013 |
| **AB** | | IVAX SUB TEVA PHARMS | **0.5MG** | **A077750** | **001** | Mar 07, 2007 |
| **AB** | | MYLAN PHARMS INC | **0.5MG** | **A202947** | **001** | Dec 02, 2013 |
| **AB** | **!** | PAR PHARM | **0.5MG** | **A076310** | **001** | Dec 29, 2005 |

CABOZANTINIB S-MALATE

CAPSULE;ORAL

COMETRIQ

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | EXELIXIS | EQ 20MG BASE | N203756 | 001 | Nov 29, 2012 |
| | +! | | EQ 80MG BASE | N203756 | 002 | Nov 29, 2012 |

TABLET;ORAL

CABOMETYX

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | EXELIXIS INC | EQ 20MG BASE | N208692 | 001 | Apr 25, 2016 |
| | + | | EQ 40MG BASE | N208692 | 002 | Apr 25, 2016 |
| | +! | | EQ 60MG BASE | N208692 | 003 | Apr 25, 2016 |

CAFFEINE CITRATE

SOLUTION;INTRAVENOUS

**CAFCIT**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | WEST-WARD PHARMS INT | **EQ 30MG BASE/3ML (EQ 10MG BASE/ML)** | **N020793** | **001** | Sep 21, 1999 |

**CAFFEINE CITRATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AUROBINDO PHARMA LTD | **EQ 30MG BASE/3ML (EQ 10MG BASE/ML)** | **A205013** | **001** | Sep 22, 2015 |
| **AP** | | EXELA PHARMA SCIENCE | **EQ 30MG BASE/3ML (EQ 10MG BASE/ML)** | **A077233** | **001** | Sep 21, 2006 |
| **AP** | | FRESENIUS KABI USA | **EQ 30MG BASE/3ML (EQ 10MG BASE/ML)** | **A077997** | **001** | Jul 20, 2007 |
| **AP** | | LUITPOLD | **EQ 30MG BASE/3ML (EQ 10MG BASE/ML)** | **A077906** | **001** | May 15, 2007 |
| **AP** | | MICRO LABS | **EQ 30MG BASE/3ML (EQ 10MG BASE/ML)** | **A207400** | **001** | Dec 14, 2017 |
| **AP** | | SAGENT PHARMS | **EQ 30MG BASE/3ML (EQ 10MG BASE/ML)** | **A090827** | **001** | Aug 29, 2012 |
| **AP** | | SUN PHARMA GLOBAL | **EQ 30MG BASE/3ML (EQ 10MG BASE/ML)** | **A090077** | **001** | Sep 30, 2009 |

SOLUTION;ORAL

**CAFCIT**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **+!** | WEST-WARD PHARMS INT | **EQ 30MG BASE/3ML (EQ 10MG BASE/ML)** | **N020793** | **002** | Apr 12, 2000 |

**CAFFEINE CITRATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | EXELA PHARMA SCS LLC | **EQ 30MG BASE/3ML (EQ 10MG BASE/ML)** | **A077304** | **001** | Sep 21, 2006 |
| **AA** | | FRESENIUS KABI USA | **EQ 30MG BASE/3ML (EQ 10MG BASE/ML)** | **A078002** | **001** | Jan 31, 2008 |
| **AA** | | LUITPOLD | **EQ 30MG BASE/3ML (EQ 10MG BASE/ML)** | **A090064** | **001** | Nov 20, 2009 |
| **AA** | | SAGENT PHARMS | **EQ 30MG BASE/3ML (EQ 10MG BASE/ML)** | **A091102** | **001** | Aug 29, 2012 |
| **AA** | | SUN PHARMA GLOBAL | **EQ 30MG BASE/3ML (EQ 10MG BASE/ML)** | **A090357** | **001** | Sep 30, 2009 |

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY;RECTAL

MIGERGOT

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | HORIZON PHARMA | 100MG;2MG | A086557 | 001 | Oct 04, 1983 |

TABLET;ORAL

**CAFERGOT**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **!** | SANDOZ | **100MG;1MG** | **A084294** | **001** | |

**ERGOTAMINE TARTRATE AND CAFFEINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | HIKMA INTL PHARMS | **100MG;1MG** | **A040510** | **001** | Sep 17, 2004 |
| **AA** | | MIKART | **100MG;1MG** | **A040590** | **001** | Sep 16, 2005 |

CALCIFEDIOL

CAPSULE, EXTENDED RELEASE;ORAL

RAYALDEE

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | OPKO IRELAND GLOBAL | 0.03MG | N208010 | 001 | Jun 17, 2016 |

CALCIPOTRIENE

AEROSOL, FOAM;TOPICAL

SORILUX

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | MAYNE PHARMA | 0.005% | N022563 | 001 | Oct 06, 2010 |

CREAM;TOPICAL

**CALCIPOTRIENE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | GLENMARK PHARMS | **0.005%** | **A205772** | **001** | Jun 09, 2015 |
| **AB** | | TOLMAR | **0.005%** | **A200935** | **001** | May 30, 2012 |

CALCIPOTRIENE

CREAM;TOPICAL

**DOVONEX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | LEO PHARMA AS | **0.005%** | **N020554** | **001** | Jul 22, 1996 |

OINTMENT;TOPICAL

CALCIPOTRIENE

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | GLENMARK PHARMS INC | 0.005% | A090633 | 001 | Mar 24, 2010 |

SOLUTION;TOPICAL

**CALCIPOTRIENE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | FOUGERA PHARMS | **0.005%** | **A078305** | **001** | May 06, 2008 |
| **AT** | | G AND W LABS INC | **0.005%** | **A078468** | **001** | Mar 24, 2011 |
| **AT** | | HI TECH PHARMA | **0.005%** | **A077579** | **001** | Nov 19, 2009 |
| **AT** | | NOVEL LABS INC | **0.005%** | **A207163** | **001** | Dec 26, 2017 |
| **AT** | **!** | TOLMAR | **0.005%** | **A077029** | **001** | Nov 20, 2009 |

CALCITONIN SALMON

INJECTABLE;INJECTION

MIACALCIN

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | MYLAN IRELAND LTD | 200 IU/ML | N017808 | 002 | Mar 29, 1991 |

SPRAY, METERED;NASAL

**CALCITONIN-SALMON**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **!** | APOTEX INC | **200 IU/SPRAY** | **A076396** | **001** | Nov 17, 2008 |
| **AB** | | PAR PHARM | **200 IU/SPRAY** | **A076979** | **001** | Jun 08, 2009 |

CALCITRIOL

CAPSULE;ORAL

**CALCITRIOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AMNEAL PHARMS | **0.25MCG** | **A203289** | **002** | Jun 14, 2017 |
| **AB** | | | **0.5MCG** | **A203289** | **001** | Jun 14, 2017 |
| **AB** | | BIONPHARMA INC | **0.25MCG** | **A091174** | **001** | May 24, 2013 |
| **AB** | | | **0.5MCG** | **A091174** | **002** | May 24, 2013 |
| **AB** | | STRIDES PHARMA | **0.25MCG** | **A091356** | **001** | Dec 12, 2014 |
| **AB** | | | **0.5MCG** | **A091356** | **002** | Dec 12, 2014 |
| **AB** | | TEVA | **0.25MCG** | **A075765** | **001** | Oct 12, 2001 |
| **AB** | | | **0.5MCG** | **A075765** | **002** | Oct 12, 2001 |
| **AB** | | WEST-WARD PHARMS INT | **0.25MCG** | **A076917** | **001** | Mar 27, 2006 |

**ROCALTROL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | VALIDUS PHARMS | **0.25MCG** | **N018044** | **001** | |
| **AB** | **+!** | | **0.5MCG** | **N018044** | **002** | |

INJECTABLE;INJECTION

CALCITRIOL

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | AKORN | 0.001MG/ML | A078066 | 001 | Jan 29, 2008 |

OINTMENT;TOPICAL

VECTICAL

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | GALDERMA LABS LP | 3MCG/GM | N022087 | 001 | Jan 23, 2009 |

SOLUTION;ORAL

**CALCITRIOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | WEST-WARD PHARMS INT | **1MCG/ML** | **A076242** | **001** | Jul 18, 2003 |

**ROCALTROL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **+!** | VALIDUS PHARMS | **1MCG/ML** | **N021068** | **001** | Nov 20, 1998 |

CALCIUM ACETATE

CAPSULE;ORAL

**CALCIUM ACETATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AMNEAL PHARMS | **667MG** | **A201658** | **001** | Oct 06, 2014 |
| **AB** | | CHARTWELL RX | **667MG** | **A091312** | **001** | Jun 01, 2012 |
| **AB** | | ECI PHARMS LLC | **667MG** | **A203298** | **001** | Jul 26, 2016 |
| **AB** | | HERITAGE PHARMS INC | **667MG** | **A202315** | **001** | Jun 29, 2015 |
| **AB** | | INVAGEN PHARMS | **667MG** | **A203135** | **001** | Feb 07, 2013 |
| **AB** | | LUPIN LTD | **667MG** | **A202127** | **001** | Jul 09, 2015 |
| **AB** | | NOSTRUM LABS INC | **667MG** | **A203179** | **001** | Oct 26, 2015 |
| **AB** | | WEST-WARD PHARMS INT | **667MG** | **A077728** | **001** | Feb 26, 2008 |

**PHOSLO GELCAPS**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | FRESENIUS MEDCL | **667MG** | **N021160** | **003** | Apr 02, 2001 |

SOLUTION;ORAL

PHOSLYRA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | FRESENIUS MEDCL | 667MG/5ML | N022581 | 001 | Apr 18, 2011 |

TABLET;ORAL

**CALCIUM ACETATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | HERITAGE PHARMS INC | **667MG** | **A202885** | **001** | Jan 22, 2015 |
| **AB** | | INVAGEN PHARMS | **667MG** | **A202420** | **001** | Feb 05, 2013 |

CALCIUM ACETATE

TABLET;ORAL

**CALCIUM ACETATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **!** | PADDOCK LLC | **667MG** | **A091561** | **001** | Apr 13, 2011 |

**ELIPHOS**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | CYPRESS PHARM | **667MG** | **A078502** | **001** | Nov 25, 2008 |

CALCIUM CHLORIDE

INJECTABLE;INJECTION

**CALCIUM CHLORIDE 10%**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | LUITPOLD PHARMS INC | **100MG/ML** | **A209088** | **001** | Jul 27, 2017 |

**CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | HOSPIRA | **100MG/ML** | **N021117** | **001** | Jan 28, 2000 |

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION;IRRIGATION

**BSS PLUS**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **+!** | ALCON | **0.154MG/ML;0.92MG/ML;0.184MG/ML;0.2MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML** | **N018469** | **001** | |

**ENDOSOL EXTRA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **+!** | AKORN | **0.154MG/ML;0.92MG/ML;0.184MG/ML;0.2MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML** | **N020079** | **001** | Nov 27, 1991 |

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| +! | BAXTER HLTHCARE CORP | N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML) | N021703 | 010 | Oct 10, 2008 |

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| +! | BAXTER HLTHCARE CORP | N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML) | N021703 | 011 | Oct 10, 2008 |

PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| +! | BAXTER HLTHCARE CORP | 3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML) | N021703 | 013 | Oct 10, 2008 |

PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| +! | BAXTER HLTHCARE CORP | 3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML) | N021703 | 006 | Oct 25, 2006 |

PRISMASOL BGK 2/0 IN PLASTIC CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| +! | BAXTER HLTHCARE CORP | N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML) | N021703 | 002 | Oct 25, 2006 |

PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| +! | BAXTER HLTHCARE CORP | 5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML) | N021703 | 003 | Oct 25, 2006 |

PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| +! | BAXTER HLTHCARE CORP | N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.44GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML) | N021703 | 015 | Oct 10, 2008 |

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| +! | BAXTER HLTHCARE CORP | 3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML) | N021703 | 004 | Oct 25, 2006 |

PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| +! | BAXTER HLTHCARE CORP | N/A/1000ML;N/A/1000ML;5.4GM/1000ML;2.44GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML) | N021703 | 014 | Oct 10, 2008 |

PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| +! | BAXTER HLTHCARE CORP | 5.15GM/1000ML;N/A/1000ML;5.4GM/1000ML;2.03GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML) | N021703 | 001 | Oct 25, 2006 |

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

**DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | FRESENIUS MEDCL | **25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML** | **N018883** | **001** | Nov 30, 1984 |

**DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | FRESENIUS MEDCL | **25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML** | **N018883** | **004** | Nov 30, 1984 |

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER** | | | | | | |
| **AT** | FRESENIUS MEDCL | **18.4MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML** | **N020171** | **001** | Aug 19, 1992 | |
| **DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER** | | | | | | |
| **AT** | FRESENIUS MEDCL | **25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML** | **N018883** | **002** | Nov 30, 1984 | |
| **DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER** | | | | | | |
| **AT** | FRESENIUS MEDCL | **25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML** | **N018883** | **005** | Nov 30, 1984 | |
| **DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER** | | | | | | |
| **AT** | FRESENIUS MEDCL | **18.4MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML** | **N020171** | **002** | Aug 19, 1992 | |
| **DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER** | | | | | | |
| **AT** | FRESENIUS MEDCL | **25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML** | **N018883** | **003** | Nov 30, 1984 | |
| **DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER** | | | | | | |
| **AT** | FRESENIUS MEDCL | **25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML** | **N018883** | **006** | Nov 30, 1984 | |
| **DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER** | | | | | | |
| **AT** | FRESENIUS MEDCL | **18.4MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML** | **N020171** | **003** | Aug 19, 1992 | |
| **DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER** | | | | | | |
| **AT** | BAXTER HLTHCARE | **25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML** | **N017512** | **001** | | |
| **DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER** | | | | | | |
| **AT** | BAXTER HLTHCARE | **25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML** | **N017512** | **003** | | |
| **DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER** | | | | | | |
| **AT** | BAXTER HLTHCARE | **25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML** | **N017512** | **002** | | |
| **DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER** | | | | | | |
| **AT** | BAXTER HLTHCARE | **18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML** | **N020183** | **001** | Dec 04, 1992 | |
| **DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER** | | | | | | |
| **AT** | BAXTER HLTHCARE | **25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML** | **N017512** | **007** | Jul 09, 1984 | |
| **DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER** | | | | | | |
| **AT** | BAXTER HLTHCARE | **25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML** | **N017512** | **008** | Jul 09, 1984 | |
| **DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER** | | | | | | |
| **AT** | BAXTER HLTHCARE | **25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML** | **N017512** | **009** | Jul 09, 1984 | |
| **DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER** | | | | | | |
| **AT** | BAXTER HLTHCARE | **18.3MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML** | **N017512** | **004** | | |
| **AT** | | **25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML** | **N020163** | **001** | Dec 04, 1992 | |
| **DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER** | | | | | | |
| **AT** | BAXTER HLTHCARE | **25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML** | **N017512** | **005** | | |
| **AT** | | **25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML** | **N020163** | **002** | Dec 04, 1992 | |
| **DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER** | | | | | | |
| **AT** | BAXTER HLTHCARE | **25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML** | **N017512** | **006** | | |
| **AT** | | **25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML** | **N020163** | **003** | Dec 04, 1992 | |
| DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER | | | | | | |
| | BAXTER HLTHCARE | 18.3MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML | N020183 | 002 | Dec 04, 1992 | |
| DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER | | | | | | |
| | BAXTER HLTHCARE | 18.3MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML | N020183 | 003 | Dec 04, 1992 | |
| DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER | | | | | | |
| | BAXTER HLTHCARE | 18.3MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML | N020183 | 004 | Dec 04, 1992 | |
| DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER | | | | | | |
| | BAXTER HLTHCARE | 25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML | N017512 | 010 | Nov 18, 1985 | |
| DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER | | | | | | |
| | BAXTER HLTHCARE | 25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML | N017512 | 011 | Nov 18, 1985 | |

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INTRATHECAL

ELLIOTTS B SOLUTION

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | LUKARE MEDICAL LLC | 0.2MG/ML;0.8MG/ML;0.3MG/ML;0.3MG/ML;1.9 MG/ML;7.3MG/ML;0.2MG/ML | N020577 | 001 | Sep 27, 1996 |

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

| | | | | | | |
|---|---|---|---|---|---|---|
| | | B BRAUN | 33MG/100ML;5GM/100ML;30MG/100ML;860MG/100ML | N020000 | 001 | Apr 17, 1992 |

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

**DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+** | ICU MEDICAL INC | **20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML** | **N017608** | **001** | |

**DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | B BRAUN | **20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML** | **N019634** | **003** | Feb 24, 1988 |

**LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | BAXTER HLTHCARE | **20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML** | **N016679** | **001** | |

**POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | BAXTER HLTHCARE | **20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML** | **N019367** | **006** | Apr 05, 1985 |

**POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | BAXTER HLTHCARE | **20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML** | **N019367** | **004** | Apr 05, 1985 |
| **AP** | | | **20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML** | **N019367** | **005** | Apr 05, 1985 |
| **AP** | | ICU MEDICAL INC | **20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML** | **N019685** | **002** | Oct 17, 1988 |
| **AP** | | | **20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML** | **N019685** | **008** | Oct 17, 1988 |

**POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | BAXTER HLTHCARE | **20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML** | **N019367** | **007** | Apr 05, 1985 |

**POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | BAXTER HLTHCARE | **20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML** | **N019367** | **008** | Apr 05, 1985 |
| **AP** | | ICU MEDICAL INC | **20MG/100ML;5GM/100ML;328MG/100ML;600MG/100ML;310MG/100ML** | **N019685** | **004** | Oct 17, 1988 |

DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER

| | | | | | | |
|---|---|---|---|---|---|---|
| | | B BRAUN | 10MG/100ML;2.5GM/100ML;15MG/100ML;300MG /100ML;160MG/100ML | N019634 | 001 | Feb 24, 1988 |

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

| | | | | | | |
|---|---|---|---|---|---|---|
| | | BAXTER HLTHCARE | 20MG/100ML;5GM/100ML;105MG/100ML;600MG/100ML;310MG/100ML | N019367 | 002 | Apr 05, 1985 |
| | | | 20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML | N019367 | 003 | Apr 05, 1985 |

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

| | | | | | | |
|---|---|---|---|---|---|---|
| | | BAXTER HLTHCARE | 20MG/100ML;5GM/100ML;105MG/100ML;600MG/100ML;310MG/100ML | N019367 | 001 | Apr 05, 1985 |

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | HOSPIRA | 16.5MG/ML;25.4MG/ML;74.6MG/ML;121MG/ML;16.1MG/ML | N018895 | 001 | Jul 20, 1984 |

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

SOLUTION;IRRIGATION

**BALANCED SALT**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | AKORN | **0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6.4MG/ML;1.7MG/ML** | **A075503** | **001** | Sep 27, 2006 |
| **AT** | | B BRAUN | **0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6.4MG/ML;1.7MG/ML** | **A091387** | **001** | Feb 03, 2010 |

**BSS**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **+!** | ALCON | **0.48MG/ML;0.3MG/ML;0.75MG/ML;3.9MG/ML;6.4MG/ML;1.7MG/ML** | **N020742** | **001** | Dec 10, 1997 |

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE;INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| +! | BAXTER HLTHCARE CORP | N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML) | N207026 | 002 | Jan 13, 2015 |

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| +! | BAXTER HLTHCARE CORP | 3.68GM/1000ML;3.05GM/1000ML;0.314GM/100 0ML ;3.09GM/1000ML;6.34GM/1000ML;0.187GM/10 | N207026 | 001 | Jan 13, 2015 |

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

SOLUTION;PERFUSION, CARDIAC

**CARDIOPLEGIC IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | BAXTER HLTHCARE | **17.6MG/100ML;325.3MG/100ML;119.3MG/100ML;643MG/100ML** | **A075323** | **001** | Apr 21, 2000 |

**PLEGISOL IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **+!** | HOSPIRA | **17.6MG/100ML;325.3MG/100ML;119.3MG/100ML;643MG/100ML** | **N018608** | **001** | Feb 26, 1982 |

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

**RINGER'S IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | B BRAUN | **33MG/100ML;30MG/100ML;860MG/100ML** | **N020002** | **001** | Apr 17, 1992 |
| **AP** | | BAXTER HLTHCARE | **33MG/100ML;30MG/100ML;860MG/100ML** | **N016693** | **001** | |
| **AP** | | ICU MEDICAL INC | **33MG/100ML;30MG/100ML;860MG/100ML** | **N018251** | **001** | |

SOLUTION;IRRIGATION

**RINGER'S IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | B BRAUN | **33MG/100ML;30MG/100ML;860MG/100ML** | **N018156** | **001** | |
| **AT** | | BAXTER HLTHCARE | **33MG/100ML;30MG/100ML;860MG/100ML** | **N018495** | **001** | Feb 19, 1982 |
| **AT** | | ICU MEDICAL INC | **33MG/100ML;30MG/100ML;860MG/100ML** | **N017635** | **001** | |

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

**LACTATED RINGER'S IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | B BRAUN | **20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML** | **N019632** | **001** | Feb 29, 1988 |
| **AP** | **+!** | BAXTER HLTHCARE | **20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML** | **N016682** | **001** | |
| **AP** | | ICU MEDICAL INC | **20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML** | **N017641** | **001** | |

SOLUTION;IRRIGATION

**LACTATED RINGER'S IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **+!** | B BRAUN | **20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML** | **N018681** | **001** | Dec 27, 1982 |
| **AT** | | BAXTER HLTHCARE | **20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML** | **N018494** | **001** | Feb 19, 1982 |
| **AT** | **+!** | | **20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML** | **N018921** | **001** | Apr 03, 1984 |
| **AT** | **+!** | ICU MEDICAL INC | **20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML** | **N019416** | **001** | Jan 17, 1986 |

CALCIUM GLUCONATE

SOLUTION;IV (INFUSION)

CALCIUM GLUCONATE

| | | | | | |
|---|---|---|---|---|---|
| +! | FRESENIUS KABI USA | 1GM/10ML (100MG/ML) | N208418 | 001 | Jun 15, 2017 |
| +! | | 5GM/50ML (100MG/ML) | N208418 | 002 | Jun 15, 2017 |
| +! | | 10GM/100ML (100MG/ML) | N208418 | 003 | Jun 15, 2017 |

CALFACTANT

SUSPENSION;INTRATRACHEAL

INFASURF PRESERVATIVE FREE

| | | | | | |
|---|---|---|---|---|---|
| +! | ONY | 35MG/ML | N020521 | 001 | Jul 01, 1998 |

CANAGLIFLOZIN

TABLET;ORAL

INVOKANA

| | | | | | |
|---|---|---|---|---|---|
| + | JANSSEN PHARMS | 100MG | N204042 | 001 | Mar 29, 2013 |
| +! | | 300MG | N204042 | 002 | Mar 29, 2013 |

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET;ORAL

INVOKAMET

| | | | | | |
|---|---|---|---|---|---|
| + | JANSSEN PHARMS | 50MG;500MG | N204353 | 001 | Aug 08, 2014 |
| + | | 50MG;1GM | N204353 | 002 | Aug 08, 2014 |
| + | | 150MG;500MG | N204353 | 003 | Aug 08, 2014 |
| +! | | 150MG;1GM | N204353 | 004 | Aug 08, 2014 |

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

INVOKAMET XR

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | JANSSEN PHARMS | 50MG;500MG | N205879 | 001 | Sep 20, 2016 |
| | + | | 50MG;1GM | N205879 | 002 | Sep 20, 2016 |
| | + | | 150MG;500MG | N205879 | 003 | Sep 20, 2016 |
| | +! | | 150MG;1GM | N205879 | 004 | Sep 20, 2016 |

CANDESARTAN CILEXETIL

TABLET;ORAL

**ATACAND**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | ASTRAZENECA | **4MG** | **N020838** | **001** | Jun 04, 1998 |
| **AB** | **+** | | **8MG** | **N020838** | **002** | Jun 04, 1998 |
| **AB** | **+** | | **16MG** | **N020838** | **003** | Jun 04, 1998 |
| **AB** | **+!** | | **32MG** | **N020838** | **004** | Jun 04, 1998 |

**CANDESARTAN CILEXETIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALEMBIC PHARMS LTD | **32MG** | **A209119** | **001** | Jun 20, 2017 |
| **AB** | | APOTEX INC | **4MG** | **A202079** | **001** | Jan 10, 2014 |
| **AB** | | | **8MG** | **A202079** | **002** | Jan 10, 2014 |
| **AB** | | | **16MG** | **A202079** | **003** | Jan 10, 2014 |
| **AB** | | | **32MG** | **A202079** | **004** | Jan 10, 2014 |
| **AB** | | MACLEODS PHARMS LTD | **4MG** | **A203813** | **001** | Dec 05, 2016 |
| **AB** | | | **8MG** | **A203813** | **002** | Dec 05, 2016 |
| **AB** | | | **16MG** | **A203813** | **003** | Dec 05, 2016 |
| **AB** | | | **32MG** | **A203813** | **004** | Dec 05, 2016 |
| **AB** | | SANDOZ | **4MG** | **A078702** | **001** | May 03, 2013 |
| **AB** | | | **8MG** | **A078702** | **002** | May 03, 2013 |
| **AB** | | | **16MG** | **A078702** | **003** | May 03, 2013 |
| **AB** | | | **32MG** | **A078702** | **004** | May 03, 2013 |
| **AB** | | ZYDUS PHARMS USA INC | **4MG** | **A091390** | **001** | Aug 23, 2017 |
| **AB** | | | **8MG** | **A091390** | **002** | Aug 23, 2017 |
| **AB** | | | **16MG** | **A091390** | **003** | Aug 23, 2017 |
| **AB** | | | **32MG** | **A091390** | **004** | Aug 23, 2017 |

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

**ATACAND HCT**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | ASTRAZENECA | **16MG;12.5MG** | **N021093** | **001** | Sep 05, 2000 |
| **AB** | **+** | | **32MG;12.5MG** | **N021093** | **002** | Sep 05, 2000 |
| **AB** | **+!** | | **32MG;25MG** | **N021093** | **003** | May 16, 2008 |

**CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | APOTEX INC | **16MG;12.5MG** | **A202884** | **001** | Dec 04, 2012 |
| **AB** | | | **32MG;12.5MG** | **A202884** | **002** | Dec 04, 2012 |
| **AB** | | | **32MG;25MG** | **A202884** | **003** | Jun 03, 2013 |
| **AB** | | DR REDDYS LABS LTD | **16MG;12.5MG** | **A202965** | **001** | Jun 03, 2013 |
| **AB** | | | **32MG;12.5MG** | **A202965** | **002** | Jun 03, 2013 |
| **AB** | | | **32MG;25MG** | **A202965** | **003** | Jun 03, 2013 |
| **AB** | | MACLEODS PHARMS LTD | **16MG;12.5MG** | **A204100** | **001** | Feb 27, 2015 |
| **AB** | | | **32MG;12.5MG** | **A204100** | **002** | Feb 27, 2015 |
| **AB** | | | **32MG;25MG** | **A204100** | **003** | Feb 27, 2015 |
| **AB** | | MYLAN PHARMS INC | **16MG;12.5MG** | **A090704** | **001** | Dec 04, 2012 |
| **AB** | | | **32MG;12.5MG** | **A090704** | **002** | Dec 04, 2012 |
| **AB** | | | **32MG;25MG** | **A090704** | **003** | Dec 04, 2012 |
| **AB** | | ZYDUS PHARMS USA INC | **16MG;12.5MG** | **A203466** | **001** | Nov 27, 2017 |
| **AB** | | | **32MG;12.5MG** | **A203466** | **002** | Nov 27, 2017 |
| **AB** | | | **32MG;25MG** | **A203466** | **003** | Nov 27, 2017 |

CANGRELOR

POWDER;IV (INFUSION)

KENGREAL

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | CHIESI USA INC | 50MG/VIAL | N204958 | 001 | Jun 22, 2015 |

CAPECITABINE

TABLET;ORAL

**CAPECITABINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACCORD HLTHCARE | **150MG** | **A202593** | **001** | Apr 23, 2015 |
| **AB** | | | **500MG** | **A202593** | **002** | Apr 23, 2015 |
| **AB** | | ALKEM LABS LTD | **150MG** | **A207652** | **001** | Nov 24, 2017 |
| **AB** | | | **500MG** | **A207652** | **002** | Nov 24, 2017 |
| **AB** | | AMNEAL PHARMS | **150MG** | **A204741** | **001** | Feb 28, 2017 |
| **AB** | | | **500MG** | **A204741** | **002** | Feb 28, 2017 |
| **AB** | | MYLAN PHARMS INC | **150MG** | **A090943** | **001** | Aug 08, 2014 |
| **AB** | | | **500MG** | **A090943** | **002** | Aug 08, 2014 |

CAPECITABINE

TABLET;ORAL

**CAPECITABINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | SHILPA MEDICARE LTD | **150MG** | **A207456** | **001** | Dec 12, 2016 |
| **AB** | | | **500MG** | **A207456** | **002** | Dec 12, 2016 |
| **AB** | | TEVA PHARMS USA | **150MG** | **A091649** | **001** | Sep 16, 2013 |
| **AB** | | | **500MG** | **A091649** | **002** | Sep 16, 2013 |
| **AB** | | WEST-WARD PHARMS INT | **150MG** | **A200483** | **001** | Jul 14, 2016 |
| **AB** | | | **500MG** | **A200483** | **002** | Jul 14, 2016 |

**XELODA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | HOFFMANN LA ROCHE | **150MG** | **N020896** | **001** | Apr 30, 1998 |
| **AB** | +! | | **500MG** | **N020896** | **002** | Apr 30, 1998 |

CAPREOMYCIN SULFATE

INJECTABLE;INJECTION

**CAPASTAT SULFATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | +! | AKORN | **EQ 1GM BASE/VIAL** | **N050095** | **001** | |

**CAPREOMYCIN SULFATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | MYLAN LABS LTD | **EQ 1GM BASE/VIAL** | **A202634** | **001** | Nov 27, 2017 |

CAPSAICIN

PATCH;TOPICAL

QUTENZA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ACORDA | 8% | N022395 | 001 | Nov 16, 2009 |

CAPTOPRIL

TABLET;ORAL

**CAPTOPRIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | HIKMA INTL PHARMS | **12.5MG** | **A074505** | **001** | Feb 13, 1996 |
| **AB** | | | **25MG** | **A074505** | **002** | Feb 13, 1996 |
| **AB** | | | **50MG** | **A074505** | **003** | Feb 13, 1996 |
| **AB** | | | **100MG** | **A074505** | **004** | Feb 13, 1996 |
| **AB** | | MYLAN PHARMS INC | **12.5MG** | **A074434** | **001** | Feb 13, 1996 |
| **AB** | | | **25MG** | **A074434** | **002** | Feb 13, 1996 |
| **AB** | | | **50MG** | **A074434** | **003** | Feb 13, 1996 |
| **AB** | ! | | **100MG** | **A074434** | **004** | Feb 13, 1996 |
| **AB** | | PRINSTON INC | **12.5MG** | **A074477** | **001** | Feb 13, 1996 |
| **AB** | | | **25MG** | **A074477** | **002** | Feb 13, 1996 |
| **AB** | | | **50MG** | **A074477** | **003** | Feb 13, 1996 |
| **AB** | | | **100MG** | **A074477** | **004** | Feb 13, 1996 |
| **AB** | | TEVA | **12.5MG** | **A074322** | **001** | Feb 13, 1996 |
| **AB** | | | **25MG** | **A074322** | **002** | Feb 13, 1996 |
| **AB** | | | **50MG** | **A074322** | **003** | Feb 13, 1996 |
| **AB** | | | **100MG** | **A074322** | **004** | Feb 13, 1996 |
| **AB** | | WATSON LABS | **12.5MG** | **A074386** | **001** | May 23, 1996 |
| **AB** | | | **25MG** | **A074386** | **002** | May 23, 1996 |
| **AB** | | | **50MG** | **A074386** | **003** | May 23, 1996 |
| **AB** | | | **100MG** | **A074386** | **004** | May 23, 1996 |
| **AB** | | WOCKHARDT LTD | **12.5MG** | **A074532** | **001** | Mar 28, 1997 |
| **AB** | | | **25MG** | **A074532** | **002** | Mar 28, 1997 |
| **AB** | | | **50MG** | **A074532** | **003** | Mar 28, 1997 |
| **AB** | | | **100MG** | **A074532** | **004** | Mar 28, 1997 |

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

**CAPTOPRIL AND HYDROCHLOROTHIAZIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | G AND W LABS INC | **25MG;15MG** | **A074827** | **001** | Dec 29, 1997 |
| **AB** | | | **25MG;25MG** | **A074827** | **002** | Dec 29, 1997 |
| **AB** | | | **50MG;15MG** | **A074827** | **004** | Dec 29, 1997 |
| **AB** | | | **50MG;25MG** | **A074827** | **003** | Dec 29, 1997 |
| **AB** | | MYLAN | **25MG;15MG** | **A074896** | **001** | Dec 29, 1997 |
| **AB** | ! | | **25MG;25MG** | **A074896** | **002** | Dec 29, 1997 |
| **AB** | ! | | **50MG;15MG** | **A074896** | **004** | Dec 29, 1997 |
| **AB** | | | **50MG;25MG** | **A074896** | **003** | Dec 29, 1997 |

CARBACHOL

SOLUTION;INTRAOCULAR

MIOSTAT

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ALCON | 0.01% | N016968 | 001 | |

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **CARBAMAZEPINE** | | | | | | |
| **AB** | | APOTEX INC | **100MG** | **A078986** | **001** | Nov 25, 2011 |
| **AB** | | | **200MG** | **A078986** | **002** | Nov 25, 2011 |
| **AB** | | | **300MG** | **A078986** | **003** | Nov 25, 2011 |
| **AB** | | MYLAN IRELAND LTD | **100MG** | **A076697** | **001** | May 20, 2011 |
| **AB** | | | **200MG** | **A076697** | **002** | May 20, 2011 |
| **AB** | | | **300MG** | **A076697** | **003** | May 20, 2011 |
| **AB** | | TARO | **100MG** | **A201106** | **001** | Jun 21, 2013 |
| **AB** | | | **200MG** | **A201106** | **002** | Jun 21, 2013 |
| **AB** | | | **300MG** | **A201106** | **003** | Jun 21, 2013 |
| **AB** | | TEVA PHARMS | **100MG** | **A078592** | **001** | Sep 20, 2012 |
| **AB** | | | **200MG** | **A078592** | **002** | Sep 20, 2012 |
| **AB** | | | **300MG** | **A078592** | **003** | Sep 20, 2012 |
| **CARBATROL** | | | | | | |
| **AB** | **+** | SHIRE | **100MG** | **N020712** | **003** | Sep 30, 1997 |
| **AB** | **+** | | **200MG** | **N020712** | **001** | Sep 30, 1997 |
| **AB** | **+!** | | **300MG** | **N020712** | **002** | Sep 30, 1997 |
| EQUETRO | | | | | | |
| | + | VALIDUS PHARMS | 100MG | N021710 | 001 | Dec 10, 2004 |
| | + | | 200MG | N021710 | 002 | Dec 10, 2004 |
| | +! | | 300MG | N021710 | 003 | Dec 10, 2004 |

SOLUTION;IV (INFUSION)

| | | | | | | |
|---|---|---|---|---|---|---|
| CARNEXIV | | | | | | |
| | +! | LUNDBECK PHARMS LLC | 200MG/20ML (10MG/ML) | N206030 | 001 | Oct 07, 2016 |

SUSPENSION;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **CARBAMAZEPINE** | | | | | | |
| **AB** | | WOCKHARDT BIO AG | **100MG/5ML** | **A075714** | **001** | Jun 05, 2002 |
| **TEGRETOL** | | | | | | |
| **AB** | **+!** | NOVARTIS | **100MG/5ML** | **N018927** | **001** | Dec 18, 1987 |
| **TERIL** | | | | | | |
| **AB** | | TARO PHARM | **100MG/5ML** | **A076729** | **001** | Sep 20, 2004 |

TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **CARBAMAZEPINE** | | | | | | |
| **AB** | | APOTEX INC | **200MG** | **A075948** | **001** | Feb 27, 2002 |
| **AB** | | TARO | **200MG** | **A074649** | **001** | Oct 03, 1996 |
| **AB** | | TORRENT PHARMS | **200MG** | **A077272** | **002** | Dec 07, 2005 |
| **EPITOL** | | | | | | |
| **AB** | | TEVA | **200MG** | **A070541** | **001** | Sep 17, 1986 |
| **TEGRETOL** | | | | | | |
| **AB** | **+!** | NOVARTIS | **200MG** | **N016608** | **001** | |
| CARBAMAZEPINE | | | | | | |
| | | TORRENT PHARMS | 100MG | A077272 | 001 | Dec 07, 2005 |
| | | | 300MG | A077272 | 003 | Dec 07, 2005 |
| | | | 400MG | A077272 | 004 | Dec 07, 2005 |

TABLET, CHEWABLE;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **CARBAMAZEPINE** | | | | | | |
| **AB** | | TARO PHARM INDS | **100MG** | **A075687** | **001** | Oct 24, 2000 |
| **AB** | | TORRENT PHARMS | **100MG** | **A075712** | **001** | Jul 05, 2001 |
| **EPITOL** | | | | | | |
| **AB** | | TEVA | **100MG** | **A073524** | **001** | Jul 29, 1992 |
| **TEGRETOL** | | | | | | |
| **AB** | **+!** | NOVARTIS | **100MG** | **N018281** | **001** | |
| CARBAMAZEPINE | | | | | | |
| | ! | TARO PHARM INDS | 200MG | A075687 | 002 | Jul 29, 2002 |

TABLET, EXTENDED RELEASE;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **CARBAMAZEPINE** | | | | | | |
| **AB** | | TARO | **100MG** | **A078115** | **001** | Mar 31, 2009 |
| **AB** | | | **200MG** | **A078115** | **002** | Mar 31, 2009 |
| **AB** | | | **400MG** | **A078115** | **003** | Mar 31, 2009 |
| **TEGRETOL-XR** | | | | | | |
| **AB** | **+** | NOVARTIS | **100MG** | **N020234** | **001** | Mar 25, 1996 |
| **AB** | **+** | | **200MG** | **N020234** | **002** | Mar 25, 1996 |
| **AB** | **+!** | | **400MG** | **N020234** | **003** | Mar 25, 1996 |

CARBIDOPA

TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **CARBIDOPA** | | | | | | |
| **AB** | | ALVOGEN MALTA | **25MG** | **A204291** | **001** | Jan 08, 2016 |
| **AB** | | AMERIGEN PHARMS LTD | **25MG** | **A203261** | **001** | Mar 10, 2014 |
| **AB** | | EDENBRIDGE PHARMS | **25MG** | **A205304** | **001** | Feb 17, 2016 |
| **AB** | | NOVEL LABS INC | **25MG** | **A204763** | **001** | Oct 20, 2017 |

CARBIDOPA

TABLET;ORAL

**LODOSYN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | ATON | **25MG** | **N017830** | **001** | |

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET;ORAL

**CARBIDOPA, LEVODOPA AND ENTACAPONE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | SUN PHARMA GLOBAL | **25MG;200MG;100MG** | **A079085** | **001** | May 10, 2012 |
| **AB** | | | **37.5MG;200MG;150MG** | **A079085** | **002** | May 10, 2012 |
| **AB** | | WOCKHARDT LTD | **12.5MG;200MG;50MG** | **A090786** | **001** | Nov 20, 2012 |
| **AB** | | | **18.75MG;200MG;75MG** | **A090833** | **001** | Nov 20, 2012 |
| **AB** | | | **25MG;200MG;100MG** | **A090833** | **002** | Nov 20, 2012 |
| **AB** | | | **31.25MG;200MG;125MG** | **A090833** | **003** | Nov 20, 2012 |
| **AB** | | | **37.5MG;200MG;150MG** | **A090833** | **004** | Nov 20, 2012 |
| **AB** | | | **50MG;200MG;200MG** | **A090833** | **005** | Nov 20, 2012 |

**STALEVO 100**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | ORION PHARMA | **25MG;200MG;100MG** | **N021485** | **002** | Jun 11, 2003 |

**STALEVO 125**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | ORION PHARMA | **31.25MG;200MG;125MG** | **N021485** | **006** | Aug 29, 2008 |

**STALEVO 150**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | ORION PHARMA | **37.5MG;200MG;150MG** | **N021485** | **003** | Jun 11, 2003 |

**STALEVO 200**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | ORION PHARMA | **50MG;200MG;200MG** | **N021485** | **004** | Aug 02, 2007 |

**STALEVO 50**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | ORION PHARMA | **12.5MG;200MG;50MG** | **N021485** | **001** | Jun 11, 2003 |

**STALEVO 75**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | ORION PHARMA | **18.75MG;200MG;75MG** | **N021485** | **005** | Aug 29, 2008 |

CARBIDOPA; LEVODOPA

CAPSULE, EXTENDED RELEASE;ORAL

RYTARY

| | | | | | |
|---|---|---|---|---|---|
| + | IMPAX LABS INC | 23.75MG;95MG | N203312 | 001 | Jan 07, 2015 |
| + | | 36.25MG;145MG | N203312 | 002 | Jan 07, 2015 |
| + | | 48.75MG;195MG | N203312 | 003 | Jan 07, 2015 |
| +! | | 61.25MG;245MG | N203312 | 004 | Jan 07, 2015 |

SUSPENSION;ENTERAL

DUOPA

| | | | | | |
|---|---|---|---|---|---|
| +! | ABBVIE INC | 4.63MG/ML;20MG/ML | N203952 | 001 | Jan 09, 2015 |

TABLET;ORAL

**CARBIDOPA AND LEVODOPA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS ELIZABETH | **10MG;100MG** | **A074260** | **001** | Sep 03, 1993 |
| **AB** | | | **25MG;100MG** | **A074260** | **002** | Sep 03, 1993 |
| **AB** | | | **25MG;250MG** | **A074260** | **003** | Sep 03, 1993 |
| **AB** | | APOTEX INC | **10MG;100MG** | **A077120** | **001** | Jun 02, 2008 |
| **AB** | | | **25MG;100MG** | **A077120** | **002** | Jun 02, 2008 |
| **AB** | | | **25MG;250MG** | **A077120** | **003** | Jun 02, 2008 |
| **AB** | | MAYNE PHARMA | **10MG;100MG** | **A073618** | **001** | Aug 28, 1992 |
| **AB** | | | **25MG;100MG** | **A073589** | **001** | Aug 28, 1992 |
| **AB** | | | **25MG;250MG** | **A073607** | **001** | Aug 28, 1992 |
| **AB** | | MYLAN | **10MG;100MG** | **A090324** | **001** | Sep 28, 2009 |
| **AB** | | | **25MG;100MG** | **A090324** | **002** | Sep 28, 2009 |
| **AB** | | | **25MG;250MG** | **A090324** | **003** | Sep 28, 2009 |
| **AB** | | SUN PHARM INDS | **10MG;100MG** | **A078536** | **001** | Oct 28, 2008 |
| **AB** | | | **25MG;100MG** | **A078536** | **002** | Oct 28, 2008 |
| **AB** | | | **25MG;250MG** | **A078536** | **003** | Oct 28, 2008 |

**SINEMET**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | MERCK SHARP DOHME | **10MG;100MG** | **N017555** | **001** | |
| **AB** | **+** | | **25MG;100MG** | **N017555** | **003** | |
| **AB** | **+!** | | **25MG;250MG** | **N017555** | **002** | |

TABLET, EXTENDED RELEASE;ORAL

**CARBIDOPA AND LEVODOPA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACCORD HLTHCARE | **25MG;100MG** | **A202323** | **001** | Feb 08, 2013 |
| **AB** | | | **50MG;200MG** | **A202323** | **002** | Feb 08, 2013 |
| **AB** | | APOTEX | **25MG;100MG** | **A076212** | **001** | Jun 16, 2004 |
| **AB** | | | **50MG;200MG** | **A076212** | **002** | Jun 16, 2004 |
| **AB** | | IMPAX LABS | **25MG;100MG** | **A076521** | **001** | May 14, 2004 |
| **AB** | | | **50MG;200MG** | **A076521** | **002** | May 14, 2004 |
| **AB** | | MYLAN | **25MG;100MG** | **A075091** | **002** | Apr 21, 2000 |
| **AB** | | | **50MG;200MG** | **A075091** | **001** | Sep 30, 1999 |
| **AB** | | SUN PHARM INDS | **25MG;100MG** | **A077828** | **001** | Aug 23, 2007 |
| **AB** | | | **50MG;200MG** | **A077828** | **002** | Aug 23, 2007 |

CARBIDOPA; LEVODOPA

TABLET, EXTENDED RELEASE;ORAL

**SINEMET CR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | MERCK SHARP DOHME | **25MG;100MG** | **N019856** | **002** | Dec 24, 1992 |
| **AB** | **+!** | | **50MG;200MG** | **N019856** | **001** | May 30, 1991 |

TABLET, ORALLY DISINTEGRATING;ORAL

**CARBIDOPA AND LEVODOPA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | MYLAN | **10MG;100MG** | **A078893** | **001** | Sep 18, 2008 |
| **AB** | | | **25MG;100MG** | **A078893** | **002** | Sep 18, 2008 |
| **AB** | **!** | | **25MG;250MG** | **A078893** | **003** | Sep 18, 2008 |
| **AB** | | SUN PHARMA GLOBAL | **10MG;100MG** | **A078690** | **001** | Jul 31, 2009 |
| **AB** | | | **25MG;100MG** | **A078690** | **002** | Jul 31, 2009 |
| **AB** | | | **25MG;250MG** | **A078690** | **003** | Jul 31, 2009 |

CARBINOXAMINE MALEATE

SOLUTION;ORAL

**CARBINOXAMINE MALEATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | CYPRESS PHARM | **4MG/5ML** | **A090418** | **001** | May 04, 2010 |
| **AA** | **!** | MIKART | **4MG/5ML** | **A040458** | **001** | Apr 25, 2003 |
| **AA** | | VINTAGE PHARMS | **4MG/5ML** | **A040814** | **001** | Feb 26, 2008 |

SUSPENSION, EXTENDED RELEASE;ORAL

KARBINAL ER

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | TRIS PHARMA INC | 4MG/5ML | N022556 | 001 | Mar 28, 2013 |

TABLET;ORAL

**CARBINOXAMINE MALEATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | CYPRESS PHARM | **4MG** | **A090417** | **001** | Aug 23, 2010 |
| **AA** | | INVAGEN PHARMS | **4MG** | **A090435** | **001** | Apr 15, 2010 |
| **AA** | **!** | MIKART | **4MG** | **A040442** | **001** | Mar 19, 2003 |
| **AA** | | MISSION PHARMACAL CO | **4MG** | **A090756** | **001** | May 27, 2011 |
| **AA** | | VINTAGE PHARMS | **4MG** | **A040639** | **002** | May 30, 2008 |
| | | MIKART INC | 6MG | A207484 | 001 | May 31, 2016 |

CARBOPLATIN

INJECTABLE;IV (INFUSION)

**CARBOPLATIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | ACCORD HLTHCARE | **50MG/5ML (10MG/ML)** | **A206775** | **001** | Feb 09, 2017 |
| **AP** | | | **150MG/15ML (10MG/ML)** | **A206775** | **002** | Feb 09, 2017 |
| **AP** | | | **450MG/45ML (10MG/ML)** | **A206775** | **003** | Feb 09, 2017 |
| **AP** | | | **600MG/60ML (10MG/ML)** | **A206775** | **004** | Feb 09, 2017 |
| **AP** | | AKORN | **50MG/5ML (10MG/ML)** | **A090475** | **001** | Jul 29, 2009 |
| **AP** | | | **150MG/15ML (10MG/ML)** | **A090475** | **002** | Jul 29, 2009 |
| **AP** | | | **450MG/45ML (10MG/ML)** | **A090475** | **003** | Jul 29, 2009 |
| **AP** | | | **600MG/60ML (10MG/ML)** | **A091268** | **002** | Jul 28, 2010 |
| **AP** | | CIPLA LTD | **50MG/5ML (10MG/ML)** | **A077861** | **001** | Jan 18, 2007 |
| **AP** | | | **150MG/15ML (10MG/ML)** | **A077861** | **002** | Jan 18, 2007 |
| **AP** | | | **450MG/45ML (10MG/ML)** | **A077861** | **003** | Jan 18, 2007 |
| **AP** | | | **600MG/60ML (10MG/ML)** | **A077861** | **004** | Jan 18, 2007 |
| **AP** | | FRESENIUS KABI ONCOL | **50MG/5ML (10MG/ML)** | **A077432** | **001** | Sep 29, 2006 |
| **AP** | | | **150MG/15ML (10MG/ML)** | **A077432** | **002** | Sep 29, 2006 |
| **AP** | | | **450MG/45ML (10MG/ML)** | **A077432** | **003** | Sep 29, 2006 |
| **AP** | | FRESENIUS KABI USA | **450MG/45ML (10MG/ML)** | **A077247** | **003** | Oct 21, 2004 |
| **AP** | | | **450MG/45ML (10MG/ML)** | **A077266** | **003** | Feb 15, 2006 |
| **AP** | | | **600MG/60ML (10MG/ML)** | **A077266** | **004** | Feb 15, 2006 |
| **AP** | | GLAND PHARMA LTD | **50MG/5ML (10MG/ML)** | **A207324** | **001** | Feb 15, 2017 |
| **AP** | | | **150MG/15ML (10MG/ML)** | **A207324** | **002** | Feb 15, 2017 |
| **AP** | | | **450MG/45ML (10MG/ML)** | **A207324** | **003** | Feb 15, 2017 |
| **AP** | | | **600MG/60ML (10MG/ML)** | **A207324** | **004** | Feb 15, 2017 |
| **AP** | | HOSPIRA | **50MG/5ML (10MG/ML)** | **A076517** | **001** | Oct 14, 2004 |
| **AP** | | | **150MG/15ML (10MG/ML)** | **A076517** | **002** | Oct 14, 2004 |
| **AP** | | | **450MG/45ML (10MG/ML)** | **A076517** | **003** | Oct 14, 2004 |
| **AP** | | | **600MG/60ML (10MG/ML)** | **A077059** | **001** | Nov 23, 2004 |
| **AP** | | INGENUS PHARMS LLC | **50MG/5ML (10MG/ML)** | **A208487** | **001** | Apr 26, 2017 |
| **AP** | | | **150MG/15ML (10MG/ML)** | **A208487** | **002** | Apr 26, 2017 |
| **AP** | | | **450MG/45ML (10MG/ML)** | **A208487** | **003** | Apr 26, 2017 |
| **AP** | | | **600MG/60ML (10MG/ML)** | **A208487** | **004** | Apr 26, 2017 |
| **AP** | | MYLAN INSTITUTIONAL | **50MG/5ML (10MG/ML)** | **A077998** | **001** | Apr 24, 2007 |
| **AP** | | | **150MG/15ML (10MG/ML)** | **A077998** | **002** | Apr 24, 2007 |
| **AP** | | | **450MG/45ML (10MG/ML)** | **A077998** | **003** | Apr 24, 2007 |
| **AP** | | MYLAN LABS LTD | **50MG/5ML (10MG/ML)** | **A091063** | **001** | Nov 09, 2011 |
| **AP** | | | **150MG/15ML (10MG/ML)** | **A091063** | **002** | Nov 09, 2011 |
| **AP** | | | **450MG/45ML (10MG/ML)** | **A091063** | **003** | Nov 09, 2011 |
| **AP** | | | **600MG/60ML (10MG/ML)** | **A091063** | **004** | Nov 09, 2011 |

CARBOPLATIN

INJECTABLE;IV (INFUSION)

**CARBOPLATIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | NANJING KING-FRIEND | **50MG/5ML (10MG/ML)** | **A077096** | **001** | Jun 14, 2005 |
| **AP** | | | **150MG/15ML (10MG/ML)** | **A077096** | **002** | Jun 14, 2005 |
| **AP** | | | **450MG/45ML (10MG/ML)** | **A077096** | **003** | Jun 14, 2005 |
| **AP** | | | **600MG/60ML (10MG/ML)** | **A077096** | **004** | Jun 03, 2013 |
| **AP** | ! | PHARMACHEMIE BV | **50MG/5ML (10MG/ML)** | **A077269** | **001** | Oct 14, 2004 |
| **AP** | ! | | **150MG/15ML (10MG/ML)** | **A077269** | **002** | Oct 14, 2004 |
| **AP** | ! | | **450MG/45ML (10MG/ML)** | **A077269** | **003** | Oct 14, 2004 |
| **AP** | ! | | **600MG/60ML (10MG/ML)** | **A077269** | **004** | Dec 28, 2007 |
| **AP** | | PLIVA LACHEMA | **50MG/5ML (10MG/ML)** | **A078631** | **001** | Dec 02, 2008 |
| **AP** | | | **150MG/15ML (10MG/ML)** | **A078631** | **002** | Dec 02, 2008 |
| **AP** | | | **450MG/45ML (10MG/ML)** | **A078631** | **003** | Dec 02, 2008 |
| **AP** | | | **600MG/60ML (10MG/ML)** | **A078631** | **004** | Dec 02, 2008 |
| **AP** | | SANDOZ INC | **50MG/5ML (10MG/ML)** | **A078280** | **001** | May 08, 2008 |
| **AP** | | | **150MG/15ML (10MG/ML)** | **A078280** | **002** | May 08, 2008 |
| **AP** | | | **450MG/45ML (10MG/ML)** | **A078280** | **003** | May 08, 2008 |
| **AP** | | SANJA PHARMS CO | **50MG/5ML (10MG/ML)** | **A205487** | **001** | Mar 28, 2016 |
| **AP** | | | **150MG/15ML (10MG/ML)** | **A205487** | **002** | Mar 28, 2016 |
| **AP** | | | **450MG/45ML (10MG/ML)** | **A205487** | **003** | Mar 28, 2016 |
| **AP** | | SUN PHARMA GLOBAL | **50MG/5ML (10MG/ML)** | **A077926** | **001** | Sep 19, 2008 |
| **AP** | | | **150MG/15ML (10MG/ML)** | **A077926** | **002** | Sep 19, 2008 |
| **AP** | | | **450MG/45ML (10MG/ML)** | **A077926** | **003** | Sep 19, 2008 |
| **AP** | ! | TEVA PHARMS USA | **50MG/5ML (10MG/ML)** | **A077139** | **001** | Sep 21, 2005 |
| **AP** | ! | | **150MG/15ML (10MG/ML)** | **A077139** | **002** | Sep 21, 2005 |
| **AP** | ! | | **450MG/45ML (10MG/ML)** | **A077139** | **003** | Sep 21, 2005 |
| **AP** | ! | | **600MG/60ML (10MG/ML)** | **A077139** | **004** | Sep 21, 2005 |
| **AP** | | WEST-WARD PHARMS INT | **50MG/5ML (10MG/ML)** | **A077244** | **001** | Oct 15, 2004 |
| **AP** | | | **150MG/15ML (10MG/ML)** | **A077244** | **002** | Oct 15, 2004 |
| **AP** | | | **450MG/45ML (10MG/ML)** | **A077244** | **003** | Oct 15, 2004 |
| **AP** | | | **600MG/60ML (10MG/ML)** | **A077244** | **004** | Jan 20, 2006 |
| | ! | MYLAN LABS LTD | 1GM/100ML (10MG/ML) | A091478 | 001 | Nov 23, 2011 |

CARBOPROST TROMETHAMINE

INJECTABLE;INJECTION

HEMABATE

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | PHARMACIA AND UPJOHN | EQ 0.25MG BASE/ML | N017989 | 001 | |

CARFILZOMIB

POWDER;INTRAVENOUS

KYPROLIS

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | ONYX THERAP | 30MG/VIAL | N202714 | 002 | Jun 03, 2016 |
| | +! | | 60MG/VIAL | N202714 | 001 | Jul 20, 2012 |

CARGLUMIC ACID

TABLET;ORAL

CARBAGLU

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ORPHAN EUROPE | 200MG | N022562 | 001 | Mar 18, 2010 |

CARIPRAZINE HYDROCHLORIDE

CAPSULE;ORAL

VRAYLAR

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | FOREST RES INST INC | EQ 1.5MG BASE | N204370 | 001 | Sep 17, 2015 |
| | + | | EQ 3MG BASE | N204370 | 002 | Sep 17, 2015 |
| | + | | EQ 4.5MG BASE | N204370 | 003 | Sep 17, 2015 |
| | +! | | EQ 6MG BASE | N204370 | 004 | Sep 17, 2015 |

CARISOPRODOL

TABLET;ORAL

**CARISOPRODOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | ACCELRX LABS | **350MG** | **A040576** | **001** | Jun 07, 2005 |
| **AA** | | AUROBINDO PHARMA | **350MG** | **A040792** | **001** | Aug 06, 2009 |
| **AA** | | HIKMA INTL PHARMS | **350MG** | **A040124** | **001** | Jan 24, 1996 |
| **AA** | | INGENUS PHARMS NJ | **350MG** | **A040823** | **001** | Oct 22, 2008 |
| **AA** | | NATCO PHARMA LTD | **350MG** | **A090988** | **001** | Oct 28, 2014 |
| **AA** | | ORIENT PHARMA CO LTD | **350MG** | **A205085** | **001** | Oct 28, 2014 |
| **AA** | | SCIEGEN PHARMS INC | **350MG** | **A203374** | **001** | Jan 27, 2014 |
| **AA** | | STRIDES PHARMA | **350MG** | **A205513** | **002** | Nov 12, 2015 |
| **AA** | | SUN PHARM INDUSTRIES | **350MG** | **A089346** | **001** | Oct 17, 1991 |
| **AA** | | VINTAGE PHARMS | **350MG** | **A040245** | **001** | Sep 08, 1997 |
| **AA** | | WATSON LABS | **350MG** | **A087499** | **001** | Apr 20, 1982 |

| | | | | | | |
|---|---|---|---|---|---|---|
| CARISOPRODOL | | | | | | |
| TABLET;ORAL | | | | | | |
| **CARISOPRODOL** | | | | | | |
| **AA** | | WILSHIRE PHARMS INC | **350MG** | **A205126** | **002** | Jul 08, 2015 |
| **SOMA** | | | | | | |
| **AA** | + | MYLAN SPECIALITY LP | **350MG** | **N011792** | **001** | |
| **CARISOPRODOL** | | | | | | |
| **AB** | | AUROBINDO PHARMA | **250MG** | **A040792** | **002** | Nov 08, 2016 |
| **AB** | | NOSTRUM LABS INC | **250MG** | **A207237** | **001** | May 11, 2017 |
| **AB** | | STRIDES PHARMA | **250MG** | **A205513** | **001** | Nov 12, 2015 |
| **AB** | | WILSHIRE PHARMS INC | **250MG** | **A205126** | **001** | Jul 08, 2015 |
| **SOMA** | | | | | | |
| **AB** | **+!** | MYLAN SPECIALITY LP | **250MG** | **N011792** | **004** | Sep 13, 2007 |
| CARMUSTINE | | | | | | |
| IMPLANT;INTRACRANIAL | | | | | | |
| GLIADEL | | | | | | |
| | +! | ARBOR PHARMS LLC | 7.7MG | N020637 | 001 | Sep 23, 1996 |
| INJECTABLE;INJECTION | | | | | | |
| BICNU | | | | | | |
| | +! | EMCURE PHARMS LTD | 100MG/VIAL | N017422 | 001 | |
| CARTEOLOL HYDROCHLORIDE | | | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | | | |
| **CARTEOLOL HYDROCHLORIDE** | | | | | | |
| **AT** | | BAUSCH AND LOMB | **1%** | **A075546** | **001** | Jan 20, 2000 |
| **AT** | **!** | SANDOZ INC | **1%** | **A075476** | **001** | Jan 03, 2000 |
| CARVEDILOL | | | | | | |
| TABLET;ORAL | | | | | | |
| **CARVEDILOL** | | | | | | |
| **AB** | | APOTEX INC | **3.125MG** | **A078165** | **001** | Sep 05, 2007 |
| **AB** | | | **6.25MG** | **A078165** | **002** | Sep 05, 2007 |
| **AB** | | | **12.5MG** | **A078165** | **003** | Sep 05, 2007 |
| **AB** | | | **25MG** | **A078165** | **004** | Sep 05, 2007 |
| **AB** | | AUROBINDO PHARMA | **3.125MG** | **A078332** | **001** | Sep 05, 2007 |
| **AB** | | | **6.25MG** | **A078332** | **002** | Sep 05, 2007 |
| **AB** | | | **12.5MG** | **A078332** | **003** | Sep 05, 2007 |
| **AB** | | | **25MG** | **A078332** | **004** | Sep 05, 2007 |
| **AB** | | BEXIMCO USA | **3.125MG** | **A078384** | **001** | Sep 05, 2007 |
| **AB** | | | **6.25MG** | **A078384** | **002** | Sep 05, 2007 |
| **AB** | | | **12.5MG** | **A078384** | **003** | Sep 05, 2007 |
| **AB** | | | **25MG** | **A078384** | **004** | Sep 05, 2007 |
| **AB** | | CIPLA LTD | **3.125MG** | **A077474** | **001** | Sep 05, 2007 |
| **AB** | | | **6.25MG** | **A077474** | **002** | Sep 05, 2007 |
| **AB** | | | **12.5MG** | **A077474** | **003** | Sep 05, 2007 |
| **AB** | | | **25MG** | **A077474** | **004** | Sep 05, 2007 |
| **AB** | | DR REDDYS LABS LTD | **3.125MG** | **A076649** | **001** | Sep 05, 2007 |
| **AB** | | | **6.25MG** | **A076649** | **002** | Sep 05, 2007 |
| **AB** | | | **12.5MG** | **A076649** | **003** | Sep 05, 2007 |
| **AB** | | | **25MG** | **A076649** | **004** | Sep 05, 2007 |
| **AB** | | GLENMARK GENERICS | **3.125MG** | **A078251** | **001** | Sep 05, 2007 |
| **AB** | | | **6.25MG** | **A078251** | **002** | Sep 05, 2007 |
| **AB** | | | **12.5MG** | **A078251** | **003** | Sep 05, 2007 |
| **AB** | | | **25MG** | **A078251** | **004** | Sep 05, 2007 |
| **AB** | | LUPIN | **3.125MG** | **A078217** | **001** | Sep 05, 2007 |
| **AB** | | | **6.25MG** | **A078217** | **002** | Sep 05, 2007 |
| **AB** | | | **12.5MG** | **A078217** | **003** | Sep 05, 2007 |
| **AB** | | | **25MG** | **A078217** | **004** | Sep 05, 2007 |
| **AB** | | MYLAN | **3.125MG** | **A077316** | **001** | Sep 05, 2007 |
| **AB** | | | **6.25MG** | **A077316** | **002** | Sep 05, 2007 |
| **AB** | | | **12.5MG** | **A077316** | **003** | Sep 05, 2007 |
| **AB** | | | **25MG** | **A077316** | **004** | Sep 05, 2007 |
| **AB** | | SANDOZ | **3.125MG** | **A078227** | **001** | Sep 05, 2007 |
| **AB** | | | **6.25MG** | **A078227** | **002** | Sep 05, 2007 |
| **AB** | | | **12.5MG** | **A078227** | **003** | Sep 05, 2007 |
| **AB** | | | **25MG** | **A078227** | **004** | Sep 05, 2007 |
| **AB** | | SUN PHARM INDS INC | **3.125MG** | **A077346** | **004** | Sep 05, 2007 |
| **AB** | | | **6.25MG** | **A077346** | **001** | Sep 05, 2007 |
| **AB** | | | **12.5MG** | **A077346** | **002** | Sep 05, 2007 |
| **AB** | | | **25MG** | **A077346** | **003** | Sep 05, 2007 |
| **AB** | | SUN PHARM INDS LTD | **3.125MG** | **A076989** | **001** | Sep 05, 2007 |
| **AB** | | | **6.25MG** | **A076989** | **002** | Sep 05, 2007 |
| **AB** | | | **12.5MG** | **A076989** | **003** | Sep 05, 2007 |

CARVEDILOL

TABLET;ORAL

**CARVEDILOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **25MG** | **A076989** | **004** | Sep 05, 2007 |
| **AB** | | TARO | **3.125MG** | **A077780** | **001** | Sep 05, 2007 |
| **AB** | | | **6.25MG** | **A077780** | **002** | Sep 05, 2007 |
| **AB** | | | **12.5MG** | **A077780** | **003** | Sep 05, 2007 |
| **AB** | | | **25MG** | **A077780** | **004** | Sep 05, 2007 |
| **AB** | | TEVA | **3.125MG** | **A076373** | **001** | Sep 05, 2007 |
| **AB** | | | **6.25MG** | **A076373** | **002** | Sep 05, 2007 |
| **AB** | | | **12.5MG** | **A076373** | **003** | Sep 05, 2007 |
| **AB** | | | **25MG** | **A076373** | **004** | Sep 05, 2007 |
| **AB** | | ZYDUS PHARMS USA INC | **3.125MG** | **A077614** | **004** | Sep 05, 2007 |
| **AB** | | | **6.25MG** | **A077614** | **001** | Sep 05, 2007 |
| **AB** | | | **12.5MG** | **A077614** | **002** | Sep 05, 2007 |
| **AB** | | | **25MG** | **A077614** | **003** | Sep 05, 2007 |

**COREG**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | SMITHKLINE BEECHAM | **3.125MG** | **N020297** | **004** | May 29, 1997 |
| **AB** | **+** | | **6.25MG** | **N020297** | **003** | Sep 14, 1995 |
| **AB** | **+!** | | **12.5MG** | **N020297** | **002** | Sep 14, 1995 |
| **AB** | **+** | | **25MG** | **N020297** | **001** | Sep 14, 1995 |

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE;ORAL

**CARVEDILOL PHOSPHATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | SUN PHARM INDUSTRIES | **10MG** | **A090132** | **001** | Oct 25, 2017 |
| **AB** | | | **20MG** | **A090132** | **002** | Oct 25, 2017 |
| **AB** | | | **40MG** | **A090132** | **003** | Oct 25, 2017 |
| **AB** | | | **80MG** | **A090132** | **004** | Oct 25, 2017 |

**COREG CR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | SMITHKLINE BEECHAM | **10MG** | **N022012** | **001** | Oct 20, 2006 |
| **AB** | **+** | | **20MG** | **N022012** | **002** | Oct 20, 2006 |
| **AB** | **+!** | | **40MG** | **N022012** | **003** | Oct 20, 2006 |
| **AB** | **+** | | **80MG** | **N022012** | **004** | Oct 20, 2006 |

CASPOFUNGIN ACETATE

POWDER;IV (INFUSION)

**CANCIDAS**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | MERCK | **50MG/VIAL** | **N021227** | **001** | Jan 26, 2001 |
| **AP** | **+!** | | **70MG/VIAL** | **N021227** | **002** | Jan 26, 2001 |

**CASPOFUNGIN ACETATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | FRESENIUS KABI USA | **50MG/VIAL** | **N206110** | **001** | Dec 30, 2016 |
| **AP** | | | **70MG/VIAL** | **N206110** | **002** | Dec 30, 2016 |
| **AP** | | GLAND PHARMA LTD | **50MG/VIAL** | **A207092** | **001** | Sep 29, 2017 |
| **AP** | | | **70MG/VIAL** | **A207092** | **002** | Sep 29, 2017 |
| **AP** | | MYLAN LABS LTD | **50MG/VIAL** | **A207650** | **001** | Sep 29, 2017 |
| **AP** | | | **70MG/VIAL** | **A207650** | **002** | Sep 29, 2017 |

CEFACLOR

CAPSULE;ORAL

**CEFACLOR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | HIKMA | **EQ 250MG BASE** | **A065350** | **001** | Apr 03, 2007 |
| **AB** | **!** | | **EQ 500MG BASE** | **A065350** | **002** | Apr 03, 2007 |
| **AB** | | YUNG SHIN PHARM | **EQ 250MG BASE** | **A065146** | **001** | Jan 22, 2004 |
| **AB** | | | **EQ 500MG BASE** | **A065146** | **002** | Jan 22, 2004 |

FOR SUSPENSION;ORAL

CEFACLOR

| | | | | | |
|---|---|---|---|---|---|
| | YUNG SHIN PHARM | EQ 125MG BASE/5ML | A065412 | 001 | Feb 17, 2012 |
| | | EQ 187MG BASE/5ML | A065412 | 002 | Feb 17, 2012 |
| | | EQ 250MG BASE/5ML | A065412 | 003 | Feb 17, 2012 |
| ! | | EQ 375MG BASE/5ML | A065412 | 004 | Feb 17, 2012 |

TABLET, EXTENDED RELEASE;ORAL

CEFACLOR

| | | | | | |
|---|---|---|---|---|---|
| | TEVA | EQ 375MG BASE | A065058 | 001 | Sep 04, 2002 |
| ! | | EQ 500MG BASE | A065058 | 002 | Sep 04, 2002 |

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE;ORAL

**CEFADROXIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AUROBINDO PHARMA | **EQ 500MG BASE** | **A065352** | **001** | Jan 25, 2007 |
| **AB** | | CSPC OUYI PHARM CO | **EQ 500MG BASE** | **A205072** | **001** | Jul 28, 2017 |
| **AB** | | HIKMA | **EQ 500MG BASE** | **A065311** | **001** | Feb 07, 2006 |
| **AB** | | LUPIN | **EQ 500MG BASE** | **A065392** | **001** | May 29, 2007 |

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE;ORAL

**CEFADROXIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ORCHID HLTHCARE | **EQ 500MG BASE** | **A065309** | **001** | Sep 18, 2006 |
| **AB** | ! | TEVA PHARMS | **EQ 500MG BASE** | **A065282** | **001** | Jan 20, 2006 |

FOR SUSPENSION;ORAL

**CEFADROXIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AUROBINDO | **EQ 250MG BASE/5ML** | **A065349** | **001** | Apr 25, 2013 |
| **AB** | | | **EQ 500MG BASE/5ML** | **A065349** | **002** | Apr 25, 2013 |
| **AB** | | HIKMA PHARMS | **EQ 250MG BASE/5ML** | **A091036** | **001** | Nov 28, 2012 |
| **AB** | | | **EQ 500MG BASE/5ML** | **A091036** | **002** | Nov 28, 2012 |
| **AB** | | LUPIN | **EQ 250MG BASE/5ML** | **A065396** | **001** | Feb 21, 2008 |
| **AB** | ! | | **EQ 500MG BASE/5ML** | **A065396** | **002** | Feb 21, 2008 |
| **AB** | | ORCHID HLTHCARE | **EQ 250MG BASE/5ML** | **A065307** | **002** | Oct 16, 2006 |
| **AB** | | | **EQ 500MG BASE/5ML** | **A065307** | **003** | Oct 16, 2006 |

TABLET;ORAL

**CEFADROXIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | HIKMA | **EQ 1GM BASE** | **A065260** | **001** | Mar 30, 2006 |
| **AB** | | ORCHID HLTHCARE | **EQ 1GM BASE** | **A065301** | **001** | Sep 18, 2006 |
| | ! | TEVA PHARMS | EQ 1GM BASE | A062774 | 001 | Apr 08, 1987 |

CEFAZOLIN SODIUM

INJECTABLE;INJECTION

**CEFAZOLIN SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | ACS DOBFAR | **EQ 500MG BASE/VIAL** | **A065303** | **001** | Oct 22, 2008 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A065303** | **002** | Oct 22, 2008 |
| **AP** | | | **EQ 10GM BASE/VIAL** | **A065306** | **001** | Oct 22, 2008 |
| **AP** | | HIKMA FARMACEUTICA | **EQ 500MG BASE/VIAL** | **A065047** | **001** | Sep 18, 2001 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A065047** | **002** | Sep 18, 2001 |
| **AP** | | | **EQ 10GM BASE/VIAL** | **A065143** | **001** | Oct 18, 2004 |
| **AP** | ! | HOSPIRA INC | **EQ 500MG BASE/VIAL** | **A065226** | **001** | Apr 21, 2005 |
| **AP** | ! | | **EQ 1GM BASE/VIAL** | **A065226** | **002** | Apr 21, 2005 |
| **AP** | ! | | **EQ 1GM BASE/VIAL** | **A065244** | **001** | Aug 12, 2005 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A201654** | **001** | Feb 03, 2016 |
| **AP** | ! | | **EQ 10GM BASE/VIAL** | **A065247** | **001** | Aug 12, 2005 |
| **AP** | | QILU PHARM CO LTD | **EQ 1GM BASE/VIAL** | **A203661** | **001** | Dec 28, 2015 |
| **AP** | | SANDOZ | **EQ 500MG BASE/VIAL** | **A062831** | **001** | Dec 09, 1988 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A062831** | **002** | Dec 09, 1988 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A065345** | **001** | May 09, 2007 |
| **AP** | | | **EQ 10GM BASE/VIAL** | **A062831** | **003** | Sep 25, 1992 |

**KEFZOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | ACS DOBFAR | **EQ 500MG BASE/VIAL** | **A061773** | **002** | |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A061773** | **003** | |
| **AP** | | | **EQ 10GM BASE/VIAL** | **A061773** | **004** | |

ANCEF IN PLASTIC CONTAINER

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | BAXTER HLTHCARE | EQ 10MG BASE/ML | A063002 | 001 | Mar 28, 1991 |
| | ! | | EQ 20MG BASE/ML | A063002 | 002 | Mar 28, 1991 |

CEFAZOLIN AND DEXTROSE

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | B BRAUN | EQ 1GM BASE/VIAL | N050779 | 002 | Jul 27, 2000 |
| | + | | EQ 2GM BASE/VIAL | N050779 | 003 | Jan 13, 2012 |

CEFAZOLIN SODIUM

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | ACS DOBFAR | EQ 20GM BASE/VIAL | A065306 | 002 | Aug 18, 2014 |
| | ! | SAMSON MEDCL | EQ 100GM BASE/VIAL | A065141 | 001 | Nov 29, 2006 |
| | ! | | EQ 300GM BASE/VIAL | A065141 | 002 | Nov 29, 2006 |

SOLUTION;INTRAVENOUS

CEFAZOLIN IN PLASTIC CONTAINER

| | | | | | | |
|---|---|---|---|---|---|---|
| | | BAXTER HLTHCARE CORP | EQ 2GM BASE/100ML (EQ 20MG BASE/ML) | N207131 | 001 | Aug 07, 2015 |

CEFDINIR

CAPSULE;ORAL

**CEFDINIR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AUROBINDO PHARMA | **300MG** | **A065434** | **001** | Jan 07, 2008 |
| **AB** | | LUPIN | **300MG** | **A065264** | **001** | May 19, 2006 |
| **AB** | | ORCHID HLTHCARE | **300MG** | **A065418** | **001** | Jul 18, 2007 |
| **AB** | ! | SANDOZ | **300MG** | **A065330** | **001** | Apr 06, 2007 |
| **AB** | | TEVA PHARMS | **300MG** | **A065368** | **001** | May 09, 2007 |

FOR SUSPENSION;ORAL

**CEFDINIR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AUROBINDO PHARMA | **125MG/5ML** | **A065473** | **001** | Dec 14, 2007 |
| **AB** | | | **250MG/5ML** | **A065473** | **002** | Dec 14, 2007 |
| **AB** | | LUPIN | **125MG/5ML** | **A065259** | **001** | May 31, 2006 |
| **AB** | | | **250MG/5ML** | **A065259** | **002** | May 07, 2007 |
| **AB** | | ORCHID HLTHCARE | **125MG/5ML** | **A065429** | **001** | Jul 18, 2007 |

CEFDINIR

FOR SUSPENSION;ORAL

**CEFDINIR**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | | **250MG/5ML** | **A065429** | **002** | Jul 18, 2007 |
| **AB** | SANDOZ | **125MG/5ML** | **A065337** | **001** | Apr 06, 2007 |
| **AB** ! | | **250MG/5ML** | **A065337** | **002** | Apr 06, 2007 |
| **AB** | TEVA PHARMS | **125MG/5ML** | **A065332** | **001** | May 04, 2007 |
| **AB** | | **250MG/5ML** | **A065332** | **002** | May 04, 2007 |

CEFEPIME HYDROCHLORIDE

INJECTABLE;INJECTION

**CEFEPIME HYDROCHLORIDE**

| | | | | | |
|---|---|---|---|---|---|
| **AP** | ACS DOBFAR | **EQ 1GM BASE/VIAL** | **A065441** | **001** | Mar 20, 2008 |
| **AP** | | **EQ 2GM BASE/VIAL** | **A065441** | **002** | Mar 20, 2008 |
| **AP** | HOSPIRA INC | **EQ 500MG BASE/VIAL** | **A065369** | **001** | Jun 18, 2007 |
| **AP** | | **EQ 1GM BASE/VIAL** | **A065369** | **002** | Jun 18, 2007 |
| **AP** | | **EQ 1GM BASE/VIAL** | **A202268** | **001** | Jul 30, 2012 |
| **AP** | | **EQ 2GM BASE/VIAL** | **A065369** | **003** | Jun 18, 2007 |
| **AP** | | **EQ 2GM BASE/VIAL** | **A202268** | **002** | Jul 30, 2012 |
| **AP** | QILU PHARM CO LTD | **EQ 500MG BASE/VIAL** | **A203704** | **001** | Feb 01, 2016 |
| **AP** | | **EQ 1GM BASE/VIAL** | **A203704** | **002** | Feb 01, 2016 |
| **AP** | | **EQ 2GM BASE/VIAL** | **A203704** | **003** | Feb 01, 2016 |
| **AP** | SAGENT PHARMS | **EQ 1GM BASE/VIAL** | **A091048** | **001** | Jan 04, 2017 |
| **AP** | | **EQ 2GM BASE/VIAL** | **A091048** | **002** | Jan 04, 2017 |

**MAXIPIME**

| | | | | | |
|---|---|---|---|---|---|
| **AP** **+!** | HOSPIRA INC | **EQ 500MG BASE/VIAL** | **N050679** | **001** | Jan 18, 1996 |
| **AP** **+!** | | **EQ 1GM BASE/VIAL** | **N050679** | **002** | Jan 18, 1996 |
| **AP** **+!** | | **EQ 2GM BASE/VIAL** | **N050679** | **003** | Jan 18, 1996 |

CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| | B BRAUN | EQ 1GM BASE/VIAL | N050821 | 001 | May 06, 2010 |
| | | EQ 2GM BASE/VIAL | N050821 | 002 | May 06, 2010 |

CEFEPIME IN PLASTIC CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| +! | BAXTER HLTHCARE | EQ 1GM BASE/50ML (EQ 20MG BASE/ML) | N050817 | 001 | Aug 05, 2008 |
| +! | | EQ 2GM BASE/100ML (EQ 20MG BASE/ML) | N050817 | 002 | Aug 05, 2008 |

CEFIXIME

CAPSULE;ORAL

SUPRAX

| | | | | | |
|---|---|---|---|---|---|
| +! | LUPIN LTD | 400MG | N203195 | 001 | Jun 01, 2012 |

FOR SUSPENSION;ORAL

**CEFIXIME**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | AUROBINDO PHARMA LTD | **100MG/5ML** | **A204835** | **001** | Apr 14, 2015 |
| **AB** | | **200MG/5ML** | **A204835** | **002** | Apr 14, 2015 |
| **AB** | BELCHER PHARMS LLC | **100MG/5ML** | **A206938** | **001** | Feb 06, 2017 |
| **AB** | | **200MG/5ML** | **A206938** | **002** | Feb 06, 2017 |
| **AB** | | **500MG/5ML** | **A206939** | **001** | Feb 06, 2017 |
| **AB** | SANDOZ INC | **100MG/5ML** | **A206144** | **001** | Nov 17, 2017 |
| **AB** | | **200MG/5ML** | **A206144** | **002** | Nov 17, 2017 |

**SUPRAX**

| | | | | | |
|---|---|---|---|---|---|
| **AB** **+!** | LUPIN LTD | **500MG/5ML** | **N202091** | **001** | Feb 20, 2013 |
| **AB** | LUPIN PHARMS | **100MG/5ML** | **A065129** | **001** | Feb 23, 2004 |
| **AB** | | **200MG/5ML** | **A065355** | **001** | Apr 10, 2007 |

TABLET;ORAL

SUPRAX

| | | | | | |
|---|---|---|---|---|---|
| ! | LUPIN PHARMS | 400MG | A065130 | 001 | Feb 12, 2004 |

TABLET, CHEWABLE;ORAL

SUPRAX

| | | | | | |
|---|---|---|---|---|---|
| | LUPIN LTD | 100MG | A065380 | 001 | Oct 25, 2010 |
| | | 150MG | A065380 | 002 | Oct 25, 2010 |
| ! | | 200MG | A065380 | 003 | Oct 25, 2010 |

CEFOTAXIME SODIUM

INJECTABLE;INJECTION

**CEFOTAXIME**

| | | | | | |
|---|---|---|---|---|---|
| **AP** | HIKMA | **EQ 500MG BASE/VIAL** | **A065072** | **001** | Nov 20, 2002 |
| **AP** | | **EQ 1GM BASE/VIAL** | **A065072** | **002** | Nov 20, 2002 |
| **AP** | | **EQ 2GM BASE/VIAL** | **A065072** | **003** | Nov 20, 2002 |
| **AP** | | **EQ 10GM BASE/VIAL** | **A065071** | **001** | Nov 20, 2002 |
| **AP** | WOCKHARDT | **EQ 1GM BASE/VIAL** | **A065197** | **001** | Aug 29, 2006 |

**CEFOTAXIME SODIUM**

| | | | | | |
|---|---|---|---|---|---|
| **AP** | HOSPIRA INC | **EQ 500MG BASE/VIAL** | **A065290** | **001** | Aug 11, 2006 |
| **AP** | | **EQ 1GM BASE/VIAL** | **A065290** | **002** | Aug 11, 2006 |
| **AP** | | **EQ 1GM BASE/VIAL** | **A065293** | **001** | Aug 10, 2006 |

CEFOTAXIME SODIUM

INJECTABLE;INJECTION

**CEFOTAXIME SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | | **EQ 1GM BASE/VIAL** | **A203132** | **001** | Feb 19, 2016 |
| **AP** | | | **EQ 2GM BASE/VIAL** | **A065290** | **003** | Aug 11, 2006 |
| **AP** | | | **EQ 2GM BASE/VIAL** | **A065293** | **002** | Aug 10, 2006 |
| **AP** | | | **EQ 2GM BASE/VIAL** | **A203132** | **002** | Feb 19, 2016 |
| **AP** | | | **EQ 10GM BASE/VIAL** | **A065292** | **001** | Aug 10, 2006 |
| **AP** | | LUPIN | **EQ 500MG BASE/VIAL** | **A065124** | **001** | Sep 24, 2003 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A065124** | **002** | Sep 24, 2003 |
| **AP** | | | **EQ 2GM BASE/VIAL** | **A065124** | **003** | Sep 24, 2003 |
| **AP** | | WOCKHARDT | **EQ 500MG BASE/VIAL** | **A065197** | **002** | Jun 20, 2008 |
| **AP** | | | **EQ 2GM BASE/VIAL** | **A065197** | **003** | Jun 20, 2008 |

**CLAFORAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | US PHARM HOLDINGS | **EQ 500MG BASE/VIAL** | **N050547** | **001** | |
| **AP** | **+!** | | **EQ 1GM BASE/VIAL** | **N050547** | **002** | |
| **AP** | **+!** | | **EQ 2GM BASE/VIAL** | **N050547** | **003** | |
| **AP** | **+!** | | **EQ 10GM BASE/VIAL** | **N050547** | **004** | Dec 29, 1983 |

CEFOTETAN DISODIUM

INJECTABLE;INJECTION

**CEFOTAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+** | TELIGENT | **EQ 1GM BASE/VIAL** | **N050588** | **001** | Dec 27, 1985 |
| **AP** | **+** | | **EQ 2GM BASE/VIAL** | **N050588** | **002** | Dec 27, 1985 |

**CEFOTETAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **!** | FRESENIUS KABI USA | **EQ 1GM BASE/VIAL** | **A065374** | **001** | Aug 09, 2007 |
| **AP** | **!** | | **EQ 2GM BASE/VIAL** | **A065374** | **002** | Aug 09, 2007 |
| **AP** | **!** | | **EQ 10GM BASE/VIAL** | **A065375** | **001** | Aug 09, 2007 |
| **AP** | | HIKMA FARMACEUTICA | **EQ 1GM BASE/VIAL** | **A091031** | **001** | Oct 26, 2011 |
| **AP** | | | **EQ 2GM BASE/VIAL** | **A091031** | **002** | Oct 26, 2011 |
| **AP** | | WEST-WARD PHARM CORP | **EQ 10GM BASE/VIAL** | **A091030** | **001** | Oct 26, 2011 |

CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| +! | B BRAUN | EQ 1GM BASE/VIAL | N065430 | 001 | Aug 09, 2007 |
| +! | | EQ 2GM BASE/VIAL | N065430 | 002 | Aug 09, 2007 |

CEFOXITIN SODIUM

INJECTABLE;INJECTION

**CEFOXITIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **!** | ACS DOBFAR | **EQ 1GM BASE/VIAL** | **A065414** | **001** | Jun 12, 2009 |
| **AP** | **!** | | **EQ 2GM BASE/VIAL** | **A065414** | **002** | Jun 12, 2009 |
| **AP** | **!** | | **EQ 10GM BASE/VIAL** | **A065415** | **001** | May 19, 2010 |
| **AP** | | HIKMA FARMACEUTICA | **EQ 1GM BASE/VIAL** | **A065238** | **001** | Mar 12, 2010 |
| **AP** | | | **EQ 2GM BASE/VIAL** | **A065238** | **002** | Mar 12, 2010 |
| **AP** | | | **EQ 10GM BASE/VIAL** | **A065239** | **001** | Mar 02, 2010 |
| **AP** | | HOSPIRA INC | **EQ 1GM BASE/VIAL** | **A065313** | **001** | Jan 23, 2006 |
| **AP** | | | **EQ 2GM BASE/VIAL** | **A065313** | **002** | Jan 23, 2006 |
| **AP** | | | **EQ 10GM BASE/VIAL** | **A065312** | **001** | Feb 13, 2006 |
| **AP** | | WEST-WARD PHARMS INT | **EQ 1GM BASE/VIAL** | **A065051** | **001** | Sep 11, 2000 |
| **AP** | | | **EQ 2GM BASE/VIAL** | **A065051** | **002** | Sep 11, 2000 |
| **AP** | | | **EQ 10GM BASE/VIAL** | **A065050** | **001** | Sep 11, 2000 |

**CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | B BRAUN | **EQ 1GM BASE/VIAL** | **N065214** | **001** | Mar 10, 2006 |
| **AP** | **+!** | | **EQ 2GM BASE/VIAL** | **N065214** | **002** | Mar 10, 2006 |

MEFOXIN IN PLASTIC CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| ! | MYLAN INSTITUTIONAL | EQ 20MG BASE/ML | A063182 | 001 | Jan 25, 1993 |
| ! | | EQ 40MG BASE/ML | A063182 | 002 | Jan 25, 1993 |

POWDER;IV (INFUSION)

CEFOXITIN IN PLASTIC CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| | SAMSON MEDCL | EQ 100GM BASE | A200938 | 001 | Nov 16, 2015 |

CEFPODOXIME PROXETIL

FOR SUSPENSION;ORAL

**CEFPODOXIME PROXETIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AUROBINDO PHARMA LTD | **EQ 50MG BASE/5ML** | **A065409** | **001** | Jun 08, 2007 |
| **AB** | | | **EQ 100MG BASE/5ML** | **A065409** | **002** | Jun 08, 2007 |
| **AB** | | SANDOZ | **EQ 50MG BASE/5ML** | **A090031** | **001** | Jan 14, 2009 |
| **AB** | **!** | | **EQ 100MG BASE/5ML** | **A090031** | **002** | Jan 14, 2009 |

TABLET;ORAL

**CEFPODOXIME PROXETIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AUROBINDO PHARMA | **EQ 100MG BASE** | **A065370** | **001** | Jun 11, 2007 |
| **AB** | | | **EQ 200MG BASE** | **A065370** | **002** | Jun 11, 2007 |

CEFPODOXIME PROXETIL

TABLET;ORAL

**CEFPODOXIME PROXETIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ORCHID HLTHCARE | **EQ 100MG BASE** | **A065388** | **001** | Nov 14, 2007 |
| **AB** | | | **EQ 200MG BASE** | **A065388** | **002** | Nov 14, 2007 |
| **AB** | | SANDOZ | **EQ 100MG BASE** | **A065462** | **001** | May 28, 2008 |
| **AB** | **!** | | **EQ 200MG BASE** | **A065462** | **002** | May 28, 2008 |

CEFPROZIL

FOR SUSPENSION;ORAL

**CEFPROZIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | APOTEX INC | **125MG/5ML** | **A065351** | **001** | Feb 29, 2012 |
| **AB** | | | **250MG/5ML** | **A065351** | **002** | Feb 29, 2012 |
| **AB** | | AUROBINDO PHARMA | **125MG/5ML** | **A065381** | **001** | Jan 30, 2007 |
| **AB** | | | **250MG/5ML** | **A065381** | **002** | Jan 30, 2007 |
| **AB** | | LUPIN | **125MG/5ML** | **A065261** | **001** | Dec 19, 2005 |
| **AB** | **!** | | **250MG/5ML** | **A065261** | **002** | Dec 19, 2005 |
| **AB** | | ORCHID HLTHCARE | **125MG/5ML** | **A065284** | **002** | Dec 30, 2005 |
| **AB** | | | **250MG/5ML** | **A065284** | **001** | Dec 30, 2005 |
| **AB** | | SANDOZ | **125MG/5ML** | **A065257** | **001** | Dec 08, 2005 |
| **AB** | | | **250MG/5ML** | **A065257** | **002** | Dec 08, 2005 |
| **AB** | | TEVA PHARMS | **125MG/5ML** | **A065236** | **001** | Dec 08, 2005 |
| **AB** | | | **250MG/5ML** | **A065236** | **002** | Dec 08, 2005 |

TABLET;ORAL

**CEFPROZIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | APOTEX INC | **250MG** | **A065327** | **001** | Mar 26, 2008 |
| **AB** | | | **500MG** | **A065327** | **002** | Mar 26, 2008 |
| **AB** | | AUROBINDO PHARMA LTD | **250MG** | **A065340** | **001** | May 24, 2007 |
| **AB** | | | **500MG** | **A065340** | **002** | May 24, 2007 |
| **AB** | | LUPIN | **250MG** | **A065276** | **001** | Dec 08, 2005 |
| **AB** | **!** | | **500MG** | **A065276** | **002** | Dec 08, 2005 |
| **AB** | | ORCHID HLTHCARE | **250MG** | **A065267** | **001** | Dec 19, 2005 |
| **AB** | | | **500MG** | **A065267** | **002** | Dec 19, 2005 |
| **AB** | | SANDOZ | **250MG** | **A065235** | **001** | Nov 14, 2005 |
| **AB** | | | **500MG** | **A065235** | **002** | Nov 14, 2005 |
| **AB** | | TEVA | **250MG** | **A065208** | **001** | Dec 06, 2005 |
| **AB** | | | **500MG** | **A065208** | **002** | Dec 06, 2005 |
| **AB** | | WOCKHARDT | **250MG** | **A065428** | **001** | Jun 14, 2007 |
| **AB** | | | **500MG** | **A065428** | **002** | Jun 14, 2007 |

CEFTAROLINE FOSAMIL

POWDER;IV (INFUSION)

TEFLARO

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | CEREXA | 400MG/VIAL | N200327 | 001 | Oct 29, 2010 |
| | +! | | 600MG/VIAL | N200327 | 002 | Oct 29, 2010 |

CEFTAZIDIME

INJECTABLE;INJECTION

**CEFTAZIDIME**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | ACS DOBFAR | **500MG/VIAL** | **A062640** | **001** | Nov 20, 1985 |
| **AP** | | | **1GM/VIAL** | **A062640** | **002** | Nov 20, 1985 |
| **AP** | | | **2GM/VIAL** | **A062640** | **003** | Nov 20, 1985 |
| **AP** | | | **6GM/VIAL** | **A062640** | **004** | Feb 03, 1992 |
| **AP** | | WOCKHARDT | **1GM/VIAL** | **A065196** | **001** | Oct 15, 2008 |

**FORTAZ**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | TELIGENT | **500MG/VIAL** | **N050578** | **001** | Jul 19, 1985 |
| **AP** | **+!** | | **1GM/VIAL** | **N050578** | **002** | Jul 19, 1985 |
| **AP** | **+!** | | **2GM/VIAL** | **N050578** | **003** | Jul 19, 1985 |
| **AP** | **+!** | | **6GM/VIAL** | **N050578** | **004** | Jul 19, 1985 |

**TAZICEF**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | HOSPIRA | **500MG/VIAL** | **A062662** | **001** | Mar 06, 1986 |
| **AP** | | | **1GM/VIAL** | **A062662** | **002** | Mar 06, 1986 |
| **AP** | | | **1GM/VIAL** | **A064032** | **001** | Oct 31, 1993 |
| **AP** | | | **2GM/VIAL** | **A062662** | **003** | Mar 06, 1986 |
| **AP** | | | **2GM/VIAL** | **A064032** | **002** | Oct 31, 1993 |
| **AP** | | | **6GM/VIAL** | **A062662** | **004** | Mar 06, 1986 |

CEFTAZIDIME IN DEXTROSE CONTAINER

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | B BRAUN | EQ 1GM BASE | N050823 | 001 | Jun 13, 2011 |
| | +! | | EQ 2GM BASE | N050823 | 002 | Jun 13, 2011 |

CEFTAZIDIME SODIUM

INJECTABLE;INJECTION

FORTAZ IN PLASTIC CONTAINER

| | | | | | | |
|---|---|---|---|---|---|---|
| +! | TELIGENT | EQ 20MG BASE/ML | N050634 | 002 | Apr 28, 1989 |
| +! | | EQ 40MG BASE/ML | N050634 | 003 | Apr 28, 1989 |

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM

POWDER;IV (INFUSION)

ZERBAXA

| | | | | | | |
|---|---|---|---|---|---|---|
| +! | CUBIST PHARMS LLC | EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL | N206829 | 001 | Dec 19, 2014 |

CEFTRIAXONE SODIUM

INJECTABLE;INJECTION

**CEFTRIAXONE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | ACS DOBFAR | **EQ 500MG BASE/VIAL** | **A065329** | **001** | Jul 24, 2008 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A065329** | **002** | Jul 24, 2008 |
| **AP** | | | **EQ 2GM BASE/VIAL** | **A065329** | **003** | Jul 24, 2008 |
| **AP** | | | **EQ 10GM BASE/VIAL** | **A065328** | **001** | Jul 24, 2008 |
| **AP** | | BEDFORD | **EQ 10GM BASE/VIAL** | **A065475** | **001** | Aug 18, 2008 |
| **AP** | | HOSPIRA INC | **EQ 10GM BASE/VIAL** | **A065232** | **001** | Aug 02, 2005 |
| **AP** | | LUPIN | **EQ 10GM BASE/VIAL** | **A065263** | **001** | Sep 12, 2006 |
| **AP** | **!** | SANDOZ | **EQ 10GM BASE/VIAL** | **A065168** | **001** | May 17, 2005 |
| **AP** | **!** | SANDOZ INC | **EQ 1GM BASE/VIAL** | **A065204** | **001** | May 03, 2005 |
| **AP** | **!** | | **EQ 2GM BASE/VIAL** | **A065204** | **002** | May 03, 2005 |
| **AP** | | WOCKHARDT | **EQ 1GM BASE/VIAL** | **A065180** | **001** | May 12, 2006 |

**CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | B BRAUN | **EQ 1GM BASE/VIAL** | **N050796** | **001** | Apr 20, 2005 |
| **AP** | **+!** | | **EQ 2GM BASE/VIAL** | **N050796** | **002** | Apr 20, 2005 |

**CEFTRIAXONE SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | HIKMA FARMACEUTICA | **EQ 10GM BASE/VIAL** | **A090701** | **001** | Oct 04, 2017 |
| **AP** | | SAGENT PHARMS | **EQ 10GM BASE/VIAL** | **A091117** | **001** | Jan 20, 2017 |

CEFTRIAXONE

| | | | | | | |
|---|---|---|---|---|---|---|
| | | SAMSON MEDCL | EQ 100GM BASE/VIAL | A090057 | 001 | Apr 25, 2014 |

CEFTRIAXONE IN PLASTIC CONTAINER

| | | | | | | |
|---|---|---|---|---|---|---|
| ! | | BAXTER HLTHCARE | EQ 20MG BASE/ML | A065224 | 001 | Aug 23, 2005 |
| ! | | | EQ 40MG BASE/ML | A065224 | 002 | Aug 23, 2005 |

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

**CEFTRIAXONE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AKORN INC | **EQ 250MG BASE/VIAL** | **A065305** | **001** | Jan 11, 2008 |
| **AP** | | | **EQ 500MG BASE/VIAL** | **A065305** | **002** | Jan 11, 2008 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A065305** | **003** | Jan 11, 2008 |
| **AP** | | | **EQ 2GM BASE/VIAL** | **A065305** | **004** | Jan 11, 2008 |
| **AP** | | HIKMA FARMACEUTICA | **EQ 250MG BASE/VIAL** | **A065342** | **001** | Jan 10, 2008 |
| **AP** | | | **EQ 500MG BASE/VIAL** | **A065342** | **002** | Jan 10, 2008 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A065342** | **003** | Jan 10, 2008 |
| **AP** | | | **EQ 2GM BASE/VIAL** | **A065342** | **004** | Jan 10, 2008 |
| **AP** | | HOSPIRA INC | **EQ 250MG BASE/VIAL** | **A065230** | **001** | Aug 02, 2005 |
| **AP** | | | **EQ 500MG BASE/VIAL** | **A065230** | **002** | Aug 02, 2005 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A065230** | **003** | Aug 02, 2005 |
| **AP** | | | **EQ 2GM BASE/VIAL** | **A065230** | **004** | Aug 02, 2005 |
| **AP** | | LUPIN | **EQ 250MG BASE/VIAL** | **A065125** | **001** | Sep 30, 2003 |
| **AP** | | | **EQ 500MG BASE/VIAL** | **A065125** | **002** | Sep 30, 2003 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A065125** | **003** | Sep 30, 2003 |
| **AP** | | | **EQ 2GM BASE/VIAL** | **A065125** | **004** | Sep 30, 2003 |
| **AP** | | QILU PHARM CO LTD | **EQ 250MG BASE/VIAL** | **A203702** | **001** | Jun 29, 2016 |
| **AP** | | | **EQ 500MG BASE/VIAL** | **A203702** | **002** | Jun 29, 2016 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A203702** | **003** | Jun 29, 2016 |
| **AP** | | | **EQ 2GM BASE/VIAL** | **A203702** | **004** | Jun 29, 2016 |
| **AP** | **!** | SANDOZ | **EQ 250MG BASE/VIAL** | **A065169** | **001** | May 09, 2005 |
| **AP** | **!** | | **EQ 500MG BASE/VIAL** | **A065169** | **002** | May 09, 2005 |
| **AP** | **!** | | **EQ 1GM BASE/VIAL** | **A065169** | **003** | May 09, 2005 |
| **AP** | **!** | | **EQ 2GM BASE/VIAL** | **A065169** | **004** | May 09, 2005 |
| **AP** | | WOCKHARDT | **EQ 250MG BASE/VIAL** | **A065391** | **001** | Apr 12, 2007 |
| **AP** | | | **EQ 500MG BASE/VIAL** | **A065391** | **002** | Apr 12, 2007 |
| **AP** | | | **EQ 2GM BASE/VIAL** | **A065391** | **003** | Apr 12, 2007 |

CEFUROXIME AXETIL

FOR SUSPENSION;ORAL

CEFTIN

| | | | | | | |
|---|---|---|---|---|---|---|
| + | | GLAXOSMITHKLINE | EQ 125MG BASE/5ML | N050672 | 001 | Jun 30, 1994 |
| +! | | | EQ 250MG BASE/5ML | N050672 | 002 | Apr 29, 1997 |

CEFUROXIME AXETIL

TABLET;ORAL

**CEFTIN**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **AB** | + | GLAXOSMITHKLINE | **EQ 125MG BASE** | **N050605** | **001** | Dec 28, 1987 |
| **AB** | + | | **EQ 250MG BASE** | **N050605** | **002** | Dec 28, 1987 |
| **AB** | +! | | **EQ 500MG BASE** | **N050605** | **003** | Dec 28, 1987 |

**CEFUROXIME AXETIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALKEM LABS LTD | **EQ 250MG BASE** | **A065496** | **001** | Jun 07, 2010 |
| **AB** | | | **EQ 500MG BASE** | **A065496** | **002** | Jun 07, 2010 |
| **AB** | | ANI PHARMS INC | **EQ 250MG BASE** | **A065190** | **001** | Oct 18, 2004 |
| **AB** | | | **EQ 500MG BASE** | **A065190** | **002** | Oct 18, 2004 |
| **AB** | | APOTEX | **EQ 250MG BASE** | **A065069** | **001** | Oct 02, 2002 |
| **AB** | | | **EQ 500MG BASE** | **A065069** | **002** | Oct 02, 2002 |
| **AB** | | AUROBINDO PHARMA LTD | **EQ 125MG BASE** | **A065308** | **001** | Mar 29, 2006 |
| **AB** | | | **EQ 250MG BASE** | **A065308** | **002** | Mar 29, 2006 |
| **AB** | | | **EQ 500MG BASE** | **A065308** | **003** | Mar 29, 2006 |
| **AB** | | LUPIN | **EQ 250MG BASE** | **A065135** | **001** | Jul 25, 2003 |
| **AB** | | | **EQ 500MG BASE** | **A065135** | **002** | Jul 25, 2003 |
| **AB** | | ORCHID HLTHCARE | **EQ 125MG BASE** | **A065359** | **001** | Feb 15, 2008 |
| **AB** | | | **EQ 250MG BASE** | **A065359** | **002** | Feb 15, 2008 |
| **AB** | | | **EQ 500MG BASE** | **A065359** | **003** | Feb 15, 2008 |
| **AB** | | WOCKHARDT | **EQ 125MG BASE** | **A065166** | **001** | Jul 29, 2005 |
| **AB** | | | **EQ 250MG BASE** | **A065166** | **002** | Jul 29, 2005 |
| **AB** | | | **EQ 500MG BASE** | **A065166** | **003** | Jul 29, 2005 |

CEFUROXIME SODIUM

INJECTABLE;INJECTION

**CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | +! | B BRAUN | **EQ 750MG BASE/VIAL** | **N050780** | **001** | Feb 21, 2001 |
| **AP** | +! | | **EQ 1.5GM BASE/VIAL** | **N050780** | **002** | Feb 21, 2001 |

**CEFUROXIME SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | ACS DOBFAR SPA | **EQ 1.5GM BASE/VIAL** | **A064125** | **002** | May 30, 1997 |
| **AP** | | | **EQ 7.5GM BASE/VIAL** | **A064124** | **001** | May 30, 1997 |
| **AP** | | HIKMA FARMACEUTICA | **EQ 1.5GM BASE/VIAL** | **A065048** | **002** | Jan 09, 2004 |
| **AP** | | | **EQ 7.5GM BASE/VIAL** | **A065046** | **001** | Jan 09, 2004 |
| **AP** | | HOSPIRA INC | **EQ 1.5GM BASE/VIAL** | **A065483** | **002** | Oct 15, 2008 |
| **AP** | | | **EQ 1.5GM BASE/VIAL** | **A065503** | **001** | Oct 15, 2008 |
| **AP** | | | **EQ 7.5GM BASE/VIAL** | **A065484** | **001** | Oct 15, 2008 |

**ZINACEF**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | +! | TELIGENT | **EQ 1.5GM BASE/VIAL** | **N050558** | **003** | Oct 19, 1983 |
| **AP** | +! | | **EQ 7.5GM BASE/VIAL** | **N050558** | **004** | Oct 23, 1986 |

ZINACEF IN PLASTIC CONTAINER

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | TELIGENT | EQ 30MG BASE/ML | N050643 | 002 | Apr 28, 1989 |

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

**CEFUROXIME SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACS DOBFAR SPA | **EQ 750MG BASE/VIAL** | **A064125** | **001** | May 30, 1997 |
| **AB** | | HIKMA FARMACEUTICA | **EQ 750MG BASE/VIAL** | **A065048** | **001** | Jan 09, 2004 |

**ZINACEF**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | +! | TELIGENT | **EQ 750MG BASE/VIAL** | **N050558** | **002** | Oct 19, 1983 |

**CEFUROXIME SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | HOSPIRA INC | **EQ 750MG BASE/VIAL** | **A065483** | **001** | Oct 15, 2008 |

CELECOXIB

CAPSULE;ORAL

**CELEBREX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | GD SEARLE | **50MG** | **N020998** | **004** | Dec 15, 2006 |
| **AB** | + | | **100MG** | **N020998** | **001** | Dec 31, 1998 |
| **AB** | + | | **200MG** | **N020998** | **002** | Dec 31, 1998 |
| **AB** | +! | | **400MG** | **N020998** | **003** | Aug 29, 2002 |

**CELECOXIB**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALEMBIC PHARMS LTD | **50MG** | **A204519** | **001** | Aug 21, 2015 |
| **AB** | | | **100MG** | **A204519** | **002** | Aug 21, 2015 |
| **AB** | | | **200MG** | **A204519** | **003** | Aug 21, 2015 |
| **AB** | | | **400MG** | **A204519** | **004** | Aug 21, 2015 |
| **AB** | | APOTEX INC | **50MG** | **A204197** | **001** | Jun 02, 2015 |
| **AB** | | | **100MG** | **A204197** | **002** | Jun 02, 2015 |
| **AB** | | | **200MG** | **A204197** | **003** | Jun 02, 2015 |
| **AB** | | AUROBINDO PHARMA LTD | **50MG** | **A206827** | **001** | Feb 01, 2016 |
| **AB** | | | **100MG** | **A206827** | **002** | Feb 01, 2016 |
| **AB** | | | **200MG** | **A206827** | **003** | Feb 01, 2016 |
| **AB** | | | **400MG** | **A206827** | **004** | Feb 01, 2016 |
| **AB** | | CIPLA LTD | **50MG** | **A207446** | **001** | Sep 23, 2015 |

CELECOXIB

CAPSULE;ORAL

**CELECOXIB**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | | **100MG** | **A207446** | **002** | Sep 23, 2015 |
| **AB** | | **200MG** | **A207446** | **003** | Sep 23, 2015 |
| **AB** | | **400MG** | **A207446** | **004** | Sep 23, 2015 |
| **AB** | JUBILANT GENERICS | **50MG** | **A207061** | **001** | Apr 04, 2017 |
| **AB** | | **100MG** | **A207061** | **002** | Apr 04, 2017 |
| **AB** | | **200MG** | **A207061** | **003** | Apr 04, 2017 |
| **AB** | | **400MG** | **A207061** | **004** | Apr 04, 2017 |
| **AB** | LUPIN LTD | **50MG** | **A202240** | **001** | Oct 29, 2014 |
| **AB** | | **100MG** | **A202240** | **002** | Jun 09, 2015 |
| **AB** | | **200MG** | **A202240** | **003** | Jun 09, 2015 |
| **AB** | | **400MG** | **A202240** | **004** | Jun 09, 2015 |
| **AB** | MACLEODS PHARMS LTD | **50MG** | **A204590** | **001** | Mar 16, 2016 |
| **AB** | | **100MG** | **A204590** | **002** | Mar 16, 2016 |
| **AB** | | **200MG** | **A204590** | **003** | Mar 16, 2016 |
| **AB** | | **400MG** | **A204590** | **004** | Mar 16, 2016 |
| **AB** | MYLAN PHARMS INC | **50MG** | **A078857** | **001** | May 30, 2014 |
| **AB** | | **100MG** | **A078857** | **002** | Feb 11, 2015 |
| **AB** | | **200MG** | **A078857** | **003** | Feb 11, 2015 |
| **AB** | | **400MG** | **A078857** | **004** | Feb 11, 2015 |
| **AB** | TEVA | **50MG** | **A076898** | **001** | May 30, 2014 |
| **AB** | | **100MG** | **A076898** | **002** | May 30, 2014 |
| **AB** | | **200MG** | **A076898** | **003** | May 30, 2014 |
| **AB** | | **400MG** | **A076898** | **004** | May 30, 2014 |
| **AB** | TORRENT PHARMS LTD | **50MG** | **A207677** | **001** | Dec 23, 2015 |
| **AB** | | **100MG** | **A207677** | **002** | Dec 23, 2015 |
| **AB** | | **200MG** | **A207677** | **003** | Dec 23, 2015 |
| **AB** | | **400MG** | **A207677** | **004** | Dec 23, 2015 |
| **AB** | WATSON LABS INC | **50MG** | **A200562** | **001** | Feb 11, 2015 |
| **AB** | | **100MG** | **A200562** | **002** | Feb 11, 2015 |
| **AB** | | **200MG** | **A200562** | **003** | Feb 11, 2015 |
| **AB** | | **400MG** | **A200562** | **004** | Feb 11, 2015 |

CEPHALEXIN

CAPSULE;ORAL

**CEPHALEXIN**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | ALKEM LABS LTD | **EQ 250MG BASE** | **A090836** | **001** | Dec 20, 2010 |
| **AB** | | **EQ 500MG BASE** | **A090836** | **002** | Dec 20, 2010 |
| **AB** | | **EQ 750MG BASE** | **A090836** | **004** | Mar 29, 2013 |
| **AB** | AUROBINDO PHARMA LTD | **EQ 250MG BASE** | **A065253** | **001** | Nov 16, 2005 |
| **AB** | | **EQ 500MG BASE** | **A065253** | **002** | Nov 16, 2005 |
| **AB** | BELCHER PHARMS | **EQ 250MG BASE** | **A062713** | **001** | Jul 15, 1988 |
| **AB** | | **EQ 500MG BASE** | **A062713** | **002** | Jul 15, 1988 |
| **AB** | HIKMA | **EQ 250MG BASE** | **A065215** | **001** | Jan 24, 2006 |
| **AB** | | **EQ 500MG BASE** | **A065215** | **002** | Jan 24, 2006 |
| **AB** | LUPIN | **EQ 250MG BASE** | **A065229** | **001** | Nov 25, 2005 |
| **AB** | | **EQ 500MG BASE** | **A065229** | **002** | Nov 25, 2005 |
| **AB** | ORCHID HLTHCARE | **EQ 250MG BASE** | **A065248** | **001** | Jun 28, 2005 |
| **AB** | | **EQ 500MG BASE** | **A065248** | **002** | Jun 28, 2005 |
| **AB** | SUN PHARM INDS (IN) | **EQ 250MG BASE** | **A062791** | **001** | Jun 11, 1987 |
| **AB** | | **EQ 500MG BASE** | **A062791** | **002** | Jun 11, 1987 |
| **AB** | TEVA | **EQ 250MG BASE** | **A062702** | **001** | Feb 13, 1987 |
| **AB** | | **EQ 500MG BASE** | **A062702** | **002** | Feb 13, 1987 |
| **AB** | YUNG SHIN PHARM | **EQ 250MG BASE** | **A065152** | **001** | Feb 24, 2005 |
| **AB** | | **EQ 500MG BASE** | **A065152** | **002** | Feb 24, 2005 |

**KEFLEX**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | **+** PRAGMA PHARMS LLC | **EQ 250MG BASE** | **N050405** | **002** | |
| **AB** | **+** | **EQ 500MG BASE** | **N050405** | **003** | |
| **AB** | **+!** | **EQ 750MG BASE** | **N050405** | **005** | May 12, 2006 |

CEPHALEXIN

| | | | | | |
|---|---|---|---|---|---|
| | ALKEM LABS LTD | EQ 333MG BASE | A090836 | 003 | Mar 29, 2013 |

FOR SUSPENSION;ORAL

**CEPHALEXIN**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | LUPIN | **EQ 125MG BASE/5ML** | **A065234** | **001** | Aug 17, 2005 |
| **AB** | | **EQ 250MG BASE/5ML** | **A065234** | **002** | Aug 17, 2005 |
| **AB** | ORCHID HLTHCARE | **EQ 125MG BASE/5ML** | **A065326** | **001** | Jul 10, 2006 |
| **AB** | | **EQ 250MG BASE/5ML** | **A065326** | **002** | Jul 10, 2006 |
| **AB** | TEVA | **EQ 125MG BASE/5ML** | **A062703** | **001** | Feb 13, 1987 |
| **AB** | **!** | **EQ 250MG BASE/5ML** | **A062703** | **002** | Feb 13, 1987 |
| **AB** | YUNG SHIN PHARM | **EQ 125MG BASE/5ML** | **A065336** | **001** | Jul 25, 2007 |

CEPHALEXIN
FOR SUSPENSION;ORAL
**CEPHALEXIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **EQ 250MG BASE/5ML** | **A065336** | **002** | Jul 25, 2007 |

TABLET;ORAL
CEPHALEXIN

| | | | | | |
|---|---|---|---|---|---|
| | TEVA | EQ 250MG BASE | A063023 | 001 | Jan 12, 1989 |
| ! | | EQ 500MG BASE | A063024 | 001 | Jan 12, 1989 |

CERITINIB
CAPSULE;ORAL
ZYKADIA

| | | | | | |
|---|---|---|---|---|---|
| +! | NOVARTIS PHARMS CORP | 150MG | N205755 | 001 | Apr 29, 2014 |

CETIRIZINE HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC
ZERVIATE

| | | | | | |
|---|---|---|---|---|---|
| +! | EYEVANCE PHARMS | EQ 0.24% BASE | N208694 | 001 | May 30, 2017 |

SYRUP;ORAL
**CETIRIZINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | ALLIED PHARMA INC | **5MG/5ML** | **A090191** | **001** | Nov 12, 2009 |
| **AA** | | AMNEAL PHARMS | **5MG/5ML** | **A090766** | **001** | Oct 07, 2009 |
| **AA** | | BIO PHARM INC | **5MG/5ML** | **A078870** | **001** | Apr 27, 2009 |
| **AA** | | BRECKENRIDGE PHARM | **5MG/5ML** | **A078488** | **001** | Oct 06, 2008 |
| **AA** | ! | PERRIGO R AND D | **5MG/5ML** | **A078398** | **001** | Jun 17, 2008 |
| **AA** | | SILARX | **5MG/5ML** | **A078876** | **001** | May 11, 2012 |
| **AA** | | TARO | **5MG/5ML** | **A076601** | **001** | Jun 20, 2008 |
| **AA** | | TEVA PHARMS | **5MG/5ML** | **A077279** | **001** | May 27, 2008 |
| **AA** | | VINTAGE | **5MG/5ML** | **A078496** | **001** | Sep 25, 2009 |

CETRORELIX
INJECTABLE;INJECTION
CETROTIDE

| | | | | | |
|---|---|---|---|---|---|
| +! | EMD SERONO INC | EQ 0.25MG BASE/ML | N021197 | 001 | Aug 11, 2000 |

CEVIMELINE HYDROCHLORIDE
CAPSULE;ORAL
**CEVIMELINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | APOTEX INC | **30MG** | **A091260** | **001** | Aug 25, 2011 |
| **AB** | | NOVEL LABS INC | **30MG** | **A204746** | **001** | Dec 30, 2016 |
| **AB** | | RISING PHARMS INC | **30MG** | **A203775** | **001** | Jun 04, 2014 |
| **AB** | | WEST-WARD PHARMS INT | **30MG** | **A091591** | **001** | Jul 08, 2013 |

**EVOXAC**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | DAIICHI SANKYO INC | **30MG** | **N020989** | **002** | Jan 11, 2000 |

CHENODIOL
TABLET;ORAL
CHENODIOL

| | | | | | |
|---|---|---|---|---|---|
| ! | NEXGEN PHARMA | 250MG | A091019 | 001 | Oct 22, 2009 |

CHLORAMBUCIL
TABLET;ORAL
LEUKERAN

| | | | | | |
|---|---|---|---|---|---|
| +! | ASPEN GLOBAL INC | 2MG | N010669 | 002 | |

CHLORAMPHENICOL SODIUM SUCCINATE
INJECTABLE;INJECTION
CHLORAMPHENICOL SODIUM SUCCINATE

| | | | | | |
|---|---|---|---|---|---|
| ! | FRESENIUS KABI USA | EQ 1GM BASE/VIAL | A062365 | 001 | Aug 25, 1982 |

CHLORDIAZEPOXIDE HYDROCHLORIDE
CAPSULE;ORAL
**CHLORDIAZEPOXIDE HYDROCHLORIDE**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | | BARR | **5MG** | **A084768** | **001** |
| **AB** | | | **10MG** | **A083116** | **001** |
| **AB** | | | **25MG** | **A084769** | **001** |

**LIBRIUM**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | | VALEANT PHARM INTL | **5MG** | **A085461** | **001** |
| **AB** | | | **10MG** | **A085472** | **001** |
| **AB** | ! | | **25MG** | **A085475** | **001** |

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

CAPSULE;ORAL

LIBRAX

| | | | | | |
|---|---|---|---|---|---|
| +! | VALEANT PHARMS | 5MG;2.5MG | N012750 | 001 | |

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL

**CHLORHEXIDINE GLUCONATE**

| | | | | | |
|---|---|---|---|---|---|
| **AT** | HI TECH PHARMA | **0.12%** | **A074356** | **001** | May 07, 1996 |
| **AT** | LYNE | **0.12%** | **A074291** | **001** | Dec 28, 1995 |
| **AT** | TEVA | **0.12%** | **A074522** | **001** | Dec 15, 1995 |
| **AT** | WOCKHARDT BIO AG | **0.12%** | **A075006** | **001** | Mar 03, 2004 |
| **AT** | XTTRIUM | **0.12%** | **A077789** | **001** | Jun 18, 2009 |

**PAROEX**

| | | | | | |
|---|---|---|---|---|---|
| **AT** | SUNSTAR AMERICAS | **0.12%** | **A076434** | **001** | Nov 29, 2005 |

**PERIDEX**

| | | | | | |
|---|---|---|---|---|---|
| **AT** **+!** | 3M | **0.12%** | **N019028** | **001** | Aug 13, 1986 |

**PERIOGARD**

| | | | | | |
|---|---|---|---|---|---|
| **AT** | COLGATE PALMOLIVE CO | **0.12%** | **A073695** | **001** | Jan 14, 1994 |
| **AT** | COLGATE-PALMOLIVE CO | **0.12%** | **A203212** | **001** | Jan 28, 2016 |

TABLET;DENTAL

PERIOCHIP

| | | | | | |
|---|---|---|---|---|---|
| +! | DEXCEL PHARMA | 2.5MG | N020774 | 001 | May 15, 1998 |

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

**CHLOROPROCAINE HYDROCHLORIDE**

| | | | | | |
|---|---|---|---|---|---|
| **AP** | HOSPIRA | **2%** | **A087447** | **001** | Apr 16, 1982 |
| **AP** | | **3%** | **A087446** | **001** | Apr 16, 1982 |
| **AP** | WEST-WARD PHARMS INT | **2%** | **A040273** | **001** | Sep 09, 1998 |
| **AP** | | **3%** | **A040273** | **002** | Sep 09, 1998 |

**NESACAINE**

| | | | | | |
|---|---|---|---|---|---|
| **AP** **+** | FRESENIUS KABI USA | **2%** | **N009435** | **002** | |

**NESACAINE-MPF**

| | | | | | |
|---|---|---|---|---|---|
| **AP** **+!** | FRESENIUS KABI USA | **2%** | **N009435** | **006** | May 02, 1996 |
| **AP** **+!** | | **3%** | **N009435** | **007** | May 02, 1996 |

NESACAINE

| | | | | | |
|---|---|---|---|---|---|
| +! | FRESENIUS KABI USA | 1% | N009435 | 001 | |

SOLUTION;INTRATHECAL

CLOROTEKAL

| | | | | | |
|---|---|---|---|---|---|
| + | B BRAUN MEDICAL INC | 50MG/5ML (10MG/ML) | N208791 | 001 | Sep 26, 2017 |

CHLOROQUINE PHOSPHATE

TABLET;ORAL

**CHLOROQUINE PHOSPHATE**

| | | | | | |
|---|---|---|---|---|---|
| **AA** **!** | HIKMA PHARMS | **EQ 150MG BASE** | **A083082** | **001** | |
| **AA** | | **EQ 300MG BASE** | **A083082** | **002** | Sep 17, 1999 |
| **AA** | IPCA LABS LTD | **EQ 150MG BASE** | **A090610** | **001** | Dec 03, 2009 |
| **AA** | | **EQ 300MG BASE** | **A090249** | **001** | Dec 03, 2009 |
| **AA** | NATCO PHARMA LTD | **EQ 150MG BASE** | **A091621** | **001** | Jan 21, 2011 |
| **AA** **!** | | **EQ 300MG BASE** | **A090612** | **001** | Jan 21, 2011 |

CHLOROTHIAZIDE

SUSPENSION;ORAL

DIURIL

| | | | | | |
|---|---|---|---|---|---|
| +! | SALIX PHARMS | 250MG/5ML | N011870 | 001 | |

TABLET;ORAL

CHLOROTHIAZIDE

| | | | | | |
|---|---|---|---|---|---|
| ! | MYLAN | 250MG | A084217 | 002 | |
| | | 500MG | A084217 | 001 | |

CHLOROTHIAZIDE SODIUM

INJECTABLE;INJECTION

**CHLOROTHIAZIDE SODIUM**

| | | | | | |
|---|---|---|---|---|---|
| **AP** | FRESENIUS KABI USA | **EQ 500MG BASE/VIAL** | **A090896** | **001** | Oct 16, 2009 |
| **AP** | LUITPOLD | **EQ 500MG BASE/VIAL** | **A202561** | **001** | Apr 22, 2013 |
| **AP** | MYLAN INSTITUTIONAL | **EQ 500MG BASE/VIAL** | **A202493** | **001** | Jun 18, 2014 |
| **AP** | SAGENT PHARMS | **EQ 500MG BASE/VIAL** | **A202462** | **001** | May 29, 2015 |
| **AP** | SUN PHARMA GLOBAL | **EQ 500MG BASE/VIAL** | **A091546** | **001** | Jul 26, 2011 |

**DIURIL**

| | | | | | |
|---|---|---|---|---|---|
| **AP** **+!** | OAK PHARMS AKORN | **EQ 500MG BASE/VIAL** | **N011145** | **005** | |

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

SOLUTION;ORAL

**HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | ACELLA PHARMS LLC | **4MG/5ML;5MG/5ML** | **A206891** | **001** | Jun 09, 2017 |

**VITUZ**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **+!** | CYPRESS PHARM | **4MG/5ML;5MG/5ML** | **N204307** | **001** | Feb 20, 2013 |

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

**HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | BIO-PHARM INC | **4MG/5ML;5MG/5ML;60MG/5ML** | **A206660** | **001** | May 15, 2017 |

**HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | PADDOCK LLC | **4MG/5ML;5MG/5ML;60MG/5ML** | **A204627** | **001** | Apr 29, 2014 |

**HYDROCODONE BITARTRATE,CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | MAYNE PHARMA INC | **4MG/5ML;5MG/5ML;60MG/5ML** | **A205657** | **001** | Aug 03, 2015 |

**ZUTRIPRO**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **+!** | CYPRESS PHARM | **4MG/5ML;5MG/5ML;60MG/5ML** | **N022439** | **001** | Jun 08, 2011 |

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

TUZISTRA XR

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | VERNALIS R AND D LTD | EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML | N207768 | 001 | Apr 30, 2015 |

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

CAPSULE, EXTENDED RELEASE;ORAL

TUSSICAPS

| | | | | | | |
|---|---|---|---|---|---|---|
| | | ECR PHARMA | EQ 4MG MALEATE;EQ 5MG BITARTRATE | A077273 | 002 | Sep 24, 2007 |
| | ! | | EQ 8MG MALEATE;EQ 10MG BITARTRATE | A077273 | 001 | Sep 24, 2007 |

SUSPENSION, EXTENDED RELEASE;ORAL

**HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | TRIS PHARMA INC | **EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML** | **A091632** | **001** | Oct 01, 2010 |

**HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | NEOS THERAP INC | **EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML** | **A091671** | **001** | Jun 29, 2012 |

**TUSSIONEX PENNKINETIC**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | UCB INC | **EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML** | **N019111** | **001** | Dec 31, 1987 |

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

CHLORPROMAZINE HYDROCHLORIDE

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | WEST-WARD PHARMS INT | 25MG/ML | A083329 | 001 | |

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

| | | | | | | |
|---|---|---|---|---|---|---|
| | | USL PHARMA | 10MG | A083386 | 001 | |
| | ! | | 25MG | A084112 | 001 | |
| | | | 50MG | A084113 | 001 | |
| | ! | | 100MG | A084114 | 001 | |
| | | | 200MG | A084115 | 001 | |

CHLORPROPAMIDE

TABLET;ORAL

**CHLORPROPAMIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ANI PHARMS INC | **100MG** | **A088921** | **001** | Apr 12, 1985 |
| **AB** | | | **250MG** | **A088922** | **001** | Apr 12, 1985 |
| **AB** | | MYLAN | **100MG** | **A088549** | **002** | Jun 01, 1984 |
| **AB** | | | **250MG** | **A088549** | **001** | Jun 01, 1984 |

**DIABINESE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | PFIZER | **100MG** | **N011641** | **003** | |
| **AB** | **+!** | | **250MG** | **N011641** | **006** | |

**GLUCAMIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ANI PHARMS INC | **250MG** | **A088641** | **001** | Oct 11, 1984 |

CHLORTHALIDONE

TABLET;ORAL

**CHLORTHALIDONE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | MYLAN | **25MG** | **A086831** | **002** | |
| **AB** | **!** | | **50MG** | **A086831** | **001** | |
| **AB** | | RICONPHARMA LLC | **25MG** | **A206904** | **001** | Mar 30, 2017 |
| **AB** | | | **50MG** | **A206904** | **002** | Mar 30, 2017 |
| **AB** | | SUN PHARM INDUSTRIES | **25MG** | **A089286** | **002** | Jul 21, 1986 |
| **AB** | | | **50MG** | **A089286** | **001** | Jul 21, 1986 |

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLORPRES

| | | | | | | |
|---|---|---|---|---|---|---|
| | | MYLAN | 15MG;0.1MG | A071325 | 003 | Feb 09, 1987 |
| | | | 15MG;0.2MG | A071325 | 002 | Feb 09, 1987 |
| | ! | | 15MG;0.3MG | A071325 | 001 | Feb 09, 1987 |

CHLORZOXAZONE

TABLET;ORAL

**CHLORZOXAZONE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | BARR | **500MG** | **A089895** | **001** | May 04, 1988 |
| **AA** | **!** | WATSON LABS | **500MG** | **A089859** | **001** | May 04, 1988 |
| | | MIKART | 375MG | A040861 | 001 | Jun 01, 2010 |
| | ! | | 750MG | A040861 | 002 | Jun 01, 2010 |
| | ! | MIKART INC | 250MG | A207483 | 001 | Jun 24, 2016 |

CHOLESTYRAMINE

POWDER;ORAL

**CHOLESTYRAMINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | PAR PHARM | **EQ 4GM RESIN/PACKET** | **A077204** | **001** | Aug 26, 2005 |
| **AB** | | | **EQ 4GM RESIN/SCOOPFUL** | **A077204** | **002** | Aug 26, 2005 |
| **AB** | **!** | SANDOZ | **EQ 4GM RESIN/PACKET** | **A074557** | **001** | Aug 15, 1996 |
| **AB** | | | **EQ 4GM RESIN/SCOOPFUL** | **A074557** | **002** | Aug 15, 1996 |

**CHOLESTYRAMINE LIGHT**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | PAR PHARM | **EQ 4GM RESIN/PACKET** | **A077203** | **001** | Aug 26, 2005 |
| **AB** | | | **EQ 4GM RESIN/SCOOPFUL** | **A077203** | **002** | Aug 26, 2005 |
| **AB** | **!** | SANDOZ | **EQ 4GM RESIN/PACKET** | **A074558** | **001** | Aug 15, 1996 |
| **AB** | | | **EQ 4GM RESIN/SCOOPFUL** | **A074558** | **002** | Aug 15, 1996 |
| **AB** | | ZYDUS PHARMS USA INC | **EQ 4GM RESIN/SCOOPFUL** | **A202902** | **001** | Apr 25, 2017 |

**PREVALITE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | UPSHER-SMITH LABS | **EQ 4GM RESIN/PACKET** | **A073263** | **001** | Feb 22, 1996 |
| **AB** | | | **EQ 4GM RESIN/SCOOPFUL** | **A073263** | **002** | Oct 30, 1997 |

CHOLIC ACID

CAPSULE;ORAL

CHOLBAM

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | RTRX | 50MG | N205750 | 001 | Mar 17, 2015 |
| | +! | | 250MG | N205750 | 002 | Mar 17, 2015 |

CHOLINE C-11

INJECTABLE;INTRAVENOUS

**CHOLINE C-11**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | GLOBAL ISOTOPES LLC | **4-33.1mCi/ML** | **A206319** | **001** | Nov 13, 2015 |
| **AP** | **+!** | MCPRF | **4-33.1mCi/ML** | **N203155** | **001** | Sep 12, 2012 |
| **AP** | | UCSF RODIOPHARM | **4-33.1mCi/ML** | **A208444** | **001** | Nov 20, 2017 |
| **AP** | | WA UNIV SCH MED | **4-33.1mCi/ML** | **A208413** | **001** | Jan 10, 2017 |
| | | UNIV TX MD ANDERSON | 4-100mCi/ML | A205690 | 001 | Oct 29, 2015 |

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE;ORAL

**FENOFIBRIC ACID**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS ELIZABETH | **EQ 45MG FENOFIBRIC ACID** | **A200920** | **001** | Oct 07, 2015 |
| **AB** | | | **EQ 135MG FENOFIBRIC ACID** | **A200920** | **002** | Oct 07, 2015 |
| **AB** | | ALEMBIC PHARMS LTD | **EQ 45MG FENOFIBRIC ACID** | **A208705** | **001** | May 12, 2017 |
| **AB** | | | **EQ 135MG FENOFIBRIC ACID** | **A208705** | **002** | May 12, 2017 |
| **AB** | | ANCHEN PHARMS | **EQ 45MG FENOFIBRIC ACID** | **A201573** | **002** | Jul 18, 2013 |
| **AB** | | | **EQ 135MG FENOFIBRIC ACID** | **A201573** | **001** | Jul 18, 2013 |
| **AB** | | IMPAX LABS INC | **EQ 45MG FENOFIBRIC ACID** | **A200264** | **001** | Sep 07, 2016 |
| **AB** | | | **EQ 135MG FENOFIBRIC ACID** | **A200264** | **002** | Sep 07, 2016 |
| **AB** | | LUPIN LTD | **EQ 45MG FENOFIBRIC ACID** | **A200750** | **001** | Dec 04, 2013 |
| **AB** | | | **EQ 135MG FENOFIBRIC ACID** | **A200750** | **002** | Dec 04, 2013 |
| **AB** | | MYLAN PHARMS INC | **EQ 45MG FENOFIBRIC ACID** | **A200913** | **001** | Mar 25, 2013 |
| **AB** | | | **EQ 135MG FENOFIBRIC ACID** | **A200913** | **002** | Mar 25, 2013 |

**TRILIPIX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | ABBVIE | **EQ 45MG FENOFIBRIC ACID** | **N022224** | **001** | Dec 15, 2008 |
| **AB** | **+!** | | **EQ 135MG FENOFIBRIC ACID** | **N022224** | **002** | Dec 15, 2008 |

CHORIOGONADOTROPIN ALFA

INJECTABLE;SUBCUTANEOUS

OVIDREL

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | EMD SERONO | EQ 0.25MG /0.5ML | N021149 | 002 | Oct 06, 2003 |

CHROMIC CHLORIDE

INJECTABLE;INJECTION

CHROMIC CHLORIDE IN PLASTIC CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| +! | HOSPIRA | EQ 0.004MG CHROMIUM/ML | N018961 | 001 | Jun 26, 1986 |

CICLESONIDE

AEROSOL, METERED;INHALATION

ALVESCO

| | | | | | |
|---|---|---|---|---|---|
| +! | ASTRAZENECA PHARMS | 0.08MG/INH | N021658 | 002 | Jan 10, 2008 |
| +! | | 0.16MG/INH | N021658 | 003 | Jan 10, 2008 |

AEROSOL, METERED;NASAL

ZETONNA

| | | | | | |
|---|---|---|---|---|---|
| +! | ASTRAZENECA PHARMS | 0.037MG/INH | N202129 | 001 | Jan 20, 2012 |

SPRAY, METERED;NASAL

OMNARIS

| | | | | | |
|---|---|---|---|---|---|
| +! | ASTRAZENECA PHARMS | 0.05MG/INH | N022004 | 001 | Oct 20, 2006 |

CICLOPIROX

CREAM;TOPICAL

**CICLOPIROX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | FOUGERA PHARMS | **0.77%** | **A076435** | **001** | Dec 29, 2004 |
| **AB** | | G AND W LABS INC | **0.77%** | **A078463** | **001** | Dec 20, 2010 |
| **AB** | | GLENMARK PHARMS | **0.77%** | **A090273** | **001** | Nov 10, 2009 |
| **AB** | | PERRIGO NEW YORK | **0.77%** | **A077364** | **001** | Mar 03, 2006 |
| **AB** | | TARO | **0.77%** | **A076790** | **001** | Apr 12, 2005 |

**LOPROX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | MEDIMETRIKS PHARMS | **0.77%** | **N018748** | **001** | Dec 30, 1982 |

GEL;TOPICAL

**CICLOPIROX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | CNTY LINE PHARMS | **0.77%** | **N020519** | **001** | Jul 21, 1997 |
| **AB** | | FOUGERA PHARMS | **0.77%** | **A077896** | **001** | Jun 10, 2008 |
| **AB** | | GLENMARK GENERICS | **0.77%** | **A091595** | **001** | Feb 29, 2012 |
| **AB** | | PADDOCK LLC | **0.77%** | **A078266** | **001** | Jan 07, 2009 |

SHAMPOO;TOPICAL

**CICLOPIROX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | ACTAVIS MID ATLANTIC | **1%** | **A090490** | **001** | Nov 24, 2009 |
| **AT** | | FOUGERA PHARMS | **1%** | **A090146** | **001** | May 25, 2010 |
| **AT** | | PERRIGO CO | **1%** | **A078594** | **001** | Feb 16, 2010 |
| **AT** | | TARO | **1%** | **A090269** | **001** | Feb 23, 2011 |

**LOPROX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **+!** | MEDICIS | **1%** | **N021159** | **001** | Feb 28, 2003 |

SOLUTION;TOPICAL

**CICLOPIROX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | ACTAVIS MID ATLANTIC | **8%** | **A078046** | **001** | Sep 18, 2007 |
| **AT** | | AKORN | **8%** | **A078975** | **001** | Feb 17, 2010 |
| **AT** | | APOTEX INC | **8%** | **A078172** | **001** | Sep 18, 2007 |
| **AT** | | CIPLA LTD | **8%** | **A078124** | **001** | Sep 18, 2007 |
| **AT** | | G AND W LABS | **8%** | **A078233** | **001** | Sep 18, 2007 |
| **AT** | | HI TECH PHARMA | **8%** | **A078270** | **001** | Sep 18, 2007 |
| **AT** | | PERRIGO NEW YORK | **8%** | **A077623** | **001** | Sep 18, 2007 |
| **AT** | | TARO PHARM INDS | **8%** | **A078144** | **001** | Sep 18, 2007 |
| **AT** | | TOLMAR | **8%** | **A077687** | **001** | Sep 18, 2007 |

**PENLAC**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **+!** | VALEANT BERMUDA | **8%** | **N021022** | **001** | Dec 17, 1999 |

SUSPENSION;TOPICAL

**CICLOPIROX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | FOUGERA PHARMS | **0.77%** | **A076422** | **001** | Aug 06, 2004 |
| **AB** | | PERRIGO NEW YORK | **0.77%** | **A077676** | **001** | Dec 15, 2006 |
| **AB** | | TARO | **0.77%** | **A077092** | **001** | Aug 10, 2005 |

**LOPROX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | MEDIMETRIKS PHARMS | **0.77%** | **N019824** | **001** | Dec 30, 1988 |

CIDOFOVIR

INJECTABLE;INJECTION

**CIDOFOVIR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | EMCURE PHARMS LTD | **EQ 75MG BASE/ML** | **A202501** | **001** | Jul 26, 2012 |
| **AP** | **!** | MYLAN INSTITUTIONAL | **EQ 75MG BASE/ML** | **A201276** | **001** | Jun 27, 2012 |

| | | | | | | |
|---|---|---|---|---|---|---|
| CILASTATIN SODIUM; IMIPENEM | | | | | | |
| POWDER;INTRAVENOUS | | | | | | |
| **IMIPENEM AND CILASTATIN** | | | | | | |
| **AP** | | ACS DOBFAR | **EQ 250MG BASE/VIAL;250MG/VIAL** | **A090577** | **001** | Dec 21, 2011 |
| **AP** | | | **EQ 500MG BASE/VIAL;500MG/VIAL** | **A090577** | **002** | Dec 21, 2011 |
| **AP** | | HOSPIRA INC | **EQ 250MG BASE/VIAL;250MG/VIAL** | **A090825** | **001** | Nov 16, 2011 |
| **AP** | | | **EQ 500MG BASE/VIAL;500MG/VIAL** | **A090825** | **002** | Nov 16, 2011 |
| **AP** | | | **EQ 500MG BASE/VIAL;500MG/VIAL** | **A091007** | **001** | Nov 16, 2011 |
| **PRIMAXIN** | | | | | | |
| **AP** | **+!** | MERCK | **EQ 250MG BASE/VIAL;250MG/VIAL** | **N050587** | **001** | Nov 26, 1985 |
| **AP** | **+!** | | **EQ 500MG BASE/VIAL;500MG/VIAL** | **N050587** | **002** | Nov 26, 1985 |
| CILOSTAZOL | | | | | | |
| TABLET;ORAL | | | | | | |
| **CILOSTAZOL** | | | | | | |
| **AB** | | APOTEX INC | **50MG** | **A077030** | **001** | Dec 10, 2004 |
| **AB** | | | **100MG** | **A077030** | **002** | Dec 10, 2004 |
| **AB** | | BRECKENRIDGE PHARM | **50MG** | **A077708** | **001** | Sep 28, 2009 |
| **AB** | | | **100MG** | **A077708** | **002** | Sep 28, 2009 |
| **AB** | | CHARTWELL RX | **50MG** | **A077722** | **001** | Sep 24, 2012 |
| **AB** | | | **100MG** | **A077831** | **001** | Sep 24, 2012 |
| **AB** | | SANDOZ | **50MG** | **A077310** | **001** | Nov 08, 2005 |
| **AB** | | | **100MG** | **A077021** | **001** | Nov 23, 2004 |
| **AB** | **!** | TEVA | **50MG** | **A077027** | **001** | Nov 24, 2004 |
| **AB** | **!** | | **100MG** | **A077027** | **002** | Nov 24, 2004 |
| **AB** | | WEST-WARD PHARMS INT | **50MG** | **A077024** | **001** | May 17, 2005 |
| **AB** | | | **100MG** | **A077024** | **002** | May 17, 2005 |
| CIMETIDINE | | | | | | |
| TABLET;ORAL | | | | | | |
| **CIMETIDINE** | | | | | | |
| **AB** | | APOTEX | **200MG** | **A074890** | **001** | Dec 18, 1998 |
| **AB** | | | **300MG** | **A074890** | **002** | Dec 18, 1998 |
| **AB** | | | **400MG** | **A074890** | **003** | Dec 18, 1998 |
| **AB** | | | **800MG** | **A074890** | **004** | Dec 18, 1998 |
| **AB** | | MYLAN | **200MG** | **A074246** | **001** | May 17, 1994 |
| **AB** | | | **300MG** | **A074246** | **002** | May 17, 1994 |
| **AB** | | | **400MG** | **A074246** | **003** | May 17, 1994 |
| **AB** | **!** | | **800MG** | **A074246** | **004** | May 17, 1994 |
| **AB** | | PLIVA | **800MG** | **A074566** | **001** | Feb 27, 1997 |
| **AB** | | TEVA | **200MG** | **A074151** | **001** | May 17, 1994 |
| **AB** | | | **300MG** | **A074151** | **002** | May 17, 1994 |
| **AB** | | | **400MG** | **A074151** | **003** | May 17, 1994 |
| **AB** | | | **800MG** | **A074463** | **001** | May 17, 1994 |
| CIMETIDINE HYDROCHLORIDE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| CIMETIDINE HYDROCHLORIDE | | | | | | |
| | | DAVA PHARMS INC | EQ 300MG BASE/2ML | A074428 | 001 | Apr 25, 1996 |
| SOLUTION;ORAL | | | | | | |
| **CIMETIDINE HYDROCHLORIDE** | | | | | | |
| **AA** | | ANI PHARMS INC | **EQ 300MG BASE/5ML** | **A074610** | **001** | Sep 26, 1996 |
| **AA** | **!** | HI TECH PHARMA | **EQ 300MG BASE/5ML** | **A074664** | **001** | Oct 28, 1997 |
| **AA** | | PHARM ASSOC | **EQ 300MG BASE/5ML** | **A074553** | **001** | Jan 27, 1997 |
| **AA** | | WOCKHARDT BIO AG | **EQ 300MG BASE/5ML** | **A074757** | **001** | Oct 17, 1997 |
| CINACALCET HYDROCHLORIDE | | | | | | |
| TABLET;ORAL | | | | | | |
| SENSIPAR | | | | | | |
| | + | AMGEN | EQ 30MG BASE | N021688 | 001 | Mar 08, 2004 |
| | + | | EQ 60MG BASE | N021688 | 002 | Mar 08, 2004 |
| | +! | | EQ 90MG BASE | N021688 | 003 | Mar 08, 2004 |
| CIPROFLOXACIN | | | | | | |
| FOR SUSPENSION;ORAL | | | | | | |
| **CIPRO** | | | | | | |
| **AB** | **+** | BAYER HLTHCARE | **250MG/5ML** | **N020780** | **001** | Sep 26, 1997 |
| **AB** | **+!** | | **500MG/5ML** | **N020780** | **002** | Sep 26, 1997 |
| **CIPROFLOXACIN** | | | | | | |
| **AB** | | LUPIN LTD | **250MG/5ML** | **A200563** | **001** | Mar 05, 2014 |
| **AB** | | | **500MG/5ML** | **A200563** | **002** | Mar 05, 2014 |
| INJECTABLE;INJECTION | | | | | | |
| **CIPROFLOXACIN** | | | | | | |
| **AP** | **!** | BAXTER HLTHCARE | **200MG/20ML (10MG/ML)** | **A078062** | **001** | Apr 29, 2008 |

| | | | | | | |
|---|---|---|---|---|---|---|
| CIPROFLOXACIN | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| **CIPROFLOXACIN** | | | | | | |
| | | CORP | | | | |
| **AP** | **!** | | **400MG/40ML (10MG/ML)** | **A078062** | **002** | Apr 29, 2008 |
| **AP** | | HIKMA FARMACEUTICA | **200MG/20ML (10MG/ML)** | **A076717** | **001** | Dec 22, 2009 |
| **AP** | | | **400MG/40ML (10MG/ML)** | **A076717** | **002** | Dec 22, 2009 |
| **AP** | | HOSPIRA | **200MG/20ML (10MG/ML)** | **A077245** | **001** | Aug 28, 2006 |
| **AP** | | | **400MG/40ML (10MG/ML)** | **A077245** | **002** | Aug 28, 2006 |
| **CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER** | | | | | | |
| **AP** | | ACS DOBFAR INFO SA | **200MG/100ML** | **A078252** | **001** | Mar 18, 2008 |
| **AP** | | | **400MG/200ML** | **A078252** | **002** | Mar 18, 2008 |
| **AP** | | BAXTER HLTHCARE CORP | **200MG/100ML** | **A078024** | **001** | Mar 18, 2008 |
| **AP** | | | **400MG/200ML** | **A078024** | **002** | Mar 18, 2008 |
| **AP** | | HIKMA FARMACEUTICA | **400MG/200ML** | **A078431** | **001** | Nov 18, 2009 |
| **AP** | **!** | HOSPIRA | **200MG/100ML** | **A077753** | **001** | Mar 18, 2008 |
| **AP** | **!** | | **400MG/200ML** | **A077753** | **002** | Mar 18, 2008 |
| INJECTABLE, SUSPENSION;OTIC | | | | | | |
| OTIPRIO | | | | | | |
| | +! | OTONOMY INC | 6% (60MG/ML) | N207986 | 001 | Dec 10, 2015 |
| CIPROFLOXACIN HYDROCHLORIDE | | | | | | |
| OINTMENT;OPHTHALMIC | | | | | | |
| CILOXAN | | | | | | |
| | +! | NOVARTIS PHARMS CORP | EQ 0.3% BASE | N020369 | 001 | Mar 30, 1998 |
| SOLUTION/DROPS;OPHTHALMIC | | | | | | |
| **CILOXAN** | | | | | | |
| **AT** | **+!** | NOVARTIS PHARMS CORP | **EQ 0.3% BASE** | **N019992** | **001** | Dec 31, 1990 |
| **CIPROFLOXACIN HYDROCHLORIDE** | | | | | | |
| **AT** | | AKORN INC | **EQ 0.3% BASE** | **A076555** | **001** | Dec 11, 2008 |
| **AT** | | FDC LTD | **EQ 0.3% BASE** | **A077568** | **001** | Jun 30, 2008 |
| **AT** | | RISING PHARMS INC | **EQ 0.3% BASE** | **A077689** | **001** | Dec 13, 2006 |
| **AT** | | TELIGENT | **EQ 0.3% BASE** | **A076754** | **001** | Jun 09, 2004 |
| **AT** | | WATSON LABS INC | **EQ 0.3% BASE** | **A076673** | **001** | Jan 21, 2005 |
| SOLUTION/DROPS;OTIC | | | | | | |
| CETRAXAL | | | | | | |
| | +! | WRASER PHARMS | EQ 0.2% BASE | N021918 | 001 | May 01, 2009 |
| TABLET;ORAL | | | | | | |
| **CIPRO** | | | | | | |
| **AB** | **+** | BAYER HLTHCARE | **EQ 100MG BASE** | **N019537** | **001** | Apr 08, 1996 |
| **AB** | **+** | | **EQ 250MG BASE** | **N019537** | **002** | Oct 22, 1987 |
| **AB** | **+!** | | **EQ 500MG BASE** | **N019537** | **003** | Oct 22, 1987 |
| **AB** | **+** | | **EQ 750MG BASE** | **N019537** | **004** | Oct 22, 1987 |
| **CIPROFLOXACIN HYDROCHLORIDE** | | | | | | |
| **AB** | | APOTEX | **EQ 250MG BASE** | **A076896** | **001** | Nov 04, 2004 |
| **AB** | | | **EQ 500MG BASE** | **A076896** | **002** | Nov 04, 2004 |
| **AB** | | | **EQ 750MG BASE** | **A076896** | **003** | Nov 04, 2004 |
| **AB** | | AUROBINDO PHARMA | **EQ 250MG BASE** | **A077859** | **001** | Apr 26, 2007 |
| **AB** | | | **EQ 500MG BASE** | **A077859** | **002** | Apr 26, 2007 |
| **AB** | | | **EQ 750MG BASE** | **A077859** | **003** | Apr 26, 2007 |
| **AB** | | CARLSBAD | **EQ 250MG BASE** | **A076126** | **002** | Jun 09, 2004 |
| **AB** | | | **EQ 500MG BASE** | **A076126** | **003** | Jun 09, 2004 |
| **AB** | | | **EQ 750MG BASE** | **A076126** | **004** | Jun 09, 2004 |
| **AB** | | DR REDDYS LABS LTD | **EQ 100MG BASE** | **A075593** | **002** | Jun 09, 2004 |
| **AB** | | | **EQ 250MG BASE** | **A075593** | **003** | Jun 09, 2004 |
| **AB** | | | **EQ 500MG BASE** | **A075593** | **004** | Jun 09, 2004 |
| **AB** | | | **EQ 750MG BASE** | **A075593** | **001** | Jun 09, 2004 |
| **AB** | | HIKMA | **EQ 250MG BASE** | **A076558** | **002** | Jun 09, 2004 |
| **AB** | | | **EQ 500MG BASE** | **A076558** | **003** | Jun 09, 2004 |
| **AB** | | | **EQ 750MG BASE** | **A076558** | **004** | Jun 09, 2004 |
| **AB** | | IVAX SUB TEVA PHARMS | **EQ 250MG BASE** | **A076089** | **002** | Jun 09, 2004 |
| **AB** | | | **EQ 500MG BASE** | **A076089** | **003** | Jun 09, 2004 |
| **AB** | | | **EQ 750MG BASE** | **A076089** | **004** | Jun 09, 2004 |
| **AB** | | MYLAN | **EQ 100MG BASE** | **A075817** | **001** | Jun 25, 2007 |
| **AB** | | | **EQ 250MG BASE** | **A075817** | **002** | Jun 09, 2004 |
| **AB** | | | **EQ 500MG BASE** | **A075817** | **003** | Jun 09, 2004 |
| **AB** | | | **EQ 750MG BASE** | **A075817** | **004** | Jun 09, 2004 |
| **AB** | | SUN PHARM INDS LTD | **EQ 250MG BASE** | **A075747** | **001** | Jun 09, 2004 |
| **AB** | | | **EQ 500MG BASE** | **A075747** | **002** | Jun 09, 2004 |
| **AB** | | | **EQ 750MG BASE** | **A075747** | **003** | Jun 09, 2004 |

CIPROFLOXACIN HYDROCHLORIDE

TABLET;ORAL

**CIPROFLOXACIN HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | TARO PHARM | **EQ 100MG BASE** | **A076912** | **001** | Feb 18, 2005 |
| **AB** | | | **EQ 250MG BASE** | **A076912** | **002** | Oct 06, 2004 |
| **AB** | | | **EQ 500MG BASE** | **A076912** | **003** | Oct 06, 2004 |
| **AB** | | | **EQ 750MG BASE** | **A076912** | **004** | Oct 06, 2004 |
| **AB** | | UNIQUE PHARM LABS | **EQ 250MG BASE** | **A076639** | **001** | Sep 10, 2004 |
| **AB** | | | **EQ 500MG BASE** | **A076639** | **002** | Sep 10, 2004 |
| **AB** | | | **EQ 750MG BASE** | **A076639** | **003** | Sep 10, 2004 |
| **AB** | | WATSON LABS | **EQ 100MG BASE** | **A076794** | **001** | Feb 10, 2005 |
| **AB** | | | **EQ 250MG BASE** | **A076794** | **002** | Jun 09, 2004 |
| **AB** | | | **EQ 500MG BASE** | **A076794** | **003** | Jun 09, 2004 |
| **AB** | | | **EQ 750MG BASE** | **A076794** | **004** | Jun 09, 2004 |

CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE

SOLUTION/DROPS;OTIC

OTOVEL

| | | | | | |
|---|---|---|---|---|---|
| +! | LABORATORIOS SALVAT | EQ 0.3% BASE;0.025% | N208251 | 001 | Apr 29, 2016 |

CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE

SUSPENSION/DROPS;OTIC

CIPRO HC

| | | | | | |
|---|---|---|---|---|---|
| +! | NOVARTIS PHARMS CORP | EQ 0.2% BASE;1% | N020805 | 001 | Feb 10, 1998 |

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

**CIPROFLOXACIN EXTENDED RELEASE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ANCHEN PHARMS | **212.6MG;EQ 287.5MG BASE** | **A078166** | **002** | Nov 27, 2007 |
| **AB** | | | **425.2MG;EQ 574.9MG BASE** | **A078166** | **001** | Nov 27, 2007 |
| **AB** | | DR REDDYS LABS LTD | **425.2MG;EQ 574.9MG BASE** | **A077701** | **001** | Mar 26, 2007 |
| **AB** | **!** | MYLAN PHARMS INC | **212.6MG;EQ 287.5MG BASE** | **A078183** | **001** | Mar 22, 2007 |
| **AB** | **!** | | **425.2MG;EQ 574.9MG BASE** | **A078183** | **002** | Mar 22, 2007 |

CIPROFLOXACIN; DEXAMETHASONE

SUSPENSION/DROPS;OTIC

CIPRODEX

| | | | | | |
|---|---|---|---|---|---|
| +! | NOVARTIS PHARMS CORP | 0.3%;0.1% | N021537 | 001 | Jul 18, 2003 |

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

**CISATRACURIUM BESYLATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | ACCORD HLTHCARE | **EQ 2MG BASE/ML** | **A205873** | **001** | Jun 16, 2017 |
| **AP** | | FRESENIUS KABI USA | **EQ 2MG BASE/ML** | **A203183** | **001** | Feb 26, 2015 |
| **AP** | | JIANGSU HENGRUI MED | **EQ 2MG BASE/ML** | **A209334** | **001** | Aug 30, 2017 |
| **AP** | | SANDOZ INC | **EQ 2MG BASE/ML** | **A200159** | **001** | Feb 03, 2012 |

**CISATRACURIUM BESYLATE PRESERVATIVE FREE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | ACCORD HLTHCARE | **EQ 2MG BASE/ML** | **A205872** | **001** | Jun 16, 2017 |
| **AP** | | | **EQ 10MG BASE/ML** | **A205872** | **002** | Jun 16, 2017 |
| **AP** | | FRESENIUS KABI USA | **EQ 2MG BASE/ML** | **A203182** | **001** | Feb 26, 2015 |
| **AP** | | | **EQ 10MG BASE/ML** | **A203182** | **002** | Feb 26, 2015 |
| **AP** | | JIANGSU HENGRUI MED | **EQ 2MG BASE/ML** | **A204960** | **001** | Jan 27, 2017 |
| **AP** | | | **EQ 10MG BASE/ML** | **A204960** | **002** | Sep 19, 2017 |
| **AP** | | SANDOZ INC | **EQ 2MG BASE/ML** | **A200154** | **001** | Feb 03, 2012 |
| **AP** | | | **EQ 10MG BASE/ML** | **A200154** | **002** | Feb 03, 2012 |

**NIMBEX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | ABBVIE | **EQ 2MG BASE/ML** | **N020551** | **001** | Dec 15, 1995 |

**NIMBEX PRESERVATIVE FREE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | ABBVIE | **EQ 2MG BASE/ML** | **N020551** | **003** | Dec 15, 1995 |
| **AP** | **+!** | | **EQ 10MG BASE/ML** | **N020551** | **002** | Dec 15, 1995 |

CISPLATIN

INJECTABLE;INJECTION

**CISPLATIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | ACCORD HLTHCARE | **1MG/ML** | **A206774** | **001** | Aug 18, 2015 |
| **AP** | **!** | FRESENIUS KABI USA | **1MG/ML** | **A074735** | **001** | Jul 16, 1999 |
| **AP** | | GLAND PHARMA LTD | **1MG/ML** | **A207323** | **001** | Mar 17, 2017 |
| **AP** | **+** | HQ SPCLT PHARMA | **1MG/ML** | **N018057** | **004** | Nov 08, 1988 |
| **AP** | | MYLAN LABS LTD | **1MG/ML** | **A091062** | **001** | Apr 18, 2012 |
| **AP** | | PHARMACHEMIE BV | **1MG/ML** | **A074656** | **001** | May 16, 2000 |
| **AP** | | WEST-WARD PHARMS INT | **1MG/ML** | **A075036** | **001** | Nov 07, 2000 |

CITALOPRAM HYDROBROMIDE

SOLUTION;ORAL

**CITALOPRAM HYDROBROMIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | AUROBINDO PHARMA LTD | **EQ 10MG BASE/5ML** | **A077812** | **001** | Aug 28, 2006 |
| **AA** | | HETERO LABS LTD III | **EQ 10MG BASE/5ML** | **A201450** | **001** | Dec 15, 2015 |
| **AA** | | SILARX | **EQ 10MG BASE/5ML** | **A077629** | **001** | Jun 15, 2006 |
| **AA** | ! | WEST-WARD PHARMS INT | **EQ 10MG BASE/5ML** | **A077043** | **001** | Dec 13, 2004 |

TABLET;ORAL

**CELEXA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | FOREST LABS | **EQ 10MG BASE** | **N020822** | **001** | Apr 27, 2000 |
| **AB** | + | | **EQ 20MG BASE** | **N020822** | **002** | Jul 17, 1998 |
| **AB** | +! | | **EQ 40MG BASE** | **N020822** | **003** | Jul 17, 1998 |

**CITALOPRAM HYDROBROMIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AMNEAL PHARMS NY | **EQ 10MG BASE** | **A077289** | **001** | Nov 30, 2006 |
| **AB** | | | **EQ 20MG BASE** | **A077289** | **002** | Nov 30, 2006 |
| **AB** | | | **EQ 40MG BASE** | **A077289** | **003** | Nov 30, 2006 |
| **AB** | | APOTEX INC | **EQ 10MG BASE** | **A077046** | **001** | Nov 24, 2004 |
| **AB** | | AUROBINDO | **EQ 10MG BASE** | **A077031** | **001** | Oct 28, 2004 |
| **AB** | | | **EQ 20MG BASE** | **A077031** | **002** | Oct 28, 2004 |
| **AB** | | | **EQ 40MG BASE** | **A077031** | **003** | Oct 28, 2004 |
| **AB** | | CIPLA LTD | **EQ 10MG BASE** | **A077044** | **001** | Nov 05, 2004 |
| **AB** | | | **EQ 20MG BASE** | **A077044** | **002** | Nov 05, 2004 |
| **AB** | | | **EQ 40MG BASE** | **A077044** | **003** | Nov 05, 2004 |
| **AB** | | DR REDDYS LABS LTD | **EQ 10MG BASE** | **A077038** | **001** | Oct 28, 2004 |
| **AB** | | | **EQ 20MG BASE** | **A077038** | **002** | Oct 28, 2004 |
| **AB** | | | **EQ 40MG BASE** | **A077038** | **003** | Oct 28, 2004 |
| **AB** | | EPIC PHARMA | **EQ 10MG BASE** | **A077045** | **003** | Apr 29, 2005 |
| **AB** | | | **EQ 20MG BASE** | **A077045** | **002** | Apr 29, 2005 |
| **AB** | | | **EQ 40MG BASE** | **A077045** | **001** | Apr 29, 2005 |
| **AB** | | G AND W LABS INC | **EQ 10MG BASE** | **A077048** | **001** | Nov 16, 2004 |
| **AB** | | | **EQ 20MG BASE** | **A077048** | **002** | Nov 16, 2004 |
| **AB** | | | **EQ 40MG BASE** | **A077048** | **003** | Nov 16, 2004 |
| **AB** | | GLENMARK GENERICS | **EQ 10MG BASE** | **A077654** | **001** | Feb 27, 2009 |
| **AB** | | | **EQ 20MG BASE** | **A077654** | **002** | Feb 27, 2009 |
| **AB** | | | **EQ 40MG BASE** | **A077654** | **003** | Feb 27, 2009 |
| **AB** | | INVAGEN PHARMS | **EQ 10MG BASE** | **A077534** | **001** | Oct 03, 2006 |
| **AB** | | | **EQ 20MG BASE** | **A077534** | **002** | Oct 03, 2006 |
| **AB** | | | **EQ 40MG BASE** | **A077534** | **003** | Oct 03, 2006 |
| **AB** | | JUBILANT GENERICS | **EQ 10MG BASE** | **A205407** | **001** | Dec 23, 2015 |
| **AB** | | | **EQ 20MG BASE** | **A205407** | **002** | Dec 23, 2015 |
| **AB** | | | **EQ 40MG BASE** | **A205407** | **003** | Dec 23, 2015 |
| **AB** | | MYLAN | **EQ 10MG BASE** | **A077042** | **001** | Nov 05, 2004 |
| **AB** | | | **EQ 20MG BASE** | **A077042** | **002** | Nov 05, 2004 |
| **AB** | | | **EQ 40MG BASE** | **A077042** | **003** | Nov 05, 2004 |
| **AB** | | PLIVA | **EQ 10MG BASE** | **A077232** | **001** | Oct 31, 2005 |
| **AB** | | | **EQ 20MG BASE** | **A077232** | **002** | Oct 31, 2005 |
| **AB** | | | **EQ 40MG BASE** | **A077232** | **003** | Oct 31, 2005 |
| **AB** | | SUN PHARM INDS INC | **EQ 10MG BASE** | **A077032** | **001** | Nov 12, 2004 |
| **AB** | | | **EQ 20MG BASE** | **A077032** | **002** | Nov 12, 2004 |
| **AB** | | | **EQ 40MG BASE** | **A077032** | **003** | Nov 12, 2004 |
| **AB** | | TORPHARM | **EQ 20MG BASE** | **A077046** | **002** | Nov 24, 2004 |
| **AB** | | | **EQ 40MG BASE** | **A077046** | **003** | Nov 24, 2004 |
| **AB** | | TORRENT PHARMS | **EQ 10MG BASE** | **A078216** | **001** | Mar 27, 2007 |
| **AB** | | | **EQ 20MG BASE** | **A078216** | **002** | Mar 27, 2007 |
| **AB** | | | **EQ 40MG BASE** | **A078216** | **003** | Mar 27, 2007 |

CITRIC ACID; GLUCONOLACTONE; MAGNESIUM CARBONATE

SOLUTION;IRRIGATION

RENACIDIN

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | UNITED GUARDIAN | 6.602GM/100ML;198MG/100ML;3.177GM/100ML | N019481 | 001 | Oct 02, 1990 |

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION;ORAL

PREPOPIK

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | FERRING PHARMS INC | 12GM/PACKET;3.5GM/PACKET;10MG/PACKET | N202535 | 001 | Jul 16, 2012 |

SOLUTION;ORAL

CLENPIQ

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | FERRING PHARMS INC | 12GM/160ML;3.5GM/160ML;10MG/160ML | N209589 | 001 | Nov 28, 2017 |

CITRIC ACID; UREA C-13

FOR SOLUTION, TABLET, FOR SOLUTION;ORAL

IDKIT:HP

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | EXALENZ BIOSCIENCE | N/A,4GM;75MG,N/A | N021314 | 001 | Dec 17, 2002 |

CLADRIBINE

INJECTABLE;INJECTION

**CLADRIBINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | ! | FRESENIUS KABI USA | **1MG/ML** | **A076571** | **001** | Apr 22, 2004 |
| **AP** | | MYLAN LABS LTD | **1MG/ML** | **A200510** | **001** | Oct 06, 2011 |
| **AP** | | WEST-WARD PHARMS INT | **1MG/ML** | **A075405** | **001** | Feb 28, 2000 |

CLARITHROMYCIN

FOR SUSPENSION;ORAL

**BIAXIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | ABBVIE | **125MG/5ML** | **N050698** | **001** | Dec 23, 1993 |
| **AB** | +! | | **250MG/5ML** | **N050698** | **002** | Dec 23, 1993 |

**CLARITHROMYCIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | SANDOZ | **125MG/5ML** | **A065283** | **002** | Sep 04, 2007 |
| **AB** | | | **250MG/5ML** | **A065283** | **003** | Sep 04, 2007 |
| **AB** | | SUN PHARM INDS LTD | **125MG/5ML** | **A065382** | **001** | Aug 30, 2007 |
| **AB** | | | **250MG/5ML** | **A065382** | **002** | Aug 30, 2007 |

TABLET;ORAL

**BIAXIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | +! | ABBVIE | **250MG** | **N050662** | **001** | Oct 31, 1991 |
| **AB** | +! | | **500MG** | **N050662** | **002** | Oct 31, 1991 |

**CLARITHROMYCIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALLIED PHARMA INC | **250MG** | **A202710** | **001** | Jun 10, 2013 |
| **AB** | | | **500MG** | **A202710** | **002** | Jun 10, 2013 |
| **AB** | | APOTEX CORP | **250MG** | **A065384** | **001** | Aug 20, 2007 |
| **AB** | | | **500MG** | **A065384** | **002** | Aug 20, 2007 |
| **AB** | | AUROBINDO | **250MG** | **A065489** | **001** | Jul 25, 2012 |
| **AB** | | | **500MG** | **A065489** | **002** | Jul 25, 2012 |
| **AB** | | HEC PHARM USA INC | **250MG** | **A203584** | **001** | Sep 28, 2015 |
| **AB** | | | **500MG** | **A203584** | **002** | Sep 28, 2015 |
| **AB** | | SANDOZ | **250MG** | **A065144** | **001** | Oct 18, 2005 |
| **AB** | | | **500MG** | **A065136** | **001** | Aug 25, 2005 |
| **AB** | | SUN PHARM INDS LTD | **250MG** | **A065174** | **001** | Sep 24, 2004 |
| **AB** | | | **500MG** | **A065174** | **002** | Sep 24, 2004 |
| **AB** | | TEVA | **250MG** | **A065155** | **001** | May 31, 2005 |
| **AB** | | | **500MG** | **A065155** | **002** | May 31, 2005 |
| **AB** | | WEST-WARD PHARMS INT | **250MG** | **A065178** | **002** | May 25, 2004 |
| **AB** | | | **500MG** | **A065178** | **001** | May 25, 2004 |
| **AB** | | WOCKHARDT | **250MG** | **A065266** | **001** | May 31, 2006 |
| **AB** | | | **500MG** | **A065266** | **002** | May 31, 2006 |

TABLET, EXTENDED RELEASE;ORAL

**CLARITHROMYCIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS LABS FL INC | **500MG** | **A065145** | **001** | Jun 24, 2004 |
| **AB** | | ALLIED PHARMA INC | **500MG** | **A203243** | **001** | Feb 29, 2016 |
| **AB** | | LUPIN LTD | **500MG** | **A202532** | **001** | Sep 15, 2015 |
| **AB** | ! | MAYNE PHARMA | **500MG** | **A065154** | **001** | May 18, 2005 |

CLEMASTINE FUMARATE

SYRUP;ORAL

**CLEMASTINE FUMARATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | ! | TEVA | **EQ 0.5MG BASE/5ML** | **A073399** | **001** | Jun 30, 1994 |
| **AA** | | WOCKHARDT | **EQ 0.5MG BASE/5ML** | **A074863** | **001** | Mar 13, 1998 |

TABLET;ORAL

CLEMASTINE FUMARATE

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | TEVA | 2.68MG | A073283 | 001 | Jan 31, 1992 |

CLEVIDIPINE

EMULSION;INTRAVENOUS

CLEVIPREX

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | CHIESI USA INC | 25MG/50ML (0.5MG/ML) | N022156 | 001 | Aug 01, 2008 |
| | +! | | 50MG/100ML (0.5MG/ML) | N022156 | 002 | Aug 01, 2008 |
| | +! | | 125MG/250ML (0.5MG/ML) | N022156 | 003 | Nov 08, 2013 |

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL

**CLEOCIN HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | PHARMACIA AND UPJOHN | **EQ 75MG BASE** | **N050162** | **001** | |
| **AB** | **+** | | **EQ 150MG BASE** | **N050162** | **002** | |
| **AB** | **+!** | | **EQ 300MG BASE** | **N050162** | **003** | Apr 14, 1988 |

**CLINDAMYCIN HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AUROBINDO PHARMA | **EQ 150MG BASE** | **A065442** | **001** | Aug 26, 2009 |
| **AB** | | | **EQ 300MG BASE** | **A065442** | **002** | Aug 26, 2009 |
| **AB** | | EPIC PHARMA LLC | **EQ 150MG BASE** | **A065194** | **001** | Mar 22, 2004 |
| **AB** | | | **EQ 300MG BASE** | **A065194** | **002** | Mar 22, 2004 |
| **AB** | | G AND W LABS INC | **EQ 150MG BASE** | **A063029** | **001** | Sep 20, 1989 |
| **AB** | | | **EQ 300MG BASE** | **A063029** | **002** | Aug 05, 2005 |
| **AB** | | LANNETT | **EQ 75MG BASE** | **A065243** | **002** | Aug 12, 2005 |
| **AB** | | | **EQ 300MG BASE** | **A065243** | **001** | Aug 12, 2005 |
| **AB** | | SUN PHARM INDS LTD | **EQ 150MG BASE** | **A065061** | **001** | Feb 02, 2001 |
| **AB** | | | **EQ 300MG BASE** | **A065061** | **002** | Feb 02, 2001 |
| **AB** | | WATSON LABS | **EQ 150MG BASE** | **A063083** | **001** | Jul 31, 1991 |
| **AB** | | | **EQ 300MG BASE** | **A063083** | **002** | Mar 18, 2003 |
| **AB** | | ZYDUS PHARMS USA | **EQ 75MG BASE** | **A065217** | **001** | Jan 31, 2005 |
| **AB** | | | **EQ 150MG BASE** | **A065217** | **002** | Jan 31, 2005 |
| **AB** | | | **EQ 300MG BASE** | **A065217** | **003** | Jan 31, 2005 |

**CLINDAMYCIN HYDROCLHORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | LANNETT | **EQ 150MG BASE** | **A065243** | **003** | Aug 12, 2005 |

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

**CLEOCIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **!** | PHARMACIA AND UPJOHN | **EQ 75MG BASE/5ML** | **A062644** | **001** | Apr 07, 1986 |

**CLINDAMYCIN PALMITATE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | AMNEAL PHARMS | **EQ 75MG BASE/5ML** | **A203513** | **001** | Mar 13, 2014 |
| **AA** | | AUROBINDO PHARMA LTD | **EQ 75MG BASE/5ML** | **A202409** | **001** | Apr 30, 2013 |
| **AA** | | LYNE | **EQ 75MG BASE/5ML** | **A201821** | **001** | Aug 28, 2012 |
| **AA** | | MYLAN PHARMS INC | **EQ 75MG BASE/5ML** | **A203063** | **001** | May 25, 2016 |
| **AA** | | ORIT LABS LLC | **EQ 75MG BASE/5ML** | **A206958** | **001** | May 05, 2017 |
| **AA** | | PADDOCK LLC | **EQ 75MG BASE/5ML** | **A090902** | **001** | Jul 07, 2010 |

CLINDAMYCIN PHOSPHATE

AEROSOL, FOAM;TOPICAL

**CLINDAMYCIN PHOSPHATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | PERRIGO UK FINCO | **1%** | **A090785** | **001** | Mar 31, 2010 |

**EVOCLIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **+!** | MYLAN PHARMS INC | **1%** | **N050801** | **001** | Oct 22, 2004 |

CREAM;VAGINAL

**CLEOCIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | PHARMACIA AND UPJOHN | **EQ 2% BASE** | **N050680** | **002** | Mar 02, 1998 |

**CLINDAMYCIN PHOSPHATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | FOUGERA PHARMS | **EQ 2% BASE** | **A065139** | **001** | Dec 27, 2004 |

CLINDESSE

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | PERRIGO PHARMA INTL | EQ 2% BASE | N050793 | 001 | Nov 30, 2004 |

GEL;TOPICAL

**CLEOCIN T**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | PHARMACIA AND UPJOHN | **EQ 1% BASE** | **N050615** | **001** | Jan 07, 1987 |

**CLINDAMYCIN PHOSPHATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | FOUGERA PHARMS | **EQ 1% BASE** | **A064160** | **001** | Jan 28, 2000 |

CLINDAGEL

| | | | | | | |
|---|---|---|---|---|---|---|
| BT | +! | PRECISION DERMAT | EQ 1% BASE | N050782 | 001 | Nov 27, 2000 |

INJECTABLE;INJECTION

**CLEOCIN PHOSPHATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | PHARMACIA AND UPJOHN | **EQ 150MG BASE/ML** | **A062803** | **001** | Oct 16, 1987 |
| **AP** | **+!** | | **EQ 150MG BASE/ML** | **N050441** | **001** | |

**CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | PHARMACIA AND UPJOHN | **EQ 6MG BASE/ML** | **N050639** | **001** | Aug 30, 1989 |
| **AP** | **+!** | | **EQ 12MG BASE/ML** | **N050639** | **002** | Aug 30, 1989 |
| **AP** | **+!** | | **EQ 18MG BASE/ML** | **N050639** | **003** | Apr 10, 1991 |

**CLINDAMYCIN PHOSPHATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | ALVOGEN INC | **EQ 150MG BASE/ML** | **A062800** | **001** | Jul 24, 1987 |
| **AP** | | | **EQ 150MG BASE/ML** | **A062801** | **001** | Jul 24, 1987 |

CLINDAMYCIN PHOSPHATE

INJECTABLE;INJECTION

**CLINDAMYCIN PHOSPHATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | | **EQ 150MG BASE/ML** | **A062943** | **001** | Sep 29, 1988 |
| **AP** | | FRESENIUS KABI USA | **EQ 150MG BASE/ML** | **A065346** | **001** | Mar 29, 2007 |
| **AP** | | | **EQ 150MG BASE/ML** | **A065347** | **001** | May 09, 2007 |
| **AP** | | MYLAN LABS LTD | **EQ 150MG BASE/ML** | **A204748** | **001** | Oct 10, 2017 |
| **AP** | | | **EQ 150MG BASE/ML** | **A204749** | **001** | Oct 10, 2017 |
| **AP** | | SAGENT PHARMS | **EQ 150MG BASE/ML** | **A090108** | **001** | Sep 30, 2011 |
| **AP** | | | **EQ 150MG BASE/ML** | **A090109** | **001** | Sep 30, 2011 |
| **AP** | | WEST-WARD PHARMS INT | **EQ 150MG BASE/ML** | **A062889** | **001** | Apr 25, 1988 |
| **AP** | | | **EQ 150MG BASE/ML** | **A065206** | **001** | Sep 24, 2004 |

**CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AKORN INC | **EQ 6MG BASE/ML** | **A203048** | **001** | Apr 04, 2013 |
| **AP** | | | **EQ 12MG BASE/ML** | **A203048** | **002** | Apr 04, 2013 |
| **AP** | | | **EQ 18MG BASE/ML** | **A203048** | **003** | Apr 04, 2013 |
| **AP** | | BAXTER HLTHCARE CORP | **EQ 6MG BASE/ML** | **A208084** | **001** | Jun 28, 2017 |
| **AP** | | | **EQ 12MG BASE/ML** | **A208084** | **002** | Jun 28, 2017 |
| **AP** | | | **EQ 18MG BASE/ML** | **A208084** | **003** | Jun 28, 2017 |
| **AP** | | SANDOZ INC | **EQ 6MG BASE/ML** | **A201692** | **001** | May 31, 2012 |
| **AP** | | | **EQ 12MG BASE/ML** | **A201692** | **002** | May 31, 2012 |
| **AP** | | | **EQ 18MG BASE/ML** | **A201692** | **003** | May 31, 2012 |

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%

| | | | | | |
|---|---|---|---|---|---|
| +! | ABRAXIS PHARM | EQ 900MG BASE/100ML | N050635 | 001 | Dec 22, 1989 |

LOTION;TOPICAL

**CLEOCIN T**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | PHARMACIA AND UPJOHN | **EQ 1% BASE** | **N050600** | **001** | May 31, 1989 |

**CLINDAMYCIN PHOSPHATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | FOUGERA PHARMS | **EQ 1% BASE** | **A065067** | **001** | Jan 31, 2002 |

SOLUTION;IV (INFUSION)

CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE

| | | | | | |
|---|---|---|---|---|---|
| +! | BAXTER HLTHCARE CORP | EQ 300MG BASE/50ML (EQ 6MG BASE/ML) | N208083 | 001 | Apr 20, 2017 |
| +! | | EQ 600MG BASE/50ML (EQ 12MG BASE/ML) | N208083 | 002 | Apr 20, 2017 |
| +! | | EQ 900MG BASE/50ML (EQ 18MG BASE/ML) | N208083 | 003 | Apr 20, 2017 |

SOLUTION;TOPICAL

**CLEOCIN T**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **+!** | PHARMACIA AND UPJOHN | **EQ 1% BASE** | **N050537** | **001** | |

**CLINDA-DERM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | PADDOCK LLC | **EQ 1% BASE** | **A063329** | **001** | Sep 30, 1992 |

**CLINDAMYCIN PHOSPHATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | FOUGERA PHARMS | **EQ 1% BASE** | **A065254** | **001** | Feb 14, 2006 |
| **AT** | | FOUGERA PHARMS INC | **EQ 1% BASE** | **A064159** | **001** | Jun 05, 1997 |
| **AT** | | G AND W LABS INC | **EQ 1% BASE** | **A062811** | **001** | Sep 01, 1988 |
| **AT** | | PERRIGO NEW YORK | **EQ 1% BASE** | **A064050** | **001** | Nov 30, 1995 |
| **AT** | | TARO PHARM INDS | **EQ 1% BASE** | **A065184** | **001** | Mar 31, 2004 |
| **AT** | | TELIGENT PHARMA INC | **EQ 1% BASE** | **A206945** | **001** | Dec 30, 2016 |
| **AT** | | VINTAGE PHARMS | **EQ 1% BASE** | **A203343** | **001** | May 29, 2015 |
| **AT** | | WOCKHARDT | **EQ 1% BASE** | **A063304** | **001** | Jul 15, 1997 |

SUPPOSITORY;VAGINAL

CLEOCIN

| | | | | | |
|---|---|---|---|---|---|
| +! | PHARMACIA AND UPJOHN | 100MG | N050767 | 001 | Aug 13, 1999 |

SWAB;TOPICAL

**CLEOCIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **+** | PHARMACIA AND UPJOHN | **EQ 1% BASE** | **N050537** | **002** | Feb 22, 1994 |

**CLINDAMYCIN PHOSPHATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | AKORN | **EQ 1% BASE** | **A065513** | **001** | Jun 17, 2010 |
| **AT** | | PERRIGO NEW YORK | **EQ 1% BASE** | **A065049** | **001** | May 25, 2000 |

**CLINDETS**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | PERRIGO CO | **EQ 1% BASE** | **A064136** | **001** | Sep 30, 1996 |

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL;TOPICAL

**CLINDAMYCIN PHOSPHATE AND TRETINOIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS MID ATLANTIC | **1.2%;0.025%** | **A202564** | **001** | Jun 12, 2015 |

**ZIANA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | MEDICIS | **1.2%;0.025%** | **N050802** | **001** | Nov 07, 2006 |

CLINDAMYCIN PHOSPHATE; TRETINOIN
GEL;TOPICAL
VELTIN
BX +! AQUA PHARMS LLC 1.2%;0.025% N050803 001 Jul 16, 2010

CLOBAZAM
SUSPENSION;ORAL
ONFI
+! LUNDBECK PHARMS LLC 2.5MG/ML N203993 001 Dec 14, 2012
TABLET;ORAL
ONFI
+ LUNDBECK PHARMS LLC 10MG N202067 002 Oct 21, 2011
+! 20MG N202067 003 Oct 21, 2011

CLOBETASOL PROPIONATE
AEROSOL, FOAM;TOPICAL
**CLOBETASOL PROPIONATE**
**AB1** INGENUS PHARMS LLC **0.05%** **A206805 001** Jul 31, 2017
**AB1** PERRIGO ISRAEL **0.05%** **A077763 001** Mar 10, 2008
**OLUX**
**AB1 +!** MYLAN PHARMS INC **0.05%** **N021142 001** May 26, 2000
**CLOBETASOL PROPIONATE**
**AB2** PERRIGO ISRAEL **0.05%** **A201402 001** Aug 14, 2012
**OLUX E**
**AB2 +!** MYLAN PHARMS INC **0.05%** **N022013 001** Jan 12, 2007
CREAM;TOPICAL
**CLOBETASOL PROPIONATE**
**AB1** FOUGERA PHARMS INC **0.05%** **A074392 001** Sep 30, 1996
**AB1** G AND W LABS INC **0.05%** **A074139 001** Aug 03, 1994
**AB1** MYLAN PHARMS INC **0.05%** **A075338 001** Feb 09, 2001
**AB1** TARO **0.05%** **A074249 001** Jul 08, 1996
**CORMAX**
**AB1 !** HI TECH PHARMA **0.05%** **A074220 001** May 16, 1997
**CLOBETASOL PROPIONATE (EMOLLIENT)**
**AB2 !** FOUGERA PHARMS **0.05%** **A075430 001** May 26, 1999
**AB2** TARO **0.05%** **A075633 001** May 17, 2000
**AB2** TELIGENT PHARMA INC **0.05%** **A209411 001** Aug 21, 2017
**EMBELINE E**
**AB2** HI TECH PHARMA **0.05%** **A075325 001** Dec 24, 1998
IMPOYZ
+! PROMIUS PHARMA LLC 0.025% N209483 001 Nov 28, 2017
GEL;TOPICAL
**CLOBETASOL PROPIONATE**
**AB !** FOUGERA PHARMS **0.05%** **A075368 001** Feb 15, 2000
**AB** PERRIGO CO **0.05%** **A075027 001** Oct 31, 1997
**AB** TARO **0.05%** **A075279 001** May 28, 1999
**AB** TELIGENT PHARMA INC **0.05%** **A208881 001** Mar 06, 2017
**EMBELINE**
**AB** HI TECH PHARMA **0.05%** **A076141 001** Apr 12, 2002
LOTION;TOPICAL
**CLOBETASOL PROPIONATE**
**AB** ACTAVIS MID ATLANTIC **0.05%** **A078223 001** Dec 04, 2008
**AB** LUPIN LTD **0.05%** **A209147 001** Sep 22, 2017
**AB** TARO **0.05%** **A200302 001** Jul 02, 2012
**AB** TELIGENT PHARMA INC **0.05%** **A208667 001** Nov 29, 2016
**CLOBEX**
**AB +!** GALDERMA LABS LP **0.05%** **N021535 001** Jul 24, 2003
OINTMENT;TOPICAL
**CLOBETASOL PROPIONATE**
**AB !** FOUGERA PHARMS **0.05%** **A074407 001** Feb 23, 1996
**AB** G AND W LABS INC **0.05%** **A074089 001** Feb 16, 1994
**AB** GLENMARK PHARMS **0.05%** **A208933 001** Mar 20, 2017
**AB** MYLAN PHARMS INC **0.05%** **A075057 001** Aug 12, 1998
**AB** TARO **0.05%** **A074248 001** Jul 12, 1996
**AB** ZYDUS PHARMS USA INC **0.05%** **A210199 001** Oct 27, 2017
**EMBELINE**
**AB** HI TECH PHARMA **0.05%** **A074221 001** Mar 31, 1995
SHAMPOO;TOPICAL
**CLOBETASOL PROPIONATE**
**AB** ACTAVIS MID ATLANTIC **0.05%** **A078854 001** Jun 07, 2011
**AB** HI-TECH PHARMACAL **0.05%** **A209871 001** Oct 27, 2017

| | | | | | | |
|---|---|---|---|---|---|---|
| CLOBETASOL PROPIONATE | | | | | | |
| SHAMPOO;TOPICAL | | | | | | |
| **CLOBETASOL PROPIONATE** | | | | | | |
| **AB** | | PERRIGO ISRAEL | **0.05%** | **A090974** | **001** | Aug 09, 2012 |
| **CLOBEX** | | | | | | |
| **AB** | **+!** | GALDERMA LABS | **0.05%** | **N021644** | **001** | Feb 05, 2004 |
| SOLUTION;TOPICAL | | | | | | |
| **CLOBETASOL PROPIONATE** | | | | | | |
| **AT** | | FOUGERA PHARMS | **0.05%** | **A075391** | **001** | Feb 08, 1999 |
| **AT** | | G AND W LABS INC | **0.05%** | **A074331** | **001** | Dec 15, 1995 |
| **AT** | | MACLEODS PHARMS LTD | **0.05%** | **A209361** | **001** | Oct 25, 2017 |
| **AT** | | NOVEL LABS INC | **0.05%** | **A206075** | **001** | Nov 23, 2015 |
| **AT** | | TARO | **0.05%** | **A075224** | **001** | Nov 16, 1998 |
| **AT** | | | **0.05%** | **A075363** | **001** | Dec 29, 2000 |
| **AT** | | TOLMAR | **0.05%** | **A076977** | **001** | Aug 05, 2005 |
| **AT** | | WOCKHARDT BIO AG | **0.05%** | **A075205** | **001** | Nov 13, 1998 |
| **EMBELINE** | | | | | | |
| **AT** | **!** | HI TECH PHARMA | **0.05%** | **A074222** | **001** | Dec 06, 1995 |
| SPRAY;TOPICAL | | | | | | |
| **CLOBETASOL PROPIONATE** | | | | | | |
| **AT** | | AKORN | **0.05%** | **A207218** | **001** | Apr 28, 2017 |
| **AT** | | PADDOCK LLC | **0.05%** | **A090898** | **001** | Jun 16, 2011 |
| **AT** | | ZYDUS PHARMS USA INC | **0.05%** | **A206378** | **001** | Feb 16, 2017 |
| **CLOBEX** | | | | | | |
| **AT** | **+!** | GALDERMA LABS LP | **0.05%** | **N021835** | **001** | Oct 27, 2005 |
| CLOCORTOLONE PIVALATE | | | | | | |
| CREAM;TOPICAL | | | | | | |
| CLODERM | | | | | | |
| | +! | PROMIUS PHARMA LLC | 0.1% | N017765 | 001 | |
| CLOFARABINE | | | | | | |
| INJECTABLE;IV (INFUSION) | | | | | | |
| **CLOFARABINE** | | | | | | |
| **AP** | | ABON PHARMS LLC | **20MG/20ML (1MG/ML)** | **A204029** | **001** | May 09, 2017 |
| **AP** | | AMNEAL PHARMS CO | **20MG/20ML (1MG/ML)** | **A208857** | **001** | Nov 06, 2017 |
| **AP** | | DR REDDYS LABS LTD | **20MG/20ML (1MG/ML)** | **A205375** | **001** | Nov 06, 2017 |
| **AP** | | MSN LABS PVT LTD | **20MG/20ML (1MG/ML)** | **A209775** | **001** | Dec 06, 2017 |
| **AP** | | MYLAN LABS LTD | **20MG/20ML (1MG/ML)** | **A208860** | **001** | Nov 06, 2017 |
| **CLOLAR** | | | | | | |
| **AP** | **+!** | GENZYME | **20MG/20ML (1MG/ML)** | **N021673** | **001** | Dec 28, 2004 |
| CLOMIPHENE CITRATE | | | | | | |
| TABLET;ORAL | | | | | | |
| **CLOMID** | | | | | | |
| **AB** | **+!** | SANOFI AVENTIS US | **50MG** | **N016131** | **002** | |
| **CLOMIPHENE CITRATE** | | | | | | |
| **AB** | | PAR PHARM | **50MG** | **A075528** | **001** | Aug 30, 1999 |
| CLOMIPRAMINE HYDROCHLORIDE | | | | | | |
| CAPSULE;ORAL | | | | | | |
| **ANAFRANIL** | | | | | | |
| **AB** | **+!** | SPECGX LLC | **25MG** | **N019906** | **001** | Dec 29, 1989 |
| **AB** | **+** | | **50MG** | **N019906** | **002** | Dec 29, 1989 |
| **AB** | **+** | | **75MG** | **N019906** | **003** | Dec 29, 1989 |
| **CLOMIPRAMINE HYDROCHLORIDE** | | | | | | |
| **AB** | | MYLAN | **25MG** | **A074947** | **001** | Apr 30, 1998 |
| **AB** | | | **50MG** | **A074947** | **002** | Apr 30, 1998 |
| **AB** | | | **75MG** | **A074947** | **003** | Apr 30, 1998 |
| **AB** | | SANDOZ | **25MG** | **A074364** | **001** | Mar 29, 1996 |
| **AB** | | | **25MG** | **A074953** | **001** | Jun 25, 1997 |
| **AB** | | | **50MG** | **A074364** | **002** | Mar 29, 1996 |
| **AB** | | | **50MG** | **A074953** | **002** | Jun 25, 1997 |
| **AB** | | | **75MG** | **A074364** | **003** | Mar 29, 1996 |
| **AB** | | | **75MG** | **A074953** | **003** | Jun 25, 1997 |
| **AB** | | TARO | **25MG** | **A074694** | **001** | Dec 31, 1996 |
| **AB** | | | **50MG** | **A074694** | **002** | Dec 31, 1996 |
| **AB** | | | **75MG** | **A074694** | **003** | Dec 31, 1996 |
| **AB** | | TEVA | **25MG** | **A074958** | **001** | Aug 26, 1997 |
| **AB** | | | **50MG** | **A074958** | **002** | Aug 26, 1997 |
| **AB** | | | **75MG** | **A074958** | **003** | Aug 26, 1997 |
| **AB** | | ZYDUS PHARMS USA INC | **25MG** | **A208961** | **001** | Dec 27, 2017 |
| **AB** | | | **50MG** | **A208961** | **002** | Dec 27, 2017 |

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL

**CLOMIPRAMINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **75MG** | **A208961** | **003** | Dec 27, 2017 |

CLONAZEPAM

TABLET;ORAL

**CLONAZEPAM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACCORD HLTHCARE | **0.5MG** | **A077147** | **001** | May 02, 2005 |
| **AB** | | | **1MG** | **A077147** | **002** | May 02, 2005 |
| **AB** | | | **2MG** | **A077147** | **003** | May 02, 2005 |
| **AB** | | ACTAVIS ELIZABETH | **0.5MG** | **A074869** | **001** | Oct 31, 1996 |
| **AB** | | | **1MG** | **A074869** | **002** | Oct 31, 1996 |
| **AB** | | | **2MG** | **A074869** | **003** | Oct 31, 1996 |
| **AB** | | MYLAN | **0.5MG** | **A075150** | **001** | Oct 05, 1998 |
| **AB** | | | **1MG** | **A075150** | **002** | Oct 05, 1998 |
| **AB** | | | **2MG** | **A075150** | **003** | Oct 05, 1998 |
| **AB** | | PRINSTON INC | **0.5MG** | **A077856** | **001** | Jun 28, 2006 |
| **AB** | | | **1MG** | **A077856** | **002** | Jun 28, 2006 |
| **AB** | | | **2MG** | **A077856** | **003** | Jun 28, 2006 |
| **AB** | | SANDOZ | **0.5MG** | **A074979** | **001** | Aug 29, 1997 |
| **AB** | | | **1MG** | **A074979** | **002** | Aug 29, 1997 |
| **AB** | | | **2MG** | **A074979** | **003** | Aug 29, 1997 |
| **AB** | | SUN PHARM INDS INC | **0.5MG** | **A075423** | **001** | Apr 27, 2001 |
| **AB** | | | **1MG** | **A075423** | **002** | Apr 27, 2001 |
| **AB** | | | **2MG** | **A075423** | **003** | Apr 27, 2001 |
| **AB** | | TEVA | **0.5MG** | **A074569** | **001** | Sep 10, 1996 |
| **AB** | | | **1MG** | **A074569** | **002** | Sep 10, 1996 |
| **AB** | | | **2MG** | **A074569** | **003** | Sep 10, 1996 |
| **AB** | | WATSON LABS | **0.5MG** | **A074964** | **001** | Dec 30, 1997 |
| **AB** | | | **1MG** | **A074964** | **002** | Dec 30, 1997 |
| **AB** | | | **2MG** | **A074964** | **003** | Dec 30, 1997 |

**KLONOPIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | ROCHE | **0.5MG** | **N017533** | **001** | |
| **AB** | +! | | **1MG** | **N017533** | **002** | |
| **AB** | + | | **2MG** | **N017533** | **003** | |

TABLET, ORALLY DISINTEGRATING;ORAL

**CLONAZEPAM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | BARR | **0.125MG** | **A077194** | **001** | Aug 10, 2005 |
| **AB** | | | **0.25MG** | **A077194** | **002** | Aug 10, 2005 |
| **AB** | | | **0.5MG** | **A077194** | **003** | Aug 10, 2005 |
| **AB** | | | **1MG** | **A077194** | **004** | Aug 10, 2005 |
| **AB** | | | **2MG** | **A077194** | **005** | Aug 10, 2005 |
| **AB** | | PAR PHARM | **0.125MG** | **A077171** | **001** | Aug 03, 2005 |
| **AB** | | | **0.25MG** | **A077171** | **002** | Aug 03, 2005 |
| **AB** | | | **0.5MG** | **A077171** | **003** | Aug 03, 2005 |
| **AB** | ! | | **1MG** | **A077171** | **004** | Aug 03, 2005 |
| **AB** | | | **2MG** | **A077171** | **005** | Aug 03, 2005 |
| **AB** | | SUN PHARM INDS INC | **0.125MG** | **A078654** | **001** | Aug 27, 2014 |
| **AB** | | | **0.25MG** | **A078654** | **002** | Aug 27, 2014 |
| **AB** | | | **0.5MG** | **A078654** | **003** | Aug 27, 2014 |
| **AB** | | | **1MG** | **A078654** | **004** | Aug 27, 2014 |
| **AB** | | | **2MG** | **A078654** | **005** | Aug 27, 2014 |

CLONIDINE

FILM, EXTENDED RELEASE;TRANSDERMAL

**CATAPRES-TTS-1**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | BOEHRINGER INGELHEIM | **0.1MG/24HR** | **N018891** | **001** | Oct 10, 1984 |

**CATAPRES-TTS-2**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | BOEHRINGER INGELHEIM | **0.2MG/24HR** | **N018891** | **002** | Oct 10, 1984 |

**CATAPRES-TTS-3**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | +! | BOEHRINGER INGELHEIM | **0.3MG/24HR** | **N018891** | **003** | Oct 10, 1984 |

**CLONIDINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS LABS UT INC | **0.1MG/24HR** | **A090873** | **001** | May 06, 2014 |
| **AB** | | | **0.2MG/24HR** | **A090873** | **002** | May 06, 2014 |
| **AB** | | | **0.3MG/24HR** | **A090873** | **003** | May 06, 2014 |
| **AB** | | AVEVA | **0.1MG/24HR** | **A076157** | **001** | Aug 18, 2009 |
| **AB** | | | **0.2MG/24HR** | **A076157** | **002** | Aug 18, 2009 |
| **AB** | | | **0.3MG/24HR** | **A076157** | **003** | Aug 18, 2009 |
| **AB** | | MAYNE PHARMA | **0.1MG/24HR** | **A079090** | **001** | Aug 20, 2010 |
| **AB** | | | **0.2MG/24HR** | **A079090** | **002** | Aug 20, 2010 |

CLONIDINE

FILM, EXTENDED RELEASE;TRANSDERMAL

**CLONIDINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **0.3MG/24HR** | **A079090** | **003** | Aug 20, 2010 |
| **AB** | | MYLAN TECHNOLOGIES | **0.1MG/24HR** | **A076166** | **001** | Jul 16, 2010 |
| **AB** | | | **0.2MG/24HR** | **A076166** | **002** | Jul 16, 2010 |
| **AB** | | | **0.3MG/24HR** | **A076166** | **003** | Jul 16, 2010 |

CLONIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

**CLONIDINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | EXELA PHARMA SCS LLC | **1MG/10ML (0.1MG/ML)** | **A203167** | **001** | Oct 29, 2013 |
| **AP** | | | **5MG/10ML (0.5MG/ML)** | **A203167** | **002** | Oct 29, 2013 |
| **AP** | | FRESENIUS KABI USA | **1MG/10ML (0.1MG/ML)** | **A200673** | **001** | Jul 08, 2011 |
| **AP** | | | **5MG/10ML (0.5MG/ML)** | **A200673** | **002** | Jul 08, 2011 |
| **AP** | | HIKMA FARMACEUTICA | **1MG/10ML (0.1MG/ML)** | **A200300** | **001** | Jan 26, 2011 |
| **AP** | | | **5MG/10ML (0.5MG/ML)** | **A200300** | **002** | Jan 26, 2011 |
| **AP** | | LUITPOLD | **1MG/10ML (0.1MG/ML)** | **A091104** | **001** | Oct 08, 2009 |
| **AP** | | | **5MG/10ML (0.5MG/ML)** | **A091104** | **002** | Oct 08, 2009 |
| **AP** | | ZYDUS PHARMS USA INC | **1MG/10ML (0.1MG/ML)** | **A202601** | **001** | Feb 20, 2014 |
| **AP** | | | **5MG/10ML (0.5MG/ML)** | **A202601** | **002** | Feb 20, 2014 |

**DURACLON**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+** | MYLAN INSTITUTIONAL | **1MG/10ML (0.1MG/ML)** | **N020615** | **001** | Oct 02, 1996 |
| **AP** | **+!** | | **5MG/10ML (0.5MG/ML)** | **N020615** | **002** | Apr 27, 1999 |

TABLET;ORAL

**CATAPRES**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | BOEHRINGER INGELHEIM | **0.1MG** | **N017407** | **001** | |
| **AB** | **+** | | **0.2MG** | **N017407** | **002** | |
| **AB** | **+!** | | **0.3MG** | **N017407** | **003** | |

**CLONIDINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS ELIZABETH | **0.1MG** | **A070974** | **001** | Dec 16, 1986 |
| **AB** | | | **0.2MG** | **A070975** | **001** | Dec 16, 1986 |
| **AB** | | | **0.3MG** | **A070976** | **001** | Dec 16, 1986 |
| **AB** | | ALEMBIC PHARMS LTD | **0.1MG** | **A091368** | **001** | Dec 06, 2011 |
| **AB** | | | **0.2MG** | **A091368** | **002** | Dec 06, 2011 |
| **AB** | | | **0.3MG** | **A091368** | **003** | Dec 06, 2011 |
| **AB** | | FRONTIDA BIOPHARM | **0.1MG** | **A070925** | **001** | Sep 04, 1987 |
| **AB** | | | **0.2MG** | **A070924** | **001** | Sep 04, 1987 |
| **AB** | | | **0.3MG** | **A070923** | **001** | Sep 04, 1987 |
| **AB** | | IMPAX LABS | **0.1MG** | **A078099** | **001** | Aug 27, 2009 |
| **AB** | | | **0.2MG** | **A078099** | **002** | Aug 27, 2009 |
| **AB** | | | **0.3MG** | **A078099** | **003** | Aug 27, 2009 |
| **AB** | | MYLAN | **0.1MG** | **A070317** | **002** | Jul 09, 1987 |
| **AB** | | | **0.2MG** | **A070317** | **003** | Jun 09, 1987 |
| **AB** | | | **0.3MG** | **A070317** | **001** | Jun 09, 1987 |
| **AB** | | PRINSTON INC | **0.1MG** | **A077901** | **001** | Mar 09, 2007 |
| **AB** | | | **0.2MG** | **A077901** | **002** | Mar 09, 2007 |
| **AB** | | | **0.3MG** | **A077901** | **003** | Mar 09, 2007 |
| **AB** | | SUN PHARM INDS INC | **0.1MG** | **A090329** | **001** | Jul 03, 2014 |
| **AB** | | | **0.2MG** | **A090329** | **002** | Jul 03, 2014 |
| **AB** | | | **0.3MG** | **A090329** | **003** | Jul 03, 2014 |
| **AB** | | UNICHEM | **0.1MG** | **A078895** | **001** | Aug 26, 2009 |
| **AB** | | | **0.2MG** | **A078895** | **002** | Aug 26, 2009 |
| **AB** | | | **0.3MG** | **A078895** | **003** | Aug 26, 2009 |
| **AB** | | YUNG SHIN PHARM | **0.1MG** | **A202297** | **001** | Jun 13, 2013 |
| **AB** | | | **0.2MG** | **A202297** | **002** | Jun 13, 2013 |
| **AB** | | | **0.3MG** | **A202297** | **003** | Jun 13, 2013 |
| | | CHARTWELL MOLECULES | 0.1MG | A071785 | 002 | Apr 05, 1988 |
| | | | 0.2MG | A071785 | 003 | Apr 05, 1988 |

TABLET, EXTENDED RELEASE;ORAL

**CLONIDINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB1** | | ACTAVIS ELIZABETH | **0.1MG** | **A203320** | **001** | May 15, 2015 |
| **AB1** | | AJANTA PHARMA LTD | **0.1MG** | **A209686** | **001** | Nov 20, 2017 |
| **AB1** | | AMNEAL PHARMS NY | **0.1MG** | **A210052** | **001** | Nov 20, 2017 |
| **AB1** | | LUPIN LTD | **0.1MG** | **A209285** | **001** | Oct 23, 2017 |
| **AB1** | | XIAMEN LP PHARM CO | **0.1MG** | **A209757** | **001** | Nov 20, 2017 |

**CLONIDINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB1** | | ANCHEN PHARMS | **0.1MG** | **A202984** | **001** | Sep 30, 2013 |

**KAPVAY**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB1** | **+!** | CONCORDIA PHARMS INC | **0.1MG** | **N022331** | **003** | Sep 28, 2010 |

CLONIDINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

**CLONIDINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB2** | | ACTAVIS ELIZABETH | **0.1MG** | **A202792** | **001** | May 15, 2015 |

CLOPIDOGREL BISULFATE

TABLET;ORAL

**CLOPIDOGREL BISULFATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACCORD HLTHCARE | **EQ 75MG BASE** | **A202925** | **001** | Mar 27, 2013 |
| **AB** | | | **EQ 300MG BASE** | **A202925** | **002** | Mar 27, 2013 |
| **AB** | | ACME LABS | **EQ 75MG BASE** | **A078004** | **001** | May 17, 2012 |
| **AB** | | AMNEAL PHARMS | **EQ 75MG BASE** | **A203751** | **001** | Apr 11, 2014 |
| **AB** | | APOTEX INC | **EQ 75MG BASE** | **A076274** | **001** | May 17, 2012 |
| **AB** | | | **EQ 300MG BASE** | **A076274** | **002** | Mar 04, 2014 |
| **AB** | | AUROBINDO PHARMA LTD | **EQ 75MG BASE** | **A090540** | **001** | May 17, 2012 |
| **AB** | | CSPC OUYI PHARM CO | **EQ 75MG BASE** | **A204359** | **001** | Feb 02, 2017 |
| **AB** | | DR REDDYS LABS INC | **EQ 75MG BASE** | **A076273** | **001** | Jan 14, 2008 |
| **AB** | | DR REDDYS LABS LTD | **EQ 300MG BASE** | **A091023** | **001** | May 17, 2012 |
| **AB** | | GATE PHARMS | **EQ 300MG BASE** | **A091216** | **001** | May 17, 2012 |
| **AB** | | MACLEODS PHARMS LTD | **EQ 75MG BASE** | **A202928** | **001** | Feb 10, 2014 |
| **AB** | | MYLAN PHARMS INC | **EQ 75MG BASE** | **A077665** | **001** | May 17, 2012 |
| **AB** | | | **EQ 300MG BASE** | **A077665** | **002** | May 17, 2012 |
| **AB** | | SCIEGEN PHARMS INC | **EQ 75MG BASE** | **A204165** | **001** | Sep 15, 2014 |
| **AB** | | | **EQ 300MG BASE** | **A204165** | **002** | Sep 15, 2014 |
| **AB** | | SUN PHARM INDUSTRIES | **EQ 75MG BASE** | **A078133** | **001** | Jun 10, 2013 |
| **AB** | | SUN PHARMA GLOBAL | **EQ 75MG BASE** | **A090494** | **001** | May 17, 2012 |
| **AB** | | TEVA | **EQ 75MG BASE** | **A076999** | **001** | May 17, 2012 |
| **AB** | | TEVA PHARMS | **EQ 300MG BASE** | **A090625** | **001** | May 17, 2012 |
| **AB** | | TORRENT PHARMS LTD | **EQ 75MG BASE** | **A090844** | **001** | May 17, 2012 |
| **AB** | | WOCKHARDT LTD | **EQ 75MG BASE** | **A202266** | **001** | Aug 14, 2012 |
| **AB** | | | **EQ 300MG BASE** | **A202266** | **002** | Nov 20, 2012 |
| **AB** | | ZYDUS PHARMS USA INC | **EQ 75MG BASE** | **A201686** | **001** | Oct 10, 2012 |

**PLAVIX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | SANOFI AVENTIS US | **EQ 75MG BASE** | **N020839** | **001** | Nov 17, 1997 |
| **AB** | **+!** | | **EQ 300MG BASE** | **N020839** | **002** | Sep 20, 2007 |

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL

CLORAZEPATE DIPOTASSIUM

| | | | | | | |
|---|---|---|---|---|---|---|
| | | AUROLIFE PHARMA LLC | 3.75MG | A072112 | 002 | Aug 11, 2017 |
| | | | 7.5MG | A072112 | 003 | Aug 11, 2017 |

TABLET;ORAL

**CLORAZEPATE DIPOTASSIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | MYLAN | **3.75MG** | **A071858** | **002** | Jul 17, 1987 |
| **AB** | | | **7.5MG** | **A071858** | **003** | Jul 17, 1987 |
| **AB** | | | **15MG** | **A071858** | **001** | Jul 17, 1987 |
| **AB** | | TARO PHARM | **3.75MG** | **A075731** | **003** | Apr 27, 2000 |
| **AB** | | | **7.5MG** | **A075731** | **002** | Apr 27, 2000 |
| **AB** | | | **15MG** | **A075731** | **001** | Apr 27, 2000 |

**GEN-XENE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALRA | **3.75MG** | **A071787** | **001** | Apr 26, 1988 |
| **AB** | | | **7.5MG** | **A071788** | **001** | Apr 26, 1988 |
| **AB** | | | **15MG** | **A071789** | **001** | Apr 26, 1988 |

**TRANXENE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | RECORDATI RARE | **7.5MG** | **N017105** | **007** | |
| **AB** | **+!** | | **15MG** | **N017105** | **008** | |

CLOTRIMAZOLE

CREAM;TOPICAL

**CLOTRIMAZOLE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | FOUGERA PHARMS | **1%** | **A078338** | **001** | Sep 02, 2008 |
| **AB** | | GLENMARK PHARMS | **1%** | **A090219** | **001** | Aug 03, 2010 |
| **AB** | **!** | TARO | **1%** | **A072640** | **001** | Aug 31, 1993 |

SOLUTION;TOPICAL

**CLOTRIMAZOLE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **!** | TARO | **1%** | **A074580** | **001** | Jul 29, 1996 |
| **AT** | | TEVA | **1%** | **A073306** | **001** | Feb 28, 1995 |

TROCHE/LOZENGE;ORAL

**CLOTRIMAZOLE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | PADDOCK LLC | **10MG** | **A076763** | **001** | Oct 28, 2005 |
| **AB** | **!** | WEST-WARD PHARMS INT | **10MG** | **A076387** | **001** | Jul 29, 2004 |

| | | | | | | |
|---|---|---|---|---|---|---|
| CLOZAPINE | | | | | | |
| SUSPENSION;ORAL | | | | | | |
| VERSACLOZ | | | | | | |
| | +! | TASMAN PHARMA | 50MG/ML | N203479 | 001 | Feb 06, 2013 |
| TABLET;ORAL | | | | | | |
| **CLOZAPINE** | | | | | | |
| **AB** | | ACCORD HLTHCARE | **25MG** | **A202873** | **001** | Nov 25, 2015 |
| **AB** | | | **100MG** | **A202873** | **002** | Nov 25, 2015 |
| **AB** | | AUROBINDO PHARMA LTD | **25MG** | **A206433** | **001** | Nov 29, 2016 |
| **AB** | | | **50MG** | **A206433** | **002** | Nov 29, 2016 |
| **AB** | | | **100MG** | **A206433** | **003** | Nov 29, 2016 |
| **AB** | | | **200MG** | **A206433** | **004** | Nov 29, 2016 |
| **AB** | | IVAX SUB TEVA PHARMS | **12.5MG** | **A074949** | **003** | Jul 31, 2003 |
| **AB** | | | **25MG** | **A074949** | **001** | Nov 26, 1997 |
| **AB** | | | **50MG** | **A074949** | **004** | Apr 25, 2005 |
| **AB** | | | **50MG** | **A076809** | **003** | Dec 16, 2005 |
| **AB** | | | **100MG** | **A074949** | **002** | Nov 26, 1997 |
| **AB** | | | **100MG** | **A076809** | **002** | Dec 16, 2005 |
| **AB** | | | **200MG** | **A076809** | **001** | Dec 16, 2005 |
| **AB** | | MAYNE PHARMA | **25MG** | **A203807** | **001** | Sep 17, 2015 |
| **AB** | | | **50MG** | **A203807** | **003** | Aug 22, 2017 |
| **AB** | | | **100MG** | **A203807** | **002** | Sep 17, 2015 |
| **AB** | | | **200MG** | **A203807** | **004** | Aug 22, 2017 |
| **AB** | | MYLAN | **12.5MG** | **A075417** | **003** | Apr 15, 2010 |
| **AB** | | | **25MG** | **A075417** | **001** | May 27, 1999 |
| **AB** | | | **50MG** | **A075417** | **004** | Apr 15, 2010 |
| **AB** | | | **100MG** | **A075417** | **002** | May 27, 1999 |
| **AB** | | | **200MG** | **A075417** | **005** | Apr 15, 2010 |
| **AB** | | SUN PHARM INDS INC | **25MG** | **A075713** | **001** | Nov 15, 2002 |
| **AB** | | | **50MG** | **A075713** | **003** | Aug 19, 2005 |
| **AB** | | | **100MG** | **A075713** | **002** | Nov 15, 2002 |
| **AB** | | | **200MG** | **A075713** | **004** | Nov 07, 2017 |
| **AB** | | ZYDUS PHARMS USA INC | **25MG** | **A209480** | **001** | Dec 06, 2017 |
| **AB** | | | **50MG** | **A209480** | **002** | Dec 06, 2017 |
| **AB** | | | **100MG** | **A209480** | **003** | Dec 06, 2017 |
| **AB** | | | **200MG** | **A209480** | **004** | Dec 06, 2017 |
| **CLOZARIL** | | | | | | |
| **AB** | **+** | HERITAGE LIFE | **25MG** | **N019758** | **001** | Sep 26, 1989 |
| **AB** | **+!** | | **100MG** | **N019758** | **002** | Sep 26, 1989 |
| TABLET, ORALLY DISINTEGRATING;ORAL | | | | | | |
| **CLOZAPINE** | | | | | | |
| **AB** | | BARR LABS INC | **25MG** | **A090308** | **001** | Nov 25, 2015 |
| **AB** | | | **100MG** | **A090308** | **002** | Nov 25, 2015 |
| **AB** | | MYLAN PHARMS INC | **25MG** | **A201824** | **002** | Sep 15, 2015 |
| **AB** | | | **100MG** | **A201824** | **003** | Sep 15, 2015 |
| **AB** | | TEVA PHARMS USA | **150MG** | **A203039** | **001** | Nov 25, 2015 |
| **AB** | | | **200MG** | **A203039** | **002** | Nov 25, 2015 |
| **FAZACLO ODT** | | | | | | |
| **AB** | **+** | JAZZ PHARMS III | **25MG** | **N021590** | **001** | Feb 10, 2004 |
| **AB** | **+!** | | **100MG** | **N021590** | **002** | Feb 10, 2004 |
| **AB** | **+** | | **150MG** | **N021590** | **005** | Jul 09, 2010 |
| **AB** | **+** | | **200MG** | **N021590** | **006** | Jul 09, 2010 |
| | + | | 12.5MG | N021590 | 004 | May 30, 2007 |
| COBICISTAT | | | | | | |
| TABLET;ORAL | | | | | | |
| TYBOST | | | | | | |
| | +! | GILEAD SCIENCES INC | 150MG | N203094 | 001 | Sep 24, 2014 |
| COBICISTAT; DARUNAVIR ETHANOLATE | | | | | | |
| TABLET;ORAL | | | | | | |
| PREZCOBIX | | | | | | |
| | +! | JANSSEN PRODS | 150MG;EQ 800MG BASE | N205395 | 001 | Jan 29, 2015 |
| COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE | | | | | | |
| TABLET;ORAL | | | | | | |
| GENVOYA | | | | | | |
| | +! | GILEAD SCIENCES INC | 150MG;150MG;200MG;EQ 10MG BASE | N207561 | 001 | Nov 05, 2015 |

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

STRIBILD

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | GILEAD SCIENCES INC | 150MG;150MG;200MG;300MG | N203100 | 001 | Aug 27, 2012 |

COBIMETINIB FUMARATE

TABLET;ORAL

COTELLIC

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | GENENTECH INC | EQ 20MG BASE | N206192 | 001 | Nov 10, 2015 |

COCAINE HYDROCHLORIDE

SOLUTION;NASAL

GOPRELTO

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | GENUS LIFESCIENCES | 4% | N209963 | 001 | Dec 14, 2017 |

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

**PROMETH HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | VINTAGE | **10MG/5ML;5MG/5ML;6.25MG/5ML** | **A040660** | **001** | Dec 07, 2006 |

**PROMETH VC W/ CODEINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **!** | ACTAVIS MID ATLANTIC | **10MG/5ML;5MG/5ML;6.25MG/5ML** | **A088764** | **001** | Oct 31, 1984 |

**PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | HI-TECH PHARMA CO | **10MG/5ML;5MG/5ML;6.25MG/5ML** | **A040674** | **001** | Dec 23, 2014 |

**PROMETHAZINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | AMNEAL PHARMS | **10MG/5ML;5MG/5ML;6.25MG/5ML** | **A200963** | **001** | Aug 26, 2015 |

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

**PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **!** | ACTAVIS MID ATLANTIC | **10MG/5ML;6.25MG/5ML** | **A088763** | **001** | Oct 31, 1984 |
| **AA** | | AMNEAL PHARMS | **10MG/5ML;6.25MG/5ML** | **A200894** | **001** | Apr 24, 2013 |
| **AA** | | HI TECH PHARMA | **10MG/5ML;6.25MG/5ML** | **A040151** | **001** | Aug 26, 1997 |
| **AA** | | NOSTRUM LABS INC | **10MG/5ML;6.25MG/5ML** | **A090180** | **001** | Mar 17, 2010 |
| **AA** | | TRIS PHARMA INC | **10MG/5ML;6.25MG/5ML** | **A200386** | **001** | Jun 29, 2012 |
| **AA** | | WOCKHARDT BIO AG | **10MG/5ML;6.25MG/5ML** | **A088875** | **001** | Dec 17, 1984 |

**PROMETHAZINE WITH CODEINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | VINTAGE | **10MG/5ML;6.25MG/5ML** | **A040650** | **001** | Jan 31, 2006 |

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP;ORAL

TRIACIN-C

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | STI PHARMA LLC | 10MG/5ML;30MG/5ML;1.25MG/5ML | A088704 | 001 | Mar 22, 1985 |

CODEINE SULFATE

TABLET;ORAL

**CODEINE SULFATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | LANNETT HOLDINGS INC | **15MG** | **A203046** | **001** | Jun 13, 2014 |
| **AB** | | | **30MG** | **A203046** | **002** | Jun 13, 2014 |
| **AB** | | | **60MG** | **A203046** | **003** | Jun 13, 2014 |
| **AB** | **+** | WEST-WARD PHARMS INT | **15MG** | **N022402** | **001** | Jul 16, 2009 |
| **AB** | **+** | | **30MG** | **N022402** | **002** | Jul 16, 2009 |
| **AB** | **+!** | | **60MG** | **N022402** | **003** | Jul 16, 2009 |

COLCHICINE

CAPSULE;ORAL

MITIGARE

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | HIKMA INTL PHARMS | 0.6MG | N204820 | 001 | Sep 26, 2014 |

TABLET;ORAL

COLCRYS

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | TAKEDA PHARMS USA | 0.6MG | N022352 | 001 | Jul 29, 2009 |

COLCHICINE; PROBENECID

TABLET;ORAL

**COL-PROBENECID**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **!** | WATSON LABS | **0.5MG;500MG** | **A084279** | **001** | |

**PROBENECID AND COLCHICINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | INGENUS PHARMS NJ | **0.5MG;500MG** | **A040618** | **001** | May 13, 2008 |

COLESEVELAM HYDROCHLORIDE

FOR SUSPENSION;ORAL

WELCHOL

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | DAIICHI SANKYO | 1.875GM/PACKET | N022362 | 001 | Oct 02, 2009 |
| | +! | | 3.75GM/PACKET | N022362 | 002 | Oct 02, 2009 |

TABLET;ORAL

WELCHOL

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | DAIICHI SANKYO | 625MG | N021176 | 001 | May 26, 2000 |

COLESTIPOL HYDROCHLORIDE

GRANULE;ORAL

**COLESTID**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | PHARMACIA UPJOHN | **5GM/SCOOPFUL** | **N017563** | **003** | Sep 22, 1995 |
| **AB** | **+!** | | **5GM/PACKET** | **N017563** | **004** | Sep 22, 1995 |

**COLESTIPOL HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | IMPAX LABS | **5GM/SCOOPFUL** | **A077277** | **001** | May 02, 2006 |
| **AB** | | | **5GM/PACKET** | **A077277** | **002** | May 02, 2006 |

FLAVORED COLESTID

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | PHARMACIA UPJOHN | 5GM/PACKET | N017563 | 001 | |
| | + | | 5GM/SCOOPFUL | N017563 | 002 | |

TABLET;ORAL

**COLESTID**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | PHARMACIA UPJOHN | **1GM** | **N020222** | **001** | Jul 19, 1994 |

**COLESTIPOL HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | IMPAX LABS | **1GM** | **A077510** | **001** | Oct 24, 2006 |

COLISTIMETHATE SODIUM

INJECTABLE;INJECTION

**COLISTIMETHATE SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | EMCURE PHARMS LTD | **EQ 150MG BASE/VIAL** | **A202359** | **001** | Sep 28, 2012 |
| **AP** | | FRESENIUS KABI USA | **EQ 150MG BASE/VIAL** | **A065364** | **001** | Apr 17, 2008 |
| **AP** | | PADDOCK LLC | **EQ 150MG BASE/VIAL** | **A065177** | **001** | Mar 19, 2004 |
| **AP** | | SAGENT PHARMS | **EQ 150MG BASE/VIAL** | **A201365** | **001** | Feb 19, 2014 |
| **AP** | | X GEN PHARMS | **EQ 150MG BASE/VIAL** | **A064216** | **001** | Feb 26, 1999 |
| **AP** | | XELLIA PHARMS APS | **EQ 150MG BASE/VIAL** | **A205356** | **001** | May 29, 2015 |

**COLY-MYCIN M**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | PAR STERILE PRODUCTS | **EQ 150MG BASE/VIAL** | **N050108** | **002** | |

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS;OTIC

COLY-MYCIN S

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ENDO PHARMS INC | EQ 3MG BASE/ML;10MG/ML;EQ 3.3MG BASE/ML;0.5MG/ML | N050356 | 001 | |

CONIVAPTAN HYDROCHLORIDE

INJECTABLE;IV (INFUSION)

VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | CUMBERLAND PHARMS | 20MG/100ML (0.2MG/ML) | N021697 | 002 | Oct 08, 2008 |

COPANLISIB DIHYDROCHLORIDE

POWDER;IV (INFUSION)

ALIQOPA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | BAYER HEALTHCARE | 60MG/VIAL | N209936 | 001 | Sep 14, 2017 |

COPPER

INTRAUTERINE DEVICE;INTRAUTERINE

PARAGARD T 380A

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | COOPERSURGICAL | 309MG/COPPER | N018680 | 001 | Nov 15, 1984 |

CORTICORELIN OVINE TRIFLUTATE

INJECTABLE;INJECTION

ACTHREL

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | FERRING | EQ 0.1MG BASE/VIAL | N020162 | 001 | May 23, 1996 |

CORTICOTROPIN

INJECTABLE;INJECTION

H.P. ACTHAR GEL

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | MALLINCKRODT ARD | 80 UNITS/ML | N008372 | 008 | |

CORTISONE ACETATE

TABLET;ORAL

CORTISONE ACETATE

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | HIKMA INTL PHARMS | 25MG | A080776 | 002 | |

COSYNTROPIN
INJECTABLE;INJECTION
**CORTROSYN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | AMPHASTAR PHARMS INC | **0.25MG/VIAL** | **N016750** | **001** | |

**COSYNTROPIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | MYLAN INSTITUTIONAL | **0.25MG/VIAL** | **A090574** | **001** | Dec 17, 2009 |
| **AP** | | SANDOZ | **0.25MG/VIAL** | **A202147** | **001** | Jun 29, 2012 |

CRISABOROLE
OINTMENT;TOPICAL
EUCRISA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ANACOR PHARMS INC | 2% | N207695 | 001 | Dec 14, 2016 |

CRIZOTINIB
CAPSULE;ORAL
XALKORI

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | PF PRISM CV | 200MG | N202570 | 001 | Aug 26, 2011 |
| | +! | | 250MG | N202570 | 002 | Aug 26, 2011 |

CROFELEMER
TABLET, DELAYED RELEASE;ORAL
FULYZAQ

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | NAPO PHARMS INC | 125MG | N202292 | 001 | Dec 31, 2012 |

CROMOLYN SODIUM
CONCENTRATE;ORAL
**CROMOLYN SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | AILEX PHARMS LLC | **100MG/5ML** | **A209264** | **001** | Oct 16, 2017 |
| **AA** | | MICRO LABS LTD INDIA | **100MG/5ML** | **A202745** | **001** | Apr 04, 2013 |
| **AA** | | RISING PHARMS INC | **100MG/5ML** | **A202583** | **001** | Oct 27, 2011 |

**GASTROCROM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **+!** | MYLAN SPECIALITY LP | **100MG/5ML** | **N020479** | **001** | Feb 29, 1996 |

SOLUTION;INHALATION
**CROMOLYN SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AN** | | AILEX PHARMS LLC | **10MG/ML** | **A209453** | **001** | Oct 16, 2017 |
| **AN** | | MYLAN SPECIALITY LP | **10MG/ML** | **A074209** | **001** | Apr 26, 1994 |
| **AN** | **!** | TEVA PHARMS | **10MG/ML** | **A075271** | **001** | Jan 18, 2000 |
| **AN** | | WOCKHARDT BIO AG | **10MG/ML** | **A075346** | **001** | Oct 25, 1999 |

SOLUTION/DROPS;OPHTHALMIC
**CROMOLYN SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **!** | AKORN | **4%** | **A074706** | **001** | Apr 29, 1998 |
| **AT** | | ALCON | **4%** | **A075282** | **001** | Jun 16, 1999 |

CROTAMITON
CREAM;TOPICAL
EURAX

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | RANBAXY | 10% | N006927 | 001 | |

LOTION;TOPICAL
**CROTAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | MARNEL PHARMS | **10%** | **A087204** | **001** | |

**EURAX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **+!** | RANBAXY | **10%** | **N009112** | **003** | |

CUPRIC CHLORIDE
INJECTABLE;INJECTION
CUPRIC CHLORIDE IN PLASTIC CONTAINER

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | HOSPIRA | EQ 0.4MG COPPER/ML | N018960 | 001 | Jun 26, 1986 |

CYANOCOBALAMIN
INJECTABLE;INJECTION
**CYANOCOBALAMIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **!** | LUITPOLD | **1MG/ML** | **A080737** | **001** | |
| **AP** | | MYLAN LABS LTD | **1MG/ML** | **A204829** | **001** | Jun 05, 2017 |
| **AP** | | SOMERSET THERAPS LLC | **1MG/ML** | **A206503** | **001** | Dec 11, 2015 |
| **AP** | | WEST-WARD PHARMS INT | **1MG/ML** | **A080515** | **002** | |

**VIBISONE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **!** | FRESENIUS KABI USA | **1MG/ML** | **A080557** | **003** | |

SPRAY, METERED;NASAL
NASCOBAL

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ENDO PHARMS INC | 0.5MG/SPRAY | N021642 | 001 | Jan 31, 2005 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| CYCLOBENZAPRINE HYDROCHLORIDE | | | | | | | |
| CAPSULE, EXTENDED RELEASE;ORAL | | | | | | | |
| AMRIX | | | | | | | |
| | + | TEVA PHARMS INTL | 15MG | | N021777 | 001 | Feb 01, 2007 |
| | +! | | 30MG | | N021777 | 002 | Feb 01, 2007 |
| TABLET;ORAL | | | | | | | |
| **CYCLOBENZAPRINE HYDROCHLORIDE** | | | | | | | |
| **AB** | | ACTAVIS LABS FL INC | **5MG** | | **A071611** | **002** | Feb 03, 2006 |
| **AB** | | | **7.5MG** | | **A071611** | **003** | Feb 03, 2006 |
| **AB** | | | **10MG** | | **A071611** | **001** | May 03, 1989 |
| **AB** | | AUROBINDO PHARMA | **5MG** | | **A078643** | **001** | Sep 26, 2008 |
| **AB** | | | **10MG** | | **A078643** | **002** | Sep 26, 2008 |
| **AB** | | FRONTIDA BIOPHARM | **5MG** | | **A073541** | **002** | Apr 06, 2006 |
| **AB** | | | **10MG** | | **A073541** | **001** | May 23, 1995 |
| **AB** | | INVAGEN PHARMS | **5MG** | | **A090478** | **001** | Jul 23, 2010 |
| **AB** | | | **10MG** | | **A090478** | **002** | Jul 23, 2010 |
| **AB** | | JUBILANT CADISTA | **5MG** | | **A077563** | **001** | Apr 19, 2006 |
| **AB** | | | **7.5MG** | | **A077563** | **003** | Aug 25, 2017 |
| **AB** | | | **10MG** | | **A077563** | **002** | Apr 19, 2006 |
| **AB** | | KVK TECH | **5MG** | | **A078048** | **001** | Feb 28, 2011 |
| **AB** | | | **10MG** | | **A078048** | **002** | Feb 28, 2011 |
| **AB** | | MYLAN PHARMS INC | **5MG** | | **A073144** | **002** | Feb 03, 2006 |
| **AB** | | | **7.5MG** | | **A073144** | **003** | Mar 25, 2013 |
| **AB** | **!** | | **10MG** | | **A073144** | **001** | May 30, 1991 |
| **AB** | | ORIT LABS LLC | **5MG** | | **A078218** | **002** | Jun 19, 2015 |
| **AB** | | | **10MG** | | **A078218** | **001** | Apr 18, 2008 |
| **AB** | | OXFORD PHARMS | **5MG** | | **A077209** | **002** | Feb 03, 2006 |
| **AB** | | | **10MG** | | **A077209** | **001** | Oct 04, 2005 |
| **AB** | | PLIVA | **10MG** | | **A074421** | **001** | Sep 29, 1995 |
| **AB** | | PRINSTON INC | **5MG** | | **A077797** | **001** | Feb 28, 2007 |
| **AB** | | | **10MG** | | **A077797** | **002** | Feb 28, 2007 |
| **AB** | | RUBICON RES PVT LTD | **5MG** | | **A208170** | **001** | May 31, 2017 |
| **AB** | | | **7.5MG** | | **A208170** | **002** | May 31, 2017 |
| **AB** | | | **10MG** | | **A208170** | **003** | May 31, 2017 |
| **AB** | | SUN PHARM INDS LTD | **5MG** | | **A078722** | **001** | May 12, 2008 |
| **AB** | | | **7.5MG** | | **A078722** | **002** | May 12, 2008 |
| **AB** | | | **10MG** | | **A078722** | **003** | May 12, 2008 |
| CYCLOPENTOLATE HYDROCHLORIDE | | | | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | | | | |
| **AKPENTOLATE** | | | | | | | |
| **AT** | | AKORN | **1%** | | **A040164** | **001** | Jan 13, 1997 |
| **CYCLOGYL** | | | | | | | |
| **AT** | **!** | NOVARTIS PHARMS CORP | **0.5%** | | **A084109** | **001** | |
| **AT** | **!** | | **1%** | | **A084110** | **001** | |
| **CYCLOPENTOLATE HYDROCHLORIDE** | | | | | | | |
| **AT** | | AKORN INC | **0.5%** | | **A205937** | **001** | Dec 09, 2015 |
| **PENTOLAIR** | | | | | | | |
| **AT** | | BAUSCH AND LOMB | **1%** | | **A040075** | **001** | Apr 29, 1994 |
| CYCLOGYL | | | | | | | |
| | ! | NOVARTIS PHARMS CORP | 2% | | A084108 | 001 | |
| CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE | | | | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | | | | |
| CYCLOMYDRIL | | | | | | | |
| | ! | NOVARTIS PHARMS CORP | 0.2%;1% | | A084300 | 001 | |
| CYCLOPHOSPHAMIDE | | | | | | | |
| CAPSULE;ORAL | | | | | | | |
| CYCLOPHOSPHAMIDE | | | | | | | |
| | + | WEST-WARD PHARMS INT | 25MG | | N203856 | 001 | Sep 16, 2013 |
| | +! | | 50MG | | N203856 | 002 | Sep 16, 2013 |
| INJECTABLE;INJECTION | | | | | | | |
| **CYCLOPHOSPHAMIDE** | | | | | | | |
| **AP** | **!** | BAXTER HLTHCARE | **500MG/VIAL** | | **A040745** | **001** | May 21, 2008 |
| **AP** | **!** | | **1GM/VIAL** | | **A040745** | **002** | May 21, 2008 |
| **AP** | **!** | | **2GM/VIAL** | | **A040745** | **003** | May 21, 2008 |
| **AP** | | JIANGSU HENGRUI MED | **500MG/VIAL** | | **A204555** | **001** | Oct 31, 2014 |
| **AP** | | | **1GM/VIAL** | | **A204555** | **002** | Oct 31, 2014 |
| **AP** | | | **2GM/VIAL** | | **A204555** | **003** | Oct 31, 2014 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| CYCLOSERINE | | | | | | | |
| CAPSULE;ORAL | | | | | | | |
| SEROMYCIN | | | | | | | |
| | ! | PURDUE GMP | 250MG | | A060593 | 001 | |
| CYCLOSPORINE | | | | | | | |
| CAPSULE;ORAL | | | | | | | |
| **CYCLOSPORINE** | | | | | | | |
| **AB1** | | IVAX SUB TEVA PHARMS | **25MG** | | **A065110** | **003** | Mar 29, 2005 |
| **AB1** | | | **50MG** | | **A065110** | **001** | Mar 29, 2005 |
| **AB1** | | | **100MG** | | **A065110** | **002** | Mar 29, 2005 |
| **AB1** | | MAYNE PHARMA | **25MG** | | **A065044** | **002** | Dec 20, 2000 |
| **AB1** | | | **100MG** | | **A065044** | **001** | Dec 20, 2000 |
| **AB1** | | SANDOZ | **25MG** | | **A065017** | **002** | Jan 13, 2000 |
| **AB1** | | | **100MG** | | **A065017** | **001** | Jan 13, 2000 |
| **GENGRAF** | | | | | | | |
| **AB1** | | ABBVIE | **25MG** | | **A065003** | **001** | May 12, 2000 |
| **AB1** | | | **50MG** | | **A065003** | **002** | May 12, 2000 |
| **AB1** | | | **100MG** | | **A065003** | **003** | May 12, 2000 |
| **NEORAL** | | | | | | | |
| **AB1** | + | NOVARTIS | **25MG** | | **N050715** | **001** | Jul 14, 1995 |
| **AB1** | +! | | **100MG** | | **N050715** | **002** | Jul 14, 1995 |
| **CYCLOSPORINE** | | | | | | | |
| **AB2** | | APOTEX | **25MG** | | **A065040** | **001** | May 09, 2002 |
| **AB2** | | | **100MG** | | **A065040** | **002** | May 09, 2002 |
| **SANDIMMUNE** | | | | | | | |
| **AB2** | + | NOVARTIS | **25MG** | | **N050625** | **001** | Mar 02, 1990 |
| **AB2** | +! | | **100MG** | | **N050625** | **002** | Mar 02, 1990 |
| BX | + | | 50MG | | N050625 | 003 | Nov 23, 1992 |
| EMULSION;OPHTHALMIC | | | | | | | |
| RESTASIS | | | | | | | |
| | +! | ALLERGAN | 0.05% | | N050790 | 001 | Dec 23, 2002 |
| RESTASIS MULTIDOSE | | | | | | | |
| | +! | ALLERGAN | 0.05% | | N050790 | 002 | Oct 27, 2016 |
| INJECTABLE;INJECTION | | | | | | | |
| **CYCLOSPORINE** | | | | | | | |
| **AP** | | LUITPOLD | **50MG/ML** | | **A065151** | **001** | Oct 07, 2003 |
| **AP** | | WEST-WARD PHARMS INT | **50MG/ML** | | **A065004** | **001** | Oct 29, 1999 |
| **SANDIMMUNE** | | | | | | | |
| **AP** | +! | NOVARTIS | **50MG/ML** | | **N050573** | **001** | Nov 14, 1983 |
| SOLUTION;ORAL | | | | | | | |
| **CYCLOSPORINE** | | | | | | | |
| **AB1** | | ABBVIE | **100MG/ML** | | **A065025** | **001** | Mar 03, 2000 |
| **AB1** | | IVAX SUB TEVA PHARMS | **100MG/ML** | | **A065078** | **001** | Mar 25, 2005 |
| **AB1** | | MAYNE PHARMA | **100MG/ML** | | **A065054** | **001** | Dec 18, 2001 |
| **NEORAL** | | | | | | | |
| **AB1** | +! | NOVARTIS | **100MG/ML** | | **N050716** | **001** | Jul 14, 1995 |
| **CYCLOSPORINE** | | | | | | | |
| **AB2** | | WOCKHARDT BIO AG | **100MG/ML** | | **A065133** | **001** | Sep 17, 2004 |
| **SANDIMMUNE** | | | | | | | |
| **AB2** | +! | NOVARTIS | **100MG/ML** | | **N050574** | **001** | Nov 14, 1983 |
| CYPROHEPTADINE HYDROCHLORIDE | | | | | | | |
| SYRUP;ORAL | | | | | | | |
| **CYPROHEPTADINE HYDROCHLORIDE** | | | | | | | |
| **AA** | | BIO-PHARM INC | **2MG/5ML** | | **A204823** | **001** | Dec 27, 2016 |
| **AA** | ! | LYNE | **2MG/5ML** | | **A040668** | **001** | Jun 28, 2006 |
| **AA** | | PHARM ASSOC | **2MG/5ML** | | **A091295** | **001** | Mar 28, 2013 |
| **AA** | | SILARX PHARMS INC | **2MG/5ML** | | **A203191** | **001** | Jul 13, 2017 |
| TABLET;ORAL | | | | | | | |
| **CYPROHEPTADINE HYDROCHLORIDE** | | | | | | | |
| **AA** | | AILEX PHARMS LLC | **4MG** | | **A207555** | **001** | Jan 31, 2017 |
| **AA** | | APEX PHARMS INC | **4MG** | | **A207783** | **001** | Dec 29, 2016 |
| **AA** | | APPCO PHARMA LLC | **4MG** | | **A206553** | **001** | Nov 29, 2016 |
| **AA** | | COREPHARMA | **4MG** | | **A040537** | **001** | Sep 30, 2003 |
| **AA** | | INGENUS PHARMS NJ | **4MG** | | **A205087** | **001** | Sep 23, 2015 |
| **AA** | ! | IVAX SUB TEVA PHARMS | **4MG** | | **A087056** | **001** | |
| **AA** | | PAR PHARM | **4MG** | | **A087129** | **001** | |
| **AA** | | SANTOS BIOTECH | **4MG** | | **A040644** | **001** | May 30, 2006 |
| **AA** | | ZYDUS PHARMS USA | **4MG** | | **A208938** | **001** | May 19, 2017 |

CYPROHEPTADINE HYDROCHLORIDE
TABLET;ORAL
**CYPROHEPTADINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| | | INC | | | | |

CYSTEAMINE BITARTRATE
CAPSULE;ORAL
CYSTAGON

| | | | | | | |
|---|---|---|---|---|---|---|
| + | | MYLAN | EQ 50MG BASE | N020392 | 001 | Aug 15, 1994 |
| +! | | | EQ 150MG BASE | N020392 | 002 | Aug 15, 1994 |

CAPSULE, DELAYED RELEASE;ORAL
PROCYSBI

| | | | | | | |
|---|---|---|---|---|---|---|
| + | | HORIZON PHARMA USA | EQ 25MG BASE | N203389 | 001 | Apr 30, 2013 |
| +! | | | EQ 75MG BASE | N203389 | 002 | Apr 30, 2013 |

CYSTEAMINE HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC
CYSTARAN

| | | | | | | |
|---|---|---|---|---|---|---|
| +! | | LEADIANT BIOSCI INC | EQ 0.44% BASE | N200740 | 001 | Oct 02, 2012 |

CYTARABINE
INJECTABLE;INJECTION
**CYTARABINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **!** | FRESENIUS KABI USA | **100MG/ML** | **A076512** | **001** | Jan 15, 2004 |
| **AP** | | HONG KONG | **20MG/ML** | **A206190** | **001** | Nov 09, 2017 |
| **AP** | **!** | HOSPIRA | **20MG/ML** | **A071868** | **001** | Jun 04, 1990 |
| **AP** | **!** | | **20MG/ML** | **A072168** | **001** | Aug 31, 1990 |
| **AP** | **!** | | **20MG/ML** | **A072945** | **001** | Feb 28, 1994 |
| **AP** | | | **100MG/ML** | **A075383** | **001** | Nov 22, 1999 |
| **AP** | | MYLAN LABS LTD | **20MG/ML** | **A200914** | **001** | Dec 13, 2011 |
| **AP** | | | **20MG/ML** | **A200915** | **001** | Dec 13, 2011 |
| **AP** | | | **100MG/ML** | **A201784** | **001** | Jan 30, 2012 |
| **AP** | | MYLAN PHARMS INC | **20MG/ML** | **A200916** | **001** | Dec 13, 2011 |
| | | WEST-WARD PHARMS INT | 100MG/VIAL | A071471 | 001 | Aug 02, 1989 |
| | ! | | 500MG/VIAL | A071472 | 001 | Aug 02, 1989 |
| | ! | | 1GM/VIAL | A074245 | 001 | Aug 31, 1994 |
| | ! | | 2GM/VIAL | A074245 | 002 | Aug 31, 1994 |

INJECTABLE, LIPOSOMAL;INJECTION
DEPOCYT

| | | | | | | |
|---|---|---|---|---|---|---|
| +! | | PACIRA PHARMS INC | 10MG/ML | N021041 | 001 | Apr 01, 1999 |

CYTARABINE; DAUNORUBICIN
POWDER;IV (INFUSION)
VYXEOS

| | | | | | | |
|---|---|---|---|---|---|---|
| +! | | CELATOR PHARMS | 100MG;44MG | N209401 | 001 | Aug 03, 2017 |

DABIGATRAN ETEXILATE MESYLATE
CAPSULE;ORAL
PRADAXA

| | | | | | | |
|---|---|---|---|---|---|---|
| + | | BOEHRINGER INGELHEIM | EQ 75MG BASE | N022512 | 001 | Oct 19, 2010 |
| + | | | EQ 110MG BASE | N022512 | 003 | Nov 20, 2015 |
| +! | | | EQ 150MG BASE | N022512 | 002 | Oct 19, 2010 |

DABRAFENIB MESYLATE
CAPSULE;ORAL
TAFINLAR

| | | | | | | |
|---|---|---|---|---|---|---|
| + | | NOVARTIS PHARMS CORP | EQ 50MG BASE | N202806 | 001 | May 29, 2013 |
| +! | | | EQ 75MG BASE | N202806 | 002 | May 29, 2013 |

DACARBAZINE
INJECTABLE;INJECTION
**DACARBAZINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **!** | FRESENIUS KABI USA | **200MG/VIAL** | **A075371** | **002** | Aug 27, 1999 |
| **AP** | | HOSPIRA | **200MG/VIAL** | **A075940** | **001** | Oct 18, 2001 |
| **AP** | | TEVA PHARMS USA | **200MG/VIAL** | **A075259** | **002** | Aug 27, 1998 |
| **AP** | **!** | | **500MG/VIAL** | **A075259** | **001** | Sep 22, 2000 |
| **AP** | | WEST-WARD PHARMS INT | **200MG/VIAL** | **A075812** | **001** | Jun 15, 2001 |
| **AP** | | | **500MG/VIAL** | **A075812** | **002** | Oct 31, 2002 |
| | ! | FRESENIUS KABI USA | 100MG/VIAL | A075371 | 001 | Aug 27, 1999 |

| | | | | | | |
|---|---|---|---|---|---|---|
| DACLATASVIR DIHYDROCHLORIDE | | | | | | |
| TABLET;ORAL | | | | | | |
| DAKLINZA | | | | | | |
| | + | BRISTOL-MYERS SQUIBB | EQ 30MG BASE | N206843 | 001 | Jul 24, 2015 |
| | +! | | EQ 60MG BASE | N206843 | 002 | Jul 24, 2015 |
| | + | | EQ 90MG BASE | N206843 | 003 | Apr 13, 2016 |
| DACTINOMYCIN | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| **COSMEGEN** | | | | | | |
| **AP** | **+!** | RECORDATI RARE | **0.5MG/VIAL** | **N050682** | **001** | |
| **DACTINOMYCIN** | | | | | | |
| **AP** | | LUITPOLD PHARMS INC | **0.5MG/VIAL** | **A202562** | **001** | Aug 23, 2013 |
| **AP** | | MYLAN LABS LTD | **0.5MG/VIAL** | **A203385** | **001** | Nov 09, 2017 |
| DALBAVANCIN HYDROCHLORIDE | | | | | | |
| POWDER;IV (INFUSION) | | | | | | |
| DALVANCE | | | | | | |
| | +! | ALLERGAN SALES LLC | EQ 500MG BASE/VIAL | N021883 | 001 | May 23, 2014 |
| DALFAMPRIDINE | | | | | | |
| TABLET, EXTENDED RELEASE;ORAL | | | | | | |
| **AMPYRA** | | | | | | |
| **AB** | **+!** | ACORDA | **10MG** | **N022250** | **001** | Jan 22, 2010 |
| **DALFAMPRIDINE** | | | | | | |
| **AB** | | ACTAVIS LABS FL INC | **10MG** | **A206836** | **001** | Jan 23, 2017 |
| **AB** | | AUROBINDO PHARMA LTD | **10MG** | **A206811** | **001** | Jan 23, 2017 |
| DALFOPRISTIN; QUINUPRISTIN | | | | | | |
| INJECTABLE;IV (INFUSION) | | | | | | |
| SYNERCID | | | | | | |
| | +! | KING PHARMS | 350MG/VIAL;150MG/VIAL | N050748 | 001 | Sep 21, 1999 |
| DALTEPARIN SODIUM | | | | | | |
| INJECTABLE;SUBCUTANEOUS | | | | | | |
| FRAGMIN | | | | | | |
| | + | PFIZER INC | 2,500IU/0.2ML (12,500IU/ML) | N020287 | 001 | Dec 22, 1994 |
| | + | | 5,000IU/0.2ML (25,000IU/ML) | N020287 | 003 | Mar 18, 1996 |
| | + | | 7,500IU/0.3ML (25,000IU/ML) | N020287 | 005 | Apr 04, 2002 |
| | + | | 10,000IU/ML (10,000IU/ML) | N020287 | 004 | Jan 30, 1998 |
| | + | | 12,500IU/0.5ML (25,000IU/ML) | N020287 | 009 | May 01, 2007 |
| | + | | 15,000IU/0.6ML (25,000IU/ML) | N020287 | 010 | May 01, 2007 |
| | + | | 18,000IU/0.72ML (25,000IU/ML) | N020287 | 011 | May 01, 2007 |
| | +! | | 95,000IU/3.8ML (25,000IU/ML) | N020287 | 006 | Apr 04, 2002 |
| DANAZOL | | | | | | |
| CAPSULE;ORAL | | | | | | |
| **DANAZOL** | | | | | | |
| **AB** | | BARR | **50MG** | **A074582** | **003** | May 29, 1998 |
| **AB** | | | **100MG** | **A074582** | **002** | May 29, 1998 |
| **AB** | **!** | | **200MG** | **A074582** | **001** | Aug 09, 1996 |
| **AB** | | LANNETT | **50MG** | **A077246** | **002** | Apr 19, 2007 |
| **AB** | | | **100MG** | **A077246** | **003** | Apr 19, 2007 |
| **AB** | | | **200MG** | **A077246** | **001** | Sep 28, 2005 |
| DANTROLENE SODIUM | | | | | | |
| CAPSULE;ORAL | | | | | | |
| **DANTRIUM** | | | | | | |
| **AB** | **+** | PAR STERILE PRODUCTS | **25MG** | **N017443** | **001** | |
| **AB** | **+** | | **50MG** | **N017443** | **003** | |
| **AB** | **+!** | | **100MG** | **N017443** | **002** | |
| **DANTROLENE SODIUM** | | | | | | |
| **AB** | | ELITE LABS INC | **25MG** | **A076686** | **001** | Oct 24, 2005 |
| **AB** | | | **50MG** | **A076686** | **002** | Oct 24, 2005 |
| **AB** | | | **100MG** | **A076686** | **003** | Oct 24, 2005 |
| **AB** | | IMPAX LABS | **25MG** | **A076856** | **001** | Mar 01, 2005 |
| **AB** | | | **50MG** | **A076856** | **002** | Mar 01, 2005 |
| **AB** | | | **100MG** | **A076856** | **003** | Mar 01, 2005 |
| FOR SUSPENSION;INTRAVENOUS | | | | | | |
| RYANODEX | | | | | | |
| | +! | EAGLE PHARMS | 250MG/VIAL | N205579 | 001 | Jul 22, 2014 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| DANTROLENE SODIUM | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| **DANTRIUM** | | | | | | | |
| **AP** | **+!** | PAR STERILE PRODUCTS | **20MG/VIAL** | **N018264** | **001** | | |
| **DANTROLENE SODIUM** | | | | | | | |
| **AP** | | HIKMA PHARMS | **20MG/VIAL** | **A204762** | **001** | Jun 19, 2017 | |
| **AP** | | MYLAN INSTITUTIONAL | **20MG/VIAL** | **A205239** | **001** | Feb 18, 2016 | |
| **REVONTO** | | | | | | | |
| **AP** | | US WORLDMEDS | **20MG/VIAL** | **A078378** | **001** | Jul 24, 2007 | |
| DAPAGLIFLOZIN PROPANEDIOL | | | | | | | |
| TABLET;ORAL | | | | | | | |
| FARXIGA | | | | | | | |
| | + | ASTRAZENECA AB | EQ 5MG BASE | N202293 | 001 | Jan 08, 2014 | |
| | +! | | EQ 10MG BASE | N202293 | 002 | Jan 08, 2014 | |
| DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE | | | | | | | |
| TABLET, EXTENDED RELEASE;ORAL | | | | | | | |
| XIGDUO XR | | | | | | | |
| | + | ASTRAZENECA AB | EQ 2.5MG BASE;1GM | N205649 | 005 | Jul 28, 2017 | |
| | + | | EQ 5MG BASE;500MG | N205649 | 001 | Oct 29, 2014 | |
| | + | | EQ 5MG BASE;1GM | N205649 | 002 | Oct 29, 2014 | |
| | + | | EQ 10MG BASE;500MG | N205649 | 003 | Oct 29, 2014 | |
| | +! | | EQ 10MG BASE;1GM | N205649 | 004 | Oct 29, 2014 | |
| DAPAGLIFLOZIN PROPANEDIOL; SAXAGLIPTIN HYDROCHLORIDE | | | | | | | |
| TABLET;ORAL | | | | | | | |
| QTERN | | | | | | | |
| | +! | ASTRAZENECA AB | EQ 10MG BASE;EQ 5MG BASE | N209091 | 001 | Feb 27, 2017 | |
| DAPSONE | | | | | | | |
| GEL;TOPICAL | | | | | | | |
| **ACZONE** | | | | | | | |
| **AB** | **+!** | ALLERGAN | **5%** | **N021794** | **001** | Jul 07, 2005 | |
| **DAPSONE** | | | | | | | |
| **AB** | | TARO | **5%** | **A209506** | **001** | Oct 16, 2017 | |
| ACZONE | | | | | | | |
| | +! | ALLERGAN INC | 7.5% | N207154 | 001 | Feb 24, 2016 | |
| TABLET;ORAL | | | | | | | |
| **DAPSONE** | | | | | | | |
| **AB** | | ACTAVIS LLC | **25MG** | **A204380** | **001** | Mar 23, 2017 | |
| **AB** | | | **100MG** | **A204380** | **002** | Mar 23, 2017 | |
| **AB** | | ALVOGEN | **25MG** | **A205429** | **001** | Jan 07, 2016 | |
| **AB** | | | **100MG** | **A205429** | **002** | Jan 07, 2016 | |
| **AB** | | JACOBUS | **25MG** | **A086841** | **001** | | |
| **AB** | **!** | | **100MG** | **A086842** | **001** | | |
| **AB** | | NOSTRUM LABS INC | **25MG** | **A203887** | **001** | May 06, 2016 | |
| **AB** | | | **100MG** | **A203887** | **002** | May 06, 2016 | |
| **AB** | | NOVITIUM PHARMA | **25MG** | **A206505** | **001** | Dec 01, 2016 | |
| **AB** | | | **100MG** | **A206505** | **002** | Dec 01, 2016 | |
| **AB** | | VIRTUS PHARMS | **25MG** | **A204074** | **001** | May 10, 2016 | |
| **AB** | | | **100MG** | **A204074** | **002** | May 10, 2016 | |
| DAPTOMYCIN | | | | | | | |
| POWDER;INTRAVENOUS | | | | | | | |
| **CUBICIN** | | | | | | | |
| **AP** | **+!** | CUBIST PHARMS LLC | **500MG/VIAL** | **N021572** | **002** | Sep 12, 2003 | |
| **DAPTOMYCIN** | | | | | | | |
| **AP** | | CRANE PHARMS LLC | **500MG/VIAL** | **A206005** | **001** | Jun 15, 2016 | |
| **AP** | | HOSPIRA INC | **500MG/VIAL** | **A202857** | **001** | Sep 12, 2014 | |
| **AP** | | TEVA PARENTERAL | **500MG/VIAL** | **A091039** | **001** | Mar 25, 2016 | |
| CUBICIN RF | | | | | | | |
| | +! | CUBIST PHARMS LLC | 500MG/VIAL | N021572 | 003 | Jul 06, 2016 | |
| POWDER;IV (INFUSION) | | | | | | | |
| DAPTOMYCIN | | | | | | | |
| | +! | SAGENT PHARMS | 350MG/VIAL | N208385 | 001 | Sep 12, 2017 | |
| | +! | XELLIA PHARMS APS | 350MG/VIAL | N209949 | 001 | Oct 20, 2017 | |
| DARIFENACIN HYDROBROMIDE | | | | | | | |
| TABLET, EXTENDED RELEASE;ORAL | | | | | | | |
| **DARIFENACIN** | | | | | | | |
| **AB** | | MACLEODS PHARMS LTD | **EQ 7.5MG BASE** | **A207302** | **001** | Jul 28, 2017 | |
| **AB** | | | **EQ 15MG BASE** | **A207302** | **002** | Jul 28, 2017 | |

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

**DARIFENACIN HYDROBROMIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALEMBIC PHARMS LTD | **EQ 7.5MG BASE** | **A207681** | **001** | Dec 08, 2017 |
| **AB** | | | **EQ 15MG BASE** | **A207681** | **002** | Dec 08, 2017 |
| **AB** | | ANCHEN PHARMS | **EQ 7.5MG BASE** | **A091190** | **001** | Mar 13, 2015 |
| **AB** | | | **EQ 15MG BASE** | **A091190** | **002** | Mar 13, 2015 |
| **AB** | | AUROBINDO PHARMA LTD | **EQ 7.5MG BASE** | **A206743** | **001** | Sep 19, 2016 |
| **AB** | | | **EQ 15MG BASE** | **A206743** | **002** | Sep 19, 2016 |
| **AB** | | CIPLA LTD | **EQ 7.5MG BASE** | **A207664** | **001** | Sep 01, 2016 |
| **AB** | | | **EQ 15MG BASE** | **A207664** | **002** | Sep 01, 2016 |
| **AB** | | JUBILANT GENERICS | **EQ 7.5MG BASE** | **A205550** | **001** | Oct 12, 2016 |
| **AB** | | | **EQ 15MG BASE** | **A205550** | **002** | Oct 12, 2016 |
| **AB** | | TORRENT PHARMS LTD | **EQ 7.5MG BASE** | **A205209** | **001** | Nov 17, 2016 |
| **AB** | | | **EQ 15MG BASE** | **A205209** | **002** | Nov 17, 2016 |

**ENABLEX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | APIL | **EQ 7.5MG BASE** | **N021513** | **001** | Dec 22, 2004 |
| **AB** | **+!** | | **EQ 15MG BASE** | **N021513** | **002** | Dec 22, 2004 |

DARUNAVIR ETHANOLATE

SUSPENSION;ORAL

PREZISTA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | JANSSEN PRODS | EQ 100MG BASE/ML | N202895 | 001 | Dec 16, 2011 |

TABLET;ORAL

**DARUNAVIR ETHANOLATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | TEVA PHARMS USA | **EQ 600MG BASE** | **A202118** | **001** | Nov 21, 2017 |

**PREZISTA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | JANSSEN PRODS | **EQ 600MG BASE** | **N021976** | **002** | Feb 25, 2008 |
| | + | | EQ 75MG BASE | N021976 | 004 | Dec 18, 2008 |
| | + | | EQ 150MG BASE | N021976 | 005 | Dec 18, 2008 |
| | +! | | EQ 800MG BASE | N021976 | 006 | Nov 09, 2012 |

DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET, TABLET;ORAL

VIEKIRA PAK (COPACKAGED)

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ABBVIE INC | EQ 250MG BASE,N/A,N/A,N/A; N/A,12.5MG,75MG,50MG | N206619 | 001 | Dec 19, 2014 |

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET, EXTENDED RELEASE;ORAL

VIEKIRA XR

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ABBVIE INC | EQ 200MG BASE;8.33MG;50MG;33.33MG | N208624 | 001 | Jul 22, 2016 |

DASATINIB

TABLET;ORAL

**DASATINIB**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | APOTEX INC | **20MG** | **A202103** | **001** | Jun 10, 2016 |
| **AB** | | | **50MG** | **A202103** | **002** | Jun 10, 2016 |
| **AB** | | | **70MG** | **A202103** | **003** | Jun 10, 2016 |
| **AB** | | | **100MG** | **A202103** | **004** | Jun 10, 2016 |

**SPRYCEL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | BRISTOL MYERS SQUIBB | **20MG** | **N021986** | **001** | Jun 28, 2006 |
| **AB** | **+** | | **50MG** | **N021986** | **002** | Jun 28, 2006 |
| **AB** | **+** | | **70MG** | **N021986** | **003** | Jun 28, 2006 |
| **AB** | **+!** | | **100MG** | **N021986** | **004** | May 30, 2008 |
| | + | | 80MG | N021986 | 005 | Oct 28, 2010 |
| | + | | 140MG | N021986 | 006 | Oct 28, 2010 |

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

**CERUBIDINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **!** | WEST-WARD PHARMS INT | **EQ 20MG BASE/VIAL** | **A064103** | **001** | Feb 03, 1995 |

**DAUNORUBICIN HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | FRESENIUS KABI USA | **EQ 20MG BASE/VIAL** | **A065000** | **001** | May 25, 1999 |
| **AP** | | TEVA PHARMS USA | **EQ 5MG BASE/ML** | **A065035** | **001** | Jan 24, 2000 |
| **AP** | **+!** | WEST-WARD PHARMS INT | **EQ 5MG BASE/ML** | **N050731** | **001** | Jan 30, 1998 |
| | | FRESENIUS KABI USA | EQ 5MG BASE/VIAL | A065034 | 001 | Nov 20, 2001 |

DECITABINE

INJECTABLE;INTRAVENOUS

| | | | | | | |
|---|---|---|---|---|---|---|
| **DACOGEN** | | | | | | |
| **AP** | **+!** | OTSUKA PHARM CO LTD | **50MG/VIAL** | **N021790** | **001** | May 02, 2006 |
| **DECITABINE** | | | | | | |
| **AP** | | ACCORD HLTHCARE | **50MG/VIAL** | **A203475** | **001** | Feb 27, 2017 |
| **AP** | | CHEMI SPA | **50MG/VIAL** | **A206033** | **001** | Sep 22, 2017 |
| **AP** | | CIPLA LTD | **50MG/VIAL** | **A208601** | **001** | Nov 16, 2017 |
| **AP** | | DR REDDYS LABS LTD | **50MG/VIAL** | **A203131** | **001** | Jul 11, 2013 |
| **AP** | | PHARMASCIENCE INC | **50MG/VIAL** | **A204607** | **001** | May 31, 2017 |
| **AP** | | SANDOZ INC | **50MG/VIAL** | **A202969** | **001** | Aug 28, 2014 |

POWDER;INTRAVENOUS

| | | | | | | |
|---|---|---|---|---|---|---|
| DECITABINE | | | | | | |
| | +! | SUN PHARMA GLOBAL | 50MG/VIAL | N205582 | 001 | Jan 28, 2014 |

DEFERASIROX

GRANULE;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| JADENU SPRINKLE | | | | | | |
| | + | NOVARTIS PHARMS CORP | 90MG | N207968 | 001 | May 18, 2017 |
| | + | | 180MG | N207968 | 002 | May 18, 2017 |
| | +! | | 360MG | N207968 | 003 | May 18, 2017 |

TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| JADENU | | | | | | |
| | + | NOVARTIS PHARMS CORP | 90MG | N206910 | 001 | Mar 30, 2015 |
| | + | | 180MG | N206910 | 002 | Mar 30, 2015 |
| | +! | | 360MG | N206910 | 003 | Mar 30, 2015 |

TABLET, FOR SUSPENSION;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **DEFERASIROX** | | | | | | |
| **AB** | | ACTAVIS ELIZABETH | **125MG** | **A203560** | **001** | Jan 26, 2016 |
| **AB** | | | **250MG** | **A203560** | **002** | Jan 26, 2016 |
| **AB** | | | **500MG** | **A203560** | **003** | Jan 26, 2016 |
| **EXJADE** | | | | | | |
| **AB** | **+** | NOVARTIS | **125MG** | **N021882** | **001** | Nov 02, 2005 |
| **AB** | **+** | | **250MG** | **N021882** | **002** | Nov 02, 2005 |
| **AB** | **+!** | | **500MG** | **N021882** | **003** | Nov 02, 2005 |

DEFERIPRONE

SOLUTION;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| FERRIPROX | | | | | | |
| | +! | APOPHARMA INC | 100MG/ML | N208030 | 001 | Sep 09, 2015 |

TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| FERRIPROX | | | | | | |
| | +! | APOPHARMA INC | 500MG | N021825 | 001 | Oct 14, 2011 |

DEFEROXAMINE MESYLATE

INJECTABLE;INJECTION

| | | | | | | |
|---|---|---|---|---|---|---|
| **DEFEROXAMINE MESYLATE** | | | | | | |
| **AP** | | FRESENIUS KABI USA | **500MG/VIAL** | **A078718** | **001** | Sep 15, 2009 |
| **AP** | | | **2GM/VIAL** | **A078718** | **002** | Sep 15, 2009 |
| **AP** | | GLAND PHARMA LTD | **500MG/VIAL** | **A207384** | **001** | Sep 29, 2017 |
| **AP** | | | **2GM/VIAL** | **A207384** | **002** | Sep 29, 2017 |
| **AP** | | HOSPIRA | **500MG/VIAL** | **A076019** | **001** | Mar 17, 2004 |
| **AP** | | | **2GM/VIAL** | **A076019** | **002** | Mar 17, 2004 |
| **AP** | | WEST-WARD PHARMS INT | **500MG/VIAL** | **A078086** | **001** | May 30, 2007 |
| **AP** | | | **2GM/VIAL** | **A078086** | **002** | May 30, 2007 |
| **DESFERAL** | | | | | | |
| **AP** | **+!** | NOVARTIS | **500MG/VIAL** | **N016267** | **001** | |
| **AP** | **+!** | | **2GM/VIAL** | **N016267** | **002** | May 25, 2000 |

DEFIBROTIDE SODIUM

SOLUTION;IV (INFUSION)

| | | | | | | |
|---|---|---|---|---|---|---|
| DEFITELIO | | | | | | |
| | +! | JAZZ PHARMS INC | 200MG/2.5ML (80MG/ML) | N208114 | 001 | Mar 30, 2016 |

DEFLAZACORT

SUSPENSION;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| EMFLAZA | | | | | | |
| | +! | PTC THERAP | 22.75MG/ML | N208685 | 001 | Feb 09, 2017 |

TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| EMFLAZA | | | | | | |
| | + | PTC THERAP | 6MG | N208684 | 001 | Feb 09, 2017 |
| | + | | 18MG | N208684 | 002 | Feb 09, 2017 |

DEFLAZACORT
TABLET;ORAL
EMFLAZA

| | | | | | |
|---|---|---|---|---|---|
| + | | 30MG | N208684 | 003 | Feb 09, 2017 |
| +! | | 36MG | N208684 | 004 | Feb 09, 2017 |

DEGARELIX ACETATE
POWDER;SUBCUTANEOUS
FIRMAGON

| | | | | | |
|---|---|---|---|---|---|
| + | FERRING | EQ 80MG BASE/VIAL | N022201 | 001 | Dec 24, 2008 |
| +! | | EQ 120MG BASE/VIAL | N022201 | 002 | Dec 24, 2008 |

DELAFLOXACIN MEGLUMINE
POWDER;IV (INFUSION)
BAXDELA

| | | | | | |
|---|---|---|---|---|---|
| +! | MELINTA | EQ 300MG BASE/VIAL | N208611 | 001 | Jun 19, 2017 |

TABLET;ORAL
BAXDELA

| | | | | | |
|---|---|---|---|---|---|
| +! | MELINTA | EQ 450MG BASE | N208610 | 001 | Jun 19, 2017 |

DELAVIRDINE MESYLATE
TABLET;ORAL
RESCRIPTOR

| | | | | | |
|---|---|---|---|---|---|
| + | VIIV HLTHCARE | 100MG | N020705 | 001 | Apr 04, 1997 |
| +! | | 200MG | N020705 | 002 | Jul 14, 1999 |

DEMECLOCYCLINE HYDROCHLORIDE
TABLET;ORAL
**DEMECLOCYCLINE HYDROCHLORIDE**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | AKORN | **150MG** | **A065389** | **001** | Dec 01, 2008 |
| **AB** | | **300MG** | **A065389** | **002** | Dec 01, 2008 |
| **AB** | AMNEAL PHARM | **150MG** | **A065425** | **001** | Feb 27, 2008 |
| **AB** ! | | **300MG** | **A065425** | **002** | Feb 27, 2008 |
| **AB** | BARR | **150MG** | **A065171** | **001** | Dec 13, 2004 |
| **AB** | | **300MG** | **A065171** | **002** | Dec 13, 2004 |
| **AB** | EPIC PHARMA LLC | **150MG** | **A065447** | **001** | Aug 18, 2015 |
| **AB** | | **300MG** | **A065447** | **002** | Aug 18, 2015 |

DEOXYCHOLIC ACID
SOLUTION;SUBCUTANEOUS
KYBELLA

| | | | | | |
|---|---|---|---|---|---|
| +! | KYTHERA BIOPHARMS | 20MG/2ML (10MG/ML) | N206333 | 001 | Apr 29, 2015 |

DESFLURANE
LIQUID;INHALATION
SUPRANE

| | | | | | |
|---|---|---|---|---|---|
| +! | BAXTER HLTHCARE | 99.9% | N020118 | 001 | Sep 18, 1992 |

DESIPRAMINE HYDROCHLORIDE
TABLET;ORAL
**DESIPRAMINE HYDROCHLORIDE**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | ACTAVIS TOTOWA | **10MG** | **A074430** | **001** | Feb 09, 1996 |
| **AB** | | **25MG** | **A071601** | **001** | Jun 05, 1987 |
| **AB** | | **50MG** | **A071588** | **001** | Jun 05, 1987 |
| **AB** | | **75MG** | **A071602** | **001** | Oct 05, 1987 |
| **AB** | | **100MG** | **A071766** | **001** | Oct 05, 1987 |
| **AB** | | **150MG** | **A074430** | **002** | Feb 09, 1996 |
| **AB** | AMNEAL PHARMS CO | **10MG** | **A208105** | **001** | Mar 17, 2016 |
| **AB** | | **25MG** | **A208105** | **002** | Mar 17, 2016 |
| **AB** | | **50MG** | **A208105** | **003** | Mar 17, 2016 |
| **AB** | | **75MG** | **A208105** | **004** | Mar 17, 2016 |
| **AB** | | **100MG** | **A208105** | **005** | Mar 17, 2016 |
| **AB** | | **150MG** | **A208105** | **006** | Mar 17, 2016 |
| **AB** | COREPHARMA | **10MG** | **A205153** | **001** | Oct 28, 2016 |
| **AB** | | **25MG** | **A205153** | **002** | Oct 28, 2016 |
| **AB** | | **50MG** | **A205153** | **003** | Oct 28, 2016 |
| **AB** | | **75MG** | **A205153** | **004** | Oct 28, 2016 |
| **AB** | | **100MG** | **A205153** | **005** | Oct 28, 2016 |
| **AB** | | **150MG** | **A205153** | **006** | Oct 28, 2016 |
| **AB** | HERITAGE PHARMS INC | **10MG** | **A207433** | **001** | May 05, 2016 |
| **AB** | | **25MG** | **A207433** | **002** | May 05, 2016 |
| **AB** | | **50MG** | **A207433** | **003** | May 05, 2016 |
| **AB** | | **75MG** | **A207433** | **004** | May 05, 2016 |
| **AB** | | **100MG** | **A207433** | **005** | May 05, 2016 |
| **AB** | | **150MG** | **A207433** | **006** | May 05, 2016 |
| **AB** | INGENUS PHARMS LLC | **10MG** | **A204963** | **001** | Dec 26, 2017 |

DESIPRAMINE HYDROCHLORIDE

TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **DESIPRAMINE HYDROCHLORIDE** | | | | | | |
| **AB** | | | **25MG** | **A204963** | **002** | Dec 26, 2017 |
| **AB** | | | **50MG** | **A204963** | **003** | Dec 26, 2017 |
| **AB** | | | **75MG** | **A204963** | **004** | Dec 26, 2017 |
| **AB** | | | **100MG** | **A204963** | **005** | Dec 26, 2017 |
| **AB** | | | **150MG** | **A204963** | **006** | Dec 26, 2017 |
| **AB** | | SANDOZ | **10MG** | **A072099** | **001** | May 24, 1988 |
| **AB** | | | **25MG** | **A072100** | **001** | May 24, 1988 |
| **AB** | | | **50MG** | **A072101** | **001** | May 24, 1988 |
| **AB** | | | **75MG** | **A072102** | **001** | Jun 20, 1988 |
| **AB** | | | **100MG** | **A072103** | **001** | Jun 20, 1988 |
| **AB** | | | **150MG** | **A072104** | **001** | Jun 20, 1988 |
| **NORPRAMIN** | | | | | | |
| **AB** | + | US PHARM HOLDINGS | **10MG** | **N014399** | **007** | Feb 11, 1982 |
| **AB** | + | | **25MG** | **N014399** | **001** | |
| **AB** | + | | **50MG** | **N014399** | **003** | |
| **AB** | + | | **75MG** | **N014399** | **004** | |
| **AB** | +! | | **100MG** | **N014399** | **005** | |
| **AB** | + | | **150MG** | **N014399** | **006** | |
| DESIPRAMINE HYDROCHLORIDE | | | | | | |
| | | ANI PHARMS INC | 25MG | A071803 | 002 | Dec 08, 1987 |
| | | | 50MG | A071803 | 003 | Dec 08, 1987 |
| | | | 75MG | A071803 | 004 | Dec 08, 1987 |
| | | | 150MG | A071803 | 005 | May 29, 1997 |

DESIRUDIN RECOMBINANT

INJECTABLE;SUBCUTANEOUS

| | | | | | | |
|---|---|---|---|---|---|---|
| IPRIVASK | | | | | | |
| | +! | VALEANT PHARMS NORTH | 15MG/VIAL | N021271 | 001 | Apr 04, 2003 |

DESLORATADINE

SOLUTION;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **CLARINEX** | | | | | | |
| **AA** | **+!** | MERCK SHARP DOHME | **0.5MG/ML** | **N021300** | **001** | Sep 01, 2004 |
| **DESLORATADINE** | | | | | | |
| **AA** | | TARO PHARM | **0.5MG/ML** | **A202936** | **001** | May 26, 2016 |
| **AA** | | TARO PHARM INDS | **0.5MG/ML** | **A202592** | **001** | Jun 30, 2015 |

TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **CLARINEX** | | | | | | |
| **AB** | **+!** | MERCK SHARP DOHME | **5MG** | **N021165** | **001** | Dec 21, 2001 |
| **DESLORATADINE** | | | | | | |
| **AB** | | BELCHER PHARMS | **5MG** | **A078355** | **001** | Apr 19, 2012 |
| **AB** | | DR REDDYS LABS LTD | **5MG** | **A078365** | **001** | Mar 08, 2011 |
| **AB** | | LUPIN PHARMS | **5MG** | **A078352** | **001** | Oct 25, 2010 |
| **AB** | | MYLAN PHARMS INC | **5MG** | **A078351** | **001** | Feb 10, 2012 |
| **AB** | | ORCHID HLTHCARE | **5MG** | **A078357** | **001** | Feb 19, 2010 |
| **AB** | | PERRIGO R AND D | **5MG** | **A078361** | **001** | Dec 22, 2011 |
| **AB** | | SANDOZ | **5MG** | **A078364** | **001** | Dec 03, 2010 |
| **AB** | | SUN PHARM INDS | **5MG** | **A078359** | **001** | Nov 16, 2010 |

TABLET, ORALLY DISINTEGRATING;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **CLARINEX** | | | | | | |
| **AB** | + | MERCK SHARP DOHME | **2.5MG** | **N021312** | **002** | Jul 14, 2005 |
| **AB** | **+!** | | **5MG** | **N021312** | **001** | Jun 26, 2002 |
| **DESLORATADINE** | | | | | | |
| **AB** | | REDDYS | **2.5MG** | **A078367** | **001** | Jul 12, 2010 |
| **AB** | | | **5MG** | **A078367** | **002** | Jul 12, 2010 |

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **CLARINEX D 24 HOUR** | | | | | | |
| **AB** | **+!** | MERCK SHARP DOHME | **5MG;240MG** | **N021605** | **001** | Mar 03, 2005 |
| **DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR** | | | | | | |
| **AB** | | DR REDDYS LABS LTD | **5MG;240MG** | **A078366** | **001** | Apr 26, 2011 |
| CLARINEX-D 12 HOUR | | | | | | |
| | +! | MERCK SHARP DOHME | 2.5MG;120MG | N021313 | 001 | Feb 01, 2006 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| DESMOPRESSIN ACETATE | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| **DDAVP** | | | | | | | |
| **AP** | **+!** | FERRING PHARMS INC | **0.004MG/ML** | **N018938** | **001** | Mar 30, 1984 |
| **DESMOPRESSIN ACETATE** | | | | | | | |
| **AP** | | SAGENT PHARMS | **0.004MG/ML** | **A204695** | **001** | Aug 22, 2017 |
| **AP** | | | **0.004MG/ML** | **A204751** | **001** | Aug 22, 2017 |
| **AP** | | SUN PHARM INDS LTD | **0.004MG/ML** | **A091280** | **001** | Jan 25, 2013 |
| SOLUTION;NASAL | | | | | | | |
| **DDAVP** | | | | | | | |
| **AB** | **+!** | FERRING PHARMS INC | **0.01%** | **N017922** | **001** | |
| **DESMOPRESSIN ACETATE** | | | | | | | |
| **AB** | | SUN PHARM INDS | **0.01%** | **A077212** | **001** | Apr 12, 2012 |
| SPRAY, METERED;NASAL | | | | | | | |
| **DDAVP (NEEDS NO REFRIGERATION)** | | | | | | | |
| **AB** | **+!** | FERRING PHARMS INC | **0.01MG/SPRAY** | **N017922** | **003** | Aug 07, 1996 |
| **DESMOPRESSIN ACETATE** | | | | | | | |
| **AB** | **!** | BAUSCH AND LOMB | **0.01MG/SPRAY** | **A074830** | **001** | Jan 25, 1999 |
| **DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)** | | | | | | | |
| **AB** | | APOTEX INC | **0.01MG/SPRAY** | **A076703** | **001** | Jan 27, 2005 |
| **AB** | | SUN PHARMA GLOBAL | **0.01MG/SPRAY** | **A078271** | **001** | Dec 23, 2013 |
| **AB** | | ZYDUS PHARMS USA INC | **0.01MG/SPRAY** | **A091345** | **001** | Oct 03, 2017 |
| **MINIRIN** | | | | | | | |
| **AB** | **+!** | FERRING | **0.01MG/SPRAY** | **N021333** | **001** | Sep 16, 2002 |
| NOCTIVA | | | | | | | |
| | + | AVADEL SPECLT | 0.00083MG/SPRAY | N201656 | 001 | Mar 03, 2017 |
| | +! | | 0.00166MG/SPRAY | N201656 | 002 | Mar 03, 2017 |
| STIMATE (NEEDS NO REFRIGERATION) | | | | | | | |
| | +! | FERRING PHARMS INC | 0.15MG/SPRAY | N020355 | 002 | Oct 24, 2007 |
| TABLET;ORAL | | | | | | | |
| **DDAVP** | | | | | | | |
| **AB** | **+** | FERRING PHARMS INC | **0.1MG** | **N019955** | **001** | Sep 06, 1995 |
| **AB** | **+!** | | **0.2MG** | **N019955** | **002** | Sep 06, 1995 |
| **DESMOPRESSIN ACETATE** | | | | | | | |
| **AB** | | ACTAVIS LABS FL INC | **0.1MG** | **A076470** | **001** | Jul 01, 2005 |
| **AB** | | | **0.2MG** | **A076470** | **002** | Jul 01, 2005 |
| **AB** | | APOTEX INC | **0.1MG** | **A077414** | **001** | Mar 07, 2006 |
| **AB** | | | **0.2MG** | **A077414** | **002** | Mar 07, 2006 |
| **AB** | | GLENMARK PHARMS LTD | **0.1MG** | **A201831** | **001** | May 28, 2015 |
| **AB** | | | **0.2MG** | **A201831** | **002** | May 28, 2015 |
| **AB** | | HERITAGE PHARMA | **0.1MG** | **A207880** | **001** | May 26, 2017 |
| **AB** | | | **0.2MG** | **A207880** | **002** | May 26, 2017 |
| **AB** | | IMPAX LABS INC | **0.1MG** | **A077122** | **001** | Jan 25, 2006 |
| **AB** | | | **0.2MG** | **A077122** | **002** | Jan 25, 2006 |
| **AB** | | MYLAN PHARMS INC | **0.1MG** | **A200653** | **001** | Jun 27, 2014 |
| **AB** | | | **0.2MG** | **A200653** | **002** | Jun 27, 2014 |
| DESOGESTREL; ETHINYL ESTRADIOL | | | | | | | |
| TABLET;ORAL-28 | | | | | | | |
| **BEKYREE** | | | | | | | |
| **AB** | | LUPIN LTD | **0.15MG,N/A;0.02MG,0.01MG** | **A202226** | **001** | Aug 12, 2015 |
| **CYCLESSA** | | | | | | | |
| **AB** | **+!** | ASPEN GLOBAL INC | **0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG** | **N021090** | **001** | Dec 20, 2000 |
| **DESOGEN** | | | | | | | |
| **AB** | | ORGANON USA INC | **0.15MG;0.03MG** | **N020071** | **002** | Dec 10, 1992 |
| **DESOGESTREL AND ETHINYL ESTRADIOL** | | | | | | | |
| **AB** | | ACCORD HLTHCARE | **0.15MG,N/A;0.02MG,0.01MG** | **A209170** | **001** | Jun 05, 2017 |
| **AB** | | AUROBINDO PHARMA LTD | **0.15MG,N/A;0.02MG,0.01MG** | **A206853** | **001** | Mar 22, 2017 |
| **AB** | **!** | DURAMED PHARMS BARR | **0.15MG;0.03MG** | **A075256** | **002** | Aug 12, 1999 |
| **AB** | | MAYNE PHARMA | **0.15MG,N/A;0.02MG,0.01MG** | **A076916** | **001** | Dec 29, 2008 |
| **AB** | | | **0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG** | **A077182** | **001** | Jan 24, 2006 |
| **AB** | | MYLAN LABS LTD | **0.15MG,N/A;0.02MG,0.01MG** | **A202296** | **001** | Aug 30, 2013 |
| **AB** | | | **0.15MG;0.03MG** | **A202085** | **001** | May 20, 2015 |
| **AB** | | NOVAST LABS LTD | **0.15MG;0.03MG** | **A091234** | **001** | Jul 12, 2013 |
| **AB** | | WATSON LABS | **0.15MG;0.03MG** | **A076915** | **001** | Jul 29, 2005 |
| **EMOQUETTE** | | | | | | | |
| **AB** | | VINTAGE PHARMS LLC | **0.15MG;0.03MG** | **A076675** | **001** | Feb 25, 2011 |
| **ENSKYCE** | | | | | | | |
| **AB** | | LUPIN LTD | **0.15MG;0.03MG** | **A201887** | **001** | Mar 07, 2013 |

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-28

| | | | | | | |
|---|---|---|---|---|---|---|
| **ISIBLOOM** | | | | | | |
| **AB** | | LABS LEON FARMA | **0.15MG;0.03MG** | **A202789** | **001** | Aug 12, 2015 |
| **KALLIGA** | | | | | | |
| **AB** | | AUROBINDO PHARMA LTD | **0.15MG;0.03MG** | **A207081** | **001** | May 17, 2017 |
| **KARIVA** | | | | | | |
| **AB** | **!** | BARR | **0.15MG,N/A;0.02MG,0.01MG** | **A075863** | **001** | Apr 05, 2002 |
| **KIMIDESS** | | | | | | |
| **AB** | | VINTAGE PHARMS | **0.15MG,N/A;0.02MG,0.01MG** | **A076681** | **001** | Apr 30, 2015 |
| **PIMTREA** | | | | | | |
| **AB** | | NOVAST LABS LTD | **0.15MG,N/A;0.02MG,0.01MG** | **A091247** | **001** | Aug 01, 2013 |
| **VELIVET** | | | | | | |
| **AB** | | DURAMED PHARMS BARR | **0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG** | **A076455** | **001** | Feb 24, 2004 |
| **VIORELE** | | | | | | |
| **AB** | | GLENMARK GENERICS | **0.15MG,N/A;0.02MG,0.01MG** | **A091346** | **001** | Apr 02, 2012 |
| **VOLNEA** | | | | | | |
| **AB** | | LABS LEON FARMA | **0.15MG,N/A;0.02MG,0.01MG** | **A202689** | **001** | Sep 09, 2016 |

DESONIDE

AEROSOL, FOAM;TOPICAL

| | | | | | | |
|---|---|---|---|---|---|---|
| VERDESO | | | | | | |
| | +! | AQUA PHARMS | 0.05% | N021978 | 001 | Sep 19, 2006 |

CREAM;TOPICAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **DESONIDE** | | | | | | |
| **AB** | | G AND W LABS INC | **0.05%** | **A074027** | **001** | Sep 28, 1992 |
| **AB** | | GLENMARK PHARMS | **0.05%** | **A209729** | **001** | Jul 24, 2017 |
| **AB** | **+!** | PERRIGO NEW YORK | **0.05%** | **N017010** | **001** | |
| **AB** | | TARO | **0.05%** | **A073548** | **001** | Jun 30, 1992 |
| **DESOWEN** | | | | | | |
| **AB** | | GALDERMA LABS LP | **0.05%** | **N019048** | **001** | Dec 14, 1984 |

GEL;TOPICAL

| | | | | | | |
|---|---|---|---|---|---|---|
| DESONATE | | | | | | |
| | +! | BAYER HLTHCARE | 0.05% | N021844 | 001 | Oct 20, 2006 |

LOTION;TOPICAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **DESONIDE** | | | | | | |
| **AB** | | FOUGERA PHARMS | **0.05%** | **A075860** | **001** | Mar 19, 2002 |
| **AB** | | GLENMARK PHARMS | **0.05%** | **A209494** | **001** | Sep 26, 2017 |
| **AB** | | TARO PHARM | **0.05%** | **A202161** | **001** | Oct 31, 2014 |
| **AB** | | TELIGENT PHARMA INC | **0.05%** | **A207855** | **001** | Sep 28, 2017 |
| **DESOWEN** | | | | | | |
| **AB** | **!** | GALDERMA LABS LP | **0.05%** | **A072354** | **001** | Jan 24, 1992 |

OINTMENT;TOPICAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **DESONIDE** | | | | | | |
| **AB** | | FOUGERA PHARMS | **0.05%** | **A075751** | **001** | Mar 12, 2001 |
| **AB** | | GLENMARK PHARMS LTD | **0.05%** | **A209996** | **001** | Sep 15, 2017 |
| **AB** | | HI-TECH PHARMACAL | **0.05%** | **A208836** | **001** | Mar 27, 2017 |
| **AB** | **+!** | PERRIGO NEW YORK | **0.05%** | **N017426** | **001** | |
| **AB** | | TARO | **0.05%** | **A074254** | **001** | Aug 03, 1994 |
| **DESOWEN** | | | | | | |
| **AB** | | GALDERMA LABS LP | **0.05%** | **A071425** | **001** | Jun 15, 1988 |

DESOXIMETASONE

CREAM;TOPICAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **DESOXIMETASONE** | | | | | | |
| **AB** | | ACTAVIS MID ATLANTIC | **0.25%** | **A205082** | **001** | Sep 04, 2015 |
| **AB** | | AKORN | **0.05%** | **A203787** | **001** | Jan 06, 2017 |
| **AB** | | | **0.25%** | **A203234** | **001** | Jun 12, 2015 |
| **AB** | | FOUGERA PHARMS | **0.25%** | **A078369** | **001** | Jun 29, 2010 |
| **AB** | | LUPIN ATLANTIS | **0.05%** | **A208163** | **001** | Jan 10, 2017 |
| **AB** | | | **0.25%** | **A208164** | **001** | Jan 09, 2017 |
| **AB** | | PERRIGO NEW YORK | **0.25%** | **A076510** | **001** | Jul 01, 2003 |
| **TOPICORT** | | | | | | |
| **AB** | **!** | TARO | **0.05%** | **A073210** | **001** | Nov 30, 1990 |
| **AB** | **!** | | **0.25%** | **A073193** | **001** | Nov 30, 1990 |

GEL;TOPICAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **DESOXIMETASONE** | | | | | | |
| **AB** | | AKORN | **0.05%** | **A090727** | **001** | Mar 10, 2011 |
| **AB** | | PERRIGO NEW YORK | **0.05%** | **A077552** | **001** | Jan 09, 2006 |
| **AB** | | RISING PHARMS INC | **0.05%** | **A204675** | **001** | Aug 12, 2016 |

DESOXIMETASONE

GEL;TOPICAL

**TOPICORT**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **!** | TARO | **0.05%** | **A074904** | **001** | Jul 14, 1998 |

OINTMENT;TOPICAL

**DESOXIMETASONE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS MID ATLANTIC | **0.25%** | **A204965** | **001** | Nov 07, 2016 |
| **AB** | | AKORN | **0.25%** | **A201005** | **001** | Apr 24, 2014 |
| **AB** | | FOUGERA PHARMS | **0.25%** | **A078657** | **001** | Sep 28, 2012 |
| **AB** | | G AND W LABS INC | **0.25%** | **A206740** | **001** | Dec 23, 2016 |
| **AB** | | GLENMARK GENERICS | **0.25%** | **A202838** | **001** | Sep 20, 2013 |
| **AB** | | LUPIN ATLANTIS | **0.05%** | **A208044** | **001** | Dec 12, 2016 |
| **AB** | | | **0.25%** | **A208104** | **001** | Dec 01, 2016 |
| **AB** | | NOVEL LABS INC | **0.25%** | **A206792** | **001** | May 10, 2016 |
| **AB** | | PERRIGO ISRAEL | **0.25%** | **A077770** | **001** | Apr 20, 2015 |
| **AB** | | RISING PHARMS INC | **0.25%** | **A204272** | **001** | Nov 30, 2016 |
| **AB** | | TELIGENT PHARMA INC | **0.25%** | **A208101** | **001** | Feb 25, 2016 |
| **AB** | | ZYDUS PHARMS USA INC | **0.25%** | **A205206** | **001** | Sep 19, 2017 |

**TOPICORT**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | TARO | **0.05%** | **N018594** | **001** | Jan 17, 1985 |
| **AB** | **!** | | **0.25%** | **A074286** | **001** | Jun 07, 1996 |

SPRAY;TOPICAL

**DESOXIMETASONE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | PERRIGO ISRAEL | **0.25%** | **A206441** | **001** | Jan 20, 2017 |

**TOPICORT**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **+!** | TARO | **0.25%** | **N204141** | **001** | Apr 11, 2013 |

DESVENLAFAXINE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE

| | | | | | | |
|---|---|---|---|---|---|---|
| BC | +! | ALEMBIC PHARMS LTD | 50MG | N204150 | 001 | Mar 04, 2013 |
| BC | +! | | 100MG | N204150 | 002 | Mar 04, 2013 |

KHEDEZLA

| | | | | | | |
|---|---|---|---|---|---|---|
| BC | | OSMOTICA PHARM CORP | 50MG | N204683 | 001 | Jul 10, 2013 |
| BC | | | 100MG | N204683 | 002 | Jul 10, 2013 |

DESVENLAFAXINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | SUN PHARMA GLOBAL | EQ 50MG BASE | N205583 | 001 | Jan 28, 2014 |
| | +! | | EQ 100MG BASE | N205583 | 002 | Jan 28, 2014 |

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

**DESVENLAFAXINE SUCCINATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS LABS FL | **EQ 25MG BASE** | **A204065** | **001** | Jul 29, 2016 |
| **AB** | | | **EQ 50MG BASE** | **A204065** | **002** | Jul 29, 2016 |
| **AB** | | | **EQ 100MG BASE** | **A204065** | **003** | Jul 29, 2016 |
| **AB** | | ALEMBIC PHARMS LTD | **EQ 50MG BASE** | **A204003** | **001** | Jun 29, 2015 |
| **AB** | | | **EQ 100MG BASE** | **A204003** | **002** | Jun 29, 2015 |
| **AB** | | LUPIN LTD | **EQ 50MG BASE** | **A204172** | **001** | Jun 29, 2015 |
| **AB** | | | **EQ 100MG BASE** | **A204172** | **002** | Jun 29, 2015 |
| **AB** | | MYLAN PHARMS INC | **EQ 50MG BASE** | **A204095** | **001** | Jun 29, 2015 |
| **AB** | | | **EQ 100MG BASE** | **A204095** | **002** | Jun 29, 2015 |
| **AB** | | SANDOZ INC | **EQ 50MG BASE** | **A204028** | **001** | Jun 29, 2015 |
| **AB** | | | **EQ 100MG BASE** | **A204028** | **002** | Jun 29, 2015 |
| **AB** | | WEST-WARD PHARMS INT | **EQ 25MG BASE** | **A204082** | **002** | Aug 28, 2017 |
| **AB** | | | **EQ 50MG BASE** | **A204082** | **001** | Feb 16, 2016 |
| **AB** | | | **EQ 100MG BASE** | **A204083** | **001** | Feb 16, 2016 |
| **AB** | | ZYDUS PHARMS USA INC | **EQ 50MG BASE** | **A204020** | **001** | Oct 11, 2017 |
| **AB** | | | **EQ 100MG BASE** | **A204020** | **002** | Oct 11, 2017 |

**PRISTIQ**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | WYETH PHARMS INC | **EQ 25MG BASE** | **N021992** | **003** | Aug 20, 2014 |
| **AB** | **+!** | | **EQ 50MG BASE** | **N021992** | **001** | Feb 29, 2008 |
| **AB** | **+!** | | **EQ 100MG BASE** | **N021992** | **002** | Feb 29, 2008 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| DEUTETRABENAZINE | | | | | | | |
| TABLET;ORAL | | | | | | | |
| AUSTEDO | | | | | | | |
| | + | TEVA BRANDED PHARM | 6MG | N208082 | 001 | Apr 03, 2017 |
| | + | | 9MG | N208082 | 002 | Apr 03, 2017 |
| | +! | | 12MG | N208082 | 003 | Apr 03, 2017 |
| DEXAMETHASONE | | | | | | | |
| CONCENTRATE;ORAL | | | | | | | |
| DEXAMETHASONE INTENSOL | | | | | | | |
| | ! | WEST-WARD PHARMS INT | 1MG/ML | A088252 | 001 | Sep 01, 1983 |
| ELIXIR;ORAL | | | | | | | |
| **DEXAMETHASONE** | | | | | | | |
| **AA** | | LYNE | **0.5MG/5ML** | **A090891** | **001** | Jul 12, 2011 |
| **AA** | **!** | STI PHARMA LLC | **0.5MG/5ML** | **A084754** | **001** | |
| **AA** | | VINTAGE PHARMS | **0.5MG/5ML** | **A091188** | **001** | May 11, 2011 |
| **AA** | | WOCKHARDT BIO AG | **0.5MG/5ML** | **A088254** | **001** | Jul 27, 1983 |
| IMPLANT;INTRAVITREAL | | | | | | | |
| OZURDEX | | | | | | | |
| | +! | ALLERGAN | 0.7MG | N022315 | 001 | Jun 17, 2009 |
| SOLUTION;ORAL | | | | | | | |
| DEXAMETHASONE | | | | | | | |
| | ! | WEST-WARD PHARMS INT | 0.5MG/5ML | A088248 | 001 | Sep 01, 1983 |
| SUSPENSION/DROPS;OPHTHALMIC | | | | | | | |
| MAXIDEX | | | | | | | |
| | +! | NOVARTIS PHARMS CORP | 0.1% | N013422 | 001 | |
| TABLET;ORAL | | | | | | | |
| **DEXAMETHASONE** | | | | | | | |
| **AB** | | ECR | **1.5MG** | **A040700** | **001** | Aug 15, 2008 |
| **AB** | | LARKEN LABS INC | **1.5MG** | **A201270** | **001** | Jul 17, 2017 |
| **AB** | | WEST-WARD PHARMS INT | **1.5MG** | **A084610** | **001** | |
| BP | | PAR PHARM | 0.5MG | A088148 | 001 | Apr 28, 1983 |
| BP | | | 0.75MG | A088160 | 001 | Apr 28, 1983 |
| BP | | | 4MG | A088238 | 001 | Apr 28, 1983 |
| BP | | | 6MG | A088481 | 001 | Nov 28, 1983 |
| BP | | WEST-WARD PHARMS INT | 0.5MG | A084611 | 001 | |
| BP | | | 0.75MG | A084613 | 001 | |
| BP | | | 1MG | A088306 | 001 | Sep 15, 1983 |
| BP | | | 2MG | A087916 | 001 | Aug 26, 1982 |
| BP | | | 4MG | A084612 | 001 | |
| BP | ! | | 6MG | A088316 | 001 | Sep 15, 1983 |
| BP | | XSPIRE PHARMA | 1.5MG | A088237 | 001 | Apr 28, 1983 |
| DEXAMETHASONE SODIUM PHOSPHATE | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| **DEXAMETHASONE SODIUM PHOSPHATE** | | | | | | | |
| **AP** | | AUROBINDO PHARMA LTD | **EQ 4MG PHOSPHATE/ML** | **A206781** | **001** | Dec 01, 2015 |
| **AP** | | FRESENIUS KABI USA | **EQ 4MG PHOSPHATE/ML** | **A084916** | **001** | |
| **AP** | | | **EQ 4MG PHOSPHATE/ML** | **A203129** | **001** | Sep 30, 2015 |
| **AP** | **!** | | **EQ 10MG PHOSPHATE/ML** | **A040572** | **001** | Apr 22, 2005 |
| **AP** | **!** | LUITPOLD | **EQ 4MG PHOSPHATE/ML** | **A087440** | **001** | Jul 21, 1982 |
| **AP** | | MYLAN LABS LTD | **EQ 4MG PHOSPHATE/ML** | **A040803** | **001** | Aug 29, 2008 |
| **AP** | | | **EQ 10MG PHOSPHATE/ML** | **A040802** | **001** | Aug 29, 2008 |
| **AP** | | WEST-WARD PHARMS INT | **EQ 4MG PHOSPHATE/ML** | **A084282** | **001** | |
| **AP** | **!** | | **EQ 10MG PHOSPHATE/ML** | **A087702** | **001** | Sep 07, 1982 |
| **DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE** | | | | | | | |
| **AP** | **!** | FRESENIUS KABI USA | **EQ 10MG PHOSPHATE/ML** | **A040491** | **001** | Apr 11, 2003 |
| SOLUTION/DROPS;OPHTHALMIC, OTIC | | | | | | | |
| **DEXAMETHASONE SODIUM PHOSPHATE** | | | | | | | |
| **AT** | | BAUSCH AND LOMB | **EQ 0.1% PHOSPHATE** | **A040069** | **001** | Jul 26, 1996 |
| **AT** | **!** | SANDOZ INC | **EQ 0.1% PHOSPHATE** | **A088771** | **001** | Jan 16, 1985 |

| | | | | | | |
|---|---|---|---|---|---|---|
| DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE | | | | | | |
| OINTMENT;OPHTHALMIC | | | | | | |
| **MAXITROL** | | | | | | |
| **AT** | **+!** | NOVARTIS PHARMS CORP | **0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM** | **N050065** | **002** | |
| **NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE** | | | | | | |
| **AT** | | BAUSCH AND LOMB | **0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM** | **A064063** | **001** | Jul 25, 1994 |
| **AT** | | PERRIGO CO TENNESSEE | **0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM** | **A062938** | **001** | Jul 31, 1989 |
| SUSPENSION/DROPS;OPHTHALMIC | | | | | | |
| **DEXASPORIN** | | | | | | |
| **AT** | | BAUSCH AND LOMB | **0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML** | **A064135** | **001** | Sep 13, 1995 |
| **MAXITROL** | | | | | | |
| **AT** | **+!** | NOVARTIS PHARMS CORP | **0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML** | **N050023** | **002** | |
| **AT** | | SANDOZ INC | **0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML** | **A062341** | **001** | May 22, 1984 |
| DEXAMETHASONE; TOBRAMYCIN | | | | | | |
| OINTMENT;OPHTHALMIC | | | | | | |
| TOBRADEX | | | | | | |
| | +! | NOVARTIS PHARMS CORP | 0.1%;0.3% | N050616 | 001 | Sep 28, 1988 |
| SUSPENSION/DROPS;OPHTHALMIC | | | | | | |
| **TOBRADEX** | | | | | | |
| **AB** | **+!** | NOVARTIS PHARMS CORP | **0.1%;0.3%** | **N050592** | **001** | Aug 18, 1988 |
| **TOBRAMYCIN AND DEXAMETHASONE** | | | | | | |
| **AB** | | BAUSCH AND LOMB | **0.1%;0.3%** | **A064134** | **001** | Oct 27, 1999 |
| TOBRADEX ST | | | | | | |
| | +! | NOVARTIS PHARMS CORP | 0.05%;0.3% | N050818 | 001 | Feb 13, 2009 |
| DEXCHLORPHENIRAMINE MALEATE | | | | | | |
| SYRUP;ORAL | | | | | | |
| DEXCHLORPHENIRAMINE MALEATE | | | | | | |
| | ! | WOCKHARDT BIO AG | 2MG/5ML | A088251 | 001 | Mar 23, 1984 |
| DEXLANSOPRAZOLE | | | | | | |
| CAPSULE, DELAYED RELEASE;ORAL | | | | | | |
| **DEXILANT** | | | | | | |
| **AB** | **+!** | TAKEDA PHARMS USA | **60MG** | **N022287** | **002** | Jan 30, 2009 |
| **DEXLANSOPRAZOLE** | | | | | | |
| **AB** | | PAR PHARM INC | **60MG** | **A202294** | **001** | Apr 19, 2017 |
| DEXILANT | | | | | | |
| | + | TAKEDA PHARMS USA | 30MG | N022287 | 001 | Jan 30, 2009 |
| DEXMEDETOMIDINE HYDROCHLORIDE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| **DEXMEDETOMIDINE HYDROCHLORIDE** | | | | | | |
| **AP** | | ACCORD HLTHCARE | **EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)** | **A204023** | **001** | Feb 09, 2016 |
| **AP** | | ACTAVIS INC | **EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)** | **A204686** | **001** | Oct 17, 2016 |
| **AP** | | AKORN INC | **EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)** | **A202585** | **001** | Nov 24, 2014 |
| **AP** | | AUROBINDO PHARMA LTD | **EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)** | **A205867** | **001** | Mar 17, 2016 |
| **AP** | | FRESENIUS KABI USA | **EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)** | **A201072** | **001** | Sep 18, 2015 |
| **AP** | | JIANGSU HENGRUI MED | **EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)** | **A209065** | **001** | Sep 19, 2017 |
| **AP** | | LUITPOLD PHARMS INC | **EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)** | **A203773** | **001** | May 12, 2017 |
| **AP** | | MYLAN INSTITUTIONAL | **EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)** | **A202881** | **001** | Aug 18, 2014 |
| **AP** | | PAR STERILE PRODUCTS | **EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)** | **A203972** | **001** | Aug 18, 2014 |
| **AP** | | SANDOZ INC | **EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)** | **A091465** | **001** | Jun 14, 2016 |
| **AP** | | SUN PHARM INDS INC | **EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)** | **A202126** | **001** | Aug 20, 2015 |
| **AP** | | TEVA PHARMS USA | **EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)** | **A205272** | **001** | Nov 28, 2017 |
| **AP** | | WEST-WARD PHARMS INT | **EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)** | **A205046** | **001** | Apr 26, 2017 |
| **PRECEDEX** | | | | | | |
| **AP** | **+!** | HOSPIRA | **EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)** | **N021038** | **001** | Dec 17, 1999 |
| | +! | | EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML) | N021038 | 004 | Nov 14, 2014 |
| | +! | | EQ 200MCG BASE/50ML (EQ 4MCG BASE/ML) | N021038 | 002 | Mar 13, 2013 |
| | +! | | EQ 400MCG BASE/100ML (EQ 4MCG BASE/ML) | N021038 | 003 | Mar 13, 2013 |
| SOLUTION;IV (INFUSION) | | | | | | |
| DEXMEDETOMIDINE HYDROCHLORIDE | | | | | | |
| | +! | HQ SPCLT PHARMA | EQ 1MG BASE/10ML (EQ 100MCG BASE/ML) | N206628 | 002 | Oct 21, 2015 |
| | + | | EQ 400MCG BASE/4ML (EQ 100MCG BASE/ML) | N206628 | 001 | Oct 21, 2015 |

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

**DEXMETHYLPHENIDATE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| AB | | IMPAX LABS INC | 5MG | A079108 | 001 | Aug 05, 2015 |
| AB | | | 10MG | A079108 | 002 | Aug 05, 2015 |
| AB | | | 15MG | A079108 | 003 | May 19, 2014 |
| AB | | | 20MG | A079108 | 004 | Dec 21, 2015 |
| AB | | | 25MG | A203614 | 001 | Jul 05, 2017 |
| AB | | | 30MG | A079108 | 005 | Nov 21, 2013 |
| AB | | | 35MG | A203614 | 002 | Jul 05, 2017 |
| AB | | INTELLIPHARMACEUTICS | 15MG | A078992 | 003 | Nov 18, 2013 |
| AB | | | 30MG | A078992 | 004 | Nov 18, 2013 |
| AB | | MYLAN PHARMS INC | 5MG | A204266 | 001 | Aug 25, 2015 |
| AB | | | 10MG | A204266 | 002 | Aug 25, 2015 |
| AB | | | 15MG | A204266 | 003 | Aug 25, 2015 |
| AB | | | 20MG | A204266 | 004 | Dec 21, 2015 |
| AB | | | 30MG | A202580 | 001 | Aug 28, 2013 |
| AB | | | 40MG | A204266 | 007 | Aug 25, 2015 |
| AB | | PAR PHARM INC | 5MG | A202842 | 001 | Nov 30, 2016 |
| AB | | | 10MG | A202842 | 002 | Nov 30, 2016 |
| AB | | | 15MG | A202842 | 003 | Nov 30, 2016 |
| AB | | | 20MG | A202842 | 004 | Nov 30, 2016 |
| AB | | | 25MG | A202842 | 005 | Nov 30, 2016 |
| AB | | | 30MG | A202842 | 006 | Nov 30, 2016 |
| AB | | | 35MG | A202842 | 007 | Nov 30, 2016 |
| AB | | | 40MG | A202842 | 008 | Nov 30, 2016 |
| AB | | TEVA PHARMS USA | 5MG | A078908 | 001 | Nov 19, 2013 |
| AB | | | 10MG | A078908 | 002 | Nov 19, 2013 |
| AB | | | 15MG | A078908 | 004 | May 19, 2014 |
| AB | | | 20MG | A078908 | 003 | Nov 19, 2013 |
| AB | | | 25MG | A202731 | 001 | Jul 05, 2017 |
| AB | | | 30MG | A202731 | 003 | May 19, 2014 |
| AB | | | 35MG | A202731 | 004 | Jul 05, 2017 |
| AB | | | 40MG | A202731 | 002 | Nov 19, 2013 |

**FOCALIN XR**

| | | | | | | |
|---|---|---|---|---|---|---|
| AB | + | NOVARTIS | 5MG | N021802 | 001 | May 26, 2005 |
| AB | + | | 10MG | N021802 | 002 | May 26, 2005 |
| AB | + | | 15MG | N021802 | 004 | Aug 01, 2006 |
| AB | + | | 20MG | N021802 | 003 | May 26, 2005 |
| AB | + | | 25MG | N021802 | 008 | Apr 21, 2011 |
| AB | + | | 30MG | N021802 | 005 | Oct 23, 2009 |
| AB | + | | 35MG | N021802 | 007 | Apr 21, 2011 |
| AB | +! | | 40MG | N021802 | 006 | Aug 11, 2010 |

TABLET;ORAL

**DEXMETHYLPHENIDATE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| AB | | ABHAI INC | 2.5MG | A206931 | 001 | Dec 04, 2015 |
| AB | | | 5MG | A206931 | 002 | Dec 04, 2015 |
| AB | | | 10MG | A206931 | 003 | Dec 04, 2015 |
| AB | | LANNETT CO INC | 2.5MG | A209468 | 001 | Sep 25, 2017 |
| AB | | | 5MG | A209468 | 002 | Sep 25, 2017 |
| AB | | | 10MG | A209468 | 003 | Sep 25, 2017 |
| AB | | NOVEL LABS INC | 2.5MG | A204534 | 001 | Dec 04, 2015 |
| AB | | | 5MG | A204534 | 002 | Dec 04, 2015 |
| AB | | | 10MG | A204534 | 003 | Dec 04, 2015 |
| AB | | RHODES PHARMS | 2.5MG | A208756 | 001 | Nov 20, 2017 |
| AB | | | 5MG | A208756 | 002 | Nov 20, 2017 |
| AB | | | 10MG | A208756 | 003 | Nov 20, 2017 |
| AB | | SUN PHARM INDUSTRIES | 2.5MG | A201231 | 001 | Sep 24, 2015 |
| AB | | | 5MG | A201231 | 002 | Sep 24, 2015 |
| AB | | | 10MG | A201231 | 003 | Sep 24, 2015 |
| AB | | TEVA PHARMS | 2.5MG | A077107 | 003 | Jan 29, 2007 |
| AB | | | 5MG | A077107 | 001 | Jan 29, 2007 |
| AB | | | 10MG | A077107 | 002 | Jan 29, 2007 |
| AB | | TRIS PHARMA INC | 2.5MG | A207901 | 001 | Aug 26, 2016 |
| AB | | | 5MG | A207901 | 002 | Aug 26, 2016 |
| AB | | | 10MG | A207901 | 003 | Aug 26, 2016 |

**FOCALIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| AB | + | NOVARTIS | 2.5MG | N021278 | 001 | Nov 13, 2001 |
| AB | + | | 5MG | N021278 | 002 | Nov 13, 2001 |
| AB | +! | | 10MG | N021278 | 003 | Nov 13, 2001 |

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE;INJECTION

**DEXRAZOXANE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | GLAND PHARMA LTD | **EQ 500MG BASE/VIAL** | **A207321** | **001** | Nov 28, 2016 |
| **AP** | | MYLAN INSTITUTIONAL | **EQ 250MG BASE/VIAL** | **A200752** | **001** | Oct 19, 2011 |
| **AP** | | | **EQ 500MG BASE/VIAL** | **A200752** | **002** | Oct 19, 2011 |
| **AP** | | WEST-WARD PHARMS INT | **EQ 250MG BASE/VIAL** | **A076068** | **001** | Sep 28, 2004 |
| **AP** | | | **EQ 500MG BASE/VIAL** | **A076068** | **002** | Sep 28, 2004 |

**ZINECARD**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | PHARMACIA AND UPJOHN | **EQ 250MG BASE/VIAL** | **N020212** | **001** | May 26, 1995 |
| **AP** | **+!** | | **EQ 500MG BASE/VIAL** | **N020212** | **002** | May 26, 1995 |

TOTECT

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | CLINIGEN HLTHCARE | EQ 500MG BASE/VIAL | N022025 | 001 | Sep 06, 2007 |

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

**DEXEDRINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | IMPAX LABS INC | **5MG** | **N017078** | **001** | |
| **AB** | **+** | | **10MG** | **N017078** | **002** | |
| **AB** | **+!** | | **15MG** | **N017078** | **003** | |

**DEXTROAMPHETAMINE SULFATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS ELIZABETH | **5MG** | **A203901** | **001** | Nov 30, 2012 |
| **AB** | | | **10MG** | **A203901** | **002** | Nov 30, 2012 |
| **AB** | | | **15MG** | **A203901** | **003** | Nov 30, 2012 |
| **AB** | | MAYNE PHARMA | **5MG** | **A076137** | **001** | Jan 18, 2002 |
| **AB** | | | **10MG** | **A076137** | **002** | Jan 18, 2002 |
| **AB** | | | **15MG** | **A076137** | **003** | Jan 18, 2002 |
| **AB** | | MYLAN PHARMS INC | **5MG** | **A206735** | **001** | Jan 27, 2016 |
| **AB** | | | **10MG** | **A206735** | **002** | Jan 27, 2016 |
| **AB** | | | **15MG** | **A206735** | **003** | Jan 27, 2016 |
| **AB** | | NESHER PHARMS | **5MG** | **A209111** | **001** | Jun 27, 2017 |
| **AB** | | | **10MG** | **A209111** | **002** | Jun 27, 2017 |
| **AB** | | | **15MG** | **A209111** | **003** | Jun 27, 2017 |
| **AB** | | SPECGX LLC | **5MG** | **A076353** | **001** | May 06, 2003 |
| **AB** | | | **10MG** | **A076353** | **002** | May 06, 2003 |
| **AB** | | | **15MG** | **A076353** | **003** | May 06, 2003 |
| **AB** | | VINTAGE PHARMS | **5MG** | **A205673** | **001** | Oct 31, 2017 |
| **AB** | | | **10MG** | **A205673** | **002** | Oct 31, 2017 |
| **AB** | | | **15MG** | **A205673** | **003** | Oct 31, 2017 |

SOLUTION;ORAL

**DEXTROAMPHETAMINE SULFATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **!** | OUTLOOK PHARMS | **5MG/5ML** | **A040776** | **001** | Jan 29, 2008 |
| **AA** | | TRIS PHARMA INC | **5MG/5ML** | **A203644** | **001** | May 29, 2013 |

TABLET;ORAL

**DEXTROAMPHETAMINE SULFATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | AUROLIFE PHARMA LLC | **5MG** | **A202893** | **001** | Jul 31, 2013 |
| **AA** | | | **10MG** | **A202893** | **002** | Jul 31, 2013 |
| **AA** | | AVANTHI INC | **5MG** | **A203548** | **001** | Nov 23, 2015 |
| **AA** | | | **10MG** | **A203548** | **002** | Nov 23, 2015 |
| **AA** | | BARR | **5MG** | **A040361** | **001** | Jan 31, 2001 |
| **AA** | **!** | | **10MG** | **A040361** | **002** | Jan 31, 2001 |
| **AA** | | MIKART | **5MG** | **A090533** | **002** | Oct 25, 2011 |
| **AA** | | | **10MG** | **A090533** | **004** | Oct 25, 2011 |
| **AA** | | NESHER PHARMS | **5MG** | **A206588** | **001** | Mar 28, 2016 |
| **AA** | | | **10MG** | **A206588** | **002** | Mar 28, 2016 |
| **AA** | | NOVEL LABS INC | **5MG** | **A204330** | **001** | Mar 16, 2016 |
| **AA** | | | **10MG** | **A204330** | **002** | Mar 16, 2016 |
| **AA** | | SPECGX LLC | **5MG** | **A040436** | **001** | Jan 29, 2002 |
| **AA** | | | **10MG** | **A040436** | **002** | Jan 29, 2002 |
| **AA** | | SUNRISE PHARM INC | **5MG** | **A210059** | **001** | Oct 18, 2017 |
| **AA** | | | **10MG** | **A210059** | **002** | Oct 18, 2017 |
| | | MIKART | 2.5MG | A090533 | 001 | Oct 25, 2011 |
| | | | 7.5MG | A090533 | 003 | Oct 25, 2011 |
| | | | 15MG | A090533 | 005 | Oct 25, 2011 |
| | | | 20MG | A090533 | 006 | Oct 25, 2011 |
| | | | 30MG | A090533 | 007 | Oct 25, 2011 |

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

**PROMETH W/ DEXTROMETHORPHAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | G AND W LABS INC | **15MG/5ML;6.25MG/5ML** | **A088762** | **001** | Oct 31, 1984 |

**PROMETHAZINE DM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **!** | VINTAGE | **15MG/5ML;6.25MG/5ML** | **A040649** | **001** | Feb 14, 2006 |

**PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | HI TECH PHARMA | **15MG/5ML;6.25MG/5ML** | **A040027** | **001** | Jul 31, 1996 |

**PROMETHAZINE W/ DEXTROMETHORPHAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | WOCKHARDT BIO AG | **15MG/5ML;6.25MG/5ML** | **A088864** | **001** | Jan 04, 1985 |

DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE

CAPSULE;ORAL

**DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS ELIZABETH | **20MG;10MG** | **A202934** | **001** | Oct 10, 2017 |

**NUEDEXTA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | AVANIR PHARMS | **20MG;10MG** | **N021879** | **001** | Oct 29, 2010 |

DEXTROSE

INJECTABLE;INJECTION

**DEXTROSE 10% IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | B BRAUN | **10GM/100ML** | **N019626** | **004** | Feb 02, 1988 |
| **AP** | **+!** | BAXTER HLTHCARE | **10GM/100ML** | **N016694** | **001** | |
| **AP** | **+!** | ICU MEDICAL INC | **10GM/100ML** | **N018080** | **001** | |

**DEXTROSE 20% IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | BAXTER HLTHCARE | **20GM/100ML** | **N017521** | **004** | |
| **AP** | **+!** | ICU MEDICAL INC | **20GM/100ML** | **N018564** | **001** | Mar 23, 1982 |

**DEXTROSE 30% IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | BAXTER HLTHCARE | **30GM/100ML** | **N017521** | **003** | |
| **AP** | **+!** | ICU MEDICAL INC | **30GM/100ML** | **N019345** | **001** | Jan 26, 1985 |

**DEXTROSE 40% IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | BAXTER HLTHCARE | **40GM/100ML** | **N017521** | **002** | |
| **AP** | **+!** | ICU MEDICAL INC | **40GM/100ML** | **N018562** | **001** | Mar 23, 1982 |

**DEXTROSE 5% IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | B BRAUN | **50MG/ML** | **N016730** | **002** | |
| **AP** | **+!** | | **5GM/100ML** | **N016730** | **001** | |
| **AP** | **+!** | | **5GM/100ML** | **N019626** | **002** | Feb 02, 1988 |
| **AP** | **+!** | BAXTER HLTHCARE | **50MG/ML** | **N016673** | **003** | Oct 30, 1985 |
| **AP** | **+!** | | **50MG/ML** | **N020179** | **002** | Dec 07, 1992 |
| **AP** | **+!** | | **5GM/100ML** | **N016673** | **001** | |
| **AP** | **+!** | | **5GM/100ML** | **N020179** | **001** | Dec 07, 1992 |
| **AP** | | FRESENIUS KABI USA | **50MG/ML** | **A207449** | **001** | Oct 21, 2016 |
| **AP** | **+!** | HOSPIRA | **50MG/ML** | **N019222** | **001** | Jul 13, 1984 |
| **AP** | **+!** | | **5GM/100ML** | **N019466** | **001** | Jul 15, 1985 |
| **AP** | **+!** | | **5GM/100ML** | **N019479** | **001** | Sep 17, 1985 |
| **AP** | **+!** | ICU MEDICAL INC | **50MG/ML** | **N016367** | **002** | |

**DEXTROSE 50% IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | BAXTER HLTHCARE | **50GM/100ML** | **N017521** | **001** | |
| **AP** | **+!** | | **50GM/100ML** | **N020047** | **001** | Jul 02, 1991 |
| **AP** | **+!** | ICU MEDICAL INC | **50GM/100ML** | **N018563** | **001** | Mar 23, 1982 |

**DEXTROSE 70% IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | BAXTER HLTHCARE | **70GM/100ML** | **N017521** | **006** | Mar 26, 1982 |
| **AP** | **+!** | | **70GM/100ML** | **N020047** | **003** | Jul 02, 1991 |
| **AP** | **+!** | ICU MEDICAL INC | **70GM/100ML** | **N018561** | **001** | Mar 23, 1982 |
| **AP** | **+!** | | **70GM/100ML** | **N019893** | **001** | Dec 26, 1989 |

DEXTROSE 25%

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | HOSPIRA | 250MG/ML | N019445 | 002 | Nov 23, 1998 |

DEXTROSE 50%

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | HOSPIRA | 500MG/ML | N019445 | 003 | Sep 03, 2014 |

DEXTROSE 50% IN PLASTIC CONTAINER

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | HOSPIRA | 500MG/ML | N019445 | 001 | Jun 03, 1986 |

DEXTROSE 60% IN PLASTIC CONTAINER

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | BAXTER HLTHCARE | 60GM/100ML | N017521 | 005 | Mar 26, 1982 |

DEXTROSE; MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER

| | | | | | | |
|---|---|---|---|---|---|---|
| | | BAXTER HLTHCARE | 5GM/100ML;32MG/100ML;128MG/100ML;234MG/100ML | N017385 | 001 | |

DEXTROSE; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| | ICU MEDICAL INC | 5GM/100ML;21MG/100ML;128MG/100ML;234MG/100ML | N017610 | 001 | |

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE;INJECTION

ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| | B BRAUN | 5GM/100ML;31MG/100ML;130MG/100ML;26MG/100ML;320MG/100ML | N019873 | 001 | Jun 10, 1993 |

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| | BAXTER HLTHCARE | 5GM/100ML;31MG/100ML;141MG/100ML;20MG/100ML;12MG/100ML;260MG/100ML | N017484 | 001 | |

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE;INJECTION

IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| | ICU MEDICAL INC | 5GM/100ML;30MG/100ML;141MG/100ML;15MG/100ML;260MG/100ML;25MG/100ML | N019513 | 001 | May 08, 1986 |

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| | ICU MEDICAL INC | 5GM/100ML;30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML | N017609 | 001 | |

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE;INJECTION

**DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER**

| | | | | | |
|---|---|---|---|---|---|
| **AP** | **+** BAXTER HLTHCARE | **5GM/100ML;150MG/100ML** | **N017634** | **001** | |

**DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER**

| | | | | | |
|---|---|---|---|---|---|
| **AP** | **+** BAXTER HLTHCARE | **5GM/100ML;224MG/100ML** | **N017634** | **003** | |

**DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER**

| | | | | | |
|---|---|---|---|---|---|
| **AP** | **+** BAXTER HLTHCARE | **5GM/100ML;300MG/100ML** | **N017634** | **002** | |

**POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER**

| | | | | | |
|---|---|---|---|---|---|
| **AP** | B BRAUN | **5GM/100ML;150MG/100ML** | **N019699** | **004** | Sep 29, 1989 |

**POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER**

| | | | | | |
|---|---|---|---|---|---|
| **AP** | B BRAUN | **5GM/100ML;300MG/100ML** | **N019699** | **006** | Sep 29, 1989 |

**POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER**

| | | | | | |
|---|---|---|---|---|---|
| **AP** | ICU MEDICAL INC | **5GM/100ML;224MG/100ML** | **N018371** | **003** | |

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| | + BAXTER HLTHCARE | 5GM/100ML;75MG/100ML | N017634 | 004 | |

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| | ICU MEDICAL INC | 5GM/100ML;149MG/100ML | N018371 | 001 | |

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| | ICU MEDICAL INC | 5GM/100ML;298MG/100ML | N018371 | 002 | |

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

**DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ**

| | | | | | |
|---|---|---|---|---|---|
| **AP** | BAXTER HLTHCARE | **5GM/100ML;75MG/100ML;200MG/100ML** | **N018037** | **006** | Apr 13, 1982 |
| **AP** | | **5GM/100ML;150MG/100ML;200MG/100ML** | **N018037** | **007** | Apr 13, 1982 |

**DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K)**

| | | | | | |
|---|---|---|---|---|---|
| **AP** | BAXTER HLTHCARE | **5GM/100ML;224MG/100ML;200MG/100ML** | **N018037** | **004** | |

**DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ**

| | | | | | |
|---|---|---|---|---|---|
| **AP** | BAXTER HLTHCARE | **5GM/100ML;150MG/100ML;200MG/100ML** | **N018037** | **008** | Apr 13, 1982 |

**DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K)**

| | | | | | |
|---|---|---|---|---|---|
| **AP** | BAXTER HLTHCARE | **5GM/100ML;300MG/100ML;200MG/100ML** | **N018037** | **001** | |

**DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ**

| | | | | | |
|---|---|---|---|---|---|
| **AP** | BAXTER HLTHCARE | **5GM/100ML;224MG/100ML;200MG/100ML** | **N018037** | **005** | Apr 13, 1982 |

**DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ**

| | | | | | |
|---|---|---|---|---|---|
| **AP** | BAXTER HLTHCARE | **5GM/100ML;300MG/100ML;200MG/100ML** | **N018037** | **009** | Apr 13, 1982 |

**DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ**

| | | | | | |
|---|---|---|---|---|---|
| **AP** | BAXTER HLTHCARE | **5GM/100ML;75MG/100ML;200MG/100ML** | **N018037** | **002** | |

**DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K)**

| | | | | | |
|---|---|---|---|---|---|
| **AP** | BAXTER HLTHCARE | **5GM/100ML;150MG/100ML;200MG/100ML** | **N018037** | **003** | |

**DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER**

| | | | | | |
|---|---|---|---|---|---|
| **AP** | BAXTER HLTHCARE | **5GM/100ML;75MG/100ML;330MG/100ML** | **N018629** | **005** | Mar 23, 1982 |
| **AP** | | **5GM/100ML;150MG/100ML;330MG/100ML** | **N018629** | **002** | Mar 23, 1982 |

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

| | | | | | |
|---|---|---|---|---|---|
| **DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER** | | | | | |
| **AP** | BAXTER HLTHCARE | **5GM/100ML;224MG/100ML;330MG/100ML** | **N018629** | **003** | Mar 23, 1982 |
| **DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER** | | | | | |
| **AP** | BAXTER HLTHCARE | **5GM/100ML;150MG/100ML;330MG/100ML** | **N018629** | **004** | Mar 23, 1982 |
| **AP** | | **5GM/100ML;300MG/100ML;330MG/100ML** | **N018629** | **006** | Mar 23, 1982 |
| **DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER** | | | | | |
| **AP** | BAXTER HLTHCARE | **5GM/100ML;224MG/100ML;330MG/100ML** | **N018629** | **007** | Mar 23, 1982 |
| **DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER** | | | | | |
| **AP** | BAXTER HLTHCARE | **5GM/100ML;300MG/100ML;330MG/100ML** | **N018629** | **008** | Mar 23, 1982 |
| **DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER** | | | | | |
| **AP** | BAXTER HLTHCARE | **5GM/100ML;75MG/100ML;330MG/100ML** | **N018629** | **001** | Mar 23, 1982 |
| **DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER** | | | | | |
| **AP** | BAXTER HLTHCARE | **5GM/100ML;300MG/100ML;450MG/100ML** | **N018008** | **010** | |
| **POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER** | | | | | |
| **AP** | B BRAUN | **5GM/100ML;75MG/100ML;200MG/100ML** | **N019630** | **008** | Feb 17, 1988 |
| **POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER** | | | | | |
| **AP** | B BRAUN | **5GM/100ML;75MG/100ML;330MG/100ML** | **N019630** | **014** | Feb 17, 1988 |
| **POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER** | | | | | |
| **AP** | B BRAUN | **5GM/100ML;75MG/100ML;450MG/100ML** | **N019630** | **020** | Feb 17, 1988 |
| **POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER** | | | | | |
| **AP** | B BRAUN | **5GM/100ML;75MG/100ML;900MG/100ML** | **N019630** | **026** | Feb 17, 1988 |
| **POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER** | | | | | |
| **AP** | B BRAUN | **5GM/100ML;150MG/100ML;200MG/100ML** | **N019630** | **010** | Feb 17, 1988 |
| **POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER** | | | | | |
| **AP** | B BRAUN | **5GM/100ML;150MG/100ML;330MG/100ML** | **N019630** | **016** | Feb 17, 1988 |
| **POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER** | | | | | |
| **AP** | B BRAUN | **5GM/100ML;150MG/100ML;450MG/100ML** | **N019630** | **022** | Feb 17, 1988 |
| **POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER** | | | | | |
| **AP** | B BRAUN | **5GM/100ML;150MG/100ML;900MG/100ML** | **N019630** | **028** | Feb 17, 1988 |
| **POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER** | | | | | |
| **AP** | B BRAUN | **5GM/100ML;300MG/100ML;200MG/100ML** | **N019630** | **012** | Feb 17, 1988 |
| **POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER** | | | | | |
| **AP** | B BRAUN | **5GM/100ML;300MG/100ML;330MG/100ML** | **N019630** | **018** | Feb 17, 1988 |
| **POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER** | | | | | |
| **AP** | B BRAUN | **5GM/100ML;300MG/100ML;450MG/100ML** | **N019630** | **024** | Feb 17, 1988 |
| **POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER** | | | | | |
| **AP** | B BRAUN | **5GM/100ML;300MG/100ML;900MG/100ML** | **N019630** | **030** | Feb 17, 1988 |
| **POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER** | | | | | |
| **AP** | BAXTER HLTHCARE | **5GM/100ML;75MG/100ML;450MG/100ML** | **N018008** | **005** | Apr 28, 1982 |
| **AP** | | **5GM/100ML;150MG/100ML;450MG/100ML** | **N018008** | **006** | Apr 28, 1982 |
| **AP** | ICU MEDICAL INC | **5GM/100ML;74.5MG/100ML;450MG/100ML** | **N018362** | **005** | Mar 28, 1988 |
| **AP** | | **5GM/100ML;74.5MG/100ML;450MG/100ML** | **N018362** | **009** | Jul 05, 1983 |
| **POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER** | | | | | |
| **AP** | BAXTER HLTHCARE | **5GM/100ML;75MG/100ML;900MG/100ML** | **N019308** | **004** | Apr 05, 1985 |
| **AP** | | **5GM/100ML;150MG/100ML;900MG/100ML** | **N019308** | **002** | Apr 05, 1985 |
| **AP** | ICU MEDICAL INC | **5GM/100ML;74.5MG/100ML;900MG/100ML** | **N019691** | **002** | Mar 24, 1988 |
| **AP** | | **5GM/100ML;149MG/100ML;900MG/100ML** | **N019691** | **004** | Mar 24, 1988 |
| **POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER** | | | | | |
| **AP** | ICU MEDICAL INC | **5GM/100ML;224MG/100ML;450MG/100ML** | **N018362** | **006** | Mar 28, 1988 |
| **POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER** | | | | | |
| **AP** | ICU MEDICAL INC | **5GM/100ML;224MG/100ML;900MG/100ML** | **N019691** | **006** | Mar 24, 1988 |
| **POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER** | | | | | |
| **AP** | BAXTER HLTHCARE | **5GM/100ML;150MG/100ML;450MG/100ML** | **N018008** | **007** | Apr 28, 1982 |
| **AP** | ICU MEDICAL INC | **5GM/100ML;149MG/100ML;450MG/100ML** | **N018362** | **010** | Jul 05, 1983 |
| **AP** | | **5GM/100ML;298MG/100ML;450MG/100ML** | **N018362** | **007** | Mar 28, 1988 |
| **POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER** | | | | | |
| **AP** | BAXTER HLTHCARE | **5GM/100ML;150MG/100ML;900MG/100ML** | **N019308** | **005** | Apr 05, 1985 |
| **AP** | | **5GM/100ML;300MG/100ML;900MG/100ML** | **N019308** | **003** | Apr 05, 1985 |
| **AP** | ICU MEDICAL INC | **5GM/100ML;149MG/100ML;900MG/100ML** | **N019691** | **005** | Mar 24, 1988 |
| **AP** | | **5GM/100ML;298MG/100ML;900MG/100ML** | **N019691** | **008** | Mar 24, 1988 |
| **POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER** | | | | | |
| **AP** | BAXTER HLTHCARE | **5GM/100ML;224MG/100ML;450MG/100ML** | **N018008** | **008** | Apr 28, 1982 |
| **AP** | ICU MEDICAL INC | **5GM/100ML;224MG/100ML;450MG/100ML** | **N018362** | **002** | |
| **POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER** | | | | | |
| **AP** | BAXTER HLTHCARE | **5GM/100ML;224MG/100ML;900MG/100ML** | **N019308** | **006** | Apr 05, 1985 |
| **AP** | ICU MEDICAL INC | **5GM/100ML;224MG/100ML;900MG/100ML** | **N019691** | **007** | Mar 24, 1988 |
| **POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER** | | | | | |
| **AP** | BAXTER HLTHCARE | **5GM/100ML;300MG/100ML;450MG/100ML** | **N018008** | **009** | Apr 28, 1982 |
| **AP** | ICU MEDICAL INC | **5GM/100ML;298MG/100ML;450MG/100ML** | **N018362** | **003** | |

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

**POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER**

| | | | | |
|---|---|---|---|---|
| **AP** | BAXTER HLTHCARE | **5GM/100ML;300MG/100ML;900MG/100ML** | **N019308 007** | Apr 05, 1985 |
| **AP** | ICU MEDICAL INC | **5GM/100ML;298MG/100ML;900MG/100ML** | **N019691 009** | Mar 24, 1988 |

**POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER**

| | | | | |
|---|---|---|---|---|
| **AP** | BAXTER HLTHCARE | **5GM/100ML;150MG/100ML;450MG/100ML** | **N018008 004** | |
| **AP** | ICU MEDICAL INC | **5GM/100ML;74.5MG/100ML;450MG/100ML** | **N018362 008** | Mar 28, 1988 |
| **AP** | | **5GM/100ML;149MG/100ML;450MG/100ML** | **N018362 004** | Mar 28, 1988 |

**POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER**

| | | | | |
|---|---|---|---|---|
| **AP** | BAXTER HLTHCARE | **5GM/100ML;150MG/100ML;900MG/100ML** | **N019308 001** | Apr 05, 1985 |
| **AP** | ICU MEDICAL INC | **5GM/100ML;74.5MG/100ML;900MG/100ML** | **N019691 001** | Mar 24, 1988 |
| **AP** | | **5GM/100ML;149MG/100ML;900MG/100ML** | **N019691 003** | Mar 24, 1988 |

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

| | | | |
|---|---|---|---|
| B BRAUN | 10GM/100ML;37MG/100ML;200MG/100ML | N019630 031 | Feb 17, 1988 |

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

| | | | |
|---|---|---|---|
| B BRAUN | 10GM/100ML;37MG/100ML;450MG/100ML | N019630 037 | Feb 17, 1988 |

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

| | | | |
|---|---|---|---|
| B BRAUN | 10GM/100ML;37MG/100ML;900MG/100ML | N019630 043 | Feb 17, 1988 |

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

| | | | |
|---|---|---|---|
| B BRAUN | 5GM/100ML;37MG/100ML;110MG/100ML | N019630 001 | Feb 17, 1988 |

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

| | | | |
|---|---|---|---|
| B BRAUN | 5GM/100ML;37MG/100ML;200MG/100ML | N019630 007 | Feb 17, 1988 |

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

| | | | |
|---|---|---|---|
| B BRAUN | 5GM/100ML;37MG/100ML;330MG/100ML | N019630 013 | Feb 17, 1988 |

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

| | | | |
|---|---|---|---|
| B BRAUN | 5GM/100ML;37MG/100ML;450MG/100ML | N019630 019 | Feb 17, 1988 |

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

| | | | |
|---|---|---|---|
| B BRAUN | 5GM/100ML;37MG/100ML;900MG/100ML | N019630 025 | Feb 17, 1988 |

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

| | | | |
|---|---|---|---|
| B BRAUN | 10GM/100ML;75MG/100ML;200MG/100ML | N019630 032 | Feb 17, 1988 |

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

| | | | |
|---|---|---|---|
| B BRAUN | 10GM/100ML;75MG/100ML;450MG/100ML | N019630 038 | Feb 17, 1988 |

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

| | | | |
|---|---|---|---|
| B BRAUN | 10GM/100ML;75MG/100ML;900MG/100ML | N019630 044 | Feb 17, 1988 |

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

| | | | |
|---|---|---|---|
| B BRAUN | 3.3GM/100ML;75MG/100ML;300MG/100ML | N019630 049 | May 07, 1992 |

POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

| | | | |
|---|---|---|---|
| B BRAUN | 5GM/100ML;75MG/100ML;110MG/100ML | N019630 002 | Feb 17, 1988 |

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

| | | | |
|---|---|---|---|
| B BRAUN | 10GM/100ML;110MG/100ML;200MG/100ML | N019630 033 | Feb 17, 1988 |

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

| | | | |
|---|---|---|---|
| B BRAUN | 10GM/100ML;110MG/100ML;450MG/100ML | N019630 039 | Feb 17, 1988 |

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

| | | | |
|---|---|---|---|
| B BRAUN | 10GM/100ML;110MG/100ML;900MG/100ML | N019630 045 | Feb 17, 1988 |

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

| | | | |
|---|---|---|---|
| B BRAUN | 3.3GM/100ML;110MG/100ML;300MG/100ML | N019630 050 | May 07, 1992 |

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

| | | | |
|---|---|---|---|
| B BRAUN | 5GM/100ML;110MG/100ML;110MG/100ML | N019630 003 | Feb 17, 1988 |

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

| | | | |
|---|---|---|---|
| B BRAUN | 5GM/100ML;110MG/100ML;200MG/100ML | N019630 009 | Feb 17, 1988 |

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER

| | | | |
|---|---|---|---|
| B BRAUN | 5GM/100ML;110MG/100ML;330MG/100ML | N019630 015 | Feb 17, 1988 |

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

| | | | |
|---|---|---|---|
| B BRAUN | 5GM/100ML;110MG/100ML;450MG/100ML | N019630 021 | Feb 17, 1988 |

POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

| | | | |
|---|---|---|---|
| B BRAUN | 5GM/100ML;110MG/100ML;900MG/100ML | N019630 027 | Feb 17, 1988 |

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

| | | | |
|---|---|---|---|
| B BRAUN | 10GM/100ML;150MG/100ML;200MG/100ML | N019630 034 | Feb 17, 1988 |

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

| | | | |
|---|---|---|---|
| B BRAUN | 10GM/100ML;150MG/100ML;450MG/100ML | N019630 040 | Feb 17, 1988 |

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

| | | | |
|---|---|---|---|
| B BRAUN | 10GM/100ML;150MG/100ML;900MG/100ML | N019630 046 | Feb 17, 1988 |

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER

| | | | |
|---|---|---|---|
| B BRAUN | 3.3GM/100ML;150MG/100ML;300MG/100ML | N019630 051 | May 07, 1992 |

POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER

| | | | |
|---|---|---|---|
| B BRAUN | 5GM/100ML;150MG/100ML;110MG/100ML | N019630 004 | Feb 17, 1988 |

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER

| | | | |
|---|---|---|---|
| B BRAUN | 10GM/100ML;220MG/100ML;200MG/100ML | N019630 035 | Feb 17, 1988 |

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

| | | | |
|---|---|---|---|
| B BRAUN | 10GM/100ML;220MG/100ML;450MG/100ML | N019630 041 | Feb 17, 1988 |

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;220MG/100ML;900MG/100ML N019630 047 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 3.3GM/100ML;220MG/100ML;300MG/100ML N019630 052 May 07, 1992

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML;110MG/100ML N019630 005 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML;200MG/100ML N019630 011 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML;330MG/100ML N019630 017 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML;450MG/100ML N019630 023 Feb 17, 1988

POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;220MG/100ML;900MG/100ML N019630 029 Feb 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;300MG/100ML;200MG/100ML N019630 036 Feb 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;300MG/100ML;450MG/100ML N019630 042 Feb 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN 10GM/100ML;300MG/100ML;900MG/100ML N019630 048 Feb 17, 1988

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
B BRAUN 3.3GM/100ML;300MG/100ML;300MG/100ML N019630 053 May 07, 1992

POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER
B BRAUN 5GM/100ML;300MG/100ML;110MG/100ML N019630 006 Feb 17, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
\+ ICU MEDICAL INC 5GM/100ML;74.5MG/100ML;225MG/100ML N018365 002 Jul 05, 1983
\+ 5GM/100ML;149MG/100ML;225MG/100ML N018365 006 Mar 28, 1988

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
ICU MEDICAL INC 5GM/100ML;74.5MG/100ML;300MG/100ML N018876 001 Jan 17, 1986
5GM/100ML;149MG/100ML;300MG/100ML N018876 006 Mar 28, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
ICU MEDICAL INC 5GM/100ML;224MG/100ML;225MG/100ML N018365 008 Mar 28, 1988

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
ICU MEDICAL INC 5GM/100ML;224MG/100ML;300MG/100ML N018876 007 Mar 28, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
\+ ICU MEDICAL INC 5GM/100ML;149MG/100ML;225MG/100ML N018365 001
\+ 5GM/100ML;298MG/100ML;225MG/100ML N018365 009 Mar 28, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
ICU MEDICAL INC 5GM/100ML;298MG/100ML;300MG/100ML N018876 008 Mar 28, 1988

POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
ICU MEDICAL INC 5GM/100ML;149MG/100ML;300MG/100ML N018876 002 Jan 17, 1986

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
ICU MEDICAL INC 5GM/100ML;224MG/100ML;225MG/100ML N018365 003 Jul 05, 1983

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
ICU MEDICAL INC 5GM/100ML;224MG/100ML;300MG/100ML N018876 003 Jan 17, 1986

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
ICU MEDICAL INC 5GM/100ML;298MG/100ML;225MG/100ML N018365 004 Jul 05, 1983

POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
ICU MEDICAL INC 5GM/100ML;298MG/100ML;300MG/100ML N018876 004 Mar 28, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER
ICU MEDICAL INC 5GM/100ML;74.5MG/100ML;225MG/100ML N018365 005 Mar 28, 1988
5GM/100ML;149MG/100ML;225MG/100ML N018365 007 Mar 28, 1988

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER
ICU MEDICAL INC 5GM/100ML;74.5MG/100ML;300MG/100ML N018876 005 Mar 28, 1988
5GM/100ML;149MG/100ML;300MG/100ML N018876 009 Mar 28, 1988

DEXTROSE; SODIUM CHLORIDE

INJECTABLE;INJECTION

**DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER**

**AP** B BRAUN **2.5GM/100ML;450MG/100ML** **N019631 004** Feb 24, 1988

**AP** **+!** BAXTER HLTHCARE **2.5GM/100ML;450MG/100ML** **N016697 001**

**DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER**

**AP** B BRAUN **5GM/100ML;200MG/100ML** **N019631 007** Feb 24, 1988

**DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER**

**AP** B BRAUN **5GM/100ML;330MG/100ML** **N019631 008** Feb 24, 1988

**DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER**

**AP** B BRAUN **5GM/100ML;450MG/100ML** **N019631 009** Feb 24, 1988

**AP** ICU MEDICAL INC **5GM/100ML;450MG/100ML** **N017607 001**

**DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER**

**AP** B BRAUN **5GM/100ML;900MG/100ML** **N019631 010** Feb 24, 1988

**AP** **+!** ICU MEDICAL INC **5GM/100ML;900MG/100ML** **N017585 001**

| | | | | | | |
|---|---|---|---|---|---|---|
| DEXTROSE; SODIUM CHLORIDE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| **DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER** | | | | | | |
| **AP** | | BAXTER HLTHCARE | **5GM/100ML;200MG/100ML** | **N016689** | **001** | |
| **DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER** | | | | | | |
| **AP** | | BAXTER HLTHCARE | **5GM/100ML;330MG/100ML** | **N016687** | **001** | |
| **DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER** | | | | | | |
| **AP** | | BAXTER HLTHCARE | **5GM/100ML;450MG/100ML** | **N016683** | **001** | |
| **DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER** | | | | | | |
| **AP** | | BAXTER HLTHCARE | **5GM/100ML;900MG/100ML** | **N016678** | **001** | |
| DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER | | | | | | |
| | | B BRAUN | 10GM/100ML;110MG/100ML | N019631 | 011 | Feb 24, 1988 |
| DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER | | | | | | |
| | | B BRAUN | 10GM/100ML;200MG/100ML | N019631 | 012 | Feb 24, 1988 |
| DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER | | | | | | |
| | | B BRAUN | 10GM/100ML;330MG/100ML | N019631 | 013 | Feb 24, 1988 |
| DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER | | | | | | |
| | | B BRAUN | 10GM/100ML;450MG/100ML | N019631 | 014 | Feb 24, 1988 |
| DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | | | | | | |
| | | B BRAUN | 10GM/100ML;900MG/100ML | N019631 | 015 | Feb 24, 1988 |
| DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER | | | | | | |
| | | B BRAUN | 2.5GM/100ML;110MG/100ML | N019631 | 001 | Feb 24, 1988 |
| DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER | | | | | | |
| | | B BRAUN | 2.5GM/100ML;200MG/100ML | N019631 | 002 | Feb 24, 1988 |
| DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER | | | | | | |
| | | B BRAUN | 2.5GM/100ML;330MG/100ML | N019631 | 003 | Feb 24, 1988 |
| DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | | | | | | |
| | | B BRAUN | 2.5GM/100ML;900MG/100ML | N019631 | 005 | Feb 24, 1988 |
| DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER | | | | | | |
| | | B BRAUN | 3.3GM/100ML;300MG/100ML | N019631 | 016 | Jan 19, 1990 |
| DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER | | | | | | |
| | | B BRAUN | 5GM/100ML;110MG/100ML | N019631 | 006 | Feb 24, 1988 |
| DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER | | | | | | |
| | +! | ICU MEDICAL INC | 5GM/100ML;225MG/100ML | N017606 | 001 | |
| DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER | | | | | | |
| | +! | ICU MEDICAL INC | 5GM/100ML;300MG/100ML | N017799 | 001 | |
| DIATRIZOATE MEGLUMINE | | | | | | |
| SOLUTION;URETHRAL | | | | | | |
| CYSTOGRAFIN | | | | | | |
| | + | BRACCO | 30% | N010040 | 018 | |
| CYSTOGRAFIN DILUTE | | | | | | |
| | + | BRACCO | 18% | N010040 | 022 | Nov 09, 1982 |
| DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| RENOGRAFIN-76 | | | | | | |
| | +! | BRACCO | 66%;10% | N010040 | 001 | |
| SOLUTION;ORAL, RECTAL | | | | | | |
| **GASTROGRAFIN** | | | | | | |
| **AA** | **+!** | BRACCO | **66%;10%** | **N011245** | **003** | |
| **MD-GASTROVIEW** | | | | | | |
| **AA** | | LIEBEL-FLARSHEIM | **66%;10%** | **A087388** | **001** | |
| DIATRIZOATE MEGLUMINE; IODIPAMIDE MEGLUMINE | | | | | | |
| SOLUTION;INTRAUTERINE | | | | | | |
| SINOGRAFIN | | | | | | |
| | +! | BRACCO | 52.7%;26.8% | N011324 | 002 | |
| DIAZEPAM | | | | | | |
| CONCENTRATE;ORAL | | | | | | |
| **DIAZEPAM** | | | | | | |
| **AA** | | LANNETT HOLDINGS INC | **5MG/ML** | **A204433** | **001** | Apr 14, 2014 |
| **DIAZEPAM INTENSOL** | | | | | | |
| **AA** | **!** | WEST-WARD PHARMS INT | **5MG/ML** | **A071415** | **001** | Apr 03, 1987 |
| GEL;RECTAL | | | | | | |
| DIASTAT | | | | | | |
| | + | VALEANT PHARMS NORTH | 2.5MG/0.5ML (5MG/ML) | N020648 | 001 | Jul 29, 1997 |
| DIASTAT ACUDIAL | | | | | | |
| | + | VALEANT PHARMS NORTH | 10MG/2ML (5MG/ML) | N020648 | 007 | Sep 15, 2005 |
| | +! | | 20MG/4ML (5MG/ML) | N020648 | 006 | Sep 15, 2005 |

| | | | | | | |
|---|---|---|---|---|---|---|
| DIAZEPAM | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| DIAZEPAM | | | | | | |
| | ! | HOSPIRA | 10MG/2ML (5MG/ML) | A072079 | 001 | Dec 20, 1988 |
| | ! | | 50MG/10ML (5MG/ML) | A071583 | 001 | Oct 13, 1987 |
| SOLUTION;ORAL | | | | | | |
| **DIAZEPAM** | | | | | | |
| **AA** | | LANNETT HOLDINGS INC | **5MG/5ML** | **A206477** | **001** | Jun 24, 2016 |
| **AA** | **!** | WEST-WARD PHARMS INT | **5MG/5ML** | **A070928** | **001** | Apr 03, 1987 |
| TABLET;ORAL | | | | | | |
| **DIAZEPAM** | | | | | | |
| **AB** | | BARR | **2MG** | **A070152** | **001** | Nov 01, 1985 |
| **AB** | | | **10MG** | **A070154** | **001** | Nov 01, 1985 |
| **AB** | | IVAX SUB TEVA PHARMS | **2MG** | **A071307** | **001** | Dec 10, 1986 |
| **AB** | | | **5MG** | **A071321** | **001** | Dec 10, 1986 |
| **AB** | | | **10MG** | **A071322** | **001** | Dec 10, 1986 |
| **AB** | | MAYNE PHARMA | **2MG** | **A071134** | **001** | Feb 03, 1987 |
| **AB** | | | **5MG** | **A071135** | **001** | Feb 03, 1987 |
| **AB** | | | **10MG** | **A071136** | **001** | Feb 03, 1987 |
| **AB** | | MYLAN | **2MG** | **A070325** | **002** | Sep 04, 1985 |
| **AB** | | | **5MG** | **A070325** | **003** | Sep 04, 1985 |
| **AB** | | | **10MG** | **A070325** | **001** | Sep 04, 1985 |
| **AB** | | VINTAGE PHARMS | **2MG** | **A077749** | **001** | Mar 31, 2006 |
| **AB** | | | **5MG** | **A077749** | **002** | Mar 31, 2006 |
| **AB** | | | **10MG** | **A077749** | **003** | Mar 31, 2006 |
| **VALIUM** | | | | | | |
| **AB** | **+** | ROCHE | **2MG** | **N013263** | **002** | |
| **AB** | **+** | | **5MG** | **N013263** | **004** | |
| **AB** | **+!** | | **10MG** | **N013263** | **006** | |
| DIAZEPAM | | | | | | |
| | | DAVA PHARMS INC | 2MG | A070228 | 002 | Sep 26, 1985 |
| | | | 5MG | A070228 | 003 | Sep 26, 1985 |
| DIAZOXIDE | | | | | | |
| SUSPENSION;ORAL | | | | | | |
| PROGLYCEM | | | | | | |
| | +! | TEVA BRANDED PHARM | 50MG/ML | N017453 | 001 | |
| DICHLORPHENAMIDE | | | | | | |
| TABLET;ORAL | | | | | | |
| KEVEYIS | | | | | | |
| | +! | STRONGBRIDGE US | 50MG | N011366 | 002 | Aug 07, 2015 |
| DICLOFENAC | | | | | | |
| CAPSULE;ORAL | | | | | | |
| ZORVOLEX | | | | | | |
| | + | IROKO PHARMS LLC | 18MG | N204592 | 001 | Oct 18, 2013 |
| | +! | | 35MG | N204592 | 002 | Oct 18, 2013 |
| DICLOFENAC EPOLAMINE | | | | | | |
| PATCH;TOPICAL | | | | | | |
| FLECTOR | | | | | | |
| | +! | INST BIOCHEM | 1.3% | N021234 | 001 | Jan 31, 2007 |
| DICLOFENAC POTASSIUM | | | | | | |
| CAPSULE;ORAL | | | | | | |
| **DICLOFENAC POTASSIUM** | | | | | | |
| **AB** | | BIONPHARMA INC | **25MG** | **A204648** | **001** | Feb 23, 2016 |
| **ZIPSOR** | | | | | | |
| **AB** | **+!** | DEPOMED INC | **25MG** | **N022202** | **001** | Jun 16, 2009 |
| FOR SOLUTION;ORAL | | | | | | |
| **CAMBIA** | | | | | | |
| **AB** | **+!** | DEPOMED INC | **50MG** | **N022165** | **001** | Jun 17, 2009 |
| **DICLOFENAC POTASSIUM** | | | | | | |
| **AB** | | PAR FORM | **50MG** | **A202964** | **001** | May 02, 2016 |
| TABLET;ORAL | | | | | | |
| **DICLOFENAC POTASSIUM** | | | | | | |
| **AB** | | APOTEX | **50MG** | **A076561** | **001** | Mar 18, 2004 |
| **AB** | **!** | MYLAN | **50MG** | **A075463** | **001** | Jul 26, 1999 |
| **AB** | | SANDOZ | **50MG** | **A075229** | **001** | Nov 20, 1998 |
| **AB** | | TEVA | **50MG** | **A075219** | **001** | Aug 06, 1998 |

DICLOFENAC SODIUM

GEL;TOPICAL

**DICLOFENAC SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS MID ATLANTIC | **3%** | **A206493** | **001** | Dec 02, 2015 |
| **AB** | | AMNEAL PHARMS | **1%** | **A208077** | **001** | Mar 18, 2016 |
| **AB** | | GLENMARK PHARMS LTD | **3%** | **A208301** | **001** | Sep 13, 2016 |
| **AB** | | TARO | **3%** | **A206298** | **001** | Apr 28, 2016 |

**DICLOFENAC SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | TOLMAR | **3%** | **A200936** | **001** | Oct 28, 2013 |

**SOLARAZE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | FOUGERA PHARMS | **3%** | **N021005** | **001** | Oct 16, 2000 |

**VOLTAREN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | GLAXOSMITHKLINE CONS | **1%** | **N022122** | **001** | Oct 17, 2007 |

SOLUTION;INTRAVENOUS

DYLOJECT

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | JAVELIN PHARMS INC | 37.5MG/ML (37.5MG/ML) | N022396 | 001 | Dec 23, 2014 |

SOLUTION;TOPICAL

**DICLOFENAC SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | AMNEAL PHARMS | **1.5%** | **A206116** | **001** | Sep 02, 2016 |
| **AT** | | ANDA REPOSITORY | **1.5%** | **A202393** | **001** | Nov 24, 2014 |
| **AT** | **!** | APOTEX INC | **1.5%** | **A202027** | **001** | May 27, 2014 |
| **AT** | | LUPIN LTD | **1.5%** | **A204132** | **001** | Aug 20, 2015 |
| **AT** | | NOVEL LABS INC | **1.5%** | **A205878** | **001** | Dec 09, 2015 |
| **AT** | | RICONPHARMA LLC | **1.5%** | **A206715** | **001** | Aug 07, 2017 |
| **AT** | | TARO | **1.5%** | **A203818** | **001** | Nov 26, 2014 |
| **AT** | | TELIGENT PHARMA INC | **1.5%** | **A202769** | **001** | Jul 08, 2015 |
| **AT** | | WATSON LABS INC | **1.5%** | **A202852** | **001** | Nov 24, 2014 |

PENNSAID

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | HORIZON PHARMA | 2% | N204623 | 001 | Jan 16, 2014 |

SOLUTION/DROPS;OPHTHALMIC

**DICLOFENAC SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | AKORN | **0.1%** | **A077845** | **001** | Apr 17, 2008 |
| **AT** | | ALTAIRE PHARMS INC | **0.1%** | **A203383** | **001** | Nov 16, 2015 |
| **AT** | | BAUSCH AND LOMB | **0.1%** | **A078792** | **001** | Dec 28, 2007 |
| **AT** | | RISING PHARMS INC | **0.1%** | **A078553** | **001** | Dec 28, 2007 |
| **AT** | | SANDOZ INC | **0.1%** | **A078031** | **001** | Feb 06, 2008 |

**VOLTAREN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **+!** | NOVARTIS | **0.1%** | **N020037** | **001** | Mar 28, 1991 |

TABLET, DELAYED RELEASE;ORAL

**DICLOFENAC SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS ELIZABETH | **50MG** | **A074514** | **001** | Mar 26, 1996 |
| **AB** | | | **75MG** | **A074514** | **002** | Mar 26, 1996 |
| **AB** | | CARLSBAD | **25MG** | **A075185** | **002** | Nov 13, 1998 |
| **AB** | | | **50MG** | **A075185** | **003** | Nov 13, 1998 |
| **AB** | | | **75MG** | **A075185** | **001** | Nov 13, 1998 |
| **AB** | | MYLAN PHARMS INC | **50MG** | **A075281** | **002** | Feb 12, 2002 |
| **AB** | | | **75MG** | **A075281** | **003** | Feb 12, 2002 |
| **AB** | **!** | SANDOZ | **25MG** | **A074376** | **001** | Sep 28, 1995 |
| **AB** | **!** | | **50MG** | **A074376** | **002** | Sep 28, 1995 |
| **AB** | **!** | | **75MG** | **A074394** | **001** | Nov 30, 1995 |
| **AB** | | UNIQUE PHARM LABS | **25MG** | **A090066** | **001** | Dec 01, 2010 |
| **AB** | | | **50MG** | **A090066** | **002** | Dec 01, 2010 |
| **AB** | | | **75MG** | **A077863** | **003** | Jun 08, 2007 |

TABLET, EXTENDED RELEASE;ORAL

**DICLOFENAC SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **!** | DEXCEL LTD | **100MG** | **A076201** | **001** | Nov 06, 2002 |
| **AB** | | MYLAN | **100MG** | **A076152** | **001** | Dec 13, 2001 |
| **AB** | | VPNA | **100MG** | **A075492** | **001** | Feb 11, 2000 |

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL

**ARTHROTEC**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | GD SEARLE LLC | **50MG;0.2MG** | **N020607** | **001** | Dec 24, 1997 |
| **AB** | **+!** | | **75MG;0.2MG** | **N020607** | **002** | Dec 24, 1997 |

**DICLOFENAC SODIUM AND MISOPROSTOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS LABS FL INC | **50MG;0.2MG** | **A201089** | **001** | Jul 09, 2012 |
| **AB** | | | **75MG;0.2MG** | **A201089** | **002** | Jul 09, 2012 |
| **AB** | | AMNEAL PHARMS | **50MG;0.2MG** | **A203995** | **001** | Nov 25, 2016 |
| **AB** | | | **75MG;0.2MG** | **A203995** | **002** | Nov 25, 2016 |
| **AB** | | EXELA HOLDINGS | **50MG;0.2MG** | **A200540** | **001** | Mar 14, 2014 |
| **AB** | | | **75MG;0.2MG** | **A200540** | **002** | Mar 14, 2014 |

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL

**DICLOFENAC SODIUM AND MISOPROSTOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | SANDOZ | **50MG;0.2MG** | **A200158** | **001** | May 09, 2013 |
| **AB** | | | **75MG;0.2MG** | **A200158** | **002** | May 09, 2013 |

DICLOXACILLIN SODIUM

CAPSULE;ORAL

**DICLOXACILLIN SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | SANDOZ | **EQ 250MG BASE** | **A061454** | **001** | |
| **AB** | ! | | **EQ 500MG BASE** | **A061454** | **003** | |
| **AB** | | TEVA | **EQ 250MG BASE** | **A062286** | **001** | Jun 03, 1982 |
| **AB** | | | **EQ 500MG BASE** | **A062286** | **002** | Jun 03, 1982 |
| | | SANDOZ | EQ 125MG BASE | A061454 | 002 | |

DICYCLOMINE HYDROCHLORIDE

CAPSULE;ORAL

**BENTYL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | FOREST LABS INC | **10MG** | **N007409** | **003** | Oct 15, 1984 |

**DICYCLOMINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | LANNETT | **10MG** | **A084285** | **001** | |
| **AB** | | MYLAN | **10MG** | **A040319** | **001** | Sep 07, 1999 |
| **AB** | | WATSON LABS | **10MG** | **A085082** | **001** | Jun 19, 1986 |

INJECTABLE;INJECTION

**BENTYL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | FOREST LABS INC | **10MG/ML** | **N008370** | **001** | Oct 15, 1984 |

**BENTYL PRESERVATIVE FREE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | FOREST LABS INC | **10MG/ML** | **N008370** | **002** | Oct 15, 1984 |

**DICYCLOMINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | LUITPOLD PHARMS INC | **10MG/ML** | **A208353** | **001** | Feb 17, 2017 |

**DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE)**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | WEST-WARD PHARMS INT | **10MG/ML** | **A040465** | **001** | Jun 30, 2003 |

SYRUP;ORAL

DICYCLOMINE HYDROCHLORIDE

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | MIKART | 10MG/5ML | A040169 | 001 | Mar 24, 2005 |

TABLET;ORAL

**BENTYL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | FOREST LABS INC | **20MG** | **N007409** | **001** | Oct 15, 1984 |

**DICYCLOMINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | LANNETT | **20MG** | **A040230** | **001** | Feb 26, 1999 |
| **AB** | | MYLAN | **20MG** | **A040317** | **001** | Sep 07, 1999 |
| **AB** | | WATSON LABS | **20MG** | **A085223** | **001** | Jul 30, 1986 |

DIDANOSINE

CAPSULE, DELAYED REL PELLETS;ORAL

**DIDANOSINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AURO BINDO PHARMA | **125MG** | **A090094** | **001** | Sep 24, 2008 |
| **AB** | | | **200MG** | **A090094** | **002** | Sep 24, 2008 |
| **AB** | | | **250MG** | **A090094** | **003** | Sep 24, 2008 |
| **AB** | | | **400MG** | **A090094** | **004** | Sep 24, 2008 |
| **AB** | | BARR | **200MG** | **A077167** | **001** | Dec 03, 2004 |
| **AB** | | | **250MG** | **A077167** | **002** | Dec 03, 2004 |
| **AB** | | | **400MG** | **A077167** | **003** | Dec 03, 2004 |

**VIDEX EC**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | BRISTOL MYERS SQUIBB | **125MG** | **N021183** | **001** | Oct 31, 2000 |
| **AB** | **+** | | **200MG** | **N021183** | **002** | Oct 31, 2000 |
| **AB** | **+** | | **250MG** | **N021183** | **003** | Oct 31, 2000 |
| **AB** | **+!** | | **400MG** | **N021183** | **004** | Oct 31, 2000 |

FOR SOLUTION;ORAL

VIDEX

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | BRISTOL-MYERS SQUIBB | 10MG/ML | N020156 | 001 | Oct 09, 1991 |

DIENOGEST; ESTRADIOL VALERATE

TABLET;ORAL

NATAZIA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | BAYER HLTHCARE | N/A,2MG,3MG,N/A,N/A;3MG,2MG,2MG,1MG,N/A | N022252 | 001 | May 06, 2010 |

DIETHYLPROPION HYDROCHLORIDE

TABLET;ORAL

**DIETHYLPROPION HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | AVANTHI INC | **25MG** | **A201212** | **001** | Dec 22, 2010 |
| **AA** | | LANNETT HOLDINGS INC | **25MG** | **A200177** | **001** | Jul 18, 2011 |

**TENUATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **+!** | ACTAVIS LABS UT INC | **25MG** | **N011722** | **002** | |

TABLET, EXTENDED RELEASE;ORAL

**DIETHYLPROPION HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | LANNETT HOLDINGS INC | **75MG** | **A091680** | **001** | Oct 24, 2011 |

**TENUATE DOSPAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | ACTAVIS LABS UT INC | **75MG** | **N012546** | **001** | |

DIFLORASONE DIACETATE

CREAM;TOPICAL

DIFLORASONE DIACETATE

| | | | | | | |
|---|---|---|---|---|---|---|
| BX | ! | FOUGERA PHARMS | 0.05% | A076263 | 001 | Dec 20, 2002 |
| BX | ! | TARO | 0.05% | A075508 | 001 | Apr 24, 2000 |

OINTMENT;TOPICAL

**DIFLORASONE DIACETATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AKORN | **0.05%** | **A206572** | **001** | Jul 24, 2015 |
| **AB** | | FOUGERA PHARMS | **0.05%** | **A075374** | **001** | Apr 27, 1999 |
| **AB** | | RICONPHARMA LLC | **0.05%** | **A207440** | **001** | Feb 27, 2017 |
| **AB** | **!** | TARO | **0.05%** | **A075331** | **001** | May 14, 1999 |

DIFLUNISAL

TABLET;ORAL

**DIFLUNISAL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | HERITAGE PHARMA | **500MG** | **A202845** | **001** | Mar 08, 2012 |
| **AB** | **!** | TEVA | **500MG** | **A073673** | **001** | Jul 31, 1992 |
| **AB** | | ZYDUS PHARMS USA INC | **500MG** | **A203547** | **001** | Jun 16, 2017 |

DIFLUPREDNATE

EMULSION;OPHTHALMIC

DUREZOL

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | NOVARTIS PHARMS CORP | 0.05% | N022212 | 001 | Jun 23, 2008 |

DIGOXIN

ELIXIR;ORAL

DIGOXIN

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | WEST-WARD PHARMS INT | 0.05MG/ML | N021648 | 001 | Aug 26, 2004 |

INJECTABLE;INJECTION

**DIGOXIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | SANDOZ INC | **0.25MG/ML** | **A040481** | **001** | Aug 21, 2003 |
| **AP** | | WEST-WARD PHARMS INT | **0.25MG/ML** | **A083391** | **001** | |

**LANOXIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | COVIS PHARMA BV | **0.25MG/ML** | **N009330** | **002** | |

LANOXIN PEDIATRIC

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | COVIS PHARMA BV | 0.1MG/ML | N009330 | 004 | |

TABLET;ORAL

**DIGOXIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | HIKMA INTL PHARMS | **0.125MG** | **A077002** | **002** | Oct 30, 2007 |
| **AB** | | | **0.25MG** | **A077002** | **001** | Oct 30, 2007 |
| **AB** | | IMPAX LABS | **0.125MG** | **A078556** | **001** | Jul 20, 2009 |
| **AB** | | | **0.25MG** | **A078556** | **002** | Jul 20, 2009 |
| **AB** | | MYLAN PHARMS INC | **0.125MG** | **A040282** | **001** | Dec 23, 1999 |
| **AB** | | | **0.25MG** | **A040282** | **002** | Dec 23, 1999 |
| **AB** | | STEVENS J | **0.125MG** | **A076268** | **001** | Jul 26, 2002 |
| **AB** | | | **0.25MG** | **A076268** | **002** | Jul 26, 2002 |
| **AB** | | SUN PHARM INDS INC | **0.125MG** | **A076363** | **001** | Jan 31, 2003 |
| **AB** | | | **0.25MG** | **A076363** | **002** | Jan 31, 2003 |

**LANOXIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | CONCORDIA PHARMS INC | **0.125MG** | **N020405** | **002** | Sep 30, 1997 |
| **AB** | **+!** | | **0.25MG** | **N020405** | **004** | Sep 30, 1997 |
| | + | | 0.0625MG | N020405 | 001 | Sep 30, 1997 |
| | + | | 0.1875MG | N020405 | 003 | Sep 30, 1997 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| DIHYDROERGOTAMINE MESYLATE | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| **D.H.E. 45** | | | | | | | |
| **AP** | **+!** | VALEANT | **1MG/ML** | **N005929** | **001** | | |
| **DIHYDROERGOTAMINE MESYLATE** | | | | | | | |
| **AP** | | HIKMA PHARMS | **1MG/ML** | **A206621** | **001** | Sep 15, 2017 | |
| **AP** | | PADDOCK LLC | **1MG/ML** | **A040475** | **001** | Apr 28, 2003 | |
| **AP** | | WEST-WARD PHARMS INT | **1MG/ML** | **A040453** | **001** | Jun 09, 2003 | |
| SPRAY, METERED;NASAL | | | | | | | |
| MIGRANAL | | | | | | | |
| | +! | VALEANT | 0.5MG/INH | N020148 | 001 | Dec 08, 1997 | |
| DILTIAZEM HYDROCHLORIDE | | | | | | | |
| CAPSULE, EXTENDED RELEASE;ORAL | | | | | | | |
| **DILTIAZEM HYDROCHLORIDE** | | | | | | | |
| **AB2** | | APOTEX | **120MG** | **A074943** | **003** | Dec 19, 2000 | |
| **AB2** | | | **180MG** | **A074943** | **002** | Dec 19, 2000 | |
| **AB2** | | | **240MG** | **A074943** | **001** | Aug 06, 1998 | |
| **AB2** | | MYLAN | **120MG** | **A075124** | **002** | Mar 18, 1998 | |
| **AB2** | | | **180MG** | **A075124** | **003** | Mar 18, 1998 | |
| **AB2** | **!** | | **240MG** | **A075124** | **001** | Mar 18, 1998 | |
| **CARDIZEM CD** | | | | | | | |
| **AB3** | **+** | VALEANT INTL | **120MG** | **N020062** | **001** | Aug 10, 1992 | |
| **AB3** | **+** | | **180MG** | **N020062** | **002** | Dec 27, 1991 | |
| **AB3** | **+** | | **240MG** | **N020062** | **003** | Dec 27, 1991 | |
| **AB3** | **+** | | **300MG** | **N020062** | **004** | Dec 27, 1991 | |
| **AB3** | **+!** | | **360MG** | **N020062** | **005** | Aug 24, 1999 | |
| **CARTIA XT** | | | | | | | |
| **AB3** | | ACTAVIS LABS FL INC | **120MG** | **A074752** | **002** | Jul 09, 1998 | |
| **AB3** | | | **180MG** | **A074752** | **001** | Jul 09, 1998 | |
| **AB3** | | | **240MG** | **A074752** | **003** | Jul 09, 1998 | |
| **AB3** | | | **300MG** | **A074752** | **004** | Jul 09, 1998 | |
| **DILTIAZEM HYDROCHLORIDE** | | | | | | | |
| **AB3** | | ACTAVIS ELIZABETH | **360MG** | **A202463** | **001** | Dec 07, 2012 | |
| **AB3** | | PAR PHARM | **120MG** | **A074984** | **001** | Dec 20, 1999 | |
| **AB3** | | | **180MG** | **A074984** | **002** | Dec 20, 1999 | |
| **AB3** | | | **240MG** | **A074984** | **003** | Dec 20, 1999 | |
| **AB3** | | | **300MG** | **A074984** | **004** | Dec 20, 1999 | |
| **AB3** | | SUN PHARM INDS LTD | **120MG** | **A203023** | **001** | Jun 08, 2017 | |
| **AB3** | | | **180MG** | **A203023** | **002** | Jun 08, 2017 | |
| **AB3** | | | **240MG** | **A203023** | **003** | Jun 08, 2017 | |
| **AB3** | | | **300MG** | **A203023** | **004** | Jun 08, 2017 | |
| **AB3** | | | **360MG** | **A203023** | **005** | Jun 08, 2017 | |
| **AB3** | | SUN PHARMA GLOBAL | **120MG** | **A090492** | **001** | Oct 28, 2011 | |
| **AB3** | | | **180MG** | **A090492** | **002** | Oct 28, 2011 | |
| **AB3** | | | **240MG** | **A090492** | **003** | Oct 28, 2011 | |
| **AB3** | | | **300MG** | **A090492** | **004** | Oct 28, 2011 | |
| **AB3** | | | **360MG** | **A090492** | **005** | Oct 28, 2011 | |
| **AB3** | | VALEANT PHARMS NORTH | **120MG** | **A075116** | **001** | Dec 23, 1999 | |
| **AB3** | | | **180MG** | **A075116** | **002** | Dec 23, 1999 | |
| **AB3** | | | **240MG** | **A075116** | **003** | Dec 23, 1999 | |
| **AB3** | | | **300MG** | **A075116** | **004** | Dec 23, 1999 | |
| **AB3** | | ZYDUS PHARMS USA INC | **120MG** | **A206534** | **001** | Aug 08, 2017 | |
| **AB3** | | | **180MG** | **A206534** | **002** | Aug 08, 2017 | |
| **AB3** | | | **240MG** | **A206534** | **003** | Aug 08, 2017 | |
| **AB3** | | | **300MG** | **A206534** | **004** | Aug 08, 2017 | |
| **AB3** | | | **360MG** | **A206534** | **005** | Aug 08, 2017 | |
| **AB4** | | SANDOZ | **120MG** | **A091022** | **001** | Sep 28, 2012 | |
| **AB4** | | | **180MG** | **A091022** | **002** | Sep 28, 2012 | |
| **AB4** | | | **240MG** | **A091022** | **003** | Sep 28, 2012 | |
| **AB4** | | | **300MG** | **A091022** | **004** | Sep 28, 2012 | |
| **AB4** | | | **360MG** | **A091022** | **005** | Sep 28, 2012 | |
| **AB4** | | | **420MG** | **A091022** | **006** | Sep 28, 2012 | |
| **AB4** | | SUN PHARMA GLOBAL | **120MG** | **A090421** | **001** | Nov 15, 2010 | |
| **AB4** | | | **180MG** | **A090421** | **002** | Nov 15, 2010 | |
| **AB4** | | | **240MG** | **A090421** | **003** | Nov 15, 2010 | |
| **AB4** | | | **300MG** | **A090421** | **004** | Nov 15, 2010 | |
| **AB4** | | | **360MG** | **A090421** | **005** | Nov 15, 2010 | |
| **AB4** | | ZYDUS PHARMS USA INC | **120MG** | **A206641** | **001** | Aug 11, 2017 | |
| **AB4** | | | **180MG** | **A206641** | **002** | Aug 11, 2017 | |

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

**DILTIAZEM HYDROCHLORIDE**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **AB4** | | | **240MG** | **A206641** | **003** | Aug 11, 2017 |
| **AB4** | | | **300MG** | **A206641** | **004** | Aug 11, 2017 |
| **AB4** | | | **360MG** | **A206641** | **005** | Aug 11, 2017 |
| **AB4** | | | **420MG** | **A206641** | **006** | Aug 11, 2017 |

**DILTZAC**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **AB4** | | APOTEX INC | **120MG** | **A076395** | **001** | Feb 01, 2006 |
| **AB4** | | | **180MG** | **A076395** | **002** | Feb 01, 2006 |
| **AB4** | | | **240MG** | **A076395** | **003** | Feb 01, 2006 |
| **AB4** | | | **300MG** | **A076395** | **004** | Feb 01, 2006 |
| **AB4** | | | **360MG** | **A076395** | **005** | Feb 01, 2006 |

**TAZTIA XT**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **AB4** | | ACTAVIS LABS FL INC | **120MG** | **A075401** | **001** | Apr 10, 2003 |
| **AB4** | | | **180MG** | **A075401** | **002** | Apr 10, 2003 |
| **AB4** | | | **240MG** | **A075401** | **003** | Apr 10, 2003 |
| **AB4** | | | **300MG** | **A075401** | **004** | Apr 10, 2003 |
| **AB4** | | | **360MG** | **A075401** | **005** | Apr 10, 2003 |

**TIAZAC**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **AB4** | **+** | VALEANT PHARMS NORTH | **120MG** | **N020401** | **001** | Sep 11, 1995 |
| **AB4** | **+** | | **180MG** | **N020401** | **002** | Sep 11, 1995 |
| **AB4** | **+** | | **240MG** | **N020401** | **003** | Sep 11, 1995 |
| **AB4** | **+** | | **300MG** | **N020401** | **004** | Sep 11, 1995 |
| **AB4** | **+** | | **360MG** | **N020401** | **005** | Sep 11, 1995 |
| **AB4** | **+!** | | **420MG** | **N020401** | **006** | Oct 16, 1998 |

DILTIAZEM HYDROCHLORIDE

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| BC | ! | MYLAN | 120MG | A074910 | 003 | May 02, 1997 |
| | | | 60MG | A074910 | 001 | May 02, 1997 |
| | | | 90MG | A074910 | 002 | May 02, 1997 |

INJECTABLE;INJECTION

**DILTIAZEM HYDROCHLORIDE**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **AP** | | AKORN INC | **5MG/ML** | **A075086** | **001** | Apr 09, 1998 |
| **AP** | **!** | ATHENEX INC | **5MG/ML** | **A074617** | **001** | Feb 28, 1996 |
| **AP** | | HIKMA FARMACEUTICA | **5MG/ML** | **A202651** | **001** | Aug 09, 2012 |
| **AP** | | HOSPIRA | **5MG/ML** | **A074941** | **001** | Apr 15, 1998 |
| **AP** | | INTL MEDICATION | **5MG/ML** | **A075749** | **001** | Nov 21, 2001 |
| **AP** | | WEST-WARD PHARMS INT | **5MG/ML** | **A078538** | **001** | Dec 17, 2008 |
| | ! | HOSPIRA | 100MG/VIAL | A075853 | 001 | Dec 17, 2002 |

TABLET;ORAL

**CARDIZEM**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **AB** | **+** | VALEANT INTL | **30MG** | **N018602** | **001** | Nov 05, 1982 |
| **AB** | **+** | | **60MG** | **N018602** | **002** | Nov 05, 1982 |
| **AB** | **+** | | **90MG** | **N018602** | **003** | Dec 08, 1986 |
| **AB** | **+!** | | **120MG** | **N018602** | **004** | Dec 08, 1986 |

**DILTIAZEM HYDROCHLORIDE**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **AB** | | MYLAN | **30MG** | **A072838** | **004** | Nov 05, 1992 |
| **AB** | | | **60MG** | **A072838** | **003** | Nov 05, 1992 |
| **AB** | | | **90MG** | **A072838** | **002** | Nov 05, 1992 |
| **AB** | | | **120MG** | **A072838** | **001** | Nov 05, 1992 |
| **AB** | | TEVA | **30MG** | **A074185** | **001** | May 31, 1995 |
| **AB** | | | **60MG** | **A074185** | **002** | May 31, 1995 |
| **AB** | | | **90MG** | **A074185** | **003** | May 31, 1995 |
| **AB** | | | **120MG** | **A074185** | **004** | May 31, 1995 |

TABLET, EXTENDED RELEASE;ORAL

**CARDIZEM LA**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **AB** | **+** | VALEANT INTL | **120MG** | **N021392** | **001** | Feb 06, 2003 |
| **AB** | **+** | | **180MG** | **N021392** | **002** | Feb 06, 2003 |
| **AB** | **+** | | **240MG** | **N021392** | **003** | Feb 06, 2003 |
| **AB** | **+** | | **300MG** | **N021392** | **004** | Feb 06, 2003 |
| **AB** | **+** | | **360MG** | **N021392** | **005** | Feb 06, 2003 |
| **AB** | **+!** | | **420MG** | **N021392** | **006** | Feb 06, 2003 |

**DILTIAZEM HYDROCHLORIDE**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS LABS FL INC | **120MG** | **A077686** | **006** | Mar 15, 2010 |
| **AB** | | | **180MG** | **A077686** | **005** | Mar 15, 2010 |
| **AB** | | | **240MG** | **A077686** | **004** | Mar 15, 2010 |
| **AB** | | | **300MG** | **A077686** | **003** | Mar 15, 2010 |
| **AB** | | | **360MG** | **A077686** | **002** | Mar 15, 2010 |
| **AB** | | | **420MG** | **A077686** | **001** | Mar 15, 2010 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| DIMENHYDRINATE | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| DIMENHYDRINATE | | | | | | | |
| | ! | FRESENIUS KABI USA | 50MG/ML | | A040519 | 001 | Jun 23, 2004 |
| DIMERCAPROL | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| BAL | | | | | | | |
| | +! | AKORN | 10% | | N005939 | 001 | |
| DIMETHYL FUMARATE | | | | | | | |
| CAPSULE, DELAYED RELEASE;ORAL | | | | | | | |
| TECFIDERA | | | | | | | |
| | + | BIOGEN IDEC INC | 120MG | | N204063 | 001 | Mar 27, 2013 |
| | +! | | 240MG | | N204063 | 002 | Mar 27, 2013 |
| DIMETHYL SULFOXIDE | | | | | | | |
| SOLUTION;INTRAVESICAL | | | | | | | |
| **DIMETHYL SULFOXIDE** | | | | | | | |
| **AT** | | MYLAN INSTITUTIONAL | **50%** | | **A076185** | **001** | Nov 29, 2002 |
| **RIMSO-50** | | | | | | | |
| **AT** | **+!** | MYLAN INSTITUTIONAL | **50%** | | **N017788** | **001** | |
| DINOPROSTONE | | | | | | | |
| GEL;ENDOCERVICAL | | | | | | | |
| PREPIDIL | | | | | | | |
| | +! | PHARMACIA AND UPJOHN | 0.5MG/3GM | | N019617 | 001 | Dec 09, 1992 |
| INSERT, EXTENDED RELEASE;VAGINAL | | | | | | | |
| CERVIDIL | | | | | | | |
| | +! | FERRING PHARMS INC | 10MG | | N020411 | 001 | Mar 30, 1995 |
| SUPPOSITORY;VAGINAL | | | | | | | |
| PROSTIN E2 | | | | | | | |
| | +! | PHARMACIA AND UPJOHN | 20MG | | N017810 | 001 | |
| DIPHENHYDRAMINE HYDROCHLORIDE | | | | | | | |
| CAPSULE;ORAL | | | | | | | |
| DIPHENHYDRAMINE HYDROCHLORIDE | | | | | | | |
| | ! | BARR | 50MG | | A080738 | 001 | |
| ELIXIR;ORAL | | | | | | | |
| DIPHENHYDRAMINE HYDROCHLORIDE | | | | | | | |
| | ! | PHARM ASSOC | 12.5MG/5ML | | A087513 | 001 | Feb 10, 1982 |
| INJECTABLE;INJECTION | | | | | | | |
| **DIPHENHYDRAMINE HYDROCHLORIDE** | | | | | | | |
| **AP** | | APP PHARMS | **50MG/ML** | | **A040466** | **001** | May 28, 2002 |
| **AP** | | HOSPIRA | **50MG/ML** | | **A040140** | **001** | Nov 20, 1998 |
| **AP** | | MYLAN INSTITUTIONAL | **50MG/ML** | | **A040498** | **001** | Jul 12, 2005 |
| **AP** | **!** | WEST-WARD PHARMS INT | **50MG/ML** | | **A080817** | **002** | |
| **DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE** | | | | | | | |
| **AP** | | FRESENIUS KABI USA | **50MG/ML** | | **A091526** | **001** | Mar 26, 2013 |
| DIPYRIDAMOLE | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| **DIPYRIDAMOLE** | | | | | | | |
| **AP** | **!** | ATHENEX INC | **5MG/ML** | | **A074939** | **001** | Apr 13, 1998 |
| **AP** | | FRESENIUS KABI USA | **5MG/ML** | | **A074956** | **001** | Sep 30, 1998 |
| **AP** | | WEST-WARD PHARMS INT | **5MG/ML** | | **A074521** | **001** | Oct 18, 1996 |
| TABLET;ORAL | | | | | | | |
| **DIPYRIDAMOLE** | | | | | | | |
| **AB** | | BARR | **25MG** | | **A087184** | **001** | Oct 03, 1990 |
| **AB** | | | **50MG** | | **A087716** | **001** | Oct 03, 1990 |
| **AB** | | | **75MG** | | **A087717** | **001** | Oct 03, 1990 |
| **AB** | | IMPAX LABS | **25MG** | | **A040782** | **001** | Jul 18, 2007 |
| **AB** | | | **50MG** | | **A040782** | **002** | Jul 18, 2007 |
| **AB** | | | **75MG** | | **A040782** | **003** | Jul 18, 2007 |
| **AB** | | MURTY PHARMS | **25MG** | | **A040733** | **001** | Feb 13, 2007 |
| **AB** | | | **50MG** | | **A040733** | **002** | Feb 13, 2007 |
| **AB** | | | **75MG** | | **A040733** | **003** | Feb 13, 2007 |
| **AB** | | ZYDUS PHARMS USA INC | **25MG** | | **A040874** | **001** | Jan 28, 2008 |
| **AB** | | | **50MG** | | **A040874** | **002** | Jan 28, 2008 |
| **AB** | | | **75MG** | | **A040874** | **003** | Jan 28, 2008 |

DIPYRIDAMOLE

TABLET;ORAL

**PERSANTINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | BOEHRINGER INGELHEIM | **25MG** | **N012836** | **003** | Dec 22, 1986 |
| **AB** | + | | **50MG** | **N012836** | **004** | Feb 06, 1987 |
| **AB** | +! | | **75MG** | **N012836** | **005** | Feb 06, 1987 |

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL

**DISOPYRAMIDE PHOSPHATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | MAYNE PHARMA | **EQ 100MG BASE** | **A070173** | **001** | May 31, 1985 |
| **AB** | | | **EQ 150MG BASE** | **A070173** | **002** | May 31, 1985 |
| **AB** | | TEVA | **EQ 100MG BASE** | **A070101** | **001** | Feb 22, 1985 |
| **AB** | | | **EQ 150MG BASE** | **A070102** | **001** | Feb 22, 1985 |

**NORPACE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | GD SEARLE LLC | **EQ 100MG BASE** | **N017447** | **001** | |
| **AB** | +! | | **EQ 150MG BASE** | **N017447** | **002** | |

CAPSULE, EXTENDED RELEASE;ORAL

NORPACE CR

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | GD SEARLE LLC | EQ 100MG BASE | N018655 | 001 | Jul 20, 1982 |
| | +! | | EQ 150MG BASE | N018655 | 002 | Jul 20, 1982 |

DISULFIRAM

TABLET;ORAL

**ANTABUSE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ODYSSEY PHARMS | **250MG** | **A088482** | **001** | Dec 08, 1983 |
| **AB** | ! | | **500MG** | **A088483** | **001** | Dec 08, 1983 |

**DISULFIRAM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | CHARTWELL MOLECULES | **250MG** | **A091563** | **001** | Dec 31, 2012 |
| **AB** | | | **500MG** | **A091563** | **002** | Dec 31, 2012 |
| **AB** | | MYLAN PHARMS INC | **250MG** | **A203916** | **001** | Mar 04, 2015 |
| **AB** | | | **500MG** | **A203916** | **002** | Mar 04, 2015 |
| **AB** | | SIGMAPHARM LABS LLC | **250MG** | **A091619** | **001** | Mar 28, 2011 |
| **AB** | | | **500MG** | **A091619** | **002** | Mar 28, 2011 |
| **AB** | | WEST-WARD PHARMS INT | **250MG** | **A202652** | **001** | Feb 05, 2014 |
| **AB** | | | **500MG** | **A202652** | **002** | Feb 05, 2014 |

**DISULFIRAM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALVOGEN MALTA | **250MG** | **A091681** | **001** | Aug 08, 2013 |

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS;ORAL

**DEPAKOTE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | +! | ABBVIE | **EQ 125MG VALPROIC ACID** | **N019680** | **001** | Sep 12, 1989 |

**DIVALPROEX SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | DR REDDYS LABS LTD | **EQ 125MG VALPROIC ACID** | **A078979** | **001** | Jan 23, 2009 |
| **AB** | | MYLAN | **EQ 125MG VALPROIC ACID** | **A090407** | **001** | Mar 28, 2011 |
| **AB** | | ZYDUS PHARMS USA INC | **EQ 125MG VALPROIC ACID** | **A078919** | **001** | Jan 27, 2009 |

TABLET, DELAYED RELEASE;ORAL

**DEPAKOTE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | ABBVIE | **EQ 125MG VALPROIC ACID** | **N018723** | **003** | Oct 26, 1984 |
| **AB** | + | | **EQ 250MG VALPROIC ACID** | **N018723** | **001** | Mar 10, 1983 |
| **AB** | +! | | **EQ 500MG VALPROIC ACID** | **N018723** | **002** | Mar 10, 1983 |

**DIVALPROEX SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS LABS FL INC | **EQ 500MG VALPROIC ACID** | **A079080** | **001** | Feb 25, 2011 |
| **AB** | | ANCHEN PHARMS | **EQ 500MG VALPROIC ACID** | **A078411** | **001** | Nov 03, 2008 |
| **AB** | | AUROBINDO PHARMA LTD | **EQ 125MG VALPROIC ACID** | **A090554** | **001** | Apr 21, 2011 |
| **AB** | | | **EQ 250MG VALPROIC ACID** | **A090554** | **002** | Apr 21, 2011 |
| **AB** | | | **EQ 500MG VALPROIC ACID** | **A090554** | **003** | Apr 21, 2011 |
| **AB** | | DR REDDYS LABS LTD | **EQ 125MG VALPROIC ACID** | **A078755** | **001** | Jul 29, 2008 |
| **AB** | | | **EQ 250MG VALPROIC ACID** | **A078755** | **002** | Jul 29, 2008 |
| **AB** | | | **EQ 500MG VALPROIC ACID** | **A078755** | **003** | Jul 29, 2008 |
| **AB** | | LUPIN | **EQ 125MG VALPROIC ACID** | **A078790** | **001** | Jul 29, 2008 |
| **AB** | | | **EQ 250MG VALPROIC ACID** | **A078790** | **002** | Jul 29, 2008 |
| **AB** | | | **EQ 500MG VALPROIC ACID** | **A078790** | **003** | Jul 29, 2008 |
| **AB** | | MYLAN | **EQ 125MG VALPROIC ACID** | **A090062** | **001** | Mar 17, 2009 |
| **AB** | | | **EQ 250MG VALPROIC ACID** | **A090062** | **002** | Mar 17, 2009 |
| **AB** | | | **EQ 500MG VALPROIC ACID** | **A090062** | **003** | Mar 17, 2009 |
| **AB** | | NU PHARM | **EQ 125MG VALPROIC ACID** | **A077615** | **003** | Jul 29, 2008 |
| **AB** | | | **EQ 250MG VALPROIC ACID** | **A077615** | **002** | Jul 29, 2008 |
| **AB** | | | **EQ 500MG VALPROIC ACID** | **A077615** | **001** | Jul 29, 2008 |
| **AB** | | ORCHID HLTHCARE | **EQ 125MG VALPROIC ACID** | **A078853** | **001** | Nov 25, 2008 |

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE;ORAL

**DIVALPROEX SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **EQ 250MG VALPROIC ACID** | **A078853** | **002** | Nov 25, 2008 |
| **AB** | | | **EQ 500MG VALPROIC ACID** | **A078853** | **003** | Nov 25, 2008 |
| **AB** | | PRINSTON INC | **EQ 125MG VALPROIC ACID** | **A090210** | **001** | Nov 30, 2009 |
| **AB** | | | **EQ 250MG VALPROIC ACID** | **A090210** | **002** | Nov 30, 2009 |
| **AB** | | | **EQ 500MG VALPROIC ACID** | **A090210** | **003** | Nov 30, 2009 |
| **AB** | | SANDOZ | **EQ 125MG VALPROIC ACID** | **A078290** | **003** | Jul 29, 2008 |
| **AB** | | | **EQ 250MG VALPROIC ACID** | **A078290** | **002** | Jul 29, 2008 |
| **AB** | | | **EQ 500MG VALPROIC ACID** | **A078290** | **001** | Jul 29, 2008 |
| **AB** | | SUN PHARM INDS | **EQ 125MG VALPROIC ACID** | **A078597** | **001** | Jul 29, 2008 |
| **AB** | | | **EQ 250MG VALPROIC ACID** | **A078597** | **002** | Jul 29, 2008 |
| **AB** | | | **EQ 500MG VALPROIC ACID** | **A078597** | **003** | Jul 29, 2008 |
| **AB** | | TEVA | **EQ 125MG VALPROIC ACID** | **A076941** | **001** | Jul 29, 2008 |
| **AB** | | | **EQ 250MG VALPROIC ACID** | **A076941** | **002** | Jul 29, 2008 |
| **AB** | | | **EQ 500MG VALPROIC ACID** | **A076941** | **003** | Jul 29, 2008 |
| **AB** | | UNICHEM LABS LTD | **EQ 125MG VALPROIC ACID** | **A079163** | **001** | Apr 05, 2011 |
| **AB** | | | **EQ 250MG VALPROIC ACID** | **A079163** | **002** | Apr 05, 2011 |
| **AB** | | | **EQ 500MG VALPROIC ACID** | **A079163** | **003** | Apr 05, 2011 |
| **AB** | | UPSHER-SMITH LABS | **EQ 125MG VALPROIC ACID** | **A078182** | **001** | Jul 29, 2008 |
| **AB** | | | **EQ 250MG VALPROIC ACID** | **A078182** | **002** | Jul 29, 2008 |
| **AB** | | | **EQ 500MG VALPROIC ACID** | **A078182** | **003** | Jul 29, 2008 |
| **AB** | | WOCKHARDT | **EQ 125MG VALPROIC ACID** | **A077296** | **001** | Jul 31, 2008 |
| **AB** | | | **EQ 250MG VALPROIC ACID** | **A077296** | **002** | Jul 31, 2008 |
| **AB** | | | **EQ 500MG VALPROIC ACID** | **A077296** | **003** | Jul 31, 2008 |
| **AB** | | ZYDUS PHARMS USA INC | **EQ 125MG VALPROIC ACID** | **A077100** | **001** | Mar 05, 2009 |
| **AB** | | | **EQ 250MG VALPROIC ACID** | **A077100** | **002** | Mar 05, 2009 |
| **AB** | | | **EQ 500MG VALPROIC ACID** | **A077100** | **003** | Mar 05, 2009 |

TABLET, EXTENDED RELEASE;ORAL

**DEPAKOTE ER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | ABBVIE | **EQ 250MG VALPROIC ACID** | **N021168** | **002** | May 31, 2002 |
| **AB** | +! | | **EQ 500MG VALPROIC ACID** | **N021168** | **001** | Aug 04, 2000 |

**DIVALPROEX SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AMNEAL PHARMS | **EQ 250MG VALPROIC ACID** | **A203730** | **001** | May 29, 2015 |
| **AB** | | | **EQ 500MG VALPROIC ACID** | **A203730** | **002** | May 29, 2015 |
| **AB** | | ANCHEN PHARMS | **EQ 250MG VALPROIC ACID** | **A078445** | **001** | Feb 26, 2009 |
| **AB** | | | **EQ 500MG VALPROIC ACID** | **A078445** | **002** | Aug 04, 2009 |
| **AB** | | AUROBINDO PHARMA LTD | **EQ 250MG VALPROIC ACID** | **A202419** | **001** | Jun 02, 2014 |
| **AB** | | | **EQ 500MG VALPROIC ACID** | **A202419** | **002** | Jun 02, 2014 |
| **AB** | | DR REDDYS LABS LTD | **EQ 250MG VALPROIC ACID** | **A090161** | **001** | Mar 15, 2012 |
| **AB** | | IMPAX LABS | **EQ 250MG VALPROIC ACID** | **A078791** | **001** | May 06, 2009 |
| **AB** | | | **EQ 500MG VALPROIC ACID** | **A078791** | **002** | Aug 04, 2009 |
| **AB** | | MYLAN | **EQ 250MG VALPROIC ACID** | **A077567** | **001** | Jan 29, 2009 |
| **AB** | | | **EQ 500MG VALPROIC ACID** | **A077567** | **002** | Jan 29, 2009 |
| **AB** | | REDDYS | **EQ 500MG VALPROIC ACID** | **A090070** | **001** | Mar 12, 2012 |
| **AB** | | WOCKHARDT | **EQ 250MG VALPROIC ACID** | **A078705** | **002** | Feb 10, 2009 |
| **AB** | | | **EQ 500MG VALPROIC ACID** | **A078705** | **001** | Aug 04, 2009 |
| **AB** | | ZYDUS PHARMS USA INC | **EQ 250MG VALPROIC ACID** | **A078239** | **001** | Feb 27, 2009 |
| **AB** | | | **EQ 500MG VALPROIC ACID** | **A078239** | **002** | Aug 04, 2009 |

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

**DOBUTAMINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | HOSPIRA | **EQ 12.5MG BASE/ML** | **A074086** | **001** | Nov 29, 1993 |
| **AP** | ! | | **EQ 12.5MG BASE/ML** | **A074292** | **001** | Feb 16, 1995 |
| **AP** | | WEST-WARD PHARMS INT | **EQ 12.5MG BASE/ML** | **A074277** | **001** | Oct 31, 1994 |

**DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | +! | BAXTER HLTHCARE | **EQ 50MG BASE/100ML** | **N020255** | **001** | Oct 19, 1993 |
| **AP** | +! | | **EQ 100MG BASE/100ML** | **N020255** | **003** | Oct 19, 1993 |
| **AP** | +! | | **EQ 200MG BASE/100ML** | **N020255** | **004** | Oct 19, 1993 |
| **AP** | +! | | **EQ 400MG BASE/100ML** | **N020255** | **005** | Oct 19, 1993 |
| **AP** | +! | HOSPIRA | **EQ 50MG BASE/100ML** | **N020201** | **003** | Oct 19, 1993 |
| **AP** | +! | | **EQ 100MG BASE/100ML** | **N020201** | **002** | Oct 19, 1993 |
| **AP** | +! | | **EQ 200MG BASE/100ML** | **N020201** | **001** | Oct 19, 1993 |
| **AP** | +! | | **EQ 400MG BASE/100ML** | **N020201** | **006** | Jul 07, 1994 |

DOCETAXEL

INJECTABLE;INJECTION

**DOCETAXEL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | + | ACCORD HLTHCARE | **20MG/ML (20MG/ML)** | **N201195** | **003** | Apr 20, 2012 |
| **AP** | + | | **80MG/4ML (20MG/ML)** | **N201195** | **004** | Apr 20, 2012 |
| **AP** | +! | | **160MG/8ML (20MG/ML)** | **N201195** | **005** | Apr 20, 2012 |
| **AP** | | ACTAVIS LLC | **20MG/ML (20MG/ML)** | **N203551** | **001** | Apr 12, 2013 |
| **AP** | | | **80MG/4ML (20MG/ML)** | **N203551** | **002** | Apr 12, 2013 |
| **AP** | | DFB ONCOLOGY LTD | **20MG/ML (20MG/ML)** | **A206177** | **001** | Jan 20, 2017 |
| **AP** | | | **80MG/4ML (20MG/ML)** | **A206177** | **002** | Jan 20, 2017 |
| **AP** | | DR REDDYS LABS LTD | **20MG/ML (20MG/ML)** | **A204193** | **001** | Nov 05, 2014 |
| **AP** | | | **80MG/4ML (20MG/ML)** | **A204193** | **002** | Nov 05, 2014 |
| **AP** | +! | HOSPIRA INC | **20MG/2ML (10MG/ML)** | **N022234** | **001** | Mar 08, 2011 |
| **AP** | +! | | **80MG/8ML (10MG/ML)** | **N022234** | **002** | Mar 08, 2011 |
| **AP** | +! | | **160MG/16ML (10MG/ML)** | **N022234** | **003** | Mar 08, 2011 |
| **AP** | | INGENUS PHARMS LLC | **20MG/2ML (10MG/ML)** | **A207563** | **001** | Aug 31, 2017 |
| **AP** | | | **80MG/8ML (10MG/ML)** | **A207563** | **002** | Aug 31, 2017 |
| **AP** | | | **160MG/16ML (10MG/ML)** | **A207563** | **003** | Aug 31, 2017 |
| **AP** | | JIANGSU HENGRUI MED | **20MG/ML (20MG/ML)** | **A207252** | **001** | Aug 09, 2017 |
| **AP** | | | **80MG/4ML (20MG/ML)** | **A207252** | **002** | Aug 09, 2017 |
| **AP** | | | **160MG/8ML (20MG/ML)** | **A207252** | **003** | Aug 09, 2017 |
| **AP** | | SANDOZ | **20MG/2ML (10MG/ML)** | **N201525** | **001** | Jun 29, 2011 |
| **AP** | | | **80MG/8ML (10MG/ML)** | **N201525** | **002** | Jun 29, 2011 |
| **AP** | | | **160MG/16ML (10MG/ML)** | **N201525** | **003** | Jun 29, 2011 |
| **AP** | | TEVA PHARMS USA | **20MG/ML (20MG/ML)** | **A203877** | **001** | Sep 16, 2015 |
| **AP** | | | **80MG/4ML (20MG/ML)** | **A203877** | **002** | Sep 16, 2015 |

**TAXOTERE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | +! | SANOFI AVENTIS US | **20MG/ML (20MG/ML)** | **N020449** | **003** | Aug 03, 2010 |
| **AP** | +! | | **80MG/4ML (20MG/ML)** | **N020449** | **004** | Aug 02, 2010 |
| **AP** | +! | | **160MG/8ML (20MG/ML)** | **N020449** | **005** | Apr 13, 2012 |

DOCETAXEL

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | ACCORD HLTHCARE | 20MG/0.5ML (40MG/ML) | N201195 | 001 | Jun 08, 2011 |
| | + | | 80MG/2ML (40MG/ML) | N201195 | 002 | Jun 08, 2011 |
| | | ACTAVIS LLC | 140MG/7ML (20MG/ML) | N203551 | 003 | Apr 12, 2013 |
| | | DFB ONCOLOGY LTD | 200MG/10ML (20MG/ML) | A206177 | 003 | Jan 20, 2017 |
| | + | HOSPIRA INC | 20MG/ML (20MG/ML) | N022234 | 004 | Jun 23, 2016 |
| | + | | 80MG/4ML (20MG/ML) | N022234 | 005 | Jun 23, 2016 |
| | + | | 160MG/8ML (20MG/ML) | N022234 | 007 | Jan 24, 2017 |
| | ! | JIANGSU HENGRUI MED | 40MG/ML | A203170 | 001 | Feb 15, 2017 |

SOLUTION;IV (INFUSION)

DOCETAXEL

| | | | | | | |
|---|---|---|---|---|---|---|
| | | EAGLE PHARMS | 20MG/ML (20MG/ML) | N205934 | 001 | Dec 22, 2015 |
| | | | 80MG/4ML (20MG/ML) | N205934 | 002 | Dec 22, 2015 |
| | | | 160MG/8ML (20MG/ML) | N205934 | 003 | Dec 22, 2015 |

DOFETILIDE

CAPSULE;ORAL

**DOFETILIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | MAYNE PHARMA INC | **0.125MG** | **A207058** | **001** | Jun 06, 2016 |
| **AB** | | | **0.25MG** | **A207058** | **002** | Jun 06, 2016 |
| **AB** | | | **0.5MG** | **A207058** | **003** | Jun 06, 2016 |

**TIKOSYN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | PFIZER | **0.125MG** | **N020931** | **001** | Oct 01, 1999 |
| **AB** | + | | **0.25MG** | **N020931** | **002** | Oct 01, 1999 |
| **AB** | +! | | **0.5MG** | **N020931** | **003** | Oct 01, 1999 |

DOLUTEGRAVIR SODIUM

TABLET;ORAL

TIVICAY

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | VIIV HLTHCARE | EQ 10MG BASE | N204790 | 002 | Jun 09, 2016 |
| | + | | EQ 25MG BASE | N204790 | 003 | Jun 09, 2016 |
| | +! | | EQ 50MG BASE | N204790 | 001 | Aug 12, 2013 |

DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE

TABLET;ORAL

JULUCA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | VIIV HLTHCARE | EQ 50MG BASE;EQ 25MG BASE | N210192 | 001 | Nov 21, 2017 |

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **ARICEPT** | | | | | | | |
| **AB** | + | EISAI INC | **5MG** | **N020690** | **002** | Nov 25, 1996 | |
| **AB** | +! | | **10MG** | **N020690** | **001** | Nov 25, 1996 | |
| **AB** | +! | | **23MG** | **N022568** | **001** | Jul 23, 2010 | |
| **DONEPEZIL HYDROCHLORIDE** | | | | | | | |
| **AB** | | ACI HEALTHCARE LTD | **5MG** | **A078662** | **001** | May 31, 2011 | |
| **AB** | | | **10MG** | **A078662** | **002** | May 31, 2011 | |
| **AB** | | ACTAVIS ELIZABETH | **23MG** | **A202415** | **001** | Dec 17, 2015 | |
| **AB** | | ALEMBIC PHARMS LTD | **5MG** | **A201724** | **001** | Feb 25, 2013 | |
| **AB** | | | **10MG** | **A201724** | **002** | Feb 25, 2013 | |
| **AB** | | APOTEX | **5MG** | **A078841** | **001** | Jun 02, 2011 | |
| **AB** | | | **10MG** | **A078841** | **002** | Jun 02, 2011 | |
| **AB** | | AUROBINDO | **5MG** | **A090056** | **001** | May 31, 2011 | |
| **AB** | | | **10MG** | **A090056** | **002** | May 31, 2011 | |
| **AB** | | CADILA PHARMS LTD | **5MG** | **A204609** | **001** | Sep 19, 2017 | |
| **AB** | | | **10MG** | **A204609** | **002** | Sep 19, 2017 | |
| **AB** | | CIPLA LTD | **5MG** | **A077518** | **001** | May 31, 2011 | |
| **AB** | | | **10MG** | **A077518** | **002** | May 31, 2011 | |
| **AB** | | CSPC OUYI PHARM CO | **5MG** | **A202114** | **001** | Jul 05, 2013 | |
| **AB** | | | **10MG** | **A202114** | **002** | Jul 05, 2013 | |
| **AB** | | DEXCEL PHARMA | **23MG** | **A203713** | **001** | Feb 19, 2016 | |
| **AB** | | DR REDDYS LABS LTD | **5MG** | **A201001** | **001** | May 31, 2011 | |
| **AB** | | | **10MG** | **A201001** | **002** | May 31, 2011 | |
| **AB** | | | **23MG** | **A202723** | **001** | Jul 24, 2013 | |
| **AB** | | HETERO LABS LTD V | **5MG** | **A203034** | **001** | Jan 30, 2015 | |
| **AB** | | | **10MG** | **A203034** | **002** | Jan 30, 2015 | |
| **AB** | | INDICUS PHARMA | **5MG** | **A201634** | **001** | Jun 13, 2012 | |
| **AB** | | | **10MG** | **A201634** | **002** | Jun 13, 2012 | |
| **AB** | | | **23MG** | **A203419** | **001** | Apr 12, 2016 | |
| **AB** | | JUBILANT GENERICS | **5MG** | **A090768** | **001** | May 31, 2011 | |
| **AB** | | | **10MG** | **A090768** | **002** | May 31, 2011 | |
| **AB** | | LUPIN LTD | **23MG** | **A202782** | **001** | Oct 30, 2015 | |
| **AB** | | MACLEODS PHARMS LTD | **5MG** | **A201146** | **001** | Aug 17, 2012 | |
| **AB** | | | **10MG** | **A201146** | **002** | Aug 17, 2012 | |
| **AB** | | | **23MG** | **A202631** | **001** | Jan 22, 2014 | |
| **AB** | | MYLAN PHARMS INC | **5MG** | **A090521** | **001** | May 31, 2011 | |
| **AB** | | | **10MG** | **A090521** | **002** | May 31, 2011 | |
| **AB** | | | **23MG** | **A202656** | **001** | Oct 22, 2015 | |
| **AB** | | OSMOTICA PHARM US | **23MG** | **A203114** | **001** | Jan 26, 2016 | |
| **AB** | | PAR PHARM | **23MG** | **A202542** | **001** | Jul 24, 2013 | |
| **AB** | | PLIVA HRVATSKA DOO | **5MG** | **A090425** | **001** | May 31, 2011 | |
| **AB** | | | **10MG** | **A090425** | **002** | May 31, 2011 | |
| **AB** | | PRINSTON INC | **5MG** | **A200292** | **001** | May 31, 2011 | |
| **AB** | | | **10MG** | **A200292** | **002** | May 31, 2011 | |
| **AB** | | SANDOZ | **5MG** | **A090290** | **001** | May 31, 2011 | |
| **AB** | | | **10MG** | **A090290** | **002** | May 31, 2011 | |
| **AB** | | SCIEGEN PHARMS INC | **5MG** | **A203907** | **001** | Oct 29, 2014 | |
| **AB** | | | **10MG** | **A203907** | **002** | Oct 29, 2014 | |
| **AB** | | SUN PHARM INDS | **5MG** | **A090493** | **001** | May 31, 2011 | |
| **AB** | | | **10MG** | **A090493** | **002** | May 31, 2011 | |
| **AB** | | SUN PHARM INDS LTD | **5MG** | **A076786** | **001** | Nov 26, 2010 | |
| **AB** | | | **10MG** | **A076786** | **002** | Nov 26, 2010 | |
| **AB** | | | **23MG** | **A204293** | **001** | Jun 05, 2015 | |
| **AB** | | TEVA | **5MG** | **A077344** | **001** | May 31, 2011 | |
| **AB** | | | **10MG** | **A077344** | **002** | May 31, 2011 | |
| **AB** | | TORRENT PHARMS | **5MG** | **A090686** | **001** | May 31, 2011 | |
| **AB** | | | **10MG** | **A090686** | **002** | May 31, 2011 | |
| **AB** | | TWI PHARMS INC | **23MG** | **A203104** | **001** | Oct 29, 2014 | |
| **AB** | | UNICHEM LABS LTD | **5MG** | **A203656** | **001** | Jun 23, 2016 | |
| **AB** | | | **10MG** | **A203656** | **002** | Jun 23, 2016 | |
| **AB** | | VIVIMED GLOBAL | **5MG** | **A090551** | **001** | May 31, 2011 | |
| **AB** | | | **10MG** | **A090551** | **002** | May 31, 2011 | |
| **AB** | | WOCKHARDT | **5MG** | **A091267** | **001** | May 31, 2011 | |
| **AB** | | | **10MG** | **A091267** | **002** | May 31, 2011 | |
| **AB** | | ZHEJIANG HISUN PHARM | **23MG** | **A202410** | **001** | Mar 24, 2017 | |
| **AB** | | ZYDUS PHARMS USA INC | **5MG** | **A090100** | **001** | Oct 24, 2012 | |
| **AB** | | | **10MG** | **A090100** | **002** | Oct 24, 2012 | |
| **AB** | | | **23MG** | **A203162** | **001** | Aug 31, 2017 | |

DONEPEZIL HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING;ORAL

**ARICEPT ODT**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | EISAI INC | **5MG** | **N021720** | **001** | Oct 18, 2004 |
| **AB** | **+!** | | **10MG** | **N021720** | **002** | Oct 18, 2004 |

**DONEPEZIL HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | BARR | **5MG** | **A078388** | **002** | Nov 26, 2010 |
| **AB** | | | **10MG** | **A078388** | **001** | Nov 26, 2010 |
| **AB** | | MACLEODS PHARMS LTD | **5MG** | **A201787** | **001** | Dec 14, 2012 |
| **AB** | | | **10MG** | **A201787** | **002** | Dec 14, 2012 |
| **AB** | | SANDOZ | **5MG** | **A091198** | **001** | May 10, 2011 |
| **AB** | | | **10MG** | **A091198** | **002** | May 10, 2011 |
| **AB** | | UNICHEM LABS LTD | **5MG** | **A204831** | **001** | Nov 10, 2016 |
| **AB** | | | **10MG** | **A204831** | **002** | Nov 10, 2016 |
| **AB** | | ZYDUS PHARMS USA INC | **5MG** | **A090175** | **001** | May 10, 2011 |
| **AB** | | | **10MG** | **A090175** | **002** | May 10, 2011 |

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

**MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AMNEAL PHARMS | **10MG;14MG** | **A208328** | **001** | Jan 27, 2017 |
| **AB** | | | **10MG;28MG** | **A208328** | **002** | Jan 27, 2017 |

**NAMZARIC**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | FOREST LABS LLC | **10MG;14MG** | **N206439** | **001** | Dec 23, 2014 |
| **AB** | **+!** | | **10MG;28MG** | **N206439** | **002** | Dec 23, 2014 |
| | + | | 10MG;7MG | N206439 | 003 | Jul 18, 2016 |
| | + | | 10MG;21MG | N206439 | 004 | Jul 18, 2016 |

DOPAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

**DOPAMINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | HOSPIRA | **40MG/ML** | **N018132** | **001** | |
| **AP** | **+!** | | **80MG/100ML** | **N018132** | **002** | Feb 04, 1982 |
| **AP** | **+!** | | **80MG/ML** | **N018132** | **004** | Jul 09, 1982 |
| **AP** | **+!** | | **160MG/100ML** | **N018132** | **003** | Feb 04, 1982 |
| **AP** | **!** | LUITPOLD | **40MG/ML** | **A070799** | **001** | Feb 11, 1987 |
| **AP** | **!** | | **80MG/ML** | **A070820** | **001** | Feb 11, 1987 |

**DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | B BRAUN | **80MG/100ML** | **N019099** | **002** | Oct 15, 1986 |
| **AP** | **+!** | | **320MG/100ML** | **N019099** | **004** | Oct 15, 1986 |

**DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | B BRAUN | **160MG/100ML** | **N019099** | **003** | Oct 15, 1986 |

**DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | BAXTER HLTHCARE | **80MG/100ML** | **N019615** | **001** | Mar 27, 1987 |
| **AP** | **+!** | | **160MG/100ML** | **N019615** | **002** | Mar 27, 1987 |
| **AP** | **+!** | | **320MG/100ML** | **N019615** | **003** | Mar 27, 1987 |
| **AP** | **+!** | HOSPIRA | **80MG/100ML** | **N018826** | **001** | Sep 30, 1983 |
| **AP** | **+!** | | **160MG/100ML** | **N018826** | **002** | Sep 30, 1983 |
| **AP** | **+!** | | **320MG/100ML** | **N018826** | **003** | Sep 30, 1983 |

DOPAMINE HYDROCHLORIDE

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | LUITPOLD | 160MG/ML | A070826 | 001 | Feb 11, 1987 |

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | B BRAUN | 40MG/100ML | N019099 | 001 | Oct 15, 1986 |

DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | BAXTER HLTHCARE | 640MG/100ML | N019615 | 004 | Mar 27, 1987 |

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

**DORZOLAMIDE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | BAUSCH AND LOMB | **EQ 2% BASE** | **A090143** | **001** | Jun 25, 2009 |
| **AT** | | HI TECH PHARMA | **EQ 2% BASE** | **A077846** | **001** | Oct 28, 2008 |
| **AT** | | LUITPOLD | **EQ 2% BASE** | **A079186** | **001** | Nov 18, 2009 |
| **AT** | | SANDOZ INC | **EQ 2% BASE** | **A078748** | **001** | Nov 06, 2008 |
| **AT** | | | **EQ 2% BASE** | **A078981** | **001** | Apr 13, 2009 |
| **AT** | | TEVA PHARMS | **EQ 2% BASE** | **A078756** | **001** | Dec 04, 2008 |
| **AT** | | WATSON LABS INC | **EQ 2% BASE** | **A202053** | **001** | Sep 11, 2014 |

**TRUSOPT**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **+!** | MERCK | **EQ 2% BASE** | **N020408** | **001** | Dec 09, 1994 |

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC

| | | | | | | |
|---|---|---|---|---|---|---|
| **COSOPT** | | | | | | |
| **AT** | **+!** | OAK PHARMS INC | **EQ 2% BASE;EQ 0.5% BASE** | **N020869** | **001** | Apr 07, 1998 |
| **DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE** | | | | | | |
| **AT** | | AKORN INC | **EQ 2% BASE;EQ 0.5% BASE** | **A203058** | **001** | Sep 22, 2014 |
| **AT** | | BAUSCH AND LOMB | **EQ 2% BASE;EQ 0.5% BASE** | **A090037** | **001** | Jul 14, 2009 |
| **AT** | | HI TECH PHARMA | **EQ 2% BASE;EQ 0.5% BASE** | **A077847** | **001** | Oct 28, 2008 |
| **AT** | | SANDOZ | **EQ 2% BASE;EQ 0.5% BASE** | **A078749** | **001** | Nov 06, 2008 |
| **AT** | | SANDOZ INC | **EQ 2% BASE;EQ 0.5% BASE** | **A090604** | **001** | Nov 18, 2009 |
| **AT** | | TEVA PHARMS | **EQ 2% BASE;EQ 0.5% BASE** | **A078704** | **001** | Sep 28, 2009 |
| **AT** | | WATSON LABS INC | **EQ 2% BASE;EQ 0.5% BASE** | **A202054** | **001** | Sep 03, 2014 |
| **AT** | | ZAMBON SPA | **EQ 2% BASE;EQ 0.5% BASE** | **A091180** | **001** | Dec 04, 2013 |
| COSOPT PF | | | | | | |
| | +! | OAK PHARMS INC | EQ 2% BASE;EQ 0.5% BASE | N202667 | 001 | Feb 01, 2012 |

DOXAPRAM HYDROCHLORIDE

INJECTABLE;INJECTION

| | | | | | | |
|---|---|---|---|---|---|---|
| **DOPRAM** | | | | | | |
| **AP** | **+!** | WEST-WARD PHARMS INT | **20MG/ML** | **N014879** | **001** | |
| **DOXAPRAM HYDROCHLORIDE** | | | | | | |
| **AP** | | ATHENEX INC | **20MG/ML** | **A076266** | **001** | Jan 10, 2003 |

DOXAZOSIN MESYLATE

TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **CARDURA** | | | | | | |
| **AB** | **+!** | PFIZER | **EQ 1MG BASE** | **N019668** | **001** | Nov 02, 1990 |
| **AB** | **+** | | **EQ 2MG BASE** | **N019668** | **002** | Nov 02, 1990 |
| **AB** | **+** | | **EQ 4MG BASE** | **N019668** | **003** | Nov 02, 1990 |
| **AB** | **+** | | **EQ 8MG BASE** | **N019668** | **004** | Nov 02, 1990 |
| **DOXAZOSIN MESYLATE** | | | | | | |
| **AB** | | ACCORD HLTHCARE | **EQ 1MG BASE** | **A202824** | **001** | Jun 11, 2014 |
| **AB** | | | **EQ 2MG BASE** | **A202824** | **002** | Jun 11, 2014 |
| **AB** | | | **EQ 4MG BASE** | **A202824** | **003** | Jun 11, 2014 |
| **AB** | | | **EQ 8MG BASE** | **A202824** | **004** | Jun 11, 2014 |
| **AB** | | APOTEX | **EQ 1MG BASE** | **A075580** | **001** | Oct 18, 2000 |
| **AB** | | | **EQ 2MG BASE** | **A075580** | **002** | Oct 18, 2000 |
| **AB** | | | **EQ 4MG BASE** | **A075580** | **003** | Oct 18, 2000 |
| **AB** | | | **EQ 8MG BASE** | **A075580** | **004** | Oct 18, 2000 |
| **AB** | | DAVA PHARMS INC | **EQ 1MG BASE** | **A076161** | **001** | Jun 10, 2004 |
| **AB** | | | **EQ 2MG BASE** | **A076161** | **002** | Jun 10, 2004 |
| **AB** | | | **EQ 4MG BASE** | **A076161** | **003** | Jun 10, 2004 |
| **AB** | | | **EQ 8MG BASE** | **A076161** | **004** | Jun 10, 2004 |
| **AB** | | MYLAN | **EQ 1MG BASE** | **A075509** | **001** | Oct 19, 2000 |
| **AB** | | | **EQ 2MG BASE** | **A075509** | **002** | Oct 19, 2000 |
| **AB** | | | **EQ 4MG BASE** | **A075509** | **003** | Oct 19, 2000 |
| **AB** | | | **EQ 8MG BASE** | **A075509** | **004** | Oct 19, 2000 |
| **AB** | | PLIVA | **EQ 1MG BASE** | **A075750** | **001** | Jun 08, 2001 |
| **AB** | | | **EQ 2MG BASE** | **A075750** | **002** | Jun 08, 2001 |
| **AB** | | | **EQ 4MG BASE** | **A075750** | **003** | Jun 08, 2001 |
| **AB** | | | **EQ 8MG BASE** | **A075750** | **004** | Jun 08, 2001 |
| **AB** | | TEVA | **EQ 1MG BASE** | **A075536** | **001** | Oct 18, 2000 |
| **AB** | | | **EQ 2MG BASE** | **A075536** | **002** | Oct 18, 2000 |
| **AB** | | | **EQ 4MG BASE** | **A075536** | **003** | Oct 18, 2000 |
| **AB** | | | **EQ 8MG BASE** | **A075536** | **004** | Oct 18, 2000 |
| **AB** | | ZYDUS PHARMS USA INC | **EQ 1MG BASE** | **A208719** | **001** | Jul 07, 2017 |
| **AB** | | | **EQ 2MG BASE** | **A208719** | **002** | Jul 07, 2017 |
| **AB** | | | **EQ 4MG BASE** | **A208719** | **003** | Jul 07, 2017 |
| **AB** | | | **EQ 8MG BASE** | **A208719** | **004** | Jul 07, 2017 |

TABLET, EXTENDED RELEASE;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| CARDURA XL | | | | | | |
| | + | PFIZER | EQ 4MG BASE | N021269 | 001 | Feb 22, 2005 |
| | +! | | EQ 8MG BASE | N021269 | 002 | Feb 22, 2005 |

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **DOXEPIN HYDROCHLORIDE** | | | | | | |
| **AB** | | AMNEAL PHARMS CO | **EQ 10MG BASE** | **A207482** | **001** | Jun 28, 2017 |
| **AB** | | | **EQ 25MG BASE** | **A207482** | **002** | Jun 28, 2017 |
| **AB** | | | **EQ 50MG BASE** | **A207482** | **003** | Jun 28, 2017 |
| **AB** | | | **EQ 75MG BASE** | **A207482** | **004** | Jun 28, 2017 |
| **AB** | | | **EQ 100MG BASE** | **A207482** | **005** | Jun 28, 2017 |

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

**DOXEPIN HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | MYLAN PHARMS INC | **EQ 10MG BASE** | **A070791** | **002** | May 13, 1986 |
| **AB** | ! | | **EQ 25MG BASE** | **A070791** | **003** | May 13, 1986 |
| **AB** | | | **EQ 50MG BASE** | **A070791** | **001** | May 13, 1986 |
| **AB** | | | **EQ 75MG BASE** | **A070791** | **004** | May 13, 1986 |
| **AB** | ! | | **EQ 100MG BASE** | **A070791** | **005** | May 13, 1986 |
| | ! | PAR PHARM | EQ 150MG BASE | A071669 | 001 | Nov 09, 1987 |

CONCENTRATE;ORAL

**DOXEPIN HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | SILARX | **EQ 10MG BASE/ML** | **A074721** | **001** | Dec 29, 1998 |
| **AA** | ! | TEVA PHARMS | **EQ 10MG BASE/ML** | **A071609** | **001** | Nov 09, 1987 |
| **AA** | | WOCKHARDT BIO AG | **EQ 10MG BASE/ML** | **A071918** | **001** | Jul 20, 1988 |

CREAM;TOPICAL

ZONALON

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | MYLAN PHARMS INC | 5% | N020126 | 001 | Apr 01, 1994 |

TABLET;ORAL

**DOXEPIN HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS ELIZABETH | **EQ 3MG BASE** | **A201951** | **001** | Jul 26, 2013 |
| **AB** | | | **EQ 6MG BASE** | **A201951** | **002** | Jul 26, 2013 |

**SILENOR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | PERNIX THERAPS LLC | **EQ 3MG BASE** | **N022036** | **001** | Mar 17, 2010 |
| **AB** | +! | | **EQ 6MG BASE** | **N022036** | **002** | Mar 17, 2010 |

DOXERCALCIFEROL

CAPSULE;ORAL

**DOXERCALCIFEROL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | RISING PHARMS INC | **0.5MCG** | **A201518** | **001** | Sep 09, 2016 |
| **AB** | | | **1MCG** | **A201518** | **002** | Sep 09, 2016 |
| **AB** | | | **2.5MCG** | **A201518** | **003** | Sep 09, 2016 |
| **AB** | | WEST-WARD PHARMS INT | **0.5MCG** | **A091433** | **001** | Sep 23, 2011 |
| **AB** | | | **1MCG** | **A091433** | **002** | Jan 14, 2014 |
| **AB** | | | **2.5MCG** | **A091433** | **003** | Jan 14, 2014 |

**HECTOROL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | GENZYME CORP | **0.5MCG** | **N020862** | **002** | Apr 23, 2004 |
| **AB** | + | | **1MCG** | **N020862** | **003** | Jul 13, 2009 |
| **AB** | +! | | **2.5MCG** | **N020862** | **001** | Jun 09, 1999 |

INJECTABLE;INJECTION

**DOXERCALCIFEROL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AKORN INC | **2MCG/ML (2MCG/ML)** | **A203929** | **002** | Mar 28, 2016 |
| **AP** | | | **4MCG/2ML (2MCG/ML)** | **A203929** | **001** | May 07, 2015 |
| **AP** | | AMNEAL PHARMS CO | **2MCG/ML (2MCG/ML)** | **A208974** | **001** | May 24, 2017 |
| **AP** | | | **4MCG/2ML (2MCG/ML)** | **A208974** | **002** | May 24, 2017 |
| **AP** | | | **4MCG/2ML (2MCG/ML)** | **A208975** | **001** | May 24, 2017 |
| **AP** | | HIKMA PHARMS | **4MCG/2ML (2MCG/ML)** | **A091101** | **001** | Aug 30, 2013 |
| **AP** | | SANDOZ INC | **4MCG/2ML (2MCG/ML)** | **A091333** | **001** | May 05, 2014 |
| **AP** | | | **4MCG/2ML (2MCG/ML)** | **A200926** | **001** | Feb 04, 2014 |

**HECTOROL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | + | GENZYME CORP | **2MCG/ML (2MCG/ML)** | **N021027** | **002** | Apr 06, 2000 |
| **AP** | +! | | **4MCG/2ML (2MCG/ML)** | **N021027** | **001** | Apr 06, 2000 |

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

**DOXORUBICIN HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | ACTAVIS INC | **2MG/ML** | **A203622** | **001** | Jun 27, 2014 |
| **AP** | | | **200MG/100ML** | **A203622** | **002** | Jun 27, 2014 |
| **AP** | | ALVOGEN INC | **2MG/ML** | **A065515** | **001** | Nov 08, 2012 |
| **AP** | | AMNEAL PHARMS CO | **20MG/VIAL** | **A208888** | **001** | Feb 17, 2017 |
| **AP** | | | **50MG/VIAL** | **A208888** | **002** | Feb 17, 2017 |
| **AP** | | FRESENIUS KABI USA | **2MG/ML** | **A063277** | **001** | Oct 26, 1995 |
| **AP** | | GLAND PHARMA LTD | **2MG/ML** | **A209825** | **001** | Aug 11, 2017 |
| **AP** | | MYLAN LABS LTD | **2MG/ML** | **A200901** | **001** | Feb 14, 2012 |
| **AP** | | | **10MG/VIAL** | **A200170** | **001** | Oct 28, 2011 |
| **AP** | | | **50MG/VIAL** | **A200170** | **002** | Oct 28, 2011 |
| **AP** | | PHARMACHEMIE BV | **2MG/ML** | **A063336** | **001** | Feb 28, 1995 |
| **AP** | | | **10MG/VIAL** | **A063097** | **001** | May 21, 1990 |
| **AP** | | | **20MG/VIAL** | **A063097** | **002** | May 21, 1990 |
| **AP** | | | **50MG/VIAL** | **A063097** | **003** | May 21, 1990 |
| **AP** | | | **200MG/100ML** | **A063336** | **004** | Feb 28, 1995 |
| **AP** | +! | PHARMACIA AND UPJOHN | **2MG/ML** | **N050629** | **001** | Dec 23, 1987 |
| **AP** | +! | | **200MG/100ML** | **N050629** | **002** | May 03, 1988 |

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

**DOXORUBICIN HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | SAGENT PHARMS | **2MG/ML** | **A091495** | **001** | Mar 18, 2013 |
| **AP** | | SUN PHARM INDS | **2MG/ML** | **A091418** | **001** | Feb 15, 2012 |
| **AP** | | TEVA PHARMS USA | **2MG/ML** | **A064140** | **001** | Jul 28, 1995 |
| **AP** | | | **200MG/100ML** | **A064140** | **002** | Jul 28, 1995 |
| **AP** | | WEST-WARD PHARMS INT | **2MG/ML** | **A062975** | **001** | Mar 17, 1989 |
| **AP** | **!** | | **10MG/VIAL** | **A062921** | **001** | Mar 17, 1989 |
| **AP** | **!** | | **20MG/VIAL** | **A062921** | **002** | Mar 17, 1989 |
| **AP** | **!** | | **50MG/VIAL** | **A062921** | **003** | Mar 17, 1989 |
| **AP** | | | **200MG/100ML** | **A064097** | **001** | Sep 13, 1994 |
| | + | PHARMACIA AND UPJOHN | 150MG/75ML | N050629 | 003 | Mar 28, 2011 |

INJECTABLE, LIPOSOMAL;INJECTION

**DOXIL (LIPOSOMAL)**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | JANSSEN RES AND DEV | **20MG/10ML (2MG/ML)** | **N050718** | **001** | Nov 17, 1995 |
| **AB** | **+** | | **50MG/25ML (2MG/ML)** | **N050718** | **002** | Jun 13, 2000 |

**DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | DR REDDYS LABS LTD | **20MG/10ML (2MG/ML)** | **A208657** | **001** | May 15, 2017 |
| **AB** | | | **50MG/25ML (2MG/ML)** | **A208657** | **002** | May 15, 2017 |
| **AB** | **!** | SUN PHARMA GLOBAL | **20MG/10ML (2MG/ML)** | **A203263** | **001** | Feb 04, 2013 |
| **AB** | **!** | | **50MG/25ML (2MG/ML)** | **A203263** | **002** | Feb 04, 2013 |

DOXYCYCLINE

CAPSULE;ORAL

**DOXYCYCLINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALEMBIC PHARMS LTD | **EQ 75MG BASE** | **A209165** | **001** | Jul 28, 2017 |
| **AB** | | | **EQ 100MG BASE** | **A209165** | **002** | Jul 28, 2017 |
| **AB** | | G AND W LABS INC | **EQ 50MG BASE** | **A204446** | **001** | May 28, 2015 |
| **AB** | | | **EQ 75MG BASE** | **A204446** | **002** | May 28, 2015 |
| **AB** | | | **EQ 100MG BASE** | **A204446** | **003** | May 28, 2015 |
| **AB** | | IMPAX LABS INC | **EQ 150MG BASE** | **A200065** | **001** | Feb 17, 2011 |
| **AB** | | LUPIN LTD | **EQ 50MG BASE** | **A204234** | **001** | Mar 05, 2014 |
| **AB** | | | **EQ 75MG BASE** | **A204234** | **002** | Mar 05, 2014 |
| **AB** | | | **EQ 100MG BASE** | **A204234** | **003** | Mar 05, 2014 |
| **AB** | | MAYNE PHARMA INC | **EQ 50MG BASE** | **A209396** | **001** | Sep 29, 2017 |
| **AB** | | | **EQ 75MG BASE** | **A209396** | **002** | Sep 29, 2017 |
| **AB** | | | **EQ 100MG BASE** | **A209396** | **003** | Sep 29, 2017 |
| **AB** | | MYLAN PHARMS INC | **EQ 150MG BASE** | **A202778** | **001** | Jun 08, 2012 |
| **AB** | | PAR PHARM | **EQ 50MG BASE** | **A065055** | **001** | Dec 01, 2000 |
| **AB** | | | **EQ 100MG BASE** | **A065055** | **002** | Dec 01, 2000 |
| **AB** | **!** | | **EQ 150MG BASE** | **A065055** | **003** | Jul 15, 2005 |
| **AB** | | SUN PHARM INDS LTD | **EQ 50MG BASE** | **A065053** | **001** | Nov 22, 2000 |
| **AB** | | | **EQ 75MG BASE** | **A065053** | **003** | Sep 10, 2003 |
| **AB** | | | **EQ 100MG BASE** | **A065053** | **002** | Nov 22, 2000 |
| **AB** | | ZYDUS PHARMS USA INC | **EQ 50MG BASE** | **A205115** | **001** | Feb 18, 2016 |
| **AB** | | | **EQ 75MG BASE** | **A205115** | **002** | Feb 18, 2016 |
| **AB** | | | **EQ 100MG BASE** | **A205115** | **003** | Feb 18, 2016 |

**MONODOX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | AQUA PHARMS | **EQ 50MG BASE** | **N050641** | **002** | Feb 10, 1992 |
| **AB** | **+** | | **EQ 75MG BASE** | **N050641** | **003** | Oct 18, 2006 |
| **AB** | **+!** | | **EQ 100MG BASE** | **N050641** | **001** | Dec 29, 1989 |

ORACEA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | GALDERMA LABS LP | 40MG | N050805 | 001 | May 26, 2006 |

FOR SUSPENSION;ORAL

**DOXYCYCLINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | CHARTWELL LIFE SCI | **EQ 25MG BASE/5ML** | **A065454** | **001** | Jul 16, 2008 |
| **AB** | | LUPIN LTD | **EQ 25MG BASE/5ML** | **A201678** | **001** | Mar 18, 2013 |

**VIBRAMYCIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | PFIZER | **EQ 25MG BASE/5ML** | **N050006** | **001** | |

TABLET;ORAL

**DOXYCYCLINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | HERITAGE PHARMS INC | **EQ 50MG BASE** | **A091605** | **001** | Dec 20, 2011 |
| **AB** | | | **EQ 75MG BASE** | **A091605** | **002** | Dec 20, 2011 |
| **AB** | | | **EQ 100MG BASE** | **A091605** | **003** | Dec 20, 2011 |
| **AB** | | | **EQ 150MG BASE** | **A091605** | **004** | Dec 20, 2011 |
| **AB** | | LANNETT | **EQ 50MG BASE** | **A065285** | **001** | Dec 08, 2005 |
| **AB** | | | **EQ 75MG BASE** | **A065285** | **003** | Jul 30, 2008 |
| **AB** | | | **EQ 100MG BASE** | **A065285** | **002** | Dec 08, 2005 |
| **AB** | | | **EQ 150MG BASE** | **A065285** | **004** | Jul 30, 2008 |

DOXYCYCLINE

TABLET;ORAL

**DOXYCYCLINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | MYLAN | **EQ 50MG BASE** | **A065377** | **001** | Nov 07, 2006 |
| **AB** | | | **EQ 75MG BASE** | **A065377** | **002** | Nov 07, 2006 |
| **AB** | | | **EQ 100MG BASE** | **A065377** | **003** | Nov 07, 2006 |
| **AB** | | | **EQ 150MG BASE** | **A065427** | **001** | Jun 07, 2007 |
| **AB** | | PAR PHARM | **EQ 50MG BASE** | **A065070** | **001** | Dec 15, 2000 |
| **AB** | | | **EQ 75MG BASE** | **A065070** | **003** | Dec 30, 2002 |
| **AB** | | | **EQ 100MG BASE** | **A065070** | **002** | Dec 15, 2000 |
| **AB** | **!** | | **EQ 150MG BASE** | **A065070** | **004** | Jul 14, 2005 |
| **AB** | | SUN PHARM INDS LTD | **EQ 50MG BASE** | **A065356** | **001** | May 31, 2006 |
| **AB** | | | **EQ 75MG BASE** | **A065356** | **002** | May 31, 2006 |
| **AB** | | | **EQ 100MG BASE** | **A065356** | **003** | May 31, 2006 |
| **AB** | | ZYDUS PHARMS USA INC | **EQ 50MG BASE** | **A209582** | **001** | Sep 28, 2017 |
| **AB** | | | **EQ 75MG BASE** | **A209582** | **002** | Sep 28, 2017 |
| **AB** | | | **EQ 100MG BASE** | **A209582** | **003** | Sep 28, 2017 |
| **AB** | | | **EQ 150MG BASE** | **A209582** | **004** | Sep 28, 2017 |

DOXYCYCLINE CALCIUM

SUSPENSION;ORAL

VIBRAMYCIN

| | | | | | |
|---|---|---|---|---|---|
| | +! | PFIZER | EQ 50MG BASE/5ML | N050480 | 001 |

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

**DOXYCYCLINE HYCLATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS LABS FL INC | **EQ 50MG BASE** | **A062031** | **002** | Oct 13, 1982 |
| **AB** | | | **EQ 100MG BASE** | **A062031** | **001** | |
| **AB** | | AMNEAL PHARMS | **EQ 100MG BASE** | **A207289** | **001** | Jun 27, 2016 |
| **AB** | | CHARTWELL LIFE SCI | **EQ 50MG BASE** | **A062500** | **001** | Sep 11, 1984 |
| **AB** | | | **EQ 100MG BASE** | **A062500** | **002** | Sep 11, 1984 |
| **AB** | | HIKMA INTL PHARMS | **EQ 50MG BASE** | **A062396** | **002** | Nov 07, 1984 |
| **AB** | | | **EQ 100MG BASE** | **A062396** | **001** | May 07, 1984 |
| **AB** | | MUTUAL PHARM | **EQ 50MG BASE** | **A062675** | **001** | Jul 10, 1986 |
| **AB** | | MYLAN | **EQ 50MG BASE** | **A062337** | **001** | Mar 29, 1982 |
| **AB** | | | **EQ 100MG BASE** | **A062337** | **002** | Mar 29, 1982 |
| **AB** | | SUN PHARM INDUSTRIES | **EQ 100MG BASE** | **A062676** | **001** | Jul 10, 1986 |

**VIBRAMYCIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | PFIZER | **EQ 100MG BASE** | **N050007** | **002** | |

ACTICLATE CAP

| | | | | | |
|---|---|---|---|---|---|
| | +! | AQUA PHARMS | EQ 75MG BASE | N208253 | 001 Apr 26, 2016 |

DOXYCYCLINE HYCLATE

| | | | | | |
|---|---|---|---|---|---|
| | ! | HIKMA INTL PHARMS | EQ 20MG BASE | A065103 | 001 May 13, 2005 |

INJECTABLE;INJECTION

**DOXY 100**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **!** | FRESENIUS KABI USA | **EQ 100MG BASE/VIAL** | **A062475** | **001** | Dec 09, 1983 |

**DOXY 200**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **!** | FRESENIUS KABI USA | **EQ 200MG BASE/VIAL** | **A062475** | **002** | Dec 09, 1983 |

**DOXYCYCLINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | MYLAN LABS LTD | **EQ 100MG BASE/VIAL** | **A091406** | **001** | Aug 21, 2012 |
| **AP** | **!** | WEST-WARD PHARMS INT | **EQ 100MG BASE/VIAL** | **A062569** | **001** | Mar 09, 1988 |
| **AP** | | ZYDUS PHARMS USA INC | **EQ 100MG BASE/VIAL** | **A207757** | **001** | Sep 28, 2017 |
| **AP** | | | **EQ 200MG BASE/VIAL** | **A207757** | **002** | Sep 28, 2017 |

SYSTEM, EXTENDED RELEASE;PERIODONTAL

ATRIDOX

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | TOLMAR | 50MG | N050751 | 001 | Sep 03, 1998 |

TABLET;ORAL

**ACTICLATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | AQUA PHARMS LLC | **EQ 75MG BASE** | **N205931** | **001** | Jul 25, 2014 |
| **AB** | **+!** | | **EQ 150MG BASE** | **N205931** | **002** | Jul 25, 2014 |

**DOXYCYCLINE HYCLATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS LABS FL INC | **EQ 100MG BASE** | **A062421** | **001** | Feb 02, 1983 |
| **AB** | | AMNEAL PHARMS CO | **EQ 75MG BASE** | **A209372** | **001** | Oct 06, 2017 |
| **AB** | | | **EQ 150MG BASE** | **A209372** | **002** | Oct 06, 2017 |
| **AB** | | CARIBE HOLDINGS | **EQ 100MG BASE** | **A062269** | **002** | Nov 08, 1982 |
| **AB** | | CHARTWELL LIFE SCI | **EQ 100MG BASE** | **A062505** | **001** | Sep 11, 1984 |
| **AB** | **!** | HIKMA INTL PHARMS | **EQ 100MG BASE** | **A065095** | **001** | Jul 02, 2003 |
| **AB** | | IVAX SUB TEVA PHARMS | **EQ 20MG BASE** | **A065163** | **001** | May 13, 2005 |

DOXYCYCLINE HYCLATE

TABLET;ORAL

**DOXYCYCLINE HYCLATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **!** | LANNETT | **EQ 20MG BASE** | **A065277** | **001** | Nov 10, 2005 |
| **AB** | | LARKEN LABS | **EQ 20MG BASE** | **A065287** | **001** | Feb 28, 2006 |
| **AB** | | LUPIN LTD | **EQ 75MG BASE** | **A208818** | **001** | Sep 27, 2017 |
| **AB** | | | **EQ 150MG BASE** | **A208818** | **002** | Sep 27, 2017 |
| **AB** | | MAYNE PHARMA INC | **EQ 75MG BASE** | **A208765** | **001** | Jun 14, 2017 |
| **AB** | | | **EQ 150MG BASE** | **A208765** | **002** | Jun 14, 2017 |
| **AB** | | MYLAN | **EQ 100MG BASE** | **A062432** | **001** | Feb 15, 1983 |
| **AB** | | NOVEL LABS INC | **EQ 100MG BASE** | **A207558** | **001** | Sep 06, 2017 |
| **AB** | | SUN PHARM INDUSTRIES | **EQ 20MG BASE** | **A065134** | **001** | May 13, 2005 |
| **AB** | | | **EQ 100MG BASE** | **A062677** | **001** | Jul 10, 1986 |
| **AB** | | ZYDUS PHARMS USA INC | **EQ 100MG BASE** | **A207773** | **001** | Oct 30, 2017 |
| | | CARIBE HOLDINGS | EQ 50MG BASE | A062269 | 003 | |

TABLET, DELAYED RELEASE;ORAL

**DORYX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | MAYNE PHARMA | **EQ 50MG BASE** | **N050795** | **006** | Dec 19, 2014 |
| **AB** | **+** | | **EQ 75MG BASE** | **N050795** | **001** | May 06, 2005 |
| **AB** | **+** | | **EQ 80MG BASE** | **N050795** | **004** | Apr 11, 2013 |
| **AB** | **+** | | **EQ 100MG BASE** | **N050795** | **002** | May 06, 2005 |
| **AB** | **+** | | **EQ 150MG BASE** | **N050795** | **003** | Jun 20, 2008 |
| **AB** | **+!** | | **EQ 200MG BASE** | **N050795** | **005** | Apr 11, 2013 |

**DOXYCYCLINE HYCLATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS ELIZABETH | **EQ 75MG BASE** | **A090134** | **001** | Dec 14, 2011 |
| **AB** | | | **EQ 100MG BASE** | **A090134** | **002** | Dec 14, 2011 |
| **AB** | | HERITAGE PHARMS INC | **EQ 75MG BASE** | **A200856** | **001** | Apr 30, 2013 |
| **AB** | | | **EQ 100MG BASE** | **A200856** | **002** | Apr 30, 2013 |
| **AB** | | | **EQ 150MG BASE** | **A200856** | **003** | Apr 30, 2013 |
| **AB** | | MYLAN | **EQ 50MG BASE** | **A090431** | **003** | May 23, 2016 |
| **AB** | | | **EQ 75MG BASE** | **A090431** | **001** | Dec 28, 2010 |
| **AB** | | | **EQ 80MG BASE** | **A090431** | **004** | Apr 29, 2016 |
| **AB** | | | **EQ 100MG BASE** | **A090431** | **002** | Dec 28, 2010 |
| **AB** | | | **EQ 200MG BASE** | **A090431** | **005** | May 19, 2016 |
| **AB** | | MYLAN PHARMS INC | **EQ 150MG BASE** | **A091052** | **001** | Feb 08, 2012 |
| **AB** | | PRINSTON INC | **EQ 150MG BASE** | **A207494** | **001** | Nov 15, 2016 |
| **AB** | | | **EQ 200MG BASE** | **A207494** | **002** | Nov 15, 2016 |

DORYX MPC

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | MAYNE PHARMA | EQ 120MG BASE | N050795 | 008 | May 20, 2016 |

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

TABLET, DELAYED RELEASE;ORAL

**DICLEGIS**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | DUCHESNAY | **10MG;10MG** | **N021876** | **001** | Apr 08, 2013 |

**DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS LABS FL INC | **10MG;10MG** | **A205811** | **001** | Aug 19, 2016 |
| **AB** | | PAR PHARM INC | **10MG;10MG** | **A208518** | **001** | Dec 06, 2017 |

TABLET, EXTENDED RELEASE;ORAL

BONJESTA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | DUCHESNAY | 20MG;20MG | N209661 | 001 | Nov 07, 2016 |

DRONABINOL

CAPSULE;ORAL

**DRONABINOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AKORN INC | **2.5MG** | **A079217** | **001** | Jun 20, 2014 |
| **AB** | | | **5MG** | **A079217** | **002** | Jun 20, 2014 |
| **AB** | | | **10MG** | **A079217** | **003** | Jun 20, 2014 |
| **AB** | | SVC PHARMA | **2.5MG** | **A078292** | **001** | Jun 27, 2008 |
| **AB** | | | **5MG** | **A078292** | **002** | Jun 27, 2008 |
| **AB** | | | **10MG** | **A078292** | **003** | Jun 27, 2008 |

**MARINOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | ABBVIE | **2.5MG** | **N018651** | **001** | May 31, 1985 |
| **AB** | **+!** | | **5MG** | **N018651** | **002** | May 31, 1985 |
| **AB** | **+** | | **10MG** | **N018651** | **003** | May 31, 1985 |

SOLUTION;ORAL

SYNDROS

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | INSYS DEV CO INC | 5MG/ML | N205525 | 001 | Mar 23, 2017 |

DRONEDARONE HYDROCHLORIDE

TABLET;ORAL

MULTAQ

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | SANOFI AVENTIS US | EQ 400MG BASE | N022425 | 001 | Jul 01, 2009 |

DROPERIDOL

INJECTABLE;INJECTION

**DROPERIDOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | EUROHLTH INTL SARL | **2.5MG/ML** | **A208197** | **001** | Dec 14, 2017 |
| **AP** | | HOSPIRA | **2.5MG/ML** | **A071981** | **001** | Feb 29, 1988 |
| **AP** | | LUITPOLD | **2.5MG/ML** | **A072123** | **001** | Oct 24, 1988 |

**INAPSINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | AKORN INC | **2.5MG/ML** | **N016796** | **001** | |

DROSPIRENONE; ESTRADIOL

TABLET;ORAL

ANGELIQ

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | BAYER HLTHCARE | 0.25MG;0.5MG | N021355 | 001 | Feb 29, 2012 |
| | +! | | 0.5MG;1MG | N021355 | 002 | Sep 28, 2005 |

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

**DROSPIRENONE AND ETHINYL ESTRADIOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | BARR | **3MG;0.02MG** | **A078515** | **001** | Mar 30, 2009 |
| **AB** | | CYNDEA PHARMA | **3MG;0.02MG** | **A209423** | **001** | Dec 22, 2017 |
| **AB** | | GLENMARK PHARMS LTD | **3MG;0.02MG** | **A204296** | **001** | Aug 17, 2015 |
| **AB** | | MYLAN LABS LTD | **3MG;0.02MG** | **A202594** | **001** | Oct 22, 2015 |
| **AB** | | PII | **3MG;0.02MG** | **A203291** | **001** | Jul 18, 2017 |
| **AB** | | WATSON LABS | **3MG;0.02MG** | **A078833** | **001** | Nov 28, 2011 |

**LORYNA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | LABS LEON FARMA | **3MG;0.02MG** | **A079221** | **001** | Mar 28, 2011 |

**MELAMISA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | NOVAST LABS LTD | **3MG;0.02MG** | **A202016** | **001** | Jan 26, 2016 |

**NIKKI**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | LUPIN LTD | **3MG;0.02MG** | **A201661** | **001** | May 27, 2014 |

**YAZ**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | BAYER HLTHCARE | **3MG;0.02MG** | **N021676** | **001** | Mar 16, 2006 |

TABLET;ORAL-28

**DROSPIRENONE AND ETHINYL ESTRADIOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACCORD HLTHCARE | **3MG;0.03MG** | **A207245** | **001** | Nov 22, 2016 |
| **AB** | | APOTEX INC | **3MG;0.03MG** | **A205876** | **001** | Sep 21, 2016 |
| **AB** | | BARR | **3MG;0.03MG** | **A077527** | **001** | May 09, 2008 |
| **AB** | | GLENMARK PHARMS LTD | **3MG;0.03MG** | **A204848** | **001** | Mar 25, 2016 |
| **AB** | | LUPIN LTD | **3MG;0.03MG** | **A201663** | **001** | Dec 18, 2012 |
| **AB** | | MAYNE PHARMA | **3MG;0.03MG** | **A090081** | **001** | Sep 07, 2010 |
| **AB** | | MYLAN LABS LTD | **3MG;0.03MG** | **A202131** | **001** | May 04, 2015 |

**SYEDA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | LABS LEON FARMA | **3MG;0.03MG** | **A090114** | **001** | Mar 28, 2011 |

**YAELA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | NOVAST LABS LTD | **3MG;0.03MG** | **A202015** | **001** | Nov 19, 2014 |

**YASMIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | BAYER HLTHCARE | **3MG;0.03MG** | **N021098** | **001** | May 11, 2001 |

DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM

TABLET;ORAL

**BEYAZ**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | BAYER HLTHCARE | **3MG,N/A;0.02MG,N/A;0.451MG,0.451MG** | **N022532** | **001** | Sep 24, 2010 |

**DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | WATSON LABS INC | **3MG,N/A;0.02MG,N/A;0.451MG,0.451MG** | **A203593** | **001** | Oct 11, 2016 |
| **AB** | | | **3MG,N/A;0.03MG,N/A;0.451MG,0.451MG** | **A203594** | **001** | Oct 11, 2016 |

**SAFYRAL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | BAYER HLTHCARE | **3MG,N/A;0.03MG,N/A;0.451MG,0.451MG** | **N022574** | **001** | Dec 16, 2010 |

**TYDEMY**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | LUPIN LTD | **3MG,N/A;0.03MG,N/A;0.451MG,0.451MG** | **A205948** | **001** | Dec 12, 2017 |

DROXIDOPA

CAPSULE;ORAL

NORTHERA

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | LUNDBECK NA LTD | 100MG | N203202 | 001 | Feb 18, 2014 |
| | + | | 200MG | N203202 | 002 | Feb 18, 2014 |
| | +! | | 300MG | N203202 | 003 | Feb 18, 2014 |

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **CYMBALTA** | | | | | | | |
| **AB** | + | LILLY | **EQ 20MG BASE** | **N021427** | **001** | Aug 03, 2004 |
| **AB** | + | | **EQ 30MG BASE** | **N021427** | **002** | Aug 03, 2004 |
| **AB** | +! | | **EQ 60MG BASE** | **N021427** | **004** | Aug 03, 2004 |
| **DULOXETINE HYDROCHLORIDE** | | | | | | | |
| **AB** | | ACTAVIS ELIZABETH | **EQ 20MG BASE** | **A090776** | **001** | Dec 17, 2013 |
| **AB** | | | **EQ 30MG BASE** | **A090776** | **002** | Dec 17, 2013 |
| **AB** | | | **EQ 60MG BASE** | **A090776** | **003** | Dec 17, 2013 |
| **AB** | | AJANTA PHARMA LTD | **EQ 20MG BASE** | **A208706** | **001** | Jan 06, 2017 |
| **AB** | | | **EQ 30MG BASE** | **A208706** | **002** | Jan 06, 2017 |
| **AB** | | | **EQ 60MG BASE** | **A208706** | **003** | Jan 06, 2017 |
| **AB** | | ALEMBIC PHARMS LTD | **EQ 20MG BASE** | **A202949** | **001** | Jun 09, 2014 |
| **AB** | | | **EQ 30MG BASE** | **A202949** | **002** | Jun 09, 2014 |
| **AB** | | | **EQ 60MG BASE** | **A202949** | **003** | Jun 09, 2014 |
| **AB** | | ALKEM LABS LTD | **EQ 20MG BASE** | **A203197** | **001** | Aug 26, 2015 |
| **AB** | | | **EQ 30MG BASE** | **A203197** | **002** | Aug 26, 2015 |
| **AB** | | | **EQ 60MG BASE** | **A203197** | **003** | Aug 26, 2015 |
| **AB** | | ANCHEN PHARMS | **EQ 20MG BASE** | **A090780** | **001** | Oct 28, 2015 |
| **AB** | | | **EQ 30MG BASE** | **A090780** | **002** | Oct 28, 2015 |
| **AB** | | | **EQ 60MG BASE** | **A090780** | **003** | Oct 28, 2015 |
| **AB** | | APOTEX INC | **EQ 20MG BASE** | **A202045** | **001** | Jun 11, 2014 |
| **AB** | | | **EQ 30MG BASE** | **A202045** | **002** | Jun 11, 2014 |
| **AB** | | | **EQ 60MG BASE** | **A202045** | **003** | Jun 11, 2014 |
| **AB** | | AUROBINDO PHARMA LTD | **EQ 20MG BASE** | **A090778** | **001** | Dec 11, 2013 |
| **AB** | | | **EQ 30MG BASE** | **A090778** | **002** | Dec 11, 2013 |
| **AB** | | | **EQ 60MG BASE** | **A090778** | **003** | Dec 11, 2013 |
| **AB** | | BRECKENRIDGE PHARM | **EQ 20MG BASE** | **A203088** | **001** | Jun 11, 2014 |
| **AB** | | | **EQ 30MG BASE** | **A203088** | **002** | Jun 11, 2014 |
| **AB** | | | **EQ 60MG BASE** | **A203088** | **003** | Jun 11, 2014 |
| **AB** | | DR REDDYS LABS LTD | **EQ 20MG BASE** | **A090723** | **001** | Dec 11, 2013 |
| **AB** | | | **EQ 30MG BASE** | **A090723** | **002** | Dec 11, 2013 |
| **AB** | | | **EQ 60MG BASE** | **A090723** | **003** | Dec 11, 2013 |
| **AB** | | HETERO LABS LTD III | **EQ 20MG BASE** | **A204343** | **001** | Aug 03, 2016 |
| **AB** | | | **EQ 30MG BASE** | **A204343** | **002** | Aug 03, 2016 |
| **AB** | | | **EQ 60MG BASE** | **A204343** | **003** | Aug 03, 2016 |
| **AB** | | INVENTIA HLTHCARE | **EQ 20MG BASE** | **A202336** | **001** | Oct 28, 2015 |
| **AB** | | | **EQ 30MG BASE** | **A202336** | **002** | Oct 28, 2015 |
| **AB** | | | **EQ 60MG BASE** | **A202336** | **003** | Oct 28, 2015 |
| **AB** | | LUPIN LTD | **EQ 20MG BASE** | **A090694** | **001** | Dec 11, 2013 |
| **AB** | | | **EQ 30MG BASE** | **A090694** | **002** | Dec 11, 2013 |
| **AB** | | | **EQ 60MG BASE** | **A090694** | **004** | Dec 11, 2013 |
| **AB** | | MACLEODS PHARMS LTD | **EQ 20MG BASE** | **A204815** | **001** | Mar 23, 2017 |
| **AB** | | | **EQ 30MG BASE** | **A204815** | **002** | Mar 23, 2017 |
| **AB** | | | **EQ 60MG BASE** | **A204815** | **003** | Mar 23, 2017 |
| **AB** | | PRINSTON INC | **EQ 20MG BASE** | **A206653** | **001** | May 18, 2017 |
| **AB** | | | **EQ 30MG BASE** | **A206653** | **002** | May 18, 2017 |
| **AB** | | | **EQ 60MG BASE** | **A206653** | **003** | May 18, 2017 |
| **AB** | | SUN PHARMA GLOBAL | **EQ 20MG BASE** | **A090745** | **001** | Dec 11, 2013 |
| **AB** | | | **EQ 30MG BASE** | **A090745** | **002** | Dec 11, 2013 |
| **AB** | | | **EQ 60MG BASE** | **A090745** | **003** | Dec 11, 2013 |
| **AB** | | TEVA PHARMS USA | **EQ 20MG BASE** | **A090783** | **001** | Dec 11, 2013 |
| **AB** | | | **EQ 30MG BASE** | **A090783** | **002** | Dec 11, 2013 |
| **AB** | | | **EQ 60MG BASE** | **A090783** | **003** | Dec 11, 2013 |
| **AB** | | TORRENT PHARMS LTD | **EQ 20MG BASE** | **A090774** | **001** | Dec 11, 2013 |
| **AB** | | | **EQ 30MG BASE** | **A090774** | **002** | Dec 11, 2013 |
| **AB** | | | **EQ 60MG BASE** | **A090774** | **003** | Dec 11, 2013 |
| **AB** | | ZYDUS HLTHCARE | **EQ 20MG BASE** | **A090739** | **001** | Jan 08, 2014 |
| **AB** | | | **EQ 30MG BASE** | **A090739** | **002** | Jan 08, 2014 |
| **AB** | | | **EQ 60MG BASE** | **A090739** | **003** | Jan 08, 2014 |
| **AB** | | ZYDUS PHARMS USA INC | **EQ 20MG BASE** | **A090728** | **001** | Jan 08, 2014 |
| **AB** | | | **EQ 30MG BASE** | **A090728** | **002** | Jan 08, 2014 |
| **AB** | | | **EQ 60MG BASE** | **A090728** | **003** | Jan 08, 2014 |
| | | LUPIN LTD | EQ 40MG BASE | A090694 | 003 | Dec 11, 2013 |

DUTASTERIDE

CAPSULE;ORAL

**AVODART**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | GLAXOSMITHKLINE | **0.5MG** | **N021319** | **001** | Nov 20, 2001 |

**DUTASTERIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS LABS FL INC | **0.5MG** | **A202808** | **001** | Nov 20, 2015 |
| **AB** | | AMNEAL PHARMS | **0.5MG** | **A203118** | **001** | Nov 20, 2015 |
| **AB** | | APOTEX INC | **0.5MG** | **A204292** | **001** | Nov 24, 2015 |
| **AB** | | ASCENT PHARMS INC | **0.5MG** | **A206574** | **001** | Oct 21, 2016 |
| **AB** | | AUROLIFE PHARMA LLC | **0.5MG** | **A202660** | **001** | Nov 20, 2015 |
| **AB** | | BARR | **0.5MG** | **A090095** | **001** | Dec 21, 2010 |
| **AB** | | BIONPHARMA INC | **0.5MG** | **A200899** | **001** | Nov 20, 2015 |
| **AB** | | BRECKENRIDGE PHARM | **0.5MG** | **A204705** | **001** | Nov 20, 2015 |
| **AB** | | HAUPT PHARMA | **0.5MG** | **A207935** | **001** | Oct 13, 2017 |
| **AB** | | HUMANWELL PURACAP | **0.5MG** | **A209909** | **001** | Nov 21, 2017 |
| **AB** | | INTERGEL PHARMS INC | **0.5MG** | **A206373** | **001** | Mar 17, 2016 |
| **AB** | | MARKSANS PHARMA | **0.5MG** | **A204376** | **001** | Apr 07, 2017 |
| **AB** | | MYLAN PHARMS INC | **0.5MG** | **A203241** | **001** | Jun 14, 2016 |
| **AB** | | RISING PHARMS INC | **0.5MG** | **A202530** | **001** | Nov 20, 2015 |
| **AB** | | STRIDES PHARMA | **0.5MG** | **A204262** | **001** | Nov 20, 2015 |
| **AB** | | VINTAGE PHARMS LLC | **0.5MG** | **A202421** | **001** | Nov 20, 2015 |
| **AB** | | WEST-WARD PHARMS INT | **0.5MG** | **A202204** | **001** | Nov 23, 2015 |
| **AB** | | ZYDUS PHARMS USA INC | **0.5MG** | **A204373** | **001** | Oct 04, 2017 |

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

**DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS LABS FL INC | **0.5MG;0.4MG** | **A202975** | **001** | Nov 20, 2015 |
| **AB** | | ANCHEN PHARMS | **0.5MG;0.4MG** | **A202509** | **001** | Feb 26, 2014 |

**JALYN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | GLAXOSMITHKLINE | **0.5MG;0.4MG** | **N022460** | **001** | Jun 14, 2010 |

ECHOTHIOPHATE IODIDE

FOR SOLUTION;OPHTHALMIC

PHOSPHOLINE IODIDE

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | WYETH PHARMS INC | 0.125% | N011963 | 001 | |

ECONAZOLE NITRATE

AEROSOL, FOAM;TOPICAL

ECOZA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | CHEMO RESEARCH SL | 1% | N205175 | 001 | Oct 24, 2013 |

CREAM;TOPICAL

**ECONAZOLE NITRATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | FOUGERA PHARMS | **1%** | **A076075** | **001** | Nov 26, 2002 |
| **AB** | **!** | PERRIGO NEW YORK | **1%** | **A076479** | **001** | Jun 23, 2004 |
| **AB** | | TARO | **1%** | **A076005** | **001** | Nov 26, 2002 |
| **AB** | | TELIGENT PHARMA INC | **1%** | **A076574** | **001** | Dec 17, 2004 |

**SPECTAZOLE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | ALVOGEN MALTA | **1%** | **N018751** | **001** | Dec 23, 1982 |

EDARAVONE

SOLUTION;IV (INFUSION)

RADICAVA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | MITSUBISHI TANABE | 30MG/100ML (0.3MG/ML) | N209176 | 001 | May 05, 2017 |

EDETATE CALCIUM DISODIUM

INJECTABLE;INJECTION

CALCIUM DISODIUM VERSENATE

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | MEDICIS | 200MG/ML | N008922 | 001 | |

EDOXABAN TOSYLATE

TABLET;ORAL

SAVAYSA

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | DAIICHI SANKYO INC | EQ 15MG BASE | N206316 | 001 | Jan 08, 2015 |
| | + | | EQ 30MG BASE | N206316 | 002 | Jan 08, 2015 |
| | +! | | EQ 60MG BASE | N206316 | 003 | Jan 08, 2015 |

EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION

ENLON

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | MYLAN INSTITUTIONAL | 10MG/ML | A088873 | 001 | Aug 06, 1985 |

EFAVIRENZ

CAPSULE;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **EFAVIRENZ** | | | | | | |
| **AB** | | AUROBINDO PHARMA LTD | **50MG** | **A078064** | **001** | Dec 15, 2017 |
| **AB** | | | **200MG** | **A078064** | **003** | Dec 15, 2017 |
| **SUSTIVA** | | | | | | |
| **AB** | + | BRISTOL MYERS SQUIBB | **50MG** | **N020972** | **001** | Sep 17, 1998 |
| **AB** | +! | | **200MG** | **N020972** | **003** | Sep 17, 1998 |
| EFAVIRENZ | | | | | | |
| | | AUROBINDO PHARMA LTD | 100MG | A078064 | 002 | Dec 15, 2017 |

TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **EFAVIRENZ** | | | | | | |
| **AB** | | MYLAN PHARMS INC | **600MG** | **A091471** | **001** | Feb 17, 2016 |
| **SUSTIVA** | | | | | | |
| **AB** | +! | BRISTOL MYERS SQUIBB | **600MG** | **N021360** | **002** | Feb 01, 2002 |

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| ATRIPLA | | | | | | |
| | +! | GILEAD | 600MG;200MG;300MG | N021937 | 001 | Jul 12, 2006 |

EFINACONAZOLE

SOLUTION;TOPICAL

| | | | | | | |
|---|---|---|---|---|---|---|
| JUBLIA | | | | | | |
| | +! | DOW PHARM | 10% | N203567 | 001 | Jun 06, 2014 |

EFLORNITHINE HYDROCHLORIDE

CREAM;TOPICAL

| | | | | | | |
|---|---|---|---|---|---|---|
| VANIQA | | | | | | |
| | +! | SKINMEDICA | 13.9% | N021145 | 001 | Jul 27, 2000 |

ELBASVIR; GRAZOPREVIR

TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| ZEPATIER | | | | | | |
| | +! | MERCK SHARP DOHME | 50MG;100MG | N208261 | 001 | Jan 28, 2016 |

ELETRIPTAN HYDROBROMIDE

TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **ELETRIPTAN HYDROBROMIDE** | | | | | | |
| **AB** | | AJANTA PHARMA LTD | **EQ 20MG BASE** | **A205186** | **001** | Aug 29, 2017 |
| **AB** | | | **EQ 40MG BASE** | **A205186** | **002** | Aug 29, 2017 |
| **AB** | | MYLAN PHARMS INC | **EQ 20MG BASE** | **A205152** | **001** | Aug 11, 2017 |
| **AB** | | | **EQ 40MG BASE** | **A205152** | **002** | Aug 11, 2017 |
| **AB** | | TEVA PHARMS USA | **EQ 20MG BASE** | **A202040** | **001** | Jun 27, 2017 |
| **AB** | | | **EQ 40MG BASE** | **A202040** | **002** | Jun 27, 2017 |
| **AB** | | ZYDUS PHARMS USA INC | **EQ 20MG BASE** | **A206409** | **001** | Jun 16, 2017 |
| **AB** | | | **EQ 40MG BASE** | **A206409** | **002** | Jun 16, 2017 |
| **RELPAX** | | | | | | |
| **AB** | + | PFIZER IRELAND | **EQ 20MG BASE** | **N021016** | **001** | Dec 26, 2002 |
| **AB** | +! | | **EQ 40MG BASE** | **N021016** | **002** | Dec 26, 2002 |

ELIGLUSTAT TARTRATE

CAPSULE;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| CERDELGA | | | | | | |
| | +! | GENZYME CORP | EQ 84MG BASE | N205494 | 001 | Aug 19, 2014 |

ELTROMBOPAG OLAMINE

FOR SUSPENSION;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| PROMACTA | | | | | | |
| | +! | NOVARTIS PHARMS CORP | EQ 25MG ACID/PACKET | N207027 | 001 | Aug 24, 2015 |

TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| PROMACTA | | | | | | |
| | + | NOVARTIS PHARMS CORP | EQ 12.5MG ACID | N022291 | 004 | Oct 20, 2011 |
| | + | | EQ 25MG ACID | N022291 | 001 | Nov 20, 2008 |
| | + | | EQ 50MG ACID | N022291 | 002 | Nov 20, 2008 |
| | +! | | EQ 75MG ACID | N022291 | 003 | Sep 08, 2009 |
| | +! | | EQ 100MG ACID | N022291 | 005 | Nov 16, 2012 |

| | | | | | | |
|---|---|---|---|---|---|---|
| ELUXADOLINE | | | | | | |
| TABLET;ORAL | | | | | | |
| VIBERZI | | | | | | |
| + | ALLERGAN HOLDINGS | 75MG | | N206940 | 001 | May 27, 2015 |
| +! | | 100MG | | N206940 | 002 | May 27, 2015 |
| EMEDASTINE DIFUMARATE | | | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | | | |
| EMADINE | | | | | | |
| +! | NOVARTIS PHARMS CORP | 0.05% | | N020706 | 001 | Dec 29, 1997 |
| EMPAGLIFLOZIN | | | | | | |
| TABLET;ORAL | | | | | | |
| JARDIANCE | | | | | | |
| + | BOEHRINGER INGELHEIM | 10MG | | N204629 | 001 | Aug 01, 2014 |
| +! | | 25MG | | N204629 | 002 | Aug 01, 2014 |
| EMPAGLIFLOZIN; LINAGLIPTIN | | | | | | |
| TABLET;ORAL | | | | | | |
| GLYXAMBI | | | | | | |
| + | BOEHRINGER INGELHEIM | 10MG;5MG | | N206073 | 001 | Jan 30, 2015 |
| +! | | 25MG;5MG | | N206073 | 002 | Jan 30, 2015 |
| EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE | | | | | | |
| TABLET;ORAL | | | | | | |
| SYNJARDY | | | | | | |
| + | BOEHRINGER INGELHEIM | 5MG;500MG | | N206111 | 001 | Aug 26, 2015 |
| + | | 5MG;1GM | | N206111 | 002 | Aug 26, 2015 |
| + | | 12.5MG;500MG | | N206111 | 003 | Aug 26, 2015 |
| +! | | 12.5MG;1GM | | N206111 | 004 | Aug 26, 2015 |
| TABLET, EXTENDED RELEASE;ORAL | | | | | | |
| SYNJARDY XR | | | | | | |
| + | BOEHRINGER INGELHEIM | 5MG;1GM | | N208658 | 001 | Dec 09, 2016 |
| + | | 10MG;1GM | | N208658 | 002 | Dec 09, 2016 |
| + | | 12.5MG;1GM | | N208658 | 003 | Dec 09, 2016 |
| +! | | 25MG;1GM | | N208658 | 004 | Dec 09, 2016 |
| EMTRICITABINE | | | | | | |
| CAPSULE;ORAL | | | | | | |
| EMTRIVA | | | | | | |
| +! | GILEAD | 200MG | | N021500 | 001 | Jul 02, 2003 |
| SOLUTION;ORAL | | | | | | |
| EMTRIVA | | | | | | |
| +! | GILEAD | 10MG/ML | | N021896 | 001 | Sep 28, 2005 |
| EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE | | | | | | |
| TABLET;ORAL | | | | | | |
| ODEFSEY | | | | | | |
| +! | GILEAD SCIENCES INC | 200MG;EQ 25MG BASE;EQ 25MG BASE | | N208351 | 001 | Mar 01, 2016 |
| EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE | | | | | | |
| TABLET;ORAL | | | | | | |
| COMPLERA | | | | | | |
| +! | GILEAD SCIENCES INC | 200MG;EQ 25MG BASE;300MG | | N202123 | 001 | Aug 10, 2011 |
| EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE | | | | | | |
| TABLET;ORAL | | | | | | |
| DESCOVY | | | | | | |
| +! | GILEAD SCIENCES INC | 200MG;EQ 25MG BASE | | N208215 | 001 | Apr 04, 2016 |
| EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE | | | | | | |
| TABLET;ORAL | | | | | | |
| **EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE** | | | | | | |
| **AB** | TEVA PHARMS USA | **200MG;300MG** | | **A090894** | **001** | Jun 08, 2017 |
| **TRUVADA** | | | | | | |
| **AB** | **+!** GILEAD | **200MG;300MG** | | **N021752** | **001** | Aug 02, 2004 |
| + | | 100MG;150MG | | N021752 | 002 | Mar 10, 2016 |
| + | | 133MG;200MG | | N021752 | 003 | Mar 10, 2016 |
| + | | 167MG;250MG | | N021752 | 004 | Mar 10, 2016 |

ENALAPRIL MALEATE

FOR SOLUTION;ORAL

EPANED KIT

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | SILVERGATE PHARMS | 1MG/ML | N204308 | 001 | Aug 13, 2013 |

SOLUTION;ORAL

EPANED

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | SILVERGATE PHARMS | 1MG/ML | N208686 | 001 | Sep 20, 2016 |

TABLET;ORAL

**ENALAPRIL MALEATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | APOTEX | **2.5MG** | **A075178** | **002** | Mar 23, 2001 |
| **AB** | | | **5MG** | **A075178** | **001** | Mar 23, 2001 |
| **AB** | | | **10MG** | **A075178** | **003** | Mar 23, 2001 |
| **AB** | | | **20MG** | **A075178** | **004** | Mar 23, 2001 |
| **AB** | | MYLAN | **2.5MG** | **A075480** | **001** | Aug 22, 2000 |
| **AB** | | | **5MG** | **A075480** | **002** | Aug 22, 2000 |
| **AB** | | | **10MG** | **A075480** | **003** | Aug 22, 2000 |
| **AB** | | | **20MG** | **A075480** | **004** | Aug 22, 2000 |
| **AB** | | SANDOZ INC | **2.5MG** | **A075496** | **001** | Aug 22, 2000 |
| **AB** | | | **5MG** | **A075496** | **002** | Aug 22, 2000 |
| **AB** | | | **10MG** | **A075459** | **001** | Aug 22, 2000 |
| **AB** | | | **20MG** | **A075459** | **002** | Aug 22, 2000 |
| **AB** | | TARO | **2.5MG** | **A075657** | **001** | Jan 23, 2001 |
| **AB** | | | **5MG** | **A075657** | **002** | Jan 23, 2001 |
| **AB** | | | **10MG** | **A075657** | **003** | Jan 23, 2001 |
| **AB** | | | **20MG** | **A075657** | **004** | Jan 23, 2001 |
| **AB** | | TEVA | **2.5MG** | **A075479** | **001** | Aug 22, 2000 |
| **AB** | | | **5MG** | **A075479** | **002** | Aug 22, 2000 |
| **AB** | | | **10MG** | **A075479** | **003** | Aug 22, 2000 |
| **AB** | | | **20MG** | **A075479** | **004** | Aug 22, 2000 |
| **AB** | | WOCKHARDT LTD | **2.5MG** | **A075483** | **001** | Aug 22, 2000 |
| **AB** | | | **5MG** | **A075483** | **002** | Aug 22, 2000 |
| **AB** | | | **10MG** | **A075483** | **003** | Aug 22, 2000 |
| **AB** | | | **20MG** | **A075483** | **004** | Aug 22, 2000 |

**VASOTEC**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | VALEANT PHARMS NORTH | **2.5MG** | **N018998** | **005** | Jul 26, 1988 |
| **AB** | + | | **5MG** | **N018998** | **001** | Dec 24, 1985 |
| **AB** | + | | **10MG** | **N018998** | **002** | Dec 24, 1985 |
| **AB** | +! | | **20MG** | **N018998** | **003** | Dec 24, 1985 |

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

**ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | APOTEX INC | **5MG;12.5MG** | **A076486** | **001** | Oct 27, 2004 |
| **AB** | | | **10MG;25MG** | **A076486** | **002** | Oct 27, 2004 |
| **AB** | | DR REDDYS LABS LTD | **5MG;12.5MG** | **A075909** | **001** | Oct 15, 2001 |
| **AB** | | | **10MG;25MG** | **A075909** | **002** | Oct 15, 2001 |
| **AB** | | G AND W LABS INC | **5MG;12.5MG** | **A075727** | **001** | Sep 18, 2001 |
| **AB** | | | **10MG;25MG** | **A075727** | **002** | Sep 18, 2001 |
| **AB** | | MYLAN | **5MG;12.5MG** | **A075624** | **001** | Sep 18, 2001 |
| **AB** | | | **10MG;25MG** | **A075624** | **002** | Sep 18, 2001 |
| **AB** | | TARO PHARM INDS | **5MG;12.5MG** | **A075788** | **001** | Sep 18, 2001 |
| **AB** | | | **10MG;25MG** | **A075788** | **002** | Sep 18, 2001 |

**VASERETIC**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | VALEANT INTL | **5MG;12.5MG** | **N019221** | **003** | Jul 12, 1995 |
| **AB** | +! | | **10MG;25MG** | **N019221** | **001** | Oct 31, 1986 |

ENALAPRILAT

INJECTABLE;INJECTION

**ENALAPRILAT**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | ! | ATHENEX INC | **1.25MG/ML** | **A075634** | **001** | Aug 22, 2000 |
| **AP** | | HIKMA FARMACEUTICA | **1.25MG/ML** | **A078687** | **001** | Dec 23, 2008 |
| **AP** | ! | HOSPIRA | **1.25MG/ML** | **A075458** | **001** | Aug 22, 2000 |
| **AP** | | TEVA PHARMS USA | **1.25MG/ML** | **A075578** | **001** | Aug 22, 2000 |

ENASIDENIB MESYLATE

TABLET;ORAL

IDHIFA

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | CELGENE CORP | EQ 50MG BASE | N209606 | 001 | Aug 01, 2017 |
| | +! | | EQ 100MG BASE | N209606 | 002 | Aug 01, 2017 |

ENFUVIRTIDE

INJECTABLE;SUBCUTANEOUS

FUZEON

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ROCHE | 90MG/VIAL | N021481 | 001 | Mar 13, 2003 |

ENOXAPARIN SODIUM

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS

**ENOXAPARIN SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | SANDOZ INC | **300MG/3ML (100MG/ML)** | **A078660** | **001** | Nov 28, 2011 |

**LOVENOX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | SANOFI AVENTIS US | **300MG/3ML (100MG/ML)** | **N020164** | **009** | Jan 23, 2003 |

INJECTABLE;SUBCUTANEOUS

**ENOXAPARIN SODIUM (PRESERVATIVE FREE)**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AMPHASTAR PHARM | **30MG/0.3ML (100MG/ML)** | **A076684** | **001** | Sep 19, 2011 |
| **AP** | | | **40MG/0.4ML (100MG/ML)** | **A076684** | **002** | Sep 19, 2011 |
| **AP** | | | **60MG/0.6ML (100MG/ML)** | **A076684** | **003** | Sep 19, 2011 |
| **AP** | | | **80MG/0.8ML (100MG/ML)** | **A076684** | **004** | Sep 19, 2011 |
| **AP** | | | **100MG/ML (100MG/ML)** | **A076684** | **005** | Sep 19, 2011 |
| **AP** | | | **120MG/0.8ML (150MG/ML)** | **A076684** | **006** | Sep 19, 2011 |
| **AP** | | | **150MG/ML (150MG/ML)** | **A076684** | **007** | Sep 19, 2011 |
| **AP** | | SANDOZ | **30MG/0.3ML (100MG/ML)** | **A077857** | **002** | Jul 23, 2010 |
| **AP** | | | **40MG/0.4ML (100MG/ML)** | **A077857** | **003** | Jul 23, 2010 |
| **AP** | | | **60MG/0.6ML (100MG/ML)** | **A077857** | **004** | Jul 23, 2010 |
| **AP** | | | **80MG/0.8ML (100MG/ML)** | **A077857** | **005** | Jul 23, 2010 |
| **AP** | | | **100MG/ML (100MG/ML)** | **A077857** | **001** | Jul 23, 2010 |
| **AP** | | | **120MG/0.8ML (150MG/ML)** | **A077857** | **006** | Jul 23, 2010 |
| **AP** | | | **150MG/ML (150MG/ML)** | **A077857** | **007** | Jul 23, 2010 |
| **AP** | | TEVA | **30MG/0.3ML (100MG/ML)** | **A076726** | **001** | Jun 23, 2014 |
| **AP** | | | **40MG/0.4ML (100MG/ML)** | **A076726** | **002** | Jun 23, 2014 |
| **AP** | | | **60MG/0.6ML (100MG/ML)** | **A076726** | **003** | Jun 23, 2014 |
| **AP** | | | **80MG/0.8ML (100MG/ML)** | **A076726** | **004** | Jun 23, 2014 |
| **AP** | | | **100MG/ML (100MG/ML)** | **A076726** | **005** | Jun 23, 2014 |
| **AP** | | | **120MG/0.8ML (150MG/ML)** | **A076726** | **006** | Jun 23, 2014 |
| **AP** | | | **150MG/ML (150MG/ML)** | **A076726** | **007** | Jun 23, 2014 |

**LOVENOX (PRESERVATIVE FREE)**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | + | SANOFI AVENTIS US | **30MG/0.3ML (100MG/ML)** | **N020164** | **001** | Mar 29, 1993 |
| **AP** | + | | **40MG/0.4ML (100MG/ML)** | **N020164** | **002** | Jan 30, 1998 |
| **AP** | + | | **60MG/0.6ML (100MG/ML)** | **N020164** | **003** | Mar 27, 1998 |
| **AP** | + | | **80MG/0.8ML (100MG/ML)** | **N020164** | **004** | Mar 27, 1998 |
| **AP** | +! | | **100MG/ML (100MG/ML)** | **N020164** | **005** | Mar 27, 1998 |
| **AP** | + | | **120MG/0.8ML (150MG/ML)** | **N020164** | **007** | Jun 02, 2000 |
| **AP** | + | | **150MG/ML (150MG/ML)** | **N020164** | **008** | Jun 02, 2000 |

ENTACAPONE

TABLET;ORAL

**COMTAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | +! | ORION PHARMA | **200MG** | **N020796** | **001** | Oct 19, 1999 |

**ENTACAPONE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AJANTA PHARMA LTD | **200MG** | **A205792** | **001** | Aug 31, 2017 |
| **AB** | | AUROBINDO PHARMA LTD | **200MG** | **A203437** | **001** | Jun 19, 2015 |
| **AB** | | MACLEODS PHARMS LTD | **200MG** | **A207210** | **001** | Jun 05, 2017 |
| **AB** | | SUN PHARMA GLOBAL | **200MG** | **A090690** | **001** | Jul 16, 2012 |
| **AB** | | WOCKHARDT LTD | **200MG** | **A078941** | **001** | Aug 16, 2012 |

ENTECAVIR

SOLUTION;ORAL

BARACLUDE

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | BRISTOL MYERS SQUIBB | 0.05MG/ML | N021798 | 001 | Mar 29, 2005 |

TABLET;ORAL

**BARACLUDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | BRISTOL MYERS SQUIBB | **0.5MG** | **N021797** | **001** | Mar 29, 2005 |
| **AB** | +! | | **1MG** | **N021797** | **002** | Mar 29, 2005 |

**ENTECAVIR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACCORD HLTHCARE | **0.5MG** | **A205824** | **001** | Aug 25, 2017 |
| **AB** | | | **1MG** | **A205824** | **002** | Aug 25, 2017 |
| **AB** | | AMNEAL PHARMS | **0.5MG** | **A206652** | **001** | Nov 12, 2015 |
| **AB** | | | **1MG** | **A206652** | **002** | Nov 12, 2015 |
| **AB** | | AUROBINDO PHARMA LTD | **0.5MG** | **A206217** | **001** | Aug 26, 2015 |
| **AB** | | | **1MG** | **A206217** | **002** | Aug 26, 2015 |
| **AB** | | CIPLA LTD | **0.5MG** | **A206872** | **001** | Dec 06, 2016 |
| **AB** | | | **1MG** | **A206872** | **002** | Dec 06, 2016 |

| | | | | | | |
|---|---|---|---|---|---|---|
| ENTECAVIR | | | | | | |
| TABLET;ORAL | | | | | | |
| **ENTECAVIR** | | | | | | |
| **AB** | | HETERO LABS LTD V | **0.5MG** | **A205740** | **001** | Aug 21, 2015 |
| **AB** | | | **1MG** | **A205740** | **002** | Aug 21, 2015 |
| **AB** | | PAR PHARM INC | **0.5MG** | **A206294** | **001** | Nov 23, 2016 |
| **AB** | | | **1MG** | **A206294** | **002** | Nov 23, 2016 |
| **AB** | | PRINSTON INC | **0.5MG** | **A208782** | **001** | Oct 10, 2017 |
| **AB** | | | **1MG** | **A208782** | **002** | Oct 10, 2017 |
| **AB** | | SANDOZ INC | **0.5MG** | **A206672** | **001** | May 11, 2017 |
| **AB** | | | **1MG** | **A206672** | **002** | May 11, 2017 |
| **AB** | | TEVA PHARMS USA | **0.5MG** | **A202122** | **001** | Aug 26, 2014 |
| **AB** | | | **1MG** | **A202122** | **002** | Aug 26, 2014 |
| **AB** | | ZYDUS PHARMS USA INC | **0.5MG** | **A206745** | **001** | Jun 23, 2017 |
| **AB** | | | **1MG** | **A206745** | **002** | Jun 23, 2017 |
| ENZALUTAMIDE | | | | | | |
| CAPSULE;ORAL | | | | | | |
| XTANDI | | | | | | |
| | +! | ASTELLAS | 40MG | N203415 | 001 | Aug 31, 2012 |
| EPHEDRINE SULFATE | | | | | | |
| SOLUTION;INTRAVENOUS | | | | | | |
| **AKOVAZ** | | | | | | |
| **AP** | **+!** | FLAMEL IRELAND LTD | **50MG/ML (50MG/ML)** | **N208289** | **001** | Apr 29, 2016 |
| **EPHEDRINE SULFATE** | | | | | | |
| **AP** | | AKORN INC | **50MG/ML (50MG/ML)** | **N208609** | **001** | Mar 01, 2017 |
| **AP** | | SANDOZ INC | **50MG/ML (50MG/ML)** | **A209784** | **001** | Aug 23, 2017 |
| SOLUTION;IV (INFUSION) | | | | | | |
| CORPHEDRA | | | | | | |
| | | PAR STERILE PRODUCTS | 50MG/ML (50MG/ML) | N208943 | 001 | Jan 27, 2017 |
| EPINASTINE HYDROCHLORIDE | | | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | | | |
| **ELESTAT** | | | | | | |
| **AT** | **+!** | ALLERGAN | **0.05%** | **N021565** | **001** | Oct 16, 2003 |
| **EPINASTINE HYDROCHLORIDE** | | | | | | |
| **AT** | | AKORN | **0.05%** | **A204055** | **001** | May 05, 2017 |
| **AT** | | APOTEX | **0.05%** | **A090919** | **001** | Oct 31, 2011 |
| **AT** | | BRECKENRIDGE PHARM | **0.05%** | **A090870** | **001** | Mar 14, 2011 |
| **AT** | | SANDOZ INC | **0.05%** | **A203384** | **001** | Dec 07, 2016 |
| **AT** | | SOMERSET THERAPS LLC | **0.05%** | **A090951** | **001** | Oct 31, 2011 |
| **AT** | | SUN PHARM INDS | **0.05%** | **A091626** | **001** | Oct 31, 2011 |
| EPINEPHRINE | | | | | | |
| INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS | | | | | | |
| ADRENACLICK | | | | | | |
| BX | +! | IMPAX LABS INC | EQ 0.15MG/DELIVERY | N020800 | 003 | Nov 25, 2009 |
| BX | +! | | EQ 0.3MG/DELIVERY | N020800 | 004 | Nov 25, 2009 |
| EPIPEN | | | | | | |
| BX | +! | MYLAN SPECIALITY LP | 0.3MG/DELIVERY | N019430 | 001 | Dec 22, 1987 |
| EPIPEN JR. | | | | | | |
| BX | +! | MYLAN SPECIALITY LP | 0.15MG/DELIVERY | N019430 | 002 | Dec 22, 1987 |
| SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | | | | | | |
| AUVI-Q | | | | | | |
| BX | +! | KALEO INC | EQ 0.15MG/DELIVERY | N201739 | 002 | Aug 10, 2012 |
| BX | + | | EQ 0.3MG/DELIVERY | N201739 | 001 | Aug 10, 2012 |
| ADRENALIN | | | | | | |
| | +! | PAR STERILE PRODUCTS | EQ 1MG BASE/ML (EQ 1MG BASE/ML) | N204200 | 001 | Dec 07, 2012 |
| | +! | | EQ 30MG BASE/30ML (EQ 1MG BASE/ML) | N204640 | 001 | Dec 18, 2013 |
| AUVI-Q | | | | | | |
| | + | KALEO INC | EQ 0.1MG/DELIVERY | N201739 | 003 | Nov 17, 2017 |
| SYMJEPI | | | | | | |
| | +! | ADAMIS PHARMS CORP | 0.3MG/0.3ML (0.3MG/0.3ML) | N207534 | 001 | Jun 15, 2017 |
| SOLUTION;IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS | | | | | | |
| EPINEPHRINE | | | | | | |
| | | BELCHER PHARMS LLC | EQ 1MG BASE/ML (EQ 1MG BASE/ML) | N205029 | 001 | Jul 29, 2014 |

EPINEPHRINE BITARTRATE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIGNOSPAN FORTE

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | DEPROCO | EQ 0.02MG BASE/ML;2% | A088389 | 001 | Jan 22, 1985 |

LIGNOSPAN STANDARD

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | DEPROCO | EQ 0.01MG BASE/ML;2% | A088390 | 001 | Jan 22, 1985 |

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

**CITANEST FORTE DENTAL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | DENTSPLY PHARM | **0.005MG/ML;4%** | **N021383** | **001** | |

**PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | SEPTODONT INC | **0.005MG/ML;4%** | **A078959** | **001** | Aug 30, 2011 |

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

**LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | EASTMAN KODAK | **0.01MG/ML;2%** | **A040057** | **002** | Feb 26, 1993 |
| **AP** | | | **0.02MG/ML;2%** | **A040057** | **001** | Feb 26, 1993 |
| **AP** | | HOSPIRA | **0.005MG/ML;0.5%** | **A089635** | **001** | Jun 21, 1988 |
| **AP** | | | **0.005MG/ML;1.5%** | **A088571** | **001** | Sep 13, 1985 |
| **AP** | | | **0.005MG/ML;1.5%** | **A089645** | **001** | Jun 21, 1988 |
| **AP** | | | **0.005MG/ML;2%** | **A089651** | **001** | Jun 21, 1988 |
| **AP** | | | **0.01MG/ML;1%** | **A089644** | **001** | Jun 21, 1988 |
| **AP** | | | **0.01MG/ML;2%** | **A078772** | **001** | May 12, 2008 |
| **AP** | | | **0.01MG/ML;2%** | **A089646** | **001** | Jun 21, 1988 |
| **AP** | | | **0.02MG/ML;2%** | **A078772** | **002** | May 12, 2008 |

**OCTOCAINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **!** | SEPTODONT | **0.01MG/ML;2%** | **A084048** | **001** | |
| **AP** | **!** | | **0.02MG/ML;2%** | **A084048** | **002** | |

**XYLOCAINE W/ EPINEPHRINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | FRESENIUS KABI USA | **0.005MG/ML;0.5%** | **N006488** | **012** | |
| **AP** | **+!** | | **0.005MG/ML;1.5%** | **N006488** | **017** | |
| **AP** | **+!** | | **0.005MG/ML;2%** | **N006488** | **019** | Nov 13, 1986 |
| **AP** | **+!** | | **0.01MG/ML;1%** | **N006488** | **004** | |
| **AP** | **+!** | | **0.02MG/ML;2%** | **N006488** | **005** | |
| | +! | | 0.005MG/ML;1% | N006488 | 018 | Nov 13, 1986 |

EPIRUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

**ELLENCE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | PFIZER INC | **200MG/100ML (2MG/ML)** | **N050778** | **001** | Sep 15, 1999 |
| **AP** | **+** | | **50MG/25ML (2MG/ML)** | **N050778** | **002** | Sep 15, 1999 |

**EPIRUBICIN HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | ACTAVIS TOTOWA | **10MG/5ML (2MG/ML)** | **A065445** | **001** | Sep 18, 2008 |
| **AP** | | | **50MG/25ML (2MG/ML)** | **A065445** | **002** | Sep 18, 2008 |
| **AP** | | | **200MG/100ML (2MG/ML)** | **A065445** | **003** | Sep 18, 2008 |
| **AP** | | AKORN INC | **50MG/25ML (2MG/ML)** | **A090163** | **001** | Jun 24, 2009 |
| **AP** | | CIPLA LTD | **50MG/25ML (2MG/ML)** | **A065361** | **001** | Oct 22, 2007 |
| **AP** | | | **200MG/100ML (2MG/ML)** | **A065361** | **002** | Oct 22, 2007 |
| **AP** | | FRESENIUS KABI ONCOL | **200MG/100ML (2MG/ML)** | **A065411** | **001** | Aug 20, 2007 |
| **AP** | | | **50MG/25ML (2MG/ML)** | **A065411** | **002** | Aug 20, 2007 |
| **AP** | | FRESENIUS KABI USA | **10MG/5ML (2MG/ML)** | **A065408** | **001** | Oct 15, 2007 |
| **AP** | | | **50MG/25ML (2MG/ML)** | **A065408** | **002** | Oct 15, 2007 |
| **AP** | | | **150MG/75ML (2MG/ML)** | **A065408** | **003** | Oct 15, 2007 |
| **AP** | | | **200MG/100ML (2MG/ML)** | **A065408** | **004** | Oct 15, 2007 |
| **AP** | | HISUN PHARM HANGZHOU | **50MG/25ML (2MG/ML)** | **A090075** | **001** | Mar 25, 2010 |
| **AP** | | | **200MG/100ML (2MG/ML)** | **A090075** | **002** | Mar 25, 2010 |
| **AP** | | HOSPIRA | **10MG/5ML (2MG/ML)** | **A065343** | **001** | Apr 19, 2007 |
| **AP** | | | **150MG/75ML (2MG/ML)** | **A065343** | **003** | Apr 19, 2007 |
| **AP** | | | **200MG/100ML (2MG/ML)** | **A065343** | **004** | Apr 19, 2007 |
| **AP** | | IMPAX LABS INC | **50MG/25ML (2MG/ML)** | **A065331** | **001** | Aug 09, 2007 |
| **AP** | | | **200MG/100ML (2MG/ML)** | **A065331** | **002** | Aug 09, 2007 |
| **AP** | | MYLAN LABS LTD | **50MG/25ML (2MG/ML)** | **A091599** | **001** | Mar 12, 2012 |
| **AP** | | | **200MG/100ML (2MG/ML)** | **A091599** | **002** | Mar 12, 2012 |
| **AP** | | WEST-WARD PHARMS INT | **50MG/25ML (2MG/ML)** | **A065289** | **001** | Jun 27, 2007 |
| **AP** | | | **200MG/100ML (2MG/ML)** | **A065289** | **002** | Jun 27, 2007 |

EPLERENONE

TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **EPLERENONE** | | | | | | |
| **AB** | | ACCORD HLTHCARE | **25MG** | **A206922** | **001** | Jul 13, 2017 |
| **AB** | | | **50MG** | **A206922** | **002** | Jul 13, 2017 |
| **AB** | | APOTEX | **25MG** | **A078482** | **001** | Jul 30, 2008 |
| **AB** | | | **50MG** | **A078482** | **002** | Jul 30, 2008 |
| **AB** | | MYLAN PHARMS INC | **25MG** | **A203896** | **001** | Feb 02, 2017 |
| **AB** | | | **50MG** | **A203896** | **002** | Feb 02, 2017 |
| **AB** | | SANDOZ | **25MG** | **A078510** | **001** | Aug 01, 2008 |
| **AB** | | | **50MG** | **A078510** | **002** | Aug 01, 2008 |
| **INSPRA** | | | | | | |
| **AB** | **+** | GD SEARLE LLC | **25MG** | **N021437** | **001** | Sep 27, 2002 |
| **AB** | **+!** | | **50MG** | **N021437** | **002** | Sep 27, 2002 |

EPOPROSTENOL SODIUM

INJECTABLE;INJECTION

| | | | | | | |
|---|---|---|---|---|---|---|
| **EPOPROSTENOL SODIUM** | | | | | | |
| **AP** | | TEVA PHARMS USA | **EQ 0.5MG BASE/VIAL** | **A078396** | **001** | Apr 23, 2008 |
| **AP** | | | **EQ 1.5MG BASE/VIAL** | **A078396** | **002** | Apr 23, 2008 |
| **FLOLAN** | | | | | | |
| **AP** | **+!** | GLAXOSMITHKLINE LLC | **EQ 0.5MG BASE/VIAL** | **N020444** | **001** | Sep 20, 1995 |
| **AP** | **+!** | | **EQ 1.5MG BASE/VIAL** | **N020444** | **002** | Sep 20, 1995 |
| VELETRI | | | | | | |
| | + | ACTELION PHARMS LTD | EQ 0.5MG BASE/VIAL | N022260 | 002 | Jun 28, 2012 |
| | +! | | EQ 1.5MG BASE/VIAL | N022260 | 001 | Jun 27, 2008 |

EPROSARTAN MESYLATE

TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **EPROSARTAN MESYLATE** | | | | | | |
| **AB** | | MYLAN PHARMS INC | **EQ 400MG BASE** | **A202012** | **001** | Nov 16, 2011 |
| **AB** | | | **EQ 600MG BASE** | **A202012** | **002** | Nov 16, 2011 |
| **TEVETEN** | | | | | | |
| **AB** | **+** | ABBVIE | **EQ 400MG BASE** | **N020738** | **005** | Dec 22, 1997 |
| **AB** | **+!** | | **EQ 600MG BASE** | **N020738** | **006** | May 27, 1999 |

EPTIFIBATIDE

INJECTABLE;INJECTION

| | | | | | | |
|---|---|---|---|---|---|---|
| **EPTIFIBATIDE** | | | | | | |
| **AP** | | ACCORD HLTHCARE | **2MG/ML** | **A205557** | **001** | Nov 06, 2017 |
| **AP** | | | **75MG/100ML** | **A205557** | **002** | Nov 06, 2017 |
| **AP** | | AKORN | **2MG/ML** | **A204589** | **001** | Apr 18, 2017 |
| **AP** | | | **75MG/100ML** | **A204589** | **002** | Apr 18, 2017 |
| **AP** | | AMNEAL PHARMS | **2MG/ML** | **A205581** | **001** | Dec 08, 2016 |
| **AP** | | | **75MG/100ML** | **A205581** | **002** | Dec 08, 2016 |
| **AP** | | AUROBINDO PHARMA LTD | **2MG/ML** | **A206127** | **001** | Dec 08, 2015 |
| **AP** | | | **75MG/100ML** | **A206127** | **002** | Dec 08, 2015 |
| **AP** | | TEVA PHARMS USA | **2MG/ML** | **A090854** | **001** | Jun 12, 2015 |
| **INTEGRILIN** | | | | | | |
| **AP** | **+!** | SCHERING | **2MG/ML** | **N020718** | **001** | May 18, 1998 |
| **AP** | **+!** | | **75MG/100ML** | **N020718** | **002** | May 18, 1998 |

ERGOCALCIFEROL

CAPSULE;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **DRISDOL** | | | | | | |
| **AA** | **+!** | US PHARM HOLDINGS | **50,000 IU** | **N003444** | **001** | |
| **ERGOCALCIFEROL** | | | | | | |
| **AA** | | ORIT LABS LLC | **50,000 IU** | **A040833** | **001** | May 20, 2009 |
| **AA** | | SIGMAPHARM LABS LLC | **50,000 IU** | **A091004** | **001** | Jul 14, 2010 |
| **AA** | | STRIDES PHARMA | **50,000 IU** | **A090455** | **001** | Aug 03, 2010 |
| **AA** | | SUN PHARM INDS INC | **50,000 IU** | **A040865** | **001** | Dec 29, 2009 |
| **VITAMIN D** | | | | | | |
| **AA** | | BIONPHARMA INC | **50,000 IU** | **A080704** | **001** | |

ERGOLOID MESYLATES

TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| ERGOLOID MESYLATES | | | | | | |
| | ! | SUN PHARM INDUSTRIES | 1MG | A081113 | 001 | Oct 31, 1991 |

ERGOTAMINE TARTRATE
TABLET;SUBLINGUAL
ERGOMAR
! TERSERA THERAPS LLC 2MG A087693 001 Feb 24, 1983

ERIBULIN MESYLATE
SOLUTION;INTRAVENOUS
HALAVEN
+! EISAI INC 1MG/2ML (0.5MG/ML) N201532 001 Nov 15, 2010

ERLOTINIB HYDROCHLORIDE
TABLET;ORAL
TARCEVA
+ OSI PHARMS EQ 25MG BASE N021743 001 Nov 18, 2004
+ EQ 100MG BASE N021743 002 Nov 18, 2004
+! EQ 150MG BASE N021743 003 Nov 18, 2004

ERTAPENEM SODIUM
INJECTABLE;INTRAMUSCULAR, IV (INFUSION)
INVANZ
+! MERCK SHARP DOHME EQ 1GM BASE/VIAL N021337 001 Nov 21, 2001

ERTUGLIFLOZIN
TABLET;ORAL
STEGLATRO
+ MERCK SHARP DOHME 5MG N209803 001 Dec 19, 2017
+! 15MG N209803 002 Dec 19, 2017

ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE
TABLET;ORAL
SEGLUROMET
+ MERCK SHARP DOHME 2.5MG;500MG N209806 001 Dec 19, 2017
+ 2.5MG;1GM N209806 002 Dec 19, 2017
+ 7.5MG;500MG N209806 003 Dec 19, 2017
+! 7.5MG;1GM N209806 004 Dec 19, 2017

ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE
TABLET;ORAL
STELUJAN
+ MERCK SHARP DOHME 5MG;EQ 100MG BASE N209805 001 Dec 19, 2017
+! 15MG;EQ 100MG BASE N209805 002 Dec 19, 2017

ERYTHROMYCIN
CAPSULE, DELAYED REL PELLETS;ORAL
**ERYC**
**AB +!** MAYNE PHARMA **250MG** **N050536 001**
**ERYTHROMYCIN**
**AB** ARBOR PHARMS LLC **250MG** **A062746 001** Dec 22, 1986
GEL;TOPICAL
**ERYGEL**
**AT +!** MYLAN PHARMS INC **2%** **N050617 001** Oct 21, 1987
**ERYTHROMYCIN**
**AT** FOUGERA PHARMS **2%** **A064184 001** Sep 30, 1997
**AT** PERRIGO CO **2%** **A063211 001** Jan 29, 1993
**AT** TELIGENT PHARMA INC **2%** **A208154 001** Jul 19, 2017
OINTMENT;OPHTHALMIC
**ERYTHROMYCIN**
**AT** AKORN **0.5%** **A064030 001** Jul 18, 1996
**AT** BAUSCH AND LOMB **0.5%** **A064067 001** Jul 29, 1994
**AT !** PERRIGO CO TENNESSEE **0.5%** **A062447 001** Sep 26, 1983
SOLUTION;TOPICAL
**ERYTHROMYCIN**
**AT !** PERRIGO NEW YORK **2%** **A063038 001** Jan 11, 1991
**AT** TELIGENT PHARMA INC **2%** **A208100 001** Nov 20, 2017
**AT** WOCKHARDT BIO AG **2%** **A062825 001** Oct 23, 1987
SWAB;TOPICAL
**ERYTHROMYCIN**
**AT** AKORN **2%** **A090215 001** May 12, 2010
**AT !** PERRIGO CO **2%** **A064126 001** Jul 03, 1996
TABLET;ORAL
ERYTHROMYCIN
ARBOR PHARMS LLC 250MG A061621 001
! 500MG A061621 002

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| ERYTHROMYCIN | | | | | | | |
| TABLET, COATED PARTICLES;ORAL | | | | | | | |
| PCE | | | | | | | |
| | + | ARBOR PHARMS LLC | 333MG | | N050611 | 001 | Sep 09, 1986 |
| | +! | | 500MG | | N050611 | 002 | Aug 22, 1990 |
| TABLET, DELAYED RELEASE;ORAL | | | | | | | |
| ERY-TAB | | | | | | | |
| | | ARBOR PHARMS LLC | 250MG | | A062298 | 001 | |
| | | | 333MG | | A062298 | 003 | Mar 29, 1982 |
| | ! | | 500MG | | A062298 | 002 | |
| ERYTHROMYCIN ETHYLSUCCINATE | | | | | | | |
| GRANULE;ORAL | | | | | | | |
| E.E.S. | | | | | | | |
| | + | ARBOR PHARMS LLC | EQ 200MG BASE/5ML | | N050207 | 001 | |
| ERYPED | | | | | | | |
| | + | ARBOR PHARMS LLC | EQ 200MG BASE/5ML | | N050207 | 003 | Mar 30, 1987 |
| | +! | | EQ 400MG BASE/5ML | | N050207 | 002 | |
| TABLET;ORAL | | | | | | | |
| E.E.S. 400 | | | | | | | |
| BX | ! | ARBOR PHARMS LLC | EQ 400MG BASE | | A061905 | 002 | Aug 12, 1982 |
| ERYTHROMYCIN ETHYLSUCCINATE | | | | | | | |
| BX | ! | ARBOR PHARMS LLC | EQ 400MG BASE | | A061904 | 001 | |
| ERYTHROMYCIN LACTOBIONATE | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| **ERYTHROCIN** | | | | | | | |
| **AP** | | HOSPIRA | **EQ 500MG BASE/VIAL** | | **A062638** | **001** | Oct 31, 1986 |
| **AP** | **+!** | | **EQ 500MG BASE/VIAL** | | **N050609** | **001** | Sep 24, 1986 |
| | ! | | EQ 1GM BASE/VIAL | | A062638 | 002 | Oct 31, 1986 |
| ERYTHROMYCIN STEARATE | | | | | | | |
| TABLET;ORAL | | | | | | | |
| ERYTHROCIN STEARATE | | | | | | | |
| | ! | ARBOR PHARMS LLC | EQ 250MG BASE | | A060359 | 001 | |
| ESCITALOPRAM OXALATE | | | | | | | |
| SOLUTION;ORAL | | | | | | | |
| **ESCITALOPRAM OXALATE** | | | | | | | |
| **AA** | | AMNEAL PHARMS | **EQ 5MG BASE/5ML** | | **A202227** | **001** | Mar 14, 2012 |
| **AA** | | ANTRIM PHARMS LLC | **EQ 5MG BASE/5ML** | | **A203967** | **001** | May 26, 2015 |
| **AA** | | AUROBINDO PHARMA LTD | **EQ 5MG BASE/5ML** | | **A079062** | **001** | Apr 02, 2012 |
| **AA** | | HETERO LABS LTD III | **EQ 5MG BASE/5ML** | | **A202221** | **001** | Jun 12, 2012 |
| **AA** | | MACLEODS PHARMS LTD | **EQ 5MG BASE/5ML** | | **A202754** | **001** | Mar 31, 2016 |
| **AA** | | SILARX PHARMS INC | **EQ 5MG BASE/5ML** | | **A090477** | **001** | Jun 12, 2013 |
| **AA** | | TARO | **EQ 5MG BASE/5ML** | | **A079121** | **001** | May 03, 2012 |
| **LEXAPRO** | | | | | | | |
| **AA** | **+!** | FOREST LABS | **EQ 5MG BASE/5ML** | | **N021365** | **001** | Nov 27, 2002 |
| TABLET;ORAL | | | | | | | |
| **ESCITALOPRAM OXALATE** | | | | | | | |
| **AB** | | ACCORD HLTHCARE | **EQ 5MG BASE** | | **A202389** | **001** | Sep 11, 2012 |
| **AB** | | | **EQ 10MG BASE** | | **A202389** | **002** | Sep 11, 2012 |
| **AB** | | | **EQ 20MG BASE** | | **A202389** | **003** | Sep 11, 2012 |
| **AB** | | AMNEAL PHARMS | **EQ 5MG BASE** | | **A205619** | **001** | May 17, 2017 |
| **AB** | | | **EQ 10MG BASE** | | **A205619** | **002** | May 17, 2017 |
| **AB** | | | **EQ 20MG BASE** | | **A205619** | **003** | May 17, 2017 |
| **AB** | | APOTEX INC | **EQ 5MG BASE** | | **A078777** | **001** | Sep 11, 2012 |
| **AB** | | | **EQ 10MG BASE** | | **A078777** | **002** | Sep 11, 2012 |
| **AB** | | | **EQ 20MG BASE** | | **A078777** | **003** | Sep 11, 2012 |
| **AB** | | AUROBINDO PHARMA LTD | **EQ 5MG BASE** | | **A090432** | **001** | Sep 11, 2012 |
| **AB** | | | **EQ 10MG BASE** | | **A090432** | **002** | Sep 11, 2012 |
| **AB** | | | **EQ 20MG BASE** | | **A090432** | **003** | Sep 11, 2012 |
| **AB** | | HIKMA PHARMS | **EQ 5MG BASE** | | **A078766** | **001** | Sep 11, 2012 |
| **AB** | | | **EQ 10MG BASE** | | **A078766** | **002** | Sep 11, 2012 |
| **AB** | | | **EQ 20MG BASE** | | **A078766** | **003** | Sep 11, 2012 |
| **AB** | | INVAGEN PHARMS | **EQ 5MG BASE** | | **A078604** | **001** | Sep 11, 2012 |
| **AB** | | | **EQ 10MG BASE** | | **A078604** | **002** | Sep 11, 2012 |
| **AB** | | | **EQ 20MG BASE** | | **A078604** | **003** | Sep 11, 2012 |
| **AB** | | JUBILANT GENERICS | **EQ 5MG BASE** | | **A202280** | **001** | Sep 12, 2012 |
| **AB** | | | **EQ 10MG BASE** | | **A202280** | **002** | Sep 12, 2012 |
| **AB** | | | **EQ 20MG BASE** | | **A202280** | **003** | Sep 12, 2012 |
| **AB** | | LUPIN LTD | **EQ 5MG BASE** | | **A078169** | **001** | Sep 11, 2012 |
| **AB** | | | **EQ 10MG BASE** | | **A078169** | **002** | Sep 11, 2012 |

ESCITALOPRAM OXALATE

TABLET;ORAL

**ESCITALOPRAM OXALATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **EQ 20MG BASE** | **A078169** | **003** | Sep 11, 2012 |
| **AB** | | MACLEODS PHARMS LTD | **EQ 5MG BASE** | **A202210** | **001** | Sep 11, 2012 |
| **AB** | | | **EQ 10MG BASE** | **A202210** | **002** | Sep 11, 2012 |
| **AB** | | | **EQ 20MG BASE** | **A202210** | **003** | Sep 11, 2012 |
| **AB** | | PRINSTON INC | **EQ 5MG BASE** | **A078032** | **001** | Aug 28, 2015 |
| **AB** | | | **EQ 10MG BASE** | **A078032** | **002** | Aug 28, 2015 |
| **AB** | | | **EQ 20MG BASE** | **A078032** | **003** | Aug 28, 2015 |
| **AB** | | STI PHARMA LLC | **EQ 5MG BASE** | **A077512** | **001** | Sep 12, 2012 |
| **AB** | | | **EQ 10MG BASE** | **A077512** | **002** | Sep 12, 2012 |
| **AB** | | | **EQ 20MG BASE** | **A077512** | **003** | Sep 12, 2012 |
| **AB** | | TEVA PHARMS USA | **EQ 5MG BASE** | **A076765** | **001** | Mar 14, 2012 |
| **AB** | | | **EQ 10MG BASE** | **A076765** | **002** | Mar 14, 2012 |
| **AB** | | | **EQ 20MG BASE** | **A076765** | **003** | Mar 14, 2012 |
| **AB** | | TORRENT PHARMS LTD | **EQ 5MG BASE** | **A090939** | **001** | Sep 11, 2012 |
| **AB** | | | **EQ 10MG BASE** | **A090939** | **002** | Sep 11, 2012 |
| **AB** | | | **EQ 20MG BASE** | **A090939** | **003** | Sep 11, 2012 |
| **AB** | | ZYDUS PHARMS USA INC | **EQ 5MG BASE** | **A077734** | **001** | Sep 11, 2012 |
| **AB** | | | **EQ 10MG BASE** | **A077734** | **002** | Sep 11, 2012 |
| **AB** | | | **EQ 20MG BASE** | **A077734** | **003** | Sep 11, 2012 |

**LEXAPRO**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | FOREST LABS | **EQ 5MG BASE** | **N021323** | **001** | Aug 14, 2002 |
| **AB** | **+** | | **EQ 10MG BASE** | **N021323** | **002** | Aug 14, 2002 |
| **AB** | **+!** | | **EQ 20MG BASE** | **N021323** | **003** | Aug 14, 2002 |

ESLICARBAZEPINE ACETATE

TABLET;ORAL

APTIOM

| | | | | | |
|---|---|---|---|---|---|
| + | SUNOVION PHARMS INC | 200MG | N022416 | 001 | Nov 08, 2013 |
| + | | 400MG | N022416 | 002 | Nov 08, 2013 |
| + | | 600MG | N022416 | 003 | Nov 08, 2013 |
| +! | | 800MG | N022416 | 004 | Nov 08, 2013 |

ESMOLOL HYDROCHLORIDE

INJECTABLE;INJECTION

**BREVIBLOC**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | BAXTER HLTHCARE | **10MG/ML** | **N019386** | **006** | Feb 25, 2003 |

**ESMOLOL HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AUROBINDO PHARMA LTD | **10MG/ML** | **A205520** | **001** | Jul 23, 2015 |
| **AP** | | FRESENIUS KABI USA | **10MG/ML** | **A076573** | **001** | May 02, 2005 |
| **AP** | | LUITPOLD PHARMS INC | **10MG/ML** | **A201126** | **001** | Feb 20, 2015 |
| **AP** | | MYLAN INSTITUTIONAL | **10MG/ML** | **A076474** | **001** | May 02, 2005 |
| **AP** | | WEST-WARD PHARMS INT | **10MG/ML** | **A076323** | **001** | Aug 10, 2004 |

BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| +! | BAXTER HLTHCARE | 2GM/100ML | N019386 | 005 | Jan 27, 2003 |

BREVIBLOC IN PLASTIC CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| +! | BAXTER HLTHCARE | 1GM/100ML | N019386 | 004 | Feb 16, 2001 |

SOLUTION;INTRAVENOUS

ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| +! | HQ SPCLT PHARMA | 2GM/100ML (20MG/ML) | N205703 | 002 | Apr 07, 2016 |

ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| +! | HQ SPCLT PHARMA | 2.5GM/250ML (10MG/ML) | N205703 | 001 | Apr 07, 2016 |

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

**ESOMEPRAZOLE MAGNESIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALKEM LABS LTD | **EQ 20MG BASE** | **A208333** | **001** | Oct 20, 2017 |
| **AB** | | | **EQ 40MG BASE** | **A208333** | **002** | Oct 20, 2017 |
| **AB** | | AUROBINDO PHARMA LTD | **EQ 20MG BASE** | **A205606** | **001** | Apr 21, 2016 |
| **AB** | | | **EQ 40MG BASE** | **A205606** | **002** | Apr 21, 2016 |
| **AB** | | DR REDDYS LABS LTD | **EQ 20MG BASE** | **A078279** | **001** | Sep 25, 2015 |
| **AB** | | | **EQ 40MG BASE** | **A078279** | **002** | Sep 25, 2015 |
| **AB** | | IVAX SUB TEVA PHARMS | **EQ 20MG BASE** | **A078003** | **001** | Jan 26, 2015 |
| **AB** | | | **EQ 40MG BASE** | **A078003** | **002** | Jan 26, 2015 |
| **AB** | | KREMERS URBAN PHARMS | **EQ 20MG BASE** | **A205563** | **001** | Sep 01, 2017 |
| **AB** | | | **EQ 40MG BASE** | **A205563** | **002** | Sep 01, 2017 |
| **AB** | | MYLAN PHARMS INC | **EQ 20MG BASE** | **A078936** | **001** | Aug 02, 2015 |

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

**ESOMEPRAZOLE MAGNESIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **EQ 40MG BASE** | **A078936** | **002** | Aug 03, 2015 |
| **AB** | | TORRENT PHARMS LTD | **EQ 20MG BASE** | **A203636** | **001** | Oct 19, 2015 |
| **AB** | | | **EQ 40MG BASE** | **A203636** | **002** | Oct 19, 2015 |

**NEXIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | ASTRAZENECA PHARMS | **EQ 20MG BASE** | **N021153** | **001** | Feb 20, 2001 |
| **AB** | **+!** | | **EQ 40MG BASE** | **N021153** | **002** | Feb 20, 2001 |

ESOMEPRAZOLE MAGNESIUM

| | | | | | | |
|---|---|---|---|---|---|---|
| BX | | HETERO LABS LTD III | EQ 20MG BASE | A202784 | 001 | Sep 21, 2015 |
| BX | | | EQ 40MG BASE | A202784 | 002 | Sep 21, 2015 |

FOR SUSPENSION, DELAYED RELEASE;ORAL

NEXIUM

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | ASTRAZENECA PHARMS | EQ 2.5MG BASE/PACKET | N021957 | 003 | Dec 15, 2011 |
| | + | | EQ 5MG BASE/PACKET | N021957 | 004 | Dec 15, 2011 |
| | + | | EQ 10MG BASE/PACKET | N022101 | 001 | Feb 27, 2008 |
| | + | | EQ 20MG BASE/PACKET | N021957 | 001 | Oct 20, 2006 |
| | +! | | EQ 40MG BASE/PACKET | N021957 | 002 | Oct 20, 2006 |

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE;ORAL

**NAPROXEN AND ESOMEPRAZOLE MAGNESIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | DR REDDYS LABS LTD | **EQ 20MG BASE;375MG** | **A202461** | **001** | Sep 27, 2013 |
| **AB** | | | **EQ 20MG BASE;500MG** | **A202461** | **002** | Sep 27, 2013 |

**VIMOVO**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | HORIZON PHARMA USA | **EQ 20MG BASE;375MG** | **N022511** | **002** | Apr 30, 2010 |
| **AB** | **+!** | | **EQ 20MG BASE;500MG** | **N022511** | **001** | Apr 30, 2010 |

ESOMEPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS

**ESOMEPRAZOLE SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | ACCORD HLTHCARE | **EQ 40MG BASE/VIAL** | **A205379** | **001** | Sep 25, 2015 |
| **AP** | **!** | AUROBINDO PHARMA LTD | **EQ 40MG BASE/VIAL** | **A204657** | **002** | Aug 10, 2016 |
| **AP** | | DEVA HOLDING AS | **EQ 40MG BASE/VIAL** | **A207181** | **001** | Mar 06, 2017 |
| **AP** | | MYLAN LABS LTD | **EQ 40MG BASE/VIAL** | **A202686** | **002** | May 17, 2017 |
| **AP** | | SUN PHARMA GLOBAL | **EQ 40MG BASE/VIAL** | **A200882** | **002** | Mar 18, 2013 |

**NEXIUM IV**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | ASTRAZENECA PHARMS | **EQ 40MG BASE/VIAL** | **N021689** | **002** | Mar 31, 2005 |

ESOMEPRAZOLE STRONTIUM

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE STRONTIUM

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | R2 PHARMA LLC | 49.3MG | N202342 | 002 | Aug 06, 2013 |

ESTAZOLAM

TABLET;ORAL

**ESTAZOLAM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | MAYNE PHARMA | **1MG** | **A074921** | **001** | Jul 10, 1997 |
| **AB** | **!** | | **2MG** | **A074921** | **002** | Jul 10, 1997 |
| **AB** | | PAR PHARM | **1MG** | **A074826** | **001** | Jul 03, 1997 |
| **AB** | | | **2MG** | **A074826** | **002** | Jul 03, 1997 |
| **AB** | | WATSON LABS | **1MG** | **A074818** | **001** | Aug 19, 1997 |
| **AB** | | | **2MG** | **A074818** | **002** | Aug 19, 1997 |

ESTRADIOL

CREAM;VAGINAL

**ESTRACE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **!** | ALLERGAN SALES LLC | **0.01%** | **A086069** | **001** | Jan 31, 1984 |

**ESTRADIOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | MYLAN PHARMS INC | **0.01%** | **A208788** | **001** | Dec 29, 2017 |

FILM, EXTENDED RELEASE;TRANSDERMAL

**CLIMARA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | BAYER HLTHCARE | **0.0375MG/24HR** | **N020375** | **005** | May 27, 2003 |
| **AB** | **+** | | **0.06MG/24HR** | **N020375** | **006** | May 27, 2003 |

**ESTRADIOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | MYLAN TECHNOLOGIES | **0.0375MG/24HR** | **A075182** | **004** | Jul 20, 2006 |
| **AB** | | | **0.06MG/24HR** | **A075182** | **005** | Jul 20, 2006 |
| **AB1** | | | **0.025MG/24HR** | **A201675** | **001** | Dec 19, 2014 |
| **AB1** | | | **0.0375MG/24HR** | **A201675** | **002** | Dec 19, 2014 |
| **AB1** | | | **0.05MG/24HR** | **A201675** | **003** | Dec 19, 2014 |
| **AB1** | | | **0.075MG/24HR** | **A201675** | **004** | Dec 19, 2014 |
| **AB1** | | | **0.1MG/24HR** | **A201675** | **005** | Dec 19, 2014 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| ESTRADIOL | | | | | | | |
| FILM, EXTENDED RELEASE;TRANSDERMAL | | | | | | | |
| **VIVELLE-DOT** | | | | | | | |
| **AB1** | **+** | NOVARTIS | **0.025MG/24HR** | **N020538** | **009** | May 03, 2002 |
| **AB1** | **+** | | **0.0375MG/24HR** | **N020538** | **005** | Jan 08, 1999 |
| **AB1** | **+** | | **0.05MG/24HR** | **N020538** | **006** | Jan 08, 1999 |
| **AB1** | **+** | | **0.075MG/24HR** | **N020538** | **007** | Jan 08, 1999 |
| **AB1** | **+!** | | **0.1MG/24HR** | **N020538** | **008** | Jan 08, 1999 |
| **CLIMARA** | | | | | | | |
| **AB2** | **+** | BAYER HLTHCARE | **0.025MG/24HR** | **N020375** | **004** | Mar 05, 1999 |
| **AB2** | **+** | | **0.05MG/24HR** | **N020375** | **001** | Dec 22, 1994 |
| **AB2** | **+** | | **0.075MG/24HR** | **N020375** | **003** | Mar 23, 1998 |
| **AB2** | **+!** | | **0.1MG/24HR** | **N020375** | **002** | Dec 22, 1994 |
| **ESTRADIOL** | | | | | | | |
| **AB2** | | MYLAN TECHNOLOGIES | **0.025MG/24HR** | **A075182** | **003** | Jan 26, 2005 |
| **AB2** | | | **0.05MG/24HR** | **A075182** | **006** | Feb 24, 2000 |
| **AB2** | | | **0.075MG/24HR** | **A075182** | **002** | Jan 26, 2005 |
| **AB2** | | | **0.1MG/24HR** | **A075182** | **001** | Feb 24, 2000 |
| ALORA | | | | | | | |
| BX | | ALLERGAN SALES LLC | 0.025MG/24HR | N020655 | 004 | Apr 05, 2002 |
| BX | | | 0.05MG/24HR | N020655 | 001 | Dec 20, 1996 |
| BX | | | 0.075MG/24HR | N020655 | 002 | Dec 20, 1996 |
| BX | | | 0.1MG/24HR | N020655 | 003 | Dec 20, 1996 |
| MENOSTAR | | | | | | | |
| | +! | BAYER HLTHCARE | 0.014MG/24HR | N021674 | 001 | Jun 08, 2004 |
| MINIVELLE | | | | | | | |
| | + | NOVEN | 0.025MG/24HR | N203752 | 005 | Sep 23, 2014 |
| | + | | 0.0375MG/24HR | N203752 | 001 | Oct 29, 2012 |
| | + | | 0.05MG/24HR | N203752 | 003 | Oct 29, 2012 |
| | + | | 0.075MG/24HR | N203752 | 002 | Oct 29, 2012 |
| | +! | | 0.1MG/24HR | N203752 | 004 | Oct 29, 2012 |
| GEL;TRANSDERMAL | | | | | | | |
| DIVIGEL | | | | | | | |
| | + | VERTICAL PHARMS LLC | 0.1% (0.25GM/PACKET) | N022038 | 001 | Jun 04, 2007 |
| | + | | 0.1% (0.5GM/PACKET) | N022038 | 002 | Jun 04, 2007 |
| | +! | | 0.1% (1GM/PACKET) | N022038 | 003 | Jun 04, 2007 |
| GEL, METERED;TRANSDERMAL | | | | | | | |
| ELESTRIN | | | | | | | |
| | +! | MYLAN SPECIALITY LP | 0.06% (0.87GM/ACTIVATION) | N021813 | 001 | Dec 15, 2006 |
| ESTROGEL | | | | | | | |
| | +! | ASCEND THERAPS US | 0.06% (1.25GM/ACTIVATION) | N021166 | 002 | Feb 09, 2004 |
| INSERT, EXTENDED RELEASE;VAGINAL | | | | | | | |
| ESTRING | | | | | | | |
| | +! | PHARMACIA AND UPJOHN | 0.0075MG/24HR | N020472 | 001 | Apr 26, 1996 |
| SPRAY;TRANSDERMAL | | | | | | | |
| EVAMIST | | | | | | | |
| | +! | PERRIGO PHARMA INTL | 1.53MG/SPRAY | N022014 | 001 | Jul 27, 2007 |
| TABLET;ORAL | | | | | | | |
| **ESTRADIOL** | | | | | | | |
| **AB** | | BARR LABS INC | **0.5MG** | **A040197** | **001** | Oct 22, 1997 |
| **AB** | | | **1MG** | **A040197** | **002** | Oct 22, 1997 |
| **AB** | **!** | | **2MG** | **A040197** | **003** | Oct 22, 1997 |
| **AB** | | EPIC PHARMA INC | **0.5MG** | **A040275** | **001** | Dec 29, 1998 |
| **AB** | | | **1MG** | **A040275** | **002** | Dec 29, 1998 |
| **AB** | | | **2MG** | **A040275** | **003** | Dec 29, 1998 |
| **AB** | | MAYNE PHARMA | **0.5MG** | **A040114** | **003** | Mar 14, 1996 |
| **AB** | | | **1MG** | **A040114** | **001** | Mar 14, 1996 |
| **AB** | | | **2MG** | **A040114** | **002** | Mar 14, 1996 |
| **AB** | | MYLAN | **0.5MG** | **A040326** | **001** | Apr 21, 1999 |
| **AB** | | | **1MG** | **A040326** | **002** | Apr 21, 1999 |
| **AB** | | | **2MG** | **A040326** | **003** | Apr 21, 1999 |
| TABLET;VAGINAL | | | | | | | |
| **ESTRADIOL** | | | | | | | |
| **AB** | | AMNEAL PHARMS | **10MCG** | **A205256** | **001** | May 29, 2015 |
| **AB** | | TEVA PHARMS USA | **10MCG** | **A206388** | **001** | Jul 21, 2017 |
| **VAGIFEM** | | | | | | | |
| **AB** | **+!** | NOVO NORDISK INC | **10MCG** | **N020908** | **002** | Nov 25, 2009 |

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE;VAGINAL

FEMRING

| | | | | | |
|---|---|---|---|---|---|
| + | APIL | EQ 0.05MG BASE/24HR | N021367 | 001 | Mar 20, 2003 |
| +! | | EQ 0.1MG BASE/24HR | N021367 | 002 | Mar 20, 2003 |

ESTRADIOL CYPIONATE

INJECTABLE;INJECTION

DEPO-ESTRADIOL

| | | | | | |
|---|---|---|---|---|---|
| ! | PHARMACIA AND UPJOHN | 5MG/ML | A085470 | 003 | |

ESTRADIOL HEMIHYDRATE

EMULSION;TOPICAL

ESTRASORB

| | | | | | |
|---|---|---|---|---|---|
| +! | EXELTIS USA INC | 0.25% | N021371 | 001 | Oct 09, 2003 |

ESTRADIOL VALERATE

INJECTABLE;INJECTION

**DELESTROGEN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AO** | **+!** | PAR STERILE PRODUCTS | **20MG/ML** | **N009402** | **004** | |
| **AO** | **+!** | | **40MG/ML** | **N009402** | **003** | |

**ESTRADIOL VALERATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AO** | | LUITPOLD | **20MG/ML** | **A090920** | **001** | Jan 19, 2010 |
| **AO** | | | **40MG/ML** | **A090920** | **002** | Jan 19, 2010 |

DELESTROGEN

| | | | | | | |
|---|---|---|---|---|---|---|
| +! | PAR STERILE PRODUCTS | 10MG/ML | N009402 | 002 | |

ESTRADIOL; LEVONORGESTREL

FILM, EXTENDED RELEASE;TRANSDERMAL

CLIMARA PRO

| | | | | | |
|---|---|---|---|---|---|
| +! | BAYER HLTHCARE | 0.045MG/24HR;0.015MG/24HR | N021258 | 001 | Nov 21, 2003 |

ESTRADIOL; NORETHINDRONE ACETATE

FILM, EXTENDED RELEASE;TRANSDERMAL

COMBIPATCH

| | | | | | |
|---|---|---|---|---|---|
| + | NOVEN PHARMS INC | 0.05MG/24HR;0.14MG/24HR | N020870 | 001 | Aug 07, 1998 |
| +! | | 0.05MG/24HR;0.25MG/24HR | N020870 | 002 | Aug 07, 1998 |

TABLET;ORAL

**ACTIVELLA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | AMNEAL PHARMS LLC | **0.5MG;0.1MG** | **N020907** | **002** | Dec 28, 2006 |
| **AB** | **+!** | | **1MG;0.5MG** | **N020907** | **001** | Nov 18, 1998 |

**AMABELZ**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | LUPIN LTD | **0.5MG;0.1MG** | **A203339** | **001** | Jun 20, 2016 |
| **AB** | | | **1MG;0.5MG** | **A203339** | **002** | Jun 20, 2016 |

**ESTRADIOL AND NORETHINDRONE ACETATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | BARR | **1MG;0.5MG** | **A079193** | **001** | May 11, 2010 |
| **AB** | | BRECKENRIDGE PHARM | **0.5MG;0.1MG** | **A078324** | **002** | Jun 09, 2011 |
| **AB** | | | **1MG;0.5MG** | **A078324** | **001** | Apr 17, 2008 |
| **AB** | | MYLAN LABS LTD | **0.5MG;0.1MG** | **A207261** | **001** | Feb 10, 2017 |
| **AB** | | | **1MG;0.5MG** | **A207261** | **002** | Feb 10, 2017 |
| **AB** | | TEVA PHARMS USA | **0.5MG;0.1MG** | **A200747** | **001** | Mar 08, 2012 |

ESTRADIOL; NORGESTIMATE

TABLET;ORAL

ESTRADIOL AND NORGESTIMATE

| | | | | | |
|---|---|---|---|---|---|
| ! | BARR | 1MG,1MG;N/A,0.09MG | A076812 | 001 | Apr 29, 2005 |

ESTRAMUSTINE PHOSPHATE SODIUM

CAPSULE;ORAL

EMCYT

| | | | | | |
|---|---|---|---|---|---|
| +! | PHARMACIA AND UPJOHN | EQ 140MG PHOSPHATE | N018045 | 001 | |

ESTROGENS, CONJUGATED

CREAM;TOPICAL, VAGINAL

PREMARIN

| | | | | | |
|---|---|---|---|---|---|
| +! | WYETH PHARMS INC | 0.625MG/GM | N020216 | 001 | |

INJECTABLE;INJECTION

PREMARIN

| | | | | | |
|---|---|---|---|---|---|
| +! | WYETH PHARMS INC | 25MG/VIAL | N010402 | 001 | |

TABLET;ORAL

PREMARIN

| | | | | | |
|---|---|---|---|---|---|
| + | WYETH PHARMS INC | 0.3MG | N004782 | 003 | |
| + | | 0.45MG | N004782 | 006 | Jul 16, 2003 |

ESTROGENS, CONJUGATED

TABLET;ORAL

PREMARIN

| | | | | | |
|---|---|---|---|---|---|
| +! | | 0.625MG | N004782 | 004 | |
| +! | | 0.9MG | N004782 | 005 | Jan 26, 1984 |
| +! | | 1.25MG | N004782 | 001 | |

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

TABLET;ORAL-28

PREMPHASE 14/14

| | | | | | |
|---|---|---|---|---|---|
| +! | WYETH PHARMS INC | 0.625MG,0.625MG;N/A,5MG | N020527 | 002 | Nov 17, 1995 |

PREMPRO

| | | | | | |
|---|---|---|---|---|---|
| +! | WYETH PHARMS INC | 0.3MG;1.5MG | N020527 | 005 | Jun 04, 2003 |
| +! | | 0.45MG;1.5MG | N020527 | 004 | Mar 12, 2003 |
| +! | | 0.625MG;2.5MG | N020527 | 001 | Nov 17, 1995 |
| +! | | 0.625MG;5MG | N020527 | 003 | Jan 09, 1998 |

ESTROGENS, ESTERIFIED

TABLET;ORAL

MENEST

| | | | | | |
|---|---|---|---|---|---|
| | MONARCH PHARMS | 0.3MG | A084951 | 001 | |
| | | 0.625MG | A084948 | 001 | |
| | | 1.25MG | A084950 | 001 | |
| ! | | 2.5MG | A084949 | 001 | |

ESTROPIPATE

TABLET;ORAL

ESTROPIPATE

| | | | | | |
|---|---|---|---|---|---|
| | MYLAN | 0.75MG | A040359 | 001 | Aug 26, 1999 |
| | | 1.5MG | A040359 | 002 | Aug 26, 1999 |

OGEN 5

| | | | | | |
|---|---|---|---|---|---|
| | PHARMACIA AND UPJOHN | 6MG | A083220 | 004 | |

ESZOPICLONE

TABLET;ORAL

**ESZOPICLONE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | AUROBINDO PHARMA LTD | **1MG** | **A208451** | **001** | Sep 15, 2016 |
| **AB** | | **2MG** | **A208451** | **002** | Sep 15, 2016 |
| **AB** | | **3MG** | **A208451** | **003** | Sep 15, 2016 |
| **AB** | DR REDDYS LABS LTD | **1MG** | **A091024** | **001** | Apr 15, 2014 |
| **AB** | | **2MG** | **A091024** | **002** | Apr 15, 2014 |
| **AB** | | **3MG** | **A091024** | **003** | Apr 15, 2014 |
| **AB** | GLENMARK GENERICS | **1MG** | **A091166** | **001** | Apr 15, 2014 |
| **AB** | | **2MG** | **A091166** | **002** | Apr 15, 2014 |
| **AB** | | **3MG** | **A091166** | **003** | Apr 15, 2014 |
| **AB** | LUPIN LTD | **1MG** | **A091124** | **001** | Sep 13, 2011 |
| **AB** | | **2MG** | **A091124** | **002** | Sep 13, 2011 |
| **AB** | | **3MG** | **A091124** | **003** | Sep 13, 2011 |
| **AB** | MACLEODS PHARMS LTD | **1MG** | **A202929** | **001** | Jan 30, 2015 |
| **AB** | | **2MG** | **A202929** | **002** | Jan 30, 2015 |
| **AB** | | **3MG** | **A202929** | **003** | Jan 30, 2015 |
| **AB** | MYLAN PHARMS INC | **1MG** | **A091151** | **001** | Mar 26, 2013 |
| **AB** | | **2MG** | **A091151** | **002** | Mar 26, 2013 |
| **AB** | | **3MG** | **A091151** | **003** | Mar 26, 2013 |
| **AB** | ORCHID HLTHCARE | **1MG** | **A091113** | **001** | Jun 10, 2014 |
| **AB** | | **2MG** | **A091113** | **002** | Jun 10, 2014 |
| **AB** | | **3MG** | **A091113** | **003** | Jun 10, 2014 |
| **AB** | SUN PHARMA GLOBAL | **1MG** | **A091103** | **001** | Apr 03, 2013 |
| **AB** | | **2MG** | **A091103** | **002** | Apr 03, 2013 |
| **AB** | | **3MG** | **A091103** | **003** | Apr 03, 2013 |
| **AB** | TEVA | **1MG** | **A091169** | **001** | May 23, 2011 |
| **AB** | | **2MG** | **A091169** | **002** | May 23, 2011 |
| **AB** | | **3MG** | **A091169** | **003** | May 23, 2011 |
| **AB** | WEST-WARD PHARMS INT | **1MG** | **A091153** | **001** | Apr 15, 2014 |
| **AB** | | **2MG** | **A091153** | **002** | Apr 15, 2014 |
| **AB** | | **3MG** | **A091153** | **003** | Apr 15, 2014 |

**LUNESTA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | SUNOVION PHARMS INC | **1MG** | **N021476** | **001** | Dec 15, 2004 |
| **AB** | + | | **2MG** | **N021476** | **002** | Dec 15, 2004 |
| **AB** | +! | | **3MG** | **N021476** | **003** | Dec 15, 2004 |

ETELCALCETIDE

SOLUTION;INTRAVENOUS

PARSABIV

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | KAI PHARMS INC | 2.5MG/0.5ML (2.5MG/0.5ML) | N208325 | 001 | Feb 07, 2017 |
| | +! | | 5MG/ML (5MG/ML) | N208325 | 002 | Feb 07, 2017 |
| | +! | | 10MG/2ML (5MG/ML) | N208325 | 003 | Feb 07, 2017 |

ETEPLIRSEN

SOLUTION;IV (INFUSION)

EXONDYS 51

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | SAREPTA THERAPS INC | 100MG/2ML (50MG/ML) | N206488 | 001 | Sep 19, 2016 |
| | +! | | 500MG/10ML (50MG/ML) | N206488 | 002 | Sep 19, 2016 |

ETHACRYNATE SODIUM

INJECTABLE;INJECTION

**EDECRIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | ATON | **EQ 50MG BASE/VIAL** | **N016093** | **001** | |

**ETHACRYNATE SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | MYLAN INSTITUTIONAL | **EQ 50MG BASE/VIAL** | **A204634** | **001** | Aug 23, 2016 |
| **AP** | | PAR STERILE PRODUCTS | **EQ 50MG BASE/VIAL** | **A205473** | **001** | Jul 29, 2015 |
| **AP** | | ZYDUS PHARMS USA INC | **EQ 50MG BASE/VIAL** | **A207758** | **001** | Nov 17, 2017 |

ETHACRYNIC ACID

TABLET;ORAL

**EDECRIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | ATON | **25MG** | **N016092** | **001** | |

**ETHACRYNIC ACID**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | EDENBRIDGE PHARMS | **25MG** | **A205609** | **001** | Jun 30, 2016 |
| **AB** | | PAR PHARM INC | **25MG** | **A208501** | **001** | Jul 21, 2017 |
| **AB** | | WEST-WARD PHARMS INT | **25MG** | **A207262** | **001** | Feb 23, 2017 |

ETHAMBUTOL HYDROCHLORIDE

TABLET;ORAL

**ETHAMBUTOL HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AKORN | **100MG** | **A075095** | **001** | Nov 30, 1999 |
| **AB** | | | **400MG** | **A075095** | **002** | Nov 30, 1999 |
| **AB** | | BARR | **400MG** | **A076057** | **001** | Nov 26, 2001 |
| **AB** | | LUPIN | **100MG** | **A078939** | **001** | Jun 17, 2009 |
| **AB** | | | **400MG** | **A078939** | **002** | Jun 17, 2009 |

**MYAMBUTOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | STI PHARMA LLC | **100MG** | **N016320** | **001** | |
| **AB** | **+!** | | **400MG** | **N016320** | **003** | |

ETHANOLAMINE OLEATE

INJECTABLE;INJECTION

ETHAMOLIN

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | QOL MEDCL | 50MG/ML | N019357 | 001 | Dec 22, 1988 |

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-28

**ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | MYLAN LABS LTD | **0.035MG;1MG** | **A204703** | **001** | Jul 28, 2016 |
| **AB** | | | **0.05MG;1MG** | **A204704** | **001** | Feb 09, 2016 |

**KELNOR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | BARR | **0.035MG;1MG** | **A076785** | **001** | May 23, 2005 |

**ZOVIA 1/35E-28**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | MAYNE PHARMA | **0.035MG;1MG** | **A072721** | **001** | Dec 30, 1991 |

**ZOVIA 1/50E-28**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **!** | WATSON LABS | **0.05MG;1MG** | **A072723** | **001** | Dec 30, 1991 |

ETHINYL ESTRADIOL; ETONOGESTREL

RING;VAGINAL

NUVARING

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ORGANON SUB MERCK | 0.015MG/24HR;0.12MG/24HR | N021187 | 001 | Oct 03, 2001 |

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

**ASHLYNA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | GLENMARK GENERICS | **0.03MG,0.01MG;0.15MG,N/A** | **A203163** | **001** | Feb 23, 2015 |

**DAYSEE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | LUPIN LTD | **0.03MG,0.01MG;0.15MG,N/A** | **A091467** | **001** | Apr 10, 2013 |

**FAYOSIM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | LUPIN LTD | **0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A** | **A205943** | **001** | Mar 29, 2016 |

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **INTROVALE** | | | | | | |
| **AB** | | LABS LEON FARMA | **0.03MG;0.15MG** | **A079064** | **001** | Sep 27, 2010 |
| **JAIMIESS** | | | | | | |
| **AB** | | LABS LEON FARMA | **0.03MG,0.01MG;0.15MG,N/A** | **A203770** | **001** | Dec 27, 2017 |
| **LEVONORGESTREL AND ETHINYL ESTRADIOL** | | | | | | |
| **AB** | | AMNEAL PHARMS | **0.03MG;0.15MG** | **A203871** | **001** | Nov 13, 2015 |
| **AB** | | | **0.03MG,0.01MG;0.15MG,N/A** | **A203872** | **001** | Dec 22, 2015 |
| **AB** | | GLENMARK GENERICS | **0.02MG;0.09MG** | **A202791** | **001** | Apr 09, 2015 |
| **AB** | | GLENMARK PHARMS LTD | **0.03MG;0.15MG** | **A203164** | **001** | Jun 12, 2015 |
| **AB** | | LUPIN LTD | **0.02MG,0.01MG;0.1MG,N/A** | **A091674** | **001** | Oct 26, 2011 |
| **AB** | | | **0.03MG;0.15MG** | **A091440** | **001** | Oct 23, 2012 |
| **AB** | | MAYNE PHARMA | **0.02MG,0.01MG;0.1MG,N/A** | **A200407** | **001** | Oct 25, 2011 |
| **AB** | | MYLAN LABS LTD | **0.03MG;0.15MG** | **A200490** | **001** | Apr 21, 2015 |
| **AB** | **!** | WATSON LABS | **0.02MG;0.09MG** | **A079218** | **001** | Jun 06, 2011 |
| **LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL** | | | | | | |
| **AB** | | LABS LEON FARMA | **0.02MG,0.01MG;0.1MG,N/A** | **A205131** | **001** | Dec 14, 2017 |
| **AB** | | MAYNE PHARMA | **0.03MG,0.01MG;0.15MG,N/A** | **A078834** | **001** | May 31, 2011 |
| **AB** | | MYLAN LABS LTD | **0.02MG,0.15MG;<br>0.025MG,0.15MG;0.03MG,0.15MG;** | **A206053** | **001** | Oct 02, 2017 |
| **AB** | | | **0.02MG,0.01MG;0.1MG,N/A** | **A200493** | **001** | Jun 17, 2015 |
| **AB** | | | **0.03MG,0.01MG;0.15MG,N/A** | **A200492** | **001** | May 27, 2015 |
| **LO SIMPESSE** | | | | | | |
| **AB** | | AUROBINDO PHARMA LTD | **0.02MG,0.01MG;0.01MG,N/A** | **A206852** | **001** | Apr 28, 2017 |
| **LOSEASONIQUE** | | | | | | |
| **AB** | | TEVA BRANDED PHARM | **0.02MG,0.01MG;0.1MG,N/A** | **N022262** | **001** | Oct 24, 2008 |
| **QUARTETTE** | | | | | | |
| **AB** | **+!** | TEVA BRANDED PHARM | **0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A** | **N204061** | **001** | Mar 28, 2013 |
| **QUASENSE** | | | | | | |
| **AB** | | WATSON LABS | **0.03MG;0.15MG** | **A077101** | **001** | Sep 06, 2006 |
| **SEASONALE** | | | | | | |
| **AB** | **+!** | TEVA BRANDED PHARM | **0.03MG;0.15MG** | **N021544** | **001** | Sep 05, 2003 |
| **SEASONIQUE** | | | | | | |
| **AB** | **+!** | TEVA BRANDED PHARM | **0.03MG,0.01MG;0.15MG,N/A** | **N021840** | **001** | May 25, 2006 |
| **SETLAKIN** | | | | | | |
| **AB** | | NOVAST LABS LTD | **0.03MG;0.15MG** | **A090716** | **001** | Sep 15, 2014 |
| **SIMPESSE** | | | | | | |
| **AB** | | AUROBINDO PHARMA LTD | **0.03MG,0.01MG;0.15MG,N/A** | **A206851** | **001** | Apr 07, 2017 |

TABLET;ORAL-28

| | | | | | | |
|---|---|---|---|---|---|---|
| **ALTAVERA** | | | | | | |
| **AB** | | LABS LEON FARMA | **0.03MG;0.15MG** | **A079102** | **001** | Aug 03, 2010 |
| **AYUNA** | | | | | | |
| **AB** | | AUROBINDO PHARMA LTD | **0.03MG;0.15MG** | **A206866** | **001** | Sep 23, 2016 |
| **ELIFEMME** | | | | | | |
| **AB** | | LABS LEON FARMA | **0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG** | **A202507** | **001** | Dec 04, 2015 |
| **ENPRESSE-28** | | | | | | |
| **AB** | | DURAMED PHARMS BARR | **0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG** | **A075809** | **002** | Jul 16, 2001 |
| **KURVELO** | | | | | | |
| **AB** | | LUPIN LTD | **0.03MG;0.15MG** | **A091408** | **001** | Oct 17, 2012 |
| **LEVONEST** | | | | | | |
| **AB** | | NOVAST LABS LTD | **0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG** | **A090719** | **001** | Dec 29, 2010 |
| **LEVONORGESTREL AND ETHINYL ESTRADIOL** | | | | | | |
| **AB** | | AMNEAL PHARMS | **0.03MG;0.15MG** | **A201095** | **001** | Dec 08, 2014 |
| **AB** | | LUPIN LTD | **0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG** | **A200248** | **001** | Nov 19, 2015 |
| **AB** | | MYLAN LABS LTD | **0.03MG;0.15MG** | **A091663** | **001** | Dec 21, 2012 |
| **LEVORA 0.15/30-28** | | | | | | |
| **AB** | **!** | MAYNE PHARMA | **0.03MG;0.15MG** | **A073594** | **001** | Dec 13, 1993 |
| **MARLISSA** | | | | | | |
| **AB** | | GLENMARK GENERICS | **0.03MG;0.15MG** | **A091452** | **001** | Feb 29, 2012 |
| **MYZILRA** | | | | | | |
| **AB** | | VINTAGE PHARMS LLC | **0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG** | **A077502** | **001** | Nov 23, 2011 |
| **PORTIA-28** | | | | | | |
| **AB** | | BARR | **0.03MG;0.15MG** | **A075866** | **002** | May 23, 2002 |

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL-28

| | | | | | | |
|---|---|---|---|---|---|---|
| **TRIVORA-28** | | | | | | |
| **AB** | **!** | MAYNE PHARMA | **0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG** | **A074538** | **002** | Dec 18, 1997 |
| **AFIRMELLE** | | | | | | |
| **AB1** | | AUROBINDO PHARMA LTD | **0.02MG;0.1MG** | **A206886** | **001** | Nov 14, 2016 |
| **AVIANE-28** | | | | | | |
| **AB1** | | DURAMED PHARMS BARR | **0.02MG;0.1MG** | **A075796** | **001** | Apr 30, 2001 |
| **FALMINA** | | | | | | |
| **AB1** | | NOVAST LABS LTD | **0.02MG;0.1MG** | **A090721** | **001** | Mar 28, 2012 |
| **LEVONORGESTREL AND ETHINYL ESTRADIOL** | | | | | | |
| **AB1** | | AMNEAL PHARMS | **0.02MG;0.1MG** | **A201108** | **001** | Feb 05, 2014 |
| **AB1** | | LUPIN LTD | **0.02MG;0.1MG** | **A091425** | **001** | Jan 18, 2013 |
| **AB1** | **!** | MAYNE PHARMA | **0.02MG;0.1MG** | **A076625** | **001** | Nov 18, 2004 |
| **AB1** | | MYLAN LABS LTD | **0.02MG;0.1MG** | **A200245** | **001** | Oct 09, 2013 |
| **ORSYTHIA** | | | | | | |
| **AB1** | | VINTAGE PHARMS LLC | **0.02MG;0.1MG** | **A077099** | **001** | May 11, 2011 |
| **VIENVA** | | | | | | |
| **AB1** | | LABS LEON FARMA | **0.02MG;0.1MG** | **A201088** | **001** | May 21, 2015 |
| **LESSINA-28** | | | | | | |
| **AB2** | | BARR | **0.02MG;0.1MG** | **A075803** | **002** | Mar 20, 2002 |
| **LEVONORGESTREL AND ETHINYL ESTRADIOL** | | | | | | |
| **AB2** | **!** | MAYNE PHARMA | **0.02MG;0.1MG** | **A077681** | **001** | May 31, 2006 |
| **AB2** | | MYLAN LABS LTD | **0.02MG;0.1MG** | **A202247** | **001** | Dec 08, 2014 |

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL

| | | | | | | |
|---|---|---|---|---|---|---|
| XULANE | | | | | | |
| | ! | MYLAN TECHNOLOGIES | 0.035MG/24HR;0.15MG/24HR | A200910 | 001 | Apr 16, 2014 |

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-21

| | | | | | | |
|---|---|---|---|---|---|---|
| **NORINYL 1+35 21-DAY** | | | | | | |
| **AB** | | ALLERGAN SALES LLC | **0.035MG;1MG** | **N017565** | **001** | |
| **NORTREL 1/35-21** | | | | | | |
| **AB** | | BARR | **0.035MG;1MG** | **A072693** | **001** | Feb 28, 1992 |
| NORTREL 7/7/7 | | | | | | |
| | | BARR | 0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG | A075478 | 001 | Aug 30, 2002 |

TABLET;ORAL-28

| | | | | | | |
|---|---|---|---|---|---|---|
| **ALYACEN 1/35** | | | | | | |
| **AB** | | GLENMARK GENERICS | **0.035MG;1MG** | **A091634** | **001** | Jan 19, 2012 |
| **ALYACEN 7/7/7** | | | | | | |
| **AB** | | GLENMARK GENERICS | **0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG** | **A091636** | **001** | Jan 19, 2012 |
| **ARANELLE** | | | | | | |
| **AB** | | BARR | **0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG** | **A076783** | **001** | Sep 29, 2004 |
| **BALZIVA-28** | | | | | | |
| **AB** | | BARR | **0.035MG;0.4MG** | **A076238** | **001** | Apr 22, 2004 |
| **BREVICON 28-DAY** | | | | | | |
| **AB** | | ALLERGAN SALES LLC | **0.035MG;0.5MG** | **N017743** | **001** | |
| **BRIELLYN** | | | | | | |
| **AB** | | GLENMARK GENERICS | **0.035MG;0.4MG** | **A090538** | **001** | Mar 22, 2011 |
| **CYCLAFEM 0.5/35** | | | | | | |
| **AB** | | VINTAGE PHARMS | **0.035MG;0.5MG** | **A203413** | **001** | Dec 16, 2015 |
| **CYCLAFEM 1/35** | | | | | | |
| **AB** | | VINTAGE PHARMS LLC | **0.035MG;1MG** | **A076337** | **001** | Nov 12, 2010 |
| **CYCLAFEM 7/7/7** | | | | | | |
| **AB** | | VINTAGE PHARMS LLC | **0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG** | **A076338** | **001** | Nov 16, 2010 |
| **CYONANZ** | | | | | | |
| **AB** | | AUROBINDO PHARMA LTD | **0.035MG;0.5MG** | **A207055** | **001** | Oct 21, 2016 |
| **DASETTA 1/35** | | | | | | |
| **AB** | | NOVAST LABS LTD | **0.035MG;1MG** | **A090948** | **001** | Dec 22, 2011 |
| **DASETTA 7/7/7** | | | | | | |
| **AB** | | NOVAST LABS LTD | **0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG** | **A090946** | **001** | Dec 22, 2011 |
| **GILDAGIA** | | | | | | |
| **AB** | | VINTAGE PHARMS | **0.035MG;0.4MG** | **A078376** | **001** | Nov 06, 2012 |
| **MODICON 28** | | | | | | |
| **AB** | **+!** | JANSSEN PHARMS | **0.035MG;0.5MG** | **N017735** | **001** | |

| | | | | | | |
|---|---|---|---|---|---|---|
| ETHINYL ESTRADIOL; NORETHINDRONE | | | | | | |
| TABLET;ORAL-28 | | | | | | |
| **NORETHINDRONE AND ETHINYL ESTRADIOL** | | | | | | |
| **AB** | | ACCORD HLTHCARE | **0.035MG;1MG** | **A206864** | **001** | Apr 28, 2017 |
| **AB** | | MAYNE PHARMA | **0.035MG;0.5MG** | **A070686** | **001** | Jan 29, 1987 |
| **AB** | ! | MYLAN LABS LTD | **0.035MG;0.4MG** | **A200897** | **001** | May 11, 2015 |
| **AB** | | WATSON LABS | **0.035MG;0.4MG** | **A078323** | **001** | Feb 04, 2010 |
| **AB** | | WATSON LABS TEVA | **0.035MG;1MG** | **A070687** | **001** | Jan 29, 1987 |
| **NORINYL 1+35 28-DAY** | | | | | | |
| **AB** | | ALLERGAN SALES LLC | **0.035MG;1MG** | **N017565** | **002** | |
| **NORTREL 0.5/35-28** | | | | | | |
| **AB** | | BARR | **0.035MG;0.5MG** | **A072695** | **001** | Feb 28, 1992 |
| **NORTREL 1/35-28** | | | | | | |
| **AB** | | BARR | **0.035MG;1MG** | **A072696** | **001** | Feb 28, 1992 |
| **NORTREL 7/7/7** | | | | | | |
| **AB** | | BARR | **0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG** | **A075478** | **002** | Aug 30, 2002 |
| **NYLIA 1/35** | | | | | | |
| **AB** | | AUROBINDO PHARMA LTD | **0.035MG;1MG** | **A207056** | **001** | Oct 21, 2016 |
| **NYLIA 7/7/7** | | | | | | |
| **AB** | | AUROBINDO PHARMA LTD | **0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG** | **A207054** | **001** | Oct 21, 2016 |
| **ORTHO-NOVUM 1/35-28** | | | | | | |
| **AB** | **+!** | JANSSEN PHARMS | **0.035MG;1MG** | **N017919** | **002** | |
| **ORTHO-NOVUM 7/7/7-28** | | | | | | |
| **AB** | **+!** | JANSSEN PHARMS | **0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG** | **N018985** | **002** | Apr 04, 1984 |
| **PHILITH** | | | | | | |
| **AB** | | NOVAST LABS LTD | **0.035MG;0.4MG** | **A090947** | **001** | Dec 22, 2011 |
| **PIRMELLA 1/35** | | | | | | |
| **AB** | | LUPIN LTD | **0.035MG;1MG** | **A201512** | **001** | Apr 24, 2013 |
| **PIRMELLA 7/7/7** | | | | | | |
| **AB** | | LUPIN LTD | **0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG** | **A201510** | **001** | Apr 24, 2013 |
| **TRI-NORINYL 28-DAY** | | | | | | |
| **AB** | **+!** | MAYNE PHARMA | **0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG** | **N018977** | **002** | Apr 13, 1984 |
| **VYFEMLA** | | | | | | |
| **AB** | | LUPIN LTD | **0.035MG;0.4MG** | **A201886** | **001** | Sep 26, 2013 |
| **WERA** | | | | | | |
| **AB** | | NOVAST LABS LTD | **0.035MG;0.5MG** | **A091204** | **001** | Mar 27, 2012 |
| NORETHINDRONE AND ETHINYL ESTRADIOL | | | | | | |
| | ! | MYLAN LABS LTD | 0.05MG;1MG | A203006 | 001 | Aug 05, 2013 |
| NORETHINDRONE AND ETHINYL ESTRADIOL (10/11) | | | | | | |
| | | WATSON LABS TEVA | 0.035MG,0.035MG;0.5MG,1MG | A071044 | 001 | Apr 01, 1988 |
| TABLET, CHEWABLE;ORAL | | | | | | |
| **FEMCON FE** | | | | | | |
| **AB** | **+!** | APIL | **0.035MG;0.4MG** | **N021490** | **001** | Nov 14, 2003 |
| **KAITLIB FE** | | | | | | |
| **AB** | | LUPIN LTD | **0.025MG;0.8MG** | **A203448** | **001** | Dec 17, 2015 |
| **NEXESTA FE** | | | | | | |
| **AB** | | AUROBINDO PHARMA LTD | **0.035MG;0.4MG** | **A207535** | **001** | Feb 02, 2017 |
| **NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE** | | | | | | |
| **AB** | | ACCORD HLTHCARE | **0.035MG;0.4MG** | **A207066** | **001** | Mar 29, 2017 |
| **AB** | | AMNEAL PHARMS | **0.035MG;0.4MG** | **A078892** | **001** | Sep 26, 2011 |
| **AB** | **+!** | APIL | **0.025MG;0.8MG** | **N022573** | **001** | Dec 22, 2010 |
| **AB** | | BARR | **0.035MG;0.4MG** | **A078965** | **001** | Aug 05, 2010 |
| **AB** | | LUPIN LTD | **0.035MG;0.4MG** | **A091332** | **001** | Mar 23, 2016 |
| **AB** | | MYLAN LABS LTD | **0.025MG;0.8MG** | **A203371** | **001** | Apr 23, 2014 |
| **AB** | | | **0.035MG;0.4MG** | **A202086** | **001** | Apr 01, 2015 |
| ETHINYL ESTRADIOL; NORETHINDRONE ACETATE | | | | | | |
| CAPSULE;ORAL | | | | | | |
| TAYTULLA | | | | | | |
| | +! | APIL | 0.02MG;1MG | N204426 | 001 | Apr 19, 2013 |
| TABLET;ORAL | | | | | | |
| **AUROVELA 24 FE** | | | | | | |
| **AB** | | AUROBINDO PHARMA LTD | **0.02MG;1MG** | **A207504** | **001** | Jun 15, 2017 |
| **BLISOVI 24 FE** | | | | | | |
| **AB** | | LUPIN LTD | **0.02MG;1MG** | **A091398** | **001** | Oct 28, 2015 |
| **FEMHRT** | | | | | | |
| **AB** | | APIL | **0.0025MG;0.5MG** | **N021065** | **001** | Jan 14, 2005 |

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| | **FYAVOLV** | | | | | |
| **AB** | LUPIN LTD | **0.005MG;1MG** | **A204213** | **002** | Dec 10, 2015 | |
| **AB** | | **0.0025MG;0.5MG** | **A204213** | **001** | Dec 10, 2015 | |
| | **GILDESS 24 FE** | | | | | |
| **AB** | VINTAGE PHARMS | **0.02MG;1MG** | **A090293** | **001** | Dec 01, 2014 | |
| | **LARIN 24 FE** | | | | | |
| **AB** | NOVAST LABS LTD | **0.02MG;1MG** | **A202994** | **001** | Feb 18, 2015 | |
| | **LERIBANE** | | | | | |
| **AB** | NOVAST LABS LTD | **0.0025MG;0.5MG** | **A203435** | **002** | Jun 03, 2016 | |
| **AB** | | **0.005MG;1MG** | **A203435** | **001** | Jun 03, 2016 | |
| | **LO LOESTRIN FE** | | | | | |
| **AB** | **+!** APIL | **0.01MG,0.01MG;1MG,N/A** | **N022501** | **001** | Oct 21, 2010 | |
| | **LOESTRIN 24 FE** | | | | | |
| **AB** | **+** APIL | **0.02MG;1MG** | **N021871** | **001** | Feb 17, 2006 | |
| | **NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL** | | | | | |
| **AB** | **!** BARR LABS INC | **0.005MG;1MG** | **A076221** | **001** | Nov 06, 2009 | |
| **AB** | GLENMARK GENERICS | **0.0025MG;0.5MG** | **A203038** | **001** | Apr 02, 2015 | |
| **AB** | | **0.005MG;1MG** | **A203038** | **002** | Apr 02, 2015 | |
| **AB** | MYLAN LABS LTD | **0.0025MG;0.5MG** | **A207260** | **001** | Feb 02, 2017 | |
| **AB** | | **0.005MG;1MG** | **A207259** | **001** | Dec 27, 2016 | |
| | **NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE** | | | | | |
| **AB** | MYLAN LABS LTD | **0.01MG,0.01MG;1MG,N/A** | **A205049** | **001** | May 31, 2016 | |
| | **NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE** | | | | | |
| **AB** | **!** AMNEAL PHARMS | **0.02MG;1MG** | **A078267** | **001** | Sep 01, 2009 | |
| **AB** | BARR LABS INC | **0.02MG;1MG** | **A090938** | **001** | Dec 01, 2014 | |
| **AB** | GLENMARK PHARMS LTD | **0.02MG;1MG** | **A204847** | **001** | Nov 17, 2017 | |
| **AB** | MYLAN LABS LTD | **0.02MG;1MG** | **A202742** | **001** | Oct 30, 2014 | |

TABLET;ORAL-21

| | | | | | | |
|---|---|---|---|---|---|---|
| | **AUROVELA 1.5/30** | | | | | |
| **AB** | AUROBINDO PHARMA LTD | **0.03MG;1.5MG** | **A207581** | **001** | Jun 26, 2017 | |
| | **AUROVELA 1/20** | | | | | |
| **AB** | AUROBINDO PHARMA LTD | **0.02MG;1MG** | **A207506** | **001** | Jun 16, 2017 | |
| | **GILDESS 1.5/30** | | | | | |
| **AB** | VINTAGE PHARMS LLC | **0.03MG;1.5MG** | **A077075** | **002** | Jul 24, 2012 | |
| | **GILDESS 1/20** | | | | | |
| **AB** | VINTAGE PHARMS LLC | **0.02MG;1MG** | **A077077** | **002** | Jul 24, 2012 | |
| | **JUNEL 1.5/30** | | | | | |
| **AB** | BARR | **0.03MG;1.5MG** | **A076381** | **001** | May 30, 2003 | |
| | **JUNEL 1/20** | | | | | |
| **AB** | BARR | **0.02MG;1MG** | **A076380** | **001** | May 30, 2003 | |
| | **LARIN 1.5/30** | | | | | |
| **AB** | NOVAST LABS LTD | **0.03MG;1.5MG** | **A202996** | **001** | Mar 20, 2014 | |
| | **LARIN 1/20** | | | | | |
| **AB** | NOVAST LABS LTD | **0.02MG;1MG** | **A202995** | **001** | Dec 04, 2013 | |
| | **LOESTRIN 21 1.5/30** | | | | | |
| **AB** | APIL | **0.03MG;1.5MG** | **N017875** | **001** | | |
| | **LOESTRIN 21 1/20** | | | | | |
| **AB** | APIL | **0.02MG;1MG** | **N017876** | **001** | | |
| | **MICROGESTIN 1.5/30** | | | | | |
| **AB** | MAYNE PHARMA | **0.03MG;1.5MG** | **A075548** | **002** | Jul 30, 2003 | |
| | **MICROGESTIN 1/20** | | | | | |
| **AB** | MAYNE PHARMA | **0.02MG;1MG** | **A075647** | **002** | Jul 30, 2003 | |
| | **NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL** | | | | | |
| **AB** | GLENMARK PHARMS LTD | **0.02MG;1MG** | **A206969** | **001** | Jan 20, 2016 | |
| **AB** | MYLAN LABS LTD | **0.02MG;1MG** | **A202771** | **001** | Nov 06, 2013 | |
| **AB** | | **0.03MG;1.5MG** | **A202770** | **001** | Feb 19, 2015 | |
| | TRI-LEGEST 21 | | | | | |
| | BARR | 0.02MG,0.03MG,0.035MG;1MG,1MG,1MG | A076405 | 001 | Oct 26, 2007 | |

TABLET;ORAL-28

| | | | | | | |
|---|---|---|---|---|---|---|
| | **AUROVELA FE 1.5/30** | | | | | |
| **AB** | AUROBINDO PHARMA LTD | **0.03MG;1.5MG** | **A207580** | **001** | Jun 15, 2017 | |
| | **AUROVELA FE 1/20** | | | | | |
| **AB** | AUROBINDO PHARMA LTD | **0.02MG;1MG** | **A207505** | **001** | Jun 16, 2017 | |
| | **BLISOVI FE 1.5/30** | | | | | |
| **AB** | LUPIN LTD | **0.03MG;1.5MG** | **A201585** | **001** | Nov 18, 2015 | |
| | **BLISOVI FE 1/20** | | | | | |
| **AB** | LUPIN LTD | **0.02MG;1MG** | **A201584** | **001** | Nov 18, 2015 | |

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL-28

**ESTROSTEP FE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | APIL | **0.02MG,0.03MG,0.035MG;1MG,1MG,1MG** | **N020130** | **002** | Oct 09, 1996 |

**GILDESS FE 1.5/30**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | VINTAGE PHARMS LLC | **0.03MG;1.5MG** | **A077075** | **001** | Apr 28, 2005 |

**GILDESS FE 1/20**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | VINTAGE PHARMS LLC | **0.02MG;1MG** | **A077077** | **001** | May 20, 2005 |

**HAILEY FE 1/20**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | GLENMARK PHARMS LTD | **0.02MG;1MG** | **A206597** | **001** | Nov 21, 2017 |

**JUNEL FE 1.5/30**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | BARR | **0.03MG;1.5MG** | **A076064** | **001** | Sep 18, 2003 |

**JUNEL FE 1/20**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | BARR | **0.02MG;1MG** | **A076081** | **001** | Sep 18, 2003 |

**LARIN FE 1.5/30**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | NOVAST LABS LTD | **0.03MG;1.5MG** | **A091453** | **001** | Aug 23, 2013 |

**LARIN FE 1/20**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | NOVAST LABS LTD | **0.02MG;1MG** | **A091454** | **001** | Aug 26, 2013 |

**LOESTRIN FE 1.5/30**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | APIL | **0.03MG;1.5MG** | **N017355** | **001** | |

**LOESTRIN FE 1/20**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | APIL | **0.02MG;1MG** | **N017354** | **001** | |

**MICROGESTIN FE 1.5/30**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | MAYNE PHARMA | **0.03MG;1.5MG** | **A075548** | **001** | Feb 05, 2001 |

**MICROGESTIN FE 1/20**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | MAYNE PHARMA | **0.02MG;1MG** | **A075647** | **001** | Feb 05, 2001 |

**NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | MAYNE PHARMA | **0.02MG,0.03MG,0.035MG;1MG,1MG,1MG** | **A076629** | **001** | Mar 18, 2010 |
| **AB** | | MYLAN LABS LTD | **0.02MG;1MG** | **A202772** | **001** | Nov 14, 2013 |
| **AB** | | | **0.03MG;1.5MG** | **A202741** | **001** | Feb 20, 2015 |

**TRI-LEGEST FE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | BARR | **0.02MG,0.03MG,0.035MG;1MG,1MG,1MG** | **A076105** | **001** | Oct 26, 2007 |

TABLET, CHEWABLE;ORAL

**MIBELAS 24 FE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | LUPIN ATLANTIS | **0.02MG;1MG** | **A206287** | **001** | May 24, 2016 |

**MINASTRIN 24 FE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | APIL | **0.02MG;1MG** | **N203667** | **001** | May 08, 2013 |

**NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AMNEAL PHARMS | **0.02MG;1MG** | **A207514** | **001** | Sep 11, 2017 |
| **AB** | | GLENMARK PHARMS LTD | **0.02MG;1MG** | **A210369** | **001** | Dec 26, 2017 |
| **AB** | | MYLAN LABS LTD | **0.02MG;1MG** | **A206120** | **001** | Sep 12, 2017 |

TABLET, CHEWABLE, TABLET;ORAL

LO MINASTRIN FE

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | APIL | 0.01MG,0.01MG,N/A;1MG,N/A,N/A | N204654 | 001 | Jul 24, 2013 |

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL

**NORGESTIMATE AND ETHINYL ESTRADIOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | GLENMARK GENERICS | **0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG** | **A200494** | **001** | Jun 17, 2011 |

TABLET;ORAL-28

**ESTARYLLA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | LABS LEON FARMA | **0.035MG;0.25MG** | **A090794** | **001** | Jan 30, 2013 |

**MILI**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AUROBINDO PHARMA LTD | **0.035MG;0.25MG** | **A205449** | **001** | Jul 07, 2016 |

**MONO-LINYAH**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | NOVAST LABS LTD | **0.035MG;0.25MG** | **A090523** | **001** | May 23, 2012 |

**NORGESTIMATE AND ETHINYL ESTRADIOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AMNEAL PHARMS | **0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG** | **A203870** | **001** | Nov 12, 2015 |
| **AB** | | | **0.035MG;0.25MG** | **A203865** | **001** | Oct 27, 2015 |
| **AB** | | | **0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG** | **A203873** | **001** | May 12, 2016 |
| **AB** | | GLENMARK GENERICS | **0.035MG;0.25MG** | **A200538** | **001** | Apr 05, 2012 |
| **AB** | | GLENMARK PHARMS | **0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG** | **A204057** | **001** | Feb 23, 2016 |
| **AB** | | LUPIN LTD | **0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG** | **A205588** | **001** | Apr 26, 2016 |
| **AB** | | | **0.035MG;0.25MG** | **A205630** | **001** | Oct 27, 2016 |
| **AB** | | LUPIN PHARMS | **0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG** | **A200541** | **001** | Jun 25, 2012 |
| **AB** | | MYLAN LABS LTD | **0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG** | **A202132** | **001** | Sep 09, 2015 |

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET;ORAL-28

**NORGESTIMATE AND ETHINYL ESTRADIOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG** | **A201897** | **001** | Jan 27, 2016 |
| **AB** | | | **0.035MG;0.25MG** | **A201896** | **001** | Jan 27, 2016 |
| **AB** | | OC PHARMA | **0.035MG;0.035MG;0.035MG;0.18MG;0.215MG; 0.25MG** | **A200383** | **001** | Apr 07, 2015 |
| **AB** | | | **0.035MG;0.25MG** | **A200384** | **001** | Apr 07, 2015 |

**ORTHO CYCLEN-28**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | JANSSEN PHARMS | **0.035MG;0.25MG** | **N019653** | **002** | Dec 29, 1989 |

**ORTHO TRI-CYCLEN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | JANSSEN PHARMS | **0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG** | **N019697** | **001** | Jul 03, 1992 |

**ORTHO TRI-CYCLEN LO**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | JANSSEN PHARMS | **0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG** | **N021241** | **001** | Aug 22, 2002 |

**PREVIFEM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | VINTAGE PHARMS LLC | **0.035MG;0.25MG** | **A076334** | **001** | Jan 09, 2004 |

**SPRINTEC**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | BARR | **0.035MG;0.25MG** | **A075804** | **001** | Sep 25, 2002 |

**TRI LO SPRINTEC**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | BARR LABS INC | **0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG** | **A076784** | **001** | Jun 29, 2009 |

**TRI-ESTARYLLA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | LABS LEON FARMA | **0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG** | **A090793** | **001** | Jan 30, 2013 |

**TRI-LINYAH**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | NOVAST LABS LTD | **0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG** | **A090524** | **001** | May 30, 2012 |

**TRI-LO-ESTARYLLA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | LABS LEON FARMA | **0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG** | **A091232** | **001** | Jun 29, 2015 |

**TRI-LO-MILI**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AUROBINDO PHARMA LTD | **0.025MG,0.025MG,0.025MG;0.18MG,0.215MG, 0.25MG** | **A205762** | **001** | Nov 04, 2016 |

**TRI-MILI**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AUROBINDO PHARMA LTD | **0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG** | **A205441** | **001** | Jul 06, 2016 |

**TRI-PREVIFEM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | VINTAGE PHARMS LLC | **0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG** | **A076335** | **001** | Mar 26, 2004 |

**TRI-SPRINTEC**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | BARR | **0.035MG,0.035MG,0.035MG;0.18MG,0.215MG, 0.25MG** | **A075808** | **001** | Dec 29, 2003 |

ETHINYL ESTRADIOL; NORGESTREL

TABLET;ORAL-21

**CRYSELLE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | DURAMED PHARMS BARR | **0.03MG;0.3MG** | **A075840** | **001** | Nov 30, 2001 |

TABLET;ORAL-28

**CRYSELLE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | DURAMED PHARMS BARR | **0.03MG;0.3MG** | **A075840** | **002** | Nov 30, 2001 |

**ELINEST**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | NOVAST LABS LTD | **0.03MG;0.3MG** | **A091105** | **001** | Mar 28, 2012 |

**LOW-OGESTREL-28**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | MAYNE PHARMA | **0.03MG;0.3MG** | **A075288** | **002** | Jul 28, 1999 |

OGESTREL 0.5/50-28

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | WATSON LABS | 0.05MG;0.5MG | A075406 | 002 | Dec 15, 1999 |

ETHIODIZED OIL

OIL;INTRALYMPHATIC, INTRAUTERINE

LIPIODOL

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | GUERBET | EQ 4.8GM IODINE/10ML (EQ 480MG IODINE/ML) | N009190 | 001 | |

ETHIONAMIDE

TABLET;ORAL

TRECATOR

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | WYETH PHARMS INC | 250MG | N013026 | 002 | |

ETHOSUXIMIDE

CAPSULE;ORAL

**ETHOSUXIMIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AKORN | **250MG** | **A040686** | **001** | May 28, 2008 |
| **AB** | | BIONPHARMA INC | **250MG** | **A040430** | **001** | Oct 28, 2002 |
| **AB** | | HERITAGE PHARMS INC | **250MG** | **A200892** | **001** | Sep 25, 2012 |

**ZARONTIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | PARKE DAVIS | **250MG** | **N012380** | **001** | |

SYRUP;ORAL

**ETHOSUXIMIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | MIKART | **250MG/5ML** | **A040506** | **001** | Dec 22, 2003 |
| **AA** | | PHARM ASSOC | **250MG/5ML** | **A040253** | **001** | Nov 22, 2000 |
| **AA** | | TEVA PHARMS | **250MG/5ML** | **A081306** | **001** | Jul 30, 1993 |

**ZARONTIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **!** | PARKE-DAVIS | **250MG/5ML** | **A080258** | **001** | |

ETHOTOIN

TABLET;ORAL

PEGANONE

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | RECORDATI RARE | 250MG | N010841 | 001 | |

ETIDRONATE DISODIUM

TABLET;ORAL

ETIDRONATE DISODIUM

| | | | | | | |
|---|---|---|---|---|---|---|
| | | MYLAN | 200MG | A075800 | 001 | Jan 24, 2003 |
| | ! | | 400MG | A075800 | 002 | Jan 24, 2003 |

ETODOLAC

CAPSULE;ORAL

**ETODOLAC**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ANI PHARMS INC | **200MG** | **A075126** | **001** | Sep 16, 1999 |
| **AB** | | | **300MG** | **A075126** | **002** | Sep 16, 1999 |
| **AB** | | APOTEX | **200MG** | **A075419** | **001** | Jul 28, 2000 |
| **AB** | | | **300MG** | **A075419** | **002** | Jul 28, 2000 |
| **AB** | | TARO | **200MG** | **A075078** | **001** | Apr 30, 1998 |
| **AB** | **!** | | **300MG** | **A075078** | **002** | Apr 30, 1998 |

TABLET;ORAL

**ETODOLAC**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | APOTEX INC | **400MG** | **A076004** | **001** | Dec 03, 2002 |
| **AB** | | | **500MG** | **A076004** | **002** | Dec 03, 2002 |
| **AB** | | SANDOZ | **400MG** | **A074903** | **001** | Apr 11, 1997 |
| **AB** | | | **500MG** | **A074903** | **002** | Apr 19, 1999 |
| **AB** | | TARO PHARM INDS | **400MG** | **A075074** | **001** | Mar 11, 1998 |
| **AB** | **!** | | **500MG** | **A075074** | **002** | Apr 25, 2000 |
| **AB** | | TEVA | **400MG** | **A075009** | **001** | Nov 26, 1997 |
| **AB** | | | **500MG** | **A075009** | **002** | Dec 28, 1999 |

TABLET, EXTENDED RELEASE;ORAL

**ETODOLAC**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | TARO | **400MG** | **A076174** | **001** | Mar 13, 2003 |
| **AB** | | | **500MG** | **A076174** | **002** | Mar 13, 2003 |
| **AB** | | | **600MG** | **A076174** | **003** | Mar 13, 2003 |
| **AB** | | TEVA | **400MG** | **A075665** | **003** | Feb 05, 2001 |
| **AB** | | | **500MG** | **A075665** | **002** | Jul 31, 2000 |
| **AB** | **!** | | **600MG** | **A075665** | **001** | Jul 31, 2000 |
| **AB** | | ZYDUS PHARMS USA INC | **400MG** | **A091134** | **001** | Jan 23, 2014 |
| **AB** | | | **500MG** | **A091134** | **002** | Jan 23, 2014 |
| **AB** | | | **600MG** | **A091134** | **003** | Jan 23, 2014 |

ETOMIDATE

INJECTABLE;INJECTION

**AMIDATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | HOSPIRA | **2MG/ML** | **N018227** | **001** | Sep 07, 1982 |

**ETOMIDATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AUROBINDO PHARMA LTD | **2MG/ML** | **A206126** | **001** | Feb 24, 2017 |
| **AP** | | EMCURE PHARMS LTD | **2MG/ML** | **A204618** | **001** | Aug 13, 2014 |
| **AP** | | GLAND PHARMA LTD | **2MG/ML** | **A209058** | **001** | Apr 18, 2017 |
| **AP** | | HIKMA FARMACEUTICA | **2MG/ML** | **A202354** | **001** | Feb 25, 2016 |
| **AP** | | LUITPOLD | **2MG/ML** | **A078867** | **001** | Dec 22, 2009 |
| **AP** | | MYLAN LABS LTD | **2MG/ML** | **A078289** | **001** | Jan 02, 2009 |
| **AP** | | | **2MG/ML** | **A201044** | **001** | Feb 07, 2017 |
| **AP** | | PAR STERILE PRODUCTS | **2MG/ML** | **A091297** | **001** | Jun 20, 2012 |
| **AP** | | WEST-WARD PHARMS | **2MG/ML** | **A074593** | **001** | Nov 04, 1996 |

| | | | | | | |
|---|---|---|---|---|---|---|
| ETOMIDATE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| **ETOMIDATE** | | | | | | |
| | | INT | | | | |
| **AP** | | ZYDUS PHARMS USA INC | **2MG/ML** | **A202360** | **001** | Jul 18, 2014 |
| ETONOGESTREL | | | | | | |
| IMPLANT;IMPLANTATION | | | | | | |
| NEXPLANON | | | | | | |
| | +! | ORGANON USA INC | 68MG/IMPLANT | N021529 | 002 | May 31, 2011 |
| ETOPOSIDE | | | | | | |
| CAPSULE;ORAL | | | | | | |
| ETOPOSIDE | | | | | | |
| | ! | MYLAN | 50MG | A075635 | 001 | Sep 19, 2001 |
| INJECTABLE;INJECTION | | | | | | |
| **ETOPOSIDE** | | | | | | |
| **AP** | | ACCORD HLTHCARE | **20MG/ML** | **A074513** | **001** | Mar 14, 1996 |
| **AP** | **!** | FRESENIUS KABI USA | **20MG/ML** | **A074983** | **001** | Sep 30, 1998 |
| **AP** | | MYLAN LABS LTD | **20MG/ML** | **A203507** | **001** | Nov 20, 2017 |
| **AP** | | | **20MG/ML** | **A204927** | **001** | Oct 31, 2017 |
| **AP** | | TEVA PHARMS USA | **20MG/ML** | **A074529** | **001** | Jul 24, 1996 |
| **AP** | | WEST-WARD PHARMS INT | **20MG/ML** | **A074290** | **001** | Jul 17, 1995 |
| ETOPOSIDE PHOSPHATE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| ETOPOPHOS PRESERVATIVE FREE | | | | | | |
| | +! | BRISTOL MYERS SQUIBB | EQ 100MG BASE/VIAL | N020457 | 001 | May 17, 1996 |
| ETRAVIRINE | | | | | | |
| TABLET;ORAL | | | | | | |
| INTELENCE | | | | | | |
| | + | JANSSEN R AND D | 25MG | N022187 | 003 | Mar 26, 2012 |
| | + | | 100MG | N022187 | 001 | Jan 18, 2008 |
| | +! | | 200MG | N022187 | 002 | Dec 22, 2010 |
| EVEROLIMUS | | | | | | |
| TABLET;ORAL | | | | | | |
| AFINITOR | | | | | | |
| | + | NOVARTIS | 2.5MG | N022334 | 003 | Jul 09, 2010 |
| | + | | 5MG | N022334 | 001 | Mar 30, 2009 |
| | + | | 7.5MG | N022334 | 004 | Mar 30, 2012 |
| | +! | | 10MG | N022334 | 002 | Mar 30, 2009 |
| ZORTRESS | | | | | | |
| | + | NOVARTIS | 0.25MG | N021560 | 001 | Apr 20, 2010 |
| | + | | 0.5MG | N021560 | 002 | Apr 20, 2010 |
| | +! | | 0.75MG | N021560 | 003 | Apr 20, 2010 |
| TABLET, FOR SUSPENSION;ORAL | | | | | | |
| AFINITOR DISPERZ | | | | | | |
| | + | NOVARTIS PHARM | 2MG | N203985 | 001 | Aug 29, 2012 |
| | + | | 3MG | N203985 | 002 | Aug 29, 2012 |
| | +! | | 5MG | N203985 | 003 | Aug 29, 2012 |
| EXEMESTANE | | | | | | |
| TABLET;ORAL | | | | | | |
| **AROMASIN** | | | | | | |
| **AB** | **+!** | PHARMACIA AND UPJOHN | **25MG** | **N020753** | **001** | Oct 21, 1999 |
| **EXEMESTANE** | | | | | | |
| **AB** | | ALVOGEN MALTA | **25MG** | **A200898** | **001** | Jul 28, 2014 |
| **AB** | | MYLAN PHARMS INC | **25MG** | **A203315** | **001** | Mar 10, 2017 |
| **AB** | | UPSHER-SMITH LABS | **25MG** | **A209208** | **001** | Jul 26, 2017 |
| **AB** | | WEST-WARD PHARMS INT | **25MG** | **A077431** | **001** | Apr 01, 2011 |
| EXENATIDE | | | | | | |
| SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | | | | | | |
| BYDUREON BCISE | | | | | | |
| | +! | ASTRAZENECA AB | 2MG/0.85ML (2MG/0.85ML) | N209210 | 001 | Oct 20, 2017 |

EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

BYDUREON

| | | | | | |
|---|---|---|---|---|---|
| +! | ASTRAZENECA AB | 2MG/VIAL | N022200 | 001 | Jan 27, 2012 |

BYDUREON PEN

| | | | | | |
|---|---|---|---|---|---|
| +! | ASTRAZENECA AB | 2MG | N022200 | 002 | Feb 28, 2014 |

INJECTABLE;SUBCUTANEOUS

BYETTA

| | | | | | |
|---|---|---|---|---|---|
| +! | ASTRAZENECA AB | 300MCG/1.2ML (250MCG/ML) | N021773 | 001 | Apr 28, 2005 |
| +! | | 600MCG/2.4ML (250MCG/ML) | N021773 | 002 | Apr 28, 2005 |

EZETIMIBE

TABLET;ORAL

**EZETIMIBE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALKEM LABS LTD | **10MG** | **A209234** | **001** | Dec 21, 2017 |
| **AB** | | AMNEAL PHARMS CO | **10MG** | **A208803** | **001** | Jun 12, 2017 |
| **AB** | | APOTEX INC | **10MG** | **A208332** | **001** | Jun 12, 2017 |
| **AB** | | AUROBINDO PHARMA LTD | **10MG** | **A209838** | **001** | Aug 25, 2017 |
| **AB** | | GLENMARK PHARMS LTD | **10MG** | **A078560** | **001** | Jun 26, 2015 |
| **AB** | | OHM LABS INC | **10MG** | **A207311** | **001** | Jun 12, 2017 |
| **AB** | | SANDOZ INC | **10MG** | **A203931** | **001** | Jun 12, 2017 |
| **AB** | | TEVA PHARMS USA | **10MG** | **A078724** | **001** | Jun 12, 2017 |
| **AB** | | WATSON LABS INC | **10MG** | **A200831** | **001** | Jun 12, 2017 |
| **AB** | | ZYDUS PHARMS USA INC | **10MG** | **A204331** | **001** | Jun 12, 2017 |

**ZETIA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | MSD INTL GMBH | **10MG** | **N021445** | **001** | Oct 25, 2002 |

EZETIMIBE; SIMVASTATIN

TABLET;ORAL

**EZETIMIBE AND SIMVASTATIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALKEM LABS LTD | **10MG;10MG** | **A209222** | **001** | Dec 22, 2017 |
| **AB** | | | **10MG;20MG** | **A209222** | **002** | Dec 22, 2017 |
| **AB** | | | **10MG;40MG** | **A209222** | **003** | Dec 22, 2017 |
| **AB** | | | **10MG;80MG** | **A209222** | **004** | Dec 22, 2017 |
| **AB** | | AMNEAL PHARMS CO | **10MG;10MG** | **A208831** | **001** | Nov 21, 2017 |
| **AB** | | | **10MG;20MG** | **A208831** | **002** | Nov 21, 2017 |
| **AB** | | | **10MG;40MG** | **A208831** | **003** | Nov 21, 2017 |
| **AB** | | | **10MG;80MG** | **A208831** | **004** | Nov 21, 2017 |
| **AB** | | DR REDDYS LABS SA | **10MG;10MG** | **A200909** | **001** | Apr 26, 2017 |
| **AB** | | | **10MG;20MG** | **A200909** | **002** | Apr 26, 2017 |
| **AB** | | | **10MG;40MG** | **A200909** | **003** | Apr 26, 2017 |
| **AB** | | | **10MG;80MG** | **A200909** | **004** | Apr 26, 2017 |
| **AB** | | IMPAX LABS INC | **10MG;10MG** | **A201890** | **001** | Apr 26, 2017 |
| **AB** | | | **10MG;20MG** | **A201890** | **002** | Apr 26, 2017 |
| **AB** | | | **10MG;40MG** | **A201890** | **003** | Apr 26, 2017 |
| **AB** | | | **10MG;80MG** | **A201890** | **004** | Apr 26, 2017 |
| **AB** | | WATSON LABS INC | **10MG;10MG** | **A202968** | **001** | Apr 26, 2017 |
| **AB** | | | **10MG;20MG** | **A202968** | **002** | Apr 26, 2017 |
| **AB** | | | **10MG;40MG** | **A202968** | **003** | Apr 26, 2017 |
| **AB** | | | **10MG;80MG** | **A202968** | **004** | Apr 26, 2017 |

**VYTORIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | MSD INTL | **10MG;10MG** | **N021687** | **001** | Jul 23, 2004 |
| **AB** | **+** | | **10MG;20MG** | **N021687** | **002** | Jul 23, 2004 |
| **AB** | **+** | | **10MG;40MG** | **N021687** | **003** | Jul 23, 2004 |
| **AB** | **+!** | | **10MG;80MG** | **N021687** | **004** | Jul 23, 2004 |

FAMCICLOVIR

TABLET;ORAL

**FAMCICLOVIR**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | APOTEX | **125MG** | **A091480** | **001** | Jul 22, 2011 |
| **AB** | | **250MG** | **A091480** | **002** | Jul 22, 2011 |
| **AB** | | **500MG** | **A091480** | **003** | Jul 22, 2011 |
| **AB** | AUROBINDO PHARMA LTD | **125MG** | **A091114** | **001** | Mar 21, 2011 |
| **AB** | | **250MG** | **A091114** | **002** | Mar 21, 2011 |
| **AB** | | **500MG** | **A091114** | **003** | Mar 21, 2011 |
| **AB** | CIPLA LTD | **125MG** | **A078278** | **001** | Mar 21, 2011 |
| **AB** | | **250MG** | **A078278** | **002** | Mar 21, 2011 |
| **AB** | | **500MG** | **A078278** | **003** | Mar 21, 2011 |
| **AB** | HETERO LABS LTD V | **125MG** | **A202438** | **001** | Sep 10, 2014 |
| **AB** | | **250MG** | **A202438** | **002** | Sep 10, 2014 |
| **AB** | | **500MG** | **A202438** | **003** | Sep 10, 2014 |

FAMCICLOVIR

TABLET;ORAL

**FAMCICLOVIR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | MACLEODS PHARMS LTD | **125MG** | **A201022** | **001** | Jan 12, 2012 |
| **AB** | | | **250MG** | **A201022** | **002** | Jan 12, 2012 |
| **AB** | | | **500MG** | **A201022** | **003** | Jan 12, 2012 |
| **AB** | | MYLAN | **125MG** | **A201333** | **001** | Mar 24, 2011 |
| **AB** | | | **250MG** | **A201333** | **002** | Mar 24, 2011 |
| **AB** | | | **500MG** | **A201333** | **003** | Mar 24, 2011 |
| **AB** | | TEVA PHARMS | **125MG** | **A077487** | **001** | Aug 24, 2007 |
| **AB** | | | **250MG** | **A077487** | **002** | Aug 24, 2007 |
| **AB** | **!** | | **500MG** | **A077487** | **003** | Aug 24, 2007 |
| **AB** | | WEST-WARD PHARMS INT | **125MG** | **A090128** | **001** | Mar 21, 2011 |
| **AB** | | | **250MG** | **A090128** | **002** | Mar 21, 2011 |
| **AB** | | | **500MG** | **A090128** | **003** | Mar 21, 2011 |

FAMOTIDINE

FOR SUSPENSION;ORAL

**FAMOTIDINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | HI-TECH PHARMA CO | **40MG/5ML** | **A201995** | **001** | May 30, 2014 |
| **AB** | | LUPIN LTD | **40MG/5ML** | **A090440** | **001** | Jun 29, 2010 |
| **AB** | | NAVINTA LLC | **40MG/5ML** | **A091020** | **001** | May 27, 2010 |
| **AB** | | NOVEL LABS INC | **40MG/5ML** | **A201695** | **001** | Dec 17, 2012 |

**PEPCID**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | SALIX PHARMS | **40MG/5ML** | **N019527** | **001** | Feb 02, 1987 |

INJECTABLE;INJECTION

**FAMOTIDINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | ATHENEX INC | **10MG/ML** | **A075651** | **001** | Apr 16, 2001 |
| **AP** | | | **10MG/ML** | **A075684** | **001** | Apr 16, 2001 |
| **AP** | | FRESENIUS KABI USA | **10MG/ML** | **A075709** | **001** | Apr 16, 2001 |
| **AP** | | MYLAN LABS LTD | **10MG/ML** | **A078641** | **001** | Jun 25, 2008 |
| **AP** | **!** | WEST-WARD PHARMS INT | **10MG/ML** | **A075488** | **001** | Apr 16, 2001 |

**FAMOTIDINE PRESERVATIVE FREE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | ATHENEX INC | **10MG/ML** | **A075622** | **001** | Apr 16, 2001 |
| **AP** | | | **10MG/ML** | **A075825** | **001** | Apr 17, 2001 |
| **AP** | | FRESENIUS KABI USA | **10MG/ML** | **A075813** | **001** | Apr 16, 2001 |
| **AP** | | MYLAN LABS LTD | **10MG/ML** | **A078642** | **001** | Jun 25, 2008 |
| **AP** | **!** | WEST-WARD PHARMS INT | **10MG/ML** | **A075486** | **001** | Apr 16, 2001 |

FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | BAXTER HLTHCARE | 0.4MG/ML | A075591 | 001 | May 10, 2001 |

TABLET;ORAL

**FAMOTIDINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALEMBIC PHARMS LTD | **20MG** | **A078916** | **001** | May 22, 2009 |
| **AB** | | | **40MG** | **A078916** | **002** | May 22, 2009 |
| **AB** | | APOTEX | **20MG** | **A075611** | **001** | Jul 23, 2001 |
| **AB** | | | **40MG** | **A075611** | **002** | Jul 23, 2001 |
| **AB** | | AUROBINDO PHARMA LTD | **20MG** | **A206530** | **001** | Dec 22, 2015 |
| **AB** | | | **40MG** | **A206530** | **002** | Dec 22, 2015 |
| **AB** | | CARLSBAD | **20MG** | **A075805** | **001** | Apr 16, 2001 |
| **AB** | | | **40MG** | **A075805** | **002** | Apr 16, 2001 |
| **AB** | | DR REDDYS LABS LTD | **20MG** | **A075718** | **001** | Apr 16, 2001 |
| **AB** | | | **40MG** | **A075718** | **002** | Apr 16, 2001 |
| **AB** | | IVAX SUB TEVA PHARMS | **20MG** | **A075511** | **001** | Apr 16, 2001 |
| **AB** | | | **40MG** | **A075511** | **002** | Apr 16, 2001 |
| **AB** | | MYLAN | **20MG** | **A075704** | **001** | Apr 16, 2001 |
| **AB** | | | **40MG** | **A075704** | **002** | Apr 16, 2001 |
| **AB** | | PERRIGO R AND D | **20MG** | **A077352** | **002** | Jul 27, 2005 |
| **AB** | | | **40MG** | **A077352** | **001** | Jul 27, 2005 |
| **AB** | | TEVA | **20MG** | **A075311** | **001** | Apr 16, 2001 |
| **AB** | | | **40MG** | **A075311** | **002** | Apr 16, 2001 |
| **AB** | | WOCKHARDT LTD | **20MG** | **A075786** | **001** | Apr 16, 2001 |
| **AB** | | | **40MG** | **A075786** | **002** | Apr 16, 2001 |

**PEPCID**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | VALEANT PHARMS NORTH | **20MG** | **N019462** | **001** | Oct 15, 1986 |
| **AB** | **+!** | | **40MG** | **N019462** | **002** | Oct 15, 1986 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| FAMOTIDINE; IBUPROFEN | | | | | | | |
| TABLET;ORAL | | | | | | | |
| DUEXIS | | | | | | | |
| | +! | HORIZON PHARMA | 26.6MG;800MG | N022519 | 001 | Apr 23, 2011 |
| FEBUXOSTAT | | | | | | | |
| TABLET;ORAL | | | | | | | |
| ULORIC | | | | | | | |
| | + | TAKEDA PHARMS USA | 40MG | N021856 | 001 | Feb 13, 2009 |
| | +! | | 80MG | N021856 | 002 | Feb 13, 2009 |
| FELBAMATE | | | | | | | |
| SUSPENSION;ORAL | | | | | | | |
| **FELBAMATE** | | | | | | | |
| **AB** | | AMNEAL PHARMS | **600MG/5ML** | **A202385** | **001** | Dec 16, 2011 |
| **AB** | | TARO PHARM | **600MG/5ML** | **A206314** | **001** | Jun 16, 2017 |
| **FELBATOL** | | | | | | | |
| **AB** | **+!** | MYLAN SPECIALITY LP | **600MG/5ML** | **N020189** | **003** | Jul 29, 1993 |
| TABLET;ORAL | | | | | | | |
| **FELBAMATE** | | | | | | | |
| **AB** | | ALVOGEN MALTA | **400MG** | **A204595** | **001** | Jan 11, 2016 |
| **AB** | | | **600MG** | **A204595** | **002** | Jan 11, 2016 |
| **AB** | | AMNEAL PHARMS | **400MG** | **A201680** | **001** | Sep 13, 2011 |
| **AB** | | | **600MG** | **A201680** | **002** | Sep 13, 2011 |
| **AB** | | IMPAX LABS INC | **400MG** | **A202284** | **001** | Nov 04, 2015 |
| **AB** | | | **600MG** | **A202284** | **002** | Nov 04, 2015 |
| **AB** | | TARO PHARM | **400MG** | **A207093** | **001** | Apr 20, 2017 |
| **AB** | | | **600MG** | **A207093** | **002** | Apr 20, 2017 |
| **AB** | | ZYDUS PHARMS USA INC | **400MG** | **A208970** | **001** | May 30, 2017 |
| **AB** | | | **600MG** | **A208970** | **002** | May 30, 2017 |
| **FELBATOL** | | | | | | | |
| **AB** | **+** | MYLAN SPECIALITY LP | **400MG** | **N020189** | **001** | Jul 29, 1993 |
| **AB** | **+!** | | **600MG** | **N020189** | **002** | Jul 29, 1993 |
| FELODIPINE | | | | | | | |
| TABLET, EXTENDED RELEASE;ORAL | | | | | | | |
| **FELODIPINE** | | | | | | | |
| **AB** | | AUROBINDO PHARMA LTD | **2.5MG** | **A203417** | **001** | Jan 17, 2013 |
| **AB** | | | **5MG** | **A203417** | **002** | Jan 17, 2013 |
| **AB** | | | **10MG** | **A203417** | **003** | Jan 17, 2013 |
| **AB** | | GLENMARK GENERICS | **2.5MG** | **A090365** | **001** | Dec 17, 2010 |
| **AB** | | | **5MG** | **A090365** | **002** | Dec 17, 2010 |
| **AB** | | | **10MG** | **A090365** | **003** | Dec 17, 2010 |
| **AB** | | HERITAGE PHARMS INC | **2.5MG** | **A201964** | **001** | Nov 08, 2013 |
| **AB** | | | **5MG** | **A201964** | **002** | Nov 08, 2013 |
| **AB** | | | **10MG** | **A201964** | **003** | Nov 08, 2013 |
| **AB** | | JUBILANT GENERICS | **2.5MG** | **A203983** | **001** | Aug 19, 2016 |
| **AB** | | | **5MG** | **A203983** | **002** | Aug 19, 2016 |
| **AB** | | | **10MG** | **A203983** | **003** | Aug 19, 2016 |
| **AB** | | MYLAN | **2.5MG** | **A078855** | **001** | Apr 17, 2008 |
| **AB** | | | **5MG** | **A078855** | **002** | Apr 17, 2008 |
| **AB** | **!** | | **10MG** | **A078855** | **003** | Apr 17, 2008 |
| **AB** | | ORCHID HLTHCARE | **2.5MG** | **A203032** | **001** | May 21, 2015 |
| **AB** | | | **5MG** | **A203032** | **002** | May 21, 2015 |
| **AB** | | | **10MG** | **A203032** | **003** | May 21, 2015 |
| **AB** | | SUN PHARM INDS LTD | **2.5MG** | **A091200** | **001** | Dec 13, 2013 |
| **AB** | | | **5MG** | **A091200** | **002** | Dec 13, 2013 |
| **AB** | | | **10MG** | **A091200** | **003** | Dec 13, 2013 |
| **AB** | | SUN PHARM INDUSTRIES | **2.5MG** | **A075896** | **001** | Nov 02, 2004 |
| **AB** | | | **5MG** | **A075896** | **002** | Nov 02, 2004 |
| **AB** | | | **10MG** | **A075896** | **003** | Nov 02, 2004 |
| **AB** | | TORRENT PHARMS LTD | **2.5MG** | **A202170** | **001** | Nov 28, 2011 |
| **AB** | | | **5MG** | **A202170** | **002** | Nov 28, 2011 |
| **AB** | | | **10MG** | **A202170** | **003** | Nov 28, 2011 |
| **AB** | | VINTAGE PHARMS LLC | **2.5MG** | **A200815** | **001** | Oct 28, 2011 |
| **AB** | | | **5MG** | **A200815** | **002** | Oct 28, 2011 |
| **AB** | | | **10MG** | **A200815** | **003** | Oct 28, 2011 |

FENOFIBRATE

CAPSULE;ORAL

**ANTARA (MICRONIZED)**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **AB** | + | LUPIN ATLANTIS | **43MG** | **N021695** | **001** | Nov 30, 2004 |
| **AB** | +! | | **130MG** | **N021695** | **003** | Nov 30, 2004 |

**FENOFIBRATE**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **AB** | | SUN PHARM INDS LTD | **43MG** | **A201748** | **001** | Oct 31, 2014 |
| **AB** | | | **130MG** | **A201748** | **002** | Oct 31, 2014 |

**FENOFIBRATE (MICRONIZED)**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **AB** | | APOTEX INC | **43MG** | **A202252** | **001** | Jul 26, 2013 |
| **AB** | | | **130MG** | **A202252** | **002** | Jul 26, 2013 |
| **AB** | | CNTY LINE PHARMS | **67MG** | **A207805** | **001** | Nov 16, 2017 |
| **AB** | | | **134MG** | **A207805** | **002** | Nov 16, 2017 |
| **AB** | | | **200MG** | **A207805** | **003** | Nov 16, 2017 |
| **AB** | | DR REDDYS LABS SA | **43MG** | **A090859** | **001** | Mar 01, 2012 |
| **AB** | | | **130MG** | **A090859** | **002** | Mar 01, 2012 |
| **AB** | | GLENMARK PHARMS LTD | **67MG** | **A205566** | **001** | Apr 07, 2017 |
| **AB** | | | **134MG** | **A205566** | **002** | Apr 07, 2017 |
| **AB** | | | **200MG** | **A205566** | **003** | Apr 07, 2017 |
| **AB** | | IMPAX LABS | **67MG** | **A075868** | **001** | Oct 27, 2003 |
| **AB** | | | **134MG** | **A075868** | **002** | Oct 27, 2003 |
| **AB** | ! | | **200MG** | **A075868** | **003** | Oct 27, 2003 |
| **AB** | | INVAGEN PHARMS | **67MG** | **A207378** | **001** | Mar 28, 2017 |
| **AB** | | | **134MG** | **A207378** | **002** | Mar 28, 2017 |
| **AB** | | | **200MG** | **A207378** | **003** | Mar 28, 2017 |
| **AB** | | MYLAN PHARMS INC | **43MG** | **A202579** | **001** | Jan 10, 2013 |
| **AB** | | | **67MG** | **A202676** | **001** | Oct 23, 2012 |
| **AB** | | | **130MG** | **A202579** | **002** | Jan 10, 2013 |
| **AB** | | | **134MG** | **A202676** | **002** | Oct 23, 2012 |
| **AB** | | | **200MG** | **A202676** | **003** | Oct 23, 2012 |
| **AB** | | RHODES PHARMS | **67MG** | **A075753** | **001** | Sep 03, 2002 |
| **AB** | | | **134MG** | **A075753** | **002** | Apr 09, 2002 |
| **AB** | | | **200MG** | **A075753** | **003** | Apr 09, 2002 |

ANTARA (MICRONIZED)

| | | | | | | |
|---|---|---|---|---|---|---|
| + | LUPIN ATLANTIS | 30MG | N021695 | 004 | Oct 18, 2013 |
| + | | 90MG | N021695 | 005 | Oct 18, 2013 |

LIPOFEN

| | | | | | | |
|---|---|---|---|---|---|---|
| + | CIPHER PHARMS INC | 50MG | N021612 | 001 | Jan 11, 2006 |
| +! | | 150MG | N021612 | 003 | Jan 11, 2006 |

TABLET;ORAL

**FENOFIBRATE**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **AB** | | AUROBINDO PHARMA LTD | **48MG** | **A205118** | **001** | May 05, 2016 |
| **AB** | | | **145MG** | **A205118** | **002** | May 05, 2016 |
| **AB** | | CIPLA LTD | **48MG** | **A208709** | **001** | Dec 15, 2016 |
| **AB** | | | **145MG** | **A208709** | **002** | Dec 15, 2016 |
| **AB** | | CNTY LINE PHARMS | **54MG** | **A207803** | **001** | Dec 19, 2017 |
| **AB** | | | **160MG** | **A207803** | **002** | Dec 19, 2017 |
| **AB** | | HETERO LABS LTD III | **48MG** | **A204598** | **001** | Jul 12, 2016 |
| **AB** | | | **145MG** | **A204598** | **002** | Jul 12, 2016 |
| **AB** | | IMPAX LABS | **54MG** | **A076509** | **001** | Mar 26, 2008 |
| **AB** | ! | | **160MG** | **A076509** | **002** | Mar 26, 2008 |
| **AB** | | LUPIN LTD | **48MG** | **A090856** | **001** | Dec 23, 2011 |
| **AB** | | | **54MG** | **A204019** | **001** | Aug 17, 2015 |
| **AB** | | | **145MG** | **A090856** | **002** | Dec 23, 2011 |
| **AB** | | | **160MG** | **A204019** | **002** | Aug 17, 2015 |
| **AB** | | MYLAN | **40MG** | **A204475** | **001** | Jun 23, 2016 |
| **AB** | | | **54MG** | **A076520** | **001** | Oct 25, 2007 |
| **AB** | | | **120MG** | **A204475** | **002** | Jun 23, 2016 |
| **AB** | | | **160MG** | **A076520** | **003** | Oct 25, 2007 |
| **AB** | | MYLAN PHARMS INC | **48MG** | **A202856** | **001** | Dec 07, 2012 |
| **AB** | | | **145MG** | **A202856** | **002** | Dec 07, 2012 |
| **AB** | | RHODES PHARMS | **54MG** | **A076433** | **001** | May 13, 2005 |
| **AB** | | | **160MG** | **A076433** | **002** | May 13, 2005 |
| **AB** | | SUN PHARM INDS LTD | **48MG** | **A200884** | **001** | Sep 07, 2017 |
| **AB** | | | **54MG** | **A076635** | **001** | Oct 31, 2005 |
| **AB** | | | **145MG** | **A200884** | **002** | Sep 07, 2017 |
| **AB** | | | **160MG** | **A076635** | **003** | Oct 31, 2005 |
| **AB** | | VALEANT PHARMS NORTH | **48MG** | **A090715** | **001** | Apr 05, 2012 |
| **AB** | | | **145MG** | **A090715** | **002** | Apr 05, 2012 |

| | | | | | | |
|---|---|---|---|---|---|---|
| FENOFIBRATE | | | | | | |
| TABLET;ORAL | | | | | | |
| **FENOGLIDE** | | | | | | |
| **AB** | **+** | SANTARUS INC | **40MG** | **N022118** | **001** | Aug 10, 2007 |
| **AB** | **+!** | | **120MG** | **N022118** | **002** | Aug 10, 2007 |
| **TRICOR** | | | | | | |
| **AB** | **+** | ABBVIE | **48MG** | **N021656** | **001** | Nov 05, 2004 |
| **AB** | **+!** | | **145MG** | **N021656** | **002** | Nov 05, 2004 |
| TRIGLIDE | | | | | | |
| BX | +! | SKYEPHARMA AG | 160MG | N021350 | 002 | May 07, 2005 |
| FENOFIBRATE | | | | | | |
| | | SUN PHARM INDS LTD | 107MG | A076635 | 002 | Oct 31, 2005 |
| FENOFIBRIC ACID | | | | | | |
| TABLET;ORAL | | | | | | |
| FIBRICOR | | | | | | |
| | + | ARALEZ PHARMS INC | 35MG | N022418 | 001 | Aug 14, 2009 |
| | +! | | 105MG | N022418 | 002 | Aug 14, 2009 |
| FENOLDOPAM MESYLATE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| **CORLOPAM** | | | | | | |
| **AP** | **+!** | HOSPIRA | **EQ 10MG BASE/ML** | **N019922** | **001** | Sep 23, 1997 |
| **FENOLDOPAM MESYLATE** | | | | | | |
| **AP** | | SANDOZ INC | **EQ 10MG BASE/ML** | **A077155** | **001** | Feb 15, 2005 |
| **AP** | | WEST-WARD PHARMS INT | **EQ 10MG BASE/ML** | **A076582** | **001** | Oct 12, 2004 |
| FENOPROFEN CALCIUM | | | | | | |
| CAPSULE;ORAL | | | | | | |
| NALFON | | | | | | |
| | +! | XSPIRE PHARMA | EQ 200MG BASE | N017604 | 003 | |
| | + | | EQ 400MG BASE | N017604 | 004 | Jul 21, 2009 |
| TABLET;ORAL | | | | | | |
| FENOPROFEN CALCIUM | | | | | | |
| | ! | XSPIRE PHARMA | EQ 600MG BASE | A072267 | 001 | Aug 17, 1988 |
| FENTANYL | | | | | | |
| FILM, EXTENDED RELEASE;TRANSDERMAL | | | | | | |
| **DURAGESIC-100** | | | | | | |
| **AB** | **+** | JANSSEN PHARMS | **100MCG/HR** | **N019813** | **001** | Aug 07, 1990 |
| **DURAGESIC-12** | | | | | | |
| **AB** | **+** | JANSSEN PHARMS | **12.5MCG/HR** | **N019813** | **005** | Feb 04, 2005 |
| **DURAGESIC-25** | | | | | | |
| **AB** | **+!** | JANSSEN PHARMS | **25MCG/HR** | **N019813** | **004** | Aug 07, 1990 |
| **DURAGESIC-50** | | | | | | |
| **AB** | **+** | JANSSEN PHARMS | **50MCG/HR** | **N019813** | **003** | Aug 07, 1990 |
| **DURAGESIC-75** | | | | | | |
| **AB** | **+** | JANSSEN PHARMS | **75MCG/HR** | **N019813** | **002** | Aug 07, 1990 |
| **FENTANYL-100** | | | | | | |
| **AB** | | 3M DRUG DELIVERY | **100MCG/HR** | **A202097** | **005** | Nov 04, 2016 |
| **AB** | | ACTAVIS LABS UT INC | **100MCG/HR** | **A076709** | **004** | Aug 20, 2007 |
| **AB** | | AVEVA | **100MCG/HR** | **A077449** | **004** | Oct 20, 2008 |
| **AB** | | LAVIPHARM LABS | **100MCG/HR** | **A077051** | **004** | Aug 04, 2006 |
| **AB** | | MAYNE PHARMA | **100MCG/HR** | **A077062** | **004** | Aug 20, 2007 |
| **AB** | | MYLAN TECHNOLOGIES | **100MCG/HR** | **A076258** | **004** | Jan 28, 2005 |
| **AB** | | SPECGX LLC | **100MCG/HR** | **A077154** | **004** | Feb 09, 2011 |
| **FENTANYL-12** | | | | | | |
| **AB** | | 3M DRUG DELIVERY | **12.5MCG/HR** | **A202097** | **001** | Nov 04, 2016 |
| **AB** | | AVEVA | **12.5MCG/HR** | **A077449** | **005** | Sep 11, 2015 |
| **AB** | | MYLAN TECHNOLOGIES | **12.5MCG/HR** | **A076258** | **005** | Jan 23, 2007 |
| **AB** | | SPECGX LLC | **12.5MCG/HR** | **A077154** | **005** | Jun 11, 2015 |
| **FENTANYL-25** | | | | | | |
| **AB** | | 3M DRUG DELIVERY | **25MCG/HR** | **A202097** | **002** | Nov 04, 2016 |
| **AB** | | ACTAVIS LABS UT INC | **25MCG/HR** | **A076709** | **001** | Aug 20, 2007 |
| **AB** | | AVEVA | **25MCG/HR** | **A077449** | **001** | Oct 20, 2008 |
| **AB** | | LAVIPHARM LABS | **25MCG/HR** | **A077051** | **001** | Aug 04, 2006 |
| **AB** | | MAYNE PHARMA | **25MCG/HR** | **A077062** | **001** | Aug 20, 2007 |
| **AB** | | MYLAN TECHNOLOGIES | **25MCG/HR** | **A076258** | **001** | Jan 28, 2005 |
| **AB** | | SPECGX LLC | **25MCG/HR** | **A077154** | **001** | Feb 09, 2011 |
| **FENTANYL-37** | | | | | | |
| **AB** | | AVEVA | **37.5MCG/HR** | **A077449** | **006** | Dec 06, 2017 |
| **FENTANYL-50** | | | | | | |
| **AB** | | 3M DRUG DELIVERY | **50MCG/HR** | **A202097** | **003** | Nov 04, 2016 |
| **AB** | | ACTAVIS LABS UT INC | **50MCG/HR** | **A076709** | **002** | Aug 20, 2007 |

| | | | | | | |
|---|---|---|---|---|---|---|
| FENTANYL | | | | | | |
| FILM, EXTENDED RELEASE;TRANSDERMAL | | | | | | |
| **FENTANYL-50** | | | | | | |
| **AB** | | AVEVA | **50MCG/HR** | **A077449** | **002** | Oct 20, 2008 |
| **AB** | | LAVIPHARM LABS | **50MCG/HR** | **A077051** | **002** | Aug 04, 2006 |
| **AB** | | MAYNE PHARMA | **50MCG/HR** | **A077062** | **002** | Aug 20, 2007 |
| **AB** | | MYLAN TECHNOLOGIES | **50MCG/HR** | **A076258** | **002** | Jan 28, 2005 |
| **AB** | | SPECGX LLC | **50MCG/HR** | **A077154** | **002** | Feb 09, 2011 |
| **FENTANYL-62** | | | | | | |
| **AB** | | AVEVA | **62.5MCG/HR** | **A077449** | **007** | Dec 06, 2017 |
| **FENTANYL-75** | | | | | | |
| **AB** | | 3M DRUG DELIVERY | **75MCG/HR** | **A202097** | **004** | Nov 04, 2016 |
| **AB** | | ACTAVIS LABS UT INC | **75MCG/HR** | **A076709** | **003** | Aug 20, 2007 |
| **AB** | | AVEVA | **75MCG/HR** | **A077449** | **003** | Oct 20, 2008 |
| **AB** | | LAVIPHARM LABS | **75MCG/HR** | **A077051** | **003** | Aug 04, 2006 |
| **AB** | | MAYNE PHARMA | **75MCG/HR** | **A077062** | **003** | Aug 20, 2007 |
| **AB** | | MYLAN TECHNOLOGIES | **75MCG/HR** | **A076258** | **003** | Jan 28, 2005 |
| **AB** | | SPECGX LLC | **75MCG/HR** | **A077154** | **003** | Feb 09, 2011 |
| **FENTANYL-87** | | | | | | |
| **AB** | | AVEVA | **87.5MCG/HR** | **A077449** | **008** | Dec 06, 2017 |
| FENTANYL-37 | | | | | | |
| | | MYLAN TECHNOLOGIES | 37.5MCG/HR | A076258 | 006 | Dec 29, 2014 |
| FENTANYL-62 | | | | | | |
| | | MYLAN TECHNOLOGIES | 62.5MCG/HR | A076258 | 007 | Dec 29, 2014 |
| FENTANYL-87 | | | | | | |
| | | MYLAN TECHNOLOGIES | 87.5MCG/HR | A076258 | 008 | Dec 29, 2014 |
| SPRAY;SUBLINGUAL | | | | | | |
| SUBSYS | | | | | | |
| | + | INSYS DEV CO INC | 0.1MG | N202788 | 001 | Jan 04, 2012 |
| | + | | 0.2MG | N202788 | 002 | Jan 04, 2012 |
| | +! | | 0.4MG | N202788 | 003 | Jan 04, 2012 |
| | + | | 0.6MG | N202788 | 004 | Jan 04, 2012 |
| | + | | 0.8MG | N202788 | 005 | Jan 04, 2012 |
| | + | | 1.2MG | N202788 | 006 | Aug 30, 2012 |
| | + | | 1.6MG | N202788 | 007 | Aug 30, 2012 |
| FENTANYL CITRATE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| **FENTANYL CITRATE** | | | | | | |
| **AP** | | HOSPIRA | **EQ 0.05MG BASE/ML** | **N019115** | **001** | Jan 12, 1985 |
| **FENTANYL CITRATE PRESERVATIVE FREE** | | | | | | |
| **AP** | | HOSPIRA | **EQ 0.05MG BASE/ML** | **A072786** | **001** | Sep 24, 1991 |
| **AP** | **+!** | WEST-WARD PHARMS INT | **EQ 0.05MG BASE/ML** | **N019101** | **001** | Jul 11, 1984 |
| **SUBLIMAZE PRESERVATIVE FREE** | | | | | | |
| **AP** | **+!** | AKORN | **EQ 0.05MG BASE/ML** | **N016619** | **001** | |
| SPRAY, METERED;NASAL | | | | | | |
| LAZANDA | | | | | | |
| | + | ELEFSEE PHARMS INTL | EQ 0.1MG BASE | N022569 | 001 | Jun 30, 2011 |
| | + | | EQ 0.3MG BASE | N022569 | 003 | Dec 21, 2015 |
| | +! | | EQ 0.4MG BASE | N022569 | 002 | Jun 30, 2011 |
| TABLET;BUCCAL, SUBLINGUAL | | | | | | |
| FENTORA | | | | | | |
| | + | CEPHALON | EQ 0.1MG BASE | N021947 | 001 | Sep 25, 2006 |
| | + | | EQ 0.2MG BASE | N021947 | 002 | Sep 25, 2006 |
| | +! | | EQ 0.4MG BASE | N021947 | 003 | Sep 25, 2006 |
| | + | | EQ 0.6MG BASE | N021947 | 004 | Sep 25, 2006 |
| | + | | EQ 0.8MG BASE | N021947 | 005 | Sep 25, 2006 |
| TABLET;SUBLINGUAL | | | | | | |
| **ABSTRAL** | | | | | | |
| **AB** | **+** | SENTYNL THERAPS INC | **EQ 0.1MG BASE** | **N022510** | **001** | Jan 07, 2011 |
| **AB** | **+** | | **EQ 0.2MG BASE** | **N022510** | **002** | Jan 07, 2011 |
| **AB** | **+** | | **EQ 0.3MG BASE** | **N022510** | **003** | Jan 07, 2011 |
| **AB** | **+!** | | **EQ 0.4MG BASE** | **N022510** | **004** | Jan 07, 2011 |
| **AB** | **+** | | **EQ 0.6MG BASE** | **N022510** | **005** | Jan 07, 2011 |
| **AB** | **+** | | **EQ 0.8MG BASE** | **N022510** | **006** | Jan 07, 2011 |
| **FENTANYL CITRATE** | | | | | | |
| **AB** | | ACTAVIS LABS FL INC | **EQ 0.1MG BASE** | **A207338** | **001** | Nov 17, 2017 |
| **AB** | | | **EQ 0.2MG BASE** | **A207338** | **002** | Nov 17, 2017 |
| **AB** | | | **EQ 0.3MG BASE** | **A207338** | **003** | Nov 17, 2017 |
| **AB** | | | **EQ 0.4MG BASE** | **A207338** | **004** | Nov 17, 2017 |
| **AB** | | | **EQ 0.6MG BASE** | **A207338** | **005** | Nov 17, 2017 |
| **AB** | | | **EQ 0.8MG BASE** | **A207338** | **006** | Nov 17, 2017 |

FENTANYL CITRATE
TROCHE/LOZENGE;TRANSMUCOSAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **ACTIQ** | | | | | | |
| **AB** | + | CEPHALON | **EQ 0.2MG BASE** | **N020747** | **001** | Nov 04, 1998 |
| **AB** | +! | | **EQ 0.4MG BASE** | **N020747** | **002** | Nov 04, 1998 |
| **AB** | + | | **EQ 0.6MG BASE** | **N020747** | **003** | Nov 04, 1998 |
| **AB** | + | | **EQ 0.8MG BASE** | **N020747** | **004** | Nov 04, 1998 |
| **AB** | + | | **EQ 1.2MG BASE** | **N020747** | **005** | Nov 04, 1998 |
| **AB** | + | | **EQ 1.6MG BASE** | **N020747** | **006** | Nov 04, 1998 |
| **FENTANYL CITRATE** | | | | | | |
| **AB** | | PAR PHARM | **EQ 0.2MG BASE** | **A077312** | **001** | Oct 30, 2009 |
| **AB** | | | **EQ 0.4MG BASE** | **A077312** | **002** | Oct 30, 2009 |
| **AB** | | | **EQ 0.6MG BASE** | **A077312** | **003** | Oct 30, 2009 |
| **AB** | | | **EQ 0.8MG BASE** | **A077312** | **004** | Oct 30, 2009 |
| **AB** | | | **EQ 1.2MG BASE** | **A077312** | **005** | Oct 30, 2009 |
| **AB** | | | **EQ 1.6MG BASE** | **A077312** | **006** | Oct 30, 2009 |
| **AB** | | SPECGX LLC | **EQ 0.2MG BASE** | **A078907** | **001** | Oct 30, 2009 |
| **AB** | | | **EQ 0.4MG BASE** | **A078907** | **002** | Oct 30, 2009 |
| **AB** | | | **EQ 0.6MG BASE** | **A078907** | **003** | Oct 30, 2009 |
| **AB** | | | **EQ 0.8MG BASE** | **A078907** | **004** | Oct 30, 2009 |
| **AB** | | | **EQ 1.2MG BASE** | **A078907** | **005** | Oct 30, 2009 |
| **AB** | | | **EQ 1.6MG BASE** | **A078907** | **006** | Oct 30, 2009 |

FENTANYL HYDROCHLORIDE
SYSTEM;IONTOPHORESIS, TRANSDERMAL

| | | | | | | |
|---|---|---|---|---|---|---|
| IONSYS | | | | | | |
| | +! | THE MEDICINES CO | EQ 40MCG BASE/ACTIVATION | N021338 | 001 | May 22, 2006 |

FERRIC CARBOXYMALTOSE
INJECTABLE;INTRAVENOUS

| | | | | | | |
|---|---|---|---|---|---|---|
| INJECTAFER | | | | | | |
| | +! | LUITPOLD PHARMS INC | 750MG IRON/15ML (50MG IRON/ML) | N203565 | 001 | Jul 25, 2013 |

FERRIC CITRATE
TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| AURYXIA | | | | | | |
| | +! | KERYX BIOPHARMS | EQ 210MG IRON | N205874 | 001 | Sep 05, 2014 |

FERRIC HEXACYANOFERRATE(II)
CAPSULE;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| RADIOGARDASE (PRUSSIAN BLUE) | | | | | | |
| | +! | HEYL CHEMISCH | 500MG | N021626 | 001 | Oct 02, 2003 |

FERRIC PYROPHOSPHATE CITRATE
FOR SOLUTION;INTRAVENOUS

| | | | | | | |
|---|---|---|---|---|---|---|
| TRIFERIC | | | | | | |
| | +! | ROCKWELL MEDICAL INC | 272MG IRON/PACKET | N208551 | 001 | Apr 25, 2016 |

SOLUTION;IV (INFUSION)

| | | | | | | |
|---|---|---|---|---|---|---|
| TRIFERIC | | | | | | |
| | +! | ROCKWELL MEDICAL INC | 27.2MG IRON/5ML (5.44MG IRON/ML) | N206317 | 001 | Jan 23, 2015 |
| | + | | 272MG IRON/50ML (5.44MG IRON/ML) | N206317 | 002 | Sep 04, 2015 |

FERUMOXYTOL
SOLUTION;INTRAVENOUS

| | | | | | | |
|---|---|---|---|---|---|---|
| FERAHEME | | | | | | |
| | +! | AMAG PHARMS INC | EQ 510MG IRON/17ML (EQ 30MG IRON/ML) | N022180 | 001 | Jun 30, 2009 |

FESOTERODINE FUMARATE
TABLET, EXTENDED RELEASE;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **FESOTERODINE FUMARATE** | | | | | | |
| **AB** | | AUROBINDO PHARMA LTD | **4MG** | **A205007** | **001** | Feb 17, 2017 |
| **AB** | | | **8MG** | **A205007** | **002** | Feb 17, 2017 |
| **AB** | | ZYDUS PHARMS USA INC | **4MG** | **A204946** | **001** | Oct 03, 2017 |
| **AB** | | | **8MG** | **A204946** | **002** | Oct 03, 2017 |
| **TOVIAZ** | | | | | | |
| **AB** | + | PFIZER | **4MG** | **N022030** | **001** | Oct 31, 2008 |
| **AB** | +! | | **8MG** | **N022030** | **002** | Oct 31, 2008 |

FEXOFENADINE HYDROCHLORIDE

SUSPENSION;ORAL

**ALLEGRA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | SANOFI AVENTIS US | **30MG/5ML** | **N021963** | **001** | Oct 16, 2006 |

**FEXOFENADINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS MID ATLANTIC | **30MG/5ML** | **A201311** | **001** | Jul 25, 2012 |

TABLET;ORAL

**FEXOFENADINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | BARR | **30MG** | **A076191** | **001** | Aug 31, 2005 |
| **AB** | | | **60MG** | **A076191** | **002** | Aug 31, 2005 |
| **AB** | | | **180MG** | **A076191** | **003** | Aug 31, 2005 |
| **AB** | | DR REDDYS LABS LTD | **30MG** | **A076502** | **001** | Apr 11, 2006 |
| **AB** | | | **60MG** | **A076502** | **002** | Apr 11, 2006 |
| **AB** | | | **180MG** | **A076502** | **003** | Apr 11, 2006 |
| **AB** | | MYLAN | **30MG** | **A077081** | **002** | Apr 11, 2008 |
| **AB** | | | **60MG** | **A077081** | **003** | Apr 11, 2008 |
| **AB** | | | **180MG** | **A077081** | **001** | Apr 16, 2007 |
| **AB** | | TEVA | **30MG** | **A076447** | **001** | Sep 01, 2005 |
| **AB** | | | **60MG** | **A076447** | **002** | Sep 01, 2005 |
| **AB** | | | **180MG** | **A076447** | **003** | Sep 01, 2005 |

FIDAXOMICIN

TABLET;ORAL

DIFICID

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | CUBIST PHARMS LLC | 200MG | N201699 | 001 | May 27, 2011 |

FINAFLOXACIN

SUSPENSION/DROPS;OTIC

XTORO

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | NOVARTIS PHARMS CORP | 0.3% | N206307 | 001 | Dec 17, 2014 |

FINASTERIDE

TABLET;ORAL

**FINASTERIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACCORD HLTHCARE | **1MG** | **A091643** | **001** | Nov 05, 2013 |
| **AB** | | | **5MG** | **A090121** | **001** | Feb 23, 2010 |
| **AB** | | ACTAVIS TOTOWA | **1MG** | **A078371** | **001** | Nov 05, 2013 |
| **AB** | | ACTAVIS TOTOWA TEVA | **5MG** | **A077914** | **001** | Mar 28, 2007 |
| **AB** | | ALKEM LABS LTD | **1MG** | **A207750** | **001** | Jan 06, 2017 |
| **AB** | | | **5MG** | **A204304** | **001** | Jan 05, 2017 |
| **AB** | | AUROBINDO PHARMA | **5MG** | **A078341** | **001** | Oct 30, 2007 |
| **AB** | | AUROBINDO PHARMA LTD | **1MG** | **A203687** | **001** | Nov 05, 2013 |
| **AB** | | CIPLA LTD | **1MG** | **A077335** | **001** | Nov 20, 2014 |
| **AB** | | DR REDDYS LABS INC | **1MG** | **A076436** | **001** | Jul 28, 2006 |
| **AB** | | DR REDDYS LABS LTD | **5MG** | **A076437** | **001** | Feb 28, 2007 |
| **AB** | | GEDEON RICHTER USA | **5MG** | **A077251** | **001** | Dec 22, 2006 |
| **AB** | | HETERO LABS LTD III | **1MG** | **A090060** | **001** | Jul 01, 2013 |
| **AB** | | | **5MG** | **A090061** | **001** | Jun 07, 2010 |
| **AB** | | MYLAN | **5MG** | **A077578** | **001** | Dec 18, 2006 |
| **AB** | | MYLAN PHARMS INC | **1MG** | **A078161** | **001** | Nov 05, 2013 |
| **AB** | | SUN PHARMA GLOBAL | **1MG** | **A090508** | **001** | Jul 01, 2013 |
| **AB** | | | **5MG** | **A090507** | **001** | Aug 16, 2011 |
| **AB** | | TEVA | **1MG** | **A076905** | **001** | Nov 05, 2013 |
| **AB** | | | **5MG** | **A076511** | **001** | Dec 15, 2006 |
| **AB** | | ZYDUS PHARMS USA INC | **5MG** | **A078900** | **001** | Dec 28, 2009 |

**PROPECIA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | MERCK | **1MG** | **N020788** | **001** | Dec 19, 1997 |

**PROSCAR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | MERCK | **5MG** | **N020180** | **001** | Jun 19, 1992 |

FINGOLIMOD

CAPSULE;ORAL

GILENYA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | NOVARTIS | 0.5MG | N022527 | 001 | Sep 21, 2010 |

FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL

EMULSION;INTRAVENOUS

SMOFLIPID 20%

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | FRESENIUS KABI USA | 3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (100ML) | N207648 | 001 | Jul 13, 2016 |
| | +! | | 3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (250ML) | N207648 | 002 | Jul 13, 2016 |

FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL

EMULSION;INTRAVENOUS

SMOFLIPID 20%

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | | 3GM/100ML;6GM/100ML;5GM/100ML;6GM/100ML (500ML) | N207648 | 003 | Jul 13, 2016 |

FLAVOXATE HYDROCHLORIDE

TABLET;ORAL

**FLAVOXATE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | EPIC PHARMA | **100MG** | **A076835** | **001** | Nov 30, 2005 |
| **AB** | ! | PADDOCK LLC | **100MG** | **A076831** | **001** | Dec 16, 2004 |

FLECAINIDE ACETATE

TABLET;ORAL

**FLECAINIDE ACETATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AMNEAL PHARM | **50MG** | **A075442** | **001** | Jul 31, 2001 |
| **AB** | | | **100MG** | **A075442** | **002** | Jul 31, 2001 |
| **AB** | | | **150MG** | **A075442** | **003** | Jul 31, 2001 |
| **AB** | | ANI PHARMS INC | **50MG** | **A075882** | **001** | Oct 28, 2002 |
| **AB** | | | **100MG** | **A075882** | **002** | Oct 28, 2002 |
| **AB** | | | **150MG** | **A075882** | **003** | Oct 28, 2002 |
| **AB** | | AUROBINDO PHARMA LTD | **50MG** | **A202821** | **001** | Nov 03, 2017 |
| **AB** | | | **100MG** | **A202821** | **002** | Nov 03, 2017 |
| **AB** | | | **150MG** | **A202821** | **003** | Nov 03, 2017 |
| **AB** | | SUN PHARM INDS LTD | **50MG** | **A076421** | **001** | Mar 28, 2003 |
| **AB** | | | **100MG** | **A076421** | **002** | Mar 28, 2003 |
| **AB** | | | **150MG** | **A076421** | **003** | Mar 28, 2003 |
| **AB** | | WEST-WARD PHARMS INT | **50MG** | **A076278** | **001** | Jan 14, 2003 |
| **AB** | | | **100MG** | **A076278** | **002** | Jan 14, 2003 |
| **AB** | ! | | **150MG** | **A076278** | **003** | Jan 14, 2003 |

**TAMBOCOR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | CNTY LINE PHARMS | **50MG** | **N018830** | **004** | Aug 23, 1988 |
| **AB** | + | | **100MG** | **N018830** | **001** | Oct 31, 1985 |
| **AB** | + | | **150MG** | **N018830** | **003** | Jun 03, 1988 |

FLIBANSERIN

TABLET;ORAL

ADDYI

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | SPROUT PHARMS | 100MG | N022526 | 001 | Aug 18, 2015 |

FLORBETABEN F-18

SOLUTION;INTRAVENOUS

NEURACEQ

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | PIRAMAL IMAGING | 30ML (1.4-135mCi/ML) | N204677 | 001 | Mar 19, 2014 |

FLORBETAPIR F-18

SOLUTION;INTRAVENOUS

AMYVID

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | AVID RADIOPHARMS INC | 10-30ML (13.5-51mCi/ML) | N202008 | 002 | Apr 06, 2012 |
| | +! | | 10-50ML (13.5-51mCi/ML) | N202008 | 003 | Apr 06, 2012 |

FLOXURIDINE

INJECTABLE;INJECTION

**FLOXURIDINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | FRESENIUS KABI USA | **500MG/VIAL** | **A075837** | **001** | Feb 22, 2001 |
| **AP** | | PHARMAFORCE | **500MG/VIAL** | **A203008** | **001** | Nov 22, 2017 |
| **AP** | ! | WEST-WARD PHARMS INT | **500MG/VIAL** | **A075387** | **001** | Apr 16, 2000 |

FLUCICLOVINE F-18

SOLUTION;INTRAVENOUS

AXUMIN

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | BLUE EARTH | 9-221mCi/ML | N208054 | 001 | May 27, 2016 |

FLUCONAZOLE

FOR SUSPENSION;ORAL

**DIFLUCAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | PFIZER | **50MG/5ML** | **N020090** | **001** | Dec 23, 1993 |
| **AB** | +! | | **200MG/5ML** | **N020090** | **002** | Dec 23, 1993 |

**FLUCONAZOLE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AUROBINDO PHARMA LTD | **50MG/5ML** | **A079150** | **001** | Sep 18, 2009 |
| **AB** | | | **200MG/5ML** | **A079150** | **002** | Sep 18, 2009 |
| **AB** | | IVAX SUB TEVA PHARMS | **50MG/5ML** | **A077523** | **001** | Sep 12, 2007 |

FLUCONAZOLE

FOR SUSPENSION;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **FLUCONAZOLE** | | | | | | |
| **AB** | | | **200MG/5ML** | **A077523** | **002** | Sep 12, 2007 |
| **AB** | | WEST-WARD PHARMS INT | **50MG/5ML** | **A076246** | **001** | Jul 29, 2004 |
| **AB** | | | **200MG/5ML** | **A076246** | **002** | Jul 29, 2004 |

INJECTABLE;INJECTION

| | | | | | | |
|---|---|---|---|---|---|---|
| **FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER** | | | | | | |
| **AP** | | HIKMA FARMACEUTICA | **200MG/100ML (2MG/ML)** | **A078764** | **001** | Jan 30, 2012 |
| **AP** | | | **400MG/200ML (2MG/ML)** | **A078764** | **002** | Jan 30, 2012 |
| **AP** | ! | HOSPIRA | **200MG/100ML (2MG/ML)** | **A076304** | **001** | Jul 29, 2004 |
| **AP** | ! | | **400MG/200ML (2MG/ML)** | **A076304** | **002** | Jul 29, 2004 |
| **AP** | | RENAISSANCE SSA LLC | **200MG/100ML (2MG/ML)** | **A077988** | **001** | May 26, 2010 |
| **AP** | | | **400MG/200ML (2MG/ML)** | **A077988** | **002** | May 26, 2010 |
| **FLUCONAZOLE IN SODIUM CHLORIDE 0.9%** | | | | | | |
| **AP** | | BAXTER HLTHCARE CORP | **200MG/100ML (2MG/ML)** | **A077947** | **001** | May 26, 2010 |
| **AP** | | | **400MG/200ML (2MG/ML)** | **A077947** | **002** | May 26, 2010 |
| **AP** | | FRESENIUS KABI USA | **200MG/100ML (2MG/ML)** | **A076145** | **001** | Jul 29, 2004 |
| **AP** | | | **400MG/200ML (2MG/ML)** | **A076145** | **002** | Jul 29, 2004 |
| **AP** | | HIKMA FARMACEUTICA | **200MG/100ML (2MG/ML)** | **A076736** | **001** | Aug 23, 2005 |
| **AP** | | WEST-WARD PHARMS INT | **200MG/100ML (2MG/ML)** | **A076087** | **001** | Jul 29, 2004 |
| **AP** | | | **400MG/200ML (2MG/ML)** | **A076087** | **003** | Jul 29, 2004 |
| **FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER** | | | | | | |
| **AP** | ! | ACS DOBFAR INFO SA | **200MG/100ML (2MG/ML)** | **A079104** | **001** | Jul 30, 2009 |
| **AP** | ! | | **400MG/200ML (2MG/ML)** | **A079104** | **002** | Jul 30, 2009 |
| **AP** | | BAXTER HLTHCARE | **200MG/100ML (2MG/ML)** | **A076766** | **001** | Jul 29, 2004 |
| **AP** | | | **400MG/200ML (2MG/ML)** | **A076766** | **002** | Jul 29, 2004 |
| **AP** | | HIKMA FARMACEUTICA | **200MG/100ML (2MG/ML)** | **A078698** | **001** | Jan 30, 2012 |
| **AP** | | | **400MG/200ML (2MG/ML)** | **A078698** | **002** | Jan 30, 2012 |
| **AP** | | HOSPIRA | **200MG/100ML (2MG/ML)** | **A076303** | **001** | Jul 29, 2004 |
| **AP** | | | **400MG/200ML (2MG/ML)** | **A076303** | **002** | Jul 29, 2004 |
| **AP** | | RENAISSANCE SSA LLC | **200MG/100ML (2MG/ML)** | **A077909** | **001** | May 26, 2010 |
| **AP** | | | **400MG/200ML (2MG/ML)** | **A077909** | **002** | May 26, 2010 |
| **AP** | | WEST-WARD PHARMS INT | **200MG/100ML (2MG/ML)** | **A078107** | **001** | Jul 30, 2008 |
| **AP** | | | **400MG/200ML (2MG/ML)** | **A078107** | **002** | Jul 30, 2008 |
| FLUCONAZOLE IN SODIUM CHLORIDE 0.9% | | | | | | |
| | | WEST-WARD PHARMS INT | 100MG/50ML (2MG/ML) | A076087 | 002 | Sep 26, 2008 |
| FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | | | | | | |
| | | RENAISSANCE SSA LLC | 100MG/50ML (2MG/ML) | A077909 | 003 | Apr 20, 2015 |

TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **DIFLUCAN** | | | | | | |
| **AB** | + | PFIZER | **50MG** | **N019949** | **001** | Jan 29, 1990 |
| **AB** | + | | **100MG** | **N019949** | **002** | Jan 29, 1990 |
| **AB** | + | | **150MG** | **N019949** | **004** | Jun 30, 1994 |
| **AB** | +! | | **200MG** | **N019949** | **003** | Jan 29, 1990 |
| **FLUCONAZOLE** | | | | | | |
| **AB** | | APOTEX | **50MG** | **A076665** | **001** | Jul 29, 2004 |
| **AB** | | | **100MG** | **A076665** | **002** | Jul 29, 2004 |
| **AB** | | | **150MG** | **A076665** | **003** | Jul 29, 2004 |
| **AB** | | | **200MG** | **A076665** | **004** | Jul 29, 2004 |
| **AB** | | AUROBINDO PHARMA | **50MG** | **A077731** | **001** | Oct 07, 2008 |
| **AB** | | | **100MG** | **A077731** | **002** | Oct 07, 2008 |
| **AB** | | | **150MG** | **A077731** | **003** | Oct 07, 2008 |
| **AB** | | | **200MG** | **A077731** | **004** | Oct 07, 2008 |
| **AB** | | DR REDDYS LABS INC | **50MG** | **A076658** | **001** | Jul 29, 2004 |
| **AB** | | | **100MG** | **A076658** | **002** | Jul 29, 2004 |
| **AB** | | | **150MG** | **A076658** | **003** | Jul 29, 2004 |
| **AB** | | | **200MG** | **A076658** | **004** | Jul 29, 2004 |
| **AB** | | GLENMARK GENERICS | **50MG** | **A077253** | **001** | Jan 25, 2006 |
| **AB** | | | **100MG** | **A077253** | **002** | Jan 25, 2006 |
| **AB** | | | **150MG** | **A077253** | **003** | Jan 25, 2006 |
| **AB** | | | **200MG** | **A077253** | **004** | Jan 25, 2006 |
| **AB** | | HARRIS PHARM | **50MG** | **A078423** | **001** | Mar 07, 2011 |
| **AB** | | | **100MG** | **A078423** | **002** | Mar 07, 2011 |
| **AB** | | | **150MG** | **A078423** | **003** | Mar 07, 2011 |
| **AB** | | | **200MG** | **A078423** | **004** | Mar 07, 2011 |
| **AB** | | IVAX SUB TEVA PHARMS | **50MG** | **A076077** | **001** | Jul 29, 2004 |
| **AB** | | | **100MG** | **A076077** | **002** | Jul 29, 2004 |

FLUCONAZOLE

TABLET;ORAL

**FLUCONAZOLE**

| | | | | | | |
|---|---|---|---|---|---|---|
| AB | | | 150MG | A076077 | 003 | Jul 29, 2004 |
| AB | | | 200MG | A076077 | 004 | Jul 29, 2004 |
| AB | | MYLAN | 50MG | A076351 | 001 | Jul 29, 2004 |
| AB | | | 100MG | A076351 | 002 | Jul 29, 2004 |
| AB | | | 150MG | A076351 | 003 | Jul 29, 2004 |
| AB | | | 200MG | A076351 | 004 | Jul 29, 2004 |
| AB | | TARO | 50MG | A076507 | 001 | Jul 29, 2004 |
| AB | | | 100MG | A076507 | 002 | Jul 29, 2004 |
| AB | | | 150MG | A076507 | 003 | Jul 29, 2004 |
| AB | | | 200MG | A076507 | 004 | Jul 29, 2004 |
| AB | | TEVA | 50MG | A074681 | 001 | Jul 29, 2004 |
| AB | | | 100MG | A074681 | 002 | Jul 29, 2004 |
| AB | | | 150MG | A074681 | 003 | Jul 29, 2004 |
| AB | | | 200MG | A074681 | 004 | Jul 29, 2004 |
| AB | | UNIQUE PHARM LABS | 50MG | A076957 | 001 | Sep 28, 2005 |
| AB | | | 100MG | A076957 | 002 | Sep 28, 2005 |
| AB | | | 150MG | A076957 | 004 | Feb 27, 2017 |
| AB | | | 200MG | A076957 | 003 | Sep 28, 2005 |
| AB | | ZYDUS PHARMS USA INC | 50MG | A208963 | 001 | Feb 16, 2017 |
| AB | | | 100MG | A208963 | 002 | Feb 16, 2017 |
| AB | | | 150MG | A208963 | 003 | Feb 16, 2017 |
| AB | | | 200MG | A208963 | 004 | Feb 16, 2017 |

FLUCYTOSINE

CAPSULE;ORAL

**ANCOBON**

| | | | | | | |
|---|---|---|---|---|---|---|
| AB | + | VALEANT | 250MG | N017001 | 001 | |
| AB | +! | | 500MG | N017001 | 002 | |

**FLUCYTOSINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| AB | | NOVEL LABS INC | 250MG | A204652 | 001 | Jul 07, 2017 |
| AB | | | 500MG | A204652 | 002 | Jul 07, 2017 |
| AB | | SIGMAPHARM LABS LLC | 250MG | A201566 | 001 | Jun 28, 2011 |
| AB | | | 500MG | A201566 | 002 | Jun 28, 2011 |
| AB | | WEST-WARD PHARMS INT | 250MG | A206550 | 001 | Oct 17, 2017 |
| AB | | | 500MG | A206550 | 002 | Oct 17, 2017 |

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION

**FLUDARABINE PHOSPHATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| AP | | ACTAVIS LLC | 50MG/2ML (25MG/ML) | A203738 | 001 | Feb 28, 2017 |
| AP | | ACTAVIS TOTOWA | 50MG/VIAL | A078610 | 001 | Feb 11, 2009 |
| AP | | CUSTOPHARM INC | 50MG/VIAL | A076349 | 001 | Aug 28, 2003 |
| AP | ! | FRESENIUS KABI USA | 50MG/2ML (25MG/ML) | A078393 | 001 | Oct 15, 2007 |
| AP | | | 50MG/VIAL | A078544 | 001 | Oct 15, 2007 |
| AP | ! | HOSPIRA | 50MG/VIAL | A077790 | 001 | Apr 06, 2007 |
| AP | | MUSTAFA NEVZAT ILAC | 50MG/2ML (25MG/ML) | A090724 | 001 | Sep 27, 2010 |
| AP | | MYLAN LABS LTD | 50MG/2ML (25MG/ML) | A200647 | 001 | Dec 21, 2011 |
| AP | | | 50MG/VIAL | A200648 | 001 | Oct 16, 2012 |
| AP | | SAGENT PHARMS | 50MG/2ML (25MG/ML) | A076661 | 001 | Apr 28, 2004 |
| AP | +! | SANDOZ | 50MG/2ML (25MG/ML) | N022137 | 001 | Sep 21, 2007 |

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS

**FLUDEOXYGLUCOSE F18**

| | | | | | | |
|---|---|---|---|---|---|---|
| AP | | 3D IMAGING DRUG | 20-300mCi/ML | A203778 | 001 | Oct 30, 2015 |
| AP | | BIOMEDCL RES FDN | 20-300mCi/ML | A203710 | 001 | May 01, 2015 |
| AP | | | 20-300mCi/ML | A203837 | 001 | May 01, 2015 |
| AP | | BRIGHAM WOMENS | 20-300mCi/ML | A203816 | 001 | Oct 30, 2014 |
| AP | | CARDINAL HEALTH 414 | 20-300mCi/ML | A203603 | 001 | Nov 13, 2015 |
| AP | | CHILDRENS HOSP MI | 20-300mCi/ML | A204385 | 001 | Oct 29, 2014 |
| AP | | CPDC | 20-300mCi/ML | A204525 | 001 | Oct 29, 2014 |
| AP | | ESSENTIAL ISOTOPES | 20-300mCi/ML | A203946 | 001 | Feb 05, 2014 |
| AP | +! | FEINSTEIN | 20-200mCi/ML | N021870 | 001 | Aug 19, 2005 |
| AP | +! | | 20-400mCi/ML | N021870 | 002 | Nov 21, 2008 |
| AP | | GLOBAL ISOTOPES LLC | 20-300mCi/ML | A204463 | 001 | Oct 21, 2014 |
| AP | ! | HOUSTON CYCLOTRON | 20-500mCi/ML | A203665 | 001 | Feb 14, 2013 |
| AP | | JUBILANT DRAXIMAGE | 20-300mCi/ML | A203920 | 001 | Jun 23, 2015 |
| AP | | KETTERING MEDCTR | 4-40mCi/ML | A204759 | 001 | Oct 27, 2015 |
| AP | | KREITCHMAN PET CTR | 10-100mCi/ML | A203942 | 001 | Apr 11, 2016 |

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS

**FLUDEOXYGLUCOSE F18**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | LANTHEUS MEDICAL | **20-200mCi/ML** | **A203664** | **001** | Feb 04, 2014 |
| **AP** | | MA GENERAL HOSP | **20-300mCi/ML** | **A204333** | **001** | Sep 25, 2014 |
| **AP** | | MCPRF | **20-240mCi/ML** | **A203612** | **001** | Aug 05, 2013 |
| **AP** | | MEM SLOAN-KETTERING | **20-300mCi/ML** | **A208679** | **001** | Dec 08, 2016 |
| **AP** | | METHODIST HOSP RES | **20-300mCi/ML** | **A203904** | **001** | Apr 23, 2015 |
| **AP** | | MIDWEST MEDCL | **20-200mCi/ML** | **A203736** | **001** | Nov 19, 2015 |
| **AP** | | MIPS CRF | **20-300mCi/ML** | **A204472** | **001** | Sep 11, 2015 |
| **AP** | | NCM USA BRONX LLC | **20-300mCi/ML** | **A204512** | **001** | Jan 07, 2015 |
| **AP** | | PETNET | **20-200mCi/ML** | **A079086** | **001** | Feb 25, 2011 |
| **AP** | ! | QUEEN HAMAMATSU PET | **10-100mCi/ML** | **A203771** | **001** | Aug 31, 2015 |
| **AP** | | SHERTECH LABS LLC | **20-300mCi/ML** | **A204264** | **001** | Dec 18, 2014 |
| **AP** | | SOFIE | **20-300mCi/ML** | **A203591** | **001** | Aug 31, 2015 |
| **AP** | | TRUSTEES UNIV PA | **20-200mCi/ML** | **A203801** | **001** | Oct 29, 2014 |
| **AP** | ! | UCLA BIOMEDICAL | **4-40mCi/ML** | **A203811** | **001** | Jun 27, 2013 |
| **AP** | | UCSF RODIOPHARM | **20-300mCi/ML** | **A203902** | **001** | May 09, 2014 |
| **AP** | | UIHC PET IMAGING | **20-300mCi/ML** | **A203990** | **001** | Aug 06, 2014 |
| **AP** | | UNIV MICHIGAN | **20-300mCi/ML** | **A204531** | **001** | Jul 17, 2015 |
| **AP** | | UNIV TX MD ANDERSON | **20-300mCi/ML** | **A203246** | **002** | Jan 13, 2014 |
| **AP** | | UNIV UTAH CYCLOTRON | **20-300mCi/ML** | **A204498** | **001** | Jun 23, 2015 |
| **AP** | | WI MEDCL CYCLOTRON | **20-500mCi/ML** | **A203709** | **001** | Oct 23, 2013 |
| **AP** | | WUSM CYCLOTRON | **20-300mCi/ML** | **A203935** | **001** | Feb 05, 2014 |
| | | HOT SHOTS NM LLC | 4-500mCi/ML | A203937 | 001 | Oct 30, 2014 |
| | | PRECISION NUCLEAR | 20-500mCi/ML | A204546 | 001 | Apr 07, 2015 |
| | | SPECTRON MRC LLC | 4-500mCi/ML | A203911 | 001 | Apr 22, 2015 |
| | | UNIV NORTH DAKOTA | 4-500mCi/ML | A203994 | 001 | Feb 04, 2015 |
| | | UNIV TX MD ANDERSON | 20-150mCi/ML | A203246 | 001 | Jan 13, 2014 |

FLUDROCORTISONE ACETATE

TABLET;ORAL

**FLUDROCORTISONE ACETATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | BARR | **0.1MG** | **A040425** | **001** | Jan 21, 2003 |
| **AB** | | HIKMA PHARMS | **0.1MG** | **A091302** | **001** | Jul 22, 2011 |
| **AB** | ! | IMPAX LABS | **0.1MG** | **A040431** | **001** | Mar 18, 2002 |

FLUMAZENIL

INJECTABLE;INJECTION

**FLUMAZENIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | FRESENIUS KABI USA | **0.5MG/5ML (0.1MG/ML)** | **A076955** | **002** | Oct 12, 2004 |
| **AP** | | | **1MG/10ML (0.1MG/ML)** | **A076955** | **001** | Oct 12, 2004 |
| **AP** | | HIKMA FARMACEUTICA | **0.5MG/5ML (0.1MG/ML)** | **A078527** | **001** | Mar 23, 2009 |
| **AP** | | | **1MG/10ML (0.1MG/ML)** | **A078527** | **002** | Mar 23, 2009 |
| **AP** | | MYLAN LABS LTD | **0.5MG/5ML (0.1MG/ML)** | **A078595** | **001** | May 13, 2008 |
| **AP** | ! | | **1MG/10ML (0.1MG/ML)** | **A078595** | **002** | May 13, 2008 |
| **AP** | | SAGENT PHARMS | **0.5MG/5ML (0.1MG/ML)** | **A090584** | **001** | Aug 28, 2012 |
| **AP** | | | **1MG/10ML (0.1MG/ML)** | **A090584** | **002** | Aug 28, 2012 |
| **AP** | | SANDOZ INC | **0.5MG/5ML (0.1MG/ML)** | **A077071** | **001** | May 03, 2005 |
| **AP** | | | **1MG/10ML (0.1MG/ML)** | **A077071** | **002** | May 03, 2005 |
| **AP** | | WEST-WARD PHARMS INT | **0.5MG/5ML (0.1MG/ML)** | **A076256** | **002** | Oct 12, 2004 |
| **AP** | | | **0.5MG/5ML (0.1MG/ML)** | **A076787** | **002** | Oct 12, 2004 |
| **AP** | | | **1MG/10ML (0.1MG/ML)** | **A076256** | **001** | Oct 12, 2004 |
| **AP** | | | **1MG/10ML (0.1MG/ML)** | **A076787** | **001** | Oct 12, 2004 |

FLUNISOLIDE

AEROSOL, METERED;INHALATION

AEROSPAN HFA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | MYLAN SPECIALITY LP | 0.078MG/INH | N021247 | 001 | Jan 27, 2006 |

SPRAY, METERED;NASAL

**FLUNISOLIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | ! | BAUSCH AND LOMB | **0.025MG/SPRAY** | **A074805** | **001** | Feb 20, 2002 |
| **AB** | | HI TECH PHARMA CO | **0.025MG/SPRAY** | **A077704** | **001** | Aug 03, 2006 |
| | ! | APOTEX INC | 0.029MG/SPRAY | A077436 | 001 | Aug 09, 2007 |

FLUOCINOLONE ACETONIDE

CREAM;TOPICAL

**FLUOCINOLONE ACETONIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | FOUGERA PHARMS INC | **0.01%** | **A088170** | **001** | Dec 16, 1982 |
| **AT** | | | **0.025%** | **A088169** | **001** | Dec 16, 1982 |
| **AT** | | G AND W LABS | **0.01%** | **A089526** | **001** | Jul 26, 1988 |
| **AT** | | | **0.025%** | **A089525** | **001** | Jul 26, 1988 |
| **AT** | | TARO | **0.025%** | **A087104** | **001** | Apr 27, 1982 |

FLUOCINOLONE ACETONIDE

CREAM;TOPICAL

**SYNALAR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **+!** | MEDIMETRIKS PHARMS | **0.01%** | **N012787** | **004** | |
| **AT** | **+!** | | **0.025%** | **N012787** | **002** | |
| **AT** | **+!** | | **0.025%** | **N012787** | **005** | |

IMPLANT;INTRAVITREAL

ILUVIEN

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ALIMERA SCIENCES INC | 0.19MG | N201923 | 001 | Sep 26, 2014 |

RETISERT

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | BAUSCH AND LOMB | 0.59MG | N021737 | 001 | Apr 08, 2005 |

OIL;TOPICAL

**DERMA-SMOOTHE/FS**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **+!** | HILL DERMAC | **0.01%** | **N019452** | **001** | Feb 03, 1988 |
| **AT** | **+!** | | **0.01%** | **N019452** | **002** | Nov 09, 2005 |

**FLUOCINOLONE ACETONIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | AKORN | **0.01%** | **A091514** | **001** | Jun 25, 2015 |
| **AT** | | IDENTI PHARMS INC | **0.01%** | **A201759** | **001** | Oct 17, 2011 |
| **AT** | | | **0.01%** | **A201764** | **001** | Oct 17, 2011 |
| **AT** | | LYNE | **0.01%** | **A090982** | **001** | Apr 25, 2016 |
| **AT** | | | **0.01%** | **A203377** | **001** | Apr 25, 2016 |
| **AT** | | PERRIGO ISRAEL | **0.01%** | **A202847** | **001** | Aug 09, 2013 |
| **AT** | | | **0.01%** | **A202848** | **001** | Aug 09, 2013 |
| **AT** | | TARO | **0.01%** | **A202368** | **001** | May 19, 2016 |
| **AT** | | | **0.01%** | **A209336** | **001** | May 19, 2016 |

OIL/DROPS;OTIC

**DERMOTIC**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **+!** | HILL DERMAC | **0.01%** | **N019452** | **003** | Nov 09, 2005 |

**FLUOCINOLONE ACETONIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | AKORN | **0.01%** | **A202705** | **001** | Sep 09, 2016 |
| **AT** | | IDENTI PHARMS INC | **0.01%** | **A091306** | **001** | Oct 17, 2011 |
| **AT** | | LYNE | **0.01%** | **A203378** | **001** | Apr 25, 2016 |
| **AT** | | PERRIGO ISRAEL | **0.01%** | **A202849** | **001** | Jul 17, 2017 |

OINTMENT;TOPICAL

**FLUOCINOLONE ACETONIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | FOUGERA PHARMS INC | **0.025%** | **A088168** | **001** | Dec 16, 1982 |
| **AT** | | G AND W LABS | **0.025%** | **A089524** | **001** | Jul 26, 1988 |
| **AT** | | TARO | **0.025%** | **A040041** | **001** | Sep 15, 1994 |

**SYNALAR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **+!** | MEDIMETRIKS PHARMS | **0.025%** | **N013960** | **001** | |

SHAMPOO;TOPICAL

CAPEX

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | GALDERMA LABS LP | 0.01% | N020001 | 001 | Aug 27, 1990 |

SOLUTION;TOPICAL

**FLUOCINOLONE ACETONIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | ACTAVIS LABS UT INC | **0.01%** | **A208386** | **001** | Oct 21, 2016 |
| **AT** | | FOUGERA PHARMS INC | **0.01%** | **A088167** | **001** | Dec 16, 1982 |
| **AT** | | G AND W LABS INC | **0.01%** | **A207441** | **001** | Sep 28, 2016 |
| **AT** | | GAVIS PHARMS LLC | **0.01%** | **A206422** | **001** | Sep 02, 2015 |
| **AT** | | GLASSHOUSE PHARMS | **0.01%** | **A209596** | **001** | Dec 26, 2017 |
| **AT** | | TARO | **0.01%** | **A089124** | **001** | Sep 11, 1985 |

**SYNALAR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **+!** | MEDIMETRIKS PHARMS | **0.01%** | **N015296** | **001** | |

FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN

CREAM;TOPICAL

TRI-LUMA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | GALDERMA LABS LP | 0.01%;4%;0.05% | N021112 | 001 | Jan 18, 2002 |

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE

CREAM;TOPICAL

NEO-SYNALAR

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | MEDIMETRIKS PHARMS | 0.025%;EQ 3.5MG BASE/GM | A060700 | 001 | |

FLUOCINONIDE

CREAM;TOPICAL

**FLUOCINONIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | FOUGERA PHARMS INC | **0.1%** | **A200735** | **001** | Jul 14, 2014 |
| **AB** | | GLENMARK GENERICS | **0.1%** | **A091282** | **001** | Jul 14, 2014 |
| **AB** | | PERRIGO ISRAEL | **0.1%** | **A090256** | **001** | Jan 14, 2014 |
| **AB** | | TARO | **0.1%** | **A200734** | **001** | Jul 14, 2014 |

**VANOS**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | MEDICIS | **0.1%** | **N021758** | **001** | Feb 11, 2005 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| FLUOCINONIDE | | | | | | | |
| CREAM;TOPICAL | | | | | | | |
| **FLUOCINONIDE** | | | | | | | |
| **AB1** | | FOUGERA PHARMS INC | **0.05%** | **A073030** | **001** | Oct 17, 1994 |
| **AB1** | | G AND W LABS INC | **0.05%** | **A073085** | **001** | Feb 14, 1992 |
| **AB1** | | TARO | **0.05%** | **A071500** | **001** | Jun 10, 1987 |
| **AB1** | **+!** | | **0.05%** | **N019117** | **001** | Jun 26, 1984 |
| **AB1** | | TEVA | **0.05%** | **A072488** | **001** | Feb 06, 1989 |
| **FLUOCINONIDE EMULSIFIED BASE** | | | | | | | |
| **AB2** | | FOUGERA PHARMS | **0.05%** | **A076586** | **001** | Jun 23, 2004 |
| **AB2** | | G AND W LABS INC | **0.05%** | **A074204** | **001** | Jun 13, 1995 |
| **AB2** | **!** | TARO | **0.05%** | **A072494** | **001** | Jan 19, 1989 |
| **AB2** | | TEVA | **0.05%** | **A072490** | **001** | Feb 07, 1989 |
| GEL;TOPICAL | | | | | | | |
| **FLUOCINONIDE** | | | | | | | |
| **AB** | **+** | CNTY LINE PHARMS | **0.05%** | **N017373** | **001** | |
| **AB** | | FOUGERA PHARMS INC | **0.05%** | **A072933** | **001** | Dec 30, 1994 |
| **AB** | | G AND W LABS INC | **0.05%** | **A072537** | **001** | Feb 07, 1989 |
| **AB** | **!** | TARO | **0.05%** | **A074935** | **001** | Jul 29, 1997 |
| OINTMENT;TOPICAL | | | | | | | |
| **FLUOCINONIDE** | | | | | | | |
| **AB** | | FOUGERA PHARMS | **0.05%** | **A074905** | **001** | Aug 26, 1997 |
| **AB** | | NOVEL LABS INC | **0.05%** | **A207538** | **001** | Jul 31, 2017 |
| **AB** | **!** | TARO | **0.05%** | **A075008** | **001** | Jun 30, 1999 |
| **AB** | | TEVA | **0.05%** | **A073481** | **001** | Dec 27, 1991 |
| **LIDEX** | | | | | | | |
| **AB** | **+** | CNTY LINE PHARMS | **0.05%** | **N016909** | **002** | |
| SOLUTION;TOPICAL | | | | | | | |
| **FLUOCINONIDE** | | | | | | | |
| **AT** | | FOUGERA PHARMS INC | **0.05%** | **A072934** | **001** | Feb 27, 1995 |
| **AT** | | G AND W LABS INC | **0.05%** | **A071535** | **001** | Dec 02, 1988 |
| **AT** | | NOVEL LABS INC | **0.05%** | **A206003** | **001** | Jul 21, 2017 |
| **AT** | **!** | TARO | **0.05%** | **A074799** | **001** | Dec 31, 1996 |
| **AT** | | TEVA | **0.05%** | **A072511** | **001** | Feb 07, 1989 |
| **LIDEX** | | | | | | | |
| **AT** | **+** | CNTY LINE PHARMS | **0.05%** | **N018849** | **001** | Apr 06, 1984 |
| FLUORESCEIN SODIUM | | | | | | | |
| INJECTABLE;INTRAVENOUS | | | | | | | |
| **AK-FLUOR 10%** | | | | | | | |
| **AP** | **+** | AKORN | **EQ 500MG BASE/5ML (EQ 100MG BASE/ML)** | **N022186** | **001** | Aug 08, 2008 |
| **FLUORESCITE** | | | | | | | |
| **AP** | **+!** | NOVARTIS PHARMS CORP | **EQ 500MG BASE/5ML (EQ 100MG BASE/ML)** | **N021980** | **001** | Mar 28, 2006 |
| AK-FLUOR 25% | | | | | | | |
| | +! | AKORN | EQ 500MG BASE/2ML (EQ 250MG BASE/ML) | N022186 | 002 | Aug 08, 2008 |
| FLUOROMETHOLONE | | | | | | | |
| OINTMENT;OPHTHALMIC | | | | | | | |
| FML | | | | | | | |
| | +! | ALLERGAN | 0.1% | N017760 | 001 | Sep 04, 1985 |
| SUSPENSION/DROPS;OPHTHALMIC | | | | | | | |
| FML | | | | | | | |
| | +! | ALLERGAN | 0.1% | N016851 | 002 | Jul 28, 1982 |
| FML FORTE | | | | | | | |
| | | ALLERGAN | 0.25% | N019216 | 001 | Apr 23, 1986 |
| FLUOROMETHOLONE ACETATE | | | | | | | |
| SUSPENSION/DROPS;OPHTHALMIC | | | | | | | |
| FLAREX | | | | | | | |
| | +! | NOVARTIS PHARMS CORP | 0.1% | N019079 | 001 | Feb 11, 1986 |
| FLUOROURACIL | | | | | | | |
| CREAM;TOPICAL | | | | | | | |
| **CARAC** | | | | | | | |
| **AB** | **+!** | VALEANT PHARMS NORTH | **0.5%** | **N020985** | **001** | Oct 27, 2000 |
| **EFUDEX** | | | | | | | |
| **AB** | **+!** | VALEANT PHARM INTL | **5%** | **N016831** | **003** | |
| **FLUOROURACIL** | | | | | | | |
| **AB** | | MYLAN PHARMS INC | **0.5%** | **A203122** | **001** | Apr 20, 2015 |
| **AB** | | SPEAR PHARMS | **5%** | **A077524** | **001** | Apr 11, 2008 |
| **AB** | | TARO | **5%** | **A090368** | **001** | Mar 05, 2010 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| FLUOROURACIL | | | | | | | |
| CREAM;TOPICAL | | | | | | | |
| FLUOROPLEX | | | | | | | |
| | +! | AQUA PHARMS | 1% | N016988 | 001 | | |
| TOLAK | | | | | | | |
| | +! | HILL DERMACEUTICALS | 4% | N022259 | 001 | Sep 18, 2015 | |
| INJECTABLE;INJECTION | | | | | | | |
| **FLUOROURACIL** | | | | | | | |
| **AP** | ! | ACCORD HLTHCARE | **500MG/10ML (50MG/ML)** | **A040743** | **002** | Apr 26, 2007 | |
| **AP** | ! | | **1GM/20ML (50MG/ML)** | **A040743** | **001** | Apr 26, 2007 | |
| **AP** | ! | | **2.5GM/50ML (50MG/ML)** | **A040798** | **002** | Apr 26, 2007 | |
| **AP** | ! | | **5GM/100ML (50MG/ML)** | **A040798** | **001** | Apr 26, 2007 | |
| **AP** | ! | FRESENIUS KABI USA | **500MG/10ML (50MG/ML)** | **A040279** | **002** | Sep 30, 1998 | |
| **AP** | ! | | **1GM/20ML (50MG/ML)** | **A040279** | **001** | Sep 30, 1998 | |
| **AP** | ! | | **2.5GM/50ML (50MG/ML)** | **A040278** | **001** | Sep 30, 1998 | |
| **AP** | ! | | **5GM/100ML (50MG/ML)** | **A040278** | **002** | Sep 30, 1998 | |
| **AP** | | GLAND PHARMA LTD | **500MG/10ML (50MG/ML)** | **A210123** | **001** | Oct 27, 2017 | |
| **AP** | | | **1GM/20ML (50MG/ML)** | **A210123** | **002** | Oct 27, 2017 | |
| **AP** | | | **2.5GM/50ML (50MG/ML)** | **A210124** | **001** | Dec 26, 2017 | |
| **AP** | | | **5GM/100ML (50MG/ML)** | **A210124** | **002** | Dec 26, 2017 | |
| **AP** | | MYLAN LABS LTD | **500MG/10ML (50MG/ML)** | **A202668** | **001** | Jul 17, 2012 | |
| **AP** | | | **1GM/20ML (50MG/ML)** | **A202668** | **002** | Jul 17, 2012 | |
| **AP** | | | **2.5GM/50ML (50MG/ML)** | **A202669** | **001** | Jul 17, 2012 | |
| **AP** | | | **5GM/100ML (50MG/ML)** | **A202669** | **002** | Jul 17, 2012 | |
| **AP** | | SAGENT PHARMS | **500MG/10ML (50MG/ML)** | **A203608** | **001** | May 11, 2017 | |
| **AP** | | | **1GM/20ML (50MG/ML)** | **A203608** | **002** | May 11, 2017 | |
| **AP** | | | **2.5GM/50ML (50MG/ML)** | **A203609** | **001** | Feb 17, 2016 | |
| **AP** | | | **5GM/100ML (50MG/ML)** | **A203609** | **002** | Feb 17, 2016 | |
| **AP** | ! | TEVA PHARMS USA | **500MG/10ML (50MG/ML)** | **A040333** | **001** | Jan 27, 2000 | |
| **AP** | ! | | **2.5GM/50ML (50MG/ML)** | **A040334** | **001** | Feb 25, 2000 | |
| **AP** | ! | | **5GM/100ML (50MG/ML)** | **A040334** | **002** | Feb 25, 2000 | |
| SOLUTION;TOPICAL | | | | | | | |
| **EFUDEX** | | | | | | | |
| **AT** | +! | VALEANT PHARM INTL | **2%** | **N016831** | **001** | | |
| **AT** | +! | | **5%** | **N016831** | **002** | | |
| **FLUOROURACIL** | | | | | | | |
| **AT** | | TARO PHARM | **2%** | **A076526** | **001** | Nov 05, 2003 | |
| **AT** | | | **5%** | **A076526** | **002** | Nov 05, 2003 | |
| FLUOXETINE HYDROCHLORIDE | | | | | | | |
| CAPSULE;ORAL | | | | | | | |
| **FLUOXETINE HYDROCHLORIDE** | | | | | | | |
| **AB** | | ALEMBIC PHARMS LTD | **EQ 40MG BASE** | **A090223** | **003** | Mar 19, 2009 | |
| **AB** | | AUROBINDO PHARMA | **EQ 40MG BASE** | **A078619** | **003** | Jan 31, 2008 | |
| **AB** | | DR REDDYS LABS LTD | **EQ 40MG BASE** | **A075465** | **003** | Aug 02, 2001 | |
| **AB** | | HERITAGE PHARMS INC | **EQ 40MG BASE** | **A201336** | **003** | Oct 01, 2012 | |
| **AB** | | IVAX SUB TEVA PHARMS | **EQ 40MG BASE** | **A075245** | **003** | Sep 28, 2004 | |
| **AB** | | PAR PHARM | **EQ 40MG BASE** | **A076922** | **003** | Dec 16, 2004 | |
| **AB** | | SANDOZ | **EQ 40MG BASE** | **A075049** | **003** | Jan 29, 2002 | |
| **AB** | | SCIEGEN PHARMS INC | **EQ 40MG BASE** | **A204597** | **003** | Mar 16, 2015 | |
| **AB** | | SUN PHARM INDS LTD | **EQ 40MG BASE** | **A076990** | **001** | Dec 13, 2004 | |
| **AB** | | TEVA | **EQ 40MG BASE** | **A075452** | **003** | Jan 29, 2002 | |
| **PROZAC** | | | | | | | |
| **AB** | +! | ELI LILLY AND CO | **EQ 40MG BASE** | **N018936** | **003** | Jun 15, 1999 | |
| **FLUOXETINE HYDROCHLORIDE** | | | | | | | |
| **AB1** | | ALEMBIC PHARMS LTD | **EQ 10MG BASE** | **A090223** | **001** | Mar 19, 2009 | |
| **AB1** | | | **EQ 20MG BASE** | **A090223** | **002** | Mar 19, 2009 | |
| **AB1** | | AUROBINDO PHARMA | **EQ 10MG BASE** | **A078619** | **001** | Jan 31, 2008 | |
| **AB1** | | | **EQ 20MG BASE** | **A078619** | **002** | Jan 31, 2008 | |
| **AB1** | | BARR | **EQ 10MG BASE** | **A074803** | **002** | Jan 30, 2002 | |
| **AB1** | | | **EQ 20MG BASE** | **A074803** | **001** | Aug 02, 2001 | |
| **AB1** | | DR REDDYS LABS LTD | **EQ 10MG BASE** | **A075465** | **001** | Jan 29, 2002 | |
| **AB1** | | | **EQ 20MG BASE** | **A075465** | **002** | Jan 29, 2002 | |
| **AB1** | | HERITAGE PHARMS INC | **EQ 10MG BASE** | **A201336** | **001** | Oct 01, 2012 | |
| **AB1** | | | **EQ 20MG BASE** | **A201336** | **002** | Oct 01, 2012 | |
| **AB1** | | IVAX SUB TEVA PHARMS | **EQ 10MG BASE** | **A075245** | **002** | Jan 31, 2002 | |
| **AB1** | | | **EQ 20MG BASE** | **A075245** | **001** | Jan 31, 2002 | |
| **AB1** | | LANDELA PHARM | **EQ 10MG BASE** | **A075464** | **001** | Jan 30, 2002 | |
| **AB1** | | | **EQ 20MG BASE** | **A075464** | **002** | Jan 30, 2002 | |
| **AB1** | | SANDOZ | **EQ 10MG BASE** | **A075049** | **001** | Aug 02, 2001 | |
| **AB1** | | | **EQ 20MG BASE** | **A075049** | **002** | Jan 29, 2002 | |

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

**FLUOXETINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB1** | | SCIEGEN PHARMS INC | **EQ 10MG BASE** | **A204597** | **001** | Mar 16, 2015 |
| **AB1** | | | **EQ 20MG BASE** | **A204597** | **002** | Mar 16, 2015 |
| **AB1** | | SPECGX LLC | **EQ 10MG BASE** | **A075658** | **001** | Jan 29, 2002 |
| **AB1** | | | **EQ 20MG BASE** | **A075658** | **002** | Jan 29, 2002 |
| **AB1** | | TEVA | **EQ 10MG BASE** | **A075452** | **001** | Jan 29, 2002 |
| **AB1** | | | **EQ 20MG BASE** | **A075452** | **002** | Jan 29, 2002 |
| **AB1** | | TEVA PHARMS USA | **EQ 10MG BASE** | **A076001** | **001** | Jan 29, 2002 |
| **AB1** | | | **EQ 20MG BASE** | **A076001** | **002** | Jan 29, 2002 |

**PROZAC**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB1** | **+** | ELI LILLY AND CO | **EQ 10MG BASE** | **N018936** | **006** | Dec 23, 1992 |
| **AB1** | **+** | | **EQ 20MG BASE** | **N018936** | **001** | Dec 29, 1987 |

FLUOXETINE HYDROCHLORIDE

| | | | | | | |
|---|---|---|---|---|---|---|
| | | MYLAN | EQ 10MG BASE | A078045 | 001 | Nov 17, 2008 |
| | ! | | EQ 20MG BASE | A078045 | 002 | Nov 17, 2008 |

CAPSULE, DELAYED REL PELLETS;ORAL

**FLUOXETINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | BARR | **EQ 90MG BASE** | **A076237** | **001** | Mar 24, 2010 |
| **AB** | | DR REDDYS LABS LTD | **EQ 90MG BASE** | **A078572** | **001** | Mar 22, 2010 |

**PROZAC WEEKLY**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | LILLY | **EQ 90MG BASE** | **N021235** | **001** | Feb 26, 2001 |

SOLUTION;ORAL

**FLUOXETINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | AUROBINDO PHARMA LTD | **EQ 20MG BASE/5ML** | **A079209** | **001** | Mar 20, 2009 |
| **AA** | **!** | PHARM ASSOC | **EQ 20MG BASE/5ML** | **A076015** | **001** | Jan 30, 2002 |
| **AA** | | SILARX | **EQ 20MG BASE/5ML** | **A077849** | **001** | Feb 09, 2007 |
| **AA** | | SPECGX LLC | **EQ 20MG BASE/5ML** | **A075920** | **001** | Jan 29, 2002 |
| **AA** | | TEVA | **EQ 20MG BASE/5ML** | **A075506** | **001** | Aug 02, 2001 |
| **AA** | | WOCKHARDT BIO AG | **EQ 20MG BASE/5ML** | **A075514** | **001** | Aug 29, 2002 |

TABLET;ORAL

**FLUOXETINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALEMBIC PHARMS LTD | **EQ 10MG BASE** | **A208698** | **001** | Apr 05, 2017 |
| **AB** | | | **EQ 20MG BASE** | **A208698** | **002** | Apr 05, 2017 |
| **AB** | **+!** | ALVOGEN | **EQ 60MG BASE** | **N202133** | **001** | Oct 06, 2011 |
| **AB** | | DR REDDYS LABS INC | **EQ 10MG BASE** | **A076006** | **001** | Jan 30, 2002 |
| **AB** | | INVENTIA HLTHCARE | **EQ 60MG BASE** | **A209695** | **001** | Nov 20, 2017 |
| **AB** | | MYLAN | **EQ 10MG BASE** | **A075755** | **001** | Aug 02, 2001 |
| **AB** | **!** | | **EQ 20MG BASE** | **A075755** | **002** | Aug 02, 2001 |
| **AB** | | PAR FORM | **EQ 10MG BASE** | **A203836** | **001** | Aug 19, 2016 |
| **AB** | | | **EQ 20MG BASE** | **A203836** | **002** | Aug 19, 2016 |
| **AB** | | PAR PHARM INC | **EQ 60MG BASE** | **A209419** | **001** | Nov 16, 2017 |
| **AB** | | TEVA | **EQ 10MG BASE** | **A075872** | **001** | Jan 29, 2002 |
| **AB1** | | TORRENT PHARMS LTD | **EQ 10MG BASE** | **A206937** | **001** | Oct 21, 2016 |
| **AB1** | | | **EQ 20MG BASE** | **A206937** | **002** | Oct 21, 2016 |

**SARAFEM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB1** | **+** | APIL | **EQ 10MG BASE** | **N021860** | **001** | May 19, 2006 |
| **AB1** | **+** | | **EQ 15MG BASE** | **N021860** | **002** | May 19, 2006 |
| **AB1** | **+!** | | **EQ 20MG BASE** | **N021860** | **003** | May 19, 2006 |

**SELFEMRA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB1** | | TEVA PHARMS USA | **EQ 10MG BASE** | **A200151** | **001** | Feb 03, 2014 |
| **AB1** | | | **EQ 15MG BASE** | **A200151** | **002** | Feb 03, 2014 |
| **AB1** | | | **EQ 20MG BASE** | **A200151** | **003** | Feb 03, 2014 |

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE;ORAL

**OLANZAPINE AND FLUOXETINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | PAR PHARM | **EQ 25MG BASE;EQ 3MG BASE** | **A077742** | **001** | Nov 02, 2012 |
| **AB** | | | **EQ 25MG BASE;EQ 6MG BASE** | **A077742** | **002** | Nov 02, 2012 |
| **AB** | | | **EQ 25MG BASE;EQ 12MG BASE** | **A077742** | **003** | Nov 02, 2012 |
| **AB** | | | **EQ 50MG BASE;EQ 6MG BASE** | **A077742** | **004** | Nov 02, 2012 |
| **AB** | | | **EQ 50MG BASE;EQ 12MG BASE** | **A077742** | **005** | Nov 02, 2012 |
| **AB** | | SANDOZ | **EQ 25MG BASE;EQ 3MG BASE** | **A078901** | **005** | Nov 16, 2012 |
| **AB** | | | **EQ 25MG BASE;EQ 6MG BASE** | **A078901** | **001** | Nov 16, 2012 |
| **AB** | | | **EQ 25MG BASE;EQ 12MG BASE** | **A078901** | **003** | Nov 16, 2012 |
| **AB** | | | **EQ 50MG BASE;EQ 6MG BASE** | **A078901** | **002** | Nov 16, 2012 |
| **AB** | | | **EQ 50MG BASE;EQ 12MG BASE** | **A078901** | **004** | Nov 16, 2012 |
| **AB** | | TEVA PHARMS | **EQ 25MG BASE;EQ 3MG BASE** | **A202074** | **001** | Mar 25, 2013 |
| **AB** | | | **EQ 25MG BASE;EQ 6MG BASE** | **A077528** | **001** | Jun 19, 2012 |
| **AB** | | | **EQ 25MG BASE;EQ 12MG BASE** | **A077528** | **002** | Jun 19, 2012 |
| **AB** | | | **EQ 50MG BASE;EQ 6MG BASE** | **A077528** | **003** | Jun 19, 2012 |

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE;ORAL

**OLANZAPINE AND FLUOXETINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **EQ 50MG BASE;EQ 12MG BASE** | **A077528** | **004** | Jun 19, 2012 |

**SYMBYAX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | LILLY | **EQ 25MG BASE;EQ 3MG BASE** | **N021520** | **001** | Apr 09, 2007 |
| **AB** | + | | **EQ 25MG BASE;EQ 6MG BASE** | **N021520** | **002** | Dec 24, 2003 |
| **AB** | + | | **EQ 25MG BASE;EQ 12MG BASE** | **N021520** | **004** | Dec 24, 2003 |
| **AB** | +! | | **EQ 50MG BASE;EQ 6MG BASE** | **N021520** | **003** | Dec 24, 2003 |
| **AB** | + | | **EQ 50MG BASE;EQ 12MG BASE** | **N021520** | **005** | Dec 24, 2003 |

FLUOXYMESTERONE

TABLET;ORAL

FLUOXYMESTERONE

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | USL PHARMA | 10MG | A088342 | 001 | Oct 21, 1983 |

FLUPHENAZINE DECANOATE

INJECTABLE;INJECTION

**FLUPHENAZINE DECANOATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AO** | | AUROBINDO PHARMA LTD | **25MG/ML** | **A207739** | **001** | Oct 17, 2017 |
| **AO** | ! | FRESENIUS KABI USA | **25MG/ML** | **A071413** | **001** | Jul 14, 1987 |
| **AO** | | PAR STERILE PRODUCTS | **25MG/ML** | **A203732** | **001** | Jul 03, 2014 |
| **AO** | | WEST-WARD PHARMS INT | **25MG/ML** | **A074531** | **001** | Aug 30, 1996 |

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

FLUPHENAZINE HYDROCHLORIDE

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | PHARM ASSOC | 5MG/ML | A074725 | 001 | Sep 16, 1996 |

ELIXIR;ORAL

FLUPHENAZINE HYDROCHLORIDE

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | PHARM ASSOC | 2.5MG/5ML | A040146 | 001 | Aug 21, 1996 |

INJECTABLE;INJECTION

FLUPHENAZINE HYDROCHLORIDE

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | FRESENIUS KABI USA | 2.5MG/ML | A089556 | 001 | Apr 16, 1987 |

TABLET;ORAL

**FLUPHENAZINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | LANNETT | **1MG** | **A089743** | **002** | Aug 25, 1988 |
| **AB** | | | **2.5MG** | **A089743** | **003** | Aug 25, 1988 |
| **AB** | | | **5MG** | **A089743** | **004** | Aug 25, 1988 |
| **AB** | | | **10MG** | **A089743** | **001** | Aug 25, 1988 |
| **AB** | | MYLAN | **1MG** | **A089804** | **002** | Aug 12, 1988 |
| **AB** | | | **2.5MG** | **A089804** | **003** | Aug 12, 1988 |
| **AB** | | | **5MG** | **A089804** | **004** | Aug 12, 1988 |
| **AB** | ! | | **10MG** | **A089804** | **001** | Aug 12, 1988 |
| **AB** | | SANDOZ | **1MG** | **A089586** | **002** | Oct 16, 1987 |
| **AB** | | | **2.5MG** | **A089586** | **003** | Oct 16, 1987 |
| **AB** | | | **5MG** | **A089586** | **004** | Oct 16, 1987 |
| **AB** | | | **10MG** | **A089586** | **001** | Oct 16, 1987 |

FLURANDRENOLIDE

CREAM;TOPICAL

**CORDRAN SP**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | +! | AQUA PHARMS | **0.05%** | **N012806** | **002** | |

**FLURANDRENOLIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | CINTEX SVCS | **0.05%** | **A205342** | **001** | Apr 13, 2016 |

CORDRAN SP

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | AQUA PHARMS | 0.025% | N012806 | 003 | |

LOTION;TOPICAL

**CORDRAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | +! | AQUA PHARMS | **0.05%** | **N013790** | **001** | |

**FLURANDRENOLIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | CINTEX SVCS | **0.05%** | **A205343** | **001** | Dec 22, 2016 |
| **AT** | | PERRIGO UK FINCO | **0.05%** | **A207133** | **001** | Aug 30, 2016 |

OINTMENT;TOPICAL

**CORDRAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | +! | AQUA PHARMS | **0.05%** | **N012806** | **001** | |

**FLURANDRENOLIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | TELIGENT PHARMA INC | **0.05%** | **A207851** | **001** | Dec 30, 2016 |

TAPE;TOPICAL

CORDRAN

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ALLERGAN SALES LLC | 0.004MG/SQ CM | N016455 | 001 | |

FLURAZEPAM HYDROCHLORIDE
CAPSULE;ORAL
FLURAZEPAM HYDROCHLORIDE

| | | | | | | |
|---|---|---|---|---|---|---|
| | | MYLAN PHARMS INC | 15MG | A070345 | 002 | Nov 27, 1985 |
| | ! | | 30MG | A070345 | 001 | Nov 27, 1985 |

FLURBIPROFEN
TABLET;ORAL
**FLURBIPROFEN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | MYLAN | **50MG** | **A074358** | **001** | Jun 20, 1994 |
| **AB** | ! | | **100MG** | **A074358** | **002** | Jun 20, 1994 |
| **AB** | | SUN PHARM INDS INC | **50MG** | **A075058** | **001** | Apr 27, 2001 |
| **AB** | | | **100MG** | **A075058** | **002** | Apr 27, 2001 |
| **AB** | | TEVA | **100MG** | **A074431** | **001** | May 31, 1995 |

FLURBIPROFEN SODIUM
SOLUTION/DROPS;OPHTHALMIC
**FLURBIPROFEN SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | BAUSCH AND LOMB | **0.03%** | **A074447** | **001** | Jan 04, 1995 |

**OCUFEN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **+!** | ALLERGAN | **0.03%** | **N019404** | **001** | Dec 31, 1986 |

FLUTAMIDE
CAPSULE;ORAL
**FLUTAMIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS LABS FL INC | **125MG** | **A075820** | **001** | Sep 18, 2001 |
| **AB** | ! | CIPLA LTD | **125MG** | **A075780** | **001** | Sep 19, 2001 |
| **AB** | | PAR PHARM | **125MG** | **A075298** | **001** | Sep 18, 2001 |

FLUTEMETAMOL F-18
INJECTABLE;INTRAVENOUS
VIZAMYL

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | GE HEALTHCARE | 40.5mCi/10ML (4.05mCi/ML) | N203137 | 001 | Oct 25, 2013 |
| | +! | | 121.5mCi/30ML (4.05mCi/ML) | N203137 | 002 | Oct 25, 2013 |

FLUTICASONE FUROATE
POWDER;INHALATION
ARNUITY ELLIPTA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | GLAXOSMITHKLINE | 0.1MG/INH | N205625 | 001 | Aug 20, 2014 |
| | +! | | 0.2MG/INH | N205625 | 002 | Aug 20, 2014 |

FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE
POWDER;INHALATION
TRELEGY ELLIPTA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | GLAXOSMITHKLINE | 0.1MG/INH;EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH | N209482 | 001 | Sep 18, 2017 |

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE
POWDER;INHALATION
BREO ELLIPTA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | GLAXO GRP LTD | 0.1MG/INH;EQ 0.025MG BASE/INH | N204275 | 001 | May 10, 2013 |
| | +! | | 0.2MG/INH;EQ 0.025MG BASE/INH | N204275 | 002 | Apr 30, 2015 |

FLUTICASONE PROPIONATE
AEROSOL, METERED;INHALATION
FLOVENT HFA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | GLAXO GRP LTD | 0.044MG/INH | N021433 | 003 | May 14, 2004 |
| | +! | | 0.11MG/INH | N021433 | 002 | May 14, 2004 |
| | +! | | 0.22MG/INH | N021433 | 001 | May 14, 2004 |

CREAM;TOPICAL
**FLUTICASONE PROPIONATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | FOUGERA PHARMS | **0.05%** | **A076451** | **001** | May 14, 2004 |
| **AB** | | G AND W LABS | **0.05%** | **A077055** | **001** | Jun 30, 2006 |
| **AB** | ! | PERRIGO NEW YORK | **0.05%** | **A076793** | **001** | May 14, 2004 |
| **AB** | | TOLMAR | **0.05%** | **A076633** | **001** | May 14, 2004 |

LOTION;TOPICAL
**CUTIVATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | FOUGERA PHARMS | **0.05%** | **N021152** | **001** | Mar 31, 2005 |

**FLUTICASONE PROPIONATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | GLENMARK GENERICS | **0.05%** | **A090759** | **001** | May 02, 2011 |
| **AB** | | PERRIGO ISRAEL | **0.05%** | **A091553** | **001** | Jul 30, 2013 |

OINTMENT;TOPICAL
**CUTIVATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | FOUGERA PHARMS | **0.005%** | **N019957** | **001** | Dec 14, 1990 |

**FLUTICASONE PROPIONATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | FOUGERA PHARMS | **0.005%** | **A076300** | **001** | May 14, 2004 |
| **AB** | | G AND W LABS | **0.005%** | **A077168** | **001** | Mar 03, 2006 |

| | | | | | | |
|---|---|---|---|---|---|---|
| FLUTICASONE PROPIONATE | | | | | | |
| OINTMENT;TOPICAL | | | | | | |
| **FLUTICASONE PROPIONATE** | | | | | | |
| **AB** | | PERRIGO NEW YORK | **0.005%** | **A076668** | **001** | May 14, 2004 |
| POWDER;INHALATION | | | | | | |
| ARMONAIR RESPICLICK | | | | | | |
| | + | TEVA PHARM | 0.055MG/INH | N208798 | 001 | Jan 27, 2017 |
| | + | | 0.113MG/INH | N208798 | 002 | Jan 27, 2017 |
| | +! | | 0.232MG/INH | N208798 | 003 | Jan 27, 2017 |
| FLOVENT DISKUS 100 | | | | | | |
| | +! | GLAXO GRP LTD | 0.1MG/INH | N020833 | 002 | Sep 29, 2000 |
| FLOVENT DISKUS 250 | | | | | | |
| | +! | GLAXO GRP LTD | 0.25MG/INH | N020833 | 003 | Sep 29, 2000 |
| FLOVENT DISKUS 50 | | | | | | |
| | +! | GLAXO GRP LTD | 0.05MG/INH | N020833 | 001 | Sep 29, 2000 |
| SPRAY, METERED;NASAL | | | | | | |
| **FLUTICASONE PROPIONATE** | | | | | | |
| **AB** | | APOTEX INC | **0.05MG/SPRAY** | **A077538** | **001** | Sep 12, 2007 |
| **AB** | | HI TECH PHARMA | **0.05MG/SPRAY** | **A077570** | **001** | Jan 16, 2008 |
| **AB** | **!** | WEST-WARD PHARMS INT | **0.05MG/SPRAY** | **A076504** | **001** | Feb 22, 2006 |
| **AB** | | WOCKHARDT BIO AG | **0.05MG/SPRAY** | **A078492** | **001** | Jan 09, 2012 |
| XHANCE | | | | | | |
| | +! | OPTNOSE US | 0.093MG | N209022 | 001 | Sep 18, 2017 |
| FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE | | | | | | |
| AEROSOL, METERED;INHALATION | | | | | | |
| ADVAIR HFA | | | | | | |
| | +! | GLAXO GRP LTD | 0.045MG/INH;EQ 0.021MG BASE/INH | N021254 | 001 | Jun 08, 2006 |
| | +! | | 0.115MG/INH;EQ 0.021MG BASE/INH | N021254 | 002 | Jun 08, 2006 |
| | +! | | 0.23MG/INH;EQ 0.021MG BASE/INH | N021254 | 003 | Jun 08, 2006 |
| POWDER;INHALATION | | | | | | |
| ADVAIR DISKUS 100/50 | | | | | | |
| | +! | GLAXO GRP LTD | 0.1MG/INH;EQ 0.05MG BASE/INH | N021077 | 001 | Aug 24, 2000 |
| ADVAIR DISKUS 250/50 | | | | | | |
| | +! | GLAXO GRP LTD | 0.25MG/INH;EQ 0.05MG BASE/INH | N021077 | 002 | Aug 24, 2000 |
| ADVAIR DISKUS 500/50 | | | | | | |
| | +! | GLAXO GRP LTD | 0.5MG/INH;EQ 0.05MG BASE/INH | N021077 | 003 | Aug 24, 2000 |
| AIRDUO RESPICLICK | | | | | | |
| | + | TEVA PHARM | 0.055MG/INH;EQ 0.014MG BASE/INH | N208799 | 001 | Jan 27, 2017 |
| | + | | 0.113MG/INH;EQ 0.014MG BASE/INH | N208799 | 002 | Jan 27, 2017 |
| | +! | | 0.232MG/INH;EQ 0.014MG BASE/INH | N208799 | 003 | Jan 27, 2017 |
| FLUVASTATIN SODIUM | | | | | | |
| CAPSULE;ORAL | | | | | | |
| **FLUVASTATIN SODIUM** | | | | | | |
| **AB** | | MYLAN PHARMS INC | **EQ 20MG BASE** | **A090595** | **001** | Apr 11, 2012 |
| **AB** | **!** | | **EQ 40MG BASE** | **A090595** | **002** | Apr 11, 2012 |
| **AB** | | TEVA PHARMS | **EQ 20MG BASE** | **A078407** | **001** | Jun 12, 2012 |
| **AB** | | | **EQ 40MG BASE** | **A078407** | **002** | Jun 12, 2012 |
| TABLET, EXTENDED RELEASE;ORAL | | | | | | |
| **FLUVASTATIN SODIUM** | | | | | | |
| **AB** | | MYLAN PHARMS INC | **EQ 80MG BASE** | **A202458** | **001** | Sep 11, 2015 |
| **AB** | | TEVA PHARMS USA | **EQ 80MG BASE** | **A079011** | **001** | Jan 27, 2016 |
| **LESCOL XL** | | | | | | |
| **AB** | **+!** | NOVARTIS | **EQ 80MG BASE** | **N021192** | **001** | Oct 06, 2000 |
| FLUVOXAMINE MALEATE | | | | | | |
| CAPSULE, EXTENDED RELEASE;ORAL | | | | | | |
| **FLUVOXAMINE MALEATE** | | | | | | |
| **AB** | | ACTAVIS ELIZABETH | **100MG** | **A091482** | **001** | Apr 23, 2013 |
| **AB** | **!** | | **150MG** | **A091482** | **002** | Nov 18, 2013 |
| **AB** | | ANCHEN PHARMS | **100MG** | **A091476** | **001** | Mar 13, 2013 |
| **AB** | | | **150MG** | **A091476** | **002** | Mar 13, 2013 |
| **AB** | | TORRENT PHARMS LTD | **100MG** | **A203240** | **001** | Oct 31, 2014 |
| **AB** | | | **150MG** | **A203240** | **002** | Oct 31, 2014 |
| TABLET;ORAL | | | | | | |
| **FLUVOXAMINE MALEATE** | | | | | | |
| **AB** | | ANI PHARMS INC | **25MG** | **A075897** | **001** | Jan 25, 2001 |
| **AB** | | | **50MG** | **A075897** | **002** | Jan 25, 2001 |
| **AB** | | | **100MG** | **A075897** | **003** | Jan 25, 2001 |
| **AB** | | APOTEX | **25MG** | **A075902** | **001** | May 07, 2001 |
| **AB** | | | **50MG** | **A075902** | **002** | May 07, 2001 |
| **AB** | | | **100MG** | **A075902** | **003** | May 07, 2001 |

| | | | | | | |
|---|---|---|---|---|---|---|
| FLUVOXAMINE MALEATE | | | | | | |
| TABLET;ORAL | | | | | | |
| **FLUVOXAMINE MALEATE** | | | | | | |
| **AB** | | MYLAN | **25MG** | **A075889** | **001** | Nov 29, 2000 |
| **AB** | | | **50MG** | **A075889** | **002** | Nov 29, 2000 |
| **AB** | | | **100MG** | **A075889** | **003** | Nov 29, 2000 |
| **AB** | | TEVA | **25MG** | **A075893** | **001** | Sep 10, 2002 |
| **AB** | | | **50MG** | **A075893** | **002** | Sep 10, 2002 |
| **AB** | | | **100MG** | **A075893** | **003** | Sep 10, 2002 |
| **AB** | | UPSHER-SMITH LABS | **25MG** | **A075888** | **001** | Nov 29, 2000 |
| **AB** | | | **50MG** | **A075888** | **002** | Nov 29, 2000 |
| **AB** | **!** | | **100MG** | **A075888** | **003** | Nov 29, 2000 |
| **LUVOX** | | | | | | |
| **AB** | | ANI PHARMS | **25MG** | **N021519** | **001** | Dec 20, 2007 |
| **AB** | | | **50MG** | **N021519** | **002** | Dec 20, 2007 |
| **AB** | | | **100MG** | **N021519** | **003** | Dec 20, 2007 |
| FOLIC ACID | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| FOLIC ACID | | | | | | |
| | ! | FRESENIUS KABI USA | 5MG/ML | A089202 | 001 | Feb 18, 1986 |
| TABLET;ORAL | | | | | | |
| **FOLIC ACID** | | | | | | |
| **AA** | | AIPING PHARM INC | **1MG** | **A091145** | **001** | Jul 12, 2013 |
| **AA** | **!** | AMNEAL PHARM | **1MG** | **A040625** | **001** | Jul 21, 2005 |
| **AA** | | CADILA PHARMS LTD | **1MG** | **A202437** | **001** | Jan 27, 2014 |
| **AA** | | HIKMA PHARMS | **1MG** | **A080600** | **001** | |
| **AA** | | INVAGEN PHARMS | **1MG** | **A090035** | **001** | Jun 09, 2009 |
| **AA** | | LEADING PHARMA LLC | **1MG** | **A040796** | **001** | Jan 12, 2009 |
| **AA** | | NUVO PHARM INC | **1MG** | **A204418** | **001** | Jul 28, 2015 |
| **AA** | | VINTAGE | **1MG** | **A040756** | **001** | Jun 04, 2010 |
| **AA** | **!** | WATSON LABS | **1MG** | **A080680** | **001** | |
| FOLLITROPIN ALFA/BETA | | | | | | |
| INJECTABLE;SUBCUTANEOUS | | | | | | |
| FOLLISTIM AQ | | | | | | |
| | +! | ORGANON USA INC | 300 IU/0.36ML | N021211 | 001 | Mar 23, 2004 |
| | +! | | 600 IU/0.72ML | N021211 | 002 | Mar 23, 2004 |
| | +! | | 900 IU/1.08ML | N021211 | 004 | Feb 11, 2005 |
| GONAL-F | | | | | | |
| | +! | EMD SERONO | 450 IU/VIAL | N020378 | 005 | Mar 26, 2004 |
| | + | | 1,050 IU/VIAL | N020378 | 004 | Feb 28, 2001 |
| GONAL-F RFF | | | | | | |
| | +! | EMD SERONO | 75 IU/VIAL | N021765 | 002 | Mar 25, 2004 |
| GONAL-F RFF REDI-JECT | | | | | | |
| | +! | EMD SERONO | 300 IU/0.5ML | N021684 | 001 | May 25, 2004 |
| | +! | | 450 IU/0.75ML | N021684 | 002 | May 25, 2004 |
| | +! | | 900 IU/1.5ML | N021684 | 003 | May 25, 2004 |
| FOMEPIZOLE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| **ANTIZOL** | | | | | | |
| **AP** | **+!** | PAR PHARM INC | **1.5GM/1.5ML (1GM/ML)** | **N020696** | **001** | Dec 04, 1997 |
| **FOMEPIZOLE** | | | | | | |
| **AP** | | LUITPOLD | **1.5GM/1.5ML (1GM/ML)** | **A078368** | **001** | Dec 14, 2007 |
| **AP** | | MYLAN INSTITUTIONAL | **1.5GM/1.5ML (1GM/ML)** | **A078639** | **001** | Mar 03, 2008 |
| **AP** | | NAVINTA LLC | **1.5GM/1.5ML (1GM/ML)** | **A078537** | **001** | Mar 06, 2008 |
| FONDAPARINUX SODIUM | | | | | | |
| INJECTABLE;SUBCUTANEOUS | | | | | | |
| **ARIXTRA** | | | | | | |
| **AP** | **+!** | MYLAN IRELAND LTD | **2.5MG/0.5ML** | **N021345** | **001** | Dec 07, 2001 |
| **AP** | **+!** | | **5MG/0.4ML** | **N021345** | **002** | May 28, 2004 |
| **AP** | **+!** | | **7.5MG/0.6ML** | **N021345** | **003** | May 28, 2004 |
| **AP** | **+!** | | **10MG/0.8ML** | **N021345** | **004** | May 28, 2004 |
| **FONDAPARINUX SODIUM** | | | | | | |
| **AP** | | AUROBINDO PHARMA LTD | **2.5MG/0.5ML** | **A206918** | **001** | Dec 26, 2017 |
| **AP** | | | **5MG/0.4ML** | **A206918** | **002** | Dec 26, 2017 |
| **AP** | | | **7.5MG/0.6ML** | **A206918** | **003** | Dec 26, 2017 |
| **AP** | | | **10MG/0.8ML** | **A206918** | **004** | Dec 26, 2017 |
| **AP** | | DR REDDYS LABS LTD | **2.5MG/0.5ML** | **A091316** | **001** | Jul 11, 2011 |
| **AP** | | | **5MG/0.4ML** | **A091316** | **002** | Jul 11, 2011 |
| **AP** | | | **7.5MG/0.6ML** | **A091316** | **003** | Jul 11, 2011 |
| **AP** | | | **10MG/0.8ML** | **A091316** | **004** | Jul 11, 2011 |

| | | | | | | |
|---|---|---|---|---|---|---|
| FORMOTEROL FUMARATE | | | | | | |
| SOLUTION;INHALATION | | | | | | |
| PERFOROMIST | | | | | | |
| | +! | MYLAN SPECLT | 0.02MG/2ML | N022007 | 001 | May 11, 2007 |
| FORMOTEROL FUMARATE; GLYCOPYRROLATE | | | | | | |
| AEROSOL, METERED;INHALATION | | | | | | |
| BEVESPI AEROSPHERE | | | | | | |
| | +! | ASTRAZENECA PHARMS | 0.0048MG/INH;0.0090MG/INH | N208294 | 001 | Apr 25, 2016 |
| FORMOTEROL FUMARATE; MOMETASONE FUROATE | | | | | | |
| AEROSOL, METERED;INHALATION | | | | | | |
| DULERA | | | | | | |
| | +! | MERCK SHARP DOHME | 0.005MG/INH;0.1MG/INH | N022518 | 001 | Jun 22, 2010 |
| | +! | | 0.005MG/INH;0.2MG/INH | N022518 | 002 | Jun 22, 2010 |
| FOSAMPRENAVIR CALCIUM | | | | | | |
| SUSPENSION;ORAL | | | | | | |
| LEXIVA | | | | | | |
| | +! | VIIV HLTHCARE | EQ 50MG BASE/ML | N022116 | 001 | Jun 14, 2007 |
| TABLET;ORAL | | | | | | |
| **FOSAMPRENAVIR CALCIUM** | | | | | | |
| **AB** | | MYLAN PHARMS INC | **EQ 700MG BASE** | **A204060** | **001** | Apr 15, 2016 |
| **LEXIVA** | | | | | | |
| **AB** | **+!** | VIIV HLTHCARE | **EQ 700MG BASE** | **N021548** | **001** | Oct 20, 2003 |
| FOSAPREPITANT DIMEGLUMINE | | | | | | |
| POWDER;INTRAVENOUS | | | | | | |
| **EMEND** | | | | | | |
| **AP** | **+!** | MERCK AND CO INC | **EQ 150MG BASE/VIAL** | **N022023** | **002** | Nov 12, 2010 |
| **FOSAPREPITANT DIMEGLUMINE** | | | | | | |
| **AP** | | FRESENIUS KABI USA | **EQ 150MG BASE/VIAL** | **A206197** | **001** | Jun 09, 2016 |
| FOSCARNET SODIUM | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| FOSCAVIR | | | | | | |
| | +! | CLINIGEN HLTHCARE | 2.4GM/100ML | N020068 | 001 | Sep 27, 1991 |
| FOSFOMYCIN TROMETHAMINE | | | | | | |
| FOR SUSPENSION;ORAL | | | | | | |
| MONUROL | | | | | | |
| | +! | ZAMBON SPA | EQ 3GM BASE/PACKET | N050717 | 001 | Dec 19, 1996 |
| FOSINOPRIL SODIUM | | | | | | |
| TABLET;ORAL | | | | | | |
| **FOSINOPRIL SODIUM** | | | | | | |
| **AB** | | APOTEX INC | **10MG** | **A076906** | **001** | May 17, 2005 |
| **AB** | | | **20MG** | **A076906** | **002** | May 17, 2005 |
| **AB** | | | **40MG** | **A076906** | **003** | May 17, 2005 |
| **AB** | | AUROBINDO PHARMA LTD | **10MG** | **A091163** | **001** | Mar 30, 2011 |
| **AB** | | | **20MG** | **A091163** | **002** | Mar 30, 2011 |
| **AB** | | | **40MG** | **A091163** | **003** | Mar 30, 2011 |
| **AB** | | INVAGEN PHARMS | **10MG** | **A077222** | **001** | Apr 20, 2005 |
| **AB** | | | **20MG** | **A077222** | **002** | Apr 20, 2005 |
| **AB** | | | **40MG** | **A077222** | **003** | Apr 20, 2005 |
| **AB** | | PRINSTON INC | **10MG** | **A205670** | **001** | Aug 29, 2016 |
| **AB** | | | **20MG** | **A205670** | **002** | Aug 29, 2016 |
| **AB** | | | **40MG** | **A205670** | **003** | Aug 29, 2016 |
| **AB** | | TEVA | **10MG** | **A076139** | **001** | Nov 25, 2003 |
| **AB** | | | **20MG** | **A076139** | **002** | Nov 25, 2003 |
| **AB** | **!** | | **40MG** | **A076139** | **003** | Nov 25, 2003 |
| **AB** | | UPSHER-SMITH LABS | **10MG** | **A076483** | **001** | Apr 23, 2004 |
| **AB** | | | **20MG** | **A076483** | **002** | Apr 23, 2004 |
| **AB** | | | **40MG** | **A076483** | **003** | Apr 23, 2004 |
| FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE | | | | | | |
| TABLET;ORAL | | | | | | |
| **FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE** | | | | | | |
| **AB** | | AUROBINDO PHARMA | **10MG;12.5MG** | **A079245** | **001** | Jul 09, 2009 |
| **AB** | | | **20MG;12.5MG** | **A079245** | **002** | Jul 09, 2009 |
| **AB** | | EMCURE PHARMS INDIA | **10MG;12.5MG** | **A079025** | **001** | Sep 17, 2010 |
| **AB** | **!** | | **20MG;12.5MG** | **A079025** | **002** | Sep 17, 2010 |
| **AB** | | INVAGEN PHARMS | **10MG;12.5MG** | **A090228** | **001** | Jul 09, 2009 |
| **AB** | | | **20MG;12.5MG** | **A090228** | **002** | Jul 09, 2009 |
| **AB** | | SANDOZ | **10MG;12.5MG** | **A076961** | **001** | Sep 28, 2005 |
| **AB** | | | **20MG;12.5MG** | **A076961** | **002** | Sep 28, 2005 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| FOSPHENYTOIN SODIUM | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| **CEREBYX** | | | | | | | |
| **AP** | **+!** | PARKE DAVIS | **EQ 50MG PHENYTOIN NA/ML** | **N020450** | **001** | Aug 05, 1996 |
| **FOSPHENYTOIN SODIUM** | | | | | | | |
| **AP** | | AMNEAL PHARMS CO | **EQ 50MG PHENYTOIN NA/ML** | **A078476** | **001** | Mar 18, 2008 |
| **AP** | | FRESENIUS KABI USA | **EQ 50MG PHENYTOIN NA/ML** | **A078052** | **001** | Aug 06, 2007 |
| **AP** | | HIKMA FARMACEUTICA | **EQ 50MG PHENYTOIN NA/ML** | **A078765** | **001** | Dec 02, 2009 |
| **AP** | | LUITPOLD | **EQ 50MG PHENYTOIN NA/ML** | **A078277** | **001** | Aug 06, 2007 |
| **AP** | | | **EQ 50MG PHENYTOIN NA/ML** | **A090099** | **001** | May 13, 2010 |
| **AP** | | MYLAN LABS LTD | **EQ 50MG PHENYTOIN NA/ML** | **A078736** | **001** | Jun 08, 2010 |
| **AP** | | SUN PHARMA GLOBAL | **EQ 50MG PHENYTOIN NA/ML** | **A078417** | **001** | Mar 18, 2008 |
| **AP** | | WEST-WARD PHARMS INT | **EQ 50MG PHENYTOIN NA/ML** | **A077481** | **001** | Aug 06, 2007 |
| **AP** | | | **EQ 50MG PHENYTOIN NA/ML** | **A077989** | **001** | Aug 06, 2007 |
| **AP** | | WOCKHARDT | **EQ 50MG PHENYTOIN NA/ML** | **A078137** | **001** | Aug 06, 2007 |
| FROVATRIPTAN SUCCINATE | | | | | | | |
| TABLET;ORAL | | | | | | | |
| **FROVA** | | | | | | | |
| **AB** | **+!** | ENDO PHARMS | **EQ 2.5MG BASE** | **N021006** | **001** | Nov 08, 2001 |
| **FROVATRIPTAN SUCCINATE** | | | | | | | |
| **AB** | | GLENMARK PHARMS LTD | **EQ 2.5MG BASE** | **A204730** | **001** | Mar 11, 2016 |
| **AB** | | MYLAN PHARMS INC | **EQ 2.5MG BASE** | **A202931** | **001** | Aug 28, 2014 |
| FULVESTRANT | | | | | | | |
| INJECTABLE;INTRAMUSCULAR | | | | | | | |
| FASLODEX | | | | | | | |
| | +! | ASTRAZENECA | 50MG/ML | N021344 | 001 | Apr 25, 2002 |
| FUROSEMIDE | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| **FUROSEMIDE** | | | | | | | |
| **AP** | | AMNEAL PHARMS CO | **10MG/ML** | **A207552** | **001** | Jul 20, 2016 |
| **AP** | | BAXTER HLTHCARE CORP | **10MG/ML** | **A202747** | **001** | Jan 27, 2014 |
| **AP** | | EMCURE PHARMS LTD | **10MG/ML** | **A203428** | **001** | Aug 26, 2014 |
| **AP** | | FRESENIUS KABI USA | **10MG/ML** | **N018902** | **001** | May 22, 1984 |
| **AP** | | HOSPIRA | **10MG/ML** | **A075241** | **001** | May 28, 1999 |
| **AP** | | | **10MG/ML** | **N018667** | **001** | May 28, 1982 |
| **AP** | | WOCKHARDT | **10MG/ML** | **A077941** | **001** | Mar 22, 2007 |
| SOLUTION;ORAL | | | | | | | |
| **FUROSEMIDE** | | | | | | | |
| **AA** | **!** | WEST-WARD PHARMS INT | **10MG/ML** | **A070434** | **001** | Apr 22, 1987 |
| **AA** | | WOCKHARDT BIO AG | **10MG/ML** | **A070655** | **001** | Oct 02, 1987 |
| | | WEST-WARD PHARMS INT | 40MG/5ML | A070433 | 001 | Apr 22, 1987 |
| TABLET;ORAL | | | | | | | |
| **FUROSEMIDE** | | | | | | | |
| **AB** | | IPCA LABS LTD | **20MG** | **A078010** | **001** | Sep 18, 2006 |
| **AB** | | | **40MG** | **A078010** | **002** | Sep 18, 2006 |
| **AB** | | | **80MG** | **A078010** | **003** | Sep 18, 2006 |
| **AB** | | IVAX SUB TEVA PHARMS | **20MG** | **N018413** | **001** | Nov 30, 1983 |
| **AB** | | | **40MG** | **N018413** | **002** | Nov 30, 1983 |
| **AB** | | LEADING PHARMA LLC | **20MG** | **A077293** | **001** | Nov 09, 2005 |
| **AB** | | | **40MG** | **A077293** | **002** | Nov 09, 2005 |
| **AB** | | | **80MG** | **A077293** | **003** | Nov 09, 2005 |
| **AB** | | MYLAN | **20MG** | **N018487** | **001** | |
| **AB** | | | **40MG** | **N018487** | **002** | |
| **AB** | | | **80MG** | **A070082** | **001** | Oct 29, 1986 |
| **AB** | | PRINSTON INC | **20MG** | **A076796** | **001** | Mar 26, 2004 |
| **AB** | | | **40MG** | **A076796** | **002** | Mar 26, 2004 |
| **AB** | | | **80MG** | **A076796** | **003** | Mar 26, 2004 |
| **AB** | | SANDOZ | **20MG** | **N018569** | **002** | |
| **AB** | | | **40MG** | **N018569** | **001** | |
| **AB** | | | **80MG** | **N018569** | **005** | Aug 14, 1984 |
| **AB** | | WEST-WARD PHARMS INT | **20MG** | **N018823** | **001** | Nov 10, 1983 |
| **AB** | | | **40MG** | **N018823** | **002** | Nov 10, 1983 |
| **AB** | | | **80MG** | **A070086** | **001** | Jan 24, 1986 |
| **LASIX** | | | | | | | |
| **AB** | **+** | US PHARM HOLDINGS | **20MG** | **N016273** | **002** | |
| **AB** | **+** | | **40MG** | **N016273** | **001** | |

FUROSEMIDE

TABLET;ORAL

**LASIX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | | **80MG** | **N016273** | **003** | |

GABAPENTIN

CAPSULE;ORAL

**GABAPENTIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS ELIZABETH | **100MG** | **A075350** | **001** | Sep 12, 2003 |
| **AB** | | | **300MG** | **A075350** | **002** | Sep 12, 2003 |
| **AB** | | | **400MG** | **A075350** | **003** | Sep 12, 2003 |
| **AB** | | ALKEM | **100MG** | **A090858** | **001** | Dec 17, 2010 |
| **AB** | | | **300MG** | **A090858** | **002** | Dec 17, 2010 |
| **AB** | | | **400MG** | **A090858** | **003** | Dec 17, 2010 |
| **AB** | | AMNEAL PHARMS NY | **100MG** | **A078428** | **001** | Jul 25, 2007 |
| **AB** | | | **300MG** | **A078428** | **002** | Jul 25, 2007 |
| **AB** | | | **400MG** | **A078428** | **003** | Jul 25, 2007 |
| **AB** | | APOTEX INC | **100MG** | **A075360** | **001** | Apr 06, 2005 |
| **AB** | | | **300MG** | **A075360** | **002** | Apr 06, 2005 |
| **AB** | | | **400MG** | **A075360** | **003** | Apr 06, 2005 |
| **AB** | | AUROBINDO PHARMA LTD | **100MG** | **A078787** | **001** | Jan 31, 2008 |
| **AB** | | | **300MG** | **A078787** | **002** | Jan 31, 2008 |
| **AB** | | | **400MG** | **A078787** | **003** | Jan 31, 2008 |
| **AB** | | EPIC PHARMA LLC | **100MG** | **A207099** | **001** | Mar 24, 2017 |
| **AB** | | | **300MG** | **A207099** | **002** | Mar 24, 2017 |
| **AB** | | | **400MG** | **A207099** | **003** | Mar 24, 2017 |
| **AB** | | INVAGEN PHARMS | **100MG** | **A090705** | **001** | Dec 30, 2009 |
| **AB** | | | **300MG** | **A090705** | **002** | Dec 30, 2009 |
| **AB** | | | **400MG** | **A090705** | **003** | Dec 30, 2009 |
| **AB** | | JIANGSU HENGRUI MED | **100MG** | **A091008** | **001** | Oct 26, 2017 |
| **AB** | | | **300MG** | **A091008** | **002** | Oct 26, 2017 |
| **AB** | | | **400MG** | **A091008** | **003** | Oct 26, 2017 |
| **AB** | | MARKSANS PHARMA | **100MG** | **A090007** | **001** | Jul 21, 2011 |
| **AB** | | | **300MG** | **A090007** | **002** | Jul 21, 2011 |
| **AB** | | | **400MG** | **A090007** | **003** | Jul 21, 2011 |
| **AB** | | MYLAN | **100MG** | **A090158** | **001** | Feb 14, 2011 |
| **AB** | | | **300MG** | **A090158** | **002** | Feb 14, 2011 |
| **AB** | | | **400MG** | **A090158** | **003** | Feb 14, 2011 |
| **AB** | | SCIEGEN PHARMS INC | **100MG** | **A204989** | **001** | Feb 18, 2016 |
| **AB** | | | **300MG** | **A204989** | **002** | Feb 18, 2016 |
| **AB** | | | **400MG** | **A204989** | **003** | Feb 18, 2016 |
| **AB** | | SUN PHARM INDS LTD | **100MG** | **A077242** | **001** | Aug 24, 2006 |
| **AB** | | | **300MG** | **A077242** | **002** | Aug 24, 2006 |
| **AB** | | | **400MG** | **A077242** | **003** | Aug 24, 2006 |
| **AB** | | TARO PHARM | **100MG** | **A077261** | **001** | Aug 02, 2013 |
| **AB** | | | **300MG** | **A077261** | **002** | Aug 02, 2013 |
| **AB** | | | **400MG** | **A077261** | **003** | Aug 02, 2013 |
| **AB** | | TEVA PHARMS | **100MG** | **A075435** | **001** | Oct 08, 2004 |
| **AB** | | | **300MG** | **A075435** | **002** | Oct 08, 2004 |
| **AB** | | | **400MG** | **A075435** | **003** | Oct 08, 2004 |

**NEURONTIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | PFIZER PHARMS | **100MG** | **N020235** | **001** | Dec 30, 1993 |
| **AB** | **+** | | **300MG** | **N020235** | **002** | Dec 30, 1993 |
| **AB** | **+!** | | **400MG** | **N020235** | **003** | Dec 30, 1993 |

SOLUTION;ORAL

**GABAPENTIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | ACELLA PHARMS LLC | **250MG/5ML** | **A076403** | **001** | May 01, 2012 |
| **AA** | | AMNEAL PHARMS | **250MG/5ML** | **A202024** | **001** | Mar 23, 2012 |
| **AA** | | HI TECH PHARMA | **250MG/5ML** | **A078974** | **001** | Feb 18, 2011 |
| **AA** | | TARO | **250MG/5ML** | **A076672** | **001** | Jul 03, 2013 |
| **AA** | | TRIS PHARMA INC | **250MG/5ML** | **A091286** | **001** | Mar 14, 2016 |

**NEURONTIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **+!** | PARKE DAVIS | **250MG/5ML** | **N021129** | **001** | Mar 02, 2000 |

TABLET;ORAL

**GABAPENTIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACI HEALTHCARE LTD | **600MG** | **A203244** | **002** | Jul 12, 2013 |
| **AB** | | | **800MG** | **A203244** | **001** | Jul 12, 2013 |
| **AB** | | ACTAVIS ELIZABETH | **600MG** | **A075694** | **001** | Oct 21, 2004 |
| **AB** | | | **800MG** | **A075694** | **002** | Oct 21, 2004 |
| **AB** | | ALKEM LABS LTD | **600MG** | **A206402** | **001** | Dec 23, 2015 |
| **AB** | | | **800MG** | **A206402** | **002** | Dec 23, 2015 |
| **AB** | | APOTEX INC | **100MG** | **A077894** | **001** | Oct 10, 2006 |

GABAPENTIN

TABLET;ORAL

**GABAPENTIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **300MG** | **A077894** | **002** | Oct 10, 2006 |
| **AB** | | | **400MG** | **A077894** | **003** | Oct 10, 2006 |
| **AB** | | | **600MG** | **A077661** | **004** | Sep 13, 2006 |
| **AB** | | | **800MG** | **A077661** | **005** | Sep 13, 2006 |
| **AB** | | AUROBINDO PHARMA LTD | **600MG** | **A200651** | **001** | Oct 06, 2011 |
| **AB** | | | **800MG** | **A200651** | **002** | Oct 06, 2011 |
| **AB** | | CSPC OUYI PHARM CO | **600MG** | **A207057** | **001** | Oct 26, 2017 |
| **AB** | | | **800MG** | **A207057** | **002** | Oct 26, 2017 |
| **AB** | | GLENMARK PHARMS LTD | **600MG** | **A077662** | **001** | Aug 18, 2006 |
| **AB** | | | **800MG** | **A077662** | **002** | Aug 18, 2006 |
| **AB** | | INVAGEN PHARMS | **600MG** | **A202764** | **001** | Oct 16, 2012 |
| **AB** | | | **800MG** | **A202764** | **002** | Oct 16, 2012 |
| **AB** | | IVAX SUB TEVA PHARMS | **100MG** | **A076017** | **001** | Apr 28, 2004 |
| **AB** | | | **300MG** | **A076017** | **002** | Apr 28, 2004 |
| **AB** | | | **400MG** | **A076017** | **003** | Apr 28, 2004 |
| **AB** | | | **600MG** | **A076017** | **004** | Apr 29, 2005 |
| **AB** | | | **800MG** | **A076017** | **005** | Apr 29, 2005 |
| **AB** | | MYLAN PHARMS INC | **600MG** | **A090335** | **001** | Jun 01, 2010 |
| **AB** | | | **800MG** | **A090335** | **002** | Jun 01, 2010 |
| **AB** | | SCIEGEN PHARMS INC | **600MG** | **A205101** | **001** | Feb 04, 2016 |
| **AB** | | | **800MG** | **A205101** | **002** | Feb 04, 2016 |
| **AB** | | SUN PHARM INDS LTD | **600MG** | **A077525** | **001** | Aug 24, 2006 |
| **AB** | | | **800MG** | **A077525** | **002** | Aug 24, 2006 |
| **AB** | | TEVA PHARMS USA | **600MG** | **A205807** | **001** | Mar 10, 2017 |
| **AB** | | | **800MG** | **A205807** | **002** | Mar 10, 2017 |
| **AB** | | ZYDUS PHARMS USA INC | **600MG** | **A078926** | **001** | Feb 11, 2011 |
| **AB** | | | **800MG** | **A078926** | **002** | Feb 11, 2011 |

**NEURONTIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | PFIZER PHARMS | **600MG** | **N020882** | **001** | Oct 09, 1998 |
| **AB** | **+!** | | **800MG** | **N020882** | **002** | Oct 09, 1998 |

GRALISE

| | | | | | | |
|---|---|---|---|---|---|---|
| BX | +! | DEPOMED INC | 300MG | N022544 | 001 | Jan 28, 2011 |
| BX | +! | | 600MG | N022544 | 002 | Jan 28, 2011 |

GABAPENTIN ENACARBIL

TABLET, EXTENDED RELEASE;ORAL

HORIZANT

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | ARBOR PHARMS LLC | 300MG | N022399 | 002 | Dec 13, 2011 |
| | +! | | 600MG | N022399 | 001 | Apr 06, 2011 |

GADOBENATE DIMEGLUMINE

INJECTABLE;INTRAVENOUS

MULTIHANCE

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | BRACCO | 2.645GM/5ML (529MG/ML) | N021357 | 001 | Nov 23, 2004 |
| | +! | | 5.29GM/10ML (529MG/ML) | N021357 | 002 | Nov 23, 2004 |
| | +! | | 7.935GM/15ML (529MG/ML) | N021357 | 003 | Nov 23, 2004 |
| | +! | | 10.58GM/20ML (529MG/ML) | N021357 | 004 | Nov 23, 2004 |

MULTIHANCE MULTIPACK

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | BRACCO | 26.45GM/50ML (529MG/ML) | N021358 | 001 | Nov 23, 2004 |
| | +! | | 52.9GM/100ML (529MG/ML) | N021358 | 002 | Nov 23, 2004 |

GADOBUTROL

SOLUTION;INTRAVENOUS

GADAVIST

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | BAYER HLTHCARE | 1.20944GM/2ML (604.72MG/ML) | N201277 | 006 | Dec 18, 2013 |
| | +! | | 4.5354GM/7.5ML (604.72MG/ML) | N201277 | 001 | Mar 14, 2011 |
| | +! | | 6.0472GM/10ML (604.72MG/ML) | N201277 | 002 | Mar 14, 2011 |
| | +! | | 9.0708GM/15ML (604.72MG/ML) | N201277 | 003 | Mar 14, 2011 |
| | +! | | 18.1416GM/30ML (604.72MG/ML) | N201277 | 004 | Mar 14, 2011 |
| | +! | | 39.3068GM/65ML (604.72MG/ML) | N201277 | 005 | Mar 14, 2011 |

GADODIAMIDE

INJECTABLE;INJECTION

OMNISCAN

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | GE HEALTHCARE | 287MG/ML | N020123 | 001 | Jan 08, 1993 |
| | +! | | 28.7GM/100ML (287MG/ML) | N022066 | 002 | Sep 05, 2007 |

GADOPENTETATE DIMEGLUMINE

INJECTABLE;INJECTION

MAGNEVIST

| | | | | | |
|---|---|---|---|---|---|
| +! | BAYER HLTHCARE | 469.01MG/ML | N019596 | 001 | Jun 02, 1988 |
| +! | | 469.01MG/ML | N021037 | 001 | Mar 10, 2000 |

GADOTERATE MEGLUMINE

SOLUTION;INTRAVENOUS

DOTAREM

| | | | | | |
|---|---|---|---|---|---|
| +! | GUERBET | 37.69GM/100ML (376.9MG/ML) | N204781 | 001 | Mar 20, 2013 |
| +! | | 1.8845GM/5ML (376.9MG/ML) | N204781 | 005 | Mar 31, 2017 |
| +! | | 3.769GM/10ML (376.9MG/ML) | N204781 | 002 | Mar 20, 2013 |
| +! | | 5.6535GM/15ML (376.9MG/ML) | N204781 | 003 | Mar 20, 2013 |
| +! | | 7.538GM/20ML (376.9MG/ML) | N204781 | 004 | Mar 20, 2013 |

GADOTERIDOL

INJECTABLE;INJECTION

PROHANCE

| | | | | | |
|---|---|---|---|---|---|
| +! | BRACCO | 279.3MG/ML | N020131 | 001 | Nov 16, 1992 |

PROHANCE MULTIPACK

| | | | | | |
|---|---|---|---|---|---|
| +! | BRACCO | 279.3MG/ML | N021489 | 001 | Oct 09, 2003 |

GADOVERSETAMIDE

INJECTABLE;INJECTION

OPTIMARK

| | | | | | |
|---|---|---|---|---|---|
| +! | LIEBEL-FLARSHEIM | 1654.5MG/5ML (330.9MG/ML) | N020937 | 001 | Dec 08, 1999 |
| +! | | 3309MG/10ML (330.9MG/ML) | N020937 | 002 | Dec 08, 1999 |
| +! | | 4963.5MG/15ML (330.9MG/ML) | N020937 | 003 | Dec 08, 1999 |
| +! | | 6618MG/20ML (330.9MG/ML) | N020937 | 004 | Dec 08, 1999 |
| +! | | 16.545GM/50ML (330.9MG/ML) | N020975 | 001 | Dec 08, 1999 |

OPTIMARK IN PLASTIC CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| +! | LIEBEL-FLARSHEIM | 3309MG/10ML (330.9MG/ML) | N020976 | 002 | Dec 08, 1999 |
| +! | | 4963.5MG/15ML (330.9MG/ML) | N020976 | 003 | Dec 08, 1999 |
| +! | | 6618MG/20ML (330.9MG/ML) | N020976 | 004 | Dec 08, 1999 |
| +! | | 9927MG/30ML (330.9MG/ML) | N020976 | 001 | Dec 08, 1999 |

GADOXETATE DISODIUM

SOLUTION;INTRAVENOUS

EOVIST

| | | | | | |
|---|---|---|---|---|---|
| +! | BAYER HLTHCARE | 1.8143GM/10ML (181.43MG/ML) | N022090 | 001 | Jul 03, 2008 |
| + | | 2.72145GM/15ML (181.43MG/ML) | N022090 | 002 | Feb 04, 2013 |

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE;ORAL

**GALANTAMINE HYDROBROMIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | AUROBINDO PHARMA LTD | **EQ 8MG BASE** | **A204895** | **001** | Aug 05, 2016 |
| **AB** | | **EQ 16MG BASE** | **A204895** | **002** | Aug 05, 2016 |
| **AB** | | **EQ 24MG BASE** | **A204895** | **003** | Aug 05, 2016 |
| **AB** | BARR | **EQ 8MG BASE** | **A078189** | **001** | Sep 15, 2008 |
| **AB** | | **EQ 16MG BASE** | **A078189** | **002** | Sep 15, 2008 |
| **AB** | | **EQ 24MG BASE** | **A078189** | **003** | Sep 15, 2008 |
| **AB** | MYLAN | **EQ 8MG BASE** | **A090900** | **001** | Jan 24, 2011 |
| **AB** | | **EQ 16MG BASE** | **A090900** | **002** | Jan 24, 2011 |
| **AB** | | **EQ 24MG BASE** | **A090900** | **003** | Jan 24, 2011 |
| **AB** | SUN PHARMA GLOBAL | **EQ 8MG BASE** | **A090178** | **001** | Feb 02, 2011 |
| **AB** | | **EQ 16MG BASE** | **A090178** | **002** | Feb 02, 2011 |
| **AB** | | **EQ 24MG BASE** | **A090178** | **003** | Feb 02, 2011 |
| **AB** | WATSON LABS | **EQ 8MG BASE** | **A079028** | **001** | Dec 15, 2008 |
| **AB** | | **EQ 16MG BASE** | **A079028** | **002** | Dec 15, 2008 |
| **AB** | | **EQ 24MG BASE** | **A079028** | **003** | Dec 15, 2008 |

**RAZADYNE ER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | JANSSEN PHARMS | **EQ 8MG BASE** | **N021615** | **001** | Apr 01, 2005 |
| **AB** | **+** | | **EQ 16MG BASE** | **N021615** | **002** | Apr 01, 2005 |
| **AB** | **+** | | **EQ 24MG BASE** | **N021615** | **003** | Apr 01, 2005 |

SOLUTION;ORAL

GALANTAMINE HYDROBROMIDE

| | | | | | |
|---|---|---|---|---|---|
| ! | WEST-WARD PHARMS INT | 4MG/ML | A078185 | 001 | Jan 30, 2009 |

TABLET;ORAL

**GALANTAMINE HYDROBROMIDE**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | APOTEX INC | **EQ 4MG BASE** | **A077781** | **001** | Sep 27, 2011 |
| **AB** | | **EQ 8MG BASE** | **A077781** | **002** | Sep 27, 2011 |
| **AB** | | **EQ 12MG BASE** | **A077781** | **003** | Sep 27, 2011 |
| **AB** | AUROBINDO PHARMA | **EQ 4MG BASE** | **A090957** | **001** | Mar 29, 2011 |

GALANTAMINE HYDROBROMIDE

TABLET;ORAL

**GALANTAMINE HYDROBROMIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| | | LTD | | | | |
| **AB** | | | **EQ 8MG BASE** | **A090957** | **002** | Mar 29, 2011 |
| **AB** | | | **EQ 12MG BASE** | **A090957** | **003** | Mar 29, 2011 |
| **AB** | | BARR | **EQ 4MG BASE** | **A077605** | **001** | Aug 28, 2008 |
| **AB** | | | **EQ 8MG BASE** | **A077605** | **002** | Aug 28, 2008 |
| **AB** | | | **EQ 12MG BASE** | **A077605** | **003** | Aug 28, 2008 |
| **AB** | | DR REDDYS LABS LTD | **EQ 4MG BASE** | **A077593** | **001** | Sep 11, 2008 |
| **AB** | | | **EQ 8MG BASE** | **A077593** | **002** | Sep 11, 2008 |
| **AB** | | | **EQ 12MG BASE** | **A077593** | **003** | Sep 11, 2008 |
| **AB** | | MYLAN | **EQ 4MG BASE** | **A077590** | **001** | May 29, 2009 |
| **AB** | | | **EQ 8MG BASE** | **A077590** | **002** | May 29, 2009 |
| **AB** | | | **EQ 12MG BASE** | **A077590** | **003** | May 29, 2009 |
| **AB** | | SANDOZ | **EQ 4MG BASE** | **A077589** | **001** | Jun 22, 2009 |
| **AB** | | | **EQ 8MG BASE** | **A077589** | **002** | Jun 22, 2009 |
| **AB** | | | **EQ 12MG BASE** | **A077589** | **003** | Jun 22, 2009 |
| **AB** | | TEVA PHARMS | **EQ 4MG BASE** | **A077587** | **001** | Jul 09, 2009 |
| **AB** | | | **EQ 8MG BASE** | **A077587** | **002** | Jul 09, 2009 |
| **AB** | | | **EQ 12MG BASE** | **A077587** | **003** | Jul 09, 2009 |
| **AB** | | WEST-WARD PHARMS INT | **EQ 4MG BASE** | **A077608** | **001** | Feb 11, 2009 |
| **AB** | | | **EQ 8MG BASE** | **A077608** | **002** | Feb 11, 2009 |
| **AB** | | | **EQ 12MG BASE** | **A077608** | **003** | Feb 11, 2009 |
| **AB** | | YABAO PHARM | **EQ 4MG BASE** | **A077604** | **001** | Feb 06, 2009 |
| **AB** | | | **EQ 8MG BASE** | **A077604** | **002** | Feb 06, 2009 |
| **AB** | | | **EQ 12MG BASE** | **A077604** | **003** | Feb 06, 2009 |
| **AB** | | ZYDUS PHARMS USA INC | **EQ 4MG BASE** | **A078898** | **001** | Feb 17, 2011 |
| **AB** | | | **EQ 8MG BASE** | **A078898** | **002** | Feb 17, 2011 |
| **AB** | | | **EQ 12MG BASE** | **A078898** | **003** | Feb 17, 2011 |

**RAZADYNE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | JANSSEN PHARMS | **EQ 4MG BASE** | **N021169** | **001** | Feb 28, 2001 |
| **AB** | **+** | | **EQ 8MG BASE** | **N021169** | **002** | Feb 28, 2001 |
| **AB** | **+** | | **EQ 12MG BASE** | **N021169** | **003** | Feb 28, 2001 |

GALLIUM CITRATE GA-67

INJECTABLE;INJECTION

GALLIUM CITRATE GA 67

| | | | | | |
|---|---|---|---|---|---|
| BS | | LANTHEUS MEDCL | 2mCi/ML | N017478 | 001 |
| BS | | MALLINKRODT NUCLEAR | 2mCi/ML | N018058 | 001 |

GALLIUM DOTATATE GA-68

POWDER;INTRAVENOUS

NETSPOT

| | | | | | |
|---|---|---|---|---|---|
| | +! | AAA USA INC | 2.1-5.5mCi/ML | N208547 001 | Jun 01, 2016 |

GANCICLOVIR

GEL;OPHTHALMIC

ZIRGAN

| | | | | | |
|---|---|---|---|---|---|
| | +! | BAUSCH AND LOMB | 0.15% | N022211 001 | Sep 15, 2009 |

GANCICLOVIR

SOLUTION;IV (INFUSION)

GANCICLOVIR

| | | | | | |
|---|---|---|---|---|---|
| | +! | EXELA PHARMA SCS LLC | 500MG/250ML (2MG/ML) | N209347 001 | Feb 17, 2017 |

GANCICLOVIR SODIUM

INJECTABLE;INJECTION

**CYTOVENE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | ROCHE PALO | **EQ 500MG BASE/VIAL** | **N019661** | **001** | Jun 23, 1989 |

**GANCICLOVIR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | FRESENIUS KABI USA | **EQ 500MG BASE/VIAL** | **A090658** | **001** | Jun 21, 2010 |
| **AP** | | LUITPOLD PHARMS INC | **EQ 500MG BASE/VIAL** | **A202624** | **001** | Sep 18, 2013 |
| **AP** | | MYLAN LABS LTD | **EQ 500MG BASE/VIAL** | **A204560** | **001** | Nov 17, 2017 |
| **AP** | | PAR STERILE PRODUCTS | **EQ 500MG BASE/VIAL** | **A204950** | **001** | Dec 06, 2016 |

**GANCICLOVIR SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | PHARMASCIENCE INC | **EQ 500MG BASE/VIAL** | **A207645** | **001** | Dec 08, 2017 |

GANIRELIX ACETATE
INJECTABLE;INJECTION
GANIRELIX ACETATE

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ORGANON USA INC | EQ 250MCG BASE/0.5ML | N021057 | 001 | Jul 29, 1999 |

GATIFLOXACIN
SOLUTION/DROPS;OPHTHALMIC

| | | | | | | |
|---|---|---|---|---|---|---|
| **GATIFLOXACIN** | | | | | | |
| **AT** | | HI-TECH PHARMA CO | **0.5%** | **A203189** | **001** | Sep 03, 2014 |
| **AT** | | LUPIN LTD | **0.5%** | **A202653** | **001** | Aug 28, 2013 |
| **AT** | | SANDOZ INC | **0.5%** | **A204227** | **001** | Jul 11, 2016 |
| **ZYMAXID** | | | | | | |
| **AT** | **+!** | ALLERGAN | **0.5%** | **N022548** | **001** | May 18, 2010 |
| ZYMAR | | | | | | |
| | +! | ALLERGAN | 0.3% | N021493 | 001 | Mar 28, 2003 |

GEFITINIB
TABLET;ORAL
IRESSA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ASTRAZENECA PHARMS | 250MG | N206995 | 001 | Jul 13, 2015 |

GEMCITABINE HYDROCHLORIDE
INJECTABLE;INJECTION

| | | | | | | |
|---|---|---|---|---|---|---|
| **GEMCITABINE HYDROCHLORIDE** | | | | | | |
| **AP** | | ACCORD HLTHCARE | **EQ 200MG BASE/VIAL** | **A091594** | **001** | Jul 25, 2011 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A091594** | **002** | Jul 25, 2011 |
| **AP** | | | **EQ 2GM BASE/VIAL** | **A091594** | **003** | Jul 25, 2011 |
| **AP** | | ACTAVIS INC | **200MG/5.26ML (38MG/ML)** | **A204549** | **001** | Apr 11, 2016 |
| **AP** | | | **1GM/26.3ML (38MG/ML)** | **A204549** | **002** | Apr 11, 2016 |
| **AP** | | | **2GM/52.6ML (38MG/ML)** | **A204549** | **003** | Apr 11, 2016 |
| **AP** | | ACTAVIS TOTOWA | **EQ 200MG BASE/VIAL** | **A079160** | **001** | Jul 25, 2011 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A079160** | **002** | Jul 25, 2011 |
| **AP** | | | **EQ 2GM BASE/VIAL** | **A079160** | **003** | Jul 28, 2016 |
| **AP** | | APOTEX INC | **200MG/5.26ML (38MG/ML)** | **A206776** | **001** | May 23, 2017 |
| **AP** | | | **1GM/26.3ML (38MG/ML)** | **A206776** | **002** | May 23, 2017 |
| **AP** | | | **2GM/52.6ML (38MG/ML)** | **A206776** | **003** | May 23, 2017 |
| **AP** | | CIPLA LTD | **EQ 200MG BASE/VIAL** | **A078759** | **001** | Jul 25, 2011 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A078759** | **002** | Jul 25, 2011 |
| **AP** | | DR REDDYS LABS LTD | **EQ 200MG BASE/VIAL** | **A091365** | **001** | Jul 25, 2011 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A091365** | **002** | Jul 25, 2011 |
| **AP** | | | **EQ 2GM BASE/VIAL** | **A202997** | **001** | May 07, 2013 |
| **AP** | | EMCURE PHARMS LTD | **EQ 200MG BASE/VIAL** | **A202063** | **001** | Sep 11, 2012 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A202063** | **002** | Sep 11, 2012 |
| **AP** | | FRESENIUS KABI ONCOL | **EQ 200MG BASE/VIAL** | **A090799** | **001** | Jul 25, 2011 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A090799** | **002** | Jul 25, 2011 |
| **AP** | | | **EQ 2GM BASE/VIAL** | **A090799** | **003** | May 16, 2011 |
| **AP** | | FRESENIUS KABI USA | **EQ 2GM BASE/VIAL** | **A090242** | **003** | May 16, 2011 |
| **AP** | | GLAND PHARMA LTD | **EQ 200MG BASE/VIAL** | **A204520** | **001** | Jan 05, 2016 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A204520** | **002** | Jan 05, 2016 |
| **AP** | | HAMELN RDS GMBH | **EQ 200MG BASE/VIAL** | **A090663** | **001** | Sep 10, 2012 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A090663** | **002** | Sep 10, 2012 |
| **AP** | | HOSPIRA | **EQ 200MG BASE/VIAL** | **A078339** | **001** | Jul 25, 2011 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A078339** | **002** | Jul 25, 2011 |
| **AP** | **+!** | HOSPIRA INC | **200MG/5.26ML (38MG/ML)** | **N200795** | **001** | Aug 04, 2011 |
| **AP** | **+!** | | **1GM/26.3ML (38MG/ML)** | **N200795** | **002** | Aug 04, 2011 |
| **AP** | **!** | | **EQ 2GM BASE/VIAL** | **A079183** | **001** | Nov 15, 2010 |
| **AP** | **+!** | | **2GM/52.6ML (38MG/ML)** | **N200795** | **003** | Aug 04, 2011 |
| **AP** | | JIANGSU HANSOH PHARM | **EQ 200MG BASE/VIAL** | **A202485** | **001** | May 07, 2013 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A202485** | **002** | May 07, 2013 |
| **AP** | | LUITPOLD PHARMS INC | **EQ 200MG BASE/VIAL** | **A202031** | **001** | May 07, 2013 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A202031** | **002** | May 07, 2013 |
| **AP** | | MYLAN LABS LTD | **EQ 200MG BASE/VIAL** | **A200145** | **001** | Jul 25, 2011 |
| **AP** | | | **200MG/5.26ML (38MG/ML)** | **A205242** | **001** | Dec 06, 2017 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A200145** | **002** | Jul 25, 2011 |
| **AP** | | | **1GM/26.3ML (38MG/ML)** | **A205242** | **002** | Dec 06, 2017 |
| **AP** | | | **EQ 2GM BASE/VIAL** | **A200145** | **003** | Jul 25, 2011 |
| **AP** | | | **2GM/52.6ML (38MG/ML)** | **A205242** | **003** | Dec 06, 2017 |
| **AP** | | SUN PHARMA GLOBAL | **EQ 200MG BASE/VIAL** | **A078433** | **001** | Jul 25, 2011 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A078433** | **002** | Jul 25, 2011 |
| **AP** | | TEVA PHARMS | **EQ 200MG BASE/VIAL** | **A077983** | **002** | Jan 25, 2011 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A077983** | **001** | Jan 25, 2011 |

| | | | | | | |
|---|---|---|---|---|---|---|
| GEMCITABINE HYDROCHLORIDE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| **GEMZAR** | | | | | | |
| **AP** | **+!** | LILLY | **EQ 200MG BASE/VIAL** | **N020509** | **001** | May 15, 1996 |
| **AP** | **+!** | | **EQ 1GM BASE/VIAL** | **N020509** | **002** | May 15, 1996 |
| SOLUTION;IV (INFUSION) | | | | | | |
| GEMCITABINE HYDROCHLORIDE | | | | | | |
| | +! | ACCORD HLTHCARE | 1GM/10ML (100MG/ML) | N209604 | 002 | Aug 03, 2017 |
| | +! | | 1.5GM/15ML (100MG/ML) | N209604 | 003 | Aug 03, 2017 |
| | +! | | 2GM/20ML (100MG/ML) | N209604 | 004 | Aug 03, 2017 |
| | +! | | 200MG/2ML (100MG/ML) | N209604 | 001 | Aug 03, 2017 |
| GEMFIBROZIL | | | | | | |
| TABLET;ORAL | | | | | | |
| **GEMFIBROZIL** | | | | | | |
| **AB** | | APOTEX | **600MG** | **A075034** | **001** | Jul 20, 1998 |
| **AB** | | AUROBINDO PHARMA LTD | **600MG** | **A202726** | **001** | Sep 16, 2015 |
| **AB** | | CADILA PHARMS LTD | **600MG** | **A203266** | **001** | Jun 17, 2016 |
| **AB** | | CARIBE HOLDINGS | **600MG** | **A078012** | **001** | Mar 26, 2007 |
| **AB** | | CHARTWELL MOLECULES | **600MG** | **A074270** | **001** | Sep 27, 1993 |
| **AB** | | HIKMA PHARMS | **600MG** | **A078599** | **001** | Aug 16, 2010 |
| **AB** | | IMPAX PHARMS | **600MG** | **A078207** | **001** | Jun 01, 2007 |
| **AB** | | INVAGEN PHARMS | **600MG** | **A077836** | **001** | Jul 27, 2006 |
| **AB** | | NORTHSTAR HLTHCARE | **600MG** | **A079072** | **001** | Sep 13, 2010 |
| **AB** | | SUN PHARM INDS INC | **600MG** | **A079239** | **001** | Dec 29, 2008 |
| **AB** | | TEVA | **600MG** | **A074256** | **001** | Oct 31, 1993 |
| **LOPID** | | | | | | |
| **AB** | **+!** | PFIZER PHARMS | **600MG** | **N018422** | **003** | Nov 20, 1986 |
| GEMIFLOXACIN MESYLATE | | | | | | |
| TABLET;ORAL | | | | | | |
| **FACTIVE** | | | | | | |
| **AB** | **+!** | LG CHEM LTD | **EQ 320MG BASE** | **N021158** | **001** | Apr 04, 2003 |
| **GEMIFLOXACIN MESYLATE** | | | | | | |
| **AB** | | ORCHID HLTHCARE | **EQ 320MG BASE** | **A090466** | **001** | Jun 15, 2015 |
| GENTAMICIN SULFATE | | | | | | |
| CREAM;TOPICAL | | | | | | |
| **GENTAMICIN SULFATE** | | | | | | |
| **AT** | | G AND W LABS INC | **EQ 0.1% BASE** | **A064056** | **001** | Apr 29, 1994 |
| **AT** | **!** | PERRIGO NEW YORK | **EQ 0.1% BASE** | **A062307** | **001** | |
| INJECTABLE;INJECTION | | | | | | |
| **GENTAMICIN SULFATE** | | | | | | |
| **AP** | | FRESENIUS KABI USA | **EQ 10MG BASE/ML** | **A062366** | **002** | Feb 06, 1986 |
| **AP** | **!** | | **EQ 40MG BASE/ML** | **A062366** | **001** | Aug 04, 1983 |
| **AP** | | HOSPIRA | **EQ 10MG BASE/ML** | **A062420** | **001** | Aug 15, 1983 |
| **AP** | | | **EQ 10MG BASE/ML** | **A062612** | **004** | Feb 20, 1986 |
| **AP** | | | **EQ 40MG BASE/ML** | **A062420** | **002** | Aug 15, 1983 |
| **GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER** | | | | | | |
| **AP** | | BAXTER HLTHCARE | **EQ 1.2MG BASE/ML** | **A062373** | **007** | Sep 07, 1982 |
| **AP** | | | **EQ 1.6MG BASE/ML** | **A062373** | **008** | Sep 07, 1982 |
| **AP** | | | **EQ 80MG BASE/100ML** | **A062373** | **002** | Sep 07, 1982 |
| **AP** | | | **EQ 100MG BASE/100ML** | **A062373** | **005** | Sep 07, 1982 |
| **AP** | | HOSPIRA | **EQ 1.2MG BASE/ML** | **A062414** | **001** | Aug 15, 1983 |
| **AP** | | | **EQ 1.6MG BASE/ML** | **A062414** | **003** | Aug 15, 1983 |
| **AP** | | | **EQ 80MG BASE/100ML** | **A062414** | **008** | Aug 15, 1983 |
| **AP** | | | **EQ 100MG BASE/100ML** | **A062414** | **010** | Aug 15, 1983 |
| | ! | BAXTER HLTHCARE | EQ 2MG BASE/ML | A062373 | 009 | Sep 07, 1982 |
| | ! | | EQ 120MG BASE/100ML | A062373 | 006 | Sep 07, 1982 |
| OINTMENT;OPHTHALMIC | | | | | | |
| **GENTAMICIN SULFATE** | | | | | | |
| **AT** | **!** | AKORN | **EQ 0.3% BASE** | **A064093** | **001** | Aug 31, 1995 |
| **AT** | | PERRIGO CO TENNESSEE | **EQ 0.3% BASE** | **A065024** | **001** | Jul 30, 2004 |
| OINTMENT;TOPICAL | | | | | | |
| **GENTAMICIN SULFATE** | | | | | | |
| **AT** | | FOUGERA PHARMS INC | **EQ 0.1% BASE** | **A062533** | **001** | Oct 05, 1984 |
| **AT** | **!** | PERRIGO NEW YORK | **EQ 0.1% BASE** | **A062351** | **001** | Feb 18, 1982 |
| **AT** | | TARO | **EQ 0.1% BASE** | **A062477** | **001** | Dec 23, 1983 |
| SOLUTION/DROPS;OPHTHALMIC | | | | | | |
| **GENOPTIC** | | | | | | |
| **AT** | **!** | ALLERGAN | **EQ 0.3% BASE** | **A062452** | **001** | Oct 10, 1984 |

GENTAMICIN SULFATE

SOLUTION/DROPS;OPHTHALMIC

**GENTAK**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | AKORN | **EQ 0.3% BASE** | **A064163** | **001** | Oct 12, 2001 |

**GENTAMICIN SULFATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | AKORN | **EQ 0.3% BASE** | **A062635** | **001** | Jan 08, 1987 |
| **AT** | | BAUSCH AND LOMB | **EQ 0.3% BASE** | **A064048** | **001** | May 11, 1994 |
| **AT** | | PERRIGO CO TENNESSEE | **EQ 0.3% BASE** | **A065121** | **001** | Jan 30, 2004 |
| **AT** | | SANDOZ INC | **EQ 0.3% BASE** | **A062196** | **001** | |

GENTAMICIN SULFATE; PREDNISOLONE ACETATE

OINTMENT;OPHTHALMIC

PRED-G

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ALLERGAN | EQ 0.3% BASE;0.6% | N050612 | 001 | Dec 01, 1989 |

SUSPENSION/DROPS;OPHTHALMIC

PRED-G

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ALLERGAN | EQ 0.3% BASE;1% | N050586 | 001 | Jun 10, 1988 |

GLATIRAMER ACETATE

INJECTABLE;SUBCUTANEOUS

**COPAXONE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | TEVA PHARMS USA | **20MG/ML** | **N020622** | **002** | Feb 12, 2002 |
| **AP** | **+!** | | **40MG/ML** | **N020622** | **003** | Jan 28, 2014 |

**GLATIRAMER ACETATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | MYLAN PHARMS INC | **20MG/ML** | **A091646** | **001** | Oct 03, 2017 |
| **AP** | | | **40MG/ML** | **A206936** | **001** | Oct 03, 2017 |

**GLATOPA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | SANDOZ INC | **20MG/ML** | **A090218** | **001** | Apr 16, 2015 |

GLECAPREVIR; PIBRENTASVIR

TABLET;ORAL

MAVYRET

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ABBVIE INC | 100MG;40MG | N209394 | 001 | Aug 03, 2017 |

GLIMEPIRIDE

TABLET;ORAL

**AMARYL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | SANOFI AVENTIS US | **1MG** | **N020496** | **001** | Nov 30, 1995 |
| **AB** | **+** | | **2MG** | **N020496** | **002** | Nov 30, 1995 |
| **AB** | **+** | | **4MG** | **N020496** | **003** | Nov 30, 1995 |

**GLIMEPIRIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACCORD HLTHCARE | **1MG** | **A078181** | **001** | Aug 23, 2007 |
| **AB** | | | **2MG** | **A078181** | **002** | Aug 23, 2007 |
| **AB** | | | **4MG** | **A078181** | **003** | Aug 23, 2007 |
| **AB** | | AUROBINDO PHARMA LTD | **1MG** | **A202759** | **001** | Jun 29, 2012 |
| **AB** | | | **2MG** | **A202759** | **002** | Jun 29, 2012 |
| **AB** | | | **4MG** | **A202759** | **003** | Jun 29, 2012 |
| **AB** | | CARLSBAD | **1MG** | **A077911** | **001** | Sep 22, 2009 |
| **AB** | | | **2MG** | **A077911** | **002** | Sep 22, 2009 |
| **AB** | | | **4MG** | **A077911** | **003** | Sep 22, 2009 |
| **AB** | | DR REDDYS LABS LTD | **1MG** | **A077091** | **001** | Oct 06, 2005 |
| **AB** | | | **2MG** | **A077091** | **002** | Oct 06, 2005 |
| **AB** | | | **4MG** | **A077091** | **003** | Oct 06, 2005 |
| **AB** | | INDOCO REMEDIES | **1MG** | **A202112** | **001** | Apr 17, 2013 |
| **AB** | | | **2MG** | **A202112** | **002** | Apr 17, 2013 |
| **AB** | | | **4MG** | **A202112** | **003** | Apr 17, 2013 |
| **AB** | | INVAGEN PHARMS | **1MG** | **A077295** | **001** | Oct 06, 2005 |
| **AB** | | | **2MG** | **A077295** | **002** | Oct 06, 2005 |
| **AB** | | | **4MG** | **A077295** | **003** | Oct 06, 2005 |
| **AB** | | MYLAN | **1MG** | **A077624** | **001** | Nov 28, 2005 |
| **AB** | | | **2MG** | **A077624** | **002** | Nov 28, 2005 |
| **AB** | | | **4MG** | **A077624** | **003** | Nov 28, 2005 |
| **AB** | | PRINSTON INC | **1MG** | **A077370** | **001** | Dec 23, 2005 |
| **AB** | | | **2MG** | **A077370** | **002** | Dec 23, 2005 |
| **AB** | | | **4MG** | **A077370** | **003** | Dec 23, 2005 |
| **AB** | | | **8MG** | **A077370** | **004** | Dec 23, 2005 |
| **AB** | | TEVA | **1MG** | **A076802** | **001** | Oct 06, 2005 |
| **AB** | | | **2MG** | **A076802** | **002** | Oct 06, 2005 |
| **AB** | | | **4MG** | **A076802** | **003** | Oct 06, 2005 |
| **AB** | | VIVA HLTHCARE | **1MG** | **A091220** | **001** | Jun 29, 2012 |
| **AB** | | | **2MG** | **A091220** | **002** | Jun 29, 2012 |
| **AB** | | | **4MG** | **A091220** | **004** | Jun 29, 2012 |
| **AB** | | | **8MG** | **A091220** | **006** | Jun 29, 2012 |

GLIMEPIRIDE

TABLET;ORAL

GLIMEPIRIDE

| | | | | | | |
|---|---|---|---|---|---|---|
| | | | 3MG | | A091220 003 | Jun 29, 2012 |
| | | | 6MG | | A091220 005 | Jun 29, 2012 |

GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

**DUETACT**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | TAKEDA PHARMS USA | **2MG;30MG** | | **N021925 001** | Jul 28, 2006 |
| **AB** | **+** | | **4MG;30MG** | | **N021925 002** | Jul 28, 2006 |

**PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | SANDOZ | **2MG;30MG** | | **A201049 001** | Jan 04, 2013 |
| **AB** | | | **4MG;30MG** | | **A201049 002** | Jan 04, 2013 |

GLIMEPIRIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL

ROSIGLITAZONE MALEATE AND GLIMEPIRIDE

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | TEVA PHARMS USA | 1MG;4MG | | A078709 001 | Apr 01, 2016 |
| | | | 2MG;4MG | | A078709 002 | Apr 01, 2016 |
| | | | 2MG;8MG | | A078709 004 | Apr 01, 2016 |
| | | | 4MG;4MG | | A078709 003 | Apr 01, 2016 |
| | | | 4MG;8MG | | A078709 005 | Apr 01, 2016 |

GLIPIZIDE

TABLET;ORAL

**GLIPIZIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACCORD HLTHCARE | **5MG** | | **A074550 001** | Sep 11, 1997 |
| **AB** | | | **10MG** | | **A074550 002** | Sep 11, 1997 |
| **AB** | | ANI PHARMS INC | **5MG** | | **A074497 001** | Aug 31, 1995 |
| **AB** | | | **10MG** | | **A074497 002** | Aug 31, 1995 |
| **AB** | | APOTEX | **5MG** | | **A075795 001** | Jun 13, 2001 |
| **AB** | | | **10MG** | | **A075795 002** | Jun 13, 2001 |
| **AB** | | MYLAN | **5MG** | | **A074226 001** | May 10, 1994 |
| **AB** | | | **10MG** | | **A074226 002** | May 10, 1994 |
| **AB** | | SANDOZ | **5MG** | | **A074305 001** | Apr 07, 1995 |
| **AB** | | | **10MG** | | **A074305 002** | Apr 07, 1995 |
| **AB** | | SUN PHARM INDS INC | **5MG** | | **A077820 001** | Jul 11, 2006 |
| **AB** | | | **10MG** | | **A077820 002** | Jul 11, 2006 |
| **AB** | | WATSON LABS TEVA | **5MG** | | **A074223 001** | Feb 27, 1995 |
| **AB** | | | **10MG** | | **A074223 002** | Feb 27, 1995 |

**GLUCOTROL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | PFIZER | **5MG** | | **N017783 001** | May 08, 1984 |
| **AB** | **+!** | | **10MG** | | **N017783 002** | May 08, 1984 |

TABLET, EXTENDED RELEASE;ORAL

**GLIPIZIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AUROBINDO PHARMA LTD | **2.5MG** | | **A206928 001** | May 12, 2017 |
| **AB** | | | **5MG** | | **A206928 002** | May 12, 2017 |
| **AB** | | | **10MG** | | **A206928 003** | May 12, 2017 |
| **AB** | | MYLAN PHARMS INC | **2.5MG** | | **A202298 001** | May 19, 2015 |
| **AB** | | | **5MG** | | **A202298 002** | May 19, 2015 |
| **AB** | | | **10MG** | | **A202298 003** | May 19, 2015 |
| **AB** | | PAR PHARM | **5MG** | | **A076159 002** | Sep 20, 2013 |
| **AB** | | | **10MG** | | **A076159 001** | Sep 20, 2013 |
| **AB** | | UNIQUE PHARM LABS | **2.5MG** | | **A204720 001** | Dec 29, 2016 |
| **AB** | | | **5MG** | | **A204720 002** | Dec 29, 2016 |
| **AB** | | | **10MG** | | **A204720 003** | Dec 29, 2016 |
| **AB** | | WATSON LABS | **2.5MG** | | **A076467 003** | Mar 27, 2006 |
| **AB** | | | **5MG** | | **A076467 001** | Sep 08, 2003 |
| **AB** | | | **10MG** | | **A076467 002** | Nov 07, 2003 |

**GLUCOTROL XL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | PFIZER | **2.5MG** | | **N020329 003** | Aug 10, 1999 |
| **AB** | **+** | | **5MG** | | **N020329 001** | Apr 26, 1994 |
| **AB** | **+!** | | **10MG** | | **N020329 002** | Apr 26, 1994 |

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

**GLIPIZIDE AND METFORMIN HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | EPIC PHARMA LLC | **2.5MG;250MG** | | **A077507 001** | Oct 27, 2005 |
| **AB** | | | **2.5MG;500MG** | | **A077507 002** | Oct 27, 2005 |
| **AB** | | | **5MG;500MG** | | **A077507 003** | Oct 27, 2005 |
| **AB** | | HERITAGE PHARMS INC | **2.5MG;250MG** | | **A078728 001** | Jun 23, 2010 |
| **AB** | | | **2.5MG;500MG** | | **A078728 002** | Jun 23, 2010 |
| **AB** | | | **5MG;500MG** | | **A078728 003** | Jun 23, 2010 |

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

**GLIPIZIDE AND METFORMIN HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | MYLAN | **2.5MG;250MG** | **A078083** | **001** | Apr 12, 2007 |
| **AB** | | | **2.5MG;500MG** | **A078083** | **002** | Apr 12, 2007 |
| **AB** | | | **5MG;500MG** | **A078083** | **003** | Apr 12, 2007 |
| **AB** | | SUN PHARM INDS INC | **2.5MG;250MG** | **A077620** | **001** | Jan 11, 2008 |
| **AB** | | | **2.5MG;500MG** | **A077620** | **002** | Jan 11, 2008 |
| **AB** | | | **5MG;500MG** | **A077620** | **003** | Jan 11, 2008 |
| **AB** | | TEVA PHARMS | **2.5MG;250MG** | **A077270** | **001** | Oct 28, 2005 |
| **AB** | | | **2.5MG;500MG** | **A077270** | **002** | Oct 28, 2005 |
| **AB** | **!** | | **5MG;500MG** | **A077270** | **003** | Oct 28, 2005 |
| **AB** | | ZYDUS PHARMS USA INC | **2.5MG;250MG** | **A078905** | **001** | Jan 31, 2011 |
| **AB** | | | **2.5MG;500MG** | **A078905** | **002** | Jan 31, 2011 |
| **AB** | | | **5MG;500MG** | **A078905** | **003** | Jan 31, 2011 |

GLUCAGON HYDROCHLORIDE

POWDER;INTRAMUSCULAR, INTRAVENOUS

GLUCAGON

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | FRESENIUS KABI USA | EQ 1MG BASE/VIAL | N201849 | 001 | May 08, 2015 |

GLUCAGON HYDROCHLORIDE RECOMBINANT

INJECTABLE;INJECTION

GLUCAGEN

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | NOVO NORDISK | EQ 1MG BASE/VIAL | N020918 | 001 | Jun 22, 1998 |

GLUCAGON RECOMBINANT

INJECTABLE;INJECTION

GLUCAGON

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | LILLY | 1MG/VIAL | N020928 | 001 | Sep 11, 1998 |

GLYBURIDE

TABLET;ORAL

**GLYBURIDE (MICRONIZED)**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | DAVA PHARMS INC | **1.5MG** | **A074591** | **001** | Dec 22, 1997 |
| **AB** | | | **3MG** | **A074591** | **002** | Dec 22, 1997 |
| **AB** | | | **4.5MG** | **A074591** | **003** | Dec 22, 1997 |
| **AB** | | | **6MG** | **A074591** | **004** | Dec 22, 1997 |
| **AB** | | HIKMA | **1.5MG** | **A075890** | **001** | Jul 31, 2003 |
| **AB** | | | **3MG** | **A075890** | **002** | Jul 31, 2003 |
| **AB** | | | **6MG** | **A075890** | **003** | Jul 31, 2003 |
| **AB** | | MYLAN | **1.5MG** | **A074792** | **001** | Jun 26, 1998 |
| **AB** | | | **3MG** | **A074792** | **002** | Jun 26, 1998 |
| **AB** | | | **6MG** | **A074792** | **003** | Aug 17, 1999 |
| **AB** | | TEVA | **1.5MG** | **A074686** | **001** | Apr 20, 1999 |
| **AB** | | | **3MG** | **A074686** | **002** | Apr 20, 1999 |
| **AB** | | | **4.5MG** | **A074686** | **003** | Apr 20, 1999 |
| **AB** | | | **6MG** | **A074686** | **004** | Apr 20, 1999 |

**GLYNASE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | PHARMACIA AND UPJOHN | **1.5MG** | **N020051** | **001** | Mar 04, 1992 |
| **AB** | **+** | | **3MG** | **N020051** | **002** | Mar 04, 1992 |
| **AB** | **+!** | | **6MG** | **N020051** | **004** | Sep 24, 1993 |

**GLYBURIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB1** | | AUROBINDO PHARMA | **1.25MG** | **A077537** | **001** | Oct 18, 2007 |
| **AB1** | | | **2.5MG** | **A077537** | **002** | Oct 18, 2007 |
| **AB1** | | | **5MG** | **A077537** | **003** | Oct 18, 2007 |
| **AB1** | | EPIC PHARMA LLC | **1.25MG** | **A076257** | **001** | Jun 27, 2002 |
| **AB1** | | | **2.5MG** | **A076257** | **002** | Jun 27, 2002 |
| **AB1** | | | **5MG** | **A076257** | **003** | Jun 27, 2002 |
| **AB1** | | HERITAGE PHARMS INC | **1.25MG** | **A090937** | **001** | Feb 28, 2011 |
| **AB1** | | | **2.5MG** | **A090937** | **002** | Feb 28, 2011 |
| **AB1** | | | **5MG** | **A090937** | **003** | Feb 28, 2011 |
| **AB1** | | PHARMADAX INC | **1.25MG** | **A203581** | **001** | Apr 14, 2016 |
| **AB1** | | | **2.5MG** | **A203581** | **002** | Apr 14, 2016 |
| **AB1** | | | **5MG** | **A203581** | **003** | Apr 14, 2016 |
| **AB1** | | TEVA | **1.25MG** | **A074388** | **001** | Aug 29, 1995 |
| **AB1** | | | **2.5MG** | **A074388** | **002** | Aug 29, 1995 |
| **AB1** | **!** | | **5MG** | **A074388** | **003** | Aug 29, 1995 |
| **AB1** | | ZYDUS PHARMS USA INC | **1.25mg** | **A206749** | **001** | May 10, 2016 |
| **AB1** | | | **2.5mg** | **A206749** | **002** | May 10, 2016 |
| **AB1** | | | **5MG** | **A206749** | **003** | May 10, 2016 |

GLYBURIDE

TABLET;ORAL

**DIABETA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB2** | + | SANOFI AVENTIS US | **1.25MG** | **N017532** | **001** | May 01, 1984 |
| **AB2** | + | | **2.5MG** | **N017532** | **002** | May 01, 1984 |
| **AB2** | +! | | **5MG** | **N017532** | **003** | May 01, 1984 |

**GLYBURIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB2** | | IMPAX LABS INC | **1.25MG** | **A206079** | **001** | Sep 30, 2015 |
| **AB2** | | | **2.5MG** | **A206079** | **002** | Sep 30, 2015 |
| **AB2** | | | **5MG** | **A206079** | **003** | Sep 30, 2015 |

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

**GLYBURIDE AND METFORMIN HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS ELIZABETH | **1.25MG;250MG** | **A076716** | **001** | Jun 28, 2005 |
| **AB** | | | **2.5MG;500MG** | **A076716** | **002** | Jun 28, 2005 |
| **AB** | | | **5MG;500MG** | **A076716** | **003** | Jun 28, 2005 |
| **AB** | | AUROBINDO PHARMA | **1.25MG;250MG** | **A077870** | **001** | Nov 14, 2007 |
| **AB** | ! | | **2.5MG;500MG** | **A077870** | **002** | Nov 14, 2007 |
| **AB** | | | **5MG;500MG** | **A077870** | **003** | Nov 14, 2007 |
| **AB** | | HERITAGE PHARMS INC | **1.25MG;250MG** | **A079009** | **001** | Jun 03, 2009 |
| **AB** | | | **2.5MG;500MG** | **A079009** | **002** | Jun 03, 2009 |
| **AB** | | | **5MG;500MG** | **A079009** | **003** | Jun 03, 2009 |
| **AB** | | IMPAX LABS INC | **1.25MG;250MG** | **A076345** | **001** | Feb 18, 2004 |
| **AB** | | | **2.5MG;500MG** | **A076345** | **002** | Feb 18, 2004 |
| **AB** | | | **5MG;500MG** | **A076345** | **003** | Feb 18, 2004 |
| **AB** | | ZYDUS PHARMS USA INC | **1.25MG;250MG** | **A206748** | **001** | Feb 29, 2016 |
| **AB** | | | **2.5MG;500MG** | **A206748** | **002** | Feb 29, 2016 |
| **AB** | | | **5MG;500MG** | **A206748** | **003** | Feb 29, 2016 |

GLYCEROL PHENYLBUTYRATE

LIQUID;ORAL

RAVICTI

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | HORIZON THERAPS INC | 1.1GM/ML | N203284 | 001 | Feb 01, 2013 |

GLYCINE

SOLUTION;IRRIGATION

**AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | BAXTER HLTHCARE | **1.5GM/100ML** | **N017865** | **001** | |

**GLYCINE 1.5% IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | B BRAUN | **1.5GM/100ML** | **N016784** | **001** | |
| **AT** | | ICU MEDICAL INC | **1.5GM/100ML** | **N018315** | **001** | |

GLYCOPYRROLATE

INJECTABLE;INJECTION

**GLYCOPYRROLATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AMNEAL PHARMS CO | **0.2MG/ML** | **A208973** | **001** | Jun 15, 2017 |
| **AP** | | FRESENIUS KABI USA | **0.2MG/ML** | **A209328** | **001** | Oct 27, 2017 |
| **AP** | ! | HIKMA FARMACEUTICA | **0.2MG/ML** | **A090963** | **001** | Sep 21, 2011 |
| **AP** | | LUITPOLD | **0.2MG/ML** | **A089335** | **001** | Jul 23, 1986 |
| **AP** | | SOMERSET THERAPS LLC | **0.2MG/ML** | **A207639** | **001** | Jun 23, 2017 |

POWDER;INHALATION

SEEBRI

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | SUNOVION PHARMS INC | 15.6MCG/INH | N207923 | 001 | Oct 29, 2015 |

SOLUTION;INHALATION

LONHALA MAGNAIR KIT

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | SUNOVION RESP | 25MCG/ML | N208437 | 001 | Dec 05, 2017 |

SOLUTION;ORAL

CUVPOSA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | MERZ PHARMS | 1MG/5ML | N022571 | 001 | Jul 28, 2010 |

TABLET;ORAL

**GLYCOPYRROLATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | APPCO PHARMA LLC | **1MG** | **A207201** | **001** | Jan 03, 2017 |
| **AA** | | | **2MG** | **A207201** | **002** | Jan 03, 2017 |
| **AA** | | AUROLIFE PHARMA LLC | **1MG** | **A202675** | **001** | Apr 15, 2013 |
| **AA** | | DR REDDYS LABS LTD | **1MG** | **A040847** | **001** | Mar 21, 2008 |
| **AA** | | | **2MG** | **A040847** | **002** | Mar 21, 2008 |
| **AA** | | LEADING PHARMA LLC | **1MG** | **A090195** | **001** | Sep 21, 2012 |
| **AA** | | | **2MG** | **A090195** | **002** | Sep 21, 2012 |
| **AA** | | NATCO PHARMA LTD | **1MG** | **A091413** | **001** | Jun 20, 2016 |
| **AA** | | | **2MG** | **A091413** | **002** | Jun 20, 2016 |
| **AA** | | PAR PHARM | **1MG** | **A040653** | **001** | Aug 31, 2006 |
| **AA** | | | **2MG** | **A040653** | **002** | Aug 31, 2006 |

GLYCOPYRROLATE

TABLET;ORAL

**GLYCOPYRROLATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | RISING PHARMS INC | **1MG** | **A040821** | **001** | Dec 29, 2008 |
| **AA** | | | **2MG** | **A040821** | **002** | Dec 29, 2008 |
| **AA** | | SANTOS BIOTECH | **1MG** | **A091182** | **001** | Feb 03, 2014 |
| **AA** | | | **2MG** | **A091182** | **002** | Feb 03, 2014 |
| **AA** | | SUN PHARM INDS LTD | **1MG** | **A040844** | **001** | Aug 18, 2009 |
| **AA** | | | **2MG** | **A040844** | **002** | Aug 18, 2009 |
| **AA** | | VINTAGE PHARMS | **1MG** | **A090020** | **001** | Oct 19, 2011 |
| **AA** | | | **2MG** | **A090020** | **002** | Oct 19, 2011 |

**ROBINUL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **+!** | CASPER PHARMA LLC | **1MG** | **N012827** | **001** | |

**ROBINUL FORTE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **+!** | CASPER PHARMA LLC | **2MG** | **N012827** | **002** | |

GLYCOPYRROLATE

| | | | | | | |
|---|---|---|---|---|---|---|
| | | NEXGEN PHARMA | 1.5MG | A091522 | 001 | Mar 12, 2012 |

GLYCOPYRROLATE ; INDACATEROL MALEATE

POWDER;INHALATION

UTIBRON

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | SUNOVION PHARMS INC | 15.6MCG/INH;27.5MCG/INH | N207930 | 001 | Oct 29, 2015 |

GONADOTROPIN, CHORIONIC

INJECTABLE;INJECTION

**CHORIONIC GONADOTROPIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | FERRING | **10,000 UNITS/VIAL** | **N017016** | **007** | |
| **AP** | **+!** | FRESENIUS KABI USA | **10,000 UNITS/VIAL** | **N017067** | **002** | |

**PREGNYL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | ORGANON USA INC | **10,000 UNITS/VIAL** | **N017692** | **001** | |

CHORIONIC GONADOTROPIN

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | FERRING | 5,000 UNITS/VIAL | N017016 | 006 | |

GOSERELIN ACETATE

IMPLANT;IMPLANTATION

ZOLADEX

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | TERSERA THERAPS LLC | EQ 3.6MG BASE | N019726 | 001 | Dec 29, 1989 |
| | +! | | EQ 10.8MG BASE | N020578 | 001 | Jan 11, 1996 |

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS;OPHTHALMIC

**NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | AMRING PHARMS | **0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML** | **A065187** | **001** | Oct 28, 2005 |
| **AT** | **!** | BAUSCH AND LOMB | **0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML** | **A064047** | **001** | Jan 31, 1996 |

**NEOSPORIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **!** | MONARCH PHARMS | **0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML** | **A060582** | **001** | |

GRANISETRON

FILM, EXTENDED RELEASE;TRANSDERMAL

SANCUSO

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | KYOWA KIRIN | 3.1MG/24HR | N022198 | 001 | Sep 12, 2008 |

INJECTION, EXTENDED RELEASE;SUBCUTANEOUS

SUSTOL

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | HERON THERAPS INC | 10MG/0.4ML (10MG/0.4ML) | N022445 | 001 | Aug 09, 2016 |

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION

**GRANISETRON HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AKORN INC | **EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)** | **A079119** | **001** | Sep 10, 2009 |
| **AP** | | | **EQ 1MG BASE/ML (EQ 1MG BASE/ML)** | **A079078** | **001** | Sep 14, 2009 |
| **AP** | | | **EQ 4MG BASE/4ML (EQ 1MG BASE/ML)** | **A079078** | **002** | Sep 14, 2009 |
| **AP** | | AUROBINDO PHARMA LTD | **EQ 1MG BASE/ML (EQ 1MG BASE/ML)** | **A204238** | **001** | Jul 06, 2016 |
| **AP** | | | **EQ 4MG BASE/4ML (EQ 1MG BASE/ML)** | **A204238** | **002** | Jul 06, 2016 |
| **AP** | | BIONPHARMA INC | **EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)** | **A078863** | **001** | Jun 30, 2008 |
| **AP** | | | **EQ 4MG BASE/4ML (EQ 1MG BASE/ML)** | **A078880** | **001** | Jun 30, 2008 |
| **AP** | | CIPLA LTD | **EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)** | **A078262** | **001** | Dec 31, 2007 |
| **AP** | | | **EQ 1MG BASE/ML (EQ 1MG BASE/ML)** | **A078258** | **001** | Jun 30, 2008 |
| **AP** | | | **EQ 4MG BASE/4ML (EQ 1MG BASE/ML)** | **A078258** | **002** | Jun 30, 2008 |
| **AP** | | FRESENIUS KABI USA | **EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)** | **A078522** | **001** | Dec 31, 2007 |
| **AP** | | | **EQ 4MG BASE/4ML (EQ 1MG BASE/ML)** | **A078090** | **001** | Jun 30, 2008 |
| **AP** | | HIKMA FARMACEUTICA | **EQ 1MG BASE/ML (EQ 1MG BASE/ML)** | **A078629** | **001** | Dec 23, 2009 |
| **AP** | | | **EQ 4MG BASE/4ML (EQ 1MG BASE/ML)** | **A078629** | **002** | Dec 23, 2009 |

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION

**GRANISETRON HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | LUITPOLD | **EQ 1MG BASE/ML (EQ 1MG BASE/ML)** | **A091274** | **001** | Sep 22, 2010 |
| **AP** | | MYLAN ASI | **EQ 4MG BASE/4ML (EQ 1MG BASE/ML)** | **A091137** | **002** | Apr 09, 2010 |
| **AP** | | MYLAN LABS LTD | **EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)** | **A203454** | **001** | Apr 04, 2017 |
| **AP** | | | **EQ 1MG BASE/ML (EQ 1MG BASE/ML)** | **A203454** | **002** | Apr 04, 2017 |
| **AP** | | | **EQ 4MG BASE/4ML (EQ 1MG BASE/ML)** | **A203453** | **001** | Jan 31, 2017 |
| **AP** | | SAGENT STRIDES | **EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)** | **A091136** | **001** | Apr 09, 2010 |
| **AP** | | | **EQ 1MG BASE/ML (EQ 1MG BASE/ML)** | **A091136** | **002** | Apr 09, 2010 |
| **AP** | | SANDOZ INC | **EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)** | **A078534** | **001** | Apr 30, 2009 |
| **AP** | | | **EQ 1MG BASE/ML (EQ 1MG BASE/ML)** | **A078531** | **001** | Apr 30, 2009 |
| **AP** | | | **EQ 1MG BASE/ML (EQ 1MG BASE/ML)** | **A078835** | **001** | Jun 30, 2008 |
| **AP** | | | **EQ 4MG BASE/4ML (EQ 1MG BASE/ML)** | **A078531** | **002** | Apr 30, 2009 |
| **AP** | | | **EQ 4MG BASE/4ML (EQ 1MG BASE/ML)** | **A078835** | **002** | Jun 30, 2008 |
| **AP** | ! | TEVA PHARMS USA | **EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)** | **A078392** | **001** | Dec 31, 2007 |
| **AP** | ! | | **EQ 1MG BASE/ML (EQ 1MG BASE/ML)** | **A077963** | **001** | Jan 03, 2008 |
| **AP** | ! | | **EQ 4MG BASE/4ML (EQ 1MG BASE/ML)** | **A077297** | **001** | Jun 30, 2008 |
| **AP** | | WEST-WARD PHARMS INT | **EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)** | **A077913** | **001** | Jun 26, 2008 |
| **AP** | | | **EQ 4MG BASE/4ML (EQ 1MG BASE/ML)** | **A077186** | **001** | Jun 30, 2008 |
| **AP** | | | **EQ 1MG BASE/ML (EQ 1MG BASE/ML)** | **A077187** | **001** | Jun 30, 2008 |
| **AP** | | | **EQ 4MG BASE/4ML (EQ 1MG BASE/ML)** | **A077177** | **001** | Dec 31, 2007 |
| **AP** | | WOCKHARDT USA | **EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)** | **A078566** | **001** | Feb 29, 2008 |
| **AP** | | | **EQ 1MG BASE/ML (EQ 1MG BASE/ML)** | **A078564** | **001** | Jun 30, 2008 |
| **AP** | | | **EQ 4MG BASE/4ML (EQ 1MG BASE/ML)** | **A078565** | **001** | Jun 30, 2008 |

**GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | BIONPHARMA INC | **EQ 1MG BASE/ML (EQ 1MG BASE/ML)** | **A078863** | **002** | Jun 30, 2008 |
| **AP** | ! | FRESENIUS KABI USA | **EQ 1MG BASE/ML (EQ 1MG BASE/ML)** | **A078096** | **001** | Jun 30, 2008 |

TABLET;ORAL

**GRANISETRON HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | APOTEX INC | **EQ 1MG BASE** | **A078843** | **001** | Feb 27, 2008 |
| **AB** | | CIPLA LTD | **EQ 1MG BASE** | **A078037** | **001** | Feb 27, 2008 |
| **AB** | | DR REDDYS LABS LTD | **EQ 1MG BASE** | **A078846** | **001** | Feb 27, 2009 |
| **AB** | | MYLAN | **EQ 1MG BASE** | **A078725** | **001** | Jan 30, 2008 |
| **AB** | | NATCO PHARMA | **EQ 1MG BASE** | **A078969** | **001** | Jun 22, 2009 |
| **AB** | | ORCHID HLTHCARE | **EQ 1MG BASE** | **A078678** | **001** | Feb 13, 2008 |
| **AB** | | TARO PHARM | **EQ 1MG BASE** | **A090817** | **001** | May 28, 2010 |
| **AB** | ! | TEVA PHARMS | **EQ 1MG BASE** | **A078080** | **001** | Dec 31, 2007 |
| **AB** | | WEST-WARD PHARMS INT | **EQ 1MG BASE** | **A077842** | **001** | Dec 31, 2007 |

GRISEOFULVIN, MICROSIZE

SUSPENSION;ORAL

**GRISEOFULVIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | ! | ACTAVIS MID ATLANTIC | **125MG/5ML** | **A065394** | **001** | Jul 06, 2007 |
| **AB** | | CHARTWELL RX | **125MG/5ML** | **A065200** | **001** | Mar 02, 2005 |
| **AB** | | CIPLA LTD | **125MG/5ML** | **A065354** | **001** | Sep 10, 2007 |
| **AB** | | VINTAGE PHARMS | **125MG/5ML** | **A065438** | **001** | Oct 08, 2010 |

TABLET;ORAL

**GRISEOFULVIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | ! | SANDOZ INC | **500MG** | **A091592** | **002** | Aug 07, 2013 |
| **AB** | | SIGMAPHARM LABS LLC | **500MG** | **A202482** | **001** | Oct 22, 2012 |
| | | SANDOZ INC | 250MG | A091592 | 001 | Aug 07, 2013 |

GRISEOFULVIN, ULTRAMICROSIZE

TABLET;ORAL

**GRIS-PEG**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | VALEANT PHARMS INC | **125MG** | **N050475** | **001** | |
| **AB** | +! | | **250MG** | **N050475** | **002** | |

**GRISEOFULVIN, ULTRAMICROSIZE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | COREPHARMA | **125MG** | **A204371** | **001** | Jan 09, 2014 |
| **AB** | | | **250MG** | **A204371** | **002** | Jan 09, 2014 |

**GRISEOFULVIN,ULTRAMICROSIZE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | SIGMAPHARM LABS LLC | **125MG** | **A202545** | **001** | Oct 22, 2012 |
| **AB** | | | **250MG** | **A202545** | **002** | Oct 22, 2012 |

GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

FLOWTUSS

| | | | | | |
|---|---|---|---|---|---|
| | MISSION PHARMACAL CO | 200MG/5ML;2.5MG/5ML | N022424 | 001 | May 14, 2015 |

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYCOFENIX

| | | | | | |
|---|---|---|---|---|---|
| +! | MISSION PHARMACAL CO | 200MG/5ML;2.5MG/5ML;30MG/5ML | N022279 | 001 | May 14, 2015 |

GUANABENZ ACETATE

TABLET;ORAL

GUANABENZ ACETATE

| | | | | | |
|---|---|---|---|---|---|
| | ANI PHARMS INC | EQ 4MG BASE | A074149 | 001 | Apr 07, 1995 |
| ! | | EQ 8MG BASE | A074149 | 002 | Apr 07, 1995 |

GUANFACINE HYDROCHLORIDE

TABLET;ORAL

**GUANFACINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AMNEAL PHARM | **EQ 1MG BASE** | **A075109** | **001** | Nov 25, 1998 |
| **AB** | | | **EQ 2MG BASE** | **A075109** | **002** | Nov 25, 1998 |
| **AB** | | EPIC PHARMA LLC | **EQ 1MG BASE** | **A074673** | **001** | Feb 28, 1997 |
| **AB** | | | **EQ 2MG BASE** | **A074673** | **002** | Feb 28, 1997 |
| **AB** | | MYLAN | **EQ 1MG BASE** | **A074796** | **001** | Jan 27, 1997 |
| **AB** | | | **EQ 2MG BASE** | **A074796** | **002** | Jan 27, 1997 |
| **AB** | | WATSON LABS | **EQ 1MG BASE** | **A074145** | **001** | Oct 17, 1995 |
| **AB** | | | **EQ 2MG BASE** | **A074145** | **002** | Oct 17, 1995 |

**TENEX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | PROMIUS PHARMA | **EQ 1MG BASE** | **N019032** | **001** | Oct 27, 1986 |
| **AB** | +! | | **EQ 2MG BASE** | **N019032** | **002** | Nov 07, 1988 |

TABLET, EXTENDED RELEASE;ORAL

**GUANFACINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS ELIZABETH | **EQ 1MG BASE** | **A200881** | **001** | Oct 05, 2012 |
| **AB** | | | **EQ 2MG BASE** | **A200881** | **002** | Oct 05, 2012 |
| **AB** | | | **EQ 3MG BASE** | **A200881** | **003** | Oct 05, 2012 |
| **AB** | | | **EQ 4MG BASE** | **A200881** | **004** | Oct 05, 2012 |
| **AB** | | MYLAN PHARMS INC | **EQ 1MG BASE** | **A202578** | **001** | Jun 02, 2015 |
| **AB** | | | **EQ 2MG BASE** | **A202578** | **002** | Jun 02, 2015 |
| **AB** | | | **EQ 3MG BASE** | **A202578** | **003** | Jun 02, 2015 |
| **AB** | | | **EQ 4MG BASE** | **A202578** | **004** | Jun 02, 2015 |
| **AB** | | SANDOZ INC | **EQ 1MG BASE** | **A202568** | **001** | Jun 03, 2015 |
| **AB** | | | **EQ 2MG BASE** | **A202568** | **002** | Jun 03, 2015 |
| **AB** | | | **EQ 3MG BASE** | **A202568** | **003** | Jun 03, 2015 |
| **AB** | | | **EQ 4MG BASE** | **A202568** | **004** | Jun 03, 2015 |
| **AB** | | SUN PHARM INDS LTD | **EQ 1MG BASE** | **A205689** | **001** | Nov 16, 2017 |
| **AB** | | | **EQ 2MG BASE** | **A205689** | **002** | Nov 16, 2017 |
| **AB** | | | **EQ 3MG BASE** | **A205689** | **003** | Nov 16, 2017 |
| **AB** | | | **EQ 4MG BASE** | **A205689** | **004** | Nov 16, 2017 |
| **AB** | | TEVA PHARMS USA | **EQ 1MG BASE** | **A201382** | **001** | Jun 02, 2015 |
| **AB** | | | **EQ 2MG BASE** | **A201382** | **002** | Jun 02, 2015 |
| **AB** | | | **EQ 3MG BASE** | **A201382** | **003** | Jun 02, 2015 |
| **AB** | | | **EQ 4MG BASE** | **A201382** | **004** | Jun 02, 2015 |
| **AB** | | TWI PHARMS INC | **EQ 1MG BASE** | **A201408** | **001** | Jun 02, 2015 |
| **AB** | | | **EQ 2MG BASE** | **A201408** | **002** | Jun 02, 2015 |
| **AB** | | | **EQ 3MG BASE** | **A201408** | **003** | Jun 02, 2015 |
| **AB** | | | **EQ 4MG BASE** | **A201408** | **004** | Jun 02, 2015 |

**INTUNIV**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | SHIRE | **EQ 1MG BASE** | **N022037** | **001** | Sep 02, 2009 |
| **AB** | + | | **EQ 2MG BASE** | **N022037** | **002** | Sep 02, 2009 |
| **AB** | + | | **EQ 3MG BASE** | **N022037** | **003** | Sep 02, 2009 |
| **AB** | +! | | **EQ 4MG BASE** | **N022037** | **004** | Sep 02, 2009 |

GUANIDINE HYDROCHLORIDE

TABLET;ORAL

GUANIDINE HYDROCHLORIDE

| | | | | | |
|---|---|---|---|---|---|
| | MERCK SHARP DOHME | 125MG | N001546 | 001 | |

HALCINONIDE

CREAM;TOPICAL

HALOG

| | | | | | | |
|---|---|---|---|---|---|---|
| +! | RANBAXY | 0.1% | | N017556 | 001 | |

OINTMENT;TOPICAL

HALOG

| | | | | | | |
|---|---|---|---|---|---|---|
| +! | SUN PHARM INDS INC | 0.1% | | N017824 | 001 | |

HALOBETASOL PROPIONATE

CREAM;TOPICAL

**HALOBETASOL PROPIONATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | FOUGERA PHARMS | **0.05%** | **A077001** | **001** | Dec 16, 2004 |
| **AB** | **!** | G AND W LABS | **0.05%** | **A078162** | **001** | Apr 24, 2007 |
| **AB** | | PERRIGO ISRAEL | **0.05%** | **A077123** | **001** | Dec 16, 2004 |
| **AB** | | TARO | **0.05%** | **A077227** | **001** | Aug 04, 2005 |

**ULTRAVATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | SUN PHARM INDS LTD | **0.05%** | **N019967** | **001** | Dec 27, 1990 |

LOTION;TOPICAL

ULTRAVATE

| | | | | | | |
|---|---|---|---|---|---|---|
| +! | | SUN PHARM INDUSTRIES | 0.05% | N208183 | 001 | Nov 06, 2015 |

OINTMENT;TOPICAL

**HALOBETASOL PROPIONATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **!** | G AND W LABS | **0.05%** | **A077721** | **001** | Sep 07, 2006 |
| **AB** | | G AND W LABS INC | **0.05%** | **A077109** | **001** | Jun 14, 2005 |
| **AB** | | PERRIGO ISRAEL | **0.05%** | **A076872** | **001** | Dec 16, 2004 |
| **AB** | | TARO | **0.05%** | **A076994** | **001** | Dec 16, 2004 |

**ULTRAVATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | RANBAXY | **0.05%** | **N019968** | **001** | Dec 17, 1990 |

HALOPERIDOL

TABLET;ORAL

**HALOPERIDOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | MYLAN | **0.5MG** | **A070278** | **006** | Jun 10, 1986 |
| **AB** | | | **1MG** | **A070278** | **004** | Jun 10, 1986 |
| **AB** | | | **2MG** | **A070278** | **001** | Jun 10, 1986 |
| **AB** | | | **5MG** | **A070278** | **005** | Jun 10, 1986 |
| **AB** | | | **10MG** | **A070278** | **002** | Jul 16, 2009 |
| **AB** | | | **20MG** | **A070278** | **003** | Jul 16, 2009 |
| **AB** | | SANDOZ | **0.5MG** | **A071206** | **001** | Nov 17, 1986 |
| **AB** | | | **1MG** | **A071207** | **001** | Nov 17, 1986 |
| **AB** | **!** | | **2MG** | **A071208** | **001** | Nov 17, 1986 |
| **AB** | | | **5MG** | **A071209** | **001** | Nov 17, 1986 |
| **AB** | | | **10MG** | **A071210** | **001** | Mar 11, 1988 |
| **AB** | | | **20MG** | **A071211** | **001** | Mar 11, 1988 |
| **AB** | | ZYDUS PHARMS USA | **5MG** | **A077580** | **003** | Nov 29, 2007 |
| **AB** | | | **10MG** | **A077580** | **004** | Nov 29, 2007 |
| **AB** | | | **20MG** | **A077580** | **005** | Nov 29, 2007 |

HALOPERIDOL DECANOATE

INJECTABLE;INJECTION

**HALDOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AO** | **+!** | JANSSEN PHARMS | **EQ 50MG BASE/ML** | **N018701** | **001** | Jan 14, 1986 |
| **AO** | **+!** | | **EQ 100MG BASE/ML** | **N018701** | **002** | Jan 31, 1997 |

**HALOPERIDOL DECANOATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AO** | | FRESENIUS KABI USA | **EQ 50MG BASE/ML** | **A074893** | **001** | Dec 19, 1997 |
| **AO** | | | **EQ 100MG BASE/ML** | **A074893** | **002** | Dec 19, 1997 |
| **AO** | | GLAND PHARMA LTD | **EQ 50MG BASE/ML** | **A205241** | **001** | May 12, 2017 |
| **AO** | | | **EQ 100MG BASE/ML** | **A205241** | **002** | May 12, 2017 |
| **AO** | | MYLAN LABS LTD | **EQ 50MG BASE/ML** | **A075440** | **001** | Feb 28, 2000 |
| **AO** | | | **EQ 100MG BASE/ML** | **A075440** | **002** | Feb 28, 2000 |
| **AO** | | TEVA PHARMS USA | **EQ 50MG BASE/ML** | **A075393** | **001** | May 11, 1999 |
| **AO** | | | **EQ 100MG BASE/ML** | **A075393** | **002** | May 11, 1999 |
| **AO** | | WEST-WARD PHARMS INT | **EQ 50MG BASE/ML** | **A074811** | **001** | Jan 30, 1998 |
| **AO** | | | **EQ 100MG BASE/ML** | **A075305** | **001** | Sep 28, 1998 |

HALOPERIDOL LACTATE

CONCENTRATE;ORAL

**HALOPERIDOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | PHARM ASSOC | **EQ 2MG BASE/ML** | **A073037** | **001** | Feb 26, 1993 |
| **AA** | | SILARX | **EQ 2MG BASE/ML** | **A073364** | **001** | Sep 28, 1993 |
| **AA** | **!** | TEVA PHARMS | **EQ 2MG BASE/ML** | **A071617** | **001** | Dec 01, 1988 |

HALOPERIDOL LACTATE

INJECTABLE;INJECTION

| | | | | | | |
|---|---|---|---|---|---|---|
| **HALDOL** | | | | | | |
| **AP** | **+!** | JANSSEN PHARMS | **EQ 5MG BASE/ML** | **N015923** | **001** | |
| **HALOPERIDOL** | | | | | | |
| **AP** | | AKORN | **EQ 5MG BASE/ML** | **A204849** | **001** | Sep 06, 2017 |
| **AP** | | FRESENIUS KABI USA | **EQ 5MG BASE/ML** | **A075689** | **001** | Mar 09, 2001 |
| **AP** | | GLAND PHARMA LTD | **EQ 5MG BASE/ML** | **A076774** | **001** | Aug 25, 2004 |
| **AP** | | MYLAN LABS LTD | **EQ 5MG BASE/ML** | **A078347** | **001** | Sep 14, 2009 |
| **AP** | | SAGENT PHARMS | **EQ 5MG BASE/ML** | **A091637** | **001** | Sep 02, 2011 |
| **AP** | | | **EQ 5MG BASE/ML** | **A200742** | **001** | Sep 02, 2011 |
| **AP** | | TEVA PHARMS USA | **EQ 5MG BASE/ML** | **A076035** | **001** | Aug 29, 2001 |
| **AP** | | WEST-WARD PHARMS INT | **EQ 5MG BASE/ML** | **A075858** | **001** | Jun 18, 2001 |

HEPARIN SODIUM

INJECTABLE;INJECTION

| | | | | | | |
|---|---|---|---|---|---|---|
| **HEPARIN SODIUM** | | | | | | |
| **AP** | **+!** | FRESENIUS KABI USA | **1,000 UNITS/ML** | **N017029** | **001** | |
| **AP** | | | **5,000 UNITS/ML** | **A206552** | **001** | Jun 10, 2016 |
| **AP** | **+!** | | **5,000 UNITS/ML** | **N017651** | **006** | |
| **AP** | **+!** | | **10,000 UNITS/ML** | **N017029** | **003** | |
| **AP** | **+!** | | **20,000 UNITS/ML** | **N017029** | **004** | |
| **AP** | | GLAND PHARMA LTD | **5,000 UNITS/ML** | **A205323** | **001** | Feb 06, 2017 |
| **AP** | | HOSPIRA INC | **1,000 UNITS/ML** | **A090571** | **001** | Aug 31, 2009 |
| **AP** | | | **5,000 UNITS/ML** | **A090571** | **002** | Aug 31, 2009 |
| **AP** | | | **10,000 UNITS/ML** | **A090571** | **003** | Aug 31, 2009 |
| **AP** | | MYLAN LABS LTD | **1,000 UNITS/ML** | **A203851** | **001** | Nov 30, 2017 |
| **AP** | | | **5,000 UNITS/ML** | **A203851** | **002** | Nov 30, 2017 |
| **AP** | | | **10,000 UNITS/ML** | **A203851** | **003** | Nov 30, 2017 |
| **AP** | | | **20,000 UNITS/ML** | **A203852** | **001** | Nov 30, 2017 |
| **AP** | | SAGENT PHARMS | **1,000 UNITS/ML** | **A090808** | **001** | Jun 30, 2010 |
| **AP** | | | **5,000 UNITS/ML** | **A090808** | **002** | Jun 30, 2010 |
| **AP** | | | **10,000 UNITS/ML** | **A090808** | **003** | Jun 30, 2010 |
| **AP** | | | **20,000 UNITS/ML** | **A090809** | **001** | Jun 30, 2010 |
| **AP** | | SANDOZ | **1,000 UNITS/ML** | **A091682** | **001** | Jun 08, 2011 |
| **AP** | | | **5,000 UNITS/ML** | **A091659** | **001** | Jun 08, 2011 |
| **AP** | | | **5,000 UNITS/ML** | **A091682** | **002** | Jun 08, 2011 |
| **AP** | | | **10,000 UNITS/ML** | **A201002** | **001** | Jun 08, 2011 |
| **AP** | | SHENZHEN TECHDOW | **1,000 UNITS/ML** | **A202957** | **001** | Jun 12, 2014 |
| **AP** | | | **5,000 UNITS/ML** | **A202733** | **001** | Jun 12, 2014 |
| **AP** | | | **5,000 UNITS/ML** | **A202957** | **002** | Jun 12, 2014 |
| **AP** | | | **10,000 UNITS/ML** | **A203198** | **001** | Jun 12, 2014 |
| **AP** | | | **20,000 UNITS/ML** | **A203198** | **002** | Jun 12, 2014 |
| **AP** | **+!** | WEST-WARD PHARMS INT | **1,000 UNITS/ML** | **N017037** | **001** | |
| **AP** | **+!** | | **5,000 UNITS/ML** | **N017037** | **002** | |
| **AP** | **+!** | | **10,000 UNITS/ML** | **N017037** | **003** | |
| **HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER** | | | | | | |
| **AP** | | BAXTER HLTHCARE | **200 UNITS/100ML** | **N018609** | **001** | Apr 28, 1982 |
| **HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER** | | | | | | |
| **AP** | **+!** | B BRAUN | **200 UNITS/100ML** | **N019953** | **001** | Jul 20, 1992 |
| **AP** | | HOSPIRA | **200 UNITS/100ML** | **N018916** | **010** | Jun 23, 1989 |
| **HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER** | | | | | | |
| **AP** | | HOSPIRA | **10,000 UNITS/100ML** | **N019339** | **003** | Mar 27, 1985 |
| **HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER** | | | | | | |
| **AP** | | BAXTER HLTHCARE | **200 UNITS/100ML** | **N018609** | **002** | Apr 28, 1982 |
| **HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER** | | | | | | |
| **AP** | | HOSPIRA | **200 UNITS/100ML** | **N018916** | **011** | Jun 23, 1989 |
| **HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER** | | | | | | |
| **AP** | **+!** | B BRAUN | **4,000 UNITS/100ML** | **N019952** | **001** | Jul 20, 1992 |
| **AP** | | HOSPIRA | **4,000 UNITS/100ML** | **N019805** | **001** | Jan 25, 1989 |
| **HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER** | | | | | | |
| **AP** | **+!** | B BRAUN | **5,000 UNITS/100ML** | **N019952** | **004** | Jul 20, 1992 |
| **AP** | **+!** | | **10,000 UNITS/100ML** | **N019952** | **005** | Jul 20, 1992 |
| **AP** | | HOSPIRA | **5,000 UNITS/100ML** | **N019339** | **004** | Mar 27, 1985 |
| **AP** | | | **5,000 UNITS/100ML** | **N019805** | **002** | Jan 25, 1989 |
| **AP** | | | **10,000 UNITS/100ML** | **N019339** | **002** | Mar 27, 1985 |
| **HEPARIN SODIUM IN PLASTIC CONTAINER** | | | | | | |
| **AP** | **+!** | FRESENIUS KABI USA | **1,000 UNITS/ML** | **N017029** | **013** | Dec 05, 1985 |
| **AP** | **+!** | | **5,000 UNITS/ML** | **N017029** | **014** | Dec 05, 1985 |
| **AP** | **+!** | | **10,000 UNITS/ML** | **N017029** | **015** | Dec 05, 1985 |
| **AP** | **+!** | | **20,000 UNITS/ML** | **N017029** | **016** | Dec 05, 1985 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| HEPARIN SODIUM | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| **HEPARIN SODIUM PRESERVATIVE FREE** | | | | | | | |
| **AP** | **+!** | FRESENIUS KABI USA | **1,000 UNITS/ML** | **N017029** | **010** | Apr 28, 1986 |
| **AP** | | SAGENT PHARMS | **1,000 UNITS/ML** | **A090810** | **001** | Jun 30, 2010 |
| **AP** | | SHENZHEN TECHDOW | **1,000 UNITS/ML** | **A202732** | **001** | Jun 12, 2014 |
| HEPARIN SODIUM | | | | | | | |
| | +! | FRESENIUS KABI USA | 10,000 UNITS/ML | N017029 | 020 | Mar 31, 2011 |
| | ! | HOSPIRA | 5,000 UNITS/ML | A088100 | 001 | Apr 28, 1983 |
| | +! | PFIZER | 1,000 UNITS/ML | N201370 | 001 | Jul 21, 2011 |
| | +! | | 5,000 UNITS/ML | N201370 | 002 | Jul 21, 2011 |
| | +! | | 10,000 UNITS/ML | N201370 | 003 | Jul 21, 2011 |
| HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | | | | |
| | | HOSPIRA | 5,000 UNITS/100ML | N019339 | 001 | Mar 27, 1985 |
| HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER | | | | | | | |
| | | HOSPIRA | 5,000 UNITS/100ML | N018916 | 006 | Jan 31, 1984 |
| HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER | | | | | | | |
| | | HOSPIRA | 5,000 UNITS/100ML | N018916 | 007 | Jan 31, 1984 |
| | | | 10,000 UNITS/100ML | N018916 | 008 | Jan 31, 1984 |
| HEPARIN SODIUM PRESERVATIVE FREE | | | | | | | |
| | +! | FRESENIUS KABI USA | 10,000 UNITS/ML | N017029 | 019 | Nov 22, 2010 |
| | ! | HOSPIRA | 10,000 UNITS/ML | A089522 | 001 | May 04, 1987 |
| | +! | PFIZER | 1,000 UNITS/ML | N201370 | 004 | Jul 21, 2011 |
| HEXACHLOROPHENE | | | | | | | |
| SPONGE;TOPICAL | | | | | | | |
| **PRE-OP** | | | | | | | |
| **AT** | **+!** | DAVIS AND GECK | **480MG** | **N017433** | **001** | | |
| **PRE-OP II** | | | | | | | |
| **AT** | **+** | DAVIS AND GECK | **480MG** | **N017433** | **002** | | |
| HEXAMINOLEVULINATE HYDROCHLORIDE | | | | | | | |
| FOR SOLUTION;INTRAVESICAL | | | | | | | |
| CYSVIEW KIT | | | | | | | |
| | +! | PHOTOCURE ASA | 100MG/VIAL | N022555 | 001 | May 28, 2010 |
| HISTRELIN ACETATE | | | | | | | |
| IMPLANT;SUBCUTANEOUS | | | | | | | |
| SUPPRELIN LA | | | | | | | |
| | +! | ENDO PHARM | 50MG | N022058 | 001 | May 03, 2007 |
| VANTAS | | | | | | | |
| | +! | ENDO PHARM | 50MG | N021732 | 001 | Oct 12, 2004 |
| HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE | | | | | | | |
| SYRUP;ORAL | | | | | | | |
| **HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE** | | | | | | | |
| **AA** | | ABHAI LLC | **1.5MG/5ML;5MG/5ML** | **A207487** | **001** | Feb 21, 2017 |
| **AA** | | ACTAVIS MID ATLANTIC | **1.5MG/5ML;5MG/5ML** | **A088017** | **001** | Jul 05, 1983 |
| **AA** | | BIO-PHARM INC | **1.5MG/5ML;5MG/5ML** | **A204765** | **001** | Mar 06, 2017 |
| **AA** | **!** | HI TECH PHARMA | **1.5MG/5ML;5MG/5ML** | **A040613** | **001** | Feb 08, 2008 |
| **AA** | | NOVEL LABS INC | **1.5MG/5ML;5MG/5ML** | **A203535** | **001** | Feb 13, 2017 |
| **AA** | | PADDOCK LLC | **1.5MG/5ML;5MG/5ML** | **A205731** | **001** | Feb 15, 2017 |
| **AA** | | WOCKHARDT BIO AG | **1.5MG/5ML;5MG/5ML** | **A088008** | **001** | Mar 03, 1983 |
| TABLET;ORAL | | | | | | | |
| **HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE** | | | | | | | |
| **AA** | | AVANTHI INC | **1.5MG;5MG** | **A207176** | **001** | Aug 07, 2017 |
| **AA** | | NOVEL LABS INC | **1.5MG;5MG** | **A091528** | **001** | Apr 20, 2011 |
| **TUSSIGON** | | | | | | | |
| **AA** | **!** | KING PHARMS | **1.5MG;5MG** | **A088508** | **001** | Jul 30, 1985 |
| HYALURONIDASE | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| AMPHADASE | | | | | | | |
| | +! | AMPHASTAR PHARM | 150 UNITS/ML | N021665 | 001 | Oct 26, 2004 |
| VITRASE | | | | | | | |
| | +! | BAUSCH AND LOMB | 200 UNITS/VIAL | N021640 | 002 | Dec 02, 2004 |
| HYALURONIDASE RECOMBINANT HUMAN | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| HYLENEX RECOMBINANT | | | | | | | |
| | +! | HALOZYME THERAP | 150 UNITS/ML | N021859 | 001 | Dec 02, 2005 |

HYDRALAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

**HYDRALAZINE HYDROCHLORIDE**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **AP** | ! | AKORN | **20MG/ML** | **A040730** | **001** | Apr 21, 2009 |
| **AP** | | FRESENIUS KABI USA | **20MG/ML** | **A040388** | **001** | Mar 13, 2001 |
| **AP** | | LUITPOLD | **20MG/ML** | **A040136** | **001** | Jun 30, 1997 |
| **AP** | | MYLAN INSTITUTIONAL | **20MG/ML** | **A204680** | **001** | Apr 28, 2016 |
| **AP** | | NAVINTA LLC | **20MG/ML** | **A202938** | **001** | Mar 28, 2013 |
| **AP** | | X-GEN PHARMS INC | **20MG/ML** | **A203110** | **001** | Jun 29, 2015 |

TABLET;ORAL

**HYDRALAZINE HYDROCHLORIDE**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **AA** | | ALKEM LABS LTD | **10MG** | **A200737** | **001** | Dec 07, 2012 |
| **AA** | | | **25MG** | **A200737** | **002** | Dec 07, 2012 |
| **AA** | | | **50MG** | **A200737** | **003** | Dec 07, 2012 |
| **AA** | | | **100MG** | **A200737** | **004** | Dec 07, 2012 |
| **AA** | | CADILA PHARMS LTD | **25MG** | **A203845** | **001** | Sep 18, 2014 |
| **AA** | | | **50MG** | **A203845** | **002** | Sep 18, 2014 |
| **AA** | | | **100MG** | **A203845** | **003** | Sep 18, 2014 |
| **AA** | | GLENMARK PHARMS LTD | **10MG** | **A090527** | **001** | May 27, 2009 |
| **AA** | | | **25MG** | **A090527** | **002** | May 27, 2009 |
| **AA** | | | **50MG** | **A090527** | **003** | May 27, 2009 |
| **AA** | | | **100MG** | **A090527** | **004** | May 27, 2009 |
| **AA** | | HERITAGE PHARMS INC | **10MG** | **A086242** | **001** | Feb 04, 2010 |
| **AA** | | | **25MG** | **A086242** | **003** | |
| **AA** | | | **50MG** | **A086242** | **002** | |
| **AA** | | | **100MG** | **A086242** | **004** | Feb 04, 2010 |
| **AA** | | HETERO LABS LTD III | **10MG** | **A040901** | **001** | Sep 12, 2008 |
| **AA** | | | **25MG** | **A040901** | **002** | Sep 12, 2008 |
| **AA** | | | **50MG** | **A040901** | **003** | Sep 12, 2008 |
| **AA** | | | **100MG** | **A040901** | **004** | Sep 12, 2008 |
| **AA** | | INVAGEN PHARMS | **10MG** | **A090255** | **001** | Dec 15, 2008 |
| **AA** | | | **25MG** | **A090255** | **002** | Dec 15, 2008 |
| **AA** | | | **50MG** | **A090255** | **003** | Dec 15, 2008 |
| **AA** | | | **100MG** | **A090255** | **004** | Dec 15, 2008 |
| **AA** | | PAR PHARM | **10MG** | **A087836** | **001** | Oct 05, 1982 |
| **AA** | | | **25MG** | **A086961** | **002** | |
| **AA** | | | **50MG** | **A086962** | **001** | |
| **AA** | | | **100MG** | **A088391** | **001** | Sep 27, 1983 |
| **AA** | ! | PLIVA | **10MG** | **A089097** | **001** | Dec 18, 1985 |
| **AA** | ! | | **25MG** | **A088467** | **001** | May 01, 1984 |
| **AA** | ! | | **50MG** | **A088468** | **001** | May 01, 1984 |
| **AA** | ! | | **100MG** | **A089098** | **001** | Dec 18, 1985 |
| **AA** | | STRIDES PHARMA | **25MG** | **A200770** | **001** | May 03, 2013 |
| **AA** | | | **50MG** | **A200770** | **002** | May 03, 2013 |
| **AA** | | | **100MG** | **A200770** | **003** | May 03, 2013 |
| **AA** | | TECH ORGANIZED | **10MG** | **A205236** | **001** | May 26, 2017 |
| **AA** | | | **25MG** | **A205236** | **002** | May 26, 2017 |
| **AA** | | | **50MG** | **A205236** | **003** | May 26, 2017 |
| **AA** | | | **100MG** | **A205236** | **004** | May 26, 2017 |

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

HYDRA-ZIDE

| | | | | | | |
|---|---|---|---|---|---|---|
| | PAR PHARM | 25MG;25MG | A088957 | 001 | Oct 21, 1985 |
| ! | | 50MG;50MG | A088946 | 001 | Oct 21, 1985 |

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET;ORAL

BIDIL

| | | | | | | |
|---|---|---|---|---|---|---|
| +! | ARBOR PHARMS LLC | 37.5MG;20MG | N020727 | 001 | Jun 23, 2005 |

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

**HYDROCHLOROTHIAZIDE**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **AB** | | ALEMBIC PHARMS LTD | **12.5MG** | **A200645** | **001** | Nov 30, 2010 |
| **AB** | | APOTEX | **12.5MG** | **A078389** | **001** | May 16, 2008 |
| **AB** | | AUROBINDO PHARMA | **12.5MG** | **A078164** | **001** | Sep 18, 2007 |
| **AB** | | IPCA LABS LTD | **12.5MG** | **A079237** | **001** | Apr 02, 2009 |
| **AB** | | IVAX SUB TEVA PHARMS | **12.5MG** | **A077005** | **001** | Jul 13, 2005 |
| **AB** | | JUBILANT CADISTA | **12.5MG** | **A078391** | **001** | Feb 11, 2008 |
| **AB** | | MYLAN | **12.5MG** | **A075640** | **001** | Jan 28, 2000 |
| **AB** | | PRINSTON INC | **12.5MG** | **A075907** | **001** | Sep 17, 2002 |
| **AB** | | SUN PHARM INDS INC | **12.5MG** | **A090651** | **001** | Apr 07, 2014 |

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

**HYDROCHLOROTHIAZIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | UNICHEM | **12.5MG** | **A090510** | **001** | Jan 19, 2010 |

**MICROZIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | ALLERGAN SALES LLC | **12.5MG** | **N020504** | **001** | Dec 27, 1996 |

TABLET;ORAL

**HYDROCHLOROTHIAZIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACCORD HLTHCARE | **12.5MG** | **A202556** | **001** | Sep 24, 2012 |
| **AB** | | | **25MG** | **A202556** | **002** | Sep 24, 2012 |
| **AB** | | | **50MG** | **A202556** | **003** | Sep 24, 2012 |
| **AB** | | ACTAVIS ELIZABETH | **12.5MG** | **A040707** | **001** | Feb 27, 2007 |
| **AB** | | APOTEX | **25MG** | **A040774** | **001** | Oct 03, 2007 |
| **AB** | | | **50MG** | **A040774** | **002** | Oct 03, 2007 |
| **AB** | | AUROBINDO PHARMA | **25MG** | **A040780** | **001** | Jul 20, 2007 |
| **AB** | | | **50MG** | **A040780** | **002** | Jul 20, 2007 |
| **AB** | | DAVA PHARMS INC | **25MG** | **A087059** | **001** | |
| **AB** | | | **50MG** | **A087068** | **001** | |
| **AB** | | HERITAGE PHARMS INC | **25MG** | **A085182** | **002** | |
| **AB** | | | **50MG** | **A085182** | **001** | |
| **AB** | | HIKMA INTL PHARMS | **50MG** | **A084878** | **001** | |
| **AB** | | IPCA LABS LTD | **12.5MG** | **A040807** | **001** | Jul 20, 2007 |
| **AB** | | | **25MG** | **A040807** | **002** | Jul 20, 2007 |
| **AB** | | | **50MG** | **A040807** | **003** | Jul 20, 2007 |
| **AB** | | IVAX SUB TEVA PHARMS | **25MG** | **A083177** | **001** | |
| **AB** | **!** | | **50MG** | **A083177** | **002** | |
| **AB** | | LEADING PHARMA LLC | **12.5MG** | **A040702** | **003** | May 10, 2017 |
| **AB** | | | **25MG** | **A040702** | **001** | Mar 16, 2007 |
| **AB** | | | **50MG** | **A040702** | **002** | Mar 16, 2007 |
| **AB** | | MYLAN PHARMS INC | **25MG** | **A040735** | **002** | Jan 23, 2007 |
| **AB** | | | **50MG** | **A040735** | **003** | Jan 23, 2007 |
| **AB** | | PRINSTON INC | **25MG** | **A040412** | **001** | Mar 29, 2002 |
| **AB** | | | **50MG** | **A040412** | **002** | Mar 29, 2002 |
| **AB** | | SUN PHARM INDS INC | **12.5MG** | **A040857** | **001** | May 30, 2008 |
| **AB** | | | **25MG** | **A040810** | **001** | Mar 27, 2007 |
| **AB** | | | **50MG** | **A040810** | **002** | Mar 27, 2007 |
| **AB** | | TECH ORGANIZED | **25MG** | **A203018** | **001** | Jul 23, 2014 |
| **AB** | | | **50MG** | **A203018** | **002** | Jul 23, 2014 |
| **AB** | | UNICHEM | **25MG** | **A040907** | **001** | Aug 15, 2008 |
| **AB** | | | **50MG** | **A040907** | **002** | Aug 15, 2008 |

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL

**AVALIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | SANOFI AVENTIS US | **12.5MG;150MG** | **N020758** | **002** | Sep 30, 1997 |
| **AB** | **+!** | | **12.5MG;300MG** | **N020758** | **003** | Aug 31, 1998 |

**IRBESARTAN AND HYDROCHLOROTHIAZIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALEMBIC PHARMS LTD | **12.5MG;150MG** | **A091370** | **001** | Oct 15, 2012 |
| **AB** | | | **12.5MG;300MG** | **A091370** | **002** | Oct 15, 2012 |
| **AB** | | | **25MG;300MG** | **A091370** | **003** | Oct 12, 2016 |
| **AB** | | APOTEX INC | **12.5MG;150MG** | **A201505** | **001** | Oct 15, 2012 |
| **AB** | | | **12.5MG;300MG** | **A201505** | **002** | Oct 15, 2012 |
| **AB** | | ATLAS PHARMS LLC | **12.5MG;150MG** | **A203036** | **001** | Jan 15, 2016 |
| **AB** | | | **12.5MG;300MG** | **A203036** | **002** | Jan 15, 2016 |
| **AB** | | | **25MG;300MG** | **A203036** | **003** | Jan 15, 2016 |
| **AB** | | AUROBINDO PHARMA LTD | **12.5MG;150MG** | **A203630** | **001** | Feb 22, 2013 |
| **AB** | | | **12.5MG;300MG** | **A203630** | **002** | Feb 22, 2013 |
| **AB** | | | **25MG;300MG** | **A203630** | **003** | Mar 31, 2016 |
| **AB** | | DR REDDYS LABS LTD | **12.5MG;150MG** | **A203500** | **001** | Sep 27, 2012 |
| **AB** | | | **12.5MG;300MG** | **A203500** | **002** | Sep 27, 2012 |
| **AB** | | HISUN PHARM HANGZHOU | **12.5MG;150MG** | **A207896** | **001** | Oct 14, 2016 |
| **AB** | | | **12.5MG;300MG** | **A207896** | **002** | Oct 14, 2016 |
| **AB** | | LUPIN LTD | **12.5MG;150MG** | **A201524** | **001** | Feb 27, 2013 |
| **AB** | | | **12.5MG;300MG** | **A201524** | **002** | Feb 27, 2013 |
| **AB** | | MACLEODS PHARMS LTD | **12.5MG;150MG** | **A202414** | **001** | Sep 27, 2012 |
| **AB** | | | **12.5MG;300MG** | **A202414** | **002** | Sep 27, 2012 |
| **AB** | | MYLAN PHARMS INC | **12.5MG;150MG** | **A077969** | **001** | Sep 27, 2012 |
| **AB** | | | **12.5MG;300MG** | **A077969** | **002** | Sep 27, 2012 |
| **AB** | | | **25MG;300MG** | **A077969** | **003** | Jul 20, 2016 |
| **AB** | | PRINSTON INC | **12.5MG;150MG** | **A203072** | **001** | May 09, 2014 |

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL

**IRBESARTAN AND HYDROCHLOROTHIAZIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| AB | | 12.5MG;300MG | A203072 | 002 | May 09, 2014 |
| AB | SANDOZ | 12.5MG;150MG | A077446 | 001 | Sep 27, 2012 |
| AB | | 12.5MG;300MG | A077446 | 002 | Sep 27, 2012 |
| AB | TEVA | 12.5MG;150MG | A077369 | 001 | Mar 30, 2012 |
| AB | | 12.5MG;300MG | A077369 | 002 | Mar 30, 2012 |
| AB | UNICHEM LABS LTD | 12.5MG;150MG | A207018 | 001 | Sep 19, 2017 |
| AB | | 12.5MG;300MG | A207018 | 002 | Sep 19, 2017 |
| AB | WEST-WARD PHARMS INT | 12.5MG;150MG | A090351 | 001 | Oct 15, 2012 |
| AB | | 12.5MG;300MG | A090351 | 002 | Oct 15, 2012 |
| AB | | 25MG;300MG | A090351 | 003 | Jun 08, 2017 |

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL

**LISINOPRIL AND HYDROCHLOROTHIAZIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| AB | APOTEX INC | 12.5MG;10MG | A076674 | 001 | Oct 05, 2004 |
| AB | | 12.5MG;20MG | A076674 | 002 | Oct 05, 2004 |
| AB | | 25MG;20MG | A076674 | 003 | Oct 05, 2004 |
| AB | AUROBINDO | 12.5MG;10MG | A077606 | 001 | Mar 14, 2006 |
| AB | | 12.5MG;20MG | A077606 | 002 | Mar 14, 2006 |
| AB | | 25MG;20MG | A077606 | 003 | Mar 14, 2006 |
| AB | HIKMA INTL PHARMS | 12.5MG;10MG | A076265 | 001 | Jul 08, 2002 |
| AB | | 12.5MG;20MG | A076265 | 002 | Jul 08, 2002 |
| AB | | 25MG;20MG | A076265 | 003 | Jul 08, 2002 |
| AB | INVAGEN PHARMS | 12.5MG;10MG | A204058 | 001 | May 23, 2017 |
| AB | | 12.5MG;20MG | A204058 | 002 | May 23, 2017 |
| AB | | 25MG;20MG | A204058 | 003 | May 23, 2017 |
| AB | IVAX SUB TEVA PHARMS | 12.5MG;10MG | A075776 | 001 | Jul 01, 2002 |
| AB | | 12.5MG;20MG | A075776 | 002 | Jul 01, 2002 |
| AB | | 25MG;20MG | A075776 | 003 | Jul 01, 2002 |
| AB | LUPIN | 12.5MG;10MG | A077912 | 001 | Sep 27, 2006 |
| AB | | 12.5MG;20MG | A077912 | 002 | Sep 27, 2006 |
| AB | | 25MG;20MG | A077912 | 003 | Sep 27, 2006 |
| AB | MYLAN | 12.5MG;10MG | A076113 | 001 | Jul 01, 2002 |
| AB | | 12.5MG;20MG | A076113 | 002 | Jul 01, 2002 |
| AB | | 25MG;20MG | A076113 | 003 | Jul 01, 2002 |
| AB | PRINSTON INC | 12.5MG;10MG | A076230 | 001 | Jul 01, 2002 |
| AB | | 12.5MG;20MG | A076230 | 002 | Jul 01, 2002 |
| AB | | 25MG;20MG | A076230 | 003 | Jul 01, 2002 |
| AB | SANDOZ | 12.5MG;10MG | A076262 | 001 | Jul 01, 2002 |
| AB | | 12.5MG;20MG | A076262 | 002 | Jul 01, 2002 |
| AB | | 25MG;20MG | A076262 | 003 | Jul 01, 2002 |
| AB | SUN PHARM INDS LTD | 12.5MG;10MG | A076007 | 001 | Jul 01, 2002 |
| AB | | 12.5MG;20MG | A076007 | 002 | Jul 01, 2002 |
| AB | | 25MG;20MG | A076007 | 003 | Jul 01, 2002 |
| AB | WATSON LABS | 12.5MG;10MG | A076194 | 003 | Jul 01, 2002 |
| AB | | 12.5MG;20MG | A076194 | 001 | Jul 01, 2002 |
| AB | | 25MG;20MG | A076194 | 002 | Jul 01, 2002 |

**ZESTORETIC**

| | | | | | | |
|---|---|---|---|---|---|---|
| AB | + | ALVOGEN MALTA | 12.5MG;10MG | N019888 | 003 | Nov 18, 1993 |
| AB | +! | | 12.5MG;20MG | N019888 | 001 | Sep 20, 1990 |
| AB | +! | | 25MG;20MG | N019888 | 002 | Jul 20, 1989 |

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET;ORAL

**HYZAAR**

| | | | | | | |
|---|---|---|---|---|---|---|
| AB | + | MERCK SHARP DOHME | 12.5MG;50MG | N020387 | 001 | Apr 28, 1995 |
| AB | + | | 12.5MG;100MG | N020387 | 003 | Oct 20, 2005 |
| AB | +! | | 25MG;100MG | N020387 | 002 | Nov 10, 1998 |

**LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| AB | ALEMBIC PHARMS LTD | 12.5MG;50MG | A091617 | 001 | Feb 17, 2012 |
| AB | | 12.5MG;100MG | A091617 | 002 | Feb 17, 2012 |
| AB | | 25MG;100MG | A091617 | 003 | Feb 17, 2012 |
| AB | APOTEX | 12.5MG;50MG | A090150 | 001 | Oct 06, 2010 |
| AB | | 12.5MG;100MG | A090150 | 002 | Aug 11, 2010 |
| AB | | 25MG;100MG | A090150 | 003 | Oct 06, 2010 |
| AB | AUROBINDO PHARMA | 12.5MG;50MG | A091629 | 001 | Oct 06, 2010 |
| AB | | 12.5MG;100MG | A091629 | 002 | Oct 06, 2010 |
| AB | | 25MG;100MG | A091629 | 003 | Jan 06, 2010 |
| AB | CADISTA PHARMS | 12.5MG;50MG | A201845 | 001 | Sep 18, 2012 |

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET;ORAL

**LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **12.5MG;100MG** | **A201845** | **002** | Sep 18, 2012 |
| **AB** | | | **25MG;100MG** | **A201845** | **003** | Sep 18, 2012 |
| **AB** | | IPCA LABS LTD | **12.5MG;50MG** | **A201682** | **001** | Mar 01, 2013 |
| **AB** | | | **12.5MG;100MG** | **A201682** | **002** | Mar 01, 2013 |
| **AB** | | | **25MG;100MG** | **A201682** | **003** | Mar 01, 2013 |
| **AB** | | LUPIN LTD | **12.5MG;50MG** | **A078245** | **001** | Oct 06, 2010 |
| **AB** | | | **12.5MG;100MG** | **A078245** | **002** | May 21, 2010 |
| **AB** | | | **25MG;100MG** | **A078245** | **003** | Oct 06, 2010 |
| **AB** | | MACLEODS PHARMS LTD | **12.5MG;50MG** | **A202289** | **001** | Aug 09, 2012 |
| **AB** | | | **12.5MG;100MG** | **A202289** | **002** | Aug 09, 2012 |
| **AB** | | | **25MG;100MG** | **A202289** | **003** | Aug 09, 2012 |
| **AB** | | MYLAN | **12.5MG;50MG** | **A091652** | **001** | Oct 06, 2010 |
| **AB** | | | **12.5MG;100MG** | **A091652** | **002** | Apr 06, 2010 |
| **AB** | | | **25MG;100MG** | **A091652** | **003** | Oct 06, 2010 |
| **AB** | | PRINSTON INC | **12.5MG;50MG** | **A204901** | **001** | Nov 06, 2017 |
| **AB** | | | **12.5MG;100MG** | **A204901** | **002** | Nov 06, 2017 |
| **AB** | | | **25MG;100MG** | **A204901** | **003** | Nov 06, 2017 |
| **AB** | | SANDOZ | **12.5MG;50MG** | **A077948** | **001** | Oct 06, 2010 |
| **AB** | | | **12.5MG;100MG** | **A077948** | **003** | Aug 19, 2010 |
| **AB** | | | **25MG;100MG** | **A077948** | **002** | Oct 06, 2010 |
| **AB** | | TEVA PHARMS | **12.5MG;50MG** | **A077157** | **001** | Apr 06, 2010 |
| **AB** | | | **12.5MG;100MG** | **A077157** | **002** | Apr 06, 2010 |
| **AB** | | | **25MG;100MG** | **A077157** | **003** | Apr 06, 2010 |
| **AB** | | TORRENT PHARMS | **12.5MG;50MG** | **A090528** | **001** | Oct 06, 2010 |
| **AB** | | | **12.5MG;100MG** | **A090528** | **003** | Apr 06, 2010 |
| **AB** | | | **25MG;100MG** | **A090528** | **002** | Oct 06, 2010 |
| **AB** | | UNICHEM LABS LTD | **12.5MG;50MG** | **A204832** | **001** | Jul 21, 2017 |
| **AB** | | | **12.5MG;100MG** | **A204832** | **002** | Jul 21, 2017 |
| **AB** | | | **25MG;100MG** | **A204832** | **003** | Jul 21, 2017 |
| **AB** | | WEST-WARD PHARMS INT | **12.5MG;50MG** | **A077732** | **002** | Oct 06, 2010 |
| **AB** | | | **12.5MG;100MG** | **A077732** | **001** | Apr 06, 2010 |
| **AB** | | | **25MG;100MG** | **A077732** | **003** | Oct 06, 2010 |
| **AB** | | ZYDUS PHARMS USA INC | **12.5MG;50MG** | **A078385** | **001** | Oct 06, 2010 |
| **AB** | | | **25MG;100MG** | **A078385** | **002** | Oct 06, 2010 |

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET;ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

| | | | | | | |
|---|---|---|---|---|---|---|
| | | MYLAN | 15MG;250MG | A070265 | 002 | Jan 23, 1986 |
| | ! | | 25MG;250MG | A070265 | 001 | Jan 23, 1986 |

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DUTOPROL

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | CONCORDIA PHARMS INC | 12.5MG;EQ 25MG TARTRATE | N021956 | 001 | Aug 28, 2006 |
| | + | | 12.5MG;EQ 50MG TARTRATE | N021956 | 002 | Aug 28, 2006 |
| | +! | | 12.5MG;EQ 100MG TARTRATE | N021956 | 003 | Aug 28, 2006 |

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET;ORAL

**LOPRESSOR HCT**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | US PHARMS HOLDINGS I | **25MG;50MG** | **N018303** | **001** | Dec 31, 1984 |
| **AB** | **+!** | | **25MG;100MG** | **N018303** | **002** | Dec 31, 1984 |

**METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALEMBIC PHARMS LTD | **25MG;50MG** | **A202870** | **001** | Nov 06, 2013 |
| **AB** | | | **25MG;100MG** | **A202870** | **002** | Nov 06, 2013 |
| **AB** | | | **50MG;100MG** | **A202870** | **003** | Nov 06, 2013 |
| **AB** | | MYLAN | **25MG;50MG** | **A076792** | **001** | Aug 20, 2004 |
| **AB** | | | **25MG;100MG** | **A076792** | **002** | Aug 20, 2004 |
| **AB** | | | **50MG;100MG** | **A076792** | **003** | Aug 20, 2004 |
| **AB** | | SUN PHARM INDS | **25MG;50MG** | **A090654** | **001** | Jan 19, 2012 |
| **AB** | | | **25MG;100MG** | **A090654** | **002** | Jan 19, 2012 |
| **AB** | | | **50MG;100MG** | **A090654** | **003** | Jan 19, 2012 |

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

**MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| AB | | GLENMARK PHARMS | 12.5MG;7.5MG | A090718 | 001 | Mar 17, 2010 |
| AB | | | 12.5MG;15MG | A090718 | 002 | Mar 17, 2010 |
| AB | | | 25MG;15MG | A090718 | 003 | Mar 17, 2010 |
| AB | | HERITAGE PHARMS INC | 12.5MG;7.5MG | A202150 | 001 | Mar 07, 2014 |
| AB | | | 12.5MG;15MG | A202150 | 002 | Mar 07, 2014 |
| AB | | | 25MG;15MG | A202150 | 003 | Mar 07, 2014 |
| AB | | TEVA | 12.5MG;7.5MG | A076980 | 001 | Mar 07, 2007 |
| AB | | | 12.5MG;15MG | A076980 | 003 | Mar 07, 2007 |
| AB | ! | | 25MG;15MG | A076980 | 002 | Mar 07, 2007 |

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

**BENICAR HCT**

| | | | | | | |
|---|---|---|---|---|---|---|
| AB | + | DAIICHI SANKYO | 12.5MG;20MG | N021532 | 002 | Jun 05, 2003 |
| AB | + | | 12.5MG;40MG | N021532 | 003 | Jun 05, 2003 |
| AB | +! | | 25MG;40MG | N021532 | 005 | Jun 05, 2003 |

**OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| AB | | ALEMBIC PHARMS LTD | 12.5MG;20MG | A204233 | 001 | Apr 24, 2017 |
| AB | | | 12.5MG;40MG | A204233 | 002 | Apr 24, 2017 |
| AB | | | 25MG;40MG | A204233 | 003 | Apr 24, 2017 |
| AB | | AUROBINDO PHARMA LTD | 12.5MG;20MG | A205391 | 001 | Apr 24, 2017 |
| AB | | | 12.5MG;40MG | A205391 | 002 | Apr 24, 2017 |
| AB | | | 25MG;40MG | A205391 | 003 | Apr 24, 2017 |
| AB | | MYLAN PHARMS INC | 12.5MG;20MG | A078827 | 001 | Oct 26, 2016 |
| AB | | | 12.5MG;40MG | A078827 | 002 | Oct 26, 2016 |
| AB | | | 25MG;40MG | A078827 | 003 | Oct 26, 2016 |
| AB | | PRINSTON INC | 12.5MG;20MG | A207804 | 001 | Apr 24, 2017 |
| AB | | | 12.5MG;40MG | A207804 | 002 | Apr 24, 2017 |
| AB | | | 25MG;40MG | A207804 | 003 | Apr 24, 2017 |
| AB | | TEVA PHARMS USA | 12.5MG;20MG | A200532 | 001 | Apr 24, 2017 |
| AB | | | 12.5MG;40MG | A200532 | 002 | Apr 24, 2017 |
| AB | | | 25MG;40MG | A200532 | 003 | Apr 24, 2017 |
| AB | | TORRENT PHARMS LTD | 12.5MG;20MG | A206515 | 001 | May 03, 2017 |
| AB | | | 12.5MG;40MG | A206515 | 002 | May 03, 2017 |
| AB | | | 25MG;40MG | A206515 | 003 | May 03, 2017 |

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL

**PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| AB | | ANI PHARMS INC | 25MG;40MG | A072042 | 001 | Mar 14, 1988 |
| AB | | | 25MG;80MG | A072043 | 001 | Mar 14, 1988 |
| AB | ! | MYLAN | 25MG;40MG | A070947 | 002 | Mar 04, 1987 |
| AB | ! | | 25MG;80MG | A070947 | 001 | Apr 01, 1987 |

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

**ACCURETIC**

| | | | | | | |
|---|---|---|---|---|---|---|
| AB | + | PFIZER PHARMS | 12.5MG;EQ 10MG BASE | N020125 | 001 | Dec 28, 1999 |
| AB | + | | 12.5MG;EQ 20MG BASE | N020125 | 002 | Dec 28, 1999 |
| AB | +! | | 25MG;EQ 20MG BASE | N020125 | 003 | Dec 28, 1999 |

**QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| AB | | APOTEX CORP | 12.5MG;EQ 10MG BASE | A091524 | 001 | Mar 12, 2013 |
| AB | | | 12.5MG;EQ 20MG BASE | A091524 | 002 | Mar 12, 2013 |
| AB | | | 25MG;EQ 20MG BASE | A091524 | 003 | Mar 12, 2013 |
| AB | | AUROBINDO PHARMA | 12.5MG;EQ 10MG BASE | A078450 | 001 | Aug 24, 2007 |
| AB | | | 12.5MG;EQ 20MG BASE | A078450 | 002 | Aug 24, 2007 |
| AB | | | 25MG;EQ 20MG BASE | A078450 | 003 | Aug 24, 2007 |
| AB | | INVAGEN PHARMS | 12.5MG;EQ 10MG BASE | A201356 | 001 | Apr 20, 2011 |
| AB | | | 12.5MG;EQ 20MG BASE | A201356 | 002 | Apr 20, 2011 |
| AB | | | 25MG;EQ 20MG BASE | A201356 | 003 | Apr 20, 2011 |
| AB | | MYLAN | 12.5MG;EQ 10MG BASE | A077093 | 001 | Mar 28, 2005 |
| AB | | | 12.5MG;EQ 20MG BASE | A077093 | 002 | Mar 28, 2005 |
| AB | | | 25MG;EQ 20MG BASE | A077093 | 003 | Mar 28, 2005 |

**QUINARETIC**

| | | | | | | |
|---|---|---|---|---|---|---|
| AB | | GAVIS PHARMS | 12.5MG;EQ 10MG BASE | A076374 | 001 | Mar 31, 2004 |
| AB | | | 12.5MG;EQ 20MG BASE | A076374 | 002 | Mar 31, 2004 |
| AB | | | 25MG;EQ 20MG BASE | A076374 | 003 | Mar 31, 2004 |

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET;ORAL

**ALDACTAZIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | GD SEARLE LLC | **25MG;25MG** | **N012616** | **004** | Dec 30, 1982 |

**SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | MYLAN | **25MG;25MG** | **A086513** | **001** | |
| **AB** | | SUN PHARM INDUSTRIES | **25MG;25MG** | **A089534** | **001** | Jul 02, 1987 |

ALDACTAZIDE

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | GD SEARLE LLC | 50MG;50MG | N012616 | 005 | Dec 30, 1982 |

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET;ORAL

**MICARDIS HCT**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | BOEHRINGER INGELHEIM | **12.5MG;40MG** | **N021162** | **001** | Nov 17, 2000 |
| **AB** | + | | **12.5MG;80MG** | **N021162** | **002** | Nov 17, 2000 |
| **AB** | +! | | **25MG;80MG** | **N021162** | **003** | Apr 19, 2004 |

**TELMISARTAN AND HYDROCHLOROTHIAZIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALEMBIC PHARMS LTD | **12.5MG;40MG** | **A203010** | **001** | Feb 25, 2014 |
| **AB** | | | **12.5MG;80MG** | **A203010** | **002** | Feb 25, 2014 |
| **AB** | | | **25MG;80MG** | **A203010** | **003** | Feb 25, 2014 |
| **AB** | | AUROBINDO PHARMA LTD | **12.5MG;40MG** | **A208727** | **001** | Dec 15, 2016 |
| **AB** | | | **12.5MG;80MG** | **A208727** | **002** | Dec 15, 2016 |
| **AB** | | | **25MG;80MG** | **A208727** | **003** | Dec 15, 2016 |
| **AB** | | LUPIN LTD | **12.5MG;40MG** | **A091351** | **001** | Aug 07, 2014 |
| **AB** | | | **12.5MG;80MG** | **A091351** | **002** | Aug 07, 2014 |
| **AB** | | | **25MG;80MG** | **A091351** | **003** | Aug 07, 2014 |
| **AB** | | MACLEODS PHARMS LTD | **12.5MG;40MG** | **A204169** | **001** | Nov 02, 2015 |
| **AB** | | | **12.5MG;80MG** | **A204169** | **002** | Nov 02, 2015 |
| **AB** | | | **25MG;80MG** | **A204169** | **003** | Nov 02, 2015 |
| **AB** | | MYLAN PHARMS INC | **12.5MG;40MG** | **A091648** | **001** | Feb 25, 2014 |
| **AB** | | | **12.5MG;80MG** | **A091648** | **002** | Feb 25, 2014 |
| **AB** | | | **25MG;80MG** | **A091648** | **003** | Feb 25, 2014 |
| **AB** | | PRINSTON INC | **12.5MG;40MG** | **A209028** | **001** | Nov 06, 2017 |
| **AB** | | | **12.5MG;80MG** | **A209028** | **002** | Nov 06, 2017 |
| **AB** | | | **25MG;80MG** | **A209028** | **003** | Nov 06, 2017 |
| **AB** | | TORRENT PHARMS LTD | **12.5MG;40MG** | **A201192** | **001** | Feb 25, 2014 |
| **AB** | | | **12.5MG;80MG** | **A201192** | **002** | Feb 25, 2014 |
| **AB** | | | **25MG;80MG** | **A201192** | **003** | Feb 25, 2014 |
| **AB** | | ZYDUS PHARMS USA INC | **12.5MG;40MG** | **A204221** | **001** | Aug 15, 2017 |
| **AB** | | | **12.5MG;80MG** | **A204221** | **002** | Aug 15, 2017 |
| **AB** | | | **25MG;80MG** | **A204221** | **003** | Aug 15, 2017 |

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE;ORAL

**DYAZIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | +! | GLAXOSMITHKLINE LLC | **25MG;37.5MG** | **N016042** | **003** | Mar 03, 1994 |

**TRIAMTERENE AND HYDROCHLOROTHIAZIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | DURAMED PHARMS BARR | **25MG;37.5MG** | **A075052** | **001** | Jun 18, 1999 |
| **AB** | | IVAX SUB TEVA PHARMS | **25MG;50MG** | **A074259** | **001** | Mar 30, 1995 |
| **AB** | | LANNETT HOLDINGS INC | **25MG;37.5MG** | **A201407** | **001** | Dec 09, 2011 |
| **AB** | | MYLAN | **25MG;37.5MG** | **A074701** | **001** | Jun 07, 1996 |
| **AB** | | SANDOZ | **25MG;37.5MG** | **A074821** | **001** | Jun 05, 1997 |
| **AB** | ! | | **25MG;50MG** | **A073191** | **001** | Jul 31, 1991 |

TABLET;ORAL

**MAXZIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | +! | MYLAN PHARMS INC | **50MG;75MG** | **N019129** | **001** | Oct 22, 1984 |

**MAXZIDE-25**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | MYLAN PHARMS INC | **25MG;37.5MG** | **N019129** | **003** | May 13, 1988 |

**TRIAMTERENE AND HYDROCHLOROTHIAZIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ANI PHARMS INC | **50MG;75MG** | **A073467** | **001** | Jan 31, 1996 |
| **AB** | | APOTEX INC | **25MG;37.5MG** | **A071251** | **002** | May 05, 1998 |
| **AB** | | | **50MG;75MG** | **A071251** | **001** | Apr 17, 1988 |
| **AB** | | PLIVA | **25MG;37.5MG** | **A074026** | **001** | Apr 26, 1996 |
| **AB** | | SANDOZ | **25MG;37.5MG** | **A073281** | **001** | Apr 30, 1992 |
| **AB** | | | **50MG;75MG** | **A072011** | **001** | Jun 17, 1988 |
| **AB** | | WATSON LABS | **25MG;37.5MG** | **A073449** | **001** | Sep 23, 1993 |
| **AB** | | | **50MG;75MG** | **A071851** | **001** | Nov 30, 1988 |

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

**DIOVAN HCT**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | NOVARTIS | **12.5MG;80MG** | **N020818** | **001** | Mar 06, 1998 |
| **AB** | + | | **12.5MG;160MG** | **N020818** | **002** | Mar 06, 1998 |
| **AB** | + | | **12.5MG;320MG** | **N020818** | **004** | Apr 28, 2006 |
| **AB** | + | | **25MG;160MG** | **N020818** | **003** | Jan 17, 2002 |
| **AB** | +! | | **25MG;320MG** | **N020818** | **005** | Apr 28, 2006 |

**VALSARTAN AND HYDROCHLOROTHIAZIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALEMBIC PHARMS LTD | **12.5MG;80MG** | **A201662** | **001** | Mar 21, 2013 |
| **AB** | | | **12.5MG;160MG** | **A201662** | **002** | Mar 21, 2013 |
| **AB** | | | **12.5MG;320MG** | **A201662** | **003** | Mar 21, 2013 |
| **AB** | | | **25MG;160MG** | **A201662** | **004** | Mar 21, 2013 |
| **AB** | | | **25MG;320MG** | **A201662** | **005** | Mar 21, 2013 |
| **AB** | | APOTEX INC | **12.5MG;80MG** | **A203026** | **001** | Mar 21, 2013 |
| **AB** | | | **12.5MG;160MG** | **A203026** | **002** | Mar 21, 2013 |
| **AB** | | | **12.5MG;320MG** | **A203026** | **003** | Mar 21, 2013 |
| **AB** | | | **25MG;160MG** | **A203026** | **004** | Mar 21, 2013 |
| **AB** | | | **25MG;320MG** | **A203026** | **005** | Mar 21, 2013 |
| **AB** | | AUROBINDO PHARMA LTD | **12.5MG;80MG** | **A202519** | **001** | Mar 21, 2013 |
| **AB** | | | **12.5MG;160MG** | **A202519** | **002** | Mar 21, 2013 |
| **AB** | | | **12.5MG;320MG** | **A202519** | **003** | Mar 21, 2013 |
| **AB** | | | **25MG;160MG** | **A202519** | **004** | Mar 21, 2013 |
| **AB** | | | **25MG;320MG** | **A202519** | **005** | Mar 21, 2013 |
| **AB** | | LUPIN LTD | **12.5MG;80MG** | **A078946** | **003** | Mar 21, 2013 |
| **AB** | | | **12.5MG;160MG** | **A078946** | **004** | Mar 21, 2013 |
| **AB** | | | **12.5MG;320MG** | **A078946** | **001** | Mar 21, 2013 |
| **AB** | | | **25MG;160MG** | **A078946** | **005** | Mar 21, 2013 |
| **AB** | | | **25MG;320MG** | **A078946** | **002** | Mar 21, 2013 |
| **AB** | | MACLEODS PHARMS LTD | **12.5MG;80MG** | **A203145** | **001** | Apr 19, 2013 |
| **AB** | | | **12.5MG;160MG** | **A203145** | **002** | Apr 19, 2013 |
| **AB** | | | **12.5MG;320MG** | **A203145** | **003** | Apr 19, 2013 |
| **AB** | | | **25MG;160MG** | **A203145** | **004** | Apr 19, 2013 |
| **AB** | | | **25MG;320MG** | **A203145** | **005** | Apr 19, 2013 |
| **AB** | | MYLAN PHARMS INC | **12.5MG;80MG** | **A078020** | **001** | Sep 21, 2012 |
| **AB** | | | **12.5MG;160MG** | **A078020** | **002** | Sep 21, 2012 |
| **AB** | | | **12.5MG;320MG** | **A078020** | **004** | Sep 21, 2012 |
| **AB** | | | **25MG;160MG** | **A078020** | **003** | Sep 21, 2012 |
| **AB** | | | **25MG;320MG** | **A078020** | **005** | Sep 21, 2012 |
| **AB** | | PRINSTON INC | **12.5MG;80MG** | **A206083** | **001** | Feb 08, 2016 |
| **AB** | | | **12.5MG;160MG** | **A206083** | **002** | Feb 08, 2016 |
| **AB** | | | **12.5MG;320MG** | **A206083** | **003** | Feb 08, 2016 |
| **AB** | | | **25MG;160MG** | **A206083** | **004** | Feb 08, 2016 |
| **AB** | | | **25MG;320MG** | **A206083** | **005** | Feb 08, 2016 |
| **AB** | | WATSON LABS TEVA | **12.5MG;80MG** | **A091519** | **001** | Mar 21, 2013 |
| **AB** | | | **12.5MG;160MG** | **A091519** | **002** | Mar 21, 2013 |
| **AB** | | | **12.5MG;320MG** | **A091519** | **003** | Mar 21, 2013 |
| **AB** | | | **25MG;160MG** | **A091519** | **004** | Mar 21, 2013 |
| **AB** | | | **25MG;320MG** | **A091519** | **005** | Mar 21, 2013 |

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

ZOHYDRO ER

| | | | | | |
|---|---|---|---|---|---|
| +! | PERNIX IRELAND PAIN | 10MG | N202880 | 001 | Oct 25, 2013 |
| + | | 15MG | N202880 | 002 | Oct 25, 2013 |
| + | | 20MG | N202880 | 003 | Oct 25, 2013 |
| + | | 30MG | N202880 | 004 | Oct 25, 2013 |
| + | | 40MG | N202880 | 005 | Oct 25, 2013 |
| + | | 50MG | N202880 | 006 | Oct 25, 2013 |

TABLET, EXTENDED RELEASE;ORAL

HYSINGLA

| | | | | | |
|---|---|---|---|---|---|
| +! | PURDUE PHARMA LP | 20MG | N206627 | 001 | Nov 20, 2014 |
| + | | 30MG | N206627 | 002 | Nov 20, 2014 |
| + | | 40MG | N206627 | 003 | Nov 20, 2014 |
| + | | 60MG | N206627 | 004 | Nov 20, 2014 |
| + | | 80MG | N206627 | 005 | Nov 20, 2014 |
| + | | 100MG | N206627 | 006 | Nov 20, 2014 |
| + | | 120MG | N206627 | 007 | Nov 20, 2014 |

VANTRELA ER

| | | | | | |
|---|---|---|---|---|---|
| + | TEVA BRANDED PHARM | 15MG | N207975 | 001 | Jan 17, 2017 |
| + | | 30MG | N207975 | 002 | Jan 17, 2017 |
| + | | 45MG | N207975 | 003 | Jan 17, 2017 |

HYDROCODONE BITARTRATE

TABLET, EXTENDED RELEASE;ORAL

VANTRELA ER

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | | 60MG | N207975 | 004 | Jan 17, 2017 |
| | + | | 90MG | N207975 | 005 | Jan 17, 2017 |

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET;ORAL

**HYDROCODONE BITARTRATE AND IBUPROFEN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS LABS FL INC | **7.5MG;200MG** | **A076604** | **001** | Dec 31, 2003 |
| **AB** | | AMNEAL PHARMS NY | **5MG;200MG** | **A076642** | **002** | Mar 18, 2004 |
| **AB** | ! | | **7.5MG;200MG** | **A076642** | **001** | Oct 12, 2004 |
| **AB** | | AUROLIFE PHARMA LLC | **7.5MG;200MG** | **A204575** | **001** | Jun 02, 2016 |
| **AB** | | SUN PHARM INDS INC | **2.5MG;200MG** | **A091633** | **001** | May 28, 2013 |
| **AB** | | | **5MG;200MG** | **A091633** | **002** | May 28, 2013 |
| **AB** | | | **7.5MG;200MG** | **A091633** | **003** | May 28, 2013 |
| **AB** | | | **10MG;200MG** | **A091633** | **004** | May 28, 2013 |
| **AB** | | TEVA | **7.5MG;200MG** | **A076023** | **001** | Apr 11, 2003 |
| **AB** | | VINTAGE PHARMS | **5MG;200MG** | **A077727** | **001** | Nov 06, 2006 |
| **AB** | | | **7.5MG;200MG** | **A077723** | **001** | Nov 06, 2006 |
| **AB** | | | **10MG;200MG** | **A077723** | **002** | Nov 06, 2006 |

**REPREXAIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AMNEAL PHARMS NY | **2.5MG;200MG** | **A076642** | **003** | Oct 19, 2007 |
| **AB** | | | **10MG;200MG** | **A076642** | **004** | Oct 19, 2007 |

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

**HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | MAYNE PHARMA INC | **5MG/5ML;60MG/5ML** | **A205658** | **001** | Nov 17, 2015 |
| **AA** | | PADDOCK LLC | **5MG/5ML;60MG/5ML** | **A204658** | **001** | Apr 29, 2014 |

**REZIRA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **+!** | CYPRESS PHARM | **5MG/5ML;60MG/5ML** | **N022442** | **001** | Jun 08, 2011 |

HYDROCORTISONE

CREAM;TOPICAL

**ALA-CORT**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | CROWN LABS | **2.5%** | **A080706** | **007** | Jan 05, 2016 |
| **AT** | | | **1%** | **A080706** | **006** | |

**ANUSOL HC**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | SALIX PHARMS | **2.5%** | **A088250** | **001** | Jun 06, 1984 |

**HYDROCORTISONE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | ACTAVIS MID ATLANTIC | **1%** | **A087795** | **001** | May 03, 1983 |
| **AT** | | | **2.5%** | **A089682** | **001** | Mar 10, 1988 |
| **AT** | ! | FOUGERA PHARMS INC | **1%** | **A080693** | **003** | |
| **AT** | ! | | **2.5%** | **A089414** | **001** | Dec 16, 1986 |
| **AT** | | PERRIGO NEW YORK | **2.5%** | **A085025** | **001** | |
| **AT** | | RISING PHARMS INC | **2.5%** | **A040879** | **001** | Aug 20, 2010 |
| **AT** | | TARO | **2.5%** | **A088799** | **001** | Nov 09, 1984 |
| **AT** | | VINTAGE PHARMS | **2.5%** | **A040503** | **001** | Mar 12, 2004 |

ENEMA;RECTAL

**COLOCORT**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | PADDOCK LLC | **100MG/60ML** | **A075172** | **001** | Dec 03, 1999 |

**CORTENEMA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | ANI PHARMS | **100MG/60ML** | **N016199** | **001** | |

**HYDROCORTISONE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | TEVA PHARMS | **100MG/60ML** | **A074171** | **001** | May 27, 1994 |

LOTION;TOPICAL

**HYDROCORTISONE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | ! | FOUGERA PHARMS | **2.5%** | **A040351** | **001** | Jul 25, 2000 |
| **AT** | | TARO | **2.5%** | **A040247** | **001** | Jul 23, 1999 |
| **AT** | | VINTAGE PHARMS | **2.5%** | **A040417** | **001** | Jul 30, 2003 |

**STIE-CORT**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | PERRIGO CO | **2.5%** | **A089074** | **001** | Nov 26, 1985 |

ALA-SCALP

| | | | | | | |
|---|---|---|---|---|---|---|
| | | CROWN LABS | 2% | A083231 | 001 | |

OINTMENT;TOPICAL

**HYDROCORTISONE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | ACTAVIS MID ATLANTIC | **1%** | **A087796** | **001** | Oct 13, 1982 |
| **AT** | ! | FOUGERA PHARMS | **1%** | **A080692** | **001** | |
| **AT** | ! | FOUGERA PHARMS INC | **2.5%** | **A081203** | **001** | May 28, 1993 |
| **AT** | | PERRIGO NEW YORK | **2.5%** | **A085027** | **001** | |
| **AT** | | TARO | **1%** | **A086257** | **001** | |

| | | | | | | |
|---|---|---|---|---|---|---|
| HYDROCORTISONE | | | | | | |
| OINTMENT;TOPICAL | | | | | | |
| **HYDROCORTISONE IN ABSORBASE** | | | | | | |
| **AT** | | CMP PHARMA INC | **1%** | **A088138** | **001** | Sep 06, 1985 |
| SOLUTION;TOPICAL | | | | | | |
| TEXACORT | | | | | | |
| | ! | MISSION PHARMA | 2.5% | A081271 | 001 | Apr 17, 1992 |
| TABLET;ORAL | | | | | | |
| **CORTEF** | | | | | | |
| **AB** | **+** | PHARMACIA AND UPJOHN | **5MG** | **N008697** | **003** | |
| **AB** | **+** | | **10MG** | **N008697** | **001** | |
| **AB** | **+!** | | **20MG** | **N008697** | **002** | |
| **HYDROCORTISONE** | | | | | | |
| **AB** | | HIKMA INTL PHARMS | **5MG** | **A083365** | **002** | Feb 23, 2015 |
| **AB** | | | **10MG** | **A083365** | **003** | Feb 23, 2015 |
| **AB** | | | **20MG** | **A083365** | **001** | |
| **AB** | | IMPAX LABS INC | **5MG** | **A040646** | **001** | Mar 30, 2007 |
| **AB** | | | **10MG** | **A040646** | **002** | Mar 30, 2007 |
| **AB** | | | **20MG** | **A040646** | **003** | Mar 30, 2007 |
| **AB** | | PII | **5MG** | **A207029** | **001** | Apr 27, 2017 |
| **AB** | | | **10MG** | **A207029** | **002** | Apr 27, 2017 |
| **AB** | | | **20MG** | **A207029** | **003** | Apr 27, 2017 |
| **AB** | | VINTAGE | **5MG** | **A040761** | **001** | Jul 16, 2007 |
| **AB** | | | **10MG** | **A040761** | **002** | Jul 16, 2007 |
| **AB** | | | **20MG** | **A040761** | **003** | Jul 16, 2007 |
| HYDROCORTISONE ACETATE | | | | | | |
| AEROSOL, METERED;RECTAL | | | | | | |
| CORTIFOAM | | | | | | |
| | +! | MYLAN SPECIALITY LP | 10% | N017351 | 001 | Feb 10, 1982 |
| CREAM;TOPICAL | | | | | | |
| MICORT-HC | | | | | | |
| | | SEBELA IRELAND LTD | 2.5% | A040396 | 001 | Feb 27, 2001 |
| HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE | | | | | | |
| CREAM;TOPICAL | | | | | | |
| CORTISPORIN | | | | | | |
| | +! | MONARCH PHARMS | 0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM | N050218 | 001 | Aug 09, 1985 |
| HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE | | | | | | |
| AEROSOL, METERED;TOPICAL | | | | | | |
| EPIFOAM | | | | | | |
| BX | | MYLAN SPECIALITY LP | 1%;1% | A086457 | 001 | |
| PROCTOFOAM HC | | | | | | |
| BX | | MYLAN SPECIALITY LP | 1%;1% | A086195 | 001 | |
| CREAM;TOPICAL | | | | | | |
| PRAMOSONE | | | | | | |
| | | SEBELA IRELAND LTD | 0.5%;1% | A083778 | 001 | |
| | | | 1%;1% | A085368 | 001 | |
| LOTION;TOPICAL | | | | | | |
| PRAMOSONE | | | | | | |
| | | SEBELA IRELAND LTD | 1%;1% | A085980 | 001 | |
| | | | 2.5%;1% | A085979 | 001 | |
| HYDROCORTISONE ACETATE; UREA | | | | | | |
| CREAM;TOPICAL | | | | | | |
| U-CORT | | | | | | |
| | | TARO | 1%;10% | A089472 | 001 | Jun 13, 1988 |
| HYDROCORTISONE BUTYRATE | | | | | | |
| CREAM;TOPICAL | | | | | | |
| **HYDROCORTISONE BUTYRATE** | | | | | | |
| **AB1** | | TARO PHARM INDS | **0.1%** | **A076654** | **001** | Aug 03, 2005 |
| **LOCOID** | | | | | | |
| **AB1** | **+!** | PRECISION DERMAT | **0.1%** | **N018514** | **001** | Mar 31, 1982 |
| **HYDROCORTISONE BUTYRATE** | | | | | | |
| **AB2** | | ACTAVIS MID ATLANTIC | **0.1%** | **A205134** | **001** | Dec 08, 2017 |
| **AB2** | | GLENMARK GENERICS | **0.1%** | **A202145** | **001** | Sep 27, 2013 |
| **LOCOID LIPOCREAM** | | | | | | |
| **AB2** | **+!** | PRECISION DERMAT | **0.1%** | **N020769** | **001** | Sep 08, 1997 |
| LOTION;TOPICAL | | | | | | |
| **HYDROCORTISONE BUTYRATE** | | | | | | |
| **AB** | | TELIGENT PHARMA INC | **0.1%** | **A209556** | **001** | Nov 21, 2017 |

| | | | | | | |
|---|---|---|---|---|---|---|
| HYDROCORTISONE BUTYRATE | | | | | | |
| LOTION;TOPICAL | | | | | | |
| **LOCOID** | | | | | | |
| **AB** | **+!** | PRECISION DERMAT | **0.1%** | **N022076** | **001** | May 18, 2007 |
| OINTMENT;TOPICAL | | | | | | |
| **HYDROCORTISONE BUTYRATE** | | | | | | |
| **AB** | | TARO | **0.1%** | **A076842** | **001** | Dec 27, 2004 |
| **LOCOID** | | | | | | |
| **AB** | **+!** | PRECISION DERMAT | **0.1%** | **N018652** | **001** | Oct 29, 1982 |
| SOLUTION;TOPICAL | | | | | | |
| **HYDROCORTISONE BUTYRATE** | | | | | | |
| **AT** | | TARO PHARM INDS | **0.1%** | **A076364** | **001** | Jan 14, 2004 |
| **LOCOID** | | | | | | |
| **AT** | **+!** | PRECISION DERMAT | **0.1%** | **N019116** | **001** | Feb 25, 1987 |
| HYDROCORTISONE PROBUTATE | | | | | | |
| CREAM;TOPICAL | | | | | | |
| PANDEL | | | | | | |
| | +! | FOUGERA PHARMS | 0.1% | N020453 | 001 | Feb 28, 1997 |
| HYDROCORTISONE SODIUM SUCCINATE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| SOLU-CORTEF | | | | | | |
| | +! | PHARMACIA AND UPJOHN | EQ 100MG BASE/VIAL | N009866 | 001 | |
| | +! | | EQ 250MG BASE/VIAL | N009866 | 002 | |
| | +! | | EQ 500MG BASE/VIAL | N009866 | 003 | |
| | +! | | EQ 1GM BASE/VIAL | N009866 | 004 | |
| HYDROCORTISONE VALERATE | | | | | | |
| CREAM;TOPICAL | | | | | | |
| **HYDROCORTISONE VALERATE** | | | | | | |
| **AB** | | PERRIGO NEW YORK | **0.2%** | **A075666** | **001** | May 24, 2000 |
| **AB** | **!** | TARO | **0.2%** | **A075042** | **001** | Aug 25, 1998 |
| OINTMENT;TOPICAL | | | | | | |
| HYDROCORTISONE VALERATE | | | | | | |
| | ! | TARO | 0.2% | A075043 | 001 | Aug 25, 1998 |
| HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE | | | | | | |
| SOLUTION/DROPS;OTIC | | | | | | |
| **CORTISPORIN** | | | | | | |
| **AT** | **+!** | MONARCH PHARMS | **1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML** | **N050479** | **001** | |
| **NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE** | | | | | | |
| **AT** | | AMRING PHARMS | **1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML** | **A065216** | **001** | Oct 31, 2005 |
| **AT** | | BAUSCH AND LOMB | **1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML** | **A064053** | **001** | Dec 29, 1995 |
| **AT** | | SANDOZ INC | **1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML** | **A062423** | **001** | Aug 25, 1983 |
| SUSPENSION/DROPS;OPHTHALMIC | | | | | | |
| NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE | | | | | | |
| | ! | SANDOZ INC | 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML | A062874 | 001 | May 11, 1988 |
| SUSPENSION/DROPS;OTIC | | | | | | |
| **CASPORYN HC** | | | | | | |
| **AT** | **+!** | CASPER PHARMA LLC | **1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML** | **N060613** | **001** | |
| **NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE** | | | | | | |
| **AT** | | AMRING PHARMS | **1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML** | **A065219** | **001** | May 01, 2006 |
| **AT** | | SANDOZ INC | **1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML** | **A062488** | **001** | Nov 06, 1985 |
| **OTICAIR** | | | | | | |
| **AT** | | BAUSCH AND LOMB | **1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML** | **A064065** | **001** | Aug 28, 1996 |
| HYDROGEN PEROXIDE | | | | | | |
| SOLUTION;TOPICAL | | | | | | |
| ESKATA | | | | | | |
| | +! | ACLARIS THERAPS INC | 40% | N209305 | 001 | Dec 14, 2017 |
| HYDROMORPHONE HYDROCHLORIDE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| **DILAUDID** | | | | | | |
| **AP** | **+!** | FRESENIUS KABI USA | **1MG/ML** | **N019034** | **003** | Apr 30, 2009 |
| **AP** | **+!** | | **2MG/ML** | **N019034** | **004** | Apr 30, 2009 |
| **AP** | **+!** | | **4MG/ML** | **N019034** | **005** | Apr 30, 2009 |
| **DILAUDID-HP** | | | | | | |
| **AP** | **+!** | FRESENIUS KABI USA | **10MG/ML** | **N019034** | **001** | Jan 11, 1984 |
| **HYDROMORPHONE HYDROCHLORIDE** | | | | | | |
| **AP** | | AKORN | **10MG/ML** | **A078228** | **001** | Apr 14, 2010 |
| **AP** | | | **10MG/ML** | **A078261** | **001** | Apr 14, 2010 |
| **AP** | | BARR | **10MG/ML** | **A076444** | **001** | Apr 25, 2003 |
| **AP** | | HOSPIRA INC | **1MG/ML** | **N200403** | **001** | Dec 01, 2011 |

HYDROMORPHONE HYDROCHLORIDE

| | | | | | | |
|---|---|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | | | |
| **HYDROMORPHONE HYDROCHLORIDE** | | | | | | |
| **AP** | | | **2MG/ML** | **N200403** | **002** | Dec 01, 2011 |
| **AP** | | | **4MG/ML** | **N200403** | **003** | Dec 01, 2011 |
| **AP** | | | **10MG/ML** | **A078591** | **001** | Jun 17, 2008 |
| SOLUTION;ORAL | | | | | | |
| **DILAUDID** | | | | | | |
| **AA** | **+!** | RHODES PHARMS | **5MG/5ML** | **N019891** | **001** | Dec 07, 1992 |
| **HYDROMORPHONE HYDROCHLORIDE** | | | | | | |
| **AA** | | ASCENT PHARMS INC | **5MG/5ML** | **A210176** | **001** | Oct 27, 2017 |
| **AA** | | WEST-WARD PHARMS INT | **5MG/5ML** | **A074653** | **001** | Jul 29, 1998 |
| TABLET;ORAL | | | | | | |
| **DILAUDID** | | | | | | |
| **AB** | **+** | RHODES PHARMS | **2MG** | **N019892** | **003** | Nov 09, 2007 |
| **AB** | **+** | | **4MG** | **N019892** | **002** | Nov 09, 2007 |
| **AB** | **+!** | | **8MG** | **N019892** | **001** | Dec 07, 1992 |
| **HYDROMORPHONE HYDROCHLORIDE** | | | | | | |
| **AB** | | AUROLIFE PHARMA LLC | **2MG** | **A205814** | **001** | May 13, 2016 |
| **AB** | | | **4MG** | **A205814** | **002** | May 13, 2016 |
| **AB** | | | **8MG** | **A205814** | **003** | May 13, 2016 |
| **AB** | | ELITE LABS | **8MG** | **A076723** | **001** | Oct 18, 2005 |
| **AB** | | LANNETT | **2MG** | **A077471** | **002** | Dec 09, 2009 |
| **AB** | | | **2MG** | **A078439** | **001** | Dec 09, 2009 |
| **AB** | | | **4MG** | **A077471** | **003** | Dec 09, 2009 |
| **AB** | | | **4MG** | **A078439** | **002** | Dec 09, 2009 |
| **AB** | | | **8MG** | **A077471** | **001** | Dec 09, 2009 |
| **AB** | | SPECGX LLC | **2MG** | **A076855** | **002** | Sep 19, 2007 |
| **AB** | | | **4MG** | **A076855** | **003** | Sep 19, 2007 |
| **AB** | | | **8MG** | **A076855** | **001** | Dec 23, 2004 |
| **AB** | | WEST-WARD PHARMS INT | **4MG** | **A074597** | **003** | May 29, 2009 |
| **AB** | | | **8MG** | **A074597** | **001** | Jul 29, 1998 |
| TABLET, EXTENDED RELEASE;ORAL | | | | | | |
| **EXALGO** | | | | | | |
| **AB** | **+** | SPECGX LLC | **8MG** | **N021217** | **001** | Mar 01, 2010 |
| **AB** | **+** | | **12MG** | **N021217** | **002** | Mar 01, 2010 |
| **AB** | **+** | | **16MG** | **N021217** | **003** | Mar 01, 2010 |
| **AB** | **+!** | | **32MG** | **N021217** | **004** | Aug 24, 2012 |
| **HYDROMORPHONE HYDROCHLORIDE** | | | | | | |
| **AB** | | ACTAVIS LABS FL INC | **8MG** | **A202144** | **001** | May 12, 2014 |
| **AB** | | | **12MG** | **A202144** | **002** | May 12, 2014 |
| **AB** | | | **16MG** | **A202144** | **003** | May 12, 2014 |
| **AB** | | | **32MG** | **A202144** | **004** | Jun 30, 2016 |
| **AB** | | OSMOTICA | **8MG** | **A205629** | **001** | Jul 07, 2016 |
| **AB** | | | **12MG** | **A205629** | **002** | Jul 07, 2016 |
| **AB** | | | **16MG** | **A205629** | **003** | Jul 07, 2016 |
| **AB** | | | **32MG** | **A205629** | **004** | Jul 07, 2016 |
| **AB** | | PADDOCK LLC | **8MG** | **A204278** | **001** | Apr 06, 2015 |
| **AB** | | | **12MG** | **A204278** | **002** | Apr 06, 2015 |
| **AB** | | | **16MG** | **A204278** | **003** | Apr 06, 2015 |
| **AB** | | | **32MG** | **A204278** | **004** | Sep 20, 2017 |

HYDROXOCOBALAMIN

| | | | | | | |
|---|---|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | | | |
| CYANOKIT | | | | | | |
| | +! | SERB SA | 5GM/VIAL (5GM/KIT) | N022041 | 001 | Apr 08, 2011 |
| HYDROXOCOBALAMIN | | | | | | |
| | ! | ACTAVIS LLC | 1MG/ML | A085998 | 001 | |

HYDROXYAMPHETAMINE HYDROBROMIDE; TROPICAMIDE

| | | | | | | |
|---|---|---|---|---|---|---|
| SOLUTION/DROPS;OPHTHALMIC | | | | | | |
| PAREMYD | | | | | | |
| | +! | AKORN | 1%;0.25% | N019261 | 001 | Jan 30, 1992 |

HYDROXYCHLOROQUINE SULFATE

| | | | | | | |
|---|---|---|---|---|---|---|
| TABLET;ORAL | | | | | | |
| **HYDROXYCHLOROQUINE SULFATE** | | | | | | |
| **AB** | | HIKMA PHARMS | **200MG** | **A040760** | **001** | Aug 15, 2007 |
| **AB** | | IPCA LABS LTD | **200MG** | **A040766** | **001** | Jun 14, 2007 |
| **AB** | | MYLAN | **200MG** | **A040274** | **001** | May 29, 1998 |
| **AB** | | SANDOZ | **200MG** | **A040104** | **001** | Nov 30, 1995 |
| **AB** | | TEVA PHARMS | **200MG** | **A040081** | **001** | Sep 30, 1994 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| HYDROXYCHLOROQUINE SULFATE | | | | | | | |
| TABLET;ORAL | | | | | | | |
| **HYDROXYCHLOROQUINE SULFATE** | | | | | | | |
| **AB** | | WATSON LABS | **200MG** | **A040133** | **001** | Nov 30, 1995 |
| **AB** | | ZYDUS PHARMS USA INC | **200MG** | **A040657** | **001** | Sep 21, 2007 |
| **PLAQUENIL** | | | | | | | |
| **AB** | **+!** | CONCORDIA PHARMS INC | **200MG** | **N009768** | **001** | |
| HYDROXYPROGESTERONE CAPROATE | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| HYDROXYPROGESTERONE CAPROATE | | | | | | | |
| | ! | ASPEN GLOBAL INC | 250MG/ML | A200271 | 001 | Aug 24, 2015 |
| SOLUTION;INTRAMUSCULAR | | | | | | | |
| MAKENA | | | | | | | |
| | +! | AMAG PHARMA USA | 1250MG/5ML (250MG/ML) | N021945 | 001 | Feb 03, 2011 |
| MAKENA PRESERVATIVE FREE | | | | | | | |
| | +! | AMAG PHARMA USA | 250MG/ML (250MG/ML) | N021945 | 002 | Feb 19, 2016 |
| HYDROXYPROPYL CELLULOSE | | | | | | | |
| INSERT;OPHTHALMIC | | | | | | | |
| LACRISERT | | | | | | | |
| | +! | ATON | 5MG | N018771 | 001 | |
| HYDROXYUREA | | | | | | | |
| CAPSULE;ORAL | | | | | | | |
| **HYDREA** | | | | | | | |
| **AB** | **+!** | BRISTOL MYERS SQUIBB | **500MG** | **N016295** | **001** | |
| **HYDROXYUREA** | | | | | | | |
| **AB** | | BARR | **500MG** | **A075143** | **001** | Oct 16, 1998 |
| **AB** | | PAR PHARM | **500MG** | **A075340** | **001** | Feb 24, 1999 |
| DROXIA | | | | | | | |
| | + | BRISTOL MYERS SQUIBB | 200MG | N016295 | 002 | Feb 25, 1998 |
| | + | | 300MG | N016295 | 003 | Feb 25, 1998 |
| | + | | 400MG | N016295 | 004 | Feb 25, 1998 |
| TABLET;ORAL | | | | | | | |
| SIKLOS | | | | | | | |
| | + | ADDMEDICA SAS | 100MG | N208843 | 001 | Dec 21, 2017 |
| | + | | 1GM | N208843 | 002 | Dec 21, 2017 |
| HYDROXYZINE HYDROCHLORIDE | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| **HYDROXYZINE HYDROCHLORIDE** | | | | | | | |
| **AP** | **!** | FRESENIUS KABI USA | **25MG/ML** | **A087329** | **001** | |
| **AP** | **!** | | **50MG/ML** | **A087329** | **002** | |
| **AP** | | LUITPOLD | **25MG/ML** | **A087408** | **001** | |
| **AP** | | | **50MG/ML** | **A087408** | **002** | |
| SYRUP;ORAL | | | | | | | |
| **HYDROXYZINE HYDROCHLORIDE** | | | | | | | |
| **AA** | **!** | HI TECH PHARMA | **10MG/5ML** | **A040010** | **001** | Oct 28, 1994 |
| **AA** | | SILARX PHARMS INC | **10MG/5ML** | **A201674** | **001** | Aug 21, 2013 |
| **AA** | **!** | VINTAGE PHARMS | **10MG/5ML** | **A040391** | **001** | Apr 10, 2002 |
| **AA** | **!** | WOCKHARDT BIO AG | **10MG/5ML** | **A087294** | **001** | Apr 12, 1982 |
| TABLET;ORAL | | | | | | | |
| **HYDROXYZINE HYDROCHLORIDE** | | | | | | | |
| **AB** | | AMNEAL PHARM | **10MG** | **A040808** | **001** | Sep 24, 2008 |
| **AB** | | | **25MG** | **A040808** | **002** | Sep 24, 2008 |
| **AB** | | | **50MG** | **A040808** | **003** | Sep 24, 2008 |
| **AB** | | ECI PHARMS LLC | **10MG** | **A040804** | **001** | Jun 30, 2008 |
| **AB** | | | **25MG** | **A040804** | **002** | Jun 30, 2008 |
| **AB** | | | **50MG** | **A040804** | **003** | Jun 30, 2008 |
| **AB** | | ELITE LABS INC | **10MG** | **A040604** | **002** | Dec 28, 2004 |
| **AB** | | | **25MG** | **A040604** | **003** | Dec 28, 2004 |
| **AB** | | | **50MG** | **A040604** | **001** | Dec 28, 2004 |
| **AB** | | HERITAGE PHARMA | **10MG** | **A204279** | **001** | Aug 20, 2014 |
| **AB** | | | **25MG** | **A204279** | **002** | Aug 20, 2014 |
| **AB** | | | **50MG** | **A204279** | **003** | Aug 20, 2014 |
| **AB** | | HETERO LABS LTD III | **10MG** | **A040805** | **001** | May 29, 2008 |
| **AB** | | | **25MG** | **A040805** | **002** | May 29, 2008 |
| **AB** | | | **50MG** | **A040805** | **003** | May 29, 2008 |
| **AB** | | INVAGEN PHARMS | **10MG** | **A040812** | **001** | Mar 12, 2008 |
| **AB** | | | **25MG** | **A040812** | **002** | Mar 12, 2008 |

HYDROXYZINE HYDROCHLORIDE

TABLET;ORAL

**HYDROXYZINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **50MG** | **A040812** | **003** | Mar 12, 2008 |
| **AB** | | KVK TECH | **10MG** | **A040786** | **001** | Mar 20, 2007 |
| **AB** | | | **25MG** | **A040787** | **001** | Mar 20, 2007 |
| **AB** | | | **50MG** | **A040788** | **001** | Mar 20, 2007 |
| **AB** | | MYLAN | **10MG** | **A091176** | **001** | Jun 07, 2010 |
| **AB** | | | **25MG** | **A091176** | **002** | Jun 07, 2010 |
| **AB** | | | **50MG** | **A091176** | **003** | Jun 07, 2010 |
| **AB** | | NORTHSTAR HLTHCARE | **10MG** | **A040840** | **002** | Mar 31, 2008 |
| **AB** | | | **25MG** | **A040840** | **003** | Mar 31, 2008 |
| **AB** | | | **50MG** | **A040840** | **001** | Mar 31, 2008 |
| **AB** | | NUVO PHARM | **10MG** | **A207120** | **001** | Mar 29, 2017 |
| **AB** | | | **50MG** | **A207122** | **001** | Mar 29, 2017 |
| **AB** | | NUVO PHARM INC | **25MG** | **A207121** | **001** | Mar 29, 2017 |
| **AB** | **!** | PLIVA | **10MG** | **A088617** | **001** | Jan 10, 1986 |
| **AB** | **!** | | **25MG** | **A088618** | **001** | Jan 10, 1986 |
| **AB** | **!** | | **50MG** | **A088619** | **001** | Jan 10, 1986 |
| **AB** | | PRINSTON INC | **10MG** | **A040579** | **001** | May 27, 2005 |
| **AB** | | | **25MG** | **A040574** | **001** | May 27, 2005 |
| **AB** | | | **50MG** | **A040580** | **001** | May 27, 2005 |

HYDROXYZINE PAMOATE

CAPSULE;ORAL

**HYDROXYZINE PAMOATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | BARR | **EQ 25MG HCL** | **A088496** | **001** | Jun 15, 1984 |
| **AB** | | | **EQ 50MG HCL** | **A088487** | **001** | Jun 15, 1984 |
| **AB** | | HERITAGE PHARMA | **EQ 25MG HYDROCHLORIDE** | **A201507** | **001** | Jun 03, 2013 |
| **AB** | | | **EQ 50MG HYDROCHLORIDE** | **A201507** | **002** | Jun 03, 2013 |
| **AB** | | IMPAX LABS INC | **EQ 25MG HCL** | **A040156** | **001** | Jul 15, 1996 |
| **AB** | | | **EQ 50MG HCL** | **A040156** | **002** | Jul 15, 1996 |
| **AB** | | SANDOZ | **EQ 25MG HCL** | **A087479** | **001** | |
| **AB** | | | **EQ 50MG HCL** | **A086183** | **001** | |

**VISTARIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | PFIZER | **EQ 25MG HCL** | **N011459** | **002** | |
| **AB** | **+!** | | **EQ 50MG HCL** | **N011459** | **004** | |

HYDROXYZINE PAMOATE

| | | | | | | |
|---|---|---|---|---|---|---|
| | | BARR | EQ 100MG HCL | A088488 | 001 | Jun 15, 1984 |

IBANDRONATE SODIUM

INJECTABLE;INTRAVENOUS

**BONIVA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | ROCHE | **EQ 3MG BASE/3ML** | **N021858** | **001** | Jan 06, 2006 |

**IBANDRONATE SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | ACCORD HLTHCARE | **EQ 3MG BASE/3ML** | **A206058** | **001** | Feb 05, 2016 |
| **AP** | | APOTEX INC | **EQ 3MG BASE/3ML** | **A204222** | **001** | Oct 16, 2015 |
| **AP** | | AUROBINDO PHARMA LTD | **EQ 3MG BASE/3ML** | **A205332** | **001** | Aug 19, 2015 |
| **AP** | | EMCURE PHARMS LTD | **EQ 3MG BASE/3ML** | **A203987** | **001** | Sep 02, 2014 |
| **AP** | | MYLAN LABS LTD | **EQ 3MG BASE/3ML** | **A202671** | **001** | Sep 02, 2014 |
| **AP** | | SAGENT PHARMS | **EQ 3MG BASE/3ML** | **A202235** | **001** | Sep 02, 2014 |
| **AP** | | SUN PHARM INDS LTD | **EQ 3MG BASE/3ML** | **A090853** | **001** | Feb 14, 2014 |

TABLET;ORAL

**BONIVA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | HOFFMANN LA ROCHE | **EQ 150MG BASE** | **N021455** | **002** | Mar 24, 2005 |

**IBANDRONATE SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | APOTEX INC | **EQ 150MG BASE** | **A078948** | **001** | Mar 19, 2012 |
| **AB** | | AUROBINDO PHARMA LTD | **EQ 150MG BASE** | **A204502** | **001** | Mar 11, 2016 |
| **AB** | | DR REDDYS LABS LTD | **EQ 150MG BASE** | **A078997** | **001** | Apr 30, 2012 |
| **AB** | | MACLEODS PHARMS LTD | **EQ 150MG BASE** | **A206887** | **001** | Oct 31, 2017 |
| **AB** | | ORCHID HLTHCARE | **EQ 150MG BASE** | **A078998** | **001** | Mar 19, 2012 |
| **AB** | | SUN PHARM INDUSTRIES | **EQ 150MG BASE** | **A078996** | **001** | Aug 15, 2012 |
| **AB** | | WATSON LABS TEVA | **EQ 150MG BASE** | **A079003** | **001** | Mar 20, 2012 |

IBRUTINIB

CAPSULE;ORAL

IMBRUVICA

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | PHARMACYCLICS INC | 70MG | N205552 | 002 | Dec 20, 2017 |
| | +! | | 140MG | N205552 | 001 | Nov 13, 2013 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| IBUPROFEN | | | | | | | |
| SOLUTION;INTRAVENOUS | | | | | | | |
| CALDOLOR | | | | | | | |
| | +! | CUMBERLAND PHARMS | 800MG/8ML (100MG/ML) | N022348 | 002 | Jun 11, 2009 |
| SUSPENSION;ORAL | | | | | | | |
| **IBUPROFEN** | | | | | | | |
| **AB** | **!** | ACTAVIS MID ATLANTIC | **100MG/5ML** | **A074978** | **001** | Mar 25, 1998 |
| **AB** | | HI-TECH PHARMACAL | **100MG/5ML** | **A205647** | **001** | Nov 03, 2016 |
| **AB** | | PERRIGO R AND D | **100MG/5ML** | **A076925** | **001** | Sep 23, 2004 |
| **AB** | | TARO | **100MG/5ML** | **A209204** | **001** | Jun 23, 2017 |
| TABLET;ORAL | | | | | | | |
| **IBU-TAB** | | | | | | | |
| **AB** | | ALRA | **400MG** | **A071058** | **001** | Aug 11, 1988 |
| **AB** | | | **600MG** | **A071059** | **001** | Aug 11, 1988 |
| **IBUPROFEN** | | | | | | | |
| **AB** | | AIPING PHARM INC | **400MG** | **A202413** | **001** | Nov 23, 2016 |
| **AB** | | | **600MG** | **A202413** | **002** | Nov 23, 2016 |
| **AB** | | | **800MG** | **A202413** | **003** | Nov 23, 2016 |
| **AB** | | AMNEAL PHARMS NY | **400MG** | **A071334** | **001** | Nov 25, 1986 |
| **AB** | | | **400MG** | **A078558** | **001** | Jun 18, 2007 |
| **AB** | | | **600MG** | **A071335** | **001** | Nov 25, 1986 |
| **AB** | | | **600MG** | **A078558** | **002** | Jun 18, 2007 |
| **AB** | | | **800MG** | **A071935** | **001** | Oct 13, 1987 |
| **AB** | | | **800MG** | **A078558** | **003** | Jun 18, 2007 |
| **AB** | | CONTRACT PHARMACAL | **400MG** | **A071268** | **002** | Oct 15, 1986 |
| **AB** | | | **600MG** | **A071268** | **001** | Oct 15, 1986 |
| **AB** | | | **800MG** | **A071268** | **003** | Jul 01, 1988 |
| **AB** | | DR REDDYS LA | **400MG** | **A075682** | **001** | Nov 14, 2001 |
| **AB** | | | **600MG** | **A075682** | **002** | Nov 14, 2001 |
| **AB** | **!** | | **800MG** | **A075682** | **003** | Nov 14, 2001 |
| **AB** | | DR REDDYS LABS INC | **400MG** | **A076112** | **001** | Oct 31, 2001 |
| **AB** | | | **600MG** | **A076112** | **002** | Oct 31, 2001 |
| **AB** | | | **800MG** | **A076112** | **003** | Oct 31, 2001 |
| **AB** | | GRANULES INDIA LTD | **400MG** | **A091625** | **001** | Sep 15, 2015 |
| **AB** | | | **600MG** | **A091625** | **002** | Sep 15, 2015 |
| **AB** | | | **800MG** | **A091625** | **003** | Sep 15, 2015 |
| **AB** | | MARKSANS PHARMA | **400MG** | **A090796** | **001** | Dec 21, 2010 |
| **AB** | | | **600MG** | **A090796** | **002** | Dec 21, 2010 |
| **AB** | | | **800MG** | **A090796** | **003** | Dec 21, 2010 |
| **AB** | | PERRIGO R AND D | **400MG** | **A077114** | **001** | Jul 18, 2005 |
| **AB** | | | **600MG** | **A077114** | **002** | Jul 18, 2005 |
| **AB** | | | **800MG** | **A077114** | **003** | Jul 18, 2005 |
| **AB** | | STRIDES PHARMA | **400MG** | **A078329** | **001** | Feb 05, 2009 |
| **AB** | | | **600MG** | **A078329** | **002** | Feb 05, 2009 |
| **AB** | | | **800MG** | **A078329** | **003** | Feb 05, 2009 |
| **AB** | | VINTAGE PHARMS | **400MG** | **A071644** | **001** | Feb 01, 1988 |
| IBUPROFEN LYSINE | | | | | | | |
| INJECTABLE;INTRAVENOUS | | | | | | | |
| **IBUPROFEN LYSINE** | | | | | | | |
| **AP** | | EXELA PHARMA SCIENCE | **EQ 20MG BASE/2ML (EQ 10MG BASE/ML)** | **A202402** | **001** | Mar 30, 2016 |
| **NEOPROFEN** | | | | | | | |
| **AP** | **+!** | RECORDATI RARE | **EQ 20MG BASE/2ML (EQ 10MG BASE/ML)** | **N021903** | **001** | Apr 13, 2006 |
| IBUPROFEN; OXYCODONE HYDROCHLORIDE | | | | | | | |
| TABLET;ORAL | | | | | | | |
| **OXYCODONE HYDROCHLORIDE AND IBUPROFEN** | | | | | | | |
| **AB** | | ACTAVIS ELIZABETH | **400MG;5MG** | **A078769** | **001** | Jan 04, 2008 |
| **AB** | **!** | BARR LABS INC | **400MG;5MG** | **A078316** | **001** | Nov 29, 2007 |
| IBUTILIDE FUMARATE | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| **CORVERT** | | | | | | | |
| **AP** | **+!** | PHARMACIA AND UPJOHN | **0.1MG/ML** | **N020491** | **001** | Dec 28, 1995 |
| **IBUTILIDE FUMARATE** | | | | | | | |
| **AP** | | LUITPOLD | **0.1MG/ML** | **A090240** | **001** | Jan 11, 2010 |
| **AP** | | MYLAN INSTITUTIONAL | **0.1MG/ML** | **A090643** | **001** | Jan 11, 2010 |
| **AP** | | | **0.1MG/ML** | **A090924** | **001** | Jan 11, 2010 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| ICATIBANT ACETATE | | | | | | | |
| INJECTABLE;SUBCUTANEOUS | | | | | | | |
| FIRAZYR | | | | | | | |
| | +! | SHIRE ORPHAN THERAP | EQ 30MG BASE/3ML (EQ 10MG BASE/ML) | | N022150 | 001 | Aug 25, 2011 |
| ICODEXTRIN | | | | | | | |
| SOLUTION;INTRAPERITONEAL | | | | | | | |
| EXTRANEAL | | | | | | | |
| | +! | BAXTER HLTHCARE | 7.5GM/100ML | | N021321 | 001 | Dec 20, 2002 |
| ICOSAPENT ETHYL | | | | | | | |
| CAPSULE;ORAL | | | | | | | |
| VASCEPA | | | | | | | |
| | + | AMARIN PHARMS | 500MG | | N202057 | 002 | Feb 16, 2017 |
| | +! | | 1GM | | N202057 | 001 | Jul 26, 2012 |
| IDARUBICIN HYDROCHLORIDE | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| **IDAMYCIN PFS** | | | | | | | |
| **AP** | **+!** | PHARMACIA AND UPJOHN | **1MG/ML** | | **N050734** | **001** | Feb 17, 1997 |
| **IDARUBICIN HYDROCHLORIDE** | | | | | | | |
| **AP** | | FRESENIUS KABI USA | **1MG/ML** | | **A065440** | **001** | Aug 04, 2009 |
| **AP** | | MYLAN LABS LTD | **1MG/ML** | | **A200144** | **001** | Oct 11, 2012 |
| **AP** | | WEST-WARD PHARMS INT | **1MG/ML** | | **A065275** | **001** | Dec 14, 2006 |
| **AP** | | | **1MG/ML** | | **A065288** | **001** | May 15, 2007 |
| **IDARUBICIN HYDROCHLORIDE PFS** | | | | | | | |
| **AP** | | TEVA PHARMS USA | **1MG/ML** | | **A065036** | **001** | May 01, 2002 |
| IDELALISIB | | | | | | | |
| TABLET;ORAL | | | | | | | |
| ZYDELIG | | | | | | | |
| | + | GILEAD SCIENCES INC | 100MG | | N205858 | 001 | Jul 23, 2014 |
| | +! | | 150MG | | N205858 | 002 | Jul 23, 2014 |
| IFOSFAMIDE | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| **IFEX** | | | | | | | |
| **AP** | **+** | BAXTER HLTHCARE | **1GM/VIAL** | | **N019763** | **001** | Dec 30, 1988 |
| **AP** | **+** | | **3GM/VIAL** | | **N019763** | **002** | Dec 30, 1988 |
| **IFOSFAMIDE** | | | | | | | |
| **AP** | **!** | FRESENIUS KABI USA | **1GM/VIAL** | | **A076078** | **001** | May 28, 2002 |
| **AP** | | | **1GM/20ML (50MG/ML)** | | **A090181** | **001** | Sep 22, 2009 |
| **AP** | **!** | | **3GM/VIAL** | | **A076078** | **002** | May 28, 2002 |
| **AP** | | | **3GM/60ML (50MG/ML)** | | **A090181** | **002** | Sep 22, 2009 |
| **AP** | | MYLAN LABS LTD | **1GM/20ML (50MG/ML)** | | **A201689** | **001** | Nov 26, 2012 |
| **AP** | | | **3GM/60ML (50MG/ML)** | | **A201689** | **002** | Nov 26, 2012 |
| **AP** | **!** | TEVA PHARMS USA | **1GM/20ML (50MG/ML)** | | **A076657** | **001** | Apr 04, 2007 |
| **AP** | **!** | | **3GM/60ML (50MG/ML)** | | **A076657** | **002** | Apr 04, 2007 |
| **AP** | | WEST-WARD PHARMS INT | **1GM/20ML (50MG/ML)** | | **A076619** | **001** | Jun 29, 2011 |
| **AP** | | | **3GM/60ML (50MG/ML)** | | **A076619** | **002** | Jun 29, 2011 |
| ILOPERIDONE | | | | | | | |
| TABLET;ORAL | | | | | | | |
| **FANAPT** | | | | | | | |
| **AB** | **+!** | VANDA PHARMS INC | **1MG** | | **N022192** | **001** | May 06, 2009 |
| **AB** | **+** | | **2MG** | | **N022192** | **002** | May 06, 2009 |
| **AB** | **+** | | **4MG** | | **N022192** | **003** | May 06, 2009 |
| **AB** | **+** | | **6MG** | | **N022192** | **004** | May 06, 2009 |
| **AB** | **+** | | **8MG** | | **N022192** | **005** | May 06, 2009 |
| **AB** | **+** | | **10MG** | | **N022192** | **006** | May 06, 2009 |
| **AB** | **+** | | **12MG** | | **N022192** | **007** | May 06, 2009 |
| **ILOPERIDONE** | | | | | | | |
| **AB** | | INVENTIA HLTHCARE | **1MG** | | **A207231** | **001** | Nov 28, 2016 |
| **AB** | | | **2MG** | | **A207231** | **002** | Nov 28, 2016 |
| **AB** | | | **4MG** | | **A207231** | **003** | Nov 28, 2016 |
| **AB** | | | **6MG** | | **A207231** | **004** | Nov 28, 2016 |
| **AB** | | | **8MG** | | **A207231** | **005** | Nov 28, 2016 |
| **AB** | | | **10MG** | | **A207231** | **006** | Nov 28, 2016 |
| **AB** | | | **12MG** | | **A207231** | **007** | Nov 28, 2016 |

| | | | | | | |
|---|---|---|---|---|---|---|
| ILOPROST | | | | | | |
| SOLUTION;INHALATION | | | | | | |
| VENTAVIS | | | | | | |
| | +! | ACTELION PHARMS LTD | 10MCG/ML (10MCG/ML) | N021779 | 002 | Dec 08, 2005 |
| | +! | | 20MCG/ML (20MCG/ML) | N021779 | 003 | Aug 07, 2009 |
| IMATINIB MESYLATE | | | | | | |
| TABLET;ORAL | | | | | | |
| **GLEEVEC** | | | | | | |
| **AB** | **+** | NOVARTIS | **EQ 100MG BASE** | **N021588** | **001** | Apr 18, 2003 |
| **AB** | **+!** | | **EQ 400MG BASE** | **N021588** | **002** | Apr 18, 2003 |
| **IMATINIB MESYLATE** | | | | | | |
| **AB** | | APOTEX INC | **EQ 100MG BASE** | **A079179** | **001** | Aug 05, 2016 |
| **AB** | | | **EQ 400MG BASE** | **A079179** | **002** | Aug 05, 2016 |
| **AB** | | MYLAN PHARMS INC | **EQ 100MG BASE** | **A204644** | **001** | Jun 21, 2017 |
| **AB** | | | **EQ 400MG BASE** | **A204644** | **002** | Jun 21, 2017 |
| **AB** | | SUN PHARMA GLOBAL | **EQ 100MG BASE** | **A078340** | **001** | Dec 03, 2015 |
| **AB** | | | **EQ 400MG BASE** | **A078340** | **002** | Dec 03, 2015 |
| **AB** | | TEVA PHARMS USA | **EQ 100MG BASE** | **A204285** | **001** | Aug 04, 2016 |
| **AB** | | | **EQ 400MG BASE** | **A204285** | **002** | Aug 04, 2016 |
| IMIGLUCERASE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| CEREZYME | | | | | | |
| | + | GENZYME | 200 UNITS/VIAL | N020367 | 001 | May 23, 1994 |
| | +! | | 400 UNITS/VIAL | N020367 | 002 | Sep 22, 1999 |
| IMIPRAMINE HYDROCHLORIDE | | | | | | |
| TABLET;ORAL | | | | | | |
| **IMIPRAMINE HYDROCHLORIDE** | | | | | | |
| **AB** | | LEADING PHARMA LLC | **10MG** | **A040903** | **001** | Oct 24, 2012 |
| **AB** | | | **25MG** | **A040903** | **002** | Oct 24, 2012 |
| **AB** | | | **50MG** | **A040903** | **003** | Oct 24, 2012 |
| **AB** | | LUPIN LTD | **10MG** | **A090441** | **002** | Mar 11, 2010 |
| **AB** | | | **25MG** | **A090441** | **003** | Mar 11, 2010 |
| **AB** | | | **50MG** | **A090441** | **001** | Mar 11, 2010 |
| **AB** | | PAR PHARM | **10MG** | **A088292** | **001** | Oct 21, 1983 |
| **AB** | | | **25MG** | **A088262** | **001** | Oct 21, 1983 |
| **AB** | | | **50MG** | **A088276** | **001** | Oct 21, 1983 |
| **AB** | | SANDOZ | **10MG** | **A084936** | **002** | |
| **AB** | | | **25MG** | **A083745** | **001** | |
| **AB** | | | **50MG** | **A084937** | **001** | |
| **AB** | | SPECGX LLC | **10MG** | **A087846** | **002** | May 22, 1984 |
| **AB** | | | **25MG** | **A087846** | **003** | May 22, 1984 |
| **AB** | | SUN PHARM INDUSTRIES | **10MG** | **A081048** | **001** | Jun 05, 1990 |
| **AB** | | | **25MG** | **A081049** | **001** | Jun 05, 1990 |
| **AB** | | | **50MG** | **A081050** | **001** | Jun 05, 1990 |
| **TOFRANIL** | | | | | | |
| **AB** | **!** | SPECGX LLC | **50MG** | **A087846** | **001** | May 22, 1984 |
| IMIPRAMINE HYDROCHLORIDE | | | | | | |
| | | OXFORD PHARMS | 10MG | A040751 | 003 | Feb 28, 2008 |
| | | | 25MG | A040751 | 002 | Feb 28, 2008 |
| IMIPRAMINE PAMOATE | | | | | | |
| CAPSULE;ORAL | | | | | | |
| **IMIPRAMINE PAMOATE** | | | | | | |
| **AB** | | LUPIN LTD | **EQ 75MG HCL** | **A090444** | **001** | Apr 16, 2010 |
| **AB** | | | **EQ 100MG HCL** | **A090444** | **002** | Apr 16, 2010 |
| **AB** | | | **EQ 125MG HCL** | **A090444** | **003** | Apr 16, 2010 |
| **AB** | | | **EQ 150MG HCL** | **A090444** | **004** | Apr 16, 2010 |
| **AB** | **!** | WEST-WARD PHARMS INT | **EQ 75MG HCL** | **A091099** | **001** | Apr 16, 2010 |
| **AB** | | | **EQ 100MG HCL** | **A091099** | **002** | Apr 16, 2010 |
| **AB** | | | **EQ 125MG HCL** | **A091099** | **003** | Apr 16, 2010 |
| **AB** | | | **EQ 150MG HCL** | **A091099** | **004** | Apr 16, 2010 |
| IMIQUIMOD | | | | | | |
| CREAM;TOPICAL | | | | | | |
| **ALDARA** | | | | | | |
| **AB** | **+!** | MEDICIS | **5%** | **N020723** | **001** | Feb 27, 1997 |
| **IMIQUIMOD** | | | | | | |
| **AB** | | APOTEX INC | **5%** | **A091308** | **001** | Apr 06, 2012 |
| **AB** | | FOUGERA PHARMS | **5%** | **A078548** | **001** | Feb 25, 2010 |
| **AB** | | G AND W LABS INC | **5%** | **A200481** | **001** | Apr 18, 2011 |

| | | | | | | |
|---|---|---|---|---|---|---|
| IMIQUIMOD | | | | | | |
| CREAM;TOPICAL | | | | | | |
| **IMIQUIMOD** | | | | | | |
| **AB** | | GLENMARK GENERICS | **5%** | **A201994** | **001** | Mar 06, 2012 |
| **AB** | | PERRIGO ISRAEL | **5%** | **A078837** | **001** | Sep 07, 2010 |
| **AB** | | STRIDES PHARMA | **5%** | **A202002** | **001** | Jun 24, 2014 |
| **AB** | | TARO | **5%** | **A200173** | **001** | Apr 15, 2011 |
| **AB** | | TOLMAR | **5%** | **A091044** | **001** | Feb 28, 2011 |
| ZYCLARA | | | | | | |
| | +! | MEDICIS | 2.5% | N022483 | 002 | Jul 15, 2011 |
| | +! | | 3.75% | N022483 | 001 | Mar 25, 2010 |
| INAMRINONE LACTATE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| AMRINONE LACTATE | | | | | | |
| | ! | WEST-WARD PHARMS INT | EQ 5MG BASE/ML | A075513 | 001 | May 09, 2000 |
| INDACATEROL MALEATE | | | | | | |
| POWDER;INHALATION | | | | | | |
| ARCAPTA NEOHALER | | | | | | |
| | +! | SUNOVION PHARMS INC | EQ 75MCG BASE | N022383 | 001 | Jul 01, 2011 |
| INDAPAMIDE | | | | | | |
| TABLET;ORAL | | | | | | |
| **INDAPAMIDE** | | | | | | |
| **AB** | | ACTAVIS ELIZABETH | **1.25MG** | **A074722** | **001** | Jun 17, 1996 |
| **AB** | | | **2.5MG** | **A074722** | **002** | Jun 17, 1996 |
| **AB** | | AMERIGEN PHARMS LTD | **1.25MG** | **A075201** | **001** | Dec 04, 1998 |
| **AB** | | | **2.5MG** | **A075201** | **002** | Dec 04, 1998 |
| **AB** | | ANI PHARMS INC | **1.25MG** | **A074299** | **002** | Apr 29, 1996 |
| **AB** | | | **2.5MG** | **A074299** | **001** | Jul 27, 1995 |
| **AB** | | MYLAN | **1.25MG** | **A074461** | **002** | Mar 26, 1997 |
| **AB** | **!** | | **2.5MG** | **A074461** | **001** | Mar 27, 1996 |
| INDINAVIR SULFATE | | | | | | |
| CAPSULE;ORAL | | | | | | |
| CRIXIVAN | | | | | | |
| | + | MERCK SHARP DOHME | EQ 200MG BASE | N020685 | 003 | Mar 13, 1996 |
| | +! | | EQ 400MG BASE | N020685 | 001 | Mar 13, 1996 |
| INDIUM IN-111 CHLORIDE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| INDICLOR | | | | | | |
| | +! | GE HEALTHCARE | 2mCi/0.2ML | N019862 | 001 | Dec 29, 1992 |
| INDIUM IN 111 CHLORIDE | | | | | | |
| | +! | MALLINKRODT NUCLEAR | 5mCi/0.5ML | N019841 | 001 | Sep 27, 1994 |
| INDIUM IN-111 OXYQUINOLINE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| INDIUM IN 111 OXYQUINOLINE | | | | | | |
| | +! | GE HEALTHCARE | 1mCi/ML | N019044 | 001 | Dec 24, 1985 |
| INDIUM IN-111 PENTETATE DISODIUM | | | | | | |
| INJECTABLE;INTRATHECAL | | | | | | |
| MPI INDIUM DTPA IN 111 | | | | | | |
| | +! | GE HEALTHCARE | 1mCi/ML | N017707 | 001 | Feb 18, 1982 |
| INDIUM IN-111 PENTETREOTIDE KIT | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| OCTREOSCAN | | | | | | |
| | +! | MALLINKRODT NUCLEAR | 3mCi/ML | N020314 | 001 | Jun 02, 1994 |
| INDOCYANINE GREEN | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| **IC-GREEN** | | | | | | |
| **AP** | **+!** | AKORN | **25MG/VIAL** | **N011525** | **001** | |
| **INDOCYANINE GREEN** | | | | | | |
| **AP** | | DIAGNOSTIC GREEN | **25MG/VIAL** | **A040811** | **001** | Nov 21, 2007 |
| INDOMETHACIN | | | | | | |
| CAPSULE;ORAL | | | | | | |
| **INDOMETHACIN** | | | | | | |
| **AB** | | GLENMARK GENERICS | **25MG** | **A091276** | **001** | Dec 22, 2010 |
| **AB** | | | **50MG** | **A091276** | **002** | Dec 22, 2010 |
| **AB** | | HERITAGE PHARMS INC | **25MG** | **N018851** | **001** | May 18, 1984 |
| **AB** | | | **50MG** | **N018851** | **002** | May 18, 1984 |
| **AB** | | HETERO LABS LTD III | **25MG** | **A091240** | **001** | Apr 12, 2011 |

INDOMETHACIN

CAPSULE;ORAL

**INDOMETHACIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **50MG** | **A091240** | **002** | Apr 12, 2011 |
| **AB** | | IVAX SUB TEVA PHARMS | **25MG** | **A070719** | **001** | Feb 12, 1986 |
| **AB** | | | **50MG** | **A070756** | **001** | Feb 12, 1986 |
| **AB** | | JUBILANT GENERICS | **25MG** | **A205215** | **001** | Aug 25, 2017 |
| **AB** | | | **50MG** | **A205215** | **002** | Aug 25, 2017 |
| **AB** | | MYLAN | **25MG** | **N018858** | **001** | Apr 20, 1984 |
| **AB** | **!** | | **50MG** | **A070624** | **001** | Sep 04, 1985 |
| **AB** | | SANDOZ | **25MG** | **A070673** | **001** | Apr 29, 1987 |
| **AB** | | | **50MG** | **A070674** | **001** | Apr 29, 1987 |
| **AB** | | SUN PHARM INDS INC | **25MG** | **A091401** | **001** | Mar 28, 2013 |
| **AB** | | | **50MG** | **A091401** | **002** | Mar 28, 2013 |
| **AB** | | ZYDUS PHARMS USA INC | **25MG** | **A090403** | **001** | Nov 15, 2010 |
| **AB** | | | **50MG** | **A090403** | **002** | Nov 15, 2010 |

TIVORBEX

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | IROKO PHARMS LLC | 20MG | N204768 | 001 | Feb 24, 2014 |
| | +! | | 40MG | N204768 | 002 | Feb 24, 2014 |

CAPSULE, EXTENDED RELEASE;ORAL

**INDOMETHACIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AMNEAL PHARMS | **75MG** | **A091549** | **001** | Dec 01, 2010 |
| **AB** | | AUROBINDO PHARMA LTD | **75MG** | **A204243** | **001** | Dec 27, 2016 |
| **AB** | | AVANTHI INC | **75MG** | **A079175** | **001** | Mar 06, 2009 |
| **AB** | | CHARTWELL RX | **75MG** | **A200529** | **001** | Nov 30, 2010 |
| **AB** | | GLENMARK PHARMS LTD | **75MG** | **A203501** | **001** | Jun 22, 2017 |
| **AB** | | HETERO LABS LTD III | **75MG** | **A201807** | **001** | Sep 28, 2012 |
| **AB** | | JUBILANT GENERICS | **75MG** | **A202706** | **001** | Oct 05, 2015 |
| **AB** | | MYLAN PHARMS INC | **75MG** | **A202139** | **001** | Mar 20, 2014 |
| **AB** | | NOVAST LABS LTD | **75MG** | **A204853** | **001** | May 08, 2017 |
| **AB** | **!** | SANDOZ | **75MG** | **A074464** | **001** | May 28, 1998 |
| **AB** | | ZYDUS PHARMS USA INC | **75MG** | **A202711** | **001** | Sep 25, 2017 |

INJECTABLE;INJECTION

INDOMETHACIN

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | FRESENIUS KABI USA | EQ 1MG BASE/VIAL | N022536 | 001 | Mar 17, 2010 |

SUPPOSITORY;RECTAL

INDOMETHACIN

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | G AND W LABS | 50MG | A073314 | 001 | Aug 31, 1992 |

SUSPENSION;ORAL

INDOCIN

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | IROKO PHARMS | 25MG/5ML | N018332 | 001 | Oct 10, 1985 |

INDOMETHACIN SODIUM

INJECTABLE;INJECTION

**INDOCIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | RECORDATI RARE | **EQ 1MG BASE/VIAL** | **N018878** | **001** | Jan 30, 1985 |

**INDOMETHACIN SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | HOSPIRA INC | **EQ 1MG BASE/VIAL** | **A204118** | **001** | Apr 19, 2016 |
| **AP** | | NAVINTA LLC | **EQ 1MG BASE/VIAL** | **A206561** | **001** | Jul 19, 2017 |
| **AP** | | WEST-WARD PHARMS INT | **EQ 1MG BASE/VIAL** | **A078713** | **001** | Jul 16, 2008 |

INGENOL MEBUTATE

GEL;TOPICAL

PICATO

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | LEO LABS | 0.015% | N202833 | 001 | Jan 23, 2012 |
| | +! | | 0.05% | N202833 | 002 | Jan 23, 2012 |

INSULIN ASPART

SOLUTION;IV (INFUSION), SUBCUTANEOUS

FIASP

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | NOVO NORDISK INC | 1000 UNITS/10ML (100 UNITS/ML) | N208751 | 001 | Sep 29, 2017 |

SOLUTION;SUBCUTANEOUS

FIASP FLEXTOUCH

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | NOVO NORDISK INC | 300 UNITS/3ML (100 UNITS/ML) | N208751 | 002 | Sep 29, 2017 |

| | | | | |
|---|---|---|---|---|
| INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT | | | | |
| INJECTABLE;SUBCUTANEOUS | | | | |
| NOVOLOG MIX 70/30 | | | | |
| +! | NOVO NORDISK INC | 700 UNITS/10ML; 300 UNITS/10ML (70 UNITS/ML; 30 UNITS/ML) | N021172 001 | Nov 01, 2001 |
| NOVOLOG MIX 70/30 FLEXPEN | | | | |
| +! | NOVO NORDISK INC | 210 UNITS/3ML; 90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML) | N021172 004 | May 03, 2002 |
| INSULIN ASPART RECOMBINANT | | | | |
| INJECTABLE;SUBCUTANEOUS | | | | |
| NOVOLOG | | | | |
| +! | NOVO NORDISK INC | 1000 UNITS/10ML (100 UNITS/ML) | N020986 001 | Jun 07, 2000 |
| NOVOLOG FLEXPEN | | | | |
| +! | NOVO NORDISK INC | 300 UNITS/3ML (100 UNITS/ML) | N020986 003 | Jan 19, 2001 |
| NOVOLOG FLEXTOUCH | | | | |
| +! | NOVO NORDISK INC | 300 UNITS/3ML (100 UNITS/ML) | N020986 005 | Oct 31, 2013 |
| NOVOLOG PENFILL | | | | |
| +! | NOVO NORDISK INC | 300 UNITS/3ML (100 UNITS/ML) | N020986 002 | Jun 07, 2000 |
| INSULIN ASPART; INSULIN DEGLUDEC | | | | |
| SOLUTION;SUBCUTANEOUS | | | | |
| RYZODEG 70/30 | | | | |
| +! | NOVO NORDISK INC | 90 UNITS/3ML;210 UNITS/3ML (30 UNITS/ML;70 UNITS/ML) | N203313 001 | Sep 25, 2015 |
| INSULIN DEGLUDEC | | | | |
| SOLUTION;SUBCUTANEOUS | | | | |
| TRESIBA | | | | |
| + | NOVO NORDISK INC | 300 UNITS/3ML (100 UNITS/ML) | N203314 001 | Sep 25, 2015 |
| +! | | 600 UNITS/3ML (200 UNITS/ML) | N203314 002 | Sep 25, 2015 |
| INSULIN DEGLUDEC; LIRAGLUTIDE | | | | |
| SOLUTION;SUBCUTANEOUS | | | | |
| XULTOPHY 100/3.6 | | | | |
| +! | NOVO NORDISK INC | 300 UNITS/3ML;10.8MG/3ML (100 UNITS/ML;3.6MG/ML) | N208583 001 | Nov 21, 2016 |
| INSULIN DETEMIR RECOMBINANT | | | | |
| INJECTABLE;SUBCUTANEOUS | | | | |
| LEVEMIR | | | | |
| +! | NOVO NORDISK INC | 1000 UNITS/10ML (100 UNITS/ML) | N021536 001 | Jun 16, 2005 |
| LEVEMIR FLEXTOUCH | | | | |
| +! | NOVO NORDISK INC | 300 UNITS/3ML (100 UNITS/ML) | N021536 005 | Oct 31, 2013 |
| INSULIN GLARGINE | | | | |
| SOLUTION;SUBCUTANEOUS | | | | |
| BASAGLAR | | | | |
| | ELI LILLY AND CO | 300 UNITS/3ML (100 UNITS/ML) | N205692 001 | Dec 16, 2015 |
| INSULIN GLARGINE RECOMBINANT | | | | |
| INJECTABLE;INJECTION | | | | |
| LANTUS | | | | |
| +! | SANOFI AVENTIS US | 100 UNITS/ML | N021081 001 | Apr 20, 2000 |
| LANTUS SOLOSTAR | | | | |
| +! | SANOFI AVENTIS US | 300 UNITS/3ML (100 UNITS/ML) | N021081 002 | Apr 27, 2007 |
| SOLUTION;SUBCUTANEOUS | | | | |
| TOUJEO SOLOSTAR | | | | |
| +! | SANOFI US SERVICES | 300 UNITS/ML (300 UNITS/ML) | N206538 001 | Feb 25, 2015 |
| INSULIN GLARGINE; LIXISENATIDE | | | | |
| SOLUTION;SUBCUTANEOUS | | | | |
| SOLIQUA 100/33 | | | | |
| +! | SANOFI-AVENTIS US | 300 UNITS/3ML;99MCG/3ML (100 UNITS/ML;33MCG/ML) | N208673 001 | Nov 21, 2016 |
| INSULIN GLULISINE RECOMBINANT | | | | |
| INJECTABLE;IV (INFUSION), SUBCUTANEOUS | | | | |
| APIDRA | | | | |
| +! | SANOFI AVENTIS US | 1000 UNITS/10ML (100 UNITS/ML) | N021629 001 | Apr 16, 2004 |
| +! | | 300 UNITS/3ML (100 UNITS/ML) | N021629 002 | Dec 20, 2005 |
| INJECTABLE;SUBCUTANEOUS | | | | |
| APIDRA SOLOSTAR | | | | |
| + | SANOFI AVENTIS US | 300 UNITS/3ML | N021629 003 | Feb 24, 2009 |

INSULIN HUMAN

SOLUTION;SUBCUTANEOUS

| | | | | | |
|---|---|---|---|---|---|
| HUMULIN R | | | | | |
| +! | LILLY | 10000 UNITS/20ML (500 UNITS/ML) | N018780 | 004 | Mar 31, 1994 |
| HUMULIN R KWIKPEN | | | | | |
| +! | LILLY | 1500 UNITS/3ML (500 UNITS/ML) | N018780 | 002 | Dec 29, 2015 |

INSULIN LISPRO

SOLUTION;IV (INFUSION), SUBCUTANEOUS

| | | | | | |
|---|---|---|---|---|---|
| ADMELOG | | | | | |
| + | SANOFI-AVENTIS US | 1000 UNITS/10ML (100 UNITS/ML) | N209196 | 001 | Dec 11, 2017 |
| ADMELOG SOLOSTAR | | | | | |
| + | SANOFI-AVENTIS US | 300 UNITS/3ML (100 UNITS/ML) | N209196 | 002 | Dec 11, 2017 |

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

INJECTABLE;INJECTION

| | | | | | |
|---|---|---|---|---|---|
| HUMALOG MIX 50/50 | | | | | |
| +! | LILLY | 50 UNITS/ML;50 UNITS/ML | N021018 | 001 | Dec 22, 1999 |
| HUMALOG MIX 50/50 KWIKPEN | | | | | |
| +! | LILLY | 50 UNITS/ML;50 UNITS/ML | N021018 | 002 | Sep 06, 2007 |
| HUMALOG MIX 75/25 | | | | | |
| +! | LILLY | 75 UNITS/ML;25 UNITS/ML | N021017 | 001 | Dec 22, 1999 |
| HUMALOG MIX 75/25 KWIKPEN | | | | | |
| +! | LILLY | 75 UNITS/ML;25 UNITS/ML | N021017 | 002 | Sep 06, 2007 |

INSULIN LISPRO RECOMBINANT

INJECTABLE;INJECTION

| | | | | | |
|---|---|---|---|---|---|
| HUMALOG | | | | | |
| +! | LILLY | 100 UNITS/ML | N020563 | 001 | Jun 14, 1996 |
| HUMALOG KWIKPEN | | | | | |
| +! | LILLY | 100 UNITS/ML | N020563 | 003 | Sep 06, 2007 |

SOLUTION;SUBCUTANEOUS

| | | | | | |
|---|---|---|---|---|---|
| HUMALOG KWIKPEN | | | | | |
| +! | ELI LILLY AND CO | 200 UNITS/ML | N205747 | 001 | May 26, 2015 |

INSULIN RECOMBINANT HUMAN

POWDER;INHALATION

| | | | | | |
|---|---|---|---|---|---|
| AFREZZA | | | | | |
| + | MANNKIND | 4 UNITS/INH | N022472 | 001 | Jun 27, 2014 |
| +! | | 8 UNITS/INH | N022472 | 002 | Jun 27, 2014 |
| + | | 12 UNITS/INH | N022472 | 003 | Apr 17, 2015 |

IOBENGUANE SULFATE I-123

SOLUTION;INTRAVENOUS

| | | | | | |
|---|---|---|---|---|---|
| ADREVIEW | | | | | |
| +! | GE HEALTHCARE | 10mCi/5ML (2mCi/ML) | N022290 | 001 | Sep 19, 2008 |

IODIXANOL

INJECTABLE;INJECTION

| | | | | | |
|---|---|---|---|---|---|
| VISIPAQUE 270 | | | | | |
| +! | GE HEALTHCARE | 55% | N020351 | 001 | Mar 22, 1996 |
| VISIPAQUE 320 | | | | | |
| +! | GE HEALTHCARE | 65.2% | N020351 | 002 | Mar 22, 1996 |
| | | 65.2% | N020808 | 002 | Aug 29, 1997 |

IOFLUPANE I-123

SOLUTION;INTRAVENOUS

| | | | | | |
|---|---|---|---|---|---|
| DATSCAN | | | | | |
| +! | GE HLTHCARE INC | 5mCi/2.5ML (2mCi/ML) | N022454 | 001 | Jan 14, 2011 |

IOHEXOL

FOR SOLUTION;ORAL

| | | | | | |
|---|---|---|---|---|---|
| ORALTAG | | | | | |
| | INTERPHARMA PRAHA AS | 9.7GM/BOT | N205383 | 001 | Mar 26, 2015 |

INJECTABLE;INJECTION

| | | | | | |
|---|---|---|---|---|---|
| OMNIPAQUE 140 | | | | | |
| +! | GE HEALTHCARE | 30.2% | N018956 | 005 | Nov 30, 1988 |

SOLUTION;INJECTION, ORAL

| | | | | | |
|---|---|---|---|---|---|
| OMNIPAQUE 350 | | | | | |
| +! | GE HEALTHCARE | 75.5% | N018956 | 004 | Dec 26, 1985 |
| | | 75.5% | N020608 | 003 | Oct 24, 1995 |

SOLUTION;INJECTION, ORAL, RECTAL

| | | | | | |
|---|---|---|---|---|---|
| OMNIPAQUE 180 | | | | | |
| +! | GE HEALTHCARE | 38.8% | N018956 | 001 | Dec 26, 1985 |

IOHEXOL

SOLUTION;INJECTION, ORAL, RECTAL

| | | | | | |
|---|---|---|---|---|---|
| OMNIPAQUE 240 | | | | | |
| +! | GE HEALTHCARE | 51.8% | N018956 | 002 | Dec 26, 1985 |
| | | 51.8% | N020608 | 001 | Oct 24, 1995 |
| OMNIPAQUE 300 | | | | | |
| +! | GE HEALTHCARE | 64.7% | N018956 | 003 | Dec 26, 1985 |
| | | 64.7% | N020608 | 002 | Oct 24, 1995 |

IOPAMIDOL

INJECTABLE;INJECTION

| | | | | | | |
|---|---|---|---|---|---|---|
| **ISOVUE-300** | | | | | | |
| **AP** **+!** | BRACCO | **61%** | **N018735** | **002** | Dec 31, 1985 |
| **ISOVUE-370** | | | | | | |
| **AP** **+!** | BRACCO | **76%** | **N018735** | **003** | Dec 31, 1985 |
| **SCANLUX-300** | | | | | | |
| **AP** | SANOCHEMIA CORP USA | **61%** | **A090394** | **001** | Jun 18, 2010 |
| **SCANLUX-370** | | | | | | |
| **AP** | SANOCHEMIA CORP USA | **76%** | **A090394** | **002** | Jun 18, 2010 |
| ISOVUE-200 | | | | | | |
| +! | BRACCO | 41% | N018735 | 006 | Jul 07, 1987 |
| ISOVUE-250 | | | | | | |
| +! | BRACCO | 51% | N018735 | 007 | Jul 06, 1992 |
| +! | | 51% | N020327 | 002 | Oct 12, 1994 |
| ISOVUE-300 | | | | | | |
| +! | BRACCO | 61% | N020327 | 003 | Oct 12, 1994 |
| ISOVUE-370 | | | | | | |
| +! | BRACCO | 76% | N020327 | 004 | Oct 12, 1994 |
| ISOVUE-M 200 | | | | | | |
| +! | BRACCO | 41% | N018735 | 001 | Dec 31, 1985 |
| ISOVUE-M 300 | | | | | | |
| +! | BRACCO | 61% | N018735 | 004 | Dec 31, 1985 |

IOPROMIDE

INJECTABLE;INJECTION

| | | | | | |
|---|---|---|---|---|---|
| ULTRAVIST (PHARMACY BULK) | | | | | |
| +! | BAYER HLTHCARE | 49.9% | N021425 | 003 | Mar 12, 2004 |
| +! | | 62.3% | N021425 | 001 | Sep 20, 2002 |
| +! | | 76.9% | N021425 | 002 | Sep 20, 2002 |
| ULTRAVIST 240 | | | | | |
| +! | BAYER HLTHCARE | 49.9% | N020220 | 003 | May 10, 1995 |
| ULTRAVIST 300 | | | | | |
| +! | BAYER HLTHCARE | 62.3% | N020220 | 002 | May 10, 1995 |
| ULTRAVIST 370 | | | | | |
| +! | BAYER HLTHCARE | 76.9% | N020220 | 001 | May 10, 1995 |

IOTHALAMATE MEGLUMINE

INJECTABLE;INJECTION

| | | | | |
|---|---|---|---|---|
| CONRAY | | | | |
| +! | LIEBEL-FLARSHEIM | 60% | N013295 | 001 |
| CONRAY 30 | | | | |
| +! | LIEBEL-FLARSHEIM | 30% | N016983 | 001 |
| CONRAY 43 | | | | |
| +! | LIEBEL-FLARSHEIM | 43% | N013295 | 002 |

SOLUTION;INTRAVESICAL

| | | | | |
|---|---|---|---|---|
| CYSTO-CONRAY II | | | | |
| | LIEBEL-FLARSHEIM | 17.2% | N017057 | 002 |

IOTHALAMATE SODIUM I-125

INJECTABLE;INJECTION

| | | | | |
|---|---|---|---|---|
| GLOFIL-125 | | | | |
| | ISOTEX | 250-300uCi/ML | N017279 | 001 |

IOVERSOL

INJECTABLE;INJECTION

| | | | | | |
|---|---|---|---|---|---|
| OPTIRAY 240 | | | | | |
| +! | LIEBEL-FLARSHEIM | 51% | N019710 | 002 | Dec 30, 1988 |
| OPTIRAY 300 | | | | | |
| +! | LIEBEL-FLARSHEIM | 64% | N019710 | 004 | Jan 22, 1992 |
| +! | | 64% | N020923 | 004 | May 13, 1999 |
| OPTIRAY 320 | | | | | |
| +! | LIEBEL-FLARSHEIM | 68% | N019710 | 001 | Dec 30, 1988 |
| +! | | 68% | N020923 | 002 | May 29, 1998 |

IOVERSOL

INJECTABLE;INJECTION

OPTIRAY 350

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | LIEBEL-FLARSHEIM | 74% | N019710 | 005 | Jan 22, 1992 |
| | +! | | 74% | N020923 | 003 | May 28, 1998 |

IPRATROPIUM BROMIDE

AEROSOL, METERED;INHALATION

ATROVENT HFA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | BOEHRINGER INGELHEIM | 0.021MG/INH | N021527 | 001 | Nov 27, 2004 |

SOLUTION;INHALATION

**IPRATROPIUM BROMIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AN** | | AUROBINDO PHARMA LTD | **0.02%** | **A206543** | **001** | Oct 27, 2016 |
| **AN** | | LANDELA PHARM | **0.02%** | **A077072** | **001** | Jul 19, 2005 |
| **AN** | | NEPHRON | **0.02%** | **A075562** | **001** | Sep 27, 2001 |
| **AN** | ! | RITEDOSE CORP | **0.02%** | **A075693** | **001** | Jan 26, 2001 |
| **AN** | | SUN PHARMA GLOBAL | **0.02%** | **A207903** | **001** | Jan 03, 2017 |
| **AN** | | WATSON LABS | **0.02%** | **A076291** | **001** | May 09, 2005 |

SPRAY, METERED;NASAL

**ATROVENT**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | BOEHRINGER INGELHEIM | **0.021MG/SPRAY** | **N020393** | **001** | Oct 20, 1995 |
| **AB** | **+!** | | **0.042MG/SPRAY** | **N020394** | **001** | Oct 20, 1995 |

**IPRATROPIUM BROMIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | BAUSCH AND LOMB | **0.021MG/SPRAY** | **A076025** | **001** | Mar 31, 2003 |
| **AB** | | | **0.042MG/SPRAY** | **A076103** | **001** | Mar 31, 2003 |
| **AB** | | MYLAN SPECIALITY LP | **0.021MG/SPRAY** | **A075552** | **001** | Mar 31, 2003 |
| **AB** | | | **0.042MG/SPRAY** | **A075553** | **001** | Mar 31, 2003 |
| **AB** | | WEST-WARD PHARMS INT | **0.021MG/SPRAY** | **A076664** | **001** | Nov 05, 2003 |
| **AB** | | | **0.042MG/SPRAY** | **A076598** | **001** | Nov 05, 2003 |

IRBESARTAN

TABLET;ORAL

**AVAPRO**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | SANOFI AVENTIS US | **75MG** | **N020757** | **001** | Sep 30, 1997 |
| **AB** | **+** | | **150MG** | **N020757** | **002** | Sep 30, 1997 |
| **AB** | **+!** | | **300MG** | **N020757** | **003** | Sep 30, 1997 |

**IRBESARTAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALEMBIC PHARMS LTD | **75MG** | **A091236** | **001** | Oct 15, 2012 |
| **AB** | | | **150MG** | **A091236** | **002** | Oct 15, 2012 |
| **AB** | | | **300MG** | **A091236** | **003** | Oct 15, 2012 |
| **AB** | | APOTEX INC | **75MG** | **A200832** | **001** | Oct 15, 2012 |
| **AB** | | | **150MG** | **A200832** | **002** | Oct 15, 2012 |
| **AB** | | | **300MG** | **A200832** | **003** | Oct 15, 2012 |
| **AB** | | AUROBINDO PHARMA LTD | **75MG** | **A203081** | **001** | Sep 27, 2012 |
| **AB** | | | **150MG** | **A203081** | **002** | Sep 27, 2012 |
| **AB** | | | **300MG** | **A203081** | **003** | Sep 27, 2012 |
| **AB** | | CIPLA LTD | **75MG** | **A077205** | **001** | Nov 14, 2012 |
| **AB** | | | **150MG** | **A077205** | **002** | Nov 14, 2012 |
| **AB** | | | **300MG** | **A077205** | **003** | Nov 14, 2012 |
| **AB** | | DR REDDYS LABS LTD | **75MG** | **A203161** | **001** | Sep 27, 2012 |
| **AB** | | | **150MG** | **A203161** | **002** | Sep 27, 2012 |
| **AB** | | | **300MG** | **A203161** | **003** | Sep 27, 2012 |
| **AB** | | HETERO LABS LTD V | **75MG** | **A202910** | **001** | Sep 27, 2012 |
| **AB** | | | **150MG** | **A202910** | **002** | Sep 27, 2012 |
| **AB** | | | **300MG** | **A202910** | **003** | Sep 27, 2012 |
| **AB** | | HISUN PHARM HANGZHOU | **75MG** | **A206194** | **001** | Jun 14, 2016 |
| **AB** | | | **150MG** | **A206194** | **002** | Jun 14, 2016 |
| **AB** | | | **300MG** | **A206194** | **003** | Jun 14, 2016 |
| **AB** | | JUBILANT GENERICS | **75MG** | **A203534** | **001** | Feb 23, 2015 |
| **AB** | | | **150MG** | **A203534** | **002** | Feb 23, 2015 |
| **AB** | | | **300MG** | **A203534** | **003** | Feb 23, 2015 |
| **AB** | | LUPIN LTD | **75MG** | **A201531** | **001** | Oct 15, 2012 |
| **AB** | | | **150MG** | **A201531** | **002** | Oct 15, 2012 |
| **AB** | | | **300MG** | **A201531** | **003** | Oct 15, 2012 |
| **AB** | | MACLEODS PHARMS LTD | **75MG** | **A202254** | **001** | Oct 03, 2012 |
| **AB** | | | **150MG** | **A202254** | **002** | Oct 03, 2012 |
| **AB** | | | **300MG** | **A202254** | **003** | Oct 03, 2012 |
| **AB** | | PRINSTON INC | **75MG** | **A203071** | **001** | Sep 27, 2012 |
| **AB** | | | **150MG** | **A203071** | **002** | Sep 27, 2012 |

IRBESARTAN

TABLET;ORAL

**IRBESARTAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | **300MG** | **A203071** | **003** | Sep 27, 2012 |
| **AB** | SANDOZ | **75MG** | **A077466** | **001** | Sep 27, 2012 |
| **AB** | | **150MG** | **A077466** | **002** | Sep 27, 2012 |
| **AB** | | **300MG** | **A077466** | **003** | Sep 27, 2012 |
| **AB** | SCIEGEN PHARMS INC | **75MG** | **A204774** | **001** | Dec 07, 2015 |
| **AB** | | **150MG** | **A204774** | **002** | Dec 07, 2015 |
| **AB** | | **300MG** | **A204774** | **003** | Dec 07, 2015 |
| **AB** | TEVA PHARMS | **75MG** | **A077159** | **001** | Mar 30, 2012 |
| **AB** | | **150MG** | **A077159** | **002** | Mar 30, 2012 |
| **AB** | | **300MG** | **A077159** | **003** | Mar 30, 2012 |
| **AB** | UNICHEM LABS LTD | **75MG** | **A203020** | **001** | Dec 07, 2015 |
| **AB** | | **150MG** | **A203020** | **002** | Dec 07, 2015 |
| **AB** | | **300MG** | **A203020** | **003** | Dec 07, 2015 |
| **AB** | WEST-WARD PHARMS INT | **75MG** | **A090201** | **001** | Oct 15, 2012 |
| **AB** | | **150MG** | **A090201** | **002** | Oct 15, 2012 |
| **AB** | | **300MG** | **A090201** | **003** | Oct 15, 2012 |
| **AB** | ZYDUS PHARMS USA INC | **75MG** | **A079213** | **001** | Sep 27, 2012 |
| **AB** | | **150MG** | **A079213** | **002** | Sep 27, 2012 |
| **AB** | | **300MG** | **A079213** | **003** | Sep 27, 2012 |

IRINOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION

**CAMPTOSAR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | PFIZER INC | **40MG/2ML (20MG/ML)** | **N020571** | **001** | Jun 14, 1996 |
| **AP** | **+!** | | **100MG/5ML (20MG/ML)** | **N020571** | **002** | Jun 14, 1996 |
| **AP** | **+!** | | **300MG/15ML (20MG/ML)** | **N020571** | **003** | Aug 05, 2010 |

**IRINOTECAN HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | ACCORD HLTHCARE | **40MG/2ML (20MG/ML)** | **A079068** | **001** | Nov 21, 2008 |
| **AP** | | | **100MG/5ML (20MG/ML)** | **A079068** | **002** | Nov 21, 2008 |
| **AP** | | ACTAVIS TOTOWA | **40MG/2ML (20MG/ML)** | **A078589** | **001** | Feb 27, 2008 |
| **AP** | | | **100MG/5ML (20MG/ML)** | **A078589** | **002** | Feb 27, 2008 |
| **AP** | | | **500MG/25ML (20MG/ML)** | **A078589** | **003** | Nov 18, 2015 |
| **AP** | | AKORN | **40MG/2ML (20MG/ML)** | **A090726** | **001** | Sep 16, 2009 |
| **AP** | | | **100MG/5ML (20MG/ML)** | **A090726** | **002** | Sep 16, 2009 |
| **AP** | | CIPLA LTD | **40MG/2ML (20MG/ML)** | **A077219** | **001** | Feb 20, 2008 |
| **AP** | | | **100MG/5ML (20MG/ML)** | **A077219** | **002** | Feb 20, 2008 |
| **AP** | | DR REDDYS LABS LTD | **40MG/2ML (20MG/ML)** | **A078953** | **001** | Apr 15, 2010 |
| **AP** | | | **100MG/5ML (20MG/ML)** | **A078953** | **002** | Apr 15, 2010 |
| **AP** | | EMCURE PHARMS LTD | **40MG/2ML (20MG/ML)** | **A200771** | **001** | Feb 14, 2012 |
| **AP** | | | **100MG/5ML (20MG/ML)** | **A200771** | **002** | Feb 14, 2012 |
| **AP** | | FRESENIUS KABI ONCOL | **40MG/2ML (20MG/ML)** | **A078188** | **001** | Feb 27, 2008 |
| **AP** | | | **100MG/5ML (20MG/ML)** | **A078188** | **002** | Feb 27, 2008 |
| **AP** | | FRESENIUS KABI USA | **40MG/2ML (20MG/ML)** | **A077776** | **001** | Feb 27, 2008 |
| **AP** | | | **100MG/5ML (20MG/ML)** | **A077776** | **002** | Feb 27, 2008 |
| **AP** | | HIKMA FARMACEUTICA | **40MG/2ML (20MG/ML)** | **A091032** | **001** | Dec 20, 2010 |
| **AP** | | | **100MG/5ML (20MG/ML)** | **A091032** | **002** | Dec 20, 2010 |
| **AP** | | HISUN PHARM HANGZHOU | **40MG/2ML (20MG/ML)** | **A090016** | **001** | Jan 28, 2009 |
| **AP** | | | **100MG/5ML (20MG/ML)** | **A090016** | **002** | Jan 28, 2009 |
| **AP** | | HOSPIRA | **40MG/2ML (20MG/ML)** | **A077915** | **001** | Feb 27, 2008 |
| **AP** | | | **100MG/5ML (20MG/ML)** | **A077915** | **002** | Feb 27, 2008 |
| **AP** | **!** | | **500MG/25ML (20MG/ML)** | **A078796** | **001** | Feb 27, 2008 |
| **AP** | | INGENUS PHARMS LLC | **40MG/2ML (20MG/ML)** | **A206935** | **001** | May 26, 2017 |
| **AP** | | | **100MG/5ML (20MG/ML)** | **A206935** | **002** | May 26, 2017 |
| **AP** | | INTAS PHARMS USA | **40MG/2ML (20MG/ML)** | **A203054** | **001** | Aug 31, 2017 |
| **AP** | | | **100MG/5ML (20MG/ML)** | **A203054** | **002** | Aug 31, 2017 |
| **AP** | | JIANGSU HENGRUI MED | **40MG/2ML (20MG/ML)** | **A090675** | **002** | Dec 16, 2011 |
| **AP** | | | **100MG/5ML (20MG/ML)** | **A090675** | **001** | Dec 16, 2011 |
| **AP** | | MUSTAFA NEVZAT ILAC | **40MG/2ML (20MG/ML)** | **A090393** | **002** | May 13, 2011 |
| **AP** | | | **100MG/5ML (20MG/ML)** | **A090393** | **003** | May 13, 2011 |
| **AP** | | PLIVA LACHEMA | **40MG/2ML (20MG/ML)** | **A078122** | **001** | Oct 31, 2008 |
| **AP** | | | **100MG/5ML (20MG/ML)** | **A078122** | **002** | Oct 31, 2008 |
| **AP** | | QILU PHARM CO LTD | **40MG/2ML (20MG/ML)** | **A203380** | **001** | May 03, 2016 |
| **AP** | | | **100MG/5ML (20MG/ML)** | **A203380** | **002** | May 03, 2016 |
| **AP** | | | **300MG/15ML (20MG/ML)** | **A203380** | **003** | May 03, 2016 |
| **AP** | | SUN PHARMA GLOBAL | **40MG/2ML (20MG/ML)** | **A078805** | **001** | Apr 21, 2008 |
| **AP** | | | **100MG/5ML (20MG/ML)** | **A078805** | **002** | Apr 21, 2008 |
| **AP** | | TEVA PHARMS USA | **40MG/2ML (20MG/ML)** | **A090101** | **002** | Feb 27, 2008 |

| | | | | | | |
|---|---|---|---|---|---|---|
| IRINOTECAN HYDROCHLORIDE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| **IRINOTECAN HYDROCHLORIDE** | | | | | | |
| **AP** | | | **100MG/5ML (20MG/ML)** | **A090101** | **003** | Feb 27, 2008 |
| **AP** | | | **500MG/25ML (20MG/ML)** | **A090101** | **001** | Nov 26, 2008 |
| **AP** | | WEST-WARD PHARMS INT | **40MG/2ML (20MG/ML)** | **A078753** | **001** | Dec 24, 2008 |
| **AP** | | | **100MG/5ML (20MG/ML)** | **A078753** | **002** | Dec 24, 2008 |
| INJECTABLE, LIPOSOMAL;IV (INFUSION) | | | | | | |
| ONIVYDE | | | | | | |
| | +! | IPSEN INC | EQ 43MG BASE/10ML (EQ 4.3MG BASE/ML) | N207793 | 001 | Oct 22, 2015 |
| IRON DEXTRAN | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| DEXFERRUM | | | | | | |
| BP | | LUITPOLD | EQ 50MG IRON/ML | N040024 | 001 | Feb 23, 1996 |
| INFED | | | | | | |
| BP | +! | ALLERGAN SALES LLC | EQ 50MG IRON/ML | N017441 | 001 | |
| PROFERDEX | | | | | | |
| BP | | NEW RIVER | EQ 50MG IRON/ML | N017807 | 001 | |
| IRON SUCROSE | | | | | | |
| INJECTABLE;INTRAVENOUS | | | | | | |
| VENOFER | | | | | | |
| | + | LUITPOLD | EQ 50MG BASE/2.5ML (EQ 20MG BASE/ML) | N021135 | 002 | Mar 20, 2005 |
| | +! | | EQ 100MG BASE/5ML (EQ 20MG BASE/ML) | N021135 | 001 | Nov 06, 2000 |
| | + | | EQ 200MG BASE/10ML (EQ 20MG BASE/ML) | N021135 | 004 | Feb 09, 2007 |
| ISAVUCONAZONIUM SULFATE | | | | | | |
| CAPSULE;ORAL | | | | | | |
| CRESEMBA | | | | | | |
| | +! | ASTELLAS | 186MG | N207500 | 001 | Mar 06, 2015 |
| POWDER;IV (INFUSION) | | | | | | |
| CRESEMBA | | | | | | |
| | +! | ASTELLAS | 372MG | N207501 | 001 | Mar 06, 2015 |
| ISOCARBOXAZID | | | | | | |
| TABLET;ORAL | | | | | | |
| MARPLAN | | | | | | |
| | +! | VALIDUS PHARMS INC | 10MG | N011961 | 001 | |
| ISOFLURANE | | | | | | |
| LIQUID;INHALATION | | | | | | |
| **FORANE** | | | | | | |
| **AN** | **+!** | BAXTER HLTHCARE | **99.9%** | **N017624** | **001** | |
| **ISOFLURANE** | | | | | | |
| **AN** | | HALOCARBON PRODS | **99.9%** | **A075225** | **001** | Oct 20, 1999 |
| **AN** | | HOSPIRA | **99.9%** | **A074097** | **001** | Jan 25, 1993 |
| **AN** | | PIRAMAL CRITICAL | **99.9%** | **A074416** | **001** | Sep 30, 1994 |
| **AN** | | PIRAMAL ENT | **99.9%** | **A074502** | **001** | Jun 27, 1995 |
| ISONIAZID | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| ISONIAZID | | | | | | |
| | ! | SANDOZ INC | 100MG/ML | A040648 | 001 | Jul 05, 2005 |
| SYRUP;ORAL | | | | | | |
| ISONIAZID | | | | | | |
| | ! | CMP PHARMA INC | 50MG/5ML | A088235 | 001 | Nov 10, 1983 |
| TABLET;ORAL | | | | | | |
| **ISONIAZID** | | | | | | |
| **AA** | | BARR | **100MG** | **A080936** | **001** | |
| **AA** | | | **300MG** | **A080937** | **002** | |
| **AA** | | MIKART | **100MG** | **A040090** | **001** | Jun 26, 1997 |
| **AA** | | | **300MG** | **A040090** | **002** | Jun 26, 1997 |
| **AA** | **+!** | SANDOZ | **100MG** | **N008678** | **002** | |
| **AA** | **+!** | | **300MG** | **N008678** | **003** | |
| **AA** | | THEPHARMANETWORK LLC | **100MG** | **A202610** | **001** | Oct 29, 2014 |
| **AA** | | | **300MG** | **A202610** | **002** | Oct 29, 2014 |
| **LANIAZID** | | | | | | |
| **AA** | | LANNETT | **300MG** | **A089776** | **001** | Jun 13, 1988 |

| | | | | | | |
|---|---|---|---|---|---|---|
| ISONIAZID; PYRAZINAMIDE; RIFAMPIN | | | | | | |
| TABLET;ORAL | | | | | | |
| RIFATER | | | | | | |
| | +! | SANOFI AVENTIS US | 50MG;300MG;120MG | N050705 | 001 | May 31, 1994 |
| ISONIAZID; RIFAMPIN | | | | | | |
| CAPSULE;ORAL | | | | | | |
| RIFAMATE | | | | | | |
| | ! | SANOFI AVENTIS US | 150MG;300MG | A061884 | 001 | |
| ISOPROTERENOL HYDROCHLORIDE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| **ISOPROTERENOL HYDROCHLORIDE** | | | | | | |
| **AP** | | NEXUS PHARMS | **0.2MG/ML** | **A206961** | **001** | Aug 02, 2017 |
| **ISUPREL** | | | | | | |
| **AP** | **+!** | HOSPIRA | **0.2MG/ML** | **N010515** | **001** | |
| ISOSORBIDE DINITRATE | | | | | | |
| CAPSULE, EXTENDED RELEASE;ORAL | | | | | | |
| DILATRATE-SR | | | | | | |
| | +! | AUXILIUM PHARMS LLC | 40MG | N019790 | 001 | Sep 02, 1988 |
| TABLET;ORAL | | | | | | |
| **ISORDIL** | | | | | | |
| **AB** | **+** | VALEANT PHARMS NORTH | **5MG** | **N012093** | **007** | Jul 29, 1988 |
| **ISOSORBIDE DINITRATE** | | | | | | |
| **AB** | | HIKMA INTL PHARMS | **5MG** | **A086067** | **001** | Oct 29, 1987 |
| **AB** | | | **10MG** | **A086066** | **001** | Oct 29, 1987 |
| **AB** | | | **20MG** | **A088088** | **001** | Nov 02, 1987 |
| **AB** | | | **30MG** | **A040591** | **001** | Jan 10, 2007 |
| **AB** | | PAR PHARM | **5MG** | **A086923** | **001** | Mar 12, 1987 |
| **AB** | | | **10MG** | **A086925** | **001** | Mar 12, 1987 |
| **AB** | | | **20MG** | **A087537** | **001** | Oct 02, 1987 |
| **AB** | **!** | | **30MG** | **A087946** | **001** | Jan 12, 1988 |
| **AB** | | SANDOZ | **5MG** | **A086221** | **001** | Jan 07, 1988 |
| **AB** | | | **10MG** | **A086223** | **001** | Jan 07, 1988 |
| **AB** | | | **20MG** | **A089367** | **001** | Apr 07, 1988 |
| ISORDIL | | | | | | |
| | +! | VALEANT PHARMS NORTH | 40MG | N012093 | 001 | Jul 29, 1988 |
| TABLET, EXTENDED RELEASE;ORAL | | | | | | |
| ISOSORBIDE DINITRATE | | | | | | |
| | ! | SUN PHARM INDS INC | 40MG | A040009 | 001 | Dec 30, 1998 |
| ISOSORBIDE MONONITRATE | | | | | | |
| TABLET;ORAL | | | | | | |
| **ISOSORBIDE MONONITRATE** | | | | | | |
| **AB** | | ACTAVIS ELIZABETH | **10MG** | **A075037** | **002** | Oct 30, 1998 |
| **AB** | | | **20MG** | **A075037** | **001** | Oct 30, 1998 |
| **AB** | | ANI PHARMS INC | **20MG** | **A075147** | **001** | Nov 27, 1998 |
| **AB** | | HIKMA PHARMS | **20MG** | **A075361** | **001** | Oct 05, 2000 |
| **MONOKET** | | | | | | |
| **AB** | **+** | LANNETT CO INC | **10MG** | **N020215** | **002** | Jun 30, 1993 |
| **AB** | **+!** | | **20MG** | **N020215** | **001** | Jun 30, 1993 |
| TABLET, EXTENDED RELEASE;ORAL | | | | | | |
| **ISOSORBIDE MONONITRATE** | | | | | | |
| **AB** | | ACCORD HLTHCARE | **30MG** | **A209684** | **001** | Oct 24, 2017 |
| **AB** | | | **60MG** | **A209684** | **002** | Oct 24, 2017 |
| **AB** | | | **120MG** | **A209684** | **003** | Oct 24, 2017 |
| **AB** | | DEXCEL LTD | **30MG** | **A075522** | **002** | Sep 20, 2016 |
| **AB** | | | **60MG** | **A075522** | **001** | Apr 17, 2000 |
| **AB** | | HIKMA PHARMS | **30MG** | **A076813** | **002** | Mar 30, 2006 |
| **AB** | | | **60MG** | **A076813** | **001** | Jan 07, 2005 |
| **AB** | | KREMERS URBAN PHARMS | **30MG** | **A075155** | **002** | Jan 13, 2000 |
| **AB** | | | **60MG** | **A075155** | **001** | Oct 30, 1998 |
| **AB** | **!** | | **120MG** | **A075155** | **003** | Aug 04, 2000 |
| **AB** | | NESHER PHARMS | **30MG** | **A075395** | **001** | Mar 16, 2000 |
| **AB** | | | **60MG** | **A075395** | **002** | Mar 16, 2000 |
| **AB** | | | **120MG** | **A075395** | **003** | Mar 16, 2000 |
| **AB** | | TORRENT PHARMS | **30MG** | **A200270** | **001** | Jun 03, 2011 |
| **AB** | | | **60MG** | **A200495** | **001** | Jun 03, 2011 |
| **AB** | | | **120MG** | **A200495** | **002** | Jun 03, 2011 |
| **AB** | | VINTAGE PHARMS | **30MG** | **A090598** | **001** | Aug 11, 2010 |
| **AB** | | | **60MG** | **A090598** | **002** | Aug 11, 2010 |

ISOSORBIDE MONONITRATE

TABLET, EXTENDED RELEASE;ORAL

**ISOSORBIDE MONONITRATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **120MG** | **A090598** | **003** | Aug 11, 2010 |

ISOSULFAN BLUE

INJECTABLE;INJECTION

**ISOSULFAN BLUE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AUROBINDO PHARMA LTD | **1%** | **A206831** | **001** | Feb 02, 2016 |
| **AP** | **!** | MYLAN INSTITUTIONAL | **1%** | **A090874** | **001** | Jul 20, 2010 |

ISOTRETINOIN

CAPSULE;ORAL

**AMNESTEEM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | MYLAN PHARMS INC | **10MG** | **A075945** | **001** | Nov 08, 2002 |
| **AB** | | | **20MG** | **A075945** | **002** | Nov 08, 2002 |
| **AB** | | | **40MG** | **A075945** | **003** | Nov 08, 2002 |

**CLARAVIS**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | TEVA PHARMS USA | **10MG** | **A076356** | **001** | Apr 11, 2003 |
| **AB** | | | **20MG** | **A076135** | **002** | Apr 11, 2003 |
| **AB** | | | **30MG** | **A076135** | **003** | May 11, 2006 |
| **AB** | **!** | | **40MG** | **A076135** | **001** | Apr 11, 2003 |

**ISOTRETINOIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AMNEAL PHARMS NY | **10MG** | **A207792** | **001** | Sep 29, 2017 |
| **AB** | | | **20MG** | **A207792** | **002** | Sep 29, 2017 |
| **AB** | | | **30MG** | **A207792** | **003** | Sep 29, 2017 |
| **AB** | | | **40MG** | **A207792** | **004** | Sep 29, 2017 |

**MYORISAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | DOUGLAS PHARMS | **10MG** | **A076485** | **001** | Jan 19, 2012 |
| **AB** | | | **20MG** | **A076485** | **002** | Jan 19, 2012 |
| **AB** | | | **30MG** | **A076485** | **004** | Aug 25, 2015 |
| **AB** | | | **40MG** | **A076485** | **003** | Jan 19, 2012 |

**ZENATANE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | DR REDDYS LABS LTD | **10MG** | **A202099** | **001** | Mar 25, 2013 |
| **AB** | | | **20MG** | **A202099** | **002** | Mar 25, 2013 |
| **AB** | | | **30MG** | **A202099** | **004** | Feb 23, 2015 |
| **AB** | | | **40MG** | **A202099** | **003** | Mar 25, 2013 |

ABSORICA

| | | | | | | |
|---|---|---|---|---|---|---|
| BX | + | SUN PHARM INDS INC | 10MG | N021951 | 001 | May 25, 2012 |
| BX | + | | 20MG | N021951 | 002 | May 25, 2012 |
| BX | + | | 30MG | N021951 | 003 | May 25, 2012 |
| BX | +! | | 40MG | N021951 | 004 | May 25, 2012 |
| | + | | 25MG | N021951 | 005 | Aug 15, 2014 |
| | + | | 35MG | N021951 | 006 | Aug 15, 2014 |

ISRADIPINE

CAPSULE;ORAL

**ISRADIPINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ELITE LABS INC | **2.5MG** | **A077169** | **001** | Apr 24, 2006 |
| **AB** | | | **5MG** | **A077169** | **002** | Apr 24, 2006 |
| **AB** | | WATSON LABS TEVA | **2.5MG** | **A077317** | **001** | Jan 05, 2006 |
| **AB** | **!** | | **5MG** | **A077317** | **002** | Jan 05, 2006 |

ITRACONAZOLE

CAPSULE;ORAL

**ITRACONAZOLE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACCORD HLTHCARE | **100MG** | **A205991** | **001** | May 26, 2016 |
| **AB** | | ALEMBIC PHARMS LTD | **100MG** | **A206741** | **001** | Dec 13, 2016 |
| **AB** | | ALKEM LABS LTD | **100MG** | **A208591** | **001** | Jun 12, 2017 |
| **AB** | | AMNEAL PHARMS | **100MG** | **A205080** | **001** | Sep 26, 2016 |
| **AB** | | JUBILANT GENERICS | **100MG** | **A203445** | **001** | Feb 23, 2017 |
| **AB** | | MYLAN PHARMS INC | **100MG** | **A200463** | **001** | Jul 20, 2012 |
| **AB** | | PAR PHARM INC | **100MG** | **A205724** | **001** | Dec 13, 2016 |
| **AB** | | SANDOZ | **100MG** | **A076104** | **001** | May 28, 2004 |
| **AB** | | ZYDUS PHARMS USA INC | **100MG** | **A204672** | **001** | Sep 19, 2017 |

**SPORANOX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | JANSSEN PHARMS | **100MG** | **N020083** | **001** | Sep 11, 1992 |

SOLUTION;ORAL

SPORANOX

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | JANSSEN PHARMS | 10MG/ML | N020657 | 001 | Feb 21, 1997 |

| | | | | | | |
|---|---|---|---|---|---|---|
| ITRACONAZOLE | | | | | | |
| TABLET;ORAL | | | | | | |
| ONMEL | | | | | | |
| +! | SEBELA IRELAND LTD | 200MG | | N022484 | 001 | Apr 29, 2010 |
| IVABRADINE HYDROCHLORIDE | | | | | | |
| TABLET;ORAL | | | | | | |
| CORLANOR | | | | | | |
| + | AMGEN INC | EQ 5MG BASE | | N206143 | 001 | Apr 15, 2015 |
| +! | | EQ 7.5MG BASE | | N206143 | 002 | Apr 15, 2015 |
| IVACAFTOR | | | | | | |
| GRANULE;ORAL | | | | | | |
| KALYDECO | | | | | | |
| + | VERTEX PHARMS INC | 50MG/PACKET | | N207925 | 001 | Mar 17, 2015 |
| +! | | 75MG/PACKET | | N207925 | 002 | Mar 17, 2015 |
| TABLET;ORAL | | | | | | |
| KALYDECO | | | | | | |
| +! | VERTEX PHARMS | 150MG | | N203188 | 001 | Jan 31, 2012 |
| IVACAFTOR; LUMACAFTOR | | | | | | |
| TABLET;ORAL | | | | | | |
| ORKAMBI | | | | | | |
| + | VERTEX PHARMS INC | 125MG;100MG | | N206038 | 002 | Sep 28, 2016 |
| +! | | 125MG;200MG | | N206038 | 001 | Jul 02, 2015 |
| IVERMECTIN | | | | | | |
| CREAM;TOPICAL | | | | | | |
| SOOLANTRA | | | | | | |
| +! | GALDERMA LABS LP | 1% | | N206255 | 001 | Dec 19, 2014 |
| LOTION;TOPICAL | | | | | | |
| SKLICE | | | | | | |
| +! | ARBOR PHARMS LLC | 0.5% | | N202736 | 001 | Feb 07, 2012 |
| TABLET;ORAL | | | | | | |
| **IVERMECTIN** | | | | | | |
| **AB** | EDENBRIDGE PHARMS | **3MG** | | **A204154** | **001** | Oct 24, 2014 |
| **STROMECTOL** | | | | | | |
| **AB** **+!** | MERCK SHARP DOHME | **3MG** | | **N050742** | **002** | Oct 08, 1998 |
| IXABEPILONE | | | | | | |
| INJECTABLE;IV (INFUSION) | | | | | | |
| IXEMPRA KIT | | | | | | |
| +! | R-PHARM US LLC | 15MG/VIAL | | N022065 | 001 | Oct 16, 2007 |
| +! | | 45MG/VIAL | | N022065 | 002 | Oct 16, 2007 |
| IXAZOMIB CITRATE | | | | | | |
| CAPSULE;ORAL | | | | | | |
| NINLARO | | | | | | |
| + | MILLENNIUM PHARMS | EQ 2.3MG BASE | | N208462 | 001 | Nov 20, 2015 |
| + | | EQ 3MG BASE | | N208462 | 002 | Nov 20, 2015 |
| +! | | EQ 4MG BASE | | N208462 | 003 | Nov 20, 2015 |
| KANAMYCIN SULFATE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| KANAMYCIN SULFATE | | | | | | |
| | FRESENIUS KABI USA | EQ 500MG BASE/2ML | | A065111 | 001 | Dec 17, 2002 |
| ! | | EQ 1GM BASE/3ML | | A065111 | 002 | Dec 17, 2002 |
| KETAMINE HYDROCHLORIDE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| **KETALAR** | | | | | | |
| **AP** **+!** | PAR STERILE PRODUCTS | **EQ 10MG BASE/ML** | | **N016812** | **001** | |
| **AP** **+!** | | **EQ 50MG BASE/ML** | | **N016812** | **002** | |
| **AP** **+!** | | **EQ 100MG BASE/ML** | | **N016812** | **003** | |
| **KETAMINE HYDROCHLORIDE** | | | | | | |
| **AP** | HOSPIRA | **EQ 50MG BASE/ML** | | **A074549** | **001** | Jun 27, 1996 |
| **AP** | | **EQ 100MG BASE/ML** | | **A074549** | **002** | Jun 27, 1996 |
| **AP** | MYLAN INSTITUTIONAL | **EQ 10MG BASE/ML** | | **A076092** | **001** | Sep 30, 2008 |
| **AP** | | **EQ 50MG BASE/ML** | | **A076092** | **002** | Dec 28, 2001 |
| **AP** | | **EQ 100MG BASE/ML** | | **A076092** | **003** | Oct 25, 2002 |
| **AP** | WEST-WARD PHARMS INT | **EQ 50MG BASE/ML** | | **A074524** | **001** | Mar 22, 1996 |
| **AP** | | **EQ 100MG BASE/ML** | | **A074524** | **002** | Mar 22, 1996 |

KETOCONAZOLE

AEROSOL, FOAM;TOPICAL

**EXTINA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **+!** | MYLAN PHARMS INC | **2%** | **N021738** | **001** | Jun 12, 2007 |

**KETOCONAZOLE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | PERRIGO ISRAEL | **2%** | **A091550** | **001** | Aug 25, 2011 |

CREAM;TOPICAL

**KETOCONAZOLE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | FOUGERA PHARMS | **2%** | **A076294** | **001** | Apr 28, 2004 |
| **AB** | **!** | TEVA | **2%** | **A075581** | **001** | Apr 25, 2000 |

**KETOZOLE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | TARO | **2%** | **A075638** | **001** | Dec 18, 2002 |

GEL;TOPICAL

XOLEGEL

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | AQUA PHARMS | 2% | N021946 | 001 | Jul 28, 2006 |

SHAMPOO;TOPICAL

**KETOCONAZOLE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | PERRIGO NEW YORK | **2%** | **A076419** | **001** | Jan 07, 2004 |
| **AB** | | TOLMAR | **2%** | **A076942** | **001** | Apr 11, 2005 |

**NIZORAL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | JANSSEN PHARMS | **2%** | **N019927** | **001** | Aug 31, 1990 |

TABLET;ORAL

**KETOCONAZOLE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | MYLAN | **200MG** | **A075597** | **001** | Dec 23, 1999 |
| **AB** | | TARO | **200MG** | **A075319** | **001** | Jun 15, 1999 |
| **AB** | **!** | TEVA | **200MG** | **A075273** | **001** | Jun 15, 1999 |

KETOPROFEN

CAPSULE;ORAL

**KETOPROFEN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | HERITAGE PHARMS INC | **50MG** | **A074014** | **002** | Jan 29, 1993 |
| **AB** | | | **75MG** | **A074014** | **003** | Jan 29, 1993 |
| **AB** | | MYLAN | **50MG** | **A074035** | **002** | Dec 31, 1996 |
| **AB** | | | **75MG** | **A074035** | **003** | Dec 31, 1996 |
| **AB** | | TEVA | **50MG** | **A073516** | **001** | Dec 22, 1992 |
| **AB** | **!** | | **75MG** | **A073517** | **001** | Dec 22, 1992 |
| | | HERITAGE PHARMS INC | 25MG | A074014 | 001 | Jan 29, 1993 |

CAPSULE, EXTENDED RELEASE;ORAL

**KETOPROFEN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS LABS FL INC | **100MG** | **A075270** | **002** | Mar 24, 1999 |
| **AB** | | | **150MG** | **A075270** | **003** | Mar 24, 1999 |
| **AB** | | | **200MG** | **A075270** | **001** | Mar 24, 1999 |
| **AB** | | MYLAN | **100MG** | **A075679** | **003** | Feb 20, 2002 |
| **AB** | | | **150MG** | **A075679** | **002** | Feb 20, 2002 |
| **AB** | **!** | | **200MG** | **A075679** | **001** | Feb 20, 2002 |

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION

**KETOROLAC TROMETHAMINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AMPHASTAR PHARM | **15MG/ML** | **A076209** | **001** | Jul 21, 2004 |
| **AP** | | | **30MG/ML** | **A076209** | **002** | Jul 21, 2004 |
| **AP** | | CYCLE PHARMS LTD | **30MG/ML** | **A209900** | **001** | Sep 15, 2017 |
| **AP** | | FRESENIUS KABI USA | **15MG/ML** | **A075784** | **001** | Jan 11, 2002 |
| **AP** | | | **15MG/ML** | **A203242** | **001** | Oct 07, 2015 |
| **AP** | | | **30MG/ML** | **A075784** | **002** | Jan 11, 2002 |
| **AP** | | | **30MG/ML** | **A203242** | **002** | Oct 07, 2015 |
| **AP** | | GLAND PHARMA LTD | **15MG/ML** | **A204216** | **001** | Nov 01, 2016 |
| **AP** | | | **30MG/ML** | **A204216** | **002** | Nov 01, 2016 |
| **AP** | **!** | HOSPIRA | **15MG/ML** | **A074802** | **001** | Jun 05, 1997 |
| **AP** | | | **15MG/ML** | **A074993** | **001** | Jan 27, 1999 |
| **AP** | **!** | | **30MG/ML** | **A074802** | **002** | Jun 05, 1997 |
| **AP** | | | **30MG/ML** | **A074993** | **002** | Jan 27, 1999 |
| **AP** | | SAGENT PHARMS | **15MG/ML** | **A091065** | **001** | Nov 27, 2013 |
| **AP** | | | **30MG/ML** | **A091065** | **002** | Nov 27, 2013 |
| **AP** | | SANDOZ INC | **30MG/ML** | **A076271** | **002** | Oct 06, 2004 |
| **AP** | | WOCKHARDT | **15MG/ML** | **A077942** | **001** | Mar 27, 2007 |
| **AP** | | | **30MG/ML** | **A077942** | **002** | Mar 27, 2007 |

SOLUTION/DROPS;OPHTHALMIC

**ACULAR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **+!** | ALLERGAN | **0.5%** | **N019700** | **001** | Nov 09, 1992 |

**ACULAR LS**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **+!** | ALLERGAN | **0.4%** | **N021528** | **001** | May 30, 2003 |

KETOROLAC TROMETHAMINE

SOLUTION/DROPS;OPHTHALMIC

**KETOROLAC TROMETHAMINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | AKORN | **0.4%** | **A078399** | **001** | Nov 05, 2009 |
| **AT** | | | **0.5%** | **A078434** | **001** | Nov 05, 2009 |
| **AT** | | ALCON PHARMS LTD | **0.4%** | **A078721** | **001** | Nov 05, 2009 |
| **AT** | | APOTEX INC | **0.4%** | **A077308** | **001** | Nov 05, 2009 |
| **AT** | | | **0.5%** | **A076109** | **001** | Nov 05, 2009 |
| **AT** | | SANDOZ INC | **0.5%** | **A076583** | **001** | Nov 05, 2009 |
| **AT** | | SUN PHARMA GLOBAL | **0.5%** | **A090017** | **001** | Nov 05, 2009 |

ACUVAIL

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ALLERGAN | 0.45% | N022427 | 001 | Jul 22, 2009 |

SPRAY, METERED;NASAL

SPRIX

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | EGALET US INC | 15.75MG/SPRAY | N022382 | 001 | May 14, 2010 |

TABLET;ORAL

**KETOROLAC TROMETHAMINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **!** | MYLAN | **10MG** | **A074761** | **001** | May 16, 1997 |
| **AB** | | PLIVA | **10MG** | **A075284** | **001** | Jun 23, 1999 |
| **AB** | | TEVA | **10MG** | **A074754** | **001** | May 16, 1997 |

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;IRRIGATION

OMIDRIA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | OMEROS | EQ 0.3% BASE;EQ 1% BASE | N205388 | 001 | May 30, 2014 |

L-GLUTAMINE

FOR SOLUTION;ORAL

ENDARI

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | EMMAUS MEDCL | 5GM/PACKET | N208587 | 001 | Jul 07, 2017 |

NUTRESTORE

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | EMMAUS MEDCL | 5GM/PACKET | N021667 | 001 | Jun 10, 2004 |

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION

**LABETALOL HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AKORN INC | **5MG/ML** | **A075431** | **001** | Nov 29, 1999 |
| **AP** | | | **5MG/ML** | **A075524** | **001** | Nov 29, 1999 |
| **AP** | | GLAND PHARMA LTD | **5MG/ML** | **A090699** | **001** | Apr 03, 2012 |
| **AP** | **!** | HOSPIRA | **5MG/ML** | **A075239** | **001** | Nov 29, 1999 |
| **AP** | **!** | | **5MG/ML** | **A075240** | **001** | Nov 29, 1999 |
| **AP** | | SAGENT AGILA LLC | **5MG/ML** | **A079134** | **001** | Feb 03, 2010 |
| **AP** | | WEST-WARD PHARMS INT | **5MG/ML** | **A075303** | **001** | May 28, 1999 |

TABLET;ORAL

**LABETALOL HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | INNOGENIX | **100MG** | **A075215** | **001** | Jul 29, 1999 |
| **AB** | | | **200MG** | **A075215** | **002** | Jul 29, 1999 |
| **AB** | | | **300MG** | **A075215** | **003** | Jul 29, 1999 |
| **AB** | | IVAX SUB TEVA PHARMS | **100MG** | **A074787** | **001** | Aug 03, 1998 |
| **AB** | | | **200MG** | **A074787** | **002** | Aug 03, 1998 |
| **AB** | | | **300MG** | **A074787** | **003** | Aug 03, 1998 |
| **AB** | | PAR FORM | **100MG** | **A200908** | **001** | Jul 10, 2012 |
| **AB** | | | **200MG** | **A200908** | **002** | Jul 10, 2012 |
| **AB** | | | **300MG** | **A200908** | **003** | Jul 10, 2012 |
| **AB** | | SANDOZ | **100MG** | **A075113** | **001** | Aug 04, 1998 |
| **AB** | **!** | | **200MG** | **A075113** | **002** | Aug 04, 1998 |
| **AB** | | | **300MG** | **A075113** | **003** | Aug 04, 1998 |
| **AB** | | WATSON LABS | **100MG** | **A075133** | **001** | Aug 03, 1998 |
| **AB** | | | **200MG** | **A075133** | **002** | Aug 03, 1998 |
| **AB** | | | **300MG** | **A075133** | **003** | Aug 03, 1998 |
| **AB** | | ZYDUS PHARMS USA INC | **100MG** | **A207743** | **001** | Sep 19, 2017 |
| **AB** | | | **200MG** | **A207743** | **002** | Sep 19, 2017 |
| **AB** | | | **300MG** | **A207743** | **003** | Sep 19, 2017 |

**TRANDATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | CNTY LINE PHARMS | **100MG** | **N018716** | **001** | May 24, 1985 |
| **AB** | | | **200MG** | **N018716** | **002** | Aug 01, 1984 |
| **AB** | | | **300MG** | **N018716** | **003** | Aug 01, 1984 |

| | | | | | | |
|---|---|---|---|---|---|---|
| LACOSAMIDE | | | | | | |
| SOLUTION;INTRAVENOUS | | | | | | |
| VIMPAT | | | | | | |
| +! | UCB INC | 200MG/20ML (10MG/ML) | N022254 | 001 | Oct 28, 2008 |
| SOLUTION;ORAL | | | | | | |
| VIMPAT | | | | | | |
| +! | UCB INC | 10MG/ML | N022255 | 001 | Apr 20, 2010 |
| TABLET;ORAL | | | | | | |
| VIMPAT | | | | | | |
| + | UCB INC | 50MG | N022253 | 001 | Oct 28, 2008 |
| + | | 100MG | N022253 | 002 | Oct 28, 2008 |
| + | | 150MG | N022253 | 003 | Oct 28, 2008 |
| +! | | 200MG | N022253 | 004 | Oct 28, 2008 |
| LACTULOSE | | | | | | |
| FOR SOLUTION;ORAL | | | | | | |
| LACTULOSE | | | | | | |
| ! | CUMBERLAND PHARMS | 10GM/PACKET | A074712 | 001 | Dec 10, 1997 |
| ! | | 20GM/PACKET | A074712 | 002 | Dec 10, 1997 |
| SOLUTION;ORAL | | | | | | |
| **CONSTILAC** | | | | | | |
| **AA** | ALRA | **10GM/15ML** | **A071054** | **001** | Jul 26, 1988 |
| **LACTULOSE** | | | | | | |
| **AA** | ANI PHARMS | **10GM/15ML** | **A078430** | **001** | Nov 28, 2007 |
| **AA** | FRESENIUS KABI | **10GM/15ML** | **A090503** | **001** | Jan 25, 2012 |
| **AA** ! | HI TECH PHARMA | **10GM/15ML** | **A074076** | **001** | Jul 03, 1995 |
| **AA** | PHARM ASSOC | **10GM/15ML** | **A074623** | **001** | Jul 30, 1996 |
| **AA** | VINTAGE PHARMS | **10GM/15ML** | **A075993** | **001** | Jul 26, 2001 |
| **AA** | VISTAPHARM | **10GM/15ML** | **A074138** | **001** | Sep 30, 1992 |
| **AA** | WEST-WARD PHARMS INT | **10GM/15ML** | **A073591** | **001** | May 29, 1992 |
| **AA** | WOCKHARDT BIO AG | **10GM/15ML** | **A074602** | **001** | Nov 14, 1996 |
| SOLUTION;ORAL, RECTAL | | | | | | |
| **CHOLAC** | | | | | | |
| **AA** | ALRA | **10GM/15ML** | **A071331** | **001** | Jul 26, 1988 |
| **ENULOSE** | | | | | | |
| **AA** ! | ACTAVIS MID ATLANTIC | **10GM/15ML** | **A071548** | **001** | Aug 15, 1988 |
| **GENERLAC** | | | | | | |
| **AA** | WOCKHARDT BIO AG | **10GM/15ML** | **A074603** | **001** | Oct 31, 1996 |
| **LACTULOSE** | | | | | | |
| **AA** | ANI PHARMS | **10GM/15ML** | **A090426** | **001** | Nov 21, 2008 |
| **AA** | BIO-PHARM INC | **10GM/15ML** | **A203762** | **001** | Mar 27, 2015 |
| **AA** | FRESENIUS KABI | **10GM/15ML** | **A090502** | **001** | Jan 25, 2012 |
| **AA** | HI TECH PHARMA | **10GM/15ML** | **A074077** | **001** | Jul 03, 1995 |
| LAMIVUDINE | | | | | | |
| SOLUTION;ORAL | | | | | | |
| **EPIVIR** | | | | | | |
| **AA** +! | VIIV HLTHCARE | **10MG/ML** | **N020596** | **001** | Nov 17, 1995 |
| **LAMIVUDINE** | | | | | | |
| **AA** | AUROBINDO PHARMA LTD | **10MG/ML** | **A077695** | **001** | Nov 21, 2016 |
| **AA** | SILARX PHARMS INC | **10MG/ML** | **A203564** | **001** | Oct 31, 2014 |
| EPIVIR-HBV | | | | | | |
| +! | GLAXOSMITHKLINE | 5MG/ML | N021004 | 001 | Dec 08, 1998 |
| TABLET;ORAL | | | | | | |
| **EPIVIR** | | | | | | |
| **AB** + | VIIV HLTHCARE | **150MG** | **N020564** | **001** | Nov 17, 1995 |
| **AB** +! | | **300MG** | **N020564** | **003** | Jun 24, 2002 |
| **EPIVIR-HBV** | | | | | | |
| **AB** +! | GLAXOSMITHKLINE | **100MG** | **N021003** | **001** | Dec 08, 1998 |
| **LAMIVUDINE** | | | | | | |
| **AB** | APOTEX | **150MG** | **A091606** | **001** | Dec 02, 2011 |
| **AB** | | **300MG** | **A091606** | **002** | Dec 02, 2011 |
| **AB** | APOTEX INC | **100MG** | **A202941** | **001** | Jan 02, 2014 |
| **AB** | APPCO PHARMA LLC | **150MG** | **A206974** | **001** | Nov 21, 2016 |
| **AB** | | **300MG** | **A206974** | **002** | Nov 21, 2016 |
| **AB** | AUROBINDO PHARMA LTD | **150MG** | **A077464** | **001** | Nov 21, 2016 |
| **AB** | | **150MG** | **A202032** | **001** | Nov 17, 2011 |
| **AB** | | **300MG** | **A077464** | **002** | Nov 21, 2016 |
| **AB** | | **300MG** | **A202032** | **002** | Nov 17, 2011 |
| **AB** | CIPLA LTD | **150MG** | **A077221** | **001** | Mar 03, 2017 |

LAMIVUDINE

TABLET;ORAL

**LAMIVUDINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **300MG** | **A077221** | **002** | Mar 03, 2017 |
| **AB** | | ECI PHARMS LLC | **150MG** | **A203586** | **001** | Nov 21, 2016 |
| **AB** | | HETERO LABS LTD V | **100MG** | **A203260** | **001** | Jan 02, 2014 |
| **AB** | | | **150MG** | **A203277** | **001** | Jan 06, 2014 |
| **AB** | | | **300MG** | **A203277** | **002** | Jan 06, 2014 |
| **AB** | | LUPIN LTD | **150MG** | **A205217** | **001** | Dec 18, 2014 |
| **AB** | | | **300MG** | **A205217** | **002** | Dec 18, 2014 |
| **AB** | | MYLAN PHARMS INC | **100MG** | **A204002** | **001** | Dec 31, 2014 |
| **AB** | | | **150MG** | **A204528** | **001** | Mar 04, 2016 |
| **AB** | | | **300MG** | **A204528** | **002** | Mar 04, 2016 |

LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

**COMBIVIR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | VIIV HLTHCARE | **150MG;300MG** | **N020857** | **001** | Sep 26, 1997 |

**LAMIVUDINE AND ZIDOVUDINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AUROBINDO PHARMA LTD | **150MG;300MG** | **A077558** | **001** | May 05, 2017 |
| **AB** | | | **150MG;300MG** | **A202418** | **001** | May 15, 2012 |
| **AB** | | HETERO LABS LTD III | **150MG;300MG** | **A079124** | **001** | Sep 17, 2015 |
| **AB** | | HETERO LABS LTD V | **150MG;300MG** | **A203259** | **001** | Feb 03, 2014 |
| **AB** | | LUPIN LTD | **150MG;300MG** | **A090246** | **001** | May 15, 2012 |
| **AB** | | MYLAN PHARMS INC | **150MG;300MG** | **A204005** | **001** | Aug 28, 2014 |
| **AB** | | STRIDES PHARMA | **150MG;300MG** | **A079128** | **001** | May 13, 2015 |
| **AB** | | TEVA PHARMS | **150MG;300MG** | **A079081** | **001** | May 25, 2011 |
| BX | | PHARMACARE | 150MG;300MG | N022018 | 001 | Mar 17, 2017 |

LAMOTRIGINE

TABLET;ORAL

**LAMICTAL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | GLAXOSMITHKLINE LLC | **25MG** | **N020241** | **005** | Dec 27, 1994 |
| **AB** | **+** | | **100MG** | **N020241** | **001** | Dec 27, 1994 |
| **AB** | **+** | | **150MG** | **N020241** | **002** | Dec 27, 1994 |
| **AB** | **+** | | **200MG** | **N020241** | **003** | Dec 27, 1994 |

**LAMOTRIGINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALEMBIC PHARMS LTD | **25MG** | **A090607** | **001** | Jan 13, 2011 |
| **AB** | | | **100MG** | **A090607** | **002** | Jan 13, 2011 |
| **AB** | | | **150MG** | **A090607** | **003** | Jan 13, 2011 |
| **AB** | | | **200MG** | **A090607** | **004** | Jan 13, 2011 |
| **AB** | | ALKEM LABS LTD | **25MG** | **A200694** | **001** | Jun 14, 2013 |
| **AB** | | | **100MG** | **A200694** | **002** | Jun 14, 2013 |
| **AB** | | | **150MG** | **A200694** | **003** | Jun 14, 2013 |
| **AB** | | | **200MG** | **A200694** | **004** | Jun 14, 2013 |
| **AB** | | APOTEX INC | **25MG** | **A078625** | **001** | Jan 27, 2009 |
| **AB** | | | **100MG** | **A078625** | **002** | Jan 27, 2009 |
| **AB** | | | **150MG** | **A078625** | **003** | Jan 27, 2009 |
| **AB** | | | **200MG** | **A078625** | **004** | Jan 27, 2009 |
| **AB** | | AUROBINDO PHARMA | **25MG** | **A078956** | **001** | Jan 27, 2009 |
| **AB** | | | **100MG** | **A078956** | **002** | Jan 27, 2009 |
| **AB** | | | **150MG** | **A078956** | **003** | Jan 27, 2009 |
| **AB** | | | **200MG** | **A078956** | **004** | Jan 27, 2009 |
| **AB** | | CIPLA LTD | **25MG** | **A077783** | **001** | Nov 01, 2010 |
| **AB** | | | **100MG** | **A077783** | **002** | Nov 01, 2010 |
| **AB** | | | **150MG** | **A077783** | **003** | Nov 01, 2010 |
| **AB** | | | **200MG** | **A077783** | **004** | Nov 01, 2010 |
| **AB** | | DR REDDYS LABS LTD | **25MG** | **A076708** | **001** | Jan 27, 2009 |
| **AB** | | | **100MG** | **A076708** | **002** | Jan 27, 2009 |
| **AB** | | | **150MG** | **A076708** | **003** | Jan 27, 2009 |
| **AB** | | | **200MG** | **A076708** | **004** | Jan 27, 2009 |
| **AB** | | GLENMARK GENERICS | **25MG** | **A090169** | **001** | May 12, 2012 |
| **AB** | | | **100MG** | **A090169** | **002** | May 12, 2012 |
| **AB** | | | **150MG** | **A090169** | **003** | May 12, 2012 |
| **AB** | | | **200MG** | **A090169** | **004** | May 12, 2012 |
| **AB** | | JUBILANT CADISTA | **25MG** | **A079132** | **001** | Jan 27, 2009 |
| **AB** | | | **100MG** | **A079132** | **002** | Jan 27, 2009 |
| **AB** | | | **150MG** | **A079132** | **003** | Jan 27, 2009 |
| **AB** | | | **200MG** | **A079132** | **004** | Jan 27, 2009 |
| **AB** | | LUPIN LTD | **25MG** | **A078691** | **001** | Jun 01, 2010 |
| **AB** | | | **100MG** | **A078691** | **002** | Jun 01, 2010 |
| **AB** | | | **150MG** | **A078691** | **003** | Jun 01, 2010 |
| **AB** | | | **200MG** | **A078691** | **004** | Jun 01, 2010 |

LAMOTRIGINE

TABLET;ORAL

**LAMOTRIGINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | MYLAN | **25MG** | **A077420** | **001** | Jan 27, 2009 |
| **AB** | | | **100MG** | **A077420** | **002** | Jan 27, 2009 |
| **AB** | | | **150MG** | **A077420** | **003** | Jan 27, 2009 |
| **AB** | | | **200MG** | **A077420** | **004** | Jan 27, 2009 |
| **AB** | | TARO PHARM INDS | **25MG** | **A078525** | **001** | Jan 27, 2009 |
| **AB** | | | **100MG** | **A078525** | **002** | Jan 27, 2009 |
| **AB** | | | **150MG** | **A078525** | **003** | Jan 27, 2009 |
| **AB** | | | **200MG** | **A078525** | **004** | Jan 27, 2009 |
| **AB** | | TEVA | **25MG** | **A076388** | **001** | Aug 30, 2006 |
| **AB** | | | **100MG** | **A076388** | **002** | Aug 30, 2006 |
| **AB** | | | **150MG** | **A076388** | **003** | Aug 30, 2006 |
| **AB** | | | **200MG** | **A076388** | **004** | Aug 30, 2006 |
| **AB** | | TORRENT PHARMS | **25MG** | **A078947** | **001** | Jan 27, 2009 |
| **AB** | | | **100MG** | **A078947** | **002** | Jan 27, 2009 |
| **AB** | | | **150MG** | **A078947** | **003** | Jan 27, 2009 |
| **AB** | | | **200MG** | **A078947** | **004** | Jan 27, 2009 |
| **AB** | | UNICHEM LABS LTD | **25MG** | **A090170** | **001** | Oct 06, 2011 |
| **AB** | | | **100MG** | **A090170** | **002** | Oct 06, 2011 |
| **AB** | | | **150MG** | **A090170** | **003** | Oct 06, 2011 |
| **AB** | | | **200MG** | **A090170** | **004** | Oct 06, 2011 |
| **AB** | | ZYDUS PHARMS USA | **25MG** | **A077633** | **001** | Jan 27, 2009 |
| **AB** | | | **100MG** | **A077633** | **003** | Jan 27, 2009 |
| **AB** | | | **150MG** | **A077633** | **004** | Jan 27, 2009 |
| **AB** | | | **200MG** | **A077633** | **005** | Jan 27, 2009 |
| | | | 50MG | A077633 | 002 | Jan 27, 2009 |
| | | | 250MG | A077633 | 006 | Jan 27, 2009 |

TABLET, CHEWABLE;ORAL

**LAMICTAL CD**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | GLAXOSMITHKLINE LLC | **2MG** | **N020764** | **004** | Sep 08, 2000 |
| **AB** | **+** | | **5MG** | **N020764** | **001** | Aug 24, 1998 |
| **AB** | **+!** | | **25MG** | **N020764** | **002** | Aug 24, 1998 |

**LAMOTRIGINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALEMBIC PHARMS LTD | **5MG** | **A201168** | **001** | Jun 12, 2014 |
| **AB** | | | **25MG** | **A201168** | **002** | Jun 12, 2014 |
| **AB** | | AUROBINDO PHARMA | **5MG** | **A090401** | **002** | Nov 04, 2009 |
| **AB** | | | **25MG** | **A090401** | **003** | Nov 04, 2009 |
| **AB** | | DR REDDYS LABS LTD | **5MG** | **A076701** | **001** | Jan 22, 2009 |
| **AB** | | | **25MG** | **A076701** | **002** | Jan 22, 2009 |
| **AB** | | GLENMARK PHARMS LTD | **5MG** | **A079099** | **001** | Feb 19, 2009 |
| **AB** | | | **25MG** | **A079099** | **002** | Feb 19, 2009 |
| **AB** | | JUBILANT GENERICS | **5MG** | **A200220** | **001** | Feb 28, 2011 |
| **AB** | | | **25MG** | **A200220** | **002** | Feb 28, 2011 |
| **AB** | | TARO | **5MG** | **A079204** | **001** | Feb 04, 2009 |
| **AB** | | | **25MG** | **A079204** | **002** | Feb 04, 2009 |
| **AB** | | TEVA | **5MG** | **A076420** | **001** | Jun 21, 2006 |
| **AB** | | | **25MG** | **A076420** | **002** | Jun 21, 2006 |
| **AB** | | WATSON LABS | **2MG** | **A076928** | **001** | Jan 22, 2009 |
| **AB** | | | **5MG** | **A076928** | **002** | Jan 22, 2009 |
| **AB** | | | **25MG** | **A076928** | **003** | Jan 22, 2009 |
| **AB** | | ZYDUS PHARMS USA INC | **5MG** | **A078009** | **002** | Jan 22, 2009 |
| **AB** | | | **25MG** | **A078009** | **003** | Jan 22, 2009 |

TABLET, EXTENDED RELEASE;ORAL

**LAMICTAL XR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | GLAXOSMITHKLINE LLC | **25MG** | **N022115** | **001** | May 29, 2009 |
| **AB** | **+!** | | **50MG** | **N022115** | **002** | May 29, 2009 |
| **AB** | **+** | | **100MG** | **N022115** | **003** | May 29, 2009 |
| **AB** | **+!** | | **200MG** | **N022115** | **004** | May 29, 2009 |
| **AB** | **+** | | **250MG** | **N022115** | **006** | Jun 21, 2011 |
| **AB** | **+** | | **300MG** | **N022115** | **005** | Apr 14, 2010 |

**LAMOTRIGINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS ELIZABETH | **100MG** | **A200672** | **003** | Oct 17, 2013 |
| **AB** | | | **200MG** | **A200672** | **004** | Oct 17, 2013 |
| **AB** | | | **25MG** | **A200672** | **001** | Oct 17, 2013 |
| **AB** | | | **50MG** | **A200672** | **002** | Oct 17, 2013 |
| **AB** | | | **250MG** | **A203733** | **001** | Nov 13, 2013 |
| **AB** | | | **300MG** | **A200672** | **005** | Oct 17, 2013 |
| **AB** | | ANCHEN PHARMS | **25MG** | **A201374** | **001** | Dec 26, 2012 |
| **AB** | | | **50MG** | **A201374** | **002** | Dec 26, 2012 |
| **AB** | | | **100MG** | **A201374** | **003** | Dec 26, 2012 |

LAMOTRIGINE

TABLET, EXTENDED RELEASE;ORAL

**LAMOTRIGINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **200MG** | **A201374** | **004** | Dec 26, 2012 |
| **AB** | | | **250MG** | **A201374** | **005** | Dec 26, 2012 |
| **AB** | | | **300MG** | **A201374** | **006** | Dec 26, 2012 |
| **AB** | | DR REDDYS LABS LTD | **25MG** | **A202383** | **001** | Jun 19, 2013 |
| **AB** | | | **50MG** | **A202383** | **002** | Jun 19, 2013 |
| **AB** | | | **100MG** | **A202383** | **003** | Jun 19, 2013 |
| **AB** | | | **200MG** | **A202383** | **004** | Jun 19, 2013 |
| **AB** | | | **300MG** | **A202383** | **005** | Jun 19, 2013 |
| **AB** | | HANDA PHARMS LLC | **25MG** | **A202887** | **001** | Jun 17, 2013 |
| **AB** | | | **50MG** | **A202887** | **002** | Jun 17, 2013 |
| **AB** | | | **100MG** | **A202887** | **003** | Jun 17, 2013 |
| **AB** | | | **200MG** | **A202887** | **004** | Jun 17, 2013 |
| **AB** | | PAR PHARM | **25MG** | **A201791** | **001** | Jan 18, 2013 |
| **AB** | | | **50MG** | **A201791** | **002** | Jan 18, 2013 |
| **AB** | | | **100MG** | **A201791** | **003** | Jan 18, 2013 |
| **AB** | | | **200MG** | **A201791** | **004** | Jan 18, 2013 |
| **AB** | | | **250MG** | **A201791** | **005** | Jan 18, 2013 |
| **AB** | | | **300MG** | **A201791** | **006** | Jan 18, 2013 |
| **AB** | | TORRENT PHARMS LTD | **25MG** | **A203370** | **001** | Dec 23, 2013 |
| **AB** | | | **50MG** | **A203370** | **002** | Dec 23, 2013 |
| **AB** | | | **100MG** | **A203370** | **003** | Dec 23, 2013 |
| **AB** | | | **200MG** | **A203370** | **004** | Dec 23, 2013 |
| **AB** | | WOCKHARDT LTD | **25MG** | **A202498** | **001** | Jan 04, 2013 |
| **AB** | | | **50MG** | **A202498** | **002** | Jan 04, 2013 |
| **AB** | | | **100MG** | **A202498** | **003** | Jan 04, 2013 |
| **AB** | | | **200MG** | **A202498** | **004** | Jan 04, 2013 |
| **AB** | | | **300MG** | **A202498** | **005** | Jan 04, 2013 |

TABLET, ORALLY DISINTEGRATING;ORAL

**LAMICTAL ODT**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | GLAXOSMITHKLINE LLC | **25MG** | **N022251** | **001** | May 08, 2009 |
| **AB** | **+!** | | **50MG** | **N022251** | **002** | May 08, 2009 |
| **AB** | **+** | | **100MG** | **N022251** | **003** | May 08, 2009 |
| **AB** | **+** | | **200MG** | **N022251** | **004** | May 08, 2009 |

**LAMOTRIGINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | IMPAX LABS INC | **25MG** | **A200828** | **001** | Jul 15, 2013 |
| **AB** | | | **50MG** | **A200828** | **002** | Jul 15, 2013 |
| **AB** | | | **100MG** | **A200828** | **003** | Jul 15, 2013 |
| **AB** | | | **200MG** | **A200828** | **004** | Jul 15, 2013 |
| **AB** | | PAR PHARM | **25MG** | **A204158** | **001** | Oct 27, 2015 |
| **AB** | | | **50MG** | **A204158** | **002** | Oct 27, 2015 |
| **AB** | | | **100MG** | **A204158** | **003** | Oct 27, 2015 |
| **AB** | | | **200MG** | **A204158** | **004** | Oct 27, 2015 |
| **AB** | | SCIEGEN PHARMS INC | **25MG** | **A206382** | **001** | Jun 17, 2016 |
| **AB** | | | **50MG** | **A206382** | **002** | Jun 17, 2016 |
| **AB** | | | **100MG** | **A206382** | **003** | Jun 17, 2016 |
| **AB** | | | **200MG** | **A206382** | **004** | Jun 17, 2016 |

LANREOTIDE ACETATE

SOLUTION;SUBCUTANEOUS

SOMATULINE DEPOT

| | | | | | |
|---|---|---|---|---|---|
| +! | IPSEN PHARMA | EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML) | N022074 | 001 | Aug 30, 2007 |
| +! | | EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML) | N022074 | 002 | Aug 30, 2007 |
| +! | | EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML) | N022074 | 003 | Aug 30, 2007 |

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

**LANSOPRAZOLE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AJANTA PHARMA LTD | **15MG** | **A203957** | **001** | Oct 14, 2016 |
| **AB** | | | **30MG** | **A203957** | **002** | Oct 14, 2016 |
| **AB** | | DR REDDYS LABS LTD | **15MG** | **A091269** | **001** | Oct 15, 2010 |
| **AB** | | | **30MG** | **A091269** | **002** | Oct 15, 2010 |
| **AB** | | INVENTIA HLTHCARE | **15MG** | **A205868** | **001** | Aug 30, 2017 |
| **AB** | | | **30MG** | **A205868** | **002** | Aug 30, 2017 |
| **AB** | | KREMERS URBAN PHARMS | **15MG** | **A207156** | **001** | Sep 28, 2017 |
| **AB** | | | **30MG** | **A207156** | **002** | Sep 28, 2017 |
| **AB** | | LABS LICONSA | **15MG** | **A203203** | **001** | Jul 25, 2016 |
| **AB** | | | **30MG** | **A203203** | **002** | Jul 25, 2016 |
| **AB** | | MYLAN PHARMS INC | **15MG** | **A090763** | **001** | Nov 10, 2009 |
| **AB** | | | **30MG** | **A090763** | **002** | Nov 10, 2009 |

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **LANSOPRAZOLE** | | | | | | |
| **AB** | | NATCO PHARMA LTD | **15MG** | **A201921** | **001** | Dec 18, 2012 |
| **AB** | | | **30MG** | **A201921** | **002** | Dec 18, 2012 |
| **AB** | | SANDOZ | **15MG** | **A090331** | **001** | Apr 23, 2010 |
| **AB** | | | **30MG** | **A090331** | **002** | Apr 23, 2010 |
| **AB** | | SUN PHARM INDS LTD | **15MG** | **A202637** | **001** | Sep 13, 2013 |
| **AB** | | | **30MG** | **A091509** | **001** | Sep 13, 2013 |
| **AB** | | TEVA PHARMS | **15MG** | **A077255** | **001** | Nov 10, 2009 |
| **AB** | | | **30MG** | **A077255** | **002** | Nov 10, 2009 |
| **AB** | | WOCKHARDT USA | **15MG** | **A202176** | **001** | Sep 14, 2012 |
| **AB** | | | **30MG** | **A202176** | **002** | Sep 14, 2012 |
| **AB** | | ZYDUS HLTHCARE | **15MG** | **A202366** | **001** | Aug 19, 2013 |
| **AB** | | | **30MG** | **A202366** | **002** | Aug 19, 2013 |
| **LANSOPRAZOLE** | | | | | | |
| **AB** | | KRKA TOVARNA ZDRAVIL | **15MG** | **A091212** | **001** | Sep 16, 2013 |
| **AB** | | | **30MG** | **A091212** | **002** | Sep 16, 2013 |
| **PREVACID** | | | | | | |
| **AB** | **+** | TAKEDA PHARMS USA | **15MG** | **N020406** | **001** | May 10, 1995 |
| **AB** | **+!** | | **30MG** | **N020406** | **002** | May 10, 1995 |

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **LANSOPRAZOLE** | | | | | | |
| **AB** | | TEVA PHARMS USA | **15MG** | **A208784** | **001** | Sep 21, 2017 |
| **AB** | | | **30MG** | **A208784** | **002** | Sep 21, 2017 |
| **PREVACID** | | | | | | |
| **AB** | **+** | TAKEDA PHARMS USA | **15MG** | **N021428** | **001** | Aug 30, 2002 |
| **AB** | **+!** | | **30MG** | **N021428** | **002** | Aug 30, 2002 |

LANTHANUM CARBONATE

POWDER;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| FOSRENOL | | | | | | |
| | + | SHIRE DEV LLC | EQ 750MG BASE | N204734 | 001 | Sep 24, 2014 |
| | +! | | EQ 1GM BASE | N204734 | 002 | Sep 24, 2014 |

TABLET, CHEWABLE;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **FOSRENOL** | | | | | | |
| **AB** | **+** | SHIRE LLC | **EQ 500MG BASE** | **N021468** | **002** | Oct 26, 2004 |
| **AB** | **+** | | **EQ 750MG BASE** | **N021468** | **003** | Nov 23, 2005 |
| **AB** | **+!** | | **EQ 1GM BASE** | **N021468** | **004** | Nov 23, 2005 |
| **LANTHANUM CARBONATE** | | | | | | |
| **AB** | | NATCO PHARMA LTD | **EQ 500MG BASE** | **A090978** | **001** | Aug 11, 2017 |
| **AB** | | | **EQ 750MG BASE** | **A090978** | **002** | Aug 11, 2017 |
| **AB** | | | **EQ 1GM BASE** | **A090978** | **003** | Aug 11, 2017 |

LAPATINIB DITOSYLATE

TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| TYKERB | | | | | | |
| | +! | NOVARTIS PHARMS CORP | EQ 250MG BASE | N022059 | 001 | Mar 13, 2007 |

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC

| | | | | | | |
|---|---|---|---|---|---|---|
| **LATANOPROST** | | | | | | |
| **AT** | | AKORN | **0.005%** | **A090887** | **001** | Jul 19, 2011 |
| **AT** | | AMRING PHARMS | **0.005%** | **A200925** | **001** | Mar 22, 2011 |
| **AT** | | BAUSCH AND LOMB | **0.005%** | **A201006** | **001** | Mar 22, 2011 |
| **AT** | | DR REDDYS LABS LTD | **0.005%** | **A202077** | **001** | Feb 11, 2013 |
| **AT** | | FDC LTD | **0.005%** | **A202442** | **001** | Apr 22, 2016 |
| **AT** | | MYLAN | **0.005%** | **A201786** | **001** | Mar 22, 2011 |
| **AT** | | SANDOZ INC | **0.005%** | **A091449** | **001** | Mar 22, 2011 |
| **XALATAN** | | | | | | |
| **AT** | **+!** | PHARMACIA AND UPJOHN | **0.005%** | **N020597** | **001** | Jun 05, 1996 |

LATANOPROSTENE BUNOD

SOLUTION/DROPS;OPHTHALMIC

| | | | | | | |
|---|---|---|---|---|---|---|
| VYZULTA | | | | | | |
| | +! | BAUSCH AND LOMB | 0.024% | N207795 | 001 | Nov 02, 2017 |

| | | | | | | |
|---|---|---|---|---|---|---|
| LEDIPASVIR; SOFOSBUVIR | | | | | | |
| TABLET;ORAL | | | | | | |
| HARVONI | | | | | | |
| | +! | GILEAD SCIENCES INC | 90MG;400MG | N205834 | 001 | Oct 10, 2014 |
| LEFLUNOMIDE | | | | | | |
| TABLET;ORAL | | | | | | |
| **ARAVA** | | | | | | |
| **AB** | **+** | SANOFI AVENTIS US | **10MG** | **N020905** | **001** | Sep 10, 1998 |
| **AB** | **+!** | | **20MG** | **N020905** | **002** | Sep 10, 1998 |
| **LEFLUNOMIDE** | | | | | | |
| **AB** | | ALEMBIC PHARMS LTD | **10MG** | **A091369** | **001** | Nov 21, 2011 |
| **AB** | | | **20MG** | **A091369** | **002** | Nov 21, 2011 |
| **AB** | | APOTEX INC | **10MG** | **A077090** | **001** | Sep 13, 2005 |
| **AB** | | | **20MG** | **A077090** | **002** | Sep 13, 2005 |
| **AB** | | BARR | **10MG** | **A077083** | **001** | Sep 13, 2005 |
| **AB** | | | **20MG** | **A077083** | **002** | Sep 13, 2005 |
| **AB** | | HERITAGE PHARMS INC | **10MG** | **A077086** | **001** | Sep 13, 2005 |
| **AB** | | | **20MG** | **A077086** | **002** | Sep 13, 2005 |
| **AB** | | TEVA PHARMS | **10MG** | **A077084** | **001** | Sep 13, 2005 |
| **AB** | | | **20MG** | **A077084** | **002** | Sep 13, 2005 |
| ARAVA | | | | | | |
| | +! | SANOFI AVENTIS US | 100MG | N020905 | 003 | Sep 10, 1998 |
| LENALIDOMIDE | | | | | | |
| CAPSULE;ORAL | | | | | | |
| REVLIMID | | | | | | |
| | + | CELGENE | 2.5MG | N021880 | 005 | Dec 21, 2011 |
| | + | | 5MG | N021880 | 001 | Dec 27, 2005 |
| | + | | 10MG | N021880 | 002 | Dec 27, 2005 |
| | + | | 15MG | N021880 | 003 | Jun 29, 2006 |
| | + | | 20MG | N021880 | 006 | Jun 05, 2013 |
| | +! | | 25MG | N021880 | 004 | Jun 29, 2006 |
| LENVATINIB MESYLATE | | | | | | |
| CAPSULE;ORAL | | | | | | |
| LENVIMA | | | | | | |
| | + | EISAI INC | EQ 4MG BASE | N206947 | 001 | Feb 13, 2015 |
| | +! | | EQ 10MG BASE | N206947 | 002 | Feb 13, 2015 |
| LESINURAD | | | | | | |
| TABLET;ORAL | | | | | | |
| ZURAMPIC | | | | | | |
| | +! | IRONWOOD PHARMS INC | 200MG | N207988 | 001 | Dec 22, 2015 |
| LETERMOVIR | | | | | | |
| SOLUTION;IV (INFUSION) | | | | | | |
| PREVYMIS | | | | | | |
| | +! | MERCK SHARP DOHME | 240MG/12ML (20MG/ML) | N209940 | 001 | Nov 08, 2017 |
| | +! | | 480MG/24ML (20MG/ML) | N209940 | 002 | Nov 08, 2017 |
| TABLET;ORAL | | | | | | |
| PREVYMIS | | | | | | |
| | + | MERCK SHARP DOHME | 240MG | N209939 | 001 | Nov 08, 2017 |
| | +! | | 480MG | N209939 | 002 | Nov 08, 2017 |
| LETROZOLE | | | | | | |
| TABLET;ORAL | | | | | | |
| **FEMARA** | | | | | | |
| **AB** | **+!** | NOVARTIS PHARMS | **2.5MG** | **N020726** | **001** | Jul 25, 1997 |
| **LETROZOLE** | | | | | | |
| **AB** | | ACCORD HLTHCARE | **2.5MG** | **A090934** | **001** | Jun 03, 2011 |
| **AB** | | APOTEX INC | **2.5MG** | **A091303** | **001** | Apr 19, 2012 |
| **AB** | | DR REDDYS LABS LTD | **2.5MG** | **A091191** | **001** | Jun 03, 2011 |
| **AB** | | FRESENIUS KABI ONCOL | **2.5MG** | **A090491** | **001** | Jun 03, 2011 |
| **AB** | | HIKMA PHARMS | **2.5MG** | **A203796** | **001** | Jun 03, 2016 |
| **AB** | | INDICUS PHARMA | **2.5MG** | **A201804** | **001** | Jun 03, 2011 |
| **AB** | | JIANGSU HENGRUI MED | **2.5MG** | **A202716** | **001** | May 16, 2013 |
| **AB** | | MYLAN | **2.5MG** | **A078190** | **001** | Dec 24, 2008 |
| **AB** | | NATCO PHARMA LTD | **2.5MG** | **A200161** | **001** | Jun 03, 2011 |
| **AB** | | TEVA PHARMS | **2.5MG** | **A090289** | **001** | Jun 03, 2011 |
| **AB** | | VINTAGE PHARMS LLC | **2.5MG** | **A090789** | **001** | Jun 03, 2011 |
| **AB** | | WEST-WARD PHARMS INT | **2.5MG** | **A090838** | **001** | Jun 03, 2011 |

| | | | | | | |
|---|---|---|---|---|---|---|
| LETROZOLE; RIBOCICLIB SUCCINATE | | | | | | |
| TABLET, TABLET;ORAL | | | | | | |
| KISQALI FEMARA CO-PACK (COPACKAGED) | | | | | | |
| +! | NOVARTIS PHARMS CORP | 2.5MG,N/A;N/A,EQ 200MG BASE | N209935 | 001 | May 04, 2017 |
| LEUCOVORIN CALCIUM | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| **LEUCOVORIN CALCIUM** | | | | | | |
| **AP** | TEVA PHARMS USA | **EQ 100MG BASE/VIAL** | **A081277** | **001** | Sep 28, 1993 |
| **AP** | | **EQ 350MG BASE/VIAL** | **A040174** | **001** | Jun 12, 1997 |
| **AP** ! | WEST-WARD PHARMS INT | **EQ 50MG BASE/VIAL** | **A089384** | **001** | Sep 14, 1987 |
| **AP** ! | | **EQ 100MG BASE/VIAL** | **A089717** | **001** | Mar 28, 1988 |
| **LEUCOVORIN CALCIUM PRESERVATIVE FREE** | | | | | | |
| **AP** | FRESENIUS KABI USA | **EQ 200MG BASE/VIAL** | **A040258** | **001** | Feb 26, 1999 |
| **AP** ! | | **EQ 500MG BASE/VIAL** | **A040286** | **001** | Feb 26, 1999 |
| **AP** | MYLAN LABS LTD | **EQ 100MG BASE/VIAL** | **A203800** | **001** | May 19, 2017 |
| **AP** | | **EQ 200MG BASE/VIAL** | **A203800** | **002** | May 19, 2017 |
| **AP** | | **EQ 350MG BASE/VIAL** | **A203800** | **003** | May 19, 2017 |
| **AP** | SAGENT PHARMS | **EQ 50MG BASE/VIAL** | **A200753** | **001** | Sep 06, 2012 |
| **AP** | | **EQ 100MG BASE/VIAL** | **A200753** | **002** | Sep 06, 2012 |
| **AP** | | **EQ 200MG BASE/VIAL** | **A200753** | **003** | Sep 06, 2012 |
| **AP** | | **EQ 350MG BASE/VIAL** | **A200855** | **001** | Sep 06, 2012 |
| **AP** | | **EQ 500MG BASE/VIAL** | **A209110** | **001** | Oct 26, 2017 |
| **AP** ! | WEST-WARD PHARMS INT | **EQ 200MG BASE/VIAL** | **A040056** | **001** | May 23, 1995 |
| **AP** ! | | **EQ 350MG BASE/VIAL** | **A040335** | **001** | Apr 20, 2000 |
| ! | | EQ 10MG BASE/ML | A040347 | 001 | Apr 25, 2000 |
| TABLET;ORAL | | | | | | |
| **LEUCOVORIN CALCIUM** | | | | | | |
| **AB** | BARR | **EQ 5MG BASE** | **A071198** | **001** | Sep 24, 1987 |
| **AB** | | **EQ 25MG BASE** | **A071199** | **001** | Sep 24, 1987 |
| **AB** | WEST-WARD PHARMS INT | **EQ 5MG BASE** | **A072733** | **001** | Feb 22, 1993 |
| **AB** ! | | **EQ 25MG BASE** | **A072736** | **001** | Feb 22, 1993 |
| | | EQ 10MG BASE | A072734 | 001 | Feb 22, 1993 |
| | | EQ 15MG BASE | A072735 | 001 | Feb 22, 1993 |
| LEUPROLIDE ACETATE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| **LEUPROLIDE ACETATE** | | | | | | |
| **AP** ! | SANDOZ | **1MG/0.2ML** | **A074728** | **001** | Aug 04, 1998 |
| **AP** | SUN PHARMA GLOBAL | **1MG/0.2ML** | **A078885** | **001** | Mar 09, 2009 |
| **AP** | TEVA PHARMS USA | **1MG/0.2ML** | **A075471** | **001** | Oct 25, 2000 |
| LUPRON DEPOT | | | | | | |
| +! | ABBVIE ENDOCRINE INC | 3.75MG | N020011 | 002 | Oct 26, 1995 |
| +! | | 7.5MG/VIAL | N019732 | 001 | Jan 26, 1989 |
| +! | | 11.25MG/VIAL | N020708 | 001 | Mar 07, 1997 |
| +! | | 22.5MG/VIAL | N020517 | 001 | Dec 22, 1995 |
| +! | | 30MG/VIAL | N020517 | 002 | May 30, 1997 |
| + | | 45MG/VIAL | N020517 | 003 | Jun 17, 2011 |
| LUPRON DEPOT-PED | | | | | | |
| +! | ABBVIE ENDOCRINE INC | 7.5MG/VIAL | N020263 | 002 | Apr 16, 1993 |
| +! | | 11.25MG/VIAL | N020263 | 005 | Jan 21, 1994 |
| +! | | 11.25MG/VIAL | N020263 | 007 | Aug 15, 2011 |
| +! | | 15MG/VIAL | N020263 | 006 | Jan 21, 1994 |
| +! | | 30MG/VIAL | N020263 | 008 | Aug 15, 2011 |
| INJECTABLE;SUBCUTANEOUS | | | | | | |
| ELIGARD | | | | | | |
| +! | TOLMAR THERAP | 7.5MG/VIAL | N021343 | 001 | Jan 23, 2002 |
| +! | | 22.5MG/VIAL | N021379 | 001 | Jul 24, 2002 |
| +! | | 30MG/VIAL | N021488 | 001 | Feb 13, 2003 |
| +! | | 45MG/VIAL | N021731 | 001 | Dec 14, 2004 |
| LEUPROLIDE ACETATE; NORETHINDRONE ACETATE | | | | | | |
| INJECTABLE, TABLET;INTRAMUSCULAR, ORAL | | | | | | |
| LUPANETA PACK | | | | | | |
| + | ABBVIE ENDOCRINE | 3.75MG/VIAL,N/A;N/A,5MG | N203696 | 001 | Dec 14, 2012 |
| +! | | 11.25MG/VIAL,N/A;N/A,5MG | N203696 | 002 | Dec 14, 2012 |

LEVALBUTEROL HYDROCHLORIDE

SOLUTION;INHALATION

**LEVALBUTEROL HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AN** | | AUROBINDO PHARMA LTD | **EQ 0.25% BASE** | **A207628** | **001** | Jan 31, 2017 |
| **AN** | | | **EQ 0.0103% BASE** | **A207625** | **001** | Dec 30, 2016 |
| **AN** | | | **EQ 0.021% BASE** | **A207625** | **002** | Dec 30, 2016 |
| **AN** | | | **EQ 0.042% BASE** | **A207625** | **003** | Dec 30, 2016 |
| **AN** | | CIPLA LTD | **EQ 0.021% BASE** | **A078171** | **002** | Dec 13, 2013 |
| **AN** | | | **EQ 0.042% BASE** | **A078171** | **003** | Dec 13, 2013 |
| **AN** | | | **EQ 0.0103% BASE** | **A078171** | **001** | Dec 13, 2013 |
| **AN** | | IMPAX LABS INC | **EQ 0.0103% BASE** | **A077756** | **003** | Apr 09, 2008 |
| **AN** | | | **EQ 0.021% BASE** | **A077756** | **001** | Apr 09, 2008 |
| **AN** | | | **EQ 0.042% BASE** | **A077756** | **002** | Apr 09, 2008 |
| **AN** | | MYLAN SPECIALITY LP | **EQ 0.0103% BASE** | **A077800** | **001** | Mar 15, 2013 |
| **AN** | | | **EQ 0.021% BASE** | **A077800** | **002** | Mar 15, 2013 |
| **AN** | | | **EQ 0.042% BASE** | **A077800** | **003** | Mar 15, 2013 |
| **AN** | | | **EQ 0.25% BASE** | **A078309** | **001** | Mar 20, 2009 |
| **AN** | | RITEDOSE CORP | **EQ 0.0103% BASE** | **A203653** | **001** | Mar 22, 2016 |
| **AN** | | | **EQ 0.021% BASE** | **A203653** | **002** | Mar 22, 2016 |
| **AN** | | | **EQ 0.042% BASE** | **A203653** | **003** | Mar 22, 2016 |
| **AN** | | TEVA PARENTERAL | **EQ 0.25% BASE** | **A200875** | **001** | Sep 11, 2014 |
| **AN** | | TEVA PHARMS USA | **EQ 0.0103% BASE** | **A090297** | **001** | Apr 26, 2013 |
| **AN** | | | **EQ 0.021% BASE** | **A090297** | **002** | Apr 26, 2013 |
| **AN** | | | **EQ 0.042% BASE** | **A090297** | **003** | Apr 26, 2013 |

**XOPENEX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AN** | **+!** | OAK PHARMS INC | **EQ 0.0103% BASE** | **N020837** | **003** | Jan 30, 2002 |
| **AN** | **+!** | | **EQ 0.021% BASE** | **N020837** | **001** | Mar 25, 1999 |
| **AN** | **+!** | | **EQ 0.042% BASE** | **N020837** | **002** | Mar 25, 1999 |
| **AN** | **+!** | | **EQ 0.25% BASE** | **N020837** | **004** | Jul 18, 2003 |

LEVALBUTEROL TARTRATE

AEROSOL, METERED;INHALATION

XOPENEX HFA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | SUNOVION | EQ 0.045MG BASE/INH | N021730 | 001 | Mar 11, 2005 |

LEVETIRACETAM

INJECTABLE;IV (INFUSION)

**KEPPRA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | UCB INC | **500MG/5ML (100MG/ML)** | **N021872** | **001** | Jul 31, 2006 |

**LEVETIRACETAM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AUROBINDO PHARMA LTD | **500MG/5ML (100MG/ML)** | **A204312** | **001** | Feb 01, 2016 |
| **AP** | | FRESENIUS KABI USA | **500MG/5ML (100MG/ML)** | **A090813** | **001** | May 26, 2010 |
| **AP** | | | **500MG/5ML (100MG/ML)** | **A090876** | **001** | Aug 13, 2015 |
| **AP** | | HIKMA FARMACEUTICA | **500MG/5ML (100MG/ML)** | **A090981** | **001** | Oct 13, 2011 |
| **AP** | | HOSPIRA INC | **500MG/5ML (100MG/ML)** | **A202869** | **001** | Apr 06, 2012 |
| **AP** | | JUBILANT GENERICS | **500MG/5ML (100MG/ML)** | **A206838** | **001** | Jun 02, 2016 |
| **AP** | | LUITPOLD | **500MG/5ML (100MG/ML)** | **A202143** | **001** | Jan 31, 2012 |
| **AP** | | MYLAN LABS LTD | **500MG/5ML (100MG/ML)** | **A203308** | **001** | Sep 16, 2016 |
| **AP** | | SAGENT PHARMS | **500MG/5ML (100MG/ML)** | **A091627** | **001** | Jun 26, 2013 |
| **AP** | | SUN PHARM INDS LTD | **500MG/5ML (100MG/ML)** | **A090754** | **001** | Jun 16, 2010 |
| **AP** | | X GEN PHARMS | **500MG/5ML (100MG/ML)** | **A091485** | **001** | Aug 05, 2011 |

**LEVETIRACETAM IN SODIUM CHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AUROBINDO PHARMA LTD | **500MG/100ML (5MG/ML)** | **A207160** | **001** | Jan 04, 2017 |
| **AP** | | | **1000MG/100ML (10MG/ML)** | **A207160** | **002** | Jan 04, 2017 |
| **AP** | | | **1500MG/100ML (15MG/ML)** | **A207160** | **003** | Jan 04, 2017 |
| **AP** | | GLAND PHARMA LTD | **500MG/100ML (5MG/ML)** | **A206880** | **001** | Oct 25, 2017 |
| **AP** | | | **1000MG/100ML (10MG/ML)** | **A206880** | **002** | Oct 25, 2017 |
| **AP** | | | **1500MG/100ML (15MG/ML)** | **A206880** | **003** | Oct 25, 2017 |
| **AP** | **+!** | HQ SPECIALITY PHARMA | **500MG/100ML (5MG/ML)** | **N202543** | **001** | Nov 09, 2011 |
| **AP** | **+!** | | **1000MG/100ML (10MG/ML)** | **N202543** | **002** | Nov 09, 2011 |
| **AP** | **+!** | | **1500MG/100ML (15MG/ML)** | **N202543** | **003** | Nov 09, 2011 |

SOLUTION;ORAL

**KEPPRA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **+!** | UCB INC | **100MG/ML** | **N021505** | **001** | Jul 15, 2003 |

**LEVETIRACETAM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | ACTAVIS MID ATLANTIC | **100MG/ML** | **A078976** | **001** | Jan 15, 2009 |
| **AA** | | ALLIED PHARMA INC | **100MG/ML** | **A078582** | **001** | Jan 15, 2009 |
| **AA** | | AMNEAL PHARMS | **100MG/ML** | **A090992** | **001** | Oct 27, 2009 |
| **AA** | | AUROBINDO PHARMA | **100MG/ML** | **A079063** | **001** | Jan 15, 2009 |

LEVETIRACETAM

SOLUTION;ORAL

**LEVETIRACETAM**

| | | | | | | |
|---|---|---|---|---|---|---|
| | | LTD | | | | |
| **AA** | | BRECKENRIDGE PHARM | **100MG/ML** | **A079120** | **001** | Jan 16, 2009 |
| **AA** | | HETERO LABS LTD III | **100MG/ML** | **A203052** | **001** | Feb 28, 2013 |
| **AA** | | HI-TECH PHARMACAL | **100MG/ML** | **A090601** | **001** | Feb 28, 2012 |
| **AA** | | LUPIN LTD | **100MG/ML** | **A090893** | **001** | Oct 17, 2011 |
| **AA** | | ORIT LABS LLC | **100MG/ML** | **A203067** | **001** | May 09, 2013 |
| **AA** | | PHARM ASSOC | **100MG/ML** | **A201157** | **001** | Jun 04, 2015 |
| **AA** | | SILARX | **100MG/ML** | **A090263** | **001** | Apr 03, 2009 |
| **AA** | | TARO | **100MG/ML** | **A078774** | **001** | Feb 10, 2009 |
| **AA** | | TOLMAR | **100MG/ML** | **A079107** | **001** | Jan 15, 2009 |
| **AA** | | TRIS PHARMA INC | **100MG/ML** | **A090461** | **001** | Sep 30, 2010 |
| **AA** | | VINTAGE PHARMS | **100MG/ML** | **A090079** | **001** | Apr 11, 2012 |
| **AA** | | WOCKHARDT BIO AG | **100MG/ML** | **A090028** | **001** | Mar 03, 2010 |

TABLET;ORAL

**KEPPRA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | UCB INC | **250MG** | **N021035** | **001** | Nov 30, 1999 |
| **AB** | + | | **500MG** | **N021035** | **002** | Nov 30, 1999 |
| **AB** | + | | **750MG** | **N021035** | **003** | Nov 30, 1999 |
| **AB** | +! | | **1GM** | **N021035** | **004** | Jan 06, 2006 |

**LEVETIRACETAM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACCORD HLTHCARE | **250MG** | **A090843** | **001** | Feb 14, 2011 |
| **AB** | | | **500MG** | **A090843** | **002** | Feb 14, 2011 |
| **AB** | | | **750MG** | **A090843** | **003** | Feb 14, 2011 |
| **AB** | | | **1GM** | **A090843** | **004** | Feb 14, 2011 |
| **AB** | | ACI HEALTHCARE LTD | **250MG** | **A078042** | **001** | Jan 15, 2009 |
| **AB** | | | **500MG** | **A078042** | **002** | Jan 15, 2009 |
| **AB** | | | **750MG** | **A078042** | **003** | Jan 15, 2009 |
| **AB** | | | **1GM** | **A078042** | **004** | Jan 15, 2009 |
| **AB** | | ACIC PHARMS | **250MG** | **A090767** | **001** | Jul 28, 2010 |
| **AB** | | | **500MG** | **A090767** | **002** | Jul 28, 2010 |
| **AB** | | | **750MG** | **A090767** | **003** | Jul 28, 2010 |
| **AB** | | | **1GM** | **A090767** | **004** | Jul 28, 2010 |
| **AB** | | AJANTA PHARMA | **250MG** | **A201293** | **001** | Jun 14, 2011 |
| **AB** | | | **500MG** | **A201293** | **002** | Jun 14, 2011 |
| **AB** | | | **750MG** | **A201293** | **003** | Jun 14, 2011 |
| **AB** | | | **1GM** | **A201293** | **004** | Jun 14, 2011 |
| **AB** | | APOTEX INC | **250MG** | **A078869** | **001** | Mar 13, 2009 |
| **AB** | | | **500MG** | **A078869** | **002** | Mar 13, 2009 |
| **AB** | | | **750MG** | **A078869** | **003** | Mar 13, 2009 |
| **AB** | | | **1GM** | **A078869** | **004** | Mar 13, 2009 |
| **AB** | | AUROBINDO PHARMA | **250MG** | **A078993** | **001** | Jan 15, 2009 |
| **AB** | | | **500MG** | **A078993** | **002** | Jan 15, 2009 |
| **AB** | | | **750MG** | **A078993** | **003** | Jan 15, 2009 |
| **AB** | | | **1GM** | **A078993** | **004** | Jan 15, 2009 |
| **AB** | | BRECKENRIDGE PHARM | **250MG** | **A090511** | **001** | Aug 18, 2011 |
| **AB** | | | **500MG** | **A090511** | **002** | Aug 18, 2011 |
| **AB** | | | **750MG** | **A090511** | **003** | Aug 18, 2011 |
| **AB** | | | **1GM** | **A090511** | **004** | Aug 18, 2011 |
| **AB** | | DR REDDYS LABS LTD | **250MG** | **A076920** | **001** | Jan 15, 2009 |
| **AB** | | | **500MG** | **A076920** | **002** | Jan 15, 2009 |
| **AB** | | | **750MG** | **A076920** | **003** | Jan 15, 2009 |
| **AB** | | | **1GM** | **A078904** | **001** | Jan 15, 2009 |
| **AB** | | HETERO LABS LTD III | **250MG** | **A090515** | **001** | Oct 08, 2010 |
| **AB** | | | **500MG** | **A090515** | **002** | Oct 08, 2010 |
| **AB** | | | **750MG** | **A090515** | **003** | Oct 08, 2010 |
| **AB** | | | **1GM** | **A090515** | **004** | Oct 08, 2010 |
| **AB** | | INVAGEN PHARMS | **250MG** | **A078234** | **001** | Jan 15, 2009 |
| **AB** | | | **500MG** | **A078234** | **002** | Jan 15, 2009 |
| **AB** | | | **750MG** | **A078234** | **003** | Jan 15, 2009 |
| **AB** | | LUPIN | **250MG** | **A078154** | **001** | Jan 15, 2009 |
| **AB** | | | **500MG** | **A078154** | **002** | Jan 15, 2009 |
| **AB** | | | **750MG** | **A078154** | **003** | Jan 15, 2009 |
| **AB** | | | **1GM** | **A090025** | **001** | Jan 15, 2009 |
| **AB** | | MYLAN | **250MG** | **A076919** | **001** | Nov 04, 2008 |
| **AB** | | | **500MG** | **A076919** | **002** | Nov 04, 2008 |
| **AB** | | | **750MG** | **A076919** | **003** | Nov 04, 2008 |
| **AB** | | | **1GM** | **A090261** | **001** | Dec 08, 2009 |
| **AB** | | ORCHID HLTHCARE | **250MG** | **A078526** | **001** | Jan 15, 2009 |
| **AB** | | | **500MG** | **A078526** | **002** | Jan 15, 2009 |

LEVETIRACETAM

TABLET;ORAL

**LEVETIRACETAM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | **750MG** | **A078526** | **003** | Jan 15, 2009 |
| **AB** | | **1GM** | **A090484** | **001** | Aug 05, 2010 |
| **AB** | PRINSTON INC | **250MG** | **A078106** | **001** | Feb 10, 2009 |
| **AB** | | **500MG** | **A078106** | **002** | Feb 10, 2009 |
| **AB** | | **750MG** | **A078106** | **003** | Feb 10, 2009 |
| **AB** | | **1GM** | **A078106** | **004** | Feb 10, 2009 |
| **AB** | SECAN PHARMS | **500MG** | **A205102** | **004** | Dec 16, 2015 |
| **AB** | | **1GM** | **A205102** | **003** | Dec 16, 2015 |
| **AB** | TARO | **250MG** | **A078960** | **004** | Feb 01, 2010 |
| **AB** | | **500MG** | **A078960** | **003** | Feb 01, 2010 |
| **AB** | | **750MG** | **A078960** | **002** | Feb 01, 2010 |
| **AB** | | **1GM** | **A078960** | **001** | Feb 01, 2010 |
| **AB** | TEVA PHARMS | **250MG** | **A078101** | **001** | Jan 15, 2009 |
| **AB** | | **500MG** | **A078101** | **002** | Jan 15, 2009 |
| **AB** | | **750MG** | **A078101** | **003** | Jan 15, 2009 |
| **AB** | | **1GM** | **A078101** | **004** | Jan 15, 2009 |
| **AB** | TORRENT PHARMS | **250MG** | **A078858** | **001** | Jan 15, 2009 |
| **AB** | | **500MG** | **A078858** | **002** | Jan 15, 2009 |
| **AB** | | **750MG** | **A078858** | **003** | Jan 15, 2009 |
| **AB** | | **1GM** | **A078858** | **004** | Jan 15, 2009 |
| **AB** | VINTAGE PHARMS | **250MG** | **A077319** | **001** | Mar 20, 2009 |
| **AB** | | **250MG** | **A091491** | **001** | Dec 14, 2010 |
| **AB** | | **500MG** | **A077319** | **002** | Mar 20, 2009 |
| **AB** | | **500MG** | **A091491** | **002** | Dec 14, 2010 |
| **AB** | | **750MG** | **A077319** | **003** | Mar 20, 2009 |
| **AB** | | **750MG** | **A091491** | **003** | Dec 14, 2010 |
| **AB** | | **1GM** | **A091491** | **004** | Dec 14, 2010 |
| **AB** | WOCKHARDT | **250MG** | **A079042** | **001** | Jan 15, 2009 |
| **AB** | | **500MG** | **A079042** | **002** | Jan 15, 2009 |
| **AB** | | **750MG** | **A079042** | **003** | Jan 15, 2009 |
| **AB** | | **1GM** | **A079042** | **004** | Jan 15, 2009 |
| **AB** | ZYDUS PHARMS USA INC | **250MG** | **A078918** | **001** | Apr 29, 2009 |
| **AB** | | **1GM** | **A078918** | **002** | Apr 29, 2009 |

**ROWEEPRA**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | LOTUS PHARM CO LTD | **250MG** | **A090906** | **002** | Oct 31, 2016 |
| **AB** | | **500MG** | **A090906** | **001** | Nov 05, 2010 |
| **AB** | | **750MG** | **A090906** | **003** | Oct 31, 2016 |
| **AB** | | **1GM** | **A090906** | **004** | Oct 31, 2016 |

TABLET, EXTENDED RELEASE;ORAL

**KEPPRA XR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | UCB INC | **500MG** | **N022285** | **001** | Sep 12, 2008 |
| **AB** | +! | | **750MG** | **N022285** | **002** | Feb 12, 2009 |

**LEVETIRACETAM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS ELIZABETH | **500MG** | **A091557** | **001** | Sep 12, 2011 |
| **AB** | | | **750MG** | **A091557** | **002** | Sep 12, 2011 |
| **AB** | | ACTAVIS LABS FL INC | **500MG** | **A091093** | **001** | Sep 12, 2011 |
| **AB** | | | **750MG** | **A091093** | **002** | Sep 12, 2011 |
| **AB** | | ANCHEN PHARMS | **500MG** | **A091360** | **001** | Oct 04, 2011 |
| **AB** | | | **750MG** | **A091360** | **002** | Oct 04, 2011 |
| **AB** | | APOTEX INC | **500MG** | **A091261** | **001** | Sep 12, 2011 |
| **AB** | | | **750MG** | **A091261** | **002** | Sep 12, 2011 |
| **AB** | | DEXCEL PHARMA | **500MG** | **A202167** | **001** | Sep 04, 2015 |
| **AB** | | | **750MG** | **A202167** | **002** | Sep 04, 2015 |
| **AB** | | ECI PHARMS LLC | **500MG** | **A204754** | **001** | Aug 26, 2016 |
| **AB** | | | **750MG** | **A204754** | **002** | Aug 26, 2016 |
| **AB** | | INTELLIPHARMACEUTICS | **500MG** | **A204511** | **001** | Feb 23, 2016 |
| **AB** | | | **750MG** | **A204511** | **002** | Feb 23, 2016 |
| **AB** | | LOTUS PHARM CO LTD | **500MG** | **A202095** | **002** | Jun 06, 2016 |
| **AB** | | | **750MG** | **A202095** | **001** | Jun 06, 2016 |
| **AB** | | LUPIN LTD | **500MG** | **A091399** | **001** | Sep 12, 2011 |
| **AB** | | | **750MG** | **A091399** | **002** | Sep 12, 2011 |
| **AB** | | PHARMADAX INC | **500MG** | **A201464** | **001** | May 25, 2012 |
| **AB** | | | **750MG** | **A201464** | **002** | May 25, 2012 |
| **AB** | | PHARMTAK INC | **500MG** | **A207175** | **001** | Sep 28, 2017 |
| **AB** | | | **750MG** | **A207175** | **002** | Sep 28, 2017 |
| **AB** | | PRINSTON INC | **500MG** | **A202533** | **001** | Jul 20, 2012 |
| **AB** | | | **500MG** | **A203468** | **001** | May 21, 2015 |
| **AB** | | | **750MG** | **A202533** | **002** | Jul 20, 2012 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| LEVETIRACETAM | | | | | | | |
| TABLET, EXTENDED RELEASE;ORAL | | | | | | | |
| **LEVETIRACETAM** | | | | | | | |
| **AB** | | | **750MG** | **A203468** | **002** | May 21, 2015 |
| **AB** | | ROUSES POINT PHARMS | **500MG** | **A202524** | **001** | Aug 27, 2012 |
| **AB** | | | **750MG** | **A202524** | **002** | Aug 27, 2012 |
| **AB** | | SUN PHARM INDUSTRIES | **500MG** | **A091285** | **001** | Sep 12, 2011 |
| **AB** | | | **750MG** | **A091285** | **002** | Sep 12, 2011 |
| **AB** | | SUN PHARMA GLOBAL | **500MG** | **A203059** | **001** | Sep 09, 2013 |
| **AB** | | | **750MG** | **A203059** | **002** | Sep 09, 2013 |
| **AB** | | TEVA PHARMS | **500MG** | **A091430** | **001** | Sep 12, 2011 |
| **AB** | | | **750MG** | **A091430** | **002** | Sep 12, 2011 |
| **AB** | | TORRENT PHARMS LTD | **500MG** | **A091338** | **001** | May 29, 2012 |
| **AB** | | | **750MG** | **A091338** | **002** | May 29, 2012 |
| **AB** | | VIRTUS PHARMS | **500MG** | **A091291** | **001** | Sep 12, 2011 |
| **AB** | | | **750MG** | **A091291** | **002** | Sep 12, 2011 |
| | | APOTEX INC | 1GM | A202958 | 001 | Feb 25, 2015 |
| TABLET, FOR SUSPENSION;ORAL | | | | | | | |
| SPRITAM | | | | | | | |
| | + | APRECIA PHARMS | 250MG | N207958 | 001 | Jul 31, 2015 |
| | + | | 500MG | N207958 | 002 | Jul 31, 2015 |
| | + | | 750MG | N207958 | 003 | Jul 31, 2015 |
| | +! | | 1GM | N207958 | 004 | Jul 31, 2015 |
| LEVOBUNOLOL HYDROCHLORIDE | | | | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | | | | |
| **AKBETA** | | | | | | | |
| **AT** | | AKORN | **0.25%** | **A074779** | **001** | Oct 29, 1996 |
| **AT** | | | **0.5%** | **A074780** | **001** | Oct 29, 1996 |
| **BETAGAN** | | | | | | | |
| **AT** | **+!** | ALLERGAN | **0.25%** | **N019814** | **001** | Jun 28, 1989 |
| **AT** | **+!** | | **0.5%** | **N019219** | **002** | Dec 19, 1985 |
| **LEVOBUNOLOL HYDROCHLORIDE** | | | | | | | |
| **AT** | | BAUSCH AND LOMB | **0.5%** | **A074326** | **001** | Mar 04, 1994 |
| **AT** | | SANDOZ INC | **0.5%** | **A074850** | **001** | Oct 28, 1996 |
| LEVOCARNITINE | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| **CARNITOR** | | | | | | | |
| **AP** | **+!** | LEADIANT BIOSCI INC | **200MG/ML** | **N020182** | **001** | Dec 16, 1992 |
| **LEVOCARNITINE** | | | | | | | |
| **AP** | | LUITPOLD | **200MG/ML** | **A075861** | **001** | Jun 22, 2001 |
| **AP** | | WEST-WARD PHARMS INT | **200MG/ML** | **A075567** | **001** | Mar 29, 2001 |
| SOLUTION;ORAL | | | | | | | |
| **CARNITOR** | | | | | | | |
| **AA** | **+!** | LEADIANT BIOSCI INC | **1GM/10ML** | **N019257** | **001** | Apr 10, 1986 |
| **CARNITOR SF** | | | | | | | |
| **AA** | **+** | LEADIANT BIOSCI INC | **1GM/10ML** | **N019257** | **002** | Mar 28, 2007 |
| **LEVOCARNITINE** | | | | | | | |
| **AA** | | HI TECH PHARMA | **1GM/10ML** | **A077399** | **001** | Oct 25, 2007 |
| **AA** | | LYNE | **1GM/10ML** | **A076851** | **001** | Aug 10, 2004 |
| TABLET;ORAL | | | | | | | |
| **CARNITOR** | | | | | | | |
| **AB** | **+!** | LEADIANT BIOSCI INC | **330MG** | **N018948** | **001** | Dec 27, 1985 |
| **LEVOCARNITINE** | | | | | | | |
| **AB** | | RISING PHARMS INC | **330MG** | **A076858** | **001** | Sep 20, 2004 |
| LEVOCETIRIZINE DIHYDROCHLORIDE | | | | | | | |
| SOLUTION;ORAL | | | | | | | |
| **LEVOCETIRIZINE DIHYDROCHLORIDE** | | | | | | | |
| **AA** | | APOTEX INC | **2.5MG/5ML** | **A202915** | **001** | Aug 21, 2014 |
| **AA** | | L PERRIGO CO | **2.5MG/5ML** | **A091263** | **001** | Nov 07, 2011 |
| **AA** | | SILARX PHARMS INC | **2.5MG/5ML** | **A204599** | **001** | May 15, 2017 |
| **AA** | | TARO PHARM INDS | **2.5MG/5ML** | **A202673** | **001** | Jul 26, 2013 |
| **XYZAL** | | | | | | | |
| **AA** | **+!** | SANOFI-AVENTIS US | **2.5MG/5ML** | **N022157** | **001** | Jan 28, 2008 |
| TABLET;ORAL | | | | | | | |
| **LEVOCETIRIZINE DIHYDROCHLORIDE** | | | | | | | |
| **AB** | | ALLIED PHARMA INC | **5MG** | **A204323** | **001** | Dec 20, 2016 |
| **AB** | | APOTEX INC | **5MG** | **A203027** | **001** | Feb 13, 2015 |
| **AB** | | DR REDDYS LABS LTD | **5MG** | **A090392** | **001** | Feb 24, 2011 |
| **AB** | | GLENMARK GENERICS | **5MG** | **A090385** | **001** | Feb 24, 2011 |

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL

**LEVOCETIRIZINE DIHYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | HETERO LABS LTD III | **5MG** | **A091264** | **001** | Jun 29, 2012 |
| **AB** | | MACLEODS PHARMS LTD | **5MG** | **A205564** | **001** | Jan 11, 2016 |
| **AB** | | MICRO LABS LTD INDIA | **5MG** | **A202046** | **001** | Sep 17, 2013 |
| **AB** | | SCIEGEN PHARMS INC | **5MG** | **A203646** | **001** | Sep 09, 2014 |
| **AB** | | SUN PHARM INDS LTD | **5MG** | **A201653** | **001** | Jun 26, 2015 |
| **AB** | | SUN PHARMA GLOBAL | **5MG** | **A090362** | **001** | Jan 31, 2013 |
| **AB** | | SYNTHON PHARMS | **5MG** | **A090229** | **001** | Nov 26, 2010 |
| **AB** | | TEVA PHARMS | **5MG** | **A090199** | **001** | Aug 22, 2011 |

**XYZAL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | SANOFI-AVENTIS US | **5MG** | **N022064** | **001** | May 25, 2007 |

LEVOFLOXACIN

INJECTABLE;INJECTION

**LEVAQUIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | JANSSEN PHARMS | **EQ 500MG/20ML (EQ 25MG/ML)** | **N020635** | **001** | Dec 20, 1996 |
| **AP** | **+!** | | **EQ 750MG/30ML (EQ 25MG/ML)** | **N020635** | **004** | Dec 20, 1996 |

**LEVOFLOXACIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AUROBINDO PHARMA LTD | **EQ 500MG/20ML (EQ 25MG/ML)** | **A202328** | **001** | Jan 24, 2013 |
| **AP** | | | **EQ 750MG/30ML (EQ 25MG/ML)** | **A202328** | **002** | Jan 24, 2013 |
| **AP** | | BAXTER HLTHCARE CORP | **EQ 500MG/20ML (EQ 25MG/ML)** | **A091436** | **001** | Jun 05, 2013 |
| **AP** | | EMCURE PHARMS LTD | **EQ 500MG/20ML (EQ 25MG/ML)** | **A202590** | **001** | Jan 24, 2013 |
| **AP** | | | **EQ 750MG/30ML (EQ 25MG/ML)** | **A202590** | **002** | Jan 24, 2013 |
| **AP** | | SAGENT AGILA LLC | **EQ 500MG/20ML (EQ 25MG/ML)** | **A200560** | **001** | Jun 20, 2011 |
| **AP** | | | **EQ 750MG/30ML (EQ 25MG/ML)** | **A200560** | **002** | Jun 20, 2011 |
| **AP** | | ZYDUS PHARMS USA INC | **EQ 500MG/20ML (EQ 25MG/ML)** | **A205968** | **001** | Jun 01, 2017 |
| **AP** | | | **EQ 750MG/30ML (EQ 25MG/ML)** | **A205968** | **002** | Jun 01, 2017 |

**LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **!** | ACS DOBFAR INFO SA | **EQ 250MG/50ML (EQ 5MG/ML)** | **A090343** | **001** | Jul 07, 2011 |
| **AP** | **!** | | **EQ 500MG/100ML (EQ 5MG/ML)** | **A090343** | **002** | Jul 07, 2011 |
| **AP** | **!** | | **EQ 750MG/150ML (EQ 5MG/ML)** | **A090343** | **003** | Jul 07, 2011 |
| **AP** | | AUROBINDO PHARMA LTD | **EQ 250MG/50ML (EQ 5MG/ML)** | **A206919** | **001** | Feb 10, 2016 |
| **AP** | | | **EQ 500MG/100ML (EQ 5MG/ML)** | **A206919** | **002** | Feb 10, 2016 |
| **AP** | | | **EQ 750MG/150ML (EQ 5MG/ML)** | **A206919** | **003** | Feb 10, 2016 |
| **AP** | | BAXTER HLTHCARE CORP | **EQ 250MG/50ML (EQ 5MG/ML)** | **A091397** | **001** | Aug 08, 2013 |
| **AP** | | | **EQ 500MG/100ML (EQ 5MG/ML)** | **A091397** | **002** | Aug 08, 2013 |
| **AP** | | | **EQ 750MG/150ML (EQ 5MG/ML)** | **A091397** | **003** | Aug 08, 2013 |
| **AP** | | FRESENIUS KABI USA | **EQ 250MG/50ML (EQ 5MG/ML)** | **A200674** | **001** | Jun 19, 2013 |
| **AP** | | | **EQ 500MG/100ML (EQ 5MG/ML)** | **A200674** | **002** | Jun 19, 2013 |
| **AP** | | | **EQ 750MG/150ML (EQ 5MG/ML)** | **A200674** | **003** | Jun 19, 2013 |
| **AP** | | HIKMA FARMACEUTICA | **EQ 250MG/50ML (EQ 5MG/ML)** | **A091375** | **001** | Sep 16, 2011 |
| **AP** | | | **EQ 500MG/100ML (EQ 5MG/ML)** | **A091375** | **002** | Sep 16, 2011 |
| **AP** | | | **EQ 750MG/150ML (EQ 5MG/ML)** | **A091375** | **003** | Sep 16, 2011 |
| **AP** | | HOSPIRA INC | **EQ 250MG/50ML (EQ 5MG/ML)** | **A078579** | **001** | Sep 03, 2015 |
| **AP** | | | **EQ 500MG/100ML (EQ 5MG/ML)** | **A078579** | **002** | Sep 03, 2015 |
| **AP** | | | **EQ 750MG/150ML (EQ 5MG/ML)** | **A078579** | **003** | Sep 03, 2015 |

SOLUTION;ORAL

LEVOFLOXACIN

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | HI TECH PHARMA | 250MG/10ML | A091678 | 001 | Jun 20, 2011 |

SOLUTION/DROPS;OPHTHALMIC

**LEVOFLOXACIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | AKORN | **0.5%** | **A090268** | **001** | Dec 20, 2010 |
| **AT** | | MYLAN LABS LTD | **0.5%** | **A204899** | **001** | Dec 08, 2017 |
| **AT** | **!** | RISING PHARMS INC | **0.5%** | **A077700** | **001** | Dec 20, 2010 |
| **AT** | | WATSON LABS TEVA | **0.5%** | **A076826** | **001** | Feb 10, 2011 |

TABLET;ORAL

**LEVAQUIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | JANSSEN PHARMS | **250MG** | **N020634** | **001** | Dec 20, 1996 |
| **AB** | **+** | | **500MG** | **N020634** | **002** | Dec 20, 1996 |
| **AB** | **+!** | | **750MG** | **N020634** | **003** | Sep 08, 2000 |

**LEVOFLOXACIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | APOTEX INC | **250MG** | **A090787** | **001** | Sep 29, 2011 |
| **AB** | | | **500MG** | **A090787** | **002** | Sep 29, 2011 |
| **AB** | | | **750MG** | **A090787** | **003** | Sep 29, 2011 |
| **AB** | | AUROBINDO PHARMA LTD | **250MG** | **A201043** | **001** | Jun 20, 2011 |

LEVOFLOXACIN

TABLET;ORAL

**LEVOFLOXACIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | **500MG** | **A201043** | **002** | Jun 20, 2011 |
| **AB** | | **750MG** | **A201043** | **003** | Jun 20, 2011 |
| **AB** | CIPLA LTD | **250MG** | **A076890** | **001** | Mar 30, 2012 |
| **AB** | | **500MG** | **A076890** | **002** | Mar 30, 2012 |
| **AB** | | **750MG** | **A076890** | **003** | Mar 30, 2012 |
| **AB** | DR REDDYS LABS INC | **250MG** | **A076710** | **001** | Jun 20, 2011 |
| **AB** | | **500MG** | **A076710** | **002** | Jun 20, 2011 |
| **AB** | | **750MG** | **A076710** | **003** | Jun 20, 2011 |
| **AB** | GLENMARK GENERICS | **250MG** | **A200250** | **001** | Jun 20, 2011 |
| **AB** | | **500MG** | **A200250** | **002** | Jun 20, 2011 |
| **AB** | | **750MG** | **A200250** | **003** | Jun 20, 2011 |
| **AB** | HETERO LABS LTD V | **250MG** | **A202801** | **001** | Jan 08, 2015 |
| **AB** | | **500MG** | **A202801** | **002** | Jan 08, 2015 |
| **AB** | | **750MG** | **A202801** | **003** | Jan 08, 2015 |
| **AB** | JUBILANT GENERICS | **250MG** | **A203613** | **001** | Jun 19, 2015 |
| **AB** | | **500MG** | **A203613** | **002** | Jun 19, 2015 |
| **AB** | LUPIN | **250MG** | **A078424** | **001** | Jun 20, 2011 |
| **AB** | | **500MG** | **A078424** | **002** | Jun 20, 2011 |
| **AB** | | **750MG** | **A078424** | **003** | Jun 20, 2011 |
| **AB** | MACLEODS PHARMS LTD | **250MG** | **A200839** | **001** | Mar 22, 2012 |
| **AB** | | **500MG** | **A200839** | **002** | Mar 22, 2012 |
| **AB** | | **750MG** | **A200839** | **003** | Mar 22, 2012 |
| **AB** | ORCHID HLTHCARE | **250MG** | **A202200** | **001** | Jan 30, 2012 |
| **AB** | | **500MG** | **A202200** | **002** | Jan 30, 2012 |
| **AB** | | **750MG** | **A202200** | **003** | Jan 30, 2012 |
| **AB** | SANDOZ | **250MG** | **A077438** | **001** | Jun 20, 2011 |
| **AB** | | **500MG** | **A077438** | **002** | Jun 20, 2011 |
| **AB** | | **750MG** | **A077438** | **003** | Jun 20, 2011 |
| **AB** | TEVA | **250MG** | **A076361** | **001** | Jun 20, 2011 |
| **AB** | | **500MG** | **A076361** | **002** | Jun 20, 2011 |
| **AB** | | **750MG** | **A076361** | **003** | Jun 20, 2011 |
| **AB** | TORRENT PHARMS | **250MG** | **A090722** | **001** | Jun 20, 2011 |
| **AB** | | **500MG** | **A090722** | **002** | Jun 20, 2011 |
| **AB** | | **750MG** | **A090722** | **003** | Jun 20, 2011 |
| **AB** | WOCKHARDT | **250MG** | **A090367** | **001** | Jun 20, 2011 |
| **AB** | | **500MG** | **A090367** | **002** | Jun 20, 2011 |
| **AB** | | **750MG** | **A090367** | **003** | Jun 20, 2011 |
| **AB** | ZYDUS PHARMS USA INC | **250MG** | **A077652** | **001** | Sep 07, 2012 |
| **AB** | | **500MG** | **A077652** | **002** | Sep 07, 2012 |
| **AB** | | **750MG** | **A077652** | **003** | Sep 07, 2012 |

LEVOLEUCOVORIN CALCIUM

POWDER;IV (INFUSION)

**FUSILEV**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | SPECTRUM PHARMS | **EQ 50MG BASE/VIAL** | **N020140** | **001** | Mar 07, 2008 |

**LEVOLEUCOVORIN CALCIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | ACTAVIS LLC | **EQ 50MG BASE/VIAL** | **A206516** | **001** | Feb 13, 2017 |
| **AP** | | AMNEAL PHARMS CO | **EQ 50MG BASE/VIAL** | **A207547** | **001** | Feb 13, 2017 |
| **AP** | | WEST-WARD PHARMS INT | **EQ 50MG BASE/VIAL** | **A206263** | **001** | Jun 16, 2016 |
| | +! | ACTAVIS LLC | EQ 175MG BASE/VIAL | N208723 | 001 | Sep 29, 2016 |

SOLUTION;IV (INFUSION)

**LEVOLEUCOVORIN CALCIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AMNEAL PHARMS CO | **EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)** | **A207548** | **001** | Sep 08, 2017 |
| **AP** | | MYLAN TEORANTA | **EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)** | **A203576** | **001** | Oct 20, 2015 |
| **AP** | | | **EQ 250MG BASE/25ML (EQ 10MG BASE/ML)** | **A203576** | **002** | Oct 20, 2015 |
| **AP** | | SANDOZ INC | **EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)** | **A203563** | **001** | Mar 09, 2015 |
| **AP** | **!** | | **EQ 250MG BASE/25ML (EQ 10MG BASE/ML)** | **A203563** | **002** | Mar 09, 2015 |

LEVOMILNACIPRAN HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

FETZIMA

| | | | | | |
|---|---|---|---|---|---|
| + | FOREST LABS INC | EQ 20MG BASE | N204168 | 001 | Jul 25, 2013 |
| + | | EQ 40MG BASE | N204168 | 002 | Jul 25, 2013 |
| + | | EQ 80MG BASE | N204168 | 003 | Jul 25, 2013 |
| +! | | EQ 120MG BASE | N204168 | 004 | Jul 25, 2013 |

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

SCANDONEST L

| | | | | | |
|---|---|---|---|---|---|
| ! | DEPROCO | 0.05MG/ML;2% | A088388 | 001 | Oct 10, 1984 |

LEVONORGESTREL

INTRAUTERINE DEVICE;INTRAUTERINE

KYLEENA

| | | | | | |
|---|---|---|---|---|---|
| +! | BAYER HLTHCARE | 19.5MG | N208224 | 001 | Sep 16, 2016 |

LILETTA

| | | | | | |
|---|---|---|---|---|---|
| | MEDICINES360 | 52MG | N206229 | 001 | Feb 26, 2015 |

MIRENA

| | | | | | |
|---|---|---|---|---|---|
| +! | BAYER HLTHCARE | 52MG | N021225 | 001 | Dec 06, 2000 |

SKYLA

| | | | | | |
|---|---|---|---|---|---|
| +! | BAYER HLTHCARE | 13.5MG | N203159 | 001 | Jan 09, 2013 |

TABLET;ORAL

**LEVONORGESTREL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | LOTUS PHARM CO LTD | **0.75MG** | **A202684** | **001** | Sep 02, 2016 |
| **AB** | | MYLAN LABS LTD | **0.75MG** | **A202740** | **001** | Sep 02, 2016 |
| **AB** | **!** | PERRIGO R AND D | **0.75MG** | **A090740** | **001** | Dec 30, 2010 |

LEVORPHANOL TARTRATE

TABLET;ORAL

LEVORPHANOL TARTRATE

| | | | | | |
|---|---|---|---|---|---|
| ! | SENTYNL THERAPS INC | 2MG | A074278 | 001 | Mar 31, 2000 |

LEVOTHYROXINE SODIUM

CAPSULE;ORAL

TIROSINT

| | | | | | |
|---|---|---|---|---|---|
| + | INSTITUT BIOCHIMIQUE | 0.013MG | N021924 | 013 | Aug 01, 2007 |
| + | | 0.025MG | N021924 | 002 | Oct 13, 2006 |
| + | | 0.05MG | N021924 | 003 | Oct 13, 2006 |
| + | | 0.075MG | N021924 | 004 | Oct 13, 2006 |
| + | | 0.088MG | N021924 | 010 | Oct 02, 2009 |
| + | | 0.1MG | N021924 | 005 | Oct 13, 2006 |
| + | | 0.112MG | N021924 | 008 | Oct 02, 2009 |
| + | | 0.125MG | N021924 | 006 | Oct 13, 2006 |
| + | | 0.137MG | N021924 | 009 | Oct 02, 2009 |
| +! | | 0.15MG | N021924 | 007 | Oct 13, 2006 |
| + | | 0.175MG | N021924 | 011 | Apr 25, 2017 |
| + | | 0.200MG | N021924 | 012 | Apr 25, 2017 |

POWDER;INTRAVENOUS

**LEVOTHYROXINE SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | FERA PHARMS LLC | **100MCG/VIAL** | **A206163** | **001** | Jun 29, 2016 |
| **AP** | | | **500MCG/VIAL** | **A206163** | **002** | Jun 29, 2016 |
| **AP** | **+!** | FRESENIUS KABI USA | **100MCG/VIAL** | **N202231** | **001** | Jun 24, 2011 |
| **AP** | **+!** | | **200MCG/VIAL** | **N202231** | **002** | Jun 24, 2011 |
| **AP** | **+!** | | **500MCG/VIAL** | **N202231** | **003** | Jun 24, 2011 |
| **AP** | | PAR STERILE PRODUCTS | **200MCG/VIAL** | **A205366** | **001** | Dec 07, 2015 |

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

**SYNTHROID**

| | | | | | | |
|---|---|---|---|---|---|---|
| **-->** | **+** | ABBVIE | **--> AB1,AB2** | **0.025MG** | N021402 | 001 Jul 24, 2002 |
| **-->** | **+** | | **--> AB1,AB2** | **0.05MG** | N021402 | 002 Jul 24, 2002 |
| **-->** | **+** | | **--> AB1,AB2** | **0.075MG** | N021402 | 003 Jul 24, 2002 |
| **-->** | **+** | | **--> AB1,AB2** | **0.088MG** | N021402 | 004 Jul 24, 2002 |
| **-->** | **+** | | **--> AB1,AB2** | **0.1MG** | N021402 | 005 Jul 24, 2002 |
| **-->** | **+** | | **--> AB1,AB2** | **0.112MG** | N021402 | 006 Jul 24, 2002 |
| **-->** | **+** | | **--> AB1,AB2** | **0.125MG** | N021402 | 007 Jul 24, 2002 |
| **-->** | **+** | | **--> AB1,AB2** | **0.137MG** | N021402 | 008 Jul 24, 2002 |
| **-->** | **+** | | **--> AB1,AB2** | **0.15MG** | N021402 | 009 Jul 24, 2002 |
| **-->** | **+** | | **--> AB1,AB2** | **0.175MG** | N021402 | 010 Jul 24, 2002 |
| **-->** | **+** | | **--> AB1,AB2** | **0.2MG** | N021402 | 012 Jul 24, 2002 |
| **-->** | **+!** | | **--> AB1,AB2** | **0.3MG** | N021402 | 011 Jul 24, 2002 |

**LEVO-T**

| | | | | | | |
|---|---|---|---|---|---|---|
| **-->** | **+** | CEDIPROF INC | **--> AB1,AB2,AB3** | **0.025MG** | N021342 | 001 Mar 01, 2002 |
| **-->** | **+** | | **--> AB1,AB2,AB3** | **0.05MG** | N021342 | 002 Mar 01, 2002 |
| **-->** | **+** | | **--> AB1,AB2,AB3** | **0.075MG** | N021342 | 003 Mar 01, 2002 |

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | **LEVO-T** | | | | | | |
| --> | + | | --> AB1,AB2,AB3 | 0.088MG | N021342 | 004 | Mar 01, 2002 |
| --> | + | | --> AB1,AB2,AB3 | 0.1MG | N021342 | 005 | Mar 01, 2002 |
| --> | + | | --> AB1,AB2,AB3 | 0.112MG | N021342 | 006 | Mar 01, 2002 |
| --> | + | | --> AB1,AB2,AB3 | 0.125MG | N021342 | 007 | Mar 01, 2002 |
| --> | + | | --> AB1,AB2,AB3 | 0.137MG | N021342 | 012 | Dec 08, 2003 |
| --> | + | | --> AB1,AB2,AB3 | 0.15MG | N021342 | 008 | Mar 01, 2002 |
| --> | + | | --> AB1,AB2,AB3 | 0.175MG | N021342 | 009 | Mar 01, 2002 |
| --> | + | | --> AB1,AB2,AB3 | 0.2MG | N021342 | 010 | Mar 01, 2002 |
| --> | +! | | --> AB1,AB2,AB3 | 0.3MG | N021342 | 011 | Mar 01, 2002 |
| | **UNITHROID** | | | | | | |
| --> | + | STEVENS J | --> AB1,AB2,AB3 | 0.025MG | N021210 | 001 | Aug 21, 2000 |
| --> | + | | --> AB1,AB2,AB3 | 0.05MG | N021210 | 002 | Aug 21, 2000 |
| --> | + | | --> AB1,AB2,AB3 | 0.075MG | N021210 | 003 | Aug 21, 2000 |
| --> | + | | --> AB1,AB2,AB3 | 0.088MG | N021210 | 004 | Aug 21, 2000 |
| --> | + | | --> AB1,AB2,AB3 | 0.1MG | N021210 | 005 | Aug 21, 2000 |
| --> | + | | --> AB1,AB2,AB3 | 0.112MG | N021210 | 006 | Aug 21, 2000 |
| --> | + | | --> AB1,AB2,AB3 | 0.125MG | N021210 | 007 | Aug 21, 2000 |
| --> | + | | --> AB1,AB2,AB3 | 0.137MG | N021210 | 012 | Feb 08, 2008 |
| --> | + | | --> AB1,AB2,AB3 | 0.15MG | N021210 | 008 | Aug 21, 2000 |
| --> | + | | --> AB1,AB2,AB3 | 0.175MG | N021210 | 009 | Aug 21, 2000 |
| --> | + | | --> AB1,AB2,AB3 | 0.2MG | N021210 | 010 | Aug 21, 2000 |
| --> | +! | | --> AB1,AB2,AB3 | 0.3MG | N021210 | 011 | Aug 21, 2000 |
| | **LEVOTHYROXINE SODIUM** | | | | | | |
| --> | | MYLAN | --> AB1,AB2,AB3,AB4 | 0.025MG | A076187 | 001 | Jun 05, 2002 |
| --> | | | --> AB1,AB2,AB3,AB4 | 0.05MG | A076187 | 002 | Jun 05, 2002 |
| --> | | | --> AB1,AB2,AB3,AB4 | 0.075MG | A076187 | 003 | Jun 05, 2002 |
| --> | | | --> AB1,AB2,AB3,AB4 | 0.088MG | A076187 | 004 | Jun 05, 2002 |
| --> | | | --> AB1,AB2,AB3,AB4 | 0.1MG | A076187 | 005 | Jun 05, 2002 |
| --> | | | --> AB1,AB2,AB3,AB4 | 0.112MG | A076187 | 006 | Jun 05, 2002 |
| --> | | | --> AB1,AB2,AB3,AB4 | 0.125MG | A076187 | 007 | Jun 05, 2002 |
| --> | | | --> AB1,AB2,AB3,AB4 | 0.137MG | A076187 | 012 | Dec 13, 2006 |
| --> | | | --> AB1,AB2,AB3,AB4 | 0.15MG | A076187 | 008 | Jun 05, 2002 |
| --> | | | --> AB1,AB2,AB3,AB4 | 0.175MG | A076187 | 009 | Jun 05, 2002 |
| --> | | | --> AB1,AB2,AB3,AB4 | 0.2MG | A076187 | 010 | Jun 05, 2002 |
| --> | ! | | --> AB1,AB2,AB3,AB4 | 0.3MG | A076187 | 011 | Jun 05, 2002 |
| | **LEVOXYL** | | | | | | |
| --> | + | KING PHARMS | --> AB1,AB3 | 0.025MG | N021301 | 001 | May 25, 2001 |
| --> | + | | --> AB1,AB3 | 0.05MG | N021301 | 002 | May 25, 2001 |
| --> | + | | --> AB1,AB3 | 0.075MG | N021301 | 003 | May 25, 2001 |
| --> | + | | --> AB1,AB3 | 0.088MG | N021301 | 004 | May 25, 2001 |
| --> | + | | --> AB1,AB3 | 0.1MG | N021301 | 005 | May 25, 2001 |
| --> | + | | --> AB1,AB3 | 0.112MG | N021301 | 006 | May 25, 2001 |

LEVOTHYROXINE SODIUM **

**See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

TABLET;ORAL

**LEVOXYL**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| --> | + | | --> AB1,AB3 | 0.125MG | N021301 | 007 | May 25, 2001 |
| --> | + | | --> AB1,AB3 | 0.137MG | N021301 | 008 | May 25, 2001 |
| --> | + | | --> AB1,AB3 | 0.15MG | N021301 | 009 | May 25, 2001 |
| --> | + | | --> AB1,AB3 | 0.175MG | N021301 | 010 | May 25, 2001 |
| --> | +! | | --> AB1,AB3 | 0.2MG | N021301 | 011 | May 25, 2001 |

LIDOCAINE

OINTMENT;TOPICAL

**LIDOCAINE**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AT | | ALKEM LABS LTD | 5% | A207810 | 001 | Mar 10, 2017 |
| AT | | AMNEAL PHARMS | 5% | A206297 | 001 | Aug 07, 2015 |
| AT | ! | FOUGERA PHARMS INC | 5% | A080198 | 001 | |
| AT | | GLENMARK PHARMS LTD | 5% | A206498 | 001 | Sep 09, 2016 |
| AT | | RICONPHARMA LLC | 5% | A208604 | 001 | Sep 20, 2017 |
| AT | | SEPTODONT INC | 5% | A040911 | 001 | May 23, 2011 |
| AT | | TARO | 5% | A086724 | 001 | |
| AT | | TELIGENT PHARMA INC | 5% | A205318 | 001 | Feb 01, 2016 |
| AT | | VITRUVIAS THERAP | 5% | A208822 | 001 | Sep 25, 2017 |

PATCH;TOPICAL

**LIDOCAINE**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | | ACTAVIS LABS UT INC | 5% | A200675 | 001 | Aug 23, 2012 |
| AB | | MYLAN TECHNOLOGIES | 5% | A202346 | 001 | Aug 07, 2015 |

**LIDODERM**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AB | +! | TEIKOKU PHARMA USA | 5% | N020612 | 001 | Mar 19, 1999 |

LIDOCAINE HYDROCHLORIDE

GEL;OPHTHALMIC

AKTEN

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | AKORN | 3.5% | N022221 | 001 | Oct 07, 2008 |

INJECTABLE;INJECTION

**LIDOCAINE HYDROCHLORIDE**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | | AUROBINDO PHARMA LTD | 1% | A207182 | 001 | Oct 30, 2017 |
| AP | | | 2% | A207182 | 002 | Oct 30, 2017 |
| AP | | HOSPIRA | 0.5% | A088328 | 001 | May 17, 1984 |
| AP | | | 1% | A083158 | 001 | |
| AP | | | 1% | A088329 | 001 | May 17, 1984 |
| AP | | | 2% | A040078 | 001 | Jun 23, 1995 |
| AP | | | 2% | A083158 | 002 | |
| AP | | | 2% | A088294 | 001 | May 17, 1984 |
| AP | | | 20% | A083158 | 003 | |
| AP | | INTL MEDICATION | 1% | A083173 | 001 | |
| AP | | | 2% | A083173 | 002 | |
| AP | | LUITPOLD | 1% | A080850 | 001 | |
| AP | | LUITPOLD PHARMS INC | 1% | A091564 | 001 | Aug 14, 2015 |

**LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | | B BRAUN | 200MG/100ML | N019830 | 002 | Apr 08, 1992 |
| AP | | BAXTER HLTHCARE | 200MG/100ML | N018461 | 002 | |

**LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | | B BRAUN | 400MG/100ML | N019830 | 003 | Apr 08, 1992 |
| AP | | BAXTER HLTHCARE | 400MG/100ML | N018461 | 003 | |

**LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | | B BRAUN | 800MG/100ML | N019830 | 004 | Apr 08, 1992 |
| AP | | BAXTER HLTHCARE | 800MG/100ML | N018461 | 004 | Feb 22, 1982 |

**LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | | FRESENIUS KABI USA | 1% | A088586 | 001 | Jul 24, 1985 |
| AP | | HOSPIRA | 0.5% | A088325 | 001 | Jul 31, 1984 |
| AP | | | 1% | A088299 | 001 | Jul 31, 1984 |
| AP | | | 2% | A088327 | 001 | Jul 31, 1984 |

**LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| AP | | AUROBINDO PHARMA LTD | 1% | A203040 | 001 | Mar 14, 2013 |
| AP | | | 1% | A203082 | 001 | Mar 14, 2013 |
| AP | | | 2% | A203040 | 002 | Mar 14, 2013 |
| AP | | | 2% | A203082 | 002 | Mar 14, 2013 |
| AP | | FRESENIUS KABI USA | 1% | A080404 | 002 | |
| AP | | | 2% | A080404 | 003 | |
| AP | | | 2% | N017584 | 001 | |
| AP | | | 4% | N017584 | 002 | |
| AP | | HOSPIRA | 1% | A080408 | 001 | |

| | | | | | | |
|---|---|---|---|---|---|---|
| LIDOCAINE HYDROCHLORIDE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| **LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE** | | | | | | |
| **AP** | | | **1.5%** | **A080408** | **002** | |
| **AP** | | | **4%** | **A088295** | **001** | May 17, 1984 |
| **AP** | | INTL MEDICATION | **20%** | **N017702** | **001** | |
| **LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER** | | | | | | |
| **AP** | | HOSPIRA | **1%** | **A040302** | **001** | Sep 28, 1998 |
| **AP** | | | **2%** | **A040302** | **002** | Sep 28, 1998 |
| **XYLOCAINE** | | | | | | |
| **AP** | **+!** | FRESENIUS KABI USA | **0.5%** | **N006488** | **008** | |
| **AP** | **+!** | | **1%** | **N006488** | **007** | |
| **AP** | **+!** | | **1.5%** | **N006488** | **010** | |
| **AP** | **+!** | | **2%** | **N006488** | **002** | |
| **XYLOCAINE 4% PRESERVATIVE FREE** | | | | | | |
| **AP** | **+!** | FRESENIUS KABI USA | **4%** | **N010417** | **001** | |
| **XYLOCAINE PRESERVATIVE FREE** | | | | | | |
| **AP** | **+!** | FRESENIUS KABI USA | **1%** | **N016801** | **005** | Jan 19, 1988 |
| **AP** | **+!** | | **2%** | **N016801** | **001** | |
| **AP** | **+!** | | **4%** | **N016801** | **002** | |
| **AP** | **+!** | | **20%** | **N016801** | **004** | |
| INJECTABLE;SPINAL | | | | | | |
| LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5% | | | | | | |
| | ! | HOSPIRA | 5% | A083914 | 001 | |
| JELLY;TOPICAL | | | | | | |
| **GLYDO** | | | | | | |
| **AT** | | SAGENT PHARMS | **2%** | **A201094** | **001** | Apr 28, 2014 |
| **LIDOCAINE HYDROCHLORIDE** | | | | | | |
| **AT** | | AKORN | **2%** | **A040433** | **001** | Feb 12, 2003 |
| **AT** | | INTL MEDICATION | **2%** | **A086283** | **001** | |
| **AT** | | WATSON LABS INC | **2%** | **A040837** | **001** | Mar 23, 2011 |
| **XYLOCAINE** | | | | | | |
| **AT** | **+!** | OAK PHARMS | **2%** | **N008816** | **001** | |
| SOLUTION;ORAL | | | | | | |
| **LIDOCAINE HYDROCHLORIDE** | | | | | | |
| **AT** | | HI TECH PHARMA | **2%** | **A040014** | **001** | Jul 10, 1995 |
| **AT** | | WOCKHARDT BIO AG | **2%** | **A087872** | **001** | Nov 18, 1982 |
| **LIDOCAINE HYDROCHLORIDE VISCOUS** | | | | | | |
| **AT** | **!** | VINTAGE | **2%** | **A040708** | **001** | Feb 27, 2007 |
| **LIDOCAINE VISCOUS** | | | | | | |
| **AT** | | WEST-WARD PHARMS INT | **2%** | **A088802** | **001** | Apr 26, 1985 |
| SOLUTION;TOPICAL | | | | | | |
| **LARYNG-O-JET KIT** | | | | | | |
| **AT** | | INTL MEDICATION | **4%** | **A086364** | **001** | |
| **LIDOCAINE HYDROCHLORIDE** | | | | | | |
| **AT** | | TELIGENT PHARMA INC | **4%** | **A204494** | **001** | Mar 12, 2014 |
| **AT** | | VINTAGE | **4%** | **A040710** | **001** | Feb 27, 2007 |
| **AT** | | WEST-WARD PHARMS INT | **4%** | **A088803** | **001** | Apr 03, 1985 |
| **AT** | | WOCKHARDT BIO AG | **4%** | **A087881** | **001** | Nov 18, 1982 |
| **LTA II KIT** | | | | | | |
| **AT** | | HOSPIRA | **4%** | **A080409** | **001** | |
| **XYLOCAINE 4% PRESERVATIVE FREE** | | | | | | |
| **AT** | **+!** | FRESENIUS KABI USA | **4%** | **N010417** | **002** | |
| SYSTEM;INTRADERMAL | | | | | | |
| ZINGO | | | | | | |
| | | POWDER PHARMS | 0.5MG | N022114 | 001 | Aug 16, 2007 |
| LIDOCAINE; PRILOCAINE | | | | | | |
| CREAM;TOPICAL | | | | | | |
| **EMLA** | | | | | | |
| **AB** | **+!** | ACTAVIS LABS UT INC | **2.5%;2.5%** | **N019941** | **001** | Dec 30, 1992 |
| **LIDOCAINE AND PRILOCAINE** | | | | | | |
| **AB** | | FOUGERA PHARMS | **2.5%;2.5%** | **A076453** | **001** | Aug 18, 2003 |
| **AB** | | HI TECH PHARMA | **2.5%;2.5%** | **A076290** | **001** | Sep 25, 2003 |
| **AB** | | TOLMAR | **2.5%;2.5%** | **A076320** | **001** | Aug 27, 2003 |
| GEL;PERIODONTAL | | | | | | |
| ORAQIX | | | | | | |
| | +! | DENTSPLY PHARM | 2.5%;2.5% | N021451 | 001 | Dec 19, 2003 |

| | | | | | | |
|---|---|---|---|---|---|---|
| LIDOCAINE; TETRACAINE | | | | | | |
| CREAM;TOPICAL | | | | | | |
| PLIAGLIS | | | | | | |
| | +! | TARO PHARMS | 7%;7% | N021717 | 001 | Jun 29, 2006 |
| PATCH;TOPICAL | | | | | | |
| SYNERA | | | | | | |
| | +! | GALEN SPECIALTY | 70MG;70MG | N021623 | 001 | Jun 23, 2005 |
| LIFITEGRAST | | | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | | | |
| XIIDRA | | | | | | |
| | +! | SHIRE DEV LLC | 5% | N208073 | 001 | Jul 11, 2016 |
| LINACLOTIDE | | | | | | |
| CAPSULE;ORAL | | | | | | |
| LINZESS | | | | | | |
| | + | FOREST LABS LLC | 72MCG | N202811 | 003 | Jan 25, 2017 |
| | + | | 145MCG | N202811 | 001 | Aug 30, 2012 |
| | +! | | 290MCG | N202811 | 002 | Aug 30, 2012 |
| LINAGLIPTIN | | | | | | |
| TABLET;ORAL | | | | | | |
| TRADJENTA | | | | | | |
| | +! | BOEHRINGER INGELHEIM | 5MG | N201280 | 001 | May 02, 2011 |
| LINAGLIPTIN; METFORMIN HYDROCHLORIDE | | | | | | |
| TABLET;ORAL | | | | | | |
| JENTADUETO | | | | | | |
| | + | BOEHRINGER INGELHEIM | 2.5MG;500MG | N201281 | 001 | Jan 30, 2012 |
| | + | | 2.5MG;850MG | N201281 | 002 | Jan 30, 2012 |
| | +! | | 2.5MG;1GM | N201281 | 003 | Jan 30, 2012 |
| TABLET, EXTENDED RELEASE;ORAL | | | | | | |
| JENTADUETO XR | | | | | | |
| | + | BOEHRINGER INGELHEIM | 2.5MG;1GM | N208026 | 001 | May 27, 2016 |
| | +! | | 5MG;1GM | N208026 | 002 | May 27, 2016 |
| LINCOMYCIN HYDROCHLORIDE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| **LINCOCIN** | | | | | | |
| **AP** | **+!** | PHARMACIA AND UPJOHN | **EQ 300MG BASE/ML** | **N050317** | **001** | |
| **LINCOMYCIN** | | | | | | |
| **AP** | | X-GEN PHARMS INC | **EQ 300MG BASE/ML** | **A201746** | **001** | Jun 04, 2015 |
| LINDANE | | | | | | |
| LOTION;TOPICAL | | | | | | |
| **LINDANE** | | | | | | |
| **AT** | | OLTA PHARMS | **1%** | **A087313** | **001** | |
| **AT** | **!** | WOCKHARDT | **1%** | **A088190** | **001** | Aug 16, 1984 |
| SHAMPOO;TOPICAL | | | | | | |
| **LINDANE** | | | | | | |
| **AT** | | OLTA PHARMS | **1%** | **A087266** | **001** | |
| **AT** | **!** | WOCKHARDT BIO AG | **1%** | **A088191** | **001** | Sep 18, 1984 |
| LINEZOLID | | | | | | |
| FOR SUSPENSION;ORAL | | | | | | |
| **LINEZOLID** | | | | | | |
| **AB** | | WEST-WARD PHARMS INT | **100MG/5ML** | **A200068** | **001** | Jun 03, 2015 |
| **ZYVOX** | | | | | | |
| **AB** | **+!** | PHARMACIA AND UPJOHN | **100MG/5ML** | **N021132** | **001** | Apr 18, 2000 |
| SOLUTION;IV (INFUSION) | | | | | | |
| **LINEZOLID** | | | | | | |
| **AP** | | AUROBINDO PHARMA LTD | **600MG/300ML (2MG/ML)** | **A206917** | **001** | Aug 04, 2016 |
| **AP** | | FRESENIUS KABI USA | **600MG/300ML (2MG/ML)** | **A204764** | **001** | Mar 15, 2016 |
| **AP** | | HOSPIRA INC | **600MG/300ML (2MG/ML)** | **A205442** | **001** | Jul 07, 2015 |
| **AP** | | HQ SPCLT PHARMA | **200MG/100ML (2MG/ML)** | **A207001** | **001** | Jul 07, 2017 |
| **AP** | | | **600MG/300ML (2MG/ML)** | **A207001** | **002** | Jul 07, 2017 |
| **AP** | | MYLAN LABS LTD | **200MG/100ML (2MG/ML)** | **A205154** | **001** | Dec 06, 2017 |
| **AP** | | | **600MG/300ML (2MG/ML)** | **A205154** | **002** | Dec 06, 2017 |
| **AP** | | NANG KUANG PHARM CO | **200MG/100ML (2MG/ML)** | **A207354** | **001** | Dec 20, 2016 |
| **AP** | | | **600MG/300ML (2MG/ML)** | **A207354** | **002** | Dec 20, 2016 |

LINEZOLID

SOLUTION;IV (INFUSION)

**LINEZOLID**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | SAGENT PHARMS | **200MG/100ML (2MG/ML)** | **A204696** | **001** | Mar 02, 2017 |
| **AP** | | | **600MG/300ML (2MG/ML)** | **A204696** | **002** | Mar 02, 2017 |
| **AP** | | SANDOZ INC | **200MG/100ML (2MG/ML)** | **A200904** | **001** | Jul 16, 2015 |
| **AP** | | | **600MG/300ML (2MG/ML)** | **A200904** | **002** | Jul 16, 2015 |
| **AP** | | TEVA PHARMS | **600MG/300ML (2MG/ML)** | **A200222** | **001** | Jun 27, 2012 |

**ZYVOX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | + | PHARMACIA AND UPJOHN | **200MG/100ML (2MG/ML)** | **N021131** | **001** | Apr 18, 2000 |
| **AP** | +! | | **600MG/300ML (2MG/ML)** | **N021131** | **003** | Apr 18, 2000 |

LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | HOSPIRA INC | 600MG/300ML (2MG/ML) | N206473 | 001 | Jun 18, 2015 |

ZYVOX

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | PHARMACIA AND UPJOHN | 400MG/200ML (2MG/ML) | N021131 | 002 | Apr 18, 2000 |

TABLET;ORAL

**LINEZOLID**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALEMBIC PHARMS LTD | **600MG** | **A205233** | **001** | Dec 21, 2015 |
| **AB** | | ALKEM LABS LTD | **600MG** | **A205517** | **001** | Dec 21, 2015 |
| **AB** | | AMNEAL PHARMS | **600MG** | **A204536** | **001** | Dec 21, 2015 |
| **AB** | | GATE PHARMS | **600MG** | **A091210** | **001** | Feb 05, 2016 |
| **AB** | | GLENMARK PHARMS | **600MG** | **A078987** | **001** | Dec 21, 2015 |
| **AB** | | HETERO LABS LTD V | **600MG** | **A204239** | **001** | Dec 21, 2015 |
| **AB** | | MYLAN PHARMS INC | **600MG** | **A078845** | **001** | Dec 21, 2015 |
| **AB** | | NOVEL LABS INC | **600MG** | **A207526** | **001** | Aug 22, 2016 |
| **AB** | | TEVA PHARMS USA | **600MG** | **A078061** | **001** | May 18, 2015 |
| **AB** | | ZYDUS PHARMS USA INC | **600MG** | **A206097** | **001** | Feb 22, 2017 |

**ZYVOX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | +! | PHARMACIA AND UPJOHN | **600MG** | **N021130** | **002** | Apr 18, 2000 |

LIOTHYRONINE SODIUM

INJECTABLE;INJECTION

**LIOTHYRONINE SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | X GEN PHARMS | **EQ 0.01MG BASE/ML** | **A076923** | **001** | Aug 17, 2005 |

**TRIOSTAT**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | +! | PAR STERILE PRODUCTS | **EQ 0.01MG BASE/ML** | **N020105** | **001** | Dec 31, 1991 |

TABLET;ORAL

**CYTOMEL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | KING PHARMS | **EQ 0.005MG BASE** | **N010379** | **001** | |
| **AB** | + | | **EQ 0.025MG BASE** | **N010379** | **002** | |
| **AB** | +! | | **EQ 0.05MG BASE** | **N010379** | **003** | |

**LIOTHYRONINE SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | MAYNE PHARMA INC | **EQ 0.005MG BASE** | **A090097** | **001** | Mar 20, 2009 |
| **AB** | | | **EQ 0.025MG BASE** | **A090097** | **002** | Mar 20, 2009 |
| **AB** | | | **EQ 0.05MG BASE** | **A090097** | **003** | Mar 20, 2009 |
| **AB** | | MYLAN | **EQ 0.005MG BASE** | **A090326** | **001** | Jul 14, 2009 |
| **AB** | | | **EQ 0.025MG BASE** | **A090326** | **002** | Jul 14, 2009 |
| **AB** | | | **EQ 0.05MG BASE** | **A090326** | **003** | Jul 14, 2009 |
| **AB** | | SIGMAPHARM LABS LLC | **EQ 0.005MG BASE** | **A200295** | **001** | Nov 29, 2012 |
| **AB** | | | **EQ 0.025MG BASE** | **A200295** | **002** | Nov 29, 2012 |
| **AB** | | | **EQ 0.05MG BASE** | **A200295** | **003** | Nov 29, 2012 |
| **AB** | | SUN PHARM INDS LTD | **EQ 0.005MG BASE** | **A091382** | **001** | Apr 20, 2016 |
| **AB** | | | **EQ 0.025MG BASE** | **A091382** | **002** | Apr 20, 2016 |
| **AB** | | | **EQ 0.05MG BASE** | **A091382** | **003** | Apr 20, 2016 |

LIOTRIX (T4;T3)

TABLET;ORAL

THYROLAR-0.25

| | | | | |
|---|---|---|---|---|
| + | FOREST LABS | 0.0125MG;0.0031MG | N016807 | 001 |

THYROLAR-0.5

| | | | | |
|---|---|---|---|---|
| + | FOREST LABS | 0.025MG;0.0063MG | N016807 | 005 |

THYROLAR-1

| | | | | |
|---|---|---|---|---|
| + | FOREST LABS | 0.05MG;0.0125MG | N016807 | 004 |

THYROLAR-2

| | | | | |
|---|---|---|---|---|
| + | FOREST LABS | 0.1MG;0.025MG | N016807 | 002 |

THYROLAR-3

| | | | | |
|---|---|---|---|---|
| +! | FOREST LABS | 0.15MG;0.0375MG | N016807 | 003 |

| | | | | | | |
|---|---|---|---|---|---|---|
| LIRAGLUTIDE RECOMBINANT | | | | | | |
| SOLUTION;SUBCUTANEOUS | | | | | | |
| SAXENDA | | | | | | |
| +! | NOVO NORDISK INC | 18MG/3ML (6MG/ML) | | N206321 | 001 | Dec 23, 2014 |
| VICTOZA | | | | | | |
| +! | NOVO NORDISK INC | 18MG/3ML (6MG/ML) | | N022341 | 001 | Jan 25, 2010 |
| LISDEXAMFETAMINE DIMESYLATE | | | | | | |
| CAPSULE;ORAL | | | | | | |
| VYVANSE | | | | | | |
| + | SHIRE DEVELOPMENT | 10MG | | N021977 | 007 | Oct 30, 2014 |
| + | | 20MG | | N021977 | 004 | Dec 10, 2007 |
| + | | 30MG | | N021977 | 001 | Feb 23, 2007 |
| + | | 40MG | | N021977 | 005 | Dec 10, 2007 |
| + | | 50MG | | N021977 | 002 | Feb 23, 2007 |
| + | | 60MG | | N021977 | 006 | Dec 10, 2007 |
| +! | | 70MG | | N021977 | 003 | Feb 23, 2007 |
| TABLET, CHEWABLE;ORAL | | | | | | |
| VYVANSE | | | | | | |
| + | SHIRE DEV LLC | 10MG | | N208510 | 001 | Jan 28, 2017 |
| + | | 20MG | | N208510 | 002 | Jan 28, 2017 |
| + | | 30MG | | N208510 | 003 | Jan 28, 2017 |
| + | | 40MG | | N208510 | 004 | Jan 28, 2017 |
| + | | 50MG | | N208510 | 005 | Jan 28, 2017 |
| +! | | 60MG | | N208510 | 006 | Jan 28, 2017 |
| LISINOPRIL | | | | | | |
| SOLUTION;ORAL | | | | | | |
| QBRELIS | | | | | | |
| +! | SILVERGATE PHARMS | 1MG/ML | | N208401 | 001 | Jul 29, 2016 |
| TABLET;ORAL | | | | | | |
| **LISINOPRIL** | | | | | | |
| **AB** | ACCORD HLTHCARE | **2.5MG** | | **A202554** | **001** | Jul 30, 2013 |
| **AB** | | **5MG** | | **A202554** | **002** | Jul 30, 2013 |
| **AB** | | **10MG** | | **A202554** | **003** | Jul 30, 2013 |
| **AB** | | **20MG** | | **A202554** | **004** | Jul 30, 2013 |
| **AB** | | **30MG** | | **A202554** | **005** | Jul 30, 2013 |
| **AB** | | **40MG** | | **A202554** | **006** | Jul 30, 2013 |
| **AB** | APOTEX INC | **2.5MG** | | **A076102** | **001** | Sep 30, 2002 |
| **AB** | | **5MG** | | **A076102** | **002** | Sep 30, 2002 |
| **AB** | | **10MG** | | **A076102** | **003** | Sep 30, 2002 |
| **AB** | | **20MG** | | **A076102** | **004** | Sep 30, 2002 |
| **AB** | | **30MG** | | **A076102** | **005** | Sep 30, 2002 |
| **AB** | | **40MG** | | **A076102** | **006** | Sep 30, 2002 |
| **AB** | AUROBINDO | **2.5MG** | | **A077622** | **001** | Feb 22, 2006 |
| **AB** | | **5MG** | | **A077622** | **002** | Feb 22, 2006 |
| **AB** | | **10MG** | | **A077622** | **003** | Feb 22, 2006 |
| **AB** | | **20MG** | | **A077622** | **004** | Feb 22, 2006 |
| **AB** | | **30MG** | | **A077622** | **005** | Feb 22, 2006 |
| **AB** | | **40MG** | | **A077622** | **006** | Feb 22, 2006 |
| **AB** | HIKMA INTL PHARMS | **2.5MG** | | **A076063** | **001** | Jul 01, 2002 |
| **AB** | | **5MG** | | **A076063** | **002** | Jul 01, 2002 |
| **AB** | | **10MG** | | **A076063** | **003** | Jul 01, 2002 |
| **AB** | | **20MG** | | **A076063** | **004** | Jul 01, 2002 |
| **AB** | | **30MG** | | **A076063** | **006** | Jun 27, 2003 |
| **AB** | | **40MG** | | **A076063** | **005** | Jul 01, 2002 |
| **AB** | INVAGEN PHARMS | **2.5MG** | | **A203508** | **001** | Oct 29, 2013 |
| **AB** | | **5MG** | | **A203508** | **002** | Oct 29, 2013 |
| **AB** | | **10MG** | | **A203508** | **003** | Oct 29, 2013 |
| **AB** | | **20MG** | | **A203508** | **004** | Oct 29, 2013 |
| **AB** | | **30MG** | | **A203508** | **005** | Oct 29, 2013 |
| **AB** | | **40MG** | | **A203508** | **006** | Oct 29, 2013 |
| **AB** | IVAX SUB TEVA PHARMS | **2.5MG** | | **A075752** | **001** | Jul 01, 2002 |
| **AB** | | **5MG** | | **A075752** | **002** | Jul 01, 2002 |
| **AB** | | **10MG** | | **A075752** | **003** | Jul 01, 2002 |
| **AB** | | **20MG** | | **A075752** | **004** | Jul 01, 2002 |
| **AB** | | **30MG** | | **A075752** | **005** | Jul 01, 2002 |
| **AB** | | **40MG** | | **A075752** | **006** | Jul 01, 2002 |
| **AB** | LUPIN | **2.5MG** | | **A077321** | **001** | Sep 09, 2005 |
| **AB** | | **5MG** | | **A077321** | **002** | Sep 09, 2005 |
| **AB** | | **10MG** | | **A077321** | **003** | Sep 09, 2005 |
| **AB** | | **20MG** | | **A077321** | **004** | Sep 09, 2005 |
| **AB** | | **30MG** | | **A077321** | **005** | Sep 09, 2005 |

LISINOPRIL

TABLET;ORAL

**LISINOPRIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | **40MG** | **A077321** | **006** | Sep 09, 2005 |
| **AB** | MYLAN | **2.5MG** | **A076071** | **001** | Jul 01, 2002 |
| **AB** | | **5MG** | **A076071** | **002** | Jul 01, 2002 |
| **AB** | | **10MG** | **A076071** | **003** | Jul 01, 2002 |
| **AB** | | **20MG** | **A076071** | **004** | Jul 01, 2002 |
| **AB** | | **30MG** | **A076071** | **005** | Jul 01, 2002 |
| **AB** | | **40MG** | **A076071** | **006** | Jul 01, 2002 |
| **AB** | PRINSTON INC | **2.5MG** | **A075743** | **001** | Jul 01, 2002 |
| **AB** | | **2.5MG** | **A076180** | **001** | Jul 01, 2002 |
| **AB** | | **5MG** | **A075743** | **002** | Jul 01, 2002 |
| **AB** | | **5MG** | **A076180** | **002** | Jul 01, 2002 |
| **AB** | | **10MG** | **A075743** | **003** | Jul 01, 2002 |
| **AB** | | **10MG** | **A076180** | **003** | Jul 01, 2002 |
| **AB** | | **20MG** | **A075743** | **004** | Jul 01, 2002 |
| **AB** | | **20MG** | **A076164** | **001** | Jul 01, 2002 |
| **AB** | | **30MG** | **A075743** | **005** | Jul 01, 2002 |
| **AB** | | **30MG** | **A076164** | **002** | Jul 01, 2002 |
| **AB** | | **40MG** | **A075743** | **006** | Jul 01, 2002 |
| **AB** | | **40MG** | **A076164** | **003** | Jul 01, 2002 |
| **AB** | SANDOZ | **2.5MG** | **A075994** | **001** | Jul 01, 2002 |
| **AB** | | **5MG** | **A075994** | **002** | Jul 01, 2002 |
| **AB** | | **10MG** | **A075994** | **003** | Jul 01, 2002 |
| **AB** | | **20MG** | **A075994** | **004** | Jul 01, 2002 |
| **AB** | | **30MG** | **A075994** | **005** | Jul 01, 2002 |
| **AB** | | **40MG** | **A075994** | **006** | Jul 01, 2002 |
| **AB** | SUN PHARM INDS LTD | **2.5MG** | **A075944** | **001** | Jul 01, 2002 |
| **AB** | | **5MG** | **A075944** | **002** | Jul 01, 2002 |
| **AB** | | **10MG** | **A075944** | **003** | Jul 01, 2002 |
| **AB** | | **20MG** | **A075944** | **004** | Jul 01, 2002 |
| **AB** | | **30MG** | **A075944** | **006** | Feb 11, 2003 |
| **AB** | | **40MG** | **A075944** | **005** | Jul 01, 2002 |
| **AB** | WATSON LABS | **2.5MG** | **A076059** | **001** | Jul 01, 2002 |
| **AB** | | **5MG** | **A076059** | **002** | Jul 01, 2002 |
| **AB** | | **10MG** | **A076059** | **003** | Jul 01, 2002 |
| **AB** | | **20MG** | **A076059** | **004** | Jul 01, 2002 |
| **AB** | | **30MG** | **A076059** | **005** | Jul 01, 2002 |
| **AB** | | **40MG** | **A076059** | **006** | Jul 01, 2002 |
| **AB** | WOCKHARDT | **2.5MG** | **A078402** | **001** | Apr 19, 2007 |
| **AB** | | **5MG** | **A078402** | **002** | Apr 19, 2007 |
| **AB** | | **10MG** | **A078402** | **003** | Apr 19, 2007 |
| **AB** | | **20MG** | **A078402** | **004** | Apr 19, 2007 |
| **AB** | | **30MG** | **A078402** | **005** | Apr 19, 2007 |
| **AB** | | **40MG** | **A078402** | **006** | Apr 19, 2007 |

**PRINIVIL**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | MERCK | **5MG** | **N019558** | **001** | Dec 29, 1987 |
| **AB** | | **10MG** | **N019558** | **002** | Dec 29, 1987 |
| **AB** | | **20MG** | **N019558** | **003** | Dec 29, 1987 |
| **AB** | | **40MG** | **N019558** | **004** | Oct 25, 1988 |

**ZESTRIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | ALVOGEN MALTA | **2.5MG** | **N019777** | **005** | Apr 29, 1993 |
| **AB** | + | | **5MG** | **N019777** | **001** | May 19, 1988 |
| **AB** | + | | **10MG** | **N019777** | **002** | May 19, 1988 |
| **AB** | + | | **20MG** | **N019777** | **003** | May 19, 1988 |
| **AB** | + | | **30MG** | **N019777** | **006** | Jan 20, 1999 |
| **AB** | +! | | **40MG** | **N019777** | **004** | May 19, 1988 |

LITHIUM CARBONATE

CAPSULE;ORAL

**LITHIUM CARBONATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | ALEMBIC LTD | **150MG** | **A079159** | **001** | Jan 12, 2009 |
| **AB** | | **300MG** | **A079159** | **002** | Jan 12, 2009 |
| **AB** | | **600MG** | **A079159** | **003** | Jan 12, 2009 |
| **AB** | GLENMARK GENERICS | **150MG** | **A079139** | **001** | Feb 03, 2009 |
| **AB** | | **300MG** | **A079139** | **002** | Feb 03, 2009 |
| **AB** | | **600MG** | **A079139** | **003** | Feb 03, 2009 |
| **AB** | HETERO LABS LTD III | **150MG** | **A090702** | **001** | Sep 25, 2009 |
| **AB** | | **300MG** | **A090702** | **002** | Sep 25, 2009 |
| **AB** | | **600MG** | **A090702** | **003** | Sep 25, 2009 |
| **AB** | MYLAN PHARMS INC | **150MG** | **A076243** | **002** | Feb 24, 2003 |
| **AB** | | **300MG** | **A076243** | **001** | Jun 27, 2002 |

LITHIUM CARBONATE

CAPSULE;ORAL

**LITHIUM CARBONATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **600MG** | **A078763** | **001** | Apr 15, 2008 |
| **AB** | + | WEST-WARD PHARMS INT | **150MG** | **N017812** | **002** | Jan 28, 1987 |
| **AB** | + | | **300MG** | **N017812** | **001** | |
| **AB** | +! | | **600MG** | **N017812** | **003** | Jan 28, 1987 |

TABLET;ORAL

**LITHIUM CARBONATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | SUN PHARM INDS INC | **300MG** | **A091027** | **001** | Jun 24, 2010 |
| **AB** | +! | WEST-WARD PHARMS INT | **300MG** | **N018558** | **001** | Jan 29, 1982 |

TABLET, EXTENDED RELEASE;ORAL

**LITHIUM CARBONATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALEMBIC PHARMS LTD | **300MG** | **A204445** | **001** | Jun 10, 2015 |
| **AB** | | GLENMARK GENERICS | **450MG** | **A091616** | **001** | Feb 14, 2011 |
| **AB** | | GLENMARK PHARMS INC | **300MG** | **A091544** | **001** | Dec 27, 2010 |
| **AB** | | HERITAGE PHARMA | **300MG** | **A205532** | **001** | Sep 29, 2016 |
| **AB** | | MYLAN PHARMS INC | **300MG** | **A202288** | **001** | Jun 29, 2012 |
| **AB** | | | **450MG** | **A202219** | **001** | Aug 08, 2012 |
| **AB** | | UNIQUE PHARM LABS | **300MG** | **A204779** | **001** | Jul 27, 2015 |
| **AB** | | | **450MG** | **A205663** | **001** | Jun 05, 2017 |
| **AB** | | WEST-WARD PHARMS INT | **300MG** | **A076832** | **001** | Oct 28, 2004 |
| **AB** | ! | | **450MG** | **A076691** | **001** | Jan 05, 2004 |

**LITHOBID**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | +! | ANI PHARMS INC | **300MG** | **N018027** | **001** | |

LITHIUM CITRATE

SYRUP;ORAL

**LITHIUM CITRATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | +! | WEST-WARD PHARMS INT | **EQ 300MG CARBONATE/5ML** | **N018421** | **001** | |
| **AA** | | WOCKHARDT BIO AG | **EQ 300MG CARBONATE/5ML** | **A070755** | **001** | May 21, 1986 |

LIXISENATIDE

SOLUTION;SUBCUTANEOUS

ADLYXIN

| | | | | | |
|---|---|---|---|---|---|
| +! | SANOFI-AVENTIS US | 0.15MG/3ML (0.05MG/ML) | N208471 | 001 | Jul 27, 2016 |
| +! | | 0.3MG/3ML (0.1MG/ML) | N208471 | 002 | Jul 27, 2016 |

LODOXAMIDE TROMETHAMINE

SOLUTION/DROPS;OPHTHALMIC

ALOMIDE

| | | | | | |
|---|---|---|---|---|---|
| +! | NOVARTIS PHARMS CORP | EQ 0.1% BASE | N020191 | 001 | Sep 23, 1993 |

LOMITAPIDE MESYLATE

CAPSULE;ORAL

JUXTAPID

| | | | | | |
|---|---|---|---|---|---|
| + | AEGERION | EQ 5MG BASE | N203858 | 001 | Dec 21, 2012 |
| + | | EQ 10MG BASE | N203858 | 002 | Dec 21, 2012 |
| + | | EQ 20MG BASE | N203858 | 003 | Dec 21, 2012 |
| + | | EQ 30MG BASE | N203858 | 004 | Apr 23, 2015 |
| + | | EQ 40MG BASE | N203858 | 005 | Apr 23, 2015 |
| +! | | EQ 60MG BASE | N203858 | 006 | Apr 23, 2015 |

LOMUSTINE

CAPSULE;ORAL

GLEOSTINE

| | | | | | |
|---|---|---|---|---|---|
| + | CORDEN PHARMA | 5MG | N017588 | 004 | Dec 19, 2014 |
| + | | 10MG | N017588 | 001 | |
| + | | 40MG | N017588 | 002 | |
| +! | | 100MG | N017588 | 003 | |

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

**LOPERAMIDE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | ! | MYLAN | **2MG** | **A072741** | **001** | Sep 18, 1991 |
| **AB** | | TEVA | **2MG** | **A073192** | **001** | Apr 30, 1992 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| LOPINAVIR; RITONAVIR | | | | | | | |
| SOLUTION;ORAL | | | | | | | |
| **KALETRA** | | | | | | | |
| **AA** | **+!** | ABBVIE | **80MG/ML;20MG/ML** | **N021251** | **001** | Sep 15, 2000 |
| **LOPINAVIR AND RITONAVIR** | | | | | | | |
| **AA** | | SILARX PHARMS INC | **80MG/ML;20MG/ML** | **A207407** | **001** | Dec 27, 2016 |
| TABLET;ORAL | | | | | | | |
| KALETRA | | | | | | | |
| | + | ABBVIE | 100MG;25MG | N021906 | 002 | Nov 09, 2007 |
| | +! | | 200MG;50MG | N021906 | 001 | Oct 28, 2005 |
| LORAZEPAM | | | | | | | |
| CONCENTRATE;ORAL | | | | | | | |
| **LORAZEPAM** | | | | | | | |
| **AA** | | AMNEAL PHARMS | **2MG/ML** | **A091383** | **001** | Dec 23, 2009 |
| **AA** | | HI-TECH PHARMA CO | **2MG/ML** | **A200169** | **001** | Jan 30, 2012 |
| **AA** | | LUPIN LTD | **2MG/ML** | **A091407** | **001** | Feb 19, 2013 |
| **AA** | | PHARM ASSOC | **2MG/ML** | **A090260** | **001** | Jun 15, 2010 |
| **AA** | | SAPTALIS PHARMS | **2MG/ML** | **A079244** | **001** | Apr 28, 2009 |
| **LORAZEPAM INTENSOL** | | | | | | | |
| **AA** | **!** | WEST-WARD PHARMS INT | **2MG/ML** | **A072755** | **001** | Jun 28, 1991 |
| INJECTABLE;INJECTION | | | | | | | |
| **ATIVAN** | | | | | | | |
| **AP** | **+!** | WEST-WARD PHARMS INT | **2MG/ML** | **N018140** | **001** | |
| **AP** | **+!** | | **4MG/ML** | **N018140** | **002** | |
| **LORAZEPAM** | | | | | | | |
| **AP** | | AKORN | **2MG/ML** | **A075025** | **001** | Jul 23, 1998 |
| **AP** | | HOSPIRA | **2MG/ML** | **A074243** | **001** | Apr 12, 1994 |
| **AP** | | | **2MG/ML** | **A074282** | **001** | May 27, 1994 |
| **AP** | | | **4MG/ML** | **A074243** | **002** | Apr 12, 1994 |
| **AP** | | | **4MG/ML** | **A074282** | **002** | May 27, 1994 |
| **AP** | | INTL MEDICATION SYS | **2MG/ML** | **A076150** | **001** | Nov 15, 2004 |
| **LORAZEPAM PRESERVATIVE FREE** | | | | | | | |
| **AP** | | BEDFORD LABS | **2MG/ML** | **A077074** | **001** | Jul 13, 2005 |
| **AP** | | | **4MG/ML** | **A077074** | **002** | Jul 13, 2005 |
| TABLET;ORAL | | | | | | | |
| **ATIVAN** | | | | | | | |
| **AB** | **+** | VALEANT INTL | **0.5MG** | **N017794** | **001** | |
| **AB** | **+** | | **1MG** | **N017794** | **002** | |
| **AB** | **+!** | | **2MG** | **N017794** | **003** | |
| **LORAZEPAM** | | | | | | | |
| **AB** | | AMNEAL PHARMS | **0.5MG** | **A078826** | **001** | Jun 23, 2010 |
| **AB** | | | **1MG** | **A078826** | **002** | Jun 23, 2010 |
| **AB** | | | **2MG** | **A078826** | **003** | Jun 23, 2010 |
| **AB** | | ANI PHARMS INC | **0.5MG** | **A077396** | **001** | Dec 13, 2006 |
| **AB** | | | **1MG** | **A077396** | **002** | Dec 13, 2006 |
| **AB** | | | **2MG** | **A077396** | **003** | Dec 13, 2006 |
| **AB** | | AUROLIFE PHARMA LLC | **0.5MG** | **A203572** | **001** | Dec 22, 2017 |
| **AB** | | | **1MG** | **A203572** | **002** | Dec 22, 2017 |
| **AB** | | | **2MG** | **A203572** | **003** | Dec 22, 2017 |
| **AB** | | LEADING PHARMA LLC | **0.5MG** | **A078203** | **001** | Jul 30, 2007 |
| **AB** | | | **1MG** | **A078203** | **002** | Jul 30, 2007 |
| **AB** | | | **2MG** | **A078203** | **003** | Jul 30, 2007 |
| **AB** | | MYLAN | **0.5MG** | **A071589** | **001** | Oct 13, 1987 |
| **AB** | | | **0.5MG** | **A077657** | **001** | Mar 16, 2006 |
| **AB** | | | **1MG** | **A071590** | **001** | Oct 13, 1987 |
| **AB** | | | **1MG** | **A077657** | **002** | Mar 16, 2006 |
| **AB** | | | **2MG** | **A077657** | **003** | Mar 16, 2006 |
| **AB** | | SANDOZ | **0.5MG** | **A071141** | **002** | Apr 21, 1987 |
| **AB** | | | **1MG** | **A071141** | **003** | Apr 21, 1987 |
| **AB** | | | **2MG** | **A071141** | **001** | Apr 21, 1987 |
| **AB** | | SUN PHARM INDS LTD | **0.5MG** | **A076045** | **001** | Aug 29, 2001 |
| **AB** | | | **1MG** | **A076045** | **002** | Aug 29, 2001 |
| **AB** | | | **2MG** | **A076045** | **003** | Aug 29, 2001 |
| **AB** | | VINTAGE PHARMS | **0.5MG** | **A077754** | **001** | May 10, 2006 |
| **AB** | | | **1MG** | **A077754** | **002** | May 10, 2006 |
| **AB** | | | **2MG** | **A077754** | **003** | May 10, 2006 |
| **AB** | | WATSON LABS | **0.5MG** | **A072926** | **001** | Oct 31, 1991 |
| **AB** | | | **1MG** | **A072927** | **001** | Oct 31, 1991 |
| **AB** | | | **2MG** | **A072928** | **001** | Oct 31, 1991 |

LORCASERIN HYDROCHLORIDE

TABLET;ORAL

BELVIQ

| | | | | | | |
|---|---|---|---|---|---|---|
| +! | EISAI INC | 10MG | | N022529 | 001 | Jun 27, 2012 |

TABLET, EXTENDED RELEASE;ORAL

BELVIQ XR

| | | | | | | |
|---|---|---|---|---|---|---|
| +! | EISAI INC | 20MG | | N208524 | 001 | Jul 15, 2016 |

LOSARTAN POTASSIUM

TABLET;ORAL

**COZAAR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | MERCK SHARP DOHME | **25MG** | **N020386** | **001** | Apr 14, 1995 |
| **AB** | **+** | | **50MG** | **N020386** | **002** | Apr 14, 1995 |
| **AB** | **+!** | | **100MG** | **N020386** | **003** | Oct 13, 1998 |

**LOSARTAN POTASSIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALEMBIC PHARMS LTD | **25MG** | **A090428** | **001** | Oct 06, 2010 |
| **AB** | | | **50MG** | **A090428** | **002** | Oct 06, 2010 |
| **AB** | | | **100MG** | **A090428** | **003** | Oct 06, 2010 |
| **AB** | | APOTEX CORP | **25MG** | **A090790** | **001** | Oct 06, 2010 |
| **AB** | | | **50MG** | **A090790** | **002** | Oct 06, 2010 |
| **AB** | | | **100MG** | **A090790** | **003** | Oct 06, 2010 |
| **AB** | | AUROBINDO PHARMA | **25MG** | **A090083** | **001** | Oct 06, 2010 |
| **AB** | | | **50MG** | **A090083** | **002** | Oct 06, 2010 |
| **AB** | | | **100MG** | **A090083** | **003** | Oct 06, 2010 |
| **AB** | | CADISTA PHARMS | **25MG** | **A201170** | **001** | Sep 18, 2012 |
| **AB** | | | **50MG** | **A201170** | **002** | Sep 18, 2012 |
| **AB** | | | **100MG** | **A201170** | **003** | Sep 18, 2012 |
| **AB** | | HETERO LABS LTD V | **25MG** | **A203835** | **001** | Aug 12, 2015 |
| **AB** | | | **50MG** | **A203835** | **002** | Aug 12, 2015 |
| **AB** | | | **100MG** | **A203835** | **003** | Aug 12, 2015 |
| **AB** | | IPCA LABS LTD | **25MG** | **A200290** | **001** | Aug 30, 2013 |
| **AB** | | | **50MG** | **A200290** | **002** | Aug 30, 2013 |
| **AB** | | | **100MG** | **A200290** | **003** | Aug 30, 2013 |
| **AB** | | LUPIN LTD | **25MG** | **A078232** | **001** | Oct 06, 2010 |
| **AB** | | | **50MG** | **A078232** | **002** | Oct 06, 2010 |
| **AB** | | | **100MG** | **A078232** | **003** | Oct 06, 2010 |
| **AB** | | MACLEODS PHARMS LTD | **25MG** | **A202230** | **001** | May 30, 2012 |
| **AB** | | | **50MG** | **A202230** | **002** | May 30, 2012 |
| **AB** | | | **100MG** | **A202230** | **003** | May 30, 2012 |
| **AB** | | MYLAN | **25MG** | **A091590** | **001** | Oct 06, 2010 |
| **AB** | | | **50MG** | **A091590** | **002** | Oct 06, 2010 |
| **AB** | | | **100MG** | **A091590** | **003** | Oct 06, 2010 |
| **AB** | | PRINSTON INC | **25MG** | **A091497** | **001** | Jun 06, 2011 |
| **AB** | | | **50MG** | **A091497** | **002** | Jun 06, 2011 |
| **AB** | | | **100MG** | **A091497** | **003** | Jun 06, 2011 |
| **AB** | | SANDOZ | **25MG** | **A077424** | **001** | Oct 06, 2010 |
| **AB** | | | **50MG** | **A077424** | **002** | Oct 06, 2010 |
| **AB** | | | **100MG** | **A077424** | **003** | Oct 06, 2010 |
| **AB** | | TEVA | **25MG** | **A076958** | **001** | Apr 06, 2010 |
| **AB** | | | **50MG** | **A076958** | **002** | Apr 06, 2010 |
| **AB** | | | **100MG** | **A076958** | **003** | Apr 06, 2010 |
| **AB** | | TORRENT PHARMS | **25MG** | **A090467** | **001** | Oct 06, 2010 |
| **AB** | | | **50MG** | **A090467** | **002** | Oct 06, 2010 |
| **AB** | | | **100MG** | **A090467** | **003** | Oct 06, 2010 |
| **AB** | | UNICHEM LABS LTD | **25MG** | **A203030** | **001** | Oct 14, 2015 |
| **AB** | | | **50MG** | **A203030** | **002** | Oct 14, 2015 |
| **AB** | | | **100MG** | **A203030** | **003** | Oct 14, 2015 |
| **AB** | | UPSHER-SMITH LABS | **25MG** | **A090544** | **001** | Oct 06, 2010 |
| **AB** | | | **50MG** | **A090544** | **002** | Oct 06, 2010 |
| **AB** | | | **100MG** | **A090544** | **003** | Oct 06, 2010 |
| **AB** | | VIVA HLTHCARE | **25MG** | **A091541** | **001** | Sep 24, 2012 |
| **AB** | | | **50MG** | **A091541** | **002** | Sep 24, 2012 |
| **AB** | | | **100MG** | **A091541** | **003** | Sep 24, 2012 |
| **AB** | | VIVIMED GLOBAL | **25MG** | **A090382** | **001** | Oct 06, 2010 |
| **AB** | | | **50MG** | **A090382** | **002** | Oct 06, 2010 |
| **AB** | | | **100MG** | **A090382** | **003** | Oct 06, 2010 |
| **AB** | | WATSON LABS | **25MG** | **A091129** | **001** | Oct 06, 2010 |
| **AB** | | | **50MG** | **A091129** | **002** | Oct 06, 2010 |
| **AB** | | | **100MG** | **A091129** | **003** | Oct 06, 2010 |
| **AB** | | WEST-WARD PHARMS INT | **25MG** | **A077459** | **001** | Oct 06, 2010 |
| **AB** | | | **50MG** | **A077459** | **002** | Oct 06, 2010 |
| **AB** | | | **100MG** | **A077459** | **003** | Oct 06, 2010 |

LOSARTAN POTASSIUM

TABLET;ORAL

**LOSARTAN POTASSIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ZYDUS PHARMS USA INC | **25MG** | **A078243** | **001** | Oct 06, 2010 |
| **AB** | | | **50MG** | **A078243** | **002** | Oct 06, 2010 |
| **AB** | | | **100MG** | **A078243** | **003** | Oct 06, 2010 |

LOTEPREDNOL ETABONATE

GEL;OPHTHALMIC

LOTEMAX

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | BAUSCH AND LOMB INC | 0.5% | N202872 | 001 | Sep 28, 2012 |

OINTMENT;OPHTHALMIC

LOTEMAX

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | BAUSCH AND LOMB | 0.5% | N200738 | 001 | Apr 15, 2011 |

SUSPENSION/DROPS;OPHTHALMIC

ALREX

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | BAUSCH AND LOMB | 0.2% | N020803 | 001 | Mar 09, 1998 |

LOTEMAX

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | BAUSCH AND LOMB | 0.5% | N020583 | 001 | Mar 09, 1998 |

LOTEPREDNOL ETABONATE; TOBRAMYCIN

SUSPENSION/DROPS;OPHTHALMIC

ZYLET

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | BAUSCH AND LOMB | 0.5%;0.3% | N050804 | 001 | Dec 14, 2004 |

LOVASTATIN

TABLET;ORAL

**LOVASTATIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS ELIZABETH | **10MG** | **A075828** | **001** | Dec 17, 2001 |
| **AB** | | | **20MG** | **A075828** | **002** | Dec 17, 2001 |
| **AB** | | | **40MG** | **A075828** | **003** | Dec 17, 2001 |
| **AB** | | APOTEX INC | **10MG** | **A077748** | **001** | Feb 28, 2007 |
| **AB** | | | **20MG** | **A077748** | **002** | Feb 28, 2007 |
| **AB** | | | **40MG** | **A077748** | **003** | Feb 28, 2007 |
| **AB** | | CARLSBAD | **10MG** | **A075991** | **001** | Jun 05, 2002 |
| **AB** | | | **20MG** | **A075991** | **002** | Jun 05, 2002 |
| **AB** | **!** | | **40MG** | **A075991** | **003** | Jun 05, 2002 |
| **AB** | | LUPIN | **10MG** | **A078296** | **001** | Mar 14, 2008 |
| **AB** | | | **20MG** | **A078296** | **002** | Nov 01, 2007 |
| **AB** | | | **40MG** | **A078296** | **003** | Nov 01, 2007 |
| **AB** | | MYLAN | **10MG** | **A075451** | **001** | Dec 17, 2001 |
| **AB** | | | **20MG** | **A075451** | **002** | Dec 17, 2001 |
| **AB** | | | **40MG** | **A075451** | **003** | Dec 17, 2001 |
| **AB** | | SANDOZ | **10MG** | **A075300** | **001** | Dec 17, 2001 |
| **AB** | | | **10MG** | **A075636** | **001** | Dec 17, 2001 |
| **AB** | | | **20MG** | **A075300** | **002** | Dec 17, 2001 |
| **AB** | | | **20MG** | **A075636** | **002** | Dec 17, 2001 |
| **AB** | | | **40MG** | **A075300** | **003** | Dec 17, 2001 |
| **AB** | | | **40MG** | **A075636** | **003** | Dec 17, 2001 |
| **AB** | | SUN PHARM INDUSTRIES | **10MG** | **A077520** | **001** | Apr 14, 2006 |
| **AB** | | | **20MG** | **A077520** | **002** | Apr 14, 2006 |
| **AB** | | | **40MG** | **A077520** | **003** | Apr 14, 2006 |
| **AB** | | TEVA | **10MG** | **A075551** | **003** | Dec 17, 2001 |
| **AB** | | | **20MG** | **A075551** | **002** | Dec 17, 2001 |
| **AB** | | | **40MG** | **A075551** | **001** | Dec 17, 2001 |

TABLET, EXTENDED RELEASE;ORAL

ALTOPREV

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | COVIS PHARMA BV | 20MG | N021316 | 002 | Jun 26, 2002 |
| | + | | 40MG | N021316 | 003 | Jun 26, 2002 |
| | +! | | 60MG | N021316 | 004 | Jun 26, 2002 |

LOXAPINE

POWDER;INHALATION

ADASUVE

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | GALEN UK | 10MG | N022549 | 001 | Dec 21, 2012 |

LOXAPINE SUCCINATE

CAPSULE;ORAL

**LOXAPINE SUCCINATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ELITE LABS INC | **EQ 5MG BASE** | **A076868** | **001** | Aug 04, 2005 |
| **AB** | | | **EQ 10MG BASE** | **A076868** | **002** | Aug 04, 2005 |
| **AB** | | | **EQ 25MG BASE** | **A076868** | **003** | Aug 04, 2005 |
| **AB** | | | **EQ 50MG BASE** | **A076868** | **004** | Aug 04, 2005 |

LOXAPINE SUCCINATE

CAPSULE;ORAL

**LOXAPINE SUCCINATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | LANNETT HOLDINGS INC | **EQ 5MG BASE** | **A090695** | **001** | Sep 26, 2011 |
| **AB** | | | **EQ 10MG BASE** | **A090695** | **002** | Sep 26, 2011 |
| **AB** | | | **EQ 25MG BASE** | **A090695** | **003** | Sep 26, 2011 |
| **AB** | | | **EQ 50MG BASE** | **A090695** | **004** | Sep 26, 2011 |
| **AB** | | MYLAN | **EQ 5MG BASE** | **A076762** | **001** | Nov 01, 2004 |
| **AB** | | | **EQ 10MG BASE** | **A076762** | **002** | Nov 01, 2004 |
| **AB** | | | **EQ 25MG BASE** | **A076762** | **003** | Nov 01, 2004 |
| **AB** | | | **EQ 50MG BASE** | **A076762** | **004** | Nov 01, 2004 |
| **AB** | | WATSON LABS | **EQ 5MG BASE** | **A072204** | **001** | Jun 15, 1988 |
| **AB** | | | **EQ 10MG BASE** | **A072205** | **001** | Jun 15, 1988 |
| **AB** | **!** | | **EQ 25MG BASE** | **A072206** | **001** | Jun 15, 1988 |
| **AB** | | | **EQ 50MG BASE** | **A072062** | **001** | Jun 15, 1988 |

LUBIPROSTONE

CAPSULE;ORAL

AMITIZA

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | SUCAMPO PHARMA LLC | 8MCG | N021908 | 002 | Apr 29, 2008 |
| | +! | | 24MCG | N021908 | 001 | Jan 31, 2006 |

LULICONAZOLE

CREAM;TOPICAL

LUZU

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | MEDICIS | 1% | N204153 | 001 | Nov 14, 2013 |

LURASIDONE HYDROCHLORIDE

TABLET;ORAL

LATUDA

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | SUNOVION PHARMS INC | 20MG | N200603 | 003 | Dec 07, 2011 |
| | +! | | 40MG | N200603 | 001 | Oct 28, 2010 |
| | + | | 60MG | N200603 | 005 | Jul 12, 2013 |
| | + | | 80MG | N200603 | 002 | Oct 28, 2010 |
| | + | | 120MG | N200603 | 004 | Apr 26, 2012 |

MACIMORELIN ACETATE

FOR SOLUTION;ORAL

MACRILEN

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | AETERNA ZENTARIS | EQ 60MG BASE/POUCH | N205598 | 001 | Dec 21, 2017 |

MACITENTAN

TABLET;ORAL

OPSUMIT

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ACTELION PHARMS LTD | 10MG | N204410 | 001 | Oct 18, 2013 |

MAFENIDE ACETATE

CREAM;TOPICAL

SULFAMYLON

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | MYLAN INSTITUTIONAL | EQ 85MG BASE/GM | N016763 | 001 | |

FOR SOLUTION;TOPICAL

**MAFENIDE ACETATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | NOVAST LABS LTD | **5%** | **A206716** | **001** | Jul 31, 2017 |
| **AT** | | PAR FORM | **5%** | **A201511** | **001** | Feb 12, 2013 |

**SULFAMYLON**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **+!** | MYLAN INSTITUTIONAL | **5%** | **N019832** | **003** | Jun 05, 1998 |

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INJECTION

ISOLYTE S PH 7.4 IN PLASTIC CONTAINER

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | B BRAUN | 30MG/100ML;37MG/100ML;0.82MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML;12MG/100ML | N019696 | 001 | Sep 29, 1989 |

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

**PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | BAXTER HLTHCARE | **30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML** | **N017378** | **001** | |

**PLASMA-LYTE A IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | BAXTER HLTHCARE | **30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML** | **N017378** | **002** | Nov 22, 1982 |

ISOLYTE S IN PLASTIC CONTAINER

| | | | | | | |
|---|---|---|---|---|---|---|
| | | B BRAUN | 30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML | N019711 | 001 | Sep 29, 1989 |

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

NORMOSOL-R IN PLASTIC CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| | ICU MEDICAL INC | 30MG/100ML;37MG/100ML;222MG/100ML;526MG /100ML;502MG/100ML | N017586 | 001 | |

SOLUTION;IRRIGATION

PHYSIOLYTE IN PLASTIC CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| | B BRAUN | 30MG/100ML;37MG/100ML;370MG/100ML;530MG /100ML;500MG/100ML | N019024 | 001 | Jun 08, 1984 |

PHYSIOSOL IN PLASTIC CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| | ICU MEDICAL INC | 30MG/100ML;37MG/100ML;222MG/100ML;526MG /100ML;502MG/100ML | N017637 | 002 | Jul 08, 1982 |

MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

SOLUTION;INJECTION

NORMOCARB HF 25

| | | | | | |
|---|---|---|---|---|---|
| +! | DIALYSIS SUPS | 0.21GM/100ML;2.8GM/100ML;9.07GM/100ML | N021910 | 001 | Jul 26, 2006 |

NORMOCARB HF 35

| | | | | | |
|---|---|---|---|---|---|
| +! | DIALYSIS SUPS | 0.21GM/100ML;3.97GM/100ML;8.3GM/100ML | N021910 | 002 | Jul 26, 2006 |

MAGNESIUM SULFATE

INJECTABLE;INJECTION

**MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | FRESENIUS KABI USA | **1GM/100ML** | **A206486** | **001** | Mar 07, 2016 |
| **AP** | **+!** | HOSPIRA | **1GM/100ML** | **N020488** | **001** | Jul 11, 1995 |
| **AP** | | HQ SPCLT PHARMA | **1GM/100ML** | **A207349** | **001** | Mar 02, 2016 |

**MAGNESIUM SULFATE IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | FRESENIUS KABI USA | **4GM/100ML (40MG/ML)** | **A206485** | **001** | Mar 15, 2016 |
| **AP** | | | **4GM/50ML (80MG/ML)** | **A206485** | **002** | Mar 15, 2016 |
| **AP** | | | **2GM/50ML (40MG/ML)** | **A206485** | **003** | Mar 15, 2016 |
| **AP** | | | **20GM/500ML (40MG/ML)** | **A206485** | **004** | Mar 15, 2016 |
| **AP** | | | **40GM/1000ML (40MG/ML)** | **A206485** | **005** | Mar 15, 2016 |
| **AP** | **+** | HOSPIRA | **2GM/50ML (40MG/ML)** | **N020309** | **003** | Jan 26, 2007 |
| **AP** | **+!** | | **4GM/100ML (40MG/ML)** | **N020309** | **001** | Jun 24, 1994 |
| **AP** | **+!** | | **4GM/50ML (80MG/ML)** | **N020309** | **002** | Jun 24, 1994 |
| **AP** | **+** | | **20GM/500ML (40MG/ML)** | **N020309** | **004** | Jan 18, 1995 |
| **AP** | **+** | | **40GM/1000ML (40MG/ML)** | **N020309** | **005** | Jan 18, 1995 |
| **AP** | | HQ SPCLT PHARMA | **2GM/50ML (40MG/ML)** | **A207350** | **001** | Dec 06, 2017 |
| **AP** | | | **4GM/100ML (40MG/ML)** | **A207350** | **002** | Dec 06, 2017 |
| **AP** | | | **4GM/50ML (80MG/ML)** | **A207350** | **003** | Dec 06, 2017 |
| **AP** | | | **20GM/500ML (40MG/ML)** | **A207350** | **004** | Dec 06, 2017 |
| **AP** | | | **40GM/1000ML (40MG/ML)** | **A207350** | **005** | Dec 06, 2017 |

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| +! | HOSPIRA | 2GM/100ML | N020488 | 002 | Jul 11, 1995 |

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

**MAGNESIUM SULFATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | EXELA PHARMA SCS LLC | **5GM/10ML (500MG/ML)** | **A206039** | **001** | Dec 18, 2014 |
| **AP** | **+!** | FRESENIUS KABI USA | **5GM/10ML (500MG/ML)** | **N019316** | **001** | Sep 08, 1986 |
| **AP** | **!** | HOSPIRA | **5GM/10ML (500MG/ML)** | **A075151** | **001** | Apr 25, 2000 |
| | +! | FRESENIUS KABI USA | 10GM/20ML (500MG/ML) | N019316 | 003 | Jan 29, 2016 |
| | +! | | 25GM/50ML (500MG/ML) | N019316 | 004 | Jan 29, 2016 |
| | | HOSPIRA INC | 10GM/20ML (500MG/ML) | A202411 | 001 | May 14, 2015 |

MAGNESIUM SULFATE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

| | | | | | |
|---|---|---|---|---|---|
| +! | FRESENIUS KABI USA | 1GM/2ML (500MG/ML) | N019316 | 002 | Sep 08, 1986 |

MAGNESIUM SULFATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION;IRRIGATION

**TIS-U-SOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | BAXTER HLTHCARE | **20MG/100ML;40MG/100ML;6.25MG/100ML;800M G/100ML;8.75MG/100ML** | **N018508** | **001** | Feb 19, 1982 |

**TIS-U-SOL IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | BAXTER HLTHCARE | **20MG/100ML;40MG/100ML;6.25MG/100ML;800M G/100ML;8.75MG/100ML** | **N018336** | **001** | |

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

POWDER;ORAL

COLPREP KIT

| | | | | | |
|---|---|---|---|---|---|
| +! | GATOR PHARMS | 1.6GM/BOT;3.13GM/BOT;17.5GM/BOT | N204553 | 001 | Dec 27, 2016 |

SOLUTION;ORAL

**SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | NOVEL LABS INC | **1.6GM/BOT;3.13GM/BOT;17.5GM/BOT** | **A202511** | **001** | Feb 23, 2017 |

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION;ORAL

**SUPREP BOWEL PREP KIT**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **+!** | BRAINTREE LABS | **1.6GM/BOT;3.13GM/BOT;17.5GM/BOT** | **N022372** | **001** | Aug 05, 2010 |

MALATHION

LOTION;TOPICAL

**MALATHION**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | SUVEN LIFE | **0.5%** | **A091559** | **001** | May 23, 2012 |

**OVIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **+!** | TARO PHARM | **0.5%** | **N018613** | **001** | Aug 02, 1982 |

MANGANESE CHLORIDE

INJECTABLE;INJECTION

MANGANESE CHLORIDE IN PLASTIC CONTAINER

| | | | | | | |
|---|---|---|---|---|---|---|
| | | HOSPIRA | EQ 0.1MG MANGANESE/ML | N018962 | 001 | Jun 26, 1986 |

MANNITOL

INJECTABLE;INJECTION

**MANNITOL 10% IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | B BRAUN | **10GM/100ML** | **N020006** | **002** | Jul 26, 1993 |
| **AP** | | ICU MEDICAL INC | **10GM/100ML** | **N019603** | **002** | Jan 08, 1987 |

**MANNITOL 15% IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | B BRAUN | **15GM/100ML** | **N020006** | **003** | Jul 26, 1993 |
| **AP** | | ICU MEDICAL INC | **15GM/100ML** | **N019603** | **003** | Jan 08, 1990 |

**MANNITOL 20% IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | B BRAUN | **20GM/100ML** | **N020006** | **004** | Jul 26, 1993 |
| **AP** | | ICU MEDICAL INC | **20GM/100ML** | **N019603** | **004** | Jan 08, 1990 |

**MANNITOL 25%**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | FRESENIUS KABI USA | **12.5GM/50ML** | **A080677** | **001** | |
| **AP** | | HOSPIRA | **12.5GM/50ML** | **N016269** | **006** | Aug 25, 1994 |
| **AP** | | INTL MEDICATION | **12.5GM/50ML** | **A083051** | **001** | |
| **AP** | | LUITPOLD | **12.5GM/50ML** | **A087409** | **001** | Jan 21, 1982 |

**MANNITOL 5% IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | B BRAUN | **5GM/100ML** | **N020006** | **001** | Jul 26, 1993 |
| **AP** | | ICU MEDICAL INC | **5GM/100ML** | **N019603** | **001** | Jan 08, 1987 |

**OSMITROL 10% IN WATER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | BAXTER HLTHCARE | **10GM/100ML** | **N013684** | **002** | |

**OSMITROL 10% IN WATER IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | BAXTER HLTHCARE | **10GM/100ML** | **N013684** | **006** | |

**OSMITROL 15% IN WATER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | BAXTER HLTHCARE | **15GM/100ML** | **N013684** | **004** | |

**OSMITROL 15% IN WATER IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | BAXTER HLTHCARE | **15GM/100ML** | **N013684** | **008** | |

**OSMITROL 20% IN WATER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | BAXTER HLTHCARE | **20GM/100ML** | **N013684** | **003** | |

**OSMITROL 20% IN WATER IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | BAXTER HLTHCARE | **20GM/100ML** | **N013684** | **007** | |

**OSMITROL 5% IN WATER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | BAXTER HLTHCARE | **5GM/100ML** | **N013684** | **001** | |

**OSMITROL 5% IN WATER IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | BAXTER HLTHCARE | **5GM/100ML** | **N013684** | **005** | |

SOLUTION;IRRIGATION

RESECTISOL IN PLASTIC CONTAINER

| | | | | | | |
|---|---|---|---|---|---|---|
| | | B BRAUN | 5GM/100ML | N016772 | 002 | |

MANNITOL; SORBITOL

SOLUTION;IRRIGATION

SORBITOL-MANNITOL IN PLASTIC CONTAINER

| | | | | | | |
|---|---|---|---|---|---|---|
| | | ICU MEDICAL INC | 540MG/100ML;2.7GM/100ML | N018316 | 001 | |

MAPROTILINE HYDROCHLORIDE

TABLET;ORAL

MAPROTILINE HYDROCHLORIDE

| | | | | | | |
|---|---|---|---|---|---|---|
| | | MYLAN | 25MG | A072285 | 002 | Oct 03, 1988 |
| | ! | | 50MG | A072285 | 001 | Oct 03, 1988 |
| | | | 75MG | A072285 | 003 | Oct 03, 1988 |

MARAVIROC

SOLUTION;ORAL

SELZENTRY

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | VIIV HLTHCARE | 20MG/ML | N208984 | 001 | Nov 04, 2016 |

TABLET;ORAL

SELZENTRY

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | VIIV HLTHCARE | 25MG | N022128 | 003 | Nov 04, 2016 |

MARAVIROC
TABLET;ORAL
SELZENTRY

| | | | | | |
|---|---|---|---|---|---|
| + | | 75MG | N022128 | 004 | Nov 04, 2016 |
| + | | 150MG | N022128 | 001 | Aug 06, 2007 |
| +! | | 300MG | N022128 | 002 | Aug 06, 2007 |

MEBENDAZOLE
TABLET, CHEWABLE;ORAL
EMVERM

| | | | | | |
|---|---|---|---|---|---|
| ! | IMPAX LABS INC | 100MG | A073580 | 001 | Jan 04, 1995 |

VERMOX

| | | | | | |
|---|---|---|---|---|---|
| +! | JANSSEN PHARMS | 500MG | N208398 | 001 | Oct 19, 2016 |

MECAMYLAMINE HYDROCHLORIDE
TABLET;ORAL
MECAMYLAMINE HYDROCHLORIDE

| | | | | | |
|---|---|---|---|---|---|
| ! | NEXGEN PHARMA | 2.5MG | A204054 | 001 | Mar 19, 2013 |

MECASERMIN RECOMBINANT
INJECTABLE;SUBCUTANEOUS
INCRELEX

| | | | | | |
|---|---|---|---|---|---|
| +! | IPSEN INC | 40MG/4ML (10MG/ML) | N021839 | 001 | Aug 30, 2005 |

MECHLORETHAMINE HYDROCHLORIDE
GEL;TOPICAL
VALCHLOR

| | | | | | |
|---|---|---|---|---|---|
| +! | ACTELION PHARMS LTD | EQ 0.016% BASE | N202317 | 001 | Aug 23, 2013 |

INJECTABLE;INJECTION
MUSTARGEN

| | | | | | |
|---|---|---|---|---|---|
| +! | RECORDATI RARE | 10MG/VIAL | N006695 | 001 | |

MECLIZINE HYDROCHLORIDE
TABLET;ORAL
**MECLIZINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | AMNEAL PHARMS | **12.5MG** | **A201451** | **001** | Feb 23, 2011 |
| **AA** | | **25MG** | **A201451** | **002** | Feb 23, 2011 |
| **AA** | EPIC PHARMA LLC | **12.5MG** | **A200294** | **001** | Apr 13, 2012 |
| **AA** | | **25MG** | **A200294** | **002** | Apr 13, 2012 |
| **AA** | JUBILANT CADISTA | **12.5MG** | **A040659** | **001** | Jun 04, 2010 |
| **AA** | | **25MG** | **A040659** | **002** | Jun 04, 2010 |
| **AA** | MYLAN PHARMS INC | **12.5MG** | **A202640** | **001** | Sep 17, 2012 |
| **AA** | | **25MG** | **A202640** | **002** | Sep 17, 2012 |
| **AA** | PAR PHARM | **12.5MG** | **A087127** | **001** | |
| **AA** | | **25MG** | **A087128** | **001** | |
| **AA** | SANDOZ | **12.5MG** | **A084843** | **002** | May 22, 1989 |
| **AA** | | **25MG** | **A084092** | **003** | May 22, 1989 |

MECLOFENAMATE SODIUM
CAPSULE;ORAL
MECLOFENAMATE SODIUM

| | | | | | |
|---|---|---|---|---|---|
| | MYLAN | EQ 50MG BASE | A071081 | 002 | Sep 03, 1986 |
| ! | | EQ 100MG BASE | A071081 | 001 | Sep 03, 1986 |

MEDROXYPROGESTERONE ACETATE
INJECTABLE;INJECTION
**DEPO-PROVERA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | PHARMACIA AND UPJOHN | **150MG/ML** | **N020246** | **001** | Oct 29, 1992 |

**MEDROXYPROGESTERONE ACETATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AMPHASTAR PHARMS INC | **150MG/ML** | **A077235** | **001** | Nov 28, 2017 |
| **AB** | | | **150MG/ML** | **A077334** | **001** | Nov 28, 2017 |
| **AB** | | TEVA PHARMS USA | **150MG/ML** | **A076553** | **001** | Jul 28, 2004 |

DEPO-PROVERA

| | | | | | |
|---|---|---|---|---|---|
| +! | PHARMACIA AND UPJOHN | 400MG/ML | N012541 | 003 | |

INJECTABLE;SUBCUTANEOUS
DEPO-SUBQ PROVERA 104

| | | | | | |
|---|---|---|---|---|---|
| +! | PHARMACIA AND UPJOHN | 104MG/0.65ML | N021583 | 001 | Dec 17, 2004 |

TABLET;ORAL
**MEDROXYPROGESTERONE ACETATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | BARR | **2.5MG** | **A040159** | **001** | Aug 09, 1996 |
| **AB** | | **5MG** | **A040159** | **002** | Aug 09, 1996 |
| **AB** | | **10MG** | **A040159** | **003** | Aug 09, 1996 |

MEDROXYPROGESTERONE ACETATE

TABLET;ORAL

**PROVERA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | PHARMACIA AND UPJOHN | **2.5MG** | **N011839** | **001** | |
| **AB** | + | | **5MG** | **N011839** | **003** | |
| **AB** | +! | | **10MG** | **N011839** | **004** | |

MEFENAMIC ACID

CAPSULE;ORAL

**MEFENAMIC ACID**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | BRECKENRIDGE PHARM | **250MG** | **A090359** | **001** | Feb 05, 2013 |
| **AB** | | LUPIN LTD | **250MG** | **A091322** | **001** | Jul 22, 2011 |
| **AB** | | VINTAGE PHARMS LLC | **250MG** | **A091608** | **001** | Jun 02, 2014 |
| **AB** | | VIVA HLTHCARE | **250MG** | **A090562** | **001** | Nov 19, 2010 |

**PONSTEL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | +! | SHIONOGI INC | **250MG** | **N015034** | **003** | |

MEFLOQUINE HYDROCHLORIDE

TABLET;ORAL

**MEFLOQUINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | ! | BARR | **250MG** | **A076392** | **001** | Dec 29, 2003 |
| **AB** | | WEST-WARD PHARMS INT | **250MG** | **A076523** | **001** | Oct 01, 2004 |

MEGESTROL ACETATE

SUSPENSION;ORAL

**MEGACE ES**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | +! | ENDO PHARMS INC | **125MG/ML** | **N021778** | **001** | Jul 05, 2005 |

**MEGESTROL ACETATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | BRECKENRIDGE PHARM | **125MG/ML** | **A204688** | **001** | Dec 01, 2017 |
| **AB** | | HI-TECH PHARMACAL | **40MG/ML** | **A203960** | **001** | Jun 09, 2017 |
| **AB** | | PAR PHARM | **40MG/ML** | **A075671** | **001** | Jul 25, 2001 |
| **AB** | | TEVA PHARMS | **40MG/ML** | **A075681** | **001** | May 05, 2003 |
| **AB** | | TWI PHARMS INC | **125MG/ML** | **A203139** | **001** | Aug 27, 2014 |
| **AB** | ! | WEST-WARD PHARMS INT | **40MG/ML** | **A075997** | **001** | Feb 15, 2002 |
| **AB** | | WOCKHARDT BIO AG | **40MG/ML** | **A076721** | **001** | Nov 01, 2004 |

TABLET;ORAL

**MEGESTROL ACETATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | BARR | **20MG** | **A074621** | **002** | Aug 16, 1996 |
| **AB** | | | **40MG** | **A074621** | **001** | Nov 30, 1995 |
| **AB** | | PAR PHARM | **20MG** | **A072422** | **001** | Aug 08, 1988 |
| **AB** | ! | | **40MG** | **A072423** | **001** | Aug 08, 1988 |
| **AB** | | WEST-WARD PHARMS INT | **20MG** | **A074458** | **001** | Sep 29, 1995 |
| **AB** | | | **40MG** | **A074458** | **002** | Sep 29, 1995 |

MELOXICAM

CAPSULE;ORAL

VIVLODEX

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | IROKO PHARMS LLC | 5MG | N207233 | 001 | Oct 22, 2015 |
| | +! | | 10MG | N207233 | 002 | Oct 22, 2015 |

TABLET;ORAL

**MELOXICAM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | APOTEX INC | **7.5MG** | **A077882** | **001** | Jul 20, 2006 |
| **AB** | | | **15MG** | **A077882** | **002** | Jul 20, 2006 |
| **AB** | | AUROBINDO PHARMA | **7.5MG** | **A078008** | **001** | Oct 02, 2006 |
| **AB** | | | **15MG** | **A078008** | **002** | Oct 02, 2006 |
| **AB** | | BRECKENRIDGE PHARM | **7.5MG** | **A077920** | **001** | Jul 19, 2006 |
| **AB** | | | **15MG** | **A077920** | **002** | Jul 19, 2006 |
| **AB** | | CIPLA LTD | **7.5MG** | **A077929** | **001** | Jul 19, 2006 |
| **AB** | | | **15MG** | **A077929** | **002** | Jul 19, 2006 |
| **AB** | | DR REDDYS LABS INC | **7.5MG** | **A077931** | **001** | Jul 25, 2006 |
| **AB** | | | **15MG** | **A077931** | **002** | Jul 25, 2006 |
| **AB** | | GLENMARK GENERICS | **7.5MG** | **A077932** | **001** | Jul 19, 2006 |
| **AB** | | | **15MG** | **A077932** | **002** | Jul 19, 2006 |
| **AB** | | LUPIN PHARMS | **7.5MG** | **A077944** | **001** | Jul 19, 2006 |
| **AB** | | | **15MG** | **A077944** | **002** | Jul 19, 2006 |
| **AB** | | MYLAN | **7.5MG** | **A077923** | **001** | Jul 19, 2006 |
| **AB** | | | **15MG** | **A077923** | **002** | Jul 19, 2006 |
| **AB** | | PURACAP PHARM | **7.5MG** | **A077938** | **001** | Jul 19, 2006 |
| **AB** | | | **15MG** | **A077938** | **002** | Jul 19, 2006 |
| **AB** | | STRIDES PHARMA | **7.5MG** | **A077928** | **001** | May 13, 2009 |
| **AB** | | | **15MG** | **A077928** | **002** | May 13, 2009 |

MELOXICAM

TABLET;ORAL

**MELOXICAM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | TARO | **7.5MG** | **A078102** | **001** | Nov 07, 2006 |
| **AB** | | | **15MG** | **A078102** | **002** | Nov 07, 2006 |
| **AB** | | TEVA PHARMS | **7.5MG** | **A077936** | **001** | Jul 19, 2006 |
| **AB** | | | **15MG** | **A077936** | **002** | Jul 19, 2006 |
| **AB** | | UNICHEM | **7.5MG** | **A077927** | **001** | Dec 20, 2006 |
| **AB** | | | **15MG** | **A077927** | **002** | Dec 20, 2006 |
| **AB** | | YUNG SHIN PHARM | **7.5MG** | **A077918** | **001** | Dec 07, 2006 |
| **AB** | | | **15MG** | **A077918** | **002** | Dec 07, 2006 |
| **AB** | | ZYDUS PHARMS USA | **7.5MG** | **A077921** | **001** | Jul 19, 2006 |
| **AB** | | | **15MG** | **A077921** | **002** | Jul 19, 2006 |

**MOBIC**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | BOEHRINGER INGELHEIM | **7.5MG** | **N020938** | **001** | Apr 13, 2000 |
| **AB** | +! | | **15MG** | **N020938** | **002** | Aug 23, 2000 |

MELPHALAN

TABLET;ORAL

**ALKERAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | +! | APOTEX INC | **2MG** | **N014691** | **002** | |

**MELPHALAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALVOGEN MALTA | **2MG** | **A207809** | **001** | Mar 22, 2017 |

MELPHALAN HYDROCHLORIDE

INJECTABLE;INJECTION

**MELPHALAN HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | ACTAVIS LLC | **EQ 50MG BASE/VIAL** | **A206018** | **001** | Dec 19, 2016 |
| **AP** | | DR REDDYS LABS LTD | **EQ 50MG BASE/VIAL** | **A203655** | **001** | Dec 08, 2017 |
| **AP** | | FRESENIUS KABI USA | **EQ 50MG BASE/VIAL** | **A203393** | **001** | Dec 22, 2017 |
| **AP** | ! | MYLAN INSTITUTIONAL | **EQ 50MG BASE/VIAL** | **A090270** | **001** | Jun 09, 2009 |
| **AP** | | PAR STERILE PRODUCTS | **EQ 50MG BASE/VIAL** | **A204773** | **001** | Aug 22, 2016 |
| **AP** | | SAGENT PHARMS | **EQ 50MG BASE/VIAL** | **A201379** | **001** | Feb 28, 2017 |
| **AP** | | WEST-WARD PHARMS INT | **EQ 50MG BASE/VIAL** | **A090303** | **001** | Oct 28, 2010 |

POWDER;IV (INFUSION)

EVOMELA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | SPECTRUM PHARMS | EQ 50MG BASE/VIAL | N207155 | 001 | Mar 10, 2016 |

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

**MEMANTINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AMNEAL PHARMS | **7MG** | **A205825** | **001** | Oct 12, 2016 |
| **AB** | | | **14MG** | **A205825** | **002** | Oct 12, 2016 |
| **AB** | | | **21MG** | **A205825** | **003** | Oct 12, 2016 |
| **AB** | | | **28MG** | **A205825** | **004** | Oct 12, 2016 |
| **AB** | | ANCHEN PHARMS | **7MG** | **A205784** | **001** | Jun 09, 2017 |
| **AB** | | | **14MG** | **A205784** | **002** | Jun 09, 2017 |
| **AB** | | | **21MG** | **A205784** | **003** | Jun 09, 2017 |
| **AB** | | | **28MG** | **A205784** | **004** | Jun 09, 2017 |
| **AB** | | APOTEX INC | **7MG** | **A206135** | **001** | Nov 22, 2016 |
| **AB** | | | **14MG** | **A206135** | **002** | Nov 22, 2016 |
| **AB** | | | **21MG** | **A206135** | **003** | Nov 22, 2016 |
| **AB** | | | **28MG** | **A206135** | **004** | Nov 22, 2016 |
| **AB** | | LUPIN LTD | **7MG** | **A206028** | **001** | Sep 28, 2016 |
| **AB** | | | **14MG** | **A206028** | **002** | Sep 28, 2016 |
| **AB** | | | **21MG** | **A206028** | **003** | Sep 28, 2016 |
| **AB** | | | **28MG** | **A206028** | **004** | Sep 28, 2016 |
| **AB** | | MYLAN PHARMS INC | **7MG** | **A206032** | **001** | Sep 28, 2016 |
| **AB** | | | **14MG** | **A206032** | **002** | Sep 28, 2016 |
| **AB** | | | **21MG** | **A206032** | **003** | Sep 28, 2016 |
| **AB** | | | **28MG** | **A206032** | **004** | Sep 28, 2016 |
| **AB** | | SUN PHARMA GLOBAL | **7MG** | **A205905** | **001** | Sep 28, 2016 |
| **AB** | | | **14MG** | **A205905** | **002** | Sep 28, 2016 |
| **AB** | | | **21MG** | **A205905** | **003** | Sep 28, 2016 |
| **AB** | | | **28MG** | **A205905** | **004** | Sep 28, 2016 |
| **AB** | | ZYDUS PHARMS USA INC | **7MG** | **A203293** | **001** | Aug 03, 2017 |
| **AB** | | | **14MG** | **A203293** | **002** | Aug 03, 2017 |
| **AB** | | | **21MG** | **A203293** | **003** | Aug 03, 2017 |
| **AB** | | | **28MG** | **A203293** | **004** | Aug 03, 2017 |

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

**NAMENDA XR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | FOREST LABS LLC | **7MG** | **N022525** | **001** | Jun 21, 2010 |
| **AB** | + | | **14MG** | **N022525** | **002** | Jun 21, 2010 |
| **AB** | + | | **21MG** | **N022525** | **003** | Jun 21, 2010 |
| **AB** | +! | | **28MG** | **N022525** | **004** | Jun 21, 2010 |

SOLUTION;ORAL

**MEMANTINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | BIO-PHARM INC | **2MG/ML** | **A205446** | **001** | Dec 07, 2015 |
| **AA** | | MACLEODS PHARMS LTD | **2MG/ML** | **A202790** | **001** | Oct 13, 2015 |
| **AA** | | SILARX PHARMS INC | **2MG/ML** | **A204033** | **001** | Oct 13, 2015 |

**NAMENDA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | +! | FOREST LABS LLC | **2MG/ML** | **N021627** | **001** | Apr 18, 2005 |

TABLET;ORAL

**MEMANTINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AJANTA PHARMA LTD | **5MG** | **A206528** | **001** | Nov 30, 2015 |
| **AB** | | | **10MG** | **A206528** | **002** | Nov 30, 2015 |
| **AB** | | ALEMBIC PHARMS LTD | **5MG** | **A200891** | **001** | Oct 13, 2015 |
| **AB** | | | **10MG** | **A200891** | **002** | Oct 13, 2015 |
| **AB** | | AMNEAL PHARMS | **5MG** | **A090041** | **001** | Apr 10, 2015 |
| **AB** | | | **10MG** | **A090041** | **002** | Apr 10, 2015 |
| **AB** | | AUROBINDO PHARMA LTD | **5MG** | **A203175** | **001** | Oct 13, 2015 |
| **AB** | | | **10MG** | **A203175** | **002** | Oct 13, 2015 |
| **AB** | | DR REDDYS LABS LTD | **5MG** | **A090048** | **001** | Apr 14, 2010 |
| **AB** | | | **10MG** | **A090048** | **002** | Apr 14, 2010 |
| **AB** | | JUBILANT GENERICS | **5MG** | **A091585** | **001** | Oct 13, 2015 |
| **AB** | | | **10MG** | **A091585** | **002** | Oct 13, 2015 |
| **AB** | | LUPIN LTD | **5MG** | **A090051** | **001** | Apr 10, 2015 |
| **AB** | | | **10MG** | **A090051** | **002** | Apr 10, 2015 |
| **AB** | | MACLEODS PHARMS LTD | **5MG** | **A202840** | **001** | Oct 13, 2015 |
| **AB** | | | **10MG** | **A202840** | **002** | Oct 13, 2015 |
| **AB** | | MYLAN PHARMS INC | **5MG** | **A079225** | **001** | Jan 30, 2015 |
| **AB** | | | **10MG** | **A079225** | **002** | Jan 30, 2015 |
| **AB** | | PURACAP PHARM LLC | **5MG** | **A206855** | **001** | Nov 17, 2015 |
| **AB** | | | **10MG** | **A206855** | **002** | Nov 17, 2015 |
| **AB** | | SILARX PHARMS INC | **5MG** | **A207236** | **001** | Nov 10, 2016 |
| **AB** | | | **10MG** | **A207236** | **002** | Nov 10, 2016 |
| **AB** | | STRIDES PHARMA | **5MG** | **A202350** | **001** | May 23, 2017 |
| **AB** | | | **10MG** | **A202350** | **002** | May 23, 2017 |
| **AB** | | SUN PHARMA GLOBAL | **5MG** | **A090058** | **001** | May 05, 2010 |
| **AB** | | | **10MG** | **A090058** | **002** | May 05, 2010 |
| **AB** | | TEVA PHARMS | **5MG** | **A090052** | **001** | Oct 25, 2011 |
| **AB** | | | **10MG** | **A090052** | **002** | Oct 25, 2011 |
| **AB** | | TORRENT PHARMS LTD | **5MG** | **A200155** | **001** | Oct 13, 2015 |
| **AB** | | | **10MG** | **A200155** | **002** | Oct 13, 2015 |
| **AB** | | UNICHEM LABS LTD | **5MG** | **A200022** | **001** | Oct 13, 2015 |
| **AB** | | | **10MG** | **A200022** | **002** | Oct 13, 2015 |
| **AB** | | UPSHER-SMITH LABS | **5MG** | **A090043** | **001** | Jul 31, 2015 |
| **AB** | | | **10MG** | **A090043** | **002** | Jul 31, 2015 |
| **AB** | | WOCKHARDT LTD | **5MG** | **A090073** | **001** | Sep 04, 2015 |
| **AB** | | | **10MG** | **A090073** | **002** | Sep 04, 2015 |
| **AB** | | ZYDUS PHARMS USA INC | **5MG** | **A090961** | **001** | Jul 10, 2017 |
| **AB** | | | **10MG** | **A090961** | **002** | Jul 10, 2017 |

**NAMENDA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | FOREST LABS LLC | **5MG** | **N021487** | **001** | Oct 16, 2003 |
| **AB** | +! | | **10MG** | **N021487** | **002** | Oct 16, 2003 |

MENOTROPINS (FSH;LH)

INJECTABLE;SUBCUTANEOUS

MENOPUR

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | FERRING | 75 IU/VIAL;75 IU/VIAL | N021663 | 001 | Oct 29, 2004 |

MEPERIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

**DEMEROL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | +! | HOSPIRA | **25MG/ML** | **N021171** | **001** | |
| **AP** | +! | | **50MG/ML** | **N021171** | **002** | |
| **AP** | +! | | **75MG/ML** | **N021171** | **003** | |
| **AP** | +! | | **100MG/ML** | **N021171** | **004** | |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| MEPERIDINE HYDROCHLORIDE | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| **MEPERIDINE HYDROCHLORIDE** | | | | | | | |
| **AP** | | WEST-WARD PHARMS INT | **25MG/ML** | **A080445** | **001** | | |
| **AP** | | | **25MG/ML** | **A080455** | **007** | | |
| **AP** | | | **50MG/ML** | **A080445** | **002** | | |
| **AP** | | | **50MG/ML** | **A080455** | **008** | | |
| **AP** | | | **75MG/ML** | **A080445** | **003** | | |
| **AP** | | | **75MG/ML** | **A080455** | **009** | | |
| **AP** | | | **100MG/ML** | **A080445** | **004** | | |
| **AP** | | | **100MG/ML** | **A080455** | **010** | | |
| **MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE** | | | | | | | |
| **AP** | **!** | ICU MEDICAL INC | **10MG/ML** | **A088432** | **001** | Aug 16, 1984 | |
| **AP** | | WEST-WARD PHARMS INT | **10MG/ML** | **A081002** | **001** | Jul 30, 1993 | |
| SYRUP;ORAL | | | | | | | |
| MEPERIDINE HYDROCHLORIDE | | | | | | | |
| | ! | WEST-WARD PHARMS INT | 50MG/5ML | A088744 | 001 | Jan 30, 1985 | |
| TABLET;ORAL | | | | | | | |
| **DEMEROL** | | | | | | | |
| **AA** | **+!** | US PHARM HOLDINGS | **50MG** | **N005010** | **001** | | |
| **AA** | **+!** | | **100MG** | **N005010** | **004** | | |
| **MEPERIDINE HYDROCHLORIDE** | | | | | | | |
| **AA** | | BARR | **50MG** | **A088639** | **001** | Jul 02, 1984 | |
| **AA** | | | **100MG** | **A088640** | **001** | Sep 19, 1984 | |
| **AA** | | EPIC PHARMA | **50MG** | **A040331** | **001** | May 28, 1999 | |
| **AA** | | | **100MG** | **A040331** | **002** | May 28, 1999 | |
| **AA** | | MIKART | **50MG** | **A040893** | **001** | Jun 24, 2009 | |
| **AA** | | | **100MG** | **A040893** | **003** | Jun 24, 2009 | |
| **AA** | | SPECGX LLC | **50MG** | **A040352** | **001** | Jun 13, 2000 | |
| **AA** | | | **100MG** | **A040352** | **002** | Jun 13, 2000 | |
| **AA** | | SUN PHARM INDS INC | **50MG** | **A040446** | **001** | Aug 08, 2002 | |
| **AA** | | | **100MG** | **A040446** | **002** | Aug 08, 2002 | |
| **AA** | | VINTAGE PHARMS | **50MG** | **A040191** | **001** | Dec 17, 1998 | |
| **AA** | | | **100MG** | **A040191** | **002** | Dec 17, 1998 | |
| **AA** | | WEST-WARD PHARMS INT | **50MG** | **A040110** | **001** | Mar 12, 1997 | |
| **AA** | | | **100MG** | **A040110** | **002** | Mar 12, 1997 | |
| | | MIKART | 75MG | A040893 | 002 | Jun 24, 2009 | |
| | | | 150MG | A040893 | 004 | Jun 24, 2009 | |
| MEPIVACAINE HYDROCHLORIDE | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| **CARBOCAINE** | | | | | | | |
| **AP** | **+!** | HOSPIRA | **1%** | **N012250** | **001** | | |
| **AP** | **+!** | | **1.5%** | **N012250** | **005** | | |
| **AP** | **+!** | | **2%** | **N012250** | **002** | | |
| **ISOCAINE HYDROCHLORIDE** | | | | | | | |
| **AP** | **!** | SEPTODONT INC | **3%** | **A080925** | **001** | | |
| **MEPIVACAINE HYDROCHLORIDE** | | | | | | | |
| **AP** | | HOSPIRA INC | **3%** | **A040806** | **001** | Apr 28, 2008 | |
| **POLOCAINE** | | | | | | | |
| **AP** | | FRESENIUS KABI USA | **1%** | **A089407** | **001** | Dec 01, 1986 | |
| **AP** | | | **2%** | **A089410** | **001** | Dec 01, 1986 | |
| **POLOCAINE-MPF** | | | | | | | |
| **AP** | | FRESENIUS KABI USA | **1%** | **A089406** | **001** | Dec 01, 1986 | |
| **AP** | | | **1.5%** | **A089408** | **001** | Dec 01, 1986 | |
| **AP** | | | **2%** | **A089409** | **001** | Dec 01, 1986 | |
| **SCANDONEST PLAIN** | | | | | | | |
| **AP** | **!** | DEPROCO | **3%** | **A088387** | **001** | Oct 10, 1984 | |
| MEPROBAMATE | | | | | | | |
| TABLET;ORAL | | | | | | | |
| **MEPROBAMATE** | | | | | | | |
| **AA** | | ALEMBIC PHARMS LTD | **200MG** | **A090122** | **001** | Feb 18, 2009 | |
| **AA** | | | **400MG** | **A090122** | **002** | Feb 18, 2009 | |
| **AA** | | INVAGEN PHARMS | **200MG** | **A040797** | **001** | Feb 27, 2008 | |
| **AA** | | | **400MG** | **A040797** | **002** | Feb 27, 2008 | |
| **AA** | **!** | WATSON LABS | **200MG** | **A083304** | **001** | | |
| **AA** | **!** | | **400MG** | **A083308** | **001** | | |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| MERCAPTOPURINE | | | | | | | |
| SUSPENSION;ORAL | | | | | | | |
| PURIXAN | | | | | | | |
| | +! | NOVA LABS LTD | 20MG/ML | | N205919 | 001 | Apr 28, 2014 |
| TABLET;ORAL | | | | | | | |
| **MERCAPTOPURINE** | | | | | | | |
| **AB** | | DR REDDYS LABS SA | **50MG** | | **A040461** | **001** | Feb 11, 2004 |
| **AB** | | MYLAN | **50MG** | | **A040594** | **001** | Jul 01, 2005 |
| **AB** | **!** | WEST-WARD PHARMS INT | **50MG** | | **A040528** | **001** | Feb 13, 2004 |
| **PURINETHOL** | | | | | | | |
| **AB** | **+** | STASON PHARMS | **50MG** | | **N009053** | **002** | |
| MEROPENEM | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| **MEROPENEM** | | | | | | | |
| **AP** | | ACS DOBFAR | **500MG/VIAL** | | **A091404** | **001** | Oct 26, 2011 |
| **AP** | | | **1GM/VIAL** | | **A091404** | **002** | Oct 26, 2011 |
| **AP** | | AMNEAL PHARMS | **500MG/VIAL** | | **A205883** | **001** | Apr 12, 2016 |
| **AP** | | | **1GM/VIAL** | | **A205883** | **002** | Apr 12, 2016 |
| **AP** | | AUROBINDO PHARMA LTD | **500MG/VIAL** | | **A205835** | **001** | Mar 27, 2017 |
| **AP** | | | **1GM/VIAL** | | **A205835** | **002** | Mar 27, 2017 |
| **AP** | | DAEWOONG PHARM CO | **500MG/VIAL** | | **A204854** | **001** | Dec 18, 2015 |
| **AP** | | | **1GM/VIAL** | | **A204854** | **002** | Dec 18, 2015 |
| **AP** | | GLAND PHARMA LTD | **500MG/VIAL** | | **A206141** | **001** | Jun 08, 2016 |
| **AP** | | | **1GM/VIAL** | | **A206141** | **002** | Jun 08, 2016 |
| **AP** | | HOSPIRA INC | **500MG/VIAL** | | **A090940** | **001** | Jun 22, 2010 |
| **AP** | | | **1GM/VIAL** | | **A090940** | **002** | Jun 22, 2010 |
| **AP** | | PAR STERILE PRODUCTS | **500MG/VIAL** | | **A204139** | **001** | Jun 09, 2016 |
| **AP** | | | **1GM/VIAL** | | **A204139** | **002** | Jun 09, 2016 |
| **AP** | | SAVIOR LIFETEC CORP | **500MG/VIAL** | | **A206086** | **001** | Apr 19, 2016 |
| **AP** | | | **1GM/VIAL** | | **A206086** | **002** | Apr 19, 2016 |
| **MERREM** | | | | | | | |
| **AP** | **+!** | PFIZER | **500MG/VIAL** | | **N050706** | **003** | Jun 21, 1996 |
| **AP** | **+!** | | **1GM/VIAL** | | **N050706** | **001** | Jun 21, 1996 |
| POWDER;IV (INFUSION) | | | | | | | |
| MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER | | | | | | | |
| | | B BRAUN MEDICAL INC | 500MG/VIAL | | N202106 | 001 | Apr 30, 2015 |
| | | | 1GM/VIAL | | N202106 | 002 | Apr 30, 2015 |
| MEROPENEM; VABORBACTAM | | | | | | | |
| POWDER;IV (INFUSION) | | | | | | | |
| VABOMERE | | | | | | | |
| | +! | REMPEX PHARMS MEDCNS | 1GM/VIAL;1GM/VIAL | | N209776 | 001 | Aug 29, 2017 |
| MESALAMINE | | | | | | | |
| CAPSULE, DELAYED RELEASE;ORAL | | | | | | | |
| DELZICOL | | | | | | | |
| | +! | APIL | 400MG | | N204412 | 001 | Feb 01, 2013 |
| CAPSULE, EXTENDED RELEASE;ORAL | | | | | | | |
| APRISO | | | | | | | |
| | +! | VALEANT PHARMS INTL | 375MG | | N022301 | 001 | Oct 31, 2008 |
| PENTASA | | | | | | | |
| | + | SHIRE | 250MG | | N020049 | 001 | May 10, 1993 |
| | +! | | 500MG | | N020049 | 002 | Jul 08, 2004 |
| ENEMA;RECTAL | | | | | | | |
| **MESALAMINE** | | | | | | | |
| **AB** | | G AND W LABS INC | **4GM/60ML** | | **A076841** | **001** | Sep 30, 2004 |
| **AB** | | PERRIGO ISRAEL | **4GM/60ML** | | **A076751** | **001** | Sep 17, 2004 |
| **ROWASA** | | | | | | | |
| **AB** | **+!** | MYLAN SPECIALITY LP | **4GM/60ML** | | **N019618** | **001** | Dec 24, 1987 |
| **SFROWASA** | | | | | | | |
| **AB** | **+** | MYLAN SPECIALITY LP | **4GM/60ML** | | **N019618** | **002** | Jun 20, 2008 |
| SUPPOSITORY;RECTAL | | | | | | | |
| **CANASA** | | | | | | | |
| **AB** | **+!** | FOREST LABS LLC | **1GM** | | **N021252** | **002** | Nov 05, 2004 |
| **MESALAMINE** | | | | | | | |
| **AB** | | MYLAN PHARMS INC | **1GM** | | **A204354** | **001** | Nov 24, 2015 |
| TABLET, DELAYED RELEASE;ORAL | | | | | | | |
| **ASACOL HD** | | | | | | | |
| **AB** | **+!** | APIL | **800MG** | | **N021830** | **001** | May 29, 2008 |

| | | | | | | |
|---|---|---|---|---|---|---|
| MESALAMINE | | | | | | |
| TABLET, DELAYED RELEASE;ORAL | | | | | | |
| **LIALDA** | | | | | | |
| **AB** | **+!** | SHIRE | **1.2GM** | **N022000** | **001** | Jan 16, 2007 |
| **MESALAMINE** | | | | | | |
| **AB** | | ZYDUS PHARMS USA INC | **800MG** | **A203286** | **001** | Jul 21, 2017 |
| **AB** | | | **1.2GM** | **A091640** | **001** | Jun 05, 2017 |
| MESNA | | | | | | |
| INJECTABLE;INTRAVENOUS | | | | | | |
| **MESNA** | | | | | | |
| **AP** | | FRESENIUS KABI USA | **100MG/ML** | **A075811** | **001** | Apr 26, 2001 |
| **AP** | | GLAND PHARMA LTD | **100MG/ML** | **A206992** | **001** | Dec 18, 2017 |
| **AP** | | MYLAN INSTITUTIONAL | **100MG/ML** | **A076488** | **001** | Mar 08, 2012 |
| **AP** | | SAGENT PHARMS | **100MG/ML** | **A090913** | **001** | Apr 13, 2010 |
| **AP** | | TEVA PHARMS USA | **100MG/ML** | **A075764** | **001** | Apr 27, 2001 |
| **AP** | | WEST-WARD PHARMS INT | **100MG/ML** | **A075739** | **001** | Jan 09, 2004 |
| **MESNEX** | | | | | | |
| **AP** | **+!** | BAXTER HLTHCARE | **100MG/ML** | **N019884** | **001** | Dec 30, 1988 |
| TABLET;ORAL | | | | | | |
| MESNEX | | | | | | |
| | +! | BAXTER HLTHCARE | 400MG | N020855 | 001 | Mar 21, 2002 |
| MESTRANOL; NORETHINDRONE | | | | | | |
| TABLET;ORAL-28 | | | | | | |
| NORINYL 1+50 28-DAY | | | | | | |
| | +! | ACTAVIS LABS UT INC | 0.05MG;1MG | N016659 | 001 | |
| METAPROTERENOL SULFATE | | | | | | |
| SYRUP;ORAL | | | | | | |
| METAPROTERENOL SULFATE | | | | | | |
| | ! | SILARX | 10MG/5ML | A073632 | 001 | Jul 22, 1992 |
| TABLET;ORAL | | | | | | |
| METAPROTERENOL SULFATE | | | | | | |
| | | PAR PHARM | 10MG | A072024 | 001 | Jun 28, 1988 |
| | ! | | 20MG | A072025 | 001 | Jun 28, 1988 |
| METARAMINOL BITARTRATE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| METARAMINOL BITARTRATE | | | | | | |
| | ! | FRESENIUS KABI USA | EQ 10MG BASE/ML | A080722 | 001 | |
| METAXALONE | | | | | | |
| TABLET;ORAL | | | | | | |
| **METAXALONE** | | | | | | |
| **AB** | | ACTAVIS LABS FL INC | **800MG** | **A203695** | **001** | Jun 15, 2017 |
| **AB** | | AMNEAL PHARMS | **800MG** | **A203399** | **001** | Jun 21, 2013 |
| **AB** | | LANNETT HOLDINGS INC | **800MG** | **A204770** | **001** | Nov 22, 2016 |
| **AB** | | SANDOZ | **800MG** | **A040445** | **001** | Mar 31, 2010 |
| **AB** | | SCIEGEN PHARMS INC | **800MG** | **A207466** | **001** | Aug 31, 2017 |
| **SKELAXIN** | | | | | | |
| **AB** | **+!** | KING PHARMS | **800MG** | **N013217** | **003** | Aug 30, 2002 |
| METAXALONE | | | | | | |
| | | COREPHARMA | 400MG | A040486 | 001 | Feb 27, 2015 |
| METFORMIN HYDROCHLORIDE | | | | | | |
| SOLUTION;ORAL | | | | | | |
| RIOMET | | | | | | |
| | +! | SUN PHARM INDS LTD | 500MG/5ML | N021591 | 001 | Sep 11, 2003 |
| TABLET;ORAL | | | | | | |
| **GLUCOPHAGE** | | | | | | |
| **AB** | **+** | BRISTOL MYERS SQUIBB | **500MG** | **N020357** | **001** | Mar 03, 1995 |
| **AB** | **+** | | **850MG** | **N020357** | **002** | Mar 03, 1995 |
| **AB** | **+!** | | **1GM** | **N020357** | **005** | Nov 05, 1998 |
| **METFORMIN HYDROCHLORIDE** | | | | | | |
| **AB** | | ALKEM | **500MG** | **A091184** | **001** | Nov 01, 2010 |
| **AB** | | | **850MG** | **A091184** | **002** | Nov 01, 2010 |
| **AB** | | | **1GM** | **A091184** | **003** | Nov 01, 2010 |
| **AB** | | AMNEAL PHARMS NY | **500MG** | **A077880** | **001** | Jun 05, 2006 |
| **AB** | | | **850MG** | **A077880** | **002** | Jun 05, 2006 |
| **AB** | | | **1GM** | **A077880** | **003** | Jun 05, 2006 |
| **AB** | | APOTEX | **500MG** | **A075984** | **001** | Apr 23, 2002 |

METFORMIN HYDROCHLORIDE

TABLET;ORAL

**METFORMIN HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | **500MG** | **A090666** | **001** | Dec 07, 2011 |
| **AB** | | **850MG** | **A075984** | **002** | Apr 23, 2002 |
| **AB** | | **850MG** | **A090666** | **002** | Dec 07, 2011 |
| **AB** | | **1GM** | **A075984** | **003** | Apr 23, 2002 |
| **AB** | | **1GM** | **A090666** | **003** | Dec 07, 2011 |
| **AB** | ATLAS PHARMS LLC | **500MG** | **A076033** | **001** | Jan 24, 2002 |
| **AB** | | **850MG** | **A076033** | **002** | Jan 24, 2002 |
| **AB** | | **1GM** | **A076033** | **003** | Jan 24, 2002 |
| **AB** | AUROBINDO | **500MG** | **A077095** | **001** | Jan 14, 2005 |
| **AB** | | **850MG** | **A077095** | **002** | Jan 14, 2005 |
| **AB** | | **1GM** | **A077095** | **003** | Jan 14, 2005 |
| **AB** | CHARTWELL LIFE SCI | **500MG** | **A075972** | **001** | Jan 24, 2002 |
| **AB** | | **850MG** | **A075972** | **002** | Jan 24, 2002 |
| **AB** | | **1GM** | **A075972** | **003** | Jan 24, 2002 |
| **AB** | CSPC OUYI PHARM CO | **500MG** | **A205096** | **001** | Jul 11, 2016 |
| **AB** | | **850MG** | **A205096** | **002** | Jul 11, 2016 |
| **AB** | | **1GM** | **A205096** | **003** | Jul 11, 2016 |
| **AB** | DR REDDYS LABS INC | **500MG** | **A077787** | **001** | Aug 23, 2006 |
| **AB** | | **850MG** | **A077787** | **002** | Aug 23, 2006 |
| **AB** | | **1GM** | **A077787** | **003** | Aug 23, 2006 |
| **AB** | GLENMARK GENERICS | **500MG** | **A078170** | **001** | May 23, 2008 |
| **AB** | | **850MG** | **A078170** | **002** | May 23, 2008 |
| **AB** | | **1GM** | **A078170** | **003** | May 23, 2008 |
| **AB** | GRANULES INDIA | **500MG** | **A090564** | **001** | Apr 22, 2010 |
| **AB** | | **850MG** | **A090564** | **002** | Apr 22, 2010 |
| **AB** | | **1GM** | **A090564** | **003** | Apr 22, 2010 |
| **AB** | INDICUS PHARMA | **500MG** | **A079148** | **001** | Nov 25, 2008 |
| **AB** | | **850MG** | **A079148** | **002** | Nov 25, 2008 |
| **AB** | | **1GM** | **A079148** | **003** | Nov 25, 2008 |
| **AB** | MACLEODS PHARMS LTD | **500MG** | **A205330** | **001** | Oct 31, 2017 |
| **AB** | | **850MG** | **A205330** | **002** | Oct 31, 2017 |
| **AB** | | **1GM** | **A205330** | **003** | Oct 31, 2017 |
| **AB** | MARKSANS PHARMA | **500MG** | **A090888** | **001** | Mar 12, 2012 |
| **AB** | | **850MG** | **A090888** | **002** | Mar 12, 2012 |
| **AB** | | **1GM** | **A090888** | **003** | Mar 12, 2012 |
| **AB** | MYLAN | **500MG** | **A075973** | **001** | Jan 25, 2002 |
| **AB** | | **500MG** | **A075976** | **001** | Jan 24, 2002 |
| **AB** | | **850MG** | **A075973** | **002** | Jan 25, 2002 |
| **AB** | | **850MG** | **A075976** | **002** | Jan 24, 2002 |
| **AB** | | **1GM** | **A075973** | **003** | Jan 25, 2002 |
| **AB** | | **1GM** | **A075976** | **003** | Jan 24, 2002 |
| **AB** | PROVIDENT PHARM | **500MG** | **A077853** | **001** | Jul 28, 2006 |
| **AB** | | **850MG** | **A077853** | **002** | Jul 28, 2006 |
| **AB** | | **1GM** | **A077853** | **003** | Jul 28, 2006 |
| **AB** | SANDOZ | **500MG** | **A075965** | **001** | Jan 25, 2002 |
| **AB** | | **500MG** | **A075985** | **001** | Jan 25, 2002 |
| **AB** | | **850MG** | **A075965** | **002** | Jan 25, 2002 |
| **AB** | | **850MG** | **A075985** | **002** | Jan 25, 2002 |
| **AB** | | **1GM** | **A075965** | **003** | Jan 25, 2002 |
| **AB** | | **1GM** | **A075985** | **003** | Jan 25, 2002 |
| **AB** | SCIEGEN PHARMS INC | **500MG** | **A203769** | **001** | Sep 11, 2013 |
| **AB** | | **850MG** | **A203769** | **002** | Sep 11, 2013 |
| **AB** | | **1GM** | **A203769** | **003** | Sep 11, 2013 |
| **AB** | SUN PHARM INDS INC | **500MG** | **A075967** | **001** | Jan 29, 2002 |
| **AB** | | **850MG** | **A075967** | **002** | Jan 29, 2002 |
| **AB** | | **1GM** | **A075967** | **003** | Jan 29, 2002 |
| **AB** | SUN PHARM INDUSTRIES | **500MG** | **A076038** | **001** | Feb 21, 2002 |
| **AB** | | **850MG** | **A076038** | **002** | Feb 21, 2002 |
| **AB** | | **1GM** | **A076038** | **003** | Feb 21, 2002 |
| **AB** | TEVA | **500MG** | **A075978** | **001** | Jan 25, 2002 |
| **AB** | | **850MG** | **A075978** | **002** | Jan 25, 2002 |
| **AB** | | **1GM** | **A075978** | **003** | Nov 05, 2002 |
| **AB** | TORRENT PHARMS | **500MG** | **A077711** | **001** | Jan 24, 2007 |
| **AB** | | **850MG** | **A077711** | **002** | Jan 24, 2007 |
| **AB** | | **1GM** | **A077711** | **003** | Jan 24, 2007 |
| **AB** | ZYDUS HLTHCARE | **500MG** | **A203686** | **001** | Aug 28, 2014 |
| **AB** | | **850MG** | **A203686** | **002** | Aug 28, 2014 |
| **AB** | | **1GM** | **A203686** | **003** | Aug 28, 2014 |
| **AB** | ZYDUS PHARMS USA | **500MG** | **A077064** | **001** | Apr 18, 2005 |

METFORMIN HYDROCHLORIDE

TABLET;ORAL

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **METFORMIN HYDROCHLORIDE** | | | | | | | |
| **AB** | | | **850MG** | **A077064** | **002** | Apr 18, 2005 |
| **AB** | | | **1GM** | **A077064** | **003** | Apr 18, 2005 |
| | | CHARTWELL LIFE SCI | 625MG | A075972 | 005 | Jan 24, 2002 |
| | | | 750MG | A075972 | 004 | Jan 24, 2002 |

TABLET, EXTENDED RELEASE;ORAL

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **GLUCOPHAGE XR** | | | | | | | |
| **AB** | **+!** | BRISTOL MYERS SQUIBB | **750MG** | **N021202** | **004** | Apr 11, 2003 |
| **METFORMIN HYDROCHLORIDE** | | | | | | | |
| **AB** | | ACTAVIS LABS FL INC | **750MG** | **A076869** | **001** | Apr 12, 2005 |
| **AB** | | AMNEAL PHARMS NY | **750MG** | **A078596** | **002** | Jan 03, 2008 |
| **AB** | | APOTEX | **750MG** | **A076706** | **002** | Dec 29, 2005 |
| **AB** | | AUROBINDO PHARMA LTD | **750MG** | **A079118** | **002** | Jul 20, 2012 |
| **AB** | | BARR | **750MG** | **A076863** | **001** | Oct 14, 2004 |
| **AB** | | BEXIMCO PHARMS USA | **750MG** | **A207427** | **002** | Dec 13, 2016 |
| **AB** | | CSPC OUYI PHARM CO | **750MG** | **A078321** | **002** | Apr 17, 2008 |
| **AB** | | INTELLIPHARMACEUTICS | **750MG** | **A202306** | **002** | Feb 23, 2017 |
| **AB** | | MACLEODS PHARMS LTD | **750MG** | **A206955** | **002** | Dec 07, 2016 |
| **AB** | | MARKSANS PHARMA | **750MG** | **A090295** | **002** | Apr 29, 2016 |
| **AB** | | NOSTRUM PHARMS LLC | **750MG** | **A076756** | **002** | Dec 12, 2011 |
| **AB** | | SUN PHARM INDS (IN) | **750MG** | **A077336** | **002** | Feb 09, 2006 |
| **AB** | | TEVA | **750MG** | **A076864** | **001** | Apr 12, 2005 |
| **AB** | | ZYDUS PHARMS USA | **750MG** | **A077078** | **001** | Apr 21, 2005 |
| **GLUCOPHAGE XR** | | | | | | | |
| **AB1** | **+** | BRISTOL MYERS SQUIBB | **500MG** | **N021202** | **001** | Oct 13, 2000 |
| **METFORMIN HYDROCHLORIDE** | | | | | | | |
| **AB1** | | ACTAVIS LABS FL INC | **500MG** | **A076172** | **001** | Jun 16, 2004 |
| **AB1** | | AMNEAL PHARMS NY | **500MG** | **A078596** | **001** | Jan 03, 2008 |
| **AB1** | | APOTEX | **500MG** | **A076706** | **001** | Dec 14, 2004 |
| **AB1** | | AUROBINDO PHARMA LTD | **500MG** | **A079118** | **001** | Jul 20, 2012 |
| **AB1** | | BEXIMCO PHARMS USA | **500MG** | **A207427** | **001** | Dec 13, 2016 |
| **AB1** | | CSPC OUYI PHARM CO | **500MG** | **A078321** | **001** | Apr 17, 2008 |
| **AB1** | | INTELLIPHARMACEUTICS | **500MG** | **A202306** | **001** | Feb 23, 2017 |
| **AB1** | | INVENTIA HLTHCARE | **500MG** | **A201991** | **001** | Jan 18, 2012 |
| **AB1** | | MACLEODS PHARMS LTD | **500MG** | **A206955** | **001** | Dec 07, 2016 |
| **AB1** | | MARKSANS PHARMA | **500MG** | **A090295** | **001** | Apr 29, 2016 |
| **AB1** | | NOSTRUM PHARMS LLC | **500MG** | **A076756** | **001** | Jul 26, 2006 |
| **AB1** | | SANDOZ | **500MG** | **A076873** | **001** | Dec 14, 2004 |
| **AB1** | | SUN PHARM INDS (IN) | **500MG** | **A077336** | **001** | Feb 09, 2006 |
| **AB1** | | TEVA | **500MG** | **A076269** | **001** | Jun 18, 2004 |
| **AB1** | | TORRENT PHARMS LTD | **500MG** | **A090014** | **001** | Dec 30, 2009 |
| **AB1** | | ZYDUS PHARMS USA | **500MG** | **A077060** | **001** | Apr 20, 2005 |
| **FORTAMET** | | | | | | | |
| **AB2** | **+** | ANDRX LABS LLC | **500MG** | **N021574** | **001** | Apr 27, 2004 |
| **AB2** | **+!** | | **1GM** | **N021574** | **002** | Apr 27, 2004 |
| **METFORMIN HYDROCHLORIDE** | | | | | | | |
| **AB2** | | LUPIN LTD | **500MG** | **A090692** | **001** | Jun 29, 2011 |
| **AB2** | | | **1GM** | **A090692** | **002** | Jun 29, 2011 |
| **AB2** | | MYLAN PHARMS INC | **500MG** | **A200690** | **001** | Aug 01, 2012 |
| **AB2** | | | **1GM** | **A200690** | **002** | Aug 01, 2012 |
| **AB2** | | NOSTRUM LABS INC | **500MG** | **A203832** | **001** | Dec 26, 2017 |
| **AB2** | | | **1GM** | **A203832** | **002** | Dec 26, 2017 |
| **GLUMETZA** | | | | | | | |
| **AB3** | **+** | SANTARUS INC | **500MG** | **N021748** | **001** | Jun 03, 2005 |
| **AB3** | **+!** | | **1GM** | **N021748** | **002** | Jun 03, 2005 |
| **METFORMIN HYDROCHLORIDE** | | | | | | | |
| **AB3** | | ACTAVIS LABS FL INC | **500MG** | **A203755** | **001** | Aug 01, 2016 |
| **AB3** | | | **1GM** | **A203755** | **002** | Aug 01, 2016 |
| **AB3** | | LUPIN LTD | **500MG** | **A091664** | **001** | Jul 19, 2013 |
| **AB3** | | | **1GM** | **A091664** | **002** | Jul 19, 2013 |
| **AB3** | | SUN PHARMA GLOBAL | **500MG** | **A202917** | **001** | Aug 01, 2016 |
| **AB3** | | | **1GM** | **A202917** | **002** | Aug 01, 2016 |

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

**ACTOPLUS MET**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | TAKEDA PHARMS USA | **500MG;EQ 15MG BASE** | **N021842** | **001** | Aug 29, 2005 |
| **AB** | **+!** | | **850MG;EQ 15MG BASE** | **N021842** | **002** | Aug 29, 2005 |

**PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AUROBINDO PHARMA LTD | **500MG;EQ 15MG BASE** | **A200823** | **001** | Feb 13, 2013 |
| **AB** | | | **850MG;EQ 15MG BASE** | **A200823** | **002** | Feb 13, 2013 |
| **AB** | | MACLEODS PHARMS LTD | **500MG;EQ 15MG BASE** | **A204802** | **001** | Nov 05, 2015 |
| **AB** | | | **850MG;EQ 15MG BASE** | **A204802** | **002** | Nov 05, 2015 |
| **AB** | | MYLAN | **500MG;EQ 15MG BASE** | **A090406** | **001** | Feb 25, 2011 |
| **AB** | | | **850MG;EQ 15MG BASE** | **A090406** | **002** | Feb 25, 2011 |
| **AB** | | SANDOZ | **500MG;EQ 15MG BASE** | **A091273** | **001** | Apr 16, 2013 |
| **AB** | | | **850MG;EQ 15MG BASE** | **A091273** | **002** | Apr 16, 2013 |
| **AB** | | TEVA PHARMS USA | **500MG;EQ 15MG BASE** | **A091155** | **001** | Mar 10, 2014 |
| **AB** | | | **850MG;EQ 15MG BASE** | **A091155** | **002** | Mar 10, 2014 |
| **AB** | | TORRENT PHARMS LTD | **500MG;EQ 15MG BASE** | **A202001** | **001** | Feb 13, 2013 |
| **AB** | | | **850MG;EQ 15MG BASE** | **A202001** | **002** | Feb 13, 2013 |

TABLET, EXTENDED RELEASE;ORAL

ACTOPLUS MET XR

| | | | | | |
|---|---|---|---|---|---|
| + | TAKEDA PHARMS USA | 1GM;EQ 15MG BASE | N022024 | 001 | May 12, 2009 |
| +! | | 1GM;EQ 30MG BASE | N022024 | 002 | May 12, 2009 |

METFORMIN HYDROCHLORIDE; REPAGLINIDE

TABLET;ORAL

REPAGLINIDE AND METFORMIN HYDROCHLORIDE

| | | | | | |
|---|---|---|---|---|---|
| | LUPIN LTD | 500MG;1MG | A200624 | 001 | Jul 15, 2015 |
| ! | | 500MG;2MG | A200624 | 002 | Jul 15, 2015 |

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

| | | | | | |
|---|---|---|---|---|---|
| | TEVA | 500MG;EQ 2MG BASE | A077337 | 001 | May 07, 2014 |
| | | 500MG;EQ 1MG BASE | A077337 | 005 | May 19, 2017 |
| | | 500MG;EQ 4MG BASE | A077337 | 002 | May 07, 2014 |
| ! | | 1GM;EQ 4MG BASE | A077337 | 004 | May 07, 2014 |
| | | 1GM;EQ 2MG BASE | A077337 | 003 | May 07, 2014 |

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

KOMBIGLYZE XR

| | | | | | |
|---|---|---|---|---|---|
| + | ASTRAZENECA AB | 500MG;EQ 5MG BASE | N200678 | 001 | Nov 05, 2010 |
| + | | 1GM;EQ 2.5MG BASE | N200678 | 003 | Nov 05, 2010 |
| +! | | 1GM;EQ 5MG BASE | N200678 | 002 | Nov 05, 2010 |

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET;ORAL

JANUMET

| | | | | | |
|---|---|---|---|---|---|
| + | MERCK SHARP DOHME | 500MG;EQ 50MG BASE | N022044 | 001 | Mar 30, 2007 |
| +! | | 1GM;EQ 50MG BASE | N022044 | 002 | Mar 30, 2007 |

TABLET, EXTENDED RELEASE;ORAL

JANUMET XR

| | | | | | |
|---|---|---|---|---|---|
| + | MERCK SHARP DOHME | 500MG;EQ 50MG BASE | N202270 | 001 | Feb 02, 2012 |
| + | | 1GM;EQ 50MG BASE | N202270 | 002 | Feb 02, 2012 |
| +! | | 1GM;EQ 100MG BASE | N202270 | 003 | Feb 02, 2012 |

METHACHOLINE CHLORIDE

FOR SOLUTION;INHALATION

PROVOCHOLINE

| | | | | | |
|---|---|---|---|---|---|
| +! | METHAPHARM | 100MG/VIAL | N019193 | 001 | Oct 31, 1986 |

METHADONE HYDROCHLORIDE

CONCENTRATE;ORAL

**METHADONE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | VISTAPHARM | **10MG/ML** | **A040088** | **001** | Nov 30, 1994 |
| **AA** | | WEST-WARD PHARMS INT | **10MG/ML** | **A040180** | **001** | Apr 30, 1998 |

**METHADONE HYDROCHLORIDE INTENSOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | WEST-WARD PHARMS INT | **10MG/ML** | **A089897** | **001** | Sep 06, 1988 |

**METHADOSE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **+!** | SPECGX LLC | **10MG/ML** | **N017116** | **002** | |

| | | | | | | |
|---|---|---|---|---|---|---|
| METHADONE HYDROCHLORIDE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| **METHADONE HYDROCHLORIDE** | | | | | | |
| **AP** | | AKORN | **10MG/ML** | **A208306** | **001** | Oct 27, 2017 |
| **AP** | **+!** | MYLAN INSTITUTIONAL | **10MG/ML** | **N021624** | **001** | |
| SOLUTION;ORAL | | | | | | |
| **METHADONE HYDROCHLORIDE** | | | | | | |
| **AA** | | VISTAPHARM | **5MG/5ML** | **A090707** | **001** | Jun 30, 2010 |
| **AA** | | | **10MG/5ML** | **A090707** | **002** | Jun 30, 2010 |
| **AA** | **!** | WEST-WARD PHARMS INT | **5MG/5ML** | **A087393** | **001** | |
| **AA** | **!** | | **10MG/5ML** | **A087997** | **001** | Aug 30, 1982 |
| TABLET;ORAL | | | | | | |
| **DOLOPHINE HYDROCHLORIDE** | | | | | | |
| **AA** | **+!** | WEST-WARD PHARMS INT | **5MG** | **N006134** | **002** | |
| **AA** | **+!** | | **10MG** | **N006134** | **010** | |
| **METHADONE HYDROCHLORIDE** | | | | | | |
| **AA** | | AUROLIFE PHARMA LLC | **5MG** | **A203502** | **001** | Aug 31, 2015 |
| **AA** | | | **10MG** | **A203502** | **002** | Aug 31, 2015 |
| **AA** | | EPIC PHARMA LLC | **5MG** | **A090065** | **001** | Aug 18, 2015 |
| **AA** | | | **10MG** | **A090065** | **002** | Aug 18, 2015 |
| **AA** | | SANDOZ | **10MG** | **A040241** | **002** | May 29, 1998 |
| **AA** | | SPECGX LLC | **5MG** | **A040517** | **001** | Apr 27, 2004 |
| **AA** | | | **10MG** | **A040517** | **002** | Apr 27, 2004 |
| **AA** | | THE PHARMANETWORK | **10MG** | **A090635** | **001** | Nov 25, 2009 |
| **METHADOSE** | | | | | | |
| **AA** | | SPECGX LLC | **5MG** | **A040050** | **001** | Apr 15, 1993 |
| **AA** | | | **10MG** | **A040050** | **002** | Apr 15, 1993 |
| TABLET, FOR SUSPENSION;ORAL | | | | | | |
| **METHADONE HYDROCHLORIDE** | | | | | | |
| **AA** | | SANDOZ | **40MG** | **A075082** | **001** | Mar 25, 1998 |
| **AA** | | SPECGX LLC | **40MG** | **A077142** | **001** | Jul 12, 2005 |
| **AA** | **+!** | WEST-WARD PHARMS INT | **40MG** | **N017058** | **001** | |
| **METHADOSE** | | | | | | |
| **AA** | | SPECGX LLC | **40MG** | **A074184** | **001** | Apr 29, 1993 |
| METHAMPHETAMINE HYDROCHLORIDE | | | | | | |
| TABLET;ORAL | | | | | | |
| **DESOXYN** | | | | | | |
| **AA** | **+!** | RECORDATI RARE | **5MG** | **N005378** | **002** | |
| **METHAMPHETAMINE HYDROCHLORIDE** | | | | | | |
| **AA** | | MAYNE PHARMA INC | **5MG** | **A091189** | **001** | Apr 21, 2010 |
| **AA** | | WEST-WARD PHARMS INT | **5MG** | **A203846** | **001** | Nov 17, 2015 |
| METHAZOLAMIDE | | | | | | |
| TABLET;ORAL | | | | | | |
| **METHAZOLAMIDE** | | | | | | |
| **AB** | | ANI PHARMS INC | **25MG** | **A040001** | **001** | Jun 30, 1993 |
| **AB** | | | **50MG** | **A040001** | **002** | Jun 30, 1993 |
| **AB** | | MIKART | **25MG** | **A040062** | **001** | Jan 27, 1994 |
| **AB** | **!** | | **50MG** | **A040062** | **002** | Jan 27, 1994 |
| **AB** | | SANDOZ | **25MG** | **A040036** | **001** | Jun 30, 1993 |
| **AB** | | | **50MG** | **A040036** | **002** | Jun 30, 1993 |
| METHENAMINE HIPPURATE | | | | | | |
| TABLET;ORAL | | | | | | |
| **HIPREX** | | | | | | |
| **AB** | **+!** | US PHARM HOLDINGS | **1GM** | **N017681** | **001** | |
| **METHENAMINE HIPPURATE** | | | | | | |
| **AB** | | AUROBINDO PHARMA LTD | **1GM** | **A205661** | **001** | Jul 05, 2016 |
| **AB** | | IMPAX LABS INC | **1GM** | **A076411** | **001** | Jun 20, 2003 |
| **UREX** | | | | | | |
| **AB** | | CNTY LINE PHARMS | **1GM** | **N016151** | **001** | |
| METHIMAZOLE | | | | | | |
| TABLET;ORAL | | | | | | |
| **METHIMAZOLE** | | | | | | |
| **AB** | | ECI PHARMS LLC | **5MG** | **A040547** | **001** | Feb 18, 2005 |
| **AB** | | | **10MG** | **A040547** | **002** | Feb 18, 2005 |
| **AB** | | HERITAGE PHARMA | **5MG** | **A040734** | **001** | Dec 14, 2007 |
| **AB** | | | **10MG** | **A040734** | **002** | Dec 14, 2007 |

METHIMAZOLE

TABLET;ORAL

**METHIMAZOLE**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | MYLAN | **5MG** | **A040350** | **001** | Mar 29, 2000 |
| **AB** ! | | **10MG** | **A040350** | **002** | Mar 29, 2000 |
| **AB** | RISING PHARMS INC | **5MG** | **A202068** | **001** | Mar 07, 2012 |
| **AB** | | **10MG** | **A202068** | **002** | Mar 07, 2012 |
| **AB** | SANDOZ | **5MG** | **A040411** | **001** | Mar 27, 2001 |
| **AB** | | **10MG** | **A040411** | **002** | Mar 27, 2001 |
| **AB** | SUN PHARM INDS INC | **5MG** | **A040870** | **001** | Sep 25, 2007 |
| **AB** | | **10MG** | **A040870** | **002** | Sep 25, 2007 |

**TAPAZOLE**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | KING PHARMS LLC | **5MG** | **A040320** | **001** | Mar 31, 2000 |
| **AB** | | **10MG** | **A040320** | **002** | Mar 31, 2000 |

METHOCARBAMOL

SOLUTION;IM-IV

**METHOCARBAMOL**

| | | | | | |
|---|---|---|---|---|---|
| **AP** | AUROBINDO PHARMA LTD | **1GM/10ML (100MG/ML)** | **A206128** | **001** | May 27, 2016 |
| **AP** | LUITPOLD PHARMS INC | **1GM/10ML (100MG/ML)** | **A207496** | **001** | Jun 22, 2017 |
| **AP** | MONTEREY PHARMS LLC | **1GM/10ML (100MG/ML)** | **A205354** | **001** | Oct 27, 2016 |
| **AP** | MYLAN INSTITUTIONAL | **1GM/10ML (100MG/ML)** | **A204404** | **001** | Dec 05, 2014 |
| **AP** | NAVINTA LLC | **1GM/10ML (100MG/ML)** | **A206071** | **001** | Nov 24, 2017 |
| **AP** | RENAISSANCE SSA LLC | **1GM/10ML (100MG/ML)** | **A208116** | **001** | Jan 19, 2017 |
| **AP** | SAGENT PHARMS | **1GM/10ML (100MG/ML)** | **A205404** | **001** | Jul 18, 2017 |
| **AP** | SOMERSET THERAPS LLC | **1GM/10ML (100MG/ML)** | **A207522** | **001** | Jul 31, 2017 |

**ROBAXIN**

| | | | | | |
|---|---|---|---|---|---|
| **AP** **+!** | WEST-WARD PHARMS INT | **1GM/10ML (100MG/ML)** | **N011790** | **001** | |

TABLET;ORAL

**METHOCARBAMOL**

| | | | | | |
|---|---|---|---|---|---|
| **AA** | ATLAS PHARMS LLC | **500MG** | **A203550** | **001** | Feb 08, 2017 |
| **AA** | | **750MG** | **A203550** | **002** | Feb 08, 2017 |
| **AA** | AUSTARPHARMA LLC | **500MG** | **A200958** | **001** | Oct 21, 2011 |
| **AA** | | **750MG** | **A200958** | **002** | Oct 21, 2011 |
| **AA** | BEXIMCO PHARMS USA | **500MG** | **A208507** | **001** | Jul 21, 2017 |
| **AA** | | **750MG** | **A208507** | **002** | Jul 21, 2017 |
| **AA** | HETERO LABS LTD III | **500MG** | **A090200** | **001** | Nov 06, 2009 |
| **AA** | | **750MG** | **A090200** | **002** | Nov 06, 2009 |
| **AA** | HIKMA INTL PHARMS | **500MG** | **A085159** | **001** | |
| **AA** | | **750MG** | **A085123** | **001** | |
| **AA** | PRINSTON INC | **500MG** | **A086989** | **001** | |
| **AA** | | **750MG** | **A086988** | **001** | |
| **AA** | VINTAGE PHARMS | **500MG** | **A040489** | **001** | Jan 29, 2003 |
| **AA** | | **750MG** | **A040489** | **002** | Jan 29, 2003 |
| **AA** | WATSON LABS | **500MG** | **A084277** | **001** | |
| **AA** | | **750MG** | **A084276** | **002** | |

**ROBAXIN**

| | | | | | |
|---|---|---|---|---|---|
| **AA** **+!** | AUXILIUM PHARMS LLC | **500MG** | **N011011** | **004** | |

**ROBAXIN-750**

| | | | | | |
|---|---|---|---|---|---|
| **AA** **+!** | AUXILIUM PHARMS LLC | **750MG** | **N011011** | **006** | |

METHOHEXITAL SODIUM

INJECTABLE;INJECTION

BREVITAL SODIUM

| | | | | | |
|---|---|---|---|---|---|
| +! | PAR STERILE PRODUCTS | 500MG/VIAL | N011559 | 001 | |
| +! | | 2.5GM/VIAL | N011559 | 002 | |

METHOTREXATE

SOLUTION;SUBCUTANEOUS

OTREXUP

| | | | | | |
|---|---|---|---|---|---|
| +! | ANTARES PHARMA INC | 10MG/0.4ML (10MG/0.4ML) | N204824 | 001 | Oct 11, 2013 |
| +! | | 12.5MG/0.4ML (12.5MG/0.4ML) | N204824 | 006 | Mar 24, 2016 |
| +! | | 15MG/0.4ML (15MG/0.4ML) | N204824 | 002 | Oct 11, 2013 |
| +! | | 17.5MG/0.4ML (17.5MG/0.4ML) | N204824 | 007 | Mar 24, 2016 |
| +! | | 20MG/0.4ML (20MG/0.4ML) | N204824 | 003 | Oct 11, 2013 |
| +! | | 22.5MG/0.4ML (22.5MG/0.4ML) | N204824 | 008 | Mar 24, 2016 |
| +! | | 25MG/0.4ML (25MG/0.4ML) | N204824 | 004 | Oct 11, 2013 |

RASUVO

| | | | | | |
|---|---|---|---|---|---|
| + | MEDAC PHARMA INC | 7.5MG/0.15ML (7.5MG/0.15ML) | N205776 | 001 | Jul 10, 2014 |
| + | | 10MG/0.20ML (10MG/0.20ML) | N205776 | 002 | Jul 10, 2014 |
| + | | 12.5MG/0.25ML (12.5MG/0.25ML) | N205776 | 003 | Jul 10, 2014 |

| | | | | | | |
|---|---|---|---|---|---|---|
| METHOTREXATE | | | | | | |
| SOLUTION;SUBCUTANEOUS | | | | | | |
| RASUVO | | | | | | |
| | + | | 15MG/0.30ML (15MG/0.30ML) | N205776 | 004 | Jul 10, 2014 |
| | + | | 17.5MG/0.35ML (17.5MG/0.35ML) | N205776 | 005 | Jul 10, 2014 |
| | + | | 20MG/0.4ML (20MG/0.4ML) | N205776 | 006 | Jul 10, 2014 |
| | + | | 22.5MG/0.45ML (22.5MG/0.45ML) | N205776 | 007 | Jul 10, 2014 |
| | + | | 25MG/0.5ML (25MG/0.5ML) | N205776 | 008 | Jul 10, 2014 |
| | + | | 30MG/0.6ML (30MG/0.6ML) | N205776 | 010 | Jul 10, 2014 |
| METHOTREXATE SODIUM | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| **METHOTREXATE PRESERVATIVE FREE** | | | | | | |
| **AP** | | FRESENIUS KABI USA | **EQ 25MG BASE/ML** | **A040265** | **001** | Feb 26, 1999 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A040266** | **001** | Feb 26, 1999 |
| **METHOTREXATE SODIUM** | | | | | | |
| **AP** | **!** | FRESENIUS KABI USA | **EQ 50MG BASE/2ML (EQ 25MG BASE/ML)** | **A040263** | **001** | Feb 26, 1999 |
| **AP** | **!** | | **EQ 250MG BASE/10ML (EQ 25MG BASE/ML)** | **A040263** | **002** | Feb 26, 1999 |
| **AP** | **+!** | HOSPIRA | **EQ 50MG BASE/2ML (EQ 25MG BASE/ML)** | **N011719** | **010** | Dec 15, 2004 |
| **AP** | **!** | WEST-WARD PHARMS INT | **EQ 100MG BASE/4ML (EQ 25MG BASE/ML)** | **A089341** | **001** | Sep 16, 1986 |
| **METHOTREXATE SODIUM PRESERVATIVE FREE** | | | | | | |
| **AP** | **!** | ACCORD HLTHCARE | **EQ 50MG BASE/2ML (EQ 25MG BASE/ML)** | **A040767** | **001** | Apr 30, 2007 |
| **AP** | **!** | | **EQ 250MG BASE/10ML (EQ 25MG BASE/ML)** | **A040768** | **001** | Apr 30, 2007 |
| **AP** | **!** | | **EQ 1GM BASE/40ML (EQ 25MG BASE/ML)** | **A040716** | **001** | Apr 30, 2007 |
| **AP** | **+!** | HOSPIRA | **EQ 1GM BASE/40ML (EQ 25MG BASE/ML)** | **N011719** | **012** | Apr 13, 2005 |
| **AP** | | MYLAN LABS LTD | **EQ 50MG BASE/2ML (EQ 25MG BASE/ML)** | **A201529** | **001** | Mar 29, 2012 |
| **AP** | | | **EQ 100MG BASE/4ML (EQ 25MG BASE/ML)** | **A201529** | **002** | Mar 29, 2012 |
| **AP** | | | **EQ 200MG BASE/8ML (EQ 25MG BASE/ML)** | **A201529** | **003** | Mar 29, 2012 |
| **AP** | | | **EQ 250MG BASE/10ML (EQ 25MG BASE/ML)** | **A201529** | **004** | Mar 29, 2012 |
| **AP** | | | **EQ 1GM BASE/40ML (EQ 25MG BASE/ML)** | **A201530** | **001** | Mar 29, 2012 |
| **AP** | | PHARMACHEMIE BV | **EQ 50MG BASE/2ML (EQ 25MG BASE/ML)** | **A040843** | **002** | Jan 11, 2010 |
| **AP** | | | **EQ 100MG BASE/4ML (EQ 25MG BASE/ML)** | **A040843** | **003** | Feb 27, 2012 |
| **AP** | | | **EQ 250MG BASE/10ML (EQ 25MG BASE/ML)** | **A040843** | **004** | Jan 11, 2010 |
| **AP** | | | **EQ 1GM BASE/40ML (EQ 25MG BASE/ML)** | **A040843** | **001** | Jan 11, 2010 |
| **AP** | | SANDOZ INC | **EQ 50MG BASE/2ML (EQ 25MG BASE/ML)** | **A090039** | **001** | Mar 31, 2009 |
| **AP** | | | **EQ 250MG BASE/10ML (EQ 25MG BASE/ML)** | **A090039** | **002** | Mar 31, 2009 |
| **AP** | | | **EQ 1GM BASE/40ML (EQ 25MG BASE/ML)** | **A090029** | **001** | Mar 31, 2009 |
| **AP** | **!** | WEST-WARD PHARMS INT | **EQ 50MG BASE/2ML (EQ 25MG BASE/ML)** | **A089340** | **001** | Sep 16, 1986 |
| **AP** | **!** | | **EQ 250MG BASE/10ML (EQ 25MG BASE/ML)** | **A089343** | **001** | Sep 16, 1986 |
| METHOTREXATE SODIUM | | | | | | |
| | ! | WEST-WARD PHARMS INT | EQ 200MG BASE/8ML (EQ 25MG BASE/ML) | A089342 | 001 | Sep 16, 1986 |
| METHOTREXATE SODIUM PRESERVATIVE FREE | | | | | | |
| | ! | WEST-WARD PHARMS INT | EQ 1GM BASE/VIAL | A040632 | 001 | Aug 12, 2005 |
| SOLUTION;ORAL | | | | | | |
| XATMEP | | | | | | |
| | +! | SILVERGATE PHARMS | EQ 2.5MG BASE/ML | N208400 | 001 | Apr 25, 2017 |
| TABLET;ORAL | | | | | | |
| **METHOTREXATE SODIUM** | | | | | | |
| **AB** | | AMNEAL PHARMS | **EQ 2.5MG BASE** | **A210040** | **001** | Dec 22, 2017 |
| **AB** | | BARR | **EQ 2.5MG BASE** | **A081099** | **001** | Oct 15, 1990 |
| **AB** | **+!** | DAVA PHARMS INC | **EQ 2.5MG BASE** | **N008085** | **002** | |
| **AB** | | MYLAN | **EQ 2.5MG BASE** | **A081235** | **001** | May 15, 1992 |
| **AB** | | SUN PHARMA GLOBAL | **EQ 2.5MG BASE** | **A201749** | **001** | May 21, 2015 |
| **AB** | | WEST-WARD PHARMS INT | **EQ 2.5MG BASE** | **A040054** | **001** | Aug 01, 1994 |
| **AB** | | ZYDUS PHARMS USA INC | **EQ 2.5MG BASE** | **A207812** | **001** | Jan 13, 2017 |
| TREXALL | | | | | | |
| | | BARR | EQ 5MG BASE | A040385 | 001 | Mar 21, 2001 |
| | | | EQ 7.5MG BASE | A040385 | 002 | Mar 21, 2001 |
| | | | EQ 10MG BASE | A040385 | 003 | Mar 21, 2001 |
| | ! | | EQ 15MG BASE | A040385 | 004 | Mar 21, 2001 |
| METHOXSALEN | | | | | | |
| CAPSULE;ORAL | | | | | | |
| **METHOXSALEN** | | | | | | |
| **AB** | | ACTAVIS INC | **10MG** | **A202603** | **001** | Jun 09, 2015 |
| **AB** | | STRIDES PHARMA | **10MG** | **A202687** | **001** | Jun 05, 2014 |
| **OXSORALEN-ULTRA** | | | | | | |
| **AB** | **+!** | DOW PHARM | **10MG** | **N019600** | **001** | Oct 30, 1986 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| METHOXSALEN | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| UVADEX | | | | | | | |
| | +! | MALLINCKRODT HOSP | 0.02MG/ML | | N020969 | 001 | Feb 25, 1999 |
| METHSCOPOLAMINE BROMIDE | | | | | | | |
| TABLET;ORAL | | | | | | | |
| **METHSCOPOLAMINE BROMIDE** | | | | | | | |
| **AA** | | BAYSHORE PHARMS LLC | **2.5MG** | | **A200602** | **001** | Sep 24, 2012 |
| **AA** | | | **5MG** | | **A200602** | **002** | Sep 24, 2012 |
| **AA** | | BRECKENRIDGE PHARM | **2.5MG** | | **A040642** | **001** | Dec 06, 2011 |
| **AA** | | | **5MG** | | **A040642** | **002** | Dec 06, 2011 |
| **AA** | **!** | VINTAGE PHARMS | **2.5MG** | | **A040624** | **001** | Dec 28, 2006 |
| **AA** | **!** | | **5MG** | | **A040624** | **002** | Dec 28, 2006 |
| METHSUXIMIDE | | | | | | | |
| CAPSULE;ORAL | | | | | | | |
| CELONTIN | | | | | | | |
| | + | PARKE DAVIS | 150MG | | N010596 | 007 | |
| | +! | | 300MG | | N010596 | 008 | |
| METHYCLOTHIAZIDE | | | | | | | |
| TABLET;ORAL | | | | | | | |
| METHYCLOTHIAZIDE | | | | | | | |
| | ! | MYLAN PHARMS INC | 5MG | | A087672 | 001 | Aug 17, 1982 |
| METHYLDOPA | | | | | | | |
| TABLET;ORAL | | | | | | | |
| **METHYLDOPA** | | | | | | | |
| **AB** | | ACCORD HLTHCARE | **250MG** | | **A070084** | **001** | Oct 15, 1985 |
| **AB** | | | **500MG** | | **A070085** | **001** | Oct 15, 1985 |
| **AB** | | IVAX SUB TEVA PHARMS | **250MG** | | **A070098** | **001** | Feb 20, 1986 |
| **AB** | | | **500MG** | | **A070343** | **001** | Feb 20, 1986 |
| **AB** | | MYLAN | **250MG** | | **A070076** | **002** | Apr 18, 1985 |
| **AB** | **!** | | **500MG** | | **A070076** | **001** | Apr 18, 1985 |
| **AB** | | WATSON LABS | **500MG** | | **A070625** | **001** | Jun 06, 1986 |
| METHYLDOPATE HYDROCHLORIDE | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| METHYLDOPATE HYDROCHLORIDE | | | | | | | |
| | ! | LUITPOLD | 50MG/ML | | A071279 | 001 | Oct 02, 1987 |
| METHYLENE BLUE | | | | | | | |
| SOLUTION;INTRAVENOUS | | | | | | | |
| PROVAYBLUE | | | | | | | |
| | +! | PROVEPHARM SAS | 50MG/10ML (5MG/ML) | | N204630 | 001 | Apr 08, 2016 |
| METHYLERGONOVINE MALEATE | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| **METHERGINE** | | | | | | | |
| **AP** | **+!** | EDISON THERAPS LLC | **0.2MG/ML** | | **N006035** | **004** | |
| **METHYLERGONOVINE MALEATE** | | | | | | | |
| **AP** | | BRECKENRIDGE PHARM | **0.2MG/ML** | | **A040889** | **001** | Sep 13, 2010 |
| **AP** | | LUITPOLD | **0.2MG/ML** | | **A090193** | **001** | Nov 24, 2008 |
| TABLET;ORAL | | | | | | | |
| METHYLERGONOVINE MALEATE | | | | | | | |
| | ! | NOVEL LABS INC | 0.2MG | | A091577 | 001 | May 02, 2011 |
| METHYLNALTREXONE BROMIDE | | | | | | | |
| SOLUTION;SUBCUTANEOUS | | | | | | | |
| RELISTOR | | | | | | | |
| | +! | SALIX PHARMS | 8MG/0.4ML (8MG/0.4ML) | | N021964 | 002 | Sep 27, 2010 |
| | +! | | 12MG/0.6ML (12MG/0.6ML) | | N021964 | 001 | Apr 24, 2008 |
| | +! | | 12MG/0.6ML (12MG/0.6ML) | | N021964 | 003 | Sep 27, 2010 |
| TABLET;ORAL | | | | | | | |
| RELISTOR | | | | | | | |
| | +! | SALIX PHARMS INC | 150MG | | N208271 | 001 | Jul 19, 2016 |
| METHYLPHENIDATE | | | | | | | |
| FILM, EXTENDED RELEASE;TRANSDERMAL | | | | | | | |
| DAYTRANA | | | | | | | |
| | + | NOVEN PHARMS INC | 10MG/9HR (1.1MG/HR) | | N021514 | 001 | Apr 06, 2006 |
| | + | | 15MG/9HR (1.6MG/HR) | | N021514 | 002 | Apr 06, 2006 |
| | + | | 20MG/9HR (2.2MG/HR) | | N021514 | 003 | Apr 06, 2006 |
| | +! | | 30MG/9HR (3.3MG/HR) | | N021514 | 004 | Apr 06, 2006 |

| | | | | | | |
|---|---|---|---|---|---|---|
| METHYLPHENIDATE | | | | | | |
| TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL | | | | | | |
| COTEMPLA XR-ODT | | | | | | |
| | + | NEOS THERAPS INC | 8.6MG | N205489 | 001 | Jun 19, 2017 |
| | + | | 17.3MG | N205489 | 002 | Jun 19, 2017 |
| | + | | 25.9MG | N205489 | 003 | Jun 19, 2017 |
| METHYLPHENIDATE HYDROCHLORIDE | | | | | | |
| CAPSULE, EXTENDED RELEASE;ORAL | | | | | | |
| **METHYLPHENIDATE HYDROCHLORIDE** | | | | | | |
| **AB1** | | BARR LABS INC | **10MG** | **A079031** | **004** | Oct 15, 2014 |
| **AB1** | | | **20MG** | **A079031** | **001** | Jul 13, 2012 |
| **AB1** | | | **30MG** | **A079031** | **002** | Jul 13, 2012 |
| **AB1** | | | **40MG** | **A079031** | **003** | Jul 13, 2012 |
| **AB1** | | MAYNE PHARMA | **20MG** | **A078458** | **001** | Dec 01, 2011 |
| **AB1** | | | **30MG** | **A078458** | **002** | Dec 01, 2011 |
| **AB1** | | | **40MG** | **A078458** | **003** | Dec 01, 2011 |
| **RITALIN LA** | | | | | | |
| **AB1** | **+** | NOVARTIS | **10MG** | **N021284** | **004** | Apr 10, 2004 |
| **AB1** | **+** | | **20MG** | **N021284** | **001** | Jun 05, 2002 |
| **AB1** | **+** | | **30MG** | **N021284** | **002** | Jun 05, 2002 |
| **AB1** | **+** | | **40MG** | **N021284** | **003** | Jun 05, 2002 |
| **METADATE CD** | | | | | | |
| **AB2** | **+** | UCB INC | **10MG** | **N021259** | **003** | May 27, 2003 |
| **AB2** | **+** | | **20MG** | **N021259** | **001** | Apr 03, 2001 |
| **AB2** | **+** | | **30MG** | **N021259** | **002** | Jun 19, 2003 |
| **AB2** | **+** | | **40MG** | **N021259** | **004** | Feb 19, 2006 |
| **AB2** | **+** | | **50MG** | **N021259** | **005** | Feb 19, 2006 |
| **AB2** | **+!** | | **60MG** | **N021259** | **006** | Feb 19, 2006 |
| **METHYLPHENIDATE HYDROCHLORIDE** | | | | | | |
| **AB2** | | IMPAX LABS INC | **10MG** | **A205105** | **001** | Jul 28, 2016 |
| **AB2** | | | **20MG** | **A205105** | **002** | Jul 28, 2016 |
| **AB2** | | | **30MG** | **A205105** | **003** | Jul 28, 2016 |
| **AB2** | | | **40MG** | **A205105** | **004** | Jul 28, 2016 |
| **AB2** | | | **50MG** | **A205105** | **005** | Jul 28, 2016 |
| **AB2** | | | **60MG** | **A205105** | **006** | Jul 28, 2016 |
| **AB2** | | SPECGX LLC | **10MG** | **A203583** | **001** | Sep 29, 2015 |
| **AB2** | | | **20MG** | **A203583** | **002** | Sep 29, 2015 |
| **AB2** | | | **30MG** | **A203583** | **003** | Sep 29, 2015 |
| **AB2** | | | **40MG** | **A203583** | **004** | Sep 29, 2015 |
| **AB2** | | | **50MG** | **A203583** | **005** | Sep 29, 2015 |
| **AB2** | | | **60MG** | **A203583** | **006** | Sep 29, 2015 |
| **AB2** | | TEVA PHARMS | **10MG** | **A077707** | **001** | Jul 19, 2012 |
| **AB2** | | | **20MG** | **A077707** | **002** | Jul 19, 2012 |
| **AB2** | | | **30MG** | **A077707** | **003** | Jul 19, 2012 |
| **AB2** | | | **40MG** | **A078873** | **001** | Jul 19, 2012 |
| **AB2** | | | **50MG** | **A078873** | **002** | Jul 19, 2012 |
| **AB2** | | | **60MG** | **A078873** | **003** | Jul 19, 2012 |
| APTENSIO XR | | | | | | |
| | + | RHODES PHARMS | 10MG | N205831 | 001 | Apr 17, 2015 |
| | + | | 15MG | N205831 | 002 | Apr 17, 2015 |
| | + | | 20MG | N205831 | 003 | Apr 17, 2015 |
| | + | | 30MG | N205831 | 004 | Apr 17, 2015 |
| | + | | 40MG | N205831 | 005 | Apr 17, 2015 |
| | + | | 50MG | N205831 | 006 | Apr 17, 2015 |
| | +! | | 60MG | N205831 | 007 | Apr 17, 2015 |
| METHYLPHENIDATE HYDROCHLORIDE | | | | | | |
| | ! | MAYNE PHARMA | 60MG | A078458 | 004 | Jun 23, 2016 |
| FOR SUSPENSION, EXTENDED RELEASE;ORAL | | | | | | |
| QUILLIVANT XR | | | | | | |
| | +! | NEXTWAVE PHARMS | 5MG/ML | N202100 | 001 | Sep 27, 2012 |
| SOLUTION;ORAL | | | | | | |
| **METHYLIN** | | | | | | |
| **AA** | **+!** | SPECGX LLC | **5MG/5ML** | **N021419** | **001** | Dec 19, 2002 |
| **AA** | **+!** | | **10MG/5ML** | **N021419** | **002** | Dec 19, 2002 |
| **METHYLPHENIDATE HYDROCHLORIDE** | | | | | | |
| **AA** | | ABHAI LLC | **5MG/5ML** | **A207485** | **001** | Nov 18, 2016 |
| **AA** | | | **10MG/5ML** | **A207485** | **002** | Nov 18, 2016 |
| **AA** | | BRECKENRIDGE PHARM | **5MG/5ML** | **A201466** | **001** | Nov 12, 2013 |
| **AA** | | | **10MG/5ML** | **A201466** | **002** | Nov 12, 2013 |
| **AA** | | NOVEL LABS INC | **5MG/5ML** | **A204602** | **001** | Aug 14, 2015 |
| **AA** | | | **10MG/5ML** | **A204602** | **002** | Aug 14, 2015 |
| **AA** | | TRIS PHARMA INC | **5MG/5ML** | **A091601** | **001** | Jul 23, 2010 |

METHYLPHENIDATE HYDROCHLORIDE

SOLUTION;ORAL

**METHYLPHENIDATE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | | **10MG/5ML** | **A091601** | **002** | Jul 23, 2010 |

TABLET;ORAL

**METHYLPHENIDATE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ABHAI INC | **5MG** | **A206932** | **001** | May 11, 2017 |
| **AB** | | | **10MG** | **A206932** | **002** | May 11, 2017 |
| **AB** | | | **20MG** | **A206932** | **003** | May 11, 2017 |
| **AB** | | ACTAVIS LABS FL INC | **5MG** | **A040220** | **001** | Aug 29, 1997 |
| **AB** | | | **10MG** | **A040220** | **002** | Aug 29, 1997 |
| **AB** | | | **20MG** | **A040220** | **003** | Aug 29, 1997 |
| **AB** | | ASCENT PHARMS INC | **5MG** | **A207416** | **001** | Sep 22, 2015 |
| **AB** | | | **10MG** | **A207416** | **002** | Sep 22, 2015 |
| **AB** | | | **20MG** | **A207416** | **003** | Sep 22, 2015 |
| **AB** | | BRECKENRIDGE PHARM | **5MG** | **A207587** | **001** | Mar 03, 2017 |
| **AB** | | | **10MG** | **A207587** | **002** | Mar 03, 2017 |
| **AB** | | | **20MG** | **A207587** | **003** | Mar 03, 2017 |
| **AB** | | CNTY LINE PHARMS | **5MG** | **A206840** | **001** | Sep 15, 2016 |
| **AB** | | | **10MG** | **A206840** | **002** | Sep 15, 2016 |
| **AB** | | | **20MG** | **A206840** | **003** | Sep 15, 2016 |
| **AB** | | COREPHARMA | **5MG** | **A091159** | **001** | Mar 12, 2014 |
| **AB** | | | **10MG** | **A091159** | **002** | Mar 12, 2014 |
| **AB** | | | **20MG** | **A091159** | **003** | Mar 12, 2014 |
| **AB** | | NOVEL LABS INC | **5MG** | **A207884** | **001** | Nov 13, 2015 |
| **AB** | | | **10MG** | **A207884** | **002** | Nov 13, 2015 |
| **AB** | | | **20MG** | **A207884** | **003** | Nov 13, 2015 |
| **AB** | | SPECGX LLC | **5MG** | **A040300** | **001** | Nov 27, 1998 |
| **AB** | | | **10MG** | **A040300** | **002** | Nov 27, 1998 |
| **AB** | | | **20MG** | **A040300** | **003** | Nov 27, 1998 |
| **AB** | | SUN PHARM INDS INC | **5MG** | **A090710** | **001** | Mar 15, 2012 |
| **AB** | | | **10MG** | **A090710** | **002** | Mar 15, 2012 |
| **AB** | | | **20MG** | **A090710** | **003** | Mar 15, 2012 |
| **AB** | | UCB INC | **5MG** | **A086429** | **001** | |
| **AB** | | | **10MG** | **A085799** | **001** | |
| **AB** | | | **20MG** | **A086428** | **001** | |
| **AB** | | VINTAGE PHARMS | **5MG** | **A202892** | **001** | Sep 23, 2014 |
| **AB** | | | **10MG** | **A202892** | **002** | Sep 23, 2014 |
| **AB** | | | **20MG** | **A202892** | **003** | Sep 23, 2014 |

**RITALIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | NOVARTIS | **5MG** | **N010187** | **003** | |
| **AB** | + | | **10MG** | **N010187** | **006** | |
| **AB** | +! | | **20MG** | **N010187** | **010** | |

TABLET, CHEWABLE;ORAL

**METHYLPHENIDATE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ASCENT PHARMS INC | **2.5MG** | **A210354** | **001** | Dec 29, 2017 |
| **AB** | | | **5MG** | **A210354** | **002** | Dec 29, 2017 |
| **AB** | | | **10MG** | **A210354** | **003** | Dec 29, 2017 |
| **AB** | | BRECKENRIDGE PHARM | **2.5MG** | **A204954** | **001** | Jan 26, 2017 |
| **AB** | | | **5MG** | **A204954** | **002** | Jan 26, 2017 |
| **AB** | | | **10MG** | **A204954** | **003** | Jan 26, 2017 |
| **AB** | | NOVEL LABS INC | **2.5MG** | **A204115** | **001** | Feb 25, 2015 |
| **AB** | | | **5MG** | **A204115** | **002** | Feb 25, 2015 |
| **AB** | ! | | **10MG** | **A204115** | **003** | Feb 25, 2015 |
| **AB** | | TEDOR PHARMA INC | **2.5MG** | **A205756** | **001** | Nov 07, 2016 |
| **AB** | | | **5MG** | **A205756** | **002** | Nov 07, 2016 |
| **AB** | | | **10MG** | **A205756** | **003** | Nov 07, 2016 |

TABLET, EXTENDED RELEASE;ORAL

**CONCERTA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | JANSSEN PHARMS | **18MG** | **N021121** | **001** | Aug 01, 2000 |
| **AB** | + | | **27MG** | **N021121** | **004** | Apr 01, 2002 |
| **AB** | + | | **36MG** | **N021121** | **002** | Aug 01, 2000 |
| **AB** | +! | | **54MG** | **N021121** | **003** | Dec 08, 2000 |

**METADATE ER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | ! | UCB INC | **20MG** | **A089601** | **001** | Jun 01, 1988 |

**METHYLIN ER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | SPECGX LLC | **10MG** | **A075629** | **001** | May 09, 2000 |
| **AB** | | | **20MG** | **A075629** | **002** | May 09, 2000 |

**METHYLPHENIDATE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ABHAI LLC | **10MG** | **A207488** | **001** | Jun 09, 2015 |
| **AB** | | | **20MG** | **A207488** | **002** | Jun 09, 2015 |
| **AB** | | CNTY LINE PHARMS | **10MG** | **A204772** | **001** | Feb 29, 2016 |

METHYLPHENIDATE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

**METHYLPHENIDATE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **20MG** | **A204772** | **002** | Feb 29, 2016 |
| **AB** | | COREPHARMA | **18MG** | **A208607** | **001** | Jul 14, 2017 |
| **AB** | | | **27MG** | **A208607** | **002** | Jul 14, 2017 |
| **AB** | | | **36MG** | **A208607** | **003** | Jul 14, 2017 |
| **AB** | | | **54MG** | **A208607** | **004** | Jul 14, 2017 |
| **AB** | | MYLAN PHARMS INC | **18MG** | **A206726** | **001** | Oct 21, 2016 |
| **AB** | | | **27MG** | **A206726** | **002** | Oct 21, 2016 |
| **AB** | | | **36MG** | **A206726** | **003** | Oct 21, 2016 |
| **AB** | | | **54MG** | **A206726** | **004** | Oct 21, 2016 |
| **AB** | | OSMOTICA | **18MG** | **A205327** | **001** | Jul 28, 2017 |
| **AB** | | | **27MG** | **A205327** | **002** | Jul 28, 2017 |
| **AB** | | | **36MG** | **A205327** | **003** | Jul 28, 2017 |
| **AB** | | | **54MG** | **A205327** | **004** | Jul 28, 2017 |

**RITALIN-SR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | NOVARTIS | **20MG** | **N018029** | **001** | Mar 30, 1982 |

METHYLPHENIDATE HYDROCHLORIDE

| | | | | | | |
|---|---|---|---|---|---|---|
| BX | | KREMERS URBAN PHARMS | 18MG | A091695 | 001 | Jul 09, 2013 |
| BX | | | 27MG | A091695 | 002 | Jul 09, 2013 |
| BX | | | 36MG | A091695 | 003 | Sep 23, 2013 |
| BX | | | 54MG | A091695 | 004 | Sep 23, 2013 |
| BX | | SPECGX LLC | 27MG | A202608 | 001 | Dec 28, 2012 |
| BX | | | 36MG | A202608 | 002 | Dec 28, 2012 |
| BX | | | 54MG | A202608 | 003 | Dec 28, 2012 |
| | | OSMOTICA | 72MG | A205327 | 005 | Jul 28, 2017 |

TABLET, EXTENDED RELEASE, CHEWABLE;ORAL

QUILLICHEW ER

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | PFIZER INC | 20MG | N207960 | 001 | Dec 04, 2015 |
| | + | | 30MG | N207960 | 002 | Dec 04, 2015 |
| | +! | | 40MG | N207960 | 003 | Dec 04, 2015 |

METHYLPREDNISOLONE

TABLET;ORAL

**MEDROL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | PHARMACIA AND UPJOHN | **4MG** | **N011153** | **001** | |
| **AB** | **+** | | **8MG** | **N011153** | **004** | |
| **AB** | **+** | | **16MG** | **N011153** | **003** | |
| **AB** | **+!** | | **32MG** | **N011153** | **006** | |

**METHYLPREDNISOLONE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | DURAMED PHARMS BARR | **4MG** | **A088497** | **001** | Feb 21, 1984 |
| **AB** | | JUBILANT CADISTA | **4MG** | **A040189** | **001** | Oct 31, 1997 |
| **AB** | | | **8MG** | **A040189** | **002** | Oct 31, 1997 |
| **AB** | | | **16MG** | **A040189** | **003** | Jul 20, 2007 |
| **AB** | | | **32MG** | **A040189** | **004** | Jul 20, 2007 |
| **AB** | | SANDOZ | **4MG** | **A040194** | **001** | Oct 31, 1997 |
| **AB** | | VINTAGE PHARMS | **4MG** | **A040183** | **001** | Dec 22, 1998 |
| **AB** | | WATSON LABS | **4MG** | **A040232** | **001** | Oct 16, 1997 |

MEDROL

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | PHARMACIA AND UPJOHN | 2MG | N011153 | 002 | |

METHYLPREDNISOLONE ACETATE

INJECTABLE;INJECTION

**DEPO-MEDROL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | PHARMACIA AND UPJOHN | **40MG/ML** | **N011757** | **001** | |
| **AB** | **+!** | | **80MG/ML** | **N011757** | **004** | |

**METHYLPREDNISOLONE ACETATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | SANDOZ INC | **40MG/ML** | **A040719** | **001** | Jan 29, 2009 |
| **AB** | | | **40MG/ML** | **A040794** | **001** | Mar 05, 2009 |
| **AB** | | | **80MG/ML** | **A040719** | **002** | Jan 29, 2009 |
| **AB** | | | **80MG/ML** | **A040794** | **002** | Mar 05, 2009 |
| **AB** | | TEVA PHARMS USA | **40MG/ML** | **A040557** | **001** | Feb 23, 2005 |
| **AB** | | | **40MG/ML** | **A040620** | **001** | Oct 27, 2006 |
| **AB** | | | **80MG/ML** | **A040557** | **002** | Feb 23, 2005 |
| **AB** | | | **80MG/ML** | **A040620** | **002** | Oct 27, 2006 |

DEPO-MEDROL

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | PHARMACIA AND UPJOHN | 20MG/ML | N011757 | 002 | |

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE;INJECTION

**A-METHAPRED**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | HOSPIRA | **EQ 40MG BASE/VIAL** | **A040664** | **001** | Dec 20, 2005 |
| **AP** | | | **EQ 125MG BASE/VIAL** | **A040665** | **001** | Dec 20, 2005 |

**METHYLPREDNISOLONE SODIUM SUCCINATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AMNEAL PHARMS CO | **EQ 40MG BASE/VIAL** | **A207549** | **001** | Nov 09, 2016 |
| **AP** | | | **EQ 125MG BASE/VIAL** | **A207549** | **002** | Nov 09, 2016 |
| **AP** | | AUROBINDO PHARMA LTD | **EQ 40MG BASE/VIAL** | **A207667** | **001** | Dec 15, 2015 |
| **AP** | | | **EQ 125MG BASE/VIAL** | **A207667** | **002** | Dec 15, 2015 |
| **AP** | | | **EQ 500MG BASE/VIAL** | **A207667** | **003** | Dec 15, 2015 |
| **AP** | | | **EQ 2GM BASE/VIAL** | **A207667** | **004** | Dec 15, 2015 |
| **AP** | | FRESENIUS KABI USA | **EQ 40MG BASE/VIAL** | **A040583** | **001** | Jul 30, 2004 |
| **AP** | | | **EQ 125MG BASE/VIAL** | **A040583** | **002** | Jul 30, 2004 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A040612** | **001** | Aug 12, 2004 |
| **AP** | | HIKMA FARMACEUTICA | **EQ 500MG BASE/VIAL** | **A202691** | **001** | Feb 16, 2016 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A202691** | **002** | Feb 16, 2016 |
| **AP** | | SAGENT PHARMS | **EQ 40MG BASE/VIAL** | **A040888** | **001** | Jul 18, 2011 |
| **AP** | | | **EQ 125MG BASE/VIAL** | **A040888** | **002** | Jul 18, 2011 |
| **AP** | | | **EQ 500MG BASE/VIAL** | **A040888** | **003** | Jul 18, 2011 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A040888** | **004** | Jul 18, 2011 |
| **AP** | | | **EQ 2GM BASE/VIAL** | **A040888** | **005** | Jul 18, 2011 |

**SOLU-MEDROL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | PHARMACIA AND UPJOHN | **EQ 40MG BASE/VIAL** | **N011856** | **003** | |
| **AP** | **+!** | | **EQ 125MG BASE/VIAL** | **N011856** | **004** | |
| **AP** | **+!** | | **EQ 500MG BASE/VIAL** | **N011856** | **005** | |
| **AP** | **+!** | | **EQ 1GM BASE/VIAL** | **N011856** | **006** | |
| **AP** | **+!** | | **EQ 2GM BASE/VIAL** | **N011856** | **007** | Feb 27, 1985 |

METHYLTESTOSTERONE

CAPSULE;ORAL

**METHYLTESTOSTERONE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | IMPAX LABS INC | **10MG** | **A204851** | **001** | Sep 21, 2015 |

**TESTRED**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **!** | VALEANT PHARM INTL | **10MG** | **A083976** | **001** | |

TABLET;ORAL

ANDROID 25

| | | | | | | |
|---|---|---|---|---|---|---|
| BP | | VALEANT PHARM INTL | 25MG | A087147 | 001 | |

METHYLTESTOSTERONE

| | | | | | | |
|---|---|---|---|---|---|---|
| BP | | IMPAX LABS | 10MG | A080767 | 002 | |

METIPRANOLOL HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

**METIPRANOLOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | SANDOZ INC | **0.3%** | **A075720** | **001** | Aug 06, 2001 |

**OPTIPRANOLOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **+!** | BAUSCH AND LOMB | **0.3%** | **N019907** | **001** | Dec 29, 1989 |

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION

**METOCLOPRAMIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | EMCURE PHARMS LTD | **EQ 5MG BASE/ML** | **A204756** | **001** | Dec 20, 2013 |

**METOCLOPRAMIDE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | FRESENIUS KABI USA | **EQ 5MG BASE/ML** | **A091392** | **001** | Apr 19, 2013 |
| **AP** | **!** | HOSPIRA | **EQ 5MG BASE/ML** | **A073118** | **001** | Jan 17, 1991 |
| **AP** | | TEVA PHARMS USA | **EQ 5MG BASE/ML** | **A073135** | **001** | Nov 27, 1991 |

SOLUTION;ORAL

**METOCLOPRAMIDE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | ANI PHARMS | **EQ 5MG BASE/5ML** | **A071402** | **001** | Jun 25, 1993 |
| **AA** | | PHARM ASSOC | **EQ 5MG BASE/5ML** | **A072744** | **001** | May 28, 1991 |
| **AA** | | VISTAPHARM | **EQ 5MG BASE/5ML** | **A075051** | **001** | Jan 26, 2001 |
| **AA** | **!** | WOCKHARDT BIO AG | **EQ 5MG BASE/5ML** | **A074703** | **001** | Oct 31, 1997 |

TABLET;ORAL

**METOCLOPRAMIDE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | IMPAX LABS INC | **EQ 5MG BASE** | **A071250** | **002** | Dec 28, 1995 |
| **AB** | | | **EQ 10MG BASE** | **A071250** | **001** | Feb 03, 1988 |
| **AB** | | IPCA LABS LTD | **EQ 5MG BASE** | **A078807** | **001** | Jun 12, 2008 |
| **AB** | | | **EQ 10MG BASE** | **A078807** | **002** | Jun 12, 2008 |
| **AB** | | PAR PHARM INC | **EQ 10MG BASE** | **A070581** | **001** | Oct 17, 1985 |
| **AB** | | TEVA | **EQ 5MG BASE** | **A072801** | **001** | Jun 15, 1993 |
| **AB** | | | **EQ 10MG BASE** | **A070184** | **001** | Jul 29, 1985 |
| **AB** | | VINTAGE PHARMS | **EQ 5MG BASE** | **A077878** | **001** | Aug 28, 2006 |

METOCLOPRAMIDE HYDROCHLORIDE

TABLET;ORAL

**METOCLOPRAMIDE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **EQ 10MG BASE** | **A077878** | **002** | Aug 28, 2006 |

**REGLAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | ANI PHARMS | **EQ 5MG BASE** | **N017854** | **002** | May 05, 1987 |
| **AB** | **+!** | | **EQ 10MG BASE** | **N017854** | **001** | |

TABLET, ORALLY DISINTEGRATING;ORAL

**METOCLOPRAMIDE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | NOVEL LABS INC | **EQ 5MG BASE** | **A202191** | **001** | Aug 15, 2014 |

**METOZOLV ODT**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | SALIX PHARMS | **EQ 5MG BASE** | **N022246** | **001** | Sep 04, 2009 |
| | | METOCLOPRAMIDE HYDROCHLORIDE | | | | |
| | | NOVEL LABS INC | EQ 10MG BASE | A202191 | 002 | Aug 15, 2014 |

METOLAZONE

TABLET;ORAL

**METOLAZONE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | MYLAN | **2.5MG** | **A076698** | **001** | Dec 23, 2003 |
| **AB** | | | **5MG** | **A076698** | **002** | Oct 19, 2004 |
| **AB** | | | **10MG** | **A076698** | **003** | Oct 19, 2004 |
| **AB** | | SANDOZ | **2.5MG** | **A076732** | **001** | Dec 19, 2003 |
| **AB** | | | **5MG** | **A076466** | **001** | Dec 19, 2003 |
| **AB** | | | **10MG** | **A076466** | **002** | Dec 19, 2003 |

**ZAROXOLYN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | UCB INC | **2.5MG** | **N017386** | **001** | |
| **AB** | **+!** | | **5MG** | **N017386** | **002** | |
| **AB** | **+!** | | **10MG** | **N017386** | **003** | |

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

**METOPROLOL SUCCINATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS ELIZABETH | **EQ 25MG TARTRATE** | **A204161** | **001** | Nov 25, 2016 |
| **AB** | | | **EQ 50MG TARTRATE** | **A204161** | **002** | Nov 25, 2016 |
| **AB** | | | **EQ 100MG TARTRATE** | **A204161** | **003** | Nov 25, 2016 |
| **AB** | | | **EQ 200MG TARTRATE** | **A204161** | **004** | Nov 25, 2016 |
| **AB** | | ACTAVIS LABS FL INC | **EQ 25MG TARTRATE** | **A077118** | **001** | Aug 03, 2009 |
| **AB** | | | **EQ 50MG TARTRATE** | **A076862** | **001** | Aug 03, 2009 |
| **AB** | | | **EQ 100MG TARTRATE** | **A077298** | **001** | Apr 15, 2010 |
| **AB** | | | **EQ 200MG TARTRATE** | **A077298** | **002** | Apr 15, 2010 |
| **AB** | | DR REDDYS LABS LTD | **EQ 25MG TARTRATE** | **A090617** | **001** | Aug 01, 2012 |
| **AB** | | | **EQ 50MG TARTRATE** | **A090617** | **002** | Aug 01, 2012 |
| **AB** | | MYLAN PHARMS INC | **EQ 25MG TARTRATE** | **A202033** | **001** | Dec 15, 2011 |
| **AB** | | | **EQ 50MG TARTRATE** | **A202033** | **002** | Dec 15, 2011 |
| **AB** | | | **EQ 100MG TARTRATE** | **A202033** | **003** | Dec 15, 2011 |
| **AB** | | | **EQ 200MG TARTRATE** | **A202033** | **004** | Dec 15, 2011 |
| **AB** | | REDDYS | **EQ 100MG TARTRATE** | **A078889** | **001** | Aug 15, 2012 |
| **AB** | | | **EQ 200MG TARTRATE** | **A078889** | **002** | Aug 15, 2012 |
| **AB** | | WOCKHARDT | **EQ 25MG TARTRATE** | **A090615** | **001** | Jul 22, 2010 |
| **AB** | | | **EQ 50MG TARTRATE** | **A090615** | **002** | Jul 22, 2010 |
| **AB** | | | **EQ 100MG TARTRATE** | **A090615** | **003** | Jul 22, 2010 |
| **AB** | | | **EQ 200MG TARTRATE** | **A090615** | **004** | Jul 22, 2010 |

**TOPROL-XL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | ARALEZ PHARMS | **EQ 25MG TARTRATE** | **N019962** | **004** | Feb 05, 2001 |
| **AB** | **+!** | | **EQ 50MG TARTRATE** | **N019962** | **001** | Jan 10, 1992 |
| **AB** | **+** | | **EQ 100MG TARTRATE** | **N019962** | **002** | Jan 10, 1992 |
| **AB** | **+!** | | **EQ 200MG TARTRATE** | **N019962** | **003** | Jan 10, 1992 |

METOPROLOL TARTRATE

INJECTABLE;INJECTION

**LOPRESSOR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | NOVARTIS | **1MG/ML** | **N018704** | **001** | Mar 30, 1984 |

**METOPROLOL TARTRATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | BAXTER HLTHCARE CORP | **1MG/ML** | **A078950** | **001** | Apr 29, 2013 |
| **AP** | | FRESENIUS KABI USA | **1MG/ML** | **A091045** | **001** | Oct 25, 2010 |
| **AP** | | GLAND PHARMA LTD | **1MG/ML** | **A204205** | **001** | Aug 27, 2014 |
| **AP** | | HIKMA FARMACEUTICA | **1MG/ML** | **A077761** | **001** | May 30, 2007 |
| **AP** | | HOSPIRA | **1MG/ML** | **A074133** | **001** | Dec 21, 1993 |
| **AP** | | | **1MG/ML** | **A075160** | **001** | Jul 06, 1998 |
| **AP** | | | **1MG/ML** | **A078085** | **001** | Apr 29, 2008 |
| **AP** | | LUITPOLD | **1MG/ML** | **A090386** | **001** | Sep 30, 2009 |
| **AP** | | | **1MG/ML** | **A091307** | **001** | Dec 29, 2010 |
| **AP** | | SAGENT STRIDES | **1MG/ML** | **A090317** | **001** | Apr 19, 2010 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| METOPROLOL TARTRATE | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| **METOPROLOL TARTRATE** | | | | | | | |
| **AP** | | SANDOZ INC | **1MG/ML** | **A077360** | **001** | Oct 02, 2007 |
| **AP** | | WEST-WARD PHARMS INT | **1MG/ML** | **A076495** | **001** | Jul 07, 2003 |
| TABLET;ORAL | | | | | | | |
| **LOPRESSOR** | | | | | | | |
| **AB** | + | US PHARMS HOLDINGS I | **50MG** | **N017963** | **001** | |
| **AB** | + | | **100MG** | **N017963** | **002** | |
| **METOPROLOL TARTRATE** | | | | | | | |
| **AB** | | ALEMBIC PHARMS LTD | **25MG** | **A202871** | **001** | May 28, 2013 |
| **AB** | | | **50MG** | **A202871** | **002** | May 28, 2013 |
| **AB** | | | **100MG** | **A202871** | **003** | May 28, 2013 |
| **AB** | | AUROBINDO PHARMA | **25MG** | **A077739** | **001** | Sep 11, 2007 |
| **AB** | | | **50MG** | **A077739** | **002** | Sep 11, 2007 |
| **AB** | | | **100MG** | **A077739** | **003** | Sep 11, 2007 |
| **AB** | | IPCA LABS LTD | **25MG** | **A078459** | **001** | Jun 17, 2008 |
| **AB** | | | **50MG** | **A078459** | **002** | Jun 17, 2008 |
| **AB** | | | **100MG** | **A078459** | **003** | Jun 17, 2008 |
| **AB** | | MYLAN | **25MG** | **A076704** | **001** | Jan 16, 2004 |
| **AB** | | | **50MG** | **A076704** | **002** | Jan 16, 2004 |
| **AB** | ! | | **100MG** | **A076704** | **003** | Jan 16, 2004 |
| **AB** | | RUBICON RES PVT LTD | **25MG** | **A200981** | **001** | Oct 28, 2014 |
| **AB** | | | **50MG** | **A200981** | **002** | Oct 28, 2014 |
| **AB** | | | **100MG** | **A200981** | **003** | Oct 28, 2014 |
| **AB** | | SUN PHARM INDS INC | **25MG** | **A076670** | **001** | Jan 15, 2004 |
| **AB** | | | **50MG** | **A074644** | **001** | Dec 10, 1996 |
| **AB** | | | **100MG** | **A074644** | **002** | Dec 10, 1996 |
| **AB** | | SUN PHARM INDUSTRIES | **25MG** | **A073654** | **002** | Jul 15, 2009 |
| **AB** | | | **50MG** | **A073654** | **003** | Dec 21, 1993 |
| **AB** | | | **100MG** | **A073654** | **001** | Dec 21, 1993 |
| **AB** | | TEVA | **50MG** | **A074141** | **001** | Jan 31, 1995 |
| **AB** | | | **100MG** | **A074141** | **002** | Jan 31, 1995 |
| **AB** | | WATSON LABS | **50MG** | **A074217** | **001** | May 27, 1994 |
| **AB** | | | **100MG** | **A074217** | **002** | May 27, 1994 |
| | | MYLAN | 37.5MG | A076704 | 004 | Mar 18, 2015 |
| | | | 75MG | A076704 | 005 | Mar 18, 2015 |
| METRONIDAZOLE | | | | | | | |
| CAPSULE;ORAL | | | | | | | |
| **FLAGYL** | | | | | | | |
| **AB** | +! | GD SEARLE LLC | **375MG** | **N020334** | **001** | May 03, 1995 |
| **METRONIDAZOLE** | | | | | | | |
| **AB** | | ALEMBIC PHARMS LTD | **375MG** | **A079065** | **001** | Jun 23, 2009 |
| **AB** | | PAR PHARM | **375MG** | **A076522** | **001** | Jan 29, 2004 |
| CREAM;TOPICAL | | | | | | | |
| **METROCREAM** | | | | | | | |
| **AB** | +! | GALDERMA LABS LP | **0.75%** | **N020531** | **001** | Sep 20, 1995 |
| **METRONIDAZOLE** | | | | | | | |
| **AB** | | FOUGERA PHARMS | **0.75%** | **A076408** | **001** | May 28, 2004 |
| **AB** | | G AND W LABS | **0.75%** | **A077549** | **001** | Dec 19, 2007 |
| NORITATE | | | | | | | |
| | +! | VALEANT PHARMS NORTH | 1% | N020743 | 001 | Sep 26, 1997 |
| GEL;TOPICAL | | | | | | | |
| **METROGEL** | | | | | | | |
| **AB** | +! | GALDERMA LABS LP | **0.75%** | **N019737** | **001** | Nov 22, 1988 |
| **AB** | +! | | **1%** | **N021789** | **001** | Jun 30, 2005 |
| **METRONIDAZOLE** | | | | | | | |
| **AB** | | FOUGERA PHARMS | **0.75%** | **A077018** | **001** | Jun 06, 2006 |
| **AB** | | G AND W LABS INC | **0.75%** | **A078178** | **001** | Jan 19, 2011 |
| **AB** | | TARO | **0.75%** | **A077819** | **001** | Jul 18, 2006 |
| **AB** | | TARO PHARM | **1%** | **A204651** | **001** | Mar 14, 2017 |
| **AB** | | TOLMAR | **0.75%** | **A077547** | **001** | Jul 13, 2006 |
| **AB** | | | **1%** | **A090903** | **001** | Jul 22, 2011 |
| GEL;VAGINAL | | | | | | | |
| **METROGEL-VAGINAL** | | | | | | | |
| **AB** | +! | MEDICIS | **0.75%** | **N020208** | **001** | Aug 17, 1992 |
| **METRONIDAZOLE** | | | | | | | |
| **AB** | | TOLMAR | **0.75%** | **A077264** | **001** | Oct 31, 2006 |

| | | | | | | |
|---|---|---|---|---|---|---|
| METRONIDAZOLE | | | | | | |
| GEL;VAGINAL | | | | | | |
| VANDAZOLE | | | | | | |
| BX | | TEVA PHARMS | 0.75% | N021806 | 001 | May 20, 2005 |
| NUVESSA | | | | | | |
| | +! | CHEMO RESEARCH SL | 1.3% | N205223 | 001 | Mar 24, 2014 |
| INJECTABLE;INJECTION | | | | | | |
| **FLAGYL I.V. RTU IN PLASTIC CONTAINER** | | | | | | |
| **AP** | **+!** | BAXTER HLTHCARE | **500MG/100ML** | **N018657** | **001** | |
| **METRO I.V. IN PLASTIC CONTAINER** | | | | | | |
| **AP** | **+!** | B BRAUN | **500MG/100ML** | **N018900** | **001** | Sep 29, 1983 |
| **METRONIDAZOLE IN PLASTIC CONTAINER** | | | | | | |
| **AP** | | BAXTER HLTHCARE CORP | **500MG/100ML** | **A078084** | **001** | Mar 31, 2008 |
| **AP** | **+!** | HOSPIRA | **500MG/100ML** | **N018890** | **002** | Nov 18, 1983 |
| **AP** | | MYLAN LABS LTD | **500MG/100ML** | **A205531** | **001** | May 09, 2017 |
| LOTION;TOPICAL | | | | | | |
| **METROLOTION** | | | | | | |
| **AB** | **+!** | GALDERMA LABS LP | **0.75%** | **N020901** | **001** | Nov 24, 1998 |
| **METRONIDAZOLE** | | | | | | |
| **AB** | | FOUGERA PHARMS | **0.75%** | **A077197** | **001** | May 24, 2006 |
| TABLET;ORAL | | | | | | |
| **FLAGYL** | | | | | | |
| **AB** | **+** | GD SEARLE LLC | **250MG** | **N012623** | **001** | |
| **AB** | **+!** | | **500MG** | **N012623** | **003** | |
| **METRONIDAZOLE** | | | | | | |
| **AB** | | ALEMBIC PHARMS LTD | **250MG** | **A079067** | **001** | Mar 13, 2009 |
| **AB** | | | **500MG** | **A079067** | **002** | Mar 13, 2009 |
| **AB** | | APPCO PHARMA LLC | **250MG** | **A205245** | **001** | Sep 23, 2015 |
| **AB** | | | **500MG** | **A205245** | **002** | Sep 23, 2015 |
| **AB** | | AUROBINDO PHARMA LTD | **250MG** | **A203974** | **001** | May 29, 2015 |
| **AB** | | | **500MG** | **A203974** | **002** | May 29, 2015 |
| **AB** | | CADILA PHARMS LTD | **250MG** | **A209794** | **001** | Dec 12, 2017 |
| **AB** | | | **500MG** | **A209794** | **002** | Dec 12, 2017 |
| **AB** | | FLAMINGO PHARMS | **250MG** | **A207309** | **001** | May 16, 2016 |
| **AB** | | | **500MG** | **A207309** | **002** | May 16, 2016 |
| **AB** | | INNOGENIX | **250MG** | **A070772** | **001** | Jul 16, 1986 |
| **AB** | | | **500MG** | **A070772** | **002** | Jul 16, 1986 |
| **AB** | | LUPIN LTD | **250MG** | **A209096** | **001** | Sep 12, 2017 |
| **AB** | | | **500MG** | **A209096** | **002** | Sep 12, 2017 |
| **AB** | | ORIT LABS LLC | **250MG** | **A208681** | **001** | Jun 20, 2017 |
| **AB** | | | **500MG** | **A208681** | **002** | Jun 20, 2017 |
| **AB** | | PLIVA | **500MG** | **A070033** | **001** | Dec 06, 1984 |
| **AB** | | STRIDES PHARMA | **250MG** | **A208162** | **001** | May 25, 2016 |
| **AB** | | | **500MG** | **A208162** | **002** | May 25, 2016 |
| **AB** | | TEVA PHARMS USA | **250MG** | **A070027** | **001** | Nov 06, 1984 |
| **AB** | | UNICHEM LABS LTD | **250MG** | **A203458** | **001** | Jan 22, 2014 |
| **AB** | | | **500MG** | **A203458** | **002** | Jan 22, 2014 |
| **AB** | | VIVIMED GLOBAL | **250MG** | **A070040** | **001** | Jan 29, 1985 |
| **AB** | | | **500MG** | **A070039** | **001** | Jan 29, 1985 |
| **AB** | | WATSON LABS | **250MG** | **A070035** | **001** | Dec 20, 1984 |
| **AB** | | WATSON LABS INC | **500MG** | **A070044** | **001** | Feb 08, 1985 |
| **AB** | | ZYDUS PHARMS USA INC | **250MG** | **A206560** | **001** | Nov 16, 2016 |
| **AB** | | | **500MG** | **A206560** | **002** | Nov 16, 2016 |
| TABLET, EXTENDED RELEASE;ORAL | | | | | | |
| **FLAGYL ER** | | | | | | |
| **AB** | **+!** | GD SEARLE LLC | **750MG** | **N020868** | **001** | Nov 26, 1997 |
| **METRONIDAZOLE** | | | | | | |
| **AB** | | ALEMBIC PHARMS LTD | **750MG** | **A090222** | **001** | May 05, 2010 |
| METYRAPONE | | | | | | |
| CAPSULE;ORAL | | | | | | |
| METOPIRONE | | | | | | |
| | +! | HRA PHARMA | 250MG | N012911 | 002 | Aug 09, 1996 |
| METYROSINE | | | | | | |
| CAPSULE;ORAL | | | | | | |
| DEMSER | | | | | | |
| | +! | ATON PHARMA VPNA | 250MG | N017871 | 001 | |

| | | | | | | |
|---|---|---|---|---|---|---|
| MEXILETINE HYDROCHLORIDE | | | | | | |
| CAPSULE;ORAL | | | | | | |
| MEXILETINE HYDROCHLORIDE | | | | | | |
| | TEVA | 150MG | | A074377 | 001 | May 16, 1995 |
| | | 200MG | | A074377 | 002 | May 16, 1995 |
| | ! | 250MG | | A074377 | 003 | May 16, 1995 |
| MICAFUNGIN SODIUM | | | | | | |
| INJECTABLE;IV (INFUSION) | | | | | | |
| MYCAMINE | | | | | | |
| +! | ASTELLAS | EQ 50MG BASE/VIAL | | N021506 | 002 | Mar 16, 2005 |
| +! | | EQ 100MG BASE/VIAL | | N021506 | 003 | Jun 27, 2006 |
| MICONAZOLE | | | | | | |
| TABLET;BUCCAL | | | | | | |
| ORAVIG | | | | | | |
| +! | MIDATECH PHARMA US | 50MG | | N022404 | 001 | Apr 16, 2010 |
| MICONAZOLE NITRATE | | | | | | |
| SUPPOSITORY;VAGINAL | | | | | | |
| **MICONAZOLE NITRATE** | | | | | | |
| **AB** | ACTAVIS PHARMA | **200MG** | | **A073508** | **001** | Nov 19, 1993 |
| **MONISTAT 3** | | | | | | |
| **AB** **+!** | MEDTECH PRODUCTS | **200MG** | | **N018888** | **001** | Aug 15, 1984 |
| MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE | | | | | | |
| OINTMENT;TOPICAL | | | | | | |
| VUSION | | | | | | |
| +! | MYLAN PHARMS INC | 0.25%;81.35%;15% | | N021026 | 001 | Feb 16, 2006 |
| MIDAZOLAM HYDROCHLORIDE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| **MIDAZOLAM HYDROCHLORIDE** | | | | | | |
| **AP** | AKORN INC | **EQ 1MG BASE/ML** | | **A075494** | **001** | Jun 30, 2000 |
| **AP** | | **EQ 5MG BASE/ML** | | **A075481** | **001** | Jun 30, 2000 |
| **AP** | | **EQ 5MG BASE/ML** | | **A075494** | **002** | Jun 30, 2000 |
| **AP** | FRESENIUS KABI USA | **EQ 1MG BASE/ML** | | **A075154** | **002** | Jun 20, 2000 |
| **AP** | | **EQ 5MG BASE/ML** | | **A075154** | **001** | Jun 20, 2000 |
| **AP** | GLAND PHARMA LTD | **EQ 1MG BASE/ML** | | **A090696** | **001** | Feb 29, 2012 |
| **AP** | | **EQ 5MG BASE/ML** | | **A090850** | **001** | Jan 25, 2012 |
| **AP** **!** | HOSPIRA | **EQ 1MG BASE/ML** | | **A075293** | **001** | Jun 20, 2000 |
| **AP** | | **EQ 1MG BASE/ML** | | **A075856** | **001** | Jun 13, 2002 |
| **AP** **!** | | **EQ 5MG BASE/ML** | | **A075293** | **002** | Jun 20, 2000 |
| **AP** | | **EQ 5MG BASE/ML** | | **A075856** | **002** | Jun 13, 2002 |
| **AP** | WEST-WARD PHARMS INT | **EQ 1MG BASE/ML** | | **A075243** | **001** | Jun 20, 2000 |
| **AP** | | **EQ 1MG BASE/ML** | | **A075247** | **002** | Jun 23, 2000 |
| **AP** | | **EQ 1MG BASE/ML** | | **A075324** | **001** | Jun 20, 2000 |
| **AP** | | **EQ 1MG BASE/ML** | | **A075421** | **002** | Jun 20, 2000 |
| **AP** | | **EQ 5MG BASE/ML** | | **A075243** | **002** | Jun 20, 2000 |
| **AP** | | **EQ 5MG BASE/ML** | | **A075247** | **001** | Jun 23, 2000 |
| **AP** | | **EQ 5MG BASE/ML** | | **A075324** | **002** | Jun 20, 2000 |
| **AP** | | **EQ 5MG BASE/ML** | | **A075421** | **001** | Jun 20, 2000 |
| **MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE** | | | | | | |
| **AP** | FRESENIUS KABI USA | **EQ 1MG BASE/ML** | | **A203460** | **001** | Aug 22, 2014 |
| **AP** | | **EQ 5MG BASE/ML** | | **A203460** | **002** | Aug 22, 2014 |
| **AP** **!** | HOSPIRA | **EQ 1MG BASE/ML** | | **A075857** | **001** | Jul 22, 2002 |
| **AP** **!** | | **EQ 5MG BASE/ML** | | **A075857** | **002** | Jul 22, 2002 |
| **AP** | SAGENT AGILA LLC | **EQ 1MG BASE/ML** | | **A090315** | **001** | Nov 29, 2010 |
| **AP** | | **EQ 5MG BASE/ML** | | **A090315** | **002** | Nov 29, 2010 |
| **MIDOZALAM HYDROCHLORIDE** | | | | | | |
| **AP** | SAGENT STRIDES | **EQ 1MG BASE/ML** | | **A090316** | **001** | May 04, 2011 |
| **AP** | | **EQ 5MG BASE/ML** | | **A090316** | **002** | May 04, 2011 |
| MIDAZOLAM HYDROCHLORIDE | | | | | | |
| | FRESENIUS KABI USA | EQ 5MG BASE/ML | | A208878 | 001 | Mar 28, 2017 |
| SYRUP;ORAL | | | | | | |
| **MIDAZOLAM HYDROCHLORIDE** | | | | | | |
| **AA** | HI TECH PHARMA | **EQ 2MG BASE/ML** | | **A075958** | **001** | Sep 04, 2003 |
| **AA** | PADDOCK LLC | **EQ 2MG BASE/ML** | | **A076379** | **001** | May 02, 2005 |
| **AA** **!** | WEST-WARD PHARMS INT | **EQ 2MG BASE/ML** | | **A075873** | **001** | Apr 30, 2002 |

MIDODRINE HYDROCHLORIDE

TABLET;ORAL

**MIDODRINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | IMPAX PHARMS | **2.5MG** | **A076449** | **001** | May 27, 2004 |
| **AB** | | | **5MG** | **A076449** | **002** | May 27, 2004 |
| **AB** | | | **10MG** | **A076449** | **003** | Dec 16, 2005 |
| **AB** | | MYLAN PHARMS INC | **2.5MG** | **A076577** | **001** | Sep 10, 2003 |
| **AB** | **!** | | **5MG** | **A076577** | **002** | Sep 10, 2003 |
| **AB** | | | **10MG** | **A076577** | **003** | Sep 10, 2003 |
| **AB** | | SANDOZ | **2.5MG** | **A076514** | **001** | Sep 11, 2003 |
| **AB** | | | **5MG** | **A076514** | **002** | Sep 11, 2003 |
| **AB** | | | **10MG** | **A076514** | **003** | Jul 02, 2004 |

**ORVATEN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | UPSHER-SMITH LABS | **2.5MG** | **A076725** | **001** | Nov 03, 2004 |
| **AB** | | | **5MG** | **A076725** | **002** | Nov 03, 2004 |
| **AB** | | | **10MG** | **A076725** | **003** | Nov 03, 2004 |

MIDODRINE HYDROCHLORIDE

| | | | | | | |
|---|---|---|---|---|---|---|
| BX | | APOTEX INC | 2.5MG | A077746 | 001 | Sep 12, 2006 |
| BX | | | 5MG | A077746 | 002 | Sep 12, 2006 |
| BX | | | 10MG | A077746 | 003 | Sep 12, 2006 |

MIDOSTAURIN

CAPSULE;ORAL

RYDAPT

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | NOVARTIS PHARMS CORP | 25MG | N207997 | 001 | Apr 28, 2017 |

MIFEPRISTONE

TABLET;ORAL

KORLYM

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | CORCEPT THERAP | 300MG | N202107 | 001 | Feb 17, 2012 |

MIFEPREX

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | DANCO LABS LLC | 200MG | N020687 | 001 | Sep 28, 2000 |

MIGLITOL

TABLET;ORAL

**GLYSET**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | PHARMACIA AND UPJOHN | **25MG** | **N020682** | **001** | Dec 18, 1996 |
| **AB** | **+** | | **50MG** | **N020682** | **002** | Dec 18, 1996 |
| **AB** | **+** | | **100MG** | **N020682** | **003** | Dec 18, 1996 |

**MIGLITOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ORIENT PHARMA CO LTD | **25MG** | **A203965** | **001** | Feb 24, 2015 |
| **AB** | | | **50MG** | **A203965** | **002** | Feb 24, 2015 |
| **AB** | | | **100MG** | **A203965** | **003** | Feb 24, 2015 |

MIGLUSTAT

CAPSULE;ORAL

ZAVESCA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ACTELION PHARMS LTD | 100MG | N021348 | 001 | Jul 31, 2003 |

MILNACIPRAN HYDROCHLORIDE

TABLET;ORAL

**MILNACIPRAN HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AMNEAL PHARMS | **12.5MG** | **A205081** | **001** | Apr 22, 2016 |
| **AB** | | | **25MG** | **A205081** | **002** | Apr 22, 2016 |
| **AB** | | | **50MG** | **A205081** | **003** | Apr 22, 2016 |
| **AB** | | | **100MG** | **A205081** | **004** | Apr 22, 2016 |

**SAVELLA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | ALLERGAN SALES LLC | **12.5MG** | **N022256** | **001** | Jan 14, 2009 |
| **AB** | **+** | | **25MG** | **N022256** | **002** | Jan 14, 2009 |
| **AB** | **+!** | | **50MG** | **N022256** | **003** | Jan 14, 2009 |
| **AB** | **+** | | **100MG** | **N022256** | **004** | Jan 14, 2009 |

MILRINONE LACTATE

INJECTABLE;INJECTION

**MILRINONE LACTATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | FRESENIUS KABI USA | **EQ 1MG BASE/ML** | **A075936** | **001** | May 28, 2002 |
| **AP** | | GLAND PHARMA LTD | **EQ 1MG BASE/ML** | **A077190** | **001** | Oct 31, 2006 |
| **AP** | **!** | HIKMA FARMACEUTICA | **EQ 1MG BASE/ML** | **A077966** | **001** | Dec 03, 2010 |
| **AP** | | HOSPIRA INC | **EQ 1MG BASE/ML** | **A203280** | **001** | Sep 03, 2014 |
| **AP** | | INTL MEDICATED | **EQ 1MG BASE/ML** | **A076013** | **001** | Aug 02, 2002 |
| **AP** | | WEST-WARD PHARMS INT | **EQ 1MG BASE/ML** | **A075530** | **001** | May 28, 2002 |
| **AP** | | | **EQ 1MG BASE/ML** | **A075660** | **001** | May 28, 2002 |

MILRINONE LACTATE

INJECTABLE;INJECTION

**MILRINONE LACTATE IN DEXTROSE 5%**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | RENAISSANCE SSA LLC | **EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)** | **A077151** | **002** | Jul 20, 2005 |

**MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **!** | BAXTER HLTHCARE | **EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)** | **A075834** | **001** | May 28, 2002 |
| **AP** | **!** | | **EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)** | **A075834** | **002** | May 28, 2002 |
| **AP** | | HOSPIRA | **EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)** | **A075885** | **001** | May 28, 2002 |
| **AP** | | | **EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)** | **A075885** | **002** | May 28, 2002 |
| **AP** | | WEST-WARD PHARMS INT | **EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)** | **A078113** | **001** | May 21, 2008 |
| **AP** | | | **EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)** | **A078113** | **002** | May 21, 2008 |

**MILRINONE LACTATE IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | HIKMA FARMACEUTICA | **EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)** | **A090038** | **001** | Jan 21, 2010 |
| **AP** | | | **EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)** | **A090038** | **002** | Jan 21, 2010 |

MILTEFOSINE

CAPSULE;ORAL

IMPAVIDO

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | KNIGHT THERAPS | 50MG | N204684 | 001 | Mar 19, 2014 |

MINOCYCLINE HYDROCHLORIDE

CAPSULE;ORAL

**DYNACIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | CNTY LINE PHARMS | **EQ 50MG BASE** | **A063067** | **003** | Aug 14, 1990 |
| **AB** | | | **EQ 75MG BASE** | **A063067** | **002** | Sep 15, 1999 |
| **AB** | | | **EQ 100MG BASE** | **A063067** | **001** | Jul 31, 1990 |

**MINOCIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | PRECISION DERMAT | **EQ 50MG BASE** | **N050649** | **001** | May 31, 1990 |
| **AB** | **+** | | **EQ 100MG BASE** | **N050649** | **002** | May 31, 1990 |

**MINOCYCLINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AUROBINDO PHARMA | **EQ 50MG BASE** | **A065470** | **001** | Mar 11, 2008 |
| **AB** | | | **EQ 75MG BASE** | **A065470** | **002** | Mar 11, 2008 |
| **AB** | | | **EQ 100MG BASE** | **A065470** | **003** | Mar 11, 2008 |
| **AB** | | IMPAX LABS | **EQ 50MG BASE** | **A065005** | **001** | Mar 23, 1999 |
| **AB** | | | **EQ 75MG BASE** | **A065005** | **003** | Apr 18, 2001 |
| **AB** | | | **EQ 100MG BASE** | **A065005** | **002** | Mar 23, 1999 |
| **AB** | | SUN PHARM INDS INC | **EQ 50MG BASE** | **A090867** | **001** | May 13, 2013 |
| **AB** | | | **EQ 75MG BASE** | **A090867** | **002** | May 13, 2013 |
| **AB** | | | **EQ 100MG BASE** | **A090867** | **003** | May 13, 2013 |
| **AB** | | TORRENT PHARMA INC | **EQ 50MG BASE** | **A065062** | **001** | Nov 30, 2000 |
| **AB** | | | **EQ 75MG BASE** | **A065062** | **002** | Nov 30, 2000 |
| **AB** | | | **EQ 100MG BASE** | **A065062** | **003** | Nov 30, 2000 |
| **AB** | | WATSON LABS | **EQ 75MG BASE** | **A063065** | **002** | Jun 10, 1999 |
| **AB** | | | **EQ 100MG BASE** | **A063065** | **001** | Dec 30, 1991 |
| **AB** | | WATSON LABS TEVA | **EQ 50MG BASE** | **A063181** | **001** | Dec 30, 1991 |
| **AB** | | ZYDUS WORLDWIDE | **EQ 50MG BASE** | **A063011** | **001** | Mar 02, 1992 |
| **AB** | | | **EQ 75MG BASE** | **A063009** | **002** | Aug 12, 2003 |
| **AB** | **!** | | **EQ 100MG BASE** | **A063009** | **001** | Mar 02, 1992 |

CAPSULE, EXTENDED RELEASE;ORAL

XIMINO

| | | | | | | |
|---|---|---|---|---|---|---|
| | | SUN PHARM INDS LTD | EQ 45MG BASE | N201922 | 001 | Jul 11, 2012 |
| | | | EQ 90MG BASE | N201922 | 003 | Jul 11, 2012 |
| | | | EQ 135MG BASE | N201922 | 005 | Jul 11, 2012 |

INJECTABLE;INJECTION

MINOCIN

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | REMPEX PHARMS INC | EQ 100MG BASE/VIAL | N050444 | 001 | |

POWDER, EXTENDED RELEASE;DENTAL

ARESTIN

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ORAPHARMA | EQ 1MG BASE | N050781 | 001 | Feb 16, 2001 |

TABLET;ORAL

**MINOCYCLINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | DR REDDYS LABS LTD | **EQ 50MG BASE** | **A065436** | **001** | Dec 26, 2007 |
| **AB** | | | **EQ 75MG BASE** | **A065436** | **002** | Dec 26, 2007 |
| **AB** | | | **EQ 100MG BASE** | **A065436** | **003** | Dec 26, 2007 |
| **AB** | | PAR PHARM | **EQ 50MG BASE** | **A065131** | **001** | Apr 16, 2003 |
| **AB** | | | **EQ 75MG BASE** | **A065131** | **002** | Apr 16, 2003 |
| **AB** | **!** | | **EQ 100MG BASE** | **A065131** | **003** | Apr 16, 2003 |
| **AB** | | SUN PHARM INDUSTRIES | **EQ 50MG BASE** | **A090217** | **001** | Jan 29, 2016 |
| **AB** | | | **EQ 75MG BASE** | **A090217** | **002** | Jan 29, 2016 |
| **AB** | | | **EQ 100MG BASE** | **A090217** | **003** | Jan 29, 2016 |
| **AB** | | TORRENT PHARMA INC | **EQ 50MG BASE** | **A065156** | **001** | Jan 06, 2004 |
| **AB** | | | **EQ 75MG BASE** | **A065156** | **002** | Jan 06, 2004 |

MINOCYCLINE HYDROCHLORIDE

TABLET;ORAL

**MINOCYCLINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **EQ 100MG BASE** | **A065156** | **003** | Jan 06, 2004 |

TABLET, EXTENDED RELEASE;ORAL

**MINOCYCLINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALKEM LABS LTD | **EQ 45MG BASE** | **A204453** | **001** | Sep 28, 2016 |
| **AB** | | | **EQ 80MG BASE** | **A204453** | **002** | Sep 28, 2016 |
| **AB** | | | **EQ 90MG BASE** | **A204453** | **003** | Sep 28, 2016 |
| **AB** | | | **EQ 105MG BASE** | **A204453** | **004** | Sep 28, 2016 |
| **AB** | | | **EQ 135MG BASE** | **A204453** | **005** | Sep 28, 2016 |
| **AB** | | AUROBINDO PHARMA LTD | **EQ 45MG BASE** | **A202261** | **001** | Nov 19, 2012 |
| **AB** | | | **EQ 80MG BASE** | **A202261** | **006** | Jun 13, 2016 |
| **AB** | | | **EQ 90MG BASE** | **A202261** | **003** | Nov 19, 2012 |
| **AB** | | | **EQ 105MG BASE** | **A202261** | **007** | Jun 13, 2016 |
| **AB** | | | **EQ 135MG BASE** | **A202261** | **005** | Nov 19, 2012 |
| **AB** | | LUPIN LTD | **EQ 45MG BASE** | **A091424** | **001** | Nov 30, 2011 |
| **AB** | | | **EQ 90MG BASE** | **A091424** | **003** | Nov 30, 2011 |
| **AB** | | | **EQ 135MG BASE** | **A091424** | **004** | Nov 30, 2011 |
| **AB** | | SANDOZ | **EQ 45MG BASE** | **A090422** | **001** | Aug 13, 2009 |
| **AB** | | | **EQ 90MG BASE** | **A090422** | **002** | Aug 13, 2009 |
| **AB** | **!** | | **EQ 135MG BASE** | **A090422** | **003** | Aug 13, 2009 |
| **AB** | | SIDMAK LABS INDIA | **EQ 45MG BASE** | **A204394** | **001** | Dec 30, 2015 |
| **AB** | | | **EQ 80MG BASE** | **A204394** | **004** | Dec 30, 2015 |
| **AB** | | | **EQ 105MG BASE** | **A204394** | **005** | Dec 30, 2015 |
| **AB** | | | **EQ 135MG BASE** | **A204394** | **007** | Dec 30, 2015 |
| **AB** | | SUN PHARM INDS LTD | **EQ 45MG BASE** | **A091118** | **001** | Sep 25, 2014 |
| **AB** | | | **EQ 80MG BASE** | **A091118** | **004** | Sep 25, 2014 |
| **AB** | | | **EQ 90MG BASE** | **A091118** | **005** | Sep 25, 2014 |
| **AB** | | | **EQ 105MG BASE** | **A091118** | **006** | Sep 25, 2014 |
| **AB** | | | **EQ 135MG BASE** | **A091118** | **008** | Sep 25, 2014 |
| **AB** | | ZYDUS PHARMS USA INC | **EQ 45MG BASE** | **A203553** | **001** | Nov 16, 2017 |
| **AB** | | | **EQ 80MG BASE** | **A203553** | **004** | Nov 16, 2017 |
| **AB** | | | **EQ 90MG BASE** | **A203553** | **005** | Nov 16, 2017 |
| **AB** | | | **EQ 105MG BASE** | **A203553** | **006** | Nov 16, 2017 |
| **AB** | | | **EQ 135MG BASE** | **A203553** | **008** | Nov 16, 2017 |

**SOLODYN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | MEDICIS | **EQ 80MG BASE** | **N050808** | **007** | Aug 27, 2010 |
| **AB** | **+** | | **EQ 105MG BASE** | **N050808** | **006** | Aug 27, 2010 |

MINOLIRA

| | | | | | | |
|---|---|---|---|---|---|---|
| | | DR REDDYS LABS LTD | EQ 105MG BASE | N209269 | 001 | May 08, 2017 |
| | | | EQ 135MG BASE | N209269 | 002 | May 08, 2017 |

SOLODYN

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | MEDICIS | EQ 55MG BASE | N050808 | 008 | Aug 27, 2010 |
| | + | | EQ 65MG BASE | N050808 | 004 | Jul 23, 2009 |
| | +! | | EQ 115MG BASE | N050808 | 005 | Jul 23, 2009 |

MINOXIDIL

TABLET;ORAL

**MINOXIDIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | MUTUAL PHARM | **2.5MG** | **A072708** | **001** | Dec 14, 1995 |
| **AB** | | PAR PHARM | **2.5MG** | **A071826** | **001** | Nov 14, 1988 |
| **AB** | | | **10MG** | **A071839** | **001** | Nov 14, 1988 |
| **AB** | | SUN PHARM INDUSTRIES | **10MG** | **A072709** | **001** | Dec 14, 1995 |
| **AB** | | WATSON LABS | **2.5MG** | **A071344** | **001** | Mar 03, 1987 |
| **AB** | **!** | | **10MG** | **A071345** | **001** | Mar 03, 1987 |

MIPOMERSEN SODIUM

SOLUTION;SUBCUTANEOUS

KYNAMRO

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | KASTLE THERAPS LLC | 200MG/ML (200MG/ML) | N203568 | 001 | Jan 29, 2013 |

MIRABEGRON

TABLET, EXTENDED RELEASE;ORAL

MYRBETRIQ

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | APGDI | 25MG | N202611 | 001 | Jun 28, 2012 |
| | +! | | 50MG | N202611 | 002 | Jun 28, 2012 |

MIRTAZAPINE

TABLET;ORAL

**MIRTAZAPINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | APOTEX INC | **15MG** | **A077666** | **001** | Aug 22, 2007 |
| **AB** | | | **30MG** | **A077666** | **002** | Aug 22, 2007 |
| **AB** | | | **45MG** | **A077666** | **003** | Aug 22, 2007 |
| **AB** | | AUROBINDO | **7.5MG** | **A076921** | **001** | Oct 22, 2004 |
| **AB** | | | **15MG** | **A076921** | **002** | Oct 22, 2004 |
| **AB** | | | **30MG** | **A076921** | **003** | Oct 22, 2004 |
| **AB** | | | **45MG** | **A076921** | **004** | Oct 22, 2004 |
| **AB** | | MYLAN | **15MG** | **A076122** | **001** | Jun 19, 2003 |
| **AB** | | | **30MG** | **A076122** | **002** | Jun 19, 2003 |
| **AB** | | | **45MG** | **A076122** | **003** | Jun 19, 2003 |
| **AB** | | SUN PHARM INDS INC | **7.5MG** | **A076541** | **004** | Apr 22, 2004 |
| **AB** | | | **15MG** | **A076541** | **001** | Apr 22, 2004 |
| **AB** | | | **30MG** | **A076541** | **002** | Apr 22, 2004 |
| **AB** | | | **45MG** | **A076541** | **003** | Apr 22, 2004 |
| **AB** | | TEVA | **15MG** | **A076119** | **001** | Jan 24, 2003 |
| **AB** | | | **30MG** | **A076119** | **002** | Jan 24, 2003 |
| **AB** | | | **45MG** | **A076119** | **003** | Jun 19, 2003 |
| **AB** | | UPSHER-SMITH LABS | **15MG** | **A076219** | **001** | Jun 19, 2003 |
| **AB** | | | **30MG** | **A076219** | **002** | Jun 19, 2003 |
| **AB** | | | **45MG** | **A076219** | **003** | Jun 19, 2003 |
| **AB** | | WATSON LABS | **15MG** | **A076312** | **001** | Jun 19, 2003 |
| **AB** | | | **30MG** | **A076312** | **002** | Jun 19, 2003 |
| **AB** | | | **45MG** | **A076312** | **003** | Jun 19, 2003 |

**REMERON**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | ORGANON USA INC | **15MG** | **N020415** | **001** | Jun 14, 1996 |
| **AB** | **+** | | **30MG** | **N020415** | **002** | Jun 14, 1996 |
| **AB** | **+** | | **45MG** | **N020415** | **003** | Mar 17, 1997 |

TABLET, ORALLY DISINTEGRATING;ORAL

**MIRTAZAPINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS LABS FL INC | **15MG** | **A076307** | **001** | Dec 17, 2003 |
| **AB** | | | **30MG** | **A076307** | **002** | Dec 17, 2003 |
| **AB** | | | **45MG** | **A076307** | **003** | Feb 28, 2006 |
| **AB** | | AUROBINDO PHARMA LTD | **15MG** | **A077376** | **002** | Dec 08, 2005 |
| **AB** | | | **30MG** | **A077376** | **003** | Dec 08, 2005 |
| **AB** | | | **45MG** | **A077376** | **004** | Feb 28, 2006 |
| **AB** | | IMPAX LABS INC | **15MG** | **A076901** | **001** | Jun 28, 2005 |
| **AB** | | | **30MG** | **A076901** | **002** | Jun 28, 2005 |
| **AB** | | | **45MG** | **A076901** | **003** | Jun 28, 2005 |
| **AB** | | ZYDUS PHARMS USA INC | **15MG** | **A205798** | **001** | Jun 01, 2017 |
| **AB** | | | **30MG** | **A205798** | **002** | Jun 01, 2017 |
| **AB** | | | **45MG** | **A205798** | **003** | Jun 01, 2017 |

**REMERON SOLTAB**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | ORGANON USA INC | **15MG** | **N021208** | **001** | Jan 12, 2001 |
| **AB** | **+** | | **30MG** | **N021208** | **002** | Jan 12, 2001 |
| **AB** | **+** | | **45MG** | **N021208** | **003** | Jan 12, 2001 |

MISOPROSTOL

TABLET;ORAL

**CYTOTEC**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | GD SEARLE LLC | **0.1MG** | **N019268** | **003** | Sep 21, 1990 |
| **AB** | **+!** | | **0.2MG** | **N019268** | **001** | Dec 27, 1988 |

**MISOPROSTOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | IVAX SUB TEVA PHARMS | **0.1MG** | **A076095** | **001** | Jul 10, 2002 |
| **AB** | | | **0.2MG** | **A076095** | **002** | Jul 10, 2002 |
| **AB** | | NOVEL LABS INC | **0.1MG** | **A091667** | **001** | Jul 25, 2012 |
| **AB** | | | **0.2MG** | **A091667** | **002** | Jul 25, 2012 |

MITOMYCIN

FOR SOLUTION;TOPICAL

MITOSOL

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | MOBIUS THERAP | 0.2MG/VIAL | N022572 | 001 | Feb 07, 2012 |

INJECTABLE;INJECTION

**MITOMYCIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **!** | ACCORD HLTHCARE | **5MG/VIAL** | **A064144** | **001** | Apr 30, 1998 |
| **AP** | **!** | | **20MG/VIAL** | **A064144** | **002** | Apr 30, 1998 |
| **AP** | **!** | | **40MG/VIAL** | **A064144** | **003** | Aug 11, 2009 |
| **AP** | | MYLAN LABS LTD | **5MG/VIAL** | **A202670** | **001** | Oct 13, 2017 |
| **AP** | | | **20MG/VIAL** | **A202670** | **002** | Oct 13, 2017 |

MITOMYCIN

INJECTABLE;INJECTION

**MITOMYCIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | | **40MG/VIAL** | **A203386** | **001** | Oct 13, 2017 |
| **AP** | | WEST-WARD PHARMS INT | **5MG/VIAL** | **A064117** | **001** | Apr 19, 1995 |
| **AP** | | | **5MG/VIAL** | **A064180** | **001** | Dec 23, 1999 |
| **AP** | | | **20MG/VIAL** | **A064117** | **002** | Apr 19, 1995 |
| **AP** | | | **20MG/VIAL** | **A064180** | **002** | Dec 23, 1999 |

MITOTANE

TABLET;ORAL

LYSODREN

| | | | | | |
|---|---|---|---|---|---|
| +! | | BRISTOL MYERS SQUIBB | 500MG | N016885 | 001 |

MITOXANTRONE HYDROCHLORIDE

INJECTABLE;INJECTION

**MITOXANTRONE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | FRESENIUS KABI USA | **EQ 20MG BASE/10ML (EQ 2MG BASE/ML)** | **A077496** | **001** | Apr 11, 2006 |
| **AP** | | | **EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)** | **A077496** | **002** | Apr 11, 2006 |
| **AP** | | | **EQ 30MG BASE/15ML (EQ 2MG BASE/ML)** | **A077496** | **003** | Apr 11, 2006 |
| **AP** | **!** | HOSPIRA | **EQ 20MG BASE/10ML (EQ 2MG BASE/ML)** | **A076871** | **001** | Apr 11, 2006 |
| **AP** | **!** | | **EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)** | **A076871** | **002** | Apr 11, 2006 |
| **AP** | **!** | | **EQ 30MG BASE/15ML (EQ 2MG BASE/ML)** | **A076871** | **003** | Apr 11, 2006 |
| **AP** | | MYLAN INSTITUTIONAL | **EQ 20MG BASE/10ML (EQ 2MG BASE/ML)** | **A078980** | **001** | Apr 13, 2009 |
| **AP** | | | **EQ 30MG BASE/15ML (EQ 2MG BASE/ML)** | **A078980** | **002** | Apr 13, 2009 |
| **AP** | | MYLAN LABS LTD | **EQ 20MG BASE/10ML (EQ 2MG BASE/ML)** | **A201014** | **001** | Dec 11, 2012 |
| **AP** | | TEVA PHARMS USA | **EQ 20MG BASE/10ML (EQ 2MG BASE/ML)** | **A077356** | **001** | Apr 11, 2006 |
| **AP** | | | **EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)** | **A077356** | **002** | Apr 11, 2006 |
| **AP** | | | **EQ 30MG BASE/15ML (EQ 2MG BASE/ML)** | **A077356** | **003** | Apr 11, 2006 |
| **AP** | | WEST-WARD PHARMS INT | **EQ 20MG BASE/10ML (EQ 2MG BASE/ML)** | **A076611** | **001** | Apr 11, 2006 |
| **AP** | | | **EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)** | **A076611** | **002** | Apr 11, 2006 |
| **AP** | | | **EQ 30MG BASE/15ML (EQ 2MG BASE/ML)** | **A076611** | **003** | Apr 11, 2006 |

MIVACURIUM CHLORIDE

SOLUTION;INTRAVENOUS

MIVACRON

| | | | | | | |
|---|---|---|---|---|---|---|
| + | | ABBVIE | EQ 10MG BASE/5ML (EQ 2MG BASE/ML) | N020098 | 004 | Jan 22, 1992 |
| +! | | | EQ 20MG BASE/10ML (EQ 2MG BASE/ML) | N020098 | 005 | Jan 22, 1992 |

MODAFINIL

TABLET;ORAL

**MODAFINIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALEMBIC PHARMS LTD | **100MG** | **A202700** | **001** | Oct 18, 2012 |
| **AB** | | | **200MG** | **A202700** | **002** | Oct 18, 2012 |
| **AB** | | APOTEX INC | **100MG** | **A077667** | **001** | Feb 03, 2014 |
| **AB** | | | **200MG** | **A077667** | **002** | Feb 03, 2014 |
| **AB** | | APPCO PHARMA LLC | **100MG** | **A207196** | **001** | Aug 16, 2017 |
| **AB** | | | **200MG** | **A207196** | **002** | Aug 16, 2017 |
| **AB** | | AUROBINDO PHARMA LTD | **100MG** | **A202566** | **001** | Sep 27, 2012 |
| **AB** | | | **200MG** | **A202566** | **002** | Sep 27, 2012 |
| **AB** | | HIKMA PHARMS | **100MG** | **A090543** | **001** | Sep 26, 2012 |
| **AB** | | | **200MG** | **A090543** | **002** | Sep 26, 2012 |
| **AB** | | MYLAN PHARMS INC | **100MG** | **A076594** | **001** | Jul 16, 2012 |
| **AB** | | | **200MG** | **A076594** | **002** | Jul 16, 2012 |
| **AB** | | ORCHID HLTHCARE | **100MG** | **A078963** | **001** | Sep 26, 2012 |
| **AB** | | | **200MG** | **A078963** | **002** | Sep 26, 2012 |
| **AB** | | WATSON LABS INC | **100MG** | **A076715** | **001** | Nov 01, 2012 |
| **AB** | | | **200MG** | **A076715** | **002** | Nov 01, 2012 |
| **AB** | | ZYDUS PHARMS USA INC | **100MG** | **A209966** | **001** | Sep 14, 2017 |
| **AB** | | | **200MG** | **A209966** | **002** | Sep 14, 2017 |

**PROVIGIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | CEPHALON | **100MG** | **N020717** | **001** | Dec 24, 1998 |
| **AB** | **+!** | | **200MG** | **N020717** | **002** | Dec 24, 1998 |

MOEXIPRIL HYDROCHLORIDE

TABLET;ORAL

**MOEXIPRIL HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | APOTEX INC | **7.5MG** | **A078454** | **001** | Jun 02, 2008 |
| **AB** | | | **15MG** | **A078454** | **002** | Jun 02, 2008 |
| **AB** | | CHARTWELL RX | **7.5MG** | **A077536** | **001** | Nov 30, 2006 |
| **AB** | | | **15MG** | **A077536** | **002** | Nov 30, 2006 |

| | | | | | | |
|---|---|---|---|---|---|---|
| MOEXIPRIL HYDROCHLORIDE | | | | | | |
| TABLET;ORAL | | | | | | |
| **MOEXIPRIL HYDROCHLORIDE** | | | | | | |
| **AB** | | GLENMARK GENERICS | **7.5MG** | **A090416** | **001** | Mar 30, 2010 |
| **AB** | | | **15MG** | **A090416** | **002** | Mar 30, 2010 |
| **AB** | | TEVA | **7.5MG** | **A076204** | **001** | May 08, 2003 |
| **AB** | **!** | | **15MG** | **A076204** | **002** | May 08, 2003 |
| MOLINDONE HYDROCHLORIDE | | | | | | |
| TABLET;ORAL | | | | | | |
| MOLINDONE HYDROCHLORIDE | | | | | | |
| | | EPIC PHARMA LLC | 5MG | A090453 | 001 | Mar 20, 2015 |
| | | | 10MG | A090453 | 002 | Mar 20, 2015 |
| | ! | | 25MG | A090453 | 003 | Mar 20, 2015 |
| MOMETASONE FUROATE | | | | | | |
| AEROSOL, METERED;INHALATION | | | | | | |
| ASMANEX HFA | | | | | | |
| | + | MERCK SHARP DOHME | 0.10MG/INH | N205641 | 001 | Apr 25, 2014 |
| | +! | | 0.20MG/INH | N205641 | 002 | Apr 25, 2014 |
| CREAM;TOPICAL | | | | | | |
| **ELOCON** | | | | | | |
| **AB** | **+!** | MERCK SHARP DOHME | **0.1%** | **N019625** | **002** | Apr 19, 2013 |
| **MOMETASONE FUROATE** | | | | | | |
| **AB** | | FOUGERA PHARMS | **0.1%** | **A076171** | **001** | Apr 08, 2005 |
| **AB** | | G AND W LABS | **0.1%** | **A077447** | **001** | May 22, 2006 |
| **AB** | | GLENMARK GENERICS | **0.1%** | **A078541** | **001** | May 28, 2008 |
| **AB** | | TARO | **0.1%** | **A076679** | **001** | Dec 21, 2004 |
| **AB** | | TOLMAR | **0.1%** | **A076591** | **001** | Apr 18, 2007 |
| IMPLANT;IMPLANTATION | | | | | | |
| SINUVA | | | | | | |
| | + | INTERSECT ENT INC | 1.35MG | N209310 | 001 | Dec 08, 2017 |
| LOTION;TOPICAL | | | | | | |
| **ELOCON** | | | | | | |
| **AB** | **+!** | MERCK SHARP DOHME | **0.1%** | **N019796** | **001** | Mar 30, 1989 |
| **MOMETASONE FUROATE** | | | | | | |
| **AB** | | FOUGERA PHARMS | **0.1%** | **A075919** | **001** | Nov 29, 2007 |
| **AB** | | G AND W LABS | **0.1%** | **A077678** | **001** | Nov 21, 2007 |
| **AB** | | GLENMARK GENERICS | **0.1%** | **A090506** | **001** | Aug 09, 2010 |
| **AB** | | PERRIGO ISRAEL | **0.1%** | **A077180** | **001** | Apr 06, 2005 |
| **AB** | | TARO | **0.1%** | **A076788** | **001** | Mar 15, 2006 |
| **AB** | | TOLMAR | **0.1%** | **A076499** | **001** | Nov 21, 2007 |
| OINTMENT;TOPICAL | | | | | | |
| **ELOCON** | | | | | | |
| **AB** | **+!** | MERCK SHARP DOHME | **0.1%** | **N019543** | **001** | Apr 30, 1987 |
| **MOMETASONE FUROATE** | | | | | | |
| **AB** | | FOUGERA PHARMS | **0.1%** | **A077061** | **001** | Mar 28, 2005 |
| **AB** | | G AND W LABS | **0.1%** | **A077401** | **001** | Jun 20, 2006 |
| **AB** | | GLENMARK GENERICS | **0.1%** | **A078571** | **001** | May 28, 2008 |
| **AB** | | PERRIGO NEW YORK | **0.1%** | **A076067** | **001** | Mar 18, 2002 |
| **AB** | | TOLMAR | **0.1%** | **A076481** | **001** | Nov 14, 2003 |
| POWDER;INHALATION | | | | | | |
| ASMANEX TWISTHALER | | | | | | |
| | + | MERCK SHARP DOHME | 0.11MG/INH | N021067 | 002 | Feb 01, 2008 |
| | +! | | 0.22MG/INH | N021067 | 001 | Mar 30, 2005 |
| SPRAY, METERED;NASAL | | | | | | |
| **MOMETASONE FUROATE** | | | | | | |
| **AB** | | AMNEAL PHARMS | **EQ 0.05MG BASE/SPRAY** | **A207989** | **001** | Apr 03, 2017 |
| **AB** | | APOTEX INC | **EQ 0.05MG BASE/SPRAY** | **A091161** | **001** | Mar 22, 2016 |
| **NASONEX** | | | | | | |
| **AB** | **+!** | MERCK SHARP DOHME | **EQ 0.05MG BASE/SPRAY** | **N020762** | **001** | Oct 01, 1997 |
| MONTELUKAST SODIUM | | | | | | |
| GRANULE;ORAL | | | | | | |
| **MONTELUKAST SODIUM** | | | | | | |
| **AB** | | AJANTA PHARMA LTD | **EQ 4MG BASE/PACKET** | **A203438** | **001** | Jul 31, 2015 |
| **AB** | | DR REDDYS LABS LTD | **EQ 4MG BASE/PACKET** | **A202906** | **001** | Sep 17, 2012 |
| **AB** | | MYLAN PHARMS INC | **EQ 4MG BASE/PACKET** | **A202776** | **001** | Dec 18, 2012 |
| **AB** | | TEVA PHARMS | **EQ 4MG BASE/PACKET** | **A090955** | **001** | Aug 03, 2012 |
| **SINGULAIR** | | | | | | |
| **AB** | **+!** | MERCK | **EQ 4MG BASE/PACKET** | **N021409** | **001** | Jul 26, 2002 |

MONTELUKAST SODIUM

TABLET;ORAL

**MONTELUKAST SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACCORD HLTHCARE | **EQ 10MG BASE** | **A202717** | **001** | Sep 21, 2012 |
| **AB** | | AJANTA PHARMA LTD | **EQ 10MG BASE** | **A203432** | **001** | Jul 31, 2015 |
| **AB** | | AMNEAL PHARMS | **EQ 10MG BASE** | **A204604** | **001** | Sep 04, 2015 |
| **AB** | | ANBISON LAB CO LTD | **EQ 10MG BASE** | **A205683** | **001** | Jan 12, 2016 |
| **AB** | | APOTEX CORP | **EQ 10MG BASE** | **A201294** | **001** | Aug 03, 2012 |
| **AB** | | AUROBINDO PHARMA LTD | **EQ 10MG BASE** | **A202468** | **001** | Aug 03, 2012 |
| **AB** | | CIPLA LTD | **EQ 10MG BASE** | **A207463** | **001** | Oct 28, 2016 |
| **AB** | | CSPC OUYI PHARM CO | **EQ 10MG BASE** | **A209012** | **001** | Apr 24, 2017 |
| **AB** | | DR REDDYS LABS LTD | **EQ 10MG BASE** | **A201582** | **001** | Aug 06, 2012 |
| **AB** | | GLENMARK GENERICS | **EQ 10MG BASE** | **A090926** | **001** | Aug 03, 2012 |
| **AB** | | HETERO LABS LTD V | **EQ 10MG BASE** | **A202843** | **001** | Sep 10, 2014 |
| **AB** | | KREMERS URBAN PHARMS | **EQ 10MG BASE** | **A201522** | **001** | Aug 03, 2012 |
| **AB** | | MACLEODS PHARMS LTD | **EQ 10MG BASE** | **A203366** | **001** | Sep 11, 2014 |
| **AB** | | MYLAN PHARMS INC | **EQ 10MG BASE** | **A079103** | **001** | Aug 03, 2012 |
| **AB** | | PERRIGO R AND D | **EQ 10MG BASE** | **A206112** | **001** | Apr 26, 2017 |
| **AB** | | SANDOZ INC | **EQ 10MG BASE** | **A200889** | **001** | Aug 03, 2012 |
| **AB** | | TEVA PHARMS | **EQ 10MG BASE** | **A078605** | **001** | Aug 03, 2012 |
| **AB** | | TORRENT PHARMS LTD | **EQ 10MG BASE** | **A201515** | **001** | Aug 03, 2012 |
| **AB** | | UNICHEM LABS LTD | **EQ 10MG BASE** | **A204290** | **001** | Oct 08, 2015 |
| **AB** | | UNIMARK REMEDIES LTD | **EQ 10MG BASE** | **A202859** | **001** | Oct 30, 2014 |
| **AB** | | VINTAGE PHARMS LLC | **EQ 10MG BASE** | **A091576** | **001** | Aug 03, 2012 |
| **AB** | | WEST-WARD PHARMS INT | **EQ 10MG BASE** | **A090655** | **001** | Aug 03, 2012 |

**SINGULAIR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | MSD MERCK CO | **EQ 10MG BASE** | **N020829** | **002** | Feb 20, 1998 |

TABLET, CHEWABLE;ORAL

**MONTELUKAST SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AJANTA PHARMA LTD | **EQ 4MG BASE** | **A203328** | **001** | Jul 31, 2015 |
| **AB** | | | **EQ 5MG BASE** | **A203328** | **002** | Jul 31, 2015 |
| **AB** | | ANBISON LAB CO LTD | **EQ 4MG BASE** | **A205695** | **001** | Nov 05, 2015 |
| **AB** | | | **EQ 5MG BASE** | **A205695** | **002** | Nov 05, 2015 |
| **AB** | | APOTEX INC | **EQ 4MG BASE** | **A201508** | **001** | Aug 03, 2012 |
| **AB** | | | **EQ 5MG BASE** | **A201508** | **002** | Aug 03, 2012 |
| **AB** | | AUROBINDO PHARMA LTD | **EQ 4MG BASE** | **A202096** | **001** | Aug 03, 2012 |
| **AB** | | | **EQ 5MG BASE** | **A202096** | **002** | Aug 03, 2012 |
| **AB** | | CSPC OUYI PHARM CO | **EQ 4MG BASE** | **A209011** | **001** | Apr 18, 2017 |
| **AB** | | | **EQ 5MG BASE** | **A209011** | **002** | Apr 18, 2017 |
| **AB** | | DR REDDYS LABS LTD | **EQ 4MG BASE** | **A201581** | **001** | Aug 06, 2012 |
| **AB** | | | **EQ 5MG BASE** | **A201581** | **002** | Aug 06, 2012 |
| **AB** | | HETERO LABS LTD V | **EQ 4MG BASE** | **A204093** | **001** | May 22, 2015 |
| **AB** | | | **EQ 5MG BASE** | **A204093** | **002** | May 22, 2015 |
| **AB** | | JUBILANT GENERICS | **EQ 4MG BASE** | **A203795** | **001** | Feb 27, 2015 |
| **AB** | | | **EQ 5MG BASE** | **A203795** | **002** | Feb 27, 2015 |
| **AB** | | KREMERS URBAN PHARMS | **EQ 4MG BASE** | **A200405** | **001** | Aug 03, 2012 |
| **AB** | | | **EQ 5MG BASE** | **A200405** | **002** | Aug 03, 2012 |
| **AB** | | MACLEODS PHARMS LTD | **EQ 4MG BASE** | **A203582** | **001** | Mar 12, 2015 |
| **AB** | | | **EQ 5MG BASE** | **A203582** | **002** | Mar 12, 2015 |
| **AB** | | MYLAN PHARMS INC | **EQ 4MG BASE** | **A079142** | **001** | Aug 03, 2012 |
| **AB** | | | **EQ 5MG BASE** | **A079142** | **002** | Aug 03, 2012 |
| **AB** | | SANDOZ INC | **EQ 4MG BASE** | **A091414** | **001** | Aug 03, 2012 |
| **AB** | | | **EQ 5MG BASE** | **A091414** | **002** | Aug 03, 2012 |
| **AB** | | TEVA PHARMS | **EQ 4MG BASE** | **A078723** | **001** | Aug 03, 2012 |
| **AB** | | | **EQ 5MG BASE** | **A078723** | **002** | Aug 03, 2012 |
| **AB** | | TORRENT PHARMS LTD | **EQ 4MG BASE** | **A090984** | **001** | Aug 03, 2012 |
| **AB** | | | **EQ 5MG BASE** | **A090984** | **002** | Aug 03, 2012 |
| **AB** | | UNIMARK REMEDIES LTD | **EQ 4MG BASE** | **A203037** | **001** | Oct 30, 2014 |
| **AB** | | | **EQ 5MG BASE** | **A203037** | **002** | Oct 30, 2014 |
| **AB** | | VINTAGE PHARMS LLC | **EQ 4MG BASE** | **A091588** | **001** | Aug 03, 2012 |
| **AB** | | | **EQ 5MG BASE** | **A091588** | **002** | Aug 03, 2012 |
| **AB** | | WEST-WARD PHARMS INT | **EQ 4MG BASE** | **A091128** | **001** | Aug 03, 2012 |
| **AB** | | | **EQ 5MG BASE** | **A091128** | **002** | Aug 03, 2012 |

**SINGULAIR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | MSD MERCK CO | **EQ 4MG BASE** | **N020830** | **002** | Mar 03, 2000 |
| **AB** | **+!** | | **EQ 5MG BASE** | **N020830** | **001** | Feb 20, 1998 |

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | | **KADIAN** | | | | | |
| **AB** | **+!** | ALLERGAN SALES LLC | **10MG** | **N020616** | **008** | Apr 20, 2007 |
| **AB** | **+** | | **20MG** | **N020616** | **001** | Jul 03, 1996 |
| **AB** | **+** | | **30MG** | **N020616** | **004** | Mar 09, 2001 |
| **AB** | **+** | | **40MG** | **N020616** | **009** | Jul 09, 2012 |
| **AB** | **+** | | **50MG** | **N020616** | **002** | Jul 03, 1996 |
| **AB** | **+** | | **60MG** | **N020616** | **005** | Mar 09, 2001 |
| **AB** | **+** | | **70MG** | **N020616** | **010** | Jul 09, 2012 |
| **AB** | **+** | | **80MG** | **N020616** | **006** | Oct 27, 2006 |
| **AB** | **+!** | | **100MG** | **N020616** | **003** | Jul 03, 1996 |
| | | **MORPHINE SULFATE** | | | | |
| **AB** | | IMPAX LABS INC | **20MG** | **A200411** | **001** | Apr 12, 2016 |
| **AB** | | | **30MG** | **A200411** | **002** | Apr 12, 2016 |
| **AB** | | | **50MG** | **A200411** | **003** | Apr 12, 2016 |
| **AB** | | | **60MG** | **A200411** | **004** | Apr 12, 2016 |
| **AB** | | | **80MG** | **A200411** | **005** | Apr 12, 2016 |
| **AB** | | | **100MG** | **A200411** | **006** | Apr 12, 2016 |
| **AB** | | PAR PHARM INC | **20MG** | **A200812** | **001** | Nov 10, 2011 |
| **AB** | | | **30MG** | **A200812** | **002** | Nov 10, 2011 |
| **AB** | | | **50MG** | **A200812** | **003** | Nov 10, 2011 |
| **AB** | | | **60MG** | **A200812** | **004** | Nov 10, 2011 |
| **AB** | | | **80MG** | **A200812** | **005** | Nov 10, 2011 |
| **AB** | | | **100MG** | **A200812** | **006** | Nov 10, 2011 |
| **AB** | | TEVA PHARMS USA | **20MG** | **A202718** | **001** | Dec 29, 2014 |
| **AB** | | | **30MG** | **A202718** | **002** | Dec 29, 2014 |
| **AB** | | | **40MG** | **A202718** | **007** | Jun 03, 2015 |
| **AB** | | | **50MG** | **A202718** | **003** | Dec 29, 2014 |
| **AB** | | | **60MG** | **A202718** | **004** | Dec 29, 2014 |
| **AB** | | | **70MG** | **A202718** | **008** | Jun 03, 2015 |
| **AB** | | | **80MG** | **A202718** | **005** | Dec 29, 2014 |
| **AB** | | | **100MG** | **A202718** | **006** | Dec 29, 2014 |
| **AB** | | UPSHER-SMITH LABS | **10MG** | **A202104** | **001** | Jun 03, 2013 |
| **AB** | | | **20MG** | **A202104** | **002** | Jun 03, 2013 |
| **AB** | | | **30MG** | **A202104** | **003** | Jun 03, 2013 |
| **AB** | | | **50MG** | **A202104** | **004** | Jun 03, 2013 |
| **AB** | | | **60MG** | **A202104** | **005** | Jun 03, 2013 |
| **AB** | | | **80MG** | **A202104** | **006** | Jun 03, 2013 |
| **AB** | | | **100MG** | **A202104** | **007** | Jun 03, 2013 |
| | | KADIAN | | | | |
| | + | ALLERGAN SALES LLC | 130MG | N020616 | 011 | Jul 09, 2012 |
| | + | | 150MG | N020616 | 012 | Jul 09, 2012 |
| | +! | | 200MG | N020616 | 007 | Feb 27, 2007 |
| | | MORPHINE SULFATE | | | | |
| | | ACTAVIS ELIZABETH | 30MG | A079040 | 001 | Jan 16, 2013 |
| | | | 45MG | A079040 | 002 | Jan 16, 2013 |
| | | | 60MG | A079040 | 003 | Jan 16, 2013 |
| | | | 75MG | A079040 | 004 | Jan 16, 2013 |
| | | | 90MG | A079040 | 005 | Jan 16, 2013 |
| | ! | | 120MG | A079040 | 006 | Jan 16, 2013 |

INJECTABLE;INJECTION

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | | **ASTRAMORPH PF** | | | | | |
| **AP** | | FRESENIUS KABI USA | **0.5MG/ML** | **A071050** | **001** | Oct 07, 1986 |
| **AP** | | | **0.5MG/ML** | **A071051** | **001** | Oct 07, 1986 |
| **AP** | | | **1MG/ML** | **A071052** | **001** | Oct 07, 1986 |
| **AP** | | | **1MG/ML** | **A071053** | **001** | Oct 07, 1986 |
| | | **DURAMORPH PF** | | | | | |
| **AP** | **+!** | WEST-WARD PHARMS INT | **0.5MG/ML** | **N018565** | **001** | Sep 18, 1984 |
| **AP** | **+!** | | **1MG/ML** | **N018565** | **002** | Sep 18, 1984 |
| | | **MORPHINE SULFATE** | | | | | |
| **AP** | | EUROHLTH INTL SARL | **4MG/ML** | **A205758** | **001** | May 21, 2015 |
| **AP** | | | **8MG/ML** | **A205758** | **002** | May 21, 2015 |
| **AP** | | | **10MG/ML** | **A205758** | **003** | May 21, 2015 |
| **AP** | | HOSPIRA | **0.5MG/ML** | **A071849** | **001** | May 11, 1988 |
| **AP** | | | **0.5MG/ML** | **A073509** | **001** | Sep 30, 1992 |
| **AP** | | | **1MG/ML** | **A071850** | **001** | May 11, 1988 |
| **AP** | | | **1MG/ML** | **A073510** | **001** | Sep 30, 1992 |
| **AP** | **+!** | HOSPIRA INC | **4MG/ML** | **N202515** | **002** | Nov 14, 2011 |
| **AP** | **+!** | | **8MG/ML** | **N202515** | **003** | Nov 14, 2011 |
| **AP** | **+!** | | **10MG/ML** | **N202515** | **004** | Nov 14, 2011 |
| **AP** | **+!** | ICU MEDICAL INC | **1MG/ML** | **N019916** | **001** | Oct 30, 1992 |

MORPHINE SULFATE

INJECTABLE;INJECTION

INFUMORPH

| | | | | | | |
|---|---|---|---|---|---|---|
| +! | WEST-WARD PHARMS INT | 10MG/ML | N018565 | 003 | Jul 19, 1991 |
| +! | | 25MG/ML | N018565 | 004 | Jul 19, 1991 |

MORPHINE SULFATE

| | | | | | | |
|---|---|---|---|---|---|---|
| +! | HOSPIRA INC | 2MG/ML | N202515 | 001 | Nov 14, 2011 |
| +! | ICU MEDICAL INC | 5MG/ML | N019916 | 002 | Oct 27, 2006 |
| +! | MERIDIAN MEDCL TECHN | 15MG/ML | N019999 | 001 | Jul 12, 1990 |

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

MORPHINE SULFATE

| | | | | | | |
|---|---|---|---|---|---|---|
| +! | FRESENIUS KABI USA | 2MG/ML (2MG/ML) | N204223 | 001 | Oct 30, 2013 |
| +! | | 4MG/ML (4MG/ML) | N204223 | 002 | Oct 30, 2013 |
| +! | | 5MG/ML (5MG/ML) | N204223 | 003 | Oct 30, 2013 |
| +! | | 8MG/ML (8MG/ML) | N204223 | 004 | Oct 30, 2013 |
| +! | | 10MG/ML (10MG/ML) | N204223 | 005 | Oct 30, 2013 |

SOLUTION;ORAL

**MORPHINE SULFATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | HI-TECH PHARMACAL | **100MG/5ML** | **A208809** | **001** | Jul 06, 2017 |
| **AA** | NOSTRUM LABS INC | **10MG/5ML** | **A201011** | **001** | Feb 05, 2014 |
| **AA** | | **20MG/5ML** | **A201011** | **002** | Feb 05, 2014 |
| **AA** | | **100MG/5ML** | **A204053** | **001** | Oct 06, 2016 |
| **AA** | PADDOCK LLC | **100MG/5ML** | **A201574** | **001** | Aug 06, 2012 |
| **AA** | PHARM ASSOC | **100MG/5ML** | **A206573** | **001** | Nov 14, 2016 |
| **AA** | RHODES PHARMS | **10MG/5ML** | **A206308** | **001** | Jun 22, 2017 |
| **AA** | | **20MG/5ML** | **A206420** | **001** | Jul 12, 2016 |
| **AA** | | **100MG/5ML** | **A206308** | **002** | Jun 22, 2017 |
| **AA** | SPECGX LLC | **100MG/5ML** | **A202348** | **001** | Jul 15, 2011 |
| **AA** | TRIS PHARMA INC | **10MG/5ML** | **A203518** | **001** | May 12, 2015 |
| **AA** | | **20MG/5ML** | **A203519** | **001** | May 18, 2016 |
| **AA** | | **100MG/5ML** | **A203518** | **002** | May 12, 2015 |
| **AA** | VINTAGE PHARMS LLC | **10MG/5ML** | **A202309** | **001** | Nov 25, 2015 |
| **AA** | | **20MG/5ML** | **A202310** | **001** | Oct 30, 2015 |
| **AA** | VISTAPHARM | **10MG/5ML** | **A201947** | **001** | Jan 05, 2012 |
| **AA** | | **20MG/5ML** | **A201947** | **002** | Jan 05, 2012 |
| **AA** + | WEST-WARD PHARMS INT | **10MG/5ML** | **N022195** | **001** | Mar 17, 2008 |
| **AA** + | | **20MG/5ML** | **N022195** | **002** | Mar 17, 2008 |
| **AA** +! | | **100MG/5ML** | **N022195** | **003** | Jan 25, 2010 |
| | LANNETT HOLDINGS INC | 100MG/5ML | N201517 | 001 | Jun 23, 2011 |

TABLET;ORAL

MORPHINE SULFATE

| | | | | | | |
|---|---|---|---|---|---|---|
| + | WEST-WARD PHARMS INT | 15MG | N022207 | 001 | Mar 17, 2008 |
| +! | | 30MG | N022207 | 002 | Mar 17, 2008 |

TABLET, EXTENDED RELEASE;ORAL

**MORPHINE SULFATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | ACTAVIS ELIZABETH | **15MG** | **A203849** | **001** | Apr 06, 2015 |
| **AB** | | **30MG** | **A203849** | **002** | Apr 06, 2015 |
| **AB** | | **60MG** | **A203849** | **003** | Apr 06, 2015 |
| **AB** | | **100MG** | **A203849** | **004** | Apr 06, 2015 |
| **AB** | | **200MG** | **A203849** | **005** | Apr 06, 2015 |
| **AB** | DAVA PHARMS INC | **15MG** | **A075407** | **001** | Jan 28, 2000 |
| **AB** | EPIC PHARMA LLC | **15MG** | **A091357** | **001** | Jun 23, 2016 |
| **AB** | | **30MG** | **A091357** | **002** | Jun 23, 2016 |
| **AB** | | **60MG** | **A091357** | **003** | Jun 23, 2016 |
| **AB** | | **100MG** | **A091357** | **004** | Jun 23, 2016 |
| **AB** | | **200MG** | **A091357** | **005** | Jun 23, 2016 |
| **AB** | MAYNE PHARMA INC | **15MG** | **A205386** | **001** | Oct 28, 2016 |
| **AB** | | **30MG** | **A205386** | **002** | Oct 28, 2016 |
| **AB** | | **60MG** | **A205386** | **003** | Oct 28, 2016 |
| **AB** | | **100MG** | **A205386** | **004** | Oct 28, 2016 |
| **AB** | MYLAN PHARMS INC | **15MG** | **A200824** | **001** | Oct 18, 2011 |
| **AB** | | **30MG** | **A200824** | **002** | Oct 18, 2011 |
| **AB** | | **60MG** | **A200824** | **003** | Oct 18, 2011 |
| **AB** | | **100MG** | **A200824** | **004** | Oct 18, 2011 |
| **AB** | | **200MG** | **A200824** | **005** | Oct 18, 2011 |
| **AB** | NESHER PHARMS | **15MG** | **A076733** | **001** | May 19, 2004 |
| **AB** | | **30MG** | **A076720** | **002** | Dec 23, 2005 |
| **AB** | | **60MG** | **A076720** | **001** | May 19, 2004 |

MORPHINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

**MORPHINE SULFATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **100MG** | **A077855** | **001** | Sep 27, 2007 |
| **AB** | | | **200MG** | **A077855** | **002** | Sep 27, 2007 |
| **AB** | | NOVEL LABS INC | **15MG** | **A203602** | **001** | Dec 16, 2015 |
| **AB** | | | **30MG** | **A203602** | **002** | Dec 16, 2015 |
| **AB** | | | **60MG** | **A203602** | **003** | Dec 16, 2015 |
| **AB** | | | **100MG** | **A203602** | **004** | Dec 16, 2015 |
| **AB** | | | **200MG** | **A203602** | **005** | Dec 16, 2015 |
| **AB** | | RHODES PHARMS | **15MG** | **A074862** | **001** | Jul 07, 1998 |
| **AB** | | | **30MG** | **A074862** | **002** | Jul 07, 1998 |
| **AB** | | | **60MG** | **A074862** | **003** | Jul 07, 1998 |
| **AB** | | | **100MG** | **A074769** | **001** | Jul 02, 1998 |
| **AB** | | | **200MG** | **A074769** | **002** | Jul 02, 1998 |
| **AB** | | SPECGX LLC | **15MG** | **A076412** | **001** | Jul 31, 2003 |
| **AB** | | | **30MG** | **A076412** | **002** | Jul 31, 2003 |
| **AB** | | | **60MG** | **A076412** | **003** | Jul 31, 2003 |
| **AB** | | | **100MG** | **A076438** | **001** | Jul 03, 2003 |
| **AB** | | | **200MG** | **A076438** | **002** | Jul 03, 2003 |
| **AB** | | SUN PHARM INDS LTD | **15MG** | **A078761** | **001** | May 11, 2012 |
| **AB** | | | **30MG** | **A078761** | **002** | May 11, 2012 |
| **AB** | | | **60MG** | **A078761** | **003** | May 11, 2012 |
| **AB** | | | **100MG** | **A078761** | **004** | May 11, 2012 |
| **AB** | | | **200MG** | **A078761** | **005** | May 11, 2012 |
| **AB** | | SUN PHARM INDUSTRIES | **15MG** | **A205634** | **001** | Aug 25, 2016 |
| **AB** | | | **30MG** | **A205634** | **002** | Aug 25, 2016 |
| **AB** | | | **60MG** | **A205634** | **003** | Aug 25, 2016 |
| **AB** | | | **100MG** | **A205634** | **004** | Aug 25, 2016 |
| **AB** | | | **200MG** | **A205634** | **005** | Aug 25, 2016 |
| **AB** | | VINTAGE PHARMS LLC | **15MG** | **A075295** | **001** | Oct 28, 1998 |
| **AB** | | | **30MG** | **A075295** | **002** | Oct 28, 1998 |
| **AB** | | | **60MG** | **A075295** | **003** | Oct 28, 1998 |
| **AB** | | | **100MG** | **A075295** | **004** | Sep 15, 2000 |
| **AB** | | | **200MG** | **A075295** | **005** | Sep 15, 2000 |

**MS CONTIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | PURDUE PHARMA LP | **15MG** | **N019516** | **003** | Sep 12, 1989 |
| **AB** | **+** | | **30MG** | **N019516** | **001** | May 29, 1987 |
| **AB** | **+** | | **60MG** | **N019516** | **002** | Apr 08, 1988 |
| **AB** | **+!** | | **100MG** | **N019516** | **004** | Jan 16, 1990 |
| **AB** | **+** | | **200MG** | **N019516** | **005** | Nov 08, 1993 |

ARYMO ER

| | | | | | |
|---|---|---|---|---|---|
| + | EGALET | 15MG | N208603 | 001 | Jan 09, 2017 |
| + | | 30MG | N208603 | 002 | Jan 09, 2017 |
| + | | 60MG | N208603 | 003 | Jan 09, 2017 |

MORPHABOND ER

| | | | | | |
|---|---|---|---|---|---|
| + | DAIICHI SANKYO INC | 15MG | N206544 | 001 | Oct 02, 2015 |
| + | | 30MG | N206544 | 002 | Oct 02, 2015 |
| + | | 60MG | N206544 | 003 | Oct 02, 2015 |
| +! | | 100MG | N206544 | 004 | Oct 02, 2015 |

MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

EMBEDA

| | | | | | |
|---|---|---|---|---|---|
| + | ALPHARMA PHARMS | 20MG;0.8MG | N022321 | 001 | Aug 13, 2009 |
| + | | 30MG;1.2MG | N022321 | 002 | Aug 13, 2009 |
| + | | 50MG;2MG | N022321 | 003 | Aug 13, 2009 |
| +! | | 60MG;2.4MG | N022321 | 004 | Aug 13, 2009 |
| + | | 80MG;3.2MG | N022321 | 005 | Aug 13, 2009 |
| + | | 100MG;4MG | N022321 | 006 | Aug 13, 2009 |

MOXIFLOXACIN HYDROCHLORIDE

SOLUTION;IV (INFUSION)

MOXIFLOXACIN HYDROCHLORIDE

| | | | | | |
|---|---|---|---|---|---|
| +! | FRESENIUS KABI USA | EQ 400MG BASE/250ML (EQ 1.6MG BASE/ML) | N205572 | 001 | Apr 03, 2015 |

MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| ! | MYLAN LABS LTD | 400MG/250ML (1.6MG/ML) | A205833 | 001 | May 05, 2017 |

SOLUTION/DROPS;OPHTHALMIC

**MOXIFLOXACIN HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT1** | | AKORN | **EQ 0.5% BASE** | **A202916** | **001** | Nov 09, 2017 |
| **AT1** | | APOTEX INC | **EQ 0.5% BASE** | **A090080** | **001** | Jun 30, 2017 |
| **AT1** | | AUROBINDO PHARMA LTD | **EQ 0.5% BASE** | **A206242** | **001** | Oct 04, 2017 |

| | | | | | | |
|---|---|---|---|---|---|---|
| MOXIFLOXACIN HYDROCHLORIDE | | | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | | | |
| **MOXIFLOXACIN HYDROCHLORIDE** | | | | | | |
| **AT1** | | LUPIN LTD | **EQ 0.5% BASE** | **A202867** | **001** | Sep 04, 2014 |
| **AT1** | | WATSON LABS INC | **EQ 0.5% BASE** | **A202525** | **001** | Mar 06, 2015 |
| **VIGAMOX** | | | | | | |
| **AT1** | **+!** | NOVARTIS PHARMS CORP | **EQ 0.5% BASE** | **N021598** | **001** | Apr 15, 2003 |
| **MOXEZA** | | | | | | |
| **AT2** | **+!** | NOVARTIS PHARMS CORP | **EQ 0.5% BASE** | **N022428** | **001** | Nov 19, 2010 |
| **MOXIFLOXACIN HYDROCHLORIDE** | | | | | | |
| **AT2** | | LUPIN LTD | **EQ 0.5% BASE** | **A204079** | **001** | May 28, 2015 |
| TABLET;ORAL | | | | | | |
| **AVELOX** | | | | | | |
| **AB** | **+!** | BAYER HLTHCARE | **EQ 400MG BASE** | **N021085** | **001** | Dec 10, 1999 |
| **MOXIFLOXACIN HYDROCHLORIDE** | | | | | | |
| **AB** | | AUROBINDO PHARMA LTD | **EQ 400MG BASE** | **A202632** | **001** | Mar 04, 2014 |
| **AB** | | CROSSMEDIKA SA | **EQ 400MG BASE** | **A205348** | **001** | Jan 14, 2016 |
| **AB** | | DR REDDYS LABS LTD | **EQ 400MG BASE** | **A076938** | **001** | Mar 04, 2014 |
| **AB** | | MSN LABS PVT LTD | **EQ 400MG BASE** | **A208682** | **001** | Sep 22, 2017 |
| **AB** | | MYLAN PHARMS INC | **EQ 400MG BASE** | **A204635** | **001** | Aug 31, 2015 |
| **AB** | | NOVEL LABS INC | **EQ 400MG BASE** | **A207285** | **001** | Feb 13, 2017 |
| **AB** | | TEVA PHARMS USA | **EQ 400MG BASE** | **A077437** | **001** | Feb 18, 2014 |
| **AB** | | TORRENT PHARMS LTD | **EQ 400MG BASE** | **A200160** | **001** | Apr 03, 2014 |
| MUPIROCIN | | | | | | |
| OINTMENT;TOPICAL | | | | | | |
| **MUPIROCIN** | | | | | | |
| **AB** | | FOUGERA PHARMS | **2%** | **A065192** | **001** | Nov 30, 2005 |
| **AB** | | GLENMARK PHARMS | **2%** | **A090480** | **001** | Jun 08, 2011 |
| **AB** | **!** | PERRIGO NEW YORK | **2%** | **A065123** | **001** | Nov 07, 2003 |
| **AB** | | TARO | **2%** | **A065170** | **001** | Sep 23, 2005 |
| **AB** | | TEVA | **2%** | **A065085** | **001** | Nov 07, 2003 |
| CENTANY | | | | | | |
| BX | | PERRIGO NEW YORK | 2% | N050788 | 001 | Dec 04, 2002 |
| MUPIROCIN CALCIUM | | | | | | |
| CREAM;TOPICAL | | | | | | |
| **BACTROBAN** | | | | | | |
| **AB** | **+!** | GLAXOSMITHKLINE | **EQ 2% BASE** | **N050746** | **001** | Dec 11, 1997 |
| **MUPIROCIN** | | | | | | |
| **AB** | | GLENMARK PHARMS INC | **EQ 2% BASE** | **A201587** | **001** | Jan 24, 2013 |
| OINTMENT;NASAL | | | | | | |
| BACTROBAN | | | | | | |
| | +! | GLAXOSMITHKLINE | EQ 2% BASE | N050703 | 001 | Sep 18, 1995 |
| MYCOPHENOLATE MOFETIL | | | | | | |
| CAPSULE;ORAL | | | | | | |
| **CELLCEPT** | | | | | | |
| **AB** | **+!** | ROCHE PALO | **250MG** | **N050722** | **001** | May 03, 1995 |
| **MYCOPHENOLATE MOFETIL** | | | | | | |
| **AB** | | ACCORD HLTHCARE | **250MG** | **A090253** | **001** | May 04, 2009 |
| **AB** | | ALKEM LABS LTD | **250MG** | **A200197** | **001** | Jun 13, 2013 |
| **AB** | | APOTEX CORP | **250MG** | **A090419** | **001** | Apr 22, 2009 |
| **AB** | | MYLAN | **250MG** | **A065520** | **001** | May 04, 2009 |
| **AB** | | SANDOZ | **250MG** | **A065379** | **001** | Oct 15, 2008 |
| **AB** | | STRIDES PHARMA | **250MG** | **A090055** | **001** | Jun 10, 2010 |
| **AB** | | TEVA PHARMS | **250MG** | **A065491** | **001** | May 06, 2009 |
| **AB** | | VINTAGE PHARMS LLC | **250MG** | **A090111** | **001** | Dec 22, 2009 |
| **AB** | | WEST-WARD PHARMS INT | **250MG** | **A065410** | **001** | Jul 29, 2008 |
| **AB** | | ZHEJIANG HISUN PHARM | **250MG** | **A204077** | **001** | Nov 13, 2017 |
| SUSPENSION;ORAL | | | | | | |
| **CELLCEPT** | | | | | | |
| **AB** | **+!** | ROCHE PALO | **200MG/ML** | **N050759** | **001** | Oct 01, 1998 |
| **MYCOPHENOLATE MOFETIL** | | | | | | |
| **AB** | | ALKEM LABS LTD | **200MG/ML** | **A203005** | **001** | Nov 14, 2014 |
| TABLET;ORAL | | | | | | |
| **CELLCEPT** | | | | | | |
| **AB** | **+!** | ROCHE PALO | **500MG** | **N050723** | **001** | Jun 19, 1997 |

MYCOPHENOLATE MOFETIL

TABLET;ORAL

**MYCOPHENOLATE MOFETIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACCORD HLTHCARE | **500MG** | **A065416** | **001** | May 04, 2009 |
| **AB** | | ALKEM LABS LTD | **500MG** | **A091249** | **001** | Nov 04, 2011 |
| **AB** | | APOTEX | **500MG** | **A090499** | **001** | Apr 22, 2009 |
| **AB** | | MYLAN | **500MG** | **A065521** | **001** | May 04, 2009 |
| **AB** | | SANDOZ | **500MG** | **A065451** | **001** | Oct 15, 2008 |
| **AB** | | STRIDES PHARMA | **500MG** | **A090456** | **001** | Jun 10, 2010 |
| **AB** | | TEVA PHARMS | **500MG** | **A065457** | **001** | May 04, 2009 |
| **AB** | | VINTAGE PHARMS LLC | **500MG** | **A090606** | **001** | Jul 16, 2010 |
| **AB** | | WEST-WARD PHARMS INT | **500MG** | **A065413** | **001** | Jul 29, 2008 |
| **AB** | | ZHEJIANG HISUN PHARM | **500MG** | **A204076** | **001** | Nov 16, 2017 |

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE;INJECTION

**CELLCEPT**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | ROCHE PALO | **500MG/VIAL** | **N050758** | **001** | Aug 12, 1998 |

**MYCOPHENOLATE MOFETIL HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AKORN INC | **500MG/VIAL** | **A204043** | **001** | Feb 28, 2017 |
| **AP** | | MYLAN LABS LTD | **500MG/VIAL** | **A203859** | **001** | Mar 31, 2017 |
| **AP** | | PAR STERILE PRODUCTS | **500MG/VIAL** | **A203575** | **001** | Oct 28, 2016 |
| **AP** | | ZYDUS PHARMS USA INC | **500MG/VIAL** | **A204473** | **001** | Aug 31, 2017 |

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE;ORAL

**MYCOPHENOLIC ACID**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACCORD HLTHCARE | **180MG** | **A202555** | **001** | Aug 23, 2017 |
| **AB** | | | **360MG** | **A202555** | **002** | Aug 23, 2017 |
| **AB** | | APOTEX INC | **180MG** | **A091558** | **001** | Aug 21, 2012 |
| **AB** | | | **360MG** | **A091558** | **002** | Aug 19, 2014 |
| **AB** | | MYLAN PHARMS INC | **180MG** | **A091248** | **002** | Jan 08, 2014 |
| **AB** | | | **360MG** | **A091248** | **001** | Jan 08, 2014 |
| **AB** | | TEVA PHARMS USA | **180MG** | **A202720** | **001** | Oct 30, 2014 |
| **AB** | | | **360MG** | **A202720** | **002** | Oct 30, 2014 |

**MYFORTIC**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | NOVARTIS | **180MG** | **N050791** | **001** | Feb 27, 2004 |
| **AB** | **+!** | | **360MG** | **N050791** | **002** | Feb 27, 2004 |

NABILONE

CAPSULE;ORAL

CESAMET

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | MYLAN SPECIALITY LP | 1MG | N018677 | 001 | Dec 26, 1985 |

NABUMETONE

TABLET;ORAL

**NABUMETONE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | APOTEX INC | **500MG** | **A090427** | **001** | Dec 30, 2011 |
| **AB** | | | **750MG** | **A090427** | **002** | Dec 30, 2011 |
| **AB** | | CHARTWELL MOLECULES | **500MG** | **A076009** | **001** | Jan 24, 2003 |
| **AB** | | | **750MG** | **A076009** | **002** | Jan 24, 2003 |
| **AB** | | IMPAX LABS INC | **500MG** | **A075189** | **001** | May 26, 2000 |
| **AB** | **!** | | **750MG** | **A075189** | **002** | Sep 24, 2001 |
| **AB** | | INVAGEN PHARMS | **500MG** | **A078671** | **001** | Mar 07, 2008 |
| **AB** | | | **750MG** | **A078671** | **002** | Mar 07, 2008 |
| **AB** | | LUPIN LTD | **500MG** | **A090445** | **001** | Jan 12, 2011 |
| **AB** | | | **750MG** | **A090445** | **002** | Jan 12, 2011 |
| **AB** | | MYLAN PHARMS INC | **500MG** | **A090516** | **001** | Jul 12, 2010 |
| **AB** | | | **750MG** | **A090516** | **002** | Jul 12, 2010 |
| **AB** | | SANDOZ | **500MG** | **A075280** | **001** | Feb 25, 2002 |
| **AB** | | | **750MG** | **A075280** | **002** | Feb 25, 2002 |
| **AB** | | WATSON LABS | **500MG** | **A091083** | **001** | Jun 13, 2011 |
| **AB** | | | **750MG** | **A091083** | **002** | Jun 13, 2011 |

NADOLOL

TABLET;ORAL

**CORGARD**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | US WORLDMEDS LLC | **20MG** | **N018063** | **005** | Oct 28, 1986 |
| **AB** | **+** | | **40MG** | **N018063** | **001** | |
| **AB** | **+!** | | **80MG** | **N018063** | **002** | |

NADOLOL

TABLET;ORAL

**NADOLOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AMNEAL PHARMS CO | **20MG** | **A208832** | **001** | Jun 02, 2017 |
| **AB** | | | **40MG** | **A208832** | **002** | Jun 02, 2017 |
| **AB** | | | **80MG** | **A208832** | **003** | Jun 02, 2017 |
| **AB** | | AUROBINDO PHARMA LTD | **40MG** | **A201893** | **001** | Sep 16, 2015 |
| **AB** | | | **80MG** | **A201893** | **002** | Sep 16, 2015 |
| **AB** | | INVAGEN PHARMS | **20MG** | **A203455** | **001** | Dec 18, 2015 |
| **AB** | | | **40MG** | **A203455** | **002** | Dec 18, 2015 |
| **AB** | | | **80MG** | **A203455** | **003** | Dec 18, 2015 |
| **AB** | | IVAX SUB TEVA PHARMS | **20MG** | **A074229** | **001** | Aug 30, 1996 |
| **AB** | | | **40MG** | **A074229** | **002** | Aug 30, 1996 |
| **AB** | | | **80MG** | **A074255** | **001** | Jan 24, 1996 |
| **AB** | | LUPIN LTD | **20MG** | **A209309** | **001** | Oct 05, 2017 |
| **AB** | | | **40MG** | **A209309** | **002** | Oct 05, 2017 |
| **AB** | | | **80MG** | **A209309** | **003** | Oct 05, 2017 |
| **AB** | | MYLAN | **20MG** | **A074172** | **001** | Oct 31, 1993 |
| **AB** | | | **40MG** | **A074172** | **002** | Oct 31, 1993 |
| **AB** | | | **80MG** | **A074172** | **003** | Oct 31, 1993 |
| **AB** | | SANDOZ | **20MG** | **A074501** | **001** | Nov 09, 1995 |
| **AB** | | | **40MG** | **A074501** | **002** | Nov 09, 1995 |
| **AB** | | | **80MG** | **A074501** | **003** | Nov 09, 1995 |
| **AB** | | ZYDUS PHARMS USA INC | **20MG** | **A207761** | **001** | Jul 28, 2017 |
| **AB** | | | **40MG** | **A207761** | **002** | Jul 28, 2017 |
| **AB** | | | **80MG** | **A207761** | **003** | Jul 28, 2017 |

NAFARELIN ACETATE

SPRAY, METERED;NASAL

SYNAREL

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | GD SEARLE LLC | EQ 0.2MG BASE/SPRAY | N019886 | 001 | Feb 13, 1990 |

NAFCILLIN SODIUM

INJECTABLE;INJECTION

**NAFCILLIN SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | ANTIBIOTICE | **EQ 1GM BASE/VIAL** | **A090560** | **001** | Oct 03, 2011 |
| **AP** | | | **EQ 2GM BASE/VIAL** | **A090560** | **002** | Oct 03, 2011 |
| **AP** | | AUROBINDO PHARMA LTD | **EQ 1GM BASE/VIAL** | **A091613** | **001** | Dec 26, 2012 |
| **AP** | | | **EQ 2GM BASE/VIAL** | **A091613** | **002** | Dec 26, 2012 |
| **AP** | | | **EQ 10GM BASE/VIAL** | **A091614** | **001** | Dec 26, 2012 |
| **AP** | | ISTITUTO BIO ITA SPA | **EQ 1GM BASE/VIAL** | **A090002** | **001** | Jun 30, 2011 |
| **AP** | | | **EQ 2GM BASE/VIAL** | **A090002** | **002** | Jun 30, 2011 |
| **AP** | | | **EQ 10GM BASE/VIAL** | **A090005** | **001** | Apr 20, 2011 |
| **AP** | | MYLAN LABS LTD | **EQ 1GM BASE/VIAL** | **A200002** | **001** | Apr 07, 2014 |
| **AP** | | | **EQ 2GM BASE/VIAL** | **A200002** | **002** | Apr 07, 2014 |
| **AP** | | SAGENT PHARMS | **EQ 1GM BASE/VIAL** | **A090582** | **001** | Aug 24, 2012 |
| **AP** | | | **EQ 2GM BASE/VIAL** | **A090582** | **002** | Aug 24, 2012 |
| **AP** | | | **EQ 10GM BASE/VIAL** | **A090580** | **001** | Aug 24, 2012 |
| **AP** | **!** | SANDOZ | **EQ 1GM BASE/VIAL** | **A062527** | **002** | Aug 02, 1984 |
| **AP** | **!** | | **EQ 1GM BASE/VIAL** | **A062732** | **001** | Dec 23, 1986 |
| **AP** | **!** | | **EQ 2GM BASE/VIAL** | **A062527** | **003** | Aug 02, 1984 |
| **AP** | **!** | | **EQ 2GM BASE/VIAL** | **A062732** | **002** | Dec 23, 1986 |
| **AP** | **!** | | **EQ 10GM BASE/VIAL** | **A062527** | **004** | Aug 02, 1984 |

NALLPEN IN PLASTIC CONTAINER

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | BAXTER HLTHCARE | EQ 20MG BASE/ML | N050655 | 001 | Oct 31, 1989 |
| | +! | | EQ 2GM BASE/100ML | N050655 | 002 | Oct 31, 1989 |

NAFTIFINE HYDROCHLORIDE

CREAM;TOPICAL

**NAFTIFINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | TARO | **1%** | **A205975** | **001** | Sep 08, 2016 |
| **AB** | | | **2%** | **A206901** | **001** | Jan 06, 2016 |
| **AB** | | TOLMAR | **2%** | **A206960** | **001** | Apr 10, 2017 |

**NAFTIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | SEBELA IRELAND LTD | **1%** | **N019599** | **001** | Feb 29, 1988 |
| **AB** | **+!** | | **2%** | **N019599** | **002** | Jan 13, 2012 |

GEL;TOPICAL

NAFTIN

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | SEBELA IRELAND LTD | 1% | N019356 | 001 | Jun 18, 1990 |
| | +! | | 2% | N204286 | 001 | Jun 27, 2013 |

NALBUPHINE HYDROCHLORIDE

INJECTABLE;INJECTION

**NALBUPHINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **!** | HOSPIRA | **10MG/ML** | **A070914** | **001** | Feb 03, 1989 |
| **AP** | **!** | | **10MG/ML** | **A070915** | **001** | Feb 03, 1989 |
| **AP** | **!** | | **20MG/ML** | **A070916** | **001** | Feb 03, 1989 |
| **AP** | **!** | | **20MG/ML** | **A070918** | **001** | Feb 03, 1989 |

NALDEMEDINE TOSYLATE

TABLET;ORAL

SYMPROIC

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | SHIONOGI INC | EQ 0.2MG BASE | N208854 | 001 | Mar 23, 2017 |

NALOXEGOL OXALATE

TABLET;ORAL

MOVANTIK

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | ASTRAZENECA PHARMS | EQ 12.5MG BASE | N204760 | 001 | Sep 16, 2014 |
| | +! | | EQ 25MG BASE | N204760 | 002 | Sep 16, 2014 |

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION

**NALOXONE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | WEST-WARD PHARMS INT | **0.4MG/ML** | **A070299** | **001** | Sep 24, 1986 |

**NALOXONE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AKORN | **0.4MG/ML** | **A208871** | **001** | Feb 28, 2017 |
| **AP** | | | **0.4MG/ML** | **A208872** | **001** | Mar 14, 2017 |
| **AP** | **!** | HOSPIRA | **0.4MG/ML** | **A070172** | **001** | Sep 24, 1986 |
| **AP** | **!** | | **0.4MG/ML** | **A070254** | **001** | Jan 07, 1987 |
| **AP** | **!** | | **0.4MG/ML** | **A070256** | **001** | Jan 07, 1987 |
| **AP** | **!** | | **0.4MG/ML** | **A070257** | **001** | Jan 07, 1987 |
| **AP** | | INTL MEDICATION | **0.4MG/ML** | **A070639** | **001** | Sep 24, 1986 |
| **AP** | | MYLAN INSTITUTIONAL | **0.4MG/ML** | **A204997** | **001** | Mar 06, 2014 |
| **AP** | | | **0.4MG/ML** | **A205014** | **001** | Jun 29, 2016 |
| **AP** | | SOMERSET THERAPS LLC | **0.4MG/ML** | **A207633** | **001** | Aug 08, 2017 |
| **AP** | | | **0.4MG/ML** | **A207634** | **001** | Jul 26, 2017 |
| | ! | INTL MEDICATION | 1MG/ML | A072076 | 001 | Mar 24, 1988 |

SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

EVZIO

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | KALEO INC | 2MG/0.4ML (2MG/0.4ML) | N209862 | 001 | Oct 19, 2016 |

SPRAY, METERED;NASAL

NARCAN

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | ADAPT | 2MG/SPRAY | N208411 | 002 | Jan 24, 2017 |
| | +! | | 4MG/SPRAY | N208411 | 001 | Nov 18, 2015 |

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET;ORAL

**NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | GAVIS PHARMS | **EQ 0.5MG BASE;EQ 50MG BASE** | **A075735** | **001** | Jul 11, 2001 |
| **AB** | | SUN PHARM INDS LTD | **EQ 0.5MG BASE;EQ 50MG BASE** | **A075523** | **001** | Mar 17, 2000 |
| **AB** | **!** | WATSON LABS | **EQ 0.5MG BASE;EQ 50MG BASE** | **A074736** | **001** | Jan 21, 1997 |

NALTREXONE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

VIVITROL

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ALKERMES | 380MG/VIAL | N021897 | 001 | Apr 13, 2006 |

NALTREXONE HYDROCHLORIDE

TABLET;ORAL

**NALTREXONE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACCORD HLTHCARE | **50MG** | **A091205** | **001** | Aug 17, 2011 |
| **AB** | | APOTEX INC | **50MG** | **A207905** | **001** | Jul 21, 2017 |
| **AB** | | BARR | **50MG** | **A074918** | **001** | May 08, 1998 |
| **AB** | | ELITE LABS | **50MG** | **A075274** | **001** | May 26, 1999 |
| **AB** | **!** | SPECGX LLC | **50MG** | **A076264** | **002** | Mar 22, 2002 |
| **AB** | | SUN PHARMA GLOBAL | **50MG** | **A090356** | **001** | Feb 24, 2012 |
| | | SPECGX LLC | 25MG | A076264 | 001 | Mar 22, 2002 |
| | | | 100MG | A076264 | 003 | Mar 22, 2002 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| NANDROLONE DECANOATE | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| NANDROLONE DECANOATE | | | | | | | |
| | ! | LUITPOLD PHARMS INC | 200MG/ML | | A091252 | 001 | Aug 30, 2010 |
| NAPHAZOLINE HYDROCHLORIDE | | | | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | | | | |
| NAPHAZOLINE HYDROCHLORIDE | | | | | | | |
| | ! | AKORN INC | 0.1% | | A083590 | 001 | |
| NAPROXEN | | | | | | | |
| SUSPENSION;ORAL | | | | | | | |
| **NAPROSYN** | | | | | | | |
| **AB** | **+!** | ATNAHS PHARMA US | **25MG/ML** | | **N018965** | **001** | Mar 23, 1987 |
| **NAPROXEN** | | | | | | | |
| **AB** | | WEST-WARD PHARMS INT | **25MG/ML** | | **A074190** | **001** | Mar 30, 1994 |
| TABLET;ORAL | | | | | | | |
| **NAPROSYN** | | | | | | | |
| **AB** | **+** | ATNAHS PHARMA US | **250MG** | | **N017581** | **002** | |
| **AB** | **+** | | **375MG** | | **N017581** | **003** | |
| **AB** | **+!** | | **500MG** | | **N017581** | **004** | Apr 15, 1982 |
| **NAPROXEN** | | | | | | | |
| **AB** | | AMNEAL PHARMS NY | **250MG** | | **A075927** | **001** | Dec 18, 2001 |
| **AB** | | | **375MG** | | **A075927** | **002** | Dec 18, 2001 |
| **AB** | | | **500MG** | | **A075927** | **003** | Dec 18, 2001 |
| **AB** | | AUROBINDO PHARMA LTD | **250MG** | | **A200429** | **001** | Nov 08, 2011 |
| **AB** | | | **375MG** | | **A200429** | **002** | Nov 08, 2011 |
| **AB** | | | **500MG** | | **A200429** | **003** | Nov 08, 2011 |
| **AB** | | GLENMARK GENERICS | **250MG** | | **A078250** | **001** | Mar 28, 2007 |
| **AB** | | | **375MG** | | **A078250** | **002** | Mar 28, 2007 |
| **AB** | | | **500MG** | | **A078250** | **003** | Mar 28, 2007 |
| **AB** | | INVAGEN PHARMS | **250MG** | | **A091305** | **001** | Aug 24, 2011 |
| **AB** | | | **375MG** | | **A091305** | **002** | Aug 24, 2011 |
| **AB** | | | **500MG** | | **A091305** | **003** | Aug 24, 2011 |
| **AB** | | MARKSANS PHARMA | **250MG** | | **A091416** | **001** | Feb 14, 2011 |
| **AB** | | | **375MG** | | **A091416** | **002** | Feb 14, 2011 |
| **AB** | | | **500MG** | | **A091416** | **003** | Feb 14, 2011 |
| **AB** | | MYLAN | **250MG** | | **A074121** | **001** | Dec 21, 1993 |
| **AB** | | | **375MG** | | **A074121** | **002** | Dec 21, 1993 |
| **AB** | | | **500MG** | | **A074121** | **003** | Dec 21, 1993 |
| **AB** | | PERRIGO R AND D | **250MG** | | **A077339** | **001** | Apr 27, 2005 |
| **AB** | | | **375MG** | | **A077339** | **002** | Apr 27, 2005 |
| **AB** | | | **500MG** | | **A077339** | **003** | Apr 27, 2005 |
| **AB** | | TEVA | **250MG** | | **A074201** | **001** | Dec 21, 1993 |
| **AB** | | | **375MG** | | **A074201** | **002** | Dec 21, 1993 |
| **AB** | | | **500MG** | | **A074201** | **003** | Dec 21, 1993 |
| **AB** | | ZYDUS PHARMS USA | **250MG** | | **A078620** | **001** | Jun 07, 2007 |
| **AB** | | | **375MG** | | **A078620** | **002** | Jun 07, 2007 |
| **AB** | | | **500MG** | | **A078620** | **003** | Jun 07, 2007 |
| TABLET, DELAYED RELEASE;ORAL | | | | | | | |
| **EC-NAPROSYN** | | | | | | | |
| **AB** | **+!** | ATNAHS PHARMA US | **375MG** | | **N020067** | **002** | Oct 14, 1994 |
| **AB** | **+!** | | **500MG** | | **N020067** | **003** | Oct 14, 1994 |
| **NAPROXEN** | | | | | | | |
| **AB** | | INVAGEN PHARMS | **375MG** | | **A091432** | **001** | Sep 19, 2011 |
| **AB** | | | **500MG** | | **A091432** | **002** | Sep 19, 2011 |
| **AB** | | PLIVA | **375MG** | | **A075337** | **001** | May 26, 1999 |
| **AB** | | | **500MG** | | **A075337** | **002** | May 26, 1999 |
| **AB** | | TEVA | **375MG** | | **A075227** | **001** | Jun 30, 1998 |
| **AB** | | | **500MG** | | **A075227** | **002** | Jun 30, 1998 |
| NAPROXEN SODIUM | | | | | | | |
| TABLET;ORAL | | | | | | | |
| **ANAPROX** | | | | | | | |
| **AB** | **+** | ATNAHS PHARMA US | **EQ 250MG BASE** | | **N018164** | **001** | |
| **ANAPROX DS** | | | | | | | |
| **AB** | **+!** | ATNAHS PHARMA US | **EQ 500MG BASE** | | **N018164** | **003** | Sep 30, 1987 |
| **NAPROXEN SODIUM** | | | | | | | |
| **AB** | | AMNEAL PHARMS NY | **EQ 250MG BASE** | | **A078432** | **001** | Apr 25, 2007 |
| **AB** | | | **EQ 500MG BASE** | | **A078432** | **002** | Apr 25, 2007 |
| **AB** | | AUROBINDO PHARMA LTD | **EQ 250MG BASE** | | **A200629** | **001** | Oct 31, 2011 |

NAPROXEN SODIUM

TABLET;ORAL

**NAPROXEN SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **EQ 500MG BASE** | **A200629** | **002** | Oct 31, 2011 |
| **AB** | | DR REDDYS LABS LTD | **EQ 250MG BASE** | **A078486** | **001** | Jul 26, 2007 |
| **AB** | | | **EQ 500MG BASE** | **A078486** | **002** | Jul 26, 2007 |
| **AB** | | GLENMARK PHARMS LTD | **EQ 250MG BASE** | **A078314** | **001** | Apr 27, 2007 |
| **AB** | | | **EQ 500MG BASE** | **A078314** | **002** | Apr 27, 2007 |
| **AB** | | TEVA | **EQ 250MG BASE** | **A074198** | **001** | Dec 21, 1993 |
| **AB** | | | **EQ 500MG BASE** | **A074198** | **002** | Dec 21, 1993 |

TABLET, EXTENDED RELEASE;ORAL

**NAPRELAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | ALVOGEN MALTA | **EQ 375MG BASE** | **N020353** | **001** | Jan 05, 1996 |
| **AB** | **+** | | **EQ 500MG BASE** | **N020353** | **002** | Jan 05, 1996 |
| **AB** | **+!** | | **EQ 750MG BASE** | **N020353** | **003** | Jan 05, 1996 |

**NAPROXEN SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS LABS FL INC | **EQ 375MG BASE** | **A075416** | **002** | Apr 23, 2003 |
| **AB** | | | **EQ 500MG BASE** | **A075416** | **001** | Aug 27, 2002 |
| **AB** | | | **EQ 750MG BASE** | **A075416** | **003** | Aug 11, 2016 |

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET;ORAL

TREXIMET

| | | | | | |
|---|---|---|---|---|---|
| + | PERNIX IRELAND LTD | 60MG;EQ 10MG BASE | N021926 | 002 | May 14, 2015 |
| +! | | 500MG;EQ 85MG BASE | N021926 | 001 | Apr 15, 2008 |

NARATRIPTAN HYDROCHLORIDE

TABLET;ORAL

**AMERGE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | GLAXOSMITHKLINE LLC | **EQ 1MG BASE** | **N020763** | **002** | Feb 10, 1998 |
| **AB** | **+!** | | **EQ 2.5MG BASE** | **N020763** | **001** | Feb 10, 1998 |

**NARATRIPTAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | APOTEX CORP | **EQ 1MG BASE** | **A091373** | **001** | Apr 22, 2011 |
| **AB** | | | **EQ 2.5MG BASE** | **A091373** | **002** | Apr 22, 2011 |
| **AB** | | HERITAGE PHARMS INC | **EQ 1MG BASE** | **A200502** | **001** | Feb 28, 2011 |
| **AB** | | | **EQ 2.5MG BASE** | **A200502** | **002** | Feb 28, 2011 |
| **AB** | | MYLAN PHARMS INC | **EQ 1MG BASE** | **A202431** | **001** | May 31, 2012 |
| **AB** | | | **EQ 2.5MG BASE** | **A202431** | **002** | May 31, 2012 |
| **AB** | | ORCHID HLTHCARE | **EQ 1MG BASE** | **A091441** | **001** | Apr 30, 2012 |
| **AB** | | | **EQ 2.5MG BASE** | **A091441** | **002** | Apr 30, 2012 |
| **AB** | | PADDOCK LLC | **EQ 1MG BASE** | **A091326** | **001** | Jul 08, 2010 |
| **AB** | | | **EQ 2.5MG BASE** | **A091326** | **002** | Jul 08, 2010 |
| **AB** | | SANDOZ | **EQ 1MG BASE** | **A090288** | **001** | Jul 07, 2010 |
| **AB** | | | **EQ 2.5MG BASE** | **A090288** | **002** | Jul 07, 2010 |
| **AB** | | SUN PHARM INDS LTD | **EQ 2.5MG BASE** | **A091552** | **001** | Feb 14, 2011 |
| **AB** | | TEVA PHARMS | **EQ 1MG BASE** | **A078751** | **001** | Jul 07, 2010 |
| **AB** | | | **EQ 2.5MG BASE** | **A078751** | **002** | Jul 07, 2010 |
| **AB** | | WEST-WARD PHARMS INT | **EQ 1MG BASE** | **A090381** | **001** | Jul 07, 2010 |
| **AB** | | | **EQ 2.5MG BASE** | **A090381** | **002** | Jul 07, 2010 |

NATAMYCIN

SUSPENSION;OPHTHALMIC

NATACYN

| | | | | | |
|---|---|---|---|---|---|
| +! | NOVARTIS PHARMS CORP | 5% | N050514 | 001 | |

NATEGLINIDE

TABLET;ORAL

**NATEGLINIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALVOGEN MALTA | **60MG** | **A205055** | **001** | Dec 11, 2015 |
| **AB** | | | **120MG** | **A205055** | **002** | Dec 11, 2015 |
| **AB** | | DR REDDYS LABS LTD | **60MG** | **A077461** | **001** | Sep 09, 2009 |
| **AB** | | | **120MG** | **A077461** | **002** | Sep 09, 2009 |
| **AB** | | PAR PHARM | **60MG** | **A077463** | **001** | Sep 09, 2009 |
| **AB** | | | **120MG** | **A077463** | **002** | Sep 09, 2009 |
| **AB** | | WATSON LABS | **60MG** | **A077462** | **001** | Mar 30, 2011 |
| **AB** | | | **120MG** | **A077462** | **002** | Mar 30, 2011 |
| **AB** | | ZYDUS PHARMS USA INC | **60MG** | **A205248** | **001** | Jul 06, 2016 |
| **AB** | | | **120MG** | **A205248** | **002** | Jul 06, 2016 |

**STARLIX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | NOVARTIS | **60MG** | **N021204** | **001** | Dec 22, 2000 |
| **AB** | **+!** | | **120MG** | **N021204** | **002** | Dec 22, 2000 |

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL

BYSTOLIC

| | | | | | |
|---|---|---|---|---|---|
| + | FOREST LABS | EQ 2.5MG BASE | N021742 | 002 | Dec 17, 2007 |
| + | | EQ 5MG BASE | N021742 | 003 | Dec 17, 2007 |
| + | | EQ 10MG BASE | N021742 | 004 | Dec 17, 2007 |
| +! | | EQ 20MG BASE | N021742 | 005 | Oct 08, 2008 |

NEBIVOLOL HYDROCHLORIDE; VALSARTAN

TABLET;ORAL

BYVALSON

| | | | | | |
|---|---|---|---|---|---|
| +! | FOREST LABS LLC | EQ 5MG BASE;80MG | N206302 | 001 | Jun 03, 2016 |

NEDOCROMIL SODIUM

SOLUTION/DROPS;OPHTHALMIC

**ALOCRIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **+!** | ALLERGAN | **2%** | **N021009** | **001** | Dec 08, 1999 |

**NEDOCROMIL SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | AKORN | **2%** | **A090638** | **001** | Aug 22, 2012 |

NEFAZODONE HYDROCHLORIDE

TABLET;ORAL

NEFAZODONE HYDROCHLORIDE

| | | | | | |
|---|---|---|---|---|---|
| | TEVA | 50MG | A076037 | 001 | Sep 16, 2003 |
| | | 100MG | A076037 | 002 | Sep 16, 2003 |
| | | 150MG | A076037 | 003 | Sep 16, 2003 |
| | | 200MG | A076037 | 004 | Sep 16, 2003 |
| ! | | 250MG | A076037 | 005 | Sep 16, 2003 |

NELARABINE

INJECTABLE;IV (INFUSION)

ARRANON

| | | | | | |
|---|---|---|---|---|---|
| +! | NOVARTIS PHARMS CORP | 250MG/50ML (5MG/ML) | N021877 | 001 | Oct 28, 2005 |

NELFINAVIR MESYLATE

TABLET;ORAL

VIRACEPT

| | | | | | |
|---|---|---|---|---|---|
| +! | AGOURON PHARMS | EQ 250MG BASE | N020779 | 001 | Mar 14, 1997 |
| +! | | EQ 625MG BASE | N021503 | 001 | Apr 30, 2003 |

NEOMYCIN SULFATE

TABLET;ORAL

**NEOMYCIN SULFATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | BRECKENRIDGE PHARM | **500MG** | **A065468** | **001** | Mar 29, 2010 |
| **AA** | | LANNETT HOLDINGS INC | **500MG** | **A204435** | **001** | Jun 10, 2016 |
| **AA** | **!** | TEVA | **500MG** | **A060304** | **001** | |
| **AA** | | X GEN PHARMS | **500MG** | **A065220** | **001** | Jul 28, 2006 |

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION;IRRIGATION

**NEOMYCIN AND POLYMYXIN B SULFATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | WATSON LABS | **EQ 40MG BASE/ML;200,000 UNITS/ML** | **A062664** | **001** | Apr 08, 1986 |
| **AT** | | X GEN PHARMS | **EQ 40MG BASE/ML;200,000 UNITS/ML** | **A065106** | **001** | Jan 31, 2006 |
| **AT** | | | **EQ 40MG BASE/ML;200,000 UNITS/ML** | **A065108** | **001** | Jan 31, 2006 |

**NEOSPORIN G.U. IRRIGANT**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **!** | MONARCH PHARMS | **EQ 40MG BASE/ML;200,000 UNITS/ML** | **A060707** | **001** | |

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

**BLOXIVERZ**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | ECLAT PHARMS LLC | **5MG/10ML (0.5MG/ML)** | **N204078** | **001** | May 31, 2013 |
| **AP** | **+!** | | **10MG/10ML (1MG/ML)** | **N204078** | **002** | May 31, 2013 |

**NEOSTIGMINE METHYLSULFATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AMPHASTAR PHARMS INC | **5MG/10ML (0.5MG/ML)** | **A209933** | **001** | Sep 25, 2017 |
| **AP** | | | **10MG/10ML (1MG/ML)** | **A209933** | **002** | Sep 25, 2017 |
| **AP** | | EUROHLTH INTL SARL | **5MG/10ML (0.5MG/ML)** | **A207042** | **001** | Dec 28, 2015 |
| **AP** | | | **10MG/10ML (1MG/ML)** | **A207042** | **002** | Dec 28, 2015 |
| **AP** | | PAR STERILE PRODUCTS | **5MG/10ML (0.5MG/ML)** | **A208405** | **001** | Apr 26, 2017 |
| **AP** | | | **10MG/10ML (1MG/ML)** | **A208405** | **002** | Apr 26, 2017 |
| | | FRESENIUS KABI USA | 5MG/10ML (0.5MG/ML) | N203629 | 001 | Jan 08, 2015 |
| | | | 10MG/10ML (1MG/ML) | N203629 | 002 | Jan 08, 2015 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| NEPAFENAC | | | | | | | |
| SUSPENSION/DROPS;OPHTHALMIC | | | | | | | |
| ILEVRO | | | | | | | |
| | +! | NOVARTIS PHARMS CORP | 0.3% | N203491 | 001 | Oct 16, 2012 |
| NEVANAC | | | | | | | |
| | +! | NOVARTIS PHARMS CORP | 0.1% | N021862 | 001 | Aug 19, 2005 |
| NERATINIB MALEATE | | | | | | | |
| TABLET;ORAL | | | | | | | |
| NERLYNX | | | | | | | |
| | +! | PUMA BIOTECH | EQ 40MG BASE | N208051 | 001 | Jul 17, 2017 |
| NESIRITIDE RECOMBINANT | | | | | | | |
| FOR SOLUTION;INTRAVENOUS | | | | | | | |
| NATRECOR | | | | | | | |
| | +! | SCIOS LLC | 1.5MG/VIAL | N020920 | 001 | Aug 10, 2001 |
| NETARSUDIL DIMESYLATE | | | | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | | | | |
| RHOPRESSA | | | | | | | |
| | +! | AERIE PHARMS INC | EQ 0.02% BASE | N208254 | 001 | Dec 18, 2017 |
| NETUPITANT; PALONOSETRON HYDROCHLORIDE | | | | | | | |
| CAPSULE;ORAL | | | | | | | |
| AKYNZEO | | | | | | | |
| | +! | HELSINN HLTHCARE | 300MG;EQ 0.5MG BASE | N205718 | 001 | Oct 10, 2014 |
| NEVIRAPINE | | | | | | | |
| SUSPENSION;ORAL | | | | | | | |
| **NEVIRAPINE** | | | | | | | |
| **AA** | | AUROBINDO | **50MG/5ML** | **A077702** | **001** | May 22, 2012 |
| **AA** | | CIPLA LTD | **50MG/5ML** | **A207684** | **001** | Aug 03, 2017 |
| **VIRAMUNE** | | | | | | | |
| **AA** | **+!** | BOEHRINGER INGELHEIM | **50MG/5ML** | **N020933** | **001** | Sep 11, 1998 |
| TABLET;ORAL | | | | | | | |
| **NEVIRAPINE** | | | | | | | |
| **AB** | | APOTEX INC | **200MG** | **A203021** | **001** | May 22, 2012 |
| **AB** | | AUROBINDO | **200MG** | **A077521** | **001** | May 22, 2012 |
| **AB** | | CIPLA | **200MG** | **A077956** | **001** | May 22, 2012 |
| **AB** | | HETERO LABS LTD III | **200MG** | **A078584** | **001** | May 22, 2012 |
| **AB** | | MICRO LABS LTD | **200MG** | **A203080** | **001** | May 22, 2012 |
| **AB** | | MYLAN LABS | **200MG** | **A078864** | **001** | May 22, 2012 |
| **AB** | | MYLAN PHARMS INC | **200MG** | **A202523** | **001** | May 22, 2012 |
| **AB** | | PRINSTON INC | **200MG** | **A078644** | **001** | May 22, 2012 |
| **AB** | | STRIDES PHARMA | **200MG** | **A078195** | **001** | May 22, 2012 |
| **AB** | | TECH ORGANIZED | **200MG** | **A203176** | **001** | May 22, 2012 |
| **VIRAMUNE** | | | | | | | |
| **AB** | **+!** | BOEHRINGER INGELHEIM | **200MG** | **N020636** | **001** | Jun 21, 1996 |
| TABLET, EXTENDED RELEASE;ORAL | | | | | | | |
| **NEVIRAPINE** | | | | | | | |
| **AB** | | ALVOGEN MALTA | **100MG** | **A204621** | **002** | Nov 09, 2015 |
| **AB** | | | **400MG** | **A204621** | **001** | Jul 10, 2015 |
| **AB** | | APOTEX INC | **400MG** | **A205258** | **001** | Apr 03, 2014 |
| **AB** | | AUROBINDO PHARMA LTD | **100MG** | **A208616** | **001** | Nov 23, 2016 |
| **AB** | | | **400MG** | **A207698** | **001** | Feb 28, 2017 |
| **AB** | | CIPLA LTD | **400MG** | **A206448** | **001** | Oct 15, 2015 |
| **AB** | | MACLEODS PHARMS LTD | **400MG** | **A206879** | **001** | Oct 06, 2017 |
| **AB** | | MYLAN PHARMS INC | **100MG** | **A206271** | **001** | Nov 09, 2015 |
| **AB** | | | **400MG** | **A205651** | **001** | Oct 27, 2014 |
| **AB** | | SANDOZ INC | **400MG** | **A203411** | **001** | Apr 03, 2014 |
| **AB** | | TECH ORGANIZED | **100MG** | **A207467** | **001** | Jul 31, 2017 |
| **AB** | | | **400MG** | **A207467** | **002** | Jul 31, 2017 |
| **VIRAMUNE XR** | | | | | | | |
| **AB** | **+** | BOEHRINGER INGELHEIM | **100MG** | **N201152** | **002** | Nov 08, 2012 |
| **AB** | **+!** | | **400MG** | **N201152** | **001** | Mar 25, 2011 |

NIACIN

TABLET;ORAL

**NIACIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | WOCKHARDT | **500MG** | **A081134** | **001** | Apr 28, 1992 |

**NIACOR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **!** | AVONDALE PHARMS | **500MG** | **A040378** | **001** | May 03, 2000 |

TABLET, EXTENDED RELEASE;ORAL

**NIACIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AMNEAL PHARMS | **500MG** | **A203578** | **001** | Jul 24, 2015 |
| **AB** | | | **750MG** | **A204178** | **001** | Dec 11, 2015 |
| **AB** | | | **1GM** | **A203578** | **002** | Jul 24, 2015 |
| **AB** | | BARR | **500MG** | **A076378** | **001** | Apr 26, 2005 |
| **AB** | | | **750MG** | **A076378** | **002** | Apr 26, 2005 |
| **AB** | | | **1GM** | **A076250** | **001** | Apr 14, 2005 |
| **AB** | | LANNETT CO INC | **500MG** | **A203899** | **001** | Jun 16, 2017 |
| **AB** | | | **1GM** | **A203899** | **002** | Jun 16, 2017 |
| **AB** | | LUPIN LTD | **500MG** | **A090860** | **001** | Mar 20, 2014 |
| **AB** | | | **750MG** | **A090892** | **001** | Mar 20, 2014 |
| **AB** | | | **1GM** | **A090446** | **001** | Mar 20, 2014 |
| **AB** | | SUN PHARMA GLOBAL | **500MG** | **A200484** | **001** | Apr 23, 2014 |
| **AB** | | | **750MG** | **A201273** | **001** | Apr 23, 2014 |
| **AB** | | | **1GM** | **A200484** | **002** | Apr 23, 2014 |

**NIASPAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | ABBVIE | **500MG** | **N020381** | **002** | Jul 28, 1997 |
| **AB** | **+!** | | **750MG** | **N020381** | **003** | Jul 28, 1997 |
| **AB** | **+!** | | **1GM** | **N020381** | **004** | Jul 28, 1997 |

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL

**NICARDIPINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ANI PHARMS INC | **20MG** | **A074439** | **001** | Dec 10, 1996 |
| **AB** | | | **20MG** | **A074540** | **001** | Oct 28, 1996 |
| **AB** | | | **30MG** | **A074439** | **002** | Dec 10, 1996 |
| **AB** | | | **30MG** | **A074540** | **002** | Oct 28, 1996 |
| **AB** | | EPIC PHARMA | **20MG** | **A074928** | **001** | Mar 19, 1998 |
| **AB** | | | **30MG** | **A074928** | **002** | Mar 19, 1998 |
| **AB** | | MYLAN | **20MG** | **A074642** | **001** | Jul 18, 1996 |
| **AB** | **!** | | **30MG** | **A074642** | **002** | Jul 18, 1996 |

INJECTABLE;INJECTION

**CARDENE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | CHIESI USA INC | **25MG/10ML (2.5MG/ML)** | **N019734** | **001** | Jan 30, 1992 |

**NICARDIPINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | EXELA PHARMA SCIENCE | **25MG/10ML (2.5MG/ML)** | **N022276** | **001** | Jul 24, 2008 |
| **AP** | | LUITPOLD PHARMS INC | **25MG/10ML (2.5MG/ML)** | **A090534** | **001** | Nov 17, 2009 |
| **AP** | | MYLAN INSTITUTIONAL | **25MG/10ML (2.5MG/ML)** | **A090664** | **001** | Nov 17, 2009 |
| **AP** | | NAVINTA LLC | **25MG/10ML (2.5MG/ML)** | **A090125** | **001** | Nov 17, 2009 |
| **AP** | | SUN PHARMA GLOBAL | **25MG/10ML (2.5MG/ML)** | **N078405** | **001** | Nov 17, 2009 |
| **AP** | | WEST-WARD PHARMS INT | **25MG/10ML (2.5MG/ML)** | **A078714** | **001** | Dec 28, 2009 |
| **AP** | | WOCKHARDT | **25MG/10ML (2.5MG/ML)** | **A090671** | **001** | Nov 17, 2009 |

INJECTABLE;INTRAVENOUS

CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | CHIESI USA INC | 40MG/200ML (0.2MG/ML) | N019734 | 004 | Nov 07, 2008 |

CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | CHIESI USA INC | 20MG/200ML (0.1MG/ML) | N019734 | 003 | Jul 31, 2008 |

CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | CHIESI USA INC | 20MG/200ML (0.1MG/ML) | N019734 | 002 | Jul 31, 2008 |

CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | CHIESI USA INC | 40MG/200ML (0.2MG/ML) | N019734 | 005 | Nov 07, 2008 |

NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE

| | | | | | | |
|---|---|---|---|---|---|---|
| | | EXELA PHARMA SCIENCE | 20MG/200ML (0.1MG/ML) | N022276 | 002 | Apr 07, 2016 |
| | | | 40MG/200ML (0.2MG/ML) | N022276 | 003 | Apr 07, 2016 |

NICOTINE

INHALANT;ORAL

NICOTROL

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | PHARMACIA AND UPJOHN | 4MG/CARTRIDGE | N020714 | 001 | May 02, 1997 |

SPRAY, METERED;NASAL

NICOTROL

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | PFIZER INC | 0.5MG/SPRAY | N020385 | 001 | Mar 22, 1996 |

NIFEDIPINE

CAPSULE;ORAL

**NIFEDIPINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS ELIZABETH | **10MG** | **A072579** | **001** | Jan 08, 1991 |
| **AB** | | | **20MG** | **A072556** | **001** | Sep 20, 1990 |
| **AB** | | HERITAGE PHARMA | **10MG** | **A202644** | **001** | Apr 25, 2013 |
| **AB** | | | **20MG** | **A202644** | **002** | Apr 25, 2013 |
| **AB** | | INTERGEL PHARM | **10MG** | **A072781** | **001** | Jul 30, 1993 |
| **AB** | | VALIDUS PHARMS | **10MG** | **A073250** | **001** | Oct 08, 1991 |
| **AB** | | | **20MG** | **A074045** | **001** | Apr 30, 1992 |

**PROCARDIA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | PFIZER | **10MG** | **N018482** | **001** | |

TABLET, EXTENDED RELEASE;ORAL

**ADALAT CC**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB1** | **+** | ALVOGEN | **30MG** | **N020198** | **001** | Apr 21, 1993 |
| **AB1** | **+!** | | **60MG** | **N020198** | **002** | Apr 21, 1993 |
| **AB1** | **+!** | | **90MG** | **N020198** | **003** | Apr 21, 1993 |

**AFEDITAB CR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB1** | | WATSON LABS | **60MG** | **A075659** | **001** | Oct 26, 2001 |
| **AB1** | | WATSON LABS TEVA | **30MG** | **A075128** | **001** | Mar 10, 2000 |

**NIFEDIPINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB1** | | MYLAN | **30MG** | **A201071** | **001** | Dec 03, 2010 |
| **AB1** | | | **60MG** | **A201071** | **002** | Dec 03, 2010 |
| **AB1** | | | **90MG** | **A201071** | **003** | Dec 03, 2010 |
| **AB1** | | NOVAST LABS LTD | **30MG** | **A202987** | **001** | Aug 25, 2016 |
| **AB1** | | | **60MG** | **A202987** | **002** | Aug 25, 2016 |
| **AB1** | | | **90MG** | **A202987** | **003** | Aug 25, 2016 |
| **AB1** | | PAR PHARM | **30MG** | **A077899** | **001** | Dec 13, 2006 |
| **AB1** | | | **60MG** | **A077899** | **002** | Dec 13, 2006 |
| **AB1** | | | **90MG** | **A077899** | **003** | May 25, 2012 |
| **AB1** | | VALEANT PHARMS NORTH | **30MG** | **A075269** | **001** | Dec 04, 2000 |
| **AB1** | | | **60MG** | **A075269** | **002** | Dec 04, 2000 |
| **AB1** | | | **90MG** | **A076070** | **001** | Aug 16, 2002 |
| **AB2** | | MYLAN | **30MG** | **A090649** | **001** | Jun 21, 2010 |
| **AB2** | | | **60MG** | **A090649** | **002** | Jun 21, 2010 |
| **AB2** | | | **90MG** | **A090649** | **003** | Jun 21, 2010 |
| **AB2** | | OSMOTICA PHARM US | **30MG** | **A077127** | **001** | Nov 21, 2005 |
| **AB2** | | | **60MG** | **A077127** | **002** | Nov 21, 2005 |
| **AB2** | | | **90MG** | **A077410** | **001** | Oct 03, 2007 |
| **AB2** | | TWI PHARMS INC | **30MG** | **A203126** | **001** | Apr 03, 2014 |
| **AB2** | | | **60MG** | **A203126** | **002** | Apr 03, 2014 |
| **AB2** | | | **90MG** | **A203126** | **003** | Apr 03, 2014 |
| **AB2** | | VALEANT PHARMS NORTH | **30MG** | **A075289** | **002** | Feb 06, 2001 |
| **AB2** | | | **60MG** | **A075289** | **001** | Sep 27, 2000 |
| **AB2** | | ZYDUS PHARMS USA INC | **30MG** | **A210012** | **001** | Dec 19, 2017 |
| **AB2** | | | **60MG** | **A210012** | **002** | Dec 19, 2017 |
| **AB2** | | | **90MG** | **A210012** | **003** | Dec 19, 2017 |

**PROCARDIA XL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB2** | **+** | PFIZER | **30MG** | **N019684** | **001** | Sep 06, 1989 |
| **AB2** | **+** | | **60MG** | **N019684** | **002** | Sep 06, 1989 |
| **AB2** | **+!** | | **90MG** | **N019684** | **003** | Sep 06, 1989 |

NILOTINIB HYDROCHLORIDE MONOHYDRATE

CAPSULE;ORAL

TASIGNA

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | NOVARTIS | EQ 150MG BASE | N022068 | 002 | Jun 17, 2010 |
| | +! | | EQ 200MG BASE | N022068 | 001 | Oct 29, 2007 |

NILUTAMIDE

TABLET;ORAL

**NILANDRON**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | CONCORDIA PHARMS INC | **150MG** | **N020169** | **002** | Apr 30, 1999 |

**NILUTAMIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ANI PHARMS INC | **150MG** | **A207631** | **001** | Jul 15, 2016 |

NIMODIPINE

CAPSULE;ORAL

**NIMODIPINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **!** | BIONPHARMA INC | **30MG** | **A076740** | **001** | Jan 17, 2008 |
| **AB** | | HERITAGE PHARMS INC | **30MG** | **A077811** | **001** | May 02, 2007 |
| **AB** | | SOFGEN PHARMS | **30MG** | **A201832** | **001** | Jul 24, 2015 |
| **AB** | | SUN PHARM INDS INC | **30MG** | **A077067** | **001** | Apr 17, 2007 |
| **AB** | | THEPHARMANETWORK LLC | **30MG** | **A090103** | **001** | Apr 07, 2014 |

SOLUTION;ORAL

NYMALIZE

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ARBOR PHARMS LLC | 60MG/20ML | N203340 | 001 | May 10, 2013 |

NINTEDANIB ESYLATE

CAPSULE;ORAL

OFEV

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | BOEHRINGER INGELHEIM | EQ 100MG BASE | N205832 | 001 | Oct 15, 2014 |
| | +! | | EQ 150MG BASE | N205832 | 002 | Oct 15, 2014 |

NIRAPARIB TOSYLATE

CAPSULE;ORAL

ZEJULA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | TESARO INC | EQ 100MG BASE | N208447 | 001 | Mar 27, 2017 |

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL

**NISOLDIPINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | MYLAN | **8.5MG** | **A091001** | **001** | Jan 26, 2011 |
| **AB** | | | **17MG** | **A091001** | **002** | Jan 26, 2011 |
| **AB** | | | **34MG** | **A091001** | **004** | Jan 26, 2011 |

**SULAR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | COVIS PHARMA BV | **8.5MG** | **N020356** | **008** | Jan 02, 2008 |
| **AB** | **+!** | | **17MG** | **N020356** | **007** | Jan 02, 2008 |
| **AB** | **+!** | | **34MG** | **N020356** | **005** | Jan 02, 2008 |

NISOLDIPINE

| | | | | | | |
|---|---|---|---|---|---|---|
| | | MYLAN | 20MG | A079051 | 001 | Jul 25, 2008 |
| | | | 25.5MG | A091001 | 003 | Jan 26, 2011 |
| | ! | | 30MG | A079051 | 002 | Jul 25, 2008 |
| | ! | | 40MG | A079051 | 003 | Jul 25, 2008 |

NITAZOXANIDE

FOR SUSPENSION;ORAL

ALINIA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ROMARK | 100MG/5ML | N021498 | 001 | Nov 22, 2002 |

TABLET;ORAL

ALINIA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ROMARK | 500MG | N021497 | 001 | Jul 21, 2004 |

NITISINONE

CAPSULE;ORAL

ORFADIN

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | SWEDISH ORPHAN | 2MG | N021232 | 001 | Jan 18, 2002 |
| | + | | 5MG | N021232 | 002 | Jan 18, 2002 |
| | + | | 10MG | N021232 | 003 | Jan 18, 2002 |
| | +! | | 20MG | N021232 | 004 | Jun 13, 2016 |

SUSPENSION;ORAL

ORFADIN

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | SWEDISH ORPHAN | 4MG/ML | N206356 | 001 | Apr 22, 2016 |

TABLET;ORAL

NITYR

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | CYCLE PHARMS LTD | 2MG | N209449 | 001 | Jul 26, 2017 |
| | + | | 5MG | N209449 | 002 | Jul 26, 2017 |
| | +! | | 10MG | N209449 | 003 | Jul 26, 2017 |

NITRIC OXIDE

GAS;INHALATION

INOMAX

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | MALLINCKRODT HOSP | 800PPM | N020845 | 003 | Dec 23, 1999 |

NITROFURANTOIN

SUSPENSION;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **FURADANTIN** | | | | | | |
| **AB** | **+!** | CASPER PHARMA LLC | **25MG/5ML** | **N009175** | **001** | |
| **NITROFURANTOIN** | | | | | | |
| **AB** | | ACTAVIS MID ATLANTIC | **25MG/5ML** | **A205180** | **001** | May 03, 2016 |
| **AB** | | AMNEAL PHARMS | **25MG/5ML** | **A201679** | **001** | May 11, 2011 |
| **AB** | | NOSTRUM LABS INC | **25MG/5ML** | **A201355** | **001** | Aug 14, 2013 |
| **AB** | | NOVEL LABS INC | **25MG/5ML** | **A201693** | **001** | Sep 08, 2014 |

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **MACRODANTIN** | | | | | | |
| **AB** | **+** | ALVOGEN MALTA | **25MG** | **N016620** | **003** | |
| **AB** | **+** | | **50MG** | **N016620** | **001** | |
| **AB** | **+!** | | **100MG** | **N016620** | **002** | |
| **NITROFURANTOIN** | | | | | | |
| **AB** | | ACTAVIS LABS FL INC | **25MG** | **A091095** | **001** | Jun 18, 2015 |
| **AB** | | | **50MG** | **A091095** | **002** | Jun 18, 2015 |
| **AB** | | | **100MG** | **A091095** | **003** | Jun 18, 2015 |
| **AB** | | IMPAX LABS INC | **50MG** | **A073671** | **001** | Jan 28, 1993 |
| **AB** | | | **100MG** | **A073652** | **001** | Jan 28, 1993 |
| **AB** | | MYLAN | **50MG** | **A074967** | **001** | Jul 09, 1997 |
| **AB** | | | **100MG** | **A077025** | **001** | Aug 18, 2004 |
| **AB** | | SUN PHARM INDUSTRIES | **25MG** | **A201722** | **001** | Feb 16, 2016 |
| **AB** | | | **50MG** | **A201722** | **002** | Feb 16, 2016 |
| **AB** | | | **100MG** | **A201722** | **003** | Feb 16, 2016 |
| **AB** | | ZYDUS PHARMS USA INC | **50MG** | **A205005** | **001** | Dec 12, 2017 |
| **AB** | | | **100MG** | **A205005** | **002** | Dec 12, 2017 |

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **MACROBID** | | | | | | |
| **AB** | **+!** | ALVOGEN MALTA | **75MG;25MG** | **N020064** | **001** | Dec 24, 1991 |
| **NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)** | | | | | | |
| **AB** | | AMNEAL PHARMS | **75MG;25MG** | **A207372** | **001** | May 15, 2017 |
| **AB** | | MYLAN | **75MG;25MG** | **A076648** | **001** | Mar 22, 2004 |
| **AB** | | SANDOZ | **75MG;25MG** | **A077066** | **001** | Apr 05, 2005 |
| **AB** | | WATSON LABS INC | **75MG;25MG** | **A202250** | **001** | Jul 08, 2015 |

NITROGLYCERIN

AEROSOL, METERED;SUBLINGUAL

| | | | | | | |
|---|---|---|---|---|---|---|
| NITROMIST | | | | | | |
| | +! | MIST PHARMS LLC | 0.4MG/SPRAY | N021780 | 001 | Nov 02, 2006 |

FILM, EXTENDED RELEASE;TRANSDERMAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **MINITRAN** | | | | | | |
| **AB1** | | MEDICIS | **0.4MG/HR** | **A089773** | **001** | Aug 30, 1996 |
| **AB1** | | VALEANT PHARMS | **0.1MG/HR** | **A089771** | **001** | Aug 30, 1996 |
| **AB1** | | | **0.6MG/HR** | **A089774** | **001** | Aug 30, 1996 |
| **AB1** | | VALEANT PHARMS NORTH | **0.2MG/HR** | **A089772** | **001** | Aug 30, 1996 |
| **NITRO-DUR** | | | | | | |
| **AB1** | **+!** | USPHARMA | **0.1MG/HR** | **N020145** | **001** | Apr 04, 1995 |
| **AB1** | **+!** | | **0.2MG/HR** | **N020145** | **002** | Apr 04, 1995 |
| **AB1** | **+!** | | **0.4MG/HR** | **N020145** | **004** | Apr 04, 1995 |
| **AB1** | **+!** | | **0.6MG/HR** | **N020145** | **005** | Apr 04, 1995 |
| **NITROGLYCERIN** | | | | | | |
| **AB2** | | HERCON PHARM | **0.2MG/HR** | **A089884** | **001** | Oct 30, 1998 |
| **AB2** | | | **0.4MG/HR** | **A089885** | **001** | Oct 30, 1998 |
| **AB2** | | | **0.6MG/HR** | **A089886** | **001** | Oct 30, 1998 |
| **AB2** | **!** | MYLAN TECHNOLOGIES | **0.2MG/HR** | **A074559** | **003** | Aug 30, 1996 |
| **AB2** | **!** | | **0.4MG/HR** | **A074559** | **002** | Aug 30, 1996 |
| **AB2** | **!** | | **0.6MG/HR** | **A074559** | **001** | Aug 30, 1996 |
| NITRO-DUR | | | | | | |
| | +! | USPHARMA | 0.3MG/HR | N020145 | 003 | Apr 04, 1995 |
| | +! | | 0.8MG/HR | N020145 | 006 | Apr 04, 1995 |
| NITROGLYCERIN | | | | | | |
| | ! | MYLAN TECHNOLOGIES | 0.1MG/HR | A074559 | 004 | Feb 06, 1998 |

INJECTABLE;INJECTION

| | | | | | | |
|---|---|---|---|---|---|---|
| **NITROGLYCERIN IN DEXTROSE 5%** | | | | | | |
| **AP** | **+!** | BAXTER HLTHCARE | **10MG/100ML** | **N019970** | **001** | Dec 29, 1989 |
| **AP** | **+!** | | **20MG/100ML** | **N019970** | **002** | Dec 29, 1989 |

NITROGLYCERIN

INJECTABLE;INJECTION

**NITROGLYCERIN IN DEXTROSE 5%**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | | **40MG/100ML** | **N019970** | **003** | Dec 29, 1989 |
| **AP** | | HOSPIRA | **10MG/100ML** | **A071846** | **001** | Aug 31, 1990 |
| **AP** | | | **20MG/100ML** | **A071847** | **001** | Aug 31, 1990 |
| **AP** | | | **40MG/100ML** | **A071848** | **001** | Aug 31, 1990 |

NITROGLYCERIN

| | | | | | |
|---|---|---|---|---|---|
| | ! | LUITPOLD | 5MG/ML | A072034 | 001 | May 24, 1988 |

OINTMENT;INTRA-ANAL

RECTIV

| | | | | | |
|---|---|---|---|---|---|
| | +! | FOREST LABS INC | 0.4% | N021359 | 001 | Jun 21, 2011 |

OINTMENT;TRANSDERMAL

NITROGLYCERIN

| | | | | | |
|---|---|---|---|---|---|
| | ! | FOUGERA PHARMS INC | 2% | A087355 | 001 | Jul 08, 1988 |

POWDER;SUBLINGUAL

GONITRO

| | | | | | |
|---|---|---|---|---|---|
| | +! | POHL BOSKAMP | 0.4MG/PACKET | N208424 | 001 | Jun 08, 2016 |

SPRAY, METERED;SUBLINGUAL

**NITROGLYCERIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | PERRIGO ISRAEL | **0.4MG/SPRAY** | **A091496** | **001** | Sep 20, 2013 |

**NITROLINGUAL PUMPSPRAY**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | POHL BOSKAMP | **0.4MG/SPRAY** | **N018705** | **002** | Jan 10, 1997 |

TABLET;SUBLINGUAL

**NITROGLYCERIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS LABS FL INC | **0.3MG** | **A203693** | **001** | Oct 16, 2017 |
| **AB** | | | **0.4MG** | **A203693** | **002** | Oct 16, 2017 |
| **AB** | | | **0.6MG** | **A203693** | **003** | Oct 16, 2017 |
| **AB** | | DR REDDYS LABS INC | **0.3MG** | **A208191** | **001** | Aug 26, 2016 |
| **AB** | | | **0.4MG** | **A208191** | **002** | Aug 26, 2016 |
| **AB** | | | **0.6MG** | **A208191** | **003** | Aug 26, 2016 |
| **AB** | | GLENMARK PHARMS LTD | **0.3MG** | **A206391** | **001** | Sep 19, 2017 |
| **AB** | | | **0.4MG** | **A206391** | **002** | Sep 19, 2017 |
| **AB** | | | **0.6MG** | **A206391** | **003** | Sep 19, 2017 |

**NITROSTAT**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | PFIZER PHARMS | **0.3MG** | **N021134** | **001** | May 01, 2000 |
| **AB** | **+** | | **0.4MG** | **N021134** | **002** | May 01, 2000 |
| **AB** | **+!** | | **0.6MG** | **N021134** | **003** | May 01, 2000 |

NIZATIDINE

CAPSULE;ORAL

**NIZATIDINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ANI PHARMS INC | **150MG** | **A075668** | **001** | Sep 12, 2002 |
| **AB** | | | **300MG** | **A075668** | **002** | Sep 12, 2002 |
| **AB** | | DR REDDYS LABS LTD | **150MG** | **A077314** | **001** | Sep 15, 2005 |
| **AB** | | | **300MG** | **A077314** | **002** | Sep 15, 2005 |
| **AB** | | GLENMARK GENERICS | **150MG** | **A090618** | **001** | Jul 15, 2011 |
| **AB** | | | **300MG** | **A090618** | **002** | Jul 15, 2011 |
| **AB** | | MYLAN PHARMS INC | **150MG** | **A075806** | **001** | Jul 05, 2002 |
| **AB** | **!** | | **300MG** | **A075806** | **002** | Jul 05, 2002 |
| **AB** | | SANDOZ | **150MG** | **A076178** | **001** | Jul 05, 2002 |
| **AB** | | | **300MG** | **A076178** | **002** | Jul 05, 2002 |
| **AB** | | WATSON LABS | **150MG** | **A075616** | **001** | Jul 09, 2002 |
| **AB** | | | **300MG** | **A075616** | **002** | Jul 09, 2002 |

SOLUTION;ORAL

NIZATIDINE

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | AMNEAL PHARMS | 15MG/ML | A090576 | 001 | Nov 18, 2009 |

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

**LEVOPHED**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | HOSPIRA | **EQ 1MG BASE/ML** | **N007513** | **001** | |

**NOREPINEPHRINE BITARTRATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | BAXTER HLTHCARE CORP | **EQ 1MG BASE/ML** | **A040859** | **001** | Mar 27, 2012 |
| **AP** | | TEVA PHARMS USA | **EQ 1MG BASE/ML** | **A040455** | **001** | Mar 03, 2003 |
| **AP** | | WEST-WARD PHARMS INT | **EQ 1MG BASE/ML** | **A040462** | **001** | Oct 31, 2003 |

NORETHINDRONE

TABLET;ORAL-28

| | | | | | | |
|---|---|---|---|---|---|---|
| **CAMILA** | | | | | | |
| **AB1** | | MAYNE PHARMA | **0.35MG** | **A076177** | **001** | Oct 21, 2002 |
| **HEATHER** | | | | | | |
| **AB1** | | GLENMARK GENERICS | **0.35MG** | **A090454** | **001** | Apr 23, 2010 |
| **INCASSIA** | | | | | | |
| **AB1** | | AUROBINDO PHARMA LTD | **0.35MG** | **A207304** | **001** | Sep 23, 2016 |
| **NOR-QD** | | | | | | |
| **AB1** | **+!** | APIL | **0.35MG** | **N017060** | **001** | |
| **NORETHINDRONE** | | | | | | |
| **AB1** | | ACCORD HLTHCARE | **0.35MG** | **A206807** | **001** | Dec 13, 2016 |
| **AB1** | | AMNEAL PHARMS | **0.35MG** | **A202260** | **001** | Aug 01, 2013 |
| **AB1** | | LUPIN LTD | **0.35MG** | **A091325** | **001** | Sep 19, 2011 |
| **AB1** | | MYLAN LABS LTD | **0.35MG** | **A201483** | **001** | Jun 24, 2013 |
| **AB1** | | NOVAST LABS LTD | **0.35MG** | **A202014** | **001** | Sep 13, 2013 |
| **ERRIN** | | | | | | |
| **AB2** | | MAYNE PHARMA | **0.35MG** | **A076225** | **001** | Oct 21, 2002 |
| **JENCYCLA** | | | | | | |
| **AB2** | | LUPIN LTD | **0.35MG** | **A091323** | **001** | Mar 28, 2013 |
| **MICRONOR** | | | | | | |
| **AB2** | **+!** | JANSSEN PHARMS | **0.35MG** | **N016954** | **001** | |
| **NORETHINDRONE** | | | | | | |
| **AB2** | | GLENMARK GENERICS | **0.35MG** | **A091209** | **001** | Jul 22, 2010 |
| **AB2** | | MYLAN LABS LTD | **0.35MG** | **A200980** | **001** | Jun 12, 2013 |
| **AB2** | | NOVAST LABS | **0.35MG** | **A200961** | **001** | Sep 13, 2013 |

NORETHINDRONE ACETATE

TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **AYGESTIN** | | | | | | |
| **AB** | **+!** | DURAMED RES | **5MG** | **N018405** | **001** | Apr 21, 1982 |
| **NORETHINDRONE ACETATE** | | | | | | |
| **AB** | | AMNEAL PHARMS | **5MG** | **A200275** | **001** | Jul 30, 2012 |
| **AB** | | AUROBINDO PHARMA LTD | **5MG** | **A204236** | **001** | Jan 08, 2016 |
| **AB** | | BARR | **5MG** | **A075951** | **001** | May 25, 2001 |
| **AB** | | GLENMARK GENERICS | **5MG** | **A091090** | **001** | Jul 21, 2010 |
| **AB** | | MYLAN LABS LTD | **5MG** | **A205278** | **001** | Nov 10, 2016 |

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **NORTRIPTYLINE HYDROCHLORIDE** | | | | | | |
| **AB** | | MAYNE PHARMA | **EQ 10MG BASE** | **A073553** | **001** | Mar 30, 1992 |
| **AB** | | | **EQ 25MG BASE** | **A073554** | **001** | Mar 30, 1992 |
| **AB** | | | **EQ 50MG BASE** | **A073555** | **001** | Mar 30, 1992 |
| **AB** | | | **EQ 75MG BASE** | **A073556** | **001** | Mar 30, 1992 |
| **AB** | | TARO PHARM | **EQ 10MG BASE** | **A075520** | **004** | May 08, 2000 |
| **AB** | | | **EQ 25MG BASE** | **A075520** | **003** | May 08, 2000 |
| **AB** | | | **EQ 50MG BASE** | **A075520** | **001** | May 08, 2000 |
| **AB** | | | **EQ 75MG BASE** | **A075520** | **002** | May 08, 2000 |
| **AB** | | TEVA | **EQ 10MG BASE** | **A074132** | **001** | Mar 27, 1995 |
| **AB** | | | **EQ 25MG BASE** | **A074132** | **002** | Mar 27, 1995 |
| **AB** | | | **EQ 50MG BASE** | **A074132** | **003** | Mar 27, 1995 |
| **AB** | | | **EQ 75MG BASE** | **A074132** | **004** | Mar 27, 1995 |
| **PAMELOR** | | | | | | |
| **AB** | **+** | SPECGX LLC | **EQ 10MG BASE** | **N018013** | **001** | |
| **AB** | **+** | | **EQ 25MG BASE** | **N018013** | **002** | |
| **AB** | **+** | | **EQ 50MG BASE** | **N018013** | **004** | |
| **AB** | **+!** | | **EQ 75MG BASE** | **N018013** | **003** | |

SOLUTION;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **NORTRIPTYLINE HYDROCHLORIDE** | | | | | | |
| **AA** | **!** | PHARM ASSOC | **EQ 10MG BASE/5ML** | **A075606** | **001** | Aug 28, 2000 |
| **AA** | | TARO | **EQ 10MG BASE/5ML** | **A077965** | **001** | Jun 20, 2006 |

NUSINERSEN SODIUM

SOLUTION;INTRATHECAL

| | | | | | | |
|---|---|---|---|---|---|---|
| SPINRAZA | | | | | | |
| | +! | BIOGEN IDEC | 12MG/5ML (2.4MG/ML) | N209531 | 001 | Dec 23, 2016 |

NYSTATIN

CREAM;TOPICAL

**NYSTATIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | ACTAVIS MID ATLANTIC | **100,000 UNITS/GM** | **A062949** | **001** | Jun 13, 1988 |
| **AT** | | CROWN LABS INC | **100,000 UNITS/GM** | **A207733** | **001** | Sep 26, 2017 |
| **AT** | | FOUGERA PHARMS | **100,000 UNITS/GM** | **A062129** | **001** | |
| **AT** | | G AND W LABS INC | **100,000 UNITS/GM** | **A061966** | **001** | |
| **AT** | | PERRIGO NEW YORK | **100,000 UNITS/GM** | **A062225** | **001** | |
| **AT** | ! | TARO | **100,000 UNITS/GM** | **A064022** | **001** | Jan 29, 1993 |
| **AT** | | VINTAGE | **100,000 UNITS/GM** | **A065315** | **001** | May 31, 2006 |

OINTMENT;TOPICAL

**NYSTATIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | ACTAVIS MID ATLANTIC | **100,000 UNITS/GM** | **A062840** | **001** | Nov 13, 1987 |
| **AT** | ! | FOUGERA PHARMS | **100,000 UNITS/GM** | **A062124** | **002** | Sep 23, 1982 |
| **AT** | | G AND W LABS INC | **100,000 UNITS/GM** | **A209114** | **001** | Oct 06, 2017 |
| **AT** | | PERRIGO NEW YORK | **100,000 UNITS/GM** | **A062472** | **001** | Feb 13, 1984 |

POWDER;TOPICAL

**NYSTATIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | GAVIS PHARMS | **100,000 UNITS/GM** | **A065138** | **001** | Jul 23, 2004 |
| **AT** | | LYNE | **100,000 UNITS/GM** | **A208838** | **001** | May 30, 2017 |
| **AT** | ! | MAYNE PHARMA INC | **100,000 UNITS/GM** | **A065203** | **001** | Jul 15, 2004 |
| **AT** | | NESHER PHARMS | **100,000 UNITS/GM** | **A208581** | **001** | Jun 08, 2017 |
| **AT** | | UPSHER-SMITH LABS | **100,000 UNITS/GM** | **A065183** | **001** | May 03, 2005 |
| **AT** | | X GEN PHARMS | **100,000 UNITS/GM** | **A065175** | **001** | Dec 17, 2004 |

**NYSTOP**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | PADDOCK LLC | **100,000 UNITS/GM** | **A064118** | **001** | Aug 16, 1996 |

SUSPENSION;ORAL

**NYSTATIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | FOUGERA PHARMS INC | **100,000 UNITS/ML** | **A062517** | **001** | Jun 07, 1984 |
| **AA** | | G AND W LABS INC | **100,000 UNITS/ML** | **A062349** | **001** | Jul 14, 1982 |
| **AA** | | HI TECH PHARMA | **100,000 UNITS/ML** | **A064042** | **001** | Feb 28, 1994 |
| **AA** | | PHARM ASSOC | **100,000 UNITS/ML** | **A203621** | **001** | Jan 07, 2016 |
| **AA** | | TARO PHARM | **100,000 UNITS/ML** | **A062876** | **001** | Feb 29, 1988 |
| **AA** | | VINTAGE PHARMS | **100,000 UNITS/ML** | **A065148** | **001** | Jun 28, 2005 |
| **AA** | | VISTAPHARM | **100,000 UNITS/ML** | **A064142** | **001** | Jun 25, 1998 |
| **AA** | | | **100,000 UNITS/ML** | **A065422** | **001** | Mar 07, 2011 |
| **AA** | ! | WOCKHARDT BIO AG | **100,000 UNITS/ML** | **A062512** | **001** | Oct 29, 1984 |

TABLET;ORAL

**NYSTATIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | HERITAGE PHARMS INC | **500,000 UNITS** | **A062474** | **001** | Dec 22, 1983 |
| **AA** | | SUN PHARM INDUSTRIES | **500,000 UNITS** | **A062838** | **001** | Dec 22, 1988 |
| **AA** | ! | TEVA | **500,000 UNITS** | **A062506** | **001** | Jan 16, 1984 |

TABLET;VAGINAL

NYSTATIN

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | ODYSSEY PHARMS | 100,000 UNITS | A062615 | 001 | Oct 17, 1985 |

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

**MYKACET**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | G AND W LABS INC | **100,000 UNITS/GM;0.1%** | **A062367** | **001** | May 28, 1985 |

**NYSTATIN AND TRIAMCINOLONE ACETONIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | CROWN LABS INC | **100,000 UNITS/GM;0.1%** | **A207730** | **001** | Dec 26, 2017 |
| **AT** | | DR REDDYS LABS LTD | **100,000 UNITS/GM;0.1%** | **A208326** | **001** | Oct 26, 2016 |
| **AT** | | FOUGERA PHARMS INC | **100,000 UNITS/GM;0.1%** | **A062599** | **001** | Oct 08, 1985 |
| **AT** | | GLENMARK PHARMS LTD | **100,000 UNITS/GM;0.1%** | **A208136** | **001** | Oct 24, 2016 |
| **AT** | | PERRIGO UK FINCO | **100,000 UNITS/GM;0.1%** | **A208479** | **001** | Aug 14, 2017 |
| **AT** | ! | TARO | **100,000 UNITS/GM;0.1%** | **A062364** | **001** | Dec 22, 1987 |

OINTMENT;TOPICAL

**MYKACET**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | G AND W LABS INC | **100,000 UNITS/GM;0.1%** | **A062733** | **001** | Mar 06, 1987 |

**NYSTATIN AND TRIAMCINOLONE ACETONIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | AKORN | **100,000 UNITS/GM;0.1%** | **A207217** | **001** | Aug 04, 2017 |
| **AT** | | CROWN LABS INC | **100,000 UNITS/GM;0.1%** | **A207731** | **001** | Dec 26, 2017 |
| **AT** | | DR REDDYS LABS LTD | **100,000 UNITS/GM;0.1%** | **A207741** | **001** | Jan 31, 2017 |
| **AT** | | FOUGERA PHARMS INC | **100,000 UNITS/GM;0.1%** | **A062602** | **001** | Oct 09, 1985 |
| **AT** | | GLENMARK PHARMS LTD | **100,000 UNITS/GM;0.1%** | **A208300** | **001** | Jun 23, 2016 |
| **AT** | | PERRIGO UK FINCO | **100,000 UNITS/GM;0.1%** | **A207380** | **001** | Dec 20, 2016 |
| **AT** | | RICONPHARMA LLC | **100,000 UNITS/GM;0.1%** | **A206785** | **001** | Dec 29, 2016 |
| **AT** | ! | TARO | **100,000 UNITS/GM;0.1%** | **A063305** | **001** | Mar 29, 1993 |
| **AT** | | TELIGENT PHARMA INC | **100,000 UNITS/GM;0.1%** | **A208287** | **001** | Dec 30, 2016 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| OBETICHOLIC ACID | | | | | | | |
| TABLET;ORAL | | | | | | | |
| OCALIVA | | | | | | | |
| | + | INTERCEPT PHARMS INC | 5MG | N207999 | 001 | May 27, 2016 |
| | +! | | 10MG | N207999 | 002 | May 27, 2016 |
| OCTREOTIDE ACETATE | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| **OCTREOTIDE ACETATE** | | | | | | | |
| **AP** | | FRESENIUS KABI USA | **EQ 0.2MG BASE/ML** | **A077450** | **001** | Feb 10, 2006 |
| **AP** | | | **EQ 1MG BASE/ML** | **A077450** | **002** | Feb 10, 2006 |
| **AP** | | SAGENT PHARMS | **EQ 0.2MG BASE/ML** | **A091041** | **001** | Nov 12, 2013 |
| **AP** | | | **EQ 1MG BASE/ML** | **A091041** | **002** | Nov 12, 2013 |
| **AP** | | SUN PHARM INDS | **EQ 0.05MG BASE/ML** | **A077372** | **001** | Aug 14, 2007 |
| **AP** | | | **EQ 0.1MG BASE/ML** | **A077372** | **002** | Aug 14, 2007 |
| **AP** | | | **EQ 0.2MG BASE/ML** | **A077373** | **001** | Aug 14, 2007 |
| **AP** | | | **EQ 0.5MG BASE/ML** | **A077372** | **003** | Aug 14, 2007 |
| **AP** | | | **EQ 1MG BASE/ML** | **A077373** | **002** | Aug 14, 2007 |
| **AP** | | TEVA PHARMS USA | **EQ 0.05MG BASE/ML** | **A075957** | **001** | Oct 03, 2005 |
| **AP** | | | **EQ 0.1MG BASE/ML** | **A075957** | **002** | Oct 03, 2005 |
| **AP** | | | **EQ 0.2MG BASE/ML** | **A075959** | **001** | Nov 21, 2005 |
| **AP** | | | **EQ 0.5MG BASE/ML** | **A075957** | **003** | Oct 03, 2005 |
| **AP** | | | **EQ 1MG BASE/ML** | **A075959** | **002** | Nov 21, 2005 |
| **AP** | ! | WEST-WARD PHARMS INT | **EQ 0.2MG BASE/ML** | **A076330** | **001** | Apr 08, 2005 |
| **AP** | ! | | **EQ 1MG BASE/ML** | **A076330** | **002** | Apr 08, 2005 |
| **OCTREOTIDE ACETATE (PRESERVATIVE FREE)** | | | | | | | |
| **AP** | | FRESENIUS KABI USA | **EQ 0.05MG BASE/ML** | **A077457** | **001** | Feb 10, 2006 |
| **AP** | | | **EQ 0.1MG BASE/ML** | **A077457** | **002** | Feb 10, 2006 |
| **AP** | | | **EQ 0.5MG BASE/ML** | **A077457** | **003** | Feb 10, 2006 |
| **AP** | | MYLAN INSTITUTIONAL | **EQ 0.05MG BASE/ML** | **A079198** | **001** | Feb 10, 2011 |
| **AP** | | | **EQ 0.1MG BASE/ML** | **A079198** | **002** | Feb 10, 2011 |
| **AP** | | | **EQ 0.5MG BASE/ML** | **A079198** | **003** | Feb 10, 2011 |
| **AP** | | SAGENT PHARMS | **EQ 0.05MG BASE/ML** | **A090834** | **001** | Nov 12, 2013 |
| **AP** | | | **EQ 0.1MG BASE/ML** | **A090834** | **002** | Nov 12, 2013 |
| **AP** | | | **EQ 0.5MG BASE/ML** | **A090834** | **003** | Nov 12, 2013 |
| **AP** | ! | WEST-WARD PHARMS INT | **EQ 0.05MG BASE/ML** | **A076313** | **001** | Mar 28, 2005 |
| **AP** | ! | | **EQ 0.1MG BASE/ML** | **A076313** | **003** | Mar 28, 2005 |
| **AP** | ! | | **EQ 0.5MG BASE/ML** | **A076313** | **002** | Mar 28, 2005 |
| **SANDOSTATIN** | | | | | | | |
| **AP** | +! | NOVARTIS | **EQ 0.05MG BASE/ML** | **N019667** | **001** | Oct 21, 1988 |
| **AP** | +! | | **EQ 0.1MG BASE/ML** | **N019667** | **002** | Oct 21, 1988 |
| **AP** | +! | | **EQ 0.2MG BASE/ML** | **N019667** | **004** | Jun 12, 1991 |
| **AP** | +! | | **EQ 0.5MG BASE/ML** | **N019667** | **003** | Oct 21, 1988 |
| **AP** | +! | | **EQ 1MG BASE/ML** | **N019667** | **005** | Jun 12, 1991 |
| SANDOSTATIN LAR | | | | | | | |
| | + | NOVARTIS | EQ 10MG BASE/VIAL | N021008 | 001 | Nov 25, 1998 |
| | + | | EQ 20MG BASE/VIAL | N021008 | 002 | Nov 25, 1998 |
| | +! | | EQ 30MG BASE/VIAL | N021008 | 003 | Nov 25, 1998 |
| OFLOXACIN | | | | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | | | | |
| **OCUFLOX** | | | | | | | |
| **AT** | +! | ALLERGAN | **0.3%** | **N019921** | **001** | Jul 30, 1993 |
| **OFLOXACIN** | | | | | | | |
| **AT** | | AKORN | **0.3%** | **A076407** | **001** | Apr 15, 2008 |
| **AT** | | ALTAIRE PHARMS INC | **0.3%** | **A202692** | **001** | Apr 29, 2013 |
| **AT** | | ALVOGEN | **0.3%** | **A076830** | **001** | Aug 31, 2004 |
| **AT** | | BAUSCH AND LOMB | **0.3%** | **A076622** | **001** | May 14, 2004 |
| **AT** | | FDC LTD | **0.3%** | **A078559** | **001** | Feb 25, 2009 |
| **AT** | | HI TECH PHARMA | **0.3%** | **A076615** | **001** | May 14, 2004 |
| **AT** | | SANDOZ INC | **0.3%** | **A076231** | **001** | May 14, 2004 |
| SOLUTION/DROPS;OTIC | | | | | | | |
| **OFLOXACIN** | | | | | | | |
| **AT** | | ALVOGEN | **0.3%** | **A090395** | **001** | Aug 11, 2009 |
| **AT** | | APOTEX INC | **0.3%** | **A076527** | **001** | Sep 28, 2007 |
| **AT** | ! | BAUSCH AND LOMB | **0.3%** | **A076128** | **001** | Mar 17, 2008 |
| **AT** | | HI TECH PHARMA | **0.3%** | **A076616** | **001** | Mar 17, 2008 |
| **AT** | | SANDOZ INC | **0.3%** | **A078222** | **001** | Mar 17, 2008 |

OFLOXACIN

TABLET;ORAL

**OFLOXACIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | CADILA PHARMS LTD | **200MG** | **A091656** | **001** | Sep 18, 2014 |
| **AB** | | | **300MG** | **A091656** | **002** | Sep 18, 2014 |
| **AB** | | | **400MG** | **A091656** | **003** | Sep 18, 2014 |
| **AB** | | DR REDDYS LABS LTD | **200MG** | **A077098** | **001** | Feb 10, 2006 |
| **AB** | | | **300MG** | **A077098** | **002** | Feb 10, 2006 |
| **AB** | | | **400MG** | **A077098** | **003** | Feb 10, 2006 |
| **AB** | | LARKEN LABS | **400MG** | **A076093** | **003** | Sep 02, 2003 |
| **AB** | | TEVA | **200MG** | **A076182** | **001** | Sep 02, 2003 |
| **AB** | | | **300MG** | **A076182** | **002** | Sep 02, 2003 |
| **AB** | **!** | | **400MG** | **A076182** | **003** | Sep 02, 2003 |

OLANZAPINE

INJECTABLE;INTRAMUSCULAR

**OLANZAPINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | LUITPOLD | **10MG/VIAL** | **A201741** | **001** | Mar 20, 2012 |
| **AP** | | SANDOZ INC | **10MG/VIAL** | **A201588** | **001** | Oct 24, 2011 |

**ZYPREXA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | LILLY | **10MG/VIAL** | **N021253** | **001** | Mar 29, 2004 |

TABLET;ORAL

**OLANZAPINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALKEM LABS LTD | **2.5MG** | **A202295** | **001** | Oct 20, 2015 |
| **AB** | | | **5MG** | **A202295** | **002** | Oct 20, 2015 |
| **AB** | | | **7.5MG** | **A202295** | **003** | Oct 20, 2015 |
| **AB** | | | **10MG** | **A202295** | **004** | Oct 20, 2015 |
| **AB** | | | **15MG** | **A202295** | **005** | Oct 20, 2015 |
| **AB** | | | **20MG** | **A202295** | **006** | Oct 20, 2015 |
| **AB** | | APOTEX INC | **2.5MG** | **A090798** | **001** | Apr 23, 2012 |
| **AB** | | | **5MG** | **A090798** | **002** | Apr 23, 2012 |
| **AB** | | | **7.5MG** | **A090798** | **003** | Apr 23, 2012 |
| **AB** | | | **10MG** | **A090798** | **004** | Apr 23, 2012 |
| **AB** | | | **15MG** | **A090798** | **005** | Apr 23, 2012 |
| **AB** | | | **20MG** | **A090798** | **006** | Apr 23, 2012 |
| **AB** | | AUROBINDO PHARMA LTD | **2.5MG** | **A202050** | **001** | Apr 23, 2012 |
| **AB** | | | **5MG** | **A202050** | **002** | Apr 23, 2012 |
| **AB** | | | **7.5MG** | **A202050** | **003** | Apr 23, 2012 |
| **AB** | | | **10MG** | **A202050** | **004** | Apr 23, 2012 |
| **AB** | | | **15MG** | **A202050** | **005** | Apr 23, 2012 |
| **AB** | | | **20MG** | **A202050** | **006** | Apr 23, 2012 |
| **AB** | | DR REDDYS LABS LTD | **2.5MG** | **A076255** | **001** | Apr 23, 2012 |
| **AB** | | | **5MG** | **A076255** | **002** | Apr 23, 2012 |
| **AB** | | | **7.5MG** | **A076255** | **003** | Apr 23, 2012 |
| **AB** | | | **10MG** | **A076255** | **004** | Apr 23, 2012 |
| **AB** | | | **15MG** | **A076133** | **001** | Apr 23, 2012 |
| **AB** | | | **20MG** | **A076133** | **002** | Oct 24, 2011 |
| **AB** | | HIKMA PHARMS | **2.5MG** | **A204866** | **001** | Jun 16, 2017 |
| **AB** | | | **5MG** | **A204866** | **002** | Jun 16, 2017 |
| **AB** | | | **7.5MG** | **A204866** | **003** | Jun 16, 2017 |
| **AB** | | | **10MG** | **A204866** | **004** | Jun 16, 2017 |
| **AB** | | | **15MG** | **A204866** | **005** | Jun 16, 2017 |
| **AB** | | | **20MG** | **A204866** | **006** | Jun 16, 2017 |
| **AB** | | INVAGEN PHARMS | **2.5MG** | **A203333** | **001** | Mar 15, 2016 |
| **AB** | | | **5MG** | **A203333** | **002** | Mar 15, 2016 |
| **AB** | | | **7.5MG** | **A203333** | **003** | Mar 15, 2016 |
| **AB** | | | **10MG** | **A203333** | **004** | Mar 15, 2016 |
| **AB** | | | **15MG** | **A203333** | **005** | Mar 15, 2016 |
| **AB** | | | **20MG** | **A203333** | **006** | Mar 15, 2016 |
| **AB** | | IVAX PHARMS INC | **20MG** | **A077301** | **001** | Apr 29, 2015 |
| **AB** | | MACLEODS PHARMS LTD | **2.5MG** | **A202862** | **001** | Aug 15, 2014 |
| **AB** | | | **5MG** | **A202862** | **002** | Aug 15, 2014 |
| **AB** | | | **7.5MG** | **A202862** | **003** | Aug 15, 2014 |
| **AB** | | | **10MG** | **A202862** | **004** | Aug 15, 2014 |
| **AB** | | | **15MG** | **A202862** | **005** | Aug 15, 2014 |
| **AB** | | | **20MG** | **A202862** | **006** | Aug 15, 2014 |
| **AB** | | ORCHID HLTHCARE | **2.5MG** | **A202287** | **001** | Apr 23, 2012 |
| **AB** | | | **5MG** | **A202287** | **002** | Apr 23, 2012 |
| **AB** | | | **7.5MG** | **A202287** | **003** | Apr 23, 2012 |
| **AB** | | | **10MG** | **A202287** | **004** | Apr 23, 2012 |
| **AB** | | | **15MG** | **A202287** | **005** | Apr 23, 2012 |
| **AB** | | | **20MG** | **A202287** | **006** | Apr 23, 2012 |

OLANZAPINE

TABLET;ORAL

**OLANZAPINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| AB | | QILU PHARM CO LTD | 2.5MG | A204319 | 001 | Jan 27, 2016 |
| AB | | | 5MG | A204319 | 002 | Jan 27, 2016 |
| AB | | | 7.5MG | A204319 | 003 | Jan 27, 2016 |
| AB | | | 10MG | A204319 | 004 | Jan 27, 2016 |
| AB | | | 15MG | A204319 | 005 | Jan 27, 2016 |
| AB | | | 20MG | A204319 | 006 | Jan 27, 2016 |
| AB | | SUN PHARM INDS | 2.5MG | A091038 | 001 | Apr 23, 2012 |
| AB | | | 5MG | A091038 | 002 | Apr 23, 2012 |
| AB | | | 7.5MG | A091038 | 003 | Apr 23, 2012 |
| AB | | | 10MG | A091038 | 004 | Apr 23, 2012 |
| AB | | | 15MG | A091038 | 005 | Apr 23, 2012 |
| AB | | | 20MG | A091038 | 006 | Apr 23, 2012 |
| AB | | TEVA PHARMS | 2.5MG | A076000 | 001 | Oct 24, 2011 |
| AB | | | 5MG | A076000 | 002 | Oct 24, 2011 |
| AB | | | 7.5MG | A076000 | 003 | Oct 24, 2011 |
| AB | | | 10MG | A076000 | 004 | Oct 24, 2011 |
| AB | | | 15MG | A076000 | 005 | Oct 24, 2011 |
| AB | | TORRENT PHARMS LTD | 2.5MG | A091434 | 001 | Apr 23, 2012 |
| AB | | | 5MG | A091434 | 002 | Apr 23, 2012 |
| AB | | | 7.5MG | A091434 | 003 | Apr 23, 2012 |
| AB | | | 10MG | A091434 | 004 | Apr 23, 2012 |
| AB | | | 15MG | A091434 | 005 | Apr 23, 2012 |
| AB | | | 20MG | A091434 | 006 | Apr 23, 2012 |

**ZYPREXA**

| | | | | | | |
|---|---|---|---|---|---|---|
| AB | + | LILLY | 2.5MG | N020592 | 001 | Sep 30, 1996 |
| AB | +! | | 5MG | N020592 | 002 | Sep 30, 1996 |
| AB | + | | 7.5MG | N020592 | 003 | Sep 30, 1996 |
| AB | + | | 10MG | N020592 | 004 | Sep 30, 1996 |
| AB | + | | 15MG | N020592 | 005 | Sep 09, 1997 |
| AB | + | | 20MG | N020592 | 006 | Sep 09, 1997 |

TABLET, ORALLY DISINTEGRATING;ORAL

**OLANZAPINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| AB | | AJANTA PHARMA LTD | 5MG | A204320 | 001 | May 30, 2017 |
| AB | | | 10MG | A204320 | 002 | May 30, 2017 |
| AB | | | 15MG | A204320 | 003 | May 30, 2017 |
| AB | | | 20MG | A204320 | 004 | May 30, 2017 |
| AB | | APOTEX INC | 5MG | A091265 | 001 | Oct 24, 2011 |
| AB | | | 10MG | A091265 | 002 | Oct 24, 2011 |
| AB | | | 15MG | A091265 | 003 | Oct 24, 2011 |
| AB | | | 20MG | A091265 | 004 | Oct 24, 2011 |
| AB | | AUROBINDO PHARMA LTD | 5MG | A203708 | 001 | May 15, 2014 |
| AB | | | 10MG | A203708 | 002 | May 15, 2014 |
| AB | | | 15MG | A203708 | 003 | May 15, 2014 |
| AB | | | 20MG | A203708 | 004 | May 15, 2014 |
| AB | | BARR LABS INC | 5MG | A077243 | 001 | Jan 30, 2012 |
| AB | | | 10MG | A077243 | 002 | Jan 30, 2012 |
| AB | | | 15MG | A077243 | 003 | Jan 30, 2012 |
| AB | | | 20MG | A077243 | 004 | Jan 30, 2012 |
| AB | | DR REDDYS LABS LTD | 5MG | A076534 | 001 | Oct 24, 2011 |
| AB | | | 10MG | A076534 | 002 | Oct 24, 2011 |
| AB | | | 15MG | A076534 | 003 | Oct 24, 2011 |
| AB | | | 20MG | A076534 | 004 | Oct 24, 2011 |
| AB | | INVAGEN PHARMS | 5MG | A203456 | 001 | Mar 16, 2016 |
| AB | | | 10MG | A203456 | 002 | Mar 16, 2016 |
| AB | | | 15MG | A203456 | 003 | Mar 16, 2016 |
| AB | | | 20MG | A203456 | 004 | Mar 16, 2016 |
| AB | | JUBILANT GENERICS | 5MG | A200221 | 001 | Sep 12, 2012 |
| AB | | | 10MG | A200221 | 002 | Sep 12, 2012 |
| AB | | | 15MG | A200221 | 003 | Sep 12, 2012 |
| AB | | | 20MG | A200221 | 004 | Sep 12, 2012 |
| AB | | MACLEODS PHARMS LTD | 5MG | A203044 | 001 | Feb 20, 2015 |
| AB | | | 10MG | A203044 | 002 | Feb 20, 2015 |
| AB | | | 15MG | A203044 | 003 | Feb 20, 2015 |
| AB | | | 20MG | A203044 | 004 | Feb 20, 2015 |
| AB | | MYLAN PHARMS INC | 5MG | A202285 | 001 | May 12, 2014 |
| AB | | | 10MG | A202285 | 002 | May 12, 2014 |
| AB | | | 15MG | A202285 | 003 | May 12, 2014 |
| AB | | | 20MG | A202285 | 004 | May 12, 2014 |
| AB | | ORCHID HLTHCARE | 5MG | A202937 | 001 | Mar 02, 2015 |

OLANZAPINE

TABLET, ORALLY DISINTEGRATING;ORAL

**OLANZAPINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **10MG** | **A202937** | **002** | Mar 02, 2015 |
| **AB** | | | **15MG** | **A202937** | **003** | Mar 02, 2015 |
| **AB** | | | **20MG** | **A202937** | **004** | Mar 02, 2015 |
| **AB** | | PAR PHARM | **5MG** | **A078109** | **001** | Oct 24, 2011 |
| **AB** | | | **10MG** | **A078109** | **002** | Oct 24, 2011 |
| **AB** | | | **15MG** | **A078109** | **003** | Oct 24, 2011 |
| **AB** | | | **20MG** | **A078109** | **004** | Oct 24, 2011 |
| **AB** | | SUN PHARM INDS | **5MG** | **A090881** | **001** | Feb 28, 2012 |
| **AB** | | | **10MG** | **A090881** | **002** | Feb 28, 2012 |
| **AB** | | | **15MG** | **A090881** | **003** | Feb 28, 2012 |
| **AB** | | | **20MG** | **A090881** | **004** | Feb 28, 2012 |
| **AB** | | TORRENT PHARMS LLC | **5MG** | **A091415** | **001** | Oct 25, 2011 |
| **AB** | | | **10MG** | **A091415** | **002** | Oct 25, 2011 |
| **AB** | | | **15MG** | **A091415** | **003** | Oct 25, 2011 |
| **AB** | | | **20MG** | **A091415** | **004** | Oct 25, 2011 |

**ZYPREXA ZYDIS**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | LILLY | **5MG** | **N021086** | **001** | Apr 06, 2000 |
| **AB** | **+** | | **10MG** | **N021086** | **002** | Apr 06, 2000 |
| **AB** | **+** | | **15MG** | **N021086** | **003** | Apr 06, 2000 |
| **AB** | **+** | | **20MG** | **N021086** | **004** | Apr 06, 2000 |

OLANZAPINE PAMOATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

ZYPREXA RELPREVV

| | | | | | |
|---|---|---|---|---|---|
| + | ELI LILLY CO | EQ 210MG BASE/VIAL | N022173 | 001 | Dec 11, 2009 |
| + | | EQ 300MG BASE/VIAL | N022173 | 002 | Dec 11, 2009 |
| +! | | EQ 405MG BASE/VIAL | N022173 | 003 | Dec 11, 2009 |

OLAPARIB

CAPSULE;ORAL

LYNPARZA

| | | | | | |
|---|---|---|---|---|---|
| +! | ASTRAZENECA PHARMS | 50MG | N206162 | 001 | Dec 19, 2014 |

TABLET;ORAL

LYNPARZA

| | | | | | |
|---|---|---|---|---|---|
| + | ASTRAZENECA PHARMS | 100MG | N208558 | 001 | Aug 17, 2017 |
| +! | | 150MG | N208558 | 002 | Aug 17, 2017 |

OLMESARTAN MEDOXOMIL

TABLET;ORAL

**BENICAR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | DAIICHI SANKYO | **5MG** | **N021286** | **001** | Apr 25, 2002 |
| **AB** | **+** | | **20MG** | **N021286** | **003** | Apr 25, 2002 |
| **AB** | **+!** | | **40MG** | **N021286** | **004** | Apr 25, 2002 |

**OLMESARTAN MEDOXOMIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACCORD HLTHCARE | **5MG** | **A207662** | **001** | Apr 24, 2017 |
| **AB** | | | **20MG** | **A207662** | **002** | Apr 24, 2017 |
| **AB** | | | **40MG** | **A207662** | **003** | Apr 24, 2017 |
| **AB** | | ALEMBIC PHARMS LTD | **5MG** | **A203012** | **001** | Apr 24, 2017 |
| **AB** | | | **20MG** | **A203012** | **002** | Apr 24, 2017 |
| **AB** | | | **40MG** | **A203012** | **003** | Apr 24, 2017 |
| **AB** | | ALKEM LABS LTD | **5MG** | **A206763** | **001** | Apr 24, 2017 |
| **AB** | | | **20MG** | **A206763** | **002** | Apr 24, 2017 |
| **AB** | | | **40MG** | **A206763** | **003** | Apr 24, 2017 |
| **AB** | | AUROBINDO PHARMA LTD | **5MG** | **A204798** | **001** | Apr 24, 2017 |
| **AB** | | | **20MG** | **A204798** | **002** | Apr 24, 2017 |
| **AB** | | | **40MG** | **A204798** | **003** | Apr 24, 2017 |
| **AB** | | GLENMARK PHARMS LTD | **5MG** | **A203281** | **001** | May 25, 2017 |
| **AB** | | | **20MG** | **A203281** | **002** | May 25, 2017 |
| **AB** | | | **40MG** | **A203281** | **003** | May 25, 2017 |
| **AB** | | JUBILANT GENERICS | **5MG** | **A205482** | **001** | Apr 24, 2017 |
| **AB** | | | **20MG** | **A205482** | **002** | Apr 24, 2017 |
| **AB** | | | **40MG** | **A205482** | **003** | Apr 24, 2017 |
| **AB** | | LUPIN LTD | **5MG** | **A206631** | **001** | Apr 27, 2017 |
| **AB** | | | **20MG** | **A206631** | **002** | Apr 27, 2017 |
| **AB** | | | **40MG** | **A206631** | **003** | Apr 27, 2017 |
| **AB** | | MACLEODS PHARMS LTD | **5MG** | **A204814** | **001** | Apr 24, 2017 |
| **AB** | | | **20MG** | **A204814** | **002** | Apr 24, 2017 |
| **AB** | | | **40MG** | **A204814** | **003** | Apr 24, 2017 |
| **AB** | | MYLAN PHARMS INC | **5MG** | **A078276** | **001** | Oct 26, 2016 |
| **AB** | | | **20MG** | **A078276** | **002** | Oct 26, 2016 |

OLMESARTAN MEDOXOMIL

TABLET;ORAL

**OLMESARTAN MEDOXOMIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | **40MG** | **A078276** | **003** | Oct 26, 2016 |
| **AB** | TEVA PHARMS USA | **5MG** | **A091079** | **001** | Apr 24, 2017 |
| **AB** | | **20MG** | **A091079** | **002** | Apr 24, 2017 |
| **AB** | | **40MG** | **A091079** | **003** | Apr 24, 2017 |
| **AB** | TORRENT PHARMS LTD | **5MG** | **A202375** | **001** | Apr 24, 2017 |
| **AB** | | **20MG** | **A202375** | **002** | Apr 24, 2017 |
| **AB** | | **40MG** | **A202375** | **003** | Apr 24, 2017 |
| **AB** | ZYDUS PHARMS USA INC | **5MG** | **A205192** | **001** | Apr 24, 2017 |
| **AB** | | **20MG** | **A205192** | **002** | Apr 24, 2017 |
| **AB** | | **40MG** | **A205192** | **003** | Apr 24, 2017 |

OLODATEROL HYDROCHLORIDE

SPRAY, METERED;INHALATION

STRIVERDI RESPIMAT

| | | | | | |
|---|---|---|---|---|---|
| +! | BOEHRINGER INGELHEIM | EQ 0.0025MG BASE/INH | N203108 | 001 | Jul 31, 2014 |

OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE

SPRAY, METERED;INHALATION

STIOLTO RESPIMAT

| | | | | | |
|---|---|---|---|---|---|
| +! | BOEHRINGER INGELHEIM | EQ 0.0025MG BASE/INH;EQ 0.0025MG BASE/INH | N206756 | 001 | May 21, 2015 |

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

**OLOPATADINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | AKORN | **EQ 0.2% BASE** | **A204723** | **001** | Dec 05, 2017 |
| **AT** | AKORN INC | **EQ 0.1% BASE** | **A204532** | **001** | Jan 10, 2017 |
| **AT** | APOTEX INC | **EQ 0.1% BASE** | **A078350** | **001** | Dec 07, 2015 |
| **AT** | | **EQ 0.2% BASE** | **A090918** | **001** | Dec 05, 2017 |
| **AT** | AUROBINDO PHARMA LTD | **EQ 0.1% BASE** | **A204812** | **001** | Dec 18, 2015 |
| **AT** | BARR LABS INC | **EQ 0.2% BASE** | **A090848** | **001** | Jul 13, 2015 |
| **AT** | CIPLA LTD | **EQ 0.1% BASE** | **A206046** | **001** | Jul 26, 2017 |
| **AT** | | **EQ 0.2% BASE** | **A206087** | **001** | Dec 05, 2017 |
| **AT** | SOMERSET THERAPS LLC | **EQ 0.1% BASE** | **A206306** | **001** | Dec 07, 2015 |
| **AT** | USV NORTH AMERICA | **EQ 0.1% BASE** | **A203152** | **001** | Dec 07, 2015 |
| **AT** | WOCKHARDT LTD | **EQ 0.1% BASE** | **A200810** | **001** | Jun 28, 2017 |
| **AT** | ZAMBON SPA | **EQ 0.1% BASE** | **A204706** | **001** | Dec 07, 2015 |

**PATADAY**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **+!** | NOVARTIS PHARMS CORP | **EQ 0.2% BASE** | **N021545** | **001** | Dec 22, 2004 |

**PATANOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **+!** | NOVARTIS PHARMS CORP | **EQ 0.1% BASE** | **N020688** | **001** | Dec 18, 1996 |

PAZEO

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | NOVARTIS PHARMS CORP | EQ 0.7% BASE | N206276 | 001 | Jan 30, 2015 |

SPRAY, METERED;NASAL

**OLOPATADINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | APOTEX INC | **0.665MG/SPRAY** | **A091572** | **001** | Oct 08, 2014 |
| **AB** | | PERRIGO ISRAEL | **0.665MG/SPRAY** | **A202853** | **001** | Jan 31, 2017 |

**PATANASE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | NOVARTIS PHARMS CORP | **0.665MG/SPRAY** | **N021861** | **001** | Apr 15, 2008 |

OLSALAZINE SODIUM

CAPSULE;ORAL

DIPENTUM

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | MYLAN SPECIALITY LP | 250MG | N019715 | 001 | Jul 31, 1990 |

OMACETAXINE MEPESUCCINATE

POWDER;SUBCUTANEOUS

SYNRIBO

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | TEVA PHARMS INTL | 3.5MG/VIAL | N203585 | 001 | Oct 26, 2012 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| OMBITASVIR; PARITAPREVIR; RITONAVIR | | | | | | | |
| TABLET;ORAL | | | | | | | |
| TECHNIVIE | | | | | | | |
| | +! | ABBVIE INC | 12.5MG;75MG;50MG | N207931 | 001 | Jul 24, 2015 | |
| OMEGA-3-ACID ETHYL ESTERS | | | | | | | |
| CAPSULE;ORAL | | | | | | | |
| **LOVAZA** | | | | | | | |
| **AB** | **+!** | SMITHKLINE BEECHAM | **1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS** | **N021654** | **001** | Nov 10, 2004 | |
| **OMEGA-3-ACID ETHYL ESTERS** | | | | | | | |
| **AB** | | AMNEAL PHARMS | **1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS** | **A204940** | **001** | Nov 27, 2015 | |
| **AB** | | APOTEX INC | **1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS** | **A090973** | **001** | Sep 30, 2014 | |
| **AB** | | PAR PHARM INC | **1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS** | **A091018** | **001** | Jun 24, 2014 | |
| **AB** | | STRIDES PHARMA | **1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS** | **A203893** | **001** | Sep 19, 2017 | |
| **AB** | | TEVA PHARMS USA | **1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS** | **A091028** | **001** | Apr 07, 2014 | |
| OMEGA-3-CARBOXYLIC ACIDS | | | | | | | |
| CAPSULE;ORAL | | | | | | | |
| EPANOVA | | | | | | | |
| | +! | ASTRAZENECA PHARMS | 1GM CONTAINS AT LEAST 850MG OF POLYUNSATURATED FATTY ACIDS | N205060 | 001 | May 05, 2014 | |
| OMEPRAZOLE | | | | | | | |
| CAPSULE, DELAYED REL PELLETS;ORAL | | | | | | | |
| **OMEPRAZOLE** | | | | | | | |
| **AB** | | ACTAVIS LABS FL INC | **10MG** | **A075347** | **001** | May 30, 2008 | |
| **AB** | | | **20MG** | **A075347** | **002** | May 30, 2008 | |
| **AB** | | | **40MG** | **A075347** | **003** | May 30, 2008 | |
| **AB** | | APOTEX | **10MG** | **A076048** | **001** | Oct 22, 2007 | |
| **AB** | | | **20MG** | **A076048** | **002** | Oct 22, 2007 | |
| **AB** | | | **40MG** | **A076048** | **003** | Jan 21, 2009 | |
| **AB** | | AUROBINDO PHARMA LTD | **10MG** | **A203270** | **001** | Aug 19, 2015 | |
| **AB** | | | **20MG** | **A203270** | **002** | Aug 19, 2015 | |
| **AB** | | | **40MG** | **A203270** | **003** | Aug 19, 2015 | |
| **AB** | | BRECKENRIDGE PHARM | **10MG** | **A203481** | **001** | Jul 03, 2017 | |
| **AB** | | | **20MG** | **A203481** | **002** | Jul 03, 2017 | |
| **AB** | | | **40MG** | **A203481** | **003** | Jul 03, 2017 | |
| **AB** | | DR REDDYS LABS LTD | **10MG** | **A075576** | **003** | Oct 22, 2007 | |
| **AB** | | | **10MG** | **A078490** | **002** | Mar 16, 2009 | |
| **AB** | | | **20MG** | **A075576** | **002** | Oct 22, 2007 | |
| **AB** | | | **20MG** | **A078490** | **003** | Mar 16, 2009 | |
| **AB** | | | **40MG** | **A075576** | **001** | Jan 21, 2009 | |
| **AB** | | | **40MG** | **A078490** | **001** | Apr 17, 2009 | |
| **AB** | | GLENMARK GENERICS | **10MG** | **A091672** | **001** | Oct 31, 2014 | |
| **AB** | | | **20MG** | **A091672** | **002** | Oct 31, 2014 | |
| **AB** | | | **40MG** | **A091672** | **003** | Oct 31, 2014 | |
| **AB** | | IMPAX LABS | **10MG** | **A075785** | **001** | Oct 22, 2007 | |
| **AB** | | | **20MG** | **A075785** | **002** | Oct 22, 2007 | |
| **AB** | | | **40MG** | **A075785** | **003** | Jan 21, 2009 | |
| **AB** | | KREMERS URBAN PHARMS | **10MG** | **A075410** | **001** | Nov 01, 2002 | |
| **AB** | | | **20MG** | **A075410** | **002** | Nov 01, 2002 | |
| **AB** | | | **40MG** | **A075410** | **003** | Jan 23, 2009 | |
| **AB** | | LUPIN LTD | **40MG** | **A202384** | **001** | Aug 25, 2015 | |
| **AB** | | MYLAN | **10MG** | **A075876** | **001** | May 29, 2003 | |
| **AB** | | | **20MG** | **A075876** | **002** | May 29, 2003 | |
| **AB** | | | **40MG** | **A075876** | **003** | Jan 21, 2009 | |
| **AB** | | SANDOZ | **10MG** | **A075757** | **001** | Jan 28, 2003 | |
| **AB** | **!** | | **20MG** | **A075757** | **002** | Jan 28, 2003 | |
| **AB** | **!** | | **40MG** | **A076515** | **001** | Jan 21, 2009 | |
| **AB** | | TEVA PHARMS USA | **20MG** | **A204661** | **001** | Jun 13, 2017 | |
| **AB** | | | **40MG** | **A204661** | **002** | Jun 13, 2017 | |
| **AB** | | ZYDUS PHARMS USA INC | **10MG** | **A091352** | **001** | Nov 19, 2012 | |
| **AB** | | | **20MG** | **A091352** | **002** | Nov 19, 2012 | |
| **AB** | | | **40MG** | **A091352** | **003** | Nov 19, 2012 | |

OMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL

PRILOSEC

| | | | | | |
|---|---|---|---|---|---|
| | + | COVIS PHARMA BV | EQ 2.5MG BASE/PACKET | N022056 001 | Mar 20, 2008 |
| | +! | | EQ 10MG BASE/PACKET | N022056 002 | Mar 20, 2008 |

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

**OMEPRAZOLE AND SODIUM BICARBONATE**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | | AJANTA PHARMA LTD | **20MG;1.1GM** | **A204228 001** | Jul 15, 2016 |
| **AB** | | | **40MG;1.1GM** | **A204228 002** | Jul 15, 2016 |
| **AB** | | AUROLIFE PHARMA LLC | **20MG;1.1GM** | **A204922 001** | Aug 19, 2016 |
| **AB** | | | **40MG;1.1GM** | **A204922 002** | Aug 19, 2016 |
| **AB** | | DR REDDYS LABS LTD | **20MG;1.1GM** | **A204068 001** | Jul 15, 2016 |
| **AB** | | | **40MG;1.1GM** | **A204068 002** | Jul 15, 2016 |
| **AB** | | PAR PHARM | **20MG;1.1GM** | **A078966 001** | May 25, 2010 |
| **AB** | | | **40MG;1.1GM** | **A078966 002** | May 25, 2010 |
| **AB** | | SCIEGEN PHARMS INC | **20MG;1.1GM** | **A207476 001** | Dec 06, 2016 |
| **AB** | | | **40MG;1.1GM** | **A207476 002** | Dec 06, 2016 |

**ZEGERID**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | **+** | SANTARUS INC | **20MG;1.1GM** | **N021849 001** | Feb 27, 2006 |
| **AB** | **+!** | | **40MG;1.1GM** | **N021849 002** | Feb 27, 2006 |

FOR SUSPENSION;ORAL

**OMEPRAZOLE AND SODIUM BICARBONATE**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | | AJANTA PHARMA LTD | **20MG/PACKET;1.68GM/PACKET** | **A205545 001** | Jul 27, 2016 |
| **AB** | | | **40MG/PACKET;1.68GM/PACKET** | **A205545 002** | Jul 27, 2016 |
| **AB** | | PAR PHARM | **20MG/PACKET;1.68GM/PACKET** | **A079182 001** | Apr 19, 2013 |
| **AB** | | | **40MG/PACKET;1.68GM/PACKET** | **A079182 002** | Apr 19, 2013 |

**ZEGERID**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | **+** | SANTARUS INC | **20MG/PACKET;1.68GM/PACKET** | **N021636 001** | Jun 15, 2004 |
| **AB** | **+!** | | **40MG/PACKET;1.68GM/PACKET** | **N021636 002** | Dec 21, 2004 |

ONDANSETRON

FILM;ORAL

ZUPLENZ

| | | | | | |
|---|---|---|---|---|---|
| | + | MIDATECH PHARMA US | 4MG | N022524 001 | Jul 02, 2010 |
| | +! | | 8MG | N022524 002 | Jul 02, 2010 |

TABLET, ORALLY DISINTEGRATING;ORAL

**ONDANSETRON**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | | AUROBINDO PHARMA | **4MG** | **A090469 001** | Apr 12, 2010 |
| **AB** | | | **8MG** | **A090469 002** | Apr 12, 2010 |
| **AB** | | BARR | **4MG** | **A076693 001** | Jun 25, 2007 |
| **AB** | | | **8MG** | **A076693 002** | Jun 25, 2007 |
| **AB** | | GLENMARK GENERICS | **4MG** | **A078152 001** | Jun 27, 2007 |
| **AB** | | | **8MG** | **A078152 002** | Jun 27, 2007 |
| **AB** | | MYLAN | **4MG** | **A078139 001** | Jun 25, 2007 |
| **AB** | | | **8MG** | **A078139 002** | Jun 25, 2007 |
| **AB** | | SANDOZ | **4MG** | **A078050 001** | Aug 13, 2007 |
| **AB** | | | **8MG** | **A078050 002** | Aug 13, 2007 |
| **AB** | | SUN PHARM INDS | **4MG** | **A077557 001** | Aug 02, 2007 |
| **AB** | | | **8MG** | **A077557 002** | Aug 02, 2007 |
| **AB** | | SUN PHARM INDS LTD | **4MG** | **A078602 001** | Feb 24, 2011 |
| **AB** | | | **8MG** | **A078602 002** | Feb 24, 2011 |
| **AB** | | TEVA | **4MG** | **A076810 001** | Jun 25, 2007 |
| **AB** | | | **8MG** | **A076810 002** | Jun 25, 2007 |

**ZOFRAN ODT**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | **+** | NOVARTIS PHARMS CORP | **4MG** | **N020781 001** | Jan 27, 1999 |
| **AB** | **+!** | | **8MG** | **N020781 002** | Jan 27, 1999 |

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

**ONDANSETRON HYDROCHLORIDE**

| | | | | | |
|---|---|---|---|---|---|
| **AP** | | ACCORD HLTHCARE | **EQ 2MG BASE/ML** | **A206846 001** | Jul 13, 2015 |
| **AP** | | AUROBINDO PHARMA LTD | **EQ 2MG BASE/ML** | **A202599 001** | Dec 21, 2012 |
| **AP** | **!** | BAXTER HLTHCARE CORP | **EQ 2MG BASE/ML** | **A078288 001** | Feb 22, 2013 |
| **AP** | | EMCURE PHARMS | **EQ 2MG BASE/ML** | **A090424 001** | Apr 16, 2010 |
| **AP** | | FRESENIUS KABI USA | **EQ 2MG BASE/ML** | **A076974 001** | Dec 26, 2006 |
| **AP** | | GLAND PHARMA LTD | **EQ 2MG BASE/ML** | **A079224 001** | Sep 25, 2009 |
| **AP** | | | **EQ 2MG BASE/ML** | **A090648 001** | Jun 15, 2012 |
| **AP** | | HIKMA FARMACEUTICA | **EQ 2MG BASE/ML** | **A076781 001** | Dec 26, 2006 |
| **AP** | | HOSPIRA | **EQ 2MG BASE/ML** | **A077473 001** | Dec 26, 2006 |

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

**ONDANSETRON HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | | **EQ 2MG BASE/ML** | **A077840** | **001** | Jan 19, 2007 |
| **AP** | | LUITPOLD | **EQ 2MG BASE/ML** | **A079039** | **001** | Nov 18, 2008 |
| **AP** | | MYLAN LABS LTD | **EQ 2MG BASE/ML** | **A204906** | **001** | Jul 31, 2017 |
| **AP** | | QILU PHARM CO LTD | **EQ 2MG BASE/ML** | **A203711** | **001** | Sep 08, 2014 |
| **AP** | | SANDOZ INC | **EQ 2MG BASE/ML** | **A077430** | **001** | Jun 27, 2007 |
| **AP** | | TEVA | **EQ 2MG BASE/ML** | **A076876** | **001** | Nov 22, 2006 |
| **AP** | | WEST-WARD PHARMS INT | **EQ 2MG BASE/ML** | **A076967** | **001** | Dec 26, 2006 |
| **AP** | | | **EQ 2MG BASE/ML** | **A077365** | **001** | Dec 26, 2006 |
| **AP** | | WOCKHARDT | **EQ 2MG BASE/ML** | **A077577** | **001** | Dec 26, 2006 |

**ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | ACCORD HLTHCARE | **EQ 2MG BASE/ML** | **A206845** | **001** | Mar 10, 2016 |
| **AP** | | AUROBINDO PHARMA LTD | **EQ 2MG BASE/ML** | **A202600** | **001** | Dec 21, 2012 |
| **AP** | **!** | BAXTER HLTHCARE CORP | **EQ 2MG BASE/ML** | **A078287** | **001** | Feb 22, 2013 |
| **AP** | | EMCURE PHARMS LTD | **EQ 2MG BASE/ML** | **A078945** | **001** | Jan 03, 2013 |
| **AP** | | FRESENIUS KABI USA | **EQ 2MG BASE/ML** | **A076972** | **001** | Dec 26, 2006 |
| **AP** | | | **EQ 2MG BASE/ML** | **A202253** | **001** | Jul 19, 2013 |
| **AP** | | HIKMA FARMACEUTICA | **EQ 2MG BASE/ML** | **A076780** | **001** | Dec 26, 2006 |
| **AP** | | HOSPIRA | **EQ 2MG BASE/ML** | **A077548** | **001** | Dec 26, 2006 |
| **AP** | | LUITPOLD | **EQ 2MG BASE/ML** | **A079032** | **001** | Nov 18, 2008 |
| **AP** | | SANDOZ INC | **EQ 2MG BASE/ML** | **A077551** | **001** | Jun 27, 2007 |
| **AP** | | SUN PHARM INDS LTD | **EQ 2MG BASE/ML** | **A077173** | **001** | Dec 26, 2006 |
| **AP** | | TEVA | **EQ 2MG BASE/ML** | **A076759** | **001** | Nov 22, 2006 |
| **AP** | | WEST-WARD PHARMS INT | **EQ 2MG BASE/ML** | **A077011** | **001** | Dec 26, 2006 |
| **AP** | | | **EQ 2MG BASE/ML** | **A077541** | **001** | Dec 26, 2006 |
| **AP** | | WOCKHARDT | **EQ 2MG BASE/ML** | **A077716** | **001** | Dec 26, 2006 |

SOLUTION;ORAL

**ONDANSETRON HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | AMNEAL PHARMS | **EQ 4MG BASE/5ML** | **A091483** | **001** | Jan 31, 2011 |
| **AA** | | APOTEX | **EQ 4MG BASE/5ML** | **A078127** | **001** | Jun 25, 2007 |
| **AA** | | AUROBINDO PHARMA | **EQ 4MG BASE/5ML** | **A078776** | **001** | Nov 28, 2007 |
| **AA** | | SILARX | **EQ 4MG BASE/5ML** | **A091342** | **001** | Jan 27, 2011 |
| **AA** | | TARO | **EQ 4MG BASE/5ML** | **A077009** | **001** | Nov 30, 2007 |
| **AA** | | WEST-WARD PHARMS INT | **EQ 4MG BASE/5ML** | **A076960** | **001** | Dec 26, 2006 |

**ZOFRAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **+!** | NOVARTIS PHARMS CORP | **EQ 4MG BASE/5ML** | **N020605** | **001** | Jan 24, 1997 |

TABLET;ORAL

**ONDANSETRON HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | APOTEX | **EQ 4MG BASE** | **A077306** | **001** | Jun 25, 2007 |
| **AB** | | | **EQ 8MG BASE** | **A077306** | **002** | Jun 25, 2007 |
| **AB** | | AUROBINDO PHARMA | **EQ 4MG BASE** | **A078539** | **001** | Jul 31, 2007 |
| **AB** | | | **EQ 8MG BASE** | **A078539** | **002** | Jul 31, 2007 |
| **AB** | | | **EQ 24MG BASE** | **A078539** | **003** | Jul 31, 2007 |
| **AB** | | DR REDDYS LABS LTD | **EQ 4MG BASE** | **A076183** | **003** | Dec 26, 2006 |
| **AB** | | | **EQ 8MG BASE** | **A076183** | **002** | Dec 26, 2006 |
| **AB** | | | **EQ 24MG BASE** | **A076183** | **001** | Dec 26, 2006 |
| **AB** | | GLENMARK GENERICS | **EQ 4MG BASE** | **A077535** | **001** | Jun 25, 2007 |
| **AB** | | | **EQ 8MG BASE** | **A077535** | **002** | Jun 25, 2007 |
| **AB** | | | **EQ 24MG BASE** | **A077535** | **003** | Jun 25, 2007 |
| **AB** | | IPCA LABS LTD | **EQ 4MG BASE** | **A203761** | **001** | Jan 23, 2014 |
| **AB** | | | **EQ 8MG BASE** | **A203761** | **002** | Jan 23, 2014 |
| **AB** | | MYLAN | **EQ 4MG BASE** | **A076930** | **001** | Jun 25, 2007 |
| **AB** | | | **EQ 8MG BASE** | **A076930** | **002** | Jun 25, 2007 |
| **AB** | | | **EQ 24MG BASE** | **A076930** | **004** | Jun 25, 2007 |
| **AB** | | NATCO PHARMA LTD | **EQ 4MG BASE** | **A077851** | **001** | Jun 25, 2007 |
| **AB** | | | **EQ 8MG BASE** | **A077851** | **002** | Jun 25, 2007 |
| **AB** | | PLIVA HRVATSKA DOO | **EQ 4MG BASE** | **A077112** | **001** | Jun 25, 2007 |
| **AB** | | | **EQ 8MG BASE** | **A077112** | **002** | Jun 25, 2007 |
| **AB** | | | **EQ 24MG BASE** | **A077112** | **003** | Jun 25, 2007 |
| **AB** | | SANDOZ | **EQ 4MG BASE** | **A077517** | **001** | Jun 25, 2007 |
| **AB** | | | **EQ 8MG BASE** | **A077517** | **002** | Jun 25, 2007 |
| **AB** | | | **EQ 24MG BASE** | **A077517** | **003** | Jun 25, 2007 |
| **AB** | | SUN PHARM INDS (IN) | **EQ 4MG BASE** | **A077050** | **001** | Jun 25, 2007 |
| **AB** | | | **EQ 8MG BASE** | **A077050** | **002** | Jun 25, 2007 |
| **AB** | | TEVA | **EQ 4MG BASE** | **A076252** | **001** | Jun 25, 2007 |
| **AB** | | | **EQ 8MG BASE** | **A076252** | **002** | Jun 25, 2007 |

ONDANSETRON HYDROCHLORIDE

TABLET;ORAL

**ONDANSETRON HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **EQ 24MG BASE** | **A076252** | **003** | Jun 25, 2007 |

**ZOFRAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | NOVARTIS PHARMS CORP | **EQ 4MG BASE** | **N020103** | **001** | Dec 31, 1992 |
| **AB** | + | | **EQ 8MG BASE** | **N020103** | **002** | Dec 31, 1992 |
| **AB** | +! | | **EQ 24MG BASE** | **N020103** | **003** | Aug 27, 1999 |

ONDANSETRON HYDROCHLORIDE

| | | | | | |
|---|---|---|---|---|---|
| | DR REDDYS LABS LTD | EQ 16MG BASE | A076183 | 004 | Dec 26, 2006 |

ORITAVANCIN DIPHOSPHATE

POWDER;IV (INFUSION)

ORBACTIV

| | | | | | |
|---|---|---|---|---|---|
| +! | THE MEDICINES CO | EQ 400MG BASE/VIAL | N206334 | 001 | Aug 06, 2014 |

ORLISTAT

CAPSULE;ORAL

XENICAL

| | | | | | |
|---|---|---|---|---|---|
| +! | CHEPLAPHARM | 120MG | N020766 | 001 | Apr 23, 1999 |

ORPHENADRINE CITRATE

INJECTABLE;INJECTION

**ORPHENADRINE CITRATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | ! | AKORN | **30MG/ML** | **A040484** | **001** | May 24, 2006 |
| **AP** | | SAGENT PHARMS | **30MG/ML** | **A090585** | **001** | Aug 30, 2011 |
| **AP** | | WATSON LABS | **30MG/ML** | **A084779** | **001** | Mar 15, 1982 |
| **AP** | | WEST-WARD PHARMS INT | **30MG/ML** | **A040463** | **001** | Mar 04, 2003 |

TABLET, EXTENDED RELEASE;ORAL

**ORPHENADRINE CITRATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | GAVIS PHARMS | **100MG** | **A040284** | **001** | Jun 19, 1998 |
| **AB** | | IMPAX PHARMS | **100MG** | **A040368** | **001** | Jun 23, 2000 |
| **AB** | | INVAGEN PHARMS | **100MG** | **A091158** | **001** | Jul 27, 2012 |
| **AB** | ! | SANDOZ | **100MG** | **A040327** | **001** | Feb 15, 2000 |
| **AB** | | TEDOR PHARMA INC | **100MG** | **A040249** | **001** | Jan 29, 1999 |

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

**OSELTAMIVIR PHOSPHATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AMNEAL PHARMS | **EQ 30MG BASE** | **A209093** | **001** | May 17, 2017 |
| **AB** | | | **EQ 45MG BASE** | **A209093** | **002** | May 17, 2017 |
| **AB** | | | **EQ 75MG BASE** | **A209093** | **003** | May 17, 2017 |
| **AB** | | LUPIN ATLANTIS | **EQ 30MG BASE** | **A208348** | **001** | Jan 09, 2018 |
| **AB** | | | **EQ 45MG BASE** | **A208348** | **002** | Jan 09, 2018 |
| **AB** | | | **EQ 75MG BASE** | **A208348** | **003** | Jan 09, 2018 |
| **AB** | | MACLEODS PHARMS LTD | **EQ 30MG BASE** | **A207211** | **001** | Sep 14, 2017 |
| **AB** | | | **EQ 45MG BASE** | **A207211** | **002** | Sep 14, 2017 |
| **AB** | | | **EQ 75MG BASE** | **A207211** | **003** | Sep 14, 2017 |
| **AB** | | NATCO PHARMA LTD | **EQ 30MG BASE** | **A202595** | **001** | Aug 03, 2016 |
| **AB** | | | **EQ 45MG BASE** | **A202595** | **002** | Aug 03, 2016 |
| **AB** | | | **EQ 75MG BASE** | **A202595** | **003** | Aug 03, 2016 |
| **AB** | | NESHER PHARMS | **EQ 30MG BASE** | **A208578** | **001** | Feb 24, 2017 |
| **AB** | | | **EQ 45MG BASE** | **A208578** | **002** | Feb 24, 2017 |
| **AB** | | | **EQ 75MG BASE** | **A208578** | **003** | Feb 24, 2017 |

**TAMIFLU**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | ROCHE | **EQ 30MG BASE** | **N021087** | **003** | Jul 02, 2007 |
| **AB** | + | | **EQ 45MG BASE** | **N021087** | **002** | Jul 02, 2007 |
| **AB** | +! | | **EQ 75MG BASE** | **N021087** | **001** | Oct 27, 1999 |

FOR SUSPENSION;ORAL

**OSELTAMIVIR PHOSPHATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALVOGEN PINE BROOK | **EQ 6MG BASE/ML** | **A208823** | **001** | Oct 31, 2017 |
| **AB** | | NESHER PHARMS | **EQ 6MG BASE/ML** | **A209113** | **001** | Sep 14, 2017 |

**TAMIFLU**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | +! | ROCHE | **EQ 6MG BASE/ML** | **N021246** | **002** | Mar 21, 2011 |

OSIMERTINIB MESYLATE

TABLET;ORAL

TAGRISSO

| | | | | | |
|---|---|---|---|---|---|
| + | ASTRAZENECA PHARMS | EQ 40MG BASE | N208065 | 001 | Nov 13, 2015 |
| +! | | EQ 80MG BASE | N208065 | 002 | Nov 13, 2015 |

OSPEMIFENE

TABLET;ORAL

OSPHENA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | DUCHESNAY | 60MG | N203505 | 001 | Feb 26, 2013 |

OXACILLIN SODIUM

INJECTABLE;INJECTION

**OXACILLIN SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AURORBINDO PHARMA LTD | **EQ 1GM BASE/VIAL** | **A201539** | **001** | Jan 18, 2013 |
| **AP** | | | **EQ 2GM BASE/VIAL** | **A201539** | **002** | Jan 18, 2013 |
| **AP** | | | **EQ 10GM BASE/VIAL** | **A201538** | **001** | Jan 18, 2013 |
| **AP** | | HOSPIRA INC | **EQ 1GM BASE/VIAL** | **A203950** | **001** | Dec 11, 2015 |
| **AP** | | | **EQ 2GM BASE/VIAL** | **A203950** | **002** | Dec 11, 2015 |
| **AP** | | RENAISSANCE SSA LLC | **EQ 1GM BASE/VIAL** | **A206681** | **001** | Sep 11, 2017 |
| **AP** | | | **EQ 2GM BASE/VIAL** | **A206681** | **002** | Sep 11, 2017 |
| **AP** | | | **EQ 10GM BASE/VIAL** | **A206760** | **001** | Oct 26, 2017 |
| **AP** | | SAGENT PHARMS | **EQ 1GM BASE/VIAL** | **A091246** | **001** | Mar 30, 2012 |
| **AP** | | | **EQ 2GM BASE/VIAL** | **A091246** | **002** | Mar 30, 2012 |
| **AP** | | | **EQ 10GM BASE/VIAL** | **A091245** | **001** | Mar 30, 2012 |
| **AP** | **!** | SANDOZ | **EQ 1GM BASE/VIAL** | **A061490** | **003** | |
| **AP** | **!** | | **EQ 2GM BASE/VIAL** | **A061490** | **004** | |
| **AP** | **!** | | **EQ 10GM BASE/VIAL** | **A061490** | **006** | May 09, 1991 |
| **AP** | | WOCKHARDT BIO AG | **EQ 1GM BASE/VIAL** | **A207147** | **001** | Jul 31, 2017 |
| **AP** | | | **EQ 2GM BASE/VIAL** | **A207147** | **002** | Jul 31, 2017 |
| **AP** | | | **EQ 10GM BASE/VIAL** | **A207148** | **001** | Nov 24, 2017 |

BACTOCILL IN PLASTIC CONTAINER

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | BAXTER HLTHCARE | EQ 20MG BASE/ML | N050640 | 001 | Oct 26, 1989 |
| | +! | | EQ 40MG BASE/ML | N050640 | 002 | Oct 26, 1989 |

POWDER;INTRAVENOUS

**OXACILLIN SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **!** | SANDOZ | **EQ 1GM BASE/VIAL** | **A062737** | **001** | Dec 23, 1986 |
| **AP** | **!** | | **EQ 2GM BASE/VIAL** | **A062737** | **002** | Dec 23, 1986 |

OXALIPLATIN

INJECTABLE;IV (INFUSION)

**ELOXATIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | SANOFI AVENTIS US | **50MG/10ML (5MG/ML)** | **N021759** | **001** | Jan 31, 2005 |
| **AP** | **+!** | | **100MG/20ML (5MG/ML)** | **N021759** | **002** | Jan 31, 2005 |

**OXALIPLATIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | ACCORD HLTHCARE | **50MG/10ML (5MG/ML)** | **A207474** | **001** | Mar 21, 2017 |
| **AP** | | | **100MG/20ML (5MG/ML)** | **A207474** | **002** | Mar 21, 2017 |
| **AP** | | | **200MG/40ML (5MG/ML)** | **A207474** | **003** | Mar 21, 2017 |
| **AP** | | ACTAVIS TOTOWA | **50MG/VIAL** | **A078803** | **001** | Aug 08, 2012 |
| **AP** | | | **100MG/VIAL** | **A078803** | **002** | Aug 08, 2012 |
| **AP** | | CIPLA LTD | **50MG/10ML (5MG/ML)** | **A208523** | **001** | Feb 10, 2017 |
| **AP** | | | **100MG/20ML (5MG/ML)** | **A208523** | **002** | Feb 10, 2017 |
| **AP** | | FRESENIUS KABI ONCOL | **50MG/10ML (5MG/ML)** | **A078811** | **001** | Jun 10, 2010 |
| **AP** | | | **100MG/20ML (5MG/ML)** | **A078811** | **002** | Jun 10, 2010 |
| **AP** | | | **50MG/VIAL** | **A078810** | **001** | Aug 07, 2009 |
| **AP** | | | **100MG/VIAL** | **A078810** | **002** | Aug 07, 2009 |
| **AP** | | FRESENIUS KABI USA | **50MG/VIAL** | **A078819** | **001** | Jun 02, 2010 |
| **AP** | | | **50MG/10ML (5MG/ML)** | **A090030** | **001** | Jan 31, 2017 |
| **AP** | | | **100MG/VIAL** | **A078819** | **002** | Jun 02, 2010 |
| **AP** | | | **100MG/20ML (5MG/ML)** | **A090030** | **002** | Jan 31, 2017 |
| **AP** | | | **200MG/40ML (5MG/ML)** | **A090030** | **003** | Jan 31, 2017 |
| **AP** | | GLAND PHARMA LTD | **50MG/10ML (5MG/ML)** | **A207325** | **001** | Feb 10, 2017 |
| **AP** | | | **50MG/VIAL** | **A207385** | **001** | May 23, 2017 |
| **AP** | | | **100MG/20ML (5MG/ML)** | **A207325** | **002** | Feb 10, 2017 |
| **AP** | | | **100MG/VIAL** | **A207385** | **002** | May 23, 2017 |
| **AP** | | | **200MG/40ML (5MG/ML)** | **A207325** | **003** | Oct 18, 2017 |
| **AP** | | HOSPIRA INC | **50MG/VIAL** | **A078815** | **001** | Sep 30, 2009 |
| **AP** | | | **100MG/VIAL** | **A078815** | **002** | Sep 30, 2009 |
| **AP** | | HOSPIRA WORLDWIDE | **50MG/10ML (5MG/ML)** | **A078813** | **001** | Aug 07, 2009 |
| **AP** | | | **100MG/20ML (5MG/ML)** | **A078813** | **002** | Aug 07, 2009 |
| **AP** | | JIANGSU HENGRUI MED | **50MG/10ML (5MG/ML)** | **A203869** | **001** | Jun 18, 2014 |
| **AP** | | | **100MG/20ML (5MG/ML)** | **A203869** | **002** | Jun 18, 2014 |
| **AP** | | LUITPOLD PHARMS INC | **50MG/10ML (5MG/ML)** | **A204378** | **001** | May 12, 2017 |
| **AP** | | | **100MG/20ML (5MG/ML)** | **A204378** | **002** | May 12, 2017 |
| **AP** | | MYLAN LABS LTD | **50MG/10ML (5MG/ML)** | **A091358** | **001** | Aug 07, 2012 |
| **AP** | | | **50MG/VIAL** | **A200979** | **001** | Aug 08, 2012 |
| **AP** | | | **100MG/20ML (5MG/ML)** | **A091358** | **002** | Aug 07, 2012 |
| **AP** | | | **100MG/VIAL** | **A200979** | **002** | Aug 08, 2012 |

OXALIPLATIN

INJECTABLE;IV (INFUSION)

**OXALIPLATIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | | **200MG/40ML (5MG/ML)** | **A091358** | **003** | Nov 14, 2017 |
| **AP** | | QILU PHARM CO LTD | **50MG/10ML (5MG/ML)** | **A204368** | **001** | Jun 07, 2016 |
| **AP** | | | **50MG/VIAL** | **A204616** | **001** | May 11, 2016 |
| **AP** | | | **100MG/20ML (5MG/ML)** | **A204368** | **002** | Jun 07, 2016 |
| **AP** | | | **100MG/VIAL** | **A204616** | **002** | May 11, 2016 |
| **AP** | **!** | | **200MG/40ML (5MG/ML)** | **A204368** | **003** | Jun 07, 2016 |
| **AP** | | SANDOZ | **50MG/10ML (5MG/ML)** | **A078817** | **001** | Jan 24, 2011 |
| **AP** | | | **100MG/20ML (5MG/ML)** | **A078817** | **002** | Jan 24, 2011 |
| **AP** | | SANJA PHARMS CO | **50MG/10ML (5MG/ML)** | **A205529** | **001** | Sep 06, 2017 |
| **AP** | | | **100MG/20ML (5MG/ML)** | **A205529** | **002** | Sep 06, 2017 |
| **AP** | **!** | SUN PHARMA GLOBAL | **50MG/VIAL** | **A078818** | **001** | Aug 07, 2009 |
| **AP** | | | **50MG/10ML (5MG/ML)** | **A202922** | **001** | Apr 08, 2014 |
| **AP** | **!** | | **100MG/VIAL** | **A078818** | **002** | Aug 07, 2009 |
| **AP** | | | **100MG/20ML (5MG/ML)** | **A202922** | **002** | Apr 08, 2014 |
| **AP** | **+!** | TEVA PHARMS | **50MG/10ML (5MG/ML)** | **N022160** | **001** | Aug 07, 2009 |
| **AP** | **+!** | | **100MG/20ML (5MG/ML)** | **N022160** | **002** | Aug 07, 2009 |

OXANDROLONE

TABLET;ORAL

**OXANDRIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | GEMINI LABS LLC | **2.5MG** | **N013718** | **001** | |
| **AB** | **+!** | | **10MG** | **N013718** | **002** | Nov 05, 2001 |

**OXANDROLONE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | PAR PHARM | **2.5MG** | **A077827** | **001** | Jun 22, 2007 |
| **AB** | | | **10MG** | **A077827** | **002** | Jun 22, 2007 |
| **AB** | | UPSHER-SMITH LABS | **2.5MG** | **A076761** | **001** | Dec 01, 2006 |
| **AB** | | | **10MG** | **A078033** | **001** | Mar 22, 2007 |

OXAPROZIN

TABLET;ORAL

**DAYPRO**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | GD SEARLE | **600MG** | **N018841** | **004** | Oct 29, 1992 |

**OXAPROZIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AMNEAL PHARMS CO | **600MG** | **A208633** | **001** | May 04, 2017 |
| **AB** | | APOTEX INC | **600MG** | **A075987** | **001** | Sep 02, 2004 |
| **AB** | | DR REDDYS LABS LTD | **600MG** | **A075855** | **001** | Jan 31, 2001 |
| **AB** | | IVAX SUB TEVA PHARMS | **600MG** | **A075846** | **001** | May 13, 2002 |
| **AB** | | SANDOZ | **600MG** | **A075845** | **001** | Jan 31, 2001 |
| **AB** | | SUN PHARM INDS INC | **600MG** | **A075844** | **001** | Jan 03, 2002 |
| **AB** | | TEVA | **600MG** | **A075849** | **001** | Jul 03, 2002 |

OXAZEPAM

CAPSULE;ORAL

**OXAZEPAM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS ELIZABETH | **10MG** | **A072253** | **002** | Apr 14, 1988 |
| **AB** | | | **15MG** | **A072253** | **003** | Apr 14, 1988 |
| **AB** | **!** | | **30MG** | **A072253** | **001** | Apr 14, 1988 |
| **AB** | | SANDOZ | **10MG** | **A071813** | **001** | Apr 19, 1988 |
| **AB** | | | **15MG** | **A071756** | **001** | Apr 19, 1988 |
| **AB** | | | **30MG** | **A071814** | **001** | Apr 19, 1988 |

OXCARBAZEPINE

SUSPENSION;ORAL

**OXCARBAZEPINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AMNEAL PHARMS | **300MG/5ML** | **A202961** | **001** | Sep 17, 2012 |
| **AB** | | SUN PHARM INDS LTD | **300MG/5ML** | **A078734** | **001** | Jun 26, 2009 |
| **AB** | | WEST-WARD PHARMS INT | **300MG/5ML** | **A201193** | **001** | Oct 03, 2012 |

**TRILEPTAL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | NOVARTIS | **300MG/5ML** | **N021285** | **001** | May 25, 2001 |

TABLET;ORAL

**OXCARBAZEPINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ANI PHARMS INC | **150MG** | **A078005** | **001** | Dec 11, 2007 |
| **AB** | | | **300MG** | **A078005** | **002** | Dec 11, 2007 |
| **AB** | | | **600MG** | **A078005** | **003** | Dec 11, 2007 |
| **AB** | | APOTEX INC | **150MG** | **A077747** | **001** | Apr 09, 2008 |
| **AB** | | | **300MG** | **A077747** | **002** | Apr 09, 2008 |
| **AB** | | | **600MG** | **A077747** | **003** | Apr 09, 2008 |
| **AB** | | BRECKENRIDGE PHARM | **150MG** | **A078069** | **001** | Jan 11, 2008 |
| **AB** | | | **300MG** | **A078069** | **002** | Jan 11, 2008 |
| **AB** | | | **600MG** | **A078069** | **003** | Jan 11, 2008 |

OXCARBAZEPINE

TABLET;ORAL

**OXCARBAZEPINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | GLENMARK PHARMS LTD | **150MG** | **A077802** | **001** | Oct 09, 2007 |
| **AB** | | | **300MG** | **A077802** | **002** | Oct 09, 2007 |
| **AB** | | | **600MG** | **A077802** | **003** | Oct 09, 2007 |
| **AB** | | SUN PHARM INDS | **150MG** | **A077794** | **001** | Oct 09, 2007 |
| **AB** | | | **300MG** | **A077794** | **002** | Oct 09, 2007 |
| **AB** | | | **600MG** | **A077794** | **003** | Oct 09, 2007 |
| **AB** | | TARO | **150MG** | **A077801** | **001** | Nov 15, 2007 |
| **AB** | | | **300MG** | **A077801** | **002** | Nov 15, 2007 |
| **AB** | | | **600MG** | **A077801** | **003** | Nov 15, 2007 |
| **AB** | | WEST-WARD PHARMS INT | **150MG** | **A077795** | **001** | Oct 09, 2007 |
| **AB** | | | **300MG** | **A077795** | **002** | Oct 09, 2007 |
| **AB** | | | **600MG** | **A077795** | **003** | Oct 09, 2007 |

**TRILEPTAL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | NOVARTIS | **150MG** | **N021014** | **001** | Jan 14, 2000 |
| **AB** | **+** | | **300MG** | **N021014** | **002** | Jan 14, 2000 |
| **AB** | **+!** | | **600MG** | **N021014** | **003** | Jan 14, 2000 |

TABLET, EXTENDED RELEASE;ORAL

OXTELLAR XR

| | | | | | |
|---|---|---|---|---|---|
| + | SUPERNUS PHARMS | 150MG | N202810 | 001 | Oct 19, 2012 |
| + | | 300MG | N202810 | 002 | Oct 19, 2012 |
| +! | | 600MG | N202810 | 003 | Oct 19, 2012 |

OXICONAZOLE NITRATE

CREAM;TOPICAL

**OXICONAZOLE NITRATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | TARO | **EQ 1% BASE** | **A205076** | **001** | Mar 07, 2016 |

**OXISTAT**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | FOUGERA PHARMS | **EQ 1% BASE** | **N019828** | **001** | Dec 30, 1988 |

LOTION;TOPICAL

OXISTAT

| | | | | | |
|---|---|---|---|---|---|
| +! | FOUGERA PHARMS | EQ 1% BASE | N020209 | 001 | Sep 30, 1992 |

OXTRIPHYLLINE

TABLET, EXTENDED RELEASE;ORAL

CHOLEDYL SA

| | | | | | |
|---|---|---|---|---|---|
| ! | WARNER CHILCOTT LLC | 400MG | A087863 | 001 | May 24, 1983 |

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

**OXYBUTYNIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | BARR LABS DIV TEVA | **3.9MG/24HR** | **A090526** | **001** | Mar 04, 2014 |

**OXYTROL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | ALLERGAN SALES LLC | **3.9MG/24HR** | **N021351** | **002** | Feb 26, 2003 |

OXYBUTYNIN CHLORIDE

GEL;TRANSDERMAL

GELNIQUE

| | | | | | |
|---|---|---|---|---|---|
| +! | ALLERGAN SALES LLC | 10%(100MG/PACKET) | N022204 | 001 | Jan 27, 2009 |

SYRUP;ORAL

**OXYBUTYNIN CHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | PHARM ASSOC | **5MG/5ML** | **A075137** | **001** | Dec 18, 1998 |
| **AA** | | SILARX | **5MG/5ML** | **A074520** | **001** | Mar 29, 1996 |
| **AA** | | VINTAGE PHARMS | **5MG/5ML** | **A076682** | **001** | Dec 28, 2004 |
| **AA** | **!** | WOCKHARDT BIO AG | **5MG/5ML** | **A074868** | **001** | Feb 12, 1997 |

TABLET;ORAL

**OXYBUTYNIN CHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ABHAI LLC | **5MG** | **A209335** | **001** | Dec 22, 2017 |
| **AB** | | APPCO PHARMA LLC | **5MG** | **A209025** | **001** | Dec 21, 2017 |
| **AB** | | NOVITIUM PHARMA | **5MG** | **A209823** | **001** | Oct 23, 2017 |
| **AB** | | TEVA PHARMS USA | **5MG** | **A071655** | **001** | Nov 14, 1988 |
| **AB** | | UPSHER-SMITH LABS | **5MG** | **A074625** | **001** | Jul 31, 1996 |
| **AB** | **!** | VINTAGE PHARMS | **5MG** | **A075079** | **001** | Oct 31, 1997 |

TABLET, EXTENDED RELEASE;ORAL

**DITROPAN XL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | JANSSEN PHARMS | **5MG** | **N020897** | **001** | Dec 16, 1998 |
| **AB** | **+** | | **10MG** | **N020897** | **002** | Dec 16, 1998 |
| **AB** | **+!** | | **15MG** | **N020897** | **003** | Jun 22, 1999 |

**OXYBUTYNIN CHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACCORD HLTHCARE | **5MG** | **A207138** | **001** | Feb 29, 2016 |
| **AB** | | | **10MG** | **A207138** | **002** | Feb 29, 2016 |
| **AB** | | | **15MG** | **A207138** | **003** | Feb 29, 2016 |

OXYBUTYNIN CHLORIDE

TABLET, EXTENDED RELEASE;ORAL

**OXYBUTYNIN CHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AMNEAL PHARMS | **5MG** | **A204010** | **001** | Nov 23, 2015 |
| **AB** | | | **10MG** | **A204010** | **002** | Nov 23, 2015 |
| **AB** | | | **15MG** | **A204010** | **003** | Nov 23, 2015 |
| **AB** | | IMPAX PHARMS | **5MG** | **A076745** | **002** | May 09, 2007 |
| **AB** | | | **10MG** | **A076745** | **003** | May 09, 2007 |
| **AB** | | | **15MG** | **A076745** | **001** | Nov 09, 2006 |
| **AB** | | MYLAN | **5MG** | **A076702** | **001** | Nov 09, 2006 |
| **AB** | | MYLAN PHARMS INC | **10MG** | **A076644** | **001** | Nov 09, 2006 |
| **AB** | | | **15MG** | **A076644** | **002** | May 10, 2007 |
| **AB** | | OSMOTICA PHARM US | **5MG** | **A078503** | **001** | Feb 04, 2009 |
| **AB** | | | **10MG** | **A078503** | **002** | Feb 04, 2009 |
| **AB** | | | **15MG** | **A078503** | **003** | Feb 04, 2009 |
| **AB** | | UNIQUE PHARM LABS | **5MG** | **A206121** | **001** | May 27, 2016 |
| **AB** | | | **10MG** | **A206121** | **002** | May 27, 2016 |
| **AB** | | | **15MG** | **A206121** | **003** | May 27, 2016 |
| **AB** | | ZYDUS PHARMS USA INC | **5MG** | **A202332** | **001** | Jun 26, 2017 |
| **AB** | | | **10MG** | **A202332** | **002** | Jun 26, 2017 |
| **AB** | | | **15MG** | **A202332** | **003** | Jun 26, 2017 |

OXYCODONE

CAPSULE, EXTENDED RELEASE;ORAL

XTAMPZA ER

| | | | | | |
|---|---|---|---|---|---|
| + | COLLEGIUM PHARM INC | 9MG | N208090 | 001 | Apr 26, 2016 |
| + | | 13.5MG | N208090 | 002 | Apr 26, 2016 |
| + | | 18MG | N208090 | 003 | Apr 26, 2016 |
| + | | 27MG | N208090 | 004 | Apr 26, 2016 |
| +! | | 36MG | N208090 | 005 | Apr 26, 2016 |

OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL

**OXYCODONE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ANI PHARMS INC | **5MG** | **A205177** | **001** | Mar 31, 2016 |
| **AB** | | AVANTHI INC | **5MG** | **A202773** | **001** | Aug 17, 2015 |
| **AB** | | LANNETT HOLDINGS INC | **5MG** | **A203823** | **001** | Aug 01, 2014 |
| **AB** | **+!** | LEHIGH VALLEY | **5MG** | **N200534** | **001** | Oct 20, 2010 |
| **AB** | | MAYNE PHARMA INC | **5MG** | **A203107** | **001** | Jul 26, 2012 |
| **AB** | | NOVEL LABS INC | **5MG** | **A204752** | **001** | Aug 24, 2015 |

SOLUTION;ORAL

**OXYCODONE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | ABHAI LLC | **5MG/5ML** | **A208593** | **001** | Jul 21, 2017 |
| **AA** | | | **100MG/5ML** | **A208593** | **002** | Jul 21, 2017 |
| **AA** | | ANI PHARMS INC | **5MG/5ML** | **A204979** | **001** | Jun 01, 2015 |
| **AA** | | | **100MG/5ML** | **A203447** | **001** | Aug 30, 2017 |
| **AA** | | ASCENT PHARMS INC | **5MG/5ML** | **A209021** | **001** | Nov 09, 2017 |
| **AA** | | | **100MG/5ML** | **A209021** | **002** | Nov 09, 2017 |
| **AA** | | HI-TECH PHARMACAL | **5MG/5ML** | **A208817** | **001** | Aug 10, 2017 |
| **AA** | | | **100MG/5ML** | **A208795** | **001** | Aug 07, 2017 |
| **AA** | | LANNETT HOLDINGS INC | **100MG/5ML** | **A204085** | **001** | Sep 09, 2014 |
| **AA** | **+** | LEHIGH VALLEY | **5MG/5ML** | **N200535** | **002** | Aug 22, 2013 |
| **AA** | **+!** | | **100MG/5ML** | **N200535** | **001** | Oct 20, 2010 |
| **AA** | | MAYNE PHARMA INC | **100MG/5ML** | **A204092** | **001** | Jun 05, 2014 |
| **AA** | | NOVEL LABS INC | **100MG/5ML** | **A204603** | **001** | Apr 29, 2015 |
| **AA** | | PHARM ASSOC | **100MG/5ML** | **A206822** | **001** | Aug 15, 2017 |
| **AA** | **+!** | VISTAPHARM | **5MG/5ML** | **N201194** | **001** | Jan 12, 2012 |
| **AA** | | | **100MG/5ML** | **A202537** | **001** | Jul 30, 2012 |
| **AA** | | WES PHARMA INC | **5MG/5ML** | **A207511** | **001** | Nov 23, 2016 |
| **AA** | | | **100MG/5ML** | **A209897** | **001** | Sep 06, 2017 |
| **AA** | | WEST-WARD PHARMS INT | **5MG/5ML** | **A204037** | **001** | Jul 15, 2013 |
| **AA** | | | **100MG/5ML** | **A203208** | **001** | Jul 12, 2013 |
| **AA** | | WOCKHARDT BIO AG | **5MG/5ML** | **A206456** | **001** | Jun 16, 2015 |

TABLET;ORAL

**OXYCODONE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS ELIZABETH | **5MG** | **A076636** | **003** | Apr 07, 2015 |
| **AB** | | | **15MG** | **A076636** | **001** | Feb 06, 2004 |
| **AB** | | | **30MG** | **A076636** | **002** | Feb 06, 2004 |
| **AB** | | ALVOGEN MALTA | **5MG** | **A202116** | **001** | Dec 30, 2011 |
| **AB** | | | **15MG** | **A202116** | **002** | Dec 30, 2011 |

OXYCODONE HYDROCHLORIDE

TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **OXYCODONE HYDROCHLORIDE** | | | | | | |
| **AB** | | **30MG** | **A202116** | **003** | Dec 30, 2011 | |
| **AB** | AMNEAL PHARMS | **5MG** | **A203638** | **001** | Jun 03, 2014 | |
| **AB** | | **10MG** | **A203638** | **002** | Jun 03, 2014 | |
| **AB** | | **15MG** | **A203638** | **003** | Jun 03, 2014 | |
| **AB** | | **20MG** | **A203638** | **004** | Jun 03, 2014 | |
| **AB** | | **30MG** | **A203638** | **005** | Jun 03, 2014 | |
| **AB** | ASCENT PHARMS INC | **15MG** | **A207418** | **001** | Aug 07, 2017 | |
| **AB** | | **30MG** | **A207418** | **002** | Aug 07, 2017 | |
| **AB** | AUROLIFE PHARMA LLC | **5MG** | **A202160** | **001** | Nov 19, 2012 | |
| **AB** | | **15MG** | **A202160** | **002** | Nov 19, 2012 | |
| **AB** | | **30MG** | **A202160** | **003** | Nov 19, 2012 | |
| **AB** | AVANTHI INC | **5MG** | **A091393** | **001** | Aug 31, 2009 | |
| **AB** | | **10MG** | **A091393** | **002** | Aug 31, 2009 | |
| **AB** | | **15MG** | **A091393** | **003** | Aug 31, 2009 | |
| **AB** | | **20MG** | **A091393** | **004** | Aug 31, 2009 | |
| **AB** | | **30MG** | **A091393** | **005** | Aug 31, 2009 | |
| **AB** | EPIC PHARMA LLC | **5MG** | **A090895** | **001** | Aug 24, 2009 | |
| **AB** | | **5MG** | **A202662** | **001** | Sep 22, 2015 | |
| **AB** | | **10MG** | **A202662** | **002** | Sep 22, 2015 | |
| **AB** | | **15MG** | **A090895** | **002** | Aug 24, 2009 | |
| **AB** | | **15MG** | **A202662** | **003** | Sep 22, 2015 | |
| **AB** | | **30MG** | **A090895** | **003** | Aug 24, 2009 | |
| **AB** | | **30MG** | **A202662** | **004** | Sep 22, 2015 | |
| **AB** | KEN LIFESCIENCE | **5MG** | **A207119** | **001** | Apr 12, 2016 | |
| **AB** | | **10MG** | **A207119** | **002** | Apr 12, 2016 | |
| **AB** | | **15MG** | **A207119** | **003** | Apr 12, 2016 | |
| **AB** | | **20MG** | **A207119** | **004** | Apr 12, 2016 | |
| **AB** | | **30MG** | **A207119** | **005** | Apr 12, 2016 | |
| **AB** | MAYNE PHARMA INC | **5MG** | **A091313** | **001** | Feb 18, 2011 | |
| **AB** | | **10MG** | **A091313** | **004** | Apr 29, 2016 | |
| **AB** | | **15MG** | **A091313** | **002** | Feb 18, 2011 | |
| **AB** | | **20MG** | **A091313** | **005** | Apr 29, 2016 | |
| **AB** | | **30MG** | **A091313** | **003** | Feb 18, 2011 | |
| **AB** | NESHER PHARMS | **5MG** | **A077290** | **001** | Dec 08, 2005 | |
| **AB** | | **10MG** | **A077290** | **002** | Dec 08, 2005 | |
| **AB** | | **15MG** | **A077290** | **003** | Dec 08, 2005 | |
| **AB** | | **20MG** | **A077290** | **004** | Dec 08, 2005 | |
| **AB** | | **30MG** | **A077290** | **005** | Dec 08, 2005 | |
| **AB** | NOVEL LABS INC | **5MG** | **A204021** | **001** | Jun 12, 2017 | |
| **AB** | | **10MG** | **A204021** | **002** | Jun 12, 2017 | |
| **AB** | | **15MG** | **A204021** | **003** | Jun 12, 2017 | |
| **AB** | | **20MG** | **A204021** | **004** | Jun 12, 2017 | |
| **AB** | | **30MG** | **A204021** | **005** | Jun 12, 2017 | |
| **AB** | RHODES PHARMS | **5MG** | **A091490** | **001** | Mar 09, 2011 | |
| **AB** | | **10MG** | **A091490** | **002** | Mar 09, 2011 | |
| **AB** | | **15MG** | **A091490** | **003** | Mar 09, 2011 | |
| **AB** | | **20MG** | **A091490** | **004** | Mar 09, 2011 | |
| **AB** | | **30MG** | **A091490** | **005** | Mar 09, 2011 | |
| **AB** | SPECGX LLC | **5MG** | **A076758** | **003** | Mar 19, 2007 | |
| **AB** | | **15MG** | **A076758** | **001** | Jun 30, 2004 | |
| **AB** | | **30MG** | **A076758** | **002** | Jun 30, 2004 | |
| **AB** | SUN PHARM INDS INC | **5MG** | **A090659** | **001** | Apr 10, 2009 | |
| **AB** | | **10MG** | **A090659** | **005** | Nov 06, 2012 | |
| **AB** | | **15MG** | **A090659** | **002** | Apr 10, 2009 | |
| **AB** | | **20MG** | **A090659** | **004** | Nov 06, 2012 | |
| **AB** | | **30MG** | **A090659** | **003** | Apr 10, 2009 | |
| **AB** | VINTAGE PHARMS | **5MG** | **A077712** | **003** | Mar 02, 2009 | |
| **AB** | | **10MG** | **A077712** | **004** | Apr 13, 2015 | |
| **AB** | | **15MG** | **A077712** | **001** | Jan 31, 2007 | |
| **AB** | | **20MG** | **A077712** | **005** | Apr 13, 2015 | |
| **AB** | | **30MG** | **A077712** | **002** | Jan 31, 2007 | |
| **ROXICODONE** | | | | | | |
| **AB** + | SPECGX LLC | **5MG** | **N021011** | **003** | May 15, 2009 | |
| **AB** +! | | **15MG** | **N021011** | **001** | Aug 31, 2000 | |
| **AB** + | | **30MG** | **N021011** | **002** | Aug 31, 2000 | |
| OXAYDO | | | | | | |
| | EGALET US INC | 5MG | N202080 | 001 | Jun 17, 2011 | |
| | | 7.5MG | N202080 | 002 | Jun 17, 2011 | |

OXYCODONE HYDROCHLORIDE

TABLET;ORAL

ROXYBOND

| | | | | | |
|---|---|---|---|---|---|
| | DAIICHI SANKYO INC | 5MG | N209777 | 001 | Apr 20, 2017 |
| | | 15MG | N209777 | 002 | Apr 20, 2017 |
| | | 30MG | N209777 | 003 | Apr 20, 2017 |

TABLET, EXTENDED RELEASE;ORAL

OXYCONTIN

| | | | | | |
|---|---|---|---|---|---|
| + | PURDUE PHARMA LP | 10MG | N022272 | 001 | Apr 05, 2010 |
| + | | 15MG | N022272 | 002 | Apr 05, 2010 |
| + | | 20MG | N022272 | 003 | Apr 05, 2010 |
| + | | 30MG | N022272 | 004 | Apr 05, 2010 |
| +! | | 40MG | N022272 | 005 | Apr 05, 2010 |
| + | | 60MG | N022272 | 006 | Apr 05, 2010 |
| + | | 80MG | N022272 | 007 | Apr 05, 2010 |

OXYMETAZOLINE HYDROCHLORIDE

CREAM;TOPICAL

RHOFADE

| | | | | | |
|---|---|---|---|---|---|
| +! | ALLERGAN INC | 1% | N208552 | 001 | Jan 18, 2017 |

OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE

SPRAY, METERED;NASAL

KOVANAZE

| | | | | | |
|---|---|---|---|---|---|
| +! | ST RENATUS | 0.1MG/SPRAY;6MG/SPRAY | N208032 | 001 | Jun 29, 2016 |

OXYMETHOLONE

TABLET;ORAL

ANADROL-50

| | | | | | |
|---|---|---|---|---|---|
| +! | MYLAN SPECIALITY LP | 50MG | N016848 | 001 | |

OXYMORPHONE HYDROCHLORIDE

TABLET;ORAL

**OPANA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | ENDO PHARMS | **5MG** | **N021611** | **001** | Jun 22, 2006 |
| **AB** | **+!** | | **10MG** | **N021611** | **002** | Jun 22, 2006 |

**OXYMORPHONE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AUROLIFE PHARMA LLC | **5MG** | **A204459** | **001** | Apr 26, 2016 |
| **AB** | | | **10MG** | **A204459** | **002** | Apr 26, 2016 |
| **AB** | | AVANTHI INC | **5MG** | **A203601** | **001** | Jan 30, 2013 |
| **AB** | | | **10MG** | **A203601** | **002** | Jan 30, 2013 |
| **AB** | | EPIC PHARMA LLC | **5MG** | **A201187** | **001** | Dec 15, 2014 |
| **AB** | | | **10MG** | **A201187** | **002** | Dec 15, 2014 |
| **AB** | | SPECGX LLC | **5MG** | **A202321** | **001** | Apr 25, 2013 |
| **AB** | | | **10MG** | **A202321** | **002** | Apr 25, 2013 |
| **AB** | | TEVA | **5MG** | **A091443** | **002** | Feb 15, 2011 |
| **AB** | | | **10MG** | **A091443** | **001** | Feb 15, 2011 |
| **AB** | | WEST-WARD PHARMS INT | **5MG** | **A090964** | **001** | Sep 27, 2010 |
| **AB** | | | **10MG** | **A090964** | **002** | Sep 27, 2010 |

TABLET, EXTENDED RELEASE;ORAL

**OXYMORPHONE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS ELIZABETH | **5MG** | **A079046** | **003** | Jul 11, 2013 |
| **AB** | | | **7.5MG** | **A079046** | **001** | Dec 13, 2010 |
| **AB** | | | **10MG** | **A079046** | **004** | Jul 11, 2013 |
| **AB** | | | **15MG** | **A079046** | **002** | Dec 13, 2010 |
| **AB** | | | **20MG** | **A079046** | **005** | Jul 11, 2013 |
| **AB** | | | **30MG** | **A079046** | **006** | Jul 11, 2013 |
| **AB** | | | **40MG** | **A079046** | **007** | Jul 11, 2013 |
| **AB** | | IMPAX LABS | **5MG** | **A079087** | **001** | Jun 14, 2010 |
| **AB** | | | **7.5MG** | **A079087** | **002** | Dec 21, 2010 |
| **AB** | | | **10MG** | **A079087** | **003** | Jun 14, 2010 |
| **AB** | | | **15MG** | **A079087** | **004** | Dec 21, 2010 |
| **AB** | | | **20MG** | **A079087** | **005** | Jun 14, 2010 |
| **AB** | | | **30MG** | **A079087** | **006** | Jul 22, 2010 |
| **AB** | | | **40MG** | **A079087** | **007** | Jun 14, 2010 |
| **AB** | | SPECGX LLC | **5MG** | **A202946** | **001** | Jun 27, 2014 |
| **AB** | | | **7.5MG** | **A202946** | **002** | Jun 27, 2014 |
| **AB** | | | **10MG** | **A202946** | **003** | Jun 27, 2014 |
| **AB** | | | **15MG** | **A202946** | **004** | Jun 27, 2014 |
| **AB** | | | **20MG** | **A202946** | **005** | Jun 27, 2014 |
| **AB** | | | **30MG** | **A202946** | **006** | Jun 27, 2014 |
| **AB** | | | **40MG** | **A202946** | **007** | Jun 27, 2014 |
| **AB** | | SUN PHARM INDS LTD | **5MG** | **A203506** | **001** | Apr 24, 2015 |
| **AB** | | | **7.5MG** | **A203506** | **002** | Apr 24, 2015 |

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

**OXYMORPHONE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **10MG** | **A203506** | **003** | Apr 24, 2015 |
| **AB** | | | **15MG** | **A203506** | **004** | Apr 24, 2015 |
| **AB** | | | **20MG** | **A203506** | **005** | Apr 24, 2015 |
| **AB** | | | **30MG** | **A203506** | **006** | Apr 24, 2015 |
| **AB** | | | **40MG** | **A203506** | **007** | Apr 24, 2015 |
| **AB** | | WEST-WARD PHARMS INT | **5MG** | **A200822** | **002** | Jul 15, 2013 |
| **AB** | | | **7.5MG** | **A200822** | **003** | Jul 15, 2013 |
| **AB** | | | **10MG** | **A200822** | **004** | Jul 15, 2013 |
| **AB** | | | **15MG** | **A200822** | **005** | Jul 15, 2013 |
| **AB** | | | **20MG** | **A200822** | **006** | Jul 15, 2013 |
| **AB** | | | **30MG** | **A200822** | **007** | Jul 15, 2013 |
| **AB** | | | **40MG** | **A200822** | **001** | Jul 15, 2013 |

OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

TERRAMYCIN W/ POLYMYXIN B SULFATE

| | | | | | |
|---|---|---|---|---|---|
| ! | CASPER PHARMA LLC | EQ 5MG BASE/GM;10,000 UNITS/GM | A061015 | 001 | |

OXYTOCIN

INJECTABLE;INJECTION

**OXYTOCIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | FRESENIUS KABI USA | **10USP UNITS/ML (10USP UNITS/ML)** | **N018248** | **001** | |
| **AP** | **+!** | | **100USP UNITS/10ML (10USP UNITS/ML)** | **N018248** | **002** | |
| **AP** | | HIKMA FARMACEUTICA | **10USP UNITS/ML (10USP UNITS/ML)** | **A200219** | **001** | Feb 13, 2013 |
| **AP** | **+!** | WEST-WARD PHARMS INT | **10USP UNITS/ML (10USP UNITS/ML)** | **N018243** | **001** | |
| **AP** | **+!** | | **100USP UNITS/10ML (10USP UNITS/ML)** | **N018243** | **002** | Jan 10, 2007 |

**PITOCIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | PAR STERILE PRODUCTS | **10USP UNITS/ML (10USP UNITS/ML)** | **N018261** | **001** | |
| **AP** | **+** | | **100USP UNITS/10ML (10USP UNITS/ML)** | **N018261** | **002** | Jul 27, 2007 |

OXYTOCIN

| | | | | | |
|---|---|---|---|---|---|
| +! | FRESENIUS KABI USA | 300USP UNITS/30ML (10USP UNITS/ML) | N018248 | 003 | Jul 27, 2007 |

PITOCIN

| | | | | | |
|---|---|---|---|---|---|
| + | PAR STERILE PRODUCTS | 500USP UNITS/50ML (10USP UNITS/ML) | N018261 | 003 | Sep 05, 2012 |

OZENOXACIN

CREAM;TOPICAL

XEPI

| | | | | | |
|---|---|---|---|---|---|
| +! | FERRER INTERNACIONAL | 1% | N208945 | 001 | Dec 11, 2017 |

PACLITAXEL

FOR SUSPENSION;IV (INFUSION)

ABRAXANE

| | | | | | |
|---|---|---|---|---|---|
| +! | ABRAXIS BIOSCIENCE | 100MG/VIAL | N021660 | 001 | Jan 07, 2005 |

INJECTABLE;INJECTION

**PACITAXEL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | GLAND PHARMA LTD | **6MG/ML** | **A207326** | **001** | Aug 23, 2016 |

**PACLITAXEL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | ACTAVIS TOTOWA | **6MG/ML** | **A090130** | **001** | Dec 09, 2009 |
| **AP** | | FRESENIUS KABI ONCOL | **6MG/ML** | **A077574** | **001** | Nov 27, 2006 |
| **AP** | **!** | HOSPIRA | **6MG/ML** | **A076131** | **001** | May 08, 2002 |
| **AP** | | MYLAN LABS LTD | **6MG/ML** | **A091540** | **001** | Sep 29, 2011 |
| **AP** | | SANDOZ INC | **6MG/ML** | **A078167** | **001** | Dec 26, 2007 |
| **AP** | | TEVA PHARMS | **6MG/ML** | **A075184** | **001** | Jan 25, 2002 |
| **AP** | | WEST-WARD PHARMS INT | **6MG/ML** | **A075190** | **001** | Jan 28, 2002 |

**TAXOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+** | HQ SPCLT PHARMA | **6MG/ML** | **N020262** | **001** | Dec 29, 1992 |

PALBOCICLIB

CAPSULE;ORAL

IBRANCE

| | | | | | |
|---|---|---|---|---|---|
| + | PFIZER INC | 75MG | N207103 | 001 | Feb 03, 2015 |
| + | | 100MG | N207103 | 002 | Feb 03, 2015 |
| +! | | 125MG | N207103 | 003 | Feb 03, 2015 |

PALIPERIDONE

TABLET, EXTENDED RELEASE;ORAL

**INVEGA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | JANSSEN PHARMS | **1.5MG** | **N021999** | **006** | Aug 26, 2008 |
| **AB** | **+** | | **3MG** | **N021999** | **001** | Dec 19, 2006 |
| **AB** | **+!** | | **6MG** | **N021999** | **002** | Dec 19, 2006 |
| **AB** | **+** | | **9MG** | **N021999** | **003** | Dec 19, 2006 |

**PALIPERIDONE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS LABS FL INC | **1.5MG** | **A202645** | **001** | Aug 03, 2015 |
| **AB** | | | **3MG** | **A202645** | **002** | Aug 03, 2015 |
| **AB** | | | **6MG** | **A202645** | **003** | Aug 03, 2015 |
| **AB** | | | **9MG** | **A202645** | **004** | Aug 03, 2015 |
| **AB** | | MYLAN PHARMS INC | **1.5MG** | **A203802** | **001** | Sep 24, 2015 |
| **AB** | | | **3MG** | **A203802** | **002** | Sep 24, 2015 |
| **AB** | | | **6MG** | **A203802** | **003** | Sep 24, 2015 |
| **AB** | | | **9MG** | **A203802** | **004** | Sep 24, 2015 |

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

INVEGA SUSTENNA

| | | | | | |
|---|---|---|---|---|---|
| + | JANSSEN PHARMS | 39MG/0.25ML (39MG/0.25ML) | N022264 | 001 | Jul 31, 2009 |
| + | | 78MG/0.5ML (78MG/0.5ML) | N022264 | 002 | Jul 31, 2009 |
| + | | 117MG/0.75ML (117MG/0.75ML) | N022264 | 003 | Jul 31, 2009 |
| +! | | 156MG/ML (156MG/ML) | N022264 | 004 | Jul 31, 2009 |
| + | | 234MG/1.5ML (156MG/ML) | N022264 | 005 | Jul 31, 2009 |

INVEGA TRINZA

| | | | | | |
|---|---|---|---|---|---|
| + | JANSSEN PHARMS | 273MG/0.875ML (273MG/0.875ML) | N207946 | 001 | May 18, 2015 |
| + | | 410MG/1.315ML (311.79MG/ML) | N207946 | 002 | May 18, 2015 |
| + | | 546MG/1.75ML (312MG/ML) | N207946 | 003 | May 18, 2015 |
| +! | | 819MG/2.625ML (312MG/ML) | N207946 | 004 | May 18, 2015 |

PALONOSETRON HYDROCHLORIDE

INJECTABLE;INTRAVENOUS

**ALOXI**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | HELSINN HLTHCARE | **EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)** | **N021372** | **002** | Feb 29, 2008 |
| **AP** | **+!** | | **EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)** | **N021372** | **001** | Jul 25, 2003 |

**PALONOSETRON HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | DR REDDYS LABS LTD | **EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)** | **A201533** | **001** | Apr 21, 2016 |
| **AP** | | | **EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)** | **A201533** | **002** | Apr 21, 2016 |
| **AP** | | SANDOZ INC | **EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)** | **A202521** | **001** | Oct 13, 2015 |

SOLUTION;INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

| | | | | | |
|---|---|---|---|---|---|
| | EXELA PHARMA SCIENCE | EQ 0.25MG BASE/2ML (EQ 0.125MG BASE/ML) | N207963 | 001 | Aug 22, 2016 |
| + | FRESENIUS KABI USA | EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) | N208109 | 001 | Nov 21, 2017 |

PAMIDRONATE DISODIUM

INJECTABLE;INJECTION

**PAMIDRONATE DISODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AREVA PHARMS | **30MG/VIAL** | **A077433** | **001** | Nov 26, 2008 |
| **AP** | | | **90MG/VIAL** | **A077433** | **003** | Nov 26, 2008 |
| **AP** | | FRESENIUS KABI USA | **30MG/VIAL** | **A075773** | **001** | May 06, 2002 |
| **AP** | | | **30MG/10ML (3MG/ML)** | **A076207** | **001** | May 17, 2002 |
| **AP** | | | **90MG/VIAL** | **A075773** | **002** | May 06, 2002 |
| **AP** | | | **90MG/10ML (9MG/ML)** | **A076207** | **002** | May 17, 2002 |
| **AP** | **!** | HOSPIRA | **30MG/10ML (3MG/ML)** | **A075841** | **001** | Jun 27, 2002 |
| **AP** | **!** | | **60MG/10ML (6MG/ML)** | **A075841** | **002** | Jun 27, 2002 |
| **AP** | **!** | | **90MG/10ML (9MG/ML)** | **A075841** | **003** | Jun 27, 2002 |
| **AP** | | LUITPOLD | **30MG/10ML (3MG/ML)** | **A078942** | **001** | Jul 25, 2008 |
| **AP** | | | **90MG/10ML (9MG/ML)** | **A078942** | **002** | Jul 25, 2008 |
| **AP** | | MYLAN LABS LTD | **30MG/10ML (3MG/ML)** | **A078520** | **001** | Oct 31, 2008 |
| **AP** | | | **90MG/10ML (9MG/ML)** | **A078520** | **002** | Oct 31, 2008 |
| **AP** | | PLIVA LACHEMA | **30MG/10ML (3MG/ML)** | **A078156** | **001** | Aug 19, 2008 |
| **AP** | | | **60MG/10ML (6MG/ML)** | **A078156** | **002** | Aug 19, 2008 |
| **AP** | | | **90MG/10ML (9MG/ML)** | **A078156** | **003** | Aug 19, 2008 |
| **AP** | | SAGENT PHARMS | **30MG/10ML (3MG/ML)** | **A078373** | **001** | Dec 23, 2008 |
| **AP** | | | **90MG/10ML (9MG/ML)** | **A078373** | **002** | Dec 23, 2008 |
| **AP** | | SUN PHARMA GLOBAL | **30MG/VIAL** | **A077703** | **001** | Dec 24, 2008 |
| **AP** | | | **90MG/VIAL** | **A077703** | **002** | Dec 24, 2008 |
| **AP** | | TEVA PHARMS USA | **30MG/10ML (3MG/ML)** | **A076153** | **001** | Mar 27, 2002 |
| **AP** | | | **90MG/10ML (9MG/ML)** | **A076153** | **002** | Mar 27, 2002 |
| **AP** | | WEST-WARD PHARMS INT | **30MG/VIAL** | **A075290** | **001** | Apr 30, 2001 |

PAMIDRONATE DISODIUM

INJECTABLE;INJECTION

**PAMIDRONATE DISODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | | **30MG/10ML (3MG/ML)** | **N021113** | **001** | Mar 04, 2002 |
| **AP** | | | **90MG/VIAL** | **A075290** | **003** | Apr 30, 2001 |
| **AP** | **+!** | | **90MG/10ML (9MG/ML)** | **N021113** | **002** | Mar 04, 2002 |
| | | AREVA PHARMS | 60MG/VIAL | A077433 | 002 | Nov 26, 2008 |

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE;ORAL

CREON

| | | | | | |
|---|---|---|---|---|---|
| + | ABBVIE | 60,000USP UNITS;12,000USP UNITS;38,000USP UNITS | N020725 | 002 | Apr 30, 2009 |
| + | | 15,000USP UNITS;3,000USP UNITS;9,500USP UNITS | N020725 | 004 | Jul 12, 2011 |
| + | | 30,000USP UNITS;6,000USP UNITS;19,000USP UNITS | N020725 | 001 | Apr 30, 2009 |
| + | | 180,000USP UNITS;36,000USP UNITS;114,000USP UNITS | N020725 | 005 | Mar 14, 2013 |
| +! | | 120,000USP UNITS;24,000USP UNITS;76,000USP UNITS | N020725 | 003 | Apr 30, 2009 |

PANCREAZE

| | | | | | |
|---|---|---|---|---|---|
| + | JANSSEN PHARMS | 10,850USP UNITS;2,600USP UNITS;6,200USP UNITS | N022523 | 005 | Mar 07, 2014 |
| + | | 17,500USP/ UNITS;4,200USP/ UNITS;10,000USP/ UNITS | N022523 | 001 | Apr 12, 2010 |
| + | | 43,750USP/ UNITS;10,500USP/ UNITS;25,000USP/ UNITS | N022523 | 002 | Apr 12, 2010 |
| +! | | 61,000USP/ UNITS;21,000USP/ UNITS;37,000USP/ UNITS | N022523 | 003 | Apr 12, 2010 |
| + | | 70,000USP/ UNITS;16,800USP/ UNITS;40,000USP/ UNITS | N022523 | 004 | Apr 12, 2010 |

PERTZYE

| | | | | | |
|---|---|---|---|---|---|
| + | DIGESTIVE CARE INC | 30,250USP UNITS;8,000USP UNITS;28,750USP UNITS | N022175 | 001 | May 17, 2012 |
| +! | | 60,500USP UNITS;16,000USP UNITS;57,500USP UNITS | N022175 | 002 | May 17, 2012 |
| + | | 15,125USP UNITS;4,000USP UNITS;14,375USP UNITS | N022175 | 003 | Oct 06, 2016 |
| + | | 90,750USP UNITS;24,000USP UNITS;86,250USP UNITS | N022175 | 004 | Jul 13, 2017 |

ULTRESA

| | | | | | |
|---|---|---|---|---|---|
| + | FOREST LABS INC | 27,600USP UNITS;13,800USP UNITS;27,600USP UNITS | N022222 | 001 | Mar 01, 2012 |
| + | | 41,400USP UNITS;20,700USP UNITS;41,400USP UNITS | N022222 | 002 | Mar 01, 2012 |
| +! | | 46,000USP UNITS;23,000USP UNITS;46,000USP UNITS | N022222 | 003 | Mar 01, 2012 |

ZENPEP

| | | | | | |
|---|---|---|---|---|---|
| + | FOREST LABS INC | 168,000USP UNITS;40,000USP UNITS;126,000USP UNITS | N022210 | 007 | Mar 25, 2014 |
| + | | 14,000USP UNITS;3,000USP UNITS;10,000USP UNITS | N022210 | 005 | Jun 15, 2011 |
| + | | 24,000USP UNITS;5,000USP UNITS;17,000USP UNITS | N022210 | 001 | Aug 27, 2009 |
| + | | 42,000USP UNITS;10,000USP UNITS;32,000USP UNITS | N022210 | 002 | Aug 27, 2009 |
| + | | 63,000USP UNITS;15,000USP UNITS;47,000USP UNITS | N022210 | 003 | Aug 27, 2009 |
| + | | 84,000USP UNITS;20,000USP UNITS;63,000USP UNITS | N022210 | 004 | Aug 27, 2009 |
| +! | | 105,000USP UNITS;25,000USP UNITS;79,000USP UNITS | N022210 | 006 | Jul 13, 2011 |

TABLET;ORAL

VIOKACE

| | | | | | |
|---|---|---|---|---|---|
| + | FOREST LABS INC | 39,150USP UNITS;10,440USP UNITS;39,150USP UNITS | N022542 | 001 | Mar 01, 2012 |
| +! | | 78,300USP UNITS;20,880USP UNITS;78,300USP UNITS | N022542 | 002 | Mar 01, 2012 |

PANCURONIUM BROMIDE

INJECTABLE;INJECTION

**PANCURONIUM BROMIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | HOSPIRA | **1MG/ML** | **A072320** | **001** | Jan 19, 1989 |
| **AP** | **!** | TEVA PHARMS USA | **1MG/ML** | **A072759** | **001** | Jul 31, 1990 |
| | ! | | 2MG/ML | A072760 | 001 | Jul 31, 1990 |

| | | | | | | |
|---|---|---|---|---|---|---|
| PANOBINOSTAT LACTATE | | | | | | |
| CAPSULE;ORAL | | | | | | |
| FARYDAK | | | | | | |
| | + | NOVARTIS PHARMS CORP | EQ 10MG BASE | N205353 | 001 | Feb 23, 2015 |
| | + | | EQ 15MG BASE | N205353 | 002 | Feb 23, 2015 |
| | +! | | EQ 20MG BASE | N205353 | 003 | Feb 23, 2015 |
| PANTOPRAZOLE SODIUM | | | | | | |
| FOR SUSPENSION, DELAYED RELEASE;ORAL | | | | | | |
| PROTONIX | | | | | | |
| | +! | WYETH PHARMS INC | EQ 40MG BASE | N022020 | 001 | Nov 14, 2007 |
| INJECTABLE;IV (INFUSION) | | | | | | |
| **PANTOPRAZOLE SODIUM** | | | | | | |
| **AP** | | AKORN INC | **EQ 40MG BASE/VIAL** | **A079197** | **001** | Nov 08, 2012 |
| **AP** | | AUROBINDO PHARMA LTD | **EQ 40MG BASE/VIAL** | **A205675** | **001** | Mar 30, 2016 |
| **AP** | | SANDOZ INC | **EQ 40MG BASE/VIAL** | **A090296** | **001** | Jul 14, 2015 |
| **PROTONIX IV** | | | | | | |
| **AP** | **+!** | WYETH PHARMS INC | **EQ 40MG BASE/VIAL** | **N020988** | **001** | Mar 22, 2001 |
| POWDER;IV (INFUSION) | | | | | | |
| PANTOPRAZOLE SODIUM | | | | | | |
| | | EXELA PHARMA SCS LLC | EQ 40MG BASE/VIAL | N209463 | 001 | Jun 30, 2017 |
| TABLET, DELAYED RELEASE;ORAL | | | | | | |
| **PANTOPRAZOLE SODIUM** | | | | | | |
| **AB** | | ACTAVIS TOTOWA | **EQ 20MG BASE** | **A090797** | **001** | Feb 07, 2011 |
| **AB** | | | **EQ 40MG BASE** | **A090797** | **002** | Feb 07, 2011 |
| **AB** | | AMNEAL PHARMS | **EQ 20MG BASE** | **A205119** | **001** | Jan 26, 2016 |
| **AB** | | | **EQ 40MG BASE** | **A205119** | **002** | Jan 26, 2016 |
| **AB** | | APOTEX INC | **EQ 20MG BASE** | **A090807** | **001** | May 02, 2012 |
| **AB** | | | **EQ 40MG BASE** | **A090807** | **002** | May 02, 2012 |
| **AB** | | AUROBINDO PHARMA LTD | **EQ 20MG BASE** | **A202038** | **001** | Sep 28, 2012 |
| **AB** | | | **EQ 40MG BASE** | **A202038** | **002** | Sep 28, 2012 |
| **AB** | | DR REDDYS LABS LTD | **EQ 20MG BASE** | **A077619** | **001** | Jan 19, 2011 |
| **AB** | | | **EQ 40MG BASE** | **A077619** | **002** | Jan 19, 2011 |
| **AB** | | HETERO LABS LTD V | **EQ 20MG BASE** | **A202882** | **001** | Sep 10, 2014 |
| **AB** | | | **EQ 40MG BASE** | **A202882** | **002** | Sep 10, 2014 |
| **AB** | | JUBILANT GENERICS | **EQ 20MG BASE** | **A090901** | **001** | Aug 30, 2011 |
| **AB** | | | **EQ 40MG BASE** | **A090901** | **002** | Aug 30, 2011 |
| **AB** | | KREMERS URBAN PHARMS | **EQ 20MG BASE** | **A078281** | **001** | Jan 20, 2011 |
| **AB** | | | **EQ 40MG BASE** | **A078281** | **002** | Jan 20, 2011 |
| **AB** | | MACLEODS PHARMS LTD | **EQ 20MG BASE** | **A200821** | **001** | Feb 16, 2012 |
| **AB** | | | **EQ 40MG BASE** | **A200821** | **002** | Feb 16, 2012 |
| **AB** | | MYLAN PHARMS INC | **EQ 20MG BASE** | **A090970** | **001** | Jan 19, 2011 |
| **AB** | | | **EQ 40MG BASE** | **A090970** | **002** | Jan 19, 2011 |
| **AB** | | ORCHID HLTHCARE | **EQ 20MG BASE** | **A202052** | **001** | Dec 02, 2014 |
| **AB** | | | **EQ 40MG BASE** | **A202052** | **002** | Dec 02, 2014 |
| **AB** | | PERRIGO R AND D | **EQ 20MG BASE** | **A203024** | **001** | May 07, 2014 |
| **AB** | | SUN PHARM INDS LTD | **EQ 20MG BASE** | **A200794** | **001** | May 02, 2012 |
| **AB** | | | **EQ 40MG BASE** | **A200794** | **002** | May 02, 2012 |
| **AB** | | TEVA | **EQ 20MG BASE** | **A077056** | **001** | Aug 02, 2007 |
| **AB** | | | **EQ 40MG BASE** | **A077056** | **002** | Aug 02, 2007 |
| **AB** | | TORRENT PHARMS | **EQ 20MG BASE** | **A090074** | **001** | Jan 19, 2011 |
| **AB** | | | **EQ 40MG BASE** | **A090074** | **002** | Jan 19, 2011 |
| **AB** | | WOCKHARDT | **EQ 20MG BASE** | **A091231** | **001** | Jan 19, 2011 |
| **AB** | | | **EQ 40MG BASE** | **A091231** | **002** | Jan 19, 2011 |
| **PROTONIX** | | | | | | |
| **AB** | **+** | WYETH PHARMS INC | **EQ 20MG BASE** | **N020987** | **002** | Jun 12, 2001 |
| **AB** | **+!** | | **EQ 40MG BASE** | **N020987** | **001** | Feb 02, 2000 |
| PARICALCITOL | | | | | | |
| CAPSULE;ORAL | | | | | | |
| **PARICALCITOL** | | | | | | |
| **AB** | | AMNEAL PHARMS | **1MCG** | **A204327** | **001** | Jan 13, 2016 |
| **AB** | | | **2MCG** | **A204327** | **002** | Jan 13, 2016 |
| **AB** | | | **4MCG** | **A204327** | **003** | Jan 13, 2016 |
| **AB** | | AUROBINDO PHARMA LTD | **1MCG** | **A207672** | **001** | Jan 14, 2016 |
| **AB** | | | **2MCG** | **A207672** | **002** | Jan 14, 2016 |
| **AB** | | | **4MCG** | **A207672** | **003** | Jan 14, 2016 |
| **AB** | | BIONPHARMA INC | **1MCG** | **A202539** | **001** | Mar 27, 2014 |
| **AB** | | | **2MCG** | **A202539** | **002** | Mar 27, 2014 |

PARICALCITOL

CAPSULE;ORAL

**PARICALCITOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **4MCG** | **A202539** | **003** | Mar 27, 2014 |
| **AB** | | DR REDDYS LABS LTD | **1MCG** | **A091412** | **001** | Jun 24, 2014 |
| **AB** | | | **2MCG** | **A091412** | **002** | Jun 24, 2014 |
| **AB** | | | **4MCG** | **A091412** | **003** | Jun 24, 2014 |
| **AB** | | ECI PHARMS LLC | **1MCG** | **A206710** | **001** | Feb 24, 2016 |
| **AB** | | | **2MCG** | **A206710** | **002** | Feb 24, 2016 |
| **AB** | | | **4MCG** | **A206710** | **003** | Feb 24, 2016 |
| **AB** | | MARKSANS PHARMA | **1MCG** | **A204948** | **001** | Oct 07, 2016 |
| **AB** | | | **2MCG** | **A204948** | **002** | Oct 07, 2016 |
| **AB** | | | **4MCG** | **A204948** | **003** | Oct 07, 2016 |
| **AB** | | RISING PHARMS INC | **1MCG** | **A202124** | **001** | Jun 24, 2014 |
| **AB** | | | **2MCG** | **A202124** | **002** | Jun 24, 2014 |
| **AB** | | | **4MCG** | **A202124** | **003** | Jun 24, 2014 |
| **AB** | | TEVA PHARMS USA | **1MCG** | **A090829** | **001** | Sep 27, 2013 |
| **AB** | | | **2MCG** | **A090829** | **002** | Sep 27, 2013 |
| **AB** | **!** | | **4MCG** | **A090829** | **003** | Sep 27, 2013 |

**ZEMPLAR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | ABBVIE | **1MCG** | **N021606** | **001** | May 26, 2005 |
| **AB** | **+** | | **2MCG** | **N021606** | **002** | May 26, 2005 |

SOLUTION;INTRAVENOUS

**PARICALCITOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | ACCORD HLTHCARE | **0.002MG/ML (0.002MG/ML)** | **N207174** | **001** | Feb 04, 2016 |
| **AP** | | | **0.005MG/ML (0.005MG/ML)** | **N207174** | **002** | Feb 04, 2016 |
| **AP** | | | **0.01MG/2ML (0.005MG/ML)** | **N207174** | **003** | Feb 04, 2016 |
| **AP** | | AKORN | **0.005MG/ML (0.005MG/ML)** | **A207692** | **001** | Oct 16, 2017 |
| **AP** | | AMNEAL PHARMS CO | **0.002MG/ML (0.002MG/ML)** | **A206699** | **001** | Mar 09, 2017 |
| **AP** | | | **0.005MG/ML (0.005MG/ML)** | **A206699** | **002** | Mar 09, 2017 |
| **AP** | | | **0.01MG/2ML (0.005MG/ML)** | **A206699** | **003** | Mar 09, 2017 |
| **AP** | | DR REDDYS LABS LTD | **0.002MG/ML (0.002MG/ML)** | **A204910** | **001** | Aug 17, 2016 |
| **AP** | | | **0.005MG/ML (0.005MG/ML)** | **A204910** | **002** | Aug 17, 2016 |
| **AP** | | | **0.01MG/2ML (0.005MG/ML)** | **A204910** | **003** | Aug 17, 2016 |
| **AP** | | HIKMA PHARMS | **0.002MG/ML (0.002MG/ML)** | **N205917** | **001** | Nov 18, 2014 |
| **AP** | | | **0.005MG/ML (0.005MG/ML)** | **N205917** | **002** | Nov 18, 2014 |
| **AP** | | | **0.01MG/2ML (0.005MG/ML)** | **N205917** | **003** | Nov 18, 2014 |
| **AP** | | HOSPIRA INC | **0.002MG/ML (0.002MG/ML)** | **N201657** | **001** | Oct 21, 2014 |
| **AP** | | | **0.005MG/ML (0.005MG/ML)** | **N201657** | **002** | Oct 21, 2014 |
| **AP** | | | **0.01MG/2ML (0.005MG/ML)** | **N201657** | **003** | Oct 21, 2014 |
| **AP** | | MYLAN LABS LTD | **0.002MG/ML (0.002MG/ML)** | **A203897** | **001** | Nov 02, 2017 |
| **AP** | | | **0.005MG/ML (0.005MG/ML)** | **A203897** | **002** | Nov 02, 2017 |
| **AP** | | | **0.01MG/2ML (0.005MG/ML)** | **A203897** | **003** | Nov 02, 2017 |
| **AP** | | SANDOZ INC | **0.002MG/ML (0.002MG/ML)** | **A091108** | **001** | Jul 27, 2011 |
| **AP** | | | **0.005MG/ML (0.005MG/ML)** | **A091108** | **002** | Jul 27, 2011 |
| **AP** | | | **0.01MG/2ML (0.005MG/ML)** | **A091108** | **003** | Jul 27, 2011 |

**ZEMPLAR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | ABBVIE | **0.002MG/ML (0.002MG/ML)** | **N020819** | **002** | Feb 01, 2000 |
| **AP** | **+!** | | **0.005MG/ML (0.005MG/ML)** | **N020819** | **001** | Apr 17, 1998 |
| **AP** | **+!** | | **0.01MG/2ML (0.005MG/ML)** | **N020819** | **003** | Feb 01, 2000 |

PAROMOMYCIN SULFATE

CAPSULE;ORAL

**PAROMOMYCIN SULFATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | HERITAGE PHARMS INC | **EQ 250MG BASE** | **A065173** | **001** | Dec 14, 2007 |
| **AA** | **!** | SUN PHARM INDS INC | **EQ 250MG BASE** | **A064171** | **001** | Jun 30, 1997 |

PAROXETINE HYDROCHLORIDE

SUSPENSION;ORAL

PAXIL

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | APOTEX TECHNOLOGIES | EQ 10MG BASE/5ML | N020710 | 001 | Jun 25, 1997 |

TABLET;ORAL

**PAROXETINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | PRINSTON INC | **EQ 10MG BASE** | **A203854** | **001** | Oct 31, 2014 |
| **AB** | | | **EQ 20MG BASE** | **A203854** | **002** | Oct 31, 2014 |
| **AB** | | | **EQ 30MG BASE** | **A203854** | **003** | Oct 31, 2014 |
| **AB** | | | **EQ 40MG BASE** | **A203854** | **004** | Oct 31, 2014 |

**PAROXETINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | APOTEX | **EQ 10MG BASE** | **A075356** | **001** | Jul 30, 2003 |
| **AB** | | | **EQ 20MG BASE** | **A075356** | **002** | Jul 30, 2003 |
| **AB** | | | **EQ 30MG BASE** | **A075356** | **003** | Jul 30, 2003 |
| **AB** | | | **EQ 40MG BASE** | **A075356** | **004** | Jul 30, 2003 |
| **AB** | | AUROBINDO PHARMA | **EQ 10MG BASE** | **A078406** | **001** | Jul 25, 2007 |

PAROXETINE HYDROCHLORIDE

TABLET;ORAL

**PAROXETINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **EQ 20MG BASE** | **A078406** | **002** | Jul 25, 2007 |
| **AB** | | | **EQ 30MG BASE** | **A078406** | **003** | Jul 25, 2007 |
| **AB** | | | **EQ 40MG BASE** | **A078406** | **004** | Jul 25, 2007 |
| **AB** | | JUBILANT GENERICS | **EQ 10MG BASE** | **A205528** | **001** | Nov 27, 2015 |
| **AB** | | | **EQ 20MG BASE** | **A205528** | **002** | Nov 27, 2015 |
| **AB** | | | **EQ 30MG BASE** | **A205528** | **003** | Nov 27, 2015 |
| **AB** | | | **EQ 40MG BASE** | **A205528** | **004** | Nov 27, 2015 |
| **AB** | | MYLAN | **EQ 10MG BASE** | **A078902** | **001** | Mar 13, 2008 |
| **AB** | | | **EQ 20MG BASE** | **A078902** | **002** | Mar 13, 2008 |
| **AB** | | | **EQ 30MG BASE** | **A078902** | **003** | Mar 13, 2008 |
| **AB** | | | **EQ 40MG BASE** | **A078902** | **004** | Mar 13, 2008 |
| **AB** | | OXFORD PHARMS | **EQ 10MG BASE** | **A076968** | **001** | Jun 21, 2010 |
| **AB** | | | **EQ 20MG BASE** | **A076968** | **002** | Jun 21, 2010 |
| **AB** | | | **EQ 30MG BASE** | **A076968** | **003** | Jun 21, 2010 |
| **AB** | | | **EQ 40MG BASE** | **A076968** | **004** | Jun 21, 2010 |
| **AB** | | SUN PHARM INDS INC | **EQ 10MG BASE** | **A078194** | **001** | Jun 29, 2007 |
| **AB** | | | **EQ 20MG BASE** | **A078194** | **002** | Jun 29, 2007 |
| **AB** | | | **EQ 30MG BASE** | **A078194** | **003** | Jun 29, 2007 |
| **AB** | | | **EQ 40MG BASE** | **A078194** | **004** | Jun 29, 2007 |
| **AB** | | TEVA | **EQ 10MG BASE** | **A076618** | **001** | Aug 15, 2005 |
| **AB** | | | **EQ 20MG BASE** | **A076618** | **002** | Aug 15, 2005 |
| **AB** | | | **EQ 30MG BASE** | **A076618** | **003** | Aug 15, 2005 |
| **AB** | | | **EQ 40MG BASE** | **A076618** | **004** | Aug 15, 2005 |
| **AB** | | ZYDUS PHARMS USA | **EQ 10MG BASE** | **A077584** | **001** | Mar 07, 2007 |
| **AB** | | | **EQ 20MG BASE** | **A077584** | **002** | Mar 07, 2007 |
| **AB** | | | **EQ 30MG BASE** | **A077584** | **003** | Mar 07, 2007 |
| **AB** | | | **EQ 40MG BASE** | **A077584** | **004** | Mar 07, 2007 |

**PAXIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | APOTEX TECHNOLOGIES | **EQ 10MG BASE** | **N020031** | **001** | Dec 29, 1992 |
| **AB** | **+** | | **EQ 20MG BASE** | **N020031** | **002** | Dec 29, 1992 |
| **AB** | **+** | | **EQ 30MG BASE** | **N020031** | **003** | Dec 29, 1992 |
| **AB** | **+!** | | **EQ 40MG BASE** | **N020031** | **005** | Dec 29, 1992 |

TABLET, EXTENDED RELEASE;ORAL

**PAROXETINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | KREMERS URBAN PHARMS | **EQ 12.5MG BASE** | **A204744** | **001** | Jun 10, 2016 |
| **AB** | | | **EQ 25MG BASE** | **A204744** | **002** | Jun 10, 2016 |
| **AB** | | | **EQ 37.5MG BASE** | **A204744** | **003** | Jun 10, 2016 |
| **AB** | | LUPIN LTD | **EQ 12.5MG BASE** | **A204134** | **001** | Jan 20, 2017 |
| **AB** | | | **EQ 25MG BASE** | **A204134** | **002** | Jan 20, 2017 |
| **AB** | | | **EQ 37.5MG BASE** | **A204134** | **003** | Jan 20, 2017 |
| **AB** | | MYLAN | **EQ 12.5MG BASE** | **A077873** | **001** | Jun 29, 2007 |
| **AB** | | | **EQ 25MG BASE** | **A077873** | **002** | Jun 29, 2007 |
| **AB** | | | **EQ 37.5MG BASE** | **A091427** | **001** | Apr 14, 2011 |

**PAXIL CR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | APOTEX TECHNOLOGIES | **EQ 12.5MG BASE** | **N020936** | **001** | Feb 16, 1999 |
| **AB** | **+** | | **EQ 25MG BASE** | **N020936** | **002** | Feb 16, 1999 |
| **AB** | **+!** | | **EQ 37.5MG BASE** | **N020936** | **003** | Dec 06, 2000 |

PAROXETINE MESYLATE

CAPSULE;ORAL

**BRISDELLE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | SEBELA IRELAND LTD | **EQ 7.5MG BASE** | **N204516** | **001** | Jun 28, 2013 |

**PAROXETINE MESYLATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS LABS FL INC | **EQ 7.5MG BASE** | **A207139** | **001** | Jun 20, 2017 |
| **AB** | | PRINSTON INC | **EQ 7.5MG BASE** | **A207188** | **001** | Aug 18, 2017 |

TABLET;ORAL

PEXEVA

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | SEBELA IRELAND LTD | EQ 10MG BASE | N021299 | 001 | Jul 03, 2003 |
| | + | | EQ 20MG BASE | N021299 | 002 | Jul 03, 2003 |
| | + | | EQ 30MG BASE | N021299 | 003 | Jul 03, 2003 |
| | +! | | EQ 40MG BASE | N021299 | 004 | Jul 03, 2003 |

PASIREOTIDE DIASPARTATE

SOLUTION;SUBCUTANEOUS

SIGNIFOR

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | NOVARTIS | EQ 0.3MG BASE/ML (EQ 0.3MG BASE/ML) | N200677 | 001 | Dec 14, 2012 |
| | + | | EQ 0.6MG BASE/ML (EQ 0.6MG BASE/ML) | N200677 | 002 | Dec 14, 2012 |
| | +! | | EQ 0.9MG BASE/ML (EQ 0.9MG BASE/ML) | N200677 | 003 | Dec 14, 2012 |

| | | | | | |
|---|---|---|---|---|---|
| PASIREOTIDE PAMOATE | | | | | |
| POWDER;INTRAMUSCULAR | | | | | |
| SIGNIFOR LAR | | | | | |
| + | NOVARTIS PHARMS CORP | EQ 20MG BASE/VIAL | N203255 | 001 | Dec 15, 2014 |
| + | | EQ 40MG BASE/VIAL | N203255 | 002 | Dec 15, 2014 |
| +! | | EQ 60MG BASE/VIAL | N203255 | 003 | Dec 15, 2014 |
| PATIROMER SORBITEX CALCIUM | | | | | |
| POWDER;ORAL | | | | | |
| VELTASSA | | | | | |
| + | RELYPSA INC | EQ 8.4GM BASE/PACKET | N205739 | 001 | Oct 21, 2015 |
| + | | EQ 16.8GM BASE/PACKET | N205739 | 002 | Oct 21, 2015 |
| +! | | EQ 25.2GM BASE/PACKET | N205739 | 003 | Oct 21, 2015 |
| PAZOPANIB HYDROCHLORIDE | | | | | |
| TABLET;ORAL | | | | | |
| VOTRIENT | | | | | |
| +! | NOVARTIS PHARMS CORP | EQ 200MG BASE | N022465 | 001 | Oct 19, 2009 |
| PEGADEMASE BOVINE | | | | | |
| INJECTABLE;INJECTION | | | | | |
| ADAGEN | | | | | |
| +! | SIGMA TAU | 250 UNITS/ML | N019818 | 001 | Mar 21, 1990 |
| PEGAPTANIB SODIUM | | | | | |
| INJECTABLE;INTRAVITREAL | | | | | |
| MACUGEN | | | | | |
| +! | VALEANT PHARMS LLC | EQ 0.3MG ACID/0.09ML | N021756 | 001 | Dec 17, 2004 |
| PEGVISOMANT | | | | | |
| INJECTABLE;SUBCUTANEOUS | | | | | |
| SOMAVERT | | | | | |
| +! | PHARMACIA AND UPJOHN | 10MG/VIAL | N021106 | 001 | Mar 25, 2003 |
| +! | | 15MG/VIAL | N021106 | 002 | Mar 25, 2003 |
| +! | | 20MG/VIAL | N021106 | 003 | Mar 25, 2003 |
| +! | | 25MG/VIAL | N021106 | 004 | Jul 31, 2014 |
| +! | | 30MG/VIAL | N021106 | 005 | Jul 31, 2014 |
| PEMETREXED DISODIUM | | | | | |
| INJECTABLE;IV (INFUSION) | | | | | |
| ALIMTA | | | | | |
| +! | LILLY | EQ 100MG BASE/VIAL | N021462 | 002 | Sep 07, 2007 |
| +! | | EQ 500MG BASE/VIAL | N021462 | 001 | Feb 04, 2004 |
| PENCICLOVIR | | | | | |
| CREAM;TOPICAL | | | | | |
| DENAVIR | | | | | |
| +! | MYLAN PHARMS INC | 1% | N020629 | 001 | Sep 24, 1996 |
| PENICILLAMINE | | | | | |
| CAPSULE;ORAL | | | | | |
| CUPRIMINE | | | | | |
| +! | ATON | 250MG | N019853 | 001 | |
| TABLET;ORAL | | | | | |
| DEPEN | | | | | |
| +! | MYLAN SPECIALITY LP | 250MG | N019854 | 001 | |
| PENICILLIN G BENZATHINE | | | | | |
| INJECTABLE;INJECTION | | | | | |
| BICILLIN L-A | | | | | |
| BC +! | KING PHARMS LLC | 600,000 UNITS/ML | N050141 | 001 | |
| PERMAPEN | | | | | |
| BC | CASPER PHARMA LLC | 600,000 UNITS/ML | A060014 | 001 | |
| BICILLIN L-A | | | | | |
| +! | KING PHARMS LLC | 300,000 UNITS/ML | N050141 | 003 | |
| PENICILLIN G BENZATHINE; PENICILLIN G PROCAINE | | | | | |
| INJECTABLE;INJECTION | | | | | |
| BICILLIN C-R | | | | | |
| +! | KING PHARMS LLC | 150,000 UNITS/ML;150,000 UNITS/ML | N050138 | 002 | |
| +! | | 300,000 UNITS/ML;300,000 UNITS/ML | N050138 | 001 | |
| BICILLIN C-R 900/300 | | | | | |
| +! | KING PHARMS LLC | 900,000 UNITS/2ML;300,000 UNITS/2ML | N050138 | 003 | |

| | | | | | | |
|---|---|---|---|---|---|---|
| PENICILLIN G POTASSIUM | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| **PENICILLIN G POTASSIUM** | | | | | | |
| **AP** | | HANFORD GC | **5,000,000 UNITS/VIAL** | **A065149** | **002** | Jul 23, 2009 |
| **AP** | | | **20,000,000 UNITS/VIAL** | **A065149** | **003** | Jul 23, 2009 |
| **AP** | | ISTITUTO BIO ITA SPA | **5,000,000 UNITS/VIAL** | **A065448** | **001** | Aug 18, 2009 |
| **AP** | | | **20,000,000 UNITS/VIAL** | **A065448** | **002** | Aug 18, 2009 |
| **AP** | | SANDOZ | **5,000,000 UNITS/VIAL** | **A065079** | **002** | Aug 30, 2002 |
| **AP** | | | **20,000,000 UNITS/VIAL** | **A065079** | **003** | Aug 30, 2002 |
| **PFIZERPEN** | | | | | | |
| **AP** | **!** | PFIZER | **5,000,000 UNITS/VIAL** | **A060657** | **002** | |
| **AP** | **!** | | **20,000,000 UNITS/VIAL** | **A060657** | **003** | |
| PENICILLIN G POTASSIUM | | | | | | |
| | | HANFORD GC | 1,000,000 UNITS/VIAL | A065149 | 001 | Jul 23, 2009 |
| PENICILLIN G POTASSIUM IN PLASTIC CONTAINER | | | | | | |
| | +! | BAXTER HLTHCARE | 20,000 UNITS/ML | N050638 | 001 | Jun 25, 1990 |
| | +! | | 40,000 UNITS/ML | N050638 | 002 | Jun 25, 1990 |
| | +! | | 60,000 UNITS/ML | N050638 | 003 | Jun 25, 1990 |
| PENICILLIN G PROCAINE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| PENICILLIN G PROCAINE | | | | | | |
| | ! | KING PHARMS LLC | 300,000 UNITS/ML | A060101 | 002 | |
| | ! | | 600,000 UNITS/ML | A060101 | 001 | |
| PENICILLIN G SODIUM | | | | | | |
| INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | | | | | | |
| PENICILLIN G SODIUM | | | | | | |
| | ! | SANDOZ | 5,000,000 UNITS/VIAL | A065068 | 001 | Feb 26, 2001 |
| PENICILLIN V POTASSIUM | | | | | | |
| FOR SOLUTION;ORAL | | | | | | |
| **PENICILLIN V POTASSIUM** | | | | | | |
| **AA** | | DAVA PHARMS INC | **EQ 125MG BASE/5ML** | **A062981** | **001** | Feb 10, 1989 |
| **AA** | | | **EQ 250MG BASE/5ML** | **A062981** | **002** | Feb 10, 1989 |
| **PENICILLIN-VK** | | | | | | |
| **AA** | | TEVA | **EQ 125MG BASE/5ML** | **A060456** | **001** | |
| **AA** | **!** | | **EQ 250MG BASE/5ML** | **A060456** | **002** | |
| TABLET;ORAL | | | | | | |
| **PENICILLIN V POTASSIUM** | | | | | | |
| **AB** | | AUROBINDO PHARMA | **EQ 250MG BASE** | **A065435** | **001** | Apr 29, 2008 |
| **AB** | | | **EQ 500MG BASE** | **A065435** | **002** | Apr 29, 2008 |
| **AB** | | DAVA PHARMS INC | **EQ 250MG BASE** | **A062936** | **001** | Nov 25, 1988 |
| **AB** | | | **EQ 500MG BASE** | **A062935** | **001** | Nov 23, 1988 |
| **AB** | | HIKMA PHARMS | **EQ 250MG BASE** | **A090549** | **001** | Oct 11, 2013 |
| **AB** | | | **EQ 500MG BASE** | **A090549** | **002** | Oct 11, 2013 |
| **AB** | | SANDOZ | **EQ 250MG BASE** | **A064071** | **001** | Nov 30, 1995 |
| **AB** | **!** | | **EQ 500MG BASE** | **A064071** | **002** | Nov 30, 1995 |
| **PENICILLIN-VK** | | | | | | |
| **AB** | | TEVA | **EQ 250MG BASE** | **A060711** | **002** | |
| **AB** | | | **EQ 500MG BASE** | **A060711** | **003** | |
| PENTAMIDINE ISETHIONATE | | | | | | |
| FOR SOLUTION;INHALATION | | | | | | |
| NEBUPENT | | | | | | |
| | +! | FRESENIUS KABI USA | 300MG/VIAL | N019887 | 001 | Jun 15, 1989 |
| INJECTABLE;INJECTION | | | | | | |
| **PENTAM** | | | | | | |
| **AP** | **+!** | FRESENIUS KABI USA | **300MG/VIAL** | **N019264** | **001** | Oct 16, 1984 |
| **PENTAMIDINE ISETHIONATE** | | | | | | |
| **AP** | | SETON PHARMS | **300MG/VIAL** | **A206666** | **001** | Sep 28, 2017 |
| PENTAZOCINE LACTATE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| TALWIN | | | | | | |
| | +! | HOSPIRA | EQ 30MG BASE/ML | N016194 | 001 | |
| PENTETATE CALCIUM TRISODIUM | | | | | | |
| SOLUTION;INHALATION, INTRAVENOUS | | | | | | |
| PENTETATE CALCIUM TRISODIUM | | | | | | |
| | +! | HAMELN PHARMA PLUS | EQ 1GM BASE/5ML (EQ 200MG BASE/ML) | N021749 | 001 | Aug 11, 2004 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| PENTETATE ZINC TRISODIUM | | | | | | | |
| SOLUTION;INHALATION, INTRAVENOUS | | | | | | | |
| PENTETATE ZINC TRISODIUM | | | | | | | |
| | +! | HAMELN PHARMA PLUS | EQ 1GM BASE/5ML (EQ 200MG BASE/ML) | N021751 | 001 | Aug 11, 2004 |
| PENTOBARBITAL SODIUM | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| **NEMBUTAL SODIUM** | | | | | | | |
| **AP** | **!** | OAK PHARMS | **50MG/ML** | **A083246** | **001** | |
| **PENTOBARBITAL SODIUM** | | | | | | | |
| **AP** | | CUSTOPHARM INC | **50MG/ML** | **A203619** | **001** | Nov 13, 2017 |
| **AP** | | RENAISSANCE SSA LLC | **50MG/ML** | **A206677** | **001** | Nov 27, 2017 |
| **AP** | | SAGENT PHARMS | **50MG/ML** | **A206404** | **001** | May 23, 2016 |
| PENTOSAN POLYSULFATE SODIUM | | | | | | | |
| CAPSULE;ORAL | | | | | | | |
| ELMIRON | | | | | | | |
| | +! | JANSSEN PHARMS | 100MG | N020193 | 001 | Sep 26, 1996 |
| PENTOSTATIN | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| **NIPENT** | | | | | | | |
| **AP** | **+!** | HOSPIRA INC | **10MG/VIAL** | **N020122** | **001** | Oct 11, 1991 |
| **PENTOSTATIN** | | | | | | | |
| **AP** | | MYLAN INSTITUTIONAL | **10MG/VIAL** | **A203554** | **001** | Sep 19, 2014 |
| **AP** | | WEST-WARD PHARMS INT | **10MG/VIAL** | **A077841** | **001** | Aug 07, 2007 |
| PENTOXIFYLLINE | | | | | | | |
| TABLET, EXTENDED RELEASE;ORAL | | | | | | | |
| **PENTOXIFYLLINE** | | | | | | | |
| **AB** | **!** | APOTEX | **400MG** | **A075191** | **001** | Jun 09, 1999 |
| **AB** | | MYLAN | **400MG** | **A074425** | **001** | Jul 08, 1997 |
| **AB** | | VALEANT PHARMS | **400MG** | **A075028** | **001** | Jul 20, 1998 |
| **PENTOXIL** | | | | | | | |
| **AB** | | UPSHER-SMITH LABS | **400MG** | **A074962** | **001** | Mar 31, 1999 |
| PERAMIVIR | | | | | | | |
| SOLUTION;IV (INFUSION) | | | | | | | |
| RAPIVAB | | | | | | | |
| | +! | BIOCRYST | 200MG/20ML (10MG/ML) | N206426 | 001 | Dec 19, 2014 |
| PERAMPANEL | | | | | | | |
| SUSPENSION;ORAL | | | | | | | |
| FYCOMPA | | | | | | | |
| | +! | EISAI INC | 0.5MG/ML | N208277 | 001 | Apr 29, 2016 |
| TABLET;ORAL | | | | | | | |
| FYCOMPA | | | | | | | |
| | + | EISAI INC | 2MG | N202834 | 001 | Oct 22, 2012 |
| | + | | 4MG | N202834 | 002 | Oct 22, 2012 |
| | + | | 6MG | N202834 | 003 | Oct 22, 2012 |
| | + | | 8MG | N202834 | 004 | Oct 22, 2012 |
| | + | | 10MG | N202834 | 005 | Oct 22, 2012 |
| | +! | | 12MG | N202834 | 006 | Oct 22, 2012 |
| PERFLUTREN | | | | | | | |
| INJECTABLE;INTRAVENOUS | | | | | | | |
| DEFINITY | | | | | | | |
| | +! | LANTHEUS MEDCL | 6.52MG/ML | N021064 | 001 | Jul 31, 2001 |
| PERINDOPRIL ERBUMINE | | | | | | | |
| TABLET;ORAL | | | | | | | |
| **PERINDOPRIL ERBUMINE** | | | | | | | |
| **AB** | | ANI PHARMS INC | **2MG** | **A078138** | **001** | Nov 10, 2009 |
| **AB** | | | **4MG** | **A078138** | **002** | Nov 10, 2009 |
| **AB** | | | **8MG** | **A078138** | **003** | Nov 10, 2009 |
| **AB** | | APOTEX | **2MG** | **A090463** | **001** | Aug 30, 2010 |
| **AB** | | | **4MG** | **A090463** | **002** | Aug 30, 2010 |
| **AB** | | | **8MG** | **A090463** | **003** | Aug 30, 2010 |
| **AB** | **!** | AUROBINDO PHARMA | **2MG** | **A079070** | **001** | Nov 10, 2009 |
| **AB** | **!** | | **4MG** | **A079070** | **002** | Nov 10, 2009 |
| **AB** | **!** | | **8MG** | **A079070** | **003** | Nov 10, 2009 |
| **AB** | | WEST-WARD PHARMS INT | **2MG** | **A090072** | **001** | Nov 10, 2009 |
| **AB** | | | **4MG** | **A090072** | **002** | Nov 10, 2009 |
| **AB** | | | **8MG** | **A090072** | **003** | Nov 10, 2009 |

PERMETHRIN

CREAM;TOPICAL

**ELIMITE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | MYLAN PHARMS INC | **5%** | **N019855** | **001** | Aug 25, 1989 |

**PERMETHRIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS LABS | **5%** | **A074806** | **001** | Jan 23, 1998 |
| **AB** | | PERRIGO NEW YORK | **5%** | **A076369** | **001** | Apr 21, 2003 |

PERPHENAZINE

TABLET;ORAL

**PERPHENAZINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | MYLAN PHARMS INC | **2MG** | **A206691** | **001** | Apr 14, 2017 |
| **AB** | | | **4MG** | **A206691** | **002** | Apr 14, 2017 |
| **AB** | | | **8MG** | **A206691** | **003** | Apr 14, 2017 |
| **AB** | | | **16MG** | **A206691** | **004** | Apr 14, 2017 |
| **AB** | | SANDOZ | **2MG** | **A089685** | **002** | Dec 08, 1988 |
| **AB** | | | **4MG** | **A089685** | **003** | Dec 08, 1988 |
| **AB** | | | **8MG** | **A089685** | **001** | Dec 08, 1988 |
| **AB** | **!** | | **16MG** | **A089685** | **004** | Dec 08, 1988 |
| **AB** | | VINTAGE PHARMS | **2MG** | **A040226** | **001** | Dec 31, 1998 |
| **AB** | | | **4MG** | **A040226** | **002** | Dec 31, 1998 |
| **AB** | | | **8MG** | **A040226** | **003** | Dec 31, 1998 |
| **AB** | | | **16MG** | **A040226** | **004** | Dec 31, 1998 |
| **AB** | | WATSON LABS INC | **2MG** | **A207582** | **001** | Oct 17, 2016 |
| **AB** | | | **4MG** | **A207582** | **002** | Oct 17, 2016 |
| **AB** | | | **8MG** | **A207582** | **003** | Oct 17, 2016 |
| **AB** | | | **16MG** | **A207582** | **004** | Oct 17, 2016 |
| **AB** | | WILSHIRE PHARMS INC | **2MG** | **A205973** | **001** | Dec 17, 2015 |
| **AB** | | | **4MG** | **A205973** | **002** | Dec 17, 2015 |
| **AB** | | | **8MG** | **A205973** | **003** | Dec 17, 2015 |
| **AB** | | | **16MG** | **A205973** | **004** | Dec 17, 2015 |

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

PHENDIMETRAZINE TARTRATE

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | SANDOZ | 105MG | N018074 | 001 | |

TABLET;ORAL

**BONTRIL PDM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **!** | VALEANT | **35MG** | **A085272** | **001** | |

**PHENDIMETRAZINE TARTRATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | ELITE LABS INC | **35MG** | **A040762** | **001** | Jan 28, 2008 |
| **AA** | | | **35MG** | **A203600** | **001** | Dec 27, 2017 |
| **AA** | | KVK TECH | **35MG** | **A091042** | **001** | Aug 31, 2010 |
| **AA** | | MIKART | **35MG** | **A089452** | **001** | Oct 30, 1991 |
| **AA** | | SANDOZ | **35MG** | **A085588** | **001** | |

PHENELZINE SULFATE

TABLET;ORAL

**NARDIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | PARKE DAVIS | **EQ 15MG BASE** | **N011909** | **002** | |

**PHENELZINE SULFATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | NOVEL LABS INC | **EQ 15MG BASE** | **A200181** | **001** | Dec 08, 2010 |

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE;ORAL

**DIBENZYLINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | CONCORDIA PHARMS INC | **10MG** | **N008708** | **001** | |

**PHENOXYBENZAMINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | PAR PHARM INC | **10MG** | **A204522** | **001** | Jan 24, 2017 |
| **AB** | | WEST-WARD PHARMS INT | **10MG** | **A201050** | **001** | Jul 16, 2012 |

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL

**ADIPEX-P**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **!** | TEVA | **37.5MG** | **A088023** | **001** | Aug 02, 1983 |

**PHENTERMINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | AUROLIFE PHARMA LLC | **15MG** | **A204318** | **001** | Nov 09, 2016 |
| **AA** | | | **30MG** | **A204318** | **002** | Nov 09, 2016 |
| **AA** | | BARR | **15MG** | **A090591** | **001** | Mar 18, 2010 |
| **AA** | | | **30MG** | **A090591** | **002** | Mar 18, 2010 |
| **AA** | | ELITE LABS | **15MG** | **A202248** | **001** | Sep 28, 2012 |
| **AA** | | | **30MG** | **A202248** | **002** | Sep 28, 2012 |
| **AA** | | ELITE LABS INC | **37.5MG** | **A040228** | **001** | Jun 19, 1997 |

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL

**PHENTERMINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | INVAGEN PHARMS | **15MG** | **A202858** | **001** | Feb 14, 2014 |
| **AA** | | | **30MG** | **A202858** | **002** | Feb 14, 2014 |
| **AA** | | | **30MG** | **A204414** | **001** | May 05, 2014 |
| **AA** | | | **37.5MG** | **A202846** | **001** | Feb 05, 2014 |
| **AA** | | KEN LIFESCIENCE | **15MG** | **A205019** | **001** | Dec 05, 2014 |
| **AA** | | | **30MG** | **A205019** | **002** | Dec 05, 2014 |
| **AA** | | | **37.5MG** | **A205017** | **001** | Sep 25, 2014 |
| **AA** | | KVK TECH | **15MG** | **A040886** | **002** | Mar 31, 2008 |
| **AA** | | | **30MG** | **A040875** | **001** | Mar 21, 2008 |
| **AA** | | | **30MG** | **A040886** | **001** | Mar 31, 2008 |
| **AA** | | | **37.5MG** | **A040887** | **001** | Apr 24, 2008 |
| **AA** | | LANNETT | **15MG** | **A087022** | **002** | Jan 20, 2012 |
| **AA** | | | **30MG** | **A087022** | **001** | Feb 03, 1983 |
| **AA** | | | **30MG** | **A091359** | **001** | Jul 16, 2010 |
| **AA** | | LANNETT HOLDINGS INC | **37.5MG** | **A201961** | **001** | Jul 20, 2011 |
| **AA** | ! | SANDOZ | **15MG** | **A087190** | **002** | |
| **AA** | ! | | **30MG** | **A086945** | **001** | Jul 20, 1983 |
| **AA** | ! | | **30MG** | **A087190** | **001** | |
| **AA** | | SUN PHARM INDUSTRIES | **30MG** | **A040525** | **001** | Oct 23, 2003 |

TABLET;ORAL

**ADIPEX-P**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | ! | TEVA | **37.5MG** | **A085128** | **001** | |

**LOMAIRA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | ! | AVANTHI INC | **8MG** | **A203495** | **001** | Sep 12, 2016 |

**PHENTERMINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | AUROLIFE PHARMA LLC | **37.5MG** | **A203068** | **001** | Aug 06, 2014 |
| **AA** | | BARR | **37.5MG** | **A090470** | **001** | Aug 31, 2009 |
| **AA** | | ELITE LABS | **37.5MG** | **A200272** | **001** | Jan 31, 2011 |
| **AA** | | ELITE LABS INC | **37.5MG** | **A040190** | **001** | May 30, 1997 |
| **AA** | | INGENUS PHARMS NJ | **37.5MG** | **A091451** | **001** | Sep 21, 2012 |
| **AA** | | INVAGEN PHARMS | **37.5MG** | **A202942** | **001** | Feb 05, 2014 |
| **AA** | | KEN LIFESCIENCE | **37.5MG** | **A205008** | **001** | Sep 25, 2014 |
| **AA** | | KVK TECH | **37.5MG** | **A040876** | **001** | Mar 31, 2008 |
| **AA** | | KVK TECH INC | **8MG** | **A203436** | **001** | Mar 17, 2017 |
| **AA** | | LANNETT | **37.5MG** | **A040555** | **001** | Apr 15, 2005 |
| **AA** | | POLYGEN PHARMS | **37.5MG** | **A206342** | **001** | Nov 18, 2016 |
| **AA** | | PRINSTON INC | **37.5MG** | **A040377** | **001** | Jan 04, 2002 |
| **AA** | | SUN PHARM INDS INC | **37.5MG** | **A040790** | **001** | Aug 21, 2007 |
| **AA** | | SUN PHARM INDUSTRIES | **37.5MG** | **A040526** | **001** | Oct 23, 2003 |

TABLET, ORALLY DISINTEGRATING;ORAL

PHENTERMINE HYDROCHLORIDE

| | | | | | | |
|---|---|---|---|---|---|---|
| | | ZYDUS PHARMS USA INC | 15MG | A204663 | 001 | Jun 28, 2017 |
| | | | 30MG | A204663 | 002 | Jun 28, 2017 |
| | | | 37.5MG | A204663 | 003 | Jun 28, 2017 |

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

CAPSULE, EXTENDED RELEASE;ORAL

QSYMIA

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | VIVUS | EQ 3.75MG BASE;23MG | N022580 | 001 | Jul 17, 2012 |
| | + | | EQ 7.5MG BASE;46MG | N022580 | 002 | Jul 17, 2012 |
| | + | | EQ 11.25MG BASE;69MG | N022580 | 003 | Jul 17, 2012 |
| | +! | | EQ 15MG BASE;92MG | N022580 | 004 | Jul 17, 2012 |

PHENTOLAMINE MESYLATE

INJECTABLE;INJECTION

**PHENTOLAMINE MESYLATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | PRECISION DOSE INC | **5MG/VIAL** | **A207686** | **001** | Jul 14, 2017 |
| **AP** | ! | WEST-WARD PHARMS INT | **5MG/VIAL** | **A040235** | **001** | Mar 11, 1998 |

ORAVERSE

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | SEPTODONT HOLDING | 0.4MG/1.7ML | N022159 | 001 | May 09, 2008 |

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;IV (INFUSION)

PHENYLEPHRINE HYDROCHLORIDE

| | | | | | |
|---|---|---|---|---|---|
| +! | WEST WARD PHARM CORP | 10MG/ML (10MG/ML) | N203826 | 001 | Dec 20, 2012 |

VAZCULEP

| | | | | | |
|---|---|---|---|---|---|
| + | AVADEL LEGACY | 10MG/ML (10MG/ML) | N204300 | 001 | Jun 27, 2014 |
| + | | 50MG/5ML (10MG/ML) | N204300 | 002 | Jun 27, 2014 |
| +! | | 100MG/10ML (10MG/ML) | N204300 | 003 | Jun 27, 2014 |

SOLUTION/DROPS;OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

| | | | | | |
|---|---|---|---|---|---|
| +! | AKORN INC | 2.5% | N207926 | 001 | Jan 15, 2015 |
| +! | | 10% | N207926 | 002 | Jan 15, 2015 |
| +! | PARAGON BIOTECK | 2.5% | N203510 | 001 | Mar 21, 2013 |
| +! | | 10% | N203510 | 002 | Mar 21, 2013 |

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

**PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | HI-TECH PHARMACAL | **5MG/5ML;6.25MG/5ML** | **A040675** | **001** | Dec 23, 2014 |
| **AA** | | VINTAGE | **5MG/5ML;6.25MG/5ML** | **A040654** | **001** | Dec 07, 2006 |

**PROMETH VC PLAIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **!** | G AND W LABS INC | **5MG/5ML;6.25MG/5ML** | **A088761** | **001** | Nov 08, 1984 |

**PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | AMNEAL PHARMS | **5MG/5ML;6.25MG/5ML** | **A040902** | **001** | Aug 25, 2009 |

PHENYTOIN

SUSPENSION;ORAL

**DILANTIN-125**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | PARKE DAVIS | **125MG/5ML** | **N008762** | **001** | |

**PHENYTOIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | TARO | **125MG/5ML** | **A040521** | **001** | Mar 08, 2004 |
| **AB** | | VISTAPHARM | **125MG/5ML** | **A040342** | **001** | Jan 31, 2001 |
| **AB** | | | **125MG/5ML** | **A040610** | **001** | Aug 18, 2005 |
| **AB** | | WOCKHARDT EU OPERATN | **125MG/5ML** | **A040420** | **001** | Apr 19, 2002 |

TABLET, CHEWABLE;ORAL

**DILANTIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **!** | PFIZER | **50MG** | **A084427** | **001** | |

**PHENYTOIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | EPIC PHARMA LLC | **50MG** | **A040884** | **001** | Nov 28, 2014 |
| **AB** | | MYLAN PHARMS INC | **50MG** | **A200691** | **001** | Dec 26, 2012 |
| **AB** | | TARO | **50MG** | **A200565** | **001** | Apr 17, 2014 |

PHENYTOIN SODIUM

CAPSULE;ORAL

**DILANTIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **!** | PARKE-DAVIS | **100MG EXTENDED** | **A084349** | **002** | |

**EXTENDED PHENYTOIN SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AMNEAL PHARMS NY | **100MG EXTENDED** | **A040765** | **001** | Nov 12, 2008 |
| **AB** | | MYLAN | **100MG EXTENDED** | **A040298** | **001** | Dec 28, 1998 |
| **AB** | | SUN PHARM INDS | **200MG EXTENDED** | **A040731** | **001** | Jun 30, 2008 |
| **AB** | | | **300MG EXTENDED** | **A040731** | **002** | Jun 30, 2008 |
| **AB** | | SUN PHARM INDS (IN) | **100MG EXTENDED** | **A040621** | **001** | Dec 11, 2006 |
| **AB** | | TARO | **100MG EXTENDED** | **A040684** | **001** | Sep 05, 2006 |

**PHENYTEK**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | MYLAN | **200MG EXTENDED** | **A040298** | **002** | Dec 06, 2001 |
| **AB** | **!** | | **300MG EXTENDED** | **A040298** | **003** | Dec 06, 2001 |

**PHENYTOIN SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AUROBINDO PHARMA LTD | **100MG EXTENDED** | **A204309** | **001** | Jun 10, 2015 |

DILANTIN

| | | | | | |
|---|---|---|---|---|---|
| ! | PARKE-DAVIS | 30MG EXTENDED | A084349 | 001 | |

INJECTABLE;INJECTION

**PHENYTOIN SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | ACELLA PHARMS LLC | **50MG/ML** | **A040573** | **001** | Sep 13, 2006 |
| **AP** | | LUITPOLD | **50MG/ML** | **A040781** | **001** | Dec 04, 2007 |
| **AP** | **!** | WEST-WARD PHARMS INT | **50MG/ML** | **A084307** | **001** | |

PHYTONADIONE

INJECTABLE;INJECTION

PHYTONADIONE

| | | | | | | |
|---|---|---|---|---|---|---|
| BP | ! | INTL MEDICATION | 1MG/0.5ML | A083722 | 001 | |

VITAMIN K1

| | | | | | | |
|---|---|---|---|---|---|---|
| BP | ! | HOSPIRA | 1MG/0.5ML | A087954 | 001 | Jul 25, 1983 |
| | ! | | 10MG/ML | A087955 | 001 | Jul 25, 1983 |

TABLET;ORAL

MEPHYTON

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | VALEANT PHARMS | 5MG | N010104 | 003 | |

PILOCARPINE HYDROCHLORIDE

SOLUTION;OPHTHALMIC

**ISOPTO CARPINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **+** | NOVARTIS PHARMS CORP | **1%** | **N200890** | **001** | Jun 22, 2010 |
| **AT** | **+** | | **2%** | **N200890** | **002** | Jun 22, 2010 |
| **AT** | **+!** | | **4%** | **N200890** | **003** | Jun 22, 2010 |

**PILOCARPINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | AKORN INC | **1%** | **A204398** | **001** | Sep 27, 2017 |
| **AT** | | | **2%** | **A204398** | **002** | Sep 27, 2017 |
| **AT** | | | **4%** | **A204398** | **003** | Sep 27, 2017 |

TABLET;ORAL

**PILOCARPINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | IMPAX LABS | **5MG** | **A077248** | **001** | Mar 31, 2006 |
| **AB** | | | **7.5MG** | **A077248** | **002** | Mar 31, 2006 |
| **AB** | | INNOGENIX | **5MG** | **A076963** | **001** | Dec 22, 2004 |
| **AB** | | | **7.5MG** | **A076963** | **002** | Feb 27, 2007 |
| **AB** | | LANNETT | **5MG** | **A077220** | **001** | Oct 14, 2005 |
| **AB** | | | **7.5MG** | **A077220** | **002** | May 06, 2009 |
| **AB** | | PERRIGO PHARMA INTL | **5MG** | **A076746** | **001** | Nov 16, 2004 |

**SALAGEN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | EISAI INC | **5MG** | **N020237** | **001** | Mar 22, 1994 |
| **AB** | **+!** | | **7.5MG** | **N020237** | **002** | Apr 18, 2003 |

PIMAVANSERIN TARTRATE

TABLET;ORAL

NUPLAZID

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ACADIA PHARMS INC | EQ 17MG BASE | N207318 | 001 | Apr 29, 2016 |

PIMECROLIMUS

CREAM;TOPICAL

ELIDEL

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | VALEANT BERMUDA | 1% | N021302 | 001 | Dec 13, 2001 |

PIMOZIDE

TABLET;ORAL

**ORAP**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | TEVA | **1MG** | **N017473** | **003** | Aug 27, 1997 |
| **AB** | **+!** | | **2MG** | **N017473** | **001** | Jul 31, 1984 |

**PIMOZIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | PAR PHARM | **1MG** | **A204521** | **001** | Sep 28, 2015 |
| **AB** | | | **2MG** | **A204521** | **002** | Sep 28, 2015 |

PINDOLOL

TABLET;ORAL

**PINDOLOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | IDT AUSTRALIA LTD | **5MG** | **A073608** | **001** | Mar 29, 1993 |
| **AB** | | | **10MG** | **A073609** | **001** | Mar 29, 1993 |
| **AB** | | MYLAN PHARMS INC | **5MG** | **A074019** | **001** | Sep 03, 1992 |
| **AB** | **!** | | **10MG** | **A074019** | **002** | Sep 03, 1992 |
| **AB** | | NOSTRUM LABS INC | **5MG** | **A205415** | **001** | Jan 13, 2016 |
| **AB** | | | **10MG** | **A205415** | **002** | Jan 13, 2016 |
| **AB** | | SUN PHARM INDUSTRIES | **5MG** | **A074063** | **001** | Jan 27, 1994 |
| **AB** | | | **10MG** | **A074063** | **002** | Jan 27, 1994 |
| **AB** | | ZYDUS PHARMS USA INC | **5MG** | **A209866** | **001** | Aug 18, 2017 |
| **AB** | | | **10MG** | **A209866** | **002** | Aug 18, 2017 |

PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL

**ACTOS**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | TAKEDA PHARMS USA | **EQ 15MG BASE** | **N021073** | **001** | Jul 15, 1999 |
| **AB** | + | | **EQ 30MG BASE** | **N021073** | **002** | Jul 15, 1999 |
| **AB** | +! | | **EQ 45MG BASE** | **N021073** | **003** | Jul 15, 1999 |

**PIOGLITAZONE HYDROCHLORIDE**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | ACCORD HLTHCARE | **EQ 15MG BASE** | **A200044** | **001** | Feb 13, 2013 |
| **AB** | | **EQ 30MG BASE** | **A200044** | **002** | Feb 13, 2013 |
| **AB** | | **EQ 45MG BASE** | **A200044** | **003** | Feb 13, 2013 |
| **AB** | AUROBINDO PHARMA LTD | **EQ 15MG BASE** | **A200268** | **001** | Feb 13, 2013 |
| **AB** | | **EQ 30MG BASE** | **A200268** | **002** | Feb 13, 2013 |
| **AB** | | **EQ 45MG BASE** | **A200268** | **003** | Feb 13, 2013 |
| **AB** | BRECKENRIDGE PHARM | **EQ 15MG BASE** | **A078472** | **001** | Feb 13, 2013 |
| **AB** | | **EQ 30MG BASE** | **A078472** | **002** | Feb 13, 2013 |
| **AB** | | **EQ 45MG BASE** | **A078472** | **003** | Feb 13, 2013 |
| **AB** | CIPLA LTD | **EQ 15MG BASE** | **A076798** | **001** | Oct 26, 2012 |
| **AB** | | **EQ 30MG BASE** | **A076798** | **002** | Oct 26, 2012 |
| **AB** | | **EQ 45MG BASE** | **A076798** | **003** | Oct 26, 2012 |
| **AB** | DR REDDYS LABS LTD | **EQ 15MG BASE** | **A078383** | **001** | Mar 12, 2013 |
| **AB** | | **EQ 30MG BASE** | **A078383** | **002** | Mar 12, 2013 |
| **AB** | | **EQ 45MG BASE** | **A078383** | **003** | Mar 12, 2013 |
| **AB** | LUPIN LTD | **EQ 15MG BASE** | **A204133** | **001** | Apr 07, 2014 |
| **AB** | | **EQ 30MG BASE** | **A204133** | **002** | Apr 07, 2014 |
| **AB** | | **EQ 45MG BASE** | **A204133** | **003** | Apr 07, 2014 |
| **AB** | MACLEODS PHARMS LTD | **EQ 15MG BASE** | **A202467** | **001** | Feb 06, 2013 |
| **AB** | | **EQ 30MG BASE** | **A202467** | **002** | Feb 06, 2013 |
| **AB** | | **EQ 45MG BASE** | **A202467** | **003** | Feb 06, 2013 |
| **AB** | MYLAN PHARMS INC | **EQ 15MG BASE** | **A076801** | **001** | Aug 17, 2012 |
| **AB** | | **EQ 30MG BASE** | **A076801** | **002** | Aug 17, 2012 |
| **AB** | | **EQ 45MG BASE** | **A076801** | **003** | Aug 17, 2012 |
| **AB** | PURACAP PHARM LLC | **EQ 15MG BASE** | **A206738** | **001** | Oct 06, 2017 |
| **AB** | | **EQ 30MG BASE** | **A206738** | **002** | Oct 06, 2017 |
| **AB** | | **EQ 45MG BASE** | **A206738** | **003** | Oct 06, 2017 |
| **AB** | SANDOZ | **EQ 15MG BASE** | **A078670** | **001** | Feb 13, 2013 |
| **AB** | | **EQ 30MG BASE** | **A078670** | **002** | Feb 13, 2013 |
| **AB** | | **EQ 45MG BASE** | **A078670** | **003** | Feb 13, 2013 |
| **AB** | TEVA PHARMS USA | **EQ 15MG BASE** | **A077210** | **001** | Jan 10, 2014 |
| **AB** | | **EQ 30MG BASE** | **A077210** | **002** | Jan 10, 2014 |
| **AB** | | **EQ 45MG BASE** | **A077210** | **003** | Jan 10, 2014 |
| **AB** | TORRENT PHARMS LTD | **EQ 15MG BASE** | **A091298** | **001** | Feb 13, 2013 |
| **AB** | | **EQ 30MG BASE** | **A091298** | **002** | Feb 13, 2013 |
| **AB** | | **EQ 45MG BASE** | **A091298** | **003** | Feb 13, 2013 |
| **AB** | ZYDUS PHARMS USA INC | **EQ 15MG BASE** | **A202456** | **001** | Feb 13, 2013 |
| **AB** | | **EQ 30MG BASE** | **A202456** | **002** | Feb 13, 2013 |
| **AB** | | **EQ 45MG BASE** | **A202456** | **003** | Feb 13, 2013 |

PIPERACILLIN SODIUM

INJECTABLE;INJECTION

PIPERACILLIN

| | | | | | |
|---|---|---|---|---|---|
| ! | ISTITUTO BIO ITA SPA | EQ 2GM BASE/VIAL | A065114 | 001 | Nov 14, 2003 |
| ! | | EQ 3GM BASE/VIAL | A065114 | 002 | Nov 14, 2003 |
| ! | | EQ 4GM BASE/VIAL | A065114 | 003 | Nov 14, 2003 |
| ! | | EQ 40GM BASE/VIAL | A065157 | 001 | Jul 12, 2004 |

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

**PIPERACILLIN AND TAZOBACTAM**

| | | | | | |
|---|---|---|---|---|---|
| **AP** | APOLLO PHARMS INC | **EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL** | **A207847** | **001** | Jan 13, 2017 |
| **AP** | | **EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL** | **A207847** | **002** | Jan 13, 2017 |
| **AP** | | **EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL** | **A207848** | **002** | Jan 13, 2017 |
| **AP** | | **EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL** | **A207847** | **003** | Jan 13, 2017 |
| **AP** | AUROBINDO PHARMA LTD | **EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL** | **A065498** | **001** | May 23, 2011 |
| **AP** | | **EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL** | **A065498** | **002** | May 23, 2011 |
| **AP** | | **EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL** | **A065498** | **003** | May 23, 2011 |
| **AP** | HOSPIRA INC | **EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL** | **A065386** | **001** | Sep 15, 2009 |
| **AP** | | **EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL** | **A065386** | **002** | Sep 15, 2009 |
| **AP** | | **EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL** | **A065386** | **003** | Sep 15, 2009 |
| **AP** | | **EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL** | **A065446** | **001** | Sep 15, 2009 |
| **AP** | ISTITUTO BIO ITA | **EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL** | **A065523** | **001** | May 31, 2011 |

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

**PIPERACILLIN AND TAZOBACTAM**

SPA

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | | **EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL** | **A065523** | **002** | May 31, 2011 |
| **AP** | | | **EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL** | **A065523** | **003** | May 31, 2011 |
| **AP** | | | **EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL** | **A090498** | **001** | May 31, 2011 |
| **AP** | | MYLAN LABS LTD | **EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL** | **A065458** | **001** | Aug 15, 2014 |
| **AP** | | | **EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL** | **A065458** | **002** | Aug 15, 2014 |
| **AP** | | | **EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL** | **A065458** | **003** | Aug 15, 2014 |
| **AP** | | SANDOZ | **EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL** | **A065362** | **001** | Oct 21, 2010 |
| **AP** | | | **EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL** | **A065363** | **001** | Oct 21, 2010 |
| **AP** | | | **EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL** | **A065362** | **002** | Oct 21, 2010 |
| **AP** | | | **EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL** | **A065363** | **002** | Oct 21, 2010 |
| **AP** | | | **EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL** | **A065362** | **003** | Oct 21, 2010 |
| **AP** | | | **EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL** | **A065363** | **003** | Oct 21, 2010 |
| **AP** | | WOCKHARDT BIO AG | **EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL** | **A207146** | **001** | Mar 17, 2017 |
| **AP** | | | **EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL** | **A206996** | **001** | Mar 22, 2017 |
| **AP** | | | **EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL** | **A206996** | **002** | Mar 22, 2017 |
| **AP** | | | **EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL** | **A206996** | **003** | Mar 22, 2017 |

**ZOSYN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | WYETH PHARMS INC | **EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL** | **N050684** | **001** | Oct 22, 1993 |
| **AP** | **+!** | | **EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL** | **N050684** | **002** | Oct 22, 1993 |
| **AP** | **+!** | | **EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL** | **N050684** | **003** | Oct 22, 1993 |
| **AP** | **+!** | | **EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL** | **N050684** | **004** | Oct 22, 1993 |

ZOSYN IN PLASTIC CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| +! | WYETH PHARMS INC | EQ 40MG BASE/ML;EQ 5MG BASE/ML | N050750 | 001 | Feb 24, 1998 |
| +! | | EQ 60MG BASE/ML;EQ 7.5MG BASE/ML | N050750 | 002 | Feb 24, 1998 |
| +! | | EQ 4GM BASE/100ML;EQ 500MG BASE/100ML | N050750 | 003 | Feb 24, 1998 |

INJECTABLE;IV (INFUSION)

PIPERACILLIN AND TAZOBACTAM

| | | | | | |
|---|---|---|---|---|---|
| | SANDOZ INC | EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL | A203557 | 001 | Oct 29, 2014 |

PIRFENIDONE

CAPSULE;ORAL

ESBRIET

| | | | | | |
|---|---|---|---|---|---|
| +! | GENENTECH INC | 267MG | N022535 | 001 | Oct 15, 2014 |

TABLET;ORAL

ESBRIET

| | | | | | |
|---|---|---|---|---|---|
| + | GENENTECH INC | 267MG | N208780 | 001 | Jan 11, 2017 |
| +! | | 801MG | N208780 | 003 | Jan 11, 2017 |

PIROXICAM

CAPSULE;ORAL

**FELDENE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | PFIZER | **10MG** | **N018147** | **002** | Apr 06, 1982 |
| **AB** | **+!** | | **20MG** | **N018147** | **003** | Apr 06, 1982 |

**PIROXICAM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | FLAMINGO PHARMS | **10MG** | **A207938** | **001** | Sep 09, 2016 |
| **AB** | | | **20MG** | **A207938** | **002** | Sep 09, 2016 |
| **AB** | | HIKMA PHARMS | **10MG** | **A209256** | **001** | Aug 11, 2017 |
| **AB** | | | **20MG** | **A209256** | **002** | Aug 11, 2017 |
| **AB** | **+** | MICRO LABS | **10MG** | **A206152** | **001** | Dec 29, 2017 |
| **AB** | **+** | | **20MG** | **A206152** | **002** | Dec 29, 2017 |
| **AB** | | MYLAN IRELAND LTD | **10MG** | **A074116** | **001** | Jun 15, 1993 |
| **AB** | | | **20MG** | **A074118** | **001** | Jun 15, 1993 |
| **AB** | | PII | **10MG** | **A206136** | **001** | Jun 20, 2017 |
| **AB** | | | **20MG** | **A206136** | **002** | Jun 20, 2017 |
| **AB** | | SUN PHARM INDUSTRIES | **10MG** | **A073536** | **002** | Jan 23, 2008 |
| **AB** | | | **20MG** | **A073536** | **001** | Mar 12, 1993 |
| **AB** | | TEVA | **10MG** | **A074131** | **001** | Dec 11, 1992 |
| **AB** | | | **20MG** | **A074131** | **002** | Dec 11, 1992 |
| **AB** | | UNICHEM LABS LTD | **10MG** | **A208340** | **001** | Apr 13, 2017 |
| **AB** | | | **20MG** | **A208340** | **002** | Apr 13, 2017 |

PITAVASTATIN CALCIUM

TABLET;ORAL

**LIVALO**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | KOWA CO | **EQ 1MG BASE** | **N022363** | **001** | Aug 03, 2009 |
| **AB** | **+** | | **EQ 2MG BASE** | **N022363** | **002** | Aug 03, 2009 |
| **AB** | **+!** | | **EQ 4MG BASE** | **N022363** | **003** | Aug 03, 2009 |

**PITAVASTATIN CALCIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AUROBINDO PHARMA | **EQ 1MG BASE** | **A206015** | **001** | Dec 20, 2016 |

PITAVASTATIN CALCIUM

TABLET;ORAL

**PITAVASTATIN CALCIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| | | LTD | | | | |
| **AB** | | | **EQ 2MG BASE** | **A206015** | **002** | Dec 20, 2016 |
| **AB** | | | **EQ 4MG BASE** | **A206015** | **003** | Dec 20, 2016 |
| **AB** | | ORIENT PHARMA CO LTD | **EQ 1MG BASE** | **A205932** | **001** | Feb 03, 2017 |
| **AB** | | | **EQ 2MG BASE** | **A205932** | **002** | Feb 03, 2017 |
| **AB** | | | **EQ 4MG BASE** | **A205932** | **003** | Feb 03, 2017 |
| **AB** | | SAWAI USA | **EQ 1MG BASE** | **A205955** | **001** | Feb 03, 2017 |
| **AB** | | | **EQ 2MG BASE** | **A205955** | **002** | Feb 03, 2017 |
| **AB** | | | **EQ 4MG BASE** | **A205955** | **003** | Feb 03, 2017 |

PITAVASTATIN MAGNESIUM

TABLET;ORAL

ZYPITAMAG

| | | | | | | |
|---|---|---|---|---|---|---|
| + | | ZYDUS PHARMS USA INC | EQ 1MG BASE | N208379 | 001 | Jul 14, 2017 |
| + | | | EQ 2MG BASE | N208379 | 002 | Jul 14, 2017 |
| +! | | | EQ 4MG BASE | N208379 | 003 | Jul 14, 2017 |

PLECANATIDE

TABLET;ORAL

TRULANCE

| | | | | | | |
|---|---|---|---|---|---|---|
| +! | | SYNERGY PHARMS | 3MG | N208745 | 001 | Jan 19, 2017 |

PLERIXAFOR

SOLUTION;SUBCUTANEOUS

MOZOBIL

| | | | | | | |
|---|---|---|---|---|---|---|
| +! | | GENZYME | 24MG/1.2ML (20MG/ML) | N022311 | 001 | Dec 15, 2008 |

PODOFILOX

GEL;TOPICAL

CONDYLOX

| | | | | | | |
|---|---|---|---|---|---|---|
| +! | | ALLERGAN SALES LLC | 0.5% | N020529 | 001 | Mar 13, 1997 |

SOLUTION;TOPICAL

**CONDYLOX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **+!** | ALLERGAN SALES LLC | **0.5%** | **N019795** | **001** | Dec 13, 1990 |

**PODOFILOX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | PADDOCK LLC | **0.5%** | **A075600** | **001** | Jan 29, 2002 |

POLIDOCANOL

SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

VARITHENA

| | | | | | | |
|---|---|---|---|---|---|---|
| +! | | PROVENSIS | 77.5MG/7.75ML (10MG/ML) | N205098 | 002 | Dec 21, 2017 |

SOLUTION;INTRAVENOUS

ASCLERA

| | | | | | | |
|---|---|---|---|---|---|---|
| + | | CHEMISCH FBRK KRSSLR | 10MG/2ML (5MG/ML) | N021201 | 001 | Mar 30, 2010 |
| +! | | | 20MG/2ML (10MG/ML) | N021201 | 002 | Mar 30, 2010 |

VARITHENA

| | | | | | | |
|---|---|---|---|---|---|---|
| +! | | PROVENSIS | 180MG/18ML (10MG/ML) | N205098 | 001 | Nov 25, 2013 |

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

**GLYCOLAX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | KREMERS URBAN PHARMS | **17GM/SCOOPFUL** | **A076652** | **001** | Jul 02, 2004 |

**POLYETHYLENE GLYCOL 3350**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | BRECKENRIDGE PHARM | **17GM/SCOOPFUL** | **A077736** | **001** | May 26, 2006 |
| **AA** | | NEXGEN PHARMA INC | **17GM/SCOOPFUL** | **A077706** | **001** | Sep 27, 2006 |
| **AA** | | PADDOCK LLC | **17GM/SCOOPFUL** | **A077893** | **001** | May 26, 2006 |

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL

**LAX-LYTE WITH FLAVOR PACKS**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | PADDOCK LLC | **420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT** | **A079232** | **001** | Feb 25, 2010 |

**NULYTELY**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **+!** | BRAINTREE | **420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT** | **N019797** | **001** | Apr 22, 1991 |

**NULYTELY-FLAVORED**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **+!** | BRAINTREE | **420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT** | **N019797** | **002** | Nov 18, 1994 |

**PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | NOVEL LABS INC | **420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2** | **A090019** | **001** | May 27, 2009 |

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE** | | | | | | |
| **AA** | | STRIDES PHARMA | **420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT** | **A204559** | **001** | Apr 13, 2015 |
| **PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE** | | | | | | |
| **AA** | | BRECKENRIDGE PHARM | **420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT** | **A202060** | **001** | Mar 08, 2017 |
| **TRILYTE** | | | | | | |
| **AA** | | MYLAN PHARMS INC | **420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT** | **A076491** | **001** | Feb 05, 2004 |

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **COLYTE WITH FLAVOR PACKS** | | | | | | |
| **AA** | | MYLAN SPECIALITY LP | **240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT** | **N018983** | **012** | Oct 08, 1998 |
| **GOLYTELY** | | | | | | |
| **AA** | **+!** | BRAINTREE | **236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT** | **N019011** | **001** | Jul 13, 1984 |
| **PEG 3350 AND ELECTROLYTES** | | | | | | |
| **AA** | | NOVEL LABS INC | **236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT** | **A090231** | **001** | Jun 01, 2009 |
| **AA** | | | **240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT** | **A090186** | **001** | Jun 01, 2009 |
| GOLYTELY | | | | | | |
| | +! | BRAINTREE | 227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET | N019011 | 002 | Jun 02, 1992 |

POLYMYXIN B SULFATE

INJECTABLE;INJECTION

| | | | | | | |
|---|---|---|---|---|---|---|
| **POLYMYCIN B SULFATE** | | | | | | |
| **AP** | | SAGENT STRIDES | **EQ 500,000 UNITS BASE/VIAL** | **A090110** | **001** | Jun 29, 2011 |
| **POLYMYXIN B SULFATE** | | | | | | |
| **AP** | | AUROBINDO PHARMA LTD | **EQ 500,000 UNITS BASE/VIAL** | **A206589** | **001** | Apr 04, 2016 |
| **AP** | | FRESENIUS KABI USA | **EQ 500,000 UNITS BASE/VIAL** | **A065372** | **001** | Jan 10, 2008 |
| **AP** | | GLAND PHARMA LTD | **EQ 500,000 UNITS BASE/VIAL** | **A207322** | **001** | Apr 14, 2016 |
| **AP** | **!** | WEST-WARD PHARMS INT | **EQ 500,000 UNITS BASE/VIAL** | **A060716** | **001** | |
| **AP** | | X GEN PHARMS | **EQ 500,000 UNITS BASE/VIAL** | **A063000** | **001** | Sep 30, 1994 |
| **AP** | | XELLIA PHARMS APS | **EQ 500,000 UNITS BASE/VIAL** | **A202766** | **001** | Jan 15, 2014 |

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC

| | | | | | | |
|---|---|---|---|---|---|---|
| **POLYTRIM** | | | | | | |
| **AT** | **+!** | ALLERGAN | **10,000 UNITS/ML;EQ 1MG BASE/ML** | **N050567** | **001** | Oct 20, 1988 |
| **TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE** | | | | | | |
| **AT** | | AKORN INC | **10,000 UNITS/ML;EQ 1MG BASE/ML** | **A065006** | **001** | Dec 17, 1998 |
| **AT** | | BAUSCH AND LOMB | **10,000 UNITS/ML;EQ 1MG BASE/ML** | **A064120** | **001** | Feb 14, 1997 |
| **AT** | | SANDOZ INC | **10,000 UNITS/ML;EQ 1MG BASE/ML** | **A064211** | **001** | Apr 13, 1998 |

POMALIDOMIDE

CAPSULE;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| POMALYST | | | | | | |
| | + | CELGENE | 1MG | N204026 | 001 | Feb 08, 2013 |
| | + | | 2MG | N204026 | 002 | Feb 08, 2013 |
| | + | | 3MG | N204026 | 003 | Feb 08, 2013 |
| | +! | | 4MG | N204026 | 004 | Feb 08, 2013 |

PONATINIB HYDROCHLORIDE

TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| ICLUSIG | | | | | | |
| | + | ARIAD | EQ 15MG BASE | N203469 | 001 | Dec 14, 2012 |
| | + | | EQ 30MG BASE | N203469 | 003 | Apr 23, 2015 |
| | +! | | EQ 45MG BASE | N203469 | 002 | Dec 14, 2012 |

PORACTANT ALFA

SUSPENSION;INTRATRACHEAL

| | | | | | | |
|---|---|---|---|---|---|---|
| CUROSURF | | | | | | |
| | +! | CHIESI USA INC | 80MG/ML | N020744 | 001 | Nov 18, 1999 |

PORFIMER SODIUM

INJECTABLE;INJECTION

PHOTOFRIN

| | | | | | | |
|---|---|---|---|---|---|---|
| | | CONCORDIA LABS INC | 75MG/VIAL | N020451 | 001 | Dec 27, 1995 |

POSACONAZOLE

SOLUTION;IV (INFUSION)

NOXAFIL

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | MERCK SHARP DOHME | 300MG/16.7ML (18MG/ML) | N205596 | 001 | Mar 13, 2014 |

SUSPENSION;ORAL

NOXAFIL

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | SCHERING | 40MG/ML | N022003 | 001 | Sep 15, 2006 |

TABLET, DELAYED RELEASE;ORAL

NOXAFIL

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | MERCK SHARP DOHME | 100MG | N205053 | 001 | Nov 25, 2013 |

POTASSIUM ACETATE

INJECTABLE;INJECTION

**POTASSIUM ACETATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | EXELA PHARMA SCS LLC | **2MEQ/ML** | **A206203** | **001** | Dec 29, 2015 |
| **AP** | **+!** | HOSPIRA | **2MEQ/ML** | **N018896** | **001** | Jul 20, 1984 |

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

**KLOR-CON**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | UPSHER-SMITH LABS | **8MEQ** | **A203106** | **001** | Jul 10, 2015 |
| **AB** | | | **10MEQ** | **A203106** | **002** | Jul 10, 2015 |

**MICRO-K**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | NESHER PHARMS | **8MEQ** | **N018238** | **001** | |

**MICRO-K 10**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | NESHER PHARMS | **10MEQ** | **N018238** | **002** | May 14, 1984 |

**POTASSIUM CHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS LABS FL INC | **8MEQ** | **A077419** | **001** | Jun 02, 2008 |
| **AB** | **!** | | **10MEQ** | **A077419** | **002** | Jun 02, 2008 |
| **AB** | | ADARE PHARMS INC | **8MEQ** | **A208864** | **001** | Mar 17, 2017 |
| **AB** | | | **10MEQ** | **A208864** | **002** | Mar 17, 2017 |
| **AB** | | AMNEAL PHARMS | **10MEQ** | **A202128** | **001** | Feb 22, 2013 |
| **AB** | | ANCHEN PHARMS | **8MEQ** | **A202886** | **001** | Dec 26, 2013 |
| **AB** | | | **10MEQ** | **A202886** | **002** | Dec 26, 2013 |
| **AB** | | GLENMARK PHARMS LTD | **10MEQ** | **A202868** | **001** | Jan 19, 2016 |
| **AB** | | KREMERS URBAN PHARMS | **8MEQ** | **A204210** | **001** | Mar 28, 2016 |
| **AB** | | | **10MEQ** | **A204210** | **002** | Mar 28, 2016 |
| **AB** | | LUPIN LTD | **8MEQ** | **A203002** | **001** | Dec 18, 2015 |
| **AB** | | | **10MEQ** | **A203002** | **002** | Dec 18, 2015 |
| **AB** | | NOVEL LABS INC | **8MEQ** | **A204828** | **001** | Aug 16, 2016 |
| **AB** | | | **10MEQ** | **A204828** | **002** | Aug 16, 2016 |
| **AB** | | PADDOCK LLC | **8MEQ** | **A200185** | **001** | May 18, 2011 |
| **AB** | | | **10MEQ** | **A200185** | **002** | May 18, 2011 |
| **AB** | | PII | **8MEQ** | **A205549** | **001** | Dec 08, 2015 |
| **AB** | | | **10MEQ** | **A205549** | **002** | Dec 08, 2015 |
| **AB** | | TRIS PHARMA INC | **8MEQ** | **A201944** | **001** | Mar 04, 2016 |
| **AB** | | | **10MEQ** | **A201944** | **002** | Mar 04, 2016 |

FOR SOLUTION;ORAL

**KLOR-CON**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | UPSHER-SMITH LABS | **20MEQ** | **A209662** | **001** | Oct 23, 2017 |

**POTASSIUM CHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **+!** | PHARMA RES SOFTWARE | **20MEQ** | **N208019** | **001** | Aug 19, 2015 |

INJECTABLE;INJECTION

**POTASSIUM CHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | B BRAUN | **2MEQ/ML** | **A085870** | **001** | |
| **AP** | | FRESENIUS KABI USA | **2MEQ/ML** | **A080225** | **001** | |
| **AP** | **!** | HOSPIRA | **2MEQ/ML** | **A080205** | **001** | |

**POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | BAXTER HLTHCARE | **14.9MG/ML** | **N019904** | **001** | Dec 26, 1989 |
| **AP** | **+!** | | **746MG/100ML** | **N019904** | **005** | Dec 17, 1990 |
| **AP** | **+** | ICU MEDICAL INC | **14.9MG/ML** | **N020161** | **005** | Nov 30, 1992 |
| **AP** | **+** | | **745MG/100ML** | **N020161** | **001** | Nov 30, 1992 |

**POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | BAXTER HLTHCARE | **29.8MG/ML** | **N019904** | **002** | Dec 26, 1989 |
| **AP** | **+!** | | **1.49GM/100ML** | **N019904** | **006** | Dec 17, 1990 |
| **AP** | **+!** | ICU MEDICAL INC | **29.8MG/ML** | **N020161** | **006** | Aug 11, 1998 |
| **AP** | **+** | | **1.49GM/100ML** | **N020161** | **002** | Nov 30, 1992 |

POTASSIUM CHLORIDE

INJECTABLE;INJECTION

**POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | BAXTER HLTHCARE | **2.24GM/100ML** | **N019904** | **003** | Dec 26, 1989 |
| **AP** | **+!** | ICU MEDICAL INC | **2.24GM/100ML** | **N020161** | **003** | Aug 11, 1998 |

**POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | BAXTER HLTHCARE | **2.98GM/100ML** | **N019904** | **004** | Dec 26, 1989 |
| **AP** | **+!** | ICU MEDICAL INC | **2.98GM/100ML** | **N020161** | **004** | Aug 11, 1998 |

**POTASSIUM CHLORIDE IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | FRESENIUS KABI USA | **2MEQ/ML** | **A088901** | **001** | Jan 25, 1985 |
| **AP** | | | **2MEQ/ML** | **A088908** | **001** | Jan 25, 1985 |
| | | POTASSIUM CHLORIDE | | | | |
| | ! | FRESENIUS KABI USA | 3MEQ/ML | A080225 | 003 | |

SOLUTION;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| | | POTASSIUM CHLORIDE | | | | |
| | + | GENUS LIFESCIENCES | 20MEQ/15ML | N206814 | 001 | Dec 22, 2014 |
| | +! | | 40MEQ/15ML | N206814 | 002 | Dec 22, 2014 |

TABLET, EXTENDED RELEASE;ORAL

**KLOR-CON M10**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB1** | | UPSHER-SMITH LABS | **10MEQ** | **A074726** | **002** | Aug 09, 2000 |

**KLOR-CON M20**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB1** | **!** | UPSHER-SMITH LABS | **20MEQ** | **A074726** | **001** | Nov 20, 1998 |

**POTASSIUM CHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB1** | | ACTAVIS LABS FL INC | **10MEQ** | **A075604** | **001** | Apr 10, 2002 |
| **AB1** | | | **20MEQ** | **A075604** | **002** | Apr 10, 2002 |
| **AB1** | | ADARE PHARMS INC | **20MEQ** | **A076368** | **001** | Aug 18, 2004 |
| **AB1** | | GLENMARK PHARMS LTD | **10MEQ** | **A203562** | **001** | Jul 26, 2016 |
| **AB1** | | | **20MEQ** | **A203562** | **002** | Jul 26, 2016 |
| **AB1** | | NOVEL LABS INC | **10MEQ** | **A206347** | **001** | Jan 21, 2016 |
| **AB1** | | | **20MEQ** | **A206347** | **002** | Jan 21, 2016 |

**KLOR-CON**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB2** | **+** | UPSHER-SMITH LABS | **8MEQ** | **N019123** | **001** | Apr 17, 1986 |
| **AB2** | **+!** | | **10MEQ** | **N019123** | **002** | Apr 17, 1986 |

**POTASSIUM CHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB2** | | MYLAN PHARMS INC | **8MEQ** | **A204662** | **001** | Aug 21, 2014 |
| **AB2** | | | **10MEQ** | **A204662** | **002** | Aug 21, 2014 |
| **AB2** | | NOVEL LABS INC | **8MEQ** | **A206759** | **001** | Aug 09, 2016 |
| **AB2** | | | **10MEQ** | **A206759** | **002** | Aug 09, 2016 |
| **AB2** | | PADDOCK LLC | **8MEQ** | **A205993** | **001** | Nov 05, 2015 |
| **AB2** | | | **10MEQ** | **A205993** | **002** | Nov 05, 2015 |
| **AB2** | | SIGMAPHARM LABS LLC | **8MEQ** | **A207528** | **001** | Aug 19, 2016 |
| **AB2** | | | **10MEQ** | **A207528** | **002** | Aug 19, 2016 |
| | | K-TAB | | | | |
| BC | + | ABBVIE | 8MEQ | N018279 | 002 | Aug 01, 1988 |
| BC | + | | 10MEQ | N018279 | 001 | |
| BC | +! | | 20MEQ | N018279 | 003 | Nov 25, 2013 |
| | | KLOR-CON M15 | | | | |
| | | UPSHER-SMITH LABS | 15MEQ | A074726 | 003 | Jun 06, 2003 |

POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

**POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | ICU MEDICAL INC | **149MG/100ML;450MG/100ML** | **A078446** | **001** | Sep 10, 2008 |

**POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | BAXTER HLTHCARE | **150MG/100ML;450MG/100ML** | **N017648** | **005** | Nov 26, 2002 |

**POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | B BRAUN | **150MG/100ML;900MG/100ML** | **N019708** | **004** | Sep 29, 1989 |
| **AP** | **+** | BAXTER HLTHCARE | **150MG/100ML;900MG/100ML** | **N017648** | **001** | |

**POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+** | BAXTER HLTHCARE | **300MG/100ML;900MG/100ML** | **N017648** | **002** | |

**POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | ICU MEDICAL INC | **149MG/100ML;900MG/100ML** | **N019686** | **001** | Oct 17, 1988 |

**POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | ICU MEDICAL INC | **298MG/100ML;900MG/100ML** | **N019686** | **002** | Oct 17, 1988 |
| | | POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9% | | | | |
| | + | BAXTER HLTHCARE | 224MG/100ML;900MG/100ML | N017648 | 003 | |

| | | | | | | |
|---|---|---|---|---|---|---|
| POTASSIUM CITRATE | | | | | | |
| TABLET, EXTENDED RELEASE;ORAL | | | | | | |
| **POTASSIUM CITRATE** | | | | | | |
| **AB** | | COREPHARMA | **5MEQ** | **A077440** | **001** | Jun 09, 2006 |
| **AB** | | | **10MEQ** | **A077440** | **002** | Jun 09, 2006 |
| **AB** | | STRIDES PHARMA | **5MEQ** | **A206813** | **001** | Sep 11, 2017 |
| **AB** | | | **10MEQ** | **A206813** | **002** | Sep 11, 2017 |
| **AB** | | | **15MEQ** | **A206813** | **003** | Sep 11, 2017 |
| **AB** | | ZYDUS PHARMS USA INC | **5MEQ** | **A203546** | **001** | Aug 06, 2014 |
| **AB** | | | **10MEQ** | **A203546** | **002** | Aug 06, 2014 |
| **AB** | | | **15MEQ** | **A203546** | **003** | Aug 06, 2014 |
| **UROCIT-K** | | | | | | |
| **AB** | + | MISSION PHARMA | **5MEQ** | **N019071** | **001** | Aug 30, 1985 |
| **AB** | + | | **10MEQ** | **N019071** | **002** | Aug 31, 1992 |
| **AB** | +! | | **15MEQ** | **N019071** | **003** | Dec 30, 2009 |
| POVIDONE-IODINE | | | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | | | |
| BETADINE | | | | | | |
| | +! | ALCON PHARMS LTD | 5% | N018634 | 001 | Dec 17, 1986 |
| PRALATREXATE | | | | | | |
| SOLUTION;INTRAVENOUS | | | | | | |
| FOLOTYN | | | | | | |
| | + | ALLOS | 20MG/ML (20MG/ML) | N022468 | 001 | Sep 24, 2009 |
| | +! | | 40MG/2ML (20MG/ML) | N022468 | 002 | Sep 24, 2009 |
| PRALIDOXIME CHLORIDE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| PRALIDOXIME CHLORIDE | | | | | | |
| | +! | MERIDIAN MEDCL TECHN | 300MG/ML | N018986 | 001 | Apr 26, 1983 |
| PROTOPAM CHLORIDE | | | | | | |
| | +! | BAXTER HLTHCARE CORP | 1GM/VIAL | N014134 | 001 | |
| PRAMIPEXOLE DIHYDROCHLORIDE | | | | | | |
| TABLET;ORAL | | | | | | |
| **MIRAPEX** | | | | | | |
| **AB** | + | BOEHRINGER INGELHEIM | **0.125MG** | **N020667** | **001** | Jul 01, 1997 |
| **AB** | +! | | **0.25MG** | **N020667** | **002** | Jul 01, 1997 |
| **AB** | + | | **0.5MG** | **N020667** | **006** | Feb 12, 1998 |
| **AB** | + | | **0.75MG** | **N020667** | **007** | Jul 30, 2007 |
| **AB** | + | | **1MG** | **N020667** | **003** | Jul 01, 1997 |
| **AB** | + | | **1.5MG** | **N020667** | **005** | Jul 01, 1997 |
| **PRAMIPEXOLE DIHYDROCHLORIDE** | | | | | | |
| **AB** | | ALEMBIC PHARMS LTD | **0.125MG** | **A078894** | **001** | Oct 08, 2010 |
| **AB** | | | **0.25MG** | **A078894** | **002** | Oct 08, 2010 |
| **AB** | | | **0.5MG** | **A078894** | **003** | Oct 08, 2010 |
| **AB** | | | **1MG** | **A078894** | **004** | Oct 08, 2010 |
| **AB** | | | **1.5MG** | **A078894** | **005** | Oct 08, 2010 |
| **AB** | | APOTEX INC | **0.125MG** | **A090151** | **001** | Apr 30, 2012 |
| **AB** | | | **0.25MG** | **A090151** | **002** | Apr 30, 2012 |
| **AB** | | | **0.5MG** | **A090151** | **003** | Apr 30, 2012 |
| **AB** | | | **0.75MG** | **A090151** | **006** | Apr 30, 2012 |
| **AB** | | | **1MG** | **A090151** | **004** | Apr 30, 2012 |
| **AB** | | | **1.5MG** | **A090151** | **005** | Apr 30, 2012 |
| **AB** | | AUROBINDO PHARMA LTD | **0.125MG** | **A202633** | **001** | Oct 26, 2012 |
| **AB** | | | **0.25MG** | **A202633** | **002** | Oct 26, 2012 |
| **AB** | | | **0.5MG** | **A202633** | **003** | Oct 26, 2012 |
| **AB** | | | **0.75MG** | **A202633** | **004** | Oct 26, 2012 |
| **AB** | | | **1MG** | **A202633** | **005** | Oct 26, 2012 |
| **AB** | | | **1.5MG** | **A202633** | **006** | Oct 26, 2012 |
| **AB** | | BARR | **0.125MG** | **A077724** | **001** | Feb 19, 2008 |
| **AB** | | | **0.25MG** | **A077724** | **002** | Feb 19, 2008 |
| **AB** | | | **0.5MG** | **A077724** | **003** | Feb 19, 2008 |
| **AB** | | | **1MG** | **A077724** | **004** | Feb 19, 2008 |
| **AB** | | | **1.5MG** | **A077724** | **005** | Feb 19, 2008 |
| **AB** | | BRECKENRIDGE PHARM | **0.125MG** | **A091450** | **001** | Oct 08, 2010 |
| **AB** | | | **0.25MG** | **A091450** | **002** | Oct 08, 2010 |
| **AB** | | | **0.5MG** | **A091450** | **003** | Oct 08, 2010 |
| **AB** | | | **1MG** | **A091450** | **004** | Oct 08, 2010 |

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

**PRAMIPEXOLE DIHYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| AB | | | 1.5MG | A091450 | 005 | Oct 08, 2010 |
| AB | | GLENMARK GENERICS | 0.125MG | A090781 | 001 | Oct 08, 2010 |
| AB | | | 0.25MG | A090781 | 002 | Oct 08, 2010 |
| AB | | | 0.5MG | A090781 | 003 | Oct 08, 2010 |
| AB | | | 0.75MG | A090781 | 006 | Sep 11, 2015 |
| AB | | | 1MG | A090781 | 004 | Oct 08, 2010 |
| AB | | | 1.5MG | A090781 | 005 | Oct 08, 2010 |
| AB | | MACLEODS PHARMS LTD | 0.125MG | A202164 | 001 | Sep 20, 2012 |
| AB | | | 0.25MG | A202164 | 002 | Sep 20, 2012 |
| AB | | | 0.5MG | A202164 | 003 | Sep 20, 2012 |
| AB | | | 1MG | A202164 | 004 | Sep 20, 2012 |
| AB | | | 1.5MG | A202164 | 005 | Sep 20, 2012 |
| AB | | MYLAN | 0.125MG | A077854 | 001 | Oct 08, 2010 |
| AB | | | 0.25MG | A077854 | 002 | Oct 08, 2010 |
| AB | | | 0.5MG | A077854 | 003 | Oct 08, 2010 |
| AB | | | 0.75MG | A090764 | 001 | Apr 09, 2010 |
| AB | | | 1MG | A077854 | 004 | Oct 08, 2010 |
| AB | | | 1.5MG | A077854 | 005 | Oct 08, 2010 |
| AB | | SCIEGEN PHARMS INC | 0.125MG | A203855 | 001 | Oct 28, 2014 |
| AB | | | 0.25MG | A203855 | 002 | Oct 28, 2014 |
| AB | | | 0.5MG | A203855 | 003 | Oct 28, 2014 |
| AB | | | 0.75MG | A203855 | 004 | Oct 28, 2014 |
| AB | | | 1MG | A203855 | 005 | Oct 28, 2014 |
| AB | | | 1.5MG | A203855 | 006 | Oct 28, 2014 |
| AB | | STRIDES PHARMA | 0.125MG | A202702 | 001 | Jun 03, 2014 |
| AB | | | 0.25MG | A202702 | 002 | Jun 03, 2014 |
| AB | | | 0.5MG | A202702 | 003 | Jun 03, 2014 |
| AB | | | 0.75MG | A202702 | 004 | Jun 03, 2014 |
| AB | | | 1MG | A202702 | 005 | Jun 03, 2014 |
| AB | | | 1.5MG | A202702 | 006 | Jun 03, 2014 |
| AB | | SUN PHARM INDS INC | 0.125MG | A091683 | 001 | Mar 27, 2013 |
| AB | | | 0.25MG | A091683 | 002 | Mar 27, 2013 |
| AB | | | 0.5MG | A091683 | 003 | Mar 27, 2013 |
| AB | | | 0.75MG | A091683 | 004 | Mar 27, 2013 |
| AB | | | 1MG | A091683 | 005 | Mar 27, 2013 |
| AB | | | 1.5MG | A091683 | 006 | Mar 27, 2013 |
| AB | | TEVA PHARMS | 0.125MG | A090241 | 001 | Oct 08, 2010 |
| AB | | | 0.25MG | A090241 | 002 | Oct 08, 2010 |
| AB | | | 0.5MG | A090241 | 003 | Oct 08, 2010 |
| AB | | | 0.75MG | A090241 | 004 | Oct 08, 2010 |
| AB | | | 1MG | A090241 | 005 | Oct 08, 2010 |
| AB | | | 1.5MG | A090241 | 006 | Oct 08, 2010 |
| AB | | TORRENT PHARMS | 0.125MG | A090865 | 001 | Oct 08, 2010 |
| AB | | | 0.25MG | A090865 | 002 | Oct 08, 2010 |
| AB | | | 0.5MG | A090865 | 003 | Oct 08, 2010 |
| AB | | | 0.75MG | A090865 | 004 | Oct 08, 2010 |
| AB | | | 1MG | A090865 | 005 | Oct 08, 2010 |
| AB | | | 1.5MG | A090865 | 006 | Oct 08, 2010 |
| AB | | ZYDUS PHARMS USA INC | 0.125MG | A078920 | 001 | Jul 06, 2010 |
| AB | | | 0.25MG | A078920 | 002 | Jul 06, 2010 |
| AB | | | 0.5MG | A078920 | 003 | Jul 06, 2010 |
| AB | | | 1MG | A078920 | 004 | Jul 06, 2010 |
| AB | | | 1.5MG | A078920 | 005 | Jul 06, 2010 |

TABLET, EXTENDED RELEASE;ORAL

**MIRAPEX ER**

| | | | | | | |
|---|---|---|---|---|---|---|
| AB | +! | BOEHRINGER INGELHEIM | 0.375MG | N022421 | 001 | Feb 19, 2010 |
| AB | + | | 0.75MG | N022421 | 002 | Feb 19, 2010 |
| AB | + | | 1.5MG | N022421 | 003 | Feb 19, 2010 |
| AB | + | | 2.25MG | N022421 | 006 | Jun 17, 2011 |
| AB | + | | 3MG | N022421 | 004 | Feb 19, 2010 |
| AB | + | | 3.75MG | N022421 | 007 | Jun 17, 2011 |
| AB | + | | 4.5MG | N022421 | 005 | Feb 19, 2010 |

**PRAMIPEXOLE DIHYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| AB | | ACTAVIS ELIZABETH | 0.375MG | A201963 | 001 | Apr 21, 2016 |
| AB | | | 0.75MG | A201963 | 002 | Apr 21, 2016 |
| AB | | | 1.5MG | A201963 | 003 | Apr 21, 2016 |
| AB | | | 2.25MG | A203615 | 001 | Oct 14, 2016 |
| AB | | | 3MG | A201963 | 004 | Apr 21, 2016 |

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

**PRAMIPEXOLE DIHYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **3.75MG** | **A203615** | **002** | Jan 03, 2017 |
| **AB** | | | **4.5MG** | **A201963** | **005** | Apr 21, 2016 |
| **AB** | | ANCHEN PHARMS | **0.375MG** | **A202206** | **001** | Feb 06, 2014 |
| **AB** | | | **0.75MG** | **A202206** | **002** | Feb 06, 2014 |
| **AB** | | | **1.5MG** | **A202206** | **003** | Feb 06, 2014 |
| **AB** | | | **2.25MG** | **A202206** | **004** | Feb 06, 2014 |
| **AB** | | | **3MG** | **A202206** | **005** | Feb 06, 2014 |
| **AB** | | | **3.75MG** | **A202206** | **006** | Feb 06, 2014 |
| **AB** | | | **4.5MG** | **A202206** | **007** | Feb 06, 2014 |
| **AB** | | DR REDDYS LABS LTD | **0.375MG** | **A203354** | **001** | Aug 07, 2015 |
| **AB** | | | **0.75MG** | **A203354** | **002** | Aug 07, 2015 |
| **AB** | | | **1.5MG** | **A203354** | **003** | Aug 07, 2015 |
| **AB** | | | **3MG** | **A203354** | **004** | Aug 07, 2015 |
| **AB** | | | **4.5MG** | **A203354** | **005** | Aug 07, 2015 |
| **AB** | | MACLEODS PHARMS LTD | **0.375MG** | **A206156** | **001** | Jun 24, 2016 |
| **AB** | | | **0.75MG** | **A206156** | **002** | Jun 24, 2016 |
| **AB** | | | **1.5MG** | **A206156** | **003** | Jun 24, 2016 |
| **AB** | | | **2.25MG** | **A206156** | **004** | Jun 24, 2016 |
| **AB** | | | **3MG** | **A206156** | **005** | Jun 24, 2016 |
| **AB** | | | **3.75MG** | **A206156** | **007** | Jan 23, 2017 |
| **AB** | | | **4.5MG** | **A206156** | **006** | Jun 24, 2016 |
| **AB** | | SANDOZ INC | **0.375MG** | **A202353** | **001** | Dec 04, 2014 |
| **AB** | | | **0.75MG** | **A202353** | **002** | Dec 04, 2014 |
| **AB** | | | **1.5MG** | **A202353** | **003** | Dec 04, 2014 |
| **AB** | | | **3MG** | **A202353** | **004** | Dec 04, 2014 |
| **AB** | | | **4.5MG** | **A202353** | **005** | Dec 04, 2014 |
| **AB** | | ZYDUS PHARMS USA INC | **0.375MG** | **A202891** | **001** | Dec 12, 2017 |
| **AB** | | | **0.75MG** | **A202891** | **002** | Dec 12, 2017 |
| **AB** | | | **1.5MG** | **A202891** | **003** | Dec 12, 2017 |
| **AB** | | | **2.25MG** | **A202891** | **004** | Dec 12, 2017 |
| **AB** | | | **3MG** | **A202891** | **005** | Dec 12, 2017 |
| **AB** | | | **3.75MG** | **A202891** | **006** | Dec 12, 2017 |
| **AB** | | | **4.5MG** | **A202891** | **007** | Dec 12, 2017 |

PRAMLINTIDE ACETATE

INJECTABLE;SUBCUTANEOUS

SYMLIN

| | | | | | |
|---|---|---|---|---|---|
| + | ASTRAZENECA AB | EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML) | N021332 | 002 | Sep 25, 2007 |
| +! | | EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML) | N021332 | 003 | Sep 25, 2007 |

PRASTERONE

INSERT;VAGINAL

INTRAROSA

| | | | | | |
|---|---|---|---|---|---|
| +! | AMAG PHARMS INC | 6.5MG | N208470 | 001 | Nov 16, 2016 |

PRASUGREL HYDROCHLORIDE

TABLET;ORAL

**EFFIENT**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | ELI LILLY AND CO | **EQ 5MG BASE** | **N022307** | **001** | Jul 10, 2009 |
| **AB** | **+!** | | **EQ 10MG BASE** | **N022307** | **002** | Jul 10, 2009 |

**PRASUGREL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AUROBINDO PHARMA LTD | **EQ 5MG BASE** | **A205888** | **001** | Oct 16, 2017 |
| **AB** | | | **EQ 10MG BASE** | **A205888** | **002** | Oct 16, 2017 |
| **AB** | | LIBERTY PHARMA INC | **EQ 5MG BASE** | **A205790** | **001** | Oct 16, 2017 |
| **AB** | | | **EQ 10MG BASE** | **A205790** | **002** | Oct 16, 2017 |
| **AB** | | MYLAN PHARMS INC | **EQ 5MG BASE** | **A205927** | **001** | Jul 12, 2017 |
| **AB** | | | **EQ 10MG BASE** | **A205927** | **002** | Jul 12, 2017 |
| **AB** | | PANACEA BIOTEC LTD | **EQ 5MG BASE** | **A205897** | **001** | Oct 16, 2017 |
| **AB** | | | **EQ 10MG BASE** | **A205897** | **002** | Oct 16, 2017 |

PRAVASTATIN SODIUM

TABLET;ORAL

**PRAVACHOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | BRISTOL MYERS SQUIBB | **20MG** | **N019898** | **003** | Oct 31, 1991 |
| **AB** | **+** | | **40MG** | **N019898** | **004** | Mar 22, 1993 |
| **AB** | **+!** | | **80MG** | **N019898** | **008** | Dec 18, 2001 |

**PRAVASTATIN SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACCORD HLTHCARE | **10MG** | **A207068** | **001** | Nov 17, 2016 |
| **AB** | | | **20MG** | **A207068** | **002** | Nov 17, 2016 |

PRAVASTATIN SODIUM

TABLET;ORAL

**PRAVASTATIN SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | **40MG** | **A207068** | **003** | Nov 17, 2016 |
| **AB** | | **80MG** | **A207068** | **004** | Nov 17, 2016 |
| **AB** | APOTEX INC | **10MG** | **A076341** | **001** | Oct 23, 2006 |
| **AB** | | **20MG** | **A076341** | **002** | Oct 23, 2006 |
| **AB** | | **40MG** | **A076341** | **003** | Oct 23, 2006 |
| **AB** | | **80MG** | **A076341** | **004** | Dec 28, 2007 |
| **AB** | AUROBINDO PHARMA LTD | **10MG** | **A203367** | **001** | Feb 02, 2017 |
| **AB** | | **20MG** | **A203367** | **002** | Feb 02, 2017 |
| **AB** | | **40MG** | **A203367** | **003** | Feb 02, 2017 |
| **AB** | | **80MG** | **A203367** | **004** | Feb 02, 2017 |
| **AB** | CIPLA LTD | **10MG** | **A077904** | **001** | Oct 23, 2006 |
| **AB** | | **20MG** | **A077904** | **002** | Oct 23, 2006 |
| **AB** | | **40MG** | **A077904** | **003** | Oct 23, 2006 |
| **AB** | | **80MG** | **A077904** | **004** | Mar 22, 2016 |
| **AB** | DR REDDYS LABS INC | **10MG** | **A076714** | **001** | Oct 23, 2006 |
| **AB** | | **20MG** | **A076714** | **002** | Oct 23, 2006 |
| **AB** | | **40MG** | **A076714** | **003** | Oct 23, 2006 |
| **AB** | | **80MG** | **A076714** | **004** | Dec 28, 2007 |
| **AB** | GLENMARK GENERICS | **10MG** | **A077987** | **001** | May 11, 2007 |
| **AB** | | **20MG** | **A077987** | **002** | May 11, 2007 |
| **AB** | | **40MG** | **A077987** | **003** | May 11, 2007 |
| **AB** | | **80MG** | **A077987** | **004** | Dec 28, 2007 |
| **AB** | LUPIN PHARMS | **10MG** | **A077917** | **001** | Jan 08, 2008 |
| **AB** | | **20MG** | **A077917** | **002** | Jan 08, 2008 |
| **AB** | | **40MG** | **A077917** | **003** | Jan 08, 2008 |
| **AB** | | **80MG** | **A077917** | **004** | Jan 08, 2008 |
| **AB** | MYLAN PHARMS INC | **10MG** | **A079187** | **001** | May 27, 2010 |
| **AB** | | **20MG** | **A079187** | **002** | May 27, 2010 |
| **AB** | | **40MG** | **A079187** | **003** | May 27, 2010 |
| **AB** | | **80MG** | **A079187** | **004** | May 27, 2010 |
| **AB** | SANDOZ | **10MG** | **A076397** | **003** | Oct 23, 2006 |
| **AB** | | **20MG** | **A076397** | **002** | Oct 23, 2006 |
| **AB** | | **40MG** | **A076397** | **001** | Oct 23, 2006 |
| **AB** | | **80MG** | **A077491** | **001** | Feb 11, 2008 |
| **AB** | TEVA | **10MG** | **A076056** | **001** | Apr 24, 2006 |
| **AB** | | **20MG** | **A076056** | **002** | Apr 24, 2006 |
| **AB** | | **40MG** | **A076056** | **003** | Apr 24, 2006 |
| **AB** | TEVA PHARMS | **80MG** | **A077793** | **001** | Jan 15, 2008 |
| **AB** | WATSON LABS | **10MG** | **A076939** | **004** | Oct 23, 2006 |
| **AB** | | **20MG** | **A076939** | **003** | Oct 23, 2006 |
| **AB** | | **40MG** | **A076939** | **002** | Oct 23, 2006 |
| **AB** | | **80MG** | **A076939** | **001** | Dec 28, 2007 |
| **AB** | ZYDUS PHARMS USA | **10MG** | **A077751** | **001** | Apr 30, 2008 |
| **AB** | | **20MG** | **A077751** | **002** | Apr 30, 2008 |
| **AB** | | **40MG** | **A077751** | **003** | Apr 30, 2008 |
| **AB** | | **80MG** | **A077751** | **004** | Apr 30, 2008 |

PRAZIQUANTEL

TABLET;ORAL

**BILTRICIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | BAYER HLTHCARE | **600MG** | **N018714** | **001** | Dec 29, 1982 |

**PRAZIQUANTEL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | PAR PHARM INC | **600MG** | **A208820** | **001** | Nov 27, 2017 |

PRAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

**MINIPRESS**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | PFIZER | **EQ 1MG BASE** | **N017442** | **002** | |
| **AB** | **+!** | | **EQ 2MG BASE** | **N017442** | **003** | |
| **AB** | **+** | | **EQ 5MG BASE** | **N017442** | **001** | |

**PRAZOSIN HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | MYLAN | **EQ 1MG BASE** | **A072575** | **003** | May 16, 1989 |
| **AB** | | | **EQ 2MG BASE** | **A072575** | **002** | May 16, 1989 |
| **AB** | | | **EQ 5MG BASE** | **A072575** | **001** | May 16, 1989 |
| **AB** | | TEVA PHARMS | **EQ 1MG BASE** | **A071745** | **002** | Sep 12, 1988 |
| **AB** | | | **EQ 2MG BASE** | **A071745** | **003** | Sep 12, 1988 |
| **AB** | | | **EQ 5MG BASE** | **A071745** | **001** | Sep 12, 1988 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| PREDNICARBATE | | | | | | | |
| CREAM;TOPICAL | | | | | | | |
| **DERMATOP E EMOLLIENT** | | | | | | | |
| **AB** | **+!** | VALEANT BERMUDA | **0.1%** | **N020279** | **001** | Oct 29, 1993 |
| **PREDNICARBATE** | | | | | | | |
| **AB** | | FOUGERA PHARMS | **0.1%** | **A077287** | **001** | Sep 19, 2006 |
| OINTMENT;TOPICAL | | | | | | | |
| **DERMATOP** | | | | | | | |
| **AB** | **+!** | VALEANT PHARMS NORTH | **0.1%** | **N019568** | **001** | Sep 23, 1991 |
| **PREDNICARBATE** | | | | | | | |
| **AB** | | FOUGERA PHARMS | **0.1%** | **A077236** | **001** | Mar 09, 2007 |
| PREDNISOLONE | | | | | | | |
| SYRUP;ORAL | | | | | | | |
| **PREDNISOLONE** | | | | | | | |
| **AA** | **!** | HI TECH PHARMA CO | **15MG/5ML** | **A040401** | **001** | Feb 27, 2003 |
| **AA** | | PHARM ASSOC | **15MG/5ML** | **A040399** | **001** | Mar 05, 2003 |
| **AA** | | VINTAGE | **15MG/5ML** | **A040775** | **001** | Sep 21, 2007 |
| **AA** | | VISTAPHARM | **15MG/5ML** | **A040323** | **001** | May 13, 1999 |
| **AA** | | WOCKHARDT BIO AG | **15MG/5ML** | **A040313** | **001** | Sep 10, 2003 |
| **PRELONE** | | | | | | | |
| **AA** | | TEVA | **15MG/5ML** | **A089081** | **001** | Feb 04, 1986 |
| TABLET;ORAL | | | | | | | |
| PREDNISOLONE | | | | | | | |
| | ! | WATSON LABS | 5MG | A080354 | 001 | | |
| PREDNISOLONE ACETATE | | | | | | | |
| SUSPENSION/DROPS;OPHTHALMIC | | | | | | | |
| **OMNIPRED** | | | | | | | |
| **AB** | | NOVARTIS PHARMS CORP | **1%** | **N017469** | **001** | | |
| **PRED FORTE** | | | | | | | |
| **AB** | **+!** | ALLERGAN | **1%** | **N017011** | **001** | | |
| PRED MILD | | | | | | | |
| | +! | ALLERGAN | 0.12% | N017100 | 001 | | |
| PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM | | | | | | | |
| OINTMENT;OPHTHALMIC | | | | | | | |
| BLEPHAMIDE S.O.P. | | | | | | | |
| | ! | ALLERGAN | 0.2%;10% | A087748 | 001 | Dec 03, 1986 |
| SUSPENSION;OPHTHALMIC | | | | | | | |
| BLEPHAMIDE | | | | | | | |
| | +! | ALLERGAN | 0.2%;10% | N012813 | 002 | | |
| PREDNISOLONE SODIUM PHOSPHATE | | | | | | | |
| SOLUTION;ORAL | | | | | | | |
| **PEDIAPRED** | | | | | | | |
| **AA** | **+!** | SETON PHARM | **EQ 5MG BASE/5ML** | **N019157** | **001** | May 28, 1986 |
| **PREDNISOLONE SODIUM PHOSPHATE** | | | | | | | |
| **AA** | | CHARTWELL RX | **EQ 5MG BASE/5ML** | **A075988** | **001** | May 25, 2004 |
| **AA** | | EDENBRIDGE PHARMS | **EQ 10MG BASE/5ML** | **A203559** | **001** | Dec 20, 2016 |
| **AA** | | | **EQ 20MG BASE/5ML** | **A203559** | **002** | Dec 20, 2016 |
| **AA** | | HI TECH PHARMA | **EQ 5MG BASE/5ML** | **A075183** | **001** | Mar 26, 2003 |
| **AA** | **!** | PHARM ASSOC | **EQ 10MG BASE/5ML** | **A078465** | **001** | Mar 07, 2008 |
| **AA** | | | **EQ 15MG BASE/5ML** | **A076913** | **001** | Apr 25, 2005 |
| **AA** | **!** | | **EQ 20MG BASE/5ML** | **A078988** | **001** | Jun 09, 2008 |
| **AA** | | VINTAGE | **EQ 15MG BASE/5ML** | **A079010** | **001** | May 26, 2009 |
| **AA** | **!** | WOCKHARDT | **EQ 15MG BASE/5ML** | **A076895** | **001** | Oct 04, 2004 |
| **AA** | | WOCKHARDT BIO AG | **EQ 5MG BASE/5ML** | **A075099** | **001** | Jun 28, 2002 |
| | ! | MISSION PHARMA | EQ 25MG BASE/5ML | A091396 | 001 | Sep 13, 2010 |
| SOLUTION/DROPS;OPHTHALMIC | | | | | | | |
| PREDNISOLONE SODIUM PHOSPHATE | | | | | | | |
| | ! | BAUSCH AND LOMB | EQ 0.9% PHOSPHATE | A040070 | 001 | Jul 29, 1994 |
| TABLET, ORALLY DISINTEGRATING;ORAL | | | | | | | |
| **ORAPRED ODT** | | | | | | | |
| **AB** | **+** | CONCORDIA PHARMS INC | **EQ 10MG BASE** | **N021959** | **001** | Jun 01, 2006 |
| **AB** | **+** | | **EQ 15MG BASE** | **N021959** | **002** | Jun 01, 2006 |
| **AB** | **+!** | | **EQ 30MG BASE** | **N021959** | **003** | Jun 01, 2006 |
| **PREDNISOLONE SODIUM PHOSPHATE** | | | | | | | |
| **AB** | | MYLAN PHARMS INC | **EQ 10MG BASE** | **A202179** | **001** | Apr 10, 2013 |
| **AB** | | | **EQ 15MG BASE** | **A202179** | **002** | Apr 10, 2013 |
| **AB** | | | **EQ 30MG BASE** | **A202179** | **003** | Apr 10, 2013 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM | | | | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | | | | |
| **SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE** | | | | | | | |
| **AT** | **!** | BAUSCH AND LOMB | **EQ 0.23% PHOSPHATE;10%** | **A074449** | **001** | Dec 29, 1995 |
| **AT** | | SANDOZ INC | **EQ 0.23% PHOSPHATE;10%** | **A073630** | **001** | May 27, 1993 |
| PREDNISONE | | | | | | | |
| SOLUTION;ORAL | | | | | | | |
| PREDNISONE | | | | | | | |
| | ! | WEST-WARD PHARMS INT | 5MG/5ML | A088703 | 001 | Nov 08, 1984 |
| PREDNISONE INTENSOL | | | | | | | |
| | ! | WEST-WARD PHARMS INT | 5MG/ML | A088810 | 001 | Feb 20, 1985 |
| TABLET;ORAL | | | | | | | |
| **PREDNISONE** | | | | | | | |
| **AB** | | HIKMA PHARMS | **2.5MG** | **A040538** | **001** | Jan 08, 2004 |
| **AB** | | | **50MG** | **A088465** | **001** | Jun 01, 1984 |
| **AB** | | JUBILANT CADISTA | **1MG** | **A040611** | **001** | Jun 06, 2005 |
| **AB** | | | **5MG** | **A040362** | **002** | Aug 29, 2001 |
| **AB** | | | **10MG** | **A040362** | **001** | Aug 29, 2001 |
| **AB** | | | **20MG** | **A040362** | **003** | Jun 29, 2005 |
| **AB** | | MUTUAL PHARM | **5MG** | **A089245** | **001** | Dec 04, 1985 |
| **AB** | | MYLAN PHARMS INC | **5MG** | **A080292** | **001** | |
| **AB** | | | **10MG** | **A088832** | **001** | Dec 04, 1985 |
| **AB** | | | **20MG** | **A083677** | **001** | |
| **AB** | | SUN PHARM INDUSTRIES | **10MG** | **A089246** | **001** | Dec 04, 1985 |
| **AB** | | | **20MG** | **A089247** | **001** | Dec 04, 1985 |
| **AB** | | VINTAGE PHARMS | **1MG** | **A040584** | **001** | Dec 21, 2004 |
| **AB** | | | **2.5MG** | **A040581** | **001** | Dec 21, 2004 |
| **AB** | | | **5MG** | **A040256** | **001** | Jul 12, 2002 |
| **AB** | | | **10MG** | **A040256** | **002** | Jul 12, 2002 |
| **AB** | | | **20MG** | **A040392** | **001** | Feb 12, 2003 |
| **AB** | | WATSON LABS | **5MG** | **A080356** | **001** | |
| **AB** | | | **10MG** | **A085162** | **001** | |
| **AB** | | | **20MG** | **A085161** | **001** | |
| **AB** | **!** | WEST-WARD PHARMS INT | **1MG** | **A087800** | **001** | Apr 22, 1982 |
| **AB** | **!** | | **2.5MG** | **A087801** | **001** | Apr 22, 1982 |
| **AB** | **!** | | **5MG** | **A080352** | **001** | |
| **AB** | **!** | | **10MG** | **A084122** | **001** | |
| **AB** | **!** | | **20MG** | **A087342** | **001** | |
| **AB** | **!** | | **50MG** | **A084283** | **001** | |
| TABLET, DELAYED RELEASE;ORAL | | | | | | | |
| **PREDNISONE** | | | | | | | |
| **AB** | | ACTAVIS LABS FL INC | **1MG** | **A204867** | **001** | Apr 25, 2017 |
| **AB** | | | **2MG** | **A204867** | **002** | Apr 25, 2017 |
| **AB** | | | **5MG** | **A204867** | **003** | Apr 25, 2017 |
| **RAYOS** | | | | | | | |
| **AB** | **+** | HORIZON PHARMA | **1MG** | **N202020** | **001** | Jul 26, 2012 |
| **AB** | **+** | | **2MG** | **N202020** | **002** | Jul 26, 2012 |
| **AB** | **+!** | | **5MG** | **N202020** | **003** | Jul 26, 2012 |
| PREGABALIN | | | | | | | |
| CAPSULE;ORAL | | | | | | | |
| LYRICA | | | | | | | |
| | + | PF PRISM CV | 25MG | N021446 | 001 | Dec 30, 2004 |
| | + | | 50MG | N021446 | 002 | Dec 30, 2004 |
| | + | | 75MG | N021446 | 003 | Dec 30, 2004 |
| | + | | 100MG | N021446 | 004 | Dec 30, 2004 |
| | + | | 150MG | N021446 | 005 | Dec 30, 2004 |
| | + | | 200MG | N021446 | 006 | Dec 30, 2004 |
| | + | | 225MG | N021446 | 007 | Dec 30, 2004 |
| | +! | | 300MG | N021446 | 008 | Dec 30, 2004 |
| SOLUTION;ORAL | | | | | | | |
| LYRICA | | | | | | | |
| | +! | PF PRISM CV | 20MG/ML | N022488 | 001 | Jan 04, 2010 |
| TABLET, EXTENDED RELEASE;ORAL | | | | | | | |
| LYRICA CR | | | | | | | |
| | + | PFIZER INC | 82.5MG | N209501 | 001 | Oct 11, 2017 |
| | + | | 165MG | N209501 | 002 | Oct 11, 2017 |
| | +! | | 330MG | N209501 | 003 | Oct 11, 2017 |

PRILOCAINE HYDROCHLORIDE
INJECTABLE;INJECTION
PRILOCAINE HYDROCHLORIDE

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | SEPTODONT INC | 4% | A079235 | 001 | Sep 29, 2010 |

PRIMAQUINE PHOSPHATE
TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **PRIMAQUINE** | | | | | | |
| **AB** | **+!** | SANOFI AVENTIS US | **EQ 15MG BASE** | **N008316** | **001** | |
| **PRIMAQUINE PHOSPHATE** | | | | | | |
| **AB** | | ALVOGEN INC | **EQ 15MG BASE** | **A203924** | **001** | Feb 03, 2014 |
| **AB** | | BAYSHORE PHARMS LLC | **EQ 15MG BASE** | **A204476** | **001** | Feb 25, 2014 |
| **AB** | | INGENUS PHARMS NJ | **EQ 15MG BASE** | **A206043** | **001** | Jun 23, 2016 |

PRIMIDONE
TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **MYSOLINE** | | | | | | |
| **AB** | **+!** | VALEANT | **50MG** | **N009170** | **003** | |
| **AB** | **+** | | **250MG** | **N009170** | **002** | |
| **PRIMIDONE** | | | | | | |
| **AB** | | AMNEAL PHARM | **50MG** | **A040866** | **001** | Apr 23, 2008 |
| **AB** | | | **250MG** | **A040866** | **002** | Apr 23, 2008 |
| **AB** | | ANDA REPOSITORY | **50MG** | **A040626** | **001** | Sep 29, 2005 |
| **AB** | | | **250MG** | **A040626** | **002** | Sep 29, 2005 |
| **AB** | | HIKMA INTL PHARMS | **250MG** | **A040667** | **002** | Jul 27, 2006 |
| **AB** | | LANNETT | **50MG** | **A084903** | **002** | May 24, 2001 |
| **AB** | | | **250MG** | **A084903** | **001** | |
| **AB** | | VINTAGE PHARMS | **50MG** | **A040586** | **001** | Feb 24, 2005 |
| **AB** | | | **250MG** | **A040586** | **002** | Feb 24, 2005 |
| **AB** | | WATSON LABS | **250MG** | **A083551** | **001** | |

PROBENECID
TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **PROBALAN** | | | | | | |
| **AB** | | LANNETT | **500MG** | **A080966** | **001** | |
| **PROBENECID** | | | | | | |
| **AB** | **!** | MYLAN | **500MG** | **A084211** | **002** | |
| **AB** | | WATSON LABS TEVA | **500MG** | **A084442** | **004** | Mar 29, 1983 |

PROCAINAMIDE HYDROCHLORIDE
INJECTABLE;INJECTION
**PROCAINAMIDE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **!** | HOSPIRA | **100MG/ML** | **A089069** | **001** | Feb 12, 1986 |
| **AP** | | INTL MEDICATION | **100MG/ML** | **A088636** | **001** | Jul 31, 1984 |
| **AP** | | NEXUS PHARMS | **100MG/ML** | **A206332** | **001** | Oct 13, 2017 |
| **AP** | | | **500MG/ML** | **A206332** | **002** | Oct 13, 2017 |
| | ! | HOSPIRA | 500MG/ML | A089070 | 001 | Feb 12, 1986 |

PROCARBAZINE HYDROCHLORIDE
CAPSULE;ORAL
MATULANE

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | LEADIANT BIOSCI INC | EQ 50MG BASE | N016785 | 001 | |

PROCHLORPERAZINE
SUPPOSITORY;RECTAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **COMPRO** | | | | | | |
| **AB** | | PADDOCK LLC | **25MG** | **A040246** | **001** | Jun 28, 2000 |
| **PROCHLORPERAZINE** | | | | | | |
| **AB** | **!** | G AND W LABS | **25MG** | **A040058** | **001** | Nov 24, 1993 |

PROCHLORPERAZINE EDISYLATE
INJECTABLE;INJECTION
**PROCHLORPERAZINE EDISYLATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **!** | EMCURE PHARMS LTD | **EQ 5MG BASE/ML** | **A204147** | **001** | Oct 15, 2013 |
| **AP** | | WEST-WARD PHARMS INT | **EQ 5MG BASE/ML** | **A089903** | **001** | Aug 29, 1989 |

PROCHLORPERAZINE MALEATE
TABLET;ORAL
**PROCHLORPERAZINE MALEATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | MYLAN | **EQ 5MG BASE** | **A040185** | **002** | Oct 28, 1996 |
| **AB** | | | **EQ 10MG BASE** | **A040185** | **001** | Oct 28, 1996 |
| **AB** | | SANDOZ | **EQ 5MG BASE** | **A040101** | **001** | Jul 19, 1996 |
| **AB** | **!** | | **EQ 10MG BASE** | **A040101** | **002** | Jul 19, 1996 |
| **AB** | | TEVA PHARMS | **EQ 5MG BASE** | **A040120** | **001** | Jul 11, 1996 |
| **AB** | | | **EQ 10MG BASE** | **A040120** | **002** | Jul 11, 1996 |

PROCHLORPERAZINE MALEATE

TABLET;ORAL

**PROCOMP**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | JUBILANT CADISTA | **EQ 5MG BASE** | **A040268** | **001** | Feb 27, 1998 |
| **AB** | | | **EQ 10MG BASE** | **A040268** | **002** | Feb 27, 1998 |

PROGESTERONE

CAPSULE;ORAL

**PROGESTERONE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AMNEAL PHARMS NY | **100MG** | **A207724** | **001** | Sep 07, 2017 |
| **AB** | | | **200MG** | **A207724** | **002** | Sep 07, 2017 |
| **AB** | | BIONPHARMA INC | **100MG** | **A200900** | **001** | Aug 16, 2013 |
| **AB** | | | **200MG** | **A200900** | **002** | Aug 16, 2013 |
| **AB** | | DR REDDYS LABS INC | **100MG** | **A208801** | **001** | Feb 28, 2017 |
| **AB** | | | **200MG** | **A208801** | **002** | Feb 28, 2017 |
| **AB** | | SANDOZ INC | **100MG** | **A205229** | **001** | Oct 20, 2017 |
| **AB** | | | **200MG** | **A205229** | **002** | Oct 20, 2017 |
| **AB** | | SOFGEN PHARMS | **100MG** | **A200456** | **001** | Sep 28, 2012 |
| **AB** | | | **200MG** | **A200456** | **002** | Sep 28, 2012 |
| **AB** | | TEVA PHARMS | **100MG** | **A202121** | **001** | Feb 29, 2012 |
| **AB** | | | **200MG** | **A202121** | **002** | Feb 29, 2012 |

**PROMETRIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | VIRTUS PHARMS | **100MG** | **N019781** | **001** | May 14, 1998 |
| **AB** | **+!** | | **200MG** | **N019781** | **002** | Oct 15, 1999 |

GEL;VAGINAL

CRINONE

| | | | | | |
|---|---|---|---|---|---|
| +! | ALLERGAN SALES LLC | 4% | N020701 | 001 | Jul 31, 1997 |
| +! | | 8% | N020701 | 002 | Jul 31, 1997 |

INJECTABLE;INJECTION

**PROGESTERONE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AO** | **+!** | ACTAVIS LABS UT INC | **50MG/ML** | **N017362** | **002** | |
| **AO** | | FRESENIUS KABI USA | **50MG/ML** | **A075906** | **001** | Apr 25, 2001 |
| **AO** | | HIKMA FARMACEUTICA | **50MG/ML** | **A091033** | **001** | Oct 28, 2010 |
| **AO** | | LUITPOLD | **50MG/ML** | **A090845** | **001** | Jun 22, 2009 |

INSERT;VAGINAL

ENDOMETRIN

| | | | | | |
|---|---|---|---|---|---|
| +! | FERRING | 100MG | N022057 | 001 | Jun 21, 2007 |

PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

**PROMETHAZINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **!** | WEST-WARD PHARMS INT | **25MG/ML** | **A083312** | **001** | |
| **AP** | **!** | | **50MG/ML** | **A083312** | **002** | |
| **AP** | | X-GEN PHARMS | **25MG/ML** | **A040737** | **001** | Apr 24, 2008 |
| **AP** | | | **50MG/ML** | **A040737** | **002** | Apr 24, 2008 |

SUPPOSITORY;RECTAL

**PROMETHAZINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | G AND W LABS | **12.5MG** | **A040428** | **002** | Mar 31, 2003 |
| **AB** | **!** | | **25MG** | **A040428** | **001** | Feb 05, 2002 |
| **AB** | | PERRIGO NEW YORK | **12.5MG** | **A040500** | **001** | Jun 30, 2003 |
| **AB** | | | **25MG** | **A040500** | **002** | Jun 30, 2003 |
| **AB** | | TARO | **12.5MG** | **A040603** | **001** | Oct 26, 2006 |
| **AB** | | | **25MG** | **A040603** | **002** | Oct 26, 2006 |
| **AB** | | WATSON LABS INC | **12.5MG** | **A040479** | **001** | Jun 24, 2003 |
| **AB** | | | **25MG** | **A040479** | **002** | Jun 24, 2003 |

PROMETHEGAN

| | | | | | |
|---|---|---|---|---|---|
| ! | G AND W LABS | 50MG | A087165 | 001 | Aug 14, 1987 |

SYRUP;ORAL

**PROMETHAZINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | AMNEAL PHARMS | **6.25MG/5ML** | **A040882** | **001** | Dec 30, 2009 |
| **AA** | | HI TECH PHARMA | **6.25MG/5ML** | **A040026** | **001** | Sep 25, 1998 |
| **AA** | | NOSTRUM LABS INC | **6.25MG/5ML** | **A040891** | **001** | Mar 13, 2009 |
| **AA** | | TARO | **6.25MG/5ML** | **A040718** | **001** | Apr 04, 2007 |
| **AA** | | TRIS PHARMA INC | **6.25MG/5ML** | **A091675** | **001** | Jun 28, 2012 |
| **AA** | | VINTAGE | **6.25MG/5ML** | **A040643** | **001** | Apr 26, 2006 |

**PROMETHAZINE PLAIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **!** | WOCKHARDT BIO AG | **6.25MG/5ML** | **A087953** | **001** | Nov 15, 1982 |

TABLET;ORAL

**PROMETHAZINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AMNEAL PHARMS NY | **12.5MG** | **A091179** | **001** | Dec 13, 2010 |
| **AB** | | | **25MG** | **A091179** | **002** | Dec 13, 2010 |
| **AB** | | | **50MG** | **A091179** | **003** | Dec 13, 2010 |
| **AB** | | HERITAGE PHARMA | **12.5MG** | **A040673** | **001** | Mar 05, 2008 |

PROMETHAZINE HYDROCHLORIDE

TABLET;ORAL

**PROMETHAZINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **25MG** | **A040673** | **002** | Mar 05, 2008 |
| **AB** | | | **50MG** | **A040673** | **003** | Mar 05, 2008 |
| **AB** | | KVK TECH | **12.5MG** | **A040712** | **002** | May 04, 2007 |
| **AB** | | | **25MG** | **A040712** | **001** | Jul 31, 2006 |
| **AB** | | | **50MG** | **A040712** | **003** | Jul 31, 2006 |
| **AB** | | PRINSTON INC | **12.5MG** | **A040622** | **001** | Jul 18, 2006 |
| **AB** | | | **25MG** | **A040622** | **002** | Jul 18, 2006 |
| **AB** | | | **50MG** | **A040622** | **003** | Jul 18, 2006 |
| **AB** | | SANDOZ | **25MG** | **A084176** | **003** | |
| **AB** | **!** | | **50MG** | **A084176** | **001** | |
| **AB** | | STRIDES PHARMA | **12.5MG** | **A209177** | **001** | Jun 30, 2017 |
| **AB** | | | **25MG** | **A209177** | **002** | Jun 30, 2017 |
| **AB** | | | **50MG** | **A209177** | **003** | Jun 30, 2017 |
| **AB** | | SUN PHARM INDS INC | **12.5MG** | **A040863** | **001** | Dec 30, 2008 |
| **AB** | | | **25MG** | **A040863** | **002** | Dec 30, 2008 |
| **AB** | | | **50MG** | **A040863** | **003** | Dec 30, 2008 |
| **AB** | | WATSON LABS | **25MG** | **A083426** | **001** | |
| **AB** | | | **50MG** | **A083711** | **001** | |
| **AB** | | ZYDUS PHARMS USA | **12.5MG** | **A040596** | **001** | Nov 18, 2005 |
| **AB** | | | **25MG** | **A040596** | **002** | Nov 18, 2005 |
| **AB** | | | **50MG** | **A040596** | **003** | Nov 18, 2005 |
| | | IMPAX LABS | 12.5MG | A040791 | 002 | Feb 12, 2008 |
| | | | 25MG | A040791 | 003 | Feb 12, 2008 |

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

**PROPAFENONE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | GLENMARK PHARMS LTD | **225MG** | **A205268** | **001** | Sep 08, 2017 |
| **AB** | | | **325MG** | **A205268** | **002** | Sep 08, 2017 |
| **AB** | | | **425MG** | **A205268** | **003** | Sep 08, 2017 |
| **AB** | | MYLAN PHARMS INC | **225MG** | **A203803** | **001** | Apr 29, 2016 |
| **AB** | | | **325MG** | **A203803** | **002** | Apr 29, 2016 |
| **AB** | | | **425MG** | **A203803** | **003** | Apr 29, 2016 |
| **AB** | | PAR PHARM | **225MG** | **A078540** | **001** | Oct 18, 2010 |
| **AB** | | | **325MG** | **A078540** | **002** | Oct 18, 2010 |
| **AB** | | | **425MG** | **A078540** | **003** | Oct 18, 2010 |
| **AB** | | WATSON LABS INC | **225MG** | **A202688** | **001** | Aug 24, 2015 |
| **AB** | | | **325MG** | **A202688** | **002** | Aug 24, 2015 |
| **AB** | | | **425MG** | **A202688** | **003** | Aug 24, 2015 |

**RYTHMOL SR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | GLAXOSMITHKLINE LLC | **225MG** | **N021416** | **001** | Sep 04, 2003 |
| **AB** | **+** | | **325MG** | **N021416** | **002** | Sep 04, 2003 |
| **AB** | **+!** | | **425MG** | **N021416** | **003** | Sep 04, 2003 |

TABLET;ORAL

**PROPAFENONE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ANI PHARMS INC | **150MG** | **A076550** | **001** | Apr 23, 2004 |
| **AB** | | | **225MG** | **A076550** | **002** | Apr 23, 2004 |
| **AB** | | | **300MG** | **A076550** | **003** | Apr 23, 2004 |
| **AB** | | AUROBINDO PHARMA LTD | **150MG** | **A202445** | **001** | May 11, 2016 |
| **AB** | | | **225MG** | **A202445** | **002** | May 11, 2016 |
| **AB** | | | **300MG** | **A202445** | **003** | May 11, 2016 |
| **AB** | | SUN PHARM INDUSTRIES | **150MG** | **A075998** | **001** | Nov 29, 2001 |
| **AB** | | | **225MG** | **A075998** | **002** | Nov 29, 2001 |
| **AB** | | | **300MG** | **A075998** | **003** | Nov 29, 2001 |
| **AB** | | VINTAGE PHARMS | **150MG** | **A075938** | **001** | Oct 17, 2002 |
| **AB** | | | **225MG** | **A075938** | **002** | Oct 17, 2002 |
| **AB** | | | **300MG** | **A075938** | **003** | Oct 17, 2002 |
| **AB** | | WATSON LABS | **150MG** | **A075203** | **001** | Oct 24, 2000 |
| **AB** | | | **225MG** | **A075203** | **002** | Oct 24, 2000 |

**RYTHMOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | GLAXOSMITHKLINE LLC | **150MG** | **N019151** | **001** | Nov 27, 1989 |
| **AB** | **+** | | **225MG** | **N019151** | **003** | Nov 20, 1992 |
| **AB** | **+!** | | **300MG** | **N019151** | **002** | Nov 27, 1989 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| PROPANTHELINE BROMIDE | | | | | | | |
| TABLET;ORAL | | | | | | | |
| PROPANTHELINE BROMIDE | | | | | | | |
| | ! | WEST-WARD PHARMS INT | 15MG | | A080927 | 002 | |
| PROPARACAINE HYDROCHLORIDE | | | | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | | | | |
| **ALCAINE** | | | | | | | |
| **AT** | **!** | NOVARTIS PHARMS CORP | **0.5%** | | **A080027** | **001** | |
| **PROPARACAINE HYDROCHLORIDE** | | | | | | | |
| **AT** | | AKORN INC | **0.5%** | | **A040277** | **001** | Mar 16, 2000 |
| **AT** | | BAUSCH AND LOMB | **0.5%** | | **A040074** | **001** | Sep 29, 1995 |
| PROPOFOL | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| **DIPRIVAN** | | | | | | | |
| **AB** | **+!** | FRESENIUS KABI USA | **10MG/ML** | | **N019627** | **002** | Jun 11, 1996 |
| **PROPOFOL** | | | | | | | |
| **AB** | | HOSPIRA | **10MG/ML** | | **A077908** | **001** | Mar 17, 2006 |
| **AB** | | SAGENT PHARMS | **10MG/ML** | | **A075102** | **001** | Jan 04, 1999 |
| **AB** | | WATSON LABS INC | **10MG/ML** | | **A205307** | **001** | Dec 22, 2015 |
| PROPRANOLOL HYDROCHLORIDE | | | | | | | |
| CAPSULE, EXTENDED RELEASE;ORAL | | | | | | | |
| **INDERAL LA** | | | | | | | |
| **AB** | **+** | ANI PHARMS INC | **60MG** | | **N018553** | **004** | Mar 18, 1987 |
| **AB** | **+** | | **80MG** | | **N018553** | **002** | Apr 19, 1983 |
| **AB** | **+** | | **120MG** | | **N018553** | **003** | Apr 19, 1983 |
| **AB** | **+!** | | **160MG** | | **N018553** | **001** | Apr 19, 1983 |
| **PROPRANOLOL HYDROCHLORIDE** | | | | | | | |
| **AB** | | ACTAVIS ELIZABETH | **60MG** | | **A078494** | **001** | Aug 10, 2007 |
| **AB** | | | **80MG** | | **A078494** | **002** | Aug 10, 2007 |
| **AB** | | | **120MG** | | **A078494** | **003** | Aug 10, 2007 |
| **AB** | | | **160MG** | | **A078494** | **004** | Aug 10, 2007 |
| **AB** | | MYLAN | **60MG** | | **A078022** | **001** | Feb 15, 2007 |
| **AB** | | | **80MG** | | **A078022** | **002** | Feb 15, 2007 |
| **AB** | | | **120MG** | | **A078022** | **003** | Feb 15, 2007 |
| **AB** | | | **160MG** | | **A078022** | **004** | Feb 15, 2007 |
| **AB** | | NORTEC DEV ASSOC | **60MG** | | **A078065** | **001** | Jan 26, 2007 |
| **AB** | | | **80MG** | | **A078065** | **002** | Jan 26, 2007 |
| **AB** | | | **120MG** | | **A078065** | **003** | Jan 26, 2007 |
| **AB** | | | **160MG** | | **A078065** | **004** | Jan 26, 2007 |
| **AB** | | RP SCHERER | **60MG** | | **A078703** | **001** | Jul 15, 2011 |
| **AB** | | | **80MG** | | **A078703** | **002** | Jul 15, 2011 |
| **AB** | | | **120MG** | | **A078703** | **003** | Jul 15, 2011 |
| **AB** | | | **160MG** | | **A078703** | **004** | Jul 15, 2011 |
| **AB** | | ZYDUS PHARMS USA INC | **60MG** | | **A090321** | **001** | Mar 25, 2011 |
| **AB** | | | **80MG** | | **A090321** | **002** | Mar 25, 2011 |
| **AB** | | | **120MG** | | **A090321** | **003** | Mar 25, 2011 |
| **AB** | | | **160MG** | | **A090321** | **004** | Mar 25, 2011 |
| INNOPRAN XL | | | | | | | |
| BX | | ANI PHARMS INC | 80MG | | N021438 | 001 | Mar 12, 2003 |
| BX | | | 120MG | | N021438 | 002 | Mar 12, 2003 |
| INJECTABLE;INJECTION | | | | | | | |
| **PROPRANOLOL HYDROCHLORIDE** | | | | | | | |
| **AP** | | ATHENEX INC | **1MG/ML** | | **A075792** | **001** | Aug 29, 2000 |
| **AP** | **+!** | BAXTER HLTHCARE CORP | **1MG/ML** | | **N016419** | **001** | |
| **AP** | | FRESENIUS KABI USA | **1MG/ML** | | **A075826** | **001** | Aug 31, 2001 |
| **AP** | | HIKMA FARMACEUTICA | **1MG/ML** | | **A077760** | **001** | Jan 31, 2008 |
| SOLUTION;ORAL | | | | | | | |
| HEMANGEOL | | | | | | | |
| | +! | PIERRE FABRE DERMA | 4.28MG/ML | | N205410 | 001 | Mar 14, 2014 |
| PROPRANOLOL HYDROCHLORIDE | | | | | | | |
| | ! | WEST-WARD PHARMS INT | 20MG/5ML | | A070979 | 001 | May 15, 1987 |
| | ! | | 40MG/5ML | | A070690 | 001 | May 15, 1987 |
| TABLET;ORAL | | | | | | | |
| **PROPRANOLOL HYDROCHLORIDE** | | | | | | | |
| **AB** | | IMPAX LABS INC | **10MG** | | **A071972** | **001** | Apr 06, 1988 |
| **AB** | | | **20MG** | | **A071973** | **001** | Apr 06, 1988 |
| **AB** | | | **40MG** | | **A071974** | **001** | Apr 06, 1988 |

PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL

**PROPRANOLOL HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **60MG** | **A071975** | **001** | Apr 06, 1988 |
| **AB** | **!** | | **80MG** | **A071976** | **001** | Apr 06, 1988 |
| **AB** | | IPCA LABS LTD | **10MG** | **A078955** | **001** | Jun 02, 2008 |
| **AB** | | | **20MG** | **A078955** | **002** | Jun 02, 2008 |
| **AB** | | | **40MG** | **A078955** | **003** | Jun 02, 2008 |
| **AB** | | | **60MG** | **A078955** | **004** | Jun 02, 2008 |
| **AB** | | | **80MG** | **A078955** | **005** | Jun 02, 2008 |
| **AB** | | MYLAN | **10MG** | **A070213** | **002** | Nov 19, 1985 |
| **AB** | | | **20MG** | **A070213** | **003** | Nov 19, 1985 |
| **AB** | | | **40MG** | **A070213** | **001** | Nov 19, 1985 |
| **AB** | | | **60MG** | **A070213** | **005** | Apr 08, 2011 |
| **AB** | | | **80MG** | **A070213** | **004** | Nov 19, 1985 |
| **AB** | | NORTHSTAR HLTHCARE | **10MG** | **A078213** | **001** | Jan 10, 2008 |
| **AB** | | | **20MG** | **A078213** | **002** | Jan 10, 2008 |
| **AB** | | | **40MG** | **A078213** | **003** | Jan 10, 2008 |
| **AB** | | | **60MG** | **A078213** | **004** | Jan 10, 2008 |
| **AB** | | | **80MG** | **A078213** | **005** | Jan 10, 2008 |
| **AB** | | VINTAGE PHARMS | **10MG** | **A070221** | **002** | Aug 01, 1986 |
| **AB** | | | **20MG** | **A070221** | **003** | Aug 01, 1986 |
| **AB** | | | **40MG** | **A070219** | **001** | Aug 01, 1986 |
| **AB** | | | **40MG** | **A070221** | **004** | Aug 01, 1986 |
| **AB** | | | **60MG** | **A070221** | **005** | Sep 24, 1986 |
| **AB** | | | **80MG** | **A070221** | **001** | Apr 14, 1986 |
| **AB** | | WATSON LABS | **10MG** | **A070175** | **001** | May 13, 1986 |
| **AB** | | | **20MG** | **A070176** | **001** | May 13, 1986 |
| **AB** | | | **40MG** | **A070177** | **001** | May 13, 1986 |
| **AB** | | | **80MG** | **A070178** | **001** | May 13, 1986 |

PROPYLTHIOURACIL

TABLET;ORAL

PROPYLTHIOURACIL

| | | | | | | |
|---|---|---|---|---|---|---|
| BD | | ACTAVIS ELIZABETH | 50MG | A080172 | 001 | |
| BD | +! | DAVA PHARMS INC | 50MG | N006188 | 001 | |

PROTAMINE SULFATE

INJECTABLE;INJECTION

PROTAMINE SULFATE

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | FRESENIUS KABI USA | 10MG/ML | A089454 | 001 | Apr 07, 1987 |

PROTRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

**PROTRIPTYLINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | EPIC PHARMA LLC | **5MG** | **A202220** | **001** | Nov 19, 2012 |
| **AB** | | | **10MG** | **A202220** | **002** | Nov 19, 2012 |
| **AB** | | SIGMAPHARM LABS LLC | **5MG** | **A090462** | **001** | May 03, 2010 |
| **AB** | | | **10MG** | **A090462** | **002** | May 03, 2010 |
| **AB** | | WEST-WARD PHARMS INT | **5MG** | **A078913** | **001** | Sep 16, 2008 |
| **AB** | | | **10MG** | **A078913** | **002** | Sep 16, 2008 |

**VIVACTIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ODYSSEY PHARMS | **5MG** | **A073644** | **001** | Aug 24, 1995 |
| **AB** | **!** | | **10MG** | **A073645** | **001** | Aug 24, 1995 |

PYRAZINAMIDE

TABLET;ORAL

**PYRAZINAMIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AKORN | **500MG** | **A081319** | **001** | Jun 30, 1992 |
| **AB** | **!** | DAVA PHARMS INC | **500MG** | **A080157** | **001** | |

PYRIDOSTIGMINE BROMIDE

INJECTABLE;INJECTION

**MESTINON**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | VALEANT PHARM INTL | **5MG/ML** | **N009830** | **001** | |

**REGONOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | SANDOZ INC | **5MG/ML** | **N017398** | **001** | |

SYRUP;ORAL

MESTINON

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | VALEANT PHARMS | 60MG/5ML | N015193 | 001 | |

TABLET;ORAL

**MESTINON**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | VALEANT PHARMS LLC | **60MG** | **N009829** | **002** | |

PYRIDOSTIGMINE BROMIDE

TABLET;ORAL

**PYRIDOSTIGMINE BROMIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | IMPAX LABS | **60MG** | **A040502** | **001** | Apr 24, 2003 |
| **AB** | | ZYDUS PHARMS USA INC | **60MG** | **A205650** | **001** | Jun 22, 2015 |

TABLET, EXTENDED RELEASE;ORAL

**MESTINON**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | VALEANT PHARMS LLC | **180MG** | **N011665** | **001** | |

**PYRIDOSTIGMINE BROMIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALVOGEN MALTA | **180MG** | **A204737** | **001** | Jun 26, 2015 |
| **AB** | | IMPAX LABS INC | **180MG** | **A203184** | **001** | Sep 15, 2015 |
| **AB** | | KINEDEXE UK | **180MG** | **A205464** | **001** | Aug 15, 2017 |

PYRIDOXINE HYDROCHLORIDE

INJECTABLE;INJECTION

**PYRIDOXINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **!** | FRESENIUS KABI USA | **100MG/ML** | **A080618** | **001** | |
| **AP** | | MYLAN INSTITUTIONAL | **100MG/ML** | **A204879** | **001** | Jul 14, 2016 |

PYRIMETHAMINE

TABLET;ORAL

DARAPRIM

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | VYERA PHARMS LLC | 25MG | N008578 | 001 | |

QUAZEPAM

TABLET;ORAL

DORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | CUTIS HEALTH LLC | 15MG | N018708 | 001 | Dec 27, 1985 |

QUETIAPINE FUMARATE

TABLET;ORAL

**QUETIAPINE FUMARATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACCORD HLTHCARE | **EQ 25MG BASE** | **A202152** | **001** | Mar 27, 2012 |
| **AB** | | | **EQ 50MG BASE** | **A202152** | **002** | Mar 27, 2012 |
| **AB** | | | **EQ 100MG BASE** | **A202152** | **003** | Mar 27, 2012 |
| **AB** | | | **EQ 200MG BASE** | **A202152** | **004** | Mar 27, 2012 |
| **AB** | | | **EQ 300MG BASE** | **A202152** | **005** | Mar 27, 2012 |
| **AB** | | | **EQ 400MG BASE** | **A202152** | **006** | Mar 27, 2012 |
| **AB** | | ALEMBIC PHARMS LTD | **EQ 25MG BASE** | **A203390** | **001** | Oct 28, 2014 |
| **AB** | | | **EQ 50MG BASE** | **A203390** | **002** | Oct 28, 2014 |
| **AB** | | | **EQ 100MG BASE** | **A203390** | **003** | Oct 28, 2014 |
| **AB** | | | **EQ 200MG BASE** | **A203390** | **004** | Oct 28, 2014 |
| **AB** | | | **EQ 300MG BASE** | **A203390** | **005** | Oct 28, 2014 |
| **AB** | | | **EQ 400MG BASE** | **A203390** | **006** | Oct 28, 2014 |
| **AB** | | ALKEM LABS LTD | **EQ 25MG BASE** | **A201504** | **001** | Feb 12, 2013 |
| **AB** | | | **EQ 50MG BASE** | **A201504** | **002** | Feb 12, 2013 |
| **AB** | | | **EQ 100MG BASE** | **A201504** | **003** | Feb 12, 2013 |
| **AB** | | | **EQ 150MG BASE** | **A201504** | **004** | Feb 12, 2013 |
| **AB** | | | **EQ 200MG BASE** | **A201504** | **005** | Feb 12, 2013 |
| **AB** | | | **EQ 300MG BASE** | **A201504** | **006** | Feb 12, 2013 |
| **AB** | | | **EQ 400MG BASE** | **A201504** | **007** | Feb 12, 2013 |
| **AB** | | APOTEX INC | **EQ 25MG BASE** | **A090960** | **001** | Mar 27, 2012 |
| **AB** | | | **EQ 50MG BASE** | **A090960** | **002** | Mar 27, 2012 |
| **AB** | | | **EQ 100MG BASE** | **A090960** | **003** | Mar 27, 2012 |
| **AB** | | | **EQ 200MG BASE** | **A090960** | **004** | Mar 27, 2012 |
| **AB** | | | **EQ 300MG BASE** | **A090960** | **005** | Mar 27, 2012 |
| **AB** | | | **EQ 400MG BASE** | **A090960** | **006** | Mar 27, 2012 |
| **AB** | | AUROBINDO PHARMA LTD | **EQ 25MG BASE** | **A091388** | **001** | Mar 27, 2012 |
| **AB** | | | **EQ 50MG BASE** | **A091388** | **002** | Mar 27, 2012 |
| **AB** | | | **EQ 100MG BASE** | **A091388** | **003** | Mar 27, 2012 |
| **AB** | | | **EQ 150MG BASE** | **A091388** | **004** | Mar 27, 2012 |
| **AB** | | | **EQ 200MG BASE** | **A091388** | **005** | Mar 27, 2012 |
| **AB** | | | **EQ 300MG BASE** | **A091388** | **006** | Mar 27, 2012 |
| **AB** | | | **EQ 400MG BASE** | **A091388** | **007** | Mar 27, 2012 |
| **AB** | | DR REDDYS LABS LTD | **EQ 25MG BASE** | **A077380** | **001** | Mar 27, 2012 |
| **AB** | | | **EQ 50MG BASE** | **A077380** | **002** | Mar 27, 2012 |
| **AB** | | | **EQ 100MG BASE** | **A077380** | **003** | Mar 27, 2012 |
| **AB** | | | **EQ 150MG BASE** | **A077380** | **004** | Mar 27, 2012 |
| **AB** | | | **EQ 200MG BASE** | **A077380** | **005** | Mar 27, 2012 |
| **AB** | | | **EQ 300MG BASE** | **A077380** | **006** | Mar 27, 2012 |
| **AB** | | | **EQ 400MG BASE** | **A077380** | **007** | Mar 27, 2012 |
| **AB** | | JUBILANT GENERICS | **EQ 25MG BASE** | **A203150** | **001** | Nov 26, 2013 |
| **AB** | | LUPIN LTD | **EQ 25MG BASE** | **A201109** | **001** | Mar 27, 2012 |

QUETIAPINE FUMARATE

TABLET;ORAL

**QUETIAPINE FUMARATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | **EQ 50MG BASE** | **A201109** | **002** | Mar 27, 2012 |
| **AB** | | **EQ 100MG BASE** | **A201109** | **003** | Mar 27, 2012 |
| **AB** | | **EQ 200MG BASE** | **A201109** | **004** | Mar 27, 2012 |
| **AB** | | **EQ 300MG BASE** | **A201109** | **005** | Mar 27, 2012 |
| **AB** | | **EQ 400MG BASE** | **A201109** | **006** | Mar 27, 2012 |
| **AB** | MACLEODS PHARMS LTD | **EQ 25MG BASE** | **A203359** | **001** | May 17, 2016 |
| **AB** | | **EQ 50MG BASE** | **A203359** | **002** | May 17, 2016 |
| **AB** | | **EQ 100MG BASE** | **A203359** | **003** | May 17, 2016 |
| **AB** | | **EQ 200MG BASE** | **A203359** | **004** | May 17, 2016 |
| **AB** | | **EQ 300MG BASE** | **A203359** | **005** | May 17, 2016 |
| **AB** | | **EQ 400MG BASE** | **A203359** | **006** | May 17, 2016 |
| **AB** | SANDOZ | **EQ 25MG BASE** | **A078679** | **001** | Dec 14, 2012 |
| **AB** | | **EQ 50MG BASE** | **A078679** | **002** | Dec 14, 2012 |
| **AB** | | **EQ 100MG BASE** | **A078679** | **003** | Dec 14, 2012 |
| **AB** | | **EQ 150MG BASE** | **A078679** | **004** | Dec 14, 2012 |
| **AB** | | **EQ 200MG BASE** | **A078679** | **005** | Dec 14, 2012 |
| **AB** | | **EQ 300MG BASE** | **A078679** | **006** | Dec 14, 2012 |
| **AB** | | **EQ 400MG BASE** | **A078679** | **007** | Dec 14, 2012 |
| **AB** | SUN PHARMA GLOBAL | **EQ 25MG BASE** | **A201190** | **001** | Mar 27, 2012 |
| **AB** | | **EQ 50MG BASE** | **A201190** | **002** | Mar 27, 2012 |
| **AB** | | **EQ 100MG BASE** | **A201190** | **003** | Mar 27, 2012 |
| **AB** | | **EQ 200MG BASE** | **A201190** | **004** | Mar 27, 2012 |
| **AB** | | **EQ 300MG BASE** | **A201190** | **005** | Mar 27, 2012 |
| **AB** | | **EQ 400MG BASE** | **A201190** | **006** | Mar 27, 2012 |
| **AB** | TEVA PHARMS | **EQ 25MG BASE** | **A077745** | **001** | Mar 27, 2012 |
| **AB** | | **EQ 50MG BASE** | **A077745** | **002** | Mar 27, 2012 |
| **AB** | | **EQ 100MG BASE** | **A077745** | **003** | Mar 27, 2012 |
| **AB** | | **EQ 150MG BASE** | **A077745** | **004** | Mar 27, 2012 |
| **AB** | | **EQ 200MG BASE** | **A077745** | **005** | Mar 27, 2012 |
| **AB** | | **EQ 300MG BASE** | **A077745** | **006** | Mar 27, 2012 |
| **AB** | | **EQ 400MG BASE** | **A077745** | **007** | Mar 27, 2012 |
| **AB** | TORRENT PHARMS LTD | **EQ 25MG BASE** | **A200363** | **001** | Mar 27, 2012 |
| **AB** | | **EQ 50MG BASE** | **A200363** | **002** | Mar 27, 2012 |
| **AB** | | **EQ 100MG BASE** | **A200363** | **003** | Mar 27, 2012 |
| **AB** | | **EQ 200MG BASE** | **A200363** | **004** | Mar 27, 2012 |
| **AB** | | **EQ 300MG BASE** | **A200363** | **005** | Mar 27, 2012 |
| **AB** | | **EQ 400MG BASE** | **A200363** | **006** | Mar 27, 2012 |
| **AB** | UNICHEM LABS LTD | **EQ 25MG BASE** | **A202674** | **001** | Mar 08, 2016 |
| **AB** | | **EQ 50MG BASE** | **A202674** | **002** | Mar 08, 2016 |
| **AB** | | **EQ 100MG BASE** | **A202674** | **003** | Mar 08, 2016 |
| **AB** | | **EQ 200MG BASE** | **A202674** | **004** | Mar 08, 2016 |
| **AB** | | **EQ 300MG BASE** | **A202674** | **005** | Mar 08, 2016 |
| **AB** | | **EQ 400MG BASE** | **A202674** | **006** | Mar 08, 2016 |
| **AB** | WEST-WARD PHARMS INT | **EQ 25MG BASE** | **A090120** | **001** | Mar 27, 2012 |
| **AB** | | **EQ 50MG BASE** | **A090749** | **001** | Mar 27, 2012 |
| **AB** | | **EQ 100MG BASE** | **A090749** | **002** | Mar 27, 2012 |
| **AB** | | **EQ 200MG BASE** | **A090749** | **003** | Mar 27, 2012 |
| **AB** | | **EQ 300MG BASE** | **A090749** | **004** | Mar 27, 2012 |
| **AB** | | **EQ 400MG BASE** | **A090749** | **005** | Mar 27, 2012 |

**SEROQUEL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | ASTRAZENECA PHARMS | **EQ 25MG BASE** | **N020639** | **001** | Sep 26, 1997 |
| **AB** | **+** | | **EQ 50MG BASE** | **N020639** | **007** | Oct 04, 2005 |
| **AB** | **+** | | **EQ 100MG BASE** | **N020639** | **002** | Sep 26, 1997 |
| **AB** | **+** | | **EQ 200MG BASE** | **N020639** | **003** | Sep 26, 1997 |
| **AB** | **+!** | | **EQ 300MG BASE** | **N020639** | **005** | Jul 26, 2000 |
| **AB** | **+** | | **EQ 400MG BASE** | **N020639** | **006** | Oct 04, 2005 |

TABLET, EXTENDED RELEASE;ORAL

**QUETIAPINE FUMARATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | ACCORD HLTHCARE | **EQ 50MG BASE** | **A206252** | **001** | Nov 29, 2017 |
| **AB** | | **EQ 150MG BASE** | **A090681** | **001** | May 09, 2017 |
| **AB** | | **EQ 200MG BASE** | **A090681** | **002** | May 09, 2017 |
| **AB** | | **EQ 300MG BASE** | **A090681** | **003** | May 09, 2017 |
| **AB** | | **EQ 400MG BASE** | **A090681** | **004** | Nov 01, 2016 |
| **AB** | ANCHEN PHARMS | **EQ 150MG BASE** | **A090757** | **001** | Dec 01, 2017 |
| **AB** | | **EQ 200MG BASE** | **A090757** | **002** | Dec 01, 2017 |
| **AB** | | **EQ 300MG BASE** | **A090757** | **003** | Dec 01, 2017 |
| **AB** | | **EQ 400MG BASE** | **A090757** | **004** | Dec 01, 2017 |
| **AB** | AUROBINDO PHARMA LTD | **EQ 50MG BASE** | **A207655** | **001** | Nov 29, 2017 |

QUETIAPINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL

**QUETIAPINE FUMARATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **EQ 150MG BASE** | **A207655** | **002** | Nov 29, 2017 |
| **AB** | | | **EQ 200MG BASE** | **A207655** | **003** | Nov 29, 2017 |
| **AB** | | | **EQ 300MG BASE** | **A207655** | **004** | Nov 29, 2017 |
| **AB** | | | **EQ 400MG BASE** | **A207655** | **005** | Nov 29, 2017 |
| **AB** | | INTELLIPHARMACEUTICS | **EQ 50MG BASE** | **A202939** | **001** | May 09, 2017 |
| **AB** | | | **EQ 150MG BASE** | **A202939** | **002** | May 09, 2017 |
| **AB** | | | **EQ 200MG BASE** | **A202939** | **003** | May 09, 2017 |
| **AB** | | | **EQ 300MG BASE** | **A202939** | **004** | May 09, 2017 |
| **AB** | | | **EQ 400MG BASE** | **A202939** | **005** | May 09, 2017 |
| **AB** | | LUPIN LTD | **EQ 50MG BASE** | **A204203** | **001** | May 17, 2017 |
| **AB** | | | **EQ 150MG BASE** | **A204203** | **002** | May 17, 2017 |
| **AB** | | | **EQ 200MG BASE** | **A204203** | **003** | May 17, 2017 |
| **AB** | | | **EQ 300MG BASE** | **A204203** | **004** | May 17, 2017 |
| **AB** | | | **EQ 400MG BASE** | **A204203** | **005** | May 17, 2017 |
| **AB** | | MACLEODS PHARMS LTD | **EQ 150MG BASE** | **A204253** | **001** | Nov 29, 2017 |
| **AB** | | | **EQ 200MG BASE** | **A204253** | **002** | Nov 29, 2017 |
| **AB** | | | **EQ 300MG BASE** | **A204253** | **003** | Nov 29, 2017 |
| **AB** | | | **EQ 400MG BASE** | **A204253** | **004** | Nov 29, 2017 |
| **AB** | | NOVAST LABS LTD | **EQ 50MG BASE** | **A208947** | **001** | Nov 29, 2017 |
| **AB** | | | **EQ 150MG BASE** | **A208947** | **002** | Nov 29, 2017 |
| **AB** | | | **EQ 200MG BASE** | **A208947** | **003** | Nov 29, 2017 |
| **AB** | | | **EQ 300MG BASE** | **A208947** | **004** | Nov 29, 2017 |
| **AB** | | | **EQ 400MG BASE** | **A208947** | **005** | Nov 29, 2017 |
| **AB** | | PAR PHARM | **EQ 50MG BASE** | **A090482** | **001** | May 09, 2017 |
| **AB** | | | **EQ 150MG BASE** | **A090482** | **002** | May 09, 2017 |
| **AB** | | | **EQ 200MG BASE** | **A090482** | **003** | May 09, 2017 |
| **AB** | | | **EQ 300MG BASE** | **A090482** | **004** | May 09, 2017 |
| **AB** | | | **EQ 400MG BASE** | **A090482** | **005** | May 09, 2017 |
| **AB** | | PHARMADAX INC | **EQ 50MG BASE** | **A206260** | **001** | May 09, 2017 |
| **AB** | | | **EQ 150MG BASE** | **A206260** | **002** | May 09, 2017 |
| **AB** | | | **EQ 200MG BASE** | **A206260** | **003** | May 09, 2017 |
| **AB** | | | **EQ 300MG BASE** | **A206260** | **004** | May 09, 2017 |
| **AB** | | | **EQ 400MG BASE** | **A206260** | **005** | May 09, 2017 |
| **AB** | | SCIEGEN PHARMS INC | **EQ 150MG BASE** | **A209635** | **001** | Nov 29, 2017 |
| **AB** | | | **EQ 200MG BASE** | **A209635** | **002** | Nov 29, 2017 |
| **AB** | | | **EQ 300MG BASE** | **A209635** | **003** | Nov 29, 2017 |
| **AB** | | | **EQ 400MG BASE** | **A209635** | **004** | Nov 29, 2017 |

**SEROQUEL XR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | ASTRAZENECA | **EQ 50MG BASE** | **N022047** | **001** | May 17, 2007 |
| **AB** | + | | **EQ 150MG BASE** | **N022047** | **005** | Aug 11, 2008 |
| **AB** | +! | | **EQ 200MG BASE** | **N022047** | **002** | May 17, 2007 |
| **AB** | + | | **EQ 300MG BASE** | **N022047** | **003** | May 17, 2007 |
| **AB** | + | | **EQ 400MG BASE** | **N022047** | **004** | May 17, 2007 |

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

**ACCUPRIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | PFIZER PHARMS | **EQ 5MG BASE** | **N019885** | **001** | Nov 19, 1991 |
| **AB** | + | | **EQ 10MG BASE** | **N019885** | **002** | Nov 19, 1991 |
| **AB** | + | | **EQ 20MG BASE** | **N019885** | **003** | Nov 19, 1991 |
| **AB** | +! | | **EQ 40MG BASE** | **N019885** | **004** | Nov 19, 1991 |

**QUINAPRIL HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AUROBINDO PHARMA LTD | **EQ 5MG BASE** | **A202725** | **001** | Apr 29, 2013 |
| **AB** | | | **EQ 10MG BASE** | **A202725** | **002** | Apr 29, 2013 |
| **AB** | | | **EQ 20MG BASE** | **A202725** | **003** | Apr 29, 2013 |
| **AB** | | | **EQ 40MG BASE** | **A202725** | **004** | Apr 29, 2013 |
| **AB** | | INVAGEN PHARMS | **EQ 5MG BASE** | **A078457** | **001** | Aug 24, 2007 |
| **AB** | | | **EQ 10MG BASE** | **A078457** | **002** | Aug 24, 2007 |
| **AB** | | | **EQ 20MG BASE** | **A078457** | **003** | Aug 24, 2007 |
| **AB** | | | **EQ 40MG BASE** | **A078457** | **004** | Aug 24, 2007 |
| **AB** | | LUPIN | **EQ 5MG BASE** | **A077690** | **001** | Jun 20, 2006 |
| **AB** | | | **EQ 10MG BASE** | **A077690** | **002** | Jun 20, 2006 |
| **AB** | | | **EQ 20MG BASE** | **A077690** | **003** | Jun 20, 2006 |
| **AB** | | | **EQ 40MG BASE** | **A077690** | **004** | Jun 20, 2006 |
| **AB** | | MYLAN | **EQ 5MG BASE** | **A076694** | **001** | Dec 23, 2004 |
| **AB** | | | **EQ 10MG BASE** | **A076694** | **002** | Dec 23, 2004 |
| **AB** | | | **EQ 20MG BASE** | **A076694** | **003** | Dec 23, 2004 |
| **AB** | | | **EQ 40MG BASE** | **A076694** | **004** | Dec 23, 2004 |

QUINAPRIL HYDROCHLORIDE
TABLET;ORAL
**QUINAPRIL HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | PRINSTON INC | **EQ 5MG BASE** | **A205823** | **001** | Sep 15, 2016 |
| **AB** | | | **EQ 10MG BASE** | **A205823** | **002** | Sep 15, 2016 |
| **AB** | | | **EQ 20MG BASE** | **A205823** | **003** | Sep 15, 2016 |
| **AB** | | | **EQ 40MG BASE** | **A205823** | **004** | Sep 15, 2016 |
| **AB** | | SUN PHARM INDS LTD | **EQ 5MG BASE** | **A076607** | **001** | Dec 15, 2004 |
| **AB** | | | **EQ 10MG BASE** | **A076607** | **002** | Dec 15, 2004 |
| **AB** | | | **EQ 20MG BASE** | **A076607** | **003** | Dec 15, 2004 |
| **AB** | | | **EQ 40MG BASE** | **A076607** | **004** | Dec 15, 2004 |
| **AB** | | TEVA | **EQ 5MG BASE** | **A075504** | **001** | Aug 24, 2007 |
| **AB** | | | **EQ 10MG BASE** | **A075504** | **002** | Aug 24, 2007 |
| **AB** | | | **EQ 20MG BASE** | **A075504** | **003** | Aug 24, 2007 |
| **AB** | | | **EQ 40MG BASE** | **A075504** | **004** | Aug 24, 2007 |

QUINIDINE GLUCONATE
TABLET, EXTENDED RELEASE;ORAL
QUINIDINE GLUCONATE

| | | | | | | |
|---|---|---|---|---|---|---|
| BX | ! | SUN PHARM INDUSTRIES | 324MG | A089338 | 001 | Feb 11, 1987 |

QUINIDINE SULFATE
TABLET;ORAL
**QUINIDINE SULFATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | SANDOZ | **200MG** | **A088072** | **002** | |
| **AB** | | | **300MG** | **A088072** | **001** | Sep 26, 1983 |
| **AB** | | SUN PHARM INDUSTRIES | **200MG** | **A081030** | **001** | Apr 14, 1989 |
| **AB** | | | **300MG** | **A081031** | **001** | Apr 14, 1989 |
| **AB** | **!** | WATSON LABS | **200MG** | **A083288** | **001** | |
| **AB** | **!** | | **300MG** | **A085583** | **001** | |

TABLET, EXTENDED RELEASE;ORAL
QUINIDINE SULFATE

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | G AND W LABS INC | 300MG | A040045 | 001 | Jun 30, 1994 |

QUININE SULFATE
CAPSULE;ORAL
**QUALAQUIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | SUN PHARM INDUSTRIES | **324MG** | **N021799** | **001** | Aug 12, 2005 |

**QUININE SULFATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AMNEAL PHARMS | **324MG** | **A203729** | **001** | Jul 15, 2015 |
| **AB** | | LUPIN LTD | **324MG** | **A203112** | **001** | Apr 24, 2015 |
| **AB** | | MYLAN PHARMS INC | **324MG** | **A202581** | **001** | Dec 14, 2012 |
| **AB** | | RICONPHARMA LLC | **324MG** | **A204372** | **001** | Jul 22, 2015 |
| **AB** | | TEVA PHARMS | **324MG** | **A091661** | **001** | Sep 28, 2012 |

RABEPRAZOLE SODIUM
CAPSULE, DELAYED RELEASE;ORAL
ACIPHEX SPRINKLE

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | AVADEL PHARMS | 5MG | N204736 | 001 | Mar 26, 2013 |
| | +! | | 10MG | N204736 | 002 | Mar 26, 2013 |

TABLET, DELAYED RELEASE;ORAL
**ACIPHEX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | EISAI INC | **20MG** | **N020973** | **002** | Aug 19, 1999 |

**RABEPRAZOLE SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AMNEAL PHARMS | **20MG** | **A204179** | **001** | Jul 31, 2015 |
| **AB** | | AUROBINDO PHARMA LTD | **20MG** | **A205761** | **001** | Feb 17, 2017 |
| **AB** | | BRECKENRIDGE PHARM | **20MG** | **A204237** | **001** | Nov 18, 2015 |
| **AB** | | DR REDDYS LABS LTD | **20MG** | **A076824** | **001** | Nov 08, 2013 |
| **AB** | | KREMERS URBAN PHARMS | **20MG** | **A090678** | **001** | Nov 08, 2013 |
| **AB** | | LUPIN LTD | **20MG** | **A078964** | **001** | Nov 08, 2013 |
| **AB** | | MYLAN PHARMS INC | **20MG** | **A076885** | **001** | Nov 08, 2013 |
| **AB** | | TEVA PHARMS USA | **20MG** | **A076822** | **001** | Nov 08, 2013 |
| **AB** | | TORRENT PHARMS LTD | **20MG** | **A202376** | **001** | Nov 08, 2013 |

RADIUM RA-223 DICHLORIDE
SOLUTION;INTRAVENOUS
XOFIGO

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | BAYER HLTHCARE | 162mCi/6ML (27mCi/ML) | N203971 | 001 | May 15, 2013 |

RALOXIFENE HYDROCHLORIDE

TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **EVISTA** | | | | | | |
| **AB** | **+!** | LILLY | **60MG** | **N020815** | **001** | Dec 09, 1997 |
| **RALOXIFENE HYDROCHLORIDE** | | | | | | |
| **AB** | | AMNEAL PHARMS | **60MG** | **A208206** | **001** | Apr 08, 2016 |
| **AB** | | AUROBINDO PHARMA LTD | **60MG** | **A204310** | **001** | Aug 28, 2015 |
| **AB** | | GLENMARK PHARMS LTD | **60MG** | **A204491** | **001** | Mar 22, 2016 |
| **AB** | | INVAGEN PHARMS | **60MG** | **A090842** | **001** | Sep 24, 2014 |
| **AB** | | SCIEGEN PHARMS INC | **60MG** | **A206384** | **001** | Oct 12, 2016 |
| **AB** | | TEVA PHARMS USA | **60MG** | **A078193** | **001** | Mar 04, 2014 |
| **AB** | | WATSON LABS INC | **60MG** | **A200825** | **001** | Jan 21, 2015 |

RALTEGRAVIR POTASSIUM

POWDER;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| ISENTRESS | | | | | | |
| | +! | MERCK SHARP DOHME | EQ 100MG BASE/PACKET | N205786 | 001 | Dec 20, 2013 |

TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| ISENTRESS | | | | | | |
| | +! | MERCK SHARP DOHME | EQ 400MG BASE | N022145 | 001 | Oct 12, 2007 |
| ISENTRESS HD | | | | | | |
| | + | MERCK SHARP DOHME | EQ 600MG BASE | N022145 | 002 | May 26, 2017 |

TABLET, CHEWABLE;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| ISENTRESS | | | | | | |
| | + | MERCK SHARP DOHME | EQ 25MG BASE | N203045 | 001 | Dec 21, 2011 |
| | +! | | EQ 100MG BASE | N203045 | 002 | Dec 21, 2011 |

RAMELTEON

TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **RAMELTEON** | | | | | | |
| **AB** | | ACTAVIS LABS FL INC | **8MG** | **A091610** | **001** | Aug 19, 2015 |
| **AB** | | DR REDDYS LABS INTL | **8MG** | **A091693** | **001** | Jul 26, 2013 |
| **ROZEREM** | | | | | | |
| **AB** | **+!** | TAKEDA PHARMS USA | **8MG** | **N021782** | **001** | Jul 22, 2005 |

RAMIPRIL

CAPSULE;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **ALTACE** | | | | | | |
| **AB** | **+** | KING PHARMS LLC | **1.25MG** | **N019901** | **001** | Jan 28, 1991 |
| **AB** | **+** | | **2.5MG** | **N019901** | **002** | Jan 28, 1991 |
| **AB** | **+** | | **5MG** | **N019901** | **003** | Jan 28, 1991 |
| **AB** | **+!** | | **10MG** | **N019901** | **004** | Jan 28, 1991 |
| **RAMIPRIL** | | | | | | |
| **AB** | | ACCORD HLTHCARE | **1.25MG** | **A202392** | **001** | Apr 15, 2014 |
| **AB** | | | **2.5MG** | **A202392** | **002** | Apr 15, 2014 |
| **AB** | | | **5MG** | **A202392** | **003** | Apr 15, 2014 |
| **AB** | | | **10MG** | **A202392** | **004** | Apr 15, 2014 |
| **AB** | | APOTEX | **1.25MG** | **A079116** | **001** | Jun 20, 2008 |
| **AB** | | | **2.5MG** | **A079116** | **002** | Jun 20, 2008 |
| **AB** | | | **5MG** | **A079116** | **003** | Jun 20, 2008 |
| **AB** | | | **10MG** | **A079116** | **004** | Jun 20, 2008 |
| **AB** | | AUROBINDO PHARMA LTD | **1.25MG** | **A091604** | **001** | Jun 08, 2011 |
| **AB** | | | **2.5MG** | **A091604** | **002** | Jun 08, 2011 |
| **AB** | | | **5MG** | **A091604** | **003** | Jun 08, 2011 |
| **AB** | | | **10MG** | **A091604** | **004** | Jun 08, 2011 |
| **AB** | | DR REDDYS LABS LTD | **1.25MG** | **A078191** | **001** | Jun 18, 2008 |
| **AB** | | | **2.5MG** | **A078191** | **002** | Jun 18, 2008 |
| **AB** | | | **5MG** | **A078191** | **003** | Jun 18, 2008 |
| **AB** | | | **10MG** | **A078191** | **004** | Jun 18, 2008 |
| **AB** | | INVAGEN PHARMS | **1.25MG** | **A078745** | **001** | Jun 18, 2008 |
| **AB** | | | **2.5MG** | **A078745** | **002** | Jun 18, 2008 |
| **AB** | | | **5MG** | **A078745** | **003** | Jun 18, 2008 |
| **AB** | | | **10MG** | **A078745** | **004** | Jun 18, 2008 |
| **AB** | | LUPIN | **1.25MG** | **A077626** | **001** | Jun 09, 2008 |
| **AB** | | | **2.5MG** | **A077626** | **002** | Jun 09, 2008 |
| **AB** | | | **5MG** | **A077626** | **003** | Jun 09, 2008 |
| **AB** | | | **10MG** | **A077626** | **004** | Jun 09, 2008 |
| **AB** | | TEVA PHARMS | **1.25MG** | **A077470** | **001** | Jun 18, 2008 |
| **AB** | | | **2.5MG** | **A077470** | **002** | Jun 18, 2008 |
| **AB** | | | **5MG** | **A077470** | **003** | Jun 18, 2008 |
| **AB** | | | **10MG** | **A077470** | **004** | Jun 18, 2008 |
| **AB** | | WATSON LABS | **1.25MG** | **A076549** | **001** | Oct 24, 2005 |

| | | | | | | |
|---|---|---|---|---|---|---|
| RAMIPRIL | | | | | | |
| CAPSULE;ORAL | | | | | | |
| **RAMIPRIL** | | | | | | |
| **AB** | | | **2.5MG** | **A076549** | **002** | Oct 24, 2005 |
| **AB** | | | **5MG** | **A076549** | **003** | Oct 24, 2005 |
| **AB** | | | **10MG** | **A076549** | **004** | Oct 24, 2005 |
| **AB** | | WEST-WARD PHARMS INT | **1.25MG** | **A077900** | **001** | Jun 18, 2008 |
| **AB** | | | **2.5MG** | **A077900** | **002** | Jun 18, 2008 |
| **AB** | | | **5MG** | **A077900** | **003** | Jun 18, 2008 |
| **AB** | | | **10MG** | **A077900** | **004** | Jun 18, 2008 |
| **AB** | | ZYDUS PHARMS USA | **1.25MG** | **A078832** | **001** | Sep 02, 2008 |
| **AB** | | | **2.5MG** | **A078832** | **002** | Sep 02, 2008 |
| **AB** | | | **5MG** | **A078832** | **003** | Sep 02, 2008 |
| **AB** | | | **10MG** | **A078832** | **004** | Sep 02, 2008 |
| TABLET;ORAL | | | | | | |
| RAMIPRIL | | | | | | |
| | | APOTEX INC | 1.25MG | A091069 | 001 | Dec 02, 2015 |
| | | | 2.5MG | A091069 | 002 | Dec 02, 2015 |
| | | | 5MG | A091069 | 003 | Dec 02, 2015 |
| | ! | | 10MG | A091069 | 004 | Dec 02, 2015 |
| RANITIDINE HYDROCHLORIDE | | | | | | |
| CAPSULE;ORAL | | | | | | |
| **RANITIDINE HYDROCHLORIDE** | | | | | | |
| **AB** | | DR REDDYS LABS LTD | **EQ 150MG BASE** | **A075742** | **001** | Nov 29, 2000 |
| **AB** | | | **EQ 300MG BASE** | **A075742** | **002** | Nov 29, 2000 |
| **AB** | | SANDOZ | **EQ 150MG BASE** | **A074655** | **001** | Oct 22, 1997 |
| **AB** | **!** | | **EQ 300MG BASE** | **A074655** | **002** | Oct 22, 1997 |
| INJECTABLE;INJECTION | | | | | | |
| **RANITIDINE HYDROCHLORIDE** | | | | | | |
| **AP** | | MYLAN LABS LTD | **EQ 25MG BASE/ML** | **A079076** | **001** | Jun 09, 2016 |
| **AP** | | WEST-WARD PHARMS INT | **EQ 25MG BASE/ML** | **A074777** | **001** | Mar 02, 2005 |
| **AP** | | | **EQ 25MG BASE/ML** | **A077458** | **001** | Feb 16, 2006 |
| **AP** | | ZYDUS PHARMS USA INC | **EQ 25MG BASE/ML** | **A091534** | **001** | Feb 22, 2013 |
| **ZANTAC** | | | | | | |
| **AP** | **+!** | TELIGENT | **EQ 25MG BASE/ML** | **N019090** | **001** | Oct 19, 1984 |
| SYRUP;ORAL | | | | | | |
| **RANITIDINE HYDROCHLORIDE** | | | | | | |
| **AA** | | ACTAVIS MID ATLANTIC | **EQ 15MG BASE/ML** | **A076124** | **001** | Feb 21, 2007 |
| **AA** | | AMNEAL PHARMS | **EQ 15MG BASE/ML** | **A078312** | **001** | Sep 02, 2008 |
| **AA** | | AUROBINDO PHARMA LTD | **EQ 15MG BASE/ML** | **A090623** | **001** | Jul 28, 2010 |
| **AA** | | BIO PHARM INC | **EQ 15MG BASE/ML** | **A090102** | **001** | May 26, 2009 |
| **AA** | | BRECKENRIDGE PHARM | **EQ 15MG BASE/ML** | **A078684** | **001** | Aug 27, 2009 |
| **AA** | | HI TECH PHARMA | **EQ 15MG BASE/ML** | **A091078** | **001** | Mar 22, 2011 |
| **AA** | | NOSTRUM LABS INC | **EQ 15MG BASE/ML** | **A091091** | **001** | Sep 20, 2011 |
| **AA** | | PHARM ASSOC | **EQ 15MG BASE/ML** | **A077405** | **001** | Sep 21, 2007 |
| **AA** | | SILARX | **EQ 15MG BASE/ML** | **A091288** | **001** | Dec 09, 2010 |
| **AA** | | TARO | **EQ 15MG BASE/ML** | **A077476** | **001** | Jun 13, 2011 |
| **AA** | | TOLMAR | **EQ 15MG BASE/ML** | **A090054** | **001** | Nov 15, 2010 |
| **AA** | | VINTAGE PHARMS | **EQ 15MG BASE/ML** | **A078890** | **001** | Jul 01, 2010 |
| **ZANTAC** | | | | | | |
| **AA** | **+!** | GLAXO GRP LTD | **EQ 15MG BASE/ML** | **N019675** | **001** | Dec 30, 1988 |
| TABLET;ORAL | | | | | | |
| **RANITIDINE HYDROCHLORIDE** | | | | | | |
| **AB** | | ACIC PHARMS | **EQ 150MG BASE** | **A203694** | **001** | Nov 30, 2017 |
| **AB** | | | **EQ 300MG BASE** | **A203694** | **002** | Nov 30, 2017 |
| **AB** | | AMNEAL PHARMS NY | **EQ 150MG BASE** | **A077824** | **001** | Oct 13, 2006 |
| **AB** | | | **EQ 300MG BASE** | **A077824** | **002** | Oct 13, 2006 |
| **AB** | | APOTEX | **EQ 150MG BASE** | **A074680** | **001** | Sep 12, 1997 |
| **AB** | | | **EQ 300MG BASE** | **A074680** | **002** | Sep 12, 1997 |
| **AB** | | DR REDDYS LABS INC | **EQ 150MG BASE** | **A076705** | **001** | Jul 27, 2005 |
| **AB** | | | **EQ 300MG BASE** | **A076705** | **002** | Jul 27, 2005 |
| **AB** | | GLENMARK PHARMS INC | **EQ 150MG BASE** | **A078542** | **001** | Nov 19, 2008 |
| **AB** | | | **EQ 300MG BASE** | **A078542** | **002** | Nov 19, 2008 |
| **AB** | | IVAX SUB TEVA PHARMS | **EQ 150MG BASE** | **A075165** | **001** | Sep 30, 1998 |
| **AB** | | | **EQ 300MG BASE** | **A075165** | **002** | Sep 30, 1998 |
| **AB** | | PAR PHARM | **EQ 150MG BASE** | **A075180** | **001** | Jan 28, 1999 |
| **AB** | | | **EQ 300MG BASE** | **A075180** | **002** | Jan 28, 1999 |

RANITIDINE HYDROCHLORIDE
TABLET;ORAL
**RANITIDINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | SANDOZ | **EQ 150MG BASE** | **A074467** | **001** | Aug 29, 1997 |
| **AB** | | | **EQ 300MG BASE** | **A074467** | **002** | Aug 29, 1997 |
| **AB** | | STRIDES PHARMA | **EQ 150MG BASE** | **A205512** | **001** | Aug 22, 2016 |
| **AB** | | | **EQ 300MG BASE** | **A205512** | **002** | Aug 22, 2016 |
| **AB** | | TEVA | **EQ 150MG BASE** | **A074488** | **001** | Jul 31, 1997 |
| **AB** | | | **EQ 300MG BASE** | **A074488** | **002** | Jul 31, 1997 |
| **AB** | | WOCKHARDT LTD | **EQ 150MG BASE** | **A075208** | **001** | Dec 17, 1998 |
| **AB** | | | **EQ 300MG BASE** | **A075208** | **002** | Dec 17, 1998 |

**ZANTAC 150**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | GLAXO GRP LTD | **EQ 150MG BASE** | **N018703** | **001** | Jun 09, 1983 |

**ZANTAC 300**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | GLAXO GRP LTD | **EQ 300MG BASE** | **N018703** | **002** | Dec 09, 1985 |

RANOLAZINE
TABLET, EXTENDED RELEASE;ORAL
RANEXA

| | | | | | |
|---|---|---|---|---|---|
| | + | GILEAD | 500MG | N021526 | 002 Jan 27, 2006 |
| | +! | | 1GM | N021526 | 001 Feb 12, 2007 |

RASAGILINE MESYLATE
TABLET;ORAL
**AZILECT**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | TEVA | **EQ 0.5MG BASE** | **N021641** | **001** | May 16, 2006 |
| **AB** | **+!** | | **EQ 1MG BASE** | **N021641** | **002** | May 16, 2006 |

**RASAGILINE MESYLATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALKEM LABS LTD | **EQ 0.5MG BASE** | **A201889** | **001** | Oct 30, 2017 |
| **AB** | | | **EQ 1MG BASE** | **A201889** | **002** | Oct 30, 2017 |
| **AB** | | APOTEX INC | **EQ 0.5MG BASE** | **A201950** | **001** | Sep 12, 2013 |
| **AB** | | | **EQ 1MG BASE** | **A201950** | **002** | Sep 12, 2013 |
| **AB** | | MYLAN PHARMS INC | **EQ 0.5MG BASE** | **A201971** | **001** | May 15, 2017 |
| **AB** | | | **EQ 1MG BASE** | **A201971** | **002** | May 15, 2017 |
| **AB** | | ORCHID HLTHCARE | **EQ 0.5MG BASE** | **A201970** | **001** | Mar 15, 2016 |
| **AB** | | | **EQ 1MG BASE** | **A201970** | **002** | Mar 15, 2016 |
| **AB** | | WATSON LABS INC | **EQ 0.5MG BASE** | **A201823** | **001** | Jul 01, 2013 |
| **AB** | | | **EQ 1MG BASE** | **A201823** | **002** | Jul 01, 2013 |

REGADENOSON
SOLUTION;INTRAVENOUS
LEXISCAN

| | | | | | |
|---|---|---|---|---|---|
| | +! | ASTELLAS | 0.4MG/5ML (0.08MG/ML) | N022161 | 001 Apr 10, 2008 |

REGORAFENIB
TABLET;ORAL
STIVARGA

| | | | | | |
|---|---|---|---|---|---|
| | +! | BAYER HLTHCARE | 40MG | N203085 | 001 Sep 27, 2012 |

REMIFENTANIL HYDROCHLORIDE
INJECTABLE;INJECTION
ULTIVA

| | | | | | |
|---|---|---|---|---|---|
| | + | MYLAN INSTITUTIONAL | EQ 1MG BASE/VIAL | N020630 | 001 Jul 12, 1996 |
| | + | | EQ 2MG BASE/VIAL | N020630 | 002 Jul 12, 1996 |
| | +! | | EQ 5MG BASE/VIAL | N020630 | 003 Jul 12, 1996 |

REPAGLINIDE
TABLET;ORAL
**PRANDIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | GEMINI LABS LLC | **0.5MG** | **N020741** | **001** | Dec 22, 1997 |
| **AB** | **+** | | **1MG** | **N020741** | **002** | Dec 22, 1997 |
| **AB** | **+!** | | **2MG** | **N020741** | **003** | Dec 22, 1997 |

**REPAGLINIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS TOTOWA | **0.5MG** | **A090008** | **001** | Jan 22, 2014 |
| **AB** | | | **1MG** | **A090008** | **002** | Jan 22, 2014 |
| **AB** | | | **2MG** | **A090008** | **003** | Jan 22, 2014 |
| **AB** | | AUROBINDO PHARMA LTD | **0.5MG** | **A203820** | **001** | Jan 22, 2014 |
| **AB** | | | **1MG** | **A203820** | **002** | Jan 22, 2014 |
| **AB** | | | **2MG** | **A203820** | **003** | Jan 22, 2014 |
| **AB** | | BOSCOGEN | **0.5MG** | **A091517** | **001** | Apr 24, 2015 |
| **AB** | | | **1MG** | **A091517** | **002** | Apr 24, 2015 |
| **AB** | | | **2MG** | **A091517** | **003** | Apr 24, 2015 |
| **AB** | | MYLAN PHARMS INC | **0.5MG** | **A090252** | **001** | Aug 23, 2013 |
| **AB** | | | **1MG** | **A090252** | **002** | Jan 22, 2014 |
| **AB** | | | **2MG** | **A090252** | **003** | Jan 22, 2014 |

REPAGLINIDE

TABLET;ORAL

**REPAGLINIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | PADDOCK LLC | **0.5MG** | **A201189** | **001** | Jul 17, 2013 |
| **AB** | | | **1MG** | **A201189** | **002** | Jan 22, 2014 |
| **AB** | | | **2MG** | **A201189** | **003** | Jan 22, 2014 |
| **AB** | | SANDOZ INC | **0.5MG** | **A078555** | **001** | Nov 22, 2013 |
| **AB** | | | **1MG** | **A078555** | **002** | Jan 22, 2014 |
| **AB** | | | **2MG** | **A078555** | **003** | Jan 22, 2014 |
| **AB** | | SUN PHARM INDS INC | **1MG** | **A077571** | **002** | Jul 11, 2013 |
| **AB** | | | **2MG** | **A077571** | **003** | Jul 11, 2013 |

RETAPAMULIN

OINTMENT;TOPICAL

ALTABAX

| | | | | | |
|---|---|---|---|---|---|
| | +! | AQUA PHARMS LLC | 1% | N022055 | 001 Apr 12, 2007 |

RIBAVIRIN

CAPSULE;ORAL

**REBETOL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | MERCK SHARP DOHME | **200MG** | **N020903** | **002** | Jul 25, 2001 |

**RIBASPHERE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | KADMON PHARMS LLC | **200MG** | **A076203** | **001** | Apr 06, 2004 |

**RIBAVARIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AUROBINDO PHARMA | **200MG** | **A079117** | **001** | Sep 17, 2009 |

**RIBAVIRIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | SANDOZ | **200MG** | **A076192** | **001** | Apr 06, 2004 |
| **AB** | | TEVA | **200MG** | **A076277** | **001** | Oct 04, 2004 |
| **AB** | | ZYDUS PHARMS USA | **200MG** | **A077224** | **001** | Oct 28, 2005 |

FOR SOLUTION;INHALATION

**RIBAVIRIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AN** | | NAVINTA LLC | **6GM/VIAL** | **A207366** | **001** | Oct 06, 2016 |

**VIRAZOLE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AN** | **+!** | VALEANT PHARM INTL | **6GM/VIAL** | **N018859** | **001** | Dec 31, 1985 |

SOLUTION;ORAL

REBETOL

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | SCHERING | 40MG/ML | N021546 | 001 | Jul 29, 2003 |

TABLET;ORAL

**COPEGUS**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ROCHE | **200MG** | **N021511** | **001** | Dec 03, 2002 |

**RIBAVIRIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AUROBINDO PHARMA | **200MG** | **A079111** | **001** | Sep 17, 2009 |
| **AB** | | KADMON PHARMS LLC | **200MG** | **A077456** | **001** | Dec 05, 2005 |
| **AB** | | | **400MG** | **A077456** | **002** | Dec 05, 2005 |
| **AB** | **!** | | **600MG** | **A077456** | **003** | Dec 05, 2005 |
| **AB** | | SANDOZ | **200MG** | **A077743** | **001** | Oct 03, 2006 |
| **AB** | | SANDOZ INC | **200MG** | **A202546** | **001** | Aug 12, 2014 |
| **AB** | | | **400MG** | **A202546** | **002** | Aug 12, 2014 |
| **AB** | | | **500MG** | **A202546** | **003** | Aug 12, 2014 |
| **AB** | | | **600MG** | **A202546** | **004** | Aug 12, 2014 |
| **AB** | | TEVA | **200MG** | **A077053** | **001** | Dec 05, 2005 |
| **AB** | | ZYDUS PHARMS USA | **200MG** | **A077094** | **001** | Dec 05, 2005 |
| **AB** | | | **400MG** | **A077094** | **002** | Mar 16, 2007 |
| **AB** | | | **500MG** | **A077094** | **004** | Apr 18, 2008 |
| **AB** | | | **600MG** | **A077094** | **003** | Mar 16, 2007 |

RIBOCICLIB SUCCINATE

TABLET;ORAL

KISQALI

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | NOVARTIS PHARMS CORP | EQ 200MG BASE | N209092 | 001 | Mar 13, 2017 |

RIBOFLAVIN 5'-PHOSPHATE SODIUM

SOLUTION/DROPS;OPHTHALMIC

PHOTREXA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | AVEDRO INC | 0.146% | N203324 | 001 | Apr 15, 2016 |

PHOTREXA VISCOUS IN DEXTRAN 20%

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | AVEDRO INC | 0.146% | N203324 | 002 | Apr 15, 2016 |

RIFABUTIN

CAPSULE;ORAL

**MYCOBUTIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | PHARMACIA AND UPJOHN | **150MG** | **N050689** | **001** | Dec 23, 1992 |

**RIFABUTIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | LUPIN LTD | **150MG** | **A090033** | **001** | Feb 24, 2014 |

RIFAMPIN

CAPSULE;ORAL

**RIFADIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | SANOFI AVENTIS US | **150MG** | **A062303** | **001** | |
| **AB** | **+!** | | **300MG** | **N050420** | **001** | |

**RIFAMPIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AKORN | **150MG** | **A065028** | **001** | Mar 14, 2001 |
| **AB** | | | **300MG** | **A065028** | **002** | Mar 14, 2001 |
| **AB** | | LANNETT | **150MG** | **A065390** | **001** | Mar 28, 2008 |
| **AB** | | | **300MG** | **A065390** | **002** | Mar 28, 2008 |
| **AB** | | LUPIN PHARMS | **150MG** | **A090034** | **001** | Aug 21, 2013 |
| **AB** | | | **300MG** | **A090034** | **002** | Aug 21, 2013 |
| **AB** | | SANDOZ | **150MG** | **A064150** | **002** | Jan 02, 1998 |
| **AB** | | | **300MG** | **A064150** | **001** | May 28, 1997 |

**RIMACTANE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | OXFORD PHARMS | **300MG** | **N050429** | **001** | |

INJECTABLE;INJECTION

**RIFADIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | SANOFI AVENTIS US | **600MG/VIAL** | **N050627** | **001** | May 25, 1989 |

**RIFAMPIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AKORN | **600MG/VIAL** | **A065502** | **001** | Sep 21, 2010 |
| **AP** | | EMCURE PHARMS LTD | **600MG/VIAL** | **A204101** | **001** | Aug 18, 2014 |
| **AP** | | FRESENIUS KABI USA | **600MG/VIAL** | **A091181** | **001** | Aug 21, 2014 |
| **AP** | | HIKMA PHARMS | **600MG/VIAL** | **A205039** | **001** | Mar 03, 2016 |
| **AP** | | MYLAN LABS LTD | **600MG/VIAL** | **A065421** | **001** | May 22, 2008 |
| **AP** | | WATSON PHARMS TEVA | **600MG/VIAL** | **A206736** | **001** | Jan 19, 2016 |
| **AP** | | WEST-WARD PHARMS INT | **600MG/VIAL** | **A064217** | **001** | Oct 29, 1999 |

RIFAPENTINE

TABLET;ORAL

PRIFTIN

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | SANOFI AVENTIS US | 150MG | N021024 | 001 | Jun 22, 1998 |

RIFAXIMIN

TABLET;ORAL

XIFAXAN

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | SALIX PHARMS | 200MG | N021361 | 001 | May 25, 2004 |
| | +! | | 550MG | N022554 | 001 | Mar 24, 2010 |

RILPIVIRINE HYDROCHLORIDE

TABLET;ORAL

EDURANT

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | JANSSEN PRODS | EQ 25MG BASE | N202022 | 001 | May 20, 2011 |

RILUZOLE

TABLET;ORAL

**RILUTEK**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | COVIS PHARMA BV | **50MG** | **N020599** | **001** | Dec 12, 1995 |

**RILUZOLE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALKEM LABS LTD | **50MG** | **A204048** | **001** | Mar 30, 2016 |
| **AB** | | APOTEX CORP | **50MG** | **A091300** | **001** | Jun 18, 2013 |
| **AB** | | GLENMARK PHARMS LTD | **50MG** | **A091394** | **001** | Jun 18, 2013 |
| **AB** | | IMPAX LABS | **50MG** | **A076173** | **001** | Jan 29, 2003 |
| **AB** | | MYLAN PHARMS INC | **50MG** | **A203042** | **001** | Jul 01, 2013 |
| **AB** | | SUN PHARM INDS LTD | **50MG** | **A091417** | **001** | Jun 18, 2013 |

RIMANTADINE HYDROCHLORIDE

TABLET;ORAL

**FLUMADINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | SUN PHARM INDS INC | **100MG** | **N019649** | **001** | Sep 17, 1993 |

**RIMANTADINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | IMPAX LABS | **100MG** | **A076132** | **001** | Aug 30, 2002 |

RIOCIGUAT

TABLET;ORAL

ADEMPAS

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | BAYER HLTHCARE | 0.5MG | N204819 | 001 | Oct 08, 2013 |
| | + | | 1MG | N204819 | 002 | Oct 08, 2013 |
| | + | | 1.5MG | N204819 | 003 | Oct 08, 2013 |
| | + | | 2MG | N204819 | 004 | Oct 08, 2013 |
| | +! | | 2.5MG | N204819 | 005 | Oct 08, 2013 |

RISEDRONATE SODIUM

TABLET;ORAL

**ACTONEL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | APIL | **5MG** | **N020835** | **002** | Apr 14, 2000 |
| **AB** | **+** | | **30MG** | **N020835** | **001** | Mar 27, 1998 |
| **AB** | **+!** | | **35MG** | **N020835** | **003** | May 25, 2002 |
| **AB** | **+!** | | **150MG** | **N020835** | **005** | Apr 22, 2008 |

**RISEDRONATE SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | APOTEX INC | **35MG** | **A090877** | **001** | Nov 30, 2015 |
| **AB** | | | **75MG** | **A090877** | **002** | Jun 10, 2014 |
| **AB** | | | **150MG** | **A090877** | **003** | Jun 10, 2014 |
| **AB** | | AUROBINDO PHARMA LTD | **5MG** | **A200296** | **001** | Nov 30, 2015 |
| **AB** | | | **30MG** | **A200296** | **002** | Nov 30, 2015 |
| **AB** | | | **35MG** | **A200296** | **003** | Nov 30, 2015 |
| **AB** | | | **150MG** | **A206768** | **001** | Oct 21, 2016 |
| **AB** | | MACLEODS PHARMS LTD | **5MG** | **A203533** | **001** | Dec 09, 2015 |
| **AB** | | | **30MG** | **A203533** | **002** | Dec 09, 2015 |
| **AB** | | | **35MG** | **A203533** | **003** | Nov 29, 2016 |
| **AB** | | MYLAN PHARMS INC | **5MG** | **A200477** | **001** | Nov 30, 2015 |
| **AB** | | | **30MG** | **A200477** | **002** | Nov 30, 2015 |
| **AB** | | | **35MG** | **A200477** | **003** | Nov 30, 2015 |
| **AB** | | | **75MG** | **A200477** | **004** | Jun 10, 2014 |
| **AB** | | | **150MG** | **A200477** | **005** | Jun 10, 2014 |
| **AB** | | SUN PHARMA GLOBAL | **5MG** | **A090886** | **001** | Nov 30, 2015 |
| **AB** | | | **30MG** | **A090886** | **002** | Nov 30, 2015 |
| **AB** | | | **35MG** | **A090886** | **003** | Nov 30, 2015 |
| **AB** | | | **75MG** | **A090886** | **004** | Jun 10, 2014 |
| **AB** | | | **150MG** | **A090886** | **005** | Jun 10, 2014 |
| **AB** | | TEVA PHARMS USA | **5MG** | **A077132** | **001** | Oct 05, 2007 |
| **AB** | | | **30MG** | **A077132** | **002** | Oct 05, 2007 |
| **AB** | | | **35MG** | **A077132** | **003** | Oct 05, 2007 |
| **AB** | | | **150MG** | **A079215** | **001** | Jun 13, 2014 |

TABLET, DELAYED RELEASE;ORAL

**ATELVIA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | APIL | **35MG** | **N022560** | **001** | Oct 08, 2010 |

**RISEDRONATE SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | TEVA PHARMS USA | **35MG** | **A203217** | **001** | May 18, 2015 |

RISPERIDONE

INJECTABLE;INTRAMUSCULAR

RISPERDAL CONSTA

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | JANSSEN PHARMS | 12.5MG/VIAL | N021346 | 004 | Apr 12, 2007 |
| | +! | | 25MG/VIAL | N021346 | 001 | Oct 29, 2003 |
| | + | | 37.5MG/VIAL | N021346 | 002 | Oct 29, 2003 |
| | + | | 50MG/VIAL | N021346 | 003 | Oct 29, 2003 |

SOLUTION;ORAL

**RISPERDAL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **+!** | JANSSEN PHARMS | **1MG/ML** | **N020588** | **001** | Jun 10, 1996 |

**RISPERIDONE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | AMNEAL PHARMS | **1MG/ML** | **A091384** | **001** | May 25, 2011 |
| **AA** | | ANI PHARMS INC | **1MG/ML** | **A076440** | **001** | Jan 30, 2009 |
| **AA** | | APOTEX INC | **1MG/ML** | **A077719** | **001** | Jul 29, 2009 |
| **AA** | | BIO PHARM INC | **1MG/ML** | **A078909** | **001** | Jul 29, 2009 |
| **AA** | | LIFESTAR PHARMA | **1MG/ML** | **A078452** | **001** | Sep 04, 2009 |
| **AA** | | PRECISION DOSE | **1MG/ML** | **A076797** | **001** | Jun 28, 2010 |
| **AA** | | TARO | **1MG/ML** | **A090347** | **001** | Feb 07, 2011 |
| **AA** | | TRIS PHARMA INC | **1MG/ML** | **A079059** | **001** | Dec 12, 2012 |
| **AA** | | VINTAGE | **1MG/ML** | **A079158** | **001** | Dec 03, 2010 |
| **AA** | | WEST-WARD PHARMS INT | **1MG/ML** | **A076904** | **001** | Jul 29, 2009 |

TABLET;ORAL

**RISPERDAL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | JANSSEN PHARMS | **0.25MG** | **N020272** | **008** | May 10, 1999 |
| **AB** | **+** | | **0.5MG** | **N020272** | **007** | Jan 27, 1999 |

RISPERIDONE

TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **RISPERDAL** | | | | | | |
| **AB** | +! | | **1MG** | **N020272** | **001** | Dec 29, 1993 |
| **AB** | + | | **2MG** | **N020272** | **002** | Dec 29, 1993 |
| **AB** | + | | **3MG** | **N020272** | **003** | Dec 29, 1993 |
| **AB** | + | | **4MG** | **N020272** | **004** | Dec 29, 1993 |
| **RISPERIDONE** | | | | | | |
| **AB** | | AJANTA PHARMA LTD | **0.25MG** | **A201003** | **001** | Aug 24, 2011 |
| **AB** | | | **0.5MG** | **A201003** | **002** | Aug 24, 2011 |
| **AB** | | | **1MG** | **A201003** | **003** | Aug 24, 2011 |
| **AB** | | | **2MG** | **A201003** | **004** | Aug 24, 2011 |
| **AB** | | | **3MG** | **A201003** | **005** | Aug 24, 2011 |
| **AB** | | | **4MG** | **A201003** | **006** | Aug 24, 2011 |
| **AB** | | APOTEX INC | **0.25MG** | **A077953** | **001** | Sep 15, 2008 |
| **AB** | | | **0.5MG** | **A077953** | **002** | Sep 15, 2008 |
| **AB** | | | **1MG** | **A077953** | **003** | Sep 15, 2008 |
| **AB** | | | **2MG** | **A077953** | **004** | Sep 15, 2008 |
| **AB** | | | **3MG** | **A077953** | **005** | Sep 15, 2008 |
| **AB** | | | **4MG** | **A077953** | **006** | Sep 15, 2008 |
| **AB** | | AUROBINDO PHARMA | **0.25MG** | **A078269** | **001** | Oct 08, 2008 |
| **AB** | | | **0.5MG** | **A078269** | **002** | Oct 08, 2008 |
| **AB** | | | **1MG** | **A078269** | **003** | Oct 08, 2008 |
| **AB** | | | **2MG** | **A078269** | **004** | Oct 08, 2008 |
| **AB** | | | **3MG** | **A078269** | **005** | Oct 08, 2008 |
| **AB** | | | **4MG** | **A078269** | **006** | Oct 08, 2008 |
| **AB** | | CIPLA | **0.25MG** | **A077543** | **001** | May 18, 2011 |
| **AB** | | | **0.5MG** | **A077543** | **002** | May 18, 2011 |
| **AB** | | | **1MG** | **A077543** | **003** | May 18, 2011 |
| **AB** | | | **2MG** | **A077543** | **004** | May 18, 2011 |
| **AB** | | | **3MG** | **A077543** | **005** | May 18, 2011 |
| **AB** | | | **4MG** | **A077543** | **006** | May 18, 2011 |
| **AB** | | DR REDDYS LABS LTD | **0.25MG** | **A076879** | **001** | Oct 24, 2008 |
| **AB** | | | **0.5MG** | **A076879** | **002** | Oct 24, 2008 |
| **AB** | | | **1MG** | **A076879** | **003** | Oct 24, 2008 |
| **AB** | | | **2MG** | **A076879** | **004** | Oct 24, 2008 |
| **AB** | | | **3MG** | **A076879** | **005** | Oct 24, 2008 |
| **AB** | | | **4MG** | **A076879** | **006** | Oct 24, 2008 |
| **AB** | | MYLAN | **0.25MG** | **A076288** | **001** | Sep 15, 2008 |
| **AB** | | | **0.5MG** | **A076288** | **002** | Sep 15, 2008 |
| **AB** | | | **1MG** | **A076288** | **003** | Sep 15, 2008 |
| **AB** | | | **2MG** | **A076288** | **004** | Sep 15, 2008 |
| **AB** | | | **3MG** | **A076288** | **005** | Sep 15, 2008 |
| **AB** | | | **4MG** | **A076288** | **006** | Sep 15, 2008 |
| **AB** | | OXFORD PHARMS | **0.25MG** | **A078071** | **001** | Jun 17, 2009 |
| **AB** | | | **0.5MG** | **A078071** | **002** | Jun 17, 2009 |
| **AB** | | | **1MG** | **A078071** | **003** | Jun 17, 2009 |
| **AB** | | | **2MG** | **A078071** | **004** | Jun 17, 2009 |
| **AB** | | | **3MG** | **A078071** | **005** | Jun 17, 2009 |
| **AB** | | | **4MG** | **A078071** | **006** | Jun 17, 2009 |
| **AB** | | PLIVA HRVATSKA DOO | **0.25MG** | **A077769** | **001** | Oct 16, 2008 |
| **AB** | | | **0.5MG** | **A077769** | **002** | Oct 16, 2008 |
| **AB** | | | **1MG** | **A077769** | **003** | Oct 16, 2008 |
| **AB** | | | **2MG** | **A077769** | **004** | Oct 16, 2008 |
| **AB** | | | **3MG** | **A077769** | **005** | Oct 16, 2008 |
| **AB** | | | **4MG** | **A077769** | **006** | Oct 16, 2008 |
| **AB** | | PRINSTON INC | **0.25MG** | **A077493** | **001** | Nov 29, 2011 |
| **AB** | | | **0.25MG** | **A078707** | **001** | Dec 29, 2008 |
| **AB** | | | **0.5MG** | **A077493** | **002** | Nov 29, 2011 |
| **AB** | | | **0.5MG** | **A078707** | **002** | Dec 29, 2008 |
| **AB** | | | **1MG** | **A077493** | **003** | Nov 29, 2011 |
| **AB** | | | **1MG** | **A078707** | **003** | Dec 29, 2008 |
| **AB** | | | **2MG** | **A077493** | **004** | Nov 29, 2011 |
| **AB** | | | **2MG** | **A078707** | **004** | Dec 29, 2008 |
| **AB** | | | **3MG** | **A077493** | **005** | Nov 29, 2011 |
| **AB** | | | **3MG** | **A078707** | **005** | Dec 29, 2008 |
| **AB** | | | **4MG** | **A077493** | **006** | Nov 29, 2011 |
| **AB** | | | **4MG** | **A078707** | **006** | Dec 29, 2008 |
| **AB** | | SANDOZ | **0.25MG** | **A078528** | **001** | Oct 16, 2009 |
| **AB** | | | **0.5MG** | **A078528** | **002** | Oct 16, 2009 |
| **AB** | | | **1MG** | **A078528** | **003** | Oct 16, 2009 |
| **AB** | | | **2MG** | **A078528** | **004** | Oct 16, 2009 |

RISPERIDONE

TABLET;ORAL

**RISPERIDONE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **3MG** | **A078528** | **005** | Oct 16, 2009 |
| **AB** | | | **4MG** | **A078528** | **006** | Oct 16, 2009 |
| **AB** | | SUN PHARM INDS INC | **0.25MG** | **A078036** | **001** | Mar 10, 2014 |
| **AB** | | | **0.5MG** | **A078036** | **002** | Mar 10, 2014 |
| **AB** | | | **1MG** | **A078036** | **003** | Mar 10, 2014 |
| **AB** | | | **2MG** | **A078036** | **004** | Mar 10, 2014 |
| **AB** | | | **3MG** | **A078036** | **005** | Mar 10, 2014 |
| **AB** | | | **4MG** | **A078036** | **006** | Mar 10, 2014 |
| **AB** | | TEVA | **0.25MG** | **A076228** | **001** | Jun 30, 2008 |
| **AB** | | | **0.5MG** | **A076228** | **002** | Jun 30, 2008 |
| **AB** | | | **1MG** | **A076228** | **003** | Jun 30, 2008 |
| **AB** | | | **2MG** | **A076228** | **004** | Jun 30, 2008 |
| **AB** | | | **3MG** | **A076228** | **005** | Jun 30, 2008 |
| **AB** | | | **4MG** | **A076228** | **006** | Jun 30, 2008 |
| **AB** | | TORRENT PHARMS | **0.25MG** | **A079088** | **001** | Oct 30, 2008 |
| **AB** | | | **0.5MG** | **A079088** | **002** | Oct 30, 2008 |
| **AB** | | | **1MG** | **A079088** | **003** | Oct 30, 2008 |
| **AB** | | | **2MG** | **A079088** | **004** | Oct 30, 2008 |
| **AB** | | | **3MG** | **A079088** | **005** | Oct 30, 2008 |
| **AB** | | | **4MG** | **A079088** | **006** | Oct 30, 2008 |
| **AB** | | WOCKHARDT | **0.25MG** | **A078871** | **001** | Oct 09, 2008 |
| **AB** | | | **0.5MG** | **A078871** | **002** | Oct 09, 2008 |
| **AB** | | | **1MG** | **A078871** | **003** | Oct 09, 2008 |
| **AB** | | | **2MG** | **A078871** | **004** | Oct 09, 2008 |
| **AB** | | | **3MG** | **A078871** | **005** | Oct 09, 2008 |
| **AB** | | | **4MG** | **A078871** | **006** | Oct 09, 2008 |
| **AB** | | ZYDUS PHARMS USA INC | **0.25MG** | **A078040** | **001** | Oct 16, 2008 |
| **AB** | | | **0.5MG** | **A078040** | **002** | Oct 16, 2008 |
| **AB** | | | **1MG** | **A078040** | **003** | Oct 16, 2008 |
| **AB** | | | **2MG** | **A078040** | **004** | Oct 16, 2008 |
| **AB** | | | **3MG** | **A078040** | **005** | Oct 16, 2008 |
| **AB** | | | **4MG** | **A078040** | **006** | Oct 16, 2008 |

TABLET, ORALLY DISINTEGRATING;ORAL

**RISPERDAL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | JANSSEN PHARMS | **0.5MG** | **N021444** | **001** | Apr 02, 2003 |
| **AB** | +! | | **1MG** | **N021444** | **002** | Apr 02, 2003 |
| **AB** | + | | **2MG** | **N021444** | **003** | Apr 02, 2003 |
| **AB** | + | | **3MG** | **N021444** | **004** | Dec 23, 2004 |
| **AB** | + | | **4MG** | **N021444** | **005** | Dec 23, 2004 |

**RISPERIDONE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS LABS FL INC | **0.5MG** | **A076996** | **001** | Apr 19, 2011 |
| **AB** | | | **1MG** | **A076996** | **002** | Apr 19, 2011 |
| **AB** | | | **2MG** | **A076996** | **003** | Apr 19, 2011 |
| **AB** | | | **3MG** | **A076996** | **004** | Apr 19, 2011 |
| **AB** | | | **4MG** | **A076996** | **005** | Apr 19, 2011 |
| **AB** | | DR REDDYS LABS LTD | **0.5MG** | **A077328** | **001** | Feb 24, 2009 |
| **AB** | | | **1MG** | **A077328** | **002** | Oct 05, 2009 |
| **AB** | | | **2MG** | **A077328** | **003** | Feb 24, 2009 |
| **AB** | | | **3MG** | **A077328** | **004** | Nov 30, 2009 |
| **AB** | | | **4MG** | **A077328** | **005** | Nov 30, 2009 |
| **AB** | | JUBILANT GENERICS | **0.5MG** | **A090839** | **001** | Nov 04, 2011 |
| **AB** | | | **1MG** | **A090839** | **002** | Nov 04, 2011 |
| **AB** | | | **2MG** | **A090839** | **003** | Nov 04, 2011 |
| **AB** | | | **3MG** | **A090839** | **004** | Nov 04, 2011 |
| **AB** | | | **4MG** | **A090839** | **005** | Nov 04, 2011 |
| **AB** | | PAR PHARM | **0.5MG** | **A077494** | **002** | Apr 30, 2009 |
| **AB** | | | **1MG** | **A077494** | **003** | Oct 26, 2009 |
| **AB** | | | **2MG** | **A077494** | **004** | Apr 30, 2009 |
| **AB** | | | **3MG** | **A077494** | **005** | Apr 30, 2009 |
| **AB** | | | **4MG** | **A077494** | **006** | Apr 30, 2009 |
| **AB** | | SANDOZ | **0.5MG** | **A078116** | **001** | Dec 22, 2009 |
| **AB** | | | **1MG** | **A078116** | **002** | Dec 22, 2009 |
| **AB** | | | **2MG** | **A078116** | **003** | Dec 22, 2009 |
| **AB** | | | **3MG** | **A078116** | **004** | Dec 22, 2009 |
| **AB** | | | **4MG** | **A078116** | **005** | Dec 22, 2009 |
| **AB** | | SUN PHARM INDS LTD | **0.5MG** | **A077542** | **001** | Aug 06, 2010 |
| **AB** | | | **0.5MG** | **A078464** | **001** | Apr 08, 2013 |
| **AB** | | | **1MG** | **A077542** | **002** | Aug 06, 2010 |
| **AB** | | | **1MG** | **A078464** | **002** | Apr 08, 2013 |

| | | | | | | |
|---|---|---|---|---|---|---|
| RISPERIDONE | | | | | | |
| TABLET, ORALLY DISINTEGRATING;ORAL | | | | | | |
| **RISPERIDONE** | | | | | | |
| **AB** | | | **2MG** | **A077542** | **003** | Aug 06, 2010 |
| **AB** | | | **2MG** | **A078464** | **003** | Apr 08, 2013 |
| **AB** | | | **3MG** | **A078464** | **004** | Apr 08, 2013 |
| **AB** | | | **3MG** | **A078474** | **001** | Aug 06, 2010 |
| **AB** | | | **4MG** | **A078464** | **005** | Apr 08, 2013 |
| **AB** | | | **4MG** | **A078474** | **002** | Aug 06, 2010 |
| **AB** | | TEVA | **0.5MG** | **A076908** | **001** | Mar 12, 2012 |
| **AB** | | | **1MG** | **A076908** | **002** | Mar 12, 2012 |
| **AB** | | | **2MG** | **A076908** | **003** | Mar 12, 2012 |
| **AB** | | ZYDUS PHARMS USA | **0.5MG** | **A078516** | **001** | May 01, 2009 |
| **AB** | | | **2MG** | **A078516** | **003** | May 01, 2009 |
| | | PAR PHARM | 0.25MG | A077494 | 001 | Apr 30, 2009 |
| RITONAVIR | | | | | | |
| CAPSULE;ORAL | | | | | | |
| NORVIR | | | | | | |
| | +! | ABBVIE | 100MG | N020945 | 001 | Jun 29, 1999 |
| POWDER;ORAL | | | | | | |
| NORVIR | | | | | | |
| | +! | ABBVIE INC | 100MG/PACKET | N209512 | 001 | Jun 07, 2017 |
| SOLUTION;ORAL | | | | | | |
| NORVIR | | | | | | |
| | +! | ABBVIE | 80MG/ML | N020659 | 001 | Mar 01, 1996 |
| TABLET;ORAL | | | | | | |
| **NORVIR** | | | | | | |
| **AB** | **+!** | ABBVIE | **100MG** | **N022417** | **001** | Feb 10, 2010 |
| **RITONAVIR** | | | | | | |
| **AB** | | WEST-WARD PHARMS INT | **100MG** | **A202573** | **001** | Jan 15, 2015 |
| RIVAROXABAN | | | | | | |
| TABLET;ORAL | | | | | | |
| XARELTO | | | | | | |
| | + | JANSSEN PHARMS | 10MG | N022406 | 001 | Jul 01, 2011 |
| | + | | 15MG | N022406 | 002 | Nov 04, 2011 |
| | +! | | 20MG | N022406 | 003 | Nov 04, 2011 |
| RIVASTIGMINE | | | | | | |
| FILM, EXTENDED RELEASE;TRANSDERMAL | | | | | | |
| **EXELON** | | | | | | |
| **AB** | **+** | NOVARTIS | **4.6MG/24HR** | **N022083** | **001** | Jul 06, 2007 |
| **AB** | **+!** | | **9.5MG/24HR** | **N022083** | **002** | Jul 06, 2007 |
| **AB** | **+** | | **13.3MG/24HR** | **N022083** | **005** | Aug 31, 2012 |
| **RIVASTIGMINE** | | | | | | |
| **AB** | | ALVOGEN MALTA | **4.6MG/24HR** | **A204403** | **001** | Sep 03, 2015 |
| **AB** | | | **9.5MG/24HR** | **A204403** | **002** | Sep 03, 2015 |
| **AB** | | | **13.3MG/24HR** | **A204403** | **003** | Aug 31, 2015 |
| RIVASTIGMINE TARTRATE | | | | | | |
| CAPSULE;ORAL | | | | | | |
| **EXELON** | | | | | | |
| **AB** | **+!** | NOVARTIS | **EQ 1.5MG BASE** | **N020823** | **003** | Apr 21, 2000 |
| **AB** | **+** | | **EQ 3MG BASE** | **N020823** | **004** | Apr 21, 2000 |
| **AB** | **+** | | **EQ 4.5MG BASE** | **N020823** | **005** | Apr 21, 2000 |
| **AB** | **+!** | | **EQ 6MG BASE** | **N020823** | **006** | Apr 21, 2000 |
| **RIVASTIGMINE TARTRATE** | | | | | | |
| **AB** | | AJANTA PHARMA LTD | **EQ 1.5MG BASE** | **A207797** | **001** | Sep 28, 2017 |
| **AB** | | | **EQ 3MG BASE** | **A207797** | **002** | Sep 28, 2017 |
| **AB** | | | **EQ 4.5MG BASE** | **A207797** | **003** | Sep 28, 2017 |
| **AB** | | | **EQ 6MG BASE** | **A207797** | **004** | Sep 28, 2017 |
| **AB** | | ALEMBIC PHARMS LTD | **EQ 1.5MG BASE** | **A091689** | **001** | Jun 12, 2012 |
| **AB** | | | **EQ 3MG BASE** | **A091689** | **002** | Jun 12, 2012 |
| **AB** | | | **EQ 4.5MG BASE** | **A091689** | **003** | Jun 12, 2012 |
| **AB** | | | **EQ 6MG BASE** | **A091689** | **004** | Jun 12, 2012 |
| **AB** | | APOTEX INC | **EQ 1.5MG BASE** | **A091072** | **001** | May 16, 2013 |
| **AB** | | | **EQ 3MG BASE** | **A091072** | **002** | May 16, 2013 |
| **AB** | | | **EQ 4.5MG BASE** | **A091072** | **003** | May 16, 2013 |
| **AB** | | | **EQ 6MG BASE** | **A091072** | **004** | May 16, 2013 |
| **AB** | | AUROBINDO PHARMA LTD | **EQ 1.5MG BASE** | **A204572** | **001** | Mar 25, 2016 |
| **AB** | | | **EQ 3MG BASE** | **A204572** | **002** | Mar 25, 2016 |
| **AB** | | | **EQ 4.5MG BASE** | **A204572** | **003** | Mar 25, 2016 |

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

**RIVASTIGMINE TARTRATE**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | | **EQ 6MG BASE** | **A204572** | **004** | Mar 25, 2016 |
| **AB** | CADILA PHARMS LTD | **EQ 1.5MG BASE** | **A203844** | **001** | Feb 13, 2017 |
| **AB** | | **EQ 3MG BASE** | **A203844** | **002** | Feb 13, 2017 |
| **AB** | | **EQ 4.5MG BASE** | **A203844** | **003** | Feb 13, 2017 |
| **AB** | | **EQ 6MG BASE** | **A203844** | **004** | Feb 13, 2017 |
| **AB** | DR REDDYS LABS INC | **EQ 1.5MG BASE** | **A077130** | **001** | Oct 31, 2007 |
| **AB** | | **EQ 3MG BASE** | **A077130** | **002** | Oct 31, 2007 |
| **AB** | | **EQ 4.5MG BASE** | **A077130** | **003** | Oct 31, 2007 |
| **AB** | | **EQ 6MG BASE** | **A077130** | **004** | Oct 31, 2007 |
| **AB** | MACLEODS PHARMS LTD | **EQ 1.5MG BASE** | **A203148** | **001** | Aug 22, 2014 |
| **AB** | | **EQ 3MG BASE** | **A203148** | **002** | Aug 22, 2014 |
| **AB** | | **EQ 4.5MG BASE** | **A203148** | **003** | Aug 22, 2014 |
| **AB** | | **EQ 6MG BASE** | **A203148** | **004** | Aug 22, 2014 |
| **AB** | ORCHID HLTHCARE | **EQ 1.5MG BASE** | **A090879** | **001** | Jun 10, 2015 |
| **AB** | | **EQ 3MG BASE** | **A090879** | **002** | Jun 10, 2015 |
| **AB** | | **EQ 4.5MG BASE** | **A090879** | **003** | Jun 10, 2015 |
| **AB** | | **EQ 6MG BASE** | **A090879** | **004** | Jun 10, 2015 |
| **AB** | SUN PHARM INDS LTD | **EQ 1.5MG BASE** | **A077131** | **001** | Oct 22, 2007 |
| **AB** | | **EQ 3MG BASE** | **A077131** | **002** | Oct 22, 2007 |
| **AB** | | **EQ 4.5MG BASE** | **A077131** | **003** | Oct 22, 2007 |
| **AB** | | **EQ 6MG BASE** | **A077131** | **004** | Oct 22, 2007 |
| **AB** | WATSON LABS | **EQ 1.5MG BASE** | **A077129** | **001** | Jan 08, 2008 |
| **AB** | | **EQ 3MG BASE** | **A077129** | **002** | Jan 08, 2008 |
| **AB** | | **EQ 4.5MG BASE** | **A077129** | **003** | Jan 08, 2008 |
| **AB** | | **EQ 6MG BASE** | **A077129** | **004** | Jan 08, 2008 |

RIZATRIPTAN BENZOATE

TABLET;ORAL

**MAXALT**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | **+** MERCK | **EQ 5MG BASE** | **N020864** | **001** | Jun 29, 1998 |
| **AB** | **+!** | **EQ 10MG BASE** | **N020864** | **002** | Jun 29, 1998 |

**RIZATRIPTAN BENZOATE**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | ALKEM LABS LTD | **EQ 5MG BASE** | **A203269** | **001** | Feb 18, 2016 |
| **AB** | | **EQ 10MG BASE** | **A203269** | **002** | Feb 18, 2016 |
| **AB** | APOTEX INC | **EQ 5MG BASE** | **A202244** | **001** | Dec 31, 2012 |
| **AB** | | **EQ 10MG BASE** | **A202244** | **002** | Dec 31, 2012 |
| **AB** | AUROBINDO PHARMA LTD | **EQ 5MG BASE** | **A202490** | **001** | Dec 31, 2012 |
| **AB** | | **EQ 10MG BASE** | **A202490** | **002** | Dec 31, 2012 |
| **AB** | CIPLA LTD | **EQ 5MG BASE** | **A077526** | **001** | Mar 26, 2013 |
| **AB** | | **EQ 10MG BASE** | **A077526** | **002** | Mar 26, 2013 |
| **AB** | ECI PHARMS LLC | **EQ 5MG BASE** | **A202047** | **001** | Dec 31, 2012 |
| **AB** | | **EQ 10MG BASE** | **A202047** | **002** | Dec 31, 2012 |
| **AB** | EMCURE PHARMS LTD | **EQ 5MG BASE** | **A204090** | **001** | Nov 26, 2013 |
| **AB** | | **EQ 10MG BASE** | **A204090** | **002** | Nov 26, 2013 |
| **AB** | GLENMARK GENERICS | **EQ 5MG BASE** | **A201967** | **001** | Dec 31, 2012 |
| **AB** | | **EQ 10MG BASE** | **A201967** | **002** | Dec 31, 2012 |
| **AB** | INVAGEN PHARMS | **EQ 5MG BASE** | **A204339** | **001** | Jul 01, 2013 |
| **AB** | | **EQ 10MG BASE** | **A204339** | **002** | Jul 01, 2013 |
| **AB** | JUBILANT GENERICS | **EQ 5MG BASE** | **A203252** | **001** | Dec 31, 2014 |
| **AB** | | **EQ 10MG BASE** | **A203252** | **002** | Dec 31, 2014 |
| **AB** | MACLEODS PHARMS LTD | **EQ 5MG BASE** | **A203147** | **001** | Feb 11, 2014 |
| **AB** | | **EQ 10MG BASE** | **A203147** | **002** | Feb 11, 2014 |
| **AB** | MYLAN PHARMS INC | **EQ 5MG BASE** | **A201993** | **001** | Dec 31, 2012 |
| **AB** | | **EQ 10MG BASE** | **A201993** | **002** | Dec 31, 2012 |
| **AB** | NATCO PHARMA LTD | **EQ 5MG BASE** | **A200482** | **001** | Dec 31, 2012 |
| **AB** | | **EQ 10MG BASE** | **A200482** | **002** | Dec 31, 2012 |
| **AB** | SANDOZ | **EQ 5MG BASE** | **A079230** | **001** | Dec 31, 2012 |
| **AB** | | **EQ 10MG BASE** | **A079230** | **002** | Dec 31, 2012 |
| **AB** | TEVA PHARMS | **EQ 5MG BASE** | **A077263** | **001** | Dec 31, 2012 |
| **AB** | | **EQ 10MG BASE** | **A077263** | **002** | Dec 31, 2012 |
| **AB** | UNICHEM LABS LTD | **EQ 5MG BASE** | **A207836** | **001** | Mar 07, 2017 |
| **AB** | | **EQ 10MG BASE** | **A207836** | **002** | Mar 07, 2017 |

TABLET, ORALLY DISINTEGRATING;ORAL

**MAXALT-MLT**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | **+** MERCK | **EQ 5MG BASE** | **N020865** | **001** | Jun 29, 1998 |
| **AB** | **+!** | **EQ 10MG BASE** | **N020865** | **002** | Jun 29, 1998 |

**RIZATRIPTAN BENZOATE**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | APOTEX INC | **EQ 5MG BASE** | **A202477** | **001** | Jul 01, 2013 |
| **AB** | | **EQ 10MG BASE** | **A202477** | **002** | Jul 01, 2013 |

RIZATRIPTAN BENZOATE

TABLET, ORALLY DISINTEGRATING;ORAL

**RIZATRIPTAN BENZOATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AUROBINDO PHARMA LTD | **EQ 5MG BASE** | **A203062** | **001** | Jul 01, 2013 |
| **AB** | | | **EQ 10MG BASE** | **A203062** | **002** | Jul 01, 2013 |
| **AB** | | GLENMARK PHARMS LTD | **EQ 5MG BASE** | **A201914** | **001** | Jul 01, 2013 |
| **AB** | | | **EQ 10MG BASE** | **A201914** | **002** | Jul 01, 2013 |
| **AB** | | JUBILANT GENERICS | **EQ 5MG BASE** | **A203334** | **001** | Oct 16, 2015 |
| **AB** | | | **EQ 10MG BASE** | **A203334** | **002** | Oct 16, 2015 |
| **AB** | | MACLEODS PHARMS LTD | **EQ 5MG BASE** | **A203146** | **001** | Sep 19, 2014 |
| **AB** | | | **EQ 10MG BASE** | **A203146** | **002** | Sep 19, 2014 |
| **AB** | | MYLAN PHARMS INC | **EQ 5MG BASE** | **A078173** | **001** | Dec 31, 2012 |
| **AB** | | | **EQ 10MG BASE** | **A078173** | **002** | Dec 31, 2012 |
| **AB** | | NATCO PHARMA LTD | **EQ 5MG BASE** | **A203478** | **001** | Jul 01, 2013 |
| **AB** | | | **EQ 10MG BASE** | **A203478** | **002** | Jul 01, 2013 |
| **AB** | | PANACEA BIOTEC LTD | **EQ 5MG BASE** | **A204722** | **001** | Jan 11, 2017 |
| **AB** | | | **EQ 10MG BASE** | **A204722** | **002** | Jan 11, 2017 |
| **AB** | | SANDOZ | **EQ 5MG BASE** | **A078739** | **001** | Jul 01, 2013 |
| **AB** | | | **EQ 10MG BASE** | **A078739** | **002** | Jul 01, 2013 |
| **AB** | | UNICHEM LABS LTD | **EQ 5MG BASE** | **A207835** | **001** | Mar 07, 2017 |
| **AB** | | | **EQ 10MG BASE** | **A207835** | **002** | Mar 07, 2017 |

ROCURONIUM BROMIDE

INJECTABLE;INJECTION

**ROCURONIUM BROMIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AUROBINDO PHARMA LTD | **50MG/5ML (10MG/ML)** | **A206206** | **001** | Apr 12, 2017 |
| **AP** | | | **100MG/10ML (10MG/ML)** | **A206206** | **002** | Apr 12, 2017 |
| **AP** | | FRESENIUS KABI USA | **50MG/5ML (10MG/ML)** | **A078651** | **001** | Dec 29, 2008 |
| **AP** | | | **100MG/10ML (10MG/ML)** | **A078651** | **002** | Dec 29, 2008 |
| **AP** | | HOSPIRA | **50MG/5ML (10MG/ML)** | **A078519** | **001** | Nov 26, 2008 |
| **AP** | | | **100MG/10ML (10MG/ML)** | **A078519** | **002** | Nov 26, 2008 |
| **AP** | | MYLAN INSTITUTIONAL | **50MG/5ML (10MG/ML)** | **A079199** | **001** | Nov 26, 2008 |
| **AP** | | | **100MG/10ML (10MG/ML)** | **A079199** | **002** | Nov 26, 2008 |
| **AP** | | SAGENT PHARMS | **50MG/5ML (10MG/ML)** | **A091458** | **001** | Jul 28, 2010 |
| **AP** | | | **100MG/10ML (10MG/ML)** | **A091458** | **002** | Jul 28, 2010 |
| **AP** | **!** | SANDOZ INC | **50MG/5ML (10MG/ML)** | **A079195** | **001** | Dec 05, 2008 |
| **AP** | **!** | | **100MG/10ML (10MG/ML)** | **A079195** | **002** | Dec 05, 2008 |
| **AP** | | TAMARANG | **50MG/5ML (10MG/ML)** | **A091115** | **001** | Aug 27, 2012 |
| **AP** | | | **100MG/10ML (10MG/ML)** | **A091115** | **002** | Aug 27, 2012 |
| **AP** | | TEVA PHARMS | **50MG/5ML (10MG/ML)** | **A078717** | **001** | Nov 26, 2008 |
| **AP** | | | **100MG/10ML (10MG/ML)** | **A078717** | **002** | Nov 26, 2008 |
| **AP** | | WEST WARD PHARM CORP | **50MG/5ML (10MG/ML)** | **A204679** | **001** | Feb 28, 2017 |
| **AP** | | | **100MG/10ML (10MG/ML)** | **A204679** | **002** | Feb 28, 2017 |

ROFLUMILAST

TABLET;ORAL

DALIRESP

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ASTRAZENECA PHARMS | 500MCG | N022522 | 001 | Feb 28, 2011 |

ROLAPITANT HYDROCHLORIDE

EMULSION;IV (INFUSION)

VARUBI

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | TESARO INC | EQ 166.5MG BASE/92.5ML (EQ 1.8MG BASE/ML) | N208399 | 001 | Oct 25, 2017 |

TABLET;ORAL

VARUBI

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | TESARO INC | EQ 90MG BASE | N206500 | 001 | Sep 01, 2015 |

ROMIDEPSIN

POWDER;IV (INFUSION)

ISTODAX

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | CELGENE | 10MG/VIAL | N022393 | 001 | Nov 05, 2009 |

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

**REQUIP**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | GLAXOSMITHKLINE LLC | **EQ 0.25MG BASE** | **N020658** | **001** | Sep 19, 1997 |
| **AB** | **+** | | **EQ 0.5MG BASE** | **N020658** | **002** | Sep 19, 1997 |
| **AB** | **+** | | **EQ 1MG BASE** | **N020658** | **003** | Sep 19, 1997 |
| **AB** | **+** | | **EQ 2MG BASE** | **N020658** | **004** | Sep 19, 1997 |
| **AB** | **+** | | **EQ 3MG BASE** | **N020658** | **006** | Jan 27, 1999 |
| **AB** | **+** | | **EQ 4MG BASE** | **N020658** | **007** | Jan 27, 1999 |
| **AB** | **+** | | **EQ 5MG BASE** | **N020658** | **005** | Sep 19, 1997 |

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

**ROPINIROLE HYDROCHLORIDE**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | ACCORD HLTHCARE | **EQ 0.25MG BASE** | **A204022** | **001** | Feb 28, 2017 |
| **AB** | | **EQ 0.5MG BASE** | **A204022** | **002** | Feb 28, 2017 |
| **AB** | | **EQ 1MG BASE** | **A204022** | **003** | Feb 28, 2017 |
| **AB** | | **EQ 2MG BASE** | **A204022** | **004** | Feb 28, 2017 |
| **AB** | | **EQ 3MG BASE** | **A204022** | **005** | Feb 28, 2017 |
| **AB** | | **EQ 4MG BASE** | **A204022** | **006** | Feb 28, 2017 |
| **AB** | | **EQ 5MG BASE** | **A204022** | **007** | Feb 28, 2017 |
| **AB** | ALEMBIC LTD | **EQ 0.25MG BASE** | **A090429** | **001** | Mar 24, 2010 |
| **AB** | | **EQ 0.5MG BASE** | **A090429** | **002** | Mar 24, 2010 |
| **AB** | | **EQ 1MG BASE** | **A090429** | **003** | Mar 24, 2010 |
| **AB** | | **EQ 2MG BASE** | **A090429** | **004** | Mar 24, 2010 |
| **AB** | | **EQ 3MG BASE** | **A090429** | **005** | Mar 24, 2010 |
| **AB** | | **EQ 4MG BASE** | **A090429** | **006** | Mar 24, 2010 |
| **AB** | | **EQ 5MG BASE** | **A090429** | **007** | Mar 24, 2010 |
| **AB** | APOTEX | **EQ 0.25MG BASE** | **A079165** | **001** | Feb 07, 2012 |
| **AB** | | **EQ 0.5MG BASE** | **A079165** | **002** | Feb 07, 2012 |
| **AB** | | **EQ 1MG BASE** | **A079165** | **003** | Feb 07, 2012 |
| **AB** | | **EQ 2MG BASE** | **A079165** | **004** | Feb 07, 2012 |
| **AB** | | **EQ 3MG BASE** | **A079165** | **005** | Feb 07, 2012 |
| **AB** | | **EQ 4MG BASE** | **A079165** | **006** | Feb 07, 2012 |
| **AB** | | **EQ 5MG BASE** | **A079165** | **007** | Feb 07, 2012 |
| **AB** | G AND W LABS INC | **EQ 0.25MG BASE** | **A077460** | **001** | May 05, 2008 |
| **AB** | | **EQ 0.5MG BASE** | **A077460** | **002** | May 05, 2008 |
| **AB** | | **EQ 1MG BASE** | **A077460** | **003** | May 05, 2008 |
| **AB** | | **EQ 2MG BASE** | **A077460** | **004** | May 05, 2008 |
| **AB** | | **EQ 3MG BASE** | **A077460** | **005** | May 05, 2008 |
| **AB** | | **EQ 4MG BASE** | **A077460** | **006** | May 05, 2008 |
| **AB** | | **EQ 5MG BASE** | **A077460** | **007** | May 19, 2008 |
| **AB** | GLENMARK GENERICS | **EQ 0.25MG BASE** | **A090135** | **001** | Feb 25, 2010 |
| **AB** | | **EQ 0.5MG BASE** | **A090135** | **002** | Feb 25, 2010 |
| **AB** | | **EQ 1MG BASE** | **A090135** | **003** | Feb 25, 2010 |
| **AB** | | **EQ 2MG BASE** | **A090135** | **004** | Feb 25, 2010 |
| **AB** | | **EQ 3MG BASE** | **A090135** | **005** | Feb 25, 2010 |
| **AB** | | **EQ 4MG BASE** | **A090135** | **006** | Feb 25, 2010 |
| **AB** | | **EQ 5MG BASE** | **A090135** | **007** | Feb 25, 2010 |
| **AB** | MYLAN | **EQ 0.25MG BASE** | **A078881** | **001** | May 05, 2008 |
| **AB** | | **EQ 0.5MG BASE** | **A078881** | **002** | May 05, 2008 |
| **AB** | | **EQ 1MG BASE** | **A078881** | **003** | May 05, 2008 |
| **AB** | | **EQ 2MG BASE** | **A078881** | **004** | May 05, 2008 |
| **AB** | | **EQ 3MG BASE** | **A078881** | **005** | May 05, 2008 |
| **AB** | | **EQ 4MG BASE** | **A078881** | **006** | May 05, 2008 |
| **AB** | | **EQ 5MG BASE** | **A078881** | **007** | May 19, 2008 |
| **AB** | ORCHID HLTHCARE | **EQ 0.25MG BASE** | **A079229** | **001** | Nov 28, 2012 |
| **AB** | | **EQ 0.5MG BASE** | **A079229** | **002** | Nov 28, 2012 |
| **AB** | | **EQ 1MG BASE** | **A079229** | **003** | Nov 28, 2012 |
| **AB** | | **EQ 2MG BASE** | **A079229** | **004** | Nov 28, 2012 |
| **AB** | | **EQ 3MG BASE** | **A079229** | **005** | Nov 28, 2012 |
| **AB** | | **EQ 4MG BASE** | **A079229** | **006** | Nov 28, 2012 |
| **AB** | | **EQ 5MG BASE** | **A079229** | **007** | Nov 28, 2012 |
| **AB** | PRINSTON INC | **EQ 0.25MG BASE** | **A078110** | **001** | May 05, 2008 |
| **AB** | | **EQ 0.5MG BASE** | **A078110** | **002** | May 05, 2008 |
| **AB** | | **EQ 1MG BASE** | **A078110** | **003** | May 05, 2008 |
| **AB** | | **EQ 2MG BASE** | **A078110** | **004** | May 05, 2008 |
| **AB** | | **EQ 3MG BASE** | **A078110** | **005** | May 05, 2008 |
| **AB** | | **EQ 4MG BASE** | **A078110** | **006** | May 05, 2008 |
| **AB** | | **EQ 5MG BASE** | **A078110** | **007** | Jul 11, 2008 |
| **AB** | WEST-WARD PHARMS INT | **EQ 0.25MG BASE** | **A077852** | **001** | May 05, 2008 |
| **AB** | | **EQ 0.5MG BASE** | **A077852** | **002** | May 05, 2008 |
| **AB** | | **EQ 1MG BASE** | **A077852** | **003** | May 05, 2008 |
| **AB** | | **EQ 2MG BASE** | **A077852** | **004** | May 05, 2008 |
| **AB** | | **EQ 3MG BASE** | **A077852** | **005** | May 05, 2008 |
| **AB** | | **EQ 4MG BASE** | **A077852** | **006** | May 05, 2008 |
| **AB** | | **EQ 5MG BASE** | **A077852** | **007** | May 19, 2008 |
| **AB** | WOCKHARDT | **EQ 0.25MG BASE** | **A079050** | **001** | May 29, 2008 |
| **AB** | | **EQ 0.5MG BASE** | **A079050** | **002** | May 29, 2008 |
| **AB** | | **EQ 1MG BASE** | **A079050** | **003** | May 29, 2008 |
| **AB** | | **EQ 2MG BASE** | **A079050** | **004** | May 29, 2008 |
| **AB** | | **EQ 3MG BASE** | **A079050** | **005** | May 29, 2008 |
| **AB** | | **EQ 4MG BASE** | **A079050** | **006** | May 29, 2008 |

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

**ROPINIROLE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **EQ 5MG BASE** | **A079050** | **007** | May 29, 2008 |
| **AB** | | ZYDUS PHARMS USA INC | **EQ 0.25MG BASE** | **A090411** | **001** | Jun 01, 2009 |
| **AB** | | | **EQ 0.5MG BASE** | **A090411** | **002** | Jun 01, 2009 |
| **AB** | | | **EQ 1MG BASE** | **A090411** | **003** | Jun 01, 2009 |
| **AB** | | | **EQ 2MG BASE** | **A090411** | **004** | Jun 01, 2009 |
| **AB** | | | **EQ 3MG BASE** | **A090411** | **005** | Jun 01, 2009 |
| **AB** | | | **EQ 4MG BASE** | **A090411** | **006** | Jun 01, 2009 |
| **AB** | | | **EQ 5MG BASE** | **A090411** | **007** | Jun 01, 2009 |

TABLET, EXTENDED RELEASE;ORAL

**REQUIP XL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | GLAXOSMITHKLINE LLC | **EQ 2MG BASE** | **N022008** | **001** | Jun 13, 2008 |
| **AB** | **+** | | **EQ 4MG BASE** | **N022008** | **003** | Jun 13, 2008 |
| **AB** | **+** | | **EQ 6MG BASE** | **N022008** | **006** | Apr 10, 2009 |
| **AB** | **+** | | **EQ 8MG BASE** | **N022008** | **004** | Jun 13, 2008 |
| **AB** | **+** | | **EQ 12MG BASE** | **N022008** | **005** | Oct 31, 2008 |

**ROPINIROLE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS ELIZABETH | **EQ 2MG BASE** | **A090869** | **001** | May 17, 2012 |
| **AB** | | | **EQ 4MG BASE** | **A090869** | **002** | May 17, 2012 |
| **AB** | | | **EQ 6MG BASE** | **A090869** | **003** | May 17, 2012 |
| **AB** | | | **EQ 8MG BASE** | **A090869** | **004** | May 17, 2012 |
| **AB** | | | **EQ 12MG BASE** | **A090869** | **005** | May 17, 2012 |
| **AB** | | ALEMBIC PHARMS LTD | **EQ 2MG BASE** | **A202786** | **001** | Apr 22, 2013 |
| **AB** | | | **EQ 4MG BASE** | **A202786** | **002** | Apr 22, 2013 |
| **AB** | | | **EQ 6MG BASE** | **A202786** | **003** | Apr 22, 2013 |
| **AB** | | | **EQ 8MG BASE** | **A202786** | **004** | Apr 22, 2013 |
| **AB** | | | **EQ 12MG BASE** | **A202786** | **005** | Apr 22, 2013 |
| **AB** | | DR REDDYS LABS LTD | **EQ 2MG BASE** | **A201576** | **001** | Jun 06, 2012 |
| **AB** | | | **EQ 4MG BASE** | **A201576** | **002** | Jun 06, 2012 |
| **AB** | | | **EQ 6MG BASE** | **A201576** | **003** | Jun 06, 2012 |
| **AB** | | | **EQ 8MG BASE** | **A201576** | **004** | Jun 06, 2012 |
| **AB** | | | **EQ 12MG BASE** | **A201576** | **005** | Jun 06, 2012 |
| **AB** | | MYLAN PHARMS INC | **EQ 2MG BASE** | **A200462** | **001** | Oct 15, 2012 |
| **AB** | | | **EQ 4MG BASE** | **A200462** | **003** | Oct 15, 2012 |
| **AB** | | | **EQ 6MG BASE** | **A200462** | **004** | Oct 15, 2012 |
| **AB** | | | **EQ 8MG BASE** | **A200462** | **005** | Oct 15, 2012 |
| **AB** | | | **EQ 12MG BASE** | **A200462** | **006** | Oct 15, 2012 |
| **AB** | | SANDOZ INC | **EQ 2MG BASE** | **A201047** | **001** | Jun 06, 2012 |
| **AB** | | | **EQ 4MG BASE** | **A201047** | **003** | Jun 06, 2012 |
| **AB** | | | **EQ 6MG BASE** | **A201047** | **004** | Jun 06, 2012 |
| **AB** | | | **EQ 8MG BASE** | **A201047** | **005** | Jun 06, 2012 |
| **AB** | | | **EQ 12MG BASE** | **A201047** | **006** | Jun 06, 2012 |
| **AB** | | WATSON LABS INC | **EQ 2MG BASE** | **A200431** | **001** | Jun 06, 2012 |
| **AB** | | | **EQ 4MG BASE** | **A200431** | **002** | Jun 06, 2012 |
| **AB** | | | **EQ 6MG BASE** | **A200431** | **003** | Jun 06, 2012 |
| **AB** | | | **EQ 8MG BASE** | **A200431** | **004** | Jun 06, 2012 |
| **AB** | | | **EQ 12MG BASE** | **A200431** | **005** | Jun 06, 2012 |
| **AB** | | WOCKHARDT LTD | **EQ 2MG BASE** | **A091395** | **001** | Aug 27, 2012 |
| **AB** | | | **EQ 4MG BASE** | **A091395** | **002** | Aug 27, 2012 |
| **AB** | | | **EQ 6MG BASE** | **A091395** | **003** | Aug 27, 2012 |
| **AB** | | | **EQ 8MG BASE** | **A091395** | **004** | Aug 27, 2012 |
| **AB** | | | **EQ 12MG BASE** | **A091395** | **005** | Aug 27, 2012 |

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION

**NAROPIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+** | FRESENIUS KABI USA | **20MG/10ML (2MG/ML)** | **N020533** | **001** | May 01, 1998 |
| **AP** | **+** | | **40MG/20ML (2MG/ML)** | **N020533** | **002** | Sep 24, 1996 |
| **AP** | **+** | | **100MG/20ML (5MG/ML)** | **N020533** | **003** | May 01, 1998 |
| **AP** | **+** | | **100MG/10ML (10MG/ML)** | **N020533** | **005** | Sep 24, 1996 |
| **AP** | **+** | | **150MG/20ML (7.5MG/ML)** | **N020533** | **004** | Sep 24, 1996 |
| **AP** | **+** | | **150MG/30ML (5MG/ML)** | **N020533** | **008** | Sep 24, 1996 |
| **AP** | **+** | | **200MG/100ML (2MG/ML)** | **N020533** | **006** | Sep 24, 1996 |
| **AP** | **+!** | | **200MG/20ML (10MG/ML)** | **N020533** | **011** | Sep 24, 1996 |

**ROPIVACAINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AKORN INC | **150MG/30ML (5MG/ML)** | **A203955** | **001** | Apr 11, 2016 |
| **AP** | | AUROBINDO PHARMA LTD | **40MG/20ML (2MG/ML)** | **A205612** | **001** | Jul 13, 2016 |
| **AP** | | | **100MG/20ML (5MG/ML)** | **A205612** | **003** | Jul 13, 2016 |
| **AP** | | | **100MG/10ML (10MG/ML)** | **A205612** | **006** | Jul 13, 2016 |

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION

**ROPIVACAINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | | **150MG/30ML (5MG/ML)** | **A205612** | **004** | Jul 13, 2016 |
| **AP** | | | **150MG/20ML (7.5MG/ML)** | **A205612** | **005** | Jul 13, 2016 |
| **AP** | | | **200MG/100ML (2MG/ML)** | **A205612** | **002** | Jul 13, 2016 |
| **AP** | | | **200MG/20ML (10MG/ML)** | **A205612** | **007** | Jul 13, 2016 |
| **AP** | | HOSPIRA | **20MG/10ML (2MG/ML)** | **A090194** | **001** | Sep 23, 2014 |
| **AP** | | | **40MG/20ML (2MG/ML)** | **A090194** | **005** | Sep 23, 2014 |
| **AP** | | | **100MG/10ML (10MG/ML)** | **A090194** | **004** | Sep 23, 2014 |
| **AP** | | | **150MG/30ML (5MG/ML)** | **A090194** | **002** | Sep 23, 2014 |
| **AP** | | | **150MG/20ML (7.5MG/ML)** | **A090194** | **003** | Sep 23, 2014 |
| **AP** | | | **200MG/20ML (10MG/ML)** | **A090194** | **006** | Sep 23, 2014 |
| **AP** | | NAVINTA LLC | **150MG/30ML (5MG/ML)** | **A078601** | **002** | Jul 17, 2014 |
| **AP** | | | **200MG/20ML (10MG/ML)** | **A078601** | **003** | Jul 17, 2014 |
| **AP** | | SAGENT STRIDES | **40MG/20ML (2MG/ML)** | **A090318** | **001** | Sep 23, 2014 |
| **AP** | | | **150MG/30ML (5MG/ML)** | **A090318** | **002** | Sep 23, 2014 |
| **AP** | | | **150MG/20ML (7.5MG/ML)** | **A090318** | **003** | Sep 23, 2014 |
| **AP** | | | **200MG/20ML (10MG/ML)** | **A090318** | **004** | Sep 23, 2014 |
| | NAROPIN | | | | | |
| | + | FRESENIUS KABI USA | 400MG/200ML (2MG/ML) | N020533 | 007 | Sep 24, 1996 |
| | + | | 500MG/100ML (5MG/ML) | N020533 | 009 | Jan 04, 2011 |
| | + | | 1GM/200ML (5MG/ML) | N020533 | 010 | Jan 04, 2011 |

ROSIGLITAZONE MALEATE

TABLET;ORAL

**AVANDIA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | SB PHARMCO | **EQ 2MG BASE** | **N021071** | **002** | May 25, 1999 |
| **AB** | + | | **EQ 4MG BASE** | **N021071** | **003** | May 25, 1999 |
| **AB** | +! | | **EQ 8MG BASE** | **N021071** | **004** | May 25, 1999 |

**ROSIGLITAZONE MALEATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | TEVA | **EQ 2MG BASE** | **A076747** | **001** | Jan 25, 2013 |
| **AB** | | | **EQ 4MG BASE** | **A076747** | **002** | Jan 25, 2013 |
| **AB** | | | **EQ 8MG BASE** | **A076747** | **003** | Jan 25, 2013 |

ROSUVASTATIN CALCIUM

TABLET;ORAL

**CRESTOR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | IPR | **5MG** | **N021366** | **002** | Aug 12, 2003 |
| **AB** | + | | **10MG** | **N021366** | **003** | Aug 12, 2003 |
| **AB** | + | | **20MG** | **N021366** | **004** | Aug 12, 2003 |
| **AB** | +! | | **40MG** | **N021366** | **005** | Aug 12, 2003 |

**ROSUVASTATIN CALCIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACCORD HLTHCARE | **5MG** | **A206434** | **001** | Oct 31, 2016 |
| **AB** | | | **10MG** | **A206434** | **002** | Oct 31, 2016 |
| **AB** | | | **20MG** | **A206434** | **003** | Oct 31, 2016 |
| **AB** | | | **40MG** | **A206434** | **004** | Oct 31, 2016 |
| **AB** | | ALKEM LABS LTD | **5MG** | **A206465** | **001** | Mar 21, 2017 |
| **AB** | | | **10MG** | **A206465** | **002** | Mar 21, 2017 |
| **AB** | | | **20MG** | **A206465** | **003** | Mar 21, 2017 |
| **AB** | | | **40MG** | **A206465** | **004** | Mar 21, 2017 |
| **AB** | | APOTEX INC | **5MG** | **A079145** | **001** | Jul 19, 2016 |
| **AB** | | | **10MG** | **A079145** | **002** | Jul 19, 2016 |
| **AB** | | | **20MG** | **A079145** | **003** | Jul 19, 2016 |
| **AB** | | | **40MG** | **A079145** | **004** | Jul 19, 2016 |
| **AB** | | AUROBINDO PHARMA LTD | **5MG** | **A079170** | **001** | Jul 19, 2016 |
| **AB** | | | **10MG** | **A079170** | **002** | Jul 19, 2016 |
| **AB** | | | **20MG** | **A079170** | **003** | Jul 19, 2016 |
| **AB** | | | **40MG** | **A079170** | **004** | Jul 19, 2016 |
| **AB** | | BIOCON LTD | **5MG** | **A207752** | **001** | Oct 31, 2016 |
| **AB** | | | **10MG** | **A207752** | **002** | Oct 31, 2016 |
| **AB** | | | **20MG** | **A207752** | **003** | Oct 31, 2016 |
| **AB** | | | **40MG** | **A207752** | **004** | Oct 31, 2016 |
| **AB** | | CADILA PHARMS LTD | **5MG** | **A207453** | **001** | Nov 23, 2016 |
| **AB** | | | **10MG** | **A207453** | **002** | Nov 23, 2016 |
| **AB** | | | **20MG** | **A207453** | **003** | Nov 23, 2016 |
| **AB** | | | **40MG** | **A207453** | **004** | Nov 23, 2016 |
| **AB** | | CHANGZHOU PHARM | **5MG** | **A207408** | **001** | Oct 31, 2016 |
| **AB** | | | **10MG** | **A207408** | **002** | Oct 31, 2016 |
| **AB** | | | **20MG** | **A207408** | **003** | Oct 31, 2016 |
| **AB** | | | **40MG** | **A207408** | **004** | Oct 31, 2016 |
| **AB** | | GLENMARK PHARMS | **5MG** | **A079172** | **001** | Jul 19, 2016 |
| **AB** | | | **10MG** | **A079172** | **002** | Jul 19, 2016 |

ROSUVASTATIN CALCIUM

TABLET;ORAL

**ROSUVASTATIN CALCIUM**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | | **20MG** | **A079172** | **003** | Jul 19, 2016 |
| **AB** | | **40MG** | **A079172** | **004** | Jul 19, 2016 |
| **AB** | HETERO LABS LTD V | **5MG** | **A207616** | **001** | Oct 31, 2016 |
| **AB** | | **10MG** | **A207616** | **002** | Oct 31, 2016 |
| **AB** | | **20MG** | **A207616** | **003** | Oct 31, 2016 |
| **AB** | | **40MG** | **A207616** | **004** | Oct 31, 2016 |
| **AB** | JUBILANT GENERICS | **5MG** | **A207062** | **001** | Oct 31, 2016 |
| **AB** | | **10MG** | **A207062** | **002** | Oct 31, 2016 |
| **AB** | | **20MG** | **A207062** | **003** | Oct 31, 2016 |
| **AB** | | **40MG** | **A207062** | **004** | Oct 31, 2016 |
| **AB** | LUPIN LTD | **5MG** | **A205587** | **001** | Jul 31, 2017 |
| **AB** | | **10MG** | **A205587** | **002** | Jul 31, 2017 |
| **AB** | | **20MG** | **A205587** | **003** | Jul 31, 2017 |
| **AB** | | **40MG** | **A205587** | **004** | Jul 31, 2017 |
| **AB** | MSN LABS PVT LTD | **5MG** | **A208898** | **001** | Nov 22, 2017 |
| **AB** | | **10MG** | **A208898** | **002** | Nov 22, 2017 |
| **AB** | | **20MG** | **A208898** | **003** | Nov 22, 2017 |
| **AB** | | **40MG** | **A208898** | **004** | Nov 22, 2017 |
| **AB** | MYLAN PHARMS INC | **5MG** | **A079161** | **001** | Jul 19, 2016 |
| **AB** | | **10MG** | **A079161** | **002** | Jul 19, 2016 |
| **AB** | | **20MG** | **A079161** | **003** | Jul 19, 2016 |
| **AB** | | **40MG** | **A079161** | **004** | Jul 19, 2016 |
| **AB** | PAR PHARM INC | **5MG** | **A079168** | **001** | Jul 19, 2016 |
| **AB** | | **10MG** | **A079168** | **002** | Jul 19, 2016 |
| **AB** | | **20MG** | **A079168** | **003** | Jul 19, 2016 |
| **AB** | | **40MG** | **A079168** | **004** | Jul 19, 2016 |
| **AB** | SANDOZ INC | **5MG** | **A079171** | **001** | Jul 19, 2016 |
| **AB** | | **10MG** | **A079171** | **002** | Jul 19, 2016 |
| **AB** | | **20MG** | **A079171** | **003** | Jul 19, 2016 |
| **AB** | | **40MG** | **A079171** | **004** | Jul 19, 2016 |
| **AB** | SUN PHARMA GLOBAL | **5MG** | **A079169** | **001** | Jul 19, 2016 |
| **AB** | | **10MG** | **A079169** | **002** | Jul 19, 2016 |
| **AB** | | **20MG** | **A079169** | **003** | Jul 19, 2016 |
| **AB** | | **40MG** | **A079169** | **004** | Jul 19, 2016 |
| **AB** | TEVA PHARMS USA | **5MG** | **A079166** | **001** | Jul 19, 2016 |
| **AB** | | **10MG** | **A079166** | **002** | Jul 19, 2016 |
| **AB** | | **20MG** | **A079166** | **003** | Jul 19, 2016 |
| **AB** | | **40MG** | **A079166** | **004** | Jul 19, 2016 |
| **AB** | TORRENT PHARMS LTD | **5MG** | **A201619** | **001** | Oct 31, 2016 |
| **AB** | | **10MG** | **A201619** | **002** | Oct 31, 2016 |
| **AB** | | **20MG** | **A201619** | **003** | Oct 31, 2016 |
| **AB** | | **40MG** | **A201619** | **004** | Oct 31, 2016 |
| **AB** | WATSON LABS INC | **5MG** | **A079167** | **001** | Apr 29, 2016 |
| **AB** | | **10MG** | **A079167** | **002** | Apr 29, 2016 |
| **AB** | | **20MG** | **A079167** | **003** | Apr 29, 2016 |
| **AB** | | **40MG** | **A079167** | **004** | Apr 29, 2016 |

ROTIGOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL

NEUPRO

| | | | | | |
|---|---|---|---|---|---|
| + | UCB INC | 1MG/24HR | N021829 | 004 | Apr 02, 2012 |
| +! | | 2MG/24HR | N021829 | 001 | May 09, 2007 |
| + | | 3MG/24HR | N021829 | 005 | Apr 02, 2012 |
| + | | 4MG/24HR | N021829 | 002 | May 09, 2007 |
| + | | 6MG/24HR | N021829 | 003 | May 09, 2007 |
| + | | 8MG/24HR | N021829 | 006 | Apr 02, 2012 |

RUBIDIUM CHLORIDE RB-82

INJECTABLE;INJECTION

CARDIOGEN-82

| | | | | | |
|---|---|---|---|---|---|
| | BRACCO | N/A | N019414 | 001 | Dec 29, 1989 |

SOLUTION;INTRAVENOUS

RUBY-FILL

| | | | | | |
|---|---|---|---|---|---|
| | JUBILANT DRAXIMAGE | N/A | N202153 | 001 | Sep 30, 2016 |

RUCAPARIB CAMSYLATE

TABLET;ORAL

RUBRACA

| | | | | | |
|---|---|---|---|---|---|
| + | CLOVIS ONCOLOGY INC | EQ 200MG BASE | N209115 | 001 | Dec 19, 2016 |
| + | | EQ 250MG BASE | N209115 | 003 | May 01, 2017 |
| +! | | EQ 300MG BASE | N209115 | 002 | Dec 19, 2016 |

RUFINAMIDE

SUSPENSION;ORAL

BANZEL

| | | | | | |
|---|---|---|---|---|---|
| +! | EISAI INC | 40MG/ML | N201367 | 001 | Mar 03, 2011 |

TABLET;ORAL

**BANZEL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | EISAI INC | **200MG** | **N021911** | **002** | Nov 14, 2008 |
| **AB** | **+!** | | **400MG** | **N021911** | **003** | Nov 14, 2008 |

**RUFINAMIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | GLENMARK PHARMS LTD | **200MG** | **A205075** | **001** | May 16, 2016 |
| **AB** | | | **400MG** | **A205075** | **002** | May 16, 2016 |
| **AB** | | MYLAN PHARMS INC | **200MG** | **A205095** | **001** | May 16, 2016 |
| **AB** | | | **400MG** | **A205095** | **002** | May 16, 2016 |
| **AB** | | WEST-WARD PHARMS INT | **200MG** | **A204988** | **001** | May 16, 2016 |
| **AB** | | | **400MG** | **A204988** | **002** | May 16, 2016 |

RUXOLITINIB PHOSPHATE

TABLET;ORAL

JAKAFI

| | | | | | |
|---|---|---|---|---|---|
| + | INCYTE CORP | EQ 5MG BASE | N202192 | 001 | Nov 16, 2011 |
| + | | EQ 10MG BASE | N202192 | 002 | Nov 16, 2011 |
| + | | EQ 15MG BASE | N202192 | 003 | Nov 16, 2011 |
| + | | EQ 20MG BASE | N202192 | 004 | Nov 16, 2011 |
| +! | | EQ 25MG BASE | N202192 | 005 | Nov 16, 2011 |

SACROSIDASE

SOLUTION;ORAL

SUCRAID

| | | | | | |
|---|---|---|---|---|---|
| +! | QOL MEDCL | 8,500 IU/ML | N020772 | 001 | Apr 09, 1998 |

SACUBITRIL; VALSARTAN

TABLET;ORAL

ENTRESTO

| | | | | | |
|---|---|---|---|---|---|
| + | NOVARTIS PHARMS CORP | 24MG;26MG | N207620 | 001 | Jul 07, 2015 |
| + | | 49MG;51MG | N207620 | 002 | Jul 07, 2015 |
| +! | | 97MG;103MG | N207620 | 003 | Jul 07, 2015 |

SAFINAMIDE MESYLATE

TABLET;ORAL

XADAGO

| | | | | | |
|---|---|---|---|---|---|
| + | US WORLDMEDS LLC | 50MG | N207145 | 001 | Mar 21, 2017 |
| +! | | 100MG | N207145 | 002 | Mar 21, 2017 |

SALMETEROL XINAFOATE

POWDER;INHALATION

SEREVENT

| | | | | | |
|---|---|---|---|---|---|
| +! | GLAXOSMITHKLINE | EQ 0.05MG BASE/INH | N020692 | 001 | Sep 19, 1997 |

SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

INJECTABLE;INJECTION

QUADRAMET

| | | | | | |
|---|---|---|---|---|---|
| +! | LANTHEUS MEDICAL | 50mCi/ML | N020570 | 001 | Mar 28, 1997 |

SAPROPTERIN DIHYDROCHLORIDE

POWDER;ORAL

KUVAN

| | | | | | |
|---|---|---|---|---|---|
| +! | BIOMARIN PHARM | 100MG/PACKET | N205065 | 001 | Dec 19, 2013 |
| + | | 500MG/PACKET | N205065 | 002 | Oct 27, 2015 |

TABLET;ORAL

KUVAN

| | | | | | |
|---|---|---|---|---|---|
| +! | BIOMARIN PHARM | 100MG | N022181 | 001 | Dec 13, 2007 |

SAQUINAVIR MESYLATE

CAPSULE;ORAL

INVIRASE

| | | | | | |
|---|---|---|---|---|---|
| +! | HOFFMANN LA ROCHE | EQ 200MG BASE | N020628 | 001 | Dec 06, 1995 |

TABLET;ORAL

INVIRASE

| | | | | | |
|---|---|---|---|---|---|
| +! | HOFFMANN-LA ROCHE | EQ 500MG BASE | N021785 | 001 | Dec 17, 2004 |

SAXAGLIPTIN HYDROCHLORIDE

TABLET;ORAL

ONGLYZA

| | | | | | |
|---|---|---|---|---|---|
| + | ASTRAZENECA AB | EQ 2.5MG BASE | N022350 | 001 | Jul 31, 2009 |
| +! | | EQ 5MG BASE | N022350 | 002 | Jul 31, 2009 |

SCOPOLAMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

**SCOPOLAMINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | PERRIGO PHARMS CO | **1MG/72HR** | **A078830** | **001** | Jan 30, 2015 |

**TRANSDERM SCOP**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | GLAXOSMITHKLINE CON | **1MG/72HR** | **N017874** | **001** | |

SECNIDAZOLE

GRANULE;ORAL

SOLOSEC

| | | | | | |
|---|---|---|---|---|---|
| +! | LUPIN | 2GM/PACKET | N209363 | 001 | Sep 15, 2017 |

SECOBARBITAL SODIUM

CAPSULE;ORAL

SECONAL SODIUM

| | | | | | |
|---|---|---|---|---|---|
| ! | VALEANT PHARMS NORTH | 50MG | A086101 | 001 | Oct 03, 1983 |
| ! | | 100MG | A086101 | 002 | Oct 03, 1983 |

SECRETIN SYNTHETIC HUMAN

FOR SOLUTION;INTRAVENOUS

CHIRHOSTIM

| | | | | | |
|---|---|---|---|---|---|
| +! | CHIRHOCLIN | 16MCG/VIAL | N021256 | 001 | Apr 09, 2004 |
| + | | 40MCG/VIAL | N021256 | 002 | Jun 21, 2007 |

SELEGILINE

FILM, EXTENDED RELEASE;TRANSDERMAL

EMSAM

| | | | | | |
|---|---|---|---|---|---|
| +! | SOMERSET | 6MG/24HR | N021336 | 001 | Feb 27, 2006 |
| + | | 9MG/24HR | N021336 | 002 | Feb 27, 2006 |
| + | | 12MG/24HR | N021336 | 003 | Feb 27, 2006 |

SELEGILINE HYDROCHLORIDE

CAPSULE;ORAL

**ELDEPRYL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | SOMERSET | **5MG** | **N020647** | **001** | May 15, 1996 |

**SELEGILINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | APOTEX | **5MG** | **A075321** | **001** | Dec 04, 1998 |
| **AB** | | DAVA PHARMS INC | **5MG** | **A075352** | **001** | Nov 30, 1998 |

TABLET;ORAL

**SELEGILINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **!** | APOTEX INC | **5MG** | **A074871** | **001** | Jun 06, 1997 |
| **AB** | | BOSCOGEN | **5MG** | **A074912** | **001** | Apr 30, 1998 |
| **AB** | | MYLAN | **5MG** | **A074866** | **001** | Nov 26, 1997 |

TABLET, ORALLY DISINTEGRATING;ORAL

ZELAPAR

| | | | | | |
|---|---|---|---|---|---|
| +! | VALEANT PHARM INTL | 1.25MG | N021479 | 001 | Jun 14, 2006 |

SELENIUM SULFIDE

LOTION/SHAMPOO;TOPICAL

**SELENIUM SULFIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | PERRIGO NEW YORK | **2.5%** | **A089996** | **001** | Jan 10, 1991 |
| **AT** | | WOCKHARDT BIO AG | **2.5%** | **A088228** | **001** | Sep 01, 1983 |

**SELSUN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **+!** | CHATTEM | **2.5%** | **N007936** | **001** | |

SELEXIPAG

TABLET;ORAL

UPTRAVI

| | | | | | |
|---|---|---|---|---|---|
| + | ACTELION PHARMS LTD | 0.2MG | N207947 | 001 | Dec 21, 2015 |
| + | | 0.4MG | N207947 | 002 | Dec 21, 2015 |
| + | | 0.6MG | N207947 | 003 | Dec 21, 2015 |
| + | | 0.8MG | N207947 | 004 | Dec 21, 2015 |

| | | | | | | |
|---|---|---|---|---|---|---|
| SELEXIPAG | | | | | | |
| TABLET;ORAL | | | | | | |
| UPTRAVI | | | | | | |
| + | | 1MG | N207947 | 005 | Dec 21, 2015 |
| + | | 1.2MG | N207947 | 006 | Dec 21, 2015 |
| + | | 1.4MG | N207947 | 007 | Dec 21, 2015 |
| +! | | 1.6MG | N207947 | 008 | Dec 21, 2015 |
| SEMAGLUTIDE | | | | | | |
| SOLUTION;SUBCUTANEOUS | | | | | | |
| OZEMPIC | | | | | | |
| +! | NOVO NORDISK INC | 2MG/1.5ML (1.34MG/ML) | N209637 | 001 | Dec 05, 2017 |
| SERTACONAZOLE NITRATE | | | | | | |
| CREAM;TOPICAL | | | | | | |
| ERTACZO | | | | | | |
| +! | VALEANT LUXEMBOURG | 2% | N021385 | 001 | Dec 10, 2003 |
| SERTRALINE HYDROCHLORIDE | | | | | | |
| CONCENTRATE;ORAL | | | | | | |
| **SERTRALINE HYDROCHLORIDE** | | | | | | |
| **AA** | AUROBINDO PHARMA | **EQ 20MG BASE/ML** | **A078861** | **001** | Oct 31, 2008 |
| **ZOLOFT** | | | | | | |
| **AA** | **+!** PFIZER | **EQ 20MG BASE/ML** | **N020990** | **001** | Dec 07, 1999 |
| TABLET;ORAL | | | | | | |
| **SERTRALINE HYDROCHLORIDE** | | | | | | |
| **AB** | ACCORD HLTHCARE | **EQ 25MG BASE** | **A202825** | **001** | Nov 07, 2014 |
| **AB** | | **EQ 50MG BASE** | **A202825** | **002** | Nov 07, 2014 |
| **AB** | | **EQ 100MG BASE** | **A202825** | **003** | Nov 07, 2014 |
| **AB** | APOTEX INC | **EQ 25MG BASE** | **A076882** | **001** | Feb 06, 2007 |
| **AB** | | **EQ 50MG BASE** | **A076882** | **002** | Feb 06, 2007 |
| **AB** | | **EQ 100MG BASE** | **A076882** | **003** | Feb 06, 2007 |
| **AB** | AUROBINDO PHARMA | **EQ 25MG BASE** | **A077206** | **001** | Feb 06, 2007 |
| **AB** | | **EQ 50MG BASE** | **A077206** | **002** | Feb 06, 2007 |
| **AB** | | **EQ 100MG BASE** | **A077206** | **003** | Feb 06, 2007 |
| **AB** | AUSTARPHARMA LLC | **EQ 25MG BASE** | **A078677** | **001** | Mar 04, 2009 |
| **AB** | | **EQ 50MG BASE** | **A078677** | **002** | Mar 04, 2009 |
| **AB** | | **EQ 100MG BASE** | **A078677** | **003** | Mar 04, 2009 |
| **AB** | INVAGEN PHARMS | **EQ 25MG BASE** | **A077397** | **001** | Feb 06, 2007 |
| **AB** | | **EQ 50MG BASE** | **A077397** | **002** | Feb 06, 2007 |
| **AB** | | **EQ 100MG BASE** | **A077397** | **003** | Feb 06, 2007 |
| **AB** | LUPIN | **EQ 25MG BASE** | **A077670** | **001** | Feb 06, 2007 |
| **AB** | | **EQ 50MG BASE** | **A077670** | **002** | Feb 06, 2007 |
| **AB** | | **EQ 100MG BASE** | **A077670** | **003** | Feb 06, 2007 |
| **AB** | MYLAN PHARMS INC | **EQ 25MG BASE** | **A078626** | **001** | Jan 31, 2008 |
| **AB** | | **EQ 50MG BASE** | **A078626** | **002** | Jan 31, 2008 |
| **AB** | | **EQ 100MG BASE** | **A078626** | **003** | Jan 31, 2008 |
| **AB** | OXFORD PHARMS | **EQ 25MG BASE** | **A078175** | **001** | Jul 21, 2010 |
| **AB** | | **EQ 50MG BASE** | **A078175** | **002** | Jul 21, 2010 |
| **AB** | | **EQ 100MG BASE** | **A078175** | **003** | Jul 21, 2010 |
| **AB** | SUN PHARM INDS LTD | **EQ 25MG BASE** | **A077977** | **001** | Feb 06, 2007 |
| **AB** | | **EQ 50MG BASE** | **A077977** | **002** | Feb 06, 2007 |
| **AB** | | **EQ 100MG BASE** | **A077977** | **003** | Feb 06, 2007 |
| **AB** | TEVA | **EQ 25MG BASE** | **A076465** | **001** | Aug 11, 2006 |
| **AB** | | **EQ 50MG BASE** | **A076465** | **002** | Aug 11, 2006 |
| **AB** | | **EQ 100MG BASE** | **A076465** | **003** | Aug 11, 2006 |
| **AB** | TORRENT PHARMS | **EQ 25MG BASE** | **A077765** | **001** | Feb 06, 2007 |
| **AB** | | **EQ 50MG BASE** | **A077765** | **002** | Feb 06, 2007 |
| **AB** | | **EQ 100MG BASE** | **A077765** | **003** | Feb 06, 2007 |
| **AB** | WOCKHARDT | **EQ 25MG BASE** | **A078403** | **001** | Jan 08, 2008 |
| **AB** | | **EQ 50MG BASE** | **A078403** | **002** | Jan 08, 2008 |
| **AB** | | **EQ 100MG BASE** | **A078403** | **003** | Jan 08, 2008 |
| **AB** | ZYDUS PHARMS USA | **EQ 25MG BASE** | **A077106** | **001** | Feb 06, 2007 |
| **AB** | | **EQ 50MG BASE** | **A077106** | **002** | Feb 06, 2007 |
| **AB** | | **EQ 100MG BASE** | **A077106** | **003** | Feb 06, 2007 |
| **ZOLOFT** | | | | | | |
| **AB** | **+** PFIZER | **EQ 25MG BASE** | **N019839** | **005** | Mar 06, 1996 |
| **AB** | **+** | **EQ 50MG BASE** | **N019839** | **001** | Dec 30, 1991 |
| **AB** | **+!** | **EQ 100MG BASE** | **N019839** | **002** | Dec 30, 1991 |
| SERTRALINE HYDROCHLORIDE | | | | | | |
| | SUN PHARM INDS LTD | EQ 150MG BASE | A077977 | 004 | Feb 06, 2007 |
| | | EQ 200MG BASE | A077977 | 005 | Feb 06, 2007 |

| | | | | | | |
|---|---|---|---|---|---|---|
| SEVELAMER CARBONATE | | | | | | |
| FOR SUSPENSION;ORAL | | | | | | |
| **RENVELA** | | | | | | |
| **AB** | **+** | GENZYME | **800MG/PACKET** | **N022318** | **001** | Aug 12, 2009 |
| **AB** | **+!** | | **2.4GM/PACKET** | **N022318** | **002** | Feb 18, 2009 |
| **SEVELAMER CARBONATE** | | | | | | |
| **AB** | | AUROBINDO PHARMA LTD | **800MG/PACKET** | **A207624** | **001** | Jun 13, 2017 |
| **AB** | | | **2.4GM/PACKET** | **A207624** | **002** | Jun 13, 2017 |
| TABLET;ORAL | | | | | | |
| **RENVELA** | | | | | | |
| **AB** | **+!** | GENZYME | **800MG** | **N022127** | **001** | Oct 19, 2007 |
| **SEVELAMER CARBONATE** | | | | | | |
| **AB** | | AMNEAL PHARMS CO | **800MG** | **A207288** | **001** | Nov 28, 2017 |
| **AB** | | AUROBINDO PHARMA LTD | **800MG** | **A207179** | **001** | Jul 17, 2017 |
| **AB** | | DR REDDYS LABS LTD | **800MG** | **A206094** | **001** | Sep 29, 2017 |
| **AB** | | IMPAX LABS INC | **800MG** | **A090975** | **001** | Oct 23, 2017 |
| **AB** | | INVAGEN PHARMS | **800MG** | **A203860** | **001** | Oct 26, 2017 |
| SEVELAMER HYDROCHLORIDE | | | | | | |
| TABLET;ORAL | | | | | | |
| RENAGEL | | | | | | |
| | + | GENZYME | 400MG | N021179 | 001 | Jul 12, 2000 |
| | +! | | 800MG | N021179 | 002 | Jul 12, 2000 |
| SEVOFLURANE | | | | | | |
| LIQUID;INHALATION | | | | | | |
| **SEVOFLURANE** | | | | | | |
| **AN** | | BAXTER HLTHCARE | **100%** | **A075895** | **001** | Jul 02, 2002 |
| **AN** | | HALOCARBON PRODS | **100%** | **A078650** | **001** | Nov 19, 2007 |
| **AN** | | SHANGHAI HENGRUI | **100%** | **A203793** | **001** | Nov 03, 2015 |
| **SOJOURN** | | | | | | |
| **AN** | | PIRAMAL CRITICAL | **100%** | **A077867** | **001** | May 02, 2007 |
| **ULTANE** | | | | | | |
| **AN** | **+!** | ABBVIE | **100%** | **N020478** | **001** | Jun 07, 1995 |
| SILDENAFIL CITRATE | | | | | | |
| FOR SUSPENSION;ORAL | | | | | | |
| REVATIO | | | | | | |
| | +! | PFIZER | EQ 10MG BASE/ML | N203109 | 001 | Aug 30, 2012 |
| SOLUTION;INTRAVENOUS | | | | | | |
| **REVATIO** | | | | | | |
| **AP** | **+!** | PFIZER | **EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)** | **N022473** | **001** | Nov 18, 2009 |
| **SILDENAFIL CITRATE** | | | | | | |
| **AP** | | AUROBINDO PHARMA LTD | **EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)** | **A203988** | **001** | Apr 01, 2015 |
| TABLET;ORAL | | | | | | |
| **REVATIO** | | | | | | |
| **AB** | **+!** | PFIZER | **EQ 20MG BASE** | **N021845** | **001** | Jun 03, 2005 |
| **SILDENAFIL CITRATE** | | | | | | |
| **AB** | | AMNEAL PHARMS | **EQ 20MG BASE** | **A202025** | **001** | Feb 28, 2013 |
| **AB** | | APOTEX CORP | **EQ 20MG BASE** | **A091379** | **001** | Nov 06, 2012 |
| **AB** | | AUROBINDO PHARMA LTD | **EQ 20MG BASE** | **A203963** | **001** | Nov 18, 2015 |
| **AB** | | DR REDDYS LABS LTD | **EQ 20MG BASE** | **A202598** | **001** | Nov 06, 2012 |
| **AB** | | HETERO LABS LTD V | **EQ 20MG BASE** | **A203623** | **001** | Nov 26, 2014 |
| **AB** | | MACLEODS PHARMS LTD | **EQ 20MG BASE** | **A203814** | **001** | Dec 17, 2013 |
| **AB** | | MYLAN PHARMS INC | **EQ 20MG BASE** | **A201150** | **001** | Nov 09, 2012 |
| **AB** | | RUBICON RES PVT LTD | **EQ 20MG BASE** | **A204883** | **001** | Jun 20, 2016 |
| **AB** | | TEVA | **EQ 25MG BASE** | **A077342** | **001** | Mar 09, 2016 |
| **AB** | | | **EQ 50MG BASE** | **A077342** | **002** | Mar 09, 2016 |
| **AB** | | | **EQ 100MG BASE** | **A077342** | **003** | Mar 09, 2016 |
| **AB** | | TEVA PHARMS | **EQ 20MG BASE** | **A078380** | **001** | Jan 07, 2013 |
| **AB** | | TORRENT PHARMS LTD | **EQ 20MG BASE** | **A091479** | **001** | Nov 06, 2012 |
| **AB** | | WATSON LABS INC | **EQ 20MG BASE** | **A202503** | **001** | Nov 06, 2012 |
| **VIAGRA** | | | | | | |
| **AB** | **+** | PFIZER INC | **EQ 25MG BASE** | **N020895** | **001** | Mar 27, 1998 |
| **AB** | **+** | | **EQ 50MG BASE** | **N020895** | **002** | Mar 27, 1998 |
| **AB** | **+!** | | **EQ 100MG BASE** | **N020895** | **003** | Mar 27, 1998 |

SILODOSIN

CAPSULE;ORAL

**RAPAFLO**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | ALLERGAN SALES LLC | **4MG** | **N022206** | **001** | Oct 08, 2008 |
| **AB** | **+** | | **8MG** | **N022206** | **002** | Oct 08, 2008 |

**SILODOSIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | SANDOZ INC | **4MG** | **A204726** | **001** | Mar 31, 2017 |
| **AB** | | | **8MG** | **A204726** | **002** | Mar 31, 2017 |

SILVER SULFADIAZINE

CREAM;TOPICAL

**SILVADENE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | KING PHARMS LLC | **1%** | **N017381** | **001** | |

**SSD**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | DR REDDYS LA | **1%** | **N018578** | **001** | Feb 25, 1982 |

**THERMAZENE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | THEPHARMANETWORK LLC | **1%** | **N018810** | **001** | Dec 23, 1985 |

SSD AF

| | | | | | | |
|---|---|---|---|---|---|---|
| BX | | DR REDDYS LA | 1% | N018578 | 003 | Jul 11, 1990 |

SIMEPREVIR SODIUM

CAPSULE;ORAL

OLYSIO

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | JANSSEN PRODS | EQ 150MG BASE | N205123 | 001 | Nov 22, 2013 |

SIMVASTATIN

SUSPENSION;ORAL

FLOLIPID

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | TCG FLUENT PHARMA | 20MG/5ML | N206679 | 001 | Apr 21, 2016 |
| | +! | | 40MG/5ML | N206679 | 002 | Apr 21, 2016 |

TABLET;ORAL

**SIMVASTATIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACCORD HLTHCARE | **5MG** | **A078155** | **005** | Apr 05, 2013 |
| **AB** | | | **10MG** | **A078155** | **002** | Feb 26, 2008 |
| **AB** | | | **20MG** | **A078155** | **003** | Feb 26, 2008 |
| **AB** | | | **40MG** | **A078155** | **004** | Feb 26, 2008 |
| **AB** | | | **80MG** | **A078155** | **001** | Feb 26, 2008 |
| **AB** | | AUROBINDO PHARMA | **5MG** | **A077691** | **001** | Dec 20, 2006 |
| **AB** | | | **10MG** | **A077691** | **002** | Dec 20, 2006 |
| **AB** | | | **20MG** | **A077691** | **003** | Dec 20, 2006 |
| **AB** | | | **40MG** | **A077691** | **004** | Dec 20, 2006 |
| **AB** | | | **80MG** | **A077691** | **005** | Dec 20, 2006 |
| **AB** | | BIOCON LIMITED | **5MG** | **A078034** | **001** | Dec 20, 2006 |
| **AB** | | | **10MG** | **A078034** | **002** | Dec 20, 2006 |
| **AB** | | | **20MG** | **A078034** | **003** | Dec 20, 2006 |
| **AB** | | | **40MG** | **A078034** | **004** | Dec 20, 2006 |
| **AB** | | | **80MG** | **A078034** | **005** | Dec 20, 2006 |
| **AB** | | DR REDDYS LABS INC | **5MG** | **A077752** | **005** | Jan 23, 2008 |
| **AB** | | | **10MG** | **A077752** | **001** | Dec 20, 2006 |
| **AB** | | | **20MG** | **A077752** | **002** | Dec 20, 2006 |
| **AB** | | | **40MG** | **A077752** | **003** | Dec 20, 2006 |
| **AB** | | | **80MG** | **A077752** | **004** | Dec 20, 2006 |
| **AB** | | HETERO LABS LTD III | **5MG** | **A200895** | **001** | Nov 25, 2014 |
| **AB** | | | **10MG** | **A200895** | **002** | Nov 25, 2014 |
| **AB** | | | **20MG** | **A200895** | **003** | Nov 25, 2014 |
| **AB** | | | **40MG** | **A200895** | **004** | Nov 25, 2014 |
| **AB** | | | **80MG** | **A200895** | **005** | Nov 25, 2014 |
| **AB** | | HISUN PHARM HANGZHOU | **10MG** | **A206557** | **001** | Nov 13, 2017 |
| **AB** | | | **20MG** | **A206557** | **002** | Nov 13, 2017 |
| **AB** | | | **40MG** | **A206557** | **003** | Nov 13, 2017 |
| **AB** | | | **80MG** | **A206557** | **004** | Nov 13, 2017 |
| **AB** | | IVAX SUB TEVA PHARMS | **5MG** | **A076052** | **001** | Jun 23, 2006 |
| **AB** | | | **10MG** | **A076052** | **002** | Jun 23, 2006 |
| **AB** | | | **20MG** | **A076052** | **003** | Jun 23, 2006 |
| **AB** | | | **40MG** | **A076052** | **004** | Jun 23, 2006 |
| **AB** | | | **80MG** | **A076052** | **005** | Dec 20, 2006 |
| **AB** | | LUPIN | **5MG** | **A078103** | **005** | Apr 14, 2009 |
| **AB** | | | **10MG** | **A078103** | **001** | May 11, 2007 |
| **AB** | | | **20MG** | **A078103** | **002** | May 11, 2007 |
| **AB** | | | **40MG** | **A078103** | **003** | May 11, 2007 |
| **AB** | | | **80MG** | **A078103** | **004** | May 11, 2007 |

| | | | | | | |
|---|---|---|---|---|---|---|
| SIMVASTATIN | | | | | | |
| TABLET;ORAL | | | | | | |
| **SIMVASTATIN** | | | | | | |
| **AB** | | OXFORD PHARMS | **5MG** | **A078735** | **001** | Aug 30, 2010 |
| **AB** | | | **10MG** | **A078735** | **002** | Aug 30, 2010 |
| **AB** | | | **20MG** | **A078735** | **003** | Aug 30, 2010 |
| **AB** | | | **40MG** | **A078735** | **004** | Aug 30, 2010 |
| **AB** | | | **80MG** | **A078735** | **005** | Aug 30, 2010 |
| **AB** | | VIVA HLTHCARE | **5MG** | **A090383** | **001** | Sep 16, 2011 |
| **AB** | | | **10MG** | **A090383** | **002** | Sep 16, 2011 |
| **AB** | | | **20MG** | **A090383** | **003** | Sep 16, 2011 |
| **AB** | | | **40MG** | **A090383** | **004** | Sep 16, 2011 |
| **AB** | | | **80MG** | **A090383** | **005** | Sep 16, 2011 |
| **AB** | | WATSON LABS TEVA | **5MG** | **A076685** | **001** | Dec 20, 2006 |
| **AB** | | | **10MG** | **A076685** | **002** | Dec 20, 2006 |
| **AB** | | | **20MG** | **A076685** | **003** | Dec 20, 2006 |
| **AB** | | | **40MG** | **A076685** | **004** | Dec 20, 2006 |
| **AB** | | | **80MG** | **A076685** | **005** | Dec 20, 2006 |
| **AB** | | ZYDUS PHARMS USA | **5MG** | **A077837** | **001** | Dec 20, 2006 |
| **AB** | | | **10MG** | **A077837** | **002** | Dec 20, 2006 |
| **AB** | | | **20MG** | **A077837** | **003** | Dec 20, 2006 |
| **AB** | | | **40MG** | **A077837** | **004** | Dec 20, 2006 |
| **AB** | | | **80MG** | **A077837** | **005** | Dec 20, 2006 |
| **ZOCOR** | | | | | | |
| **AB** | + | MSD MERCK CO | **5MG** | **N019766** | **001** | Dec 23, 1991 |
| **AB** | + | | **10MG** | **N019766** | **002** | Dec 23, 1991 |
| **AB** | + | | **20MG** | **N019766** | **003** | Dec 23, 1991 |
| **AB** | + | | **40MG** | **N019766** | **004** | Dec 23, 1991 |
| **AB** | +! | | **80MG** | **N019766** | **005** | Jul 10, 1998 |
| SINCALIDE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| KINEVAC | | | | | | |
| | +! | BRACCO | 0.005MG/VIAL | N017697 | 001 | |
| SINECATECHINS | | | | | | |
| OINTMENT;TOPICAL | | | | | | |
| VEREGEN | | | | | | |
| | +! | MEDIGENE AG | 15% | N021902 | 001 | Oct 31, 2006 |
| SIROLIMUS | | | | | | |
| SOLUTION;ORAL | | | | | | |
| RAPAMUNE | | | | | | |
| | +! | PF PRISM CV | 1MG/ML | N021083 | 001 | Sep 15, 1999 |
| TABLET;ORAL | | | | | | |
| **RAPAMUNE** | | | | | | |
| **AB** | + | PF PRISM CV | **0.5MG** | **N021110** | **004** | Jan 25, 2010 |
| **AB** | + | | **1MG** | **N021110** | **001** | Aug 25, 2000 |
| **AB** | +! | | **2MG** | **N021110** | **002** | Aug 22, 2002 |
| **SIROLIMUS** | | | | | | |
| **AB** | | DR REDDYS LABS LTD | **1MG** | **A201578** | **001** | Oct 27, 2014 |
| **AB** | | | **2MG** | **A201578** | **002** | Oct 27, 2014 |
| **AB** | | ZYDUS PHARMS USA INC | **0.5MG** | **A201676** | **003** | Jan 08, 2014 |
| SITAGLIPTIN PHOSPHATE | | | | | | |
| TABLET;ORAL | | | | | | |
| JANUVIA | | | | | | |
| | + | MERCK SHARP DOHME | EQ 25MG BASE | N021995 | 001 | Oct 16, 2006 |
| | + | | EQ 50MG BASE | N021995 | 002 | Oct 16, 2006 |
| | +! | | EQ 100MG BASE | N021995 | 003 | Oct 16, 2006 |
| SODIUM ACETATE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| SODIUM ACETATE | | | | | | |
| | | FRESENIUS KABI USA | 4MEQ/ML | A206687 | 001 | Oct 30, 2017 |
| | +! | HOSPIRA | 2MEQ/ML | N018893 | 001 | May 04, 1983 |
| SODIUM BENZOATE; SODIUM PHENYLACETATE | | | | | | |
| SOLUTION;IV (INFUSION) | | | | | | |
| **AMMONUL** | | | | | | |
| **AP** | +! | MEDICIS | **10%;10% (5GM/50ML;5GM/50ML)** | **N020645** | **001** | Feb 17, 2005 |
| **SODIUM PHENYLACETATE AND SODIUM BENZOATE** | | | | | | |
| **AP** | | AILEX PHARMS LLC | **10%;10% (5GM/50ML;5GM/50ML)** | **A207096** | **001** | Feb 24, 2016 |
| **AP** | | MAIA PHARMS INC | **10%;10% (5GM/50ML;5GM/50ML)** | **A208521** | **001** | May 08, 2017 |
| **AP** | | NAVINTA LLC | **10%;10% (5GM/50ML;5GM/50ML)** | **A205880** | **001** | Aug 04, 2016 |

SODIUM BICARBONATE

INJECTABLE;INJECTION

**SODIUM BICARBONATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **!** | HOSPIRA | **0.9MEQ/ML** | **A077394** | **001** | Nov 09, 2005 |
| **AP** | **!** | | **1MEQ/ML** | **A077394** | **002** | Nov 09, 2005 |
| **AP** | | HOSPIRA INC | **0.9MEQ/ML** | **A202494** | **001** | Mar 06, 2017 |
| **AP** | | | **1MEQ/ML** | **A202432** | **001** | Sep 26, 2017 |
| **AP** | | | **1MEQ/ML** | **A202494** | **002** | Mar 06, 2017 |
| **AP** | | INTL MEDICATION SYS | **1MEQ/ML** | **A203449** | **001** | Sep 19, 2017 |
| | | HOSPIRA INC | 0.5MEQ/ML | A202679 | 001 | Mar 07, 2017 |
| | | | 0.5MEQ/ML | A202981 | 001 | Mar 04, 2016 |
| | | | 1MEQ/ML | A202495 | 001 | Mar 06, 2017 |

SODIUM CHLORIDE

INJECTABLE;INJECTION

**BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | FRESENIUS KABI USA | **9MG/ML** | **A088911** | **001** | Feb 07, 1985 |
| **AP** | **+!** | HOSPIRA | **9MG/ML** | **N018800** | **001** | Oct 29, 1982 |

**SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+** | B BRAUN | **450MG/100ML** | **N019635** | **001** | Mar 09, 1988 |
| **AP** | | BAXTER HLTHCARE | **450MG/100ML** | **N018016** | **001** | |
| **AP** | | HOSPIRA | **450MG/100ML** | **N019759** | **001** | Jun 08, 1988 |
| **AP** | **+!** | ICU MEDICAL INC | **450MG/100ML** | **N018090** | **001** | |

**SODIUM CHLORIDE 0.9%**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | SPECTRA MDCL DEVICES | **9MG/ML** | **A206171** | **001** | Jul 21, 2017 |
| **AP** | | WEST-WARD PHARMS INT | **9MG/ML** | **A201850** | **001** | Jan 20, 2012 |

**SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | B BRAUN | **900MG/100ML** | **N017464** | **001** | |
| **AP** | **+!** | | **900MG/100ML** | **N019635** | **002** | Mar 09, 1988 |
| **AP** | **+!** | BAXTER HLTHCARE | **9MG/ML** | **N016677** | **004** | Oct 30, 1985 |
| **AP** | **+** | | **9MG/ML** | **N020178** | **002** | Dec 07, 1992 |
| **AP** | **+!** | | **900MG/100ML** | **N016677** | **001** | |
| **AP** | **+!** | | **900MG/100ML** | **N020178** | **001** | Dec 07, 1992 |
| **AP** | **!** | FRESENIUS KABI USA | **9MG/ML** | **A088912** | **001** | Jan 10, 1985 |
| **AP** | | | **900MG/100ML** | **A207310** | **001** | Sep 19, 2017 |
| **AP** | | FRESENIUS MEDCL | **900MG/100ML** | **A078177** | **001** | Apr 12, 2007 |
| **AP** | | HAEMONETICS | **900MG/100ML** | **A076316** | **001** | Oct 27, 2004 |
| **AP** | **+!** | HOSPIRA | **9MG/ML** | **N018803** | **001** | Oct 29, 1982 |
| **AP** | **+!** | | **9MG/ML** | **N019217** | **001** | Jul 13, 1984 |
| **AP** | **+** | | **9MG/ML** | **N019465** | **002** | Jul 15, 1985 |
| **AP** | **+!** | | **900MG/100ML** | **N019465** | **001** | Jul 15, 1985 |
| **AP** | **+!** | | **900MG/100ML** | **N019480** | **001** | Sep 17, 1985 |
| **AP** | **+!** | ICU MEDICAL INC | **900MG/100ML** | **N016366** | **001** | |
| **AP** | | JUBILANT HOLLISTRSTR | **9MG/ML** | **A203352** | **001** | May 18, 2016 |
| **AP** | | LABORATORIOS GRIFOLS | **900MG/100ML** | **A207956** | **001** | May 25, 2017 |
| **AP** | **!** | TARO | **9MG/ML** | **A077407** | **001** | Aug 11, 2006 |

**SODIUM CHLORIDE 3% IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | B BRAUN | **3GM/100ML** | **N019635** | **003** | Mar 09, 1988 |
| **AP** | **+!** | BAXTER HLTHCARE | **3GM/100ML** | **N019022** | **001** | Nov 01, 1983 |

**SODIUM CHLORIDE 5% IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | B BRAUN | **5GM/100ML** | **N019635** | **004** | Mar 09, 1988 |
| **AP** | **+** | BAXTER HLTHCARE | **5GM/100ML** | **N019022** | **002** | Nov 01, 1983 |

SODIUM CHLORIDE 0.9%

| | | | | | | |
|---|---|---|---|---|---|---|
| | **+** | B BRAUN | 900MG/10ML | N019635 | 005 | Aug 11, 2016 |
| | | MEDEFIL INC | 90MG/10ML (9MG/ML) | N202832 | 006 | Jan 06, 2012 |

SODIUM CHLORIDE 0.9%

| | | | | | | |
|---|---|---|---|---|---|---|
| | | WEST-WARD PHARMS INT | 9MG/ML | A201833 | 001 | Sep 24, 2013 |

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

| | | | | | | |
|---|---|---|---|---|---|---|
| | **+!** | LIEBEL-FLARSHEIM | 405MG/50ML (9MG/ML) | N021569 | 001 | Jul 27, 2006 |
| | **+** | | 1012.5MG/125ML (9MG/ML) | N021569 | 002 | Jul 27, 2006 |

SODIUM CHLORIDE IN PLASTIC CONTAINER

| | | | | | | |
|---|---|---|---|---|---|---|
| | **+** | HOSPIRA | 2.5MEQ/ML | N018897 | 001 | Jul 20, 1984 |

SOLUTION;IRRIGATION

**SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | B BRAUN | **900MG/100ML** | **N016733** | **001** | |
| **AT** | | BAXTER HLTHCARE | **900MG/100ML** | **N017427** | **001** | |
| **AT** | | | **900MG/100ML** | **N017867** | **001** | |
| **AT** | | ICU MEDICAL INC | **900MG/100ML** | **N017514** | **001** | |
| **AT** | | | **900MG/100ML** | **N018314** | **001** | |

SODIUM CHLORIDE

SOLUTION FOR SLUSH;IRRIGATION

SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER

| | | | | | | |
|---|---|---|---|---|---|---|
| | | BAXTER HLTHCARE | 900MG/100ML | N019319 | 002 | May 17, 1985 |

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE;INJECTION

**FERRLECIT**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | SANOFI AVENTIS US | **62.5MG/5ML** | **N020955** | **001** | Feb 18, 1999 |

**SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | WEST-WARD PHARMS INT | **62.5MG/5ML** | **A078215** | **001** | Mar 31, 2011 |

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS

**SODIUM FLUORIDE F-18**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | 3D IMAGING DRUG | **10-200mCi/ML** | **A203777** | **001** | Oct 19, 2015 |
| **AP** | | BIOMEDCL RES FDN | **10-200mCi/ML** | **A204351** | **001** | Jan 09, 2015 |
| **AP** | | CARDINAL HEALTH 414 | **10-200mCi/ML** | **A203780** | **001** | Jul 30, 2015 |
| **AP** | | ESSENTIAL ISOTOPES | **10-200mCi/ML** | **A204541** | **001** | Oct 29, 2014 |
| **AP** | | GLOBAL ISOTOPES LLC | **10-200mCi/ML** | **A204464** | **001** | Oct 21, 2014 |
| **AP** | | HOT SHOTS NM LLC | **10-200mCi/ML** | **A204530** | **001** | Jul 29, 2015 |
| **AP** | **!** | HOUSTON CYCLOTRON | **10-200mCi/ML** | **A203544** | **001** | Dec 26, 2012 |
| **AP** | | JUBILANT DRAXIMAGE | **10-200mCi/ML** | **A203968** | **001** | Oct 23, 2015 |
| **AP** | | KREITCHMAN PET CTR | **10-200mCi/ML** | **A203936** | **001** | May 19, 2016 |
| **AP** | | MIDWEST MEDCL | **10-200mCi/ML** | **A204440** | **001** | Nov 17, 2015 |
| **AP** | | MIPS CRF | **10-200mCi/ML** | **A204517** | **001** | Jul 21, 2015 |
| **AP** | | NCM USA BRONX LLC | **10-200mCi/ML** | **A204513** | **001** | Nov 28, 2014 |
| **AP** | | PETNET | **10-200mCi/ML** | **A203890** | **001** | Sep 28, 2015 |
| **AP** | | PRECISION NUCLEAR | **10-200mCi/ML** | **A204542** | **001** | Feb 27, 2015 |
| **AP** | | SHERTECH LABS LLC | **10-200mCi/ML** | **A204315** | **001** | Sep 22, 2014 |
| **AP** | | SPECTRON MRC LLC | **10-200mCi/ML** | **A203912** | **001** | Apr 22, 2015 |
| **AP** | | UCSF RODIOPHARM | **10-200mCi/ML** | **A204437** | **001** | Mar 13, 2014 |
| **AP** | | UNIV TX MD ANDERSON | **10-200mCi/ML** | **A203247** | **001** | Dec 23, 2013 |
| **AP** | | UNIV UTAH CYCLOTRON | **10-200mCi/ML** | **A204497** | **001** | Apr 20, 2015 |
| **AP** | | ZEVACOR PHARMA INC | **10-200mCi/ML** | **A203592** | **001** | Aug 18, 2015 |
| | ! | MCPRF | 10-91.5mCi/ML | A203605 | 001 | Jun 28, 2013 |
| | | THE FEINSTEIN INST | 20-600mCi/ML | A204328 | 001 | Nov 19, 2014 |

SODIUM IODIDE I-123

CAPSULE;ORAL

**SODIUM IODIDE I 123**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **+!** | CARDINAL HEALTH 418 | **100uCi** | **N018671** | **001** | May 27, 1982 |
| **AA** | **+!** | | **200uCi** | **N018671** | **002** | May 27, 1982 |
| **AA** | | MALLINKRODT NUCLEAR | **100uCi** | **A071909** | **001** | Feb 28, 1989 |
| **AA** | | | **200uCi** | **A071910** | **001** | Feb 28, 1989 |

SODIUM IODIDE I-131

CAPSULE;ORAL

SODIUM IODIDE I 131

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | JUBILANT DRAXIMAGE | 0.009-0.1mCi | N021305 | 006 | May 19, 2005 |
| | +! | MALLINKRODT NUCLEAR | 0.8-100mCi | N016517 | 001 | |

SOLUTION;ORAL

HICON

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | JUBILANT DRAXIMAGE | 250-1000mCi | N021305 | 007 | Dec 05, 2011 |

SODIUM IODIDE I 131

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | MALLINKRODT NUCLEAR | 3.5-150mCi/VIAL | N016515 | 001 | |

SODIUM LACTATE

INJECTABLE;INJECTION

SODIUM LACTATE IN PLASTIC CONTAINER

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | HOSPIRA | 5MEQ/ML | N018947 | 001 | Sep 05, 1984 |

SODIUM NITRITE

SOLUTION;INTRAVENOUS

SODIUM NITRITE

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | HOPE PHARMS | 300MG/10ML (30MG/ML) | N203922 | 001 | Feb 14, 2012 |

SODIUM NITRITE; SODIUM THIOSULFATE

SOLUTION, SOLUTION;INTRAVENOUS, INTRAVENOUS

NITHIODOTE

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | HOPE PHARMS | 300MG/10ML(30MG/ML),N/A;N/A,12.5GM/50ML (250MG/ML) | N201444 | 001 | Jan 14, 2011 |

SODIUM NITROPRUSSIDE

INJECTABLE;INJECTION

**NITROPRESS**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **!** | HOSPIRA | **25MG/ML** | **A071961** | **001** | Aug 01, 1988 |

**SODIUM NITROPRUSSIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AKORN | **25MG/ML** | **A208635** | **001** | May 04, 2017 |
| **AP** | | AMNEAL PHARMS CO | **25MG/ML** | **A209493** | **001** | Nov 07, 2017 |
| **AP** | | AMPHASTAR PHARMS INC | **25MG/ML** | **A209832** | **001** | Dec 18, 2017 |
| **AP** | | MICRO LABS | **25MG/ML** | **A209352** | **001** | Dec 08, 2017 |
| **AP** | | NAMIGEN LLC | **25MG/ML** | **A207426** | **001** | Dec 08, 2016 |
| **AP** | | NEXUS PHARMS | **25MG/ML** | **A207499** | **001** | May 25, 2017 |

SOLUTION;IV (INFUSION)

NIPRIDE RTU IN SODIUM CHLORIDE 0.9%

| | | | | | |
|---|---|---|---|---|---|
| +! | EXELA PHARMA SCS LLC | 10MG/50ML (0.2MG/ML) | N209387 | 002 | Dec 07, 2017 |
| +! | | 50MG/100ML (0.5MG/ML) | N209387 | 001 | Mar 08, 2017 |

SODIUM OXYBATE

SOLUTION;ORAL

**SODIUM OXYBATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | WEST-WARD PHARMS INT | **500MG/ML** | **A202090** | **001** | Jan 17, 2017 |

**XYREM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **+!** | JAZZ PHARMS | **500MG/ML** | **N021196** | **001** | Jul 17, 2002 |

SODIUM PHENYLBUTYRATE

POWDER;ORAL

**BUPHENYL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | HORIZON PHARMA INC | **3GM/TEASPOONFUL** | **N020573** | **001** | Apr 30, 1996 |

**SODIUM PHENYLBUTYRATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | PAR PHARM | **3GM/TEASPOONFUL** | **A203918** | **001** | Jun 15, 2016 |
| **AB** | | SIGMAPHARM LABS LLC | **3GM/TEASPOONFUL** | **A202819** | **001** | Mar 22, 2013 |

TABLET;ORAL

**BUPHENYL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | HORIZON PHARMA INC | **500MG** | **N020572** | **001** | May 13, 1996 |

**SODIUM PHENYLBUTYRATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALVOGEN MALTA | **500MG** | **A090910** | **001** | Nov 18, 2011 |
| **AB** | | PAR PHARM | **500MG** | **A204395** | **001** | Apr 15, 2016 |

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET;ORAL

OSMOPREP

| | | | | | |
|---|---|---|---|---|---|
| +! | SALIX PHARMS | 0.398GM;1.102GM | N021892 | 001 | Mar 16, 2006 |

SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE; SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS

INJECTABLE;INJECTION

SODIUM PHOSPHATES IN PLASTIC CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| +! | HOSPIRA | 142MG/ML;276MG/ML | N018892 | 001 | May 10, 1983 |

SODIUM POLYSTYRENE SULFONATE

POWDER;ORAL, RECTAL

**KALEXATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **!** | KVK TECH | **454GM/BOT** | **A040905** | **001** | Mar 30, 2009 |

**KIONEX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | PADDOCK LLC | **454GM/BOT** | **A040029** | **001** | Feb 06, 1998 |

**SODIUM POLYSTYRENE SULFONATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | AILEX PHARMS LLC | **454GM/BOT** | **A206815** | **001** | Feb 18, 2016 |
| **AA** | | BELCHER PHARMS LLC | **454GM/BOT** | **A205727** | **001** | Feb 23, 2016 |
| **AA** | | CMP PHARMA INC | **454GM/BOT** | **A089910** | **001** | Jan 19, 1989 |
| **AA** | | ECI PHARMS LLC | **453.6GM/BOT** | **A090313** | **001** | Dec 21, 2011 |
| **AA** | | EPIC PHARMA LLC | **453.6GM/BOT** | **A202333** | **001** | Mar 19, 2014 |
| **AA** | | NUVO PHARM INC | **454GM/BOT** | **A204071** | **001** | Nov 28, 2014 |

KALEXATE

| | | | | | |
|---|---|---|---|---|---|
| | KVK TECH | 15GM/BOT | A040905 | 002 | Apr 03, 2015 |

SODIUM POLYSTYRENE SULFONATE

| | | | | | |
|---|---|---|---|---|---|
| | NUVO PHARM INC | 15GM/BOT | A204071 | 002 | Nov 28, 2014 |

SUSPENSION;ORAL, RECTAL

**KIONEX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | PADDOCK LLC | **15GM/60ML** | **A040028** | **001** | Sep 17, 2007 |

**SODIUM POLYSTYRENE SULFONATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | PADDOCK LLC | **15GM/60ML** | **A090590** | **001** | May 13, 2011 |
| **AA** | | WEST-WARD PHARMS INT | **15GM/60ML** | **A089049** | **001** | Nov 17, 1986 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| SODIUM POLYSTYRENE SULFONATE | | | | | | | |
| SUSPENSION;ORAL, RECTAL | | | | | | | |
| **SPS** | | | | | | | |
| **AA** | **!** | CMP PHARMA INC | **15GM/60ML** | **A087859** | **001** | Dec 08, 1982 | |
| SODIUM TETRADECYL SULFATE | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| SOTRADECOL | | | | | | | |
| | ! | MYLAN INSTITUTIONAL | 20MG/2ML (10MG/ML) | A040541 | 001 | Nov 12, 2004 | |
| | ! | | 60MG/2ML (30MG/ML) | A040541 | 002 | Nov 12, 2004 | |
| SODIUM THIOSULFATE | | | | | | | |
| SOLUTION;INTRAVENOUS | | | | | | | |
| SODIUM THIOSULFATE | | | | | | | |
| | +! | HOPE PHARMS | 12.5GM/50ML (250MG/ML) | N203923 | 001 | Feb 14, 2012 | |
| SOFOSBUVIR | | | | | | | |
| TABLET;ORAL | | | | | | | |
| SOVALDI | | | | | | | |
| | +! | GILEAD SCIENCES INC | 400MG | N204671 | 001 | Dec 06, 2013 | |
| SOFOSBUVIR; VELPATASVIR | | | | | | | |
| TABLET;ORAL | | | | | | | |
| EPCLUSA | | | | | | | |
| | +! | GILEAD SCIENCES INC | 400MG;100MG | N208341 | 001 | Jun 28, 2016 | |
| SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR | | | | | | | |
| TABLET;ORAL | | | | | | | |
| VOSEVI | | | | | | | |
| | +! | GILEAD SCIENCES INC | 400MG;100MG;100MG | N209195 | 001 | Jul 18, 2017 | |
| SOLIFENACIN SUCCINATE | | | | | | | |
| TABLET;ORAL | | | | | | | |
| **SOLIFENACIN SUCCINATE** | | | | | | | |
| **AB** | | TEVA PHARMS USA | **5MG** | **A091464** | **001** | Apr 02, 2014 | |
| **AB** | | | **10MG** | **A091464** | **002** | Apr 02, 2014 | |
| **VESICARE** | | | | | | | |
| **AB** | **+** | ASTELLAS | **5MG** | **N021518** | **001** | Nov 19, 2004 | |
| **AB** | **+!** | | **10MG** | **N021518** | **002** | Nov 19, 2004 | |
| SOMATROPIN RECOMBINANT | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| GENOTROPIN | | | | | | | |
| BX | +! | PHARMACIA AND UPJOHN | 5.8MG/VIAL | N020280 | 006 | Aug 24, 1995 | |
| GENOTROPIN PRESERVATIVE FREE | | | | | | | |
| BX | + | PHARMACIA AND UPJOHN | 1.5MG/VIAL | N020280 | 004 | Aug 24, 1995 | |
| HUMATROPE | | | | | | | |
| BX | +! | LILLY | 5MG/VIAL | N019640 | 004 | Mar 08, 1987 | |
| BX | + | | 6MG/VIAL | N019640 | 005 | Feb 04, 1999 | |
| NORDITROPIN FLEXPRO | | | | | | | |
| BX | | NOVO NORDISK INC | 5MG/1.5ML | N021148 | 008 | Mar 01, 2010 | |
| BX | | | 10MG/1.5ML | N021148 | 009 | Mar 01, 2010 | |
| OMNITROPE | | | | | | | |
| BX | | SANDOZ | 1.5MG/VIAL | N021426 | 002 | May 30, 2006 | |
| BX | | | 5MG/1.5ML | N021426 | 003 | Jan 16, 2008 | |
| BX | | | 5.8MG/VIAL | N021426 | 001 | May 30, 2006 | |
| BX | | | 10MG/1.5ML | N021426 | 004 | Aug 25, 2008 | |
| SAIZEN | | | | | | | |
| BX | + | EMD SERONO | 5MG/VIAL | N019764 | 002 | Oct 08, 1996 | |
| SEROSTIM | | | | | | | |
| BX | | EMD SERONO | 5MG/VIAL | N020604 | 002 | Aug 23, 1996 | |
| BX | | | 6MG/VIAL | N020604 | 001 | Aug 23, 1996 | |
| VALTROPIN | | | | | | | |
| BX | | LG CHEM LTD | 5MG/VIAL | N021905 | 001 | Apr 19, 2007 | |
| ZOMACTON | | | | | | | |
| BX | +! | FERRING | 5MG/VIAL | N019774 | 002 | Jan 04, 2002 | |
| GENOTROPIN | | | | | | | |
| | +! | PHARMACIA AND UPJOHN | 13.8MG/VIAL | N020280 | 007 | Oct 23, 1996 | |
| GENOTROPIN PRESERVATIVE FREE | | | | | | | |
| | + | PHARMACIA AND UPJOHN | 0.2MG/VIAL | N020280 | 001 | Jan 27, 1998 | |
| | + | | 0.4MG/VIAL | N020280 | 002 | Jan 27, 1998 | |
| | + | | 0.6MG/VIAL | N020280 | 003 | Jan 27, 1998 | |
| | + | | 0.8MG/VIAL | N020280 | 005 | Jan 27, 1998 | |

| | | | | | | |
|---|---|---|---|---|---|---|
| SOMATROPIN RECOMBINANT | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| GENOTROPIN PRESERVATIVE FREE | | | | | | |
| + | | 1MG/VIAL | N020280 | 008 | Jan 27, 1998 |
| + | | 1.2MG/VIAL | N020280 | 009 | Jan 27, 1998 |
| + | | 1.4MG/VIAL | N020280 | 010 | Jan 27, 1998 |
| + | | 1.6MG/VIAL | N020280 | 011 | Jan 27, 1998 |
| + | | 1.8MG/VIAL | N020280 | 012 | Jan 27, 1998 |
| +! | | 2MG/VIAL | N020280 | 013 | Jan 27, 1998 |
| HUMATROPE | | | | | | |
| +! | LILLY | 12MG/VIAL | N019640 | 006 | Feb 04, 1999 |
| +! | | 24MG/VIAL | N019640 | 007 | Feb 04, 1999 |
| NORDITROPIN FLEXPRO | | | | | | |
| | NOVO NORDISK INC | 15MG/1.5ML | N021148 | 010 | Mar 01, 2010 |
| | | 30MG/3ML | N021148 | 011 | Jan 23, 2015 |
| NUTROPIN AQ NUSPIN | | | | | | |
| +! | GENENTECH | 5MG/2ML (2.5MG/ML) | N020522 | 003 | Jan 03, 2008 |
| +! | | 10MG/2ML (5MG/ML) | N020522 | 005 | Jan 03, 2008 |
| +! | | 20MG/2ML (10MG/ML) | N020522 | 004 | Jan 03, 2008 |
| NUTROPIN AQ PEN | | | | | | |
| +! | GENENTECH | 10MG/2ML (5MG/ML) | N020522 | 002 | Apr 22, 2002 |
| +! | | 20MG/2ML (10MG/ML) | N020522 | 006 | Jan 03, 2008 |
| SAIZEN | | | | | | |
| +! | EMD SERONO | 8.8MG/VIAL | N019764 | 003 | Aug 29, 2000 |
| SEROSTIM | | | | | | |
| | EMD SERONO | 4MG/VIAL | N020604 | 003 | Jul 25, 1997 |
| ZOMACTON | | | | | | |
| + | FERRING | 10MG/VIAL | N019774 | 003 | Mar 07, 2012 |
| ZORBTIVE | | | | | | |
| +! | EMD SERONO | 8.8MG/VIAL | N021597 | 004 | Dec 01, 2003 |
| SONIDEGIB PHOSPHATE | | | | | | |
| CAPSULE;ORAL | | | | | | |
| ODOMZO | | | | | | |
| +! | SUN PHARMA GLOBAL | EQ 200MG BASE | N205266 | 001 | Jul 24, 2015 |
| SORAFENIB TOSYLATE | | | | | | |
| TABLET;ORAL | | | | | | |
| NEXAVAR | | | | | | |
| +! | BAYER HLTHCARE | EQ 200MG BASE | N021923 | 001 | Dec 20, 2005 |
| SORBITOL | | | | | | |
| SOLUTION;IRRIGATION | | | | | | |
| SORBITOL 3% IN PLASTIC CONTAINER | | | | | | |
| | BAXTER HLTHCARE | 3GM/100ML | N017863 | 001 | | |
| SORBITOL 3.3% IN PLASTIC CONTAINER | | | | | | |
| | B BRAUN | 3.3GM/100ML | N016741 | 001 | | |
| SOTALOL HYDROCHLORIDE | | | | | | |
| SOLUTION;INTRAVENOUS | | | | | | |
| SOTALOL HYDROCHLORIDE | | | | | | |
| +! | ALTATHERA PHARMS LLC | 150MG/10ML (15MG/ML) | N022306 | 001 | Jul 02, 2009 |
| SOLUTION;ORAL | | | | | | |
| SOTYLIZE | | | | | | |
| +! | ARBOR PHARMS LLC | 5MG/ML (5MG/ML) | N205108 | 001 | Oct 22, 2014 |
| TABLET;ORAL | | | | | | |
| **BETAPACE** | | | | | | |
| **AB1** + | COVIS PHARMA BV | **80MG** | **N019865** | **001** | Oct 30, 1992 |
| **AB1** + | | **120MG** | **N019865** | **005** | Apr 20, 1994 |
| **AB1** +! | | **160MG** | **N019865** | **002** | Oct 30, 1992 |
| **AB1** + | | **240MG** | **N019865** | **003** | Oct 30, 1992 |
| **SORINE** | | | | | | |
| **AB1** | UPSHER-SMITH LABS | **80MG** | **A075500** | **001** | Apr 27, 2001 |
| **AB1** | | **120MG** | **A075500** | **004** | Apr 27, 2001 |
| **AB1** | | **160MG** | **A075500** | **002** | Apr 27, 2001 |
| **AB1** | | **240MG** | **A075500** | **003** | Apr 27, 2001 |
| **SOTALOL HYDROCHLORIDE** | | | | | | |
| **AB1** | APOTEX INC | **80MG** | **A076140** | **001** | Sep 26, 2002 |
| **AB1** | | **120MG** | **A076140** | **002** | Sep 26, 2002 |
| **AB1** | | **160MG** | **A076140** | **003** | Sep 26, 2002 |
| **AB1** | | **240MG** | **A076140** | **004** | Sep 26, 2002 |
| **AB1** | BEXIMCO PHARMS USA | **80MG** | **A207428** | **001** | Oct 21, 2016 |
| **AB1** | | **120MG** | **A207428** | **002** | Oct 21, 2016 |
| **AB1** | | **160MG** | **A207428** | **003** | Oct 21, 2016 |

SOTALOL HYDROCHLORIDE

TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **SOTALOL HYDROCHLORIDE** | | | | | | |
| **AB1** | | TEVA | **80MG** | **A075429** | **001** | May 01, 2000 |
| **AB1** | | | **120MG** | **A075429** | **002** | May 01, 2000 |
| **AB1** | | | **160MG** | **A075429** | **003** | May 01, 2000 |
| **AB1** | | | **240MG** | **A075429** | **004** | May 01, 2000 |
| **AB1** | | UPSHER-SMITH LABS | **80MG** | **A075366** | **001** | May 01, 2000 |
| **AB1** | | | **120MG** | **A075366** | **002** | May 01, 2000 |
| **AB1** | | | **160MG** | **A075366** | **003** | May 01, 2000 |
| **AB1** | | | **240MG** | **A075366** | **004** | May 01, 2000 |
| **AB1** | | VINTAGE PHARMS | **80MG** | **A075563** | **001** | Nov 07, 2003 |
| **AB1** | | | **120MG** | **A075563** | **002** | Nov 07, 2003 |
| **AB1** | | | **160MG** | **A075563** | **003** | Nov 07, 2003 |
| **AB1** | | | **240MG** | **A075563** | **004** | Nov 07, 2003 |
| **BETAPACE AF** | | | | | | |
| **AB2** | **+** | COVIS PHARMA BV | **80MG** | **N021151** | **001** | Feb 22, 2000 |
| **AB2** | **+** | | **120MG** | **N021151** | **002** | Feb 22, 2000 |
| **AB2** | **+!** | | **160MG** | **N021151** | **003** | Feb 22, 2000 |
| **SOTALOL HYDROCHLORIDE** | | | | | | |
| **AB2** | | APOTEX | **80MG** | **A076214** | **001** | Aug 27, 2003 |
| **AB2** | | | **120MG** | **A076214** | **002** | Aug 27, 2003 |
| **AB2** | | | **160MG** | **A076214** | **003** | Aug 27, 2003 |
| **AB2** | | EPIC PHARMA INC | **80MG** | **A077070** | **001** | Nov 04, 2005 |
| **AB2** | | | **120MG** | **A077070** | **002** | Nov 04, 2005 |
| **AB2** | | | **160MG** | **A077070** | **003** | Nov 04, 2005 |
| **AB2** | | MYLAN | **80MG** | **A077616** | **001** | Feb 07, 2007 |
| **AB2** | | | **120MG** | **A077616** | **002** | Feb 07, 2007 |
| **AB2** | | | **160MG** | **A077616** | **003** | Feb 07, 2007 |

SOYBEAN OIL

INJECTABLE;INJECTION

| | | | | | | |
|---|---|---|---|---|---|---|
| **INTRALIPID 10%** | | | | | | |
| **AP** | **+!** | FRESENIUS | **10%** | **N017643** | **001** | |
| **INTRALIPID 20%** | | | | | | |
| **AP** | **+!** | FRESENIUS | **20%** | **N018449** | **001** | |
| **AP** | **+!** | | **20%** | **N020248** | **001** | Aug 07, 1996 |
| **NUTRILIPID 10%** | | | | | | |
| **AP** | **+!** | B BRAUN | **10%** | **N019531** | **001** | May 28, 1993 |
| **NUTRILIPID 20%** | | | | | | |
| **AP** | **+!** | B BRAUN | **20%** | **N019531** | **002** | May 28, 1993 |
| INTRALIPID 30% | | | | | | |
| | +! | FRESENIUS | 30% | N019942 | 001 | Dec 30, 1993 |

SPINOSAD

SUSPENSION;TOPICAL

| | | | | | | |
|---|---|---|---|---|---|---|
| NATROBA | | | | | | |
| | +! | PARAPRO LLC | 0.9% | N022408 | 001 | Jan 18, 2011 |

SPIRONOLACTONE

SUSPENSION;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| CAROSPIR | | | | | | |
| | +! | CMP DEV LLC | 25MG/5ML | N209478 | 001 | Aug 04, 2017 |

TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **ALDACTONE** | | | | | | |
| **AB** | **+** | GD SEARLE LLC | **25MG** | **N012151** | **009** | Dec 30, 1983 |
| **AB** | **+** | | **50MG** | **N012151** | **008** | Dec 30, 1982 |
| **AB** | **+!** | | **100MG** | **N012151** | **010** | Dec 30, 1983 |
| **SPIRONOLACTONE** | | | | | | |
| **AB** | | ACCORD HLTHCARE | **25MG** | **A203512** | **001** | Sep 19, 2016 |
| **AB** | | | **50MG** | **A203512** | **002** | Sep 19, 2016 |
| **AB** | | | **100MG** | **A203512** | **003** | Sep 19, 2016 |
| **AB** | | ACTAVIS ELIZABETH | **25MG** | **A040353** | **003** | Mar 15, 2006 |
| **AB** | | | **50MG** | **A040353** | **001** | Jul 29, 1999 |
| **AB** | | | **100MG** | **A040353** | **002** | Jul 29, 1999 |
| **AB** | | AMNEAL PHARMS | **25MG** | **A091426** | **001** | Jul 02, 2010 |
| **AB** | | | **50MG** | **A091426** | **002** | Jul 02, 2010 |
| **AB** | | | **100MG** | **A091426** | **003** | Jul 02, 2010 |
| **AB** | | AUROBINDO PHARMA LTD | **25MG** | **A202187** | **001** | Mar 06, 2014 |
| **AB** | | | **50MG** | **A202187** | **002** | Mar 06, 2014 |
| **AB** | | | **100MG** | **A202187** | **003** | Mar 06, 2014 |
| **AB** | | JUBILANT GENERICS | **25MG** | **A203253** | **001** | Apr 23, 2014 |
| **AB** | | | **50MG** | **A203253** | **002** | Apr 23, 2014 |

SPIRONOLACTONE

TABLET;ORAL

**SPIRONOLACTONE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **100MG** | **A203253** | **003** | Apr 23, 2014 |
| **AB** | | MYLAN | **25MG** | **A040424** | **001** | Aug 20, 2001 |
| **AB** | | | **50MG** | **A040424** | **002** | Aug 20, 2001 |
| **AB** | | | **100MG** | **A040424** | **003** | Aug 20, 2001 |
| **AB** | | SANDOZ | **25MG** | **A086809** | **001** | |
| **AB** | | SUN PHARM INDUSTRIES | **25MG** | **A089424** | **001** | Jul 23, 1986 |
| **AB** | | | **50MG** | **A089424** | **002** | Aug 11, 1999 |
| **AB** | | | **100MG** | **A089424** | **003** | Aug 11, 1999 |
| **AB** | | VINTAGE | **25MG** | **A040750** | **001** | Aug 29, 2006 |
| **AB** | | | **50MG** | **A040750** | **002** | Aug 29, 2006 |
| **AB** | | | **100MG** | **A040750** | **003** | Aug 29, 2006 |

STAVUDINE

CAPSULE;ORAL

**STAVUDINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AUROBINDO PHARMA | **15MG** | **A077672** | **003** | Dec 29, 2008 |
| **AB** | | | **20MG** | **A077672** | **004** | Dec 29, 2008 |
| **AB** | | | **30MG** | **A077672** | **001** | Dec 29, 2008 |
| **AB** | | | **40MG** | **A077672** | **002** | Dec 29, 2008 |
| **AB** | | HETERO LABS LTD III | **15MG** | **A078957** | **001** | Dec 29, 2008 |
| **AB** | | | **20MG** | **A078957** | **002** | Dec 29, 2008 |
| **AB** | | | **30MG** | **A078957** | **003** | Dec 29, 2008 |
| **AB** | | | **40MG** | **A078957** | **004** | Dec 29, 2008 |
| **AB** | | MYLAN | **15MG** | **A079069** | **001** | Dec 29, 2008 |
| **AB** | | | **20MG** | **A079069** | **002** | Dec 29, 2008 |
| **AB** | | | **30MG** | **A079069** | **003** | Dec 29, 2008 |
| **AB** | | | **40MG** | **A079069** | **004** | Dec 29, 2008 |

**ZERIT**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | BRISTOL MYERS SQUIBB | **15MG** | **N020412** | **002** | Jun 24, 1994 |
| **AB** | + | | **20MG** | **N020412** | **003** | Jun 24, 1994 |
| **AB** | + | | **30MG** | **N020412** | **004** | Jun 24, 1994 |
| **AB** | +! | | **40MG** | **N020412** | **005** | Jun 24, 1994 |

FOR SOLUTION;ORAL

**STAVUDINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | CIPLA LTD | **1MG/ML** | **A078030** | **001** | Mar 20, 2009 |

**ZERIT**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | +! | BRISTOL MYERS SQUIBB | **1MG/ML** | **N020413** | **001** | Sep 06, 1996 |

STERILE WATER FOR INJECTION

LIQUID;N/A

**BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | +! | HOSPIRA | **100%** | **N018802** | **001** | Oct 27, 1982 |

**STERILE WATER FOR INJECTION**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | FRESENIUS KABI USA | **100%** | **A209689** | **001** | Nov 24, 2017 |
| **AP** | | WEST-WARD PHARMS INT | **100%** | **A206369** | **001** | Sep 02, 2015 |

**STERILE WATER FOR INJECTION IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | +! | B BRAUN | **100%** | **N019633** | **001** | Feb 29, 1988 |
| **AP** | +! | BAXTER HLTHCARE | **100%** | **N018632** | **001** | Jun 30, 1982 |
| **AP** | +! | | **100%** | **N018632** | **002** | Apr 19, 1988 |
| **AP** | | FRESENIUS KABI USA | **100%** | **A088400** | **001** | Jan 16, 1984 |
| **AP** | +! | HOSPIRA | **100%** | **N018801** | **001** | Oct 27, 1982 |
| **AP** | +! | ICU MEDICAL INC | **100%** | **N018233** | **001** | |
| **AP** | +! | | **100%** | **N019869** | **001** | Dec 26, 1989 |
| **AP** | | TARO | **100%** | **A077393** | **001** | Aug 11, 2006 |

STERILE WATER FOR IRRIGATION

LIQUID;IRRIGATION

**STERILE WATER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | BAXTER HLTHCARE | **100%** | **N017428** | **001** | |

**STERILE WATER IN PLASTIC CONTAINER**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | B BRAUN | **100%** | **N016734** | **001** | |
| **AT** | | BAXTER HLTHCARE | **100%** | **N017866** | **001** | |
| **AT** | | ICU MEDICAL INC | **100%** | **N017513** | **001** | |
| **AT** | | | **100%** | **N018313** | **001** | |

| | | | | | | |
|---|---|---|---|---|---|---|
| STREPTOMYCIN SULFATE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| STREPTOMYCIN SULFATE | | | | | | |
| | ! | X GEN PHARMS | EQ 1GM BASE/VIAL | A064210 | 001 | Jun 30, 1998 |
| STREPTOZOCIN | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| ZANOSAR | | | | | | |
| | +! | TEVA PHARMS USA | 1GM/VIAL | N050577 | 001 | May 07, 1982 |
| STRONTIUM CHLORIDE SR-89 | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| **METASTRON** | | | | | | |
| **AP** | **+!** | GE HEALTHCARE | **1mCi/ML** | **N020134** | **001** | Jun 18, 1993 |
| **STRONTIUM CHLORIDE SR-89** | | | | | | |
| **AP** | | BIO NUCLEONICS | **1mCi/ML** | **A075941** | **001** | Jan 06, 2003 |
| SUCCIMER | | | | | | |
| CAPSULE;ORAL | | | | | | |
| CHEMET | | | | | | |
| | +! | RECORDATI RARE | 100MG | N019998 | 002 | Jan 30, 1991 |
| SUCCINYLCHOLINE CHLORIDE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| **ANECTINE** | | | | | | |
| **AP** | **+!** | SANDOZ INC | **20MG/ML** | **N008453** | **002** | |
| **QUELICIN** | | | | | | |
| **AP** | **+!** | HOSPIRA | **20MG/ML** | **N008845** | **006** | |
| **QUELICIN PRESERVATIVE FREE** | | | | | | |
| **AP** | **+!** | HOSPIRA | **20MG/ML** | **N008845** | **001** | |
| SUCRALFATE | | | | | | |
| SUSPENSION;ORAL | | | | | | |
| CARAFATE | | | | | | |
| | +! | FOREST LABS INC | 1GM/10ML | N019183 | 001 | Dec 16, 1993 |
| TABLET;ORAL | | | | | | |
| **CARAFATE** | | | | | | |
| **AB** | **+!** | FOREST LABS INC | **1GM** | **N018333** | **001** | |
| **SUCRALFATE** | | | | | | |
| **AB** | | MYLAN IRELAND LTD | **1GM** | **A074415** | **001** | Jun 08, 1998 |
| **AB** | | TEVA | **1GM** | **A070848** | **001** | Mar 29, 1996 |
| SUCROFERRIC OXYHYDROXIDE | | | | | | |
| TABLET, CHEWABLE;ORAL | | | | | | |
| VELPHORO | | | | | | |
| | +! | VIFOR FRESENIUS | 500MG | N205109 | 001 | Nov 27, 2013 |
| SUFENTANIL CITRATE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| **SUFENTA PRESERVATIVE FREE** | | | | | | |
| **AP** | **+!** | AKORN | **EQ 0.05MG BASE/ML** | **N019050** | **001** | May 04, 1984 |
| **SUFENTANIL CITRATE** | | | | | | |
| **AP** | | HOSPIRA | **EQ 0.05MG BASE/ML** | **A074534** | **001** | Dec 11, 1996 |
| **AP** | | WEST-WARD PHARMS INT | **EQ 0.05MG BASE/ML** | **A074413** | **001** | Dec 15, 1995 |
| SUGAMMADEX SODIUM | | | | | | |
| SOLUTION;INTRAVENOUS | | | | | | |
| BRIDION | | | | | | |
| | + | ORGANON SUB MERCK | EQ 200MG BASE/2ML (EQ 100MG BASE/ML) | N022225 | 002 | Dec 15, 2015 |
| | +! | | EQ 500MG BASE/5ML (EQ 100MG BASE/ML) | N022225 | 001 | Dec 15, 2015 |
| SULCONAZOLE NITRATE | | | | | | |
| CREAM;TOPICAL | | | | | | |
| EXELDERM | | | | | | |
| | +! | SUN PHARM INDS INC | 1% | N018737 | 001 | Feb 28, 1989 |
| SOLUTION;TOPICAL | | | | | | |
| EXELDERM | | | | | | |
| | +! | SUN PHARM INDS INC | 1% | N018738 | 001 | Aug 30, 1985 |
| SULFACETAMIDE SODIUM | | | | | | |
| LOTION;TOPICAL | | | | | | |
| **KLARON** | | | | | | |
| **AB** | **+!** | VALEANT PHARMS NORTH | **10%** | **N019931** | **001** | Dec 23, 1996 |
| **SULFACETAMIDE SODIUM** | | | | | | |
| **AB** | | FOUGERA PHARMS | **10%** | **A077015** | **001** | Nov 17, 2006 |
| **AB** | | PERRIGO CO | **10%** | **A078649** | **001** | Mar 23, 2009 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| SULFACETAMIDE SODIUM | | | | | | | |
| LOTION;TOPICAL | | | | | | | |
| **SULFACETAMIDE SODIUM** | | | | | | | |
| | | TENNESSEE | | | | | |
| **AB** | | TARO | **10%** | **A078668** | **001** | May 20, 2009 | |
| OINTMENT;OPHTHALMIC | | | | | | | |
| SULFACETAMIDE SODIUM | | | | | | | |
| | ! | PERRIGO CO | 10% | A080029 | 001 | | |
| | | TENNESSEE | | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | | | | |
| **BLEPH-10** | | | | | | | |
| **AT** | **!** | ALLERGAN | **10%** | **A080028** | **001** | | |
| **SULFACETAMIDE SODIUM** | | | | | | | |
| **AT** | | AKORN | **10%** | **A040215** | **001** | May 25, 1999 | |
| **AT** | | BAUSCH AND LOMB | **10%** | **A040066** | **001** | Dec 28, 1994 | |
| **AT** | | SANDOZ INC | **10%** | **A089560** | **001** | Oct 18, 1988 | |
| SULFADIAZINE | | | | | | | |
| TABLET;ORAL | | | | | | | |
| SULFADIAZINE | | | | | | | |
| | ! | SANDOZ | 500MG | A040091 | 001 | Jul 29, 1994 | |
| SULFAMETHOXAZOLE; TRIMETHOPRIM | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| **SULFAMETHOXAZOLE AND TRIMETHOPRIM** | | | | | | | |
| **AP** | | MYLAN LABS LTD | **80MG/ML;16MG/ML** | **A206607** | **001** | Aug 30, 2017 | |
| **AP** | **!** | TEVA PHARMS USA | **80MG/ML;16MG/ML** | **A073303** | **001** | Oct 31, 1991 | |
| SUSPENSION;ORAL | | | | | | | |
| **SULFAMETHOXAZOLE AND TRIMETHOPRIM** | | | | | | | |
| **AB** | | AUROBINDO PHARMA | **200MG/5ML;40MG/5ML** | **A091348** | **001** | Jun 08, 2010 | |
| **AB** | **!** | HI TECH PHARMA | **200MG/5ML;40MG/5ML** | **A074650** | **001** | Dec 29, 1997 | |
| **AB** | | VINTAGE | **200MG/5ML;40MG/5ML** | **A077785** | **001** | Jan 24, 2007 | |
| **SULFATRIM PEDIATRIC** | | | | | | | |
| **AB** | | STI PHARMA LLC | **200MG/5ML;40MG/5ML** | **N018615** | **001** | Jan 07, 1983 | |
| TABLET;ORAL | | | | | | | |
| **BACTRIM** | | | | | | | |
| **AB** | **+** | SUN PHARM | **400MG;80MG** | **N017377** | **001** | | |
| | | INDUSTRIES | | | | | |
| **BACTRIM DS** | | | | | | | |
| **AB** | **+!** | SUN PHARM | **800MG;160MG** | **N017377** | **002** | | |
| | | INDUSTRIES | | | | | |
| **SEPTRA** | | | | | | | |
| **AB** | | MONARCH PHARMS | **400MG;80MG** | **N017376** | **001** | | |
| **SEPTRA DS** | | | | | | | |
| **AB** | | MONARCH PHARMS | **800MG;160MG** | **N017376** | **002** | | |
| **SULFAMETHOXAZOLE AND TRIMETHOPRIM** | | | | | | | |
| **AB** | | AMNEAL PHARMS NY | **400MG;80MG** | **A076899** | **001** | Jan 27, 2005 | |
| **AB** | | | **800MG;160MG** | **A076899** | **002** | Jan 27, 2005 | |
| **AB** | | AUROBINDO PHARMA | **400MG;80MG** | **A090624** | **001** | Feb 16, 2010 | |
| **AB** | | | **800MG;160MG** | **A090624** | **002** | Feb 16, 2010 | |
| **AB** | | CHARTWELL MOLECULES | **400MG;80MG** | **A078060** | **002** | Jan 25, 2007 | |
| **AB** | | | **800MG;160MG** | **A078060** | **001** | Jan 25, 2007 | |
| **AB** | | GLENMARK GENERICS | **400MG;80MG** | **A090828** | **002** | Dec 22, 2010 | |
| **AB** | | | **800MG;160MG** | **A090828** | **001** | Dec 22, 2010 | |
| **AB** | | SUN PHARM | **800MG;160MG** | **A071017** | **001** | Aug 25, 1986 | |
| | | INDUSTRIES | | | | | |
| **AB** | | VISTA PHARMS | **400MG;80MG** | **A076817** | **001** | Oct 07, 2005 | |
| **AB** | | | **800MG;160MG** | **A076817** | **002** | Oct 07, 2005 | |
| **SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH** | | | | | | | |
| **AB** | | TEVA | **800MG;160MG** | **A070037** | **001** | Jun 02, 1987 | |
| **SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH** | | | | | | | |
| **AB** | | TEVA PHARMS | **400MG;80MG** | **A070030** | **001** | Jun 02, 1987 | |
| SULFAMETHOXAZOLE AND TRIMETHOPRIM | | | | | | | |
| | | SUN PHARM | 400MG;80MG | A071017 | 002 | Aug 25, 1986 | |
| | | INDUSTRIES | | | | | |
| SULFANILAMIDE | | | | | | | |
| CREAM;VAGINAL | | | | | | | |
| AVC | | | | | | | |
| | +! | MYLAN SPECIALITY LP | 15% | N006530 | 003 | Jan 27, 1987 | |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| SULFASALAZINE | | | | | | | |
| SUSPENSION;ORAL | | | | | | | |
| AZULFIDINE | | | | | | | |
| | ! | PHARMACIA AND UPJOHN | 250MG/5ML | | A086983 | 001 | |
| TABLET;ORAL | | | | | | | |
| **AZULFIDINE** | | | | | | | |
| **AB** | **+!** | PHARMACIA AND UPJOHN | **500MG** | | **N007073** | **001** | |
| **SULFASALAZINE** | | | | | | | |
| **AB** | | VINTAGE PHARMS | **500MG** | | **A040349** | **001** | Jan 11, 2002 |
| **AB** | | WATSON LABS | **500MG** | | **A085828** | **001** | |
| TABLET, DELAYED RELEASE;ORAL | | | | | | | |
| **AZULFIDINE EN-TABS** | | | | | | | |
| **AB** | **+!** | PHARMACIA AND UPJOHN | **500MG** | | **N007073** | **002** | Apr 06, 1983 |
| **SULFASALAZINE** | | | | | | | |
| **AB** | | VINTAGE PHARMS | **500MG** | | **A075339** | **001** | Jan 11, 2002 |
| SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES | | | | | | | |
| FOR SUSPENSION;INTRAVENOUS | | | | | | | |
| LUMASON | | | | | | | |
| | +! | BRACCO | 60.7MG/25MG | | N203684 | 001 | Oct 15, 2014 |
| SULINDAC | | | | | | | |
| TABLET;ORAL | | | | | | | |
| **SULINDAC** | | | | | | | |
| **AB** | | EPIC PHARMA | **150MG** | | **A072710** | **001** | Mar 25, 1991 |
| **AB** | | | **200MG** | | **A072711** | **001** | Mar 25, 1991 |
| **AB** | | EPIC PHARMA LLC | **150MG** | | **A073262** | **002** | Sep 06, 1991 |
| **AB** | | | **200MG** | | **A073262** | **001** | Sep 06, 1991 |
| **AB** | | MYLAN | **150MG** | | **A073039** | **002** | Jun 22, 1993 |
| **AB** | | | **200MG** | | **A073039** | **001** | Jun 22, 1993 |
| **AB** | | SUN PHARM INDUSTRIES | **150MG** | | **A072050** | **001** | Apr 17, 1991 |
| **AB** | | | **200MG** | | **A072051** | **001** | Apr 17, 1991 |
| **AB** | | WATSON LABS | **150MG** | | **A071891** | **001** | Apr 03, 1990 |
| **AB** | **!** | | **200MG** | | **A071795** | **001** | Apr 03, 1990 |
| SUMATRIPTAN | | | | | | | |
| SPRAY;NASAL | | | | | | | |
| **IMITREX** | | | | | | | |
| **AB** | **+!** | GLAXOSMITHKLINE | **5MG/SPRAY** | | **N020626** | **001** | Aug 26, 1997 |
| **AB** | **+!** | | **20MG/SPRAY** | | **N020626** | **003** | Aug 26, 1997 |
| **SUMATRIPTAN** | | | | | | | |
| **AB** | | LANNETT CO INC | **5MG/SPRAY** | | **A204841** | **001** | Feb 19, 2016 |
| **AB** | | | **20MG/SPRAY** | | **A204841** | **002** | Feb 19, 2016 |
| SUMATRIPTAN SUCCINATE | | | | | | | |
| INJECTABLE;SUBCUTANEOUS | | | | | | | |
| **IMITREX STATDOSE** | | | | | | | |
| **AB** | **+!** | GLAXOSMITHKLINE | **EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)** | | **N020080** | **002** | Feb 01, 2006 |
| **AB** | **+!** | | **EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)** | | **N020080** | **003** | Dec 23, 1996 |
| **SUMATRIPTAN SUCCINATE** | | | | | | | |
| **AB** | | ANTARES PHARMA INC | **EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)** | | **A078319** | **001** | Dec 10, 2015 |
| **AB** | | | **EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)** | | **A078319** | **002** | Dec 10, 2015 |
| **AB** | | DR REDDYS LABS INC | **EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)** | | **A090495** | **001** | Jan 29, 2014 |
| **AB** | | SUN PHARMA GLOBAL | **EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)** | | **A090358** | **001** | Jun 21, 2011 |
| **IMITREX** | | | | | | | |
| **AP** | **+!** | GLAXOSMITHKLINE | **EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)** | | **N020080** | **001** | Dec 28, 1992 |
| **SUMATRIPTAN SUCCINATE** | | | | | | | |
| **AP** | | AUROBINDO PHARMA LTD | **EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)** | | **A202758** | **001** | Apr 23, 2013 |
| **AP** | | FRESENIUS KABI USA | **EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)** | | **A079242** | **001** | Mar 02, 2009 |
| **AP** | | HIKMA FARMACEUTICA | **EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)** | | **A200183** | **001** | Sep 16, 2013 |
| **AP** | | INJECTALIA | **EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)** | | **A090310** | **001** | Aug 11, 2010 |
| **AP** | | MYLAN LABS LTD | **EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)** | | **A203322** | **001** | Apr 14, 2014 |
| **AP** | | PAR PHARM | **EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)** | | **A077332** | **001** | Oct 09, 2009 |
| **AP** | | PAR STERILE PRODUCTS | **EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)** | | **A077871** | **001** | Jul 09, 2009 |
| **AP** | | SAGENT AGILA | **EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)** | | **A090641** | **001** | Jul 28, 2010 |
| **AP** | | SAGENT AGILA LLC | **EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)** | | **A090314** | **001** | Jun 10, 2010 |
| **AP** | | TEVA PHARMS USA | **EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)** | | **A077907** | **001** | Feb 06, 2009 |
| **AP** | | WEST-WARD PHARMS INT | **EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)** | | **A079123** | **001** | Feb 06, 2009 |
| **AP** | | WOCKHARDT | **EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)** | | **A078593** | **001** | Feb 06, 2009 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| SUMATRIPTAN SUCCINATE | | | | | | | |
| INJECTABLE;SUBCUTANEOUS | | | | | | | |
| SUMAVEL DOSEPRO | | | | | | | |
| BX | +! | ENDO VENTURES LTD | EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) | N022239 | 002 | Nov 26, 2013 |
| BX | +! | | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | N022239 | 001 | Jul 15, 2009 |
| POWDER;INHALATION | | | | | | | |
| ONZETRA XSAIL | | | | | | | |
| | +! | AVANIR PHARMS | EQ 11MG BASE | N206099 | 001 | Jan 27, 2016 |
| SOLUTION;SUBCUTANEOUS | | | | | | | |
| ZEMBRACE SYMTOUCH | | | | | | | |
| | | DR REDDYS LABS LTD | EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) | N208223 | 001 | Jan 28, 2016 |
| TABLET;ORAL | | | | | | | |
| **IMITREX** | | | | | | | |
| **AB** | **+** | GLAXOSMITHKLINE | **EQ 25MG BASE** | **N020132** | **002** | Jun 01, 1995 |
| **AB** | **+** | | **EQ 50MG BASE** | **N020132** | **003** | Jun 01, 1995 |
| **AB** | **+!** | | **EQ 100MG BASE** | **N020132** | **001** | Jun 01, 1995 |
| **SUMATRIPTAN SUCCINATE** | | | | | | | |
| **AB** | | APOTEX INC | **EQ 25MG BASE** | **A200263** | **001** | Jun 19, 2012 |
| **AB** | | | **EQ 50MG BASE** | **A200263** | **002** | Jun 19, 2012 |
| **AB** | | | **EQ 100MG BASE** | **A200263** | **003** | Jun 19, 2012 |
| **AB** | | AUROBINDO PHARMA | **EQ 25MG BASE** | **A078327** | **001** | Aug 10, 2009 |
| **AB** | | | **EQ 50MG BASE** | **A078327** | **002** | Aug 10, 2009 |
| **AB** | | | **EQ 100MG BASE** | **A078327** | **003** | Aug 10, 2009 |
| **AB** | | DR REDDYS LABS INC | **EQ 25MG BASE** | **A076847** | **001** | Aug 10, 2009 |
| **AB** | | | **EQ 50MG BASE** | **A076847** | **002** | Aug 10, 2009 |
| **AB** | | | **EQ 100MG BASE** | **A076847** | **003** | Aug 10, 2009 |
| **AB** | | MYLAN | **EQ 25MG BASE** | **A077744** | **001** | Aug 10, 2009 |
| **AB** | | | **EQ 50MG BASE** | **A077744** | **002** | Aug 10, 2009 |
| **AB** | | | **EQ 100MG BASE** | **A077744** | **003** | Aug 10, 2009 |
| **AB** | | ORCHID HLTHCARE | **EQ 25MG BASE** | **A078284** | **001** | Aug 10, 2009 |
| **AB** | | | **EQ 50MG BASE** | **A078284** | **002** | Aug 10, 2009 |
| **AB** | | | **EQ 100MG BASE** | **A078284** | **003** | Aug 10, 2009 |
| **AB** | | SUN PHARM INDS | **EQ 25MG BASE** | **A078295** | **001** | Aug 10, 2009 |
| **AB** | | | **EQ 50MG BASE** | **A078295** | **002** | Aug 10, 2009 |
| **AB** | | | **EQ 100MG BASE** | **A078295** | **003** | Aug 10, 2009 |
| **AB** | | SUN PHARM INDS LTD | **EQ 25MG BASE** | **A076554** | **001** | Aug 10, 2009 |
| **AB** | | | **EQ 50MG BASE** | **A076554** | **002** | Aug 10, 2009 |
| **AB** | | | **EQ 100MG BASE** | **A076572** | **001** | Feb 09, 2009 |
| **AB** | | WATSON LABS | **EQ 25MG BASE** | **A076933** | **001** | Aug 10, 2009 |
| **AB** | | | **EQ 50MG BASE** | **A076933** | **002** | Aug 10, 2009 |
| **AB** | | | **EQ 100MG BASE** | **A076933** | **003** | Aug 10, 2009 |
| SUNITINIB MALATE | | | | | | | |
| CAPSULE;ORAL | | | | | | | |
| SUTENT | | | | | | | |
| | + | CPPI CV | EQ 12.5MG BASE | N021938 | 001 | Jan 26, 2006 |
| | + | | EQ 25MG BASE | N021938 | 002 | Jan 26, 2006 |
| | + | | EQ 37.5MG BASE | N021938 | 004 | Mar 31, 2009 |
| | +! | | EQ 50MG BASE | N021938 | 003 | Jan 26, 2006 |
| SUVOREXANT | | | | | | | |
| TABLET;ORAL | | | | | | | |
| BELSOMRA | | | | | | | |
| | + | MERCK SHARP DOHME | 5MG | N204569 | 001 | Aug 13, 2014 |
| | + | | 10MG | N204569 | 002 | Aug 13, 2014 |
| | + | | 15MG | N204569 | 003 | Aug 13, 2014 |
| | +! | | 20MG | N204569 | 004 | Aug 13, 2014 |
| TACROLIMUS | | | | | | | |
| CAPSULE;ORAL | | | | | | | |
| **PROGRAF** | | | | | | | |
| **AB** | **+** | ASTELLAS | **EQ 0.5MG BASE** | **N050708** | **003** | Aug 24, 1998 |
| **AB** | **+** | | **EQ 1MG BASE** | **N050708** | **001** | Apr 08, 1994 |
| **AB** | **+!** | | **EQ 5MG BASE** | **N050708** | **002** | Apr 08, 1994 |
| **TACROLIMUS** | | | | | | | |
| **AB** | | ACCORD HLTHCARE | **EQ 0.5MG BASE** | **A091195** | **001** | Aug 31, 2011 |
| **AB** | | | **EQ 1MG BASE** | **A091195** | **002** | Aug 31, 2011 |
| **AB** | | | **EQ 5MG BASE** | **A091195** | **003** | Aug 31, 2011 |
| **AB** | | BELCHER PHARMS LLC | **EQ 0.5MG BASE** | **A206651** | **001** | Nov 30, 2017 |
| **AB** | | | **EQ 1MG BASE** | **A206651** | **002** | Nov 30, 2017 |
| **AB** | | | **EQ 5MG BASE** | **A206651** | **003** | Nov 30, 2017 |
| **AB** | | DR REDDYS LABS LTD | **EQ 0.5MG BASE** | **A090509** | **001** | May 12, 2010 |
| **AB** | | | **EQ 1MG BASE** | **A090509** | **002** | May 12, 2010 |
| **AB** | | | **EQ 5MG BASE** | **A090509** | **003** | May 12, 2010 |

| | | | | | | |
|---|---|---|---|---|---|---|
| TACROLIMUS | | | | | | |
| CAPSULE;ORAL | | | | | | |
| **TACROLIMUS** | | | | | | |
| **AB** | MYLAN | **EQ 0.5MG BASE** | **A090596** | **001** | Sep 17, 2010 |
| **AB** | | **EQ 1MG BASE** | **A090596** | **002** | Sep 17, 2010 |
| **AB** | | **EQ 5MG BASE** | **A090596** | **003** | Sep 17, 2010 |
| **AB** | PANACEA BIOTEC LTD | **EQ 0.5MG BASE** | **A090802** | **001** | Sep 28, 2012 |
| **AB** | | **EQ 1MG BASE** | **A090802** | **002** | Sep 28, 2012 |
| **AB** | | **EQ 5MG BASE** | **A090802** | **003** | Sep 28, 2012 |
| **AB** | SANDOZ | **EQ 0.5MG BASE** | **A065461** | **001** | Aug 10, 2009 |
| **AB** | | **EQ 1MG BASE** | **A065461** | **002** | Aug 10, 2009 |
| **AB** | | **EQ 5MG BASE** | **A065461** | **003** | Aug 10, 2009 |
| **AB** | STRIDES PHARMA | **EQ 0.5MG BASE** | **A090687** | **001** | Jul 22, 2014 |
| **AB** | | **EQ 1MG BASE** | **A090687** | **002** | Jul 22, 2014 |
| **AB** | | **EQ 5MG BASE** | **A090687** | **003** | Jul 22, 2014 |
| CAPSULE, EXTENDED RELEASE;ORAL | | | | | | |
| ASTAGRAF XL | | | | | | |
| + | ASTELLAS | EQ 0.5MG BASE | N204096 | 001 | Jul 19, 2013 |
| + | | EQ 1MG BASE | N204096 | 002 | Jul 19, 2013 |
| +! | | EQ 5MG BASE | N204096 | 003 | Jul 19, 2013 |
| INJECTABLE;INJECTION | | | | | | |
| **PROGRAF** | | | | | | |
| **AP** **+!** | ASTELLAS | **EQ 5MG BASE/ML** | **N050709** | **001** | Apr 08, 1994 |
| **TACROLIMUS** | | | | | | |
| **AP** | HOSPIRA INC | **EQ 5MG BASE/ML** | **A203900** | **001** | Aug 25, 2017 |
| OINTMENT;TOPICAL | | | | | | |
| **PROTOPIC** | | | | | | |
| **AB** **+!** | LEO PHARMA AS | **0.03%** | **N050777** | **001** | Dec 08, 2000 |
| **AB** **+!** | | **0.1%** | **N050777** | **002** | Dec 08, 2000 |
| **TACROLIMUS** | | | | | | |
| **AB** | FOUGERA PHARMS INC | **0.03%** | **A200744** | **001** | Sep 09, 2014 |
| **AB** | | **0.1%** | **A200744** | **002** | Sep 09, 2014 |
| TABLET, EXTENDED RELEASE;ORAL | | | | | | |
| ENVARSUS XR | | | | | | |
| + | VELOXIS PHARMS INC | EQ 0.75MG BASE | N206406 | 001 | Jul 10, 2015 |
| + | | EQ 1MG BASE | N206406 | 002 | Jul 10, 2015 |
| +! | | EQ 4MG BASE | N206406 | 003 | Jul 10, 2015 |
| TADALAFIL | | | | | | |
| TABLET;ORAL | | | | | | |
| ADCIRCA | | | | | | |
| +! | ELI LILLY CO | 20MG | N022332 | 001 | May 22, 2009 |
| CIALIS | | | | | | |
| + | LILLY | 2.5MG | N021368 | 004 | Jan 07, 2008 |
| + | | 5MG | N021368 | 001 | Nov 21, 2003 |
| + | | 10MG | N021368 | 002 | Nov 21, 2003 |
| +! | | 20MG | N021368 | 003 | Nov 21, 2003 |
| TAFLUPROST | | | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | | | |
| ZIOPTAN | | | | | | |
| +! | OAK PHARMS INC | 0.0015% | N202514 | 001 | Feb 10, 2012 |
| TALC | | | | | | |
| AEROSOL, METERED;INTRAPLEURAL | | | | | | |
| SCLEROSOL | | | | | | |
| +! | LYMOL MEDCL | 400MG/SPRAY | N020587 | 001 | Dec 24, 1997 |
| POWDER;INTRAPLEURAL | | | | | | |
| STERITALC | | | | | | |
| + | NOVATECH SA | 2GM/VIAL | N205555 | 001 | May 01, 2017 |
| + | | 3GM/VIAL | N205555 | 002 | May 01, 2017 |
| +! | | 4GM/VIAL | N205555 | 003 | May 01, 2017 |
| TALC | | | | | | |
| +! | LYMOL MEDCL | 5GM/BOT | N021388 | 001 | Dec 15, 2003 |
| TALIGLUCERASE ALFA | | | | | | |
| POWDER;IV (INFUSION) | | | | | | |
| ELELYSO | | | | | | |
| +! | PFIZER | 200 UNITS/VIAL | N022458 | 001 | May 01, 2012 |

| | | | | | | |
|---|---|---|---|---|---|---|
| TAMOXIFEN CITRATE | | | | | | |
| SOLUTION;ORAL | | | | | | |
| SOLTAMOX | | | | | | |
| | | MIDATECH PHARMA US | EQ 10MG BASE/5ML | N021807 | 001 | Oct 29, 2005 |
| TABLET;ORAL | | | | | | |
| **TAMOXIFEN CITRATE** | | | | | | |
| **AB** | | ACTAVIS LABS FL INC | **EQ 10MG BASE** | **A070929** | **001** | Feb 20, 2003 |
| **AB** | | | **EQ 20MG BASE** | **A070929** | **002** | Feb 20, 2003 |
| **AB** | | APOTEX | **EQ 10MG BASE** | **A090878** | **001** | Sep 23, 2011 |
| **AB** | | | **EQ 20MG BASE** | **A090878** | **002** | Sep 23, 2011 |
| **AB** | | MAYNE PHARMA | **EQ 10MG BASE** | **A075797** | **001** | Feb 20, 2003 |
| **AB** | ! | | **EQ 20MG BASE** | **A075797** | **002** | Feb 20, 2003 |
| **AB** | | MYLAN | **EQ 10MG BASE** | **A074732** | **002** | Feb 20, 2003 |
| **AB** | | | **EQ 20MG BASE** | **A074732** | **001** | Feb 20, 2003 |
| **AB** | | ZYDUS PHARMS USA INC | **EQ 10MG BASE** | **A206694** | **001** | Oct 27, 2017 |
| **AB** | | | **EQ 20MG BASE** | **A206694** | **002** | Oct 27, 2017 |
| TAMSULOSIN HYDROCHLORIDE | | | | | | |
| CAPSULE;ORAL | | | | | | |
| **FLOMAX** | | | | | | |
| **AB** | **+!** | BOEHRINGER INGELHEIM | **0.4MG** | **N020579** | **001** | Apr 15, 1997 |
| **TAMSULOSIN HYDROCHLORIDE** | | | | | | |
| **AB** | | ANCHEN PHARMS | **0.4MG** | **A202010** | **001** | Jan 04, 2013 |
| **AB** | | AUROBINDO PHARMA LTD | **0.4MG** | **A202433** | **001** | Apr 30, 2013 |
| **AB** | | IMPAX LABS | **0.4MG** | **A090377** | **001** | Mar 02, 2010 |
| **AB** | | MACLEODS PHARMS LTD | **0.4MG** | **A204645** | **001** | Jan 20, 2017 |
| **AB** | | MYLAN | **0.4MG** | **A090408** | **001** | Apr 27, 2010 |
| **AB** | | SANDOZ | **0.4MG** | **A078015** | **001** | Apr 27, 2010 |
| **AB** | | SUN PHARM INDS LTD | **0.4MG** | **A090931** | **001** | Jul 15, 2010 |
| **AB** | | SYNTHON PHARMS | **0.4MG** | **A078801** | **001** | Apr 27, 2010 |
| **AB** | | TEVA PHARMS | **0.4MG** | **A077630** | **001** | Apr 27, 2010 |
| **AB** | | WOCKHARDT | **0.4MG** | **A078938** | **001** | Apr 27, 2010 |
| **AB** | | ZYDUS PHARMS USA INC | **0.4MG** | **A078225** | **001** | Apr 27, 2010 |
| **TAMSULOSIN HYDROCHLORIDE** | | | | | | |
| **AB** | | ALKEM LABS LTD | **0.4MG** | **A207405** | **001** | Aug 11, 2017 |
| TAPENTADOL HYDROCHLORIDE | | | | | | |
| SOLUTION;ORAL | | | | | | |
| NUCYNTA | | | | | | |
| | +! | DEPOMED INC | EQ 20MG BASE/ML | N203794 | 001 | Oct 15, 2012 |
| TABLET;ORAL | | | | | | |
| NUCYNTA | | | | | | |
| | + | DEPOMED INC | EQ 50MG BASE | N022304 | 001 | Nov 20, 2008 |
| | + | | EQ 75MG BASE | N022304 | 002 | Nov 20, 2008 |
| | +! | | EQ 100MG BASE | N022304 | 003 | Nov 20, 2008 |
| TABLET, EXTENDED RELEASE;ORAL | | | | | | |
| NUCYNTA ER | | | | | | |
| | + | DEPOMED INC | EQ 50MG BASE | N200533 | 001 | Aug 25, 2011 |
| | + | | EQ 100MG BASE | N200533 | 002 | Aug 25, 2011 |
| | + | | EQ 150MG BASE | N200533 | 003 | Aug 25, 2011 |
| | + | | EQ 200MG BASE | N200533 | 004 | Aug 25, 2011 |
| | +! | | EQ 250MG BASE | N200533 | 005 | Aug 25, 2011 |
| TASIMELTEON | | | | | | |
| CAPSULE;ORAL | | | | | | |
| HETLIOZ | | | | | | |
| | +! | VANDA PHARMS INC | 20MG | N205677 | 001 | Jan 31, 2014 |
| TAVABOROLE | | | | | | |
| SOLUTION;TOPICAL | | | | | | |
| KERYDIN | | | | | | |
| | +! | ANACOR PHARMS INC | 5% | N204427 | 001 | Jul 07, 2014 |
| TAZAROTENE | | | | | | |
| AEROSOL, FOAM;TOPICAL | | | | | | |
| FABIOR | | | | | | |
| | +! | MAYNE PHARMA | 0.1% | N202428 | 001 | May 11, 2012 |
| CREAM;TOPICAL | | | | | | |
| **AVAGE** | | | | | | |
| **AB** | **+!** | ALLERGAN | **0.1%** | **N021184** | **003** | Sep 30, 2002 |

TAZAROTENE

CREAM;TOPICAL

**TAZAROTENE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | G AND W LABS INC | **0.1%** | **A208662** | **001** | Dec 22, 2017 |
| **AB** | | TARO | **0.1%** | **A208258** | **001** | Apr 03, 2017 |

**TAZORAC**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | ALLERGAN | **0.1%** | **N021184** | **002** | Sep 29, 2000 |
| | +! | | 0.05% | N021184 | 001 | Sep 29, 2000 |

GEL;TOPICAL

TAZORAC

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ALLERGAN | 0.05% | N020600 | 001 | Jun 13, 1997 |
| | +! | | 0.1% | N020600 | 002 | Jun 13, 1997 |

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE;INJECTION

PULMOLITE

| | | | | | | |
|---|---|---|---|---|---|---|
| BS | +! | JUBILANT DRAXIMAGE | N/A | N017776 | 001 | |

TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT

| | | | | | | |
|---|---|---|---|---|---|---|
| BS | +! | DRAXIMAGE | N/A | N017881 | 001 | Dec 30, 1987 |

TECHNETIUM TC-99M BICISATE KIT

INJECTABLE;INJECTION

NEUROLITE

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | LANTHEUS MEDCL | N/A | N020256 | 001 | Nov 23, 1994 |

TECHNETIUM TC-99M DISOFENIN KIT

INJECTABLE;INJECTION

HEPATOLITE

| | | | | | | |
|---|---|---|---|---|---|---|
| | | PHARMALUCENCE | N/A | N018467 | 001 | Mar 16, 1982 |

TECHNETIUM TC-99M EXAMETAZIME KIT

INJECTABLE;INJECTION

CERETEC

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | GE HEALTHCARE | N/A | N019829 | 001 | Dec 30, 1988 |

POWDER;INTRAVENOUS

DRAX EXAMETAZIME

| | | | | | | |
|---|---|---|---|---|---|---|
| | | JUBILANT DRAXIMAGE | N/A | N208870 | 001 | Aug 17, 2017 |

TECHNETIUM TC-99M MEBROFENIN KIT

INJECTABLE;INJECTION

**CHOLETEC**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | BRACCO | **N/A** | **N018963** | **001** | Jan 21, 1987 |

**TECHNETIUM TC-99M MEBROFENIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | PHARMALUCENCE | **N/A** | **A078242** | **001** | Jan 29, 2008 |

TECHNETIUM TC-99M MEDRONATE

INJECTABLE;INJECTION

DRAXIMAGE MDP-25

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | JUBILANT DRAXIMAGE | N/A | N018035 | 002 | Feb 27, 2004 |

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE;INJECTION

**CIS-MDP**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | PHARMALUCENCE | **N/A** | **N018124** | **001** | |

**MDP-BRACCO**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | CARDINAL HEALTH 414 | **N/A** | **N018107** | **001** | |

TECHNETIUM TC-99M MERTIATIDE KIT

INJECTABLE;INJECTION

TECHNESCAN MAG3

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | MALLINKRODT NUCLEAR | N/A | N019882 | 001 | Jun 15, 1990 |

TECHNETIUM TC-99M OXIDRONATE KIT

INJECTABLE;INJECTION

TECHNESCAN

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | MALLINKRODT NUCLEAR | N/A | N018321 | 001 | |

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE;INJECTION

DTPA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | DRAXIMAGE | N/A | N018511 | 001 | Dec 29, 1989 |

| | | | | | | |
|---|---|---|---|---|---|---|
| TECHNETIUM TC-99M PYROPHOSPHATE KIT | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| **CIS-PYRO** | | | | | | |
| **AP** | | PHARMALUCENCE | **N/A** | **N019039** | **001** | Jun 30, 1987 |
| **TECHNESCAN PYP KIT** | | | | | | |
| **AP** | | MALLINKRODT NUCLEAR | **N/A** | **N017538** | **001** | |
| TECHNETIUM TC-99M RED BLOOD CELL KIT | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| ULTRATAG | | | | | | |
| | +! | MALLINKRODT NUCLEAR | N/A | N019981 | 001 | Jun 10, 1991 |
| TECHNETIUM TC-99M SESTAMIBI KIT | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| **CARDIOLITE** | | | | | | |
| **AP** | **+!** | LANTHEUS MEDCL | **N/A** | **N019785** | **001** | Dec 21, 1990 |
| **TECHNETIUM TC 99M SESTAMIBI** | | | | | | |
| **AP** | | CARDINAL HEALTH 414 | **N/A** | **A078809** | **001** | Apr 28, 2009 |
| **AP** | | JUBILANT DRAXIMAGE | **N/A** | **A078806** | **001** | Apr 29, 2009 |
| **AP** | | PHARMALUCENCE | **10-30mCi** | **A079157** | **001** | Jul 10, 2009 |
| **TECHNETIUM TC-99M SESTAMIBI** | | | | | | |
| **AP** | | MALLINKRODT NUCLEAR | **N/A** | **A078098** | **001** | Sep 22, 2008 |
| TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR | | | | | | |
| SOLUTION;INTRAVENOUS | | | | | | |
| TECHNELITE | | | | | | |
| | +! | LANTHEUS MEDCL | 1-20 CI/GENERATOR | N017771 | 002 | Feb 12, 2014 |
| ULTRA-TECHNEKOW FM | | | | | | |
| | +! | MALLINKRODT NUCLEAR | 1-19 CI/GENERATOR | N017243 | 003 | Feb 18, 2014 |
| SOLUTION;INTRAVENOUS, ORAL | | | | | | |
| TECHNETIUM TC 99M GENERATOR | | | | | | |
| | +! | GE HEALTHCARE | 68-2703mCi/GENERATOR | N017693 | 002 | Dec 13, 2013 |
| TECHNETIUM TC-99M SULFUR COLLOID KIT | | | | | | |
| SOLUTION;INJECTION, ORAL | | | | | | |
| AN-SULFUR COLLOID | | | | | | |
| | +! | PHARMALUCENCE | N/A | N017858 | 001 | |
| TECHNETIUM TC-99M TETROFOSMIN KIT | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| MYOVIEW 30ML | | | | | | |
| | +! | GE HEALTHCARE | N/A | N020372 | 002 | Jul 07, 2005 |
| TECHNETIUM TC-99M TILMANOCEPT | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| LYMPHOSEEK KIT | | | | | | |
| | +! | CARDINAL HEALTH 414 | N/A | N202207 | 001 | Mar 13, 2013 |
| TEDIZOLID PHOSPHATE | | | | | | |
| POWDER;IV (INFUSION) | | | | | | |
| SIVEXTRO | | | | | | |
| | +! | CUBIST PHARMS LLC | 200MG/VIAL | N205436 | 001 | Jun 20, 2014 |
| TABLET;ORAL | | | | | | |
| SIVEXTRO | | | | | | |
| | +! | CUBIST PHARMS LLC | 200MG | N205435 | 001 | Jun 20, 2014 |
| TEDUGLUTIDE RECOMBINANT | | | | | | |
| POWDER;SUBCUTANEOUS | | | | | | |
| GATTEX KIT | | | | | | |
| | +! | NPS PHARMS INC | 5MG/VIAL | N203441 | 001 | Dec 21, 2012 |
| TELAVANCIN HYDROCHLORIDE | | | | | | |
| POWDER;IV (INFUSION) | | | | | | |
| VIBATIV | | | | | | |
| | +! | THERAVANCE BIOPHARMA | EQ 750MG BASE/VIAL | N022110 | 002 | Sep 11, 2009 |
| TELMISARTAN | | | | | | |
| TABLET;ORAL | | | | | | |
| **MICARDIS** | | | | | | |
| **AB** | **+** | BOEHRINGER INGELHEIM | **20MG** | **N020850** | **003** | Apr 04, 2000 |
| **AB** | **+** | | **40MG** | **N020850** | **001** | Nov 10, 1998 |
| **AB** | **+!** | | **80MG** | **N020850** | **002** | Nov 10, 1998 |
| **TELMISARTAN** | | | | | | |
| **AB** | | ALEMBIC PHARMS LTD | **20MG** | **A202130** | **001** | Jul 07, 2014 |
| **AB** | | | **40MG** | **A202130** | **002** | Jul 07, 2014 |
| **AB** | | | **80MG** | **A202130** | **003** | Jul 07, 2014 |

TELMISARTAN

TABLET;ORAL

**TELMISARTAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AMNEAL PHARMS | **20MG** | **A204415** | **001** | Sep 08, 2015 |
| **AB** | | | **40MG** | **A204415** | **002** | Sep 08, 2015 |
| **AB** | | | **80MG** | **A204415** | **003** | Sep 08, 2015 |
| **AB** | | AUROBINDO PHARMA LTD | **20MG** | **A206511** | **001** | Sep 03, 2015 |
| **AB** | | | **40MG** | **A206511** | **002** | Sep 03, 2015 |
| **AB** | | | **80MG** | **A206511** | **003** | Sep 03, 2015 |
| **AB** | | CADILA PHARMS LTD | **20MG** | **A208605** | **001** | Jul 25, 2017 |
| **AB** | | | **40MG** | **A208605** | **002** | Jul 25, 2017 |
| **AB** | | | **80MG** | **A208605** | **003** | Jul 25, 2017 |
| **AB** | | GLENMARK PHARMS LTD | **20MG** | **A090032** | **001** | Jul 07, 2014 |
| **AB** | | | **40MG** | **A090032** | **002** | Jul 07, 2014 |
| **AB** | | | **80MG** | **A090032** | **003** | Jul 07, 2014 |
| **AB** | | HETERO LABS LTD V | **20MG** | **A205901** | **001** | Apr 22, 2016 |
| **AB** | | | **40MG** | **A205901** | **002** | Apr 22, 2016 |
| **AB** | | | **80MG** | **A205901** | **003** | Apr 22, 2016 |
| **AB** | | INVENTIA HLTHCARE | **20MG** | **A205150** | **001** | Oct 30, 2015 |
| **AB** | | | **40MG** | **A205150** | **002** | Oct 30, 2015 |
| **AB** | | | **80MG** | **A205150** | **003** | Oct 30, 2015 |
| **AB** | | JUBILANT GENERICS | **20MG** | **A204164** | **001** | Aug 22, 2016 |
| **AB** | | | **40MG** | **A204164** | **002** | Aug 22, 2016 |
| **AB** | | | **80MG** | **A204164** | **003** | Aug 22, 2016 |
| **AB** | | MICRO LABS | **20MG** | **A207016** | **001** | Oct 03, 2017 |
| **AB** | | | **40MG** | **A207016** | **002** | Oct 03, 2017 |
| **AB** | | | **80MG** | **A207016** | **003** | Oct 03, 2017 |
| **AB** | | MYLAN PHARMS INC | **20MG** | **A202397** | **001** | Jul 07, 2014 |
| **AB** | | | **40MG** | **A202397** | **002** | Jul 07, 2014 |
| **AB** | | | **80MG** | **A202397** | **003** | Jul 07, 2014 |
| **AB** | | PRINSTON INC | **20MG** | **A207882** | **001** | May 03, 2017 |
| **AB** | | | **40MG** | **A207882** | **002** | May 03, 2017 |
| **AB** | | | **80MG** | **A207882** | **003** | May 03, 2017 |
| **AB** | | SANDOZ INC | **20MG** | **A203867** | **001** | Nov 03, 2014 |
| **AB** | | | **40MG** | **A203867** | **002** | Nov 03, 2014 |
| **AB** | | | **80MG** | **A203867** | **003** | Nov 03, 2014 |
| **AB** | | TORRENT PHARMS LTD | **20MG** | **A203171** | **001** | Jul 07, 2014 |
| **AB** | | | **40MG** | **A203171** | **002** | Jul 07, 2014 |
| **AB** | | | **80MG** | **A203171** | **003** | Jul 07, 2014 |
| **AB** | | WATSON LABS | **20MG** | **A078710** | **001** | Jan 08, 2014 |
| **AB** | | | **40MG** | **A078710** | **002** | Jan 08, 2014 |
| **AB** | | | **80MG** | **A078710** | **003** | Jan 08, 2014 |
| **AB** | | ZYDUS PHARMS USA INC | **20MG** | **A203325** | **001** | Aug 26, 2014 |
| **AB** | | | **40MG** | **A203325** | **002** | Aug 26, 2014 |
| **AB** | | | **80MG** | **A203325** | **003** | Aug 26, 2014 |

TELOTRISTAT ETIPRATE

TABLET;ORAL

XERMELO

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | LEXICON PHARMS INC | EQ 250MG BASE | N208794 | 001 | Feb 28, 2017 |

TEMAZEPAM

CAPSULE;ORAL

**RESTORIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | SPECGX LLC | **7.5MG** | **N018163** | **003** | Oct 25, 1991 |
| **AB** | + | | **15MG** | **N018163** | **001** | |
| **AB** | + | | **22.5MG** | **N018163** | **004** | Nov 02, 2004 |
| **AB** | +! | | **30MG** | **N018163** | **002** | |

**TEMAZEPAM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS ELIZABETH | **15MG** | **A071620** | **002** | Aug 07, 1987 |
| **AB** | | | **30MG** | **A071620** | **001** | Aug 07, 1987 |
| **AB** | | AMNEAL PHARMS | **7.5MG** | **A203482** | **001** | May 23, 2016 |
| **AB** | | | **15MG** | **A203482** | **002** | May 23, 2016 |
| **AB** | | | **22.5MG** | **A203482** | **003** | May 23, 2016 |
| **AB** | | | **30MG** | **A203482** | **004** | May 23, 2016 |
| **AB** | | MYLAN | **7.5MG** | **A070920** | **002** | May 21, 2010 |
| **AB** | | | **15MG** | **A070920** | **004** | Jul 07, 1986 |
| **AB** | | | **22.5MG** | **A070920** | **003** | Jun 12, 2009 |
| **AB** | | | **30MG** | **A070920** | **001** | Jul 10, 1986 |
| **AB** | | NOVEL LABS INC | **7.5MG** | **A071457** | **002** | Jun 22, 2012 |
| **AB** | | | **15MG** | **A071456** | **001** | Apr 21, 1987 |
| **AB** | | | **22.5MG** | **A071457** | **003** | Jun 22, 2012 |

TEMAZEPAM

CAPSULE;ORAL

**TEMAZEPAM**

| | | | | | | |
|---|---|---|---|---|---|---|
| AB | | | 30MG | A071457 | 001 | Apr 21, 1987 |
| AB | | PRINSTON INC | 7.5MG | A201781 | 001 | Jun 04, 2015 |
| AB | | | 15MG | A201781 | 002 | Jun 04, 2015 |
| AB | | | 22.5MG | A201781 | 003 | Jun 04, 2015 |
| AB | | | 30MG | A201781 | 004 | Jun 04, 2015 |
| AB | | SANDOZ | 15MG | A071427 | 001 | Jan 12, 1988 |
| AB | | | 30MG | A071428 | 001 | Jan 12, 1988 |
| AB | | SUN PHARM INDUSTRIES | 7.5MG | A078581 | 001 | Sep 08, 2009 |
| AB | | | 22.5MG | A071175 | 002 | Sep 14, 2009 |

TEMOZOLOMIDE

CAPSULE;ORAL

**TEMODAR**

| | | | | | | |
|---|---|---|---|---|---|---|
| AB | + | MERCK SHARP DOHME | 5MG | N021029 | 001 | Aug 11, 1999 |
| AB | + | | 20MG | N021029 | 002 | Aug 11, 1999 |
| AB | + | | 100MG | N021029 | 003 | Aug 11, 1999 |
| AB | + | | 140MG | N021029 | 005 | Oct 19, 2006 |
| AB | + | | 180MG | N021029 | 006 | Oct 19, 2006 |
| AB | +! | | 250MG | N021029 | 004 | Aug 11, 1999 |

**TEMOZOLOMIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| AB | | ACCORD HLTHCARE | 5MG | A201528 | 001 | Feb 27, 2017 |
| AB | | | 20MG | A201528 | 002 | Feb 27, 2017 |
| AB | | | 100MG | A201528 | 003 | Feb 27, 2017 |
| AB | | | 140MG | A201528 | 004 | Feb 27, 2017 |
| AB | | | 180MG | A201528 | 005 | Feb 27, 2017 |
| AB | | | 250MG | A201528 | 006 | Feb 27, 2017 |
| AB | | AMERIGEN PHARMS LTD | 5MG | A203490 | 001 | Jul 13, 2016 |
| AB | | | 20MG | A203490 | 002 | Jul 13, 2016 |
| AB | | | 100MG | A203490 | 003 | Jul 13, 2016 |
| AB | | | 140MG | A203490 | 004 | Jul 13, 2016 |
| AB | | | 180MG | A203490 | 005 | Jul 13, 2016 |
| AB | | | 250MG | A203490 | 006 | Jul 13, 2016 |
| AB | | AMNEAL PHARMS | 5MG | A203691 | 001 | May 08, 2015 |
| AB | | | 20MG | A203691 | 002 | May 08, 2015 |
| AB | | | 100MG | A203691 | 003 | May 08, 2015 |
| AB | | | 140MG | A203691 | 004 | May 08, 2015 |
| AB | | | 180MG | A203691 | 005 | May 08, 2015 |
| AB | | | 250MG | A203691 | 006 | May 08, 2015 |
| AB | | BARR | 5MG | A078879 | 001 | Mar 01, 2010 |
| AB | | | 20MG | A078879 | 002 | Mar 01, 2010 |
| AB | | | 100MG | A078879 | 003 | Mar 01, 2010 |
| AB | | | 140MG | A078879 | 005 | Mar 01, 2010 |
| AB | | | 180MG | A078879 | 006 | Mar 01, 2010 |
| AB | | | 250MG | A078879 | 004 | Mar 01, 2010 |
| AB | | CHEMI SPA | 5MG | A204639 | 001 | Nov 23, 2016 |
| AB | | | 20MG | A204639 | 002 | Nov 23, 2016 |
| AB | | | 100MG | A204639 | 003 | Nov 23, 2016 |
| AB | | | 140MG | A204639 | 004 | Nov 23, 2016 |
| AB | | | 180MG | A204639 | 005 | Nov 23, 2016 |
| AB | | | 250MG | A204639 | 006 | Nov 23, 2016 |
| AB | | DEVA HOLDING AS | 5MG | A207658 | 001 | Apr 26, 2017 |
| AB | | | 20MG | A207658 | 002 | Apr 26, 2017 |
| AB | | | 100MG | A207658 | 003 | Apr 26, 2017 |
| AB | | | 140MG | A207658 | 004 | Apr 26, 2017 |
| AB | | | 180MG | A207658 | 005 | Apr 26, 2017 |
| AB | | | 250MG | A207658 | 006 | Apr 26, 2017 |
| AB | | IDT AUSTRALIA LTD | 5MG | A206413 | 001 | Apr 12, 2016 |
| AB | | | 20MG | A206413 | 002 | Apr 12, 2016 |
| AB | | | 100MG | A206413 | 003 | Apr 12, 2016 |
| AB | | | 140MG | A206413 | 004 | Apr 12, 2016 |
| AB | | | 180MG | A206413 | 005 | Apr 12, 2016 |
| AB | | | 250MG | A206413 | 006 | Apr 12, 2016 |
| AB | | KREMERS URBAN PHARMS | 5MG | A203898 | 001 | Feb 10, 2016 |
| AB | | | 20MG | A203898 | 002 | Feb 10, 2016 |
| AB | | | 100MG | A203898 | 003 | Feb 10, 2016 |
| AB | | | 140MG | A203898 | 004 | Feb 10, 2016 |
| AB | | | 180MG | A203898 | 005 | Feb 10, 2016 |
| AB | | | 250MG | A203898 | 006 | Feb 10, 2016 |

TEMOZOLOMIDE

CAPSULE;ORAL

**TEMOZOLOMIDE**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | MYLAN PHARMS INC | **5MG** | **A205227** | **001** | Jun 29, 2016 |
| **AB** | | **20MG** | **A205227** | **002** | Jun 29, 2016 |
| **AB** | | **100MG** | **A205227** | **003** | Jun 29, 2016 |
| **AB** | | **140MG** | **A205227** | **004** | Jun 29, 2016 |
| **AB** | | **180MG** | **A205227** | **005** | Jun 29, 2016 |
| **AB** | | **250MG** | **A205227** | **006** | Jun 29, 2016 |
| **AB** | RISING PHARMS INC | **5MG** | **A206309** | **001** | Apr 27, 2016 |
| **AB** | | **20MG** | **A206309** | **002** | Apr 27, 2016 |
| **AB** | | **100MG** | **A206309** | **003** | Apr 27, 2016 |
| **AB** | | **140MG** | **A206309** | **004** | Apr 27, 2016 |
| **AB** | | **180MG** | **A206309** | **005** | Apr 27, 2016 |
| **AB** | | **250MG** | **A206309** | **006** | Apr 27, 2016 |
| **AB** | SUN PHARMA GLOBAL | **5MG** | **A201742** | **001** | Feb 12, 2014 |
| **AB** | | **20MG** | **A201742** | **002** | Feb 12, 2014 |
| **AB** | | **100MG** | **A201742** | **003** | Feb 12, 2014 |
| **AB** | | **140MG** | **A201742** | **004** | Feb 12, 2014 |
| **AB** | | **180MG** | **A201742** | **005** | Feb 12, 2014 |
| **AB** | | **250MG** | **A201742** | **006** | Feb 12, 2014 |
| **AB** | WATSON LABS TEVA | **5MG** | **A203959** | **001** | Apr 18, 2017 |
| **AB** | | **20MG** | **A203959** | **002** | Apr 18, 2017 |
| **AB** | | **100MG** | **A203959** | **003** | Apr 18, 2017 |
| **AB** | | **140MG** | **A203959** | **004** | Apr 18, 2017 |
| **AB** | | **250MG** | **A203959** | **005** | Apr 18, 2017 |
| **AB** | ZYDUS PHARMS USA INC | **5MG** | **A206750** | **001** | Jul 31, 2017 |
| **AB** | | **20MG** | **A206750** | **002** | Jul 31, 2017 |
| **AB** | | **100MG** | **A206750** | **003** | Jul 31, 2017 |
| **AB** | | **140MG** | **A206750** | **004** | Jul 31, 2017 |
| **AB** | | **180MG** | **A206750** | **005** | Jul 31, 2017 |
| **AB** | | **250MG** | **A206750** | **006** | Jul 31, 2017 |

POWDER;INTRAVENOUS

TEMODAR

| | | | | | |
|---|---|---|---|---|---|
| +! | MERCK SHARP DOHME | 100MG/VIAL | N022277 | 001 | Feb 27, 2009 |

TEMSIROLIMUS

SOLUTION;INTRAVENOUS

TORISEL

| | | | | | |
|---|---|---|---|---|---|
| +! | PF PRISM CV | 25MG/ML (25MG/ML) | N022088 | 001 | May 30, 2007 |

TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

VEMLIDY

| | | | | | |
|---|---|---|---|---|---|
| +! | GILEAD SCIENCES INC | EQ 25MG BASE | N208464 | 001 | Nov 10, 2016 |

TENOFOVIR DISOPROXIL FUMARATE

POWDER;ORAL

VIREAD

| | | | | | |
|---|---|---|---|---|---|
| +! | GILEAD SCIENCES INC | 40MG/SCOOPFUL | N022577 | 001 | Jan 18, 2012 |

TABLET;ORAL

**TENOFOVIR DISOPROXIL FUMARATE**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | TEVA PHARMS USA | **300MG** | **A091612** | **001** | Mar 18, 2015 |

**VIREAD**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | **+!** GILEAD SCIENCES INC | **300MG** | **N021356** | **001** | Oct 26, 2001 |
| | + | 150MG | N021356 | 002 | Jan 18, 2012 |
| | + | 200MG | N021356 | 003 | Jan 18, 2012 |
| | + | 250MG | N021356 | 004 | Jan 18, 2012 |

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

**TERAZOSIN HYDROCHLORIDE**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | APOTEX | **EQ 1MG BASE** | **A075498** | **001** | Apr 12, 2001 |
| **AB** | | **EQ 2MG BASE** | **A075498** | **002** | Apr 12, 2001 |
| **AB** | | **EQ 5MG BASE** | **A075498** | **003** | Apr 12, 2001 |
| **AB** | | **EQ 10MG BASE** | **A075498** | **004** | Apr 12, 2001 |
| **AB** | IVAX SUB TEVA PHARMS | **EQ 1MG BASE** | **A075614** | **002** | Jan 30, 2001 |
| **AB** | | **EQ 2MG BASE** | **A075614** | **001** | Jan 30, 2001 |
| **AB** | | **EQ 5MG BASE** | **A075614** | **003** | Jan 30, 2001 |
| **AB** | | **EQ 10MG BASE** | **A075614** | **004** | Jan 30, 2001 |
| **AB** | JUBILANT CADISTA | **EQ 1MG BASE** | **A075317** | **001** | Dec 20, 2004 |
| **AB** | | **EQ 2MG BASE** | **A075317** | **002** | Dec 20, 2004 |
| **AB** | | **EQ 5MG BASE** | **A075317** | **003** | Dec 20, 2004 |

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

**TERAZOSIN HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **EQ 10MG BASE** | **A075317** | **004** | Dec 20, 2004 |
| **AB** | | MYLAN PHARMS INC | **EQ 1MG BASE** | **A075140** | **002** | Feb 11, 2000 |
| **AB** | | | **EQ 2MG BASE** | **A075140** | **003** | Feb 11, 2000 |
| **AB** | | | **EQ 5MG BASE** | **A075140** | **001** | Feb 11, 2000 |
| **AB** | | | **EQ 10MG BASE** | **A075140** | **004** | Feb 11, 2000 |
| **AB** | | SANDOZ | **EQ 1MG BASE** | **A074823** | **001** | Mar 30, 1998 |
| **AB** | **!** | | **EQ 2MG BASE** | **A074823** | **002** | Mar 30, 1998 |
| **AB** | | | **EQ 5MG BASE** | **A074823** | **003** | Mar 30, 1998 |
| **AB** | | | **EQ 10MG BASE** | **A074823** | **004** | Mar 30, 1998 |

TERBINAFINE HYDROCHLORIDE

TABLET;ORAL

**LAMISIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | NOVARTIS | **EQ 250MG BASE** | **N020539** | **001** | May 10, 1996 |

**TERBINAFINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | APOTEX | **EQ 250MG BASE** | **A078199** | **001** | Jul 02, 2007 |
| **AB** | | AUROBINDO PHARMA | **EQ 250MG BASE** | **A078297** | **001** | Jul 02, 2007 |
| **AB** | | BRECKENRIDGE PHARM | **EQ 250MG BASE** | **A077714** | **001** | Jun 04, 2010 |
| **AB** | | CIPLA LTD | **EQ 250MG BASE** | **A077137** | **001** | Jul 02, 2007 |
| **AB** | | DR REDDYS LABS INC | **EQ 250MG BASE** | **A076390** | **001** | Jul 02, 2007 |
| **AB** | | GLENMARK GENERICS | **EQ 250MG BASE** | **A078157** | **001** | Jul 02, 2007 |
| **AB** | | HARRIS PHARM | **EQ 250MG BASE** | **A077919** | **001** | Jul 02, 2007 |
| **AB** | | INVAGEN PHARMS | **EQ 250MG BASE** | **A077533** | **001** | Jul 02, 2007 |
| **AB** | | ORCHID HLTHCARE | **EQ 250MG BASE** | **A078163** | **001** | Jul 02, 2007 |
| **AB** | | TEVA | **EQ 250MG BASE** | **A076377** | **001** | Jul 02, 2007 |

TERBUTALINE SULFATE

INJECTABLE;INJECTION

**TERBUTALINE SULFATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AKORN | **1MG/ML** | **A078151** | **001** | Jan 07, 2008 |
| **AP** | **!** | ATHENEX INC | **1MG/ML** | **A076770** | **001** | Apr 23, 2004 |
| **AP** | | FRESENIUS KABI USA | **1MG/ML** | **A076887** | **001** | May 26, 2004 |
| **AP** | | HIKMA FARMACEUTICA | **1MG/ML** | **A078630** | **001** | May 20, 2009 |
| **AP** | | UNITED BIOMEDCL | **1MG/ML** | **A200122** | **001** | Nov 08, 2013 |

TABLET;ORAL

**TERBUTALINE SULFATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | IMPAX LABS | **2.5MG** | **A075877** | **001** | Jun 26, 2001 |
| **AB** | | | **5MG** | **A075877** | **002** | Jun 26, 2001 |
| **AB** | | LANNETT | **2.5MG** | **A077152** | **001** | Mar 25, 2005 |
| **AB** | **!** | | **5MG** | **A077152** | **002** | Mar 25, 2005 |

TERCONAZOLE

CREAM;VAGINAL

**TERAZOL 7**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | JANSSEN PHARMS | **0.4%** | **N019579** | **001** | Dec 31, 1987 |

**TERCONAZOLE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | FOUGERA PHARMS | **0.4%** | **A076712** | **001** | Feb 18, 2005 |
| **AB** | | TARO | **0.4%** | **A076043** | **001** | Jan 19, 2005 |
| BX | +! | NYCOMED US | 0.8% | N021735 | 001 | Oct 01, 2004 |
| BX | ! | TARO | 0.8% | A075953 | 001 | Apr 06, 2004 |

SUPPOSITORY;VAGINAL

**TERAZOL 3**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | JANSSEN PHARMS | **80MG** | **N019641** | **001** | May 24, 1988 |

**TERCONAZOLE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | PERRIGO NEW YORK | **80MG** | **A077149** | **001** | Mar 17, 2006 |
| **AB** | | TARO | **80MG** | **A077553** | **001** | Mar 09, 2007 |

TERIFLUNOMIDE

TABLET;ORAL

AUBAGIO

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | SANOFI AVENTIS US | 7MG | N202992 | 001 | Sep 12, 2012 |
| | +! | | 14MG | N202992 | 002 | Sep 12, 2012 |

TERIPARATIDE RECOMBINANT HUMAN

INJECTABLE;SUBCUTANEOUS

FORTEO

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | LILLY | 0.6MG/2.4ML (0.25MG/ML) | N021318 | 002 | Jun 25, 2008 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| TESAMORELIN ACETATE | | | | | | | |
| POWDER;SUBCUTANEOUS | | | | | | | |
| EGRIFTA | | | | | | | |
| | +! | THERATECHNOLOGIES | EQ 1MG BASE/VIAL | | N022505 | 001 | Nov 10, 2010 |
| TESTOSTERONE | | | | | | | |
| FILM, EXTENDED RELEASE;TRANSDERMAL | | | | | | | |
| ANDRODERM | | | | | | | |
| | +! | ALLERGAN SALES LLC | 2MG/24HR | | N020489 | 003 | Oct 20, 2011 |
| | +! | | 4MG/24HR | | N020489 | 004 | Oct 20, 2011 |
| GEL;TRANSDERMAL | | | | | | | |
| **ANDROGEL** | | | | | | | |
| **AB1** | **+** | ABBVIE | **25MG/2.5GM PACKET** | | **N021015** | **001** | Feb 28, 2000 |
| **AB1** | **+!** | | **50MG/5GM PACKET** | | **N021015** | **002** | Feb 28, 2000 |
| **TESTOSTERONE** | | | | | | | |
| **AB1** | | ACTAVIS LABS UT INC | **25MG/2.5GM PACKET** | | **A076737** | **001** | Jan 27, 2006 |
| **AB1** | | | **50MG/5GM PACKET** | | **A076737** | **002** | Jan 27, 2006 |
| **AB1** | | PAR PHARM | **25MG/2.5GM PACKET** | | **A076744** | **001** | May 23, 2007 |
| **AB1** | | | **50MG/5GM PACKET** | | **A076744** | **002** | May 23, 2007 |
| **AB1** | | PERRIGO ISRAEL | **25MG/2.5GM PACKET** | | **N203098** | **002** | Jan 31, 2013 |
| **AB1** | | | **50MG/5GM PACKET** | | **N203098** | **003** | Jan 31, 2013 |
| **ANDROGEL** | | | | | | | |
| **AB2** | **+** | ABBVIE | **1.62% (20.25MG/1.25GM PACKET)** | | **N022309** | **002** | Sep 07, 2012 |
| **AB2** | **+!** | | **1.62% (40.5MG/2.5GM PACKET)** | | **N022309** | **003** | Sep 07, 2012 |
| **TESTIM** | | | | | | | |
| **AB2** | **+!** | AUXILIUM PHARMS LLC | **50MG/5GM PACKET** | | **N021454** | **001** | Oct 31, 2002 |
| **TESTOSTERONE** | | | | | | | |
| **AB2** | | ACTAVIS LABS UT INC | **50MG/5GM PACKET** | | **A091073** | **001** | Sep 18, 2017 |
| **AB2** | | PERRIGO UK FINCO | **1.62% (20.25MG/1.25GM PACKET)** | | **A205781** | **001** | Jul 12, 2017 |
| **AB2** | | | **1.62% (40.5MG/2.5GM PACKET)** | | **A205781** | **002** | Jul 12, 2017 |
| **VOGELXO** | | | | | | | |
| **AB2** | | UPSHER-SMITH LABS | **50MG/5GM PACKET** | | **N204399** | **002** | Jun 04, 2014 |
| TESTOSTERONE | | | | | | | |
| BX | | ANI PHARMS INC | 25MG/2.5GM PACKET | | N202763 | 001 | Feb 14, 2012 |
| BX | | | 50MG/5GM PACKET | | N202763 | 002 | Feb 14, 2012 |
| GEL, METERED;NASAL | | | | | | | |
| NATESTO | | | | | | | |
| | | AYTU BIOSCIENCE INC | 5.5MG/0.122GM ACTUATION | | N205488 | 001 | May 28, 2014 |
| GEL, METERED;TRANSDERMAL | | | | | | | |
| **ANDROGEL** | | | | | | | |
| **AB** | **+!** | ABBVIE | **1.62% (20.25MG/1.25GM ACTUATION)** | | **N022309** | **001** | Apr 29, 2011 |
| **AB** | **+!** | | **12.5MG/1.25GM ACTUATION** | | **N021015** | **003** | Sep 26, 2003 |
| **FORTESTA** | | | | | | | |
| **AB** | **+!** | ENDO PHARMS | **10MG/0.5GM ACTUATION** | | **N021463** | **001** | Dec 29, 2010 |
| **TESTOSTERONE** | | | | | | | |
| **AB** | | ACTAVIS LABS UT INC | **10MG/0.5GM ACTUATION** | | **A204571** | **001** | Aug 05, 2015 |
| **AB** | | | **12.5MG/1.25GM ACTUATION** | | **A076737** | **003** | Mar 09, 2015 |
| **AB** | | PERRIGO ISRAEL | **12.5MG/1.25GM ACTUATION** | | **N203098** | **001** | Jan 31, 2013 |
| **AB** | | | **1.62% (20.25MG/1.25GM ACTUATION)** | | **A204268** | **001** | Aug 04, 2015 |
| VOGELXO | | | | | | | |
| BX | | UPSHER-SMITH LABS | 12.5MG/1.25GM ACTUATION | | N204399 | 003 | Jun 04, 2014 |
| PELLET;IMPLANTATION | | | | | | | |
| TESTOPEL | | | | | | | |
| | ! | AUXILIUM PHARMS INC | 75MG | | A080911 | 001 | |
| SOLUTION, METERED;TRANSDERMAL | | | | | | | |
| **TESTOSTERONE** | | | | | | | |
| **AT** | | ACTAVIS LABS UT INC | **30MG/1.5ML ACTUATION** | | **A205328** | **001** | Aug 07, 2017 |
| **AT** | | LUPIN LTD | **30MG/1.5ML ACTUATION** | | **A208061** | **001** | Oct 23, 2017 |
| **AT** | **!** | PERRIGO ISRAEL | **30MG/1.5ML ACTUATION** | | **A204255** | **001** | Feb 28, 2017 |
| TABLET, EXTENDED RELEASE;BUCCAL | | | | | | | |
| STRIANT | | | | | | | |
| | +! | AUXILIUM PHARMS LLC | 30MG | | N021543 | 001 | Jun 19, 2003 |
| TESTOSTERONE CYPIONATE | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| **DEPO-TESTOSTERONE** | | | | | | | |
| **AO** | **!** | PHARMACIA AND UPJOHN | **100MG/ML** | | **A085635** | **002** | |
| **AO** | **!** | | **200MG/ML** | | **A085635** | **003** | |
| **TESTOSTERONE CYPIONATE** | | | | | | | |
| **AO** | | HIKMA FARMACEUTICA | **200MG/ML** | | **A091244** | **001** | May 01, 2012 |
| **AO** | | LUITPOLD PHARMS INC | **200MG/ML** | | **A207742** | **001** | Jun 16, 2017 |
| **AO** | | MYLAN INSTITUTIONAL | **200MG/ML** | | **A040652** | **001** | Dec 11, 2006 |
| **AO** | | PADDOCK LLC | **200MG/ML** | | **A040530** | **001** | Jan 31, 2005 |

TESTOSTERONE CYPIONATE

INJECTABLE;INJECTION

**TESTOSTERONE CYPIONATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AO** | | SANDOZ INC | **100MG/ML** | **A040615** | **001** | Aug 10, 2006 |
| **AO** | | | **200MG/ML** | **A040615** | **002** | Aug 10, 2006 |
| **AO** | | SUN PHARM INDS LTD | **100MG/ML** | **A201720** | **001** | Jun 03, 2013 |
| **AO** | | | **200MG/ML** | **A201720** | **002** | Jun 03, 2013 |
| **AO** | | WATSON PHARMS INC | **200MG/ML** | **A086030** | **001** | |
| **AO** | | WEST-WARD PHARMS INT | **100MG/ML** | **A090387** | **001** | Jul 15, 2010 |
| **AO** | | | **200MG/ML** | **A090387** | **002** | Jul 15, 2010 |

TESTOSTERONE ENANTHATE

INJECTABLE;INJECTION

**DELATESTRYL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AO** | **+!** | ENDO PHARMS | **200MG/ML** | **N009165** | **003** | |

**TESTOSTERONE ENANTHATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AO** | | HIKMA FARMACEUTICA | **200MG/ML** | **A091120** | **001** | Sep 18, 2012 |
| **AO** | | MYLAN INSTITUTIONAL | **200MG/ML** | **A040647** | **001** | Oct 05, 2009 |
| **AO** | | PADDOCK LLC | **200MG/ML** | **A040575** | **001** | Jun 14, 2006 |
| **AO** | | WATSON PHARMS INC | **200MG/ML** | **A085598** | **001** | |

TESTOSTERONE UNDECANOATE

INJECTABLE;INTRAMUSCULAR

AVEED

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ENDO PHARMS INC | 750MG/3ML (250MG/ML) | N022219 | 001 | Mar 05, 2014 |

TETRABENAZINE

TABLET;ORAL

**TETRABENAZINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS LABS FL INC | **25MG** | **A206686** | **001** | Jul 07, 2017 |
| **AB** | | APICORE US | **12.5MG** | **A207682** | **001** | Jan 31, 2017 |
| **AB** | | | **25MG** | **A207682** | **002** | Jan 31, 2017 |
| **AB** | | BIONPHARMA INC | **12.5MG** | **A208826** | **001** | Dec 18, 2017 |
| **AB** | | | **25MG** | **A208826** | **002** | Dec 18, 2017 |
| **AB** | | DR REDDYS LABS LTD | **12.5MG** | **A209284** | **001** | Jan 08, 2018 |
| **AB** | | | **25MG** | **A209284** | **002** | Jan 08, 2018 |
| **AB** | | HETERO LABS LTD V | **12.5MG** | **A204574** | **001** | Feb 03, 2016 |
| **AB** | | | **25MG** | **A204574** | **002** | Feb 03, 2016 |
| **AB** | | SUN PHARMA GLOBAL | **12.5MG** | **A206129** | **001** | Aug 17, 2015 |
| **AB** | | | **25MG** | **A206129** | **002** | Aug 17, 2015 |

**XENAZINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | VALEANT PHARMS NORTH | **12.5MG** | **N021894** | **001** | Aug 15, 2008 |
| **AB** | **+!** | | **25MG** | **N021894** | **002** | Aug 15, 2008 |

TETRACAINE HYDROCHLORIDE

SOLUTION;OPHTHALMIC

TETRACAINE HYDROCHLORIDE

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | NOVARTIS PHARMS CORP | 0.5% | N208135 | 001 | Feb 29, 2016 |

TETRACYCLINE HYDROCHLORIDE

CAPSULE;ORAL

**ACHROMYCIN V**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | HERITAGE PHARMA | **250MG** | **N050278** | **003** | |
| **AB** | **+!** | | **500MG** | **N050278** | **001** | |

**TETRACYCLINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | CHARTWELL TETRA | **250MG** | **A062752** | **001** | Aug 12, 1988 |
| **AB** | | | **500MG** | **A062752** | **002** | Aug 12, 1988 |
| **AB** | | WATSON LABS | **250MG** | **A061837** | **001** | |
| **AB** | | | **500MG** | **A061837** | **002** | |

TETRAHYDROZOLINE HYDROCHLORIDE

SOLUTION;NASAL

TYZINE

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | FOUGERA PHARMS | 0.05% | A086576 | 002 | |
| | | | 0.1% | A086576 | 001 | |

SPRAY;NASAL

TYZINE

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | FOUGERA PHARMS | 0.1% | A086576 | 003 | |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| THALIDOMIDE | | | | | | | |
| CAPSULE;ORAL | | | | | | | |
| THALOMID | | | | | | | |
| | + | CELGENE | 50MG | N020785 | 001 | Jul 16, 1998 |
| | + | | 100MG | N020785 | 002 | Jan 17, 2003 |
| | + | | 150MG | N020785 | 004 | Jan 10, 2007 |
| | +! | | 200MG | N020785 | 003 | Jan 17, 2003 |
| THALLOUS CHLORIDE TL-201 | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| **THALLOUS CHLORIDE TL 201** | | | | | | | |
| **AP** | **+!** | GE HEALTHCARE | **1mCi/ML** | **N018110** | **002** | Feb 27, 1996 |
| **AP** | **+!** | LANTHEUS MEDCL | **1mCi/ML** | **N017806** | **001** | |
| **AP** | **+!** | MALLINKRODT NUCLEAR | **1mCi/ML** | **N018150** | **001** | |
| INJECTABLE;INTRAVENOUS | | | | | | | |
| **THALLOUS CHLORIDE TL 201** | | | | | | | |
| **AP** | **+!** | LANTHEUS MEDCL | **2mCi/ML** | **N017806** | **002** | Oct 09, 1998 |
| THEOPHYLLINE | | | | | | | |
| CAPSULE, EXTENDED RELEASE;ORAL | | | | | | | |
| THEO-24 | | | | | | | |
| | | ACTIENT PHARMS | 100MG | A087942 | 001 | Aug 22, 1983 |
| | ! | AUXILIUM PHARMS INC | 400MG | A081034 | 001 | Feb 28, 1992 |
| | | AUXILIUM PHARMS LLC | 200MG | A087943 | 001 | Aug 22, 1983 |
| | | | 300MG | A087944 | 001 | Aug 22, 1983 |
| INJECTABLE;INJECTION | | | | | | | |
| **THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER** | | | | | | | |
| **AP** | **+!** | B BRAUN | **40MG/100ML** | **N019826** | **001** | Aug 14, 1992 |
| **THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER** | | | | | | | |
| **AP** | **+!** | B BRAUN | **160MG/100ML** | **N019826** | **003** | Aug 14, 1992 |
| **THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER** | | | | | | | |
| **AP** | **+!** | B BRAUN | **320MG/100ML** | **N019826** | **006** | Aug 14, 1992 |
| **THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER** | | | | | | | |
| **AP** | **+!** | HOSPIRA INC | **40MG/100ML** | **N019211** | **001** | Dec 14, 1984 |
| **AP** | **+!** | | **160MG/100ML** | **N019211** | **003** | Dec 14, 1984 |
| **AP** | **+!** | | **320MG/100ML** | **N019211** | **006** | Jan 20, 1988 |
| THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER | | | | | | | |
| | +! | B BRAUN | 80MG/100ML | N019826 | 002 | Aug 14, 1992 |
| THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | | | | |
| | +! | HOSPIRA INC | 4MG/ML | N019211 | 007 | Dec 14, 1984 |
| SOLUTION;ORAL | | | | | | | |
| **THEOPHYLLINE** | | | | | | | |
| **AA** | **!** | SILARX | **80MG/15ML** | **A091156** | **001** | Apr 13, 2011 |
| **AA** | | TRIS PHARMA INC | **80MG/15ML** | **A091586** | **001** | Jun 15, 2012 |
| SOLUTION, ELIXIR;ORAL | | | | | | | |
| **ELIXOPHYLLIN** | | | | | | | |
| **AA** | **!** | NOSTRUM LABS INC | **80MG/15ML** | **A085186** | **001** | |
| **THEOPHYLLINE** | | | | | | | |
| **AA** | | PHARM ASSOC | **80MG/15ML** | **A206344** | **001** | Dec 16, 2016 |
| TABLET, EXTENDED RELEASE;ORAL | | | | | | | |
| **THEOPHYLLINE** | | | | | | | |
| **AB** | | ALEMBIC PHARMS LTD | **300MG** | **A090430** | **001** | Oct 27, 2010 |
| **AB** | | GLENMARK GENERICS | **400MG** | **A090355** | **001** | Jul 13, 2010 |
| **AB** | | | **600MG** | **A090355** | **002** | Jul 13, 2010 |
| **AB** | | MYLAN IRELAND LTD | **400MG** | **A040560** | **003** | Apr 21, 2006 |
| **AB** | **!** | | **600MG** | **A040560** | **002** | Apr 21, 2006 |
| **AB** | **!** | PLIVA | **100MG** | **A089807** | **001** | Apr 30, 1990 |
| **AB** | **!** | | **200MG** | **A089808** | **001** | Apr 30, 1990 |
| **AB** | | | **300MG** | **A089763** | **001** | Apr 30, 1990 |
| **AB** | | RHODES PHARMS | **400MG** | **A087571** | **001** | Sep 01, 1982 |
| **AB** | | | **600MG** | **A040086** | **001** | Apr 15, 1996 |
| THEOCHRON | | | | | | | |
| | | NOSTRUM PHARMS LLC | 100MG | A087400 | 003 | Feb 21, 1985 |
| | | | 200MG | A087400 | 004 | Feb 21, 1985 |
| THEOPHYLLINE | | | | | | | |
| | ! | ALEMBIC PHARMS LTD | 450MG | A090430 | 002 | Oct 27, 2010 |
| THIAMINE HYDROCHLORIDE | | | | | | | |
| INJECTABLE;INJECTION | | | | | | | |
| **THIAMINE HYDROCHLORIDE** | | | | | | | |
| **AP** | **!** | FRESENIUS KABI USA | **100MG/ML** | **A080556** | **001** | |
| **AP** | | MYLAN INSTITUTIONAL | **100MG/ML** | **A091623** | **001** | Jun 25, 2012 |
| **AP** | | SAGENT PHARMS | **100MG/ML** | **A206106** | **001** | Dec 01, 2017 |

THIOGUANINE
TABLET;ORAL
THIOGUANINE

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ASPEN GLOBAL INC | 40MG | N012429 | 001 | |

THIORIDAZINE HYDROCHLORIDE
TABLET;ORAL
**THIORIDAZINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | MYLAN | **10MG** | **A088004** | **002** | Mar 15, 1983 |
| **AB** | | | **25MG** | **A088004** | **003** | Mar 15, 1983 |
| **AB** | | | **50MG** | **A088004** | **004** | Mar 15, 1983 |
| **AB** | **!** | | **100MG** | **A088004** | **001** | Nov 18, 1983 |
| **AB** | | SUN PHARM INDUSTRIES | **10MG** | **A089953** | **004** | Aug 01, 1986 |
| **AB** | | | **25MG** | **A089953** | **003** | Aug 01, 1986 |
| **AB** | | | **50MG** | **A089953** | **002** | Aug 01, 1986 |
| **AB** | | | **100MG** | **A089953** | **001** | Oct 07, 1988 |

THIOTEPA
INJECTABLE;INJECTION
THIOTEPA

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | WEST-WARD PHARMS INT | 15MG/VIAL | A075547 | 001 | Apr 02, 2001 |

POWDER;IV (INFUSION)
TEPADINA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ADIENNE SA | 15MG/VIAL | N208264 | 001 | Jan 26, 2017 |
| | +! | | 100MG/VIAL | N208264 | 002 | Jan 26, 2017 |

THIOTHIXENE
CAPSULE;ORAL
THIOTHIXENE

| | | | | | | |
|---|---|---|---|---|---|---|
| | | MYLAN | 1MG | A071093 | 002 | Jun 23, 1987 |
| | | | 2MG | A071093 | 003 | Jun 23, 1987 |
| | ! | | 5MG | A071093 | 004 | Jun 23, 1987 |
| | | | 10MG | A071093 | 001 | Jun 23, 1987 |

THYROTROPIN ALFA
INJECTABLE;INJECTION
THYROGEN

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | GENZYME | 1.1MG/VIAL | N020898 | 001 | Nov 30, 1998 |

TIAGABINE HYDROCHLORIDE
TABLET;ORAL
**GABITRIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | CEPHALON | **2MG** | **N020646** | **005** | Apr 16, 1999 |
| **AB** | **+!** | | **4MG** | **N020646** | **001** | Sep 30, 1997 |
| **AB** | **+** | | **12MG** | **N020646** | **002** | Sep 30, 1997 |
| **AB** | **+** | | **16MG** | **N020646** | **003** | Sep 30, 1997 |

**TIAGABINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AMNEAL PHARMS CO | **2MG** | **A208181** | **001** | Dec 08, 2017 |
| **AB** | | | **4MG** | **A208181** | **002** | Dec 08, 2017 |
| **AB** | | | **12MG** | **A208181** | **003** | Dec 08, 2017 |
| **AB** | | | **16MG** | **A208181** | **004** | Dec 08, 2017 |
| **AB** | | SUN PHARM INDS | **2MG** | **A077555** | **001** | Nov 04, 2011 |
| **AB** | | | **4MG** | **A077555** | **002** | Nov 04, 2011 |
| **AB** | | WILSHIRE PHARMS INC | **2MG** | **A206857** | **001** | Oct 13, 2017 |
| **AB** | | | **4MG** | **A206857** | **002** | Oct 13, 2017 |
| **AB** | | | **12MG** | **A206857** | **003** | Oct 13, 2017 |
| **AB** | | | **16MG** | **A206857** | **004** | Oct 13, 2017 |

TICAGRELOR
TABLET;ORAL
BRILINTA

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | ASTRAZENECA PHARMS | 60MG | N022433 | 002 | Sep 03, 2015 |
| | +! | | 90MG | N022433 | 001 | Jul 20, 2011 |

TICLOPIDINE HYDROCHLORIDE
TABLET;ORAL
**TICLOPIDINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | APOTEX | **250MG** | **A075089** | **001** | Jul 01, 1999 |
| **AB** | | SUN PHARM INDS INC | **250MG** | **A075526** | **001** | Sep 26, 2002 |
| **AB** | **!** | TEVA | **250MG** | **A075149** | **001** | Aug 20, 1999 |

TIGECYCLINE
POWDER;IV (INFUSION)

| | | | | | | |
|---|---|---|---|---|---|---|
| **TIGECYCLINE** | | | | | | |
| **AP** | | FRESENIUS KABI USA | **50MG/VIAL** | **N205645** | **001** | Dec 01, 2016 |
| **AP** | | SANDOZ INC | **50MG/VIAL** | **A091620** | **001** | May 27, 2015 |
| **TYGACIL** | | | | | | |
| **AP** | **+!** | PF PRISM CV | **50MG/VIAL** | **N021821** | **001** | Jun 15, 2005 |

TIMOLOL
SOLUTION/DROPS;OPHTHALMIC

| | | | | | | |
|---|---|---|---|---|---|---|
| **BETIMOL** | | | | | | |
| **AT** | **+!** | OAK PHARMS INC | **EQ 0.25% BASE** | **N020439** | **001** | Mar 31, 1995 |
| **AT** | **+!** | | **EQ 0.5% BASE** | **N020439** | **002** | Mar 31, 1995 |
| **TIMOLOL** | | | | | | |
| **AT** | | AKORN | **EQ 0.25% BASE** | **A205309** | **001** | Sep 30, 2016 |
| **AT** | | | **EQ 0.5% BASE** | **A205309** | **002** | Sep 30, 2016 |

TIMOLOL MALEATE
SOLUTION, GEL FORMING/DROPS;OPHTHALMIC

| | | | | | | |
|---|---|---|---|---|---|---|
| **TIMOLOL MALEATE** | | | | | | |
| **AB** | | SANDOZ INC | **EQ 0.25% BASE** | **N020963** | **001** | Oct 21, 1998 |
| **AB** | | | **EQ 0.5% BASE** | **N020963** | **002** | Oct 21, 1998 |
| **TIMOPTIC-XE** | | | | | | |
| **AB** | **+!** | VALEANT PHARMS LLC | **EQ 0.25% BASE** | **N020330** | **001** | Nov 04, 1993 |
| **AB** | **+!** | | **EQ 0.5% BASE** | **N020330** | **002** | Nov 04, 1993 |

SOLUTION/DROPS;OPHTHALMIC

| | | | | | | |
|---|---|---|---|---|---|---|
| **TIMOLOL MALEATE** | | | | | | |
| **AT** | | BAUSCH AND LOMB | **EQ 0.25% BASE** | **A074778** | **001** | Mar 25, 1997 |
| **AT** | | FDC LTD | **EQ 0.25% BASE** | **A077259** | **001** | Apr 30, 2008 |
| **AT** | | PACIFIC PHARMA | **EQ 0.25% BASE** | **A074746** | **001** | Mar 25, 1997 |
| **AT** | **!** | SANDOZ INC | **EQ 0.25% BASE** | **A074261** | **001** | Apr 28, 1995 |
| **AT** | | WOCKHARDT | **EQ 0.25% BASE** | **A078771** | **001** | Sep 28, 2009 |
| **AT1** | | AKORN | **EQ 0.5% BASE** | **A074466** | **001** | Mar 25, 1997 |
| **AT1** | | | **EQ 0.5% BASE** | **A074516** | **001** | Mar 25, 1997 |
| **AT1** | | BAUSCH AND LOMB | **EQ 0.5% BASE** | **A074776** | **001** | Mar 25, 1997 |
| **AT1** | | FDC LTD | **EQ 0.5% BASE** | **A077259** | **002** | Apr 30, 2008 |
| **AT1** | | HI TECH PHARMA | **EQ 0.5% BASE** | **A075163** | **001** | Sep 10, 2002 |
| **AT1** | | PACIFIC PHARMA | **EQ 0.5% BASE** | **A074747** | **001** | Mar 25, 1997 |
| **AT1** | **!** | SANDOZ INC | **EQ 0.5% BASE** | **A074262** | **001** | Apr 28, 1995 |
| **AT1** | | WOCKHARDT | **EQ 0.5% BASE** | **A078771** | **002** | Sep 28, 2009 |
| **ISTALOL** | | | | | | |
| **AT2** | **+!** | BAUSCH AND LOMB | **EQ 0.5% BASE** | **N021516** | **001** | Jun 04, 2004 |
| **TIMOLOL MALEATE** | | | | | | |
| **AT2** | | APOTEX INC | **EQ 0.5% BASE** | **A204936** | **001** | Apr 17, 2015 |
| TIMOPTIC IN OCUDOSE | | | | | | |
| | +! | ATON | EQ 0.25% BASE | N019463 | 001 | Nov 05, 1986 |
| | +! | | EQ 0.5% BASE | N019463 | 002 | Nov 05, 1986 |

TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| TIMOLOL MALEATE | | | | | | |
| | | MYLAN | 5MG | A072668 | 002 | Jun 08, 1990 |
| | | | 10MG | A072668 | 003 | Jun 08, 1990 |
| | ! | | 20MG | A072668 | 001 | Jun 08, 1990 |

TINIDAZOLE
TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **TINDAMAX** | | | | | | |
| **AB** | **+** | MISSION PHARMA | **250MG** | **N021618** | **001** | May 17, 2004 |
| **AB** | **+!** | | **500MG** | **N021618** | **002** | May 17, 2004 |
| **TINIDAZOLE** | | | | | | |
| **AB** | | EDENBRIDGE PHARMS | **250MG** | **A203808** | **001** | Aug 04, 2015 |
| **AB** | | | **500MG** | **A203808** | **002** | Aug 04, 2015 |
| **AB** | | NOVEL LABS INC | **250MG** | **A202044** | **001** | Apr 30, 2012 |
| **AB** | | | **500MG** | **A202044** | **002** | Apr 30, 2012 |
| **AB** | | UNIQUE PHARM LABS | **250MG** | **A202489** | **001** | Oct 09, 2013 |
| **AB** | | | **500MG** | **A202489** | **002** | Oct 09, 2013 |
| **AB** | | WEST-WARD PHARMS INT | **250MG** | **A201172** | **001** | Apr 30, 2012 |
| **AB** | | | **500MG** | **A201172** | **002** | Apr 30, 2012 |

TIOPRONIN

TABLET;ORAL

THIOLA

| | | | | | |
|---|---|---|---|---|---|
| +! | MISSION PHARMA | 100MG | N019569 | 001 | Aug 11, 1988 |

TIOTROPIUM BROMIDE

POWDER;INHALATION

SPIRIVA

| | | | | | |
|---|---|---|---|---|---|
| +! | BOEHRINGER INGELHEIM | EQ 0.018MG BASE/INH | N021395 | 001 | Jan 30, 2004 |

SPRAY, METERED;INHALATION

SPIRIVA RESPIMAT

| | | | | | |
|---|---|---|---|---|---|
| + | BOEHRINGER INGELHEIM | EQ 0.00125MG BASE/INH | N021936 | 002 | Sep 15, 2015 |
| +! | | EQ 0.0025MG BASE/INH | N021936 | 001 | Sep 24, 2014 |

TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE

TABLET;ORAL

LONSURF

| | | | | | |
|---|---|---|---|---|---|
| + | TAIHO ONCOLOGY | EQ 6.14MG BASE;15MG | N207981 | 001 | Sep 22, 2015 |
| +! | | EQ 8.19MG BASE;20MG | N207981 | 002 | Sep 22, 2015 |

TIPRANAVIR

CAPSULE;ORAL

APTIVUS

| | | | | | |
|---|---|---|---|---|---|
| +! | BOEHRINGER INGELHEIM | 250MG | N021814 | 001 | Jun 22, 2005 |

SOLUTION;ORAL

APTIVUS

| | | | | | |
|---|---|---|---|---|---|
| +! | BOEHRINGER INGELHEIM | 100MG/ML | N022292 | 001 | Jun 23, 2008 |

TIROFIBAN HYDROCHLORIDE

INJECTABLE;INJECTION

AGGRASTAT

| | | | | | |
|---|---|---|---|---|---|
| + | MEDICURE | EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML) | N020913 | 002 | May 17, 2002 |
| +! | | EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML) | N020913 | 003 | Apr 20, 2000 |

SOLUTION;INJECTION

AGGRASTAT

| | | | | | |
|---|---|---|---|---|---|
| +! | MEDICURE | EQ 3.75MG BASE/15ML (EQ 0.25MG BASE/ML) | N020912 | 002 | Aug 31, 2016 |

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL

**TIZANIDINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | APOTEX INC | **EQ 2MG BASE** | **A078868** | **001** | Feb 03, 2012 |
| **AB** | | | **EQ 4MG BASE** | **A078868** | **002** | Feb 03, 2012 |
| **AB** | | | **EQ 6MG BASE** | **A078868** | **003** | Feb 03, 2012 |
| **AB** | | JUBILANT GENERICS | **EQ 2MG BASE** | **A209605** | **001** | Aug 04, 2017 |
| **AB** | | | **EQ 4MG BASE** | **A209605** | **002** | Aug 04, 2017 |
| **AB** | | | **EQ 6MG BASE** | **A209605** | **003** | Aug 04, 2017 |
| **AB** | | MYLAN PHARMS INC | **EQ 2MG BASE** | **A091502** | **001** | Nov 09, 2012 |
| **AB** | | | **EQ 4MG BASE** | **A091502** | **002** | Nov 09, 2012 |
| **AB** | | | **EQ 6MG BASE** | **A091502** | **003** | Nov 09, 2012 |
| **AB** | | PAR PHARM INC | **EQ 2MG BASE** | **A207199** | **001** | Mar 14, 2017 |
| **AB** | | | **EQ 4MG BASE** | **A207199** | **002** | Mar 14, 2017 |
| **AB** | | | **EQ 6MG BASE** | **A207199** | **003** | Mar 14, 2017 |
| **AB** | | ZYDUS PHARMS USA INC | **EQ 2MG BASE** | **A208622** | **001** | Mar 03, 2017 |
| **AB** | | | **EQ 4MG BASE** | **A208622** | **002** | Mar 03, 2017 |
| **AB** | | | **EQ 6MG BASE** | **A208622** | **003** | Mar 03, 2017 |

**ZANAFLEX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | COVIS PHARMA BV | **EQ 2MG BASE** | **N021447** | **001** | Aug 29, 2002 |
| **AB** | **+** | | **EQ 4MG BASE** | **N021447** | **002** | Aug 29, 2002 |
| **AB** | **+!** | | **EQ 6MG BASE** | **N021447** | **003** | Aug 29, 2002 |

TABLET;ORAL

**TIZANIDINE HYDROCHLORIDE**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | APOTEX | **EQ 2MG BASE** | **A076533** | **001** | Jan 16, 2004 |
| **AB** | | **EQ 4MG BASE** | **A076533** | **002** | Jan 16, 2004 |
| **AB** | DR REDDYS LABS INC | **EQ 2MG BASE** | **A076286** | **001** | Jul 03, 2002 |
| **AB** | | **EQ 4MG BASE** | **A076286** | **002** | Jul 03, 2002 |
| **AB** | EPIC PHARMA LLC | **EQ 2MG BASE** | **A076347** | **001** | Oct 11, 2002 |
| **AB** | | **EQ 4MG BASE** | **A076347** | **002** | Oct 11, 2002 |
| **AB** | MYLAN | **EQ 2MG BASE** | **A076354** | **001** | Mar 28, 2003 |
| **AB** | | **EQ 4MG BASE** | **A076354** | **002** | Mar 28, 2003 |
| **AB** | OXFORD PHARMS | **EQ 2MG BASE** | **A076281** | **001** | Oct 20, 2003 |

| | | | | | | |
|---|---|---|---|---|---|---|
| TIZANIDINE HYDROCHLORIDE | | | | | | |
| TABLET;ORAL | | | | | | |
| **TIZANIDINE HYDROCHLORIDE** | | | | | | |
| **AB** | | | **EQ 4MG BASE** | **A076281** | **002** | Oct 20, 2003 |
| **AB** | | PAR PHARM INC | **EQ 2MG BASE** | **A207170** | **001** | Jan 26, 2017 |
| **AB** | | | **EQ 4MG BASE** | **A207170** | **002** | Jan 26, 2017 |
| **AB** | | SANDOZ INC | **EQ 2MG BASE** | **A076280** | **001** | Nov 26, 2002 |
| **AB** | | | **EQ 4MG BASE** | **A076280** | **002** | Jun 27, 2002 |
| **AB** | | SUN PHARM INDS INC | **EQ 2MG BASE** | **A076416** | **001** | Sep 29, 2003 |
| **AB** | | | **EQ 4MG BASE** | **A076416** | **002** | Sep 29, 2003 |
| **AB** | | TEVA | **EQ 2MG BASE** | **A076284** | **001** | Jul 03, 2002 |
| **AB** | | | **EQ 4MG BASE** | **A076284** | **002** | Jul 03, 2002 |
| **AB** | | UNICHEM LABS LTD | **EQ 2MG BASE** | **A091283** | **001** | Nov 28, 2012 |
| **AB** | | | **EQ 4MG BASE** | **A091283** | **002** | Nov 28, 2012 |
| **ZANAFLEX** | | | | | | |
| **AB** | **+!** | COVIS PHARMA BV | **EQ 4MG BASE** | **N020397** | **001** | Nov 27, 1996 |
| TOBRAMYCIN | | | | | | |
| OINTMENT;OPHTHALMIC | | | | | | |
| TOBREX | | | | | | |
| | +! | NOVARTIS PHARMS CORP | 0.3% | N050555 | 001 | |
| POWDER;INHALATION | | | | | | |
| TOBI PODHALER | | | | | | |
| | +! | NOVARTIS | 28MG | N201688 | 001 | Mar 22, 2013 |
| SOLUTION;INHALATION | | | | | | |
| **KITABIS PAK** | | | | | | |
| **AN** | | PULMOFLOW INC | **300MG/5ML** | **N205433** | **001** | Dec 02, 2014 |
| **TOBI** | | | | | | |
| **AN** | **+!** | NOVARTIS PHARMS | **300MG/5ML** | **N050753** | **001** | Dec 22, 1997 |
| **TOBRAMYCIN** | | | | | | |
| **AN** | | AKORN INC | **300MG/5ML** | **A201422** | **001** | May 28, 2014 |
| **AN** | | AMNEAL PHARMS | **300MG/5ML** | **A205501** | **001** | Jul 13, 2015 |
| **AN** | | LUPIN ATLANTIS | **300MG/5ML** | **A208964** | **001** | Mar 22, 2017 |
| **AN** | | MYLAN PHARMS INC | **300MG/5ML** | **A209554** | **001** | Oct 13, 2017 |
| **AN** | | TEVA PHARMS USA | **300MG/5ML** | **A091589** | **001** | Oct 10, 2013 |
| BETHKIS | | | | | | |
| | +! | CHIESI USA INC | 300MG/4ML | N201820 | 001 | Oct 12, 2012 |
| SOLUTION/DROPS;OPHTHALMIC | | | | | | |
| **AKTOB** | | | | | | |
| **AT** | | AKORN | **0.3%** | **A064096** | **001** | Jan 31, 1996 |
| **TOBRAMYCIN** | | | | | | |
| **AT** | | BAUSCH AND LOMB | **0.3%** | **A064052** | **001** | Nov 29, 1993 |
| **AT** | | FERA PHARMS | **0.3%** | **A065026** | **001** | Sep 11, 2001 |
| **AT** | | SOMERSET THERAPS LLC | **0.3%** | **A207444** | **001** | Jun 28, 2017 |
| **TOBREX** | | | | | | |
| **AT** | **+!** | NOVARTIS PHARMS CORP | **0.3%** | **N050541** | **001** | |
| **AT** | | SANDOZ INC | **0.3%** | **A062535** | **001** | Dec 13, 1984 |
| TOBRAMYCIN SULFATE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| **TOBRAMYCIN SULFATE** | | | | | | |
| **AP** | | AKORN | **EQ 40MG BASE/ML** | **A205179** | **001** | Sep 16, 2014 |
| **AP** | | BAXTER HLTHCARE CORP | **EQ 40MG BASE/ML** | **A206965** | **001** | Jul 01, 2016 |
| **AP** | | FRESENIUS KABI USA | **EQ 10MG BASE/ML** | **A065122** | **001** | Nov 29, 2002 |
| **AP** | **!** | | **EQ 40MG BASE/ML** | **A065122** | **002** | Nov 29, 2002 |
| **AP** | | | **EQ 1.2GM BASE/VIAL** | **N050789** | **001** | Jul 13, 2004 |
| **AP** | **!** | HOSPIRA | **EQ 10MG BASE/ML** | **A063112** | **001** | Apr 30, 1991 |
| **AP** | | | **EQ 40MG BASE/ML** | **A063111** | **001** | Apr 30, 1991 |
| **AP** | | MYLAN LABS LTD | **EQ 40MG BASE/ML** | **A065407** | **001** | Mar 11, 2008 |
| **AP** | | TEVA PHARMS USA | **EQ 40MG BASE/ML** | **A063100** | **001** | Jan 30, 1992 |
| **AP** | | WEST-WARD PHARMS INT | **EQ 40MG BASE/ML** | **A063117** | **001** | Apr 26, 1991 |
| **AP** | **!** | X GEN PHARMS | **EQ 1.2GM BASE/VIAL** | **A065013** | **001** | Aug 17, 2001 |
| **AP** | | XELLIA PHARMS APS | **EQ 1.2GM BASE/VIAL** | **A205685** | **001** | Sep 16, 2014 |
| TOBRAMYCIN SULFATE (PHARMACY BULK) | | | | | | |
| | ! | FRESENIUS KABI USA | EQ 40MG BASE/ML | A065120 | 001 | Nov 29, 2002 |
| TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | | | | | | |
| | ! | HOSPIRA | EQ 1.2MG BASE/ML | A063081 | 003 | Jul 31, 1990 |
| | ! | | EQ 1.6MG BASE/ML | A063081 | 006 | Jun 02, 1993 |
| | ! | | EQ 80MG BASE/100ML | A063081 | 001 | Jul 31, 1990 |

| | | | | | | |
|---|---|---|---|---|---|---|
| TOFACITINIB CITRATE | | | | | | |
| TABLET;ORAL | | | | | | |
| XELJANZ | | | | | | |
| +! | PF PRISM CV | EQ 5MG BASE | | N203214 | 001 | Nov 06, 2012 |
| TABLET, EXTENDED RELEASE;ORAL | | | | | | |
| XELJANZ XR | | | | | | |
| +! | PFIZER INC | EQ 11MG BASE | | N208246 | 001 | Feb 23, 2016 |
| TOLAZAMIDE | | | | | | |
| TABLET;ORAL | | | | | | |
| TOLAZAMIDE | | | | | | |
| | MYLAN PHARMS INC | 250MG | | A070259 | 001 | Jan 02, 1986 |
| ! | | 500MG | | A070259 | 003 | Mar 17, 1986 |
| TOLBUTAMIDE | | | | | | |
| TABLET;ORAL | | | | | | |
| TOLBUTAMIDE | | | | | | |
| ! | MYLAN PHARMS INC | 500MG | | A086445 | 001 | |
| TOLCAPONE | | | | | | |
| TABLET;ORAL | | | | | | |
| **TASMAR** | | | | | | |
| **AB** **+!** | VALEANT PHARMS LLC | **100MG** | | **N020697** | **001** | Jan 29, 1998 |
| **TOLCAPONE** | | | | | | |
| **AB** | PAR PHARM INC | **100MG** | | **A204584** | **001** | Mar 26, 2015 |
| TOLMETIN SODIUM | | | | | | |
| CAPSULE;ORAL | | | | | | |
| **TOLMETIN SODIUM** | | | | | | |
| **AB** | MYLAN | **EQ 400MG BASE** | | **A073393** | **001** | May 27, 1993 |
| **AB** **!** | TEVA | **EQ 400MG BASE** | | **A073290** | **001** | Nov 27, 1991 |
| TABLET;ORAL | | | | | | |
| TOLMETIN SODIUM | | | | | | |
| ! | MYLAN | EQ 600MG BASE | | A074473 | 001 | Aug 30, 1994 |
| TOLTERODINE TARTRATE | | | | | | |
| CAPSULE, EXTENDED RELEASE;ORAL | | | | | | |
| **DETROL LA** | | | | | | |
| **AB** **+** | PHARMACIA AND UPJOHN | **2MG** | | **N021228** | **001** | Dec 22, 2000 |
| **AB** **+!** | | **4MG** | | **N021228** | **002** | Dec 22, 2000 |
| **TOLTERODINE TARTRATE** | | | | | | |
| **AB** | HETERO LABS LTD III | **2MG** | | **A206419** | **001** | Dec 12, 2017 |
| **AB** | | **4MG** | | **A206419** | **002** | Dec 12, 2017 |
| **AB** | MYLAN PHARMS INC | **2MG** | | **A201486** | **001** | Oct 31, 2013 |
| **AB** | | **4MG** | | **A201486** | **002** | Oct 31, 2013 |
| **AB** | TEVA PHARMS USA | **2MG** | | **A079141** | **001** | Nov 22, 2016 |
| **AB** | | **4MG** | | **A079141** | **002** | Nov 22, 2016 |
| **AB** | TORRENT PHARMS LTD | **2MG** | | **A203016** | **001** | Aug 11, 2015 |
| **AB** | | **4MG** | | **A203016** | **002** | Aug 11, 2015 |
| TABLET;ORAL | | | | | | |
| **DETROL** | | | | | | |
| **AB** **+** | PHARMACIA AND UPJOHN | **1MG** | | **N020771** | **001** | Mar 25, 1998 |
| **AB** **+!** | | **2MG** | | **N020771** | **002** | Mar 25, 1998 |
| **TOLTERODINE TARTRATE** | | | | | | |
| **AB** | APOTEX CORP | **1MG** | | **A200164** | **001** | Sep 25, 2012 |
| **AB** | | **2MG** | | **A200164** | **002** | Sep 25, 2012 |
| **AB** | IVAX SUB TEVA PHARMS | **1MG** | | **A077006** | **001** | Feb 23, 2015 |
| **AB** | | **2MG** | | **A077006** | **002** | Feb 23, 2015 |
| **AB** | MACLEODS PHARMS LTD | **1MG** | | **A203409** | **001** | Aug 31, 2015 |
| **AB** | | **2MG** | | **A203409** | **002** | Aug 31, 2015 |
| **AB** | MYLAN PHARMS INC | **1MG** | | **A202641** | **001** | Nov 27, 2012 |
| **AB** | | **2MG** | | **A202641** | **002** | Nov 27, 2012 |
| TOLVAPTAN | | | | | | |
| TABLET;ORAL | | | | | | |
| SAMSCA | | | | | | |
| + | OTSUKA AMERICA PHARM | 15MG | | N022275 | 001 | May 19, 2009 |
| +! | | 30MG | | N022275 | 002 | May 19, 2009 |

TOPIRAMATE

CAPSULE;ORAL

**TOPAMAX**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **AB** | **+** | JANSSEN PHARMS | **15MG** | **N020844** | **001** | Oct 26, 1998 |
| **AB** | **+!** | | **25MG** | **N020844** | **002** | Oct 26, 1998 |

**TOPIRAMATE**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **AB** | | TEVA | **15MG** | **A076575** | **001** | Apr 17, 2009 |
| **AB** | | | **25MG** | **A076575** | **002** | Apr 17, 2009 |
| **AB** | | WATSON LABS | **15MG** | **A077868** | **001** | Apr 15, 2009 |
| **AB** | | | **25MG** | **A077868** | **002** | Apr 15, 2009 |
| **AB** | | ZYDUS PHARMS USA INC | **15MG** | **A078877** | **001** | Oct 14, 2009 |
| **AB** | | | **25MG** | **A078877** | **002** | Oct 14, 2009 |

CAPSULE, EXTENDED RELEASE;ORAL

**TOPIRAMATE**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **AB** | | ZYDUS PHARMS USA INC | **25MG** | **A207382** | **001** | Nov 24, 2017 |
| **AB** | | | **50MG** | **A207382** | **002** | Nov 24, 2017 |
| **AB** | | | **100MG** | **A207382** | **003** | Nov 24, 2017 |

**TROKENDI XR**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **AB** | **+** | SUPERNUS PHARMS | **25MG** | **N201635** | **001** | Aug 16, 2013 |
| **AB** | **+** | | **50MG** | **N201635** | **002** | Aug 16, 2013 |
| **AB** | **+** | | **100MG** | **N201635** | **003** | Aug 16, 2013 |

QUDEXY XR

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | + | UPSHER-SMITH LABS | 25MG | N205122 | 001 | Mar 11, 2014 |
| | + | | 50MG | N205122 | 002 | Mar 11, 2014 |
| | + | | 100MG | N205122 | 003 | Mar 11, 2014 |
| | + | | 150MG | N205122 | 004 | Mar 11, 2014 |
| | +! | | 200MG | N205122 | 005 | Mar 11, 2014 |

TROKENDI XR

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | +! | SUPERNUS PHARMS | 200MG | N201635 | 004 | Aug 16, 2013 |

TABLET;ORAL

**TOPAMAX**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **AB** | **+** | JANSSEN PHARMS | **25MG** | **N020505** | **004** | Dec 24, 1996 |
| **AB** | **+** | | **50MG** | **N020505** | **005** | Dec 24, 1996 |
| **AB** | **+!** | | **100MG** | **N020505** | **001** | Dec 24, 1996 |
| **AB** | **+** | | **200MG** | **N020505** | **002** | Dec 24, 1996 |

**TOPIRAMATE**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **AB** | | ACCORD HLTHCARE | **25MG** | **A076311** | **001** | Mar 27, 2009 |
| **AB** | | | **50MG** | **A076311** | **002** | Mar 27, 2009 |
| **AB** | | | **100MG** | **A076311** | **003** | Mar 27, 2009 |
| **AB** | | | **200MG** | **A076311** | **004** | Mar 27, 2009 |
| **AB** | | APOTEX INC | **25MG** | **A077733** | **001** | Mar 27, 2009 |
| **AB** | | | **50MG** | **A077733** | **002** | Mar 27, 2009 |
| **AB** | | | **100MG** | **A077733** | **003** | Mar 27, 2009 |
| **AB** | | | **200MG** | **A077733** | **004** | Mar 27, 2009 |
| **AB** | | AUROBINDO PHARMA | **25MG** | **A078462** | **001** | Mar 27, 2009 |
| **AB** | | | **50MG** | **A078462** | **002** | Mar 27, 2009 |
| **AB** | | | **100MG** | **A078462** | **003** | Mar 27, 2009 |
| **AB** | | | **200MG** | **A078462** | **004** | Mar 27, 2009 |
| **AB** | | CIPLA LTD | **25MG** | **A076343** | **001** | Mar 27, 2009 |
| **AB** | | | **50MG** | **A076343** | **002** | Mar 27, 2009 |
| **AB** | | | **100MG** | **A076343** | **003** | Mar 27, 2009 |
| **AB** | | | **200MG** | **A076343** | **004** | Mar 27, 2009 |
| **AB** | | GLENMARK GENERICS | **25MG** | **A077627** | **001** | Mar 27, 2009 |
| **AB** | | | **50MG** | **A077627** | **002** | Mar 27, 2009 |
| **AB** | | | **100MG** | **A077627** | **003** | Mar 27, 2009 |
| **AB** | | | **200MG** | **A077627** | **004** | Mar 27, 2009 |
| **AB** | | INVAGEN PHARMS | **25MG** | **A079162** | **001** | Mar 27, 2009 |
| **AB** | | | **50MG** | **A079162** | **002** | Mar 27, 2009 |
| **AB** | | | **100MG** | **A079162** | **003** | Mar 27, 2009 |
| **AB** | | | **200MG** | **A079162** | **004** | Mar 27, 2009 |
| **AB** | | LUPIN | **25MG** | **A078410** | **001** | Sep 11, 2013 |
| **AB** | | | **50MG** | **A078410** | **002** | Sep 11, 2013 |
| **AB** | | | **100MG** | **A078410** | **003** | Sep 11, 2013 |
| **AB** | | | **200MG** | **A078410** | **004** | Sep 11, 2013 |
| **AB** | | SUN PHARM INDS LTD | **25MG** | **A076327** | **001** | Mar 27, 2009 |
| **AB** | | | **100MG** | **A076327** | **002** | Mar 27, 2009 |
| **AB** | | | **200MG** | **A076327** | **003** | Mar 27, 2009 |
| **AB** | | SUN PHARMA GLOBAL | **25MG** | **A090278** | **001** | Mar 27, 2009 |
| **AB** | | | **50MG** | **A090278** | **002** | Mar 27, 2009 |
| **AB** | | | **100MG** | **A090278** | **003** | Mar 27, 2009 |
| **AB** | | | **200MG** | **A090278** | **004** | Mar 27, 2009 |

TOPIRAMATE

TABLET;ORAL

**TOPIRAMATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | TEVA | **25MG** | **A076317** | **001** | Mar 27, 2009 |
| **AB** | | | **50MG** | **A076317** | **002** | Mar 27, 2009 |
| **AB** | | | **100MG** | **A076317** | **003** | Mar 27, 2009 |
| **AB** | | | **200MG** | **A076317** | **004** | Mar 27, 2009 |
| **AB** | | TORRENT PHARMS | **25MG** | **A079153** | **001** | Mar 27, 2009 |
| **AB** | | | **50MG** | **A079153** | **002** | Mar 27, 2009 |
| **AB** | | | **100MG** | **A079153** | **003** | Mar 27, 2009 |
| **AB** | | | **200MG** | **A079153** | **004** | Mar 27, 2009 |
| **AB** | | UNICHEM LABS LTD | **25MG** | **A090162** | **001** | Mar 27, 2009 |
| **AB** | | | **50MG** | **A090162** | **002** | Mar 27, 2009 |
| **AB** | | | **100MG** | **A090162** | **003** | Mar 27, 2009 |
| **AB** | | | **200MG** | **A090162** | **004** | Feb 19, 2013 |
| **AB** | | UPSHER-SMITH LABS | **25MG** | **A078499** | **001** | Jan 07, 2010 |
| **AB** | | | **50MG** | **A078499** | **002** | Jan 07, 2010 |
| **AB** | | | **100MG** | **A078499** | **003** | Jan 07, 2010 |
| **AB** | | | **200MG** | **A078499** | **004** | Jan 07, 2010 |
| **AB** | | ZYDUS PHARMS USA INC | **25MG** | **A078235** | **001** | Mar 27, 2009 |
| **AB** | | | **50MG** | **A078235** | **002** | Mar 27, 2009 |
| **AB** | | | **100MG** | **A078235** | **003** | Mar 27, 2009 |
| **AB** | | | **200MG** | **A078235** | **004** | Mar 27, 2009 |

TOPOTECAN HYDROCHLORIDE

CAPSULE;ORAL

HYCAMTIN

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | NOVARTIS PHARMS CORP | EQ 0.25MG BASE | N020981 | 001 | Oct 11, 2007 |
| | +! | | EQ 1MG BASE | N020981 | 002 | Oct 11, 2007 |

INJECTABLE;INJECTION

**HYCAMTIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | NOVARTIS PHARMS CORP | **EQ 4MG BASE/VIAL** | **N020671** | **001** | May 28, 1996 |

**TOPOTECAN HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | ACCORD HLTHCARE | **EQ 4MG BASE/VIAL** | **A202351** | **001** | Jun 26, 2013 |
| **AP** | | ACTAVIS TOTOWA | **EQ 4MG BASE/VIAL** | **A090620** | **001** | Dec 02, 2010 |
| **AP** | | CIPLA LTD | **EQ 4MG BASE/VIAL** | **A091199** | **001** | Dec 01, 2010 |
| **AP** | | DR REDDYS LABS LTD | **EQ 4MG BASE/VIAL** | **A201191** | **001** | Mar 09, 2011 |
| **AP** | | FRESENIUS KABI USA | **EQ 4MG BASE/VIAL** | **A091089** | **001** | Nov 29, 2010 |
| **AP** | | HONG KONG | **EQ 4MG BASE/VIAL** | **A201166** | **001** | Aug 08, 2012 |
| **AP** | | MYLAN LABS LTD | **EQ 4MG BASE/VIAL** | **A091542** | **001** | Aug 28, 2012 |
| **AP** | | NOVAST LABS LTD | **EQ 4MG BASE/VIAL** | **A206962** | **001** | Nov 30, 2016 |
| **AP** | | SAGENT PHARMS | **EQ 4MG BASE/VIAL** | **A091284** | **001** | Jan 26, 2011 |

SOLUTION;INTRAVENOUS

**TOPOTECAN HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | ACCORD HLTHCARE | **EQ 4MG BASE/4ML (EQ 1MG BASE/ML)** | **A204406** | **002** | Jul 06, 2017 |
| **AP** | **+!** | HOSPIRA INC | **EQ 4MG BASE/4ML (EQ 1MG BASE/ML)** | **N200582** | **001** | Feb 02, 2011 |
| **AP** | | MYLAN LABS LTD | **EQ 4MG BASE/4ML (EQ 1MG BASE/ML)** | **A206074** | **001** | Nov 24, 2017 |
| **AP** | | TEVA PHARMS USA | **EQ 4MG BASE/4ML (EQ 1MG BASE/ML)** | **N022453** | **001** | Dec 20, 2012 |
| | | ACCORD HLTHCARE | EQ 1MG BASE/ML (EQ 1MG BASE/ML) | A204406 | 001 | Jul 06, 2017 |

TOREMIFENE CITRATE

TABLET;ORAL

FARESTON

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | KYOWA KIRIN | EQ 60MG BASE | N020497 | 001 | May 29, 1997 |

TORSEMIDE

TABLET;ORAL

**DEMADEX**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | MYLAN SPECIALITY LP | **5MG** | **N020136** | **001** | Aug 23, 1993 |
| **AB** | **+** | | **10MG** | **N020136** | **002** | Aug 23, 1993 |
| **AB** | **+!** | | **20MG** | **N020136** | **003** | Aug 23, 1993 |
| **AB** | **+** | | **100MG** | **N020136** | **004** | Aug 23, 1993 |

**TORSEMIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | APOTEX INC | **5MG** | **A076894** | **001** | May 31, 2005 |
| **AB** | | | **10MG** | **A076894** | **002** | May 31, 2005 |
| **AB** | | | **20MG** | **A076894** | **003** | May 31, 2005 |
| **AB** | | | **100MG** | **A076894** | **004** | May 31, 2005 |
| **AB** | | AUROBINDO PHARMA | **5MG** | **A078249** | **001** | Oct 17, 2007 |
| **AB** | | | **10MG** | **A078249** | **002** | Oct 17, 2007 |
| **AB** | | | **20MG** | **A078249** | **003** | Oct 17, 2007 |
| **AB** | | | **100MG** | **A078249** | **004** | Oct 17, 2007 |

TORSEMIDE

TABLET;ORAL

**TORSEMIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | HETERO LABS LTD III | **5MG** | **A079234** | **001** | Jan 27, 2009 |
| **AB** | | | **10MG** | **A079234** | **002** | Jan 27, 2009 |
| **AB** | | | **20MG** | **A079234** | **003** | Jan 27, 2009 |
| **AB** | | | **100MG** | **A079234** | **004** | Jan 27, 2009 |
| **AB** | | PAR PHARM | **5MG** | **A076226** | **001** | May 27, 2003 |
| **AB** | | | **10MG** | **A076226** | **002** | May 27, 2003 |
| **AB** | | | **20MG** | **A076226** | **003** | May 27, 2003 |
| **AB** | | | **100MG** | **A076226** | **004** | May 27, 2003 |
| **AB** | | PLIVA PHARM IND | **5MG** | **A076346** | **001** | May 30, 2003 |
| **AB** | | | **10MG** | **A076346** | **002** | May 30, 2003 |
| **AB** | | | **20MG** | **A076346** | **003** | May 30, 2003 |
| **AB** | | | **100MG** | **A076346** | **004** | Oct 19, 2004 |
| **AB** | | TEVA | **5MG** | **A076110** | **001** | May 14, 2002 |
| **AB** | | | **10MG** | **A076110** | **002** | May 14, 2002 |
| **AB** | | | **20MG** | **A076110** | **003** | May 14, 2002 |
| **AB** | | | **100MG** | **A076110** | **004** | May 14, 2002 |
| **AB** | | VINTAGE PHARMS | **5MG** | **A090613** | **001** | Mar 22, 2011 |
| **AB** | | | **10MG** | **A090613** | **002** | Mar 22, 2011 |
| **AB** | | | **20MG** | **A090613** | **003** | Mar 22, 2011 |
| **AB** | | | **100MG** | **A090613** | **004** | Mar 22, 2011 |
| **AB** | | WEST-WARD PHARMS INT | **5MG** | **A076943** | **001** | Mar 01, 2005 |
| **AB** | | | **10MG** | **A076943** | **002** | Mar 01, 2005 |
| **AB** | | | **20MG** | **A076943** | **003** | Mar 01, 2005 |

TRABECTEDIN

POWDER;IV (INFUSION)

YONDELIS

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | JANSSEN PRODS | 1MG/VIAL | N207953 | 001 | Oct 23, 2015 |

TRAMADOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

CONZIP

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | CIPHER PHARMS INC | 100MG | N022370 | 001 | May 07, 2010 |
| | + | | 150MG | N022370 | 004 | Aug 01, 2011 |
| | + | | 200MG | N022370 | 002 | May 07, 2010 |
| | + | | 300MG | N022370 | 003 | May 07, 2010 |

TABLET;ORAL

**TRAMADOL HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACI HEALTHCARE LTD | **50MG** | **A202075** | **001** | Nov 28, 2011 |
| **AB** | | AMNEAL PHARMS | **50MG** | **A076003** | **001** | Jun 20, 2002 |
| **AB** | | APOTEX | **50MG** | **A075981** | **001** | Jul 10, 2002 |
| **AB** | | AUROBINDO PHARMA LTD | **50MG** | **A203494** | **001** | Mar 31, 2014 |
| **AB** | | CSPC OUYI PHARM CO | **50MG** | **A091498** | **001** | Mar 29, 2013 |
| **AB** | | IPCA LABS LTD | **50MG** | **A201973** | **001** | Nov 16, 2012 |
| **AB** | | MACLEODS PHARMS LTD | **50MG** | **A205702** | **001** | Sep 25, 2015 |
| **AB** | | MYLAN | **50MG** | **A075986** | **001** | Jun 21, 2002 |
| **AB** | | PLIVA | **50MG** | **A075982** | **001** | Jul 01, 2002 |
| **AB** | | SPECGX LLC | **50MG** | **A075983** | **001** | Jun 25, 2002 |
| **AB** | | SUN PHARM INDS INC | **50MG** | **A075964** | **001** | Jun 19, 2002 |
| **AB** | | SUN PHARM INDUSTRIES | **50MG** | **A076100** | **001** | Jun 20, 2002 |
| **AB** | | TEVA | **50MG** | **A075977** | **001** | Jun 19, 2002 |
| **AB** | | ZYDUS PHARMS USA INC | **50MG** | **A090404** | **001** | Jan 31, 2011 |

**ULTRAM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | JANSSEN PHARMS | **50MG** | **N020281** | **002** | Mar 03, 1995 |

TABLET, EXTENDED RELEASE;ORAL

**TRAMADOL HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB1** | | AUROBINDO PHARMA LTD | **100MG** | **A204421** | **001** | Oct 20, 2015 |
| **AB1** | | | **200MG** | **A204421** | **002** | Oct 20, 2015 |
| **AB1** | | | **300MG** | **A204421** | **003** | Oct 20, 2015 |
| **AB1** | **!** | LUPIN LTD | **100MG** | **A200503** | **001** | Aug 29, 2011 |
| **AB1** | | | **200MG** | **A200503** | **002** | Aug 29, 2011 |
| **AB1** | | | **300MG** | **A200503** | **003** | Aug 29, 2011 |
| **AB1** | | MYLAN PHARMS INC | **100MG** | **A205257** | **001** | Dec 22, 2015 |
| **AB1** | | | **200MG** | **A205257** | **002** | Dec 22, 2015 |
| **AB1** | | | **300MG** | **A205257** | **003** | Dec 22, 2015 |
| **AB1** | | PAR PHARM INC | **100MG** | **A078783** | **001** | Nov 13, 2009 |

TRAMADOL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

**TRAMADOL HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB1** | | | **200MG** | **A078783** | **002** | Nov 13, 2009 |
| **AB1** | | | **300MG** | **A078783** | **003** | Sep 20, 2011 |
| **AB1** | | SUN PHARMA GLOBAL | **100MG** | **A201384** | **001** | Dec 07, 2011 |
| **AB1** | | | **200MG** | **A201384** | **002** | Dec 07, 2011 |
| **AB1** | | | **300MG** | **A201384** | **003** | Dec 07, 2011 |
| **AB2** | | ACTAVIS ELIZABETH | **100MG** | **A091609** | **001** | Jun 27, 2012 |
| **AB2** | | | **200MG** | **A091609** | **002** | Jun 27, 2012 |
| **AB2** | | | **300MG** | **A091609** | **003** | Jun 27, 2012 |
| **AB2** | | ANCHEN PHARMS | **100MG** | **A200491** | **001** | Jun 27, 2012 |
| **AB2** | | | **200MG** | **A200491** | **002** | Jun 27, 2012 |
| **AB2** | | | **300MG** | **A200491** | **003** | Jun 27, 2012 |
| **AB2** | ! | SUN PHARMA GLOBAL | **100MG** | **A091607** | **001** | Dec 30, 2011 |
| **AB2** | | | **200MG** | **A091607** | **002** | Dec 30, 2011 |
| **AB2** | | | **300MG** | **A091607** | **003** | Dec 30, 2011 |

TRAMETINIB DIMETHYL SULFOXIDE

TABLET;ORAL

MEKINIST

| | | | | | |
|---|---|---|---|---|---|
| + | NOVARTIS PHARMS CORP | EQ 0.5MG | N204114 | 001 | May 29, 2013 |
| +! | | EQ 2MG | N204114 | 003 | May 29, 2013 |

TRANDOLAPRIL

TABLET;ORAL

**MAVIK**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | ABBVIE | **1MG** | **N020528** | **001** | Apr 26, 1996 |
| **AB** | + | | **2MG** | **N020528** | **002** | Apr 26, 1996 |
| **AB** | +! | | **4MG** | **N020528** | **003** | Apr 26, 1996 |

**TRANDOLAPRIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AUROBINDO PHARMA | **1MG** | **A078438** | **001** | Jun 12, 2007 |
| **AB** | | | **2MG** | **A078438** | **002** | Jun 12, 2007 |
| **AB** | | | **4MG** | **A078438** | **003** | Jun 12, 2007 |
| **AB** | | EPIC PHARMA | **1MG** | **A078508** | **003** | Jun 18, 2008 |
| **AB** | | | **2MG** | **A078508** | **001** | Jun 18, 2008 |
| **AB** | | | **4MG** | **A078508** | **002** | Jun 18, 2008 |
| **AB** | | LUPIN | **1MG** | **A077522** | **001** | Jun 12, 2007 |
| **AB** | | | **2MG** | **A077522** | **002** | Jun 12, 2007 |
| **AB** | | | **4MG** | **A077522** | **003** | Jun 12, 2007 |
| **AB** | | TEVA PHARMS | **1MG** | **A077489** | **001** | Dec 12, 2006 |
| **AB** | | | **2MG** | **A077489** | **002** | Dec 12, 2006 |
| **AB** | | | **4MG** | **A077489** | **003** | Dec 12, 2006 |
| **AB** | | WATSON LABS | **1MG** | **A077805** | **001** | Jun 12, 2007 |
| **AB** | | | **2MG** | **A077805** | **002** | Jun 12, 2007 |
| **AB** | | | **4MG** | **A077805** | **003** | Jun 12, 2007 |

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

**TARKA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | + | ABBVIE | **1MG;240MG** | **N020591** | **003** | Oct 22, 1996 |
| **AB** | + | | **2MG;180MG** | **N020591** | **001** | Oct 22, 1996 |
| **AB** | + | | **2MG;240MG** | **N020591** | **004** | Oct 22, 1996 |
| **AB** | +! | | **4MG;240MG** | **N020591** | **002** | Oct 22, 1996 |

**TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | GLENMARK GENERICS | **1MG;240MG** | **A079135** | **004** | Aug 30, 2010 |
| **AB** | | | **2MG;180MG** | **A079135** | **001** | May 26, 2010 |
| **AB** | | | **2MG;240MG** | **A079135** | **002** | May 26, 2010 |
| **AB** | | | **4MG;240MG** | **A079135** | **003** | May 05, 2010 |

TRANEXAMIC ACID

INJECTABLE;INJECTION

**CYKLOKAPRON**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | +! | PHARMACIA AND UPJOHN | **100MG/ML** | **N019281** | **001** | Dec 30, 1986 |

**TRANEXAMIC ACID**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | ACIC FINE CHEMS | **100MG/ML** | **A202436** | **001** | Feb 11, 2014 |
| **AP** | | AKORN | **100MG/ML** | **A202373** | **001** | Nov 17, 2011 |
| **AP** | | | **100MG/ML** | **A206594** | **001** | Sep 28, 2017 |
| **AP** | | | **100MG/ML** | **A206634** | **001** | Jun 09, 2016 |
| **AP** | | AMNEAL PHARMS CO | **100MG/ML** | **A208840** | **001** | Feb 28, 2017 |
| **AP** | | AUROBINDO PHARMA LTD | **100MG/ML** | **A205035** | **001** | Jan 14, 2016 |
| **AP** | | EMCURE PHARMS LTD | **100MG/ML** | **A203521** | **001** | Aug 12, 2014 |

TRANEXAMIC ACID

INJECTABLE;INJECTION

**TRANEXAMIC ACID**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | FRESENIUS KABI USA | **100MG/ML** | **A091596** | **001** | Mar 02, 2012 |
| **AP** | | GLAND PHARMA LTD | **100MG/ML** | **A207239** | **001** | Feb 13, 2017 |
| **AP** | | LUITPOLD | **100MG/ML** | **A201885** | **001** | Aug 10, 2011 |
| **AP** | | MYLAN INSTITUTIONAL | **100MG/ML** | **A091657** | **001** | Nov 03, 2011 |
| **AP** | | VIRTUS PHARMS | **100MG/ML** | **A202755** | **001** | Feb 25, 2016 |
| **AP** | | VIVA HLTHCARE | **100MG/ML** | **A206713** | **001** | Jun 27, 2017 |
| **AP** | | X-GEN PHARMS INC | **100MG/ML** | **A201580** | **001** | Jun 14, 2013 |
| **AP** | | ZYDUS PHARMS USA INC | **100MG/ML** | **A205228** | **001** | Jul 17, 2017 |

TABLET;ORAL

**LYSTEDA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | FERRING PHARMS INC | **650MG** | **N022430** | **001** | Nov 13, 2009 |

**TRANEXAMIC ACID**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS LABS FL INC | **650MG** | **A202093** | **001** | Dec 27, 2012 |
| **AB** | | APOTEX INC | **650MG** | **A202286** | **001** | Jan 27, 2014 |
| **AB** | | MYLAN | **650MG** | **A205133** | **001** | Sep 21, 2015 |

TRANYLCYPROMINE SULFATE

TABLET;ORAL

**PARNATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | CONCORDIA PHARMS INC | **EQ 10MG BASE** | **N012342** | **003** | Aug 16, 1985 |

**TRANYLCYPROMINE SULFATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | PAR PHARM | **EQ 10MG BASE** | **A040640** | **001** | Jun 29, 2006 |

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC

**TRAVATAN Z**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **+!** | NOVARTIS PHARMS CORP | **0.004%** | **N021994** | **001** | Sep 21, 2006 |

**TRAVOPROST**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | | APOTEX INC | **0.004%** | **A203431** | **001** | Jul 10, 2015 |
| **AT** | | MYLAN PHARMS INC | **0.004%** | **A205050** | **001** | Jul 07, 2017 |
| | ! | PAR PHARM | 0.004% | A091340 | 001 | Mar 01, 2013 |

TRAZODONE HYDROCHLORIDE

TABLET;ORAL

**TRAZODONE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACCORD HLTHCARE | **50MG** | **A206923** | **001** | Sep 08, 2017 |
| **AB** | | | **100MG** | **A206923** | **002** | Sep 08, 2017 |
| **AB** | | | **150MG** | **A206923** | **003** | Sep 08, 2017 |
| **AB** | | | **300MG** | **A206923** | **004** | Sep 08, 2017 |
| **AB** | | ALVOGEN | **50MG** | **A071636** | **001** | Apr 18, 1988 |
| **AB** | | | **100MG** | **A071514** | **001** | Apr 18, 1988 |
| **AB** | | APOTEX | **50MG** | **A071258** | **001** | Mar 25, 1987 |
| **AB** | **!** | APOTEX INC | **100MG** | **A071196** | **001** | Mar 25, 1987 |
| **AB** | | | **150MG** | **A071196** | **002** | Apr 26, 1999 |
| **AB** | | | **300MG** | **A071196** | **003** | Apr 26, 1999 |
| **AB** | | PLIVA | **150MG** | **A071525** | **001** | Mar 09, 1988 |
| **AB** | | SUN PHARM INDUSTRIES | **50MG** | **A073137** | **002** | Mar 24, 1993 |
| **AB** | | | **100MG** | **A073137** | **001** | Mar 24, 1993 |
| **AB** | | | **150MG** | **A073137** | **003** | Dec 22, 1995 |
| **AB** | | TEVA PHARMS USA | **50MG** | **A071523** | **001** | Dec 11, 1987 |
| **AB** | | | **100MG** | **A071524** | **001** | Dec 11, 1987 |
| **AB** | | TORRENT PHARMS LTD | **50MG** | **A202180** | **001** | Nov 27, 2013 |
| **AB** | | | **100MG** | **A202180** | **002** | Nov 27, 2013 |
| **AB** | | | **150MG** | **A202180** | **003** | Nov 27, 2013 |
| **AB** | | | **300MG** | **A202180** | **004** | Nov 27, 2013 |
| **AB** | | VINTAGE | **50MG** | **A072192** | **001** | Feb 02, 1989 |
| **AB** | | | **100MG** | **A072193** | **001** | Feb 02, 1989 |
| **AB** | | ZYDUS PHARMS USA INC | **50MG** | **A205253** | **001** | Oct 10, 2017 |
| **AB** | | | **100MG** | **A205253** | **002** | Oct 10, 2017 |
| **AB** | | | **150MG** | **A205253** | **003** | Oct 10, 2017 |
| **AB** | | | **300MG** | **A205253** | **004** | Oct 10, 2017 |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| TREPROSTINIL | | | | | | | |
| INJECTABLE;IV (INFUSION), SUBCUTANEOUS | | | | | | | |
| **REMODULIN** | | | | | | | |
| **AP** | **+!** | UNITED THERAP | **1MG/ML** | **N021272** | **001** | May 21, 2002 |
| **AP** | **+!** | | **2.5MG/ML** | **N021272** | **002** | May 21, 2002 |
| **AP** | **+!** | | **5MG/ML** | **N021272** | **003** | May 21, 2002 |
| **AP** | **+!** | | **10MG/ML** | **N021272** | **004** | May 21, 2002 |
| **TREPROSTINIL** | | | | | | | |
| **AP** | | SANDOZ INC | **1MG/ML** | **A203649** | **001** | Nov 30, 2017 |
| **AP** | | | **2.5MG/ML** | **A203649** | **002** | Nov 30, 2017 |
| **AP** | | | **5MG/ML** | **A203649** | **003** | Nov 30, 2017 |
| **AP** | | | **10MG/ML** | **A203649** | **004** | Nov 30, 2017 |
| SOLUTION;INHALATION | | | | | | | |
| TYVASO | | | | | | | |
| | +! | UNITED THERAP | 0.6MG/ML | N022387 | 001 | Jul 30, 2009 |
| TREPROSTINIL DIOLAMINE | | | | | | | |
| TABLET, EXTENDED RELEASE;ORAL | | | | | | | |
| ORENITRAM | | | | | | | |
| | + | UNITED THERAP | EQ 0.125MG BASE | N203496 | 001 | Dec 20, 2013 |
| | + | | EQ 0.25MG BASE | N203496 | 002 | Dec 20, 2013 |
| | + | | EQ 1MG BASE | N203496 | 003 | Dec 20, 2013 |
| | +! | | EQ 2.5MG BASE | N203496 | 004 | Dec 20, 2013 |
| | + | | EQ 5MG BASE | N203496 | 005 | Oct 07, 2016 |
| TRETINOIN | | | | | | | |
| CAPSULE;ORAL | | | | | | | |
| **TRETINOIN** | | | | | | | |
| **AB** | | ANCHEN PHARMS | **10MG** | **A201687** | **001** | Oct 24, 2012 |
| **AB** | **!** | BARR LABS INC | **10MG** | **A077684** | **001** | Jun 22, 2007 |
| **AB** | | GLENMARK PHARMS LTD | **10MG** | **A208279** | **001** | Dec 23, 2016 |
| CREAM;TOPICAL | | | | | | | |
| **AVITA** | | | | | | | |
| **AB** | | MYLAN PHARMS INC | **0.025%** | **N020404** | **003** | Jan 14, 1997 |
| **RETIN-A** | | | | | | | |
| **AB** | **+!** | VALEANT BERMUDA | **0.025%** | **N019049** | **001** | Sep 16, 1988 |
| **AB** | **+!** | VALEANT PHARMS NORTH | **0.1%** | **N017340** | **001** | |
| **TRETINOIN** | | | | | | | |
| **AB** | | PERRIGO PHARMA INTL | **0.025%** | **A075264** | **001** | Dec 24, 1998 |
| **AB** | | | **0.1%** | **A075213** | **001** | Dec 24, 1998 |
| **RETIN-A** | | | | | | | |
| **AB1** | **+!** | VALEANT BERMUDA | **0.05%** | **N017522** | **001** | |
| **TRETINOIN** | | | | | | | |
| **AB1** | | PERRIGO PHARMA INTL | **0.05%** | **A075265** | **001** | Dec 24, 1998 |
| **RENOVA** | | | | | | | |
| **AB2** | **+!** | VALEANT PHARMS NORTH | **0.05%** | **N019963** | **001** | Dec 29, 1995 |
| **TRETINOIN** | | | | | | | |
| **AB2** | | ZO SKIN HEALTH | **0.05%** | **A076498** | **001** | Sep 15, 2005 |
| RENOVA | | | | | | | |
| | +! | VALEANT PHARMS NORTH | 0.02% | N021108 | 001 | Aug 31, 2000 |
| GEL;TOPICAL | | | | | | | |
| **ATRALIN** | | | | | | | |
| **AB** | **+!** | DOW PHARM | **0.05%** | **N022070** | **001** | Jul 26, 2007 |
| **RETIN-A** | | | | | | | |
| **AB** | **+!** | VALEANT INTL | **0.01%** | **N017955** | **001** | |
| **AB** | **+!** | | **0.025%** | **N017579** | **002** | |
| **RETIN-A MICRO** | | | | | | | |
| **AB** | **+!** | VALEANT INTL | **0.04%** | **N020475** | **002** | May 10, 2002 |
| **AB** | **+!** | | **0.1%** | **N020475** | **001** | Feb 07, 1997 |
| **TRETINOIN** | | | | | | | |
| **AB** | | MYLAN PHARMS INC | **0.04%** | **A202567** | **001** | Jul 17, 2013 |
| **AB** | | | **0.05%** | **A207955** | **001** | Aug 13, 2015 |
| **AB** | | | **0.1%** | **A202026** | **001** | Jul 17, 2013 |
| **AB** | | PERRIGO PHARMA INTL | **0.01%** | **A075589** | **001** | Jun 11, 2002 |
| **AB** | | | **0.025%** | **A075529** | **001** | Feb 22, 2000 |
| AVITA | | | | | | | |
| BT | | MYLAN | 0.025% | N020400 | 001 | Jan 29, 1998 |
| RETIN-A-MICRO | | | | | | | |
| | +! | VALEANT INTL | 0.06% | N020475 | 004 | Oct 23, 2017 |
| | +! | | 0.08% | N020475 | 003 | Jan 28, 2014 |

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

**TRIAMCINOLONE ACETONIDE**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **AT** | | ALKEM LABS LTD | **0.025%** | **A207651** | **001** | Dec 26, 2017 |
| **AT** | | | **0.1%** | **A207651** | **002** | Dec 26, 2017 |
| **AT** | | | **0.5%** | **A207651** | **003** | Dec 26, 2017 |
| **AT** | **!** | FOUGERA PHARMS | **0.025%** | **A085692** | **001** | |
| **AT** | **!** | | **0.1%** | **A085692** | **003** | |
| **AT** | **!** | | **0.5%** | **A085692** | **002** | |
| **AT** | | G AND W LABS | **0.025%** | **A089797** | **001** | May 31, 1991 |
| **AT** | | | **0.1%** | **A089798** | **001** | May 31, 1991 |
| **AT** | | GLENMARK PHARMS LTD | **0.1%** | **A207117** | **001** | Aug 05, 2016 |
| **AT** | | LUPIN ATLANTIS | **0.025%** | **A208763** | **001** | Feb 01, 2017 |
| **AT** | | | **0.1%** | **A208763** | **002** | Feb 01, 2017 |
| **AT** | | | **0.5%** | **A208763** | **003** | Feb 01, 2017 |
| **AT** | **+** | MYLAN PHARMS INC | **0.025%** | **N011601** | **003** | |
| **AT** | **+** | | **0.1%** | **N011601** | **006** | |
| **AT** | | PERRIGO NEW YORK | **0.025%** | **A086415** | **001** | |
| **AT** | | | **0.1%** | **A086414** | **001** | |
| **AT** | | | **0.5%** | **A086413** | **001** | |
| **AT** | | TARO | **0.1%** | **A040039** | **001** | Nov 26, 1997 |
| **AT** | | TELIGENT PHARMA INC | **0.1%** | **A208848** | **001** | Sep 18, 2017 |
| **AT** | | VINTAGE | **0.025%** | **A040671** | **001** | Jun 09, 2006 |
| **AT** | | | **0.1%** | **A040671** | **002** | Jun 09, 2006 |

**TRIDERM**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **AT** | | CROWN LABS | **0.025%** | **A088042** | **002** | Mar 25, 2015 |
| **AT** | | | **0.1%** | **A088042** | **001** | Mar 19, 1984 |
| **AT** | | | **0.5%** | **A088042** | **003** | Mar 25, 2015 |

FOR SUSPENSION, EXTENDED RELEASE;INTRA-ARTICULAR

ZILRETTA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | FLEXION THERAPS INC | 32MG/VIAL | N208845 | 001 | Oct 06, 2017 |

INJECTABLE;INJECTION

**KENALOG-40**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | APOTHECON | **40MG/ML** | **N014901** | **001** | |

**TRIAMCINOLONE ACETONIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AMNEAL PHARMS CO | **40MG/ML** | **A207550** | **001** | Dec 11, 2017 |

KENALOG-10

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | APOTHECON | 10MG/ML | N012041 | 001 | |

INJECTABLE;INTRAVITREAL

TRIESENCE

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | NOVARTIS PHARMS CORP | 40MG/ML (40MG/ML) | N022048 | 001 | Nov 29, 2007 |

LOTION;TOPICAL

**TRIAMCINOLONE ACETONIDE**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **AT** | | AKORN | **0.025%** | **A202374** | **001** | May 08, 2013 |
| **AT** | | | **0.1%** | **A202374** | **002** | May 08, 2013 |
| **AT** | | FOUGERA PHARMS | **0.025%** | **A040467** | **001** | Apr 21, 2003 |
| **AT** | | | **0.1%** | **A040467** | **002** | Apr 21, 2003 |
| **AT** | | G AND W LABS INC | **0.1%** | **A089129** | **001** | Aug 14, 1986 |
| **AT** | | TELIGENT PHARMA INC | **0.025%** | **A204608** | **001** | Jul 07, 2016 |
| **AT** | | | **0.1%** | **A204606** | **001** | Jul 07, 2016 |
| **AT** | | VINTAGE | **0.1%** | **A040672** | **002** | Dec 13, 2006 |
| **AT** | **!** | WOCKHARDT BIO AG | **0.025%** | **A088450** | **001** | Apr 01, 1985 |
| **AT** | **!** | | **0.1%** | **A088451** | **001** | Apr 03, 1985 |

OINTMENT;TOPICAL

**TRIAMCINOLONE ACETONIDE**

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **AT** | | FOUGERA PHARMS | **0.025%** | **A085691** | **001** | |
| **AT** | | | **0.1%** | **A085691** | **003** | |
| **AT** | | | **0.5%** | **A085691** | **002** | |
| **AT** | | G AND W LABS | **0.025%** | **A089795** | **001** | Dec 23, 1988 |
| **AT** | | | **0.1%** | **A089796** | **001** | Dec 23, 1988 |
| **AT** | | G AND W LABS INC | **0.5%** | **A208925** | **001** | Oct 06, 2017 |
| **AT** | | GLENMARK PHARMS | **0.1%** | **A208320** | **001** | Aug 22, 2017 |
| **AT** | | GLENMARK PHARMS LTD | **0.5%** | **A206379** | **001** | Jul 22, 2016 |
| **AT** | **!** | PERRIGO NEW YORK | **0.025%** | **A087356** | **001** | |
| **AT** | **!** | | **0.1%** | **A087357** | **001** | |
| **AT** | **!** | | **0.5%** | **A087385** | **001** | |
| **AT** | | TARO | **0.1%** | **A040037** | **001** | Sep 30, 1994 |
| **AT** | | TELIGENT PHARMA INC | **0.1%** | **A205373** | **001** | May 13, 2016 |
| **AT** | | | **0.5%** | **A208590** | **001** | Mar 03, 2017 |

TRIAMCINOLONE ACETONIDE IN ABSORBASE

| | | | | | | |
|---|---|---|---|---|---|---|
| | ! | CMP PHARMA INC | 0.05% | A089595 | 001 | Mar 23, 1995 |

| | | | | | | |
|---|---|---|---|---|---|---|
| TRIAMCINOLONE ACETONIDE | | | | | | |
| PASTE;DENTAL | | | | | | |
| **TRIAMCINOLONE ACETONIDE** | | | | | | |
| **AT** | | AKORN | **0.1%** | **A206312** | **001** | Aug 11, 2016 |
| **AT** | | G AND W LABS INC | **0.1%** | **A205592** | **001** | Jan 12, 2017 |
| **AT** | | LYNE | **0.1%** | **A040771** | **001** | Jul 01, 2010 |
| **AT** | **!** | TARO | **0.1%** | **A070730** | **001** | Oct 01, 1986 |
| SPRAY;TOPICAL | | | | | | |
| **KENALOG** | | | | | | |
| **AT** | **+!** | RANBAXY LABS LTD | **0.147MG/GM** | **N012104** | **001** | |
| **TRIAMCINOLONE ACETONIDE** | | | | | | |
| **AT** | | AKORN | **0.147MG/GM** | **A207094** | **001** | Dec 07, 2016 |
| **AT** | | PERRIGO UK FINCO | **0.147MG/GM** | **A205782** | **001** | Apr 13, 2015 |
| **AT** | | RICONPHARMA LLC | **0.147MG/GM** | **A206786** | **001** | Sep 08, 2017 |
| TRIAMCINOLONE HEXACETONIDE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| ARISTOSPAN | | | | | | |
| | +! | SANDOZ INC | 5MG/ML | N016466 | 001 | |
| | +! | | 20MG/ML | N016466 | 002 | |
| TRIAMTERENE | | | | | | |
| CAPSULE;ORAL | | | | | | |
| DYRENIUM | | | | | | |
| | + | CONCORDIA PHARMS INC | 50MG | N013174 | 001 | |
| | +! | | 100MG | N013174 | 002 | |
| TRIAZOLAM | | | | | | |
| TABLET;ORAL | | | | | | |
| **HALCION** | | | | | | |
| **AB** | **+** | PHARMACIA AND UPJOHN | **0.125MG** | **N017892** | **003** | Apr 26, 1985 |
| **AB** | **+!** | | **0.25MG** | **N017892** | **001** | Nov 15, 1982 |
| **TRIAZOLAM** | | | | | | |
| **AB** | | MYLAN PHARMS INC | **0.125MG** | **A074031** | **001** | Mar 25, 1994 |
| **AB** | | | **0.25MG** | **A074031** | **002** | Mar 25, 1994 |
| **AB** | | WEST-WARD PHARMS INT | **0.125MG** | **A074224** | **001** | Jun 01, 1994 |
| **AB** | | | **0.25MG** | **A074224** | **002** | Jun 01, 1994 |
| TRIENTINE HYDROCHLORIDE | | | | | | |
| CAPSULE;ORAL | | | | | | |
| SYPRINE | | | | | | |
| | +! | ATON | 250MG | N019194 | 001 | Nov 08, 1985 |
| TRIFLUOPERAZINE HYDROCHLORIDE | | | | | | |
| TABLET;ORAL | | | | | | |
| **TRIFLUOPERAZINE HYDROCHLORIDE** | | | | | | |
| **AB** | | MYLAN | **EQ 1MG BASE** | **A040209** | **001** | Jul 07, 1997 |
| **AB** | | | **EQ 2MG BASE** | **A040209** | **002** | Jul 07, 1997 |
| **AB** | | | **EQ 5MG BASE** | **A040209** | **003** | Jul 07, 1997 |
| **AB** | **!** | | **EQ 10MG BASE** | **A040209** | **004** | Jul 07, 1997 |
| **AB** | | SANDOZ | **EQ 1MG BASE** | **A085785** | **001** | |
| **AB** | | | **EQ 2MG BASE** | **A085786** | **001** | |
| **AB** | | | **EQ 5MG BASE** | **A085789** | **001** | |
| **AB** | | | **EQ 10MG BASE** | **A085788** | **001** | |
| TRIFLURIDINE | | | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | | | |
| **TRIFLURIDINE** | | | | | | |
| **AT** | | HI-TECH PHARMACAL | **1%** | **A205438** | **001** | Jul 28, 2017 |
| **AT** | | SANDOZ INC | **1%** | **A074311** | **001** | Oct 06, 1995 |
| **VIROPTIC** | | | | | | |
| **AT** | **+!** | MONARCH PHARMS | **1%** | **N018299** | **001** | |
| TRIHEXYPHENIDYL HYDROCHLORIDE | | | | | | |
| ELIXIR;ORAL | | | | | | |
| **TRIHEXYPHENIDYL HYDROCHLORIDE** | | | | | | |
| **AA** | | MIKART | **2MG/5ML** | **A040251** | **001** | Sep 27, 1999 |
| **AA** | **!** | PHARM ASSOC | **2MG/5ML** | **A040177** | **001** | Apr 17, 1997 |
| TABLET;ORAL | | | | | | |
| **TRIHEXYPHENIDYL HYDROCHLORIDE** | | | | | | |
| **AA** | | NATCO PHARMA LTD | **2MG** | **A091630** | **001** | Nov 17, 2010 |
| **AA** | | | **5MG** | **A091630** | **002** | Nov 17, 2010 |
| **AA** | | VINTAGE PHARMS LLC | **2MG** | **A040254** | **001** | Dec 24, 1998 |

TRIHEXYPHENIDYL HYDROCHLORIDE

TABLET;ORAL

**TRIHEXYPHENIDYL HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | | **5MG** | **A040254** | **002** | Dec 24, 1998 |
| **AA** | **!** | WATSON LABS | **2MG** | **A084363** | **001** | |
| **AA** | **!** | | **5MG** | **A084364** | **001** | |

TRIMETHADIONE

TABLET;ORAL

TRIDIONE

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ABBVIE | 150MG | N005856 | 009 | |

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE;ORAL

**TIGAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | KING PHARMS LLC | **300MG** | **N017531** | **006** | Dec 13, 2001 |

**TRIMETHOBENZAMIDE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | GAVIS PHARMS | **300MG** | **A076546** | **001** | Aug 20, 2003 |
| **AB** | | SUN PHARM INDUSTRIES | **300MG** | **A076570** | **001** | Aug 28, 2003 |

INJECTABLE;INJECTION

**TIGAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | PAR STERILE PRODUCTS | **100MG/ML** | **N017530** | **001** | |

**TRIMETHOBENZAMIDE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | LUITPOLD | **100MG/ML** | **A091330** | **001** | Mar 08, 2011 |

**TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | LUITPOLD | **100MG/ML** | **A091329** | **001** | Mar 08, 2011 |

TRIMETHOPRIM

TABLET;ORAL

**TRIMETHOPRIM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | MAYNE PHARMA | **100MG** | **N018679** | **001** | Jul 30, 1982 |
| **AB** | | NOVEL LABS INC | **100MG** | **A091437** | **001** | Jun 15, 2011 |
| **AB** | | WATSON LABS | **100MG** | **A070049** | **001** | Jun 06, 1985 |

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION;ORAL

PRIMSOL

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ALLEGIS | EQ 50MG BASE/5ML | N074973 | 001 | Jan 24, 2000 |

TRIMIPRAMINE MALEATE

CAPSULE;ORAL

**SURMONTIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | ODYSSEY PHARMS | **EQ 25MG BASE** | **N016792** | **001** | |
| **AB** | **+!** | | **EQ 50MG BASE** | **N016792** | **002** | |
| **AB** | **+** | | **EQ 100MG BASE** | **N016792** | **003** | Sep 15, 1982 |

**TRIMIPRAMINE MALEATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | CROSSMEDIKA SA | **EQ 25MG BASE** | **A208127** | **001** | Apr 15, 2016 |
| **AB** | | | **EQ 50MG BASE** | **A208127** | **002** | Apr 15, 2016 |
| **AB** | | | **EQ 100MG BASE** | **A208127** | **003** | Apr 15, 2016 |
| **AB** | | ELITE LABS INC | **EQ 25MG BASE** | **A077361** | **001** | Aug 02, 2006 |
| **AB** | | | **EQ 50MG BASE** | **A077361** | **002** | Aug 02, 2006 |
| **AB** | | | **EQ 100MG BASE** | **A077361** | **003** | Aug 02, 2006 |

TRIPTORELIN PAMOATE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

TRIPTODUR KIT

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ARBOR PHARMS LLC | EQ 22.5MG BASE/VIAL | N208956 | 001 | Jun 29, 2017 |

INJECTABLE;INTRAMUSCULAR

TRELSTAR

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ALLERGAN SALES LLC | EQ 3.75MG BASE/VIAL | N020715 | 001 | Jun 15, 2000 |
| | +! | | EQ 11.25MG BASE/VIAL | N021288 | 001 | Jun 29, 2001 |
| | +! | | EQ 22.5MG BASE/VIAL | N022437 | 001 | Mar 10, 2010 |

TROMETHAMINE

INJECTABLE;INJECTION

THAM

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | HOSPIRA | 3.6GM/100ML | N013025 | 002 | |

TROPICAMIDE

SOLUTION/DROPS;OPHTHALMIC

**MYDRIACYL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AT** | **!** | NOVARTIS PHARMS CORP | **1%** | **A084306** | **001** | |
| **AT** | **!** | SANDOZ INC | **0.5%** | **A084305** | **001** | |

TROPICAMIDE

SOLUTION/DROPS;OPHTHALMIC

| | | | | | | |
|---|---|---|---|---|---|---|
| **TROPICACYL** | | | | | | |
| **AT** | | AKORN | **0.5%** | **A040314** | **001** | Sep 29, 2000 |
| **AT** | | | **1%** | **A040315** | **001** | Sep 29, 2000 |
| **TROPICAMIDE** | | | | | | |
| **AT** | | BAUSCH AND LOMB | **0.5%** | **A040067** | **001** | Jul 27, 1994 |
| **AT** | | | **1%** | **A040064** | **001** | Jul 27, 1994 |

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **TROSPIUM CHLORIDE** | | | | | | |
| **AB** | **!** | ACTAVIS LABS FL INC | **60MG** | **A091289** | **001** | Oct 12, 2012 |
| **AB** | | PADDOCK LLC | **60MG** | **A201291** | **001** | May 24, 2013 |

TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **TROSPIUM CHLORIDE** | | | | | | |
| **AB** | | APOTEX | **20MG** | **A091513** | **001** | Dec 06, 2011 |
| **AB** | **!** | GLENMARK GENERICS | **20MG** | **A091575** | **001** | Aug 13, 2010 |
| **AB** | | HERITAGE PHARMS INC | **20MG** | **A204945** | **001** | Aug 30, 2016 |
| **AB** | | INVAGEN PHARMS | **20MG** | **A091688** | **001** | Aug 23, 2016 |
| **AB** | | PADDOCK LLC | **20MG** | **A091573** | **001** | Nov 17, 2010 |

TRYPAN BLUE

SOLUTION;OPHTHALMIC

| | | | | | | |
|---|---|---|---|---|---|---|
| MEMBRANEBLUE | | | | | | |
| | +! | DORC | 0.15% | N022278 | 001 | Feb 20, 2009 |
| VISIONBLUE | | | | | | |
| | +! | DORC | 0.06% | N021670 | 001 | Dec 16, 2004 |

ULIPRISTAL ACETATE

TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **ELLA** | | | | | | |
| **AB** | **+!** | LAB HRA PHARMA | **30MG** | **N022474** | **001** | Aug 13, 2010 |
| **LOGILIA** | | | | | | |
| **AB** | | TEVA PHARMS USA | **30MG** | **A207952** | **001** | Feb 13, 2017 |

UMECLIDINIUM BROMIDE

POWDER;INHALATION

| | | | | | | |
|---|---|---|---|---|---|---|
| INCRUSE ELLIPTA | | | | | | |
| | +! | GLAXO GRP ENGLAND | EQ 62.5MCG BASE/INH | N205382 | 001 | Apr 30, 2014 |

UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE

POWDER;INHALATION

| | | | | | | |
|---|---|---|---|---|---|---|
| ANORO ELLIPTA | | | | | | |
| | +! | GLAXOSMITHKLINE | EQ 0.0625MG BASE/INH;EQ 0.025MG BASE/INH | N203975 | 001 | Dec 18, 2013 |

UREA, C-14

CAPSULE;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| PYTEST | | | | | | |
| | +! | AVENT | 1uCi | N020617 | 001 | May 09, 1997 |
| PYTEST KIT | | | | | | |
| | +! | AVENT | 1uCi | N020617 | 002 | May 09, 1997 |

URIDINE TRIACETATE

GRANULE;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| VISTOGARD | | | | | | |
| | +! | WELLSTAT THERAP | 10GM/PACKET | N208159 | 001 | Dec 11, 2015 |
| XURIDEN | | | | | | |
| | +! | WELLSTAT THERAP | 2GM/PACKET | N208169 | 001 | Sep 04, 2015 |

UROFOLLITROPIN

INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS

| | | | | | | |
|---|---|---|---|---|---|---|
| BRAVELLE | | | | | | |
| | +! | FERRING | 75 IU/VIAL | N021289 | 001 | May 06, 2002 |

URSODIOL

CAPSULE;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **ACTIGALL** | | | | | | |
| **AB** | **+!** | ALLERGAN SALES LLC | **300MG** | **N019594** | **002** | Dec 31, 1987 |
| **URSODIOL** | | | | | | |
| **AB** | | EPIC PHARMA | **300MG** | **A075517** | **001** | Mar 14, 2000 |
| **AB** | | LANNETT | **300MG** | **A079082** | **001** | Dec 15, 2008 |
| **AB** | | MYLAN | **300MG** | **A090530** | **001** | Feb 17, 2010 |
| **AB** | | TEVA PHARMS | **300MG** | **A075592** | **001** | May 25, 2000 |

URSODIOL

TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **URSO 250** | | | | | | |
| **AB** | **+** | FOREST LABS INC | **250MG** | **N020675** | **001** | Dec 10, 1997 |
| **URSO FORTE** | | | | | | |
| **AB** | **+!** | FOREST LABS INC | **500MG** | **N020675** | **002** | Jul 21, 2004 |
| **URSODIOL** | | | | | | |
| **AB** | | GLENMARK GENERICS | **250MG** | **A090801** | **001** | Jul 12, 2011 |
| **AB** | | | **500MG** | **A090801** | **002** | Jul 12, 2011 |
| **AB** | | IMPAX LABS INC | **250MG** | **A200826** | **001** | Dec 23, 2011 |
| **AB** | | | **500MG** | **A200826** | **002** | Dec 23, 2011 |
| **AB** | | PAR PHARM | **250MG** | **A202540** | **001** | Feb 14, 2013 |
| **AB** | | | **500MG** | **A202540** | **002** | Feb 14, 2013 |

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **VALACYCLOVIR HYDROCHLORIDE** | | | | | | |
| **AB** | | APOTEX INC | **EQ 500MG BASE** | **A090500** | **001** | Apr 04, 2014 |
| **AB** | | | **EQ 1GM BASE** | **A090500** | **002** | Apr 04, 2014 |
| **AB** | | AUROBINDO PHARMA | **EQ 500MG BASE** | **A090682** | **001** | May 24, 2010 |
| **AB** | | | **EQ 1GM BASE** | **A090682** | **002** | May 24, 2010 |
| **AB** | | CIPLA LTD | **EQ 500MG BASE** | **A077135** | **001** | May 24, 2010 |
| **AB** | | | **EQ 1GM BASE** | **A077135** | **002** | May 24, 2010 |
| **AB** | | DR REDDYS LABS LTD | **EQ 500MG BASE** | **A079012** | **001** | May 24, 2010 |
| **AB** | | | **EQ 1GM BASE** | **A079012** | **002** | May 24, 2010 |
| **AB** | | HETERO LABS LTD V | **EQ 500MG BASE** | **A203047** | **001** | Apr 08, 2015 |
| **AB** | | | **EQ 1GM BASE** | **A203047** | **002** | Apr 08, 2015 |
| **AB** | | JUBILANT GENERICS | **EQ 500MG BASE** | **A201506** | **001** | Apr 03, 2012 |
| **AB** | | | **EQ 1GM BASE** | **A201506** | **002** | Apr 03, 2012 |
| **AB** | | MYLAN PHARMS INC | **EQ 500MG BASE** | **A078518** | **001** | May 24, 2010 |
| **AB** | | | **EQ 1GM BASE** | **A078518** | **002** | May 24, 2010 |
| **AB** | | SANDOZ | **EQ 500MG BASE** | **A077478** | **001** | May 24, 2010 |
| **AB** | | | **EQ 1GM BASE** | **A077478** | **002** | May 24, 2010 |
| **AB** | | SUN PHARM INDS LTD | **EQ 500MG BASE** | **A076588** | **001** | Jan 31, 2007 |
| **AB** | | | **EQ 1GM BASE** | **A076588** | **002** | Jan 31, 2007 |
| **AB** | | TEVA PHARMS | **EQ 500MG BASE** | **A077655** | **001** | May 24, 2010 |
| **AB** | | | **EQ 1GM BASE** | **A077655** | **002** | May 24, 2010 |
| **AB** | | WATSON LABS INC | **EQ 500MG BASE** | **A090370** | **001** | Mar 16, 2011 |
| **AB** | | | **EQ 1GM BASE** | **A090370** | **002** | Mar 16, 2011 |
| **AB** | | WEST-WARD PHARMS INT | **EQ 500MG BASE** | **A078656** | **001** | May 24, 2010 |
| **AB** | | | **EQ 1GM BASE** | **A078656** | **002** | May 24, 2010 |
| **AB** | | WOCKHARDT | **EQ 500MG BASE** | **A090216** | **001** | May 24, 2010 |
| **AB** | | | **EQ 1GM BASE** | **A090216** | **002** | May 24, 2010 |
| **AB** | | ZYDUS PHARMS USA INC | **EQ 500MG BASE** | **A079137** | **001** | Dec 29, 2017 |
| **AB** | | | **EQ 1GM BASE** | **A079137** | **002** | Dec 29, 2017 |
| **VALTREX** | | | | | | |
| **AB** | **+** | GLAXOSMITHKLINE | **EQ 500MG BASE** | **N020487** | **001** | Jun 23, 1995 |
| **AB** | **+!** | | **EQ 1GM BASE** | **N020487** | **002** | Jun 23, 1995 |

VALBENAZINE TOSYLATE

CAPSULE;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| INGREZZA | | | | | | |
| | +! | NEUROCRINE | 40MG | N209241 | 001 | Apr 11, 2017 |
| | + | | 80MG | N209241 | 002 | Oct 04, 2017 |

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **VALCYTE** | | | | | | |
| **AB** | **+!** | HOFFMANN LA ROCHE | **50MG/ML** | **N022257** | **001** | Aug 28, 2009 |
| **VALGANCICLOVIR HYDROCHLORIDE** | | | | | | |
| **AB** | | ACTAVIS LABS FL INC | **50MG/ML** | **A205220** | **001** | Jul 18, 2016 |

TABLET;ORAL

| | | | | | | |
|---|---|---|---|---|---|---|
| **VALCYTE** | | | | | | |
| **AB** | **+!** | HOFFMANN LA ROCHE | **EQ 450MG BASE** | **N021304** | **001** | Mar 29, 2001 |
| **VALGANCICLOVIR HYDROCHLORIDE** | | | | | | |
| **AB** | | AUROBINDO PHARMA LTD | **EQ 450MG BASE** | **A204750** | **001** | Mar 31, 2016 |
| **AB** | | DR REDDYS LABS LTD | **EQ 450MG BASE** | **A203511** | **001** | Nov 04, 2014 |
| **AB** | | | **EQ 450MG BASE** | **A206876** | **001** | Dec 12, 2017 |
| **AB** | | ENDO PHARMS INC | **EQ 450MG BASE** | **A200790** | **001** | Nov 04, 2014 |
| **AB** | | HETERO LABS LTD V | **EQ 450MG BASE** | **A205166** | **001** | Mar 18, 2016 |

VALPROATE SODIUM

INJECTABLE;INJECTION

**DEPACON**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | ABBVIE | **EQ 100MG BASE/ML** | **N020593** | **001** | Dec 30, 1996 |

**VALPROATE SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | ATHENEX INC | **EQ 100MG BASE/ML** | **A076295** | **001** | Nov 14, 2002 |
| **AP** | | FRESENIUS KABI USA | **EQ 100MG BASE/ML** | **A076539** | **001** | Jun 26, 2003 |
| **AP** | | HIKMA FARMACEUTICA | **EQ 100MG BASE/ML** | **A078523** | **001** | Feb 17, 2010 |

VALPROIC ACID

CAPSULE;ORAL

**DEPAKENE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | ABBVIE | **250MG** | **N018081** | **001** | |

**VALPROIC ACID**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | BIONPHARMA INC | **250MG** | **A073484** | **001** | Jun 29, 1993 |
| **AB** | | CATALENT | **250MG** | **A073229** | **001** | Oct 29, 1991 |
| **AB** | | SUN PHARM INDS LTD | **250MG** | **A091037** | **001** | Feb 22, 2013 |

SYRUP;ORAL

**DEPAKENE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **+!** | ABBVIE | **250MG/5ML** | **N018082** | **001** | |

**VALPROIC ACID**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | ANI PHARMS INC | **250MG/5ML** | **A073178** | **001** | Aug 25, 1992 |
| **AA** | | ECI PHARMS LLC | **250MG/5ML** | **A090517** | **001** | May 28, 2010 |
| **AA** | | HIGH TECH PHARMA | **250MG/5ML** | **A074060** | **001** | Jan 13, 1995 |
| **AA** | | PHARM ASSOC | **250MG/5ML** | **A075379** | **001** | Dec 15, 2000 |
| **AA** | | VINTAGE | **250MG/5ML** | **A077960** | **001** | Oct 13, 2006 |
| **AA** | | VISTAPHARM | **250MG/5ML** | **A075782** | **001** | Dec 22, 2000 |
| **AA** | | WOCKHARDT BIO AG | **250MG/5ML** | **A070868** | **001** | Jul 01, 1986 |

VALRUBICIN

SOLUTION;INTRAVESICAL

VALSTAR PRESERVATIVE FREE

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | ENDO PHARM | 40MG/ML | N020892 | 001 | Sep 25, 1998 |

VALSARTAN

SOLUTION;ORAL

PREXXARTAN

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | CARMEL BIOSCIENCES | 20MG/5ML | N209139 | 001 | Dec 19, 2017 |
| | +! | | 80MG/20ML | N209139 | 002 | Dec 19, 2017 |

TABLET;ORAL

**DIOVAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | NOVARTIS | **40MG** | **N021283** | **004** | Aug 14, 2002 |
| **AB** | **+** | | **80MG** | **N021283** | **001** | Jul 18, 2001 |
| **AB** | **+** | | **160MG** | **N021283** | **002** | Jul 18, 2001 |
| **AB** | **+!** | | **320MG** | **N021283** | **003** | Jul 18, 2001 |

**VALSARTAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALEMBIC PHARMS LTD | **40MG** | **A091367** | **001** | Jan 05, 2015 |
| **AB** | | | **80MG** | **A091367** | **002** | Jan 05, 2015 |
| **AB** | | | **160MG** | **A091367** | **003** | Jan 05, 2015 |
| **AB** | | | **320MG** | **A091367** | **004** | Jan 05, 2015 |
| **AB** | | AMNEAL PHARMS | **40MG** | **A204011** | **001** | Jan 11, 2016 |
| **AB** | | | **80MG** | **A204011** | **002** | Jan 11, 2016 |
| **AB** | | | **160MG** | **A204011** | **003** | Jan 11, 2016 |
| **AB** | | | **320MG** | **A204011** | **004** | Jan 11, 2016 |
| **AB** | | AUROBINDO PHARMA LTD | **40MG** | **A202223** | **001** | Jan 05, 2015 |
| **AB** | | | **80MG** | **A202223** | **002** | Jan 05, 2015 |
| **AB** | | | **160MG** | **A202223** | **003** | Jan 05, 2015 |
| **AB** | | | **320MG** | **A202223** | **004** | Jan 05, 2015 |
| **AB** | | HETERO LABS LTD V | **40MG** | **A203311** | **001** | Jan 05, 2015 |
| **AB** | | | **80MG** | **A203311** | **002** | Jan 05, 2015 |
| **AB** | | | **160MG** | **A203311** | **003** | Jan 05, 2015 |
| **AB** | | | **320MG** | **A203311** | **004** | Jan 05, 2015 |
| **AB** | | IVAX PHARMS | **40MG** | **A077530** | **001** | Jan 04, 2016 |
| **AB** | | | **80MG** | **A077530** | **002** | Jan 04, 2016 |
| **AB** | | | **160MG** | **A077530** | **003** | Jan 04, 2016 |
| **AB** | | | **320MG** | **A077530** | **004** | Jan 04, 2016 |
| **AB** | | JUBILANT GENERICS | **40MG** | **A203536** | **001** | Jan 05, 2015 |
| **AB** | | | **80MG** | **A203536** | **002** | Jan 05, 2015 |
| **AB** | | | **160MG** | **A203536** | **003** | Jan 05, 2015 |
| **AB** | | | **320MG** | **A203536** | **004** | Jan 05, 2015 |
| **AB** | | LUPIN LTD | **40MG** | **A201677** | **001** | Jan 05, 2015 |
| **AB** | | | **80MG** | **A201677** | **002** | Jan 05, 2015 |
| **AB** | | | **160MG** | **A201677** | **003** | Jan 05, 2015 |

VALSARTAN

TABLET;ORAL

**VALSARTAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **320MG** | **A201677** | **004** | Jan 05, 2015 |
| **AB** | | MACLEODS PHARMS LTD | **40MG** | **A202696** | **001** | Sep 16, 2016 |
| **AB** | | | **80MG** | **A202696** | **002** | Sep 16, 2016 |
| **AB** | | | **160MG** | **A202696** | **003** | Sep 16, 2016 |
| **AB** | | | **320MG** | **A202696** | **004** | Sep 16, 2016 |
| **AB** | | MYLAN PHARMS INC | **40MG** | **A090866** | **001** | Jan 05, 2015 |
| **AB** | | | **80MG** | **A090866** | **002** | Jan 05, 2015 |
| **AB** | | | **160MG** | **A090866** | **003** | Jan 05, 2015 |
| **AB** | | | **320MG** | **A090866** | **004** | Jan 05, 2015 |
| **AB** | | OHM LABS INC | **40MG** | **A077492** | **001** | Jun 26, 2014 |
| **AB** | | | **80MG** | **A077492** | **002** | Jun 26, 2014 |
| **AB** | | | **160MG** | **A077492** | **003** | Jun 26, 2014 |
| **AB** | | | **320MG** | **A077492** | **004** | Jun 26, 2014 |
| **AB** | | PRINSTON INC | **40MG** | **A204821** | **001** | Jun 09, 2015 |
| **AB** | | | **80MG** | **A204821** | **002** | Jun 09, 2015 |
| **AB** | | | **160MG** | **A204821** | **003** | Jun 09, 2015 |
| **AB** | | | **320MG** | **A204821** | **004** | Jun 09, 2015 |
| **AB** | | TORRENT PHARMS LTD | **40MG** | **A202728** | **001** | Jan 05, 2015 |
| **AB** | | | **80MG** | **A202728** | **002** | Jan 05, 2015 |
| **AB** | | | **160MG** | **A202728** | **003** | Jan 05, 2015 |
| **AB** | | | **320MG** | **A202728** | **004** | Jan 05, 2015 |
| **AB** | | WATSON LABS INC | **40MG** | **A090642** | **001** | Jan 05, 2015 |
| **AB** | | | **80MG** | **A090642** | **002** | Jan 05, 2015 |
| **AB** | | | **160MG** | **A090642** | **003** | Jan 05, 2015 |
| **AB** | | | **320MG** | **A090642** | **004** | Jan 05, 2015 |

VANCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL

**VANCOCIN HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | ANI PHARMS INC | **EQ 125MG BASE** | **N050606** | **001** | Apr 15, 1986 |
| **AB** | **+!** | | **EQ 250MG BASE** | **N050606** | **002** | Apr 15, 1986 |

**VANCOMYCIN HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AKORN | **EQ 125MG BASE** | **A065478** | **001** | Apr 09, 2012 |
| **AB** | | | **EQ 250MG BASE** | **A065478** | **002** | Apr 09, 2012 |
| **AB** | | FRESENIUS KABI USA | **EQ 125MG BASE** | **A065453** | **001** | Jun 18, 2012 |
| **AB** | | | **EQ 250MG BASE** | **A065453** | **002** | Jun 18, 2012 |
| **AB** | | LUPIN LTD | **EQ 125MG BASE** | **A090439** | **001** | Jan 28, 2015 |
| **AB** | | | **EQ 250MG BASE** | **A090439** | **002** | Jan 28, 2015 |
| **AB** | | STRIDES PHARMA | **EQ 125MG BASE** | **A065490** | **001** | Apr 09, 2012 |
| **AB** | | | **EQ 250MG BASE** | **A065490** | **002** | Apr 09, 2012 |
| **AB** | | WATSON LABS | **EQ 125MG BASE** | **A065510** | **001** | Apr 09, 2012 |
| **AB** | | | **EQ 250MG BASE** | **A065510** | **002** | Apr 09, 2012 |

INJECTABLE;INJECTION

**VANCOMYCIN HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AUROBINDO PHARMA LTD | **EQ 500MG BASE/VIAL** | **A205780** | **001** | Mar 31, 2016 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A205780** | **002** | Mar 31, 2016 |
| **AP** | | | **EQ 5GM BASE/VIAL** | **A205779** | **001** | Mar 29, 2016 |
| **AP** | | | **EQ 10GM BASE/VIAL** | **A205779** | **002** | Mar 29, 2016 |
| **AP** | | CFT PHARMS LLC | **EQ 5GM BASE/VIAL** | **A204125** | **001** | Dec 28, 2015 |
| **AP** | | | **EQ 10GM BASE/VIAL** | **A204125** | **002** | Dec 28, 2015 |
| **AP** | | | **EQ 500MG BASE/VIAL** | **A204107** | **001** | Dec 28, 2015 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A204107** | **002** | Dec 28, 2015 |
| **AP** | | EMCURE PHARMS LTD | **EQ 500MG BASE/VIAL** | **A202275** | **001** | Oct 31, 2013 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A202275** | **002** | Oct 31, 2013 |
| **AP** | | | **EQ 10GM BASE/VIAL** | **A202464** | **001** | Oct 09, 2013 |
| **AP** | | | **EQ 5GM BASE/VIAL** | **A202274** | **001** | Oct 31, 2013 |
| **AP** | **!** | FRESENIUS KABI USA | **EQ 500MG BASE/VIAL** | **A062663** | **001** | Mar 17, 1987 |
| **AP** | | | **EQ 750MG BASE/VIAL** | **A062663** | **005** | Aug 17, 2016 |
| **AP** | **!** | | **EQ 1GM BASE/VIAL** | **A062663** | **002** | Jul 31, 1987 |
| **AP** | **!** | | **EQ 5GM BASE/VIAL** | **A062663** | **003** | Jun 03, 1988 |
| **AP** | **!** | | **EQ 10GM BASE/VIAL** | **A062663** | **004** | Nov 28, 1997 |
| **AP** | | GLAND PHARMA LTD | **EQ 500MG BASE/VIAL** | **A205694** | **001** | Jan 21, 2016 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A205694** | **002** | Jan 21, 2016 |
| **AP** | **!** | HOSPIRA | **EQ 500MG BASE/VIAL** | **A062911** | **001** | Aug 04, 1988 |
| **AP** | **!** | | **EQ 500MG BASE/VIAL** | **A062931** | **001** | Oct 29, 1992 |
| **AP** | **!** | | **EQ 750MG BASE/VIAL** | **A062912** | **002** | Jan 07, 2009 |
| **AP** | **!** | | **EQ 750MG BASE/VIAL** | **A062933** | **002** | May 27, 2009 |
| **AP** | **!** | | **EQ 1GM BASE/VIAL** | **A062912** | **001** | Aug 04, 1988 |
| **AP** | **!** | | **EQ 1GM BASE/VIAL** | **A062933** | **001** | Oct 29, 1992 |

| | | | | | | |
|---|---|---|---|---|---|---|
| VANCOMYCIN HYDROCHLORIDE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| **VANCOMYCIN HYDROCHLORIDE** | | | | | | |
| **AP** | ! | | **EQ 5GM BASE/VIAL** | **A063076** | **001** | Dec 21, 1990 |
| **AP** | | HOSPIRA INC | **EQ 10GM BASE/VIAL** | **A065455** | **001** | Apr 29, 2009 |
| **AP** | | MUSTAFA NEVZAT ILAC | **EQ 500MG BASE/VIAL** | **A065401** | **001** | Jun 30, 2008 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A065401** | **002** | Jun 30, 2008 |
| **AP** | | MYLAN LABS LTD | **EQ 500MG BASE/VIAL** | **A065397** | **001** | Dec 30, 2008 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A065397** | **002** | Dec 30, 2008 |
| **AP** | | | **EQ 5GM BASE/VIAL** | **A065432** | **001** | Dec 30, 2008 |
| **AP** | | | **EQ 10GM BASE/VIAL** | **A091469** | **001** | Jul 01, 2011 |
| **AP** | | | **EQ 10GM BASE/VIAL** | **A091554** | **001** | Sep 19, 2011 |
| **AP** | | SAGENT PHARMS | **EQ 5GM BASE/VIAL** | **A200837** | **001** | Aug 10, 2012 |
| **AP** | | | **EQ 10GM BASE/VIAL** | **A200837** | **002** | Sep 02, 2014 |
| **AP** | | SANDOZ | **EQ 500MG BASE/VIAL** | **A090250** | **001** | Apr 27, 2010 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A090250** | **002** | Apr 27, 2010 |
| **AP** | | SANDOZ INC | **EQ 5GM BASE/VIAL** | **A201048** | **001** | Aug 10, 2012 |
| **AP** | | | **EQ 10GM BASE/VIAL** | **A201048** | **002** | Aug 10, 2012 |
| **AP** | | XELLIA PHARMS APS | **EQ 500MG BASE/VIAL** | **A091377** | **001** | Sep 09, 2015 |
| **AP** | | | **EQ 1GM BASE/VIAL** | **A091377** | **002** | Sep 09, 2015 |
| **AP** | | | **EQ 5GM BASE/VIAL** | **A206243** | **001** | Dec 23, 2015 |
| **AP** | | | **EQ 10GM BASE/VIAL** | **A206243** | **002** | Dec 23, 2015 |
| VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER | | | | | | |
| | +! | BAXTER HLTHCARE | EQ 500MG BASE/100ML | N050671 | 001 | Apr 29, 1993 |
| | +! | | EQ 750MG BASE/150ML | N050671 | 002 | Dec 20, 2010 |
| POWDER;IV (INFUSION) | | | | | | |
| VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER | | | | | | |
| | | SAMSON MEDCL | EQ 100GM BASE | A091532 | 001 | Jan 06, 2016 |
| VANDETANIB | | | | | | |
| TABLET;ORAL | | | | | | |
| CAPRELSA | | | | | | |
| | + | GENZYME CORP | 100MG | N022405 | 001 | Apr 06, 2011 |
| | +! | | 300MG | N022405 | 002 | Apr 06, 2011 |
| VARDENAFIL HYDROCHLORIDE | | | | | | |
| TABLET;ORAL | | | | | | |
| LEVITRA | | | | | | |
| | + | BAYER HLTHCARE | 2.5MG | N021400 | 003 | Aug 19, 2003 |
| | + | | 5MG | N021400 | 001 | Aug 19, 2003 |
| | + | | 10MG | N021400 | 002 | Aug 19, 2003 |
| | +! | | 20MG | N021400 | 004 | Aug 19, 2003 |
| TABLET, ORALLY DISINTEGRATING;ORAL | | | | | | |
| STAXYN | | | | | | |
| | +! | BAYER HLTHCARE | 10MG | N200179 | 001 | Jun 17, 2010 |
| VARENICLINE TARTRATE | | | | | | |
| TABLET;ORAL | | | | | | |
| CHANTIX | | | | | | |
| | + | PFIZER INC | EQ 0.5MG BASE | N021928 | 001 | May 10, 2006 |
| | +! | | EQ 1MG BASE | N021928 | 002 | May 10, 2006 |
| VASOPRESSIN | | | | | | |
| SOLUTION;IV (INFUSION) | | | | | | |
| VASOSTRICT | | | | | | |
| | +! | PAR STERILE PRODUCTS | 20UNITS/ML (20UNITS/ML) | N204485 | 001 | Apr 17, 2014 |
| | +! | | 200UNITS/10ML (20UNITS/ML) | N204485 | 002 | Dec 17, 2016 |
| VECURONIUM BROMIDE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| **VECURONIUM BROMIDE** | | | | | | |
| **AP** | | GLAND PHARMA LTD | **10MG/VIAL** | **A205390** | **001** | May 26, 2016 |
| **AP** | | | **20MG/VIAL** | **A205390** | **002** | May 26, 2016 |
| **AP** | | HOSPIRA | **10MG/VIAL** | **A075164** | **001** | Oct 21, 1999 |
| **AP** | | | **20MG/VIAL** | **A075164** | **002** | Oct 21, 1999 |
| **AP** | | MYLAN LABS LTD | **10MG/VIAL** | **A090243** | **001** | May 11, 2010 |
| **AP** | | | **20MG/VIAL** | **A090243** | **002** | May 11, 2010 |
| **AP** | | SAGENT PHARMS | **10MG/VIAL** | **A078274** | **001** | Dec 29, 2008 |
| **AP** | | | **20MG/VIAL** | **A078274** | **002** | Dec 29, 2008 |
| **AP** | ! | SUN PHARMA GLOBAL | **10MG/VIAL** | **A079001** | **001** | Jun 17, 2009 |
| **AP** | ! | | **20MG/VIAL** | **A079001** | **002** | Jun 17, 2009 |
| **AP** | | TEVA PHARMS USA | **10MG/VIAL** | **A074688** | **001** | Aug 25, 1999 |
| **AP** | | | **20MG/VIAL** | **A074688** | **002** | Aug 25, 1999 |
| **AP** | | WEST-WARD PHARMS | **10MG/VIAL** | **A075549** | **001** | Jun 13, 2000 |

VECURONIUM BROMIDE

INJECTABLE;INJECTION

**VECURONIUM BROMIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| | | INT | | | | |
| **AP** | | | **20MG/VIAL** | **A075549** | **002** | Jun 13, 2000 |

VELAGLUCERASE ALFA

INJECTABLE;IV (INFUSION)

VPRIV

| | | | | | |
|---|---|---|---|---|---|
| | SHIRE HUMAN GENETIC | 400 UNITS/VIAL | N022575 | 001 | Feb 26, 2010 |

VEMURAFENIB

TABLET;ORAL

ZELBORAF

| | | | | | |
|---|---|---|---|---|---|
| +! | HOFFMANN LA ROCHE | 240MG | N202429 | 001 | Aug 17, 2011 |

VENETOCLAX

TABLET;ORAL

VENCLEXTA

| | | | | | |
|---|---|---|---|---|---|
| + | ABBVIE INC | 10MG | N208573 | 001 | Apr 11, 2016 |
| + | | 50MG | N208573 | 002 | Apr 11, 2016 |
| +! | | 100MG | N208573 | 003 | Apr 11, 2016 |

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

**EFFEXOR XR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | WYETH PHARMS INC | **EQ 37.5MG BASE** | **N020699** | **001** | Oct 20, 1997 |
| **AB** | **+** | | **EQ 75MG BASE** | **N020699** | **002** | Oct 20, 1997 |
| **AB** | **+!** | | **EQ 150MG BASE** | **N020699** | **004** | Oct 20, 1997 |

**VENLAFAXINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ANCHEN PHARMS | **EQ 37.5MG BASE** | **A078087** | **001** | Mar 16, 2012 |
| **AB** | | | **EQ 75MG BASE** | **A078087** | **002** | Mar 16, 2012 |
| **AB** | | | **EQ 150MG BASE** | **A078087** | **003** | Mar 16, 2012 |
| **AB** | | AUROBINDO PHARMA LTD | **EQ 37.5MG BASE** | **A200834** | **001** | Apr 14, 2011 |
| **AB** | | | **EQ 75MG BASE** | **A200834** | **002** | Apr 14, 2011 |
| **AB** | | | **EQ 150MG BASE** | **A200834** | **003** | Apr 14, 2011 |
| **AB** | | DR REDDYS LABS LTD | **EQ 37.5MG BASE** | **A078421** | **001** | May 06, 2011 |
| **AB** | | | **EQ 75MG BASE** | **A078421** | **002** | May 06, 2011 |
| **AB** | | | **EQ 150MG BASE** | **A078421** | **003** | May 06, 2011 |
| **AB** | | MACLEODS PHARMS LTD | **EQ 37.5MG BASE** | **A204889** | **001** | Oct 05, 2017 |
| **AB** | | | **EQ 75MG BASE** | **A204889** | **002** | Oct 05, 2017 |
| **AB** | | | **EQ 150MG BASE** | **A204889** | **003** | Oct 05, 2017 |
| **AB** | | ORCHID HLTHCARE | **EQ 37.5MG BASE** | **A091123** | **001** | Jul 11, 2011 |
| **AB** | | | **EQ 75MG BASE** | **A091123** | **002** | Jul 11, 2011 |
| **AB** | | | **EQ 150MG BASE** | **A091123** | **003** | Jul 11, 2011 |
| **AB** | | TEVA | **EQ 37.5MG BASE** | **A076565** | **001** | Jun 28, 2010 |
| **AB** | | | **EQ 75MG BASE** | **A076565** | **002** | Jun 28, 2010 |
| **AB** | | | **EQ 150MG BASE** | **A076565** | **003** | Jun 28, 2010 |
| **AB** | | TORRENT PHARMS LLC | **EQ 37.5MG BASE** | **A090899** | **001** | Jun 01, 2011 |
| **AB** | | | **EQ 75MG BASE** | **A090899** | **002** | Jun 01, 2011 |
| **AB** | | | **EQ 150MG BASE** | **A090899** | **003** | Jun 01, 2011 |
| **AB** | | VALEANT PHARMS NORTH | **EQ 37.5MG BASE** | **A090071** | **001** | Apr 15, 2011 |
| **AB** | | | **EQ 75MG BASE** | **A090071** | **002** | Apr 15, 2011 |
| **AB** | | | **EQ 150MG BASE** | **A090071** | **003** | Apr 15, 2011 |
| **AB** | | WOCKHARDT | **EQ 37.5MG BASE** | **A078865** | **001** | Apr 14, 2011 |
| **AB** | | | **EQ 75MG BASE** | **A078865** | **002** | Apr 14, 2011 |
| **AB** | | | **EQ 150MG BASE** | **A078865** | **003** | Apr 14, 2011 |
| **AB** | | ZYDUS PHARMS USA INC | **EQ 37.5MG BASE** | **A090174** | **001** | Apr 14, 2011 |
| **AB** | | | **EQ 75MG BASE** | **A090174** | **002** | Apr 14, 2011 |
| **AB** | | | **EQ 150MG BASE** | **A090174** | **003** | Apr 14, 2011 |

TABLET;ORAL

**VENLAFAXINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALEMBIC PHARMS LTD | **EQ 25MG BASE** | **A078932** | **001** | Dec 14, 2010 |
| **AB** | | | **EQ 37.5MG BASE** | **A078932** | **002** | Dec 14, 2010 |
| **AB** | | | **EQ 50MG BASE** | **A078932** | **003** | Dec 14, 2010 |
| **AB** | | | **EQ 75MG BASE** | **A078932** | **004** | Dec 14, 2010 |
| **AB** | | | **EQ 100MG BASE** | **A078932** | **005** | Dec 14, 2010 |
| **AB** | | AMNEAL PHARMS | **EQ 25MG BASE** | **A079098** | **001** | May 11, 2010 |
| **AB** | | | **EQ 37.5MG BASE** | **A079098** | **002** | May 11, 2010 |
| **AB** | | | **EQ 50MG BASE** | **A079098** | **003** | May 11, 2010 |
| **AB** | | | **EQ 75MG BASE** | **A079098** | **004** | May 11, 2010 |
| **AB** | | | **EQ 100MG BASE** | **A079098** | **005** | May 11, 2010 |

VENLAFAXINE HYDROCHLORIDE

TABLET;ORAL

**VENLAFAXINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| AB | | AUROBINDO PHARMA | EQ 25MG BASE | A090555 | 001 | Apr 07, 2010 |
| AB | | | EQ 37.5MG BASE | A090555 | 002 | Apr 07, 2010 |
| AB | | | EQ 50MG BASE | A090555 | 003 | Apr 07, 2010 |
| AB | | | EQ 75MG BASE | A090555 | 004 | Apr 07, 2010 |
| AB | | | EQ 100MG BASE | A090555 | 005 | Apr 07, 2010 |
| AB | | DR REDDYS LABS LTD | EQ 25MG BASE | A078301 | 001 | Jun 13, 2008 |
| AB | | | EQ 37.5MG BASE | A078301 | 002 | Jun 13, 2008 |
| AB | | | EQ 50MG BASE | A078301 | 003 | Jun 13, 2008 |
| AB | | | EQ 75MG BASE | A078301 | 004 | Jun 13, 2008 |
| AB | | | EQ 100MG BASE | A078301 | 005 | Jun 13, 2008 |
| AB | | HERITAGE PHARMS INC | EQ 25MG BASE | A078554 | 001 | Jan 09, 2009 |
| AB | | | EQ 37.5MG BASE | A078554 | 002 | Jan 09, 2009 |
| AB | | | EQ 50MG BASE | A078554 | 003 | Jan 09, 2009 |
| AB | | | EQ 75MG BASE | A078554 | 004 | Jan 09, 2009 |
| AB | | | EQ 100MG BASE | A078554 | 005 | Jan 09, 2009 |
| AB | | MYLAN | EQ 25MG BASE | A077166 | 001 | Jun 13, 2008 |
| AB | | | EQ 37.5MG BASE | A077166 | 002 | Jun 13, 2008 |
| AB | | | EQ 50MG BASE | A077166 | 003 | Jun 13, 2008 |
| AB | | | EQ 75MG BASE | A077166 | 004 | Jun 13, 2008 |
| AB | | | EQ 100MG BASE | A077166 | 005 | Jun 13, 2008 |
| AB | | PRINSTON INC | EQ 25MG BASE | A090027 | 001 | Aug 04, 2010 |
| AB | | | EQ 37.5MG BASE | A090027 | 002 | Aug 04, 2010 |
| AB | | | EQ 50MG BASE | A090027 | 003 | Aug 04, 2010 |
| AB | | | EQ 75MG BASE | A090027 | 004 | Aug 04, 2010 |
| AB | | | EQ 100MG BASE | A090027 | 005 | Aug 04, 2010 |
| AB | | SUN PHARM INDS INC | EQ 25MG BASE | A078627 | 001 | Jun 13, 2008 |
| AB | | | EQ 37.5MG BASE | A078627 | 002 | Jun 13, 2008 |
| AB | | | EQ 50MG BASE | A078627 | 003 | Jun 13, 2008 |
| AB | | | EQ 75MG BASE | A078627 | 004 | Jun 13, 2008 |
| AB | | | EQ 100MG BASE | A078627 | 005 | Jun 13, 2008 |
| AB | | TEVA | EQ 25MG BASE | A076690 | 001 | Aug 03, 2006 |
| AB | | | EQ 37.5MG BASE | A076690 | 002 | Aug 03, 2006 |
| AB | ! | | EQ 50MG BASE | A076690 | 003 | Aug 03, 2006 |
| AB | | | EQ 75MG BASE | A076690 | 004 | Aug 03, 2006 |
| AB | | | EQ 100MG BASE | A076690 | 005 | Aug 03, 2006 |
| AB | | YAOPHARMA CO LTD | EQ 25MG BASE | A202036 | 001 | May 28, 2015 |
| AB | | | EQ 37.5MG BASE | A202036 | 002 | May 28, 2015 |
| AB | | | EQ 50MG BASE | A202036 | 003 | May 28, 2015 |
| AB | | | EQ 75MG BASE | A202036 | 004 | May 28, 2015 |
| AB | | | EQ 100MG BASE | A202036 | 005 | May 28, 2015 |
| AB | | ZYDUS PHARMS USA | EQ 25MG BASE | A077653 | 001 | Jun 13, 2008 |
| AB | | | EQ 37.5MG BASE | A077653 | 002 | Jun 13, 2008 |
| AB | | | EQ 50MG BASE | A077653 | 003 | Jun 13, 2008 |
| AB | | | EQ 75MG BASE | A077653 | 004 | Jun 13, 2008 |
| AB | | | EQ 100MG BASE | A077653 | 005 | Jun 13, 2008 |

TABLET, EXTENDED RELEASE;ORAL

**VENLAFAXINE HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| AB | | NOSTRUM LABS INC | EQ 150MG BASE | A205468 | 002 | Mar 24, 2017 |
| AB | | | EQ 225MG BASE | A205468 | 003 | Mar 24, 2017 |
| AB | + | OSMOTICA PHARM | EQ 37.5MG BASE | N022104 | 001 | May 20, 2008 |
| AB | + | | EQ 75MG BASE | N022104 | 002 | May 20, 2008 |
| AB | +! | | EQ 150MG BASE | N022104 | 003 | May 20, 2008 |
| AB | + | | EQ 225MG BASE | N022104 | 004 | May 20, 2008 |
| AB | | SUN PHARMA GLOBAL | EQ 37.5MG BASE | A091272 | 001 | Aug 18, 2010 |
| AB | | | EQ 75MG BASE | A091272 | 002 | Aug 18, 2010 |
| AB | | | EQ 150MG BASE | A091272 | 003 | Aug 18, 2010 |

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

**VERAPAMIL HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| AB | | MYLAN | 100MG | A078306 | 001 | Aug 09, 2007 |
| AB | | | 120MG | A075138 | 001 | Apr 20, 1999 |
| AB | | | 180MG | A075138 | 002 | Apr 20, 1999 |
| AB | | | 200MG | A078306 | 002 | Aug 09, 2007 |
| AB | | | 240MG | A075138 | 003 | Apr 20, 1999 |
| AB | | | 300MG | A078306 | 003 | Aug 09, 2007 |

**VERELAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| AB | + | RECRO GAINESVILLE | 120MG | N019614 | 001 | May 29, 1990 |
| AB | + | | 180MG | N019614 | 003 | Jan 09, 1992 |
| AB | + | | 240MG | N019614 | 002 | May 29, 1990 |

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

**VERELAN PM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | RECRO GAINESVILLE | **100MG** | **N020943** | **001** | Nov 25, 1998 |
| **AB** | **+** | | **200MG** | **N020943** | **002** | Nov 25, 1998 |
| **AB** | **+!** | | **300MG** | **N020943** | **003** | Nov 25, 1998 |

VERELAN

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | RECRO GAINESVILLE | 360MG | N019614 | 004 | May 10, 1996 |

SOLUTION;INTRAVENOUS

**VERAPAMIL HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | EXELA PHARMA SCS LLC | **5MG/2ML (2.5MG/ML)** | **N018925** | **001** | Mar 30, 1984 |
| **AP** | **!** | HOSPIRA | **10MG/4ML (2.5MG/ML)** | **A070738** | **001** | May 06, 1987 |
| **AP** | **!** | | **5MG/2ML (2.5MG/ML)** | **A075136** | **001** | Oct 20, 1998 |
| **AP** | **!** | | **5MG/2ML (2.5MG/ML)** | **A070737** | **001** | May 06, 1987 |
| **AP** | **!** | | **10MG/4ML (2.5MG/ML)** | **A070737** | **002** | May 06, 1987 |

TABLET;ORAL

**CALAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | GD SEARLE LLC | **80MG** | **N018817** | **001** | Sep 10, 1984 |
| **AB** | **+!** | | **120MG** | **N018817** | **002** | Sep 10, 1984 |

**VERAPAMIL HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | HERITAGE PHARMS INC | **40MG** | **A071881** | **002** | Oct 14, 2015 |
| **AB** | | | **80MG** | **A071881** | **003** | Apr 05, 1988 |
| **AB** | | | **120MG** | **A071881** | **001** | Apr 05, 1988 |
| **AB** | | MYLAN | **80MG** | **A071483** | **002** | Feb 15, 1989 |
| **AB** | | | **120MG** | **A071483** | **001** | Feb 15, 1989 |
| **AB** | | WATSON LABS | **40MG** | **A072924** | **001** | Jun 29, 1993 |
| **AB** | | | **80MG** | **A070995** | **001** | Oct 01, 1986 |
| **AB** | | | **120MG** | **A070994** | **001** | Oct 01, 1986 |

TABLET, EXTENDED RELEASE;ORAL

**CALAN SR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | PFIZER | **120MG** | **N019152** | **003** | Mar 06, 1991 |
| **AB** | **+!** | | **240MG** | **N019152** | **001** | Dec 16, 1986 |

**VERAPAMIL HYDROCHLORIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | APOTEX CORP | **120MG** | **A200878** | **001** | Apr 20, 2012 |
| **AB** | | | **180MG** | **A200878** | **002** | Apr 20, 2012 |
| **AB** | | | **240MG** | **A200878** | **003** | Apr 20, 2012 |
| **AB** | | CADILA PHARMS LTD | **180MG** | **A206173** | **001** | May 05, 2017 |
| **AB** | | | **240MG** | **A206173** | **002** | May 05, 2017 |
| **AB** | | GLENMARK GENERICS | **120MG** | **A090700** | **001** | Aug 03, 2011 |
| **AB** | **!** | | **180MG** | **A090700** | **002** | Aug 03, 2011 |
| **AB** | | | **240MG** | **A078906** | **001** | Sep 17, 2009 |
| **AB** | | IVAX SUB TEVA PHARMS | **120MG** | **A073568** | **002** | Oct 10, 1997 |
| **AB** | | | **180MG** | **A074330** | **001** | Jan 31, 1994 |
| **AB** | | | **240MG** | **A073568** | **001** | Jul 31, 1992 |
| **AB** | | MYLAN | **120MG** | **A074587** | **002** | Feb 21, 1997 |
| **AB** | | | **180MG** | **A074587** | **003** | Sep 09, 1997 |
| **AB** | | | **240MG** | **A074587** | **001** | Mar 23, 1996 |
| **AB** | | PAR PHARM | **120MG** | **A075072** | **001** | May 25, 1999 |
| **AB** | | | **240MG** | **A075072** | **003** | May 25, 1999 |
| **AB** | | SUN PHARM INDS INC | **120MG** | **A090529** | **001** | Dec 30, 2011 |
| **AB** | | | **180MG** | **A090529** | **002** | Dec 30, 2011 |
| **AB** | | | **240MG** | **A090529** | **003** | Dec 30, 2011 |

VERTEPORFIN

INJECTABLE;INJECTION

VISUDYNE

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | VALEANT LUXEMBOURG | 15MG/VIAL | N021119 | 001 | Apr 12, 2000 |

VIGABATRIN

FOR SOLUTION;ORAL

**SABRIL**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **+!** | LUNDBECK PHARMS LLC | **500MG/PACKET** | **N022006** | **001** | Aug 21, 2009 |

**VIGABATRIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | PAR PHARM INC | **500MG/PACKET** | **A208218** | **001** | Apr 27, 2017 |

TABLET;ORAL

SABRIL

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | LUNDBECK PHARMS LLC | 500MG | N020427 | 001 | Aug 21, 2009 |

| | | | | | | |
|---|---|---|---|---|---|---|
| VILAZODONE HYDROCHLORIDE | | | | | | |
| TABLET;ORAL | | | | | | |
| VIIBRYD | | | | | | |
| | +! | FOREST LABS LLC | 10MG | N022567 | 001 | Jan 21, 2011 |
| | + | | 20MG | N022567 | 002 | Jan 21, 2011 |
| | + | | 40MG | N022567 | 003 | Jan 21, 2011 |
| VINBLASTINE SULFATE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| VINBLASTINE SULFATE | | | | | | |
| | ! | FRESENIUS KABI USA | 1MG/ML | A089515 | 001 | Apr 29, 1987 |
| | ! | WEST-WARD PHARMS INT | 10MG/VIAL | A089395 | 001 | Apr 09, 1987 |
| VINCRISTINE SULFATE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| **VINCRISTINE SULFATE PFS** | | | | | | |
| **AP** | **!** | HOSPIRA | **1MG/ML** | **A071484** | **001** | Apr 19, 1988 |
| **AP** | | TEVA PHARMS USA | **1MG/ML** | **A075493** | **001** | Sep 01, 1999 |
| INJECTABLE, LIPOSOMAL;INTRAVENOUS | | | | | | |
| MARQIBO KIT | | | | | | |
| | +! | TALON THERAP | 5MG/5ML (1MG/ML) | N202497 | 001 | Aug 09, 2012 |
| VINORELBINE TARTRATE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| **NAVELBINE** | | | | | | |
| **AP** | **+!** | PIERRE FABRE | **EQ 10MG BASE/ML** | **N020388** | **001** | Dec 23, 1994 |
| **VINORELBINE TARTRATE** | | | | | | |
| **AP** | | ACTAVIS TOTOWA | **EQ 10MG BASE/ML** | **A078011** | **001** | Jul 22, 2009 |
| **AP** | | DR REDDYS LABS LTD | **EQ 10MG BASE/ML** | **A202017** | **001** | Sep 12, 2013 |
| **AP** | | FRESENIUS KABI USA | **EQ 10MG BASE/ML** | **A076849** | **001** | Apr 18, 2005 |
| **AP** | | HOSPIRA | **EQ 10MG BASE/ML** | **A076827** | **001** | Jun 02, 2005 |
| **AP** | | JIANGSU HANSOH PHARM | **EQ 10MG BASE/ML** | **A091106** | **001** | Sep 26, 2012 |
| **AP** | | TEVA PHARMS USA | **EQ 10MG BASE/ML** | **A076028** | **001** | Feb 03, 2003 |
| **AP** | | WEST-WARD PHARMS INT | **EQ 10MG BASE/ML** | **A075992** | **001** | Jun 10, 2003 |
| **AP** | | | **EQ 10MG BASE/ML** | **A076461** | **001** | Dec 11, 2003 |
| VISMODEGIB | | | | | | |
| CAPSULE;ORAL | | | | | | |
| ERIVEDGE | | | | | | |
| | +! | GENENTECH | 150MG | N203388 | 001 | Jan 30, 2012 |
| VITAMIN A PALMITATE | | | | | | |
| INJECTABLE;INJECTION | | | | | | |
| AQUASOL A | | | | | | |
| | +! | HOSPIRA | EQ 50,000 UNITS BASE/ML | N006823 | 001 | |
| VORAPAXAR SULFATE | | | | | | |
| TABLET;ORAL | | | | | | |
| ZONTIVITY | | | | | | |
| | +! | ARALEZ PHARMS | EQ 2.08MG BASE | N204886 | 001 | May 08, 2014 |
| VORICONAZOLE | | | | | | |
| FOR SUSPENSION;ORAL | | | | | | |
| **VFEND** | | | | | | |
| **AB** | **+!** | PF PRISM CV | **200MG/5ML** | **N021630** | **001** | Dec 19, 2003 |
| **VORICONAZOLE** | | | | | | |
| **AB** | | AMNEAL PHARMS | **200MG/5ML** | **A205034** | **001** | Apr 13, 2016 |
| **AB** | | MYLAN PHARMS INC | **200MG/5ML** | **A202361** | **001** | May 28, 2013 |
| **AB** | | NOVEL LABS INC | **200MG/5ML** | **A206799** | **001** | May 31, 2016 |
| INJECTABLE;IV (INFUSION) | | | | | | |
| **VFEND** | | | | | | |
| **AP** | **+!** | PF PRISM CV | **200MG/VIAL** | **N021267** | **001** | May 24, 2002 |
| **VORICONAZOLE** | | | | | | |
| **AP** | | ALVOGEN INC | **200MG/VIAL** | **A206398** | **001** | Mar 23, 2016 |
| **AP** | | SANDOZ INC | **200MG/VIAL** | **A090862** | **001** | May 30, 2012 |
| POWDER;IV (INFUSION) | | | | | | |
| VORICONAZOLE | | | | | | |
| | | XELLIA PHARMS APS | 200MG/VIAL | N208562 | 001 | Mar 09, 2017 |
| TABLET;ORAL | | | | | | |
| **VFEND** | | | | | | |
| **AB** | **+** | PF PRISM CV | **50MG** | **N021266** | **001** | May 24, 2002 |
| **AB** | **+!** | | **200MG** | **N021266** | **002** | May 24, 2002 |

VORICONAZOLE

TABLET;ORAL

**VORICONAZOLE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AJANTA PHARMA LTD | **50MG** | **A206181** | **001** | May 24, 2016 |
| **AB** | | | **200MG** | **A206181** | **002** | May 24, 2016 |
| **AB** | | AKORN | **50MG** | **A207049** | **001** | Sep 07, 2016 |
| **AB** | | | **200MG** | **A207049** | **002** | Sep 07, 2016 |
| **AB** | | APPCO PHARMA LLC | **50MG** | **A206762** | **001** | May 24, 2016 |
| **AB** | | | **200MG** | **A206762** | **002** | May 24, 2016 |
| **AB** | | AUROBINDO PHARMA LTD | **50MG** | **A206837** | **001** | Jan 22, 2016 |
| **AB** | | | **200MG** | **A206837** | **002** | Jan 22, 2016 |
| **AB** | | GLENMARK PHARMS LTD | **50MG** | **A203503** | **001** | Sep 02, 2015 |
| **AB** | | | **200MG** | **A203503** | **002** | Sep 02, 2015 |
| **AB** | | MYLAN PHARMS INC | **50MG** | **A090547** | **001** | Apr 22, 2010 |
| **AB** | | | **200MG** | **A090547** | **002** | Apr 22, 2010 |
| **AB** | | NOVEL LABS INC | **50MG** | **A207371** | **001** | May 24, 2016 |
| **AB** | | | **200MG** | **A207371** | **002** | May 24, 2016 |
| **AB** | | PRINSTON INC | **50MG** | **A206654** | **001** | Aug 08, 2016 |
| **AB** | | | **200MG** | **A206654** | **002** | Aug 08, 2016 |
| **AB** | | SANDOZ INC | **50MG** | **A200265** | **001** | Dec 12, 2011 |
| **AB** | | | **200MG** | **A200265** | **002** | Dec 12, 2011 |
| **AB** | | TEVA PHARMS | **50MG** | **A091658** | **001** | Apr 06, 2012 |
| **AB** | | | **200MG** | **A091658** | **002** | Apr 06, 2012 |
| **AB** | | ZYDUS PHARMS USA INC | **50MG** | **A206747** | **001** | May 24, 2016 |
| **AB** | | | **200MG** | **A206747** | **002** | May 24, 2016 |

VORINOSTAT

CAPSULE;ORAL

ZOLINZA

| | | | | | | |
|---|---|---|---|---|---|---|
| +! | | MERCK | 100MG | N021991 | 001 | Oct 06, 2006 |

VORTIOXETINE HYDROBROMIDE

TABLET;ORAL

TRINTELLIX

| | | | | | | |
|---|---|---|---|---|---|---|
| + | | TAKEDA PHARMS USA | EQ 5MG BASE | N204447 | 001 | Sep 30, 2013 |
| + | | | EQ 10MG BASE | N204447 | 002 | Sep 30, 2013 |
| +! | | | EQ 20MG BASE | N204447 | 004 | Sep 30, 2013 |

WARFARIN SODIUM

TABLET;ORAL

**COUMADIN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | BRISTOL MYERS SQUIBB | **1MG** | **N009218** | **022** | Mar 01, 1990 |
| **AB** | **+** | | **2MG** | **N009218** | **013** | |
| **AB** | **+** | | **2.5MG** | **N009218** | **018** | |
| **AB** | **+** | | **3MG** | **N009218** | **025** | Nov 18, 1996 |
| **AB** | **+** | | **4MG** | **N009218** | **023** | Aug 24, 1993 |
| **AB** | **+** | | **5MG** | **N009218** | **007** | |
| **AB** | **+** | | **6MG** | **N009218** | **026** | Nov 18, 1996 |
| **AB** | **+** | | **7.5MG** | **N009218** | **016** | |
| **AB** | **+!** | | **10MG** | **N009218** | **005** | |

**JANTOVEN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | USL PHARMA | **1MG** | **A040416** | **001** | Oct 02, 2003 |
| **AB** | | | **2MG** | **A040416** | **002** | Oct 02, 2003 |
| **AB** | | | **2.5MG** | **A040416** | **003** | Oct 02, 2003 |
| **AB** | | | **3MG** | **A040416** | **004** | Oct 02, 2003 |
| **AB** | | | **4MG** | **A040416** | **005** | Oct 02, 2003 |
| **AB** | | | **5MG** | **A040416** | **006** | Oct 02, 2003 |
| **AB** | | | **6MG** | **A040416** | **007** | Oct 02, 2003 |
| **AB** | | | **7.5MG** | **A040416** | **008** | Oct 02, 2003 |
| **AB** | | | **10MG** | **A040416** | **009** | Oct 02, 2003 |

**WARFARIN SODIUM**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AMNEAL PHARMS | **1MG** | **A202202** | **001** | Mar 04, 2013 |
| **AB** | | | **2MG** | **A202202** | **002** | Mar 04, 2013 |
| **AB** | | | **2.5MG** | **A202202** | **003** | Mar 04, 2013 |
| **AB** | | | **3MG** | **A202202** | **004** | Mar 04, 2013 |
| **AB** | | | **4MG** | **A202202** | **005** | Mar 04, 2013 |
| **AB** | | | **5MG** | **A202202** | **006** | Mar 04, 2013 |
| **AB** | | | **6MG** | **A202202** | **007** | Mar 04, 2013 |
| **AB** | | | **7.5MG** | **A202202** | **008** | Mar 04, 2013 |
| **AB** | | | **10MG** | **A202202** | **009** | Mar 04, 2013 |
| **AB** | | BARR | **1MG** | **A040145** | **001** | Mar 26, 1997 |

WARFARIN SODIUM

TABLET;ORAL

**WARFARIN SODIUM**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | | **2MG** | **A040145** | **002** | Mar 26, 1997 |
| **AB** | | **2.5MG** | **A040145** | **003** | Mar 26, 1997 |
| **AB** | | **3MG** | **A040145** | **008** | Nov 05, 1998 |
| **AB** | | **4MG** | **A040145** | **004** | Mar 26, 1997 |
| **AB** | | **5MG** | **A040145** | **005** | Mar 26, 1997 |
| **AB** | | **6MG** | **A040145** | **009** | Nov 05, 1998 |
| **AB** | | **7.5MG** | **A040145** | **006** | Mar 26, 1997 |
| **AB** | | **10MG** | **A040145** | **007** | Mar 26, 1997 |
| **AB** | INVAGEN PHARMS | **1MG** | **A090935** | **001** | May 25, 2011 |
| **AB** | | **2MG** | **A090935** | **002** | May 25, 2011 |
| **AB** | | **2.5MG** | **A090935** | **003** | May 25, 2011 |
| **AB** | | **3MG** | **A090935** | **004** | May 25, 2011 |
| **AB** | | **4MG** | **A090935** | **005** | May 25, 2011 |
| **AB** | | **5MG** | **A090935** | **006** | May 25, 2011 |
| **AB** | | **6MG** | **A090935** | **007** | May 25, 2011 |
| **AB** | | **7.5MG** | **A090935** | **008** | May 25, 2011 |
| **AB** | | **10MG** | **A090935** | **009** | May 25, 2011 |
| **AB** | IPCA LABS LTD | **1MG** | **A200104** | **001** | Jun 27, 2013 |
| **AB** | | **2MG** | **A200104** | **002** | Jun 27, 2013 |
| **AB** | | **2.5MG** | **A200104** | **003** | Jun 27, 2013 |
| **AB** | | **3MG** | **A200104** | **004** | Jun 27, 2013 |
| **AB** | | **4MG** | **A200104** | **005** | Jun 27, 2013 |
| **AB** | | **5MG** | **A200104** | **006** | Jun 27, 2013 |
| **AB** | | **6MG** | **A200104** | **007** | Jun 27, 2013 |
| **AB** | | **7.5MG** | **A200104** | **008** | Jun 27, 2013 |
| **AB** | | **10MG** | **A200104** | **009** | Jun 27, 2013 |
| **AB** | PLIVA | **1MG** | **A040616** | **009** | Jul 05, 2006 |
| **AB** | | **2MG** | **A040616** | **001** | Jul 05, 2006 |
| **AB** | | **2.5MG** | **A040616** | **002** | Jul 05, 2006 |
| **AB** | | **3MG** | **A040616** | **003** | Jul 05, 2006 |
| **AB** | | **4MG** | **A040616** | **004** | Jul 05, 2006 |
| **AB** | | **5MG** | **A040616** | **005** | Jul 05, 2006 |
| **AB** | | **6MG** | **A040616** | **006** | Jul 05, 2006 |
| **AB** | | **7.5MG** | **A040616** | **007** | Jul 05, 2006 |
| **AB** | | **10MG** | **A040616** | **008** | Jul 05, 2006 |
| **AB** | TARO PHARM | **1MG** | **A040301** | **002** | Jul 15, 1999 |
| **AB** | | **2MG** | **A040301** | **003** | Jul 15, 1999 |
| **AB** | | **2.5MG** | **A040301** | **004** | Jul 15, 1999 |
| **AB** | | **3MG** | **A040301** | **005** | Jul 15, 1999 |
| **AB** | | **4MG** | **A040301** | **006** | Jul 15, 1999 |
| **AB** | | **5MG** | **A040301** | **007** | Jul 15, 1999 |
| **AB** | | **6MG** | **A040301** | **008** | Jul 15, 1999 |
| **AB** | | **7.5MG** | **A040301** | **009** | Jul 15, 1999 |
| **AB** | | **10MG** | **A040301** | **001** | Jul 15, 1999 |
| **AB** | ZYDUS PHARMS USA | **1MG** | **A040663** | **001** | May 30, 2006 |
| **AB** | | **2MG** | **A040663** | **002** | May 30, 2006 |
| **AB** | | **2.5MG** | **A040663** | **003** | May 30, 2006 |
| **AB** | | **3MG** | **A040663** | **004** | May 30, 2006 |
| **AB** | | **4MG** | **A040663** | **005** | May 30, 2006 |
| **AB** | | **5MG** | **A040663** | **006** | May 30, 2006 |
| **AB** | | **6MG** | **A040663** | **007** | May 30, 2006 |
| **AB** | | **7.5MG** | **A040663** | **008** | May 30, 2006 |
| **AB** | | **10MG** | **A040663** | **009** | May 30, 2006 |

XENON XE-133

GAS;INHALATION

XENON XE 133

| | | | | | |
|---|---|---|---|---|---|
| | LANTHEUS MEDCL | 10mCi/VIAL | N017284 | 001 | |
| | | 20mCi/VIAL | N017284 | 002 | |
| | MALLINKRODT NUCLEAR | 10mCi/VIAL | N018327 | 001 | Mar 09, 1982 |
| | | 20mCi/VIAL | N018327 | 002 | Mar 09, 1982 |

ZAFIRLUKAST

TABLET;ORAL

**ACCOLATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | PAR PHARM INC | **10MG** | **N020547** | **003** | Sep 17, 1999 |
| **AB** | **+!** | | **20MG** | **N020547** | **001** | Sep 26, 1996 |

**ZAFIRLUKAST**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | DR REDDYS LABS LTD | **10MG** | **A090372** | **001** | Nov 18, 2010 |
| **AB** | | | **20MG** | **A090372** | **002** | Nov 18, 2010 |

ZALEPLON

CAPSULE;ORAL

**SONATA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | PFIZER | **5MG** | **N020859** | **001** | Aug 13, 1999 |
| **AB** | **+!** | | **10MG** | **N020859** | **002** | Aug 13, 1999 |

**ZALEPLON**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AUROBINDO PHARMA | **5MG** | **A078829** | **001** | Jun 06, 2008 |
| **AB** | | | **10MG** | **A078829** | **002** | Jun 06, 2008 |
| **AB** | | CIPLA LTD | **5MG** | **A077505** | **001** | Jun 20, 2008 |
| **AB** | | | **10MG** | **A077505** | **002** | Jun 20, 2008 |
| **AB** | | HIKMA PHARMS | **5MG** | **A078147** | **001** | Nov 25, 2008 |
| **AB** | | | **10MG** | **A078147** | **002** | Nov 25, 2008 |
| **AB** | | ORCHID HLTHCARE | **5MG** | **A090374** | **001** | Sep 17, 2009 |
| **AB** | | | **10MG** | **A090374** | **002** | Sep 17, 2009 |
| **AB** | | TEVA PHARMS | **5MG** | **A077239** | **001** | Jun 06, 2008 |
| **AB** | | | **10MG** | **A077239** | **002** | Jun 06, 2008 |
| **AB** | | UNICHEM | **5MG** | **A078989** | **001** | Jun 06, 2008 |
| **AB** | | | **10MG** | **A078989** | **002** | Jun 06, 2008 |
| **AB** | | WEST-WARD PHARMS INT | **5MG** | **A077237** | **001** | Jun 06, 2008 |
| **AB** | | | **10MG** | **A077237** | **002** | Jun 06, 2008 |

ZANAMIVIR

POWDER;INHALATION

RELENZA

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | GLAXOSMITHKLINE | 5MG | N021036 | 001 | Jul 26, 1999 |

ZICONOTIDE ACETATE

INJECTABLE;INTRATHECAL

PRIALT

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | JAZZ PHARMS INTL | 100MCG/1ML (100MCG/ML) | N021060 | 002 | Dec 28, 2004 |
| | +! | | 500MCG/20ML (25MCG/ML) | N021060 | 001 | Dec 28, 2004 |
| | +! | | 500MCG/5ML (100MCG/ML) | N021060 | 004 | Dec 28, 2004 |

ZIDOVUDINE

CAPSULE;ORAL

**RETROVIR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | VIIV HLTHCARE | **100MG** | **N019655** | **001** | Mar 19, 1987 |

**ZIDOVUDINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AUROBINDO PHARMA LTD | **100MG** | **A078128** | **001** | Mar 27, 2006 |
| **AB** | | CIPLA LTD | **100MG** | **A078349** | **001** | May 23, 2007 |

INJECTABLE;INJECTION

**RETROVIR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | VIIV HLTHCARE | **10MG/ML** | **N019951** | **001** | Feb 02, 1990 |

**ZIDOVUDINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | LUITPOLD | **10MG/ML** | **A091457** | **001** | May 06, 2010 |

SYRUP;ORAL

**RETROVIR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | **+!** | VIIV HLTHCARE | **50MG/5ML** | **N019910** | **001** | Sep 28, 1989 |

**ZIDOVUDINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AA** | | AUROBINDO | **50MG/5ML** | **A077268** | **001** | Sep 19, 2005 |
| **AA** | | CIPLA LTD | **50MG/5ML** | **A077981** | **001** | Jun 26, 2008 |

TABLET;ORAL

**ZIDOVUDINE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AUROBINDO | **300MG** | **A077267** | **001** | Sep 19, 2005 |
| **AB** | | CIPLA | **300MG** | **A090561** | **001** | Oct 27, 2010 |
| **AB** | **!** | HETERO LABS LTD III | **300MG** | **A090092** | **001** | Apr 25, 2008 |
| **AB** | | MYLAN PHARMS INC | **300MG** | **A078922** | **001** | Feb 14, 2008 |
| **AB** | | WEST-WARD PHARMS INT | **300MG** | **A076844** | **001** | Sep 19, 2005 |

ZILEUTON

TABLET;ORAL

ZYFLO

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | CHIESI USA INC | 600MG | N020471 | 003 | Dec 09, 1996 |

TABLET, EXTENDED RELEASE;ORAL

**ZILEUTON**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | RISING PHARMS INC | **600MG** | **A204929** | **001** | Mar 17, 2017 |

**ZYFLO CR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | CHIESI USA INC | **600MG** | **N022052** | **001** | May 30, 2007 |

ZINC ACETATE

CAPSULE;ORAL

GALZIN

| | | | | | |
|---|---|---|---|---|---|
| + | TEVA | EQ 25MG ZINC | N020458 | 001 | Jan 28, 1997 |
| +! | | EQ 50MG ZINC | N020458 | 002 | Jan 28, 1997 |

ZINC CHLORIDE

INJECTABLE;INJECTION

ZINC CHLORIDE IN PLASTIC CONTAINER

| | | | | | |
|---|---|---|---|---|---|
| +! | HOSPIRA | EQ 1MG ZINC/ML | N018959 | 001 | Jun 26, 1986 |

ZIPRASIDONE HYDROCHLORIDE

CAPSULE;ORAL

**GEODON**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+!** | PFIZER | **EQ 20MG BASE** | **N020825** | **001** | Feb 05, 2001 |
| **AB** | **+** | | **EQ 40MG BASE** | **N020825** | **002** | Feb 05, 2001 |
| **AB** | **+** | | **EQ 60MG BASE** | **N020825** | **003** | Feb 05, 2001 |
| **AB** | **+** | | **EQ 80MG BASE** | **N020825** | **004** | Feb 05, 2001 |

**ZIPRASIDONE HYDROCHLORIDE**

| | | | | | |
|---|---|---|---|---|---|
| **AB** | APOTEX INC | **EQ 20MG BASE** | **A077561** | **001** | Mar 02, 2012 |
| **AB** | | **EQ 40MG BASE** | **A077561** | **002** | Mar 02, 2012 |
| **AB** | | **EQ 60MG BASE** | **A077561** | **003** | Mar 02, 2012 |
| **AB** | | **EQ 80MG BASE** | **A077561** | **004** | Mar 02, 2012 |
| **AB** | AUROBINDO PHARMA LTD | **EQ 20MG BASE** | **A204117** | **001** | Dec 27, 2016 |
| **AB** | | **EQ 40MG BASE** | **A204117** | **002** | Dec 27, 2016 |
| **AB** | | **EQ 60MG BASE** | **A204117** | **003** | Dec 27, 2016 |
| **AB** | | **EQ 80MG BASE** | **A204117** | **004** | Dec 27, 2016 |
| **AB** | DR REDDYS LABS INC | **EQ 20MG BASE** | **A077565** | **001** | Mar 02, 2012 |
| **AB** | | **EQ 40MG BASE** | **A077565** | **002** | Mar 02, 2012 |
| **AB** | | **EQ 60MG BASE** | **A077565** | **003** | Mar 02, 2012 |
| **AB** | | **EQ 80MG BASE** | **A077565** | **004** | Mar 02, 2012 |
| **AB** | LUPIN PHARMS | **EQ 20MG BASE** | **A077560** | **001** | Mar 02, 2012 |
| **AB** | | **EQ 40MG BASE** | **A077560** | **002** | Mar 02, 2012 |
| **AB** | | **EQ 60MG BASE** | **A077560** | **003** | Mar 02, 2012 |
| **AB** | | **EQ 80MG BASE** | **A077560** | **004** | Mar 02, 2012 |
| **AB** | MACLEODS PHARMS LTD | **EQ 20MG BASE** | **A204375** | **001** | Feb 17, 2017 |
| **AB** | | **EQ 40MG BASE** | **A204375** | **002** | Feb 17, 2017 |
| **AB** | | **EQ 60MG BASE** | **A204375** | **003** | Feb 17, 2017 |
| **AB** | | **EQ 80MG BASE** | **A204375** | **004** | Feb 17, 2017 |
| **AB** | MYLAN PHARMS INC | **EQ 20MG BASE** | **A202395** | **001** | Oct 10, 2013 |
| **AB** | | **EQ 40MG BASE** | **A202395** | **002** | Oct 10, 2013 |
| **AB** | | **EQ 60MG BASE** | **A202395** | **003** | Oct 10, 2013 |
| **AB** | | **EQ 80MG BASE** | **A202395** | **004** | Oct 10, 2013 |
| **AB** | SANDOZ INC | **EQ 20MG BASE** | **A077562** | **001** | Jun 01, 2012 |
| **AB** | | **EQ 40MG BASE** | **A077562** | **002** | Jun 01, 2012 |
| **AB** | | **EQ 60MG BASE** | **A077562** | **003** | Jun 01, 2012 |
| **AB** | | **EQ 80MG BASE** | **A077562** | **004** | Jun 01, 2012 |
| **AB** | WOCKHARDT LTD | **EQ 20MG BASE** | **A090348** | **001** | Sep 05, 2012 |
| **AB** | | **EQ 40MG BASE** | **A090348** | **002** | Sep 05, 2012 |
| **AB** | | **EQ 60MG BASE** | **A090348** | **003** | Sep 05, 2012 |
| **AB** | | **EQ 80MG BASE** | **A090348** | **004** | Sep 05, 2012 |
| **AB** | ZYDUS PHARMS USA INC | **EQ 20MG BASE** | **A208988** | **001** | Aug 22, 2017 |
| **AB** | | **EQ 40MG BASE** | **A208988** | **002** | Aug 22, 2017 |
| **AB** | | **EQ 60MG BASE** | **A208988** | **003** | Aug 22, 2017 |
| **AB** | | **EQ 80MG BASE** | **A208988** | **004** | Aug 22, 2017 |

ZIPRASIDONE MESYLATE

INJECTABLE;INTRAMUSCULAR

GEODON

| | | | | | |
|---|---|---|---|---|---|
| +! | PFIZER | EQ 20MG BASE/ML | N020919 | 001 | Jun 21, 2002 |

ZOLEDRONIC ACID

INJECTABLE;IV (INFUSION)

**RECLAST**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | NOVARTIS | **EQ 5MG BASE/100ML** | **N021817** | **001** | Apr 16, 2007 |

**ZOLEDRONIC ACID**

| | | | | | |
|---|---|---|---|---|---|
| **AP** | ACCORD HLTHCARE | **EQ 4MG BASE/5ML** | **A205279** | **001** | Nov 28, 2016 |
| **AP** | ACS DOBFAR INFO SA | **EQ 4MG BASE/100ML** | **N203231** | **001** | Aug 02, 2013 |
| **AP** | | **EQ 5MG BASE/100ML** | **A202828** | **001** | Sep 23, 2013 |
| **AP** | ACTAVIS INC | **EQ 4MG BASE/5ML** | **A202472** | **001** | Mar 04, 2013 |
| **AP** | AKORN | **EQ 5MG BASE/100ML** | **A200918** | **001** | Aug 21, 2014 |
| **AP** | AKORN INC | **EQ 4MG BASE/5ML** | **A202548** | **001** | May 22, 2014 |
| **AP** | APOTEX INC | **EQ 5MG BASE/100ML** | **A204367** | **001** | Dec 24, 2015 |

ZOLEDRONIC ACID

INJECTABLE;IV (INFUSION)

**ZOLEDRONIC ACID**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | | AUROBINDO PHARMA LTD | **EQ 4MG BASE/5ML** | **A207751** | **001** | Sep 26, 2016 |
| **AP** | | | **EQ 5MG BASE/100ML** | **A209125** | **001** | Dec 08, 2017 |
| **AP** | | BPI LABS LLC | **EQ 4MG BASE/5ML** | **A207341** | **001** | Dec 29, 2017 |
| **AP** | | BRECKENRIDGE PHARM | **EQ 4MG BASE/5ML** | **A091170** | **001** | Mar 04, 2013 |
| **AP** | | | **EQ 4MG BASE/5ML** | **A202571** | **001** | May 07, 2013 |
| **AP** | | | **EQ 5MG BASE/100ML** | **A202163** | **001** | Aug 05, 2013 |
| **AP** | | CIPLA LTD | **EQ 4MG BASE/100ML** | **A210174** | **001** | Oct 27, 2017 |
| **AP** | | DR REDDYS LABS LTD | **EQ 4MG BASE/5ML** | **A091186** | **001** | Mar 04, 2013 |
| **AP** | | | **EQ 5MG BASE/100ML** | **A091363** | **001** | Mar 29, 2013 |
| **AP** | | EMCURE PHARMS LTD | **EQ 4MG BASE/5ML** | **A201783** | **001** | Mar 12, 2013 |
| **AP** | | | **EQ 5MG BASE/100ML** | **A201801** | **001** | Mar 29, 2013 |
| **AP** | | FRESENIUS KABI USA | **EQ 4MG BASE/5ML** | **A091516** | **001** | Apr 23, 2015 |
| **AP** | | GLAND PHARMA LTD | **EQ 4MG BASE/5ML** | **A202930** | **001** | Aug 05, 2013 |
| **AP** | | | **EQ 5MG BASE/100ML** | **A204217** | **001** | Aug 18, 2016 |
| **AP** | | HIKMA FARMACEUTICA | **EQ 4MG BASE/5ML** | **A202182** | **001** | Jun 03, 2013 |
| **AP** | | HOSPIRA INC | **EQ 4MG BASE/5ML** | **A090621** | **001** | Mar 19, 2015 |
| **AP** | | | **EQ 5MG BASE/100ML** | **A202837** | **001** | Apr 05, 2013 |
| **AP** | | MYLAN LABS LTD | **EQ 4MG BASE/5ML** | **A202650** | **001** | Mar 04, 2013 |
| **AP** | | | **EQ 5MG BASE/100ML** | **A203841** | **001** | Feb 14, 2017 |
| **AP** | | | **EQ 5MG BASE/100ML** | **A205254** | **001** | Oct 27, 2017 |
| **AP** | | SAGENT PHARMS | **EQ 4MG BASE/5ML** | **A091493** | **001** | Nov 24, 2014 |
| **AP** | **!** | SUN PHARMA GLOBAL | **EQ 4MG BASE/VIAL** | **A090018** | **001** | Mar 04, 2013 |
| **AP** | | USV NORTH AMERICA | **EQ 4MG BASE/5ML** | **A202923** | **001** | Sep 04, 2014 |

**ZOMETA**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AP** | **+!** | NOVARTIS | **EQ 4MG BASE/5ML** | **N021223** | **002** | Mar 07, 2003 |
| **AP** | **+!** | | **EQ 4MG BASE/100ML** | **N021223** | **003** | Jun 17, 2011 |

SOLUTION;IV (INFUSION)

ZOLEDRONIC ACID

| | | | | | | |
|---|---|---|---|---|---|---|
| | | HOSPIRA INC | EQ 4MG BASE/100ML (EQ 0.04MG BASE/ML) | N204016 | 001 | Dec 28, 2015 |

ZOLMITRIPTAN

SPRAY;NASAL

ZOMIG

| | | | | | | |
|---|---|---|---|---|---|---|
| | + | ASTRAZENECA | 2.5MG/SPRAY | N021450 | 003 | Sep 16, 2013 |
| | +! | | 5MG/SPRAY | N021450 | 004 | Sep 30, 2003 |

TABLET;ORAL

**ZOLMITRIPTAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | AJANTA PHARMA LTD | **2.5MG** | **A204041** | **001** | May 20, 2016 |
| **AB** | | | **5MG** | **A204041** | **002** | May 20, 2016 |
| **AB** | | ALEMBIC PHARMS LTD | **2.5MG** | **A204232** | **001** | Sep 30, 2015 |
| **AB** | | | **5MG** | **A204232** | **002** | Sep 30, 2015 |
| **AB** | | APOTEX INC | **2.5MG** | **A202078** | **001** | May 14, 2013 |
| **AB** | | | **5MG** | **A202078** | **002** | May 14, 2013 |
| **AB** | | APPCO PHARMA LLC | **2.5MG** | **A206973** | **001** | Jun 30, 2017 |
| **AB** | | | **5MG** | **A206973** | **002** | Jun 30, 2017 |
| **AB** | | AUROBINDO PHARMA LTD | **2.5MG** | **A207021** | **001** | May 11, 2016 |
| **AB** | | | **5MG** | **A207021** | **002** | May 11, 2016 |
| **AB** | | GLENMARK GENERICS | **2.5MG** | **A201779** | **001** | May 14, 2013 |
| **AB** | | | **5MG** | **A201779** | **002** | May 14, 2013 |
| **AB** | | INVAGEN PHARMS | **2.5MG** | **A204284** | **001** | Apr 09, 2014 |
| **AB** | | | **5MG** | **A204284** | **002** | Apr 09, 2014 |
| **AB** | | JUBILANT GENERICS | **2.5MG** | **A202279** | **001** | Nov 20, 2014 |
| **AB** | | | **5MG** | **A202279** | **002** | Nov 20, 2014 |
| **AB** | | MACLEODS PHARMS LTD | **2.5MG** | **A203772** | **001** | Sep 30, 2015 |
| **AB** | | | **5MG** | **A203772** | **002** | Sep 30, 2015 |
| **AB** | | MYLAN PHARMS INC | **2.5MG** | **A203186** | **001** | May 14, 2013 |
| **AB** | | | **5MG** | **A203186** | **002** | May 14, 2013 |
| **AB** | | PLD ACQUISITIONS LLC | **2.5MG** | **A207867** | **001** | Feb 27, 2017 |
| **AB** | | | **5MG** | **A207867** | **002** | Feb 27, 2017 |
| **AB** | | TEVA PHARMS USA | **2.5MG** | **A090861** | **001** | Mar 04, 2014 |
| **AB** | | | **5MG** | **A090861** | **002** | Mar 04, 2014 |

**ZOMIG**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | IPR | **2.5MG** | **N020768** | **001** | Nov 25, 1997 |
| **AB** | **+!** | | **5MG** | **N020768** | **002** | Nov 25, 1997 |

TABLET, ORALLY DISINTEGRATING;ORAL

**ZOLMITRIPTAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ALEMBIC PHARMS LTD | **2.5MG** | **A205074** | **001** | Dec 01, 2016 |

ZOLMITRIPTAN

TABLET, ORALLY DISINTEGRATING;ORAL

**ZOLMITRIPTAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **5MG** | **A205074** | **002** | Dec 01, 2016 |
| **AB** | | APOTEX INC | **2.5MG** | **A202476** | **001** | May 14, 2013 |
| **AB** | | | **5MG** | **A202476** | **002** | May 14, 2013 |
| **AB** | | GLENMARK GENERICS | **2.5MG** | **A202560** | **001** | May 14, 2013 |
| **AB** | | | **5MG** | **A202560** | **002** | May 14, 2013 |
| **AB** | | JUBILANT GENERICS | **2.5MG** | **A202956** | **001** | Sep 17, 2015 |
| **AB** | | | **5MG** | **A202956** | **002** | Sep 17, 2015 |
| **AB** | | MACLEODS PHARMS LTD | **2.5MG** | **A204336** | **001** | Oct 22, 2015 |
| **AB** | | | **5MG** | **A204336** | **002** | Oct 22, 2015 |
| **AB** | | ZYDUS PHARMS USA INC | **2.5MG** | **A202890** | **001** | May 15, 2013 |
| **AB** | | | **5MG** | **A202890** | **002** | May 15, 2013 |

**ZOMIG-ZMT**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | ASTRAZENECA | **2.5MG** | **N021231** | **001** | Feb 13, 2001 |
| **AB** | **+!** | | **5MG** | **N021231** | **002** | Sep 17, 2001 |

ZOLPIDEM TARTRATE

SPRAY, METERED;ORAL

ZOLPIMIST

| | | | | | | |
|---|---|---|---|---|---|---|
| | +! | MAGNA PHARMS | 5MG/SPRAY | N022196 | 001 | Dec 19, 2008 |

TABLET;ORAL

**AMBIEN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | SANOFI AVENTIS US | **5MG** | **N019908** | **001** | Dec 16, 1992 |
| **AB** | **+!** | | **10MG** | **N019908** | **002** | Dec 16, 1992 |

**ZOLPIDEM TARTRATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACME LABS | **5MG** | **A077214** | **001** | Apr 23, 2007 |
| **AB** | | | **10MG** | **A077214** | **002** | Apr 23, 2007 |
| **AB** | | APOTEX INC | **5MG** | **A077884** | **001** | Apr 23, 2007 |
| **AB** | | | **10MG** | **A077884** | **002** | Apr 23, 2007 |
| **AB** | | AUROBINDO PHARMA | **5MG** | **A078413** | **001** | May 04, 2007 |
| **AB** | | | **10MG** | **A078413** | **002** | May 04, 2007 |
| **AB** | | CIPLA LTD | **5MG** | **A077388** | **001** | Jul 30, 2012 |
| **AB** | | | **10MG** | **A077388** | **002** | Jul 30, 2012 |
| **AB** | | INVAGEN PHARMS | **5MG** | **A078184** | **001** | Sep 07, 2007 |
| **AB** | | | **10MG** | **A078184** | **002** | Sep 07, 2007 |
| **AB** | | MYLAN | **5MG** | **A076578** | **001** | Apr 23, 2007 |
| **AB** | | | **10MG** | **A076578** | **002** | Apr 23, 2007 |
| **AB** | | SANDOZ INC | **5MG** | **A077322** | **001** | Apr 23, 2007 |
| **AB** | | | **10MG** | **A077322** | **002** | Apr 23, 2007 |
| **AB** | | SUN PHARM INDS INC | **5MG** | **A077359** | **001** | Apr 23, 2007 |
| **AB** | | | **10MG** | **A077359** | **002** | Apr 23, 2007 |
| **AB** | | SUN PHARM INDS LTD | **5MG** | **A078055** | **001** | Apr 23, 2007 |
| **AB** | | | **10MG** | **A078055** | **002** | Apr 23, 2007 |
| **AB** | | TEVA | **5MG** | **A076410** | **001** | Apr 23, 2007 |
| **AB** | | | **10MG** | **A076410** | **002** | Apr 23, 2007 |
| **AB** | | TORRENT PHARMS | **5MG** | **A077903** | **001** | Aug 17, 2007 |
| **AB** | | | **10MG** | **A077903** | **002** | Aug 17, 2007 |
| **AB** | | VINTAGE | **5MG** | **A078616** | **001** | Nov 21, 2008 |
| **AB** | | | **10MG** | **A078616** | **002** | Nov 21, 2008 |
| **AB** | | WOCKHARDT | **5MG** | **A078426** | **001** | May 15, 2007 |
| **AB** | | | **10MG** | **A078426** | **002** | May 15, 2007 |
| **AB** | | YUNG SHIN PHARM | **5MG** | **A077990** | **001** | Apr 23, 2007 |
| **AB** | | | **10MG** | **A077990** | **002** | Apr 23, 2007 |

TABLET;SUBLINGUAL

**EDLUAR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | MYLAN SPECIALITY LP | **5MG** | **N021997** | **001** | Mar 13, 2009 |
| **AB** | **+!** | | **10MG** | **N021997** | **002** | Mar 13, 2009 |

**INTERMEZZO**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | PURDUE PHARMA | **1.75MG** | **N022328** | **001** | Nov 23, 2011 |
| **AB** | **+!** | | **3.5MG** | **N022328** | **002** | Nov 23, 2011 |

**ZOLPIDEM TARTRATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | DR REDDYS LABS INC | **1.75MG** | **A204503** | **001** | Nov 18, 2016 |
| **AB** | | | **3.5MG** | **A204503** | **002** | Nov 18, 2016 |
| **AB** | | MYLAN PHARMS INC | **5MG** | **A202657** | **001** | Aug 08, 2016 |
| **AB** | | | **10MG** | **A202657** | **002** | Aug 08, 2016 |
| **AB** | | NOVEL LABS INC | **1.75MG** | **A204299** | **001** | Jun 03, 2015 |
| **AB** | | | **3.5MG** | **A204299** | **002** | Jun 03, 2015 |
| **AB** | | PAR FORM | **5MG** | **A201509** | **001** | Aug 01, 2016 |
| **AB** | | | **10MG** | **A201509** | **002** | Aug 01, 2016 |
| **AB** | | PAR PHARM INC | **1.75MG** | **A204229** | **001** | Sep 11, 2017 |

ZOLPIDEM TARTRATE

TABLET;SUBLINGUAL

**ZOLPIDEM TARTRATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | | **3.5MG** | **A204229** | **002** | Sep 11, 2017 |

TABLET, EXTENDED RELEASE;ORAL

**AMBIEN CR**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | SANOFI AVENTIS US | **6.25MG** | **N021774** | **002** | Sep 02, 2005 |
| **AB** | **+!** | | **12.5MG** | **N021774** | **001** | Sep 02, 2005 |

**ZOLPIDEM TARTRATE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | ACTAVIS ELIZABETH | **6.25MG** | **A078179** | **002** | Oct 13, 2010 |
| **AB** | | | **12.5MG** | **A078179** | **001** | Jun 06, 2011 |
| **AB** | | ACTAVIS LABS FL INC | **6.25MG** | **A090153** | **001** | Mar 25, 2013 |
| **AB** | | | **12.5MG** | **A090153** | **002** | Mar 25, 2013 |
| **AB** | | ANCHEN PHARMS | **6.25MG** | **A078148** | **002** | Apr 14, 2011 |
| **AB** | | | **12.5MG** | **A078148** | **001** | Dec 03, 2010 |
| **AB** | | APOTEX INC | **6.25MG** | **A200266** | **001** | Sep 10, 2013 |
| **AB** | | | **12.5MG** | **A200266** | **002** | Sep 10, 2013 |
| **AB** | | LUPIN LTD | **6.25MG** | **A078970** | **001** | Sep 11, 2013 |
| **AB** | | | **12.5MG** | **A078970** | **002** | Sep 11, 2013 |
| **AB** | | SANDOZ | **6.25MG** | **A090107** | **001** | Jul 01, 2011 |
| **AB** | | | **12.5MG** | **A090107** | **002** | Jul 01, 2011 |
| **AB** | | SUN PHARMA GLOBAL | **6.25MG** | **A204170** | **001** | Jan 24, 2017 |
| **AB** | | | **12.5MG** | **A204170** | **002** | Jan 24, 2017 |

ZONISAMIDE

CAPSULE;ORAL

**ZONEGRAN**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | **+** | SUNOVION PHARMS INC | **25MG** | **N020789** | **003** | Aug 22, 2003 |
| **AB** | **+** | | **50MG** | **N020789** | **002** | Aug 22, 2003 |
| **AB** | **+!** | | **100MG** | **N020789** | **001** | Mar 27, 2000 |

**ZONISAMIDE**

| | | | | | | |
|---|---|---|---|---|---|---|
| **AB** | | APOTEX INC | **25MG** | **A077642** | **001** | Dec 22, 2005 |
| **AB** | | | **50MG** | **A077642** | **002** | Dec 22, 2005 |
| **AB** | | | **100MG** | **A077642** | **003** | Dec 22, 2005 |
| **AB** | | BIONPHARMA INC | **25MG** | **A077813** | **001** | Aug 16, 2006 |
| **AB** | | | **50MG** | **A077813** | **002** | Aug 16, 2006 |
| **AB** | | | **100MG** | **A077813** | **003** | Aug 16, 2006 |
| **AB** | | GLENMARK GENERICS | **25MG** | **A077651** | **001** | Jan 30, 2006 |
| **AB** | | | **50MG** | **A077651** | **002** | Jan 30, 2006 |
| **AB** | | | **100MG** | **A077651** | **003** | Jan 30, 2006 |
| **AB** | | INVAGEN PHARMS | **25MG** | **A077869** | **001** | May 31, 2006 |
| **AB** | | | **50MG** | **A077869** | **002** | May 31, 2006 |
| **AB** | | | **100MG** | **A077869** | **003** | May 31, 2006 |
| **AB** | | MYLAN | **25MG** | **A077637** | **001** | Dec 22, 2005 |
| **AB** | | | **50MG** | **A077637** | **002** | Dec 22, 2005 |
| **AB** | | | **100MG** | **A077637** | **003** | Dec 22, 2005 |
| **AB** | | SUN PHARM INDS (IN) | **25MG** | **A077634** | **001** | Mar 17, 2006 |
| **AB** | | | **50MG** | **A077634** | **002** | Mar 17, 2006 |
| **AB** | | | **100MG** | **A077634** | **003** | Mar 17, 2006 |
| **AB** | | WOCKHARDT | **25MG** | **A077636** | **003** | Jul 27, 2006 |
| **AB** | | | **50MG** | **A077636** | **002** | Jul 27, 2006 |
| **AB** | | | **100MG** | **A077636** | **001** | Dec 22, 2005 |
| **AB** | | ZYDUS PHARMS USA | **25MG** | **A077625** | **001** | Oct 16, 2006 |
| **AB** | | | **50MG** | **A077625** | **002** | Oct 16, 2006 |
| **AB** | | | **100MG** | **A077625** | **003** | Oct 16, 2006 |

ACETAMINOPHEN

| | | | | | | |
|---|---|---|---|---|---|---|
| SUPPOSITORY;RECTAL | | | | | | |
| ACEPHEN | | | | | | |
| | G AND W LABS | 120MG | | N018060 | 001 | |
| | | 325MG | | A072344 | 001 | Mar 27, 1992 |
| | | 325MG | | N018060 | 003 | Dec 18, 1986 |
| | | 650MG | | A072237 | 001 | Mar 27, 1992 |
| | | 650MG | | N018060 | 002 | |
| ACETAMINOPHEN | | | | | | |
| | PERRIGO NEW YORK | 120MG | | A070607 | 001 | Apr 06, 1987 |
| | | 650MG | | A070608 | 001 | Dec 01, 1986 |
| + | TARO PHARMS NORTH | 120MG | | N018337 | 003 | Sep 12, 1983 |
| + | | 325MG | | N018337 | 002 | |
| +! | | 650MG | | N018337 | 001 | |
| INFANTS' FEVERALL | | | | | | |
| + | TARO PHARMS NORTH | 80MG | | N018337 | 004 | Aug 26, 1992 |
| NEOPAP | | | | | | |
| | POLYMEDICA | 120MG | | N016401 | 001 | |
| TABLET, EXTENDED RELEASE;ORAL | | | | | | |
| ACETAMINOPHEN | | | | | | |
| | AUROBINDO PHARMA LTD | 650MG | | A207229 | 001 | Nov 09, 2016 |
| | OHM LABS | 650MG | | A076200 | 001 | Mar 19, 2002 |
| | PERRIGO | 650MG | | A075077 | 001 | Feb 25, 2000 |
| | SUN PHARM INDS LTD | 650MG | | A078569 | 001 | Dec 14, 2011 |
| TYLENOL | | | | | | |
| +! | J AND J CONSUMER INC | 650MG | | N019872 | 001 | Jun 08, 1994 |
| +! | | 650MG | | N019872 | 002 | Jan 11, 2001 |

ACETAMINOPHEN; ASPIRIN; CAFFEINE

| | | | | | | |
|---|---|---|---|---|---|---|
| TABLET;ORAL | | | | | | |
| ACETAMINOPHEN, ASPIRIN AND CAFFEINE | | | | | | |
| | PERRIGO | 250MG;250MG;65MG | | A075794 | 001 | Nov 26, 2001 |
| EXCEDRIN (MIGRAINE) | | | | | | |
| +! | GLAXOSMITHKLINE CONS | 250MG;250MG;65MG | | N020802 | 001 | Jan 14, 1998 |

ADAPALENE

| | | | | | | |
|---|---|---|---|---|---|---|
| GEL;TOPICAL | | | | | | |
| DIFFERIN | | | | | | |
| +! | GALDERMA LABS LP | 0.1% | | N020380 | 002 | Jul 08, 2016 |

ALCOHOL; CHLORHEXIDINE GLUCONATE

| | | | | | | |
|---|---|---|---|---|---|---|
| SOLUTION;TOPICAL | | | | | | |
| AVAGARD | | | | | | |
| +! | 3M | 61%;1% | | N021074 | 001 | Jun 07, 2001 |

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

| | | | | | | |
|---|---|---|---|---|---|---|
| TABLET, CHEWABLE;ORAL | | | | | | |
| GAVISCON | | | | | | |
| + | SANOFI AVENTIS US | 80MG;20MG | | N018685 | 001 | Dec 09, 1983 |
| +! | | 160MG;40MG | | N018685 | 002 | Dec 09, 1983 |

ASPIRIN

| | | | | | | |
|---|---|---|---|---|---|---|
| CAPSULE;ORAL | | | | | | |
| ASPIRIN | | | | | | |
| +! | PLX PHARMA | 325MG | | N203697 | 001 | Jan 14, 2013 |

AVOBENZONE; ECAMSULE; OCTOCRYLENE

| | | | | | | |
|---|---|---|---|---|---|---|
| CREAM;TOPICAL | | | | | | |
| ANTHELIOS SX | | | | | | |
| +! | LOREAL USA | 2%;2%;10% | | N021502 | 001 | Jul 21, 2006 |
| CAPITAL SOLEIL 15 | | | | | | |
| +! | LOREAL USA | 2%;3%;10% | | N021501 | 001 | Oct 02, 2006 |

AVOBENZONE; ECAMSULE; OCTOCRYLENE; TITANIUM DIOXIDE

| | | | | | | |
|---|---|---|---|---|---|---|
| CREAM;TOPICAL | | | | | | |
| ANTHELIOS 20 | | | | | | |
| +! | LOREAL USA | 2%;2%;10%;2% | | N021471 | 001 | Oct 05, 2006 |
| ANTHELIOS 40 | | | | | | |
| +! | LOREAL USA | 2%;3%;10%;5% | | N022009 | 001 | Mar 31, 2008 |
| +! | | 2%;3%;10%;5% | | N022009 | 002 | Oct 29, 2009 |

BENTOQUATAM

LOTION;TOPICAL

IVY BLOCK

| | | | | | |
|---|---|---|---|---|---|
| +! | STAND HOMEOPATH | 5% | N020532 | 001 | Aug 26, 1996 |

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC

LUMIFY

| | | | | | |
|---|---|---|---|---|---|
| +! | BAUSCH AND LOMB INC | 0.025% | N208144 | 001 | Dec 22, 2017 |

BUDESONIDE

SPRAY, METERED;NASAL

BUDESONIDE

| | | | | | |
|---|---|---|---|---|---|
| | APOTEX INC | 0.032MG/SPRAY | A078949 | 002 | Nov 20, 2015 |

RHINOCORT ALLERGY

| | | | | | |
|---|---|---|---|---|---|
| +! | ASTRAZENECA PHARMS | 0.032MG/SPRAY | N020746 | 003 | Mar 23, 2015 |

BUTENAFINE HYDROCHLORIDE

CREAM;TOPICAL

BUTENAFINE HYDROCHLORIDE

| | | | | | |
|---|---|---|---|---|---|
| | TARO | 1% | A205181 | 001 | Nov 16, 2017 |

LOTRIMIN ULTRA

| | | | | | |
|---|---|---|---|---|---|
| +! | BAYER HEALTHCARE LLC | 1% | N021307 | 001 | Dec 07, 2001 |

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE;ORAL

FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE

| | | | | | |
|---|---|---|---|---|---|
| | PERRIGO R AND D | 800MG;10MG;165MG | A077355 | 001 | Feb 06, 2008 |
| | | 800MG;10MG;165MG | A204782 | 001 | Aug 29, 2016 |

PEPCID COMPLETE

| | | | | | |
|---|---|---|---|---|---|
| +! | J AND J CONSUMER INC | 800MG;10MG;165MG | N020958 | 001 | Oct 16, 2000 |

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

| | | | | | |
|---|---|---|---|---|---|
| | APOTEX INC | 10MG | A207235 | 001 | Aug 12, 2016 |
| + | BIONPHARMA INC | 5MG | N022429 | 001 | Jul 23, 2009 |
| +! | | 10MG | N022429 | 004 | Jul 23, 2009 |
| | STRIDES PHARMA | 10MG | A205291 | 001 | Jul 21, 2017 |

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

| | | | | | |
|---|---|---|---|---|---|
| + | BIONPHARMA INC | 5MG | N022429 | 003 | Jul 23, 2009 |
| +! | | 10MG | N022429 | 002 | Jul 23, 2009 |

SYRUP;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

| | | | | | |
|---|---|---|---|---|---|
| | ALLIED PHARMA INC | 5MG/5ML | A091327 | 001 | Oct 17, 2011 |
| | AMNEAL PHARMS | 5MG/5ML | A090765 | 002 | Oct 07, 2009 |
| | AUROBINDO PHARMA | 5MG/5ML | A090750 | 002 | Feb 02, 2010 |
| | BIO PHARM INC | 5MG/5ML | A090474 | 002 | Mar 30, 2009 |
| | PERRIGO R AND D | 5MG/5ML | A204226 | 001 | Sep 09, 2013 |
| | | 5MG/5ML | A090254 | 002 | Apr 09, 2008 |
| | SILARX | 5MG/5ML | A091130 | 001 | Apr 22, 2011 |
| | TARO | 5MG/5ML | A090182 | 002 | Apr 22, 2008 |
| | | 5MG/5ML | A201546 | 001 | May 20, 2011 |
| | TRIS PHARMA INC | 5MG/5ML | A090572 | 001 | Nov 16, 2012 |

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

| | | | | | |
|---|---|---|---|---|---|
| | ALLIED PHARMA INC | 5MG/5ML | A091327 | 002 | Oct 17, 2011 |
| | AMNEAL PHARMS | 5MG/5ML | A090765 | 001 | Oct 07, 2009 |
| | AUROBINDO PHARMA | 5MG/5ML | A090750 | 001 | Feb 02, 2010 |
| | BIO PHARM INC | 5MG/5ML | A090474 | 001 | Mar 30, 2009 |
| | PERRIGO R AND D | 5MG/5ML | A090254 | 001 | Apr 09, 2008 |
| | SILARX | 5MG/5ML | A091130 | 002 | Apr 22, 2011 |
| | TARO | 5MG/5ML | A090182 | 001 | Apr 22, 2008 |
| | | 5MG/5ML | A201546 | 002 | May 20, 2011 |
| | TRIS PHARMA INC | 5MG/5ML | A090572 | 002 | Nov 16, 2012 |

CHILDREN'S ZYRTEC ALLERGY

| | | | | | |
|---|---|---|---|---|---|
| +! | J AND J CONSUMER INC | 5MG/5ML | N022155 | 002 | Nov 16, 2007 |

CHILDREN'S ZYRTEC HIVES RELIEF

| | | | | | |
|---|---|---|---|---|---|
| +! | J AND J CONSUMER INC | 5MG/5ML | N022155 | 001 | Nov 16, 2007 |

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

| | | | | | |
|---|---|---|---|---|---|
| | AMNEAL PHARMS NY | 5MG | A078780 | 001 | Jan 21, 2010 |
| | | 10MG | A078780 | 004 | Jan 21, 2010 |

CETIRIZINE HYDROCHLORIDE

TABLET;ORAL

| | | | | |
|---|---|---|---|---|
| **CETIRIZINE HYDROCHLORIDE ALLERGY** | | | | |
| APOTEX INC | 5MG | A078317 | 001 | Dec 27, 2007 |
| | 10MG | A078317 | 002 | Dec 27, 2007 |
| AUROBINDO PHARMA LTD | 5MG | A090760 | 001 | Aug 05, 2015 |
| | 10MG | A090760 | 003 | Aug 05, 2015 |
| CIPLA LTD | 5MG | A077318 | 001 | Jul 25, 2013 |
| | 10MG | A077318 | 002 | Jul 25, 2013 |
| CONTRACT PHARMACAL | 5MG | A076047 | 001 | Dec 27, 2007 |
| | 10MG | A076047 | 002 | Dec 27, 2007 |
| DR REDDYS LABS LTD | 5MG | A078343 | 004 | Jan 15, 2008 |
| | 10MG | A078343 | 003 | Jan 15, 2008 |
| GRANULES INDIA LTD | 10MG | A209274 | 001 | Dec 22, 2017 |
| IPCA LABS LTD | 5MG | A202277 | 002 | Mar 11, 2014 |
| | 10MG | A202277 | 004 | Mar 11, 2014 |
| JUBILANT CADISTA | 5MG | A078933 | 001 | Jun 15, 2010 |
| | 10MG | A078933 | 002 | Jun 15, 2010 |
| MYLAN | 5MG | A076677 | 001 | Dec 27, 2007 |
| | 10MG | A076677 | 002 | Dec 27, 2007 |
| ORCHID HLTHCARE | 5MG | A078862 | 001 | Feb 19, 2009 |
| | 10MG | A078862 | 002 | Feb 19, 2009 |
| PERRIGO R AND D | 5MG | A078336 | 001 | Dec 27, 2007 |
| | 10MG | A078336 | 002 | Dec 27, 2007 |
| SANDOZ | 5MG | A077946 | 001 | Dec 27, 2007 |
| | 10MG | A077946 | 002 | Dec 27, 2007 |
| SUN PHARM INDS INC | 5MG | A077499 | 001 | Dec 27, 2007 |
| | 10MG | A077499 | 002 | Dec 27, 2007 |
| SUN PHARM INDS LTD | 5MG | A077498 | 001 | Dec 27, 2007 |
| | 10MG | A077498 | 002 | Dec 27, 2007 |
| TARO | 5MG | A078072 | 001 | Jul 22, 2009 |
| | 5MG | A078072 | 003 | Jul 22, 2009 |
| TORRENT PHARMS LLC | 5MG | A079191 | 001 | Apr 15, 2010 |
| | 10MG | A079191 | 004 | Apr 15, 2010 |
| UNICHEM | 5MG | A078680 | 003 | Jun 26, 2009 |
| | 10MG | A078680 | 004 | Jun 26, 2009 |
| UNIQUE PHARM LABS | 5MG | A077829 | 001 | Aug 26, 2009 |
| | 10MG | A077829 | 004 | Aug 26, 2009 |
| WOCKHARDT | 5MG | A078427 | 003 | Dec 28, 2007 |
| | 10MG | A078427 | 004 | Dec 28, 2007 |
| **CETIRIZINE HYDROCHLORIDE HIVES** | | | | |
| DR REDDYS LABS LTD | 5MG | A078343 | 001 | Jan 15, 2008 |
| | 10MG | A078343 | 002 | Jan 15, 2008 |
| IPCA LABS LTD | 5MG | A202277 | 001 | Mar 11, 2014 |
| | 10MG | A202277 | 003 | Mar 11, 2014 |
| JUBILANT CADISTA | 5MG | A078933 | 003 | Jun 15, 2010 |
| | 10MG | A078933 | 004 | Jun 15, 2010 |
| MYLAN | 5MG | A076677 | 004 | Dec 27, 2007 |
| | 10MG | A076677 | 003 | Dec 27, 2007 |
| ORCHID HLTHCARE | 5MG | A078862 | 003 | Feb 19, 2009 |
| | 10MG | A078862 | 004 | Feb 19, 2009 |
| PERRIGO R AND D | 5MG | A078336 | 003 | Dec 27, 2007 |
| | 10MG | A078336 | 004 | Dec 27, 2007 |
| SUN PHARM INDS INC | 5MG | A077499 | 003 | Dec 27, 2007 |
| | 10MG | A077499 | 004 | Dec 27, 2007 |
| SUN PHARM INDS LTD | 5MG | A077498 | 003 | Dec 27, 2007 |
| | 10MG | A077498 | 004 | Dec 27, 2007 |
| UNICHEM | 5MG | A078680 | 001 | Jun 26, 2009 |
| | 10MG | A078680 | 002 | Jun 26, 2009 |
| UNIQUE PHARM LABS | 5MG | A077829 | 003 | Aug 26, 2009 |
| | 10MG | A077829 | 002 | Aug 26, 2009 |
| **CETIRIZINE HYDROCHLORIDE HIVES RELIEF** | | | | |
| AMNEAL PHARMS NY | 5MG | A078780 | 003 | Jan 21, 2010 |
| | 10MG | A078780 | 002 | Jan 21, 2010 |
| AUROBINDO PHARMA LTD | 5MG | A090760 | 002 | Aug 05, 2015 |
| | 10MG | A090760 | 004 | Aug 05, 2015 |
| TARO | 10MG | A078072 | 002 | Jul 22, 2009 |
| | 10MG | A078072 | 004 | Jul 22, 2009 |
| TORRENT PHARMS LLC | 5MG | A079191 | 003 | Apr 15, 2010 |
| | 10MG | A079191 | 002 | Apr 15, 2010 |

CETIRIZINE HYDROCHLORIDE

| | | | | | |
|---|---|---|---|---|---|
| TABLET;ORAL | | | | | |
| ZYRTEC ALLERGY | | | | | |
| + | J AND J CONSUMER INC | 5MG | N019835 | 003 | Nov 16, 2007 |
| +! | | 10MG | N019835 | 004 | Nov 16, 2007 |
| ZYRTEC HIVES RELIEF | | | | | |
| + | J AND J CONSUMER INC | 5MG | N019835 | 005 | Nov 16, 2007 |
| +! | | 10MG | N019835 | 006 | Nov 16, 2007 |
| TABLET, CHEWABLE;ORAL | | | | | |
| CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY | | | | | |
| | JUBILANT GENERICS | 5MG | A091116 | 001 | Feb 19, 2015 |
| | | 10MG | A091116 | 002 | Feb 19, 2015 |
| | NOVEL LABS INC | 5MG | A206793 | 001 | Mar 08, 2016 |
| | | 10MG | A206793 | 002 | Mar 08, 2016 |
| | SANDOZ | 5MG | A078692 | 001 | Feb 14, 2008 |
| ! | | 10MG | A078692 | 002 | Feb 14, 2008 |
| | SUN PHARMA GLOBAL | 5MG | A090142 | 001 | Aug 30, 2011 |
| | | 10MG | A090142 | 002 | Aug 30, 2011 |
| CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF | | | | | |
| | JUBILANT GENERICS | 5MG | A091116 | 003 | Feb 19, 2015 |
| | | 10MG | A091116 | 004 | Feb 19, 2015 |
| | SUN PHARMA GLOBAL | 5MG | A090142 | 003 | Aug 30, 2011 |
| | | 10MG | A090142 | 004 | Aug 30, 2011 |
| TABLET, ORALLY DISINTEGRATING;ORAL | | | | | |
| CETIRIZINE HYDROCHLORIDE ALLERGY | | | | | |
| | PERRIGO R AND D | 10MG | A205490 | 001 | Sep 02, 2015 |
| ZYRTEC ALLERGY | | | | | |
| +! | J AND J CONSUMER INC | 10MG | N022578 | 001 | Sep 03, 2010 |

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

| | | | | | |
|---|---|---|---|---|---|
| TABLET, EXTENDED RELEASE;ORAL | | | | | |
| CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE | | | | | |
| | IVAX SUB TEVA PHARMS | 5MG;120MG | A077170 | 001 | Feb 25, 2008 |
| | SANDOZ | 5MG;120MG | A077991 | 001 | Mar 05, 2008 |
| | SUN PHARM INDS LTD | 5MG;120MG | A090922 | 001 | Sep 28, 2012 |
| ZYRTEC-D 12 HOUR | | | | | |
| +! | J AND J CONSUMER INC | 5MG;120MG | N021150 | 002 | Nov 09, 2007 |

CHLORHEXIDINE GLUCONATE

| | | | | | |
|---|---|---|---|---|---|
| AEROSOL, METERED;TOPICAL | | | | | |
| EXIDINE | | | | | |
| +! | XTTRIUM | 4% | N019127 | 001 | Dec 24, 1984 |
| CLOTH;TOPICAL | | | | | |
| CHLORHEXIDINE GLUCONATE | | | | | |
| +! | SAGE PRODS | 2% | N021669 | 001 | Apr 25, 2005 |
| SOLUTION;TOPICAL | | | | | |
| BRIAN CARE | | | | | |
| | SOAPCO | 4% | A071419 | 001 | Dec 17, 1987 |
| CHG SCRUB | | | | | |
| | ECOLAB | 4% | N019258 | 002 | Jul 22, 1986 |
| CIDA-STAT | | | | | |
| | ECOLAB | 2% | N019258 | 001 | Jul 22, 1986 |
| DYNA-HEX | | | | | |
| | BAJAJ MEDICAL LLC | 0.75% | N020111 | 001 | Sep 11, 1997 |
| EXIDINE | | | | | |
| +! | XTTRIUM | 2% | N019422 | 001 | Dec 17, 1985 |
| | | 4% | N019125 | 001 | Dec 24, 1984 |
| HIBICLENS | | | | | |
| +! | MOLNLYCKE HLTH | 4% | N017768 | 001 | |
| HIBISTAT | | | | | |
| +! | MOLNLYCKE HLTH | 0.5% | N018300 | 001 | |
| SPONGE;TOPICAL | | | | | |
| BIOSCRUB | | | | | |
| | GRIFFEN | 4% | N019822 | 001 | Mar 31, 1989 |
| CHLORHEXIDINE GLUCONATE | | | | | |
| ! | BECTON DICKINSON | 4% | A072525 | 001 | Oct 24, 1989 |

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

| | | | | | |
|---|---|---|---|---|---|
| SPONGE;TOPICAL | | | | | |
| CHLORAPREP ONE-STEP | | | | | |
| +! | BECTON DICKINSON CO | 2%;70% (3ML) | N020832 | 001 | Jul 14, 2000 |
| +! | | 2%;70% (10.5ML) | N020832 | 004 | Aug 20, 2003 |
| +! | | 2%;70% (26ML) | N020832 | 006 | Nov 21, 2006 |
| CHLORAPREP ONE-STEP FREPP | | | | | |
| +! | BECTON DICKINSON CO | 2%;70% (1.5ML) | N020832 | 003 | Apr 26, 2002 |
| CHLORAPREP WITH TINT | | | | | |
| +! | BECTON DICKINSON CO | 2%;70% (26ML) | N020832 | 002 | May 03, 2005 |
| +! | | 2%;70% (10.5ML) | N020832 | 005 | Apr 03, 2006 |
| +! | | 2%;70% (3ML) | N020832 | 007 | Oct 10, 2006 |
| SWAB;TOPICAL | | | | | |
| CHLORAPREP ONE-STEP SEPP | | | | | |
| +! | BECTON DICKINSON CO | 2%;70% (0.67ML) | N021555 | 001 | Oct 07, 2002 |
| CHLORAPREP SINGLE SWABSTICK | | | | | |
| +! | BECTON DICKINSON CO | 2%;70% (1.75ML) | N021555 | 002 | May 10, 2005 |
| CHLORAPREP TRIPLE SWABSTICK | | | | | |
| +! | BECTON DICKINSON CO | 2%;70% (5.25ML) | N021555 | 003 | Jun 10, 2009 |
| PREVANTICS MAXI SWABSTICK | | | | | |
| +! | PROF DSPLS | 3.15%;70% (5.1ML) | N021524 | 003 | Jun 03, 2005 |
| PREVANTICS SWAB | | | | | |
| +! | PROF DSPLS | 3.15%;70% (1ML) | N021524 | 001 | Jun 03, 2005 |
| PREVANTICS SWABSTICK | | | | | |
| +! | PROF DSPLS | 3.15%;70% (1.6ML) | N021524 | 002 | Jun 03, 2005 |

CHLORPHENIRAMINE MALEATE

| | | | | | |
|---|---|---|---|---|---|
| TABLET, EXTENDED RELEASE;ORAL | | | | | |
| CHLOR-TRIMETON | | | | | |
| +! | BAYER HEALTHCARE LLC | 12MG | N007638 | 002 | |
| CHLORPHENIRAMINE MALEATE | | | | | |
| | AVANTHI INC | 12MG | A040829 | 001 | May 13, 2009 |

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

| | | | | | |
|---|---|---|---|---|---|
| TABLET;ORAL | | | | | |
| ADVIL ALLERGY AND CONGESTION RELIEF | | | | | |
| +! | PFIZER | 4MG;200MG;10MG | N022113 | 001 | Dec 21, 2011 |
| ADVIL MULTI-SYMPTOM COLD & FLU | | | | | |
| +! | PFIZER | 4MG;200MG;10MG | N022113 | 002 | Apr 28, 2017 |

CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

| | | | | | |
|---|---|---|---|---|---|
| SUSPENSION;ORAL | | | | | |
| CHILDREN'S ADVIL ALLERGY SINUS | | | | | |
| +! | PFIZER | 1MG/5ML;100MG/5ML;15MG/5ML | N021587 | 001 | Feb 24, 2004 |
| TABLET;ORAL | | | | | |
| ADVIL ALLERGY SINUS | | | | | |
| +! | PFIZER | 2MG;200MG;30MG | N021441 | 001 | Dec 19, 2002 |

CIMETIDINE

| | | | | | |
|---|---|---|---|---|---|
| TABLET;ORAL | | | | | |
| CIMETIDINE | | | | | |
| | APOTEX | 100MG | A074948 | 001 | Jun 19, 1998 |
| | | 200MG | A074948 | 002 | Jul 26, 2002 |
| | IVAX SUB TEVA PHARMS | 200MG | A075345 | 001 | Jun 16, 1999 |
| | L PERRIGO CO | 200MG | A075285 | 001 | Oct 29, 1998 |
| TAGAMET HB | | | | | |
| +! | MEDTECH PRODUCTS | 200MG | N020238 | 002 | Aug 21, 1996 |

CLEMASTINE FUMARATE

| | | | | | |
|---|---|---|---|---|---|
| TABLET;ORAL | | | | | |
| CLEMASTINE FUMARATE | | | | | |
| | L PERRIGO CO | 1.34MG | A074512 | 001 | Nov 22, 1995 |
| | SANDOZ | 1.34MG | A073458 | 001 | Oct 31, 1993 |
| TAVIST-1 | | | | | |
| +! | GLAXOSMITHKLINE CONS | 1.34MG | N020925 | 001 | Aug 21, 1992 |

CLOTRIMAZOLE

| | | | | | |
|---|---|---|---|---|---|
| CREAM;VAGINAL | | | | | |
| CLOTRIMAZOLE | | | | | |
| ! | ACTAVIS MID ATLANTIC | 1% | A074165 | 001 | Jul 16, 1993 |
| | TARO | 1% | A072641 | 001 | Dec 04, 1995 |

CLOTRIMAZOLE

| | | | | | |
|---|---|---|---|---|---|
| CREAM;VAGINAL | | | | | |
| MYCELEX-7 | | | | | |
| | BAYER HEALTHCARE LLC | 1% | N018230 | 002 | Dec 26, 1991 |
| TRIVAGIZOLE 3 | | | | | |
| | TARO | 2% | N021143 | 001 | Apr 12, 2000 |
| CREAM, TABLET;TOPICAL, VAGINAL | | | | | |
| MYCELEX-7 COMBINATION PACK | | | | | |
| | BAYER HEALTHCARE LLC | 1%,100MG | N020389 | 002 | Jun 23, 1994 |
| TABLET;VAGINAL | | | | | |
| MYCELEX-7 | | | | | |
| | BAYER HEALTHCARE LLC | 100MG | N018182 | 002 | Dec 26, 1991 |

CROMOLYN SODIUM

| | | | | | |
|---|---|---|---|---|---|
| SPRAY, METERED;NASAL | | | | | |
| CROMOLYN SODIUM | | | | | |
| ! | BAUSCH AND LOMB | 5.2MG/SPRAY | A075702 | 001 | Jul 03, 2001 |
| | PERRIGO | 5.2MG/SPRAY | A075427 | 001 | Dec 12, 2001 |

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

| | | | | | |
|---|---|---|---|---|---|
| TABLET, EXTENDED RELEASE;ORAL | | | | | |
| DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE | | | | | |
| ! | AVANTHI INC | 6MG;120MG | A078648 | 001 | Feb 27, 2013 |

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

| | | | | | |
|---|---|---|---|---|---|
| TABLET, EXTENDED RELEASE;ORAL | | | | | |
| GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE | | | | | |
| | ACTAVIS LABS FL | 30MG;600MG | A091070 | 001 | Aug 31, 2015 |
| | | 60MG;1.2GM | A091070 | 002 | Aug 31, 2015 |
| | AUROBINDO PHARMA LTD | 30MG;600MG | A206941 | 001 | Mar 17, 2017 |
| | | 60MG;1.2GM | A206941 | 002 | Mar 17, 2017 |
| MUCINEX DM | | | | | |
| + | RECKITT BENCKISER | 30MG;600MG | N021620 | 002 | Apr 29, 2004 |
| +! | | 60MG;1.2GM | N021620 | 001 | Apr 29, 2004 |

DEXTROMETHORPHAN POLISTIREX

| | | | | | |
|---|---|---|---|---|---|
| SUSPENSION, EXTENDED RELEASE;ORAL | | | | | |
| DELSYM | | | | | |
| +! | RECKITT BENCKISER | EQ 30MG HBR/5ML | N018658 | 001 | Oct 08, 1982 |
| DEXTROMETHORPHAN POLISTIREX | | | | | |
| | AMNEAL PHARMS LLC | EQ 30MG HBR/5ML | A203133 | 001 | Jul 28, 2017 |
| | TRIS PHARMA INC | EQ 30MG HBR/5ML | A091135 | 001 | May 25, 2012 |

DIPHENHYDRAMINE CITRATE; IBUPROFEN

| | | | | | |
|---|---|---|---|---|---|
| TABLET;ORAL | | | | | |
| ADVIL PM | | | | | |
| +! | PFIZER | 38MG;200MG | N021394 | 001 | Dec 21, 2005 |
| IBUPROFEN AND DIPHENHYDRAMINE CITRATE | | | | | |
| | DR REDDYS LABS LTD | 38MG;200MG | A090619 | 001 | Jul 08, 2009 |
| | PERRIGO R AND D | 38MG;200MG | A079113 | 001 | Dec 22, 2008 |

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

| | | | | | |
|---|---|---|---|---|---|
| CAPSULE;ORAL | | | | | |
| ADVIL PM | | | | | |
| +! | PFIZER | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | N021393 | 001 | Dec 21, 2005 |
| IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE | | | | | |
| | BIONPHARMA INC | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | A090397 | 001 | Nov 22, 2010 |
| | STRIDES PHARMA | 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT | A200888 | 001 | Mar 05, 2012 |

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

| | | | | | |
|---|---|---|---|---|---|
| TABLET;ORAL | | | | | |
| ALEVE PM | | | | | |
| +! | BAYER HLTHCARE | 25MG;220MG | N205352 | 001 | Jan 17, 2014 |

DOCOSANOL

| | | | | | |
|---|---|---|---|---|---|
| CREAM;TOPICAL | | | | | |
| ABREVA | | | | | |
| +! | GLAXOSMITHKLINE | 10% | N020941 | 001 | Jul 25, 2000 |

DOXYLAMINE SUCCINATE

TABLET;ORAL

DOXYLAMINE SUCCINATE

| | | | | | |
|---|---|---|---|---|---|
| | LNK | 25MG | A040564 | 001 | Aug 27, 2004 |
| | PERRIGO | 25MG | A040167 | 001 | Sep 18, 1996 |

UNISOM

| | | | | | |
|---|---|---|---|---|---|
| +! | CHATTEM | 25MG | N018066 | 001 | |

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE MAGNESIUM

| | | | | | |
|---|---|---|---|---|---|
| | AUROBINDO PHARMA LTD | EQ 20MG BASE | A209339 | 001 | Oct 16, 2017 |
| | PERRIGO R AND D | EQ 20MG BASE | A207193 | 001 | Aug 18, 2017 |

NEXIUM 24HR

| | | | | | |
|---|---|---|---|---|---|
| +! | ASTRAZENECA LP | EQ 20MG BASE | N204655 | 001 | Mar 28, 2014 |

TABLET, DELAYED RELEASE;ORAL

NEXIUM 24HR

| | | | | | |
|---|---|---|---|---|---|
| +! | ASTRAZENECA LP | EQ 20MG BASE | N207920 | 001 | Nov 23, 2015 |

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

| | | | | | |
|---|---|---|---|---|---|
| | AUROBINDO PHARMA LTD | 10MG | A206531 | 001 | Apr 26, 2016 |
| | | 20MG | A206531 | 002 | Apr 26, 2016 |
| | DR REDDYS LABS LTD | 10MG | A075758 | 001 | Aug 17, 2001 |
| | | 20MG | A077367 | 001 | Sep 25, 2006 |
| | IVAX SUB TEVA PHARMS | 10MG | A075512 | 001 | Jul 26, 2001 |
| | MYLAN | 10MG | A075674 | 001 | Dec 21, 2001 |
| | PERRIGO | 10MG | A075400 | 001 | Mar 18, 2005 |
| | PERRIGO R AND D | 20MG | A077351 | 001 | Sep 25, 2006 |
| | SUN PHARM INDS LTD | 10MG | A090283 | 001 | Nov 17, 2009 |
| | | 20MG | A090283 | 002 | Nov 17, 2009 |
| | TEVA | 10MG | A075312 | 001 | May 31, 2001 |
| | WOCKHARDT | 10MG | A077146 | 001 | Mar 07, 2005 |
| | | 20MG | A090837 | 001 | Aug 04, 2010 |

PEPCID AC

| | | | | | |
|---|---|---|---|---|---|
| + | J AND J CONSUMER INC | 10MG | N020325 | 001 | Apr 28, 1995 |
| +! | | 20MG | N020325 | 002 | Sep 23, 2003 |

PEPCID AC

| | | | | | |
|---|---|---|---|---|---|
| | J AND J CONSUMER INC | 10MG | N020902 | 001 | Aug 05, 1999 |

TABLET, CHEWABLE;ORAL

FAMOTIDINE

| | | | | | |
|---|---|---|---|---|---|
| | PERRIGO | 10MG | A075715 | 001 | Aug 22, 2003 |

PEPCID AC

| | | | | | |
|---|---|---|---|---|---|
| +! | J AND J CONSUMER INC | 20MG | N020801 | 002 | Dec 17, 2007 |

FEXOFENADINE HYDROCHLORIDE

SUSPENSION;ORAL

CHILDREN'S ALLEGRA ALLERGY

| | | | | | |
|---|---|---|---|---|---|
| +! | SANOFI AVENTIS US | 30MG/5ML | N201373 | 001 | Jan 24, 2011 |

CHILDREN'S ALLEGRA HIVES

| | | | | | |
|---|---|---|---|---|---|
| +! | SANOFI AVENTIS US | 30MG/5ML | N201373 | 002 | Jan 24, 2011 |

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

| | | | | | |
|---|---|---|---|---|---|
| | ACTAVIS MID ATLANTIC | 30MG/5ML | A203330 | 001 | Nov 18, 2014 |
| | TARO PHARM | 30MG/5ML | A208123 | 001 | Nov 09, 2017 |

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

| | | | | | |
|---|---|---|---|---|---|
| | ACTAVIS MID ATLANTIC | 30MG/5ML | A203330 | 002 | Nov 18, 2014 |
| | TARO PHARM | 30MG/5ML | A208123 | 002 | Nov 09, 2017 |

TABLET;ORAL

ALLEGRA ALLERGY

| | | | | | |
|---|---|---|---|---|---|
| + | SANOFI AVENTIS US | 60MG | N020872 | 007 | Jan 24, 2011 |
| +! | | 180MG | N020872 | 010 | Jan 24, 2011 |

ALLEGRA HIVES

| | | | | | |
|---|---|---|---|---|---|
| + | SANOFI AVENTIS US | 60MG | N020872 | 008 | Jan 24, 2011 |
| +! | | 180MG | N020872 | 009 | Jan 24, 2011 |

CHILDREN'S ALLEGRA ALLERGY

| | | | | | |
|---|---|---|---|---|---|
| + | SANOFI AVENTIS US | 30MG | N020872 | 005 | Jan 24, 2011 |

FEXOFENADINE HYDROCHLORIDE

| | | | | | |
|---|---|---|---|---|---|
| TABLET;ORAL | | | | | |
| CHILDREN'S ALLEGRA HIVES | | | | | |
| + | SANOFI AVENTIS US | 30MG | N020872 | 006 | Jan 24, 2011 |
| CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY | | | | | |
| | AUROLIFE PHARMA LLC | 30MG | A202039 | 001 | Nov 19, 2014 |
| | DR REDDYS LABS LTD | 30MG | A076502 | 004 | Apr 12, 2011 |
| | HETERO LABS LTD V | 30MG | A204097 | 001 | Aug 19, 2016 |
| | MYLAN | 30MG | A077081 | 004 | Jul 21, 2011 |
| | SUN PHARM INDS | 30MG | A091567 | 002 | Feb 06, 2012 |
| | TEVA | 30MG | A076447 | 004 | Apr 13, 2011 |
| | WOCKHARDT LTD | 30MG | A079112 | 002 | Feb 08, 2012 |
| CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES | | | | | |
| | DR REDDYS LABS LTD | 30MG | A076502 | 005 | Apr 12, 2011 |
| | MYLAN | 30MG | A077081 | 005 | Jul 21, 2011 |
| | SUN PHARM INDS | 30MG | A091567 | 001 | Feb 06, 2012 |
| | TEVA | 30MG | A076447 | 005 | Apr 13, 2011 |
| | WOCKHARDT LTD | 30MG | A079112 | 001 | Feb 08, 2012 |
| FEXOFENADINE HYDROCHLORIDE ALLERGY | | | | | |
| | AUROLIFE PHARMA LLC | 60MG | A202039 | 002 | Nov 19, 2014 |
| | | 180MG | A202039 | 003 | Nov 19, 2014 |
| | DR REDDYS LABS LTD | 60MG | A076502 | 006 | Apr 12, 2011 |
| | | 180MG | A076502 | 008 | Apr 12, 2011 |
| | HETERO LABS LTD V | 60MG | A204097 | 002 | Aug 19, 2016 |
| | | 180MG | A204097 | 003 | Aug 19, 2016 |
| | MYLAN | 60MG | A077081 | 006 | Jul 21, 2011 |
| | | 180MG | A077081 | 008 | Jul 21, 2011 |
| | SCIEGEN PHARMS INC | 60MG | A204507 | 002 | Sep 16, 2015 |
| | | 180MG | A204507 | 003 | Sep 16, 2015 |
| | SUN PHARM INDS | 60MG | A091567 | 004 | Feb 06, 2012 |
| | | 180MG | A091567 | 006 | Feb 06, 2012 |
| | TEVA | 60MG | A076447 | 006 | Apr 13, 2011 |
| | | 180MG | A076447 | 008 | Apr 13, 2011 |
| | WOCKHARDT LTD | 60MG | A079112 | 004 | Feb 08, 2012 |
| | | 180MG | A079112 | 006 | Feb 08, 2012 |
| FEXOFENADINE HYDROCHLORIDE HIVES | | | | | |
| | DR REDDYS LABS LTD | 60MG | A076502 | 007 | Apr 12, 2011 |
| | | 180MG | A076502 | 009 | Apr 12, 2011 |
| | MYLAN | 60MG | A077081 | 007 | Jul 21, 2011 |
| | | 180MG | A077081 | 009 | Jul 21, 2011 |
| | SCIEGEN PHARMS INC | 60MG | A204507 | 004 | Sep 16, 2015 |
| | | 180MG | A204507 | 005 | Sep 16, 2015 |
| | SUN PHARM INDS | 60MG | A091567 | 003 | Feb 06, 2012 |
| | | 180MG | A091567 | 005 | Feb 06, 2012 |
| | TEVA | 60MG | A076447 | 007 | Apr 13, 2011 |
| | | 180MG | A076447 | 009 | Apr 13, 2011 |
| | WOCKHARDT LTD | 60MG | A079112 | 003 | Feb 08, 2012 |
| | | 180MG | A079112 | 005 | Feb 08, 2012 |
| TABLET, ORALLY DISINTEGRATING;ORAL | | | | | |
| CHILDREN'S ALLEGRA ALLERGY | | | | | |
| +! | SANOFI AVENTIS US | 30MG | N021909 | 002 | Jan 24, 2011 |
| CHILDREN'S ALLEGRA HIVES | | | | | |
| +! | SANOFI AVENTIS US | 30MG | N021909 | 003 | Jan 24, 2011 |
| CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY | | | | | |
| | DR REDDYS LABS LTD | 30MG | A202978 | 001 | Jan 18, 2013 |
| CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES | | | | | |
| | DR REDDYS LABS LTD | 30MG | A202978 | 002 | Jan 18, 2013 |

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

| | | | | | |
|---|---|---|---|---|---|
| TABLET, EXTENDED RELEASE;ORAL | | | | | |
| ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION | | | | | |
| +! | SANOFI AVENTIS US | 60MG;120MG | N020786 | 002 | Jan 24, 2011 |
| ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION | | | | | |
| +! | SANOFI AVENTIS US | 180MG;240MG | N021704 | 002 | Jan 24, 2011 |
| FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE | | | | | |
| | AUROBINDO PHARMA LTD | 60MG;120MG | A209116 | 001 | Oct 30, 2017 |
| | DR REDDYS LABS LTD | 60MG;120MG | A076667 | 001 | Nov 18, 2014 |
| | | 180MG;240MG | A079043 | 002 | Jun 22, 2011 |
| | SUN PHARMA GLOBAL | 60MG;120MG | A090818 | 001 | Jan 29, 2015 |

FLUTICASONE FUROATE

SPRAY, METERED;NASAL

FLONASE SENSIMIST ALLERGY RELIEF

| | | | | | |
|---|---|---|---|---|---|
| +! | GLAXOSMITHKLINE CONS | 0.0275MG/SPRAY | N022051 | 002 | Aug 02, 2016 |

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLONASE ALLERGY RELIEF

| | | | | | |
|---|---|---|---|---|---|
| +! | GLAXOSMITHKLINE CONS | 0.05MG/SPRAY | N205434 | 001 | Jul 23, 2014 |

FLUTICASONE PROPIONATE

| | | | | | |
|---|---|---|---|---|---|
| | APOTEX INC | 0.05MG/SPRAY | A208150 | 001 | Feb 29, 2016 |
| | WEST-WARD PHARMS INT | 0.05MG/SPRAY | A207957 | 001 | May 26, 2016 |

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN

| | | | | | |
|---|---|---|---|---|---|
| | ACTAVIS LABS FL | 1.2GM | A091009 | 002 | Sep 03, 2015 |
| | GUARDIAN PHARMS | 600MG | A209215 | 001 | Sep 06, 2017 |
| | | 1.2GM | A209215 | 002 | Sep 06, 2017 |
| | PERRIGO R AND D | 600MG | A078912 | 001 | Nov 23, 2011 |

MUCINEX

| | | | | | |
|---|---|---|---|---|---|
| + | RECKITT BENCKISER | 600MG | N021282 | 001 | Jul 12, 2002 |
| +! | | 1.2GM | N021282 | 002 | Dec 18, 2002 |

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

| | | | | | |
|---|---|---|---|---|---|
| | ACTAVIS LABS FL | 600MG;60MG | A091071 | 001 | May 27, 2015 |
| | | 1.2GM;120MG | A091071 | 002 | May 27, 2015 |
| | DR REDDYS LABS LTD | 600MG;60MG | A208369 | 001 | Dec 29, 2017 |
| | | 1.2GM;120MG | A208369 | 002 | Dec 29, 2017 |

MUCINEX D

| | | | | | |
|---|---|---|---|---|---|
| + | RECKITT BENCKISER | 600MG;60MG | N021585 | 001 | Jun 22, 2004 |
| +! | | 1.2GM;120MG | N021585 | 002 | Jun 22, 2004 |

IBUPROFEN

CAPSULE;ORAL

ADVIL LIQUI-GELS

| | | | | | |
|---|---|---|---|---|---|
| +! | PFIZER | EQ 200MG FREE ACID AND POTASSIUM SALT | N020402 | 001 | Apr 20, 1995 |

ADVIL MIGRAINE LIQUI-GELS

| | | | | | |
|---|---|---|---|---|---|
| +! | PFIZER | EQ 200MG FREE ACID AND POTASSIUM SALT | N020402 | 002 | Mar 16, 2000 |

IBUPROFEN

| | | | | | |
|---|---|---|---|---|---|
| | AMNEAL PHARMS | EQ 200MG FREE ACID AND POTASSIUM SALT | A202300 | 001 | Dec 23, 2011 |
| | ASCENT PHARMS INC | EQ 200MG FREE ACID AND POTASSIUM SALT | A206999 | 001 | Dec 21, 2017 |
| | BIONPHARMA INC | EQ 200MG FREE ACID AND POTASSIUM SALT | A078682 | 001 | Mar 24, 2009 |
| | HUMANWELL PURACAP | EQ 200MG FREE ACID AND POTASSIUM SALT | A206568 | 001 | Jun 21, 2016 |
| | MARKSANS PHARMA | EQ 200MG FREE ACID AND POTASSIUM SALT | A079205 | 001 | Jun 26, 2009 |
| | P AND L DEV LLC | EQ 200MG FREE ACID AND POTASSIUM SALT | A077338 | 001 | Jul 10, 2009 |
| | SOFGEN PHARMS | EQ 200MG FREE ACID AND POTASSIUM SALT | A203599 | 001 | Sep 07, 2016 |

MIDOL LIQUID GELS

| | | | | | |
|---|---|---|---|---|---|
| +! | BIONPHARMA INC | 200MG | N021472 | 001 | Oct 18, 2002 |

SUSPENSION;ORAL

CHILDREN'S ADVIL

| | | | | | |
|---|---|---|---|---|---|
| | PFIZER | 100MG/5ML | N020589 | 001 | Jun 27, 1996 |

CHILDREN'S ADVIL-FLAVORED

| | | | | | |
|---|---|---|---|---|---|
| | PFIZER | 100MG/5ML | N020589 | 002 | Nov 07, 1997 |

CHILDREN'S ELIXSURE

| | | | | | |
|---|---|---|---|---|---|
| | MOBERG PHARMA NORTH | 100MG/5ML | N021604 | 001 | Jan 07, 2004 |

CHILDREN'S IBUPROFEN

| | | | | | |
|---|---|---|---|---|---|
| | PERRIGO | 100MG/5ML | A074937 | 001 | Dec 22, 1998 |

CHILDREN'S MOTRIN

| | | | | | |
|---|---|---|---|---|---|
| +! | J AND J CONSUMER INC | 100MG/5ML | N020516 | 001 | Jun 16, 1995 |

IBUPROFEN

| | | | | | |
|---|---|---|---|---|---|
| | ACTAVIS MID ATLANTIC | 100MG/5ML | A074916 | 001 | Apr 30, 1999 |
| | ARISE PHARMS | 100MG/5ML | A200457 | 001 | Aug 18, 2011 |
| | TARO | 100MG/5ML | A209207 | 001 | Jun 27, 2017 |

SUSPENSION/DROPS;ORAL

CHILDREN'S MOTRIN

| | | | | | |
|---|---|---|---|---|---|
| +! | J AND J CONSUMER INC | 40MG/ML | N020603 | 001 | Jun 10, 1996 |

IBUPROFEN

| | | | | | |
|---|---|---|---|---|---|
| SUSPENSION/DROPS;ORAL | | | | | |
| IBUPROFEN | | | | | |
| | L PERRIGO CO | 40MG/ML | A075217 | 001 | Dec 16, 1998 |
| | TRIS PHARMA INC | 40MG/ML | A079058 | 001 | Aug 31, 2009 |
| PEDIATRIC ADVIL | | | | | |
| +! | PFIZER | 100MG/2.5ML | N020812 | 001 | Jan 30, 1998 |
| TABLET;ORAL | | | | | |
| ADVIL | | | | | |
| | PFIZER | 200MG | N018989 | 001 | May 18, 1984 |
| IBU-TAB 200 | | | | | |
| | ALRA | 200MG | A071057 | 001 | Aug 11, 1988 |
| IBUPROFEN | | | | | |
| | AIPING PHARM INC | 200MG | A207095 | 001 | May 05, 2017 |
| | AMNEAL PHARMS | 200MG | A079233 | 001 | Mar 18, 2014 |
| | AMNEAL PHARMS NY | 200MG | A071333 | 001 | Feb 17, 1987 |
| | | 200MG | A072199 | 001 | May 23, 1988 |
| | AUROBINDO PHARMA LTD | 200MG | A208865 | 001 | Nov 08, 2017 |
| | AVEMA PHARMA | 200MG | A076460 | 001 | Nov 26, 2003 |
| | CONTRACT PHARMACAL | 200MG | A071732 | 001 | Sep 10, 1987 |
| | | 200MG | A072299 | 001 | Jul 01, 1988 |
| | DR REDDYS LA | 200MG | A075661 | 001 | Dec 12, 2001 |
| | DR REDDYS LABS INC | 100MG | A076117 | 001 | Nov 20, 2001 |
| | GRANULES INDIA | 200MG | A079174 | 001 | Dec 10, 2010 |
| | GRANULES INDIA LTD | 200MG | A202312 | 001 | Oct 07, 2016 |
| | LNK | 100MG | A076741 | 001 | Jun 17, 2004 |
| | | 200MG | A075010 | 001 | Mar 01, 1999 |
| | | 200MG | A075139 | 001 | Mar 01, 1999 |
| | MARKSANS PHARMA | 200MG | A091237 | 001 | Feb 08, 2011 |
| | | 200MG | A091239 | 001 | Feb 01, 2011 |
| | MCNEIL | 200MG | A073019 | 001 | Mar 30, 1994 |
| | MERRO PHARM | 200MG | A070985 | 001 | Oct 02, 1987 |
| | OHM | 200MG | A071163 | 001 | Jul 15, 1986 |
| | PAR PHARM | 200MG | A070481 | 001 | Sep 24, 1986 |
| | PERRIGO | 200MG | A072096 | 001 | Dec 08, 1987 |
| | | 200MG | A075995 | 001 | Mar 14, 2002 |
| | PERRIGO R AND D | 200MG | A077349 | 001 | Jun 21, 2005 |
| | STRIDES PHARMA | 200MG | A079129 | 001 | Mar 28, 2011 |
| | | 200MG | A091355 | 001 | Apr 04, 2011 |
| | | 200MG | A207052 | 001 | May 30, 2017 |
| | VINTAGE PHARMS | 200MG | A071229 | 001 | Apr 01, 1987 |
| | | 200MG | A071639 | 001 | Feb 02, 1988 |
| IBUPROHM | | | | | |
| | OHM LABS | 200MG | A071214 | 001 | Dec 01, 1986 |
| JUNIOR STRENGTH ADVIL | | | | | |
| | PFIZER | 100MG | N020267 | 002 | Dec 13, 1996 |
| JUNIOR STRENGTH IBUPROFEN | | | | | |
| | L PERRIGO CO | 100MG | A075367 | 001 | Apr 22, 1999 |
| JUNIOR STRENGTH MOTRIN | | | | | |
| | J AND J CONSUMER INC | 100MG | N020602 | 001 | Jun 10, 1996 |
| MOTRIN IB | | | | | |
| +! | J AND J CONSUMER INC | 200MG | N019012 | 003 | Dec 17, 1990 |
| PROFEN | | | | | |
| | CONTRACT PHARMACAL | 200MG | A071265 | 001 | Oct 15, 1986 |
| TAB-PROFEN | | | | | |
| | PERRIGO | 200MG | A072095 | 001 | Dec 08, 1987 |
| TABLET, CHEWABLE;ORAL | | | | | |
| CHILDREN'S ADVIL | | | | | |
| | PFIZER | 50MG | N020944 | 001 | Dec 18, 1998 |
| CHILDREN'S MOTRIN | | | | | |
| + | J AND J CONSUMER INC | 50MG | N020601 | 001 | Nov 15, 1996 |
| IBUPROFEN | | | | | |
| | PERRIGO | 50MG | A076359 | 001 | Jan 16, 2004 |
| | | 100MG | A076359 | 002 | Jan 16, 2004 |
| JUNIOR STRENGTH ADVIL | | | | | |
| | PFIZER | 100MG | N020944 | 002 | Dec 18, 1998 |
| JUNIOR STRENGTH MOTRIN | | | | | |
| +! | J AND J CONSUMER INC | 100MG | N020601 | 003 | Nov 15, 1996 |

IBUPROFEN SODIUM

| | | | | | |
|---|---|---|---|---|---|
| TABLET;ORAL | | | | | |
| ADVIL | | | | | |
| +! | PFIZER CONS HLTHCARE | EQ 200MG BASE | N201803 | 001 | Jun 12, 2012 |
| IBUPROFEN SODIUM | | | | | |
| | PERRIGO R AND D | EQ 200MG BASE | A206581 | 001 | Aug 03, 2015 |

IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

| | | | | | |
|---|---|---|---|---|---|
| TABLET;ORAL | | | | | |
| ADVIL CONGESTION RELIEF | | | | | |
| +! | PFIZER | 200MG;10MG | N022565 | 001 | May 27, 2010 |
| IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE | | | | | |
| | PERRIGO R AND D | 200MG;10MG | A203200 | 001 | Jul 03, 2014 |

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE

| | | | | | |
|---|---|---|---|---|---|
| CAPSULE;ORAL | | | | | |
| ADVIL COLD AND SINUS | | | | | |
| +! | PFIZER | EQ 200MG FREE ACID AND POTASSIUM SALT;30MG | N021374 | 001 | May 30, 2002 |
| IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE | | | | | |
| | AUROBINDO PHARMA LTD | EQ 200MG FREE ACID AND POTASSIUM SALT;30MG | A209235 | 001 | Dec 01, 2017 |
| SUSPENSION;ORAL | | | | | |
| CHILDREN'S ADVIL COLD | | | | | |
| | PFIZER | 100MG/5ML;15MG/5ML | N021373 | 001 | Apr 18, 2002 |
| CHILDREN'S MOTRIN COLD | | | | | |
| +! | J AND J CONSUMER INC | 100MG/5ML;15MG/5ML | N021128 | 001 | Aug 01, 2000 |
| IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE | | | | | |
| | PERRIGO | 100MG/5ML;15MG/5ML | A076478 | 001 | Nov 05, 2003 |
| TABLET;ORAL | | | | | |
| ADVIL COLD AND SINUS | | | | | |
| +! | PFIZER | 200MG;30MG | N019771 | 001 | Sep 19, 1989 |
| IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE | | | | | |
| | DR REDDYS LABS LTD | 200MG;30MG | A077628 | 001 | Aug 14, 2006 |
| IBUPROHM COLD AND SINUS | | | | | |
| | OHM LABS | 200MG;30MG | A074567 | 001 | Apr 17, 2001 |
| SINE-AID IB | | | | | |
| | J AND J CONSUMER INC | 200MG;30MG | N019899 | 001 | Dec 31, 1992 |

INSULIN RECOMBINANT HUMAN

| | | | | | |
|---|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | | |
| HUMULIN R PEN | | | | | |
| +! | LILLY | 100 UNITS/ML | N018780 | 005 | Aug 06, 1998 |
| NOVOLIN R | | | | | |
| +! | NOVO NORDISK INC | 100 UNITS/ML | N019938 | 001 | Jun 25, 1991 |

INSULIN RECOMBINANT HUMAN

| | | | | | |
|---|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | | |
| HUMULIN R | | | | | |
| +! | LILLY | 100 UNITS/ML | N018780 | 001 | Oct 28, 1982 |

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

| | | | | | |
|---|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | | |
| HUMULIN 70/30 | | | | | |
| +! | LILLY | 30 UNITS/ML;70 UNITS/ML | N019717 | 001 | Apr 25, 1989 |
| HUMULIN 70/30 PEN | | | | | |
| +! | LILLY | 30 UNITS/ML;70 UNITS/ML | N019717 | 002 | Aug 06, 1998 |
| NOVOLIN 70/30 | | | | | |
| +! | NOVO NORDISK INC | 30 UNITS/ML;70 UNITS/ML | N019991 | 001 | Jun 25, 1991 |

INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

| | | | | | |
|---|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | | |
| HUMULIN N | | | | | |
| +! | LILLY | 100 UNITS/ML | N018781 | 001 | Oct 28, 1982 |
| NOVOLIN N | | | | | |
| +! | NOVO NORDISK INC | 100 UNITS/ML | N019959 | 001 | Jul 01, 1991 |

IODINE POVACRYLEX; ISOPROPYL ALCOHOL

| | | | | | |
|---|---|---|---|---|---|
| SPONGE;TOPICAL | | | | | |
| DURAPREP | | | | | |
| +! | 3M | EQ 0.7% IODINE;74% (6ML) | N021586 | 001 | Sep 29, 2006 |
| +! | | EQ 0.7% IODINE;74% (26ML) | N021586 | 002 | Sep 29, 2006 |

KETOCONAZOLE

SHAMPOO;TOPICAL

| | | | | | |
|---|---|---|---|---|---|
| NIZORAL A-D | | | | | |
| +! | JOHNSON AND JOHNSON | 1% | N020310 | 001 | Oct 10, 1997 |

KETOTIFEN FUMARATE

SOLUTION/DROPS;OPHTHALMIC

| | | | | | |
|---|---|---|---|---|---|
| ALAWAY | | | | | |
| +! | BAUSCH AND LOMB | EQ 0.025% BASE | N021996 | 001 | Dec 01, 2006 |
| + | | EQ 0.035% BASE | N021996 | 002 | Feb 11, 2015 |
| KETOTIFEN FUMARATE | | | | | |
| | AKORN | EQ 0.025% BASE | A077958 | 001 | Jul 26, 2007 |
| ! | ALCON PHARMS LTD | EQ 0.025% BASE | A077200 | 001 | Sep 02, 2008 |

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

| | | | | | |
|---|---|---|---|---|---|
| LANSOPRAZOLE | | | | | |
| | DR REDDYS LABS LTD | 15MG | A202194 | 001 | May 18, 2012 |
| | KREMERS URBAN PHARMS | 15MG | A207157 | 001 | Sep 29, 2017 |
| | MYLAN PHARMS INC | 15MG | A203187 | 001 | Jun 01, 2016 |
| | NATCO PHARMA LTD | 15MG | A203306 | 001 | Jan 13, 2016 |
| | PERRIGO R AND D | 15MG | A202319 | 001 | May 18, 2012 |
| | WOCKHARDT LTD | 15MG | A202727 | 001 | May 18, 2012 |
| PREVACID 24 HR | | | | | |
| +! | GLAXOSMITHKLINE CONS | 15MG | N022327 | 001 | May 18, 2009 |

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

| | | | | | |
|---|---|---|---|---|---|
| LANSOPRAZOLE | | | | | |
| | DEXCEL PHARMA | 15MG | N208025 | 001 | Jun 07, 2016 |

LEVOCETIRIZINE DIHYDROCHLORIDE

SOLUTION;ORAL

| | | | | | |
|---|---|---|---|---|---|
| XYZAL ALLERGY 24HR | | | | | |
| + | SANOFI-AVENTIS US | 2.5MG/5ML (0.5MG/ML) | N209090 | 001 | Jan 31, 2017 |

TABLET;ORAL

| | | | | | |
|---|---|---|---|---|---|
| XYZAL ALLERGY 24HR | | | | | |
| + | SANOFI-AVENTIS US | 5MG | N209089 | 001 | Jan 31, 2017 |

LEVONORGESTREL

TABLET;ORAL

| | | | | | |
|---|---|---|---|---|---|
| ATHENTIA NEXT | | | | | |
| | AUROBINDO PHARMA LTD | 1.5MG | A206867 | 001 | Dec 08, 2015 |
| FALLBACK SOLO | | | | | |
| | LUPIN LTD | 1.5MG | A201446 | 001 | Jun 19, 2014 |
| HER STYLE | | | | | |
| | NOVAST LABS LTD | 1.5MG | A207976 | 001 | Mar 11, 2016 |
| LEVONORGESTREL | | | | | |
| | FDN CONSUMER | 1.5MG | A200670 | 001 | Jul 12, 2012 |
| | GLENMARK PHARMS LTD | 1.5MG | A207044 | 001 | Mar 25, 2016 |
| | LOTUS PHARM CO LTD | 0.75MG | A202684 | 001 | Sep 02, 2016 |
| | MYLAN LABS LTD | 0.75MG | A202740 | 001 | Sep 02, 2016 |
| | | 1.5MG | A202739 | 001 | Oct 31, 2014 |
| | NOVEL LABS INC | 1.5MG | A202508 | 001 | Feb 22, 2013 |
| | OC PHARMA | 1.5MG | A202380 | 001 | May 29, 2015 |
| ! | PERRIGO R AND D | 0.75MG | A090740 | 001 | Dec 30, 2010 |
| | | 1.5MG | A202334 | 001 | Aug 20, 2014 |
| | RECKITT BENCKISER | 1.5MG | A202246 | 001 | Jun 05, 2015 |
| OPCICON ONE-STEP | | | | | |
| | SUN PHARM INDS LTD | 1.5MG | A202635 | 001 | Sep 11, 2014 |
| PLAN B ONE-STEP | | | | | |
| +! | FDN CONSUMER | 1.5MG | N021998 | 001 | Jul 10, 2009 |

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

| | | | | | |
|---|---|---|---|---|---|
| LOPERAMIDE HYDROCHLORIDE | | | | | |
| + | BIONPHARMA INC | 1MG | N021855 | 001 | Aug 04, 2005 |
| +! | | 2MG | N021855 | 002 | Aug 04, 2005 |

SOLUTION;ORAL

| | | | | | |
|---|---|---|---|---|---|
| IMODIUM A-D | | | | | |
| +! | J AND J CONSUMER INC | 1MG/5ML | N019487 | 001 | Mar 01, 1988 |
| LOPERAMIDE HYDROCHLORIDE | | | | | |
| | ALLIED PHARMA INC | 1MG/5ML | A073079 | 001 | Apr 30, 1992 |
| | HI TECH PHARMA | 1MG/5ML | A074352 | 001 | Nov 17, 1995 |

| | | | | | |
|---|---|---|---|---|---|
| LOPERAMIDE HYDROCHLORIDE | | | | | |
| SOLUTION;ORAL | | | | | |
| LOPERAMIDE HYDROCHLORIDE | | | | | |
| | PERRIGO | 1MG/5ML | A073243 | 001 | Jan 21, 1992 |
| | WOCKHARDT BIO AG | 1MG/5ML | A074730 | 001 | Aug 28, 1997 |
| SUSPENSION;ORAL | | | | | |
| IMODIUM A-D | | | | | |
| +! | J AND J CONSUMER INC | 1MG/7.5ML | N019487 | 002 | Jul 08, 2004 |
| LOPERAMIDE HYDROCHLORIDE | | | | | |
| | PERRIGO R AND D | 1MG/7.5ML | A091292 | 001 | May 20, 2011 |
| TABLET;ORAL | | | | | |
| IMODIUM A-D | | | | | |
| +! | J AND J CONSUMER INC | 2MG | N019860 | 001 | Nov 22, 1989 |
| LOPERAMIDE HYDROCHLORIDE | | | | | |
| | AUROBINDO PHARMA LTD | 2MG | A206548 | 001 | Dec 15, 2015 |
| | L PERRIGO CO | 2MG | A075232 | 001 | Jan 06, 2000 |
| | LNK | 2MG | A076497 | 001 | Jun 10, 2003 |
| | OHM LABS | 2MG | A074091 | 001 | Dec 10, 1992 |
| LOPERAMIDE HYDROCHLORIDE; SIMETHICONE | | | | | |
| TABLET;ORAL | | | | | |
| IMODIUM MULTI-SYMPTOM RELIEF | | | | | |
| +! | J AND J CONSUMER INC | 2MG;125MG | N021140 | 001 | Nov 30, 2000 |
| LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE | | | | | |
| | SUN PHARM INDS LTD | 2MG;125MG | A077500 | 001 | Sep 06, 2006 |
| TABLET, CHEWABLE;ORAL | | | | | |
| LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE | | | | | |
| ! | PERRIGO | 2MG;125MG | A076029 | 001 | Aug 30, 2002 |
| LORATADINE | | | | | |
| CAPSULE;ORAL | | | | | |
| CLARITIN | | | | | |
| +! | BAYER HEALTHCARE LLC | 10MG | N021952 | 001 | Jun 16, 2008 |
| LORATADINE | | | | | |
| | MARKSANS PHARMA | 10MG | A206214 | 001 | Sep 23, 2016 |
| SUSPENSION;ORAL | | | | | |
| LORATADINE | | | | | |
| +! | TARO | 1MG/ML | N021734 | 001 | Oct 04, 2005 |
| SYRUP;ORAL | | | | | |
| CLARITIN | | | | | |
| +! | BAYER HEALTHCARE LLC | 1MG/ML | N020641 | 002 | Nov 27, 2002 |
| LORATADINE | | | | | |
| | PERRIGO | 1MG/ML | A075728 | 001 | Aug 20, 2004 |
| | SILARX | 1MG/ML | A077421 | 001 | Jun 29, 2006 |
| | TARO | 1MG/ML | A076805 | 001 | Aug 20, 2004 |
| | TARO PHARM | 1MG/ML | A201865 | 001 | Jul 31, 2015 |
| | TEVA | 1MG/ML | A075505 | 001 | Nov 07, 2003 |
| | WOCKHARDT BIO AG | 1MG/ML | A075815 | 001 | Aug 20, 2004 |
| TABLET;ORAL | | | | | |
| CLARITIN | | | | | |
| +! | BAYER HEALTHCARE LLC | 10MG | N019658 | 002 | Nov 27, 2002 |
| CLARITIN HIVES RELIEF | | | | | |
| +! | BAYER HEALTHCARE LLC | 10MG | N019658 | 003 | Nov 19, 2003 |
| LORATADINE | | | | | |
| | APOTEX INC | 10MG | A076471 | 001 | Feb 14, 2006 |
| | MYLAN | 10MG | A075790 | 001 | Nov 07, 2008 |
| | | 10MG | A076154 | 001 | Aug 20, 2003 |
| | | 10MG | A078447 | 001 | Aug 12, 2011 |
| | PERRIGO | 10MG | A076301 | 001 | Jun 25, 2004 |
| | SANDOZ | 10MG | A075209 | 001 | Jan 21, 2003 |
| | SUN PHARM INDS LTD | 10MG | A076134 | 001 | Aug 18, 2003 |
| TABLET, CHEWABLE;ORAL | | | | | |
| CHILDREN'S CLARITIN | | | | | |
| +! | BAYER HEALTHCARE LLC | 5MG | N021891 | 001 | Aug 23, 2006 |

LORATADINE

TABLET, ORALLY DISINTEGRATING;ORAL

| | | | | | |
|---|---|---|---|---|---|
| ALAVERT | | | | | |
| | PFIZER | 10MG | N021375 | 001 | Dec 19, 2002 |
| CLARITIN HIVES RELIEF REDITAB | | | | | |
| +! | BAYER HEALTHCARE LLC | 10MG | N020704 | 003 | Nov 19, 2003 |
| CLARITIN REDITABS | | | | | |
| +! | BAYER HEALTHCARE LLC | 5MG | N021993 | 001 | Dec 12, 2006 |
| +! | | 10MG | N020704 | 002 | Nov 27, 2002 |
| LORATADINE | | | | | |
| | ACTAVIS LABS FL INC | 10MG | A075990 | 001 | Nov 03, 2003 |
| | PERRIGO PHARMA INTL | 10MG | A076011 | 001 | Sep 29, 2003 |
| | PFIZER | 10MG | A075822 | 001 | Feb 10, 2003 |
| LORATADINE REDIDOSE | | | | | |
| | SUN PHARM INDS LTD | 10MG | A077153 | 001 | Apr 11, 2007 |

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

| | | | | | |
|---|---|---|---|---|---|
| CLARITIN-D | | | | | |
| +! | BAYER HEALTHCARE LLC | 5MG;120MG | N019670 | 002 | Nov 27, 2002 |
| CLARITIN-D 24 HOUR | | | | | |
| +! | BAYER HEALTHCARE LLC | 10MG;240MG | N020470 | 002 | Nov 27, 2002 |
| LORATADINE AND PSEUDOEPHEDRINE SULFATE | | | | | |
| | ACTAVIS LABS FL INC | 10MG;240MG | A075706 | 001 | Feb 21, 2003 |
| | PERRIGO PHARMA INTL | 5MG;120MG | A076050 | 001 | Jan 30, 2003 |
| | | 10MG;240MG | A075989 | 001 | Mar 04, 2004 |
| | SUN PHARM INDS LTD | 10MG;240MG | A076557 | 001 | Sep 22, 2004 |

MENTHOL; METHYL SALICYLATE

PATCH;TOPICAL

| | | | | | |
|---|---|---|---|---|---|
| SALONPAS | | | | | |
| +! | HISAMITSU PHARM CO | 3%;10% | N022029 | 001 | Feb 20, 2008 |
| + | | 3%;10% | N022029 | 002 | Nov 05, 2012 |

MICONAZOLE NITRATE

CREAM;TOPICAL, VAGINAL

| | | | | | |
|---|---|---|---|---|---|
| MICONAZOLE 3 COMBINATION PACK | | | | | |
| | PERRIGO | 2%,4% | A076357 | 001 | Mar 30, 2004 |
| MONISTAT 3 COMBINATION PACK | | | | | |
| + | MEDTECH PRODUCTS | 2%,4% | N021261 | 003 | Jun 17, 2003 |
| MONISTAT 3 COMBINATION PACK (PREFILLED) | | | | | |
| +! | MEDTECH PRODUCTS | 2%,4% | N021261 | 001 | Feb 02, 2001 |

CREAM;VAGINAL

| | | | | | |
|---|---|---|---|---|---|
| MICONAZOLE 3 | | | | | |
| | TARO | 4% | A076773 | 001 | Mar 02, 2005 |
| MICONAZOLE 7 | | | | | |
| | ACTAVIS MID ATLANTIC | 2% | A074164 | 001 | Mar 29, 1996 |
| MICONAZOLE NITRATE | | | | | |
| | G AND W LABS INC | 2% | A074366 | 001 | Feb 22, 1996 |
| | PERRIGO | 2% | A074760 | 001 | May 15, 1997 |
| | PERRIGO R AND D | 4% | A091366 | 001 | Jan 15, 2010 |
| | TARO | 2% | A074444 | 001 | Jan 13, 1997 |
| MONISTAT 3 | | | | | |
| +! | MEDTECH PRODUCTS | 4% | N020827 | 001 | Mar 30, 1998 |
| MONISTAT 7 | | | | | |
| +! | MEDTECH PRODUCTS | 2% | N017450 | 002 | Feb 15, 1991 |

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

| | | | | | |
|---|---|---|---|---|---|
| M-ZOLE 3 COMBINATION PACK | | | | | |
| | ACTAVIS MID ATLANTIC | 2%,200MG | A074926 | 001 | Apr 16, 1999 |
| MICONAZOLE 7 COMBINATION PACK | | | | | |
| | G AND W LABS | 2%,100MG | A076585 | 001 | Mar 26, 2004 |
| MICONAZOLE NITRATE | | | | | |
| | PERRIGO R AND D | 2%,1.2GM | A079114 | 001 | Jun 02, 2010 |
| MICONAZOLE NITRATE COMBINATION PACK | | | | | |
| | PERRIGO | 2%,200MG | A075329 | 001 | Apr 20, 1999 |
| MONISTAT 1 COMBINATION PACK | | | | | |
| +! | MEDTECH PRODUCTS | 2%,1.2GM | N021308 | 001 | Jun 29, 2001 |
| MONISTAT 3 COMBINATION PACK | | | | | |
| +! | MEDTECH PRODUCTS | 2%,200MG | N020670 | 002 | Apr 16, 1996 |

MICONAZOLE NITRATE

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

| | | | | | |
|---|---|---|---|---|---|
| MONISTAT 7 COMBINATION PACK | | | | | |
| +! | MEDTECH PRODUCTS | 2%,100MG | N020288 | 002 | Apr 26, 1993 |
| SUPPOSITORY;VAGINAL | | | | | |
| MICONAZOLE NITRATE | | | | | |
| | ACTAVIS PHARMA | 100MG | A073507 | 001 | Nov 19, 1993 |
| | G AND W LABS | 100MG | A074414 | 001 | Apr 30, 1997 |
| ! | PERRIGO | 100MG | A074395 | 001 | Mar 20, 1997 |
| MONISTAT 7 | | | | | |
| +! | MEDTECH PRODUCTS | 100MG | N018520 | 002 | Feb 15, 1991 |

MINOXIDIL

| | | | | | |
|---|---|---|---|---|---|
| AEROSOL, FOAM;TOPICAL | | | | | |
| MEN'S ROGAINE | | | | | |
| +! | JOHNSON AND JOHNSON | 5% | N021812 | 001 | Jan 20, 2006 |
| MINOXIDIL | | | | | |
| | PERRIGO ISRAEL | 5% | A091344 | 001 | Apr 28, 2011 |
| MINOXIDIL (FOR MEN) | | | | | |
| | WATSON LABS INC | 5% | A208092 | 001 | Feb 17, 2017 |
| MINOXIDIL (FOR WOMEN) | | | | | |
| | WATSON LABS INC | 5% | A208092 | 002 | Jul 27, 2017 |
| WOMEN'S ROGAINE | | | | | |
| +! | JOHNSON AND JOHNSON | 5% | N021812 | 002 | Feb 28, 2014 |
| SOLUTION;TOPICAL | | | | | |
| MINOXIDIL (FOR MEN) | | | | | |
| | ACTAVIS MID ATLANTIC | 2% | A074588 | 001 | Apr 05, 1996 |
| | HI TECH PHARMA | 2% | A074731 | 001 | Dec 24, 1996 |
| | L PERRIGO CO | 2% | A075357 | 001 | Jul 30, 1999 |
| | WOCKHARDT BIO AG | 2% | A074767 | 001 | Feb 28, 1997 |
| MINOXIDIL (FOR WOMEN) | | | | | |
| | HI TECH PHARMA | 2% | A074731 | 002 | May 11, 2005 |
| | L PERRIGO CO | 2% | A075357 | 002 | Jul 30, 1999 |
| MINOXIDIL EXTRA STRENGTH (FOR MEN) | | | | | |
| | ACTAVIS MID ATLANTIC | 5% | A075518 | 001 | Nov 17, 2000 |
| | AVACOR PRODS | 5% | A075619 | 001 | Nov 17, 2000 |
| | PERRIGO | 5% | A075598 | 001 | Jun 13, 2001 |
| | PERRIGO NEW YORK | 5% | A075737 | 001 | Mar 15, 2002 |
| | WOCKHARDT BIO AG | 5% | A075438 | 001 | Feb 27, 2003 |
| ROGAINE (FOR MEN) | | | | | |
| +! | JOHNSON AND JOHNSON | 2% | N019501 | 002 | Feb 09, 1996 |
| ROGAINE (FOR WOMEN) | | | | | |
| +! | JOHNSON AND JOHNSON | 2% | N019501 | 003 | Feb 09, 1996 |
| ROGAINE EXTRA STRENGTH (FOR MEN) | | | | | |
| +! | JOHNSON AND JOHNSON | 5% | N020834 | 001 | Nov 14, 1997 |
| THEROXIDIL | | | | | |
| | EI INC | 2% | A078176 | 001 | Nov 09, 2007 |
| | | 5% | A076239 | 001 | Aug 24, 2004 |

NAPHAZOLINE HYDROCHLORIDE; PHENIRAMINE MALEATE

| | | | | | |
|---|---|---|---|---|---|
| SOLUTION/DROPS;OPHTHALMIC | | | | | |
| NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE | | | | | |
| | AKORN INC | 0.025%;0.3% | A202795 | 001 | Jan 24, 2013 |
| | ALTAIRE PHARMS INC | 0.02675%;0.315% | A078208 | 001 | Sep 27, 2010 |
| NAPHCON-A | | | | | |
| +! | ALCON | 0.025%;0.3% | N020226 | 001 | Jun 08, 1994 |
| OPCON-A | | | | | |
| +! | BAUSCH AND LOMB | 0.02675%;0.315% | N020065 | 001 | Jun 08, 1994 |
| VISINE-A | | | | | |
| +! | JOHNSON AND JOHNSON | 0.025%;0.3% | N020485 | 001 | Jan 31, 1996 |

NAPROXEN SODIUM

| | | | | | |
|---|---|---|---|---|---|
| CAPSULE;ORAL | | | | | |
| NAPROXEN SODIUM | | | | | |
| +! | BIONPHARMA INC | EQ 200MG BASE | N021920 | 001 | Feb 17, 2006 |
| TABLET;ORAL | | | | | |
| ALEVE | | | | | |
| +! | BAYER | EQ 200MG BASE | N020204 | 002 | Jan 11, 1994 |
| NAPROXEN SODIUM | | | | | |
| | AMNEAL PHARMS NY | EQ 200MG BASE | A079096 | 001 | Dec 16, 2008 |
| | AUROBINDO PHARMA LTD | EQ 200MG BASE | A205497 | 001 | Mar 18, 2016 |

NAPROXEN SODIUM

TABLET;ORAL

| | | | | | |
|---|---|---|---|---|---|
| NAPROXEN SODIUM | | | | | |
| | CONTRACT PHARMACAL | EQ 200MG BASE | A074635 | 001 | Jan 13, 1997 |
| | DR REDDYS LABS INC | EQ 200MG BASE | A075168 | 001 | Jul 28, 1998 |
| | GRANULES INDIA | EQ 200MG BASE | A091353 | 001 | Sep 20, 2011 |
| | LNK INTL INC | EQ 200MG BASE | A204872 | 001 | Jan 23, 2017 |
| | MARKSANS PHARMA | EQ 200MG BASE | A090545 | 001 | Mar 16, 2011 |
| | PERRIGO | EQ 200MG BASE | A074661 | 001 | Jan 13, 1997 |
| | SUN PHARM INDS LTD | EQ 200MG BASE | A091183 | 001 | May 20, 2011 |

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

| | | | | | |
|---|---|---|---|---|---|
| ALEVE-D SINUS & COLD | | | | | |
| +! | BAYER | 200MG;120MG | N021076 | 001 | Nov 29, 1999 |
| NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE | | | | | |
| | DR REDDYS LABS INC | EQ 220MG BASE;120MG | A077381 | 001 | Sep 27, 2006 |
| | PERRIGO | EQ 200MG BASE;120MG | A076518 | 001 | Mar 17, 2004 |

NICOTINE

FILM, EXTENDED RELEASE;TRANSDERMAL

| | | | | | |
|---|---|---|---|---|---|
| HABITROL | | | | | |
| + | DR REDDYS LABS SA | 7MG/24HR | N020076 | 004 | Nov 12, 1999 |
| + | | 14MG/24HR | N020076 | 005 | Nov 12, 1999 |
| +! | | 21MG/24HR | N020076 | 006 | Nov 12, 1999 |
| NICODERM CQ | | | | | |
| + | SANOFI AVENTIS US | 7MG/24HR | N020165 | 006 | Aug 02, 1996 |
| + | | 14MG/24HR | N020165 | 005 | Aug 02, 1996 |
| +! | | 21MG/24HR | N020165 | 004 | Aug 02, 1996 |
| NICOTINE | | | | | |
| | AVEVA | 7MG/24HR | A074612 | 002 | Jul 28, 2003 |
| | | 14MG/24HR | A074612 | 003 | Oct 20, 1997 |
| | | 21MG/24HR | A074612 | 001 | Oct 20, 1997 |

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

| | | | | | |
|---|---|---|---|---|---|
| NICORETTE | | | | | |
| + | GLAXOSMITHKLINE | EQ 2MG BASE | N018612 | 002 | Feb 09, 1996 |
| + | | EQ 2MG BASE | N018612 | 004 | Sep 25, 2000 |
| +! | | EQ 4MG BASE | N020066 | 002 | Feb 09, 1996 |
| + | | EQ 4MG BASE | N020066 | 004 | Sep 25, 2000 |
| NICORETTE (MINT) | | | | | |
| + | GLAXOSMITHKLINE | EQ 2MG BASE | N018612 | 003 | Dec 23, 1998 |
| + | | EQ 4MG BASE | N020066 | 003 | Dec 23, 1998 |
| NICOTINE POLACRILEX | | | | | |
| | ACTAVIS LABS NY INC | EQ 2MG BASE | A074507 | 001 | Mar 15, 1999 |
| | | EQ 2MG BASE | A076569 | 001 | Jul 29, 2004 |
| | | EQ 2MG BASE | A078699 | 001 | Dec 29, 2008 |
| | | EQ 2MG BASE | A079216 | 001 | Jul 08, 2009 |
| | | EQ 2MG BASE | A204794 | 001 | May 10, 2016 |
| | | EQ 4MG BASE | A074707 | 001 | Mar 19, 1999 |
| | | EQ 4MG BASE | A076568 | 002 | Jul 29, 2004 |
| | | EQ 4MG BASE | A078697 | 001 | Dec 29, 2008 |
| | | EQ 4MG BASE | A079038 | 001 | Jul 08, 2009 |
| | | EQ 4MG BASE | A079219 | 001 | Jul 08, 2009 |
| | | EQ 4MG BASE | A204833 | 001 | Feb 26, 2016 |
| | L PERRIGO CO | EQ 2MG BASE | A076775 | 001 | Sep 16, 2004 |
| | | EQ 2MG BASE | A076776 | 001 | Sep 16, 2004 |
| | | EQ 2MG BASE | A076777 | 001 | Sep 16, 2004 |
| | | EQ 4MG BASE | A076778 | 001 | Sep 16, 2004 |
| | | EQ 4MG BASE | A076779 | 001 | Sep 16, 2004 |
| | | EQ 4MG BASE | A076789 | 001 | Sep 16, 2004 |
| | PERRIGO R AND D | EQ 2MG BASE | A078325 | 001 | Oct 30, 2006 |
| | | EQ 2MG BASE | A078547 | 001 | May 24, 2007 |
| | | EQ 2MG BASE | A078967 | 001 | Apr 23, 2008 |
| | | EQ 2MG BASE | A091349 | 001 | Jul 20, 2011 |
| | | EQ 2MG BASE | A206394 | 001 | Dec 15, 2016 |
| | | EQ 4MG BASE | A078326 | 001 | Oct 30, 2006 |
| | | EQ 4MG BASE | A078546 | 001 | May 24, 2007 |
| | | EQ 4MG BASE | A078968 | 001 | Apr 23, 2008 |
| | | EQ 4MG BASE | A091354 | 001 | Jul 20, 2011 |
| | | EQ 4MG BASE | A206393 | 001 | Dec 15, 2016 |
| | WATSON LABS | EQ 2MG BASE | A079044 | 001 | Jul 08, 2009 |

NICOTINE POLACRILEX

| | | | | | |
|---|---|---|---|---|---|
| GUM, CHEWING;BUCCAL | | | | | |
| THRIVE | | | | | |
| | NOVARTIS | EQ 2MG BASE | A077658 | 001 | Jun 19, 2007 |
| | | EQ 4MG BASE | A077656 | 001 | Jun 19, 2007 |
| TROCHE/LOZENGE;ORAL | | | | | |
| COMMIT | | | | | |
| + | GLAXOSMITHKLINE CONS | EQ 2MG BASE | N021330 | 001 | Oct 31, 2002 |
| +! | | EQ 4MG BASE | N021330 | 002 | Oct 31, 2002 |
| NICORETTE | | | | | |
| + | GLAXOSMITHKLINE CONS | EQ 2MG BASE | N022360 | 001 | May 18, 2009 |
| +! | | EQ 4MG BASE | N022360 | 002 | May 18, 2009 |
| NICOTINE POLACRILEX | | | | | |
| | PERRIGO R AND D | EQ 2MG BASE | A077007 | 001 | Jan 31, 2006 |
| | | EQ 2MG BASE | A090711 | 001 | Jul 10, 2009 |
| | | EQ 2MG BASE | A090821 | 001 | Jul 10, 2009 |
| | | EQ 2MG BASE | A203690 | 001 | Oct 09, 2012 |
| | | EQ 4MG BASE | A077007 | 002 | Jan 31, 2006 |
| | | EQ 4MG BASE | A090711 | 002 | Jul 10, 2009 |
| | | EQ 4MG BASE | A090821 | 002 | Jul 10, 2009 |
| | | EQ 4MG BASE | A203690 | 002 | Oct 09, 2012 |

NIZATIDINE

| | | | | | |
|---|---|---|---|---|---|
| TABLET;ORAL | | | | | |
| AXID AR | | | | | |
| +! | PFIZER | 75MG | N020555 | 001 | May 09, 1996 |

NONOXYNOL-9

| | | | | | |
|---|---|---|---|---|---|
| SPONGE;VAGINAL | | | | | |
| TODAY | | | | | |
| +! | MAYER LABS INC | 1GM | N018683 | 001 | Apr 01, 1983 |

OMEPRAZOLE

| | | | | | |
|---|---|---|---|---|---|
| TABLET, DELAYED RELEASE;ORAL | | | | | |
| OMEPRAZOLE | | | | | |
| +! | DEXCEL PHARMA | 20MG | N022032 | 001 | Dec 04, 2007 |
| TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL | | | | | |
| OMEPRAZOLE | | | | | |
| + | DEXCEL PHARMA | 20MG | N209400 | 001 | Jul 05, 2017 |

OMEPRAZOLE MAGNESIUM

| | | | | | |
|---|---|---|---|---|---|
| CAPSULE, DELAYED RELEASE;ORAL | | | | | |
| OMEPRAZOLE MAGNESIUM | | | | | |
| ! | DR REDDYS LABS LTD | EQ 20MG BASE | A078878 | 001 | Jun 05, 2009 |
| TABLET, DELAYED RELEASE;ORAL | | | | | |
| OMEPRAZOLE MAGNESIUM | | | | | |
| | PERRIGO R AND D | EQ 20MG BASE | A204152 | 001 | Jul 30, 2015 |
| PRILOSEC OTC | | | | | |
| +! | ASTRAZENECA PHARMS | EQ 20MG BASE | N021229 | 001 | Jun 20, 2003 |

OMEPRAZOLE; SODIUM BICARBONATE

| | | | | | |
|---|---|---|---|---|---|
| CAPSULE;ORAL | | | | | |
| OMEPRAZOLE AND SODIUM BICARBONATE | | | | | |
| | ACTAVIS ELIZABETH | 20MG;1.1GM | A204137 | 001 | Jul 15, 2016 |
| | AUROLIFE PHARMA LLC | 20MG;1.1GM | A204923 | 001 | Nov 07, 2016 |
| | PAR PHARM | 20MG;1.1GM | A201946 | 001 | Jul 15, 2016 |
| | PERRIGO R AND D | 20MG;1.1GM | A201361 | 001 | Jul 15, 2016 |
| ZEGERID OTC | | | | | |
| +! | BAYER HEALTHCARE LLC | 20MG;1.1GM | N022281 | 001 | Dec 01, 2009 |
| FOR SUSPENSION;ORAL | | | | | |
| ZEGERID OTC | | | | | |
| +! | BAYER HEALTHCARE LLC | 20MG/PACKET;1.68GM/PACKET | N022283 | 001 | Jun 17, 2013 |

ORLISTAT

| | | | | | |
|---|---|---|---|---|---|
| CAPSULE;ORAL | | | | | |
| ALLI | | | | | |
| +! | GLAXOSMITHKLINE CONS | 60MG | N021887 | 001 | Feb 07, 2007 |

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYTROL FOR WOMEN

| | | | | | |
|---|---|---|---|---|---|
| +! | ALLERGAN SALES LLC | 3.9MG/24HR | N202211 | 001 | Jan 25, 2013 |

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

VISINE L.R.

| | | | | | |
|---|---|---|---|---|---|
| +! | JOHNSON AND JOHNSON | 0.025% | N019407 | 001 | Mar 31, 1989 |

PERMETHRIN

LOTION;TOPICAL

NIX

| | | | | | |
|---|---|---|---|---|---|
| +! | MEDTECH PRODUCTS | 1% | N019918 | 001 | May 02, 1990 |

PERMETHRIN

| | | | | | |
|---|---|---|---|---|---|
| | ACTAVIS MID ATLANTIC | 1% | A075014 | 001 | Mar 28, 2000 |
| | PERRIGO NEW YORK | 1% | A076090 | 001 | Dec 20, 2001 |

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

GLYCOLAX

| | | | | | |
|---|---|---|---|---|---|
| | KREMERS URBAN PHARMS | 17GM/PACKET | A090600 | 001 | Oct 06, 2009 |
| | | 17GM/SCOOPFUL | A090600 | 002 | Oct 06, 2009 |

MIRALAX

| | | | | | |
|---|---|---|---|---|---|
| +! | BAYER HEALTHCARE LLC | 17GM/SCOOPFUL | N022015 | 001 | Oct 06, 2006 |

POLYETHYLENE GLYCOL 3350

| | | | | | |
|---|---|---|---|---|---|
| | AILEX PHARMS LLC | 17GM/SCOOPFUL | A202071 | 001 | Dec 28, 2012 |
| | ANI PHARMS INC | 17GM/SCOOPFUL | A202850 | 001 | Dec 15, 2015 |
| | MYLAN | 17GM/PACKET | A078915 | 001 | Oct 06, 2009 |
| | | 17GM/SCOOPFUL | A078915 | 002 | Oct 06, 2009 |
| | NEXGEN PHARMA | 17GM/SCOOPFUL | A090812 | 001 | Oct 07, 2009 |
| | NOVEL LABS INC | 17GM/SCOOPFUL | A091077 | 001 | Oct 06, 2009 |
| | NUVO PHARM INC | 17GM/SCOOPFUL | A206105 | 001 | Oct 28, 2016 |
| | PAR PHARM | 17GM/SCOOPFUL | A079214 | 001 | Jan 31, 2013 |
| | PERRIGO R AND D | 17GM/PACKET | A090685 | 001 | Oct 06, 2009 |
| | | 17GM/SCOOPFUL | A090685 | 002 | Oct 06, 2009 |
| | STRIDES PHARMA | 17GM/SCOOPFUL | A203928 | 001 | Aug 24, 2016 |
| | | 17GM/PACKET | A203928 | 002 | Aug 24, 2016 |

POTASSIUM IODIDE

SOLUTION;ORAL

POTASSIUM IODIDE

| | | | | | |
|---|---|---|---|---|---|
| | MISSION PHARMACAL CO | 65MG/ML | A206211 | 001 | Mar 24, 2016 |

THYROSHIELD

| | | | | | |
|---|---|---|---|---|---|
| ! | ARCO PHARMS LLC | 65MG/ML | A077218 | 001 | Jan 12, 2005 |

TABLET;ORAL

IOSAT

| | | | | | |
|---|---|---|---|---|---|
| + | ANBEX | 65MG | N018664 | 002 | May 12, 2011 |
| +! | | 130MG | N018664 | 001 | Oct 14, 1982 |

THYROSAFE

| | | | | | |
|---|---|---|---|---|---|
| ! | RECIP | 65MG | A076350 | 001 | Sep 10, 2002 |

POVIDONE-IODINE

SOLUTION;TOPICAL

POVIDONE IODINE

| | | | | | |
|---|---|---|---|---|---|
| +! | ALLEGIANCE HLTHCARE | 1% | N019522 | 001 | Mar 31, 1989 |

SPONGE;TOPICAL

E-Z SCRUB 201

| | | | | | |
|---|---|---|---|---|---|
| +! | BECTON DICKINSON | 20% | N019240 | 001 | Nov 29, 1985 |

E-Z SCRUB 241

| | | | | | |
|---|---|---|---|---|---|
| +! | BECTON DICKINSON | 10% | N019476 | 001 | Jan 07, 1987 |

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

PSEUDOEPHEDRINE HYDROCHLORIDE

| | | | | | |
|---|---|---|---|---|---|
| | AUROBINDO PHARMA LTD | 120MG | A209008 | 001 | Jun 09, 2017 |
| | L PERRIGO CO | 120MG | A075153 | 001 | Feb 26, 1999 |
| | SUN PHARM INDS LTD | 120MG | A077442 | 001 | Sep 28, 2005 |

SUDAFED 12 HOUR

| | | | | | |
|---|---|---|---|---|---|
| ! | MCNEIL CONS | 120MG | A073585 | 001 | Oct 31, 1991 |

PSEUDOEPHEDRINE HYDROCHLORIDE

| | | | | | |
|---|---|---|---|---|---|
| TABLET, EXTENDED RELEASE;ORAL | | | | | |
| SUDAFED 24 HOUR | | | | | |
| +! | J AND J CONSUMER INC | 240MG | N020021 | 002 | Dec 15, 1992 |

PSEUDOEPHEDRINE SULFATE

| | | | | | |
|---|---|---|---|---|---|
| TABLET, EXTENDED RELEASE;ORAL | | | | | |
| AFRINOL | | | | | |
| +! | SCHERING PLOUGH | 120MG | N018191 | 001 | |

PURIFIED WATER

| | | | | | |
|---|---|---|---|---|---|
| SOLUTION;OPHTHALMIC | | | | | |
| PUR-WASH | | | | | |
| +! | NIAGARA PHARMS | 98.3% | N022305 | 001 | Sep 01, 2011 |

RANITIDINE HYDROCHLORIDE

| | | | | | |
|---|---|---|---|---|---|
| TABLET;ORAL | | | | | |
| RANITIDINE HYDROCHLORIDE | | | | | |
| | APOTEX INC | EQ 75MG BASE | A075167 | 001 | May 04, 2000 |
| | | EQ 150MG BASE | A200172 | 001 | May 31, 2012 |
| | AUROBINDO PHARMA LTD | EQ 75MG BASE | A207579 | 001 | Nov 13, 2017 |
| | | EQ 150MG BASE | A207578 | 001 | Nov 13, 2017 |
| | DR REDDYS LABS LTD | EQ 75MG BASE | A075294 | 001 | Mar 28, 2000 |
| | | EQ 150MG BASE | A078192 | 001 | Aug 31, 2007 |
| | IVAX SUB TEVA PHARMS | EQ 75MG BASE | A075296 | 001 | Jan 14, 2000 |
| | MYLAN | EQ 75MG BASE | A075497 | 001 | Jan 14, 2000 |
| | PERRIGO | EQ 75MG BASE | A076195 | 001 | Aug 30, 2002 |
| | PERRIGO R AND D | EQ 150MG BASE | A091429 | 001 | May 11, 2011 |
| | | EQ 150MG BASE | A091429 | 002 | May 11, 2011 |
| | STRIDES PHARMA | EQ 75MG BASE | A201745 | 001 | Feb 29, 2012 |
| | | EQ 150MG BASE | A200536 | 001 | Jun 28, 2011 |
| | WOCKHARDT | EQ 75MG BASE | A076760 | 001 | Feb 24, 2006 |
| ZANTAC 150 | | | | | |
| +! | SANOFI US | EQ 150MG BASE | N021698 | 001 | Aug 31, 2004 |
| + | | EQ 150MG BASE | N021698 | 002 | Mar 13, 2007 |
| ZANTAC 75 | | | | | |
| + | SANOFI US | EQ 75MG BASE | N020520 | 001 | Dec 19, 1995 |

SODIUM CHLORIDE

| | | | | | |
|---|---|---|---|---|---|
| AEROSOL, METERED;INHALATION | | | | | |
| BRONCHO SALINE | | | | | |
| +! | BLAIREX | 0.9% | N019912 | 001 | Sep 03, 1992 |

SODIUM FLUORIDE; TRICLOSAN

| | | | | | |
|---|---|---|---|---|---|
| PASTE;DENTAL | | | | | |
| COLGATE TOTAL | | | | | |
| +! | COLGATE PALMOLIVE | 0.24%;0.3% | N020231 | 001 | Jul 11, 1997 |

TERBINAFINE

| | | | | | |
|---|---|---|---|---|---|
| GEL;TOPICAL | | | | | |
| LAMISIL AT | | | | | |
| +! | NOVARTIS | 1% | N021958 | 001 | Jul 24, 2006 |

TERBINAFINE HYDROCHLORIDE

| | | | | | |
|---|---|---|---|---|---|
| CREAM;TOPICAL | | | | | |
| LAMISIL | | | | | |
| +! | GLAXOSMITHKLINE | 1% | N020980 | 001 | Mar 09, 1999 |
| TERBINAFINE HYDROCHLORIDE | | | | | |
| | TARO | 1% | A077511 | 001 | Jul 02, 2007 |
| SOLUTION;TOPICAL | | | | | |
| LAMISIL AT | | | | | |
| +! | NOVARTIS | 1% | N021124 | 001 | Mar 17, 2000 |
| SPRAY;TOPICAL | | | | | |
| LAMISIL AT | | | | | |
| +! | NOVARTIS | 1% | N021124 | 002 | Mar 17, 2000 |

TIOCONAZOLE

| | | | | | |
|---|---|---|---|---|---|
| OINTMENT;VAGINAL | | | | | |
| TIOCONAZOLE | | | | | |
| | PERRIGO | 6.5% | A075915 | 001 | Nov 21, 2001 |
| VAGISTAT-1 | | | | | |
| +! | COMBE | 6.5% | N020676 | 001 | Feb 11, 1997 |

TRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL

| | | | | | |
|---|---|---|---|---|---|
| NASACORT ALLERGY 24 HOUR | | | | | |
| +! | SANOFI AVENTIS US | 0.055MG/SPRAY | N020468 | 002 | Oct 11, 2013 |
| TRIAMCINOLONE ACETONIDE | | | | | |
| | PERRIGO ISRAEL | 0.055MG/SPRAY | A078104 | 002 | Nov 14, 2014 |

# DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

ANTICOAGULANT 4% SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION

NONE

| | | |
|---|---|---|
| HAEMONETICS MANUFACTURING INC | N760305 | Jun 30, 1978 |

ANTICOAGULANT CITRATE DEXTROSE SOLUTION (ACD)

INJECTABLE; INJECTION

| | | |
|---|---|---|
| CITRA LABS LLC | N020037 | Aug 26, 2003 |

ACD-A SOLUTION

| | | |
|---|---|---|
| TERUMO BCT INC | A010228 | Feb 25, 2002 |

ADSOL WITH ACD-A

| | | |
|---|---|---|
| FENWAL INC | N000922 | Aug 29, 2002 |

ANTICOAGULANT CITRATE DEXTROSE SOLUTION FORMULA A

| | | |
|---|---|---|
| HAEMONETICS CORP | A980728 | Feb 06, 2002 |

AS3 SOLUTION/ACD-A

| | | |
|---|---|---|
| TERUMO BCT INC | N001214 | May 29, 2002 |

NONE

| | | |
|---|---|---|
| HAEMONETICS MANUFACTURING INC | A710497 | Nov 06, 1987 |

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION

NONE

| | | |
|---|---|---|
| FENWAL INC | N160918 | Mar 17, 1978 |

ANTICOAGULANT CITRATE DEXTROSE SOLUTION USP (ACD-A)

INJECTABLE; INJECTION

NONE

| | | |
|---|---|---|
| ARTERIOCYTE MEDICAL SYSTEMS, INC | N160767 | May 11, 2012 |

ANTICOAGULANT CITRATE PHOSPHATE 2X DEXTROSE SOLUTION (CP2D)

INJECTABLE; INJECTION

CITRATE PHOSPHATE DOUBLE DEXTROSE/ADDITIVE SOLUTION 3

| | | |
|---|---|---|
| HAEMONETICS CORP | N000127 | Jan 18, 2002 |

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION

INJECTABLE; INJECTION

NONE

| | | |
|---|---|---|
| TERUMO MEDICAL CORP | N820528 | Nov 03, 1982 |

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION (CPDA)

INJECTABLE; INJECTION

CPDA-1 BLOOD-PACK UNIT (PL 146 PLASTIC) 250, 450, 500 ML BLOOD PACK UNITS

| | | |
|---|---|---|
| FENWAL INC | N770420 | May 12, 1978 |

ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE SOLUTION USP

INJECTABLE; INJECTION

BLOOD PACK UNIT CPDA-1 IN PLASTIC CONTAINER

| | | |
|---|---|---|
| FENWAL INC | N940404 | Jul 28, 1994 |

## DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

### ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE ADENINE-1 SOLUTION

INJECTABLE; INJECTION

NONE

| | | | |
|---|---|---|---|
| HAEMONETICS MANUFACTURING INC | | N800077 | Nov 06, 1980 |

### ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION

INJECTABLE; INJECTION

ADSOL IN PLASTIC CONTAINER

| | | | |
|---|---|---|---|
| FENWAL INC | | N900223 | Dec 27, 1991 |

### ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION (CPD)

INJECTABLE; INJECTION

CPD ANTICOAGULANT IN PL 2209 PLASTIC CONTAINER

| | | | |
|---|---|---|---|
| FENWAL INC | | N900224 | Dec 27, 1991 |

MACOPRODUCTIONS SAS CPD/AS-1: MACOPHARMA LEUCOFLEX MTL1 LEUKOREDUCTION SYSTEM FOR BLOOD COMPONENTS KNOWN AS MTL1-WB

| | | | |
|---|---|---|---|
| MACOPRODUCTIONS SAS | | N040083 | Nov 21, 2005 |

NONE

| | | | |
|---|---|---|---|
| TERUMO BCT INC | | A070025 | Jan 06, 2008 |

### ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP

INJECTABLE; INJECTION

NONE

| | | | |
|---|---|---|---|
| FENWAL INC | | N170401 | Dec 06, 1977 |
| | | N811012 | Jun 28, 1983 |
| HAEMONETICS MANUFACTURING INC | | N800222 | Aug 23, 1982 |
| TERUMO MEDICAL CORP | | N781211 | Jun 10, 1981 |

### ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-1: DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION

ADSOL RED BLOOD CELL PRESERVATIVE SOLUTION

| | | | |
|---|---|---|---|
| FENWAL INC | | N811104 | May 16, 1983 |

### ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION USP WITH: AS-5: DEXTROSE USP; SODIUM CHLORIDE USP; MANNITOL USP; ADENINE

INJECTABLE; INJECTION

OPTISOL RED BLOOD CELL PRESERVATIVE SOLUTION

| | | | |
|---|---|---|---|
| TERUMO MEDICAL CORP | | N880217 | Oct 07, 1988 |

### ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH: AS-3: CITRIC ACID USP; MONOBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE; DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION

AS-3 NUTRICEL ADDITIVE SYSTEM

| | | | |
|---|---|---|---|
| HAEMONETICS MANUFACTURING INC | 0.042GM/100ML;0.276GM/100ML; 0.410GM/100ML;0.30GM/100ML; 1.10GM/100ML;0.588GM/100ML | N820915 | Oct 19, 1984 |

## DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

ANTICOAGULANT CITRATE PHOSPHATE DOUBLE DEXTROSE SOLUTION WITH: AS-2: CITRIC ACID USP; DIBASIC SODIUM PHOSPHATE USP; SODIUM CHLORIDE USP; ADENINE; DEXTROSE USP; SODIUM CITRATE USP

INJECTABLE; INJECTION

AS-2 NUTRICEL ADDITIVE SYSTEM

| | | | |
|---|---|---|---|
| MEDSEP CORP | 0.042GM/100ML;0.285GM/100ML; 0.718GM/100ML;0.017GM/100ML; 0.396GM/100ML;0.588GM/100ML | N820915 | Sep 22, 1983 |

ANTICOAGULANT SODIUM CITRATE 4% SOLUTION

INJECTABLE; INJECTION

NONE

| | | | |
|---|---|---|---|
| HAEMONETICS CORPORATION | | N980123 | Mar 03, 2000 |

ANTICOAGULANT SODIUM CITRATE SOLUTION

INJECTABLE; INJECTION

TRICITRASOL

| | | | |
|---|---|---|---|
| CYTOSOL LABORATORIES INC | | N010409 | Jul 10, 2003 |

ANTICOAGULANT SODIUM CITRATE SOLUTION USP

INJECTABLE; INJECTION

NONE

| | | | |
|---|---|---|---|
| FENWAL INC | | N770923 | Jan 20, 1978 |
| TERUMO MEDICAL CORP | | N781214 | Feb 08, 1980 |

CORD BLOOD STERILE COLLECTION BAG, ANTICOAGULANT CITRATE PHOSPHATE DEXTROSE SOLUTION (CPD)

STERILE CORD BLOOD COLLECTION UNIT

NONE

| | | | |
|---|---|---|---|
| MACOPHARMA | | N125552 | Dec 21, 2016 |

DEXTRAN 1 IN SODIUM CHLORIDE 0.6%

INJECTABLE; INJECTION

PROMIT

| | | | |
|---|---|---|---|
| MEDA AB | | N830715 | Oct 30, 1984 |

DEXTRAN 40, 10% IN DEXTROSE 5%

INJECTABLE; INJECTION

LMD IN GLASS BOTTLE

| | | | |
|---|---|---|---|
| HOSPIRA INC | 10GM/100ML;5GM/100ML | A720563 | Oct 30, 1992 |

DEXTRAN 40, 10% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

LMD IN PLASTIC CONTAINER

| | | | |
|---|---|---|---|
| HOSPIRA INC | 10GM/100ML;0.9GM/100ML | A720562 | Oct 30, 1992 |

HETASTARCH 6% IN LACTATED ELECTROLYTE INJECTION

INJECTABLE; INJECTION

HEXTEND

| | | | |
|---|---|---|---|
| BIOTIME INC | 6GM/100ML | N200952 | Mar 31, 1999 |

## DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

HETASTARCH 6% IN SODIUM CHLORIDE 0.9%

INJECTABLE; INJECTION

| | | | |
|---|---|---|---|
| 6% HETASTARCH IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | | | |
| HOSPIRA INC | 6GM/100ML;0.9GM/100ML | A740193 | Jan 30, 1995 |
| HESPAN IN PLASTIC CONTAINER | | | |
| B BRAUN MEDICAL INC | 6GM/100ML;0.9GM/100ML | N890105 | Apr 04, 1991 |
| NONE | | | |
| TEVA PARENTERAL MEDICINES INC | 6GM/100ML;0.9GM/100ML | A740592 | Nov 12, 1998 |

HYDROXYETHYL STARCH 130/0.4 IN 6% SODIUM CHLORIDE 0.9%

STORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE INFUSED DIRECTLY TO THE PATIENT.

| | | | |
|---|---|---|---|
| NONE | | | |
| B. BRAUN MEDICAL | | A110013 | Jan 09, 2015 |
| VOLUVEN | | | |
| FRESENIUS KABI DEUTSCHLAND GMBH | 6GM/100ML;0.9GM/100ML | N070012 | Dec 27, 2007 |

ISOPLATE SOLUTION IN THE 500 ML EXCEL CONTAINER

STORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE INFUSED DIRECTLY TO THE PATIENT.

| | | | |
|---|---|---|---|
| ISOPLATE SOLUTION | | | |
| HAEMONETICS CORP | | N90067 | Mar 05, 2013 |

LEUKOCYTE REDUCTION FILTRATION SYSTEM FOR WHOLE BLOOD WITH CPD ANTICOAGULANT AND SOLX ADDITIVE

INJECTABLE; INJECTION

| | | | |
|---|---|---|---|
| LEUKOSEP HWB-600-XL | | | |
| HAEMONETICS CORP | | N110059 | Apr 25, 2013 |

RED BLOOD CELL PROCESSING SOLUTION

STORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE INFUSED DIRECTLY TO THE PATIENT.

| | | | |
|---|---|---|---|
| REJUVESOL | | | |
| CITRA LABS LLC | | N950522 | Feb 26, 1997 |

SODIUM CHLORIDE; SODIUM ACETATE; SODIUM CITRATE DIHYDRATE; SODIUM PHOSPHATE, DIABASIC ANHYDROUS; SODIUM PHOSPHATE MONOBASIC, MONOHYDRATE

STORAGE/PROCESSING SOLUTION ONLY; SHOULD NEVER BE INFUSED DIRECTLY TO THE PATIENT.

| | | | |
|---|---|---|---|
| INTERSOL SOLUTION | | | |
| FENWAL INC. | 2.26G/500ML; 2.21G/500ML; 1.59G/500ML; 1.53G/500ML; 0.465G/500ML | N080041 | Dec 09, 2009 |

| | | | | |
|---|---|---|---|---|
| ABARELIX | | | | |
| INJECTABLE;INTRAMUSCULAR | | | | |
| PLENAXIS | | | | |
| SPECIALITY EUROPEAN | 100MG/VIAL | N021320 | 001 | Nov 25, 2003 |
| ACAMPROSATE CALCIUM | | | | |
| TABLET, DELAYED RELEASE;ORAL | | | | |
| CAMPRAL | | | | |
| + FOREST LABS | 333MG ** | N021431 | 001 | Jul 29, 2004 |
| ACEBUTOLOL HYDROCHLORIDE | | | | |
| CAPSULE;ORAL | | | | |
| ACEBUTOLOL HYDROCHLORIDE | | | | |
| WATSON LABS | EQ 200MG BASE | A074007 | 001 | Oct 18, 1995 |
| | EQ 400MG BASE | A074007 | 002 | Oct 18, 1995 |
| ACETAMINOPHEN | | | | |
| INJECTABLE;INJECTION | | | | |
| INJECTAPAP | | | | |
| ORTHO MCNEIL PHARM | 100MG/ML | N017785 | 001 | Mar 07, 1986 |
| SUPPOSITORY;RECTAL | | | | |
| ACEPHEN | | | | |
| G AND W LABS | 120MG | A072218 | 001 | Mar 27, 1992 |
| ACETAMINOPHEN | | | | |
| ABLE | 120MG | A073106 | 001 | Feb 27, 1995 |
| | 325MG | A073107 | 001 | Feb 27, 1995 |
| | 650MG | A073108 | 001 | Feb 27, 1995 |
| ACINO PRODS | 120MG | A071010 | 001 | May 12, 1987 |
| | 650MG | A071011 | 001 | May 12, 1987 |
| TYLENOL | | | | |
| J AND J CONSUMER INC | 120MG | N017756 | 002 | |
| | 650MG | N017756 | 001 | |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| ACETAMINOPHEN | | | | |
| SUN PHARM INDS LTD | 650MG | A090205 | 001 | Nov 18, 2009 |
| ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE | | | | |
| CAPSULE;ORAL | | | | |
| ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE | | | | |
| MIKART | 150MG;180MG;15MG | A081095 | 001 | Oct 26, 1990 |
| | 150MG;180MG;30MG | A081096 | 001 | Oct 26, 1990 |
| | 150MG;180MG;60MG | A081097 | 001 | Oct 26, 1990 |
| CODEINE, ASPIRIN, APAP FORMULA NO. 2 | | | | |
| SCHERER LABS | 150MG;180MG;15MG | A085640 | 001 | |
| CODEINE, ASPIRIN, APAP FORMULA NO. 3 | | | | |
| SCHERER LABS | 150MG;180MG;30MG | A085639 | 001 | |
| CODEINE, ASPIRIN, APAP FORMULA NO. 4 | | | | |
| SCHERER LABS | 150MG;180MG;60MG | A085638 | 001 | |
| ACETAMINOPHEN; BUTALBITAL | | | | |
| CAPSULE;ORAL | | | | |
| BANCAP | | | | |
| FOREST PHARMS | 325MG;50MG | A088889 | 001 | Jan 16, 1986 |
| BUCET | | | | |
| MALLINCKRODT | 650MG;50MG | A088991 | 001 | Jun 28, 1985 |
| PHRENILIN FORTE | | | | |
| VALEANT | 650MG;50MG | A088831 | 001 | Jun 19, 1985 |
| TENCON | | | | |
| MALLINCKRODT | 650MG;50MG | A089405 | 001 | May 15, 1990 |
| TRIAPRIN | | | | |
| DUNHALL | 325MG;50MG | A089268 | 001 | Jul 02, 1987 |
| TABLET;ORAL | | | | |
| BUTALBITAL AND ACETAMINOPHEN | | | | |
| HALSEY | 325MG;50MG | A089568 | 001 | Oct 05, 1988 |
| WATSON LABS | 325MG;50MG | A087550 | 001 | Oct 19, 1984 |
| BUTAPAP | | | | |
| MIKART | 650MG;50MG | A089988 | 001 | Oct 26, 1992 |
| PHRENILIN | | | | |
| VALEANT | 325MG;50MG ** | A087811 | 001 | Jun 19, 1985 |
| SEDAPAP | | | | |
| MAYRAND | 650MG;50MG | A088944 | 001 | Oct 17, 1985 |

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

| | | | | |
|---|---|---|---|---|
| CAPSULE;ORAL | | | | |
| ANOQUAN | | | | |
| | SHIRE | 325MG;50MG;40MG | A087628 001 | Oct 01, 1986 |
| BUTALBITAL, ACETAMINOPHEN AND CAFFEINE | | | | |
| | GRAHAM DM | 325MG;50MG;40MG | A088743 001 | Jul 18, 1985 |
| | | 325MG;50MG;40MG | A088765 001 | Mar 27, 1985 |
| | | 325MG;50MG;40MG | A089067 001 | Apr 19, 1985 |
| | HIKMA PHARMS | 500MG;50MG;40MG | A040261 001 | Oct 28, 1998 |
| | MALLINCKRODT | 325MG;50MG;40MG | A088758 001 | Mar 27, 1985 |
| BUTALIBITAL, ACETAMINOPHEN AND CAFFEINE | | | | |
| | GILBERT LABS | 325MG;50MG;40MG ** | A088825 001 | Dec 05, 1984 |
| ESGIC-PLUS | | | | |
| | MIKART | 500MG;50MG;40MG | A040085 001 | Mar 28, 1996 |
| FEMCET | | | | |
| | MALLINCKRODT | 325MG;50MG;40MG | A089102 001 | Jun 19, 1985 |
| MEDIGESIC PLUS | | | | |
| | US CHEM | 325MG;50MG;40MG | A089115 001 | Jan 14, 1986 |
| TRIAD | | | | |
| | MALLINCKRODT | 325MG;50MG;40MG | A089023 001 | Jun 19, 1985 |
| TABLET;ORAL | | | | |
| BUTALBITAL, ACETAMINOPHEN AND CAFFEINE | | | | |
| | ABLE | 325MG;50MG;40MG | A040390 001 | Jul 23, 2001 |
| | | 500MG;50MG;40MG | A040394 001 | Jul 23, 2001 |
| | GILBERT LABS | 325MG;50MG;40MG | A087629 001 | Nov 13, 1984 |
| | HIKMA PHARMS | 500MG;50MG;40MG | A040336 001 | Aug 18, 1999 |
| | MIKART | 750MG;50MG;40MG | A040496 001 | Dec 23, 2003 |
| | MIRROR PHARMS LLC | 500MG;50MG;40MG | A040883 001 | Dec 23, 2008 |
| | NOVAST LABS LTD | 325MG;50MG;40MG | A040864 001 | Dec 01, 2008 |
| | SUN PHARM INDUSTRIES | 325MG;50MG;40MG | A040601 001 | Jul 29, 2005 |
| | VINTAGE PHARMS | 500MG;50MG;40MG | A040513 001 | Aug 25, 2003 |
| | WATSON LABS | 325MG;50MG;40MG | A089536 001 | Feb 16, 1988 |
| | | 500MG;50MG;40MG | A040267 001 | Jul 30, 1998 |
| ESGIC | | | | |
| | FOREST PHARMS | 325MG;50MG;40MG | A089660 001 | Dec 23, 1988 |
| ESGIC-PLUS | | | | |
| | MIKART | 500MG;50MG;40MG | A089451 001 | May 23, 1988 |

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

| | | | | |
|---|---|---|---|---|
| CAPSULE;ORAL | | | | |
| BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE | | | | |
| | ABLE | 325MG;50MG;40MG;30MG | A076528 001 | Aug 21, 2003 |
| | HIKMA INTL PHARMS | 325MG;50MG;40MG;30MG | A075618 001 | Mar 23, 2001 |
| PHRENILIN WITH CAFFEINE AND CODEINE | | | | |
| | VALEANT | 325MG;50MG;40MG;30MG | A074911 001 | Aug 22, 2001 |

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

| | | | | |
|---|---|---|---|---|
| CAPSULE;ORAL | | | | |
| ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE | | | | |
| | MIKART | 356.4MG;30MG;16MG | A040109 001 | Aug 26, 1997 |
| | WRASER PHARMS LLC | 356.4MG;30MG;16MG | A040688 001 | Apr 03, 2007 |
| DHC PLUS | | | | |
| | PHARM RES ASSOC | 356.4MG;30MG;16MG | A088584 001 | Mar 04, 1986 |
| SYNALGOS-DC-A | | | | |
| | LEITNER PHARMS | 356.4MG;30MG;16MG | A089166 001 | May 14, 1986 |
| TABLET;ORAL | | | | |
| ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE | | | | |
| | BOCA PHARMA LLC | 712.8MG;60MG;32MG | A040701 001 | Apr 03, 2007 |
| | MIKART | 712.8MG;60MG;32MG | A040316 001 | Apr 28, 1999 |
| | WEST-WARD PHARM CORP | 712.8MG;60MG;32MG | A040637 001 | Sep 22, 2006 |

ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| TAVIST ALLERGY/SINUS/HEADACHE | | | | |
| | NOVARTIS | 500MG;EQ 0.25MG BASE;30MG | N021082 001 | Mar 01, 2001 |

ACETAMINOPHEN; CODEINE PHOSPHATE

| | | | | |
|---|---|---|---|---|
| CAPSULE;ORAL | | | | |
| ACETAMINOPHEN AND CODEINE PHOSPHATE | | | | |
| TEVA | 300MG;15MG | A088537 | 001 | Jun 04, 1984 |
| | 300MG;30MG | A088324 | 001 | Dec 29, 1983 |
| | 300MG;60MG | A088599 | 001 | Jun 01, 1984 |
| PHENAPHEN W/ CODEINE NO. 2 | | | | |
| ROBINS AH | 325MG;15MG | A084444 | 001 | |
| PHENAPHEN W/ CODEINE NO. 3 | | | | |
| ROBINS AH | 325MG;30MG | A084445 | 001 | |
| PHENAPHEN W/ CODEINE NO. 4 | | | | |
| ROBINS AH | 325MG;60MG | A084446 | 001 | |
| PROVAL #3 | | | | |
| SOLVAY | 325MG;30MG | A085685 | 001 | |
| TYLENOL W/ CODEINE NO. 3 | | | | |
| ORTHO MCNEIL PHARM | 300MG;30MG | A087422 | 001 | |
| TYLENOL W/ CODEINE NO. 4 | | | | |
| ORTHO MCNEIL PHARM | 300MG;60MG | A087421 | 001 | |
| SOLUTION;ORAL | | | | |
| ACETAMINOPHEN AND CODEINE PHOSPHATE | | | | |
| ACTAVIS MID ATLANTIC | 120MG/5ML;12MG/5ML | A085861 | 001 | |
| ALLIED PHARMA INC | 120MG/5ML;12MG/5ML | A086366 | 001 | |
| DAVA PHARMS INC | 120MG/5ML;12MG/5ML | A040098 | 001 | Sep 20, 1996 |
| TYLENOL W/ CODEINE | | | | |
| ORTHO MCNEIL PHARM | 120MG/5ML;12MG/5ML | A085057 | 001 | |
| SUSPENSION;ORAL | | | | |
| CAPITAL AND CODEINE | | | | |
| ACTAVIS MID ATLANTIC | 120MG/5ML;12MG/5ML | A085883 | 001 | |
| VALEANT PHARMS LLC | 120MG/5ML;12MG/5ML | A086024 | 001 | |
| TABLET;ORAL | | | | |
| ACETAMINOPHEN AND CODEINE PHOSPHATE | | | | |
| ABLE | 300MG;30MG | A040452 | 001 | Aug 01, 2002 |
| | 300MG;60MG | A040459 | 001 | Aug 01, 2002 |
| AM THERAP | 300MG;15MG | A089478 | 001 | Mar 03, 1987 |
| | 300MG;15MG | A089481 | 001 | Mar 03, 1987 |
| | 300MG;30MG | A089479 | 001 | Mar 03, 1987 |
| | 300MG;30MG | A089482 | 001 | Mar 03, 1987 |
| | 300MG;60MG | A089480 | 001 | Mar 03, 1987 |
| | 300MG;60MG | A089483 | 001 | Mar 03, 1987 |
| ANDA REPOSITORY | 300MG;15MG | A089673 | 002 | Feb 10, 1988 |
| | 300MG;30MG | A089673 | 003 | Feb 10, 1988 |
| | 300MG;60MG | A089673 | 001 | Feb 10, 1988 |
| DURAMED PHARMS BARR | 300MG;15MG | A040223 | 001 | Nov 18, 1997 |
| | 300MG;15MG | A088353 | 001 | Feb 06, 1984 |
| | 300MG;30MG | A040223 | 002 | Nov 18, 1997 |
| | 300MG;30MG | A088354 | 001 | Feb 06, 1984 |
| | 300MG;60MG | A040223 | 003 | Nov 18, 1997 |
| | 300MG;60MG | A088355 | 001 | Feb 06, 1984 |
| EVERYLIFE | 325MG;30MG | A085217 | 001 | |
| HALSEY | 300MG;15MG | A083871 | 001 | |
| | 300MG;30MG | A083872 | 001 | |
| | 300MG;60MG | A086549 | 001 | |
| KV PHARM | 300MG;30MG | A085288 | 001 | |
| | 300MG;60MG | A085365 | 001 | |
| | 325MG;15MG | A085364 | 001 | |
| | 325MG;45MG ** | A085363 | 001 | |
| LEDERLE | 300MG;30MG | A087141 | 001 | |
| MIKART | 300MG;30MG | A089238 | 001 | Feb 25, 1986 |
| | 300MG;60MG | A089244 | 001 | Feb 25, 1986 |
| | 650MG;30MG | A089231 | 001 | Mar 03, 1986 |
| | 650MG;60MG | A089363 | 001 | Sep 09, 1991 |
| MUTUAL PHARM | 300MG;15MG | A085795 | 001 | |
| | 300MG;30MG | A085794 | 001 | |
| | 300MG;60MG | A087653 | 001 | Apr 13, 1982 |
| PURACAP PHARM | 300MG;30MG | A087762 | 001 | Dec 10, 1982 |
| PUREPAC PHARM | 300MG;30MG | A086681 | 001 | |
| | 300MG;30MG | A089080 | 001 | Jul 17, 1986 |
| | 300MG;60MG | A086683 | 001 | |
| ROXANE | 300MG;15MG | A084659 | 001 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

ACETAMINOPHEN; CODEINE PHOSPHATE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| ACETAMINOPHEN AND CODEINE PHOSPHATE | | | | |
| | 300MG;30MG | A084656 | 001 | |
| | 300MG;60MG | A084667 | 001 | |
| | 500MG;15MG | A089511 | 001 | Apr 25, 1989 |
| | 500MG;30MG | A089512 | 001 | Apr 25, 1989 |
| | 500MG;60MG | A089513 | 001 | Apr 25, 1989 |
| SANDOZ | 300MG;15MG | A087433 | 001 | |
| | 300MG;30MG | A081250 | 001 | Jul 16, 1992 |
| | 300MG;30MG | A085291 | 002 | |
| | 300MG;30MG | A085917 | 001 | |
| | 300MG;60MG | A081249 | 001 | Jul 16, 1992 |
| | 300MG;60MG | A085964 | 001 | |
| | 300MG;60MG | A087423 | 001 | |
| SUPERPHARM | 300MG;15MG | A089183 | 001 | Oct 18, 1985 |
| | 300MG;30MG | A089184 | 001 | Oct 18, 1985 |
| | 300MG;30MG | A089253 | 001 | May 19, 1986 |
| | 300MG;60MG | A089185 | 001 | Oct 18, 1985 |
| | 300MG;60MG | A089254 | 001 | May 19, 1986 |
| USL PHARMA | 300MG;30MG | A087919 | 001 | Jun 22, 1982 |
| | 300MG;60MG | A087920 | 001 | Jun 22, 1982 |
| VALEANT PHARM INTL | 300MG;30MG | A085896 | 001 | |
| VITARINE | 300MG;30MG | A085676 | 001 | |
| WARNER CHILCOTT | 300MG;15MG | A085992 | 001 | |
| | 300MG;30MG | A085218 | 002 | |
| | 300MG;60MG | A087306 | 001 | |
| WATSON LABS | 300MG;15MG | A087277 | 001 | May 26, 1982 |
| | 300MG;15MG | A089997 | 001 | Dec 28, 1994 |
| | 300MG;30MG | A087276 | 001 | May 26, 1982 |
| | 300MG;30MG | A089998 | 001 | Dec 28, 1994 |
| | 300MG;60MG | A087275 | 001 | May 26, 1982 |
| | 300MG;60MG | A089999 | 001 | Dec 28, 1994 |
| WATSON LABS FLORIDA | 300MG;15MG | A040443 | 001 | Jan 22, 2003 |
| | 300MG;30MG | A040443 | 002 | Jan 22, 2003 |
| | 300MG;60MG | A040443 | 003 | Jan 22, 2003 |
| WHITEWORTH TOWN PLSN | 300MG;30MG | A084360 | 001 | |
| | 300MG;60MG | A085607 | 001 | |
| CAPITAL AND CODEINE | | | | |
| CARNRICK | 325MG;30MG | A083643 | 001 | |
| CODRIX | | | | |
| WATSON LABS FLORIDA | 500MG;15MG | A040447 | 001 | Feb 26, 2003 |
| | 500MG;30MG | A040441 | 001 | Mar 27, 2003 |
| | 500MG;60MG | A040488 | 001 | Mar 28, 2003 |
| EMPRACET W/ CODEINE PHOSPHATE #3 | | | | |
| GLAXOSMITHKLINE | 300MG;30MG | A083951 | 001 | |
| EMPRACET W/ CODEINE PHOSPHATE #4 | | | | |
| GLAXOSMITHKLINE | 300MG;60MG | A083951 | 002 | |
| PAPA-DEINE #3 | | | | |
| VANGARD | 300MG;30MG | A088037 | 001 | Mar 20, 1984 |
| PAPA-DEINE #4 | | | | |
| VANGARD | 300MG;60MG | A088715 | 001 | Mar 20, 1984 |
| PHENAPHEN-650 W/ CODEINE | | | | |
| ROBINS AH | 650MG;30MG | A085856 | 001 | |
| TYLENOL W/ CODEINE | | | | |
| ORTHO MCNEIL PHARM | 325MG;7.5MG ** | A085056 | 001 | |
| | 325MG;15MG ** | A085056 | 002 | |
| | 325MG;30MG ** | A085056 | 003 | |
| | 325MG;60MG ** | A085056 | 004 | |
| TYLENOL W/ CODEINE NO. 1 | | | | |
| JANSSEN PHARMS | 300MG;7.5MG | A085055 | 001 | |
| TYLENOL W/ CODEINE NO. 2 | | | | |
| JANSSEN PHARMS | 300MG;15MG | A085055 | 002 | |

ACETAMINOPHEN; DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

| | | | | |
|---|---|---|---|---|
| DRIXORAL PLUS | | | | |
| SCHERING PLOUGH | 500MG;3MG;60MG | N019453 | 001 | May 22, 1987 |

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE;ORAL

| | | | | |
|---|---|---|---|---|
| ACETAMINOPHEN AND HYDROCODONE BITARTRATE | | | | |
| CENT PHARMS | 500MG;5MG | A088898 | 001 | Mar 27, 1985 |
| ALLAY | | | | |
| IVAX PHARMS | 500MG;5MG | A089907 | 001 | Jan 13, 1989 |
| BANCAP HC | | | | |
| FOREST PHARMS | 500MG;5MG | A087961 | 001 | Mar 17, 1983 |
| CO-GESIC | | | | |
| CENT PHARMS | 500MG;5MG | A089360 | 001 | Mar 02, 1988 |
| HYDROCODONE BITARTRATE AND ACETAMINOPHEN | | | | |
| MALLINCKRODT | 500MG;5MG | A088956 | 001 | Jul 19, 1985 |
| | 500MG;5MG | A089006 | 001 | Aug 09, 1985 |
| MIKART | 500MG;5MG | A081067 | 001 | Nov 30, 1989 |
| | 500MG;5MG | A081068 | 001 | Nov 30, 1989 |
| | 500MG;5MG | A081069 | 001 | Nov 30, 1989 |
| | 500MG;5MG | A081070 | 001 | Nov 30, 1989 |
| | 500MG;5MG | A089008 | 001 | Feb 21, 1986 |
| LORCET-HD | | | | |
| MALLINCKRODT | 500MG;5MG | A087336 | 001 | Jul 08, 1982 |

SOLUTION;ORAL

| | | | | |
|---|---|---|---|---|
| HYDROCODONE BITARTRATE AND ACETAMINOPHEN | | | | |
| MALLINCKRODT | 500MG/15ML;7.5MG/15ML | A040418 | 001 | Jun 27, 2001 |
| MALLINCKRODT INC | 500MG/15ML;10MG/15ML | A040508 | 001 | Aug 29, 2003 |
| MIKART | 500MG/15ML;5MG/15ML | A081226 | 001 | Oct 27, 1992 |
| | 500MG/15ML;5MG/15ML | A089557 | 001 | Apr 29, 1992 |
| | 500MG/15ML;7.5MG/15ML | A081051 | 001 | Aug 28, 1992 |
| NESHER PHARMS | 500MG/15ML;7.5MG/15ML | A040366 | 001 | Jan 23, 2002 |
| PHARM ASSOC | 500MG/15ML;7.5MG/15ML | A040182 | 001 | Mar 13, 1998 |
| VINTAGE PHARMS | 500MG/15ML;7.5MG/15ML | A040520 | 001 | Oct 30, 2003 |
| ZYFREL | | | | |
| CYPRESS PHARM INC | 325MG/15ML;7.5MG/15ML | A090468 | 001 | Apr 14, 2016 |

TABLET;ORAL

| | | | | |
|---|---|---|---|---|
| ANEXSIA | | | | |
| MALLINCKRODT | 500MG;5MG | A089160 | 001 | Apr 23, 1987 |
| | 750MG;10MG | A040468 | 001 | Oct 31, 2002 |
| ANEXSIA 7.5/650 | | | | |
| MALLINCKRODT | 650MG;7.5MG | A089725 | 001 | Sep 30, 1987 |
| CO-GESIC | | | | |
| UCB INC | 500MG;5MG | A087757 | 001 | May 03, 1982 |
| DURADYNE DHC | | | | |
| FOREST PHARMS | 500MG;5MG | A087809 | 001 | Mar 17, 1983 |
| HY-PHEN | | | | |
| ASCHER | 500MG;5MG | A087677 | 001 | May 03, 1982 |
| HYDROCODONE BITARTRATE AND ACETAMINOPHEN | | | | |
| ABLE | 325MG;5MG | A040478 | 001 | Nov 08, 2002 |
| | 325MG;7.5MG | A040464 | 001 | Oct 23, 2002 |
| | 325MG;10MG | A040464 | 002 | Oct 23, 2002 |
| | 500MG;5MG | A040477 | 001 | Nov 06, 2002 |
| | 500MG;7.5MG | A040490 | 001 | May 21, 2003 |
| | 500MG;10MG | A040473 | 001 | Nov 06, 2002 |
| | 650MG;7.5MG | A040474 | 001 | Jan 02, 2003 |
| | 650MG;10MG | A040476 | 001 | Oct 23, 2002 |
| | 750MG;7.5MG | A040469 | 001 | Oct 25, 2002 |
| AMNEAL PHARMS NY | 500MG;5MG | A040729 | 001 | Aug 25, 2006 |
| | 500MG;7.5MG | A040748 | 001 | Aug 25, 2006 |
| | 500MG;10MG | A040813 | 001 | Feb 23, 2007 |
| | 650MG;7.5MG | A040754 | 001 | Aug 25, 2006 |
| | 650MG;10MG | A040757 | 001 | Aug 25, 2006 |
| | 750MG;7.5MG | A040769 | 001 | Aug 28, 2006 |
| APIL | 500MG;10MG | A040148 | 002 | Feb 14, 1997 |
| BARR | 500MG;2.5MG | A040307 | 001 | Jul 26, 2000 |
| | 500MG;5MG | A040308 | 001 | Jul 26, 2000 |
| | 500MG;5MG | A088577 | 001 | Dec 21, 1984 |
| | 500MG;7.5MG | A040307 | 002 | Jul 26, 2000 |

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

| | | | | |
|---|---|---|---|---|
| | 500MG;10MG | A040309 | 001 | Jul 26, 2000 |
| | 650MG;7.5MG | A040307 | 003 | Jul 26, 2000 |
| | 650MG;10MG | A040307 | 004 | Jul 26, 2000 |
| | 750MG;7.5MG | A040308 | 002 | Jul 26, 2000 |
| CARACO | 500MG;5MG | A090265 | 001 | Dec 23, 2008 |
| | 500MG;7.5MG | A090265 | 002 | Dec 23, 2008 |
| | 500MG;10MG | A090265 | 003 | Dec 23, 2008 |
| | 650MG;7.5MG | A090380 | 001 | Dec 23, 2008 |
| | 650MG;10MG | A090380 | 002 | Dec 23, 2008 |
| | 660MG;10MG | A090380 | 003 | Dec 23, 2008 |
| | 750MG;7.5MG | A090380 | 004 | Dec 23, 2008 |
| HALSEY | 500MG;5MG | A089554 | 001 | Jun 12, 1987 |
| IVAX PHARMS | 500MG;5MG | A089696 | 001 | Apr 21, 1988 |
| MALLINCKRODT | 500MG;5MG | A040084 | 002 | Jun 01, 1995 |
| | 500MG;7.5MG | A040201 | 001 | Feb 27, 1998 |
| | 500MG;10MG | A040201 | 002 | Feb 27, 1998 |
| | 650MG;10MG | A040084 | 004 | Oct 16, 1996 |
| | 660MG;10MG | A040084 | 003 | Jul 29, 1996 |
| | 750MG;7.5MG | A040084 | 001 | Jun 01, 1995 |
| MIKART | 500MG;2.5MG | A089698 | 001 | Aug 25, 1989 |
| | 500MG;5MG | A089271 | 001 | Jul 16, 1986 |
| | 500MG;5MG | A089697 | 001 | Jan 28, 1992 |
| | 500MG;7.5MG | A089699 | 001 | Aug 25, 1989 |
| | 650MG;5MG | A040849 | 001 | Jun 09, 2010 |
| | 650MG;7.5MG | A089689 | 001 | Jun 29, 1988 |
| | 650MG;10MG | A081223 | 001 | May 29, 1992 |
| MUTUAL PHARM | 500MG;5MG | A040236 | 001 | Sep 25, 1997 |
| | 650MG;7.5MG | A040240 | 002 | Nov 26, 1997 |
| | 650MG;10MG | A040240 | 001 | Nov 26, 1997 |
| | 750MG;7.5MG | A040236 | 002 | Sep 25, 1997 |
| RANBAXY | 500MG;5MG | A040825 | 001 | Aug 16, 2007 |
| | 500MG;10MG | A040824 | 001 | Aug 16, 2007 |
| RANBAXY LABS LTD | 750MG;7.5MG | A040822 | 001 | Aug 16, 2007 |
| SANDOZ | 500MG;5MG | A040149 | 001 | Jan 27, 1997 |
| | 750MG;7.5MG | A040149 | 002 | Jan 27, 1997 |
| SUN PHARM INDS LTD | 325MG;10MG | A040826 | 001 | Aug 16, 2007 |
| UCB INC | 500MG;10MG | A040210 | 001 | Aug 13, 1997 |
| | 650MG;7.5MG | A040134 | 001 | Nov 21, 1996 |
| USL PHARMA | 500MG;5MG | A089290 | 001 | May 29, 1987 |
| | 500MG;5MG | A089291 | 001 | May 29, 1987 |
| VINTAGE PHARMS | 500MG;2.5MG | A040144 | 002 | Apr 25, 1997 |
| | 500MG;5MG | A089831 | 001 | Sep 07, 1988 |
| | 500MG;5MG | A089971 | 001 | Dec 02, 1988 |
| | 500MG;7.5MG | A040144 | 001 | Feb 22, 1996 |
| | 500MG;10MG | A040356 | 001 | May 31, 2000 |
| | 650MG;7.5MG | A040155 | 001 | Apr 14, 1997 |
| | 650MG;10MG | A040143 | 001 | Feb 22, 1996 |
| | 660MG;10MG | A040358 | 001 | May 31, 2000 |
| | 750MG;7.5MG | A040157 | 001 | Apr 12, 1996 |
| VINTAGE PHARMS LLC | 500MG;5MG | A040281 | 001 | Sep 30, 1998 |
| | 500MG;7.5MG | A040280 | 001 | Sep 30, 1998 |
| | 650MG;7.5MG | A040280 | 002 | Sep 30, 1998 |
| | 650MG;10MG | A040280 | 003 | Sep 30, 1998 |
| | 750MG;7.5MG | A040281 | 002 | Sep 30, 1998 |
| WATSON LABS | 325MG;7.5MG | A040248 | 001 | Apr 28, 2000 |
| | 325MG;10MG | A040248 | 002 | Apr 28, 2000 |
| | 500MG;2.5MG | A040123 | 003 | Mar 04, 1996 |
| | 500MG;2.5MG | A081079 | 001 | Aug 30, 1991 |
| | 500MG;5MG | A040122 | 001 | Mar 04, 1996 |
| | 500MG;5MG | A089883 | 001 | Dec 01, 1988 |
| | 500MG;7.5MG | A040123 | 004 | Mar 04, 1996 |
| | 500MG;7.5MG | A081080 | 001 | Aug 30, 1991 |
| | 650MG;7.5MG | A040094 | 001 | Sep 29, 1995 |
| | 650MG;7.5MG | A040123 | 001 | Mar 04, 1996 |
| | 650MG;10MG | A040094 | 002 | Sep 29, 1995 |
| | 650MG;10MG | A040123 | 002 | Mar 04, 1996 |

| | | | | | |
|---|---|---|---|---|---|
| ACETAMINOPHEN; HYDROCODONE BITARTRATE | | | | | |
| TABLET;ORAL | | | | | |
| HYDROCODONE BITARTRATE AND ACETAMINOPHEN | | | | | |
| | | 660MG;10MG | A040094 | 003 | Aug 08, 2000 |
| | | 750MG;7.5MG | A040122 | 002 | Mar 04, 1996 |
| | | 750MG;7.5MG | A081083 | 001 | Aug 30, 1991 |
| | | 750MG;10MG | A040094 | 004 | Mar 22, 1999 |
| | WATSON LABS FLORIDA | 500MG;5MG | A040493 | 001 | May 28, 2003 |
| | | 660MG;10MG | A040495 | 001 | May 28, 2003 |
| | | 750MG;7.5MG | A040494 | 001 | May 28, 2003 |
| LORTAB | | | | | |
| | UCB INC | 500MG;5MG | A087722 | 001 | Jul 09, 1982 |
| | | 500MG;10MG | A040100 | 001 | Jan 26, 1996 |
| NORCET | | | | | |
| | ABANA | 500MG;5MG | A088871 | 001 | May 15, 1986 |
| TYCOLET | | | | | |
| | ORTHO MCNEIL PHARM | 500MG;5MG | A089385 | 001 | Aug 27, 1986 |
| VICODIN | | | | | |
| | ABBOTT | 500MG;5MG | A085667 | 001 | |
| | ABBVIE | 500MG;5MG | A088058 | 001 | Jan 07, 1983 |
| VICODIN ES | | | | | |
| | ABBVIE | 750MG;7.5MG | A089736 | 001 | Dec 09, 1988 |
| VICODIN HP | | | | | |
| | ABBVIE | 660MG;10MG | A040117 | 001 | Sep 23, 1996 |
| ZYDONE | | | | | |
| | VINTAGE PHARMS LLC | 400MG;5MG | A040288 | 001 | Nov 27, 1998 |
| | | 400MG;7.5MG | A040288 | 002 | Nov 27, 1998 |
| | | 400MG;10MG | A040288 | 003 | Nov 27, 1998 |
| ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE | | | | | |
| CAPSULE;ORAL | | | | | |
| OXYCODONE AND ACETAMINOPHEN | | | | | |
| | ACTAVIS ELIZABETH | 500MG;5MG | A040199 | 001 | Dec 30, 1998 |
| | BARR | 500MG;5MG | A040304 | 001 | Oct 02, 2000 |
| | DURAMED PHARMS BARR | 500MG;5MG | A040289 | 001 | Mar 16, 1999 |
| | HALSEY | 500MG;5MG | A089994 | 001 | May 04, 1989 |
| | MALLINCKRODT | 500MG;5MG | A040257 | 001 | Aug 04, 1998 |
| | MUTUAL PHARM | 500MG;5MG | A040219 | 001 | Jan 22, 1998 |
| | VINTAGE PHARMS | 500MG;5MG | A040106 | 001 | Jul 30, 1996 |
| | VINTAGE PHARMS LLC | 500MG;5MG | A040303 | 001 | Dec 30, 1999 |
| | WATSON LABS | 500MG;5MG | A040234 | 001 | Oct 30, 1997 |
| ROXILOX | | | | | |
| | ROXANE | 500MG;5MG | A040061 | 001 | Jul 03, 1995 |
| TYLOX | | | | | |
| | JANSSEN PHARMS | 500MG;5MG | A088790 | 001 | Dec 12, 1984 |
| TYLOX-325 | | | | | |
| | ORTHO MCNEIL PHARM | 325MG;5MG | A088246 | 001 | Nov 08, 1984 |
| SOLUTION;ORAL | | | | | |
| ROXICET | | | | | |
| | WEST-WARD PHARMS INT | 325MG/5ML;5MG/5ML | A089351 | 001 | Dec 03, 1986 |
| TABLET;ORAL | | | | | |
| OXYCODONE 2.5/APAP 500 | | | | | |
| | BRISTOL MYERS SQUIBB | 500MG;2.5MG | A085910 | 001 | |
| OXYCODONE 5/APAP 500 | | | | | |
| | BRISTOL MYERS SQUIBB | 500MG;5MG | A085911 | 001 | |
| OXYCODONE AND ACETAMINOPHEN | | | | | |
| | ACTAVIS ELIZABETH | 325MG;5MG | A040203 | 001 | Mar 15, 1999 |
| | | 325MG;7.5MG | A040800 | 001 | Apr 03, 2012 |
| | | 325MG;10MG | A040800 | 002 | Apr 03, 2012 |
| | AMNEAL PHARMS NY | 500MG;7.5MG | A040789 | 001 | Nov 27, 2007 |
| | | 650MG;10MG | A040789 | 002 | Nov 27, 2007 |
| | BARR | 325MG;5MG | A087406 | 001 | |
| | DURAMED PHARMS BARR | 325MG;5MG | A040272 | 001 | Jun 30, 1998 |
| | MALLINCKRODT | 500MG;7.5MG | A040550 | 001 | Jun 30, 2004 |
| | | 650MG;10MG | A040550 | 002 | Jun 30, 2004 |
| | MAYNE PHARMA INC | 500MG;7.5MG | A090177 | 005 | Oct 20, 2008 |
| | | 650MG;10MG | A090177 | 006 | Oct 20, 2008 |
| | MIKART | 400MG;2.5MG | A040679 | 001 | May 16, 2006 |
| | | 400MG;5MG | A040687 | 001 | Apr 27, 2006 |
| | | 400MG;7.5MG | A040698 | 001 | Apr 27, 2006 |

| | | | | |
|---|---|---|---|---|
| ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| OXYCODONE AND ACETAMINOPHEN | | | | |
| | 400MG;10MG | A040692 | 001 | Apr 27, 2006 |
| | 500MG;10MG | A040676 | 001 | Apr 19, 2006 |
| WATSON LABS | 500MG;7.5MG | A040371 | 001 | Dec 29, 2000 |
| | 650MG;10MG | A040371 | 002 | Dec 29, 2000 |
| PERCOCET | | | | |
| VINTAGE PHARMS LLC | 325MG;5MG | A085106 | 002 | |
| | 500MG;7.5MG | A040341 | 001 | Jul 26, 1999 |
| | 650MG;10MG | A040341 | 002 | Jul 26, 1999 |
| ROXICET 5/500 | | | | |
| ROXANE | 500MG;5MG | A089775 | 001 | Jan 12, 1989 |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| XARTEMIS XR | | | | |
| + MALLINCKRODT INC | 325MG;7.5MG | N204031 | 001 | Mar 11, 2014 |
| ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE | | | | |
| CAPSULE;ORAL | | | | |
| TYLOX | | | | |
| ORTHO MCNEIL PHARM | 500MG;4.5MG;0.38MG | A085375 | 001 | |
| ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE | | | | |
| GAVIS PHARMS | 650MG;EQ 25MG BASE | A076202 | 001 | Aug 02, 2002 |
| WATSON LABS | 650MG;EQ 25MG BASE | A074699 | 001 | Mar 24, 2000 |
| TALACEN | | | | |
| SANOFI AVENTIS US | 650MG;EQ 25MG BASE | N018458 | 001 | Sep 23, 1982 |
| ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| DARVOCET | | | | |
| AAIPHARMA LLC | 325MG;32.5MG | N016844 | 001 | |
| DOLENE AP-65 | | | | |
| LEDERLE | 650MG;65MG | A085100 | 001 | |
| PROPOXYPHENE HYDROCHLORIDE AND ACETAMINOPHEN | | | | |
| MYLAN | 325MG;32MG | A083689 | 001 | |
| | 650MG;65MG | A083978 | 001 | |
| SANDOZ | 650MG;65MG | A089959 | 001 | Jul 18, 1989 |
| VINTAGE PHARMS | 650MG;65MG | A040507 | 001 | Jul 30, 2003 |
| WATSON LABS | 650MG;65MG | A040139 | 001 | Dec 16, 1996 |
| WYGESIC | | | | |
| CARACO | 650MG;65MG | A084999 | 001 | |
| ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE | | | | |
| TABLET;ORAL | | | | |
| DARVOCET A500 | | | | |
| XANODYNE PHARM | 500MG;100MG | A076429 | 001 | Sep 10, 2003 |
| DARVOCET-N 100 | | | | |
| XANODYNE PHARM | 650MG;100MG | N017122 | 002 | |
| DARVOCET-N 50 | | | | |
| XANODYNE PHARM | 325MG;50MG | N017122 | 001 | |
| PROPACET 100 | | | | |
| TEVA | 650MG;100MG | A070107 | 001 | Jun 12, 1985 |
| PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN | | | | |
| ABLE | 650MG;100MG | A075838 | 001 | Jul 11, 2001 |
| ACTAVIS ELIZABETH | 650MG;100MG | A070910 | 001 | Jan 02, 1987 |
| CORNERSTONE | 325MG;100MG | A076743 | 001 | May 07, 2004 |
| | 500MG;100MG | A076750 | 001 | Jun 28, 2004 |
| HALSEY | 325MG;50MG | A072105 | 001 | May 13, 1988 |
| | 650MG;100MG | A072106 | 001 | May 13, 1988 |
| IVAX SUB TEVA PHARMS | 650MG;100MG | A070146 | 001 | Aug 02, 1985 |
| MALLINCKRODT | 650MG;100MG | A075738 | 001 | Feb 02, 2001 |
| MIRROR PHARMS | 650MG;100MG | A077821 | 001 | Feb 11, 2008 |
| MUTUAL PHARM | 325MG;50MG | A070115 | 001 | Jun 12, 1985 |
| | 650MG;100MG | A070116 | 001 | Jun 12, 1985 |
| | 650MG;100MG | A070615 | 001 | Mar 21, 1986 |
| | 650MG;100MG | A070771 | 001 | Mar 21, 1986 |
| | 650MG;100MG | A070775 | 001 | Mar 21, 1986 |
| MYLAN | 650MG;100MG | A072195 | 001 | Feb 16, 1988 |

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN | | | | |
| MYLAN PHARMS INC | 650MG;100MG | A070145 | 001 | Jun 12, 1985 |
| SANDOZ | 650MG;100MG | A070443 | 001 | Jan 23, 1986 |
| SUPERPHARM | 650MG;100MG | A071319 | 001 | Jan 06, 1987 |
| TEVA | 650MG;100MG | A070732 | 001 | Jan 03, 1986 |
| | 650MG;100MG | A074119 | 001 | Dec 19, 1994 |
| VINTAGE PHARMS | 325MG;50MG | A074843 | 002 | Feb 15, 2001 |
| | 650MG;100MG | A074843 | 001 | Feb 12, 1997 |
| WATSON LABS | 325MG;50MG | A070398 | 001 | Dec 18, 1986 |
| | 650MG;100MG | A070399 | 001 | Dec 18, 1986 |
| WATSON LABS FLORIDA | 500MG;100MG | A077196 | 001 | Jun 28, 2005 |
| | 650MG;100MG | A076609 | 001 | Nov 16, 2004 |
| WOCKHARDT LTD | 325MG;50MG | A077677 | 001 | Mar 16, 2007 |
| | 650MG;100MG | A077677 | 002 | Mar 16, 2007 |

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN | | | | |
| CSPC OUYI PHARM CO | 325MG;37.5MG | A076914 | 001 | Jul 26, 2006 |

ACETAZOLAMIDE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| ACETAZOLAMIDE | | | | |
| ALRA | 250MG | A083320 | 001 | |
| ASCOT | 250MG | A087686 | 001 | Oct 20, 1982 |
| SUN PHARM INDUSTRIES | 250MG | A089753 | 001 | Jun 22, 1988 |
| VANGARD | 250MG | A087654 | 001 | Feb 05, 1982 |
| WATSON LABS | 250MG | A084498 | 002 | |
| | 250MG | A088882 | 001 | Oct 22, 1985 |
| DIAMOX | | | | |
| + TEVA BRANDED PHARM | 125MG ** | N008943 | 001 | |
| + | 250MG ** | N008943 | 002 | |

ACETAZOLAMIDE SODIUM

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| ACETAZOLAMIDE SODIUM | | | | |
| HOSPIRA | EQ 500MG BASE/VIAL | A040108 | 001 | Oct 30, 1995 |
| DIAMOX | | | | |
| + TEVA WOMENS | EQ 500MG BASE/VIAL ** | N009388 | 001 | Dec 05, 1990 |

ACETIC ACID, GLACIAL

| | | | | |
|---|---|---|---|---|
| SOLUTION/DROPS;OTIC | | | | |
| ACETASOL | | | | |
| ACTAVIS MID ATLANTIC | 2% | A087146 | 001 | |
| ACETIC ACID | | | | |
| KV PHARM | 2% | A085493 | 001 | |
| ORLEX | | | | |
| WARNER CHILCOTT | 2% | A086845 | 001 | |

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

| | | | | |
|---|---|---|---|---|
| SOLUTION/DROPS;OTIC | | | | |
| ACETIC ACID 2% IN AQUEOUS ALUMINUM ACETATE | | | | |
| BAUSCH AND LOMB | 2%;0.79% | A040063 | 001 | Feb 25, 1994 |
| BOROFAIR | | | | |
| PHARMAFAIR | 2%;0.79% | A088606 | 001 | Aug 21, 1985 |
| DOMEBORO | | | | |
| BAYER PHARMS | 2%;0.79% | A084476 | 001 | |

ACETIC ACID, GLACIAL; DESONIDE

| | | | | |
|---|---|---|---|---|
| SOLUTION/DROPS;OTIC | | | | |
| TRIDESILON | | | | |
| BAYER PHARMS | 2%;0.05% | N017914 | 001 | |

ACETIC ACID, GLACIAL; HYDROCORTISONE

| | | | | |
|---|---|---|---|---|
| SOLUTION/DROPS;OTIC | | | | |
| ACETIC ACID W/ HYDROCORTISONE | | | | |
| KV PHARM | 2%;1% | A085492 | 001 | |
| HYDROCORTISONE AND ACETIC ACID | | | | |
| BAUSCH AND LOMB | 2%;1% | A040097 | 001 | Oct 31, 1994 |
| WOCKHARDT | 2%;1% | A040168 | 001 | Aug 30, 1996 |

ACETIC ACID, GLACIAL; HYDROCORTISONE

| | | | | |
|---|---|---|---|---|
| SOLUTION/DROPS;OTIC | | | | |
| ORLEX HC | | | | |
| | WARNER CHILCOTT | 2%;1% | A086844 001 | |

ACETIC ACID, GLACIAL; HYDROCORTISONE; NEOMYCIN SULFATE

| | | | | |
|---|---|---|---|---|
| SUSPENSION/DROPS;OTIC | | | | |
| NEO-CORT-DOME | | | | |
| | BAYER PHARMS | 2%;1%;EQ 0.35% BASE | N050238 001 | |

ACETOHEXAMIDE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| ACETOHEXAMIDE | | | | |
| | ANI PHARMS INC | 250MG | A070869 001 | Feb 09, 1987 |
| | | 500MG | A070870 001 | Feb 09, 1987 |
| | USL PHARMA | 250MG | A070753 001 | Nov 03, 1986 |
| | | 500MG | A070754 001 | Nov 03, 1986 |
| | WATSON LABS TEVA | 250MG | A071893 001 | Nov 25, 1987 |
| | | 500MG | A071894 001 | Nov 25, 1987 |
| DYMELOR | | | | |
| | LILLY | 250MG | N013378 002 | |
| | | 500MG | N013378 001 | |

ACETOPHENAZINE MALEATE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| TINDAL | | | | |
| | SCHERING | 20MG | N012254 002 | |

ACETRIZOATE SODIUM

| | | | | |
|---|---|---|---|---|
| SOLUTION;INTRAUTERINE | | | | |
| SALPIX | | | | |
| | ORTHO MCNEIL PHARM | 53% | N009008 001 | |

ACETYLCHOLINE CHLORIDE

| | | | | |
|---|---|---|---|---|
| FOR SOLUTION;OPHTHALMIC | | | | |
| MIOCHOL | | | | |
| | NOVARTIS | 20MG/VIAL | N016211 001 | |

ACETYLCYSTEINE

| | | | | |
|---|---|---|---|---|
| SOLUTION;INHALATION, ORAL | | | | |
| ACETYLCYSTEINE | | | | |
| | HOSPIRA | 10% | A071364 001 | May 01, 1989 |
| | | 20% | A071365 001 | May 01, 1989 |
| | ROXANE | 10% | A072323 001 | Apr 30, 1992 |
| | | 10% | A072621 001 | Sep 30, 1992 |
| | | 20% | A072324 001 | Apr 30, 1992 |
| | | 20% | A072622 001 | Sep 30, 1992 |
| MUCOMYST | | | | |
| + | APOTHECON | 10% ** | N013601 002 | |
| + | | 20% ** | N013601 001 | |
| MUCOSIL-10 | | | | |
| | DEY | 10% | A070575 001 | Oct 14, 1986 |
| MUCOSIL-20 | | | | |
| | DEY | 20% | A070576 001 | Oct 14, 1986 |

ACETYLCYSTEINE; ISOPROTERENOL HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| SOLUTION;INHALATION | | | | |
| MUCOMYST W/ ISOPROTERENOL | | | | |
| | MEAD JOHNSON | 10%;0.05% | N017366 001 | |

ACETYLDIGITOXIN

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| ACYLANID | | | | |
| | NOVARTIS | 0.1MG | N009436 001 | |

ACITRETIN

| | | | | |
|---|---|---|---|---|
| CAPSULE;ORAL | | | | |
| ACITRETIN | | | | |
| | MYLAN PHARMS INC | 17.5MG | A203707 001 | Sep 10, 2015 |
| | | 22.5MG | A203707 002 | Sep 10, 2015 |

ACRISORCIN

CREAM;TOPICAL

AKRINOL

| | | | | |
|---|---|---|---|---|
| SCHERING | 2MG/GM | N012470 | 001 | |

ACYCLOVIR

CAPSULE;ORAL

ACYCLOVIR

| | | | | |
|---|---|---|---|---|
| ACTAVIS ELIZABETH | 200MG | A074906 | 001 | Aug 26, 1997 |
| CHARTWELL MOLECULES | 200MG | A074872 | 001 | Apr 22, 1997 |
| HERITAGE PHARMS INC | 200MG | A074889 | 001 | Oct 31, 1997 |
| IVAX SUB TEVA PHARMS | 200MG | A074674 | 001 | Apr 22, 1997 |
| LEK PHARM | 200MG | A074750 | 001 | Apr 22, 1997 |
| MYLAN | 200MG | A074727 | 001 | Apr 22, 1997 |
| | 200MG | A074977 | 001 | Apr 13, 1998 |
| RANBAXY | 200MG | A074975 | 001 | Sep 30, 1998 |
| ROXANE | 200MG | A074570 | 002 | Apr 22, 1997 |
| TEVA | 200MG | A074828 | 001 | Apr 22, 1997 |
| TEVA PHARMS | 200MG | A074914 | 001 | Nov 26, 1997 |
| WATSON LABS | 200MG | A075101 | 001 | Apr 15, 1998 |

TABLET;ORAL

ACYCLOVIR

| | | | | |
|---|---|---|---|---|
| ACTAVIS ELIZABETH | 400MG | A074870 | 001 | Jun 05, 1997 |
| | 800MG | A074870 | 002 | Jun 05, 1997 |
| CHARTWELL MOLECULES | 400MG | A074834 | 001 | Apr 24, 1997 |
| | 800MG | A074834 | 002 | Apr 24, 1997 |
| IVAX SUB TEVA PHARMS | 400MG | A074836 | 001 | Apr 22, 1997 |
| | 800MG | A074836 | 002 | Apr 22, 1997 |
| LEK PHARM | 400MG | A074658 | 001 | Apr 22, 1997 |
| | 800MG | A074658 | 002 | Apr 22, 1997 |
| MYLAN | 400MG | A074976 | 001 | Apr 13, 1998 |
| | 800MG | A074976 | 002 | Apr 13, 1998 |
| SUN PHARM INDS LTD | 400MG | A074980 | 001 | Sep 30, 1998 |
| | 800MG | A074980 | 002 | Sep 30, 1998 |
| TEVA | 200MG ** | A074556 | 001 | Apr 22, 1997 |
| TEVA PHARMS | 400MG | A075021 | 001 | Mar 18, 1998 |
| | 800MG | A075021 | 002 | Mar 18, 1998 |

ACYCLOVIR SODIUM

INJECTABLE;INJECTION

ACYCLOVIR

| | | | | |
|---|---|---|---|---|
| ABBVIE | EQ 50MG BASE/ML | A075114 | 001 | Jul 26, 1999 |

ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE

| | | | | |
|---|---|---|---|---|
| EUROHLTH INTL SARL | EQ 500MG BASE/VIAL | A074885 | 001 | Dec 19, 1997 |
| | EQ 1GM BASE/VIAL | A074885 | 002 | Dec 19, 1997 |

ACYCLOVIR SODIUM

| | | | | |
|---|---|---|---|---|
| APOTHECON | EQ 500MG BASE/VIAL | A074897 | 001 | Feb 27, 1998 |
| | EQ 1GM BASE/VIAL | A074897 | 002 | Feb 27, 1998 |
| ATHENEX INC | EQ 500MG BASE/VIAL | A074596 | 002 | Apr 22, 1997 |
| | EQ 1GM BASE/VIAL | A074596 | 001 | Apr 22, 1997 |
| EUROHLTH INTL SARL | EQ 500MG BASE/VIAL | A074913 | 001 | Oct 15, 1997 |
| | EQ 1GM BASE/VIAL | A074913 | 002 | Oct 15, 1997 |
| HOSPIRA | EQ 25MG BASE/ML | A074720 | 001 | Apr 22, 1997 |
| | EQ 50MG BASE/ML | A075065 | 001 | Feb 25, 1999 |
| | EQ 500MG BASE/VIAL | A074663 | 001 | Apr 22, 1997 |
| | EQ 500MG BASE/VIAL | A074758 | 001 | Apr 22, 1997 |
| | EQ 1GM BASE/VIAL | A074663 | 002 | Apr 22, 1997 |
| | EQ 1GM BASE/VIAL | A074758 | 002 | Apr 22, 1997 |
| MYLAN LABS LTD | EQ 500MG BASE/VIAL | A203927 | 001 | Mar 29, 2017 |
| | EQ 1GM BASE/VIAL | A203927 | 002 | Mar 29, 2017 |
| TEVA PARENTERAL | EQ 50MG BASE/ML | A075627 | 001 | Mar 28, 2001 |
| | EQ 500MG BASE/VIAL | A074969 | 001 | Aug 26, 1997 |
| | EQ 1GM BASE/VIAL | A074969 | 002 | Aug 26, 1997 |

ZOVIRAX

| | | | | | |
|---|---|---|---|---|---|
| + | GLAXOSMITHKLINE | EQ 250MG BASE/VIAL ** | N018603 | 003 | Aug 30, 1983 |
| + | | EQ 500MG BASE/VIAL ** | N018603 | 001 | Oct 22, 1982 |
| + | | EQ 1GM BASE/VIAL ** | N018603 | 002 | Jun 29, 1989 |

ADAPALENE
SOLUTION;TOPICAL
DIFFERIN
+ GALDERMA LABS LP 0.1% ** N020338 001 May 31, 1996

ADENOSINE
INJECTABLE;INJECTION
ADENOSINE
TEVA PHARMS USA 3MG/ML A076564 001 Jun 16, 2004
3MG/ML A078676 001 Jul 31, 2008
WEST-WARD PHARMS INT 3MG/ML A076501 001 Jun 16, 2004
WOCKHARDT 3MG/ML A090220 001 Jul 20, 2009
SOLUTION;IV (INFUSION)
ADENOSCAN
+ ASTELLAS 60MG/20ML (3MG/ML) ** N020059 001 May 18, 1995
+ 90MG/30ML (3MG/ML) ** N020059 002 May 18, 1995

ALATROFLOXACIN MESYLATE
INJECTABLE;INJECTION
TROVAN PRESERVATIVE FREE
PFIZER EQ 200MG BASE/VIAL N020760 001 Dec 18, 1997
EQ 300MG BASE/VIAL N020760 002 Dec 18, 1997

ALBENDAZOLE
TABLET, CHEWABLE;ORAL
ALBENZA
AMEDRA PHARMS LLC 200MG N207844 001 Jun 11, 2015

ALBUMIN CHROMATED CR-51 SERUM
INJECTABLE;INJECTION
CHROMALBIN
ISO TEX 100uCi/VIAL N017835 001
250uCi/VIAL N017835 002
500uCi/VIAL N017835 003

ALBUMIN IODINATED I-125 SERUM
INJECTABLE;INJECTION
RADIO-IODINATED (I 125) SERUM ALBUMIN (HUMAN)
BAYER PHARMS 2.5uCi/AMP N017846 001
RADIOIODINATED SERUM ALBUMIN (HUMAN) IHSA I 125
MALLINCKRODT 6.67uCi/ML N017844 003
10uCi/ML N017844 001
100uCi/ML N017844 002

ALBUMIN IODINATED I-131 SERUM
INJECTABLE;INJECTION
MEGATOPE
ISO TEX 2mCi/VIAL N017837 003
5uCi/AMP N017837 004
20uCi/AMP N017837 005

ALBUTEROL
AEROSOL, METERED;INHALATION
ALBUTEROL
ARMSTRONG PHARMS 0.09MG/INH A072273 001 Aug 14, 1996
GENPHARM 0.09MG/INH A073045 001 Aug 19, 1997
IVAX SUB TEVA PHARMS 0.09MG/INH A073272 001 Dec 28, 1995
PLIVA 0.09MG/INH A074072 001 Aug 01, 1996
PROVENTIL
SCHERING 0.09MG/INH N017559 001
VENTOLIN
GLAXOSMITHKLINE 0.09MG/INH N018473 001

ALBUTEROL SULFATE
CAPSULE;INHALATION
VENTOLIN ROTACAPS
GLAXOSMITHKLINE EQ 0.2MG BASE N019489 001 May 04, 1988
SOLUTION;INHALATION
ALBUTEROL SULFATE
ACTAVIS MID ATLANTIC EQ 0.083% BASE A073533 001 Sep 26, 1995
APOTEX INC EQ 0.021% BASE A078623 001 Apr 05, 2010
EQ 0.042% BASE A078623 002 Apr 05, 2010
EQ 0.083% BASE A075717 001 Feb 02, 2007

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

ALBUTEROL SULFATE

| | | | | |
|---|---|---|---|---|
| SOLUTION;INHALATION | | | | |
| ALBUTEROL SULFATE | | | | |
| | EQ 0.5% BASE | A076391 | 001 | Apr 01, 2003 |
| BAUSCH AND LOMB | EQ 0.083% BASE | A075358 | 001 | Mar 29, 2000 |
| COPLEY PHARM | EQ 0.083% BASE | A073495 | 001 | May 28, 1993 |
| | EQ 0.5% BASE | A073307 | 001 | Nov 27, 1991 |
| HI TECH PHARMA | EQ 0.083% BASE | A075063 | 001 | Feb 09, 1999 |
| LANDELA PHARM | EQ 0.083% BASE | A077569 | 001 | Apr 04, 2006 |
| MYLAN SPECLT | EQ 0.083% BASE ** | A072652 | 001 | Feb 21, 1992 |
| ROXANE | EQ 0.083% BASE | A075129 | 001 | Feb 13, 2001 |
| TEVA PHARMS | EQ 0.083% BASE | A075343 | 001 | Nov 09, 1999 |
| WATSON LABS INC | EQ 0.083% BASE | A076370 | 001 | Nov 24, 2003 |
| WOCKHARDT EU OPERATN | EQ 0.083% BASE | A075394 | 001 | Nov 22, 1999 |
| PROVENTIL | | | | |
| SCHERING | EQ 0.083% BASE ** | N019243 | 002 | Jan 14, 1987 |
| | EQ 0.5% BASE ** | N019243 | 001 | Jan 14, 1987 |
| VENTOLIN | | | | |
| + GLAXOSMITHKLINE | EQ 0.083% BASE ** | N019773 | 001 | Apr 23, 1992 |
| | EQ 0.5% BASE ** | N019269 | 002 | Jan 16, 1987 |
| SYRUP;ORAL | | | | |
| ALBUTEROL SULFATE | | | | |
| ACTAVIS MID ATLANTIC | EQ 2MG BASE/5ML | A075262 | 001 | Mar 30, 1999 |
| MOVA | EQ 2MG BASE/5ML | A074302 | 001 | Sep 30, 1994 |
| WATSON LABS | EQ 2MG BASE/5ML | A073165 | 001 | Apr 29, 1993 |
| PROVENTIL | | | | |
| + SCHERING | EQ 2MG BASE/5ML ** | N018062 | 001 | Jan 19, 1983 |
| VENTOLIN | | | | |
| GLAXOSMITHKLINE | EQ 2MG BASE/5ML | N019621 | 001 | Jun 10, 1987 |
| TABLET;ORAL | | | | |
| ALBUTEROL SULFATE | | | | |
| AM THERAP | EQ 2MG BASE | A072449 | 001 | Dec 05, 1989 |
| | EQ 4MG BASE | A072450 | 001 | Dec 05, 1989 |
| COPLEY PHARM | EQ 2MG BASE | A072966 | 001 | Nov 22, 1991 |
| | EQ 4MG BASE | A072967 | 001 | Nov 22, 1991 |
| DAVA PHARMS INC | EQ 2MG BASE | A072860 | 002 | Dec 20, 1989 |
| | EQ 4MG BASE | A072860 | 001 | Dec 20, 1989 |
| FOSUN PHARMA | EQ 2MG BASE | A072151 | 001 | Dec 05, 1989 |
| | EQ 4MG BASE | A072152 | 001 | Dec 05, 1989 |
| PLIVA | EQ 2MG BASE | A072316 | 001 | Dec 05, 1989 |
| | EQ 4MG BASE | A072317 | 001 | Dec 05, 1989 |
| TEVA | EQ 2MG BASE | A072619 | 001 | Dec 05, 1989 |
| | EQ 2MG BASE | A072779 | 001 | Jun 25, 1993 |
| | EQ 2MG BASE | A072938 | 001 | Mar 30, 1990 |
| | EQ 4MG BASE | A072620 | 001 | Dec 05, 1989 |
| | EQ 4MG BASE | A072780 | 001 | Jun 25, 1993 |
| | EQ 4MG BASE | A072939 | 001 | Mar 30, 1990 |
| UCB INC | EQ 2MG BASE | A073120 | 001 | Sep 29, 1992 |
| | EQ 4MG BASE | A073121 | 001 | Sep 29, 1992 |
| WARNER CHILCOTT | EQ 2MG BASE | A072817 | 001 | Jan 09, 1990 |
| | EQ 4MG BASE | A072818 | 001 | Jan 09, 1990 |
| WATSON LABS | EQ 2MG BASE | A072629 | 001 | Jan 31, 1991 |
| | EQ 2MG BASE | A072764 | 001 | Aug 28, 1991 |
| | EQ 4MG BASE | A072630 | 001 | Jan 31, 1991 |
| | EQ 4MG BASE | A072765 | 001 | Aug 28, 1991 |
| PROVENTIL | | | | |
| + SCHERING | EQ 2MG BASE ** | N017853 | 001 | May 07, 1982 |
| + | EQ 4MG BASE ** | N017853 | 002 | May 07, 1982 |
| VENTOLIN | | | | |
| GLAXOSMITHKLINE | EQ 2MG BASE | N019112 | 001 | Jul 10, 1986 |
| | EQ 4MG BASE | N019112 | 002 | Jul 10, 1986 |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| PROVENTIL | | | | |
| SCHERING | EQ 4MG BASE | N019383 | 001 | Jul 13, 1987 |
| VOLMAX | | | | |
| MURO | EQ 4MG BASE | N019604 | 002 | Dec 23, 1992 |
| | EQ 8MG BASE | N019604 | 001 | Dec 23, 1992 |

| | | | | |
|---|---|---|---|---|
| ALBUTEROL SULFATE; IPRATROPIUM BROMIDE | | | | |
| AEROSOL, METERED;INHALATION | | | | |
| COMBIVENT | | | | |
| | BOEHRINGER INGELHEIM | EQ 0.09MG BASE/INH;0.018MG/INH | N020291 001 | Oct 24, 1996 |
| SOLUTION;INHALATION | | | | |
| ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE | | | | |
| | APOTEX INC | EQ 0.083% BASE;0.017% | A077117 001 | Dec 31, 2007 |
| | SANDOZ INC | EQ 0.083% BASE;0.017% | A076867 001 | Dec 21, 2006 |
| DUONEB | | | | |
| + | MYLAN SPECIALITY LP | EQ 0.083% BASE;0.017% ** | N020950 001 | Mar 21, 2001 |
| ALCLOMETASONE DIPROPIONATE | | | | |
| CREAM;TOPICAL | | | | |
| ACLOVATE | | | | |
| + | FOUGERA PHARMS | 0.05% ** | N018707 001 | Dec 14, 1982 |
| OINTMENT;TOPICAL | | | | |
| ACLOVATE | | | | |
| + | FOUGERA PHARMS | 0.05% ** | N018702 001 | Dec 14, 1982 |
| ALCOHOL | | | | |
| INJECTABLE;INJECTION | | | | |
| ALCOHOL 5% IN DEXTROSE 5% | | | | |
| | MILES | 5ML/100ML | A083483 001 | |
| ALCOHOL; DEXTROSE | | | | |
| INJECTABLE;INJECTION | | | | |
| ALCOHOL 10% AND DEXTROSE 5% | | | | |
| | B BRAUN | 10ML/100ML;5GM/100ML | N004589 006 | |
| ALCOHOL 5% AND DEXTROSE 5% | | | | |
| | B BRAUN | 5ML/100ML;5GM/100ML | N004589 004 | |
| ALCOHOL 5% IN D5-W | | | | |
| | HOSPIRA | 5ML/100ML;5GM/100ML | A083263 001 | |
| ALCOHOL 5% IN DEXTROSE 5% IN WATER | | | | |
| | BAXTER HLTHCARE | 5ML/100ML;5GM/100ML | A083256 001 | |
| ALENDRONATE SODIUM | | | | |
| SOLUTION;ORAL | | | | |
| FOSAMAX | | | | |
| + | MERCK | EQ 70MG BASE/75ML ** | N021575 001 | Sep 17, 2003 |
| TABLET;ORAL | | | | |
| ALENDRONATE SODIUM | | | | |
| | MYLAN | EQ 35MG BASE | A078638 001 | Aug 04, 2008 |
| | | EQ 70MG BASE | A078638 002 | Aug 04, 2008 |
| | TEVA PHARMS | EQ 35MG BASE | A076184 002 | Aug 04, 2008 |
| | | EQ 70MG BASE | A076184 001 | Feb 06, 2008 |
| | UPSHER-SMITH LABS | EQ 5MG BASE | A075871 001 | Apr 22, 2009 |
| | | EQ 10MG BASE | A075871 002 | Apr 22, 2009 |
| | | EQ 35MG BASE | A075871 004 | Apr 22, 2009 |
| | | EQ 40MG BASE | A075871 003 | Apr 22, 2009 |
| | | EQ 70MG BASE | A075871 005 | Apr 22, 2009 |
| FOSAMAX | | | | |
| + | MERCK AND CO INC | EQ 5MG BASE ** | N020560 003 | Apr 25, 1997 |
| + | | EQ 10MG BASE ** | N020560 001 | Sep 29, 1995 |
| + | | EQ 35MG BASE ** | N020560 004 | Oct 20, 2000 |
| + | | EQ 40MG BASE ** | N020560 002 | Sep 29, 1995 |
| ALFUZOSIN HYDROCHLORIDE | | | | |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| ALFUZOSIN HYDROCHLORIDE | | | | |
| | WOCKHARDT LTD | 10MG | A090221 001 | Aug 10, 2012 |
| ALGLUCERASE | | | | |
| INJECTABLE;INJECTION | | | | |
| CEREDASE | | | | |
| | GENZYME | 10 UNITS/ML | N020057 004 | May 08, 1992 |
| | | 80 UNITS/ML | N020057 003 | Apr 05, 1991 |

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

TABLET;ORAL

TEKAMLO

| | | | | |
|---|---|---|---|---|
| NOVARTIS | EQ 150MG BASE;EQ 5MG BASE | N022545 | 001 | Aug 26, 2010 |
| | EQ 150MG BASE;EQ 10MG BASE | N022545 | 002 | Aug 26, 2010 |
| | EQ 300MG BASE;EQ 5MG BASE | N022545 | 003 | Aug 26, 2010 |
| | EQ 300MG BASE;EQ 10MG BASE | N022545 | 004 | Aug 26, 2010 |

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

AMTURNIDE

| | | | | |
|---|---|---|---|---|
| NOVARTIS | EQ 150MG BASE;EQ 5MG BASE;12.5MG | N200045 | 001 | Dec 21, 2010 |
| | EQ 300MG BASE;EQ 5MG BASE;12.5MG | N200045 | 002 | Dec 21, 2010 |
| | EQ 300MG BASE;EQ 5MG BASE;25MG | N200045 | 003 | Dec 21, 2010 |
| | EQ 300MG BASE;EQ 10MG BASE;12.5MG | N200045 | 004 | Dec 21, 2010 |
| | EQ 300MG BASE;EQ 10MG BASE;25MG | N200045 | 005 | Dec 21, 2010 |

ALISKIREN HEMIFUMARATE; VALSARTAN

TABLET;ORAL

VALTURNA

| | | | | |
|---|---|---|---|---|
| NOVARTIS | EQ 150MG BASE;160MG | N022217 | 001 | Sep 16, 2009 |
| | EQ 300MG BASE;320MG | N022217 | 002 | Sep 16, 2009 |

ALKAVERVIR

TABLET;ORAL

VERILOID

| | | | | |
|---|---|---|---|---|
| 3M | 2MG | N007336 | 002 | |
| | 3MG | N007336 | 003 | |

ALLOPURINOL

TABLET;ORAL

ALLOPURINOL

| | | | | |
|---|---|---|---|---|
| MUTUAL PHARM | 100MG | A070466 | 001 | Dec 24, 1985 |
| | 300MG | A070467 | 001 | Dec 24, 1985 |
| PURACAP PHARM | 100MG | A070150 | 001 | Dec 10, 1985 |
| | 300MG | A070147 | 001 | Dec 10, 1985 |
| PUREPAC PHARM | 100MG | A070579 | 001 | Apr 14, 1986 |
| | 300MG | A070580 | 001 | Apr 14, 1986 |
| SANDOZ | 100MG | A070268 | 001 | Dec 31, 1985 |
| | 300MG | A070269 | 001 | Dec 31, 1985 |
| SUPERPHARM | 100MG | A070950 | 001 | Nov 30, 1988 |
| | 300MG | A070951 | 001 | Nov 30, 1988 |
| WATSON LABS | 100MG | N018241 | 001 | Nov 16, 1984 |
| | 100MG | N018785 | 001 | Sep 28, 1984 |
| | 300MG | N018241 | 002 | Nov 16, 1984 |
| | 300MG | N018785 | 002 | Sep 28, 1984 |

LOPURIN

| | | | | |
|---|---|---|---|---|
| ABBOTT | 100MG | N018297 | 001 | |
| | 300MG | N018297 | 002 | |

ALPRAZOLAM

SOLUTION;ORAL

ALPRAZOLAM

| | | | | |
|---|---|---|---|---|
| ROXANE | 0.5MG/5ML | A074314 | 001 | Oct 31, 1993 |

TABLET;ORAL

ALPRAZOLAM

| | | | | |
|---|---|---|---|---|
| ANI PHARMS INC | 0.25MG | A074085 | 001 | Feb 16, 1994 |
| | 0.5MG | A074085 | 002 | Feb 16, 1994 |
| | 1MG | A074085 | 003 | Feb 16, 1994 |
| | 2MG | A074085 | 004 | Feb 26, 1996 |
| IVAX SUB TEVA PHARMS | 0.25MG | A074294 | 001 | Jul 29, 1994 |
| | 0.5MG | A074294 | 002 | Jul 29, 1994 |
| | 1MG | A074294 | 003 | Jul 29, 1994 |
| | 2MG | A074294 | 004 | Jul 29, 1994 |
| MYLAN PHARMS INC | 0.25MG | A074046 | 001 | Oct 19, 1993 |
| | 0.5MG | A074046 | 002 | Oct 19, 1993 |
| | 1MG | A074046 | 003 | Oct 19, 1993 |
| | 2MG | A074046 | 004 | May 07, 1997 |
| ROXANE | 0.25MG | A074199 | 001 | Oct 19, 1993 |
| | 0.5MG | A074199 | 002 | Oct 19, 1993 |
| | 1MG | A074199 | 003 | Oct 19, 1993 |
| WATSON LABS | 0.25MG | A074456 | 001 | Aug 31, 1995 |

ALPRAZOLAM

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| ALPRAZOLAM | | | | |
| | 0.25MG | A074479 | 001 | Jan 21, 1997 |
| | 0.5MG | A074456 | 002 | Aug 31, 1995 |
| | 0.5MG | A074479 | 002 | Jan 21, 1997 |
| | 1MG | A074456 | 003 | Aug 31, 1995 |
| | 1MG | A074479 | 003 | Jan 21, 1997 |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| ALPRAZOLAM | | | | |
| ACTAVIS LABS FL INC | 0.5MG | A077198 | 001 | May 13, 2010 |
| | 1MG | A077198 | 002 | May 13, 2010 |
| | 2MG | A077198 | 003 | May 13, 2010 |
| | 3MG | A077198 | 004 | May 13, 2010 |
| ANI PHARMS INC | 0.5MG | A077979 | 001 | Feb 28, 2007 |
| | 1MG | A077979 | 002 | Feb 28, 2007 |
| | 2MG | A077979 | 003 | Feb 28, 2007 |
| | 3MG | A077979 | 004 | Feb 28, 2007 |
| IMPAX LABS | 0.5MG | A077968 | 004 | May 24, 2007 |
| | 1MG | A077968 | 003 | May 24, 2007 |
| | 2MG | A077968 | 002 | May 24, 2007 |
| | 3MG | A077968 | 001 | May 24, 2007 |
| IMPAX LABS INC | 0.5MG | A077996 | 001 | Jan 31, 2007 |
| | 1MG | A077996 | 002 | Jan 31, 2007 |
| | 2MG | A077996 | 003 | Jan 31, 2007 |
| | 3MG | A077996 | 004 | Jan 31, 2007 |
| MYLAN | 0.5MG | A077391 | 002 | Jan 26, 2006 |
| | 1MG | A077391 | 003 | Jan 26, 2006 |
| | 2MG | A077391 | 004 | Jan 26, 2006 |
| | 3MG | A077391 | 001 | Jan 26, 2006 |
| SANDOZ INC | 0.5MG | A077777 | 001 | Jun 30, 2006 |
| | 1MG | A077777 | 002 | Jun 30, 2006 |
| | 2MG | A077777 | 003 | Jun 30, 2006 |
| | 3MG | A077777 | 004 | Jun 30, 2006 |
| VINTAGE PHARMS | 0.5MG | A078442 | 001 | Oct 15, 2007 |
| | 1MG | A078442 | 002 | Oct 15, 2007 |
| | 2MG | A078442 | 003 | Oct 15, 2007 |
| | 3MG | A078442 | 004 | Oct 15, 2007 |
| TABLET, ORALLY DISINTEGRATING;ORAL | | | | |
| NIRAVAM | | | | |
| + UCB INC | 0.25MG ** | N021726 | 001 | Jan 19, 2005 |
| + | 0.5MG ** | N021726 | 002 | Jan 19, 2005 |
| + | 1MG ** | N021726 | 003 | Jan 19, 2005 |
| + | 2MG ** | N021726 | 004 | Jan 19, 2005 |

ALPROSTADIL

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| CAVERJECT | | | | |
| PFIZER | 0.005MG/ML | N020755 | 001 | Oct 31, 1997 |
| | 0.01MG/ML | N020755 | 002 | Oct 01, 1997 |
| | 0.02MG/ML | N020755 | 003 | Oct 01, 1997 |
| EDEX | | | | |
| AUXILIUM PHARMS LLC | 0.005MG/VIAL | N020649 | 001 | Jun 12, 1997 |

ALSEROXYLON

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| RAUTENSIN | | | | |
| NOVARTIS | 2MG | N009215 | 001 | |
| RAUWILOID | | | | |
| 3M | 2MG | N008867 | 001 | |

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

| | | | | |
|---|---|---|---|---|
| TABLET, CHEWABLE;ORAL | | | | |
| ALUMINUM HYDROXIDE AND MAGNESIUM TRISILICATE | | | | |
| PENNEX | 80MG;20MG | A089449 | 001 | Nov 27, 1987 |
| FOAMCOAT | | | | |
| GUARDIAN DRUG | 80MG;20MG | A071793 | 001 | Sep 04, 1987 |
| FOAMICON | | | | |
| NOVARTIS | 80MG;20MG | A072687 | 001 | Jun 28, 1989 |

| | | | | |
|---|---|---|---|---|
| AMANTADINE HYDROCHLORIDE | | | | |
| CAPSULE;ORAL | | | | |
| AMANTADINE HYDROCHLORIDE | | | | |
| ACTAVIS ELIZABETH | 100MG | A077659 | 001 | Feb 23, 2006 |
| WATSON LABS | 100MG | A071382 | 001 | Jan 21, 1987 |
| SYMADINE | | | | |
| SOLVAY | 100MG | A071000 | 001 | Sep 04, 1986 |
| SYMMETREL | | | | |
| + ENDO PHARMS | 100MG ** | N016020 | 001 | |
| SYRUP;ORAL | | | | |
| AMANTADINE HYDROCHLORIDE | | | | |
| G AND W LABS INC | 50MG/5ML | A072655 | 001 | Oct 30, 1990 |
| SILARX | 50MG/5ML | A076352 | 001 | Sep 10, 2004 |
| TEVA PHARMS | 50MG/5ML | A073115 | 001 | Aug 23, 1991 |
| VINTAGE | 50MG/5ML | A077992 | 001 | Dec 12, 2006 |
| SYMMETREL | | | | |
| + ENDO PHARMS | 50MG/5ML ** | N016023 | 002 | |
| TABLET;ORAL | | | | |
| SYMMETREL | | | | |
| + ENDO PHARMS | 100MG ** | N018101 | 001 | |
| AMBENONIUM CHLORIDE | | | | |
| TABLET;ORAL | | | | |
| MYTELASE | | | | |
| SANOFI AVENTIS US | 10MG | N010155 | 002 | |
| AMCINONIDE | | | | |
| CREAM;TOPICAL | | | | |
| CYCLOCORT | | | | |
| + ASTELLAS | 0.025% | N018116 | 001 | |
| + | 0.1% | N018116 | 002 | |
| LOTION;TOPICAL | | | | |
| CYCLOCORT | | | | |
| + ASTELLAS | 0.1% | N019729 | 001 | Jun 13, 1988 |
| OINTMENT;TOPICAL | | | | |
| CYCLOCORT | | | | |
| + ASTELLAS | 0.1% | N018498 | 001 | |
| AMDINOCILLIN | | | | |
| INJECTABLE;INJECTION | | | | |
| COACTIN | | | | |
| ROCHE | 250MG/VIAL | N050565 | 001 | Dec 21, 1984 |
| | 500MG/VIAL | N050565 | 002 | Dec 21, 1984 |
| | 1GM/VIAL | N050565 | 003 | Dec 21, 1984 |
| AMIFOSTINE | | | | |
| INJECTABLE;INJECTION | | | | |
| ETHYOL | | | | |
| CLINIGEN HLTHCARE | 375MG/VIAL | N020221 | 002 | Sep 10, 1999 |
| AMIKACIN SULFATE | | | | |
| INJECTABLE;INJECTION | | | | |
| AMIKACIN SULFATE | | | | |
| ABBOTT | EQ 250MG BASE/ML | A063265 | 001 | Nov 30, 1994 |
| | EQ 250MG BASE/ML | A063266 | 001 | Oct 31, 1994 |
| HOSPIRA | EQ 50MG BASE/ML | A063263 | 001 | Nov 30, 1994 |
| | EQ 50MG BASE/ML | A063350 | 001 | Jul 30, 1993 |
| | EQ 62.5MG BASE/ML | A063283 | 001 | Oct 31, 1994 |
| | EQ 250MG BASE/ML | A063264 | 001 | Nov 30, 1994 |
| | EQ 250MG BASE/ML | A063350 | 002 | Jul 30, 1993 |
| | EQ 250MG BASE/ML | A064098 | 001 | Jun 26, 1995 |
| | EQ 250MG BASE/ML | A064099 | 001 | Jun 20, 1995 |
| IGI LABS INC | EQ 50MG BASE/ML | A063167 | 001 | Dec 14, 1995 |
| | EQ 250MG BASE/ML | A063169 | 001 | Dec 14, 1995 |
| TEVA PHARMS USA | EQ 50MG BASE/ML | A064045 | 001 | Sep 28, 1993 |
| WEST-WARD PHARMS INT | EQ 50MG BASE/ML | A063274 | 001 | May 18, 1992 |
| | EQ 250MG BASE/ML | A063275 | 001 | May 18, 1992 |
| AMIKACIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | | | | |
| HOSPIRA | EQ 500MG BASE/100ML | A064146 | 001 | Apr 02, 1997 |
| AMIKIN | | | | |
| APOTHECON | EQ 50MG BASE/ML | A062311 | 001 | |
| | EQ 50MG BASE/ML | A062562 | 001 | Sep 20, 1984 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| AMIKACIN SULFATE | | | | |
| INJECTABLE;INJECTION | | | | |
| AMIKIN | | | | |
| + | EQ 50MG BASE/ML ** | N050495 | 001 | |
| | EQ 250MG BASE/ML | A062311 | 002 | |
| | EQ 250MG BASE/ML | A062562 | 002 | Sep 20, 1984 |
| + | EQ 250MG BASE/ML ** | N050495 | 002 | |
| AMIKIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | | | | |
| APOTHECON | EQ 5MG BASE/ML | N050618 | 002 | Nov 30, 1987 |
| | EQ 10MG BASE/ML | N050618 | 001 | Nov 30, 1987 |
| AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE | | | | |
| TABLET;ORAL | | | | |
| AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE | | | | |
| FOSUN PHARMA | EQ 5MG ANHYDROUS;50MG | A073357 | 001 | Nov 27, 1991 |
| TEVA | EQ 5MG ANHYDROUS;50MG | A070795 | 001 | Apr 17, 1988 |
| WATSON LABS | EQ 5MG ANHYDROUS;50MG | A073334 | 001 | Jul 19, 1991 |
| HYDRO-RIDE | | | | |
| PAR PHARM | EQ 5MG ANHYDROUS;50MG | A070347 | 001 | Dec 25, 1990 |
| MODURETIC 5-50 | | | | |
| + MERCK | EQ 5MG ANHYDROUS;50MG ** | N018201 | 001 | |
| AMINO ACIDS | | | | |
| INJECTABLE;INJECTION | | | | |
| AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE | | | | |
| HOSPIRA | 5.2% (5.2GM/100ML) | N018901 | 001 | Apr 06, 1984 |
| AMINOSYN 3.5% IN PLASTIC CONTAINER | | | | |
| ABBOTT | 3.5% (3.5GM/100ML) | N018804 | 001 | May 15, 1984 |
| | 3.5% (3.5GM/100ML) | N018875 | 001 | Aug 08, 1984 |
| AMINOSYN II 3.5% | | | | |
| ICU MEDICAL INC | 3.5% (3.5GM/100ML) | N019438 | 001 | Apr 03, 1986 |
| AMINOSYN II 3.5% IN PLASTIC CONTAINER | | | | |
| ABBOTT | 3.5% (3.5GM/100ML) | N019491 | 001 | Oct 10, 1986 |
| AMINOSYN II 5% | | | | |
| ICU MEDICAL INC | 5% (5GM/100ML) | N019438 | 002 | Apr 03, 1986 |
| AMINOSYN-HBC 7% IN PLASTIC CONTAINER | | | | |
| ABBOTT | 7% (7GM/100ML) | N019400 | 001 | Jul 23, 1986 |
| BRANCHAMIN 4% | | | | |
| BAXTER HLTHCARE | 4% (4GM/100ML) | N018678 | 001 | Sep 28, 1984 |
| BRANCHAMIN 4% IN PLASTIC CONTAINER | | | | |
| BAXTER HLTHCARE | 4% (4GM/100ML) | N018684 | 001 | Sep 28, 1984 |
| FREAMINE 8.5% | | | | |
| B BRAUN | 8.5% (8.5GM/100ML) | N016822 | 001 | |
| FREAMINE II 8.5% | | | | |
| B BRAUN | 8.5% (8.5GM/100ML) | N016822 | 002 | |
| HEPATASOL 8% | | | | |
| BAXTER HLTHCARE | 8% (8GM/100ML) | A020360 | 001 | Apr 04, 1996 |
| NEOPHAM 6.4% | | | | |
| HOSPIRA | 6.4% (6.4GM/100ML) | N018792 | 001 | Jan 17, 1984 |
| NOVAMINE 11.4% | | | | |
| HOSPIRA INC | 11.4% (11.4GM/100ML) | N017957 | 003 | Aug 09, 1982 |
| NOVAMINE 15% | | | | |
| HOSPIRA INC | 15% (75GM/500ML) | N017957 | 004 | Nov 28, 1986 |
| NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER | | | | |
| BAXTER HLTHCARE | 15% (15GM/100ML) | N020107 | 001 | Feb 05, 1993 |
| NOVAMINE 8.5% | | | | |
| HOSPIRA INC | 8.5% (8.5GM/100ML) | N017957 | 002 | Aug 09, 1982 |
| RENAMIN W/O ELECTROLYTES | | | | |
| BAXTER HLTHCARE | 6.5% (6.5GM/100ML) | N017493 | 007 | Oct 15, 1982 |
| TRAVASOL 10% W/O ELECTROLYTES | | | | |
| BAXTER HLTHCARE | 10% (10GM/100ML) | N017493 | 006 | |
| TRAVASOL 5.5% W/O ELECTROLYTES | | | | |
| BAXTER HLTHCARE | 5.5% (5.5GM/100ML) | N017493 | 004 | |
| TRAVASOL 8.5% W/O ELECTROLYTES | | | | |
| BAXTER HLTHCARE | 8.5% (8.5GM/100ML) | N017493 | 005 | |

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION

AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| ABBOTT | 3.5%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML | N019714 | 001 | Sep 12, 1988 |
| HOSPIRA INC | 3.5%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML | N019683 | 001 | Nov 07, 1988 |

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| ABBOTT | 4.25%;36.8MG/100ML;20GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML | N019714 | 002 | Sep 12, 1988 |
| HOSPIRA INC | 4.25%;36.8MG/100ML;20GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML | N019683 | 002 | Nov 07, 1988 |

AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| ABBOTT | 4.25%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML | N019714 | 004 | Sep 12, 1988 |
| HOSPIRA INC | 4.25%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML | N019683 | 003 | Nov 07, 1988 |

AMINOSYN II 5% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| ABBOTT | 5%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML | N019714 | 003 | Sep 12, 1988 |
| HOSPIRA INC | 5%;36.8MG/100ML;25GM/100ML;51MG/100ML;22.4MG/100ML;261MG/100ML;205MG/100ML | N019683 | 004 | Nov 07, 1988 |

AMINO ACIDS; DEXTROSE

INJECTABLE;INJECTION

AMINOSYN 3.5% W/ DEXTROSE 25% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| ABBOTT | 3.5%;25GM/100ML | N019118 | 001 | Oct 11, 1984 |

AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| ABBOTT | 3.5%;5GM/100ML | N019120 | 001 | Oct 11, 1984 |

AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| ABBOTT | 4.25%;25GM/100ML | N019119 | 001 | Oct 11, 1984 |

AMINOSYN II 3.5% IN DEXTROSE 25% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| ABBOTT | 3.5%;25GM/100ML | N019505 | 002 | Nov 07, 1986 |
| | 3.5%;25GM/100ML | N019713 | 006 | Sep 09, 1988 |
| HOSPIRA | 3.5%;25GM/100ML | N019681 | 001 | Nov 01, 1988 |

AMINOSYN II 3.5% IN DEXTROSE 5% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| ABBOTT | 3.5%;5GM/100ML | N019506 | 001 | Nov 07, 1986 |
| | 3.5%;5GM/100ML | N019713 | 002 | Sep 09, 1988 |
| HOSPIRA | 3.5%;5GM/100ML | N019681 | 002 | Nov 01, 1988 |

AMINOSYN II 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| ABBOTT | 4.25%;10GM/100ML | N019713 | 001 | Sep 09, 1988 |
| HOSPIRA | 4.25%;10GM/100ML | N019681 | 004 | Nov 01, 1988 |

AMINOSYN II 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| ABBOTT | 4.25%;20GM/100ML | N019713 | 004 | Sep 09, 1988 |
| HOSPIRA | 4.25%;20GM/100ML | N019681 | 005 | Nov 01, 1988 |

AMINOSYN II 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| ABBOTT | 4.25%;25GM/100ML | N019504 | 002 | Nov 07, 1986 |
| | 4.25%;25GM/100ML | N019713 | 005 | Sep 09, 1988 |
| HOSPIRA | 4.25%;25GM/100ML | N019681 | 003 | Nov 01, 1988 |

AMINOSYN II 5% IN DEXTROSE 25% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| ABBOTT | 5%;25GM/100ML | N019565 | 001 | Dec 17, 1986 |
| | 5%;25GM/100ML | N019713 | 003 | Sep 09, 1988 |
| HOSPIRA | 5%;25GM/100ML | N019681 | 006 | Nov 01, 1988 |

TRAVASOL 2.75% IN DEXTROSE 10% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| BAXTER HLTHCARE | 2.75%;10GM/100ML | N019520 | 002 | Sep 23, 1988 |

TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| BAXTER HLTHCARE | 2.75%;15GM/100ML | N019520 | 003 | Sep 23, 1988 |

TRAVASOL 2.75% IN DEXTROSE 20% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| BAXTER HLTHCARE | 2.75%;20GM/100ML | N019520 | 004 | Sep 23, 1988 |

TRAVASOL 2.75% IN DEXTROSE 25% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| BAXTER HLTHCARE | 2.75%;25GM/100ML | N019520 | 005 | Sep 23, 1988 |

TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| BAXTER HLTHCARE | 2.75%;5GM/100ML | N019520 | 001 | Sep 23, 1988 |

TRAVASOL 4.25% IN DEXTROSE 10% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| BAXTER HLTHCARE | 4.25%;10GM/100ML | N019520 | 007 | Sep 23, 1988 |

AMINO ACIDS; DEXTROSE

INJECTABLE;INJECTION

| | | | | |
|---|---|---|---|---|
| TRAVASOL 4.25% IN DEXTROSE 15% IN PLASTIC CONTAINER | | | | |
| | BAXTER HLTHCARE | 4.25%;15GM/100ML | N019520 008 | Sep 23, 1988 |
| TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER | | | | |
| | BAXTER HLTHCARE | 4.25%;20GM/100ML | N019520 009 | Sep 23, 1988 |
| TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER | | | | |
| | BAXTER HLTHCARE | 4.25%;25GM/100ML | N019520 010 | Sep 23, 1988 |
| TRAVASOL 4.25% IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| | BAXTER HLTHCARE | 4.25%;5GM/100ML | N019520 006 | Sep 23, 1988 |

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION

| | | | | |
|---|---|---|---|---|
| AMINOSYN II 4.25% W/ ELECT AND ADJUSTED PHOSPHATE IN DEXTROSE 10% IN PLASTIC CONTAINER | | | | |
| | ABBOTT | 4.25%;10GM/100ML;51MG/100ML;176.5MG/100 ML;22.4MG/100ML;104.5MG/100ML;205MG/100 ML | N019712 002 | Sep 08, 1988 |
| | HOSPIRA INC | 4.25%;10GM/100ML;51MG/100ML;176.5MG/100 ML;22.4MG/100ML;104.5MG/100ML;205MG/100 ML | N019682 003 | Nov 01, 1988 |

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE;INJECTION

| | | | | |
|---|---|---|---|---|
| AMINOSYN II 3.5% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER | | | | |
| | ABBOTT | 3.5%;25GM/100ML;51MG/100ML;22.4MG/100ML ;261MG/100ML;205MG/100ML | N019564 002 | Dec 16, 1986 |
| AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER | | | | |
| | ABBOTT | 4.25%;25GM/100ML;51MG/100ML;22.4MG/100M L;261MG/100ML;205MG/100ML | N019564 004 | Dec 16, 1986 |

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

INJECTABLE;INJECTION

| | | | | |
|---|---|---|---|---|
| AMINOSYN II 3.5% M IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| | ABBOTT | 3.5%;5GM/100ML;30MG/100ML;97MG/100ML;12 0MG/100ML;49.3MG/100ML | N019564 001 | Dec 16, 1986 |
| | | 3.5%;5GM/100ML;30MG/100ML;97MG/100ML;12 0MG/100ML;49.3MG/100ML | N019712 001 | Sep 08, 1988 |
| | HOSPIRA INC | 3.5%;5GM/100ML;30MG/100ML;97MG/100ML;12 0MG/100ML;49.3MG/100ML | N019682 001 | Nov 01, 1988 |
| AMINOSYN II 4.25% M IN DEXTROSE 10% IN PLASTIC CONTAINER | | | | |
| | ABBOTT | 4.25%;10GM/100ML;30MG/100ML;97MG/100ML; 120MG/100ML;49.3MG/100ML | N019564 003 | Dec 16, 1986 |
| | HOSPIRA INC | 4.25%;5GM/100ML;30MG/100ML;97MG/100ML;1 20MG/100ML;49.3MG/100ML | N019682 002 | Nov 01, 1988 |

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

| | | | | |
|---|---|---|---|---|
| TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER | | | | |
| | BAXTER HLTHCARE | 2.75%;10GM/100ML;51MG/100ML;261MG/100ML ;216MG/100ML;112MG/100ML | N020147 002 | Oct 23, 1995 |
| TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER | | | | |
| | BAXTER HLTHCARE | 2.75%;15GM/100ML;51MG/100ML;261MG/100ML ;216MG/100ML;112MG/100ML | N020147 003 | Oct 23, 1995 |
| TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER | | | | |
| | BAXTER HLTHCARE | 2.75%;20GM/100ML;51MG/100ML;261MG/100ML ;216MG/100ML;112MG/100ML | N020147 004 | Oct 23, 1995 |
| TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER | | | | |
| | BAXTER HLTHCARE | 2.75%;25GM/100ML;51MG/100ML;261MG/100ML ;216MG/100ML;112MG/100ML | N020147 005 | Oct 23, 1995 |
| TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| | BAXTER HLTHCARE | 2.75%;5GM/100ML;51MG/100ML;261MG/100ML; 216MG/100ML;112MG/100ML | N020147 001 | Oct 23, 1995 |
| TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 10% IN PLASTIC CONTAINER | | | | |
| | BAXTER HLTHCARE | 4.25%;10GM/100ML;51MG/100ML;261MG/100ML ;297MG/100ML;77MG/100ML | N020147 007 | Oct 23, 1995 |
| TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 15% IN PLASTIC CONTAINER | | | | |
| | BAXTER HLTHCARE | 4.25%;15GM/100ML;51MG/100ML;261MG/100ML ;297MG/100ML;77MG/100ML | N020147 008 | Oct 23, 1995 |
| TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER | | | | |
| | BAXTER HLTHCARE | 4.25%;20GM/100ML;51MG/100ML;261MG/100ML ;297MG/100ML;77MG/100ML | N020147 009 | Oct 23, 1995 |

AMINO ACIDS; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER | | | | |
| | BAXTER HLTHCARE | 4.25%;25GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML | N020147 010 | Oct 23, 1995 |
| TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| | BAXTER HLTHCARE | 4.25%;5GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML | N020147 006 | Oct 23, 1995 |

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| AMINOSYN 3.5% M IN PLASTIC CONTAINER | | | | |
| | ABBOTT | 3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML | N018804 002 | May 15, 1984 |
| | | 3.5%;21MG/100ML;40MG/100ML;128MG/100ML;234MG/100ML | N018875 002 | Aug 08, 1984 |

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| AMINOSYN 3.5% M | | | | |
| | ICU MEDICAL INC | 3.5%;21MG/100ML;128MG/100ML;234MG/100ML | N017789 005 | |

AMINO ACIDS; MAGNESIUM ACETATE; POTASSIUM ACETATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| AMINOSYN II 3.5% M IN PLASTIC CONTAINER | | | | |
| | ABBOTT | 3.5%;32MG/100ML;128MG/100ML;222MG/100ML;49MG/100ML | N019493 001 | Oct 16, 1986 |

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM ACETATE; POTASSIUM CHLORIDE; SODIUM ACETATE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| VEINAMINE 8% | | | | |
| | HOSPIRA INC | 8%;61MG/100ML;211MG/100ML;56MG/100ML;38 8MG/100ML | N017957 001 | |

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| AMINOSYN II 7% W/ ELECTROLYTES | | | | |
| | ICU MEDICAL INC | 7%;102MG/100ML;45MG/100ML;522MG/100ML;4 10MG/100ML | N019437 006 | Apr 03, 1986 |

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| AMINOSYN II 3.5% M | | | | |
| | ICU MEDICAL INC | 3.5%;30MG/100ML;97MG/100ML;120MG/100ML;49MG/100ML | N019437 007 | Apr 03, 1986 |

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER | | | | |
| | BAXTER HLTHCARE | 3.5%;51MG/100ML;131MG/100ML;218MG/100ML;35MG/100ML | N020177 001 | Oct 23, 1995 |
| TRAVASOL 3.5% W/ ELECTROLYTES | | | | |
| | BAXTER HLTHCARE | 3.5%;51MG/100ML;131MG/100ML;218MG/100ML;35MG/100ML | N017493 003 | |
| TRAVASOL 5.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER | | | | |
| | BAXTER HLTHCARE | 5.5%;102MG/100ML;522MG/100ML;431MG/100ML;224MG/100ML | N020173 001 | Oct 27, 1995 |
| TRAVASOL 5.5% W/ ELECTROLYTES | | | | |
| | BAXTER HLTHCARE | 5.5%;102MG/100ML;522MG/100ML;431MG/100ML;224MG/100ML | N017493 001 | |
| TRAVASOL 8.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER | | | | |
| | BAXTER HLTHCARE | 8.5%;102MG/100ML;522MG/100ML;594MG/100ML;154MG/100ML | N020173 002 | Oct 27, 1995 |
| TRAVASOL 8.5% W/ ELECTROLYTES | | | | |
| | BAXTER HLTHCARE | 8.5%;102MG/100ML;522MG/100ML;594MG/100ML;154MG/100ML | N017493 002 | |

AMINOCAPROIC ACID

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| AMICAR | | | | |
| + | CLOVER PHARMS | 250MG/ML ** | N015229 002 | |
| AMINOCAPROIC ACID | | | | |
| | ABRAXIS PHARM | 250MG/ML | A070522 001 | Jun 17, 1986 |
| | BAXTER HLTHCARE | 250MG/ML | N018590 001 | Oct 29, 1982 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| AMINOCAPROIC ACID | | | | |
| INJECTABLE;INJECTION | | | | |
| AMINOCAPROIC ACID | | | | |
| HOSPIRA | 250MG/ML | A070888 | 001 | Jun 16, 1988 |
| AMINOGLUTETHIMIDE | | | | |
| TABLET;ORAL | | | | |
| CYTADREN | | | | |
| NOVARTIS | 250MG | N018202 | 001 | |
| AMINOHIPPURATE SODIUM | | | | |
| INJECTABLE;INJECTION | | | | |
| AMINOHIPPURATE SODIUM | | | | |
| MERCK | 20% | N005619 | 001 | |
| AMINOPHYLLINE | | | | |
| ENEMA;RECTAL | | | | |
| SOMOPHYLLIN | | | | |
| FISONS | 300MG/5ML | N018232 | 001 | Apr 02, 1982 |
| INJECTABLE;INJECTION | | | | |
| AMINOPHYLLIN | | | | |
| GD SEARLE LLC | 25MG/ML | A087243 | 001 | May 24, 1982 |
| | 25MG/ML | A087621 | 001 | May 24, 1982 |
| AMINOPHYLLINE | | | | |
| ABRAXIS PHARM | 25MG/ML | A084568 | 001 | |
| | 25MG/ML | A087200 | 001 | |
| | 25MG/ML | A087250 | 001 | Jan 06, 1982 |
| | 25MG/ML | A087886 | 001 | Aug 30, 1983 |
| | 25MG/ML | A088407 | 001 | Jan 25, 1984 |
| ELKINS SINN | 25MG/ML | A087239 | 001 | |
| HOSPIRA | 25MG/ML | A087601 | 001 | Jul 23, 1982 |
| INTL MEDICATION | 25MG/ML | A087209 | 001 | Feb 01, 1982 |
| | 25MG/ML | A087867 | 001 | Nov 10, 1983 |
| | 25MG/ML | A087868 | 001 | Nov 10, 1983 |
| KING PHARMS | 25MG/ML | A086606 | 001 | |
| LUITPOLD | 25MG/ML | A087240 | 001 | |
| LYPHOMED | 25MG/ML | A087431 | 001 | |
| PHARMA SERVE NY | 25MG/ML | A087387 | 001 | Jun 03, 1983 |
| | 25MG/ML | A087392 | 001 | Dec 15, 1983 |
| SMITH AND NEPHEW | 25MG/ML | A088429 | 001 | May 30, 1985 |
| | 25MG/ML | A088749 | 001 | May 30, 1985 |
| TEVA PARENTERAL | 25MG/ML | A081142 | 001 | Sep 25, 1991 |
| AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% | | | | |
| HOSPIRA | 100MG/100ML | A088147 | 002 | May 03, 1983 |
| | 200MG/100ML | A088147 | 003 | May 03, 1983 |
| AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER | | | | |
| HOSPIRA | 100MG/100ML | N018924 | 001 | Dec 12, 1984 |
| | 200MG/100ML | N018924 | 002 | Dec 12, 1984 |
| | 400MG/100ML | N018924 | 003 | Dec 12, 1984 |
| | 500MG/100ML | N018924 | 004 | Dec 12, 1984 |
| SOLUTION;ORAL | | | | |
| AMINOPHYLLINE | | | | |
| MORTON GROVE | 105MG/5ML | A088156 | 001 | Dec 05, 1983 |
| ROXANE | 105MG/5ML | A088126 | 001 | Aug 19, 1983 |
| AMINOPHYLLINE DYE FREE | | | | |
| ACTAVIS MID ATLANTIC | 105MG/5ML | A087727 | 001 | Apr 16, 1982 |
| SOMOPHYLLIN | | | | |
| FISONS | 105MG/5ML | A086466 | 001 | |
| SOMOPHYLLIN-DF | | | | |
| FISONS | 105MG/5ML | A087045 | 001 | |
| SUPPOSITORY;RECTAL | | | | |
| TRUPHYLLINE | | | | |
| G AND W LABS | 250MG | A085498 | 001 | Mar 23, 1983 |
| | 500MG | A085498 | 002 | Jan 03, 1983 |
| TABLET;ORAL | | | | |
| AMINOPHYLLIN | | | | |
| GD SEARLE LLC | 100MG | N002386 | 002 | |
| | 200MG | N002386 | 003 | |
| AMINOPHYLLINE | | | | |
| ASCOT | 100MG | A087522 | 001 | Feb 12, 1982 |
| | 200MG | A087523 | 001 | Feb 12, 1982 |

| | | | | |
|---|---|---|---|---|
| AMINOPHYLLINE | | | | |
| TABLET;ORAL | | | | |
| AMINOPHYLLINE | | | | |
| BARR | 100MG | A088297 | 001 | Aug 19, 1983 |
| | 200MG | A088298 | 001 | Aug 19, 1983 |
| DURAMED PHARMS BARR | 100MG | A088182 | 001 | Mar 31, 1983 |
| | 200MG | A088183 | 001 | Mar 31, 1983 |
| HALSEY | 100MG | A084674 | 001 | |
| HIKMA INTL PHARMS | 100MG | A084540 | 001 | |
| | 200MG | A085003 | 001 | |
| IDT AUSTRALIA LTD | 100MG | A085261 | 003 | |
| | 100MG | A085262 | 002 | |
| | 200MG | A085261 | 002 | |
| IMPAX LABS | 100MG | A084574 | 001 | |
| | 200MG | A084576 | 001 | |
| KV PHARM | 100MG | A085284 | 001 | |
| | 200MG | A085289 | 001 | |
| LANNETT | 100MG | A084588 | 001 | |
| | 200MG | A084588 | 002 | |
| PAL PAK | 100MG | A084533 | 001 | |
| PANRAY | 100MG | A084552 | 001 | |
| | 200MG | A084552 | 002 | |
| PUREPAC PHARM | 100MG | A084699 | 001 | |
| | 200MG | A085333 | 001 | |
| ROXANE | 100MG | A087500 | 001 | Feb 09, 1982 |
| | 200MG | A087501 | 001 | Feb 09, 1982 |
| VALEANT PHARM INTL | 200MG | A084563 | 001 | |
| VANGARD | 100MG | A088314 | 001 | Oct 03, 1983 |
| | 200MG | A088319 | 001 | Oct 03, 1983 |
| VINTAGE PHARMS | 100MG | A085409 | 001 | |
| | 200MG | A085410 | 001 | |
| WATSON LABS | 100MG | A085567 | 001 | |
| | 200MG | A085564 | 001 | |
| TABLET, DELAYED RELEASE;ORAL | | | | |
| AMINOPHYLLINE | | | | |
| IMPAX LABS | 100MG | A084577 | 001 | |
| | 200MG | A084575 | 001 | |
| TABLICAPS | 100MG | A084632 | 002 | |
| VALE | 100MG | A084531 | 001 | |
| | 200MG | A084530 | 001 | |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| PHYLLOCONTIN | | | | |
| PHARM RES ASSOC | 225MG | A086760 | 001 | |
| AMINOSALICYLATE SODIUM | | | | |
| POWDER;ORAL | | | | |
| P.A.S. SODIUM | | | | |
| CENTURY PHARMS | 4GM/PACKET | A080947 | 001 | |
| SODIUM AMINOSALICYLATE | | | | |
| HEXCEL | 100% | A080097 | 001 | |
| TABLET;ORAL | | | | |
| PARASAL SODIUM | | | | |
| PANRAY | 500MG | N006811 | 006 | |
| | 1GM | N006811 | 011 | |
| SODIUM P.A.S. | | | | |
| LANNETT | 500MG | A080138 | 002 | |
| TEEBACIN | | | | |
| CONSOLIDATED MIDLAND | 500MG | N007320 | 002 | |
| AMINOSALICYLATE SODIUM; AMINOSALICYLIC ACID | | | | |
| TABLET;ORAL | | | | |
| NEOPASALATE | | | | |
| MEDPOINTE PHARM HLC | 846MG;112MG | A080059 | 002 | |
| AMINOSALICYLIC ACID | | | | |
| TABLET;ORAL | | | | |
| PARASAL | | | | |
| PANRAY | 500MG | N006811 | 001 | |
| | 1GM | N006811 | 002 | |

| | | | | |
|---|---|---|---|---|
| AMINOSALICYLIC ACID RESIN COMPLEX | | | | |
| POWDER;ORAL | | | | |
| REZIPAS | | | | |
| | BRISTOL MYERS SQUIBB | EQ 500MG BASE/GM | N009052 001 | |
| AMIODARONE HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| AMIODARONE HYDROCHLORIDE | | | | |
| | BEDFORD | 50MG/ML | A076018 001 | Oct 15, 2002 |
| | BEDFORD LABS | 50MG/ML | A076299 001 | Oct 24, 2002 |
| | BEN VENUE | 50MG/ML | A076088 001 | Oct 15, 2002 |
| | HOSPIRA | 50MG/ML | A076108 001 | Oct 15, 2002 |
| | INTL MEDICATION SYS | 50MG/ML | N021594 001 | Feb 04, 2004 |
| | PAR STERILE PRODUCTS | 50MG/ML | A076394 001 | Apr 25, 2003 |
| | TEVA PHARMS USA | 50MG/ML | A076163 001 | Sep 05, 2003 |
| CORDARONE | | | | |
| + | WYETH PHARMS INC | 50MG/ML ** | N020377 001 | Aug 03, 1995 |
| TABLET;ORAL | | | | |
| AMIODARONE HYDROCHLORIDE | | | | |
| | MYLAN | 200MG | A075188 001 | Feb 24, 1999 |
| | TEVA | 200MG | A074895 001 | Apr 16, 1999 |
| CORDARONE | | | | |
| + | WYETH PHARMS INC | 200MG ** | N018972 001 | Dec 24, 1985 |
| AMITRIPTYLINE HYDROCHLORIDE | | | | |
| CONCENTRATE;ORAL | | | | |
| ENDEP | | | | |
| | ROCHE | 40MG/ML | A085749 001 | |
| INJECTABLE;INJECTION | | | | |
| AMITRIPTYLINE HYDROCHLORIDE | | | | |
| | WATSON LABS | 10MG/ML | A085594 001 | |
| ELAVIL | | | | |
| | ASTRAZENECA | 10MG/ML | N012704 001 | |
| TABLET;ORAL | | | | |
| AMITID | | | | |
| | BRISTOL MYERS SQUIBB | 10MG | A086454 001 | |
| | | 25MG | A086454 002 | |
| | | 50MG | A086454 003 | |
| | | 75MG | A086454 004 | |
| | | 100MG | A086454 005 | |
| AMITRIL | | | | |
| | WARNER CHILCOTT | 10MG | A083939 001 | |
| | | 25MG | A083937 001 | |
| | | 50MG | A083938 002 | |
| | | 75MG | A084957 001 | |
| | | 100MG | A085093 001 | |
| | | 150MG | A086295 001 | |
| AMITRIPTYLINE HYDROCHLORIDE | | | | |
| | AM THERAP | 25MG | A088672 001 | Nov 20, 1984 |
| | | 50MG | A088673 001 | Nov 20, 1984 |
| | | 75MG | A088674 001 | Nov 20, 1984 |
| | | 100MG | A088675 001 | Nov 20, 1984 |
| | ANI PHARMS INC | 10MG | A085031 002 | |
| | | 25MG | A085031 001 | |
| | | 50MG | A085031 003 | |
| | | 75MG | A085031 004 | |
| | COPLEY PHARM | 10MG | A088421 001 | Apr 30, 1984 |
| | | 25MG | A088422 001 | Apr 30, 1984 |
| | | 50MG | A088423 001 | Apr 30, 1984 |
| | | 75MG | A088424 001 | Apr 30, 1984 |
| | | 100MG | A088425 001 | Apr 30, 1984 |
| | | 150MG | A088426 001 | Apr 30, 1984 |
| | HALSEY | 10MG | A085923 001 | |
| | | 25MG | A085922 001 | |
| | | 50MG | A085925 001 | |
| | | 50MG | A087557 001 | Mar 05, 1982 |
| | | 75MG | A085926 001 | May 20, 1983 |
| | | 100MG | A085927 001 | May 20, 1983 |
| | LEDERLE | 10MG | A086744 001 | |
| | | 10MG | A087366 001 | Jan 04, 1982 |

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

| | | | |
|---|---|---|---|
| | 25MG | A086746 001 | |
| | 25MG | A087367 001 | May 03, 1982 |
| | 50MG | A086743 001 | |
| | 50MG | A087181 001 | Jan 04, 1982 |
| | 75MG | A086745 001 | |
| | 75MG | A087369 001 | Jan 04, 1982 |
| | 100MG | A086747 001 | |
| | 100MG | A087368 001 | May 03, 1982 |
| | 150MG | A087370 001 | Jan 04, 1982 |
| MUTUAL PHARM | 10MG | A085744 001 | |
| | 25MG | A085627 001 | |
| | 50MG | A085745 001 | |
| | 75MG | A085743 001 | |
| | 100MG | A085742 002 | May 11, 1982 |
| | 150MG | A089423 001 | Feb 17, 1987 |
| PAR PHARM | 10MG | A088697 001 | Sep 25, 1984 |
| | 25MG | A088698 001 | Sep 25, 1984 |
| | 50MG | A088699 001 | Sep 25, 1984 |
| | 75MG | A088700 001 | Sep 25, 1984 |
| | 100MG | A088701 001 | Sep 25, 1984 |
| | 150MG | A088702 001 | Sep 25, 1984 |
| PLIVA | 10MG | A088883 001 | Sep 26, 1984 |
| | 25MG | A088884 001 | Sep 26, 1984 |
| | 50MG | A088885 001 | Sep 26, 1984 |
| | 75MG | A088886 001 | Sep 26, 1984 |
| | 100MG | A088887 001 | Sep 26, 1984 |
| | 150MG | A088888 001 | Sep 26, 1984 |
| PUREPAC PHARM | 10MG | A088075 001 | Sep 16, 1983 |
| | 10MG | A088084 001 | Jul 18, 1983 |
| | 25MG | A088076 001 | May 20, 1983 |
| | 25MG | A088085 001 | Jul 18, 1983 |
| | 50MG | A088077 001 | Sep 16, 1983 |
| | 50MG | A088105 001 | Jul 18, 1983 |
| | 75MG | A088078 001 | Sep 16, 1983 |
| | 75MG | A088106 001 | Jul 18, 1983 |
| | 100MG | A088079 001 | Sep 16, 1983 |
| | 100MG | A088107 001 | Jul 18, 1983 |
| ROXANE | 10MG | A086002 001 | |
| | 10MG | A086144 001 | |
| | 25MG | A085944 001 | |
| | 25MG | A086145 001 | |
| | 50MG | A085945 001 | |
| | 50MG | A086143 001 | |
| | 75MG | A086004 001 | |
| | 75MG | A086147 001 | |
| | 100MG | A086003 001 | |
| | 100MG | A086146 001 | |
| | 150MG | A086090 001 | |
| | 150MG | A086148 001 | |
| SUN PHARM INDS INC | 10MG | A040816 002 | Jun 27, 2008 |
| | 10MG | A089399 002 | Jul 14, 1987 |
| | 25MG | A040816 001 | Jun 27, 2008 |
| | 25MG | A089399 001 | Jul 14, 1987 |
| | 50MG | A040816 003 | Jun 27, 2008 |
| | 50MG | A089399 003 | Jul 14, 1987 |
| | 75MG | A040816 004 | Jun 27, 2008 |
| | 75MG | A089399 004 | Jul 14, 1987 |
| | 100MG | A040816 005 | Jun 27, 2008 |
| | 100MG | A089399 005 | Jul 14, 1987 |
| | 150MG | A040816 006 | Jun 27, 2008 |
| | 150MG | A089399 006 | Jul 14, 1987 |
| SUPERPHARM | 10MG | A088853 001 | Nov 13, 1984 |
| | 25MG | A088854 001 | Nov 13, 1984 |
| | 50MG | A088855 001 | Nov 13, 1984 |
| | 75MG | A088856 001 | Nov 13, 1984 |
| | 100MG | A088857 001 | Nov 13, 1984 |

AMITRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

| | | | | |
|---|---|---|---|---|
| AMITRIPTYLINE HYDROCHLORIDE | | | | |
| TEVA | 10MG | A086610 001 | | |
| | 25MG | A086859 001 | | |
| | 50MG | A086857 001 | | |
| | 75MG | A086860 001 | | |
| | 100MG | A085836 001 | | |
| | 100MG | A086854 001 | | |
| | 150MG | A086853 001 | | |
| UCB INC | 10MG | A085864 001 | | |
| | 25MG | A085935 001 | | |
| | 50MG | A085936 001 | | |
| | 75MG | A086337 001 | | |
| | 100MG | A086336 001 | | |
| | 150MG | A086335 001 | | |
| USL PHARMA | 25MG | A087775 001 | Feb 10, 1982 | |
| VANGARD | 10MG | A087632 001 | Feb 01, 1982 | |
| | 50MG | A087616 001 | Feb 08, 1982 | |
| | 75MG | A087617 001 | Feb 05, 1982 | |
| | 100MG | A087639 001 | Feb 08, 1982 | |
| WATSON LABS | 10MG | A085816 001 | | |
| | 10MG | A088620 001 | Mar 02, 1984 | |
| | 25MG | A085817 001 | | |
| | 25MG | A088621 001 | Mar 02, 1984 | |
| | 50MG | A085815 001 | | |
| | 50MG | A088622 001 | Mar 02, 1984 | |
| | 75MG | A085819 001 | | |
| | 75MG | A088633 001 | Mar 02, 1984 | |
| | 100MG | A085820 001 | | |
| | 100MG | A088634 001 | Mar 02, 1984 | |
| | 150MG | A085821 001 | | |
| | 150MG | A088635 001 | Mar 02, 1984 | |
| WEST WARD | 10MG | A087647 001 | Mar 05, 1982 | |
| | 25MG | A087278 001 | | |
| ELAVIL | | | | |
| + ASTRAZENECA | 10MG ** | N012703 001 | | |
| + | 25MG ** | N012703 003 | | |
| + | 50MG ** | N012703 004 | | |
| + | 75MG ** | N012703 005 | | |
| + | 100MG ** | N012703 006 | | |
| + | 150MG ** | N012703 007 | | |
| ENDEP | | | | |
| ROCHE | 10MG | A083639 001 | | |
| | 25MG | A083639 002 | | |
| | 50MG | A083639 003 | | |
| | 75MG | A083639 004 | | |
| | 100MG | A083639 005 | | |
| | 150MG | A085303 001 | | |

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

| | | | | |
|---|---|---|---|---|
| CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE | | | | |
| ANDA REPOSITORY | EQ 12.5MG BASE;5MG | A070765 001 | Dec 10, 1986 | |
| | EQ 25MG BASE;10MG | A070766 001 | Dec 10, 1986 | |
| PAR PHARM | EQ 12.5MG BASE;5MG | A072277 001 | May 09, 1988 | |
| | EQ 25MG BASE;10MG | A072278 001 | May 09, 1988 | |
| USL PHARMA | EQ 12.5MG BASE;5MG | A070477 001 | Jan 12, 1988 | |
| | EQ 25MG BASE;10MG | A070478 001 | Jan 12, 1988 | |
| WATSON LABS | EQ 25MG BASE;10MG | A072053 001 | Dec 16, 1988 | |
| WATSON LABS TEVA | EQ 12.5MG BASE;5MG | A072052 001 | Dec 16, 1988 | |
| LIMBITROL | | | | |
| + HERITAGE PHARMS INC | EQ 12.5MG BASE;5MG ** | N016949 001 | | |
| LIMBITROL DS | | | | |
| + HERITAGE PHARMS INC | EQ 25MG BASE;10MG ** | N016949 002 | | |

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| ETRAFON 2-10 | | | | |
| SCHERING | 10MG;2MG ** | N014713 | 007 | |
| ETRAFON 2-25 | | | | |
| SCHERING | 25MG;2MG ** | N014713 | 004 | |
| ETRAFON-A | | | | |
| SCHERING | 10MG;4MG ** | N014713 | 002 | |
| ETRAFON-FORTE | | | | |
| SCHERING | 25MG;4MG ** | N014713 | 006 | |
| PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE | | | | |
| IVAX SUB TEVA PHARMS | 10MG;2MG | A070935 | 001 | Sep 11, 1986 |
| | 10MG;4MG | A070937 | 001 | Sep 11, 1986 |
| | 25MG;2MG | A070936 | 001 | Sep 11, 1986 |
| | 25MG;4MG | A070938 | 001 | Sep 11, 1986 |
| | 50MG;4MG | A070939 | 001 | Sep 12, 1986 |
| PAR PHARM | 10MG;2MG | A070565 | 001 | Sep 11, 1986 |
| | 10MG;4MG | A070620 | 001 | Sep 11, 1986 |
| | 25MG;2MG | A070621 | 001 | Sep 11, 1986 |
| | 25MG;4MG | A070595 | 001 | Sep 11, 1986 |
| | 50MG;4MG | A070574 | 001 | Sep 11, 1986 |
| SANDOZ | 10MG;2MG | A071062 | 001 | Nov 27, 1987 |
| | 10MG;4MG | A071862 | 001 | Dec 21, 1987 |
| | 25MG;2MG | A071063 | 001 | Nov 27, 1987 |
| | 25MG;4MG | A071064 | 001 | Nov 27, 1987 |
| | 50MG;4MG | A071863 | 001 | Dec 21, 1987 |
| SUN PHARM INDUSTRIES | 10MG;2MG | A071077 | 001 | Nov 12, 1986 |
| | 10MG;4MG | A071078 | 001 | Nov 12, 1986 |
| | 25MG;2MG | A070297 | 001 | Nov 12, 1986 |
| | 25MG;4MG | A071079 | 001 | Nov 12, 1986 |
| WATSON LABS | 10MG;2MG | A070373 | 001 | Aug 25, 1986 |
| | 10MG;2MG | A072539 | 001 | Feb 15, 1989 |
| | 10MG;2MG | A073007 | 001 | Oct 17, 1991 |
| | 10MG;4MG | A070375 | 001 | Aug 25, 1986 |
| | 10MG;4MG | A072540 | 001 | Feb 15, 1989 |
| | 10MG;4MG | A073009 | 001 | Oct 17, 1991 |
| | 25MG;2MG | A070374 | 001 | Aug 25, 1986 |
| | 25MG;2MG | A072541 | 001 | Feb 15, 1989 |
| | 25MG;2MG | A073008 | 001 | Oct 17, 1991 |
| | 25MG;4MG | A070376 | 001 | Aug 25, 1986 |
| | 25MG;4MG | A072134 | 001 | Feb 15, 1989 |
| | 25MG;4MG | A073010 | 001 | Oct 17, 1991 |
| | 50MG;4MG | A070377 | 001 | Nov 04, 1986 |
| | 50MG;4MG | A071558 | 001 | Mar 02, 1987 |
| | 50MG;4MG | A072135 | 001 | Feb 15, 1989 |
| TRIAVIL 2-10 | | | | |
| NEW RIVER | 10MG;2MG ** | N014715 | 004 | |
| TRIAVIL 2-25 | | | | |
| NEW RIVER | 25MG;2MG ** | N014715 | 002 | |
| TRIAVIL 4-10 | | | | |
| NEW RIVER | 10MG;4MG ** | N014715 | 003 | |
| TRIAVIL 4-25 | | | | |
| NEW RIVER | 25MG;4MG ** | N014715 | 005 | |
| TRIAVIL 4-50 | | | | |
| NEW RIVER | 50MG;4MG ** | N014715 | 006 | |

AMLEXANOX

| | | | | |
|---|---|---|---|---|
| PASTE;DENTAL | | | | |
| APHTHASOL | | | | |
| ULURU | 5% | N020511 | 001 | Dec 17, 1996 |
| PATCH;TOPICAL | | | | |
| AMLEXANOX | | | | |
| ULURU | 2MG | N021727 | 001 | Sep 29, 2004 |

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

| | | | | |
|---|---|---|---|---|
| FOSUN PHARMA | EQ 2.5MG BASE | A076859 | 001 | Sep 10, 2007 |
| | EQ 5MG BASE | A076859 | 002 | Sep 10, 2007 |
| | EQ 10MG BASE | A076859 | 003 | Sep 10, 2007 |
| GEDEON RICHTER USA | EQ 2.5MG BASE | A077333 | 001 | Jul 17, 2007 |
| | EQ 5MG BASE | A077333 | 002 | Jul 17, 2007 |
| | EQ 10MG BASE | A077333 | 003 | Jul 17, 2007 |
| GENPHARM | EQ 2.5MG BASE | A077362 | 001 | Jul 09, 2007 |
| | EQ 5MG BASE | A077362 | 002 | Jul 09, 2007 |
| | EQ 10MG BASE | A077362 | 003 | Jul 09, 2007 |
| MYLAN PHARMS INC | EQ 2.5MG BASE | A078224 | 001 | Feb 27, 2008 |
| | EQ 5MG BASE | A078224 | 002 | Feb 27, 2008 |
| | EQ 10MG BASE | A078224 | 003 | Feb 27, 2008 |
| PURACAP PHARM | EQ 2.5MG BASE | A078131 | 001 | Sep 04, 2007 |
| | EQ 5MG BASE | A078131 | 002 | Sep 04, 2007 |
| | EQ 10MG BASE | A078131 | 003 | Sep 04, 2007 |
| SOVEREIGN PHARMS | EQ 2.5MG BASE | A204900 | 001 | Jul 23, 2015 |
| | EQ 5MG BASE | A204900 | 002 | Jul 23, 2015 |
| | EQ 10MG BASE | A204900 | 003 | Jul 23, 2015 |
| SUN PHARM INDUSTRIES | EQ 2.5MG BASE | A078081 | 001 | Jan 31, 2008 |
| | EQ 5MG BASE | A078081 | 002 | Jan 31, 2008 |
| | EQ 10MG BASE | A078081 | 003 | Jan 31, 2008 |
| SYNTHON PHARMS | EQ 2.5MG BASE | A077080 | 001 | Jun 27, 2007 |
| | EQ 5MG BASE | A077080 | 002 | Jun 27, 2007 |
| | EQ 10MG BASE | A077080 | 003 | Jun 27, 2007 |

TABLET, ORALLY DISINTEGRATING;ORAL

AMLODIPINE BESYLATE

| | | | | |
|---|---|---|---|---|
| SYNTHON PHARMS | EQ 2.5MG BASE | N022026 | 001 | Sep 27, 2007 |
| | EQ 5MG BASE | N022026 | 002 | Sep 27, 2007 |
| | EQ 10MG BASE | N022026 | 003 | Sep 27, 2007 |

AMLODIPINE MALEATE

TABLET;ORAL

AMVAZ

| | | | | |
|---|---|---|---|---|
| DR REDDYS LABS INC | 2.5MG | N021435 | 001 | Oct 31, 2003 |
| | 5MG | N021435 | 002 | Oct 31, 2003 |
| | 10MG | N021435 | 003 | Oct 31, 2003 |

AMMONIA N-13

INJECTABLE;INTRAVENOUS

AMMONIA N 13

| | | | | |
|---|---|---|---|---|
| CENTRAL RADIOPHARM | 3.75-260mCi/ML | A204539 | 001 | Jun 23, 2015 |

AMMONIUM CHLORIDE

INJECTABLE;INJECTION

AMMONIUM CHLORIDE

| | | | |
|---|---|---|---|
| ABBOTT | 5MEQ/ML | A083130 | 001 |
| GD SEARLE LLC | 3MEQ/ML | A086205 | 001 |

AMMONIUM CHLORIDE 0.9% IN NORMAL SALINE

| | | | |
|---|---|---|---|
| MCGAW | 900MG/100ML | N006580 | 001 |

AMMONIUM CHLORIDE 2.14%

| | | | |
|---|---|---|---|
| B BRAUN | 40MEQ/100ML | A085734 | 001 |

AMMONIUM LACTATE

CREAM;TOPICAL

LAC-HYDRIN

| | | | | |
|---|---|---|---|---|
| RANBAXY | EQ 12% BASE ** | N020508 | 001 | Aug 29, 1996 |

LOTION;TOPICAL

LAC-HYDRIN

| | | | | |
|---|---|---|---|---|
| + RANBAXY | EQ 12% BASE ** | N019155 | 001 | Apr 24, 1985 |

AMODIAQUINE HYDROCHLORIDE

TABLET;ORAL

CAMOQUIN HYDROCHLORIDE

| | | | |
|---|---|---|---|
| PARKE DAVIS | EQ 200MG BASE | N006441 | 001 |

| | | | | | |
|---|---|---|---|---|---|
| AMOXAPINE | | | | | |
| TABLET;ORAL | | | | | |
| AMOXAPINE | | | | | |
| | UPSHER-SMITH LABS | 25MG | A072943 | 001 | Jun 28, 1991 |
| | | 50MG | A072944 | 001 | Jun 28, 1991 |
| | | 100MG | A072878 | 001 | Jun 28, 1991 |
| | | 150MG | A072879 | 001 | Jun 28, 1991 |
| | WATSON PHARMS TEVA | 25MG | A072418 | 001 | May 11, 1989 |
| | | 50MG | A072419 | 001 | May 11, 1989 |
| | | 100MG | A072420 | 001 | May 11, 1989 |
| | | 150MG | A072421 | 001 | May 11, 1989 |
| ASENDIN | | | | | |
| | LEDERLE | 25MG | N018021 | 001 | |
| | | 50MG | N018021 | 002 | |
| | | 100MG | N018021 | 003 | |
| | | 150MG | N018021 | 004 | |
| AMOXICILLIN | | | | | |
| CAPSULE;ORAL | | | | | |
| AMOXICILLIN | | | | | |
| | LABS ATRAL | 250MG | A062528 | 001 | Aug 07, 1985 |
| | | 500MG | A062528 | 002 | Aug 07, 1985 |
| | MYLAN | 250MG | A062067 | 001 | |
| | | 500MG | A062067 | 002 | |
| | SUN PHARM INDS LTD | 250MG | A065016 | 001 | Apr 08, 1999 |
| | | 500MG | A065016 | 002 | Apr 08, 1999 |
| | TEVA | 250MG | A062853 | 001 | Dec 22, 1987 |
| | | 250MG | A063030 | 001 | Feb 28, 1989 |
| | | 500MG | A062854 | 001 | Dec 22, 1987 |
| | | 500MG | A063031 | 001 | Feb 28, 1989 |
| AMOXIL | | | | | |
| + | GLAXOSMITHKLINE | 250MG ** | N050459 | 001 | |
| + | | 500MG ** | N050459 | 002 | |
| TRIMOX | | | | | |
| | APOTHECON | 250MG | A061885 | 001 | |
| | | 250MG | A062098 | 001 | |
| | | 250MG | A062152 | 001 | |
| | | 250MG | A063099 | 001 | Mar 20, 1992 |
| | | 500MG | A061885 | 002 | |
| | | 500MG | A062098 | 002 | |
| | | 500MG | A062152 | 002 | |
| | | 500MG | A063099 | 002 | Mar 20, 1992 |
| UTIMOX | | | | | |
| | PARKE DAVIS | 250MG | A062107 | 001 | |
| | | 500MG | A062107 | 002 | |
| WYMOX | | | | | |
| | WYETH AYERST | 250MG | A062120 | 001 | |
| | | 500MG | A062120 | 002 | |
| FOR SUSPENSION;ORAL | | | | | |
| AMOXICILLIN | | | | | |
| | AM ANTIBIOTICS | 125MG/5ML | A062059 | 001 | |
| | | 250MG/5ML | A062059 | 002 | |
| | MYLAN | 125MG/5ML | A062090 | 001 | |
| | | 250MG/5ML | A062090 | 002 | |
| | SUN PHARM INDS LTD | 200MG/5ML | A065113 | 001 | Nov 29, 2002 |
| | | 400MG/5ML | A065113 | 002 | Nov 29, 2002 |
| | TEVA | 125MG/5ML | A062946 | 001 | Nov 01, 1988 |
| | | 250MG/5ML | A063001 | 001 | Jan 06, 1989 |
| AMOXIL | | | | | |
| + | DR REDDYS LABS INC | 200MG/5ML ** | N050760 | 001 | Apr 15, 1999 |
| + | | 400MG/5ML ** | N050760 | 002 | Apr 15, 1999 |
| + | GLAXOSMITHKLINE | 50MG/ML ** | N050460 | 005 | |
| + | | 125MG/5ML ** | N050460 | 001 | |
| + | | 250MG/5ML ** | N050460 | 002 | |
| LAROTID | | | | | |
| + | GLAXOSMITHKLINE | 50MG/ML ** | N050460 | 006 | |
| POLYMOX | | | | | |
| | APOTHECON | 125MG/5ML | A061851 | 001 | |
| | | 125MG/5ML | A062323 | 001 | |
| | | 250MG/5ML | A061851 | 002 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

AMOXICILLIN

| | | | | |
|---|---|---|---|---|
| FOR SUSPENSION;ORAL | | | | |
| POLYMOX | | | | |
| | 250MG/5ML | A062323 002 | | |
| TRIMOX | | | | |
| APOTHECON | 50MG/ML | A061886 001 | | |
| | 125MG/5ML | A061886 002 | | |
| | 125MG/5ML | A062099 001 | | |
| | 125MG/5ML | A062154 001 | | |
| | 125MG/5ML | A062885 001 | | Mar 08, 1988 |
| | 250MG/5ML | A061886 003 | | |
| | 250MG/5ML | A062099 002 | | |
| | 250MG/5ML | A062154 002 | | |
| | 250MG/5ML | A062885 002 | | Mar 08, 1988 |
| UTIMOX | | | | |
| PARKE DAVIS | 125MG/5ML | A062127 001 | | |
| | 250MG/5ML | A062127 002 | | |
| WYMOX | | | | |
| WYETH AYERST | 125MG/5ML | A062131 001 | | |
| | 250MG/5ML | A062131 002 | | |
| TABLET;ORAL | | | | |
| AMOXICILLIN | | | | |
| DAVA PHARMS INC | 875MG | A065344 001 | | Jan 15, 2009 |
| SUN PHARM INDS LTD | 500MG | A065059 001 | | Nov 24, 2000 |
| | 875MG | A065059 002 | | Nov 24, 2000 |
| AMOXIL | | | | |
| + DR REDDYS LABS INC | 500MG ** | N050754 002 | | Jul 10, 1998 |
| + | 875MG ** | N050754 001 | | Jul 10, 1998 |
| TABLET, CHEWABLE;ORAL | | | | |
| AMOXICILLIN | | | | |
| APOTHECON | 125MG | A064131 001 | | May 06, 1996 |
| | 250MG | A064131 002 | | May 06, 1996 |
| DAVA PHARMS INC | 125MG | A064139 001 | | Jan 29, 1996 |
| | 250MG | A064139 002 | | Jan 29, 1996 |
| SUN PHARM INDS LTD | 125MG | A065021 001 | | Dec 23, 1999 |
| | 200MG | A065060 001 | | Nov 29, 2000 |
| | 250MG | A065021 002 | | Dec 23, 1999 |
| | 400MG | A065060 002 | | Nov 29, 2000 |
| TEVA | 125MG | A064031 001 | | Dec 19, 1996 |
| | 250MG | A064031 002 | | Dec 19, 1996 |
| AMOXIL | | | | |
| + DR REDDYS LABS INC | 125MG ** | N050542 002 | | |
| | 200MG | N050761 001 | | Apr 15, 1999 |
| + | 250MG ** | N050542 001 | | |
| | 400MG | N050761 002 | | Apr 15, 1999 |
| TABLET, FOR SUSPENSION;ORAL | | | | |
| AMOXICILLIN | | | | |
| AUROBINDO PHARMA LTD | 200MG | A065324 001 | | Jan 17, 2007 |
| | 400MG | A065324 002 | | Jan 17, 2007 |
| DISPERMOX | | | | |
| RANBAXY LABS LTD | 200MG | A065080 002 | | Aug 11, 2003 |
| | 400MG | A065080 001 | | Aug 11, 2003 |
| | 600MG | A065159 001 | | Dec 04, 2003 |

AMOXICILLIN; CLAVULANATE POTASSIUM

| | | | | |
|---|---|---|---|---|
| FOR SUSPENSION;ORAL | | | | |
| AMOXICILLIN AND CLAVULANATE POTASSIUM | | | | |
| SUN PHARM INDS LTD | 200MG/5ML;EQ 28.5MG BASE/5ML | A065132 001 | | Mar 19, 2003 |
| | 400MG/5ML;EQ 57MG BASE/5ML | A065132 002 | | Mar 19, 2003 |
| | 600MG/5ML;EQ 42.9MG BASE/5ML | A065207 002 | | Jan 30, 2007 |
| AUGMENTIN '200' | | | | |
| + DR REDDYS LABS INC | 200MG/5ML;EQ 28.5MG BASE/5ML | N050725 001 | | May 31, 1996 |
| AUGMENTIN '400' | | | | |
| + DR REDDYS LABS INC | 400MG/5ML;EQ 57MG BASE/5ML | N050725 002 | | May 31, 1996 |
| AUGMENTIN ES-600 | | | | |
| + DR REDDYS LABS INC | 600MG/5ML;EQ 42.9MG BASE/5ML | N050755 001 | | Jun 22, 2001 |
| TABLET;ORAL | | | | |
| AMOXICILLIN AND CLAVULANATE POTASSIUM | | | | |
| APOTEX INC | 250MG;EQ 125MG BASE | A065333 001 | | Feb 24, 2009 |
| | 500MG;EQ 125MG BASE | A065333 002 | | Feb 24, 2009 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

AMOXICILLIN; CLAVULANATE POTASSIUM

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| AMOXICILLIN AND CLAVULANATE POTASSIUM | | | | |
| | | 875MG;EQ 125MG BASE | A065317 003 | Oct 20, 2008 |
| | SUN PHARM INDS LTD | 500MG;EQ 125MG BASE | A065109 001 | Nov 04, 2002 |
| | | 875MG;EQ 125MG BASE | A065102 001 | Sep 17, 2002 |
| AUGMENTIN '250' | | | | |
| + | DR REDDYS LABS INC | 250MG;EQ 125MG BASE ** | N050564 001 | Aug 06, 1984 |
| AUGMENTIN '500' | | | | |
| + | DR REDDYS LABS INC | 500MG;EQ 125MG BASE ** | N050564 002 | Aug 06, 1984 |
| TABLET, CHEWABLE;ORAL | | | | |
| AMOXICILLIN AND CLAVULANATE POTASSIUM | | | | |
| | SANDOZ | 200MG;EQ 28.5MG BASE | A065065 001 | Apr 18, 2002 |
| | | 400MG;EQ 57MG BASE | A065065 002 | Apr 18, 2002 |
| | SUN PHARM INDS LTD | 200MG;EQ 28.5MG BASE | A065161 001 | Dec 03, 2003 |
| | | 400MG;EQ 57MG BASE | A065161 002 | Dec 03, 2003 |
| AUGMENTIN '125' | | | | |
| + | DR REDDYS LABS INC | 125MG;EQ 31.25MG BASE ** | N050597 001 | Jul 22, 1985 |
| AUGMENTIN '200' | | | | |
| + | DR REDDYS LABS INC | 200MG;EQ 28.5MG BASE | N050726 001 | May 31, 1996 |
| AUGMENTIN '250' | | | | |
| + | DR REDDYS LABS INC | 250MG;EQ 62.5MG BASE ** | N050597 002 | Jul 22, 1985 |
| AUGMENTIN '400' | | | | |
| + | DR REDDYS LABS INC | 400MG;EQ 57MG BASE | N050726 002 | May 31, 1996 |

AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE

| | | | |
|---|---|---|---|
| CAPSULE;ORAL | | | |
| DELCOBESE | | | |
| | TEVA | 1.25MG;1.25MG;1.25MG;1.25MG ** | A083564 001 |
| | | 2.5MG;2.5MG;2.5MG;2.5MG ** | A083564 002 |
| | | 3.75MG;3.75MG;3.75MG;3.75MG ** | A083564 003 |
| | | 5MG;5MG;5MG;5MG ** | A083564 004 |
| TABLET;ORAL | | | |
| DELCOBESE | | | |
| | TEVA | 1.25MG;1.25MG;1.25MG;1.25MG | A083563 004 |
| | | 2.5MG;2.5MG;2.5MG;2.5MG | A083563 003 |
| | | 3.75MG;3.75MG;3.75MG;3.75MG | A083563 002 |
| | | 5MG;5MG;5MG;5MG | A083563 001 |

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| ADDERALL 10 | | | | |
| + | TEVA WOMENS | 2.5MG;2.5MG;2.5MG;2.5MG ** | N011522 007 | Feb 13, 1996 |
| ADDERALL 12.5 | | | | |
| + | TEVA WOMENS | 3.125MG;3.125MG;3.125MG;3.125MG ** | N011522 012 | Aug 31, 2000 |
| ADDERALL 15 | | | | |
| + | TEVA WOMENS | 3.75MG;3.75MG;3.75MG;3.75MG ** | N011522 013 | Aug 31, 2000 |
| ADDERALL 20 | | | | |
| + | TEVA WOMENS | 5MG;5MG;5MG;5MG ** | N011522 008 | Feb 13, 1996 |
| ADDERALL 30 | | | | |
| + | TEVA WOMENS | 7.5MG;7.5MG;7.5MG;7.5MG ** | N011522 010 | May 12, 1997 |
| ADDERALL 5 | | | | |
| + | TEVA WOMENS | 1.25MG;1.25MG;1.25MG;1.25MG ** | N011522 009 | May 12, 1997 |
| ADDERALL 7.5 | | | | |
| + | TEVA WOMENS | 1.875MG;1.875MG;1.875MG;1.875MG ** | N011522 011 | Aug 31, 2000 |
| DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE | | | | |
| | TEVA PHARMS | 1.25MG;1.25MG;1.25MG;1.25MG | A040472 001 | Sep 30, 2003 |
| | | 2.5MG;2.5MG;2.5MG;2.5MG | A040472 002 | Sep 30, 2003 |
| | | 5MG;5MG;5MG;5MG | A040472 003 | Sep 30, 2003 |
| | | 7.5MG;7.5MG;7.5MG;7.5MG | A040472 004 | Sep 30, 2003 |

AMPHETAMINE RESIN COMPLEX; DEXTROAMPHETAMINE RESIN COMPLEX

| | | | |
|---|---|---|---|
| CAPSULE, EXTENDED RELEASE;ORAL | | | |
| BIPHETAMINE 12.5 | | | |
| | UCB INC | EQ 6.25MG BASE;EQ 6.25MG BASE | N010093 007 |
| BIPHETAMINE 20 | | | |
| | UCB INC | EQ 10MG BASE;EQ 10MG BASE | N010093 003 |
| BIPHETAMINE 7.5 | | | |
| | UCB INC | EQ 3.75MG BASE;EQ 3.75MG BASE | N010093 009 |

| | | | | |
|---|---|---|---|---|
| AMPHETAMINE SULFATE | | | | |
| TABLET;ORAL | | | | |
| AMPHETAMINE SULFATE | | | | |
| LANNETT | 5MG | A083901 | 001 | Aug 31, 1984 |
| | 10MG | A083901 | 002 | Aug 31, 1984 |
| AMPHOTERICIN B | | | | |
| CREAM;TOPICAL | | | | |
| FUNGIZONE | | | | |
| APOTHECON | 3% | N050314 | 001 | |
| INJECTABLE;INJECTION | | | | |
| AMPHOTERICIN B | | | | |
| ABBOTT | 50MG/VIAL | A064141 | 001 | Dec 23, 1996 |
| ABRAXIS PHARM | 50MG/VIAL | A062728 | 001 | Apr 13, 1987 |
| TEVA PARENTERAL | 50MG/VIAL | A064062 | 001 | Mar 31, 1995 |
| FUNGIZONE | | | | |
| APOTHECON | 50MG/VIAL | A060517 | 001 | |
| INJECTABLE, LIPID COMPLEX;INJECTION | | | | |
| AMPHOTEC | | | | |
| ALKOPHARMA USA | 50MG/VIAL | N050729 | 001 | Nov 22, 1996 |
| | 100MG/VIAL | N050729 | 002 | Nov 22, 1996 |
| LOTION;TOPICAL | | | | |
| FUNGIZONE | | | | |
| APOTHECON | 3% | A060570 | 001 | |
| OINTMENT;TOPICAL | | | | |
| FUNGIZONE | | | | |
| APOTHECON | 3% | N050313 | 001 | |
| SUSPENSION;ORAL | | | | |
| FUNGIZONE | | | | |
| BRISTOL MYERS SQUIBB | 100MG/ML | N050341 | 003 | |
| AMPICILLIN SODIUM | | | | |
| INJECTABLE;INJECTION | | | | |
| AMPICILLIN SODIUM | | | | |
| APOTHECON | EQ 125MG BASE/VIAL | A062860 | 001 | Feb 05, 1988 |
| | EQ 250MG BASE/VIAL | A062860 | 002 | Feb 05, 1988 |
| | EQ 500MG BASE/VIAL | A062860 | 003 | Feb 05, 1988 |
| | EQ 1GM BASE/VIAL | A062860 | 004 | Feb 05, 1988 |
| | EQ 2GM BASE/VIAL | A062860 | 005 | Feb 05, 1988 |
| CONSOLIDATED PHARM | EQ 125MG BASE/VIAL | A061936 | 005 | |
| | EQ 250MG BASE/VIAL | A061936 | 001 | |
| | EQ 500MG BASE/VIAL | A061936 | 002 | |
| | EQ 1GM BASE/VIAL | A061936 | 003 | |
| | EQ 2GM BASE/VIAL | A061936 | 004 | |
| HANFORD GC | EQ 125MG BASE/VIAL | A062772 | 005 | Apr 15, 1993 |
| | EQ 500MG BASE/VIAL | A062772 | 008 | Apr 15, 1993 |
| | EQ 1GM BASE/VIAL | A062772 | 002 | Apr 15, 1993 |
| | EQ 2GM BASE/VIAL | A062772 | 004 | Apr 15, 1993 |
| INTL MEDICATION | EQ 1GM BASE/VIAL | A062634 | 002 | Jan 09, 1987 |
| | EQ 2GM BASE/VIAL | A062634 | 003 | Jan 09, 1987 |
| LILLY | EQ 500MG BASE/VIAL | A062565 | 001 | Apr 04, 1985 |
| | EQ 1GM BASE/VIAL | A062565 | 002 | Apr 04, 1985 |
| | EQ 2GM BASE/VIAL | A062565 | 003 | Jun 24, 1986 |
| WATSON LABS INC | EQ 125MG BASE/VIAL | A062816 | 001 | Oct 24, 1988 |
| | EQ 250MG BASE/VIAL | A062816 | 002 | Oct 24, 1988 |
| | EQ 500MG BASE/VIAL | A062816 | 003 | Oct 24, 1988 |
| | EQ 1GM BASE/VIAL | A062816 | 004 | Oct 24, 1988 |
| | EQ 2GM BASE/VIAL | A062816 | 005 | Oct 24, 1988 |
| | EQ 10GM BASE/VIAL | A062994 | 001 | Sep 15, 1988 |
| WEST-WARD PHARMS INT | EQ 125MG BASE/VIAL | A062692 | 001 | Jun 24, 1986 |
| | EQ 250MG BASE/VIAL | A062692 | 002 | Jun 24, 1986 |
| | EQ 500MG BASE/VIAL | A062692 | 003 | Jun 24, 1986 |
| | EQ 1GM BASE/VIAL | A062692 | 004 | Jun 24, 1986 |
| | EQ 2GM BASE/VIAL | A062692 | 005 | Jun 24, 1986 |
| | EQ 10GM BASE/VIAL | A062692 | 006 | Jun 24, 1986 |
| OMNIPEN-N | | | | |
| WYETH AYERST | EQ 125MG BASE/VIAL | A060626 | 001 | |
| | EQ 125MG BASE/VIAL | A062718 | 001 | Dec 16, 1986 |
| | EQ 250MG BASE/VIAL | A060626 | 002 | |
| | EQ 250MG BASE/VIAL | A062718 | 002 | Dec 16, 1986 |

AMPICILLIN SODIUM

INJECTABLE;INJECTION

| | | | | |
|---|---|---|---|---|
| OMNIPEN-N | | | | |
| | EQ 500MG BASE/VIAL | | A060626 003 | |
| | EQ 500MG BASE/VIAL | | A062718 003 | Dec 16, 1986 |
| | EQ 1GM BASE/VIAL | | A060626 004 | |
| | EQ 1GM BASE/VIAL | | A062718 004 | Dec 16, 1986 |
| | EQ 2GM BASE/VIAL | | A060626 005 | |
| | EQ 2GM BASE/VIAL | | A062718 005 | Dec 16, 1986 |
| PENBRITIN-S | | | | |
| + WYETH AYERST | EQ 125MG BASE/VIAL ** | | N050072 001 | |
| + | EQ 250MG BASE/VIAL ** | | N050072 002 | |
| + | EQ 500MG BASE/VIAL ** | | N050072 003 | |
| + | EQ 1GM BASE/VIAL ** | | N050072 004 | |
| + | EQ 2GM BASE/VIAL ** | | N050072 005 | |
| + | EQ 4GM BASE/VIAL ** | | N050072 006 | |
| POLYCILLIN-N | | | | |
| BRISTOL | EQ 125MG BASE/VIAL ** | | N050309 001 | |
| | EQ 250MG BASE/VIAL ** | | N050309 002 | |
| | EQ 500MG BASE/VIAL ** | | N050309 003 | |
| | EQ 1GM BASE/VIAL ** | | N050309 004 | |
| | EQ 2GM BASE/VIAL ** | | N050309 005 | |
| TOTACILLIN-N | | | | |
| GLAXOSMITHKLINE | EQ 125MG BASE/VIAL | | A060677 001 | |
| | EQ 250MG BASE/VIAL | | A060677 002 | |
| | EQ 500MG BASE/VIAL | | A060677 003 | |
| | EQ 1GM BASE/VIAL | | A060677 004 | |
| | EQ 1GM BASE/VIAL | | A062727 001 | Dec 19, 1986 |
| | EQ 2GM BASE/VIAL | | A060677 005 | |
| | EQ 2GM BASE/VIAL | | A062727 002 | Dec 19, 1986 |
| | EQ 10GM BASE/VIAL | | A060677 006 | |

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION

| | | | | |
|---|---|---|---|---|
| UNASYN | | | | |
| PFIZER | EQ 500MG BASE/VIAL;EQ 250MG BASE/VIAL | | N050608 003 | Dec 31, 1986 |

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE;ORAL

| | | | | |
|---|---|---|---|---|
| AMCILL | | | | |
| PARKE DAVIS | EQ 250MG BASE | | A062041 001 | |
| | EQ 500MG BASE | | A062041 002 | |
| AMPICILLIN TRIHYDRATE | | | | |
| AM ANTIBIOTICS | EQ 250MG BASE | | A061602 001 | |
| | EQ 500MG BASE | | A061602 002 | |
| IVAX SUB TEVA PHARMS | EQ 250MG BASE | | A060765 001 | |
| | EQ 500MG BASE | | A060765 002 | |
| LEDERLE | EQ 250MG BASE | | A062208 001 | |
| | EQ 500MG BASE | | A062208 002 | |
| MYLAN | EQ 250MG BASE | | A061755 001 | |
| | EQ 500MG BASE | | A061755 002 | |
| PUREPAC PHARM | EQ 250MG BASE | | A061853 001 | |
| | EQ 500MG BASE | | A061853 002 | |
| TEVA | EQ 250MG BASE | | A061502 001 | |
| | EQ 500MG BASE | | A061502 002 | |
| VITARINE | EQ 250MG BASE | | A061387 001 | |
| | EQ 500MG BASE | | A061387 003 | |
| OMNIPEN (AMPICILLIN) | | | | |
| WYETH AYERST | 250MG | | A060624 001 | |
| | 500MG | | A060624 002 | |
| PENBRITIN | | | | |
| WYETH AYERST | EQ 250MG BASE | | A060908 001 | |
| | EQ 500MG BASE | | A060908 002 | |
| PFIZERPEN-A | | | | |
| PFIZER | EQ 250MG BASE | | A062050 001 | |
| | EQ 500MG BASE | | A062050 002 | |
| POLYCILLIN | | | | |
| BRISTOL | EQ 250MG BASE | | N050310 001 | |
| | EQ 500MG BASE | | N050310 002 | |

AMPICILLIN/AMPICILLIN TRIHYDRATE

| | | | | |
|---|---|---|---|---|
| CAPSULE;ORAL | | | | |
| PRINCIPEN | | | | |
| | APOTHECON | EQ 250MG BASE | A062888 001 | Mar 04, 1988 |
| | | EQ 500MG BASE | A062888 002 | Mar 04, 1988 |
| | BRISTOL MYERS SQUIBB | EQ 250MG BASE | A061392 001 | |
| | | EQ 500MG BASE | A061392 002 | |
| PRINCIPEN '250' | | | | |
| | APOTHECON | EQ 250MG BASE | A062157 002 | |
| | | EQ 250MG BASE | N050056 001 | |
| PRINCIPEN '500' | | | | |
| | APOTHECON | EQ 500MG BASE | A062157 001 | |
| | | EQ 500MG BASE | N050056 002 | |
| TOTACILLIN | | | | |
| | GLAXOSMITHKLINE | EQ 250MG BASE | A060060 001 | |
| | | EQ 250MG BASE | A062212 001 | |
| | | EQ 500MG BASE | A060060 002 | |
| | | EQ 500MG BASE | A062212 002 | |
| FOR SUSPENSION;ORAL | | | | |
| AMCILL | | | | |
| | PARKE DAVIS | EQ 125MG BASE/5ML | A062030 001 | |
| | | EQ 250MG BASE/5ML | A062030 002 | |
| AMPICILLIN TRIHYDRATE | | | | |
| | AM ANTIBIOTICS | EQ 125MG BASE/5ML | A061601 001 | |
| | | EQ 250MG BASE/5ML | A061601 002 | |
| | MYLAN | EQ 125MG BASE/5ML | A061829 002 | |
| | | EQ 250MG BASE/5ML | A061829 001 | |
| | PUREPAC PHARM | EQ 125MG BASE/5ML | A061980 001 | |
| | | EQ 250MG BASE/5ML | A061980 002 | |
| | TEVA | EQ 125MG BASE/5ML | A061370 001 | |
| | | EQ 250MG BASE/5ML | A061370 002 | |
| OMNIPEN (AMPICILLIN) | | | | |
| | WYETH AYERST | 100MG/ML | A060625 001 | |
| | | 125MG/5ML | A060625 002 | |
| | | 250MG/5ML | A060625 003 | |
| | | 500MG/5ML | A060625 004 | |
| PENBRITIN | | | | |
| | WYETH AYERST | EQ 100MG BASE/ML | N050019 001 | |
| | | EQ 125MG BASE/5ML | N050019 002 | |
| | | EQ 250MG BASE/5ML | N050019 003 | |
| PFIZERPEN-A | | | | |
| | PFIZER | EQ 125MG BASE/5ML | A062049 001 | |
| | | EQ 250MG BASE/5ML | A062049 002 | |
| POLYCILLIN | | | | |
| | APOTHECON | EQ 125MG BASE/5ML | A062297 001 | |
| | | EQ 250MG BASE/5ML | A062297 002 | |
| | BRISTOL | EQ 100MG BASE/ML | N050308 004 | |
| | | EQ 125MG BASE/5ML | N050308 001 | |
| | | EQ 250MG BASE/5ML | N050308 002 | |
| | | EQ 500MG BASE/5ML | N050308 003 | |
| PRINCIPEN | | | | |
| | APOTHECON | EQ 100MG BASE/ML | A061394 001 | |
| | | EQ 125MG BASE/5ML | A061394 002 | |
| | | EQ 250MG BASE/5ML | A061394 003 | |
| PRINCIPEN '125' | | | | |
| | APOTHECON | EQ 125MG BASE/5ML | A060127 002 | |
| | | EQ 125MG BASE/5ML | A062151 001 | |
| PRINCIPEN '250' | | | | |
| | APOTHECON | EQ 250MG BASE/5ML | A060127 001 | |
| | | EQ 250MG BASE/5ML | A062151 002 | |
| TOTACILLIN | | | | |
| | GLAXOSMITHKLINE | EQ 125MG BASE/5ML | A060666 001 | |
| | | EQ 125MG BASE/5ML | A062223 001 | |
| | | EQ 250MG BASE/5ML | A060666 002 | |
| | | EQ 250MG BASE/5ML | A062223 002 | |
| TABLET, CHEWABLE;ORAL | | | | |
| POLYCILLIN | | | | |
| | BRISTOL | EQ 125MG BASE | N050093 001 | |

| | | | | |
|---|---|---|---|---|
| AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID | | | | |
| CAPSULE;ORAL | | | | |
| PRINCIPEN W/ PROBENECID | | | | |
| APOTHECON | EQ 389MG BASE;111MG | A062150 | 001 | |
| | EQ 389MG BASE;111MG | N050488 | 001 | |
| FOR SUSPENSION;ORAL | | | | |
| POLYCILLIN-PRB | | | | |
| APOTHECON | EQ 3.5GM BASE/BOT;1GM/BOT | A061898 | 001 | |
| BRISTOL | EQ 3.5GM BASE/BOT;1GM/BOT | N050457 | 001 | |
| PROBAMPACIN | | | | |
| G AND W LABS INC | EQ 3.5GM BASE/BOT;1GM/BOT | A061741 | 001 | |
| AMPRENAVIR | | | | |
| CAPSULE;ORAL | | | | |
| AGENERASE | | | | |
| GLAXOSMITHKLINE | 50MG | N021007 | 001 | Apr 15, 1999 |
| | 150MG | N021007 | 002 | Apr 15, 1999 |
| SOLUTION;ORAL | | | | |
| AGENERASE | | | | |
| + GLAXOSMITHKLINE | 15MG/ML ** | N021039 | 001 | Apr 15, 1999 |
| ANAGRELIDE HYDROCHLORIDE | | | | |
| CAPSULE;ORAL | | | | |
| AGRYLIN | | | | |
| + SHIRE LLC | EQ 1MG BASE ** | N020333 | 002 | Mar 14, 1997 |
| ANAGRELIDE HYDROCHLORIDE | | | | |
| MYLAN PHARMS INC | EQ 0.5MG BASE | A076811 | 001 | Apr 18, 2005 |
| | EQ 0.5MG BASE | A077613 | 001 | Jun 27, 2006 |
| | EQ 1MG BASE | A076811 | 002 | Apr 18, 2005 |
| | EQ 1MG BASE | A077613 | 002 | Jun 27, 2006 |
| ROXANE | EQ 0.5MG BASE | A076489 | 001 | Apr 18, 2005 |
| | EQ 1MG BASE | A076489 | 002 | Apr 18, 2005 |
| UPSHER-SMITH LABS | EQ 0.5MG BASE | A076683 | 001 | Apr 18, 2005 |
| | EQ 1MG BASE | A076683 | 002 | Apr 18, 2005 |
| WATSON LABS | EQ 0.5MG BASE | A076417 | 001 | Apr 18, 2005 |
| | EQ 1MG BASE | A076417 | 002 | Apr 18, 2005 |
| ANASTROZOLE | | | | |
| TABLET;ORAL | | | | |
| ANASTROZOLE | | | | |
| IMPAX LABS INC | 1MG | A091242 | 001 | May 31, 2012 |
| KREMERS URBAN PHARMS | 1MG | A091331 | 001 | Jan 05, 2011 |
| SANDOZ | 1MG | A079007 | 001 | Jun 28, 2010 |
| SUN PHARM INDS LTD | 1MG | A091177 | 001 | Jul 15, 2011 |
| SYNTHON PHARMS | 1MG | A078322 | 001 | Jun 28, 2010 |
| WATSON LABS TEVA | 1MG | A078984 | 001 | Jun 28, 2010 |
| ANILERIDINE HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| LERITINE | | | | |
| MERCK | EQ 25MG BASE | N010585 | 002 | |
| ANILERIDINE PHOSPHATE | | | | |
| INJECTABLE;INJECTION | | | | |
| LERITINE | | | | |
| MERCK | 25MG/ML | N010520 | 003 | |
| ANISINDIONE | | | | |
| TABLET;ORAL | | | | |
| MIRADON | | | | |
| SCHERING | 50MG | N010909 | 003 | |
| ANISOTROPINE METHYLBROMIDE | | | | |
| TABLET;ORAL | | | | |
| ANISOTROPINE METHYLBROMIDE | | | | |
| WATSON LABS | 50MG | A086046 | 001 | |
| VALPIN 50 | | | | |
| ENDO PHARMS | 50MG | N013428 | 001 | |

| | | | | | |
|---|---|---|---|---|---|
| ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE | | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | | |
| VASOCON-A | | | | | |
| | NOVARTIS | 0.5%;0.05% | N018746 | 002 | Jul 11, 1994 |
| APOMORPHINE HYDROCHLORIDE | | | | | |
| INJECTABLE;SUBCUTANEOUS | | | | | |
| APOKYN | | | | | |
| | US WORLDMEDS | 20MG/2ML (10MG/ML) | N021264 | 001 | Apr 20, 2004 |
| APROTININ | | | | | |
| INJECTABLE;INJECTION | | | | | |
| TRASYLOL | | | | | |
| | BAYER HLTHCARE | 10,000KIU/ML | N020304 | 001 | Dec 29, 1993 |
| ARBUTAMINE HYDROCHLORIDE | | | | | |
| INJECTABLE;INJECTION | | | | | |
| GENESA | | | | | |
| | GENSIA AUTOMEDICS | 0.05MG/ML | N020420 | 001 | Sep 12, 1997 |
| ARDEPARIN SODIUM | | | | | |
| INJECTABLE;INJECTION | | | | | |
| NORMIFLO | | | | | |
| + | PHARMACIA AND UPJOHN | 5,000 UNITS/0.5ML ** | N020227 | 002 | May 23, 1997 |
| + | | 10,000 UNITS/0.5ML ** | N020227 | 001 | May 23, 1997 |
| ARGATROBAN | | | | | |
| SOLUTION;IV (INFUSION) | | | | | |
| ARGATROBAN IN DEXTROSE | | | | | |
| | SANDOZ | 125MG/125ML (1MG/ML) | N201743 | 001 | May 09, 2011 |
| ARIPIPRAZOLE | | | | | |
| INJECTABLE;INTRAMUSCULAR | | | | | |
| ABILIFY | | | | | |
| | OTSUKA | 9.75MG/1.3ML (7.5MG/ML) | N021866 | 001 | Sep 20, 2006 |
| SOLUTION;ORAL | | | | | |
| ABILIFY | | | | | |
| + | OTSUKA | 1MG/ML ** | N021713 | 001 | Dec 10, 2004 |
| TABLET, ORALLY DISINTEGRATING;ORAL | | | | | |
| ABILIFY | | | | | |
| | OTSUKA | 10MG ** | N021729 | 002 | Jun 07, 2006 |
| | | 15MG ** | N021729 | 003 | Jun 07, 2006 |
| + | | 20MG ** | N021729 | 004 | Jun 07, 2006 |
| + | | 30MG ** | N021729 | 005 | Jun 07, 2006 |
| ARMODAFINIL | | | | | |
| TABLET;ORAL | | | | | |
| ARMODAFINIL | | | | | |
| | WATSON LABS INC | 100MG | A200156 | 002 | Aug 29, 2012 |
| | | 200MG | A200156 | 004 | Aug 29, 2012 |
| NUVIGIL | | | | | |
| + | CEPHALON | 100MG ** | N021875 | 002 | Mar 26, 2009 |
| ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A PALMITATE; VITAMIN E | | | | | |
| INJECTABLE;INJECTION | | | | | |
| BEROCCA PN | | | | | |
| | ROCHE | 50MG/ML;0.03MG/ML;0.0025MG/ML;7.5MG/ML;100 IU/ML;0.2MG/ML;20MG/ML;2MG/ML;1.8MG/ML; | N006071 | 003 | Oct 10, 1985 |
| ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E | | | | | |
| INJECTABLE;INJECTION | | | | | |
| M.V.C. 9+3 | | | | | |
| | ABRAXIS PHARM | 10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/ | N018440 | 002 | Aug 08, 1985 |
| M.V.I.-12 ADULT | | | | | |
| | HOSPIRA | 10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/ | N008809 | 004 | Aug 08, 1985 |
| + | | 20MG/ML;0.006MG/ML;0.05MCG/ML;1.5MG/ML; | N008809 | 006 | Sep 09, 2004 |

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION

M.V.I.-12 ADULT

| | | | | |
|---|---|---|---|---|
| | 0.0005MG/ML;0.06MG/ML;4MG/ML;0.6MG/ML;0.36MG/ML;0.6MG/ML;0.1MG/ML;1MG/ML | | | |

MVC PLUS

| | | | | |
|---|---|---|---|---|
| WATSON LABS | 10MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;0.4MG/ML;0.36MG/ | N018439 | 002 | Aug 08, 1985 |

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION

M.V.I.-12 ADULT

| | | | | |
|---|---|---|---|---|
| HOSPIRA | 20MG/ML;0.006MG/ML;0.5MCG/ML;1.5MG/ML;20 IU/ML;0.6MG/ML;4MG/ML;0.4MG/ML;0.36MG/M | N008809 | 005 | Apr 22, 2004 |

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION

M.V.I.-12 LYOPHILIZED

| | | | | |
|---|---|---|---|---|
| TELIGENT PHARMA INC | 100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;5MCG/VIAL;0.4MG/VIAL;40MG/VIAL;4MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10MG/VIAL | N018933 | 002 | Aug 08, 1985 |

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PANTOTHENIC ACID; PHYTONADIONE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; VITAMIN A PALMITATE; VITAMIN E

INJECTABLE;INJECTION

VITAPED

| | | | | |
|---|---|---|---|---|
| HOSPIRA | N/A,80MG/VIAL;N/A,0.02MG/VIAL;N/A,0.001MG/VIAL;400 IU/10ML,N/A;N/A,0.14MG/VIAL;N/A,17MG/VIAL;N/A,5MG/VIAL;0.2MG/10ML,N/A;N/A,1MG/VIAL;N/A,1.4MG/VIAL;N/A,1.2MG/VIAL;EQ 2,300 UNITS BASE/10ML,N/A;7 IU/10ML,N/A | N020176 | 001 | Dec 29, 1993 |

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL

PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC

| | | | | |
|---|---|---|---|---|
| NOVEL LABS INC | 4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM | A090145 | 001 | Jan 25, 2012 |

ASPIRIN

TABLET;ORAL

BAYER EXTRA STRENGTH ASPIRIN FOR MIGRAINE PAIN

| | | | | |
|---|---|---|---|---|
| BAYER | 500MG | N021317 | 001 | Oct 18, 2001 |

TABLET, EXTENDED RELEASE;ORAL

8-HOUR BAYER

| | | | | |
|---|---|---|---|---|
| BAYER | 650MG | N016030 | 001 | |

MEASURIN

| | | | | |
|---|---|---|---|---|
| BAYER | 650MG | N016030 | 002 | |

ASPIRIN; BUTALBITAL

TABLET;ORAL

AXOTAL

| | | | | |
|---|---|---|---|---|
| SAVAGE LABS | 650MG;50MG | A088305 | 001 | Oct 13, 1983 |

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

| | | | | |
|---|---|---|---|---|
| NOSTRUM LABS INC | 325MG;50MG;40MG | A078149 | 001 | Jun 13, 2007 |
| WATSON LABS | 325MG;50MG;40MG | A086231 | 002 | Feb 12, 1985 |

TABLET;ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

| | | | | |
|---|---|---|---|---|
| ACTAVIS ELIZABETH | 325MG;50MG;40MG | A086710 | 002 | Aug 23, 1983 |
| HALSEY | 325MG;50MG;40MG | A089448 | 001 | Dec 01, 1986 |
| IVAX PHARMS | 325MG;50MG;40MG | A085441 | 002 | Oct 31, 1984 |
| PURACAP PHARM | 325MG;50MG;40MG | A087048 | 002 | Dec 09, 1983 |
| QUANTUM PHARMICS | 325MG;50MG;40MG | A088972 | 001 | Jun 18, 1985 |
| SANDOZ | 325MG;50MG;40MG | A086398 | 002 | Apr 06, 1984 |
| WATSON LABS | 325MG;50MG;40MG | A086237 | 002 | Mar 23, 1984 |

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET;ORAL

FIORINAL

| | | | | |
|---|---|---|---|---|
| + | ALLERGAN SALES LLC | 325MG;50MG;40MG ** | N017534 003 | Apr 16, 1986 |

LANORINAL

| | | | | |
|---|---|---|---|---|
| | LANNETT | 325MG;50MG;40MG | A086986 002 | Oct 18, 1985 |

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

| | | | |
|---|---|---|---|
| VINTAGE PHARMS LLC | 325MG;50MG;40MG;30MG | A075351 001 | Mar 05, 1999 |
| WATSON LABS | 325MG;50MG;40MG;30MG | A074359 001 | Aug 31, 1995 |

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL

INVAGESIC

| | | | |
|---|---|---|---|
| SANDOZ | 385MG;30MG;25MG | A074817 001 | Nov 27, 1996 |

INVAGESIC FORTE

| | | | |
|---|---|---|---|
| SANDOZ | 770MG;60MG;50MG | A074817 002 | Nov 27, 1996 |

NORGESIC

| | | | | |
|---|---|---|---|---|
| + | MEDICIS | 385MG;30MG;25MG ** | N013416 003 | Oct 27, 1982 |

NORGESIC FORTE

| | | | | |
|---|---|---|---|---|
| + | MEDICIS | 770MG;60MG;50MG ** | N013416 004 | Oct 27, 1982 |

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

| | | | |
|---|---|---|---|
| STEVENS J | 385MG;30MG;25MG | A074988 001 | Apr 30, 1999 |
| | 770MG;60MG;50MG | A074988 002 | Apr 30, 1999 |

ORPHENGESIC

| | | | |
|---|---|---|---|
| PRINSTON INC | 385MG;30MG;25MG | A075141 001 | May 29, 1998 |

ORPHENGESIC FORTE

| | | | |
|---|---|---|---|
| PRINSTON INC | 770MG;60MG;50MG | A075141 002 | May 29, 1998 |

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

CAPSULE;ORAL

COMPOUND 65

| | | | |
|---|---|---|---|
| ALRA | 389MG;32.4MG;65MG | A084553 002 | Aug 17, 1983 |

DARVON COMPOUND

| | | | |
|---|---|---|---|
| XANODYNE PHARM | 389MG;32.4MG;32MG | N010996 006 | Mar 08, 1983 |

DARVON COMPOUND-65

| | | | |
|---|---|---|---|
| XANODYNE PHARM | 389MG;32.4MG;65MG | N010996 007 | Mar 08, 1983 |

PROPOXYPHENE COMPOUND 65

| | | | |
|---|---|---|---|
| IVAX SUB TEVA PHARMS | 389MG;32.4MG;65MG | A083077 002 | Dec 07, 1984 |
| SANDOZ | 389MG;32.4MG;65MG | A080044 002 | Sep 16, 1983 |
| TEVA | 389MG;32.4MG;65MG | A089025 001 | Mar 29, 1985 |

PROPOXYPHENE COMPOUND-65

| | | | |
|---|---|---|---|
| SANDOZ | 389MG;32.4MG;65MG | A083101 002 | Jun 24, 1985 |

PROPOXYPHENE HYDROCHLORIDE W/ ASPIRIN AND CAFFEINE

| | | | |
|---|---|---|---|
| WATSON LABS | 389MG;32.4MG;65MG | A085732 002 | Sep 03, 1984 |

ASPIRIN; CARISOPRODOL

TABLET;ORAL

CARISOPRODOL COMPOUND

| | | | |
|---|---|---|---|
| WATSON LABS | 325MG;200MG | A088809 001 | Oct 03, 1985 |

SOMA COMPOUND

| | | | |
|---|---|---|---|
| MEDA PHARMS | 325MG;200MG ** | N012365 005 | Jul 11, 1983 |

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET;ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

| | | | |
|---|---|---|---|
| OXFORD PHARMS | 325MG;200MG;16MG | A040283 001 | Dec 29, 1998 |

SOMA COMPOUND W/ CODEINE

| | | | |
|---|---|---|---|
| MEDA PHARMS | 325MG;200MG;16MG ** | N012366 002 | Jul 11, 1983 |

ASPIRIN; HYDROCODONE BITARTRATE

TABLET;ORAL

AZDONE

| | | | |
|---|---|---|---|
| SCHWARZ PHARMA | 500MG;5MG ** | A089420 001 | Jan 25, 1988 |

VICOPRIN

| | | | |
|---|---|---|---|
| ABBOTT | 500MG;5MG | A086333 001 | Sep 14, 1983 |

ASPIRIN; MEPROBAMATE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| EQUAGESIC | | | | |
| | SUN PHARM INDUSTRIES | 325MG;200MG | N011702 003 | Dec 29, 1983 |
| MEPRO-ASPIRIN | | | | |
| | SANDOZ | 325MG;200MG | A089127 001 | Mar 02, 1987 |
| MEPROBAMATE AND ASPIRIN | | | | |
| | PAR PHARM | 325MG;200MG | A089126 001 | Aug 19, 1986 |
| MICRAININ | | | | |
| | MEDPOINTE PHARM HLC | 325MG;200MG | A084978 001 | |
| Q-GESIC | | | | |
| | QUANTUM PHARMICS | 325MG;200MG | A088740 001 | Jun 01, 1984 |

ASPIRIN; METHOCARBAMOL

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| METHOCARBAMOL AND ASPIRIN | | | | |
| | IVAX SUB TEVA PHARMS | 325MG;400MG | A087211 001 | Dec 22, 1982 |
| | MCNEIL | 325MG;400MG | A089193 001 | Feb 12, 1986 |
| | PAR PHARM | 325MG;400MG | A089657 001 | Nov 04, 1988 |
| ROBAXISAL | | | | |
| | ROBINS AH | 325MG;400MG | N012281 001 | |

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| CODOXY | | | | |
| | HALSEY | 325MG;4.5MG;0.38MG | A087464 001 | Jul 01, 1982 |
| OXYCODONE AND ASPIRIN | | | | |
| | SUN PHARM INDUSTRIES | 325MG;4.5MG;0.38MG | A040260 001 | Jul 17, 1998 |
| | | 325MG;4.5MG;0.38MG | A087794 001 | May 26, 1982 |
| | WATSON LABS | 325MG;4.5MG;0.38MG | A040255 001 | Feb 27, 1998 |
| OXYCODONE AND ASPIRIN (HALF-STRENGTH) | | | | |
| | ROXANE | 325MG;2.25MG;0.19MG | A087742 001 | Jun 04, 1982 |
| PERCODAN | | | | |
| | ENDO PHARMS | 325MG;4.5MG;0.38MG ** | N007337 006 | |
| PERCODAN-DEMI | | | | |
| | ENDO PHARMS | 325MG;2.25MG;0.19MG ** | N007337 005 | |
| ROXIPRIN | | | | |
| | ROXANE | 325MG;4.5MG;0.38MG | A087743 001 | Jun 04, 1982 |

ASPIRIN; PENTAZOCINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| TALWIN COMPOUND | | | | |
| + | SANOFI AVENTIS US | 325MG;EQ 12.5MG BASE ** | N016891 001 | |

ASPIRIN; PRAVASTATIN SODIUM

| | | | | |
|---|---|---|---|---|
| TABLET, TABLET;ORAL | | | | |
| PRAVIGARD PAC (COPACKAGED) | | | | |
| | BRISTOL MYERS SQUIBB | 325MG,N/A;N/A,80MG | N021387 006 | Jun 24, 2003 |
| TABLET, TABLET, TABLET;ORAL | | | | |
| PRAVIGARD PAC (COPACKAGED) | | | | |
| | BRISTOL MYERS SQUIBB | 81MG,N/A;N/A,20MG | N021387 001 | Jun 24, 2003 |
| | | 81MG,N/A;N/A,40MG | N021387 002 | Jun 24, 2003 |
| | | 81MG,N/A;N/A,80MG | N021387 003 | Jun 24, 2003 |
| | | 325MG,N/A;N/A,20MG | N021387 004 | Jun 24, 2003 |
| | | 325MG,N/A;N/A,40MG | N021387 005 | Jun 24, 2003 |

ASPIRIN; PROPOXYPHENE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| CAPSULE;ORAL | | | | |
| DARVON W/ ASA | | | | |
| | XANODYNE PHARM | 325MG;65MG | N010996 005 | |

ASPIRIN; PROPOXYPHENE NAPSYLATE

| | | | | |
|---|---|---|---|---|
| CAPSULE;ORAL | | | | |
| DARVON-N W/ ASA | | | | |
| | AAIPHARMA LLC | 325MG;100MG | N016829 001 | |
| TABLET;ORAL | | | | |
| DARVON-N W/ ASA | | | | |
| | AAIPHARMA LLC | 325MG;100MG | N016863 001 | |

| | | | | |
|---|---|---|---|---|
| ATAZANAVIR SULFATE | | | | |
| CAPSULE;ORAL | | | | |
| REYATAZ | | | | |
| + | BRISTOL MYERS SQUIBB | EQ 100MG BASE ** | N021567 001 | Jun 20, 2003 |
| ATENOLOL | | | | |
| INJECTABLE;INJECTION | | | | |
| TENORMIN | | | | |
| + | ASTRAZENECA | 0.5MG/ML ** | N019058 001 | Sep 13, 1989 |
| TABLET;ORAL | | | | |
| ATENOLOL | | | | |
| | ABLE | 25MG | A076907 001 | Jul 30, 2004 |
| | | 50MG | A076907 002 | Jul 30, 2004 |
| | | 100MG | A076907 003 | Jul 30, 2004 |
| | APOTHECON | 50MG | A073317 001 | Mar 20, 1992 |
| | | 100MG | A073318 001 | Mar 20, 1992 |
| | DAVA PHARMS INC | 25MG | A074099 001 | Apr 28, 1992 |
| | MYLAN | 25MG | A074126 003 | Aug 26, 1998 |
| | | 50MG | A074126 001 | Mar 23, 1994 |
| | | 100MG | A074126 002 | Mar 23, 1994 |
| | NORTHSTAR HLTHCARE | 25MG | A078254 001 | Sep 25, 2009 |
| | | 50MG | A078254 002 | Sep 25, 2009 |
| | | 100MG | A078254 003 | Sep 25, 2009 |
| | NOSTRUM LABS | 50MG | A074127 001 | Feb 21, 1995 |
| | | 100MG | A074127 002 | Feb 21, 1995 |
| | PLIVA | 25MG | A074101 001 | Jul 17, 1997 |
| | | 50MG | A074101 002 | Jul 17, 1997 |
| | | 100MG | A074101 003 | Jul 17, 1997 |
| | SANDOZ | 25MG | A074265 001 | Feb 28, 1994 |
| | | 50MG | A074265 002 | Feb 28, 1994 |
| | | 100MG | A074265 003 | Feb 28, 1994 |
| | SCS | 50MG | A073676 001 | Oct 30, 1992 |
| | | 100MG | A073676 002 | Oct 30, 1992 |
| | TEVA | 50MG | A073315 001 | May 28, 1993 |
| | | 100MG | A073316 001 | May 28, 1993 |
| | TEVA PHARMS | 50MG | A074120 001 | Feb 24, 1995 |
| | | 100MG | A074120 002 | Feb 24, 1995 |
| | WATSON LABS | 50MG | A073352 001 | Dec 27, 1991 |
| | WATSON LABS TEVA | 100MG | A073353 001 | Dec 27, 1991 |
| ATENOLOL; CHLORTHALIDONE | | | | |
| TABLET;ORAL | | | | |
| ATENOLOL AND CHLORTHALIDONE | | | | |
| | NOSTRUM LABS | 50MG;25MG | A074404 001 | May 14, 1998 |
| | | 100MG;25MG | A074404 002 | May 14, 1998 |
| | PLIVA | 50MG;25MG | A074107 001 | Sep 24, 1997 |
| | | 100MG;25MG | A074107 002 | Sep 24, 1997 |
| ATOMOXETINE HYDROCHLORIDE | | | | |
| CAPSULE;ORAL | | | | |
| ATOMOXETINE HYDROCHLORIDE | | | | |
| | ZYDUS PHARMS USA INC | 18MG | A079017 001 | Sep 17, 2010 |
| | | 25MG | A079017 002 | Sep 17, 2010 |
| | | 40MG | A079017 003 | Sep 17, 2010 |
| | | 60MG | A079017 004 | Sep 17, 2010 |
| | | 80MG | A079017 005 | Sep 17, 2010 |
| | | 100MG | A079017 006 | Sep 17, 2010 |
| STRATTERA | | | | |
| | LILLY | 5MG | N021411 001 | Nov 26, 2002 |
| ATORVASTATIN CALCIUM | | | | |
| TABLET;ORAL | | | | |
| ATORVASTATIN CALCIUM | | | | |
| | TEVA PHARMS | EQ 10MG BASE | A078773 001 | May 29, 2012 |
| | | EQ 20MG BASE | A078773 002 | May 29, 2012 |
| | | EQ 40MG BASE | A078773 003 | May 29, 2012 |
| | | EQ 80MG BASE | A078773 004 | May 29, 2012 |

ATORVASTATIN CALCIUM; EZETIMIBE
TABLET;ORAL
LIPTRUZET

| | | | | | |
|---|---|---|---|---|---|
| + | MERCK SHARP DOHME | EQ 10MG BASE;10MG ** | N200153 | 001 | May 03, 2013 |
| + | | EQ 20MG BASE;10MG ** | N200153 | 002 | May 03, 2013 |
| + | | EQ 40MG BASE;10MG ** | N200153 | 003 | May 03, 2013 |
| + | | EQ 80MG BASE;10MG ** | N200153 | 004 | May 03, 2013 |

ATOVAQUONE
TABLET;ORAL
MEPRON

| | | | | | |
|---|---|---|---|---|---|
| + | GLAXOSMITHKLINE LLC | 250MG ** | N020259 | 001 | Nov 25, 1992 |

ATRACURIUM BESYLATE
INJECTABLE;INJECTION
ATRACURIUM BESYLATE

| | | | | |
|---|---|---|---|---|
| BAXTER HLTHCARE | 10MG/ML | A074824 | 001 | Sep 30, 1997 |
| BAXTER HLTHCARE CORP | 10MG/ML | A074753 | 001 | Jan 23, 1997 |
| HOSPIRA | 10MG/ML | A074632 | 001 | Dec 23, 1996 |
| | 10MG/ML | A074740 | 001 | Mar 28, 1997 |
| TEVA PARENTERAL | 10MG/ML | A074784 | 001 | Jun 11, 1997 |
| WATSON PHARMS TEVA | 10MG/ML | A074945 | 001 | Jul 28, 1998 |

ATRACURIUM BESYLATE PRESERVATIVE FREE

| | | | | |
|---|---|---|---|---|
| BAXTER HLTHCARE | 10MG/ML | A074825 | 001 | Sep 30, 1997 |
| BAXTER HLTHCARE CORP | 10MG/ML | A074768 | 001 | Jan 23, 1997 |
| HOSPIRA | 10MG/ML | A074633 | 001 | Dec 23, 1996 |
| | 10MG/ML | A074639 | 001 | Mar 25, 1997 |
| | 10MG/ML | A074741 | 001 | Mar 28, 1997 |
| WATSON LABS INC | 10MG/ML | A074944 | 001 | Jul 28, 1998 |

TRACRIUM

| | | | | | |
|---|---|---|---|---|---|
| + | HOSPIRA | 10MG/ML ** | N018831 | 002 | Jun 20, 1985 |

TRACRIUM PRESERVATIVE FREE

| | | | | | |
|---|---|---|---|---|---|
| + | HOSPIRA | 10MG/ML ** | N018831 | 001 | Nov 23, 1983 |

ATROPINE
INJECTABLE;INJECTION
ATROPINE

| | | | | |
|---|---|---|---|---|
| ABBVIE | EQ 2MG SULFATE/0.7ML | A071295 | 001 | Jan 30, 1987 |

ATROPINE SULFATE
AEROSOL, METERED;INHALATION
ATROPINE SULFATE

| | | | | |
|---|---|---|---|---|
| US ARMY | EQ 0.36MG BASE/INH | N020056 | 001 | Sep 19, 1990 |

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE
TABLET;ORAL
MOTOFEN HALF-STRENGTH

| | | | |
|---|---|---|---|
| SEBELA IRELAND LTD | 0.025MG;0.5MG | N017744 | 001 |

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE
CAPSULE;ORAL
DIPHENOXYLATE HYDROCHLORIDE W/ ATROPINE SULFATE

| | | | |
|---|---|---|---|
| SCHERER RP | 0.025MG;2.5MG | A086440 | 001 |

SOLUTION;ORAL
COLONAID

| | | | |
|---|---|---|---|
| MEDPOINTE PHARM HLC | 0.025MG/5ML;2.5MG/5ML | A085735 | 001 |

LOMANATE

| | | | |
|---|---|---|---|
| ALPHARMA US PHARMS | 0.025MG/5ML;2.5MG/5ML | A085746 | 001 |

LOMOTIL

| | | | |
|---|---|---|---|
| GD SEARLE LLC | 0.025MG/5ML;2.5MG/5ML | N012699 | 001 |

TABLET;ORAL
COLONAID

| | | | |
|---|---|---|---|
| MEDPOINTE PHARM HLC | 0.025MG;2.5MG | A085737 | 001 |

DI-ATRO

| | | | |
|---|---|---|---|
| MD PHARM | 0.025MG;2.5MG | A085266 | 001 |

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

| | | | | |
|---|---|---|---|---|
| ABLE | 0.025MG;2.5MG | A040395 | 001 | Nov 27, 2000 |
| ASCOT | 0.025MG;2.5MG | A087934 | 001 | Jul 19, 1983 |
| HEATHER | 0.025MG;2.5MG | A086798 | 001 | |
| HIKMA PHARMS | 0.025MG;2.5MG | A087765 | 001 | Mar 15, 1982 |
| INWOOD LABS | 0.025MG;2.5MG | A085509 | 001 | |
| KV PHARM | 0.025MG;2.5MG | A085659 | 001 | |

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

| | | | | |
|---|---|---|---|---|
| LEDERLE | 0.025MG;2.5MG | A086950 | 001 | |
| PARKE DAVIS | 0.025MG;2.5MG | A087131 | 001 | |
| PVT FORM | 0.025MG;2.5MG | A085766 | 001 | |
| R AND S PHARMA | 0.025MG;2.5MG | A085035 | 001 | |
| ROXANE | 0.025MG;2.5MG | A086057 | 001 | |
| SANDOZ | 0.025MG;2.5MG | A086173 | 001 | |
| SUN PHARM INDUSTRIES | 0.025MG;2.5MG | A085506 | 001 | |
| USL PHARMA | 0.025MG;2.5MG | A087842 | 001 | Mar 29, 1982 |
| VALEANT PHARM INTL | 0.025MG;2.5MG | A087195 | 001 | Feb 16, 1982 |
| WATSON LABS | 0.025MG;2.5MG | A085876 | 001 | |

LO-TROL

| | | | | |
|---|---|---|---|---|
| VANGARD | 0.025MG;2.5MG | A088009 | 001 | Mar 25, 1983 |

LOGEN

| | | | | |
|---|---|---|---|---|
| SUPERPHARM | 0.025MG;2.5MG | A088962 | 001 | May 10, 1985 |

LONOX

| | | | | |
|---|---|---|---|---|
| SANDOZ | 0.025MG;2.5MG | A085311 | 002 | |

LOW-QUEL

| | | | | |
|---|---|---|---|---|
| HALSEY | 0.025MG;2.5MG | A085211 | 001 | |

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION

ENLON-PLUS

| | | | | |
|---|---|---|---|---|
| MYLAN INSTITUTIONAL | 0.14MG/ML;10MG/ML | N019677 | 001 | Nov 06, 1991 |
| + | 0.14MG/ML;10MG/ML | N019678 | 001 | Nov 06, 1991 |

ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

ATROPINE AND DEMEROL

| | | | | |
|---|---|---|---|---|
| ABBVIE | 0.4MG/ML;50MG/ML | A087853 | 001 | Nov 26, 1982 |
| | 0.4MG/ML;75MG/ML | A087847 | 001 | Nov 26, 1982 |
| | 0.4MG/ML;100MG/ML | A087848 | 001 | Nov 26, 1982 |

MEPERIDINE AND ATROPINE SULFATE

| | | | | |
|---|---|---|---|---|
| WYETH AYERST | 0.4MG/ML;50MG/ML | A085121 | 001 | |
| | 0.4MG/ML;75MG/ML | A085121 | 002 | |
| | 0.4MG/ML;100MG/ML | A085121 | 003 | |

ATROPINE; PRALIDOXIME CHLORIDE

INJECTABLE;INTRAMUSCULAR

ATNAA

| | | | | |
|---|---|---|---|---|
| US ARMY | 2.1MG/0.7ML;600MG/2ML | N021175 | 001 | Jan 17, 2002 |

AVOBENZONE; OCTINOXATE; OXYBENZONE

LOTION;TOPICAL

SHADE UVAGUARD

| | | | | | |
|---|---|---|---|---|---|
| + | BAYER HEALTHCARE LLC | 3%;7.5%;3% | N020045 | 001 | Dec 07, 1992 |

AZATADINE MALEATE

TABLET;ORAL

OPTIMINE

| | | | | |
|---|---|---|---|---|
| SCHERING | 1MG | N017601 | 001 | |

AZATADINE MALEATE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL

TRINALIN

| | | | | |
|---|---|---|---|---|
| SCHERING | 1MG;120MG | N018506 | 001 | Mar 23, 1982 |

AZATHIOPRINE

TABLET;ORAL

IMURAN

| | | | | |
|---|---|---|---|---|
| + SEBELA IRELAND LTD | 25MG ** | N016324 | 002 | |

AZATHIOPRINE SODIUM

INJECTABLE;INJECTION

IMURAN

| | | | | |
|---|---|---|---|---|
| + CASPER PHARMA LLC | EQ 100MG BASE/VIAL ** | N017391 | 001 | |

| | | | | |
|---|---|---|---|---|
| AZELASTINE HYDROCHLORIDE | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | |
| OPTIVAR | | | | |
| + MYLAN SPECIALITY LP | 0.05% | N021127 | 001 | May 22, 2000 |
| SPRAY, METERED;NASAL | | | | |
| ASTEPRO | | | | |
| MYLAN SPECIALITY LP | EQ 0.125MG BASE/SPRAY | N022203 | 001 | Oct 15, 2008 |
| AZITHROMYCIN | | | | |
| CAPSULE;ORAL | | | | |
| ZITHROMAX | | | | |
| + PFIZER | EQ 250MG BASE ** | N050670 | 001 | Nov 01, 1991 |
| FOR SUSPENSION;ORAL | | | | |
| AZITHROMYCIN | | | | |
| SANDOZ | EQ 100MG BASE/5ML | A065297 | 001 | Sep 18, 2006 |
| | EQ 200MG BASE/5ML | A065297 | 002 | Sep 18, 2006 |
| INJECTABLE;INJECTION | | | | |
| AZITHROMYCIN | | | | |
| CSPC OUYI PHARM CO | EQ 500MG BASE/VIAL | A065265 | 001 | Jan 18, 2007 |
| TEVA PARENTERAL | EQ 500MG BASE/VIAL | N050809 | 001 | Dec 19, 2006 |
| | EQ 2.5GM BASE/VIAL | N050809 | 002 | Dec 19, 2006 |
| TABLET;ORAL | | | | |
| AZITHROMYCIN | | | | |
| MYLAN | EQ 250MG BASE | A065365 | 001 | May 30, 2007 |
| | EQ 500MG BASE | A065366 | 001 | May 30, 2007 |
| AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE | | | | |
| FOR SUSPENSION, TABLET;ORAL | | | | |
| TROVAN/ZITHROMAX COMPLIANCE PAK | | | | |
| PFIZER | EQ 1GM BASE,N/A;N/A,EQ 100MG BASE | N050762 | 001 | Dec 18, 1998 |
| AZLOCILLIN SODIUM | | | | |
| INJECTABLE;INJECTION | | | | |
| AZLIN | | | | |
| BAYER PHARMS | EQ 2GM BASE/VIAL | A062388 | 001 | Sep 08, 1982 |
| | EQ 2GM BASE/VIAL | A062417 | 001 | Oct 12, 1982 |
| | EQ 2GM BASE/VIAL | N050562 | 001 | Sep 03, 1982 |
| | EQ 3GM BASE/VIAL | A062388 | 002 | Sep 08, 1982 |
| | EQ 3GM BASE/VIAL | A062417 | 002 | Oct 12, 1982 |
| | EQ 3GM BASE/VIAL | N050562 | 002 | Sep 03, 1982 |
| | EQ 4GM BASE/VIAL | A062388 | 003 | Sep 08, 1982 |
| | EQ 4GM BASE/VIAL | A062417 | 003 | Oct 12, 1982 |
| | EQ 4GM BASE/VIAL | N050562 | 003 | Sep 03, 1982 |
| AZTREONAM | | | | |
| INJECTABLE;INJECTION | | | | |
| AZACTAM | | | | |
| BRISTOL MYERS SQUIBB | 500MG/VIAL | N050580 | 001 | Dec 31, 1986 |
| AZACTAM IN PLASTIC CONTAINER | | | | |
| BRISTOL MYERS SQUIBB | 10MG/ML | N050632 | 003 | May 24, 1989 |
| AZTREONAM | | | | |
| WEST-WARD PHARMS INT | 1GM/VIAL | A065286 | 001 | Mar 23, 2011 |
| | 2GM/VIAL | A065286 | 002 | Mar 23, 2011 |
| BACAMPICILLIN HYDROCHLORIDE | | | | |
| FOR SUSPENSION;ORAL | | | | |
| SPECTROBID | | | | |
| PFIZER | 125MG/5ML | N050556 | 001 | Mar 23, 1982 |
| TABLET;ORAL | | | | |
| SPECTROBID | | | | |
| PFIZER | 400MG | N050520 | 001 | |
| | 800MG | N050520 | 002 | Sep 12, 1983 |
| BACITRACIN | | | | |
| INJECTABLE;INJECTION | | | | |
| BACITRACIN | | | | |
| PFIZER | 50,000 UNITS/VIAL | A060282 | 001 | |
| OINTMENT;OPHTHALMIC | | | | |
| BACIGUENT | | | | |
| PHARMACIA AND UPJOHN | 500 UNITS/GM | A060734 | 001 | |
| BACITRACIN | | | | |
| LILLY | 500 UNITS/GM | A060687 | 001 | |

BACITRACIN

OINTMENT;OPHTHALMIC

BACITRACIN

| | | | | |
|---|---|---|---|---|
| PHARMADERM | 500 UNITS/GM | A062158 001 | | |
| PHARMAFAIR | 500 UNITS/GM | A062453 001 | | Mar 28, 1984 |

OINTMENT;TOPICAL

BACITRACIN

| | | | | |
|---|---|---|---|---|
| COMBE | 500 UNITS/GM | A062799 001 | | May 14, 1987 |
| NASKA | 500 UNITS/GM | A062857 001 | | Nov 13, 1987 |

POWDER;FOR RX COMPOUNDING

BACI-RX

| | | | | |
|---|---|---|---|---|
| X GEN PHARMS | 5,000,000 UNITS/BOT | A061580 001 | | |

BACITRACIN

| | | | | |
|---|---|---|---|---|
| APOTHEKERNES | 5,000,000 UNITS/BOT | A061699 001 | | |
| PADDOCK LLC | 5,000,000 UNITS/BOT | A062456 001 | | Jul 27, 1983 |

BACITRACIN ZINC

POWDER;FOR RX COMPOUNDING

ZIBA-RX

| | | | | |
|---|---|---|---|---|
| X GEN PHARMS | 500,000 UNITS/BOT | A061737 001 | | |

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

CORTISPORIN

| | | | | | |
|---|---|---|---|---|---|
| + | CASPER PHARMA LLC | 400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM ** | N050416 002 | | |

ZINC BACITRACIN,NEOMYCIN SULFATE,POLYMYXIN B SULFATE & HYDROCORTISONE

| | | | | |
|---|---|---|---|---|
| PHARMAFAIR | 400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM | A062389 001 | | Jul 02, 1982 |

OINTMENT;TOPICAL

NEOMYCIN & POLYMYXIN B SULFATES & BACITRACIN ZINC & HYDROCORTISONE

| | | | | |
|---|---|---|---|---|
| PHARMAFAIR | 400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM | A062381 001 | | Sep 06, 1985 |

BACITRACIN ZINC; LIDOCAINE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;TOPICAL

LANABIOTIC

| | | | | |
|---|---|---|---|---|
| COMBE | 400 UNITS/GM;40MG/GM;EQ 5MG BASE/GM;5,000 UNITS/GM | A062499 001 | | Jun 03, 1985 |

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE

| | | | | |
|---|---|---|---|---|
| PHARMAFAIR | 400 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM | A062386 001 | | Sep 09, 1982 |

BACITRACIN-NEOMYCIN-POLYMYXIN

| | | | | |
|---|---|---|---|---|
| PHARMADERM | 400 UNITS/GM;EQ 3.5MG BASE/GM;5,000 UNITS/GM | A062167 001 | | |

NEO-POLYCIN

| | | | | |
|---|---|---|---|---|
| DOW PHARM | 500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM | A060647 001 | | |

OINTMENT;TOPICAL

BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE

| | | | | |
|---|---|---|---|---|
| NASKA | 400 UNITS/GM;EQ 3.5MG BASE/GM;5,000 UNITS/GM | A062833 001 | | Nov 09, 1987 |

BACITRACIN ZINC; POLYMYXIN B SULFATE

AEROSOL;TOPICAL

POLYSPORIN

| | | | | |
|---|---|---|---|---|
| GLAXOSMITHKLINE | 10,000 UNITS/GM;2,000,000 UNITS/GM | N050167 002 | | Mar 01, 1985 |

OINTMENT;OPHTHALMIC

OCUMYCIN

| | | | | |
|---|---|---|---|---|
| PHARMAFAIR | 500 UNITS/GM;10,000 UNITS/GM | A062430 001 | | Apr 08, 1983 |

POLYSPORIN

| | | | | |
|---|---|---|---|---|
| MONARCH PHARMS | 500 UNITS/GM;10,000 UNITS/GM ** | A061229 001 | | |

OINTMENT;TOPICAL

BACITRACIN ZINC-POLYMYXIN B SULFATE

| | | | | |
|---|---|---|---|---|
| NASKA | 500 UNITS/GM;10,000 UNITS/GM | A062849 001 | | Nov 13, 1987 |

| | | | | |
|---|---|---|---|---|
| BACITRACIN; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE | | | | |
| OINTMENT;OPHTHALMIC | | | | |
| BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE | | | | |
| | ALTANA | 400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM | A060731 002 | |
| BACITRACIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE | | | | |
| OINTMENT;OPHTHALMIC | | | | |
| MYCITRACIN | | | | |
| | PHARMACIA AND UPJOHN | 500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM | A061048 001 | |
| BACITRACIN; POLYMYXIN B SULFATE | | | | |
| DISC;TOPICAL | | | | |
| LANABIOTIC | | | | |
| | COMBE | 500 UNITS/GM;5,000 UNITS/GM | N050598 001 | Sep 22, 1986 |
| BACLOFEN | | | | |
| TABLET;ORAL | | | | |
| BACLOFEN | | | | |
| | MYLAN | 10MG | A077181 001 | Jul 29, 2005 |
| | TEVA | 10MG | A073043 001 | Feb 27, 1992 |
| | | 20MG | A073044 001 | Feb 27, 1992 |
| | USL PHARMA | 10MG | A071260 001 | May 06, 1988 |
| | | 20MG | A071261 001 | May 06, 1988 |
| | WATSON LABS | 10MG | A072824 001 | Sep 18, 1991 |
| | | 10MG | A073092 001 | Jan 28, 1994 |
| | | 10MG | A074698 001 | Aug 20, 1996 |
| | | 20MG | A072825 001 | Sep 18, 1991 |
| | | 20MG | A073093 001 | Jan 28, 1994 |
| | | 20MG | A074698 002 | Aug 20, 1996 |
| LIORESAL | | | | |
| + | NOVARTIS | 10MG ** | N017851 001 | |
| + | | 20MG ** | N017851 003 | Jan 20, 1982 |
| TABLET, ORALLY DISINTEGRATING;ORAL | | | | |
| KEMSTRO | | | | |
| | UCB INC | 10MG | N021589 001 | Oct 30, 2003 |
| | | 20MG | N021589 002 | Oct 30, 2003 |
| BARIUM SULFATE | | | | |
| FOR SUSPENSION;ORAL | | | | |
| E-Z-CAT DRY | | | | |
| + | BRACCO | 40% (9GM/POUCH) | N208036 003 | Jan 03, 2017 |
| BECLOMETHASONE DIPROPIONATE | | | | |
| AEROSOL, METERED;INHALATION | | | | |
| BECLOVENT | | | | |
| | GLAXOSMITHKLINE | 0.042MG/INH | N018153 001 | |
| VANCERIL | | | | |
| | SCHERING | 0.042MG/INH | N017573 001 | |
| VANCERIL DOUBLE STRENGTH | | | | |
| | SCHERING | 0.084MG/INH | N020486 001 | Dec 24, 1996 |
| AEROSOL, METERED;NASAL | | | | |
| BECONASE | | | | |
| | GLAXOSMITHKLINE | 0.042MG/INH | N018584 001 | |
| VANCENASE | | | | |
| | SCHERING | 0.042MG/INH | N018521 001 | |
| BECLOMETHASONE DIPROPIONATE MONOHYDRATE | | | | |
| SPRAY, METERED;NASAL | | | | |
| VANCENASE AQ | | | | |
| | SCHERING | EQ 0.042MG DIPROP/SPRAY | N019589 001 | Dec 23, 1987 |
| | | EQ 0.084MG DIPROP/SPRAY | N020469 001 | Jun 26, 1996 |
| BENAZEPRIL HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| BENAZEPRIL HYDROCHLORIDE | | | | |
| | ACTAVIS LABS FL INC | 5MG | A076267 001 | Feb 11, 2004 |
| | | 10MG | A076267 002 | Feb 11, 2004 |
| | | 20MG | A076267 003 | Feb 11, 2004 |
| | | 40MG | A076267 004 | Feb 11, 2004 |
| | GENPHARM | 5MG | A076476 001 | Feb 11, 2004 |
| | | 10MG | A076476 002 | Feb 11, 2004 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| | 20MG | A076476 | 003 | Feb 11, 2004 |
| | 40MG | A076476 | 004 | Feb 11, 2004 |

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

| | | | | |
|---|---|---|---|---|
| ACTAVIS LABS FL INC | 5MG;6.25MG | A076342 | 001 | Feb 11, 2004 |
| | 10MG;12.5MG | A076342 | 002 | Feb 11, 2004 |
| | 20MG;12.5MG | A076342 | 003 | Feb 11, 2004 |
| | 20MG;25MG | A076342 | 004 | Feb 11, 2004 |
| IVAX SUB TEVA PHARMS | 5MG;6.25MG | A076348 | 001 | Feb 11, 2004 |
| | 10MG;12.5MG | A076348 | 002 | Feb 11, 2004 |
| | 20MG;12.5MG | A076348 | 003 | Feb 11, 2004 |
| | 20MG;25MG | A076348 | 004 | Feb 11, 2004 |
| MYLAN PHARMS INC | 5MG;6.25MG | A076612 | 001 | Feb 11, 2004 |
| | 10MG;12.5MG | A076612 | 002 | Feb 11, 2004 |
| | 20MG;12.5MG | A076612 | 003 | Feb 11, 2004 |
| | 20MG;25MG | A076612 | 004 | Feb 11, 2004 |
| SUN PHARM INDS LTD | 5MG;6.25MG | A077483 | 001 | Sep 08, 2005 |
| | 10MG;12.5MG | A077483 | 002 | Sep 08, 2005 |
| | 20MG;12.5MG | A077483 | 003 | Sep 08, 2005 |
| | 20MG;25MG | A077483 | 004 | Sep 08, 2005 |

LOTENSIN HCT

| | | | | | |
|---|---|---|---|---|---|
| + | US PHARMS HOLDINGS I | 5MG;6.25MG | N020033 | 001 | May 19, 1992 |

BENDROFLUMETHIAZIDE

TABLET;ORAL

NATURETIN-10

| | | | | |
|---|---|---|---|---|
| APOTHECON | 10MG | N012164 | 003 | |

NATURETIN-2.5

| | | | | |
|---|---|---|---|---|
| APOTHECON | 2.5MG | N012164 | 001 | |

NATURETIN-5

| | | | | |
|---|---|---|---|---|
| APOTHECON | 5MG | N012164 | 002 | |

BENDROFLUMETHIAZIDE; NADOLOL

TABLET;ORAL

NADOLOL AND BENDROFLUMETHIAZIDE

| | | | | |
|---|---|---|---|---|
| MYLAN | 5MG;40MG | A078688 | 001 | Feb 15, 2008 |
| | 5MG;80MG | A078688 | 002 | Feb 15, 2008 |

BENOXINATE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

BENOXINATE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| SOLA BARNES HIND | 0.4% | A084149 | 001 | |

BENTIROMIDE

SOLUTION;ORAL

CHYMEX

| | | | | |
|---|---|---|---|---|
| SAVAGE LABS | 500MG/7.5ML | N018366 | 001 | Dec 29, 1983 |

BENZONATATE

CAPSULE;ORAL

BENZONATATE

| | | | | |
|---|---|---|---|---|
| NESHER PHARMS | 100MG | A040795 | 001 | Oct 31, 2007 |
| | 200MG | A040795 | 002 | Oct 31, 2007 |

TESSALON

| | | | | | |
|---|---|---|---|---|---|
| + | PFIZER | 200MG ** | N011210 | 003 | Jun 25, 1999 |

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

BENZACLIN

| | | | | |
|---|---|---|---|---|
| VALEANT BERMUDA | 5%;EQ 1% BASE | N050756 | 002 | Apr 20, 2007 |

BENZPHETAMINE HYDROCHLORIDE

TABLET;ORAL

BENZPHETAMINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| EPIC PHARMA LLC | 50MG | A040714 | 001 | Oct 29, 2007 |
| IMPAX LABS | 50MG | A040845 | 001 | Nov 18, 2008 |

DIDREX

| | | | | | |
|---|---|---|---|---|---|
| + | PHARMACIA AND UPJOHN | 25MG ** | N012427 | 003 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

BENZPHETAMINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| DIDREX | | | | |
| + | | 50MG ** | N012427 002 | |

BENZQUINAMIDE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| EMETE-CON | | | | |
| | PFIZER | EQ 50MG BASE/VIAL | N016820 001 | |
| SUPPOSITORY;RECTAL | | | | |
| EMETE-CON | | | | |
| | ROERIG | EQ 100MG BASE | N016818 006 | |

BENZTHIAZIDE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| AQUATAG | | | | |
| | SOLVAY | 25MG | N016001 001 | |
| | | 50MG | N016001 002 | |
| BENZTHIAZIDE | | | | |
| | PVT FORM | 50MG | A083206 001 | |
| EXNA | | | | |
| | AH ROBINS INC | 50MG | N012489 001 | |
| FOVANE | | | | |
| | PFIZER | 50MG | N012128 002 | |
| URESE | | | | |
| | PFIZER | 25MG | N012128 003 | |

BENZTROPINE MESYLATE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| BENZTROPINE MESYLATE | | | | |
| | ANDA REPOSITORY | 1MG | A081264 001 | Jan 23, 1992 |
| | | 2MG | A081265 001 | Jan 23, 1992 |
| | LANNETT HOLDINGS INC | 0.5MG ** | A088877 001 | Apr 11, 1985 |
| | | 1MG ** | A088894 001 | Apr 11, 1985 |
| | | 2MG ** | A088895 001 | Apr 11, 1985 |
| | OXFORD PHARMS | 2MG | A040706 001 | Feb 14, 2008 |
| | QUANTUM PHARMICS | 0.5MG | A088514 001 | Jan 31, 1984 |
| | | 1MG | A088510 001 | Jan 31, 1984 |
| | | 2MG | A088511 001 | Jan 31, 1984 |
| | USL PHARMA | 0.5MG | A089211 001 | Jun 14, 1988 |
| | | 1MG | A089212 001 | Jun 14, 1988 |
| | | 2MG | A089213 001 | Jun 14, 1988 |
| COGENTIN | | | | |
| + | MERCK | 0.5MG ** | N009193 004 | |
| + | | 1MG ** | N009193 003 | |
| + | | 2MG ** | N009193 002 | |

BENZYL BENZOATE

| | | | | |
|---|---|---|---|---|
| EMULSION;TOPICAL | | | | |
| BENZYL BENZOATE | | | | |
| | LANNETT | 50% | A084535 001 | |

BEPRIDIL HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| BEPADIN | | | | |
| | MEDPOINTE PHARM HLC | 200MG | N019001 001 | Dec 28, 1990 |
| | | 300MG | N019001 002 | Dec 28, 1990 |
| | | 400MG | N019001 003 | Dec 28, 1990 |
| VASCOR | | | | |
| | JOHNSON AND JOHNSON | 200MG | N019002 001 | Dec 28, 1990 |
| | | 300MG | N019002 002 | Dec 28, 1990 |
| | | 400MG | N019002 003 | Dec 28, 1990 |

BETA CAROTENE

| | | | | |
|---|---|---|---|---|
| CAPSULE;ORAL | | | | |
| SOLATENE | | | | |
| | ROCHE | 30MG | N017589 001 | |

| | | | | |
|---|---|---|---|---|
| BETAMETHASONE | | | | |
| CREAM;TOPICAL | | | | |
| CELESTONE | | | | |
| SCHERING | 0.2% | N014762 001 | | |
| SYRUP;ORAL | | | | |
| CELESTONE | | | | |
| MERCK SHARP DOHME | 0.6MG/5ML | N014215 002 | | |
| TABLET;ORAL | | | | |
| CELESTONE | | | | |
| SCHERING | 0.6MG | N012657 003 | | |
| BETAMETHASONE BENZOATE | | | | |
| CREAM;TOPICAL | | | | |
| UTICORT | | | | |
| PARKE DAVIS | 0.025% | N016998 002 | | |
| GEL;TOPICAL | | | | |
| UTICORT | | | | |
| PARKE DAVIS | 0.025% | N017244 001 | | |
| LOTION;TOPICAL | | | | |
| UTICORT | | | | |
| PARKE DAVIS | 0.025% | N017528 001 | | |
| OINTMENT;TOPICAL | | | | |
| UTICORT | | | | |
| PARKE DAVIS | 0.025% | N018089 001 | | |
| BETAMETHASONE DIPROPIONATE | | | | |
| CREAM;TOPICAL | | | | |
| ALPHATREX | | | | |
| SAVAGE LABS | EQ 0.05% BASE | N019138 001 | Jun 26, 1984 | |
| BETAMETHASONE DIPROPIONATE | | | | |
| PERRIGO NEW YORK | EQ 0.05% BASE | A072536 001 | Jan 31, 1990 | |
| | EQ 0.05% BASE | A074579 001 | Nov 26, 1997 | |
| PHARMADERM | EQ 0.05% BASE | N019136 001 | Jun 26, 1984 | |
| TARO | EQ 0.05% BASE | A071143 001 | Jun 17, 1987 | |
| TEVA | EQ 0.05% BASE | A071476 001 | Aug 10, 1987 | |
| DIPROSONE | | | | |
| SCHERING | EQ 0.05% BASE | N017536 001 | | |
| CREAM, AUGMENTED;TOPICAL | | | | |
| DIPROLENE | | | | |
| SCHERING | EQ 0.05% BASE | N019408 001 | Jan 31, 1986 | |
| DISC;TOPICAL | | | | |
| DIPROSONE | | | | |
| SCHERING | EQ 0.1% BASE | N017829 001 | | |
| GEL, AUGMENTED;TOPICAL | | | | |
| DIPROLENE | | | | |
| SCHERING | EQ 0.05% BASE | N019408 002 | Nov 22, 1991 | |
| LOTION;TOPICAL | | | | |
| ALPHATREX | | | | |
| SAVAGE LABS | EQ 0.05% BASE | A070273 001 | Aug 12, 1985 | |
| BETAMETHASONE DIPROPIONATE | | | | |
| ALPHARMA US PHARMS | EQ 0.05% BASE | A071085 001 | Feb 03, 1987 | |
| G AND W LABS INC | EQ 0.05% BASE | A071882 001 | Jun 06, 1988 | |
| PHARMADERM | EQ 0.05% BASE | A070274 001 | Aug 12, 1985 | |
| TARO | EQ 0.05% BASE | A072276 001 | Aug 24, 1988 | |
| | EQ 0.05% BASE | A074272 001 | Sep 30, 1994 | |
| DIPROSONE | | | | |
| + SCHERING | EQ 0.05% BASE ** | N017781 001 | | |
| OINTMENT;TOPICAL | | | | |
| ALPHATREX | | | | |
| SAVAGE LABS | EQ 0.05% BASE | N019143 001 | Sep 04, 1984 | |
| BETAMETHASONE DIPROPIONATE | | | | |
| PERRIGO NEW YORK | EQ 0.05% BASE | A072526 001 | Jan 31, 1990 | |
| PHARMADERM | EQ 0.05% BASE | N019140 001 | Sep 04, 1984 | |
| TEVA | EQ 0.05% BASE | A071477 001 | Aug 10, 1987 | |
| DIPROSONE | | | | |
| SCHERING | EQ 0.05% BASE | N017691 001 | | |

| | | | | |
|---|---|---|---|---|
| BETAMETHASONE SODIUM PHOSPHATE | | | | |
| INJECTABLE;INJECTION | | | | |
| BETAMETHASONE SODIUM PHOSPHATE | | | | |
| WATSON LABS | EQ 3MG BASE/ML | A085738 001 | | |
| CELESTONE | | | | |
| + SCHERING | EQ 3MG BASE/ML ** | N017561 001 | | |
| BETAMETHASONE VALERATE | | | | |
| CREAM;TOPICAL | | | | |
| BETADERM | | | | |
| ROACO | EQ 0.1% BASE | N018839 001 | Jun 30, 1983 | |
| BETAMETHASONE VALERATE | | | | |
| PERRIGO NEW YORK | EQ 0.1% BASE | A070053 001 | Jun 10, 1986 | |
| PHARMADERM | EQ 0.1% BASE | N018860 002 | Aug 31, 1983 | |
| PHARMAFAIR | EQ 0.1% BASE | A070485 001 | May 29, 1987 | |
| TARO | EQ 0.1% BASE | A070062 001 | May 14, 1985 | |
| BETATREX | | | | |
| SAVAGE LABS | EQ 0.1% BASE | N018862 001 | Aug 31, 1983 | |
| VALISONE | | | | |
| SCHERING | EQ 0.01% BASE | N016322 002 | | |
| | EQ 0.1% BASE | N016322 001 | | |
| LOTION;TOPICAL | | | | |
| BETAMETHASONE VALERATE | | | | |
| PHARMADERM | EQ 0.1% BASE | N018870 001 | Aug 31, 1983 | |
| PHARMAFAIR | EQ 0.1% BASE | A070484 001 | May 29, 1987 | |
| TEVA PHARMS | EQ 0.1% BASE | A071883 001 | Apr 22, 1988 | |
| BETATREX | | | | |
| SAVAGE LABS | EQ 0.1% BASE | N018867 001 | Aug 31, 1983 | |
| VALISONE | | | | |
| SCHERING | EQ 0.1% BASE | N016932 001 | | |
| OINTMENT;TOPICAL | | | | |
| BETAMETHASONE VALERATE | | | | |
| PERRIGO NEW YORK | EQ 0.1% BASE | A071478 001 | Dec 23, 1987 | |
| PHARMADERM | EQ 0.1% BASE | N018864 001 | Aug 31, 1983 | |
| PHARMAFAIR | EQ 0.1% BASE | A070486 001 | May 29, 1987 | |
| BETATREX | | | | |
| SAVAGE LABS | EQ 0.1% BASE | N018863 001 | Aug 31, 1983 | |
| VALISONE | | | | |
| SCHERING | EQ 0.1% BASE | N016740 001 | | |
| BETAXOLOL HYDROCHLORIDE | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | |
| BETAXOLOL HYDROCHLORIDE | | | | |
| APOTEX INC | EQ 0.5% BASE | A075446 001 | Sep 28, 2000 | |
| TABLET;ORAL | | | | |
| KERLONE | | | | |
| SANOFI AVENTIS US | 10MG | N019507 001 | Oct 27, 1989 | |
| | 20MG | N019507 002 | Oct 27, 1989 | |
| BETAXOLOL HYDROCHLORIDE; CHLORTHALIDONE | | | | |
| TABLET;ORAL | | | | |
| KERLEDEX | | | | |
| SANOFI AVENTIS US | 5MG;12.5MG | N019807 001 | Oct 30, 1992 | |
| | 10MG;12.5MG | N019807 002 | Oct 30, 1992 | |
| BETAXOLOL HYDROCHLORIDE; PILOCARPINE HYDROCHLORIDE | | | | |
| SUSPENSION/DROPS;OPHTHALMIC | | | | |
| BETOPTIC PILO | | | | |
| ALCON | EQ 0.25% BASE;1.75% | N020619 001 | Apr 17, 1997 | |
| BETAZOLE HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| HISTALOG | | | | |
| LILLY | 50MG/ML | N009344 001 | | |
| BETHANECHOL CHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| URECHOLINE | | | | |
| + ODYSSEY PHARMS | 5MG/ML ** | N006536 001 | | |
| TABLET;ORAL | | | | |
| BETHANECHOL CHLORIDE | | | | |
| ABLE | 5MG | A040492 001 | Jul 27, 2004 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

| | | | | |
|---|---|---|---|---|
| | 10MG | A040483 | 001 | Jul 27, 2004 |
| | 25MG | A040485 | 001 | Jul 27, 2004 |
| | 50MG | A040509 | 001 | Jul 27, 2004 |
| ACTAVIS ELIZABETH | 5MG | A040552 | 001 | Oct 28, 2004 |
| | 10MG | A040553 | 001 | Oct 28, 2004 |
| | 25MG | A040554 | 001 | Oct 28, 2004 |
| | 50MG | A040551 | 001 | Oct 28, 2004 |
| ASCOT | 10MG | A088288 | 001 | Jun 08, 1983 |
| | 25MG | A088289 | 001 | Jun 08, 1983 |
| IMPAX LABS | 5MG | A040721 | 001 | Nov 01, 2006 |
| | 10MG | A040721 | 002 | Nov 01, 2006 |
| | 25MG | A040721 | 003 | Nov 01, 2016 |
| | 50MG | A040721 | 004 | Nov 01, 2006 |
| IVAX SUB TEVA PHARMS | 25MG | A084689 | 001 | |
| LANNETT | 5MG | A084702 | 001 | |
| | 10MG | A084712 | 001 | |
| | 25MG | A084074 | 001 | |
| SANDOZ | 5MG | A084353 | 001 | |
| | 10MG | A084378 | 001 | |
| | 10MG | A084379 | 001 | |
| | 25MG | A084383 | 001 | |
| | 25MG | A084384 | 001 | |
| SUN PHARM INDS INC | 5MG | A040897 | 001 | Apr 22, 2009 |
| | 10MG | A040897 | 002 | Apr 22, 2009 |
| | 25MG | A040897 | 003 | Apr 22, 2009 |
| | 50MG | A040897 | 004 | Apr 22, 2009 |
| WATSON LABS | 5MG | A084402 | 001 | |
| | 5MG | A085230 | 002 | |
| | 5MG | A085841 | 001 | |
| | 10MG | A084408 | 001 | |
| | 10MG | A085228 | 001 | |
| | 10MG | A085842 | 001 | |
| | 25MG | A084441 | 001 | |
| | 25MG | A085229 | 001 | |
| | 25MG | A085839 | 001 | |
| | 50MG | A087397 | 001 | |
| | 50MG | A087444 | 001 | |

MYOTONACHOL

| | | | | |
|---|---|---|---|---|
| GLENWOOD | 5MG | A084188 | 001 | |
| | 10MG | A084188 | 003 | |
| | 25MG | A084188 | 004 | |

URECHOLINE

| | | | | |
|---|---|---|---|---|
| + ODYSSEY PHARMS | 5MG ** | N006536 | 003 | |
| + | 10MG ** | N006536 | 002 | |
| + | 25MG ** | N006536 | 004 | |
| + | 50MG ** | N006536 | 005 | |

BETHANIDINE SULFATE

TABLET;ORAL

TENATHAN

| | | | | |
|---|---|---|---|---|
| ROBINS AH | 10MG | N017675 | 001 | |
| | 25MG | N017675 | 002 | |

BICALUTAMIDE

TABLET;ORAL

BICALUTAMIDE

| | | | | |
|---|---|---|---|---|
| KUDCO IRELAND | 50MG | A077995 | 001 | Jul 06, 2009 |
| ROXANE | 50MG | A078285 | 001 | Mar 24, 2011 |
| SYNTHON PHARMS | 50MG | A077973 | 001 | Jul 06, 2009 |

BIMATOPROST

SOLUTION/DROPS;OPHTHALMIC

LUMIGAN

| | | | | |
|---|---|---|---|---|
| + ALLERGAN | 0.03% ** | N021275 | 001 | Mar 16, 2001 |

BIPERIDEN HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| AKINETON | | | | |
| | ABBVIE | 2MG | N012003 001 | |

BIPERIDEN LACTATE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| AKINETON | | | | |
| | ABBVIE | 5MG/ML | N012418 002 | |

BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

| | | | | |
|---|---|---|---|---|
| FOR SOLUTION, TABLET, DELAYED RELEASE;ORAL | | | | |
| HALFLYTELY | | | | |
| + | BRAINTREE | 5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2.86GM;N/A,5.6GM ** | N021551 003 | Jul 16, 2010 |

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| TABLET, CHEWABLE, TABLET, CAPSULE;ORAL | | | | |
| HELIDAC | | | | |
| + | CASPER PHARMA LLC | 262.4MG,N/A,N/A;N/A,250MG,N/A;N/A,N/A,500MG ** | N050719 001 | Aug 15, 1996 |

BISOPROLOL FUMARATE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| BISOPROLOL FUMARATE | | | | |
| | ANDA REPOSITORY | 5MG | A075474 001 | Oct 25, 2002 |
| | | 10MG | A075474 002 | Oct 25, 2002 |
| ZEBETA | | | | |
| | TEVA WOMENS | 5MG ** | N019982 002 | Jul 31, 1992 |
| | | 10MG ** | N019982 001 | Jul 31, 1992 |

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE | | | | |
| | ACTAVIS ELIZABETH | 2.5MG;6.25MG | A075672 001 | Sep 25, 2000 |
| | | 5MG;6.25MG | A075672 002 | Sep 25, 2000 |
| | | 10MG;6.25MG | A075672 003 | Sep 25, 2000 |
| | APOTHECON | 2.5MG;6.25MG | A075642 002 | Dec 27, 2000 |
| | | 5MG;6.25MG | A075642 001 | Dec 27, 2000 |
| | | 10MG;6.25MG | A075642 003 | Dec 27, 2000 |
| | IVAX SUB TEVA PHARMS | 2.5MG;6.25MG | A075632 001 | Sep 27, 2000 |
| | | 5MG;6.25MG | A075632 002 | Sep 27, 2000 |
| | | 10MG;6.25MG | A075632 003 | Sep 27, 2000 |
| | SANDOZ | 2.5MG;6.25MG | A075527 001 | Sep 25, 2000 |
| | | 5MG;6.25MG | A075527 003 | Sep 25, 2000 |
| | | 10MG;6.25MG | A075527 002 | Sep 25, 2000 |
| | TEVA | 2.5MG;6.25MG | A075686 001 | Jan 19, 2001 |
| | | 5MG;6.25MG | A075686 002 | Jan 19, 2001 |
| | | 10MG;6.25MG | A075686 003 | Jan 19, 2001 |
| | WATSON LABS TEVA | 2.5MG;6.25MG | A075469 001 | Sep 25, 2000 |
| | | 5MG;6.25MG | A075469 002 | Sep 25, 2000 |
| | | 10MG;6.25MG | A075469 003 | Sep 25, 2000 |

BITOLTEROL MESYLATE

| | | | | |
|---|---|---|---|---|
| AEROSOL, METERED;INHALATION | | | | |
| TORNALATE | | | | |
| | SANOFI AVENTIS US | 0.37MG/INH | N018770 001 | Dec 28, 1984 |
| SOLUTION;INHALATION | | | | |
| TORNALATE | | | | |
| | SANOFI AVENTIS US | 0.2% | N019548 001 | Feb 19, 1992 |

BLEOMYCIN SULFATE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| BLENOXANE | | | | |
| + | BRISTOL MYERS SQUIBB | EQ 15 UNITS BASE/VIAL ** | N050443 001 | |
| + | | EQ 30 UNITS BASE/VIAL ** | N050443 002 | Sep 07, 1995 |
| BLEOMYCIN SULFATE | | | | |
| | PHARMACHEMIE BV | EQ 15 UNITS BASE/VIAL | A065201 001 | Dec 13, 2007 |
| | TEVA PARENTERAL | EQ 15 UNITS BASE/VIAL | A064084 001 | Jun 01, 1996 |
| | | EQ 30 UNITS BASE/VIAL | A064084 002 | Jun 01, 1996 |

BOCEPREVIR

CAPSULE;ORAL

VICTRELIS

| | | | | |
|---|---|---|---|---|
| MERCK SHARP DOHME | 200MG | N202258 | 001 | May 13, 2011 |

BRETYLIUM TOSYLATE

INJECTABLE;INJECTION

BRETYLIUM TOSYLATE

| | | | | |
|---|---|---|---|---|
| ABRAXIS PHARM | 50MG/ML | A070134 | 001 | Apr 29, 1986 |
| | 100MG/ML | A071298 | 001 | Feb 13, 1987 |
| ASTRAZENECA | 50MG/ML | A071151 | 001 | Aug 10, 1987 |
| | 50MG/ML | A071152 | 001 | Aug 10, 1987 |
| | 50MG/ML | A071153 | 001 | Aug 10, 1987 |
| EUROHLTH INTL SARL | 50MG/ML | A070546 | 001 | May 14, 1986 |
| + HOSPIRA | 50MG/ML ** | N019030 | 001 | Apr 29, 1986 |
| | 50MG/ML | N019033 | 001 | Apr 29, 1986 |
| INTL MEDICATION | 50MG/ML | A070119 | 001 | Apr 29, 1986 |
| LUITPOLD | 50MG/ML | A070891 | 001 | Jul 26, 1988 |
| WEST-WARD PHARMS INT | 50MG/ML | A070545 | 001 | May 14, 1986 |

BRETYLIUM TOSYLATE IN DEXTROSE 5%

| | | | | |
|---|---|---|---|---|
| ABBOTT | 200MG/100ML | N019005 | 002 | Apr 29, 1986 |
| | 400MG/100ML | N019005 | 003 | Apr 29, 1986 |
| | 800MG/100ML | N019005 | 001 | Apr 29, 1986 |

BRETYLIUM TOSYLATE IN DEXTROSE 5% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| B BRAUN | 100MG/100ML | N019121 | 001 | Apr 29, 1986 |
| | 200MG/100ML | N019121 | 002 | Apr 29, 1986 |
| | 400MG/100ML | N019121 | 003 | Apr 29, 1986 |
| BAXTER HLTHCARE | 200MG/100ML | N019837 | 002 | Apr 12, 1989 |
| | 400MG/100ML | N019837 | 001 | Apr 12, 1989 |
| HOSPIRA INC | 200MG/100ML | N019008 | 002 | Apr 29, 1986 |
| | 400MG/100ML | N019008 | 003 | Apr 29, 1986 |
| | 800MG/100ML | N019008 | 001 | Apr 29, 1986 |

BRETYLOL

| | | | | |
|---|---|---|---|---|
| HOSPIRA | 50MG/ML | N017954 | 001 | |

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC

ALPHAGAN

| | | | | |
|---|---|---|---|---|
| + ALLERGAN | 0.2% ** | N020613 | 001 | Sep 06, 1996 |
| | 0.5% | N020490 | 001 | Mar 13, 1997 |

BRIMONIDINE TARTRATE

| | | | | |
|---|---|---|---|---|
| TEVA PARENTERAL | 0.2% | A076372 | 001 | Sep 10, 2004 |

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

BROMDAY

| | | | | |
|---|---|---|---|---|
| + BAUSCH AND LOMB INC | EQ 0.09% ACID ** | N021664 | 002 | Oct 16, 2010 |

BROMFENAC SODIUM

| | | | | |
|---|---|---|---|---|
| COASTAL PHARMS | EQ 0.09% ACID | A201211 | 001 | May 11, 2011 |

XIBROM

| | | | | |
|---|---|---|---|---|
| + BAUSCH AND LOMB INC | EQ 0.09% ACID ** | N021664 | 001 | Mar 24, 2005 |

BROMOCRIPTINE MESYLATE

CAPSULE;ORAL

BROMOCRIPTINE MESYLATE

| | | | | |
|---|---|---|---|---|
| LEK PHARM | EQ 5MG BASE | A075100 | 001 | Dec 10, 1998 |

BROMODIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE;ORAL

AMBODRYL

| | | | | |
|---|---|---|---|---|
| PARKE DAVIS | 25MG | N007984 | 001 | |

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE

SYRUP;ORAL

AMBENYL

| | | | | |
|---|---|---|---|---|
| FOREST LABS | 12.5MG/5ML;10MG/5ML | N009319 | 006 | Jan 10, 1984 |

BROMANYL

| | | | | |
|---|---|---|---|---|
| ALPHARMA US PHARMS | 12.5MG/5ML;10MG/5ML | A088343 | 001 | Aug 15, 1984 |

BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE

| | | | | |
|---|---|---|---|---|
| WOCKHARDT | 12.5MG/5ML;10MG/5ML | A088626 | 001 | Oct 12, 1984 |

BROMPHENIRAMINE MALEATE

ELIXIR;ORAL

BROMPHENIRAMINE MALEATE

| | | | | |
|---|---|---|---|---|
| ALPHARMA US PHARMS | 2MG/5ML | A086936 | 001 | |
| KV PHARM | 2MG/5ML | A085466 | 001 | |
| PHARM ASSOC | 2MG/5ML | A087517 | 001 | |
| USL PHARMA | 2MG/5ML | A087964 | 001 | Jan 25, 1983 |

INJECTABLE;INJECTION

BROMPHENIRAMINE MALEATE

| | | | | |
|---|---|---|---|---|
| WATSON LABS | 10MG/ML | A083821 | 001 | |
| | 100MG/ML | A083820 | 001 | |

DIMETANE-TEN

| | | | | |
|---|---|---|---|---|
| WYETH AYERST | 10MG/ML | N011418 | 002 | |

TABLET;ORAL

BROMPHENIRAMINE MALEATE

| | | | | |
|---|---|---|---|---|
| BARR | 4MG | A084468 | 001 | |
| IVAX SUB TEVA PHARMS | 4MG | A084351 | 001 | |
| NEWTRON PHARMS | 4MG | A086987 | 001 | |
| NEXGEN PHARMA INC | 4MG | A086187 | 001 | |
| PAR PHARM | 4MG | A087009 | 001 | |
| PIONEER PHARMS | 4MG | A088604 | 001 | Jul 13, 1984 |
| UPSHER-SMITH LABS | 4MG | A083215 | 001 | |
| VITARINE | 4MG | A085850 | 001 | |
| WATSON LABS | 4MG | A083123 | 001 | |
| | 4MG | A085769 | 001 | |

DIMETANE

| | | | | |
|---|---|---|---|---|
| WYETH CONS | 4MG | N010799 | 003 | |

TABLET, EXTENDED RELEASE;ORAL

DIMETANE

| | | | | |
|---|---|---|---|---|
| WYETH CONS | 8MG | N010799 | 010 | Jun 10, 1983 |
| | 12MG | N010799 | 011 | Jun 10, 1983 |

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL

BROMANATE DM

| | | | | |
|---|---|---|---|---|
| ALPHARMA US PHARMS | 2MG/5ML;10MG/5ML;30MG/5ML | A088722 | 001 | Mar 07, 1985 |

BROMFED-DM

| | | | | |
|---|---|---|---|---|
| WOCKHARDT | 2MG/5ML;10MG/5ML;30MG/5ML | A089681 | 001 | Dec 22, 1988 |

DIMETANE-DX

| | | | | | |
|---|---|---|---|---|---|
| + | ROBINS AH | 2MG/5ML;10MG/5ML;30MG/5ML ** | N019279 | 001 | Aug 24, 1984 |

BROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE

| | | | | |
|---|---|---|---|---|
| ALZA | 16MG;240MG | N019672 | 001 | Mar 29, 1996 |

BUCLIZINE HYDROCHLORIDE

TABLET;ORAL

BUCLADIN-S

| | | | | |
|---|---|---|---|---|
| STUART PHARMS | 50MG | N010911 | 006 | |

BUDESONIDE

AEROSOL, METERED;NASAL

RHINOCORT

| | | | | |
|---|---|---|---|---|
| ASTRAZENECA | 0.032MG/INH | N020233 | 001 | Feb 14, 1994 |

POWDER, METERED;INHALATION

PULMICORT

| | | | | |
|---|---|---|---|---|
| ASTRAZENECA | 0.16MG/INH | N020441 | 002 | Jun 24, 1997 |
| | 0.32MG/INH | N020441 | 003 | Jun 24, 1997 |

BUMETANIDE

INJECTABLE;INJECTION

BUMETANIDE

| | | | | |
|---|---|---|---|---|
| HOSPIRA | 0.25MG/ML | A074160 | 001 | Oct 30, 1997 |
| TEVA PARENTERAL | 0.25MG/ML | A074613 | 001 | Nov 18, 1997 |

BUMEX

| | | | | | |
|---|---|---|---|---|---|
| + | VALIDUS PHARMS | 0.25MG/ML ** | N018226 | 001 | Feb 28, 1983 |

| | | | | |
|---|---|---|---|---|
| **BUPIVACAINE HYDROCHLORIDE** | | | | |
| INJECTABLE;INJECTION | | | | |
| BUPIVACAINE HYDROCHLORIDE | | | | |
| HOSPIRA | 0.75% | A070587 | 001 | Mar 03, 1987 |
| BUPIVACAINE HYDROCHLORIDE KIT | | | | |
| HOSPIRA | 0.075% | N019978 | 001 | Sep 03, 1992 |
| | 0.114% | N019978 | 002 | Sep 03, 1992 |
| | 0.23% | N019978 | 003 | Sep 03, 1992 |
| BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE | | | | |
| INTL MEDICATED | 0.25% | A076012 | 001 | Jan 09, 2002 |
| | 0.5% | A076012 | 002 | Jan 09, 2002 |
| | 0.75% | A076012 | 003 | Jan 09, 2002 |
| **BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE** | | | | |
| INJECTABLE;INJECTION | | | | |
| BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE | | | | |
| HOSPIRA | 0.25%;0.005MG/ML | A071166 | 001 | Jun 16, 1988 |
| | 0.5%;0.005MG/ML | A071169 | 001 | Jun 16, 1988 |
| | 0.75%;0.005MG/ML | A071171 | 001 | Jun 16, 1988 |
| **BUPIVACAINE HYDROCHLORIDE; LIDOCAINE HYDROCHLORIDE** | | | | |
| INJECTABLE;INJECTION | | | | |
| DUOCAINE | | | | |
| AMPHASTAR PHARMS INC | EQ 0.375% (37.5MG/10ML);EQ 1% (100MG/10ML) | N021496 | 001 | May 23, 2003 |
| **BUPRENORPHINE HYDROCHLORIDE** | | | | |
| TABLET;SUBLINGUAL | | | | |
| SUBUTEX | | | | |
| + INDIVIOR INC | EQ 2MG BASE ** | N020732 | 002 | Oct 08, 2002 |
| + | EQ 8MG BASE ** | N020732 | 003 | Oct 08, 2002 |
| **BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE** | | | | |
| TABLET;SUBLINGUAL | | | | |
| SUBOXONE | | | | |
| + INDIVIOR INC | EQ 2MG BASE;EQ 0.5MG BASE ** | N020733 | 001 | Oct 08, 2002 |
| + | EQ 8MG BASE;EQ 2MG BASE | N020733 | 002 | Oct 08, 2002 |
| **BUPROPION HYDROCHLORIDE** | | | | |
| TABLET;ORAL | | | | |
| BUPROPION HYDROCHLORIDE | | | | |
| SANDOZ | 75MG | A075613 | 002 | Oct 10, 2000 |
| | 100MG | A075613 | 001 | Oct 10, 2000 |
| TEVA | 75MG | A075310 | 001 | Nov 29, 1999 |
| | 100MG | A075310 | 002 | Nov 29, 1999 |
| WELLBUTRIN | | | | |
| + GLAXOSMITHKLINE | 50MG ** | N018644 | 001 | Dec 30, 1985 |
| + | 75MG ** | N018644 | 002 | Dec 30, 1985 |
| + | 100MG ** | N018644 | 003 | Dec 30, 1985 |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| BUPROPION HYDROCHLORIDE | | | | |
| ACTAVIS LABS FL INC | 300MG | A077715 | 002 | Jun 13, 2007 |
| IMPAX LABS | 300MG | A077415 | 002 | Dec 15, 2006 |
| SANDOZ | 100MG | A076845 | 001 | Jul 14, 2005 |
| | 150MG | A076834 | 001 | Jul 14, 2005 |
| | 150MG | A076845 | 002 | Jul 14, 2005 |
| WOCKHARDT LTD | 100MG | A201331 | 001 | Aug 30, 2012 |
| | 150MG | A201331 | 002 | Aug 30, 2012 |
| | 200MG | A201331 | 003 | Aug 30, 2012 |
| WELLBUTRIN SR | | | | |
| GLAXOSMITHKLINE | 50MG | N020358 | 001 | Oct 04, 1996 |
| ZYBAN | | | | |
| GLAXOSMITHKLINE | 100MG | N020711 | 002 | May 14, 1997 |
| **BUSPIRONE HYDROCHLORIDE** | | | | |
| CAPSULE;ORAL | | | | |
| BUSPAR | | | | |
| BRISTOL MYERS SQUIBB | 5MG | N021190 | 001 | Dec 20, 2000 |
| | 7.5MG | N021190 | 002 | Dec 20, 2000 |
| | 10MG | N021190 | 003 | Dec 20, 2000 |
| | 15MG | N021190 | 004 | Dec 20, 2000 |

| | | | | |
|---|---|---|---|---|
| **BUSPIRONE HYDROCHLORIDE** | | | | |
| TABLET;ORAL | | | | |
| BUSPAR | | | | |
| + BRISTOL MYERS SQUIBB | 5MG ** | N018731 | 001 | Sep 29, 1986 |
| + | 10MG ** | N018731 | 002 | Sep 29, 1986 |
| + | 15MG ** | N018731 | 003 | Apr 22, 1996 |
| + | 30MG ** | N018731 | 004 | Apr 22, 1996 |
| BUSPIRONE HYDROCHLORIDE | | | | |
| APOTEX | 5MG | A075521 | 001 | Apr 05, 2002 |
| | 10MG | A075521 | 002 | Apr 05, 2002 |
| | 15MG | A075521 | 003 | Apr 05, 2002 |
| EGIS | 5MG | A075119 | 001 | Mar 14, 2002 |
| | 10MG | A075119 | 002 | Mar 14, 2002 |
| | 15MG | A075119 | 003 | Jan 23, 2003 |
| IVAX SUB TEVA PHARMS | 5MG ** | A075385 | 001 | Mar 01, 2002 |
| | 10MG ** | A075385 | 002 | Mar 01, 2002 |
| | 15MG ** | A075385 | 003 | Mar 01, 2002 |
| MYLAN | 5MG | A075467 | 001 | Feb 28, 2002 |
| | 10MG | A075467 | 003 | Feb 28, 2002 |
| | 15MG | A075467 | 004 | Feb 28, 2002 |
| NESHER PHARMS | 5MG | A075572 | 001 | Feb 27, 2002 |
| | 10MG | A075572 | 002 | Feb 27, 2002 |
| | 15MG | A075572 | 003 | Feb 27, 2002 |
| OXFORD PHARMS | 5MG | A075388 | 001 | May 09, 2002 |
| | 10MG | A075388 | 002 | May 09, 2002 |
| | 15MG | A075388 | 003 | May 09, 2002 |
| SANDOZ | 5MG | A075413 | 001 | Mar 19, 2002 |
| | 10MG | A075413 | 002 | Mar 19, 2002 |
| | 15MG | A075413 | 003 | Mar 19, 2002 |
| **BUTABARBITAL SODIUM** | | | | |
| CAPSULE;ORAL | | | | |
| BUTICAPS | | | | |
| MEDPOINTE PHARM HLC | 15MG | A085381 | 001 | |
| | 30MG | A085381 | 002 | |
| | 50MG | A085381 | 003 | |
| | 100MG | A085381 | 004 | |
| ELIXIR;ORAL | | | | |
| BUTABARB | | | | |
| ALPHARMA US PHARMS | 30MG/5ML | A085873 | 001 | |
| BUTABARBITAL SODIUM | | | | |
| WOCKHARDT | 30MG/5ML | A085383 | 001 | |
| BUTALAN | | | | |
| LANNETT | 33.3MG/5ML | A085880 | 001 | |
| BUTISOL SODIUM | | | | |
| MEDA PHARMS | 30MG/5ML | A085380 | 001 | |
| SARISOL | | | | |
| HALSEY | 30MG/5ML | A084723 | 001 | |
| TABLET;ORAL | | | | |
| BUTABARBITAL | | | | |
| BUNDY | 30MG | A085550 | 001 | |
| BUTABARBITAL SODIUM | | | | |
| SANDOZ | 15MG | A084292 | 003 | Feb 09, 1982 |
| | 15MG | A085938 | 001 | |
| | 30MG | A084272 | 002 | |
| | 30MG | A085934 | 001 | |
| SOLVAY | 16.2MG | A083606 | 001 | |
| | 32.4MG | A083898 | 001 | |
| | 48.6MG | A083897 | 001 | |
| | 97.2MG | A083896 | 001 | |
| TEVA | 15MG | A088632 | 001 | May 18, 1985 |
| | 30MG | A088631 | 001 | May 01, 1985 |
| WATSON LABS | 15MG | A085764 | 001 | |
| | 30MG | A085772 | 001 | |
| WHITEWORTH TOWN PLSN | 15MG | A083325 | 002 | |
| | 30MG | A083337 | 001 | |
| BUTISOL SODIUM | | | | |
| MYLAN SPECIALITY LP | 15MG | N000793 | 002 | |
| | 50MG | N000793 | 003 | |
| | 100MG | N000793 | 005 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| BUTABARBITAL SODIUM | | | | |
| TABLET;ORAL | | | | |
| SARISOL NO. 1 | | | | |
| HALSEY | 15MG | A084719 001 | | |
| SARISOL NO. 2 | | | | |
| HALSEY | 30MG | A084719 002 | | |
| SODIUM BUTABARBITAL | | | | |
| HIKMA PHARMS | 15MG | A085418 001 | | |
| | 30MG | A085432 001 | | |
| IVAX SUB TEVA PHARMS | 15MG | A083484 001 | | |
| | 30MG | A084040 001 | | |
| LANNETT | 15MG | A085849 001 | | |
| | 30MG | A085866 001 | | |
| | 100MG | A085881 001 | | |
| MARSHALL PHARMA | 16.2MG | A083524 001 | | |
| | 32.4MG | A083858 001 | | |
| BUTENAFINE HYDROCHLORIDE | | | | |
| CREAM;TOPICAL | | | | |
| MENTAX-TC | | | | |
| MYLAN | 1% | N021408 001 | Oct 17, 2002 | |
| BUTOCONAZOLE NITRATE | | | | |
| CREAM;VAGINAL | | | | |
| BUTOCONAZOLE NITRATE | | | | |
| PERRIGO PHARMA INTL | 2% | N019881 001 | Feb 07, 1997 | |
| FEMSTAT | | | | |
| ROCHE PALO | 2% | N019215 001 | Nov 25, 1985 | |
| FEMSTAT 3 | | | | |
| + BAYER | 2% | N020421 001 | Dec 21, 1995 | |
| SUPPOSITORY;VAGINAL | | | | |
| FEMSTAT | | | | |
| ROCHE PALO | 100MG | N019359 001 | Nov 25, 1985 | |
| BUTORPHANOL TARTRATE | | | | |
| INJECTABLE;INJECTION | | | | |
| BUTORPHANOL TARTRATE | | | | |
| BAXTER HLTHCARE CORP | 2MG/ML | A075697 001 | Oct 23, 2001 | |
| HIKMA FARMACEUTICA | 2MG/ML | A078247 001 | Apr 29, 2009 | |
| HOSPIRA | 1MG/ML | A075342 001 | Nov 04, 1999 | |
| | 1MG/ML | A075559 001 | Mar 20, 2000 | |
| | 2MG/ML | A075342 002 | Nov 04, 1999 | |
| | 2MG/ML | A075559 002 | Mar 20, 2000 | |
| BUTORPHANOL TARTRATE PRESERVATIVE FREE | | | | |
| BAXTER HLTHCARE CORP | 1MG/ML | A075695 001 | Oct 23, 2001 | |
| | 2MG/ML | A075695 002 | Oct 23, 2001 | |
| HOSPIRA | 1MG/ML | A074620 001 | Jan 22, 1997 | |
| | 1MG/ML | A075170 001 | Sep 28, 1998 | |
| | 2MG/ML | A074620 002 | Jan 22, 1997 | |
| | 2MG/ML | A075170 002 | Sep 28, 1998 | |
| STADOL | | | | |
| APOTHECON | 2MG/ML ** | N017857 004 | | |
| STADOL PRESERVATIVE FREE | | | | |
| APOTHECON | 1MG/ML ** | N017857 001 | | |
| | 2MG/ML ** | N017857 002 | | |
| SPRAY, METERED;NASAL | | | | |
| STADOL | | | | |
| BRISTOL MYERS SQUIBB | 1MG/SPRAY ** | N019890 001 | Dec 12, 1991 | |
| CABERGOLINE | | | | |
| TABLET;ORAL | | | | |
| CABERGOLINE | | | | |
| IMPAX LABS INC | 0.5MG | A077843 001 | Jul 03, 2007 | |
| DOSTINEX | | | | |
| + PHARMACIA AND UPJOHN | 0.5MG ** | N020664 001 | Dec 23, 1996 | |

| | | | | |
|---|---|---|---|---|
| CAFFEINE; ERGOTAMINE TARTRATE | | | | |
| SUPPOSITORY;RECTAL | | | | |
| CAFERGOT | | | | |
| + NOVARTIS | 100MG;2MG ** | N009000 | 002 | |
| TABLET;ORAL | | | | |
| CAFERGOT | | | | |
| NOVARTIS | 100MG;1MG | N006620 | 001 | |
| WIGRAINE | | | | |
| ORGANON USA INC | 100MG;1MG | A086562 | 001 | |
| CALCIFEDIOL | | | | |
| CAPSULE;ORAL | | | | |
| CALDEROL | | | | |
| ORGANON USA INC | 0.02MG | N018312 | 001 | |
| | 0.05MG | N018312 | 002 | |
| CALCIPOTRIENE | | | | |
| OINTMENT;TOPICAL | | | | |
| DOVONEX | | | | |
| + LEO PHARMA AS | 0.005% ** | N020273 | 001 | Dec 29, 1993 |
| SOLUTION;TOPICAL | | | | |
| DOVONEX | | | | |
| + LEO PHARM | 0.005% ** | N020611 | 001 | Mar 03, 1997 |
| CALCITONIN HUMAN | | | | |
| INJECTABLE;INJECTION | | | | |
| CIBACALCIN | | | | |
| NOVARTIS | 0.5MG/VIAL | N018470 | 001 | Oct 31, 1986 |
| CALCITONIN SALMON | | | | |
| INJECTABLE;INJECTION | | | | |
| CALCIMAR | | | | |
| SANOFI AVENTIS US | 200 IU/ML | N017769 | 001 | |
| | 400 IU/VIAL | N017497 | 001 | |
| CALCITONIN-SALMON | | | | |
| IGI LABS INC | 200 IU/ML | A073690 | 001 | Apr 14, 1995 |
| MIACALCIN | | | | |
| MYLAN IRELAND LTD | 100 IU/ML | N017808 | 001 | Jul 03, 1986 |
| SPRAY, METERED;NASAL | | | | |
| MIACALCIN | | | | |
| + MYLAN IRELAND LTD | 200 IU/SPRAY | N020313 | 002 | Aug 17, 1995 |
| CALCITONIN SALMON RECOMBINANT | | | | |
| SPRAY, METERED;NASAL | | | | |
| FORTICAL | | | | |
| UPSHER-SMITH LABS | 200 IU/SPRAY | N021406 | 001 | Aug 12, 2005 |
| CALCITRIOL | | | | |
| INJECTABLE;INJECTION | | | | |
| CALCIJEX | | | | |
| + ABBVIE | 0.001MG/ML ** | N018874 | 001 | Sep 25, 1986 |
| + | 0.002MG/ML ** | N018874 | 002 | Sep 25, 1986 |
| CALCITRIOL | | | | |
| AKORN | 0.002MG/ML | A078066 | 002 | Jan 29, 2008 |
| FRESENIUS KABI USA | 0.001MG/ML | A075836 | 001 | Dec 31, 2002 |
| | 0.002MG/ML | A075836 | 002 | Dec 31, 2002 |
| FRESENIUS MEDCL | 0.001MG/ML | A075766 | 001 | Feb 20, 2003 |
| | 0.002MG/ML | A075766 | 002 | Feb 20, 2003 |
| HOSPIRA | 0.001MG/ML | A075816 | 001 | Jan 16, 2004 |
| | 0.002MG/ML | A075816 | 002 | Jan 16, 2004 |
| LUITPOLD | 0.001MG/ML | A075746 | 001 | Sep 26, 2003 |
| | 0.002MG/ML | A075746 | 002 | Sep 26, 2003 |
| ROCKWELL MEDCL | 0.001MG/ML | A076206 | 001 | Sep 17, 2003 |
| SAGENT PHARMS | 0.001MG/ML | A077102 | 001 | Feb 08, 2006 |
| TEVA PARENTERAL | 0.001MG/ML | A075823 | 001 | Mar 31, 2003 |
| | 0.002MG/ML | A075823 | 002 | Mar 31, 2003 |

CALCIUM ACETATE

| | | | | | |
|---|---|---|---|---|---|
| CAPSULE;ORAL | | | | | |
| PHOSLO | | | | | |
| | FRESENIUS MEDCL | 333.5MG | N021160 | 001 | Apr 02, 2001 |
| | | 667MG | N021160 | 002 | Apr 02, 2001 |
| TABLET;ORAL | | | | | |
| CALCIUM ACETATE | | | | | |
| | WEST-WARD PHARMS INT | 667MG | A077693 | 001 | Jan 30, 2008 |
| PHOSLO | | | | | |
| + | FRESENIUS MEDCL | 667MG ** | N019976 | 001 | Dec 10, 1990 |

CALCIUM CARBONATE; RISEDRONATE SODIUM

| | | | | | |
|---|---|---|---|---|---|
| TABLET, TABLET;ORAL | | | | | |
| ACTONEL WITH CALCIUM (COPACKAGED) | | | | | |
| + | WARNER CHILCOTT | EQ 500MG BASE,N/A;N/A,35MG ** | N021823 | 001 | Aug 12, 2005 |

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

| | | | | | |
|---|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | | |
| PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER | | | | | |
| | BAXTER HLTHCARE CORP | 3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML) | N021703 | 012 | Oct 10, 2008 |
| PRISMASOL BGK 4/0 IN PLASTIC CONTAINER | | | | | |
| | BAXTER HLTHCARE CORP | N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML) | N021703 | 005 | Oct 25, 2006 |
| PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER | | | | | |
| | BAXTER HLTHCARE CORP | 5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML) | N021703 | 008 | Oct 25, 2006 |
| PRISMASOL BK 0/0 IN PLASTIC CONTAINER | | | | | |
| | BAXTER HLTHCARE CORP | N/A/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML) | N021703 | 007 | Oct 25, 2006 |
| PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER | | | | | |
| | BAXTER HLTHCARE CORP | 3.68GM/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML) | N021703 | 009 | Oct 25, 2006 |

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATIONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

| | | | | | |
|---|---|---|---|---|---|
| SOLUTION;IRRIGATION | | | | | |
| NAVSTEL | | | | | |
| | ALCON PHARMS LTD | 0.154MG/ML;0.92MG/ML;0.2MG/ML;0.184MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML | N022193 | 001 | Jul 24, 2008 |

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

| | | | | | |
|---|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | | |
| ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | | |
| | B BRAUN | 37MG/100ML;5GM/100ML;31MG/100ML;120MG/100ML;330MG/100ML;88MG/100ML | N019864 | 001 | Jun 10, 1993 |
| ISOLYTE R W/ DEXTROSE 5% IN PLASTIC CONTAINER | | | | | |
| | B BRAUN | 37MG/100ML;5GM/100ML;31MG/100ML;120MG/100ML;330MG/100ML;88MG/100ML | N018271 | 001 | |

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

| | | | | | |
|---|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | | |
| ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | | |
| | B BRAUN | 35MG/100ML;5GM/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML | N019867 | 001 | Dec 20, 1993 |
| ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER | | | | | |
| | B BRAUN | 35MG/100ML;5GM/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML | N018269 | 002 | Jan 17, 1983 |

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| BAXTER HLTHCARE | 37MG/100ML;5GM/100ML;30MG/100ML;119MG/100ML;161MG/100ML;94MG/100ML;138MG/100ML | N017390 | 001 | |

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

SOLUTION;INTRAPERITONEAL

DIALYTE CONCENTRATE W/ DEXTROSE 30% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| B BRAUN | 510MG/100ML;30GM/100ML;200MG/100ML;9.2GM/100ML;9.6GM/100ML | N018807 | 001 | Aug 26, 1983 |
| | 510MG/100ML;30GM/100ML;200MG/100ML;9.4GM/100ML;11GM/100ML | N018807 | 003 | Aug 26, 1983 |

DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| B BRAUN | 510MG/100ML;50GM/100ML;200MG/100ML;9.2GM/100ML;9.6GM/100ML | N018807 | 002 | Aug 26, 1983 |
| | 510MG/100ML;50GM/100ML;200MG/100ML;9.4GM/100ML;11GM/100ML | N018807 | 004 | Aug 26, 1983 |

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| B BRAUN | 29MG/100ML;2.5GM/100ML;15MG/100ML;610MG/100ML;560MG/100ML | N018460 | 006 | Jan 29, 1986 |

DIALYTE W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| B BRAUN | 29MG/100ML;1.5GM/100ML;15MG/100ML;610MG/100ML;560MG/100ML | N018460 | 001 | |

DIALYTE W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| B BRAUN | 29MG/100ML;4.25GM/100ML;15MG/100ML;610MG/100ML;560MG/100ML | N018460 | 003 | |

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| FRESENIUS MEDCL | 25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML | N018379 | 002 | |

DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| FRESENIUS MEDCL | 25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML | N018379 | 003 | |

DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| FRESENIUS MEDCL | 25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML | N018379 | 007 | Jun 24, 1988 |

DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| FRESENIUS MEDCL | 25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML | N018379 | 001 | |

DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| FRESENIUS MEDCL | 25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML | N018379 | 004 | Jul 07, 1982 |

DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| FRESENIUS MEDCL | 25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML | N018379 | 005 | Jul 07, 1982 |

DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| FRESENIUS MEDCL | 25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML | N018379 | 008 | Jun 24, 1988 |

DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| FRESENIUS MEDCL | 25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML | N018379 | 006 | Jul 07, 1982 |

DIALYTE LM/ DEXTROSE 1.5% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| B BRAUN | 26MG/100ML;1.5GM/100ML;5MG/100ML;530MG/100ML;450MG/100ML | N018460 | 007 | Jan 29, 1986 |
| | 26MG/100ML;1.5GM/100ML;15MG/100ML;560MG/100ML;390MG/100ML | N018460 | 002 | |

DIALYTE LM/ DEXTROSE 2.5% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| B BRAUN | 26MG/100ML;2.5GM/100ML;5MG/100ML;530MG/100ML;450MG/100ML | N018460 | 005 | Nov 02, 1983 |
| | 26MG/100ML;5GM/100ML;5MG/100ML;530MG/100ML;450MG/100ML | N018460 | 008 | Jan 29, 1986 |

DIALYTE LM/ DEXTROSE 4.25% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| B BRAUN | 26MG/100ML;4.25GM/100ML;5MG/100ML;530MG/100ML;450MG/100ML | N018460 | 009 | Jan 29, 1986 |
| | 26MG/100ML;4.25GM/100ML;15MG/100ML;560MG/100ML;390MG/100ML | N018460 | 004 | |

INPERSOL-LC/LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| FRESENIUS | 18.4MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML | A020374 | 001 | Jun 13, 1994 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

INPERSOL-LC/LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| FRESENIUS | 18.4MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML | A020374 | 002 | Jun 13, 1994 |

INPERSOL-LC/LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| FRESENIUS | 18.4MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML | A020374 | 003 | Jun 13, 1994 |

INPERSOL-LC/LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| FRESENIUS | 18.4MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML | A020374 | 004 | Jun 13, 1994 |

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5% IN ACETATED RINGER'S IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| B BRAUN | 20MG/100ML;5GM/100ML;30MG/100ML;380MG/100ML;600MG/100ML | N018258 | 001 | |

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

DEXTROSE 5% AND RINGER'S IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| HOSPIRA | 33MG/100ML;5GM/100ML;30MG/100ML;860MG/100ML | N018254 | 001 | |

DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| B BRAUN | 33MG/100ML;5GM/100ML;30MG/100ML;860MG/100ML | N018256 | 001 | |
| BAXTER HLTHCARE | 33MG/100ML;5GM/100ML;30MG/100ML;860MG/100ML | N016695 | 001 | |

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

DEXTROSE 4% IN MODIFIED LACTATED RINGER'S IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| B BRAUN | 4MG/100ML;4GM/100ML;6MG/100ML;120MG/100ML;62MG/100ML | N019634 | 002 | Feb 24, 1988 |

DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| B BRAUN | 20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML | N017510 | 001 | |
| MILES | 20MG/100ML;5GM/100ML;30MG/100ML;600MG/100ML;310MG/100ML | N018499 | 001 | |

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| ICU MEDICAL INC | 20MG/100ML;5GM/100ML;104MG/100ML;600MG/100ML;310MG/100ML | N019685 | 005 | Oct 17, 1988 |
| | 20MG/100ML;5GM/100ML;179MG/100ML;600MG/100ML;310MG/100ML | N019685 | 006 | Oct 17, 1988 |

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| ICU MEDICAL INC | 20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML | N019685 | 007 | Oct 17, 1988 |

POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| ICU MEDICAL INC | 20MG/100ML;5GM/100ML;254MG/100ML;600MG/100ML;310MG/100ML | N019685 | 003 | Oct 17, 1988 |

POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| ICU MEDICAL INC | 20MG/100ML;5GM/100ML;104MG/100ML;600MG/100ML;310MG/100ML | N019685 | 001 | Oct 17, 1988 |

CALCIUM CHLORIDE; DEXTROSE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION;INTRAPERITONEAL

INPERSOL-ZM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| FRESENIUS MEDCL | 25.7MG/100ML;1.5GM/100ML;538MG/100ML;448MG/100ML | N019395 | 001 | Mar 26, 1986 |

INPERSOL-ZM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| FRESENIUS MEDCL | 25.7MG/100ML;2.5GM/100ML;538MG/100ML;448MG/100ML | N019395 | 002 | Mar 26, 1986 |

INPERSOL-ZM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| FRESENIUS MEDCL | 25.7MG/100ML;4.25GM/100ML;538MG/100ML;448MG/100ML | N019395 | 003 | Mar 26, 1986 |

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

TPN ELECTROLYTES IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| ABBOTT | 16.5MG/ML;25.4MG/ML;74.6MG/ML;121MG/ML;16.1MG/ML | N019399 | 001 | Jun 16, 1986 |

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| ISOLYTE E IN PLASTIC CONTAINER | | | | |
| B BRAUN | 35MG/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML | N018899 | 001 | Oct 31, 1983 |
| | 35MG/100ML;30MG/100ML;74MG/100ML;640MG/100ML;500MG/100ML;74MG/100ML | N019718 | 001 | Sep 29, 1989 |

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| PLASMA-LYTE R IN PLASTIC CONTAINER | | | | |
| BAXTER HLTHCARE | 36.8MG/100ML;30.5MG/100ML;74.6MG/100ML;640MG/100ML;496MG/100ML;89.6MG/100ML | N017438 | 001 | |

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| ACETATED RINGER'S IN PLASTIC CONTAINER | | | | |
| B BRAUN | 20MG/100ML;30MG/100ML;380MG/100ML;600MG/100ML | N018725 | 001 | Nov 29, 1982 |

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| RINGER'S IN PLASTIC CONTAINER | | | | |
| B BRAUN | 33MG/100ML;30MG/100ML;860MG/100ML | N018721 | 001 | Nov 09, 1982 |
| SOLUTION;IRRIGATION | | | | |
| RINGER'S IN PLASTIC CONTAINER | | | | |
| ABBOTT | 33MG/100ML;30MG/100ML;860MG/100ML | N018462 | 001 | |

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| LACTATED RINGER'S IN PLASTIC CONTAINER | | | | |
| ABBOTT | 20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML | N019485 | 001 | Oct 24, 1985 |
| B BRAUN | 20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML | N018023 | 001 | |
| MILES | 20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML | N018417 | 001 | |
| SOLUTION;IRRIGATION | | | | |
| LACTATED RINGER'S IN PLASTIC CONTAINER | | | | |
| BAXTER HLTHCARE | 20MG/100ML;30MG/100ML;600MG/100ML;310MG/100ML | N019933 | 001 | Aug 29, 1989 |

CALCIUM GLUCEPTATE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| CALCIUM GLUCEPTATE | | | | |
| ABBOTT | EQ 90MG CALCIUM/5ML | A080001 | 001 | |
| | EQ 90MG CALCIUM/5ML | A083159 | 001 | |
| ABRAXIS PHARM | EQ 90MG CALCIUM/5ML | A089373 | 001 | Apr 30, 1987 |
| LILLY | EQ 90MG CALCIUM/5ML | N006470 | 001 | |

CALCIUM METRIZOATE; MEGLUMINE METRIZOATE; METRIZOATE MAGNESIUM; METRIZOATE SODIUM

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| ISOPAQUE 440 | | | | |
| GE HEALTHCARE | 0.78MG/ML;75.9MG/ML;0.15MG/ML;16.6MG/ML | N016847 | 001 | |

CALCIUM; MEGLUMINE; METRIZOIC ACID

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| ISOPAQUE 280 | | | | |
| GE HEALTHCARE | 0.35MG/ML;140.1MG/ML;461.8MG/ML | N017506 | 001 | |

CANDICIDIN

| | | | | |
|---|---|---|---|---|
| OINTMENT;VAGINAL | | | | |
| VANOBID | | | | |
| SANOFI AVENTIS US | 0.6MG/GM | A061596 | 001 | |
| TABLET;VAGINAL | | | | |
| VANOBID | | | | |
| SANOFI AVENTIS US | 3MG | A061613 | 001 | |

CAPTOPRIL

TABLET;ORAL

| | | | | | |
|---|---|---|---|---|---|
| CAPOTEN | | | | | |
| + | PAR PHARM | 12.5MG ** | N018343 | 005 | Jan 17, 1985 |
| + | | 25MG ** | N018343 | 002 | |
| + | | 37.5MG ** | N018343 | 006 | Sep 17, 1986 |
| + | | 50MG ** | N018343 | 001 | |
| + | | 75MG ** | N018343 | 007 | Jun 13, 1995 |
| + | | 100MG ** | N018343 | 003 | |
| + | | 150MG ** | N018343 | 004 | Jun 13, 1995 |
| CAPTOPRIL | | | | | |
| | APOTEX | 12.5MG | A074737 | 001 | Oct 28, 1998 |
| | | 25MG | A074737 | 002 | Oct 28, 1998 |
| | | 50MG | A074737 | 003 | Oct 28, 1998 |
| | | 100MG | A074737 | 004 | Oct 28, 1998 |
| | APOTHECON | 12.5MG | A074472 | 001 | Mar 31, 1995 |
| | | 25MG | A074472 | 002 | Mar 31, 1995 |
| | | 50MG | A074472 | 003 | Mar 31, 1995 |
| | | 100MG | A074472 | 004 | Mar 31, 1995 |
| | BOSCOGEN | 12.5MG | A074677 | 004 | May 30, 1997 |
| | | 25MG | A074677 | 002 | May 30, 1997 |
| | | 50MG | A074677 | 001 | May 30, 1997 |
| | | 100MG | A074677 | 003 | May 30, 1997 |
| | DAVA PHARMS INC | 12.5MG | A074423 | 001 | Feb 13, 1996 |
| | | 25MG | A074423 | 002 | Feb 13, 1996 |
| | | 50MG | A074423 | 003 | Feb 13, 1996 |
| | | 100MG | A074423 | 004 | Feb 13, 1996 |
| | EGIS PHARMS | 12.5MG | A074748 | 004 | May 29, 1997 |
| | | 25MG | A074748 | 002 | May 29, 1997 |
| | | 50MG | A074748 | 001 | May 29, 1997 |
| | | 100MG | A074748 | 003 | May 29, 1997 |
| | FOSUN PHARMA | 12.5MG | A074363 | 001 | Nov 09, 1995 |
| | | 25MG | A074363 | 002 | Nov 09, 1995 |
| | | 50MG | A074363 | 003 | Nov 09, 1995 |
| | | 100MG | A074363 | 004 | Nov 09, 1995 |
| | G AND W LABS INC | 12.5MG | A074433 | 001 | Feb 13, 1996 |
| | | 12.5MG | A074462 | 001 | Feb 13, 1996 |
| | | 12.5MG | A074483 | 001 | Feb 13, 1996 |
| | | 12.5MG | A074590 | 004 | Aug 30, 1996 |
| | | 25MG | A074433 | 002 | Feb 13, 1996 |
| | | 25MG | A074462 | 002 | Feb 13, 1996 |
| | | 25MG | A074483 | 002 | Feb 13, 1996 |
| | | 25MG | A074590 | 002 | Aug 30, 1996 |
| | | 50MG | A074433 | 003 | Feb 13, 1996 |
| | | 50MG | A074462 | 003 | Feb 13, 1996 |
| | | 50MG | A074483 | 003 | Feb 13, 1996 |
| | | 50MG | A074590 | 001 | Aug 30, 1996 |
| | | 100MG | A074433 | 004 | Feb 13, 1996 |
| | | 100MG | A074462 | 004 | Feb 13, 1996 |
| | | 100MG | A074483 | 004 | Feb 13, 1996 |
| | | 100MG | A074590 | 003 | Aug 30, 1996 |
| | PAR PHARM | 12.5MG | A074493 | 001 | Feb 13, 1996 |
| | | 25MG | A074493 | 002 | Feb 13, 1996 |
| | | 50MG | A074493 | 003 | Feb 13, 1996 |
| | | 100MG | A074493 | 004 | Feb 13, 1996 |
| | PUREPAC PHARM | 12.5MG | A074640 | 001 | Mar 31, 1997 |
| | | 25MG | A074640 | 002 | Mar 31, 1997 |
| | | 50MG | A074640 | 003 | Mar 31, 1997 |
| | | 100MG | A074640 | 004 | Mar 31, 1997 |
| | SANDOZ | 12.5MG | A074481 | 001 | Feb 13, 1996 |
| | | 12.5MG | A074519 | 001 | Feb 13, 1996 |
| | | 25MG | A074481 | 002 | Feb 13, 1996 |
| | | 25MG | A074519 | 002 | Feb 13, 1996 |
| | | 50MG | A074481 | 003 | Feb 13, 1996 |
| | | 50MG | A074519 | 003 | Feb 13, 1996 |
| | | 100MG | A074481 | 004 | Feb 13, 1996 |
| | | 100MG | A074519 | 004 | Feb 13, 1996 |
| | VINTAGE PHARMS LLC | 12.5MG | A074418 | 001 | Feb 13, 1996 |
| | | 25MG | A074418 | 002 | Feb 13, 1996 |

| | | | | |
|---|---|---|---|---|
| CAPTOPRIL | | | | |
| TABLET;ORAL | | | | |
| CAPTOPRIL | | | | |
| | 50MG | A074418 | 003 | Feb 13, 1996 |
| | 100MG | A074418 | 004 | Feb 13, 1996 |
| WATSON LABS | 12.5MG | A074451 | 001 | Feb 13, 1996 |
| | 12.5MG | A074576 | 001 | Apr 23, 1996 |
| | 25MG | A074451 | 002 | Feb 13, 1996 |
| | 25MG | A074576 | 002 | Apr 23, 1996 |
| | 50MG | A074451 | 003 | Feb 13, 1996 |
| | 50MG | A074576 | 003 | Apr 23, 1996 |
| | 100MG | A074451 | 004 | Feb 13, 1996 |
| | 100MG | A074576 | 004 | Apr 23, 1996 |
| CAPTOPRIL; HYDROCHLOROTHIAZIDE | | | | |
| TABLET;ORAL | | | | |
| CAPOZIDE 25/15 | | | | |
| + APOTHECON | 25MG;15MG ** | N018709 | 001 | Oct 12, 1984 |
| CAPOZIDE 25/25 | | | | |
| + APOTHECON | 25MG;25MG ** | N018709 | 002 | Oct 12, 1984 |
| CAPOZIDE 50/15 | | | | |
| + APOTHECON | 50MG;15MG ** | N018709 | 004 | Oct 12, 1984 |
| CAPOZIDE 50/25 | | | | |
| + APOTHECON | 50MG;25MG ** | N018709 | 003 | Oct 12, 1984 |
| CAPTOPRIL AND HYDROCHLOROTHIAZIDE | | | | |
| IVAX SUB TEVA PHARMS | 25MG;15MG | A075055 | 001 | Jun 18, 1998 |
| | 25MG;25MG | A075055 | 002 | Jun 18, 1998 |
| | 50MG;15MG | A075055 | 004 | Jun 18, 1998 |
| | 50MG;25MG | A075055 | 003 | Jun 18, 1998 |
| VINTAGE PHARMS LLC | 25MG;15MG | A074788 | 001 | Dec 29, 1997 |
| | 25MG;25MG | A074788 | 002 | Dec 29, 1997 |
| | 50MG;15MG | A074788 | 004 | Dec 29, 1997 |
| | 50MG;25MG | A074788 | 003 | Dec 29, 1997 |
| WATSON LABS | 50MG;25MG | A074832 | 001 | Dec 29, 1997 |
| CARBACHOL | | | | |
| SOLUTION;INTRAOCULAR | | | | |
| CARBACHOL | | | | |
| PHARMAFAIR | 0.01% | A070292 | 001 | May 21, 1986 |
| CARBASTAT | | | | |
| NOVARTIS | 0.01% | A073677 | 001 | Apr 28, 1995 |
| CARBAMAZEPINE | | | | |
| SUSPENSION;ORAL | | | | |
| CARBAMAZEPINE | | | | |
| TARO | 100MG/5ML | A075875 | 001 | Dec 21, 2000 |
| TABLET;ORAL | | | | |
| CARBAMAZEPINE | | | | |
| ACTAVIS ELIZABETH | 200MG | A071696 | 001 | Nov 09, 1987 |
| INWOOD LABS | 200MG | A070231 | 001 | Aug 14, 1986 |
| PLIVA | 200MG | A071479 | 001 | Jul 24, 1987 |
| USL PHARMA | 200MG | A070300 | 001 | May 15, 1986 |
| WARNER CHILCOTT | 200MG | A070429 | 001 | Jan 02, 1987 |
| TERIL | | | | |
| TARO | 200MG | A076525 | 001 | Sep 26, 2003 |
| TABLET, CHEWABLE;ORAL | | | | |
| CARBAMAZEPINE | | | | |
| JUBILANT CADISTA | 100MG | A071940 | 001 | Feb 01, 1988 |
| CARBENICILLIN DISODIUM | | | | |
| INJECTABLE;INJECTION | | | | |
| GEOPEN | | | | |
| ROERIG | EQ 1GM BASE/VIAL | N050306 | 001 | |
| | EQ 2GM BASE/VIAL | N050306 | 004 | |
| | EQ 5GM BASE/VIAL | N050306 | 002 | |
| | EQ 10GM BASE/VIAL | N050306 | 006 | |
| | EQ 30GM BASE/VIAL | N050306 | 007 | |
| PYOPEN | | | | |
| GLAXOSMITHKLINE | EQ 1GM BASE/VIAL | N050298 | 001 | |
| | EQ 2GM BASE/VIAL | N050298 | 002 | |
| | EQ 5GM BASE/VIAL | N050298 | 003 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| CARBENICILLIN DISODIUM | | | | |
| INJECTABLE;INJECTION | | | | |
| PYOPEN | | | | |
| | EQ 10GM BASE/VIAL | | N050298 006 | |
| | EQ 20GM BASE/VIAL | | N050298 007 | |
| CARBENICILLIN INDANYL SODIUM | | | | |
| TABLET;ORAL | | | | |
| GEOCILLIN | | | | |
| PFIZER | EQ 382MG BASE | | N050435 001 | |
| CARBIDOPA; LEVODOPA | | | | |
| TABLET;ORAL | | | | |
| CARBIDOPA AND LEVODOPA | | | | |
| IDT AUSTRALIA LTD | 10MG;100MG | | A073587 002 | Jun 29, 1995 |
| | 25MG;100MG | | A073587 001 | Jun 29, 1995 |
| | 25MG;250MG | | A073587 003 | Jun 29, 1995 |
| SCS | 10MG;100MG | | A074080 001 | Mar 25, 1994 |
| | 25MG;100MG | | A074080 002 | Mar 25, 1994 |
| | 25MG;250MG | | A074080 003 | Mar 25, 1994 |
| WATSON LABS | 10MG;100MG | | A073381 001 | Sep 28, 1993 |
| | 25MG;100MG | | A073382 001 | Sep 28, 1993 |
| | 25MG;250MG | | A073383 001 | Sep 28, 1993 |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| CARBIDOPA AND LEVODOPA | | | | |
| KV PHARM | 50MG;200MG | | A076663 001 | Jun 24, 2004 |
| TABLET, FOR SUSPENSION;ORAL | | | | |
| CARBILEV | | | | |
| RANBAXY | 10MG;100MG | | A076643 001 | Jun 10, 2005 |
| | 25MG;100MG | | A076643 002 | Jun 10, 2005 |
| | 25MG;250MG | | A076643 003 | Jun 10, 2005 |
| TABLET, ORALLY DISINTEGRATING;ORAL | | | | |
| CARBIDOPA AND LEVODOPA | | | | |
| IMPAX LABS | 10MG;100MG | | A090631 001 | Jun 08, 2010 |
| | 25MG;100MG | | A090631 002 | Jun 08, 2010 |
| | 25MG;250MG | | A090631 003 | Jun 08, 2010 |
| PARCOPA | | | | |
| UCB INC | 10MG;100MG ** | | A076699 001 | Aug 27, 2004 |
| | 25MG;100MG ** | | A076699 002 | Aug 27, 2004 |
| | 25MG;250MG ** | | A076699 003 | Aug 27, 2004 |
| CARBINOXAMINE MALEATE | | | | |
| ELIXIR;ORAL | | | | |
| CLISTIN | | | | |
| + MCNEIL | 4MG/5ML ** | | N008955 001 | |
| TABLET;ORAL | | | | |
| CLISTIN | | | | |
| + ORTHO MCNEIL PHARM | 4MG ** | | N008915 001 | |
| CARBOPLATIN | | | | |
| INJECTABLE;INJECTION | | | | |
| CARBOPLATIN | | | | |
| CIPLA LTD | 50MG/VIAL | | A077383 001 | Jan 27, 2006 |
| | 150MG/VIAL | | A077383 002 | Jan 27, 2006 |
| | 450MG/VIAL | | A077383 003 | Jan 27, 2006 |
| FRESENIUS KABI USA | 50MG/VIAL | | A076235 001 | Oct 14, 2004 |
| | 150MG/VIAL | | A076235 002 | Oct 14, 2004 |
| | 450MG/VIAL | | A076235 003 | Oct 14, 2004 |
| HOSPIRA | 50MG/VIAL | | A076473 001 | Oct 27, 2004 |
| | 150MG/VIAL | | A076473 002 | Oct 27, 2004 |
| | 450MG/VIAL | | A076473 003 | Oct 27, 2004 |
| MYLAN LABS LTD | 50MG/VIAL | | A091510 001 | May 29, 2012 |
| | 150MG/VIAL | | A091510 002 | May 29, 2012 |
| | 450MG/VIAL | | A091510 003 | May 29, 2012 |
| PLIVA | 50MG/VIAL | | A076602 001 | Nov 16, 2004 |
| | 150MG/VIAL | | A076602 002 | Nov 16, 2004 |
| | 450MG/VIAL | | A076602 003 | Nov 16, 2004 |
| SANDOZ | 50MG/VIAL | | A076959 001 | Mar 18, 2005 |
| | 150MG/VIAL | | A076959 002 | Mar 18, 2005 |
| | 450MG/VIAL | | A076959 003 | Mar 18, 2005 |
| WATSON LABS TEVA | 50MG/VIAL | | A076162 001 | Oct 14, 2004 |

| | | | | |
|---|---|---|---|---|
| CARBOPLATIN | | | | |
| INJECTABLE;INJECTION | | | | |
| CARBOPLATIN | | | | |
| | 150MG/VIAL | A076162 | 002 | Oct 14, 2004 |
| | 450MG/VIAL | A076162 | 003 | Oct 14, 2004 |
| WEST-WARD PHARMS INT | 50MG/VIAL | A076099 | 001 | Oct 14, 2004 |
| | 150MG/VIAL | A076099 | 002 | Oct 14, 2004 |
| | 450MG/VIAL | A076099 | 003 | Oct 14, 2004 |
| PARAPLATIN | | | | |
| + CORDEN PHARMA | 50MG/VIAL ** | N019880 | 001 | Mar 03, 1989 |
| + | 150MG/VIAL ** | N019880 | 002 | Mar 03, 1989 |
| + | 450MG/VIAL ** | N019880 | 003 | Mar 03, 1989 |
| INJECTABLE;IV (INFUSION) | | | | |
| CARBOPLATIN | | | | |
| ACTAVIS TOTOWA | 50MG/5ML (10MG/ML) | A078732 | 001 | Feb 06, 2012 |
| | 150MG/15ML (10MG/ML) | A078732 | 002 | Feb 06, 2012 |
| | 450MG/45ML (10MG/ML) | A078732 | 003 | Feb 06, 2012 |
| | 600MG/60ML (10MG/ML) | A078732 | 004 | Feb 06, 2012 |
| FRESENIUS KABI USA | 50MG/5ML (10MG/ML) | A077247 | 001 | Oct 21, 2004 |
| | 50MG/5ML (10MG/ML) | A077266 | 001 | Feb 15, 2006 |
| | 150MG/15ML (10MG/ML) | A077247 | 002 | Oct 21, 2004 |
| | 150MG/15ML (10MG/ML) | A077266 | 002 | Feb 15, 2006 |
| PHARMACHEMIE BV | 50MG/5ML (10MG/ML) | A077679 | 001 | Feb 25, 2009 |
| | 150MG/15ML (10MG/ML) | A077679 | 002 | Feb 25, 2009 |
| | 450MG/45ML (10MG/ML) | A077679 | 003 | Feb 25, 2009 |
| TEVA PARENTERAL | 50MG/5ML (10MG/ML) | A077389 | 001 | Mar 30, 2007 |
| | 150MG/15ML (10MG/ML) | A077389 | 002 | Mar 30, 2007 |
| | 450MG/45ML (10MG/ML) | A077389 | 003 | Mar 30, 2007 |
| PARAPLATIN | | | | |
| + CORDENPHARMA | 50MG/5ML (10MG/ML) ** | N020452 | 001 | Jul 14, 2003 |
| + | 150MG/15ML (10MG/ML) ** | N020452 | 002 | Jul 14, 2003 |
| + | 450MG/45ML (10MG/ML) ** | N020452 | 003 | Jul 14, 2003 |
| + | 600MG/60ML (10MG/ML) ** | N020452 | 004 | Jan 15, 2004 |
| CARISOPRODOL | | | | |
| CAPSULE;ORAL | | | | |
| SOMA | | | | |
| MYLAN SPECIALITY LP | 250MG | N011792 | 003 | |
| TABLET;ORAL | | | | |
| CARISOPRODOL | | | | |
| ABLE | 350MG | A040421 | 001 | Jun 21, 2001 |
| EPIC PHARMA LLC | 350MG | A040397 | 001 | Sep 21, 2000 |
| OXFORD PHARMS | 350MG | A040188 | 001 | Mar 07, 1997 |
| PIONEER PHARMS | 350MG | A089390 | 001 | Oct 13, 1988 |
| SANDOZ | 350MG | A081025 | 001 | Apr 13, 1989 |
| | 350MG | A089566 | 001 | Aug 30, 1988 |
| SUN PHARM INDS LTD | 350MG | A040755 | 001 | Feb 27, 2007 |
| WATSON LABS | 350MG | A040152 | 001 | Dec 03, 1996 |
| | 350MG | A085433 | 001 | |
| WATSON LABS TEVA | 350MG | A086179 | 001 | |
| RELA | | | | |
| SCHERING | 350MG | N012155 | 001 | |
| CARPHENAZINE MALEATE | | | | |
| CONCENTRATE;ORAL | | | | |
| PROKETAZINE | | | | |
| WYETH AYERST | 50MG/ML | N014173 | 001 | |
| TABLET;ORAL | | | | |
| PROKETAZINE | | | | |
| WYETH AYERST | 12.5MG | N012768 | 001 | |
| | 25MG | N012768 | 002 | |
| | 50MG | N012768 | 004 | |
| CARPROFEN | | | | |
| TABLET;ORAL | | | | |
| RIMADYL | | | | |
| ROCHE | 100MG | N018550 | 002 | Dec 31, 1987 |
| | 150MG | N018550 | 003 | Dec 31, 1987 |

| | | | | |
|---|---|---|---|---|
| CARTEOLOL HYDROCHLORIDE | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | |
| CARTEOLOL HYDROCHLORIDE | | | | |
| APOTEX INC | 1% | A076097 | 001 | Feb 06, 2002 |
| OCUPRESS | | | | |
| + NOVARTIS | 1% | N019972 | 001 | May 23, 1990 |
| TABLET;ORAL | | | | |
| CARTROL | | | | |
| ABBVIE | 2.5MG | N019204 | 001 | Dec 28, 1988 |
| | 5MG | N019204 | 002 | Dec 28, 1988 |
| | 10MG | N019204 | 003 | Dec 28, 1988 |
| CARVEDILOL | | | | |
| TABLET;ORAL | | | | |
| CARVEDILOL | | | | |
| HIKMA | 3.125MG | A077887 | 001 | Sep 07, 2007 |
| | 6.25MG | A077887 | 002 | Sep 07, 2007 |
| | 12.5MG | A077887 | 003 | Sep 07, 2007 |
| | 25MG | A077887 | 004 | Sep 07, 2007 |
| PLIVA HRVATSKA DOO | 3.125MG | A078240 | 001 | Oct 30, 2007 |
| | 6.25MG | A078240 | 002 | Oct 30, 2007 |
| | 12.5MG | A078240 | 003 | Oct 30, 2007 |
| | 25MG | A078240 | 004 | Oct 30, 2007 |
| WOCKHARDT LTD | 3.125MG | A078786 | 001 | Dec 22, 2009 |
| | 6.25MG | A078786 | 002 | Dec 22, 2009 |
| | 12.5MG | A078786 | 003 | Dec 22, 2009 |
| | 25MG | A078786 | 004 | Dec 22, 2009 |
| CEFACLOR | | | | |
| CAPSULE;ORAL | | | | |
| CECLOR | | | | |
| + LILLY | EQ 250MG BASE ** | N050521 | 001 | |
| + | EQ 500MG BASE ** | N050521 | 002 | |
| CEFACLOR | | | | |
| CEPH INTL | EQ 250MG BASE | A062205 | 001 | |
| | EQ 500MG BASE | A062205 | 002 | |
| DAVA PHARMS INC | EQ 250MG BASE | A064107 | 001 | Apr 27, 1995 |
| | EQ 500MG BASE | A064107 | 002 | Apr 27, 1995 |
| IVAX SUB TEVA PHARMS | EQ 250MG BASE | A064061 | 001 | Apr 27, 1995 |
| | EQ 500MG BASE | A064061 | 002 | Apr 27, 1995 |
| RANBAXY | EQ 250MG BASE | A064156 | 001 | Aug 28, 1997 |
| | EQ 500MG BASE | A064156 | 002 | Aug 28, 1997 |
| TEVA | EQ 250MG BASE | A064081 | 001 | Sep 16, 1996 |
| | EQ 250MG BASE | A064145 | 001 | Jun 24, 1996 |
| | EQ 500MG BASE | A064081 | 002 | Sep 16, 1996 |
| | EQ 500MG BASE | A064145 | 002 | Jun 24, 1996 |
| WATSON LABS INC | EQ 250MG BASE | A064148 | 001 | May 23, 1996 |
| | EQ 500MG BASE | A064148 | 002 | May 23, 1996 |
| FOR SUSPENSION;ORAL | | | | |
| CECLOR | | | | |
| + LILLY | EQ 125MG BASE/5ML ** | N050522 | 001 | |
| + | EQ 250MG BASE/5ML ** | N050522 | 002 | |
| CEFACLOR | | | | |
| DAVA PHARMS INC | EQ 125MG BASE/5ML | A064114 | 001 | Apr 28, 1995 |
| | EQ 187MG BASE/5ML | A064115 | 001 | Apr 28, 1995 |
| | EQ 250MG BASE/5ML | A064116 | 001 | Apr 28, 1995 |
| | EQ 375MG BASE/5ML | A064110 | 001 | Apr 28, 1995 |
| FACTA FARMA | EQ 125MG BASE/5ML | A062206 | 001 | |
| | EQ 187MG BASE/5ML | A062206 | 003 | Apr 20, 1988 |
| | EQ 250MG BASE/5ML | A062206 | 002 | |
| | EQ 375MG BASE/5ML | A062206 | 004 | Apr 20, 1988 |
| IVAX SUB TEVA PHARMS | EQ 125MG BASE/5ML | A064087 | 001 | Apr 28, 1995 |
| | EQ 187MG BASE/5ML | A064086 | 001 | Apr 28, 1995 |
| | EQ 250MG BASE/5ML | A064085 | 001 | Apr 28, 1995 |
| | EQ 375MG BASE/5ML | A064070 | 001 | Apr 28, 1995 |
| RANBAXY | EQ 125MG BASE/5ML | A064166 | 001 | Oct 02, 1997 |
| | EQ 187MG BASE/5ML | A064165 | 001 | Oct 02, 1997 |
| | EQ 250MG BASE/5ML | A064164 | 001 | Oct 02, 1997 |
| | EQ 375MG BASE/5ML | A064155 | 001 | Oct 02, 1997 |
| WATSON LABS INC | EQ 125MG BASE/5ML | A064204 | 001 | Feb 18, 1998 |

CEFACLOR

| | | | | |
|---|---|---|---|---|
| FOR SUSPENSION;ORAL | | | | |
| CEFACLOR | | | | |
| | EQ 187MG BASE/5ML | | A064205 001 | Feb 18, 1998 |
| | EQ 250MG BASE/5ML | | A064206 001 | Feb 18, 1998 |
| | EQ 375MG BASE/5ML | | A064207 001 | Feb 18, 1998 |
| TABLET, CHEWABLE;ORAL | | | | |
| RANICLOR | | | | |
| RANBAXY LABS LTD | EQ 125MG BASE | | A065092 001 | Dec 22, 2003 |
| | EQ 187MG BASE | | A065092 002 | Dec 22, 2003 |
| | EQ 250MG BASE | | A065092 003 | Dec 22, 2003 |
| | EQ 375MG BASE | | A065092 004 | Dec 22, 2003 |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| CECLOR CD | | | | |
| LILLY | EQ 375MG BASE | | N050673 001 | Jun 28, 1996 |
| | EQ 500MG BASE | | N050673 002 | Jun 28, 1996 |
| CEFACLOR | | | | |
| WORLD GEN | EQ 500MG BASE | | A065057 001 | Jan 05, 2001 |

CEFADROXIL/CEFADROXIL HEMIHYDRATE

| | | | | |
|---|---|---|---|---|
| CAPSULE;ORAL | | | | |
| CEFADROXIL | | | | |
| IVAX SUB TEVA PHARMS | EQ 500MG BASE | | A062766 001 | Mar 03, 1987 |
| PUREPAC PHARM | EQ 500MG BASE | | A063017 001 | Jan 05, 1989 |
| RANBAXY LABS LTD | EQ 500MG BASE | | A065015 001 | Jun 22, 1999 |
| SANDOZ | EQ 500MG BASE | | A062291 001 | |
| TEVA | EQ 500MG BASE | | A062695 001 | Feb 10, 1989 |
| DURICEF | | | | |
| WARNER CHILCOTT | EQ 250MG BASE | | N050512 002 | |
| + | EQ 500MG BASE ** | | N050512 001 | |
| ULTRACEF | | | | |
| BRISTOL | EQ 500MG BASE | | A062378 001 | Mar 16, 1982 |
| FOR SUSPENSION;ORAL | | | | |
| CEFADROXIL | | | | |
| ANI PHARMS INC | EQ 125MG BASE/5ML | | A062698 001 | Mar 01, 1989 |
| | EQ 250MG BASE/5ML | | A062698 002 | Mar 01, 1989 |
| | EQ 250MG BASE/5ML | | A065278 001 | Jan 20, 2006 |
| | EQ 500MG BASE/5ML | | A062698 003 | Mar 01, 1989 |
| | EQ 500MG BASE/5ML | | A065278 002 | Jan 20, 2006 |
| APOTHECON | EQ 125MG BASE/5ML | | A062334 001 | |
| | EQ 250MG BASE/5ML | | A062334 002 | |
| | EQ 500MG BASE/5ML | | A062334 003 | |
| SUN PHARM INDS LTD | EQ 125MG BASE/5ML | | A065115 001 | Mar 26, 2003 |
| | EQ 250MG BASE/5ML | | A065115 002 | Mar 26, 2003 |
| | EQ 500MG BASE/5ML | | A065115 003 | Mar 26, 2003 |
| DURICEF | | | | |
| + WARNER CHILCOTT | EQ 125MG BASE/5ML ** | | N050527 002 | |
| + | EQ 250MG BASE/5ML ** | | N050527 003 | |
| + | EQ 500MG BASE/5ML ** | | N050527 001 | |
| ULTRACEF | | | | |
| BRISTOL | EQ 125MG BASE/5ML | | A062376 001 | Mar 16, 1982 |
| | EQ 250MG BASE/5ML | | A062376 002 | Mar 16, 1982 |
| | EQ 500MG BASE/5ML | | A062376 003 | Mar 16, 1982 |
| TABLET;ORAL | | | | |
| CEFADROXIL | | | | |
| RANBAXY | EQ 1GM BASE | | A065018 001 | Apr 23, 1999 |
| DURICEF | | | | |
| + WARNER CHILCOTT | EQ 1GM BASE ** | | N050528 001 | |
| ULTRACEF | | | | |
| APOTHECON | EQ 1GM BASE | | A062390 001 | Jun 10, 1982 |
| BRISTOL | EQ 1GM BASE | | A062408 001 | Aug 31, 1982 |

CEFAMANDOLE NAFATE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| MANDOL | | | | |
| LILLY | EQ 500MG BASE/VIAL | | N050504 001 | |
| | EQ 1GM BASE/VIAL | | A062560 001 | Sep 10, 1985 |
| | EQ 1GM BASE/VIAL | | N050504 002 | |
| | EQ 2GM BASE/VIAL | | A062560 002 | Sep 10, 1985 |
| | EQ 2GM BASE/VIAL | | N050504 003 | |

| | | | | |
|---|---|---|---|---|
| CEFAMANDOLE NAFATE | | | | |
| INJECTABLE;INJECTION | | | | |
| MANDOL | | | | |
| | EQ 10GM BASE/VIAL | | N050504 004 | |
| CEFAZOLIN SODIUM | | | | |
| INJECTABLE;INJECTION | | | | |
| ANCEF | | | | |
| + GLAXOSMITHKLINE | EQ 250MG BASE/VIAL ** | | N050461 001 | |
| + | EQ 500MG BASE/VIAL | | N050461 002 | |
| + | EQ 1GM BASE/VIAL ** | | N050461 003 | |
| + | EQ 5GM BASE/VIAL ** | | N050461 004 | |
| + | EQ 10GM BASE/VIAL ** | | N050461 005 | |
| ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| BAXTER HLTHCARE | EQ 10MG BASE/ML | | N050566 003 | Jun 08, 1983 |
| | EQ 20MG BASE/ML | | N050566 004 | Jun 08, 1983 |
| ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | | | | |
| BAXTER HLTHCARE | EQ 10MG BASE/ML | | N050566 001 | Jun 08, 1983 |
| | EQ 20MG BASE/ML | | N050566 002 | Jun 08, 1983 |
| CEFAZOLIN AND DEXTROSE | | | | |
| B BRAUN | EQ 500MG BASE/VIAL | | N050779 001 | Jul 27, 2000 |
| CEFAZOLIN SODIUM | | | | |
| ABRAXIS PHARM | EQ 500MG BASE/VIAL | | A062688 002 | Nov 17, 1986 |
| | EQ 1GM BASE/VIAL | | A062688 003 | Nov 17, 1986 |
| | EQ 10GM BASE/VIAL | | A062688 004 | Nov 17, 1986 |
| | EQ 20GM BASE/VIAL | | A062688 005 | Aug 03, 1987 |
| AUROBINDO PHARMA | EQ 500MG BASE/VIAL | | A065395 001 | Aug 08, 2008 |
| | EQ 1GM BASE/VIAL | | A065395 002 | Aug 08, 2008 |
| BEDFORD | EQ 250MG BASE/VIAL | | A062894 001 | Jul 21, 1988 |
| | EQ 500MG BASE/VIAL | | A062894 002 | Jul 21, 1988 |
| | EQ 1GM BASE/VIAL | | A062894 003 | Jul 21, 1988 |
| | EQ 5GM BASE/VIAL | | A062894 004 | Jul 21, 1988 |
| | EQ 10GM BASE/VIAL | | A062894 005 | Jul 21, 1988 |
| CEPHAZONE PHARMA | EQ 500MG BASE/VIAL | | A065280 001 | Mar 18, 2009 |
| | EQ 1GM BASE/VIAL | | A065280 002 | Mar 18, 2009 |
| | EQ 10GM BASE/VIAL | | A065295 001 | Mar 18, 2009 |
| | EQ 20GM BASE/VIAL | | A065296 001 | Mar 18, 2009 |
| FACTA FARMA | EQ 1GM BASE/VIAL | | A063207 001 | Dec 27, 1991 |
| | EQ 500MG BASE/VIAL | | A063214 001 | Dec 27, 1991 |
| | EQ 10GM BASE/VIAL | | A063209 001 | Dec 27, 1991 |
| | EQ 20GM BASE/VIAL | | A063209 002 | Apr 30, 1999 |
| FRESENIUS KABI USA | EQ 500MG BASE/VIAL ** | | A064169 001 | Aug 14, 1998 |
| | EQ 1GM BASE/VIAL ** | | A064169 002 | Aug 14, 1998 |
| | EQ 10GM BASE/VIAL | | A064170 001 | Mar 18, 1998 |
| | EQ 20GM BASE/VIAL | | A064170 002 | Mar 18, 1998 |
| GLAXOSMITHKLINE | EQ 1GM BASE/VIAL | | A064033 001 | Oct 31, 1993 |
| STERI PHARMA | EQ 500MG BASE/VIAL | | A063216 001 | Dec 27, 1991 |
| | EQ 1GM BASE/VIAL | | A063208 001 | Dec 27, 1991 |
| TEVA PHARMS | EQ 250MG BASE/VIAL | | A063016 001 | Mar 14, 1989 |
| | EQ 500MG BASE/VIAL | | A063016 002 | Mar 14, 1989 |
| | EQ 1GM BASE/VIAL | | A063016 003 | Mar 14, 1989 |
| | EQ 5GM BASE/VIAL | | A063018 001 | Mar 05, 1990 |
| | EQ 10GM BASE/VIAL | | A063018 002 | Mar 05, 1990 |
| WATSON LABS INC | EQ 250MG BASE/VIAL | | A062988 001 | Dec 29, 1989 |
| | EQ 500MG BASE/VIAL | | A062988 002 | Dec 29, 1989 |
| | EQ 1GM BASE/VIAL | | A062988 003 | Dec 29, 1989 |
| | EQ 5GM BASE/VIAL | | A062989 001 | Dec 29, 1989 |
| | EQ 10GM BASE/VIAL | | A062989 002 | Dec 29, 1989 |
| | EQ 20GM BASE/VIAL | | A062989 003 | Dec 29, 1989 |
| WEST-WARD PHARMS INT | EQ 250MG BASE/VIAL | | A062807 001 | Jan 12, 1988 |
| | EQ 500MG BASE/VIAL | | A062807 002 | Jan 12, 1988 |
| | EQ 1GM BASE/VIAL | | A062807 003 | Jan 12, 1988 |
| | EQ 5GM BASE/VIAL | | A062807 004 | Jan 12, 1988 |
| | EQ 10GM BASE/VIAL | | A062807 005 | Jan 12, 1988 |
| | EQ 20GM BASE/VIAL | | A062807 006 | Jan 12, 1988 |
| KEFZOL | | | | |
| ACS DOBFAR | EQ 250MG BASE/VIAL | | A061773 001 | |
| | EQ 20GM BASE/VIAL | | A061773 005 | Sep 08, 1987 |
| LILLY | EQ 500MG BASE/VIAL | | A062557 001 | Sep 10, 1985 |
| | EQ 1GM BASE/VIAL | | A062557 002 | Sep 10, 1985 |

| | | | | |
|---|---|---|---|---|
| CEFDINIR | | | | |
| CAPSULE;ORAL | | | | |
| OMNICEF | | | | |
| + | ABBVIE | 300MG ** | N050739 001 | Dec 04, 1997 |
| FOR SUSPENSION;ORAL | | | | |
| OMNICEF | | | | |
| + | ABBVIE | 125MG/5ML ** | N050749 001 | Dec 04, 1997 |
| + | | 250MG/5ML ** | N050749 002 | Jul 29, 2004 |
| CEFDITOREN PIVOXIL | | | | |
| TABLET;ORAL | | | | |
| SPECTRACEF | | | | |
| | VANSEN PHARMA | 200MG | N021222 001 | Aug 29, 2001 |
| | | 400MG | N021222 002 | Jul 21, 2008 |
| CEFEPIME HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| CEFEPIME HYDROCHLORIDE | | | | |
| | SANDOZ | EQ 1GM BASE/VIAL | A090291 002 | Dec 21, 2010 |
| | | EQ 2GM BASE/VIAL | A090291 003 | Dec 21, 2010 |
| | | EQ 500MG BASE/VIAL | A090291 001 | Dec 21, 2010 |
| CEFIXIME | | | | |
| FOR SUSPENSION;ORAL | | | | |
| SUPRAX | | | | |
| + | LEDERLE | 100MG/5ML ** | N050622 001 | Apr 28, 1989 |
| TABLET;ORAL | | | | |
| SUPRAX | | | | |
| + | LEDERLE | 200MG ** | N050621 001 | Apr 28, 1989 |
| + | | 400MG ** | N050621 002 | Apr 28, 1989 |
| CEFMENOXIME HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| CEFMAX | | | | |
| | TAP PHARM | EQ 500MG BASE/VIAL | N050571 001 | Dec 30, 1987 |
| | | EQ 1GM BASE/VIAL | N050571 002 | Dec 30, 1987 |
| | | EQ 2GM BASE/VIAL | N050571 003 | Dec 30, 1987 |
| CEFMETAZOLE SODIUM | | | | |
| INJECTABLE;INJECTION | | | | |
| ZEFAZONE | | | | |
| + | PHARMACIA AND UPJOHN | EQ 1GM BASE/VIAL ** | N050637 001 | Dec 11, 1989 |
| + | | EQ 2GM BASE/VIAL ** | N050637 002 | Dec 11, 1989 |
| ZEFAZONE IN PLASTIC CONTAINER | | | | |
| + | PHARMACIA AND UPJOHN | EQ 20MG BASE/ML ** | N050683 001 | Dec 29, 1992 |
| + | | EQ 40MG BASE/ML ** | N050683 002 | Dec 29, 1992 |
| CEFONICID SODIUM | | | | |
| INJECTABLE;INJECTION | | | | |
| MONOCID | | | | |
| | GLAXOSMITHKLINE | EQ 500MG BASE/VIAL | N050579 001 | May 23, 1984 |
| | | EQ 1GM BASE/VIAL | A063295 001 | Jul 26, 1993 |
| | | EQ 1GM BASE/VIAL | N050579 002 | May 23, 1984 |
| | | EQ 2GM BASE/VIAL | N050579 003 | May 23, 1984 |
| | | EQ 10GM BASE/VIAL | N050579 004 | May 23, 1984 |
| CEFOPERAZONE SODIUM | | | | |
| INJECTABLE;INJECTION | | | | |
| CEFOBID | | | | |
| | PFIZER | EQ 1GM BASE/VIAL | A063333 001 | Mar 31, 1995 |
| | | EQ 1GM BASE/VIAL | N050551 001 | Nov 18, 1982 |
| | | EQ 2GM BASE/VIAL | A063333 002 | Mar 31, 1995 |
| | | EQ 2GM BASE/VIAL | N050551 002 | Nov 18, 1982 |
| | | EQ 10GM BASE/VIAL | N050551 003 | Mar 05, 1990 |
| CEFOBID IN PLASTIC CONTAINER | | | | |
| | PFIZER | EQ 20MG BASE/ML | N050613 002 | Jul 31, 1987 |
| | | EQ 40MG BASE/ML | N050613 001 | Jul 23, 1986 |

CEFORANIDE
INJECTABLE;INJECTION
PRECEF

| | | | | |
|---|---|---|---|---|
| APOTHECON | 500MG/VIAL | A062579 | 001 | Nov 26, 1984 |
| | 1GM/VIAL | A062579 | 002 | Nov 26, 1984 |
| | 2GM/VIAL | A062579 | 003 | Nov 26, 1984 |
| | 10GM/VIAL | A062579 | 004 | Nov 26, 1984 |
| | 20GM/VIAL | A062579 | 005 | Nov 26, 1984 |
| BRISTOL | 500MG/VIAL | N050554 | 001 | May 24, 1984 |
| | 1GM/VIAL | N050554 | 002 | May 24, 1984 |
| | 2GM/VIAL | N050554 | 003 | May 24, 1984 |
| | 10GM/VIAL | N050554 | 004 | May 24, 1984 |
| | 20GM/VIAL | N050554 | 005 | May 24, 1984 |

CEFOTAXIME SODIUM
INJECTABLE;INJECTION
CEFOTAXIME

| | | | | |
|---|---|---|---|---|
| FRESENIUS KABI USA | EQ 500MG BASE/VIAL | A064200 | 001 | Mar 24, 2000 |
| | EQ 1GM BASE/VIAL | A064200 | 002 | Mar 24, 2000 |
| | EQ 2GM BASE/VIAL | A064200 | 003 | Mar 24, 2000 |
| | EQ 10GM BASE/VIAL | A064201 | 001 | Mar 24, 2000 |
| | EQ 20GM BASE/VIAL | A064201 | 002 | Mar 24, 2000 |

CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| B BRAUN | EQ 2GM BASE | N050792 | 001 | Jul 29, 2004 |

CEFOTAXIME AND DEXTROSE 3.9% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| B BRAUN | EQ 1GM BASE | N050792 | 002 | Jul 29, 2004 |

CEFOTAXIME SODIUM

| | | | | |
|---|---|---|---|---|
| AUROBINDO PHARMA | EQ 500MG BASE/VIAL | A065517 | 001 | Nov 06, 2009 |
| | EQ 1GM BASE/VIAL | A065517 | 002 | Nov 06, 2009 |
| | EQ 2GM BASE/VIAL | A065517 | 003 | Nov 06, 2009 |
| AUROBINDO PHARMA LTD | EQ 10GM BASE/VIAL | A065516 | 001 | Nov 06, 2009 |
| CEPHAZONE PHARMA | EQ 10GM BASE/VIAL | A065348 | 001 | Jan 25, 2010 |

CLAFORAN

| | | | | |
|---|---|---|---|---|
| SANOFI AVENTIS US | EQ 1GM BASE/VIAL | A062659 | 001 | Jan 13, 1987 |
| | EQ 2GM BASE/VIAL | A062659 | 002 | Jan 13, 1987 |

CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| US PHARM HOLDINGS | EQ 20MG BASE/ML | N050596 | 002 | May 20, 1985 |
| | EQ 40MG BASE/ML | N050596 | 004 | May 20, 1985 |

CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| US PHARM HOLDINGS | EQ 20MG BASE/ML | N050596 | 001 | May 20, 1985 |
| | EQ 40MG BASE/ML | N050596 | 003 | May 20, 1985 |

CEFOTETAN DISODIUM
INJECTABLE;INJECTION
CEFOTAN

| | | | | |
|---|---|---|---|---|
| TELIGENT | EQ 10GM BASE/VIAL | N050588 | 003 | Apr 25, 1988 |
| TELIGENT PHARMA INC | EQ 1GM BASE/VIAL | A063293 | 001 | Apr 29, 1993 |
| | EQ 2GM BASE/VIAL | A063293 | 002 | Apr 29, 1993 |

CEFOTAN IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| TELIGENT | EQ 20MG BASE/ML | N050694 | 002 | Jul 30, 1993 |
| | EQ 40MG BASE/ML | N050694 | 001 | Jul 30, 1993 |

CEFOTIAM HYDROCHLORIDE
INJECTABLE;INJECTION
CERADON

| | | | | |
|---|---|---|---|---|
| TAKEDA | EQ 1GM BASE/VIAL | N050601 | 001 | Dec 30, 1988 |

CEFOXITIN SODIUM
INJECTABLE;INJECTION
CEFOXITIN

| | | | | |
|---|---|---|---|---|
| ACS DOBFAR SPA | EQ 1GM BASE/VIAL | A065467 | 001 | Aug 31, 2011 |
| | EQ 2GM BASE/VIAL | A065467 | 002 | Aug 31, 2011 |
| | EQ 10GM BASE/VIAL | A065464 | 001 | Aug 31, 2011 |
| FRESENIUS KABI USA | EQ 1GM BASE/VIAL ** | A065012 | 001 | Jul 03, 2000 |
| | EQ 2GM BASE/VIAL ** | A065012 | 002 | Jul 03, 2000 |
| | EQ 10GM BASE/VIAL | A065011 | 001 | Jul 03, 2000 |

MEFOXIN

| | | | | |
|---|---|---|---|---|
| MYLAN INSTITUTIONAL | EQ 1GM BASE/VIAL | A062757 | 001 | Jan 08, 1987 |
| + | EQ 1GM BASE/VIAL ** | N050517 | 001 | |
| | EQ 2GM BASE/VIAL | A062757 | 002 | Jan 08, 1987 |
| + | EQ 2GM BASE/VIAL ** | N050517 | 002 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| CEFOXITIN SODIUM | | | | |
| INJECTABLE;INJECTION | | | | |
| MEFOXIN | | | | |
| + | | EQ 10GM BASE/VIAL ** | N050517 003 | |
| MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| + | MERCK | EQ 20MG BASE/ML ** | N050581 003 | Sep 20, 1984 |
| + | | EQ 40MG BASE/ML ** | N050581 004 | Sep 20, 1984 |
| MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | | | | |
| + | MERCK | EQ 20MG BASE/ML ** | N050581 002 | Sep 20, 1984 |
| + | | EQ 40MG BASE/ML ** | N050581 001 | Sep 20, 1984 |
| CEFPIRAMIDE SODIUM | | | | |
| INJECTABLE;INJECTION | | | | |
| CEFPIRAMIDE SODIUM | | | | |
| | WYETH AYERST | EQ 1GM BASE/VIAL | N050633 002 | Jan 31, 1989 |
| | | EQ 2GM BASE/VIAL | N050633 003 | Jan 31, 1989 |
| | | EQ 10GM BASE/VIAL | N050633 005 | Jan 31, 1989 |
| CEFPODOXIME PROXETIL | | | | |
| FOR SUSPENSION;ORAL | | | | |
| BANAN | | | | |
| | SANKYO | EQ 50MG BASE/5ML | N050688 002 | Aug 07, 1992 |
| | | EQ 100MG BASE/5ML | N050688 001 | Aug 07, 1992 |
| CEFPODOXIME PROXETIL | | | | |
| | SUN PHARM INDS LTD | EQ 50MG BASE/5ML | A065082 001 | May 31, 2002 |
| | | EQ 100MG BASE/5ML | A065082 002 | May 31, 2002 |
| VANTIN | | | | |
| + | PHARMACIA AND UPJOHN | EQ 50MG BASE/5ML ** | N050675 001 | Aug 07, 1992 |
| + | | EQ 100MG BASE/5ML ** | N050675 002 | Aug 07, 1992 |
| TABLET;ORAL | | | | |
| BANAN | | | | |
| | SANKYO | EQ 100MG BASE | N050687 001 | Aug 07, 1992 |
| | | EQ 200MG BASE | N050687 002 | Aug 07, 1992 |
| CEFPODOXIME PROXETIL | | | | |
| | SUN PHARM INDS LTD | EQ 100MG BASE | A065083 001 | Aug 20, 2003 |
| | | EQ 200MG BASE | A065083 002 | Aug 20, 2003 |
| VANTIN | | | | |
| + | PHARMACIA AND UPJOHN | EQ 100MG BASE ** | N050674 001 | Aug 07, 1992 |
| + | | EQ 200MG BASE ** | N050674 002 | Aug 07, 1992 |
| CEFPROZIL | | | | |
| FOR SUSPENSION;ORAL | | | | |
| CEFPROZIL | | | | |
| | RANBAXY LABS LTD | 125MG/5ML | A065202 001 | Jun 30, 2006 |
| | | 250MG/5ML | A065202 002 | Jun 30, 2006 |
| CEFZIL | | | | |
| + | CORDEN PHARMA | 125MG/5ML | N050665 001 | Dec 23, 1991 |
| + | | 250MG/5ML | N050665 002 | Dec 23, 1991 |
| TABLET;ORAL | | | | |
| CEFPROZIL | | | | |
| | RANBAXY LABS LTD | 250MG | A065198 001 | Dec 13, 2006 |
| | | 500MG | A065198 002 | Dec 13, 2006 |
| CEFZIL | | | | |
| + | CORDEN PHARMA | 250MG | N050664 001 | Dec 23, 1991 |
| + | | 500MG | N050664 002 | Dec 23, 1991 |
| CEFTAZIDIME | | | | |
| INJECTABLE;INJECTION | | | | |
| CEFTAZIDIME | | | | |
| | AUROBINDO PHARMA LTD | 500MG/VIAL | A065481 001 | May 28, 2010 |
| | | 1GM/VIAL | A065481 002 | May 28, 2010 |
| | | 2GM/VIAL | A065481 003 | May 28, 2010 |
| | | 6GM/VIAL | A065482 001 | May 28, 2010 |
| CEPTAZ | | | | |
| | GLAXOSMITHKLINE | 500MG/VIAL | N050646 001 | Sep 27, 1990 |
| | | 1GM/VIAL | N050646 002 | Sep 27, 1990 |
| | | 2GM/VIAL | N050646 003 | Sep 27, 1990 |
| | | 10GM/VIAL | N050646 004 | Sep 27, 1990 |
| PENTACEF | | | | |
| | GLAXOSMITHKLINE | 1GM/VIAL | A063322 001 | Nov 07, 1995 |
| | | 1GM/VIAL | A064006 001 | Mar 31, 1992 |

CEFTAZIDIME

INJECTABLE;INJECTION

PENTACEF

| | | | | |
|---|---|---|---|---|
| | 2GM/VIAL | A063322 | 002 | Nov 07, 1995 |
| | 2GM/VIAL | A064006 | 002 | Mar 31, 1992 |
| | 6GM/VIAL | A064008 | 001 | Mar 31, 1992 |
| | 10GM/VIAL | A064008 | 002 | Mar 31, 1992 |

TAZIDIME

| | | | | |
|---|---|---|---|---|
| LILLY | 1GM/VIAL | A062655 | 001 | Nov 20, 1985 |
| | 2GM/VIAL | A062655 | 002 | Nov 20, 1985 |

TAZIDIME IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| LILLY | 1GM/VIAL | A062739 | 001 | Jul 10, 1986 |
| | 2GM/VIAL | A062739 | 002 | Jul 10, 1986 |

CEFTAZIDIME SODIUM

INJECTABLE;INJECTION

CEFTAZIDIME SODIUM IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| BAXTER HLTHCARE | EQ 10MG BASE/ML | A063221 | 001 | Apr 29, 1993 |
| | EQ 20MG BASE/ML | A063221 | 002 | Apr 29, 1993 |
| | EQ 40MG BASE/ML | A063221 | 003 | Apr 29, 1993 |

FORTAZ IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| TELIGENT | EQ 10MG BASE/ML | N050634 | 001 | Apr 28, 1989 |

CEFTIBUTEN DIHYDRATE

CAPSULE;ORAL

CEDAX

| | | | | | |
|---|---|---|---|---|---|
| | PERNIX THERAP | EQ 400MG BASE | N050685 | 002 | Dec 20, 1995 |

FOR SUSPENSION;ORAL

CEDAX

| | | | | | |
|---|---|---|---|---|---|
| + | PERNIX THERAP | EQ 90MG BASE/5ML ** | N050686 | 001 | Dec 20, 1995 |
| + | | EQ 180MG BASE/5ML ** | N050686 | 002 | Dec 20, 1995 |

CEFTIZOXIME SODIUM

INJECTABLE;INJECTION

CEFIZOX

| | | | | |
|---|---|---|---|---|
| ASTELLAS | EQ 500MG BASE/VIAL | N050560 | 001 | Sep 15, 1983 |
| | EQ 1GM BASE/VIAL | A063294 | 002 | Mar 31, 1994 |
| | EQ 1GM BASE/VIAL | N050560 | 002 | Sep 15, 1983 |
| | EQ 2GM BASE/VIAL | A063294 | 003 | Mar 31, 1994 |
| | EQ 2GM BASE/VIAL | N050560 | 003 | Sep 15, 1983 |
| | EQ 10GM BASE/VIAL | N050560 | 005 | Mar 19, 1993 |

CEFIZOX IN DEXTROSE 5% IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| ASTELLAS | EQ 20MG BASE/ML | N050589 | 001 | Oct 03, 1984 |
| | EQ 40MG BASE/ML | N050589 | 002 | Oct 03, 1984 |

CEFIZOX IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| ASTELLAS | EQ 20MG BASE/ML | N050589 | 003 | Apr 13, 1995 |
| | EQ 40MG BASE/ML | N050589 | 004 | Apr 13, 1995 |

CEFTRIAXONE SODIUM

INJECTABLE;INJECTION

CEFTRIAXONE

| | | | | |
|---|---|---|---|---|
| AGILA SPECLTS | EQ 10GM BASE/VIAL | A091068 | 001 | Jan 07, 2013 |
| AUROBINDO PHARMA LTD | EQ 10GM BASE/VIAL | A065504 | 001 | Jul 31, 2008 |
| FACTA FARMA | EQ 10GM BASE/VIAL | A065269 | 001 | Feb 28, 2007 |
| FRESENIUS KABI USA | EQ 10GM BASE/VIAL | A065252 | 001 | Feb 15, 2006 |
| HOSPIRA INC | EQ 1GM BASE/VIAL | A065231 | 001 | Aug 02, 2005 |
| | EQ 1GM BASE/VIAL | A202563 | 001 | Aug 20, 2012 |
| | EQ 2GM BASE/VIAL | A065231 | 002 | Aug 02, 2005 |
| | EQ 2GM BASE/VIAL | A202563 | 002 | Aug 20, 2012 |
| TEVA | EQ 10GM BASE/VIAL | A065274 | 001 | May 01, 2006 |

ROCEPHIN

| | | | | |
|---|---|---|---|---|
| HOFFMANN LA ROCHE | EQ 250MG BASE/VIAL | A063239 | 001 | Aug 13, 1993 |
| | EQ 500MG BASE/VIAL | A062654 | 001 | Apr 30, 1987 |
| | EQ 500MG BASE/VIAL | A063239 | 002 | Aug 13, 1993 |
| | EQ 1GM BASE/VIAL | A062654 | 002 | Apr 30, 1987 |
| | EQ 1GM BASE/VIAL | A063239 | 003 | Aug 13, 1993 |
| | EQ 2GM BASE/VIAL | A062654 | 003 | Apr 30, 1987 |
| + | EQ 10GM BASE/VIAL | N050585 | 005 | Dec 21, 1984 |
| ROCHE | EQ 250MG BASE/VIAL | A062510 | 001 | Mar 12, 1985 |
| | EQ 500MG BASE/VIAL | A062510 | 002 | Mar 12, 1985 |
| | EQ 1GM BASE/VIAL | A062510 | 003 | Mar 12, 1985 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

CEFTRIAXONE SODIUM

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER | | | | |
| + | HOFFMANN LA ROCHE | EQ 10MG BASE/ML ** | N050624 001 | Feb 11, 1987 |
| + | | EQ 20MG BASE/ML ** | N050624 002 | Feb 11, 1987 |
| + | | EQ 40MG BASE/ML ** | N050624 003 | Feb 11, 1987 |
| INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | | | | |
| CEFTRIAXONE | | | | |
| | AUROBINDO PHARMA LTD | EQ 250MG BASE/VIAL | A065505 001 | Jul 31, 2008 |
| | | EQ 500MG BASE/VIAL | A065505 002 | Jul 31, 2008 |
| | | EQ 1GM BASE/VIAL | A065505 003 | Jul 31, 2008 |
| | | EQ 2GM BASE/VIAL | A065505 004 | Jul 31, 2008 |
| | BEDFORD | EQ 250MG BASE/VIAL | A065465 001 | Aug 18, 2008 |
| | | EQ 500MG BASE/VIAL | A065465 002 | Aug 18, 2008 |
| | | EQ 1GM BASE/VIAL | A065465 003 | Aug 18, 2008 |
| | | EQ 2GM BASE/VIAL | A065465 004 | Aug 18, 2008 |
| | CEPHAZONE PHARMA | EQ 250MG BASE/VIAL | A065294 001 | Mar 26, 2007 |
| | | EQ 500MG BASE/VIAL | A065294 002 | Mar 26, 2007 |
| | | EQ 1GM BASE/VIAL | A065294 003 | Mar 26, 2007 |
| | | EQ 2GM BASE/VIAL | A065294 004 | Mar 26, 2007 |
| | FACTA FARMA | EQ 1GM BASE/VIAL | A065268 001 | Feb 28, 2007 |
| | | EQ 2GM BASE/VIAL | A065268 002 | Feb 28, 2007 |
| | FRESENIUS KABI USA | EQ 250MG BASE/VIAL | A065245 001 | Feb 15, 2006 |
| | | EQ 500MG BASE/VIAL | A065245 002 | Feb 15, 2006 |
| | | EQ 1GM BASE/VIAL | A065245 003 | Feb 15, 2006 |
| | | EQ 2GM BASE/VIAL | A065245 004 | Feb 15, 2006 |
| | TEVA | EQ 1GM BASE/VIAL | A065262 001 | Jun 29, 2006 |
| | | EQ 2GM BASE/VIAL | A065262 002 | Jun 29, 2006 |
| | TEVA PHARMS USA | EQ 250MG BASE/VIAL | A065227 001 | Mar 15, 2007 |
| | | EQ 500MG BASE/VIAL | A065227 002 | Mar 15, 2007 |
| | | EQ 1GM BASE/VIAL | A065227 003 | Mar 15, 2007 |
| | | EQ 2GM BASE/VIAL | A065227 004 | Mar 15, 2007 |
| ROCEPHIN | | | | |
| + | HOFFMANN LA ROCHE | EQ 250MG BASE/VIAL | N050585 001 | Dec 21, 1984 |
| + | | EQ 500MG BASE/VIAL | N050585 002 | Dec 21, 1984 |
| + | | EQ 1GM BASE/VIAL | N050585 003 | Dec 21, 1984 |
| + | | EQ 2GM BASE/VIAL | N050585 004 | Dec 21, 1984 |

CEFTRIAXONE SODIUM; LIDOCAINE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| ROCEPHIN KIT | | | | |
| | HOFFMANN LA ROCHE | EQ 500MG BASE/VIAL,N/A;N/A,1% | N050585 007 | May 08, 1996 |
| | | EQ 1GM BASE/VIAL,N/A;N/A,1% | N050585 006 | May 08, 1996 |

CEFUROXIME AXETIL

| | | | | |
|---|---|---|---|---|
| FOR SUSPENSION;ORAL | | | | |
| CEFUROXIME AXETIL | | | | |
| | SUN PHARM INDS LTD | EQ 125MG BASE/5ML | A065323 001 | Feb 05, 2008 |
| | | EQ 250MG BASE/5ML | A065323 002 | Feb 05, 2008 |
| TABLET;ORAL | | | | |
| CEFUROXIME AXETIL | | | | |
| | RANBAXY LABS LTD | EQ 125MG BASE | A065043 003 | Feb 15, 2002 |
| | | EQ 250MG BASE | A065043 002 | Feb 15, 2002 |
| | | EQ 500MG BASE | A065043 001 | Feb 15, 2002 |
| | SANDOZ | EQ 250MG BASE | A065126 001 | Oct 28, 2003 |
| | | EQ 500MG BASE | A065126 002 | Oct 28, 2003 |
| | SUN PHARM INDS LTD | EQ 125MG BASE | A065118 001 | Apr 25, 2003 |
| | | EQ 250MG BASE | A065118 002 | Apr 25, 2003 |
| | | EQ 500MG BASE | A065118 003 | Apr 25, 2003 |

CEFUROXIME SODIUM

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| CEFUROXIME SODIUM | | | | |
| | FRESENIUS KABI USA | EQ 1.5GM BASE/VIAL | A065001 002 | May 30, 2001 |
| | | EQ 7.5GM BASE/VIAL | A065002 001 | Sep 28, 1998 |
| | TEVA PHARMS | EQ 7.5GM BASE/VIAL | A064191 001 | Apr 16, 1998 |
| | WATSON LABS INC | EQ 1.5GM BASE/VIAL | A064035 002 | Feb 26, 1993 |
| | | EQ 7.5GM BASE/VIAL | A064036 001 | Feb 26, 1993 |
| CEFUROXIME SODIUM IN PLASTIC CONTAINER | | | | |
| | SAMSON MEDCL | EQ 75GM BASE/VIAL | A065251 001 | Dec 30, 2009 |
| | | EQ 225GM BASE/VIAL | A065251 002 | Dec 30, 2009 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

CEFUROXIME SODIUM

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| KEFUROX | | | | |
| ACS DOBFAR | EQ 1.5GM BASE/VIAL | A062591 | 002 | Jan 10, 1986 |
| | EQ 7.5GM BASE/VIAL | A062591 | 003 | Dec 17, 1987 |
| LILLY | EQ 1.5GM BASE/VIAL | A062592 | 002 | Jan 10, 1986 |
| KEFUROX IN PLASTIC CONTAINER | | | | |
| LILLY | EQ 1.5GM BASE/VIAL | A062590 | 002 | Jan 10, 1986 |
| ZINACEF IN PLASTIC CONTAINER | | | | |
| TELIGENT | EQ 15MG BASE/ML | N050643 | 001 | Apr 28, 1989 |
| INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | | | | |
| CEFUROXIME SODIUM | | | | |
| FRESENIUS KABI USA | EQ 750MG BASE/VIAL | A065001 | 001 | May 30, 2001 |
| TEVA PHARMS | EQ 750MG BASE/VIAL | A064192 | 002 | Apr 16, 1998 |
| | EQ 1.5GM BASE/VIAL | A064192 | 001 | Apr 16, 1998 |
| WATSON LABS INC | EQ 750MG BASE/VIAL | A064035 | 001 | Feb 26, 1993 |
| KEFUROX | | | | |
| ACS DOBFAR | EQ 750MG BASE/VIAL | A062591 | 001 | Jan 10, 1986 |
| INJECTABLE;INTRAVENOUS | | | | |
| KEFUROX | | | | |
| LILLY | EQ 750MG BASE/VIAL | A062592 | 001 | Jan 10, 1986 |
| KEFUROX IN PLASTIC CONTAINER | | | | |
| LILLY | EQ 750MG BASE/VIAL | A062590 | 001 | Jan 10, 1986 |

CELLULOSE SODIUM PHOSPHATE

| | | | | |
|---|---|---|---|---|
| POWDER;ORAL | | | | |
| CALCIBIND | | | | |
| MISSION PHARMA | 2.5GM/PACKET | N018757 | 002 | Dec 28, 1982 |
| | 300GM/BOT | N018757 | 003 | Oct 16, 1984 |

CEPHALEXIN

| | | | | |
|---|---|---|---|---|
| CAPSULE;ORAL | | | | |
| CEPHALEXIN | | | | |
| APOTHECON | EQ 250MG BASE | A062973 | 001 | Nov 08, 1988 |
| | EQ 250MG BASE | A063063 | 001 | Sep 29, 1989 |
| | EQ 250MG BASE | A063186 | 001 | Dec 30, 1994 |
| | EQ 500MG BASE | A062974 | 001 | Nov 23, 1988 |
| | EQ 500MG BASE | A063063 | 002 | Sep 29, 1989 |
| | EQ 500MG BASE | A063186 | 002 | Dec 30, 1994 |
| BARR | EQ 250MG BASE | A062773 | 001 | Jun 26, 1987 |
| | EQ 500MG BASE | A062775 | 001 | Apr 22, 1987 |
| FACTA FARMA | EQ 250MG BASE | A062118 | 001 | |
| | EQ 500MG BASE | A062118 | 002 | |
| IVAX SUB TEVA PHARMS | EQ 250MG BASE | A061969 | 001 | |
| | EQ 500MG BASE | A061969 | 002 | |
| PUREPAC PHARM | EQ 250MG BASE | A062809 | 001 | Apr 22, 1987 |
| | EQ 500MG BASE | A062809 | 002 | Apr 22, 1987 |
| STEVENS J | EQ 250MG BASE | A062870 | 001 | Mar 17, 1988 |
| | EQ 500MG BASE | A062869 | 001 | Mar 17, 1988 |
| SUN PHARM INDS LTD | EQ 250MG BASE | A065007 | 001 | Sep 16, 1999 |
| | EQ 500MG BASE | A065007 | 002 | Sep 16, 1999 |
| TEVA | EQ 250MG BASE | A062760 | 001 | Apr 24, 1987 |
| | EQ 250MG BASE | A062821 | 001 | Feb 05, 1988 |
| | EQ 500MG BASE | A062761 | 001 | Apr 24, 1987 |
| | EQ 500MG BASE | A062823 | 001 | Feb 05, 1988 |
| YOSHITOMI | EQ 250MG BASE | A062872 | 001 | Jun 20, 1988 |
| | EQ 500MG BASE | A062871 | 001 | Jul 05, 1988 |
| KEFLEX | | | | |
| + PRAGMA PHARMS LLC | EQ 333MG BASE ** | N050405 | 004 | May 12, 2006 |
| FOR SUSPENSION;ORAL | | | | |
| CEPHALEXIN | | | | |
| APOTHECON | EQ 125MG BASE/5ML | A062986 | 001 | Apr 18, 1991 |
| | EQ 250MG BASE/5ML | A062987 | 001 | Jul 25, 1989 |
| BARR | EQ 125MG BASE/5ML | A062778 | 001 | Aug 06, 1987 |
| | EQ 250MG BASE/5ML | A062777 | 001 | Aug 06, 1987 |
| FACTA FARMA | EQ 100MG BASE/ML ** | A062117 | 001 | |
| | EQ 125MG BASE/5ML ** | A062117 | 002 | |
| | EQ 250MG BASE/5ML ** | A062117 | 003 | |
| HIKMA PHARMS | EQ 125MG BASE/5ML | A065444 | 001 | Aug 28, 2009 |
| | EQ 250MG BASE/5ML | A065444 | 002 | Aug 28, 2009 |

CEPHALEXIN

FOR SUSPENSION;ORAL

CEPHALEXIN

| | | | | |
|---|---|---|---|---|
| SUN PHARM INDS LTD | EQ 125MG BASE/5ML | A065081 | 001 | Jul 27, 2001 |
| | EQ 250MG BASE/5ML | A065081 | 002 | Jul 27, 2001 |
| TEVA | EQ 125MG BASE/5ML | A062767 | 001 | Jun 16, 1987 |
| | EQ 125MG BASE/5ML | A062873 | 001 | May 23, 1988 |
| | EQ 250MG BASE/5ML | A062768 | 001 | Jun 16, 1987 |
| | EQ 250MG BASE/5ML | A062867 | 001 | Apr 15, 1988 |
| VITARINE | EQ 125MG BASE/5ML | A062779 | 001 | Dec 22, 1987 |
| | EQ 250MG BASE/5ML | A062781 | 001 | Dec 22, 1987 |

KEFLEX

| | | | | |
|---|---|---|---|---|
| + PRAGMA PHARMS LLC | EQ 100MG BASE/ML ** | N050406 | 003 | |
| + | EQ 125MG BASE/5ML ** | N050406 | 001 | |
| + | EQ 250MG BASE/5ML ** | N050406 | 002 | |

TABLET;ORAL

CEPHALEXIN

| | | | | |
|---|---|---|---|---|
| BARR | EQ 250MG BASE | A062826 | 001 | Aug 17, 1987 |
| | EQ 500MG BASE | A062827 | 001 | Aug 17, 1987 |
| VITARINE | EQ 250MG BASE | A062863 | 001 | Aug 11, 1988 |
| | EQ 500MG BASE | A062863 | 002 | Aug 11, 1988 |
| | EQ 1GM BASE | A062863 | 003 | Aug 11, 1988 |

KEFLET

| | | | | |
|---|---|---|---|---|
| LILLY | EQ 250MG BASE | A062745 | 001 | Dec 01, 1986 |
| | EQ 250MG BASE | N050440 | 003 | Feb 26, 1987 |
| | EQ 500MG BASE | A062745 | 002 | Dec 01, 1986 |
| | EQ 500MG BASE | N050440 | 001 | |
| | EQ 1GM BASE | N050440 | 002 | |

TABLET, FOR SUSPENSION;ORAL

PANIXINE DISPERDOSE

| | | | | |
|---|---|---|---|---|
| RANBAXY LABS LTD | EQ 125MG BASE | A065100 | 002 | Sep 11, 2003 |
| | EQ 250MG BASE | A065100 | 001 | Sep 11, 2003 |

CEPHALEXIN HYDROCHLORIDE

TABLET;ORAL

KEFTAB

| | | | | |
|---|---|---|---|---|
| LILLY | EQ 250MG BASE | N050614 | 001 | Oct 29, 1987 |
| | EQ 333MG BASE | N050614 | 003 | May 16, 1988 |
| | EQ 500MG BASE | N050614 | 002 | Oct 29, 1987 |

CEPHALOGLYCIN

CAPSULE;ORAL

KAFOCIN

| | | | | |
|---|---|---|---|---|
| LILLY | 250MG | N050219 | 001 | |

CEPHALOTHIN SODIUM

INJECTABLE;INJECTION

CEPHALOTHIN

| | | | | |
|---|---|---|---|---|
| INTL MEDICATION | EQ 500MG BASE/VIAL | A062426 | 001 | May 03, 1985 |
| | EQ 1GM BASE/VIAL | A062426 | 002 | May 03, 1985 |
| | EQ 2GM BASE/VIAL | A062426 | 003 | May 03, 1985 |
| | EQ 4GM BASE/VIAL | A062426 | 004 | May 03, 1985 |

CEPHALOTHIN SODIUM

| | | | | |
|---|---|---|---|---|
| ABBOTT | EQ 1GM BASE/VIAL | A062547 | 001 | Sep 11, 1985 |
| | EQ 1GM BASE/VIAL | A062548 | 001 | Sep 11, 1985 |
| | EQ 2GM BASE/VIAL | A062547 | 002 | Sep 11, 1985 |
| | EQ 2GM BASE/VIAL | A062548 | 002 | Sep 11, 1985 |
| ABRAXIS PHARM | EQ 1GM BASE/VIAL | A062666 | 002 | Jun 10, 1987 |
| | EQ 2GM BASE/VIAL | A062666 | 001 | Jun 10, 1987 |
| BRISTOL | EQ 1GM BASE/VIAL | A062464 | 001 | May 07, 1984 |
| | EQ 2GM BASE/VIAL | A062464 | 002 | May 07, 1984 |
| | EQ 4GM BASE/VIAL | A062464 | 003 | May 07, 1984 |

CEPHALOTHIN SODIUM W/ DEXTROSE IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| BAXTER HLTHCARE | EQ 20MG BASE/ML | A062422 | 003 | Jan 31, 1984 |
| | EQ 20MG BASE/ML | A062422 | 005 | Jul 16, 1991 |
| | EQ 20MG BASE/ML | A062730 | 001 | Mar 05, 1987 |
| | EQ 40MG BASE/ML | A062422 | 004 | Jan 31, 1984 |
| | EQ 40MG BASE/ML | A062422 | 006 | Jul 16, 1991 |
| | EQ 40MG BASE/ML | A062730 | 002 | Mar 05, 1987 |

CEPHALOTHIN SODIUM

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| CEPHALOTHIN SODIUM W/ SODIUM CHLORIDE IN PLASTIC CONTAINER | | | | |
| BAXTER HLTHCARE | EQ 20MG BASE/ML | A062422 | 001 | Jan 31, 1984 |
| | EQ 40MG BASE/ML | A062422 | 002 | Jan 31, 1984 |
| KEFLIN | | | | |
| LILLY | EQ 1GM BASE/VIAL | N050482 | 001 | |
| | EQ 2GM BASE/VIAL | N050482 | 002 | |
| | EQ 4GM BASE/VIAL | N050482 | 003 | |
| | EQ 20GM BASE/VIAL | N050482 | 007 | |
| KEFLIN IN PLASTIC CONTAINER | | | | |
| LILLY | EQ 1GM BASE/VIAL | A062549 | 001 | Sep 10, 1985 |
| | EQ 2GM BASE/VIAL | A062549 | 002 | Sep 10, 1985 |
| SEFFIN | | | | |
| GLAXOSMITHKLINE | EQ 1GM BASE/VIAL | A062435 | 001 | Nov 15, 1983 |
| | EQ 2GM BASE/VIAL | A062435 | 002 | Nov 15, 1983 |
| | EQ 10GM BASE/VIAL | A062435 | 003 | Nov 15, 1983 |

CEPHAPIRIN SODIUM

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| CEFADYL | | | | |
| APOTHECON | EQ 500MG BASE/VIAL | A062961 | 001 | Sep 20, 1988 |
| | EQ 500MG BASE/VIAL | N050446 | 005 | |
| | EQ 1GM BASE/VIAL | A061769 | 001 | |
| | EQ 1GM BASE/VIAL | A062724 | 001 | Dec 23, 1986 |
| | EQ 1GM BASE/VIAL | A062961 | 002 | Sep 20, 1988 |
| | EQ 1GM BASE/VIAL | N050446 | 001 | |
| | EQ 2GM BASE/VIAL | A061769 | 002 | |
| | EQ 2GM BASE/VIAL | A062724 | 002 | Dec 23, 1986 |
| | EQ 2GM BASE/VIAL | A062961 | 003 | Sep 20, 1988 |
| | EQ 2GM BASE/VIAL | N050446 | 002 | |
| | EQ 4GM BASE/VIAL | A061769 | 003 | |
| | EQ 4GM BASE/VIAL | A062961 | 004 | Sep 20, 1988 |
| | EQ 4GM BASE/VIAL | N050446 | 003 | |
| | EQ 20GM BASE/VIAL | N050446 | 004 | |
| CEPHAPIRIN SODIUM | | | | |
| ABRAXIS PHARM | EQ 500MG BASE/VIAL | A062723 | 001 | Nov 17, 1986 |
| | EQ 1GM BASE/VIAL | A062723 | 002 | Nov 17, 1986 |
| | EQ 2GM BASE/VIAL | A062723 | 003 | Nov 17, 1986 |
| | EQ 4GM BASE/VIAL | A062723 | 004 | Nov 17, 1986 |
| | EQ 20GM BASE/VIAL | A062723 | 005 | Nov 17, 1986 |
| WEST-WARD PHARMS INT | EQ 500MG BASE/VIAL | A062720 | 001 | Jul 02, 1987 |
| | EQ 1GM BASE/VIAL | A062720 | 002 | Jul 02, 1987 |
| | EQ 2GM BASE/VIAL | A062720 | 003 | Jul 02, 1987 |
| | EQ 20GM BASE/VIAL | A062720 | 004 | Jul 02, 1987 |

CEPHRADINE

| | | | | |
|---|---|---|---|---|
| CAPSULE;ORAL | | | | |
| ANSPOR | | | | |
| GLAXOSMITHKLINE | 250MG | A061859 | 001 | |
| | 500MG | A061859 | 002 | |
| CEPHRADINE | | | | |
| BARR | 250MG | A062850 | 001 | Apr 22, 1988 |
| | 500MG | A062851 | 001 | Apr 22, 1988 |
| IVAX SUB TEVA PHARMS | 250MG | A062762 | 001 | Mar 06, 1987 |
| | 500MG | A062762 | 002 | Mar 06, 1987 |
| TEVA | 250MG | A062683 | 001 | Jan 09, 1987 |
| | 500MG | A062683 | 002 | Jan 09, 1987 |
| VITARINE | 250MG | A062813 | 001 | Feb 25, 1988 |
| | 500MG | A062813 | 002 | Feb 25, 1988 |
| VELOSEF | | | | |
| APOTHECON | 250MG | A061764 | 001 | |
| | 500MG | A061764 | 002 | |
| VELOSEF '250' | | | | |
| ERSANA | 250MG | N050548 | 001 | |
| VELOSEF '500' | | | | |
| ERSANA | 500MG | N050548 | 002 | |
| FOR SUSPENSION;ORAL | | | | |
| ANSPOR | | | | |
| GLAXOSMITHKLINE | 125MG/5ML | A061866 | 001 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

CEPHRADINE
FOR SUSPENSION;ORAL

| | | | | |
|---|---|---|---|---|
| ANSPOR | | | | |
| | 250MG/5ML | A061866 | 002 | |
| CEPHRADINE | | | | |
| BARR | 125MG/5ML | A062858 | 001 | May 19, 1988 |
| | 250MG/5ML | A062859 | 001 | May 19, 1988 |
| TEVA | 125MG/5ML | A062693 | 001 | Jan 09, 1987 |
| | 250MG/5ML | A062693 | 002 | Jan 09, 1987 |
| VELOSEF '125' | | | | |
| APOTHECON | 125MG/5ML | A061763 | 001 | |
| VELOSEF '250' | | | | |
| APOTHECON | 250MG/5ML | A061763 | 002 | |

INJECTABLE;INJECTION

| | | | | |
|---|---|---|---|---|
| VELOSEF | | | | |
| APOTHECON | 250MG/VIAL | A061976 | 001 | |
| | 500MG/VIAL | A061976 | 002 | |
| | 1GM/VIAL | A061976 | 004 | |
| | 2GM/VIAL | A061976 | 003 | |
| | 4GM/VIAL | A061976 | 005 | |

TABLET;ORAL

| | | | | |
|---|---|---|---|---|
| VELOSEF | | | | |
| BRISTOL MYERS SQUIBB | 1GM | N050530 | 001 | |

CERIVASTATIN SODIUM
TABLET;ORAL

| | | | | |
|---|---|---|---|---|
| BAYCOL | | | | |
| BAYER PHARMS | 0.05MG | N020740 | 001 | Jun 26, 1997 |
| | 0.1MG | N020740 | 002 | Jun 26, 1997 |
| | 0.2MG | N020740 | 003 | Jun 26, 1997 |
| | 0.3MG | N020740 | 004 | Jun 26, 1997 |
| | 0.4MG | N020740 | 005 | May 24, 1999 |
| | 0.8MG | N020740 | 006 | Jul 24, 2000 |

CERULETIDE DIETHYLAMINE
INJECTABLE;INJECTION

| | | | | |
|---|---|---|---|---|
| TYMTRAN | | | | |
| PHARMACIA AND UPJOHN | 0.02MG/ML | N018296 | 001 | |

CETIRIZINE HYDROCHLORIDE
SYRUP;ORAL

| | | | | |
|---|---|---|---|---|
| CETIRIZINE HYDROCHLORIDE | | | | |
| ACTAVIS MID ATLANTIC | 5MG/5ML | A078617 | 001 | Feb 02, 2010 |
| APOTEX INC | 5MG/5ML | A078412 | 001 | Jun 18, 2008 |
| AUROBINDO PHARMA LTD | 5MG/5ML | A090751 | 001 | Dec 16, 2009 |
| RANBAXY LABS LTD | 5MG/5ML | A077472 | 001 | Jun 18, 2008 |
| WOCKHARDT | 5MG/5ML | A078757 | 001 | Aug 28, 2009 |
| CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY | | | | |
| ACTAVIS MID ATLANTIC | 5MG/5ML | A090378 | 002 | May 09, 2008 |
| APOTEX INC | 5MG/5ML | A090188 | 002 | Apr 22, 2008 |
| CYPRESS PHARM | 5MG/5ML | A090300 | 001 | Oct 10, 2008 |
| RANBAXY LABS LTD | 5MG/5ML | A090183 | 002 | Apr 24, 2008 |
| CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF | | | | |
| ACTAVIS MID ATLANTIC | 5MG/5ML | A090378 | 001 | May 09, 2008 |
| APOTEX INC | 5MG/5ML | A090188 | 001 | Apr 22, 2008 |
| CYPRESS PHARM | 5MG/5ML | A090300 | 002 | Oct 10, 2008 |
| RANBAXY LABS LTD | 5MG/5ML | A090183 | 001 | Apr 24, 2008 |
| ZYRTEC | | | | |
| J AND J CONSUMER INC | 5MG/5ML ** | N020346 | 001 | Sep 27, 1996 |

TABLET;ORAL

| | | | | |
|---|---|---|---|---|
| CETIRIZINE HYDROCHLORIDE ALLERGY | | | | |
| ACTAVIS ELIZABETH | 5MG | A078615 | 003 | Dec 28, 2007 |
| | 10MG | A078615 | 004 | Dec 28, 2007 |

TABLET, CHEWABLE;ORAL

| | | | | |
|---|---|---|---|---|
| CETIRIZINE HYDROCHLORIDE ALLERGY | | | | |
| SUN PHARM INDS INC | 5MG | A077631 | 004 | Jan 11, 2008 |
| | 10MG | A077631 | 003 | Jan 11, 2008 |
| CETIRIZINE HYDROCHLORIDE HIVES RELIEF | | | | |
| SUN PHARM INDS INC | 5MG | A077631 | 001 | Jan 11, 2008 |
| | 10MG | A077631 | 002 | Jan 11, 2008 |

| | | | | |
|---|---|---|---|---|
| CETIRIZINE HYDROCHLORIDE | | | | |
| TABLET, CHEWABLE;ORAL | | | | |
| CHILDREN'S ZYRTEC ALLERGY | | | | |
| + J AND J CONSUMER INC | 5MG ** | N021621 | 003 | Nov 16, 2007 |
| + | 10MG ** | N021621 | 004 | Nov 16, 2007 |
| CHILDREN'S ZYRTEC HIVES RELIEF | | | | |
| + J AND J CONSUMER INC | 5MG ** | N021621 | 005 | Nov 16, 2007 |
| + | 10MG ** | N021621 | 006 | Nov 16, 2007 |
| CETRORELIX | | | | |
| INJECTABLE;INJECTION | | | | |
| CETROTIDE | | | | |
| EMD SERONO INC | EQ 3MG BASE/ML | N021197 | 002 | Aug 11, 2000 |
| CETYL ALCOHOL; COLFOSCERIL PALMITATE; TYLOXAPOL | | | | |
| FOR SUSPENSION;INTRATRACHEAL | | | | |
| EXOSURF NEONATAL | | | | |
| GLAXOSMITHKLINE | 12MG/VIAL;108MG/VIAL;8MG/VIAL | N020044 | 001 | Aug 02, 1990 |
| CHENODIOL | | | | |
| TABLET;ORAL | | | | |
| CHENIX | | | | |
| + LEADIANT BIOSCI INC | 250MG ** | N018513 | 002 | Jul 28, 1983 |
| CHLOPHEDIANOL HYDROCHLORIDE | | | | |
| SYRUP;ORAL | | | | |
| ULO | | | | |
| 3M | 25MG/5ML | N012126 | 001 | |
| CHLORAMPHENICOL | | | | |
| CREAM;TOPICAL | | | | |
| CHLOROMYCETIN | | | | |
| PARKE DAVIS | 1% | N050183 | 001 | |
| FOR SOLUTION;OPHTHALMIC | | | | |
| CHLOROMYCETIN | | | | |
| PARKEDALE | 25MG/VIAL | N050143 | 001 | |
| INJECTABLE;INJECTION | | | | |
| CHLOROMYCETIN | | | | |
| PARKE DAVIS | 250MG/ML | N050153 | 001 | |
| OINTMENT;OPHTHALMIC | | | | |
| CHLORAMPHENICOL | | | | |
| ALTANA | 1% | A060133 | 001 | |
| CHLOROFAIR | | | | |
| PHARMAFAIR | 1% | A062439 | 001 | Apr 21, 1983 |
| CHLOROMYCETIN | | | | |
| PARKEDALE | 1% | N050156 | 001 | |
| CHLOROPTIC S.O.P. | | | | |
| ALLERGAN | 1% | A061187 | 001 | |
| ECONOCHLOR | | | | |
| ALCON | 1% | A061648 | 001 | |
| SOLUTION/DROPS;OPHTHALMIC | | | | |
| CHLORAMPHENICOL | | | | |
| AKORN | 0.5% | A062042 | 001 | |
| ALCON | 0.5% | A062628 | 001 | Sep 25, 1985 |
| CHLOROFAIR | | | | |
| PHARMAFAIR | 0.5% | A062437 | 001 | Apr 14, 1983 |
| CHLOROPTIC | | | | |
| ALLERGAN | 0.5% | N050091 | 001 | |
| ECONOCHLOR | | | | |
| ALCON | 0.5% | A061645 | 001 | |
| OPHTHOCHLOR | | | | |
| PARKEDALE | 0.5% | A061220 | 001 | |
| OPTOMYCIN | | | | |
| OPTOPICS | 0.5% | A062171 | 001 | Mar 31, 1982 |
| SOLUTION/DROPS;OTIC | | | | |
| CHLOROMYCETIN | | | | |
| PARKEDALE | 0.5% | N050205 | 001 | |

| | | | | |
|---|---|---|---|---|
| CHLORAMPHENICOL SODIUM SUCCINATE | | | | |
| INJECTABLE;INJECTION | | | | |
| CHLORAMPHENICOL | | | | |
| ELKINS SINN | EQ 1GM BASE/VIAL | | A062406 001 | Nov 09, 1982 |
| CHLORAMPHENICOL SODIUM SUCCINATE | | | | |
| GRUPPO LEPETIT | EQ 1GM BASE/VIAL | | A062278 001 | |
| CHLOROMYCETIN | | | | |
| + PARKEDALE | EQ 1GM BASE/VIAL | | N050155 001 | |
| MYCHEL-S | | | | |
| ANGUS | EQ 1GM BASE/VIAL | | A060132 001 | |
| CHLORAMPHENICOL; DESOXYRIBONUCLEASE; FIBRINOLYSIN | | | | |
| OINTMENT;TOPICAL | | | | |
| ELASE-CHLOROMYCETIN | | | | |
| PARKE DAVIS | 10MG/GM;666 UNITS/GM;1 UNITS/GM | | N050294 001 | |
| CHLORAMPHENICOL; HYDROCORTISONE ACETATE | | | | |
| FOR SUSPENSION;OPHTHALMIC | | | | |
| CHLOROMYCETIN HYDROCORTISONE | | | | |
| PARKEDALE | 12.5MG/VIAL;25MG/VIAL | | N050202 001 | |
| CHLORAMPHENICOL; HYDROCORTISONE ACETATE; POLYMYXIN B SULFATE | | | | |
| OINTMENT;OPHTHALMIC | | | | |
| OPHTHOCORT | | | | |
| PARKEDALE | 10MG/GM;5MG/GM;10,000 UNITS/GM | | N050201 002 | |
| CHLORAMPHENICOL; POLYMYXIN B SULFATE | | | | |
| OINTMENT;OPHTHALMIC | | | | |
| CHLOROMYXIN | | | | |
| PARKE DAVIS | 1%;10,000 UNITS/GM | | N050203 002 | |
| CHLORAMPHENICOL; PREDNISOLONE | | | | |
| OINTMENT;OPHTHALMIC | | | | |
| CHLOROPTIC-P S.O.P. | | | | |
| ALLERGAN | 1%;0.5% | | A061188 001 | |
| CHLORDIAZEPOXIDE | | | | |
| CAPSULE, EXTENDED RELEASE;ORAL | | | | |
| LIBRELEASE | | | | |
| VALEANT PHARM INTL | 30MG | | N017813 001 | Sep 12, 1983 |
| TABLET;ORAL | | | | |
| LIBRITABS | | | | |
| VALEANT PHARM INTL | 5MG | | A085482 001 | |
| | 10MG | | A085481 001 | |
| | 25MG | | A085488 001 | |
| CHLORDIAZEPOXIDE HYDROCHLORIDE | | | | |
| CAPSULE;ORAL | | | | |
| A-POXIDE | | | | |
| ABBOTT | 5MG | | A085447 001 | |
| | 5MG | | A085517 001 | |
| | 10MG | | A085447 002 | |
| | 10MG | | A085518 001 | |
| | 25MG | | A085447 003 | |
| | 25MG | | A085513 001 | |
| CHLORDIAZACHEL | | | | |
| RACHELLE | 5MG | | A085086 001 | |
| | 10MG | | A084639 001 | |
| | 25MG | | A085087 001 | |
| CHLORDIAZEPOXIDE HYDROCHLORIDE | | | | |
| ASCOT | 5MG | | A087525 001 | Jan 07, 1982 |
| | 10MG | | A087524 001 | Jan 07, 1982 |
| | 25MG | | A087512 001 | Jan 07, 1982 |
| FERRANTE | 5MG | | A085118 001 | |
| | 10MG | | A085119 001 | |
| | 25MG | | A085120 001 | |
| HALSEY | 5MG | | A085340 001 | |
| | 10MG | | A085339 001 | |
| | 25MG | | A084685 001 | |
| IMPAX LABS | 5MG | | A086213 001 | |
| | 10MG | | A085113 001 | |
| | 25MG | | A086212 001 | |
| IVAX SUB TEVA PHARMS | 5MG | | A083741 001 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| CHLORDIAZEPOXIDE HYDROCHLORIDE | | | | |
| CAPSULE;ORAL | | | | |
| CHLORDIAZEPOXIDE HYDROCHLORIDE | | | | |
| | 10MG | | A083742 001 | |
| | 25MG | | A083570 001 | |
| LEDERLE | 5MG | | A086892 001 | |
| | 5MG | | A087234 001 | |
| | 10MG | | A086876 001 | |
| | 10MG | | A087037 001 | |
| | 25MG | | A086893 001 | |
| | 25MG | | A087231 001 | |
| MAST MM | 10MG | | A086217 001 | |
| MYLAN | 5MG | | A084886 001 | |
| | 10MG | | A084601 001 | |
| | 25MG | | A084887 001 | |
| PARKE DAVIS | 5MG | | A085163 001 | |
| | 10MG | | A084598 001 | |
| | 25MG | | A085164 001 | |
| PIONEER PHARMS | 10MG | | A089533 001 | Jul 15, 1988 |
| | 25MG | | A089558 001 | Jul 15, 1988 |
| PUREPAC PHARM | 5MG | | A085155 001 | |
| | 10MG | | A084939 002 | |
| | 25MG | | A085144 001 | |
| ROXANE | 5MG | | A084706 001 | |
| | 10MG | | A084700 001 | |
| | 25MG | | A084705 001 | |
| SUPERPHARM | 5MG | | A088987 001 | Apr 25, 1985 |
| | 10MG | | A088986 001 | Apr 25, 1985 |
| | 25MG | | A088988 001 | Apr 25, 1985 |
| TEVA | 5MG | | A088705 001 | Jan 18, 1985 |
| | 10MG | | A088706 001 | Jan 18, 1985 |
| | 25MG | | A086494 001 | |
| | 25MG | | A088707 001 | Jan 18, 1985 |
| UPSHER-SMITH LABS | 5MG | | A084678 001 | |
| | 5MG | | A084919 001 | |
| | 10MG | | A084041 001 | |
| | 10MG | | A084920 001 | |
| | 25MG | | A084679 002 | |
| | 25MG | | A084823 001 | |
| USL PHARMA | 5MG | | A084644 001 | |
| | 10MG | | A084623 001 | |
| | 25MG | | A084645 001 | |
| VANGARD | 5MG | | A088129 001 | Mar 28, 1983 |
| | 10MG | | A088010 001 | Mar 28, 1983 |
| | 25MG | | A088130 001 | Mar 28, 1983 |
| WATSON LABS | 5MG | | A086383 001 | |
| | 10MG | | A086294 001 | |
| | 25MG | | A086382 001 | |
| WEST WARD | 5MG | | A085014 001 | |
| | 10MG | | A085000 001 | |
| | 25MG | | A085294 001 | |
| LIBRIUM | | | | |
| VALEANT PHARM INTL | 5MG | | N012249 002 | |
| | 10MG | | N012249 001 | |
| | 25MG | | N012249 003 | |
| LYGEN | | | | |
| ALRA | 5MG | | A085107 001 | |
| | 10MG | | A085009 001 | |
| | 25MG | | A085108 001 | |
| INJECTABLE;INJECTION | | | | |
| LIBRIUM | | | | |
| VALEANT PHARMS LLC | 100MG/AMP | | N012301 001 | |
| CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED | | | | |
| TABLET;ORAL | | | | |
| MENRIUM 10-4 | | | | |
| ROCHE | 10MG;0.4MG | | N014740 006 | |
| MENRIUM 5-2 | | | | |
| ROCHE | 5MG;0.2MG | | N014740 002 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED
TABLET;ORAL
MENRIUM 5-4
ROCHE 5MG;0.4MG N014740 004

CHLORHEXIDINE GLUCONATE
SOLUTION;DENTAL
CHLORHEXIDINE GLUCONATE
APOTEX INC 0.12% A075561 001 Nov 14, 2000
SOLUTION;TOPICAL
EXIDINE
XTTRIUM 2.5% N019421 001 Dec 17, 1985
MICRODERM
J AND J 4% A072255 001 Apr 15, 1991
PREVACARE R
J AND J 0.5% A072292 001 Jan 28, 1992
STERI-STAT
MATRIX MEDCL 4% A070104 001 Jul 24, 1986
SPONGE;TOPICAL
CHLORHEXIDINE GLUCONATE
KENDALL IL 4% N019490 001 Mar 27, 1987
E-Z SCRUB
BECTON DICKINSON 4% A073416 001 Mar 14, 2000
HIBICLENS
\+ MOLNLYCKE HLTH 4% ** N018423 001
MICRODERM
J AND J 4% A072295 001 Feb 28, 1991
PHARMASEAL SCRUB CARE
CAREFUSION 2200 4% N019793 001 Dec 02, 1988

CHLORMERODRIN HG-197
INJECTABLE;INJECTION
CHLORMERODRIN HG 197
BRACCO 0.6-1.4mCi/ML N017269 001

CHLORMEZANONE
TABLET;ORAL
TRANCOPAL
SANOFI AVENTIS US 100MG N011467 003
200MG N011467 005

CHLOROPROCAINE HYDROCHLORIDE
INJECTABLE;INJECTION
NESACAINE-MPF
FRESENIUS KABI USA 2% N009435 003
3% N009435 004

CHLOROQUINE HYDROCHLORIDE
INJECTABLE;INJECTION
ARALEN HYDROCHLORIDE
SANOFI AVENTIS US EQ 40MG BASE/ML N006002 002

CHLOROQUINE PHOSPHATE
TABLET;ORAL
ARALEN
\+ SANOFI AVENTIS US EQ 300MG BASE N006002 001
CHLOROQUINE PHOSPHATE
IMPAX LABS EQ 150MG BASE A080880 001
EQ 300MG BASE A040516 001 Aug 29, 2003
MD PHARM EQ 150MG BASE A087228 001
PUREPAC PHARM EQ 150MG BASE A080886 001
TEVA EQ 150MG BASE A087504 001 Jan 13, 1982
WATSON LABS EQ 150MG BASE A087979 001 Dec 21, 1982
EQ 300MG BASE A088030 001 Dec 21, 1982

CHLOROQUINE PHOSPHATE; PRIMAQUINE PHOSPHATE
TABLET;ORAL
ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE
SANOFI AVENTIS US EQ 300MG BASE;EQ 45MG BASE N014860 002

CHLOROTHIAZIDE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| CHLOROTHIAZIDE | | | | |
| ABC HOLDING | 250MG | | A085569 001 | |
| HIKMA INTL PHARMS | 250MG | | A086028 001 | Jul 14, 1982 |
| | 500MG | | A087736 001 | Jul 14, 1982 |
| LEDERLE | 250MG | | A086940 001 | |
| | 500MG | | A086938 001 | |
| SANDOZ | 250MG | | A085485 001 | |
| WATSON LABS | 250MG | | A085165 001 | |
| | 250MG | | A085173 001 | |
| | 250MG | | A086795 001 | Aug 15, 1983 |
| | 500MG | | A084026 001 | Sep 01, 1982 |
| | 500MG | | A086796 001 | Aug 15, 1983 |
| DIURIL | | | | |
| + OAK PHARMS AKORN | 250MG ** | | N011145 004 | |
| + | 500MG ** | | N011145 002 | |

CHLOROTHIAZIDE; METHYLDOPA

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| ALDOCLOR-150 | | | | |
| MERCK | 150MG;250MG | | N016016 001 | |
| ALDOCLOR-250 | | | | |
| MERCK | 250MG;250MG | | N016016 002 | |
| METHYLDOPA AND CHLOROTHIAZIDE | | | | |
| PAR PHARM | 150MG;250MG | | A070783 001 | Nov 06, 1987 |
| | 250MG;250MG | | A070654 001 | Nov 06, 1987 |

CHLOROTHIAZIDE; RESERPINE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| CHLOROTHIAZIDE AND RESERPINE | | | | |
| HIKMA PHARMS | 250MG;0.125MG | | A088557 001 | Dec 22, 1983 |
| | 500MG;0.125MG | | A088365 001 | Dec 22, 1983 |
| CHLOROTHIAZIDE W/ RESERPINE | | | | |
| WATSON LABS | 250MG;0.125MG | | A084853 001 | |
| | 500MG;0.125MG | | A088151 001 | Jun 09, 1983 |
| CHLOROTHIAZIDE-RESERPINE | | | | |
| MYLAN | 250MG;0.125MG | | A087744 001 | May 06, 1982 |
| | 500MG;0.125MG | | A087745 001 | May 06, 1982 |
| DIUPRES-250 | | | | |
| MERCK | 250MG;0.125MG | | N011635 003 | Aug 26, 1987 |
| DIUPRES-500 | | | | |
| MERCK | 500MG;0.125MG | | N011635 006 | Aug 26, 1987 |

CHLOROTRIANISENE

| | | | | |
|---|---|---|---|---|
| CAPSULE;ORAL | | | | |
| CHLOROTRIANISENE | | | | |
| BANNER PHARMACAPS | 12MG | | A084652 001 | |
| TACE | | | | |
| SANOFI AVENTIS US | 12MG | | N008102 004 | |
| | 25MG | | N011444 001 | |
| | 72MG | | N016235 001 | |

CHLOROXINE

| | | | | |
|---|---|---|---|---|
| SHAMPOO;TOPICAL | | | | |
| CAPITROL | | | | |
| WESTWOOD SQUIBB | 2% | | N017594 001 | |

CHLORPHENESIN CARBAMATE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| MAOLATE | | | | |
| PAMLAB LLC | 400MG | | N014217 002 | |

CHLORPHENIRAMINE MALEATE

| | | | | |
|---|---|---|---|---|
| CAPSULE, EXTENDED RELEASE;ORAL | | | | |
| CHLORPHENIRAMINE MALEATE | | | | |
| AUROLIFE PHARMA LLC | 12MG | | A070797 001 | Aug 12, 1988 |
| TELDRIN | | | | |
| GLAXOSMITHKLINE | 8MG | | N017369 001 | |
| | 12MG | | N017369 002 | |

| | | | | |
|---|---|---|---|---|
| CHLORPHENIRAMINE MALEATE | | | | |
| INJECTABLE;INJECTION | | | | |
| CHLOR-TRIMETON | | | | |
| SCHERING PLOUGH | 10MG/ML | N008826 | 001 | |
| | 100MG/ML | N008794 | 001 | |
| CHLORPHENIRAMINE MALEATE | | | | |
| BEL MAR | 10MG/ML | A080821 | 001 | |
| ELKINS SINN | 10MG/ML | A080797 | 001 | |
| WATSON LABS | 10MG/ML | A083593 | 001 | |
| | 10MG/ML | A086096 | 001 | |
| | 100MG/ML | A086095 | 001 | |
| PYRIDAMAL 100 | | | | |
| BEL MAR | 100MG/ML | A083733 | 001 | |
| SYRUP;ORAL | | | | |
| CHLOR-TRIMETON | | | | |
| SCHERING | 2MG/5ML | N006921 | 006 | |
| CHLORPHENIRAMINE MALEATE | | | | |
| PHARM ASSOC | 2MG/5ML | A087520 | 001 | Feb 10, 1982 |
| TABLET;ORAL | | | | |
| ANTAGONATE | | | | |
| BAYER PHARMS | 4MG | A083381 | 001 | |
| CHLOR-TRIMETON | | | | |
| SCHERING | 4MG | N006921 | 002 | |
| CHLORPHENIRAMINE MALEATE | | | | |
| ANABOLIC | 4MG | A083078 | 001 | |
| AUROLIFE PHARMA LLC | 4MG | A080961 | 001 | |
| BELL PHARMA | 4MG | A083062 | 001 | |
| ELKINS SINN | 4MG | A080938 | 001 | |
| IMPAX LABS | 4MG | A080809 | 001 | |
| IVAX SUB TEVA PHARMS | 4MG | A080779 | 001 | |
| KV PHARM | 4MG | A087164 | 001 | |
| LEDERLE | 4MG | A086941 | 001 | |
| NEWTRON PHARMS | 4MG | A086519 | 001 | |
| PANRAY | 4MG | A083243 | 001 | |
| PHARMAVITE | 4MG | A085104 | 001 | |
| PHARMERAL | 4MG | A083753 | 001 | |
| PIONEER PHARMS | 4MG | A088556 | 001 | Jul 13, 1984 |
| PUREPAC PHARM | 4MG | A086306 | 001 | |
| PVT FORM | 4MG | A080786 | 001 | |
| ROXANE | 4MG | A080626 | 001 | |
| SUN PHARM INDUSTRIES | 4MG | A080700 | 001 | |
| VITARINE | 4MG | A085837 | 001 | |
| WATSON LABS | 4MG | A080696 | 001 | |
| | 4MG | A080791 | 001 | |
| | 4MG | A085139 | 001 | |
| WEST WARD | 4MG | A083787 | 001 | |
| KLOROMIN | | | | |
| HALSEY | 4MG | A083629 | 001 | |
| PHENETRON | | | | |
| LANNETT | 4MG | A080846 | 001 | |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| CHLOR-TRIMETON | | | | |
| BAYER HEALTHCARE LLC | 8MG | N007638 | 001 | |
| EFIDAC 24 CHLORPHENIRAMINE MALEATE | | | | |
| ALZA | 16MG | N019746 | 002 | Nov 18, 1994 |
| CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE | | | | |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE | | | | |
| SPRIASO LLC | 8MG;54.3MG | N206323 | 001 | Jun 22, 2015 |
| CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE | | | | |
| SOLUTION;ORAL | | | | |
| HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE | | | | |
| TRIS PHARMA INC | 4MG/5ML;5MG/5ML | A206438 | 001 | Jan 27, 2015 |

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| SOLUTION;ORAL | | | | |
| HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE | | | | |
| | TRIS PHARMA INC | 4MG/5ML;5MG/5ML;60MG/5ML | A203838 001 | Nov 26, 2014 |

CHLORPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| CAPSULE, EXTENDED RELEASE;ORAL | | | | |
| COLD CAPSULE IV | | | | |
| | GRAHAM DM | 12MG;75MG | N018793 001 | Apr 25, 1985 |
| COLD CAPSULE V | | | | |
| | GRAHAM DM | 8MG;75MG | N018794 001 | Apr 23, 1985 |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| TRIAMINIC-12 | | | | |
| | NOVARTIS | 12MG;75MG | N018115 001 | |

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| CAPSULE, EXTENDED RELEASE;ORAL | | | | |
| CODIMAL-L.A. 12 | | | | |
| | SCHWARZ PHARMA | 12MG;120MG | N018935 001 | Apr 15, 1985 |
| ISOCLOR | | | | |
| | FISONS | 8MG;120MG | N018747 001 | Mar 06, 1986 |
| PSEUDOEPHEDRINE HYDROCHLORIDE AND CHLORPHENIRAMINE MALEATE | | | | |
| | CENT PHARMS | 8MG;120MG | N019428 001 | Aug 02, 1988 |
| | GRAHAM DM | 8MG;120MG | N018844 001 | Mar 20, 1985 |
| | | 12MG;120MG | N018843 001 | Mar 18, 1985 |
| | KV PHARM | 12MG;120MG | A071455 001 | Mar 01, 1989 |

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

| | | | | |
|---|---|---|---|---|
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| CHLOR-TRIMETON | | | | |
| + | BAYER HEALTHCARE LLC | 8MG;120MG | N018397 001 | |

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

| | | | | |
|---|---|---|---|---|
| SUSPENSION, EXTENDED RELEASE;ORAL | | | | |
| CODEPREX | | | | |
| | UCB INC | EQ 4MG MALEATE/5ML;EQ 20MG BASE/5ML | N021369 001 | Jun 21, 2004 |
| PENNTUSS | | | | |
| | FISONS | EQ 4MG MALEATE/5ML;EQ 10MG BASE/5ML | N018928 001 | Aug 14, 1985 |

CHLORPHENTERMINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| PRE-SATE | | | | |
| | PARKE DAVIS | EQ 65MG BASE | N014696 001 | |

CHLORPROMAZINE

| | | | | |
|---|---|---|---|---|
| SUPPOSITORY;RECTAL | | | | |
| THORAZINE | | | | |
| + | GLAXOSMITHKLINE | 25MG ** | N009149 024 | |
| + | | 100MG ** | N009149 033 | |

CHLORPROMAZINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| CAPSULE, EXTENDED RELEASE;ORAL | | | | |
| THORAZINE | | | | |
| | GLAXOSMITHKLINE | 30MG | N011120 016 | |
| | | 75MG | N011120 017 | |
| | | 150MG | N011120 018 | |
| | | 200MG | N011120 019 | |
| | | 300MG | N011120 020 | |
| CONCENTRATE;ORAL | | | | |
| CHLORPROMAZINE HYDROCHLORIDE | | | | |
| | ACTAVIS MID ATLANTIC | 100MG/ML | A086863 001 | |
| | PHARM ASSOC | 30MG/ML | A040231 001 | Dec 30, 1999 |
| | | 100MG/ML | A040224 001 | Jan 26, 1999 |
| | WOCKHARDT | 30MG/ML | A087032 001 | Jul 08, 1982 |
| | | 100MG/ML | A087053 001 | |
| CHLORPROMAZINE HYDROCHLORIDE INTENSOL | | | | |
| | CYCLE PHARMS LTD | 30MG/ML | A088157 001 | Apr 27, 1983 |
| | | 100MG/ML | A088158 001 | Apr 27, 1983 |
| SONAZINE | | | | |
| | SANDOZ | 30MG/ML | A080983 004 | |
| | | 100MG/ML | A080983 005 | |

CHLORPROMAZINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| CONCENTRATE;ORAL | | | | |
| THORAZINE | | | | |
| + | GLAXOSMITHKLINE | 30MG/ML ** | N009149 032 | |
| + | | 100MG/ML ** | N009149 043 | |
| INJECTABLE;INJECTION | | | | |
| CHLORPROMAZINE HYDROCHLORIDE | | | | |
| | ABRAXIS PHARM | 25MG/ML | A084911 001 | |
| | MARSAM PHARMS LLC | 25MG/ML | A089563 001 | Apr 15, 1988 |
| | WATSON LABS | 25MG/ML | A080365 001 | |
| | | 25MG/ML | A085591 001 | |
| | WYETH AYERST | 25MG/ML | A080370 001 | |
| THORAZINE | | | | |
| + | GLAXOSMITHKLINE | 25MG/ML ** | N009149 011 | |
| SYRUP;ORAL | | | | |
| CHLORPROMAZINE HYDROCHLORIDE | | | | |
| | ALPHARMA US PHARMS | 10MG/5ML | A086712 001 | |
| SONAZINE | | | | |
| | SANDOZ | 10MG/5ML | A083040 001 | |
| THORAZINE | | | | |
| + | GLAXOSMITHKLINE | 10MG/5ML ** | N009149 022 | |
| TABLET;ORAL | | | | |
| CHLORPROMAZINE HYDROCHLORIDE | | | | |
| | ABBOTT | 10MG | A084414 001 | |
| | | 25MG | A084415 001 | |
| | | 50MG | A084411 001 | |
| | | 100MG | A084412 001 | |
| | | 200MG | A084413 001 | |
| | CYCLE PHARMS LTD | 10MG | A085331 001 | |
| | | 25MG | A085331 002 | |
| | | 50MG | A085331 003 | |
| | | 100MG | A085331 004 | |
| | | 200MG | A085331 005 | |
| | IVAX SUB TEVA PHARMS | 10MG | A083549 001 | |
| | | 25MG | A083549 002 | |
| | | 50MG | A083549 003 | |
| | | 100MG | A083574 001 | |
| | | 200MG | A083575 001 | |
| | KV PHARM | 10MG | A085750 002 | Jan 04, 1982 |
| | | 25MG | A085751 001 | |
| | | 50MG | A085484 001 | |
| | | 100MG | A085752 001 | |
| | | 200MG | A085748 002 | Jan 04, 1982 |
| | LEDERLE | 10MG | A084803 001 | |
| | | 25MG | A084801 001 | |
| | | 50MG | A084800 001 | |
| | | 100MG | A084789 001 | |
| | | 200MG | A084802 001 | |
| | PUREPAC PHARM | 10MG | A080403 004 | |
| | | 25MG | A080403 001 | |
| | | 50MG | A080403 002 | |
| | | 100MG | A080403 003 | |
| | | 200MG | A080403 005 | |
| | PVT FORM | 25MG | A080340 001 | |
| | | 50MG | A080340 002 | |
| | | 200MG | A080340 003 | |
| | SANDOZ | 10MG ** | A080439 001 | |
| | | 25MG ** | A080439 002 | |
| | | 50MG ** | A080439 003 | |
| | | 100MG ** | A080439 004 | |
| | | 200MG ** | A080439 005 | |
| | VANGARD | 10MG | A088038 001 | Aug 16, 1982 |
| | | 25MG | A087645 001 | |
| | | 50MG | A087646 001 | |
| | WATSON LABS | 10MG | A085959 001 | |
| | | 25MG | A085956 001 | |
| | | 50MG | A085960 001 | |
| | | 100MG | A085957 001 | |
| | | 200MG | A085958 001 | |

CHLORPROMAZINE HYDROCHLORIDE

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| WEST WARD | 10MG | A087783 | 001 | Sep 16, 1982 |
| | 25MG | A087865 | 001 | Sep 16, 1982 |
| | 50MG | A087878 | 001 | Sep 15, 1982 |
| | 100MG | A087884 | 001 | Sep 15, 1982 |
| | 200MG | A087880 | 001 | Sep 16, 1982 |

PROMAPAR

| | | | | |
|---|---|---|---|---|
| PARKE DAVIS | 10MG | A086886 | 001 | |
| | 25MG | A084423 | 001 | |
| | 50MG | A086887 | 001 | |
| | 100MG | A086888 | 001 | |
| | 200MG | A086885 | 001 | |

THORAZINE

| | | | | |
|---|---|---|---|---|
| GLAXOSMITHKLINE | 10MG ** | N009149 | 002 | |
| | 25MG ** | N009149 | 007 | |
| | 50MG ** | N009149 | 013 | |
| | 100MG ** | N009149 | 018 | |
| | 200MG ** | N009149 | 020 | |

CHLORPROPAMIDE

TABLET;ORAL

CHLORPROPAMIDE

| | | | | |
|---|---|---|---|---|
| ANI PHARMS INC | 100MG | A088768 | 001 | Oct 11, 1984 |
| | 100MG | A088812 | 001 | Oct 19, 1984 |
| | 100MG | A088840 | 001 | Oct 25, 1984 |
| | 100MG | A088918 | 001 | Oct 16, 1984 |
| | 100MG | A089446 | 001 | Nov 17, 1986 |
| | 250MG | A087353 | 001 | |
| | 250MG | A088813 | 001 | Oct 19, 1984 |
| | 250MG | A088919 | 001 | Oct 16, 1984 |
| | 250MG | A089447 | 001 | Nov 17, 1986 |
| AUROLIFE PHARMA LLC | 100MG | A088725 | 001 | Aug 31, 1984 |
| | 250MG | A088726 | 001 | Aug 31, 1984 |
| DAVA PHARMS INC | 100MG | A089561 | 001 | Sep 04, 1987 |
| | 250MG | A089562 | 001 | Sep 04, 1987 |
| HALSEY | 100MG | A089321 | 001 | Jan 16, 1986 |
| | 250MG | A088662 | 001 | Jan 09, 1986 |
| PAR PHARM | 100MG | A088175 | 001 | Feb 27, 1984 |
| | 250MG | A088176 | 001 | Feb 27, 1984 |
| SANDOZ | 250MG | A084669 | 001 | |
| SUPERPHARM | 100MG | A088694 | 001 | Sep 17, 1984 |
| | 250MG | A088695 | 001 | Sep 17, 1984 |
| USL PHARMA | 100MG | A088708 | 001 | Aug 30, 1984 |
| | 250MG | A088709 | 001 | Aug 30, 1984 |
| WATSON LABS | 100MG | A086865 | 001 | Sep 24, 1984 |
| | 100MG | A088608 | 001 | Apr 12, 1984 |
| | 250MG | A086866 | 001 | |
| | 250MG | A088568 | 001 | Apr 12, 1984 |
| WATSON LABS TEVA | 100MG | A088852 | 001 | Sep 26, 1984 |
| | 250MG | A088826 | 001 | Sep 26, 1984 |

CHLORPROTHIXENE

CONCENTRATE;ORAL

TARACTAN

| | | | | |
|---|---|---|---|---|
| ROCHE | 100MG/5ML | N016149 | 002 | |

INJECTABLE;INJECTION

TARACTAN

| | | | | |
|---|---|---|---|---|
| ROCHE | 12.5MG/ML | N012487 | 001 | |

TABLET;ORAL

TARACTAN

| | | | | |
|---|---|---|---|---|
| ROCHE | 10MG | N012486 | 005 | |
| | 25MG | N012486 | 004 | |
| | 50MG | N012486 | 003 | |
| | 100MG | N012486 | 001 | |

CHLORTETRACYCLINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| OINTMENT;OPHTHALMIC | | | | |
| AUREOMYCIN | | | | |
| LEDERLE | 1% | N050404 | 001 | |
| CHLORTHALIDONE | | | | |
| TABLET;ORAL | | | | |
| CHLORTHALIDONE | | | | |
| ABBOTT | 25MG | A087364 | 001 | |
| | 50MG | A087384 | 001 | |
| ASCOT | 25MG | A087698 | 001 | Oct 20, 1982 |
| | 50MG | A087699 | 001 | Oct 20, 1982 |
| BARR LABS INC | 25MG | A088902 | 001 | Sep 19, 1985 |
| | 50MG | A088903 | 001 | Sep 19, 1985 |
| DAVA PHARMS INC | 25MG | A087451 | 001 | |
| | 50MG | A087450 | 001 | |
| G AND W LABS INC | 50MG | A088651 | 001 | May 30, 1985 |
| IVAX PHARMS | 25MG | A087555 | 001 | |
| | 25MG | A088164 | 001 | Jan 09, 1984 |
| | 50MG | A087176 | 001 | |
| | 50MG | A087947 | 001 | Feb 27, 1984 |
| KV PHARM | 25MG | A087311 | 001 | |
| | 50MG | A087312 | 001 | |
| MUTUAL PHARM | 25MG | A087292 | 001 | |
| | 25MG | A089738 | 001 | Sep 19, 1988 |
| | 50MG | A087293 | 001 | |
| | 50MG | A089739 | 001 | Sep 19, 1988 |
| PIONEER PHARMS | 50MG | A089591 | 001 | Jul 21, 1988 |
| PUREPAC PHARM | 25MG | A088139 | 001 | Jul 16, 1986 |
| | 50MG | A088140 | 001 | Aug 11, 1983 |
| SANDOZ | 25MG | A087380 | 001 | |
| | 50MG | A087118 | 001 | |
| | 50MG | A087381 | 001 | |
| SUPERPHARM | 25MG | A087473 | 001 | Feb 09, 1983 |
| | 50MG | A087247 | 001 | Feb 09, 1983 |
| USL PHARMA | 25MG | A089051 | 001 | Jun 01, 1987 |
| | 50MG | A089052 | 001 | Jun 01, 1987 |
| VANGARD | 25MG | A088012 | 001 | Jul 14, 1982 |
| | 50MG | A088073 | 001 | Mar 25, 1983 |
| WARNER CHILCOTT | 25MG | A087515 | 001 | Jan 24, 1983 |
| | 50MG | A087516 | 001 | Feb 09, 1983 |
| WATSON LABS | 25MG | A087050 | 001 | |
| | 25MG | A087100 | 001 | |
| | 25MG | A087296 | 001 | |
| | 25MG | A087706 | 001 | |
| | 50MG | A087029 | 001 | |
| | 50MG | A087082 | 001 | |
| | 50MG | A087521 | 001 | |
| | 50MG | A087689 | 001 | |
| HYGROTON | | | | |
| + SANOFI AVENTIS US | 25MG ** | N012283 | 004 | |
| + | 50MG ** | N012283 | 003 | |
| THALITONE | | | | |
| CASPER PHARMA LLC | 15MG ** | N019574 | 001 | Dec 20, 1988 |
| | 25MG | N019574 | 002 | Feb 12, 1992 |
| MONARCH PHARMS | 25MG | A088051 | 001 | Nov 12, 1982 |

CHLORTHALIDONE; CLONIDINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| CLONIDINE HYDROCHLORIDE AND CHLORTHALIDONE | | | | |
| PAR PHARM | 15MG;0.1MG | A071179 | 001 | Dec 16, 1987 |
| | 15MG;0.2MG | A071178 | 001 | Dec 16, 1987 |
| | 15MG;0.3MG | A071142 | 001 | Dec 16, 1987 |
| COMBIPRES | | | | |
| + BOEHRINGER INGELHEIM | 15MG;0.1MG ** | N017503 | 001 | |
| + | 15MG;0.2MG ** | N017503 | 002 | |
| + | 15MG;0.3MG ** | N017503 | 003 | Apr 10, 1984 |

CHLORTHALIDONE; METOPROLOL TARTRATE

CAPSULE;ORAL

| | | | | | |
|---|---|---|---|---|---|
| LOPRESSIDONE | | | | | |
| | NOVARTIS | 25MG;100MG | N019451 | 001 | Dec 31, 1987 |
| | | 25MG;200MG | N019451 | 002 | Dec 31, 1987 |

CHLORTHALIDONE; RESERPINE

TABLET;ORAL

| | | | | | |
|---|---|---|---|---|---|
| DEMI-REGROTON | | | | | |
| | SANOFI AVENTIS US | 25MG;0.125MG | N015103 | 002 | |
| REGROTON | | | | | |
| | SANOFI AVENTIS US | 50MG;0.25MG | N015103 | 001 | |

CHLORZOXAZONE

TABLET;ORAL

| | | | | | |
|---|---|---|---|---|---|
| CHLORZOXAZONE | | | | | |
| | ACTAVIS ELIZABETH | 250MG | A088928 | 001 | May 08, 1987 |
| | | 500MG | A040113 | 001 | Sep 29, 1995 |
| | AUROLIFE PHARMA LLC | 250MG | A089852 | 001 | May 04, 1988 |
| | | 500MG | A089853 | 001 | May 04, 1988 |
| | OHM LABS | 250MG | A081298 | 001 | Dec 29, 1993 |
| | | 500MG | A081299 | 001 | Dec 29, 1993 |
| | PAR PHARM | 250MG | A087981 | 001 | Sep 20, 1983 |
| | PIONEER PHARMS | 250MG | A089592 | 001 | Jan 06, 1989 |
| | | 500MG | A089948 | 001 | Jan 06, 1989 |
| | SUN PHARM INDUSTRIES | 500MG | A089970 | 001 | Sep 27, 1990 |
| | WATSON LABS | 250MG | A086901 | 001 | |
| | | 250MG | A086948 | 001 | Aug 09, 1982 |
| | | 500MG | A040137 | 001 | Aug 09, 1996 |
| | | 500MG | A081019 | 001 | Jul 29, 1991 |
| | | 500MG | A081040 | 001 | Aug 22, 1989 |
| PARAFLEX | | | | | |
| + | ORTHO MCNEIL PHARM | 250MG ** | N011300 | 003 | |
| PARAFON FORTE DSC | | | | | |
| + | JANSSEN R AND D | 500MG ** | N011529 | 002 | Jun 15, 1987 |
| STRIFON FORTE DSC | | | | | |
| | FERNDALE LABS | 500MG | A081008 | 001 | Dec 23, 1988 |

CHOLESTYRAMINE

BAR, CHEWABLE;ORAL

| | | | | | |
|---|---|---|---|---|---|
| CHOLYBAR | | | | | |
| | PARKE DAVIS | EQ 4GM RESIN/BAR | A071621 | 001 | May 26, 1988 |
| | | EQ 4GM RESIN/BAR | A071739 | 001 | May 26, 1988 |

POWDER;ORAL

| | | | | | |
|---|---|---|---|---|---|
| CHOLESTYRAMINE | | | | | |
| | ANI PHARMS INC | EQ 4GM RESIN/PACKET | A074554 | 001 | Oct 02, 1996 |
| | | EQ 4GM RESIN/SCOOPFUL | A074554 | 002 | Oct 02, 1996 |
| | IVAX SUB TEVA PHARMS | EQ 4GM RESIN/PACKET | A074771 | 001 | Jul 09, 1997 |
| | | EQ 4GM RESIN/SCOOPFUL | A074771 | 002 | Jul 09, 1997 |
| | TEVA | EQ 4GM RESIN/PACKET | A074347 | 001 | May 28, 1998 |
| | | EQ 4GM RESIN/SCOOPFUL | A074347 | 002 | May 28, 1998 |
| CHOLESTYRAMINE LIGHT | | | | | |
| | TEVA | EQ 4GM RESIN/PACKET | A074348 | 001 | May 28, 1998 |
| | | EQ 4GM RESIN/SCOOPFUL | A074348 | 002 | May 28, 1998 |
| | TEVA PHARMS | EQ 4GM RESIN/PACKET | A074555 | 001 | Sep 30, 1998 |
| | | EQ 4GM RESIN/SCOOPFUL | A074555 | 002 | Sep 30, 1998 |
| LOCHOLEST | | | | | |
| | SANDOZ | EQ 4GM RESIN/PACKET | A074561 | 001 | Aug 15, 1996 |
| | | EQ 4GM RESIN/SCOOPFUL | A074561 | 002 | Aug 15, 1996 |
| LOCHOLEST LIGHT | | | | | |
| | SANDOZ | EQ 4GM RESIN/PACKET | A074562 | 001 | Aug 15, 1996 |
| | | EQ 4GM RESIN/SCOOPFUL | A074562 | 002 | Aug 15, 1996 |
| QUESTRAN | | | | | |
| + | BRISTOL MYERS | EQ 4GM RESIN/PACKET ** | N016640 | 001 | |
| + | | EQ 4GM RESIN/SCOOPFUL ** | N016640 | 003 | |
| QUESTRAN LIGHT | | | | | |
| + | BRISTOL MYERS | EQ 4GM RESIN/PACKET ** | N019669 | 001 | Dec 05, 1988 |
| + | | EQ 4GM RESIN/SCOOPFUL ** | N019669 | 003 | Dec 05, 1988 |

CHOLESTYRAMINE
TABLET;ORAL
QUESTRAN

| | | | | |
|---|---|---|---|---|
| APOTHECON | EQ 800MG RESIN | A073403 | 002 | Dec 27, 1999 |
| | EQ 1GM RESIN | A073403 | 001 | Apr 28, 1994 |

CHORIOGONADOTROPIN ALFA
INJECTABLE;INJECTION
OVIDREL

| | | | | |
|---|---|---|---|---|
| EMD SERONO | 0.25MG/VIAL | N021149 | 001 | Sep 20, 2000 |

CHROMIC CHLORIDE
INJECTABLE;INJECTION
CHROMIC CHLORIDE

| | | | | |
|---|---|---|---|---|
| ABRAXIS PHARM | EQ 0.004MG CHROMIUM/ML | N019271 | 001 | May 05, 1987 |

CHROMIC PHOSPHATE P-32
INJECTABLE;INJECTION
PHOSPHOCOL P32

| | | | | |
|---|---|---|---|---|
| MALLINKRODT NUCLEAR | 5mCi/ML | N017084 | 001 | |

CHYMOPAPAIN
INJECTABLE;INJECTION
CHYMODIACTIN

| | | | | |
|---|---|---|---|---|
| CHART MEDCL | 4,000 UNITS/VIAL | N018663 | 002 | Aug 21, 1984 |
| + | 10,000 UNITS/VIAL ** | N018663 | 001 | Nov 10, 1982 |

DISCASE

| | | | | |
|---|---|---|---|---|
| ABBOTT | 12,500 UNITS/VIAL | N018625 | 001 | Jan 18, 1984 |

CHYMOTRYPSIN
FOR SOLUTION;OPHTHALMIC
ALPHA CHYMAR

| | | | | |
|---|---|---|---|---|
| SOLA BARNES HIND | 750 UNITS/VIAL | N011837 | 001 | |

CATARASE

| | | | | |
|---|---|---|---|---|
| CIBA | 300 UNITS/VIAL | N016938 | 001 | |
| NOVARTIS | 150 UNITS/VIAL | N018121 | 001 | |

ZOLYSE

| | | | | |
|---|---|---|---|---|
| ALCON | 750 UNITS/VIAL | N011903 | 001 | |

CICLOPIROX
SOLUTION;TOPICAL
CICLOPIROX

| | | | | |
|---|---|---|---|---|
| MYLAN PHARMS INC | 8% | A078567 | 001 | Sep 18, 2007 |
| TEVA PHARMS | 8% | A078079 | 001 | Sep 18, 2007 |

CIDOFOVIR
INJECTABLE;INJECTION
VISTIDE

| | | | | |
|---|---|---|---|---|
| + GILEAD SCIENCES INC | EQ 75MG BASE/ML ** | N020638 | 001 | Jun 26, 1996 |

CILASTATIN SODIUM; IMIPENEM
INJECTABLE;INJECTION
PRIMAXIN

| | | | | |
|---|---|---|---|---|
| MERCK | EQ 250MG BASE/VIAL;250MG/VIAL | A062756 | 001 | Jan 08, 1987 |
| | EQ 500MG BASE/VIAL;500MG/VIAL | A062756 | 002 | Jan 08, 1987 |

POWDER;INTRAMUSCULAR
PRIMAXIN

| | | | | |
|---|---|---|---|---|
| MERCK | EQ 500MG BASE/VIAL;500MG/VIAL | N050630 | 001 | Dec 14, 1990 |
| | EQ 750MG BASE/VIAL;750MG/VIAL | N050630 | 002 | Dec 14, 1990 |

CILOSTAZOL
TABLET;ORAL
CILOSTAZOL

| | | | | |
|---|---|---|---|---|
| ACTAVIS ELIZABETH | 100MG | A077028 | 002 | Nov 26, 2004 |
| EPIC PHARMA LLC | 50MG | A077150 | 001 | Mar 11, 2005 |
| | 100MG | A077022 | 001 | Nov 23, 2004 |
| FRONTIDA BIOPHARM | 50MG | A077208 | 002 | Mar 29, 2006 |
| | 100MG | A077208 | 001 | Mar 29, 2006 |
| IVAX SUB TEVA PHARMS | 100MG | A077020 | 002 | Mar 01, 2005 |
| MYLAN | 50MG | A077323 | 002 | Apr 20, 2006 |
| | 100MG | A077323 | 001 | Apr 20, 2006 |
| MYLAN PHARMS INC | 50MG | A077019 | 001 | Nov 23, 2004 |
| | 100MG | A077019 | 002 | Nov 23, 2004 |
| PLIVA HRVATSKA DOO | 50MG | A077898 | 001 | Oct 29, 2007 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | | |
|---|---|---|---|---|---|
| CILOSTAZOL | | | | | |
| TABLET;ORAL | | | | | |
| CILOSTAZOL | | | | | |
| | | 100MG | A077898 | 002 | Oct 29, 2007 |
| PLETAL | | | | | |
| + | OTSUKA | 50MG ** | N020863 | 001 | Jan 15, 1999 |
| + | | 100MG ** | N020863 | 002 | Jan 15, 1999 |
| CIMETIDINE | | | | | |
| SUSPENSION;ORAL | | | | | |
| TAGAMET HB 200 | | | | | |
| | GLAXOSMITHKLINE | 200MG/20ML | N020951 | 001 | Jul 09, 1999 |
| TABLET;ORAL | | | | | |
| CIMETIDINE | | | | | |
| | CHARTWELL MOLECULES | 200MG | A074281 | 001 | May 17, 1994 |
| | | 300MG | A074281 | 002 | May 17, 1994 |
| | | 400MG | A074281 | 003 | May 17, 1994 |
| | | 800MG | A074329 | 001 | May 17, 1994 |
| | CONTRACT PHARMACAL | 200MG | A074961 | 001 | Jun 19, 1998 |
| | | 200MG | A074963 | 001 | Jun 19, 1998 |
| | CYCLE PHARMS LTD | 300MG | A074361 | 001 | Dec 23, 1994 |
| | | 400MG | A074361 | 002 | Dec 23, 1994 |
| | | 800MG | A074371 | 001 | Dec 23, 1994 |
| | DAVA PHARMS INC | 300MG | A074340 | 001 | Jun 23, 1995 |
| | | 400MG | A074340 | 002 | Jun 23, 1995 |
| | | 800MG | A074339 | 001 | Jun 23, 1995 |
| | FOSUN PHARMA | 200MG | A074100 | 001 | Jan 31, 1995 |
| | | 300MG | A074100 | 002 | Jan 31, 1995 |
| | | 400MG | A074100 | 003 | Jan 31, 1995 |
| | | 800MG | A074100 | 004 | Jan 31, 1995 |
| | IVAX SUB TEVA PHARMS | 200MG | A074401 | 001 | May 30, 1995 |
| | | 200MG | A074424 | 001 | Jul 28, 1995 |
| | | 300MG | A074401 | 002 | May 30, 1995 |
| | | 300MG | A074424 | 002 | Jul 28, 1995 |
| | | 400MG | A074401 | 003 | May 30, 1995 |
| | | 400MG | A074424 | 003 | Jul 28, 1995 |
| | | 800MG | A074402 | 001 | May 30, 1995 |
| | | 800MG | A074424 | 004 | Jul 28, 1995 |
| | PERRIGO | 100MG | A074972 | 001 | Jun 19, 1998 |
| | PLIVA | 200MG | A074568 | 001 | Feb 27, 1997 |
| | | 300MG | A074568 | 002 | Feb 27, 1997 |
| | | 400MG | A074568 | 003 | Feb 27, 1997 |
| | SANDOZ INC | 100MG | A075122 | 001 | Jun 19, 1998 |
| | | 200MG | A074250 | 001 | Jun 29, 1995 |
| | | 200MG | A075122 | 002 | Jun 19, 1998 |
| | | 300MG | A074250 | 002 | Jun 29, 1995 |
| | | 400MG | A074250 | 003 | Jun 29, 1995 |
| | | 800MG | A074250 | 004 | Jun 29, 1995 |
| | TEVA | 200MG | A074365 | 001 | Feb 28, 1995 |
| | | 300MG | A074365 | 002 | Feb 28, 1995 |
| | | 400MG | A074365 | 003 | Feb 28, 1995 |
| | | 800MG | A074365 | 004 | Feb 28, 1995 |
| | UPSHER-SMITH LABS | 200MG | A074506 | 001 | Jan 24, 1996 |
| | | 300MG | A074506 | 002 | Jan 24, 1996 |
| | | 400MG | A074506 | 003 | Jan 24, 1996 |
| | | 800MG | A074506 | 004 | Jan 24, 1996 |
| | WATSON LABS INC | 200MG | A074349 | 001 | Aug 30, 1996 |
| | | 300MG | A074349 | 002 | Aug 30, 1996 |
| | | 400MG | A074349 | 003 | Aug 30, 1996 |
| | | 800MG | A074316 | 001 | Feb 28, 1996 |
| | WATSON LABS TEVA | 200MG | A075425 | 001 | Jul 29, 1999 |
| TAGAMET | | | | | |
| | GLAXOSMITHKLINE | 200MG ** | N017920 | 002 | |
| | | 300MG ** | N017920 | 003 | |
| | | 400MG ** | N017920 | 004 | Dec 14, 1983 |
| | | 800MG ** | N017920 | 005 | Apr 30, 1986 |
| TAGAMET HB | | | | | |
| + | MEDTECH PRODUCTS | 100MG ** | N020238 | 001 | Jun 19, 1995 |

| | | | | | |
|---|---|---|---|---|---|
| CIMETIDINE HYDROCHLORIDE | | | | | |
| INJECTABLE;INJECTION | | | | | |
| CIMETIDINE HYDROCHLORIDE | | | | | |
| | HOSPIRA | EQ 300MG BASE/2ML | A074296 | 001 | Mar 28, 1997 |
| | | EQ 300MG BASE/2ML | A074344 | 001 | Jan 31, 1995 |
| | | EQ 300MG BASE/2ML | A074345 | 001 | Jan 31, 1995 |
| | | EQ 300MG BASE/2ML | A074412 | 001 | Mar 28, 1997 |
| | | EQ 300MG BASE/2ML | A074422 | 001 | Jan 31, 1995 |
| | LUITPOLD | EQ 300MG BASE/2ML | A074353 | 001 | Dec 20, 1994 |
| | TEVA PARENTERAL | EQ 300MG BASE/2ML | A074252 | 001 | Nov 26, 1997 |
| | VINTAGE PHARMS LLC | EQ 300MG BASE/2ML | A074005 | 001 | Aug 31, 1994 |
| CIMETIDINE HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | | | | | |
| | HOSPIRA | EQ 6MG BASE/ML | A074269 | 001 | Dec 27, 1994 |
| | | EQ 90MG BASE/100ML | A074468 | 005 | Dec 29, 1994 |
| | | EQ 120MG BASE/100ML | A074468 | 006 | Dec 29, 1994 |
| | | EQ 180MG BASE/100ML | A074468 | 003 | Dec 29, 1994 |
| | | EQ 240MG BASE/100ML | A074468 | 004 | Dec 29, 1994 |
| | | EQ 360MG BASE/100ML | A074468 | 001 | Dec 29, 1994 |
| | | EQ 480MG BASE/100ML | A074468 | 002 | Dec 29, 1994 |
| TAGAMET | | | | | |
| | GLAXOSMITHKLINE | EQ 300MG BASE/2ML ** | N017939 | 002 | |
| TAGAMET HYDROCHLORIDE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | | | | | |
| + | GLAXOSMITHKLINE | EQ 6MG BASE/ML ** | N019434 | 001 | Oct 31, 1985 |
| SOLUTION;ORAL | | | | | |
| CIMETIDINE HYDROCHLORIDE | | | | | |
| | ANI PHARMS INC | EQ 300MG BASE/5ML | A074859 | 001 | Jul 09, 1998 |
| | | EQ 300MG BASE/5ML | A075110 | 001 | Jun 18, 1998 |
| | APOTEX INC | EQ 300MG BASE/5ML | A075560 | 001 | Mar 15, 2000 |
| | CYCLE PHARMS LTD | EQ 300MG BASE/5ML | A074541 | 001 | Aug 05, 1997 |
| | G AND W LABS INC | EQ 300MG BASE/5ML | A074176 | 001 | Jun 01, 1994 |
| | VINTAGE PHARMS LLC | EQ 300MG BASE/5ML | A074251 | 001 | Dec 22, 1994 |
| TAGAMET | | | | | |
| | GLAXOSMITHKLINE | EQ 300MG BASE/5ML ** | N017924 | 001 | |
| CINOXACIN | | | | | |
| CAPSULE;ORAL | | | | | |
| CINOBAC | | | | | |
| | LILLY | 250MG | N018067 | 001 | |
| | | 500MG | N018067 | 002 | |
| CINOXACIN | | | | | |
| | TEVA | 250MG | A073005 | 001 | Feb 28, 1992 |
| | | 500MG | A073006 | 001 | Feb 28, 1992 |
| CIPROFLOXACIN | | | | | |
| INJECTABLE;INJECTION | | | | | |
| CIPRO | | | | | |
| + | BAYER HLTHCARE | 400MG/40ML (10MG/ML) | N019847 | 001 | Dec 26, 1990 |
| + | | 200MG/20ML (10MG/ML) | N019847 | 002 | Dec 26, 1990 |
| | | 1200MG/120ML (10MG/ML) | N019847 | 003 | Dec 26, 1990 |
| CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | | |
| + | BAYER HLTHCARE | 200MG/100ML | N019857 | 001 | Dec 26, 1990 |
| + | | 400MG/200ML | N019857 | 002 | Dec 26, 1990 |
| CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | | | | | |
| | BAYER PHARMS | 200MG/100ML | N019858 | 001 | Dec 26, 1990 |
| CIPROFLOXACIN | | | | | |
| | BEDFORD LABS | 200MG/20ML (10MG/ML) | A076992 | 001 | Aug 28, 2006 |
| | | 400MG/40ML (10MG/ML) | A076992 | 002 | Aug 28, 2006 |
| | | 1200MG/120ML (10MG/ML) | A076993 | 001 | Aug 28, 2006 |
| | FRESENIUS KABI USA | 200MG/20ML (10MG/ML) | A076484 | 001 | Aug 28, 2006 |
| | | 400MG/40ML (10MG/ML) | A076484 | 002 | Aug 28, 2006 |
| | TEVA PHARMS USA | 200MG/20ML (10MG/ML) | A077782 | 001 | Aug 28, 2006 |
| | | 400MG/40ML (10MG/ML) | A077782 | 002 | Aug 28, 2006 |
| CIPROFLOXACIN IN DEXTROSE 5% | | | | | |
| | HIKMA FARMACEUTICA | 200MG/100ML | A076757 | 001 | Apr 21, 2008 |
| CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | | |
| | BAXTER HLTHCARE | 200MG/100ML | A077888 | 001 | Mar 18, 2008 |
| | | 400MG/200ML | A077888 | 002 | Mar 18, 2008 |
| | BEDFORD | 200MG/100ML | A078114 | 001 | Mar 18, 2008 |
| | | 400MG/200ML | A078114 | 002 | Mar 18, 2008 |
| | TEVA PHARMS | 200MG/100ML | A077138 | 001 | Mar 18, 2008 |

CIPROFLOXACIN

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| | 400MG/200ML | A077138 | 002 | Mar 18, 2008 |

CIPROFLOXACIN HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| SOLUTION/DROPS;OPHTHALMIC | | | | |
| CIPROFLOXACIN HYDROCHLORIDE | | | | |
| AMRING PHARMS | EQ 0.3% BASE | A078598 | 001 | Jan 16, 2008 |
| APOTEX INC | EQ 0.3% BASE | A075928 | 001 | Jun 09, 2004 |
| TABLET;ORAL | | | | |
| CIPROFLOXACIN HYDROCHLORIDE | | | | |
| BARR | EQ 250MG BASE | A074124 | 001 | Jun 09, 2004 |
| | EQ 500MG BASE | A074124 | 002 | Jun 09, 2004 |
| | EQ 750MG BASE | A074124 | 003 | Jun 09, 2004 |
| IDT AUSTRALIA LTD | EQ 100MG BASE | A075939 | 001 | Mar 03, 2005 |
| | EQ 250MG BASE | A075939 | 002 | Jun 09, 2004 |
| | EQ 500MG BASE | A075939 | 003 | Jun 09, 2004 |
| | EQ 750MG BASE | A075939 | 004 | Jun 09, 2004 |
| MYLAN | EQ 250MG BASE | A075685 | 002 | Jun 09, 2004 |
| | EQ 500MG BASE | A075685 | 003 | Jun 09, 2004 |
| | EQ 750MG BASE | A075685 | 001 | Jun 09, 2004 |
| NOSTRUM LABS | EQ 250MG BASE | A076138 | 001 | Jun 09, 2004 |
| | EQ 500MG BASE | A076138 | 002 | Jun 09, 2004 |
| | EQ 750MG BASE | A076138 | 003 | Jun 09, 2004 |
| PLIVA | EQ 100MG BASE | A076426 | 001 | Jun 15, 2005 |
| | EQ 250MG BASE | A076426 | 002 | Jun 15, 2005 |
| | EQ 500MG BASE | A076426 | 003 | Jun 15, 2005 |
| | EQ 750MG BASE | A076426 | 004 | Jun 15, 2005 |
| SANDOZ | EQ 250MG BASE | A076593 | 002 | Jun 09, 2004 |
| | EQ 500MG BASE | A076593 | 003 | Jun 09, 2004 |
| | EQ 750MG BASE | A076593 | 004 | Jun 09, 2004 |
| TEVA | EQ 250MG BASE | A076136 | 001 | Jun 09, 2004 |
| | EQ 500MG BASE | A076136 | 002 | Jun 09, 2004 |
| | EQ 750MG BASE | A076136 | 003 | Jun 09, 2004 |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| PROQUIN XR | | | | |
| DEPOMED INC | EQ 500MG BASE | N021744 | 001 | May 19, 2005 |

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| CIPRO XR | | | | |
| BAYER HLTHCARE | 212.6MG;EQ 287.5MG BASE ** | N021473 | 001 | Dec 13, 2002 |
| | 425.2MG;EQ 574.9MG BASE ** | N021473 | 002 | Aug 28, 2003 |
| CIPROFLOXACIN EXTENDED RELEASE | | | | |
| ACTAVIS LABS FL INC | 212.6MG;EQ 287.5MG BASE | A077417 | 001 | Nov 30, 2010 |
| | 425.2MG;EQ 574.9MG BASE | A077809 | 001 | Nov 30, 2010 |
| DR REDDYS LABS LTD | 212.6MG;EQ 287.5MG BASE | A077701 | 002 | Oct 31, 2007 |
| SANDOZ | 212.6MG;EQ 287.5MG BASE | A078712 | 001 | Dec 11, 2007 |

CISAPRIDE MONOHYDRATE

| | | | | |
|---|---|---|---|---|
| SUSPENSION;ORAL | | | | |
| PROPULSID | | | | |
| JANSSEN PHARMS | EQ 1MG BASE/ML | N020398 | 001 | Sep 15, 1995 |
| TABLET;ORAL | | | | |
| PROPULSID | | | | |
| JANSSEN PHARMS | EQ 10MG BASE | N020210 | 001 | Jul 29, 1993 |
| | EQ 20MG BASE | N020210 | 002 | Dec 23, 1993 |
| TABLET, ORALLY DISINTEGRATING;ORAL | | | | |
| PROPULSID QUICKSOLV | | | | |
| JANSSEN PHARMA | EQ 20MG BASE | N020767 | 001 | Nov 07, 1997 |

CISPLATIN

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| CISPLATIN | | | | |
| BEDFORD | 10MG/VIAL | A074713 | 001 | Nov 14, 2000 |
| | 50MG/VIAL | A074713 | 002 | Nov 14, 2000 |
| TEVA PHARMS USA | 1MG/ML | A074814 | 001 | May 16, 2000 |
| PLATINOL | | | | |
| + HQ SPCLT PHARMA | 10MG/VIAL | N018057 | 001 | |
| + | 50MG/VIAL | N018057 | 002 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

CISPLATIN

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| PLATINOL-AQ | | | | |
| + | HQ SPCLT PHARMA | 0.5MG/ML | N018057 003 | Jul 18, 1984 |

CITALOPRAM HYDROBROMIDE

| | | | | |
|---|---|---|---|---|
| CAPSULE;ORAL | | | | |
| CITALOPRAM HYDROBROMIDE | | | | |
| | MYLAN PHARMS INC | EQ 10MG BASE | A077668 001 | Feb 28, 2007 |
| | | EQ 20MG BASE | A077668 002 | Feb 28, 2007 |
| | | EQ 40MG BASE | A077668 003 | Feb 28, 2007 |
| SOLUTION;ORAL | | | | |
| CELEXA | | | | |
| + | FOREST LABS | EQ 10MG BASE/5ML ** | N021046 001 | Dec 22, 1999 |
| CITALOPRAM HYDROBROMIDE | | | | |
| | APOTEX INC | EQ 10MG BASE/5ML | A077601 001 | Nov 15, 2005 |
| TABLET;ORAL | | | | |
| CELEXA | | | | |
| | FOREST LABS | EQ 60MG BASE | N020822 004 | Jul 17, 1998 |
| CITALOPRAM HYDROBROMIDE | | | | |
| | ACTAVIS ELIZABETH | EQ 10MG BASE | A077033 001 | Oct 28, 2004 |
| | | EQ 20MG BASE | A077033 002 | Oct 28, 2004 |
| | | EQ 40MG BASE | A077033 003 | Oct 28, 2004 |
| | EPIC PHARMA LLC | EQ 10MG BASE | A077036 001 | Oct 28, 2004 |
| | | EQ 20MG BASE | A077036 002 | Oct 28, 2004 |
| | | EQ 40MG BASE | A077036 003 | Oct 28, 2004 |
| | MYLAN | EQ 10MG BASE | A077039 001 | Feb 03, 2005 |
| | | EQ 20MG BASE | A077039 002 | Feb 03, 2005 |
| | | EQ 40MG BASE | A077039 003 | Feb 03, 2005 |
| | MYLAN PHARMS INC | EQ 10MG BASE | A077037 001 | Nov 05, 2004 |
| | | EQ 20MG BASE | A077037 002 | Nov 05, 2004 |
| | | EQ 40MG BASE | A077037 003 | Nov 05, 2004 |
| | NATCO PHARMA LTD | EQ 20MG BASE | A077141 002 | Apr 10, 2008 |
| | | EQ 40MG BASE | A077141 001 | Apr 10, 2008 |
| | ROXANE | EQ 10MG BASE | A077041 001 | Nov 23, 2004 |
| | | EQ 20MG BASE | A077041 002 | Nov 23, 2004 |
| | | EQ 40MG BASE | A077041 003 | Nov 23, 2004 |
| | SANDOZ | EQ 10MG BASE | A077035 001 | Oct 28, 2004 |
| | | EQ 10MG BASE | A077040 001 | Aug 17, 2005 |
| | | EQ 20MG BASE | A077035 002 | Oct 28, 2004 |
| | | EQ 20MG BASE | A077040 002 | Aug 17, 2005 |
| | | EQ 40MG BASE | A077035 003 | Oct 28, 2004 |
| | | EQ 40MG BASE | A077040 003 | Aug 17, 2005 |
| | SUN PHARM INDUSTRIES | EQ 10MG BASE | A077052 001 | Jul 03, 2006 |
| | | EQ 20MG BASE | A077052 002 | Jul 03, 2006 |
| | | EQ 40MG BASE | A077052 003 | Jul 03, 2006 |
| | TARO | EQ 10MG BASE | A077278 001 | Mar 22, 2006 |
| | | EQ 20MG BASE | A077278 002 | Mar 22, 2006 |
| | | EQ 40MG BASE | A077278 003 | Mar 22, 2006 |
| | TEVA PHARMS | EQ 10MG BASE | A077213 001 | Mar 31, 2006 |
| | | EQ 20MG BASE | A077213 002 | Mar 31, 2006 |
| | | EQ 40MG BASE | A077213 003 | Mar 31, 2006 |
| | WATSON LABS | EQ 10MG BASE | A077034 001 | Jun 30, 2005 |
| | | EQ 20MG BASE | A077034 002 | Jun 30, 2005 |
| | | EQ 40MG BASE | A077034 003 | Jun 30, 2005 |
| TABLET, ORALLY DISINTEGRATING;ORAL | | | | |
| CITALOPRAM HYDROBROMIDE | | | | |
| | BIOVAIL LABS INTL | EQ 10MG BASE | N021763 001 | Dec 20, 2005 |
| | | EQ 20MG BASE | N021763 002 | Dec 20, 2005 |
| | | EQ 40MG BASE | N021763 003 | Dec 20, 2005 |

CITRIC ACID; MAGNESIUM OXIDE; SODIUM CARBONATE

| | | | | |
|---|---|---|---|---|
| SOLUTION;IRRIGATION | | | | |
| IRRIGATING SOLUTION G IN PLASTIC CONTAINER | | | | |
| | BAXTER HLTHCARE | 3.24GM/100ML;380MG/100ML;430MG/100ML | N018519 001 | Jun 22, 1982 |
| UROLOGIC G IN PLASTIC CONTAINER | | | | |
| | HOSPIRA | 3.24GM/100ML;380MG/100ML;430MG/100ML | N018904 001 | May 27, 1983 |

| | | | | |
|---|---|---|---|---|
| CLADRIBINE | | | | |
| INJECTABLE;INJECTION | | | | |
| LEUSTATIN | | | | |
| + JANSSEN PHARMS | 1MG/ML ** | N020229 | 001 | Feb 26, 1993 |
| CLARITHROMYCIN | | | | |
| FOR SUSPENSION;ORAL | | | | |
| BIAXIN | | | | |
| ABBVIE | 187MG/5ML | N050698 | 003 | Sep 30, 1998 |
| TABLET;ORAL | | | | |
| CLARITHROMYCIN | | | | |
| IVAX SUB TEVA PHARMS | 250MG | A065137 | 001 | May 31, 2005 |
| | 500MG | A065137 | 002 | May 31, 2005 |
| MYLAN | 250MG | A065195 | 001 | Mar 11, 2005 |
| | 500MG | A065195 | 002 | Mar 11, 2005 |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| BIAXIN XL | | | | |
| + ABBVIE | 500MG ** | N050775 | 001 | Mar 03, 2000 |
| CLARITHROMYCIN | | | | |
| IDT AUSTRALIA LTD | 500MG | A065250 | 001 | Aug 25, 2005 |
| RANBAXY | 1GM | A065210 | 001 | Jan 26, 2005 |
| CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM | | | | |
| INJECTABLE;INJECTION | | | | |
| TIMENTIN | | | | |
| GLAXOSMITHKLINE | EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL | A062691 | 001 | Dec 19, 1986 |
| | EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL | N050590 | 001 | Apr 01, 1985 |
| | EQ 200MG BASE/VIAL;EQ 3GM BASE/VIAL | N050590 | 002 | Apr 01, 1985 |
| | EQ 1GM BASE/VIAL;EQ 30GM BASE/VIAL | N050590 | 003 | Aug 18, 1987 |
| TIMENTIN IN PLASTIC CONTAINER | | | | |
| GLAXOSMITHKLINE | EQ 100MG BASE/100ML;EQ 3GM BASE/100ML | N050658 | 001 | Dec 15, 1989 |
| CLEMASTINE FUMARATE | | | | |
| SYRUP;ORAL | | | | |
| CLEMASTINE FUMARATE | | | | |
| ACTAVIS MID ATLANTIC | EQ 0.5MG BASE/5ML | A074075 | 001 | Oct 31, 1993 |
| APOTEX INC | EQ 0.5MG BASE/5ML | A075703 | 001 | Nov 27, 2000 |
| SILARX | EQ 0.5MG BASE/5ML | A074884 | 001 | Dec 17, 1997 |
| TEVA PHARMS | EQ 0.5MG BASE/5ML | A073095 | 001 | Apr 21, 1992 |
| TAVIST | | | | |
| + NOVARTIS | EQ 0.5MG BASE/5ML ** | N018675 | 001 | Jun 28, 1985 |
| TABLET;ORAL | | | | |
| CLEMASTINE FUMARATE | | | | |
| ANI PHARMS INC | 1.34MG | A073282 | 001 | Jan 31, 1992 |
| | 1.34MG | A073282 | 002 | Dec 03, 1992 |
| SANDOZ | 2.68MG | A073459 | 001 | Oct 31, 1993 |
| TAVIST | | | | |
| NOVARTIS | 2.68MG | N017661 | 001 | |
| TAVIST-1 | | | | |
| NOVARTIS | 1.34MG | N017661 | 002 | |
| | 1.34MG | N017661 | 003 | Aug 21, 1992 |
| CLIDINIUM BROMIDE | | | | |
| CAPSULE;ORAL | | | | |
| QUARZAN | | | | |
| ROCHE | 2.5MG | N010355 | 001 | |
| | 5MG | N010355 | 002 | |
| CLINDAMYCIN HYDROCHLORIDE | | | | |
| CAPSULE;ORAL | | | | |
| CLEOCIN | | | | |
| PHARMACIA AND UPJOHN | EQ 75MG BASE | A061809 | 001 | |
| | EQ 150MG BASE | A061809 | 002 | |
| CLINDAMYCIN HYDROCHLORIDE | | | | |
| MYLAN PHARMS INC | EQ 75MG BASE | A091225 | 001 | May 31, 2011 |
| | EQ 150MG BASE | A091225 | 002 | May 31, 2011 |
| | EQ 300MG BASE | A091225 | 003 | May 31, 2011 |
| TEVA | EQ 75MG BASE | A063027 | 001 | Sep 20, 1989 |
| WATSON LABS | EQ 75MG BASE | A063082 | 001 | Jul 31, 1991 |

| | | | | |
|---|---|---|---|---|
| CLINDAMYCIN PALMITATE HYDROCHLORIDE | | | | |
| FOR SOLUTION;ORAL | | | | |
| CLEOCIN | | | | |
| PHARMACIA AND UPJOHN | EQ 75MG BASE/5ML ** | A061827 | 001 | |
| CLINDAMYCIN PHOSPHATE | | | | |
| CREAM;VAGINAL | | | | |
| CLEOCIN | | | | |
| PHARMACIA AND UPJOHN | EQ 2% BASE | N050680 | 001 | Aug 11, 1992 |
| INJECTABLE;INJECTION | | | | |
| CLEOCIN PHOSPHATE | | | | |
| PHARMACIA AND UPJOHN | EQ 150MG BASE/ML | A061839 | 001 | |
| CLINDAMYCIN PHOSPHATE | | | | |
| ABRAXIS PHARM | EQ 150MG BASE/ML | A062747 | 001 | Jun 03, 1988 |
| BEDFORD | EQ 150MG BASE/ML | A063163 | 001 | Jun 30, 1994 |
| BRISTOL MYERS SQUIBB | EQ 150MG BASE/ML | A062908 | 001 | Feb 01, 1989 |
| IGI LABS INC | EQ 150MG BASE/ML | A062928 | 001 | Feb 13, 1989 |
| LOCH | EQ 150MG BASE/ML | A062905 | 001 | May 09, 1988 |
| MARSAM PHARMS LLC | EQ 150MG BASE/ML | A062913 | 001 | Oct 20, 1988 |
| SOLOPAK | EQ 150MG BASE/ML | A062819 | 001 | Mar 15, 1988 |
| | EQ 150MG BASE/ML | A062852 | 001 | Mar 17, 1988 |
| TEVA PARENTERAL | EQ 150MG BASE/ML | A063041 | 001 | Dec 29, 1989 |
| | EQ 150MG BASE/ML | A063282 | 001 | May 29, 1992 |
| WATSON LABS | EQ 150MG BASE/ML | A062900 | 001 | Jun 08, 1988 |
| | EQ 150MG BASE/ML | A063079 | 001 | Mar 05, 1990 |
| WEST-WARD PHARMS INT | EQ 150MG BASE/ML | A062806 | 001 | Oct 15, 1987 |
| | EQ 150MG BASE/ML | A062953 | 001 | Apr 21, 1988 |
| | EQ 150MG BASE/ML | A063068 | 001 | Aug 28, 1989 |
| CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% | | | | |
| ABRAXIS PHARM | EQ 12MG BASE/ML | N050636 | 001 | Dec 22, 1989 |
| CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| ABBVIE | EQ 6MG BASE/ML | A065027 | 001 | Jun 29, 2001 |
| | EQ 12MG BASE/ML | A065027 | 002 | Jun 29, 2001 |
| | EQ 18MG BASE/ML | A065027 | 003 | Jun 29, 2001 |
| BAXTER HLTHCARE | EQ 6MG BASE/ML | N050648 | 001 | Dec 29, 1989 |
| | EQ 12MG BASE/ML | N050648 | 002 | Dec 29, 1989 |
| | EQ 900MG BASE/100ML | N050648 | 003 | Dec 29, 1989 |
| SOLUTION;TOPICAL | | | | |
| CLEOCIN T | | | | |
| PHARMACIA AND UPJOHN | EQ 1% BASE | A062363 | 001 | Feb 08, 1982 |
| CLINDAMYCIN PHOSPHATE | | | | |
| BOCA PHARMA LLC | EQ 1% BASE | A062944 | 001 | Jan 11, 1989 |
| NOVAST LABS LTD | EQ 1% BASE | A064108 | 001 | Sep 27, 1996 |
| VINTAGE PHARMS | EQ 1% BASE | A062930 | 001 | Jun 28, 1989 |
| CLIOQUINOL; NYSTATIN | | | | |
| OINTMENT;TOPICAL | | | | |
| NYSTAFORM | | | | |
| BAYER PHARMS | 10MG/GM;100,000 UNITS/GM | N050235 | 001 | |
| CLOBAZAM | | | | |
| TABLET;ORAL | | | | |
| ONFI | | | | |
| LUNDBECK PHARMS LLC | 5MG | N202067 | 001 | Oct 21, 2011 |
| CLOBETASOL PROPIONATE | | | | |
| CREAM;TOPICAL | | | | |
| CLOBETASOL PROPIONATE | | | | |
| TEVA PHARMS USA | 0.05% | A074087 | 001 | Feb 16, 1994 |
| CLOBETASOL PROPIONATE (EMOLLIENT) | | | | |
| NOVAST LABS LTD | 0.05% | A075733 | 001 | Aug 22, 2001 |
| TEMOVATE | | | | |
| + FOUGERA PHARMS | 0.05% ** | N019322 | 001 | Dec 27, 1985 |
| TEMOVATE E | | | | |
| + FOUGERA PHARMS | 0.05% ** | N020340 | 001 | Jun 17, 1994 |
| GEL;TOPICAL | | | | |
| TEMOVATE | | | | |
| + FOUGERA PHARMS | 0.05% ** | N020337 | 001 | Apr 29, 1994 |
| OINTMENT;TOPICAL | | | | |
| CLOBETASOL PROPIONATE | | | | |
| ACTAVIS MID ATLANTIC | 0.05% | A074128 | 001 | Aug 03, 1994 |

| | | | | |
|---|---|---|---|---|
| CLOBETASOL PROPIONATE | | | | |
| OINTMENT;TOPICAL | | | | |
| TEMOVATE | | | | |
| + FOUGERA PHARMS | 0.05% ** | N019323 | 001 | Dec 27, 1985 |
| SOLUTION;TOPICAL | | | | |
| TEMOVATE | | | | |
| + FOUGERA PHARMS | 0.05% ** | N019966 | 001 | Feb 22, 1990 |
| CLOFAZIMINE | | | | |
| CAPSULE;ORAL | | | | |
| LAMPRENE | | | | |
| + NOVARTIS | 50MG | N019500 | 002 | Dec 15, 1986 |
| | 100MG | N019500 | 001 | Dec 15, 1986 |
| CLOFIBRATE | | | | |
| CAPSULE;ORAL | | | | |
| ATROMID-S | | | | |
| WYETH AYERST | 500MG | N016099 | 002 | |
| CLOFIBRATE | | | | |
| BANNER PHARMACAPS | 500MG | A073396 | 001 | Mar 20, 1992 |
| SANDOZ | 500MG | A072191 | 001 | May 02, 1988 |
| TEVA | 500MG | A072600 | 001 | Jul 25, 1991 |
| USL PHARMA | 500MG | A070531 | 001 | Jun 16, 1986 |
| WATSON LABS | 500MG | A071603 | 001 | Sep 18, 1987 |
| CLOMIPHENE CITRATE | | | | |
| TABLET;ORAL | | | | |
| MILOPHENE | | | | |
| MILEX | 50MG | A072196 | 001 | Dec 20, 1988 |
| SEROPHENE | | | | |
| EMD SERONO | 50MG | N018361 | 001 | Mar 22, 1982 |
| CLOMIPRAMINE HYDROCHLORIDE | | | | |
| CAPSULE;ORAL | | | | |
| CLOMIPRAMINE HYDROCHLORIDE | | | | |
| TEVA | 25MG | A074849 | 001 | Apr 04, 1997 |
| | 50MG | A074849 | 002 | Apr 04, 1997 |
| | 75MG | A074849 | 003 | Apr 04, 1997 |
| WATSON LABS | 25MG | A074600 | 001 | Nov 27, 1996 |
| | 25MG | A074751 | 001 | Sep 30, 1998 |
| | 50MG | A074600 | 002 | Nov 27, 1996 |
| | 50MG | A074751 | 002 | Sep 30, 1998 |
| | 75MG | A074600 | 003 | Nov 27, 1996 |
| | 75MG | A074751 | 003 | Sep 30, 1998 |
| CLONAZEPAM | | | | |
| TABLET;ORAL | | | | |
| CLONAZEPAM | | | | |
| APOTEX INC | 0.5MG | A075468 | 001 | Oct 06, 2000 |
| | 1MG | A075468 | 002 | Oct 06, 2000 |
| | 2MG | A075468 | 003 | Oct 06, 2000 |
| MYLAN PHARMS INC | 0.5MG | A074940 | 001 | Oct 30, 1997 |
| | 1MG | A074940 | 002 | Oct 30, 1997 |
| | 2MG | A074940 | 003 | Oct 30, 1997 |
| SANDOZ | 0.5MG | A074925 | 001 | Sep 30, 1997 |
| | 1MG | A074925 | 002 | Sep 30, 1997 |
| | 2MG | A074925 | 003 | Sep 30, 1997 |
| TEVA | 0.5MG | A074920 | 001 | Aug 04, 1998 |
| | 1MG | A074920 | 002 | Aug 04, 1998 |
| | 2MG | A074920 | 003 | Aug 04, 1998 |
| KLONOPIN | | | | |
| ROCHE | 0.125MG | N017533 | 005 | Apr 09, 1997 |
| | 0.25MG | N017533 | 006 | Apr 09, 1997 |
| TABLET, ORALLY DISINTEGRATING;ORAL | | | | |
| KLONOPIN RAPIDLY DISINTEGRATING | | | | |
| + ROCHE | 0.125MG ** | N020813 | 001 | Dec 23, 1997 |
| + | 0.25MG ** | N020813 | 002 | Dec 23, 1997 |
| + | 0.5MG ** | N020813 | 003 | Dec 23, 1997 |
| + | 1MG ** | N020813 | 004 | Dec 23, 1997 |
| + | 2MG ** | N020813 | 005 | Dec 23, 1997 |

| | | | | |
|---|---|---|---|---|
| CLONIDINE | | | | |
| SUSPENSION, EXTENDED RELEASE;ORAL | | | | |
| CLONIDINE | | | | |
| TRIS PHARMA INC | EQ 0.09MG BASE/ML | N022499 | 001 | Dec 03, 2009 |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| CLONIDINE | | | | |
| TRIS PHARMA INC | EQ 0.17MG BASE | N022500 | 001 | Dec 03, 2009 |
| | EQ 0.26MG BASE | N022500 | 002 | Dec 03, 2009 |
| CLONIDINE HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| CLONIDINE HYDROCHLORIDE | | | | |
| AM THERAP | 0.1MG | A070881 | 001 | Jul 08, 1986 |
| | 0.2MG | A070882 | 001 | Jul 08, 1986 |
| | 0.3MG | A070883 | 001 | Jul 08, 1986 |
| AUROLIFE PHARMA LLC | 0.1MG | A070887 | 001 | Aug 31, 1988 |
| | 0.2MG | A070886 | 001 | Aug 31, 1988 |
| | 0.3MG | A071294 | 001 | Aug 31, 1988 |
| CHARTWELL MOLECULES | 0.3MG | A071785 | 001 | Apr 05, 1988 |
| DURAMED PHARMS BARR | 0.1MG | A071103 | 001 | Aug 14, 1986 |
| | 0.2MG | A071102 | 001 | Aug 14, 1986 |
| | 0.3MG | A071101 | 001 | Aug 14, 1986 |
| INTERPHARM | 0.1MG | A071252 | 001 | Oct 01, 1986 |
| | 0.2MG | A071253 | 001 | Oct 01, 1986 |
| | 0.3MG | A071254 | 001 | Oct 01, 1986 |
| PAR PHARM | 0.1MG | A070461 | 001 | Jul 08, 1986 |
| | 0.2MG | A070460 | 001 | Jul 08, 1986 |
| | 0.3MG | A070459 | 001 | Jul 08, 1986 |
| TEVA | 0.1MG | A070747 | 001 | Jul 08, 1986 |
| | 0.2MG | A070702 | 001 | Jul 08, 1986 |
| | 0.3MG | A070659 | 001 | Jul 08, 1986 |
| WARNER CHILCOTT | 0.1MG | A072138 | 001 | Jun 13, 1988 |
| | 0.2MG | A072139 | 001 | Jun 13, 1988 |
| | 0.3MG | A072140 | 001 | Jun 13, 1988 |
| WATSON LABS | 0.1MG | A070395 | 001 | Mar 23, 1987 |
| | 0.1MG | A070965 | 001 | Jul 08, 1986 |
| | 0.2MG | A070396 | 001 | Mar 23, 1987 |
| | 0.2MG | A070964 | 001 | Jul 08, 1986 |
| | 0.3MG | A070397 | 001 | Mar 23, 1987 |
| | 0.3MG | A070963 | 001 | Jul 08, 1986 |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| CLONIDINE HYDROCHLORIDE | | | | |
| ACTAVIS ELIZABETH | 0.2MG | A202792 | 002 | May 15, 2015 |
| | 0.2MG | A203320 | 002 | May 15, 2015 |
| ANCHEN PHARMS | 0.1MG | A202983 | 001 | Apr 02, 2014 |
| | 0.2MG | A202983 | 002 | Apr 02, 2014 |
| CLONIDINE HYDROCHLORIDE | | | | |
| ANCHEN PHARMS | 0.2MG | A202984 | 002 | Sep 30, 2013 |
| JENLOGA | | | | |
| + CONCORDIA PHARMS INC | 0.1MG ** | N022331 | 001 | Sep 30, 2009 |
| + | 0.2MG ** | N022331 | 002 | May 25, 2010 |
| KAPVAY | | | | |
| + CONCORDIA PHARMS INC | 0.2MG ** | N022331 | 004 | Sep 28, 2010 |
| CLOPIDOGREL BISULFATE | | | | |
| TABLET;ORAL | | | | |
| CLOPIDOGREL BISULFATE | | | | |
| ACTAVIS TOTOWA | EQ 75MG BASE | A090307 | 001 | May 28, 2013 |
| CLORAZEPATE DIPOTASSIUM | | | | |
| CAPSULE;ORAL | | | | |
| CLORAZEPATE DIPOTASSIUM | | | | |
| ABLE | 3.75MG | A071777 | 001 | Jul 14, 1987 |
| | 7.5MG | A071778 | 001 | Jul 14, 1987 |
| | 15MG | A071779 | 001 | Jul 14, 1987 |
| AM THERAP | 3.75MG | A071429 | 001 | Jun 23, 1987 |
| | 7.5MG | A071430 | 001 | Jun 23, 1987 |
| | 15MG | A071431 | 001 | Jun 23, 1987 |
| AUROLIFE PHARMA LLC | 15MG | A072112 | 001 | Aug 26, 1988 |
| DAVA PHARMS INC | 3.75MG | A071742 | 001 | Dec 14, 1987 |
| | 7.5MG | A071743 | 001 | Dec 14, 1987 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

CLORAZEPATE DIPOTASSIUM

| | | | | |
|---|---|---|---|---|
| CAPSULE;ORAL | | | | |
| CLORAZEPATE DIPOTASSIUM | | | | |
| | 15MG | A071744 | 001 | Dec 14, 1987 |
| GD SEARLE LLC | 3.75MG | A071727 | 001 | Dec 18, 1987 |
| | 7.5MG | A071728 | 001 | Dec 18, 1987 |
| | 15MG | A071729 | 001 | Dec 18, 1987 |
| MYLAN | 3.75MG | A071509 | 001 | Oct 19, 1987 |
| | 7.5MG | A071510 | 001 | Oct 19, 1987 |
| | 15MG | A071511 | 001 | Oct 19, 1987 |
| PUREPAC PHARM | 3.75MG | A071924 | 001 | Apr 25, 1988 |
| | 7.5MG | A071925 | 001 | Apr 25, 1988 |
| | 15MG | A071926 | 001 | Apr 25, 1988 |
| QUANTUM PHARMICS | 3.75MG | A071549 | 001 | Sep 12, 1988 |
| | 7.5MG | A071550 | 001 | Sep 12, 1988 |
| | 15MG | A071522 | 001 | Sep 12, 1988 |
| USL PHARMA | 3.75MG | A071242 | 001 | Jun 23, 1987 |
| | 7.5MG | A071243 | 001 | Jun 23, 1987 |
| | 15MG | A071244 | 001 | Jun 23, 1987 |
| WARNER CHILCOTT | 3.75MG | A071774 | 001 | Mar 01, 1988 |
| | 7.5MG | A071775 | 001 | Mar 01, 1988 |
| | 15MG | A071776 | 001 | Mar 01, 1988 |
| WATSON LABS | 3.75MG | A071878 | 001 | Mar 15, 1988 |
| | 7.5MG | A071879 | 001 | Mar 15, 1988 |
| | 15MG | A071860 | 001 | Mar 15, 1988 |
| TRANXENE | | | | |
| RECORDATI RARE | 3.75MG | N017105 | 001 | |
| | 7.5MG | N017105 | 002 | |
| | 15MG | N017105 | 003 | |
| TABLET;ORAL | | | | |
| CLORAZEPATE DIPOTASSIUM | | | | |
| ABLE | 3.75MG | A071780 | 001 | Jun 26, 1987 |
| | 7.5MG | A071781 | 001 | Jun 26, 1987 |
| | 15MG | A071782 | 001 | Jun 26, 1987 |
| AM THERAP | 3.75MG | A071747 | 001 | Jun 23, 1987 |
| | 7.5MG | A071748 | 001 | Jun 23, 1987 |
| | 15MG | A071749 | 001 | Jun 23, 1987 |
| AUROLIFE PHARMA LLC | 3.75MG | A072512 | 001 | May 11, 1990 |
| | 7.5MG | A072513 | 001 | May 11, 1990 |
| | 15MG | A072514 | 001 | May 11, 1990 |
| LEDERLE | 3.75MG | A072013 | 001 | Dec 15, 1987 |
| | 7.5MG | A072014 | 001 | Dec 15, 1987 |
| | 15MG | A072015 | 001 | Dec 15, 1987 |
| PUREPAC PHARM | 3.75MG | A072330 | 001 | Aug 08, 1988 |
| | 7.5MG | A072331 | 001 | Aug 08, 1988 |
| | 15MG | A072332 | 001 | Aug 08, 1988 |
| QUANTUM PHARMICS | 3.75MG | A071730 | 001 | Oct 26, 1987 |
| | 7.5MG | A071731 | 001 | Oct 26, 1987 |
| | 15MG | A071702 | 001 | Oct 26, 1987 |
| SUN PHARM INDS LTD | 3.75MG | A076911 | 001 | Sep 29, 2004 |
| | 7.5MG | A076911 | 002 | Sep 29, 2004 |
| | 15MG | A076911 | 003 | Sep 29, 2004 |
| WARNER CHILCOTT | 3.75MG | A071828 | 001 | Mar 03, 1988 |
| | 7.5MG | A071829 | 001 | Mar 03, 1988 |
| | 15MG | A071830 | 001 | Mar 03, 1988 |
| WATSON LABS | 3.75MG | A071852 | 001 | Feb 09, 1988 |
| | 7.5MG | A071853 | 001 | Feb 09, 1988 |
| | 15MG | A071854 | 001 | Feb 09, 1988 |
| TRANXENE | | | | |
| RECORDATI RARE | 3.75MG | N017105 | 006 | |
| TRANXENE SD | | | | |
| RECORDATI RARE | 11.25MG | N017105 | 005 | |
| | 22.5MG | N017105 | 004 | |

CLOTRIMAZOLE

| | | | | |
|---|---|---|---|---|
| CREAM;TOPICAL | | | | |
| LOTRIMIN | | | | |
| | SCHERING PLOUGH | 1% | N017619 001 | |
| MYCELEX | | | | |
| | BAYER HEALTHCARE LLC | 1% | N018183 001 | |
| CREAM;VAGINAL | | | | |
| GYNE-LOTRIMIN | | | | |
| + | BAYER HEALTHCARE LLC | 1% | N018052 002 | Nov 30, 1990 |
| GYNE-LOTRIMIN 3 | | | | |
| + | BAYER HEALTHCARE LLC | 2% | N020574 001 | Nov 24, 1998 |
| CREAM, TABLET;TOPICAL, VAGINAL | | | | |
| GYNE-LOTRIMIN 3 COMBINATION PACK | | | | |
| + | BAYER HEALTHCARE LLC | 1%,200MG | N020526 002 | Jul 29, 1996 |
| GYNE-LOTRIMIN COMBINATION PACK | | | | |
| + | BAYER HEALTHCARE LLC | 1%,100MG | N020289 002 | Apr 26, 1993 |
| LOTION;TOPICAL | | | | |
| LOTRIMIN | | | | |
| | SCHERING | 1% | N018813 001 | Feb 17, 1984 |
| SOLUTION;TOPICAL | | | | |
| LOTRIMIN | | | | |
| + | SCHERING PLOUGH | 1% | N017613 001 | |
| MYCELEX | | | | |
| + | BAYER HLTHCARE | 1% ** | N018181 001 | |
| TABLET;VAGINAL | | | | |
| GYNE-LOTRIMIN | | | | |
| + | BAYER HEALTHCARE LLC | 100MG | N017717 002 | Nov 30, 1990 |
| GYNE-LOTRIMIN 3 | | | | |
| + | BAYER HEALTHCARE LLC | 200MG | N020525 001 | Jul 29, 1996 |
| GYNIX | | | | |
| | TEVA PHARMS | 100MG | A073249 001 | Feb 13, 1998 |
| MYCELEX-G | | | | |
| | BAYER PHARMS | 500MG | N019069 001 | Apr 19, 1985 |
| TROCHE/LOZENGE;ORAL | | | | |
| MYCELEX | | | | |
| + | BAYER HLTHCARE | 10MG ** | N018713 001 | Jun 17, 1983 |

CLOXACILLIN SODIUM

| | | | | |
|---|---|---|---|---|
| CAPSULE;ORAL | | | | |
| CLOXACILLIN SODIUM | | | | |
| | APOTHECON | EQ 250MG BASE | A061452 001 | |
| | | EQ 500MG BASE | A061452 002 | |
| | TEVA | EQ 250MG BASE | A062240 001 | |
| | | EQ 500MG BASE | A062240 002 | |
| CLOXAPEN | | | | |
| | GLAXOSMITHKLINE | EQ 250MG BASE | A061806 001 | |
| | | EQ 250MG BASE | A062233 001 | |
| | | EQ 500MG BASE | A061806 002 | |
| | | EQ 500MG BASE | A062233 002 | |
| FOR SOLUTION;ORAL | | | | |
| CLOXACILLIN SODIUM | | | | |
| | TEVA | EQ 125MG BASE/5ML | A062268 001 | |
| | | EQ 125MG BASE/5ML | A062978 001 | Apr 06, 1989 |
| TEGOPEN | | | | |
| | APOTHECON | EQ 125MG BASE/5ML | A061453 001 | |
| | | EQ 125MG BASE/5ML | N050192 001 | |

CLOZAPINE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| CLOZAPINE | | | | |
| | PAR PHARM | 25MG | A075162 001 | Apr 26, 2005 |
| | | 100MG | A075162 002 | Apr 26, 2005 |
| | SANDOZ | 25MG | A074546 001 | Aug 30, 1996 |
| | | 100MG | A074546 002 | Aug 30, 1996 |
| TABLET, ORALLY DISINTEGRATING;ORAL | | | | |
| FAZACLO ODT | | | | |
| | JAZZ PHARMS III | 50MG | N021590 003 | Jun 03, 2005 |

COBALT CHLORIDE CO-57; CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; INTRINSIC FACTOR

N/A;N/A

RUBRATOPE-57 KIT

| | | | | |
|---|---|---|---|---|
| | BRACCO | N/A;N/A;N/A;N/A | N016089 001 | |

COBALT CHLORIDE CO-60; CYANOCOBALAMIN; CYANOCOBALAMIN CO-60; INTRINSIC FACTOR

N/A;N/A

RUBRATOPE-60 KIT

| | | | | |
|---|---|---|---|---|
| | BRACCO | N/A;N/A;N/A;N/A | N016090 001 | |

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENERGAN VC W/ CODEINE

| | | | | |
|---|---|---|---|---|
| + | ANI PHARMS | 10MG/5ML;5MG/5ML;6.25MG/5ML ** | N008306 005 | Apr 02, 1984 |

PHERAZINE VC W/ CODEINE

| | | | | |
|---|---|---|---|---|
| | HALSEY | 10MG/5ML;5MG/5ML;6.25MG/5ML | A088870 001 | Mar 02, 1987 |

PROMETHAZINE VC W/ CODEINE

| | | | | |
|---|---|---|---|---|
| | CENCI | 10MG/5ML;5MG/5ML;6.25MG/5ML | A088816 001 | Nov 22, 1985 |
| | WOCKHARDT | 10MG/5ML;5MG/5ML;6.25MG/5ML | A088896 001 | Jan 04, 1985 |

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENERGAN W/ CODEINE

| | | | | |
|---|---|---|---|---|
| + | ANI PHARMS | 10MG/5ML;6.25MG/5ML ** | N008306 004 | Apr 02, 1984 |

PHERAZINE W/ CODEINE

| | | | | |
|---|---|---|---|---|
| | HALSEY | 10MG/5ML;6.25MG/5ML | A088739 001 | Dec 23, 1988 |

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

| | | | | |
|---|---|---|---|---|
| | PHARM ASSOC | 10MG/5ML;6.25MG/5ML | A089647 001 | Dec 22, 1988 |

PROMETHAZINE W/ CODEINE

| | | | | |
|---|---|---|---|---|
| | CENCI | 10MG/5ML;6.25MG/5ML | A088814 001 | Nov 22, 1985 |

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP;ORAL

ACTIFED W/ CODEINE

| | | | | |
|---|---|---|---|---|
| | GLAXOSMITHKLINE | 10MG/5ML;30MG/5ML;1.25MG/5ML | N012575 003 | Apr 04, 1984 |

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES W/ CODEINE

| | | | | |
|---|---|---|---|---|
| | CENCI | 10MG/5ML;30MG/5ML;1.25MG/5ML | A089018 001 | Jul 23, 1986 |

TRIPROLIDINE HCL, PSEUDOEPHEDRINE HCL AND CODEINE PHOSPHATE

| | | | | |
|---|---|---|---|---|
| | WOCKHARDT | 10MG/5ML;30MG/5ML;1.25MG/5ML | A088833 001 | Nov 16, 1984 |

CODEINE SULFATE

SOLUTION;ORAL

CODEINE SULFATE

| | | | | |
|---|---|---|---|---|
| | WEST-WARD PHARMS INT | 30MG/5ML | N202245 001 | Jun 30, 2011 |

COLCHICINE; PROBENECID

TABLET;ORAL

COLBENEMID

| | | | | |
|---|---|---|---|---|
| + | MERCK | 0.5MG;500MG ** | N012383 001 | |

PROBEN-C

| | | | | |
|---|---|---|---|---|
| | WATSON LABS | 0.5MG;500MG | A085552 001 | |

PROBENECID AND COLCHICINE

| | | | | |
|---|---|---|---|---|
| | ANI PHARMS INC | 0.5MG;500MG | A083734 001 | |
| | BEECHAM | 0.5MG;500MG | A084321 001 | |
| | IMPAX LABS | 0.5MG;500MG | A083720 002 | |
| | SANDOZ | 0.5MG;500MG | A086130 001 | |

PROBENECID W/ COLCHICINE

| | | | | |
|---|---|---|---|---|
| | LEDERLE | 0.5MG;500MG | A086954 001 | |
| | WATSON LABS | 0.5MG;500MG | A083221 001 | |

COLESEVELAM HYDROCHLORIDE

CAPSULE;ORAL

WELCHOL

| | | | | |
|---|---|---|---|---|
| | DAIICHI SANKYO | 375MG | N021141 001 | May 26, 2000 |

COLISTIN SULFATE

SUSPENSION;ORAL

COLY-MYCIN S

| | | | | |
|---|---|---|---|---|
| | PARKE DAVIS | EQ 25MG BASE/5ML | N050355 001 | |

CONIVAPTAN HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;IV (INFUSION) | | | | |
| VAPRISOL | | | | |
| | CUMBERLAND PHARMS | 20MG/4ML (5MG/ML) | N021697 001 | Dec 29, 2005 |

COPPER

| | | | | |
|---|---|---|---|---|
| INTRAUTERINE DEVICE;INTRAUTERINE | | | | |
| CU-7 | | | | |
| | GD SEARLE LLC | 89MG | N017408 001 | |
| TATUM-T | | | | |
| | GD SEARLE LLC | 120MG | N018205 001 | |

CORTICOTROPIN

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| ACTH | | | | |
| | PARKEDALE | 25 UNITS/VIAL | N008317 002 | |
| | | 40 UNITS/VIAL | N008317 004 | |
| ACTHAR | | | | |
| | SANOFI AVENTIS US | 25 UNITS/VIAL | N007504 002 | |
| | | 40 UNITS/VIAL | N007504 003 | |
| CORTICOTROPIN | | | | |
| | ORGANICS LAGRANGE | 40 UNITS/ML | N010831 001 | |
| | | 80 UNITS/ML | N010831 002 | |
| | WATSON LABS | 40 UNITS/VIAL | A088772 001 | Nov 21, 1984 |
| H.P. ACTHAR GEL | | | | |
| | MALLINCKRODT ARD | 40 UNITS/ML | N008372 006 | |
| PURIFIED CORTROPHIN GEL | | | | |
| | ANI PHARMS INC | 40 UNITS/ML | N008975 001 | |
| | | 80 UNITS/ML | N008975 002 | |

CORTICOTROPIN-ZINC HYDROXIDE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| CORTROPHIN-ZINC | | | | |
| | ANI PHARMS INC | 40 UNITS/ML | N009854 001 | |

CORTISONE ACETATE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| CORTISONE ACETATE | | | | |
| | PHARMACIA AND UPJOHN | 25MG/ML | N008126 002 | |
| | WATSON LABS | 25MG/ML | A083147 003 | |
| | | 25MG/ML | A085677 001 | |
| | | 50MG/ML | A083147 004 | |
| | | 50MG/ML | A085677 002 | |
| CORTONE | | | | |
| | MERCK | 25MG/ML | N007110 002 | |
| | | 50MG/ML | N007110 003 | |
| TABLET;ORAL | | | | |
| CORTISONE ACETATE | | | | |
| | BARR | 25MG | A083471 001 | |
| | ELKINS SINN | 25MG | A080836 001 | |
| | EVERYLIFE | 25MG | A084246 001 | |
| | HEATHER | 25MG | A085736 001 | |
| | IMPAX LABS | 25MG | N009458 001 | |
| | INWOOD LABS | 25MG | A080731 001 | |
| | IVAX SUB TEVA PHARMS | 25MG | A080630 001 | |
| | | 25MG | A083536 001 | |
| | LANNETT | 25MG | A080694 001 | |
| | PANRAY | 5MG | N008284 002 | |
| | | 25MG | N008284 001 | |
| | PHARMACIA AND UPJOHN | 5MG | N008126 003 | |
| | | 10MG | N008126 004 | |
| | | 25MG | N008126 001 | |
| | PUREPAC PHARM | 25MG | A080493 001 | |
| | VITARINE | 25MG | A080333 001 | |
| | WATSON LABS | 25MG | A085884 001 | |
| | WHITEWORTH TOWN PLSN | 25MG | A080341 001 | |
| CORTONE | | | | |
| + | MERCK | 25MG ** | N007750 003 | |

| | | | | |
|---|---|---|---|---|
| COSYNTROPIN | | | | |
| SOLUTION;INTRAVENOUS | | | | |
| COSYNTROPIN | | | | |
| | SANDOZ INC | 0.25MG/ML (0.25MG/ML) | N022028 001 | Feb 21, 2008 |
| CROMOLYN SODIUM | | | | |
| AEROSOL, METERED;INHALATION | | | | |
| INTAL | | | | |
| | KING PHARMS LLC | 0.8MG/INH | N018887 001 | Dec 05, 1985 |
| CAPSULE;INHALATION | | | | |
| INTAL | | | | |
| + | SANOFI AVENTIS US | 20MG ** | N016990 001 | |
| CAPSULE;ORAL | | | | |
| GASTROCROM | | | | |
| | UCB INC | 100MG | N019188 001 | Dec 22, 1989 |
| CONCENTRATE;ORAL | | | | |
| CROMOLYN SODIUM | | | | |
| | GENERA PHARMS | 100MG/5ML | A090954 001 | Dec 18, 2009 |
| SOLUTION;INHALATION | | | | |
| CROMOLYN SODIUM | | | | |
| | ACTAVIS MID ATLANTIC | 10MG/ML | A075067 001 | Jul 19, 1999 |
| | APOTEX INC | 10MG/ML | A075333 001 | Apr 30, 2002 |
| | BAUSCH AND LOMB | 10MG/ML | A075585 001 | Dec 21, 2000 |
| | PHARMASCIENCE INC | 10MG/ML | A075437 001 | Apr 21, 2000 |
| | ROXANE | 10MG/ML | A075175 001 | Sep 30, 1999 |
| | WATSON LABS | 10MG/ML | A076469 001 | Jun 17, 2005 |
| INTAL | | | | |
| + | KING PHARMS LLC | 10MG/ML ** | N018596 001 | May 28, 1982 |
| SOLUTION/DROPS;OPHTHALMIC | | | | |
| CROLOM | | | | |
| | BAUSCH AND LOMB | 4% | A074443 001 | Jan 30, 1995 |
| CROMOLYN SODIUM | | | | |
| | APOTEX INC | 4% | A075615 001 | Jan 26, 2001 |
| CROMOPTIC | | | | |
| | KING PHARMS | 4% | A075088 001 | Apr 27, 1999 |
| OPTICROM | | | | |
| + | ALLERGAN | 4% ** | N018155 001 | Oct 03, 1984 |
| SPRAY, METERED;NASAL | | | | |
| CROMOLYN SODIUM | | | | |
| | ACTAVIS MID ATLANTIC | 5.2MG/SPRAY | A074800 001 | Jul 26, 2001 |
| | HH AND P | 5.2MG/SPRAY | A077976 001 | Sep 07, 2007 |
| NASALCROM | | | | |
| + | BLACKSMITH BRANDS | 5.2MG/SPRAY ** | N020463 001 | Jan 03, 1997 |
| CRYPTENAMINE ACETATES | | | | |
| INJECTABLE;INJECTION | | | | |
| UNITENSEN | | | | |
| | MEDPOINTE PHARM HLC | 260CSR UNIT/ML | N008814 001 | |
| CRYPTENAMINE TANNATES | | | | |
| TABLET;ORAL | | | | |
| UNITENSEN | | | | |
| | MEDPOINTE PHARM HLC | 260CSR UNIT | N009217 001 | |
| CUPRIC SULFATE | | | | |
| INJECTABLE;INJECTION | | | | |
| CUPRIC SULFATE | | | | |
| | ABRAXIS PHARM | EQ 0.4MG COPPER/ML | N019350 001 | May 05, 1987 |
| CYANOCOBALAMIN | | | | |
| GEL, METERED;NASAL | | | | |
| NASCOBAL | | | | |
| | PAR PHARM | 0.5MG/INH | N019722 001 | Nov 05, 1996 |
| INJECTABLE;INJECTION | | | | |
| BERUBIGEN | | | | |
| | PHARMACIA AND UPJOHN | 1MG/ML | N006798 001 | |
| BETALIN 12 | | | | |
| | LILLY | 0.1MG/ML | A080855 001 | |
| | | 1MG/ML | A080855 002 | |
| COBAVITE | | | | |
| | WATSON LABS | 0.1MG/ML | A083013 001 | |
| | | 1MG/ML | A083064 001 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| CYANOCOBALAMIN | | | | |
| INJECTABLE;INJECTION | | | | |
| CYANOCOBALAMIN | | | | |
| ABRAXIS PHARM | 0.03MG/ML | A080510 | 003 | |
| | 0.1MG/ML | A080510 | 001 | |
| | 1MG/ML | A080510 | 002 | |
| AKORN | 1MG/ML | A087969 | 001 | Nov 10, 1983 |
| DELL LABS | 0.03MG/ML | A080689 | 001 | |
| | 0.1MG/ML | A080689 | 002 | |
| | 1MG/ML | A080689 | 003 | |
| FRESENIUS KABI USA | 0.1MG/ML | A080557 | 002 | |
| LUITPOLD | 0.03MG/ML | A080668 | 001 | |
| LYPHOMED | 1MG/ML | A083075 | 001 | |
| MYLAN INSTITUTIONAL | 1MG/ML | A040451 | 001 | Sep 23, 2003 |
| SANOFI AVENTIS US | 1MG/ML | A080564 | 001 | |
| SOLOPAK | 1MG/ML | A087551 | 001 | Feb 29, 1984 |
| WARNER CHILCOTT | 1MG/ML | N007085 | 002 | |
| WATSON LABS | 0.1MG/ML | A080573 | 002 | |
| | 0.1MG/ML | A083120 | 001 | |
| | 1MG/ML | A080573 | 001 | |
| | 1MG/ML | A083120 | 002 | |
| WYETH AYERST | 0.1MG/ML | A080554 | 001 | |
| | 1MG/ML | A080554 | 002 | |
| DODEX | | | | |
| ACCORD HLTHCARE | 1MG/ML | A083022 | 001 | |
| REDISOL | | | | |
| MERCK | 1MG/ML | N006668 | 010 | |
| RUBIVITE | | | | |
| BEL MAR | 0.03MG/ML | N010791 | 004 | |
| | 0.05MG/ML | N010791 | 001 | |
| | 0.1MG/ML | N010791 | 002 | |
| | 0.12MG/ML | N010791 | 005 | |
| | 1MG/ML | N010791 | 003 | |
| RUBRAMIN PC | | | | |
| BRISTOL MYERS SQUIBB | 0.1MG/ML | N006799 | 002 | |
| + | 1MG/ML ** | N006799 | 004 | |
| + | 1MG/ML ** | N006799 | 010 | Apr 28, 1988 |
| RUVITE | | | | |
| SAVAGE LABS | 1MG/ML | A080570 | 002 | |
| VI-TWEL | | | | |
| BAYER HLTHCARE | 1MG/ML | N007012 | 002 | |
| SPRAY, METERED;NASAL | | | | |
| CALOMIST | | | | |
| PAR PHARM | 25MCG/SPRAY | N022102 | 001 | Jul 27, 2007 |
| TABLET;ORAL | | | | |
| CYANOCOBALAMIN | | | | |
| WEST WARD | 1MG | A084264 | 001 | |
| CYANOCOBALAMIN CO-57 | | | | |
| CAPSULE;ORAL | | | | |
| RUBRATOPE-57 | | | | |
| BRACCO | 0.5-1uCi | N016089 | 002 | |
| CYANOCOBALAMIN CO-60 | | | | |
| CAPSULE;ORAL | | | | |
| RUBRATOPE-60 | | | | |
| BRACCO | 0.5-1uCi | N016090 | 002 | |
| CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; CYANOCOBALAMIN CO-58 | | | | |
| N/A;N/A | | | | |
| DICOPAC KIT | | | | |
| GE HEALTHCARE | N/A;N/A;N/A | N017406 | 001 | |
| CYANOCOBALAMIN; CYANOCOBALAMIN CO-57; INTRINSIC FACTOR | | | | |
| N/A;N/A | | | | |
| CYANOCOBALAMIN CO 57 SCHILLING TEST KIT | | | | |
| MALLINCKRODT | 0.1MG;0.5uCi;60MG | N016635 | 001 | |

| | | | | |
|---|---|---|---|---|
| CYANOCOBALAMIN; TANNIC ACID; ZINC ACETATE | | | | |
| INJECTABLE;INJECTION | | | | |
| DEPINAR | | | | |
| | ARMOUR PHARM | 0.5MG/ML;2.3MG/ML;1MG/ML | N011208 001 | |
| CYCLACILLIN | | | | |
| FOR SUSPENSION;ORAL | | | | |
| CYCLAPEN-W | | | | |
| | WYETH AYERST | 125MG/5ML | N050508 001 | |
| | | 250MG/5ML | N050508 002 | |
| | | 500MG/5ML | N050508 003 | |
| TABLET;ORAL | | | | |
| CYCLACILLIN | | | | |
| | TEVA | 250MG | A062895 001 | Aug 04, 1988 |
| | | 500MG | A062895 002 | Aug 04, 1988 |
| CYCLAPEN-W | | | | |
| | WYETH AYERST | 250MG | N050509 001 | |
| | | 500MG | N050509 002 | |
| CYCLIZINE LACTATE | | | | |
| INJECTABLE;INJECTION | | | | |
| MAREZINE | | | | |
| | GLAXOSMITHKLINE | 50MG/ML | N009495 001 | |
| CYCLOBENZAPRINE HYDROCHLORIDE | | | | |
| CAPSULE, EXTENDED RELEASE;ORAL | | | | |
| CYCLOBENZAPRINE HYDROCHLORIDE | | | | |
| | TWI PHARMS INC | 15MG | A091281 001 | Jan 31, 2013 |
| | | 30MG | A091281 002 | Jan 31, 2013 |
| TABLET;ORAL | | | | |
| CYCLOBENZAPRINE HYDROCHLORIDE | | | | |
| | SANDOZ | 10MG | A073683 001 | Feb 26, 1993 |
| | UPSHER-SMITH LABS | 5MG | A072854 002 | Feb 03, 2006 |
| | | 10MG | A072854 001 | Nov 19, 1991 |
| | WATSON LABS | 10MG | A073143 001 | Nov 27, 1991 |
| | | 10MG | A074436 001 | Nov 30, 1994 |
| FLEXERIL | | | | |
| + | JANSSEN RES AND DEV | 5MG ** | N017821 001 | |
| + | | 10MG ** | N017821 002 | |
| CYCLOPENTOLATE HYDROCHLORIDE | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | |
| AK-PENTOLATE | | | | |
| | AKORN | 1% | A085555 001 | |
| AKPENTOLATE | | | | |
| | AKORN | 2% | A040165 001 | Jan 13, 1997 |
| CYCLOPENTOLATE HYDROCHLORIDE | | | | |
| | ALCON PHARMS LTD | 1% | A089162 001 | Jan 24, 1991 |
| | SOLA BARNES HIND | 1% | A084150 001 | |
| | | 1% | A084863 001 | |
| PENTOLAIR | | | | |
| | PHARMAFAIR | 0.5% | A088643 001 | Feb 09, 1987 |
| | | 1% | A088150 001 | Feb 25, 1983 |
| CYCLOPHOSPHAMIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| CYCLOPHOSPHAMIDE | | | | |
| | BAXTER HLTHCARE | 100MG/VIAL | A088371 001 | Jul 03, 1986 |
| | | 200MG/VIAL | A088372 001 | Jul 03, 1986 |
| | | 500MG/VIAL | A088373 001 | Jul 03, 1986 |
| | | 1GM/VIAL | A088374 001 | Sep 24, 1986 |
| CYTOXAN | | | | |
| + | BAXTER HLTHCARE | 100MG/VIAL ** | N012142 001 | |
| + | | 200MG/VIAL ** | N012142 002 | |
| CYTOXAN (LYOPHILIZED) | | | | |
| + | BAXTER HLTHCARE | 500MG/VIAL | N012142 003 | |
| + | | 500MG/VIAL ** | N012142 008 | Jan 04, 1984 |
| + | | 1GM/VIAL | N012142 004 | Aug 30, 1982 |
| + | | 1GM/VIAL ** | N012142 010 | Sep 24, 1985 |
| + | | 2GM/VIAL | N012142 005 | Aug 30, 1982 |
| + | | 2GM/VIAL ** | N012142 009 | Dec 10, 1985 |

| | | | | | |
|---|---|---|---|---|---|
| CYCLOPHOSPHAMIDE | | | | | |
| INJECTABLE;INJECTION | | | | | |
| LYOPHILIZED CYTOXAN | | | | | |
| + | BAXTER HLTHCARE | 100MG/VIAL ** | N012142 | 006 | Dec 05, 1985 |
| + | | 200MG/VIAL ** | N012142 | 007 | Dec 10, 1985 |
| NEOSAR | | | | | |
| | BEDFORD | 100MG/VIAL | A087442 | 001 | Feb 16, 1982 |
| | | 200MG/VIAL | A087442 | 002 | Feb 16, 1982 |
| | | 500MG/VIAL | A087442 | 003 | Feb 16, 1982 |
| | | 1GM/VIAL | A087442 | 004 | Jul 08, 1983 |
| | | 2GM/VIAL | A087442 | 005 | Mar 30, 1989 |
| | TEVA PARENTERAL | 100MG/VIAL | A040015 | 001 | Apr 29, 1993 |
| | | 200MG/VIAL | A040015 | 002 | Apr 29, 1993 |
| | | 500MG/VIAL | A040015 | 003 | Apr 29, 1993 |
| | | 1GM/VIAL | A040015 | 004 | Apr 29, 1993 |
| | | 2GM/VIAL | A040015 | 005 | Apr 29, 1993 |
| TABLET;ORAL | | | | | |
| CYCLOPHOSPHAMIDE | | | | | |
| | ROXANE | 25MG | A040032 | 001 | Aug 17, 1999 |
| | | 50MG | A040032 | 002 | Aug 17, 1999 |
| CYTOXAN | | | | | |
| + | BAXTER HLTHCARE | 25MG ** | N012141 | 002 | |
| + | | 50MG ** | N012141 | 001 | |
| CYCLOSPORINE | | | | | |
| CAPSULE;ORAL | | | | | |
| NEORAL | | | | | |
| + | NOVARTIS | 50MG ** | N050715 | 003 | Jul 14, 1995 |
| SOLUTION;ORAL | | | | | |
| CYCLOSPORINE | | | | | |
| | APOTEX INC | 100MG/ML | A065167 | 001 | Jan 05, 2005 |
| CYCLOTHIAZIDE | | | | | |
| TABLET;ORAL | | | | | |
| ANHYDRON | | | | | |
| | LILLY | 2MG | N013157 | 002 | |
| FLUIDIL | | | | | |
| | PHARMACIA AND UPJOHN | 2MG | N018173 | 001 | |
| CYCRIMINE HYDROCHLORIDE | | | | | |
| TABLET;ORAL | | | | | |
| PAGITANE | | | | | |
| | LILLY | 1.25MG | N008951 | 001 | |
| | | 2.5MG | N008951 | 002 | |
| CYPROHEPTADINE HYDROCHLORIDE | | | | | |
| SYRUP;ORAL | | | | | |
| CYPROHEPTADINE HYDROCHLORIDE | | | | | |
| | ACTAVIS MID ATLANTIC | 2MG/5ML ** | A086833 | 001 | |
| | HALSEY | 2MG/5ML | A089199 | 001 | Jul 03, 1986 |
| | MORTON GROVE | 2MG/5ML | A087001 | 001 | Nov 04, 1982 |
| | NASKA | 2MG/5ML | A089021 | 001 | Dec 21, 1987 |
| PERIACTIN | | | | | |
| + | MERCK | 2MG/5ML ** | N013220 | 002 | |
| TABLET;ORAL | | | | | |
| CYPROHEPTADINE HYDROCHLORIDE | | | | | |
| | AM THERAP | 4MG | A088798 | 001 | Feb 15, 1985 |
| | ASCOT | 4MG | A087685 | 001 | Oct 25, 1982 |
| | CHARTWELL RX | 4MG | A088212 | 001 | May 26, 1983 |
| | DURAMED PHARMS BARR | 4MG | A088232 | 001 | Oct 25, 1983 |
| | HALSEY | 4MG | A089057 | 001 | Jul 03, 1986 |
| | KV PHARM | 4MG | A086737 | 001 | |
| | MD PHARM | 4MG | A087566 | 001 | Nov 10, 1982 |
| | MYLAN | 4MG | A086678 | 001 | |
| | PIONEER PHARMS | 4MG | A087839 | 001 | Feb 08, 1984 |
| | PLIVA | 4MG | A088205 | 001 | Jul 26, 1983 |
| | SANDOZ | 4MG | A086808 | 001 | |
| | SUPERPHARM | 4MG | A087405 | 001 | |
| | VITARINE | 4MG | A087284 | 001 | |
| | WATSON LABS | 4MG | A085245 | 001 | |
| | | 4MG | A086165 | 001 | |

| | | | | |
|---|---|---|---|---|
| CYPROHEPTADINE HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| CYPROHEPTADINE HYDROCHLORIDE | | | | |
| | 4MG | | A086580 001 | |
| PERIACTIN | | | | |
| + MERCK | 4MG ** | | N012649 001 | |
| CYSTEINE HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| CYSTEINE HYDROCHLORIDE | | | | |
| + HOSPIRA | 7.25% ** | | N019523 001 | Oct 22, 1986 |
| CYTARABINE | | | | |
| INJECTABLE;INJECTION | | | | |
| CYTARABINE | | | | |
| + TEVA PARENTERAL | 100MG/VIAL ** | | N016793 001 | |
| + | 500MG/VIAL ** | | N016793 002 | |
| + | 1GM/VIAL ** | | N016793 003 | Dec 21, 1987 |
| + | 2GM/VIAL ** | | N016793 004 | Dec 21, 1987 |
| CYTOSAR-U | | | | |
| TEVA PHARMS USA | 100MG/VIAL | | A075206 001 | Dec 30, 1998 |
| | 500MG/VIAL | | A075206 002 | Dec 30, 1998 |
| | 1GM/VIAL | | A075206 004 | Dec 30, 1998 |
| | 2GM/VIAL | | A075206 003 | Dec 30, 1998 |
| DACARBAZINE | | | | |
| INJECTABLE;INJECTION | | | | |
| DACARBAZINE | | | | |
| ABRAXIS PHARM | 100MG/VIAL | | A070962 001 | Aug 28, 1986 |
| | 200MG/VIAL | | A070990 001 | Aug 28, 1986 |
| DTIC-DOME | | | | |
| + BAYER HLTHCARE | 100MG/VIAL | | N017575 001 | |
| + | 200MG/VIAL | | N017575 002 | |
| DACTINOMYCIN | | | | |
| INJECTABLE;INJECTION | | | | |
| DACTINOMYCIN | | | | |
| WEST-WARD PHARMS INT | 0.5MG/VIAL | | A090304 001 | Mar 16, 2010 |
| DALFOPRISTIN; QUINUPRISTIN | | | | |
| INJECTABLE;IV (INFUSION) | | | | |
| SYNERCID | | | | |
| KING PHARMS | 420MG/VIAL;180MG/VIAL | | N050748 002 | Aug 24, 2000 |
| DALTEPARIN SODIUM | | | | |
| INJECTABLE;INJECTION | | | | |
| FRAGMIN | | | | |
| PFIZER INC | 7,500 IU/0.75ML | | N020287 008 | Apr 04, 2002 |
| INJECTABLE;SUBCUTANEOUS | | | | |
| FRAGMIN | | | | |
| PFIZER INC | 10,000IU/0.4ML (25,000IU/ML) | | N020287 002 | May 01, 2007 |
| | 95,000IU/9.5ML (10,000IU/ML) | | N020287 007 | Apr 04, 2002 |
| DANAPAROID SODIUM | | | | |
| INJECTABLE;INJECTION | | | | |
| ORGARAN | | | | |
| ASPEN GLOBAL INC | 750 UNITS/0.6ML | | N020430 001 | Dec 24, 1996 |
| DANAZOL | | | | |
| CAPSULE;ORAL | | | | |
| DANAZOL | | | | |
| AM THERAP | 200MG | | A071569 001 | Dec 30, 1987 |
| DANOCRINE | | | | |
| SANOFI AVENTIS US | 50MG | | N017557 003 | |
| | 100MG | | N017557 004 | |
| | 200MG | | N017557 002 | |
| DAPIPRAZOLE HYDROCHLORIDE | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | |
| DAPIPRAZOLE HYDROCHLORIDE | | | | |
| + FERA PHARMS | 0.5% ** | | N019849 001 | Dec 31, 1990 |

DAPTOMYCIN
POWDER;IV (INFUSION)
CUBICIN
CUBIST PHARMS LLC 250MG/VIAL N021572 001 Sep 12, 2003

DARUNAVIR ETHANOLATE
TABLET;ORAL
PREZISTA
\+ JANSSEN PRODS EQ 300MG BASE ** N021976 001 Jun 23, 2006
\+ EQ 400MG BASE ** N021976 003 Oct 21, 2008

DAUNORUBICIN CITRATE
INJECTABLE, LIPOSOMAL;INJECTION
DAUNOXOME
GALEN (UK) EQ 2MG BASE/ML N050704 002 Apr 08, 1996

DAUNORUBICIN HYDROCHLORIDE
INJECTABLE;INJECTION
CERUBIDINE
SANOFI AVENTIS US EQ 20MG BASE/VIAL A061876 001
WYETH AYERST EQ 20MG BASE/VIAL N050484 001
DAUNORUBICIN HYDROCHLORIDE
TEVA PARENTERAL EQ 20MG BASE/VIAL A064212 001 Jun 23, 1998
EQ 50MG BASE/VIAL A064212 002 May 03, 1999

DECAMETHONIUM BROMIDE
INJECTABLE;INJECTION
SYNCURINE
GLAXOSMITHKLINE 1MG/ML N006931 002

DEFEROXAMINE MESYLATE
INJECTABLE;INJECTION
DEFEROXAMINE MESYLATE
WATSON LABS 500MG/VIAL A076806 001 Mar 31, 2006
2GM/VIAL A076806 002 Mar 31, 2006

DEMECARIUM BROMIDE
SOLUTION/DROPS;OPHTHALMIC
HUMORSOL
MERCK 0.125% N011860 002
0.25% N011860 001

DEMECLOCYCLINE HYDROCHLORIDE
CAPSULE;ORAL
DECLOMYCIN
LEDERLE 150MG N050262 001
SYRUP;ORAL
DECLOMYCIN
LEDERLE 75MG/5ML N050257 001
TABLET;ORAL
DECLOMYCIN
COREPHARMA 75MG N050261 001
150MG N050261 002
300MG N050261 003
DEMECLOCYCLINE HYDROCHLORIDE
IMPAX LABS 150MG A065094 001 Mar 22, 2004
300MG A065094 002 Mar 22, 2004

DESERPIDINE
TABLET;ORAL
HARMONYL
ABBVIE 0.1MG N010796 001
0.25MG N010796 002

DESERPIDINE; HYDROCHLOROTHIAZIDE
TABLET;ORAL
ORETICYL 25
ABBVIE 0.125MG;25MG N012148 001
ORETICYL 50
ABBVIE 0.125MG;50MG N012148 003
ORETICYL FORTE
ABBVIE 0.25MG;25MG N012148 002

DESERPIDINE; METHYCLOTHIAZIDE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| ENDURONYL | | | | |
| | ABBOTT | 0.25MG;5MG | N012775 001 | |
| ENDURONYL FORTE | | | | |
| | ABBOTT | 0.5MG;5MG | N012775 002 | |
| METHYCLOTHIAZIDE AND DESERPIDINE | | | | |
| | WATSON LABS | 0.25MG;5MG | A088486 001 | Aug 10, 1984 |
| | | 0.5MG;5MG | A088452 001 | Aug 10, 1984 |

DESIPRAMINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| CAPSULE;ORAL | | | | |
| PERTOFRANE | | | | |
| | SANOFI AVENTIS US | 25MG | N013621 001 | |
| | | 50MG | N013621 002 | |
| TABLET;ORAL | | | | |
| DESIPRAMINE HYDROCHLORIDE | | | | |
| | ANI PHARMS INC | 100MG | A071803 001 | May 29, 1997 |
| | USL PHARMA | 25MG | A071864 001 | Sep 09, 1987 |
| | | 50MG | A071865 001 | Sep 09, 1987 |
| | | 75MG | A071866 001 | Sep 09, 1987 |
| | | 100MG | A071867 001 | Sep 09, 1987 |

DESLANOSIDE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| CEDILANID-D | | | | |
| | NOVARTIS | 0.2MG/ML | N009282 002 | |

DESMOPRESSIN ACETATE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| DDAVP | | | | |
| | FERRING PHARMS INC | 0.015MG/ML | N018938 002 | Apr 25, 1995 |
| DESMOPRESSIN ACETATE | | | | |
| | BEDFORD | 0.004MG/ML | A074575 001 | Feb 18, 2000 |
| | HOSPIRA | 0.004MG/ML | A075220 001 | Aug 28, 2000 |
| | TEVA PHARMS USA | 0.004MG/ML | A074888 001 | Oct 15, 1997 |
| DESMOPRESSIN ACETATE PRESERVATIVE FREE | | | | |
| | BEDFORD | 0.004MG/ML | A074574 001 | Feb 18, 2000 |
| SOLUTION;NASAL | | | | |
| CONCENTRAID | | | | |
| | FERRING | 0.01% | N019776 001 | Dec 26, 1990 |
| SPRAY, METERED;NASAL | | | | |
| DDAVP | | | | |
| + | FERRING PHARMS INC | 0.01MG/SPRAY ** | N017922 002 | Feb 06, 1989 |
| STIMATE | | | | |
| | FERRING PHARMS INC | 0.15MG/SPRAY | N020355 001 | Mar 07, 1994 |
| TABLET;ORAL | | | | |
| DESMOPRESSIN ACETATE | | | | |
| | FERRING | 0.1MG | N021795 001 | May 08, 2008 |
| | | 0.2MG | N021795 002 | May 08, 2008 |

DESOGESTREL; ETHINYL ESTRADIOL

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL-21 | | | | |
| DESOGEN | | | | |
| | ORGANON USA INC | 0.15MG;0.03MG | N020071 001 | Dec 10, 1992 |
| DESOGESTREL AND ETHINYL ESTRADIOL | | | | |
| | DURAMED PHARMS BARR | 0.15MG;0.03MG | A075256 001 | Aug 12, 1999 |
| ORTHO-CEPT | | | | |
| | JANSSEN PHARMS | 0.15MG;0.03MG | N020301 001 | Dec 14, 1992 |
| TABLET;ORAL-28 | | | | |
| MIRCETTE | | | | |
| + | TEVA BRANDED PHARM | 0.15MG,N/A;0.02MG,0.01MG ** | N020713 001 | Apr 22, 1998 |
| ORTHO-CEPT | | | | |
| | JANSSEN PHARMS | 0.15MG;0.03MG | N020301 002 | Dec 14, 1992 |

DESOXIMETASONE

| | | | | |
|---|---|---|---|---|
| CREAM;TOPICAL | | | | |
| TOPICORT | | | | |
| + | TARO | 0.25% ** | N017856 001 | |
| TOPICORT LP | | | | |
| + | TARO | 0.05% ** | N018309 001 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| DESOXIMETASONE | | | | |
| GEL;TOPICAL | | | | |
| TOPICORT | | | | |
| + TARO | 0.05% ** | N018586 | 001 | Mar 29, 1982 |
| OINTMENT;TOPICAL | | | | |
| DESOXIMETASONE | | | | |
| ALTANA | 0.25% | A073440 | 001 | Apr 01, 1998 |
| TOPICORT | | | | |
| + TARO | 0.25% ** | N018763 | 001 | Sep 30, 1983 |
| DESOXYCORTICOSTERONE ACETATE | | | | |
| INJECTABLE;INJECTION | | | | |
| DOCA | | | | |
| ORGANON USA INC | 5MG/ML | N001104 | 001 | |
| PELLET;IMPLANTATION | | | | |
| PERCORTEN | | | | |
| NOVARTIS | 125MG | N005151 | 001 | |
| DESOXYCORTICOSTERONE PIVALATE | | | | |
| INJECTABLE;INJECTION | | | | |
| PERCORTEN | | | | |
| NOVARTIS | 25MG/ML | N008822 | 001 | |
| DESVENLAFAXINE FUMARATE | | | | |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| DESVENLAFAXINE | | | | |
| TEVA PHARMS USA | EQ 50MG BASE | N205208 | 001 | Oct 11, 2013 |
| | EQ 100MG BASE | N205208 | 002 | Oct 11, 2013 |
| DEXAMETHASONE | | | | |
| AEROSOL;TOPICAL | | | | |
| AEROSEB-DEX | | | | |
| ALLERGAN HERBERT | 0.01% ** | A083296 | 002 | |
| DECASPRAY | | | | |
| + MERCK | 0.04% ** | N012731 | 002 | |
| ELIXIR;ORAL | | | | |
| DECADRON | | | | |
| MERCK | 0.5MG/5ML | N012376 | 002 | |
| DEXAMETHASONE | | | | |
| ALPHARMA US PHARMS | 0.5MG/5ML | A088997 | 001 | Oct 10, 1986 |
| HEXADROL | | | | |
| ORGANON USA INC | 0.5MG/5ML | N012674 | 001 | |
| GEL;TOPICAL | | | | |
| DECADERM | | | | |
| MERCK | 0.1% | N013538 | 001 | |
| SUSPENSION/DROPS;OPHTHALMIC | | | | |
| DEXAMETHASONE | | | | |
| WATSON LABS | 0.1% | A089170 | 001 | May 09, 1989 |
| TABLET;ORAL | | | | |
| DECADRON | | | | |
| + MERCK | 0.25MG ** | N011664 | 004 | |
| + | 0.5MG ** | N011664 | 001 | |
| + | 0.75MG ** | N011664 | 002 | |
| + | 1.5MG ** | N011664 | 003 | |
| + | 4MG ** | N011664 | 005 | |
| + | 6MG ** | N011664 | 006 | Jul 30, 1982 |
| DEXAMETHASONE | | | | |
| IDT AUSTRALIA LTD | 0.75MG | A080399 | 001 | |
| IMPAX LABS | 0.75MG | A085376 | 001 | |
| PAR PHARM | 0.25MG | A088149 | 001 | Apr 28, 1983 |
| PHOENIX LABS NY | 0.75MG | A083806 | 001 | |
| PVT FORM | 0.75MG | A083420 | 001 | |
| ROXANE | 0.25MG | A084614 | 001 | |
| SUN PHARM INDUSTRIES | 0.25MG | A084013 | 001 | |
| | 0.25MG | A084764 | 001 | |
| | 0.5MG | A084084 | 001 | |
| | 0.5MG | A084766 | 001 | |
| | 0.75MG | A084081 | 001 | |
| | 0.75MG | A084765 | 001 | |
| | 1.5MG | A084086 | 001 | |
| | 1.5MG | A084763 | 001 | |

| | | | | |
|---|---|---|---|---|
| DEXAMETHASONE | | | | |
| TABLET;ORAL | | | | |
| DEXAMETHASONE | | | | |
| | UPSHER SMITH | 0.75MG | A087534 001 | |
| | | 1.5MG | A087533 001 | |
| | WATSON LABS | 0.25MG | A085455 001 | |
| | | 0.5MG | A085458 001 | |
| | | 0.75MG | A080968 001 | |
| | | 0.75MG | A084457 001 | |
| | | 0.75MG | A085818 001 | |
| | | 1.5MG | A085456 001 | |
| | | 1.5MG | A085840 001 | |
| | WHITEWORTH TOWN PLSN | 0.75MG | A084327 001 | |
| DEXONE 0.5 | | | | |
| | SOLVAY | 0.5MG | A084991 001 | |
| DEXONE 0.75 | | | | |
| | SOLVAY | 0.75MG | A084993 001 | |
| DEXONE 1.5 | | | | |
| | SOLVAY | 1.5MG | A084990 001 | |
| DEXONE 4 | | | | |
| | SOLVAY | 4MG | A084992 001 | |
| HEXADROL | | | | |
| | ASPEN GLOBAL INC | 0.5MG | N012675 004 | |
| | | 0.75MG | N012675 007 | |
| | | 1.5MG | N012675 009 | |
| | | 4MG | N012675 010 | |
| DEXAMETHASONE ACETATE | | | | |
| INJECTABLE;INJECTION | | | | |
| DECADRON-LA | | | | |
| + | MERCK | EQ 8MG BASE/ML ** | N016675 001 | |
| DEXAMETHASONE ACETATE | | | | |
| | WATSON LABS | EQ 8MG BASE/ML | A084315 001 | |
| | WATSON LABS TEVA | EQ 16MG BASE/ML | A087711 001 | May 24, 1982 |
| DEXAMETHASONE SODIUM PHOSPHATE | | | | |
| AEROSOL;NASAL | | | | |
| DEXACORT | | | | |
| | UCB INC | EQ 0.1MG PHOSPHATE/INH | N014242 001 | |
| AEROSOL, METERED;INHALATION | | | | |
| DEXACORT | | | | |
| | UCB INC | EQ 0.1MG PHOSPHATE/INH | N013413 001 | |
| CREAM;TOPICAL | | | | |
| DECADRON | | | | |
| | MERCK | EQ 0.1% PHOSPHATE | N011983 002 | |
| INJECTABLE;INJECTION | | | | |
| DECADRON | | | | |
| + | MERCK | EQ 4MG PHOSPHATE/ML ** | N012071 002 | |
| + | | EQ 24MG PHOSPHATE/ML ** | N012071 004 | |
| DEXACEN-4 | | | | |
| | CENT PHARMS | EQ 4MG PHOSPHATE/ML | A084342 001 | |
| DEXAMETHASONE | | | | |
| | ABRAXIS PHARM | EQ 4MG PHOSPHATE/ML | A088448 001 | Jan 25, 1984 |
| | FRESENIUS KABI USA | EQ 10MG PHOSPHATE/ML | A088469 001 | Jan 25, 1984 |
| DEXAMETHASONE SODIUM PHOSPHATE | | | | |
| | AKORN | EQ 4MG PHOSPHATE/ML | A084493 001 | |
| | BEL MAR | EQ 4MG PHOSPHATE/ML | A084752 001 | |
| | DELL LABS | EQ 4MG PHOSPHATE/ML | A083161 001 | |
| | INTL MEDICATION | EQ 20MG PHOSPHATE/ML | A088522 001 | Feb 17, 1984 |
| | LYPHOMED | EQ 4MG PHOSPHATE/ML | A087065 001 | |
| | TEVA PARENTERAL | EQ 4MG PHOSPHATE/ML | A081125 001 | Aug 31, 1990 |
| | | EQ 10MG PHOSPHATE/ML | A081126 001 | Aug 31, 1990 |
| | WATSON LABS | EQ 4MG PHOSPHATE/ML | A083702 001 | |
| | | EQ 4MG PHOSPHATE/ML | A084355 001 | |
| | | EQ 4MG PHOSPHATE/ML | A089169 001 | Apr 09, 1986 |
| | | EQ 10MG PHOSPHATE/ML | A087668 001 | Jul 01, 1982 |
| | | EQ 24MG PHOSPHATE/ML | A085606 001 | |
| | WYETH AYERST | EQ 4MG PHOSPHATE/ML | A085641 001 | |
| HEXADROL | | | | |
| + | ORGANON USA INC | EQ 4MG PHOSPHATE/ML ** | N014694 002 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

DEXAMETHASONE SODIUM PHOSPHATE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| HEXADROL | | | | |
| + | EQ 10MG PHOSPHATE/ML ** | N014694 | 003 | |
| | EQ 20MG PHOSPHATE/ML | N014694 | 004 | |
| OINTMENT;OPHTHALMIC | | | | |
| DECADRON | | | | |
| MERCK | EQ 0.05% PHOSPHATE | N011977 | 001 | |
| DEXAIR | | | | |
| PHARMAFAIR | EQ 0.05% PHOSPHATE | A088071 | 001 | Dec 28, 1982 |
| MAXIDEX | | | | |
| ALCON | EQ 0.05% PHOSPHATE | A083342 | 001 | |
| SOLUTION/DROPS;OPHTHALMIC | | | | |
| DEXAIR | | | | |
| PHARMAFAIR | EQ 0.1% PHOSPHATE | A088433 | 001 | Dec 15, 1983 |
| DEXAMETHASONE SODIUM PHOSPHATE | | | | |
| SOLA BARNES HIND | EQ 0.1% PHOSPHATE | A084170 | 001 | |
| | EQ 0.1% PHOSPHATE | A084173 | 001 | |
| SOLUTION/DROPS;OPHTHALMIC, OTIC | | | | |
| DECADRON | | | | |
| MERCK | EQ 0.1% PHOSPHATE | N011984 | 001 | |
| SOLUTION/DROPS;OTIC | | | | |
| DEXAMETHASONE SODIUM PHOSPHATE | | | | |
| AKORN | EQ 0.1% PHOSPHATE | A084855 | 001 | |

DEXAMETHASONE SODIUM PHOSPHATE; LIDOCAINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| DECADRON W/ XYLOCAINE | | | | |
| MERCK | EQ 4MG PHOSPHATE/ML;10MG/ML | N013334 | 002 | |

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE

| | | | | |
|---|---|---|---|---|
| OINTMENT;OPHTHALMIC | | | | |
| NEODECADRON | | | | |
| MERCK | EQ 0.05% PHOSPHATE;EQ 3.5MG BASE/GM | N050324 | 001 | |
| SOLUTION/DROPS;OPHTHALMIC | | | | |
| NEODECADRON | | | | |
| MERCK | EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML | N050322 | 001 | |
| NEOMYCIN SULFATE AND DEXAMETHASONE SODIUM PHOSPHATE | | | | |
| BAUSCH AND LOMB | EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML | A064055 | 001 | Oct 30, 1995 |
| NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE | | | | |
| ALCON PHARMS LTD | EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML | A062714 | 001 | Jul 21, 1986 |
| PHARMAFAIR | EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML | A062539 | 001 | Jan 10, 1985 |

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

| | | | | |
|---|---|---|---|---|
| OINTMENT;OPHTHALMIC | | | | |
| DEXACIDIN | | | | |
| NOVARTIS | 0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM | A062566 | 001 | Feb 22, 1985 |
| DEXASPORIN | | | | |
| PHARMAFAIR | 0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM | A062411 | 001 | May 16, 1983 |
| SUSPENSION/DROPS;OPHTHALMIC | | | | |
| DEXACIDIN | | | | |
| NOVARTIS | 0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML | A062544 | 001 | Oct 29, 1984 |
| DEXASPORIN | | | | |
| PHARMAFAIR | 0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML | A062428 | 001 | May 18, 1983 |
| NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE | | | | |
| ALCON PHARMS LTD | 0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML | A062721 | 001 | Nov 17, 1986 |

DEXBROMPHENIRAMINE MALEATE

| | | | | |
|---|---|---|---|---|
| SYRUP;ORAL | | | | |
| DISOMER | | | | |
| SCHERING | 2MG/5ML | N011814 | 002 | |
| TABLET;ORAL | | | | |
| DISOMER | | | | |
| SCHERING | 2MG | N011814 | 001 | |

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| DISOPHROL | | | | |
| SCHERING | 2MG;60MG | N012394 | 002 | |

| | | | | |
|---|---|---|---|---|
| DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE | | | | |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| BROMPHERIL | | | | |
| | COPLEY PHARM | 6MG;120MG | A089116 001 | Jan 22, 1987 |
| DISOBROM | | | | |
| | SANDOZ | 6MG;120MG | A070770 001 | Sep 30, 1991 |
| DISOPHROL | | | | |
| | SCHERING PLOUGH | 6MG;120MG | N013483 004 | Sep 13, 1982 |
| DRIXORAL | | | | |
| + | SCHERING PLOUGH | 6MG;120MG ** | N013483 003 | Sep 13, 1982 |
| RESPORAL | | | | |
| | PIONEER PHARMS | 6MG;120MG | A089139 001 | Jun 16, 1988 |
| DEXCHLORPHENIRAMINE MALEATE | | | | |
| SYRUP;ORAL | | | | |
| POLARAMINE | | | | |
| | SCHERING | 2MG/5ML | A086837 001 | Jul 19, 1982 |
| TABLET;ORAL | | | | |
| DEXCHLORPHENIRAMINE MALEATE | | | | |
| | ANI PHARMS INC | 2MG | A088682 001 | Jan 17, 1986 |
| POLARAMINE | | | | |
| | SCHERING | 2MG | A086835 001 | |
| DEXLANSOPRAZOLE | | | | |
| TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL | | | | |
| DEXILANT SOLUTAB | | | | |
| + | TAKEDA PHARMS USA | 30MG | N208056 001 | Jan 26, 2016 |
| DEXTROAMPHETAMINE SULFATE | | | | |
| CAPSULE;ORAL | | | | |
| DEXAMPEX | | | | |
| | TEVA | 15MG | A085355 001 | |
| CAPSULE, EXTENDED RELEASE;ORAL | | | | |
| DEXTROAMPHETAMINE SULFATE | | | | |
| | ABLE | 5MG | A076814 001 | Aug 25, 2004 |
| | | 10MG | A076814 002 | Aug 25, 2004 |
| | | 15MG | A076814 003 | Aug 25, 2004 |
| ELIXIR;ORAL | | | | |
| DEXEDRINE | | | | |
| | GLAXOSMITHKLINE | 5MG/5ML ** | A083902 001 | |
| TABLET;ORAL | | | | |
| DEXAMPEX | | | | |
| | TEVA | 5MG | A083735 001 | |
| | | 10MG | A083735 002 | |
| DEXEDRINE | | | | |
| | GLAXOSMITHKLINE | 5MG | A084935 001 | |
| DEXTROAMPHETAMINE SULFATE | | | | |
| | EPIC PHARMA LLC | 5MG | A090652 001 | Mar 07, 2014 |
| | | 10MG | A090652 002 | Mar 07, 2014 |
| | HALSEY | 10MG | A083930 001 | |
| | IDT AUSTRALIA LTD | 5MG | A085370 001 | |
| | LANNETT | 5MG | A083903 001 | |
| | | 10MG | A083903 003 | |
| | | 15MG | A085652 001 | |
| | MAST MM | 5MG | A086521 001 | |
| | NESHER PHARMS | 5MG | A040365 001 | Oct 31, 2002 |
| | | 10MG | A040367 001 | Oct 31, 2002 |
| | PUREPAC PHARM | 5MG | A084125 001 | |
| | SANDOZ | 10MG | A085371 001 | |
| | VINTAGE PHARMS LLC | 5MG | A040299 001 | May 13, 1999 |
| | VITARINE | 5MG | A084986 001 | |
| | | 10MG | A085892 001 | |
| DEXTROSTAT | | | | |
| | SHIRE | 5MG ** | A084051 001 | |
| | | 10MG ** | A084051 002 | |
| FERNDEX | | | | |
| | FERNDALE LABS | 5MG | A084001 001 | |

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

| | | | | | |
|---|---|---|---|---|---|
| PHERAZINE DM | | | | | |
| | HALSEY | 15MG/5ML;6.25MG/5ML | A088913 | 001 | Mar 02, 1987 |
| PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE | | | | | |
| | AMNEAL PHARMS | 15MG/5ML;6.25MG/5ML | A090575 | 001 | Feb 08, 2011 |
| + | ANI PHARMS | 15MG/5ML;6.25MG/5ML ** | N011265 | 002 | Apr 02, 1984 |
| | TRIS PHARMA INC | 15MG/5ML;6.25MG/5ML | A091687 | 001 | Jun 28, 2012 |

DEXTROSE

INJECTABLE;INJECTION

| | | | | |
|---|---|---|---|---|
| DEXTROSE 10% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 10GM/100ML | N018046 | 001 | |
| MILES | 10GM/100ML | N018504 | 001 | |
| DEXTROSE 2.5% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 2.5GM/100ML | N018358 | 001 | |
| | 2.5GM/100ML | N019626 | 001 | Feb 02, 1988 |
| DEXTROSE 38.5% IN PLASTIC CONTAINER | | | | |
| ABBOTT | 38.5GM/100ML | N018923 | 001 | Sep 19, 1984 |
| DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| DHL | 5GM/100ML | N019971 | 001 | Sep 28, 1995 |
| DEXTROSE 50% IN PLASTIC CONTAINER | | | | |
| ICU MEDICAL INC | 50GM/100ML | N019894 | 001 | Dec 26, 1989 |
| DEXTROSE 60% | | | | |
| B BRAUN | 60GM/100ML | N017995 | 002 | Sep 22, 1982 |
| DEXTROSE 60% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 60GM/100ML | N017995 | 001 | |
| BAXTER HLTHCARE | 60GM/100ML | N020047 | 002 | Jul 02, 1991 |
| HOSPIRA | 60GM/100ML | N019346 | 001 | Jan 25, 1985 |
| DEXTROSE 7.7% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 7.7GM/100ML | N019626 | 003 | Feb 02, 1988 |

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE;INJECTION

| | | | | |
|---|---|---|---|---|
| ISOLYTE P W/ DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 5GM/100ML;31MG/100ML;130MG/100ML;26MG/100ML;320MG/100ML | N019025 | 001 | Dec 27, 1984 |

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE; SODIUM LACTATE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE;INJECTION

| | | | | |
|---|---|---|---|---|
| IONOSOL B AND DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| HOSPIRA | 5GM/100ML;53MG/100ML;100MG/100ML;100MG/100ML;180MG/100ML;280MG/100ML;16MG/100ML | N019515 | 001 | May 08, 1986 |

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

| | | | | |
|---|---|---|---|---|
| ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 5GM/100ML;30MG/100ML;97MG/100ML;220MG/100ML;140MG/100ML | N019844 | 001 | Jun 10, 1993 |
| ISOLYTE H W/ DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 5GM/100ML;30MG/100ML;97MG/100ML;220MG/100ML;140MG/100ML | N018273 | 001 | |

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

| | | | | |
|---|---|---|---|---|
| ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 5GM/100ML;30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML | N019843 | 001 | Aug 09, 1993 |
| ISOLYTE S W/ DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 5GM/100ML;30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML | N018274 | 001 | |
| PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| BAXTER HLTHCARE | 5GM/100ML;30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML | N017451 | 001 | |

DEXTROSE; POTASSIUM CHLORIDE

INJECTABLE;INJECTION

| | | | | |
|---|---|---|---|---|
| POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 5GM/100ML;37MG/100ML | N019699 | 001 | Sep 29, 1989 |
| POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 5GM/100ML;75MG/100ML | N018744 | 001 | Nov 09, 1982 |
| | 5GM/100ML;75MG/100ML | N019699 | 002 | Sep 29, 1989 |
| POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 5GM/100ML;110MG/100ML | N019699 | 003 | Sep 29, 1989 |
| POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 5GM/100ML;150MG/100ML | N018744 | 002 | Nov 09, 1982 |
| POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 5GM/100ML;220MG/100ML | N018744 | 003 | Nov 09, 1982 |
| | 5GM/100ML;220MG/100ML | N019699 | 005 | Sep 29, 1989 |
| POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 5GM/100ML;300MG/100ML | N018744 | 004 | Nov 09, 1982 |

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM LACTATE; SODIUM CHLORIDE; SODIUM PHOSPHATE, MONOBASIC ANHYDROUS

INJECTABLE;INJECTION

| | | | | |
|---|---|---|---|---|
| IONOSOL T AND DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| HOSPIRA | 5GM/100ML;111MG/100ML;256MG/100ML;146MG/100ML;207MG/100ML | N019514 | 001 | May 08, 1986 |

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

| | | | | |
|---|---|---|---|---|
| ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 5GM/100ML;150MG/100ML;130MG/100ML;280MG/100ML;91MG/100ML | N019870 | 001 | Jun 10, 1993 |
| ISOLYTE M W/ DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 5GM/100ML;150MG/100ML;130MG/100ML;280MG/100ML;91MG/100ML | N018270 | 001 | |

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

| | | | | |
|---|---|---|---|---|
| DEXTROSE 5% AND ELECTROLYTE NO. 75 IN PLASTIC CONTAINER | | | | |
| BAXTER HLTHCARE | 5GM/100ML;205MG/100ML;100MG/100ML;120MG/100ML;220MG/100ML | N018840 | 001 | Jun 29, 1983 |

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION

| | | | | |
|---|---|---|---|---|
| DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.075% | | | | |
| B BRAUN | 5GM/100ML;75MG/100ML;200MG/100ML | N018268 | 009 | |
| DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 5GM/100ML;150MG/100ML;200MG/100ML | N018268 | 004 | |
| DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 5GM/100ML;220MG/100ML;200MG/100ML | N018268 | 005 | |
| DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 5GM/100ML;300MG/100ML;200MG/100ML | N018268 | 006 | |
| DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 5GM/100ML;75MG/100ML;330MG/100ML | N018268 | 011 | Jan 18, 1986 |
| DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 5GM/100ML;150MG/100ML;330MG/100ML | N018268 | 012 | Jan 18, 1986 |
| DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 5GM/100ML;220MG/100ML;330MG/100ML | N018268 | 013 | Jan 18, 1986 |
| DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 0.30% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 5GM/100ML;300MG/100ML;330MG/100ML | N018268 | 014 | Jan 18, 1986 |
| DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.075% | | | | |
| B BRAUN | 5GM/100ML;75MG/100ML;450MG/100ML | N018268 | 010 | |
| DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 5GM/100ML;150MG/100ML;450MG/100ML | N018268 | 001 | |
| DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 5GM/100ML;220MG/100ML;450MG/100ML | N018268 | 002 | |
| DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 5GM/100ML;300MG/100ML;450MG/100ML | N018268 | 003 | |
| DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER | | | | |
| BAXTER HLTHCARE | 5GM/100ML;224MG/100ML;450MG/100ML | N018008 | 003 | |
| DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER | | | | |
| BAXTER HLTHCARE | 5GM/100ML;300MG/100ML;450MG/100ML | N018008 | 001 | |
| DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER | | | | |
| BAXTER HLTHCARE | 5GM/100ML;75MG/100ML;450MG/100ML | N018008 | 002 | |

DEXTROSE; SODIUM CHLORIDE

INJECTABLE;INJECTION

| | | | | |
|---|---|---|---|---|
| DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER | | | | |
| | B BRAUN | 10GM/100ML;200MG/100ML | N018386 001 | |
| DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER | | | | |
| | B BRAUN | 10GM/100ML;450MG/100ML | N018229 001 | |
| DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | | | | |
| | B BRAUN | 10GM/100ML;900MG/100ML | N018047 001 | |
| | BAXTER HLTHCARE | 10GM/100ML;900MG/100ML | N016696 001 | |
| DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER | | | | |
| | B BRAUN | 2.5GM/100ML;450MG/100ML | N018030 001 | |
| | HOSPIRA | 2.5GM/100ML;450MG/100ML | N018096 001 | |
| DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | | | | |
| | B BRAUN | 2.5GM/100ML;900MG/100ML | N018376 001 | |
| DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER | | | | |
| | ABBOTT | 3.3GM/100ML;300MG/100ML | N018055 001 | |
| DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER | | | | |
| | B BRAUN | 5GM/100ML;110MG/100ML | N018030 005 | |
| DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER | | | | |
| | B BRAUN | 5GM/100ML;200MG/100ML | N018030 004 | |
| | MILES | 5GM/100ML;200MG/100ML | N018399 001 | |
| DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER | | | | |
| | ABBOTT | 5GM/100ML;225MG/100ML | N019482 001 | Oct 04, 1985 |
| DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER | | | | |
| | ABBOTT | 5GM/100ML;300MG/100ML | N019486 001 | Oct 04, 1985 |
| | MILES | 5GM/100ML;300MG/100ML | N018501 001 | |
| DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER | | | | |
| | B BRAUN | 5GM/100ML;330MG/100ML | N018030 003 | |
| DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER | | | | |
| | ABBOTT | 5GM/100ML;450MG/100ML | N019484 001 | Oct 04, 1985 |
| | B BRAUN | 5GM/100ML;450MG/100ML | N018030 002 | |
| | MILES | 5GM/100ML;450MG/100ML | N018400 001 | |
| DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | | | | |
| | ABBOTT | 5GM/100ML;900MG/100ML | N019483 001 | Oct 04, 1985 |
| | B BRAUN | 5GM/100ML;900MG/100ML | N018026 001 | |
| | MILES | 5GM/100ML;900MG/100ML | N018500 001 | |

DEXTROTHYROXINE SODIUM

TABLET;ORAL

| | | | | |
|---|---|---|---|---|
| CHOLOXIN | | | | |
| | ABBVIE | 1MG | N012302 005 | |
| | | 2MG | N012302 002 | |
| | | 4MG | N012302 004 | |
| | | 6MG | N012302 006 | |

DEZOCINE

INJECTABLE;INJECTION

| | | | | |
|---|---|---|---|---|
| DALGAN | | | | |
| | ASTRAZENECA | 5MG/ML | N019082 001 | Dec 29, 1989 |
| | | 10MG/ML | N019082 002 | Dec 29, 1989 |
| | | 15MG/ML | N019082 003 | Dec 29, 1989 |

DIATRIZOATE MEGLUMINE

INJECTABLE;INJECTION

| | | | | |
|---|---|---|---|---|
| ANGIOVIST 282 | | | | |
| | BAYER HLTHCARE | 60% | A087726 001 | Sep 23, 1982 |
| CARDIOGRAFIN | | | | |
| | BRACCO | 85% | N011620 002 | |
| DIATRIZOATE MEGLUMINE | | | | |
| | BRACCO | 76% | N010040 017 | |
| HYPAQUE | | | | |
| | GE HEALTHCARE | 30% | N016403 002 | |
| | | 60% | N016403 001 | |
| RENO-60 | | | | |
| | BRACCO | 60% | N010040 016 | |
| RENO-DIP | | | | |
| | BRACCO | 30% | N010040 012 | |
| UROVIST MEGLUMINE DIU/CT | | | | |
| | BAYER HLTHCARE | 30% | A087739 001 | Sep 23, 1982 |

DIATRIZOATE MEGLUMINE

| | | | | |
|---|---|---|---|---|
| SOLUTION;URETERAL | | | | |
| RENO-30 | | | | |
| | BRACCO | 30% | N010040 021 | |
| UROVIST CYSTO | | | | |
| | BAYER HLTHCARE | 30% | A087729 001 | Sep 23, 1982 |
| UROVIST CYSTO PEDIATRIC | | | | |
| | BAYER HLTHCARE | 30% | A087731 001 | Sep 23, 1982 |
| SOLUTION;URETHRAL | | | | |
| HYPAQUE-CYSTO | | | | |
| | GE HEALTHCARE | 30% | N016403 003 | |

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| ANGIOVIST 292 | | | | |
| | BAYER HLTHCARE | 52%;8% | A087724 001 | Sep 23, 1982 |
| ANGIOVIST 370 | | | | |
| | BAYER HLTHCARE | 66%;10% | A087723 001 | Sep 23, 1982 |
| DIATRIZOATE-60 | | | | |
| | INTL MEDICATION | 52%;8% | A088166 001 | Jun 17, 1983 |
| HYPAQUE-76 | | | | |
| | GE HEALTHCARE | 66%;10% | A086505 001 | |
| HYPAQUE-M,75% | | | | |
| | GE HEALTHCARE | 50%;25% | N010220 003 | |
| HYPAQUE-M,90% | | | | |
| | GE HEALTHCARE | 60%;30% | N010220 002 | |
| MD-60 | | | | |
| | MALLINCKRODT | 52%;8% | A087074 001 | |
| MD-76 | | | | |
| | MALLINCKRODT | 66%;10% | A087073 001 | |
| MD-76R | | | | |
| + | LIEBEL-FLARSHEIM | 66%;10% | N019292 001 | Sep 29, 1989 |
| RENOCAL-76 | | | | |
| | BRACCO | 66%;10% | A089347 001 | Jun 01, 1988 |
| RENOGRAFIN-60 | | | | |
| | BRACCO | 52%;8% | N010040 006 | |
| RENOVIST | | | | |
| | BRACCO | 34.3%;35% | N010040 020 | |
| RENOVIST II | | | | |
| | BRACCO | 28.5%;29.1% | N010040 019 | |
| SOLUTION;ORAL, RECTAL | | | | |
| GASTROVIST | | | | |
| | BAYER HLTHCARE | 66%;10% | A087728 001 | Sep 23, 1982 |

DIATRIZOATE SODIUM

| | | | | |
|---|---|---|---|---|
| FOR SOLUTION;ORAL, RECTAL | | | | |
| HYPAQUE | | | | |
| | GE HEALTHCARE | 100% | N011386 001 | |
| INJECTABLE;INJECTION | | | | |
| HYPAQUE | | | | |
| | GE HEALTHCARE | 25% | N009561 003 | |
| | | 50% | N009561 001 | |
| MD-50 | | | | |
| | MALLINCKRODT | 50% | A087075 001 | |
| UROVIST SODIUM 300 | | | | |
| | BAYER HLTHCARE | 50% | A087725 001 | Sep 23, 1982 |
| SOLUTION;ORAL, RECTAL | | | | |
| HYPAQUE | | | | |
| | GE HEALTHCARE | 40% | N011386 003 | |
| SOLUTION;URETERAL | | | | |
| HYPAQUE SODIUM 20% | | | | |
| | GE HEALTHCARE | 20% | N009561 002 | |

DIAZEPAM

| | | | | |
|---|---|---|---|---|
| CAPSULE, EXTENDED RELEASE;ORAL | | | | |
| VALRELEASE | | | | |
| | ROCHE | 15MG | N018179 001 | |
| GEL;RECTAL | | | | |
| DIASTAT | | | | |
| + | VALEANT PHARMS NORTH | 5MG/ML (5MG/ML) ** | N020648 002 | Jul 29, 1997 |
| + | | 10MG/2ML (5MG/ML) ** | N020648 003 | Jul 29, 1997 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

DIAZEPAM

| | | | | | |
|---|---|---|---|---|---|
| GEL;RECTAL | | | | | |
| DIASTAT | | | | | |
| + | | 15MG/3ML (5MG/ML) ** | N020648 | 004 | Jul 29, 1997 |
| + | | 20MG/4ML (5MG/ML) ** | N020648 | 005 | Jul 29, 1997 |
| INJECTABLE;INJECTION | | | | | |
| DIAZEPAM | | | | | |
| | ABRAXIS PHARM | 5MG/ML | A070662 | 001 | Jun 25, 1986 |
| | HOSPIRA | 5MG/ML | A071584 | 001 | Oct 13, 1987 |
| | MARSAM PHARMS LLC | 5MG/ML | A072371 | 001 | Jan 29, 1993 |
| | PARENTA PHARMS | 5MG/ML | A076815 | 001 | Apr 15, 2004 |
| | US ARMY | 5MG/ML ** | N020124 | 001 | Dec 05, 1990 |
| | WARNER CHILCOTT | 5MG/ML | A071613 | 001 | Oct 22, 1987 |
| | | 5MG/ML | A071614 | 001 | Oct 22, 1987 |
| | WATSON LABS | 5MG/ML | A070296 | 001 | Feb 12, 1986 |
| | | 5MG/ML | A070911 | 001 | Aug 28, 1986 |
| | | 5MG/ML | A070912 | 001 | Aug 28, 1986 |
| | | 5MG/ML | A070930 | 001 | Dec 01, 1986 |
| | WATSON LABS INC | 5MG/ML | A072370 | 001 | Jan 29, 1993 |
| | | 5MG/ML | A072397 | 001 | Jan 29, 1993 |
| | WEST-WARD PHARMS INT | 5MG/ML | A070311 | 001 | Dec 16, 1985 |
| | | 5MG/ML | A070312 | 001 | Dec 16, 1985 |
| | | 5MG/ML | A070313 | 001 | Dec 16, 1985 |
| | | 5MG/ML | A071308 | 001 | Jul 17, 1987 |
| | | 5MG/ML | A071309 | 001 | Jul 17, 1987 |
| | | 5MG/ML | A071310 | 001 | Jul 17, 1987 |
| DIZAC | | | | | |
| | PHARMACIA AND UPJOHN | 5MG/ML ** | N019287 | 001 | Jun 18, 1993 |
| VALIUM | | | | | |
| + | ROCHE | 5MG/ML ** | N016087 | 001 | |
| TABLET;ORAL | | | | | |
| DIAZEPAM | | | | | |
| | ACTAVIS ELIZABETH | 2MG | A070781 | 001 | Mar 19, 1986 |
| | | 5MG | A070706 | 001 | Mar 19, 1986 |
| | | 10MG | A070707 | 001 | Mar 19, 1986 |
| | DAVA PHARMS INC | 10MG | A070228 | 001 | Sep 26, 1985 |
| | DURAMED PHARMS BARR | 2MG | A070894 | 001 | Aug 27, 1986 |
| | | 5MG | A070895 | 001 | Aug 27, 1986 |
| | | 10MG | A070896 | 001 | Aug 27, 1986 |
| | FERNDALE LABS | 2MG | A070903 | 001 | Apr 01, 1987 |
| | | 5MG | A070904 | 001 | Apr 01, 1987 |
| | | 10MG | A070905 | 001 | Apr 01, 1987 |
| | HALSEY | 2MG | A070987 | 001 | Aug 15, 1986 |
| | | 5MG | A070996 | 001 | Aug 15, 1986 |
| | | 10MG | A070956 | 001 | Aug 15, 1986 |
| | IVAX SUB TEVA PHARMS | 2MG | A070360 | 001 | Sep 04, 1985 |
| | | 5MG | A070361 | 001 | Sep 04, 1985 |
| | | 10MG | A070362 | 001 | Sep 04, 1985 |
| | MARTEC USA LLC | 10MG | A072402 | 001 | Apr 25, 1989 |
| | PIONEER PHARMS | 2MG | A070787 | 001 | Aug 02, 1988 |
| | | 5MG | A070788 | 001 | Aug 02, 1988 |
| | | 10MG | A070776 | 001 | Aug 02, 1988 |
| | ROXANE | 2MG | A070356 | 001 | Jun 17, 1986 |
| | | 5MG | A070357 | 001 | Jun 17, 1986 |
| | | 10MG | A070358 | 001 | Jun 17, 1986 |
| | TEVA PHARMS | 5MG | A070153 | 001 | Nov 01, 1985 |
| | UPSHER-SMITH LABS | 2MG | A070302 | 001 | Dec 20, 1985 |
| | | 5MG | A070303 | 001 | Dec 20, 1985 |
| | | 10MG | A070304 | 001 | Dec 20, 1985 |
| | VIRTUS PHARMS | 2MG | A070462 | 001 | Feb 25, 1986 |
| | | 5MG | A070463 | 001 | Feb 25, 1986 |
| | | 10MG | A070464 | 001 | Feb 25, 1986 |
| | WARNER CHILCOTT | 2MG | A070209 | 001 | Sep 04, 1985 |
| | | 5MG | A070210 | 001 | Sep 04, 1985 |
| | | 10MG | A070222 | 001 | Sep 04, 1985 |
| | WATSON LABS | 2MG | A070456 | 001 | Nov 01, 1985 |
| | | 5MG | A070457 | 001 | Nov 01, 1985 |
| | | 10MG | A070458 | 001 | Nov 01, 1985 |

| | | | | |
|---|---|---|---|---|
| DIAZEPAM | | | | |
| TABLET;ORAL | | | | |
| Q-PAM | | | | |
| | QUANTUM PHARMICS | 2MG | A070423 001 | Dec 12, 1985 |
| | | 2MG | A072431 001 | Apr 29, 1988 |
| | | 5MG | A070424 001 | Dec 12, 1985 |
| | | 5MG | A072432 001 | Apr 29, 1988 |
| | | 10MG | A070425 001 | Dec 12, 1985 |
| | | 10MG | A072433 001 | Apr 29, 1988 |
| DIAZOXIDE | | | | |
| CAPSULE;ORAL | | | | |
| PROGLYCEM | | | | |
| | TEVA BRANDED PHARM | 50MG | N017425 001 | |
| | | 100MG | N017425 002 | |
| INJECTABLE;INJECTION | | | | |
| DIAZOXIDE | | | | |
| | ABRAXIS PHARM | 15MG/ML | A071519 001 | Aug 26, 1987 |
| HYPERSTAT | | | | |
| | SCHERING | 15MG/ML | N016996 001 | |
| DIBUCAINE HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| HEAVY SOLUTION NUPERCAINE | | | | |
| | NOVARTIS | 2.5MG/ML | N006203 001 | |
| DICHLORPHENAMIDE | | | | |
| TABLET;ORAL | | | | |
| DARANIDE | | | | |
| + | STRONGBRIDGE US | 50MG ** | N011366 001 | |
| DICLOFENAC POTASSIUM | | | | |
| TABLET;ORAL | | | | |
| CATAFLAM | | | | |
| + | NOVARTIS | 25MG ** | N020142 001 | Nov 24, 1993 |
| | | 50MG ** | N020142 002 | Nov 24, 1993 |
| DICLOFENAC POTASSIUM | | | | |
| | SANDOZ | 50MG | A075582 001 | Feb 23, 2001 |
| | SUN PHARM INDUSTRIES | 50MG | A075470 001 | Feb 21, 2002 |
| | WATSON LABS TEVA | 50MG | A075152 001 | Nov 27, 1998 |
| DICLOFENAC SODIUM | | | | |
| SOLUTION;TOPICAL | | | | |
| PENNSAID | | | | |
| + | NUVO PHARMS INC | 1.5% ** | N020947 001 | Nov 04, 2009 |
| SOLUTION/DROPS;OPHTHALMIC | | | | |
| DICLOFENAC SODIUM | | | | |
| | APOTEX INC | 0.1% | A077600 001 | Nov 13, 2008 |
| | FALCON PHARMS | 0.1% | N020809 001 | May 04, 1998 |
| TABLET, DELAYED RELEASE;ORAL | | | | |
| DICLOFENAC SODIUM | | | | |
| | ALLIED PHARMA INC | 50MG | A074986 001 | Feb 26, 1999 |
| | | 75MG | A074986 002 | Feb 26, 1999 |
| | PLIVA | 50MG | A074432 002 | Jul 29, 1999 |
| | | 75MG | A074432 003 | Jul 29, 1999 |
| | ROXANE | 25MG | A074391 001 | Jun 29, 1995 |
| | | 50MG | A074391 002 | Jun 29, 1995 |
| | | 75MG | A074391 003 | Jun 29, 1995 |
| | TEVA | 50MG | A074723 001 | Mar 30, 1999 |
| | | 75MG | A074390 001 | Aug 15, 1996 |
| | TEVA PHARMS | 25MG | A074459 001 | Jun 25, 1997 |
| | | 50MG | A074459 002 | Jun 25, 1997 |
| | | 75MG | A074459 003 | Jun 25, 1997 |
| VOLTAREN | | | | |
| + | NOVARTIS | 25MG ** | N019201 001 | Jul 28, 1988 |
| + | | 50MG ** | N019201 002 | Jul 28, 1988 |
| + | | 75MG ** | N019201 003 | Jul 28, 1988 |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| DICLOFENAC SODIUM | | | | |
| | ACTAVIS ELIZABETH | 100MG | A075910 001 | Jan 07, 2002 |

| | | | | |
|---|---|---|---|---|
| DICLOFENAC SODIUM | | | | |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| VOLTAREN-XR | | | | |
| + NOVARTIS | 100MG ** | N020254 | 001 | Mar 08, 1996 |
| DICLOXACILLIN SODIUM | | | | |
| CAPSULE;ORAL | | | | |
| DYCILL | | | | |
| GLAXOSMITHKLINE | EQ 250MG BASE | A060254 | 002 | |
| | EQ 250MG BASE | A062238 | 001 | |
| | EQ 500MG BASE | A060254 | 003 | |
| | EQ 500MG BASE | A062238 | 002 | |
| PATHOCIL | | | | |
| WYETH AYERST | EQ 250MG BASE | N050011 | 002 | |
| | EQ 500MG BASE | N050011 | 003 | Mar 28, 1983 |
| FOR SUSPENSION;ORAL | | | | |
| DICLOXACILLIN SODIUM | | | | |
| APOTHECON | EQ 62.5MG BASE/5ML | A061455 | 001 | |
| DYNAPEN | | | | |
| APOTHECON | EQ 62.5MG BASE/5ML | N050337 | 002 | |
| PATHOCIL | | | | |
| WYETH AYERST | EQ 62.5MG BASE/5ML | N050092 | 001 | |
| DICUMAROL | | | | |
| CAPSULE;ORAL | | | | |
| DICUMAROL | | | | |
| LILLY | 25MG | N005509 | 003 | |
| | 50MG | N005509 | 001 | |
| TABLET;ORAL | | | | |
| DICUMAROL | | | | |
| ABBVIE | 25MG | N005545 | 003 | |
| | 50MG | N005545 | 004 | |
| | 100MG | N005545 | 005 | |
| DICYCLOMINE HYDROCHLORIDE | | | | |
| CAPSULE;ORAL | | | | |
| DICYCLOMINE HYDROCHLORIDE | | | | |
| HIKMA PHARMS | 10MG | A040204 | 001 | Feb 28, 1997 |
| PIONEER PHARMS | 10MG | A089361 | 001 | Jan 10, 1989 |
| SUN PHARM INDUSTRIES | 10MG | A084505 | 001 | Oct 21, 1986 |
| WATSON LABS | 10MG | A083179 | 001 | Feb 12, 1986 |
| INJECTABLE;INJECTION | | | | |
| DICYCLOMINE HYDROCHLORIDE | | | | |
| WATSON LABS | 10MG/ML | A080614 | 001 | Feb 11, 1986 |
| SYRUP;ORAL | | | | |
| BENTYL | | | | |
| + APTALIS PHARMA US | 10MG/5ML ** | N007961 | 002 | Oct 15, 1984 |
| DICYCLOMINE HYDROCHLORIDE | | | | |
| ALPHARMA US PHARMS | 10MG/5ML | A084479 | 001 | |
| TABLET;ORAL | | | | |
| DICYCLOMINE HYDROCHLORIDE | | | | |
| HIKMA PHARMS | 20MG | A040161 | 001 | Oct 01, 1996 |
| PIONEER PHARMS | 20MG | A088585 | 001 | Aug 20, 1986 |
| SUN PHARM INDUSTRIES | 20MG | A084600 | 001 | Jul 29, 1985 |
| WATSON LABS | 20MG | A084361 | 001 | Feb 06, 1986 |
| DIDANOSINE | | | | |
| CAPSULE, DELAYED REL PELLETS;ORAL | | | | |
| DIDANOSINE | | | | |
| MYLAN PHARMS INC | 125MG | A090788 | 001 | Apr 08, 2010 |
| | 200MG | A090788 | 002 | Apr 08, 2010 |
| | 250MG | A090788 | 003 | Apr 08, 2010 |
| | 400MG | A090788 | 004 | Apr 08, 2010 |
| FOR SOLUTION;ORAL | | | | |
| DIDANOSINE | | | | |
| AUROBINDO PHARMA | 10MG/ML | A078112 | 001 | Mar 08, 2007 |
| VIDEX | | | | |
| BRISTOL MYERS SQUIBB | 100MG/PACKET | N020155 | 003 | Oct 09, 1991 |
| | 167MG/PACKET | N020155 | 004 | Oct 09, 1991 |
| | 250MG/PACKET | N020155 | 005 | Oct 09, 1991 |
| | 375MG/PACKET | N020155 | 006 | Oct 09, 1991 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

DIDANOSINE

| | | | | |
|---|---|---|---|---|
| TABLET, CHEWABLE;ORAL | | | | |
| VIDEX | | | | |
| + | BRISTOL MYERS SQUIBB | 25MG ** | N020154 002 | Oct 09, 1991 |
| + | | 50MG ** | N020154 003 | Oct 09, 1991 |
| + | | 100MG ** | N020154 004 | Oct 09, 1991 |
| + | | 150MG ** | N020154 005 | Oct 09, 1991 |
| + | | 200MG ** | N020154 006 | Oct 28, 1999 |
| TABLET, FOR SUSPENSION;ORAL | | | | |
| DIDANOSINE | | | | |
| | AUROBINDO | 100MG | A077275 001 | Aug 14, 2012 |
| | | 150MG | A077275 002 | Aug 14, 2012 |
| | | 200MG | A077275 003 | Aug 14, 2012 |

DIENESTROL

| | | | | |
|---|---|---|---|---|
| CREAM;VAGINAL | | | | |
| DIENESTROL | | | | |
| | ORTHO MCNEIL PHARM | 0.01% | N006110 005 | |
| DV | | | | |
| | SANOFI AVENTIS US | 0.01% | A083518 001 | |
| ESTRAGUARD | | | | |
| | SOLVAY | 0.01% | A084436 001 | |
| SUPPOSITORY;VAGINAL | | | | |
| DV | | | | |
| | SANOFI AVENTIS US | 0.7MG | A083517 001 | |

DIETHYLCARBAMAZINE CITRATE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| HETRAZAN | | | | |
| | LEDERLE | 50MG | N006459 001 | |

DIETHYLPROPION HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| DIETHYLPROPION HYDROCHLORIDE | | | | |
| | CHARTWELL RX | 25MG | A088267 001 | Aug 25, 1983 |
| | | 25MG | A088268 001 | Aug 25, 1983 |
| | EPIC PHARMA LLC | 25MG | A040828 001 | Nov 05, 2008 |
| | SANDOZ | 25MG | A085916 001 | |
| | TEVA | 25MG | A088642 001 | Sep 20, 1984 |
| | UCB INC | 25MG | A085544 001 | |
| | WATSON LABS | 25MG | A085741 001 | |
| TENUATE | | | | |
| | SANOFI AVENTIS US | 25MG | N017668 001 | |
| TEPANIL | | | | |
| | 3M | 25MG | N011673 001 | |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| TENUATE | | | | |
| | SANOFI AVENTIS US | 75MG | N017669 001 | |
| TEPANIL TEN-TAB | | | | |
| | 3M | 75MG | N017956 001 | |

DIETHYLSTILBESTROL

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| STILBESTROL | | | | |
| | BRISTOL MYERS SQUIBB | 0.2MG/ML | N004056 003 | |
| | | 0.5MG/ML | N004056 004 | |
| | | 1MG/ML | N004056 005 | |
| | | 5MG/ML | N004056 006 | |
| SUPPOSITORY;VAGINAL | | | | |
| DIETHYLSTILBESTROL | | | | |
| | LILLY | 0.1MG | N004040 001 | |
| | | 0.5MG | N004040 002 | |
| STILBESTROL | | | | |
| | BRISTOL MYERS SQUIBB | 0.1MG | N004056 001 | |
| | | 0.5MG | N004056 002 | |
| TABLET;ORAL | | | | |
| DIETHYLSTILBESTROL | | | | |
| | LILLY | 0.1MG | N004041 002 | |
| | | 0.5MG | N004041 003 | |
| | | 1MG | N004041 004 | |
| | | 5MG | N004041 005 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

DIETHYLSTILBESTROL

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| STILBESTROL | | | | |
| | TABLICAPS | 0.5MG | A083004 001 | |
| | | 1MG | A083002 001 | |
| | | 5MG | A083006 001 | |
| STILBETIN | | | | |
| | BRISTOL MYERS SQUIBB | 0.1MG | N004056 007 | |
| | | 0.25MG | N004056 017 | |
| | | 0.5MG | N004056 008 | |
| | | 1MG | N004056 009 | |
| | | 5MG | N004056 010 | |
| TABLET, DELAYED RELEASE;ORAL | | | | |
| DIETHYLSTILBESTROL | | | | |
| | LILLY | 0.1MG | N004039 002 | |
| | | 0.25MG | N004039 005 | |
| | | 0.5MG | N004039 003 | |
| | | 1MG | N004039 004 | |
| | | 5MG | N004039 006 | |
| STILBESTROL | | | | |
| | TABLICAPS | 0.5MG | A083003 001 | |
| | | 1MG | A083005 001 | |
| | | 5MG | A083007 001 | |
| STILBETIN | | | | |
| | BRISTOL MYERS SQUIBB | 0.1MG | N004056 011 | |
| | | 0.5MG | N004056 012 | |
| | | 1MG | N004056 013 | |
| | | 5MG | N004056 014 | |

DIETHYLSTILBESTROL DIPHOSPHATE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| STILPHOSTROL | | | | |
| | BAYER PHARMS | 250MG/5ML | N010010 001 | |
| TABLET;ORAL | | | | |
| STILPHOSTROL | | | | |
| | BAYER PHARMS | 50MG | N010010 002 | |

DIFLORASONE DIACETATE

| | | | | |
|---|---|---|---|---|
| CREAM;TOPICAL | | | | |
| DIFLORASONE DIACETATE | | | | |
| | FOUGERA PHARMS | 0.05% | A075187 001 | Mar 30, 1998 |
| FLORONE | | | | |
| | PHARMACIA AND UPJOHN | 0.05% ** | N017741 001 | |
| FLORONE E | | | | |
| | PHARMACIA AND UPJOHN | 0.05% | N019259 001 | Aug 28, 1985 |
| PSORCON | | | | |
| + | TARO PHARMS NORTH | 0.05% ** | N020205 001 | Nov 20, 1992 |
| OINTMENT;TOPICAL | | | | |
| PSORCON | | | | |
| + | PHARMACIA AND UPJOHN | 0.05% | N019260 001 | Aug 28, 1985 |
| PSORCON E | | | | |
| | PHARMACIA AND UPJOHN | 0.05% | N017994 001 | |

DIFLUNISAL

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| DIFLUNISAL | | | | |
| | ALLIED PHARMA INC | 250MG | A073562 001 | Nov 27, 1992 |
| | | 500MG | A073563 001 | Nov 27, 1992 |
| | IDT AUSTRALIA LTD | 500MG | A074604 001 | Jun 10, 1996 |
| | PUREPAC PHARM | 250MG | A074285 001 | May 07, 1996 |
| | | 500MG | A074285 002 | May 07, 1996 |
| | TEVA | 250MG | A073679 001 | Jul 31, 1992 |
| | WATSON LABS | 250MG | A074400 001 | Jul 17, 1997 |
| | | 500MG | A074400 002 | Jul 17, 1997 |
| DOLOBID | | | | |
| + | MERCK | 250MG ** | N018445 001 | Apr 19, 1982 |
| + | | 500MG ** | N018445 002 | Apr 19, 1982 |

| | | | | |
|---|---|---|---|---|
| DIGITOXIN | | | | |
| INJECTABLE;INJECTION | | | | |
| CRYSTODIGIN | | | | |
| | LILLY | 0.2MG/ML | A084100 005 | |
| DIGOXIN | | | | |
| CAPSULE;ORAL | | | | |
| LANOXICAPS | | | | |
| | GLAXOSMITHKLINE LLC | 0.05MG | N018118 002 | Jul 26, 1982 |
| | | 0.1MG | N018118 003 | Jul 26, 1982 |
| | | 0.15MG | N018118 004 | Sep 24, 1984 |
| | | 0.2MG | N018118 001 | Jul 26, 1982 |
| INJECTABLE;INJECTION | | | | |
| DIGOXIN | | | | |
| | ABRAXIS PHARM | 0.25MG/ML | A083217 001 | |
| | HOSPIRA | 0.25MG/ML | A040093 001 | May 16, 1996 |
| | | 0.25MG/ML | A040206 001 | Aug 28, 1998 |
| | WYETH AYERST | 0.25MG/ML | A084386 001 | |
| DIGOXIN PEDIATRIC | | | | |
| | HOSPIRA | 0.1MG/ML | A040092 001 | Apr 25, 1996 |
| TABLET;ORAL | | | | |
| LANOXIN | | | | |
| | CONCORDIA PHARMS INC | 0.375MG | N020405 005 | Sep 30, 1997 |
| | | 0.5MG | N020405 006 | Sep 30, 1997 |
| DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| EMBOLEX | | | | |
| | NOVARTIS | 0.5MG/0.5ML;2,500 UNITS/0.5ML;5.33MG/0.5ML | N018885 001 | Nov 30, 1984 |
| | | 0.5MG/0.7ML;5,000 UNITS/0.7ML;7.46MG/0.7ML | N018885 002 | Nov 30, 1984 |
| DILTIAZEM HYDROCHLORIDE | | | | |
| CAPSULE, EXTENDED RELEASE;ORAL | | | | |
| CARDIZEM SR | | | | |
| + | BIOVAIL | 60MG ** | N019471 001 | Jan 23, 1989 |
| + | | 90MG ** | N019471 002 | Jan 23, 1989 |
| + | | 120MG ** | N019471 003 | Jan 23, 1989 |
| + | | 180MG ** | N019471 004 | Jan 23, 1989 |
| DILACOR XR | | | | |
| + | ALLERGAN SALES LLC | 120MG ** | N020092 001 | May 29, 1992 |
| + | | 180MG ** | N020092 002 | May 29, 1992 |
| + | | 240MG ** | N020092 003 | May 29, 1992 |
| DILT-CD | | | | |
| | APOTEX | 120MG | A076151 001 | May 20, 2004 |
| | | 180MG | A076151 002 | May 20, 2004 |
| | | 240MG | A076151 003 | May 20, 2004 |
| | | 300MG | A076151 004 | May 20, 2004 |
| DILTIAZEM HYDROCHLORIDE | | | | |
| | ACTAVIS LABS FL INC | 120MG | A074852 001 | Oct 10, 1997 |
| | | 180MG | A074852 002 | Oct 10, 1997 |
| | | 240MG | A074852 003 | Oct 10, 1997 |
| | BIOVAIL | 60MG | A074845 001 | Sep 15, 1999 |
| | | 90MG | A074845 002 | Sep 15, 1999 |
| | | 120MG | A074845 003 | Sep 15, 1999 |
| | | 120MG | N020939 001 | Jan 28, 2000 |
| | | 180MG | N020939 002 | Jan 28, 2000 |
| | | 240MG | N020939 003 | Jan 28, 2000 |
| | | 300MG | N020939 004 | Jan 28, 2000 |
| | | 360MG | N020939 005 | Sep 14, 2001 |
| | | 420MG | N020939 006 | Sep 14, 2001 |
| | NESHER PHARMS | 120MG | A076563 002 | Sep 12, 2006 |
| | | 180MG | A076563 003 | Sep 12, 2006 |
| | | 240MG | A076563 004 | Sep 12, 2006 |
| | | 300MG | A076563 005 | Sep 12, 2006 |
| | | 360MG | A076563 006 | Sep 12, 2006 |
| | | 420MG | A076563 001 | Sep 12, 2006 |
| | TEVA | 60MG | A074079 001 | Nov 30, 1993 |
| | | 90MG | A074079 002 | Nov 30, 1993 |
| | | 120MG | A074079 003 | Nov 30, 1993 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

DILTIAZEM HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| CARDIZEM | | | | |
| | BIOVAIL | 100MG/VIAL | N020792 001 | Sep 05, 1997 |
| + | BIOVAIL LABS INTL | 5MG/ML ** | N020027 001 | Oct 24, 1991 |
| + | | 25MG/VIAL ** | N020027 003 | Aug 18, 1995 |
| DILTIAZEM HYDROCHLORIDE | | | | |
| | HOSPIRA | 5MG/ML | A075004 001 | Feb 16, 2000 |
| | | 5MG/ML | A075106 001 | Apr 29, 1999 |
| | MYLAN LABS LTD | 5MG/ML | A075375 001 | Sep 30, 1999 |
| | TEVA PHARMS USA | 5MG/ML | A074894 001 | Aug 26, 1997 |
| TABLET;ORAL | | | | |
| DILTIAZEM HYDROCHLORIDE | | | | |
| | APOTHECON | 30MG | A074051 001 | Mar 31, 1993 |
| | | 60MG | A074051 002 | Mar 31, 1993 |
| | | 90MG | A074051 003 | Mar 31, 1993 |
| | | 120MG | A074051 004 | Mar 31, 1993 |
| | CHARTWELL MOLECULES | 30MG | A074093 001 | Nov 05, 1992 |
| | | 60MG | A074093 002 | Nov 05, 1992 |
| | | 90MG | A074093 003 | Nov 05, 1992 |
| | | 120MG | A074093 004 | Nov 05, 1992 |
| | IVAX SUB TEVA PHARMS | 30MG | A074168 001 | Mar 03, 1995 |
| | | 60MG | A074168 002 | Mar 03, 1995 |
| | | 90MG | A074168 003 | Mar 03, 1995 |
| | | 120MG | A074168 004 | Mar 03, 1995 |
| | TEVA | 30MG | A074084 001 | Feb 25, 1994 |
| | | 60MG | A074084 002 | Feb 25, 1994 |
| | TEVA PHARMS | 30MG | A074067 001 | Nov 05, 1992 |
| | | 60MG | A074067 002 | Nov 05, 1992 |
| | | 90MG | A074067 003 | Nov 05, 1992 |
| | | 120MG | A074067 004 | Nov 05, 1992 |

DILTIAZEM MALATE

| | | | | |
|---|---|---|---|---|
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| TIAMATE | | | | |
| | MERCK | EQ 120MG HCL | N020506 001 | Oct 04, 1996 |
| | | EQ 180MG HCL | N020506 002 | Oct 04, 1996 |
| | | EQ 240MG HCL | N020506 003 | Oct 04, 1996 |

DILTIAZEM MALATE; ENALAPRIL MALEATE

| | | | | |
|---|---|---|---|---|
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| TECZEM | | | | |
| | BIOVAIL | EQ 180MG HCL;5MG | N020507 001 | Oct 04, 1996 |

DIMENHYDRINATE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| DIMENHYDRINATE | | | | |
| | BAXTER HLTHCARE | 50MG/ML | A084767 001 | |
| | WATSON LABS | 50MG/ML | A083531 001 | |
| | WATSON LABS TEVA | 50MG/ML | A080615 001 | |
| | WYETH AYERST | 50MG/ML | A084316 001 | |
| LIQUID;ORAL | | | | |
| DIMENHYDRINATE | | | | |
| | ALRA | 12.5MG/4ML | A080715 001 | |
| TABLET;ORAL | | | | |
| DIMENHYDRINATE | | | | |
| | HEATHER | 50MG | A080841 001 | |
| | NEXGEN PHARMA INC | 50MG | A085985 001 | |
| | WATSON LABS | 50MG | A085166 001 | |

DIMYRISTOYL LECITHIN; PERFLEXANE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INTRAVENOUS | | | | |
| IMAGENT | | | | |
| | VESSELON SPV LLC | 0.92MG/VIAL;0.092MG/VIAL | N021191 001 | May 31, 2002 |

DINOPROST TROMETHAMINE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| PROSTIN F2 ALPHA | | | | |
| | PHARMACIA AND UPJOHN | EQ 5MG BASE/ML | N017434 001 | |

DIPHEMANIL METHYLSULFATE

TABLET;ORAL

PRANTAL

| | | | |
|---|---|---|---|
| SCHERING | 100MG | N008114 004 | |

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE;ORAL

BENADRYL

| | | | |
|---|---|---|---|
| MCNEIL CONS | 25MG | N005845 007 | |
| | 50MG | N005845 001 | |

DIPHENHYDRAMINE HYDROCHLORIDE

| | | | |
|---|---|---|---|
| ALRA | 25MG | A080519 004 | |
| | 50MG | A080519 003 | |
| ANABOLIC | 50MG | A083275 001 | |
| ELKINS SINN | 25MG | A085701 001 | |
| | 50MG | A085701 002 | |
| HALSEY | 50MG | A087914 001 | Jun 04, 1984 |
| HEATHER | 25MG | A084524 001 | |
| | 50MG | A083953 001 | |
| HIKMA INTL PHARMS | 50MG | A083567 001 | |
| IMPAX LABS | 25MG | A080807 001 | |
| | 50MG | A080807 002 | |
| IVAX SUB TEVA PHARMS | 25MG | A080762 001 | |
| | 50MG | A080762 002 | |
| LANNETT | 25MG | A080868 001 | |
| | 50MG | A080868 002 | |
| LEDERLE | 25MG | A086874 001 | |
| | 50MG | A086875 001 | |
| LNK | 25MG | A087977 001 | Jan 27, 1983 |
| | 50MG | A087978 001 | Jan 27, 1983 |
| MK LABS | 25MG | A083087 001 | |
| | 50MG | A083087 002 | |
| MUTUAL PHARM | 25MG | A084506 001 | |
| NEWTRON PHARMS | 25MG | A086543 001 | |
| | 50MG | A086544 001 | |
| NEXGEN PHARMA INC | 25MG | A083634 001 | |
| PERRIGO | 25MG | A083061 001 | |
| | 50MG | A083061 002 | |
| PIONEER PHARMS | 25MG | A089101 001 | Dec 20, 1985 |
| | 50MG | A088880 001 | Dec 20, 1985 |
| PUREPAC PHARM | 25MG | A085156 001 | |
| | 50MG | A085150 001 | |
| PVT FORM | 25MG | A083027 001 | |
| | 50MG | A083027 002 | |
| ROXANE | 50MG | A080635 001 | |
| SANDOZ | 25MG | A080832 001 | |
| | 25MG | A080845 002 | |
| | 50MG | A080832 002 | |
| | 50MG | A080845 001 | |
| SUN PHARM INDUSTRIES | 25MG | A089488 001 | Jan 02, 1987 |
| | 50MG | A089489 001 | Jan 02, 1987 |
| SUPERPHARM | 25MG | A089040 001 | May 15, 1985 |
| | 50MG | A089041 001 | May 15, 1985 |
| TEVA | 25MG | A085874 001 | |
| | 50MG | A085874 002 | |
| VALEANT PHARM INTL | 25MG | A080596 001 | |
| | 50MG | A080592 001 | |
| VANGARD | 25MG | A088034 001 | Oct 27, 1982 |
| | 50MG | A087630 001 | |
| WATSON LABS | 25MG | A080728 001 | |
| | 25MG | A083797 001 | |
| | 25MG | A085138 001 | |
| | 50MG | A080727 001 | |
| | 50MG | A083797 002 | |
| | 50MG | A085083 001 | |
| WHITEWORTH TOWN PLSN | 25MG | A083441 001 | |
| | 50MG | A080800 001 | |

DIPHENHYDRAMINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| ELIXIR;ORAL | | | | |
| BELIX | | | | |
| | HALSEY | 12.5MG/5ML | A086586 001 | Oct 03, 1983 |
| BENADRYL | | | | |
| | MCNEIL CONS | 12.5MG/5ML | N005845 004 | |
| DIBENIL | | | | |
| | CENCI | 12.5MG/5ML | A088304 001 | Dec 16, 1983 |
| DIPHEN | | | | |
| | USL PHARMA | 12.5MG/5ML | A084640 001 | |
| DIPHENHYDRAMINE HYDROCHLORIDE | | | | |
| | BUNDY | 12.5MG/5ML | A083674 001 | |
| | CENCI | 12.5MG/5ML | A087941 001 | Dec 17, 1982 |
| | KV PHARM | 12.5MG/5ML | A085621 001 | |
| | LANNETT | 12.5MG/5ML | A080939 002 | |
| | LEDERLE | 12.5MG/5ML | A086937 001 | |
| | MK LABS | 12.5MG/5ML | A083088 002 | |
| | NASKA | 12.5MG/5ML | A088680 001 | May 31, 1985 |
| | PERRIGO | 12.5MG/5ML | A083063 001 | |
| | PUREPAC PHARM | 12.5MG/5ML | A083237 001 | Jan 25, 1982 |
| | PVT FORM | 12.5MG/5ML | A085287 001 | |
| | ROXANE | 12.5MG/5ML | A080643 001 | |
| HYDRAMINE | | | | |
| | ALPHARMA US PHARMS | 12.5MG/5ML | A080763 002 | |
| INJECTABLE;INJECTION | | | | |
| BENADRYL | | | | |
| | MCNEIL CONS | 10MG/ML | N006146 001 | |
| + | | 50MG/ML ** | N006146 002 | |
| BENADRYL PRESERVATIVE FREE | | | | |
| + | MCNEIL CONS | 50MG/ML ** | N009486 001 | |
| DIPHENHYDRAMINE HYDROCHLORIDE | | | | |
| | BEL MAR | 10MG/ML | A080822 001 | |
| | EUROHLTH INTL SARL | 50MG/ML | A083183 001 | |
| | LYPHOMED | 10MG/ML | A087066 001 | |
| | WATSON LABS | 10MG/ML | A083533 001 | |
| | WATSON LABS TEVA | 10MG/ML | A080873 001 | |
| | | 50MG/ML | A080873 002 | |
| | WYETH AYERST | 50MG/ML | A080577 001 | |
| DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE | | | | |
| | ABRAXIS PHARM | 50MG/ML | A080586 002 | |
| | INTL MEDICATION | 50MG/ML | A084094 001 | |
| | WATSON LABS TEVA | 50MG/ML | A080873 003 | |
| SYRUP;ORAL | | | | |
| ANTITUSSIVE | | | | |
| | PERRIGO | 12.5MG/5ML | A071292 001 | Apr 10, 1987 |
| BELDIN | | | | |
| | HALSEY | 12.5MG/5ML | A089179 001 | Jun 05, 1986 |
| BENYLIN | | | | |
| | PARKE DAVIS | 12.5MG/5ML | N006514 004 | |
| DIPHEN | | | | |
| | MORTON GROVE | 12.5MG/5ML | A070118 001 | Oct 01, 1985 |
| DIPHENHYDRAMINE HYDROCHLORIDE | | | | |
| | ALPHARMA US PHARMS | 12.5MG/5ML | A070497 001 | Apr 25, 1989 |
| | CUMBERLAND SWAN | 12.5MG/5ML | A073611 001 | Aug 20, 1992 |
| | HI TECH PHARMA | 12.5MG/5ML | A072416 001 | Sep 28, 1990 |
| HYDRAMINE | | | | |
| | ALPHARMA US PHARMS | 12.5MG/5ML | A070205 001 | Jan 28, 1986 |
| SILPHEN | | | | |
| | SILARX | 12.5MG/5ML | A072646 001 | Feb 27, 1992 |
| VICKS FORMULA 44 | | | | |
| | WARNER CHILCOTT | 12.5MG/5ML | A070524 001 | Jan 14, 1987 |

DIPHENHYDRAMINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| SOLUTION;ORAL | | | | |
| BENYLIN | | | | |
| | PARKE DAVIS | 12.5MG/5ML;30MG/5ML | N019014 001 | Jun 11, 1985 |

DIPHENIDOL HYDROCHLORIDE

TABLET;ORAL

VONTROL

| | | | | |
|---|---|---|---|---|
| GLAXOSMITHKLINE | EQ 25MG BASE | N016033 | 001 | |

DIPHENYLPYRALINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

HISPRIL

| | | | | |
|---|---|---|---|---|
| GLAXOSMITHKLINE | 5MG | N011945 | 001 | |

DIPIVEFRIN HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

AKPRO

| | | | | |
|---|---|---|---|---|
| AKORN | 0.1% | A074382 | 001 | Sep 29, 1995 |

DIPIVEFRIN HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| BAUSCH AND LOMB | 0.1% | A074188 | 001 | May 19, 1995 |
| FALCON PHARMS | 0.1% | A073636 | 001 | Jun 30, 1994 |

PROPINE

| | | | | |
|---|---|---|---|---|
| ALLERGAN | 0.1% | N018239 | 001 | |

DIPYRIDAMOLE

INJECTABLE;INJECTION

DIPYRIDAMOLE

| | | | | |
|---|---|---|---|---|
| HOSPIRA | 5MG/ML | A074601 | 001 | Dec 19, 1997 |
| MYLAN LABS LTD | 5MG/ML | A075769 | 001 | Nov 27, 2002 |
| TEVA PHARMS USA | 5MG/ML | A074952 | 001 | Nov 26, 1997 |

IV PERSANTINE

| | | | | | |
|---|---|---|---|---|---|
| + | BOEHRINGER INGELHEIM | 5MG/ML ** | N019817 | 001 | Dec 13, 1990 |

TABLET;ORAL

DIPYRIDAMOLE

| | | | | |
|---|---|---|---|---|
| GLENMARK GENERICS | 25MG | A088999 | 001 | Feb 05, 1991 |
| | 50MG | A089000 | 001 | Feb 05, 1991 |
| | 75MG | A089001 | 001 | Feb 05, 1991 |
| IDT AUSTRALIA LTD | 25MG | A086944 | 002 | Apr 16, 1991 |
| | 50MG | A086944 | 001 | Feb 25, 1992 |
| | 75MG | A086944 | 003 | Feb 25, 1992 |
| LANNETT | 25MG | A040898 | 001 | Apr 23, 2008 |
| | 50MG | A040898 | 002 | Apr 23, 2008 |
| | 75MG | A040898 | 003 | Apr 23, 2008 |
| OXFORD PHARMS | 25MG | A040542 | 001 | Apr 21, 2006 |
| | 50MG | A040542 | 002 | Apr 21, 2006 |
| | 75MG | A040542 | 003 | Apr 21, 2006 |
| PUREPAC PHARM | 25MG | A089425 | 001 | Jul 12, 1990 |
| | 50MG | A089426 | 001 | Jul 12, 1990 |
| | 75MG | A089427 | 001 | Jul 12, 1990 |
| WATSON LABS | 50MG | A087160 | 001 | Jun 07, 1996 |

DIRITHROMYCIN

TABLET, DELAYED RELEASE;ORAL

DYNABAC

| | | | | |
|---|---|---|---|---|
| LILLY RES LABS | 250MG | N050678 | 001 | Jun 19, 1995 |

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL

DISOPYRAMIDE PHOSPHATE

| | | | | |
|---|---|---|---|---|
| AUROLIFE PHARMA LLC | EQ 100MG BASE | A070470 | 001 | Dec 10, 1985 |
| | EQ 150MG BASE | A070471 | 001 | Dec 10, 1985 |
| INTERPHARM | EQ 100MG BASE | A071190 | 001 | Jan 15, 1987 |
| | EQ 150MG BASE | A071191 | 001 | Jan 15, 1987 |
| IVAX SUB TEVA PHARMS | EQ 100MG BASE | A070186 | 001 | Nov 18, 1985 |
| | EQ 150MG BASE | A070187 | 001 | Nov 18, 1985 |
| MYLAN | EQ 100MG BASE | A070138 | 001 | Jun 14, 1985 |
| | EQ 150MG BASE | A070139 | 001 | Jun 14, 1985 |
| SUN PHARM INDUSTRIES | EQ 100MG BASE | A070351 | 001 | Dec 17, 1985 |
| | EQ 150MG BASE | A070352 | 001 | Dec 17, 1985 |
| SUPERPHARM | EQ 100MG BASE | A070940 | 001 | Feb 09, 1987 |
| | EQ 150MG BASE | A070941 | 001 | Feb 09, 1987 |
| WATSON LABS | EQ 100MG BASE | A070240 | 001 | Feb 02, 1986 |
| | EQ 150MG BASE | A070241 | 001 | Feb 02, 1986 |

| | | | | |
|---|---|---|---|---|
| DISOPYRAMIDE PHOSPHATE | | | | |
| CAPSULE, EXTENDED RELEASE;ORAL | | | | |
| DISOPYRAMIDE PHOSPHATE | | | | |
| | NESHER PHARMS | EQ 150MG BASE | A071200 001 | Dec 15, 1987 |
| DISULFIRAM | | | | |
| TABLET;ORAL | | | | |
| ANTABUSE | | | | |
| + | TEVA WOMENS | 250MG ** | N007883 003 | |
| + | | 500MG ** | N007883 002 | |
| DISULFIRAM | | | | |
| | PAR PHARM | 250MG | A088792 001 | Aug 14, 1984 |
| | | 500MG | A088793 001 | Aug 14, 1984 |
| | WATSON LABS | 250MG | A086889 001 | |
| | | 250MG | A087973 001 | Aug 05, 1983 |
| | | 500MG | A087974 001 | Aug 05, 1983 |
| | WATSON LABS TEVA | 500MG | A086890 001 | |
| DIVALPROEX SODIUM | | | | |
| TABLET, DELAYED RELEASE;ORAL | | | | |
| DEPAKOTE CP | | | | |
| | ABBOTT | EQ 250MG BASE | N019794 001 | Jul 11, 1990 |
| | | EQ 500MG BASE | N019794 002 | Jul 11, 1990 |
| DIVALPROEX SODIUM | | | | |
| | MYLAN | EQ 125MG VALPROIC ACID | A077254 001 | Jul 29, 2008 |
| | | EQ 250MG VALPROIC ACID | A077254 002 | Jul 29, 2008 |
| | | EQ 500MG VALPROIC ACID | A077254 003 | Jul 29, 2008 |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| DIVALPROEX SODIUM | | | | |
| | G AND W LABS INC | EQ 500MG VALPROIC ACID | A078700 001 | Aug 03, 2009 |
| DOBUTAMINE HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| DOBUTAMINE HYDROCHLORIDE | | | | |
| | BAXTER HLTHCARE | EQ 12.5MG BASE/ML | A074381 001 | Sep 26, 1996 |
| | HOSPIRA | EQ 1.25GM BASE/100ML | A074634 001 | Sep 27, 1996 |
| | LUITPOLD | EQ 12.5MG BASE/ML | A074545 001 | Jun 25, 1998 |
| | TELIGENT PHARMA INC | EQ 12.5MG BASE/ML | A074098 001 | Feb 21, 1995 |
| | TEVA PARENTERAL | EQ 12.5MG BASE/ML | A074206 001 | Oct 19, 1993 |
| | WATSON LABS | EQ 12.5MG BASE/ML | A074114 001 | Nov 30, 1993 |
| | WATSON LABS INC | EQ 12.5MG BASE/ML | A074279 001 | Feb 18, 1998 |
| | | EQ 12.5MG BASE/ML | A074995 001 | Mar 31, 1998 |
| DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% | | | | |
| | HOSPIRA | EQ 50MG BASE/100ML | N020269 001 | Oct 19, 1993 |
| | | EQ 100MG BASE/100ML | N020269 002 | Oct 19, 1993 |
| | | EQ 200MG BASE/100ML | N020269 003 | Oct 19, 1993 |
| DOBUTREX | | | | |
| + | LILLY | EQ 12.5MG BASE/ML | N017820 002 | |
| DOCETAXEL | | | | |
| INJECTABLE;INJECTION | | | | |
| DOCEFREZ | | | | |
| + | SUN PHARMA GLOBAL | 20MG/VIAL | N022534 001 | May 03, 2011 |
| + | | 80MG/VIAL | N022534 002 | May 03, 2011 |
| DOCETAXEL | | | | |
| | APOTEX INC | 20MG/0.5ML (40MG/ML) | N022312 001 | Jan 11, 2012 |
| | | 80MG/2ML (40MG/ML) | N022312 002 | Jan 11, 2012 |
| + | HOSPIRA INC | 120MG/6ML (20MG/ML) | N022234 006 | Jun 23, 2016 |
| | PFIZER LABS | 20MG/2ML (10MG/ML) | N202356 001 | Mar 13, 2014 |
| | | 80MG/8ML (10MG/ML) | N202356 002 | Mar 13, 2014 |
| | | 130MG/13ML (10MG/ML) | N202356 003 | Mar 13, 2014 |
| | | 200MG/20ML (10MG/ML) | N202356 004 | Mar 13, 2014 |
| TAXOTERE | | | | |
| + | SANOFI AVENTIS US | 40MG/ML ** | N020449 001 | May 14, 1996 |
| DOLASETRON MESYLATE | | | | |
| INJECTABLE;INJECTION | | | | |
| ANZEMET | | | | |
| + | US PHARM HOLDINGS | 12.5MG/0.625ML (20MG/ML) | N020624 002 | Sep 11, 1997 |
| + | | 100MG/5ML (20MG/ML) | N020624 001 | Sep 11, 1997 |
| | | 500MG/25ML (20MG/ML) | N020624 003 | Dec 11, 2001 |

DOLASETRON MESYLATE
TABLET;ORAL
ANZEMET
+ US PHARM HOLDINGS 50MG N020623 001 Sep 11, 1997
+ 100MG N020623 002 Sep 11, 1997

DONEPEZIL HYDROCHLORIDE
SOLUTION;ORAL
ARICEPT
EISAI INC 5MG/5ML N021719 001 Oct 18, 2004
TABLET;ORAL
DONEPEZIL HYDROCHLORIDE
ACCORD HLTHCARE 5MG A201335 001 Aug 29, 2011
10MG A201335 002 Aug 29, 2011
HIKMA PHARMS 5MG A090247 001 May 31, 2011
10MG A090247 002 May 31, 2011
TABLET, ORALLY DISINTEGRATING;ORAL
DONEPEZIL HYDROCHLORIDE
SUN PHARM INDUSTRIES 5MG A077975 002 Dec 11, 2009
10MG A077975 001 Dec 11, 2009

DOPAMINE HYDROCHLORIDE
INJECTABLE;INJECTION
DOPAMINE HYDROCHLORIDE
ABBOTT 40MG/ML A070656 001 Jan 24, 1989
80MG/ML A070657 001 Jan 24, 1989
ABRAXIS PHARM 40MG/ML A070012 001 Jun 12, 1985
40MG/ML A070058 001 Mar 20, 1985
80MG/ML A070013 001 Jun 12, 1985
80MG/ML A070059 001 Mar 20, 1985
160MG/ML A070364 001 Dec 04, 1985
BAXTER HLTHCARE 40MG/ML N018398 001
80MG/ML N018398 002 Mar 22, 1982
HOSPIRA 40MG/ML A074403 001 May 23, 1996
IGI LABS INC 40MG/ML A070087 001 Oct 23, 1985
80MG/ML A070089 001 Oct 23, 1985
80MG/ML A070090 001 Oct 23, 1985
80MG/ML A070091 001 Oct 23, 1985
160MG/ML A070092 001 Oct 23, 1985
160MG/ML A070093 001 Oct 23, 1985
160MG/ML A070094 001 Oct 23, 1985
INTL MEDICATION 40MG/ML N018014 001
LYPHOMED 40MG/ML N018549 001 Mar 11, 1983
SMITH AND NEPHEW 40MG/ML A070011 001 Aug 29, 1985
40MG/ML A070046 001 Aug 29, 1985
80MG/ML A070047 001 Aug 29, 1985
TELIGENT 40MG/ML N018656 001 Jun 28, 1983
TEVA PARENTERAL 40MG/ML A072999 001 Oct 23, 1991
80MG/ML A073000 001 Oct 23, 1991
WARNER CHILCOTT 40MG/ML A070558 001 Sep 20, 1985
40MG/ML N018138 001
80MG/ML A070559 001 Sep 20, 1985
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5%
HOSPIRA 1.6MG/ML N020542 001 Aug 30, 1995
INTROPIN
HOSPIRA 40MG/ML N017395 001
80MG/ML N017395 002
160MG/ML N017395 003

DORIPENEM
INJECTABLE;IV (INFUSION)
DORIBAX
+ SHIONOGI INC 250MG/VIAL N022106 002 Oct 05, 2010
+ 500MG/VIAL N022106 001 Oct 12, 2007

DORZOLAMIDE HYDROCHLORIDE
SOLUTION/DROPS;OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| APOTEX INC | EQ 2% BASE | A078395 | 001 | Oct 28, 2008 |
| ZAMBON SPA | EQ 2% BASE | A091034 | 001 | Dec 04, 2013 |

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE
SOLUTION/DROPS;OPHTHALMIC
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

| | | | | |
|---|---|---|---|---|
| APOTEX INC | EQ 2% BASE;EQ 0.5% BASE | A078201 | 001 | Oct 28, 2008 |
| LANNETT HOLDINGS INC | EQ 2% BASE;EQ 0.5% BASE | A201998 | 001 | Dec 17, 2014 |

DOXACURIUM CHLORIDE
INJECTABLE;INJECTION
NUROMAX

| | | | | |
|---|---|---|---|---|
| ABBVIE | EQ 1MG BASE/ML | N019946 | 001 | Mar 07, 1991 |

DOXAPRAM HYDROCHLORIDE
INJECTABLE;INJECTION
DOXAPRAM HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| WATSON LABS | 20MG/ML | A073529 | 001 | Jan 30, 1992 |

DOXAZOSIN MESYLATE
TABLET;ORAL
DOXAZOSIN MESYLATE

| | | | | |
|---|---|---|---|---|
| ACTAVIS ELIZABETH | EQ 1MG BASE | A075574 | 001 | Oct 18, 2000 |
| | EQ 2MG BASE | A075574 | 002 | Oct 18, 2000 |
| | EQ 4MG BASE | A075574 | 003 | Oct 18, 2000 |
| | EQ 8MG BASE | A075574 | 004 | Oct 18, 2000 |
| FOSUN PHARMA | EQ 1MG BASE | A075646 | 001 | Oct 18, 2000 |
| | EQ 2MG BASE | A075646 | 002 | Oct 18, 2000 |
| | EQ 4MG BASE | A075646 | 003 | Oct 18, 2000 |
| | EQ 8MG BASE | A075646 | 004 | Oct 18, 2000 |
| GENPHARM | EQ 1MG BASE | A075466 | 001 | Oct 18, 2000 |
| | EQ 2MG BASE | A075466 | 002 | Oct 18, 2000 |
| | EQ 4MG BASE | A075466 | 003 | Oct 18, 2000 |
| | EQ 8MG BASE | A075466 | 004 | Oct 18, 2000 |
| IDT AUSTRALIA LTD | EQ 1MG BASE | A075432 | 001 | Oct 18, 2000 |
| | EQ 2MG BASE | A075432 | 002 | Oct 18, 2000 |
| | EQ 4MG BASE | A075432 | 003 | Oct 18, 2000 |
| | EQ 8MG BASE | A075432 | 004 | Oct 18, 2000 |
| IVAX SUB TEVA PHARMS | EQ 1MG BASE | A075453 | 001 | Oct 18, 2000 |
| | EQ 2MG BASE | A075453 | 002 | Oct 18, 2000 |
| | EQ 4MG BASE | A075453 | 003 | Oct 18, 2000 |
| | EQ 8MG BASE | A075453 | 004 | Oct 18, 2000 |
| NESHER PHARMS | EQ 1MG BASE | A075609 | 001 | Oct 18, 2000 |
| | EQ 2MG BASE | A075609 | 002 | Oct 18, 2000 |
| | EQ 4MG BASE | A075609 | 003 | Oct 18, 2000 |
| | EQ 8MG BASE | A075609 | 004 | Oct 18, 2000 |
| TEVA | EQ 1MG BASE | A075353 | 001 | Jan 12, 2001 |
| | EQ 2MG BASE | A075353 | 002 | Jan 12, 2001 |
| | EQ 4MG BASE | A075353 | 003 | Jan 12, 2001 |
| | EQ 8MG BASE | A075353 | 004 | Jan 12, 2001 |
| WATSON LABS INC | EQ 1MG BASE | A075426 | 001 | Oct 18, 2000 |
| | EQ 2MG BASE | A075426 | 002 | Oct 18, 2000 |
| | EQ 4MG BASE | A075426 | 003 | Oct 18, 2000 |
| | EQ 8MG BASE | A075426 | 004 | Oct 18, 2000 |

DOXEPIN HYDROCHLORIDE
CAPSULE;ORAL
DOXEPIN HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| DAVA PHARMS INC | EQ 10MG BASE | A071685 | 001 | Jan 05, 1988 |
| | EQ 25MG BASE | A071686 | 001 | Jan 05, 1988 |
| | EQ 50MG BASE | A071673 | 001 | Jan 05, 1988 |
| | EQ 75MG BASE | A071674 | 001 | Jan 05, 1988 |
| | EQ 100MG BASE | A071675 | 001 | Jan 05, 1988 |
| | EQ 150MG BASE | A071676 | 001 | Jan 05, 1988 |
| NEW RIVER | EQ 10MG BASE | N016987 | 001 | |
| | EQ 25MG BASE | N016987 | 002 | |
| | EQ 50MG BASE | N016987 | 003 | |
| | EQ 75MG BASE | N016987 | 006 | |
| | EQ 100MG BASE | N016987 | 004 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

DOXEPIN HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| CAPSULE;ORAL | | | | |
| DOXEPIN HYDROCHLORIDE | | | | |
| | EQ 150MG BASE | N016987 | 007 | Apr 13, 1987 |
| PAR PHARM | EQ 10MG BASE | A071697 | 001 | Nov 09, 1987 |
| | EQ 25MG BASE | A071437 | 001 | Nov 09, 1987 |
| | EQ 50MG BASE | A071595 | 001 | Nov 09, 1987 |
| | EQ 75MG BASE | A071608 | 001 | Nov 09, 1987 |
| | EQ 100MG BASE | A071422 | 001 | Nov 09, 1987 |
| PUREPAC PHARM | EQ 10MG BASE | A073054 | 001 | Dec 28, 1990 |
| | EQ 25MG BASE | A072109 | 001 | Dec 28, 1990 |
| | EQ 50MG BASE | A073055 | 001 | Dec 28, 1990 |
| | EQ 75MG BASE | A072386 | 001 | Sep 08, 1988 |
| | EQ 100MG BASE | A072110 | 001 | Sep 08, 1988 |
| | EQ 150MG BASE | A072387 | 001 | Sep 08, 1988 |
| QUANTUM PHARMICS | EQ 10MG BASE | A070972 | 001 | Sep 29, 1987 |
| | EQ 25MG BASE | A070973 | 001 | Sep 29, 1987 |
| | EQ 50MG BASE | A070931 | 001 | Sep 29, 1987 |
| | EQ 75MG BASE | A070932 | 001 | Sep 29, 1987 |
| | EQ 100MG BASE | A072375 | 001 | Mar 15, 1989 |
| | EQ 150MG BASE | A072376 | 001 | Mar 15, 1989 |
| SANDOZ | EQ 10MG BASE | A071487 | 001 | Mar 02, 1987 |
| | EQ 25MG BASE | A070827 | 001 | May 15, 1986 |
| | EQ 50MG BASE | A070828 | 001 | May 15, 1986 |
| | EQ 75MG BASE | A070825 | 001 | May 15, 1986 |
| | EQ 100MG BASE | A071562 | 001 | Mar 02, 1987 |
| SUN PHARM INDUSTRIES | EQ 25MG BASE | A071502 | 001 | Feb 18, 1988 |
| | EQ 50MG BASE | A071653 | 001 | Feb 18, 1988 |
| | EQ 75MG BASE | A071654 | 001 | Feb 18, 1988 |
| | EQ 100MG BASE | A071521 | 001 | Feb 18, 1988 |
| WATSON LABS | EQ 10MG BASE | A070952 | 001 | Mar 04, 1987 |
| | EQ 10MG BASE | A071485 | 001 | Apr 30, 1987 |
| | EQ 10MG BASE | A072985 | 001 | Mar 29, 1991 |
| | EQ 25MG BASE | A070953 | 001 | May 15, 1986 |
| | EQ 25MG BASE | A071486 | 001 | Apr 30, 1987 |
| | EQ 25MG BASE | A072986 | 001 | Mar 29, 1991 |
| | EQ 50MG BASE | A070954 | 001 | May 15, 1986 |
| | EQ 50MG BASE | A071238 | 001 | Apr 30, 1987 |
| | EQ 75MG BASE | A071326 | 001 | Apr 30, 1987 |
| | EQ 75MG BASE | A071763 | 001 | Feb 09, 1988 |
| | EQ 100MG BASE | A070955 | 001 | May 15, 1986 |
| | EQ 100MG BASE | A071239 | 001 | Apr 30, 1987 |
| | EQ 150MG BASE | A071764 | 001 | Feb 09, 1988 |
| WATSON LABS TEVA | EQ 50MG BASE | A072987 | 001 | Mar 29, 1991 |
| SINEQUAN | | | | |
| + PFIZER | EQ 10MG BASE ** | N016798 | 003 | |
| + | EQ 25MG BASE ** | N016798 | 001 | |
| + | EQ 50MG BASE ** | N016798 | 002 | |
| + | EQ 75MG BASE ** | N016798 | 006 | |
| + | EQ 100MG BASE ** | N016798 | 005 | |
| + | EQ 150MG BASE ** | N016798 | 007 | |
| CONCENTRATE;ORAL | | | | |
| DOXEPIN HYDROCHLORIDE | | | | |
| PHARM ASSOC | EQ 10MG BASE/ML | A075924 | 001 | Jan 15, 2004 |
| SINEQUAN | | | | |
| + PFIZER | EQ 10MG BASE/ML ** | N017516 | 001 | |
| TABLET;ORAL | | | | |
| DOXEPIN HYDROCHLORIDE | | | | |
| MYLAN PHARMS INC | EQ 3MG BASE | A202337 | 001 | Jan 20, 2016 |
| | EQ 6MG BASE | A202337 | 002 | Jan 20, 2016 |

DOXORUBICIN HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| ADRIAMYCIN PFS | | | | |
| PHARMACIA AND UPJOHN | 2MG/ML | A063165 | 001 | Jan 30, 1991 |
| | 200MG/100ML | A063165 | 002 | Jan 30, 1991 |
| DOXORUBICIN HYDROCHLORIDE | | | | |
| PHARMACIA AND UPJOHN | 10MG/VIAL | N050467 | 001 | |
| | 20MG/VIAL | N050467 | 003 | May 20, 1985 |
| | 50MG/VIAL | N050467 | 002 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| DOXORUBICIN HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| DOXORUBICIN HYDROCHLORIDE | | | | |
| | 150MG/VIAL | N050467 | 004 | Jul 22, 1987 |
| SANDOZ INC | 2MG/ML | A200146 | 001 | Jul 18, 2012 |
| RUBEX | | | | |
| BRISTOL MYERS SQUIBB | 10MG/VIAL | A062926 | 001 | Apr 13, 1989 |
| | 50MG/VIAL | A062926 | 002 | Apr 13, 1989 |
| | 100MG/VIAL | A062926 | 003 | Apr 13, 1989 |
| DOXYCYCLINE | | | | |
| CAPSULE;ORAL | | | | |
| DOXYCYCLINE | | | | |
| PAR PHARM | EQ 75MG BASE | A065055 | 004 | Apr 18, 2005 |
| SANDOZ INC | EQ 50MG BASE | A065032 | 001 | Jun 30, 2000 |
| | EQ 100MG BASE | A065032 | 002 | Jun 30, 2000 |
| WATSON LABS | EQ 50MG BASE | A065041 | 001 | Apr 28, 2000 |
| | EQ 100MG BASE | A065041 | 002 | Apr 28, 2000 |
| FOR SUSPENSION;ORAL | | | | |
| DOXYCHEL | | | | |
| RACHELLE | EQ 25MG BASE/5ML | A061720 | 001 | |
| TABLET;ORAL | | | | |
| DOXYCYCLINE | | | | |
| SANDOZ INC | EQ 50MG BASE | A065353 | 001 | Nov 27, 2006 |
| | EQ 75MG BASE | A065353 | 002 | Nov 27, 2006 |
| | EQ 100MG BASE | A065353 | 003 | Nov 27, 2006 |
| SUN PHARM INDUSTRIES | EQ 50MG BASE | A065471 | 001 | Apr 17, 2009 |
| | EQ 75MG BASE | A065471 | 002 | Apr 17, 2009 |
| | EQ 100MG BASE | A065471 | 003 | Apr 17, 2009 |
| DOXYCYCLINE HYCLATE | | | | |
| CAPSULE;ORAL | | | | |
| DOXY-LEMMON | | | | |
| TEVA | EQ 50MG BASE | A062497 | 001 | Aug 23, 1984 |
| | EQ 100MG BASE | A062497 | 002 | Jun 15, 1984 |
| DOXYCYCLINE HYCLATE | | | | |
| HALSEY | EQ 50MG BASE | A062119 | 002 | May 24, 1985 |
| | EQ 100MG BASE | A062119 | 001 | May 24, 1985 |
| HEATHER | EQ 50MG BASE | A062463 | 001 | Dec 07, 1983 |
| | EQ 100MG BASE | A062463 | 002 | Dec 07, 1983 |
| INTERPHARM | EQ 50MG BASE | A062763 | 001 | Sep 02, 1988 |
| | EQ 100MG BASE | A062763 | 002 | Sep 02, 1988 |
| MUTUAL PHARM | EQ 50MG BASE | A062418 | 001 | Jan 28, 1983 |
| | EQ 100MG BASE | A062418 | 002 | Jan 28, 1983 |
| PAR PHARM | EQ 50MG BASE | A062434 | 001 | Oct 19, 1984 |
| | EQ 100MG BASE | A062442 | 001 | Dec 22, 1983 |
| PVT FORM | EQ 50MG BASE | A062631 | 001 | Jul 24, 1986 |
| | EQ 100MG BASE | A062631 | 002 | Jul 24, 1986 |
| RANBAXY | EQ 50MG BASE | A062479 | 001 | Dec 23, 1983 |
| | EQ 100MG BASE | A062479 | 002 | Dec 23, 1983 |
| SUPERPHARM | EQ 50MG BASE | A062469 | 001 | Oct 31, 1984 |
| | EQ 100MG BASE | A062469 | 002 | Oct 31, 1984 |
| WARNER CHILCOTT | EQ 50MG BASE | A062594 | 001 | Dec 05, 1985 |
| | EQ 100MG BASE | A062594 | 002 | Dec 05, 1985 |
| WATSON LABS | EQ 50MG BASE | A061717 | 001 | |
| | EQ 50MG BASE | A062142 | 001 | |
| | EQ 100MG BASE | A061717 | 002 | |
| | EQ 100MG BASE | A062142 | 002 | |
| PERIOSTAT | | | | |
| + COLLAGENEX | EQ 20MG BASE ** | N050744 | 001 | Sep 30, 1998 |
| VIBRAMYCIN | | | | |
| + PFIZER | EQ 50MG BASE ** | N050007 | 001 | |
| CAPSULE, COATED PELLETS;ORAL | | | | |
| DOXYCYCLINE HYCLATE | | | | |
| PLIVA | EQ 100MG BASE | A063187 | 001 | Jun 30, 1992 |
| CAPSULE, DELAYED RELEASE;ORAL | | | | |
| DORYX | | | | |
| + MAYNE PHARMA INTL | EQ 75MG BASE | N050582 | 002 | Aug 13, 2001 |
| + | EQ 100MG BASE | N050582 | 001 | Jul 22, 1985 |
| WARNER CHILCOTT | EQ 100MG BASE | A062653 | 001 | Oct 30, 1985 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| DOXYCYCLINE HYCLATE | | | | |
| CAPSULE, DELAYED RELEASE;ORAL | | | | |
| DOXYCYCLINE HYCLATE | | | | |
| MEDICIS | EQ 75MG BASE | A065281 | 001 | Dec 21, 2005 |
| | EQ 100MG BASE | A065281 | 002 | Dec 21, 2005 |
| INJECTABLE;INJECTION | | | | |
| DOXYCHEL HYCLATE | | | | |
| RACHELLE | EQ 100MG BASE/VIAL | A061953 | 001 | |
| DOXYCYCLINE | | | | |
| WEST-WARD PHARMS INT | EQ 100MG BASE/VIAL | A062450 | 001 | Oct 27, 1983 |
| | EQ 200MG BASE/VIAL | A062450 | 002 | Oct 27, 1983 |
| | EQ 200MG BASE/VIAL | A062569 | 002 | Mar 09, 1988 |
| DOXYCYCLINE HYCLATE | | | | |
| WEST-WARD PHARMS INT | EQ 100MG BASE/VIAL | A062992 | 001 | Feb 16, 1989 |
| | EQ 200MG BASE/VIAL | A062992 | 002 | Feb 16, 1989 |
| VIBRAMYCIN | | | | |
| + PFIZER | EQ 100MG BASE/VIAL ** | N050442 | 002 | |
| + | EQ 200MG BASE/VIAL ** | N050442 | 001 | |
| TABLET;ORAL | | | | |
| DOXY-LEMMON | | | | |
| TEVA | EQ 100MG BASE | A062581 | 001 | Mar 15, 1985 |
| DOXYCYCLINE HYCLATE | | | | |
| EPIC PHARMA LLC | EQ 20MG BASE | A065182 | 001 | May 13, 2005 |
| HEATHER | EQ 100MG BASE | A062462 | 001 | May 11, 1983 |
| INTERPHARM | EQ 100MG BASE | A062764 | 001 | Sep 02, 1988 |
| MUTUAL PHARM | EQ 100MG BASE | A062391 | 001 | Sep 30, 1982 |
| SUPERPHARM | EQ 100MG BASE | A062494 | 001 | Feb 20, 1985 |
| VINTAGE PHARMS | EQ 100MG BASE | A062538 | 001 | Apr 07, 1986 |
| WARNER CHILCOTT | EQ 100MG BASE | A062593 | 001 | Aug 28, 1985 |
| WATSON LABS | EQ 50MG BASE | A062392 | 001 | Mar 31, 1983 |
| | EQ 100MG BASE | A062392 | 002 | Mar 31, 1983 |
| PERIOSTAT | | | | |
| + GALDERMA LABS LP | EQ 20MG BASE ** | N050783 | 001 | Feb 02, 2001 |
| VIBRA-TABS | | | | |
| + PFIZER | EQ 100MG BASE ** | N050533 | 001 | |
| TABLET, DELAYED RELEASE;ORAL | | | | |
| DORYX MPC | | | | |
| + MAYNE PHARMA | EQ 60MG BASE | N050795 | 007 | May 20, 2016 |
| DOXYCYCLINE HYCLATE | | | | |
| IMPAX LABS INC | EQ 75MG BASE | A090505 | 001 | Dec 28, 2010 |
| | EQ 100MG BASE | A090505 | 002 | Dec 28, 2010 |
| DOXYLAMINE SUCCINATE | | | | |
| CAPSULE;ORAL | | | | |
| UNISOM | | | | |
| PFIZER | 25MG | N019440 | 001 | Feb 05, 1986 |
| TABLET;ORAL | | | | |
| DECAPRYN | | | | |
| SANOFI AVENTIS US | 12.5MG | N006412 | 015 | |
| | 25MG | N006412 | 014 | |
| DOXY-SLEEP-AID | | | | |
| PAR PHARM | 25MG | A070156 | 001 | Jul 02, 1987 |
| DOXYLAMINE SUCCINATE | | | | |
| COPLEY PHARM | 25MG | A088900 | 002 | Feb 12, 1988 |
| QUANTUM PHARMICS | 25MG | A088603 | 001 | Aug 07, 1984 |
| DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE | | | | |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| BENDECTIN | | | | |
| SANOFI AVENTIS US | 10MG;10MG ** | N010598 | 002 | |
| DROMOSTANOLONE PROPIONATE | | | | |
| INJECTABLE;INJECTION | | | | |
| DROLBAN | | | | |
| LILLY | 50MG/ML | N012936 | 001 | |

DRONABINOL

| | | | | |
|---|---|---|---|---|
| CAPSULE;ORAL | | | | |
| DRONABINOL | | | | |
| | INSYS THERAP | 2.5MG | A078501 001 | Aug 19, 2011 |
| | | 5MG | A078501 002 | Aug 19, 2011 |
| | | 10MG | A078501 003 | Aug 19, 2011 |

DROPERIDOL

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| DROPERIDOL | | | | |
| | ABRAXIS PHARM | 2.5MG/ML | A070992 001 | Nov 17, 1986 |
| | | 2.5MG/ML | A070993 001 | Nov 17, 1986 |
| | ASTRAZENECA | 2.5MG/ML | A072018 001 | Oct 20, 1988 |
| | HOSPIRA | 2.5MG/ML | A071645 001 | Apr 07, 1988 |
| | | 2.5MG/ML | A072272 001 | Aug 31, 1995 |
| | IGI LABS INC | 2.5MG/ML | A072019 001 | Oct 19, 1988 |
| | | 2.5MG/ML | A072020 001 | Oct 19, 1988 |
| | | 2.5MG/ML | A072021 001 | Oct 19, 1988 |
| | LUITPOLD | 2.5MG/ML | A072335 001 | Oct 24, 1988 |
| | SMITH AND NEPHEW | 2.5MG/ML | A071750 001 | Sep 06, 1988 |
| | SOLOPAK | 2.5MG/ML | A071754 001 | Sep 06, 1988 |
| | | 2.5MG/ML | A071755 001 | Sep 06, 1988 |
| | WATSON LABS | 2.5MG/ML | A073520 001 | Nov 27, 1991 |
| | | 2.5MG/ML | A073521 001 | Nov 27, 1991 |
| | | 2.5MG/ML | A073523 001 | Nov 27, 1991 |

DROPERIDOL; FENTANYL CITRATE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| FENTANYL CITRATE AND DROPERIDOL | | | | |
| | ASTRAZENECA | 2.5MG/ML;EQ 0.05MG BASE/ML | A072026 001 | Apr 13, 1989 |
| | | 2.5MG/ML;EQ 0.05MG BASE/ML | A072027 001 | Apr 13, 1989 |
| | | 2.5MG/ML;EQ 0.05MG BASE/ML | A072028 001 | Apr 13, 1989 |
| | HOSPIRA | 2.5MG/ML;EQ 0.05MG BASE/ML | A071982 001 | May 04, 1988 |
| INNOVAR | | | | |
| | AKORN MFG | 2.5MG/ML;EQ 0.05MG BASE/ML | N016049 001 | |

DYCLONINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| SOLUTION;TOPICAL | | | | |
| DYCLONE | | | | |
| + | ASTRAZENECA | 0.5% ** | N009925 002 | |
| + | | 1% ** | N009925 001 | |

DYDROGESTERONE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| GYNOREST | | | | |
| | SOLVAY | 5MG ** | N017388 001 | |
| | | 10MG ** | N017388 002 | |

DYPHYLLINE

| | | | | |
|---|---|---|---|---|
| ELIXIR;ORAL | | | | |
| NEOTHYLLINE | | | | |
| | TEVA | 160MG/15ML | N007794 003 | |
| INJECTABLE;INJECTION | | | | |
| NEOTHYLLINE | | | | |
| | TEVA | 250MG/ML | N009088 001 | |
| TABLET;ORAL | | | | |
| DILOR | | | | |
| | SAVAGE LABS | 200MG | A084514 001 | |
| DILOR-400 | | | | |
| | SAVAGE LABS | 400MG | A084751 001 | |
| LUFYLLIN | | | | |
| | MYLAN SPECIALITY LP | 200MG | A084566 001 | |
| | | 400MG | A084566 002 | |
| NEOTHYLLINE | | | | |
| | TEVA | 200MG | N007794 001 | |
| | | 400MG | N007794 002 | |

| | | | | |
|---|---|---|---|---|
| ECHOTHIOPHATE IODIDE | | | | |
| FOR SOLUTION;OPHTHALMIC | | | | |
| PHOSPHOLINE IODIDE | | | | |
| WYETH PHARMS INC | 0.03% | N011963 002 | | |
| | 0.06% | N011963 004 | | |
| | 0.25% | N011963 003 | | |
| EDETATE CALCIUM DISODIUM | | | | |
| TABLET;ORAL | | | | |
| CALCIUM DISODIUM VERSENATE | | | | |
| MEDICIS | 500MG | N008922 002 | | |
| EDROPHONIUM CHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| EDROPHONIUM CHLORIDE | | | | |
| HOSPIRA | 10MG/ML | A040131 001 | Feb 24, 1998 | |
| WATSON LABS | 10MG/ML | A040044 001 | Mar 20, 1996 | |
| EDROPHONIUM CHLORIDE PRESERVATIVE FREE | | | | |
| WATSON LABS | 10MG/ML | A040043 001 | Mar 20, 1996 | |
| REVERSOL | | | | |
| ORGANON USA INC | 10MG/ML | A089624 001 | May 13, 1988 | |
| TENSILON | | | | |
| + TELIGENT | 10MG/ML ** | N007959 001 | | |
| TENSILON PRESERVATIVE FREE | | | | |
| + TELIGENT | 10MG/ML ** | N007959 002 | | |
| EFAVIRENZ | | | | |
| CAPSULE;ORAL | | | | |
| SUSTIVA | | | | |
| + BRISTOL MYERS SQUIBB | 100MG ** | N020972 002 | Sep 17, 1998 | |
| TABLET;ORAL | | | | |
| SUSTIVA | | | | |
| + BRISTOL MYERS SQUIBB | 300MG ** | N021360 001 | Feb 01, 2002 | |
| EFLORNITHINE HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| ORNIDYL | | | | |
| SANOFI AVENTIS US | 200MG/ML | N019879 002 | Nov 28, 1990 | |
| ELVITEGRAVIR | | | | |
| TABLET;ORAL | | | | |
| VITEKTA | | | | |
| + GILEAD SCIENCES INC | 85MG | N203093 001 | Sep 24, 2014 | |
| + | 150MG | N203093 002 | Sep 24, 2014 | |
| ENALAPRIL MALEATE | | | | |
| TABLET;ORAL | | | | |
| ENALAPRIL MALEATE | | | | |
| APOTHECON | 2.5MG | A075583 001 | Aug 22, 2000 | |
| | 5MG | A075583 002 | Aug 22, 2000 | |
| | 10MG | A075583 003 | Aug 22, 2000 | |
| | 20MG | A075583 004 | Aug 22, 2000 | |
| IVAX SUB TEVA PHARMS | 2.5MG | A075482 001 | Aug 22, 2000 | |
| | 5MG | A075482 002 | Aug 22, 2000 | |
| | 10MG | A075482 003 | Aug 22, 2000 | |
| | 20MG | A075482 004 | Aug 22, 2000 | |
| KRKA DD NOVO MESTO | 2.5MG | A075370 001 | Aug 22, 2000 | |
| | 5MG | A075370 002 | Aug 22, 2000 | |
| | 10MG | A075369 001 | Aug 22, 2000 | |
| | 20MG | A075369 002 | Aug 22, 2000 | |
| MYLAN | 2.5MG | A075472 001 | Aug 22, 2000 | |
| | 5MG | A075472 002 | Aug 22, 2000 | |
| | 10MG | A075472 003 | Aug 22, 2000 | |
| | 20MG | A075472 004 | Aug 22, 2000 | |
| SANDOZ | 2.5MG | A075048 001 | Aug 22, 2000 | |
| | 5MG | A075048 002 | Aug 22, 2000 | |
| | 10MG | A075048 003 | Aug 22, 2000 | |
| | 20MG | A075048 004 | Aug 22, 2000 | |
| SANDOZ INC | 2.5MG | A075621 001 | Aug 22, 2000 | |
| | 5MG | A075621 002 | Aug 22, 2000 | |
| | 10MG | A075621 003 | Aug 22, 2000 | |
| | 20MG | A075621 004 | Aug 22, 2000 | |

ENALAPRIL MALEATE
TABLET;ORAL
ENALAPRIL MALEATE

| | | | | |
|---|---|---|---|---|
| SUN PHARM INDS LTD | 2.5MG | A075556 | 001 | Aug 22, 2000 |
| | 5MG | A075556 | 002 | Aug 22, 2000 |
| | 10MG | A075556 | 003 | Aug 22, 2000 |
| | 20MG | A075556 | 004 | Aug 22, 2000 |
| WATSON LABS | 2.5MG | A075501 | 001 | Aug 22, 2000 |
| | 5MG | A075501 | 002 | Aug 22, 2000 |
| | 10MG | A075501 | 003 | Aug 22, 2000 |
| | 20MG | A075501 | 004 | Aug 22, 2000 |

ENALAPRIL MALEATE; FELODIPINE
TABLET, EXTENDED RELEASE;ORAL
LEXXEL

| | | | | |
|---|---|---|---|---|
| ASTRAZENECA | 5MG;2.5MG | N020668 | 002 | Oct 28, 1998 |
| | 5MG;5MG | N020668 | 001 | Dec 27, 1996 |

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE
TABLET;ORAL
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

| | | | | |
|---|---|---|---|---|
| IVAX SUB TEVA PHARMS | 5MG;12.5MG | A075736 | 001 | Mar 25, 2003 |
| | 10MG;25MG | A075736 | 002 | Mar 25, 2003 |
| UPSHER-SMITH LABS | 5MG;12.5MG | A076116 | 001 | Sep 19, 2001 |
| | 10MG;25MG | A076116 | 002 | Sep 19, 2001 |

ENALAPRILAT
INJECTABLE;INJECTION
ENALAPRILAT

| | | | | |
|---|---|---|---|---|
| HOSPIRA | 1.25MG/ML | A075456 | 001 | Aug 22, 2000 |
| | 1.25MG/ML | A075571 | 001 | Aug 22, 2000 |

VASOTEC

| | | | | | |
|---|---|---|---|---|---|
| + | BIOVAIL LABS INTL | 1.25MG/ML | N019309 | 001 | Feb 09, 1988 |

ENFLURANE
LIQUID;INHALATION
ENFLURANE

| | | | | |
|---|---|---|---|---|
| ABBOTT | 99.9% | A070803 | 001 | Sep 08, 1987 |
| PIRAMAL CRITICAL | 99.9% | A074396 | 001 | Jul 29, 1994 |

ETHRANE

| | | | | |
|---|---|---|---|---|
| BAXTER HLTHCARE | 99.9% | N017087 | 001 | |

ENOXACIN
TABLET;ORAL
PENETREX

| | | | | |
|---|---|---|---|---|
| SANOFI AVENTIS US | 200MG | N019616 | 004 | Dec 31, 1991 |
| | 400MG | N019616 | 005 | Dec 31, 1991 |

ENOXAPARIN SODIUM
INJECTABLE;SUBCUTANEOUS
LOVENOX (PRESERVATIVE FREE)

| | | | | | |
|---|---|---|---|---|---|
| + | SANOFI AVENTIS US | 90MG/0.6ML (150MG/ML) ** | N020164 | 006 | Jun 02, 2000 |

ENTACAPONE
TABLET;ORAL
ENTACAPONE

| | | | | |
|---|---|---|---|---|
| MYLAN PHARMS INC | 200MG | A202394 | 001 | May 13, 2013 |

EPINEPHRINE
AEROSOL, METERED;INHALATION
BRONKAID MIST

| | | | | |
|---|---|---|---|---|
| STERLING | 0.25MG/INH | N016803 | 001 | |

EPINEPHRINE

| | | | | |
|---|---|---|---|---|
| ARMSTRONG PHARMS | 0.2MG/INH | A087907 | 001 | May 23, 1984 |

PRIMATENE MIST

| | | | | |
|---|---|---|---|---|
| WYETH CONS | 0.2MG/INH | N016126 | 001 | |

INJECTABLE;INJECTION
SUS-PHRINE SULFITE FREE

| | | | | |
|---|---|---|---|---|
| FOREST LABS | 1.5MG/AMP | N007942 | 003 | Feb 05, 1999 |
| | 5MG/ML | N007942 | 001 | |

INJECTABLE;INTRAMUSCULAR
EPI E Z PEN JR

| | | | | |
|---|---|---|---|---|
| MYLAN SPECIALITY LP | 0.15MG/DELIVERY | N019430 | 004 | Aug 03, 1995 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

EPINEPHRINE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INTRAMUSCULAR | | | | |
| EPIPEN E Z PEN | | | | |
| | MYLAN SPECIALITY LP | 0.3MG/DELIVERY | N019430 003 | Aug 03, 1995 |
| INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS | | | | |
| TWINJECT 0.15 | | | | |
| | IMPAX LABS INC | EQ 0.15MG/DELIVERY | N020800 002 | May 28, 2004 |
| TWINJECT 0.3 | | | | |
| | IMPAX LABS INC | EQ 0.3MG/DELIVERY | N020800 001 | May 30, 2003 |

EPINEPHRINE BITARTRATE

| | | | | |
|---|---|---|---|---|
| AEROSOL, METERED;INHALATION | | | | |
| BRONITIN MIST | | | | |
| | WYETH CONS | 0.3MG/INH | N016126 002 | |
| MEDIHALER-EPI | | | | |
| | 3M | 0.3MG/INH | N010374 003 | |

EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| DURANEST | | | | |
| + | ASTRAZENECA | 0.005MG/ML;1% ** | N017751 006 | |
| + | | 0.005MG/ML;1.5% ** | N017751 007 | |
| + | DENTSPLY PHARM | 0.005MG/ML;1.5% ** | N021384 001 | |

EPINEPHRINE BITARTRATE; PRILOCAINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| CITANEST FORTE | | | | |
| | ASTRAZENECA | 0.005MG/ML;4% | N014763 008 | |

EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| DURANEST | | | | |
| + | ASTRAZENECA | 0.005MG/ML;0.5% ** | N017751 004 | |

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| ALPHACAINE HYDROCHLORIDE W/ EPINEPHRINE | | | | |
| | CARLISLE | 0.01MG/ML;2% | A084720 001 | |
| | | 0.02MG/ML;2% | A084732 001 | |
| LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE | | | | |
| | BELMORA LLC | 0.01MG/ML;2% | A080504 004 | Oct 19, 1983 |
| | | 0.02MG/ML;2% | A080504 005 | Oct 19, 1983 |
| | HOSPIRA | 0.005MG/ML;1% | A089649 001 | Jun 21, 1988 |
| | | 0.005MG/ML;1.5% | A089650 001 | Jun 21, 1988 |
| | WEST-WARD PHARMS INT | 0.01MG/ML;1% | A080406 001 | |
| | | 0.01MG/ML;2% | A080406 002 | |
| LIDOCAINE HYDROCHLORIDE W/ EPINEPHRINE | | | | |
| | ABBOTT | 0.01MG/ML;1% | A083154 001 | |
| | BEL MAR | 0.01MG/ML;1% | A080820 001 | |
| | | 0.01MG/ML;2% | A080757 001 | |
| | DELL LABS | 0.01MG/ML;1% | A083389 001 | |
| | | 0.01MG/ML;2% | A083390 001 | |
| | INTL MEDICATION | 0.01MG/ML;1% | A086402 001 | |
| | WATSON LABS | 0.01MG/ML;1% | A080377 003 | |
| | | 0.01MG/ML;1% | A085463 001 | |
| | | 0.01MG/ML;2% | A080377 004 | |
| LIDOCATON | | | | |
| | PHARMATON | 0.01MG/ML;2% | A084729 001 | Aug 17, 1983 |
| | | 0.02MG/ML;2% | A084728 001 | Aug 17, 1983 |
| XYLOCAINE DENTAL WITH EPINEPHRINE | | | | |
| | DENTSPLY PHARM | 0.01MG/ML;2% | N021381 001 | |
| | | 0.02MG/ML;2% | N021381 002 | |
| XYLOCAINE W/ EPINEPHRINE | | | | |
| | ASTRAZENECA | 0.005MG/ML;1% | N010418 006 | |
| | | 0.005MG/ML;1.5% | N010418 010 | |
| | | 0.005MG/ML;2% | N010418 008 | |
| | FRESENIUS KABI USA | 0.01MG/ML;2% | N006488 003 | |
| PATCH;IONTOPHORESIS, TOPICAL | | | | |
| LIDOSITE TOPICAL SYSTEM KIT | | | | |
| | VYTERIS | 1.05MG/PATCH;100MG/PATCH | N021504 001 | May 06, 2004 |

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| SOLUTION;IONTOPHORESIS | | | | |
| IONTOCAINE | | | | |
| | IOMED | 0.01MG/ML;2% | N020530 001 | Dec 21, 1995 |
| SOLUTION;IONTOPHORESIS, TOPICAL | | | | |
| LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE | | | | |
| | EMPI | 0.01MG/ML;2% | N021486 001 | Oct 26, 2004 |

EPINEPHRINE; PROCAINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| PROCAINE HYDROCHLORIDE W/ EPINEPHRINE | | | | |
| | BEL MAR | 0.02MG/ML;1% | A080758 001 | |
| | | 0.02MG/ML;2% | A080759 001 | |

EPIRUBICIN HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| EPIRUBICIN HYDROCHLORIDE | | | | |
| | EBEWE PHARMA | 50MG/25ML (2MG/ML) | A065339 001 | Dec 22, 2009 |
| | | 200MG/100ML (2MG/ML) | A065339 002 | Dec 22, 2009 |
| | HOSPIRA | 50MG/25ML (2MG/ML) | A065343 002 | Apr 19, 2007 |
| | MUSTAFA NEVSAT | 50MG/25ML (2MG/ML) | A090266 001 | Apr 15, 2011 |
| | | 200MG/100ML (2MG/ML) | A090266 002 | Apr 15, 2011 |
| | MYLAN INSTITUTIONAL | 50MG/25ML (2MG/ML) | A065371 001 | Nov 28, 2007 |
| | | 200MG/100ML (2MG/ML) | A065371 002 | Nov 28, 2007 |
| INJECTABLE;IV (INFUSION) | | | | |
| EPIRUBICIN HYDROCHLORIDE | | | | |
| | HOSPIRA | 50MG/VIAL | N050807 001 | Sep 15, 2006 |
| | | 200MG/VIAL | N050807 002 | Sep 15, 2006 |

EPLERENONE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| INSPRA | | | | |
| | GD SEARLE LLC | 100MG | N021437 003 | Sep 27, 2002 |

EPROSARTAN MESYLATE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| TEVETEN | | | | |
| | ABBVIE | EQ 300MG BASE | N020738 004 | Dec 22, 1997 |

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| TEVETEN HCT | | | | |
| | ABBVIE | 600MG;12.5MG | N021268 001 | Nov 01, 2001 |
| | | 600MG;25MG | N021268 002 | Nov 01, 2001 |

EPTIFIBATIDE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| EPTIFIBATIDE | | | | |
| | TEVA PHARMS USA | 75MG/100ML | A091555 001 | Jun 05, 2015 |

ERGOCALCIFEROL

| | | | | |
|---|---|---|---|---|
| CAPSULE;ORAL | | | | |
| DELTALIN | | | | |
| | LILLY | 50,000 IU | A080884 001 | |
| VITAMIN D | | | | |
| | CHASE CHEM | 50,000 IU | A080747 001 | |
| | EVERYLIFE | 50,000 IU | A080956 001 | |
| | IMPAX LABS | 50,000 IU | A080951 001 | |
| | LANNETT | 50,000 IU | A080825 001 | |
| | VITARINE | 50,000 IU | A084053 001 | |
| | WEST WARD | 50,000 IU | A083102 001 | |

ERGOLOID MESYLATES

| | | | | |
|---|---|---|---|---|
| CAPSULE;ORAL | | | | |
| HYDERGINE LC | | | | |
| | NOVARTIS | 1MG | N018706 001 | Jan 18, 1983 |
| SOLUTION;ORAL | | | | |
| HYDERGINE | | | | |
| | NOVARTIS | 1MG/ML | N018418 001 | |
| TABLET;ORAL | | | | |
| ERGOLOID MESYLATES | | | | |
| | MUTUAL PHARM | 1MG | A088891 001 | Nov 01, 1985 |
| | WATSON LABS | 1MG | A086433 001 | May 27, 1982 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| ERGOLOID MESYLATES | | | | |
| TABLET;ORAL | | | | |
| ERGOLOID MESYLATES | | | | |
| | 1MG | | A087244 001 | Aug 16, 1982 |
| GERIMAL | | | | |
| WATSON LABS | 1MG | | A088207 001 | Mar 22, 1984 |
| HYDERGINE | | | | |
| NOVARTIS | 0.5MG | | N017993 003 | |
| + | 1MG | | N017993 001 | |
| TABLET;SUBLINGUAL | | | | |
| ALKERGOT | | | | |
| SANDOZ | 0.5MG | | A085153 001 | |
| | 1MG | | A087417 001 | |
| CIRCANOL | | | | |
| 3M | 0.5MG | | A084868 001 | |
| | 1MG | | A085809 001 | |
| DEAPRIL-ST | | | | |
| BRISTOL MYERS SQUIBB | 1MG | | A085020 002 | |
| ERGOLOID MESYLATES | | | | |
| KV PHARM | 0.5MG | | A085899 001 | |
| | 0.5MG | | A086265 001 | |
| | 1MG | | A085900 001 | |
| | 1MG | | A086264 001 | |
| LEDERLE | 0.5MG | | A086984 001 | |
| | 1MG | | A086985 001 | |
| SUN PHARM INDUSTRIES | 0.5MG | | A087407 001 | |
| | 1MG | | A087552 001 | |
| SUPERPHARM | 0.5MG | | A089233 001 | Sep 23, 1986 |
| | 1MG | | A089234 001 | Sep 23, 1986 |
| VANGARD | 0.5MG | | A088013 001 | Sep 20, 1982 |
| | 1MG | | A088014 001 | Sep 20, 1982 |
| WATSON LABS | 0.5MG | | A084930 001 | |
| | 0.5MG | | A087233 001 | |
| | 1MG | | A085177 001 | |
| | 1MG | | A087183 001 | |
| GERIMAL | | | | |
| WATSON LABS | 0.5MG | | A086189 001 | |
| | 1MG | | A086188 001 | |
| HYDERGINE | | | | |
| NOVARTIS | 0.5MG | | N009087 002 | |
| | 1MG | | N009087 001 | |
| HYDROGENATED ERGOT ALKALOIDS | | | | |
| IVAX PHARMS | 0.5MG | | A087186 001 | |
| | 1MG | | A087185 001 | |
| ERGOTAMINE TARTRATE | | | | |
| AEROSOL, METERED;INHALATION | | | | |
| MEDIHALER ERGOTAMINE | | | | |
| 3M | 0.36MG/INH | | N012102 001 | |
| TABLET;SUBLINGUAL | | | | |
| ERGOSTAT | | | | |
| WATSON LABS INC | 2MG | | A088337 001 | Jun 08, 1984 |
| WIGRETTES | | | | |
| ORGANON USA INC | 2MG | | A086750 001 | Jul 29, 1982 |
| ERLOTINIB HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| ERLOTINIB HYDROCHLORIDE | | | | |
| MYLAN PHARMS INC | EQ 25MG BASE | | A091002 001 | Jun 11, 2014 |
| | EQ 100MG BASE | | A091002 002 | Jun 11, 2014 |
| | EQ 150MG BASE | | A091002 003 | Jun 11, 2014 |
| TEVA PHARMS USA | EQ 100MG BASE | | A091059 002 | Aug 28, 2015 |
| | EQ 150MG BASE | | A091059 003 | Aug 28, 2015 |
| ERYTHROMYCIN | | | | |
| CAPSULE, DELAYED REL PELLETS;ORAL | | | | |
| ERYC | | | | |
| PARKE DAVIS | 250MG | | A062546 001 | Jul 25, 1985 |
| | 250MG | | A062618 001 | Sep 25, 1985 |
| WARNER CHILCOTT LLC | 250MG | | A062338 001 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

ERYTHROMYCIN

| | | | | |
|---|---|---|---|---|
| CAPSULE, DELAYED REL PELLETS;ORAL | | | | |
| ERYC 125 | | | | |
| PARKE DAVIS | 125MG | A062648 | 001 | Oct 24, 1985 |
| ERYC SPRINKLES | | | | |
| HOSPIRA | 125MG | N050593 | 001 | Jul 22, 1985 |
| ERYTHROMYCIN | | | | |
| BARR | 250MG | A063098 | 001 | May 04, 1989 |
| GEL;TOPICAL | | | | |
| E-GLADES | | | | |
| MYLAN PHARMS INC | 2% | A065009 | 001 | Mar 18, 2002 |
| EMGEL | | | | |
| ALTANA | 2% | A063107 | 001 | Aug 23, 1991 |
| LOTION;TOPICAL | | | | |
| E-SOLVE 2 | | | | |
| SYOSSET | 2% | A062467 | 001 | Jul 03, 1985 |
| OINTMENT;OPHTHALMIC | | | | |
| ERYTHROMYCIN | | | | |
| PHARMADERM | 5MG/GM | A062446 | 001 | Sep 26, 1983 |
| PHARMAFAIR | 5MG/GM | A062481 | 001 | Apr 05, 1984 |
| ILOTYCIN | | | | |
| DISTA | 0.5% | N050368 | 001 | |
| OINTMENT;TOPICAL | | | | |
| AKNE-MYCIN | | | | |
| + DOW PHARM | 2% | N050584 | 001 | Jan 10, 1985 |
| POWDER;FOR RX COMPOUNDING | | | | |
| ERYTHROMYCIN | | | | |
| PADDOCK LLC | 100% | N050610 | 001 | Nov 07, 1986 |
| SOLUTION;TOPICAL | | | | |
| A/T/S | | | | |
| TARO | 2% | A062405 | 001 | Nov 18, 1982 |
| C-SOLVE-2 | | | | |
| FOUGERA PHARMS | 2% | A062468 | 001 | Jul 03, 1985 |
| ERYDERM | | | | |
| ARBOR PHARMS INC | 2% | A062290 | 001 | |
| ERYMAX | | | | |
| MERZ PHARMS | 2% | A062508 | 002 | Jul 11, 1985 |
| ERYTHRA-DERM | | | | |
| SAPTALIS PHARMS | 2% | A062687 | 001 | Feb 05, 1988 |
| ERYTHRO-STATIN | | | | |
| HI TECH PHARMA | 2% | A064101 | 001 | Oct 22, 1996 |
| ERYTHROMYCIN | | | | |
| ALPHARMA US PHARMS | 1.5% | A062328 | 001 | Apr 19, 1982 |
| | 2% | A062326 | 001 | Apr 19, 1982 |
| | 2% | A062327 | 001 | Apr 19, 1982 |
| | 2% | A062342 | 001 | Feb 25, 1982 |
| | 2% | A062957 | 001 | Jul 21, 1988 |
| BAUSCH AND LOMB | 2% | A064039 | 001 | Jan 27, 1994 |
| FOUGERA PHARMS | 2% | A064187 | 001 | Sep 30, 1997 |
| LILLY | 2% | N050532 | 001 | |
| PHARMAFAIR | 1.5% | A062485 | 001 | Jul 11, 1984 |
| | 2% | A062616 | 001 | Jul 25, 1985 |
| RENAISSANCE PHARMA | 2% | A064127 | 001 | Feb 14, 1997 |
| SANSAC | | | | |
| DOW PHARM | 2% | A062522 | 001 | Jan 24, 1985 |
| STATICIN | | | | |
| + WESTWOOD SQUIBB | 1.5% ** | N050526 | 001 | |
| T-STAT | | | | |
| WESTWOOD SQUIBB | 2% ** | A062436 | 001 | Mar 09, 1983 |
| SWAB;TOPICAL | | | | |
| C-SOLVE-2 | | | | |
| IVAX SUB TEVA PHARMS | 2% | A062751 | 001 | Jul 30, 1993 |
| ERYCETTE | | | | |
| + JOHNSON AND JOHNSON | 2% ** | N050594 | 001 | Feb 15, 1985 |
| ERYTHROMYCIN | | | | |
| FOUGERA PHARMS | 2% | A065320 | 001 | Jul 25, 2006 |
| MYLAN PHARMS INC | 2% | A064128 | 001 | Jul 03, 1996 |
| T-STAT | | | | |
| WESTWOOD SQUIBB | 2% | A062748 | 001 | Jul 23, 1987 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

ERYTHROMYCIN

| | | | | |
|---|---|---|---|---|
| TABLET, DELAYED RELEASE;ORAL | | | | |
| E-BASE | | | | |
| BARR | 333MG | | A063028 001 | May 15, 1990 |
| | 333MG | | A063086 001 | May 15, 1990 |
| | 500MG | | A062999 001 | Nov 25, 1988 |
| E-MYCIN | | | | |
| ARBOR PHARMS INC | 250MG | | A060272 001 | |
| | 333MG | | A060272 002 | |
| ILOTYCIN | | | | |
| DISTA | 250MG | | A061910 001 | |
| R-P MYCIN | | | | |
| SOLVAY | 250MG | | A061659 001 | |
| ROBIMYCIN | | | | |
| ROBINS AH | 250MG | | A061633 001 | |

ERYTHROMYCIN ESTOLATE

| | | | | |
|---|---|---|---|---|
| CAPSULE;ORAL | | | | |
| ERYTHROMYCIN ESTOLATE | | | | |
| BARR | EQ 125MG BASE | | A062162 001 | |
| | EQ 250MG BASE | | A062162 002 | |
| IVAX SUB TEVA PHARMS | EQ 250MG BASE | | A062237 001 | |
| WATSON LABS | EQ 250MG BASE | | A062087 001 | |
| ILOSONE | | | | |
| LILLY | EQ 125MG BASE | | A061897 001 | |
| | EQ 250MG BASE | | A061897 002 | |
| FOR SUSPENSION;ORAL | | | | |
| ILOSONE | | | | |
| DISTA | EQ 125MG BASE/5ML | | A061893 001 | |
| SUSPENSION;ORAL | | | | |
| ERYTHROMYCIN ESTOLATE | | | | |
| ALPHARMA US PHARMS | EQ 125MG BASE/5ML | | A062353 001 | Nov 18, 1982 |
| | EQ 250MG BASE/5ML | | A062409 001 | Dec 16, 1982 |
| G AND W LABS INC | EQ 125MG BASE/5ML | | A062169 001 | Oct 17, 1990 |
| | EQ 250MG BASE/5ML | | A062169 002 | Oct 17, 1990 |
| LIFE LABS | EQ 250MG BASE/5ML | | A062362 001 | Dec 17, 1982 |
| ILOSONE | | | | |
| LILLY | EQ 125MG BASE/5ML | | A061894 001 | |
| | EQ 125MG BASE/5ML | | N050010 001 | |
| | EQ 250MG BASE/5ML | | A061894 002 | |
| | EQ 250MG BASE/5ML | | N050010 002 | |
| SUSPENSION/DROPS;ORAL | | | | |
| ILOSONE | | | | |
| LILLY | EQ 100MG BASE/ML | | A061894 003 | |
| TABLET;ORAL | | | | |
| ILOSONE | | | | |
| LILLY | EQ 500MG BASE | | A061896 001 | |
| TABLET, CHEWABLE;ORAL | | | | |
| ILOSONE | | | | |
| DISTA | EQ 125MG BASE | | A061895 001 | |
| | EQ 250MG BASE | | A061895 002 | |

ERYTHROMYCIN ESTOLATE; SULFISOXAZOLE ACETYL

| | | | | |
|---|---|---|---|---|
| SUSPENSION;ORAL | | | | |
| ILOSONE SULFA | | | | |
| LILLY | EQ 125MG BASE/5ML;EQ 600MG BASE/5ML | | N050599 001 | Sep 29, 1989 |

ERYTHROMYCIN ETHYLSUCCINATE

| | | | | |
|---|---|---|---|---|
| GRANULE;ORAL | | | | |
| ERYTHROMYCIN ETHYLSUCCINATE | | | | |
| ANI PHARMS INC | EQ 200MG BASE/5ML | | A062055 001 | |
| PEDIAMYCIN | | | | |
| ROSS LABS | EQ 200MG BASE/5ML | | A062305 001 | |
| SUSPENSION;ORAL | | | | |
| E-MYCIN E | | | | |
| PHARMACIA AND UPJOHN | EQ 200MG BASE/5ML | | A062198 001 | |
| | EQ 400MG BASE/5ML | | A062198 002 | |
| E.E.S. 200 | | | | |
| ARBOR PHARMS LLC | EQ 200MG BASE/5ML ** | | A061639 001 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

ERYTHROMYCIN ETHYLSUCCINATE

| | | | | |
|---|---|---|---|---|
| SUSPENSION;ORAL | | | | |
| E.E.S. 400 | | | | |
| | ARBOR PHARMS LLC | EQ 400MG BASE/5ML ** | A061639 002 | |
| ERYTHROMYCIN ETHYLSUCCINATE | | | | |
| | ALPHARMA US PHARMS | EQ 200MG BASE/5ML | A062200 001 | |
| | | EQ 400MG BASE/5ML | A062200 002 | |
| | DISTA | EQ 200MG BASE/5ML | A062177 001 | |
| | | EQ 400MG BASE/5ML | A062177 002 | |
| | NASKA | EQ 400MG BASE/5ML | A062674 001 | Mar 10, 1987 |
| | PARKE DAVIS | EQ 200MG BASE/5ML | A062231 001 | |
| | | EQ 400MG BASE/5ML | A062231 002 | |
| | PHARMAFAIR | EQ 200MG BASE/5ML | A062559 001 | Mar 15, 1985 |
| | | EQ 400MG BASE/5ML | A062558 001 | Mar 15, 1985 |
| PEDIAMYCIN | | | | |
| | ARBOR PHARMS LLC | EQ 200MG BASE/5ML | A062304 001 | |
| PEDIAMYCIN 400 | | | | |
| | ARBOR PHARMS LLC | EQ 400MG BASE/5ML | A062304 002 | |
| WYAMYCIN E | | | | |
| | WYETH AYERST | EQ 200MG BASE/5ML | A062123 002 | |
| | | EQ 400MG BASE/5ML | A062123 001 | |
| SUSPENSION/DROPS;ORAL | | | | |
| PEDIAMYCIN | | | | |
| | ROSS LABS | EQ 100MG BASE/2.5ML | A062305 002 | |
| TABLET;ORAL | | | | |
| E.E.S. 400 | | | | |
| | ARBOR PHARMS LLC | EQ 400MG BASE | A061905 001 | |
| ERYTHROMYCIN ETHYLSUCCINATE | | | | |
| | BARR | EQ 400MG BASE | A062256 001 | |
| | MYLAN | EQ 400MG BASE | A062847 001 | Sep 14, 1988 |
| TABLET, CHEWABLE;ORAL | | | | |
| E.E.S. | | | | |
| | ARBOR PHARMS INC | EQ 200MG BASE | N050297 002 | |
| ERYPED | | | | |
| | ARBOR PHARMS INC | EQ 200MG BASE | N050297 003 | Jul 05, 1988 |
| PEDIAMYCIN | | | | |
| | ROSS LABS | EQ 200MG BASE | A062306 001 | |

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

| | | | | |
|---|---|---|---|---|
| GRANULE;ORAL | | | | |
| ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL | | | | |
| | BARR | EQ 200MG BASE/5ML;EQ 600MG BASE/5ML | A062759 001 | May 20, 1988 |
| ERYZOLE | | | | |
| | ALRA | EQ 200MG BASE/5ML;EQ 600MG BASE/5ML | A062758 001 | Jun 15, 1988 |
| PEDIAZOLE | | | | |
| | ROSS LABS | EQ 200MG BASE/5ML;EQ 600MG BASE/5ML | N050529 001 | |

ERYTHROMYCIN GLUCEPTATE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| ILOTYCIN GLUCEPTATE | | | | |
| | DISTA | EQ 250MG BASE/VIAL | N050370 001 | |
| | | EQ 500MG BASE/VIAL | N050370 002 | |
| | | EQ 1GM BASE/VIAL | N050370 003 | |

ERYTHROMYCIN LACTOBIONATE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| ERYTHROCIN | | | | |
| | ABBOTT | EQ 500MG BASE/VIAL | A062586 001 | Jan 04, 1988 |
| | | EQ 1GM BASE/VIAL | A062586 002 | Jan 04, 1988 |
| | HOSPIRA | EQ 500MG BASE/VIAL | N050182 002 | |
| | | EQ 1GM BASE/VIAL | N050182 003 | |
| | | EQ 1GM BASE/VIAL | N050609 002 | Sep 24, 1986 |
| ERYTHROMYCIN | | | | |
| | ELKINS SINN | EQ 500MG BASE/VIAL | A062563 001 | Mar 28, 1985 |
| | | EQ 1GM BASE/VIAL | A062563 002 | Mar 28, 1985 |
| ERYTHROMYCIN LACTOBIONATE | | | | |
| | ABRAXIS PHARM | EQ 500MG BASE/VIAL | A062604 001 | Nov 24, 1986 |
| | | EQ 1GM BASE/VIAL | A062604 002 | Nov 24, 1986 |
| | BAXTER HLTHCARE | EQ 500MG BASE/VIAL | A062993 001 | May 09, 1989 |
| | | EQ 1GM BASE/VIAL | A062993 002 | May 09, 1989 |
| | TEVA PARENTERAL | EQ 500MG BASE/VIAL | A063253 001 | Jul 30, 1993 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| ERYTHROMYCIN LACTOBIONATE | | | | |
| INJECTABLE;INJECTION | | | | |
| ERYTHROMYCIN LACTOBIONATE | | | | |
| | EQ 1GM BASE/VIAL | A063253 | 002 | Jul 30, 1993 |
| ERYTHROMYCIN STEARATE | | | | |
| TABLET;ORAL | | | | |
| BRISTAMYCIN | | | | |
| BRISTOL | EQ 250MG BASE | A061304 | 001 | |
| | EQ 250MG BASE | A061887 | 001 | |
| ERYPAR | | | | |
| PARKE DAVIS | EQ 250MG BASE | A062032 | 001 | |
| | EQ 500MG BASE | A062032 | 002 | |
| WARNER CHILCOTT | EQ 250MG BASE | A062322 | 001 | |
| ERYTHROCIN STEARATE | | | | |
| ARBOR PHARMS LLC | EQ 125MG BASE | A060359 | 002 | |
| | EQ 500MG BASE | A060359 | 003 | |
| ERYTHROMYCIN STEARATE | | | | |
| ANI PHARMS INC | EQ 250MG BASE | A061461 | 001 | |
| | EQ 250MG BASE | A061591 | 001 | |
| | EQ 500MG BASE | A061461 | 002 | |
| | EQ 500MG BASE | A063179 | 001 | May 15, 1990 |
| LEDERLE | EQ 250MG BASE | A062089 | 001 | |
| | EQ 500MG BASE | A062089 | 002 | |
| MYLAN | EQ 250MG BASE | A061505 | 001 | |
| | EQ 500MG BASE | A061505 | 002 | |
| PUREPAC PHARM | EQ 250MG BASE | A061743 | 001 | |
| WATSON LABS | EQ 250MG BASE | A062121 | 002 | |
| | EQ 500MG BASE | A062121 | 001 | |
| ETHRIL 250 | | | | |
| BRISTOL MYERS SQUIBB | EQ 250MG BASE | A061605 | 001 | |
| ETHRIL 500 | | | | |
| BRISTOL MYERS SQUIBB | EQ 500MG BASE | A061605 | 002 | |
| PFIZER-E | | | | |
| PFIZER | EQ 250MG BASE | A061791 | 001 | |
| | EQ 500MG BASE | A061791 | 002 | |
| WYAMYCIN S | | | | |
| WYETH AYERST | EQ 250MG BASE | A061675 | 001 | |
| | EQ 500MG BASE | A061675 | 002 | |
| ESCITALOPRAM OXALATE | | | | |
| CAPSULE;ORAL | | | | |
| ESCITALOPRAM OXALATE | | | | |
| MYLAN PHARMS INC | EQ 5MG BASE | A077660 | 001 | Jul 31, 2007 |
| | EQ 10MG BASE | A077660 | 002 | Jul 31, 2007 |
| | EQ 20MG BASE | A077660 | 003 | Jul 31, 2007 |
| TABLET;ORAL | | | | |
| ESCITALOPRAM OXALATE | | | | |
| MYLAN PHARMS INC | EQ 5MG BASE | A077550 | 001 | May 14, 2015 |
| | EQ 10MG BASE | A077550 | 002 | May 14, 2015 |
| | EQ 20MG BASE | A077550 | 003 | May 14, 2015 |
| ESMOLOL HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| BREVIBLOC | | | | |
| BAXTER HLTHCARE | 10MG/ML | N019386 | 003 | Aug 15, 1988 |
| | 20MG/ML | N019386 | 007 | May 28, 2003 |
| ESOMEPRAZOLE SODIUM | | | | |
| INJECTABLE;INTRAVENOUS | | | | |
| ESOMEPRAZOLE SODIUM | | | | |
| AUROBINDO PHARMA LTD | EQ 20MG BASE/VIAL | A204657 | 001 | Aug 10, 2016 |
| MYLAN LABS LTD | EQ 20MG BASE/VIAL | A202686 | 001 | May 17, 2017 |
| SUN PHARMA GLOBAL | EQ 20MG BASE/VIAL | A200882 | 001 | Mar 18, 2013 |
| NEXIUM IV | | | | |
| + ASTRAZENECA PHARMS | EQ 20MG BASE/VIAL | N021689 | 001 | Mar 31, 2005 |

| | | | | | |
|---|---|---|---|---|---|
| ESOMEPRAZOLE STRONTIUM | | | | | |
| CAPSULE, DELAYED RELEASE;ORAL | | | | | |
| ESOMEPRAZOLE STRONTIUM | | | | | |
| + | R2 PHARMA LLC | 24.65MG | N202342 | 001 | Aug 06, 2013 |
| ESTAZOLAM | | | | | |
| TABLET;ORAL | | | | | |
| PROSOM | | | | | |
| + | ABBOTT | 1MG ** | N019080 | 001 | Dec 26, 1990 |
| + | | 2MG ** | N019080 | 002 | Dec 26, 1990 |
| ESTRADIOL | | | | | |
| FILM, EXTENDED RELEASE;TRANSDERMAL | | | | | |
| ESCLIM | | | | | |
| | WOMEN FIRST HLTHCARE | 0.025MG/24HR | N020847 | 001 | Aug 04, 1998 |
| | | 0.0375MG/24HR | N020847 | 002 | Aug 04, 1998 |
| | | 0.05MG/24HR | N020847 | 003 | Aug 04, 1998 |
| | | 0.075MG/24HR | N020847 | 004 | Aug 04, 1998 |
| | | 0.1MG/24HR | N020847 | 005 | Aug 04, 1998 |
| ESTRADERM | | | | | |
| + | NOVARTIS | 0.05MG/24HR | N019081 | 002 | Sep 10, 1986 |
| + | | 0.1MG/24HR | N019081 | 003 | Sep 10, 1986 |
| ESTRADIOL | | | | | |
| | ORTHO MCNEIL PHARM | 0.05MG/24HR | N021048 | 001 | Sep 20, 1999 |
| | | 0.075MG/24HR | N021048 | 002 | Sep 20, 1999 |
| | | 0.1MG/24HR | N021048 | 003 | Sep 20, 1999 |
| FEMPATCH | | | | | |
| | PARKE DAVIS | 0.025MG/24HR | N020417 | 001 | Dec 03, 1996 |
| VIVELLE | | | | | |
| | NOVARTIS | 0.025MG/24HR | N020323 | 005 | Aug 16, 2000 |
| | | 0.0375MG/24HR | N020323 | 001 | Oct 28, 1994 |
| | | 0.05MG/24HR | N020323 | 002 | Oct 28, 1994 |
| | | 0.075MG/24HR | N020323 | 003 | Oct 28, 1994 |
| | | 0.1MG/24HR | N020323 | 004 | Oct 28, 1994 |
| GEL;TOPICAL | | | | | |
| ESTROGEL | | | | | |
| | ASCEND THERAPS US | 0.06% | N021166 | 001 | Feb 09, 2004 |
| TABLET;ORAL | | | | | |
| ESTRACE | | | | | |
| | BRISTOL MYERS SQUIBB | 0.5MG | A081295 | 001 | Jun 30, 1993 |
| | | 1MG | A084499 | 001 | |
| | | 2MG | A084500 | 001 | |
| ESTRADIOL | | | | | |
| | LANNETT HOLDINGS INC | 0.5MG | A040138 | 001 | Jan 30, 1998 |
| | | 1MG | A040138 | 002 | Jan 30, 1998 |
| | | 2MG | A040138 | 003 | Jan 30, 1998 |
| | USL PHARMA | 0.5MG | A040297 | 001 | Apr 17, 2002 |
| | | 1MG | A040297 | 002 | Apr 17, 2002 |
| | | 2MG | A040297 | 003 | Apr 17, 2002 |
| GYNODIOL | | | | | |
| | DURAMED PHARMS BARR | 0.5MG | A040212 | 001 | Dec 29, 1997 |
| | | 1MG | A040212 | 002 | Dec 29, 1997 |
| | | 1.5MG | A040212 | 003 | Dec 29, 1997 |
| | | 2MG | A040212 | 004 | Dec 29, 1997 |
| INNOFEM | | | | | |
| | NOVO NORDISK INC | 0.5MG | A040312 | 001 | Nov 19, 1999 |
| | | 1MG | A040312 | 002 | Nov 19, 1999 |
| | | 2MG | A040312 | 003 | Nov 19, 1999 |
| TABLET;VAGINAL | | | | | |
| VAGIFEM | | | | | |
| + | NOVO NORDISK INC | 25MCG ** | N020908 | 001 | Mar 26, 1999 |
| ESTRADIOL ACETATE | | | | | |
| TABLET;ORAL | | | | | |
| FEMTRACE | | | | | |
| + | APIL | 0.45MG | N021633 | 001 | Aug 20, 2004 |
| + | | 0.9MG | N021633 | 002 | Aug 20, 2004 |
| + | | 1.8MG | N021633 | 003 | Aug 20, 2004 |

ESTRADIOL CYPIONATE
INJECTABLE;INJECTION

| | | | | |
|---|---|---|---|---|
| DEPO-ESTRADIOL | | | | |
| | PHARMACIA AND UPJOHN | 1MG/ML | A085470 001 | |
| | | 3MG/ML | A085470 002 | |
| ESTRADIOL CYPIONATE | | | | |
| | WATSON LABS | 5MG/ML | A085620 001 | |

ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE
INJECTABLE;INTRAMUSCULAR

| | | | | |
|---|---|---|---|---|
| LUNELLE | | | | |
| | PHARMACIA AND UPJOHN | 5MG/0.5ML;25MG/0.5ML | N020874 001 | Oct 05, 2000 |

ESTRADIOL CYPIONATE; TESTOSTERONE CYPIONATE
INJECTABLE;INJECTION

| | | | | |
|---|---|---|---|---|
| DEPO-TESTADIOL | | | | |
| | PHARMACIA AND UPJOHN | 2MG/ML;50MG/ML | N017968 001 | |
| TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE | | | | |
| | WATSON LABS | 2MG/ML;50MG/ML | A085603 001 | Mar 13, 1986 |

ESTRADIOL VALERATE
INJECTABLE;INJECTION

| | | | | |
|---|---|---|---|---|
| ESTRADIOL VALERATE | | | | |
| | SANDOZ INC | 10MG/ML | A040628 001 | Oct 04, 2007 |
| | | 20MG/ML | A040628 002 | Oct 04, 2007 |
| | | 40MG/ML | A040628 003 | Oct 04, 2007 |
| | WATSON LABS | 10MG/ML | A083546 001 | |
| | | 40MG/ML | A083714 001 | |
| | WATSON LABS INC | 20MG/ML | A083547 001 | |

ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE
INJECTABLE;INJECTION

| | | | | |
|---|---|---|---|---|
| DITATE-DS | | | | |
| | SAVAGE LABS | 8MG/ML;180MG/ML | A086423 001 | |
| TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE | | | | |
| | WATSON LABS | 4MG/ML;90MG/ML | A085865 001 | |
| | | 8MG/ML;180MG/ML | A085860 001 | |

ESTRADIOL; NORGESTIMATE
TABLET;ORAL

| | | | | | |
|---|---|---|---|---|---|
| PREFEST | | | | | |
| + | TEVA WOMENS | 1MG,1MG;N/A,0.09MG ** | N021040 001 | Oct 22, 1999 |

ESTROGENS, CONJUGATED
TABLET;ORAL

| | | | | |
|---|---|---|---|---|
| PREMARIN | | | | |
| | WYETH PHARMS INC | 2.5MG | N004782 002 | |

ESTROGENS, CONJUGATED SYNTHETIC A
CREAM;VAGINAL

| | | | | |
|---|---|---|---|---|
| SYNTHETIC CONJUGATED ESTROGENS A | | | | |
| | TEVA WOMENS | 0.625MG/GM | N021788 001 | Nov 28, 2008 |

TABLET;ORAL

| | | | | |
|---|---|---|---|---|
| CENESTIN | | | | |
| + | TEVA BRANDED PHARM | 0.3MG ** | N020992 001 | Jun 21, 2002 |
| + | | 0.45MG ** | N020992 005 | Feb 05, 2004 |
| + | | 0.625MG ** | N020992 002 | Mar 24, 1999 |
| + | | 0.9MG ** | N020992 003 | Mar 24, 1999 |
| + | | 1.25MG ** | N020992 004 | Mar 13, 2000 |

ESTROGENS, CONJUGATED SYNTHETIC B
TABLET;ORAL

| | | | | |
|---|---|---|---|---|
| ENJUVIA | | | | |
| | TEVA BRANDED PHARM | 0.3MG | N021443 001 | Dec 20, 2004 |
| | | 0.45MG | N021443 002 | Dec 20, 2004 |
| | | 0.625MG ** | N021443 003 | May 10, 2004 |
| | | 0.9MG | N021443 005 | Apr 27, 2007 |
| | | 1.25MG ** | N021443 004 | May 10, 2004 |

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL-28 | | | | |
| PREMPHASE (PREMARIN;CYCRIN 14/14) | | | | |
| | WYETH PHARMS INC | 0.625MG,0.625MG;N/A,5MG | N020303 002 | Dec 30, 1994 |
| PREMPRO (PREMARIN;CYCRIN) | | | | |
| | WYETH PHARMS INC | 0.625MG,0.625MG;2.5MG,2.5MG | N020303 001 | Dec 30, 1994 |

ESTROGENS, CONJUGATED; MEPROBAMATE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| MILPREM-200 | | | | |
| | MEDPOINTE PHARM HLC | 0.45MG;200MG | N011045 002 | |
| MILPREM-400 | | | | |
| | MEDPOINTE PHARM HLC | 0.45MG;400MG | N011045 001 | |
| PMB 200 | | | | |
| | WYETH AYERST | 0.45MG;200MG | N010971 005 | |
| PMB 400 | | | | |
| | WYETH AYERST | 0.45MG;400MG | N010971 003 | |

ESTROGENS, ESTERIFIED

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| AMNESTROGEN | | | | |
| | BRISTOL MYERS SQUIBB | 0.3MG | A083266 001 | |
| | | 0.625MG | A083266 002 | |
| | | 1.25MG | A083266 003 | |
| | | 2.5MG | A083266 004 | |
| ESTERIFIED ESTROGENS | | | | |
| | PVT FORM | 0.625MG | A083414 001 | |
| | | 1.25MG | A083765 001 | |
| | | 2.5MG | A085907 001 | |
| | SANDOZ | 1.25MG | A085302 001 | |
| ESTRATAB | | | | |
| | SOLVAY | 0.3MG | A086715 001 | |
| | | 0.625MG | A083209 001 | |
| | | 1.25MG | A083856 001 | |
| | | 2.5MG | A083857 001 | |
| EVEX | | | | |
| | ROCHE PALO | 0.625MG | A084215 001 | |
| | | 1.25MG | A083376 002 | |
| FEMOGEN | | | | |
| | PVT FORM | 0.625MG | A085076 001 | |
| | | 1.25MG | A085008 001 | |
| | | 2.5MG | A085007 001 | |

ESTRONE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| ESTROGENIC SUBSTANCE | | | | |
| | WYETH AYERST | 2MG/ML | A083488 001 | |
| ESTRONE | | | | |
| | WATSON LABS | 2MG/ML | A083397 001 | |
| | WATSON LABS TEVA | 5MG/ML | A085239 001 | |
| NATURAL ESTROGENIC SUBSTANCE-ESTRONE | | | | |
| | WATSON LABS | 2MG/ML | A085237 001 | Nov 23, 1982 |
| THEELIN | | | | |
| | PARKEDALE | 1MG/ML | N003977 001 | |
| | | 2MG/ML | N003977 002 | |
| | | 5MG/ML | N003977 003 | |

ESTROPIPATE

| | | | | |
|---|---|---|---|---|
| CREAM;VAGINAL | | | | |
| OGEN | | | | |
| | PHARMACIA AND UPJOHN | 1.5MG/GM | A084710 001 | |
| TABLET;ORAL | | | | |
| ESTROPIPATE | | | | |
| | BARR | 0.75MG | A040135 001 | Nov 27, 1996 |
| | | 1.5MG | A040135 002 | Nov 27, 1996 |
| | | 3MG | A040135 003 | Nov 27, 1996 |
| | DURAMED PHARMS BARR | 0.75MG | A040296 001 | Nov 01, 1999 |
| | | 1.5MG | A040296 002 | Nov 01, 1999 |
| | | 3MG | A040296 003 | Nov 01, 1999 |
| | MYLAN | 3MG | A040359 003 | Aug 26, 1999 |
| | WATSON LABS | 0.75MG | A081213 001 | Sep 23, 1993 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| ESTROPIPATE | | | | |
| TABLET;ORAL | | | | |
| ESTROPIPATE | | | | |
| | 1.5MG | | A081214 001 | Sep 23, 1993 |
| | 6MG | | A081216 001 | Sep 23, 1993 |
| WATSON LABS TEVA | 3MG | | A081215 001 | Sep 23, 1993 |
| OGEN .625 | | | | |
| PHARMACIA AND UPJOHN | 0.75MG | | A083220 001 | |
| OGEN 1.25 | | | | |
| PHARMACIA AND UPJOHN | 1.5MG | | A083220 002 | |
| OGEN 2.5 | | | | |
| PHARMACIA AND UPJOHN | 3MG | | A083220 003 | |
| ORTHO-EST | | | | |
| SUN PHARM INDS INC | 0.75MG | | A089567 001 | Feb 27, 1991 |
| | 1.5MG | | A089582 001 | Jul 17, 1991 |
| ESZOPICLONE | | | | |
| TABLET;ORAL | | | | |
| ESZOPICLONE | | | | |
| WOCKHARDT LTD | 1MG | | A091165 001 | Jul 14, 2011 |
| | 2MG | | A091165 002 | Jul 14, 2011 |
| | 3MG | | A091165 003 | Jul 14, 2011 |
| ETHACRYNIC ACID | | | | |
| TABLET;ORAL | | | | |
| EDECRIN | | | | |
| ATON | 50MG | | N016092 002 | |
| ETHAMBUTOL HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| MYAMBUTOL | | | | |
| STI PHARMA LLC | 200MG | | N016320 002 | |
| | 500MG | | N016320 004 | |
| ETHCHLORVYNOL | | | | |
| CAPSULE;ORAL | | | | |
| ETHCHLORVYNOL | | | | |
| BANNER PHARMACAPS | 100MG | | A084463 001 | |
| | 200MG | | A084463 002 | |
| | 500MG | | A084463 003 | |
| | 750MG | | A084463 004 | |
| PLACIDYL | | | | |
| ABBVIE | 100MG | | N010021 004 | |
| | 200MG | | N010021 007 | |
| | 500MG | | N010021 002 | |
| | 750MG | | N010021 010 | |
| ETHINAMATE | | | | |
| CAPSULE;ORAL | | | | |
| VALMID | | | | |
| DISTA | 500MG | | N009750 001 | |
| ETHINYL ESTRADIOL | | | | |
| TABLET;ORAL | | | | |
| ESTINYL | | | | |
| SCHERING | 0.02MG | | N005292 001 | |
| | 0.05MG | | N005292 002 | |
| | 0.5MG | | N005292 003 | |
| FEMINONE | | | | |
| PHARMACIA AND UPJOHN | 0.05MG | | N016649 001 | |
| LYNORAL | | | | |
| ORGANON USA INC | 0.01MG | | N005490 003 | |
| | 0.05MG | | N005490 002 | |
| ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE | | | | |
| TABLET;ORAL-21 | | | | |
| DEMULEN 1/35-21 | | | | |
| GD SEARLE LLC | 0.035MG;1MG ** | | N018168 001 | |
| DEMULEN 1/50-21 | | | | |
| GD SEARLE LLC | 0.05MG;1MG | | N016927 001 | |
| ZOVIA 1/35E-21 | | | | |
| WATSON PHARMS TEVA | 0.035MG;1MG | | A072720 001 | Dec 30, 1991 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL-21 | | | | |
| ZOVIA 1/50E-21 | | | | |
| WATSON LABS | 0.05MG;1MG | A072722 | 001 | Dec 30, 1991 |
| TABLET;ORAL-28 | | | | |
| DEMULEN 1/35-28 | | | | |
| GD SEARLE LLC | 0.035MG;1MG ** | N018160 | 001 | |
| DEMULEN 1/50-28 | | | | |
| GD SEARLE LLC | 0.05MG;1MG ** | N016936 | 001 | |

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL-28 | | | | |
| NORQUEST FE | | | | |
| GD SEARLE LLC | 0.035MG;75MG;1MG | N018926 | 001 | Jul 18, 1986 |

ETHINYL ESTRADIOL; FERROUS FUMARATE; NORETHINDRONE ACETATE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL-28 | | | | |
| NORLESTRIN FE 1/50 | | | | |
| PARKE DAVIS | 0.05MG;75MG;1MG | N016766 | 001 | |
| NORLESTRIN FE 2.5/50 | | | | |
| PARKE DAVIS | 0.05MG;75MG;2.5MG | N016854 | 001 | |

ETHINYL ESTRADIOL; LEVONORGESTREL

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| LYBREL | | | | |
| + WYETH PHARMS INC | 0.02MG;0.09MG ** | N021864 | 001 | May 22, 2007 |
| PREVEN EMERGENCY CONTRACEPTIVE KIT | | | | |
| TEVA BRANDED PHARM | 0.05MG;0.25MG | N020946 | 001 | Sep 01, 1998 |
| TABLET;ORAL-21 | | | | |
| ALESSE | | | | |
| + WYETH PHARMS | 0.02MG;0.1MG ** | N020683 | 001 | Mar 27, 1997 |
| AVIANE-21 | | | | |
| DURAMED PHARMS BARR | 0.02MG;0.1MG | A075796 | 002 | Apr 30, 2001 |
| ENPRESSE-21 | | | | |
| DURAMED PHARMS BARR | 0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG | A075809 | 001 | Jul 16, 2001 |
| LESSINA-21 | | | | |
| BARR | 0.02MG;0.1MG | A075803 | 001 | Mar 20, 2002 |
| LEVLITE | | | | |
| + BAYER HLTHCARE | 0.02MG;0.1MG ** | N020860 | 001 | Jul 13, 1998 |
| LEVONORGESTREL AND ETHINYL ESTRADIOL | | | | |
| BARR | 0.02MG;0.1MG | A075862 | 001 | Apr 29, 2003 |
| LEVORA 0.15/30-21 | | | | |
| WATSON LABS | 0.03MG;0.15MG | A073592 | 001 | Dec 13, 1993 |
| NORDETTE-21 | | | | |
| TEVA BRANDED PHARM | 0.03MG;0.15MG | N018668 | 001 | May 10, 1982 |
| PORTIA-21 | | | | |
| BARR | 0.03MG;0.15MG | A075866 | 001 | May 23, 2002 |
| TRIPHASIL-21 | | | | |
| + WYETH PHARMS | 0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG ** | N019192 | 001 | Nov 01, 1984 |
| TRIVORA-21 | | | | |
| MAYNE PHARMA | 0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG | A074538 | 001 | Dec 18, 1997 |
| TABLET;ORAL-28 | | | | |
| ALESSE | | | | |
| + WYETH PHARMS | 0.02MG;0.1MG ** | N020683 | 002 | Mar 27, 1997 |
| LEVLITE | | | | |
| + BAYER HLTHCARE | 0.02MG;0.1MG ** | N020860 | 002 | Jul 13, 1998 |
| LEVONORGESTREL AND ETHINYL ESTRADIOL | | | | |
| BARR | 0.02MG;0.1MG | A075862 | 002 | Apr 29, 2003 |
| NORDETTE-28 | | | | |
| + TEVA BRANDED PHARM | 0.03MG;0.15MG ** | N018782 | 001 | Jul 21, 1982 |
| TRIPHASIL-28 | | | | |
| + WYETH PHARMS INC | 0.03MG,0.04MG,0.03MG;0.05MG,0.075MG,0.125MG ** | N019190 | 001 | Nov 01, 1984 |

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL

| | | | | | |
|---|---|---|---|---|---|
| ORTHO EVRA | | | | | |
| + | JANSSEN PHARMS | 0.035MG/24HR;0.15MG/24HR ** | N021180 | 001 | Nov 20, 2001 |

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-21

| | | | | | |
|---|---|---|---|---|---|
| BALZIVA-21 | | | | | |
| | BARR | 0.035MG;0.4MG | A076198 | 001 | Apr 22, 2004 |
| BREVICON 21-DAY | | | | | |
| | ALLERGAN SALES LLC | 0.035MG;0.5MG | N017566 | 001 | |
| GENCEPT 10/11-21 | | | | | |
| | BARR | 0.035MG,0.035MG;0.5MG,1MG | A072694 | 001 | Feb 28, 1992 |
| MODICON 21 | | | | | |
| | ORTHO MCNEIL PHARM | 0.035MG;0.5MG | N017488 | 001 | |
| N.E.E. 1/35 21 | | | | | |
| | LPI | 0.035MG;1MG | A071541 | 001 | Dec 14, 1987 |
| NORCEPT-E 1/35 21 | | | | | |
| | ORTHO MCNEIL PHARM | 0.035MG;1MG | A071545 | 001 | Feb 09, 1989 |
| NORETHIN 1/35E-21 | | | | | |
| | WATSON PHARMS TEVA | 0.035MG;1MG | A071480 | 001 | Apr 12, 1988 |
| NORETHINDRONE AND ETHINYL ESTRADIOL | | | | | |
| | WATSON LABS | 0.035MG;0.4MG | A078379 | 001 | Feb 23, 2010 |
| | | 0.035MG;0.5MG | A070684 | 001 | Jan 29, 1987 |
| | WATSON PHARMS TEVA | 0.035MG;1MG | A070685 | 001 | Jan 29, 1987 |
| NORETHINDRONE AND ETHINYL ESTRADIOL (10/11) | | | | | |
| | WATSON LABS | 0.035MG,0.035MG;0.5MG,1MG | A071043 | 001 | Apr 01, 1988 |
| NORETHINDRONE AND ETHINYL ESTRADIOL (7/14) | | | | | |
| | WATSON LABS TEVA | 0.035MG,0.035MG;0.5MG,1MG | A071041 | 001 | Sep 24, 1991 |
| NORTREL 0.5/35-21 | | | | | |
| | BARR | 0.035MG;0.5MG | A072692 | 001 | Feb 28, 1992 |
| ORTHO-NOVUM 1/35-21 | | | | | |
| | ORTHO MCNEIL PHARM | 0.035MG;1MG | N017489 | 002 | |
| ORTHO-NOVUM 10/11-21 | | | | | |
| + | ORTHO MCNEIL JANSSEN | 0.035MG,0.035MG;0.5MG,1MG ** | N018354 | 001 | Jan 11, 1982 |
| ORTHO-NOVUM 7/14-21 | | | | | |
| | ORTHO MCNEIL PHARM | 0.035MG,0.035MG;0.5MG,1MG | N019004 | 001 | Apr 04, 1984 |
| ORTHO-NOVUM 7/7/7-21 | | | | | |
| | JANSSEN PHARMS | 0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG | N018985 | 001 | Apr 04, 1984 |
| OVCON-35 | | | | | |
| + | WARNER CHILCOTT | 0.035MG;0.4MG ** | N018127 | 001 | |
| OVCON-50 | | | | | |
| | WARNER CHILCOTT | 0.05MG;1MG | N018128 | 001 | |
| TRI-NORINYL 21-DAY | | | | | |
| | MAYNE PHARMA | 0.035MG,0.035MG,0.035MG;0.5MG,1MG,0.5MG | N018977 | 001 | Apr 13, 1984 |

TABLET;ORAL-28

| | | | | | |
|---|---|---|---|---|---|
| GENCEPT 10/11-28 | | | | | |
| | BARR | 0.035MG,0.035MG;0.5MG,1MG | A072697 | 001 | Feb 28, 1992 |
| N.E.E. 1/35 28 | | | | | |
| | LPI | 0.035MG;1MG | A071542 | 001 | Dec 14, 1987 |
| NORCEPT-E 1/35 28 | | | | | |
| | ORTHO MCNEIL PHARM | 0.035MG;1MG | A071546 | 001 | Feb 09, 1989 |
| NORETHIN 1/35E-28 | | | | | |
| | WATSON LABS | 0.035MG;1MG | A071481 | 001 | Apr 12, 1988 |
| NORETHINDRONE AND ETHINYL ESTRADIOL | | | | | |
| | MYLAN LABS LTD | 0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG | A200486 | 001 | Dec 28, 2015 |
| | | 0.035MG;0.5MG | A200488 | 001 | Oct 21, 2015 |
| | | 0.035MG;1MG | A200489 | 001 | Oct 21, 2015 |
| | WATSON LABS | 0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG | A076393 | 001 | Feb 04, 2010 |
| NORETHINDRONE AND ETHINYL ESTRADIOL (7/14) | | | | | |
| | WATSON LABS | 0.035MG,0.035MG;0.5MG,1MG | A071042 | 001 | Sep 24, 1991 |
| ORTHO-NOVUM 10/11-28 | | | | | |
| + | ORTHO MCNEIL JANSSEN | 0.035MG,0.035MG;0.5MG,1MG | N018354 | 002 | Jan 11, 1982 |
| ORTHO-NOVUM 7/14-28 | | | | | |
| | ORTHO MCNEIL PHARM | 0.035MG,0.035MG;0.5MG,1MG | N019004 | 002 | Apr 04, 1984 |
| OVCON-35 | | | | | |
| + | WARNER CHILCOTT LLC | 0.035MG;0.4MG ** | N017716 | 001 | |

| | | | | |
|---|---|---|---|---|
| ETHINYL ESTRADIOL; NORETHINDRONE | | | | |
| TABLET;ORAL-28 | | | | |
| OVCON-50 | | | | |
| | WARNER CHILCOTT LLC | 0.05MG;1MG | N017576 001 | |
| ETHINYL ESTRADIOL; NORETHINDRONE ACETATE | | | | |
| TABLET;ORAL | | | | |
| FEMHRT | | | | |
| + | APIL | 0.005MG;1MG ** | N021065 002 | Oct 15, 1999 |
| TABLET;ORAL-21 | | | | |
| ESTROSTEP 21 | | | | |
| + | APIL | 0.02MG,0.03MG,0.035MG;1MG,1MG,1MG ** | N020130 001 | Oct 09, 1996 |
| NORLESTRIN 21 1/50 | | | | |
| | PARKE DAVIS | 0.05MG;1MG | N016749 001 | |
| NORLESTRIN 21 2.5/50 | | | | |
| | PARKE DAVIS | 0.05MG;2.5MG | N016852 001 | |
| TABLET;ORAL-28 | | | | |
| NORLESTRIN 28 1/50 | | | | |
| | PARKE DAVIS | 0.05MG;1MG | N016723 001 | |
| ETHINYL ESTRADIOL; NORGESTIMATE | | | | |
| TABLET;ORAL-21 | | | | |
| ORTHO CYCLEN-21 | | | | |
| | JANSSEN PHARMS | 0.035MG;0.25MG | N019653 001 | Dec 29, 1989 |
| ORTHO TRI-CYCLEN | | | | |
| | JANSSEN PHARMS | 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG | N019697 002 | Jul 03, 1992 |
| TABLET;ORAL-28 | | | | |
| NORGESTIMATE AND ETHINYL ESTRADIOL | | | | |
| | WATSON LABS | 0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG | A090479 001 | Mar 09, 2011 |
| | | 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG | A076626 001 | Aug 17, 2006 |
| | | 0.035MG;0.25MG | A076627 001 | Aug 17, 2006 |
| ETHINYL ESTRADIOL; NORGESTREL | | | | |
| TABLET;ORAL-21 | | | | |
| LO/OVRAL | | | | |
| | PELAGIUS | 0.03MG;0.3MG | N017612 001 | |
| LOW-OGESTREL-21 | | | | |
| | MAYNE PHARMA | 0.03MG;0.3MG | A075288 001 | Jul 28, 1999 |
| OGESTREL 0.5/50-21 | | | | |
| | WATSON LABS | 0.05MG;0.5MG | A075406 001 | Dec 15, 1999 |
| OVRAL | | | | |
| | WYETH PHARMS | 0.05MG;0.5MG | N016672 001 | |
| TABLET;ORAL-28 | | | | |
| LO/OVRAL-28 | | | | |
| | WYETH PHARMS | 0.03MG;0.3MG ** | N017802 001 | |
| NORGESTREL AND ETHINYL ESTRADIOL | | | | |
| | MYLAN LABS LTD | 0.03MG;0.3MG | A201828 001 | Jun 21, 2016 |
| | | 0.05MG;0.5MG | A202875 001 | May 08, 2017 |
| OVRAL-28 | | | | |
| | WYETH PHARMS | 0.05MG;0.5MG | N016806 001 | |
| ETHOPROPAZINE HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| PARSIDOL | | | | |
| | PARKE DAVIS | 10MG | N009078 003 | |
| | | 50MG | N009078 006 | |
| | | 100MG | N009078 008 | |
| ETHOTOIN | | | | |
| TABLET;ORAL | | | | |
| PEGANONE | | | | |
| | RECORDATI RARE | 500MG | N010841 003 | |
| ETHOXZOLAMIDE | | | | |
| TABLET;ORAL | | | | |
| CARDRASE | | | | |
| | PHARMACIA AND UPJOHN | 62.5MG | N011047 002 | |
| | | 125MG | N011047 001 | |

| | | | | |
|---|---|---|---|---|
| ETHOXZOLAMIDE | | | | |
| TABLET;ORAL | | | | |
| ETHAMIDE | | | | |
| | ALLERGAN | 125MG | N016144 001 | |
| ETHYLESTRENOL | | | | |
| ELIXIR;ORAL | | | | |
| MAXIBOLIN | | | | |
| | ORGANON USA INC | 2MG/5ML | N014006 002 | |
| TABLET;ORAL | | | | |
| MAXIBOLIN | | | | |
| | ORGANON USA INC | 2MG | N014005 002 | |
| ETHYNODIOL DIACETATE; MESTRANOL | | | | |
| TABLET;ORAL-20 | | | | |
| OVULEN | | | | |
| | GD SEARLE LLC | 1MG;0.1MG | N016029 002 | |
| TABLET;ORAL-21 | | | | |
| OVULEN-21 | | | | |
| | GD SEARLE LLC | 1MG;0.1MG | N016029 003 | |
| TABLET;ORAL-28 | | | | |
| OVULEN-28 | | | | |
| | GD SEARLE LLC | 1MG;0.1MG | N016705 001 | |
| ETIDOCAINE HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| DURANEST | | | | |
| + | ASTRAZENECA | 0.5% ** | N017751 003 | |
| + | | 1% ** | N017751 005 | |
| ETIDRONATE DISODIUM | | | | |
| INJECTABLE;INJECTION | | | | |
| DIDRONEL | | | | |
| | MGI PHARMA INC | 50MG/ML | N019545 001 | Apr 20, 1987 |
| TABLET;ORAL | | | | |
| DIDRONEL | | | | |
| + | APIL | 200MG | N017831 001 | |
| + | | 400MG | N017831 002 | |
| ETODOLAC | | | | |
| CAPSULE;ORAL | | | | |
| ETODOLAC | | | | |
| | ANI PHARMS INC | 200MG | A074899 001 | Jul 08, 1997 |
| | | 300MG | A074899 002 | Jul 08, 1997 |
| | CHARTWELL MOLECULES | 200MG | A074842 001 | Jul 17, 1997 |
| | | 300MG | A074842 002 | Jul 17, 1997 |
| | ECI PHARMS LLC | 300MG | A074929 001 | Jan 30, 1998 |
| | IDT AUSTRALIA LTD | 200MG | A074840 001 | Aug 29, 1997 |
| | | 300MG | A074840 002 | Aug 29, 1997 |
| | MYLAN | 200MG | A074932 001 | May 16, 1997 |
| | | 200MG | A075071 001 | Sep 30, 1998 |
| | | 300MG | A074932 002 | May 16, 1997 |
| | | 300MG | A075071 002 | Sep 30, 1998 |
| | SANDOZ | 200MG | A074942 001 | Sep 30, 1997 |
| | | 300MG | A074942 002 | Sep 30, 1997 |
| | WATSON LABS | 200MG | A074844 001 | Dec 23, 1997 |
| | | 300MG | A074844 002 | Dec 23, 1997 |
| LODINE | | | | |
| + | WYETH PHARMS INC | 200MG ** | N018922 002 | Jan 31, 1991 |
| + | | 300MG | N018922 003 | Jan 31, 1991 |
| TABLET;ORAL | | | | |
| ETODOLAC | | | | |
| | CHARTWELL MOLECULES | 400MG | A074841 001 | Jun 27, 1997 |
| | ECI PHARMS LLC | 400MG | A074927 001 | Oct 30, 1997 |
| | IVAX SUB TEVA PHARMS | 400MG | A074883 001 | Feb 28, 1997 |
| | | 500MG | A074883 002 | Nov 20, 1998 |
| | MYLAN | 400MG | A075012 001 | Sep 30, 1998 |
| | | 500MG | A075012 002 | Sep 30, 1998 |
| | MYLAN PHARMS INC | 400MG | A075104 001 | Feb 06, 1998 |
| | | 500MG | A075104 002 | Nov 20, 1998 |
| | OXFORD PHARMS | 400MG | A074819 001 | Feb 28, 1997 |
| | | 500MG | A074819 002 | Apr 28, 1998 |

ETODOLAC

TABLET;ORAL

ETODOLAC

| | | | | |
|---|---|---|---|---|
| RANBAXY LABS LTD | 400MG | A075226 | 001 | Nov 24, 1998 |
| | 500MG | A075226 | 002 | Nov 24, 1998 |
| SANDOZ | 400MG | A074839 | 001 | Jul 11, 1997 |
| | 400MG | A074846 | 001 | Feb 28, 1997 |
| TEVA | 400MG | A074847 | 001 | Apr 23, 1999 |
| | 500MG | A074847 | 002 | Apr 23, 1999 |
| WATSON LABS | 400MG | A074892 | 001 | Apr 16, 1997 |
| | 400MG | A075069 | 001 | Apr 16, 1998 |
| | 500MG | A074892 | 002 | Oct 29, 1998 |

LODINE

| | | | | |
|---|---|---|---|---|
| + WYETH PHARMS INC | 400MG ** | N018922 | 004 | Jul 29, 1993 |
| + | 500MG ** | N018922 | 005 | Jun 28, 1996 |

TABLET, EXTENDED RELEASE;ORAL

ETODOLAC

| | | | | |
|---|---|---|---|---|
| ACTAVIS ELIZABETH | 400MG | A075696 | 001 | Jul 31, 2000 |
| IDT AUSTRALIA LTD | 400MG | A075943 | 001 | Jul 26, 2002 |
| | 500MG | A075943 | 002 | Jul 26, 2002 |
| | 600MG | A075943 | 003 | Jul 26, 2002 |
| WATSON LABS FLORIDA | 400MG | A075829 | 001 | Nov 30, 2001 |
| | 500MG | A075829 | 002 | Nov 30, 2001 |

LODINE XL

| | | | | |
|---|---|---|---|---|
| WYETH PHARMS INC | 400MG ** | N020584 | 001 | Oct 25, 1996 |
| | 500MG ** | N020584 | 003 | Jan 20, 1998 |
| + | 600MG ** | N020584 | 002 | Oct 25, 1996 |

ETONOGESTREL

IMPLANT;IMPLANTATION

IMPLANON

| | | | | |
|---|---|---|---|---|
| ORGANON USA INC | 68MG/IMPLANT | N021529 | 001 | Jul 17, 2006 |

ETOPOSIDE

CAPSULE;ORAL

VEPESID

| | | | | |
|---|---|---|---|---|
| + DAVA PHARMS INC | 50MG | N019557 | 001 | Dec 30, 1986 |
| + | 100MG | N019557 | 002 | Dec 30, 1986 |

INJECTABLE;INJECTION

ETOPOSIDE

| | | | | |
|---|---|---|---|---|
| HOSPIRA | 20MG/ML | A074320 | 001 | Aug 30, 1995 |
| | 20MG/ML | A074351 | 001 | Aug 30, 1995 |
| PHARMACHEMIE BV | 20MG/ML | A074227 | 001 | Feb 22, 1996 |
| PIERRE FABRE | 20MG/ML | A074813 | 001 | Jul 09, 1997 |
| TEVA PARENTERAL | 20MG/ML | A074510 | 001 | Jun 29, 1995 |
| TEVA PHARMS USA | 20MG/ML | A074284 | 001 | Feb 10, 1994 |
| WATSON LABS | 20MG/ML | A074228 | 001 | Oct 15, 1996 |
| WATSON LABS INC | 20MG/ML | A074968 | 001 | Jan 09, 1998 |

TOPOSAR

| | | | | |
|---|---|---|---|---|
| TEVA PARENTERAL | 20MG/ML | A074166 | 001 | Feb 27, 1995 |

VEPESID

| | | | | |
|---|---|---|---|---|
| + CORDEN PHARMA | 20MG/ML ** | N018768 | 001 | Nov 10, 1983 |

ETOPOSIDE PHOSPHATE

INJECTABLE;INJECTION

ETOPOPHOS PRESERVATIVE FREE

| | | | | |
|---|---|---|---|---|
| BRISTOL MYERS SQUIBB | EQ 500MG BASE/VIAL | N020906 | 001 | Feb 27, 1998 |
| | EQ 1GM BASE/VIAL | N020906 | 002 | Feb 27, 1998 |

ETRETINATE

CAPSULE;ORAL

TEGISON

| | | | | |
|---|---|---|---|---|
| ROCHE | 10MG | N019369 | 001 | Sep 30, 1986 |
| | 25MG | N019369 | 002 | Sep 30, 1986 |

EVANS BLUE

INJECTABLE;INJECTION

EVANS BLUE

| | | | |
|---|---|---|---|
| PARKE DAVIS | 0.5% ** | N008041 | 001 |

| | | | | | |
|---|---|---|---|---|---|
| EZOGABINE | | | | | |
| TABLET;ORAL | | | | | |
| POTIGA | | | | | |
| + | GLAXOSMITHKLINE | 50MG | N022345 | 001 | Jun 10, 2011 |
| + | | 200MG | N022345 | 002 | Jun 10, 2011 |
| + | | 300MG | N022345 | 003 | Jun 10, 2011 |
| + | | 400MG | N022345 | 004 | Jun 10, 2011 |
| FAMCICLOVIR | | | | | |
| TABLET;ORAL | | | | | |
| FAMVIR | | | | | |
| + | NOVARTIS | 125MG | N020363 | 003 | Dec 11, 1995 |
| + | | 250MG | N020363 | 001 | Apr 26, 1996 |
| + | | 500MG | N020363 | 002 | Jun 29, 1994 |
| FAMOTIDINE | | | | | |
| INJECTABLE;INJECTION | | | | | |
| FAMOTIDINE | | | | | |
| | APOTEX INC | 10MG/ML | A075942 | 001 | Aug 02, 2002 |
| | APOTHECON | 10MG/ML | A075707 | 001 | Apr 16, 2001 |
| | HOSPIRA | 10MG/ML | A075705 | 001 | Apr 16, 2001 |
| | | 10MG/ML | A075870 | 001 | Nov 23, 2001 |
| | | 10MG/ML | A075905 | 001 | Nov 23, 2001 |
| | WEST-WARD PHARMS INT | 10MG/ML | A075799 | 001 | Apr 30, 2002 |
| FAMOTIDINE PRESERVATIVE FREE | | | | | |
| | APOTEX INC | 10MG/ML | A076324 | 001 | Nov 27, 2002 |
| | APOTHECON | 10MG/ML | A075708 | 001 | Apr 16, 2001 |
| | HOSPIRA | 10MG/ML | A075669 | 001 | Apr 16, 2001 |
| | WEST-WARD PHARMS INT | 10MG/ML | A075789 | 001 | Apr 30, 2002 |
| FAMOTIDINE PRESERVATIVE FREE (PHARMACY BULK) | | | | | |
| | APOTEX INC | 10MG/ML | A076322 | 001 | Nov 27, 2002 |
| FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER | | | | | |
| | ABBVIE | 0.4MG/ML | A075729 | 001 | Dec 17, 2001 |
| PEPCID | | | | | |
| + | MERCK | 10MG/ML ** | N019510 | 001 | Nov 04, 1986 |
| PEPCID PRESERVATIVE FREE | | | | | |
| + | MERCK | 10MG/ML ** | N019510 | 004 | Nov 04, 1986 |
| PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER | | | | | |
| + | MERCK SHARP DOHME | 0.4MG/ML ** | N020249 | 001 | Feb 18, 1994 |
| TABLET;ORAL | | | | | |
| FAMOTIDINE | | | | | |
| | ACTAVIS ELIZABETH | 20MG | A075650 | 001 | Sep 14, 2001 |
| | | 40MG | A075650 | 002 | Sep 14, 2001 |
| | APOTEX | 10MG | A075610 | 001 | Mar 12, 2002 |
| | MYLAN PHARMS INC | 20MG | A075457 | 001 | Apr 18, 2001 |
| | | 40MG | A075457 | 002 | Apr 18, 2001 |
| | SANDOZ | 10MG | A076101 | 001 | Oct 21, 2002 |
| | | 20MG | A075302 | 001 | Apr 16, 2001 |
| | | 20MG | A075607 | 001 | May 10, 2001 |
| | | 20MG | A075793 | 001 | Apr 16, 2001 |
| | | 40MG | A075302 | 002 | Apr 16, 2001 |
| | | 40MG | A075607 | 002 | May 10, 2001 |
| | | 40MG | A075793 | 002 | Apr 16, 2001 |
| | SUN PHARM INDUSTRIES | 20MG | A075639 | 002 | Dec 12, 2001 |
| | | 40MG | A075639 | 001 | Dec 12, 2001 |
| | WATSON LABS | 10MG | A075404 | 001 | Nov 28, 2001 |
| | | 20MG | A075062 | 002 | Apr 16, 2001 |
| | | 40MG | A075062 | 001 | Apr 16, 2001 |
| TABLET, CHEWABLE;ORAL | | | | | |
| PEPCID AC | | | | | |
| + | J AND J CONSUMER INC | 10MG ** | N020801 | 001 | Sep 24, 1998 |
| TABLET, ORALLY DISINTEGRATING;ORAL | | | | | |
| FLUXID | | | | | |
| | UCB INC | 20MG | N021712 | 001 | Sep 24, 2004 |
| | | 40MG | N021712 | 002 | Sep 24, 2004 |
| PEPCID RPD | | | | | |
| | MERCK | 20MG | N020752 | 001 | May 28, 1998 |
| | | 40MG | N020752 | 002 | May 28, 1998 |

| | | | | |
|---|---|---|---|---|
| FELODIPINE | | | | |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| FELODIPINE | | | | |
| WOCKHARDT LTD | 2.5MG | | A091484 001 | Aug 15, 2012 |
| | 5MG | | A091484 002 | Aug 15, 2012 |
| | 10MG | | A091484 003 | Aug 15, 2012 |
| PLENDIL | | | | |
| + ASTRAZENECA | 2.5MG ** | | N019834 004 | Sep 22, 1994 |
| + | 5MG ** | | N019834 001 | Jul 25, 1991 |
| + | 10MG ** | | N019834 002 | Jul 25, 1991 |
| FENOFIBRATE | | | | |
| CAPSULE;ORAL | | | | |
| ANTARA (MICRONIZED) | | | | |
| LUPIN ATLANTIS | 87MG | | N021695 002 | Nov 30, 2004 |
| LIPIDIL | | | | |
| ABBVIE | 100MG | | N019304 001 | Dec 31, 1993 |
| LIPOFEN | | | | |
| CIPHER PHARMS INC | 100MG | | N021612 002 | Jan 11, 2006 |
| TRICOR (MICRONIZED) | | | | |
| + ABBVIE | 67MG ** | | N019304 002 | Feb 09, 1998 |
| + | 134MG ** | | N019304 003 | Jun 30, 1999 |
| + | 200MG ** | | N019304 004 | Jun 30, 1999 |
| TABLET;ORAL | | | | |
| FENOFIBRATE | | | | |
| MYLAN | 107MG | | A076520 002 | Dec 29, 2005 |
| TRICOR | | | | |
| + ABBVIE INC | 54MG ** | | N021203 001 | Sep 04, 2001 |
| + | 160MG ** | | N021203 003 | Sep 04, 2001 |
| TRIGLIDE | | | | |
| SKYEPHARMA AG | 50MG | | N021350 001 | May 07, 2005 |
| FENOLDOPAM MESYLATE | | | | |
| INJECTABLE;INJECTION | | | | |
| FENOLDOPAM MESYLATE | | | | |
| LUITPOLD | EQ 10MG BASE/ML | | A076656 001 | Dec 01, 2003 |
| TEVA PARENTERAL | EQ 10MG BASE/ML | | A077826 001 | Mar 07, 2007 |
| FENOPROFEN CALCIUM | | | | |
| CAPSULE;ORAL | | | | |
| FENOPROFEN CALCIUM | | | | |
| AM THERAP | EQ 200MG BASE | | A072307 001 | Aug 22, 1988 |
| | EQ 300MG BASE | | A072308 001 | Aug 22, 1988 |
| AUROLIFE PHARMA LLC | EQ 200MG BASE | | A072394 001 | Oct 17, 1988 |
| | EQ 300MG BASE | | A072395 001 | Oct 17, 1988 |
| HALSEY | EQ 200MG BASE | | A072355 001 | Aug 17, 1988 |
| | EQ 300MG BASE | | A072356 001 | Aug 17, 1988 |
| PAR PHARM | EQ 200MG BASE | | A072437 001 | Aug 22, 1988 |
| | EQ 300MG BASE | | A072438 001 | Aug 22, 1988 |
| QUANTUM PHARMICS | EQ 200MG BASE | | A072214 001 | Aug 17, 1988 |
| | EQ 300MG BASE | | A071738 001 | Aug 17, 1988 |
| WARNER CHILCOTT | EQ 200MG BASE | | A072946 001 | Apr 30, 1991 |
| | EQ 300MG BASE | | A072472 001 | Apr 30, 1991 |
| WATSON LABS | EQ 200MG BASE | | A072294 001 | Aug 17, 1988 |
| | EQ 200MG BASE | | A072981 001 | Aug 19, 1991 |
| | EQ 300MG BASE | | A072293 001 | Aug 17, 1988 |
| | EQ 300MG BASE | | A072982 001 | Aug 19, 1991 |
| NALFON | | | | |
| XSPIRE PHARMA | EQ 300MG BASE | | N017604 002 | |
| TABLET;ORAL | | | | |
| FENOPROFEN CALCIUM | | | | |
| ACTAVIS ELIZABETH | EQ 600MG BASE | | A072274 001 | May 02, 1988 |
| AM THERAP | EQ 600MG BASE | | A072309 001 | Aug 17, 1988 |
| AUROLIFE PHARMA LLC | EQ 600MG BASE | | A072396 001 | Oct 17, 1988 |
| DAVA PHARMS INC | EQ 600MG BASE | | A072326 001 | Aug 17, 1988 |
| HALSEY | EQ 600MG BASE | | A072357 001 | Aug 17, 1988 |
| IVAX SUB TEVA PHARMS | EQ 600MG BASE | | A072557 001 | Aug 29, 1988 |
| PAR PHARM | EQ 600MG BASE | | A072429 001 | Aug 17, 1988 |
| QUANTUM PHARMICS | EQ 600MG BASE | | A072194 001 | Aug 17, 1988 |
| SUN PHARM INDUSTRIES | EQ 600MG BASE | | A072902 001 | Dec 21, 1990 |
| USL PHARMA | EQ 600MG BASE | | A072362 001 | Aug 17, 1988 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| FENOPROFEN CALCIUM | | | | |
| TABLET;ORAL | | | | |
| FENOPROFEN CALCIUM | | | | |
| WATSON LABS | EQ 600MG BASE | A072165 | 001 | Aug 17, 1988 |
| | EQ 600MG BASE | A072602 | 001 | Oct 11, 1988 |
| WATSON LABS TEVA | EQ 600MG BASE | A072407 | 001 | Aug 17, 1988 |
| NALFON | | | | |
| DISTA | EQ 600MG BASE | N017710 | 001 | |
| FENTANYL | | | | |
| FILM, EXTENDED RELEASE;TRANSDERMAL | | | | |
| FENTANYL-100 | | | | |
| NOVEN | 100MCG/HR | A077775 | 004 | Oct 16, 2009 |
| FENTANYL-25 | | | | |
| NOVEN | 25MCG/HR | A077775 | 001 | Oct 16, 2009 |
| FENTANYL-50 | | | | |
| NOVEN | 50MCG/HR | A077775 | 002 | Oct 16, 2009 |
| FENTANYL-75 | | | | |
| NOVEN | 75MCG/HR | A077775 | 003 | Oct 16, 2009 |
| FENTANYL CITRATE | | | | |
| FILM;BUCCAL | | | | |
| ONSOLIS | | | | |
| BDSI | EQ 0.2MG BASE | N022266 | 001 | Jul 16, 2009 |
| | EQ 0.4MG BASE | N022266 | 002 | Jul 16, 2009 |
| | EQ 0.6MG BASE | N022266 | 003 | Jul 16, 2009 |
| | EQ 0.8MG BASE | N022266 | 004 | Jul 16, 2009 |
| | EQ 1.2MG BASE | N022266 | 005 | Jul 16, 2009 |
| INJECTABLE;INJECTION | | | | |
| FENTANYL CITRATE | | | | |
| ABBOTT | EQ 0.05MG BASE/ML | A070636 | 001 | Apr 30, 1990 |
| | EQ 0.05MG BASE/ML | A070637 | 001 | Apr 30, 1990 |
| WATSON LABS | EQ 0.05MG BASE/ML | A073488 | 001 | Jun 30, 1992 |
| FENTANYL CITRATE PRESERVATIVE FREE | | | | |
| WATSON LABS INC | EQ 0.05MG BASE/ML | A074917 | 001 | Feb 03, 1998 |
| TABLET;BUCCAL, SUBLINGUAL | | | | |
| FENTANYL CITRATE | | | | |
| WATSON LABS | EQ 0.1MG BASE | A079075 | 001 | Jan 07, 2011 |
| | EQ 0.2MG BASE | A079075 | 002 | Jan 07, 2011 |
| | EQ 0.4MG BASE | A079075 | 003 | Jan 07, 2011 |
| | EQ 0.6MG BASE | A079075 | 004 | Jan 07, 2011 |
| | EQ 0.8MG BASE | A079075 | 005 | Jan 07, 2011 |
| FENTORA | | | | |
| + CEPHALON | EQ 0.3MG BASE ** | N021947 | 006 | Mar 02, 2007 |
| TROCHE/LOZENGE;ORAL | | | | |
| FENTANYL | | | | |
| CEPHALON | EQ 0.1MG BASE | N020195 | 007 | Oct 30, 1995 |
| | EQ 0.2MG BASE | N020195 | 001 | Oct 04, 1993 |
| | EQ 0.3MG BASE | N020195 | 002 | Oct 04, 1993 |
| | EQ 0.4MG BASE | N020195 | 003 | Oct 04, 1993 |
| FERRIC AMMONIUM CITRATE | | | | |
| FOR SOLUTION;ORAL | | | | |
| FERRISELTZ | | | | |
| OTSUKA | 600MG/PACKET | N020292 | 001 | Oct 14, 1997 |
| FERROUS CITRATE, FE-59 | | | | |
| INJECTABLE;INJECTION | | | | |
| FERROUS CITRATE FE 59 | | | | |
| MALLINCKRODT | 25uCi/ML | N016729 | 001 | |
| FERROUS SULFATE; FOLIC ACID | | | | |
| CAPSULE;ORAL | | | | |
| FOLVRON | | | | |
| LEDERLE | 182MG;0.33MG | N006012 | 003 | |

FERUMOXIDES
INJECTABLE;INJECTION
FERIDEX I.V.

| | | | | |
|---|---|---|---|---|
| AMAG PHARMS INC | EQ 11.2MG IRON/ML | N020416 | 001 | Aug 30, 1996 |

FERUMOXSIL
SUSPENSION;ORAL
GASTROMARK

| | | | | |
|---|---|---|---|---|
| AMAG PHARMS INC | EQ 0.175MG IRON/ML | N020410 | 001 | Dec 06, 1996 |

FESOTERODINE FUMARATE
TABLET, EXTENDED RELEASE;ORAL
FESOTERODINE FUMARATE

| | | | | |
|---|---|---|---|---|
| ALKEM LABS LTD | 4MG | A204827 | 001 | Dec 10, 2015 |
| | 8MG | A204827 | 002 | Dec 10, 2015 |

FEXOFENADINE HYDROCHLORIDE
CAPSULE;ORAL
ALLEGRA

| | | | | |
|---|---|---|---|---|
| SANOFI AVENTIS US | 60MG ** | N020625 | 001 | Jul 25, 1996 |

FEXOFENADINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| BARR | 60MG | A076169 | 001 | Jul 13, 2005 |

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE
TABLET, EXTENDED RELEASE;ORAL
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| BARR | 60MG;120MG | A076236 | 001 | Apr 14, 2005 |
| IMPAX PHARMS | 60MG;120MG | A076298 | 001 | Nov 12, 2010 |

FIBRINOGEN, I-125
INJECTABLE;INJECTION
IBRIN

| | | | | |
|---|---|---|---|---|
| GE HEALTHCARE | 154uCi/VIAL | N017879 | 001 | |

RADIONUCLIDE-LABELED (125 I) FIBRINOGEN (HUMAN) SENSOR

| | | | | |
|---|---|---|---|---|
| ABBOTT | 140uCi/ML | N017787 | 001 | |

FINASTERIDE
TABLET;ORAL
FINASTERIDE

| | | | | |
|---|---|---|---|---|
| IVAX SUB TEVA PHARMS | 5MG | A076340 | 001 | Jun 19, 2006 |

FLAVOXATE HYDROCHLORIDE
TABLET;ORAL
FLAVOXATE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| IMPAX PHARMS | 100MG | A076234 | 001 | Aug 28, 2003 |

URISPAS

| | | | | |
|---|---|---|---|---|
| ORTHO MCNEIL JANSSEN | 100MG | N016769 | 001 | |

FLECAINIDE ACETATE
TABLET;ORAL
FLECAINIDE ACETATE

| | | | | |
|---|---|---|---|---|
| APOTEX INC | 50MG | A079164 | 001 | Jul 09, 2009 |
| | 100MG | A079164 | 002 | Jul 09, 2009 |
| | 150MG | A079164 | 003 | Jul 09, 2009 |
| IDT AUSTRALIA LTD | 50MG | A076030 | 001 | Oct 28, 2002 |
| | 100MG | A076030 | 002 | Oct 28, 2002 |
| | 150MG | A076030 | 003 | Oct 28, 2002 |

TAMBOCOR

| | | | | |
|---|---|---|---|---|
| CNTY LINE PHARMS | 200MG | N018830 | 002 | Oct 31, 1985 |

FLORBETAPIR F-18
SOLUTION;INTRAVENOUS
AMYVID

| | | | | |
|---|---|---|---|---|
| AVID RADIOPHARMS INC | 10ML (13.5-51mCi/ML) | N202008 | 001 | Apr 06, 2012 |

FLOXURIDINE
INJECTABLE;INJECTION
FUDR

| | | | | |
|---|---|---|---|---|
| + HOSPIRA | 500MG/VIAL ** | N016929 | 001 | |

| | | | | | |
|---|---|---|---|---|---|
| FLUCONAZOLE | | | | | |
| FOR SUSPENSION;ORAL | | | | | |
| FLUCONAZOLE | | | | | |
| | SUN PHARM INDS LTD | 50MG/5ML | A076332 | 001 | Jul 29, 2004 |
| | | 200MG/5ML | A076332 | 002 | Jul 29, 2004 |
| | TARO PHARM INDS | 50MG/5ML | A076918 | 001 | Dec 18, 2006 |
| | | 200MG/5ML | A076918 | 002 | Dec 18, 2006 |
| INJECTABLE;INJECTION | | | | | |
| DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | | |
| + | PFIZER | 200MG/100ML (2MG/ML) | N019950 | 003 | Sep 29, 1992 |
| + | | 400MG/200ML (2MG/ML) | N019950 | 005 | Jul 08, 1994 |
| DIFLUCAN IN SODIUM CHLORIDE 0.9% | | | | | |
| + | PFIZER | 200MG/100ML (2MG/ML) | N019950 | 001 | Jan 29, 1990 |
| + | | 400MG/200ML (2MG/ML) | N019950 | 006 | Jan 29, 1990 |
| DIFLUCAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | | | | | |
| + | PFIZER | 200MG/100ML (2MG/ML) | N019950 | 002 | Jan 29, 1990 |
| + | | 400MG/200ML (2MG/ML) | N019950 | 004 | Jan 29, 1990 |
| FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | | |
| | MYLAN LABS LTD | 200MG/100ML (2MG/ML) | A076888 | 001 | Mar 25, 2005 |
| | | 400MG/200ML (2MG/ML) | A076888 | 002 | Mar 25, 2005 |
| FLUCONAZOLE IN SODIUM CHLORIDE 0.9% | | | | | |
| | TEVA PHARMS USA | 200MG/100ML (2MG/ML) | A076653 | 001 | Jul 29, 2004 |
| | | 400MG/200ML (2MG/ML) | A076653 | 002 | Jul 29, 2004 |
| FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | | | | | |
| | HOSPIRA | 200MG/100ML (2MG/ML) | A076617 | 001 | Jul 29, 2004 |
| | | 400MG/200ML (2MG/ML) | A076617 | 002 | Jul 29, 2004 |
| | MYLAN LABS LTD | 200MG/100ML (2MG/ML) | A076889 | 001 | Mar 25, 2005 |
| | | 400MG/200ML (2MG/ML) | A076889 | 002 | Mar 25, 2005 |
| | TEVA PHARMS | 200MG/100ML (2MG/ML) | A076837 | 001 | Jan 13, 2005 |
| | | 400MG/200ML (2MG/ML) | A076837 | 002 | Jan 13, 2005 |
| TABLET;ORAL | | | | | |
| FLUCONAZOLE | | | | | |
| | GEDEON RICHTER USA | 50MG | A076432 | 001 | Jul 29, 2004 |
| | | 100MG | A076432 | 002 | Jul 29, 2004 |
| | | 150MG | A076432 | 003 | Jul 29, 2004 |
| | | 200MG | A076432 | 004 | Jul 29, 2004 |
| | IDT AUSTRALIA LTD | 50MG | A076086 | 001 | Jul 29, 2004 |
| | | 100MG | A076086 | 002 | Jul 29, 2004 |
| | | 150MG | A076086 | 003 | Jul 29, 2004 |
| | | 200MG | A076086 | 004 | Jul 29, 2004 |
| | MYLAN PHARMS INC | 50MG | A076042 | 001 | Jul 29, 2004 |
| | | 100MG | A076042 | 002 | Jul 29, 2004 |
| | | 150MG | A076042 | 003 | Jul 29, 2004 |
| | | 200MG | A076042 | 004 | Jul 29, 2004 |
| | PLIVA | 50MG | A076424 | 001 | Jul 29, 2004 |
| | | 100MG | A076424 | 002 | Jul 29, 2004 |
| | | 150MG | A076424 | 003 | Jul 29, 2004 |
| | | 200MG | A076424 | 004 | Jul 29, 2004 |
| | RANBAXY LABS LTD | 50MG | A076386 | 001 | Jul 29, 2004 |
| | | 100MG | A076386 | 002 | Jul 29, 2004 |
| | | 150MG | A076386 | 003 | Jul 29, 2004 |
| | | 200MG | A076386 | 004 | Jul 29, 2004 |
| | ROXANE | 50MG | A076213 | 001 | Jul 29, 2004 |
| | | 100MG | A076213 | 002 | Jul 29, 2004 |
| | | 150MG | A076213 | 003 | Jul 29, 2004 |
| | | 200MG | A076213 | 004 | Jul 29, 2004 |
| FLUDARABINE PHOSPHATE | | | | | |
| INJECTABLE;INJECTION | | | | | |
| FLUDARA | | | | | |
| + | GENZYME CORP | 50MG/VIAL ** | N020038 | 001 | Apr 18, 1991 |
| TABLET;ORAL | | | | | |
| OFORTA | | | | | |
| | SANOFI AVENTIS US | 10MG | N022273 | 001 | Dec 18, 2008 |

| | | | | | |
|---|---|---|---|---|---|
| FLUDEOXYGLUCOSE F-18 | | | | | |
| INJECTABLE;INJECTION | | | | | |
| FLUDEOXYGLUCOSE F18 | | | | | |
| + | DOWNSTATE CLINCL | 4-40mCi/ML ** | N020306 | 001 | Aug 19, 1994 |
| + | | 4-90mCi/ML ** | N020306 | 002 | Sep 25, 2001 |
| INJECTABLE;INTRAVENOUS | | | | | |
| FLUDEOXYGLUCOSE F18 | | | | | |
| | WEILL MEDCL COLL | 10-100mCi/ML ** | N021768 | 001 | Aug 05, 2004 |
| FLUDROCORTISONE ACETATE | | | | | |
| TABLET;ORAL | | | | | |
| FLORINEF | | | | | |
| + | CASPER PHARMA LLC | 0.1MG ** | N010060 | 001 | |
| FLUMAZENIL | | | | | |
| INJECTABLE;INJECTION | | | | | |
| FLUMAZENIL | | | | | |
| | BAXTER HLTHCARE CORP | 0.5MG/5ML (0.1MG/ML) | A076755 | 002 | Oct 12, 2004 |
| | | 1MG/10ML (0.1MG/ML) | A076755 | 001 | Oct 12, 2004 |
| | TEVA PHARMS USA | 0.5MG/5ML (0.1MG/ML) | A076589 | 002 | Oct 12, 2004 |
| | | 1MG/10ML (0.1MG/ML) | A076589 | 001 | Oct 12, 2004 |
| ROMAZICON | | | | | |
| + | HOFFMANN LA ROCHE | 1MG/10ML (0.1MG/ML) ** | N020073 | 001 | Dec 20, 1991 |
| + | | 0.5MG/5ML (0.1MG/ML) ** | N020073 | 002 | Dec 20, 1991 |
| FLUMETHASONE PIVALATE | | | | | |
| CREAM;TOPICAL | | | | | |
| LOCORTEN | | | | | |
| | NOVARTIS | 0.03% | N016379 | 001 | |
| FLUNISOLIDE | | | | | |
| AEROSOL, METERED;INHALATION | | | | | |
| AEROBID | | | | | |
| | ROCHE PALO | 0.25MG/INH | N018340 | 001 | Aug 17, 1984 |
| SPRAY, METERED;NASAL | | | | | |
| NASALIDE | | | | | |
| | IVAX RES | 0.025MG/SPRAY | N018148 | 001 | |
| NASAREL | | | | | |
| | TEVA BRANDED PHARM | 0.029MG/SPRAY | N020409 | 001 | Mar 08, 1995 |
| FLUOCINOLONE ACETONIDE | | | | | |
| CREAM;TOPICAL | | | | | |
| FLUOCET | | | | | |
| | ALPHARMA US PHARMS | 0.025% | A088360 | 001 | Jan 16, 1984 |
| FLUOCINOLONE ACETONIDE | | | | | |
| | ALPHARMA US PHARMS | 0.01% | A088361 | 001 | Jan 16, 1984 |
| | PERRIGO NEW YORK | 0.01% | A086810 | 001 | Mar 04, 1982 |
| | | 0.025% | A086811 | 001 | Mar 04, 1982 |
| | PHARMADERM | 0.01% | A088047 | 001 | Dec 16, 1982 |
| | | 0.025% | A088045 | 001 | Dec 16, 1982 |
| | PHARMAFAIR | 0.01% | A088499 | 001 | Aug 02, 1984 |
| | | 0.025% | A088506 | 001 | Aug 02, 1984 |
| | TARO | 0.01% | A040035 | 001 | Oct 31, 1994 |
| | | 0.01% | A087102 | 001 | Apr 27, 1982 |
| | | 0.025% | A040042 | 001 | Oct 31, 1994 |
| | USL PHARMA | 0.01% | A088757 | 001 | Feb 11, 1985 |
| | | 0.025% | A088756 | 001 | Mar 28, 1985 |
| FLUONID | | | | | |
| | ALLERGAN HERBERT | 0.025% | A087156 | 002 | Sep 06, 1984 |
| FLUOTREX | | | | | |
| | SAVAGE LABS | 0.01% | A088174 | 001 | May 06, 1983 |
| | | 0.025% | A088173 | 001 | Mar 09, 1983 |
| SYNALAR-HP | | | | | |
| | MEDIMETRIKS PHARMS | 0.2% | N016161 | 002 | |
| GEL;TOPICAL | | | | | |
| FLUONID | | | | | |
| | ALLERGAN HERBERT | 0.025% | A087300 | 001 | May 27, 1982 |
| OINTMENT;TOPICAL | | | | | |
| FLUOCINOLONE ACETONIDE | | | | | |
| | PHARMADERM | 0.025% | A088046 | 001 | Dec 16, 1982 |
| | PHARMAFAIR | 0.025% | A088507 | 001 | Feb 27, 1984 |
| | USL PHARMA | 0.025% | A088742 | 001 | Feb 08, 1985 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

FLUOCINOLONE ACETONIDE

| | | | | |
|---|---|---|---|---|
| OINTMENT;TOPICAL | | | | |
| FLUONID | | | | |
| ALLERGAN HERBERT | 0.025% | A087157 | 001 | Sep 06, 1984 |
| FLUOTREX | | | | |
| SAVAGE LABS | 0.025% | A088172 | 001 | Mar 09, 1983 |
| SOLUTION;TOPICAL | | | | |
| FLUOCINOLONE ACETONIDE | | | | |
| ALPHARMA US PHARMS | 0.01% | A087159 | 001 | Jun 16, 1982 |
| BAUSCH AND LOMB | 0.01% | A040059 | 001 | Dec 20, 1993 |
| MORTON GROVE | 0.01% | A088312 | 001 | Jan 27, 1984 |
| PHARMADERM | 0.01% | A088048 | 001 | Dec 16, 1982 |
| PHARMAFAIR | 0.01% | A088449 | 001 | Feb 08, 1984 |
| FLUONID | | | | |
| ALLERGAN HERBERT | 0.01% | A087158 | 001 | Mar 17, 1983 |
| FLUOTREX | | | | |
| SAVAGE LABS | 0.01% | A088171 | 001 | Mar 09, 1983 |

FLUOCINONIDE

| | | | | |
|---|---|---|---|---|
| CREAM;TOPICAL | | | | |
| FLUOCINONIDE | | | | |
| PERRIGO NEW YORK | 0.05% | A071790 | 001 | Jul 13, 1988 |
| LIDEX | | | | |
| + CNTY LINE PHARMS | 0.05% | N016908 | 002 | |
| LIDEX-E | | | | |
| + CNTY LINE PHARMS | 0.05% | N016908 | 003 | |
| SOLUTION;TOPICAL | | | | |
| FLUOCINONIDE | | | | |
| TARO | 0.05% | A072857 | 001 | Aug 02, 1989 |
| TEVA PHARMS | 0.05% | A072522 | 001 | Sep 28, 1990 |

FLUORESCEIN SODIUM

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| FUNDUSCEIN-25 | | | | |
| + NOVARTIS | 25% ** | N017869 | 001 | |

FLUOROMETHOLONE

| | | | | |
|---|---|---|---|---|
| CREAM;TOPICAL | | | | |
| OXYLONE | | | | |
| PHARMACIA AND UPJOHN | 0.025% | N011748 | 001 | |
| SUSPENSION/DROPS;OPHTHALMIC | | | | |
| FLUOR-OP | | | | |
| NOVARTIS | 0.1% | A070185 | 001 | Feb 27, 1986 |

FLUOROMETHOLONE ACETATE; TOBRAMYCIN

| | | | | |
|---|---|---|---|---|
| SUSPENSION/DROPS;OPHTHALMIC | | | | |
| TOBRASONE | | | | |
| ALCON | 0.1%;0.3% | N050628 | 001 | Jul 21, 1989 |

FLUOROMETHOLONE; SULFACETAMIDE SODIUM

| | | | | |
|---|---|---|---|---|
| SUSPENSION/DROPS;OPHTHALMIC | | | | |
| FML-S | | | | |
| ALLERGAN | 0.1%;10% | N019525 | 001 | Sep 29, 1989 |

FLUOROURACIL

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| ADRUCIL | | | | |
| PHARMACIA AND UPJOHN | 50MG/ML | A081222 | 001 | Jun 28, 1991 |
| | 50MG/ML | N017959 | 001 | |
| TEVA PARENTERAL | 50MG/ML | A040023 | 001 | Oct 18, 1991 |
| | 50MG/ML | A081225 | 001 | Aug 28, 1991 |
| FLUOROURACIL | | | | |
| ABIC | 50MG/ML | A088929 | 001 | Mar 04, 1986 |
| ABRAXIS PHARM | 50MG/ML | A089152 | 001 | Mar 21, 1986 |
| | 50MG/ML | A089428 | 001 | Jan 12, 1987 |
| | 50MG/ML | A089519 | 001 | Mar 12, 1987 |
| BEDFORD | 50MG/ML | A089508 | 001 | Jan 26, 1988 |
| EBEWE PHARMA | 500MG/10ML (50MG/ML) | A040772 | 001 | Aug 11, 2008 |
| FRESENIUS KABI USA | 50MG/ML | A040291 | 001 | Mar 24, 1999 |
| | 50MG/ML | A040379 | 001 | Nov 15, 2000 |
| MARCHAR | 50MG/ML | A087791 | 001 | Jan 18, 1983 |
| SANDOZ | 2.5GM/50ML (50MG/ML) | A091299 | 001 | May 02, 2011 |

| | | | | |
|---|---|---|---|---|
| FLUOROURACIL | | | | |
| INJECTABLE;INJECTION | | | | |
| FLUOROURACIL | | | | |
| | 5GM/100ML (50MG/ML) | A091299 | 002 | May 02, 2011 |
| SMITH AND NEPHEW | 50MG/ML | A088766 | 001 | Dec 28, 1984 |
| | 50MG/ML | A088767 | 001 | Dec 28, 1984 |
| | 50MG/ML | A089434 | 001 | Mar 26, 1987 |
| SPECTRUM PHARMS | 50MG/ML | A087792 | 001 | Oct 13, 1982 |
| + | 500MG/10ML (50MG/ML) ** | N012209 | 001 | |
| + | 2.5GM/50ML (50MG/ML) | N012209 | 002 | Jul 29, 2016 |
| SOLUTION;TOPICAL | | | | |
| FLUOROPLEX | | | | |
| ELORAC | 1% | N016765 | 001 | |
| FLUOXETINE HYDROCHLORIDE | | | | |
| CAPSULE;ORAL | | | | |
| FLUOXETINE | | | | |
| SUN PHARM INDUSTRIES | EQ 10MG BASE | A075787 | 001 | Jan 29, 2002 |
| | EQ 20MG BASE | A075787 | 002 | Jan 29, 2002 |
| WATSON LABS | EQ 10MG BASE | A075662 | 001 | Jan 29, 2002 |
| | EQ 20MG BASE | A075662 | 002 | Jan 29, 2002 |
| FLUOXETINE HYDROCHLORIDE | | | | |
| ANI PHARMS INC | EQ 10MG BASE | A076287 | 001 | May 20, 2008 |
| | EQ 20MG BASE | A076287 | 002 | May 20, 2008 |
| BARR | EQ 40MG BASE | A076251 | 001 | May 18, 2005 |
| CARLSBAD | EQ 10MG BASE | A076022 | 001 | Jan 30, 2002 |
| | EQ 20MG BASE | A076022 | 002 | Jan 30, 2002 |
| CR DOUBLE CRANE | EQ 10MG BASE | A076165 | 001 | Feb 01, 2002 |
| | EQ 20MG BASE | A076165 | 002 | Feb 01, 2002 |
| MYLAN | EQ 10MG BASE | A075207 | 001 | Jan 30, 2002 |
| | EQ 20MG BASE | A075207 | 002 | Jan 30, 2002 |
| | EQ 40MG BASE | A075207 | 003 | May 25, 2007 |
| MYLAN PHARMS INC | EQ 10MG BASE | A075577 | 001 | Jan 29, 2002 |
| | EQ 20MG BASE | A075577 | 002 | Jan 29, 2002 |
| PAR PHARM | EQ 10MG BASE | A076922 | 001 | Dec 16, 2004 |
| | EQ 20MG BASE | A076922 | 002 | Dec 16, 2004 |
| SANDOZ | EQ 10MG BASE | A075807 | 001 | Jan 29, 2002 |
| | EQ 10MG BASE | A077469 | 001 | Nov 17, 2008 |
| | EQ 20MG BASE | A075807 | 002 | Jan 29, 2002 |
| | EQ 20MG BASE | A077469 | 002 | Nov 17, 2008 |
| WOCKHARDT LTD | EQ 10MG BASE | A078143 | 001 | Jan 16, 2008 |
| | EQ 20MG BASE | A078143 | 002 | Jan 16, 2008 |
| | EQ 40MG BASE | A078143 | 003 | Jan 16, 2008 |
| PROZAC | | | | |
| ELI LILLY AND CO | EQ 60MG BASE | N018936 | 004 | Jun 15, 1999 |
| SARAFEM | | | | |
| + ELI LILLY AND CO | EQ 10MG BASE ** | N018936 | 007 | Jul 06, 2000 |
| + | EQ 20MG BASE ** | N018936 | 008 | Jul 06, 2000 |
| SOLUTION;ORAL | | | | |
| FLUOXETINE HYDROCHLORIDE | | | | |
| ACTAVIS MID ATLANTIC | EQ 20MG BASE/5ML | A075690 | 001 | Jan 31, 2002 |
| APOTEX INC | EQ 20MG BASE/5ML | A075292 | 001 | Feb 07, 2002 |
| HI TECH PHARMA | EQ 20MG BASE/5ML | A075525 | 001 | Jun 27, 2002 |
| LANNETT | EQ 20MG BASE/5ML | A076458 | 001 | May 14, 2004 |
| PROZAC | | | | |
| + LILLY | EQ 20MG BASE/5ML ** | N020101 | 001 | Apr 24, 1991 |
| TABLET;ORAL | | | | |
| FLUOXETINE HYDROCHLORIDE | | | | |
| BARR | EQ 10MG BASE | A075810 | 001 | Feb 01, 2002 |
| IVAX SUB TEVA PHARMS | EQ 10MG BASE | A075865 | 001 | Feb 28, 2002 |
| | EQ 40MG BASE | A075865 | 003 | Aug 30, 2004 |
| SANDOZ | EQ 10MG BASE | A076024 | 001 | Jan 29, 2002 |
| PROZAC | | | | |
| + LILLY | EQ 10MG BASE ** | N020974 | 001 | Mar 09, 1999 |
| + | EQ 20MG BASE ** | N020974 | 002 | Mar 09, 1999 |

| | | | | |
|---|---|---|---|---|
| FLUOXYMESTERONE | | | | |
| TABLET;ORAL | | | | |
| ANDROID-F | | | | |
| VALEANT PHARM INTL | 10MG | A087196 | 001 | |
| FLUOXYMESTERONE | | | | |
| VALEANT PHARM INTL | 10MG | A088221 | 001 | May 05, 1983 |
| WATSON LABS | 2MG | A088260 | 001 | Dec 06, 1983 |
| | 5MG | A088265 | 001 | Dec 06, 1983 |
| | 10MG | A088309 | 001 | Dec 06, 1983 |
| HALOTESTIN | | | | |
| PHARMACIA AND UPJOHN | 2MG | N010611 | 002 | |
| | 5MG | N010611 | 006 | |
| | 10MG | N010611 | 010 | |
| ORA-TESTRYL | | | | |
| BRISTOL MYERS SQUIBB | 2MG | N011359 | 001 | |
| | 5MG | N011359 | 002 | |
| FLUPHENAZINE DECANOATE | | | | |
| INJECTABLE;INJECTION | | | | |
| FLUPHENAZINE DECANOATE | | | | |
| HOSPIRA | 25MG/ML | A074966 | 001 | Apr 16, 1998 |
| MYLAN LABS LTD | 25MG/ML | A075918 | 001 | Aug 17, 2001 |
| TEVA PARENTERAL | 25MG/ML | A074795 | 001 | Sep 10, 1996 |
| PROLIXIN DECANOATE | | | | |
| + BRISTOL MYERS SQUIBB | 25MG/ML ** | N016727 | 001 | |
| FLUPHENAZINE ENANTHATE | | | | |
| INJECTABLE;INJECTION | | | | |
| PROLIXIN ENANTHATE | | | | |
| APOTHECON | 25MG/ML | N016110 | 001 | |
| FLUPHENAZINE HYDROCHLORIDE | | | | |
| CONCENTRATE;ORAL | | | | |
| FLUPHENAZINE HYDROCHLORIDE | | | | |
| ANI PHARMS INC | 5MG/ML | A073058 | 001 | Aug 30, 1991 |
| PERMITIL | | | | |
| SCHERING | 5MG/ML | N016008 | 001 | |
| PROLIXIN | | | | |
| APOTHECON | 5MG/ML | A070533 | 001 | Nov 07, 1985 |
| ELIXIR;ORAL | | | | |
| FLUPHENAZINE HYDROCHLORIDE | | | | |
| ANI PHARMS INC | 2.5MG/5ML | A081310 | 001 | Apr 29, 1993 |
| PROLIXIN | | | | |
| + APOTHECON | 2.5MG/5ML ** | N012145 | 003 | |
| INJECTABLE;INJECTION | | | | |
| PROLIXIN | | | | |
| APOTHECON | 2.5MG/ML | N011751 | 005 | |
| TABLET;ORAL | | | | |
| FLUPHENAZINE HYDROCHLORIDE | | | | |
| WATSON LABS | 1MG | A088555 | 001 | Dec 18, 1987 |
| | 2.5MG | A088544 | 001 | Dec 18, 1987 |
| | 5MG | A088527 | 001 | Dec 18, 1987 |
| | 10MG | A088550 | 001 | Dec 18, 1987 |
| PERMITIL | | | | |
| SCHERING | 0.25MG | N012034 | 001 | |
| | 2.5MG | N012034 | 004 | |
| | 5MG | N012034 | 005 | |
| | 10MG | N012034 | 006 | |
| PROLIXIN | | | | |
| + APOTHECON | 1MG | N011751 | 004 | |
| + | 2.5MG | N011751 | 001 | |
| + | 5MG | N011751 | 003 | |
| + | 10MG | N011751 | 002 | |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| PERMITIL | | | | |
| SCHERING | 1MG | N012419 | 004 | |

| | | | | |
|---|---|---|---|---|
| FLUPREDNISOLONE | | | | |
| TABLET;ORAL | | | | |
| ALPHADROL | | | | |
| PHARMACIA AND UPJOHN | 1.5MG | | N012259 002 | |
| FLURANDRENOLIDE | | | | |
| LOTION;TOPICAL | | | | |
| FLURANDRENOLIDE | | | | |
| ALPHARMA US PHARMS | 0.05% | | A087203 001 | Apr 29, 1982 |
| OINTMENT;TOPICAL | | | | |
| CORDRAN | | | | |
| + AQUA PHARMS | 0.025% ** | | N012806 004 | |
| FLURANDRENOLIDE; NEOMYCIN SULFATE | | | | |
| CREAM;TOPICAL | | | | |
| CORDRAN N | | | | |
| LILLY | 0.05%;EQ 3.5MG BASE/GM | | N050346 001 | |
| OINTMENT;TOPICAL | | | | |
| CORDRAN N | | | | |
| LILLY | 0.05%;EQ 3.5MG BASE/GM | | N050345 001 | |
| FLURAZEPAM HYDROCHLORIDE | | | | |
| CAPSULE;ORAL | | | | |
| DALMANE | | | | |
| VALEANT PHARM INTL | 15MG ** | | N016721 001 | |
| + | 30MG ** | | N016721 002 | |
| FLURAZEPAM HYDROCHLORIDE | | | | |
| AUROLIFE PHARMA LLC | 15MG | | A071717 002 | Jul 31, 1991 |
| | 30MG | | A071717 001 | Jul 31, 1991 |
| HALSEY | 15MG | | A071808 001 | Jan 07, 1988 |
| | 30MG | | A071809 001 | Jan 07, 1988 |
| HIKMA INTL PHARMS | 15MG | | A071107 001 | Dec 08, 1986 |
| HIKMA PHARMS | 30MG | | A071108 001 | Dec 08, 1986 |
| PAR PHARM | 15MG | | A070444 001 | Mar 20, 1986 |
| | 30MG | | A070445 001 | Mar 20, 1986 |
| PUREPAC PHARM | 15MG | | A071927 001 | Sep 09, 1987 |
| | 30MG | | A071551 001 | Sep 09, 1987 |
| SUN PHARM INDUSTRIES | 15MG | | A070454 001 | Aug 04, 1986 |
| | 30MG | | A070455 001 | Aug 04, 1986 |
| SUPERPHARM | 15MG | | A071659 001 | Aug 04, 1988 |
| | 30MG | | A071660 001 | Aug 04, 1988 |
| USL PHARMA | 15MG | | A070562 001 | Jul 09, 1987 |
| | 30MG | | A070563 001 | Jul 09, 1987 |
| WARNER CHILCOTT | 15MG | | A071767 001 | Dec 04, 1987 |
| | 30MG | | A071768 001 | Dec 04, 1987 |
| WATSON LABS | 15MG | | A071205 001 | Nov 25, 1986 |
| | 15MG | | A072368 001 | Mar 30, 1989 |
| | 30MG | | A071068 001 | Nov 25, 1986 |
| | 30MG | | A072369 001 | Mar 30, 1989 |
| FLURBIPROFEN | | | | |
| TABLET;ORAL | | | | |
| ANSAID | | | | |
| PHARMACIA AND UPJOHN | 50MG | | N018766 002 | Oct 31, 1988 |
| | 100MG | | N018766 003 | Oct 31, 1988 |
| FLURBIPROFEN | | | | |
| AUROLIFE PHARMA LLC | 50MG | | A074448 001 | Jul 28, 1995 |
| | 100MG | | A074448 002 | Jul 28, 1995 |
| IVAX SUB TEVA PHARMS | 50MG | | A074411 001 | May 31, 1995 |
| | 100MG | | A074411 002 | May 31, 1995 |
| PLIVA | 50MG | | A074647 001 | Apr 01, 1997 |
| | 100MG | | A074647 002 | Apr 01, 1997 |
| TEVA | 50MG | | A074405 002 | May 24, 1995 |
| | 100MG | | A074405 001 | May 24, 1995 |
| THERAGEN | 100MG | | A074560 002 | May 16, 1997 |

| | | | | |
|---|---|---|---|---|
| FLUTAMIDE | | | | |
| CAPSULE;ORAL | | | | |
| EULEXIN | | | | |
| + | SCHERING | 125MG | N018554 001 | Jan 27, 1989 |
| FLUTAMIDE | | | | |
| | FOSUN PHARMA | 125MG | A075818 001 | Sep 18, 2001 |
| | MYLAN | 125MG | A076224 001 | May 09, 2003 |
| FLUTICASONE PROPIONATE | | | | |
| AEROSOL, METERED;INHALATION | | | | |
| FLOVENT | | | | |
| | GLAXOSMITHKLINE | 0.044MG/INH | N020548 001 | Mar 27, 1996 |
| | | 0.11MG/INH | N020548 002 | Mar 27, 1996 |
| | | 0.22MG/INH | N020548 003 | Mar 27, 1996 |
| CREAM;TOPICAL | | | | |
| CUTIVATE | | | | |
| + | FOUGERA PHARMS | 0.05% ** | N019958 001 | Dec 18, 1990 |
| FLUTICASONE PROPIONATE | | | | |
| | NESHER PHARMS | 0.05% | A076865 001 | Sep 10, 2004 |
| OINTMENT;TOPICAL | | | | |
| FLUTICASONE PROPIONATE | | | | |
| | TARO PHARM INDS | 0.005% | A077145 001 | Jun 14, 2005 |
| POWDER;INHALATION | | | | |
| FLOVENT | | | | |
| | GLAXOSMITHKLINE | 0.044MG/INH | N020549 001 | Nov 07, 1997 |
| | | 0.088MG/INH | N020549 002 | Nov 07, 1997 |
| | | 0.22MG/INH | N020549 003 | Nov 07, 1997 |
| SPRAY, METERED;NASAL | | | | |
| FLONASE | | | | |
| + | GLAXOSMITHKLINE | 0.05MG/SPRAY ** | N020121 001 | Oct 19, 1994 |
| FLUVASTATIN SODIUM | | | | |
| CAPSULE;ORAL | | | | |
| LESCOL | | | | |
| + | NOVARTIS | EQ 20MG BASE | N020261 001 | Dec 31, 1993 |
| + | | EQ 40MG BASE | N020261 002 | Dec 31, 1993 |
| FLUVOXAMINE MALEATE | | | | |
| CAPSULE, EXTENDED RELEASE;ORAL | | | | |
| LUVOX CR | | | | |
| + | JAZZ PHARMS | 100MG | N022033 001 | Feb 28, 2008 |
| + | | 150MG | N022033 002 | Feb 28, 2008 |
| TABLET;ORAL | | | | |
| FLUVOXAMINE MALEATE | | | | |
| | ACTAVIS ELIZABETH | 25MG | A075901 001 | Dec 28, 2000 |
| | | 50MG | A075901 002 | Dec 28, 2000 |
| | | 100MG | A075901 003 | Dec 28, 2000 |
| | ANI PHARMS INC | 25MG | A075898 001 | Mar 12, 2001 |
| | | 50MG | A075898 002 | Mar 12, 2001 |
| | | 100MG | A075898 003 | Mar 12, 2001 |
| | ECI PHARMS LLC | 25MG | A075900 001 | Feb 23, 2006 |
| | | 50MG | A075900 002 | Feb 23, 2006 |
| | | 100MG | A075900 003 | Feb 23, 2006 |
| | MYLAN | 50MG | A075950 001 | Oct 15, 2001 |
| | | 100MG | A075950 002 | Oct 15, 2001 |
| | SUN PHARM INDUSTRIES | 25MG | A076125 001 | Apr 29, 2002 |
| | | 50MG | A076125 002 | Apr 29, 2002 |
| | | 100MG | A076125 003 | Apr 29, 2002 |
| | SYNTHON PHARMS | 25MG | A075899 001 | Jan 17, 2001 |
| | | 50MG | A075899 002 | Jan 17, 2001 |
| | | 100MG | A075899 003 | Jan 17, 2001 |
| | UPSHER-SMITH LABS | 25MG | A075887 001 | Jan 05, 2001 |
| | | 50MG | A075887 002 | Jan 05, 2001 |
| | | 100MG | A075887 003 | Jan 05, 2001 |
| | WATSON LABS | 25MG | A075894 001 | Apr 18, 2001 |
| | | 50MG | A075894 002 | Apr 18, 2001 |
| | | 100MG | A075894 003 | Apr 18, 2001 |
| LUVOX | | | | |
| + | SOLVAY | 25MG ** | N020243 001 | Dec 05, 1994 |
| + | | 50MG ** | N020243 002 | Dec 05, 1994 |
| + | | 100MG ** | N020243 003 | Dec 05, 1994 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| FLUVOXAMINE MALEATE | | | | |
| TABLET;ORAL | | | | |
| LUVOX | | | | |
| + | 150MG ** | N020243 | 004 | Dec 05, 1994 |
| FOLIC ACID | | | | |
| INJECTABLE;INJECTION | | | | |
| FOLIC ACID | | | | |
| BEN VENUE | 5MG/ML | A081066 | 001 | Dec 29, 1993 |
| FOLVITE | | | | |
| WYETH PHARMS INC | 5MG/ML | N005897 | 008 | |
| TABLET;ORAL | | | | |
| FOLIC ACID | | | | |
| BARR | 1MG | A089177 | 001 | Jan 08, 1986 |
| CONTRACT PHARMACAL | 1MG | A085061 | 001 | |
| EVERYLIFE | 1MG | A080755 | 001 | |
| HALSEY | 1MG | A083598 | 001 | |
| IMPAX LABS | 1MG | A080686 | 001 | |
| IVAX SUB TEVA PHARMS | 1MG | A083000 | 001 | |
| JUBILANT CADISTA | 1MG | A040514 | 001 | Jun 14, 2005 |
| LANNETT | 1MG | A080816 | 001 | |
| LILLY | 1MG | N006135 | 003 | |
| MK LABS | 1MG | A083526 | 001 | |
| NEXGEN PHARMA INC | 1MG | A084915 | 001 | |
| PHARMERAL | 1MG | A084158 | 001 | |
| PIONEER PHARMS | 1MG | A088949 | 001 | Sep 13, 1985 |
| PUREPAC PHARM | 1MG | A080784 | 001 | |
| SANDOZ | 1MG | A084472 | 001 | |
| SUN PHARM INDUSTRIES | 1MG | A040582 | 001 | Jul 18, 2005 |
| TABLICAPS | 1MG | A083133 | 002 | |
| UDL | 1MG | A088199 | 001 | Mar 29, 1983 |
| USL PHARMA | 1MG | A087828 | 001 | May 13, 1982 |
| VALEANT PHARM INTL | 1MG | A080903 | 001 | |
| VANGARD | 1MG | A088730 | 001 | Mar 23, 1984 |
| VINTAGE PHARMS | 1MG | A086296 | 001 | |
| WATSON LABS | 1MG | A083141 | 001 | |
| | 1MG | A085141 | 002 | |
| WHITEWORTH TOWN PLSN | 1MG | A080691 | 002 | |
| FOLICET | | | | |
| MISSION PHARMA | 1MG | A087438 | 001 | |
| FOLVITE | | | | |
| WYETH PHARMS INC | 1MG | N005897 | 004 | |
| FOLLITROPIN ALFA/BETA | | | | |
| INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS | | | | |
| FOLLISTIM | | | | |
| ORGANON USA INC | 75 IU/VIAL | N020582 | 001 | Sep 29, 1997 |
| | 150 IU/VIAL | N020582 | 002 | Sep 29, 1997 |
| INJECTABLE;SUBCUTANEOUS | | | | |
| FOLLISTIM AQ | | | | |
| ORGANON USA INC | 75 IU/0.5ML | N021273 | 001 | Aug 26, 2005 |
| | 150 IU/0.18ML | N021211 | 003 | Feb 11, 2004 |
| | 150 IU/0.5ML | N021273 | 002 | Aug 26, 2005 |
| GONAL-F | | | | |
| EMD SERONO | 37.5 IU/VIAL | N020378 | 003 | May 25, 2000 |
| | 37.5 IU/VIAL | N021765 | 001 | Mar 25, 2004 |
| | 75 IU/VIAL | N020378 | 001 | Sep 29, 1997 |
| | 150 IU/VIAL | N020378 | 002 | Sep 29, 1997 |
| | 150 IU/VIAL | N021765 | 003 | Mar 25, 2004 |
| FOMEPIZOLE | | | | |
| INJECTABLE;INJECTION | | | | |
| FOMEPIZOLE | | | | |
| MYLAN INSTITUTIONAL | 1.5GM/1.5ML (1GM/ML) | A079033 | 001 | Apr 07, 2009 |

FOMIVIRSEN SODIUM
INJECTABLE;INJECTION
VITRAVENE PRESERVATIVE FREE

| | | | | | |
|---|---|---|---|---|---|
| | NOVARTIS | 6.6MG/ML | N020961 | 001 | Aug 26, 1998 |

FORMOTEROL FUMARATE
POWDER;INHALATION
FORADIL

| | | | | | |
|---|---|---|---|---|---|
| + | NOVARTIS | 0.012MG/INH | N020831 | 001 | Feb 16, 2001 |

FORADIL CERTIHALER

| | | | | | |
|---|---|---|---|---|---|
| | NOVARTIS | 0.0085MG/INH | N021592 | 001 | Dec 15, 2006 |

FOSAPREPITANT DIMEGLUMINE
POWDER;INTRAVENOUS
EMEND

| | | | | | |
|---|---|---|---|---|---|
| + | MERCK AND CO INC | EQ 115MG BASE/VIAL ** | N022023 | 001 | Jan 25, 2008 |

FOSCARNET SODIUM
INJECTABLE;INJECTION
FOSCARNET SODIUM

| | | | | | |
|---|---|---|---|---|---|
| | HOSPIRA | 2.4GM/100ML | A077174 | 001 | May 31, 2005 |

FOSINOPRIL SODIUM
TABLET;ORAL
FOSINOPRIL SODIUM

| | | | | | |
|---|---|---|---|---|---|
| | ACTAVIS LABS FL INC | 10MG | A076620 | 001 | Oct 15, 2004 |
| | | 20MG | A076620 | 002 | Oct 15, 2004 |
| | | 40MG | A076620 | 003 | Oct 15, 2004 |
| | RANBAXY LABS LTD | 10MG | A076580 | 001 | Apr 23, 2004 |
| | | 20MG | A076580 | 002 | Apr 23, 2004 |
| | | 40MG | A076580 | 003 | Apr 23, 2004 |
| | UPSHER-SMITH LABS | 10MG | A076188 | 001 | Oct 08, 2004 |
| | | 20MG | A076188 | 002 | Oct 08, 2004 |
| | | 40MG | A076188 | 003 | Oct 08, 2004 |
| | WATSON LABS | 10MG | A076987 | 001 | Dec 23, 2004 |
| | | 10MG | A077531 | 001 | Aug 31, 2006 |
| | | 20MG | A076987 | 002 | Dec 23, 2004 |
| | | 20MG | A077531 | 002 | Aug 31, 2006 |
| | | 40MG | A076987 | 003 | Dec 23, 2004 |
| | | 40MG | A077531 | 003 | Aug 31, 2006 |

MONOPRIL

| | | | | | |
|---|---|---|---|---|---|
| + | BRISTOL MYERS SQUIBB | 10MG ** | N019915 | 002 | May 16, 1991 |
| + | | 20MG ** | N019915 | 003 | May 16, 1991 |
| + | | 40MG ** | N019915 | 004 | Mar 28, 1995 |

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE
TABLET;ORAL
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

| | | | | | |
|---|---|---|---|---|---|
| | ACTAVIS LABS FL INC | 10MG;12.5MG | A076608 | 001 | Dec 03, 2004 |
| | | 20MG;12.5MG | A076608 | 002 | Dec 03, 2004 |
| | MYLAN | 10MG;12.5MG | A077705 | 001 | Aug 14, 2006 |
| | | 20MG;12.5MG | A077705 | 002 | Aug 14, 2006 |
| | SUN PHARM INDS LTD | 10MG;12.5MG | A076739 | 001 | Dec 17, 2004 |
| | | 20MG;12.5MG | A076739 | 002 | Dec 17, 2004 |
| | TEVA | 10MG;12.5MG | A076945 | 001 | Jul 05, 2006 |
| | | 20MG;12.5MG | A076945 | 002 | Jul 05, 2006 |
| | WATSON LABS | 10MG;12.5MG | A077144 | 001 | Aug 16, 2005 |
| | | 20MG;12.5MG | A077144 | 002 | Aug 16, 2005 |

MONOPRIL-HCT

| | | | | | |
|---|---|---|---|---|---|
| + | BRISTOL MYERS SQUIBB | 10MG;12.5MG ** | N020286 | 002 | Nov 30, 1994 |
| + | | 20MG;12.5MG ** | N020286 | 001 | Nov 30, 1994 |

FOSPHENYTOIN SODIUM
INJECTABLE;INJECTION
FOSPHENYTOIN SODIUM

| | | | | | |
|---|---|---|---|---|---|
| | APOTEX INC | EQ 50MG PHENYTOIN NA/ML | A078126 | 001 | Aug 06, 2007 |
| | HOSPIRA | EQ 50MG PHENYTOIN NA/ML | A078158 | 001 | Aug 06, 2007 |
| | TEVA PHARMS USA | EQ 50MG PHENYTOIN NA/ML | A076886 | 001 | Aug 06, 2007 |

| | | | | |
|---|---|---|---|---|
| FOSPROPOFOL DISODIUM | | | | |
| SOLUTION;INTRAVENOUS | | | | |
| LUSEDRA | | | | |
| EISAI INC | 1050MG/30ML (35MG/ML) | N022244 | 001 | Dec 12, 2008 |
| FURAZOLIDONE | | | | |
| SUSPENSION;ORAL | | | | |
| FUROXONE | | | | |
| SHIRE | 50MG/15ML | N011323 | 002 | |
| TABLET;ORAL | | | | |
| FUROXONE | | | | |
| SHIRE | 100MG | N011270 | 002 | |
| FUROSEMIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| FUROSEMIDE | | | | |
| ABRAXIS PHARM | 10MG/ML | N018507 | 001 | Jul 30, 1982 |
| | 10MG/ML | N019036 | 001 | Aug 13, 1984 |
| ACCORD HLTHCARE | 10MG/ML | A070017 | 001 | Dec 15, 1986 |
| ASTRAZENECA | 10MG/ML | A070014 | 001 | Sep 09, 1985 |
| HOSPIRA | 10MG/ML | A070578 | 001 | Jul 08, 1987 |
| | 10MG/ML | A072080 | 001 | Aug 13, 1991 |
| | 10MG/ML | A074337 | 001 | Oct 31, 1994 |
| IGI LABS INC | 10MG/ML | A070095 | 001 | Sep 09, 1985 |
| | 10MG/ML | A070096 | 001 | Sep 09, 1985 |
| INTL MEDICATION | 10MG/ML | N018025 | 001 | |
| + LUITPOLD | 10MG/ML ** | N018579 | 001 | Nov 30, 1983 |
| MARSAM PHARMS LLC | 10MG/ML | A074017 | 001 | Jun 30, 1994 |
| SMITH AND NEPHEW | 10MG/ML | A070023 | 001 | Feb 05, 1986 |
| | 10MG/ML | A070078 | 001 | Feb 05, 1986 |
| WARNER CHILCOTT | 10MG/ML | N018420 | 001 | Feb 26, 1982 |
| WATSON LABS | 10MG/ML | A070019 | 001 | Sep 22, 1986 |
| | 10MG/ML | A070604 | 001 | Jan 02, 1987 |
| WEST-WARD PHARMS INT | 10MG/ML | A071439 | 001 | Sep 14, 1990 |
| | 10MG/ML | N018267 | 001 | |
| WYETH AYERST | 10MG/ML | N018670 | 001 | Jul 20, 1982 |
| LASIX | | | | |
| + SANOFI AVENTIS US | 10MG/ML ** | N016363 | 001 | |
| SOLUTION;ORAL | | | | |
| LASIX | | | | |
| SANOFI AVENTIS US | 10MG/ML | N017688 | 001 | |
| TABLET;ORAL | | | | |
| FUROSEMIDE | | | | |
| DAVA PHARMS INC | 20MG | N018415 | 001 | Jul 27, 1982 |
| | 40MG | N018415 | 002 | Jul 27, 1982 |
| | 80MG | N018415 | 003 | Nov 26, 1984 |
| INTL MEDICATION | 20MG | N018753 | 001 | Feb 28, 1984 |
| | 40MG | N018753 | 002 | Feb 28, 1984 |
| KALAPHARM | 20MG | N018868 | 001 | Jun 28, 1983 |
| | 40MG | N018868 | 002 | Jun 28, 1983 |
| SANDOZ | 40MG | N018750 | 002 | Jul 30, 1984 |
| SUN PHARM INDS INC | 20MG | A091258 | 001 | Apr 01, 2014 |
| | 40MG | A091258 | 002 | Apr 01, 2014 |
| | 40MG | N018790 | 001 | Nov 29, 1983 |
| | 80MG | A091258 | 003 | Apr 01, 2014 |
| SUN PHARM INDUSTRIES | 20MG | A070043 | 001 | Sep 26, 1985 |
| | 80MG | A070100 | 001 | Jan 26, 1988 |
| SUPERPHARM | 20MG | N018370 | 002 | Jun 26, 1984 |
| | 40MG | N018370 | 001 | Feb 10, 1983 |
| WARNER CHILCOTT | 20MG | N018419 | 001 | Jan 31, 1983 |
| | 40MG | N018419 | 002 | Jan 31, 1983 |
| | 80MG | N018419 | 003 | Nov 13, 1984 |
| WATSON LABS | 20MG | A070412 | 001 | Feb 26, 1986 |
| | 20MG | A071379 | 001 | Jan 02, 1987 |
| | 20MG | N018369 | 001 | May 14, 1982 |
| | 40MG | A070413 | 001 | Feb 26, 1986 |
| | 40MG | A070450 | 001 | Nov 22, 1985 |
| | 40MG | N018369 | 002 | May 14, 1982 |
| | 80MG | A071594 | 001 | Feb 09, 1988 |
| WATSON LABS TEVA | 20MG | A070449 | 001 | Nov 22, 1985 |

| | | | | |
|---|---|---|---|---|
| FUROSEMIDE | | | | |
| TABLET;ORAL | | | | |
| FUROSEMIDE | | | | |
| | 80MG | | A070528 001 | Jan 07, 1986 |
| GABAPENTIN | | | | |
| CAPSULE;ORAL | | | | |
| GABAPENTIN | | | | |
| CSPC OUYI PHARM CO | 100MG | | A075477 001 | Mar 23, 2005 |
| | 300MG | | A075477 002 | Mar 23, 2005 |
| | 400MG | | A075477 003 | Mar 23, 2005 |
| HIKMA | 100MG | | A078150 001 | Sep 25, 2007 |
| | 300MG | | A078150 002 | Sep 25, 2007 |
| | 400MG | | A078150 003 | Sep 25, 2007 |
| SANDOZ | 100MG | | A075428 001 | Jan 24, 2006 |
| | 100MG | | A075539 001 | Apr 06, 2005 |
| | 300MG | | A075428 002 | Jan 24, 2006 |
| | 300MG | | A075539 002 | Apr 06, 2005 |
| | 400MG | | A075428 003 | Jan 24, 2006 |
| | 400MG | | A075539 003 | Apr 06, 2005 |
| SUN PHARM INDS LTD | 100MG | | A076606 001 | Oct 07, 2005 |
| | 300MG | | A076606 002 | Oct 07, 2005 |
| | 400MG | | A076606 003 | Oct 07, 2005 |
| SUN PHARM INDUSTRIES | 100MG | | A076537 001 | Jun 30, 2005 |
| | 300MG | | A076537 002 | Jun 30, 2005 |
| | 400MG | | A076537 003 | Jun 30, 2005 |
| WATSON LABS | 100MG | | A075485 003 | May 11, 2007 |
| | 300MG | | A075485 002 | May 11, 2007 |
| | 400MG | | A075485 001 | May 11, 2007 |
| TABLET;ORAL | | | | |
| GABAPENTIN | | | | |
| HIKMA PHARMS | 600MG | | A078782 001 | Jul 21, 2011 |
| | 800MG | | A078782 002 | Jul 21, 2011 |
| RANBAXY | 600MG | | A076605 001 | Sep 14, 2005 |
| | 800MG | | A076605 002 | Sep 14, 2005 |
| SANDOZ | 600MG | | A076120 001 | Jan 27, 2006 |
| | 600MG | | A076877 001 | Jul 06, 2006 |
| | 800MG | | A076120 002 | Jan 27, 2006 |
| | 800MG | | A076877 002 | Jul 06, 2006 |
| TEVA | 600MG | | A075827 001 | Dec 15, 2004 |
| | 800MG | | A075827 002 | Dec 15, 2004 |
| GADODIAMIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| OMNISCAN | | | | |
| GE HEALTHCARE | 14.35GM/50ML (287MG/ML) | | N022066 001 | Sep 05, 2007 |
| GADOFOSVESET TRISODIUM | | | | |
| SOLUTION;INTRAVENOUS | | | | |
| ABLAVAR | | | | |
| LANTHEUS MEDCL | 2440MG/10ML (244MG/ML) | | N021711 001 | Dec 22, 2008 |
| | 3660MG/15ML (244MG/ML) | | N021711 002 | Dec 22, 2008 |
| GALANTAMINE HYDROBROMIDE | | | | |
| CAPSULE, EXTENDED RELEASE;ORAL | | | | |
| GALANTAMINE HYDROBROMIDE | | | | |
| IMPAX LABS | EQ 8MG BASE | | A078484 001 | May 27, 2009 |
| | EQ 16MG BASE | | A078484 002 | May 27, 2009 |
| | EQ 24MG BASE | | A078484 003 | May 27, 2009 |
| SOLUTION;ORAL | | | | |
| RAZADYNE | | | | |
| JANSSEN PHARMS | 4MG/ML ** | | N021224 001 | Jun 22, 2001 |
| TABLET;ORAL | | | | |
| GALANTAMINE HYDROBROMIDE | | | | |
| ACTAVIS ELIZABETH | EQ 4MG BASE | | A077585 001 | Sep 15, 2009 |
| | EQ 8MG BASE | | A077585 002 | Sep 15, 2009 |
| | EQ 12MG BASE | | A077585 003 | Sep 15, 2009 |
| MYLAN | EQ 4MG BASE | | A077603 001 | Aug 28, 2008 |
| | EQ 8MG BASE | | A077603 002 | Aug 28, 2008 |
| | EQ 12MG BASE | | A077603 003 | Aug 28, 2008 |

| | | | | |
|---|---|---|---|---|
| GALLAMINE TRIETHIODIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| FLAXEDIL | | | | |
| | DAVIS AND GECK | 20MG/ML | N007842 001 | |
| | | 100MG/ML | N007842 002 | |
| GALLIUM CITRATE GA-67 | | | | |
| INJECTABLE;INJECTION | | | | |
| GALLIUM CITRATE GA 67 | | | | |
| | GE HEALTHCARE | 1mCi/ML | N017700 001 | |
| NEOSCAN | | | | |
| | GE HEALTHCARE | 2mCi/ML | N017655 001 | |
| GALLIUM NITRATE | | | | |
| INJECTABLE;INJECTION | | | | |
| GANITE | | | | |
| | CHAPTER 7 TRUSTEE | 25MG/ML ** | N019961 002 | Jan 17, 1991 |
| GANCICLOVIR | | | | |
| CAPSULE;ORAL | | | | |
| CYTOVENE | | | | |
| + | ROCHE PALO | 250MG ** | N020460 001 | Dec 22, 1994 |
| + | | 500MG ** | N020460 002 | Dec 12, 1997 |
| GANCICLOVIR | | | | |
| | RANBAXY LABS LTD | 250MG | A076457 001 | Jun 27, 2003 |
| | | 500MG | A076457 002 | Jun 27, 2003 |
| IMPLANT;IMPLANTATION | | | | |
| VITRASERT | | | | |
| | BAUSCH AND LOMB | 4.5MG | N020569 001 | Mar 04, 1996 |
| GANCICLOVIR SODIUM | | | | |
| INJECTABLE;INJECTION | | | | |
| GANCICLOVIR SODIUM | | | | |
| | WEST-WARD PHARMS INT | EQ 500MG BASE/VIAL | A076222 001 | Jul 16, 2003 |
| GATIFLOXACIN | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | |
| GATIFLOXACIN | | | | |
| | APOTEX INC | 0.3% | A079084 001 | Aug 19, 2011 |
| GEFITINIB | | | | |
| TABLET;ORAL | | | | |
| IRESSA | | | | |
| | ASTRAZENECA | 250MG | N021399 001 | May 05, 2003 |
| GEMCITABINE HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| GEMCITABINE HYDROCHLORIDE | | | | |
| | SAGENT PHARMS | EQ 200MG BASE/VIAL | A091597 001 | May 07, 2013 |
| | | EQ 1GM BASE/VIAL | A091597 002 | May 07, 2013 |
| GEMFIBROZIL | | | | |
| CAPSULE;ORAL | | | | |
| GEMFIBROZIL | | | | |
| | MYLAN | 300MG | A073466 001 | Jan 25, 1993 |
| | PUREPAC PHARM | 300MG | A072929 001 | Jan 29, 1993 |
| LOPID | | | | |
| | PFIZER PHARMS | 200MG | N018422 001 | |
| | | 300MG | N018422 002 | |
| TABLET;ORAL | | | | |
| GEMFIBROZIL | | | | |
| | FOSUN PHARMA | 600MG | A074615 001 | Sep 29, 1995 |
| | MYLAN | 600MG | A074452 001 | Feb 16, 1995 |
| | PUREPAC PHARM | 600MG | A074360 001 | Aug 31, 1994 |
| | WATSON LABS | 600MG | A074156 001 | Oct 24, 1994 |
| | | 600MG | A074442 001 | Apr 28, 1995 |
| GEMTUZUMAB OZOGAMICIN | | | | |
| INJECTABLE;INJECTION | | | | |
| MYLOTARG | | | | |
| | WYETH PHARMS INC | 5MG/VIAL | N021174 001 | May 17, 2000 |

GENTAMICIN SULFATE

| | | | | |
|---|---|---|---|---|
| CREAM;TOPICAL | | | | |
| GARAMYCIN | | | | |
| SCHERING | EQ 0.1% BASE ** | A060462 | 001 | |
| GENTAFAIR | | | | |
| PHARMAFAIR | EQ 0.1% BASE | A062458 | 001 | Sep 01, 1983 |
| GENTAMICIN SULFATE | | | | |
| ALPHARMA US PHARMS | EQ 0.1% BASE | A062471 | 001 | Sep 27, 1983 |
| FOUGERA PHARMS INC | EQ 0.1% BASE | A062531 | 001 | Jul 05, 1984 |
| PHARMADERM | EQ 1MG BASE/GM | A062530 | 001 | Jul 05, 1984 |
| TARO | EQ 0.1% BASE | A062427 | 001 | May 26, 1983 |
| INJECTABLE;INJECTION | | | | |
| APOGEN | | | | |
| KING PHARMS | EQ 10MG BASE/ML | A062289 | 001 | |
| | EQ 40MG BASE/ML | A062289 | 002 | |
| BRISTAGEN | | | | |
| BRISTOL | EQ 40MG BASE/ML | A062288 | 001 | |
| GARAMYCIN | | | | |
| SCHERING | EQ 1MG BASE/ML ** | A061716 | 002 | |
| | EQ 10MG BASE/ML ** | A061739 | 001 | |
| | EQ 40MG BASE/ML ** | A061716 | 001 | |
| GENTAFAIR | | | | |
| PHARMAFAIR | EQ 40MG BASE/ML | A062493 | 001 | Aug 28, 1985 |
| GENTAMICIN | | | | |
| INTL MEDICATION | EQ 1MG BASE/ML | A062325 | 003 | Jun 23, 1982 |
| | EQ 40MG BASE/ML | A062325 | 001 | |
| | EQ 100MG BASE/100ML | A062325 | 004 | Jun 23, 1982 |
| GENTAMICIN SULFATE | | | | |
| ABBOTT | EQ 1.2MG BASE/ML | A062413 | 001 | Aug 11, 1983 |
| | EQ 1.4MG BASE/ML | A062413 | 002 | Aug 11, 1983 |
| | EQ 1.6MG BASE/ML | A062413 | 003 | Aug 11, 1983 |
| | EQ 1.8MG BASE/ML | A062413 | 004 | Aug 11, 1983 |
| | EQ 2MG BASE/ML | A062413 | 005 | Aug 11, 1983 |
| | EQ 60MG BASE/100ML | A062413 | 006 | Aug 11, 1983 |
| | EQ 70MG BASE/100ML | A062413 | 007 | Aug 11, 1983 |
| | EQ 80MG BASE/100ML | A062413 | 008 | Aug 11, 1983 |
| | EQ 90MG BASE/100ML | A062413 | 009 | Aug 11, 1983 |
| | EQ 100MG BASE/100ML | A062413 | 010 | Aug 11, 1983 |
| FRESENIUS KABI USA | EQ 10MG BASE/ML | A062356 | 001 | Mar 04, 1982 |
| | EQ 40MG BASE/ML | A062356 | 002 | Mar 04, 1982 |
| KALAPHARM | EQ 40MG BASE/ML | A062354 | 001 | Apr 05, 1982 |
| PHARM SPEC | EQ 40MG BASE/ML | A062340 | 001 | Mar 28, 1983 |
| SOLOPAK | EQ 10MG BASE/ML | A062507 | 001 | Jun 06, 1985 |
| | EQ 40MG BASE/ML | A062507 | 002 | Jun 06, 1985 |
| TEVA PARENTERAL | EQ 10MG BASE/ML | A063149 | 001 | Nov 21, 1991 |
| | EQ 40MG BASE/ML | A063106 | 002 | Nov 21, 1991 |
| WATSON LABS | EQ 10MG BASE/ML | A062318 | 002 | |
| | EQ 40MG BASE/ML | A062318 | 001 | |
| WEST-WARD PHARMS INT | EQ 10MG BASE/ML | A062251 | 002 | |
| | EQ 40MG BASE/ML | A062251 | 001 | |
| WYETH AYERST | EQ 10MG BASE/ML | A062264 | 001 | |
| | EQ 40MG BASE/ML | A062264 | 002 | |
| GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | | | | |
| B BRAUN | EQ 0.8MG BASE/ML | A062814 | 001 | Aug 28, 1987 |
| | EQ 1.2MG BASE/ML | A062814 | 002 | Aug 28, 1987 |
| | EQ 1.4MG BASE/ML | A062814 | 003 | Aug 28, 1987 |
| | EQ 1.6MG BASE/ML | A062814 | 004 | Aug 28, 1987 |
| | EQ 1.8MG BASE/ML | A062814 | 005 | Aug 28, 1987 |
| | EQ 2MG BASE/ML | A062814 | 006 | Aug 28, 1987 |
| | EQ 2.4MG BASE/ML | A062814 | 007 | Aug 28, 1987 |
| | EQ 40MG BASE/100ML | A062814 | 008 | Aug 28, 1987 |
| | EQ 60MG BASE/100ML | A062814 | 009 | Aug 28, 1987 |
| | EQ 70MG BASE/100ML | A062814 | 010 | Aug 28, 1987 |
| | EQ 80MG BASE/100ML | A062814 | 011 | Aug 28, 1987 |
| | EQ 90MG BASE/100ML | A062814 | 012 | Aug 28, 1987 |
| | EQ 100MG BASE/100ML | A062814 | 013 | Aug 28, 1987 |
| | EQ 120MG BASE/100ML | A062814 | 014 | Aug 28, 1987 |
| BAXTER HLTHCARE | EQ 0.8MG BASE/ML | A062373 | 001 | Sep 07, 1982 |
| | EQ 2.4MG BASE/ML | A062373 | 010 | Sep 07, 1982 |

| | | | | |
|---|---|---|---|---|
| GENTAMICIN SULFATE | | | | |
| INJECTABLE;INJECTION | | | | |
| GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | | | | |
| | EQ 40MG BASE/100ML | A062373 | 003 | Sep 07, 1982 |
| | EQ 60MG BASE/100ML | A062373 | 004 | Sep 07, 1982 |
| HOSPIRA | EQ 1.2MG BASE/ML | A062588 | 001 | Jan 06, 1986 |
| | EQ 1.4MG BASE/ML | A062414 | 002 | Aug 15, 1983 |
| | EQ 1.4MG BASE/ML | A062588 | 002 | Jan 06, 1986 |
| | EQ 1.6MG BASE/ML | A062588 | 003 | Jan 06, 1986 |
| | EQ 1.8MG BASE/ML | A062414 | 004 | Aug 15, 1983 |
| | EQ 1.8MG BASE/ML | A062588 | 004 | Jan 06, 1986 |
| | EQ 2MG BASE/ML | A062414 | 005 | Aug 15, 1983 |
| | EQ 2MG BASE/ML | A062588 | 005 | Jan 06, 1986 |
| | EQ 60MG BASE/100ML | A062414 | 006 | Aug 15, 1983 |
| | EQ 60MG BASE/100ML | A062588 | 006 | Jan 06, 1986 |
| | EQ 70MG BASE/100ML | A062414 | 007 | Aug 15, 1983 |
| | EQ 70MG BASE/100ML | A062588 | 007 | Jan 06, 1986 |
| | EQ 80MG BASE/100ML | A062588 | 008 | Jan 06, 1986 |
| | EQ 90MG BASE/100ML | A062414 | 009 | Aug 15, 1983 |
| | EQ 90MG BASE/100ML | A062588 | 009 | Jan 06, 1986 |
| | EQ 100MG BASE/100ML | A062588 | 010 | Jan 06, 1986 |
| U-GENCIN | | | | |
| PHARMACIA AND UPJOHN | EQ 10MG BASE/ML | A062248 | 001 | |
| | EQ 40MG BASE/ML | A062248 | 002 | |
| INJECTABLE;INTRATHECAL | | | | |
| GARAMYCIN | | | | |
| + SCHERING | EQ 2MG BASE/ML ** | N050505 | 001 | |
| OINTMENT;OPHTHALMIC | | | | |
| GARAMYCIN | | | | |
| SCHERING | EQ 0.3% BASE | N050425 | 001 | |
| GENTACIDIN | | | | |
| NOVARTIS | EQ 0.3% BASE | A062501 | 001 | Jul 26, 1984 |
| GENTAFAIR | | | | |
| PHARMAFAIR | EQ 3MG BASE/GM | A062443 | 001 | May 26, 1983 |
| OINTMENT;TOPICAL | | | | |
| GARAMYCIN | | | | |
| SCHERING | EQ 0.1% BASE ** | A060463 | 001 | |
| GENTAFAIR | | | | |
| PHARMAFAIR | EQ 0.1% BASE | A062444 | 001 | May 26, 1983 |
| GENTAMICIN SULFATE | | | | |
| ALPHARMA US PHARMS | EQ 0.1% BASE | A062496 | 001 | Mar 14, 1984 |
| G AND W LABS INC | EQ 0.1% BASE | A064054 | 001 | Apr 29, 1994 |
| PHARMADERM | EQ 0.1% BASE | A062534 | 001 | Oct 10, 1984 |
| SOLUTION/DROPS;OPHTHALMIC | | | | |
| GARAMYCIN | | | | |
| + SCHERING | EQ 0.3% BASE ** | N050039 | 002 | |
| GENTACIDIN | | | | |
| NOVARTIS | EQ 0.3% BASE | A062480 | 001 | Mar 30, 1984 |
| GENTAFAIR | | | | |
| PHARMAFAIR | EQ 0.3% BASE | A062440 | 001 | May 03, 1983 |
| GENTAMICIN SULFATE | | | | |
| ALCON PHARMS LTD | EQ 0.3% BASE | A062523 | 001 | Nov 25, 1985 |
| PACO | EQ 3MG BASE/ML | A062932 | 001 | Nov 07, 1988 |
| GENTIAN VIOLET | | | | |
| SUPPOSITORY;VAGINAL | | | | |
| GVS | | | | |
| SAVAGE LABS | 0.4% | A083513 | 001 | |
| TAMPON;VAGINAL | | | | |
| GENAPAX | | | | |
| KEY PHARMS | 5MG | A085017 | 001 | |
| GLATIRAMER ACETATE | | | | |
| FOR SOLUTION;SUBCUTANEOUS | | | | |
| COPAXONE | | | | |
| TEVA PHARMS USA | 20MG/VIAL | N020622 | 001 | Dec 20, 1996 |

GLIMEPIRIDE

TABLET;ORAL

GLIMEPIRIDE

| | | | | |
|---|---|---|---|---|
| ACTAVIS LABS FL INC | 1MG | A076995 | 001 | Apr 27, 2010 |
| | 2MG | A076995 | 002 | Apr 27, 2010 |
| | 4MG | A076995 | 003 | Apr 27, 2010 |
| EPIC PHARMA LLC | 1MG | A077274 | 001 | Oct 06, 2005 |
| | 2MG | A077274 | 002 | Oct 06, 2005 |
| | 4MG | A077274 | 003 | Oct 06, 2005 |
| HIKMA PHARMS | 1MG | A078952 | 001 | Aug 01, 2013 |
| | 2MG | A078952 | 002 | Aug 01, 2013 |
| | 4MG | A078952 | 003 | Aug 01, 2013 |
| MYLAN | 1MG | A077486 | 001 | Feb 10, 2006 |
| | 2MG | A077486 | 002 | Feb 10, 2006 |
| | 4MG | A077486 | 003 | Feb 10, 2006 |
| RANBAXY | 3MG | A077366 | 001 | Oct 06, 2005 |
| | 6MG | A077366 | 002 | Oct 06, 2005 |
| RANBAXY LABS LTD | 1MG | A076875 | 001 | Oct 06, 2005 |
| | 2MG | A076875 | 002 | Oct 06, 2005 |
| | 4MG | A076875 | 003 | Oct 06, 2005 |
| | 8MG | A076875 | 004 | Oct 06, 2005 |
| WATSON LABS | 1MG | A077280 | 001 | Feb 03, 2006 |
| | 2MG | A077280 | 002 | Feb 03, 2006 |
| | 4MG | A077280 | 003 | Feb 03, 2006 |

GLIMEPIRIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL

AVANDARYL

| | | | | | |
|---|---|---|---|---|---|
| + | SB PHARMCO | 1MG;4MG ** | N021700 | 001 | Nov 23, 2005 |
| + | | 2MG;4MG ** | N021700 | 002 | Nov 23, 2005 |
| + | | 2MG;8MG ** | N021700 | 004 | Mar 30, 2007 |
| + | | 4MG;4MG ** | N021700 | 003 | Nov 23, 2005 |
| + | | 4MG;8MG ** | N021700 | 005 | Mar 30, 2007 |

GLIPIZIDE

TABLET;ORAL

GLIPIZIDE

| | | | | |
|---|---|---|---|---|
| ANI PHARMS INC | 5MG | A074387 | 001 | Mar 04, 1996 |
| | 10MG | A074387 | 002 | Mar 04, 1996 |
| BARR LABS INC | 5MG | A074619 | 001 | Apr 04, 1997 |
| | 10MG | A074619 | 002 | Apr 04, 1997 |
| MYLAN | 5MG | A074438 | 001 | Jun 20, 1995 |
| | 10MG | A074438 | 002 | Jun 20, 1995 |
| SANDOZ | 5MG | A074542 | 001 | Jun 20, 1995 |
| | 10MG | A074542 | 002 | Jun 20, 1995 |
| VINTAGE PHARMS LLC | 5MG | A074378 | 001 | Nov 28, 1994 |
| | 10MG | A074378 | 002 | Nov 28, 1994 |
| WATSON LABS | 5MG | A074370 | 001 | Nov 22, 1994 |
| | 10MG | A074370 | 002 | Nov 22, 1994 |

GLUCOTROL

| | | | | |
|---|---|---|---|---|
| PFIZER | 2.5MG | N017783 | 003 | May 11, 1993 |

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

METAGLIP

| | | | | | |
|---|---|---|---|---|---|
| + | BRISTOL MYERS SQUIBB | 2.5MG;250MG ** | N021460 | 001 | Oct 21, 2002 |
| + | | 2.5MG;500MG ** | N021460 | 002 | Oct 21, 2002 |
| + | | 5MG;500MG ** | N021460 | 003 | Oct 21, 2002 |

GLUCAGON HYDROCHLORIDE

INJECTABLE;INJECTION

GLUCAGON

| | | | | |
|---|---|---|---|---|
| + | LILLY | EQ 1MG BASE/VIAL ** | N012122 | 001 |
| + | | EQ 10MG BASE/VIAL ** | N012122 | 002 |

GLUTETHIMIDE

CAPSULE;ORAL

DORIDEN

| | | | | |
|---|---|---|---|---|
| SANOFI AVENTIS US | 500MG | N009519 | 008 | |

GLUTETHIMIDE

| | | | | | |
|---|---|---|---|---|---|
| TABLET;ORAL | | | | | |
| DORIDEN | | | | | |
| | SANOFI AVENTIS US | 250MG | N009519 | 002 | |
| | | 500MG | N009519 | 005 | |
| GLUTETHIMIDE | | | | | |
| | HALSEY | 250MG | A089458 | 001 | Oct 10, 1986 |
| | | 500MG | A089459 | 001 | Oct 10, 1986 |
| | LANNETT | 250MG | A083475 | 001 | |
| | | 500MG | A085571 | 001 | |
| | UCB INC | 500MG | A085171 | 001 | |
| | UPSHER-SMITH LABS | 500MG | A083234 | 002 | |
| | VITARINE | 500MG | A087297 | 001 | |
| | WATSON LABS | 500MG | A084362 | 001 | |
| | | 500MG | A085763 | 001 | |

GLYBURIDE

| | | | | | |
|---|---|---|---|---|---|
| TABLET;ORAL | | | | | |
| GLYBURIDE | | | | | |
| | ACTAVIS ELIZABETH | 1.5MG | A075947 | 001 | Nov 14, 2002 |
| | | 3MG | A075947 | 002 | Nov 14, 2002 |
| | | 6MG | A075947 | 003 | Nov 14, 2002 |
| GLYBURIDE (MICRONIZED) | | | | | |
| | FOSUN PHARMA | 1.5MG | A075174 | 001 | Jun 22, 1998 |
| | | 3MG | A075174 | 002 | Jun 22, 1998 |
| | SANOFI AVENTIS US | 1.5MG | N020055 | 001 | Apr 17, 1992 |
| | | 3MG | N020055 | 002 | Apr 17, 1992 |
| | | 6MG | N020055 | 003 | Mar 08, 2000 |
| GLYNASE | | | | | |
| + | PHARMACIA AND UPJOHN | 4.5MG ** | N020051 | 003 | Sep 24, 1993 |
| MICRONASE | | | | | |
| + | PHARMACIA AND UPJOHN | 1.25MG ** | N017498 | 001 | May 01, 1984 |
| | | 2.5MG | N017498 | 002 | May 01, 1984 |
| + | | 5MG ** | N017498 | 003 | May 01, 1984 |

GLYBURIDE; METFORMIN HYDROCHLORIDE

| | | | | | |
|---|---|---|---|---|---|
| TABLET;ORAL | | | | | |
| GLUCOVANCE | | | | | |
| + | BRISTOL MYERS SQUIBB | 1.25MG;250MG ** | N021178 | 001 | Jul 31, 2000 |
| + | | 2.5MG;500MG | N021178 | 002 | Jul 31, 2000 |
| + | | 5MG;500MG | N021178 | 003 | Jul 31, 2000 |
| GLYBURIDE AND METFORMIN HYDROCHLORIDE | | | | | |
| | IMPAX LABS INC | 1.25MG;250MG | A076731 | 001 | Nov 19, 2004 |
| | | 2.5MG;500MG | A076731 | 002 | Nov 19, 2004 |
| | | 5MG;500MG | A076731 | 003 | Nov 19, 2004 |
| | TEVA | 1.25MG;250MG | A076821 | 001 | Jan 27, 2005 |
| | | 2.5MG;500MG | A076821 | 002 | Jan 27, 2005 |
| | | 5MG;500MG | A076821 | 003 | Jan 27, 2005 |

GLYCINE

| | | | | | |
|---|---|---|---|---|---|
| SOLUTION;IRRIGATION | | | | | |
| GLYCINE 1.5% IN PLASTIC CONTAINER | | | | | |
| | BAXTER HLTHCARE | 1.5GM/100ML | N018522 | 001 | Feb 19, 1982 |
| | HOSPIRA | 1.5GM/100ML | N017633 | 001 | |

GLYCOPYRROLATE

| | | | | | |
|---|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | | |
| GLYCOPYRROLATE | | | | | |
| | ABRAXIS PHARM | 0.2MG/ML | A088475 | 001 | Jun 12, 1984 |
| | HOSPIRA | 0.2MG/ML | A089393 | 001 | Jun 15, 1988 |
| | TEVA PARENTERAL | 0.2MG/ML | A081169 | 001 | Sep 10, 1991 |
| | WATSON LABS | 0.2MG/ML | A086947 | 001 | Jun 24, 1983 |
| ROBINUL | | | | | |
| | ROBINS AH | 0.2MG/ML | N014764 | 001 | |
| + | WEST-WARD PHARMS INT | 0.2MG/ML ** | N017558 | 001 | |
| TABLET;ORAL | | | | | |
| GLYCOPYRROLATE | | | | | |
| | EPIC PHARMA LLC | 1MG | A040568 | 001 | Dec 22, 2004 |
| | | 2MG | A040568 | 002 | Dec 22, 2004 |
| | HIKMA INTL PHARMS | 1MG | A040836 | 001 | Mar 05, 2009 |
| | | 2MG | A040836 | 002 | Mar 05, 2009 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| GLYCOPYRROLATE | | | | |
| TABLET;ORAL | | | | |
| GLYCOPYRROLATE | | | | |
| WATSON LABS | 1MG | A085562 | 001 | |
| | 1MG | A086902 | 001 | |
| | 2MG | A085563 | 001 | |
| | 2MG | A086178 | 001 | |
| | 2MG | A086900 | 001 | |
| GONADORELIN ACETATE | | | | |
| INJECTABLE;INJECTION | | | | |
| LUTREPULSE KIT | | | | |
| FERRING | 0.8MG/VIAL | N019687 | 001 | Oct 10, 1989 |
| | 3.2MG/VIAL | N019687 | 002 | Oct 10, 1989 |
| GONADORELIN HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| FACTREL | | | | |
| WEST-WARD PHARMS INT | EQ 0.1MG BASE/VIAL | N018123 | 001 | Sep 30, 1982 |
| | EQ 0.2MG BASE/VIAL | N018123 | 002 | Sep 30, 1982 |
| | EQ 0.5MG BASE/VIAL | N018123 | 003 | Sep 30, 1982 |
| GONADOTROPIN, CHORIONIC | | | | |
| INJECTABLE;INJECTION | | | | |
| A.P.L. | | | | |
| FERRING | 5,000 UNITS/VIAL | N017055 | 001 | |
| | 10,000 UNITS/VIAL | N017055 | 002 | |
| | 20,000 UNITS/VIAL | N017055 | 003 | |
| CHORIONIC GONADOTROPIN | | | | |
| BEL MAR | 5,000 UNITS/VIAL | N017054 | 001 | |
| | 10,000 UNITS/VIAL | N017054 | 002 | |
| FERRING | 2,000 UNITS/VIAL | N017016 | 009 | Dec 27, 1984 |
| | 2,000 UNITS/VIAL | N017016 | 011 | Feb 16, 1990 |
| | 15,000 UNITS/VIAL | N017016 | 010 | Feb 15, 1985 |
| | 20,000 UNITS/VIAL | N017016 | 004 | |
| FRESENIUS KABI USA | 5,000 UNITS/VIAL | N017067 | 001 | |
| | 15,000 UNITS/VIAL | N017067 | 004 | |
| | 20,000 UNITS/VIAL | N017067 | 003 | |
| FOLLUTEIN | | | | |
| BRISTOL MYERS SQUIBB | 10,000 UNITS/VIAL | N017056 | 001 | |
| GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | |
| NEO-POLYCIN | | | | |
| DOW PHARM | 0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML | A060427 | 001 | |
| NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN | | | | |
| IPHARM | 0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML | A062818 | 001 | Oct 11, 1988 |
| WATSON LABS | 0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML | A062788 | 001 | Jun 11, 1987 |
| NEOMYCIN SULFATE AND POLYMYXIN B SULFATE GRAMICIDIN | | | | |
| PHARMAFAIR | 0.025MG/ML;EQ 1.75MG BASE/ML;10,000 UNITS/ML | A062383 | 001 | Aug 31, 1982 |
| GRANISETRON HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| GRANISETRON HYDROCHLORIDE | | | | |
| BAXTER HLTHCARE CORP | EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) | A078197 | 001 | Dec 31, 2007 |
| | EQ 1MG BASE/ML (EQ 1MG BASE/ML) | A078198 | 001 | Jun 30, 2008 |
| | EQ 4MG BASE/4ML (EQ 1MG BASE/ML) | A078198 | 002 | Jun 30, 2008 |
| SANDOZ INC | EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) | A078808 | 001 | Apr 29, 2008 |
| GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE | | | | |
| TEVA PHARMS USA | EQ 1MG BASE/ML (EQ 1MG BASE/ML) | A077165 | 001 | Dec 31, 2007 |
| KYTRIL | | | | |
| + ROCHE | EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML) ** | N020239 | 003 | Sep 17, 2004 |
| + | EQ 1MG BASE/ML (EQ 1MG BASE/ML) ** | N020239 | 004 | Mar 11, 1994 |
| + | EQ 3MG BASE/ML ** | N020239 | 001 | Dec 29, 1993 |
| + | EQ 4MG BASE/4ML (EQ 1MG BASE/ML) ** | N020239 | 002 | Mar 11, 1994 |
| SOLUTION;ORAL | | | | |
| GRANISOL | | | | |
| PEDIATRX | EQ 2MG BASE/10ML | A078334 | 001 | Feb 28, 2008 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| GRANISETRON HYDROCHLORIDE | | | | |
| SOLUTION;ORAL | | | | |
| KYTRIL | | | | |
| + ROCHE | EQ 2MG BASE/10ML ** | N021238 | 001 | Jun 27, 2001 |
| TABLET;ORAL | | | | |
| GRANISETRON HYDROCHLORIDE | | | | |
| BARR | EQ 1MG BASE | A078221 | 001 | Dec 31, 2007 |
| EPIC PHARMA LLC | EQ 1MG BASE | A078260 | 001 | Dec 31, 2007 |
| KYTRIL | | | | |
| + ROCHE | EQ 1MG BASE ** | N020305 | 001 | Mar 16, 1995 |
| + | EQ 2MG BASE ** | N020305 | 002 | Jun 15, 1998 |
| GREPAFLOXACIN HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| RAXAR | | | | |
| OTSUKA | EQ 200MG BASE | N020695 | 001 | Nov 06, 1997 |
| | EQ 400MG BASE | N020695 | 002 | May 14, 1998 |
| | EQ 600MG BASE | N020695 | 003 | May 14, 1998 |
| GRISEOFULVIN, MICROCRYSTALLINE | | | | |
| CAPSULE;ORAL | | | | |
| GRISACTIN | | | | |
| WYETH AYERST | 125MG | N050051 | 002 | |
| | 250MG | N050051 | 001 | |
| SUSPENSION;ORAL | | | | |
| GRIFULVIN V | | | | |
| + JOHNSON AND JOHNSON | 125MG/5ML ** | N050448 | 001 | |
| TABLET;ORAL | | | | |
| FULVICIN-U/F | | | | |
| CHARTWELL RX | 250MG | A060569 | 002 | |
| | 500MG | A060569 | 001 | |
| GRIFULVIN V | | | | |
| J AND J | 125MG | A060618 | 001 | |
| | 250MG | A060618 | 002 | |
| | 500MG | A060618 | 003 | |
| VALEANT LUXEMBOURG | 125MG | A062279 | 001 | |
| | 250MG ** | A062279 | 002 | |
| GRISACTIN | | | | |
| WYETH AYERST | 500MG | A060212 | 001 | |
| GRISEOFULVIN, MICROSIZE | | | | |
| SUSPENSION;ORAL | | | | |
| GRIFULVIN V | | | | |
| VALEANT LUXEMBOURG | 125MG/5ML ** | A062483 | 001 | Jan 26, 1984 |
| TABLET;ORAL | | | | |
| GRIFULVIN V | | | | |
| VALEANT LUXEMBOURG | 500MG | A062279 | 003 | |
| GRISEOFULVIN, ULTRAMICROCRYSTALLINE | | | | |
| TABLET;ORAL | | | | |
| FULVICIN P/G | | | | |
| CHARTWELL RX | 125MG | A061996 | 001 | |
| | 250MG | A061996 | 002 | |
| FULVICIN P/G 165 | | | | |
| CHARTWELL RX | 165MG | A061996 | 003 | Apr 06, 1982 |
| FULVICIN P/G 330 | | | | |
| CHARTWELL RX | 330MG | A061996 | 004 | Apr 06, 1982 |
| GRISACTIN ULTRA | | | | |
| WYETH AYERST | 125MG | A062178 | 001 | |
| | 165MG | A062438 | 001 | Nov 17, 1983 |
| | 250MG | A062178 | 002 | |
| | 330MG | A062438 | 002 | Nov 17, 1983 |
| ULTRAGRIS-165 | | | | |
| PLIVA | 165MG | A062645 | 001 | Jun 30, 1992 |
| ULTRAGRIS-330 | | | | |
| PLIVA | 330MG | A062646 | 001 | Jun 30, 1992 |

| | | | | |
|---|---|---|---|---|
| GUAIFENESIN; HYDROCODONE BITARTRATE | | | | |
| SOLUTION;ORAL | | | | |
| OBREDON | | | | |
| + SOVEREIGN PHARMS | 200MG/5ML;2.5MG/5ML | N205474 | 001 | Nov 14, 2014 |
| GUANABENZ ACETATE | | | | |
| TABLET;ORAL | | | | |
| GUANABENZ ACETATE | | | | |
| ANI PHARMS INC | EQ 4MG BASE | A074267 | 001 | Jun 01, 1994 |
| | EQ 8MG BASE | A074267 | 002 | Jun 01, 1994 |
| SANDOZ | EQ 4MG BASE | A074517 | 001 | Sep 30, 1998 |
| | EQ 8MG BASE | A074517 | 002 | Sep 30, 1998 |
| WATSON LABS | EQ 4MG BASE | A074025 | 001 | Feb 28, 1994 |
| | EQ 8MG BASE | A074025 | 002 | Feb 28, 1994 |
| WYTENSIN | | | | |
| WYETH AYERST | EQ 4MG BASE | N018587 | 001 | Sep 07, 1982 |
| | EQ 8MG BASE | N018587 | 002 | Sep 07, 1982 |
| | EQ 16MG BASE | N018587 | 003 | Sep 07, 1982 |
| GUANADREL SULFATE | | | | |
| TABLET;ORAL | | | | |
| HYLOREL | | | | |
| PHARMACIA AND UPJOHN | 10MG | N018104 | 001 | Dec 29, 1982 |
| | 25MG | N018104 | 002 | Dec 29, 1982 |
| GUANETHIDINE MONOSULFATE | | | | |
| TABLET;ORAL | | | | |
| GUANETHIDINE MONOSULFATE | | | | |
| WATSON LABS | EQ 10MG SULFATE | A086113 | 001 | Mar 26, 1985 |
| | EQ 25MG SULFATE | A086114 | 001 | Mar 26, 1985 |
| ISMELIN | | | | |
| NOVARTIS | EQ 10MG SULFATE | N012329 | 001 | |
| | EQ 25MG SULFATE | N012329 | 002 | |
| GUANETHIDINE MONOSULFATE; HYDROCHLOROTHIAZIDE | | | | |
| TABLET;ORAL | | | | |
| ESIMIL | | | | |
| NOVARTIS | 10MG;25MG | N013553 | 001 | |
| GUANFACINE HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| GUANFACINE HYDROCHLORIDE | | | | |
| WATSON LABS | EQ 1MG BASE | A074762 | 001 | Jun 25, 1997 |
| | EQ 2MG BASE | A074762 | 002 | Jun 25, 1997 |
| TENEX | | | | |
| PROMIUS PHARMA | EQ 3MG BASE | N019032 | 003 | Nov 07, 1988 |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| GUANFACINE HYDROCHLORIDE | | | | |
| IMPAX LABS INC | EQ 1MG BASE | A202238 | 001 | Oct 20, 2015 |
| | EQ 2MG BASE | A202238 | 002 | Oct 20, 2015 |
| | EQ 3MG BASE | A202238 | 003 | Oct 20, 2015 |
| | EQ 4MG BASE | A202238 | 004 | Oct 20, 2015 |
| HALAZEPAM | | | | |
| TABLET;ORAL | | | | |
| PAXIPAM | | | | |
| SCHERING | 20MG | N017736 | 003 | |
| | 40MG | N017736 | 004 | |
| HALCINONIDE | | | | |
| CREAM;TOPICAL | | | | |
| HALOG | | | | |
| WESTWOOD SQUIBB | 0.025% | N017818 | 001 | |
| HALOG-E | | | | |
| SUN PHARM INDS INC | 0.1% | N018234 | 001 | |
| OINTMENT;TOPICAL | | | | |
| HALOG | | | | |
| BRISTOL MYERS SQUIBB | 0.025% | N018125 | 001 | |
| SOLUTION;TOPICAL | | | | |
| HALOG | | | | |
| SUN PHARM INDS INC | 0.1% | N017823 | 001 | |

| | | | | |
|---|---|---|---|---|
| HALOBETASOL PROPIONATE | | | | |
| OINTMENT;TOPICAL | | | | |
| HALOBETASOL PROPIONATE | | | | |
| FOUGERA PHARMS | 0.05% | A076903 | 001 | Dec 16, 2004 |
| HALOFANTRINE HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| HALFAN | | | | |
| GLAXOSMITHKLINE | 250MG | N020250 | 001 | Jul 24, 1992 |
| HALOPERIDOL | | | | |
| TABLET;ORAL | | | | |
| HALDOL | | | | |
| + ORTHO MCNEIL | 0.5MG ** | N015921 | 001 | |
| + | 1MG ** | N015921 | 002 | |
| + | 2MG ** | N015921 | 003 | |
| + | 5MG ** | N015921 | 004 | |
| + | 10MG ** | N015921 | 005 | |
| + | 20MG ** | N015921 | 006 | Feb 02, 1982 |
| HALDOL SOLUTAB | | | | |
| ORTHO MCNEIL PHARM | 1MG | N017079 | 001 | |
| HALOPERIDOL | | | | |
| ANDA REPOSITORY | 0.5MG | A071156 | 001 | Jan 02, 1987 |
| | 1MG | A071157 | 001 | Jan 02, 1987 |
| | 2MG | A071172 | 001 | Jan 02, 1987 |
| | 5MG | A071212 | 001 | Jan 07, 1988 |
| | 10MG | A071173 | 001 | Jan 07, 1988 |
| | 20MG | A071177 | 001 | Jan 07, 1988 |
| CYCLE PHARMS LTD | 0.5MG | A071128 | 001 | Feb 17, 1987 |
| | 1MG | A071129 | 001 | Feb 17, 1987 |
| | 2MG | A071130 | 001 | Feb 17, 1987 |
| | 5MG | A071131 | 001 | Feb 17, 1987 |
| | 10MG | A071132 | 001 | May 12, 1987 |
| | 20MG | A071133 | 001 | May 12, 1987 |
| DURAMED PHARMS BARR | 0.5MG | A071216 | 001 | Dec 04, 1986 |
| | 1MG | A071217 | 001 | Dec 04, 1986 |
| | 2MG | A071218 | 001 | Dec 04, 1986 |
| | 5MG | A071219 | 001 | Dec 04, 1986 |
| | 10MG | A071220 | 001 | Jul 07, 1987 |
| | 20MG | A071221 | 001 | Jul 07, 1987 |
| LEDERLE | 0.5MG | A072727 | 001 | Sep 19, 1989 |
| | 1MG | A072728 | 001 | Sep 19, 1989 |
| | 2MG | A072729 | 001 | Sep 19, 1989 |
| | 5MG | A072730 | 001 | Sep 19, 1989 |
| | 10MG | A072731 | 001 | Sep 19, 1989 |
| | 20MG | A072732 | 001 | Sep 19, 1989 |
| PAR PHARM | 20MG | A071328 | 001 | Jul 20, 1987 |
| PUREPAC PHARM | 0.5MG | A071071 | 001 | Nov 03, 1986 |
| | 1MG | A071072 | 001 | Nov 03, 1986 |
| | 2MG | A071073 | 001 | Nov 03, 1986 |
| | 5MG | A071074 | 001 | Nov 03, 1986 |
| | 10MG | A071075 | 001 | Aug 04, 1987 |
| | 20MG | A071076 | 001 | Aug 04, 1987 |
| QUANTUM PHARMICS | 0.5MG | A071255 | 001 | Feb 17, 1987 |
| | 1MG | A071269 | 001 | Feb 17, 1987 |
| | 2MG | A071256 | 001 | Feb 17, 1987 |
| | 5MG | A071257 | 001 | Feb 17, 1987 |
| ROYCE LABS | 0.5MG | A071722 | 001 | Dec 24, 1987 |
| | 1MG | A071723 | 001 | Dec 24, 1987 |
| | 2MG | A071724 | 001 | Dec 24, 1987 |
| | 5MG | A071725 | 001 | Dec 24, 1987 |
| | 10MG | A072121 | 001 | Dec 24, 1987 |
| | 20MG | A072122 | 001 | Dec 24, 1987 |
| SCS | 0.5MG | A070720 | 001 | Jun 10, 1986 |
| | 1MG | A070721 | 001 | Jun 10, 1986 |
| | 2MG | A070722 | 001 | Jun 10, 1986 |
| | 5MG | A070723 | 001 | Jun 10, 1986 |
| | 10MG | A070724 | 001 | Jun 10, 1986 |
| | 20MG | A070725 | 001 | Sep 24, 1986 |
| VINTAGE | 0.5MG | A071235 | 002 | Nov 03, 1986 |

HALOPERIDOL
TABLET;ORAL
HALOPERIDOL

| | | | | |
|---|---|---|---|---|
| | 1MG | A071235 | 003 | Nov 03, 1986 |
| | 2MG | A071235 | 001 | Nov 03, 1986 |
| | 5MG | A071235 | 004 | Nov 03, 1986 |
| | 10MG | A071235 | 005 | Jul 20, 1987 |
| WATSON LABS | 0.5MG | A070981 | 001 | Mar 06, 1987 |
| | 0.5MG | A071571 | 001 | Jun 03, 1988 |
| | 1MG | A070982 | 001 | Mar 06, 1987 |
| | 1MG | A071572 | 001 | Jun 03, 1988 |
| | 2MG | A070983 | 001 | Mar 06, 1987 |
| | 2MG | A071573 | 001 | Jun 03, 1988 |
| | 5MG | A070984 | 001 | Mar 06, 1987 |
| | 5MG | A071374 | 001 | Jun 03, 1988 |
| | 10MG | A071375 | 001 | Jun 03, 1988 |
| | 10MG | A072113 | 001 | Aug 27, 1991 |
| | 20MG | A071376 | 001 | Jun 03, 1988 |
| | 20MG | A072353 | 001 | Aug 27, 1991 |

HALOPERIDOL DECANOATE
INJECTABLE;INJECTION
HALOPERIDOL DECANOATE

| | | | | |
|---|---|---|---|---|
| HOSPIRA | EQ 50MG BASE/ML | A075176 | 001 | Feb 09, 2000 |
| | EQ 100MG BASE/ML | A075176 | 002 | Feb 09, 2000 |
| SANDOZ INC | EQ 50MG BASE/ML | A076463 | 001 | Jun 24, 2005 |
| | EQ 100MG BASE/ML | A076463 | 002 | Jun 24, 2005 |

HALOPERIDOL LACTATE
CONCENTRATE;ORAL
HALDOL

| | | | | |
|---|---|---|---|---|
| ORTHO MCNEIL | EQ 2MG BASE/ML ** | N015922 | 001 | |

HALOPERIDOL

| | | | | |
|---|---|---|---|---|
| ALPHARMA | EQ 2MG BASE/ML | A070318 | 001 | Apr 11, 1986 |
| MORTON GROVE | EQ 2MG BASE/ML | A070710 | 001 | Mar 07, 1986 |
| SCS | EQ 2MG BASE/ML | A070726 | 001 | Jun 10, 1986 |
| TEVA | EQ 2MG BASE/ML | A071015 | 001 | Aug 25, 1987 |

HALOPERIDOL INTENSOL

| | | | | |
|---|---|---|---|---|
| CYCLE PHARMS LTD | EQ 2MG BASE/ML | A072045 | 001 | Apr 12, 1988 |

INJECTABLE;INJECTION
HALOPERIDOL

| | | | | |
|---|---|---|---|---|
| ABRAXIS PHARM | EQ 5MG BASE/ML | A071187 | 001 | Jan 20, 1987 |
| BAXTER HLTHCARE CORP | EQ 5MG BASE/ML | A076791 | 001 | Aug 25, 2004 |
| | EQ 5MG BASE/ML | A076828 | 001 | Aug 25, 2004 |
| MARSAM PHARMS LLC | EQ 5MG BASE/ML | A072516 | 001 | Feb 25, 1993 |
| | EQ 5MG BASE/ML | A072517 | 001 | Feb 25, 1993 |
| SANDOZ INC | EQ 5MG BASE/ML | A076464 | 001 | Sep 29, 2004 |
| SMITH AND NEPHEW | EQ 5MG BASE/ML | A070802 | 001 | Dec 14, 1987 |
| SOLOPAK | EQ 5MG BASE/ML | A070800 | 001 | Dec 14, 1987 |
| | EQ 5MG BASE/ML | A070801 | 001 | Dec 14, 1987 |
| | EQ 5MG BASE/ML | A070864 | 001 | Dec 14, 1987 |
| WATSON LABS | EQ 5MG BASE/ML | A070713 | 001 | May 17, 1988 |
| | EQ 5MG BASE/ML | A070714 | 001 | May 17, 1988 |
| | EQ 5MG BASE/ML | A070744 | 001 | May 17, 1988 |

SOLUTION;ORAL
HALOPERIDOL LACTATE

| | | | | |
|---|---|---|---|---|
| ACTAVIS MID ATLANTIC | EQ 1MG BASE/ML | A074536 | 001 | Nov 02, 1995 |

HALOPROGIN
CREAM;TOPICAL
HALOTEX

| | | | | |
|---|---|---|---|---|
| WESTWOOD SQUIBB | 1% | N016942 | 001 | |

SOLUTION;TOPICAL
HALOTEX

| | | | | |
|---|---|---|---|---|
| WESTWOOD SQUIBB | 1% | N016943 | 001 | |

| | | | | |
|---|---|---|---|---|
| HALOTHANE | | | | |
| LIQUID;INHALATION | | | | |
| FLUOTHANE | | | | |
| WYETH AYERST | 99.99% | N011338 | 001 | |
| HALOTHANE | | | | |
| BH | 99.99% | A084977 | 001 | |
| HALOCARBON | 99.99% | A080810 | 001 | |
| HOSPIRA | 99.99% | A083254 | 001 | |
| HEPARIN CALCIUM | | | | |
| INJECTABLE;INJECTION | | | | |
| CALCIPARINE | | | | |
| SANOFI AVENTIS US | 25,000 UNITS/ML | N018237 | 001 | |
| HEPARIN SODIUM | | | | |
| INJECTABLE;INJECTION | | | | |
| HEPARIN LOCK FLUSH | | | | |
| HOSPIRA | 100 UNITS/ML | N005264 | 010 | |
| INTL MEDICATION | 10 UNITS/ML | A086357 | 001 | |
| | 500 UNITS/ML | A086357 | 002 | |
| LUITPOLD | 10 UNITS/ML | A089063 | 001 | Oct 09, 1985 |
| | 100 UNITS/ML | A089064 | 001 | Oct 09, 1985 |
| PARKE DAVIS | 10 UNITS/ML | N017346 | 006 | |
| SMITH AND NEPHEW | 10 UNITS/ML | A087904 | 001 | Apr 20, 1983 |
| | 10 UNITS/ML | A087958 | 001 | Apr 20, 1983 |
| | 10 UNITS/ML | A088458 | 001 | Jul 26, 1984 |
| | 10 UNITS/ML | A088580 | 001 | Oct 25, 1984 |
| | 100 UNITS/ML | A087906 | 001 | Apr 20, 1983 |
| | 100 UNITS/ML | A087959 | 001 | Apr 20, 1983 |
| | 100 UNITS/ML | A088460 | 001 | Jul 26, 1984 |
| | 100 UNITS/ML | A088581 | 001 | Oct 25, 1984 |
| SOLOPAK | 10 UNITS/ML | A087903 | 001 | Apr 20, 1983 |
| | 10 UNITS/ML | A088457 | 001 | Oct 25, 1984 |
| | 100 UNITS/ML | A087905 | 001 | Apr 20, 1983 |
| | 100 UNITS/ML | A088459 | 001 | Jul 26, 1984 |
| HEPARIN SODIUM | | | | |
| ABRAXIS PHARM | 1,000 UNITS/ML | N017033 | 001 | |
| | 1,000 UNITS/ML | N017979 | 001 | |
| | 5,000 UNITS/ML | N017979 | 003 | |
| | 10,000 UNITS/ML | N017979 | 002 | |
| AKORN | 1,000 UNITS/ML | N017486 | 001 | |
| | 5,000 UNITS/ML | N017486 | 002 | |
| | 10,000 UNITS/ML | N017486 | 003 | |
| | 20,000 UNITS/ML | N017486 | 004 | |
| | 40,000 UNITS/ML | N017486 | 005 | |
| CHAMBERLIN PARENTERL | 1,000 UNITS/ML | N017130 | 001 | |
| | 5,000 UNITS/ML | N017130 | 002 | |
| | 10,000 UNITS/ML | N017130 | 003 | |
| | 20,000 UNITS/ML | N017130 | 004 | |
| DELL LABS | 1,000 UNITS/ML | N017540 | 001 | |
| | 5,000 UNITS/ML | N017540 | 002 | |
| | 10,000 UNITS/ML | N017540 | 003 | |
| | 20,000 UNITS/ML | N017540 | 004 | |
| | 40,000 UNITS/ML | N017540 | 005 | |
| FRESENIUS KABI USA | 1,000 UNITS/ML | N017651 | 005 | |
| | 5,000 UNITS/ML | N017029 | 002 | |
| | 10,000 UNITS/ML | N017651 | 003 | |
| | 20,000 UNITS/ML | N017651 | 008 | |
| HOSPIRA | 2,500 UNITS/ML | A088099 | 001 | Apr 28, 1983 |
| | 10,000 UNITS/ML | A040095 | 001 | Jul 26, 1996 |
| LILLY | 1,000 UNITS/ML | N005521 | 001 | |
| | 10,000 UNITS/ML | N005521 | 002 | |
| | 20,000 UNITS/ML | N005521 | 004 | |
| LUITPOLD | 1,000 UNITS/ML | A087452 | 001 | Oct 31, 1983 |
| ORGANON USA INC | 1,000 UNITS/ML | N000552 | 008 | |
| | 5,000 UNITS/ML | N000552 | 009 | |
| | 10,000 UNITS/ML | N000552 | 010 | |
| PARKE DAVIS | 1,000 UNITS/ML | N017346 | 001 | |
| | 5,000 UNITS/ML | N017346 | 002 | |
| | 7,500 UNITS/ML | N017346 | 003 | |

HEPARIN SODIUM

INJECTABLE;INJECTION

| | | | | |
|---|---|---|---|---|
| HEPARIN SODIUM | | | | |
| | 10,000 UNITS/ML | N017346 | 004 | |
| | 20,000 UNITS/ML | N017346 | 005 | |
| PHARM SPEC | 1,000 UNITS/ML | N017780 | 001 | |
| | 5,000 UNITS/ML | N017780 | 002 | |
| | 10,000 UNITS/ML | N017780 | 003 | |
| | 20,000 UNITS/ML | N017780 | 004 | |
| | 40,000 UNITS/ML | N017780 | 005 | |
| PHARMACIA AND UPJOHN | 1,000 UNITS/ML | N004570 | 001 | |
| | 5,000 UNITS/ML | N004570 | 002 | |
| | 10,000 UNITS/ML | N004570 | 003 | |
| SMITH AND NEPHEW | 1,000 UNITS/ML | A088239 | 001 | Jul 26, 1984 |
| SOLOPAK | 1,000 UNITS/ML | A087043 | 001 | |
| | 5,000 UNITS/ML | A087077 | 001 | |
| | 5,000 UNITS/0.5ML | A087395 | 001 | |
| | 10,000 UNITS/ML | A087107 | 001 | |
| | 10,000 UNITS/0.5ML | A087363 | 001 | |
| WATSON LABS | 1,000 UNITS/ML | N017064 | 002 | |
| | 2,500 UNITS/ML | N017064 | 015 | |
| | 3,000 UNITS/ML | N017064 | 016 | |
| | 4,000 UNITS/ML | N017064 | 017 | |
| | 5,000 UNITS/ML | N017064 | 003 | |
| | 6,000 UNITS/ML | N017064 | 018 | |
| | 7,500 UNITS/ML | N017064 | 019 | |
| | 10,000 UNITS/ML | N017064 | 004 | |
| | 20,000 UNITS/ML | N017064 | 005 | |
| | 40,000 UNITS/ML | N017064 | 006 | |
| WATSON LABS INC | 1,000 UNITS/ML | A040007 | 001 | Jun 07, 1996 |
| | 1,000 UNITS/ML | A040008 | 001 | Oct 10, 1995 |
| WEST-WARD PHARMS INT | 1,000 UNITS/ML | N017007 | 001 | |
| | 2,500 UNITS/ML | N017007 | 007 | |
| | 5,000 UNITS/ML | N017007 | 002 | |
| | 5,000 UNITS/0.5ML | N017007 | 010 | |
| | 5,000 UNITS/0.5ML | N017037 | 013 | Apr 07, 1986 |
| | 7,500 UNITS/ML | N017007 | 003 | |
| | 10,000 UNITS/ML | N017007 | 004 | |
| | 15,000 UNITS/ML | N017007 | 005 | |
| | 20,000 UNITS/ML | N017007 | 006 | |
| HEPARIN SODIUM 1,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| MCGAW | 200 UNITS/100ML | N019130 | 001 | Dec 31, 1984 |
| HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 200 UNITS/100ML | N019042 | 001 | Mar 29, 1985 |
| HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| BAXTER HLTHCARE | 2,000 UNITS/100ML | N018814 | 002 | Jul 09, 1985 |
| HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% | | | | |
| HOSPIRA | 10,000 UNITS/100ML | N018911 | 006 | Jan 30, 1985 |
| HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45% | | | | |
| HOSPIRA | 10,000 UNITS/100ML | N018911 | 001 | Jan 30, 1985 |
| | 10,000 UNITS/100ML | N018916 | 005 | Jan 31, 1984 |
| HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9% | | | | |
| HOSPIRA | 10,000 UNITS/100ML | N018911 | 003 | Jan 30, 1985 |
| | 10,000 UNITS/100ML | N018916 | 002 | Jan 31, 1984 |
| HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% | | | | |
| HOSPIRA | 5,000 UNITS/100ML | N018911 | 007 | Jan 30, 1985 |
| HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 5,000 UNITS/100ML | N019802 | 001 | Jul 20, 1992 |
| HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9% | | | | |
| HOSPIRA | 5,000 UNITS/100ML | N018911 | 005 | Jan 30, 1985 |
| | 5,000 UNITS/100ML | N018916 | 003 | Jan 31, 1984 |
| HEPARIN SODIUM 2,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| MCGAW | 200 UNITS/100ML | N019130 | 003 | Dec 31, 1984 |
| HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 200 UNITS/100ML | N019042 | 002 | Mar 29, 1985 |
| HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| BAXTER HLTHCARE | 4,000 UNITS/100ML | N018814 | 001 | Oct 31, 1983 |
| HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| BAXTER HLTHCARE | 5,000 UNITS/100ML | N018814 | 003 | Jul 09, 1985 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

HEPARIN SODIUM

INJECTABLE;INJECTION

| | | | | |
|---|---|---|---|---|
| HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| | 10,000 UNITS/100ML | N018814 | 004 | Jul 02, 1987 |
| HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% | | | | |
| HOSPIRA | 5,000 UNITS/100ML | N018911 | 009 | Jan 30, 1985 |
| | 10,000 UNITS/100ML | N018911 | 008 | Jan 30, 1985 |
| HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 5,000 UNITS/100ML | N019134 | 001 | Mar 29, 1985 |
| HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 5,000 UNITS/100ML | N019802 | 005 | Jul 20, 1992 |
| | 10,000 UNITS/100ML | N019802 | 002 | Jul 20, 1992 |
| HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% | | | | |
| HOSPIRA | 5,000 UNITS/100ML | N018911 | 004 | Jan 30, 1985 |
| HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 5,000 UNITS/100ML | N019135 | 001 | Mar 29, 1985 |
| | 5,000 UNITS/100ML | N019802 | 003 | Jul 20, 1992 |
| HOSPIRA | 5,000 UNITS/100ML | N018916 | 009 | Jan 31, 1984 |
| HEPARIN SODIUM 5,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | | | | |
| BAXTER HLTHCARE | 500 UNITS/100ML | N018609 | 003 | Apr 28, 1982 |
| HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| MCGAW | 1,000 UNITS/100ML | N019130 | 002 | Dec 31, 1984 |
| HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45% | | | | |
| HOSPIRA | 100 UNITS/ML | N018911 | 002 | Jan 30, 1985 |
| | 100 UNITS/ML | N018916 | 004 | Jan 31, 1984 |
| HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% | | | | |
| HOSPIRA | 1,000 UNITS/100ML | N018916 | 001 | Jan 31, 1984 |
| HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 1,000 UNITS/100ML | N019042 | 004 | Mar 29, 1985 |
| HEPARIN SODIUM PRESERVATIVE FREE | | | | |
| HOSPIRA | 2,000 UNITS/ML | N005264 | 013 | Apr 07, 1986 |
| | 2,500 UNITS/ML | N005264 | 014 | Apr 07, 1986 |
| PHARMA SERVE NY | 1,000 UNITS/ML | A086129 | 001 | |
| WATSON LABS INC | 1,000 UNITS/ML | A089464 | 001 | Jun 03, 1986 |
| LIPO-HEPIN | | | | |
| 3M | 1,000 UNITS/0.5ML | N017027 | 001 | |
| | 1,000 UNITS/ML | N017027 | 006 | |
| | 5,000 UNITS/0.5ML | N017027 | 002 | |
| | 5,000 UNITS/ML | N017027 | 008 | |
| | 7,500 UNITS/0.5ML | N017027 | 010 | |
| | 10,000 UNITS/0.5ML | N017027 | 003 | |
| | 10,000 UNITS/ML | N017027 | 009 | |
| | 15,000 UNITS/0.5ML | N017027 | 011 | |
| | 20,000 UNITS/0.5ML | N017027 | 004 | |
| | 20,000 UNITS/ML | N017027 | 007 | |
| | 40,000 UNITS/ML | N017027 | 005 | |
| LIQUAEMIN LOCK FLUSH | | | | |
| ORGANON USA INC | 100 UNITS/ML | N000552 | 007 | |
| LIQUAEMIN SODIUM | | | | |
| ORGANON USA INC | 1,000 UNITS/ML | N000552 | 004 | |
| | 5,000 UNITS/ML | N000552 | 003 | |
| | 10,000 UNITS/ML | N000552 | 005 | |
| | 20,000 UNITS/ML | N000552 | 001 | |
| | 40,000 UNITS/ML | N000552 | 002 | |
| LIQUAEMIN SODIUM PRESERVATIVE FREE | | | | |
| ORGANON USA INC | 1,000 UNITS/ML | N000552 | 011 | Apr 11, 1986 |
| | 5,000 UNITS/ML | N000552 | 012 | Apr 11, 1986 |
| | 10,000 UNITS/ML | N000552 | 013 | Apr 11, 1986 |
| PANHEPRIN | | | | |
| HOSPIRA | 1,000 UNITS/ML | N005264 | 004 | |
| | 5,000 UNITS/ML | N005264 | 006 | |
| | 10,000 UNITS/ML | N005264 | 007 | |
| | 20,000 UNITS/ML | N005264 | 008 | |
| | 40,000 UNITS/ML | N005264 | 009 | |
| SODIUM HEPARIN | | | | |
| ABRAXIS PHARM | 5,000 UNITS/ML | N017033 | 002 | |
| | 10,000 UNITS/ML | N017033 | 003 | |
| | 20,000 UNITS/ML | N017033 | 004 | |
| BAXTER HLTHCARE | 1,000 UNITS/ML | N017036 | 001 | Mar 04, 1988 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| HETACILLIN | | | | |
| FOR SUSPENSION;ORAL | | | | |
| VERSAPEN | | | | |
| | BRISTOL | EQ 112.5MG AMPICIL/ML | A061398 001 | |
| | | EQ 112.5MG AMPICIL/5ML | N050060 001 | |
| | | EQ 112.5MG AMPICIL/ML | N050060 003 | |
| | | EQ 225MG AMPICIL/5ML | A061398 002 | |
| HETACILLIN POTASSIUM | | | | |
| CAPSULE;ORAL | | | | |
| VERSAPEN-K | | | | |
| | BRISTOL | EQ 225MG AMPICIL | A061396 001 | |
| | | EQ 450MG AMPICIL | A061396 002 | |
| HEXACHLOROPHENE | | | | |
| AEROSOL;TOPICAL | | | | |
| SEPTISOL | | | | |
| | VESTAL LABS | 0.23% | N017424 001 | |
| TURGEX | | | | |
| | XTTRIUM | 3% | N018375 001 | |
| EMULSION;TOPICAL | | | | |
| HEXA-GERM | | | | |
| | HUNTINGTON LABS | 3% | N017411 001 | |
| PHISOHEX | | | | |
| | SANOFI AVENTIS US | 3% | N006882 001 | |
| | | 3% | N008402 001 | |
| SOY-DOME | | | | |
| | BAYER PHARMS | 3% | N017405 001 | |
| TURGEX | | | | |
| | XTTRIUM | 3% | N019055 001 | Nov 30, 1984 |
| SOAP;TOPICAL | | | | |
| GAMOPHEN | | | | |
| | ARBROOK | 2% | N006270 003 | |
| SOLUTION;TOPICAL | | | | |
| DIAL | | | | |
| | DIAL | 0.25% | N017421 002 | |
| GERMA-MEDICA | | | | |
| | HUNTINGTON LABS | 1% | N017412 001 | |
| GERMA-MEDICA "MG" | | | | |
| | HUNTINGTON LABS | 0.25% | N017412 002 | |
| SEPTI-SOFT | | | | |
| | CALGON | 0.25% | N017460 001 | |
| SEPTISOL | | | | |
| | VESTAL LABS | 0.25% | N017423 001 | |
| SPONGE;TOPICAL | | | | |
| E-Z SCRUB | | | | |
| | BECTON DICKINSON | 450MG | N017452 001 | |
| HEXASCRUB | | | | |
| | PROF DSPLS | 3% | N018363 001 | |
| PHISO-SCRUB | | | | |
| | SANOFI AVENTIS US | 3% | N017446 001 | |
| SCRUBTEAM SURGICAL SPONGEBRUSH | | | | |
| | 3M | 330MG | N017413 001 | |
| HEXAFLUORENIUM BROMIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| MYLAXEN | | | | |
| | MEDPOINTE PHARM HLC | 20MG/ML | N009789 003 | |
| HEXOCYCLIUM METHYLSULFATE | | | | |
| TABLET;ORAL | | | | |
| TRAL | | | | |
| | ABBVIE | 25MG | N010599 001 | |
| HEXYLCAINE HYDROCHLORIDE | | | | |
| SOLUTION;TOPICAL | | | | |
| CYCLAINE | | | | |
| | MERCK | 5% | N008472 001 | |

| | | | | |
|---|---|---|---|---|
| HISTAMINE PHOSPHATE | | | | |
| INJECTABLE;INJECTION | | | | |
| HISTAMINE PHOSPHATE | | | | |
| LILLY | EQ 0.1MG BASE/ML | N000734 | 003 | |
| | EQ 0.2MG BASE/ML | N000734 | 002 | |
| | EQ 1MG BASE/ML | N000734 | 001 | |
| HISTRELIN ACETATE | | | | |
| INJECTABLE;INJECTION | | | | |
| SUPPRELIN | | | | |
| SHIRE | EQ 0.2MG BASE/ML | N019836 | 001 | Dec 24, 1991 |
| | EQ 0.5MG BASE/ML | N019836 | 002 | Dec 24, 1991 |
| | EQ 1MG BASE/ML | N019836 | 003 | Dec 24, 1991 |
| HOMATROPINE METHYLBROMIDE | | | | |
| TABLET;ORAL | | | | |
| HOMAPIN-10 | | | | |
| MISSION PHARMA | 10MG | A086308 | 001 | |
| HOMAPIN-5 | | | | |
| MISSION PHARMA | 5MG | A086309 | 001 | |
| TABLET, CHEWABLE;ORAL | | | | |
| EQUIPIN | | | | |
| MISSION PHARMA | 3MG | A086310 | 001 | |
| HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE | | | | |
| SYRUP;ORAL | | | | |
| HYCODAN | | | | |
| + ENDO PHARMS | 1.5MG/5ML;5MG/5ML ** | N005213 | 002 | Jul 26, 1988 |
| HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE | | | | |
| IVAX SUB TEVA PHARMS | 1.5MG/5ML;5MG/5ML | A040285 | 001 | Jul 19, 1999 |
| HYDROPANE | | | | |
| HALSEY | 1.5MG/5ML;5MG/5ML | A088066 | 001 | Jun 28, 1985 |
| TABLET;ORAL | | | | |
| HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE | | | | |
| ACTAVIS ELIZABETH | 1.5MG;5MG | A040295 | 001 | Dec 01, 2000 |
| HYCODAN | | | | |
| + ENDO PHARMS | 1.5MG;5MG ** | N005213 | 001 | Jul 26, 1988 |
| HYALURONIDASE | | | | |
| INJECTABLE;INJECTION | | | | |
| HYDASE | | | | |
| AKORN INC | 150 UNITS/ML | N021716 | 001 | Oct 25, 2005 |
| VITRASE | | | | |
| BAUSCH AND LOMB | 6,200 UNITS/VIAL | N021640 | 001 | May 05, 2004 |
| WYDASE | | | | |
| BAXTER HLTHCARE | 150 UNITS/ML ** | N006343 | 002 | |
| | 150 UNITS/VIAL ** | N006343 | 006 | |
| | 1,500 UNITS/VIAL ** | N006343 | 005 | |
| HYDRALAZINE HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| APRESOLINE | | | | |
| + NOVARTIS | 20MG/ML ** | N008303 | 003 | |
| HYDRALAZINE HYDROCHLORIDE | | | | |
| ABRAXIS PHARM | 20MG/ML | A089532 | 001 | Aug 11, 1987 |
| SMITH AND NEPHEW | 20MG/ML | A088518 | 001 | Apr 20, 1984 |
| SOLOPAK | 20MG/ML | A088517 | 001 | Aug 22, 1985 |
| TEVA PARENTERAL | 20MG/ML | A040373 | 001 | Feb 23, 2000 |
| TABLET;ORAL | | | | |
| APRESOLINE | | | | |
| + NOVARTIS | 10MG ** | N008303 | 004 | |
| + | 25MG ** | N008303 | 001 | |
| + | 50MG ** | N008303 | 002 | |
| + | 100MG ** | N008303 | 005 | |
| DRALZINE | | | | |
| TEVA | 25MG | A084301 | 001 | |
| HYDRALAZINE HYDROCHLORIDE | | | | |
| ACTAVIS ELIZABETH | 25MG | A088560 | 001 | Oct 04, 1984 |
| | 50MG | A088649 | 001 | Oct 18, 1984 |
| ACTAVIS GRP PTC | 10MG | A091679 | 001 | Mar 04, 2013 |
| | 25MG | A091679 | 002 | Mar 04, 2013 |
| | 50MG | A091679 | 003 | Mar 04, 2013 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

HYDRALAZINE HYDROCHLORIDE

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| | 100MG | A091679 | 004 | Mar 04, 2013 |
| ANDA REPOSITORY | 10MG | A089359 | 001 | Jul 25, 1986 |
| | 25MG | A089258 | 001 | May 05, 1986 |
| | 50MG | A089259 | 001 | May 05, 1986 |
| | 100MG | A088729 | 001 | Apr 11, 1985 |
| ASCOT | 25MG | A088310 | 001 | Dec 19, 1984 |
| | 50MG | A088311 | 001 | Dec 19, 1984 |
| CHARTWELL RX | 10MG | A088846 | 001 | Feb 26, 1985 |
| | 25MG | A088847 | 001 | Feb 26, 1985 |
| | 50MG | A088848 | 001 | Feb 26, 1985 |
| | 100MG | A088849 | 001 | Feb 26, 1985 |
| HALSEY | 10MG | A089218 | 001 | Jan 22, 1986 |
| | 25MG | A089130 | 001 | Jan 15, 1986 |
| | 50MG | A089222 | 001 | Jan 22, 1986 |
| | 100MG | A089178 | 001 | Jan 15, 1986 |
| HERITAGE PHARMS INC | 10MG | A040858 | 001 | Feb 26, 2010 |
| | 25MG | A040858 | 002 | Feb 26, 2010 |
| | 50MG | A040858 | 003 | Feb 26, 2010 |
| | 100MG | A040858 | 004 | Feb 26, 2010 |
| IMPAX LABS | 25MG | A084922 | 001 | |
| | 50MG | A084923 | 001 | |
| IVAX SUB TEVA PHARMS | 10MG | A084443 | 001 | |
| | 25MG | A084437 | 001 | |
| | 50MG | A084469 | 002 | |
| | 100MG | A084581 | 001 | |
| MUTUAL PHARM | 10MG | A088728 | 001 | Apr 11, 1985 |
| | 25MG | A084106 | 002 | |
| | 50MG | A084107 | 002 | |
| MYLAN | 10MG | A090413 | 001 | Dec 08, 2010 |
| | 25MG | A090413 | 002 | Dec 08, 2010 |
| | 50MG | A090413 | 003 | Dec 08, 2010 |
| | 100MG | A090413 | 004 | Dec 08, 2010 |
| PUREPAC PHARM | 25MG | A088177 | 001 | Jul 29, 1983 |
| | 50MG | A088178 | 001 | Aug 15, 1983 |
| QUANTUM PHARMICS | 10MG | A088671 | 001 | May 01, 1984 |
| | 25MG | A088657 | 001 | Jun 15, 1984 |
| | 50MG | A088652 | 001 | May 08, 1984 |
| | 100MG | A088686 | 001 | May 01, 1984 |
| SUPERPHARM | 10MG | A088787 | 001 | Aug 28, 1984 |
| | 25MG | A088788 | 001 | Aug 28, 1984 |
| | 50MG | A088789 | 001 | Aug 28, 1984 |
| UPSHER-SMITH LABS | 10MG | A083241 | 001 | |
| | 25MG | A083560 | 001 | |
| | 50MG | A083561 | 001 | |
| | 50MG | A085088 | 001 | |
| USL PHARMA | 25MG | A087780 | 001 | Mar 29, 1982 |
| | 50MG | A087751 | 001 | Mar 29, 1982 |
| VANGARD | 25MG | A087712 | 001 | |
| | 50MG | A087908 | 001 | May 07, 1982 |
| VITARINE | 25MG | A086088 | 001 | |
| WATSON LABS | 25MG | A084504 | 001 | |
| | 25MG | A085532 | 002 | May 24, 1982 |
| | 50MG | A084503 | 001 | |
| | 50MG | A085533 | 002 | May 25, 1982 |
| WEST WARD | 25MG | A088240 | 001 | May 27, 1983 |
| | 50MG | A088241 | 001 | May 27, 1983 |

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

APRESAZIDE

| | | | | |
|---|---|---|---|---|
| NOVARTIS | 25MG;25MG | A084735 | 001 | |
| | 50MG;50MG | A084810 | 001 | |
| | 100MG;50MG | A084811 | 001 | |

HYDRA-ZIDE

| | | | | |
|---|---|---|---|---|
| PAR PHARM | 100MG;50MG | A088961 | 001 | Oct 21, 1985 |

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

| | | | | |
|---|---|---|---|---|
| CAPSULE;ORAL | | | | |
| HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE | | | | |
| SOLVAY | 25MG;25MG | A087608 | 001 | Feb 08, 1982 |
| | 50MG;50MG | A087213 | 001 | Feb 08, 1982 |
| | 100MG;50MG | A087609 | 001 | Feb 08, 1982 |
| SUPERPHARM | 25MG;25MG | A089200 | 001 | Feb 09, 1987 |
| | 50MG;50MG | A089201 | 001 | Feb 09, 1987 |
| WATSON LABS | 25MG;25MG | A085457 | 001 | Mar 04, 1982 |
| | 50MG;50MG | A085446 | 001 | Mar 04, 1982 |
| | 100MG;50MG | A085440 | 001 | Mar 04, 1982 |
| HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 100/50 | | | | |
| IVAX PHARMS | 100MG;50MG | A088358 | 001 | Apr 10, 1984 |
| HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 25/25 | | | | |
| IVAX PHARMS | 25MG;25MG | A088356 | 001 | Apr 10, 1984 |
| HYDRALAZINE HYDROCHLORIDE W/ HYDROCHLOROTHIAZIDE 50/50 | | | | |
| IVAX PHARMS | 50MG;50MG | A088357 | 001 | Apr 10, 1984 |
| TABLET;ORAL | | | | |
| APRESOLINE-ESIDRIX | | | | |
| NOVARTIS | 25MG;15MG | N012026 | 002 | |
| HYDRALAZINE AND HYDROCHLOROTHIAZIDE | | | | |
| WATSON LABS | 25MG;15MG | A085827 | 001 | |
| HYDROCHLOROTHIAZIDE W/ HYDRALAZINE | | | | |
| WATSON LABS | 25MG;15MG | A085373 | 001 | |

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| CAM-AP-ES | | | | |
| CHARTWELL RX | 25MG;15MG;0.1MG | A084897 | 001 | |
| HYDRALAZINE HYDROCHLORIDE, HYDROCHLOROTHIAZIDE AND RESERPINE | | | | |
| IVAX SUB TEVA PHARMS | 25MG;15MG;0.1MG | A084291 | 001 | |
| HYDRALAZINE HYDROCHLORIDE-HYDROCHLOROTHIAZIDE-RESERPINE | | | | |
| MYLAN | 25MG;15MG;0.1MG | A087085 | 001 | |
| HYDRALAZINE, HYDROCHLOROTHIAZIDE W/ RESERPINE | | | | |
| WATSON LABS | 25MG;15MG;0.1MG | A085771 | 001 | |
| HYDRAP-ES | | | | |
| SANDOZ | 25MG;15MG;0.1MG | A084876 | 001 | |
| HYDROCHLOROTHIAZIDE W/ RESERPINE AND HYDRALAZINE | | | | |
| WATSON LABS | 25MG;15MG;0.1MG | A083770 | 001 | |
| HYDROSERPINE PLUS (R-H-H) | | | | |
| IVAX SUB TEVA PHARMS | 25MG;15MG;0.1MG | A083877 | 001 | |
| RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE | | | | |
| SOLVAY | 25MG;15MG;0.1MG | A088376 | 001 | Oct 28, 1983 |
| SUN PHARM INDUSTRIES | 25MG;15MG;0.1MG | A088570 | 001 | Apr 10, 1984 |
| WATSON LABS | 25MG;15MG;0.1MG | A085549 | 001 | |
| | 25MG;15MG;0.1MG | A087556 | 001 | |
| RESERPINE, HYDROCHLOROTHIAZIDE, AND HYDRALAZINE HYDROCHLORIDE | | | | |
| LEDERLE | 25MG;15MG;0.1MG | A087709 | 001 | May 13, 1982 |
| SER-A-GEN | | | | |
| SOLVAY | 25MG;15MG;0.1MG | A087210 | 001 | |
| SER-AP-ES | | | | |
| NOVARTIS | 25MG;15MG;0.1MG | N012193 | 005 | |
| UNIPRES | | | | |
| SOLVAY | 25MG;15MG;0.1MG | A085893 | 001 | |
| | 25MG;15MG;0.1MG | A086298 | 001 | |

HYDRALAZINE HYDROCHLORIDE; RESERPINE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| DRALSERP | | | | |
| SANDOZ | 25MG;0.1MG | A084617 | 001 | |
| SERPASIL-APRESOLINE | | | | |
| NOVARTIS | 25MG;0.1MG | N009296 | 004 | |
| | 50MG;0.2MG | N009296 | 002 | |

HYDROCHLOROTHIAZIDE

| | | | | |
|---|---|---|---|---|
| CAPSULE;ORAL | | | | |
| HYDROCHLOROTHIAZIDE | | | | |
| HIKMA INTL PHARMS | 12.5MG | A077885 | 001 | Nov 26, 2007 |
| LANNETT HOLDINGS INC | 12.5MG | A091662 | 001 | Jan 27, 2012 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

HYDROCHLOROTHIAZIDE

| | | | | |
|---|---|---|---|---|
| SOLUTION;ORAL | | | | |
| HYDROCHLOROTHIAZIDE | | | | |
| MORTON GROVE | 50MG/5ML | A089661 | 001 | Jun 20, 1988 |
| ROXANE | 50MG/5ML | A088587 | 001 | Jul 02, 1984 |
| HYDROCHLOROTHIAZIDE INTENSOL | | | | |
| ROXANE | 100MG/ML | A088588 | 001 | Jul 02, 1984 |
| TABLET;ORAL | | | | |
| ESIDRIX | | | | |
| NOVARTIS | 25MG | N011793 | 005 | |
| | 50MG | N011793 | 008 | |
| | 100MG | N011793 | 009 | |
| HYDRO-D | | | | |
| HALSEY | 25MG | A086504 | 001 | |
| | 50MG | A083891 | 002 | |
| HYDROCHLOROTHIAZIDE | | | | |
| ABC HOLDING | 50MG | A085672 | 001 | |
| ACTAVIS ELIZABETH | 25MG | A085054 | 002 | |
| | 50MG | A085208 | 001 | |
| ALRA | 25MG | A086369 | 001 | |
| | 50MG | A083554 | 001 | |
| ASCOT | 25MG | A087539 | 001 | Feb 03, 1982 |
| | 50MG | A087540 | 001 | Feb 03, 1982 |
| AUROLIFE PHARMA LLC | 25MG | A083899 | 001 | |
| | 50MG | A085219 | 001 | |
| BARR | 50MG | A084771 | 001 | |
| CHARTWELL RX | 25MG | A085683 | 001 | |
| | 50MG | A083965 | 001 | |
| DAVA PHARMS INC | 100MG | A087060 | 001 | |
| ELKINS SINN | 50MG | A085152 | 002 | |
| FOSUN PHARMA | 25MG | A087565 | 001 | Mar 09, 1982 |
| | 50MG | A084912 | 001 | |
| HEATHER | 50MG | A084135 | 001 | |
| HIKMA INTL PHARMS | 25MG | A084878 | 002 | Jul 12, 2006 |
| IMPAX LABS | 25MG | A084029 | 001 | |
| | 50MG | A083607 | 002 | |
| | 100MG | A085098 | 001 | |
| INWOOD LABS | 25MG | A084776 | 001 | |
| | 25MG | A085067 | 001 | |
| | 50MG | A084776 | 002 | |
| IVAX SUB TEVA PHARMS | 50MG | A084658 | 001 | |
| | 100MG | A085022 | 001 | |
| JUBILANT CADISTA | 25MG | A040809 | 001 | Sep 04, 2007 |
| | 50MG | A040809 | 002 | Sep 04, 2007 |
| LANNETT | 25MG | A084325 | 001 | |
| | 50MG | A084324 | 001 | |
| MAST MM | 25MG | A086192 | 001 | |
| | 50MG | A086192 | 002 | |
| MYLAN | 25MG | A084880 | 001 | |
| | 50MG | A085112 | 001 | |
| MYLAN PHARMS INC | 12.5MG | A040770 | 001 | Jan 23, 2007 |
| PVT FORM | 50MG | A086597 | 001 | |
| ROXANE | 25MG | A085004 | 001 | |
| | 50MG | A084536 | 002 | |
| | 50MG | A085005 | 001 | |
| SOLVAY | 25MG | A085323 | 001 | |
| SUN PHARM INDUSTRIES | 25MG | A083972 | 001 | |
| | 50MG | A083972 | 002 | |
| | 100MG | A083972 | 003 | |
| SUPERPHARM | 25MG | A088827 | 001 | Dec 28, 1984 |
| | 50MG | A088828 | 001 | Dec 28, 1984 |
| | 100MG | A088829 | 001 | Dec 28, 1984 |
| TEVA | 25MG | A088924 | 001 | Feb 07, 1985 |
| | 50MG | A088923 | 001 | Feb 07, 1985 |
| USL PHARMA | 25MG | A087827 | 001 | Apr 19, 1982 |
| | 50MG | A087752 | 001 | Apr 19, 1982 |
| VANGARD | 25MG | A087638 | 001 | |
| | 50MG | A087610 | 001 | |
| WARNER CHILCOTT | 25MG | A087586 | 001 | May 03, 1982 |

HYDROCHLOROTHIAZIDE

| | | | | | |
|---|---|---|---|---|---|
| TABLET;ORAL | | | | | |
| HYDROCHLOROTHIAZIDE | | | | | |
| | | 50MG | A087587 | 001 | May 03, 1982 |
| | WATSON LABS | 25MG | A081189 | 001 | Jan 24, 1992 |
| | | 25MG | A083458 | 001 | |
| | | 25MG | A085232 | 002 | |
| | | 50MG | A083456 | 001 | |
| | | 50MG | A085233 | 001 | |
| | | 50MG | A086087 | 001 | |
| | | 50MG | A086594 | 001 | |
| | | 100MG | A081190 | 001 | Jan 24, 1992 |
| | | 100MG | A085099 | 001 | |
| | | 100MG | A087002 | 001 | |
| | WATSON LABS TEVA | 50MG | A083232 | 001 | |
| | WEST WARD | 25MG | A084899 | 001 | |
| | WHITEWORTH TOWN PLSN | 25MG | A083809 | 002 | |
| | | 50MG | A083809 | 001 | |
| | | 100MG | A085347 | 001 | |
| HYDRODIURIL | | | | | |
| + | MERCK | 25MG ** | N011835 | 003 | |
| + | | 50MG ** | N011835 | 006 | |
| + | | 100MG ** | N011835 | 007 | |
| ORETIC | | | | | |
| | ABBVIE | 25MG | N011971 | 001 | |
| | | 50MG | N011971 | 002 | |
| ZIDE | | | | | |
| | SOLVAY | 50MG | A083925 | 001 | |

HYDROCHLOROTHIAZIDE; IRBESARTAN

| | | | | | |
|---|---|---|---|---|---|
| TABLET;ORAL | | | | | |
| AVALIDE | | | | | |
| + | SANOFI AVENTIS US | 12.5MG;75MG ** | N020758 | 001 | Sep 30, 1997 |
| + | | 25MG;300MG ** | N020758 | 004 | Mar 15, 2005 |
| IRBESARTAN AND HYDROCHLOROTHIAZIDE | | | | | |
| | TEVA | 25MG;300MG | A077369 | 003 | Mar 30, 2012 |
| | WATSON LABS INC | 12.5MG;150MG | A091539 | 001 | Oct 22, 2012 |
| | | 12.5MG;300MG | A091539 | 002 | Oct 22, 2012 |

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

| | | | | | |
|---|---|---|---|---|---|
| TABLET;ORAL | | | | | |
| NORMOZIDE | | | | | |
| | SCHERING | 25MG;100MG | N019046 | 001 | Apr 06, 1987 |
| | | 25MG;200MG | N019046 | 002 | Apr 06, 1987 |
| | | 25MG;300MG | N019046 | 003 | Apr 06, 1987 |
| | | 25MG;400MG | N019046 | 004 | Apr 06, 1987 |
| TRANDATE HCT | | | | | |
| | GLAXOSMITHKLINE | 25MG;100MG | N019174 | 001 | Apr 10, 1987 |
| | | 25MG;200MG | N019174 | 002 | Apr 10, 1987 |
| | | 25MG;300MG | N019174 | 003 | Apr 10, 1987 |
| | | 25MG;400MG | N019174 | 004 | Apr 10, 1987 |

HYDROCHLOROTHIAZIDE; LISINOPRIL

| | | | | | |
|---|---|---|---|---|---|
| TABLET;ORAL | | | | | |
| LISINOPRIL AND HYDROCHLOROTHIAZIDE | | | | | |
| | SANDOZ | 12.5MG;10MG | A075926 | 001 | Jul 01, 2002 |
| | | 12.5MG;20MG | A075926 | 002 | Jul 01, 2002 |
| | | 25MG;20MG | A075926 | 003 | Jul 01, 2002 |
| | TEVA | 12.5MG;10MG | A075869 | 001 | Jul 01, 2002 |
| | | 12.5MG;20MG | A075869 | 002 | Jul 01, 2002 |
| | | 25MG;20MG | A075869 | 003 | Jul 01, 2002 |
| PRINZIDE | | | | | |
| + | MERCK | 12.5MG;10MG ** | N019778 | 003 | Nov 18, 1993 |
| + | | 12.5MG;20MG ** | N019778 | 001 | Feb 16, 1989 |
| + | | 25MG;20MG ** | N019778 | 002 | Feb 16, 1989 |

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE | | | | |
| WATSON LABS | 12.5MG;50MG | A200180 | 001 | Jan 12, 2011 |
| | 12.5MG;100MG | A200180 | 002 | Jan 12, 2011 |
| | 25MG;100MG | A200180 | 003 | Jan 12, 2011 |

HYDROCHLOROTHIAZIDE; METHYLDOPA

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| ALDORIL 15 | | | | |
| MERCK | 15MG;250MG | N013402 | 001 | |
| ALDORIL 25 | | | | |
| MERCK | 25MG;250MG | N013402 | 002 | |
| ALDORIL D30 | | | | |
| MERCK | 30MG;500MG | N013402 | 003 | |
| ALDORIL D50 | | | | |
| MERCK | 50MG;500MG | N013402 | 004 | |
| METHYLDOPA AND HYDROCHLOROTHIAZIDE | | | | |
| DAVA PHARMS INC | 15MG;250MG | A072507 | 001 | Jun 02, 1989 |
| | 25MG;250MG | A072508 | 001 | Jun 02, 1989 |
| | 30MG;500MG | A072509 | 001 | Jun 02, 1989 |
| | 50MG;500MG | A072510 | 001 | Jun 02, 1989 |
| FOSUN PHARMA | 15MG;250MG | A070182 | 001 | Jan 15, 1986 |
| | 25MG;250MG | A070183 | 001 | Jan 15, 1986 |
| | 30MG;500MG | A070543 | 001 | Jan 15, 1986 |
| IVAX SUB TEVA PHARMS | 15MG;250MG | A071458 | 001 | Mar 08, 1988 |
| | 25MG;250MG | A071459 | 001 | Mar 08, 1988 |
| | 30MG;500MG | A071460 | 001 | Mar 08, 1988 |
| | 50MG;500MG | A071461 | 001 | Mar 08, 1988 |
| PAR PHARM | 15MG;250MG | A070616 | 001 | Feb 02, 1987 |
| | 25MG;250MG | A070612 | 001 | Feb 02, 1987 |
| | 30MG;500MG | A070613 | 001 | Feb 02, 1987 |
| | 50MG;500MG | A070614 | 001 | Feb 02, 1987 |
| PARKE DAVIS | 15MG;250MG | A071897 | 001 | Nov 23, 1987 |
| | 25MG;250MG | A071898 | 001 | Nov 23, 1987 |
| | 30MG;500MG | A071899 | 001 | Nov 23, 1987 |
| | 50MG;500MG | A071900 | 001 | Nov 23, 1987 |
| PUREPAC PHARM | 15MG;250MG | A070853 | 001 | Oct 08, 1986 |
| | 25MG;250MG | A070688 | 001 | Apr 24, 1986 |
| | 30MG;500MG | A070854 | 001 | Oct 08, 1986 |
| | 50MG;500MG | A070689 | 001 | Apr 24, 1986 |
| SANDOZ | 15MG;250MG | A070829 | 001 | Mar 09, 1987 |
| | 25MG;250MG | A070830 | 001 | Mar 09, 1987 |
| | 50MG;500MG | A070544 | 001 | Jan 15, 1986 |
| TEVA | 15MG;250MG | A071819 | 001 | Apr 08, 1988 |
| | 25MG;250MG | A071820 | 001 | Apr 08, 1988 |
| | 30MG;500MG | A071821 | 001 | Apr 08, 1988 |
| | 50MG;500MG | A071822 | 001 | Apr 08, 1988 |
| WATSON LABS | 15MG;250MG | A070365 | 001 | Mar 19, 1986 |
| | 15MG;250MG | A070958 | 001 | Feb 06, 1989 |
| | 15MG;250MG | A071920 | 001 | Aug 29, 1988 |
| | 25MG;250MG | A070366 | 001 | Apr 16, 1986 |
| | 25MG;250MG | A070959 | 001 | Jan 19, 1989 |
| | 25MG;250MG | A071921 | 001 | Aug 29, 1988 |
| | 30MG;500MG | A070367 | 001 | Mar 19, 1986 |
| | 30MG;500MG | A071069 | 001 | Jan 19, 1989 |
| | 30MG;500MG | A071922 | 001 | Aug 29, 1988 |
| | 50MG;500MG | A070368 | 001 | Apr 16, 1986 |
| | 50MG;500MG | A070960 | 001 | Feb 06, 1989 |
| | 50MG;500MG | A071923 | 001 | Aug 29, 1988 |

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| LOPRESSOR HCT | | | | |
| + US PHARMS HOLDINGS I | 50MG;100MG ** | N018303 | 003 | Dec 31, 1984 |

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE | | | | |
| CHARTWELL RX | 12.5MG;7.5MG | A090096 | 001 | Sep 25, 2008 |
| | 12.5MG;15MG | A090096 | 002 | Sep 25, 2008 |
| | 25MG;15MG | A090096 | 003 | Sep 25, 2008 |
| UNIRETIC | | | | |
| UCB INC | 12.5MG;7.5MG ** | N020729 | 001 | Jun 27, 1997 |
| | 12.5MG;15MG ** | N020729 | 003 | Feb 14, 2002 |
| | 25MG;15MG ** | N020729 | 002 | Jun 27, 1997 |

HYDROCHLOROTHIAZIDE; PINDOLOL

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| VISKAZIDE | | | | |
| NOVARTIS | 25MG;5MG | N018872 | 001 | Jul 22, 1987 |
| | 25MG;10MG | N018872 | 002 | Jul 22, 1987 |

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| CAPSULE, EXTENDED RELEASE;ORAL | | | | |
| INDERIDE LA 120/50 | | | | |
| WYETH AYERST | 50MG;120MG | N019059 | 002 | Jul 03, 1985 |
| INDERIDE LA 160/50 | | | | |
| WYETH AYERST | 50MG;160MG | N019059 | 003 | Jul 03, 1985 |
| INDERIDE LA 80/50 | | | | |
| WYETH AYERST | 50MG;80MG | N019059 | 001 | Jul 03, 1985 |
| TABLET;ORAL | | | | |
| INDERIDE-40/25 | | | | |
| + WYETH PHARMS INC | 25MG;40MG ** | N018031 | 001 | |
| INDERIDE-80/25 | | | | |
| + WYETH PHARMS INC | 25MG;80MG ** | N018031 | 002 | |
| PROPRANOLOL HYDROCHLORIDE & HYDROCHLOROTHIAZIDE | | | | |
| DURAMED PHARMS BARR | 25MG;40MG | A071126 | 001 | Mar 02, 1987 |
| | 25MG;80MG | A071127 | 001 | Mar 02, 1987 |
| PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE | | | | |
| ACTAVIS ELIZABETH | 25MG;40MG | A070851 | 001 | May 15, 1986 |
| | 25MG;80MG | A070852 | 001 | May 15, 1986 |
| ANI PHARMS INC | 25MG;40MG | A070704 | 001 | Oct 01, 1986 |
| | 25MG;80MG | A070705 | 001 | Oct 01, 1986 |
| FOSUN PHARMA | 25MG;40MG | A071060 | 001 | Aug 26, 1987 |
| | 25MG;80MG | A071061 | 001 | Aug 26, 1987 |
| IVAX SUB TEVA PHARMS | 25MG;40MG | A071552 | 001 | Dec 01, 1988 |
| | 25MG;80MG | A071553 | 001 | Dec 01, 1988 |
| WARNER CHILCOTT | 25MG;40MG | A071771 | 001 | Jan 26, 1988 |
| | 25MG;80MG | A071772 | 001 | Jan 26, 1988 |
| WATSON LABS | 25MG;40MG | A070301 | 001 | Apr 18, 1986 |
| | 25MG;40MG | A071498 | 001 | Dec 18, 1991 |
| | 25MG;80MG | A070305 | 001 | Apr 18, 1986 |
| | 25MG;80MG | A071501 | 001 | Dec 18, 1991 |

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE | | | | |
| SUN PHARM INDS LTD | 12.5MG;EQ 10MG BASE | A078211 | 001 | Mar 04, 2009 |
| | 12.5MG;EQ 20MG BASE | A078211 | 002 | Mar 04, 2009 |
| | 25MG;EQ 20MG BASE | A078211 | 003 | Mar 04, 2009 |

HYDROCHLOROTHIAZIDE; RESERPINE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| H.R.-50 | | | | |
| WHITEWORTH TOWN PLSN | 50MG;0.125MG | A085338 | 001 | |
| HYDRO-RESERP | | | | |
| ABC HOLDING | 50MG;0.125MG | A084714 | 002 | Jun 29, 1982 |
| HYDRO-SERP "25" | | | | |
| SANDOZ | 25MG;0.125MG | A084827 | 001 | |
| HYDRO-SERP "50" | | | | |
| SANDOZ | 50MG;0.125MG | A085213 | 001 | |
| HYDROCHLOROTHIAZIDE W/ RESERPINE | | | | |
| IVAX SUB TEVA PHARMS | 25MG;0.1MG | A083572 | 001 | |
| | 25MG;0.125MG | A083571 | 001 | |
| | 50MG;0.1MG | A083568 | 001 | |
| | 50MG;0.125MG | A083573 | 001 | |

HYDROCHLOROTHIAZIDE; RESERPINE

TABLET;ORAL

HYDROCHLOROTHIAZIDE W/ RESERPINE

| | | | |
|---|---|---|---|
| PHARMERAL | 25MG;0.125MG | A085421 001 | |
| | 50MG;0.125MG | A085420 001 | |
| ROXANE | 50MG;0.125MG | A084603 001 | |
| WATSON LABS | 25MG;0.125MG | A084466 001 | |
| | 25MG;0.125MG | A085317 001 | |
| | 25MG;0.125MG | A086330 002 | |
| | 50MG;0.125MG | A083666 001 | |
| | 50MG;0.125MG | A084467 001 | |
| | 50MG;0.125MG | A086331 001 | |

HYDROPRES 25

| | | | |
|---|---|---|---|
| MERCK | 25MG;0.125MG | N011958 002 | |

HYDROPRES 50

| | | | |
|---|---|---|---|
| MERCK | 50MG;0.125MG | N011958 003 | |

RESERPINE AND HYDROCHLOROTHIAZIDE

| | | | |
|---|---|---|---|
| BARR | 25MG;0.125MG | A084580 001 | |
| | 50MG;0.125MG | A084579 001 | |
| SANDOZ | 50MG;0.125MG | A088200 001 | Jan 31, 1984 |

RESERPINE AND HYDROCHLOROTHIAZIDE-50

| | | | |
|---|---|---|---|
| WEST WARD | 50MG;0.125MG | A088189 001 | May 10, 1984 |

SERPASIL-ESIDRIX #1

| | | | |
|---|---|---|---|
| NOVARTIS | 25MG;0.1MG | N011878 003 | |

SERPASIL-ESIDRIX #2

| | | | |
|---|---|---|---|
| NOVARTIS | 50MG;0.1MG | N011878 005 | |

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

| | | | |
|---|---|---|---|
| ASCOT | 25MG;25MG | A088025 001 | Nov 23, 1984 |
| FOSUN PHARMA | 25MG;25MG | A086881 001 | |
| MUTUAL PHARM | 25MG;25MG | A087267 001 | |
| PUREPAC PHARM | 25MG;25MG | A087999 001 | Nov 06, 1985 |
| SUPERPHARM | 25MG;25MG | A089137 001 | Aug 26, 1985 |
| WATSON LABS | 25MG;25MG | A087398 001 | |

SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE

| | | | |
|---|---|---|---|
| IVAX PHARMS | 25MG;25MG | A087004 002 | May 24, 1982 |
| LEDERLE | 25MG;25MG | A087511 001 | |
| PARKE DAVIS | 25MG;25MG | A087948 001 | Feb 22, 1983 |
| PUREPAC PHARM | 25MG;25MG | A088054 001 | Aug 18, 1983 |
| UPSHER SMITH | 25MG;25MG | A087553 001 | |
| USL PHARMA | 25MG;25MG | A087651 001 | |
| VANGARD | 25MG;25MG | A087655 001 | |
| WATSON LABS | 25MG;25MG | A085974 001 | |
| | 25MG;25MG | A086026 001 | |

HYDROCHLOROTHIAZIDE; TIMOLOL MALEATE

TABLET;ORAL

TIMOLIDE 10-25

| | | | |
|---|---|---|---|
| MERCK | 25MG;10MG | N018061 001 | |

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE;ORAL

DYAZIDE

| | | | |
|---|---|---|---|
| GLAXOSMITHKLINE LLC | 25MG;50MG | N016042 002 | |

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

| | | | |
|---|---|---|---|
| ANI PHARMS INC | 25MG;37.5MG | A074970 001 | Jan 06, 1998 |
| NOVARTIS | 25MG;37.5MG | A074857 001 | Sep 09, 1997 |
| VITARINE | 25MG;50MG | A071737 001 | Feb 12, 1988 |

TABLET;ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

| | | | |
|---|---|---|---|
| AM THERAP | 50MG;75MG | A072022 001 | Apr 17, 1988 |
| QUANTUM PHARMICS | 50MG;75MG | A071980 001 | Apr 17, 1988 |
| WATSON LABS | 50MG;75MG | A071969 001 | Apr 17, 1988 |

| | | | | |
|---|---|---|---|---|
| HYDROCODONE BITARTRATE; IBUPROFEN | | | | |
| TABLET;ORAL | | | | |
| HYDROCODONE BITARTRATE AND IBUPROFEN | | | | |
| ACTAVIS LABS FL INC | 5MG;200MG | A077454 | 001 | Jun 23, 2010 |
| VICOPROFEN | | | | |
| + ABBVIE | 7.5MG;200MG | N020716 | 001 | Sep 23, 1997 |
| HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE | | | | |
| SYRUP;ORAL | | | | |
| CODAMINE | | | | |
| ALPHARMA US PHARMS | 5MG/5ML;25MG/5ML | A075103 | 001 | Sep 29, 2000 |
| HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE | | | | |
| SOLUTION;ORAL | | | | |
| HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE | | | | |
| TRIS PHARMA INC | 5MG/5ML;60MG/5ML | A203839 | 001 | Oct 28, 2014 |
| HYDROCORTAMATE HYDROCHLORIDE | | | | |
| OINTMENT;TOPICAL | | | | |
| MAGNACORT | | | | |
| PFIZER | 0.5% | N010554 | 001 | |
| HYDROCORTISONE | | | | |
| AEROSOL;TOPICAL | | | | |
| AEROSEB-HC | | | | |
| ALLERGAN HERBERT | 0.5% | A085805 | 001 | |
| CREAM;TOPICAL | | | | |
| CORT-DOME | | | | |
| BAYER PHARMS | 0.5% | N009585 | 003 | |
| | 1% | N009585 | 001 | |
| DERMACORT | | | | |
| MONARCH PHARMS | 1% | A083011 | 002 | |
| ELDECORT | | | | |
| VALEANT PHARM INTL | 1% | A080459 | 001 | |
| | 2.5% | A084055 | 001 | |
| FLEXICORT | | | | |
| WESTWOOD SQUIBB | 0.5% | A087136 | 003 | Apr 08, 1982 |
| | 1% | A087136 | 002 | Apr 08, 1982 |
| | 2.5% | A087136 | 001 | Apr 08, 1982 |
| H-CORT | | | | |
| PHARM ASSOC | 0.5% | A086823 | 001 | |
| HC #1 | | | | |
| BAYER PHARMS | 0.5% | A080438 | 001 | |
| HC #4 | | | | |
| BAYER PHARMS | 1% | A080438 | 002 | |
| HC (HYDROCORTISONE) | | | | |
| C AND M PHARMA | 0.5% | A080482 | 003 | |
| | 1% | A080482 | 004 | |
| HI-COR | | | | |
| C AND M PHARMA | 2.5% | A080483 | 001 | |
| HYDROCORTISONE | | | | |
| ALPHARMA US PHARMS | 2.5% | A089754 | 001 | Feb 01, 1989 |
| ALTANA | 0.5% | A080848 | 002 | |
| | 1% | A080848 | 003 | |
| AMBIX | 1% | A086080 | 001 | |
| | 2.5% | A086271 | 001 | |
| EVERYLIFE | 0.5% | A080452 | 001 | |
| | 1% | A080452 | 002 | |
| G AND W LABS | 1% | A084059 | 001 | |
| INGRAM PHARM | 0.5% | A080456 | 002 | |
| | 1% | A080456 | 003 | |
| IVAX PHARMS | 1% | A085733 | 001 | |
| NASKA | 1% | A089706 | 001 | Mar 10, 1988 |
| PERRIGO NEW YORK | 0.5% | A084970 | 002 | |
| | 1% | A085026 | 001 | |
| PHARMADERM | 1% | A088845 | 001 | Feb 27, 1986 |
| | 2.5% | A089413 | 001 | Dec 16, 1986 |
| PHARMAFAIR | 1% | A087838 | 001 | Jul 28, 1982 |
| STIEFEL | 1% | A086170 | 001 | |
| SYOSSET | 0.5% | A085527 | 001 | |
| TARO | 0.5% | A086154 | 001 | |

| | | | | |
|---|---|---|---|---|
| HYDROCORTISONE | | | | |
| CREAM;TOPICAL | | | | |
| HYDROCORTISONE | | | | |
| | 1% | A086155 001 | | |
| TEVA | 0.5% | A080400 002 | | |
| | 1% | A080400 003 | | |
| | 1% | A085191 001 | | |
| | 2.5% | A080400 004 | | |
| TOPIDERM | 1% | A089273 001 | Feb 17, 1989 | |
| USL PHARMA | 1% | A088027 001 | Sep 27, 1983 | |
| | 2.5% | A088029 001 | Sep 27, 1983 | |
| WHITEWORTH TOWN PLSN | 1% | A080496 002 | | |
| HYTONE | | | | |
| VALEANT INTL | 1% | A080472 003 | | |
| | 2.5% | A080472 004 | | |
| NOGENIC HC | | | | |
| IVAX PHARMS | 1% | A087427 001 | Apr 04, 1988 | |
| NUTRACORT | | | | |
| DOW PHARM | 0.5% | A080442 002 | | |
| | 1% | A080442 003 | | |
| PENECORT | | | | |
| ALLERGAN HERBERT | 1% | A088216 001 | Jun 06, 1984 | |
| PROCTOCORT | | | | |
| MONARCH PHARMS | 1% | A083011 001 | | |
| SYNACORT | | | | |
| MEDICIS | 0.5% | A087459 001 | | |
| | 1% | A087458 001 | | |
| | 2.5% | A087457 001 | | |
| GEL;TOPICAL | | | | |
| NUTRACORT | | | | |
| HEALTHPOINT | 1% | A084698 001 | | |
| PENECORT | | | | |
| ALLERGAN HERBERT | 1% | A088215 001 | Jun 06, 1984 | |
| INJECTABLE;INJECTION | | | | |
| CORTEF | | | | |
| PHARMACIA AND UPJOHN | 50MG/ML | N009864 001 | | |
| LOTION;TOPICAL | | | | |
| ACTICORT | | | | |
| BAKER NORTON | 1% | A086535 001 | | |
| ALA-CORT | | | | |
| CROWN LABS | 1% | A083201 001 | | |
| BALNEOL-HC | | | | |
| SOLVAY | 1% | A088041 001 | Dec 03, 1982 | |
| BETA-HC | | | | |
| BETA DERMAC | 1% | A089495 001 | Jan 25, 1988 | |
| CETACORT | | | | |
| DOW PHARM | 0.5% | A080426 002 | | |
| | 1% | A080426 001 | | |
| CORT-DOME | | | | |
| BAYER PHARMS | 0.5% | N009895 003 | | |
| | 1% | N009895 001 | | |
| DERMACORT | | | | |
| SOLVAY | 0.5% | A084573 002 | | |
| | 1% | A086462 001 | | |
| EPICORT | | | | |
| BLULINE | 0.5% | A083219 002 | | |
| GLYCORT | | | | |
| HERAN | 1% | A087489 001 | Oct 03, 1983 | |
| H-CORT | | | | |
| PHARM ASSOC | 0.5% | A086824 001 | | |
| HYDROCORTISONE | | | | |
| ALPHARMA US PHARMS | 0.5% | A087317 001 | Jun 07, 1982 | |
| | 1% | A087315 001 | Jun 07, 1982 | |
| MERICON | 0.5% | A085282 001 | | |
| | 1% | A085282 002 | Feb 26, 1987 | |
| NASKA | 1% | A089705 001 | Apr 25, 1988 | |
| PERRIGO NEW YORK | 0.5% | A085662 001 | | |
| | 1% | A085663 001 | | |
| TARO | 1% | A089024 001 | Feb 12, 1986 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

HYDROCORTISONE

| | | | | |
|---|---|---|---|---|
| LOTION;TOPICAL | | | | |
| HYTONE | | | | |
| VALEANT INTL | 1% | A080473 | 003 | |
| | 2.5% | A080473 | 004 | Nov 30, 1982 |
| NUTRACORT | | | | |
| DOW PHARM | 0.5% | A080443 | 002 | |
| | 1% | A080443 | 003 | |
| | 2.5% | A087644 | 001 | Aug 24, 1982 |
| STIE-CORT | | | | |
| PERRIGO CO | 1% | A089066 | 001 | Nov 25, 1985 |
| OINTMENT;TOPICAL | | | | |
| CORTRIL | | | | |
| PFIZER GLOBAL | 1% | N009176 | 001 | |
| | 2.5% | N009176 | 002 | |
| HC (HYDROCORTISONE) | | | | |
| C AND M PHARMA | 0.5% | A080481 | 001 | |
| | 1% | A080481 | 002 | |
| HYDROCORTISONE | | | | |
| ALTANA | 0.5% | A080489 | 002 | |
| | 1% | A080489 | 003 | |
| AMBIX | 1% | A086079 | 001 | |
| | 2.5% | A086272 | 001 | |
| NASKA | 1% | A089704 | 001 | Mar 10, 1988 |
| PERRIGO NEW YORK | 0.5% | A084969 | 003 | |
| | 1% | A085028 | 001 | |
| PHARMADERM | 1% | A088842 | 001 | Feb 09, 1987 |
| TARO | 0.5% | A086256 | 001 | |
| | 2.5% | A040310 | 001 | Dec 29, 2000 |
| USL PHARMA | 1% | A088061 | 001 | Sep 27, 1983 |
| | 2.5% | A088039 | 001 | Sep 27, 1983 |
| HYTONE | | | | |
| DERMIK LABS | 1% | A080474 | 003 | |
| | 2.5% | A080474 | 004 | |
| PENECORT | | | | |
| ALLERGAN HERBERT | 2.5% | A088217 | 001 | Jun 06, 1984 |
| POWDER;FOR RX COMPOUNDING | | | | |
| H-CORT | | | | |
| TORCH | 100% | A087834 | 001 | Mar 29, 1982 |
| HYDRO-RX | | | | |
| X GEN PHARMS | 100% | A085982 | 001 | |
| HYDROCORTISONE | | | | |
| PADDOCK LLC | 100% | A088082 | 001 | Apr 08, 1983 |
| SOLUTION;TOPICAL | | | | |
| PENECORT | | | | |
| ALLERGAN HERBERT | 1% | A088214 | 001 | Jun 06, 1984 |
| TEXACORT | | | | |
| MISSION PHARMA | 1% | A080425 | 001 | |
| TABLET;ORAL | | | | |
| CORTRIL | | | | |
| PFIZER | 10MG | N009127 | 005 | |
| | 20MG | N009127 | 003 | |
| HYDROCORTISONE | | | | |
| BARR | 20MG | A083999 | 001 | |
| ELKINS SINN | 20MG | A080624 | 001 | |
| FERRANTE | 10MG | A080568 | 001 | |
| | 20MG | A080568 | 002 | |
| IMPAX LABS | 20MG | A080781 | 001 | |
| INWOOD LABS | 20MG | A080732 | 001 | |
| LANNETT | 20MG | A085070 | 001 | |
| NEXGEN PHARMA INC | 20MG | A083140 | 001 | |
| PANRAY | 10MG | N009659 | 001 | |
| | 20MG | N009659 | 002 | |
| PARKE DAVIS | 20MG | A084243 | 001 | |
| PUREPAC PHARM | 10MG | A084247 | 003 | Aug 31, 1982 |
| | 20MG | A080395 | 001 | |
| | 20MG | A084247 | 002 | |
| ROXANE | 10MG | A088539 | 001 | Mar 21, 1984 |
| SANDOZ | 20MG | A080642 | 002 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| HYDROCORTISONE | | | | |
| TABLET;ORAL | | | | |
| HYDROCORTISONE | | | | |
| WATSON LABS | 20MG | | A080355 001 | |
| WHITEWORTH TOWN PLSN | 10MG | | A080344 001 | |
| | 20MG | | A080344 002 | |
| HYDROCORTONE | | | | |
| MERCK | 10MG | | N008506 007 | |
| | 20MG | | N008506 011 | |
| TABLET;VAGINAL | | | | |
| CORTRIL | | | | |
| PFIPHARMECS | 10MG | | N009796 001 | |
| HYDROCORTISONE ACETATE | | | | |
| CREAM;TOPICAL | | | | |
| HEMSOL-HC | | | | |
| ABLE | 1% | | A081274 001 | Jun 19, 1992 |
| HYDROCORTISONE ACETATE | | | | |
| CENCI | 1% | | A080419 001 | Jan 25, 1982 |
| FERNDALE LABS | 2.5% | | A040259 001 | Jul 29, 1999 |
| PARKE DAVIS | 1% | | A089914 001 | Jan 03, 1989 |
| PUREPAC PHARM | 0.5% | | A086050 001 | |
| | 1% | | A086052 001 | |
| MICORT-HC | | | | |
| SEBELA IRELAND LTD | 2% | | A040398 001 | Mar 29, 2002 |
| INJECTABLE;INJECTION | | | | |
| CORTEF ACETATE | | | | |
| PHARMACIA AND UPJOHN | 50MG/ML | | N009378 002 | |
| CORTRIL | | | | |
| PFIZER | 25MG/ML | | N009164 001 | |
| HYDROCORTISONE ACETATE | | | | |
| AKORN | 25MG/ML | | N009637 001 | |
| | 50MG/ML | | N009637 002 | |
| BEL MAR | 25MG/ML | | A083739 001 | |
| | 50MG/ML | | A083739 002 | |
| WATSON LABS | 25MG/ML | | A083128 001 | |
| | 25MG/ML | | A083759 001 | |
| | 50MG/ML | | A083759 002 | |
| | 50MG/ML | | A085214 001 | |
| HYDROCORTONE | | | | |
| MERCK | 25MG/ML | | N008228 001 | |
| | 50MG/ML | | N008228 004 | |
| LOTION;TOPICAL | | | | |
| DRICORT | | | | |
| INGRAM PHARM | 0.5% | | A086207 001 | |
| OINTMENT;OPHTHALMIC | | | | |
| HYDROCORTISONE ACETATE | | | | |
| FERA PHARMS | 0.5% | | A080828 001 | |
| OINTMENT;OPHTHALMIC, OTIC | | | | |
| HYDROCORTONE | | | | |
| MERCK | 1.5% | | N009018 003 | |
| OINTMENT;TOPICAL | | | | |
| CORTEF ACETATE | | | | |
| PHARMACIA AND UPJOHN | 1% | | N008917 002 | |
| + | 2.5% ** | | N008917 001 | |
| PASTE;TOPICAL | | | | |
| ORABASE HCA | | | | |
| COLGATE | 0.5% | | A083205 001 | |
| POWDER;FOR RX COMPOUNDING | | | | |
| HYDROCORTISONE ACETATE | | | | |
| X GEN PHARMS | 100% | | A085981 001 | |
| HYDROCORTISONE ACETATE; NEOMYCIN SULFATE | | | | |
| CREAM;TOPICAL | | | | |
| NEO-CORTEF | | | | |
| PHARMACIA AND UPJOHN | 1%;EQ 3.5MG BASE/GM | | A061049 001 | |
| | 2.5%;EQ 3.5MG BASE/GM | | A061049 002 | |
| OINTMENT;OPHTHALMIC | | | | |
| NEO-CORTEF | | | | |
| PHARMACIA AND UPJOHN | 0.5%;EQ 3.5MG BASE/GM | | A060610 001 | |

| | | | | |
|---|---|---|---|---|
| HYDROCORTISONE ACETATE; NEOMYCIN SULFATE | | | | |
| OINTMENT;OPHTHALMIC | | | | |
| NEO-CORTEF | | | | |
| | 1.5%;EQ 3.5MG BASE/GM | | A060610 002 | |
| OINTMENT;TOPICAL | | | | |
| NEO-CORTEF | | | | |
| PHARMACIA AND UPJOHN | 0.5%;EQ 3.5MG BASE/GM | | A060751 001 | |
| | 1%;EQ 3.5MG BASE/GM | | A060751 002 | |
| | 2.5%;EQ 3.5MG BASE/GM | | A060751 003 | |
| SUSPENSION/DROPS;OPHTHALMIC | | | | |
| COR-OTICIN | | | | |
| AKORN | 1.5%;EQ 3.5MG BASE/ML | | A060188 001 | |
| NEO-CORTEF | | | | |
| PHARMACIA AND UPJOHN | 0.5%;EQ 3.5MG BASE/ML | | A060612 002 | |
| | 1.5%;EQ 3.5MG BASE/ML | | A060612 001 | |
| HYDROCORTISONE ACETATE; OXYTETRACYCLINE HYDROCHLORIDE | | | | |
| SUSPENSION;OPHTHALMIC | | | | |
| TERRA-CORTRIL | | | | |
| PFIZER | 1.5%;EQ 5MG BASE/ML | | A061016 001 | |
| HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE | | | | |
| AEROSOL, METERED;TOPICAL | | | | |
| HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1% | | | | |
| VINTAGE PHARMS | 1%;1% | | A089440 001 | May 17, 1988 |
| LOTION;TOPICAL | | | | |
| PRAMOSONE | | | | |
| FERNDALE LABS | 0.5%;1% | | A083213 002 | |
| HYDROCORTISONE ACETATE; UREA | | | | |
| CREAM;TOPICAL | | | | |
| CARMOL HC | | | | |
| FOUGERA PHARMS | 1%;10% | | A080505 001 | |
| HYDROCORTISONE BUTYRATE | | | | |
| CREAM;TOPICAL | | | | |
| LOCOID | | | | |
| YAMANOUCHI | 0.1% | | N018795 001 | Jan 07, 1983 |
| OINTMENT;TOPICAL | | | | |
| LOCOID | | | | |
| YAMANOUCHI | 0.1% | | N019106 001 | Jul 03, 1984 |
| SOLUTION;TOPICAL | | | | |
| LOCOID | | | | |
| YAMANOUCHI | 0.1% | | N019819 001 | Sep 15, 1988 |
| HYDROCORTISONE CYPIONATE | | | | |
| SUSPENSION;ORAL | | | | |
| CORTEF | | | | |
| PHARMACIA AND UPJOHN | EQ 10MG BASE/5ML | | N009900 001 | |
| HYDROCORTISONE SODIUM PHOSPHATE | | | | |
| INJECTABLE;INJECTION | | | | |
| HYDROCORTONE | | | | |
| MERCK | EQ 50MG BASE/ML | | N012052 001 | |
| HYDROCORTISONE SODIUM SUCCINATE | | | | |
| INJECTABLE;INJECTION | | | | |
| A-HYDROCORT | | | | |
| ABBOTT | EQ 100MG BASE/VIAL | | A085928 001 | |
| | EQ 100MG BASE/VIAL | | A089577 001 | Apr 11, 1989 |
| | EQ 250MG BASE/VIAL | | A089578 001 | Apr 11, 1989 |
| | EQ 500MG BASE/VIAL | | A089579 001 | Apr 11, 1989 |
| | EQ 1GM BASE/VIAL | | A089580 001 | Apr 11, 1989 |
| HOSPIRA | EQ 100MG BASE/VIAL | | A040666 001 | Apr 06, 2006 |
| | EQ 100MG BASE/VIAL | | A085929 001 | |
| | EQ 250MG BASE/VIAL | | A085930 001 | |
| | EQ 500MG BASE/VIAL | | A085931 001 | |
| | EQ 1GM BASE/VIAL | | A085932 001 | |
| HYDROCORTISONE SODIUM SUCCINATE | | | | |
| ABRAXIS PHARM | EQ 100MG BASE/VIAL | | A088667 001 | Jun 08, 1984 |
| | EQ 100MG BASE/VIAL | | A088712 001 | Jun 08, 1984 |
| | EQ 250MG BASE/VIAL | | A088668 001 | Jun 08, 1984 |
| | EQ 500MG BASE/VIAL | | A088669 001 | Jun 08, 1984 |

HYDROCORTISONE SODIUM SUCCINATE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| HYDROCORTISONE SODIUM SUCCINATE | | | | |
| | EQ 1GM BASE/VIAL | A088670 | 001 | Jun 08, 1984 |
| BAXTER HLTHCARE | EQ 100MG BASE/VIAL | A086619 | 001 | |
| | EQ 250MG BASE/VIAL | A087567 | 001 | |
| | EQ 500MG BASE/VIAL | A087568 | 001 | |
| | EQ 1GM BASE/VIAL | A087569 | 001 | |
| INTL MEDICATION | EQ 100MG BASE/VIAL | A087532 | 001 | Mar 19, 1982 |
| WATSON LABS | EQ 100MG BASE/VIAL | A084737 | 002 | |
| | EQ 100MG BASE/VIAL | A084738 | 001 | |
| | EQ 250MG BASE/VIAL | A084737 | 001 | |
| | EQ 500MG BASE/VIAL | A084747 | 001 | |
| | EQ 1GM BASE/VIAL | A084748 | 001 | |

HYDROCORTISONE VALERATE

| | | | | |
|---|---|---|---|---|
| CREAM;TOPICAL | | | | |
| HYDROCORTISONE VALERATE | | | | |
| G AND W LABS INC | 0.2% | A074489 | 001 | Aug 12, 1998 |
| WESTCORT | | | | |
| + RANBAXY LABS LTD | 0.2% ** | N017950 | 001 | |
| OINTMENT;TOPICAL | | | | |
| HYDROCORTISONE VALERATE | | | | |
| FOUGERA PHARMS | 0.2% | A075085 | 001 | Jul 31, 2001 |
| WESTCORT | | | | |
| + RANBAXY | 0.2% ** | N018726 | 001 | Aug 08, 1983 |

HYDROCORTISONE; NEOMYCIN SULFATE

| | | | | |
|---|---|---|---|---|
| CREAM;TOPICAL | | | | |
| NEO-CORT-DOME | | | | |
| BAYER PHARMS | 0.5%;EQ 3.5MG BASE/GM | N050237 | 006 | Jun 05, 1984 |
| | 1%;EQ 3.5MG BASE/GM | N050237 | 005 | Jun 05, 1984 |

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

| | | | | |
|---|---|---|---|---|
| SOLUTION/DROPS;OTIC | | | | |
| NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE | | | | |
| PHARMAFAIR | 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML | A062394 | 001 | Sep 29, 1982 |
| OTOCORT | | | | |
| WATSON LABS | 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML | A060730 | 002 | |
| SUSPENSION/DROPS;OPHTHALMIC | | | | |
| CORTISPORIN | | | | |
| MONARCH PHARMS | 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML | N050169 | 001 | |
| NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE | | | | |
| PHARMAFAIR | 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML | A062623 | 001 | Sep 24, 1985 |
| SUSPENSION/DROPS;OTIC | | | | |
| NEOMYCIN SULFATE, POLYMYXIN B SULFATE & HYDROCORTISONE | | | | |
| PHARMAFAIR | 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML | A062617 | 001 | Sep 18, 1985 |
| OTICAIR | | | | |
| PHARMAFAIR | 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML | A062399 | 001 | Nov 18, 1982 |
| OTOBIONE | | | | |
| SCHERING | 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML | A061816 | 001 | |
| OTOCORT | | | | |
| ACTAVIS LABS FL INC | 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML | A062521 | 001 | Jul 11, 1985 |
| PEDIOTIC | | | | |
| MONARCH PHARMS | 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML | A062822 | 001 | Sep 29, 1987 |

HYDROCORTISONE; POLYMYXIN B SULFATE

| | | | | |
|---|---|---|---|---|
| SOLUTION/DROPS;OTIC | | | | |
| OTOBIOTIC | | | | |
| SCHERING | 5MG/ML;EQ 10,000 UNITS BASE/ML | A062302 | 001 | |
| PYOCIDIN | | | | |
| FOREST LABS | 5MG/ML;EQ 10,000 UNITS BASE/ML | A061606 | 001 | |

HYDROCORTISONE; TETRACYCLINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| OINTMENT;OPHTHALMIC | | | | |
| ACHROMYCIN | | | | |
| LEDERLE | 1.5%;1% | N050272 | 001 | |

| | | | | |
|---|---|---|---|---|
| HYDROCORTISONE; UREA | | | | |
| CREAM;TOPICAL | | | | |
| ALPHADERM | | | | |
| BIOGLAN | 1%;10% | A086008 | 001 | |
| CALMURID HC | | | | |
| PHARMACIA AND UPJOHN | 1%;10% | A083947 | 001 | |
| HYDROFLUMETHIAZIDE | | | | |
| TABLET;ORAL | | | | |
| DIUCARDIN | | | | |
| WYETH AYERST | 50MG | A083383 | 001 | |
| HYDROFLUMETHIAZIDE | | | | |
| PAR PHARM | 50MG | A088850 | 001 | May 31, 1985 |
| WATSON LABS | 50MG | A088031 | 001 | Apr 06, 1983 |
| | 50MG | A088528 | 001 | Aug 15, 1984 |
| SALURON | | | | |
| + SHIRE LLC | 50MG | N011949 | 001 | |
| HYDROFLUMETHIAZIDE; RESERPINE | | | | |
| TABLET;ORAL | | | | |
| HYDROFLUMETHIAZIDE AND RESERPINE | | | | |
| USL PHARMA | 50MG;0.125MG | A088195 | 001 | Oct 26, 1983 |
| WATSON LABS | 25MG;0.125MG | A088127 | 001 | Mar 22, 1983 |
| | 50MG;0.125MG | A088110 | 001 | Mar 22, 1983 |
| RESERPINE AND HYDROFLUMETHIAZIDE | | | | |
| IVAX PHARMS | 50MG;0.125MG | A088932 | 001 | Jan 11, 1985 |
| PAR PHARM | 50MG;0.125MG | A088907 | 001 | Sep 20, 1985 |
| SALUTENSIN | | | | |
| SHIRE | 50MG;0.125MG | N012359 | 003 | |
| SALUTENSIN-DEMI | | | | |
| SHIRE | 25MG;0.125MG | N012359 | 004 | |
| HYDROMORPHONE HYDROCHLORIDE | | | | |
| CAPSULE, EXTENDED RELEASE;ORAL | | | | |
| PALLADONE | | | | |
| PURDUE PHARMA LP | 12MG | N021044 | 001 | Sep 24, 2004 |
| | 16MG | N021044 | 002 | Sep 24, 2004 |
| | 24MG | N021044 | 003 | Sep 24, 2004 |
| | 32MG | N021044 | 004 | Sep 24, 2004 |
| INJECTABLE;INJECTION | | | | |
| DILAUDID-HP | | | | |
| FRESENIUS KABI USA | 250MG/VIAL | N019034 | 002 | Aug 04, 1994 |
| HYDROMORPHONE HYDROCHLORIDE | | | | |
| HOSPIRA | 10MG/ML | A074598 | 001 | Jun 19, 1997 |
| WATSON LABS | 10MG/ML | A074317 | 001 | Aug 23, 1995 |
| TABLET;ORAL | | | | |
| HYDROMORPHONE HYDROCHLORIDE | | | | |
| NESHER PHARMS | 2MG | A077311 | 001 | Nov 09, 2005 |
| | 4MG | A077311 | 002 | Nov 09, 2005 |
| | 8MG | A077311 | 003 | Nov 09, 2005 |
| HYDROXOCOBALAMIN | | | | |
| INJECTABLE;INJECTION | | | | |
| ALPHAREDISOL | | | | |
| MERCK | 1MG/ML | A080778 | 001 | |
| CYANOKIT | | | | |
| SERB SA | 2.5GM/VIAL (5GM/KIT) | N022041 | 002 | Dec 15, 2006 |
| HYDROXOCOBALAMIN | | | | |
| ABRAXIS PHARM | 1MG/ML | A084921 | 001 | |
| WATSON LABS | 1MG/ML | A085528 | 001 | |
| HYDROXOMIN | | | | |
| BEL MAR | 1MG/ML | A084629 | 001 | |
| HYDROXYAMPHETAMINE HYDROBROMIDE | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | |
| PAREDRINE | | | | |
| PHARMICS | 1% | N000004 | 004 | |

| | | | | |
|---|---|---|---|---|
| HYDROXYCHLOROQUINE SULFATE | | | | |
| TABLET;ORAL | | | | |
| HYDROXYCHLOROQUINE SULFATE | | | | |
| SANDOZ | 200MG | | A040150 001 | Jan 27, 1996 |
| HYDROXYPROGESTERONE CAPROATE | | | | |
| INJECTABLE;INJECTION | | | | |
| DELALUTIN | | | | |
| + BRISTOL MYERS SQUIBB | 125MG/ML ** | | N010347 004 | |
| + | 125MG/ML ** | | N016911 001 | |
| + | 250MG/ML ** | | N010347 002 | |
| + | 250MG/ML ** | | N016911 002 | |
| HYDROXYPROGESTERONE CAPROATE | | | | |
| AKORN | 125MG/ML | | N018004 001 | |
| ALLERGAN SALES LLC | 125MG/ML | | N017439 001 | |
| | 250MG/ML | | N017439 002 | |
| HYDROXYSTILBAMIDINE ISETHIONATE | | | | |
| INJECTABLE;INJECTION | | | | |
| HYDROXYSTILBAMIDINE ISETHIONATE | | | | |
| SANOFI AVENTIS US | 225MG/AMP | | N009166 001 | |
| HYDROXYUREA | | | | |
| CAPSULE;ORAL | | | | |
| HYDROXYUREA | | | | |
| BARR | 250MG | | A075143 002 | Sep 21, 2000 |
| BARR LABS INC | 250MG | | A075020 002 | Jun 26, 2000 |
| | 500MG | | A075020 001 | Jul 30, 1998 |
| ROXANE | 500MG | | A074476 001 | Aug 18, 1995 |
| TABLET;ORAL | | | | |
| HYDROXYUREA | | | | |
| BARR | 1GM | | A075734 001 | Aug 29, 2000 |
| HYDROXYZINE HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| HYDROXYZINE | | | | |
| BAXTER HLTHCARE | 50MG/ML | | A085551 002 | |
| HYDROXYZINE HYDROCHLORIDE | | | | |
| ALTANA | 25MG/ML | | A087273 001 | Apr 20, 1982 |
| | 50MG/ML | | A087273 002 | Apr 20, 1982 |
| BAXTER HLTHCARE | 25MG/ML | | A085551 001 | |
| FRESENIUS KABI USA | 25MG/ML | | A088184 001 | Mar 31, 1983 |
| | 50MG/ML | | A088185 001 | Mar 31, 1983 |
| HOSPIRA | 25MG/ML | | A087416 001 | |
| | 50MG/ML | | A086821 001 | |
| | 50MG/ML | | A087546 001 | |
| PHARMAFAIR | 25MG/ML | | A088862 001 | Feb 14, 1986 |
| | 25MG/ML | | A089106 001 | Feb 14, 1986 |
| | 50MG/ML | | A088881 001 | Feb 14, 1986 |
| | 50MG/ML | | A089107 001 | Feb 14, 1986 |
| SMITH AND NEPHEW | 25MG/ML | | A087592 001 | |
| SOLOPAK | 25MG/ML | | A086822 001 | |
| | 25MG/ML | | A087591 001 | |
| | 50MG/ML | | A087310 001 | |
| | 50MG/ML | | A087593 001 | |
| | 50MG/ML | | A087595 001 | |
| | 50MG/ML | | A087596 001 | |
| WATSON LABS | 25MG/ML | | A085778 001 | |
| | 25MG/ML | | A087274 001 | |
| | 50MG/ML | | A085779 001 | |
| | 50MG/ML | | A087274 002 | |
| WYETH AYERST | 25MG/ML | | A086258 001 | |
| | 50MG/ML | | A086258 002 | |
| ORGATRAX | | | | |
| ORGANON USA INC | 25MG/ML | | A087014 001 | |
| | 50MG/ML | | A087014 002 | |
| VISTARIL | | | | |
| + PFIZER | 25MG/ML ** | | N011111 001 | |
| + | 50MG/ML ** | | N011111 002 | |

HYDROXYZINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| SYRUP;ORAL | | | | |
| ATARAX | | | | |
| ROERIG | 10MG/5ML ** | N010485 | 001 | |
| HYDROXYZINE HYDROCHLORIDE | | | | |
| ALPHARMA US PHARMS | 10MG/5ML | A088785 | 001 | Feb 03, 1988 |
| KV PHARM | 10MG/5ML | A087730 | 001 | Jul 01, 1982 |
| STI PHARMA LLC | 10MG/5ML | A086880 | 001 | |
| TABLET;ORAL | | | | |
| ATARAX | | | | |
| PFIZER | 10MG ** | N010392 | 001 | |
| | 25MG ** | N010392 | 004 | |
| | 50MG ** | N010392 | 006 | |
| | 100MG ** | N010392 | 005 | |
| HYDROXYZINE HYDROCHLORIDE | | | | |
| ABLE | 10MG | A040559 | 001 | Jul 22, 2004 |
| | 25MG | A040562 | 001 | Jul 22, 2004 |
| | 50MG | A040563 | 001 | Jul 22, 2004 |
| ACTAVIS ELIZABETH | 10MG | A089071 | 001 | Jul 22, 1986 |
| | 25MG | A089072 | 001 | Jul 22, 1986 |
| | 50MG | A089073 | 001 | Jul 22, 1986 |
| AUROLIFE PHARMA LLC | 10MG | A087871 | 002 | Dec 20, 1982 |
| | 25MG | A087871 | 003 | Dec 20, 1982 |
| | 50MG | A087871 | 001 | Dec 20, 1982 |
| HALSEY | 10MG | A089366 | 001 | May 02, 1988 |
| | 25MG | A089117 | 001 | May 02, 1988 |
| | 50MG | A089396 | 001 | May 02, 1988 |
| IVAX PHARMS | 10MG | A087216 | 001 | |
| | 25MG | A087410 | 001 | |
| | 50MG | A087411 | 001 | |
| KV PHARM | 10MG | A087819 | 001 | Jun 23, 1982 |
| | 25MG | A087820 | 001 | Jun 23, 1982 |
| | 50MG | A087821 | 001 | Jun 23, 1982 |
| | 100MG | A087822 | 001 | Jun 23, 1982 |
| MUTUAL PHARM | 10MG | A088409 | 001 | Nov 15, 1983 |
| | 25MG | A087857 | 001 | Apr 18, 1983 |
| | 50MG | A087860 | 001 | Apr 18, 1983 |
| PLIVA | 100MG | A081054 | 001 | Sep 25, 1995 |
| PUREPAC PHARM | 10MG | A088120 | 001 | Sep 25, 1984 |
| | 25MG | A088121 | 001 | Sep 25, 1984 |
| | 50MG | A088122 | 001 | Sep 25, 1984 |
| QUANTUM PHARMICS | 10MG | A088540 | 001 | Oct 22, 1985 |
| | 25MG | A088551 | 001 | Oct 22, 1985 |
| | 50MG | A088529 | 001 | Oct 22, 1985 |
| SANDOZ | 10MG | A087246 | 002 | |
| | 25MG | A085247 | 001 | |
| | 50MG | A087245 | 001 | |
| SUN PHARM INDS INC | 10MG | A040899 | 001 | Jun 10, 2008 |
| | 25MG | A040899 | 002 | Jun 10, 2008 |
| | 50MG | A040899 | 003 | Jun 10, 2008 |
| SUN PHARM INDUSTRIES | 10MG | A089381 | 001 | May 19, 1986 |
| | 25MG | A089382 | 001 | May 19, 1986 |
| | 50MG | A089383 | 001 | May 19, 1986 |
| | 100MG | A087862 | 001 | Apr 18, 1983 |
| SUPERPHARM | 10MG | A088794 | 001 | Dec 05, 1984 |
| | 25MG | A088795 | 001 | Dec 05, 1984 |
| | 50MG | A088796 | 001 | Dec 05, 1984 |
| USL PHARMA | 10MG | A089121 | 001 | Mar 20, 1986 |
| | 25MG | A089122 | 001 | Mar 20, 1986 |
| | 50MG | A089123 | 001 | Mar 20, 1986 |
| VINTAGE | 10MG | A087602 | 001 | Jan 22, 1982 |
| | 25MG | A087603 | 001 | Jan 22, 1982 |
| | 50MG | A087604 | 001 | Jan 22, 1982 |
| WATSON LABS | 10MG | A081149 | 001 | Mar 18, 1994 |
| | 10MG | A086827 | 001 | |
| | 10MG | A088348 | 001 | Sep 15, 1983 |
| | 25MG | A081150 | 001 | Mar 18, 1994 |
| | 25MG | A086829 | 001 | |
| | 25MG | A088349 | 001 | Sep 15, 1983 |

| | | | | |
|---|---|---|---|---|
| HYDROXYZINE HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| HYDROXYZINE HYDROCHLORIDE | | | | |
| | 50MG | A081151 | 001 | Mar 18, 1994 |
| | 50MG | A086836 | 001 | |
| | 50MG | A088350 | 001 | Sep 15, 1983 |
| HYDROXYZINE PAMOATE | | | | |
| CAPSULE;ORAL | | | | |
| HY-PAM "25" | | | | |
| TEVA | EQ 25MG HCL | A088713 | 001 | Mar 04, 1985 |
| HYDROXYZINE PAMOATE | | | | |
| DURAMED PHARMS BARR | EQ 25MG HCL | A088593 | 001 | Feb 29, 1984 |
| | EQ 50MG HCL | A088594 | 001 | Feb 29, 1984 |
| | EQ 100MG HCL | A088595 | 001 | Feb 29, 1984 |
| IVAX SUB TEVA PHARMS | EQ 25MG HCL | A087761 | 001 | Mar 05, 1982 |
| | EQ 50MG HCL | A087760 | 001 | Mar 05, 1982 |
| PAR PHARM | EQ 25MG HCL | A087656 | 001 | Jun 11, 1982 |
| | EQ 25MG HCL | A089145 | 001 | Mar 17, 1986 |
| | EQ 50MG HCL | A087657 | 001 | Jun 11, 1982 |
| | EQ 50MG HCL | A089146 | 001 | Mar 17, 1986 |
| | EQ 100MG HCL | A087658 | 001 | Jun 11, 1982 |
| SANDOZ | EQ 25MG HCL | A081127 | 001 | Jun 28, 1991 |
| | EQ 50MG HCL | A081128 | 001 | Jun 28, 1991 |
| | EQ 100MG HCL | A081129 | 001 | Jun 28, 1991 |
| SUPERPHARM | EQ 25MG HCL | A089031 | 001 | Jan 02, 1987 |
| | EQ 50MG HCL | A089032 | 001 | Jan 02, 1987 |
| | EQ 100MG HCL | A089033 | 001 | Jan 02, 1987 |
| VANGARD | EQ 25MG HCL | A088392 | 001 | Sep 19, 1983 |
| | EQ 50MG HCL | A088393 | 001 | Sep 19, 1983 |
| WATSON LABS | EQ 25MG HYDROCHLORIDE | A081165 | 001 | Jul 31, 1991 |
| | EQ 25MG HCL | A086698 | 001 | |
| | EQ 25MG HCL | A086840 | 001 | Jul 01, 1982 |
| | EQ 50MG HCL | A086695 | 001 | |
| | EQ 50MG HCL | A086705 | 001 | Jul 01, 1982 |
| | EQ 50MG HCL | A087767 | 001 | Aug 16, 1982 |
| | EQ 100MG HCL | A086697 | 001 | |
| | EQ 100MG HCL | A086728 | 001 | Oct 05, 1982 |
| | EQ 100MG HCL | A087790 | 001 | Aug 16, 1982 |
| VISTARIL | | | | |
| PFIZER | EQ 100MG HCL ** | N011459 | 006 | |
| SUSPENSION;ORAL | | | | |
| VISTARIL | | | | |
| PFIZER | EQ 25MG HCL/5ML | N011795 | 001 | |
| IBANDRONATE SODIUM | | | | |
| TABLET;ORAL | | | | |
| BONIVA | | | | |
| + HOFFMANN LA ROCHE | EQ 2.5MG BASE ** | N021455 | 001 | May 16, 2003 |
| IBANDRONATE SODIUM | | | | |
| MYLAN PHARMS INC | EQ 150MG BASE | A078995 | 001 | Mar 19, 2012 |
| IBUPROFEN | | | | |
| CAPSULE;ORAL | | | | |
| IBUPROFEN | | | | |
| CONTRACT PHARMACAL | 200MG | A074782 | 001 | Jul 06, 1998 |
| MIDOL | | | | |
| BAYER | 200MG ** | A070626 | 001 | Sep 02, 1987 |
| | 200MG ** | A071002 | 001 | Sep 02, 1987 |
| SOLUTION;INTRAVENOUS | | | | |
| CALDOLOR | | | | |
| CUMBERLAND PHARMS | 400MG/4ML (100MG/ML) | N022348 | 001 | Jun 11, 2009 |
| SUSPENSION;ORAL | | | | |
| CHILDREN'S ADVIL | | | | |
| WYETH CONS | 100MG/5ML | N019833 | 002 | Sep 19, 1989 |
| IBU | | | | |
| ABBOTT | 100MG/5ML | N019784 | 001 | Dec 18, 1989 |
| MOTRIN | | | | |
| + MCNEIL CONSUMER | 100MG/5ML ** | N019842 | 001 | Sep 19, 1989 |

IBUPROFEN

| | | | | |
|---|---|---|---|---|
| SUSPENSION/DROPS;ORAL | | | | |
| MOTRIN | | | | |
| MCNEIL | 40MG/ML | N020476 | 001 | May 25, 1995 |
| TABLET;ORAL | | | | |
| ACHES-N-PAIN | | | | |
| LEDERLE | 200MG | A071065 | 001 | May 28, 1987 |
| CAP-PROFEN | | | | |
| PERRIGO | 200MG | A072097 | 001 | Dec 08, 1987 |
| IBU | | | | |
| BASF | 400MG | A070083 | 001 | Feb 22, 1985 |
| | 400MG | N018197 | 001 | |
| | 600MG | A070088 | 001 | Feb 08, 1985 |
| | 600MG | A070099 | 001 | Mar 29, 1985 |
| | 800MG | A070745 | 001 | Jul 23, 1986 |
| IBU-TAB | | | | |
| ALRA | 800MG | A071965 | 001 | Aug 11, 1988 |
| IBUPRIN | | | | |
| PLIVA | 200MG | A071773 | 001 | Jul 16, 1987 |
| IBUPROFEN | | | | |
| ABBOTT | 600MG | A070556 | 001 | Jun 14, 1985 |
| | 800MG | A071264 | 001 | Jul 25, 1986 |
| ANI PHARMS INC | 200MG | A071144 | 001 | Jan 20, 1987 |
| | 200MG | A072901 | 001 | Dec 19, 1991 |
| | 200MG | A072903 | 001 | Dec 19, 1991 |
| AUROLIFE PHARMA LLC | 300MG | A070736 | 002 | Jun 12, 1986 |
| | 400MG | A070736 | 003 | Jun 12, 1986 |
| | 600MG | A070736 | 001 | Jun 12, 1986 |
| | 800MG | A071938 | 001 | Jan 14, 1988 |
| CONTRACT PHARMACAL | 200MG | A071735 | 001 | Sep 10, 1987 |
| | 200MG | A073691 | 001 | Feb 25, 1994 |
| | 200MG | A074931 | 001 | Jul 20, 1998 |
| HALSEY | 200MG | A071027 | 001 | Sep 29, 1987 |
| | 300MG | A071028 | 001 | Mar 23, 1987 |
| | 400MG | A071029 | 001 | Mar 23, 1987 |
| | 600MG | A071030 | 001 | Mar 23, 1987 |
| | 800MG | A072137 | 001 | Feb 05, 1988 |
| IVAX SUB TEVA PHARMS | 200MG | A071154 | 001 | Oct 27, 1987 |
| | 200MG | A072040 | 001 | Apr 29, 1988 |
| | 400MG | A071145 | 001 | Sep 23, 1986 |
| | 600MG | A071146 | 001 | Sep 23, 1986 |
| | 800MG | A071769 | 001 | May 08, 1987 |
| J AND J CONSUMER INC | 400MG | A070081 | 001 | Jun 16, 1986 |
| LEDERLE | 400MG | A070629 | 001 | Sep 19, 1986 |
| | 600MG | A070630 | 001 | Sep 19, 1986 |
| LEINER | 300MG | A071266 | 001 | Oct 15, 1986 |
| MCNEIL | 600MG | A070476 | 001 | Jun 16, 1986 |
| MYLAN | 200MG | A071870 | 001 | May 05, 1988 |
| | 600MG | A070057 | 001 | Sep 24, 1985 |
| | 800MG | A071999 | 001 | Dec 03, 1987 |
| MYLAN PHARMS INC | 400MG | A070045 | 001 | Sep 24, 1985 |
| NORTHSTAR HLTHCARE | 400MG | A078132 | 001 | Sep 10, 2007 |
| | 600MG | A078132 | 002 | Sep 10, 2007 |
| | 800MG | A078132 | 003 | Sep 10, 2007 |
| OHM LABS | 400MG | A070818 | 001 | Dec 26, 1985 |
| PAR PHARM | 200MG | A071575 | 001 | May 08, 1987 |
| | 300MG | A070328 | 001 | Aug 06, 1985 |
| | 400MG | A070329 | 001 | Aug 06, 1985 |
| | 600MG | A070330 | 001 | Aug 06, 1985 |
| | 800MG | A070986 | 001 | Jul 25, 1986 |
| PERRIGO | 200MG | A072098 | 001 | Dec 08, 1987 |
| PLIVA | 400MG | A071666 | 001 | Jun 18, 1987 |
| | 600MG | A071667 | 001 | Jun 18, 1987 |
| | 800MG | A071668 | 001 | Jun 18, 1987 |
| PUREPAC PHARM | 200MG | A071122 | 001 | Oct 03, 1986 |
| | 200MG | A071664 | 001 | Feb 03, 1987 |
| | 300MG | A071123 | 001 | Sep 19, 1986 |
| | 400MG | A071124 | 001 | Sep 19, 1986 |
| | 600MG | A071125 | 001 | Sep 19, 1986 |

IBUPROFEN

| | | | | | |
|---|---|---|---|---|---|
| TABLET;ORAL | | | | | |
| IBUPROFEN | | | | | |
| | 800MG | | A071964 | 001 | Feb 01, 1988 |
| SANDOZ | 200MG | | A070733 | 001 | Sep 19, 1986 |
| | 200MG | | A071807 | 001 | Feb 25, 1988 |
| | 200MG | | A074525 | 001 | Dec 15, 1995 |
| | 200MG | | A074533 | 001 | Dec 15, 1995 |
| | 400MG | | A072064 | 001 | Jan 14, 1988 |
| | 600MG | | A072065 | 001 | Jan 14, 1988 |
| | 800MG | | A072169 | 001 | Dec 11, 1987 |
| SUN PHARM INDUSTRIES | 200MG | | A070493 | 001 | Dec 24, 1985 |
| | 200MG | | A070908 | 001 | Sep 26, 1986 |
| | 200MG | | A071462 | 001 | Oct 02, 1986 |
| | 400MG | | A070079 | 001 | Jul 24, 1985 |
| | 600MG | | A070080 | 001 | Jul 24, 1985 |
| | 800MG | | A071448 | 001 | Feb 18, 1987 |
| SUPERPHARM | 600MG | | A070709 | 001 | Apr 25, 1986 |
| TEVA | 200MG | | A073141 | 001 | May 29, 1992 |
| | 400MG | | A073343 | 001 | Jun 30, 1992 |
| | 600MG | | A073344 | 001 | Jun 30, 1992 |
| | 800MG | | A073345 | 001 | Jun 30, 1992 |
| VINTAGE PHARMS | 200MG | | A072249 | 001 | Jan 10, 1989 |
| | 300MG | | A071230 | 001 | Oct 22, 1986 |
| | 400MG | | A071231 | 001 | Oct 22, 1986 |
| | 600MG | | A071232 | 001 | Oct 22, 1986 |
| | 800MG | | A072004 | 001 | Nov 18, 1987 |
| WATSON LABS | 200MG | | A070435 | 001 | Mar 05, 1986 |
| | 200MG | | A071765 | 001 | Sep 04, 1987 |
| | 200MG | | A071905 | 001 | Mar 08, 1988 |
| | 300MG | | A071338 | 001 | Dec 01, 1986 |
| | 400MG | | A070038 | 001 | Sep 06, 1985 |
| | 400MG | | A070436 | 001 | Aug 21, 1985 |
| | 600MG | | A070041 | 001 | Sep 06, 1985 |
| | 600MG | | A070437 | 001 | Aug 21, 1985 |
| | 800MG | | A071547 | 001 | Jul 02, 1987 |
| | 800MG | | A071911 | 001 | Oct 13, 1987 |
| IBUPROHM | | | | | |
| OHM LABS | 400MG | | A070469 | 001 | Aug 29, 1985 |
| MEDIPREN | | | | | |
| MCNEIL | 200MG | | A070475 | 001 | Feb 06, 1986 |
| | 200MG | | A071215 | 001 | Jun 26, 1986 |
| MIDOL | | | | | |
| BAYER | 200MG | | A070591 | 001 | Sep 02, 1987 |
| | 200MG | | A071001 | 001 | Sep 02, 1987 |
| MOTRIN | | | | | |
| + MCNEIL CONSUMER | 300MG | ** | N017463 | 003 | |
| + | 400MG | ** | N017463 | 002 | |
| + | 600MG | ** | N017463 | 004 | |
| + | 800MG | ** | N017463 | 005 | May 22, 1985 |
| MCNEIL PED | 100MG | | N020418 | 001 | Nov 16, 1994 |
| MOTRIN MIGRAINE PAIN | | | | | |
| J AND J CONSUMER INC | 200MG | | N019012 | 004 | Feb 25, 2000 |
| NUPRIN | | | | | |
| BRISTOL MYERS | 200MG | | A072035 | 001 | Feb 16, 1988 |
| | 200MG | | A072036 | 001 | Feb 16, 1988 |
| J AND J CONSUMER INC | 200MG | | N019012 | 001 | May 18, 1984 |
| | 200MG | | N019012 | 002 | Jul 29, 1987 |
| RUFEN | | | | | |
| BASF | 600MG | | N018197 | 002 | Mar 05, 1984 |
| TABLET, CHEWABLE;ORAL | | | | | |
| MOTRIN | | | | | |
| MCNEIL PED | 50MG | | N020135 | 001 | Nov 16, 1994 |
| | 100MG | | N020135 | 002 | Nov 16, 1994 |

| | | | | |
|---|---|---|---|---|
| IBUPROFEN; OXYCODONE HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| COMBUNOX | | | | |
| | FOREST LABS | 400MG;5MG ** | N021378 001 | Nov 26, 2004 |
| OXYCODONE HYDROCHLORIDE AND IBUPROFEN | | | | |
| | WATSON LABS | 400MG;5MG | A078394 001 | Nov 26, 2007 |
| IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE | | | | |
| | CONTRACT PHARMACAL | 200MG;30MG | A075588 001 | Apr 08, 2002 |
| IDARUBICIN HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| IDAMYCIN | | | | |
| | PHARMACIA AND UPJOHN | 5MG/VIAL | N050661 002 | Sep 27, 1990 |
| | | 10MG/VIAL | N050661 001 | Sep 27, 1990 |
| | | 20MG/VIAL | N050661 003 | Apr 25, 1995 |
| IDARUBICIN HYDROCHLORIDE | | | | |
| | SANDOZ | 1MG/ML | A091293 001 | Mar 29, 2011 |
| | TEVA PARENTERAL | 5MG/VIAL | A065037 003 | May 01, 2002 |
| | | 10MG/VIAL | A065037 002 | May 01, 2002 |
| | | 20MG/VIAL | A065037 001 | May 01, 2002 |
| IDOXURIDINE | | | | |
| OINTMENT;OPHTHALMIC | | | | |
| STOXIL | | | | |
| | GLAXOSMITHKLINE | 0.5% | N015868 001 | |
| SOLUTION/DROPS;OPHTHALMIC | | | | |
| DENDRID | | | | |
| + | ALCON | 0.1% | N014169 001 | |
| HERPLEX | | | | |
| | ALLERGAN | 0.1% | N013935 002 | |
| STOXIL | | | | |
| | GLAXOSMITHKLINE | 0.1% | N013934 001 | |
| IFOSFAMIDE; MESNA | | | | |
| INJECTABLE;INJECTION | | | | |
| IFEX/MESNEX KIT | | | | |
| | BAXTER HLTHCARE | 1GM/VIAL;100MG/ML | N019763 003 | Oct 10, 1992 |
| | | 3GM/VIAL;100MG/ML | N019763 004 | Oct 10, 1992 |
| INJECTABLE;INTRAVENOUS | | | | |
| IFOSFAMIDE/MESNA KIT | | | | |
| | TEVA PHARMS USA | 1GM/20ML;1GM/10ML (50MG/ML;100MG/ML) | A075874 001 | Feb 26, 2002 |
| | | 3GM/60ML;1GM/10ML (50MG/ML;100MG/ML) | A075874 002 | Feb 26, 2002 |
| ILOPROST | | | | |
| SOLUTION;INHALATION | | | | |
| VENTAVIS | | | | |
| | ACTELION PHARMS LTD | 20MCG/2ML (10MCG/ML) | N021779 001 | Dec 29, 2004 |
| IMATINIB MESYLATE | | | | |
| CAPSULE;ORAL | | | | |
| GLEEVEC | | | | |
| + | NOVARTIS | EQ 50MG BASE ** | N021335 001 | May 10, 2001 |
| + | | EQ 100MG BASE ** | N021335 002 | May 10, 2001 |
| IMIPRAMINE HYDROCHLORIDE | | | | |
| CONCENTRATE;ORAL | | | | |
| IMIPRAMINE HYDROCHLORIDE | | | | |
| | NOVARTIS | 25MG/ML | A086765 001 | |
| INJECTABLE;INJECTION | | | | |
| TOFRANIL | | | | |
| | NOVARTIS | 12.5MG/ML | N011838 002 | |
| TABLET;ORAL | | | | |
| IMIPRAMINE HYDROCHLORIDE | | | | |
| | LEDERLE | 10MG | A086269 001 | |
| | | 25MG | A086267 001 | |
| | | 50MG | A086268 001 | |
| | OXFORD PHARMS | 50MG | A040751 001 | Feb 28, 2008 |
| | PAR PHARM | 10MG | A089422 001 | Jul 14, 1987 |
| | | 25MG | A089497 001 | Jul 14, 1987 |
| | ROXANE | 10MG | A083799 001 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| IMIPRAMINE HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| IMIPRAMINE HYDROCHLORIDE | | | | |
| | 25MG | | A083799 002 | |
| | 50MG | | A083799 003 | |
| SANDOZ | 10MG | | A085200 001 | |
| | 25MG | | A084869 002 | |
| | 50MG | | A085133 001 | |
| TEVA | 10MG | | A083729 001 | |
| | 25MG | | A083729 004 | |
| | 50MG | | A083729 003 | |
| USL PHARMA | 25MG | | A087776 001 | Feb 10, 1982 |
| VANGARD | 10MG | | A088036 001 | Nov 03, 1982 |
| | 25MG | | A087619 001 | Feb 09, 1982 |
| | 50MG | | A087631 001 | Jan 04, 1982 |
| WATSON LABS | 10MG | | A085220 001 | |
| | 10MG | | A085875 001 | |
| | 25MG | | A084252 002 | |
| | 25MG | | A085878 001 | |
| | 50MG | | A085221 001 | |
| | 50MG | | A085877 001 | |
| WEST WARD | 25MG | | A088222 001 | May 26, 1983 |
| | 50MG | | A088223 001 | May 26, 1983 |
| JANIMINE | | | | |
| ABBOTT | 10MG | | N017895 001 | |
| | 25MG | | N017895 002 | |
| | 50MG | | N017895 003 | |
| PRAMINE | | | | |
| ALRA | 10MG | | A083827 001 | |
| | 25MG | | A083827 002 | |
| | 50MG | | A083827 003 | |
| PRESAMINE | | | | |
| SANOFI AVENTIS US | 10MG | | N011836 006 | |
| | 25MG | | N011836 003 | |
| | 50MG | | N011836 007 | |
| IMIPRAMINE PAMOATE | | | | |
| CAPSULE;ORAL | | | | |
| IMIPRAMINE PAMOATE | | | | |
| MYLAN PHARMS INC | EQ 75MG HCL | | A202338 001 | Jun 28, 2013 |
| | EQ 100MG HCL | | A202338 002 | Jun 28, 2013 |
| | EQ 125MG HCL | | A202338 003 | Jun 28, 2013 |
| | EQ 150MG HCL | | A202338 004 | Jun 28, 2013 |
| TOFRANIL-PM | | | | |
| + SPECGX LLC | EQ 75MG HCL ** | | N017090 001 | |
| + | EQ 100MG HCL ** | | N017090 004 | |
| + | EQ 125MG HCL ** | | N017090 003 | |
| + | EQ 150MG HCL ** | | N017090 002 | |
| INAMRINONE LACTATE | | | | |
| INJECTABLE;INJECTION | | | | |
| AMRINONE LACTATE | | | | |
| BAXTER HLTHCARE CORP | EQ 5MG BASE/ML | | A075542 001 | May 10, 2000 |
| HOSPIRA | EQ 5MG BASE/ML | | A074616 001 | Aug 03, 1998 |
| INOCOR | | | | |
| SANOFI AVENTIS US | EQ 5MG BASE/ML | | N018700 001 | Jul 31, 1984 |
| INDAPAMIDE | | | | |
| TABLET;ORAL | | | | |
| INDAPAMIDE | | | | |
| ANI PHARMS INC | 1.25MG | | A074498 002 | Feb 12, 1998 |
| | 2.5MG | | A074498 001 | Oct 31, 1996 |
| FOSUN PHARMA | 1.25MG | | A074594 001 | May 23, 1996 |
| | 2.5MG | | A074594 002 | May 23, 1996 |
| MYLAN PHARMS INC | 1.25MG | | A075105 001 | Jul 23, 1998 |
| | 2.5MG | | A075105 002 | Jul 23, 1998 |
| TEVA | 1.25MG | | A074665 001 | Apr 04, 1997 |
| | 2.5MG | | A074665 002 | Apr 04, 1997 |
| WATSON LABS | 1.25MG | | A074585 001 | Sep 26, 1996 |
| | 2.5MG | | A074585 002 | Sep 26, 1996 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | | |
|---|---|---|---|---|---|
| INDAPAMIDE | | | | | |
| TABLET;ORAL | | | | | |
| LOZOL | | | | | |
| + | SANOFI AVENTIS US | 1.25MG ** | N018538 | 002 | Apr 29, 1993 |
| + | | 2.5MG ** | N018538 | 001 | Jul 06, 1983 |
| INDECAINIDE HYDROCHLORIDE | | | | | |
| TABLET, EXTENDED RELEASE;ORAL | | | | | |
| DECABID | | | | | |
| | LILLY | EQ 50MG BASE | N019693 | 001 | Dec 29, 1989 |
| | | EQ 75MG BASE | N019693 | 002 | Dec 29, 1989 |
| | | EQ 100MG BASE | N019693 | 003 | Dec 29, 1989 |
| INDINAVIR SULFATE | | | | | |
| CAPSULE;ORAL | | | | | |
| CRIXIVAN | | | | | |
| | MERCK SHARP DOHME | EQ 100MG BASE | N020685 | 006 | Apr 19, 2000 |
| | | EQ 333MG BASE | N020685 | 005 | Dec 17, 1998 |
| INDOCYANINE GREEN | | | | | |
| INJECTABLE;INJECTION | | | | | |
| IC-GREEN | | | | | |
| | AKORN | 10MG/VIAL | N011525 | 003 | |
| | | 40MG/VIAL | N011525 | 004 | |
| | | 50MG/VIAL | N011525 | 002 | |
| INDOMETHACIN | | | | | |
| CAPSULE;ORAL | | | | | |
| INDO-LEMMON | | | | | |
| | TEVA | 25MG | A070266 | 001 | Nov 07, 1985 |
| | | 50MG | A070267 | 001 | Nov 07, 1985 |
| INDOCIN | | | | | |
| + | IROKO PHARMS LLC | 25MG ** | N016059 | 001 | |
| + | | 50MG ** | N016059 | 002 | |
| INDOMETHACIN | | | | | |
| | ABLE | 25MG | A076666 | 001 | Dec 17, 2003 |
| | | 50MG | A076666 | 002 | Dec 17, 2003 |
| | CHARTWELL MOLECULES | 25MG | N018829 | 002 | Aug 06, 1984 |
| | | 50MG | A070651 | 001 | Mar 05, 1986 |
| | | 50MG | N018829 | 001 | Aug 06, 1984 |
| | CYCLE PHARMS LTD | 25MG | A070353 | 001 | Jun 18, 1985 |
| | | 50MG | A070354 | 001 | Jun 18, 1985 |
| | DURAMED PHARMS BARR | 25MG | A070326 | 001 | Oct 18, 1985 |
| | | 50MG | A070327 | 001 | Oct 18, 1985 |
| | HALSEY | 25MG | A070782 | 001 | Jun 03, 1987 |
| | | 50MG | A070635 | 001 | Jun 03, 1987 |
| | IVAX SUB TEVA PHARMS | 25MG | N018730 | 001 | May 04, 1984 |
| | | 50MG | N018730 | 002 | May 04, 1984 |
| | MUTUAL PHARM | 25MG | A070067 | 001 | Oct 03, 1986 |
| | | 50MG | A070068 | 001 | Oct 03, 1986 |
| | MYLAN | 50MG | N018858 | 002 | Apr 20, 1984 |
| | PARKE DAVIS | 25MG | N018806 | 001 | Nov 23, 1984 |
| | | 50MG | N018806 | 002 | Nov 23, 1984 |
| | PIONEER PHARMS | 25MG | A070813 | 001 | Aug 11, 1986 |
| | | 50MG | A070592 | 001 | Aug 11, 1986 |
| | PLIVA | 25MG | A071148 | 001 | Mar 18, 1987 |
| | | 50MG | A071149 | 001 | Mar 18, 1987 |
| | SUN PHARM INDUSTRIES | 25MG | A070900 | 002 | Feb 09, 1987 |
| | | 50MG | A070900 | 001 | Feb 09, 1987 |
| | SUPERPHARM | 25MG | A070487 | 001 | Oct 10, 1986 |
| | | 50MG | A070488 | 001 | Oct 10, 1986 |
| | TEVA | 25MG | A071342 | 001 | Apr 18, 1988 |
| | | 50MG | A071343 | 001 | Apr 18, 1988 |
| | WATSON LABS | 25MG | A070529 | 001 | Oct 18, 1985 |
| | | 25MG | A070784 | 001 | Aug 20, 1986 |
| | | 25MG | A072996 | 001 | Jul 31, 1991 |
| | | 25MG | N018690 | 001 | Jul 31, 1984 |
| | | 50MG | A070530 | 001 | Oct 18, 1985 |
| | | 50MG | A070785 | 001 | Aug 20, 1986 |
| | | 50MG | A071635 | 001 | May 18, 1987 |
| | | 50MG | A072997 | 001 | Jul 31, 1991 |

INDOMETHACIN
CAPSULE;ORAL
INDOMETHACIN

| | | | | |
|---|---|---|---|---|
| | 50MG | N018690 | 002 | Jul 31, 1984 |

CAPSULE, EXTENDED RELEASE;ORAL
INDOCIN SR

| | | | | |
|---|---|---|---|---|
| + IROKO PHARMS | 75MG ** | N018185 | 001 | Feb 23, 1982 |

INDOMETHACIN

| | | | | |
|---|---|---|---|---|
| ABLE | 75MG | A076114 | 001 | Feb 06, 2002 |
| INWOOD LABS | 75MG | A072410 | 001 | Mar 15, 1989 |
| WATSON LABS INC | 75MG | A202572 | 001 | Dec 09, 2013 |

SUPPOSITORY;RECTAL
INDOCIN

| | | | | |
|---|---|---|---|---|
| + IROKO PHARMS | 50MG ** | N017814 | 001 | Aug 13, 1984 |

SUSPENSION;ORAL
INDOMETHACIN

| | | | | |
|---|---|---|---|---|
| CYCLE PHARMS LTD | 25MG/5ML | A071412 | 001 | Mar 18, 1987 |

INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT
INJECTABLE;SUBCUTANEOUS
NOVOLOG MIX 50/50

| | | | | |
|---|---|---|---|---|
| NOVO NORDISK INC | 50 UNITS/ML;50 UNITS/ML | N021810 | 001 | Aug 26, 2008 |

NOVOLOG MIX 70/30 PENFILL

| | | | | |
|---|---|---|---|---|
| NOVO NORDISK INC | 210 UNITS/3ML;90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML) | N021172 | 002 | Nov 01, 2001 |
| | 210 UNITS/3ML;90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML) | N021172 | 003 | Nov 01, 2001 |

INSULIN ASPART RECOMBINANT
INJECTABLE;SUBCUTANEOUS
NOVOLOG INNOLET

| | | | | |
|---|---|---|---|---|
| NOVO NORDISK INC | 300 UNITS/3ML (100 UNITS/ML) | N020986 | 004 | Apr 23, 2004 |

INSULIN DETEMIR RECOMBINANT
INJECTABLE;SUBCUTANEOUS
LEVEMIR FLEXPEN

| | | | | |
|---|---|---|---|---|
| NOVO NORDISK INC | 300 UNITS/3ML (100 UNITS/ML) | N021536 | 002 | Jun 16, 2005 |

LEVEMIR INNOLET

| | | | | |
|---|---|---|---|---|
| NOVO NORDISK INC | 300 UNITS/3ML (100 UNITS/ML) | N021536 | 003 | Jun 16, 2005 |

LEVEMIR PENFILL

| | | | | |
|---|---|---|---|---|
| NOVO NORDISK INC | 300 UNITS/3ML (100 UNITS/ML) | N021536 | 004 | Jun 16, 2005 |

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT
INJECTABLE;INJECTION
HUMALOG MIX 50/50 PEN

| | | | | |
|---|---|---|---|---|
| LILLY | 50 UNITS/ML;50 UNITS/ML | N021018 | 003 | Dec 22, 1999 |

HUMALOG MIX 75/25 PEN

| | | | | |
|---|---|---|---|---|
| LILLY | 75 UNITS/ML;25 UNITS/ML | N021017 | 003 | Dec 22, 1999 |

INSULIN LISPRO RECOMBINANT
INJECTABLE;INJECTION
HUMALOG PEN

| | | | | |
|---|---|---|---|---|
| LILLY | 100 UNITS/ML | N020563 | 002 | Aug 06, 1998 |

INSULIN PORK
INJECTABLE;INJECTION
ILETIN I

| | | | | |
|---|---|---|---|---|
| LILLY | 500 UNITS/ML | N017931 | 001 | |

INSULIN

| | | | | |
|---|---|---|---|---|
| NOVO NORDISK INC | 40 UNITS/ML | N017926 | 001 | |

REGULAR INSULIN

| | | | | |
|---|---|---|---|---|
| NOVO NORDISK INC | 100 UNITS/ML | N017926 | 003 | |

INSULIN PURIFIED BEEF
INJECTABLE;INJECTION
REGULAR ILETIN II

| | | | | |
|---|---|---|---|---|
| LILLY | 100 UNITS/ML | N018478 | 001 | |

INSULIN PURIFIED PORK

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| ILETIN II | | | | |
| | LILLY | 500 UNITS/ML | N018344 002 | |
| REGULAR ILETIN II (PORK) | | | | |
| | LILLY | 100 UNITS/ML | N018344 001 | |
| REGULAR PURIFIED PORK INSULIN | | | | |
| | NOVO NORDISK INC | 100 UNITS/ML | N018381 001 | |
| VELOSULIN | | | | |
| | NOVO NORDISK INC | 100 UNITS/ML | N018193 001 | |

INSULIN PURIFIED PORK; INSULIN SUSP ISOPHANE PURIFIED PORK

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| INSULIN NORDISK MIXTARD (PORK) | | | | |
| | NOVO NORDISK INC | 30 UNITS/ML;70 UNITS/ML | N018195 001 | |

INSULIN RECOMBINANT HUMAN

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| HUMULIN BR | | | | |
| | LILLY | 100 UNITS/ML | N019529 001 | Apr 28, 1986 |
| VELOSULIN BR | | | | |
| | NOVO NORDISK INC | 100 UNITS/ML | N021028 001 | Jul 19, 1999 |
| POWDER;INHALATION | | | | |
| EXUBERA | | | | |
| | PFIZER | 1MG/INH | N021868 001 | Jan 27, 2006 |
| | | 3MG/INH | N021868 002 | Jan 27, 2006 |

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| HUMULIN 50/50 | | | | |
| | LILLY | 50 UNITS/ML;50 UNITS/ML | N020100 001 | Apr 29, 1992 |

INSULIN RECOMBINANT PURIFIED HUMAN

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| NOVOLIN R | | | | |
| | NOVO NORDISK INC | 100 UNITS/ML | N018778 001 | Aug 30, 1983 |
| VELOSULIN BR HUMAN | | | | |
| | NOVO NORDISK INC | 100 UNITS/ML | N019450 001 | May 30, 1986 |

INSULIN RECOMBINANT PURIFIED HUMAN; INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| MIXTARD HUMAN 70/30 | | | | |
| | BAYER PHARMS | 30 UNITS/ML;70 UNITS/ML | N019585 001 | Mar 11, 1988 |
| NOVOLIN 70/30 | | | | |
| | NOVO NORDISK INC | 30 UNITS/ML;70 UNITS/ML | N019441 001 | Jul 11, 1986 |

INSULIN SUSP ISOPHANE BEEF

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| NPH INSULIN | | | | |
| | NOVO NORDISK INC | 40 UNITS/ML | N017929 001 | |
| | | 100 UNITS/ML | N017929 003 | |

INSULIN SUSP ISOPHANE BEEF/PORK

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| NPH ILETIN I (BEEF-PORK) | | | | |
| | LILLY | 40 UNITS/ML | N017936 001 | |
| | | 100 UNITS/ML | N017936 002 | |

INSULIN SUSP ISOPHANE PURIFIED BEEF

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| NPH ILETIN II | | | | |
| | LILLY | 100 UNITS/ML | N018479 001 | |

INSULIN SUSP ISOPHANE PURIFIED PORK

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| INSULIN INSULATARD NPH NORDISK | | | | |
| | NOVO NORDISK INC | 100 UNITS/ML | N018194 001 | |
| NPH ILETIN II (PORK) | | | | |
| | LILLY | 100 UNITS/ML | N018345 001 | |
| NPH PURIFIED PORK ISOPHANE INSULIN | | | | |
| | NOVO NORDISK INC | 100 UNITS/ML | N018623 001 | |

INSULIN SUSP ISOPHANE SEMISYNTHETIC PURIFIED HUMAN

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| INSULATARD NPH HUMAN | | | | |
| | NOVO NORDISK INC | 100 UNITS/ML | N019449 001 | May 30, 1986 |
| NOVOLIN N | | | | |
| | NOVO NORDISK INC | 100 UNITS/ML | N019065 001 | Jan 23, 1985 |

INSULIN SUSP PROTAMINE ZINC BEEF/PORK

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| PROTAMINE ZINC & ILETIN I (BEEF-PORK) | | | | |
| | LILLY | 40 UNITS/ML | N017932 001 | |
| | | 100 UNITS/ML | N017932 002 | |

INSULIN SUSP PROTAMINE ZINC PURIFIED BEEF

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| PROTAMINE ZINC AND ILETIN II | | | | |
| | LILLY | 100 UNITS/ML | N018476 001 | |
| PROTAMINE ZINC INSULIN | | | | |
| | BRISTOL MYERS SQUIBB | 40 UNITS/ML | N017928 001 | |
| | | 100 UNITS/ML | N017928 003 | |

INSULIN SUSP PROTAMINE ZINC PURIFIED PORK

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| PROTAMINE ZINC AND ILETIN II (PORK) | | | | |
| | LILLY | 100 UNITS/ML | N018346 001 | |

INSULIN ZINC SUSP BEEF

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| LENTE INSULIN | | | | |
| | NOVO NORDISK INC | 40 UNITS/ML | N017998 001 | |
| | | 100 UNITS/ML | N017998 003 | |

INSULIN ZINC SUSP EXTENDED BEEF

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| ULTRALENTE INSULIN | | | | |
| | NOVO NORDISK INC | 100 UNITS/ML | N017997 003 | |

INSULIN ZINC SUSP EXTENDED PURIFIED BEEF

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| ULTRALENTE | | | | |
| | NOVO NORDISK INC | 100 UNITS/ML | N018385 001 | |

INSULIN ZINC SUSP EXTENDED RECOMBINANT HUMAN

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| HUMULIN U | | | | |
| | LILLY | 40 UNITS/ML | N019571 001 | Jun 10, 1987 |
| | | 100 UNITS/ML | N019571 002 | Jun 10, 1987 |

INSULIN ZINC SUSP PROMPT BEEF

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| SEMILENTE INSULIN | | | | |
| | NOVO NORDISK INC | 100 UNITS/ML | N017996 003 | |

INSULIN ZINC SUSP PROMPT PURIFIED PORK

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| SEMILENTE | | | | |
| | NOVO NORDISK INC | 100 UNITS/ML | N018382 001 | |

INSULIN ZINC SUSP PURIFIED BEEF

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| LENTE ILETIN II | | | | |
| | LILLY | 100 UNITS/ML | N018477 001 | |

INSULIN ZINC SUSP PURIFIED BEEF/PORK

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| LENTARD | | | | |
| | NOVO NORDISK INC | 100 UNITS/ML | N018384 001 | |

INSULIN ZINC SUSP PURIFIED PORK

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| LENTE | | | | |
| | NOVO NORDISK INC | 100 UNITS/ML | N018383 001 | |
| LENTE ILETIN II (PORK) | | | | |
| | LILLY | 100 UNITS/ML | N018347 001 | |

INSULIN ZINC SUSP RECOMBINANT HUMAN
INJECTABLE;INJECTION
HUMULIN L
LILLY 100 UNITS/ML N019377 002 Sep 30, 1985
NOVOLIN L
NOVO NORDISK INC 100 UNITS/ML N019965 001 Jun 25, 1991

INSULIN ZINC SUSP SEMISYNTHETIC PURIFIED HUMAN
INJECTABLE;INJECTION
NOVOLIN L
NOVO NORDISK INC 100 UNITS/ML N018777 001 Aug 30, 1983

INULIN
INJECTABLE;INJECTION
INULIN AND SODIUM CHLORIDE
ISO TEX 100MG/ML N002282 001

INVERT SUGAR
INJECTABLE;INJECTION
TRAVERT 10% IN PLASTIC CONTAINER
BAXTER HLTHCARE 10GM/100ML N016717 001

IOBENGUANE SULFATE I-131
INJECTABLE;INJECTION
IOBENGUANE SULFATE I 131
PHARMALUCENCE 2.3mCi/ML N020084 001 Mar 25, 1994

IOCETAMIC ACID
TABLET;ORAL
CHOLEBRINE
MALLINCKRODT 750MG N017129 001

IODAMIDE MEGLUMINE
INJECTABLE;INJECTION
RENOVUE-65
BRACCO 65% N017902 001
RENOVUE-DIP
BRACCO 24% N017903 001

IODIPAMIDE MEGLUMINE
INJECTABLE;INJECTION
CHOLOGRAFIN MEGLUMINE
BRACCO 10.3% N009321 007
\+ 52% N009321 003

IODIPAMIDE SODIUM
INJECTABLE;INJECTION
CHOLOGRAFIN SODIUM
BRACCO 20% N009321 001

IODIXANOL
INJECTABLE;INJECTION
VISIPAQUE 270
GE HEALTHCARE 55% N020808 001 Aug 29, 1997

IODOHIPPURATE SODIUM I-123
INJECTABLE;INJECTION
NEPHROFLOW
GE HEALTHCARE 1mCi/ML N018289 001 Dec 28, 1984

IODOHIPPURATE SODIUM I-131
INJECTABLE;INJECTION
HIPPURAN I 131
MALLINCKRODT 0.25mCi/ML N016666 001
HIPPUTOPE
BRACCO 1-2mCi/VIAL N015419 002
IODOHIPPURATE SODIUM I 131
PHARMALUCENCE 0.2mCi/ML N017313 001

| | | | | |
|---|---|---|---|---|
| IODOXAMATE MEGLUMINE | | | | |
| INJECTABLE;INJECTION | | | | |
| CHOLOVUE | | | | |
| BRACCO | 9.9% | N018077 | 001 | |
| | 40.3% | N018076 | 001 | |
| IOFETAMINE HYDROCHLORIDE I-123 | | | | |
| INJECTABLE;INJECTION | | | | |
| SPECTAMINE | | | | |
| IMP | 1mCi/ML | N019432 | 001 | Dec 24, 1987 |
| IOHEXOL | | | | |
| INJECTABLE;INJECTION | | | | |
| OMNIPAQUE 210 | | | | |
| GE HEALTHCARE | 45.3% | N018956 | 006 | Jun 30, 1989 |
| SOLUTION;URETHRAL | | | | |
| OMNIPAQUE 70 | | | | |
| GE HEALTHCARE | 15.1% | N018956 | 007 | Jun 01, 1994 |
| IOPAMIDOL | | | | |
| INJECTABLE;INJECTION | | | | |
| IOPAMIDOL | | | | |
| BAXTER HLTHCARE | 41% | A074629 | 001 | Nov 06, 1996 |
| | 51% | A074629 | 004 | Mar 31, 1998 |
| | 61% | A074629 | 002 | Nov 06, 1996 |
| | 76% | A074629 | 003 | Nov 06, 1996 |
| HOSPIRA | 61% | A074734 | 001 | Dec 10, 1996 |
| | 76% | A074734 | 002 | Dec 10, 1996 |
| IOPAMIDOL-200 | | | | |
| COOK IMAGING | 41% | A074881 | 001 | Jul 28, 2000 |
| HOSPIRA | 41% | A074898 | 001 | Dec 30, 1997 |
| IOPAMIDOL-200 IN PLASTIC CONTAINER | | | | |
| HOSPIRA | 41% | A074636 | 001 | Dec 30, 1997 |
| IOPAMIDOL-250 | | | | |
| COOK IMAGING | 51% | A074881 | 002 | Jul 28, 2000 |
| FRESENIUS KABI USA | 51% | A074679 | 001 | Apr 02, 1997 |
| HOSPIRA | 51% | A074898 | 002 | Dec 30, 1997 |
| | 51% | A075005 | 001 | Feb 24, 1998 |
| IOPAMIDOL-250 IN PLASTIC CONTAINER | | | | |
| HOSPIRA | 51% | A074636 | 002 | Dec 30, 1997 |
| IOPAMIDOL-300 | | | | |
| ABBVIE | 61% | A074638 | 001 | Apr 30, 1997 |
| COOK IMAGING | 61% | A074881 | 003 | Jul 28, 2000 |
| FRESENIUS KABI USA | 61% | A074679 | 002 | Apr 02, 1997 |
| HOSPIRA | 61% | A074898 | 003 | Dec 30, 1997 |
| | 61% | A075005 | 002 | Feb 24, 1998 |
| IOPAMIDOL-300 IN PLASTIC CONTAINER | | | | |
| HOSPIRA | 61% | A074636 | 003 | Dec 30, 1997 |
| | 61% | A074637 | 001 | Apr 03, 1997 |
| IOPAMIDOL-370 | | | | |
| COOK IMAGING | 76% | A074881 | 004 | Jul 28, 2000 |
| FRESENIUS KABI USA | 76% | A074679 | 003 | Apr 02, 1997 |
| HOSPIRA | 76% | A074898 | 004 | Dec 30, 1997 |
| | 76% | A075005 | 003 | Feb 24, 1998 |
| IOPAMIDOL-370 IN PLASTIC CONTAINER | | | | |
| HOSPIRA | 76% | A074636 | 004 | Dec 30, 1997 |
| ISOVUE-128 | | | | |
| BRACCO | 26% | N018735 | 005 | Oct 21, 1986 |
| ISOVUE-200 | | | | |
| BRACCO | 41% | N020327 | 001 | Oct 12, 1994 |
| IOPANOIC ACID | | | | |
| TABLET;ORAL | | | | |
| TELEPAQUE | | | | |
| GE HEALTHCARE | 500MG | N008032 | 001 | |

IOPHENDYLATE
INJECTABLE;INJECTION
PANTOPAQUE
ALCON 100% N005319 001

IOPROMIDE
INJECTABLE;INJECTION
ULTRAVIST 150
\+ BAYER HLTHCARE 31.2% N020220 004 May 10, 1995
ULTRAVIST 300 IN PLASTIC CONTAINER
\+ BAYER HLTHCARE 62.3% N020220 005 Nov 18, 2008

IOTHALAMATE MEGLUMINE; IOTHALAMATE SODIUM
INJECTABLE;INJECTION
VASCORAY
MALLINCKRODT 52%;26% N016783 001

IOTHALAMATE SODIUM
INJECTABLE;INJECTION
ANGIO-CONRAY
MALLINCKRODT 80% N013319 001
CONRAY 325
MALLINCKRODT 54.3% N017685 001
CONRAY 400
MALLINCKRODT 66.8% N014295 001

IOTROLAN
INJECTABLE;INTRATHECAL
OSMOVIST 190
BAYER HLTHCARE 40.6% N019580 001 Dec 07, 1989
OSMOVIST 240
BAYER HLTHCARE 51.3% N019580 002 Dec 07, 1989

IOVERSOL
INJECTABLE;INJECTION
OPTIRAY 160
LIEBEL-FLARSHEIM 34% N019710 003 Dec 30, 1988
OPTIRAY 240
LIEBEL-FLARSHEIM 51% N020923 001 May 28, 1998

IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM
INJECTABLE;INJECTION
HEXABRIX
GUERBET 39.3%;19.6% N018905 002 Jul 26, 1985

IOXILAN
INJECTABLE;INJECTION
OXILAN-300
GUERBET 62% N020316 001 Dec 21, 1995
OXILAN-350
GUERBET 73% N020316 002 Dec 21, 1995

IPODATE CALCIUM
GRANULE;ORAL
ORAGRAFIN CALCIUM
BRACCO 3GM/PACKET N012968 001

IPODATE SODIUM
CAPSULE;ORAL
BILIVIST
BAYER HLTHCARE 500MG A087768 001 Aug 11, 1982
ORAGRAFIN SODIUM
BRACCO 500MG N012967 001

IPRATROPIUM BROMIDE
AEROSOL, METERED;INHALATION
ATROVENT
BOEHRINGER INGELHEIM 0.018MG/INH N019085 001 Dec 29, 1986
SOLUTION;INHALATION
ATROVENT
\+ BOEHRINGER INGELHEIM 0.02% ** N020228 001 Sep 29, 1993
IPRATROPIUM BROMIDE
ACTAVIS MID ATLANTIC 0.02% A075111 001 Apr 22, 1999
APOTEX INC 0.02% A075441 001 Mar 28, 2001

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| IPRATROPIUM BROMIDE | | | | |
| SOLUTION;INHALATION | | | | |
| IPRATROPIUM BROMIDE | | | | |
| BAUSCH AND LOMB INC | 0.02% | A075835 | 001 | Oct 15, 2001 |
| MYLAN SPECIALITY LP | 0.02% | A074755 | 001 | Jan 10, 1997 |
| PHARMASCIENCE INC | 0.02% | A075507 | 001 | Jan 19, 2001 |
| ROXANE | 0.02% | A075867 | 001 | Jul 22, 2002 |
| TEVA PHARMS USA | 0.02% | A075313 | 001 | Feb 07, 2000 |
| SPRAY, METERED;NASAL | | | | |
| IPRATROPIUM BROMIDE | | | | |
| APOTEX INC | 0.021MG/SPRAY | A076156 | 001 | Apr 18, 2003 |
| | 0.042MG/SPRAY | A076155 | 001 | Apr 18, 2003 |
| IRBESARTAN | | | | |
| TABLET;ORAL | | | | |
| IRBESARTAN | | | | |
| AJANTA PHARMA LTD | 75MG | A203685 | 001 | Dec 10, 2015 |
| | 150MG | A203685 | 002 | Dec 10, 2015 |
| | 300MG | A203685 | 003 | Dec 10, 2015 |
| MYLAN PHARMS INC | 75MG | A200461 | 001 | Sep 27, 2012 |
| | 150MG | A200461 | 002 | Sep 27, 2012 |
| | 300MG | A200461 | 003 | Sep 27, 2012 |
| WATSON LABS INC | 75MG | A090720 | 001 | Oct 12, 2012 |
| | 150MG | A090720 | 002 | Oct 12, 2012 |
| | 300MG | A090720 | 003 | Oct 12, 2012 |
| IRINOTECAN HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| IRINOTECAN HYDROCHLORIDE | | | | |
| SANDOZ | 40MG/2ML (20MG/ML) | A077994 | 001 | Feb 27, 2008 |
| | 100MG/5ML (20MG/ML) | A077994 | 002 | Feb 27, 2008 |
| SANDOZ INC | 40MG/2ML (20MG/ML) | A090137 | 001 | Nov 12, 2009 |
| | 100MG/5ML (20MG/ML) | A090137 | 002 | Nov 12, 2009 |
| IRON DEXTRAN | | | | |
| INJECTABLE;INJECTION | | | | |
| IRON DEXTRAN | | | | |
| SANOFI AVENTIS US | EQ 50MG IRON/ML | N010787 | 002 | |
| IRON SUCROSE | | | | |
| INJECTABLE;INTRAVENOUS | | | | |
| VENOFER | | | | |
| LUITPOLD | EQ 65MG BASE/3.25ML (EQ 20MG BASE/ML) | N021135 | 005 | Mar 29, 2013 |
| | EQ 75MG BASE/3.75ML (EQ 20MG BASE/ML) | N021135 | 003 | Mar 29, 2005 |
| ISOETHARINE HYDROCHLORIDE | | | | |
| SOLUTION;INHALATION | | | | |
| BETA-2 | | | | |
| NEPHRON | 1% | A086711 | 001 | |
| BRONKOSOL | | | | |
| SANOFI AVENTIS US | 0.25% | N012339 | 009 | |
| | 1% | N012339 | 008 | |
| ISOETHARINE HYDROCHLORIDE | | | | |
| ALPHARMA US PHARMS | 1% | A087101 | 001 | |
| ASTRAZENECA | 0.062% | A087937 | 001 | Nov 15, 1982 |
| | 0.062% | A089614 | 001 | Jun 13, 1991 |
| | 0.125% | A087938 | 001 | Nov 15, 1982 |
| | 0.125% | A089615 | 001 | Jun 13, 1991 |
| | 0.167% | A088470 | 001 | Mar 14, 1984 |
| | 0.167% | A089616 | 001 | Jun 13, 1991 |
| | 0.2% | A088471 | 001 | Mar 14, 1984 |
| | 0.2% | A089617 | 001 | Jun 13, 1991 |
| | 0.25% | A088472 | 001 | Mar 14, 1984 |
| | 0.25% | A089618 | 001 | Jun 13, 1991 |
| BAXTER HLTHCARE | 0.08% | A088144 | 001 | Jul 29, 1983 |
| | 0.14% | A088145 | 001 | Mar 26, 1984 |
| | 0.25% | A088146 | 001 | Aug 01, 1983 |
| DEY | 0.08% | A088187 | 001 | Dec 03, 1982 |
| | 0.1% | A087389 | 001 | |
| | 0.17% | A087390 | 001 | |
| | 0.25% | A088188 | 001 | Dec 03, 1982 |
| | 1% | A086763 | 001 | |

ISOETHARINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| SOLUTION;INHALATION | | | | |
| ISOETHARINE HYDROCHLORIDE | | | | |
| INTL MEDICATION | 0.077% | A086651 | 001 | |
| | 0.08% | A086651 | 002 | |
| | 0.1% | A086651 | 003 | |
| | 0.143% | A086651 | 004 | |
| | 0.167% | A086651 | 005 | |
| | 0.2% | A086651 | 006 | |
| | 0.25% | A086651 | 007 | |
| | 1% | A086651 | 008 | |
| PARKE DAVIS | 0.5% | A085997 | 001 | |
| | 1% | A085889 | 001 | |
| ROXANE | 0.1% | A087396 | 001 | |
| | 0.125% | A087025 | 001 | |
| | 0.167% | A088226 | 001 | Sep 16, 1983 |
| | 0.2% | A087324 | 001 | |
| | 0.25% | A088275 | 001 | Jun 03, 1983 |
| | 1% | A086899 | 001 | |
| ISOETHARINE HYDROCHLORIDE S/F | | | | |
| DEY | 0.08% | A089817 | 001 | Nov 22, 1988 |
| | 0.1% | A089818 | 001 | Nov 22, 1988 |
| | 0.17% | A089819 | 001 | Nov 22, 1988 |
| | 0.25% | A089820 | 001 | Nov 22, 1988 |
| | 1% | A089252 | 001 | Sep 15, 1986 |

ISOETHARINE MESYLATE

| | | | | |
|---|---|---|---|---|
| AEROSOL, METERED;INHALATION | | | | |
| BRONKOMETER | | | | |
| SANOFI AVENTIS US | 0.34MG/INH | N012339 | 007 | |
| ISOETHARINE MESYLATE | | | | |
| ALPHARMA US PHARMS | 0.34MG/INH | A087858 | 001 | Aug 21, 1984 |

ISOFLURANE

| | | | | |
|---|---|---|---|---|
| LIQUID;INHALATION | | | | |
| ISOFLURANE | | | | |
| WATSON LABS INC | 99.9% | A074393 | 001 | May 12, 1995 |

ISOFLUROPHATE

| | | | | |
|---|---|---|---|---|
| OINTMENT;OPHTHALMIC | | | | |
| FLOROPRYL | | | | |
| MERCK | 0.025% | N010656 | 001 | |

ISONIAZID

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| NYDRAZID | | | | |
| SANDOZ | 100MG/ML ** | N008662 | 001 | |
| RIMIFON | | | | |
| ROCHE | 25MG/ML | N008420 | 002 | |
| | 100MG/ML | N008420 | 003 | |
| SYRUP;ORAL | | | | |
| ISONIAZID | | | | |
| MIKART | 50MG/5ML | A081118 | 001 | Jul 21, 1997 |
| LANIAZID | | | | |
| LANNETT | 50MG/5ML | A089243 | 001 | Feb 03, 1986 |
| RIMIFON | | | | |
| ROCHE | 50MG/5ML | N008420 | 001 | |
| TABLET;ORAL | | | | |
| DOW-ISONIAZID | | | | |
| DOW PHARM | 300MG | A080330 | 002 | |
| HYZYD | | | | |
| MEDPOINTE PHARM HLC | 100MG | A080134 | 003 | |
| | 300MG | A080134 | 004 | |
| INH | | | | |
| NOVARTIS | 300MG | A080935 | 001 | |
| ISONIAZID | | | | |
| DURAMED PHARMS BARR | 100MG | A088231 | 001 | Mar 17, 1983 |
| | 300MG | A088119 | 001 | Mar 17, 1983 |
| HALSEY | 50MG | A083632 | 001 | |
| HIKMA INTL PHARMS | 100MG | A080212 | 001 | |
| | 300MG | A087425 | 001 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

ISONIAZID

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| ISONIAZID | | | | |
| IMPAX LABS | 100MG | | A080153 001 | |
| IVAX SUB TEVA PHARMS | 100MG | | A080270 001 | |
| | 300MG | | A083610 001 | |
| LILLY | 100MG | | N008499 002 | |
| | 300MG | | N008499 003 | |
| MK LABS | 100MG | | A080941 001 | |
| NEXGEN PHARMA INC | 100MG | | A084050 001 | |
| PANRAY | 50MG | | N008428 001 | |
| | 100MG | | N008428 002 | |
| | 300MG | | N008428 003 | |
| PERRIGO | 100MG | | A083060 001 | |
| PHARMAVITE | 100MG | | A085091 001 | |
| PHOENIX LABS NY | 50MG | | A080368 001 | |
| | 100MG | | A080368 002 | |
| PUREPAC PHARM | 50MG | | A080132 003 | Jul 14, 1982 |
| | 100MG | | A080132 004 | Jul 14, 1982 |
| SUN PHARM INDUSTRIES | 100MG | | A080136 001 | |
| | 300MG | | A083633 001 | |
| WATSON LABS | 50MG | | A080522 001 | |
| | 100MG | | A080401 001 | |
| | 100MG | | A080523 001 | |
| | 100MG | | A085790 001 | |
| | 300MG | | A080521 001 | |
| | 300MG | | A083178 001 | |
| | 300MG | | A085784 001 | |
| WHITEWORTH TOWN PLSN | 100MG | | A080120 002 | |
| LANIAZID | | | | |
| LANNETT | 50MG | | A080140 001 | |
| | 100MG | | A080140 002 | |
| NYDRAZID | | | | |
| BRISTOL MYERS SQUIBB | 100MG | | N008392 003 | |
| STANOZIDE | | | | |
| EVERYLIFE | 100MG | | A080126 001 | |
| | 300MG | | A080126 002 | |

ISONIAZID; RIFAMPIN

| | | | | |
|---|---|---|---|---|
| CAPSULE;ORAL | | | | |
| RIFAMPIN AND ISONIAZID | | | | |
| HIKMA INTL PHARMS | 150MG;300MG | | A065221 001 | Jul 29, 2005 |

ISOPROPAMIDE IODIDE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| DARBID | | | | |
| GLAXOSMITHKLINE | EQ 5MG BASE | | N010744 001 | |

ISOPROTERENOL HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| AEROSOL, METERED;INHALATION | | | | |
| ISOPROTERENOL HYDROCHLORIDE | | | | |
| 3M | 0.12MG/INH | | N010375 004 | |
| ALPHARMA US PHARMS | 0.12MG/INH | | A085904 001 | |
| ISUPREL | | | | |
| SANOFI AVENTIS US | 0.103MG/INH | | N011178 001 | |
| DISC;INHALATION | | | | |
| NORISODRINE AEROTROL | | | | |
| ABBOTT | 0.25% | | N016814 001 | |
| INJECTABLE;INJECTION | | | | |
| ISOPROTERENOL HYDROCHLORIDE | | | | |
| ABRAXIS PHARM | 0.2MG/ML | | A083431 001 | |
| BAXTER HLTHCARE | 0.2MG/ML | | A083486 001 | |
| HOSPIRA | 0.02MG/ML | | A083283 001 | |
| | 0.2MG/ML | | A083346 001 | |
| INTL MEDICATION | 0.2MG/ML | | A083724 001 | |
| SOLUTION;INHALATION | | | | |
| AEROLONE | | | | |
| LILLY | 0.25% | | N007245 001 | |
| ISOPROTERENOL HYDROCHLORIDE | | | | |
| ARMOUR PHARM | 0.031% | | A087935 001 | Nov 18, 1982 |
| | 0.062% | | A087936 001 | Nov 18, 1982 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| ISOPROTERENOL HYDROCHLORIDE | | | | |
| SOLUTION;INHALATION | | | | |
| ISOPROTERENOL HYDROCHLORIDE | | | | |
| DEY | 0.5% | A086764 | 001 | Jan 04, 1982 |
| PARKE DAVIS | 0.25% | A085994 | 001 | |
| | 0.5% | A085540 | 001 | |
| ISUPREL | | | | |
| SANOFI AVENTIS US | 0.5% | N006327 | 002 | |
| | 1% | N006327 | 003 | |
| VAPO-ISO | | | | |
| FISONS | 0.5% | N016813 | 001 | |
| TABLET;RECTAL, SUBLINGUAL | | | | |
| ISUPREL | | | | |
| SANOFI AVENTIS US | 10MG | N006328 | 001 | |
| | 15MG | N006328 | 002 | |
| ISOPROTERENOL HYDROCHLORIDE; PHENYLEPHRINE BITARTRATE | | | | |
| AEROSOL, METERED;INHALATION | | | | |
| DUO-MEDIHALER | | | | |
| 3M | 0.16MG/INH;0.24MG/INH | N013296 | 001 | |
| ISOPROTERENOL SULFATE | | | | |
| AEROSOL, METERED;INHALATION | | | | |
| MEDIHALER-ISO | | | | |
| 3M | 0.08MG/INH | N010375 | 003 | |
| POWDER;INHALATION | | | | |
| NORISODRINE | | | | |
| ABBVIE | 10% | N006905 | 003 | |
| | 25% | N006905 | 002 | |
| ISOSORBIDE | | | | |
| SOLUTION;ORAL | | | | |
| ISMOTIC | | | | |
| ALCON | 100GM/220ML | N017063 | 001 | |
| ISOSORBIDE DINITRATE | | | | |
| CAPSULE, EXTENDED RELEASE;ORAL | | | | |
| ISORDIL | | | | |
| WYETH AYERST | 40MG | N012882 | 002 | Jul 29, 1988 |
| TABLET;ORAL | | | | |
| ISORDIL | | | | |
| + VALEANT PHARMS NORTH | 10MG ** | N012093 | 002 | Jul 29, 1988 |
| + | 20MG ** | N012093 | 006 | Jul 29, 1988 |
| + | 30MG ** | N012093 | 005 | Jul 29, 1988 |
| ISOSORBIDE DINITRATE | | | | |
| SUN PHARM INDUSTRIES | 5MG | A086166 | 002 | Sep 19, 1986 |
| | 10MG | A086169 | 001 | Sep 19, 1986 |
| | 20MG | A086167 | 001 | Sep 19, 1986 |
| | 30MG | A087564 | 001 | Sep 18, 1986 |
| SUPERPHARM | 5MG | A089190 | 001 | Feb 17, 1987 |
| | 10MG | A089191 | 001 | Feb 17, 1987 |
| | 20MG | A089192 | 001 | Feb 17, 1987 |
| WATSON LABS | 5MG | A086034 | 001 | Jan 06, 1988 |
| | 10MG | A086032 | 001 | Jan 07, 1988 |
| SORBITRATE | | | | |
| ASTRAZENECA | 5MG | N016192 | 001 | Apr 01, 1996 |
| | 10MG | N016192 | 002 | Apr 01, 1996 |
| | 20MG | A086405 | 002 | Aug 21, 1990 |
| | 30MG | A088124 | 001 | Aug 21, 1990 |
| | 40MG | A088125 | 001 | Aug 21, 1990 |
| TABLET;SUBLINGUAL | | | | |
| ISORDIL | | | | |
| + BIOVAIL | 2.5MG ** | N012940 | 004 | Jul 29, 1988 |
| + | 5MG ** | N012940 | 003 | Jul 29, 1988 |
| + | 10MG ** | N012940 | 005 | Jul 29, 1988 |
| ISOSORBIDE DINITRATE | | | | |
| HIKMA INTL PHARMS | 2.5MG | A086054 | 001 | Oct 29, 1987 |
| | 5MG | A086055 | 001 | Nov 02, 1987 |
| SANDOZ | 2.5MG | A086225 | 001 | Feb 19, 1988 |
| | 5MG | A086222 | 001 | Feb 19, 1988 |
| SUN PHARM INDUSTRIES | 2.5MG | A084204 | 001 | Sep 18, 1986 |

| | | | | |
|---|---|---|---|---|
| ISOSORBIDE DINITRATE | | | | |
| TABLET;SUBLINGUAL | | | | |
| ISOSORBIDE DINITRATE | | | | |
| | 5MG | A086168 | 001 | Sep 18, 1986 |
| | 10MG | A087545 | 001 | Sep 18, 1986 |
| WATSON LABS | 2.5MG ** | A086033 | 001 | Feb 26, 1988 |
| WATSON LABS TEVA | 5MG ** | A086031 | 001 | Sep 29, 1987 |
| SORBITRATE | | | | |
| ASTRAZENECA | 2.5MG | N016191 | 002 | Apr 01, 1996 |
| | 5MG | N016191 | 001 | Apr 01, 1996 |
| TABLET, CHEWABLE;ORAL | | | | |
| SORBITRATE | | | | |
| ASTRAZENECA | 5MG | N016776 | 002 | Apr 01, 1996 |
| | 10MG | N016776 | 003 | Apr 01, 1996 |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| ISORDIL | | | | |
| WYETH AYERST | 40MG | N012882 | 001 | Jul 29, 1988 |
| ISOSORBIDE DINITRATE | | | | |
| IMPAX LABS INC | 40MG | A040723 | 001 | Mar 17, 2008 |
| ISOSORBIDE MONONITRATE | | | | |
| TABLET;ORAL | | | | |
| ISMO | | | | |
| PROMIUS PHARMA | 20MG | N019091 | 001 | Dec 30, 1991 |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| IMDUR | | | | |
| + SCHERING PLOUGH | 30MG ** | N020225 | 001 | Aug 12, 1993 |
| + | 60MG ** | N020225 | 002 | Aug 12, 1993 |
| + | 120MG ** | N020225 | 003 | Mar 30, 1995 |
| ISOSORBIDE MONONITRATE | | | | |
| ACTAVIS ELIZABETH | 30MG | A075306 | 001 | Dec 31, 1998 |
| | 60MG | A075306 | 002 | Dec 31, 1998 |
| ALKERMES GAINESVILLE | 60MG | A075041 | 001 | Sep 22, 1998 |
| IVAX SUB TEVA PHARMS | 30MG | A075448 | 002 | Aug 07, 2001 |
| | 60MG | A075448 | 001 | Jun 19, 2000 |
| | 120MG | A075448 | 003 | Aug 07, 2001 |
| SKYEPHARMA AG | 60MG | A075166 | 001 | Oct 07, 1999 |
| ISOSULFAN BLUE | | | | |
| INJECTABLE;INJECTION | | | | |
| LYMPHAZURIN | | | | |
| + COVIDIEN | 1% ** | N018310 | 001 | |
| ISOTRETINOIN | | | | |
| CAPSULE;ORAL | | | | |
| ACCUTANE | | | | |
| + HOFFMANN LA ROCHE | 10MG ** | N018662 | 002 | May 07, 1982 |
| + | 20MG ** | N018662 | 004 | Mar 28, 1983 |
| + | 40MG ** | N018662 | 003 | May 07, 1982 |
| SOTRET | | | | |
| SUN PHARM INDS LTD | 10MG | A076041 | 001 | Dec 24, 2002 |
| | 20MG | A076041 | 002 | Dec 24, 2002 |
| | 30MG | A076503 | 001 | Jun 20, 2003 |
| | 40MG | A076041 | 003 | Dec 24, 2002 |
| ISRADIPINE | | | | |
| CAPSULE;ORAL | | | | |
| DYNACIRC | | | | |
| + SMITHKLINE BEECHAM | 2.5MG | N019546 | 001 | Dec 20, 1990 |
| + | 5MG | N019546 | 002 | Dec 20, 1990 |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| DYNACIRC CR | | | | |
| + GLAXOSMITHKLINE LLC | 5MG ** | N020336 | 001 | Jun 01, 1994 |
| + | 10MG ** | N020336 | 002 | Jun 01, 1994 |
| ISRADIPINE | | | | |
| MYLAN PHARMS INC | 5MG | A201067 | 001 | Nov 27, 2015 |
| | 10MG | A201067 | 002 | Nov 27, 2015 |

| | | | | |
|---|---|---|---|---|
| ITRACONAZOLE | | | | |
| INJECTABLE;INJECTION | | | | |
| SPORANOX | | | | |
| JANSSEN PHARMS | 10MG/ML | N020966 | 001 | Mar 30, 1999 |
| SOLUTION;ORAL | | | | |
| ITRACONAZOLE | | | | |
| AMNEAL PHARMS | 10MG/ML | A205573 | 001 | Oct 30, 2015 |
| IVERMECTIN | | | | |
| TABLET;ORAL | | | | |
| STROMECTOL | | | | |
| MERCK SHARP DOHME | 6MG | N050742 | 001 | Nov 22, 1996 |
| KANAMYCIN SULFATE | | | | |
| CAPSULE;ORAL | | | | |
| KANTREX | | | | |
| APOTHECON | EQ 500MG BASE | A060516 | 001 | |
| | EQ 500MG BASE | A061911 | 001 | |
| | EQ 500MG BASE | A062726 | 001 | Mar 06, 1987 |
| INJECTABLE;INJECTION | | | | |
| KANAMYCIN | | | | |
| WEST-WARD PHARMS INT | EQ 75MG BASE/2ML | A062324 | 001 | |
| | EQ 500MG BASE/2ML | A062324 | 002 | |
| | EQ 1GM BASE/3ML | A062324 | 003 | |
| KANAMYCIN SULFATE | | | | |
| ABRAXIS PHARM | EQ 75MG BASE/2ML | A062504 | 001 | Apr 05, 1984 |
| | EQ 500MG BASE/2ML | A062504 | 002 | Apr 05, 1984 |
| | EQ 1GM BASE/3ML | A062504 | 003 | Apr 05, 1984 |
| INTL MEDICATION | EQ 500MG BASE/2ML | A062466 | 001 | Sep 30, 1983 |
| | EQ 1GM BASE/3ML | A062466 | 002 | Sep 30, 1983 |
| LOCH | EQ 75MG BASE/2ML | A063021 | 001 | Jul 31, 1992 |
| | EQ 500MG BASE/2ML | A063022 | 001 | Jul 31, 1992 |
| | EQ 1GM BASE/3ML | A063025 | 001 | Jul 31, 1992 |
| PHARMAFAIR | EQ 75MG BASE/2ML | A062668 | 001 | May 07, 1987 |
| | EQ 500MG BASE/2ML | A062672 | 001 | May 07, 1987 |
| | EQ 1GM BASE/3ML | A062669 | 001 | May 07, 1987 |
| SOLOPAK | EQ 75MG BASE/2ML | A062605 | 003 | Feb 26, 1986 |
| | EQ 500MG BASE/2ML | A062605 | 001 | Feb 26, 1986 |
| | EQ 1GM BASE/3ML | A062605 | 002 | Feb 26, 1986 |
| WARNER CHILCOTT | EQ 1GM BASE/3ML | A063092 | 001 | Oct 11, 1989 |
| WATSON LABS | EQ 1GM BASE/3ML | A062520 | 003 | May 09, 1985 |
| KANTREX | | | | |
| APOTHECON | EQ 75MG BASE/2ML | A061655 | 003 | |
| | EQ 75MG BASE/2ML | A061901 | 003 | |
| | EQ 75MG BASE/2ML | A062564 | 001 | Sep 21, 1984 |
| | EQ 500MG BASE/2ML | A061655 | 001 | |
| | EQ 500MG BASE/2ML | A061901 | 001 | |
| | EQ 500MG BASE/2ML | A062564 | 002 | Sep 21, 1984 |
| | EQ 1GM BASE/3ML | A061655 | 002 | |
| | EQ 1GM BASE/3ML | A061901 | 002 | |
| | EQ 1GM BASE/3ML | A062564 | 003 | Sep 21, 1984 |
| KLEBCIL | | | | |
| KING PHARMS | EQ 75MG BASE/2ML | A062170 | 001 | |
| | EQ 500MG BASE/2ML | A062170 | 002 | |
| | EQ 1GM BASE/3ML | A062170 | 003 | |
| KETOCONAZOLE | | | | |
| CREAM;TOPICAL | | | | |
| NIZORAL | | | | |
| + JANSSEN PHARMA | 2% | N019084 | 001 | Dec 31, 1985 |
| SUSPENSION;ORAL | | | | |
| NIZORAL | | | | |
| JANSSEN PHARMA | 100MG/5ML | A070767 | 001 | Nov 07, 1986 |
| TABLET;ORAL | | | | |
| KETOCONAZOLE | | | | |
| AAIPHARMA LLC | 200MG | A075341 | 001 | Jul 27, 1999 |
| APOTEX | 200MG | A075912 | 001 | Jan 10, 2002 |
| PLIVA | 200MG | A075362 | 001 | Jun 15, 1999 |
| SUN PHARM INDUSTRIES | 200MG | A075314 | 001 | Jun 15, 1999 |
| TEVA | 200MG | A074971 | 001 | Jun 15, 1999 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

KETOCONAZOLE

| | | | | | |
|---|---|---|---|---|---|
| TABLET;ORAL | | | | | |
| NIZORAL | | | | | |
| + | JANSSEN PHARMS | 200MG ** | N018533 | 001 | |

KETOPROFEN

| | | | | | |
|---|---|---|---|---|---|
| CAPSULE;ORAL | | | | | |
| KETOPROFEN | | | | | |
| | AUROLIFE PHARMA LLC | 50MG | A074024 | 001 | Dec 29, 1995 |
| | | 75MG | A074024 | 002 | Dec 29, 1995 |
| | TEVA | 25MG | A073515 | 001 | Dec 22, 1992 |
| ORUDIS | | | | | |
| + | WYETH AYERST | 25MG ** | N018754 | 001 | Jul 31, 1987 |
| + | | 50MG ** | N018754 | 002 | Jan 09, 1986 |
| + | | 75MG ** | N018754 | 003 | Jan 09, 1986 |
| CAPSULE, EXTENDED RELEASE;ORAL | | | | | |
| KETOPROFEN | | | | | |
| | ALKERMES GAINESVILLE | 200MG | A074879 | 001 | Dec 10, 1997 |
| ORUVAIL | | | | | |
| + | WYETH PHARMS INC | 100MG ** | N019816 | 003 | Feb 08, 1995 |
| + | | 150MG ** | N019816 | 002 | Feb 08, 1995 |
| + | | 200MG ** | N019816 | 001 | Sep 24, 1993 |
| FILM;ORAL | | | | | |
| NEXCEDE | | | | | |
| | NOVARTIS | 12.5MG | N022470 | 001 | Nov 25, 2009 |
| TABLET;ORAL | | | | | |
| ACTRON | | | | | |
| | BAYER | 12.5MG | N020499 | 001 | Oct 06, 1995 |
| KETOPROFEN | | | | | |
| | PERRIGO | 12.5MG | A075364 | 001 | Feb 07, 2002 |
| ORUDIS KT | | | | | |
| + | WYETH CONS | 12.5MG ** | N020429 | 001 | Oct 06, 1995 |

KETOROLAC TROMETHAMINE

| | | | | | |
|---|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | | |
| KETOROLAC TROMETHAMINE | | | | | |
| | APOTEX INC | 30MG/ML | A075626 | 001 | Jul 24, 2001 |
| | | 30MG/ML | A077201 | 001 | Oct 14, 2005 |
| | APOTHECON | 15MG/ML | A075348 | 001 | Nov 28, 2000 |
| | | 30MG/ML | A075348 | 002 | Nov 28, 2000 |
| | BAXTER HLTHCARE CORP | 15MG/ML | A075631 | 002 | Jun 29, 2001 |
| | | 30MG/ML | A075631 | 001 | Jun 29, 2001 |
| | BEDFORD | 15MG/ML | A075230 | 002 | Oct 25, 1999 |
| | | 30MG/ML | A075230 | 001 | Oct 25, 1999 |
| | GLAND PHARMA LTD | 15MG/ML | A076722 | 001 | Jul 27, 2004 |
| | | 30MG/ML | A076722 | 002 | Jul 27, 2004 |
| | HOSPIRA | 15MG/ML | A074801 | 001 | Jun 05, 1997 |
| | | 30MG/ML | A074801 | 002 | Jun 05, 1997 |
| | LUITPOLD | 15MG/ML | A078145 | 001 | Jan 14, 2008 |
| | | 30MG/ML | A078145 | 002 | Jan 14, 2008 |
| | MYLAN LABS LTD | 15MG/ML | A078299 | 001 | Jul 16, 2007 |
| | | 15MG/ML | A201155 | 001 | Aug 04, 2014 |
| | | 30MG/ML | A078299 | 002 | Jul 16, 2007 |
| | | 30MG/ML | A201155 | 002 | Aug 04, 2014 |
| | SANDOZ INC | 15MG/ML | A076271 | 001 | Oct 06, 2004 |
| | SUN PHARMA GLOBAL | 15MG/ML | A078737 | 001 | Oct 06, 2008 |
| | | 30MG/ML | A078737 | 002 | Oct 06, 2008 |
| | WEST-WARD PHARMS INT | 15MG/ML ** | A075222 | 001 | Apr 26, 1999 |
| | | 15MG/ML | A075299 | 001 | Nov 03, 1999 |
| | | 15MG/ML | A075772 | 001 | Jul 21, 2004 |
| | | 30MG/ML ** | A075222 | 002 | Apr 26, 1999 |
| | | 30MG/ML ** | A075228 | 001 | Apr 26, 1999 |
| | | 30MG/ML | A075299 | 002 | Nov 03, 1999 |
| | | 30MG/ML | A075772 | 002 | Jul 21, 2004 |
| | WOCKHARDT | 30MG/ML | A077943 | 001 | Mar 27, 2007 |
| TORADOL | | | | | |
| + | ROCHE PALO | 15MG/ML ** | N019698 | 001 | Nov 30, 1989 |
| + | | 30MG/ML ** | N019698 | 002 | Nov 30, 1989 |

| | | | | |
|---|---|---|---|---|
| KETOROLAC TROMETHAMINE | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | |
| ACULAR PRESERVATIVE FREE | | | | |
| ALLERGAN | 0.5% | N020811 | 001 | Nov 03, 1997 |
| KETOROLAC TROMETHAMINE | | | | |
| AKORN | 0.45% | A203376 | 001 | Feb 10, 2014 |
| TABLET;ORAL | | | | |
| KETOROLAC TROMETHAMINE | | | | |
| CYCLE PHARMS LTD | 10MG | A074790 | 001 | Jun 26, 1997 |
| WATSON LABS | 10MG | A074955 | 001 | Sep 19, 1997 |
| TORADOL | | | | |
| + ROCHE PALO | 10MG ** | N019645 | 001 | Dec 20, 1991 |
| KETOTIFEN FUMARATE | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | |
| KETOTIFEN FUMARATE | | | | |
| APOTEX INC | EQ 0.025% BASE | A077354 | 001 | May 09, 2006 |
| ZADITOR | | | | |
| + ALCON PHARMA | EQ 0.025% BASE ** | N021066 | 002 | Oct 19, 2006 |
| KRYPTON, KR-81M | | | | |
| GAS;INHALATION | | | | |
| MPI KRYPTON 81M GENERATOR | | | | |
| GE HEALTHCARE | N/A | N018088 | 001 | |
| LABETALOL HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| LABETALOL HYDROCHLORIDE | | | | |
| APOTHECON | 5MG/ML | A075355 | 001 | Nov 29, 1999 |
| BAXTER HLTHCARE CORP | 5MG/ML | A076051 | 001 | Jul 05, 2002 |
| HOSPIRA | 5MG/ML | A075242 | 001 | Sep 30, 1999 |
| NORMODYNE | | | | |
| SCHERING | 5MG/ML | N018686 | 001 | Aug 01, 1984 |
| TRANDATE | | | | |
| + SEBELA IRELAND LTD | 5MG/ML ** | N019425 | 001 | Dec 31, 1985 |
| TABLET;ORAL | | | | |
| LABETALOL HYDROCHLORIDE | | | | |
| APOTHECON | 100MG | A075223 | 001 | Nov 20, 1998 |
| | 200MG | A075223 | 002 | Nov 20, 1998 |
| | 300MG | A075223 | 003 | Nov 20, 1998 |
| TEVA | 100MG | A074989 | 001 | Sep 30, 1998 |
| | 200MG | A074989 | 002 | Sep 30, 1998 |
| | 300MG | A074989 | 003 | Sep 30, 1998 |
| NORMODYNE | | | | |
| + SCHERING | 100MG ** | N018687 | 001 | Aug 31, 1987 |
| + | 200MG ** | N018687 | 002 | Aug 01, 1984 |
| + | 300MG ** | N018687 | 003 | Aug 01, 1984 |
| + | 400MG ** | N018687 | 004 | Aug 01, 1984 |
| TRANDATE | | | | |
| + CNTY LINE PHARMS | 400MG ** | N018716 | 004 | Aug 01, 1984 |
| LACTULOSE | | | | |
| SOLUTION;ORAL | | | | |
| CHRONULAC | | | | |
| + SANOFI AVENTIS US | 10GM/15ML ** | N017884 | 001 | |
| CONSTULOSE | | | | |
| ACTAVIS MID ATLANTIC | 10GM/15ML | A070288 | 001 | Aug 15, 1988 |
| DUPHALAC | | | | |
| SOLVAY | 10GM/15ML | A072372 | 001 | Mar 22, 1989 |
| EVALOSE | | | | |
| TEVA PHARMS | 10GM/15ML | A073497 | 001 | May 28, 1993 |
| LACTULOSE | | | | |
| APOTEX INC | 10GM/15ML | A075911 | 001 | Feb 21, 2002 |
| MORTON GROVE | 10GM/15ML | A071841 | 001 | Sep 22, 1988 |
| PACO | 10GM/15ML | A073160 | 001 | Aug 25, 1992 |
| LAXILOSE | | | | |
| NOSTRUM LABS | 10GM/15ML | A073686 | 001 | May 28, 1993 |
| SOLUTION;ORAL, RECTAL | | | | |
| ACILAC | | | | |
| NOSTRUM LABS | 10GM/15ML | A073685 | 001 | May 28, 1993 |

| | | | | |
|---|---|---|---|---|
| LACTULOSE | | | | |
| SOLUTION;ORAL, RECTAL | | | | |
| CEPHULAC | | | | |
| + | SANOFI AVENTIS US | 10GM/15ML ** | N017657 001 | |
| GENERLAC | | | | |
| | MORTON GROVE | 10GM/15ML | A071842 001 | Sep 27, 1988 |
| HEPTALAC | | | | |
| | TEVA PHARMS | 10GM/15ML | A073504 001 | May 28, 1993 |
| LACTULOSE | | | | |
| | APOTEX INC | 10GM/15ML | A076645 001 | Jul 28, 2003 |
| | PACO | 10GM/15ML | A072029 001 | Aug 25, 1992 |
| | ROXANE | 10GM/15ML | A073590 001 | May 29, 1992 |
| | SOLVAY | 10GM/15ML | N017906 001 | |
| PORTALAC | | | | |
| | SOLVAY | 10GM/15ML | A072374 001 | Mar 22, 1989 |
| LAMIVUDINE; RALTEGRAVIR POTASSIUM | | | | |
| TABLET;ORAL | | | | |
| DUTREBIS | | | | |
| | MERCK SHARP DOHME | 150MG;EQ 300MG BASE | N206510 001 | Feb 06, 2015 |
| LAMOTRIGINE | | | | |
| TABLET;ORAL | | | | |
| LAMICTAL | | | | |
| + | GLAXOSMITHKLINE LLC | 50MG ** | N020241 006 | Dec 27, 1994 |
| + | | 250MG ** | N020241 004 | Dec 27, 1994 |
| LAMOTRIGINE | | | | |
| | ACTAVIS TOTOWA | 25MG | A078669 001 | Apr 08, 2011 |
| | | 100MG | A078669 002 | Apr 08, 2011 |
| | | 150MG | A078669 003 | Apr 08, 2011 |
| | | 200MG | A078669 004 | Apr 08, 2011 |
| | HIKMA PHARMS | 25MG | A078134 001 | Apr 19, 2011 |
| | | 100MG | A078134 002 | Apr 19, 2011 |
| | | 150MG | A078134 003 | Apr 19, 2011 |
| | | 200MG | A078134 004 | Apr 19, 2011 |
| | MYLAN | 25MG | A077428 001 | Jan 27, 2009 |
| | | 100MG | A077428 002 | Jan 27, 2009 |
| | | 150MG | A077428 003 | Jan 27, 2009 |
| | | 200MG | A077428 004 | Jan 27, 2009 |
| | MYLAN LABS LTD | 25MG | A078443 001 | Feb 11, 2009 |
| | | 100MG | A078443 002 | Feb 11, 2009 |
| | | 150MG | A078443 003 | Feb 11, 2009 |
| | | 200MG | A078443 004 | Feb 11, 2009 |
| | PHARMASCIENCE INC | 25MG | A078310 001 | Feb 04, 2009 |
| | | 100MG | A078310 002 | Feb 04, 2009 |
| | | 150MG | A078310 003 | Feb 04, 2009 |
| | | 200MG | A078310 004 | Feb 04, 2009 |
| | ROXANE | 25MG | A077392 001 | Jan 27, 2009 |
| | | 100MG | A077392 002 | Jan 27, 2009 |
| | | 150MG | A077392 003 | Jan 27, 2009 |
| | | 200MG | A077392 004 | Jan 27, 2009 |
| | SANDOZ | 25MG | A078645 001 | Jan 27, 2009 |
| | | 100MG | A078645 002 | Jan 27, 2009 |
| | | 150MG | A078645 003 | Jan 27, 2009 |
| | | 200MG | A078645 004 | Jan 27, 2009 |
| | WOCKHARDT | 25MG | A078982 001 | Jan 27, 2009 |
| | | 100MG | A078982 002 | Jan 27, 2009 |
| | | 150MG | A078982 003 | Jan 27, 2009 |
| | | 200MG | A078982 004 | Jan 27, 2009 |
| TABLET, CHEWABLE;ORAL | | | | |
| LAMICTAL CD | | | | |
| | GLAXOSMITHKLINE LLC | 100MG | N020764 003 | Aug 24, 1998 |
| LAMOTRIGINE | | | | |
| | MYLAN | 5MG | A076630 001 | Jan 22, 2009 |
| | | 25MG | A076630 002 | Jan 22, 2009 |
| | SANDOZ | 5MG | A078409 002 | Jan 22, 2009 |
| | | 25MG | A078409 003 | Jan 22, 2009 |

LANSOPRAZOLE
FOR SUSPENSION, DELAYED RELEASE;ORAL
PREVACID

| | | | | | |
|---|---|---|---|---|---|
| | TAKEDA PHARMS NA | 15MG/PACKET | N021281 | 001 | May 03, 2001 |
| | | 30MG/PACKET | N021281 | 002 | May 03, 2001 |

INJECTABLE;INTRAVENOUS
PREVACID IV

| | | | | | |
|---|---|---|---|---|---|
| + | TAKEDA PHARMS NA | 30MG/VIAL ** | N021566 | 001 | May 27, 2004 |

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL
LANSOPRAZOLE

| | | | | | |
|---|---|---|---|---|---|
| | ANI PHARMS INC | 15MG | A078730 | 001 | Oct 15, 2010 |
| | | 30MG | A078730 | 002 | Oct 15, 2010 |

LANSOPRAZOLE; NAPROXEN
CAPSULE, DELAYED REL PELLETS, TABLET;ORAL
PREVACID NAPRAPAC 250 (COPACKAGED)

| | | | | | |
|---|---|---|---|---|---|
| + | TAKEDA PHARMS NA | 15MG,N/A;N/A,250MG ** | N021507 | 002 | Nov 14, 2003 |

PREVACID NAPRAPAC 375 (COPACKAGED)

| | | | | | |
|---|---|---|---|---|---|
| | TAKEDA PHARMS NA | 15MG,N/A;N/A,375MG | N021507 | 003 | Nov 14, 2003 |

PREVACID NAPRAPAC 500 (COPACKAGED)

| | | | | | |
|---|---|---|---|---|---|
| | TAKEDA PHARMS NA | 15MG,N/A;N/A,500MG | N021507 | 004 | Nov 14, 2003 |

LANTHANUM CARBONATE
TABLET, CHEWABLE;ORAL
FOSRENOL

| | | | | | |
|---|---|---|---|---|---|
| | SHIRE LLC | EQ 250MG BASE | N021468 | 001 | Oct 26, 2004 |

LAPYRIUM CHLORIDE; UNDECOYLIUM CHLORIDE IODINE COMPLEX
SOLUTION;TOPICAL
VIRAC REX

| | | | | | |
|---|---|---|---|---|---|
| | CHESEBROUGH PONDS | 0.5%;1.8% | N011914 | 001 | |

LATANOPROST
SOLUTION/DROPS;OPHTHALMIC
LATANOPROST

| | | | | | |
|---|---|---|---|---|---|
| | APOTEX INC | 0.005% | A077697 | 001 | Mar 22, 2011 |

LEFLUNOMIDE
TABLET;ORAL
LEFLUNOMIDE

| | | | | | |
|---|---|---|---|---|---|
| | SANDOZ | 10MG | A077085 | 001 | Sep 13, 2005 |
| | | 10MG | A077087 | 001 | Sep 13, 2005 |
| | | 20MG | A077085 | 002 | Sep 13, 2005 |
| | | 20MG | A077087 | 002 | Sep 13, 2005 |

LEPIRUDIN RECOMBINANT
INJECTABLE;INJECTION
REFLUDAN

| | | | | | |
|---|---|---|---|---|---|
| | BAYER HLTHCARE | 50MG/VIAL | N020807 | 001 | Mar 06, 1998 |

LETROZOLE
TABLET;ORAL
LETROZOLE

| | | | | | |
|---|---|---|---|---|---|
| | ACTAVIS TOTOWA | 2.5MG | A090292 | 001 | Jul 13, 2011 |
| | IMPAX LABS | 2.5MG | A091638 | 001 | Jun 03, 2011 |
| | KREMERS URBAN PHARMS | 2.5MG | A091098 | 001 | Jun 03, 2011 |
| | LANNETT HOLDINGS INC | 2.5MG | A202048 | 001 | Oct 29, 2014 |
| | SUN PHARM INDS LTD | 2.5MG | A091466 | 001 | Jun 03, 2011 |
| | SYNTHON PHARMS | 2.5MG | A090196 | 001 | Jun 03, 2011 |

LEUCOVORIN CALCIUM
FOR SOLUTION;ORAL
LEUCOVORIN CALCIUM

| | | | | | |
|---|---|---|---|---|---|
| | HOSPIRA | EQ 60MG BASE/VIAL | N008107 | 003 | Jan 30, 1987 |

INJECTABLE;INJECTION
LEUCOVORIN CALCIUM

| | | | | | |
|---|---|---|---|---|---|
| | ABIC | EQ 3MG BASE/ML | A089352 | 001 | Jun 01, 1988 |
| | | EQ 50MG BASE/VIAL | A089353 | 001 | Jun 01, 1988 |
| | ABRAXIS PHARM | EQ 50MG BASE/VIAL | A088939 | 001 | Dec 01, 1986 |
| | ELKINS SINN | EQ 50MG BASE/VIAL | A070480 | 001 | Jan 02, 1987 |
| | | EQ 100MG BASE/VIAL | A081224 | 001 | Jun 03, 1994 |
| + | HOSPIRA | EQ 3MG BASE/ML ** | N008107 | 001 | |
| + | | EQ 50MG BASE/VIAL ** | N008107 | 002 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| LEUCOVORIN CALCIUM | | | | |
| INJECTABLE;INJECTION | | | | |
| LEUCOVORIN CALCIUM | | | | |
| + | EQ 100MG BASE/VIAL ** | N008107 | 004 | May 23, 1988 |
| + | EQ 350MG BASE/VIAL ** | N008107 | 005 | Apr 05, 1989 |
| PHARMACHEMIE | EQ 350MG BASE/VIAL | A040262 | 001 | Dec 15, 1999 |
| PHARMACHEMIE USA | EQ 50MG BASE/VIAL | A089628 | 001 | Apr 17, 1997 |
| | EQ 100MG BASE/VIAL | A089915 | 001 | Apr 17, 1997 |
| TEVA PARENTERAL | EQ 50MG BASE/VIAL | A081278 | 001 | Sep 28, 1993 |
| LEUCOVORIN CALCIUM PRESERVATIVE FREE | | | | |
| HOSPIRA | EQ 10MG BASE/ML ** | A040147 | 001 | Jun 25, 1997 |
| LUITPOLD | EQ 50MG BASE/VIAL | A040338 | 001 | Jan 31, 2001 |
| TEVA PARENTERAL | EQ 10MG BASE/ML | A040332 | 001 | Jun 28, 1999 |
| WELLCOVORIN | | | | |
| GLAXOSMITHKLINE | EQ 5MG BASE/ML | A087439 | 001 | Oct 19, 1982 |
| | EQ 25MG BASE/VIAL | A089833 | 001 | Jan 23, 1989 |
| | EQ 50MG BASE/VIAL | A089465 | 001 | Jan 23, 1989 |
| | EQ 100MG BASE/VIAL | A089834 | 001 | Jan 23, 1989 |
| TABLET;ORAL | | | | |
| LEUCOVORIN CALCIUM | | | | |
| EPIC PHARMA LLC | EQ 5MG BASE | A074544 | 001 | Aug 28, 1997 |
| | EQ 25MG BASE | A074544 | 002 | Aug 28, 1997 |
| IDT AUSTRALIA LTD | EQ 15MG BASE | A075327 | 001 | Mar 24, 1999 |
| PAR PHARM | EQ 5MG BASE | A071600 | 001 | Oct 14, 1987 |
| | EQ 25MG BASE | A071598 | 001 | Oct 14, 1987 |
| PHARMACHEMIE | EQ 5MG BASE | A073099 | 001 | Mar 28, 1997 |
| | EQ 25MG BASE | A073101 | 001 | Mar 28, 1997 |
| XANODYNE PHARM | EQ 5MG BASE | N018459 | 001 | Jan 30, 1986 |
| | EQ 10MG BASE | A071962 | 001 | Nov 19, 1987 |
| | EQ 15MG BASE | A071104 | 001 | Mar 04, 1987 |
| WELLCOVORIN | | | | |
| + GLAXOSMITHKLINE | EQ 5MG BASE ** | N018342 | 001 | Jul 08, 1983 |
| + | EQ 25MG BASE ** | N018342 | 002 | Jul 08, 1983 |
| LEUPROLIDE ACETATE | | | | |
| IMPLANT;IMPLANTATION | | | | |
| VIADUR | | | | |
| ORTHO MCNEIL JANSSEN | EQ 65MG BASE | N021088 | 001 | Mar 03, 2000 |
| INJECTABLE;INJECTION | | | | |
| LEUPROLIDE ACETATE | | | | |
| GENZYME | 1MG/0.2ML | A075721 | 001 | Nov 29, 2001 |
| LUPRON | | | | |
| ABBVIE ENDOCRINE INC | 1MG/0.2ML | N019010 | 001 | Apr 09, 1985 |
| LUPRON DEPOT | | | | |
| + ABBVIE ENDOCRINE INC | 3.75MG/VIAL ** | N020011 | 001 | Oct 22, 1990 |
| LUPRON DEPOT-PED | | | | |
| + ABBVIE ENDOCRINE INC | 3.75MG/VIAL,7.5MG/VIAL ** | N020263 | 003 | Apr 16, 1993 |
| + | 7.5MG/VIAL,7.5MG/VIAL ** | N020263 | 004 | Apr 16, 1993 |
| LEVALLORPHAN TARTRATE | | | | |
| INJECTABLE;INJECTION | | | | |
| LORFAN | | | | |
| ROCHE | 1MG/ML | N010423 | 001 | |
| LEVAMISOLE HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| ERGAMISOL | | | | |
| JANSSEN PHARMA | EQ 50MG BASE | N020035 | 001 | Jun 18, 1990 |
| LEVETIRACETAM | | | | |
| SOLUTION;ORAL | | | | |
| LEVETIRACETAM | | | | |
| APOTEX INC | 100MG/ML | A090187 | 001 | Aug 05, 2011 |
| TABLET;ORAL | | | | |
| LEVETIRACETAM | | | | |
| ACTAVIS LABS FL INC | 250MG | A077408 | 001 | Mar 02, 2009 |
| | 500MG | A077408 | 002 | Mar 02, 2009 |
| | 750MG | A077408 | 003 | Mar 02, 2009 |
| MYLAN | 250MG | A078731 | 001 | Feb 10, 2009 |
| | 500MG | A078731 | 002 | Feb 10, 2009 |
| | 750MG | A078731 | 003 | Feb 10, 2009 |

| | | | | |
|---|---|---|---|---|
| LEVETIRACETAM | | | | |
| TABLET;ORAL | | | | |
| LEVETIRACETAM | | | | |
| | 1GM | | A078731 004 | Feb 10, 2009 |
| SANDOZ | 1GM | | A077324 004 | Jan 15, 2009 |
| | 250MG | | A077324 001 | Jan 15, 2009 |
| | 500MG | | A077324 002 | Jan 15, 2009 |
| | 750MG | | A077324 003 | Jan 15, 2009 |
| WATSON LABS INC | 250MG | | A078797 002 | Jan 15, 2009 |
| | 500MG | | A078797 003 | Jan 15, 2009 |
| | 750MG | | A078797 004 | Jan 15, 2009 |
| | 1GM | | A078797 001 | Jan 15, 2009 |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| LEVETIRACETAM | | | | |
| MYLAN PHARMS INC | 500MG | | A200475 001 | Dec 19, 2011 |
| | 750MG | | A200475 002 | Dec 19, 2011 |
| | 1GM | | A200475 003 | Dec 07, 2015 |
| SANDOZ | 500MG | | A091668 001 | Nov 01, 2012 |
| | 750MG | | A091668 002 | Nov 01, 2012 |
| LEVOBETAXOLOL HYDROCHLORIDE | | | | |
| SUSPENSION/DROPS;OPHTHALMIC | | | | |
| BETAXON | | | | |
| ALCON PHARMS LTD | EQ 0.5% BASE | | N021114 001 | Feb 23, 2000 |
| LEVOBUNOLOL HYDROCHLORIDE | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | |
| LEVOBUNOLOL HYDROCHLORIDE | | | | |
| ALCON LABS INC | 0.25% | | A074851 001 | Oct 28, 1996 |
| APOTEX INC | 0.25% | | A075473 001 | Aug 03, 2000 |
| | 0.5% | | A075475 001 | Aug 03, 2000 |
| BAUSCH AND LOMB | 0.25% | | A074307 001 | Mar 04, 1994 |
| LEVOBUPIVACAINE HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| CHIROCAINE | | | | |
| PURDUE PHARMA LP | EQ 2.5MG BASE/ML | | N020997 001 | Aug 05, 1999 |
| | EQ 5MG BASE/ML | | N020997 002 | Aug 05, 1999 |
| | EQ 7.5MG BASE/ML | | N020997 003 | Aug 05, 1999 |
| LEVOCABASTINE HYDROCHLORIDE | | | | |
| SUSPENSION/DROPS;OPHTHALMIC | | | | |
| LIVOSTIN | | | | |
| NOVARTIS | EQ 0.05% BASE | | N020219 001 | Nov 10, 1993 |
| LEVOCARNITINE | | | | |
| INJECTABLE;INJECTION | | | | |
| LEVOCARNITINE | | | | |
| TEVA PHARMS USA | 200MG/ML | | A075881 001 | Mar 29, 2001 |
| SOLUTION;ORAL | | | | |
| CARNITOR | | | | |
| LEADIANT BIOSCI INC | 1GM/10ML | | N018948 002 | Apr 27, 1988 |
| LEVOCETIRIZINE DIHYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| LEVOCETIRIZINE DIHYDROCHLORIDE | | | | |
| SANDOZ | 5MG | | A090486 001 | Mar 26, 2013 |
| LEVODOPA | | | | |
| CAPSULE;ORAL | | | | |
| BENDOPA | | | | |
| VALEANT PHARM INTL | 100MG | | N016948 003 | |
| | 250MG | | N016948 001 | |
| | 500MG | | N016948 002 | |
| DOPAR | | | | |
| SHIRE | 100MG | | N016913 003 | |
| | 250MG | | N016913 001 | |
| | 500MG | | N016913 002 | |
| LARODOPA | | | | |
| ROCHE | 100MG | | N016912 002 | |
| | 250MG | | N016912 001 | |
| | 500MG | | N016912 006 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| LEVODOPA | | | | |
| TABLET;ORAL | | | | |
| DOPAR | | | | |
| | SHIRE | 250MG | N016913 004 | |
| | | 500MG | N016913 005 | |
| LARODOPA | | | | |
| | ROCHE | 100MG | N016912 005 | |
| | | 250MG | N016912 003 | |
| | | 500MG | N016912 004 | |
| LEVOFLOXACIN | | | | |
| INJECTABLE;INJECTION | | | | |
| LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| + | JANSSEN PHARMS | EQ 250MG/50ML (EQ 5MG/ML) ** | N020635 002 | Dec 20, 1996 |
| + | | EQ 500MG/100ML (EQ 5MG/ML) ** | N020635 003 | Dec 20, 1996 |
| + | | EQ 750MG/150ML (EQ 5MG/ML) ** | N020635 005 | Dec 20, 1996 |
| LEVOFLOXACIN | | | | |
| | AKORN | EQ 500MG/20ML (EQ 25MG/ML) | A091644 001 | Jun 20, 2011 |
| | | EQ 750MG/30ML (EQ 25MG/ML) | A091644 002 | Jun 20, 2011 |
| | HOSPIRA INC | EQ 500MG/20ML (EQ 25MG/ML) | A078577 001 | Aug 12, 2015 |
| | | EQ 750MG/30ML (EQ 25MG/ML) | A078577 002 | Aug 12, 2015 |
| SOLUTION;ORAL | | | | |
| LEVAQUIN | | | | |
| + | JANSSEN PHARMS | 250MG/10ML | N021721 001 | Oct 21, 2004 |
| SOLUTION/DROPS;OPHTHALMIC | | | | |
| IQUIX | | | | |
| + | SANTEN | 1.5% ** | N021571 001 | Mar 01, 2004 |
| LEVOFLOXACIN | | | | |
| | APOTEX INC | 0.5% | A078282 001 | Dec 20, 2010 |
| QUIXIN | | | | |
| + | SANTEN | 0.5% ** | N021199 001 | Aug 18, 2000 |
| TABLET;ORAL | | | | |
| LEVOFLOXACIN | | | | |
| | MYLAN | 250MG | A076276 001 | Jun 20, 2011 |
| | | 500MG | A076276 002 | Jun 20, 2011 |
| | | 750MG | A077097 001 | Jun 20, 2011 |
| | WATSON LABS INC | 250MG | A201484 001 | Nov 22, 2013 |
| | | 500MG | A201484 002 | Nov 22, 2013 |
| | | 750MG | A201484 003 | Nov 22, 2013 |
| LEVOLEUCOVORIN CALCIUM | | | | |
| SOLUTION;IV (INFUSION) | | | | |
| FUSILEV | | | | |
| + | SPECTRUM PHARMS | EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML) ** | N020140 002 | Apr 29, 2011 |
| + | | EQ 250MG BASE/25ML (EQ 10MG BASE/ML) ** | N020140 003 | Apr 29, 2011 |
| LEVOMEPROMAZINE | | | | |
| INJECTABLE;INJECTION | | | | |
| LEVOPROME | | | | |
| | IMMUNEX | 20MG/ML | N015865 001 | |
| LEVOMETHADYL ACETATE HYDROCHLORIDE | | | | |
| CONCENTRATE;ORAL | | | | |
| ORLAAM | | | | |
| + | ROXANE | 10MG/ML ** | N020315 001 | Jul 09, 1993 |
| LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| ARESTOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN | | | | |
| | SOLVAY | 0.05MG/ML;2% | A085010 001 | |
| CARBOCAINE W/ NEO-COBEFRIN | | | | |
| | EASTMAN KODAK | 0.05MG/ML;2% | N012125 002 | |
| ISOCAINE HYDROCHLORIDE W/ LEVONORDEFRIN | | | | |
| | SEPTODONT INC | 0.05MG/ML;2% | A084697 001 | |
| MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN | | | | |
| | BELMORA LLC | 0.05MG/ML;2% | A084850 002 | Oct 21, 1983 |
| POLOCAINE W/ LEVONORDEFRIN | | | | |
| | DENTSPLY PHARM | 0.05MG/ML;2% | A089517 001 | Apr 14, 1988 |

| | | | | |
|---|---|---|---|---|
| LEVONORDEFRIN; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| RAVOCAINE AND NOVOCAIN W/ NEO-COBEFRIN | | | | |
| | EASTMAN KODAK | 0.05MG/ML;2%;0.4% | N008592 007 | |
| LEVONORGESTREL | | | | |
| IMPLANT;IMPLANTATION | | | | |
| JADELLE | | | | |
| + | POPULATION COUNCIL | 75MG/IMPLANT ** | N020544 001 | Nov 01, 1996 |
| LEVONORGESTREL | | | | |
| | WYETH PHARMS INC | 75MG/IMPLANT | N020627 001 | Aug 15, 1996 |
| NORPLANT | | | | |
| | POPULATION COUNCIL | 36MG/IMPLANT | N019897 001 | Dec 10, 1990 |
| NORPLANT SYSTEM IN PLASTIC CONTAINER | | | | |
| | WYETH PHARMS INC | 36MG/IMPLANT | N020088 001 | Dec 10, 1990 |
| TABLET;ORAL | | | | |
| LEVONORGESTREL | | | | |
| | FDN CONSUMER | 0.75MG ** | A078665 001 | Aug 28, 2009 |
| | LUPIN LTD | 0.75MG | A091328 001 | Jan 23, 2013 |
| | WATSON LABS | 0.75MG | A078666 001 | Jun 24, 2009 |
| PLAN B | | | | |
| + | FDN CONSUMER | 0.75MG ** | N021045 001 | Jul 28, 1999 |
| + | | 0.75MG ** | N021045 002 | Aug 24, 2006 |
| LEVOPROPOXYPHENE NAPSYLATE ANHYDROUS | | | | |
| CAPSULE;ORAL | | | | |
| NOVRAD | | | | |
| | LILLY | EQ 50MG BASE | N012928 006 | |
| | | EQ 100MG BASE | N012928 004 | |
| SUSPENSION;ORAL | | | | |
| NOVRAD | | | | |
| | LILLY | EQ 50MG BASE/5ML | N012928 002 | |
| LEVORPHANOL TARTRATE | | | | |
| INJECTABLE;INJECTION | | | | |
| LEVO-DROMORAN | | | | |
| | VALEANT PHARM INTL | 2MG/ML | N008719 001 | Dec 19, 1991 |
| TABLET;ORAL | | | | |
| LEVO-DROMORAN | | | | |
| + | VALEANT PHARM INTL | 2MG ** | N008720 001 | Dec 19, 1991 |
| LEVOTHYROXINE SODIUM | | | | |
| SOLUTION;ORAL | | | | |
| TIROSINT-SOL | | | | |
| + | INSTITUT BIOCHIMIQUE | 13MCG/ML | N206977 001 | Dec 15, 2016 |
| + | | 25MCG/ML | N206977 002 | Dec 15, 2016 |
| + | | 50MCG/ML | N206977 003 | Dec 15, 2016 |
| + | | 75MCG/ML | N206977 004 | Dec 15, 2016 |
| + | | 88MCG/ML | N206977 005 | Dec 15, 2016 |
| + | | 100MCG/ML | N206977 006 | Dec 15, 2016 |
| + | | 112MCG/ML | N206977 007 | Dec 15, 2016 |
| + | | 125MCG/ML | N206977 008 | Dec 15, 2016 |
| + | | 137MCG/ML | N206977 009 | Dec 15, 2016 |
| + | | 150MCG/ML | N206977 010 | Dec 15, 2016 |
| + | | 175MCG/ML | N206977 011 | Dec 15, 2016 |
| + | | 200MCG/ML | N206977 012 | Dec 15, 2016 |
| TABLET;ORAL | | | | |
| LEVOLET | | | | |
| | GENUS LIFESCIENCES | 0.025MG | N021137 001 | Jun 06, 2003 |
| | | 0.05MG | N021137 002 | Jun 06, 2003 |
| | | 0.075MG | N021137 003 | Jun 06, 2003 |
| | | 0.088MG | N021137 004 | Jun 06, 2003 |
| | | 0.1MG | N021137 005 | Jun 06, 2003 |
| | | 0.112MG | N021137 006 | Jun 06, 2003 |
| | | 0.125MG | N021137 007 | Jun 06, 2003 |
| | | 0.137MG | N021137 008 | Jun 06, 2003 |
| | | 0.15MG | N021137 009 | Jun 06, 2003 |
| | | 0.175MG | N021137 010 | Jun 06, 2003 |
| | | 0.2MG | N021137 011 | Jun 06, 2003 |
| | | 0.3MG | N021137 012 | Jun 06, 2003 |

| | | | | |
|---|---|---|---|---|
| LEVOTHYROXINE SODIUM | | | | |
| TABLET;ORAL | | | | |
| LEVOTHYROXINE SODIUM | | | | |
| MERCK KGAA | 0.025MG | A076752 | 001 | Jun 16, 2005 |
| | 0.05MG | A076752 | 002 | Jun 16, 2005 |
| | 0.075MG | A076752 | 003 | Jun 16, 2005 |
| | 0.088MG | A076752 | 004 | Jun 16, 2005 |
| | 0.1MG | A076752 | 005 | Jun 16, 2005 |
| | 0.112MG | A076752 | 006 | Jun 16, 2005 |
| | 0.125MG | A076752 | 007 | Jun 16, 2005 |
| | 0.15MG | A076752 | 008 | Jun 16, 2005 |
| | 0.175MG | A076752 | 009 | Jun 16, 2005 |
| | 0.2MG | A076752 | 010 | Jun 16, 2005 |
| | 0.3MG | A076752 | 011 | Jun 16, 2005 |
| LEVOXYL | | | | |
| + KING PHARMS | 0.3MG ** | N021301 | 012 | May 25, 2001 |
| NOVOTHYROX | | | | |
| MERCK KGAA | 0.025MG | N021292 | 001 | May 31, 2002 |
| | 0.05MG | N021292 | 002 | May 31, 2002 |
| | 0.075MG | N021292 | 003 | May 31, 2002 |
| | 0.088MG | N021292 | 004 | May 31, 2002 |
| | 0.1MG | N021292 | 005 | May 31, 2002 |
| | 0.112MG | N021292 | 006 | May 31, 2002 |
| | 0.125MG | N021292 | 007 | May 31, 2002 |
| | 0.137MG | N021292 | 008 | May 31, 2002 |
| | 0.15MG | N021292 | 009 | May 31, 2002 |
| | 0.175MG | N021292 | 010 | May 31, 2002 |
| | 0.2MG | N021292 | 011 | May 31, 2002 |
| | 0.3MG | N021292 | 012 | May 31, 2002 |
| THYRO-TABS | | | | |
| + LLOYD | 0.025MG ** | N021116 | 001 | Oct 24, 2002 |
| + | 0.05MG ** | N021116 | 002 | Oct 24, 2002 |
| + | 0.075MG ** | N021116 | 003 | Oct 24, 2002 |
| + | 0.088MG ** | N021116 | 010 | Oct 24, 2002 |
| + | 0.1MG ** | N021116 | 004 | Oct 24, 2002 |
| + | 0.112MG ** | N021116 | 011 | Oct 24, 2002 |
| + | 0.125MG ** | N021116 | 005 | Oct 24, 2002 |
| + | 0.137MG ** | N021116 | 012 | Dec 07, 2004 |
| + | 0.15MG ** | N021116 | 006 | Oct 24, 2002 |
| + | 0.175MG ** | N021116 | 007 | Oct 24, 2002 |
| + | 0.2MG ** | N021116 | 008 | Oct 24, 2002 |
| + | 0.3MG ** | N021116 | 009 | Oct 24, 2002 |
| LIDOCAINE | | | | |
| AEROSOL;ORAL | | | | |
| XYLOCAINE | | | | |
| ASTRAZENECA | 10% | N014394 | 001 | |
| FILM, EXTENDED RELEASE;BUCCAL | | | | |
| DENTIPATCH | | | | |
| NOVEN | 23MG/PATCH | N020575 | 001 | May 21, 1996 |
| OINTMENT;TOPICAL | | | | |
| ALPHACAINE | | | | |
| CARLISLE | 5% | A084944 | 001 | |
| | 5% | A084946 | 001 | |
| | 5% | A084947 | 001 | |
| LIDOCAINE | | | | |
| BELMORA LLC | 5% | A080210 | 001 | |
| XYLOCAINE | | | | |
| + ASTRAZENECA | 5% ** | N008048 | 001 | |
| PATCH;TOPICAL | | | | |
| DENTIPATCH | | | | |
| NOVEN | 46.1MG/PATCH | N020575 | 002 | May 21, 1996 |
| SOLUTION;TOPICAL | | | | |
| XYLOCAINE | | | | |
| ASTRAZENECA | 5% | N014127 | 001 | |
| SUPPOSITORY;RECTAL | | | | |
| XYLOCAINE | | | | |
| ASTRAZENECA | 100MG | N013077 | 001 | |

LIDOCAINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| ALPHACAINE HYDROCHLORIDE | | | | |
| CARLISLE | 2% | A084721 | 001 | |
| LIDOCAINE HYDROCHLORIDE | | | | |
| ABBOTT | 10% | A087980 | 001 | Feb 02, 1983 |
| | 20% | A089362 | 001 | May 25, 1988 |
| ABRAXIS PHARM | 1% | A080420 | 001 | |
| | 1% | A086761 | 001 | |
| | 1.5% | A080420 | 005 | |
| | 2% | A080420 | 002 | |
| | 2% | A080420 | 004 | |
| | 2% | A086761 | 002 | |
| | 2% | N017508 | 001 | |
| | 4% | N017508 | 002 | |
| | 20% | N017508 | 004 | |
| AKORN | 1% | A085037 | 001 | |
| | 2% | A085037 | 002 | |
| BEL MAR | 1% | A080710 | 001 | |
| | 2% | A080760 | 001 | |
| BELMORA LLC | 2% | A080504 | 001 | |
| DELL LABS | 1% | A083387 | 001 | |
| | 2% | A083388 | 001 | |
| ELKINS SINN | 0.5% | A085131 | 001 | |
| | 4% | A084626 | 001 | |
| GD SEARLE LLC | 1% | A083135 | 001 | |
| | 2% | A083135 | 002 | |
| HOSPIRA | 1% | A040013 | 001 | Jun 23, 1995 |
| | 1.5% | A088330 | 001 | May 17, 1984 |
| | 2% | A088331 | 001 | May 17, 1984 |
| INTL MEDICATION | 1% | N017701 | 002 | |
| | 2% | N017701 | 001 | |
| | 1GM/VIAL | N018543 | 001 | |
| | 2GM/VIAL | N018543 | 002 | |
| LUITPOLD | 2% | A083198 | 001 | |
| LYPHOMED | 1% | A080390 | 001 | |
| | 2% | A080390 | 002 | |
| MILES | 1% | A080414 | 001 | |
| | 2% | A080414 | 002 | |
| MYLAN LABS LTD | 0.5% | A091056 | 001 | Dec 08, 2010 |
| | 0.5% | A091058 | 001 | Sep 30, 2010 |
| | 1% | A091056 | 002 | Dec 08, 2010 |
| | 1% | A091058 | 002 | Sep 30, 2010 |
| | 2% | A202242 | 001 | Apr 11, 2014 |
| WATSON LABS | 1% | A080377 | 001 | |
| | 1% | A083627 | 001 | |
| | 2% | A080377 | 002 | |
| | 2% | A083627 | 002 | |
| WEST-WARD PHARMS INT | 1% | A080407 | 001 | |
| | 2% | A080407 | 002 | |
| WYETH AYERST | 1% | A083083 | 001 | |
| | 2% | A083083 | 002 | |
| LIDOCAINE HYDROCHLORIDE 0.1% AND DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| BAXTER HLTHCARE | 100MG/100ML | N018461 | 001 | |
| LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 200MG/100ML | N018967 | 001 | Mar 30, 1984 |
| LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% | | | | |
| HOSPIRA | 200MG/100ML | A083158 | 005 | |
| LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| ABBOTT | 200MG/100ML | N018954 | 001 | Jul 09, 1985 |
| HOSPIRA | 200MG/100ML | N018388 | 001 | |
| LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 400MG/100ML | N018967 | 002 | Mar 30, 1984 |
| LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% | | | | |
| HOSPIRA | 400MG/100ML | A083158 | 006 | |
| LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| HOSPIRA | 400MG/100ML | N018388 | 002 | |
| LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 800MG/100ML | N018967 | 003 | Mar 30, 1984 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| LIDOCAINE HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| HOSPIRA | 800MG/100ML | N018388 | 003 | Nov 05, 1982 |
| LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER | | | | |
| HOSPIRA | 1.5% | A088326 | 001 | Jul 31, 1984 |
| | 10% | A088367 | 001 | Jul 31, 1984 |
| | 20% | A088368 | 001 | Jul 31, 1984 |
| LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE | | | | |
| INTL MEDICATION | 4% | N017702 | 002 | |
| MYLAN LABS LTD | 2% | A090665 | 001 | Sep 27, 2010 |
| WEST-WARD PHARMS INT | 1% | A084625 | 001 | |
| | 2% | A084625 | 002 | |
| LIDOCATON | | | | |
| PHARMATON | 2% | A084727 | 001 | Aug 17, 1983 |
| LIDOPEN | | | | |
| MERIDIAN MEDCL TECHN | 10% | N017549 | 001 | |
| XYLOCAINE | | | | |
| ASTRAZENECA | 1% | N010418 | 005 | |
| | 1.5% | N010418 | 009 | |
| | 2% | N010418 | 007 | |
| XYLOCAINE DENTAL | | | | |
| DENTSPLY PHARM | 2% | N021380 | 001 | |
| XYLOCAINE PRESERVATIVE FREE | | | | |
| FRESENIUS KABI USA | 10% | N016801 | 003 | |
| INJECTABLE;SPINAL | | | | |
| XYLOCAINE 1.5% W/ DEXTROSE 7.5% | | | | |
| FRESENIUS KABI USA | 1.5% | N016297 | 001 | |
| XYLOCAINE 5% W/ GLUCOSE 7.5% | | | | |
| ASTRAZENECA | 5% | N010496 | 002 | Jul 07, 1982 |
| JELLY;TOPICAL | | | | |
| ANESTACON | | | | |
| BIONPHARMA INC | 2% | A080429 | 001 | |
| LIDOCAINE HYDROCHLORIDE | | | | |
| G AND W LABS INC | 2% | A081318 | 001 | Apr 29, 1993 |
| SOLUTION;ORAL | | | | |
| LIDOCAINE HYDROCHLORIDE VISCOUS | | | | |
| ACTAVIS MID ATLANTIC | 2% | A086578 | 001 | |
| INTL MEDICATION | 2% | A086389 | 001 | Feb 02, 1982 |
| XYLOCAINE VISCOUS | | | | |
| FRESENIUS KABI USA | 2% ** | N009470 | 001 | |
| SOLUTION;TOPICAL | | | | |
| LARYNGOTRACHEAL ANESTHESIA KIT | | | | |
| KENDALL IL | 4% | A087931 | 001 | Jun 10, 1983 |
| LIDOCAINE HYDROCHLORIDE | | | | |
| PACO | 4% | A089688 | 001 | Jun 30, 1989 |
| LTA II KIT | | | | |
| HOSPIRA | 4% | A088542 | 001 | Jul 31, 1984 |
| PEDIATRIC LTA KIT | | | | |
| ABBOTT | 2% | A088572 | 001 | Jul 31, 1984 |
| HOSPIRA | 2% | A085995 | 001 | |
| LIDOCAINE HYDROCHLORIDE; OXYTETRACYCLINE | | | | |
| INJECTABLE;INJECTION | | | | |
| TERRAMYCIN | | | | |
| PFIZER | 2%;50MG/ML | A060567 | 001 | |
| | 2%;125MG/ML | A060567 | 002 | |
| LIDOCAINE; PRILOCAINE | | | | |
| DISC;TOPICAL | | | | |
| EMLA | | | | |
| ASTRAZENECA | 2.5%;2.5% | N020962 | 001 | Feb 04, 1998 |
| LINCOMYCIN HYDROCHLORIDE | | | | |
| CAPSULE;ORAL | | | | |
| LINCOCIN | | | | |
| PHARMACIA AND UPJOHN | EQ 250MG BASE | N050316 | 001 | |
| | EQ 500MG BASE | N050316 | 002 | |

| | | | | |
|---|---|---|---|---|
| LINCOMYCIN HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| LINCOMYCIN HYDROCHLORIDE | | | | |
| WATSON LABS | EQ 300MG BASE/ML | A063180 | 001 | Apr 16, 1991 |
| LINDANE | | | | |
| CREAM;TOPICAL | | | | |
| KWELL | | | | |
| REED AND CARNRICK | 1% | A084218 | 001 | |
| | 1% | N006309 | 001 | |
| LOTION;TOPICAL | | | | |
| GAMENE | | | | |
| SOLA BARNES HIND | 1% | A084989 | 001 | |
| KWELL | | | | |
| REED AND CARNRICK | 1% | A084218 | 002 | |
| | 1% | N006309 | 003 | |
| SCABENE | | | | |
| STIEFEL | 1% | A086769 | 001 | |
| SHAMPOO;TOPICAL | | | | |
| GAMENE | | | | |
| SOLA BARNES HIND | 1% | A084988 | 001 | |
| KWELL | | | | |
| REED AND CARNRICK | 1% | A084219 | 001 | |
| | 1% | N010718 | 001 | |
| SCABENE | | | | |
| STIEFEL | 1% | A087940 | 001 | Apr 08, 1983 |
| LINEZOLID | | | | |
| TABLET;ORAL | | | | |
| ZYVOX | | | | |
| + PHARMACIA AND UPJOHN | 400MG ** | N021130 | 001 | Apr 18, 2000 |
| LIOTHYRONINE SODIUM | | | | |
| TABLET;ORAL | | | | |
| LIOTHYRONINE SODIUM | | | | |
| WATSON LABS | EQ 0.025MG BASE | A085755 | 001 | Jan 25, 1982 |
| | EQ 0.05MG BASE | A085753 | 001 | Feb 03, 1982 |
| LIOTRIX (T4;T3) | | | | |
| TABLET;ORAL | | | | |
| EUTHROID-0.5 | | | | |
| PARKE DAVIS | 0.03MG;0.0075MG | N016680 | 001 | |
| EUTHROID-1 | | | | |
| PARKE DAVIS | 0.06MG;0.015MG | N016680 | 002 | |
| EUTHROID-2 | | | | |
| PARKE DAVIS | 0.12MG;0.03MG | N016680 | 003 | |
| EUTHROID-3 | | | | |
| PARKE DAVIS | 0.18MG;0.045MG | N016680 | 004 | |
| THYROLAR-5 | | | | |
| FOREST LABS | 0.25MG;0.0625MG | N016807 | 006 | |
| LISINOPRIL | | | | |
| TABLET;ORAL | | | | |
| LISINOPRIL | | | | |
| SANDOZ | 2.5MG | A075903 | 001 | Jul 01, 2002 |
| | 2.5MG | A075999 | 001 | Jul 01, 2002 |
| | 5MG | A075903 | 002 | Jul 01, 2002 |
| | 5MG | A075999 | 002 | Jul 01, 2002 |
| | 10MG | A075903 | 003 | Jul 01, 2002 |
| | 10MG | A075999 | 003 | Jul 01, 2002 |
| | 20MG | A075903 | 004 | Jul 01, 2002 |
| | 20MG | A075999 | 004 | Jul 01, 2002 |
| | 30MG | A075903 | 005 | Jul 01, 2002 |
| | 30MG | A075999 | 005 | Jul 01, 2002 |
| | 40MG | A075903 | 006 | Jul 01, 2002 |
| | 40MG | A075999 | 006 | Jul 01, 2002 |
| TEVA | 2.5MG | A075783 | 001 | Jul 01, 2002 |
| | 5MG | A075783 | 002 | Jul 01, 2002 |
| | 10MG | A075783 | 003 | Jul 01, 2002 |
| | 20MG | A075783 | 004 | Jul 01, 2002 |
| | 30MG | A075783 | 005 | Jul 01, 2002 |
| | 40MG | A075783 | 006 | Jul 01, 2002 |

| | | | | |
|---|---|---|---|---|
| LISINOPRIL | | | | |
| TABLET;ORAL | | | | |
| PRINIVIL | | | | |
| MERCK | 2.5MG | N019558 | 006 | Jan 28, 1994 |
| LITHIUM CARBONATE | | | | |
| CAPSULE;ORAL | | | | |
| ESKALITH | | | | |
| NOVEN THERAP | 300MG | N016860 | 001 | |
| LITHIUM CARBONATE | | | | |
| ABLE | 150MG | A076823 | 001 | Jun 29, 2004 |
| | 300MG | A076121 | 001 | Sep 27, 2001 |
| | 300MG | A076823 | 002 | Jun 29, 2004 |
| | 600MG | A076823 | 003 | Jun 29, 2004 |
| APOTEX INC | 300MG | A076795 | 001 | Nov 22, 2004 |
| USL PHARMA | 300MG | A072542 | 001 | Feb 01, 1989 |
| WATSON LABS | 300MG | A070407 | 001 | Mar 19, 1987 |
| LITHONATE | | | | |
| SOLVAY | 300MG | N016782 | 001 | |
| TABLET;ORAL | | | | |
| ESKALITH | | | | |
| JDS PHARMS | 300MG | N017971 | 001 | |
| LITHANE | | | | |
| BAYER PHARMS | 300MG | N018833 | 001 | Jul 18, 1985 |
| LITHIUM CARBONATE | | | | |
| HIKMA INTL PHARMS | 300MG | A078715 | 001 | Dec 28, 2010 |
| PFIZER | 300MG | N016834 | 001 | |
| LITHOTABS | | | | |
| SOLVAY | 300MG | N016980 | 001 | |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| ESKALITH CR | | | | |
| JDS PHARMS | 450MG ** | N018152 | 001 | Mar 29, 1982 |
| LITHIUM CARBONATE | | | | |
| ABLE | 300MG | A076382 | 001 | Apr 21, 2003 |
| BARR | 300MG | A076170 | 001 | Jun 10, 2002 |
| | 450MG | A076366 | 001 | Aug 21, 2003 |
| HIKMA INTL PHARMS | 450MG | A076490 | 001 | Jun 17, 2003 |
| LITHIUM CITRATE | | | | |
| SYRUP;ORAL | | | | |
| LITHONATE | | | | |
| SOLVAY | EQ 300MG CARBONATE/5ML | N017672 | 001 | |
| LOMEFLOXACIN HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| MAXAQUIN | | | | |
| PHARMACIA | EQ 400MG BASE | N020013 | 001 | Feb 21, 1992 |
| LOPERAMIDE HYDROCHLORIDE | | | | |
| CAPSULE;ORAL | | | | |
| IMODIUM | | | | |
| J AND J CONSUMER INC | 2MG ** | N017690 | 001 | |
| | 2MG ** | N017694 | 001 | |
| LOPERAMIDE HYDROCHLORIDE | | | | |
| FOSUN PHARMA | 2MG | A072993 | 001 | Aug 28, 1992 |
| ROXANE | 2MG | A073080 | 001 | Nov 27, 1991 |
| TEVA | 2MG | A073122 | 001 | Aug 30, 1991 |
| SOLUTION;ORAL | | | | |
| IMODIUM | | | | |
| JANSSEN PHARMS | 1MG/5ML | N019037 | 001 | Jul 31, 1984 |
| LOPERAMIDE HYDROCHLORIDE | | | | |
| ALPHARMA US PHARMS | 1MG/5ML | A073187 | 001 | Sep 15, 1992 |
| DURAMED PHARMS BARR | 1MG/5ML | A074991 | 001 | Dec 29, 1997 |
| TEVA | 1MG/5ML | A073478 | 001 | Jun 23, 1995 |
| WATSON LABS | 1MG/5ML | A073062 | 001 | May 28, 1993 |
| TABLET;ORAL | | | | |
| LOPERAMIDE HYDROCHLORIDE | | | | |
| ABLE | 2MG | A073528 | 001 | Nov 30, 1993 |
| CONTRACT PHARMACAL | 2MG | A073254 | 001 | Jul 30, 1993 |
| PERRIGO | 2MG | A074194 | 001 | Oct 30, 1992 |

| | | | | |
|---|---|---|---|---|
| LOPERAMIDE HYDROCHLORIDE | | | | |
| TABLET, CHEWABLE;ORAL | | | | |
| IMODIUM A-D EZ CHEWS | | | | |
| + | J AND J CONSUMER INC | 2MG | N020448 001 | Jul 24, 1997 |
| LOPERAMIDE HYDROCHLORIDE; SIMETHICONE | | | | |
| TABLET, CHEWABLE;ORAL | | | | |
| IMODIUM MULTI-SYMPTOM RELIEF | | | | |
| + | J AND J CONSUMER INC | 2MG;125MG | N020606 001 | Jun 26, 1996 |
| LOPINAVIR; RITONAVIR | | | | |
| CAPSULE;ORAL | | | | |
| KALETRA | | | | |
| | ABBVIE | 133.3MG;33.3MG | N021226 001 | Sep 15, 2000 |
| LORACARBEF | | | | |
| CAPSULE;ORAL | | | | |
| LORABID | | | | |
| | KING PHARMS | 200MG | N050668 001 | Dec 31, 1991 |
| | | 400MG | N050668 002 | Apr 05, 1996 |
| FOR SUSPENSION;ORAL | | | | |
| LORABID | | | | |
| | KING PHARMS | 100MG/5ML | N050667 001 | Dec 31, 1991 |
| | | 200MG/5ML | N050667 002 | Dec 31, 1991 |
| LORATADINE | | | | |
| SYRUP;ORAL | | | | |
| CLARITIN HIVES RELIEF | | | | |
| + | BAYER HEALTHCARE LLC | 1MG/ML ** | N020641 003 | Nov 19, 2003 |
| LORATADINE | | | | |
| | APOTEX INC | 1MG/ML | A075565 001 | Oct 05, 2004 |
| | RANBAXY LABS LTD | 1MG/ML | A076529 001 | Aug 20, 2004 |
| TABLET;ORAL | | | | |
| LORATADINE | | | | |
| | PERRIGO | 10MG | N021512 001 | Jun 24, 2004 |
| LORATADINE; PSEUDOEPHEDRINE SULFATE | | | | |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| LORATADINE AND PSEUDOEPHEDRINE SULFATE | | | | |
| | ACTAVIS LABS FL INC | 5MG;120MG | A076208 001 | Jan 28, 2004 |
| LORAZEPAM | | | | |
| INJECTABLE;INJECTION | | | | |
| LORAZEPAM | | | | |
| | AKORN | 2MG/ML | A074974 001 | Jul 23, 1998 |
| | BEDFORD | 2MG/ML | A077076 001 | Jul 13, 2005 |
| | | 4MG/ML | A077076 002 | Jul 13, 2005 |
| | DAVA PHARMS INC | 2MG/ML | A074793 001 | Mar 16, 2000 |
| | | 4MG/ML | A074793 002 | Mar 16, 2000 |
| | HOSPIRA | 2MG/ML | A074280 001 | May 27, 1994 |
| | | 2MG/ML | A074300 001 | Apr 12, 1994 |
| | | 4MG/ML | A074280 002 | May 27, 1994 |
| | | 4MG/ML | A074300 003 | Mar 19, 1997 |
| | SAGENT AGILA LLC | 2MG/ML | A200217 001 | Apr 04, 2017 |
| | | 2MG/ML | A200542 001 | Apr 28, 2017 |
| | | 4MG/ML | A200217 002 | Apr 04, 2017 |
| | | 4MG/ML | A200542 002 | Apr 28, 2017 |
| | WATSON LABS | 2MG/ML | A074276 001 | Apr 15, 1994 |
| | | 4MG/ML | A074276 002 | Apr 15, 1994 |
| | WATSON LABS INC | 1MG/0.5ML | A074551 003 | Sep 12, 1996 |
| | | 2MG/ML | A074535 001 | Sep 12, 1996 |
| | | 2MG/ML | A074551 001 | Sep 12, 1996 |
| | | 4MG/ML | A074535 002 | Sep 12, 1996 |
| | | 4MG/ML | A074551 002 | Sep 12, 1996 |
| | WEST-WARD PHARMS INT | 2MG/ML | A074496 001 | Sep 28, 1998 |
| | | 4MG/ML | A074496 002 | Sep 28, 1998 |
| SOLUTION;ORAL | | | | |
| LORAZEPAM | | | | |
| | ROXANE | 0.5MG/5ML | A074648 001 | Mar 18, 1997 |
| TABLET;ORAL | | | | |
| LORAZ | | | | |
| | QUANTUM PHARMICS | 0.5MG | A070200 001 | Aug 09, 1985 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| LORAZEPAM | | | | |
| TABLET;ORAL | | | | |
| LORAZ | | | | |
| | 1MG | | A070201 001 | Aug 09, 1985 |
| | 2MG | | A070202 001 | Aug 09, 1985 |
| LORAZEPAM | | | | |
| AM THERAP | 0.5MG | | A070727 001 | Mar 07, 1986 |
| | 1MG | | A070728 001 | Mar 07, 1986 |
| | 2MG | | A070729 001 | Mar 07, 1986 |
| ANDA REPOSITORY | 0.5MG | | A072553 001 | Mar 29, 1991 |
| | 1MG | | A072554 001 | Mar 29, 1991 |
| | 2MG | | A072555 001 | Mar 29, 1991 |
| HALSEY | 0.5MG | | A071434 001 | Sep 01, 1987 |
| | 1MG | | A071435 001 | Sep 01, 1987 |
| | 2MG | | A071436 001 | Sep 01, 1987 |
| MUTUAL PHARM | 0.5MG | | A070472 001 | Dec 10, 1985 |
| | 1MG | | A070473 001 | Dec 10, 1985 |
| | 2MG | | A070474 001 | Dec 10, 1985 |
| MYLAN | 2MG | | A071591 001 | Oct 13, 1987 |
| PAR PHARM | 0.5MG | | A070675 001 | Dec 01, 1986 |
| | 1MG | | A070676 001 | Dec 01, 1986 |
| | 2MG | | A070677 001 | Dec 01, 1986 |
| SANDOZ | 0.5MG | | A071193 001 | Apr 15, 1988 |
| | 1MG | | A071194 001 | Apr 15, 1988 |
| | 2MG | | A071195 001 | Apr 15, 1988 |
| SUPERPHARM | 0.5MG | | A071245 001 | Feb 09, 1987 |
| | 1MG | | A071246 001 | Feb 09, 1987 |
| | 2MG | | A071247 001 | Feb 09, 1987 |
| USL PHARMA | 1MG | | A070539 001 | Dec 22, 1986 |
| | 2MG | | A070540 001 | Dec 22, 1986 |
| WARNER CHILCOTT | 1MG | | A071038 001 | Jan 12, 1988 |
| | 2MG | | A071039 001 | Jan 12, 1988 |
| WATSON LABS | 0.5MG | | A071086 001 | Mar 23, 1987 |
| | 0.5MG | | A071117 001 | Jul 24, 1986 |
| | 1MG | | A071087 001 | Mar 23, 1987 |
| | 1MG | | A071118 001 | Jul 24, 1986 |
| | 2MG | | A071088 001 | Mar 23, 1987 |
| | 2MG | | A071110 001 | Jul 24, 1986 |
| LOTEPREDNOL ETABONATE | | | | |
| SUSPENSION/DROPS;OPHTHALMIC | | | | |
| LOTEMAX | | | | |
| PHARMOS | 0.5% | | N020841 001 | Mar 09, 1998 |
| LOVASTATIN | | | | |
| TABLET;ORAL | | | | |
| LOVASTATIN | | | | |
| MYLAN | 10MG | | A075935 001 | Dec 17, 2001 |
| | 20MG | | A075935 002 | Dec 17, 2001 |
| | 40MG | | A075935 003 | Dec 17, 2001 |
| MEVACOR | | | | |
| + MERCK | 10MG ** | | N019643 002 | Mar 28, 1991 |
| + | 20MG ** | | N019643 003 | Aug 31, 1987 |
| + | 40MG ** | | N019643 004 | Dec 14, 1988 |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| ALTOPREV | | | | |
| COVIS PHARMA BV | 10MG | | N021316 001 | Jun 26, 2002 |
| LOXAPINE HYDROCHLORIDE | | | | |
| CONCENTRATE;ORAL | | | | |
| LOXITANE C | | | | |
| ACTAVIS LABS UT INC | EQ 25MG BASE/ML | | N017658 001 | |
| INJECTABLE;INJECTION | | | | |
| LOXITANE IM | | | | |
| ACTAVIS LABS UT INC | EQ 50MG BASE/ML | | N018039 001 | |

LOXAPINE SUCCINATE

| | | | | |
|---|---|---|---|---|
| CAPSULE;ORAL | | | | |
| LOXITANE | | | | |
| + | ACTAVIS LABS UT INC | EQ 5MG BASE ** | N017525 001 | |
| + | | EQ 10MG BASE ** | N017525 002 | |
| + | | EQ 25MG BASE ** | N017525 003 | |
| + | | EQ 50MG BASE ** | N017525 004 | |
| TABLET;ORAL | | | | |
| LOXITANE | | | | |
| + | ACTAVIS LABS UT INC | EQ 10MG BASE ** | N017525 006 | |
| + | | EQ 25MG BASE ** | N017525 007 | |
| + | | EQ 50MG BASE ** | N017525 008 | |

LUCINACTANT

| | | | | |
|---|---|---|---|---|
| SUSPENSION;INTRATRACHEAL | | | | |
| SURFAXIN | | | | |
| | WINDTREE THERAP | 8.5ML | N021746 001 | Mar 06, 2012 |

LUTROPIN ALFA

| | | | | |
|---|---|---|---|---|
| INJECTABLE;SUBCUTANEOUS | | | | |
| LUVERIS | | | | |
| | EMD SERONO | 75 IU/VIAL | N021322 001 | Oct 08, 2004 |

LYPRESSIN

| | | | | |
|---|---|---|---|---|
| SOLUTION;NASAL | | | | |
| DIAPID | | | | |
| | NOVARTIS | 0.185MG/ML | N016755 001 | |

MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| PLASMA-LYTE 56 IN PLASTIC CONTAINER | | | | |
| | BAXTER HLTHCARE | 32MG/100ML;128MG/100ML;234MG/100ML | N019047 001 | Jun 15, 1984 |

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE; SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| ISOLYTE S PH 7.4 IN PLASTIC CONTAINER | | | | |
| | B BRAUN | 30MG/100ML;37MG/100ML;0.82MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML;12MG/100ML | N019006 001 | Apr 04, 1984 |

MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| ISOLYTE S IN PLASTIC CONTAINER | | | | |
| | B BRAUN | 30MG/100ML;37MG/100ML;370MG/100ML;530MG/100ML;500MG/100ML | N018252 001 | |
| SOLUTION;IRRIGATION | | | | |
| PHYSIOSOL IN PLASTIC CONTAINER | | | | |
| | HOSPIRA INC | 14MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML | N018406 001 | |
| PHYSIOSOL PH 7.4 IN PLASTIC CONTAINER | | | | |
| | HOSPIRA INC | 30MG/100ML;37MG/100ML;222MG/100ML;526MG/100ML;502MG/100ML | N018406 002 | Jul 08, 1982 |
| SYNOVALYTE IN PLASTIC CONTAINER | | | | |
| | BAXTER HLTHCARE | 30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML | N019326 001 | Jan 25, 1985 |

MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE | | | | |
| | SANTARUS | 343MG;20MG;750MG | N022456 001 | Dec 04, 2009 |
| | | 343MG;40MG;750MG | N022456 002 | Dec 04, 2009 |
| TABLET, CHEWABLE;ORAL | | | | |
| ZEGERID | | | | |
| | SANTARUS | 700MG;20MG;600MG | N021850 001 | Mar 24, 2006 |
| | | 700MG;40MG;600MG | N021850 002 | Mar 24, 2006 |

MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

| | | | | |
|---|---|---|---|---|
| SOLUTION;ORAL | | | | |
| SUCLEAR | | | | |
| + | BRAINTREE LABS | 1.6GM/BOT,3.13GM/BOT,17.5GM/BOT,N/A,N/A,N/A,N/A;N/A,N/A,N/A,210GM,0.74GM,2.86GM,5.6GM ** | N203595 001 | Jan 18, 2013 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

MALATHION
LOTION;TOPICAL
MALATHION
MYLAN PHARMS INC 0.5% A078743 001 Mar 06, 2009

MANGAFODIPIR TRISODIUM
INJECTABLE;INJECTION
TESLASCAN
IC TARGETS 37.9MG/ML N020652 001 Nov 26, 1997

MANGANESE CHLORIDE TETRAHYDRATE
FOR SOLUTION;ORAL
LUMENHANCE
BRACCO 3.49MG/GM N020686 001 Dec 19, 1997

MANGANESE SULFATE
INJECTABLE;INJECTION
MANGANESE SULFATE
ABRAXIS PHARM EQ 0.1MG MANGANESE/ML N019228 001 May 05, 1987

MANNITOL
INJECTABLE;INJECTION
MANNITOL 10%
B BRAUN 10GM/100ML N016080 002
HOSPIRA 10GM/100ML N016269 002
MILES 10GM/100ML N016472 002
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER
B BRAUN 10GM/100ML N016080 006
MANNITOL 15%
B BRAUN 15GM/100ML N016080 003
HOSPIRA 15GM/100ML N016269 003
MILES 15GM/100ML N016472 005
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%
B BRAUN 15GM/100ML N016080 005
MANNITOL 20%
B BRAUN 20GM/100ML N014738 001
20GM/100ML N016080 004
HOSPIRA 20GM/100ML N016269 004
MILES 20GM/100ML N016472 004
MANNITOL 25%
ABRAXIS PHARM 12.5GM/50ML A086754 001
HOSPIRA 12.5GM/50ML N016269 005
IGI LABS INC 12.5GM/50ML A089239 001 May 06, 1987
12.5GM/50ML A089240 001 May 06, 1987
MERCK 12.5GM/50ML N005620 001
WATSON LABS 12.5GM/50ML A087460 001 Jun 27, 1983
MANNITOL 5%
B BRAUN 5GM/100ML N016080 001
HOSPIRA 5GM/100ML N016269 001
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%
B BRAUN 5GM/100ML N016080 007
POWDER;INHALATION
ARIDOL KIT
PHARMAXIS LTD N/A,5MG,10MG,20MG,40MG N022368 001 Oct 05, 2010
SOLUTION;IRRIGATION
RESECTISOL
B BRAUN 5GM/100ML N016704 002

MANNITOL; SORBITOL
SOLUTION;IRRIGATION
SORBITOL-MANNITOL
HOSPIRA 540MG/100ML;2.7GM/100ML A080224 001
SORBITOL-MANNITOL IN PLASTIC CONTAINER
HOSPIRA 540MG/100ML;2.7GM/100ML N017636 001

MAPROTILINE HYDROCHLORIDE
TABLET;ORAL
LUDIOMIL
NOVARTIS 25MG N017543 001
50MG N017543 002
75MG N017543 003 Sep 30, 1982

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| MAPROTILINE HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| MAPROTILINE HYDROCHLORIDE | | | | |
| AM THERAP | 25MG | A072129 | 001 | Jan 14, 1988 |
| | 50MG | A072130 | 001 | Jan 14, 1988 |
| | 75MG | A072131 | 001 | Jan 14, 1988 |
| WATSON LABS | 25MG | A071943 | 001 | Dec 30, 1987 |
| | 50MG | A071944 | 001 | Dec 30, 1987 |
| | 75MG | A071945 | 001 | Dec 30, 1987 |
| | 75MG | A072164 | 001 | Jun 01, 1988 |
| WATSON LABS TEVA | 25MG | A072162 | 001 | Jun 01, 1988 |
| | 50MG | A072163 | 001 | Jun 01, 1988 |
| MASOPROCOL | | | | |
| CREAM;TOPICAL | | | | |
| ACTINEX | | | | |
| UNIV AZ CANCER CTR | 10% | N019940 | 001 | Sep 04, 1992 |
| MAZINDOL | | | | |
| TABLET;ORAL | | | | |
| MAZANOR | | | | |
| WYETH AYERST | 1MG | N017980 | 002 | |
| | 2MG | N017980 | 001 | |
| SANOREX | | | | |
| + NOVARTIS | 1MG ** | N017247 | 001 | |
| + | 2MG ** | N017247 | 002 | |
| MEBENDAZOLE | | | | |
| TABLET, CHEWABLE;ORAL | | | | |
| VERMOX | | | | |
| + JANSSEN PHARMS | 100MG ** | N017481 | 001 | |
| MEBUTAMATE | | | | |
| TABLET;ORAL | | | | |
| DORMATE | | | | |
| MEDPOINTE PHARM HLC | 600MG | N017374 | 001 | |
| MECAMYLAMINE HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| INVERSINE | | | | |
| + TARGACEPT | 2.5MG ** | N010251 | 001 | |
| MECASERMIN RINFABATE RECOMBINANT | | | | |
| INJECTABLE;SUBCUTANEOUS | | | | |
| IPLEX | | | | |
| INSMED | 36MG/0.6ML | N021884 | 001 | Dec 12, 2005 |
| MECLIZINE HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| ANTIVERT | | | | |
| CASPER PHARMA LLC | 12.5MG | N010721 | 006 | |
| | 25MG | N010721 | 004 | |
| | 50MG | N010721 | 001 | Jan 20, 1982 |
| MECLIZINE HYDROCHLORIDE | | | | |
| ABC HOLDING | 12.5MG | A085253 | 001 | |
| | 25MG | A085252 | 001 | |
| AMNEAL PHARMS | 50MG | A201451 | 003 | Feb 23, 2011 |
| ANABOLIC | 25MG | A085891 | 001 | |
| ANI PHARMS INC | 12.5MG | A084975 | 001 | |
| | 25MG | A084657 | 001 | |
| BUNDY | 12.5MG | A084382 | 001 | |
| | 25MG | A084872 | 001 | |
| IVAX SUB TEVA PHARMS | 12.5MG | A083784 | 001 | |
| KV PHARM | 12.5MG | A085524 | 001 | |
| | 25MG | A085523 | 001 | |
| MYLAN PHARMS INC | 50MG | A202640 | 003 | Sep 17, 2012 |
| PAR PHARM | 50MG | A089674 | 001 | Mar 31, 1988 |
| PLIVA | 12.5MG | A088732 | 001 | Dec 11, 1985 |
| | 25MG | A088734 | 001 | Dec 11, 1985 |
| RISING PHARMS INC | 12.5MG | A040179 | 001 | Jan 30, 1997 |
| | 25MG | A040179 | 002 | Jan 30, 1997 |
| SUPERPHARM | 12.5MG | A089113 | 001 | Aug 20, 1985 |
| | 25MG | A089114 | 001 | Aug 20, 1985 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

MECLIZINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| MECLIZINE HYDROCHLORIDE | | | | |
| UDL | 12.5MG | A088256 | 001 | Jun 13, 1983 |
| | 25MG | A088257 | 001 | Jun 13, 1983 |
| VANGARD | 12.5MG | A087877 | 001 | Apr 20, 1982 |
| | 25MG | A087620 | 001 | Jan 04, 1982 |
| WATSON LABS | 12.5MG | A085195 | 001 | |
| | 12.5MG | A085269 | 001 | |
| | 25MG | A085740 | 001 | |
| TABLET, CHEWABLE;ORAL | | | | |
| ANTIVERT | | | | |
| CASPER PHARMA LLC | 25MG | N010721 | 005 | |
| MECLIZINE HYDROCHLORIDE | | | | |
| IVAX SUB TEVA PHARMS | 25MG | A084976 | 001 | |
| NEXGEN PHARMA INC | 25MG | A086392 | 001 | |
| PLIVA | 25MG | A088733 | 001 | Dec 11, 1985 |

MECLOCYCLINE SULFOSALICYLATE

| | | | | |
|---|---|---|---|---|
| CREAM;TOPICAL | | | | |
| MECLAN | | | | |
| JOHNSON AND JOHNSON | 1% | N050518 | 001 | |

MECLOFENAMATE SODIUM

| | | | | |
|---|---|---|---|---|
| CAPSULE;ORAL | | | | |
| MECLODIUM | | | | |
| QUANTUM PHARMICS | EQ 50MG BASE | A071380 | 001 | Jul 14, 1987 |
| | EQ 100MG BASE | A071381 | 001 | Jul 14, 1987 |
| MECLOFENAMATE SODIUM | | | | |
| AM THERAP | EQ 50MG BASE | A071362 | 001 | Feb 10, 1987 |
| | EQ 100MG BASE | A071363 | 001 | Feb 10, 1987 |
| BARR | EQ 50MG BASE | A072848 | 001 | Mar 20, 1989 |
| | EQ 100MG BASE | A072809 | 001 | Mar 20, 1989 |
| PAR PHARM | EQ 50MG BASE | A072077 | 001 | Mar 10, 1988 |
| | EQ 100MG BASE | A072078 | 001 | Mar 10, 1988 |
| SANDOZ | EQ 50MG BASE | A072262 | 001 | Nov 29, 1988 |
| | EQ 100MG BASE | A072263 | 001 | Nov 29, 1988 |
| USL PHARMA | EQ 50MG BASE | A071007 | 001 | Mar 25, 1988 |
| | EQ 100MG BASE | A071008 | 001 | Mar 25, 1988 |
| VITARINE | EQ 50MG BASE | A071710 | 001 | Jun 15, 1988 |
| | EQ 100MG BASE | A071684 | 001 | Jun 15, 1988 |
| WATSON LABS | EQ 50MG BASE | A070400 | 001 | Nov 25, 1986 |
| | EQ 50MG BASE | A071468 | 001 | Apr 15, 1987 |
| | EQ 50MG BASE | A071640 | 001 | Aug 11, 1987 |
| | EQ 100MG BASE | A070401 | 001 | Nov 25, 1986 |
| | EQ 100MG BASE | A071641 | 001 | Aug 11, 1987 |
| WATSON LABS TEVA | EQ 100MG BASE | A071469 | 001 | Apr 15, 1987 |
| MECLOMEN | | | | |
| PARKE DAVIS | EQ 50MG BASE | N018006 | 001 | |
| | EQ 100MG BASE | N018006 | 002 | |

MEDROXYPROGESTERONE ACETATE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| DEPO-PROVERA | | | | |
| + PHARMACIA AND UPJOHN | 100MG/ML ** | N012541 | 002 | |
| MEDROXYPROGESTERONE ACETATE | | | | |
| SANDOZ INC | 150MG/ML | A078711 | 001 | May 20, 2009 |
| TEVA PHARMS USA | 150MG/ML | A076552 | 001 | Oct 27, 2004 |
| TABLET;ORAL | | | | |
| AMEN | | | | |
| AMARIN PHARMS | 10MG | A083242 | 001 | |
| CURRETAB | | | | |
| SOLVAY | 10MG | A085686 | 001 | |
| CYCRIN | | | | |
| ESI | 2.5MG | A081239 | 001 | Oct 30, 1992 |
| | 5MG | A081240 | 001 | Oct 30, 1992 |
| | 10MG | A089386 | 001 | Sep 09, 1987 |
| MEDROXYPROGESTERONE ACETATE | | | | |
| DURAMED PHARMS BARR | 2.5MG | A040311 | 001 | Dec 01, 1999 |
| | 5MG | A040311 | 002 | Dec 01, 1999 |
| | 10MG | A040311 | 003 | Dec 01, 1999 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

MEDROXYPROGESTERONE ACETATE
TABLET;ORAL
MEDROXYPROGESTERONE ACETATE

| | | | | |
|---|---|---|---|---|
| USL PHARMA | 10MG | A088484 | 001 | Jul 26, 1984 |

MEDRYSONE
SUSPENSION;OPHTHALMIC
HMS

| | | | | |
|---|---|---|---|---|
| ALLERGAN | 1% | N016624 | 003 | |

MEFLOQUINE HYDROCHLORIDE
TABLET;ORAL
LARIAM

| | | | | |
|---|---|---|---|---|
| + ROCHE | 250MG ** | N019591 | 001 | May 02, 1989 |

MEFLOQUINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| HIKMA INTL PHARMS | 250MG | A077699 | 001 | Apr 21, 2010 |
| SANDOZ | 250MG | A076175 | 001 | Feb 20, 2002 |
| US ARMY WALTER REED | 250MG ** | N019578 | 001 | May 02, 1989 |

MEGESTROL ACETATE
SUSPENSION;ORAL
MEGACE

| | | | | |
|---|---|---|---|---|
| + BRISTOL MYERS SQUIBB | 40MG/ML | N020264 | 001 | Sep 10, 1993 |

MEGESTROL ACETATE

| | | | | |
|---|---|---|---|---|
| APOTEX INC | 40MG/ML | A077404 | 001 | Feb 16, 2006 |

TABLET;ORAL
MEGACE

| | | | | |
|---|---|---|---|---|
| + BRISTOL MYERS SQUIBB | 20MG ** | N016979 | 001 | |
| + | 40MG ** | N016979 | 002 | |

MEGESTROL ACETATE

| | | | | |
|---|---|---|---|---|
| TEVA | 40MG | A074745 | 001 | Feb 27, 1998 |
| USL PHARMA | 20MG | A070646 | 001 | Oct 02, 1987 |
| | 40MG | A070647 | 001 | Oct 02, 1987 |

MELOXICAM
SUSPENSION;ORAL
MOBIC

| | | | | |
|---|---|---|---|---|
| + BOEHRINGER INGELHEIM | 7.5MG/5ML | N021530 | 001 | Jun 01, 2004 |

TABLET;ORAL
MELOXICAM

| | | | | |
|---|---|---|---|---|
| ANDA REPOSITORY | 7.5MG | A077935 | 001 | Jul 19, 2006 |
| | 15MG | A077935 | 002 | Jul 19, 2006 |
| CR DOUBLE CRANE | 7.5MG | A078039 | 001 | Dec 14, 2006 |
| | 15MG | A078039 | 002 | Dec 14, 2006 |
| IMPAX LABS INC | 7.5MG | A077930 | 001 | Jul 19, 2006 |
| | 15MG | A077930 | 002 | Jul 19, 2006 |
| MYLAN | 7.5MG | A077934 | 001 | Jul 20, 2006 |
| | 15MG | A077934 | 002 | Jul 20, 2006 |
| ROXANE | 7.5MG | A077925 | 001 | Jul 19, 2006 |
| | 15MG | A077925 | 002 | Jul 19, 2006 |
| SUN PHARM INDS INC | 7.5MG | A077937 | 001 | Jul 19, 2006 |
| | 15MG | A077937 | 002 | Jul 19, 2006 |
| YABAO PHARM | 7.5MG | A077933 | 001 | Jul 19, 2006 |
| | 15MG | A077933 | 002 | Jul 19, 2006 |

MELPHALAN HYDROCHLORIDE
INJECTABLE;INJECTION
ALKERAN

| | | | | |
|---|---|---|---|---|
| + APOTEX INC | EQ 50MG BASE/VIAL | N020207 | 001 | Nov 18, 1992 |

MELPHALAN HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| MYLAN INSTITUTIONAL | EQ 50MG BASE/VIAL | A090299 | 001 | Oct 27, 2009 |

MEMANTINE HYDROCHLORIDE
TABLET;ORAL
MEMANTINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| ORCHID HLTHCARE | 5MG | A090044 | 001 | Mar 12, 2012 |
| | 10MG | A090044 | 002 | Mar 12, 2012 |

| | | | | |
|---|---|---|---|---|
| MENADIOL SODIUM DIPHOSPHATE | | | | |
| INJECTABLE;INJECTION | | | | |
| KAPPADIONE | | | | |
| | LILLY | 10MG/ML | N005725 001 | |
| SYNKAYVITE | | | | |
| | ROCHE | 5MG/ML | N003718 004 | |
| | | 10MG/ML | N003718 006 | |
| | | 37.5MG/ML | N003718 008 | |
| TABLET;ORAL | | | | |
| SYNKAYVITE | | | | |
| | ROCHE | 5MG | N003718 010 | |
| MENADIONE | | | | |
| TABLET;ORAL | | | | |
| MENADIONE | | | | |
| | LILLY | 5MG | N002139 003 | |
| MENOTROPINS (FSH;LH) | | | | |
| INJECTABLE;INJECTION | | | | |
| HUMEGON | | | | |
| | ORGANON USA INC | 75 IU/VIAL;75 IU/VIAL | N020328 001 | Sep 01, 1994 |
| | | 150 IU/VIAL;150 IU/VIAL | N020328 002 | Sep 01, 1994 |
| MENOTROPINS | | | | |
| | FERRING | 75 IU/VIAL;75 IU/VIAL | A073598 001 | Jan 30, 1997 |
| | | 150 IU/VIAL;150 IU/VIAL | A073599 001 | Jan 30, 1997 |
| PERGONAL | | | | |
| | SERONO | 75 IU/AMP;75 IU/AMP | N017646 001 | |
| | | 150 IU/AMP;150 IU/AMP | N017646 002 | May 20, 1985 |
| REPRONEX | | | | |
| | FERRING | 150 IU/VIAL;150 IU/VIAL | N021047 002 | Aug 27, 1999 |
| INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS | | | | |
| REPRONEX | | | | |
| | FERRING | 75 IU/VIAL;75 IU/VIAL | N021047 001 | Aug 27, 1999 |
| MEPENZOLATE BROMIDE | | | | |
| SOLUTION;ORAL | | | | |
| CANTIL | | | | |
| | SANOFI AVENTIS US | 25MG/5ML | N010679 004 | |
| TABLET;ORAL | | | | |
| CANTIL | | | | |
| + | SANOFI AVENTIS US | 25MG | N010679 003 | |
| MEPERIDINE HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| DEMEROL | | | | |
| | US PHARM HOLDINGS | 25MG/ML | N005010 007 | |
| | | 50MG/ML | N005010 002 | |
| | | 75MG/ML | N005010 009 | |
| | | 100MG/ML | N005010 003 | |
| MEPERIDINE HYDROCHLORIDE | | | | |
| | ABBOTT | 25MG/ML | A080388 001 | |
| | | 50MG/ML | A080385 001 | |
| | | 50MG/ML | A080387 001 | |
| | | 75MG/ML | A080389 001 | |
| | | 100MG/ML | A080386 001 | |
| | BAXTER HLTHCARE | 25MG/ML | A088279 001 | Jun 15, 1984 |
| | | 50MG/ML | A088280 001 | Jun 15, 1984 |
| | | 75MG/ML | A088281 001 | Jun 15, 1984 |
| | | 100MG/ML | A088282 001 | Jun 15, 1984 |
| | IGI LABS INC | 25MG/ML | A089781 001 | Mar 31, 1989 |
| | | 50MG/ML | A089782 001 | Mar 31, 1989 |
| | | 50MG/ML | A089783 001 | Mar 31, 1989 |
| | | 50MG/ML | A089784 001 | Mar 31, 1989 |
| | | 75MG/ML | A089785 001 | Mar 31, 1989 |
| | | 100MG/ML | A089786 001 | Mar 31, 1989 |
| | | 100MG/ML | A089787 001 | Mar 31, 1989 |
| | | 100MG/ML | A089788 001 | Mar 31, 1989 |
| | INTL MEDICATION | 10MG/ML | A086332 001 | |
| | PARKE DAVIS | 50MG/ML | A080364 002 | |
| | | 75MG/ML | A080364 003 | |
| | | 100MG/ML | A080364 001 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

MEPERIDINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| MEPERIDINE HYDROCHLORIDE | | | | |
| WATSON LABS | 50MG/ML | A073444 | 001 | Mar 17, 1992 |
| | 100MG/ML | A073445 | 001 | Mar 17, 1992 |
| MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE | | | | |
| HOSPIRA | 10MG/ML | A040305 | 001 | Mar 10, 1999 |
| INTL MEDICATION | 10MG/ML | A081309 | 001 | Aug 30, 1993 |
| SPECGX LLC | 10MG/ML | A040163 | 001 | May 12, 1997 |
| WATSON LABS | 10MG/ML | A073443 | 001 | Mar 17, 1992 |
| SYRUP;ORAL | | | | |
| DEMEROL | | | | |
| US PHARM HOLDINGS | 50MG/5ML ** | N005010 | 005 | |
| TABLET;ORAL | | | | |
| MEPERIDINE HYDROCHLORIDE | | | | |
| DURAMED PHARMS BARR | 50MG | A040318 | 001 | Oct 05, 1999 |
| | 100MG | A040318 | 002 | Oct 05, 1999 |
| SUN PHARM INDUSTRIES | 50MG | A080448 | 001 | |
| | 100MG | A080448 | 002 | |
| WATSON LABS | 50MG | A040186 | 001 | Jun 30, 1997 |
| | 100MG | A040186 | 002 | Jun 30, 1997 |
| WYETH AYERST | 50MG | A080454 | 001 | |

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| MEPERGAN | | | | |
| WEST-WARD PHARMS INT | 25MG/ML;25MG/ML | N011730 | 001 | |

MEPHENTERMINE SULFATE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| WYAMINE SULFATE | | | | |
| BAXTER HLTHCARE CORP | EQ 15MG BASE/ML | N008248 | 002 | |
| | EQ 30MG BASE/ML | N008248 | 001 | |

MEPHENYTOIN

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| MESANTOIN | | | | |
| + NOVARTIS | 100MG ** | N006008 | 001 | |

MEPIVACAINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| ARESTOCAINE HYDROCHLORIDE | | | | |
| SOLVAY | 3% | A084777 | 002 | Apr 18, 1982 |
| CARBOCAINE | | | | |
| + EASTMAN KODAK | 3% ** | N012125 | 003 | |
| MEPIVACAINE HYDROCHLORIDE | | | | |
| BELMORA LLC | 3% | A083559 | 001 | |
| INTL MEDICATION SYS | 1% | A087509 | 001 | Oct 05, 1982 |
| WATSON LABS | 1% | A088769 | 001 | Nov 20, 1984 |
| | 2% | A088770 | 001 | Nov 20, 1984 |
| POLOCAINE | | | | |
| DENTSPLY PHARM | 3% | A088653 | 001 | Aug 21, 1984 |

MEPREDNISONE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| BETAPAR | | | | |
| SCHERING | 4MG | N016053 | 002 | |

MEPROBAMATE

| | | | | |
|---|---|---|---|---|
| CAPSULE;ORAL | | | | |
| EQUANIL | | | | |
| WYETH AYERST | 400MG | N012455 | 002 | |
| CAPSULE, EXTENDED RELEASE;ORAL | | | | |
| MEPROSPAN | | | | |
| MEDPOINTE PHARM HLC | 200MG | N011284 | 001 | |
| | 400MG | N011284 | 002 | |
| TABLET;ORAL | | | | |
| AMOSENE | | | | |
| FERNDALE LABS | 400MG | A084030 | 001 | |
| BAMATE | | | | |
| ALRA | 200MG | A080380 | 001 | |
| | 400MG | A080380 | 002 | |

MEPROBAMATE

| | | | | | |
|---|---|---|---|---|---|
| TABLET;ORAL | | | | | |
| EQUANIL | | | | | |
| | WYETH AYERST | 200MG | | N010028 005 | |
| | | 400MG | | N010028 004 | |
| MEPRIAM | | | | | |
| | TEVA | 400MG | | N016069 001 | |
| MEPROBAMATE | | | | | |
| | AUROLIFE PHARMA LLC | 400MG | | A080655 001 | |
| | BARR | 600MG | | A084230 001 | |
| | ELKINS SINN | 200MG | | N015426 002 | |
| | | 400MG | | N015426 001 | |
| | HEATHER | 400MG | | N016928 003 | |
| | | 600MG | | A084329 001 | |
| | IMPAX LABS | 200MG | | N014322 002 | |
| | | 400MG | | N014322 001 | |
| | IVAX SUB TEVA PHARMS | 200MG | | N015438 001 | |
| | | 400MG | | N015438 002 | |
| | | 600MG | | A084181 001 | |
| | IVC INDS | 400MG | | A084153 001 | |
| | LANNETT | 200MG | | N014882 002 | |
| | | 400MG | | N014882 001 | |
| | LEDERLE | 400MG | | A086299 001 | |
| | LEE KM | 400MG | | A089538 001 | Nov 25, 1987 |
| | MALLARD | 400MG | | N015072 002 | |
| | MK LABS | 200MG | | N014368 004 | |
| | | 400MG | | N014368 002 | |
| | MYLAN | 400MG | | A083618 001 | |
| | NEXGEN PHARMA INC | 200MG | | A084220 001 | |
| | | 400MG | | A084589 001 | |
| | PARKE DAVIS | 200MG | | A084744 001 | |
| | | 400MG | | A084744 002 | |
| | PERRIGO | 200MG | | A084546 001 | |
| | | 400MG | | A084547 001 | |
| | PHARMAVITE | 400MG | | A084438 001 | |
| | PUREPAC PHARM | 200MG | | A084804 001 | |
| | | 400MG | | A084804 002 | |
| | PVT FORM | 400MG | | N014601 001 | |
| | ROXANE | 600MG | | A084332 001 | |
| | SANDOZ | 200MG | | N014547 002 | |
| | | 400MG | | N014547 001 | |
| | SCHERER LABS | 400MG | | A083343 001 | |
| | SOLVAY | 200MG | | A084435 001 | |
| | STANLABS PHARM | 200MG | | N014474 002 | |
| | | 400MG | | N014474 004 | |
| | SUN PHARM INDUSTRIES | 200MG | | A080699 001 | |
| | | 400MG | | A080699 002 | |
| | TABLICAPS | 400MG | | A083494 001 | |
| | TARO | 200MG | | A200998 001 | May 23, 2011 |
| | | 400MG | | A200998 002 | May 23, 2011 |
| | USL PHARMA | 200MG | | A087825 001 | Mar 18, 1982 |
| | | 400MG | | A087826 001 | Mar 18, 1982 |
| | VALEANT PHARM INTL | 200MG | | N015139 006 | |
| | | 400MG | | N015139 005 | |
| | VANGARD | 400MG | | A088011 001 | Jul 14, 1982 |
| | WATSON LABS | 200MG | | A085720 001 | |
| | | 400MG | | A085721 001 | |
| | | 600MG | | A084274 001 | |
| | | 600MG | | A085719 001 | |
| | WEST WARD | 200MG | | N015417 003 | |
| | | 400MG | | N015417 002 | |
| | WHITEWORTH TOWN PLSN | 200MG | | A083830 001 | |
| | | 400MG | | A083442 001 | |
| MILTOWN | | | | | |
| + | MEDPOINTE PHARM HLC | 200MG | ** | N009698 004 | |
| + | | 400MG | ** | N009698 002 | |
| | | 600MG | | A083919 001 | |
| NEURAMATE | | | | | |
| | HALSEY | 200MG | | N014359 002 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| MEPROBAMATE | | | | |
| TABLET;ORAL | | | | |
| NEURAMATE | | | | |
| | 400MG | | N014359 001 | |
| TRANMEP | | | | |
| SOLVAY | 400MG | | A084369 001 | |
| | 400MG | | N016249 001 | |
| MEQUINOL; TRETINOIN | | | | |
| SOLUTION;TOPICAL | | | | |
| SOLAGE | | | | |
| AQUA PHARMS | 2%;0.01% | | N020922 001 | Dec 10, 1999 |
| MEROPENEM | | | | |
| INJECTABLE;INJECTION | | | | |
| MEROPENEM | | | | |
| SANDOZ | 500MG/VIAL | | A091201 001 | Mar 29, 2011 |
| | 1GM/VIAL | | A091201 002 | Mar 29, 2011 |
| MERSALYL SODIUM; THEOPHYLLINE | | | | |
| INJECTABLE;INJECTION | | | | |
| MERSALYL-THEOPHYLLINE | | | | |
| WATSON LABS | 100MG/ML;50MG/ML | | A084875 001 | |
| MESALAMINE | | | | |
| SUPPOSITORY;RECTAL | | | | |
| CANASA | | | | |
| FOREST LABS LLC | 500MG | | N021252 001 | Jan 05, 2001 |
| ROWASA | | | | |
| + MEDA PHARMS | 500MG ** | | N019919 001 | Dec 18, 1990 |
| TABLET, DELAYED RELEASE;ORAL | | | | |
| ASACOL | | | | |
| APIL | 400MG | | N019651 001 | Jan 31, 1992 |
| MESNA | | | | |
| INJECTABLE;INTRAVENOUS | | | | |
| MESNA | | | | |
| MYLAN LABS LTD | 100MG/ML | | A203364 001 | Jul 18, 2014 |
| MESORIDAZINE BESYLATE | | | | |
| CONCENTRATE;ORAL | | | | |
| SERENTIL | | | | |
| NOVARTIS | EQ 25MG BASE/ML | | N016997 001 | |
| INJECTABLE;INJECTION | | | | |
| SERENTIL | | | | |
| NOVARTIS | EQ 25MG BASE/ML | | N016775 001 | |
| TABLET;ORAL | | | | |
| SERENTIL | | | | |
| NOVARTIS | EQ 10MG BASE | | N016774 001 | |
| | EQ 25MG BASE | | N016774 002 | |
| | EQ 50MG BASE | | N016774 003 | |
| | EQ 100MG BASE | | N016774 004 | |
| MESTRANOL; NORETHINDRONE | | | | |
| TABLET;ORAL-20 | | | | |
| NORINYL | | | | |
| ACTAVIS LABS UT INC | 0.1MG;2MG | | N013625 004 | |
| TABLET;ORAL-21 | | | | |
| NORETHIN 1/50M-21 | | | | |
| WATSON LABS | 0.05MG;1MG | | A071539 001 | Apr 12, 1988 |
| NORETHINDRONE AND MESTRANOL | | | | |
| WATSON LABS | 0.05MG;1MG | | A070758 001 | Jul 01, 1988 |
| NORINYL 1+50 21-DAY | | | | |
| ACTAVIS LABS UT INC | 0.05MG;1MG | | N013625 002 | |
| NORINYL 1+80 21-DAY | | | | |
| GD SEARLE LLC | 0.08MG;1MG | | N016724 001 | |
| ORTHO-NOVUM 1/50 21 | | | | |
| ORTHO MCNEIL PHARM | 0.05MG;1MG | | N012728 004 | |
| ORTHO-NOVUM 1/80 21 | | | | |
| ORTHO MCNEIL PHARM | 0.08MG;1MG | | N016715 001 | |
| ORTHO-NOVUM 10-21 | | | | |
| ORTHO MCNEIL PHARM | 0.06MG;10MG | | N012728 001 | |

| | | | | |
|---|---|---|---|---|
| MESTRANOL; NORETHINDRONE | | | | |
| TABLET;ORAL-21 | | | | |
| ORTHO-NOVUM 2-21 | | | | |
| | ORTHO MCNEIL PHARM | 0.1MG;2MG | N012728 005 | |
| TABLET;ORAL-28 | | | | |
| NORETHIN 1/50M-28 | | | | |
| | WATSON LABS | 0.05MG;1MG | A071540 001 | Apr 12, 1988 |
| NORETHINDRONE AND MESTRANOL | | | | |
| | WATSON LABS | 0.05MG;1MG | A070759 001 | Jul 01, 1988 |
| NORINYL 1+80 28-DAY | | | | |
| | GD SEARLE LLC | 0.08MG;1MG | N016725 001 | |
| ORTHO-NOVUM 1/50 28 | | | | |
| | ORTHO MCNEIL JANSSEN | 0.05MG;1MG | N016709 001 | |
| ORTHO-NOVUM 1/80 28 | | | | |
| | ORTHO MCNEIL PHARM | 0.08MG;1MG | N016715 002 | |
| MESTRANOL; NORETHYNODREL | | | | |
| TABLET;ORAL | | | | |
| ENOVID | | | | |
| | GD SEARLE LLC | 0.075MG;5MG | N010976 008 | |
| | | 0.15MG;9.85MG | N010976 005 | |
| TABLET;ORAL-20 | | | | |
| ENOVID | | | | |
| | GD SEARLE LLC | 0.075MG;5MG | N010976 004 | |
| ENOVID-E | | | | |
| | GD SEARLE LLC | 0.1MG;2.5MG | N010976 006 | |
| TABLET;ORAL-21 | | | | |
| ENOVID-E 21 | | | | |
| | GD SEARLE LLC | 0.1MG;2.5MG | N010976 007 | |
| METAPROTERENOL SULFATE | | | | |
| AEROSOL, METERED;INHALATION | | | | |
| ALUPENT | | | | |
| | BOEHRINGER INGELHEIM | 0.65MG/INH | N016402 001 | |
| SOLUTION;INHALATION | | | | |
| ALUPENT | | | | |
| | BOEHRINGER INGELHEIM | 0.4% | N018761 002 | Oct 10, 1986 |
| | | 0.6% | N018761 001 | Jun 30, 1983 |
| | | 5% | N017659 001 | |
| METAPROTERENOL SULFATE | | | | |
| | APOTEX INC | 0.4% | A075402 001 | Feb 28, 2001 |
| | | 0.6% | A075403 001 | Feb 28, 2001 |
| | ASTRAZENECA | 0.4% | A071275 001 | Jul 27, 1988 |
| | | 0.6% | A071018 001 | Jul 27, 1988 |
| | DEY | 0.33% | A071806 001 | Aug 05, 1988 |
| | | 0.5% | A071805 001 | Aug 05, 1988 |
| | | 5% | A070805 001 | Aug 17, 1987 |
| | MYLAN SPECIALITY LP | 0.4% | A071786 001 | Aug 05, 1988 |
| | | 0.6% | A070804 001 | Aug 17, 1987 |
| | NEPHRON | 0.4% | A071855 001 | Jul 14, 1988 |
| | | 0.6% | A071726 001 | Jul 14, 1988 |
| | WOCKHARDT | 0.4% | A075586 001 | May 30, 2002 |
| | | 0.6% | A075586 002 | May 30, 2002 |
| | | 5% | A072190 001 | Jun 07, 1988 |
| PROMETA | | | | |
| | MURO | 5% | A073340 001 | Mar 30, 1992 |
| SYRUP;ORAL | | | | |
| ALUPENT | | | | |
| | BOEHRINGER INGELHEIM | 10MG/5ML | N017571 001 | |
| METAPROTERENOL SULFATE | | | | |
| | APOTEX INC | 10MG/5ML | A075235 001 | Jan 27, 2000 |
| | G AND W LABS INC | 10MG/5ML | A072761 001 | Feb 27, 1992 |
| | | 10MG/5ML | A073034 001 | Aug 30, 1991 |
| | MORTON GROVE | 10MG/5ML | A071656 001 | Oct 13, 1987 |
| | WOCKHARDT | 10MG/5ML | A074702 001 | Mar 24, 1997 |
| PROMETA | | | | |
| | MURO | 10MG/5ML | A072023 001 | Sep 15, 1988 |
| TABLET;ORAL | | | | |
| ALUPENT | | | | |
| | BOEHRINGER INGELHEIM | 10MG | N015874 002 | |

| | | | | |
|---|---|---|---|---|
| METAPROTERENOL SULFATE | | | | |
| TABLET;ORAL | | | | |
| ALUPENT | | | | |
| | 20MG | N015874 | 001 | |
| METAPROTERENOL SULFATE | | | | |
| AM THERAP | 10MG | A072054 | 001 | Jun 23, 1988 |
| | 20MG | A072055 | 001 | Jun 23, 1988 |
| TEVA | 10MG | A072519 | 001 | Mar 30, 1990 |
| | 20MG | A072520 | 001 | Mar 30, 1990 |
| USL PHARMA | 10MG | A071013 | 001 | Jan 25, 1988 |
| | 20MG | A071014 | 001 | Jan 25, 1988 |
| WATSON LABS | 10MG | A073013 | 001 | Jan 31, 1991 |
| | 20MG | A072795 | 001 | Jan 31, 1991 |
| METARAMINOL BITARTRATE | | | | |
| INJECTABLE;INJECTION | | | | |
| ARAMINE | | | | |
| + MERCK | EQ 10MG BASE/ML ** | N009509 | 002 | Dec 22, 1987 |
| METARAMINOL BITARTRATE | | | | |
| ABRAXIS PHARM | EQ 10MG BASE/ML | A080431 | 001 | |
| ELKINS SINN | EQ 10MG BASE/ML | A083363 | 001 | |
| GD SEARLE LLC | EQ 10MG BASE/ML | A086418 | 001 | |
| | EQ 20MG BASE/ML | A086418 | 002 | |
| METAXALONE | | | | |
| TABLET;ORAL | | | | |
| METAXALONE | | | | |
| EPIC PHARMA LLC | 640MG | N022503 | 001 | Jun 01, 2015 |
| SKELAXIN | | | | |
| + KING PHARMS | 400MG ** | N013217 | 001 | |
| METFORMIN HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| GLUCOPHAGE | | | | |
| + BRISTOL MYERS SQUIBB | 625MG ** | N020357 | 003 | Nov 05, 1998 |
| + | 750MG ** | N020357 | 004 | Nov 05, 1998 |
| METFORMIN HYDROCHLORIDE | | | | |
| BARR | 500MG | A075971 | 001 | Jan 25, 2002 |
| | 850MG | A075971 | 002 | Jan 25, 2002 |
| | 1GM | A075971 | 003 | Jan 25, 2002 |
| IPCA LABS LTD | 500MG | A078422 | 001 | Aug 06, 2007 |
| | 850MG | A078422 | 002 | Aug 06, 2007 |
| | 1GM | A078422 | 003 | Aug 06, 2007 |
| IVAX SUB TEVA PHARMS | 500MG | A075975 | 001 | Jan 24, 2002 |
| | 625MG | A075975 | 004 | Jan 24, 2002 |
| | 750MG | A075975 | 005 | Jan 24, 2002 |
| | 850MG | A075975 | 002 | Jan 24, 2002 |
| | 1GM | A075975 | 003 | Jan 24, 2002 |
| MYLAN PHARMS INC | 500MG | A075969 | 001 | Jan 29, 2002 |
| | 850MG | A075969 | 002 | Jan 29, 2002 |
| | 1GM | A075969 | 003 | Jan 29, 2002 |
| TEVA | 500MG | A076328 | 001 | Dec 16, 2002 |
| | 850MG | A076328 | 002 | Dec 16, 2002 |
| | 1GM | A076328 | 003 | Dec 16, 2002 |
| WATSON LABS | 500MG | A075979 | 001 | Jan 24, 2002 |
| | 850MG | A075979 | 002 | Jan 24, 2002 |
| | 1GM | A075979 | 003 | Jan 24, 2002 |
| WATSON LABS FLORIDA | 500MG | A075961 | 001 | Jan 25, 2002 |
| | 850MG | A075961 | 002 | Jan 25, 2002 |
| | 1GM | A075961 | 003 | Jan 25, 2002 |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| METFORMIN HYDROCHLORIDE | | | | |
| ACTAVIS ELIZABETH | 500MG | A076450 | 001 | Oct 01, 2004 |
| | 750MG | A076878 | 001 | Apr 13, 2005 |
| BARR | 500MG | A076496 | 001 | Nov 25, 2005 |
| IMPAX LABS | 500MG | A076249 | 001 | Jul 30, 2004 |
| | 750MG | A076985 | 001 | Sep 13, 2005 |
| IVAX SUB TEVA PHARMS | 500MG | A076545 | 001 | Dec 01, 2003 |
| MYLAN | 500MG | A076650 | 001 | Sep 13, 2005 |
| | 750MG | A077113 | 001 | Sep 08, 2005 |
| RANBAXY LABS LTD | 500MG | A076413 | 001 | Jun 18, 2004 |

| | | | | |
|---|---|---|---|---|
| METFORMIN HYDROCHLORIDE | | | | |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| METFORMIN HYDROCHLORIDE | | | | |
| | 750MG | | A077211 001 | Jun 29, 2005 |
| SANDOZ | 500MG | | A076223 001 | Dec 14, 2004 |
| SUN PHARM INDUSTRIES | 500MG | | A077124 001 | Dec 21, 2005 |
| TORRENT PHARMS LTD | 750MG | | A079226 001 | Feb 18, 2010 |
| WATSON LABS INC | 500MG | | A076818 001 | Dec 14, 2004 |
| METFORMIN HYDROCHLORIDE; REPAGLINIDE | | | | |
| TABLET;ORAL | | | | |
| PRANDIMET | | | | |
| + NOVO NORDISK INC | 500MG;1MG | | N022386 001 | Jun 23, 2008 |
| + | 500MG;2MG | | N022386 002 | Jun 23, 2008 |
| METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE | | | | |
| TABLET;ORAL | | | | |
| AVANDAMET | | | | |
| + SB PHARMCO | 500MG;EQ 1MG BASE ** | | N021410 001 | Oct 10, 2002 |
| + | 500MG;EQ 2MG BASE ** | | N021410 002 | Oct 10, 2002 |
| + | 500MG;EQ 4MG BASE ** | | N021410 003 | Oct 10, 2002 |
| + | 1GM;EQ 2MG BASE ** | | N021410 004 | Aug 25, 2003 |
| + | 1GM;EQ 4MG BASE ** | | N021410 005 | Aug 25, 2003 |
| METHACHOLINE CHLORIDE | | | | |
| FOR SOLUTION;INHALATION | | | | |
| PROVOCHOLINE | | | | |
| + METHAPHARM | 1600MG/VIAL | | N019193 002 | Aug 29, 2016 |
| METHACYCLINE HYDROCHLORIDE | | | | |
| CAPSULE;ORAL | | | | |
| RONDOMYCIN | | | | |
| MEDPOINTE PHARM HLC | EQ 140MG BASE | | A060641 001 | |
| | EQ 280MG BASE | | A060641 002 | |
| SYRUP;ORAL | | | | |
| RONDOMYCIN | | | | |
| MEDPOINTE PHARM HLC | EQ 70MG BASE/5ML | | A060641 003 | |
| METHADONE HYDROCHLORIDE | | | | |
| POWDER;FOR RX COMPOUNDING | | | | |
| METHADONE HYDROCHLORIDE | | | | |
| MALLINCKRODT INC | 50GM/BOT | | N006383 002 | |
| | 100GM/BOT | | N006383 003 | |
| | 500GM/BOT | | N006383 004 | |
| SYRUP;ORAL | | | | |
| DOLOPHINE HYDROCHLORIDE | | | | |
| WEST-WARD PHARMS INT | 10MG/30ML | | N006134 004 | |
| TABLET;ORAL | | | | |
| METHADONE HYDROCHLORIDE | | | | |
| ROXANE | 5MG | | A088108 001 | Mar 08, 1983 |
| | 10MG | | A088109 001 | Mar 08, 1983 |
| | 40MG | | A074081 001 | Apr 28, 1995 |
| SANDOZ | 5MG | | A040241 001 | May 29, 1998 |
| TABLET, DISPERSIBLE;ORAL | | | | |
| WESTADONE | | | | |
| SANDOZ | 2.5MG | | N017108 001 | |
| TABLET, EFFERVESCENT;ORAL | | | | |
| WESTADONE | | | | |
| SANDOZ | 5MG | | N017108 002 | |
| | 10MG | | N017108 003 | |
| | 40MG | | N017108 004 | |
| METHAMPHETAMINE HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| METHAMPEX | | | | |
| TEVA | 10MG | | A083889 001 | |
| METHAMPHETAMINE HYDROCHLORIDE | | | | |
| ABLE | 5MG | | A040529 001 | Feb 25, 2004 |
| REXAR | 5MG | | A084931 001 | |
| | 10MG | | A084931 002 | |
| TEVA | 5MG | | A086359 001 | |

| | | | | |
|---|---|---|---|---|
| METHAMPHETAMINE HYDROCHLORIDE | | | | |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| DESOXYN | | | | |
| | RECORDATI RARE | 5MG | N005378 004 | |
| | | 10MG | N005378 003 | |
| | | 15MG | N005378 005 | |
| METHANTHELINE BROMIDE | | | | |
| TABLET;ORAL | | | | |
| BANTHINE | | | | |
| | SHIRE | 50MG | N007390 001 | |
| METHARBITAL | | | | |
| TABLET;ORAL | | | | |
| GEMONIL | | | | |
| | ABBVIE | 100MG | N008322 001 | |
| METHAZOLAMIDE | | | | |
| TABLET;ORAL | | | | |
| METHAZOLAMIDE | | | | |
| | APPLIED ANAL | 25MG | A040011 001 | Jul 17, 1997 |
| | | 50MG | A040011 002 | Jul 17, 1997 |
| | SANDOZ | 25MG | A040102 001 | Aug 28, 1996 |
| | | 50MG | A040102 002 | Aug 28, 1996 |
| NEPTAZANE | | | | |
| + | LEDERLE | 25MG ** | N011721 002 | Nov 25, 1991 |
| + | | 50MG ** | N011721 001 | |
| METHDILAZINE | | | | |
| TABLET, CHEWABLE;ORAL | | | | |
| TACARYL | | | | |
| | WESTWOOD SQUIBB | 3.6MG | N011950 009 | |
| METHDILAZINE HYDROCHLORIDE | | | | |
| SYRUP;ORAL | | | | |
| METHDILAZINE HYDROCHLORIDE | | | | |
| | ALPHARMA US PHARMS | 4MG/5ML | A087122 001 | |
| TACARYL | | | | |
| | WESTWOOD SQUIBB | 4MG/5ML | N011950 007 | |
| TABLET;ORAL | | | | |
| TACARYL | | | | |
| | WESTWOOD SQUIBB | 8MG | N011950 006 | |
| METHICILLIN SODIUM | | | | |
| INJECTABLE;INJECTION | | | | |
| STAPHCILLIN | | | | |
| | APOTHECON | EQ 900MG BASE/VIAL | A061449 001 | |
| | | EQ 900MG BASE/VIAL | N050117 001 | |
| | | EQ 3.6GM BASE/VIAL | A061449 002 | |
| | | EQ 3.6GM BASE/VIAL | N050117 002 | |
| | | EQ 5.4GM BASE/VIAL | A061449 003 | |
| | | EQ 5.4GM BASE/VIAL | N050117 003 | |
| METHIMAZOLE | | | | |
| TABLET;ORAL | | | | |
| METHIMAZOLE | | | | |
| | ECI PHARMS LLC | 15MG | A040619 003 | Jul 12, 2005 |
| | | 20MG | A040547 004 | Feb 18, 2005 |
| | MYLAN | 20MG | A040350 003 | Jun 07, 2001 |
| TAPAZOLE | | | | |
| + | KING PHARMS | 5MG ** | N007517 002 | |
| + | | 10MG ** | N007517 004 | |
| METHIXENE HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| TREST | | | | |
| | NOVARTIS | 1MG | N013420 001 | |

| | | | | |
|---|---|---|---|---|
| METHOCARBAMOL | | | | |
| INJECTABLE;INJECTION | | | | |
| METHOCARBAMOL | | | | |
| MARSAM PHARMS LLC | 100MG/ML | A089849 | 001 | Dec 27, 1991 |
| WATSON LABS | 100MG/ML | A086459 | 001 | |
| TABLET;ORAL | | | | |
| DELAXIN | | | | |
| FERNDALE LABS | 500MG | A085454 | 001 | |
| FORBAXIN | | | | |
| FOREST LABS | 750MG | A085136 | 001 | |
| METHOCARBAMOL | | | | |
| ABLE | 500MG | A040413 | 001 | Mar 17, 2003 |
| | 750MG | A040413 | 002 | Mar 17, 2003 |
| AM THERAP | 500MG | A089417 | 001 | Feb 11, 1987 |
| | 750MG | A089418 | 001 | Feb 11, 1987 |
| ASCOT | 500MG | A087660 | 001 | Oct 27, 1982 |
| | 750MG | A087661 | 001 | Oct 27, 1982 |
| CLONMEL HLTHCARE | 500MG | A085961 | 001 | |
| | 750MG | A085963 | 001 | |
| HEATHER | 500MG | A084675 | 001 | |
| | 750MG | A084924 | 001 | |
| IMPAX LABS | 500MG | A084927 | 001 | |
| | 750MG | A084928 | 001 | |
| INWOOD LABS | 500MG | A085137 | 001 | |
| IVAX SUB TEVA PHARMS | 500MG | A084648 | 001 | |
| | 750MG | A084649 | 001 | |
| KV PHARM | 500MG | A085660 | 001 | |
| | 750MG | A085658 | 001 | |
| LANNETT HOLDINGS INC | 500MG | A084756 | 002 | Mar 31, 2003 |
| | 750MG | A084756 | 001 | |
| MYLAN | 500MG | A084259 | 001 | |
| | 750MG | A084323 | 001 | |
| NYLOS | 750MG | A085033 | 001 | |
| PIONEER PHARMS | 500MG | A088731 | 001 | Dec 13, 1985 |
| | 750MG | A089082 | 001 | Dec 13, 1985 |
| PURACAP PHARM | 500MG | A084231 | 002 | |
| | 750MG | A084471 | 001 | |
| PUREPAC PHARM | 500MG | A085718 | 001 | |
| | 750MG | A085718 | 002 | |
| ROXANE | 500MG | A088646 | 001 | Feb 29, 1984 |
| | 750MG | A088647 | 001 | Feb 29, 1984 |
| SANDOZ | 500MG | A084616 | 001 | |
| | 500MG | A087283 | 001 | |
| | 750MG | A084615 | 001 | |
| | 750MG | A087282 | 001 | |
| SOLVAY | 500MG | A084448 | 001 | |
| | 750MG | A084449 | 001 | |
| SUN PHARM INDUSTRIES | 500MG | A084488 | 001 | |
| | 750MG | A084486 | 001 | |
| SUPERPHARM | 500MG | A087589 | 001 | Jan 22, 1982 |
| | 750MG | A087590 | 001 | Jan 22, 1982 |
| TABLICAPS | 500MG | A084846 | 001 | |
| UPSHER SMITH | 500MG | A087453 | 001 | |
| | 750MG | A087454 | 001 | |
| WATSON LABS | 500MG | A083605 | 001 | |
| | 500MG | A085180 | 001 | |
| | 750MG | A083605 | 002 | |
| | 750MG | A085192 | 001 | |
| METHOHEXITAL SODIUM | | | | |
| INJECTABLE;INJECTION | | | | |
| BREVITAL SODIUM | | | | |
| PAR STERILE PRODUCTS | 200MG/VIAL | N011559 | 004 | Dec 21, 2012 |
| | 5GM/VIAL | N011559 | 003 | |

| | | | | | |
|---|---|---|---|---|---|
| METHOTREXATE | | | | | |
| SOLUTION;SUBCUTANEOUS | | | | | |
| OTREXUP | | | | | |
| + | ANTARES PHARMA INC | 7.5MG/0.4ML (7.5MG/0.4ML) | N204824 | 005 | Nov 07, 2014 |
| OTREXUP PFS | | | | | |
| + | ANTARES PHARMA INC | 10MG/0.4ML (10MG/0.4ML) | N204824 | 009 | May 31, 2017 |
| + | | 15MG/0.6ML (15MG/0.6ML) | N204824 | 010 | May 31, 2017 |
| + | | 17.5MG/0.7ML (17.5MG/0.7ML) | N204824 | 011 | May 31, 2017 |
| + | | 20MG/0.8ML (20MG/0.8ML) | N204824 | 012 | May 31, 2017 |
| + | | 22.5MG/0.9ML (22.5MG/0.9ML) | N204824 | 013 | May 31, 2017 |
| + | | 25MG/ML (25MG/ML) | N204824 | 014 | May 31, 2017 |
| RASUVO | | | | | |
| + | MEDAC PHARMA INC | 27.5MG/0.55ML (27.5MG/0.55ML) | N205776 | 009 | Jul 10, 2014 |
| METHOTREXATE SODIUM | | | | | |
| INJECTABLE;INJECTION | | | | | |
| ABITREXATE | | | | | |
| | ABIC | EQ 25MG BASE/ML | A089161 | 001 | Mar 10, 1987 |
| | | EQ 50MG BASE/VIAL | A089354 | 001 | Jul 17, 1987 |
| | | EQ 100MG BASE/VIAL | A089355 | 001 | Jul 17, 1987 |
| | | EQ 250MG BASE/VIAL | A089356 | 001 | Jul 17, 1987 |
| FOLEX | | | | | |
| | PHARMACIA AND UPJOHN | EQ 25MG BASE/VIAL | A087695 | 001 | Apr 08, 1983 |
| | | EQ 50MG BASE/VIAL | A087695 | 002 | Apr 08, 1983 |
| | | EQ 100MG BASE/VIAL | A087695 | 003 | Apr 08, 1983 |
| | | EQ 250MG BASE/VIAL | A088954 | 001 | Oct 24, 1985 |
| FOLEX PFS | | | | | |
| | PHARMACIA AND UPJOHN | EQ 25MG BASE/ML | A081242 | 001 | Aug 23, 1991 |
| | | EQ 25MG BASE/ML | A089180 | 001 | Jan 03, 1986 |
| METHOTREXATE LPF | | | | | |
| | HOSPIRA | EQ 25MG BASE/ML | N011719 | 007 | Mar 31, 1982 |
| METHOTREXATE PRESERVATIVE FREE | | | | | |
| | HOSPIRA | EQ 20MG BASE/2ML (EQ 10MG BASE/ML) | N011719 | 014 | Apr 13, 2005 |
| + | | EQ 500MG BASE/20ML (EQ 25MG BASE/ML) ** | N011719 | 013 | Apr 13, 2005 |
| | | EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML) | N011719 | 011 | Apr 13, 2005 |
| METHOTREXATE SODIUM | | | | | |
| | ABRAXIS PHARM | EQ 2.5MG BASE/ML | A089323 | 001 | Jun 13, 1986 |
| | | EQ 20MG BASE/VIAL | A088935 | 001 | Oct 11, 1985 |
| | | EQ 25MG BASE/ML | A089263 | 001 | Jun 13, 1986 |
| | | EQ 25MG BASE/ML | A089322 | 001 | Jun 13, 1986 |
| | | EQ 50MG BASE/VIAL | A088936 | 001 | Oct 11, 1985 |
| | | EQ 100MG BASE/VIAL | A088937 | 001 | Oct 11, 1985 |
| | HOSPIRA | EQ 2.5MG BASE/ML | N011719 | 004 | |
| | | EQ 20MG BASE/VIAL | N011719 | 001 | |
| | | EQ 25MG BASE/ML | N011719 | 005 | |
| | | EQ 50MG BASE/VIAL | N011719 | 003 | |
| | | EQ 100MG BASE/VIAL | N011719 | 006 | |
| | NORBROOK | EQ 25MG BASE/ML | A088648 | 001 | May 09, 1986 |
| | PHARMACHEMIE USA | EQ 25MG BASE/ML | A089158 | 001 | Jul 08, 1988 |
| METHOTREXATE SODIUM PRESERVATIVE FREE | | | | | |
| | HOSPIRA | EQ 1GM BASE/VIAL | N011719 | 009 | Apr 07, 1988 |
| MEXATE | | | | | |
| | BRISTOL | EQ 20MG BASE/VIAL | A086358 | 001 | |
| | | EQ 50MG BASE/VIAL | A086358 | 002 | |
| | | EQ 100MG BASE/VIAL | A086358 | 003 | |
| | | EQ 250MG BASE/VIAL | A086358 | 004 | |
| MEXATE-AQ | | | | | |
| | BRISTOL MYERS | EQ 25MG BASE/ML | A088760 | 001 | Feb 14, 1985 |
| MEXATE-AQ PRESERVED | | | | | |
| | BRISTOL MYERS SQUIBB | EQ 25MG BASE/ML | A089887 | 001 | Apr 14, 1989 |
| TABLET;ORAL | | | | | |
| METHOTREXATE SODIUM | | | | | |
| | DURAMED PHARMS BARR | EQ 2.5MG BASE | A040233 | 001 | Jun 17, 1999 |

| | | | | |
|---|---|---|---|---|
| METHOXAMINE HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| VASOXYL | | | | |
| GLAXOSMITHKLINE | 10MG/ML | N006772 | 002 | |
| | 20MG/ML | N006772 | 001 | |
| METHOXSALEN | | | | |
| CAPSULE;ORAL | | | | |
| 8-MOP | | | | |
| + VALEANT PHARM INTL | 10MG | N009048 | 001 | |
| METHOXSALEN | | | | |
| IDT AUSTRALIA LTD | 10MG | A087781 | 001 | Jun 08, 1982 |
| LOTION;TOPICAL | | | | |
| OXSORALEN | | | | |
| + VALEANT PHARM INTL | 1% | N009048 | 002 | |
| METHSCOPOLAMINE BROMIDE | | | | |
| TABLET;ORAL | | | | |
| METHSCOPOLAMINE BROMIDE | | | | |
| PVT FORM | 2.5MG | A080970 | 001 | |
| PAMINE | | | | |
| FOUGERA PHARMS | 2.5MG ** | N008848 | 001 | |
| PAMINE FORTE | | | | |
| FOUGERA PHARMS | 5MG ** | N008848 | 002 | Mar 25, 2003 |
| METHYCLOTHIAZIDE | | | | |
| TABLET;ORAL | | | | |
| AQUATENSEN | | | | |
| MEDPOINTE PHARM HLC | 5MG | N017364 | 001 | |
| ENDURON | | | | |
| + ABBVIE | 2.5MG ** | N012524 | 001 | |
| + | 5MG ** | N012524 | 004 | |
| METHYCLOTHIAZIDE | | | | |
| FOSUN PHARMA | 2.5MG | A089835 | 001 | Aug 18, 1988 |
| | 5MG | A089837 | 001 | Aug 18, 1988 |
| IVAX PHARMS | 2.5MG | A087913 | 001 | Jun 03, 1982 |
| | 5MG | A087786 | 001 | May 18, 1982 |
| MYLAN | 2.5MG | A087671 | 001 | Aug 17, 1982 |
| PAR PHARM | 2.5MG | A089135 | 001 | Feb 12, 1986 |
| | 5MG | A089136 | 001 | Feb 12, 1986 |
| USL PHARMA | 5MG | A088745 | 001 | Mar 21, 1985 |
| WATSON LABS | 2.5MG | A085487 | 001 | Mar 11, 1982 |
| | 2.5MG | A088750 | 001 | Sep 06, 1984 |
| | 5MG | A085476 | 001 | Mar 11, 1982 |
| | 5MG | A088724 | 001 | Sep 06, 1984 |
| METHYCLOTHIAZIDE; PARGYLINE HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| EUTRON | | | | |
| ABBOTT | 5MG;25MG | N016047 | 001 | |
| METHYCLOTHIAZIDE; RESERPINE | | | | |
| TABLET;ORAL | | | | |
| DIUTENSEN-R | | | | |
| MEDPOINTE PHARM HLC | 2.5MG;0.1MG | N012708 | 005 | |
| METHYL AMINOLEVULINATE HYDROCHLORIDE | | | | |
| CREAM;TOPICAL | | | | |
| METVIXIA | | | | |
| GALDERMA LABS LP | EQ 16.8% BASE | N021415 | 001 | Jul 27, 2004 |
| METHYLDOPA | | | | |
| SUSPENSION;ORAL | | | | |
| ALDOMET | | | | |
| MERCK | 250MG/5ML | N018389 | 001 | |
| TABLET;ORAL | | | | |
| ALDOMET | | | | |
| + MERCK | 125MG ** | N013400 | 003 | |
| + | 250MG ** | N013400 | 001 | |
| + | 500MG ** | N013400 | 002 | |
| METHYLDOPA | | | | |
| ACCORD HLTHCARE | 125MG | A070070 | 003 | Oct 15, 1985 |
| DURAMED PHARMS BARR | 250MG | A071006 | 001 | Dec 16, 1986 |

METHYLDOPA

TABLET;ORAL

METHYLDOPA

| | | | | |
|---|---|---|---|---|
| | 500MG | A071009 | 001 | Dec 16, 1986 |
| FOSUN PHARMA | 250MG | N018934 | 001 | Jun 29, 1984 |
| | 500MG | N018934 | 002 | Jun 29, 1984 |
| HALSEY | 125MG | A071751 | 001 | Mar 28, 1988 |
| | 250MG | A071752 | 001 | Mar 28, 1988 |
| | 500MG | A071753 | 001 | Mar 28, 1988 |
| PAR PHARM | 125MG | A070535 | 001 | Jan 02, 1987 |
| | 250MG | A070536 | 001 | Jan 02, 1987 |
| | 500MG | A070537 | 001 | Jan 02, 1987 |
| PARKE DAVIS | 125MG | A070331 | 001 | Apr 15, 1986 |
| | 250MG | A070332 | 001 | Apr 15, 1986 |
| | 500MG | A070333 | 001 | Apr 15, 1986 |
| PLIVA | 125MG | A072126 | 001 | Jul 07, 1988 |
| | 250MG | A072127 | 001 | Jul 07, 1988 |
| | 500MG | A072128 | 001 | Jul 07, 1988 |
| PUREPAC PHARM | 125MG | A070749 | 001 | Feb 07, 1986 |
| | 250MG | A070750 | 001 | Feb 07, 1986 |
| | 500MG | A070452 | 001 | Feb 07, 1986 |
| ROXANE | 125MG | A070192 | 001 | Apr 25, 1986 |
| | 250MG | A070193 | 001 | Apr 25, 1986 |
| | 500MG | A070194 | 001 | Apr 25, 1986 |
| SANDOZ | 125MG | A071700 | 001 | Mar 02, 1988 |
| SUN PHARM INDUSTRIES | 125MG | A070073 | 001 | Oct 09, 1986 |
| | 250MG | A070060 | 001 | Oct 09, 1986 |
| | 500MG | A070074 | 001 | Oct 09, 1986 |
| SUPERPHARM | 250MG | A070669 | 001 | Jun 23, 1989 |
| | 500MG | A070670 | 001 | Jun 23, 1989 |
| TEVA | 125MG | A071105 | 001 | Dec 05, 1986 |
| | 250MG | A071106 | 001 | Dec 05, 1986 |
| | 500MG | A071067 | 001 | Dec 05, 1986 |
| WATSON LABS | 125MG | A070245 | 001 | Feb 25, 1986 |
| | 125MG | A070260 | 001 | Jun 24, 1985 |
| | 250MG | A070246 | 001 | Feb 25, 1986 |
| | 250MG | A070261 | 001 | Jun 24, 1985 |
| | 250MG | A070703 | 001 | Jun 06, 1986 |
| | 500MG | A070247 | 001 | Feb 25, 1986 |
| | 500MG | A070262 | 001 | Jun 24, 1985 |

METHYLDOPATE HYDROCHLORIDE

INJECTABLE;INJECTION

ALDOMET

| | | | | |
|---|---|---|---|---|
| + MERCK | 50MG/ML ** | N013401 | 001 | |

METHYLDOPATE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| ABRAXIS PHARM | 50MG/ML | A070652 | 001 | Jun 03, 1986 |
| BAXTER HLTHCARE | 50MG/ML | A070291 | 001 | Jul 01, 1986 |
| HOSPIRA | 50MG/ML | A070691 | 001 | Jun 19, 1987 |
| | 50MG/ML | A070698 | 001 | Jun 15, 1987 |
| | 50MG/ML | A070699 | 001 | Jun 15, 1987 |
| | 50MG/ML | A070849 | 001 | Jun 19, 1987 |
| MARSAM PHARMS LLC | 50MG/ML | A071812 | 001 | Dec 22, 1987 |
| SMITH AND NEPHEW | 50MG/ML | A070841 | 001 | Jan 02, 1987 |
| TEVA PARENTERAL | 50MG/ML | A072974 | 001 | Nov 22, 1991 |

METHYLERGONOVINE MALEATE

TABLET;ORAL

METHERGINE

| | | | | |
|---|---|---|---|---|
| + EDISON THERAPS LLC | 0.2MG ** | N006035 | 003 | |

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

RITALIN LA

| | | | | |
|---|---|---|---|---|
| + NOVARTIS | 60MG ** | N021284 | 005 | Oct 27, 2014 |

TABLET;ORAL

METHYLPHENIDATE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| ABLE | 5MG | A040404 | 001 | Mar 29, 2001 |
| | 10MG | A040404 | 002 | Mar 29, 2001 |
| | 20MG | A040404 | 003 | Mar 29, 2001 |
| ACTAVIS ELIZABETH | 5MG | A040321 | 001 | Feb 05, 2002 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| METHYLPHENIDATE HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| METHYLPHENIDATE HYDROCHLORIDE | | | | |
| | | 10MG | A040321 002 | Feb 05, 2002 |
| | | 20MG | A040321 003 | Feb 05, 2002 |
| TABLET, CHEWABLE;ORAL | | | | |
| METHYLIN | | | | |
| + | SPECGX LLC | 2.5MG ** | N021475 001 | Apr 15, 2003 |
| + | | 5MG ** | N021475 002 | Apr 15, 2003 |
| + | | 10MG ** | N021475 003 | Apr 15, 2003 |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| METADATE ER | | | | |
| | UCB INC | 10MG | A040306 001 | Oct 20, 1999 |
| METHYLPHENIDATE HYDROCHLORIDE | | | | |
| | ABLE | 20MG | A076032 001 | May 09, 2001 |
| | ACTAVIS ELIZABETH | 20MG | A075450 001 | Dec 21, 2001 |
| | WATSON LABS | 20MG | A040410 001 | Feb 09, 2001 |
| METHYLPREDNISOLONE | | | | |
| TABLET;ORAL | | | | |
| MEDROL | | | | |
| | PHARMACIA AND UPJOHN | 24MG | N011153 005 | |
| METHYLPREDNISOLONE | | | | |
| | HEATHER | 4MG | A085650 001 | |
| | PAR PHARM | 16MG | A089207 001 | Apr 25, 1988 |
| | | 24MG | A089208 001 | Apr 25, 1988 |
| | | 32MG | A089209 001 | Apr 25, 1988 |
| | SANDOZ | 4MG | A087341 001 | |
| | WATSON LABS | 4MG | A086161 001 | Feb 09, 1982 |
| | | 16MG | A086159 001 | Feb 09, 1982 |
| METHYLPREDNISOLONE ACETATE | | | | |
| ENEMA;RECTAL | | | | |
| MEDROL | | | | |
| | PHARMACIA AND UPJOHN | 40MG/BOT | N018102 001 | |
| INJECTABLE;INJECTION | | | | |
| M-PREDROL | | | | |
| | BEL MAR | 40MG/ML | A086666 001 | |
| | | 80MG/ML | A087135 001 | |
| METHYLPREDNISOLONE ACETATE | | | | |
| | AKORN | 40MG/ML | A086903 001 | Oct 20, 1982 |
| | | 80MG/ML | A086903 002 | Oct 20, 1982 |
| | WATSON LABS | 20MG/ML | A085597 001 | |
| | | 20MG/ML | A087248 001 | |
| | | 40MG/ML | A085374 001 | |
| | | 40MG/ML | A085600 001 | |
| | | 80MG/ML | A085595 001 | |
| | | 80MG/ML | A086507 001 | |
| OINTMENT;TOPICAL | | | | |
| MEDROL ACETATE | | | | |
| | PHARMACIA AND UPJOHN | 0.25% | N012421 001 | |
| | | 1% | N012421 002 | |
| METHYLPREDNISOLONE ACETATE; NEOMYCIN SULFATE | | | | |
| CREAM;TOPICAL | | | | |
| NEO-MEDROL ACETATE | | | | |
| | PHARMACIA AND UPJOHN | 0.25%;EQ 3.5MG BASE/GM | A060611 002 | |
| | | 1%;EQ 3.5MG BASE/GM | A060611 001 | |
| METHYLPREDNISOLONE SODIUM SUCCINATE | | | | |
| INJECTABLE;INJECTION | | | | |
| A-METHAPRED | | | | |
| | ABBOTT | EQ 40MG BASE/VIAL | A089573 001 | Feb 22, 1991 |
| | | EQ 125MG BASE/VIAL | A089574 001 | Feb 22, 1991 |
| | | EQ 500MG BASE/VIAL | A089575 001 | Feb 22, 1991 |
| | | EQ 1GM BASE/VIAL | A089576 001 | Feb 22, 1991 |
| | HOSPIRA | EQ 40MG BASE/VIAL | A085853 001 | |
| | | EQ 125MG BASE/VIAL | A085855 001 | |
| | | EQ 500MG BASE/VIAL | A085854 001 | |
| | | EQ 500MG BASE/VIAL | A089173 001 | Aug 18, 1987 |
| | | EQ 1GM BASE/VIAL | A085852 001 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| METHYLPREDNISOLONE SODIUM SUCCINATE | | | | |
| INJECTABLE;INJECTION | | | | |
| A-METHAPRED | | | | |
| | EQ 1GM BASE/VIAL | A089174 | 001 | Aug 18, 1987 |
| HOSPIRA INC | EQ 40MG BASE/VIAL | A040793 | 001 | Nov 25, 2008 |
| | EQ 125MG BASE/VIAL | A040827 | 001 | Nov 25, 2008 |
| METHYLPREDNISOLONE | | | | |
| ELKINS SINN | EQ 125MG BASE/VIAL | A086906 | 002 | |
| | EQ 500MG BASE/VIAL | A086906 | 003 | |
| | EQ 1GM BASE/VIAL | A086906 | 004 | |
| ORGANON USA INC | EQ 500MG BASE/VIAL | A087535 | 001 | Jun 25, 1982 |
| | EQ 1GM BASE/VIAL | A087535 | 002 | Jun 25, 1982 |
| METHYLPREDNISOLONE SODIUM SUCCINATE | | | | |
| ABRAXIS PHARM | EQ 40MG BASE/VIAL | A088676 | 001 | Jun 08, 1984 |
| | EQ 40MG BASE/VIAL | A089143 | 001 | Mar 28, 1986 |
| | EQ 125MG BASE/VIAL | A088677 | 001 | Jun 08, 1984 |
| | EQ 125MG BASE/VIAL | A089144 | 001 | Mar 28, 1986 |
| | EQ 500MG BASE/VIAL | A088678 | 001 | Jun 08, 1984 |
| | EQ 500MG BASE/VIAL | A089186 | 001 | Mar 28, 1986 |
| | EQ 500MG BASE/VIAL | A089187 | 001 | Mar 28, 1986 |
| | EQ 1GM BASE/VIAL | A088679 | 001 | Jun 08, 1984 |
| | EQ 1GM BASE/VIAL | A089188 | 001 | Mar 28, 1986 |
| | EQ 1GM BASE/VIAL | A089189 | 001 | Mar 28, 1986 |
| BEDFORD LABS | EQ 40MG BASE/VIAL | A040662 | 001 | Feb 21, 2007 |
| | EQ 125MG BASE/VIAL | A040641 | 002 | Feb 21, 2007 |
| | EQ 500MG BASE/VIAL | A040641 | 003 | Feb 21, 2007 |
| | EQ 500MG BASE/VIAL | A040709 | 001 | Feb 21, 2007 |
| | EQ 1GM BASE/VIAL | A040641 | 004 | Feb 21, 2007 |
| | EQ 1GM BASE/VIAL | A040709 | 002 | Feb 21, 2007 |
| ELKINS SINN | EQ 40MG BASE/VIAL | A086906 | 001 | |
| INTL MEDICATION | EQ 40MG BASE/VIAL | A087812 | 001 | Feb 09, 1983 |
| | EQ 125MG BASE/VIAL | A087813 | 001 | Feb 09, 1983 |
| | EQ 500MG BASE/VIAL | A087851 | 001 | Feb 09, 1983 |
| | EQ 1GM BASE/VIAL | A087852 | 001 | Feb 09, 1983 |
| TEVA PARENTERAL | EQ 125MG BASE/VIAL | A081266 | 001 | Nov 30, 1992 |
| | EQ 500MG BASE/VIAL | A081267 | 001 | Nov 30, 1992 |
| | EQ 1GM BASE/VIAL | A081268 | 001 | Nov 30, 1992 |
| WATSON LABS | EQ 40MG BASE/VIAL | A086953 | 001 | Jul 22, 1982 |
| | EQ 125MG BASE/VIAL | A087030 | 001 | Jul 22, 1982 |
| | EQ 500MG BASE/VIAL | A088523 | 001 | Jul 24, 1984 |
| | EQ 1GM BASE/VIAL | A088524 | 001 | Jul 24, 1984 |
| METHYLPREDNISOLONE; NEOMYCIN SULFATE | | | | |
| OINTMENT;OPHTHALMIC | | | | |
| NEO-MEDROL | | | | |
| PHARMACIA AND UPJOHN | 0.1%;EQ 3.5MG BASE/GM | A060645 | 001 | |
| METHYLTESTOSTERONE | | | | |
| CAPSULE;ORAL | | | | |
| METHYLTESTOSTERONE | | | | |
| HEATHER | 10MG | A084967 | 001 | |
| VIRILON | | | | |
| STAR PHARMS FL | 10MG | A087750 | 001 | Nov 24, 1982 |
| TABLET;BUCCAL | | | | |
| ANDROID 5 | | | | |
| VALEANT PHARM INTL | 5MG | A087222 | 001 | |
| ORETON | | | | |
| SCHERING | 10MG | A080281 | 001 | |
| TABLET;BUCCAL, SUBLINGUAL | | | | |
| METANDREN | | | | |
| NOVARTIS | 5MG | N003240 | 004 | |
| | 10MG | N003240 | 001 | |
| | 10MG | N003240 | 005 | |
| | 25MG | N003240 | 003 | |
| METHYLTESTOSTERONE | | | | |
| IMPAX LABS | 10MG | A084287 | 001 | |
| LILLY | 10MG | A080256 | 001 | |
| | 25MG | A080256 | 002 | |
| PUREPAC PHARM | 10MG | A080308 | 001 | |
| | 10MG | A080475 | 001 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| METHYLTESTOSTERONE | | | | |
| TABLET;BUCCAL, SUBLINGUAL | | | | |
| METHYLTESTOSTERONE | | | | |
| | 10MG | | A080475 002 | |
| | 25MG | | A080475 003 | |
| PVT FORM | 5MG | | A083836 001 | |
| TABLICAPS | 10MG | | A085125 001 | |
| USL PHARMA | 10MG | | A080271 001 | |
| TABLET;ORAL | | | | |
| ANDROID 10 | | | | |
| VALEANT PHARMS NORTH | 10MG | | A086450 001 | |
| METHYLTESTOSTERONE | | | | |
| IMPAX LABS | 25MG | | A084310 001 | |
| INWOOD LABS | 10MG | | A080839 001 | |
| | 25MG | | A080973 001 | |
| KV PHARM | 10MG | | A084312 001 | |
| LANNETT | 10MG | | A087092 001 | Nov 05, 1982 |
| | 25MG | | A087111 001 | Jan 27, 1983 |
| PARKE DAVIS | 10MG | | A084244 001 | |
| | 25MG | | A084241 001 | |
| PUREPAC PHARM | 10MG | | A080309 001 | |
| | 25MG | | A080310 001 | |
| PVT FORM | 5MG | | A080214 001 | |
| | 10MG | | A080214 002 | |
| | 25MG | | A080214 003 | |
| TABLICAPS | 10MG | | A080313 001 | |
| | 25MG | | A085270 001 | |
| WATSON LABS | 10MG | | A080933 001 | |
| | 25MG | | A080931 001 | |
| WEST WARD | 10MG | | A084331 001 | |
| | 25MG | | A084331 002 | |
| | 25MG | | A084642 001 | |
| ORETON METHYL | | | | |
| SCHERING | 10MG | | N003158 001 | |
| | 25MG | | N003158 002 | |
| METHYPRYLON | | | | |
| CAPSULE;ORAL | | | | |
| NOLUDAR | | | | |
| ROCHE | 300MG | | N009660 008 | |
| ELIXIR;ORAL | | | | |
| NOLUDAR | | | | |
| ROCHE | 50MG/5ML | | N009660 007 | |
| TABLET;ORAL | | | | |
| NOLUDAR | | | | |
| ROCHE | 50MG | | N009660 002 | |
| | 200MG | | N009660 004 | |
| METHYSERGIDE MALEATE | | | | |
| TABLET;ORAL | | | | |
| SANSERT | | | | |
| NOVARTIS | 2MG | | N012516 001 | |
| METOCLOPRAMIDE HYDROCHLORIDE | | | | |
| CONCENTRATE;ORAL | | | | |
| METOCLOPRAMIDE INTENSOL | | | | |
| ROXANE | EQ 10MG BASE/ML | | A072995 001 | Jan 30, 1992 |
| INJECTABLE;INJECTION | | | | |
| METOCLOPRAMIDE HYDROCHLORIDE | | | | |
| BEDFORD | EQ 5MG BASE/ML | | A072155 001 | Mar 30, 1992 |
| | EQ 5MG BASE/ML | | A072244 001 | Mar 30, 1992 |
| | EQ 5MG BASE/ML | | A072247 001 | May 18, 1992 |
| HOSPIRA | EQ 5MG BASE/ML | | A070505 001 | Jun 23, 1989 |
| | EQ 5MG BASE/ML | | A070506 001 | Jun 22, 1989 |
| | EQ 5MG BASE/ML | | A070847 001 | Nov 07, 1988 |
| | EQ 5MG BASE/ML | | A071291 001 | Mar 03, 1989 |
| | EQ 5MG BASE/ML | | A071990 001 | Jan 18, 1989 |
| | EQ 5MG BASE/ML | | A073117 001 | Jan 17, 1991 |
| | EQ 5MG BASE/ML | | A074147 001 | Aug 02, 1996 |
| LYPHOMED | EQ 10MG BASE/2ML | | A070293 001 | Jan 24, 1986 |
| NORBROOK | EQ 10MG BASE/2ML | | A070892 001 | Aug 26, 1988 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| METOCLOPRAMIDE HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| METOCLOPRAMIDE HYDROCHLORIDE | | | | |
| SMITH AND NEPHEW | EQ 5MG BASE/ML | A070623 | 001 | Mar 02, 1987 |
| | EQ 10MG BASE/2ML | A070622 | 001 | Mar 02, 1987 |
| REGLAN | | | | |
| WEST-WARD PHARMS INT | EQ 5MG BASE/ML | N017862 | 001 | |
| | EQ 10MG BASE/ML | N017862 | 004 | May 28, 1987 |
| SOLUTION;ORAL | | | | |
| METOCLOPRAMIDE HYDROCHLORIDE | | | | |
| ACTAVIS MID ATLANTIC | EQ 5MG BASE/5ML | A071340 | 001 | Aug 18, 1988 |
| MORTON GROVE | EQ 5MG BASE/5ML | A070949 | 001 | Mar 06, 1987 |
| PACO | EQ 5MG BASE/5ML | A071665 | 001 | Dec 05, 1988 |
| ROXANE | EQ 5MG BASE/5ML | A072038 | 001 | Dec 05, 1988 |
| SILARX | EQ 5MG BASE/5ML | A073680 | 001 | Oct 27, 1992 |
| TEVA | EQ 5MG BASE/5ML | A070819 | 001 | Jul 10, 1987 |
| | EQ 5MG BASE/5ML | A071315 | 001 | Jun 30, 1993 |
| REGLAN | | | | |
| + ROBINS AH | EQ 5MG BASE/5ML ** | N018821 | 001 | Mar 25, 1983 |
| TABLET;ORAL | | | | |
| CLOPRA | | | | |
| QUANTUM PHARMICS | EQ 5MG BASE | A072384 | 001 | Jun 02, 1988 |
| | EQ 10MG BASE | A070294 | 001 | Jul 29, 1985 |
| CLOPRA-"YELLOW" | | | | |
| QUANTUM PHARMICS | EQ 10MG BASE | A070632 | 001 | Oct 28, 1985 |
| MAXOLON | | | | |
| KING PHARMS | EQ 10MG BASE | A070106 | 001 | Mar 04, 1986 |
| METOCLOPRAMIDE HYDROCHLORIDE | | | | |
| CLONMEL | EQ 10MG BASE | A072639 | 001 | May 09, 1991 |
| FOSUN PHARMA | EQ 5MG BASE | A074478 | 001 | Oct 05, 1995 |
| | EQ 10MG BASE | A072215 | 001 | Jan 30, 1990 |
| | EQ 10MG BASE | A074478 | 002 | Oct 05, 1995 |
| HALSEY | EQ 10MG BASE | A070906 | 001 | Oct 28, 1986 |
| INTERPHARM | EQ 10MG BASE | A071213 | 001 | Sep 24, 1986 |
| MUTUAL PHARM | EQ 10MG BASE | A070660 | 001 | Feb 10, 1987 |
| NORTHSTAR HLTHCARE | EQ 5MG BASE | A078374 | 001 | Nov 30, 2007 |
| | EQ 10MG BASE | A078374 | 002 | Nov 30, 2007 |
| PAR PHARM | EQ 10MG BASE | A070342 | 001 | Mar 25, 1986 |
| SANDOZ | EQ 5MG BASE | A072436 | 001 | Jun 22, 1989 |
| | EQ 10MG BASE | A070850 | 001 | Feb 03, 1987 |
| SCHERING | EQ 10MG BASE | A070598 | 001 | Feb 02, 1987 |
| SUN PHARM INDUSTRIES | EQ 5MG BASE | A071536 | 002 | Jan 16, 1997 |
| | EQ 10MG BASE | A071536 | 001 | Apr 28, 1993 |
| SUPERPHARM | EQ 10MG BASE | A070926 | 001 | Jun 26, 1987 |
| USL PHARMA | EQ 10MG BASE | A070339 | 001 | Jul 29, 1985 |
| WATSON LABS | EQ 10MG BASE | A070363 | 001 | Mar 02, 1987 |
| | EQ 10MG BASE | A070453 | 001 | Jun 06, 1986 |
| | EQ 10MG BASE | A070511 | 001 | Jan 22, 1986 |
| | EQ 10MG BASE | A070645 | 001 | May 11, 1987 |
| TABLET, ORALLY DISINTEGRATING;ORAL | | | | |
| METOZOLV ODT | | | | |
| + SALIX PHARMS | EQ 10MG BASE ** | N022246 | 002 | Sep 04, 2009 |
| REGLAN ODT | | | | |
| MEDA PHARMS | EQ 5MG BASE | N021793 | 001 | Jun 10, 2005 |
| | EQ 10MG BASE | N021793 | 002 | Jun 10, 2005 |
| METOCURINE IODIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| METUBINE IODIDE | | | | |
| LILLY | 2MG/ML | N006632 | 003 | |
| METOLAZONE | | | | |
| TABLET;ORAL | | | | |
| DIULO | | | | |
| GD SEARLE LLC | 2.5MG | N018535 | 001 | |
| | 5MG | N018535 | 002 | |
| | 10MG | N018535 | 003 | |
| METOLAZONE | | | | |
| ROXANE | 10MG | A076482 | 002 | Apr 29, 2004 |
| TEVA | 2.5MG | A076600 | 001 | Jan 06, 2004 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| METOLAZONE | | | | |
| TABLET;ORAL | | | | |
| METOLAZONE | | | | |
| | 5MG | A076833 | 001 | Mar 01, 2004 |
| | 10MG | A075543 | 003 | Dec 24, 2003 |
| WATSON LABS | 10MG | A076891 | 001 | Jul 21, 2004 |
| MYKROX | | | | |
| UCB INC | 0.5MG | N019532 | 001 | Oct 30, 1987 |
| METOPROLOL FUMARATE | | | | |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| LOPRESSOR | | | | |
| NOVARTIS | EQ 100MG TARTRATE | N019786 | 001 | Dec 27, 1989 |
| | EQ 200MG TARTRATE | N019786 | 002 | Dec 27, 1989 |
| | EQ 300MG TARTRATE | N019786 | 003 | Dec 27, 1989 |
| | EQ 400MG TARTRATE | N019786 | 004 | Dec 27, 1989 |
| METOPROLOL SUCCINATE | | | | |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| METOPROLOL SUCCINATE | | | | |
| NESHER PHARMS | EQ 25MG TARTRATE | A077779 | 001 | Mar 20, 2008 |
| | EQ 50MG TARTRATE | A077176 | 001 | May 14, 2008 |
| | EQ 100MG TARTRATE | A076640 | 002 | May 18, 2007 |
| | EQ 200MG TARTRATE | A076640 | 001 | May 18, 2007 |
| SANDOZ | EQ 25MG TARTRATE | A076969 | 001 | Jul 31, 2006 |
| | EQ 50MG TARTRATE | A076969 | 002 | May 18, 2007 |
| | EQ 100MG TARTRATE | A076969 | 003 | Mar 20, 2008 |
| | EQ 200MG TARTRATE | A076969 | 004 | Mar 20, 2008 |
| METOPROLOL TARTRATE | | | | |
| INJECTABLE;INJECTION | | | | |
| METOPROLOL TARTRATE | | | | |
| WATSON LABS | 1MG/ML | A074032 | 001 | Dec 21, 1993 |
| TABLET;ORAL | | | | |
| METOPROLOL TARTRATE | | | | |
| APOTHECON | 50MG | A074258 | 001 | Jan 27, 1994 |
| | 100MG | A074258 | 002 | Jan 27, 1994 |
| FOSUN PHARMA | 50MG | A073288 | 001 | Mar 25, 1994 |
| | 100MG | A073289 | 001 | Mar 25, 1994 |
| MYLAN | 50MG | A073666 | 001 | Dec 21, 1993 |
| | 100MG | A073666 | 002 | Dec 21, 1993 |
| PRINSTON INC | 50MG | A074453 | 001 | Apr 27, 1995 |
| | 100MG | A074453 | 002 | Apr 27, 1995 |
| PUREPAC PHARM | 50MG | A074380 | 001 | Jul 29, 1994 |
| | 100MG | A074380 | 002 | Jul 29, 1994 |
| TEVA | 50MG | A074143 | 001 | Sep 30, 1994 |
| | 100MG | A074143 | 002 | Sep 30, 1994 |
| TEVA PHARMS | 50MG | A074333 | 001 | Jan 27, 1994 |
| | 100MG | A074333 | 002 | Jan 27, 1994 |
| METRIZAMIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| AMIPAQUE | | | | |
| GE HEALTHCARE | 2.5GM/VIAL | N017982 | 003 | Sep 12, 1983 |
| | 3.75GM/VIAL | N017982 | 001 | |
| | 6.75GM/VIAL | N017982 | 002 | |
| | 13.5GM/VIAL | N017982 | 004 | Sep 12, 1983 |
| METRONIDAZOLE | | | | |
| CAPSULE;ORAL | | | | |
| METRONIDAZOLE | | | | |
| ABLE | 375MG | A076505 | 001 | Nov 13, 2003 |
| INJECTABLE;INJECTION | | | | |
| FLAGYL I.V. RTU IN PLASTIC CONTAINER | | | | |
| PFIZER | 500MG/100ML | N018353 | 002 | |
| METRO I.V. | | | | |
| B BRAUN | 500MG/100ML | N018674 | 001 | Aug 31, 1982 |
| METRONIDAZOLE | | | | |
| ABBOTT | 500MG/100ML | N018889 | 001 | Nov 18, 1983 |
| ABRAXIS PHARM | 500MG/100ML | A070071 | 001 | Dec 03, 1984 |
| INTL MEDICATION | 500MG/100ML | A070004 | 001 | May 08, 1985 |
| WATSON LABS | 500MG/100ML | A070042 | 001 | Dec 20, 1984 |

| | | | | |
|---|---|---|---|---|
| METRONIDAZOLE | | | | |
| INJECTABLE;INJECTION | | | | |
| METRONIDAZOLE | | | | |
| | 500MG/100ML | A070170 | 001 | Apr 01, 1986 |
| WEST-WARD PHARMS INT | 500MG/100ML | N018907 | 001 | Mar 30, 1984 |
| TABLET;ORAL | | | | |
| METROMIDOL | | | | |
| LABS AF | 250MG | A074523 | 001 | Oct 24, 1996 |
| | 500MG | A074523 | 002 | Oct 24, 1996 |
| METRONIDAZOLE | | | | |
| ABLE | 250MG | A076519 | 001 | Jun 27, 2003 |
| | 500MG | A076519 | 002 | Jun 27, 2003 |
| CHARTWELL MOLECULES | 250MG | N018845 | 001 | Aug 18, 1983 |
| | 500MG | N018930 | 001 | Aug 18, 1983 |
| HALSEY | 250MG | A070021 | 001 | Apr 02, 1985 |
| | 500MG | A070593 | 001 | Feb 27, 1986 |
| IVAX SUB TEVA PHARMS | 250MG | N018517 | 001 | |
| | 500MG | N018517 | 002 | May 05, 1982 |
| LNK | 250MG | N019029 | 001 | Apr 10, 1984 |
| MUTUAL PHARM | 250MG | N018818 | 001 | Feb 16, 1983 |
| | 500MG | N018818 | 002 | Feb 16, 1983 |
| SANDOZ | 250MG | N018620 | 001 | Mar 04, 1982 |
| | 250MG | N018740 | 001 | Oct 22, 1982 |
| | 500MG | N018620 | 002 | Jun 02, 1983 |
| | 500MG | N018740 | 002 | Oct 22, 1982 |
| SUPERPHARM | 250MG | A070008 | 001 | Dec 11, 1984 |
| | 500MG | A070009 | 001 | Dec 11, 1984 |
| WATSON LABS | 250MG | N018599 | 001 | Sep 17, 1982 |
| | 250MG | N018764 | 001 | Sep 17, 1982 |
| | 500MG | N018599 | 002 | Feb 13, 1984 |
| | 500MG | N018764 | 002 | Dec 20, 1982 |
| PROTOSTAT | | | | |
| ORTHO MCNEIL PHARM | 250MG | N018871 | 001 | Mar 02, 1983 |
| | 500MG | N018871 | 002 | Mar 02, 1983 |
| SATRIC | | | | |
| SAVAGE LABS | 250MG | A070029 | 001 | Mar 19, 1985 |
| | 500MG | A070731 | 001 | Jun 08, 1987 |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| METRONIDAZOLE | | | | |
| ABLE | 750MG | A076462 | 001 | Jun 25, 2003 |
| METRONIDAZOLE HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| FLAGYL I.V. | | | | |
| PFIZER | EQ 500MG BASE/VIAL ** | N018353 | 001 | |
| METRONIDAZOLE HYDROCHLORIDE | | | | |
| ABRAXIS PHARM | EQ 500MG BASE/VIAL | A070295 | 001 | Oct 15, 1985 |
| METYRAPONE | | | | |
| TABLET;ORAL | | | | |
| METOPIRONE | | | | |
| HRA PHARMA | 250MG | N012911 | 001 | |
| MEXILETINE HYDROCHLORIDE | | | | |
| CAPSULE;ORAL | | | | |
| MEXILETINE HYDROCHLORIDE | | | | |
| IDT AUSTRALIA LTD | 150MG | A074450 | 001 | May 16, 1996 |
| | 200MG | A074450 | 002 | May 16, 1996 |
| | 250MG | A074450 | 003 | May 16, 1996 |
| WATSON LABS | 150MG | A074711 | 001 | Feb 26, 1997 |
| | 150MG | A074865 | 001 | Apr 13, 1998 |
| | 200MG | A074711 | 002 | Feb 26, 1997 |
| | 200MG | A074865 | 002 | Apr 13, 1998 |
| | 250MG | A074711 | 003 | Feb 26, 1997 |
| | 250MG | A074865 | 003 | Apr 13, 1998 |
| MEXITIL | | | | |
| BOEHRINGER INGELHEIM | 150MG | N018873 | 002 | Dec 30, 1985 |
| | 200MG | N018873 | 003 | Dec 30, 1985 |
| | 250MG | N018873 | 004 | Dec 30, 1985 |

MEZLOCILLIN SODIUM MONOHYDRATE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| MEZLIN | | | | |
| BAYER PHARMS | EQ 1GM BASE/VIAL | A062333 | 001 | |
| | EQ 1GM BASE/VIAL | A062372 | 005 | Jan 13, 1983 |
| | EQ 1GM BASE/VIAL | N050549 | 001 | |
| | EQ 2GM BASE/VIAL | A062333 | 002 | |
| | EQ 2GM BASE/VIAL | A062372 | 001 | May 13, 1982 |
| | EQ 2GM BASE/VIAL | N050549 | 002 | |
| | EQ 3GM BASE/VIAL | A062333 | 003 | |
| | EQ 3GM BASE/VIAL | A062372 | 002 | May 13, 1982 |
| | EQ 3GM BASE/VIAL | A062697 | 001 | Jan 22, 1987 |
| | EQ 3GM BASE/VIAL | N050549 | 003 | |
| | EQ 4GM BASE/VIAL | A062333 | 004 | |
| | EQ 4GM BASE/VIAL | A062372 | 003 | May 13, 1982 |
| | EQ 4GM BASE/VIAL | A062697 | 002 | Jan 22, 1987 |
| | EQ 4GM BASE/VIAL | N050549 | 004 | |
| | EQ 20GM BASE/VIAL | A062372 | 004 | Mar 02, 1988 |
| | EQ 20GM BASE/VIAL | N050549 | 005 | Mar 02, 1988 |

MICONAZOLE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| MONISTAT | | | | |
| JANSSEN PHARMA | 10MG/ML | N018040 | 001 | |

MICONAZOLE NITRATE

| | | | | |
|---|---|---|---|---|
| CREAM;TOPICAL | | | | |
| MONISTAT-DERM | | | | |
| INSIGHT PHARMS | 2% | N017494 | 001 | |
| CREAM;VAGINAL | | | | |
| MICONAZOLE NITRATE | | | | |
| TEVA | 2% | A074136 | 001 | Jan 04, 1995 |
| TEVA PHARMS | 2% | A074030 | 001 | Oct 30, 1992 |
| CREAM, SUPPOSITORY;TOPICAL, VAGINAL | | | | |
| M-ZOLE 7 DUAL PACK | | | | |
| ACTAVIS MID ATLANTIC | 2%,100MG | A074586 | 001 | Jul 17, 1997 |
| LOTION;TOPICAL | | | | |
| MONISTAT-DERM | | | | |
| INSIGHT PHARMS | 2% | N017739 | 001 | |
| TAMPON;VAGINAL | | | | |
| MONISTAT 5 | | | | |
| PERSONAL PRODS | 100MG | N018592 | 001 | Oct 27, 1989 |

MIDAZOLAM HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| MIDAZOLAM HYDROCHLORIDE | | | | |
| APOTHECON | EQ 1MG BASE/ML | A075620 | 001 | Nov 01, 2000 |
| | EQ 5MG BASE/ML | A075620 | 002 | Nov 01, 2000 |
| | EQ 5MG BASE/ML | A075641 | 001 | Oct 19, 2000 |
| BAXTER HLTHCARE CORP | EQ 1MG BASE/ML | A075637 | 001 | Oct 31, 2000 |
| | EQ 5MG BASE/ML | A075637 | 002 | Oct 31, 2000 |
| BEDFORD | EQ 5MG BASE/ML | A075249 | 001 | Jun 23, 2000 |
| BEN VENUE | EQ 5MG BASE/ML | A075455 | 001 | Jun 20, 2000 |
| HOSPIRA | EQ 1MG BASE/ML | A075396 | 001 | Jun 20, 2000 |
| | EQ 5MG BASE/ML | A075396 | 002 | Jun 20, 2000 |
| | EQ 5MG BASE/ML | A075484 | 001 | Jun 20, 2000 |
| HOSPIRA INC | EQ 1MG BASE/ML | A075409 | 002 | Jun 20, 2000 |
| | EQ 5MG BASE/ML | A075409 | 001 | Jun 20, 2000 |
| IGI LABS INC | EQ 5MG BASE/ML | A075263 | 001 | Jun 26, 2000 |
| INTL MEDICATED | EQ 1MG BASE/ML | A076144 | 001 | Jan 26, 2005 |
| | EQ 5MG BASE/ML | A076144 | 002 | Jan 26, 2005 |
| INTL MEDICATION | EQ 1MG BASE/ML | A076020 | 001 | Jul 16, 2004 |
| | EQ 5MG BASE/ML | A076020 | 002 | Jul 16, 2004 |
| WOCKHARDT | EQ 1MG BASE/ML | A078141 | 001 | May 30, 2008 |
| | EQ 1MG BASE/ML | A078511 | 001 | Nov 10, 2008 |
| | EQ 5MG BASE/ML | A078141 | 002 | May 30, 2008 |
| | EQ 5MG BASE/ML | A078511 | 002 | Nov 10, 2008 |
| VERSED | | | | |
| + HLR | EQ 1MG BASE/ML ** | N018654 | 002 | May 26, 1987 |
| + | EQ 5MG BASE/ML ** | N018654 | 001 | Dec 20, 1985 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| MIDAZOLAM HYDROCHLORIDE | | | | |
| SYRUP;ORAL | | | | |
| MIDAZOLAM HYDROCHLORIDE | | | | |
| APOTEX INC | EQ 2MG BASE/ML | A077115 | 001 | Sep 09, 2005 |
| SUN PHARM INDS LTD | EQ 2MG BASE/ML | A076058 | 001 | Mar 15, 2002 |
| VERSED | | | | |
| + ROCHE | EQ 2MG BASE/ML ** | N020942 | 001 | Oct 15, 1998 |
| MIDODRINE HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| PROAMATINE | | | | |
| + SHIRE LLC | 2.5MG | N019815 | 001 | Sep 06, 1996 |
| + | 5MG | N019815 | 002 | Sep 06, 1996 |
| + | 10MG | N019815 | 003 | Mar 20, 2002 |
| MILNACIPRAN HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| MILNACIPRAN HYDROCHLORIDE | | | | |
| WINDLAS HLTHCARE | 12.5MG | A205071 | 001 | Jan 27, 2016 |
| | 25MG | A205071 | 002 | Jan 27, 2016 |
| | 50MG | A205071 | 003 | Jan 27, 2016 |
| | 100MG | A205071 | 004 | Jan 27, 2016 |
| MILRINONE LACTATE | | | | |
| INJECTABLE;INJECTION | | | | |
| MILRINONE LACTATE | | | | |
| BAXTER HLTHCARE CORP | EQ 1MG BASE/ML | A076427 | 001 | Sep 21, 2004 |
| HOSPIRA | EQ 1MG BASE/ML | A075830 | 001 | May 28, 2002 |
| | EQ 1MG BASE/ML | A075884 | 001 | May 28, 2002 |
| MYLAN INSTITUTIONAL | EQ 1MG BASE/ML | A076428 | 001 | Jun 16, 2003 |
| WEST-WARD PHARMS INT | EQ 1MG BASE/ML | A075852 | 001 | May 28, 2002 |
| MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| B BRAUN | EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML) | A076414 | 001 | Aug 18, 2004 |
| BAXTER HLTHCARE | EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML) | A076259 | 001 | Aug 08, 2002 |
| RENAISSANCE SSA LLC | EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML) | A077151 | 001 | Jul 20, 2005 |
| WEST-WARD PHARMS INT | EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML) | A075510 | 001 | May 28, 2002 |
| PRIMACOR | | | | |
| + SANOFI AVENTIS US | EQ 1MG BASE/ML ** | N019436 | 001 | Dec 31, 1987 |
| PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| + SANOFI AVENTIS US | EQ 10MG BASE/100ML ** | N020343 | 001 | Aug 09, 1994 |
| + | EQ 15MG BASE/100ML ** | N020343 | 002 | Aug 09, 1994 |
| + | EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML) ** | N020343 | 003 | Aug 09, 1994 |
| + | EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML) ** | N020343 | 004 | Aug 09, 1994 |
| MINOCYCLINE HYDROCHLORIDE | | | | |
| CAPSULE;ORAL | | | | |
| MINOCIN | | | | |
| + PRECISION DERMAT | EQ 75MG BASE ** | N050649 | 003 | Feb 12, 2001 |
| TRIAX PHARMS | EQ 50MG BASE | N050315 | 002 | |
| | EQ 100MG BASE | N050315 | 001 | |
| CAPSULE, EXTENDED RELEASE;ORAL | | | | |
| XIMINO | | | | |
| SUN PHARM INDS LTD | EQ 67.5MG BASE | N201922 | 002 | Jul 11, 2012 |
| | EQ 112.5MG BASE | N201922 | 004 | Jul 11, 2012 |
| INJECTABLE;INJECTION | | | | |
| MINOCIN | | | | |
| LEDERLE | EQ 100MG BASE/VIAL | A062139 | 001 | |
| SUSPENSION;ORAL | | | | |
| MINOCIN | | | | |
| PRECISION DERMAT | EQ 50MG BASE/5ML | N050445 | 001 | |
| TABLET;ORAL | | | | |
| MINOCYCLINE HYDROCHLORIDE | | | | |
| + TRIAX PHARMS | EQ 50MG BASE ** | N050451 | 003 | Aug 10, 1982 |
| + | EQ 100MG BASE ** | N050451 | 002 | Aug 10, 1982 |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| MINOCYCLINE HYDROCHLORIDE | | | | |
| BARR LABS INC | EQ 45MG BASE | A065485 | 001 | Mar 17, 2009 |
| | EQ 65MG BASE | A065485 | 004 | May 18, 2012 |
| | EQ 80MG BASE | A065485 | 007 | Apr 26, 2017 |
| | EQ 90MG BASE | A065485 | 002 | Mar 17, 2009 |

| | | | | | |
|---|---|---|---|---|---|
| MINOCYCLINE HYDROCHLORIDE | | | | | |
| TABLET, EXTENDED RELEASE;ORAL | | | | | |
| MINOCYCLINE HYDROCHLORIDE | | | | | |
| | | EQ 105MG BASE | A065485 | 008 | Apr 26, 2017 |
| | | EQ 115MG BASE | A065485 | 005 | May 18, 2012 |
| | | EQ 135MG BASE | A065485 | 003 | Mar 17, 2009 |
| | IMPAX LABS INC | EQ 45MG BASE | A090024 | 001 | Feb 03, 2009 |
| | | EQ 90MG BASE | A090024 | 002 | Feb 03, 2009 |
| | | EQ 135MG BASE | A090024 | 003 | Feb 03, 2009 |
| | LUPIN LTD | EQ 55MG BASE | A091424 | 002 | Nov 30, 2011 |
| | MYLAN PHARMS INC | EQ 45MG BASE | A090911 | 001 | Jul 20, 2010 |
| | | EQ 80MG BASE | A203443 | 002 | Aug 22, 2014 |
| | | EQ 90MG BASE | A090911 | 002 | Jul 20, 2010 |
| | | EQ 105MG BASE | A203443 | 003 | Aug 22, 2014 |
| | | EQ 135MG BASE | A090911 | 003 | Jul 20, 2010 |
| SOLODYN | | | | | |
| + | MEDICIS | EQ 45MG BASE ** | N050808 | 001 | May 08, 2006 |
| + | | EQ 90MG BASE ** | N050808 | 002 | May 08, 2006 |
| + | | EQ 135MG BASE ** | N050808 | 003 | May 08, 2006 |
| MINOXIDIL | | | | | |
| SOLUTION;TOPICAL | | | | | |
| MINOXIDIL (FOR MEN) | | | | | |
| | APOTEX INC | 2% | A074924 | 001 | Apr 29, 1998 |
| | BAUSCH AND LOMB | 2% | A074643 | 001 | Apr 09, 1996 |
| | COPLEY PHARM | 2% | A074500 | 001 | May 23, 1996 |
| | SIGHT PHARMS | 2% | A074743 | 002 | Oct 18, 1996 |
| | TEVA | 2% | A074589 | 001 | Apr 05, 1996 |
| MINOXIDIL (FOR WOMEN) | | | | | |
| | APOTEX INC | 2% | A074924 | 002 | Apr 29, 1998 |
| | SIGHT PHARMS | 2% | A074743 | 001 | Oct 18, 1996 |
| MINOXIDIL EXTRA STRENGTH (FOR MEN) | | | | | |
| | APOTEX INC | 5% | A075839 | 001 | Oct 01, 2001 |
| TABLET;ORAL | | | | | |
| LONITEN | | | | | |
| + | PHARMACIA AND UPJOHN | 2.5MG ** | N018154 | 001 | |
| + | | 10MG ** | N018154 | 003 | |
| MINODYL | | | | | |
| | QUANTUM PHARMICS | 2.5MG | A072153 | 001 | Jul 13, 1988 |
| | | 10MG | A071534 | 001 | Mar 19, 1987 |
| MINOXIDIL | | | | | |
| | ROYCE LABS | 2.5MG | A071799 | 001 | Nov 10, 1987 |
| | | 10MG | A071796 | 001 | Nov 10, 1987 |
| | USL PHARMA | 2.5MG | A071537 | 001 | Dec 16, 1988 |
| MIRTAZAPINE | | | | | |
| TABLET;ORAL | | | | | |
| MIRTAZAPINE | | | | | |
| | ACTAVIS ELIZABETH | 15MG | A076241 | 001 | Jun 25, 2003 |
| | | 15MG | A076308 | 001 | Jun 20, 2003 |
| | | 30MG | A076241 | 002 | Jun 25, 2003 |
| | | 30MG | A076308 | 002 | Jun 20, 2003 |
| | | 45MG | A076241 | 003 | Jun 25, 2003 |
| | | 45MG | A076308 | 003 | Jun 20, 2003 |
| | ACTAVIS LABS FL INC | 15MG | A076336 | 001 | Jun 20, 2003 |
| | | 30MG | A076336 | 002 | Jun 20, 2003 |
| | | 45MG | A076336 | 003 | Jun 20, 2003 |
| | IVAX SUB TEVA PHARMS | 15MG | A076244 | 001 | Dec 22, 2003 |
| | | 30MG | A076244 | 002 | Dec 22, 2003 |
| | | 45MG | A076244 | 003 | Dec 22, 2003 |
| | MYLAN PHARMS INC | 15MG | A076176 | 001 | Jun 19, 2003 |
| | | 30MG | A076176 | 002 | Jun 19, 2003 |
| | | 45MG | A076176 | 003 | Jun 19, 2003 |
| | ROXANE | 15MG | A076270 | 001 | Jun 19, 2003 |
| | | 30MG | A076270 | 002 | Jun 19, 2003 |
| | | 45MG | A076270 | 003 | Jun 19, 2003 |
| | UPSHER-SMITH LABS | 15MG | A076189 | 001 | Jun 19, 2003 |
| | | 30MG | A076189 | 002 | Jun 19, 2003 |
| | | 45MG | A076189 | 003 | Jun 19, 2003 |

| | | | | |
|---|---|---|---|---|
| MIRTAZAPINE | | | | |
| TABLET, ORALLY DISINTEGRATING;ORAL | | | | |
| MIRTAZAPINE | | | | |
| ACTAVIS ELIZABETH | 15MG | A076689 | 001 | Aug 31, 2005 |
| | 15MG | A077959 | 001 | Feb 14, 2011 |
| | 30MG | A076689 | 002 | Aug 31, 2005 |
| | 30MG | A077959 | 002 | Feb 14, 2011 |
| | 45MG | A076689 | 003 | Aug 31, 2005 |
| | 45MG | A077959 | 003 | Feb 14, 2011 |
| MITOMYCIN | | | | |
| INJECTABLE;INJECTION | | | | |
| MITOMYCIN | | | | |
| HOSPIRA | 20MG/VIAL | A064106 | 001 | Nov 29, 1995 |
| MITOZYTREX | | | | |
| + SUPERGEN | 5MG/VIAL ** | N050763 | 001 | Nov 14, 2002 |
| MUTAMYCIN | | | | |
| + BRISTOL | 5MG/VIAL | N050450 | 001 | |
| + | 20MG/VIAL | N050450 | 002 | |
| BRISTOL MYERS | 5MG/VIAL | A062336 | 001 | |
| | 20MG/VIAL | A062336 | 002 | |
| | 40MG/VIAL | A062336 | 003 | Mar 10, 1988 |
| MITOXANTRONE HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| MITOXANTRONE HYDROCHLORIDE | | | | |
| FRESENIUS KABI ONCOL | EQ 20MG BASE/10ML (EQ 2MG BASE/ML) | A078606 | 001 | May 14, 2008 |
| | EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML) | A078606 | 002 | May 14, 2008 |
| | EQ 30MG BASE/15ML (EQ 2MG BASE/ML) | A078606 | 003 | May 14, 2008 |
| NOVANTRONE | | | | |
| EMD SERONO | EQ 20MG BASE/10ML (EQ 2MG BASE/ML) | N019297 | 001 | Dec 23, 1987 |
| + | EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML) ** | N019297 | 002 | Dec 23, 1987 |
| + | EQ 30MG BASE/15ML (EQ 2MG BASE/ML) ** | N019297 | 003 | Dec 23, 1987 |
| MIVACURIUM CHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| MIVACRON IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| ABBVIE | EQ 0.5MG BASE/ML | N020098 | 002 | Jan 22, 1992 |
| | EQ 50MG BASE/100ML | N020098 | 003 | Jan 22, 1992 |
| MIVACURIUM CHLORIDE | | | | |
| MYLAN LABS LTD | EQ 2MG BASE/ML | A078562 | 001 | Apr 30, 2009 |
| SOLUTION;INTRAVENOUS | | | | |
| MIVACRON | | | | |
| + ABBVIE | EQ 2MG BASE/ML (EQ 2MG BASE/ML) ** | N020098 | 001 | Jan 22, 1992 |
| MOEXIPRIL HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| UNIVASC | | | | |
| UCB INC | 7.5MG ** | N020312 | 001 | Apr 19, 1995 |
| | 15MG ** | N020312 | 002 | Apr 19, 1995 |
| MOLINDONE HYDROCHLORIDE | | | | |
| CAPSULE;ORAL | | | | |
| MOBAN | | | | |
| + ENDO PHARMS | 5MG ** | N017111 | 001 | |
| + | 10MG ** | N017111 | 002 | |
| + | 25MG ** | N017111 | 003 | |
| CONCENTRATE;ORAL | | | | |
| MOBAN | | | | |
| ENDO PHARMS | 20MG/ML | N017938 | 001 | |
| TABLET;ORAL | | | | |
| MOBAN | | | | |
| + ENDO PHARMS | 5MG ** | N017111 | 004 | |
| + | 10MG ** | N017111 | 005 | |
| + | 25MG ** | N017111 | 006 | |
| + | 50MG ** | N017111 | 007 | |
| + | 100MG ** | N017111 | 008 | |

MOMETASONE FUROATE
CREAM;TOPICAL
ELOCON
MERCK SHARP DOHME 0.1% N019625 001 May 06, 1987
OINTMENT;TOPICAL
MOMETASONE FUROATE
TARO 0.1% A076624 001 Dec 03, 2004

MONOBENZONE
CREAM;TOPICAL
BENOQUIN
VALEANT PHARM INTL 20% N008173 003

MONOCTANOIN
LIQUID;PERFUSION, BILIARY
MOCTANIN
ETHITEK 100% N019368 001 Oct 29, 1985

MORICIZINE HYDROCHLORIDE
TABLET;ORAL
ETHMOZINE
SHIRE 200MG N019753 001 Jun 19, 1990
250MG N019753 002 Jun 19, 1990
300MG N019753 003 Jun 19, 1990

MORPHINE SULFATE
CAPSULE, EXTENDED RELEASE;ORAL
AVINZA
KING PHARMS LLC 30MG N021260 001 Mar 20, 2002
45MG N021260 005 Dec 18, 2008
60MG N021260 002 Mar 20, 2002
75MG N021260 006 Dec 18, 2008
90MG N021260 003 Mar 20, 2002
120MG N021260 004 Mar 20, 2002
INJECTABLE;INJECTION
MORPHINE SULFATE
+ HOSPIRA INC 15MG/ML N202515 005 Nov 14, 2011
ICU MEDICAL INC 0.5MG/ML N019917 001 Oct 30, 1992
SPECGX LLC 1MG/ML N020631 001 Jul 03, 1996
2MG/ML N020631 002 Jul 03, 1996
WATSON LABS 0.5MG/ML A073373 001 Sep 30, 1991
0.5MG/ML A073375 001 Sep 30, 1991
1MG/ML A073374 001 Sep 30, 1991
1MG/ML A073376 001 Sep 30, 1991
INJECTABLE, LIPOSOMAL;EPIDURAL
DEPODUR
PACIRA PHARMS INC 10MG/ML (10MG/ML) N021671 001 May 18, 2004
15MG/1.5ML (10MG/ML) N021671 002 May 18, 2004
20MG/2ML (10MG/ML) N021671 003 May 18, 2004
TABLET, EXTENDED RELEASE;ORAL
MORPHINE SULFATE
WATSON LABS 100MG A075656 001 Jan 30, 2001
ORAMORPH SR
XANODYNE PHARMS INC 15MG N019977 004 Nov 23, 1994
30MG N019977 001 Aug 15, 1991
60MG N019977 002 Aug 15, 1991
100MG N019977 003 Aug 15, 1991

MOXALACTAM DISODIUM
INJECTABLE;INJECTION
MOXAM
LILLY EQ 250MG BASE/VIAL N050550 001
EQ 500MG BASE/VIAL N050550 002
EQ 1GM BASE/VIAL N050550 003
EQ 2GM BASE/VIAL N050550 004
EQ 10GM BASE/VIAL N050550 008

MOXIFLOXACIN HYDROCHLORIDE

| | | | | | |
|---|---|---|---|---|---|
| SOLUTION;IV (INFUSION) | | | | | |
| AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER | | | | | |
| + | BAYER HLTHCARE | 400MG/250ML (1.6MG/ML) | N021277 | 001 | Nov 30, 2001 |

MUPIROCIN

| | | | | | |
|---|---|---|---|---|---|
| OINTMENT;TOPICAL | | | | | |
| BACTROBAN | | | | | |
| + | GLAXOSMITHKLINE | 2% ** | N050591 | 001 | Dec 31, 1987 |

MYCOPHENOLATE MOFETIL

| | | | | | |
|---|---|---|---|---|---|
| CAPSULE;ORAL | | | | | |
| MYCOPHENOLATE MOFETIL | | | | | |
| | DR REDDYS LABS LTD | 250MG | A091315 | 001 | Oct 27, 2011 |
| | JUBILANT CADISTA | 250MG | A090762 | 001 | Dec 15, 2014 |
| | ZYDUS PHARMS USA INC | 250MG | A065433 | 001 | May 04, 2009 |
| TABLET;ORAL | | | | | |
| MYCOPHENOLATE MOFETIL | | | | | |
| | DR REDDYS LABS LTD | 500MG | A090464 | 001 | Sep 13, 2010 |
| | JUBILANT CADISTA | 500MG | A090661 | 001 | Dec 15, 2014 |
| | ZYDUS PHARMS USA INC | 500MG | A065477 | 001 | May 04, 2009 |

NABUMETONE

| | | | | | |
|---|---|---|---|---|---|
| TABLET;ORAL | | | | | |
| NABUMETONE | | | | | |
| | COPLEY PHARM | 750MG | A075179 | 001 | Jun 06, 2000 |
| | OXFORD PHARMS | 500MG | A079093 | 001 | Feb 27, 2009 |
| | | 750MG | A079093 | 002 | Feb 27, 2009 |
| | SANDOZ | 500MG | A075590 | 001 | Feb 25, 2002 |
| | | 750MG | A075590 | 002 | Feb 25, 2002 |
| | SCIEGEN PHARMS INC | 500MG | A078420 | 001 | Sep 24, 2008 |
| | | 750MG | A078420 | 002 | Sep 24, 2008 |
| RELAFEN | | | | | |
| + | SMITHKLINE BEECHAM | 500MG ** | N019583 | 001 | Dec 24, 1991 |
| + | | 750MG ** | N019583 | 002 | Dec 24, 1991 |

NADOLOL

| | | | | | |
|---|---|---|---|---|---|
| TABLET;ORAL | | | | | |
| CORGARD | | | | | |
| | US WORLDMEDS LLC | 120MG | N018063 | 003 | |
| | | 160MG | N018063 | 004 | |
| NADOLOL | | | | | |
| | IVAX SUB TEVA PHARMS | 120MG | A074255 | 002 | Jan 24, 1996 |
| | | 160MG | A074255 | 003 | Jan 24, 1996 |
| | TEVA PHARMS | 80MG | A074368 | 001 | Aug 31, 1994 |
| | | 120MG | A074368 | 002 | Aug 31, 1994 |
| | | 160MG | A074368 | 003 | Aug 31, 1994 |

NAFCILLIN SODIUM

| | | | | | |
|---|---|---|---|---|---|
| CAPSULE;ORAL | | | | | |
| UNIPEN | | | | | |
| | WYETH AYERST | EQ 250MG BASE | N050111 | 001 | |
| FOR SOLUTION;ORAL | | | | | |
| UNIPEN | | | | | |
| | WYETH AYERST | EQ 250MG BASE/5ML | N050199 | 001 | |
| INJECTABLE;INJECTION | | | | | |
| NAFCILLIN SODIUM | | | | | |
| | APOTHECON | EQ 500MG BASE/VIAL | A061984 | 001 | |
| | | EQ 1GM BASE/VIAL | A061984 | 002 | |
| | | EQ 2GM BASE/VIAL | A061984 | 003 | |
| | | EQ 4GM BASE/VIAL | A061984 | 005 | |
| | SANDOZ | EQ 500MG BASE/VIAL | A062527 | 001 | Aug 02, 1984 |
| | WATSON LABS INC | EQ 500MG BASE/VIAL | A062844 | 001 | Oct 26, 1988 |
| | | EQ 1GM BASE/VIAL | A062844 | 002 | Oct 26, 1988 |
| | | EQ 1.5GM BASE/VIAL | A062844 | 003 | Oct 26, 1988 |
| | | EQ 2GM BASE/VIAL | A062844 | 004 | Oct 26, 1988 |
| | | EQ 4GM BASE/VIAL | A062844 | 005 | Oct 26, 1988 |
| | | EQ 10GM BASE/VIAL | A063008 | 001 | Sep 29, 1988 |
| NALLPEN | | | | | |
| | GLAXOSMITHKLINE | EQ 500MG BASE/VIAL | A061999 | 001 | |
| | | EQ 1GM BASE/VIAL | A061999 | 002 | |
| | | EQ 1GM BASE/VIAL | A062755 | 001 | Dec 19, 1986 |

| | | | | |
|---|---|---|---|---|
| NAFCILLIN SODIUM | | | | |
| INJECTABLE;INJECTION | | | | |
| NALLPEN | | | | |
| | EQ 2GM BASE/VIAL | A061999 | 003 | |
| | EQ 2GM BASE/VIAL | A062755 | 002 | Dec 19, 1986 |
| | EQ 10GM BASE/VIAL | A061999 | 004 | |
| UNIPEN | | | | |
| WYETH AYERST | EQ 500MG BASE/VIAL ** | A062717 | 001 | Dec 16, 1986 |
| + | EQ 500MG BASE/VIAL ** | N050320 | 001 | |
| | EQ 1GM BASE/VIAL ** | A062717 | 002 | Dec 16, 1986 |
| | EQ 2GM BASE/VIAL ** | A062717 | 004 | Dec 16, 1986 |
| + | EQ 2GM BASE/VIAL ** | N050320 | 003 | |
| + | EQ 4GM BASE/VIAL ** | N050320 | 004 | |
| + | EQ 10GM BASE/VIAL ** | N050320 | 005 | |
| + | EQ 20GM BASE/VIAL ** | N050320 | 006 | |
| UNIPEN IN PLASTIC CONTAINER | | | | |
| + WYETH AYERST | EQ 1GM BASE/VIAL ** | N050320 | 002 | |
| TABLET;ORAL | | | | |
| UNIPEN | | | | |
| WYETH AYERST | EQ 500MG BASE | N050462 | 001 | |
| NALBUPHINE HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| NALBUPHINE | | | | |
| ABRAXIS PHARM | 10MG/ML | A070751 | 001 | Jul 02, 1986 |
| | 20MG/ML | A070752 | 001 | Sep 24, 1986 |
| NALBUPHINE HYDROCHLORIDE | | | | |
| ABBOTT | 20MG/ML | A070917 | 001 | Feb 03, 1989 |
| ABBVIE | 1.5MG/ML | N020200 | 001 | Mar 12, 1993 |
| BARR | 10MG/ML | A074471 | 001 | Mar 19, 1998 |
| | 20MG/ML | A074471 | 002 | Mar 19, 1998 |
| IGI LABS INC | 10MG/ML | A072070 | 001 | Apr 10, 1989 |
| | 10MG/ML | A072071 | 001 | Apr 10, 1989 |
| | 10MG/ML | A072072 | 001 | Apr 10, 1989 |
| | 20MG/ML | A072073 | 001 | Apr 10, 1989 |
| | 20MG/ML | A072074 | 001 | Apr 10, 1989 |
| | 20MG/ML | A072075 | 001 | Apr 10, 1989 |
| NUBAIN | | | | |
| + PAR PHARM INC | 10MG/ML ** | N018024 | 001 | |
| + | 20MG/ML ** | N018024 | 002 | May 27, 1982 |
| NALIDIXIC ACID | | | | |
| SUSPENSION;ORAL | | | | |
| NEGGRAM | | | | |
| SANOFI AVENTIS US | 250MG/5ML | N017430 | 001 | |
| TABLET;ORAL | | | | |
| NALIDIXIC ACID | | | | |
| SUN PHARM INDUSTRIES | 250MG | A070270 | 001 | Jun 29, 1988 |
| | 500MG | A070271 | 001 | Jun 29, 1988 |
| | 1GM | A070272 | 001 | Jun 29, 1988 |
| WATSON LABS | 250MG | A071936 | 001 | Jun 29, 1988 |
| | 500MG | A072061 | 001 | Jun 29, 1988 |
| | 1GM | A071919 | 001 | Jun 29, 1988 |
| NEGGRAM | | | | |
| SANOFI AVENTIS US | 250MG | N014214 | 002 | |
| | 500MG | N014214 | 004 | |
| | 1GM | N014214 | 005 | |
| NALMEFENE HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| REVEX | | | | |
| + EUROHLTH INTL SARL | EQ 0.1MG BASE/ML ** | N020459 | 001 | Apr 17, 1995 |
| + | EQ 1MG BASE/ML ** | N020459 | 002 | Apr 17, 1995 |
| NALOXONE HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| NALOXONE | | | | |
| WEST-WARD PHARMS INT | 0.4MG/ML | A070298 | 001 | Sep 24, 1986 |
| | 0.4MG/ML | A070496 | 001 | Sep 24, 1986 |
| WYETH AYERST | 0.02MG/ML | A070188 | 001 | Sep 24, 1986 |
| | 0.02MG/ML | A070189 | 001 | Sep 24, 1986 |

| | | | | |
|---|---|---|---|---|
| NALOXONE HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| NALOXONE | | | | |
| | 0.4MG/ML | A070190 | 001 | Sep 24, 1986 |
| | 0.4MG/ML | A070191 | 001 | Sep 24, 1986 |
| NALOXONE HYDROCHLORIDE | | | | |
| ABRAXIS PHARM | 0.02MG/ML | A070648 | 001 | Nov 17, 1986 |
| | 0.02MG/ML | A070661 | 001 | Nov 17, 1986 |
| | 0.4MG/ML | A070649 | 001 | Nov 17, 1986 |
| | 1MG/ML | A071604 | 001 | Dec 16, 1988 |
| ASTRAZENECA | 0.02MG/ML | A072081 | 001 | Apr 11, 1989 |
| EUROHLTH INTL SARL | 0.02MG/ML | A071272 | 001 | May 24, 1988 |
| | 1MG/ML | A071273 | 001 | May 24, 1988 |
| | 1MG/ML | A071274 | 001 | May 24, 1988 |
| | 1MG/ML | A071287 | 001 | May 24, 1988 |
| HOSPIRA | 0.02MG/ML | A070171 | 001 | Sep 24, 1986 |
| | 0.02MG/ML | A070252 | 001 | Jan 16, 1987 |
| | 0.02MG/ML | A070253 | 001 | Jan 16, 1987 |
| | 0.4MG/ML | A070255 | 001 | Jan 07, 1987 |
| IGI LABS INC | 0.02MG/ML | A072082 | 001 | Apr 11, 1989 |
| | 0.02MG/ML | A072083 | 001 | Apr 11, 1989 |
| | 0.02MG/ML | A072084 | 001 | Apr 11, 1989 |
| | 0.02MG/ML | A072085 | 001 | Apr 11, 1989 |
| | 0.4MG/ML | A072086 | 001 | Apr 11, 1989 |
| | 0.4MG/ML | A072087 | 001 | Apr 11, 1989 |
| | 0.4MG/ML | A072088 | 001 | Apr 11, 1989 |
| | 0.4MG/ML | A072089 | 001 | Apr 11, 1989 |
| | 0.4MG/ML | A072090 | 001 | Apr 11, 1989 |
| | 1MG/ML | A072091 | 001 | Apr 11, 1989 |
| | 1MG/ML | A072092 | 001 | Apr 11, 1989 |
| | 1MG/ML | A072093 | 001 | Apr 11, 1989 |
| INTL MEDICATION | 0.4MG/ML | A070417 | 001 | Sep 24, 1986 |
| | 1MG/ML | A072115 | 001 | Apr 27, 1988 |
| MARSAM PHARMS LLC | 0.4MG/ML | A071811 | 001 | Jul 19, 1988 |
| SMITH AND NEPHEW | 0.02MG/ML | A071671 | 001 | Nov 17, 1987 |
| | 0.4MG/ML | A071681 | 001 | Nov 17, 1987 |
| | 0.4MG/ML | A071682 | 001 | Nov 17, 1987 |
| SOLOPAK | 0.02MG/ML | A071672 | 001 | Nov 17, 1987 |
| | 0.4MG/ML | A071683 | 001 | Nov 17, 1987 |
| WATSON LABS | 0.4MG/ML | A071339 | 001 | Nov 18, 1987 |
| NARCAN | | | | |
| + ADAPT | 0.02MG/ML ** | N016636 | 002 | |
| + | 0.4MG/ML ** | N016636 | 001 | |
| + | 1MG/ML ** | N016636 | 003 | Jun 14, 1982 |
| BRISTOL MYERS SQUIBB | 0.4MG/ML | A071083 | 001 | Jul 28, 1988 |
| | 1MG/ML | A071084 | 001 | Jul 28, 1988 |
| | 1MG/ML | A071311 | 001 | Jul 28, 1988 |
| SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | | | | |
| EVZIO | | | | |
| + KALEO INC | 0.4MG/0.4ML (0.4MG/0.4ML) | N205787 | 001 | Apr 03, 2014 |
| NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE | | | | |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| TARGINIQ | | | | |
| + PURDUE PHARMA LP | 5MG;10MG | N205777 | 001 | Jul 23, 2014 |
| + | 10MG;20MG | N205777 | 002 | Jul 23, 2014 |
| + | 20MG;40MG | N205777 | 003 | Jul 23, 2014 |
| NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| TALWIN NX | | | | |
| SANOFI AVENTIS US | EQ 0.5MG BASE;EQ 50MG BASE ** | N018733 | 001 | Dec 16, 1982 |
| NALTREXONE HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| NALTREXONE HYDROCHLORIDE | | | | |
| SANDOZ | 50MG | A075434 | 001 | Mar 08, 2000 |
| REVIA | | | | |
| TEVA WOMENS | 50MG | N018932 | 001 | Nov 20, 1984 |

| | | | | |
|---|---|---|---|---|
| NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE | | | | |
| CAPSULE, EXTENDED RELEASE;ORAL | | | | |
| TROXYCA ER | | | | |
| PFIZER INC | 1.2MG;10MG | N207621 | 001 | Aug 19, 2016 |
| | 2.4MG;20MG | N207621 | 002 | Aug 19, 2016 |
| | 3.6MG;30MG | N207621 | 003 | Aug 19, 2016 |
| | 4.8MG;40MG | N207621 | 004 | Aug 19, 2016 |
| | 7.2MG;60MG | N207621 | 005 | Aug 19, 2016 |
| | 9.6MG;80MG | N207621 | 006 | Aug 19, 2016 |
| NANDROLONE DECANOATE | | | | |
| INJECTABLE;INJECTION | | | | |
| DECA-DURABOLIN | | | | |
| ASPEN GLOBAL INC | 50MG/ML | N013132 | 001 | Jun 12, 1986 |
| | 100MG/ML | N013132 | 002 | Jun 12, 1986 |
| + | 200MG/ML ** | N013132 | 003 | Jun 12, 1986 |
| NANDROLONE DECANOATE | | | | |
| ABRAXIS PHARM | 100MG/ML | A088290 | 001 | Oct 03, 1983 |
| | 200MG/ML | A088317 | 001 | Oct 14, 1983 |
| AKORN | 100MG/ML | A087519 | 001 | Sep 28, 1983 |
| WATSON LABS | 50MG/ML | A086385 | 001 | Jan 13, 1984 |
| | 50MG/ML | A087598 | 001 | Oct 06, 1983 |
| | 50MG/ML | A088554 | 001 | Feb 10, 1986 |
| | 100MG/ML | A086598 | 001 | Jan 13, 1984 |
| | 100MG/ML | A087599 | 001 | Oct 06, 1983 |
| | 200MG/ML | A088128 | 001 | Dec 05, 1983 |
| NANDROLONE PHENPROPIONATE | | | | |
| INJECTABLE;INJECTION | | | | |
| DURABOLIN | | | | |
| ORGANON USA INC | 25MG/ML | N011891 | 001 | |
| | 50MG/ML | N011891 | 002 | |
| NANDROLONE PHENPROPIONATE | | | | |
| WATSON LABS | 25MG/ML | A086386 | 001 | Jun 17, 1983 |
| | 50MG/ML | A087488 | 001 | Jun 17, 1983 |
| NAPHAZOLINE HYDROCHLORIDE | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | |
| ALBALON | | | | |
| ALLERGAN | 0.1% ** | A080248 | 001 | |
| NAFAZAIR | | | | |
| BAUSCH AND LOMB | 0.1% | A040073 | 001 | May 25, 1994 |
| PHARMAFAIR | 0.1% | A088101 | 001 | Apr 15, 1983 |
| NAPHCON FORTE | | | | |
| ALCON | 0.1% | A080229 | 001 | |
| OPCON | | | | |
| BAUSCH AND LOMB | 0.1% | A087506 | 001 | |
| VASOCON | | | | |
| NOVARTIS | 0.1% | A080235 | 002 | Mar 24, 1983 |
| NAPROXEN | | | | |
| TABLET;ORAL | | | | |
| NAPROXEN | | | | |
| CHARTWELL MOLECULES | 250MG | A074410 | 001 | Apr 28, 1995 |
| | 375MG | A074410 | 002 | Apr 28, 1995 |
| | 500MG | A074410 | 003 | Apr 28, 1995 |
| DAVA PHARMS INC | 250MG | A074105 | 001 | Dec 21, 1993 |
| | 375MG | A074105 | 002 | Dec 21, 1993 |
| | 500MG | A074105 | 003 | Dec 21, 1993 |
| HAMILTON PHARMS | 250MG | A074110 | 001 | Oct 30, 1992 |
| | 375MG | A074110 | 002 | Oct 30, 1992 |
| | 500MG | A074110 | 003 | Oct 30, 1992 |
| HIKMA INTL PHARMS | 250MG | A076494 | 001 | Jan 14, 2004 |
| | 375MG | A076494 | 002 | Jan 14, 2004 |
| | 500MG | A076494 | 003 | Jan 14, 2004 |
| IVAX SUB TEVA PHARMS | 250MG | A074111 | 001 | Feb 28, 1995 |
| | 375MG | A074111 | 002 | Feb 28, 1995 |
| | 500MG | A074111 | 003 | Feb 28, 1995 |
| PLIVA | 250MG | A074182 | 001 | Jun 27, 1996 |
| | 375MG | A074182 | 002 | Jun 27, 1996 |
| | 500MG | A074182 | 003 | Jun 27, 1996 |

NAPROXEN

TABLET;ORAL

NAPROXEN

| | | | | |
|---|---|---|---|---|
| PUREPAC PHARM | 250MG | A074263 | 001 | Dec 21, 1993 |
| | 375MG | A074263 | 002 | Dec 21, 1993 |
| | 500MG | A074263 | 003 | Dec 21, 1993 |
| ROXANE | 250MG | A074211 | 001 | Feb 28, 1994 |
| | 375MG | A074211 | 002 | Feb 28, 1994 |
| | 500MG | A074211 | 003 | Feb 28, 1994 |
| SANDOZ | 250MG | A074140 | 001 | Dec 21, 1993 |
| | 375MG | A074140 | 002 | Dec 21, 1993 |
| | 500MG | A074140 | 003 | Dec 21, 1993 |
| TEVA | 250MG | A074129 | 001 | Dec 21, 1993 |
| | 250MG | A074216 | 001 | Apr 11, 1996 |
| | 375MG | A074129 | 002 | Dec 21, 1993 |
| | 375MG | A074216 | 002 | Apr 11, 1996 |
| | 500MG | A074129 | 003 | Dec 21, 1993 |
| | 500MG | A074216 | 003 | Apr 11, 1996 |
| TEVA PHARMS | 250MG | A074207 | 001 | Dec 21, 1993 |
| | 375MG | A074207 | 002 | Dec 21, 1993 |
| | 500MG | A074207 | 003 | Dec 21, 1993 |
| WATSON LABS | 250MG | A074457 | 001 | May 31, 1995 |
| | 375MG | A074457 | 002 | May 31, 1995 |
| | 500MG | A074457 | 003 | May 31, 1995 |
| WATSON LABS TEVA | 250MG | A074163 | 001 | Feb 10, 1995 |
| | 375MG | A074163 | 002 | Feb 10, 1995 |
| | 500MG | A074163 | 003 | Feb 10, 1995 |

TABLET, DELAYED RELEASE;ORAL

NAPROXEN

| | | | | |
|---|---|---|---|---|
| ACTAVIS ELIZABETH | 375MG | A074936 | 001 | Feb 24, 1998 |
| | 500MG | A074936 | 002 | Feb 24, 1998 |
| MYLAN PHARMS INC | 375MG | A075390 | 001 | Apr 19, 2001 |
| | 500MG | A075390 | 002 | Apr 19, 2001 |
| SANDOZ | 375MG | A075061 | 001 | Feb 18, 1998 |
| | 500MG | A075061 | 002 | Feb 18, 1998 |

NAPROXEN SODIUM

TABLET;ORAL

NAPROXEN SODIUM

| | | | | |
|---|---|---|---|---|
| ABLE | EQ 250MG BASE | A076544 | 001 | Aug 22, 2003 |
| | EQ 500MG BASE | A076544 | 002 | Aug 22, 2003 |
| CONTRACT PHARMACAL | EQ 200MG BASE | A074789 | 001 | Feb 27, 1997 |
| HAMILTON PHARMS | EQ 250MG BASE | A074106 | 001 | Aug 31, 1993 |
| | EQ 500MG BASE | A074106 | 002 | Aug 31, 1993 |
| HIKMA | EQ 250MG BASE | A074480 | 002 | Feb 18, 1998 |
| | EQ 500MG BASE | A074480 | 001 | May 14, 1996 |
| IVAX SUB TEVA PHARMS | EQ 250MG BASE | A074230 | 001 | Mar 14, 1995 |
| | EQ 500MG BASE | A074230 | 002 | Mar 14, 1995 |
| MYLAN | EQ 250MG BASE | A074367 | 001 | Aug 31, 1994 |
| | EQ 500MG BASE | A074367 | 002 | Aug 31, 1994 |
| PLIVA | EQ 250MG BASE | A074242 | 001 | Jun 20, 1996 |
| | EQ 500MG BASE | A074242 | 002 | Jun 20, 1996 |
| PUREPAC PHARM | EQ 250MG BASE | A074319 | 001 | Mar 20, 1995 |
| | EQ 500MG BASE | A074319 | 002 | Mar 20, 1995 |
| ROXANE | EQ 250MG BASE | A074257 | 001 | Dec 21, 1993 |
| | EQ 500MG BASE | A074257 | 002 | Dec 21, 1993 |
| SANDOZ | EQ 200MG BASE | A074646 | 001 | Jan 13, 1997 |
| | EQ 250MG BASE | A074162 | 001 | Dec 21, 1993 |
| | EQ 250MG BASE | A074495 | 001 | Dec 05, 1994 |
| | EQ 500MG BASE | A074162 | 002 | Dec 21, 1993 |
| | EQ 500MG BASE | A074495 | 002 | Dec 05, 1994 |
| TEVA | EQ 250MG BASE | A074142 | 001 | Dec 21, 1993 |
| | EQ 500MG BASE | A074142 | 002 | Dec 21, 1993 |
| TEVA PHARMS | EQ 250MG BASE | A074289 | 001 | Jan 27, 1994 |
| | EQ 500MG BASE | A074289 | 002 | Jan 27, 1994 |
| WATSON LABS | EQ 250MG BASE | A074195 | 001 | Dec 21, 1993 |
| | EQ 250MG BASE | A074455 | 001 | May 31, 1995 |
| | EQ 500MG BASE | A074195 | 002 | Dec 21, 1993 |
| | EQ 500MG BASE | A074455 | 002 | May 31, 1995 |

| | | | | |
|---|---|---|---|---|
| NATEGLINIDE | | | | |
| TABLET;ORAL | | | | |
| NATEGLINIDE | | | | |
| TEVA PHARMS | 60MG | A077467 | 001 | Sep 09, 2009 |
| | 120MG | A077467 | 002 | Sep 09, 2009 |
| NEBIVOLOL HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| NEBIVOLOL HYDROCHLORIDE | | | | |
| ALKEM LABS LTD | EQ 2.5MG BASE | A203741 | 001 | Jun 24, 2015 |
| | EQ 5MG BASE | A203741 | 002 | Jun 24, 2015 |
| | EQ 10MG BASE | A203741 | 003 | Jun 24, 2015 |
| | EQ 20MG BASE | A203741 | 004 | Jun 24, 2015 |
| AMERIGEN PHARMS LTD | EQ 2.5MG BASE | A203659 | 001 | Apr 16, 2015 |
| | EQ 5MG BASE | A203659 | 002 | Apr 16, 2015 |
| | EQ 10MG BASE | A203659 | 003 | Apr 16, 2015 |
| | EQ 20MG BASE | A203659 | 004 | Apr 16, 2015 |
| GLENMARK PHARMS LTD | EQ 2.5MG BASE | A203821 | 001 | May 25, 2017 |
| | EQ 5MG BASE | A203821 | 002 | May 25, 2017 |
| | EQ 10MG BASE | A203821 | 003 | May 25, 2017 |
| | EQ 20MG BASE | A203821 | 004 | May 25, 2017 |
| INDCHEMIE HEALTH | EQ 2.5MG BASE | A203828 | 001 | Jul 29, 2015 |
| | EQ 5MG BASE | A203828 | 002 | Jul 29, 2015 |
| | EQ 10MG BASE | A203828 | 003 | Jul 29, 2015 |
| | EQ 20MG BASE | A203828 | 004 | Jul 29, 2015 |
| WATSON LABS INC | EQ 2.5MG BASE | A203683 | 001 | Nov 27, 2015 |
| | EQ 5MG BASE | A203683 | 002 | Nov 27, 2015 |
| | EQ 10MG BASE | A203683 | 003 | Nov 27, 2015 |
| | EQ 20MG BASE | A203683 | 004 | Nov 27, 2015 |
| NEDOCROMIL SODIUM | | | | |
| AEROSOL, METERED;INHALATION | | | | |
| TILADE | | | | |
| KING PHARMS LLC | 1.75MG/INH | N019660 | 001 | Dec 30, 1992 |
| SOLUTION;INHALATION | | | | |
| TILADE | | | | |
| SANOFI AVENTIS US | 0.5% | N020750 | 001 | Oct 01, 1997 |
| NEFAZODONE HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| NEFAZODONE HYDROCHLORIDE | | | | |
| DR REDDYS LABS INC | 50MG | A076309 | 001 | Sep 16, 2003 |
| | 100MG | A076309 | 002 | Sep 16, 2003 |
| | 150MG | A076309 | 003 | Sep 16, 2003 |
| | 200MG | A076309 | 004 | Sep 16, 2003 |
| | 250MG | A076309 | 005 | Sep 16, 2003 |
| IDT AUSTRALIA LTD | 50MG | A076072 | 001 | Sep 16, 2003 |
| | 100MG | A076072 | 002 | Sep 16, 2003 |
| | 150MG | A076072 | 003 | Sep 16, 2003 |
| | 200MG | A076072 | 004 | Sep 16, 2003 |
| | 250MG | A076072 | 005 | Sep 16, 2003 |
| IVAX SUB TEVA PHARMS | 50MG | A075763 | 001 | Sep 16, 2003 |
| | 100MG | A075763 | 002 | Sep 16, 2003 |
| | 150MG | A075763 | 003 | Sep 16, 2003 |
| | 200MG | A075763 | 004 | Sep 16, 2003 |
| | 250MG | A075763 | 005 | Sep 16, 2003 |
| MYLAN | 100MG | A076129 | 002 | Sep 16, 2003 |
| | 150MG | A076129 | 003 | Sep 16, 2003 |
| | 200MG | A076129 | 004 | Sep 16, 2003 |
| | 250MG | A076129 | 005 | Sep 16, 2003 |
| ROXANE | 50MG | A076196 | 001 | Sep 16, 2003 |
| | 100MG | A076196 | 002 | Sep 16, 2003 |
| | 150MG | A076196 | 003 | Sep 16, 2003 |
| | 200MG | A076196 | 004 | Sep 16, 2003 |
| | 250MG | A076196 | 005 | Sep 16, 2003 |
| SANDOZ | 50MG | A076302 | 001 | Sep 16, 2003 |
| | 100MG | A076302 | 002 | Sep 16, 2003 |
| | 150MG | A076302 | 003 | Sep 16, 2003 |
| | 200MG | A076302 | 004 | Sep 16, 2003 |
| | 250MG | A076302 | 005 | Sep 16, 2003 |
| SUN PHARM INDS LTD | 50MG | A076409 | 001 | Sep 16, 2003 |

NEFAZODONE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| NEFAZODONE HYDROCHLORIDE | | | | |
| | 100MG | A076409 | 002 | Sep 16, 2003 |
| | 150MG | A076409 | 003 | Sep 16, 2003 |
| | 200MG | A076409 | 004 | Sep 16, 2003 |
| | 250MG | A076409 | 005 | Sep 16, 2003 |
| WATSON LABS | 100MG | A076073 | 002 | Sep 16, 2003 |
| | 150MG | A076073 | 003 | Sep 16, 2003 |
| | 200MG | A076073 | 004 | Sep 16, 2003 |
| | 250MG | A076073 | 005 | Sep 16, 2003 |
| SERZONE | | | | |
| + BRISTOL MYERS SQUIBB | 50MG ** | N020152 | 001 | Dec 22, 1994 |
| + | 100MG ** | N020152 | 002 | Dec 22, 1994 |
| + | 150MG ** | N020152 | 003 | Dec 22, 1994 |
| + | 200MG ** | N020152 | 004 | Dec 22, 1994 |
| + | 250MG ** | N020152 | 005 | Dec 22, 1994 |
| + | 300MG ** | N020152 | 006 | Dec 22, 1994 |

NELFINAVIR MESYLATE

| | | | | |
|---|---|---|---|---|
| POWDER;ORAL | | | | |
| VIRACEPT | | | | |
| AGOURON PHARMS | EQ 50MG BASE/SCOOPFUL | N020778 | 001 | Mar 14, 1997 |

NEOMYCIN SULFATE

| | | | | |
|---|---|---|---|---|
| POWDER;FOR RX COMPOUNDING | | | | |
| NEO-RX | | | | |
| X GEN PHARMS | 100% | A061579 | 001 | |
| SOLUTION;ORAL | | | | |
| MYCIFRADIN | | | | |
| PHARMACIA AND UPJOHN | EQ 87.5MG BASE/5ML | N050285 | 001 | |
| NEO-FRADIN | | | | |
| X GEN PHARMS | EQ 87.5MG BASE/5ML | A065010 | 001 | May 23, 2002 |
| TABLET;ORAL | | | | |
| MYCIFRADIN | | | | |
| PHARMACIA AND UPJOHN | EQ 350MG BASE | A060520 | 001 | |
| NEOBIOTIC | | | | |
| PFIZER | EQ 350MG BASE | A060475 | 001 | |
| NEOMYCIN SULFATE | | | | |
| BRISTOL MYERS SQUIBB | 500MG | A060365 | 001 | |
| LANNETT | 500MG | A060607 | 001 | |
| LILLY | 500MG | A060385 | 001 | |
| ROXANE | 500MG | A062173 | 001 | |
| SANDOZ | 500MG | A061586 | 001 | |

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

| | | | | |
|---|---|---|---|---|
| CREAM;TOPICAL | | | | |
| NEOSPORIN | | | | |
| GLAXOSMITHKLINE | EQ 3.5MG BASE/GM;10,000 UNITS/GM | N050176 | 002 | Jan 14, 1985 |
| OINTMENT;OPHTHALMIC | | | | |
| STATROL | | | | |
| ALCON | EQ 3.5MG BASE/GM;10,000 UNITS/GM | N050344 | 002 | |
| SOLUTION/DROPS;OPHTHALMIC | | | | |
| STATROL | | | | |
| ALCON | EQ 3.5MG BASE/ML;16,250 UNITS/ML | A062339 | 001 | Nov 30, 1984 |
| | EQ 3.5MG BASE/ML;16,250 UNITS/ML | N050456 | 001 | |

NEOMYCIN SULFATE; POLYMYXIN B SULFATE; PREDNISOLONE ACETATE

| | | | | |
|---|---|---|---|---|
| SUSPENSION/DROPS;OPHTHALMIC | | | | |
| POLY-PRED | | | | |
| ALLERGAN | EQ 0.35% BASE;10,000 UNITS/ML;0.5% | N050081 | 002 | |

NEOMYCIN SULFATE; PREDNISOLONE ACETATE

| | | | | |
|---|---|---|---|---|
| OINTMENT;OPHTHALMIC | | | | |
| NEO-DELTA-CORTEF | | | | |
| PHARMACIA AND UPJOHN | EQ 3.5MG BASE/GM;0.25% | A061039 | 002 | |
| | EQ 3.5MG BASE/GM;0.5% | A061039 | 001 | |
| SUSPENSION/DROPS;OPHTHALMIC | | | | |
| NEO-DELTA-CORTEF | | | | |
| PHARMACIA AND UPJOHN | EQ 3.5MG BASE/ML;0.25% | A061037 | 001 | |

NEOMYCIN SULFATE; PREDNISOLONE SODIUM PHOSPHATE

OINTMENT;OPHTHALMIC

NEO-HYDELTRASOL

| | | | | |
|---|---|---|---|---|
| MERCK | EQ 3.5MG BASE/GM;EQ 0.25% PHOSPHATE | N050378 | 001 | |

NEOMYCIN SULFATE; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

MYTREX A

| | | | | |
|---|---|---|---|---|
| SAVAGE LABS | EQ 3.5MG BASE/GM;0.1% | A062598 | 001 | Jul 21, 1986 |

NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE

| | | | | |
|---|---|---|---|---|
| FOUGERA | EQ 3.5MG BASE/GM;0.1% | A062600 | 001 | Jul 21, 1986 |
| PHARMADERM | EQ 3.5MG BASE/GM;0.1% | A062595 | 001 | Jul 21, 1986 |

OINTMENT;TOPICAL

MYTREX A

| | | | | |
|---|---|---|---|---|
| SAVAGE LABS | EQ 3.5MG BASE/GM;0.1% | A062609 | 001 | May 23, 1986 |

NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE

| | | | | |
|---|---|---|---|---|
| FOUGERA | EQ 3.5MG BASE/GM;0.1% | A062608 | 001 | May 23, 1986 |
| PHARMADERM | EQ 3.5MG BASE/GM;0.1% | A062607 | 001 | May 23, 1986 |

NETILMICIN SULFATE

INJECTABLE;INJECTION

NETROMYCIN

| | | | | |
|---|---|---|---|---|
| SCHERING | EQ 10MG BASE/ML | N050544 | 001 | Feb 28, 1983 |
| | EQ 25MG BASE/ML | N050544 | 002 | Feb 28, 1983 |
| | EQ 100MG BASE/ML | N050544 | 003 | Feb 28, 1983 |

NIACIN

CAPSULE;ORAL

WAMPOCAP

| | | | | |
|---|---|---|---|---|
| MEDPOINTE PHARM HLC | 500MG | N011073 | 003 | |

TABLET;ORAL

NIACIN

| | | | | |
|---|---|---|---|---|
| EVERYLIFE | 500MG | A083203 | 001 | |
| HALSEY | 500MG | A083453 | 001 | |
| HIKMA PHARMS | 500MG | A083718 | 001 | |
| IMPAX LABS | 500MG | A083115 | 001 | |
| IVAX SUB TEVA PHARMS | 500MG | A083180 | 001 | |
| MK LABS | 500MG | A083525 | 001 | |
| PUREPAC PHARM | 500MG | A083271 | 001 | |
| SANDOZ | 500MG | A083306 | 001 | |
| TABLICAPS | 500MG | A084237 | 001 | |
| WATSON LABS | 500MG | A083136 | 001 | |
| | 500MG | A083305 | 001 | |
| | 500MG | A085172 | 001 | |

NICOLAR

| | | | | |
|---|---|---|---|---|
| SANOFI AVENTIS US | 500MG | A083823 | 001 | |

TABLET, EXTENDED RELEASE;ORAL

NIASPAN

| | | | | |
|---|---|---|---|---|
| ABBVIE | 375MG | N020381 | 001 | Jul 28, 1997 |

NIASPAN TITRATION STARTER PACK

| | | | | |
|---|---|---|---|---|
| ABBVIE | 375MG;500MG;750MG | N020381 | 005 | Jul 28, 1997 |

NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; TYROSINE

SUSPENSION;ORAL

TPN

| | | | | |
|---|---|---|---|---|
| INTL MINERALS | 15MG/5ML;3.75MG/5ML;600MG/5ML | N008378 | 003 | |

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL

CARDENE

| | | | | |
|---|---|---|---|---|
| CHIESI USA INC | 20MG ** | N019488 | 001 | Dec 21, 1988 |
| | 30MG ** | N019488 | 002 | Dec 21, 1988 |

NICARDIPINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| WATSON LABS | 20MG | A074670 | 001 | Oct 28, 1996 |
| | 30MG | A074670 | 002 | Oct 28, 1996 |

CAPSULE, EXTENDED RELEASE;ORAL

CARDENE SR

| | | | | | |
|---|---|---|---|---|---|
| + | CHIESI USA INC | 30MG ** | N020005 | 001 | Feb 21, 1992 |
| + | | 45MG ** | N020005 | 002 | Feb 21, 1992 |
| + | | 60MG ** | N020005 | 003 | Feb 21, 1992 |

NICLOSAMIDE
TABLET, CHEWABLE;ORAL
NICLOCIDE
BAYER PHARMS 500MG N018669 001 May 14, 1982

NICOTINE
FILM, EXTENDED RELEASE;TRANSDERMAL
NICOTROL
MCNEIL CONS 15MG/16HR N020536 001 Jul 03, 1996
PROSTEP
AVEVA 11MG/24HR N019983 003 Dec 23, 1998
22MG/24HR N019983 004 Dec 23, 1998

NICOTINE POLACRILEX
GUM, CHEWING;BUCCAL
NICOTINE POLACRILEX
IVAX SUB TEVA PHARMS EQ 2MG BASE A076880 001 Feb 18, 2009
EQ 4MG BASE A077850 001 Feb 18, 2009

NIFEDIPINE
CAPSULE;ORAL
ADALAT
BAYER PHARMS 10MG N019478 001 Nov 27, 1985
20MG N019478 002 Sep 17, 1986
NIFEDIPINE
CHASE LABS NJ 10MG A072409 001 Jul 04, 1990
20MG A073421 001 Jun 19, 1991
TEVA 10MG A072651 001 Feb 19, 1992
PROCARDIA
\+ PFIZER 20MG ** N018482 002 Jul 24, 1986
TABLET, EXTENDED RELEASE;ORAL
NIFEDIPINE
MARTEC USA LLC 90MG A075414 003 Mar 23, 2004
MYLAN 30MG A075108 001 Dec 17, 1999
MYLAN LABS LTD 30MG A090602 001 Sep 13, 2010
60MG A090602 002 Sep 13, 2010
90MG A090602 003 Sep 13, 2010

NILUTAMIDE
TABLET;ORAL
NILANDRON
CONCORDIA PHARMS INC 50MG N020169 001 Sep 19, 1996

NIMODIPINE
CAPSULE;ORAL
NIMOTOP
\+ BAYER PHARMS 30MG ** N018869 001 Dec 28, 1988

NISOLDIPINE
TABLET, EXTENDED RELEASE;ORAL
SULAR
\+ COVIS PHARMA BV 10MG ** N020356 001 Feb 02, 1995
\+ 20MG ** N020356 002 Feb 02, 1995
\+ 25.5MG ** N020356 006 Jan 02, 2008
\+ 30MG ** N020356 003 Feb 02, 1995
\+ 40MG ** N020356 004 Feb 02, 1995

NITRIC OXIDE
GAS;INHALATION
INOMAX
\+ MALLINCKRODT HOSP 100PPM ** N020845 002 Dec 23, 1999

NITROFURANTOIN
CAPSULE;ORAL
NITROFURANTOIN
WATSON LABS 50MG A084326 001
100MG A084326 002
TABLET;ORAL
FURADANTIN
PROCTER AND GAMBLE 50MG N008693 001
100MG N008693 002
FURALAN
LANNETT 50MG A080017 001

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

NITROFURANTOIN

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| FURALAN | | | | |
| | 100MG | | A080017 002 | |
| NITROFURANTOIN | | | | |
| ELKINS SINN | 50MG | | A080003 001 | |
| | 100MG | | A080003 002 | |
| IVAX SUB TEVA PHARMS | 50MG | | A080078 002 | |
| | 100MG | | A080078 001 | |
| SANDOZ | 50MG | | A080043 001 | |
| | 100MG | | A080043 002 | |
| WATSON LABS | 50MG | | A080447 001 | |
| | 50MG | | A085797 001 | |
| | 100MG | | A080447 002 | |
| | 100MG | | A085796 001 | |
| WHITEWORTH TOWN PLSN | 100MG | | A084085 002 | |

NITROFURANTOIN SODIUM

| | | | |
|---|---|---|---|
| INJECTABLE;INJECTION | | | |
| IVADANTIN | | | |
| PROCTER AND GAMBLE | EQ 180MG BASE/VIAL | N012402 001 | |

NITROFURANTOIN, MACROCRYSTALLINE

| | | | |
|---|---|---|---|
| CAPSULE;ORAL | | | |
| NITROFURANTOIN | | | |
| MYLAN | 100MG | A074967 002 | Jul 09, 1997 |
| SANDOZ | 25MG | A074336 001 | Jan 25, 1995 |
| | 50MG | A074336 002 | Jan 25, 1995 |
| | 100MG | A074336 003 | Jan 25, 1995 |
| WATSON LABS | 25MG | A073696 001 | Dec 31, 1992 |
| | 50MG | A073696 002 | Dec 31, 1992 |
| | 100MG | A073696 003 | Dec 31, 1992 |
| NITROFURANTOIN MACROCRYSTALLINE | | | |
| WATSON LABS | 50MG | A070248 001 | Jun 24, 1988 |
| | 100MG | A070249 001 | Jun 24, 1988 |

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

| | | | |
|---|---|---|---|
| CAPSULE;ORAL | | | |
| NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS) | | | |
| RANBAXY LABS LTD | 75MG;25MG | A076951 001 | Mar 30, 2005 |

NITROFURAZONE

| | | | |
|---|---|---|---|
| CREAM;TOPICAL | | | |
| FURACIN | | | |
| SHIRE | 0.2% | A083789 001 | |
| DRESSING;TOPICAL | | | |
| ACTIN-N | | | |
| SHERWOOD MEDCL | 0.2% | N017343 001 | |
| OINTMENT;TOPICAL | | | |
| FURACIN | | | |
| SHIRE | 0.2% | N005795 001 | |
| NITROFURAZONE | | | |
| AMBIX | 0.2% | A086077 001 | |
| LANNETT | 0.2% | A084393 001 | |
| PERRIGO NEW YORK | 0.2% | A084968 001 | |
| TARO | 0.2% | A086156 001 | |
| WENDT | 0.2% | A086766 001 | |
| POWDER;TOPICAL | | | |
| FURACIN | | | |
| SHIRE | 0.2% | A083791 001 | |
| SOLUTION;TOPICAL | | | |
| NITROFURAZONE | | | |
| PERRIGO NEW YORK | 0.2% | A085130 001 | |
| WENDT | 0.2% | A087081 001 | |

NITROGLYCERIN

| | | | |
|---|---|---|---|
| AEROSOL;SUBLINGUAL | | | |
| NITROLINGUAL | | | |
| POHL BOSKAMP | 0.4MG/SPRAY | N018705 001 | Oct 31, 1985 |

| | | | | | |
|---|---|---|---|---|---|
| NITROGLYCERIN | | | | | |
| FILM, EXTENDED RELEASE;TRANSDERMAL | | | | | |
| NITROGLYCERIN | | | | | |
| | KREMERS URBAN PHARMS | 0.2MG/HR | A075115 | 001 | Aug 10, 2004 |
| | | 0.4MG/HR | A075115 | 002 | Aug 10, 2004 |
| | MYLAN TECHNOLOGIES | 0.1MG/HR | A074992 | 004 | Nov 12, 1999 |
| | | 0.2MG/HR | A074992 | 003 | Nov 12, 1999 |
| | | 0.4MG/HR | A074992 | 002 | Nov 12, 1999 |
| | | 0.6MG/HR | A074992 | 001 | Nov 12, 1999 |
| TRANSDERM-NITRO | | | | | |
| + | NOVARTIS | 0.1MG/HR ** | N020144 | 001 | Feb 27, 1996 |
| + | | 0.2MG/HR ** | N020144 | 002 | Feb 27, 1996 |
| + | | 0.4MG/HR ** | N020144 | 003 | Feb 27, 1996 |
| + | | 0.6MG/HR ** | N020144 | 004 | Feb 27, 1996 |
| + | | 0.8MG/HR ** | N020144 | 005 | Feb 27, 1996 |
| INJECTABLE;INJECTION | | | | | |
| NITRO IV | | | | | |
| | POHL BOSKAMP | 5MG/ML | N018672 | 002 | Aug 30, 1983 |
| NITRO-BID | | | | | |
| | SANOFI AVENTIS US | 5MG/ML | N018621 | 001 | Jan 05, 1982 |
| | | 10MG/ML | A071159 | 001 | Feb 28, 1990 |
| NITROGLYCERIN | | | | | |
| | ABRAXIS PHARM | 5MG/ML | A070077 | 001 | Dec 13, 1985 |
| | | 5MG/ML | A071203 | 001 | May 08, 1987 |
| + | HOSPIRA | 5MG/ML ** | N018531 | 001 | |
| | INTL MEDICATION | 5MG/ML | A070026 | 001 | Sep 10, 1985 |
| | LUITPOLD | 5MG/ML | A071492 | 001 | May 24, 1988 |
| | SMITH AND NEPHEW | 5MG/ML | A070633 | 001 | Jun 19, 1986 |
| | | 5MG/ML | A070634 | 001 | Jun 19, 1986 |
| NITROGLYCERIN IN DEXTROSE 5% | | | | | |
| | HOSPIRA | 0.1MG/ML | A074083 | 001 | Oct 26, 1994 |
| NITROL | | | | | |
| | RORER | 0.8MG/ML | N018774 | 001 | Jan 19, 1983 |
| NITRONAL | | | | | |
| | POHL BOSKAMP | 1MG/ML | N018672 | 001 | Aug 30, 1983 |
| NITROSTAT | | | | | |
| | PARKE DAVIS | 0.8MG/ML | N018588 | 001 | |
| | | 5MG/ML | A070863 | 001 | Jan 08, 1987 |
| | | 5MG/ML | N018588 | 002 | Dec 23, 1983 |
| | | 10MG/ML | A070871 | 001 | Jan 08, 1987 |
| | | 10MG/ML | A070872 | 001 | Jan 08, 1987 |
| TRIDIL | | | | | |
| | HOSPIRA | 0.5MG/ML | N018537 | 002 | Jun 16, 1983 |
| | | 5MG/ML | N018537 | 001 | |
| NIZATIDINE | | | | | |
| CAPSULE;ORAL | | | | | |
| AXID | | | | | |
| | SMITHKLINE BEECHAM | 150MG | N019508 | 001 | Apr 12, 1988 |
| | | 300MG | N019508 | 002 | Apr 12, 1988 |
| NIZATIDINE | | | | | |
| | ANI PHARMS INC | 150MG | A075461 | 001 | Jul 08, 2002 |
| | | 300MG | A075461 | 002 | Jul 08, 2002 |
| | APOTEX INC | 150MG | A076383 | 001 | Jan 23, 2003 |
| | | 300MG | A076383 | 002 | Jan 23, 2003 |
| | MYLAN PHARMS INC | 150MG | A075934 | 001 | Jul 09, 2002 |
| | | 300MG | A075934 | 002 | Jul 09, 2002 |
| SOLUTION;ORAL | | | | | |
| AXID | | | | | |
| + | BRAINTREE | 15MG/ML ** | N021494 | 001 | May 25, 2004 |
| NONOXYNOL-9 | | | | | |
| AEROSOL;VAGINAL | | | | | |
| DELFEN | | | | | |
| | PERSONAL PRODS | 12.5% | N014349 | 002 | |

| | | | | |
|---|---|---|---|---|
| NOREPINEPHRINE BITARTRATE | | | | |
| INJECTABLE;INJECTION | | | | |
| NOREPINEPHRINE BITARTRATE | | | | |
| METRICS PHARM | EQ 1MG BASE/ML | A040522 | 001 | Sep 30, 2004 |
| NOREPINEPHRINE BITARTRATE; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| RAVOCAINE AND NOVOCAIN W/ LEVOPHED | | | | |
| EASTMAN KODAK | EQ 0.033MG BASE/ML;2%;0.4% | N008592 | 003 | |
| NORETHINDRONE | | | | |
| TABLET;ORAL | | | | |
| NORLUTIN | | | | |
| PARKE DAVIS | 5MG | N010895 | 002 | |
| NORETHINDRONE ACETATE | | | | |
| TABLET;ORAL | | | | |
| NORLUTATE | | | | |
| PARKE DAVIS | 5MG | N012184 | 002 | |
| NORFLOXACIN | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | |
| CHIBROXIN | | | | |
| MERCK | 0.3% | N019757 | 001 | Jun 17, 1991 |
| TABLET;ORAL | | | | |
| NOROXIN | | | | |
| + MERCK | 400MG ** | N019384 | 002 | Oct 31, 1986 |
| NORGESTREL | | | | |
| TABLET;ORAL | | | | |
| OPILL | | | | |
| + LABORATOIRE HRA | 0.075MG | N017031 | 001 | |
| NORTRIPTYLINE HYDROCHLORIDE | | | | |
| CAPSULE;ORAL | | | | |
| AVENTYL HYDROCHLORIDE | | | | |
| LILLY | EQ 10MG BASE | N014684 | 001 | |
| | EQ 25MG BASE | N014684 | 002 | |
| NORTRIPTYLINE HYDROCHLORIDE | | | | |
| AUROLIFE PHARMA LLC | EQ 10MG BASE | A074835 | 001 | Jun 30, 1997 |
| | EQ 25MG BASE | A074835 | 002 | Jun 30, 1997 |
| | EQ 50MG BASE | A074835 | 003 | Jun 30, 1997 |
| | EQ 75MG BASE | A074835 | 004 | Jun 30, 1997 |
| IDT AUSTRALIA LTD | EQ 10MG BASE | A074054 | 001 | Dec 31, 1992 |
| | EQ 25MG BASE | A074054 | 002 | Dec 31, 1992 |
| | EQ 50MG BASE | A074054 | 003 | Dec 31, 1992 |
| | EQ 75MG BASE | A074054 | 004 | Dec 31, 1992 |
| MYLAN | EQ 10MG BASE | A074234 | 001 | Jul 26, 1993 |
| | EQ 25MG BASE | A074234 | 002 | Jul 26, 1993 |
| | EQ 50MG BASE | A074234 | 003 | Jul 26, 1993 |
| | EQ 75MG BASE | A074234 | 004 | Jul 26, 1993 |
| TEVA | EQ 10MG BASE | A073667 | 001 | Apr 11, 1996 |
| | EQ 25MG BASE | A073667 | 002 | Apr 11, 1996 |
| | EQ 50MG BASE | A073667 | 003 | Apr 11, 1996 |
| | EQ 75MG BASE | A073667 | 004 | Apr 11, 1996 |
| SOLUTION;ORAL | | | | |
| AVENTYL | | | | |
| + RANBAXY | EQ 10MG BASE/5ML ** | N014685 | 001 | |
| PAMELOR | | | | |
| SPECGX LLC | EQ 10MG BASE/5ML | N018012 | 001 | |
| NYSTATIN | | | | |
| CREAM;TOPICAL | | | | |
| CANDEX | | | | |
| BAYER PHARMS | 100,000 UNITS/GM | A061810 | 001 | |
| MYCOSTATIN | | | | |
| DELCOR ASSET CORP | 100,000 UNITS/GM ** | A060575 | 001 | |
| MYKINAC | | | | |
| ALPHARMA US PHARMS | 100,000 UNITS/GM | A062387 | 001 | Jul 29, 1982 |
| NILSTAT | | | | |
| LEDERLE | 100,000 UNITS/GM | A061445 | 001 | |

NYSTATIN

| | | | | |
|---|---|---|---|---|
| CREAM;TOPICAL | | | | |
| NYSTATIN | | | | |
| TARO | 100,000 UNITS/GM | A062457 | 001 | Jul 28, 1983 |
| LOTION;TOPICAL | | | | |
| CANDEX | | | | |
| BAYER PHARMS | 100,000 UNITS/ML | N050233 | 001 | |
| OINTMENT;TOPICAL | | | | |
| MYCOSTATIN | | | | |
| DELCOR ASSET CORP | 100,000 UNITS/GM ** | A060571 | 001 | |
| MYKINAC | | | | |
| ALPHARMA US PHARMS | 100,000 UNITS/GM | A062731 | 001 | Sep 22, 1986 |
| NILSTAT | | | | |
| LEDERLE | 100,000 UNITS/GM | A061444 | 001 | |
| PASTILLE;ORAL | | | | |
| MYCOSTATIN | | | | |
| DELCOR ASSET CORP | 200,000 UNITS | N050619 | 001 | Apr 09, 1987 |
| POWDER;ORAL | | | | |
| BARSTATIN 100 | | | | |
| BARLAN | 100% | A062489 | 001 | Apr 27, 1988 |
| NILSTAT | | | | |
| + DAVA PHARMS INC | 100% ** | N050576 | 001 | Dec 22, 1983 |
| NYSTATIN | | | | |
| PADDOCK LLC | 100% | A062613 | 001 | Nov 26, 1985 |
| POWDER;TOPICAL | | | | |
| MYCOSTATIN | | | | |
| DELCOR ASSET CORP | 100,000 UNITS/GM ** | A060578 | 001 | |
| NYSTATIN | | | | |
| NESHER PHARMS | 100,000 UNITS/GM | A065321 | 001 | Aug 18, 2006 |
| SUPPOSITORY;VAGINAL | | | | |
| NYSERT | | | | |
| WARNER CHILCOTT | 100,000 UNITS | N050478 | 001 | |
| SUSPENSION;ORAL | | | | |
| MYCOSTATIN | | | | |
| DELCOR ASSET CORP | 100,000 UNITS/ML | A061533 | 001 | |
| NILSTAT | | | | |
| + GLENMARK GENERICS | 100,000 UNITS/ML | N050299 | 001 | |
| NYSTATIN | | | | |
| ALLIED PHARMA INC | 100,000 UNITS/ML | A062832 | 001 | Dec 27, 1991 |
| ALPHARMA US PHARMS | 100,000 UNITS/ML | A062571 | 001 | Oct 29, 1985 |
| G AND W LABS INC | 100,000 UNITS/ML | A062776 | 001 | Dec 17, 1987 |
| MORTON GROVE | 100,000 UNITS/ML | A062835 | 001 | Nov 19, 1987 |
| PHARMADERM | 100,000 UNITS/ML | A062518 | 001 | Jul 06, 1984 |
| PHARMAFAIR | 100,000 UNITS/ML | A062541 | 001 | Jan 16, 1985 |
| TEVA | 100,000 UNITS/ML | A062670 | 001 | Jun 18, 1987 |
| NYSTEX | | | | |
| SAVAGE LABS | 100,000 UNITS/ML | A062519 | 001 | Jul 06, 1984 |
| TABLET;ORAL | | | | |
| MYCOSTATIN | | | | |
| DELCOR ASSET CORP | 500,000 UNITS | A060574 | 001 | |
| NILSTAT | | | | |
| LEDERLE | 500,000 UNITS | A061151 | 001 | |
| NYSTATIN | | | | |
| QUANTUM PHARMICS | 500,000 UNITS | A062525 | 001 | Oct 29, 1984 |
| SANDOZ | 500,000 UNITS | A062065 | 001 | |
| USL PHARMA | 500,000 UNITS | A062524 | 001 | Nov 26, 1985 |
| WATSON LABS | 500,000 UNITS | A062402 | 001 | Dec 16, 1982 |
| TABLET;VAGINAL | | | | |
| KOROSTATIN | | | | |
| HOLLAND RANTOS | 100,000 UNITS | A061718 | 001 | |
| MYCOSTATIN | | | | |
| DELCOR ASSET CORP | 100,000 UNITS | A060577 | 001 | |
| NILSTAT | | | | |
| LEDERLE | 100,000 UNITS | A061325 | 001 | |
| NYSTATIN | | | | |
| FOUGERA | 100,000 UNITS | A062459 | 001 | Nov 09, 1983 |
| PHARMADERM | 100,000 UNITS | A062460 | 001 | Nov 09, 1983 |
| QUANTUM PHARMICS | 100,000 UNITS | A062509 | 001 | Apr 03, 1984 |
| SANDOZ | 100,000 UNITS | A061965 | 001 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

NYSTATIN

| | | | | |
|---|---|---|---|---|
| TABLET;VAGINAL | | | | |
| NYSTATIN | | | | |
| TEVA | 100,000 UNITS | A062502 | 001 | Dec 23, 1983 |
| WATSON LABS | 100,000 UNITS | A062176 | 001 | |

NYSTATIN; TRIAMCINOLONE ACETONIDE

| | | | | |
|---|---|---|---|---|
| CREAM;TOPICAL | | | | |
| MYCO-TRIACET II | | | | |
| TEVA | 100,000 UNITS/GM;0.1% | A061954 | 002 | Sep 20, 1985 |
| MYCOLOG-II | | | | |
| DELCOR ASSET CORP | 100,000 UNITS/GM;0.1% ** | A060576 | 002 | May 01, 1985 |
| MYLAN PHARMS INC | 100,000 UNITS/GM;0.1% ** | A062606 | 001 | May 15, 1985 |
| MYTREX F | | | | |
| SAVAGE LABS | 100,000 UNITS/GM;0.1% | A062597 | 001 | Oct 08, 1985 |
| NYSTATIN AND TRIAMCINOLONE ACETONIDE | | | | |
| ALPHARMA US PHARMS | 100,000 UNITS/GM;0.1% | A063010 | 001 | Dec 20, 1988 |
| PERRIGO NEW YORK | 100,000 UNITS/GM;0.1% | A062186 | 002 | Jun 06, 1985 |
| PHARMAFAIR | 100,000 UNITS/GM;0.1% | A062657 | 001 | Jul 30, 1986 |
| TARO | 100,000 UNITS/GM;0.1% | A062347 | 001 | Mar 30, 1987 |
| NYSTATIN TRIAMCINOLONE ACETONIDE | | | | |
| PHARMADERM | 100,000 UNITS/GM;0.1% | A062596 | 001 | Oct 08, 1985 |
| OINTMENT;TOPICAL | | | | |
| MYCO-TRIACET II | | | | |
| TEVA | 100,000 UNITS/GM;0.1% | A062045 | 002 | Nov 26, 1985 |
| MYCOLOG-II | | | | |
| MYLAN PHARMS INC | 100,000 UNITS/GM;0.1% ** | A060572 | 001 | Jun 28, 1985 |
| MYTREX F | | | | |
| SAVAGE LABS | 100,000 UNITS/GM;0.1% | A062601 | 001 | Oct 09, 1985 |
| NYSTATIN AND TRIAMCINOLONE ACETONIDE | | | | |
| PERRIGO NEW YORK | 100,000 UNITS/GM;0.1% | A062280 | 002 | Oct 10, 1985 |
| PHARMAFAIR | 100,000 UNITS/GM;0.1% | A062656 | 001 | Jul 30, 1986 |
| NYSTATIN-TRIAMCINOLONE ACETONIDE | | | | |
| PHARMADERM | 100,000 UNITS/GM;0.1% | A062603 | 001 | Oct 09, 1985 |

OCTREOTIDE ACETATE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| OCTREOTIDE ACETATE | | | | |
| SUN PHARM INDS | EQ 0.05MG BASE/ML | A077329 | 001 | Mar 04, 2008 |
| | EQ 0.1MG BASE/ML | A077329 | 002 | Mar 04, 2008 |
| | EQ 0.2MG BASE/ML | A077330 | 001 | Mar 04, 2008 |
| | EQ 0.5MG BASE/ML | A077329 | 003 | Mar 04, 2008 |
| | EQ 1MG BASE/ML | A077331 | 001 | Mar 04, 2008 |
| WOCKHARDT USA | EQ 0.2MG BASE/ML | A090986 | 001 | May 11, 2011 |
| | EQ 1MG BASE/ML | A090986 | 002 | May 11, 2011 |
| OCTREOTIDE ACETATE PRESERVATIVE FREE | | | | |
| WOCKHARDT USA | EQ 0.05MG BASE/ML | A090985 | 001 | May 11, 2011 |
| | EQ 0.1MG BASE/ML | A090985 | 002 | May 11, 2011 |
| | EQ 0.5MG BASE/ML | A090985 | 003 | May 11, 2011 |

OFLOXACIN

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| FLOXIN | | | | |
| ORTHO MCNEIL PHARM | 20MG/ML | N020087 | 002 | Mar 31, 1992 |
| | 40MG/ML | N020087 | 003 | Mar 31, 1992 |
| FLOXIN IN DEXTROSE 5% | | | | |
| ORTHO MCNEIL PHARM | 400MG/100ML | N020087 | 001 | Mar 31, 1992 |
| FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| ORTHO MCNEIL PHARM | 4MG/ML | N020087 | 004 | Mar 31, 1992 |
| | 400MG/100ML | N020087 | 005 | Mar 31, 1992 |
| OFLOXACIN | | | | |
| BEDFORD | 40MG/ML | A075762 | 001 | Jan 16, 2002 |
| SOLUTION/DROPS;OPHTHALMIC | | | | |
| OFLOXACIN | | | | |
| APOTEX INC | 0.3% | A076513 | 001 | May 14, 2004 |
| SANDOZ | 0.3% | A076848 | 001 | Nov 25, 2008 |
| SOLUTION/DROPS;OTIC | | | | |
| FLOXIN OTIC | | | | |
| + DAIICHI | 0.3% ** | N020799 | 001 | Dec 16, 1997 |

| | | | | |
|---|---|---|---|---|
| OFLOXACIN | | | | |
| TABLET;ORAL | | | | |
| FLOXIN | | | | |
| | JANSSEN PHARMS | 200MG ** | N019735 001 | Dec 28, 1990 |
| | | 300MG ** | N019735 002 | Dec 28, 1990 |
| | | 400MG ** | N019735 003 | Dec 28, 1990 |
| OFLOXACIN | | | | |
| | LARKEN LABS | 200MG | A076093 001 | Sep 02, 2003 |
| | | 300MG | A076093 002 | Sep 02, 2003 |
| | RANBAXY LABS LTD | 200MG | A076220 001 | Sep 02, 2003 |
| | | 300MG | A076220 002 | Sep 02, 2003 |
| | | 400MG | A076220 003 | Sep 02, 2003 |
| OLANZAPINE | | | | |
| TABLET;ORAL | | | | |
| OLANZAPINE | | | | |
| | AJANTA PHARMA LTD | 2.5MG | A206711 001 | Aug 30, 2016 |
| | | 5MG | A206711 002 | Aug 30, 2016 |
| | | 7.5MG | A206711 003 | Aug 30, 2016 |
| | | 10MG | A206711 004 | Aug 30, 2016 |
| | | 15MG | A206711 005 | Aug 30, 2016 |
| | | 20MG | A206711 006 | Aug 30, 2016 |
| | MYLAN PHARMS INC | 2.5MG | A076866 001 | Apr 23, 2012 |
| | | 5MG | A076866 002 | Apr 23, 2012 |
| | | 7.5MG | A076866 003 | Apr 23, 2012 |
| | | 10MG | A076866 004 | Apr 23, 2012 |
| | | 15MG | A076866 005 | Apr 23, 2012 |
| | | 20MG | A076866 006 | Apr 23, 2012 |
| OLIVE OIL; SOYBEAN OIL | | | | |
| INJECTABLE;INJECTION | | | | |
| CLINOLIPID 20% | | | | |
| + | BAXTER HLTHCARE CORP | 16%(160GM/1000ML);4% (40GM/1000ML) | N204508 001 | Oct 03, 2013 |
| OMEGA-3-ACID ETHYL ESTERS TYPE A | | | | |
| CAPSULE;ORAL | | | | |
| OMTRYG | | | | |
| + | OSMOTICA | 1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS | N204977 001 | Apr 23, 2014 |
| OMEPRAZOLE | | | | |
| CAPSULE, DELAYED REL PELLETS;ORAL | | | | |
| PRILOSEC | | | | |
| + | ASTRAZENECA PHARMS | 10MG ** | N019810 003 | Oct 05, 1995 |
| + | | 20MG ** | N019810 001 | Sep 14, 1989 |
| + | | 40MG ** | N019810 002 | Jan 15, 1998 |
| ONDANSETRON | | | | |
| TABLET, ORALLY DISINTEGRATING;ORAL | | | | |
| ONDANSETRON | | | | |
| | CHARTWELL MOLECULES | 4MG | A076506 001 | Dec 26, 2006 |
| | | 8MG | A076506 002 | Dec 26, 2006 |
| | | 16MG | A077406 001 | Dec 26, 2006 |
| | | 24MG | A077406 002 | Dec 26, 2006 |
| | NESHER PHARMS | 4MG | A077717 001 | Jun 25, 2007 |
| | | 8MG | A077717 002 | Jun 25, 2007 |
| ONDANSETRON HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| ONDANSETRON HYDROCHLORIDE | | | | |
| | APOTEX INC | EQ 2MG BASE/ML | A077368 001 | Dec 26, 2006 |
| | HOSPIRA | EQ 2MG BASE/ML | A076695 001 | Dec 26, 2006 |
| | LANNETT | EQ 2MG BASE/ML | A090116 001 | Apr 14, 2010 |
| | | EQ 2MG BASE/ML | A090883 001 | Aug 05, 2010 |
| | LUITPOLD | EQ 2MG BASE/ML | A077582 001 | Dec 26, 2006 |
| | MYLAN LABS LTD | EQ 2MG BASE/ML | A078257 001 | Apr 23, 2008 |
| | PLIVA HRVATSKA DOO | EQ 2MG BASE/ML | A077544 001 | Dec 26, 2006 |
| | SAGENT PHARMS | EQ 2MG BASE/ML | A078180 001 | Mar 26, 2007 |
| | SUN PHARM INDS (IN) | EQ 2MG BASE/ML | A077172 001 | Dec 26, 2006 |
| ONDANSETRON HYDROCHLORIDE AND DEXTROSE IN PLASTIC CONTAINER | | | | |
| | HOSPIRA | EQ 0.64MG BASE/ML | A076978 001 | Feb 26, 2007 |

| | | | | |
|---|---|---|---|---|
| ONDANSETRON HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE | | | | |
| APOTEX INC | EQ 2MG BASE/ML | A077343 | 001 | Dec 26, 2006 |
| HOSPIRA | EQ 2MG BASE/ML | A076696 | 001 | Dec 26, 2006 |
| LUITPOLD | EQ 2MG BASE/ML | A077387 | 001 | Dec 26, 2006 |
| MYLAN LABS LTD | EQ 2MG BASE/ML | A078244 | 001 | Apr 23, 2008 |
| TARO PHARMS IRELAND | EQ 2MG BASE/ML | A078014 | 001 | Mar 21, 2008 |
| ZOFRAN | | | | |
| + NOVARTIS PHARMS CORP | EQ 2MG BASE/ML ** | N020007 | 001 | Jan 04, 1991 |
| ZOFRAN AND DEXTROSE IN PLASTIC CONTAINER | | | | |
| + GLAXOSMITHKLINE | EQ 0.64MG BASE/ML ** | N020403 | 001 | Jan 31, 1995 |
| ZOFRAN PRESERVATIVE FREE | | | | |
| + NOVARTIS PHARMS CORP | EQ 2MG BASE/ML ** | N020007 | 003 | Dec 10, 1993 |
| TABLET;ORAL | | | | |
| ONDANSETRON HYDROCHLORIDE | | | | |
| CHARTWELL MOLECULES | EQ 4MG BASE | A077303 | 001 | Jun 25, 2007 |
| | EQ 8MG BASE | A077303 | 002 | Jun 25, 2007 |
| | EQ 24MG BASE | A077303 | 004 | Jun 25, 2007 |
| HIKMA INTL PHARMS | EQ 4MG BASE | A077545 | 001 | Sep 06, 2007 |
| | EQ 8MG BASE | A077545 | 002 | Sep 06, 2007 |
| | EQ 24MG BASE | A077545 | 003 | Sep 06, 2007 |
| TARO | EQ 4MG BASE | A077729 | 001 | Mar 28, 2011 |
| | EQ 8MG BASE | A077729 | 002 | Mar 28, 2011 |
| | EQ 24MG BASE | A077729 | 003 | Mar 28, 2011 |
| ORPHENADRINE CITRATE | | | | |
| INJECTABLE;INJECTION | | | | |
| NORFLEX | | | | |
| TELIGENT | 30MG/ML | N013055 | 001 | |
| ORPHENADRINE CITRATE | | | | |
| WATSON LABS | 30MG/ML | A087062 | 001 | |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| NORFLEX | | | | |
| + MEDICIS | 100MG | N012157 | 001 | |
| ORPHENADRINE CITRATE | | | | |
| ASCOT | 100MG | A088067 | 001 | Apr 06, 1983 |
| SANDOZ | 100MG | A085046 | 001 | |
| WATSON LABS | 100MG | A084303 | 001 | |
| ORPHENADRINE HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| DISIPAL | | | | |
| 3M | 50MG | N010653 | 001 | |
| OSELTAMIVIR PHOSPHATE | | | | |
| FOR SUSPENSION;ORAL | | | | |
| TAMIFLU | | | | |
| ROCHE | EQ 12MG BASE/ML | N021246 | 001 | Dec 14, 2000 |
| OXACILLIN SODIUM | | | | |
| CAPSULE;ORAL | | | | |
| BACTOCILL | | | | |
| GLAXOSMITHKLINE | EQ 250MG BASE | A061336 | 001 | |
| | EQ 250MG BASE | A062241 | 001 | |
| | EQ 500MG BASE | A061336 | 002 | |
| | EQ 500MG BASE | A062241 | 002 | |
| OXACILLIN SODIUM | | | | |
| ANI PHARMS INC | EQ 250MG BASE | A062222 | 001 | |
| | EQ 500MG BASE | A062222 | 002 | |
| APOTHECON | EQ 250MG BASE | A061450 | 002 | |
| | EQ 500MG BASE | A061450 | 001 | |
| PROSTAPHLIN | | | | |
| APOTHECON | EQ 500MG BASE | N050118 | 002 | |
| FOR SOLUTION;ORAL | | | | |
| BACTOCILL | | | | |
| GLAXOSMITHKLINE | EQ 250MG BASE/5ML | A062321 | 001 | |
| OXACILLIN SODIUM | | | | |
| APOTHECON | EQ 250MG BASE/5ML | A061457 | 001 | |
| TEVA | EQ 250MG BASE/5ML | A062252 | 001 | |

| | | | | |
|---|---|---|---|---|
| OXACILLIN SODIUM | | | | |
| FOR SOLUTION;ORAL | | | | |
| PROSTAPHLIN | | | | |
| | APOTHECON | EQ 250MG BASE/5ML | N050194 001 | |
| INJECTABLE;INJECTION | | | | |
| BACTOCILL | | | | |
| | GLAXOSMITHKLINE | EQ 500MG BASE/VIAL ** | A061334 009 | Mar 26, 1982 |
| | | EQ 1GM BASE/VIAL ** | A061334 006 | Mar 26, 1982 |
| | | EQ 1GM BASE/VIAL ** | A062736 001 | Dec 19, 1986 |
| | | EQ 2GM BASE/VIAL ** | A061334 007 | Mar 26, 1982 |
| | | EQ 2GM BASE/VIAL ** | A062736 002 | Dec 19, 1986 |
| | | EQ 4GM BASE/VIAL ** | A061334 008 | Mar 26, 1982 |
| | | EQ 10GM BASE/VIAL ** | A061334 010 | |
| OXACILLIN SODIUM | | | | |
| + | APOTHECON | EQ 250MG BASE/VIAL ** | N050195 001 | |
| + | | EQ 500MG BASE/VIAL ** | N050195 002 | |
| + | | EQ 1GM BASE/VIAL ** | N050195 003 | |
| + | | EQ 2GM BASE/VIAL ** | N050195 004 | |
| + | | EQ 4GM BASE/VIAL ** | N050195 005 | |
| | ELKINS SINN | EQ 250MG BASE/VIAL | A062711 001 | Feb 03, 1989 |
| | | EQ 500MG BASE/VIAL | A062711 002 | Feb 03, 1989 |
| | | EQ 1GM BASE/VIAL | A062711 003 | Feb 03, 1989 |
| | | EQ 2GM BASE/VIAL | A062711 004 | Feb 03, 1989 |
| | | EQ 4GM BASE/VIAL | A062711 005 | Feb 03, 1989 |
| | | EQ 10GM BASE/VIAL | A062711 006 | Feb 03, 1989 |
| | ISTITUTO BIO ITA SPA | EQ 125MG BASE/VIAL | A062798 003 | Dec 11, 1995 |
| | | EQ 250MG BASE/VIAL | A062798 004 | Dec 11, 1995 |
| | | EQ 500MG BASE/VIAL | A062798 005 | Dec 11, 1995 |
| | | EQ 1GM BASE/VIAL | A062798 001 | Dec 11, 1995 |
| | | EQ 2GM BASE/VIAL | A062798 002 | Dec 11, 1995 |
| | MYLAN LABS LTD | EQ 1GM BASE/VIAL | A091486 001 | Aug 25, 2014 |
| | | EQ 2GM BASE/VIAL | A091486 002 | Aug 25, 2014 |
| | SANDOZ | EQ 250MG BASE/VIAL | A061490 001 | |
| | | EQ 500MG BASE/VIAL | A061490 002 | |
| | WATSON LABS INC | EQ 250MG BASE/VIAL | A062856 001 | Oct 26, 1988 |
| | | EQ 500MG BASE/VIAL | A062856 002 | Oct 26, 1988 |
| | | EQ 1GM BASE/VIAL | A062856 003 | Oct 26, 1988 |
| | | EQ 2GM BASE/VIAL | A062856 004 | Oct 26, 1988 |
| | | EQ 4GM BASE/VIAL | A062856 005 | Oct 26, 1988 |
| | | EQ 10GM BASE/VIAL | A062984 001 | Sep 29, 1988 |
| OXALIPLATIN | | | | |
| INJECTABLE;IV (INFUSION) | | | | |
| ELOXATIN | | | | |
| + | SANOFI AVENTIS US | 50MG/VIAL ** | N021492 001 | Aug 09, 2002 |
| + | | 100MG/VIAL ** | N021492 002 | Aug 09, 2002 |
| + | | 200MG/40ML (5MG/ML) ** | N021759 003 | Nov 17, 2006 |
| OXALIPLATIN | | | | |
| | SANDOZ | 50MG/VIAL | A090849 001 | Apr 28, 2011 |
| | | 100MG/VIAL | A090849 002 | Apr 28, 2011 |
| | SANDOZ INC | 50MG/10ML (5MG/ML) | A078812 001 | Aug 07, 2009 |
| | | 100MG/20ML (5MG/ML) | A078812 002 | Aug 07, 2009 |
| OXAMNIQUINE | | | | |
| CAPSULE;ORAL | | | | |
| VANSIL | | | | |
| | PFIZER | 250MG | N018069 001 | |
| OXANDROLONE | | | | |
| TABLET;ORAL | | | | |
| OXANDROLONE | | | | |
| | ROXANE | 2.5MG | A077249 001 | Jul 10, 2007 |
| | | 10MG | A077249 002 | Jul 10, 2007 |
| | SANDOZ | 2.5MG | A076897 001 | Dec 01, 2006 |
| | | 10MG | A076897 002 | Dec 01, 2006 |

| | | | | |
|---|---|---|---|---|
| OXAPROZIN | | | | |
| TABLET;ORAL | | | | |
| OXAPROZIN | | | | |
| ACTAVIS ELIZABETH | 600MG | A075843 | 001 | Oct 03, 2001 |
| MYLAN | 600MG | A075851 | 001 | Aug 17, 2001 |
| MYLAN PHARMS INC | 600MG | A075847 | 001 | Feb 28, 2001 |
| SANDOZ | 600MG | A075842 | 001 | Apr 12, 2001 |
| | 600MG | A075850 | 001 | Apr 27, 2001 |
| WATSON LABS | 600MG | A075848 | 001 | Feb 09, 2001 |
| OXAPROZIN POTASSIUM | | | | |
| TABLET;ORAL | | | | |
| DAYPRO ALTA | | | | |
| GD SEARLE | 600MG | N020776 | 001 | Oct 17, 2002 |
| OXAZEPAM | | | | |
| CAPSULE;ORAL | | | | |
| OXAZEPAM | | | | |
| AM THERAP | 10MG | A071955 | 001 | Mar 03, 1988 |
| | 15MG | A071956 | 001 | Mar 03, 1988 |
| | 30MG | A071957 | 001 | Mar 03, 1988 |
| ANDA REPOSITORY | 10MG | A071026 | 002 | Aug 10, 1987 |
| | 15MG | A071026 | 003 | Aug 10, 1987 |
| | 30MG | A071026 | 001 | Aug 10, 1987 |
| IVAX SUB TEVA PHARMS | 10MG | A070943 | 001 | Aug 03, 1987 |
| | 15MG | A070944 | 001 | Aug 03, 1987 |
| | 30MG | A070945 | 001 | Aug 03, 1987 |
| MYLAN | 10MG | A071713 | 001 | Oct 20, 1987 |
| | 15MG | A071714 | 001 | Oct 20, 1987 |
| | 30MG | A071715 | 001 | Oct 20, 1987 |
| WATSON LABS | 15MG | A072953 | 001 | Sep 28, 1990 |
| | 30MG | A072954 | 001 | Sep 28, 1990 |
| WATSON LABS TEVA | 10MG | A072952 | 001 | Sep 28, 1990 |
| SERAX | | | | |
| ALPHARMA US PHARMS | 10MG ** | N015539 | 002 | |
| | 15MG ** | N015539 | 004 | |
| | 30MG ** | N015539 | 006 | |
| ZAXOPAM | | | | |
| QUANTUM PHARMICS | 10MG | A070650 | 001 | Mar 01, 1988 |
| | 15MG | A070640 | 001 | Mar 01, 1988 |
| | 30MG | A070641 | 001 | Mar 01, 1988 |
| TABLET;ORAL | | | | |
| OXAZEPAM | | | | |
| PARKE DAVIS | 15MG | A071508 | 001 | Feb 02, 1987 |
| SUN PHARM INDUSTRIES | 15MG | A070683 | 001 | Jan 16, 1987 |
| WATSON LABS | 15MG | A071494 | 001 | Apr 21, 1987 |
| SERAX | | | | |
| ALPHARMA US PHARMS | 15MG ** | N015539 | 008 | |
| OXCARBAZEPINE | | | | |
| TABLET;ORAL | | | | |
| OXCARBAZEPINE | | | | |
| JUBILANT CADISTA | 150MG | A090239 | 001 | Jan 25, 2010 |
| | 300MG | A090239 | 002 | Jan 25, 2010 |
| | 600MG | A090239 | 003 | Jan 25, 2010 |
| OXPRENOLOL HYDROCHLORIDE | | | | |
| CAPSULE;ORAL | | | | |
| TRASICOR | | | | |
| NOVARTIS | 20MG | N018166 | 001 | Dec 28, 1983 |
| | 40MG | N018166 | 002 | Dec 28, 1983 |
| | 80MG | N018166 | 003 | Dec 28, 1983 |
| | 160MG | N018166 | 004 | Dec 28, 1983 |
| OXTRIPHYLLINE | | | | |
| SOLUTION;ORAL | | | | |
| CHOLEDYL | | | | |
| PARKE DAVIS | 100MG/5ML | N009268 | 012 | Nov 27, 1984 |
| OXTRIPHYLLINE | | | | |
| MORTON GROVE | 100MG/5ML | A088243 | 001 | Dec 05, 1983 |

| | | | | | |
|---|---|---|---|---|---|
| OXTRIPHYLLINE | | | | | |
| SYRUP;ORAL | | | | | |
| CHOLEDYL | | | | | |
| | PARKE DAVIS | 50MG/5ML | N009268 | 011 | |
| OXTRIPHYLLINE PEDIATRIC | | | | | |
| | MORTON GROVE | 50MG/5ML | A088242 | 001 | Dec 05, 1983 |
| TABLET, DELAYED RELEASE;ORAL | | | | | |
| CHOLEDYL | | | | | |
| | PARKE DAVIS | 100MG | N009268 | 003 | |
| | | 200MG | N009268 | 007 | |
| OXTRIPHYLLINE | | | | | |
| | WATSON LABS | 100MG | A087866 | 001 | Aug 25, 1983 |
| | | 200MG | A087835 | 001 | Aug 25, 1983 |
| TABLET, EXTENDED RELEASE;ORAL | | | | | |
| CHOLEDYL SA | | | | | |
| | WARNER CHILCOTT LLC | 600MG | A086742 | 001 | |
| OXYBUTYNIN | | | | | |
| GEL, METERED;TRANSDERMAL | | | | | |
| GELNIQUE 3% | | | | | |
| + | ALLERGAN SALES LLC | 3% | N202513 | 001 | Dec 07, 2011 |
| OXYBUTYNIN CHLORIDE | | | | | |
| SYRUP;ORAL | | | | | |
| DITROPAN | | | | | |
| + | ORTHO MCNEIL JANSSEN | 5MG/5ML ** | N018211 | 001 | |
| OXYBUTYNIN CHLORIDE | | | | | |
| | APOTEX INC | 5MG/5ML | A074997 | 001 | Oct 15, 1997 |
| | MIKART | 5MG/5ML | A075039 | 001 | Jan 29, 1999 |
| TABLET;ORAL | | | | | |
| DITROPAN | | | | | |
| + | JANSSEN PHARMS | 5MG ** | N017577 | 001 | |
| OXYBUTYNIN CHLORIDE | | | | | |
| | QUANTUM PHARMICS | 5MG | A072296 | 001 | Dec 08, 1988 |
| | USL PHARMA | 5MG | A070746 | 001 | Mar 10, 1988 |
| | WATSON LABS | 5MG | A072485 | 001 | Apr 19, 1989 |
| OXYCODONE HYDROCHLORIDE | | | | | |
| TABLET, EXTENDED RELEASE;ORAL | | | | | |
| ROXICODONE | | | | | |
| | ROXANE | 10MG | N020932 | 001 | Oct 26, 1998 |
| | | 30MG | N020932 | 002 | Oct 26, 1998 |
| OXYMETAZOLINE HYDROCHLORIDE | | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | | |
| OCUCLEAR | | | | | |
| | BAYER HEALTHCARE LLC | 0.025% | N018471 | 001 | May 30, 1986 |
| OXYMORPHONE HYDROCHLORIDE | | | | | |
| INJECTABLE;INJECTION | | | | | |
| OPANA | | | | | |
| + | ENDO PHARMS | 1MG/ML | N011707 | 002 | |
| | | 1.5MG/ML | N011707 | 001 | |
| SUPPOSITORY;RECTAL | | | | | |
| NUMORPHAN | | | | | |
| | ENDO PHARMS | 5MG | N011738 | 004 | |
| TABLET, EXTENDED RELEASE;ORAL | | | | | |
| OPANA ER | | | | | |
| | ENDO PHARMS | 5MG ** | N021610 | 001 | Jun 22, 2006 |
| + | | 5MG | N201655 | 001 | Dec 09, 2011 |
| | | 7.5MG ** | N021610 | 005 | Feb 29, 2008 |
| + | | 7.5MG | N201655 | 002 | Dec 09, 2011 |
| | | 10MG ** | N021610 | 002 | Jun 22, 2006 |
| + | | 10MG | N201655 | 003 | Dec 09, 2011 |
| | | 15MG ** | N021610 | 006 | Feb 29, 2008 |
| + | | 15MG | N201655 | 004 | Dec 09, 2011 |
| | | 20MG ** | N021610 | 003 | Jun 22, 2006 |
| + | | 20MG | N201655 | 005 | Dec 09, 2011 |
| | | 30MG ** | N021610 | 007 | Feb 29, 2008 |
| + | | 30MG | N201655 | 006 | Dec 09, 2011 |
| | | 40MG ** | N021610 | 004 | Jun 22, 2006 |
| + | | 40MG | N201655 | 007 | Dec 09, 2011 |

| | | | | |
|---|---|---|---|---|
| OXYMORPHONE HYDROCHLORIDE | | | | |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| OXYMORPHONE HYDROCHLORIDE | | | | |
| PAR PHARM | 5MG | A200792 | 001 | Oct 24, 2014 |
| | 7.5MG | A200792 | 002 | Oct 24, 2014 |
| | 10MG | A200792 | 003 | Oct 24, 2014 |
| | 15MG | A200792 | 004 | Oct 24, 2014 |
| | 20MG | A200792 | 005 | Oct 24, 2014 |
| | 30MG | A200792 | 006 | Oct 24, 2014 |
| | 40MG | A200792 | 007 | Oct 24, 2014 |
| OXYPHENBUTAZONE | | | | |
| TABLET;ORAL | | | | |
| OXYPHENBUTAZONE | | | | |
| WATSON LABS | 100MG | A088399 | 001 | Sep 17, 1984 |
| TANDEARIL | | | | |
| NOVARTIS | 100MG | N012542 | 004 | Sep 03, 1982 |
| OXYPHENCYCLIMINE HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| DARICON | | | | |
| PFIZER | 10MG | N011612 | 001 | |
| OXYPHENONIUM BROMIDE | | | | |
| TABLET;ORAL | | | | |
| ANTRENYL | | | | |
| NOVARTIS | 5MG | N008492 | 002 | |
| OXYTETRACYCLINE | | | | |
| TABLET;ORAL | | | | |
| TERRAMYCIN | | | | |
| PFIZER | 250MG | N050287 | 001 | |
| OXYTETRACYCLINE CALCIUM | | | | |
| SYRUP;ORAL | | | | |
| TERRAMYCIN | | | | |
| PFIZER | EQ 125MG BASE/5ML | A060595 | 001 | |
| OXYTETRACYCLINE HYDROCHLORIDE | | | | |
| CAPSULE;ORAL | | | | |
| OXY-KESSO-TETRA | | | | |
| FERRANTE | EQ 250MG BASE | A060179 | 001 | |
| OXYTETRACYCLINE HYDROCHLORIDE | | | | |
| HIKMA PHARMS | EQ 250MG BASE | A060770 | 001 | |
| IMPAX LABS | EQ 250MG BASE | A060760 | 001 | |
| PROTER | EQ 250MG BASE | A060869 | 001 | |
| PUREPAC PHARM | EQ 250MG BASE | A060634 | 001 | |
| TERRAMYCIN | | | | |
| PFIZER | EQ 125MG BASE | N050286 | 001 | |
| | EQ 250MG BASE | N050286 | 002 | |
| INJECTABLE;INJECTION | | | | |
| TERRAMYCIN | | | | |
| PFIZER | EQ 250MG BASE/VIAL | A060586 | 001 | |
| | EQ 500MG BASE/VIAL | A060586 | 002 | |
| OXYTETRACYCLINE HYDROCHLORIDE; POLYMYXIN B SULFATE | | | | |
| OINTMENT;OTIC | | | | |
| TERRAMYCIN W/ POLYMYXIN | | | | |
| PFIZER | EQ 5MG BASE/GM;10,000 UNITS/GM | A061841 | 001 | |
| TABLET;VAGINAL | | | | |
| TERRAMYCIN-POLYMYXIN | | | | |
| PFIZER | EQ 100MG BASE;100,000 UNITS | A061009 | 001 | |
| OXYTOCIN | | | | |
| INJECTABLE;INJECTION | | | | |
| OXYTOCIN | | | | |
| TEVA PHARMS USA | 10USP UNITS/ML (10USP UNITS/ML) | A077453 | 001 | Jan 24, 2008 |
| | 100USP UNITS/10ML (10USP UNITS/ML) | A077453 | 002 | Jan 24, 2008 |
| OXYTOCIN 10 USP UNITS IN DEXTROSE 5% | | | | |
| + ABBOTT | 1USP UNITS/100ML ** | N019185 | 004 | Mar 29, 1985 |
| + | 2USP UNITS/100ML ** | N019185 | 003 | Mar 29, 1985 |
| OXYTOCIN 20 USP UNITS IN DEXTROSE 5% | | | | |
| + ABBOTT | 2USP UNITS/100ML ** | N019185 | 002 | Mar 29, 1985 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| OXYTOCIN | | | | |
| INJECTABLE;INJECTION | | | | |
| OXYTOCIN 5 USP UNITS IN DEXTROSE 5% | | | | |
| + ABBOTT | 1USP UNITS/100ML ** | N019185 | 001 | Mar 29, 1985 |
| SYNTOCINON | | | | |
| NOVARTIS | 10USP UNITS/ML | N018245 | 001 | |
| SOLUTION;NASAL | | | | |
| SYNTOCINON | | | | |
| RTRX | 40USP UNITS/ML | N012285 | 001 | |
| PACLITAXEL | | | | |
| INJECTABLE;INJECTION | | | | |
| PACLITAXEL | | | | |
| ACCORD HLTHCARE | 6MG/ML | A075436 | 001 | Nov 12, 2004 |
| HOSPIRA | 6MG/ML | A076233 | 001 | Aug 01, 2002 |
| MYLAN | 6MG/ML | A075278 | 001 | Jan 25, 2002 |
| PLIVA LACHEMA | 6MG/ML | A077413 | 001 | Mar 12, 2008 |
| TEVA PHARMS USA | 6MG/ML | A075297 | 001 | Jan 25, 2002 |
| PALIPERIDONE | | | | |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| INVEGA | | | | |
| + JANSSEN PHARMS | 12MG ** | N021999 | 004 | Dec 19, 2006 |
| PALONOSETRON HYDROCHLORIDE | | | | |
| CAPSULE;ORAL | | | | |
| ALOXI | | | | |
| + HELSINN HLTHCARE | EQ 0.5MG BASE ** | N022233 | 001 | Aug 22, 2008 |
| SOLUTION;INTRAVENOUS | | | | |
| PALONOSETRON HYDROCHLORIDE | | | | |
| DR REDDYS LABS LTD | EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) | N203050 | 001 | Mar 01, 2016 |
| | EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) | N203050 | 002 | Mar 01, 2016 |
| PAMIDRONATE DISODIUM | | | | |
| INJECTABLE;INJECTION | | | | |
| AREDIA | | | | |
| + NOVARTIS | 30MG/VIAL ** | N020036 | 001 | Oct 31, 1991 |
| | 60MG/VIAL | N020036 | 003 | May 06, 1993 |
| | 90MG/VIAL | N020036 | 004 | May 06, 1993 |
| PAMIDRONATE DISODIUM | | | | |
| AESGEN | 30MG/VIAL | A075594 | 001 | May 06, 2002 |
| | 90MG/VIAL | A075594 | 002 | May 06, 2002 |
| MN PHARMS | 30MG/VIAL | A078300 | 001 | Mar 10, 2009 |
| | 90MG/VIAL | A078300 | 002 | Mar 10, 2009 |
| PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) | | | | |
| CAPSULE;ORAL | | | | |
| COTAZYM | | | | |
| ORGANON USA INC | 30,000USP UNITS;8,000USP UNITS;30,000USP UNITS | N020580 | 001 | Dec 09, 1996 |
| PANCURONIUM BROMIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| PANCURONIUM BROMIDE | | | | |
| ELKINS SINN | 1MG/ML | A072058 | 001 | Mar 23, 1988 |
| | 2MG/ML | A072059 | 001 | Mar 23, 1988 |
| | 2MG/ML | A072060 | 001 | Mar 23, 1988 |
| HOSPIRA | 2MG/ML | A072321 | 001 | Jan 19, 1989 |
| IGI LABS INC | 1MG/ML | A072210 | 001 | Mar 31, 1988 |
| | 2MG/ML | A072211 | 001 | Mar 31, 1988 |
| | 2MG/ML | A072212 | 001 | Mar 31, 1988 |
| | 2MG/ML | A072213 | 001 | Mar 31, 1988 |
| PAVULON | | | | |
| + ORGANON USA INC | 1MG/ML | N017015 | 002 | |
| + | 2MG/ML | N017015 | 001 | |

| | | | | |
|---|---|---|---|---|
| PANTOPRAZOLE SODIUM | | | | |
| TABLET, DELAYED RELEASE;ORAL | | | | |
| PANTOPRAZOLE SODIUM | | | | |
| SUN PHARM INDS LTD | EQ 20MG BASE | | A077058 001 | Sep 10, 2007 |
| | EQ 40MG BASE | | A077058 002 | Sep 10, 2007 |
| PARAMETHADIONE | | | | |
| CAPSULE;ORAL | | | | |
| PARADIONE | | | | |
| ABBVIE | 150MG | | N006800 003 | |
| | 300MG | | N006800 001 | |
| SOLUTION;ORAL | | | | |
| PARADIONE | | | | |
| ABBVIE | 300MG/ML | | N006800 002 | |
| PARAMETHASONE ACETATE | | | | |
| TABLET;ORAL | | | | |
| HALDRONE | | | | |
| LILLY | 1MG | | N012772 005 | |
| | 2MG | | N012772 006 | |
| PARGYLINE HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| EUTONYL | | | | |
| ABBOTT | 10MG | | N013448 002 | |
| | 25MG | | N013448 003 | |
| | 50MG | | N013448 004 | |
| PARICALCITOL | | | | |
| CAPSULE;ORAL | | | | |
| ZEMPLAR | | | | |
| + ABBVIE | 4MCG ** | | N021606 003 | May 26, 2005 |
| PAROMOMYCIN SULFATE | | | | |
| CAPSULE;ORAL | | | | |
| HUMATIN | | | | |
| KING PFIZER | EQ 250MG BASE | | A062310 001 | |
| PARKEDALE | EQ 250MG BASE | | A060521 001 | |
| SYRUP;ORAL | | | | |
| HUMATIN | | | | |
| PARKE DAVIS | EQ 125MG BASE/5ML | | A060522 001 | |
| PAROXETINE HYDROCHLORIDE | | | | |
| CAPSULE;ORAL | | | | |
| PAXIL | | | | |
| + APOTEX TECHNOLOGIES | EQ 10MG BASE ** | | N020885 001 | Oct 09, 1998 |
| + | EQ 20MG BASE ** | | N020885 002 | Oct 09, 1998 |
| + | EQ 30MG BASE ** | | N020885 003 | Oct 09, 1998 |
| + | EQ 40MG BASE ** | | N020885 004 | Oct 09, 1998 |
| SUSPENSION;ORAL | | | | |
| PAROXETINE HYDROCHLORIDE | | | | |
| APOTEX INC | EQ 10MG BASE/5ML | | A077395 001 | Dec 05, 2006 |
| TABLET;ORAL | | | | |
| PAROXETINE HYDROCHLORIDE | | | | |
| MYLAN PHARMS INC | EQ 10MG BASE | | A075716 001 | Mar 08, 2004 |
| | EQ 20MG BASE | | A075716 002 | Mar 08, 2004 |
| | EQ 30MG BASE | | A075716 003 | Mar 08, 2004 |
| | EQ 40MG BASE | | A075716 004 | Mar 08, 2004 |
| ROXANE | EQ 10MG BASE | | A078026 001 | Jun 29, 2007 |
| | EQ 20MG BASE | | A078026 002 | Jun 29, 2007 |
| | EQ 30MG BASE | | A078026 003 | Jun 29, 2007 |
| | EQ 40MG BASE | | A078026 004 | Jun 29, 2007 |
| TEVA PHARMS | EQ 10MG BASE | | A077082 001 | Jun 29, 2007 |
| | EQ 20MG BASE | | A077082 002 | Jun 29, 2007 |
| | EQ 30MG BASE | | A077082 003 | Jun 29, 2007 |
| | EQ 40MG BASE | | A077082 004 | Jun 29, 2007 |
| UPSHER-SMITH LABS | EQ 10MG BASE | | A075566 001 | Mar 08, 2004 |
| | EQ 20MG BASE | | A075566 002 | Mar 08, 2004 |
| | EQ 30MG BASE | | A075566 003 | Mar 08, 2004 |
| | EQ 40MG BASE | | A075566 004 | Mar 08, 2004 |
| PAXIL | | | | |
| APOTEX TECHNOLOGIES | EQ 50MG BASE | | N020031 004 | Dec 29, 1992 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

PAZOPANIB HYDROCHLORIDE

TABLET;ORAL

VOTRIENT

| | | | | |
|---|---|---|---|---|
| NOVARTIS PHARMS CORP | EQ 400MG BASE | N022465 | 002 | Oct 19, 2009 |

PEGINESATIDE ACETATE

SOLUTION;INTRAVENOUS, SUBCUTANEOUS

OMONTYS

| | | | | |
|---|---|---|---|---|
| TAKEDA PHARMS USA | EQ 10MG BASE/ML (EQ 10MG BASE/ML) | N202799 | 007 | Mar 27, 2012 |
| | EQ 20MG BASE/2ML (EQ 10MG BASE/ML) | N202799 | 008 | Mar 27, 2012 |

OMONTYS PRESERVATIVE FREE

| | | | | |
|---|---|---|---|---|
| TAKEDA PHARMS USA | EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML) | N202799 | 001 | Mar 27, 2012 |
| | EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML) | N202799 | 002 | Mar 27, 2012 |
| | EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) | N202799 | 003 | Mar 27, 2012 |
| | EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML) | N202799 | 004 | Mar 27, 2012 |
| | EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML) | N202799 | 005 | Mar 27, 2012 |
| | EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML) | N202799 | 006 | Mar 27, 2012 |

PEMIROLAST POTASSIUM

SOLUTION/DROPS;OPHTHALMIC

ALAMAST

| | | | | |
|---|---|---|---|---|
| SANTEN | 0.1% | N021079 | 001 | Sep 24, 1999 |

PEMOLINE

TABLET;ORAL

CYLERT

| | | | | |
|---|---|---|---|---|
| ABBOTT | 18.75MG | N016832 | 001 | |
| | 37.5MG | N016832 | 002 | |
| | 75MG | N016832 | 003 | |

PEMOLINE

| | | | | |
|---|---|---|---|---|
| ACTAVIS ELIZABETH | 18.75MG | A075595 | 001 | Feb 28, 2000 |
| | 37.5MG | A075595 | 002 | Feb 28, 2000 |
| | 75MG | A075595 | 003 | Feb 28, 2000 |
| MALLINCKRODT | 18.75MG | A075726 | 003 | Mar 30, 2001 |
| | 37.5MG | A075726 | 002 | Mar 30, 2001 |
| | 75MG | A075726 | 001 | Mar 30, 2001 |
| SANDOZ | 18.75MG | A075286 | 001 | Dec 27, 1999 |
| | 37.5MG | A075286 | 002 | Jun 30, 1999 |
| | 75MG | A075286 | 003 | Jun 30, 1999 |
| TEVA PHARMS | 18.75MG | A075030 | 003 | Feb 22, 2000 |
| | 37.5MG | A075030 | 001 | Jan 29, 1999 |
| | 75MG | A075030 | 002 | Jan 29, 1999 |
| VINTAGE PHARMS | 18.75MG | A075328 | 001 | Apr 19, 2000 |
| | 37.5MG | A075328 | 002 | Apr 19, 2000 |
| | 75MG | A075328 | 003 | Apr 19, 2000 |
| WATSON LABS | 18.75MG | A075287 | 001 | Jun 13, 2001 |
| | 37.5MG | A075287 | 002 | Sep 18, 2000 |
| | 75MG | A075287 | 003 | Sep 18, 2000 |

TABLET, CHEWABLE;ORAL

CYLERT

| | | | | |
|---|---|---|---|---|
| ABBOTT | 37.5MG | N017703 | 001 | |

PEMOLINE

| | | | | |
|---|---|---|---|---|
| ACTAVIS ELIZABETH | 37.5MG | A075678 | 001 | Jul 26, 2000 |
| TEVA PHARMS | 37.5MG | A075555 | 001 | Feb 18, 2000 |

PENBUTOLOL SULFATE

TABLET;ORAL

LEVATOL

| | | | | | |
|---|---|---|---|---|---|
| + | AUXILIUM PHARMS LLC | 10MG ** | N018976 | 001 | Dec 30, 1987 |
| + | | 20MG ** | N018976 | 004 | Jan 05, 1989 |

PENICILLAMINE

CAPSULE;ORAL

CUPRIMINE

| | | | | |
|---|---|---|---|---|
| ATON | 125MG | N019853 | 002 | |

| | | | | |
|---|---|---|---|---|
| PENICILLIN G BENZATHINE | | | | |
| INJECTABLE;INJECTION | | | | |
| BICILLIN L-A | | | | |
| | WYETH AYERST | 300,000 UNITS/ML | N050131 001 | |
| SUSPENSION;ORAL | | | | |
| BICILLIN | | | | |
| | WYETH AYERST | 300,000 UNITS/5ML | N050126 002 | |
| TABLET;ORAL | | | | |
| BICILLIN | | | | |
| | WYETH AYERST | 200,000 UNITS | N050128 001 | |
| PENICILLIN G POTASSIUM | | | | |
| FOR SOLUTION;ORAL | | | | |
| PENICILLIN | | | | |
| | TEVA | 200,000 UNITS/5ML | A060307 002 | |
| | | 400,000 UNITS/5ML | A060307 004 | |
| PENICILLIN G POTASSIUM | | | | |
| | MYLAN | 200,000 UNITS/5ML | A060752 003 | |
| | | 250,000 UNITS/5ML | A060752 002 | |
| | | 400,000 UNITS/5ML | A060752 001 | |
| | PUREPAC PHARM | 250,000 UNITS/5ML | A061740 001 | |
| | | 400,000 UNITS/5ML | A061740 002 | |
| PENICILLIN-2 | | | | |
| | TEVA | 250,000 UNITS/5ML | A060307 003 | |
| PENTIDS '200' | | | | |
| | APOTHECON | 200,000 UNITS/5ML | A062149 001 | |
| PENTIDS '400' | | | | |
| | APOTHECON | 400,000 UNITS/5ML | A062149 002 | |
| PFIZERPEN G | | | | |
| | PFIZER | 400,000 UNITS/5ML | A060587 001 | |
| INJECTABLE;INJECTION | | | | |
| PENICILLIN G POTASSIUM | | | | |
| | APOTHECON | 1,000,000 UNITS/VIAL | A060362 001 | |
| | | 5,000,000 UNITS/VIAL | A060362 003 | |
| | | 10,000,000 UNITS/VIAL | A060362 004 | |
| | | 20,000,000 UNITS/VIAL | A060362 002 | |
| | CONSOLIDATED PHARM | 500,000 UNITS/VIAL | A060806 001 | |
| | | 1,000,000 UNITS/VIAL | A060806 002 | |
| | | 5,000,000 UNITS/VIAL | A060806 003 | |
| | | 10,000,000 UNITS/VIAL | A060806 004 | |
| | LILLY | 200,000 UNITS/VIAL | A060384 004 | |
| | | 500,000 UNITS/VIAL | A060384 003 | |
| | | 1,000,000 UNITS/VIAL | A060384 002 | |
| | | 5,000,000 UNITS/VIAL | A060384 001 | |
| | | 20,000,000 UNITS/VIAL | A060384 005 | |
| | | 20,000,000 UNITS/VIAL | A060601 001 | |
| | PARKE DAVIS | 1,000,000 UNITS/VIAL | A062003 001 | |
| | | 5,000,000 UNITS/VIAL | A062003 002 | |
| | PFIZER | 20,000,000 UNITS/VIAL | A060074 003 | |
| | SANDOZ | 1,000,000 UNITS/VIAL ** | A065079 001 | Aug 30, 2002 |
| | WATSON LABS INC | 1,000,000 UNITS/VIAL | A062991 001 | Sep 13, 1988 |
| | | 5,000,000 UNITS/VIAL | A062991 002 | Sep 13, 1988 |
| | | 10,000,000 UNITS/VIAL | A062991 003 | Sep 13, 1988 |
| | | 20,000,000 UNITS/VIAL | A062991 004 | Sep 13, 1988 |
| PFIZERPEN | | | | |
| | PFIZER | 1,000,000 UNITS/VIAL ** | A060657 001 | |
| TABLET;ORAL | | | | |
| PENICILLIN G POTASSIUM | | | | |
| | APOTHECON | 250,000 UNITS | A060392 003 | |
| | IVAX SUB TEVA PHARMS | 400,000 UNITS | A060073 004 | |
| | LILLY | 250,000 UNITS | A060403 001 | |
| | MYLAN | 200,000 UNITS | A060781 001 | |
| | | 250,000 UNITS | A060781 002 | |
| | | 400,000 UNITS | A060781 003 | |
| | | 500,000 UNITS | A060781 005 | |
| | | 800,000 UNITS | A060781 004 | |
| | PUREPAC PHARM | 200,000 UNITS | A061588 001 | |
| | | 250,000 UNITS | A061588 002 | |
| | | 400,000 UNITS | A061588 003 | |
| | TEVA | 200,000 UNITS | A060306 001 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| PENICILLIN G POTASSIUM | | | | |
| TABLET;ORAL | | | | |
| PENICILLIN G POTASSIUM | | | | |
| | | 250,000 UNITS | A060306 002 | |
| | | 400,000 UNITS | A060306 003 | |
| | | 500,000 UNITS | A060306 004 | |
| | WYETH AYERST | 200,000 UNITS | A060413 001 | |
| | | 250,000 UNITS | A060413 002 | |
| | | 400,000 UNITS | A060413 003 | |
| PENTIDS '200' | | | | |
| | APOTHECON | 200,000 UNITS | A062155 001 | |
| PENTIDS '250' | | | | |
| | APOTHECON | 250,000 UNITS | A062155 002 | |
| PENTIDS '400' | | | | |
| | APOTHECON | 400,000 UNITS | A060392 004 | |
| | | 400,000 UNITS | A062155 003 | |
| PENTIDS '800' | | | | |
| | APOTHECON | 800,000 UNITS | A060392 005 | |
| | | 800,000 UNITS | A062155 004 | |
| PFIZERPEN G | | | | |
| | PFIZER | 50,000 UNITS | A060075 001 | |
| | | 100,000 UNITS | A060075 002 | |
| | | 200,000 UNITS | A060075 003 | |
| | | 250,000 UNITS | A060075 004 | |
| | | 400,000 UNITS | A060075 005 | |
| | | 800,000 UNITS | A060075 006 | |
| PENICILLIN G PROCAINE | | | | |
| INJECTABLE;INJECTION | | | | |
| DURACILLIN A.S. | | | | |
| | LILLY | 300,000 UNITS/ML | A060093 001 | |
| PENICILLIN G PROCAINE | | | | |
| | CONSOLIDATED PHARM | 300,000 UNITS/ML | A060800 001 | |
| | | 600,000 UNITS/1.2ML | A060800 002 | |
| | PARKE DAVIS | 300,000 UNITS/ML | A062029 001 | |
| | PFIZER | 300,000 UNITS/VIAL | A060099 001 | |
| | | 1,500,000 UNITS/VIAL | A060099 002 | |
| PFIZERPEN-AS | | | | |
| | PFIZER | 300,000 UNITS/ML | A060286 001 | |
| | | 600,000 UNITS/ML | A060286 002 | |
| PENICILLIN G SODIUM | | | | |
| INJECTABLE;INJECTION | | | | |
| PENICILLIN G SODIUM | | | | |
| | BRISTOL MYERS SQUIBB | 5,000,000 UNITS/VIAL | A061935 001 | |
| | COPANOS | 5,000,000 UNITS/VIAL | A061051 001 | |
| | PHARMACIA AND UPJOHN | 1,000,000 UNITS/VIAL | A061046 001 | |
| INJECTABLE;INTRAMUSCULAR, INTRAVENOUS | | | | |
| PENICILLIN G SODIUM | | | | |
| | WATSON LABS INC | 5,000,000 UNITS/VIAL | A063014 001 | Sep 13, 1988 |
| PENICILLIN V | | | | |
| FOR SUSPENSION;ORAL | | | | |
| V-CILLIN | | | | |
| | LILLY | 125MG/0.6ML | A060002 001 | |
| PENICILLIN V POTASSIUM | | | | |
| FOR SOLUTION;ORAL | | | | |
| BEEPEN-VK | | | | |
| | GLAXOSMITHKLINE | EQ 125MG BASE/5ML | A062270 001 | |
| | | EQ 250MG BASE/5ML | A062270 002 | |
| BETAPEN-VK | | | | |
| | APOTHECON | EQ 125MG BASE/5ML | A061149 001 | |
| | | EQ 250MG BASE/5ML | A061149 002 | |
| LEDERCILLIN VK | | | | |
| | LEDERLE | EQ 125MG BASE/5ML | A060136 001 | |
| | | EQ 250MG BASE/5ML | A060136 002 | |
| PEN-VEE K | | | | |
| | WYETH AYERST | EQ 125MG BASE/5ML | A060007 001 | |
| | | EQ 250MG BASE/5ML | A060007 002 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

PENICILLIN V POTASSIUM

| | | | |
|---|---|---|---|
| FOR SOLUTION;ORAL | | | |
| PENAPAR-VK | | | |
| PARKE DAVIS | EQ 125MG BASE/5ML | | A062002 001 |
| | EQ 250MG BASE/5ML | | A062002 002 |
| PENICILLIN V POTASSIUM | | | |
| AM ANTIBIOTICS | EQ 125MG BASE/5ML | | A061529 001 |
| | EQ 250MG BASE/5ML | | A061529 002 |
| MYLAN | EQ 125MG BASE/5ML | | A061624 002 |
| | EQ 250MG BASE/5ML | | A061624 001 |
| PUREPAC PHARM | EQ 125MG BASE/5ML | | A061758 001 |
| | EQ 250MG BASE/5ML | | A061758 002 |
| PFIZERPEN VK | | | |
| PFIZER | EQ 125MG BASE/5ML | | A061815 001 |
| | EQ 250MG BASE/5ML | | A061815 002 |
| V-CILLIN K | | | |
| LILLY | EQ 125MG BASE/5ML | | A060004 001 |
| | EQ 250MG BASE/5ML | | A060004 002 |
| VEETIDS | | | |
| APOTHECON | EQ 125MG BASE/5ML | | A061410 001 |
| | EQ 250MG BASE/5ML | | A061410 002 |
| VEETIDS '125' | | | |
| APOTHECON | EQ 125MG BASE/5ML | | A061206 001 |
| | EQ 125MG BASE/5ML | | A062153 001 |
| VEETIDS '250' | | | |
| APOTHECON | EQ 250MG BASE/5ML | | A061206 002 |
| | EQ 250MG BASE/5ML | | A062153 002 |
| TABLET;ORAL | | | |
| BEEPEN-VK | | | |
| GLAXOSMITHKLINE | EQ 250MG BASE | | A062273 001 |
| | EQ 500MG BASE | | A062273 002 |
| BETAPEN-VK | | | |
| BRISTOL | EQ 250MG BASE | | A061150 001 |
| | EQ 500MG BASE | | A061150 002 |
| LEDERCILLIN VK | | | |
| LEDERLE | EQ 250MG BASE | | A060134 001 |
| | EQ 500MG BASE | | A060134 002 |
| PEN-VEE K | | | |
| WYETH AYERST | EQ 125MG BASE | | A060006 001 |
| | EQ 250MG BASE | | A060006 002 |
| | EQ 500MG BASE | | A060006 003 |
| PENAPAR-VK | | | |
| PARKE DAVIS | EQ 250MG BASE | | A062001 001 |
| | EQ 500MG BASE | | A062001 002 |
| PENICILLIN V POTASSIUM | | | |
| AM ANTIBIOTICS | EQ 250MG BASE | | A061528 001 |
| | EQ 500MG BASE | | A061528 002 |
| IVAX SUB TEVA PHARMS | EQ 125MG BASE | | A060518 001 |
| | EQ 250MG BASE | | A060518 002 |
| | EQ 500MG BASE | | A060518 003 |
| MYLAN | EQ 250MG BASE | | A061530 001 |
| | EQ 500MG BASE | | A061530 002 |
| PUREPAC PHARM | EQ 125MG BASE | | A061571 001 |
| | EQ 250MG BASE | | A061571 002 |
| | EQ 500MG BASE | | A061571 003 |
| PFIZERPEN VK | | | |
| PFIZER | EQ 250MG BASE | | A061836 001 |
| | EQ 500MG BASE | | A061836 002 |
| UTICILLIN VK | | | |
| PHARMACIA AND UPJOHN | EQ 250MG BASE | | A061651 001 |
| | EQ 500MG BASE | | A061651 002 |
| V-CILLIN K | | | |
| LILLY | EQ 125MG BASE ** | | A060003 001 |
| | EQ 250MG BASE ** | | A060003 002 |
| | EQ 500MG BASE ** | | A060003 003 |
| VEETIDS | | | |
| APOTHECON | EQ 250MG BASE | | A061411 001 |
| | EQ 500MG BASE | | A061411 002 |

PENICILLIN V POTASSIUM

| | | | |
|---|---|---|---|
| TABLET;ORAL | | | |
| VEETIDS '250' | | | |
| APOTHECON | EQ 250MG BASE | A061164 001 | |
| | EQ 250MG BASE | A062156 002 | |
| VEETIDS '500' | | | |
| APOTHECON | EQ 500MG BASE | A061164 002 | |
| | EQ 500MG BASE | A062156 001 | |

PENTAGASTRIN

| | | | |
|---|---|---|---|
| INJECTABLE;INJECTION | | | |
| PEPTAVLON | | | |
| + WYETH AYERST | 0.25MG/ML ** | N017048 001 | |

PENTAMIDINE ISETHIONATE

| | | | |
|---|---|---|---|
| FOR SOLUTION;INHALATION | | | |
| NEBUPENT | | | |
| FRESENIUS KABI USA | 600MG/VIAL | N019887 002 | Mar 22, 1996 |
| INJECTABLE;INJECTION | | | |
| PENTACARINAT | | | |
| ARMOUR PHARM | 300MG/VIAL | A073447 001 | Apr 28, 1994 |
| PENTAMIDINE ISETHIONATE | | | |
| BAXTER HLTHCARE | 300MG/VIAL | A073617 001 | Dec 18, 1995 |
| HOSPIRA | 300MG/VIAL | A073479 001 | Jun 30, 1992 |
| WATSON LABS | 300MG/VIAL | A074303 001 | Aug 17, 1995 |

PENTAZOCINE HYDROCHLORIDE

| | | | |
|---|---|---|---|
| TABLET;ORAL | | | |
| TALWIN 50 | | | |
| SANOFI AVENTIS US | EQ 50MG BASE | N016732 001 | |

PENTETATE CALCIUM TRISODIUM YB-169

| | | | |
|---|---|---|---|
| INJECTABLE;INJECTION | | | |
| YTTERBIUM YB 169 DTPA | | | |
| 3M | 2mCi/ML | N017518 001 | |

PENTOBARBITAL

| | | | |
|---|---|---|---|
| ELIXIR;ORAL | | | |
| NEMBUTAL | | | |
| OAK PHARMS | 18.2MG/5ML | A083244 001 | |

PENTOBARBITAL SODIUM

| | | | |
|---|---|---|---|
| CAPSULE;ORAL | | | |
| NEMBUTAL SODIUM | | | |
| OAK PHARMS | 30MG | A084095 001 | |
| | 50MG | A084093 001 | |
| | 100MG | A083245 001 | |
| PENTOBARBITAL SODIUM | | | |
| LANNETT | 50MG | A085937 001 | |
| | 100MG | A085915 001 | |
| VITARINE | 100MG | A083284 001 | |
| WHITEWORTH TOWN PLSN | 100MG | A083338 001 | |
| SODIUM PENTOBARBITAL | | | |
| ANABOLIC | 100MG | A084590 001 | |
| ELKINS SINN | 100MG | A083368 001 | |
| EVERYLIFE | 100MG | A083259 001 | |
| HALSEY | 100MG | A084677 001 | |
| IVAX SUB TEVA PHARMS | 50MG | A083461 001 | |
| | 100MG | A083461 002 | |
| PARKE DAVIS | 100MG | A084156 001 | |
| PERRIGO | 100MG | A084560 001 | |
| PUREPAC PHARM | 100MG | A083301 001 | |
| VALEANT PHARM INTL | 100MG | A083264 001 | |
| WATSON LABS | 100MG | A085791 001 | |
| WYETH AYERST | 100MG | A083239 001 | |
| INJECTABLE;INJECTION | | | |
| PENTOBARBITAL SODIUM | | | |
| ELKINS SINN | 50MG/ML | A083270 001 | |
| SODIUM PENTOBARBITAL | | | |
| WYETH AYERST | 50MG/ML | A083261 001 | |

PENTOBARBITAL SODIUM

| | | | | |
|---|---|---|---|---|
| SUPPOSITORY;RECTAL | | | | |
| NEMBUTAL | | | | |
| OAK PHARMS | 30MG | A083247 | 001 | Jan 25, 1982 |
| | 60MG | A083247 | 002 | Jan 25, 1982 |
| | 120MG | A083247 | 003 | Jan 25, 1982 |
| | 200MG | A083247 | 004 | Jan 25, 1982 |
| TABLET;ORAL | | | | |
| PENTOBARBITAL SODIUM | | | | |
| VITARINE | 100MG | A083285 | 001 | |
| SODIUM PENTOBARBITAL | | | | |
| NEXGEN PHARMA INC | 100MG | A084238 | 001 | |

PENTOLINIUM TARTRATE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| ANSOLYSEN | | | | |
| WYETH AYERST | 10MG/ML | N009372 | 001 | |

PENTOXIFYLLINE

| | | | | |
|---|---|---|---|---|
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| PENTOXIFYLLINE | | | | |
| ACTAVIS ELIZABETH | 400MG | A074878 | 001 | Jul 09, 1997 |
| HERITAGE PHARMS INC | 400MG | A074877 | 001 | Jul 08, 1997 |
| IMPAX LABS | 400MG | A075093 | 001 | Aug 10, 1999 |
| PLIVA | 400MG | A074874 | 001 | May 25, 1999 |
| TEVA | 400MG | A075199 | 001 | Sep 03, 1999 |
| WATSON LABS | 400MG | A075107 | 001 | Sep 04, 1998 |
| TRENTAL | | | | |
| + US PHARM HOLDINGS | 400MG ** | N018631 | 001 | Aug 30, 1984 |

PERFLUBRON

| | | | | |
|---|---|---|---|---|
| LIQUID;ORAL | | | | |
| IMAGENT | | | | |
| ALLIANCE PHARM | 100% | N020091 | 001 | Aug 13, 1993 |

PERFLUOROPOLYMETHYLISOPROPYL ETHER; POLYTETRAFLUOROETHYLENE

| | | | | |
|---|---|---|---|---|
| PASTE;TOPICAL | | | | |
| SKIN EXPOSURE REDUCTION PASTE AGAINST CHEMICAL WARFARE AGENTS | | | | |
| US ARMY | 50%;50% | N021084 | 001 | Feb 17, 2000 |

PERGOLIDE MESYLATE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| PERGOLIDE MESYLATE | | | | |
| IVAX SUB TEVA PHARMS | EQ 0.05MG BASE | A076094 | 001 | Sep 04, 2003 |
| | EQ 0.25MG BASE | A076094 | 002 | Sep 04, 2003 |
| | EQ 1MG BASE | A076094 | 003 | Sep 04, 2003 |
| PAR PHARM | EQ 0.05MG BASE | A076061 | 001 | Nov 27, 2002 |
| | EQ 0.25MG BASE | A076061 | 002 | Nov 27, 2002 |
| | EQ 1MG BASE | A076061 | 003 | Nov 27, 2002 |
| PERMAX | | | | |
| VALEANT PHARM INTL | EQ 0.05MG BASE | N019385 | 001 | Dec 30, 1988 |
| | EQ 0.25MG BASE | N019385 | 002 | Dec 30, 1988 |
| | EQ 1MG BASE | N019385 | 003 | Dec 30, 1988 |

PERINDOPRIL ERBUMINE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| ACEON | | | | |
| + SYMPLMED PHARMS LLC | 2MG | N020184 | 001 | Dec 30, 1993 |
| + | 4MG | N020184 | 002 | Dec 30, 1993 |
| + | 8MG | N020184 | 003 | Dec 30, 1993 |
| PERINDOPRIL ERBUMINE | | | | |
| LUPIN LTD | 2MG | A078263 | 001 | Jan 27, 2010 |
| | 4MG | A078263 | 002 | Jan 27, 2010 |
| | 8MG | A078263 | 003 | Jan 27, 2010 |

PERMETHRIN

| | | | | |
|---|---|---|---|---|
| LOTION;TOPICAL | | | | |
| NIX | | | | |
| GLAXOSMITHKLINE | 1% | N019435 | 001 | Mar 31, 1986 |

PERPHENAZINE

| | | | | |
|---|---|---|---|---|
| CONCENTRATE;ORAL | | | | |
| PERPHENAZINE | | | | |
| | PHARM ASSOC | 16MG/5ML | A040360 001 | May 25, 2001 |
| TRILAFON | | | | |
| | SCHERING | 16MG/5ML | N011557 001 | |
| INJECTABLE;INJECTION | | | | |
| TRILAFON | | | | |
| | SCHERING | 5MG/ML | N011213 002 | |
| SYRUP;ORAL | | | | |
| TRILAFON | | | | |
| | SCHERING | 2MG/5ML | N011294 002 | |
| TABLET;ORAL | | | | |
| PERPHENAZINE | | | | |
| | ANI PHARMS INC | 2MG | A089707 001 | Sep 10, 1987 |
| | | 4MG | A089708 001 | Sep 10, 1987 |
| | | 8MG | A089456 001 | Sep 10, 1987 |
| | | 16MG | A089457 001 | Sep 10, 1987 |
| TRILAFON | | | | |
| + | SCHERING | 2MG ** | N010775 001 | |
| + | | 4MG ** | N010775 002 | |
| + | | 8MG ** | N010775 003 | |
| + | | 16MG ** | N010775 004 | |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| TRILAFON | | | | |
| | SCHERING | 8MG | N011361 002 | |

PHENACEMIDE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| PHENURONE | | | | |
| + | ABBVIE | 500MG ** | N007707 001 | |

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| AZO GANTANOL | | | | |
| + | ROCHE | 100MG;500MG ** | N013294 001 | Sep 10, 1987 |

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PHENAZOPYRIDINE HYDROCHLORIDE | | | | |
| | ABLE | 200MG,N/A,N/A;N/A,800MG,160MG | N021105 001 | Jun 26, 2001 |

PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| AZO GANTRISIN | | | | |
| + | ROCHE | 50MG;500MG ** | N019358 001 | Aug 31, 1990 |

PHENDIMETRAZINE TARTRATE

| | | | | |
|---|---|---|---|---|
| CAPSULE;ORAL | | | | |
| PHENAZINE | | | | |
| | MAST MM | 35MG | A086523 001 | |
| | | 35MG | A086524 001 | |
| | | 35MG | A086525 001 | |
| PHENDIMETRAZINE TARTRATE | | | | |
| | SANDOZ | 35MG | A085633 001 | |
| | | 35MG | A085694 001 | |
| | | 35MG | A085695 001 | |
| | | 35MG | A085702 001 | |
| | VITARINE | 35MG | A085634 001 | |
| | | 35MG | A085645 001 | |
| | | 35MG | A085670 001 | |
| | | 35MG | A086403 001 | |
| | | 35MG | A086408 001 | |
| | | 35MG | A086410 001 | |
| | | 35MG | A087424 001 | |
| SPRX-3 | | | | |
| | SOLVAY | 35MG | A085897 001 | |
| STATOBEX | | | | |
| | TEVA | 35MG | A085507 001 | |
| X-TROZINE | | | | |
| | SHIRE RICHWOOD | 35MG | A087394 001 | Sep 22, 1982 |

PHENDIMETRAZINE TARTRATE

| | | | | |
|---|---|---|---|---|
| CAPSULE, EXTENDED RELEASE;ORAL | | | | |
| BONTRIL | | | | |
| VALEANT | 105MG | | A088021 001 | Sep 21, 1982 |
| MELFIAT-105 | | | | |
| NUMARK | 105MG | | A087487 001 | Oct 13, 1982 |
| PHENDIMETRAZINE TARTRATE | | | | |
| GRAHAM DM | 105MG | | A087214 001 | May 26, 1982 |
| | 105MG | | A088020 001 | Aug 16, 1982 |
| | 105MG | | A088028 001 | Aug 16, 1982 |
| | 105MG | | A088062 001 | Sep 13, 1982 |
| | 105MG | | A088063 001 | Sep 10, 1982 |
| | 105MG | | A088111 001 | Oct 18, 1982 |
| SANDOZ | 105MG | | A087378 001 | |
| SPRX-105 | | | | |
| NUMARK | 105MG | | A088024 001 | Dec 22, 1982 |
| X-TROZINE L.A. | | | | |
| SHIRE RICHWOOD | 105MG | | A087371 001 | Aug 24, 1982 |
| TABLET;ORAL | | | | |
| ADPHEN | | | | |
| FERNDALE LABS | 35MG | | A083655 001 | |
| ALPHAZINE | | | | |
| SANDOZ | 35MG | | A085034 001 | |
| CAM-METRAZINE | | | | |
| ABC HOLDING | 35MG | | A085511 001 | |
| CAMALL | 35MG | | A085756 001 | |
| CHARTWELL RX | 35MG | | A083922 001 | |
| | 35MG | | A085318 001 | |
| | 35MG | | A085320 001 | |
| | 35MG | | A085321 001 | |
| DI-METREX | | | | |
| PVT FORM | 35MG | | A085698 001 | |
| MELFIAT | | | | |
| NUMARK | 35MG | | A083790 002 | |
| METRA | | | | |
| FOREST PHARMS | 35MG | | A083754 001 | |
| PHENAZINE | | | | |
| MAST MM | 35MG | | A087305 001 | |
| PHENAZINE-35 | | | | |
| ABC HOLDING | 35MG | | A085512 001 | |
| PHENDIMETRAZINE TARTRATE | | | | |
| BARR | 35MG | | A083644 001 | |
| | 35MG | | A083684 001 | |
| | 35MG | | A083686 001 | |
| | 35MG | | A083687 001 | |
| | 35MG | | A084831 001 | |
| | 35MG | | A084834 001 | |
| | 35MG | | A084835 001 | |
| CHARTWELL RX | 35MG | | A085761 001 | |
| | 35MG | | A085941 001 | Jun 27, 1983 |
| FERNDALE LABS | 35MG | | A086834 001 | Sep 15, 1983 |
| INWOOD LABS | 35MG | | A084740 001 | |
| | 35MG | | A084741 001 | |
| | 35MG | | A084742 001 | |
| | 35MG | | A084743 001 | |
| IVAX PHARMS | 35MG | | A085611 001 | |
| | 35MG | | A085612 001 | |
| IVAX SUB TEVA PHARMS | 35MG | | A083682 001 | |
| KV PHARM | 35MG | | A084138 001 | |
| | 35MG | | A084141 001 | |
| | 35MG | | A085525 001 | |
| MFG CHEMISTS | 35MG | | A085914 001 | |
| NEXGEN PHARMA INC | 35MG | | A086020 001 | |
| NUMARK | 35MG | | A083790 001 | |
| PVT FORM | 35MG | | A085199 001 | |
| | 35MG | | A085697 001 | |
| SANDOZ | 35MG | | A085402 001 | |
| | 35MG | | A085497 001 | |
| | 35MG | | A085830 001 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| PHENDIMETRAZINE TARTRATE | | | | |
| TABLET;ORAL | | | | |
| PHENDIMETRAZINE TARTRATE | | | | |
| | 35MG | | A086365 001 | |
| | 35MG | | A086370 001 | |
| SOLVAY | 35MG | | A083993 001 | |
| USL PHARMA | 35MG | | A083805 001 | |
| | 35MG | | A084398 001 | |
| | 35MG | | A084399 001 | |
| VITARINE | 35MG | | A085519 001 | |
| | 35MG | | A086005 001 | |
| | 35MG | | A086106 001 | |
| WATSON LABS | 35MG | | A085767 001 | |
| | 35MG | | A085768 001 | |
| | 35MG | | A085770 001 | |
| | 35MG | | A085773 001 | |
| PLEGINE | | | | |
| WYETH AYERST | 35MG ** | | N012248 001 | |
| STATOBEX | | | | |
| TEVA | 35MG | | A086013 001 | |
| STATOBEX-G | | | | |
| TEVA | 35MG | | A085095 001 | |
| X-TROZINE | | | | |
| SHIRE RICHWOOD | 35MG | | A086550 001 | |
| | 35MG | | A086551 001 | |
| | 35MG | | A086552 001 | |
| | 35MG | | A086553 001 | |
| | 35MG | | A086554 001 | |
| PHENINDIONE | | | | |
| TABLET;ORAL | | | | |
| HEDULIN | | | | |
| SANOFI AVENTIS US | 50MG | | N008767 002 | |
| PHENMETRAZINE HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| PRELUDIN | | | | |
| BOEHRINGER INGELHEIM | 25MG | | N010460 005 | |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| PRELUDIN | | | | |
| BOEHRINGER INGELHEIM | 50MG | | N011752 004 | |
| | 75MG | | N011752 003 | |
| PHENPROCOUMON | | | | |
| TABLET;ORAL | | | | |
| LIQUAMAR | | | | |
| ORGANON USA INC | 3MG | | N011228 001 | |
| PHENSUXIMIDE | | | | |
| CAPSULE;ORAL | | | | |
| MILONTIN | | | | |
| PARKE DAVIS | 500MG | | N008855 004 | |
| PHENTERMINE HYDROCHLORIDE | | | | |
| CAPSULE;ORAL | | | | |
| FASTIN | | | | |
| GLAXOSMITHKLINE | 30MG ** | | N017352 001 | |
| OBESTIN-30 | | | | |
| FERNDALE LABS | 30MG | | A087144 001 | |
| OBY-TRIM | | | | |
| SHIRE RICHWOOD | 30MG | | A087764 001 | Mar 18, 1982 |
| ONA-MAST | | | | |
| MAST MM | 30MG | | A086511 001 | |
| | 30MG | | A086516 001 | |
| PHENTERMINE HYDROCHLORIDE | | | | |
| ABC HOLDING | 30MG | | A085411 001 | |
| ABLE | 15MG | | A040497 001 | Mar 13, 2003 |
| | 30MG | | A040403 001 | Aug 30, 2001 |
| | 30MG | | A040427 001 | Aug 30, 2001 |
| CAMALL | 15MG | | A086735 001 | |
| | 30MG | | A087226 001 | |
| CHARTWELL RX | 18.75MG | | A088576 001 | May 23, 1984 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

PHENTERMINE HYDROCHLORIDE

| | | | | | |
|---|---|---|---|---|---|
| CAPSULE;ORAL | | | | | |
| PHENTERMINE HYDROCHLORIDE | | | | | |
| | | 30MG | A085417 | 001 | |
| | | 30MG | A086732 | 002 | |
| | | 30MG | A087215 | 001 | |
| | | 37.5MG | A087915 | 001 | Dec 22, 1983 |
| | | 37.5MG | A087918 | 001 | Dec 22, 1983 |
| | | 37.5MG | A087930 | 001 | Oct 14, 1983 |
| | | 37.5MG | A088610 | 001 | Jun 04, 1984 |
| | | 37.5MG | A088611 | 001 | Jun 04, 1984 |
| | | 37.5MG | A088625 | 001 | Aug 23, 1984 |
| | DURAMED PHARMS BARR | 30MG | A088948 | 001 | Apr 25, 1986 |
| | ELITE LABS INC | 30MG | A040227 | 001 | Jun 18, 1997 |
| | | 30MG | A040448 | 001 | Jan 22, 2003 |
| | IVAX PHARMS | 30MG | A086329 | 001 | |
| | MIKAH PHARMA | 15MG | A040460 | 001 | Jan 14, 2003 |
| | SANDOZ | 30MG | A087208 | 001 | |
| | | 30MG | A087223 | 001 | |
| | | 37.5MG | A088414 | 001 | Oct 19, 1983 |
| | SUN PHARM INDUSTRIES | 37.5MG | A040527 | 001 | Oct 23, 2003 |
| | TEVA | 30MG | A086911 | 001 | |
| | | 30MG | A087126 | 001 | |
| | | 30MG | A087777 | 001 | Nov 01, 1985 |
| | | 30MG | A088612 | 001 | Apr 04, 1984 |
| | | 30MG | A088613 | 001 | Apr 09, 1984 |
| | | 30MG | A088614 | 001 | Apr 09, 1984 |
| | TG UNITED INC | 30MG | A040083 | 001 | Mar 07, 1997 |
| | UPSHER-SMITH LABS | 30MG | A084487 | 001 | Apr 09, 1982 |
| | | 30MG | A088430 | 001 | Mar 27, 1984 |
| | USL PHARMA | 30MG | A088797 | 001 | Dec 10, 1984 |
| | VITARINE | 30MG | A087202 | 001 | |
| | | 30MG | A087235 | 001 | |
| | WATSON LABS | 30MG | A086740 | 001 | Mar 21, 1985 |
| TABLET;ORAL | | | | | |
| ONA-MAST | | | | | |
| | MAST MM | 8MG | A086260 | 001 | |
| PHENTERMINE HYDROCHLORIDE | | | | | |
| | ABLE | 37.5MG | A040402 | 001 | Aug 30, 2001 |
| | ACTAVIS ELIZABETH | 37.5MG | A040276 | 001 | Nov 25, 1998 |
| | CHARTWELL RX | 8MG | A083923 | 001 | |
| | | 8MG | A085319 | 001 | |
| | | 37.5MG | A087805 | 001 | Dec 06, 1982 |
| | | 37.5MG | A088596 | 001 | Apr 04, 1984 |
| | IVAX PHARMS | 8MG | A085553 | 001 | |
| | SANDOZ | 8MG | A085671 | 001 | |
| | | 8MG | A085689 | 001 | |
| | SANDOZ INC | 30MG | A088605 | 001 | Sep 28, 1987 |
| | USL PHARMA | 8MG | A083804 | 001 | |
| | | 37.5MG | A088910 | 001 | Jul 17, 1985 |
| | | 37.5MG | A088917 | 001 | Jul 17, 1985 |
| | VITARINE | 8MG | A086453 | 001 | |
| | | 8MG | A086456 | 001 | |
| | WATSON LABS | 8MG | A085739 | 001 | |
| TORA | | | | | |
| | SOLVAY | 8MG | A084035 | 001 | |
| WILPO | | | | | |
| + | SANDOZ | 8MG ** | N012737 | 001 | |
| TABLET, ORALLY DISINTEGRATING;ORAL | | | | | |
| SUPRENZA | | | | | |
| | CITIUS PHARMS | 15MG | N202088 | 001 | Jun 13, 2011 |
| | | 30MG | N202088 | 002 | Jun 13, 2011 |
| | | 37.5MG | N202088 | 003 | Mar 27, 2012 |

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE;ORAL

| | | | | |
|---|---|---|---|---|
| IONAMIN | | | | |
| UCB INC | EQ 15MG BASE ** | N011613 | 004 | |
| | EQ 30MG BASE ** | N011613 | 002 | |
| PHENTERMINE RESIN 30 | | | | |
| QUANTUM PHARMICS | EQ 30MG BASE | A089120 | 001 | Feb 04, 1988 |
| PHENTERMINE RESIN COMPLEX | | | | |
| LANNETT HOLDINGS INC | EQ 15MG BASE | A040872 | 001 | Jul 28, 2011 |
| | EQ 30MG BASE | A040872 | 002 | Jul 28, 2011 |

PHENTOLAMINE MESYLATE

INJECTABLE;INJECTION

| | | | | |
|---|---|---|---|---|
| REGITINE | | | | |
| + NOVARTIS | 5MG/VIAL | N008278 | 003 | |

PHENYL AMINOSALICYLATE

POWDER;ORAL

| | | | | |
|---|---|---|---|---|
| PHENY-PAS-TEBAMIN | | | | |
| PHARM RES ASSOC | 50% | N011695 | 002 | |

TABLET;ORAL

| | | | | |
|---|---|---|---|---|
| PHENY-PAS-TEBAMIN | | | | |
| PHARM RES ASSOC | 500MG | N011695 | 003 | |

PHENYLBUTAZONE

CAPSULE;ORAL

| | | | | |
|---|---|---|---|---|
| AZOLID | | | | |
| SANOFI AVENTIS US | 100MG | A087260 | 001 | |
| BUTAZOLIDIN | | | | |
| NOVARTIS | 100MG | N008319 | 009 | |
| PHENYLBUTAZONE | | | | |
| IVAX PHARMS | 100MG | A088218 | 001 | Jun 24, 1983 |
| SANDOZ | 100MG | A087774 | 001 | Jun 16, 1982 |
| SUN PHARM INDUSTRIES | 100MG | A088994 | 001 | Dec 04, 1985 |
| WATSON LABS | 100MG | A087756 | 001 | Dec 17, 1982 |

TABLET;ORAL

| | | | | |
|---|---|---|---|---|
| AZOLID | | | | |
| SANOFI AVENTIS US | 100MG | A087091 | 001 | |
| BUTAZOLIDIN | | | | |
| NOVARTIS | 100MG | N008319 | 008 | |
| PHENYLBUTAZONE | | | | |
| SANDOZ | 100MG | A084339 | 001 | |
| SUN PHARM INDUSTRIES | 100MG | A088863 | 001 | Dec 04, 1985 |
| WATSON LABS | 100MG | A086151 | 001 | |
| | 100MG | A087674 | 001 | Apr 21, 1982 |

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

| | | | | |
|---|---|---|---|---|
| PHENERGAN VC | | | | |
| + ANI PHARMS | 5MG/5ML;6.25MG/5ML ** | N008604 | 003 | Apr 02, 1984 |
| PHERAZINE VC | | | | |
| HALSEY | 5MG/5ML;6.25MG/5ML | A088868 | 001 | Mar 02, 1987 |
| PROMETHAZINE VC PLAIN | | | | |
| CENCI | 5MG/5ML;6.25MG/5ML | A088815 | 001 | Nov 22, 1985 |
| WOCKHARDT | 5MG/5ML;6.25MG/5ML | A088897 | 001 | Jan 04, 1985 |

PHENYLEPHRINE HYDROCHLORIDE; PYRILAMINE MALEATE

SOLUTION/DROPS;OPHTHALMIC

| | | | | |
|---|---|---|---|---|
| PREFRIN-A | | | | |
| ALLERGAN | 0.12%;0.1% | N007953 | 001 | |

PHENYTOIN

SUSPENSION;ORAL

| | | | | |
|---|---|---|---|---|
| DILANTIN-30 | | | | |
| PARKE DAVIS | 30MG/5ML | N008762 | 002 | |
| PHENYTOIN | | | | |
| ACTAVIS MID ATLANTIC | 125MG/5ML | A089892 | 001 | Sep 25, 1992 |

| | | | | |
|---|---|---|---|---|
| PHENYTOIN SODIUM | | | | |
| CAPSULE;ORAL | | | | |
| DIPHENYLAN SODIUM | | | | |
| LANNETT | 30MG PROMPT | A080857 | 001 | |
| | 100MG PROMPT | A080857 | 002 | |
| EXTENDED PHENYTOIN SODIUM | | | | |
| ANI PHARMS INC | 100MG EXTENDED | A040435 | 001 | Jun 20, 2003 |
| | 100MG EXTENDED | A089441 | 001 | Dec 18, 1986 |
| WOCKHARDT | 30MG EXTENDED | A040759 | 001 | Dec 18, 2007 |
| WOCKHARDT USA | 100MG EXTENDED | A040732 | 001 | Jan 30, 2008 |
| PHENYTEX | | | | |
| WATSON LABS | 100MG EXTENDED | A088711 | 001 | Dec 21, 1984 |
| PHENYTOIN SODIUM | | | | |
| PHARMERAL | 100MG PROMPT | A085435 | 001 | |
| WATSON LABS | 100MG PROMPT | A085894 | 001 | |
| PROMPT PHENYTOIN SODIUM | | | | |
| ANI PHARMS INC | 100MG PROMPT | A080259 | 001 | |
| WATSON LABS | 100MG PROMPT | A080905 | 001 | |
| INJECTABLE;INJECTION | | | | |
| DILANTIN | | | | |
| PARKE DAVIS | 50MG/ML | N010151 | 001 | |
| PHENYTOIN SODIUM | | | | |
| FRESENIUS KABI USA | 50MG/ML | A089003 | 001 | May 31, 1985 |
| HOSPIRA | 50MG/ML | A089521 | 001 | Mar 17, 1987 |
| | 50MG/ML | A089744 | 001 | Dec 18, 1987 |
| MARSAM PHARMS LLC | 50MG/ML | A089501 | 001 | Oct 13, 1987 |
| | 50MG/ML | A089779 | 001 | Nov 27, 1992 |
| SMITH AND NEPHEW | 50MG/ML | A088519 | 001 | Dec 19, 1984 |
| | 50MG/ML | A088521 | 001 | Dec 18, 1984 |
| SOLOPAK | 50MG/ML | A088520 | 001 | Dec 17, 1984 |
| WARNER CHILCOTT | 50MG/ML | A089900 | 001 | Mar 30, 1990 |
| WATSON LABS | 50MG/ML | A085434 | 001 | |
| PHYTONADIONE | | | | |
| INJECTABLE;INJECTION | | | | |
| AQUAMEPHYTON | | | | |
| + TELIGENT | 1MG/0.5ML ** | N012223 | 002 | |
| + | 10MG/ML ** | N012223 | 001 | |
| KONAKION | | | | |
| ROCHE | 1MG/0.5ML | N011745 | 001 | |
| | 10MG/ML | N011745 | 003 | |
| PHYTONADIONE | | | | |
| GLAXOSMITHKLINE | 1MG/0.5ML | A084060 | 001 | |
| | 10MG/ML | A084060 | 002 | |
| VITAMIN K1 | | | | |
| HOSPIRA | 10MG/ML | A087956 | 001 | Jul 25, 1983 |
| PILOCARPINE | | | | |
| INSERT, EXTENDED RELEASE;OPHTHALMIC | | | | |
| OCUSERT PILO-20 | | | | |
| AKORN | 5MG | N017431 | 001 | |
| OCUSERT PILO-40 | | | | |
| AKORN | 11MG | N017548 | 001 | |
| PILOCARPINE HYDROCHLORIDE | | | | |
| GEL;OPHTHALMIC | | | | |
| PILOPINE HS | | | | |
| ALCON | 4% | N018796 | 001 | Oct 01, 1984 |
| PINACIDIL | | | | |
| CAPSULE, EXTENDED RELEASE;ORAL | | | | |
| PINDAC | | | | |
| LEO PHARM | 12.5MG | N019456 | 001 | Dec 28, 1989 |
| | 25MG | N019456 | 002 | Dec 28, 1989 |
| PINDOLOL | | | | |
| TABLET;ORAL | | | | |
| PINDOLOL | | | | |
| G AND W LABS INC | 5MG | A073661 | 001 | Oct 31, 1993 |
| | 5MG | A073687 | 001 | Feb 26, 1993 |
| | 5MG | A074123 | 001 | Apr 17, 1997 |
| | 10MG | A073661 | 002 | Oct 31, 1993 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

PINDOLOL

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| PINDOLOL | | | | |
| | 10MG | A073687 | 002 | Feb 26, 1993 |
| | 10MG | A074123 | 002 | Apr 17, 1997 |
| MYLAN PHARMS INC | 5MG | A074013 | 001 | Sep 24, 1992 |
| | 10MG | A074018 | 001 | Sep 24, 1992 |
| NOSTRUM LABS | 5MG | A074474 | 001 | Oct 28, 1996 |
| | 10MG | A074474 | 002 | Oct 28, 1996 |
| PUREPAC PHARM | 5MG | A074125 | 001 | Apr 28, 1993 |
| | 10MG | A074125 | 002 | Apr 28, 1993 |
| WATSON LABS | 5MG | A074437 | 001 | Feb 27, 1995 |
| | 10MG | A074437 | 002 | Feb 27, 1995 |
| VISKEN | | | | |
| + NOVARTIS | 5MG ** | N018285 | 001 | Sep 03, 1982 |
| + | 10MG ** | N018285 | 002 | Sep 03, 1982 |

PIPECURONIUM BROMIDE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| ARDUAN | | | | |
| ORGANON USA INC | 10MG/VIAL | N019638 | 001 | Jun 26, 1990 |

PIPERACETAZINE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| QUIDE | | | | |
| DOW PHARM | 10MG | N013615 | 001 | |
| | 25MG | N013615 | 002 | |

PIPERACILLIN SODIUM

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| PIPRACIL | | | | |
| WYETH PHARMS INC | EQ 2GM BASE/VIAL | A062750 | 001 | Oct 13, 1987 |
| + | EQ 2GM BASE/VIAL ** | N050545 | 002 | |
| | EQ 3GM BASE/VIAL | A062750 | 002 | Oct 13, 1987 |
| + | EQ 3GM BASE/VIAL ** | N050545 | 003 | |
| | EQ 4GM BASE/VIAL | A062750 | 003 | Oct 13, 1987 |
| + | EQ 4GM BASE/VIAL ** | N050545 | 004 | |
| + | EQ 40GM BASE/VIAL ** | N050545 | 006 | Sep 30, 1985 |

PIPERAZINE CITRATE

| | | | | |
|---|---|---|---|---|
| SYRUP;ORAL | | | | |
| ANTEPAR | | | | |
| GLAXOSMITHKLINE | EQ 500MG BASE/5ML | N009102 | 001 | |
| BRYREL | | | | |
| SANOFI AVENTIS US | EQ 500MG BASE/5ML | N017796 | 001 | |
| MULTIFUGE | | | | |
| BLULINE | EQ 500MG BASE/5ML | N009452 | 001 | |
| PIPERAZINE CITRATE | | | | |
| ALPHARMA US PHARMS | EQ 500MG BASE/5ML | A080774 | 001 | |
| LANNETT | EQ 500MG BASE/5ML | A080963 | 001 | |
| LUITPOLD | EQ 500MG BASE/5ML | A080671 | 001 | |
| VERMIDOL | | | | |
| SOLVAY | EQ 500MG BASE/5ML | A080992 | 001 | |
| TABLET;ORAL | | | | |
| ANTEPAR | | | | |
| GLAXOSMITHKLINE | EQ 500MG BASE | N009102 | 003 | |
| PIPERAZINE CITRATE | | | | |
| IMPAX LABS | EQ 250MG BASE | A080874 | 001 | |

PIPERONYL BUTOXIDE; PYRETHRINS

| | | | | |
|---|---|---|---|---|
| AEROSOL;TOPICAL | | | | |
| RID MOUSSE | | | | |
| BAYER HEALTHCARE LLC | 4%;EQ 0.33% BASE | N021043 | 001 | Mar 07, 2000 |

PIPOBROMAN

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| VERCYTE | | | | |
| ABBOTT | 10MG | N016245 | 001 | |
| | 25MG | N016245 | 002 | |

PIRBUTEROL ACETATE

AEROSOL, METERED;INHALATION

MAXAIR

| | | | | |
|---|---|---|---|---|
| MEDICIS | EQ 0.2MG BASE/INH | N020014 | 001 | Nov 30, 1992 |
| VALEANT PHARMS | EQ 0.2MG BASE/INH | N019009 | 001 | Dec 30, 1986 |

PIRFENIDONE

TABLET;ORAL

ESBRIET

| | | | | | |
|---|---|---|---|---|---|
| + | GENENTECH INC | 534MG | N208780 | 002 | Jan 11, 2017 |

PIROXICAM

CAPSULE;ORAL

PIROXICAM

| | | | | |
|---|---|---|---|---|
| CYCLE PHARMS LTD | 10MG | A073651 | 001 | Feb 26, 1993 |
| | 20MG | A073651 | 002 | Feb 26, 1993 |
| EGIS | 10MG | A074808 | 001 | Jul 08, 1997 |
| | 20MG | A074808 | 002 | Jul 08, 1997 |
| IVAX SUB TEVA PHARMS | 10MG | A074148 | 001 | Jun 03, 1996 |
| | 20MG | A074148 | 002 | Jun 03, 1996 |
| MYLAN | 10MG | A074043 | 001 | Sep 22, 1992 |
| | 10MG | A074102 | 001 | Jul 31, 1992 |
| | 20MG | A074043 | 002 | Sep 22, 1992 |
| | 20MG | A074102 | 002 | Jul 31, 1992 |
| SCS | 10MG | A074036 | 001 | May 29, 1992 |
| | 20MG | A074036 | 002 | May 29, 1992 |
| TEVA | 10MG | A073637 | 001 | Jan 28, 1994 |
| | 20MG | A073638 | 001 | Jan 28, 1994 |
| TEVA PHARMS | 10MG | A074103 | 001 | Aug 28, 1992 |
| | 20MG | A074103 | 002 | Aug 28, 1992 |
| WATSON LABS | 10MG | A074287 | 001 | May 16, 1996 |
| | 10MG | A074460 | 001 | Sep 29, 1995 |
| | 20MG | A074287 | 002 | May 16, 1996 |
| | 20MG | A074460 | 002 | Sep 29, 1995 |

PITAVASTATIN SODIUM

TABLET;ORAL

NIKITA

| | | | | | |
|---|---|---|---|---|---|
| + | LUPIN LTD | EQ 1MG BASE | N209875 | 001 | Aug 04, 2017 |
| + | | EQ 2MG BASE | N209875 | 002 | Aug 04, 2017 |
| + | | EQ 4MG BASE | N209875 | 003 | Aug 04, 2017 |

PLICAMYCIN

INJECTABLE;INJECTION

MITHRACIN

| | | | | |
|---|---|---|---|---|
| PFIZER | 2.5MG/VIAL | N050109 | 001 | |

PODOFILOX

SOLUTION;TOPICAL

PODOFILOX

| | | | | |
|---|---|---|---|---|
| BAUSCH AND LOMB INC | 0.5% | A090184 | 001 | Jul 21, 2010 |

POLYESTRADIOL PHOSPHATE

INJECTABLE;INJECTION

ESTRADURIN

| | | | | |
|---|---|---|---|---|
| WYETH AYERST | 40MG/AMP | N010753 | 001 | |

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

POLYETHYLENE GLYCOL 3350

| | | | | |
|---|---|---|---|---|
| PADDOCK LLC | 17GM/SCOOPFUL | A090567 | 001 | Oct 15, 2009 |
| TEVA PHARMS | 17GM/SCOOPFUL | A077445 | 001 | May 04, 2006 |

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION;ORAL

PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE

| | | | | |
|---|---|---|---|---|
| MYLAN | 420GM/BOT;1.48GM/BOT;5.72GM/BOT;11.2GM/BOT | A090409 | 001 | Apr 02, 2010 |

| | | | | |
|---|---|---|---|---|
| POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE | | | | |
| FOR SOLUTION;ORAL | | | | |
| CLENZ-LYTE | | | | |
| | PADDOCK LLC | 236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT | A090769 001 | Jun 07, 2010 |
| SOLUTION;ORAL | | | | |
| OCL | | | | |
| | HOSPIRA | 6GM/100ML;75MG/100ML;168MG/100ML;146MG/100ML;1.29GM/100ML | N019284 001 | Apr 30, 1986 |
| POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS | | | | |
| FOR SOLUTION;ORAL | | | | |
| COLYTE | | | | |
| | MYLAN SPECIALITY LP | 120GM/PACKET;1.49GM/PACKET;3.36GM/PACKET;2.92GM/PACKET;11.36GM/PACKET | N018983 005 | Oct 26, 1984 |
| | | 227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET | N018983 004 | Oct 26, 1984 |
| | | 227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT | N018983 010 | Jan 31, 1989 |
| | | 240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT | N018983 007 | Jun 12, 1987 |
| | | 360GM/PACKET;4.47GM/PACKET;10.08GM/PACKET;8.76GM/PACKET;34.08GM/PACKET | N018983 006 | Oct 26, 1984 |
| COLYTE-FLAVORED | | | | |
| | MYLAN SPECIALITY LP | 227.1GM/BOT;2.82GM/BOT;6.36GM/BOT;5.53GM/BOT;21.5GM/BOT | N018983 008 | Nov 14, 1991 |
| | | 240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT | N018983 009 | Nov 14, 1991 |
| PEG 3350 AND ELECTROLYTES | | | | |
| | MYLAN | 236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT | A090928 001 | Jan 28, 2010 |
| POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES | | | | |
| | PADDOCK LLC | 240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT | A090712 001 | Feb 25, 2010 |
| FOR SUSPENSION;ORAL | | | | |
| CO-LAV | | | | |
| | VINTAGE PHARMS | 240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT | A073428 001 | Jan 28, 1992 |
| COLOVAGE | | | | |
| | DYNAPHARM | 227.1GM/PACKET;2.82GM/PACKET;6.36GM/PACKET;5.53GM/PACKET;21.5GM/PACKET | A071320 001 | Apr 20, 1988 |
| E-Z-EM PREP LYTE | | | | |
| | E Z EM | 236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT | A071278 001 | Nov 21, 1988 |
| GLYCOPREP | | | | |
| | GOLDLINE | 236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT | A072319 001 | Dec 23, 1988 |
| GO-EVAC | | | | |
| | VINTAGE PHARMS | 236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT | A073433 001 | Apr 28, 1992 |
| PEG-LYTE | | | | |
| | SANDOZ | 236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT | A073098 001 | Aug 31, 1993 |
| POLYMYXIN B SULFATE | | | | |
| INJECTABLE;INJECTION | | | | |
| AEROSPORIN | | | | |
| | GLAXOSMITHKLINE | EQ 500,000 U BASE/VIAL | A062036 001 | |
| POWDER;FOR RX COMPOUNDING | | | | |
| POLY-RX | | | | |
| | X GEN PHARMS | 100,000,000 UNITS/BOT | A061578 001 | |
| POLYMYXIN B SULFATE | | | | |
| | PADDOCK LLC | 100,000,000 UNITS/BOT | A062455 001 | Jul 27, 1983 |
| POLYTHIAZIDE | | | | |
| TABLET;ORAL | | | | |
| RENESE | | | | |
| | PFIZER | 1MG | N012845 001 | |
| | | 2MG | N012845 002 | |
| | | 4MG | N012845 003 | |

| | | | | |
|---|---|---|---|---|
| POLYTHIAZIDE; PRAZOSIN HYDROCHLORIDE | | | | |
| CAPSULE;ORAL | | | | |
| MINIZIDE | | | | |
| PFIZER | 0.5MG;EQ 1MG BASE | N017986 | 001 | |
| | 0.5MG;EQ 2MG BASE | N017986 | 002 | |
| | 0.5MG;EQ 5MG BASE | N017986 | 003 | |
| POLYTHIAZIDE; RESERPINE | | | | |
| TABLET;ORAL | | | | |
| RENESE-R | | | | |
| PFIZER | 2MG;0.25MG | N013636 | 001 | |
| POTASSIUM AMINOSALICYLATE | | | | |
| CAPSULE;ORAL | | | | |
| PASKALIUM | | | | |
| GLENWOOD | 500MG | N009395 | 004 | |
| POWDER;ORAL | | | | |
| POTASSIUM AMINOSALICYLATE | | | | |
| HEXCEL | 100% | A080098 | 001 | |
| TABLET;ORAL | | | | |
| PASKALIUM | | | | |
| GLENWOOD | 1GM | N009395 | 003 | |
| POTASSIUM CHLORIDE | | | | |
| CAPSULE, EXTENDED RELEASE;ORAL | | | | |
| K-LEASE | | | | |
| SAVAGE LABS | 8MEQ | A073398 | 001 | Jan 28, 1992 |
| | 10MEQ | A072427 | 001 | Mar 28, 1990 |
| POTASSIUM CHLORIDE | | | | |
| NESHER PHARMS | 10MEQ | A070980 | 001 | Feb 17, 1987 |
| TEVA | 8MEQ | A073531 | 001 | Apr 26, 1996 |
| | 10MEQ | A073532 | 001 | Apr 26, 1996 |
| FOR SUSPENSION, EXTENDED RELEASE;ORAL | | | | |
| MICRO-K LS | | | | |
| KV PHARM | 20MEQ/PACKET | N019561 | 003 | Aug 26, 1988 |
| INJECTABLE;INJECTION | | | | |
| POTASSIUM CHLORIDE | | | | |
| ABRAXIS PHARM | 2MEQ/ML | A080204 | 001 | |
| | 2MEQ/ML | A084290 | 001 | |
| | 2MEQ/ML | A086713 | 001 | |
| | 2MEQ/ML | A086714 | 001 | |
| | 2MEQ/ML | A087787 | 001 | Apr 20, 1982 |
| | 2MEQ/ML | A087885 | 001 | Feb 03, 1983 |
| AKORN | 2MEQ/ML | A088286 | 001 | Sep 05, 1985 |
| BAXTER HLTHCARE | 2MEQ/ML | A080203 | 001 | |
| | 2MEQ/ML | A085499 | 001 | |
| FRESENIUS KABI USA | 2MEQ/ML | A087817 | 001 | Oct 20, 1982 |
| GD SEARLE LLC | 1MEQ/ML | A086219 | 001 | |
| | 2MEQ/ML | A086219 | 002 | |
| | 2MEQ/ML | A086220 | 002 | |
| | 3MEQ/ML | A086219 | 003 | |
| | 3MEQ/ML | A086220 | 001 | |
| | 4MEQ/ML | A086219 | 004 | |
| HOSPIRA | 1MEQ/ML | A080205 | 003 | |
| | 1MEQ/ML | A083345 | 003 | |
| | 1.5MEQ/ML | A083345 | 001 | |
| | 2MEQ/ML | A083345 | 002 | |
| | 2.4MEQ/ML | A080205 | 004 | |
| | 3.2MEQ/ML | A080205 | 005 | |
| INTL MEDICATION | 2MEQ/ML | A083163 | 001 | |
| LILLY | 2MEQ/ML | N007865 | 002 | |
| LUITPOLD | 2MEQ/ML | A080221 | 001 | |
| | 2MEQ/ML | A080736 | 001 | |
| | 2MEQ/ML | A087584 | 001 | |
| | 2MEQ/ML | A087585 | 001 | |
| MILES | 1MEQ/ML | A080195 | 002 | |
| | 2MEQ/ML | A080195 | 001 | |
| | 3MEQ/ML | A080195 | 003 | |
| | 4MEQ/ML | A080195 | 004 | |
| PHARMA SERVE NY | 2MEQ/ML | A086297 | 001 | |
| | 2MEQ/ML | A087362 | 001 | Mar 08, 1983 |

POTASSIUM CHLORIDE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| POTASSIUM CHLORIDE | | | | |
| | WATSON LABS | 2MEQ/ML | A086208 001 | |
| | | 2MEQ/ML | A089163 001 | Mar 10, 1988 |
| | | 2MEQ/ML | A089421 001 | Jan 02, 1987 |
| | | 3MEQ/ML | A086210 001 | |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| K+10 | | | | |
| | FUTURE PAK | 10MEQ | A070999 001 | Oct 22, 1987 |
| K+8 | | | | |
| | FUTURE PAK | 8MEQ | A070998 001 | Jan 25, 1993 |
| KAON CL | | | | |
| | SAVAGE LABS | 6.7MEQ | N017046 001 | |
| KAON CL-10 | | | | |
| | SAVAGE LABS | 10MEQ | N017046 002 | |
| KLOTRIX | | | | |
| | APOTHECON | 10MEQ | N017850 001 | |
| POTASSIUM CHLORIDE | | | | |
| | COPLEY PHARM | 8MEQ | A070618 001 | Sep 09, 1987 |
| | NESHER PHARMS | 20MEQ | A076044 001 | Apr 05, 2002 |
| + | SCHERING | 10MEQ ** | N019439 002 | Jun 13, 1986 |
| + | | 20MEQ ** | N019439 001 | Jun 13, 1986 |
| SLOW-K | | | | |
| | NOVARTIS | 8MEQ | N017476 002 | |
| TEN-K | | | | |
| | NOVARTIS | 10MEQ | N019381 001 | Apr 16, 1986 |

POTASSIUM CHLORIDE; SODIUM CHLORIDE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| POTASSIUM CHLORIDE 0.037% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | | | | |
| | B BRAUN | 37MG/100ML;900MG/100ML | N019708 001 | Sep 29, 1989 |
| POTASSIUM CHLORIDE 0.075% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | | | | |
| | B BRAUN | 75MG/100ML;900MG/100ML | N019708 002 | Sep 29, 1989 |
| POTASSIUM CHLORIDE 0.11% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | | | | |
| | B BRAUN | 110MG/100ML;900MG/100ML | N019708 003 | Sep 29, 1989 |
| POTASSIUM CHLORIDE 0.22% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | | | | |
| | B BRAUN | 220MG/100ML;900MG/100ML | N019708 005 | Sep 29, 1989 |
| POTASSIUM CHLORIDE 0.3% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | | | | |
| | B BRAUN | 300MG/100ML;900MG/100ML | N019708 006 | Sep 29, 1989 |
| SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER | | | | |
| | B BRAUN | 75MG/100ML;900MG/100ML | N018722 001 | Nov 09, 1982 |
| | BAXTER HLTHCARE | 75MG/100ML;900MG/100ML | N017648 004 | |
| SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER | | | | |
| | B BRAUN | 150MG/100ML;900MG/100ML | N018722 002 | Nov 09, 1982 |
| SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.22% IN PLASTIC CONTAINER | | | | |
| | B BRAUN | 220MG/100ML;900MG/100ML | N018722 003 | Nov 09, 1982 |
| SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER | | | | |
| | B BRAUN | 300MG/100ML;900MG/100ML | N018722 004 | Nov 09, 1982 |

POTASSIUM CHLORIDE; SODIUM CHLORIDE; TROMETHAMINE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| THAM-E | | | | |
| | HOSPIRA | 370MG/VIAL;1.75GM/VIAL;36GM/VIAL | N013025 001 | |

POTASSIUM CITRATE

| | | | | |
|---|---|---|---|---|
| FOR SOLUTION;ORAL | | | | |
| POTASSIUM CITRATE | | | | |
| + | UT SW MEDCTR | 10MEQ/PACKET ** | N019647 002 | Oct 13, 1988 |
| + | | 20MEQ/PACKET ** | N019647 001 | Oct 13, 1988 |

POTASSIUM IODIDE

| | | | | |
|---|---|---|---|---|
| SOLUTION;ORAL | | | | |
| POTASSIUM IODIDE | | | | |
| | ROXANE | 1GM/ML | N018551 001 | Feb 19, 1982 |
| TABLET;ORAL | | | | |
| THYRO-BLOCK | | | | |
| | MEDA PHARMS | 130MG | N018307 001 | |

| | | | | |
|---|---|---|---|---|
| POTASSIUM PERCHLORATE | | | | |
| CAPSULE;ORAL | | | | |
| PERCHLORACAP | | | | |
| MALLINCKRODT | 200MG | N017551 | 001 | |
| POVIDONE-IODINE | | | | |
| SOLUTION;TOPICAL | | | | |
| E-Z PREP | | | | |
| CLINIPAD | 10% | N019382 | 001 | Jul 25, 1989 |
| SPONGE;TOPICAL | | | | |
| E-Z PREP | | | | |
| CLINIPAD | 5% | N019382 | 002 | Jul 25, 1989 |
| E-Z PREP 220 | | | | |
| CLINIPAD | 5% | N019382 | 003 | Jul 25, 1989 |
| PRALIDOXIME CHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| PRALIDOXIME CHLORIDE | | | | |
| BAXTER HLTHCARE CORP | 300MG/ML | N018799 | 001 | Dec 13, 1982 |
| TABLET;ORAL | | | | |
| PROTOPAM CHLORIDE | | | | |
| WYETH AYERST | 500MG | N014122 | 002 | |
| PRAMIPEXOLE DIHYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| MIRAPEX | | | | |
| BOEHRINGER INGELHEIM | 1.25MG | N020667 | 004 | Jul 01, 1997 |
| PRAMIPEXOLE DIHYDROCHLORIDE | | | | |
| ACTAVIS GRP PTC | 0.125MG | A091254 | 001 | Nov 30, 2010 |
| | 0.25MG | A091254 | 002 | Nov 30, 2010 |
| | 0.5MG | A091254 | 003 | Nov 30, 2010 |
| | 0.75MG | A091254 | 004 | Nov 30, 2010 |
| | 1MG | A091254 | 005 | Nov 30, 2010 |
| | 1.5MG | A091254 | 006 | Nov 30, 2010 |
| SANDOZ | 0.125MG | A090190 | 001 | Jul 06, 2010 |
| | 0.25MG | A090190 | 002 | Jul 06, 2010 |
| | 0.5MG | A090190 | 003 | Jul 06, 2010 |
| | 0.75MG | A090190 | 006 | Oct 08, 2010 |
| | 1MG | A090190 | 004 | Jul 06, 2010 |
| | 1.5MG | A090190 | 005 | Jul 06, 2010 |
| WATSON LABS | 0.125MG | A078551 | 001 | Oct 08, 2010 |
| | 0.25MG | A078551 | 002 | Oct 08, 2010 |
| | 0.5MG | A078551 | 003 | Oct 08, 2010 |
| | 1MG | A078551 | 004 | Oct 08, 2010 |
| | 1.5MG | A078551 | 005 | Oct 08, 2010 |
| PRAMLINTIDE ACETATE | | | | |
| INJECTABLE;SUBCUTANEOUS | | | | |
| SYMLIN | | | | |
| ASTRAZENECA AB | EQ 3MG BASE/5ML (EQ 600MCG BASE/ML) | N021332 | 001 | Mar 16, 2005 |
| PRAVASTATIN SODIUM | | | | |
| TABLET;ORAL | | | | |
| PRAVACHOL | | | | |
| + BRISTOL MYERS SQUIBB | 10MG ** | N019898 | 002 | Oct 31, 1991 |
| PRAVASTATIN SODIUM | | | | |
| MYLAN | 10MG | A077013 | 001 | Oct 23, 2006 |
| | 20MG | A077013 | 002 | Oct 23, 2006 |
| | 40MG | A077013 | 003 | Oct 23, 2006 |
| | 80MG | A077013 | 004 | Dec 28, 2007 |
| PLIVA HRVATSKA DOO | 10MG | A077730 | 001 | Nov 21, 2006 |
| | 20MG | A077730 | 002 | Nov 21, 2006 |
| | 30MG | A077730 | 003 | Nov 21, 2006 |
| | 40MG | A077730 | 005 | Nov 21, 2006 |
| RANBAXY LABS LTD | 10MG | A076445 | 001 | Apr 23, 2007 |
| | 20MG | A076445 | 002 | Apr 23, 2007 |
| | 40MG | A076445 | 003 | Apr 23, 2007 |
| | 80MG | A076445 | 004 | Apr 23, 2007 |

| | | | | |
|---|---|---|---|---|
| PRAZEPAM | | | | |
| CAPSULE;ORAL | | | | |
| CENTRAX | | | | |
| PARKE DAVIS | 5MG | N018144 | 001 | |
| | 10MG | N018144 | 002 | |
| | 20MG | N018144 | 003 | May 10, 1982 |
| PRAZEPAM | | | | |
| USL PHARMA | 5MG | A070427 | 001 | Nov 06, 1987 |
| | 10MG | A070428 | 001 | Nov 06, 1987 |
| TABLET;ORAL | | | | |
| CENTRAX | | | | |
| PARKE DAVIS | 10MG | N017415 | 001 | |
| PRAZOSIN HYDROCHLORIDE | | | | |
| CAPSULE;ORAL | | | | |
| PRAZOSIN HYDROCHLORIDE | | | | |
| AM THERAP | EQ 1MG BASE | A072782 | 001 | May 16, 1989 |
| | EQ 2MG BASE | A072783 | 001 | May 16, 1989 |
| | EQ 5MG BASE | A072784 | 001 | May 16, 1989 |
| DAVA PHARMS INC | EQ 1MG BASE | A072705 | 001 | May 16, 1989 |
| | EQ 2MG BASE | A072706 | 001 | May 16, 1989 |
| | EQ 5MG BASE | A072707 | 001 | May 16, 1989 |
| IDT AUSTRALIA LTD | EQ 1MG BASE | A072577 | 002 | May 16, 1989 |
| | EQ 2MG BASE | A072577 | 001 | May 16, 1989 |
| | EQ 5MG BASE | A072577 | 003 | May 16, 1989 |
| PUREPAC PHARM | EQ 1MG BASE | A072991 | 001 | May 16, 1989 |
| | EQ 2MG BASE | A072921 | 001 | May 16, 1989 |
| | EQ 5MG BASE | A072992 | 001 | May 16, 1989 |
| WATSON LABS | EQ 1MG BASE | A072352 | 001 | May 16, 1989 |
| | EQ 2MG BASE | A072333 | 001 | May 16, 1989 |
| | EQ 5MG BASE | A072609 | 001 | May 16, 1989 |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| MINIPRESS XL | | | | |
| PFIZER | 2.5MG | N019775 | 001 | Jan 29, 1992 |
| | 5MG | N019775 | 002 | Jan 29, 1992 |
| PREDNISOLONE | | | | |
| CREAM;TOPICAL | | | | |
| METI-DERM | | | | |
| SCHERING | 0.5% | N010209 | 002 | |
| SYRUP;ORAL | | | | |
| PREDNISOLONE | | | | |
| APOTEX INC | 5MG/5ML | A040570 | 001 | Aug 25, 2005 |
| | 15MG/5ML | A040571 | 001 | Aug 25, 2005 |
| IVAX SUB TEVA PHARMS | 15MG/5ML | A040287 | 001 | May 28, 1999 |
| NESHER PHARMS | 5MG/5ML | A040423 | 001 | Oct 22, 2001 |
| | 15MG/5ML | A040364 | 001 | Apr 10, 2002 |
| TEVA PHARMS | 15MG/5ML | A040322 | 001 | Jan 19, 2000 |
| WE PHARMS | 15MG/5ML | A040192 | 001 | May 28, 1998 |
| PRELONE | | | | |
| MURO | 5MG/5ML | A089654 | 001 | Jan 17, 1989 |
| TABLET;ORAL | | | | |
| CORTALONE | | | | |
| HALSEY | 1MG | A080304 | 003 | |
| | 2.5MG | A080304 | 002 | |
| | 5MG | A080304 | 001 | |
| DELTA-CORTEF | | | | |
| PHARMACIA AND UPJOHN | 5MG | N009987 | 004 | |
| FERNISOLONE-P | | | | |
| FERNDALE LABS | 5MG | A083941 | 001 | |
| PREDNISOLONE | | | | |
| AUROLIFE PHARMA LLC | 5MG | A084773 | 001 | |
| BARR | 5MG | A084426 | 002 | |
| BUNDY | 5MG | A083675 | 001 | |
| CHARTWELL RX | 5MG | A084542 | 001 | |
| ELKINS SINN | 5MG | A080625 | 001 | |
| EVERYLIFE | 1MG | A084439 | 001 | |
| | 2.5MG | A084439 | 002 | |
| | 5MG | A084439 | 003 | |
| FERRANTE | 2.5MG | A080562 | 001 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

PREDNISOLONE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| PREDNISOLONE | | | | |
| | 5MG | | A080562 002 | |
| HEATHER | 5MG | | A080326 001 | |
| IMPAX LABS | 5MG | | A080780 001 | |
| INWOOD LABS | 5MG | | A080748 001 | |
| IVAX SUB TEVA PHARMS | 5MG | | A080378 001 | |
| LANNETT | 5MG | | A080531 002 | |
| MARSHALL PHARMA | 5MG | | A080307 001 | |
| PANRAY | 1MG | | A080351 001 | |
| | 5MG | | A080351 002 | |
| PHOENIX LABS NY | 5MG | | A080322 001 | |
| PUREPAC PHARM | 5MG | | A080325 001 | |
| PVT FORM | 5MG | | A080211 001 | |
| ROXANE | 5MG | | A080327 002 | |
| SANDOZ | 5MG | | A080339 001 | |
| SPERTI | 1MG | | A080358 001 | |
| | 2.5MG | | A080358 002 | |
| | 5MG | | A080358 003 | |
| SUPERPHARM | 5MG | | A088892 001 | Feb 26, 1985 |
| TABLICAPS | 5MG | | A085170 001 | |
| TEVA | 5MG | | A080398 001 | |
| UDL | 5MG | | A087987 001 | Jan 18, 1983 |
| VALEANT PHARM INTL | 5MG | | A080236 001 | |
| VITARINE | 5MG | | A080534 001 | |
| WATSON LABS | 5MG | | A085085 002 | |
| | 5MG | | A085415 001 | |
| | 5MG | | A085416 001 | |
| WEST WARD | 5MG | | A080324 001 | |
| WHITEWORTH TOWN PLSN | 5MG | | A080342 001 | |
| STERANE | | | | |
| PFIZER | 5MG | | N009996 001 | |

PREDNISOLONE ACETATE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| METICORTELONE | | | | |
| SCHERING | 25MG/ML | | N010255 002 | |
| PREDNISOLONE ACETATE | | | | |
| AKORN | 25MG/ML | | A083032 001 | |
| | 50MG/ML | | A084492 001 | |
| BEL MAR | 25MG/ML | | A083738 001 | |
| | 50MG/ML | | A083738 002 | |
| CENT PHARMS | 25MG/ML | | A084717 001 | |
| | 50MG/ML | | A084717 002 | |
| WATSON LABS | 25MG/ML | | A083398 001 | |
| | 25MG/ML | | A083654 001 | |
| | 40MG/ML | | A083767 001 | |
| | 50MG/ML | | A083764 001 | |
| | 50MG/ML | | A085781 001 | |
| STERANE | | | | |
| PFIZER | 25MG/ML | | N011446 001 | |
| SUSPENSION;ORAL | | | | |
| FLO-PRED | | | | |
| TARO | EQ 5MG BASE/5ML | | N022067 001 | Jan 17, 2008 |
| | EQ 15MG BASE/5ML | | N022067 002 | Jan 17, 2008 |
| SUSPENSION/DROPS;OPHTHALMIC | | | | |
| ECONOPRED | | | | |
| ALCON | 0.125% | | N017468 001 | |

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

| | | | | |
|---|---|---|---|---|
| OINTMENT;OPHTHALMIC | | | | |
| CETAPRED | | | | |
| ALCON | 0.25%;10% | | A087771 001 | Aug 06, 1993 |
| METIMYD | | | | |
| SCHERING | 0.5%;10% | | N010210 002 | Sep 09, 1984 |
| PREDSULFAIR | | | | |
| PHARMAFAIR | 0.5%;10% | | A088032 001 | Apr 15, 1983 |
| VASOCIDIN | | | | |
| NOVARTIS | 0.5%;10% | | A088791 001 | Oct 05, 1984 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

| | | | | |
|---|---|---|---|---|
| SUSPENSION;OPHTHALMIC | | | | |
| ISOPTO CETAPRED | | | | |
| | ALCON | 0.25%;10% | A087547 001 | |
| SUSPENSION/DROPS;OPHTHALMIC | | | | |
| METIMYD | | | | |
| | SCHERING | 0.5%;10% | N010210 001 | |
| PREDAMIDE | | | | |
| | AKORN | 0.5%;10% | A088059 001 | Jul 29, 1983 |
| PREDSULFAIR | | | | |
| | PHARMAFAIR | 0.5%;10% | A088007 001 | Apr 19, 1983 |
| PREDSULFAIR II | | | | |
| | PHARMAFAIR | 0.2%;10% | A088837 001 | Dec 24, 1985 |
| SULPHRIN | | | | |
| | BAUSCH AND LOMB | 0.5%;10% | A088089 001 | Dec 28, 1982 |

PREDNISOLONE SODIUM PHOSPHATE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| HYDELTRASOL | | | | |
| | MERCK | EQ 20MG PHOSPHATE/ML | N011583 002 | |
| PREDNISOLONE SODIUM PHOSPHATE | | | | |
| | WATSON LABS | EQ 20MG PHOSPHATE/ML | A080517 001 | |
| OINTMENT;OPHTHALMIC, OTIC | | | | |
| HYDELTRASOL | | | | |
| | MERCK | EQ 0.25% PHOSPHATE | N011028 001 | |
| SOLUTION;ORAL | | | | |
| ORAPRED | | | | |
| | CONCORDIA PHARMS INC | EQ 15MG BASE/5ML ** | A075117 001 | Dec 14, 2000 |
| PREDNISOLONE SODIUM PHOSPHATE | | | | |
| | AMNEAL PHARMS | EQ 15MG BASE/5ML | A078345 001 | Mar 10, 2009 |
| | MEDICIS PHARMS | EQ 15MG BASE/5ML | A075250 001 | Jul 12, 2002 |
| | NESHER PHARMS | EQ 5MG BASE/5ML | A076982 001 | May 24, 2005 |
| | | EQ 15MG BASE/5ML | A076988 001 | May 24, 2005 |
| | PHARM ASSOC | EQ 5MG BASE/5ML | A076123 001 | Dec 23, 2002 |
| | VINTAGE PHARMS | EQ 5MG BASE/5ML | A078416 001 | Oct 31, 2007 |
| | WE PHARMS | EQ 5MG BASE/5ML | A075181 001 | Dec 23, 2002 |
| SOLUTION/DROPS;OPHTHALMIC | | | | |
| INFLAMASE FORTE | | | | |
| | NOVARTIS | EQ 0.9% PHOSPHATE | A080751 002 | |
| INFLAMASE MILD | | | | |
| | NOVARTIS | EQ 0.11% PHOSPHATE | A080751 001 | |
| METRETON | | | | |
| | SCHERING | EQ 0.5% PHOSPHATE | A083834 001 | |
| PREDAIR | | | | |
| | PHARMAFAIR | EQ 0.11% PHOSPHATE | A088415 001 | Feb 29, 1984 |
| PREDAIR FORTE | | | | |
| | PHARMAFAIR | EQ 0.9% PHOSPHATE | A088165 001 | Mar 28, 1983 |
| PREDNISOLONE SODIUM PHOSPHATE | | | | |
| | AKORN | EQ 0.11% PHOSPHATE | A083358 001 | |
| | | EQ 0.9% PHOSPHATE | A083358 002 | |
| | ALCON PHARMS LTD | EQ 0.11% PHOSPHATE | A081043 001 | Oct 24, 1991 |
| | | EQ 0.9% PHOSPHATE | A081044 001 | Oct 24, 1991 |
| | BAUSCH AND LOMB | EQ 0.11% PHOSPHATE | A040065 001 | Jul 29, 1994 |
| | SOLA BARNES HIND | EQ 0.11% PHOSPHATE | A084171 001 | |
| | | EQ 0.9% PHOSPHATE | A084168 001 | |
| | | EQ 0.9% PHOSPHATE | A084169 001 | |
| | | EQ 0.9% PHOSPHATE | A084172 001 | |

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

| | | | | |
|---|---|---|---|---|
| SOLUTION/DROPS;OPHTHALMIC | | | | |
| SULSTER | | | | |
| | AKORN | EQ 0.23% PHOSPHATE;10% | A074511 001 | Jul 30, 1996 |
| VASOCIDIN | | | | |
| + | NOVARTIS | EQ 0.23% PHOSPHATE;10% ** | N018988 001 | Aug 26, 1988 |

| | | | | |
|---|---|---|---|---|
| PREDNISOLONE TEBUTATE | | | | |
| INJECTABLE;INJECTION | | | | |
| HYDELTRA-TBA | | | | |
| | MERCK | 20MG/ML | N010562 001 | |
| PREDNISOLONE TEBUTATE | | | | |
| | WATSON LABS | 20MG/ML | A083362 001 | Feb 17, 1984 |
| PREDNISONE | | | | |
| SOLUTION;ORAL | | | | |
| PREDNISONE | | | | |
| | WOCKHARDT | 5MG/5ML | A089726 001 | Aug 02, 1988 |
| SYRUP;ORAL | | | | |
| LIQUID PRED | | | | |
| | MURO | 5MG/5ML | A087611 002 | Sep 07, 1982 |
| TABLET;ORAL | | | | |
| CORTAN | | | | |
| | HALSEY | 20MG | A087480 001 | |
| DELTA-DOME | | | | |
| | BAYER PHARMS | 5MG | A080293 001 | |
| DELTASONE | | | | |
| + | PHARMACIA AND UPJOHN | 2.5MG ** | N009986 005 | |
| + | | 5MG ** | N009986 002 | |
| + | | 10MG ** | N009986 006 | |
| + | | 20MG ** | N009986 007 | |
| + | | 50MG ** | N009986 008 | |
| FERNISONE | | | | |
| | FERNDALE LABS | 5MG | A083364 001 | |
| METICORTEN | | | | |
| + | SCHERING | 1MG ** | N009766 002 | |
| + | | 5MG ** | N009766 001 | |
| ORASONE | | | | |
| | SOLVAY | 1MG | A083009 001 | |
| | | 5MG | A083009 002 | |
| | | 10MG | A083009 003 | |
| | | 20MG | A083009 004 | |
| | | 50MG | A085999 001 | |
| PARACORT | | | | |
| | PARKE DAVIS | 5MG | N010962 002 | |
| PREDNICEN-M | | | | |
| | SCHWARZ PHARMA | 5MG | A084655 001 | |
| PREDNISONE | | | | |
| | AM THERAP | 5MG | A089387 001 | Nov 06, 1986 |
| | | 10MG | A089388 001 | Nov 06, 1986 |
| | | 20MG | A089389 001 | Nov 06, 1986 |
| | AMNEAL PHARMS NY | 5MG | A089597 001 | Oct 05, 1987 |
| | | 10MG | A089598 001 | Oct 05, 1987 |
| | | 20MG | A089599 001 | Oct 05, 1987 |
| | AUROLIFE PHARMA LLC | 5MG | A084774 001 | |
| | | 10MG | A089983 001 | Jan 12, 1989 |
| | | 20MG | A085813 001 | |
| | | 50MG | A089984 001 | Jan 12, 1989 |
| | BUNDY | 5MG | A083676 001 | |
| | CHARTWELL RX | 5MG | A083059 001 | |
| | CONTRACT PHARMACAL | 5MG | A080209 001 | |
| | DURAMED PHARMS BARR | 5MG | A088394 001 | Oct 04, 1983 |
| | | 10MG | A088395 001 | Oct 04, 1983 |
| | | 20MG | A088396 001 | Oct 04, 1983 |
| | ELKINS SINN | 5MG | A080491 001 | |
| | | 20MG | A085811 001 | |
| | EVERYLIFE | 1MG | A084440 001 | |
| | | 2.5MG | A084440 002 | |
| | | 5MG | A084440 003 | |
| | FERRANTE | 2.5MG | A080563 001 | |
| | | 5MG | A080563 002 | |
| | HALSEY | 5MG | A080300 001 | |
| | HEATHER | 5MG | A080320 001 | |
| | | 10MG | A084341 001 | |
| | | 20MG | A084417 001 | |
| | | 20MG | A085543 001 | |
| | | 50MG | A086946 001 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

PREDNISONE

TABLET;ORAL

PREDNISONE

| | | | |
|---|---|---|---|
| HIKMA PHARMS | 1MG | A040890 001 | Nov 01, 2010 |
| IMPAX LABS | 5MG | A080782 001 | |
| INWOOD LABS | 1MG | A080328 001 | |
| | 2.5MG | A080306 001 | |
| | 5MG | A080279 001 | |
| IVAX SUB TEVA PHARMS | 5MG | A080283 001 | |
| | 10MG | A084133 001 | |
| | 20MG | A084134 001 | |
| KV PHARM | 5MG | A084236 001 | |
| LANNETT | 5MG | A080514 001 | |
| | 20MG | A084275 001 | |
| LEDERLE | 5MG | A086968 001 | |
| MARSHALL PHARMA | 5MG | A080301 001 | |
| MUTUAL PHARM | 5MG | A080701 001 | |
| | 10MG | A086595 001 | |
| | 20MG | A084634 001 | |
| NYLOS | 5MG | A085115 001 | |
| PANRAY | 1MG | A080350 001 | |
| | 2.5MG | A080350 002 | |
| | 5MG | A080350 003 | |
| PHARMAVITE | 5MG | A084662 002 | |
| PHOENIX LABS NY | 5MG | A080321 001 | |
| | 20MG | A083807 001 | |
| PUREPAC PHARM | 5MG | A080353 001 | |
| | 10MG | A086062 001 | |
| | 20MG | A086061 001 | |
| PVT FORM | 20MG | A085151 001 | |
| REXALL | 5MG | A080232 001 | |
| ROXANE | 20MG | N017109 001 | |
| | 25MG | A087833 001 | May 04, 1982 |
| SANDOZ | 5MG | A080336 002 | |
| SCHERER LABS | 5MG | A080371 001 | |
| SPERTI | 1MG | A080359 001 | |
| | 2.5MG | A080359 002 | |
| | 5MG | A080359 003 | |
| SUN PHARM INDUSTRIES | 50MG | A086596 001 | |
| SUPERPHARM | 5MG | A088865 001 | Oct 25, 1984 |
| | 10MG | A088866 001 | Oct 25, 1984 |
| | 20MG | A088867 001 | Oct 25, 1984 |
| TEVA | 5MG | A080397 001 | |
| UDL | 5MG | A087984 001 | Jan 18, 1983 |
| | 10MG | A087985 001 | Jan 18, 1983 |
| | 20MG | A087986 001 | Jan 18, 1983 |
| UPSHER SMITH | 5MG | A087471 001 | |
| | 20MG | A087470 001 | |
| VALEANT PHARM INTL | 5MG | A080237 001 | |
| VANGARD | 5MG | A087682 001 | Jan 15, 1982 |
| | 20MG | A087701 001 | Jan 15, 1982 |
| VITARINE | 5MG | A080334 001 | |
| | 5MG | A080506 001 | |
| WATSON LABS | 5MG | A085084 002 | |
| | 10MG | A087773 001 | Jul 13, 1982 |
| | 20MG | A086813 001 | |
| | 50MG | A086867 001 | |
| | 50MG | A087772 001 | Jul 13, 1982 |
| WHITEWORTH TOWN PLSN | 2.5MG | A084913 001 | |
| | 5MG | A080343 001 | |
| | 10MG | A089028 001 | Jul 24, 1986 |
| | 20MG | A084913 002 | |

SERVISONE

| | | | |
|---|---|---|---|
| LEDERLE | 5MG | A080223 001 | |

| | | | | |
|---|---|---|---|---|
| PRILOCAINE HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| CITANEST | | | | |
| + ASTRAZENECA | 1% ** | N014763 004 | | |
| + | 2% ** | N014763 005 | | |
| + | 3% ** | N014763 003 | | |
| CITANEST PLAIN | | | | |
| + ASTRAZENECA | 4% ** | N014763 007 | | |
| CITANEST PLAIN DENTAL | | | | |
| DENTSPLY PHARM | 4% | N021382 001 | | |
| PRIMIDONE | | | | |
| SUSPENSION;ORAL | | | | |
| MYSOLINE | | | | |
| NURO PHARMA | 250MG/5ML | N010401 001 | | |
| TABLET;ORAL | | | | |
| PRIMIDONE | | | | |
| DR REDDYS LABS LTD | 50MG | A040862 001 | Oct 03, 2008 | |
| | 250MG | A040862 002 | Oct 03, 2008 | |
| HIKMA INTL PHARMS | 50MG | A040667 001 | Jul 27, 2006 | |
| IMPAX LABS | 50MG | A040717 001 | Feb 12, 2008 | |
| | 250MG | A040717 002 | Feb 12, 2008 | |
| WATSON LABS | 250MG | A085052 001 | | |
| PROBENECID | | | | |
| TABLET;ORAL | | | | |
| BENEMID | | | | |
| + MERCK | 500MG ** | N007898 004 | | |
| PROBENECID | | | | |
| IVAX SUB TEVA PHARMS | 500MG | A083740 001 | May 09, 1984 | |
| LEDERLE | 500MG | A086917 001 | | |
| WATSON LABS | 500MG | A086150 002 | Apr 23, 1982 | |
| PROBUCOL | | | | |
| TABLET;ORAL | | | | |
| LORELCO | | | | |
| SANOFI AVENTIS US | 250MG | N017535 001 | | |
| | 500MG | N017535 002 | Jul 06, 1988 | |
| PROCAINAMIDE HYDROCHLORIDE | | | | |
| CAPSULE;ORAL | | | | |
| PROCAINAMIDE HYDROCHLORIDE | | | | |
| ASCOT | 250MG | A087542 001 | Jan 08, 1982 | |
| | 375MG | A087697 001 | Mar 01, 1983 | |
| | 500MG | A087543 001 | Jan 08, 1982 | |
| IDT AUSTRALIA LTD | 250MG | A089219 001 | Jul 01, 1986 | |
| | 375MG | A089219 002 | Jul 01, 1986 | |
| | 500MG | A089219 003 | Jul 01, 1986 | |
| IVAX SUB TEVA PHARMS | 250MG | A084604 001 | | |
| | 375MG | A084595 001 | | |
| | 500MG | A084606 001 | | |
| LANNETT | 250MG | A083693 001 | | |
| | 500MG | A084696 001 | | |
| LEDERLE | 250MG | A086942 001 | | |
| | 375MG | A086952 001 | | |
| | 500MG | A086943 001 | | |
| ROXANE | 250MG | A088989 001 | Apr 26, 1985 | |
| | 500MG | A088990 001 | Apr 26, 1985 | |
| VANGARD | 250MG | A087643 001 | Jun 01, 1982 | |
| | 500MG | A087875 001 | Jun 01, 1982 | |
| WATSON LABS | 250MG | A083287 001 | | |
| | 250MG | A083795 001 | | |
| | 250MG | A085167 001 | | |
| | 375MG | A084403 001 | | |
| | 375MG | A087020 001 | | |
| | 500MG | A084280 001 | | |
| | 500MG | A084357 001 | | |
| | 500MG | A087021 001 | | |
| PROCAN | | | | |
| PARKE DAVIS | 250MG | A085804 001 | | |
| | 375MG | A087502 001 | | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

PROCAINAMIDE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| CAPSULE;ORAL | | | | |
| PROCAN | | | | |
| | 500MG | | A085079 001 | |
| PROCAPAN | | | | |
| PANRAY | 250MG | | A083553 002 | |
| PRONESTYL | | | | |
| + APOTHECON | 250MG ** | | N007335 001 | |
| + | 375MG ** | | N007335 004 | |
| + | 500MG ** | | N007335 003 | |
| INJECTABLE;INJECTION | | | | |
| PROCAINAMIDE HYDROCHLORIDE | | | | |
| ABRAXIS PHARM | 100MG/ML | | A089415 001 | Nov 17, 1986 |
| | 500MG/ML | | A089416 001 | Nov 17, 1986 |
| HOSPIRA | 500MG/ML | | A089537 001 | Aug 25, 1987 |
| INTL MEDICATION | 500MG/ML | | A088637 001 | Jul 31, 1984 |
| PHARMAFAIR | 100MG/ML | | A088824 001 | Nov 20, 1985 |
| | 500MG/ML | | A088830 001 | Nov 20, 1985 |
| SMITH AND NEPHEW | 100MG/ML | | A088530 001 | Mar 04, 1985 |
| | 500MG/ML | | A088531 001 | Mar 04, 1985 |
| SOLOPAK | 500MG/ML | | A088532 001 | Mar 04, 1985 |
| WARNER CHILCOTT | 100MG/ML | | A089528 001 | May 03, 1988 |
| | 500MG/ML | | A089529 001 | May 03, 1988 |
| WATSON LABS | 100MG/ML | | A087079 001 | |
| | 500MG/ML | | A087080 001 | |
| WEST-WARD PHARMS INT | 100MG/ML | | A089029 001 | Apr 17, 1986 |
| | 500MG/ML | | A089030 001 | Apr 17, 1986 |
| PRONESTYL | | | | |
| + APOTHECON | 100MG/ML ** | | N007335 002 | |
| + | 500MG/ML ** | | N007335 005 | |
| TABLET;ORAL | | | | |
| PRONESTYL | | | | |
| APOTHECON | 250MG | | N017371 001 | |
| | 375MG | | N017371 002 | |
| | 500MG | | N017371 003 | |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| PROCAINAMIDE HYDROCHLORIDE | | | | |
| ANI PHARMS INC | 250MG | | A088958 001 | Dec 02, 1985 |
| | 500MG | | A088959 001 | Dec 02, 1985 |
| | 500MG | | A088974 001 | Jul 22, 1985 |
| | 750MG | | A089438 001 | Mar 23, 1987 |
| | 1GM | | A040111 001 | Dec 13, 1996 |
| IDT AUSTRALIA LTD | 250MG | | A089369 001 | Aug 14, 1987 |
| | 500MG | | A089369 002 | Jan 09, 1987 |
| | 750MG | | A089369 003 | Aug 14, 1987 |
| INWOOD LABS | 500MG | | A089840 001 | Mar 06, 1989 |
| SANDOZ | 500MG | | A089284 001 | Jun 23, 1986 |
| WATSON LABS | 250MG | | A088533 001 | Dec 03, 1984 |
| | 250MG | | A089026 001 | Oct 22, 1985 |
| | 500MG | | A088534 001 | Dec 03, 1984 |
| | 500MG | | A089027 001 | Oct 22, 1985 |
| | 750MG | | A088535 001 | Nov 03, 1984 |
| | 750MG | | A089042 001 | Oct 22, 1985 |
| | 1GM | | A089520 001 | Jan 15, 1987 |
| PROCAN SR | | | | |
| PARKE DAVIS | 250MG | | A086468 001 | |
| PARKEDALE | 500MG | | A086065 001 | |
| | 750MG | | A087510 001 | Apr 01, 1982 |
| | 1GM | | A088489 001 | Jan 16, 1985 |
| PROCANBID | | | | |
| KING PHARMS | 500MG | | N020545 001 | Jan 31, 1996 |
| | 1GM | | N020545 002 | Jan 31, 1996 |
| PRONESTYL-SR | | | | |
| APOTHECON | 500MG | | A087361 001 | |

PROCAINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| NOVOCAIN | | | | |
| | HOSPIRA | 1% | A085362 003 | |
| | | 2% | A085362 004 | |
| | | 10% | A086797 001 | |
| PROCAINE HYDROCHLORIDE | | | | |
| | ABRAXIS PHARM | 1% | A080384 002 | |
| | | 1% | A080421 001 | |
| | | 2% | A080384 003 | |
| | | 2% | A080421 002 | |
| | BEL MAR | 1% | A080711 001 | |
| | | 2% | A080756 001 | |
| | ELKINS SINN | 1% | A083315 001 | |
| | | 2% | A083315 002 | |
| | GD SEARLE LLC | 1% | A086202 001 | |
| | | 2% | A086202 002 | |
| | HOSPIRA | 1% | A080416 001 | |
| | | 2% | A080416 002 | |
| | MILES | 1% | A080415 001 | |
| | | 2% | A080415 002 | |
| | WATSON LABS | 1% | A080658 001 | |
| | | 1% | A083535 001 | |
| | | 2% | A080658 002 | |
| | | 2% | A083535 002 | |

PROCAINE HYDROCHLORIDE; TETRACYCLINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| ACHROMYCIN | | | | |
| | LEDERLE | 40MG/VIAL;100MG/VIAL | N050276 001 | |
| | | 40MG/VIAL;250MG/VIAL | N050276 003 | |
| TETRACYN | | | | |
| | PFIZER | 40MG/VIAL;100MG/VIAL | A060285 002 | |
| | | 40MG/VIAL;250MG/VIAL | A060285 003 | |

PROCAINE MERETHOXYLLINE; THEOPHYLLINE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| DICURIN PROCAINE | | | | |
| | LILLY | 100MG/ML;50MG/ML | N008869 001 | |

PROCHLORPERAZINE

| | | | | |
|---|---|---|---|---|
| SUPPOSITORY;RECTAL | | | | |
| COMPAZINE | | | | |
| | GLAXOSMITHKLINE | 2.5MG ** | N011127 003 | |
| | | 5MG ** | N011127 001 | |
| | | 25MG ** | N011127 002 | |
| PROCHLORPERAZINE | | | | |
| | ABLE | 2.5MG | A040407 001 | Jul 11, 2001 |
| | | 5MG | A040407 002 | Jul 11, 2001 |
| | | 25MG | A040407 003 | Jul 11, 2001 |

PROCHLORPERAZINE EDISYLATE

| | | | | |
|---|---|---|---|---|
| CONCENTRATE;ORAL | | | | |
| COMPAZINE | | | | |
| | GLAXOSMITHKLINE | EQ 10MG BASE/ML | N011276 001 | |
| PROCHLORPERAZINE | | | | |
| | ALPHARMA US PHARMS | EQ 10MG BASE/ML | A087153 001 | Jun 08, 1982 |
| PROCHLORPERAZINE EDISYLATE | | | | |
| | MORTON GROVE | EQ 10MG BASE/ML | A088598 001 | Oct 25, 1984 |
| INJECTABLE;INJECTION | | | | |
| COMPAZINE | | | | |
| + | GLAXOSMITHKLINE | EQ 5MG BASE/ML ** | N010742 002 | |
| PROCHLORPERAZINE | | | | |
| | BAXTER HLTHCARE | EQ 5MG BASE/ML | A087759 001 | Oct 01, 1982 |
| PROCHLORPERAZINE EDISYLATE | | | | |
| | ATHENEX INC | EQ 5MG BASE/ML | A040540 001 | May 28, 2004 |
| | HOSPIRA | EQ 5MG BASE/ML | A089703 001 | Apr 07, 1988 |
| | MARSAM PHARMS LLC | EQ 5MG BASE/ML | A089675 001 | Dec 05, 1988 |
| | SMITH AND NEPHEW | EQ 5MG BASE/ML | A089251 001 | Dec 04, 1986 |
| | TEVA PARENTERAL | EQ 5MG BASE/ML | A040505 001 | May 30, 2003 |
| | WATSON LABS | EQ 5MG BASE/ML | A089530 001 | Jul 08, 1987 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

PROCHLORPERAZINE EDISYLATE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| PROCHLORPERAZINE EDISYLATE | | | | |
| | EQ 5MG BASE/ML | A089605 | 001 | Jul 08, 1987 |
| | EQ 5MG BASE/ML | A089606 | 001 | Jul 08, 1987 |
| WEST-WARD PHARMS INT | EQ 5MG BASE/ML | A089523 | 001 | May 03, 1988 |
| WYETH AYERST | EQ 5MG BASE/ML | A086348 | 001 | |
| SYRUP;ORAL | | | | |
| COMPAZINE | | | | |
| GLAXOSMITHKLINE | EQ 5MG BASE/5ML | N011188 | 001 | |
| PROCHLORPERAZINE EDISYLATE | | | | |
| ALPHARMA US PHARMS | EQ 5MG BASE/5ML | A087154 | 001 | Sep 01, 1982 |
| MORTON GROVE | EQ 5MG BASE/5ML | A088597 | 001 | Oct 25, 1984 |

PROCHLORPERAZINE MALEATE

| | | | | |
|---|---|---|---|---|
| CAPSULE, EXTENDED RELEASE;ORAL | | | | |
| COMPAZINE | | | | |
| GLAXOSMITHKLINE | EQ 10MG BASE | N011000 | 001 | |
| | EQ 10MG BASE | N021019 | 001 | Oct 06, 1999 |
| | EQ 15MG BASE | N011000 | 002 | |
| | EQ 15MG BASE | N021019 | 002 | Oct 06, 1999 |
| | EQ 30MG BASE | N011000 | 003 | |
| | EQ 75MG BASE | N011000 | 004 | |
| TABLET;ORAL | | | | |
| COMPAZINE | | | | |
| GLAXOSMITHKLINE | EQ 5MG BASE ** | N010571 | 001 | |
| | EQ 10MG BASE ** | N010571 | 002 | |
| | EQ 25MG BASE ** | N010571 | 003 | |
| PROCHLORPERAZINE | | | | |
| WATSON LABS | EQ 5MG BASE | A085580 | 001 | |
| | EQ 10MG BASE | A085178 | 001 | |
| | EQ 25MG BASE | A085579 | 001 | |
| PROCHLORPERAZINE MALEATE | | | | |
| DURAMED PHARMS BARR | EQ 5MG BASE | A040207 | 001 | May 01, 1997 |
| | EQ 5MG BASE | A089484 | 001 | Jan 20, 1987 |
| | EQ 10MG BASE | A040207 | 002 | May 01, 1997 |
| | EQ 10MG BASE | A089485 | 001 | Jan 20, 1987 |
| | EQ 25MG BASE | A089486 | 001 | Jan 20, 1987 |
| IVAX SUB TEVA PHARMS | EQ 5MG BASE | A040162 | 001 | Jan 20, 1998 |
| | EQ 10MG BASE | A040162 | 002 | Jan 20, 1998 |
| SANDOZ | EQ 25MG BASE | A040101 | 003 | Jul 19, 1996 |

PROCYCLIDINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| KEMADRIN | | | | |
| MONARCH PHARMS | 2MG | N009818 | 005 | |
| | 5MG | N009818 | 003 | |

PROGESTERONE

| | | | | |
|---|---|---|---|---|
| CAPSULE;ORAL | | | | |
| PROMETRIUM | | | | |
| VIRTUS PHARMS | 300MG | N019781 | 003 | Oct 15, 1999 |
| INJECTABLE;INJECTION | | | | |
| PROGESTERONE | | | | |
| LILLY | 25MG/ML | N009238 | 002 | |
| | 50MG/ML | N009238 | 001 | |
| INSERT, EXTENDED RELEASE;INTRAUTERINE | | | | |
| PROGESTASERT | | | | |
| ALZA | 38MG | N017553 | 001 | |

PROMAZINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| CONCENTRATE;ORAL | | | | |
| SPARINE | | | | |
| WYETH AYERST | 30MG/ML | N010942 | 001 | |
| | 100MG/ML | N010942 | 004 | |
| INJECTABLE;INJECTION | | | | |
| PROMAZINE HYDROCHLORIDE | | | | |
| WATSON LABS | 25MG/ML | A084510 | 001 | |
| | 50MG/ML | A084517 | 001 | |
| SPARINE | | | | |
| BAXTER HLTHCARE CORP | 25MG/ML | N010349 | 008 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| PROMAZINE HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| SPARINE | | | | |
| | 50MG/ML | N010349 | 006 | |
| SYRUP;ORAL | | | | |
| SPARINE | | | | |
| WYETH AYERST | 10MG/5ML | N010942 | 003 | |
| TABLET;ORAL | | | | |
| SPARINE | | | | |
| WYETH AYERST | 10MG | N010348 | 006 | |
| | 25MG | N010348 | 001 | |
| | 50MG | N010348 | 002 | |
| | 100MG | N010348 | 003 | |
| | 200MG | N010348 | 004 | |
| PROMETHAZINE HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| PHENERGAN | | | | |
| WYETH AYERST | 25MG/ML | N008857 | 002 | |
| | 50MG/ML | N008857 | 003 | |
| PROMETHAZINE HYDROCHLORIDE | | | | |
| ABBOTT | 25MG/ML | A084223 | 001 | |
| | 50MG/ML | A084222 | 001 | |
| AKORN | 25MG/ML | A083955 | 002 | |
| | 50MG/ML | A083955 | 001 | |
| BEDFORD LABS | 25MG/ML | A040524 | 001 | Mar 17, 2004 |
| | 50MG/ML | A040524 | 002 | Mar 17, 2004 |
| HOSPIRA | 25MG/ML | A040372 | 001 | Jun 08, 2000 |
| | 50MG/ML | A040372 | 002 | Jun 08, 2000 |
| | 50MG/ML | A083838 | 002 | |
| LUITPOLD | 25MG/ML | A040515 | 001 | Mar 19, 2003 |
| MARSAM PHARMS LLC | 25MG/ML | A089463 | 001 | May 02, 1988 |
| | 50MG/ML | A089477 | 001 | May 02, 1988 |
| MYLAN INSTITUTIONAL | 25MG/ML | A040471 | 001 | Nov 21, 2002 |
| SANDOZ | 25MG/ML | A040593 | 001 | Nov 08, 2006 |
| | 50MG/ML | A040593 | 002 | Nov 08, 2006 |
| TEVA PHARMS USA | 25MG/ML ** | A040454 | 001 | Aug 22, 2002 |
| | 50MG/ML ** | A040454 | 002 | Aug 22, 2002 |
| WATSON LABS | 25MG/ML | A083532 | 001 | |
| | 25MG/ML | A084591 | 001 | |
| | 50MG/ML | A080629 | 002 | |
| | 50MG/ML | A083532 | 002 | |
| WOCKHARDT | 25MG/ML | A040785 | 001 | Sep 26, 2008 |
| | 50MG/ML | A040785 | 002 | Sep 26, 2008 |
| ZIPAN-25 | | | | |
| ALTANA | 25MG/ML | A083997 | 001 | |
| ZIPAN-50 | | | | |
| ALTANA | 50MG/ML | A083997 | 002 | |
| SUPPOSITORY;RECTAL | | | | |
| PHENERGAN | | | | |
| + MYLAN PHARMS INC | 12.5MG ** | N010926 | 002 | |
| + | 25MG ** | N010926 | 001 | |
| + | 50MG ** | N011689 | 001 | |
| PROMETHACON | | | | |
| POLYMEDICA | 25MG | A084901 | 001 | |
| | 50MG | A084902 | 001 | |
| PROMETHAZINE HYDROCHLORIDE | | | | |
| ABLE | 12.5MG | A040504 | 001 | Apr 11, 2003 |
| | 25MG | A040504 | 002 | Apr 11, 2003 |
| | 50MG | A040449 | 001 | Feb 27, 2003 |
| SYRUP;ORAL | | | | |
| MYMETHAZINE FORTIS | | | | |
| USL PHARMA | 25MG/5ML | A087996 | 001 | Jan 18, 1983 |
| PROMETH FORTIS | | | | |
| ALPHARMA US PHARMS | 25MG/5ML | A084772 | 001 | |
| PROMETH PLAIN | | | | |
| ACTAVIS MID ATLANTIC | 6.25MG/5ML | A085953 | 001 | |
| PROMETHAZINE | | | | |
| CENCI | 6.25MG/5ML | A089013 | 001 | Sep 20, 1985 |

PROMETHAZINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| SYRUP;ORAL | | | | |
| PROMETHAZINE HYDROCHLORIDE | | | | |
| | KV PHARM | 6.25MG/5ML | A085388 001 | |
| | | 25MG/5ML | A085385 001 | |
| | PHARM ASSOC | 6.25MG/5ML | A087518 001 | |
| | WHITEWORTH TOWN PLSN | 6.25MG/5ML | A086395 001 | |
| PROMETHAZINE HYDROCHLORIDE PLAIN | | | | |
| + | ANI PHARMS | 6.25MG/5ML ** | N008381 004 | Apr 18, 1984 |
| + | | 25MG/5ML ** | N008381 003 | |
| TABLET;ORAL | | | | |
| PHENERGAN | | | | |
| + | DELCOR ASSET CORP | 12.5MG ** | N007935 002 | |
| + | | 25MG ** | N007935 003 | |
| + | | 50MG ** | N007935 004 | |
| PROMETHAZINE HYDROCHLORIDE | | | | |
| | ABBOTT | 12.5MG | A084160 001 | |
| | | 25MG | A084166 001 | |
| | | 50MG | A084539 001 | |
| | ABLE | 12.5MG | A040558 001 | Jul 01, 2004 |
| | | 25MG | A040558 002 | Jul 01, 2004 |
| | | 50MG | A040558 003 | Jul 01, 2004 |
| | IMPAX LABS | 25MG | A084214 002 | Jul 07, 1982 |
| | | 50MG | A040791 001 | May 20, 2008 |
| | IVAX SUB TEVA PHARMS | 12.5MG | A083604 001 | |
| | | 25MG | A083603 001 | |
| | | 50MG | A083613 001 | |
| | LANNETT | 12.5MG | A080949 001 | |
| | | 25MG | A080949 002 | |
| | | 50MG | A080949 003 | |
| | MYLAN | 12.5MG | A091054 001 | Aug 30, 2011 |
| | | 25MG | A091054 002 | Aug 30, 2011 |
| | | 50MG | A091054 003 | Aug 30, 2011 |
| | PVT FORM | 12.5MG | A083214 001 | |
| | | 25MG | A083658 001 | |
| | SANDOZ | 12.5MG | A084176 002 | May 22, 2009 |
| | | 12.5MG | A084233 001 | |
| | | 25MG | A085146 001 | |
| | | 50MG | A085146 002 | |
| | SUN PHARM INDUSTRIES | 12.5MG | A084555 001 | |
| | | 25MG | A084554 001 | |
| | | 50MG | A084557 001 | |
| | TABLICAPS | 12.5MG | A084080 001 | |
| | | 25MG | A084027 001 | |
| | TEVA | 25MG | A089109 001 | Sep 10, 1985 |
| | WATSON LABS | 12.5MG | A083401 001 | |
| | | 12.5MG | A083712 001 | |
| | | 12.5MG | A085986 001 | |
| | | 25MG | A083204 001 | |
| | | 25MG | A085684 001 | |
| | | 50MG | A083403 001 | |
| | | 50MG | A085664 001 | |
| REMSED | | | | |
| | BRISTOL MYERS SQUIBB | 25MG | A083176 002 | |
| | | 50MG | A083176 001 | |

PROPAFENONE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| PROPAFENONE HYDROCHLORIDE | | | | |
| | NESHER PHARMS | 150MG | A076193 001 | Feb 07, 2002 |
| | | 225MG | A076193 002 | Feb 07, 2002 |
| | | 300MG | A076193 003 | Feb 07, 2002 |

PROPANTHELINE BROMIDE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| PRO-BANTHINE | | | | |
| | GD SEARLE LLC | 30MG/VIAL | N008843 001 | |
| TABLET;ORAL | | | | |
| PRO-BANTHINE | | | | |
| + | SHIRE | 7.5MG ** | N008732 003 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| PROPANTHELINE BROMIDE | | | | |
| TABLET;ORAL | | | | |
| PRO-BANTHINE | | | | |
| + | 15MG ** | N008732 | 002 | |
| PROPANTHELINE BROMIDE | | | | |
| ASCOT | 15MG | A087663 | 001 | Oct 25, 1982 |
| HEATHER | 15MG | A085780 | 001 | |
| IMPAX LABS | 15MG | A084541 | 002 | |
| MYLAN | 15MG | A083706 | 001 | |
| PAR PHARM | 15MG | A088377 | 001 | Dec 08, 1983 |
| PVT FORM | 15MG | A080977 | 001 | |
| SANDOZ | 15MG | A080928 | 001 | |
| TABLICAPS | 15MG | A084428 | 001 | |
| WATSON LABS | 15MG | A083029 | 002 | |
| | 15MG | A083151 | 001 | |
| WEST-WARD PHARMS INT | 7.5MG | A080927 | 001 | |
| PROPARACAINE HYDROCHLORIDE | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | |
| KAINAIR | | | | |
| PHARMAFAIR | 0.5% | A088087 | 001 | Jun 07, 1983 |
| OPHTHAINE | | | | |
| + APOTHECON | 0.5% ** | N008883 | 001 | |
| OPHTHETIC | | | | |
| + ALLERGAN | 0.5% ** | N012583 | 001 | |
| PARACAINE | | | | |
| OPTOPICS | 0.5% | A087681 | 001 | Aug 05, 1982 |
| PROPARACAINE HYDROCHLORIDE | | | | |
| SOLA BARNES HIND | 0.5% | A084144 | 001 | |
| | 0.5% | A084151 | 001 | |
| PROPIOLACTONE | | | | |
| SOLUTION;IRRIGATION | | | | |
| BETAPRONE | | | | |
| FOREST LABS | N/A | N011657 | 001 | |
| PROPIOMAZINE HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| LARGON | | | | |
| WEST-WARD PHARMS INT | 20MG/ML | N012382 | 002 | |
| PROPOFOL | | | | |
| INJECTABLE;INJECTION | | | | |
| DIPRIVAN | | | | |
| FRESENIUS KABI USA | 10MG/ML | N019627 | 001 | Oct 02, 1989 |
| PROPOFOL | | | | |
| TEVA PARENTERAL | 10MG/ML | A075392 | 001 | Sep 19, 2000 |
| WEST-WARD PHARMS INT | 10MG/ML | A074848 | 001 | Apr 19, 2005 |
| PROPOXYPHENE HYDROCHLORIDE | | | | |
| CAPSULE;ORAL | | | | |
| DARVON | | | | |
| XANODYNE PHARM | 32MG | N010997 | 001 | |
| | 65MG | N010997 | 003 | |
| DOLENE | | | | |
| HERITAGE PHARMS INC | 65MG | A080530 | 001 | |
| KESSO-GESIC | | | | |
| MK LABS | 65MG | A083544 | 001 | |
| PROPHENE 65 | | | | |
| HALSEY | 65MG | A083538 | 002 | |
| PROPOXYPHENE HYDROCHLORIDE | | | | |
| ALRA | 65MG | A083184 | 001 | |
| IMPAX LABS | 65MG | A083317 | 001 | |
| IVAX SUB TEVA PHARMS | 32MG | A083597 | 001 | |
| MUTUAL PHARM | 65MG | A083186 | 001 | |
| MYLAN | 32MG | A083528 | 001 | |
| | 65MG | A040569 | 001 | Dec 16, 2004 |
| | 65MG | A083299 | 001 | |
| NEXGEN PHARMA INC | 65MG | A083185 | 001 | |
| PAR PHARM | 65MG | A080269 | 001 | |
| PUREPAC PHARM | 65MG | A083278 | 001 | |
| PVT FORM | 32MG | A083464 | 001 | |

| | | | | |
|---|---|---|---|---|
| PROPOXYPHENE HYDROCHLORIDE | | | | |
| CAPSULE;ORAL | | | | |
| PROPOXYPHENE HYDROCHLORIDE | | | | |
| | 65MG | A083113 | 001 | |
| ROXANE | 32MG | A083089 | 001 | |
| | 65MG | A083089 | 002 | |
| SANDOZ | 32MG | A084014 | 001 | |
| | 65MG | A083125 | 002 | |
| | 65MG | A083688 | 001 | |
| | 65MG | A083870 | 002 | |
| | 65MG | A086495 | 001 | |
| TEVA | 65MG | A088615 | 001 | Oct 22, 1984 |
| VALEANT PHARM INTL | 65MG | A080783 | 001 | |
| VINTAGE PHARMS | 65MG | A040908 | 001 | Jul 17, 2009 |
| WATSON LABS | 65MG | A080908 | 002 | |
| | 65MG | A085190 | 001 | |
| WEST WARD | 65MG | A083501 | 001 | |
| WHITEWORTH TOWN PLSN | 65MG | A084551 | 001 | |
| PROPOXYPHENE HYDROCHLORIDE 65 | | | | |
| WARNER CHILCOTT | 65MG | A083786 | 001 | |
| PROPOXYPHENE NAPSYLATE | | | | |
| SUSPENSION;ORAL | | | | |
| DARVON-N | | | | |
| AAIPHARMA LLC | 50MG/5ML | N016861 | 001 | |
| TABLET;ORAL | | | | |
| DARVON-N | | | | |
| XANODYNE PHARM | 100MG | N016862 | 002 | |
| PROPRANOLOL HYDROCHLORIDE | | | | |
| CAPSULE, EXTENDED RELEASE;ORAL | | | | |
| PROPRANOLOL HYDROCHLORIDE | | | | |
| INWOOD LABS | 60MG | A072499 | 001 | Apr 11, 1989 |
| | 80MG | A072500 | 001 | Apr 11, 1989 |
| | 120MG | A072501 | 001 | Apr 11, 1989 |
| | 160MG | A072502 | 001 | Apr 11, 1989 |
| UPSHER-SMITH LABS | 60MG | A078311 | 001 | Mar 06, 2009 |
| | 80MG | A078311 | 002 | Mar 06, 2009 |
| | 120MG | A078311 | 003 | Mar 06, 2009 |
| | 160MG | A078311 | 004 | Mar 06, 2009 |
| CONCENTRATE;ORAL | | | | |
| PROPRANOLOL HYDROCHLORIDE INTENSOL | | | | |
| ROXANE | 80MG/ML | A071388 | 001 | May 15, 1987 |
| INJECTABLE;INJECTION | | | | |
| PROPRANOLOL HYDROCHLORIDE | | | | |
| SANDOZ INC | 1MG/ML | A076400 | 001 | Feb 26, 2003 |
| SMITH AND NEPHEW | 1MG/ML | A070135 | 001 | Apr 15, 1986 |
| | 1MG/ML | A070137 | 001 | Apr 15, 1986 |
| SOLOPAK | 1MG/ML | A070136 | 001 | Apr 15, 1986 |
| SOLUTION;ORAL | | | | |
| PROPRANOLOL HYDROCHLORIDE | | | | |
| MORTON GROVE | 20MG/5ML | A071984 | 001 | Mar 03, 1989 |
| | 40MG/5ML | A071985 | 001 | Mar 03, 1989 |
| SUSPENSION;ORAL | | | | |
| INDERAL | | | | |
| WYETH AYERST | 10MG/ML | N019536 | 001 | Dec 12, 1986 |
| TABLET;ORAL | | | | |
| INDERAL | | | | |
| + WYETH PHARMS INC | 10MG ** | N016418 | 001 | |
| + | 20MG ** | N016418 | 003 | |
| + | 40MG ** | N016418 | 002 | |
| + | 60MG ** | N016418 | 009 | Oct 18, 1982 |
| + | 80MG ** | N016418 | 004 | |
| + | 90MG ** | N016418 | 010 | Oct 18, 1982 |
| PROPRANOLOL HYDROCHLORIDE | | | | |
| ANDA REPOSITORY | 10MG | A070319 | 001 | Oct 22, 1985 |
| | 20MG | A070320 | 001 | Oct 22, 1985 |
| | 40MG | A070103 | 001 | Oct 22, 1985 |
| | 60MG | A070321 | 001 | Sep 24, 1986 |
| | 80MG | A070322 | 001 | Aug 04, 1986 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| ANI PHARMS INC | 90MG | A071977 | 001 | Apr 06, 1988 |
| DAVA PHARMS INC | 10MG | A070125 | 001 | Jul 30, 1985 |
| | 20MG | A070126 | 001 | Jul 30, 1985 |
| | 40MG | A070127 | 001 | Jul 30, 1985 |
| | 60MG | A071495 | 001 | Dec 31, 1987 |
| | 80MG | A070128 | 001 | Jul 30, 1985 |
| | 90MG | A071496 | 001 | Dec 31, 1987 |
| DURAMED PHARMS BARR | 10MG | A070306 | 001 | Sep 09, 1985 |
| | 20MG | A070307 | 001 | Sep 09, 1985 |
| | 40MG | A070308 | 001 | Sep 09, 1985 |
| | 60MG | A070309 | 001 | Oct 01, 1986 |
| | 80MG | A070310 | 001 | Sep 09, 1985 |
| | 90MG | A071327 | 001 | Oct 01, 1986 |
| INTERPHARM | 10MG | A071368 | 001 | May 05, 1987 |
| | 20MG | A071369 | 001 | May 05, 1987 |
| | 40MG | A071370 | 001 | May 05, 1987 |
| | 80MG | A071371 | 001 | May 05, 1987 |
| IVAX SUB TEVA PHARMS | 10MG | A072063 | 001 | Jul 29, 1988 |
| | 20MG | A072066 | 001 | Jul 29, 1988 |
| | 40MG | A072067 | 001 | Jul 29, 1988 |
| | 60MG | A072068 | 001 | Jul 29, 1988 |
| | 80MG | A072069 | 001 | Jul 29, 1988 |
| LEDERLE | 10MG | A072117 | 001 | Jun 23, 1988 |
| | 20MG | A072118 | 001 | Jun 23, 1988 |
| | 40MG | A072119 | 001 | Jun 23, 1988 |
| | 80MG | A072120 | 001 | Jun 23, 1988 |
| MYLAN | 60MG | A072275 | 001 | Jun 09, 1989 |
| PAR PHARM | 90MG | A071288 | 001 | Oct 22, 1986 |
| PUREPAC PHARM | 10MG | A070814 | 001 | Nov 03, 1986 |
| | 20MG | A070815 | 001 | Nov 03, 1986 |
| | 40MG | A070816 | 001 | Nov 03, 1986 |
| | 60MG | A070817 | 001 | Nov 03, 1986 |
| | 80MG | A070757 | 001 | Nov 03, 1986 |
| ROXANE | 10MG | A070516 | 001 | Jul 07, 1986 |
| | 20MG | A070517 | 001 | Jul 07, 1986 |
| | 40MG | A070518 | 001 | Jul 07, 1986 |
| | 60MG | A070519 | 001 | Sep 24, 1986 |
| | 80MG | A070520 | 001 | Jul 07, 1986 |
| | 90MG | A070521 | 001 | Sep 24, 1986 |
| SANDOZ | 10MG | A070663 | 001 | Jun 13, 1986 |
| | 10MG | A071658 | 001 | Jul 05, 1988 |
| | 20MG | A070664 | 001 | Jun 13, 1986 |
| | 20MG | A071687 | 001 | Jul 05, 1988 |
| | 40MG | A070665 | 001 | Jun 13, 1986 |
| | 40MG | A071688 | 001 | Jul 05, 1988 |
| | 60MG | A070666 | 001 | Oct 10, 1986 |
| | 60MG | A072197 | 001 | Jul 05, 1988 |
| | 80MG | A070667 | 001 | Jun 13, 1986 |
| | 80MG | A071689 | 001 | Jul 05, 1988 |
| | 90MG | A072198 | 001 | Jul 05, 1988 |
| SCHERING | 10MG | A070120 | 001 | Aug 06, 1985 |
| | 20MG | A070121 | 001 | Aug 06, 1985 |
| | 40MG | A070122 | 001 | Aug 06, 1985 |
| | 60MG | A070123 | 001 | Oct 29, 1986 |
| | 80MG | A070124 | 001 | Aug 06, 1985 |
| SUPERPHARM | 10MG | A071515 | 001 | Jun 08, 1988 |
| | 20MG | A071516 | 001 | Jun 08, 1988 |
| | 40MG | A071517 | 001 | Jun 08, 1988 |
| | 80MG | A071518 | 001 | Jun 08, 1988 |
| TEVA | 10MG | A070232 | 001 | Oct 07, 1987 |
| | 20MG | A070233 | 001 | Jun 23, 1986 |
| | 40MG | A070234 | 001 | Jun 23, 1986 |
| WARNER CHILCOTT | 10MG | A070438 | 001 | Sep 15, 1986 |
| | 20MG | A070439 | 001 | Sep 15, 1986 |
| | 40MG | A070440 | 001 | Sep 15, 1986 |
| | 60MG | A070441 | 001 | Sep 24, 1986 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

PROPRANOLOL HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| PROPRANOLOL HYDROCHLORIDE | | | | |
| | 80MG | A070442 | 001 | Sep 15, 1986 |
| WATSON LABS | 10MG | A070140 | 001 | Jul 30, 1985 |
| | 10MG | A070378 | 001 | Mar 19, 1987 |
| | 20MG | A070141 | 001 | Jul 30, 1985 |
| | 20MG | A070379 | 001 | Mar 19, 1987 |
| | 40MG | A070142 | 001 | Jul 30, 1985 |
| | 40MG | A070380 | 001 | Mar 19, 1987 |
| | 60MG | A070143 | 001 | Jan 15, 1987 |
| | 60MG | A070381 | 001 | Mar 19, 1987 |
| | 60MG | A071098 | 001 | Oct 06, 1986 |
| | 60MG | A071791 | 001 | Jul 15, 1987 |
| | 80MG | A070144 | 001 | Jul 30, 1985 |
| | 80MG | A070382 | 001 | Mar 19, 1987 |
| | 80MG | A070551 | 001 | Jul 10, 1986 |
| | 90MG | A071183 | 001 | Oct 06, 1986 |
| | 90MG | A071792 | 001 | Jul 15, 1987 |
| WATSON LABS TEVA | 10MG | A070548 | 001 | Jul 10, 1986 |
| | 20MG | A070549 | 001 | Apr 11, 1986 |
| | 40MG | A070550 | 001 | Apr 11, 1986 |

PROPYLIODONE

| | | | | |
|---|---|---|---|---|
| SUSPENSION;INTRATRACHEAL | | | | |
| DIONOSIL AQUEOUS | | | | |
| GLAXOSMITHKLINE | 50% | N009309 | 001 | |
| DIONOSIL OILY | | | | |
| GLAXOSMITHKLINE | 60% | N009309 | 002 | |

PROPYLTHIOURACIL

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| PROPYLTHIOURACIL | | | | |
| ABBOTT | 50MG | A084075 | 001 | |
| ANABOLIC | 50MG | A080285 | 001 | |
| ANI PHARMS INC | 50MG | A080215 | 001 | |
| CHARTWELL RX | 50MG | A084543 | 001 | |
| HALSEY | 50MG | A080015 | 001 | |
| HIKMA INTL PHARMS | 50MG | A080154 | 001 | |
| IMPAX LABS | 50MG | A080159 | 001 | |
| LANNETT | 50MG | A080016 | 001 | |
| LILLY | 50MG | N006213 | 001 | |
| SUN PHARM INDUSTRIES | 50MG | A083982 | 001 | |
| TABLICAPS | 50MG | A080840 | 001 | |
| WATSON LABS | 50MG | A080932 | 001 | |
| | 50MG | A085201 | 001 | |

PROTAMINE SULFATE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| PROTAMINE SULFATE | | | | |
| + LILLY | 10MG/ML ** | N006460 | 002 | |
| PHARMACIA AND UPJOHN | 50MG/VIAL | N007413 | 001 | |
| | 250MG/VIAL | N007413 | 002 | Aug 02, 1984 |
| WEST-WARD PHARMS INT | 10MG/ML | A089474 | 001 | Nov 05, 1986 |
| | 10MG/ML | A089475 | 001 | Nov 05, 1986 |

PROTEIN HYDROLYSATE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| AMINOSOL 5% | | | | |
| ABBVIE | 5% | N005932 | 012 | Jan 31, 1985 |
| HYPROTIGEN 5% | | | | |
| B BRAUN | 5% | N006170 | 003 | Jan 10, 1984 |

PROTIRELIN

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| THYPINONE | | | | |
| ABBOTT | 0.5MG/ML | N017638 | 001 | |
| THYREL TRH | | | | |
| FERRING | 0.5MG/ML | N018087 | 001 | |

PROTOKYLOL HYDROCHLORIDE

TABLET;ORAL

VENTAIRE

| | | | | |
|---|---|---|---|---|
| | SANOFI AVENTIS US | 2MG | A083459 001 | |

PROTRIPTYLINE HYDROCHLORIDE

TABLET;ORAL

VIVACTIL

| | | | | |
|---|---|---|---|---|
| | TEVA WOMENS | 5MG ** | N016012 001 | |
| | | 10MG ** | N016012 002 | |

PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

NOVAFED

| | | | | |
|---|---|---|---|---|
| | SANOFI AVENTIS US | 120MG | N017603 001 | |

SUDAFED 12 HOUR

| | | | | |
|---|---|---|---|---|
| + | GLAXOSMITHKLINE | 120MG ** | N017941 002 | |

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

ACTIFED

| | | | | |
|---|---|---|---|---|
| | GLAXOSMITHKLINE | 120MG;5MG | N018996 001 | Jun 17, 1985 |

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES

| | | | | |
|---|---|---|---|---|
| | KV PHARM | 120MG;5MG | A071798 001 | Mar 16, 1989 |

SYRUP;ORAL

ACTAHIST

| | | | | |
|---|---|---|---|---|
| | CENCI | 30MG/5ML;1.25MG/5ML | A088344 001 | Feb 09, 1984 |

HISTAFED

| | | | | |
|---|---|---|---|---|
| | CENCI | 30MG/5ML;1.25MG/5ML | A088283 001 | Apr 20, 1984 |

MYFED

| | | | | |
|---|---|---|---|---|
| | USL PHARMA | 30MG/5ML;1.25MG/5ML | A088116 001 | Mar 04, 1983 |

TRILITRON

| | | | | |
|---|---|---|---|---|
| | NEWTRON PHARMS | 30MG/5ML;1.25MG/5ML | A088474 001 | Feb 12, 1985 |

TABLET;ORAL

ALLERFED

| | | | | |
|---|---|---|---|---|
| | PVT FORM | 60MG;2.5MG | A088860 001 | Jan 31, 1985 |

CORPHED

| | | | | |
|---|---|---|---|---|
| | SANDOZ | 60MG;2.5MG | A088602 001 | Apr 11, 1985 |

PSEUDOEPHEDRINE HYDROCHLORIDE AND TRIPROLIDINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| | SANDOZ | 60MG;2.5MG | A088193 001 | May 17, 1983 |

TRILITRON

| | | | | |
|---|---|---|---|---|
| | NEWTRON PHARMS | 60MG;2.5MG | A088515 001 | Jan 09, 1985 |

TRIPHED

| | | | | |
|---|---|---|---|---|
| | TEVA | 60MG;2.5MG | A088630 001 | May 17, 1984 |

TRIPROLIDINE AND PSEUDOEPHEDRINE

| | | | | |
|---|---|---|---|---|
| | WATSON LABS | 60MG;2.5MG | A088318 002 | Jan 13, 1984 |
| | WEST WARD | 60MG;2.5MG | A088117 001 | Apr 19, 1983 |

TRIPROLIDINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| | IVAX SUB TEVA PHARMS | 60MG;2.5MG | A085273 001 | Dec 12, 1984 |
| | SUPERPHARM | 60MG;2.5MG | A088578 001 | Feb 21, 1985 |

TABLET, EXTENDED RELEASE;ORAL

TRIPROLIDINE AND PSEUDOEPHEDRINE HYDROCHLORIDES

| | | | | |
|---|---|---|---|---|
| | KV PHARM | 120MG;5MG | A072758 001 | Nov 25, 1991 |

PSEUDOEPHEDRINE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

PSEUDO-12

| | | | | |
|---|---|---|---|---|
| | UCB INC | EQ 60MG HCL/5ML | N019401 001 | Jun 19, 1987 |

PYRIDOSTIGMINE BROMIDE

TABLET;ORAL

PYRIDOSTIGMINE BROMIDE

| | | | | |
|---|---|---|---|---|
| | ANI PHARMS INC | 30MG | A040512 002 | Jul 20, 2005 |
| | | 60MG | A040512 001 | Oct 08, 2003 |
| | IMPAX LABS INC | 60MG | A040457 001 | Dec 26, 2002 |
| | SOLVAY | 30MG | A089572 001 | Nov 27, 1990 |
| | US ARMY | 30MG | N020414 001 | Feb 05, 2003 |

| | | | | |
|---|---|---|---|---|
| PYRIDOXINE HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| HEXA-BETALIN | | | | |
| | LILLY | 100MG/ML | A080854 001 | |
| PYRIDOXINE HYDROCHLORIDE | | | | |
| | AKORN | 100MG/ML | A087967 001 | Oct 01, 1982 |
| | BEL MAR | 100MG/ML | A080761 001 | |
| | DELL LABS | 50MG/ML | A083771 001 | |
| | | 100MG/ML | A083772 001 | |
| | ELKINS SINN | 100MG/ML | A080581 001 | |
| | LUITPOLD | 100MG/ML | A080669 001 | |
| | WATSON LABS | 100MG/ML | A080572 001 | |
| | | 100MG/ML | A083760 001 | |
| PYRILAMINE MALEATE | | | | |
| TABLET;ORAL | | | | |
| PYRILAMINE MALEATE | | | | |
| | IMPAX LABS | 25MG | A080808 001 | |
| | WATSON LABS | 25MG | A085231 001 | |
| PYRIMETHAMINE; SULFADOXINE | | | | |
| TABLET;ORAL | | | | |
| FANSIDAR | | | | |
| | ROCHE | 25MG;500MG | N018557 001 | |
| PYRITHIONE ZINC | | | | |
| LOTION;TOPICAL | | | | |
| HEAD & SHOULDERS CONDITIONER | | | | |
| | WARNER CHILCOTT | 0.3% | N019412 002 | Mar 10, 1986 |
| PYRVINIUM PAMOATE | | | | |
| SUSPENSION;ORAL | | | | |
| POVAN | | | | |
| | PARKE DAVIS | EQ 50MG BASE/5ML | N011964 001 | |
| TABLET;ORAL | | | | |
| POVAN | | | | |
| | PARKE DAVIS | EQ 50MG BASE | N012485 002 | |
| QUAZEPAM | | | | |
| TABLET;ORAL | | | | |
| DORAL | | | | |
| | CUTIS HEALTH LLC | 7.5MG | N018708 003 | Feb 26, 1987 |
| QUETIAPINE FUMARATE | | | | |
| TABLET;ORAL | | | | |
| QUETIAPINE FUMARATE | | | | |
| | ACTAVIS GRP PTC | EQ 25MG BASE | A201762 001 | Feb 27, 2013 |
| | | EQ 50MG BASE | A201762 002 | Feb 27, 2013 |
| | | EQ 100MG BASE | A201762 003 | Feb 27, 2013 |
| | | EQ 150MG BASE | A201762 004 | Feb 27, 2013 |
| | | EQ 200MG BASE | A201762 005 | Feb 27, 2013 |
| | | EQ 300MG BASE | A201762 006 | Feb 27, 2013 |
| | | EQ 400MG BASE | A201762 007 | Feb 27, 2013 |
| | MYLAN PHARMS INC | EQ 25MG BASE | A090323 001 | Mar 27, 2012 |
| SEROQUEL | | | | |
| + | ASTRAZENECA PHARMS | EQ 150MG BASE ** | N020639 004 | Dec 20, 1998 |
| QUINAPRIL HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| QUINAPRIL HYDROCHLORIDE | | | | |
| | ACTAVIS ELIZABETH | EQ 5MG BASE | A076459 001 | Dec 22, 2004 |
| | | EQ 10MG BASE | A076459 002 | Dec 22, 2004 |
| | | EQ 20MG BASE | A076459 003 | Dec 22, 2004 |
| | | EQ 40MG BASE | A076459 004 | Dec 22, 2004 |
| | ACTAVIS LABS FL INC | EQ 5MG BASE | A076049 001 | Jan 14, 2005 |
| | | EQ 10MG BASE | A076049 002 | Jan 14, 2005 |
| | | EQ 20MG BASE | A076049 003 | Jan 14, 2005 |
| | | EQ 40MG BASE | A076049 004 | Jan 14, 2005 |
| | APOTEX INC | EQ 5MG BASE | A076240 001 | Jan 26, 2006 |
| | | EQ 10MG BASE | A076240 002 | Jan 26, 2006 |
| | | EQ 20MG BASE | A076240 003 | Jan 26, 2006 |
| | | EQ 40MG BASE | A076240 004 | Jan 26, 2006 |
| | FOSUN PHARMA | EQ 5MG BASE | A076803 001 | Mar 02, 2005 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

QUINAPRIL HYDROCHLORIDE
TABLET;ORAL
QUINAPRIL HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| | EQ 10MG BASE | A076803 | 002 | Mar 02, 2005 |
| | EQ 20MG BASE | A076803 | 003 | Mar 02, 2005 |
| | EQ 40MG BASE | A076803 | 004 | Mar 02, 2005 |
| MYLAN | EQ 5MG BASE | A076036 | 001 | Jan 28, 2005 |
| | EQ 10MG BASE | A076036 | 002 | Jan 28, 2005 |
| | EQ 20MG BASE | A076036 | 003 | Jan 28, 2005 |
| | EQ 40MG BASE | A076036 | 004 | Jan 28, 2005 |
| SUN PHARM INDS LTD | EQ 5MG BASE | A090800 | 001 | Jun 18, 2009 |
| | EQ 10MG BASE | A090800 | 002 | Jun 18, 2009 |
| | EQ 20MG BASE | A090800 | 003 | Jun 18, 2009 |
| | EQ 40MG BASE | A090800 | 004 | Jun 18, 2009 |

QUINESTROL
TABLET;ORAL
ESTROVIS

| | | | | |
|---|---|---|---|---|
| PARKE DAVIS | 0.1MG | N016768 | 002 | |
| | 0.2MG | N016768 | 003 | |

QUINETHAZONE
TABLET;ORAL
HYDROMOX

| | | | | |
|---|---|---|---|---|
| LEDERLE | 50MG | N013264 | 001 | |

QUINETHAZONE; RESERPINE
TABLET;ORAL
HYDROMOX R

| | | | | |
|---|---|---|---|---|
| LEDERLE | 50MG;0.125MG | N013927 | 001 | |

QUINIDINE GLUCONATE
INJECTABLE;INJECTION
QUINIDINE GLUCONATE

| | | | | | |
|---|---|---|---|---|---|
| + | LILLY | 80MG/ML | N007529 | 002 | Feb 10, 1989 |

TABLET;ORAL
QUINACT

| | | | | |
|---|---|---|---|---|
| BAYER HLTHCARE | 266MG | A085978 | 001 | |
| | 400MG | A086099 | 001 | |

TABLET, EXTENDED RELEASE;ORAL
DURAQUIN

| | | | | |
|---|---|---|---|---|
| WARNER CHILCOTT | 330MG | N017917 | 001 | |

QUINAGLUTE

| | | | | |
|---|---|---|---|---|
| BAYER HLTHCARE | 324MG | N016647 | 001 | |

QUINALAN

| | | | | |
|---|---|---|---|---|
| LANNETT | 324MG | A088081 | 001 | Feb 10, 1986 |

QUINATIME

| | | | | |
|---|---|---|---|---|
| WATSON LABS | 324MG | A087448 | 001 | |

QUINIDINE GLUCONATE

| | | | | |
|---|---|---|---|---|
| ASCOT | 324MG | A088582 | 001 | Jun 17, 1985 |
| AUROLIFE PHARMA LLC | 324MG | A089894 | 001 | Dec 15, 1988 |
| CYCLE PHARMS LTD | 324MG | A088431 | 001 | Jan 06, 1984 |
| HALSEY | 324MG | A089476 | 001 | Apr 10, 1987 |
| SUPERPHARM | 324MG | A089164 | 001 | Nov 21, 1985 |
| WATSON LABS | 324MG | A087785 | 001 | Jan 24, 1983 |
| | 324MG | A087810 | 001 | Sep 29, 1982 |

QUINIDINE POLYGALACTURONATE
TABLET;ORAL
CARDIOQUIN

| | | | | |
|---|---|---|---|---|
| PHARM RES ASSOC | 275MG | N011642 | 002 | |

QUINIDINE SULFATE
CAPSULE;ORAL
CIN-QUIN

| | | | | |
|---|---|---|---|---|
| SOLVAY | 200MG | A085296 | 001 | |
| | 300MG | A085297 | 001 | |

QUINIDINE SULFATE

| | | | | |
|---|---|---|---|---|
| LILLY | 200MG | A085103 | 001 | |

TABLET;ORAL
CIN-QUIN

| | | | | |
|---|---|---|---|---|
| SOLVAY | 100MG | A085299 | 001 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| QUINIDINE SULFATE | | | | |
| TABLET;ORAL | | | | |
| CIN-QUIN | | | | |
| | 200MG | A084932 | 001 | |
| | 300MG | A085298 | 001 | |
| QUINIDINE SULFATE | | | | |
| BARR | 200MG | A084177 | 001 | |
| CONTRACT PHARMACAL | 200MG | A083808 | 001 | |
| CYCLE PHARMS LTD | 200MG | A083640 | 001 | |
| | 300MG | A085632 | 001 | |
| DAVA PHARMS INC | 200MG | A087011 | 001 | |
| ELKINS SINN | 200MG | A083622 | 001 | |
| EVERYLIFE | 200MG | A083439 | 001 | |
| HALSEY | 200MG | A083583 | 001 | |
| HIKMA PHARMS | 200MG | A083862 | 001 | |
| IMPAX LABS | 200MG | A083347 | 001 | |
| IVAX SUB TEVA PHARMS | 200MG | A084549 | 001 | |
| KING PHARMS | 200MG | A085175 | 001 | |
| KV PHARM | 200MG | A085276 | 001 | |
| LANNETT | 200MG | A083743 | 001 | |
| LEDERLE | 200MG | A086176 | 001 | |
| LILLY | 200MG | A085038 | 001 | |
| PERRIGO | 200MG | A085322 | 001 | |
| PHARMAVITE | 200MG | A084627 | 001 | |
| PUREPAC PHARM | 200MG | A084003 | 001 | |
| SANDOZ | 200MG | A084631 | 001 | |
| | 200MG | A084914 | 001 | |
| | 300MG | A089839 | 001 | Sep 29, 1988 |
| SCHERER LABS | 200MG | A085068 | 001 | |
| SUN PHARM INDUSTRIES | 100MG | A081029 | 001 | Apr 14, 1989 |
| SUPERPHARM | 200MG | A088973 | 001 | Apr 10, 1985 |
| USL PHARMA | 200MG | A087837 | 001 | Apr 14, 1982 |
| VALEANT PHARM INTL | 200MG | A083393 | 001 | |
| VANGARD | 200MG | A087909 | 001 | Jul 13, 1982 |
| VINTAGE PHARMS | 200MG | A083963 | 001 | |
| WARNER CHILCOTT | 200MG | A083879 | 001 | |
| WATSON LABS | 100MG | A085584 | 001 | |
| | 200MG | A085140 | 002 | |
| WHITEWORTH TOWN PLSN | 200MG | A085444 | 001 | |
| QUINORA | | | | |
| KEY PHARMS | 200MG | A083576 | 001 | |
| SCHERING | 300MG | A085222 | 001 | |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| QUINIDEX | | | | |
| WYETH PHARMS INC | 300MG | N012796 | 002 | |
| RABEPRAZOLE SODIUM | | | | |
| TABLET, DELAYED RELEASE;ORAL | | | | |
| ACIPHEX | | | | |
| + EISAI INC | 10MG ** | N020973 | 001 | May 29, 2002 |
| RAMIPRIL | | | | |
| CAPSULE;ORAL | | | | |
| RAMIPRIL | | | | |
| ACTAVIS ELIZABETH | 1.25MG | A077513 | 001 | Jun 18, 2008 |
| | 2.5MG | A077513 | 002 | Jun 18, 2008 |
| | 5MG | A077513 | 003 | Jun 18, 2008 |
| | 10MG | A077513 | 004 | Jun 18, 2008 |
| CIPLA | 1.25MG | A077004 | 001 | Aug 07, 2008 |
| | 2.5MG | A077004 | 002 | Aug 07, 2008 |
| | 5MG | A077004 | 003 | Aug 07, 2008 |
| | 10MG | A077004 | 004 | Aug 07, 2008 |
| FOSUN PHARMA | 1.25MG | A077514 | 001 | Jun 18, 2008 |
| | 2.5MG | A077514 | 002 | Jun 18, 2008 |
| | 5MG | A077514 | 003 | Jun 18, 2008 |
| | 10MG | A077514 | 004 | Jun 18, 2008 |
| RANBAXY LABS LTD | 5MG | A078849 | 001 | Mar 06, 2009 |
| | 10MG | A078849 | 002 | Mar 06, 2009 |

| | | | | |
|---|---|---|---|---|
| RAMIPRIL | | | | |
| TABLET;ORAL | | | | |
| ALTACE | | | | |
| + | KING PFIZER | 1.25MG ** | N022021 001 | Feb 27, 2007 |
| + | | 2.5MG ** | N022021 002 | Feb 27, 2007 |
| + | | 5MG ** | N022021 003 | Feb 27, 2007 |
| + | | 10MG ** | N022021 004 | Feb 27, 2007 |
| RAMIPRIL | | | | |
| | MYLAN PHARMS INC | 1.25MG | A090650 001 | Jun 30, 2011 |
| | | 2.5MG | A090650 002 | Jun 30, 2011 |
| | | 5MG | A090650 003 | Jun 30, 2011 |
| | | 10MG | A090650 004 | Jun 30, 2011 |
| | ZYDUS PHARMS USA INC | 1.25MG | A090697 001 | Sep 24, 2009 |
| | | 2.5MG | A090697 002 | Sep 24, 2009 |
| | | 5MG | A090697 003 | Sep 24, 2009 |
| | | 10MG | A090697 004 | Sep 24, 2009 |
| RANITIDINE BISMUTH CITRATE | | | | |
| TABLET;ORAL | | | | |
| TRITEC | | | | |
| | GLAXOSMITHKLINE | 400MG | N020559 001 | Aug 08, 1996 |
| RANITIDINE HYDROCHLORIDE | | | | |
| CAPSULE;ORAL | | | | |
| RANITIDINE HYDROCHLORIDE | | | | |
| | MYLAN | EQ 150MG BASE | A075564 001 | Oct 27, 2000 |
| | | EQ 300MG BASE | A075564 002 | Oct 27, 2000 |
| | TEVA | EQ 150MG BASE | A075557 001 | Oct 31, 2003 |
| | | EQ 300MG BASE | A075557 002 | Oct 31, 2003 |
| ZANTAC 150 | | | | |
| + | GLAXOSMITHKLINE | EQ 150MG BASE ** | N020095 001 | Mar 08, 1994 |
| ZANTAC 300 | | | | |
| + | GLAXOSMITHKLINE | EQ 300MG BASE ** | N020095 002 | Mar 08, 1994 |
| GRANULE, EFFERVESCENT;ORAL | | | | |
| ZANTAC 150 | | | | |
| | GLAXO GRP LTD | EQ 150MG BASE/PACKET | N020251 002 | Mar 31, 1994 |
| INJECTABLE;INJECTION | | | | |
| RANITIDINE HYDROCHLORIDE | | | | |
| | BEDFORD | EQ 25MG BASE/ML | A074764 001 | Nov 19, 2004 |
| ZANTAC IN PLASTIC CONTAINER | | | | |
| | TELIGENT | EQ 1MG BASE/ML | N019593 002 | Sep 27, 1991 |
| | | EQ 50MG BASE/100ML | N019593 001 | Dec 17, 1986 |
| SYRUP;ORAL | | | | |
| RANITIDINE HYDROCHLORIDE | | | | |
| | APOTEX INC | EQ 15MG BASE/ML | A077602 001 | Sep 17, 2007 |
| | RANBAXY | EQ 15MG BASE/ML | A078448 001 | Dec 13, 2007 |
| | WOCKHARDT | EQ 15MG BASE/ML | A079211 001 | May 26, 2009 |
| | | EQ 15MG BASE/ML | A079212 001 | Feb 23, 2009 |
| TABLET;ORAL | | | | |
| RANITIDINE HYDROCHLORIDE | | | | |
| | BOEHRINGER INGELHEIM | EQ 150MG BASE | A074662 001 | Aug 29, 1997 |
| | | EQ 300MG BASE | A074662 002 | Aug 29, 1997 |
| | CONTRACT PHARMACAL | EQ 75MG BASE | A075094 001 | Jun 21, 1999 |
| | MYLAN | EQ 150MG BASE | A074023 001 | Aug 22, 1997 |
| | | EQ 150MG BASE | A074552 001 | Jul 30, 1998 |
| | | EQ 300MG BASE | A074023 002 | Aug 22, 1997 |
| | | EQ 300MG BASE | A074552 002 | Jul 30, 1998 |
| | RANBAXY | EQ 75MG BASE | A075254 001 | Jan 14, 2000 |
| | | EQ 150MG BASE | A075000 001 | Jan 30, 1998 |
| | | EQ 300MG BASE | A075000 002 | Jan 30, 1998 |
| | SANDOZ | EQ 75MG BASE | A075519 001 | Sep 26, 2002 |
| | SUN PHARM INDS LTD | EQ 75MG BASE | A075132 001 | Jan 14, 2000 |
| | | EQ 150MG BASE | A075439 001 | Apr 19, 2000 |
| | | EQ 300MG BASE | A075439 002 | Apr 19, 2000 |
| | WATSON LABS | EQ 75MG BASE | A075212 001 | Jan 14, 2000 |
| | | EQ 150MG BASE | A074864 001 | Oct 20, 1997 |
| | | EQ 300MG BASE | A074864 002 | Oct 20, 1997 |
| | WATSON LABS INC | EQ 150MG BASE | A077426 001 | Dec 19, 2005 |
| | | EQ 300MG BASE | A077426 002 | Dec 19, 2005 |
| | WOCKHARDT | EQ 75MG BASE | A078884 001 | Jul 31, 2008 |

RANITIDINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| RANITIDINE HYDROCHLORIDE | | | | |
| | EQ 150MG BASE | A078653 | 001 | Nov 26, 2007 |
| | EQ 150MG BASE | A078701 | 001 | Nov 12, 2009 |
| | EQ 300MG BASE | A078701 | 002 | Dec 11, 2009 |
| TABLET, EFFERVESCENT;ORAL | | | | |
| ZANTAC 150 | | | | |
| GLAXO GRP LTD | EQ 150MG BASE | N020251 | 001 | Mar 31, 1994 |
| ZANTAC 25 | | | | |
| GLAXO GRP LTD | EQ 25MG BASE | N020251 | 003 | Apr 01, 2004 |
| ZANTAC 75 | | | | |
| + SANOFI US | EQ 75MG BASE ** | N020745 | 001 | Feb 26, 1998 |

RANOLAZINE

| | | | | |
|---|---|---|---|---|
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| RANOLAZINE | | | | |
| LUPIN LTD | 500MG | A201046 | 001 | Jul 29, 2013 |
| | 1GM | A201046 | 002 | Jul 29, 2013 |

RAPACURONIUM BROMIDE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| RAPLON | | | | |
| ORGANON USA INC | 100MG/VIAL | N020984 | 001 | Aug 18, 1999 |
| | 200MG/VIAL | N020984 | 002 | Aug 18, 1999 |

RAUWOLFIA SERPENTINA ROOT

| | | | |
|---|---|---|---|
| TABLET;ORAL | | | |
| HIWOLFIA | | | |
| BOWMAN PHARMS | 50MG | N009276 | 003 |
| | 50MG | N009276 | 005 |
| | 100MG | N009276 | 004 |
| HYSERPIN | | | |
| PHYS PRODS VA | 50MG | N010581 | 001 |
| KOGLUCOID | | | |
| PANRAY | 50MG | N009278 | 001 |
| | 100MG | N009278 | 002 |
| RAUDIXIN | | | |
| APOTHECON | 50MG | N008842 | 001 |
| | 100MG | N008842 | 002 |
| RAUSERPIN | | | |
| FERNDALE LABS | 50MG | N009926 | 002 |
| | 100MG | N009926 | 004 |
| RAUVAL | | | |
| PAL PAK | 50MG | N009108 | 002 |
| | 100MG | N009108 | 004 |
| RAUWOLFIA SERPENTINA | | | |
| BUNDY | 50MG | N009477 | 001 |
| | 100MG | N009477 | 002 |
| HALSEY | 50MG | A080498 | 001 |
| | 100MG | A080498 | 002 |
| IMPAX LABS | 50MG | N009273 | 001 |
| | 100MG | N009273 | 002 |
| IVAX SUB TEVA PHARMS | 50MG | N011521 | 001 |
| | 100MG | N011521 | 002 |
| PUREPAC PHARM | 50MG | A080842 | 001 |
| | 100MG | A080842 | 002 |
| PVT FORM | 50MG | A080583 | 001 |
| | 100MG | A080583 | 002 |
| SOLVAY | 50MG | A080500 | 001 |
| | 100MG | A080500 | 002 |
| TABLICAPS | 50MG | A083867 | 001 |
| | 100MG | A083444 | 001 |
| VALEANT PHARM INTL | 50MG | N009668 | 001 |
| | 100MG | N009668 | 002 |
| WATSON LABS | 50MG | A080907 | 001 |
| | 100MG | A080914 | 001 |
| WOLFINA | | | |
| FOREST PHARMS | 50MG | N009255 | 008 |
| | 100MG | N009255 | 006 |

| | | | | |
|---|---|---|---|---|
| RESCINNAMINE | | | | |
| CAPSULE;ORAL | | | | |
| CINNASIL | | | | |
| | PANRAY | 0.5MG | A084736 001 | |
| TABLET;ORAL | | | | |
| MODERIL | | | | |
| | PFIZER | 0.25MG | N010686 003 | |
| | | 0.5MG | N010686 006 | |
| RESERPINE | | | | |
| ELIXIR;ORAL | | | | |
| SERPASIL | | | | |
| | NOVARTIS | 0.2MG/4ML | N009115 005 | |
| INJECTABLE;INJECTION | | | | |
| SANDRIL | | | | |
| | LILLY | 2.5MG/ML | N010012 001 | |
| SERPASIL | | | | |
| | NOVARTIS | 2.5MG/ML | N009434 002 | |
| TABLET;ORAL | | | | |
| HISERPIA | | | | |
| | BOWMAN PHARMS | 0.1MG | N009631 002 | |
| | | 0.25MG | N009631 004 | |
| RAU-SED | | | | |
| | BRISTOL MYERS SQUIBB | 0.1MG | N009357 001 | |
| | | 0.25MG | N009357 004 | |
| | | 0.5MG | N009357 006 | |
| | | 1MG | N009357 008 | |
| RESERPINE | | | | |
| | BARR | 0.25MG | A080721 002 | |
| | BELL PHARMA | 0.1MG | A083058 001 | |
| | | 0.25MG | A083058 002 | |
| | BUNDY | 0.1MG | N009663 001 | |
| | | 0.25MG | N009663 003 | |
| | CYCLE PHARMS LTD | 0.1MG | N009859 001 | |
| | | 0.25MG | N009859 002 | |
| | ELKINS SINN | 0.1MG | A083145 001 | |
| | | 0.25MG | A083145 002 | |
| | EVERYLIFE | 0.1MG | N010441 001 | |
| | | 0.25MG | N010441 002 | |
| | | 0.5MG | N010441 003 | |
| | | 1MG | N010441 004 | |
| | HALSEY | 0.1MG | A080457 002 | |
| | | 0.25MG | A080457 001 | |
| | | 1MG | A080457 003 | |
| | HIKMA INTL PHARMS | 0.1MG | A080975 001 | |
| | | 0.25MG | A080975 002 | |
| | | 1MG | A080975 003 | |
| | IMPAX LABS | 0.1MG | N009627 001 | |
| | | 0.25MG | N009627 002 | |
| | IVAX SUB TEVA PHARMS | 0.1MG | N011185 001 | |
| | | 0.25MG | N011185 002 | |
| | MARSHALL PHARMA | 0.1MG | A080492 001 | |
| | | 0.25MG | A080492 002 | |
| | MK LABS | 0.1MG | A080525 002 | |
| | | 0.25MG | A080525 001 | |
| | MYLAN | 1MG | A084974 001 | |
| | PHARMAVITE | 0.25MG | A084663 001 | |
| | PUREPAC PHARM | 0.1MG | A080753 002 | |
| | | 0.25MG | A080753 001 | |
| | PVT FORM | 0.1MG | A086117 001 | |
| | | 0.25MG | A080582 001 | |
| | | 0.25MG | A085775 001 | |
| | | 1MG | A080582 002 | |
| | REXALL | 0.25MG | A080637 001 | |
| + | SANDOZ | 0.1MG | N009838 001 | |
| + | | 0.25MG | N009838 002 | |
| | SOLVAY | 0.25MG | A080446 001 | |
| | TABLICAPS | 0.25MG | A085207 001 | |
| | TEVA | 0.1MG | A089020 001 | Mar 07, 1985 |
| | | 0.25MG | A089019 001 | Mar 07, 1985 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

RESERPINE

TABLET;ORAL

RESERPINE

| | | | |
|---|---|---|---|
| VALEANT PHARM INTL | 0.1MG | N009667 001 | |
| | 0.25MG | N009667 002 | |
| WATSON LABS | 0.1MG | A080679 001 | |
| | 0.25MG | A080393 001 | |
| | 0.25MG | A085401 001 | |
| | 1MG | A080749 001 | |
| WHITEWORTH TOWN PLSN | 0.1MG | A080723 001 | |
| | 0.25MG | A080723 002 | |
| | 1MG | A080723 003 | |

SANDRIL

| | | | |
|---|---|---|---|
| LILLY | 0.1MG | N009376 004 | |
| | 0.25MG | N009376 001 | |

SERPALAN

| | | | |
|---|---|---|---|
| LANNETT | 0.1MG | N010124 001 | |
| | 0.25MG | N010124 002 | |

SERPANRAY

| | | | |
|---|---|---|---|
| PANRAY | 0.1MG | N009391 001 | |
| | 0.25MG | N009391 002 | |
| | 1MG | N009391 004 | |

SERPASIL

| | | | |
|---|---|---|---|
| NOVARTIS | 0.1MG | N009115 001 | |
| | 0.25MG | N009115 003 | |
| | 1MG | N009115 004 | |

SERPATE

| | | | |
|---|---|---|---|
| VALE | 0.1MG | N009453 001 | |
| | 0.25MG | N009453 002 | |

SERPIVITE

| | | | |
|---|---|---|---|
| VITARINE | 0.25MG | N009645 002 | |

RESERPINE; TRICHLORMETHIAZIDE

TABLET;ORAL

METATENSIN #2

| | | | |
|---|---|---|---|
| SANOFI AVENTIS US | 0.1MG;2MG | N012972 001 | |

METATENSIN #4

| | | | |
|---|---|---|---|
| SANOFI AVENTIS US | 0.1MG;4MG | N012972 002 | |

NAQUIVAL

| | | | |
|---|---|---|---|
| SCHERING | 0.1MG;4MG | N012265 003 | |

TRICHLORMETHIAZIDE W/ RESERPINE

| | | | |
|---|---|---|---|
| WATSON LABS | 0.1MG;4MG | A085248 001 | |

RIBAVIRIN

CAPSULE;ORAL

REBETOL

| | | | |
|---|---|---|---|
| MERCK SHARP DOHME | 200MG**Indicated for use and comarketed with Interferon ALFA-2B, Recombinant (INTRON A), as Rebetron Combination Therapy** | N020903 001 | Jun 03, 1998 |

TABLET;ORAL

COPEGUS

| | | | |
|---|---|---|---|
| ROCHE | 400MG | N021511 002 | Jun 21, 2005 |

RIMANTADINE HYDROCHLORIDE

SYRUP;ORAL

FLUMADINE

| | | | |
|---|---|---|---|
| FOREST LABS | 50MG/5ML | N019650 001 | Sep 17, 1993 |

TABLET;ORAL

RIMANTADINE HYDROCHLORIDE

| | | | |
|---|---|---|---|
| ACTAVIS ELIZABETH | 100MG | A076375 001 | Jan 14, 2003 |
| IMPAX LABS INC | 100MG | A075916 001 | Nov 02, 2001 |

RIMEXOLONE

SUSPENSION/DROPS;OPHTHALMIC

VEXOL

| | | | |
|---|---|---|---|
| ALCON | 1% | N020474 001 | Dec 30, 1994 |

| | | | | |
|---|---|---|---|---|
| RISEDRONATE SODIUM | | | | |
| TABLET;ORAL | | | | |
| ACTONEL | | | | |
| + | APIL | 75MG ** | N020835 004 | Apr 16, 2007 |
| RISPERIDONE | | | | |
| SOLUTION;ORAL | | | | |
| RISPERIDONE | | | | |
| | SILARX PHARMS INC | 1MG/ML | A202386 001 | Jan 12, 2015 |
| | WOCKHARDT | 1MG/ML | A078744 001 | Oct 08, 2009 |
| TABLET;ORAL | | | | |
| RISPERDAL | | | | |
| | JANSSEN PHARMS | 5MG | N020272 005 | Dec 29, 1993 |
| RISPERIDONE | | | | |
| | JUBILANT CADISTA | 0.25MG | A078828 001 | Mar 23, 2009 |
| | | 0.5MG | A078828 002 | Mar 23, 2009 |
| | | 1MG | A078828 003 | Mar 23, 2009 |
| | | 2MG | A078828 004 | Mar 23, 2009 |
| | | 3MG | A078828 005 | Mar 23, 2009 |
| | | 4MG | A078828 006 | Mar 23, 2009 |
| | RATIOPHARM | 0.25MG | A077784 001 | Jun 08, 2010 |
| | | 0.5MG | A077784 002 | Jun 08, 2010 |
| | | 1MG | A077784 003 | Jun 08, 2010 |
| | | 2MG | A077784 004 | Jun 08, 2010 |
| | | 3MG | A077784 005 | Jun 08, 2010 |
| | | 4MG | A077784 006 | Jun 08, 2010 |
| | SYNTHON PHARMS | 0.25MG | A078187 001 | Oct 22, 2009 |
| | | 0.5MG | A078187 002 | Oct 22, 2009 |
| | | 1MG | A078187 003 | Oct 22, 2009 |
| | | 2MG | A078187 004 | Oct 22, 2009 |
| | | 3MG | A078187 005 | Oct 22, 2009 |
| | | 4MG | A078187 006 | Oct 22, 2009 |
| | WATSON LABS | 0.25MG | A077860 001 | Dec 05, 2008 |
| | | 0.5MG | A077860 002 | Dec 05, 2008 |
| | | 1MG | A077860 003 | Dec 05, 2008 |
| | | 2MG | A077860 004 | Dec 05, 2008 |
| | | 3MG | A077860 005 | Dec 05, 2008 |
| | | 4MG | A077860 006 | Dec 05, 2008 |
| | WEST WARD PHARMS | 0.25MG | A078740 001 | May 29, 2009 |
| | | 0.5MG | A078740 002 | May 29, 2009 |
| | | 1MG | A078740 003 | May 29, 2009 |
| | | 2MG | A078740 004 | May 29, 2009 |
| | | 3MG | A078740 005 | May 29, 2009 |
| | | 4MG | A078740 006 | May 29, 2009 |
| TABLET, ORALLY DISINTEGRATING;ORAL | | | | |
| RISPERIDONE | | | | |
| | MYLAN PHARMS INC | 0.25MG | A091537 006 | Feb 12, 2013 |
| | | 0.5MG | A091537 001 | Mar 30, 2011 |
| | | 1MG | A091537 002 | Mar 30, 2011 |
| | | 2MG | A091537 003 | Mar 30, 2011 |
| | | 3MG | A091537 004 | Mar 30, 2011 |
| | | 4MG | A091537 005 | Mar 30, 2011 |
| RITODRINE HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| RITODRINE HYDROCHLORIDE | | | | |
| | ABRAXIS PHARM | 10MG/ML | A071188 001 | Jul 23, 1987 |
| | | 15MG/ML | A071189 001 | Jul 23, 1987 |
| | HOSPIRA | 10MG/ML | A071618 001 | Feb 28, 1991 |
| | | 15MG/ML | A071619 001 | Feb 28, 1991 |
| RITODRINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| | HOSPIRA | 30MG/100ML | A071438 001 | Jan 22, 1991 |
| YUTOPAR | | | | |
| | ASTRAZENECA | 10MG/ML | N018580 001 | |
| | | 15MG/ML | N018580 002 | |
| TABLET;ORAL | | | | |
| YUTOPAR | | | | |
| | ASTRAZENECA | 10MG | N018555 001 | |

| | | | | |
|---|---|---|---|---|
| RITONAVIR | | | | |
| CAPSULE;ORAL | | | | |
| NORVIR | | | | |
| | ABBOTT | 100MG | N020680 001 | Mar 01, 1996 |
| RIVASTIGMINE TARTRATE | | | | |
| SOLUTION;ORAL | | | | |
| EXELON | | | | |
| | NOVARTIS | EQ 2MG BASE/ML | N021025 001 | Apr 21, 2000 |
| ROCURONIUM BROMIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| ZEMURON | | | | |
| + | ORGANON USA INC | 50MG/5ML (10MG/ML) ** | N020214 001 | Mar 17, 1994 |
| + | | 10MG/ML (10MG/ML) ** | N020214 002 | Mar 17, 1994 |
| + | | 100MG/10ML (10MG/ML) ** | N020214 003 | Mar 17, 1994 |
| ROFECOXIB | | | | |
| SUSPENSION;ORAL | | | | |
| VIOXX | | | | |
| | MERCK | 12.5MG/5ML | N021052 001 | May 20, 1999 |
| | | 25MG/5ML | N021052 002 | May 20, 1999 |
| TABLET;ORAL | | | | |
| VIOXX | | | | |
| | MERCK | 12.5MG | N021042 001 | May 20, 1999 |
| | | 25MG | N021042 002 | May 20, 1999 |
| | | 50MG | N021042 003 | Feb 25, 2000 |
| ROPINIROLE HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| ROPINIROLE HYDROCHLORIDE | | | | |
| | EPIC PHARMA LLC | EQ 0.25MG BASE | A078230 001 | May 20, 2008 |
| | | EQ 0.5MG BASE | A078230 002 | May 20, 2008 |
| | | EQ 1MG BASE | A078230 003 | May 20, 2008 |
| | | EQ 2MG BASE | A078230 004 | May 20, 2008 |
| | | EQ 3MG BASE | A078230 005 | May 20, 2008 |
| | | EQ 4MG BASE | A078230 006 | May 20, 2008 |
| | | EQ 5MG BASE | A078230 007 | May 20, 2008 |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| REQUIP XL | | | | |
| + | GLAXOSMITHKLINE LLC | EQ 3MG BASE ** | N022008 002 | Jun 13, 2008 |
| ROPINIROLE HYDROCHLORIDE | | | | |
| | MYLAN PHARMS INC | EQ 3MG BASE | A200462 002 | Oct 15, 2012 |
| ROPIVACAINE HYDROCHLORIDE | | | | |
| SOLUTION;INJECTION | | | | |
| NAROPIN | | | | |
| | FRESENIUS KABI USA | 50MG/10ML (5MG/ML) | N020533 013 | May 01, 1998 |
| | | 75MG/10ML (7.5MG/ML) | N020533 012 | Sep 24, 1996 |
| ROSE BENGAL SODIUM I-131 | | | | |
| INJECTABLE;INJECTION | | | | |
| ROBENGATOPE | | | | |
| | BRACCO | 0.5mCi/VIAL | N016224 001 | |
| | | 1mCi/VIAL | N016224 002 | |
| | | 2mCi/VIAL | N016224 003 | |
| SODIUM ROSE BENGAL I 131 | | | | |
| | SORIN | 0.5mCi/ML | N017318 001 | |
| RUFINAMIDE | | | | |
| TABLET;ORAL | | | | |
| BANZEL | | | | |
| + | EISAI INC | 100MG ** | N021911 001 | Nov 14, 2008 |
| SAFFLOWER OIL | | | | |
| INJECTABLE;INJECTION | | | | |
| LIPOSYN 10% | | | | |
| | ABBOTT | 10% (10GM/100ML) | N018203 001 | |
| LIPOSYN 20% | | | | |
| | ABBOTT | 20% (20GM/100ML) | N018614 001 | |

| | | | | |
|---|---|---|---|---|
| SAFFLOWER OIL; SOYBEAN OIL | | | | |
| INJECTABLE;INJECTION | | | | |
| LIPOSYN II 10% | | | | |
| HOSPIRA | 5%;5% (5GM/100ML) | N018997 | 001 | Aug 27, 1984 |
| LIPOSYN II 20% | | | | |
| HOSPIRA | 10%;10% (10GM/100ML) | N018991 | 001 | Aug 27, 1984 |
| SALMETEROL XINAFOATE | | | | |
| AEROSOL, METERED;INHALATION | | | | |
| SEREVENT | | | | |
| GLAXOSMITHKLINE | EQ 0.021MG BASE/INH | N020236 | 001 | Feb 04, 1994 |
| SAQUINAVIR | | | | |
| CAPSULE;ORAL | | | | |
| FORTOVASE | | | | |
| + HOFFMANN LA ROCHE | 200MG ** | N020828 | 001 | Nov 07, 1997 |
| SARALASIN ACETATE | | | | |
| INJECTABLE;INJECTION | | | | |
| SARENIN | | | | |
| PROCTER AND GAMBLE | EQ 0.6MG BASE/ML | N018009 | 001 | |
| SECOBARBITAL SODIUM | | | | |
| CAPSULE;ORAL | | | | |
| SECOBARBITAL SODIUM | | | | |
| ANABOLIC | 100MG | A084422 | 001 | |
| BARR | 100MG | A084225 | 001 | |
| EVERYLIFE | 100MG | A085895 | 001 | |
| HALSEY | 100MG | A084676 | 001 | |
| IVAX PHARMS | 100MG | A085869 | 001 | |
| KV PHARM | 100MG | A085285 | 001 | |
| LANNETT | 50MG | A085909 | 001 | |
| | 100MG | A085903 | 001 | |
| PARKE DAVIS | 100MG | A084762 | 001 | |
| PERRIGO | 100MG | A084561 | 001 | |
| PUREPAC PHARM | 100MG | A085867 | 001 | |
| VALEANT PHARM INTL | 100MG | A085477 | 001 | |
| VITARINE | 100MG | A085898 | 001 | |
| | 100MG | A086273 | 001 | |
| WATSON LABS | 100MG | A085792 | 001 | |
| WEST WARD | 100MG | A084926 | 001 | |
| WHITEWORTH TOWN PLSN | 100MG | A085798 | 001 | |
| WYETH AYERST | 100MG | A086390 | 001 | |
| INJECTABLE;INJECTION | | | | |
| SECOBARBITAL SODIUM | | | | |
| ELKINS SINN | 100MG/VIAL | A083281 | 001 | |
| WYETH AYERST | 50MG/ML | A083262 | 001 | |
| SECONAL SODIUM | | | | |
| LILLY | 50MG/ML | N007392 | 002 | |
| SUPPOSITORY;RECTAL | | | | |
| SECONAL SODIUM | | | | |
| LILLY | 30MG | A086530 | 001 | |
| | 60MG | A086530 | 002 | |
| | 120MG | A086530 | 003 | |
| | 200MG | A086530 | 004 | |
| SECRETIN | | | | |
| INJECTABLE;INJECTION | | | | |
| SECRETIN-FERRING | | | | |
| FERRING | 75CU/VIAL | N018290 | 001 | |
| SECRETIN SYNTHETIC PORCINE | | | | |
| FOR SOLUTION;INTRAVENOUS | | | | |
| SECREFLO | | | | |
| CHIRHOCLIN | 16MCG/VIAL | N021136 | 001 | Apr 04, 2002 |
| SELEGILINE HYDROCHLORIDE | | | | |
| CAPSULE;ORAL | | | | |
| SELEGILINE HYDROCHLORIDE | | | | |
| LANNETT HOLDINGS INC | 5MG | A075145 | 001 | Sep 15, 2003 |

| | | | | |
|---|---|---|---|---|
| SELEGILINE HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| SELEGILINE HYDROCHLORIDE | | | | |
| CHARTWELL MOLECULES | 5MG | A074565 | 001 | Aug 02, 1996 |
| | 5MG | A074641 | 001 | Aug 02, 1996 |
| G AND W LABS INC | 5MG | A074537 | 001 | Aug 02, 1996 |
| | 5MG | A074744 | 001 | Jan 27, 1997 |
| | 5MG | A074756 | 001 | Nov 25, 1998 |
| SIEGFRIED | 5MG | A074672 | 001 | Apr 01, 1997 |
| + SOMERSET | 5MG ** | N019334 | 001 | Jun 05, 1989 |
| SELENIUM SULFIDE | | | | |
| LOTION/SHAMPOO;TOPICAL | | | | |
| EXSEL | | | | |
| ALLERGAN HERBERT | 2.5% | A083892 | 001 | |
| SELENIUM SULFIDE | | | | |
| ACTAVIS MID ATLANTIC | 2.5% | A084394 | 001 | |
| G AND W LABS INC | 2.5% | A086209 | 001 | |
| IVAX PHARMS | 2.5% | A085777 | 001 | |
| SELENOMETHIONINE SE-75 | | | | |
| INJECTABLE;INJECTION | | | | |
| SELENOMETHIONINE SE 75 | | | | |
| GE HEALTHCARE | 250uCi/ML | N017257 | 001 | |
| MALLINCKRODT | 100uCi/ML | N017098 | 001 | |
| PHARMALUCENCE | 500uCi/ML | N017322 | 001 | |
| SETHOTOPE | | | | |
| BRACCO | 85-550uCi/ML | N017047 | 001 | |
| SERMORELIN ACETATE | | | | |
| INJECTABLE;INJECTION | | | | |
| GEREF | | | | |
| + EMD SERONO | EQ 0.05MG BASE/AMP ** | N019863 | 001 | Dec 28, 1990 |
| + EMD SERONO INC | EQ 0.5MG BASE/VIAL ** | N020443 | 001 | Sep 26, 1997 |
| + | EQ 1MG BASE/VIAL ** | N020443 | 002 | Sep 26, 1997 |
| SERTRALINE HYDROCHLORIDE | | | | |
| CONCENTRATE;ORAL | | | | |
| SERTRALINE HYDROCHLORIDE | | | | |
| ALLIED PHARMA INC | EQ 20MG BASE/ML | A076934 | 001 | Jun 30, 2006 |
| RANBAXY LABS LTD | EQ 20MG BASE/ML | A078053 | 001 | Feb 05, 2007 |
| TABLET;ORAL | | | | |
| SERTRALINE HYDROCHLORIDE | | | | |
| ACI HEALTHCARE LTD | EQ 25MG BASE | A076881 | 001 | Feb 06, 2007 |
| | EQ 50MG BASE | A076881 | 002 | Feb 06, 2007 |
| | EQ 100MG BASE | A076881 | 003 | Feb 06, 2007 |
| ACTAVIS ELIZABETH | EQ 25MG BASE | A077345 | 001 | Feb 06, 2007 |
| | EQ 50MG BASE | A077345 | 002 | Feb 06, 2007 |
| | EQ 100MG BASE | A077345 | 003 | Feb 06, 2007 |
| ANDA REPOSITORY | EQ 25MG BASE | A077818 | 001 | Feb 06, 2007 |
| | EQ 50MG BASE | A077818 | 002 | Feb 06, 2007 |
| | EQ 100MG BASE | A077818 | 003 | Feb 06, 2007 |
| CIPLA LTD | EQ 25MG BASE | A077162 | 001 | Feb 06, 2007 |
| | EQ 50MG BASE | A077162 | 002 | Feb 06, 2007 |
| | EQ 100MG BASE | A077162 | 003 | Feb 06, 2007 |
| HIKMA PHARMS | EQ 25MG BASE | A077864 | 001 | Aug 10, 2009 |
| | EQ 50MG BASE | A077864 | 002 | Aug 10, 2009 |
| | EQ 100MG BASE | A077864 | 003 | Aug 10, 2009 |
| IVAX SUB TEVA PHARMS | EQ 25MG BASE | A075719 | 003 | Jun 30, 2006 |
| | EQ 50MG BASE | A075719 | 001 | Jun 30, 2006 |
| | EQ 100MG BASE | A075719 | 002 | Jun 30, 2006 |
| MYLAN | EQ 25MG BASE | A076671 | 001 | Feb 06, 2007 |
| | EQ 50MG BASE | A076671 | 002 | Feb 06, 2007 |
| | EQ 100MG BASE | A076671 | 003 | Feb 06, 2007 |
| MYLAN PHARMS INC | EQ 25MG BASE | A076540 | 001 | Mar 20, 2007 |
| | EQ 50MG BASE | A076540 | 002 | Mar 20, 2007 |
| | EQ 100MG BASE | A076540 | 003 | Mar 20, 2007 |
| PLIVA HRVATSKA DOO | EQ 25MG BASE | A077299 | 001 | Feb 06, 2007 |
| | EQ 50MG BASE | A077299 | 002 | Feb 06, 2007 |
| | EQ 100MG BASE | A077299 | 003 | Feb 06, 2007 |
| SANDOZ | EQ 25MG BASE | A077713 | 001 | Feb 06, 2007 |

| | | | | |
|---|---|---|---|---|
| SERTRALINE HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| SERTRALINE HYDROCHLORIDE | | | | |
| | EQ 50MG BASE | A077713 | 002 | Feb 06, 2007 |
| | EQ 100MG BASE | A077713 | 003 | Feb 06, 2007 |
| SCIEGEN PHARMS INC | EQ 25MG BASE | A076442 | 001 | Apr 30, 2007 |
| | EQ 50MG BASE | A076442 | 002 | Apr 30, 2007 |
| | EQ 100MG BASE | A076442 | 003 | Apr 30, 2007 |
| SUN PHARM INDS (IN) | EQ 25MG BASE | A078108 | 001 | Feb 06, 2007 |
| | EQ 50MG BASE | A078108 | 002 | Feb 06, 2007 |
| | EQ 100MG BASE | A078108 | 003 | Feb 06, 2007 |
| WATSON LABS TEVA | EQ 25MG BASE | A077663 | 001 | Feb 06, 2007 |
| | EQ 50MG BASE | A077663 | 002 | Feb 06, 2007 |
| | EQ 100MG BASE | A077663 | 003 | Feb 06, 2007 |
| ZOLOFT | | | | |
| + PFIZER | EQ 150MG BASE ** | N019839 | 003 | Dec 30, 1991 |
| + | EQ 200MG BASE ** | N019839 | 004 | Dec 30, 1991 |
| SEVELAMER HYDROCHLORIDE | | | | |
| CAPSULE;ORAL | | | | |
| RENAGEL | | | | |
| GENZYME | 403MG | N020926 | 001 | Oct 30, 1998 |
| SIBUTRAMINE HYDROCHLORIDE | | | | |
| CAPSULE;ORAL | | | | |
| MERIDIA | | | | |
| ABBOTT | 5MG | N020632 | 001 | Nov 22, 1997 |
| | 10MG | N020632 | 002 | Nov 22, 1997 |
| | 15MG | N020632 | 003 | Nov 22, 1997 |
| SILDENAFIL CITRATE | | | | |
| TABLET;ORAL | | | | |
| SILDENAFIL CITRATE | | | | |
| ACTAVIS GRP PTC | EQ 20MG BASE | A200149 | 001 | Feb 25, 2013 |
| SILVER SULFADIAZINE | | | | |
| DRESSING;TOPICAL | | | | |
| SILDAFLO | | | | |
| FRANKLIN PHARMS | 1% | N019608 | 001 | Nov 30, 1989 |
| SIMETHICONE-CELLULOSE | | | | |
| SUSPENSION;ORAL | | | | |
| SONORX | | | | |
| BRACCO | 7.5MG/ML | N020773 | 001 | Oct 29, 1998 |
| SIMVASTATIN | | | | |
| TABLET;ORAL | | | | |
| SIMVASTATIN | | | | |
| FOSUN PHARMA | 5MG | A077766 | 001 | Dec 20, 2006 |
| | 10MG | A077766 | 002 | Dec 20, 2006 |
| | 20MG | A077766 | 003 | Dec 20, 2006 |
| | 40MG | A077766 | 004 | Dec 20, 2006 |
| | 80MG | A077766 | 005 | Dec 20, 2006 |
| MYLAN PHARMS INC | 5MG | A090868 | 001 | Jun 08, 2010 |
| | 10MG | A090868 | 002 | Jun 08, 2010 |
| | 20MG | A090868 | 003 | Jun 08, 2010 |
| | 40MG | A090868 | 004 | Jun 08, 2010 |
| | 80MG | A090868 | 005 | Jun 08, 2010 |
| SUN PHARM INDS LTD | 5MG | A076285 | 001 | Dec 20, 2006 |
| | 10MG | A076285 | 002 | Dec 20, 2006 |
| | 20MG | A076285 | 003 | Dec 20, 2006 |
| | 40MG | A076285 | 004 | Dec 20, 2006 |
| | 80MG | A076285 | 005 | Jun 23, 2006 |
| TABLET, ORALLY DISINTEGRATING;ORAL | | | | |
| SIMVASTATIN | | | | |
| SYNTHON PHARMS | 10MG | N021961 | 001 | Oct 09, 2007 |
| | 20MG | N021961 | 002 | Oct 09, 2007 |
| | 40MG | N021961 | 003 | Oct 09, 2007 |
| | 80MG | N021961 | 004 | Oct 09, 2007 |

SIMVASTATIN; SITAGLIPTIN PHOSPHATE

| | | | | | |
|---|---|---|---|---|---|
| TABLET;ORAL | | | | | |
| JUVISYNC | | | | | |
| + | MERCK SHARP DOHME | 10MG;EQ 50MG BASE ** | N202343 | 004 | Sep 18, 2012 |
| + | | 10MG;EQ 100MG BASE ** | N202343 | 001 | Oct 07, 2011 |
| + | | 20MG;EQ 50MG BASE ** | N202343 | 005 | Sep 18, 2012 |
| + | | 20MG;EQ 100MG BASE ** | N202343 | 002 | Oct 07, 2011 |
| + | | 40MG;EQ 50MG BASE ** | N202343 | 006 | Sep 18, 2012 |
| + | | 40MG;EQ 100MG BASE ** | N202343 | 003 | Oct 07, 2011 |

SIROLIMUS

| | | | | | |
|---|---|---|---|---|---|
| TABLET;ORAL | | | | | |
| RAPAMUNE | | | | | |
| + | PF PRISM CV | 5MG ** | N021110 | 003 | Feb 23, 2004 |

SODIUM BENZOATE; SODIUM PHENYLACETATE

| | | | | | |
|---|---|---|---|---|---|
| SOLUTION;ORAL | | | | | |
| UCEPHAN | | | | | |
| | B BRAUN | 100MG/ML;100MG/ML | N019530 | 001 | Dec 23, 1987 |

SODIUM BICARBONATE

| | | | | | |
|---|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | | |
| SODIUM BICARBONATE IN PLASTIC CONTAINER | | | | | |
| + | ABBOTT | 0.9MEQ/ML ** | N019443 | 001 | Jun 03, 1986 |
| + | | 1MEQ/ML ** | N019443 | 002 | Jun 03, 1986 |

SODIUM BICARBONATE; TARTARIC ACID

| | | | | | |
|---|---|---|---|---|---|
| GRANULE, EFFERVESCENT;ORAL | | | | | |
| BAROS | | | | | |
| | MALLINCKRODT INC | 460MG/GM;420MG/GM | N018509 | 001 | Aug 07, 1985 |

SODIUM CHLORIDE

| | | | | | |
|---|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | | |
| BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | | | | | |
| | ABRAXIS PHARM | 9MG/ML | A088909 | 001 | Feb 07, 1985 |
| SODIUM CHLORIDE | | | | | |
| | ABBOTT | 20GM/100ML | N017013 | 001 | |
| | B BRAUN | 20GM/100ML | N017038 | 001 | |
| SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER | | | | | |
| | B BRAUN | 450MG/100ML | N018184 | 001 | |
| | MILES | 450MG/100ML | N018503 | 001 | |
| SODIUM CHLORIDE 0.9% | | | | | |
| | MEDEFIL INC | 18MG/2ML (9MG/ML) | N202832 | 002 | Jan 06, 2012 |
| | | 22.5MG/2.5ML (9MG/ML) | N202832 | 003 | Jan 06, 2012 |
| | | 27MG/3ML (9MG/ML) | N202832 | 004 | Jan 06, 2012 |
| | | 45MG/5ML (9MG/ML) | N202832 | 005 | Jan 06, 2012 |
| SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | | | | | |
| | ABBOTT | 9MG/ML | N019218 | 001 | Jul 13, 1984 |
| | MEDEFIL INC | 9MG/ML (9MG/ML) | N202832 | 001 | Jan 06, 2012 |
| | MILES | 900MG/100ML | N018502 | 001 | |
| SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER | | | | | |
| + | ABRAXIS PHARM | 234MG/ML ** | N019329 | 001 | Apr 22, 1987 |
| SOLUTION;IRRIGATION | | | | | |
| SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER | | | | | |
| | BAXTER HLTHCARE | 450MG/100ML | N017864 | 001 | |
| | | 450MG/100ML | N018497 | 001 | Feb 19, 1982 |
| | HOSPIRA | 450MG/100ML | N017670 | 001 | |
| | | 450MG/100ML | N018380 | 001 | |
| SODIUM CHLORIDE IN PLASTIC CONTAINER | | | | | |
| | MILES | 900MG/100ML | N018247 | 001 | |

SODIUM CHROMATE CR-51

| | | | | | |
|---|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | | |
| CHROMITOPE SODIUM | | | | | |
| | BRACCO | 2mCi/VIAL | N013993 | 002 | |
| | | 200uCi/ML | N013993 | 001 | |
| SODIUM CHROMATE CR 51 | | | | | |
| | MALLINKRODT NUCLEAR | 100uCi/ML | N016708 | 001 | |

| | | | | |
|---|---|---|---|---|
| SODIUM FLUORIDE F-18 | | | | |
| INJECTABLE;INTRAVENOUS | | | | |
| FLUORINE F-18 | | | | |
| + GE HEALTHCARE | 2mCi/ML ** | N017042 | 001 | |
| SODIUM FLUORIDE F 18 | | | | |
| NIH NCI DCTD | 10-200mCi/ML ** | N022494 | 001 | Jan 26, 2011 |
| SODIUM FLUORIDE F-18 | | | | |
| UIHC PET IMAGING | 10-200mCi/ML | A204462 | 001 | Nov 17, 2015 |
| SODIUM IODIDE I-123 | | | | |
| CAPSULE;ORAL | | | | |
| SODIUM IODIDE I 123 | | | | |
| CARDINAL HEALTH 418 | 400uCi | N018671 | 003 | May 27, 1982 |
| GE HEALTHCARE | 100uCi | N017630 | 001 | |
| SOLUTION;ORAL | | | | |
| SODIUM IODIDE I 123 | | | | |
| GE HEALTHCARE | 2mCi/ML | N017630 | 002 | |
| SODIUM IODIDE I-131 | | | | |
| CAPSULE;ORAL | | | | |
| IODOTOPE | | | | |
| BRACCO | 1-130mCi | N010929 | 001 | |
| | 1-150mCi | N010929 | 003 | |
| SODIUM IODIDE I 131 | | | | |
| CIS | 50uCi | N017316 | 001 | |
| | 100uCi | N017316 | 002 | |
| JUBILANT DRAXIMAGE | 2-200mCi | N021305 | 004 | Nov 18, 2004 |
| MALLINKRODT NUCLEAR | 0.8-100mCi | N016515 | 002 | |
| | 15-100uCi | N016517 | 002 | |
| SOLUTION;ORAL | | | | |
| HICON | | | | |
| JUBILANT DRAXIMAGE | 1-250mCi/0.25ML | N021305 | 002 | Jan 24, 2003 |
| | 1-500mCi/0.5ML | N021305 | 003 | Jan 24, 2003 |
| | 1-1000mCi/ML | N021305 | 005 | Apr 04, 2006 |
| IODOTOPE | | | | |
| BRACCO | 7-106mCi/BOT | N010929 | 002 | |
| SODIUM IODIDE I 131 | | | | |
| CIS | 50mCi/ML | N017315 | 001 | |
| SODIUM LACTATE | | | | |
| INJECTABLE;INJECTION | | | | |
| SODIUM LACTATE 0.167 MOLAR IN PLASTIC CONTAINER | | | | |
| B BRAUN | 1.87GM/100ML | N018186 | 001 | |
| BAXTER HLTHCARE | 1.87GM/100ML | N016692 | 001 | |
| HOSPIRA | 1.87GM/100ML | N018249 | 001 | |
| SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER | | | | |
| B BRAUN | 1.87GM/100ML | N020004 | 001 | Apr 21, 1992 |
| SODIUM MONOFLUOROPHOSPHATE | | | | |
| GEL;DENTAL | | | | |
| EXTRA-STRENGTH AIM | | | | |
| CHESEBROUGH PONDS | 1.2% | N019518 | 002 | Aug 06, 1986 |
| PASTE;DENTAL | | | | |
| EXTRA-STRENGTH AIM | | | | |
| CHESEBROUGH PONDS | 1.2% | N019518 | 001 | Jun 03, 1987 |
| SODIUM NITROPRUSSIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| NIPRIDE | | | | |
| ROCHE | 50MG/VIAL | N017546 | 001 | |
| NITROPRESS | | | | |
| ABBOTT | 50MG/VIAL | A071555 | 001 | Nov 16, 1987 |
| + ABBVIE | 50MG/VIAL ** | N018450 | 001 | |
| HOSPIRA | 50MG/VIAL | A070566 | 001 | Jun 09, 1986 |
| SODIUM NITROPRUSSIDE | | | | |
| ABRAXIS PHARM | 50MG/VIAL | A070031 | 001 | Jan 17, 1985 |
| + BAXTER HLTHCARE | 50MG/VIAL ** | N018581 | 001 | Jul 28, 1982 |
| TEVA PARENTERAL | 25MG/ML | A073465 | 001 | Mar 30, 1992 |

SODIUM PHOSPHATE P-32
SOLUTION;INJECTION, ORAL
PHOSPHOTOPE
BRACCO 1-8mCi/VIAL N010927 001
SODIUM PHOSPHATE P 32
MALLINCKRODT 0.67mCi/ML N011777 001
1.5mCi/VIAL N011777 002

SODIUM PHOSPHATE, DIBASIC ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE
TABLET;ORAL
VISICOL
SALIX PHARMS 0.398GM;1.102GM N021097 001 Sep 21, 2000

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE
TABLET;ORAL
MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE
NOVEL LABS INC 0.398GM;1.102GM A079247 001 Dec 30, 2011

SODIUM POLYSTYRENE SULFONATE
POWDER;ORAL, RECTAL
KAYEXALATE
\+ CONCORDIA PHARMS INC 453.6GM/BOT N011287 001
SODIUM POLYSTYRENE SULFONATE
CITRUSPHRMA 454GM/BOT A040909 001 Dec 03, 2008
WOCKHARDT 453.6GM/BOT A088786 001 Sep 11, 1984
SUSPENSION;ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE
MORTON GROVE 15GM/60ML A088717 001 Sep 11, 1984
ROXANE 15GM/60ML A088453 001 Nov 17, 1983

SODIUM SUCCINATE
INJECTABLE;INJECTION
SODIUM SUCCINATE
ELKINS SINN 30% A080516 001

SODIUM TETRADECYL SULFATE
INJECTABLE;INJECTION
SOTRADECOL
\+ ELKINS SINN 1% ** N005970 004
\+ 3% ** N005970 005

SODIUM THIOSULFATE
INJECTABLE;INJECTION
SODIUM THIOSULFATE
US ARMY 250MG/ML N020166 001 Feb 14, 1992

SOMATREM
INJECTABLE;INJECTION
PROTROPIN
GENENTECH 5MG/VIAL N019107 001 Oct 17, 1985
10MG/VIAL N019107 002 Oct 24, 1989

SOMATROPIN
INJECTABLE;INJECTION
ASELLACRIN 10
SERONO 10 IU/VIAL N017726 001
ASELLACRIN 2
SERONO 2 IU/VIAL N017726 002 Jul 21, 1983
CRESCORMON
GENENTECH 4 IU/VIAL N017992 001

SOMATROPIN RECOMBINANT
INJECTABLE;INJECTION
ACCRETROPIN
EMERGENT 5MG/ML (5MG/ML) N021538 001 Jan 23, 2008
BIO-TROPIN
FERRING 4.8MG/VIAL N019774 001 May 25, 1995
HUMATROPE
LILLY 2MG/VIAL N019640 001 Jun 23, 1987
NORDITROPIN
NOVO NORDISK INC 4MG/VIAL N019721 001 May 08, 1995
5MG/1.5ML N021148 001 Jun 20, 2000
8MG/VIAL N019721 002 May 08, 1995
10MG/1.5ML N021148 002 Jun 20, 2000

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| SOMATROPIN RECOMBINANT | | | | |
| INJECTABLE;INJECTION | | | | |
| NORDITROPIN | | | | |
| | 15MG/1.5ML | N021148 | 003 | Jun 20, 2000 |
| NORDITROPIN NORDIFLEX | | | | |
| NOVO NORDISK INC | 5MG/1.5ML | N021148 | 004 | Oct 01, 2004 |
| | 10MG/1.5ML | N021148 | 005 | Oct 01, 2004 |
| | 15MG/1.5ML | N021148 | 006 | Oct 01, 2004 |
| | 30MG/3ML | N021148 | 007 | Mar 10, 2009 |
| NUTROPIN | | | | |
| GENENTECH | 5MG/VIAL | N020168 | 001 | Nov 17, 1993 |
| | 10MG/VIAL | N020168 | 002 | Nov 17, 1993 |
| NUTROPIN AQ | | | | |
| GENENTECH | 10MG/2ML (5MG/ML) | N020522 | 001 | Dec 29, 1995 |
| NUTROPIN DEPOT | | | | |
| GENENTECH | 13.5MG/VIAL | N021075 | 001 | Dec 22, 1999 |
| | 18MG/VIAL | N021075 | 002 | Dec 22, 1999 |
| | 22.5MG/VIAL | N021075 | 003 | Dec 22, 1999 |
| SAIZEN | | | | |
| EMD SERONO | 4MG/VIAL | N019764 | 005 | Jan 16, 2007 |
| | 6MG/VIAL | N019764 | 001 | Oct 08, 1996 |
| SEROSTIM | | | | |
| EMD SERONO | 8.8MG/VIAL | N020604 | 004 | Sep 06, 2001 |
| ZORBTIVE | | | | |
| EMD SERONO | 4MG/VIAL | N021597 | 001 | Dec 01, 2003 |
| | 5MG/VIAL | N021597 | 002 | Dec 01, 2003 |
| | 6MG/VIAL | N021597 | 003 | Dec 01, 2003 |
| INJECTABLE;SUBCUTANEOUS | | | | |
| SEROSTIM LQ | | | | |
| EMD SERONO | 6MG/0.5ML (6MG/0.5ML) | N020604 | 005 | Feb 11, 2005 |
| SORBITOL | | | | |
| SOLUTION;IRRIGATION | | | | |
| SORBITOL 3% IN PLASTIC CONTAINER | | | | |
| BAXTER HLTHCARE | 3GM/100ML | N018512 | 001 | May 27, 1982 |
| SOTALOL HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| BETAPACE | | | | |
| COVIS PHARMA BV | 320MG | N019865 | 004 | Oct 30, 1992 |
| BETAPACE AF | | | | |
| COVIS PHARMA BV | 40MG | N021151 | 006 | Apr 02, 2003 |
| | 60MG | N021151 | 007 | Apr 02, 2003 |
| | 100MG | N021151 | 005 | Mar 14, 2003 |
| SOTALOL HYDROCHLORIDE | | | | |
| IMPAX PHARMS | 80MG | A075663 | 001 | Nov 07, 2000 |
| | 120MG | A075663 | 002 | Nov 07, 2000 |
| | 160MG | A075663 | 003 | Nov 07, 2000 |
| | 240MG | A075663 | 004 | Nov 07, 2000 |
| MYLAN | 80MG | A075237 | 001 | May 01, 2000 |
| | 80MG | A075725 | 001 | Dec 19, 2000 |
| | 120MG | A075237 | 002 | May 01, 2000 |
| | 120MG | A075725 | 002 | Dec 19, 2000 |
| | 160MG | A075237 | 003 | May 01, 2000 |
| | 160MG | A075725 | 003 | Dec 19, 2000 |
| | 240MG | A075237 | 004 | May 01, 2000 |
| | 240MG | A075725 | 004 | Dec 19, 2000 |
| SUN PHARM INDUSTRIES | 80MG | A075515 | 001 | Oct 15, 2001 |
| | 80MG | A076576 | 001 | Apr 08, 2004 |
| | 120MG | A075515 | 004 | Oct 15, 2001 |
| | 120MG | A076576 | 002 | Apr 08, 2004 |
| | 160MG | A075515 | 002 | Oct 15, 2001 |
| | 160MG | A076576 | 003 | Apr 08, 2004 |
| | 240MG | A075515 | 003 | Oct 15, 2001 |
| TEVA | 80MG | A076883 | 001 | Jul 26, 2004 |
| | 120MG | A076883 | 002 | Jul 26, 2004 |
| | 160MG | A076883 | 003 | Jul 26, 2004 |
| WATSON LABS | 80MG | A075238 | 001 | Jul 13, 2000 |
| | 120MG | A075238 | 002 | Jul 13, 2000 |
| | 160MG | A075238 | 003 | Jul 13, 2000 |

| | | | | |
|---|---|---|---|---|
| SOTALOL HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| SOTALOL HYDROCHLORIDE | | | | |
| | 240MG | A075238 | 004 | Jul 13, 2000 |
| SOYBEAN OIL | | | | |
| INJECTABLE;INJECTION | | | | |
| LIPOSYN III 10% | | | | |
| HOSPIRA | 10% | N018969 | 001 | Sep 24, 1984 |
| LIPOSYN III 20% | | | | |
| HOSPIRA | 20% | N018970 | 001 | Sep 25, 1984 |
| LIPOSYN III 30% | | | | |
| HOSPIRA | 30% | N020181 | 001 | Jan 13, 1998 |
| SOYACAL 10% | | | | |
| ALPHA THERA | 10% | N018465 | 001 | Jun 29, 1983 |
| SOYACAL 20% | | | | |
| ALPHA THERA | 20% | N018786 | 001 | Jun 29, 1983 |
| TRAVAMULSION 10% | | | | |
| BAXTER HLTHCARE | 10% | N018660 | 001 | Feb 26, 1982 |
| TRAVAMULSION 20% | | | | |
| BAXTER HLTHCARE | 20% | N018758 | 001 | Feb 15, 1983 |
| SPARFLOXACIN | | | | |
| TABLET;ORAL | | | | |
| ZAGAM | | | | |
| MYLAN | 200MG | N020677 | 001 | Dec 19, 1996 |
| SPECTINOMYCIN HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| TROBICIN | | | | |
| PFIZER | EQ 2GM BASE/VIAL | N050347 | 001 | |
| | EQ 4GM BASE/VIAL | N050347 | 002 | |
| SPIRAPRIL HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| RENORMAX | | | | |
| SCHERING | 3MG | N020240 | 001 | Dec 29, 1994 |
| | 6MG | N020240 | 002 | Dec 29, 1994 |
| | 12MG | N020240 | 003 | Dec 29, 1994 |
| | 24MG | N020240 | 004 | Dec 29, 1994 |
| SPIRONOLACTONE | | | | |
| TABLET;ORAL | | | | |
| SPIRONOLACTONE | | | | |
| ASCOT | 25MG | A087687 | 001 | Oct 20, 1982 |
| IVAX PHARMS | 25MG | A087108 | 001 | |
| LEDERLE | 25MG | A087634 | 001 | |
| MUTUAL PHARM | 25MG | A087265 | 001 | |
| MYLAN | 25MG | A087086 | 001 | |
| PUREPAC PHARM | 25MG | A087998 | 001 | Oct 14, 1983 |
| | 25MG | A088053 | 001 | Aug 25, 1983 |
| SUPERPHARM | 25MG | A089364 | 001 | Nov 07, 1986 |
| UPSHER SMITH | 25MG | A087554 | 001 | |
| VANGARD | 25MG | A087648 | 001 | Feb 01, 1982 |
| WARNER CHILCOTT | 25MG | A087952 | 001 | Nov 18, 1982 |
| WATSON LABS | 25MG | A086898 | 002 | Mar 02, 1982 |
| | 25MG | A087078 | 001 | |
| STANOZOLOL | | | | |
| TABLET;ORAL | | | | |
| WINSTROL | | | | |
| LUNDBECK INC | 2MG | N012885 | 001 | May 14, 1984 |
| STAVUDINE | | | | |
| CAPSULE;ORAL | | | | |
| STAVUDINE | | | | |
| MYLAN LABS LTD | 30MG | A078775 | 001 | Jan 05, 2009 |
| | 40MG | A078775 | 002 | Jan 05, 2009 |
| ZERIT | | | | |
| BRISTOL MYERS SQUIBB | 5MG | N020412 | 001 | Jun 24, 1994 |

STAVUDINE
CAPSULE, EXTENDED RELEASE;ORAL
ZERIT XR

| | | | | |
|---|---|---|---|---|
| BRISTOL MYERS SQUIBB | 37.5MG | N021453 | 001 | Dec 31, 2002 |
| | 50MG | N021453 | 002 | Dec 31, 2002 |
| | 75MG | N021453 | 003 | Dec 31, 2002 |
| | 100MG | N021453 | 004 | Dec 31, 2002 |

FOR SOLUTION;ORAL
STAVUDINE

| | | | | |
|---|---|---|---|---|
| AUROBINDO PHARMA | 1MG/ML | A077774 | 001 | Dec 29, 2008 |

STERILE WATER FOR INJECTION
LIQUID;N/A
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| ABRAXIS PHARM | 100% | A089099 | 001 | Dec 29, 1987 |
| | 100% | A089100 | 001 | Dec 29, 1987 |

STERILE WATER FOR INJECTION IN PLASTIC CONTAINER

| | | | | |
|---|---|---|---|---|
| B BRAUN | 100% | N019077 | 001 | Mar 02, 1984 |

STERILE WATER FOR IRRIGATION
LIQUID;IRRIGATION
STERILE WATER IN PLASTIC CONTAINER

| | | | |
|---|---|---|---|
| MILES | 100% | N018246 | 001 |

STREPTOMYCIN SULFATE
INJECTABLE;INJECTION
STREPTOMYCIN SULFATE

| | | | |
|---|---|---|---|
| COPANOS | EQ 500MG BASE/ML | A060684 | 001 |
| LILLY | EQ 1GM BASE/VIAL | A060107 | 001 |
| | EQ 1GM BASE/2ML | A060404 | 001 |
| | EQ 5GM BASE/VIAL | A060107 | 002 |
| PFIZER | EQ 1GM BASE/VIAL | A060076 | 001 |
| | EQ 1GM BASE/2.5ML | A060111 | 001 |
| | EQ 5GM BASE/VIAL | A060076 | 002 |

SUCCINYLCHOLINE CHLORIDE
INJECTABLE;INJECTION
ANECTINE

| | | | | |
|---|---|---|---|---|
| SANDOZ INC | 50MG/ML | N008453 | 003 | |
| | 500MG/VIAL | N008453 | 001 | |
| | 1GM/VIAL | N008453 | 004 | |

QUELICIN PRESERVATIVE FREE

| | | | | |
|---|---|---|---|---|
| HOSPIRA | 50MG/ML | N008845 | 002 | |
| | 100MG/ML | N008845 | 004 | |

SUCCINYLCHOLINE CHLORIDE

| | | | | |
|---|---|---|---|---|
| INTL MEDICATION | 100MG/VIAL | A085400 | 001 | Feb 04, 1982 |
| ORGANON USA INC | 20MG/ML | A080997 | 001 | |

SUCOSTRIN

| | | | | |
|---|---|---|---|---|
| APOTHECON | 20MG/ML | N008847 | 001 | |
| | 100MG/ML | N008847 | 003 | |

SUFENTANIL CITRATE
INJECTABLE;INJECTION
SUFENTANIL CITRATE

| | | | | |
|---|---|---|---|---|
| WATSON LABS | EQ 0.05MG BASE/ML | A074406 | 001 | Dec 15, 1995 |

SULFACETAMIDE SODIUM
OINTMENT;OPHTHALMIC
BLEPH-10

| | | | |
|---|---|---|---|
| ALLERGAN | 10% | A084015 | 001 |

CETAMIDE

| | | | |
|---|---|---|---|
| ALCON | 10% | A080021 | 001 |

SODIUM SULAMYD

| | | | | |
|---|---|---|---|---|
| + | SCHERING | 10% ** | N005963 | 002 |

SULFAIR 10

| | | | | |
|---|---|---|---|---|
| PHARMAFAIR | 10% | A088000 | 001 | Dec 22, 1982 |

SOLUTION/DROPS;OPHTHALMIC
BLEPH-30

| | | | |
|---|---|---|---|
| ALLERGAN | 30% | A080028 | 002 |

ISOPTO CETAMIDE

| | | | |
|---|---|---|---|
| ALCON | 15% | A080020 | 002 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| SULFACETAMIDE SODIUM | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | |
| OCUSULF-10 | | | | |
| MIZA PHARMS USA | 10% | A080660 | 001 | |
| OCUSULF-30 | | | | |
| MIZA PHARMS USA | 30% | A080660 | 002 | |
| SODIUM SULAMYD | | | | |
| + SCHERING | 10% ** | N005963 | 001 | |
| + | 30% ** | N005963 | 003 | |
| SODIUM SULFACETAMIDE | | | | |
| AKORN | 10% | A083021 | 001 | |
| | 15% | A083021 | 002 | |
| | 30% | A083021 | 003 | |
| SOLA BARNES HIND | 10% | A084143 | 001 | |
| | 10% | A084145 | 001 | |
| | 30% | A084146 | 001 | |
| | 30% | A084147 | 001 | |
| SULF-10 | | | | |
| NOVARTIS | 10% | A080025 | 001 | |
| SULF-15 | | | | |
| NOVARTIS | 15% | A089047 | 001 | Oct 31, 1995 |
| SULFACEL-15 | | | | |
| OPTOPICS | 15% | A080024 | 001 | |
| SULFACETAMIDE SODIUM | | | | |
| AKORN | 30% | A040216 | 001 | May 25, 1999 |
| ALCON PHARMS LTD | 30% | A089068 | 001 | May 05, 1987 |
| PHARMAFAIR | 10% | A088947 | 001 | May 17, 1985 |
| SULFAIR 10 | | | | |
| PHARMAFAIR | 10% | A087949 | 001 | Dec 13, 1982 |
| SULFAIR FORTE | | | | |
| PHARMAFAIR | 30% | A088385 | 001 | Oct 13, 1983 |
| SULFAIR-15 | | | | |
| PHARMAFAIR | 15% | A088186 | 001 | May 25, 1983 |
| SULTEN-10 | | | | |
| BAUSCH AND LOMB | 10% | A087818 | 001 | Feb 03, 1983 |
| SULFACYTINE | | | | |
| TABLET;ORAL | | | | |
| RENOQUID | | | | |
| GLENWOOD | 250MG | N017569 | 001 | |
| SULFADIAZINE | | | | |
| TABLET;ORAL | | | | |
| SULFADIAZINE | | | | |
| ABBVIE | 300MG | N004125 | 005 | |
| EVERYLIFE | 500MG | A080088 | 001 | |
| IMPAX LABS | 500MG | A080081 | 001 | |
| LANNETT | 500MG | A080084 | 001 | |
| LEDERLE | 500MG | N004054 | 001 | |
| LILLY | 500MG | N004122 | 002 | |
| SULFADIAZINE SODIUM | | | | |
| INJECTABLE;INJECTION | | | | |
| SULFADIAZINE SODIUM | | | | |
| LEDERLE | 250MG/ML | N004054 | 002 | |
| SULFADIAZINE; SULFAMERAZINE | | | | |
| SUSPENSION;ORAL | | | | |
| SULFONAMIDES DUPLEX | | | | |
| LILLY | 250MG/5ML;250MG/5ML | N006317 | 007 | |
| SULFAMETER | | | | |
| TABLET;ORAL | | | | |
| SULLA | | | | |
| BAYER HLTHCARE | 500MG | N016000 | 002 | |

| | | | | |
|---|---|---|---|---|
| SULFAMETHIZOLE | | | | |
| TABLET;ORAL | | | | |
| MICROSUL | | | | |
| FOREST PHARMS | 1GM | | A086012 001 | |
| PROKLAR | | | | |
| FOREST PHARMS | 500MG | | A080273 001 | |
| THIOSULFIL | | | | |
| WYETH AYERST | 250MG | | N008565 001 | |
| | 500MG | | N008565 004 | |
| SULFAMETHOXAZOLE | | | | |
| SUSPENSION;ORAL | | | | |
| GANTANOL | | | | |
| ROCHE | 500MG/5ML | | N013664 002 | |
| TABLET;ORAL | | | | |
| GANTANOL | | | | |
| ROCHE | 500MG | | N012715 002 | |
| GANTANOL-DS | | | | |
| ROCHE | 1GM | | N012715 003 | |
| SULFAMETHOXAZOLE | | | | |
| ASCOT | 500MG | | A087662 001 | Oct 20, 1982 |
| AUROLIFE PHARMA LLC | 500MG | | A085844 001 | |
| BARR | 500MG | | A087189 001 | Jul 25, 1983 |
| HEATHER | 500MG | | A086163 001 | |
| WATSON LABS | 500MG | | A085053 001 | |
| | 1GM | | A086000 001 | |
| UROBAK | | | | |
| SHIONOGI | 500MG | | A087307 001 | |
| SULFAMETHOXAZOLE; TRIMETHOPRIM | | | | |
| INJECTABLE;INJECTION | | | | |
| BACTRIM | | | | |
| + SUN PHARM INDS INC | 80MG/ML;16MG/ML ** | | N018374 001 | |
| SEPTRA | | | | |
| MONARCH PHARMS | 80MG/ML;16MG/ML | | N018452 001 | |
| SULFAMETHOXAZOLE AND TRIMETHOPRIM | | | | |
| ABRAXIS PHARM | 80MG/ML;16MG/ML | | A070223 001 | Dec 29, 1987 |
| BEDFORD | 80MG/ML;16MG/ML | | A072383 001 | Apr 29, 1992 |
| HOSPIRA | 80MG/ML;16MG/ML | | A073199 001 | Sep 11, 1992 |
| WATSON LABS | 80MG/ML;16MG/ML | | A071556 001 | Dec 29, 1987 |
| WEST-WARD PHARMS INT | 80MG/ML;16MG/ML | | A070627 001 | Dec 29, 1987 |
| | 80MG/ML;16MG/ML | | A070628 001 | Dec 29, 1987 |
| SUSPENSION;ORAL | | | | |
| BACTRIM | | | | |
| SUN PHARM INDUSTRIES | 200MG/5ML;40MG/5ML ** | | N017560 001 | |
| BACTRIM PEDIATRIC | | | | |
| SUN PHARM INDUSTRIES | 200MG/5ML;40MG/5ML ** | | N017560 002 | |
| SEPTRA | | | | |
| MONARCH PHARMS | 200MG/5ML;40MG/5ML ** | | N017598 001 | |
| SEPTRA GRAPE | | | | |
| MONARCH PHARMS | 200MG/5ML;40MG/5ML ** | | N017598 002 | Feb 12, 1986 |
| SULFAMETHOXAZOLE AND TRIMETHOPRIM | | | | |
| ANI PHARMS INC | 200MG/5ML;40MG/5ML | | A070028 001 | Jun 02, 1987 |
| | 200MG/5ML;40MG/5ML ** | | A077612 001 | Nov 13, 2006 |
| TEVA | 200MG/5ML;40MG/5ML | | N018812 001 | Jan 28, 1983 |
| | 200MG/5ML;40MG/5ML | | N018812 002 | Jun 10, 1983 |
| SULFATRIM | | | | |
| STI PHARMA LLC | 200MG/5ML;40MG/5ML | | N018615 002 | Jan 07, 1983 |
| SULMEPRIM | | | | |
| USL PHARMA | 200MG/5ML;40MG/5ML | | A070063 001 | Aug 01, 1986 |
| SULMEPRIM PEDIATRIC | | | | |
| USL PHARMA | 200MG/5ML;40MG/5ML | | A070064 001 | Aug 01, 1986 |
| TRIMETH/SULFA | | | | |
| ALPHARMA US PHARMS | 200MG/5ML;40MG/5ML | | A072289 001 | May 23, 1988 |
| | 200MG/5ML;40MG/5ML | | A072398 001 | May 23, 1988 |
| NASKA | 200MG/5ML;40MG/5ML | | A072399 001 | May 23, 1988 |
| TABLET;ORAL | | | | |
| COTRIM | | | | |
| TEVA | 400MG;80MG | | A070034 001 | May 16, 1985 |

| | | | | |
|---|---|---|---|---|
| SULFAMETHOXAZOLE; TRIMETHOPRIM | | | | |
| TABLET;ORAL | | | | |
| COTRIM D.S. | | | | |
| TEVA | 800MG;160MG | A070048 | 001 | Mar 18, 1985 |
| SULFAMETHOPRIM | | | | |
| NOVEL LABS INC | 400MG;80MG | A070022 | 001 | Feb 15, 1985 |
| SULFAMETHOPRIM-DS | | | | |
| NOVEL LABS INC | 800MG;160MG | A070032 | 001 | Feb 15, 1985 |
| SULFAMETHOXAZOLE AND TRIMETHOPRIM | | | | |
| HEATHER | 400MG;80MG | N018946 | 001 | Aug 10, 1984 |
| | 800MG;160MG | N018946 | 002 | Aug 10, 1984 |
| INTERPHARM | 400MG;80MG | A071299 | 001 | Oct 27, 1987 |
| | 800MG;160MG | A071300 | 001 | Oct 27, 1987 |
| MARTEC USA LLC | 400MG;80MG | A072408 | 001 | Dec 07, 1988 |
| MUTUAL PHARM | 400MG;80MG | A070006 | 001 | Nov 14, 1984 |
| PLIVA | 400MG;80MG | A070215 | 001 | Sep 10, 1985 |
| | 800MG;160MG | A070216 | 001 | Sep 10, 1985 |
| ROXANE | 400MG;80MG | A072768 | 001 | Aug 30, 1991 |
| SANDOZ | 400MG;80MG | A070889 | 001 | Nov 13, 1986 |
| | 400MG;80MG | N018598 | 003 | May 19, 1982 |
| | 800MG;160MG | A070890 | 001 | Nov 13, 1986 |
| TEVA | 400MG;80MG | N018242 | 001 | |
| | 800MG;160MG | N018242 | 002 | |
| USL PHARMA | 400MG;80MG | A070203 | 001 | Nov 08, 1985 |
| | 800MG;160MG | A070204 | 001 | Nov 08, 1985 |
| WATSON LABS | 400MG;80MG | A070002 | 001 | Nov 07, 1984 |
| | 400MG;80MG | N018852 | 001 | May 09, 1983 |
| | 800MG;160MG | A070000 | 001 | Nov 07, 1984 |
| SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH | | | | |
| MARTEC USA LLC | 800MG;160MG | A072417 | 001 | Dec 07, 1988 |
| MUTUAL PHARM | 800MG;160MG | A070007 | 001 | Nov 14, 1984 |
| ROXANE | 800MG;160MG | A072769 | 001 | Aug 30, 1991 |
| SANDOZ | 800MG;160MG | N018598 | 004 | May 19, 1982 |
| WATSON LABS | 800MG;160MG | N018854 | 001 | May 09, 1983 |
| SULFATRIM-DS | | | | |
| SUPERPHARM | 800MG;160MG | A070066 | 001 | Jun 24, 1985 |
| SULFATRIM-SS | | | | |
| SUPERPHARM | 400MG;80MG | A070065 | 002 | Jun 24, 1985 |
| UROPLUS DS | | | | |
| SHIONOGI | 800MG;160MG | A071816 | 001 | Sep 28, 1987 |
| UROPLUS SS | | | | |
| SHIONOGI | 400MG;80MG | A071815 | 001 | Sep 28, 1987 |
| SULFANILAMIDE | | | | |
| CREAM;VAGINAL | | | | |
| SULFANILAMIDE | | | | |
| G AND W LABS INC | 15% | A088718 | 001 | Sep 19, 1985 |
| SUPPOSITORY;VAGINAL | | | | |
| AVC | | | | |
| MYLAN SPECIALITY LP | 1.05GM | N006530 | 004 | Jan 27, 1987 |
| SULFAPHENAZOLE | | | | |
| SUSPENSION;ORAL | | | | |
| SULFABID | | | | |
| PHARM RES ASSOC | 500MG/5ML | N013093 | 001 | |
| TABLET;ORAL | | | | |
| SULFABID | | | | |
| PURDUE FREDERICK | 500MG | N013092 | 002 | |
| SULFAPYRIDINE | | | | |
| TABLET;ORAL | | | | |
| SULFAPYRIDINE | | | | |
| LILLY | 500MG | N000159 | 001 | |
| SULFASALAZINE | | | | |
| SUSPENSION;ORAL | | | | |
| AZULFIDINE | | | | |
| PHARMACIA AND UPJOHN | 250MG/5ML | N018605 | 001 | |
| TABLET;ORAL | | | | |
| S.A.S.-500 | | | | |
| SOLVAY | 500MG | A083450 | 001 | |

SULFASALAZINE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| SULFASALAZINE | | | | |
| HERITAGE PHARMS INC | 500MG | A080197 | 001 | |
| SANDOZ | 500MG | A086184 | 001 | |
| SUN PHARM INDUSTRIES | 500MG | A089590 | 001 | Oct 19, 1987 |
| SUPERPHARM | 500MG | A089339 | 001 | Oct 26, 1987 |
| WATSON LABS | 500MG | A084964 | 001 | |
| | 500MG | A087197 | 001 | |
| TABLET, DELAYED RELEASE;ORAL | | | | |
| SULFASALAZINE | | | | |
| WATSON LABS | 500MG | A088052 | 001 | May 24, 1983 |

SULFINPYRAZONE

| | | | | |
|---|---|---|---|---|
| CAPSULE;ORAL | | | | |
| ANTURANE | | | | |
| + NOVARTIS | 200MG ** | N011556 | 004 | |
| SULFINPYRAZONE | | | | |
| BARR | 200MG | A087666 | 001 | Sep 17, 1982 |
| IVAX PHARMS | 200MG | A087770 | 001 | Nov 19, 1982 |
| PAR PHARM | 200MG | A088934 | 001 | Sep 06, 1985 |
| VANGARD | 200MG | A088666 | 001 | Feb 17, 1984 |
| TABLET;ORAL | | | | |
| ANTURANE | | | | |
| NOVARTIS | 100MG ** | N011556 | 003 | |
| SULFINPYRAZONE | | | | |
| BARR | 100MG | A087665 | 001 | Sep 17, 1982 |
| IVAX PHARMS | 100MG | A087769 | 001 | Jun 01, 1982 |
| PAR PHARM | 100MG | A088933 | 001 | Sep 06, 1985 |
| WATSON LABS | 100MG | A087667 | 001 | May 26, 1982 |

SULFISOXAZOLE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| GANTRISIN | | | | |
| ROCHE | 500MG | N006525 | 001 | |
| SOSOL | | | | |
| MK LABS | 500MG | A080036 | 001 | |
| SOXAZOLE | | | | |
| ALRA | 500MG | A080366 | 001 | |
| SULFALAR | | | | |
| PARKE DAVIS | 500MG | A084955 | 001 | |
| SULFISOXAZOLE | | | | |
| ANI PHARMS INC | 500MG | A080142 | 001 | |
| AUROLIFE PHARMA LLC | 500MG | A085628 | 001 | |
| BARR | 500MG | A084031 | 001 | |
| HEATHER | 500MG | A080189 | 001 | |
| IMPAX LABS | 500MG | A080109 | 001 | |
| LANNETT | 500MG | A080085 | 001 | |
| LEDERLE | 500MG | A087649 | 001 | |
| PHARMERAL | 500MG | A084385 | 001 | |
| PUREPAC PHARM | 500MG | A080087 | 001 | |
| ROXANE | 500MG | A080082 | 001 | |
| VALEANT PHARM INTL | 500MG | A080268 | 002 | |
| VITARINE | 500MG | A087332 | 001 | |
| WATSON LABS | 500MG | A085534 | 001 | |
| WEST WARD | 500MG | A080379 | 001 | |
| SULSOXIN | | | | |
| SOLVAY | 500MG | A080040 | 001 | |

SULFISOXAZOLE ACETYL

| | | | | |
|---|---|---|---|---|
| EMULSION;ORAL | | | | |
| LIPO GANTRISIN | | | | |
| ROCHE | EQ 1GM BASE/5ML | N009182 | 009 | |
| SUSPENSION;ORAL | | | | |
| GANTRISIN PEDIATRIC | | | | |
| ROCHE | EQ 500MG BASE/5ML | N009182 | 004 | |
| SYRUP;ORAL | | | | |
| GANTRISIN | | | | |
| ROCHE | EQ 500MG BASE/5ML | N009182 | 002 | |

| | | | | |
|---|---|---|---|---|
| SULFISOXAZOLE DIOLAMINE | | | | |
| INJECTABLE;INJECTION | | | | |
| GANTRISIN | | | | |
| ROCHE | EQ 400MG BASE/ML | N006917 | 001 | |
| OINTMENT;OPHTHALMIC | | | | |
| GANTRISIN | | | | |
| ROCHE | EQ 4% BASE | N008414 | 002 | |
| SOLUTION/DROPS;OPHTHALMIC | | | | |
| GANTRISIN | | | | |
| ROCHE | EQ 4% BASE | N007757 | 002 | |
| SULFISOXAZOLE DIOLAMINE | | | | |
| SOLA BARNES HIND | EQ 4% BASE | A084148 | 001 | |
| SULFOXONE SODIUM | | | | |
| TABLET, DELAYED RELEASE;ORAL | | | | |
| DIASONE SODIUM | | | | |
| ABBVIE | 165MG | N006044 | 003 | |
| SULFUR | | | | |
| POWDER;TOPICAL | | | | |
| BENSULFOID | | | | |
| POYTHRESS | 33.32% | N002918 | 001 | |
| SULINDAC | | | | |
| TABLET;ORAL | | | | |
| CLINORIL | | | | |
| + MERCK | 150MG ** | N017911 | 001 | |
| + | 200MG ** | N017911 | 002 | |
| SULINDAC | | | | |
| ANI PHARMS INC | 150MG | A072972 | 001 | Feb 28, 1992 |
| | 200MG | A072973 | 001 | Feb 28, 1992 |
| SANDOZ | 150MG | A072712 | 001 | Aug 30, 1991 |
| | 200MG | A072713 | 001 | Aug 30, 1991 |
| SUMATRIPTAN | | | | |
| SPRAY;NASAL | | | | |
| IMITREX | | | | |
| GLAXOSMITHKLINE | 10MG/SPRAY | N020626 | 002 | Aug 26, 1997 |
| SUMATRIPTAN SUCCINATE | | | | |
| INJECTABLE;SUBCUTANEOUS | | | | |
| ALSUMA | | | | |
| MERIDIAN MEDCL | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | N022377 | 001 | Jun 29, 2010 |
| SUMATRIPTAN SUCCINATE | | | | |
| FRESENIUS KABI USA | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A079240 | 002 | Sep 18, 2009 |
| | EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) | A079240 | 001 | Sep 18, 2009 |
| SANDOZ INC | EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) | A078067 | 002 | Feb 06, 2009 |
| | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A078067 | 001 | Feb 06, 2009 |
| TEVA PARENTERAL | EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) | A078318 | 001 | Feb 06, 2009 |
| | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | A078318 | 002 | Feb 06, 2009 |
| SYSTEM;IONTOPHORESIS | | | | |
| ZECUITY | | | | |
| + TEVA BRANDED PHARM | EQ 6.5MG BASE/4HR | N202278 | 001 | Jan 17, 2013 |
| TABLET;ORAL | | | | |
| SUMATRIPTAN SUCCINATE | | | | |
| HIKMA PHARMS | EQ 25MG BASE | A078298 | 001 | May 21, 2013 |
| | EQ 50MG BASE | A078298 | 002 | May 21, 2013 |
| | EQ 100MG BASE | A078298 | 003 | May 21, 2013 |
| MYLAN | EQ 25MG BASE | A077163 | 001 | Nov 02, 2009 |
| | EQ 50MG BASE | A077163 | 002 | Nov 02, 2009 |
| | EQ 100MG BASE | A077163 | 003 | Nov 02, 2009 |
| ROXANE | EQ 25MG BASE | A078241 | 001 | Aug 10, 2009 |
| | EQ 50MG BASE | A078241 | 002 | Aug 10, 2009 |
| | EQ 100MG BASE | A078241 | 003 | Aug 10, 2009 |
| SANDOZ | EQ 25MG BASE | A076976 | 001 | Aug 10, 2009 |
| | EQ 50MG BASE | A076976 | 002 | Aug 10, 2009 |
| | EQ 100MG BASE | A076976 | 003 | Aug 10, 2009 |
| TEVA | EQ 25MG BASE | A076840 | 001 | Feb 09, 2009 |
| | EQ 50MG BASE | A076840 | 002 | Feb 09, 2009 |
| | EQ 100MG BASE | A076840 | 003 | Feb 09, 2009 |

SUPROFEN
SOLUTION/DROPS;OPHTHALMIC
PROFENAL

| | | | | | |
|---|---|---|---|---|---|
| | ALCON | 1% | N019387 | 001 | Dec 23, 1988 |

SUTILAINS
OINTMENT;TOPICAL
TRAVASE

| | | | | | |
|---|---|---|---|---|---|
| + | ABBOTT | 82,000 UNITS/GM ** | N012828 | 001 | |

TACRINE HYDROCHLORIDE
CAPSULE;ORAL
COGNEX

| | | | | | |
|---|---|---|---|---|---|
| | SHIONOGI INC | EQ 10MG BASE | N020070 | 001 | Sep 09, 1993 |
| | | EQ 20MG BASE | N020070 | 002 | Sep 09, 1993 |
| | | EQ 30MG BASE | N020070 | 003 | Sep 09, 1993 |
| | | EQ 40MG BASE | N020070 | 004 | Sep 09, 1993 |

TACROLIMUS
CAPSULE;ORAL
TACROLIMUS

| | | | | | |
|---|---|---|---|---|---|
| | WATSON LABS | EQ 5MG BASE | A090402 | 001 | Jul 01, 2010 |

TALBUTAL
TABLET;ORAL
LOTUSATE

| | | | | | |
|---|---|---|---|---|---|
| | SANOFI AVENTIS US | 120MG | N009410 | 005 | |

TAMOXIFEN CITRATE
TABLET;ORAL
NOLVADEX

| | | | | | |
|---|---|---|---|---|---|
| + | ASTRAZENECA | EQ 10MG BASE ** | N017970 | 001 | |
| + | | EQ 20MG BASE ** | N017970 | 002 | Mar 21, 1994 |

TAMOXIFEN CITRATE

| | | | | | |
|---|---|---|---|---|---|
| | ACTAVIS LABS FL INC | EQ 10MG BASE | A076179 | 001 | Feb 20, 2003 |
| | | EQ 20MG BASE | A076179 | 002 | Feb 20, 2003 |
| | AEGIS PHARMS | EQ 10MG BASE | A076398 | 001 | Mar 31, 2003 |
| | | EQ 20MG BASE | A076398 | 002 | Mar 31, 2003 |
| | IVAX SUB TEVA PHARMS | EQ 10MG BASE | A075740 | 001 | Feb 20, 2003 |
| | | EQ 20MG BASE | A075740 | 002 | Feb 20, 2003 |
| | PHARMACHEMIE | EQ 10MG BASE | A074539 | 001 | Mar 31, 2003 |
| | ROXANE | EQ 10MG BASE | A076027 | 001 | Feb 20, 2003 |
| | | EQ 20MG BASE | A076027 | 002 | Feb 20, 2003 |
| | TEVA | EQ 10MG BASE | A074504 | 001 | Apr 28, 2003 |
| | | EQ 20MG BASE | A074504 | 002 | Apr 28, 2003 |

TECHNETIUM TC-99M ALBUMIN AGGREGATED
INJECTABLE;INJECTION
TC 99M-LUNGAGGREGATE

| | | | | | |
|---|---|---|---|---|---|
| | GE HEALTHCARE | 5mCi/ML | N017848 | 001 | |

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
INJECTABLE;INJECTION
A-N STANNOUS AGGREGATED ALBUMIN

| | | | | | |
|---|---|---|---|---|---|
| | SYNCOR PHARMS | N/A | N017916 | 001 | |

AN-MAA

| | | | | | |
|---|---|---|---|---|---|
| | PHARMALUCENCE | N/A | N017792 | 001 | |

LUNGAGGREGATE REAGENT

| | | | | | |
|---|---|---|---|---|---|
| | GE HEALTHCARE | N/A | N017838 | 001 | |

MACROTEC

| | | | | | |
|---|---|---|---|---|---|
| | BRACCO | N/A | N017833 | 001 | |

TECHNESCAN MAA

| | | | | | |
|---|---|---|---|---|---|
| | MALLINCKRODT | N/A | N017842 | 001 | |

TECHNETIUM TC 99M MAA

| | | | | | |
|---|---|---|---|---|---|
| | GE HEALTHCARE | N/A | N017773 | 001 | |

TECHNETIUM TC-99M ALBUMIN COLLOID KIT
INJECTABLE;INJECTION
MICROLITE

| | | | | | |
|---|---|---|---|---|---|
| | PHARMALUCENCE | N/A | N018263 | 001 | Mar 25, 1983 |

TECHNETIUM TC-99M ALBUMIN KIT
INJECTABLE;INJECTION
TECHNETIUM TC 99M HSA
GE HEALTHCARE N/A N017775 001

TECHNETIUM TC-99M ALBUMIN MICROSPHERES KIT
INJECTABLE;INJECTION
INSTANT MICROSPHERES
3M N/A N017832 001

TECHNETIUM TC-99M APCITIDE
INJECTABLE;INJECTION
ACUTECT
CIS BIO INTL SA N/A N020887 001 Sep 14, 1998

TECHNETIUM TC-99M DEPREOTIDE
INJECTABLE;INJECTION
NEO TECT KIT
CIS BIO INTL SA N/A N021012 001 Aug 03, 1999

TECHNETIUM TC-99M ETIDRONATE KIT
INJECTABLE;INJECTION
CINTICHEM TECHNETIUM 99M HEDSPA
GE HEALTHCARE N/A N017653 001
MPI STANNOUS DIPHOSPHONATE
GE HEALTHCARE N/A N017667 001
OSTEOSCAN
MALLINCKRODT N/A N017454 001
TECHNETIUM TC 99M DIPHOSPHONATE-TIN KIT
GE HEALTHCARE N/A N017562 001

TECHNETIUM TC-99M FERPENTETATE KIT
INJECTABLE;INJECTION
RENOTEC
BRACCO N/A N017045 001

TECHNETIUM TC-99M GLUCEPTATE KIT
INJECTABLE;INJECTION
GLUCOSCAN
BRISTOL MYERS SQUIBB N/A N017907 001
TECHNESCAN GLUCEPTATE
DRAXIMAGE N/A N018272 001 Jan 27, 1982

TECHNETIUM TC-99M LIDOFENIN KIT
INJECTABLE;INJECTION
TECHNESCAN HIDA
DRAXIMAGE N/A N018489 001 Oct 31, 1986

TECHNETIUM TC-99M MEDRONATE
INJECTABLE;INJECTION
DRAXIMAGE MDP-10
JUBILANT DRAXIMAGE N/A N018035 001

TECHNETIUM TC-99M MEDRONATE KIT
INJECTABLE;INJECTION
AMERSCAN MDP KIT
GE HEALTHCARE N/A N018335 001 Aug 05, 1982
OSTEOLITE
PHARMALUCENCE N/A N017972 001
TECHNETIUM TC 99M MPI MDP
GE HEALTHCARE N/A N018141 001
N/A N018141 002 Jun 12, 1989

TECHNETIUM TC-99M PENTETATE KIT
INJECTABLE;INJECTION
AN-DTPA
JUBILANT DRAXIMAGE N/A N017714 001
MPI DTPA KIT - CHELATE
GE HEALTHCARE N/A N017255 001
TECHNETIUM TC-99M PENTETATE KIT
GE HEALTHCARE N/A N017264 002

TECHNETIUM TC-99M POLYPHOSPHATE KIT
INJECTABLE;INJECTION
SODIUM POLYPHOSPHATE-TIN KIT

| | | | | |
|---|---|---|---|---|
| | GE HEALTHCARE | N/A | N017664 001 | |

TECHNETIUM TC-99M PYRO/TRIMETA PHOSPHATES KIT
INJECTABLE;INJECTION
PYROLITE

| | | | | |
|---|---|---|---|---|
| | PHARMALUCENCE | N/A | N017684 001 | |

TECHNETIUM TC-99M PYROPHOSPHATE KIT
INJECTABLE;INJECTION
PHOSPHOTEC

| | | | | |
|---|---|---|---|---|
| | BRACCO | N/A | N017680 001 | |

TECHNETIUM TC-99M RED BLOOD CELL KIT
INJECTABLE;INJECTION
RBC-SCAN

| | | | | |
|---|---|---|---|---|
| | CADEMA | N/A | N020063 001 | Jun 11, 1992 |

TECHNETIUM TC-99M SESTAMIBI KIT
INJECTABLE;INJECTION
MIRALUMA

| | | | | |
|---|---|---|---|---|
| | LANTHEUS MEDCL | N/A | N019785 003 | May 23, 1997 |

TECHNETIUM TC-99M SODIUM PERTECHNETATE
SOLUTION;INJECTION, ORAL
SODIUM PERTECHNETATE TC 99M

| | | | | |
|---|---|---|---|---|
| + | GE HEALTHCARE | 2-100mCi/ML ** | N017471 001 | |
| + | MALLINCKRODT | 10-60mCi/ML ** | N017725 001 | |
| | PHARMALUCENCE | 12mCi/ML | N017321 001 | |
| | | 24mCi/ML | N017321 002 | |
| | | 48mCi/ML | N017321 003 | |

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
SOLUTION;INJECTION, ORAL
MINITEC

| | | | | |
|---|---|---|---|---|
| | BRACCO | 0.22-2.22 CI/GENERATOR | N017339 001 | |

SOLUTION;INTRAVENOUS
TECHNELITE

| | | | | |
|---|---|---|---|---|
| | LANTHEUS MEDCL | 0.0083-2.7 CI/GENERATOR | N017771 001 | |

ULTRA-TECHNEKOW FM

| | | | | |
|---|---|---|---|---|
| | MALLINKRODT NUCLEAR | 0.25-3 CI/GENERATOR | N017243 002 | |

SOLUTION;INTRAVENOUS, ORAL
TECHNETIUM TC 99M GENERATOR

| | | | | |
|---|---|---|---|---|
| | GE HEALTHCARE | 830-16600mCi/GENERATOR | N017693 001 | |

TECHNETIUM TC-99M SUCCIMER KIT
INJECTABLE;INJECTION
MPI DMSA KIDNEY REAGENT

| | | | | |
|---|---|---|---|---|
| | GE HEALTHCARE | N/A | N017944 001 | May 18, 1982 |

TECHNETIUM TC-99M SULFUR COLLOID
SOLUTION;INJECTION, ORAL
TECHNETIUM TC 99M SULFUR COLLOID

| | | | | |
|---|---|---|---|---|
| | GE HEALTHCARE | 4mCi/ML | N017456 001 | |

SOLUTION;ORAL
TECHNETIUM TC 99M SULFUR COLLOID

| | | | | |
|---|---|---|---|---|
| | MALLINCKRODT | 3mCi/ML | N017724 001 | |

TECHNETIUM TC-99M SULFUR COLLOID KIT
SOLUTION;INJECTION, ORAL
TECHNECOLL

| | | | | |
|---|---|---|---|---|
| | MALLINCKRODT | N/A | N017059 001 | |

TECHNETIUM TC 99M TSC

| | | | | |
|---|---|---|---|---|
| | GE HEALTHCARE | N/A | N017784 001 | |

TESULOID

| | | | | |
|---|---|---|---|---|
| | BRACCO | N/A | N016923 001 | |

| | | | | | |
|---|---|---|---|---|---|
| TECHNETIUM TC-99M TEBOROXIME KIT | | | | | |
| INJECTABLE;INJECTION | | | | | |
| CARDIOTEC | | | | | |
| | BRACCO | N/A | N019928 | 001 | Dec 19, 1990 |
| TECHNETIUM TC-99M TETROFOSMIN KIT | | | | | |
| INJECTABLE;INJECTION | | | | | |
| MYOVIEW | | | | | |
| + | GE HEALTHCARE | N/A | N020372 | 001 | Feb 09, 1996 |
| TEGASEROD MALEATE | | | | | |
| TABLET;ORAL | | | | | |
| ZELNORM | | | | | |
| | US WORLDMEDS LLC | EQ 2MG BASE | N021200 | 001 | Jul 24, 2002 |
| | | EQ 6MG BASE | N021200 | 002 | Jul 24, 2002 |
| TELAPREVIR | | | | | |
| TABLET;ORAL | | | | | |
| INCIVEK | | | | | |
| | VERTEX PHARMS | 375MG | N201917 | 001 | May 23, 2011 |
| TELAVANCIN HYDROCHLORIDE | | | | | |
| POWDER;IV (INFUSION) | | | | | |
| VIBATIV | | | | | |
| + | THERAVANCE BIOPHARMA | EQ 250MG BASE/VIAL | N022110 | 001 | Sep 11, 2009 |
| TELBIVUDINE | | | | | |
| SOLUTION;ORAL | | | | | |
| TYZEKA | | | | | |
| | NOVARTIS | 100MG/5ML | N022154 | 001 | Apr 28, 2009 |
| TABLET;ORAL | | | | | |
| TYZEKA | | | | | |
| + | NOVARTIS | 600MG | N022011 | 001 | Oct 25, 2006 |
| TELITHROMYCIN | | | | | |
| TABLET;ORAL | | | | | |
| KETEK | | | | | |
| | SANOFI AVENTIS US | 300MG | N021144 | 002 | Feb 09, 2005 |
| | | 400MG | N021144 | 001 | Apr 01, 2004 |
| TEMAZEPAM | | | | | |
| CAPSULE;ORAL | | | | | |
| TEMAZ | | | | | |
| | QUANTUM PHARMICS | 15MG | A070564 | 001 | Oct 15, 1985 |
| | | 30MG | A070547 | 001 | Oct 15, 1985 |
| TEMAZEPAM | | | | | |
| | DURAMED PHARMS BARR | 15MG | A071708 | 001 | Sep 29, 1988 |
| | | 30MG | A071709 | 001 | Sep 29, 1988 |
| | SUN PHARM INDUSTRIES | 15MG | A071174 | 001 | Jul 10, 1986 |
| | | 30MG | A071175 | 001 | Jul 10, 1986 |
| | USL PHARMA | 15MG | A070489 | 001 | Jul 07, 1986 |
| | | 30MG | A070490 | 001 | Jul 07, 1986 |
| | WATSON LABS | 15MG | A070383 | 001 | Mar 23, 1987 |
| | | 15MG | A071446 | 001 | May 21, 1993 |
| | | 30MG | A070384 | 001 | Mar 23, 1987 |
| | | 30MG | A071447 | 001 | May 21, 1993 |
| TENIPOSIDE | | | | | |
| INJECTABLE;INJECTION | | | | | |
| VUMON | | | | | |
| + | HQ SPECLT PHARMA | 10MG/ML | N020119 | 001 | Jul 14, 1992 |
| TERAZOSIN HYDROCHLORIDE | | | | | |
| CAPSULE;ORAL | | | | | |
| HYTRIN | | | | | |
| + | ABBOTT | EQ 1MG BASE ** | N020347 | 001 | Dec 14, 1994 |
| + | | EQ 2MG BASE ** | N020347 | 002 | Dec 14, 1994 |
| + | | EQ 5MG BASE ** | N020347 | 003 | Dec 14, 1994 |
| + | | EQ 10MG BASE ** | N020347 | 004 | Dec 14, 1994 |
| TERAZOSIN HYDROCHLORIDE | | | | | |
| | MYLAN TECHNOLOGIES | EQ 1MG BASE | A075384 | 001 | Dec 01, 2000 |
| | | EQ 2MG BASE | A075384 | 002 | Dec 01, 2000 |
| | | EQ 5MG BASE | A075384 | 003 | Dec 01, 2000 |
| | | EQ 10MG BASE | A075384 | 004 | Dec 01, 2000 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| TERAZOSIN HYDROCHLORIDE | | | | |
| CAPSULE;ORAL | | | | |
| TERAZOSIN HYDROCHLORIDE | | | | |
| RANBAXY LABS LTD | EQ 1MG BASE | A076021 | 001 | Aug 22, 2002 |
| | EQ 2MG BASE | A076021 | 002 | Aug 22, 2002 |
| | EQ 5MG BASE | A076021 | 003 | Aug 22, 2002 |
| | EQ 10MG BASE | A076021 | 004 | Aug 22, 2002 |
| SANDOZ | EQ 1MG BASE | A075667 | 001 | Jul 28, 2000 |
| | EQ 2MG BASE | A075667 | 002 | Jul 28, 2000 |
| | EQ 5MG BASE | A075667 | 003 | Jul 28, 2000 |
| | EQ 10MG BASE | A075667 | 004 | Jul 28, 2000 |
| TABLET;ORAL | | | | |
| HYTRIN | | | | |
| ABBOTT | EQ 1MG BASE | N019057 | 001 | Aug 07, 1987 |
| | EQ 2MG BASE | N019057 | 002 | Aug 07, 1987 |
| | EQ 5MG BASE | N019057 | 003 | Aug 07, 1987 |
| | EQ 10MG BASE | N019057 | 004 | Aug 07, 1987 |
| TERAZOSIN HYDROCHLORIDE | | | | |
| IVAX SUB TEVA PHARMS | EQ 1MG BASE | A074530 | 001 | Apr 21, 2000 |
| | EQ 2MG BASE | A074530 | 002 | Apr 21, 2000 |
| | EQ 5MG BASE | A074530 | 003 | Apr 21, 2000 |
| | EQ 10MG BASE | A074530 | 004 | Apr 21, 2000 |
| SANDOZ | EQ 1MG BASE | A074315 | 001 | Dec 31, 1998 |
| | EQ 1MG BASE | A074657 | 001 | Apr 28, 2000 |
| | EQ 2MG BASE | A074315 | 002 | Dec 31, 1998 |
| | EQ 2MG BASE | A074657 | 002 | Apr 28, 2000 |
| | EQ 5MG BASE | A074315 | 003 | Dec 31, 1998 |
| | EQ 5MG BASE | A074657 | 003 | Apr 28, 2000 |
| | EQ 10MG BASE | A074315 | 004 | Dec 31, 1998 |
| | EQ 10MG BASE | A074657 | 004 | Apr 28, 2000 |
| TEVA | EQ 1MG BASE | A074446 | 001 | May 18, 2000 |
| | EQ 2MG BASE | A074446 | 002 | May 18, 2000 |
| | EQ 5MG BASE | A074446 | 003 | May 18, 2000 |
| | EQ 10MG BASE | A074446 | 004 | May 18, 2000 |
| TERBINAFINE | | | | |
| GEL;TOPICAL | | | | |
| LAMISIL | | | | |
| GLAXOSMITHKLINE CONS | 1% | N020846 | 001 | Apr 29, 1998 |
| TERBINAFINE HYDROCHLORIDE | | | | |
| CREAM;TOPICAL | | | | |
| LAMISIL | | | | |
| NOVARTIS | 1% | N020192 | 001 | Dec 30, 1992 |
| GRANULE;ORAL | | | | |
| LAMISIL | | | | |
| + NOVARTIS | EQ 125MG BASE/PACKET | N022071 | 001 | Sep 28, 2007 |
| + | EQ 187.5MG BASE/PACKET | N022071 | 002 | Sep 28, 2007 |
| SOLUTION;TOPICAL | | | | |
| LAMISIL | | | | |
| GLAXOSMITHKLINE CONS | 1% | N020749 | 001 | Oct 17, 1997 |
| TABLET;ORAL | | | | |
| TERBINAFINE HYDROCHLORIDE | | | | |
| GEDEON RICHTER USA | EQ 250MG BASE | A077065 | 001 | Jul 02, 2007 |
| MYLAN | EQ 250MG BASE | A077136 | 001 | Jul 02, 2007 |
| | EQ 250MG BASE | A077195 | 001 | Jul 02, 2007 |
| ROXANE | EQ 250MG BASE | A077223 | 001 | Jul 02, 2007 |
| WOCKHARDT | EQ 250MG BASE | A078229 | 001 | Jul 02, 2007 |
| TERBUTALINE SULFATE | | | | |
| AEROSOL, METERED;INHALATION | | | | |
| BRETHAIRE | | | | |
| NOVARTIS | 0.2MG/INH | N018762 | 001 | Aug 17, 1984 |
| BRICANYL | | | | |
| SANOFI AVENTIS US | 0.2MG/INH | N018000 | 001 | Mar 19, 1985 |
| INJECTABLE;INJECTION | | | | |
| BRETHINE | | | | |
| + PHARMACARE | 1MG/ML ** | N018571 | 001 | |
| BRICANYL | | | | |
| SANOFI AVENTIS US | 1MG/ML | N017466 | 001 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| TERBUTALINE SULFATE | | | | |
| INJECTABLE;INJECTION | | | | |
| TERBUTALINE SULFATE | | | | |
| | TEVA PHARMS USA | 1MG/ML | A076853 001 | Jul 20, 2004 |
| TABLET;ORAL | | | | |
| BRETHINE | | | | |
| + | ANI PHARMS INC | 2.5MG ** | N017849 001 | |
| + | | 5MG ** | N017849 002 | |
| BRICANYL | | | | |
| | SANOFI AVENTIS US | 2.5MG | N017618 001 | |
| | | 5MG | N017618 002 | |
| TERCONAZOLE | | | | |
| CREAM;VAGINAL | | | | |
| TERAZOL 3 | | | | |
| + | JANSSEN PHARMS | 0.8% | N019964 001 | Feb 21, 1991 |
| SUPPOSITORY;VAGINAL | | | | |
| TERCONAZOLE | | | | |
| | FOUGERA PHARMS | 80MG | A076850 001 | Jul 12, 2006 |
| TERIPARATIDE ACETATE | | | | |
| INJECTABLE;INJECTION | | | | |
| PARATHAR | | | | |
| | SANOFI AVENTIS US | 200 UNITS/VIAL | N019498 001 | Dec 23, 1987 |
| TERIPARATIDE RECOMBINANT HUMAN | | | | |
| INJECTABLE;SUBCUTANEOUS | | | | |
| FORTEO | | | | |
| | LILLY | 0.75MG/3ML (0.25MG/ML) | N021318 001 | Nov 26, 2002 |
| TESAMORELIN ACETATE | | | | |
| POWDER;SUBCUTANEOUS | | | | |
| EGRIFTA | | | | |
| | THERATECHNOLOGIES | EQ 2MG BASE/VIAL | N022505 002 | Nov 29, 2011 |
| TESTOLACTONE | | | | |
| INJECTABLE;INJECTION | | | | |
| TESLAC | | | | |
| | BRISTOL MYERS SQUIBB | 100MG/ML | N016119 001 | |
| TABLET;ORAL | | | | |
| TESLAC | | | | |
| | BRISTOL MYERS SQUIBB | 50MG | N016118 001 | |
| | | 250MG | N016118 002 | |
| TESTOSTERONE | | | | |
| FILM, EXTENDED RELEASE;TRANSDERMAL | | | | |
| ANDRODERM | | | | |
| | ALLERGAN SALES LLC | 2.5MG/24HR | N020489 001 | Sep 29, 1995 |
| | | 5MG/24HR | N020489 002 | May 02, 1997 |
| TESTODERM | | | | |
| | ALZA | 4MG/24HR | N019762 001 | Oct 12, 1993 |
| | | 6MG/24HR | N019762 002 | Oct 12, 1993 |
| TESTODERM TTS | | | | |
| | ALZA | 5MG/24HR | N020791 001 | Dec 18, 1997 |
| INJECTABLE;INJECTION | | | | |
| TESTOSTERONE | | | | |
| | WATSON LABS | 25MG/ML | A086420 001 | May 10, 1983 |
| | | 50MG/ML | A086419 001 | Aug 23, 1983 |
| | | 100MG/ML | A086417 001 | Jul 07, 1983 |
| SOLUTION, METERED;TRANSDERMAL | | | | |
| AXIRON | | | | |
| + | ELI LILLY AND CO | 30MG/1.5ML ACTUATION | N022504 001 | Nov 23, 2010 |
| TESTOSTERONE CYPIONATE | | | | |
| INJECTABLE;INJECTION | | | | |
| DEPO-TESTOSTERONE | | | | |
| | PHARMACIA AND UPJOHN | 50MG/ML | A085635 001 | |
| TESTOSTERONE CYPIONATE | | | | |
| | WATSON LABS | 100MG/ML | A084401 001 | |
| | | 100MG/ML | A086029 001 | |
| | | 200MG/ML | A084401 002 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | |
|---|---|---|
| TESTOSTERONE ENANTHATE | | |
| INJECTABLE;INJECTION | | |
| DELATESTRYL | | |
| ENDO PHARMS | 200MG/ML | N009165 001 |
| TESTOSTERONE ENANTHATE | | |
| WATSON LABS | 100MG/ML | A083667 001 |
| | 100MG/ML | A085599 001 |
| | 200MG/ML | A083667 002 |
| TESTOSTERONE PROPIONATE | | |
| INJECTABLE;INJECTION | | |
| TESTOSTERONE PROPIONATE | | |
| BEL MAR | 25MG/ML | A080741 001 |
| | 50MG/ML | A080742 001 |
| | 100MG/ML | A080743 001 |
| ELKINS SINN | 25MG/ML | A080276 001 |
| LILLY | 50MG/ML | A080254 002 |
| WATSON LABS | 25MG/ML | A080188 001 |
| | 25MG/ML | A085490 001 |
| | 50MG/ML | A080188 002 |
| | 50MG/ML | A085490 002 |
| | 100MG/ML | A080188 003 |
| | 100MG/ML | A083595 003 |
| TETRACYCLINE HYDROCHLORIDE | | |
| CAPSULE;ORAL | | |
| BRISTACYCLINE | | |
| BRISTOL | 250MG | A061658 001 |
| | 250MG | A061888 001 |
| | 500MG | A061658 002 |
| | 500MG | A061888 002 |
| CYCLOPAR | | |
| WARNER CHILCOTT | 250MG | A061725 001 |
| | 250MG | A062175 001 |
| | 250MG | A062332 001 |
| | 500MG | A061725 002 |
| | 500MG | A062332 002 |
| PANMYCIN | | |
| PHARMACIA AND UPJOHN | 250MG | A060347 001 |
| RETET | | |
| SOLVAY | 250MG | A061443 001 |
| | 500MG | A061443 002 |
| ROBITET | | |
| WYETH AYERST | 250MG | A061734 001 |
| | 500MG | A061734 002 |
| SUMYCIN | | |
| APOTHECON | 100MG | A060429 002 |
| | 125MG | A060429 004 |
| | 250MG | A060429 001 |
| | 500MG | A060429 003 |
| TETRACHEL | | |
| ANGUS | 250MG | A060343 001 |
| | 500MG | A060343 003 |
| TETRACYCLINE HYDROCHLORIDE | | |
| ABBOTT | 250MG | A061802 001 |
| | 500MG | A061802 002 |
| ELKINS SINN | 250MG | A060059 001 |
| FERRANTE | 125MG | A060173 001 |
| | 250MG | A060173 002 |
| HEATHER | 250MG | A061148 001 |
| | 500MG | A061148 002 |
| HIKMA PHARMS | 250MG | A060768 001 |
| | 500MG | A060768 002 |
| IDT AUSTRALIA LTD | 250MG | A061471 001 |
| IMPAX LABS | 100MG | A060469 002 |
| | 250MG | A060469 001 |
| | 500MG | A060469 003 |
| IVAX SUB TEVA PHARMS | 250MG | A060704 001 |
| | 500MG | A060704 002 |
| MAST MM | 250MG | A062085 001 |

| | | | | |
|---|---|---|---|---|
| TETRACYCLINE HYDROCHLORIDE | | | | |
| CAPSULE;ORAL | | | | |
| TETRACYCLINE HYDROCHLORIDE | | | | |
| MYLAN | 250MG | A060783 | 001 | |
| | 500MG | A060783 | 002 | |
| PUREPAC PHARM | 250MG | A060290 | 001 | |
| | 500MG | A060290 | 002 | |
| PVT FORM | 250MG | A062686 | 001 | Jul 24, 1986 |
| | 500MG | A062686 | 002 | Jul 24, 1986 |
| ROXANE | 500MG | A061214 | 002 | |
| SUN PHARM INDUSTRIES | 250MG | A060736 | 001 | |
| | 500MG | A060736 | 002 | |
| SUPERPHARM | 250MG | A062540 | 001 | Mar 21, 1985 |
| | 500MG | A062540 | 002 | Mar 21, 1985 |
| VALEANT PHARM INTL | 250MG | A060471 | 001 | |
| | 500MG | A060471 | 002 | |
| WARNER CHILCOTT | 250MG | A062300 | 001 | |
| | 500MG | A062300 | 002 | |
| WATSON LABS | 250MG | A062103 | 001 | |
| | 250MG | A062343 | 001 | |
| | 500MG | A062103 | 002 | |
| | 500MG | A062343 | 002 | |
| WYETH AYERST | 250MG | A061685 | 001 | |
| | 500MG | A061685 | 002 | |
| TETRACYN | | | | |
| PFIPHARMECS | 250MG | A060082 | 003 | |
| | 500MG | A060082 | 004 | |
| FIBER, EXTENDED RELEASE;PERIODONTAL | | | | |
| ACTISITE | | | | |
| SCHIFF AND CO | 12.7MG/FIBER | N050653 | 001 | Mar 25, 1994 |
| FOR SOLUTION;TOPICAL | | | | |
| TOPICYCLINE | | | | |
| SHIRE | 2.2MG/ML | N050493 | 001 | |
| INJECTABLE;INJECTION | | | | |
| ACHROMYCIN | | | | |
| LEDERLE | 250MG/VIAL | N050273 | 002 | |
| | 500MG/VIAL | N050273 | 003 | |
| TETRACYN | | | | |
| PFIZER | 250MG/VIAL | A060096 | 001 | |
| | 500MG/VIAL | A060096 | 002 | |
| OINTMENT;OPHTHALMIC | | | | |
| ACHROMYCIN | | | | |
| STORZ | 10MG/GM | N050266 | 001 | |
| SUSPENSION;ORAL | | | | |
| ACHROMYCIN V | | | | |
| LEDERLE | 125MG/5ML | N050263 | 002 | |
| SUMYCIN | | | | |
| PAR PHARM | 125MG/5ML | A060400 | 001 | |
| TETRACYCLINE HYDROCHLORIDE | | | | |
| ALPHARMA US PHARMS | 125MG/5ML | A060633 | 001 | |
| FERRANTE | 125MG/5ML | A060174 | 001 | |
| PROTER | 125MG/5ML | A060446 | 001 | |
| PUREPAC PHARM | 125MG/5ML | A060291 | 001 | |
| TETRACYN | | | | |
| PFIPHARMECS | 125MG/5ML | A060095 | 001 | |
| TETRAMED | | | | |
| IVAX SUB TEVA PHARMS | 125MG/5ML | A061468 | 001 | |
| SUSPENSION/DROPS;OPHTHALMIC | | | | |
| ACHROMYCIN | | | | |
| STORZ | 1% | N050268 | 001 | |
| TABLET;ORAL | | | | |
| PANMYCIN | | | | |
| PHARMACIA AND UPJOHN | 250MG | A061705 | 001 | |
| | 500MG | A061705 | 002 | |
| SUMYCIN | | | | |
| PAR PHARM | 50MG | A061147 | 003 | |
| | 100MG | A061147 | 002 | |
| | 250MG | A061147 | 001 | |
| | 500MG | A061147 | 004 | |

| | | | | |
|---|---|---|---|---|
| TETRACYCLINE PHOSPHATE COMPLEX | | | | |
| CAPSULE;ORAL | | | | |
| TETREX | | | | |
| BRISTOL | EQ 100MG HCL | A061653 | 001 | |
| | EQ 250MG HCL | A061653 | 002 | |
| | EQ 250MG HCL | A061889 | 002 | |
| | EQ 250MG HCL | N050212 | 002 | |
| | EQ 500MG HCL | A061653 | 003 | |
| | EQ 500MG HCL | A061889 | 001 | |
| | EQ 500MG HCL | N050212 | 003 | |
| THALLOUS CHLORIDE TL-201 | | | | |
| INJECTABLE;INJECTION | | | | |
| THALLOUS CHLORIDE TL 201 | | | | |
| BRACCO | 1mCi/ML | N018548 | 001 | Dec 30, 1982 |
| TRACE LIFE | 1mCi/ML | A075569 | 001 | Nov 21, 2001 |
| INJECTABLE;INTRAVENOUS | | | | |
| THALLOUS CHLORIDE TL 201 | | | | |
| MALLINKRODT NUCLEAR | 2mCi/ML | A077698 | 001 | Nov 09, 2006 |
| THEOPHYLLINE | | | | |
| CAPSULE;ORAL | | | | |
| BRONKODYL | | | | |
| SANOFI AVENTIS US | 100MG | A085264 | 001 | |
| | 200MG | A085264 | 002 | |
| ELIXOPHYLLIN | | | | |
| FOREST LABS | 100MG | A085545 | 001 | Jul 31, 1984 |
| | 200MG | A083921 | 001 | Jul 31, 1984 |
| SOMOPHYLLIN-T | | | | |
| FISONS | 100MG | A087155 | 001 | Feb 25, 1985 |
| | 200MG | A087155 | 002 | Feb 25, 1985 |
| | 250MG | A087155 | 003 | Feb 25, 1985 |
| THEOPHYLLINE | | | | |
| KV PHARM | 100MG | A085263 | 001 | |
| | 200MG | A085263 | 002 | |
| SCHERER RP | 100MG | A084731 | 002 | Nov 07, 1986 |
| | 200MG | A084731 | 001 | Nov 07, 1986 |
| | 250MG | A084731 | 003 | Nov 07, 1986 |
| CAPSULE, EXTENDED RELEASE;ORAL | | | | |
| AEROLATE III | | | | |
| FLEMING PHARMS | 65MG | A085075 | 003 | Nov 24, 1986 |
| AEROLATE JR | | | | |
| FLEMING PHARMS | 130MG | A085075 | 002 | Nov 24, 1986 |
| AEROLATE SR | | | | |
| FLEMING PHARMS | 260MG | A085075 | 001 | Nov 24, 1986 |
| ELIXOPHYLLIN SR | | | | |
| FOREST LABS | 125MG | A086826 | 001 | Jan 29, 1985 |
| | 250MG | A086826 | 002 | Jan 29, 1985 |
| SLO-BID | | | | |
| SANOFI AVENTIS US | 50MG | A088269 | 001 | Jan 31, 1985 |
| | 75MG | A089539 | 001 | May 10, 1989 |
| | 100MG | A087892 | 001 | Jan 31, 1985 |
| | 125MG | A089540 | 001 | May 10, 1989 |
| | 200MG | A087893 | 001 | Jan 31, 1985 |
| | 300MG | A087894 | 001 | Jan 31, 1985 |
| SLO-PHYLLIN | | | | |
| SANOFI AVENTIS US | 60MG | A085206 | 001 | May 24, 1982 |
| | 125MG | A085203 | 001 | May 24, 1982 |
| | 250MG | A085205 | 001 | May 24, 1982 |
| SOMOPHYLLIN-CRT | | | | |
| GRAHAM DM | 50MG | A087763 | 001 | Feb 27, 1985 |
| | 100MG | A087194 | 001 | |
| | 200MG | A088382 | 001 | Feb 27, 1985 |
| | 250MG | A087193 | 001 | |
| | 300MG | A088383 | 001 | Feb 27, 1985 |
| THEO-DUR | | | | |
| SCHERING | 50MG | A088022 | 001 | Sep 10, 1985 |
| | 75MG | A088015 | 001 | Sep 10, 1985 |
| | 125MG | A088016 | 001 | Sep 10, 1985 |
| | 200MG | A087995 | 001 | Sep 10, 1985 |

THEOPHYLLINE

| | | | | |
|---|---|---|---|---|
| CAPSULE, EXTENDED RELEASE;ORAL | | | | |
| THEOBID | | | | |
| WHITBY | 260MG | A085983 | 001 | Mar 20, 1985 |
| THEOBID JR. | | | | |
| WHITBY | 130MG | A087854 | 001 | Mar 20, 1985 |
| THEOCLEAR L.A.-130 | | | | |
| SCHWARZ PHARMA | 130MG | A086569 | 001 | May 27, 1982 |
| THEOCLEAR L.A.-260 | | | | |
| SCHWARZ PHARMA | 260MG | A086569 | 002 | May 27, 1982 |
| THEOPHYL-SR | | | | |
| ORTHO MCNEIL PHARM | 125MG | A086480 | 001 | Feb 08, 1985 |
| | 250MG | A086471 | 001 | Feb 08, 1985 |
| THEOPHYLLINE | | | | |
| CENT PHARMS | 125MG | A088654 | 001 | Feb 12, 1985 |
| | 250MG | A088689 | 001 | Feb 12, 1985 |
| HOSPIRA | 100MG | A089976 | 001 | Jan 04, 1995 |
| | 200MG | A089977 | 001 | Jan 04, 1995 |
| | 300MG | A089932 | 001 | Jan 04, 1995 |
| INWOOD LABS | 100MG | A040052 | 001 | Feb 14, 1994 |
| | 125MG | A040052 | 002 | Feb 14, 1994 |
| | 200MG | A040052 | 003 | Feb 14, 1994 |
| | 300MG | A040052 | 004 | Feb 14, 1994 |
| SANDOZ | 260MG | A087462 | 001 | May 11, 1982 |
| THEOPHYLLINE-SR | | | | |
| SCHERER RP | 300MG | A088255 | 001 | Jun 12, 1986 |
| THEOVENT | | | | |
| SCHERING | 125MG | A087010 | 001 | Jan 31, 1985 |
| | 250MG | A087910 | 001 | Jan 31, 1985 |
| ELIXIR;ORAL | | | | |
| ELIXOMIN | | | | |
| CENCI | 80MG/15ML | A088303 | 001 | Jan 25, 1984 |
| LANOPHYLLIN | | | | |
| LANNETT | 80MG/15ML | A084578 | 001 | |
| THEOLIXIR | | | | |
| PANRAY | 80MG/15ML | A084559 | 001 | |
| THEOPHYL-225 | | | | |
| ORTHO MCNEIL PHARM | 112.5MG/15ML | A086485 | 001 | |
| THEOPHYLLINE | | | | |
| ALPHARMA US PHARMS | 80MG/15ML | A089223 | 001 | May 27, 1988 |
| CENCI | 80MG/15ML | A087679 | 001 | Apr 15, 1982 |
| CHARTWELL RX | 80MG/15ML | A085952 | 001 | |
| HALSEY | 80MG/15ML | A085169 | 001 | |
| PHARM ASSOC | 80MG/15ML | A086720 | 001 | |
| PRECISION DOSE | 80MG/15ML | A085863 | 001 | |
| ROXANE | 80MG/15ML | A084739 | 001 | |
| TARO | 80MG/15ML | A089626 | 001 | Oct 28, 1988 |
| WOCKHARDT | 80MG/15ML | A086748 | 001 | |
| INJECTABLE;INJECTION | | | | |
| THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 40MG/100ML | N019083 | 001 | Nov 07, 1984 |
| THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 80MG/100ML | N019083 | 002 | Nov 07, 1984 |
| THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 160MG/100ML | N019083 | 003 | Nov 07, 1984 |
| THEOPHYLLINE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 200MG/100ML | N019212 | 001 | Nov 07, 1984 |
| | 200MG/100ML | N019826 | 004 | Aug 14, 1992 |
| THEOPHYLLINE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| B BRAUN | 4MG/ML | N019212 | 003 | Nov 07, 1984 |
| | 400MG/100ML | N019212 | 002 | Nov 07, 1984 |
| | 400MG/100ML | N019826 | 005 | Aug 14, 1992 |
| THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| BAXTER HLTHCARE | 4MG/ML | N018649 | 007 | Jul 26, 1982 |
| | 40MG/100ML | N018649 | 001 | Jul 26, 1982 |
| | 80MG/100ML | N018649 | 002 | Jul 26, 1982 |
| | 160MG/100ML | N018649 | 003 | Jul 26, 1982 |
| | 200MG/100ML | N018649 | 004 | Jul 26, 1982 |
| | 320MG/100ML | N018649 | 006 | Nov 13, 1985 |

| | | | | |
|---|---|---|---|---|
| THEOPHYLLINE | | | | |
| INJECTABLE;INJECTION | | | | |
| THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| | 400MG/100ML | N018649 | 005 | Jul 26, 1982 |
| THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | |
| HOSPIRA INC | 80MG/100ML | N019211 | 002 | Dec 14, 1984 |
| | 200MG/100ML | N019211 | 004 | Dec 14, 1984 |
| | 400MG/100ML | N019211 | 005 | Dec 14, 1984 |
| SOLUTION;ORAL | | | | |
| AEROLATE | | | | |
| FLEMING PHARMS | 150MG/15ML | A089141 | 001 | Dec 03, 1986 |
| THEOLAIR | | | | |
| 3M | 80MG/15ML | A086107 | 001 | |
| THEOPHYLLINE | | | | |
| ROXANE | 80MG/15ML | A087449 | 001 | Sep 15, 1983 |
| SUSPENSION;ORAL | | | | |
| ELIXICON | | | | |
| FOREST LABS | 100MG/5ML | A085502 | 001 | |
| SYRUP;ORAL | | | | |
| ACCURBRON | | | | |
| SANOFI AVENTIS US | 150MG/15ML | A088746 | 001 | Nov 22, 1985 |
| AQUAPHYLLIN | | | | |
| FERNDALE LABS | 80MG/15ML | A087917 | 001 | Jan 18, 1983 |
| SLO-PHYLLIN | | | | |
| SANOFI AVENTIS US | 80MG/15ML | A085187 | 001 | |
| THEOCLEAR-80 | | | | |
| CENT PHARMS | 80MG/15ML | A087095 | 001 | Mar 01, 1982 |
| THEOPHYLLINE | | | | |
| ALPHARMA US PHARMS | 80MG/15ML | A086001 | 001 | |
| | 150MG/15ML | A086545 | 001 | |
| TABLET;ORAL | | | | |
| QUIBRON-T | | | | |
| MONARCH PHARMS | 300MG | A088656 | 001 | Aug 22, 1985 |
| SLO-PHYLLIN | | | | |
| SANOFI AVENTIS US | 100MG | A085202 | 001 | |
| | 200MG | A085204 | 001 | |
| THEOCLEAR-100 | | | | |
| CENT PHARMS | 100MG | A085353 | 002 | |
| THEOCLEAR-200 | | | | |
| CENT PHARMS | 200MG | A085353 | 001 | |
| THEOLAIR | | | | |
| MEDICIS | 125MG | A086399 | 001 | |
| | 250MG | A086399 | 002 | |
| THEOPHYL-225 | | | | |
| ORTHO MCNEIL PHARM | 225MG | A084726 | 001 | |
| TABLET, CHEWABLE;ORAL | | | | |
| THEOPHYL | | | | |
| ORTHO MCNEIL PHARM | 100MG | A086506 | 001 | Sep 12, 1985 |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| DURAPHYL | | | | |
| FOREST LABS | 100MG | A088503 | 001 | Apr 03, 1985 |
| | 200MG | A088504 | 001 | Apr 03, 1985 |
| | 300MG | A088505 | 001 | Apr 03, 1985 |
| LABID | | | | |
| WARNER CHILCOTT | 250MG | A087225 | 001 | |
| QUIBRON-T/SR | | | | |
| MONARCH PHARMS | 300MG | A087563 | 001 | Jun 21, 1983 |
| SUSTAIRE | | | | |
| ROERIG | 100MG | A085665 | 001 | |
| | 300MG | A085665 | 002 | |
| T-PHYL | | | | |
| PHARM RES ASSOC | 200MG | A088253 | 001 | Aug 17, 1983 |
| THEO-DUR | | | | |
| SCHERING | 100MG | A085328 | 001 | |
| | 200MG | A086998 | 001 | |
| | 300MG | A085328 | 002 | |
| | 450MG | A089131 | 001 | Jun 25, 1986 |
| THEOCHRON | | | | |
| NOSTRUM PHARMS LLC | 300MG | A087400 | 002 | Jan 11, 1983 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| THEOPHYLLINE | | | | |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| THEOLAIR-SR | | | | |
| 3M | 200MG | A088369 | 001 | Jul 16, 1987 |
| | 250MG | A086363 | 002 | Jul 16, 1987 |
| | 300MG | A088364 | 001 | Jul 16, 1987 |
| | 500MG | A089132 | 001 | Jul 16, 1987 |
| THEOPHYLLINE | | | | |
| ABLE | 300MG | A040548 | 001 | Apr 30, 2004 |
| | 400MG | A040543 | 001 | Apr 27, 2004 |
| | 450MG | A040546 | 001 | Apr 30, 2004 |
| | 600MG | A040539 | 001 | Apr 27, 2004 |
| INWOOD LABS | 450MG | A040034 | 001 | Apr 28, 1995 |
| TEVA PHARMS | 450MG | A081236 | 001 | Nov 09, 1992 |
| UNI-DUR | | | | |
| SCHERING | 400MG | A089822 | 001 | Jan 04, 1995 |
| | 600MG | A089823 | 001 | Jan 04, 1995 |
| THEOPHYLLINE SODIUM GLYCINATE | | | | |
| ELIXIR;ORAL | | | | |
| SYNOPHYLATE | | | | |
| CENT PHARMS | EQ 165MG BASE/15ML | N006333 | 008 | |
| TABLET;ORAL | | | | |
| ASBRON | | | | |
| NOVARTIS | EQ 150MG BASE | A085148 | 001 | |
| THIABENDAZOLE | | | | |
| SUSPENSION;ORAL | | | | |
| MINTEZOL | | | | |
| MERCK SHARP DOHME | 500MG/5ML | N016097 | 001 | |
| TABLET, CHEWABLE;ORAL | | | | |
| MINTEZOL | | | | |
| MERCK SHARP DOHME | 500MG | N016096 | 001 | |
| THIAMINE HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| BETALIN S | | | | |
| LILLY | 100MG/ML | A080853 | 001 | |
| THIAMINE HYDROCHLORIDE | | | | |
| ABRAXIS PHARM | 100MG/ML | A080509 | 001 | |
| AKORN | 100MG/ML | A087968 | 001 | Oct 01, 1982 |
| BEL MAR | 100MG/ML | A080718 | 001 | |
| | 200MG/ML | A080712 | 001 | |
| DELL LABS | 100MG/ML | A083775 | 001 | |
| HOSPIRA | 100MG/ML | A040079 | 001 | May 03, 1996 |
| LUITPOLD | 100MG/ML | A080667 | 001 | |
| PARKE DAVIS | 100MG/ML | A080770 | 001 | |
| WATSON LABS | 100MG/ML | A080571 | 001 | |
| | 100MG/ML | A083534 | 001 | |
| | 200MG/ML | A080571 | 002 | |
| | 200MG/ML | A083534 | 002 | |
| WEST-WARD PHARMS INT | 100MG/ML | A080575 | 001 | |
| WYETH AYERST | 100MG/ML | A080553 | 001 | |
| THIAMYLAL SODIUM | | | | |
| INJECTABLE;INJECTION | | | | |
| SURITAL | | | | |
| PARKEDALE | 1GM/VIAL | N007600 | 003 | |
| | 5GM/VIAL | N007600 | 005 | |
| | 10GM/VIAL | N007600 | 009 | |
| THIETHYLPERAZINE MALATE | | | | |
| INJECTABLE;INJECTION | | | | |
| TORECAN | | | | |
| NOVARTIS | 5MG/ML | N012754 | 002 | |

| | | | | |
|---|---|---|---|---|
| THIETHYLPERAZINE MALEATE | | | | |
| SUPPOSITORY;RECTAL | | | | |
| TORECAN | | | | |
| NOVARTIS | 10MG | N013247 | 001 | |
| TABLET;ORAL | | | | |
| TORECAN | | | | |
| NOVARTIS | 10MG | N012753 | 001 | |
| THIOPENTAL SODIUM | | | | |
| SUSPENSION;RECTAL | | | | |
| PENTOTHAL | | | | |
| ABBOTT | 400MG/GM | N011679 | 001 | |
| THIORIDAZINE | | | | |
| SUSPENSION;ORAL | | | | |
| MELLARIL-S | | | | |
| NOVARTIS | EQ 25MG HCL/5ML ** | N017923 | 001 | |
| | EQ 100MG HCL/5ML ** | N017923 | 002 | |
| THIORIDAZINE HYDROCHLORIDE | | | | |
| CONCENTRATE;ORAL | | | | |
| MELLARIL | | | | |
| NOVARTIS | 30MG/ML ** | N011808 | 012 | |
| | 100MG/ML ** | N011808 | 018 | |
| THIORIDAZINE HYDROCHLORIDE | | | | |
| ACTAVIS MID ATLANTIC | 100MG/ML | A088229 | 001 | Aug 23, 1983 |
| ALPHARMA US PHARMS | 30MG/ML | A087766 | 001 | Apr 26, 1983 |
| ANI PHARMS INC | 30MG/ML | A089602 | 001 | Nov 09, 1987 |
| | 100MG/ML | A089603 | 001 | Nov 09, 1987 |
| HI TECH PHARMA | 30MG/ML | A040125 | 001 | Aug 16, 1996 |
| | 100MG/ML | A040126 | 001 | Aug 16, 1996 |
| PHARM ASSOC | 30MG/ML | A040187 | 001 | Aug 28, 1997 |
| | 100MG/ML | A040213 | 001 | May 29, 1998 |
| SANDOZ | 30MG/ML | A088307 | 001 | Nov 23, 1983 |
| | 100MG/ML | A088308 | 001 | Nov 23, 1983 |
| WOCKHARDT | 30MG/ML | A088258 | 001 | Jul 25, 1983 |
| | 100MG/ML | A088227 | 001 | Jul 05, 1983 |
| THIORIDAZINE HYDROCHLORIDE INTENSOL | | | | |
| ROXANE | 30MG/ML | A088941 | 001 | Dec 16, 1985 |
| | 100MG/ML | A088942 | 001 | Dec 16, 1985 |
| TABLET;ORAL | | | | |
| MELLARIL | | | | |
| + NOVARTIS | 10MG ** | N011808 | 003 | |
| + | 15MG ** | N011808 | 016 | |
| + | 25MG ** | N011808 | 006 | |
| + | 50MG ** | N011808 | 011 | |
| + | 100MG ** | N011808 | 009 | |
| + | 150MG ** | N011808 | 017 | |
| + | 200MG ** | N011808 | 015 | |
| THIORIDAZINE HYDROCHLORIDE | | | | |
| ANI PHARMS INC | 10MG | A088270 | 001 | Apr 14, 1983 |
| | 10MG | A088493 | 001 | May 17, 1985 |
| | 15MG | A088271 | 001 | Apr 14, 1983 |
| | 25MG | A088272 | 001 | Apr 14, 1983 |
| | 50MG | A088194 | 001 | Apr 14, 1983 |
| | 100MG | A088273 | 001 | Oct 03, 1983 |
| | 100MG | A088456 | 001 | May 17, 1985 |
| MUTUAL PHARM | 10MG | A088375 | 001 | Nov 18, 1983 |
| | 25MG | A087264 | 001 | Nov 18, 1983 |
| | 50MG | A088370 | 001 | Nov 18, 1983 |
| | 100MG | A088379 | 001 | Nov 16, 1983 |
| MYLAN | 10MG | A088332 | 001 | Jun 27, 1983 |
| | 25MG | A088333 | 001 | Jun 27, 1983 |
| | 50MG | A088334 | 001 | Jun 27, 1983 |
| | 100MG | A088335 | 001 | Nov 18, 1983 |
| PAR PHARM | 10MG | A088351 | 001 | Dec 05, 1983 |
| | 15MG | A088352 | 001 | Dec 05, 1983 |
| | 25MG | A088336 | 001 | Dec 05, 1983 |
| | 50MG | A088322 | 001 | Dec 05, 1983 |
| | 100MG | A088480 | 001 | Dec 29, 1983 |
| | 150MG | A089764 | 001 | Feb 09, 1988 |

THIORIDAZINE HYDROCHLORIDE

TABLET;ORAL

| | | | | |
|---|---|---|---|---|
| THIORIDAZINE HYDROCHLORIDE | | | | |
| | 200MG | A089765 | 001 | Feb 09, 1988 |
| ROXANE | 10MG | A088663 | 001 | Mar 15, 1984 |
| | 25MG | A088664 | 001 | Mar 15, 1984 |
| | 50MG | A088665 | 001 | Mar 15, 1984 |
| | 100MG | A089048 | 001 | Feb 26, 1985 |
| SANDOZ | 10MG | A088131 | 001 | Aug 30, 1983 |
| | 15MG | A088132 | 001 | Aug 30, 1983 |
| | 25MG | A088133 | 001 | Aug 30, 1983 |
| | 50MG | A088134 | 001 | Aug 30, 1983 |
| | 100MG | A088135 | 001 | Nov 20, 1984 |
| | 150MG | A088136 | 001 | Sep 17, 1986 |
| | 200MG | A088137 | 001 | Sep 17, 1986 |
| SUN PHARM INDUSTRIES | 15MG | A088461 | 001 | Nov 18, 1983 |
| | 150MG | A088737 | 001 | Sep 26, 1984 |
| | 200MG | A088738 | 001 | Oct 16, 1984 |
| SUPERPHARM | 10MG | A089103 | 001 | Jul 02, 1985 |
| | 25MG | A089104 | 001 | Jul 02, 1985 |
| | 50MG | A089105 | 001 | Jul 02, 1985 |
| WATSON LABS | 10MG | A088412 | 001 | Sep 12, 1983 |
| | 10MG | A088476 | 001 | Nov 08, 1983 |
| | 10MG | A088561 | 001 | May 11, 1984 |
| | 15MG | A088345 | 001 | Jul 28, 1983 |
| | 15MG | A088562 | 001 | May 11, 1984 |
| | 25MG | A088296 | 001 | Jul 28, 1983 |
| | 25MG | A088478 | 001 | Nov 08, 1983 |
| | 25MG | A088755 | 001 | Jul 24, 1984 |
| | 50MG | A088323 | 001 | Jul 28, 1983 |
| | 50MG | A088479 | 001 | Nov 08, 1983 |
| | 50MG | A088563 | 001 | May 11, 1984 |
| | 100MG | A088284 | 001 | Aug 25, 1983 |
| | 100MG | A088564 | 001 | May 11, 1984 |
| | 100MG | A088736 | 001 | Jul 24, 1984 |
| | 150MG | A088410 | 001 | Mar 05, 1984 |
| | 150MG | A088869 | 001 | Jun 28, 1985 |
| | 200MG | A088381 | 001 | Mar 14, 1984 |
| WATSON LABS TEVA | 15MG | A088477 | 001 | Nov 08, 1983 |
| | 25MG | A088567 | 001 | May 11, 1984 |
| | 200MG | A088872 | 001 | Apr 26, 1985 |
| WEST WARD | 10MG | A088658 | 001 | Mar 26, 1984 |
| | 15MG | A088659 | 001 | Mar 26, 1984 |
| | 25MG | A088660 | 001 | Mar 26, 1984 |
| | 50MG | A088661 | 001 | Mar 26, 1984 |

THIOTEPA

INJECTABLE;INJECTION

| | | | | |
|---|---|---|---|---|
| THIOPLEX | | | | |
| + IMMUNEX | 15MG/VIAL ** | N020058 | 001 | Dec 22, 1994 |
| THIOTEPA | | | | |
| FRESENIUS KABI USA | 15MG/VIAL | A075698 | 001 | Sep 20, 2001 |
| IMMUNEX | 15MG/VIAL | N011683 | 001 | |
| TEVA PARENTERAL | 15MG/VIAL ** | A075730 | 001 | Apr 20, 2001 |
| | 30MG/VIAL ** | A075730 | 002 | Apr 20, 2001 |

THIOTHIXENE

CAPSULE;ORAL

| | | | | |
|---|---|---|---|---|
| NAVANE | | | | |
| PFIZER | 1MG ** | N016584 | 001 | |
| | 2MG ** | N016584 | 002 | |
| | 5MG ** | N016584 | 003 | |
| | 10MG ** | N016584 | 004 | |
| | 20MG ** | N016584 | 005 | |
| THIOTHIXENE | | | | |
| AM THERAP | 1MG | A071884 | 001 | Aug 12, 1987 |
| | 2MG | A071885 | 001 | Aug 12, 1987 |
| | 5MG | A071886 | 001 | Aug 12, 1987 |
| | 10MG | A071887 | 001 | Aug 12, 1987 |
| | 20MG | A072200 | 001 | Dec 17, 1987 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| THIOTHIXENE | | | | |
| CAPSULE;ORAL | | | | |
| THIOTHIXENE | | | | |
| SANDOZ | 1MG | A071529 | 002 | Jun 24, 1987 |
| | 2MG | A071529 | 003 | Jun 24, 1987 |
| | 5MG | A071529 | 001 | Jun 24, 1987 |
| | 10MG | A071529 | 004 | Jun 24, 1987 |
| WATSON LABS | 1MG | A070600 | 001 | Jun 05, 1987 |
| | 2MG | A070601 | 001 | Jun 05, 1987 |
| | 2MG | A071626 | 001 | Jun 25, 1987 |
| | 5MG | A070602 | 001 | Jun 05, 1987 |
| | 5MG | A071627 | 001 | Jun 25, 1987 |
| | 10MG | A070603 | 001 | Jun 05, 1987 |
| | 10MG | A071628 | 001 | Jun 25, 1987 |
| THIOTHIXENE HYDROCHLORIDE | | | | |
| CONCENTRATE;ORAL | | | | |
| NAVANE | | | | |
| PFIZER | EQ 5MG BASE/ML | N016758 | 001 | |
| THIOTHIXENE HYDROCHLORIDE | | | | |
| ALPHARMA US PHARMS | EQ 5MG BASE/ML | A070969 | 001 | Oct 16, 1987 |
| PACO | EQ 1MG BASE/ML | A071917 | 001 | Sep 20, 1989 |
| | EQ 5MG BASE/ML | A071939 | 001 | Dec 16, 1988 |
| TEVA | EQ 5MG BASE/ML | A071184 | 001 | Jun 22, 1987 |
| TEVA PHARMS | EQ 5MG BASE/ML | A071554 | 001 | Oct 16, 1987 |
| THIOTHIXENE HYDROCHLORIDE INTENSOL | | | | |
| CYCLE PHARMS LTD | EQ 5MG BASE/ML | A073494 | 001 | Jun 30, 1992 |
| INJECTABLE;INJECTION | | | | |
| NAVANE | | | | |
| PFIZER | EQ 2MG BASE/ML | N016904 | 001 | |
| | EQ 10MG BASE/VIAL | N016904 | 002 | |
| THYROGLOBULIN | | | | |
| TABLET;ORAL | | | | |
| PROLOID | | | | |
| PARKE DAVIS | 16MG | N002245 | 009 | |
| | 32MG | N002245 | 005 | |
| | 65MG | N002245 | 002 | |
| | 100MG | N002245 | 008 | |
| | 130MG | N002245 | 010 | |
| | 200MG | N002245 | 007 | |
| | 325MG | N002245 | 004 | |
| THYROGLOBULIN | | | | |
| IMPAX LABS | 64.8MG | A080151 | 001 | |
| THYROTROPIN | | | | |
| INJECTABLE;INJECTION | | | | |
| THYTROPAR | | | | |
| SANOFI AVENTIS US | 10 IU/VIAL | N008682 | 001 | |
| TIAGABINE HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| GABITRIL | | | | |
| CEPHALON | 6MG | N020646 | 006 | Nov 29, 2005 |
| | 8MG | N020646 | 007 | Nov 29, 2005 |
| | 10MG | N020646 | 008 | Nov 29, 2005 |
| | 20MG | N020646 | 004 | Sep 30, 1997 |
| TICARCILLIN DISODIUM | | | | |
| INJECTABLE;INJECTION | | | | |
| TICAR | | | | |
| GLAXOSMITHKLINE | EQ 1GM BASE/VIAL | N050497 | 001 | |
| | EQ 3GM BASE/VIAL | A062690 | 001 | Dec 19, 1986 |
| | EQ 3GM BASE/VIAL | N050497 | 002 | |
| | EQ 6GM BASE/VIAL | N050497 | 003 | |
| | EQ 20GM BASE/VIAL | N050497 | 004 | |
| | EQ 30GM BASE/VIAL | N050497 | 005 | Apr 04, 1984 |

| | | | | |
|---|---|---|---|---|
| TICLOPIDINE HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| TICLID | | | | |
| ROCHE PALO | 125MG | N019979 | 001 | Mar 24, 1993 |
| | 250MG | N019979 | 002 | Oct 31, 1991 |
| TICLOPIDINE HYDROCHLORIDE | | | | |
| ACTAVIS ELIZABETH | 250MG | A075253 | 001 | Aug 20, 1999 |
| FOSUN PHARMA | 250MG | A075318 | 001 | Aug 20, 1999 |
| | 250MG | A075326 | 001 | Aug 20, 1999 |
| MYLAN | 250MG | A075161 | 001 | Sep 13, 1999 |
| | 250MG | A075316 | 001 | Nov 02, 1999 |
| WATSON LABS | 250MG | A075309 | 001 | Apr 26, 2000 |
| TILUDRONATE DISODIUM | | | | |
| TABLET;ORAL | | | | |
| SKELID | | | | |
| + SANOFI AVENTIS US | EQ 200MG BASE ** | N020707 | 001 | Mar 07, 1997 |
| TIMOLOL MALEATE | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | |
| TIMOLOL MALEATE | | | | |
| AKORN | EQ 0.25% BASE | A074465 | 001 | Mar 25, 1997 |
| | EQ 0.25% BASE | A074515 | 001 | Mar 25, 1997 |
| APOTEX INC | EQ 0.25% BASE | A075411 | 001 | Sep 08, 2000 |
| | EQ 0.5% BASE | A075412 | 001 | Sep 08, 2000 |
| FOUGERA | EQ 0.25% BASE | A074667 | 001 | Mar 25, 1997 |
| | EQ 0.5% BASE | A074668 | 001 | Mar 25, 1997 |
| TIMOPTIC | | | | |
| + ATON | EQ 0.25% BASE ** | N018086 | 001 | |
| + | EQ 0.5% BASE ** | N018086 | 002 | |
| TABLET;ORAL | | | | |
| BLOCADREN | | | | |
| MERCK | 5MG | N018017 | 001 | |
| | 10MG | N018017 | 002 | |
| | 20MG | N018017 | 004 | |
| TIMOLOL MALEATE | | | | |
| FOSUN PHARMA | 5MG | A072550 | 001 | Apr 13, 1989 |
| | 10MG | A072551 | 001 | Apr 13, 1989 |
| | 20MG | A072552 | 001 | Apr 13, 1989 |
| QUANTUM PHARMICS | 5MG | A072466 | 001 | May 19, 1989 |
| | 10MG | A072467 | 001 | May 19, 1989 |
| | 20MG | A072468 | 001 | May 19, 1989 |
| TEVA | 5MG | A072648 | 001 | Jun 16, 1993 |
| | 10MG | A072649 | 001 | Jun 16, 1993 |
| | 20MG | A072650 | 001 | Jun 16, 1993 |
| USL PHARMA | 5MG | A072001 | 001 | Apr 11, 1989 |
| | 10MG | A072002 | 001 | Apr 11, 1989 |
| | 20MG | A072003 | 001 | Apr 11, 1989 |
| WATSON LABS | 5MG | A072269 | 001 | Apr 11, 1989 |
| | 5MG | A072917 | 001 | Jul 31, 1991 |
| | 10MG | A072270 | 001 | Apr 11, 1989 |
| | 10MG | A072918 | 001 | Jul 31, 1991 |
| | 20MG | A072271 | 001 | Apr 11, 1989 |
| | 20MG | A072919 | 001 | Jul 31, 1991 |
| TINZAPARIN SODIUM | | | | |
| INJECTABLE;INJECTION | | | | |
| INNOHEP | | | | |
| LEO PHARMA AS | 20,000 IU/ML | N020484 | 001 | Jul 14, 2000 |
| TIOCONAZOLE | | | | |
| CREAM;TOPICAL | | | | |
| TZ-3 | | | | |
| PFIZER | 1% | N018682 | 001 | Feb 18, 1983 |
| TIROFIBAN HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| AGGRASTAT | | | | |
| MEDICURE | EQ 12.5MG BASE/50ML (EQ 0.25MG BASE/ML) | N020912 | 001 | May 14, 1998 |
| | EQ 25MG BASE/500ML (EQ 0.05MG BASE/ML) | N020913 | 001 | May 14, 1998 |

| | | | | |
|---|---|---|---|---|
| TIZANIDINE HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| TIZANIDINE HYDROCHLORIDE | | | | |
| ACTAVIS ELIZABETH | EQ 2MG BASE | A076283 | 001 | Jul 12, 2002 |
| | EQ 4MG BASE | A076283 | 002 | Jul 12, 2002 |
| BARR | EQ 2MG BASE | A076371 | 001 | Apr 09, 2003 |
| | EQ 4MG BASE | A076371 | 002 | Apr 09, 2003 |
| IVAX SUB TEVA PHARMS | EQ 2MG BASE | A076321 | 001 | Sep 30, 2004 |
| | EQ 4MG BASE | A076321 | 002 | Sep 30, 2004 |
| MYLAN PHARMS INC | EQ 2MG BASE | A076282 | 001 | Dec 16, 2003 |
| | EQ 4MG BASE | A076282 | 002 | Dec 16, 2003 |
| ZANAFLEX | | | | |
| + COVIS PHARMA BV | EQ 2MG BASE ** | N020397 | 002 | Feb 04, 2000 |
| TOBRAMYCIN | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | |
| TOBRAMYCIN | | | | |
| ALCON PHARMS LTD | 0.3% | A063176 | 001 | May 25, 1994 |
| APOTEX INC | 0.3% | A065087 | 001 | Feb 25, 2002 |
| TOBRAMYCIN SULFATE | | | | |
| INJECTABLE;INJECTION | | | | |
| NEBCIN | | | | |
| LILLY | EQ 10MG BASE/ML | A062008 | 004 | |
| | EQ 10MG BASE/ML | A062707 | 001 | Apr 29, 1987 |
| + | EQ 10MG BASE/ML ** | N050477 | 005 | |
| | EQ 40MG BASE/ML | A062008 | 001 | |
| + | EQ 1.2GM BASE/VIAL ** | N050519 | 001 | |
| TOBRAMYCIN SULFATE | | | | |
| APOTHECON | EQ 10MG BASE/ML | A064021 | 001 | May 31, 1994 |
| | EQ 40MG BASE/ML | A064021 | 002 | May 31, 1994 |
| | EQ 40MG BASE/ML | A064026 | 001 | May 31, 1994 |
| HOSPIRA | EQ 10MG BASE/ML | A063080 | 001 | Apr 30, 1991 |
| | EQ 40MG BASE/ML | A063161 | 001 | May 29, 1991 |
| IGI LABS INC | EQ 10MG BASE/ML | A063119 | 001 | Oct 31, 1994 |
| | EQ 40MG BASE/ML | A063120 | 001 | Oct 31, 1994 |
| | EQ 40MG BASE/ML | A063121 | 001 | Oct 31, 1994 |
| | EQ 40MG BASE/ML | A063122 | 001 | Oct 31, 1994 |
| WATSON LABS INC | EQ 10MG BASE/ML | A062945 | 001 | Aug 09, 1989 |
| | EQ 40MG BASE/ML | A062945 | 002 | Aug 09, 1989 |
| WEST-WARD PHARMS INT | EQ 10MG BASE/ML | A063113 | 001 | Apr 26, 1991 |
| | EQ 10MG BASE/ML | A063128 | 001 | Nov 27, 1991 |
| | EQ 40MG BASE/ML | A063118 | 001 | Jul 29, 1991 |
| | EQ 40MG BASE/ML | A063127 | 001 | Nov 27, 1991 |
| TOBRAMYCIN SULFATE (PHARMACY BULK) | | | | |
| HOSPIRA | EQ 40MG BASE/ML ** | A063116 | 001 | May 18, 1992 |
| TOCAINIDE HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| TONOCARD | | | | |
| ASTRAZENECA | 400MG | N018257 | 001 | Nov 09, 1984 |
| | 600MG | N018257 | 002 | Nov 09, 1984 |
| TOLAZAMIDE | | | | |
| TABLET;ORAL | | | | |
| TOLAZAMIDE | | | | |
| BARR | 100MG | A070162 | 001 | Jan 14, 1986 |
| | 250MG | A070163 | 001 | Jan 14, 1986 |
| | 500MG | A070164 | 001 | Jan 14, 1986 |
| DURAMED PHARMS BARR | 100MG | A070165 | 001 | Jan 10, 1986 |
| | 250MG | A070166 | 001 | Jan 10, 1986 |
| | 500MG | A070167 | 001 | Jan 10, 1986 |
| FOSUN PHARMA | 250MG | A070289 | 001 | Mar 13, 1986 |
| | 500MG | A070290 | 001 | Mar 13, 1986 |
| G AND W LABS INC | 100MG | N018894 | 001 | Nov 02, 1984 |
| | 250MG | N018894 | 002 | Nov 02, 1984 |
| | 500MG | N018894 | 003 | Nov 02, 1984 |
| INTERPHARM | 250MG | A071270 | 001 | Sep 23, 1986 |
| | 500MG | A071271 | 001 | Sep 23, 1986 |
| PAR PHARM | 100MG | A070159 | 001 | Jan 06, 1986 |
| | 250MG | A070160 | 001 | Jan 06, 1986 |

| | | | | |
|---|---|---|---|---|
| TOLAZAMIDE | | | | |
| TABLET;ORAL | | | | |
| TOLAZAMIDE | | | | |
| | 500MG | A070161 | 001 | Jan 06, 1986 |
| SANDOZ | 100MG | A071633 | 001 | Dec 09, 1987 |
| SUN PHARM INDUSTRIES | 100MG | A071357 | 001 | Jul 16, 1987 |
| | 250MG | A071358 | 001 | Jul 16, 1987 |
| | 500MG | A071359 | 001 | Jul 16, 1987 |
| SUPERPHARM | 250MG | A070763 | 001 | Jun 16, 1986 |
| | 500MG | A070764 | 001 | Jun 16, 1986 |
| USL PHARMA | 100MG | A071355 | 001 | Jan 11, 1988 |
| | 250MG | A070168 | 001 | Apr 02, 1986 |
| | 500MG | A070169 | 001 | Apr 02, 1986 |
| WATSON LABS | 100MG | A070242 | 001 | Aug 01, 1986 |
| | 100MG | A070513 | 001 | Jan 09, 1986 |
| | 250MG | A070243 | 001 | Aug 01, 1986 |
| | 250MG | A070514 | 001 | Jan 09, 1986 |
| | 500MG | A070244 | 001 | Aug 01, 1986 |
| | 500MG | A070515 | 001 | Jan 09, 1986 |
| TOLINASE | | | | |
| + PHARMACIA AND UPJOHN | 100MG ** | N015500 | 002 | |
| + | 250MG ** | N015500 | 004 | |
| + | 500MG ** | N015500 | 005 | |
| TOLAZOLINE HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| PRISCOLINE | | | | |
| NOVARTIS | 25MG/ML | N006403 | 005 | Feb 22, 1985 |
| TOLBUTAMIDE | | | | |
| TABLET;ORAL | | | | |
| ORINASE | | | | |
| PHARMACIA AND UPJOHN | 250MG ** | N010670 | 002 | |
| | 500MG ** | N010670 | 001 | |
| TOLBUTAMIDE | | | | |
| ALRA | 500MG | A086141 | 001 | |
| ASCOT | 500MG | A087541 | 001 | Mar 01, 1983 |
| BARR | 500MG | A087121 | 001 | |
| DAVA PHARMS INC | 500MG | A086926 | 001 | |
| IVAX PHARMS | 500MG | A087093 | 001 | |
| PARKE DAVIS | 500MG | A086047 | 001 | |
| PUREPAC PHARM | 500MG | A088950 | 001 | Jun 17, 1985 |
| SANDOZ | 500MG | A086574 | 001 | |
| | 500MG | N012678 | 001 | |
| SUPERPHARM | 500MG | A088893 | 001 | Nov 19, 1984 |
| VANGARD | 500MG | A087876 | 001 | Apr 20, 1982 |
| WATSON LABS | 250MG | A089110 | 001 | May 29, 1987 |
| | 500MG | A086109 | 001 | |
| | 500MG | A087318 | 001 | |
| | 500MG | A089111 | 001 | May 29, 1987 |
| TOLBUTAMIDE SODIUM | | | | |
| INJECTABLE;INJECTION | | | | |
| ORINASE DIAGNOSTIC | | | | |
| PHARMACIA AND UPJOHN | EQ 1GM BASE/VIAL | N012095 | 001 | |
| TOLCAPONE | | | | |
| TABLET;ORAL | | | | |
| TASMAR | | | | |
| VALEANT PHARMS LLC | 200MG | N020697 | 002 | Jan 29, 1998 |
| TOLMETIN SODIUM | | | | |
| CAPSULE;ORAL | | | | |
| TOLECTIN DS | | | | |
| ORTHO MCNEIL JANSSEN | EQ 400MG BASE | N018084 | 001 | |
| TOLMETIN SODIUM | | | | |
| ACTAVIS ELIZABETH | EQ 400MG BASE | A073308 | 001 | Jan 24, 1992 |
| IVAX SUB TEVA PHARMS | EQ 400MG BASE | A073392 | 001 | Jan 24, 1992 |
| SANDOZ | EQ 400MG BASE | A073462 | 001 | Apr 30, 1992 |
| SUN PHARM INDUSTRIES | EQ 400MG BASE | A073311 | 001 | Nov 27, 1991 |
| TEVA | EQ 400MG BASE | A073519 | 001 | May 29, 1992 |

| | | | | |
|---|---|---|---|---|
| TOLMETIN SODIUM | | | | |
| TABLET;ORAL | | | | |
| TOLECTIN | | | | |
| ORTHO MCNEIL JANSSEN | EQ 200MG BASE | N017628 | 001 | |
| TOLECTIN 600 | | | | |
| ORTHO MCNEIL JANSSEN | EQ 600MG BASE | N017628 | 002 | Mar 08, 1989 |
| TOLMETIN SODIUM | | | | |
| ACTAVIS ELIZABETH | EQ 600MG BASE | A073527 | 001 | Jun 30, 1992 |
| G AND W LABS INC | EQ 600MG BASE | A074399 | 001 | Mar 28, 1996 |
| | EQ 600MG BASE | A074729 | 001 | Feb 27, 1997 |
| SANDOZ | EQ 200MG BASE | A073588 | 001 | Jul 31, 1992 |
| | EQ 600MG BASE | A074002 | 001 | Sep 27, 1993 |
| SUN PHARM INDUSTRIES | EQ 200MG BASE | A073310 | 001 | Nov 27, 1991 |
| TOLVAPTAN | | | | |
| TABLET;ORAL | | | | |
| SAMSCA | | | | |
| + OTSUKA AMERICA PHARM | 60MG ** | N022275 | 003 | May 19, 2009 |
| TOPIRAMATE | | | | |
| CAPSULE;ORAL | | | | |
| TOPAMAX SPRINKLE | | | | |
| JANSSEN PHARMS | 50MG | N020844 | 003 | Oct 26, 1998 |
| TOPIRAMATE | | | | |
| BARR | 15MG | A076448 | 001 | Apr 15, 2009 |
| | 25MG | A076448 | 002 | Apr 15, 2009 |
| MYLAN | 15MG | A078418 | 001 | Oct 14, 2009 |
| | 25MG | A078418 | 002 | Oct 14, 2009 |
| SANDOZ | 15MG | A079206 | 001 | Oct 14, 2009 |
| | 25MG | A079206 | 002 | Oct 14, 2009 |
| TABLET;ORAL | | | | |
| TOPAMAX | | | | |
| JANSSEN PHARMS | 300MG | N020505 | 003 | Dec 24, 1996 |
| | 400MG | N020505 | 006 | Dec 24, 1996 |
| TOPIRAMATE | | | | |
| ACTAVIS TOTOWA | 25MG | A078637 | 001 | Feb 27, 2013 |
| | 50MG | A078637 | 002 | Feb 27, 2013 |
| | 100MG | A078637 | 003 | Feb 27, 2013 |
| | 200MG | A078637 | 004 | Feb 27, 2013 |
| BARR | 25MG | A076315 | 001 | Mar 27, 2009 |
| | 100MG | A076315 | 002 | Mar 27, 2009 |
| | 200MG | A076315 | 003 | Mar 27, 2009 |
| MYLAN | 25MG | A076314 | 001 | Mar 27, 2009 |
| | 50MG | A076314 | 002 | Mar 27, 2009 |
| | 100MG | A076314 | 003 | Mar 27, 2009 |
| | 200MG | A076314 | 004 | Mar 27, 2009 |
| PLIVA HRVATSKA DOO | 25MG | A077905 | 001 | Mar 30, 2009 |
| | 50MG | A077905 | 002 | Mar 30, 2009 |
| | 100MG | A077905 | 003 | Mar 30, 2009 |
| | 200MG | A077905 | 004 | Mar 30, 2009 |
| ROXANE | 25MG | A076306 | 001 | Mar 27, 2009 |
| | 50MG | A076306 | 002 | Mar 27, 2009 |
| | 100MG | A076306 | 003 | Mar 27, 2009 |
| | 200MG | A076306 | 004 | Mar 27, 2009 |
| WATSON LABS | 25MG | A077643 | 001 | Mar 27, 2009 |
| | 50MG | A077643 | 002 | Mar 27, 2009 |
| | 100MG | A077643 | 003 | Mar 27, 2009 |
| | 200MG | A077643 | 004 | Mar 27, 2009 |
| WOCKHARDT USA | 25MG | A090353 | 001 | Sep 01, 2010 |
| | 50MG | A090353 | 002 | Sep 01, 2010 |
| | 100MG | A090353 | 003 | Sep 01, 2010 |
| | 200MG | A090353 | 004 | Sep 01, 2010 |
| TOPIRAMATE | | | | |
| HIKMA PHARMS | 25MG | A091185 | 001 | Nov 25, 2013 |
| | 50MG | A091185 | 002 | Nov 25, 2013 |
| | 100MG | A091185 | 003 | Nov 25, 2013 |
| | 200MG | A091185 | 004 | Nov 25, 2013 |

| | | | | | |
|---|---|---|---|---|---|
| TOPOTECAN HYDROCHLORIDE | | | | | |
| INJECTABLE;INJECTION | | | | | |
| TOPOTECAN HYDROCHLORIDE | | | | | |
| | FRESENIUS KABI ONCOL | EQ 4MG BASE/VIAL | A091376 | 001 | Nov 29, 2010 |
| | SUN PHARM INDS LTD | EQ 4MG BASE/VIAL | A202203 | 001 | Aug 29, 2013 |
| SOLUTION;INTRAVENOUS | | | | | |
| TOPOTECAN | | | | | |
| + | SANDOZ INC | EQ 1MG BASE/ML (EQ 1MG BASE/ML) ** | N200199 | 001 | Feb 25, 2011 |
| + | | EQ 3MG BASE/3ML (EQ 1MG BASE/ML) ** | N200199 | 002 | Feb 25, 2011 |
| + | | EQ 4MG BASE/4ML (EQ 1MG BASE/ML) ** | N200199 | 003 | Feb 25, 2011 |
| TORSEMIDE | | | | | |
| INJECTABLE;INJECTION | | | | | |
| DEMADEX | | | | | |
| + | ROCHE | 50MG/5ML (10MG/ML) ** | N020137 | 002 | Aug 23, 1993 |
| + | | 20MG/2ML (10MG/ML) ** | N020137 | 001 | Aug 23, 1993 |
| TORSEMIDE | | | | | |
| | LUITPOLD | 20MG/2ML (10MG/ML) | A090656 | 001 | Apr 21, 2010 |
| | | 50MG/5ML (10MG/ML) | A090656 | 002 | Apr 21, 2010 |
| | WEST-WARD PHARMS INT | 20MG/2ML (10MG/ML) | A078007 | 001 | Jun 11, 2008 |
| | | 50MG/5ML (10MG/ML) | A078007 | 002 | Jun 11, 2008 |
| TABLET;ORAL | | | | | |
| TORSEMIDE | | | | | |
| | SUN PHARM INDS | 5MG | A078478 | 001 | Feb 26, 2008 |
| | | 10MG | A078478 | 002 | Feb 26, 2008 |
| | | 20MG | A078478 | 003 | Feb 26, 2008 |
| | | 100MG | A078478 | 004 | Feb 26, 2008 |
| TRAMADOL HYDROCHLORIDE | | | | | |
| TABLET;ORAL | | | | | |
| TRAMADOL HYDROCHLORIDE | | | | | |
| | ACCORD HLTHCARE | 50MG | A202390 | 001 | May 16, 2013 |
| | ACTAVIS ELIZABETH | 50MG | A075960 | 001 | Jun 19, 2002 |
| | ASTA | 50MG | A075974 | 001 | Jul 12, 2002 |
| | IVAX SUB TEVA PHARMS | 50MG | A075963 | 001 | Jul 03, 2002 |
| | MYLAN PHARMS INC | 50MG | A075980 | 001 | Nov 21, 2002 |
| | NORTHSTAR HLTHCARE | 50MG | A078935 | 001 | May 26, 2010 |
| | SANDOZ | 50MG | A075968 | 001 | Jun 25, 2002 |
| | WATSON LABS | 50MG | A075962 | 001 | Jun 24, 2002 |
| ULTRAM | | | | | |
| | JANSSEN PHARMS | 100MG | N020281 | 001 | Mar 03, 1995 |
| TABLET, EXTENDED RELEASE;ORAL | | | | | |
| RYZOLT | | | | | |
| + | PURDUE PHARMA | 100MG ** | N021745 | 001 | Dec 30, 2008 |
| + | | 200MG ** | N021745 | 002 | Dec 30, 2008 |
| + | | 300MG ** | N021745 | 003 | Dec 30, 2008 |
| ULTRAM ER | | | | | |
| + | VALEANT PHARMS | 100MG | N021692 | 001 | Sep 08, 2005 |
| + | | 200MG | N021692 | 002 | Sep 08, 2005 |
| + | | 300MG | N021692 | 003 | Sep 08, 2005 |
| TABLET, ORALLY DISINTEGRATING;ORAL | | | | | |
| RYBIX ODT | | | | | |
| | SHIONOGI INC | 50MG | N021693 | 001 | May 05, 2005 |
| TRAMETINIB DIMETHYL SULFOXIDE | | | | | |
| TABLET;ORAL | | | | | |
| MEKINIST | | | | | |
| + | NOVARTIS PHARMS CORP | EQ 1MG | N204114 | 002 | May 29, 2013 |
| TRANDOLAPRIL | | | | | |
| TABLET;ORAL | | | | | |
| TRANDOLAPRIL | | | | | |
| | CIPLA | 1MG | A077307 | 002 | Jun 12, 2007 |
| | | 2MG | A077307 | 001 | Jun 12, 2007 |
| | | 4MG | A077307 | 003 | Jun 12, 2007 |
| | DR REDDYS LABS LTD | 1MG | A078493 | 001 | Aug 25, 2008 |
| | | 2MG | A078493 | 002 | Aug 25, 2008 |
| | | 4MG | A078493 | 003 | Aug 25, 2008 |
| | EPIC PHARMA LLC | 1MG | A077256 | 001 | Jun 12, 2007 |
| | | 2MG | A077256 | 002 | Jun 12, 2007 |
| | | 4MG | A077256 | 003 | Jun 12, 2007 |

| | | | | |
|---|---|---|---|---|
| TRANDOLAPRIL | | | | |
| TABLET;ORAL | | | | |
| TRANDOLAPRIL | | | | |
| INVAGEN PHARMS | 1MG | A078320 | 001 | Jun 12, 2007 |
| | 2MG | A078320 | 002 | Jun 12, 2007 |
| | 4MG | A078320 | 003 | Jun 12, 2007 |
| MYLAN | 1MG | A078346 | 001 | Apr 28, 2008 |
| | 2MG | A078346 | 002 | Apr 28, 2008 |
| | 4MG | A078346 | 003 | Apr 28, 2008 |
| TRANEXAMIC ACID | | | | |
| TABLET;ORAL | | | | |
| CYKLOKAPRON | | | | |
| PHARMACIA AND UPJOHN | 500MG | N019280 | 001 | Dec 30, 1986 |
| TRANEXAMIC ACID | | | | |
| AMERIGEN PHARMS LTD | 650MG | A203256 | 001 | Jul 25, 2016 |
| TRAVOPROST | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | |
| IZBA | | | | |
| + NOVARTIS PHARMS CORP | 0.003% ** | N204822 | 001 | May 15, 2014 |
| TRAVATAN | | | | |
| + ALCON PHARMS LTD | 0.004% ** | N021257 | 001 | Mar 16, 2001 |
| TRAZODONE HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| DESYREL | | | | |
| + PRAGMA PHARMS LLC | 50MG ** | N018207 | 001 | |
| + | 100MG ** | N018207 | 002 | |
| + | 150MG ** | N018207 | 003 | Mar 25, 1985 |
| + | 300MG ** | N018207 | 004 | Nov 07, 1988 |
| TRAZODONE HYDROCHLORIDE | | | | |
| AM THERAP | 50MG | A071139 | 001 | Oct 29, 1986 |
| | 100MG | A071140 | 001 | Oct 29, 1986 |
| AUROLIFE PHARMA LLC | 50MG | A072484 | 001 | Apr 30, 1990 |
| MYLAN | 50MG | A071405 | 001 | Feb 27, 1991 |
| | 100MG | A071406 | 001 | Feb 27, 1991 |
| MYLAN PHARMS INC | 50MG | A090514 | 001 | Jun 02, 2009 |
| | 100MG | A090514 | 002 | Jun 02, 2009 |
| | 150MG | A090514 | 003 | Jun 02, 2009 |
| | 300MG | A090514 | 004 | Jun 02, 2009 |
| QUANTUM PHARMICS | 100MG | A070921 | 001 | Dec 01, 1986 |
| SANDOZ | 100MG | A072483 | 001 | Apr 30, 1990 |
| TEVA | 150MG | A074357 | 001 | Apr 30, 1997 |
| USL PHARMA | 50MG | A070491 | 001 | Apr 29, 1987 |
| | 100MG | A070492 | 001 | Apr 29, 1987 |
| WATSON LABS | 50MG | A070857 | 001 | Oct 10, 1986 |
| | 50MG | A071112 | 001 | Nov 17, 1986 |
| | 100MG | A070858 | 001 | Oct 10, 1986 |
| | 100MG | A071113 | 001 | Nov 17, 1986 |
| TRIALODINE | | | | |
| QUANTUM PHARMICS | 50MG | A070942 | 001 | Dec 01, 1986 |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| OLEPTRO | | | | |
| + ANGELINI PHARMA | 150MG ** | N022411 | 001 | Feb 02, 2010 |
| + | 300MG ** | N022411 | 002 | Feb 02, 2010 |
| TRETINOIN | | | | |
| CAPSULE;ORAL | | | | |
| VESANOID | | | | |
| + CHEPLAPHARM | 10MG ** | N020438 | 001 | Nov 22, 1995 |
| CREAM;TOPICAL | | | | |
| TRETINOIN | | | | |
| ALLERGAN SALES LLC | 0.0375% | A090098 | 001 | Mar 22, 2010 |
| | 0.075% | A202209 | 001 | Oct 11, 2012 |
| SOLUTION;TOPICAL | | | | |
| RETIN-A | | | | |
| + VALEANT INTL | 0.05% | N016921 | 001 | |
| TRETINOIN | | | | |
| TEVA PHARMS | 0.05% | A074873 | 001 | Jun 19, 1998 |
| WOCKHARDT | 0.05% | A075260 | 001 | Jan 25, 1999 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| TRETINOIN | | | | |
| SWAB;TOPICAL | | | | |
| RETIN-A | | | | |
| | VALEANT INTL | 0.05% | N016921 002 | |
| TRIAMCINOLONE | | | | |
| TABLET;ORAL | | | | |
| ARISTOCORT | | | | |
| | ASTELLAS | 1MG | N011161 009 | |
| | | 2MG | N011161 004 | |
| | | 4MG | N011161 007 | |
| | | 8MG | N011161 011 | |
| | | 16MG | N011161 010 | |
| KENACORT | | | | |
| | DELCOR ASSET CORP | 1MG | N011283 003 | |
| | | 2MG | N011283 008 | |
| | | 4MG | N011283 006 | |
| | | 8MG | N011283 010 | |
| TRIAMCINOLONE | | | | |
| | BARR | 2MG | A084286 001 | |
| | | 2MG | A084318 001 | |
| | | 4MG | A084267 001 | |
| | | 4MG | A084319 001 | |
| | | 8MG | A084268 001 | |
| | | 8MG | A084320 001 | |
| | IMPAX LABS | 4MG | A084340 001 | |
| | IVAX SUB TEVA PHARMS | 4MG | A083750 001 | |
| | MYLAN | 2MG | A084406 001 | |
| | PUREPAC PHARM | 2MG | A084020 002 | |
| | | 4MG | A084020 003 | |
| | ROXANE | 2MG | A084708 001 | |
| | | 4MG | A084709 001 | |
| | | 8MG | A084707 001 | |
| | SANDOZ | 4MG | A085601 001 | |
| | TEVA | 4MG | A084775 001 | |
| | WATSON LABS | 4MG | A084270 001 | |
| | | 4MG | A085834 001 | |
| TRIAMCINOLONE ACETONIDE | | | | |
| AEROSOL, METERED;INHALATION | | | | |
| AZMACORT | | | | |
| | ABBVIE | 0.1MG/INH | N018117 001 | Apr 23, 1982 |
| AEROSOL, METERED;NASAL | | | | |
| NASACORT | | | | |
| | SANOFI AVENTIS US | 0.055MG/INH | N019798 001 | Jul 11, 1991 |
| CREAM;TOPICAL | | | | |
| ARISTOCORT | | | | |
| | ASTELLAS | 0.025% | A083017 003 | |
| | | 0.1% | A083016 004 | |
| | | 0.5% | A083015 002 | |
| ARISTOCORT A | | | | |
| | ASTELLAS | 0.025% | A083017 004 | |
| | | 0.025% | A088818 001 | Oct 16, 1984 |
| | | 0.1% | A083016 005 | |
| | | 0.1% | A088819 001 | Oct 16, 1984 |
| | | 0.5% | A083015 003 | |
| | | 0.5% | A088820 001 | Oct 16, 1984 |
| FLUTEX | | | | |
| | IVAX PHARMS | 0.025% | A085539 001 | |
| | | 0.1% | A085539 002 | |
| | | 0.5% | A085539 003 | |
| KENALOG | | | | |
| | DELCOR ASSET CORP | 0.5% | A083943 001 | |
| KENALOG-H | | | | |
| | DELCOR ASSET CORP | 0.1% | A086240 001 | |
| TRIACET | | | | |
| | TEVA | 0.025% | A084908 001 | |
| | | 0.1% | A084908 002 | |
| | | 0.5% | A084908 003 | |

TRIAMCINOLONE ACETONIDE

| | | | | | |
|---|---|---|---|---|---|
| CREAM;TOPICAL | | | | | |
| TRIACORT | | | | | |
| | SOLVAY | 0.1% | A087113 | 001 | |
| TRIAMCINOLONE ACETONIDE | | | | | |
| | ACTAVIS MID ATLANTIC | 0.1% | A087798 | 001 | Jun 04, 1982 |
| | ALPHARMA US PHARMS | 0.025% | A087797 | 001 | Jun 07, 1982 |
| | AMBIX | 0.025% | A087932 | 001 | May 09, 1983 |
| | MORTON GROVE | 0.025% | A088094 | 001 | Sep 01, 1983 |
| | | 0.1% | A088095 | 001 | Sep 01, 1983 |
| | | 0.5% | A088096 | 001 | Sep 01, 1983 |
| | PHARMADERM | 0.025% | A087990 | 001 | Jul 07, 1983 |
| | | 0.1% | A087991 | 001 | Jul 07, 1983 |
| | | 0.5% | A087992 | 001 | Jul 07, 1983 |
| | PHARMAFAIR | 0.025% | A087921 | 001 | Aug 10, 1982 |
| | | 0.1% | A087912 | 001 | Aug 10, 1982 |
| | | 0.5% | A087922 | 001 | Aug 10, 1982 |
| | TARO | 0.025% | A040038 | 001 | Oct 26, 1994 |
| | | 0.025% | A086277 | 001 | |
| | | 0.1% | A086276 | 001 | |
| | | 0.5% | A086275 | 001 | |
| | TOPIDERM | 0.025% | A089274 | 001 | Feb 21, 1989 |
| | | 0.1% | A089275 | 001 | Feb 21, 1989 |
| | | 0.5% | A089276 | 001 | Feb 21, 1989 |
| TRIATEX | | | | | |
| | IVAX PHARMS | 0.025% | A087430 | 001 | Nov 01, 1988 |
| | | 0.1% | A087429 | 001 | Nov 01, 1988 |
| | | 0.5% | A087428 | 001 | Nov 01, 1988 |
| TRYMEX | | | | | |
| | SAVAGE LABS | 0.025% | A088196 | 001 | Mar 25, 1983 |
| | | 0.1% | A088197 | 001 | Mar 25, 1983 |
| | | 0.5% | A088198 | 001 | Mar 25, 1983 |
| GEL;TOPICAL | | | | | |
| ARISTOGEL | | | | | |
| | ASTELLAS | 0.1% | A083380 | 001 | |
| INJECTABLE;INJECTION | | | | | |
| TRIAMCINOLONE ACETONIDE | | | | | |
| | PARNELL | 3MG/ML | N019503 | 001 | Oct 16, 1987 |
| | SANDOZ INC | 10MG/ML | A090166 | 001 | May 27, 2009 |
| | | 40MG/ML | A090164 | 001 | Jun 01, 2009 |
| | WATSON LABS | 40MG/ML | A085825 | 001 | |
| INJECTABLE;INTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREAL | | | | | |
| TRIVARIS | | | | | |
| + | ALLERGAN | 8MG/0.1ML (8MG/0.1ML) ** | N022220 | 001 | Jun 16, 2008 |
| LOTION;TOPICAL | | | | | |
| KENALOG | | | | | |
| | DELCOR ASSET CORP | 0.025% ** | A084343 | 001 | |
| + | | 0.025% ** | N011602 | 003 | |
| | | 0.1% ** | A084343 | 002 | |
| + | | 0.1% ** | N011602 | 001 | |
| TRIAMCINOLONE ACETONIDE | | | | | |
| | ALPHARMA US PHARMS | 0.025% | A087191 | 001 | Sep 08, 1982 |
| | | 0.1% | A087192 | 001 | Sep 08, 1982 |
| OINTMENT;TOPICAL | | | | | |
| ARISTOCORT | | | | | |
| | ASTELLAS | 0.1% | A080750 | 004 | |
| | | 0.5% ** | A080745 | 002 | |
| ARISTOCORT A | | | | | |
| | ASTELLAS | 0.1% | A080750 | 003 | |
| | | 0.1% | A088780 | 001 | Oct 01, 1984 |
| | | 0.5% ** | A080745 | 003 | |
| | | 0.5% | A088781 | 001 | Oct 05, 1984 |
| FLUTEX | | | | | |
| | IVAX PHARMS | 0.025% | A087375 | 001 | Nov 01, 1988 |
| | | 0.1% | A087377 | 001 | Nov 01, 1988 |
| | | 0.5% | A087376 | 001 | Nov 01, 1988 |
| KENALOG | | | | | |
| | DELCOR ASSET CORP | 0.5% ** | A083944 | 001 | |
| + | MYLAN PHARMS INC | 0.025% | N011600 | 003 | |

| | | | | |
|---|---|---|---|---|
| TRIAMCINOLONE ACETONIDE | | | | |
| OINTMENT;TOPICAL | | | | |
| KENALOG | | | | |
| + | 0.1% | N011600 001 | | |
| TRIAMCINOLONE ACETONIDE | | | | |
| ACTAVIS MID ATLANTIC | 0.1% | A087799 001 | | Jun 07, 1982 |
| ALPHARMA US PHARMS | 0.5% | A089913 001 | | Dec 23, 1988 |
| MORTON GROVE | 0.025% | A088090 001 | | Sep 01, 1983 |
| | 0.1% | A088091 001 | | Sep 01, 1983 |
| | 0.5% | A088092 001 | | Sep 01, 1983 |
| PHARMADERM | 0.025% | A088692 001 | | Aug 02, 1984 |
| | 0.1% | A088690 001 | | Aug 02, 1984 |
| TARO | 0.025% | A040040 001 | | Sep 30, 1994 |
| | 0.025% | A040374 001 | | Jun 05, 2001 |
| | 0.1% | A087902 001 | | Dec 27, 1982 |
| | 0.5% | A040386 001 | | Jun 05, 2001 |
| TRYMEX | | | | |
| SAVAGE LABS | 0.025% | A088693 001 | | Aug 02, 1984 |
| | 0.1% | A088691 001 | | Aug 02, 1984 |
| PASTE;DENTAL | | | | |
| KENALOG IN ORABASE | | | | |
| + DELCOR ASSET CORP | 0.1% ** | N012097 001 | | |
| ORALONE | | | | |
| TARO | 0.1% | A071383 001 | | Jul 06, 1987 |
| SPRAY, METERED;NASAL | | | | |
| ALLERNAZE | | | | |
| LUPIN ATLANTIS | 0.05MG/SPRAY | N020120 001 | | Feb 04, 2000 |
| NASACORT HFA | | | | |
| SANOFI AVENTIS US | 0.055MG/SPRAY | N020784 001 | | Apr 07, 2004 |
| TRIAMCINOLONE ACETONIDE | | | | |
| PERRIGO ISRAEL | 0.055MG/SPRAY | A078104 001 | | Jul 30, 2009 |
| TRIAMCINOLONE DIACETATE | | | | |
| INJECTABLE;INJECTION | | | | |
| ARISTOCORT | | | | |
| FOSUN PHARMA | 25MG/ML | N011685 003 | | |
| + | 40MG/ML ** | N012802 001 | | |
| TRIAMCINOLONE DIACETATE | | | | |
| AKORN | 25MG/ML | A085122 001 | | |
| | 40MG/ML | A086394 001 | | |
| WATSON LABS | 40MG/ML | A084072 001 | | |
| | 40MG/ML | A085529 001 | | |
| SYRUP;ORAL | | | | |
| ARISTOCORT | | | | |
| ASTELLAS | 2MG/5ML | N011960 004 | | |
| KENACORT | | | | |
| DELCOR ASSET CORP | EQ 4MG BASE/5ML | N012515 001 | | |
| TRIAZOLAM | | | | |
| TABLET;ORAL | | | | |
| HALCION | | | | |
| PHARMACIA AND UPJOHN | 0.5MG | N017892 002 | | Nov 15, 1982 |
| TRIAZOLAM | | | | |
| WATSON LABS | 0.125MG | A074445 001 | | Oct 20, 1995 |
| | 0.25MG | A074445 002 | | Oct 20, 1995 |
| TRICHLORMETHIAZIDE | | | | |
| TABLET;ORAL | | | | |
| METAHYDRIN | | | | |
| SANOFI AVENTIS US | 2MG | N012594 001 | | Jun 16, 1988 |
| | 4MG | N012594 002 | | Jun 16, 1988 |
| NAQUA | | | | |
| SCHERING | 2MG | N012265 001 | | |
| | 4MG | N012265 002 | | |
| TRICHLOREX | | | | |
| LANNETT | 4MG | A083436 001 | | |
| | 4MG | A085630 001 | | |
| TRICHLORMAS | | | | |
| MAST MM | 4MG | A086259 001 | | |

| | | | | |
|---|---|---|---|---|
| TRICHLORMETHIAZIDE | | | | |
| TABLET;ORAL | | | | |
| TRICHLORMETHIAZIDE | | | | |
| | CHARTWELL RX | 4MG | A085568 001 | |
| | IMPAX LABS | 4MG | A083967 001 | |
| | PAR PHARM | 2MG | A087007 001 | |
| | | 4MG | A087005 001 | |
| | SANDOZ | 4MG | A086171 001 | |
| | WATSON LABS | 2MG | A083847 001 | |
| | | 2MG | A086458 001 | |
| | | 4MG | A083462 001 | |
| | | 4MG | A083855 001 | |
| | | 4MG | A085962 001 | |
| TRICLOFOS SODIUM | | | | |
| SOLUTION;ORAL | | | | |
| TRICLOS | | | | |
| | SANOFI AVENTIS US | 1.5GM/15ML | N016830 001 | |
| TABLET;ORAL | | | | |
| TRICLOS | | | | |
| | SANOFI AVENTIS US | 750MG | N016809 002 | |
| TRIDIHEXETHYL CHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| PATHILON | | | | |
| | LEDERLE | 10MG/ML | N009729 001 | |
| TABLET;ORAL | | | | |
| PATHILON | | | | |
| | LEDERLE | 25MG | N009489 005 | |
| TRIFLUOPERAZINE HYDROCHLORIDE | | | | |
| CONCENTRATE;ORAL | | | | |
| STELAZINE | | | | |
| + | GLAXOSMITHKLINE | EQ 10MG BASE/ML ** | N011552 006 | |
| TRIFLUOPERAZINE HYDROCHLORIDE | | | | |
| | SANDOZ | EQ 10MG BASE/ML | A085787 001 | Apr 15, 1982 |
| | WOCKHARDT | EQ 10MG BASE/ML | A088143 001 | Jul 26, 1983 |
| INJECTABLE;INJECTION | | | | |
| STELAZINE | | | | |
| + | GLAXOSMITHKLINE | EQ 2MG BASE/ML ** | N011552 005 | |
| TABLET;ORAL | | | | |
| STELAZINE | | | | |
| + | GLAXOSMITHKLINE | EQ 1MG BASE ** | N011552 001 | |
| + | | EQ 2MG BASE ** | N011552 002 | |
| + | | EQ 5MG BASE ** | N011552 003 | |
| + | | EQ 10MG BASE ** | N011552 004 | |
| TRIFLUOPERAZINE HYDROCHLORIDE | | | | |
| | DURAMED PHARMS BARR | EQ 1MG BASE | A088967 001 | Apr 23, 1985 |
| | | EQ 2MG BASE | A088968 001 | Apr 23, 1985 |
| | | EQ 5MG BASE | A088969 001 | Apr 23, 1985 |
| | | EQ 10MG BASE | A088970 001 | Apr 23, 1985 |
| | IVAX PHARMS | EQ 1MG BASE | A087612 001 | Nov 19, 1982 |
| | | EQ 2MG BASE | A087613 001 | Nov 19, 1982 |
| | | EQ 5MG BASE | A087328 001 | Nov 19, 1982 |
| | | EQ 10MG BASE | A087614 001 | Nov 19, 1982 |
| | SANDOZ | EQ 1MG BASE | A040153 001 | Oct 25, 1996 |
| | | EQ 2MG BASE | A040153 002 | Oct 25, 1996 |
| | | EQ 5MG BASE | A040153 003 | Oct 25, 1996 |
| | | EQ 10MG BASE | A040153 004 | Oct 25, 1996 |
| | WATSON LABS | EQ 1MG BASE | A085975 001 | Jun 23, 1988 |
| | | EQ 2MG BASE | A085976 001 | Jun 23, 1988 |
| | | EQ 5MG BASE | A085973 001 | Jun 23, 1988 |
| | | EQ 10MG BASE | A088710 001 | Jun 23, 1988 |
| TRIFLUPROMAZINE | | | | |
| SUSPENSION;ORAL | | | | |
| VESPRIN | | | | |
| | APOTHECON | EQ 50MG HCL/5ML | N011491 004 | |

| | | | | |
|---|---|---|---|---|
| TRIFLUPROMAZINE HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| VESPRIN | | | | |
| | APOTHECON | 3MG/ML | N011325 005 | |
| | | 10MG/ML | N011325 004 | |
| | | 20MG/ML | N011325 001 | |
| TABLET;ORAL | | | | |
| VESPRIN | | | | |
| | BRISTOL MYERS SQUIBB | 10MG | N011123 001 | |
| | | 25MG | N011123 002 | |
| | | 50MG | N011123 003 | |
| TRIHEXYPHENIDYL HYDROCHLORIDE | | | | |
| CAPSULE, EXTENDED RELEASE;ORAL | | | | |
| ARTANE | | | | |
| | LEDERLE | 5MG | N006773 010 | |
| | | 5MG | N012947 001 | |
| ELIXIR;ORAL | | | | |
| ARTANE | | | | |
| | LEDERLE | 2MG/5ML | N006773 009 | |
| TRIHEXYPHENIDYL HYDROCHLORIDE | | | | |
| | PHARM VENTURES | 2MG/5ML | A089514 001 | Apr 07, 1989 |
| TABLET;ORAL | | | | |
| ARTANE | | | | |
| + | LEDERLE | 2MG ** | N006773 005 | |
| + | | 5MG ** | N006773 003 | |
| TREMIN | | | | |
| | SCHERING | 2MG | A080381 001 | |
| | | 5MG | A080381 003 | |
| TRIHEXYPHENIDYL HYDROCHLORIDE | | | | |
| | HIKMA PHARMS | 2MG | A040337 002 | Feb 16, 2000 |
| | | 5MG | A040337 001 | Feb 16, 2000 |
| | NYLOS | 5MG | A085622 001 | |
| | VANGARD | 2MG | A088035 001 | Jul 30, 1982 |
| | WATSON LABS | 2MG | A040184 001 | Feb 06, 1998 |
| | | 2MG | A085117 001 | |
| | | 5MG | A040184 002 | Feb 06, 1998 |
| | | 5MG | A085105 001 | |
| TRILOSTANE | | | | |
| CAPSULE;ORAL | | | | |
| MODRASTANE | | | | |
| | BIOENVISION | 30MG | N018719 002 | Dec 31, 1984 |
| | | 60MG | N018719 001 | Dec 31, 1984 |
| TRIMEPRAZINE TARTRATE | | | | |
| CAPSULE, EXTENDED RELEASE;ORAL | | | | |
| TEMARIL | | | | |
| | ALLERGAN HERBERT | EQ 5MG BASE | N011316 004 | |
| SYRUP;ORAL | | | | |
| TEMARIL | | | | |
| | ALLERGAN HERBERT | EQ 2.5MG BASE/5ML | N011316 003 | |
| TRIMEPRAZINE TARTRATE | | | | |
| | ALPHARMA US PHARMS | EQ 2.5MG BASE/5ML | A085015 001 | Feb 18, 1982 |
| | MORTON GROVE | EQ 2.5MG BASE/5ML | A088285 001 | Apr 11, 1985 |
| TABLET;ORAL | | | | |
| TEMARIL | | | | |
| | ALLERGAN HERBERT | EQ 2.5MG BASE | N011316 001 | |
| TRIMETHADIONE | | | | |
| CAPSULE;ORAL | | | | |
| TRIDIONE | | | | |
| | ABBVIE | 300MG | N005856 005 | |
| SOLUTION;ORAL | | | | |
| TRIDIONE | | | | |
| | ABBVIE | 200MG/5ML | N005856 002 | |

TRIMETHAPHAN CAMSYLATE
INJECTABLE;INJECTION
ARFONAD

| | | | | |
|---|---|---|---|---|
| ROCHE | 50MG/ML | N008983 | 001 | |

TRIMETHOBENZAMIDE HYDROCHLORIDE
INJECTABLE;INJECTION
TRIMETHOBENZAMIDE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| HOSPIRA | 100MG/ML | A088804 | 001 | Apr 03, 1987 |
| SMITH AND NEPHEW | 100MG/ML | A088960 | 001 | Apr 04, 1986 |
| | 100MG/ML | A089043 | 001 | Apr 04, 1986 |
| SOLOPAK | 100MG/ML | A089094 | 001 | Apr 04, 1986 |
| WATSON LABS | 100MG/ML | A086577 | 001 | Oct 19, 1982 |
| | 100MG/ML | A087939 | 001 | Dec 28, 1982 |

TRIMETHOPRIM
TABLET;ORAL
PROLOPRIM

| | | | | |
|---|---|---|---|---|
| MONARCH PHARMS | 100MG | N017943 | 001 | |
| | 200MG | N017943 | 003 | Jul 14, 1982 |

TRIMETHOPRIM

| | | | | |
|---|---|---|---|---|
| SUN PHARM INDUSTRIES | 100MG | A070494 | 001 | Jan 22, 1986 |
| | 200MG | A070495 | 001 | Sep 24, 1986 |
| TEVA | 200MG ** | A071259 | 001 | Jun 18, 1987 |

TRIMPEX

| | | | | |
|---|---|---|---|---|
| ROCHE | 100MG | N017952 | 001 | |

TRIMPEX 200

| | | | | |
|---|---|---|---|---|
| ROCHE | 200MG | N017952 | 002 | Nov 09, 1982 |

TRIMETHOPRIM HYDROCHLORIDE
SOLUTION;ORAL
PRIMSOL

| | | | | |
|---|---|---|---|---|
| ALLEGIS | EQ 25MG BASE/5ML | N074374 | 001 | Jun 23, 1995 |

TRIMETREXATE GLUCURONATE
INJECTABLE;INJECTION
NEUTREXIN

| | | | | |
|---|---|---|---|---|
| MEDIMMUNE ONCOLOGY | EQ 25MG BASE/VIAL | N020326 | 001 | Dec 17, 1993 |
| | EQ 200MG BASE/VIAL | N020326 | 002 | Jul 31, 1998 |

TRIMIPRAMINE MALEATE
CAPSULE;ORAL
TRIMIPRAMINE MALEATE

| | | | | |
|---|---|---|---|---|
| USL PHARMA | EQ 25MG BASE | A071283 | 001 | Dec 08, 1987 |
| | EQ 50MG BASE | A071284 | 001 | Dec 08, 1987 |
| | EQ 100MG BASE | A071285 | 001 | Dec 08, 1987 |

TRIOXSALEN
TABLET;ORAL
TRISORALEN

| | | | | |
|---|---|---|---|---|
| VALEANT PHARM INTL | 5MG | N012697 | 001 | |

TRIPELENNAMINE CITRATE
ELIXIR;ORAL
PBZ

| | | | | |
|---|---|---|---|---|
| NOVARTIS | EQ 25MG HCL/5ML | N005914 | 004 | |

TRIPELENNAMINE HYDROCHLORIDE
TABLET;ORAL
PBZ

| | | | | |
|---|---|---|---|---|
| NOVARTIS | 25MG | A083149 | 001 | |
| | 50MG | N005914 | 002 | |

TRIPELENNAMINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| ANABOLIC | 50MG | A083037 | 001 | |
| BARR | 50MG | A080744 | 001 | |
| HEATHER | 50MG | A083989 | 001 | |
| IMPAX LABS | 50MG | A080785 | 001 | |
| LANNETT | 50MG | A083557 | 001 | |
| NYLOS | 50MG | A085412 | 001 | |
| PARKE DAVIS | 25MG | A083625 | 001 | |
| | 50MG | A083626 | 001 | |
| WATSON LABS | 50MG | A080713 | 001 | |
| | 50MG | A080790 | 001 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

TRIPELENNAMINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| TRIPELENNAMINE HYDROCHLORIDE | | | | |
| | 50MG | | A085188 001 | |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| PBZ-SR | | | | |
| NOVARTIS | 50MG | | N010533 002 | |
| | 100MG | | N010533 001 | |

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

| | | | | |
|---|---|---|---|---|
| CREAM;VAGINAL | | | | |
| GYNE-SULF | | | | |
| G AND W LABS | 3.7%;2.86%;3.42% | | A088607 001 | Jun 09, 1986 |
| SULTRIN | | | | |
| ORTHO MCNEIL PHARM | 3.7%;2.86%;3.42% | | N005794 001 | |
| TRIPLE SULFA | | | | |
| ALPHARMA US PHARMS | 3.7%;2.86%;3.42% | | A087864 001 | Sep 01, 1982 |
| FOUGERA | 3.7%;2.86%;3.42% | | A086424 001 | |
| PERRIGO NEW YORK | 3.7%;2.86%;3.42% | | A087285 001 | Nov 15, 1982 |
| TRYSUL | | | | |
| SAVAGE LABS | 3.7%;2.86%;3.42% | | A087887 001 | Jul 23, 1982 |
| VAGILIA | | | | |
| G AND W LABS INC | 3.7%;2.86%;3.42% | | A088821 001 | Nov 09, 1987 |
| TABLET;VAGINAL | | | | |
| SULTRIN | | | | |
| ORTHO MCNEIL PHARM | 184MG;143.75MG;172.5MG | | N005794 002 | |
| TRIPLE SULFA | | | | |
| FOUGERA | 184MG;143.75MG;172.5MG | | A088463 001 | Jan 03, 1985 |
| PHARMADERM | 184MG;143.75MG;172.5MG | | A088462 001 | Jan 03, 1985 |

TRIPROLIDINE HYDROCHLORIDE

| | | | | |
|---|---|---|---|---|
| SYRUP;ORAL | | | | |
| ACTIDIL | | | | |
| GLAXOSMITHKLINE | 1.25MG/5ML | | N011496 002 | Jul 01, 1983 |
| MYIDYL | | | | |
| USL PHARMA | 1.25MG/5ML | | A087963 001 | Jan 18, 1983 |
| TRIPROLIDINE HYDROCHLORIDE | | | | |
| ALPHARMA US PHARMS | 1.25MG/5ML | | A085940 001 | |
| HALSEY | 1.25MG/5ML | | A088735 001 | Jan 17, 1985 |
| PHARM ASSOC | 1.25MG/5ML | | A087514 001 | Feb 10, 1982 |
| TABLET;ORAL | | | | |
| ACTIDIL | | | | |
| GLAXOSMITHKLINE | 2.5MG | | N011110 002 | Jul 01, 1983 |
| TRIPROLIDINE HYDROCHLORIDE | | | | |
| VITARINE | 2.5MG | | A085610 001 | |
| WATSON LABS | 2.5MG | | A085094 001 | |

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

| | | | | |
|---|---|---|---|---|
| SUSPENSION;ORAL | | | | |
| LANTRISUL | | | | |
| LANNETT | 167MG/5ML;167MG/5ML;167MG/5ML | | A080123 002 | |
| NEOTRIZINE | | | | |
| LILLY | 167MG/5ML;167MG/5ML;167MG/5ML | | N006317 012 | |
| SULFALOID | | | | |
| FOREST PHARMS | 167MG/5ML;167MG/5ML;167MG/5ML | | A080100 001 | |
| SULFOSE | | | | |
| WYETH AYERST | 167MG/5ML;167MG/5ML;167MG/5ML | | A080013 002 | |
| TERFONYL | | | | |
| BRISTOL MYERS SQUIBB | 167MG/5ML;167MG/5ML;167MG/5ML | | N006904 002 | |
| TRIPLE SULFA | | | | |
| ALPHARMA US PHARMS | 167MG/5ML;167MG/5ML;167MG/5ML | | A080280 001 | |
| TRIPLE SULFAS | | | | |
| LEDERLE | 167MG/5ML;167MG/5ML;167MG/5ML | | N006920 003 | |
| TABLET;ORAL | | | | |
| NEOTRIZINE | | | | |
| LILLY | 167MG;167MG;167MG | | N006317 011 | |
| SULFA-TRIPLE #2 | | | | |
| IMPAX LABS | 167MG;167MG;167MG | | A080079 001 | |
| SULFALOID | | | | |
| FOREST PHARMS | 167MG;167MG;167MG | | A080099 001 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

TRISULFAPYRIMIDINES (SULFADIAZINE;SULFAMERAZINE;SULFAMETHAZINE)

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| SULFOSE | | | | |
| | WYETH AYERST | 167MG;167MG;167MG | A080013 001 | |
| TERFONYL | | | | |
| | BRISTOL MYERS SQUIBB | 167MG;167MG;167MG | N006904 001 | |
| TRIPLE SULFA | | | | |
| | PUREPAC PHARM | 167MG;167MG;167MG | A080086 001 | |
| TRIPLE SULFAS | | | | |
| | LEDERLE | 167MG;167MG;167MG | N006920 002 | |
| TRIPLE SULFOID | | | | |
| | PAL PAK | 167MG;167MG;167MG | A080094 001 | |

TROGLITAZONE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| PRELAY | | | | |
| | SANKYO | 200MG | N020719 001 | Jan 29, 1997 |
| | | 300MG | N020719 003 | Aug 04, 1997 |
| | | 400MG | N020719 002 | Jan 29, 1997 |
| REZULIN | | | | |
| | PFIZER PHARMS | 200MG | N020720 001 | Jan 29, 1997 |
| | | 300MG | N020720 003 | Aug 04, 1997 |
| | | 400MG | N020720 002 | Jan 29, 1997 |

TROLAMINE POLYPEPTIDE OLEATE CONDENSATE

| | | | | |
|---|---|---|---|---|
| SOLUTION/DROPS;OTIC | | | | |
| CERUMENEX | | | | |
| | PHARM RES ASSOC | 10% | N011340 002 | |

TROLEANDOMYCIN

| | | | | |
|---|---|---|---|---|
| CAPSULE;ORAL | | | | |
| TAO | | | | |
| | PFIZER | EQ 250MG BASE | N050336 002 | |
| SUSPENSION;ORAL | | | | |
| TAO | | | | |
| | PFIZER | EQ 125MG BASE/5ML | N050332 001 | |

TROPICAMIDE

| | | | | |
|---|---|---|---|---|
| SOLUTION/DROPS;OPHTHALMIC | | | | |
| MYDRIACYL | | | | |
| | ALCON | 0.5% ** | N012111 002 | |
| | | 1% ** | N012111 004 | |
| MYDRIAFAIR | | | | |
| | PHARMAFAIR | 0.5% | A088274 001 | Sep 16, 1983 |
| | | 1% | A088230 001 | Sep 16, 1983 |
| TROPICAMIDE | | | | |
| | AKORN | 1% | A088447 001 | Aug 28, 1985 |
| | ALCON PHARMS LTD | 1% | A089172 001 | Dec 28, 1990 |
| | MIZA PHARMS USA | 0.5% | A087636 001 | Jul 30, 1982 |
| | | 1% | A087637 001 | Aug 09, 1982 |
| | WATSON LABS | 0.5% | A089171 001 | Dec 28, 1990 |

TROSPIUM CHLORIDE

| | | | | |
|---|---|---|---|---|
| CAPSULE, EXTENDED RELEASE;ORAL | | | | |
| SANCTURA XR | | | | |
| + | ALLERGAN | 60MG ** | N022103 001 | Aug 03, 2007 |
| TROSPIUM CHLORIDE | | | | |
| | UPSHER-SMITH LABS | 60MG | A091635 001 | Apr 29, 2015 |
| TABLET;ORAL | | | | |
| SANCTURA | | | | |
| + | ALLERGAN | 20MG ** | N021595 001 | May 28, 2004 |

TROVAFLOXACIN MESYLATE

| | | | | |
|---|---|---|---|---|
| TABLET;ORAL | | | | |
| TROVAN | | | | |
| | PFIZER | EQ 100MG BASE | N020759 001 | Dec 18, 1997 |
| | | EQ 200MG BASE | N020759 002 | Dec 18, 1997 |

| | | | | |
|---|---|---|---|---|
| TUBOCURARINE CHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| TUBOCURARINE CHLORIDE | | | | |
| BRISTOL MYERS SQUIBB | 3MG/ML | N005657 | 001 | |
| HOSPIRA | 3MG/ML | N006095 | 001 | |
| LILLY | 3MG/ML | N006325 | 001 | |
| TYROPANOATE SODIUM | | | | |
| CAPSULE;ORAL | | | | |
| BILOPAQUE | | | | |
| GE HEALTHCARE | 750MG | N013731 | 001 | |
| UNOPROSTONE ISOPROPYL | | | | |
| SOLUTION/DROPS;OPHTHALMIC | | | | |
| RESCULA | | | | |
| + SUCAMPO PHARMA LLC | 0.15% ** | N021214 | 001 | Aug 03, 2000 |
| URACIL MUSTARD | | | | |
| CAPSULE;ORAL | | | | |
| URACIL MUSTARD | | | | |
| SHIRE | 1MG | N012892 | 001 | |
| UREA | | | | |
| INJECTABLE;INJECTION | | | | |
| STERILE UREA | | | | |
| HOSPIRA | 40GM/VIAL | N017698 | 001 | |
| UREAPHIL | | | | |
| HOSPIRA | 40GM/VIAL | N012154 | 001 | |
| UREA C-13 | | | | |
| FOR SOLUTION;ORAL | | | | |
| BREATHTEK UBT FOR H-PYLORI | | | | |
| OTSUKA AMERICA | EQ 75MG/POUCH | N020586 | 002 | May 10, 2001 |
| HELICOSOL | | | | |
| METABOLIC SOLUTIONS | 125MG/VIAL | N021092 | 001 | Dec 17, 1999 |
| MERETEK UBT KIT (W/ PRANACTIN) | | | | |
| OTSUKA AMERICA | 125MG/VIAL | N020586 | 001 | Sep 17, 1996 |
| PYLORI-CHEK BREATH TEST | | | | |
| DXS DEVICES | 100MG/VIAL | N020900 | 001 | Feb 04, 1999 |
| UROFOLLITROPIN | | | | |
| INJECTABLE;INTRAMUSCULAR | | | | |
| METRODIN | | | | |
| SERONO | 75 IU/AMP | N019415 | 002 | Sep 18, 1986 |
| | 150 IU/AMP | N019415 | 003 | Sep 18, 1986 |
| INJECTABLE;SUBCUTANEOUS | | | | |
| FERTINEX | | | | |
| SERONO | 75 IU/AMP | N019415 | 005 | Aug 23, 1996 |
| | 150 IU/AMP | N019415 | 004 | Aug 23, 1996 |
| UROKINASE | | | | |
| INJECTABLE;INJECTION | | | | |
| KINLYTIC | | | | |
| MICROBIX BIOSYSTEMS | 5,000 IU/VIAL | N021846 | 003 | |
| | 9,000 IU/VIAL | N021846 | 002 | |
| | 250,000 IU/VIAL | N021846 | 001 | |
| URSODIOL | | | | |
| CAPSULE;ORAL | | | | |
| ACTIGALL | | | | |
| ALLERGAN SALES LLC | 150MG | N019594 | 001 | Dec 31, 1987 |
| URSODIOL | | | | |
| IMPAX LABS INC | 300MG | A077895 | 001 | Jul 27, 2006 |
| TABLET;ORAL | | | | |
| URSODIOL | | | | |
| TEVA PHARMS USA | 250MG | A079184 | 001 | May 13, 2009 |
| | 500MG | A079184 | 002 | May 13, 2009 |

| | | | | |
|---|---|---|---|---|
| VALACYCLOVIR HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| VALACYCLOVIR HYDROCHLORIDE | | | | |
| MYLAN | EQ 500MG BASE | A078070 | 001 | May 24, 2010 |
| | EQ 1GM BASE | A078070 | 002 | May 24, 2010 |
| VALDECOXIB | | | | |
| TABLET;ORAL | | | | |
| BEXTRA | | | | |
| GD SEARLE | 10MG | N021341 | 002 | Nov 16, 2001 |
| | 20MG | N021341 | 003 | Nov 16, 2001 |
| VALPROIC ACID | | | | |
| CAPSULE;ORAL | | | | |
| VALPROIC ACID | | | | |
| PAR PHARM | 250MG | A070431 | 001 | Feb 28, 1986 |
| SCHERER RP | 250MG | A070195 | 001 | Jul 02, 1987 |
| USL PHARMA | 250MG | A070631 | 001 | Jun 11, 1987 |
| CAPSULE, DELAYED RELEASE;ORAL | | | | |
| STAVZOR | | | | |
| + BIONPHARMA INC | 125MG ** | N022152 | 001 | Jul 29, 2008 |
| + | 250MG ** | N022152 | 002 | Jul 29, 2008 |
| + | 500MG ** | N022152 | 003 | Jul 29, 2008 |
| SYRUP;ORAL | | | | |
| VALPROIC ACID | | | | |
| APOTEX INC | 250MG/5ML | A077105 | 001 | Jul 29, 2005 |
| VALSARTAN | | | | |
| CAPSULE;ORAL | | | | |
| DIOVAN | | | | |
| NOVARTIS | 80MG | N020665 | 001 | Dec 23, 1996 |
| | 160MG | N020665 | 002 | Dec 23, 1996 |
| VANCOMYCIN HYDROCHLORIDE | | | | |
| FOR SOLUTION;ORAL | | | | |
| VANCOCIN HYDROCHLORIDE | | | | |
| ANI PHARMS INC | EQ 250MG BASE/5ML | A061667 | 002 | Jul 13, 1983 |
| | EQ 500MG BASE/6ML | A061667 | 001 | |
| VANCOLED | | | | |
| LEDERLE | EQ 250MG BASE/5ML | A063321 | 002 | Oct 15, 1993 |
| | EQ 500MG BASE/6ML | A063321 | 003 | Oct 15, 1993 |
| INJECTABLE;INJECTION | | | | |
| VANCOCIN HYDROCHLORIDE | | | | |
| ANI PHARMS INC | EQ 500MG BASE/VIAL ** | A060180 | 001 | |
| | EQ 500MG BASE/VIAL | A062476 | 001 | Mar 15, 1984 |
| | EQ 500MG BASE/VIAL | A062716 | 001 | Mar 13, 1987 |
| | EQ 500MG BASE/VIAL ** | A062812 | 001 | Nov 17, 1987 |
| | EQ 1GM BASE/VIAL ** | A060180 | 002 | Mar 21, 1986 |
| | EQ 1GM BASE/VIAL | A062476 | 002 | Mar 21, 1986 |
| | EQ 1GM BASE/VIAL | A062716 | 002 | Mar 13, 1987 |
| | EQ 1GM BASE/VIAL ** | A062812 | 002 | Nov 17, 1987 |
| | EQ 10GM BASE/VIAL ** | A062812 | 003 | Nov 17, 1987 |
| VANCOLED | | | | |
| WEST-WARD PHARMS INT | EQ 500MG BASE/VIAL ** | A062682 | 001 | Jul 22, 1986 |
| | EQ 1GM BASE/VIAL ** | A062682 | 002 | Mar 30, 1988 |
| | EQ 2GM BASE/VIAL ** | A062682 | 003 | May 11, 1988 |
| | EQ 5GM BASE/VIAL ** | A062682 | 004 | May 11, 1988 |
| | EQ 10GM BASE/VIAL ** | A062682 | 005 | May 11, 1988 |
| VANCOMYCIN HYDROCHLORIDE | | | | |
| TEVA PHARMS USA | EQ 1GM BASE/VIAL | A201251 | 002 | Dec 23, 2015 |
| | EQ 5GM BASE/VIAL | A201250 | 001 | Dec 23, 2015 |
| | EQ 10GM BASE/VIAL | A201250 | 002 | Dec 23, 2015 |
| | EQ 500MG BASE/VIAL | A201251 | 001 | Dec 23, 2015 |
| WEST-WARD PHARMS INT | EQ 500MG BASE/VIAL | A062879 | 001 | Aug 02, 1988 |
| | EQ 1GM BASE/VIAL | A062879 | 002 | Aug 02, 1988 |
| VANCOR | | | | |
| PHARMACIA AND UPJOHN | EQ 500MG BASE/VIAL | A062956 | 001 | Aug 01, 1988 |
| | EQ 1GM BASE/VIAL | A062956 | 002 | Aug 01, 1988 |

| | | | | |
|---|---|---|---|---|
| VARDENAFIL HYDROCHLORIDE | | | | |
| TABLET;ORAL | | | | |
| VARDENAFIL HYDROCHLORIDE | | | | |
| TEVA PHARMS | 2.5MG | A091347 | 001 | May 03, 2012 |
| | 5MG | A091347 | 002 | May 03, 2012 |
| | 10MG | A091347 | 003 | May 03, 2012 |
| | 20MG | A091347 | 004 | May 03, 2012 |
| VASOPRESSIN TANNATE | | | | |
| INJECTABLE;INJECTION | | | | |
| PITRESSIN TANNATE | | | | |
| + PARKE DAVIS | 5PRESSOR UNITS/ML ** | N003402 | 001 | |
| VECURONIUM BROMIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| NORCURON | | | | |
| + ORGANON USA INC | 10MG/VIAL ** | N018776 | 002 | Apr 30, 1984 |
| + | 20MG/VIAL ** | N018776 | 003 | Jan 03, 1992 |
| VECURONIUM BROMIDE | | | | |
| HOSPIRA | 4MG/VIAL | A075558 | 001 | Sep 11, 2001 |
| WATSON LABS | 10MG/VIAL | A074334 | 001 | Aug 31, 1995 |
| | 20MG/VIAL | A074334 | 002 | Aug 31, 1995 |
| WEST-WARD PHARMS INT | 10MG/VIAL | A075218 | 001 | Aug 23, 1999 |
| | 20MG/VIAL | A075218 | 002 | Aug 23, 1999 |
| VELAGLUCERASE ALFA | | | | |
| POWDER;IV (INFUSION) | | | | |
| VPRIV | | | | |
| SHIRE HUMAN GENETIC | 200 UNITS/VIAL | N022575 | 002 | Feb 26, 2010 |
| VENLAFAXINE HYDROCHLORIDE | | | | |
| CAPSULE, EXTENDED RELEASE;ORAL | | | | |
| EFFEXOR XR | | | | |
| WYETH PHARMS INC | EQ 100MG BASE | N020699 | 003 | Oct 20, 1997 |
| VENLAFAXINE HYDROCHLORIDE | | | | |
| MYLAN | EQ 37.5MG BASE | A078789 | 001 | Jun 01, 2011 |
| | EQ 75MG BASE | A078789 | 002 | Jun 01, 2011 |
| | EQ 150MG BASE | A078789 | 003 | Jun 01, 2011 |
| TABLET;ORAL | | | | |
| EFFEXOR | | | | |
| + WYETH PHARMS INC | EQ 12.5MG BASE ** | N020151 | 001 | Dec 28, 1993 |
| + | EQ 25MG BASE ** | N020151 | 002 | Dec 28, 1993 |
| + | EQ 37.5MG BASE ** | N020151 | 006 | Dec 28, 1993 |
| + | EQ 50MG BASE ** | N020151 | 003 | Dec 28, 1993 |
| + | EQ 75MG BASE ** | N020151 | 004 | Dec 28, 1993 |
| + | EQ 100MG BASE ** | N020151 | 005 | Dec 28, 1993 |
| VENLAFAXINE HYDROCHLORIDE | | | | |
| PLIVA HRVATSKA DOO | EQ 25MG BASE | A078517 | 001 | Jun 13, 2008 |
| | EQ 37.5MG BASE | A078517 | 002 | Jun 13, 2008 |
| | EQ 50MG BASE | A078517 | 003 | Jun 13, 2008 |
| | EQ 75MG BASE | A078517 | 004 | Jun 13, 2008 |
| | EQ 100MG BASE | A078517 | 005 | Jun 13, 2008 |
| SANDOZ | EQ 25MG BASE | A077515 | 001 | Jun 13, 2008 |
| | EQ 37.5MG BASE | A077515 | 002 | Jun 13, 2008 |
| | EQ 50MG BASE | A077515 | 003 | Jun 13, 2008 |
| | EQ 75MG BASE | A077515 | 004 | Jun 13, 2008 |
| | EQ 100MG BASE | A077515 | 005 | Jun 13, 2008 |
| VERAPAMIL HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| CALAN | | | | |
| GD SEARLE LLC | 2.5MG/ML | N019038 | 001 | Mar 30, 1984 |
| ISOPTIN | | | | |
| + MT ADAMS | 2.5MG/ML ** | N018485 | 001 | |
| VERAPAMIL HYDROCHLORIDE | | | | |
| ABRAXIS PHARM | 2.5MG/ML | A070348 | 001 | May 01, 1986 |
| BEDFORD | 2.5MG/ML | A072888 | 001 | Jul 28, 1995 |
| HOSPIRA | 2.5MG/ML | A070577 | 001 | Feb 02, 1987 |
| | 2.5MG/ML | A070739 | 001 | May 06, 1987 |
| | 2.5MG/ML | A070740 | 001 | May 06, 1987 |
| INTL MEDICATION | 2.5MG/ML | A070451 | 001 | Dec 16, 1985 |
| LUITPOLD | 2.5MG/ML | A070225 | 001 | Nov 12, 1985 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| VERAPAMIL HYDROCHLORIDE | | | | |
| INJECTABLE;INJECTION | | | | |
| VERAPAMIL HYDROCHLORIDE | | | | |
| | 2.5MG/ML | A070617 | 001 | Nov 12, 1985 |
| MARSAM PHARMS LLC | 2.5MG/ML | A072233 | 001 | Feb 26, 1993 |
| | 2.5MG/ML | A073485 | 001 | Sep 27, 1993 |
| SMITH AND NEPHEW | 2.5MG/ML | A070696 | 001 | Jul 31, 1987 |
| | 2.5MG/ML | A070697 | 001 | Jul 31, 1987 |
| SOLOPAK | 2.5MG/ML | A070695 | 001 | Jul 31, 1987 |
| TABLET;ORAL | | | | |
| CALAN | | | | |
| GD SEARLE LLC | 40MG | N018817 | 003 | Feb 23, 1988 |
| | 160MG | N018817 | 004 | Feb 23, 1988 |
| ISOPTIN | | | | |
| MT ADAMS | 40MG | N018593 | 003 | Nov 23, 1987 |
| | 80MG | N018593 | 001 | Mar 08, 1982 |
| | 120MG | N018593 | 002 | Mar 08, 1982 |
| VERAPAMIL HYDROCHLORIDE | | | | |
| ACTAVIS ELIZABETH | 80MG | A071019 | 001 | Sep 24, 1986 |
| | 120MG | A070468 | 001 | Sep 24, 1986 |
| FOSUN PHARMA | 40MG | A073168 | 001 | Jul 31, 1992 |
| | 80MG | A071423 | 001 | May 24, 1988 |
| | 120MG | A071424 | 001 | May 25, 1988 |
| MUTUAL PHARM | 80MG | A070482 | 001 | Sep 24, 1986 |
| | 120MG | A070483 | 001 | Sep 24, 1986 |
| PLIVA | 40MG | A072751 | 001 | Feb 23, 1996 |
| | 80MG | A072124 | 001 | Jan 26, 1989 |
| | 120MG | A072125 | 001 | Jan 26, 1989 |
| SUN PHARM INDUSTRIES | 80MG | A071489 | 002 | Jan 13, 1988 |
| | 120MG | A071489 | 001 | Jan 13, 1988 |
| WARNER CHILCOTT | 80MG | A070340 | 001 | Sep 24, 1986 |
| | 120MG | A070341 | 001 | Sep 24, 1986 |
| WATSON LABS | 40MG | A072799 | 001 | Apr 28, 1989 |
| | 40MG | A072923 | 001 | Jun 29, 1993 |
| | 80MG | A070855 | 001 | Sep 24, 1986 |
| | 80MG | A071366 | 001 | Oct 01, 1986 |
| | 120MG | A070856 | 001 | Sep 24, 1986 |
| | 120MG | A071367 | 001 | Oct 01, 1986 |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| CALAN SR | | | | |
| + PFIZER | 180MG ** | N019152 | 002 | Dec 15, 1989 |
| COVERA-HS | | | | |
| GD SEARLE LLC | 180MG | N020552 | 001 | Feb 26, 1996 |
| | 240MG | N020552 | 002 | Feb 26, 1996 |
| VERAPAMIL HYDROCHLORIDE | | | | |
| PLIVA | 240MG | A072922 | 001 | Mar 01, 1996 |
| VERATRUM VIRIDE ROOT | | | | |
| TABLET;ORAL | | | | |
| VERTAVIS | | | | |
| MEDPOINTE PHARM HLC | 130CSR UNIT | N005691 | 002 | |
| VIDARABINE | | | | |
| INJECTABLE;INJECTION | | | | |
| VIRA-A | | | | |
| PARKEDALE | EQ 187.4MG BASE/ML | N050523 | 001 | |
| OINTMENT;OPHTHALMIC | | | | |
| VIRA-A | | | | |
| PARKEDALE | 3% | N050486 | 001 | |
| VINBLASTINE SULFATE | | | | |
| INJECTABLE;INJECTION | | | | |
| VELBAN | | | | |
| LILLY | 10MG/VIAL | N012665 | 001 | |
| VINBLASTINE SULFATE | | | | |
| ABRAXIS PHARM | 10MG/VIAL | A089011 | 001 | Nov 18, 1985 |
| HOSPIRA | 10MG/VIAL | A089565 | 001 | Aug 18, 1987 |

VINCRISTINE SULFATE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| ONCOVIN | | | | |
| LILLY | 1MG/VIAL | N014103 | 001 | |
| | 1MG/ML | N014103 | 003 | Mar 07, 1984 |
| | 5MG/VIAL | N014103 | 002 | |
| VINCASAR PFS | | | | |
| TEVA PARENTERAL | 1MG/ML | A071426 | 001 | Jul 17, 1987 |
| VINCREX | | | | |
| BRISTOL MYERS SQUIBB | 5MG/VIAL | A070867 | 001 | Jul 12, 1988 |
| VINCRISTINE SULFATE | | | | |
| ABIC | 1MG/ML | A070873 | 001 | Feb 19, 1987 |
| ABRAXIS PHARM | 1MG/ML | A070411 | 001 | Sep 10, 1986 |
| FRESENIUS KABI USA | 1MG/ML | A076296 | 001 | Dec 20, 2002 |
| | 1MG/ML | A076401 | 001 | Oct 28, 2003 |
| HOSPIRA | 1MG/VIAL | A071559 | 001 | Apr 11, 1988 |
| | 2MG/VIAL | A071560 | 001 | Apr 11, 1988 |
| | 5MG/VIAL | A071561 | 001 | Apr 11, 1988 |

VINORELBINE TARTRATE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| VINORELBINE TARTRATE | | | | |
| EBEWE PHARMA | EQ 10MG BASE/ML | A078408 | 001 | Feb 13, 2008 |
| MYLAN LABS LTD | EQ 10MG BASE/ML | A200148 | 001 | Aug 31, 2012 |

VIOMYCIN SULFATE

| | | | | |
|---|---|---|---|---|
| INJECTABLE;INJECTION | | | | |
| VIOCIN SULFATE | | | | |
| PFIZER | EQ 1GM BASE/VIAL | A061086 | 001 | |
| | EQ 5GM BASE/VIAL | A061086 | 002 | |

VITAMIN A

| | | | | |
|---|---|---|---|---|
| CAPSULE;ORAL | | | | |
| AQUASOL A | | | | |
| ASTRAZENECA | 25,000USP UNITS | A083080 | 002 | |
| | 50,000USP UNITS | A083080 | 001 | |
| VITAMIN A | | | | |
| BANNER PHARMACAPS | 50,000USP UNITS | A083973 | 001 | |
| CHASE CHEM | 50,000 IU | A083351 | 001 | |
| EVERYLIFE | 50,000 IU | A083134 | 001 | |
| IMPAX LABS | 50,000USP UNITS | A080952 | 001 | |
| WEST WARD | 50,000USP UNITS | A080985 | 001 | |

VITAMIN A PALMITATE

| | | | | |
|---|---|---|---|---|
| CAPSULE;ORAL | | | | |
| AFAXIN | | | | |
| STERLING WINTHROP | EQ 50,000 UNITS BASE | A083187 | 001 | |
| ALPHALIN | | | | |
| LILLY | EQ 50,000 UNITS BASE | A080883 | 001 | |
| DEL-VI-A | | | | |
| DEL RAY LABS | EQ 50,000 UNITS BASE | A080830 | 001 | |
| VI-DOM-A | | | | |
| BAYER PHARMS | EQ 50,000 UNITS BASE | A080972 | 001 | |
| VITAMIN A | | | | |
| BANNER PHARMACAPS | EQ 50,000 UNITS BASE | A080702 | 001 | |
| BRISTOL MYERS SQUIBB | EQ 50,000 UNITS BASE | A080860 | 001 | |
| CHASE CHEM | EQ 50,000 UNITS BASE | A080746 | 001 | |
| | EQ 50,000 UNITS BASE | A083207 | 001 | |
| ELKINS SINN | EQ 50,000 UNITS BASE | A085479 | 001 | |
| EVERYLIFE | EQ 50,000 UNITS BASE | A080943 | 001 | |
| | EQ 50,000 UNITS BASE | A083114 | 001 | |
| IMPAX LABS | EQ 50,000 UNITS BASE | A080953 | 001 | |
| | EQ 50,000 UNITS BASE | A080955 | 001 | |
| IVAX SUB TEVA PHARMS | EQ 50,000 UNITS BASE | A083035 | 001 | |
| | EQ 50,000 UNITS BASE | A083190 | 001 | |
| MK LABS | EQ 25,000 UNITS BASE | A083457 | 002 | |
| | EQ 50,000 UNITS BASE | A083457 | 001 | |
| WEST WARD | EQ 50,000 UNITS BASE | A080967 | 001 | |
| WHARTON LABS | EQ 50,000 UNITS BASE | A083665 | 001 | |
| VITAMIN A PALMITATE | | | | |
| ARCUM | EQ 50,000 UNITS BASE | A083311 | 001 | |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

| | | | | |
|---|---|---|---|---|
| VITAMIN A PALMITATE | | | | |
| CAPSULE;ORAL | | | | |
| VITAMIN A PALMITATE | | | | |
| | | EQ 50,000 UNITS BASE | A083321 001 | |
| | BANNER PHARMACAPS | EQ 50,000 UNITS BASE | A083948 001 | |
| | | EQ 50,000 UNITS BASE | A083981 001 | |
| VITAMIN A SOLUBILIZED | | | | |
| | TEVA | EQ 50,000 UNITS BASE | A080921 001 | |
| INJECTABLE;INJECTION | | | | |
| VITAMIN A PALMITATE | | | | |
| | BEL MAR | EQ 50,000 UNITS BASE/ML | A080819 001 | |
| VORTIOXETINE HYDROBROMIDE | | | | |
| TABLET;ORAL | | | | |
| TRINTELLIX | | | | |
| + | TAKEDA PHARMS USA | EQ 15MG BASE ** | N204447 003 | Sep 30, 2013 |
| WARFARIN POTASSIUM | | | | |
| TABLET;ORAL | | | | |
| ATHROMBIN-K | | | | |
| | PHARM RES ASSOC | 2MG | N011771 007 | |
| | | 5MG | N011771 004 | |
| | | 10MG | N011771 005 | |
| | | 25MG | N011771 006 | |
| WARFARIN SODIUM | | | | |
| INJECTABLE;INJECTION | | | | |
| COUMADIN | | | | |
| | BRISTOL MYERS SQUIBB | 5MG/VIAL | N009218 024 | Feb 07, 1995 |
| | | 50MG/VIAL | N009218 020 | |
| | | 75MG/VIAL | N009218 012 | |
| TABLET;ORAL | | | | |
| ATHROMBIN | | | | |
| | PHARM RES ASSOC | 5MG | N011771 003 | |
| | | 10MG | N011771 002 | |
| | | 25MG | N011771 001 | |
| PANWARFIN | | | | |
| | ABBOTT | 2MG | N017020 001 | |
| | | 2.5MG | N017020 002 | |
| | | 5MG | N017020 003 | |
| | | 7.5MG | N017020 004 | |
| | | 10MG | N017020 005 | |
| WARFARIN SODIUM | | | | |
| | FOSUN PHARMA | 1MG | A040196 001 | Sep 30, 1997 |
| | | 2MG | A040196 002 | Sep 30, 1997 |
| | | 2.5MG | A040196 003 | Sep 30, 1997 |
| | | 3MG | A040196 008 | Jul 26, 2000 |
| | | 4MG | A040196 004 | Sep 30, 1997 |
| | | 5MG | A040196 005 | Sep 30, 1997 |
| | | 6MG | A040196 009 | Jul 26, 2000 |
| | | 7.5MG | A040196 006 | Sep 30, 1997 |
| | | 10MG | A040196 007 | Sep 30, 1997 |
| | MYLAN | 1MG | A040415 001 | Sep 27, 2004 |
| | | 2MG | A040415 002 | Sep 27, 2004 |
| | | 2.5MG | A040415 003 | Sep 29, 2004 |
| | | 3MG | A040415 004 | Sep 27, 2004 |
| | | 4MG | A040415 005 | Sep 27, 2004 |
| | | 5MG | A040415 006 | Sep 27, 2004 |
| | | 6MG | A040415 007 | Sep 27, 2004 |
| | | 7.5MG | A040415 008 | Sep 27, 2004 |
| | | 10MG | A040415 009 | Sep 27, 2004 |
| | USL PHARMA | 2MG | A088719 001 | Jun 27, 1985 |
| | | 2.5MG | A088720 001 | Aug 06, 1985 |
| | | 5MG | A088721 001 | Jul 02, 1985 |
| | WATSON LABS | 2MG | A086123 001 | Aug 17, 1982 |
| | | 2.5MG | A086120 001 | Aug 17, 1982 |
| | | 5MG | A086119 001 | Aug 17, 1982 |
| | | 7.5MG | A086118 001 | Aug 17, 1982 |
| | | 10MG | A086122 001 | Aug 17, 1982 |

| | | | | |
|---|---|---|---|---|
| XENON XE-127 | | | | |
| GAS;INHALATION | | | | |
| XENON XE 127 | | | | |
| | MALLINCKRODT | 5mCi/VIAL | N018536 001 | Oct 01, 1982 |
| | | 10mCi/VIAL | N018536 002 | Oct 01, 1982 |
| XENON XE-133 | | | | |
| GAS;INHALATION | | | | |
| XENON XE 133 | | | | |
| | GE HEALTHCARE | 1 CI/AMP | N017256 002 | |
| | | 10mCi/VIAL | N017687 002 | |
| | | 20mCi/VIAL | N017687 003 | |
| | GEN ELECTRIC | 5-100 CI/CYLINDER | N017550 001 | |
| | | 0.25-5 CI/AMP | N017550 003 | |
| XENON XE 133-V.S.S. | | | | |
| | GE HEALTHCARE | 10mCi/VIAL | N017687 001 | |
| INJECTABLE;INJECTION | | | | |
| XENON XE 133 | | | | |
| | GE HEALTHCARE | 1.3-1.7 CI/AMP | N017256 001 | |
| | LANTHEUS MEDCL | 6.3mCi/ML | N017283 001 | |
| SOLUTION;INHALATION, INJECTION | | | | |
| XENEISOL | | | | |
| | MALLINCKRODT | 18-25mCi/AMP | N017262 002 | |
| XYLOSE | | | | |
| POWDER;ORAL | | | | |
| XYLO-PFAN | | | | |
| | SAVAGE LABS | 25GM/BOT | N017605 001 | |
| XYLOSE | | | | |
| | LYNE | 25GM/BOT | N018856 001 | Mar 26, 1987 |
| ZALCITABINE | | | | |
| TABLET;ORAL | | | | |
| HIVID | | | | |
| | ROCHE | 0.375MG | N020199 001 | Jun 19, 1992 |
| | | 0.75MG | N020199 002 | Jun 19, 1992 |
| ZALEPLON | | | | |
| CAPSULE;ORAL | | | | |
| ZALEPLON | | | | |
| | MYLAN | 5MG | A077238 001 | Jun 06, 2008 |
| | | 10MG | A077238 002 | Jun 06, 2008 |
| | UPSHER-SMITH LABS | 5MG | A078095 001 | Jun 06, 2008 |
| | | 5MG | A078706 001 | Jun 06, 2008 |
| | | 10MG | A078095 002 | Jun 06, 2008 |
| | | 10MG | A078706 002 | Jun 06, 2008 |
| ZICONOTIDE ACETATE | | | | |
| INJECTABLE;INTRATHECAL | | | | |
| PRIALT | | | | |
| | JAZZ PHARMS INTL | 200MCG/2ML (100MCG/ML) | N021060 003 | Dec 28, 2004 |
| ZIDOVUDINE | | | | |
| INJECTABLE;INJECTION | | | | |
| ZIDOVUDINE | | | | |
| | LIAONING CHENGDA | 10MG/ML | A204538 001 | Nov 26, 2013 |
| TABLET;ORAL | | | | |
| RETROVIR | | | | |
| | VIIV HLTHCARE | 200MG | N020518 001 | Dec 19, 1995 |
| + | | 300MG ** | N020518 002 | Oct 04, 1996 |
| ZIDOVUDINE | | | | |
| | AUROBINDO PHARMA | 60MG | N022294 001 | Jul 23, 2009 |
| | HEC PHARM USA INC | 300MG | A202058 001 | Oct 07, 2011 |
| | MATRIX LABS LTD | 100MG | N200732 001 | Feb 23, 2011 |
| | RANBAXY LABS LTD | 300MG | A077327 001 | Sep 19, 2005 |
| ZILEUTON | | | | |
| TABLET;ORAL | | | | |
| ZYFLO | | | | |
| | CHIESI USA INC | 300MG | N020471 001 | Dec 09, 1996 |

| | | | | |
|---|---|---|---|---|
| ZINC SULFATE | | | | |
| INJECTABLE;INJECTION | | | | |
| ZINC SULFATE | | | | |
| ABRAXIS PHARM | EQ 1MG ZINC/ML | N019229 | 002 | May 05, 1987 |
| ZIPRASIDONE HYDROCHLORIDE | | | | |
| SUSPENSION;ORAL | | | | |
| GEODON | | | | |
| PFIZER INC | EQ 10MG BASE/ML | N021483 | 001 | Mar 29, 2006 |
| ZOLEDRONIC ACID | | | | |
| INJECTABLE;IV (INFUSION) | | | | |
| ZOLEDRONIC ACID | | | | |
| SUN PHARMA GLOBAL | EQ 4MG BASE/5ML | A202746 | 001 | Mar 04, 2013 |
| ZOMETA | | | | |
| + NOVARTIS | EQ 4MG BASE/VIAL ** | N021223 | 001 | Aug 20, 2001 |
| ZOLMITRIPTAN | | | | |
| TABLET;ORAL | | | | |
| ZOLMITRIPTAN | | | | |
| SUN PHARMA GLOBAL | 2.5MG | A203476 | 001 | Nov 13, 2014 |
| | 5MG | A203476 | 002 | Nov 13, 2014 |
| ZOLPIDEM TARTRATE | | | | |
| TABLET;ORAL | | | | |
| ZOLPIDEM TARTRATE | | | | |
| DR REDDYS LABS LTD | 5MG | A077985 | 001 | Apr 23, 2007 |
| | 10MG | A077985 | 002 | Apr 23, 2007 |
| HIKMA | 5MG | A078129 | 001 | Apr 30, 2008 |
| | 10MG | A078129 | 002 | Apr 30, 2008 |
| MYLAN PHARMS INC | 5MG | A078016 | 001 | Apr 23, 2007 |
| | 10MG | A078016 | 002 | Apr 23, 2007 |
| SUN PHARM INDUSTRIES | 5MG | A077288 | 001 | Apr 23, 2007 |
| | 10MG | A077288 | 002 | Apr 23, 2007 |
| SYNTHON PHARMS | 5MG | A077540 | 001 | Apr 23, 2007 |
| | 10MG | A077540 | 002 | Apr 23, 2007 |
| VIVIMED GLOBAL | 5MG | A076062 | 001 | Apr 23, 2007 |
| | 10MG | A076062 | 002 | Apr 23, 2007 |
| WATSON LABS | 5MG | A077773 | 001 | Apr 23, 2007 |
| | 10MG | A077773 | 002 | Apr 23, 2007 |
| TABLET, EXTENDED RELEASE;ORAL | | | | |
| ZOLPIDEM TARTRATE | | | | |
| SYNTHON PHARMS | 6.25MG | A078483 | 001 | Apr 12, 2011 |
| | 12.5MG | A078483 | 002 | Jun 06, 2011 |
| TABLET, ORALLY DISINTEGRATING;ORAL | | | | |
| TOVALT ODT | | | | |
| BIOVAIL LABS INTL | 5MG | N021412 | 001 | Apr 25, 2007 |
| | 10MG | N021412 | 002 | Apr 25, 2007 |
| ZONISAMIDE | | | | |
| CAPSULE;ORAL | | | | |
| ZONISAMIDE | | | | |
| ANI PHARMS INC | 25MG | A077639 | 001 | Dec 22, 2005 |
| | 25MG | A077641 | 003 | Dec 22, 2005 |
| | 50MG | A077639 | 002 | Dec 22, 2005 |
| | 50MG | A077641 | 002 | Dec 22, 2005 |
| | 100MG | A077639 | 003 | Dec 22, 2005 |
| | 100MG | A077641 | 001 | Dec 22, 2005 |
| DR REDDYS LABS LTD | 25MG | A077645 | 002 | Sep 29, 2006 |
| | 50MG | A077645 | 003 | Sep 29, 2006 |
| | 100MG | A077645 | 001 | Dec 22, 2005 |
| EPIC PHARMA LLC | 25MG | A077876 | 001 | Feb 21, 2007 |
| | 50MG | A077876 | 002 | Feb 21, 2007 |
| | 100MG | A077876 | 003 | Feb 21, 2007 |
| MYLAN PHARMS INC | 25MG | A077647 | 001 | Dec 22, 2005 |
| | 50MG | A077647 | 002 | Dec 22, 2005 |
| | 100MG | A077647 | 003 | Dec 22, 2005 |
| ROXANE | 25MG | A077648 | 001 | Dec 22, 2005 |
| | 50MG | A077648 | 002 | Dec 22, 2005 |
| | 100MG | A077648 | 003 | Dec 22, 2005 |
| SUN PHARM INDUSTRIES | 25MG | A077635 | 001 | Dec 22, 2005 |
| | 50MG | A077635 | 002 | Dec 22, 2005 |

**Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons**

ZONISAMIDE

CAPSULE;ORAL

ZONISAMIDE

| | | | | |
|---|---|---|---|---|
| | 100MG | A077635 | 003 | Dec 22, 2005 |
| UPSHER-SMITH LABS | 25MG | A077644 | 001 | Dec 22, 2005 |
| | 50MG | A077644 | 002 | Dec 22, 2005 |
| | 100MG | A077644 | 003 | Dec 22, 2005 |
| WATSON LABS | 25MG | A077650 | 001 | Apr 20, 2006 |
| | 50MG | A077650 | 002 | Apr 20, 2006 |
| | 100MG | A077650 | 003 | Apr 20, 2006 |

# ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:
http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/default.htm

# DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

ACETAMINOPHEN;ASPIRIN;BUTALBITAL
CAPSULE OR TABLET; ORAL
160-165MG;160-165MG;50MG
325MG;325MG;50MG

ACETAMINOPHEN;ASPIRIN;BUTALBITAL;
CAFFEINE
CAPSULE OR TABLET; ORAL
160-165MG;160-165MG;50MG;40MG
325MG;325MG;50MG;40MG

ACETAMINOPHEN;BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG;50MG

ACETAMINOPHEN;BUTALBITAL;CAFFEINE
CAPSULE OR TABLET; ORAL
325MG;50MG;40MG

AMINOPHYLLINE
TABLET; ORAL
100MG;200MG

ASPIRIN;BUTALBITAL
CAPSULE OR TABLET; ORAL
325MG;50MG
650MG;50MG

ASPIRIN;BUTALBITAL;CAFFEINE
CAPSULE OR TABLET; ORAL
325MG;50MG;40MG
650MG;50MG;40MG

ASPIRIN;CAFFEINE;CARISOPRODOL
TABLET; ORAL
160MG;32MG;200MG

ASPIRIN;CAFFEINE;CARISOPRODOL;
CODEINE PHOSPHATE
TABLET; ORAL
160MG;32MG;200MG;16MG

ASPIRIN;CARISOPRODOL
TABLET; ORAL
325MG;200MG

ASPIRIN;CARISOPRODOL;
CODEINE PHOSPHATE
TABLET; ORAL
325MG;200MG;16MG

ASPIRIN;MEPROBAMATE
TABLET; ORAL
325MG;200MG

ASPIRIN;METHOCARBAMOL
TABLET; ORAL
325MG;400MG

CHLOROTHIAZIDE
TABLET; ORAL
250MG

HYDROXYZINE HYDROCHLORIDE
TABLET; ORAL
10MG;25MG;
50MG;100MG

PREDNISONE
TABLET; ORAL
1MG;2.5MG;5MG;10MG;
20MG;25MG;50MG

# APPENDIX A - PRODUCT NAME INDEX

**** A ****

A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
ABACAVIR SULFATE, ABACAVIR SULFATE
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE, ABACAVIR SULFATE
ABELCET, AMPHOTERICIN B
ABILIFY, ARIPIPRAZOLE
ABILIFY MAINTENA KIT, ARIPIPRAZOLE
ABILIFY MYCITE KIT, ARIPIPRAZOLE
ABRAXANE, PACLITAXEL
ABREVA, DOCOSANOL (OTC)
ABSORICA, ISOTRETINOIN
ABSTRAL, FENTANYL CITRATE
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
ACANYA, BENZOYL PEROXIDE
ACARBOSE, ACARBOSE
ACCOLATE, ZAFIRLUKAST
ACCUNEB, ALBUTEROL SULFATE
ACCUPRIL, QUINAPRIL HYDROCHLORIDE
ACCURETIC, HYDROCHLOROTHIAZIDE
ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
ACEPHEN, ACETAMINOPHEN (OTC)
ACETADOTE, ACETYLCYSTEINE
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ACETAMINOPHEN
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE, ACETAMINOPHEN
ACETASOL HC, ACETIC ACID, GLACIAL
ACETAZOLAMIDE, ACETAZOLAMIDE
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ACETAZOLAMIDE SODIUM , ACETAZOLAMIDE SODIUM
ACETIC ACID, ACETIC ACID, GLACIAL
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
ACETYLCYSTEINE, ACETYLCYSTEINE
ACHROMYCIN V, TETRACYCLINE HYDROCHLORIDE
ACIPHEX, RABEPRAZOLE SODIUM
ACIPHEX SPRINKLE, RABEPRAZOLE SODIUM
ACITRETIN, ACITRETIN
ACTHREL, CORTICORELIN OVINE TRIFLUTATE
ACTICLATE, DOXYCYCLINE HYCLATE
ACTICLATE CAP, DOXYCYCLINE HYCLATE
ACTIGALL, URSODIOL
ACTIQ, FENTANYL CITRATE
ACTIVELLA, ESTRADIOL
ACTONEL, RISEDRONATE SODIUM
ACTOPLUS MET, METFORMIN HYDROCHLORIDE
ACTOPLUS MET XR, METFORMIN HYDROCHLORIDE
ACTOS, PIOGLITAZONE HYDROCHLORIDE
ACULAR, KETOROLAC TROMETHAMINE
ACULAR LS, KETOROLAC TROMETHAMINE
ACUVAIL, KETOROLAC TROMETHAMINE
ACYCLOVIR, ACYCLOVIR
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACZONE, DAPSONE
ADAGEN, PEGADEMASE BOVINE
ADALAT CC, NIFEDIPINE
ADAPALENE, ADAPALENE
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
ADASUVE, LOXAPINE
ADCIRCA, TADALAFIL
ADDERALL XR 10, AMPHETAMINE ASPARTATE
ADDERALL XR 15, AMPHETAMINE ASPARTATE
ADDERALL XR 20, AMPHETAMINE ASPARTATE
ADDERALL XR 25, AMPHETAMINE ASPARTATE
ADDERALL XR 30, AMPHETAMINE ASPARTATE

# APPENDIX A - PRODUCT NAME INDEX

**** A ****

ADDERALL XR 5, AMPHETAMINE ASPARTATE
ADDYI, FLIBANSERIN
ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL
ADEMPAS, RIOCIGUAT
ADENOCARD, ADENOSINE
ADENOSINE, ADENOSINE
ADIPEX-P, PHENTERMINE HYDROCHLORIDE
ADLYXIN, LIXISENATIDE
ADMELOG, INSULIN LISPRO
ADMELOG SOLOSTAR, INSULIN LISPRO
ADRENACLICK, EPINEPHRINE
ADRENALIN, EPINEPHRINE
ADREVIEW, IOBENGUANE SULFATE I-123
ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
ADVAIR HFA, FLUTICASONE PROPIONATE
ADVIL, IBUPROFEN (OTC)
ADVIL, IBUPROFEN SODIUM (OTC)
ADVIL ALLERGY AND CONGESTION RELIEF, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL COLD AND SINUS, IBUPROFEN (OTC)
ADVIL CONGESTION RELIEF, IBUPROFEN (OTC)
ADVIL LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MULTI-SYMPTOM COLD & FLU, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL PM, DIPHENHYDRAMINE CITRATE (OTC)
ADVIL PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ADZENYS ER, AMPHETAMINE
ADZENYS XR-ODT, AMPHETAMINE
AEROSPAN HFA, FLUNISOLIDE
AFEDITAB CR, NIFEDIPINE
AFINITOR, EVEROLIMUS
AFINITOR DISPERZ, EVEROLIMUS
AFIRMELLE, ETHINYL ESTRADIOL
AFREZZA, INSULIN RECOMBINANT HUMAN
AFRINOL, PSEUDOEPHEDRINE SULFATE (OTC)
AGGRASTAT, TIROFIBAN HYDROCHLORIDE
AGGRENOX, ASPIRIN
AGRYLIN, ANAGRELIDE HYDROCHLORIDE
AIRDUO RESPICLICK, FLUTICASONE PROPIONATE
AK-FLUOR 10%, FLUORESCEIN SODIUM
AK-FLUOR 25%, FLUORESCEIN SODIUM
AKBETA, LEVOBUNOLOL HYDROCHLORIDE
AKOVAZ, EPHEDRINE SULFATE
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE
AKTEN, LIDOCAINE HYDROCHLORIDE
AKTIPAK, BENZOYL PEROXIDE
AKTOB, TOBRAMYCIN
AKYNZEO, NETUPITANT
ALA-CORT, HYDROCORTISONE
ALA-SCALP, HYDROCORTISONE
ALAVERT, LORATADINE (OTC)
ALAWAY, KETOTIFEN FUMARATE (OTC)
ALBENZA, ALBENDAZOLE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALCAINE, PROPARACAINE HYDROCHLORIDE
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
ALDACTAZIDE, HYDROCHLOROTHIAZIDE
ALDACTONE, SPIRONOLACTONE
ALDARA, IMIQUIMOD
ALECENSA, ALECTINIB HYDROCHLORIDE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALEVE, NAPROXEN SODIUM (OTC)

# APPENDIX A - PRODUCT NAME INDEX

**** A ****

ALEVE PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ALEVE-D SINUS & COLD, NAPROXEN SODIUM (OTC)
ALFENTA, ALFENTANIL HYDROCHLORIDE
ALFENTANIL, ALFENTANIL HYDROCHLORIDE
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALIMTA, PEMETREXED DISODIUM
ALINIA, NITAZOXANIDE
ALIQOPA, COPANLISIB DIHYDROCHLORIDE
ALKERAN, MELPHALAN
ALLEGRA, FEXOFENADINE HYDROCHLORIDE
ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLI, ORLISTAT (OTC)
ALLOPURINOL, ALLOPURINOL
ALLOPURINOL SODIUM, ALLOPURINOL SODIUM
ALLZITAL, ACETAMINOPHEN
ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
ALOCRIL, NEDOCROMIL SODIUM
ALOMIDE, LODOXAMIDE TROMETHAMINE
ALOPRIM, ALLOPURINOL SODIUM
ALORA, ESTRADIOL
ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
ALOXI, PALONOSETRON HYDROCHLORIDE
ALPHAGAN P, BRIMONIDINE TARTRATE
ALPRAZOLAM, ALPRAZOLAM
ALPROSTADIL, ALPROSTADIL
ALREX, LOTEPREDNOL ETABONATE
ALTABAX, RETAPAMULIN
ALTACE, RAMIPRIL
ALTAFLUOR BENOX, BENOXINATE HYDROCHLORIDE
ALTAVERA, ETHINYL ESTRADIOL
ALTOPREV, LOVASTATIN
ALUNBRIG, BRIGATINIB
ALVESCO, CICLESONIDE
ALYACEN 1/35, ETHINYL ESTRADIOL
ALYACEN 7/7/7, ETHINYL ESTRADIOL
AMABELZ, ESTRADIOL
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMARYL, GLIMEPIRIDE
AMBIEN, ZOLPIDEM TARTRATE
AMBIEN CR, ZOLPIDEM TARTRATE
AMBISOME, AMPHOTERICIN B
AMCINONIDE, AMCINONIDE
AMELUZ, AMINOLEVULINIC ACID HYDROCHLORIDE
AMERGE, NARATRIPTAN HYDROCHLORIDE
AMICAR, AMINOCAPROIC ACID
AMIDATE, ETOMIDATE
AMIFOSTINE, AMIFOSTINE
AMIKACIN SULFATE, AMIKACIN SULFATE
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMINO ACIDS, AMINO ACIDS
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
AMINOCAPROIC, AMINOCAPROIC ACID
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
AMINOSYN 10%, AMINO ACIDS
AMINOSYN 10% (PH6), AMINO ACIDS
AMINOSYN 3.5%, AMINO ACIDS
AMINOSYN 3.5% M, AMINO ACIDS
AMINOSYN 5%, AMINO ACIDS
AMINOSYN 7%, AMINO ACIDS

# APPENDIX A - PRODUCT NAME INDEX

**** A ****

AMINOSYN 7% (PH6), AMINO ACIDS
AMINOSYN 7% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN 8.5%, AMINO ACIDS
AMINOSYN 8.5% (PH6), AMINO ACIDS
AMINOSYN 8.5% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 10%, AMINO ACIDS
AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 10% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 7%, AMINO ACIDS
AMINOSYN II 8.5%, AMINO ACIDS
AMINOSYN II 8.5% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN-HBC 7%, AMINO ACIDS
AMINOSYN-HF 8%, AMINO ACIDS
AMINOSYN-PF 10%, AMINO ACIDS
AMINOSYN-PF 7%, AMINO ACIDS
AMINOSYN-RF 5.2%, AMINO ACIDS
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMITIZA, LUBIPROSTONE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
AMMONIA N 13, AMMONIA N-13
AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
AMMONIUM LACTATE, AMMONIUM LACTATE
AMMONUL, SODIUM BENZOATE
AMNESTEEM, ISOTRETINOIN
AMOXAPINE, AMOXAPINE
AMOXICILLIN, AMOXICILLIN
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN PEDIATRIC, AMOXICILLIN
AMOXIL, AMOXICILLIN
AMPHADASE, HYALURONIDASE
AMPHOTERICIN B, AMPHOTERICIN B
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
AMPYRA, DALFAMPRIDINE
AMRINONE LACTATE, INAMRINONE LACTATE
AMRIX, CYCLOBENZAPRINE HYDROCHLORIDE
AMYVID, FLORBETAPIR F-18
AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
ANADROL-50, OXYMETHOLONE
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
ANAPROX, NAPROXEN SODIUM
ANAPROX DS, NAPROXEN SODIUM
ANASTROZOLE, ANASTROZOLE
ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
ANCOBON, FLUCYTOSINE
ANDRODERM, TESTOSTERONE
ANDROGEL, TESTOSTERONE
ANDROID 25, METHYLTESTOSTERONE
ANECTINE, SUCCINYLCHOLINE CHLORIDE
ANEXSIA 5/325, ACETAMINOPHEN
ANEXSIA 7.5/325, ACETAMINOPHEN
ANGELIQ, DROSPIRENONE
ANGIOMAX, BIVALIRUDIN
ANORO ELLIPTA, UMECLIDINIUM BROMIDE
ANTABUSE, DISULFIRAM
ANTARA (MICRONIZED), FENOFIBRATE

# APPENDIX A - PRODUCT NAME INDEX

**** A ****

# APPENDIX A - PRODUCT NAME INDEX

**** A ****

ATRIDOX, DOXYCYCLINE HYCLATE
ATRIPLA, EFAVIRENZ
ATROPEN, ATROPINE
ATROPINE SULFATE, ATROPINE SULFATE
ATROPINE SULFATE ANSYR PLASTIC SYRINGE, ATROPINE SULFATE
ATROPINE SULFATE LIFESHIELD ABBOJECT SYRINGE, ATROPINE SULFATE
ATROVENT, IPRATROPIUM BROMIDE
ATROVENT HFA, IPRATROPIUM BROMIDE
AUBAGIO, TERIFLUNOMIDE
AUGMENTIN '125', AMOXICILLIN
AUGMENTIN '250', AMOXICILLIN
AUGMENTIN '875', AMOXICILLIN
AUGMENTIN XR, AMOXICILLIN
AUROVELA 1.5/30, ETHINYL ESTRADIOL
AUROVELA 1/20, ETHINYL ESTRADIOL
AUROVELA 24 FE, ETHINYL ESTRADIOL
AUROVELA FE 1.5/30, ETHINYL ESTRADIOL
AUROVELA FE 1/20, ETHINYL ESTRADIOL
AURYXIA, FERRIC CITRATE
AUSTEDO, DEUTETRABENAZINE
AUVI-Q, EPINEPHRINE
AVAGARD, ALCOHOL (OTC)
AVAGE, TAZAROTENE
AVALIDE, HYDROCHLOROTHIAZIDE
AVANDIA, ROSIGLITAZONE MALEATE
AVAPRO, IRBESARTAN
AVC, SULFANILAMIDE
AVEED, TESTOSTERONE UNDECANOATE
AVELOX, MOXIFLOXACIN HYDROCHLORIDE
AVIANE-28, ETHINYL ESTRADIOL
AVITA, TRETINOIN
AVODART, DUTASTERIDE
AVYCAZ, AVIBACTAM SODIUM
AXERT, ALMOTRIPTAN MALATE
AXID AR, NIZATIDINE (OTC)
AXUMIN, FLUCICLOVINE F-18
AYGESTIN, NORETHINDRONE ACETATE
AYUNA, ETHINYL ESTRADIOL
AZACITIDINE, AZACITIDINE
AZACTAM, AZTREONAM
AZACTAM IN PLASTIC CONTAINER, AZTREONAM
AZASAN, AZATHIOPRINE
AZASITE, AZITHROMYCIN
AZATHIOPRINE, AZATHIOPRINE
AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE, AZELASTINE HYDROCHLORIDE
AZELEX, AZELAIC ACID
AZILECT, RASAGILINE MESYLATE
AZITHROMYCIN, AZITHROMYCIN
AZOPT, BRINZOLAMIDE
AZOR, AMLODIPINE BESYLATE
AZTREONAM, AZTREONAM
AZULFIDINE, SULFASALAZINE
AZULFIDINE EN-TABS, SULFASALAZINE

**** B ****

BACIIM, BACITRACIN
BACITRACIN, BACITRACIN
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN
BACLOFEN, BACLOFEN
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM

# APPENDIX A - PRODUCT NAME INDEX

**** B ****

BACTRIM, SULFAMETHOXAZOLE
BACTRIM DS, SULFAMETHOXAZOLE
BACTROBAN, MUPIROCIN CALCIUM
BAL, DIMERCAPROL
BALANCED SALT, CALCIUM CHLORIDE
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BALZIVA-28, ETHINYL ESTRADIOL
BANZEL, RUFINAMIDE
BARACLUDE, ENTECAVIR
BASAGLAR, INSULIN GLARGINE
BAXDELA, DELAFLOXACIN MEGLUMINE
BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
BEKYREE, DESOGESTREL
BELBUCA, BUPRENORPHINE HYDROCHLORIDE
BELEODAQ, BELINOSTAT
BELSOMRA, SUVOREXANT
BELVIQ, LORCASERIN HYDROCHLORIDE
BELVIQ XR, LORCASERIN HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
BENDEKA, BENDAMUSTINE HYDROCHLORIDE
BENICAR, OLMESARTAN MEDOXOMIL
BENICAR HCT, HYDROCHLOROTHIAZIDE
BENTYL, DICYCLOMINE HYDROCHLORIDE
BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE
BENZACLIN, BENZOYL PEROXIDE
BENZAMYCIN, BENZOYL PEROXIDE
BENZNIDAZOLE, BENZNIDAZOLE
BENZONATATE, BENZONATATE
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BEPREVE, BEPOTASTINE BESILATE
BESIVANCE, BESIFLOXACIN HYDROCHLORIDE
BETA-VAL, BETAMETHASONE VALERATE
BETADINE, POVIDONE-IODINE
BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BETAPACE, SOTALOL HYDROCHLORIDE
BETAPACE AF, SOTALOL HYDROCHLORIDE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BETHKIS, TOBRAMYCIN
BETIMOL, TIMOLOL
BETOPTIC, BETAXOLOL HYDROCHLORIDE
BETOPTIC S, BETAXOLOL HYDROCHLORIDE
BEVESPI AEROSPHERE, FORMOTEROL FUMARATE
BEVYXXA, BETRIXABAN
BEXAROTENE, BEXAROTENE
BEYAZ, DROSPIRENONE
BIAXIN, CLARITHROMYCIN
BICALUTAMIDE, BICALUTAMIDE
BICILLIN C-R, PENICILLIN G BENZATHINE
BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
BICILLIN L-A, PENICILLIN G BENZATHINE
BICNU, CARMUSTINE
BIDIL, HYDRALAZINE HYDROCHLORIDE
BILTRICIDE, PRAZIQUANTEL
BIMATOPROST, BIMATOPROST
BINOSTO, ALENDRONATE SODIUM
BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE

# APPENDIX A - PRODUCT NAME INDEX

**** B ****

BIVALIRUDIN, BIVALIRUDIN
BIVALIRUDIN IN 0.9% SODIUM CHLORIDE, BIVALIRUDIN
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BLEPH-10, SULFACETAMIDE SODIUM
BLEPHAMIDE, PREDNISOLONE ACETATE
BLEPHAMIDE S.O.P., PREDNISOLONE ACETATE
BLISOVI 24 FE, ETHINYL ESTRADIOL
BLISOVI FE 1.5/30, ETHINYL ESTRADIOL
BLISOVI FE 1/20, ETHINYL ESTRADIOL
BLOXIVERZ, NEOSTIGMINE METHYLSULFATE
BONIVA, IBANDRONATE SODIUM
BONJESTA, DOXYLAMINE SUCCINATE
BONTRIL PDM, PHENDIMETRAZINE TARTRATE
BORTEZOMIB, BORTEZOMIB
BOSULIF, BOSUTINIB MONOHYDRATE
BRAVELLE, UROFOLLITROPIN
BREO ELLIPTA, FLUTICASONE FUROATE
BREVIBLOC, ESMOLOL HYDROCHLORIDE
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVICON 28-DAY, ETHINYL ESTRADIOL
BREVITAL SODIUM, METHOHEXITAL SODIUM
BRIAN CARE, CHLORHEXIDINE GLUCONATE (OTC)
BRIDION, SUGAMMADEX SODIUM
BRIELLYN, ETHINYL ESTRADIOL
BRILINTA, TICAGRELOR
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
BRISDELLE, PAROXETINE MESYLATE
BRIVIACT, BRIVARACETAM
BROMFED-DM, BROMPHENIRAMINE MALEATE
BROMFENAC SODIUM, BROMFENAC SODIUM
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE,
BROMSITE, BROMFENAC SODIUM
BRONCHO SALINE, SODIUM CHLORIDE (OTC)
BROVANA, ARFORMOTEROL TARTRATE
BSS, CALCIUM CHLORIDE
BSS PLUS, CALCIUM CHLORIDE
BUDESONIDE, BUDESONIDE (OTC)
BUDESONIDE, BUDESONIDE
BUMETANIDE, BUMETANIDE
BUMEX, BUMETANIDE
BUNAVAIL, BUPRENORPHINE HYDROCHLORIDE
BUPHENYL, SODIUM PHENYLBUTYRATE
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
BUPRENEX, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE , BUPRENORPHINE HYDROCHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
BUSULFAN, BUSULFAN
BUSULFEX, BUSULFAN
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE, ASPIRIN
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
BUTAPAP, ACETAMINOPHEN
BUTENAFINE HYDROCHLORIDE, BUTENAFINE HYDROCHLORIDE (OTC)
BUTISOL SODIUM, BUTABARBITAL SODIUM

# APPENDIX A - PRODUCT NAME INDEX

**** B ****

BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
BUTRANS, BUPRENORPHINE
BYDUREON, EXENATIDE SYNTHETIC
BYDUREON BCISE, EXENATIDE
BYDUREON PEN, EXENATIDE SYNTHETIC
BYETTA, EXENATIDE SYNTHETIC
BYSTOLIC, NEBIVOLOL HYDROCHLORIDE
BYVALSON, NEBIVOLOL HYDROCHLORIDE

**** C ****

CABERGOLINE, CABERGOLINE
CABOMETYX, CABOZANTINIB S-MALATE
CADUET, AMLODIPINE BESYLATE
CAFCIT, CAFFEINE CITRATE
CAFERGOT, CAFFEINE
CAFFEINE CITRATE, CAFFEINE CITRATE
CALAN, VERAPAMIL HYDROCHLORIDE
CALAN SR, VERAPAMIL HYDROCHLORIDE
CALCIPOTRIENE, CALCIPOTRIENE
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCITONIN-SALMON, CALCITONIN SALMON
CALCITRIOL, CALCITRIOL
CALCIUM ACETATE, CALCIUM ACETATE
CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CALCIUM DISODIUM VERSENATE, EDETATE CALCIUM DISODIUM
CALCIUM GLUCONATE, CALCIUM GLUCONATE
CALDOLOR, IBUPROFEN
CALQUENCE, ACALABRUTINIB
CAMBIA, DICLOFENAC POTASSIUM
CAMILA, NORETHINDRONE
CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
CANASA, MESALAMINE
CANCIDAS, CASPOFUNGIN ACETATE
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CAPASTAT SULFATE, CAPREOMYCIN SULFATE
CAPECITABINE, CAPECITABINE
CAPEX, FLUOCINOLONE ACETONIDE
CAPITAL SOLEIL 15, AVOBENZONE (OTC)
CAPRELSA, VANDETANIB
CAPREOMYCIN SULFATE, CAPREOMYCIN SULFATE
CAPTOPRIL, CAPTOPRIL
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CARAC, FLUOROURACIL
CARAFATE, SUCRALFATE
CARBAGLU, CARGLUMIC ACID
CARBAMAZEPINE, CARBAMAZEPINE
CARBATROL, CARBAMAZEPINE
CARBIDOPA, CARBIDOPA
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CARBOCAINE, MEPIVACAINE HYDROCHLORIDE
CARBOPLATIN, CARBOPLATIN
CARDENE, NICARDIPINE HYDROCHLORIDE
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82
CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CARDIZEM, DILTIAZEM HYDROCHLORIDE

# APPENDIX A - PRODUCT NAME INDEX

**** C ****

CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
CARDIZEM LA, DILTIAZEM HYDROCHLORIDE
CARDURA, DOXAZOSIN MESYLATE
CARDURA XL, DOXAZOSIN MESYLATE
CARISOPRODOL, CARISOPRODOL
CARISOPRODOL AND ASPIRIN, ASPIRIN
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
CARNEXIV, CARBAMAZEPINE
CARNITOR, LEVOCARNITINE
CARNITOR SF, LEVOCARNITINE
CAROSPIR, SPIRONOLACTONE
CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
CARTIA XT, DILTIAZEM HYDROCHLORIDE
CARVEDILOL, CARVEDILOL
CARVEDILOL PHOSPHATE, CARVEDILOL PHOSPHATE
CASODEX, BICALUTAMIDE
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
CASPORYN HC, HYDROCORTISONE
CATAPRES, CLONIDINE HYDROCHLORIDE
CATAPRES-TTS-1, CLONIDINE
CATAPRES-TTS-2, CLONIDINE
CATAPRES-TTS-3, CLONIDINE
CAVERJECT, ALPROSTADIL
CAVERJECT IMPULSE, ALPROSTADIL
CAYSTON, AZTREONAM
CEFACLOR, CEFACLOR
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFAZOLIN AND DEXTROSE, CEFAZOLIN SODIUM
CEFAZOLIN IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFDINIR, CEFDINIR
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER, CEFEPIME HYDROCHLORIDE
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFEPIME IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
CEFIXIME, CEFIXIME
CEFOTAN, CEFOTETAN DISODIUM
CEFOTAXIME, CEFOTAXIME SODIUM
CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
CEFOTETAN, CEFOTETAN DISODIUM
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER, CEFOTETAN DISODIUM
CEFOXITIN, CEFOXITIN SODIUM
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER, CEFOXITIN SODIUM
CEFOXITIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CEFTAZIDIME, CEFTAZIDIME
CEFTAZIDIME IN DEXTROSE CONTAINER, CEFTAZIDIME
CEFTIN, CEFUROXIME AXETIL
CEFTRIAXONE, CEFTRIAXONE SODIUM
CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER, CEFTRIAXONE SODIUM
CEFTRIAXONE IN PLASTIC CONTAINER, CEFTRIAXONE SODIUM
CEFTRIAXONE SODIUM, CEFTRIAXONE SODIUM
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEFUROXIME SODIUM, CEFUROXIME SODIUM
CELEBREX, CELECOXIB
CELECOXIB, CELECOXIB
CELESTONE SOLUSPAN, BETAMETHASONE ACETATE
CELEXA, CITALOPRAM HYDROBROMIDE
CELLCEPT, MYCOPHENOLATE MOFETIL
CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
CELONTIN, METHSUXIMIDE
CENTANY, MUPIROCIN
CEPHALEXIN, CEPHALEXIN
CERDELGA, ELIGLUSTAT TARTRATE

# APPENDIX A - PRODUCT NAME INDEX

**** C ****

CEREBYX, FOSPHENYTOIN SODIUM
CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
CEREZYME, IMIGLUCERASE
CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
CERVIDIL, DINOPROSTONE
CESAMET, NABILONE
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CETRAXAL, CIPROFLOXACIN HYDROCHLORIDE
CETROTIDE, CETRORELIX
CETYLEV, ACETYLCYSTEINE
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CHANTIX, VARENICLINE TARTRATE
CHEMET, SUCCIMER
CHENODIOL, CHENODIOL
CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
CHILDREN'S ADVIL, IBUPROFEN (OTC)
CHILDREN'S ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)
CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
CHILDREN'S ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CLARITIN, LORATADINE (OTC)
CHILDREN'S ELIXSURE, IBUPROFEN (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
CHILDREN'S MOTRIN, IBUPROFEN (OTC)
CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CHIRHOSTIM, SECRETIN SYNTHETIC HUMAN
CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE (OTC)
CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE
CHLORAPREP ONE-STEP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP FREPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP SINGLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP TRIPLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP WITH TINT, CHLORHEXIDINE GLUCONATE (OTC)
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CHLORZOXAZONE, CHLORZOXAZONE
CHOLAC, LACTULOSE
CHOLBAM, CHOLIC ACID
CHOLEDYL SA, OXTRIPHYLLINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
CHOLINE C-11, CHOLINE C-11

# APPENDIX A - PRODUCT NAME INDEX

**** C ****

CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
CIALIS, TADALAFIL
CICLOPIROX, CICLOPIROX
CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)
CIDOFOVIR, CIDOFOVIR
CILOSTAZOL, CILOSTAZOL
CILOXAN, CIPROFLOXACIN HYDROCHLORIDE
CIMETIDINE, CIMETIDINE (OTC)
CIMETIDINE, CIMETIDINE
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
CINVANTI, APREPITANT
CIPRO, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN HYDROCHLORIDE
CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
CIPRODEX, CIPROFLOXACIN
CIPROFLOXACIN, CIPROFLOXACIN
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CISPLATIN, CISPLATIN
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CITANEST FORTE DENTAL, EPINEPHRINE BITARTRATE
CLADRIBINE, CLADRIBINE
CLAFORAN, CEFOTAXIME SODIUM
CLARAVIS, ISOTRETINOIN
CLARINEX, DESLORATADINE
CLARINEX D 24 HOUR, DESLORATADINE
CLARINEX-D 12 HOUR, DESLORATADINE
CLARITHROMYCIN, CLARITHROMYCIN
CLARITIN, LORATADINE (OTC)
CLARITIN HIVES RELIEF, LORATADINE (OTC)
CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)
CLARITIN REDITABS, LORATADINE (OTC)
CLARITIN-D, LORATADINE (OTC)
CLARITIN-D 24 HOUR, LORATADINE (OTC)
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLENPIQ, CITRIC ACID
CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PHOSPHATE
CLEOCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLEOCIN T, CLINDAMYCIN PHOSPHATE
CLEVIPREX, CLEVIDIPINE
CLIMARA, ESTRADIOL
CLIMARA PRO, ESTRADIOL
CLINDA-DERM, CLINDAMYCIN PHOSPHATE
CLINDAGEL, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLINDAMYCIN HYDROCLHORIDE, CLINDAMYCIN HYDROCHLORIDE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLINDAMYCIN PHOSPHATE AND TRETINOIN, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE
CLINDESSE, CLINDAMYCIN PHOSPHATE
CLINDETS, CLINDAMYCIN PHOSPHATE

# APPENDIX A - PRODUCT NAME INDEX

**** C ****

CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER,
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBEX, CLOBETASOL PROPIONATE
CLODERM, CLOCORTOLONE PIVALATE
CLOFARABINE, CLOFARABINE
CLOLAR, CLOFARABINE
CLOMID, CLOMIPHENE CITRATE
CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE, CLONIDINE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLONIDINE HYDROCHLORIDE , CLONIDINE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLOROTEKAL, CHLOROPROCAINE HYDROCHLORIDE
CLORPRES, CHLORTHALIDONE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
CLOTRIMAZOLE, CLOTRIMAZOLE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOZAPINE, CLOZAPINE
CLOZARIL, CLOZAPINE
COARTEM, ARTEMETHER
CODEINE SULFATE, CODEINE SULFATE
COGENTIN, BENZTROPINE MESYLATE
COL-PROBENECID, COLCHICINE
COLAZAL, BALSALAZIDE DISODIUM
COLCRYS, COLCHICINE
COLESTID, COLESTIPOL HYDROCHLORIDE
COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
COLGATE TOTAL, SODIUM FLUORIDE (OTC)
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
COLOCORT, HYDROCORTISONE
COLPREP KIT, MAGNESIUM SULFATE
COLY-MYCIN M, COLISTIMETHATE SODIUM
COLY-MYCIN S, COLISTIN SULFATE
COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
COMBIGAN, BRIMONIDINE TARTRATE
COMBIPATCH, ESTRADIOL
COMBIVENT RESPIMAT, ALBUTEROL SULFATE

# APPENDIX A - PRODUCT NAME INDEX

**** C ****

COMBIVIR, LAMIVUDINE
COMETRIQ, CABOZANTINIB S-MALATE
COMMIT, NICOTINE POLACRILEX (OTC)
COMPLERA, EMTRICITABINE
COMPRO, PROCHLORPERAZINE
COMTAN, ENTACAPONE
CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
CONDYLOX, PODOFILOX
CONRAY, IOTHALAMATE MEGLUMINE
CONRAY 30, IOTHALAMATE MEGLUMINE
CONRAY 43, IOTHALAMATE MEGLUMINE
CONSTILAC, LACTULOSE
CONTRAVE, BUPROPION HYDROCHLORIDE
CONZIP, TRAMADOL HYDROCHLORIDE
COPAXONE, GLATIRAMER ACETATE
COPEGUS, RIBAVIRIN
CORDRAN, FLURANDRENOLIDE
CORDRAN SP, FLURANDRENOLIDE
COREG, CARVEDILOL
COREG CR, CARVEDILOL PHOSPHATE
CORGARD, NADOLOL
CORLANOR, IVABRADINE HYDROCHLORIDE
CORLOPAM, FENOLDOPAM MESYLATE
CORMAX, CLOBETASOL PROPIONATE
CORPHEDRA, EPHEDRINE SULFATE
CORTEF, HYDROCORTISONE
CORTENEMA, HYDROCORTISONE
CORTIFOAM, HYDROCORTISONE ACETATE
CORTISONE ACETATE, CORTISONE ACETATE
CORTISPORIN, BACITRACIN ZINC
CORTISPORIN, HYDROCORTISONE
CORTISPORIN, HYDROCORTISONE ACETATE
CORTROSYN, COSYNTROPIN
CORVERT, IBUTILIDE FUMARATE
CORZIDE, BENDROFLUMETHIAZIDE
COSMEGEN, DACTINOMYCIN
COSOPT, DORZOLAMIDE HYDROCHLORIDE
COSOPT PF, DORZOLAMIDE HYDROCHLORIDE
COSYNTROPIN, COSYNTROPIN
COTELLIC, COBIMETINIB FUMARATE
COTEMPLA XR-ODT, METHYLPHENIDATE
COUMADIN, WARFARIN SODIUM
COZAAR, LOSARTAN POTASSIUM
CREON, PANCRELIPASE (AMYLASE
CRESEMBA, ISAVUCONAZONIUM SULFATE
CRESTOR, ROSUVASTATIN CALCIUM
CRINONE, PROGESTERONE
CRIXIVAN, INDINAVIR SULFATE
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
CROMOLYN SODIUM, CROMOLYN SODIUM
CROTAN, CROTAMITON
CRYSELLE, ETHINYL ESTRADIOL
CUBICIN, DAPTOMYCIN
CUBICIN RF, DAPTOMYCIN
CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
CUPRIMINE, PENICILLAMINE
CUROSURF, PORACTANT ALFA
CUTIVATE, FLUTICASONE PROPIONATE
CUVPOSA, GLYCOPYRROLATE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYANOKIT, HYDROXOCOBALAMIN
CYCLAFEM 0.5/35, ETHINYL ESTRADIOL
CYCLAFEM 1/35, ETHINYL ESTRADIOL
CYCLAFEM 7/7/7, ETHINYL ESTRADIOL
CYCLESSA, DESOGESTREL

# APPENDIX A - PRODUCT NAME INDEX

**** C ****

CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOPENTOLATE HYDROCHLORIDE, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
CYCLOSET, BROMOCRIPTINE MESYLATE
CYCLOSPORINE, CYCLOSPORINE
CYKLOKAPRON, TRANEXAMIC ACID
CYMBALTA, DULOXETINE HYDROCHLORIDE
CYONANZ, ETHINYL ESTRADIOL
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
CYSTADANE, BETAINE HYDROCHLORIDE
CYSTAGON, CYSTEAMINE BITARTRATE
CYSTARAN, CYSTEAMINE HYDROCHLORIDE
CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
CYSVIEW KIT, HEXAMINOLEVULINATE HYDROCHLORIDE
CYTARABINE, CYTARABINE
CYTOMEL, LIOTHYRONINE SODIUM
CYTOTEC, MISOPROSTOL
CYTOVENE, GANCICLOVIR SODIUM

**** D ****

D.H.E. 45, DIHYDROERGOTAMINE MESYLATE
DACARBAZINE, DACARBAZINE
DACOGEN, DECITABINE
DACTINOMYCIN, DACTINOMYCIN
DAKLINZA, DACLATASVIR DIHYDROCHLORIDE
DALFAMPRIDINE, DALFAMPRIDINE
DALIRESP, ROFLUMILAST
DALVANCE, DALBAVANCIN HYDROCHLORIDE
DANAZOL, DANAZOL
DANTRIUM, DANTROLENE SODIUM
DANTROLENE SODIUM, DANTROLENE SODIUM
DAPSONE, DAPSONE
DAPTOMYCIN, DAPTOMYCIN
DARAPRIM, PYRIMETHAMINE
DARIFENACIN, DARIFENACIN HYDROBROMIDE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DARUNAVIR ETHANOLATE, DARUNAVIR ETHANOLATE
DASATINIB, DASATINIB
DASETTA 1/35, ETHINYL ESTRADIOL
DASETTA 7/7/7, ETHINYL ESTRADIOL
DATSCAN, IOFLUPANE I-123
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DAYPRO, OXAPROZIN
DAYSEE, ETHINYL ESTRADIOL
DAYTRANA, METHYLPHENIDATE
DDAVP, DESMOPRESSIN ACETATE
DDAVP (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DECITABINE, DECITABINE
DEFERASIROX, DEFERASIROX
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEFINITY, PERFLUTREN
DEFITELIO, DEFIBROTIDE SODIUM
DELATESTRYL, TESTOSTERONE ENANTHATE
DELESTROGEN, ESTRADIOL VALERATE
DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

# APPENDIX A - PRODUCT NAME INDEX

**** D ****

DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
DELZICOL, MESALAMINE
DEMADEX, TORSEMIDE
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
DEMEROL, MEPERIDINE HYDROCHLORIDE
DEMSER, METYROSINE
DENAVIR, PENCICLOVIR
DEPACON, VALPROATE SODIUM
DEPAKENE, VALPROIC ACID
DEPAKOTE, DIVALPROEX SODIUM
DEPAKOTE ER, DIVALPROEX SODIUM
DEPEN, PENICILLAMINE
DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
DEPO-SUBQ PROVERA 104, MEDROXYPROGESTERONE ACETATE
DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
DEPOCYT, CYTARABINE
DERMA-SMOOTHE/FS, FLUOCINOLONE ACETONIDE
DERMABET, BETAMETHASONE VALERATE
DERMATOP, PREDNICARBATE
DERMATOP E EMOLLIENT, PREDNICARBATE
DERMOTIC, FLUOCINOLONE ACETONIDE
DESCOVY, EMTRICITABINE
DESFERAL, DEFEROXAMINE MESYLATE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DESLORATADINE, DESLORATADINE
DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR, DESLORATADINE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DESOGEN, DESOGESTREL
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DESONATE, DESONIDE
DESONIDE, DESONIDE
DESOWEN, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DESOXYN, METHAMPHETAMINE HYDROCHLORIDE
DESVENLAFAXINE, DESVENLAFAXINE
DESVENLAFAXINE, DESVENLAFAXINE FUMARATE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DETROL, TOLTERODINE TARTRATE
DETROL LA, TOLTERODINE TARTRATE
DEXAMETHASONE, DEXAMETHASONE
DEXAMETHASONE INTENSOL, DEXAMETHASONE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE
DEXASPORIN, DEXAMETHASONE
DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE, DEXBROMPHENIRAMINE MALEATE (OTC)
DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE
DEXEDRINE, DEXTROAMPHETAMINE SULFATE
DEXFERRUM, IRON DEXTRAN
DEXILANT, DEXLANSOPRAZOLE
DEXLANSOPRAZOLE, DEXLANSOPRAZOLE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMP SACCHARATE,AMP ASPARTATE,DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE, DEXTROMETHORPHAN HYDROBROMIDE
DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE

# APPENDIX A - PRODUCT NAME INDEX

**** D ****

DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 25%, DEXTROSE
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC CONTAINER,
DEXTROSE 50% , DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 60% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DIABETA, GLYBURIDE
DIABINESE, CHLORPROPAMIDE
DIAMOX, ACETAZOLAMIDE
DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE

# APPENDIX A - PRODUCT NAME INDEX

**** D ****

DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIASTAT, DIAZEPAM
DIASTAT ACUDIAL, DIAZEPAM
DIAZEPAM, DIAZEPAM
DIAZEPAM INTENSOL, DIAZEPAM
DIBENZYLINE, PHENOXYBENZAMINE HYDROCHLORIDE
DICLEGIS, DOXYLAMINE SUCCINATE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICLOFENAC SODIUM , DICLOFENAC SODIUM
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE), DICYCLOMINE HYDROCHLORIDE
DIDANOSINE, DIDANOSINE
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
DIFFERIN, ADAPALENE (OTC)
DIFFERIN, ADAPALENE
DIFICID, FIDAXOMICIN
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
DIFLUCAN, FLUCONAZOLE
DIFLUNISAL, DIFLUNISAL
DIGOXIN, DIGOXIN
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
DILANTIN, PHENYTOIN
DILANTIN, PHENYTOIN SODIUM
DILANTIN-125, PHENYTOIN
DILATRATE-SR, ISOSORBIDE DINITRATE
DILAUDID, HYDROMORPHONE HYDROCHLORIDE
DILAUDID-HP, HYDROMORPHONE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DILTZAC, DILTIAZEM HYDROCHLORIDE
DIMENHYDRINATE, DIMENHYDRINATE
DIMETHYL SULFOXIDE, DIMETHYL SULFOXIDE
DIOVAN, VALSARTAN
DIOVAN HCT, HYDROCHLOROTHIAZIDE
DIPENTUM, OLSALAZINE SODIUM
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DIPRIVAN, PROPOFOL
DIPROLENE, BETAMETHASONE DIPROPIONATE
DIPROLENE AF, BETAMETHASONE DIPROPIONATE
DIPYRIDAMOLE, DIPYRIDAMOLE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DISULFIRAM, DISULFIRAM
DISULFIRAM , DISULFIRAM
DITROPAN XL, OXYBUTYNIN CHLORIDE
DIURIL, CHLOROTHIAZIDE
DIURIL, CHLOROTHIAZIDE SODIUM
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DIVIGEL, ESTRADIOL
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
DOFETILIDE, DOFETILIDE
DOLOPHINE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE

# APPENDIX A - PRODUCT NAME INDEX

**** D ****

DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPRAM, DOXAPRAM HYDROCHLORIDE
DORAL, QUAZEPAM
DORYX, DOXYCYCLINE HYCLATE
DORYX MPC, DOXYCYCLINE HYCLATE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DOTAREM, GADOTERATE MEGLUMINE
DOVONEX, CALCIPOTRIENE
DOXAPRAM HYDROCHLORIDE, DOXAPRAM HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
DOXIL (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
DOXY 100, DOXYCYCLINE HYCLATE
DOXY 200, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE
DRAX EXAMETAZIME, TECHNETIUM TC-99M EXAMETAZIME KIT
DRAXIMAGE MDP-25, TECHNETIUM TC-99M MEDRONATE
DRISDOL, ERGOCALCIFEROL
DRONABINOL, DRONABINOL
DROPERIDOL, DROPERIDOL
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM, DROSPIRENONE
DROXIA, HYDROXYUREA
DTPA, TECHNETIUM TC-99M PENTETATE KIT
DUAC, BENZOYL PEROXIDE
DUAVEE, BAZEDOXIFENE ACETATE
DUETACT, GLIMEPIRIDE
DUEXIS, FAMOTIDINE
DULERA, FORMOTEROL FUMARATE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
DUODOTE, ATROPINE
DUOPA, CARBIDOPA
DURACLON, CLONIDINE HYDROCHLORIDE
DURAGESIC-100, FENTANYL
DURAGESIC-12, FENTANYL
DURAGESIC-25, FENTANYL
DURAGESIC-50, FENTANYL
DURAGESIC-75, FENTANYL
DURAMORPH PF, MORPHINE SULFATE
DURAPREP, IODINE POVACRYLEX (OTC)
DUREZOL, DIFLUPREDNATE
DURLAZA, ASPIRIN
DUTASTERIDE, DUTASTERIDE
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
DUTOPROL, HYDROCHLOROTHIAZIDE
DUVOID, BETHANECHOL CHLORIDE
DUZALLO, ALLOPURINOL
DYANAVEL XR, AMPHETAMINE
DYAZIDE, HYDROCHLOROTHIAZIDE
DYLOJECT, DICLOFENAC SODIUM
DYMISTA, AZELASTINE HYDROCHLORIDE
DYNA-HEX, CHLORHEXIDINE GLUCONATE (OTC)
DYNACIN, MINOCYCLINE HYDROCHLORIDE
DYRENIUM, TRIAMTERENE

# APPENDIX A - PRODUCT NAME INDEX

**** E ****

E-Z SCRUB 201, POVIDONE-IODINE (OTC)
E-Z SCRUB 241, POVIDONE-IODINE (OTC)
E-Z-HD, BARIUM SULFATE
E-Z-PAQUE, BARIUM SULFATE
E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE
EC-NAPROSYN, NAPROXEN
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ECOZA, ECONAZOLE NITRATE
EDARBI, AZILSARTAN KAMEDOXOMIL
EDARBYCLOR, AZILSARTAN KAMEDOXOMIL
EDECRIN, ETHACRYNATE SODIUM
EDECRIN, ETHACRYNIC ACID
EDEX, ALPROSTADIL
EDLUAR, ZOLPIDEM TARTRATE
EDURANT, RILPIVIRINE HYDROCHLORIDE
EFAVIRENZ, EFAVIRENZ
EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
EFFIENT, PRASUGREL HYDROCHLORIDE
EFUDEX, FLUOROURACIL
EGRIFTA, TESAMORELIN ACETATE
ELDEPRYL, SELEGILINE HYDROCHLORIDE
ELELYSO, TALIGLUCERASE ALFA
ELESTAT, EPINASTINE HYDROCHLORIDE
ELESTRIN, ESTRADIOL
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
ELIDEL, PIMECROLIMUS
ELIFEMME, ETHINYL ESTRADIOL
ELIGARD, LEUPROLIDE ACETATE
ELIMITE, PERMETHRIN
ELINEST, ETHINYL ESTRADIOL
ELIPHOS, CALCIUM ACETATE
ELIQUIS, APIXABAN
ELIXOPHYLLIN, THEOPHYLLINE
ELLA, ULIPRISTAL ACETATE
ELLENCE, EPIRUBICIN HYDROCHLORIDE
ELLIOTTS B SOLUTION, CALCIUM CHLORIDE
ELMIRON, PENTOSAN POLYSULFATE SODIUM
ELOCON, MOMETASONE FUROATE
ELOXATIN, OXALIPLATIN
EMADINE, EMEDASTINE DIFUMARATE
EMBEDA, MORPHINE SULFATE
EMBELINE, CLOBETASOL PROPIONATE
EMBELINE E, CLOBETASOL PROPIONATE
EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM
EMEND, APREPITANT
EMEND, FOSAPREPITANT DIMEGLUMINE
EMFLAZA, DEFLAZACORT
EMLA, LIDOCAINE
EMOQUETTE, DESOGESTREL
EMSAM, SELEGILINE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
EMTRIVA, EMTRICITABINE
EMVERM, MEBENDAZOLE
ENABLEX, DARIFENACIN HYDROBROMIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENALAPRILAT, ENALAPRILAT
ENDARI, L-GLUTAMINE
ENDOMETRIN, PROGESTERONE
ENDOSOL EXTRA, CALCIUM CHLORIDE
ENLON, EDROPHONIUM CHLORIDE
ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
ENPRESSE-28, ETHINYL ESTRADIOL

# APPENDIX A - PRODUCT NAME INDEX

**** E ****

ENSKYCE, DESOGESTREL
ENSTILAR, BETAMETHASONE DIPROPIONATE
ENTACAPONE, ENTACAPONE
ENTECAVIR, ENTECAVIR
ENTEREG, ALVIMOPAN
ENTOCORT EC, BUDESONIDE
ENTRESTO, SACUBITRIL
ENULOSE, LACTULOSE
ENVARSUS XR, TACROLIMUS
EOVIST, GADOXETATE DISODIUM
EPANED, ENALAPRIL MALEATE
EPANED KIT, ENALAPRIL MALEATE
EPANOVA, OMEGA-3-CARBOXYLIC ACIDS
EPCLUSA, SOFOSBUVIR
EPHEDRINE SULFATE, EPHEDRINE SULFATE
EPIDUO, ADAPALENE
EPIDUO FORTE, ADAPALENE
EPIFOAM, HYDROCORTISONE ACETATE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
EPINEPHRINE, EPINEPHRINE
EPIPEN, EPINEPHRINE
EPIPEN JR., EPINEPHRINE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
EPITOL, CARBAMAZEPINE
EPIVIR, LAMIVUDINE
EPIVIR-HBV, LAMIVUDINE
EPLERENONE, EPLERENONE
EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM
EPROSARTAN MESYLATE, EPROSARTAN MESYLATE
EPTIFIBATIDE, EPTIFIBATIDE
EPZICOM, ABACAVIR SULFATE
EQUETRO, CARBAMAZEPINE
ERAXIS, ANIDULAFUNGIN
ERGOCALCIFEROL, ERGOCALCIFEROL
ERGOLOID MESYLATES, ERGOLOID MESYLATES
ERGOMAR, ERGOTAMINE TARTRATE
ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
ERIVEDGE, VISMODEGIB
ERRIN, NORETHINDRONE
ERTACZO, SERTACONAZOLE NITRATE
ERY-TAB, ERYTHROMYCIN
ERYC, ERYTHROMYCIN
ERYGEL, ERYTHROMYCIN
ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE
ERYTHROMYCIN, ERYTHROMYCIN
ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ESBRIET, PIRFENIDONE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESKATA, HYDROGEN PEROXIDE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
ESOMEPRAZOLE STRONTIUM, ESOMEPRAZOLE STRONTIUM
ESTARYLLA, ETHINYL ESTRADIOL
ESTAZOLAM, ESTAZOLAM
ESTRACE, ESTRADIOL
ESTRADIOL, ESTRADIOL
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
ESTRADIOL AND NORGESTIMATE, ESTRADIOL

# APPENDIX A - PRODUCT NAME INDEX

**** E ****

ESTRADIOL VALERATE, ESTRADIOL VALERATE
ESTRASORB, ESTRADIOL HEMIHYDRATE
ESTRING, ESTRADIOL
ESTROGEL, ESTRADIOL
ESTROPIPATE, ESTROPIPATE
ESTROSTEP FE, ETHINYL ESTRADIOL
ESZOPICLONE, ESZOPICLONE
ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
ETHACRYNIC ACID, ETHACRYNIC ACID
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
ETHAMOLIN, ETHANOLAMINE OLEATE
ETHOSUXIMIDE, ETHOSUXIMIDE
ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
ETHYOL, AMIFOSTINE
ETIDRONATE DISODIUM, ETIDRONATE DISODIUM
ETODOLAC, ETODOLAC
ETOMIDATE, ETOMIDATE
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
ETOPOSIDE, ETOPOSIDE
EUCRISA, CRISABOROLE
EURAX, CROTAMITON
EVAMIST, ESTRADIOL
EVEKEO, AMPHETAMINE SULFATE
EVISTA, RALOXIFENE HYDROCHLORIDE
EVOCLIN, CLINDAMYCIN PHOSPHATE
EVOMELA, MELPHALAN HYDROCHLORIDE
EVOTAZ, ATAZANAVIR SULFATE
EVOXAC, CEVIMELINE HYDROCHLORIDE
EVZIO, NALOXONE HYDROCHLORIDE
EXALGO, HYDROMORPHONE HYDROCHLORIDE
EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)
EXELDERM, SULCONAZOLE NITRATE
EXELON, RIVASTIGMINE
EXELON, RIVASTIGMINE TARTRATE
EXEMESTANE, EXEMESTANE
EXFORGE, AMLODIPINE BESYLATE
EXFORGE HCT, AMLODIPINE BESYLATE
EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)
EXJADE, DEFERASIROX
EXONDYS 51, ETEPLIRSEN
EXPAREL, BUPIVACAINE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
EXTINA, KETOCONAZOLE
EXTRANEAL, ICODEXTRIN
EZETIMIBE, EZETIMIBE
EZETIMIBE AND ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
EZETIMIBE AND SIMVASTATIN, EZETIMIBE

**** F ****

FABIOR, TAZAROTENE
FACTIVE, GEMIFLOXACIN MESYLATE
FALLBACK SOLO, LEVONORGESTREL (OTC)
FALMINA, ETHINYL ESTRADIOL
FAMCICLOVIR, FAMCICLOVIR
FAMOTIDINE, FAMOTIDINE (OTC)
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE, CALCIUM CARBONATE (OTC)
FANAPT, ILOPERIDONE
FARESTON, TOREMIFENE CITRATE
FARXIGA, DAPAGLIFLOZIN PROPANEDIOL
FARYDAK, PANOBINOSTAT LACTATE
FASLODEX, FULVESTRANT
FAYOSIM, ETHINYL ESTRADIOL

# APPENDIX A - PRODUCT NAME INDEX

**** F ****

FAZACLO ODT, CLOZAPINE
FELBAMATE, FELBAMATE
FELBATOL, FELBAMATE
FELDENE, PIROXICAM
FELODIPINE, FELODIPINE
FEMARA, LETROZOLE
FEMCON FE, ETHINYL ESTRADIOL
FEMHRT, ETHINYL ESTRADIOL
FEMRING, ESTRADIOL ACETATE
FENOFIBRATE, FENOFIBRATE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FENOGLIDE, FENOFIBRATE
FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM
FENTANYL CITRATE, FENTANYL CITRATE
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-37, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-62, FENTANYL
FENTANYL-75, FENTANYL
FENTANYL-87, FENTANYL
FENTORA, FENTANYL CITRATE
FERAHEME, FERUMOXYTOL
FERRIPROX, DEFERIPRONE
FERRLECIT, SODIUM FERRIC GLUCONATE COMPLEX
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
FETZIMA, LEVOMILNACIPRAN HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FIASP, INSULIN ASPART
FIASP FLEXTOUCH, INSULIN ASPART
FIBRICOR, FENOFIBRIC ACID
FINACEA, AZELAIC ACID
FINACEA , AZELAIC ACID
FINASTERIDE, FINASTERIDE
FIORICET W/ CODEINE, ACETAMINOPHEN
FIORINAL, ASPIRIN
FIORINAL W/CODEINE, ASPIRIN
FIRAZYR, ICATIBANT ACETATE
FIRMAGON, DEGARELIX ACETATE
FLAGYL, METRONIDAZOLE
FLAGYL ER, METRONIDAZOLE
FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
FLAREX, FLUOROMETHOLONE ACETATE
FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLECTOR, DICLOFENAC EPOLAMINE
FLOLAN, EPOPROSTENOL SODIUM
FLOLIPID, SIMVASTATIN
FLOMAX, TAMSULOSIN HYDROCHLORIDE
FLONASE ALLERGY RELIEF, FLUTICASONE PROPIONATE (OTC)
FLONASE SENSIMIST ALLERGY RELIEF, FLUTICASONE FUROATE (OTC)
FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
FLOVENT DISKUS 50, FLUTICASONE PROPIONATE
FLOVENT HFA, FLUTICASONE PROPIONATE
FLOWTUSS, GUAIFENESIN
FLOXURIDINE, FLOXURIDINE

# APPENDIX A - PRODUCT NAME INDEX

**** F ****

FLUCONAZOLE, FLUCONAZOLE
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCYTOSINE, FLUCYTOSINE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
FLUMADINE, RIMANTADINE HYDROCHLORIDE
FLUMAZENIL, FLUMAZENIL
FLUNISOLIDE, FLUNISOLIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUORESCITE, FLUORESCEIN SODIUM
FLUOROPLEX, FLUOROURACIL
FLUOROURACIL, FLUOROURACIL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUOXYMESTERONE, FLUOXYMESTERONE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FLURANDRENOLIDE, FLURANDRENOLIDE
FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
FLUTAMIDE, FLUTAMIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FML, FLUOROMETHOLONE
FML FORTE, FLUOROMETHOLONE
FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE
FOCALIN XR, DEXMETHYLPHENIDATE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
FOLLISTIM AQ, FOLLITROPIN ALFA/BETA
FOLOTYN, PRALATREXATE
FOMEPIZOLE, FOMEPIZOLE
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
FORANE, ISOFLURANE
FORFIVO XL, BUPROPION HYDROCHLORIDE
FORTAMET, METFORMIN HYDROCHLORIDE
FORTAZ, CEFTAZIDIME
FORTAZ IN PLASTIC CONTAINER, CEFTAZIDIME SODIUM
FORTEO, TERIPARATIDE RECOMBINANT HUMAN
FORTESTA, TESTOSTERONE
FOSAMAX, ALENDRONATE SODIUM
FOSAMAX PLUS D, ALENDRONATE SODIUM
FOSAMPRENAVIR CALCIUM, FOSAMPRENAVIR CALCIUM
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FOSCAVIR, FOSCARNET SODIUM
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FOSRENOL, LANTHANUM CARBONATE
FRAGMIN, DALTEPARIN SODIUM
FREAMINE HBC 6.9%, AMINO ACIDS
FREAMINE III 10%, AMINO ACIDS
FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5%, AMINO ACIDS
FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS
FROVA, FROVATRIPTAN SUCCINATE
FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
FULYZAQ, CROFELEMER
FURADANTIN, NITROFURANTOIN

# APPENDIX A - PRODUCT NAME INDEX

**** F ****

FUROSEMIDE, FUROSEMIDE
FUSILEV, LEVOLEUCOVORIN CALCIUM
FUZEON, ENFUVIRTIDE
FYAVOLV, ETHINYL ESTRADIOL
FYCOMPA, PERAMPANEL

**** G ****

GABAPENTIN, GABAPENTIN
GABITRIL, TIAGABINE HYDROCHLORIDE
GABLOFEN, BACLOFEN
GADAVIST, GADOBUTROL
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
GALZIN, ZINC ACETATE
GANCICLOVIR, GANCICLOVIR
GANCICLOVIR, GANCICLOVIR SODIUM
GANCICLOVIR SODIUM, GANCICLOVIR SODIUM
GANIRELIX ACETATE, GANIRELIX ACETATE
GASTROCROM, CROMOLYN SODIUM
GASTROGRAFIN, DIATRIZOATE MEGLUMINE
GATIFLOXACIN, GATIFLOXACIN
GATTEX KIT, TEDUGLUTIDE RECOMBINANT
GAVISCON, ALUMINUM HYDROXIDE (OTC)
GELNIQUE, OXYBUTYNIN CHLORIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GEMFIBROZIL, GEMFIBROZIL
GEMIFLOXACIN MESYLATE, GEMIFLOXACIN MESYLATE
GEMZAR, GEMCITABINE HYDROCHLORIDE
GEN-XENE, CLORAZEPATE DIPOTASSIUM
GENERLAC, LACTULOSE
GENGRAF, CYCLOSPORINE
GENOPTIC, GENTAMICIN SULFATE
GENOTROPIN, SOMATROPIN RECOMBINANT
GENOTROPIN PRESERVATIVE FREE, SOMATROPIN RECOMBINANT
GENTAK, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
GENVOYA, COBICISTAT
GEODON, ZIPRASIDONE HYDROCHLORIDE
GEODON, ZIPRASIDONE MESYLATE
GIAPREZA, ANGIOTENSIN II
GIAZO, BALSALAZIDE DISODIUM
GILDAGIA, ETHINYL ESTRADIOL
GILDESS 1.5/30, ETHINYL ESTRADIOL
GILDESS 1/20, ETHINYL ESTRADIOL
GILDESS 24 FE, ETHINYL ESTRADIOL
GILDESS FE 1.5/30, ETHINYL ESTRADIOL
GILDESS FE 1/20, ETHINYL ESTRADIOL
GILENYA, FINGOLIMOD
GILOTRIF, AFATINIB DIMALEATE
GLATIRAMER ACETATE, GLATIRAMER ACETATE
GLATOPA, GLATIRAMER ACETATE
GLEEVEC, IMATINIB MESYLATE
GLEOLAN, AMINOLEVULINIC ACID HYDROCHLORIDE
GLEOSTINE, LOMUSTINE
GLIADEL, CARMUSTINE
GLIMEPIRIDE, GLIMEPIRIDE
GLIPIZIDE, GLIPIZIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLOFIL-125, IOTHALAMATE SODIUM I-125
GLUCAGEN, GLUCAGON HYDROCHLORIDE RECOMBINANT
GLUCAGON, GLUCAGON HYDROCHLORIDE
GLUCAGON, GLUCAGON RECOMBINANT
GLUCAMIDE, CHLORPROPAMIDE
GLUCOPHAGE, METFORMIN HYDROCHLORIDE

# APPENDIX A - PRODUCT NAME INDEX

**** G ****

GLUCOPHAGE XR, METFORMIN HYDROCHLORIDE
GLUCOTROL, GLIPIZIDE
GLUCOTROL XL, GLIPIZIDE
GLUMETZA, METFORMIN HYDROCHLORIDE
GLYBURIDE, GLYBURIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
GLYCOLAX, POLYETHYLENE GLYCOL 3350 (OTC)
GLYCOLAX, POLYETHYLENE GLYCOL 3350
GLYCOPYRROLATE, GLYCOPYRROLATE
GLYDO, LIDOCAINE HYDROCHLORIDE
GLYNASE, GLYBURIDE
GLYSET, MIGLITOL
GLYXAMBI, EMPAGLIFLOZIN
GOCOVRI, AMANTADINE HYDROCHLORIDE
GOLYTELY, POLYETHYLENE GLYCOL 3350
GONAL-F, FOLLITROPIN ALFA/BETA
GONAL-F RFF, FOLLITROPIN ALFA/BETA
GONAL-F RFF REDI-JECT, FOLLITROPIN ALFA/BETA
GONITRO, NITROGLYCERIN
GOPRELTO, COCAINE HYDROCHLORIDE
GRALISE, GABAPENTIN
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
GRIS-PEG, GRISEOFULVIN, ULTRAMICROSIZE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
GRISEOFULVIN,ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
GUAIFENESIN, GUAIFENESIN (OTC)
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
GUANABENZ ACETATE, GUANABENZ ACETATE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
GUANIDINE HYDROCHLORIDE, GUANIDINE HYDROCHLORIDE
GYNAZOLE-1, BUTOCONAZOLE NITRATE

**** H ****

H.P. ACTHAR GEL, CORTICOTROPIN
HABITROL, NICOTINE (OTC)
HAILEY FE 1/20, ETHINYL ESTRADIOL
HALAVEN, ERIBULIN MESYLATE
HALCION, TRIAZOLAM
HALDOL, HALOPERIDOL DECANOATE
HALDOL, HALOPERIDOL LACTATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
HALOG, HALCINONIDE
HALOPERIDOL, HALOPERIDOL
HALOPERIDOL, HALOPERIDOL LACTATE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HARVONI, LEDIPASVIR
HEATHER, NORETHINDRONE
HECTOROL, DOXERCALCIFEROL
HEMABATE, CARBOPROST TROMETHAMINE
HEMANGEOL, PROPRANOLOL HYDROCHLORIDE
HEPARIN SODIUM, HEPARIN SODIUM
HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM

# APPENDIX A - PRODUCT NAME INDEX

**** H ****



**** I ****

# APPENDIX A - PRODUCT NAME INDEX

**** I ****

IBU-TAB 200, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN LYSINE, IBUPROFEN LYSINE
IBUPROFEN SODIUM, IBUPROFEN SODIUM (OTC)
IBUPROHM, IBUPROFEN (OTC)
IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)
IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
IC-GREEN, INDOCYANINE GREEN
ICLUSIG, PONATINIB HYDROCHLORIDE
IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
IDARUBICIN HYDROCHLORIDE PFS, IDARUBICIN HYDROCHLORIDE
IDHIFA, ENASIDENIB MESYLATE
IDKIT:HP, CITRIC ACID
IFEX, IFOSFAMIDE
IFOSFAMIDE, IFOSFAMIDE
ILEVRO, NEPAFENAC
ILOPERIDONE, ILOPERIDONE
ILUVIEN, FLUOCINOLONE ACETONIDE
IMATINIB MESYLATE, IMATINIB MESYLATE
IMBRUVICA, IBRUTINIB
IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
IMIQUIMOD, IMIQUIMOD
IMITREX, SUMATRIPTAN
IMITREX, SUMATRIPTAN SUCCINATE
IMITREX STATDOSE, SUMATRIPTAN SUCCINATE
IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)
IMPAVIDO, MILTEFOSINE
IMPOYZ, CLOBETASOL PROPIONATE
IMURAN, AZATHIOPRINE
INAPSINE, DROPERIDOL
INCASSIA, NORETHINDRONE
INCRELEX, MECASERMIN RECOMBINANT
INCRUSE ELLIPTA , UMECLIDINIUM BROMIDE
INDAPAMIDE, INDAPAMIDE
INDERAL LA, PROPRANOLOL HYDROCHLORIDE
INDICLOR, INDIUM IN-111 CHLORIDE
INDIUM IN 111 CHLORIDE, INDIUM IN-111 CHLORIDE
INDIUM IN 111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE
INDOCIN, INDOMETHACIN
INDOCIN, INDOMETHACIN SODIUM
INDOCYANINE GREEN, INDOCYANINE GREEN
INDOMETHACIN, INDOMETHACIN
INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
INFANTS' FEVERALL, ACETAMINOPHEN (OTC)
INFASURF PRESERVATIVE FREE, CALFACTANT
INFED, IRON DEXTRAN
INFUMORPH, MORPHINE SULFATE
INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE
INFUVITE PEDIATRIC, ASCORBIC ACID
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE), ASCORBIC ACID
INGREZZA, VALBENAZINE TOSYLATE
INJECTAFER, FERRIC CARBOXYMALTOSE
INLYTA, AXITINIB
INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE
INOMAX, NITRIC OXIDE
INSPRA, EPLERENONE

# APPENDIX A - PRODUCT NAME INDEX

**** I ****

INTEGRILIN, EPTIFIBATIDE
INTELENCE, ETRAVIRINE
INTERMEZZO, ZOLPIDEM TARTRATE
INTRALIPID 10%, SOYBEAN OIL
INTRALIPID 20%, SOYBEAN OIL
INTRALIPID 30%, SOYBEAN OIL
INTRAROSA, PRASTERONE
INTROVALE, ETHINYL ESTRADIOL
INTUNIV, GUANFACINE HYDROCHLORIDE
INVANZ, ERTAPENEM SODIUM
INVEGA, PALIPERIDONE
INVEGA SUSTENNA, PALIPERIDONE PALMITATE
INVEGA TRINZA, PALIPERIDONE PALMITATE
INVIRASE, SAQUINAVIR MESYLATE
INVOKAMET, CANAGLIFLOZIN
INVOKAMET XR, CANAGLIFLOZIN
INVOKANA, CANAGLIFLOZIN
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
IONSYS, FENTANYL HYDROCHLORIDE
IOPIDINE, APRACLONIDINE HYDROCHLORIDE
IOSAT, POTASSIUM IODIDE (OTC)
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
IPRIVASK, DESIRUDIN RECOMBINANT
IRBESARTAN, IRBESARTAN
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRESSA, GEFITINIB
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
ISENTRESS, RALTEGRAVIR POTASSIUM
ISENTRESS HD, RALTEGRAVIR POTASSIUM
ISIBLOOM, DESOGESTREL
ISOCAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE
ISOFLURANE, ISOFLURANE
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISONIAZID, ISONIAZID
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
ISOPTO ATROPINE, ATROPINE SULFATE
ISOPTO CARPINE, PILOCARPINE HYDROCHLORIDE
ISORDIL, ISOSORBIDE DINITRATE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
ISOSULFAN BLUE, ISOSULFAN BLUE
ISOTRETINOIN, ISOTRETINOIN
ISOVUE-200, IOPAMIDOL
ISOVUE-250, IOPAMIDOL
ISOVUE-300, IOPAMIDOL
ISOVUE-370, IOPAMIDOL
ISOVUE-M 200, IOPAMIDOL
ISOVUE-M 300, IOPAMIDOL
ISRADIPINE, ISRADIPINE
ISTALOL, TIMOLOL MALEATE
ISTODAX, ROMIDEPSIN
ISUPREL, ISOPROTERENOL HYDROCHLORIDE
ITRACONAZOLE, ITRACONAZOLE
IVERMECTIN, IVERMECTIN
IVY BLOCK, BENTOQUATAM (OTC)
IXEMPRA KIT, IXABEPILONE

**** J ****

JADENU, DEFERASIROX
JADENU SPRINKLE, DEFERASIROX
JAIMIESS, ETHINYL ESTRADIOL
JAKAFI, RUXOLITINIB PHOSPHATE
JALYN, DUTASTERIDE

# APPENDIX A - PRODUCT NAME INDEX

**** J ****

JANTOVEN, WARFARIN SODIUM
JANUMET, METFORMIN HYDROCHLORIDE
JANUMET XR, METFORMIN HYDROCHLORIDE
JANUVIA, SITAGLIPTIN PHOSPHATE
JARDIANCE, EMPAGLIFLOZIN
JEANATOPE, ALBUMIN IODINATED I-125 SERUM
JENCYCLA, NORETHINDRONE
JENTADUETO, LINAGLIPTIN
JENTADUETO XR, LINAGLIPTIN
JEVTANA KIT, CABAZITAXEL
JUBLIA, EFINACONAZOLE
JULUCA, DOLUTEGRAVIR SODIUM
JUNEL 1.5/30, ETHINYL ESTRADIOL
JUNEL 1/20, ETHINYL ESTRADIOL
JUNEL FE 1.5/30, ETHINYL ESTRADIOL
JUNEL FE 1/20, ETHINYL ESTRADIOL
JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
JUNIOR STRENGTH IBUPROFEN, IBUPROFEN (OTC)
JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)
JUXTAPID, LOMITAPIDE MESYLATE

**** K ****

K-TAB, POTASSIUM CHLORIDE
KABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
KADIAN, MORPHINE SULFATE
KAITLIB FE, ETHINYL ESTRADIOL
KALETRA, LOPINAVIR
KALEXATE, SODIUM POLYSTYRENE SULFONATE
KALLIGA, DESOGESTREL
KALYDECO, IVACAFTOR
KANAMYCIN SULFATE, KANAMYCIN SULFATE
KAPVAY, CLONIDINE HYDROCHLORIDE
KARBINAL ER, CARBINOXAMINE MALEATE
KARIVA, DESOGESTREL
KAZANO, ALOGLIPTIN BENZOATE
KEFLEX, CEPHALEXIN
KEFZOL, CEFAZOLIN SODIUM
KELNOR, ETHINYL ESTRADIOL
KENALOG, TRIAMCINOLONE ACETONIDE
KENALOG-10, TRIAMCINOLONE ACETONIDE
KENALOG-40, TRIAMCINOLONE ACETONIDE
KENGREAL, CANGRELOR
KEPPRA, LEVETIRACETAM
KEPPRA XR, LEVETIRACETAM
KERYDIN, TAVABOROLE
KETALAR, KETAMINE HYDROCHLORIDE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
KETOZOLE, KETOCONAZOLE
KEVEYIS, DICHLORPHENAMIDE
KHEDEZLA, DESVENLAFAXINE
KIMIDESS, DESOGESTREL
KINEVAC, SINCALIDE
KIONEX, SODIUM POLYSTYRENE SULFONATE
KISQALI, RIBOCICLIB SUCCINATE
KISQALI FEMARA CO-PACK (COPACKAGED), LETROZOLE
KITABIS PAK, TOBRAMYCIN
KLARON, SULFACETAMIDE SODIUM
KLONOPIN, CLONAZEPAM
KLOR-CON, POTASSIUM CHLORIDE
KLOR-CON M10, POTASSIUM CHLORIDE
KLOR-CON M15, POTASSIUM CHLORIDE

# APPENDIX A - PRODUCT NAME INDEX

**** K ****

KLOR-CON M20, POTASSIUM CHLORIDE
KOMBIGLYZE XR, METFORMIN HYDROCHLORIDE
KORLYM, MIFEPRISTONE
KOVANAZE, OXYMETAZOLINE HYDROCHLORIDE
KURVELO, ETHINYL ESTRADIOL
KUVAN, SAPROPTERIN DIHYDROCHLORIDE
KYBELLA, DEOXYCHOLIC ACID
KYLEENA, LEVONORGESTREL
KYNAMRO, MIPOMERSEN SODIUM
KYPROLIS, CARFILZOMIB

**** L ****

LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LACRISERT, HYDROXYPROPYL CELLULOSE
LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTULOSE, LACTULOSE
LAMICTAL, LAMOTRIGINE
LAMICTAL CD, LAMOTRIGINE
LAMICTAL ODT, LAMOTRIGINE
LAMICTAL XR, LAMOTRIGINE
LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)
LAMISIL, TERBINAFINE HYDROCHLORIDE
LAMISIL AT, TERBINAFINE (OTC)
LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)
LAMIVUDINE, LAMIVUDINE
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMOTRIGINE, LAMOTRIGINE
LANIAZID, ISONIAZID
LANORINAL, ASPIRIN
LANOXIN, DIGOXIN
LANOXIN PEDIATRIC, DIGOXIN
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LANSOPRAZOLE, LANSOPRAZOLE
LANSOPRAZOLE , LANSOPRAZOLE
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN
LANTHANUM CARBONATE, LANTHANUM CARBONATE
LANTUS, INSULIN GLARGINE RECOMBINANT
LANTUS SOLOSTAR, INSULIN GLARGINE RECOMBINANT
LARIN 1.5/30, ETHINYL ESTRADIOL
LARIN 1/20, ETHINYL ESTRADIOL
LARIN 24 FE, ETHINYL ESTRADIOL
LARIN FE 1.5/30, ETHINYL ESTRADIOL
LARIN FE 1/20, ETHINYL ESTRADIOL
LAROTID, AMOXICILLIN
LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE
LASIX, FUROSEMIDE
LASTACAFT, ALCAFTADINE
LATANOPROST, LATANOPROST
LATISSE, BIMATOPROST
LATUDA, LURASIDONE HYDROCHLORIDE
LAX-LYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
LAZANDA, FENTANYL CITRATE
LEFLUNOMIDE, LEFLUNOMIDE
LENVIMA, LENVATINIB MESYLATE
LERIBANE, ETHINYL ESTRADIOL
LESCOL XL, FLUVASTATIN SODIUM
LESSINA-28, ETHINYL ESTRADIOL
LETAIRIS, AMBRISENTAN
LETROZOLE, LETROZOLE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEUKERAN, CHLORAMBUCIL
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE

# APPENDIX A - PRODUCT NAME INDEX

**** L ****

LEVAQUIN, LEVOFLOXACIN
LEVEMIR, INSULIN DETEMIR RECOMBINANT
LEVEMIR FLEXTOUCH, INSULIN DETEMIR RECOMBINANT
LEVETIRACETAM, LEVETIRACETAM
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
LEVITRA, VARDENAFIL HYDROCHLORIDE
LEVO-T, LEVOTHYROXINE SODIUM **
LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
LEVOCARNITINE, LEVOCARNITINE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
LEVONEST, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL (OTC)
LEVONORGESTREL, LEVONORGESTREL
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVOPHED, NOREPINEPHRINE BITARTRATE
LEVORA 0.15/30-28, ETHINYL ESTRADIOL
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
LEVOXYL, LEVOTHYROXINE SODIUM **
LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE
LEXAPRO, ESCITALOPRAM OXALATE
LEXISCAN, REGADENOSON
LEXIVA, FOSAMPRENAVIR CALCIUM
LIALDA, MESALAMINE
LIBRAX, CHLORDIAZEPOXIDE HYDROCHLORIDE
LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE
LIDEX, FLUOCINONIDE
LIDOCAINE, LIDOCAINE
LIDOCAINE AND PRILOCAINE, LIDOCAINE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDODERM, LIDOCAINE
LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE
LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
LILETTA, LEVONORGESTREL
LINCOCIN, LINCOMYCIN HYDROCHLORIDE
LINCOMYCIN, LINCOMYCIN HYDROCHLORIDE
LINDANE, LINDANE
LINEZOLID, LINEZOLID
LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, LINEZOLID
LINZESS, LINACLOTIDE
LIORESAL, BACLOFEN
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
LIPIODOL, ETHIODIZED OIL
LIPITOR, ATORVASTATIN CALCIUM
LIPOFEN, FENOFIBRATE
LIQUID E-Z-PAQUE, BARIUM SULFATE
LISINOPRIL, LISINOPRIL
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
LITHIUM CITRATE, LITHIUM CITRATE

# APPENDIX A - PRODUCT NAME INDEX

** L **

LITHOBID, LITHIUM CARBONATE
LITHOSTAT, ACETOHYDROXAMIC ACID
LIVALO, PITAVASTATIN CALCIUM
LO LOESTRIN FE, ETHINYL ESTRADIOL
LO MINASTRIN FE, ETHINYL ESTRADIOL
LO SIMPESSE, ETHINYL ESTRADIOL
LOCOID, HYDROCORTISONE BUTYRATE
LOCOID LIPOCREAM, HYDROCORTISONE BUTYRATE
LODOSYN, CARBIDOPA
LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL
LOESTRIN 21 1/20, ETHINYL ESTRADIOL
LOESTRIN 24 FE, ETHINYL ESTRADIOL
LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL
LOESTRIN FE 1/20, ETHINYL ESTRADIOL
LOGILIA, ULIPRISTAL ACETATE
LOMAIRA, PHENTERMINE HYDROCHLORIDE
LOMOTIL, ATROPINE SULFATE
LONHALA MAGNAIR KIT, GLYCOPYRROLATE
LONSURF, TIPIRACIL HYDROCHLORIDE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPID, GEMFIBROZIL
LOPINAVIR AND RITONAVIR, LOPINAVIR
LOPRESSOR, METOPROLOL TARTRATE
LOPRESSOR HCT, HYDROCHLOROTHIAZIDE
LOPROX, CICLOPIROX
LOPURIN, ALLOPURINOL
LORATADINE, LORATADINE (OTC)
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
LORATADINE REDIDOSE, LORATADINE (OTC)
LORAZEPAM, LORAZEPAM
LORAZEPAM INTENSOL, LORAZEPAM
LORAZEPAM PRESERVATIVE FREE, LORAZEPAM
LORYNA, DROSPIRENONE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSEASONIQUE, ETHINYL ESTRADIOL
LOTEMAX, LOTEPREDNOL ETABONATE
LOTENSIN, BENAZEPRIL HYDROCHLORIDE
LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
LOTREL, AMLODIPINE BESYLATE
LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)
LOTRISONE, BETAMETHASONE DIPROPIONATE
LOTRONEX, ALOSETRON HYDROCHLORIDE
LOVASTATIN, LOVASTATIN
LOVAZA, OMEGA-3-ACID ETHYL ESTERS
LOVENOX, ENOXAPARIN SODIUM
LOVENOX (PRESERVATIVE FREE), ENOXAPARIN SODIUM
LOW-OGESTREL-28, ETHINYL ESTRADIOL
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
LTA II KIT, LIDOCAINE HYDROCHLORIDE
LUMASON, SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES
LUMIFY, BRIMONIDINE TARTRATE (OTC)
LUMIGAN, BIMATOPROST
LUNESTA, ESZOPICLONE
LUPANETA PACK, LEUPROLIDE ACETATE
LUPRON DEPOT, LEUPROLIDE ACETATE
LUPRON DEPOT-PED, LEUPROLIDE ACETATE
LUVOX, FLUVOXAMINE MALEATE
LUXIQ, BETAMETHASONE VALERATE
LUZU, LULICONAZOLE
LYMPHOSEEK KIT, TECHNETIUM TC-99M TILMANOCEPT
LYNPARZA, OLAPARIB
LYRICA, PREGABALIN

# APPENDIX A - PRODUCT NAME INDEX

**** L ****

LYRICA CR, PREGABALIN
LYSODREN, MITOTANE
LYSTEDA, TRANEXAMIC ACID

**** M ****

M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
M.V.I. ADULT, ASCORBIC ACID
M.V.I. ADULT (PHARMACY BULK PACKAGE), ASCORBIC ACID
M.V.I. PEDIATRIC, ASCORBIC ACID
MACRILEN, MACIMORELIN ACETATE
MACROBID, NITROFURANTOIN
MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
MACUGEN, PEGAPTANIB SODIUM
MAFENIDE ACETATE, MAFENIDE ACETATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNEVIST, GADOPENTETATE DIMEGLUMINE
MAKENA, HYDROXYPROGESTERONE CAPROATE
MAKENA PRESERVATIVE FREE, HYDROXYPROGESTERONE CAPROATE
MALARONE, ATOVAQUONE
MALARONE PEDIATRIC, ATOVAQUONE
MALATHION, MALATHION
MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE
MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 25%, MANNITOL
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
MAPROTILINE HYDROCHLORIDE, MAPROTILINE HYDROCHLORIDE
MARCAINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARINOL, DRONABINOL
MARLISSA, ETHINYL ESTRADIOL
MARPLAN, ISOCARBOXAZID
MARQIBO KIT, VINCRISTINE SULFATE
MATULANE, PROCARBAZINE HYDROCHLORIDE
MAVIK, TRANDOLAPRIL
MAVYRET, GLECAPREVIR
MAXALT, RIZATRIPTAN BENZOATE
MAXALT-MLT, RIZATRIPTAN BENZOATE
MAXIDEX, DEXAMETHASONE
MAXIPIME, CEFEPIME HYDROCHLORIDE
MAXITROL, DEXAMETHASONE
MAXZIDE, HYDROCHLOROTHIAZIDE
MAXZIDE-25, HYDROCHLOROTHIAZIDE
MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
MDP-BRACCO, TECHNETIUM TC-99M MEDRONATE KIT
MECAMYLAMINE HYDROCHLORIDE, MECAMYLAMINE HYDROCHLORIDE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MEDROL, METHYLPREDNISOLONE
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEFENAMIC ACID, MEFENAMIC ACID
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
MEFOXIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MEGACE ES, MEGESTROL ACETATE
MEGATOPE, ALBUMIN IODINATED I-131 SERUM
MEGESTROL ACETATE, MEGESTROL ACETATE
MEKINIST, TRAMETINIB DIMETHYL SULFOXIDE
MELAMISA, DROSPIRENONE

# APPENDIX A - PRODUCT NAME INDEX

**** M ****

MELOXICAM, MELOXICAM
MELPHALAN, MELPHALAN
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
MEMBRANEBLUE, TRYPAN BLUE
MEN'S ROGAINE, MINOXIDIL (OTC)
MENEST, ESTROGENS, ESTERIFIED
MENOPUR, MENOTROPINS (FSH
MENOSTAR, ESTRADIOL
MENTAX, BUTENAFINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPHYTON, PHYTONADIONE
MEPIVACAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
MEPRON, ATOVAQUONE
MERCAPTOPURINE, MERCAPTOPURINE
MEROPENEM, MEROPENEM
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER, MEROPENEM
MERREM, MEROPENEM
MESALAMINE, MESALAMINE
MESNA, MESNA
MESNEX, MESNA
MESTINON, PYRIDOSTIGMINE BROMIDE
METADATE CD, METHYLPHENIDATE HYDROCHLORIDE
METADATE ER, METHYLPHENIDATE HYDROCHLORIDE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METARAMINOL BITARTRATE, METARAMINOL BITARTRATE
METASTRON, STRONTIUM CHLORIDE SR-89
METAXALONE, METAXALONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHADONE HYDROCHLORIDE INTENSOL, METHADONE HYDROCHLORIDE
METHADOSE, METHADONE HYDROCHLORIDE
METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
METHERGINE, METHYLERGONOVINE MALEATE
METHIMAZOLE, METHIMAZOLE
METHOCARBAMOL, METHOCARBAMOL
METHOCARBAMOL AND ASPIRIN, ASPIRIN
METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOXSALEN, METHOXSALEN
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLDOPA, METHYLDOPA
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPATE HYDROCHLORIDE, METHYLDOPATE HYDROCHLORIDE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METHYLIN, METHYLPHENIDATE HYDROCHLORIDE
METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOLAZONE, METOLAZONE
METOPIRONE, METYRAPONE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE

# APPENDIX A - PRODUCT NAME INDEX

**** M ****

METOPROLOL TARTRATE, METOPROLOL TARTRATE
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METOZOLV ODT, METOCLOPRAMIDE HYDROCHLORIDE
METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE
METROCREAM, METRONIDAZOLE
METROGEL, METRONIDAZOLE
METROGEL-VAGINAL, METRONIDAZOLE
METROLOTION, METRONIDAZOLE
METRONIDAZOLE, METRONIDAZOLE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
MIACALCIN, CALCITONIN SALMON
MIBELAS 24 FE, ETHINYL ESTRADIOL
MICARDIS, TELMISARTAN
MICARDIS HCT, HYDROCHLOROTHIAZIDE
MICONAZOLE 3, MICONAZOLE NITRATE (OTC)
MICONAZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
MICONAZOLE 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE
MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICORT-HC, HYDROCORTISONE ACETATE
MICRO-K, POTASSIUM CHLORIDE
MICRO-K 10, POTASSIUM CHLORIDE
MICROGESTIN 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN 1/20, ETHINYL ESTRADIOL
MICROGESTIN FE 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN FE 1/20, ETHINYL ESTRADIOL
MICRONOR, NORETHINDRONE
MICROZIDE, HYDROCHLOROTHIAZIDE
MIDAMOR, AMILORIDE HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MIDOL LIQUID GELS, IBUPROFEN (OTC)
MIDOZALAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MIFEPREX, MIFEPRISTONE
MIGERGOT, CAFFEINE
MIGLITOL, MIGLITOL
MIGRANAL, DIHYDROERGOTAMINE MESYLATE
MILI, ETHINYL ESTRADIOL
MILNACIPRAN HYDROCHLORIDE, MILNACIPRAN HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE
MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
MILRINONE LACTATE IN PLASTIC CONTAINER, MILRINONE LACTATE
MINASTRIN 24 FE, ETHINYL ESTRADIOL
MINIPRESS, PRAZOSIN HYDROCHLORIDE
MINIRIN, DESMOPRESSIN ACETATE
MINITRAN, NITROGLYCERIN
MINIVELLE, ESTRADIOL
MINOCIN, MINOCYCLINE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MINOLIRA, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL (OTC)
MINOXIDIL, MINOXIDIL
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
MIOCHOL-E, ACETYLCHOLINE CHLORIDE
MIOSTAT, CARBACHOL
MIRALAX, POLYETHYLENE GLYCOL 3350 (OTC)
MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE
MIRAPEX ER, PRAMIPEXOLE DIHYDROCHLORIDE

# APPENDIX A - PRODUCT NAME INDEX

**** M ****

MIRENA, LEVONORGESTREL
MIRTAZAPINE, MIRTAZAPINE
MIRVASO, BRIMONIDINE TARTRATE
MISOPROSTOL, MISOPROSTOL
MITIGARE, COLCHICINE
MITOMYCIN, MITOMYCIN
MITOSOL, MITOMYCIN
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MIVACRON, MIVACURIUM CHLORIDE
MOBIC, MELOXICAM
MODAFINIL, MODAFINIL
MODICON 28, ETHINYL ESTRADIOL
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MOLINDONE HYDROCHLORIDE, MOLINDONE HYDROCHLORIDE
MOMETASONE FUROATE, MOMETASONE FUROATE
MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE
MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)
MONISTAT 7, MICONAZOLE NITRATE (OTC)
MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONO-LINYAH, ETHINYL ESTRADIOL
MONODOX, DOXYCYCLINE
MONOKET, ISOSORBIDE MONONITRATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MONUROL, FOSFOMYCIN TROMETHAMINE
MORPHABOND ER, MORPHINE SULFATE
MORPHINE SULFATE, MORPHINE SULFATE
MOTOFEN, ATROPINE SULFATE
MOTRIN IB, IBUPROFEN (OTC)
MOVANTIK, NALOXEGOL OXALATE
MOVIPREP, ASCORBIC ACID
MOXATAG, AMOXICILLIN
MOXEZA, MOXIFLOXACIN HYDROCHLORIDE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN
MOZOBIL, PLERIXAFOR
MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
MS CONTIN, MORPHINE SULFATE
MUCINEX, GUAIFENESIN (OTC)
MUCINEX D, GUAIFENESIN (OTC)
MUCINEX DM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
MULTAQ, DRONEDARONE HYDROCHLORIDE
MULTIHANCE, GADOBENATE DIMEGLUMINE
MULTIHANCE MULTIPACK, GADOBENATE DIMEGLUMINE
MUPIROCIN, MUPIROCIN
MUPIROCIN, MUPIROCIN CALCIUM
MUSE, ALPROSTADIL
MUSTARGEN, MECHLORETHAMINE HYDROCHLORIDE
MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
MYCAMINE, MICAFUNGIN SODIUM
MYCELEX-7, CLOTRIMAZOLE (OTC)
MYCELEX-7 COMBINATION PACK, CLOTRIMAZOLE (OTC)
MYCOBUTIN, RIFABUTIN
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
MYDAYIS, AMPHETAMINE ASPARTATE
MYDRIACYL, TROPICAMIDE
MYFORTIC, MYCOPHENOLIC ACID
MYKACET, NYSTATIN
MYLERAN, BUSULFAN
MYORISAN, ISOTRETINOIN

# APPENDIX A - PRODUCT NAME INDEX

**** M ****

MYOVIEW 30ML, TECHNETIUM TC-99M TETROFOSMIN KIT
MYRBETRIQ, MIRABEGRON
MYSOLINE, PRIMIDONE
MYZILRA, ETHINYL ESTRADIOL

**** N ****

NABUMETONE, NABUMETONE
NADOLOL, NADOLOL
NADOLOL AND BENDROFLUMETHIAZIDE, BENDROFLUMETHIAZIDE
NAFCILLIN SODIUM, NAFCILLIN SODIUM
NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE
NAFTIN, NAFTIFINE HYDROCHLORIDE
NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE
NALFON, FENOPROFEN CALCIUM
NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
NALOXONE, NALOXONE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
NAMENDA, MEMANTINE HYDROCHLORIDE
NAMENDA XR, MEMANTINE HYDROCHLORIDE
NAMZARIC, DONEPEZIL HYDROCHLORIDE
NANDROLONE DECANOATE, NANDROLONE DECANOATE
NAPHAZOLINE HYDROCHLORIDE, NAPHAZOLINE HYDROCHLORIDE
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
NAPHCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
NAPRELAN, NAPROXEN SODIUM
NAPROSYN, NAPROXEN
NAPROXEN, NAPROXEN
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NARCAN, NALOXONE HYDROCHLORIDE
NARDIL, PHENELZINE SULFATE
NAROPIN, ROPIVACAINE HYDROCHLORIDE
NASACORT ALLERGY 24 HOUR, TRIAMCINOLONE ACETONIDE (OTC)
NASCOBAL, CYANOCOBALAMIN
NASONEX, MOMETASONE FUROATE
NATACYN, NATAMYCIN
NATAZIA, DIENOGEST
NATEGLINIDE, NATEGLINIDE
NATESTO, TESTOSTERONE
NATRECOR, NESIRITIDE RECOMBINANT
NATROBA, SPINOSAD
NAVELBINE, VINORELBINE TARTRATE
NEBUPENT, PENTAMIDINE ISETHIONATE
NEDOCROMIL SODIUM, NEDOCROMIL SODIUM
NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
NEO-SYNALAR, FLUOCINOLONE ACETONIDE
NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NEOPAP, ACETAMINOPHEN (OTC)
NEOPROFEN, IBUPROFEN LYSINE
NEORAL, CYCLOSPORINE
NEOSPORIN, BACITRACIN ZINC
NEOSPORIN, GRAMICIDIN
NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE

# APPENDIX A - PRODUCT NAME INDEX

**** N ****

NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NEPHRAMINE 5.4%, AMINO ACIDS
NERLYNX, NERATINIB MALEATE
NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
NESINA, ALOGLIPTIN BENZOATE
NETSPOT, GALLIUM DOTATATE GA-68
NEUPRO, ROTIGOTINE
NEURACEQ, FLORBETABEN F-18
NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
NEURONTIN, GABAPENTIN
NEVANAC, NEPAFENAC
NEVIRAPINE, NEVIRAPINE
NEXAVAR, SORAFENIB TOSYLATE
NEXESTA FE, ETHINYL ESTRADIOL
NEXIUM, ESOMEPRAZOLE MAGNESIUM
NEXIUM 24HR, ESOMEPRAZOLE MAGNESIUM (OTC)
NEXIUM IV, ESOMEPRAZOLE SODIUM
NEXPLANON, ETONOGESTREL
NEXTERONE, AMIODARONE HYDROCHLORIDE
NIACIN, NIACIN
NIACOR, NIACIN
NIASPAN, NIACIN
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE, NICARDIPINE HYDROCHLORIDE
NICODERM CQ, NICOTINE (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
NICOTINE, NICOTINE (OTC)
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
NICOTROL, NICOTINE
NIFEDIPINE, NIFEDIPINE
NIKKI, DROSPIRENONE
NILANDRON, NILUTAMIDE
NILUTAMIDE, NILUTAMIDE
NIMBEX, CISATRACURIUM BESYLATE
NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE
NIMODIPINE, NIMODIPINE
NINLARO, IXAZOMIB CITRATE
NIPENT, PENTOSTATIN
NIPRIDE RTU IN SODIUM CHLORIDE 0.9%, SODIUM NITROPRUSSIDE
NISOLDIPINE, NISOLDIPINE
NITHIODOTE, SODIUM NITRITE
NITRO-DUR, NITROGLYCERIN
NITROFURANTOIN, NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
NITROGLYCERIN, NITROGLYCERIN
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
NITROLINGUAL PUMPSPRAY, NITROGLYCERIN
NITROMIST, NITROGLYCERIN
NITROPRESS, SODIUM NITROPRUSSIDE
NITROSTAT, NITROGLYCERIN
NITYR, NITISINONE
NIX, PERMETHRIN (OTC)
NIZATIDINE, NIZATIDINE
NIZORAL, KETOCONAZOLE
NIZORAL A-D, KETOCONAZOLE (OTC)
NOCTIVA, DESMOPRESSIN ACETATE
NOR-QD, NORETHINDRONE
NORCO, ACETAMINOPHEN
NORDITROPIN FLEXPRO, SOMATROPIN RECOMBINANT
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
NORETHINDRONE, NORETHINDRONE
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE

# APPENDIX A - PRODUCT NAME INDEX

**** N ****



**** O ****

# APPENDIX A - PRODUCT NAME INDEX

** O **

OCUFLOX, OFLOXACIN
ODEFSEY, EMTRICITABINE
ODOMZO, SONIDEGIB PHOSPHATE
OFEV, NINTEDANIB ESYLATE
OFIRMEV, ACETAMINOPHEN
OFLOXACIN, OFLOXACIN
OGEN 5, ESTROPIPATE
OGESTREL 0.5/50-28, ETHINYL ESTRADIOL
OLANZAPINE, OLANZAPINE
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
OLUX, CLOBETASOL PROPIONATE
OLUX E, CLOBETASOL PROPIONATE
OLYSIO, SIMEPREVIR SODIUM
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OMEPRAZOLE, OMEPRAZOLE (OTC)
OMEPRAZOLE, OMEPRAZOLE
OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN, AMOXICILLIN
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
OMIDRIA, KETOROLAC TROMETHAMINE
OMNARIS, CICLESONIDE
OMNIPAQUE 140, IOHEXOL
OMNIPAQUE 180, IOHEXOL
OMNIPAQUE 240, IOHEXOL
OMNIPAQUE 300, IOHEXOL
OMNIPAQUE 350, IOHEXOL
OMNIPRED, PREDNISOLONE ACETATE
OMNISCAN, GADODIAMIDE
OMNITROPE, SOMATROPIN RECOMBINANT
ONDANSETRON, ONDANSETRON
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONEXTON, BENZOYL PEROXIDE
ONFI, CLOBAZAM
ONGLYZA, SAXAGLIPTIN HYDROCHLORIDE
ONIVYDE, IRINOTECAN HYDROCHLORIDE
ONMEL, ITRACONAZOLE
ONZETRA XSAIL, SUMATRIPTAN SUCCINATE
OPANA, OXYMORPHONE HYDROCHLORIDE
OPCICON ONE-STEP, LEVONORGESTREL (OTC)
OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
OPSUMIT, MACITENTAN
OPTIMARK, GADOVERSETAMIDE
OPTIMARK IN PLASTIC CONTAINER, GADOVERSETAMIDE
OPTIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
OPTIRAY 240, IOVERSOL
OPTIRAY 300, IOVERSOL
OPTIRAY 320, IOVERSOL
OPTIRAY 350, IOVERSOL
OPTISON, ALBUMIN HUMAN
ORABLOC, ARTICAINE HYDROCHLORIDE
ORACEA, DOXYCYCLINE
ORALTAG, IOHEXOL
ORAP, PIMOZIDE
ORAPRED ODT, PREDNISOLONE SODIUM PHOSPHATE
ORAQIX, LIDOCAINE
ORAVERSE, PHENTOLAMINE MESYLATE
ORAVIG, MICONAZOLE
ORBACTIV, ORITAVANCIN DIPHOSPHATE
ORENITRAM, TREPROSTINIL DIOLAMINE

# APPENDIX A - PRODUCT NAME INDEX

**** O ****



**** P ****

# APPENDIX A - PRODUCT NAME INDEX

**** P ****

PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PANCREAZE, PANCRELIPASE (AMYLASE
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PANDEL, HYDROCORTISONE PROBUTATE
PANRETIN, ALITRETINOIN
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PARAGARD T 380A, COPPER
PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE
PARICALCITOL, PARICALCITOL
PARLODEL, BROMOCRIPTINE MESYLATE
PARNATE, TRANYLCYPROMINE SULFATE
PAROEX, CHLORHEXIDINE GLUCONATE
PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
PAROXETINE, PAROXETINE HYDROCHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PAROXETINE MESYLATE, PAROXETINE MESYLATE
PARSABIV, ETELCALCETIDE
PASER, AMINOSALICYLIC ACID
PATADAY, OLOPATADINE HYDROCHLORIDE
PATANASE, OLOPATADINE HYDROCHLORIDE
PATANOL, OLOPATADINE HYDROCHLORIDE
PAXIL, PAROXETINE HYDROCHLORIDE
PAXIL CR, PAROXETINE HYDROCHLORIDE
PAZEO, OLOPATADINE HYDROCHLORIDE
PCE, ERYTHROMYCIN
PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE
PEDIATRIC ADVIL, IBUPROFEN (OTC)
PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE , POLYETHYLENE GLYCOL
PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL, BISACODYL
PEGANONE, ETHOTOIN
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
PENICILLIN G SODIUM, PENICILLIN G SODIUM
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PENICILLIN-VK, PENICILLIN V POTASSIUM
PENLAC, CICLOPIROX
PENNSAID, DICLOFENAC SODIUM
PENTAM, PENTAMIDINE ISETHIONATE
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE
PENTASA, MESALAMINE
PENTETATE CALCIUM TRISODIUM, PENTETATE CALCIUM TRISODIUM
PENTETATE ZINC TRISODIUM, PENTETATE ZINC TRISODIUM
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
PENTOSTATIN, PENTOSTATIN
PENTOXIFYLLINE, PENTOXIFYLLINE
PENTOXIL, PENTOXIFYLLINE
PEPCID, FAMOTIDINE
PEPCID AC, FAMOTIDINE (OTC)
PEPCID AC , FAMOTIDINE (OTC)
PEPCID COMPLETE, CALCIUM CARBONATE (OTC)
PERCOCET, ACETAMINOPHEN
PERCODAN, ASPIRIN
PERFOROMIST, FORMOTEROL FUMARATE
PERIDEX, CHLORHEXIDINE GLUCONATE
PERIKABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
PERIOCHIP, CHLORHEXIDINE GLUCONATE
PERIOGARD, CHLORHEXIDINE GLUCONATE
PERMAPEN, PENICILLIN G BENZATHINE
PERMETHRIN, PERMETHRIN (OTC)
PERMETHRIN, PERMETHRIN

# APPENDIX A - PRODUCT NAME INDEX

**** P ****

PERPHENAZINE, PERPHENAZINE
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
PERSANTINE, DIPYRIDAMOLE
PERTZYE, PANCRELIPASE (AMYLASE
PEXEVA, PAROXETINE MESYLATE
PFIZERPEN, PENICILLIN G POTASSIUM
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENELZINE SULFATE, PHENELZINE SULFATE
PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PHENYTEK, PHENYTOIN SODIUM
PHENYTOIN, PHENYTOIN
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PHILITH, ETHINYL ESTRADIOL
PHOSLO GELCAPS, CALCIUM ACETATE
PHOSLYRA, CALCIUM ACETATE
PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE
PHOTOFRIN, PORFIMER SODIUM
PHOTREXA, RIBOFLAVIN 5'-PHOSPHATE SODIUM
PHOTREXA VISCOUS IN DEXTRAN 20%, RIBOFLAVIN 5'-PHOSPHATE SODIUM
PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYTONADIONE, PHYTONADIONE
PICATO, INGENOL MEBUTATE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PIMOZIDE, PIMOZIDE
PIMTREA, DESOGESTREL
PINDOLOL, PINDOLOL
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE, GLIMEPIRIDE
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIPERACILLIN, PIPERACILLIN SODIUM
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PIRMELLA 1/35, ETHINYL ESTRADIOL
PIRMELLA 7/7/7, ETHINYL ESTRADIOL
PIROXICAM, PIROXICAM
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
PITOCIN, OXYTOCIN
PLAN B ONE-STEP, LEVONORGESTREL (OTC)
PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLAVIX, CLOPIDOGREL BISULFATE
PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PLIAGLIS, LIDOCAINE
PODOFILOX, PODOFILOX
POLOCAINE, MEPIVACAINE HYDROCHLORIDE
POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350
POLYMYCIN B SULFATE, POLYMYXIN B SULFATE
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
POLYTRIM, POLYMYXIN B SULFATE
POMALYST, POMALIDOMIDE
PONSTEL, MEFENAMIC ACID
PORTIA-28, ETHINYL ESTRADIOL
POTASSIUM ACETATE, POTASSIUM ACETATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,

# APPENDIX A - PRODUCT NAME INDEX

**** P ****

# APPENDIX A - PRODUCT NAME INDEX

**** P ****

POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE
POTASSIUM IODIDE, POTASSIUM IODIDE (OTC)
POVIDONE IODINE, POVIDONE-IODINE (OTC)
PRADAXA, DABIGATRAN ETEXILATE MESYLATE
PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PRAMOSONE, HYDROCORTISONE ACETATE
PRANDIN, REPAGLINIDE
PRASUGREL, PRASUGREL HYDROCHLORIDE
PRAVACHOL, PRAVASTATIN SODIUM
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PRAZIQUANTEL, PRAZIQUANTEL
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PRE-OP, HEXACHLOROPHENE
PRE-OP II, HEXACHLOROPHENE
PRE-PEN, BENZYLPENICILLOYL POLYLYSINE
PRECEDEX, DEXMEDETOMIDINE HYDROCHLORIDE
PRECOSE, ACARBOSE
PRED FORTE, PREDNISOLONE ACETATE
PRED MILD, PREDNISOLONE ACETATE
PRED-G, GENTAMICIN SULFATE
PREDNICARBATE, PREDNICARBATE
PREDNISOLONE, PREDNISOLONE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISONE, PREDNISONE
PREDNISONE INTENSOL, PREDNISONE
PREGNYL, GONADOTROPIN, CHORIONIC
PRELONE, PREDNISOLONE
PREMARIN, ESTROGENS, CONJUGATED
PREMASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS

# APPENDIX A - PRODUCT NAME INDEX

**** P ****

PREMASOL 6% IN PLASTIC CONTAINER, AMINO ACIDS
PREMPHASE 14/14, ESTROGENS, CONJUGATED
PREMPRO, ESTROGENS, CONJUGATED
PREPIDIL, DINOPROSTONE
PREPOPIK, CITRIC ACID
PRESTALIA, AMLODIPINE BESYLATE
PREVACID, LANSOPRAZOLE
PREVACID 24 HR, LANSOPRAZOLE (OTC)
PREVALITE, CHOLESTYRAMINE
PREVANTICS MAXI SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
PREVANTICS SWAB, CHLORHEXIDINE GLUCONATE (OTC)
PREVANTICS SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
PREVIFEM, ETHINYL ESTRADIOL
PREVPAC, AMOXICILLIN
PREVYMIS, LETERMOVIR
PREXXARTAN, VALSARTAN
PREZCOBIX, COBICISTAT
PREZISTA, DARUNAVIR ETHANOLATE
PRIALT, ZICONOTIDE ACETATE
PRIFTIN, RIFAPENTINE
PRILOCAINE HYDROCHLORIDE, PRILOCAINE HYDROCHLORIDE
PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, EPINEPHRINE BITARTRATE
PRILOSEC, OMEPRAZOLE MAGNESIUM
PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)
PRIMAQUINE, PRIMAQUINE PHOSPHATE
PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE
PRIMAXIN, CILASTATIN SODIUM
PRIMIDONE, PRIMIDONE
PRIMSOL, TRIMETHOPRIM HYDROCHLORIDE
PRINIVIL, LISINOPRIL
PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISTIQ, DESVENLAFAXINE SUCCINATE
PROAIR HFA, ALBUTEROL SULFATE
PROAIR RESPICLICK, ALBUTEROL SULFATE
PROBALAN, PROBENECID
PROBENECID, PROBENECID
PROBENECID AND COLCHICINE, COLCHICINE
PROBUPHINE, BUPRENORPHINE HYDROCHLORIDE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
PROCALAMINE, AMINO ACIDS
PROCARDIA, NIFEDIPINE
PROCARDIA XL, NIFEDIPINE
PROCHLORPERAZINE, PROCHLORPERAZINE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROCOMP, PROCHLORPERAZINE MALEATE
PROCTOFOAM HC, HYDROCORTISONE ACETATE
PROCYSBI, CYSTEAMINE BITARTRATE
PROFEN, IBUPROFEN (OTC)
PROFERDEX, IRON DEXTRAN
PROGESTERONE, PROGESTERONE
PROGLYCEM, DIAZOXIDE
PROGRAF, TACROLIMUS
PROHANCE, GADOTERIDOL
PROHANCE MULTIPACK, GADOTERIDOL
PROLENSA, BROMFENAC SODIUM

# APPENDIX A - PRODUCT NAME INDEX

**** P ****

PROMACTA, ELTROMBOPAG OLAMINE
PROMETH HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETH VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE
PROMETH VC W/ CODEINE, CODEINE PHOSPHATE
PROMETH W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
PROMETHAZINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE WITH CODEINE, CODEINE PHOSPHATE
PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE
PROMETRIUM, PROGESTERONE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
PROPECIA, FINASTERIDE
PROPOFOL, PROPOFOL
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PROSCAR, FINASTERIDE
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
PROSTIN E2, DINOPROSTONE
PROSTIN VR PEDIATRIC, ALPROSTADIL
PROTAMINE SULFATE, PROTAMINE SULFATE
PROTONIX, PANTOPRAZOLE SODIUM
PROTONIX IV, PANTOPRAZOLE SODIUM
PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE
PROTOPIC, TACROLIMUS
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
PROVAYBLUE, METHYLENE BLUE
PROVENTIL-HFA, ALBUTEROL SULFATE
PROVERA, MEDROXYPROGESTERONE ACETATE
PROVIGIL, MODAFINIL
PROVOCHOLINE, METHACHOLINE CHLORIDE
PROZAC, FLUOXETINE HYDROCHLORIDE
PROZAC WEEKLY, FLUOXETINE HYDROCHLORIDE
PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
PULMICORT FLEXHALER, BUDESONIDE
PULMICORT RESPULES, BUDESONIDE
PULMOLITE, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
PUR-WASH, PURIFIED WATER (OTC)
PURINETHOL, MERCAPTOPURINE
PURIXAN, MERCAPTOPURINE
PYLERA, BISMUTH SUBCITRATE POTASSIUM
PYRAZINAMIDE, PYRAZINAMIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE
PYTEST, UREA, C-14
PYTEST KIT, UREA, C-14

**** Q ****

QBRELIS, LISINOPRIL
QNASL, BECLOMETHASONE DIPROPIONATE
QOLIANA, BRIMONIDINE TARTRATE
QSYMIA, PHENTERMINE HYDROCHLORIDE
QTERN, DAPAGLIFLOZIN PROPANEDIOL
QUADRAMET, SAMARIUM SM-153 LEXIDRONAM PENTASODIUM
QUALAQUIN, QUININE SULFATE
QUARTETTE, ETHINYL ESTRADIOL

# APPENDIX A - PRODUCT NAME INDEX

**** Q ****

QUASENSE, ETHINYL ESTRADIOL
QUDEXY XR, TOPIRAMATE
QUELICIN, SUCCINYLCHOLINE CHLORIDE
QUELICIN PRESERVATIVE FREE, SUCCINYLCHOLINE CHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUILLICHEW ER, METHYLPHENIDATE HYDROCHLORIDE
QUILLIVANT XR, METHYLPHENIDATE HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
QUINARETIC, HYDROCHLOROTHIAZIDE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
QUININE SULFATE, QUININE SULFATE
QUTENZA, CAPSAICIN
QVAR 40, BECLOMETHASONE DIPROPIONATE
QVAR 80, BECLOMETHASONE DIPROPIONATE
QVAR REDIHALER, BECLOMETHASONE DIPROPIONATE

**** R ****

R-GENE 10, ARGININE HYDROCHLORIDE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RADICAVA, EDARAVONE
RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE(II)
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RAMELTEON, RAMELTEON
RAMIPRIL, RAMIPRIL
RANEXA, RANOLAZINE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RAPAFLO, SILODOSIN
RAPAMUNE, SIROLIMUS
RAPIVAB, PERAMIVIR
RASAGILINE MESYLATE, RASAGILINE MESYLATE
RASUVO, METHOTREXATE
RAVICTI, GLYCEROL PHENYLBUTYRATE
RAYALDEE, CALCIFEDIOL
RAYOS, PREDNISONE
RAZADYNE, GALANTAMINE HYDROBROMIDE
RAZADYNE ER, GALANTAMINE HYDROBROMIDE
READI-CAT 2, BARIUM SULFATE
READI-CAT 2 SMOOTHIES, BARIUM SULFATE
REBETOL, RIBAVIRIN
RECLAST, ZOLEDRONIC ACID
RECTIV, NITROGLYCERIN
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE
REGONOL, PYRIDOSTIGMINE BROMIDE
RELENZA, ZANAMIVIR
RELISTOR, METHYLNALTREXONE BROMIDE
RELPAX, ELETRIPTAN HYDROBROMIDE
REMERON, MIRTAZAPINE
REMERON SOLTAB, MIRTAZAPINE
REMODULIN, TREPROSTINIL
RENACIDIN, CITRIC ACID
RENAGEL, SEVELAMER HYDROCHLORIDE
RENOGRAFIN-76, DIATRIZOATE MEGLUMINE
RENOVA, TRETINOIN
RENVELA, SEVELAMER CARBONATE
REPAGLINIDE, REPAGLINIDE
REPAGLINIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
REPREXAIN, HYDROCODONE BITARTRATE
REQUIP, ROPINIROLE HYDROCHLORIDE
REQUIP XL, ROPINIROLE HYDROCHLORIDE
RESCRIPTOR, DELAVIRDINE MESYLATE
RESECTISOL IN PLASTIC CONTAINER, MANNITOL
RESTASIS, CYCLOSPORINE

# APPENDIX A - PRODUCT NAME INDEX

**** R ****

RESTASIS MULTIDOSE, CYCLOSPORINE
RESTORIL, TEMAZEPAM
RETIN-A, TRETINOIN
RETIN-A MICRO, TRETINOIN
RETIN-A-MICRO, TRETINOIN
RETISERT, FLUOCINOLONE ACETONIDE
RETROVIR, ZIDOVUDINE
REVATIO, SILDENAFIL CITRATE
REVLIMID, LENALIDOMIDE
REVONTO, DANTROLENE SODIUM
REXULTI, BREXPIPRAZOLE
REYATAZ, ATAZANAVIR SULFATE
REZIRA, HYDROCODONE BITARTRATE
RHINOCORT ALLERGY, BUDESONIDE (OTC)
RHOFADE, OXYMETAZOLINE HYDROCHLORIDE
RHOPRESSA, NETARSUDIL DIMESYLATE
RIBASPHERE, RIBAVIRIN
RIBAVARIN, RIBAVIRIN
RIBAVIRIN, RIBAVIRIN
RIDAURA, AURANOFIN
RIFABUTIN, RIFABUTIN
RIFADIN, RIFAMPIN
RIFAMATE, ISONIAZID
RIFAMPIN, RIFAMPIN
RIFATER, ISONIAZID
RILUTEK, RILUZOLE
RILUZOLE, RILUZOLE
RIMACTANE, RIFAMPIN
RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE
RIMSO-50, DIMETHYL SULFOXIDE
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
RIOMET, METFORMIN HYDROCHLORIDE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RISPERDAL, RISPERIDONE
RISPERDAL CONSTA, RISPERIDONE
RISPERIDONE, RISPERIDONE
RITALIN, METHYLPHENIDATE HYDROCHLORIDE
RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE
RITALIN-SR, METHYLPHENIDATE HYDROCHLORIDE
RITONAVIR, RITONAVIR
RIVASTIGMINE, RIVASTIGMINE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROBAXIN, METHOCARBAMOL
ROBAXIN-750, METHOCARBAMOL
ROBINUL, GLYCOPYRROLATE
ROBINUL FORTE, GLYCOPYRROLATE
ROCALTROL, CALCITRIOL
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROGAINE (FOR MEN), MINOXIDIL (OTC)
ROGAINE (FOR WOMEN), MINOXIDIL (OTC)
ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
ROSIGLITAZONE MALEATE, ROSIGLITAZONE MALEATE
ROSIGLITAZONE MALEATE AND GLIMEPIRIDE, GLIMEPIRIDE
ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
ROWASA, MESALAMINE
ROWEEPRA, LEVETIRACETAM
ROXICET, ACETAMINOPHEN
ROXICODONE, OXYCODONE HYDROCHLORIDE
ROXYBOND, OXYCODONE HYDROCHLORIDE
ROZEREM, RAMELTEON
RUBRACA, RUCAPARIB CAMSYLATE

# APPENDIX A - PRODUCT NAME INDEX

** R **

RUBY-FILL, RUBIDIUM CHLORIDE RB-82
RUFINAMIDE, RUFINAMIDE
RYANODEX, DANTROLENE SODIUM
RYDAPT, MIDOSTAURIN
RYTARY, CARBIDOPA
RYTHMOL, PROPAFENONE HYDROCHLORIDE
RYTHMOL SR, PROPAFENONE HYDROCHLORIDE
RYZODEG 70/30, INSULIN ASPART

** S **

SABRIL, VIGABATRIN
SAFYRAL, DROSPIRENONE
SAIZEN, SOMATROPIN RECOMBINANT
SALAGEN, PILOCARPINE HYDROCHLORIDE
SALONPAS, MENTHOL (OTC)
SAMSCA, TOLVAPTAN
SANCUSO, GRANISETRON
SANDIMMUNE, CYCLOSPORINE
SANDOSTATIN, OCTREOTIDE ACETATE
SANDOSTATIN LAR, OCTREOTIDE ACETATE
SAPHRIS, ASENAPINE MALEATE
SARAFEM, FLUOXETINE HYDROCHLORIDE
SAVAYSA, EDOXABAN TOSYLATE
SAVELLA, MILNACIPRAN HYDROCHLORIDE
SAXENDA, LIRAGLUTIDE RECOMBINANT
SCANDONEST L, LEVONORDEFRIN
SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
SCANLUX-300, IOPAMIDOL
SCANLUX-370, IOPAMIDOL
SCLEROSOL, TALC
SCOPOLAMINE, SCOPOLAMINE
SEASONALE, ETHINYL ESTRADIOL
SEASONIQUE, ETHINYL ESTRADIOL
SECONAL SODIUM, SECOBARBITAL SODIUM
SECTRAL, ACEBUTOLOL HYDROCHLORIDE
SEEBRI, GLYCOPYRROLATE
SEGLUROMET, ERTUGLIFLOZIN
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
SELENIUM SULFIDE, SELENIUM SULFIDE
SELFEMRA, FLUOXETINE HYDROCHLORIDE
SELSUN, SELENIUM SULFIDE
SELZENTRY, MARAVIROC
SEMPREX-D, ACRIVASTINE
SENSIPAR, CINACALCET HYDROCHLORIDE
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SEPTOCAINE, ARTICAINE HYDROCHLORIDE
SEPTRA, SULFAMETHOXAZOLE
SEPTRA DS, SULFAMETHOXAZOLE
SEREVENT, SALMETEROL XINAFOATE
SERNIVO, BETAMETHASONE DIPROPIONATE
SEROMYCIN, CYCLOSERINE
SEROQUEL, QUETIAPINE FUMARATE
SEROQUEL XR, QUETIAPINE FUMARATE
SEROSTIM, SOMATROPIN RECOMBINANT
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SETLAKIN, ETHINYL ESTRADIOL
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SEVOFLURANE, SEVOFLURANE
SFROWASA, MESALAMINE
SIGNIFOR, PASIREOTIDE DIASPARTATE
SIGNIFOR LAR, PASIREOTIDE PAMOATE
SIKLOS, HYDROXYUREA
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SILENOR, DOXEPIN HYDROCHLORIDE
SILODOSIN, SILODOSIN

# APPENDIX A - PRODUCT NAME INDEX

**** S ****

SILVADENE, SILVER SULFADIAZINE
SIMBRINZA, BRIMONIDINE TARTRATE
SIMPESSE, ETHINYL ESTRADIOL
SIMVASTATIN, SIMVASTATIN
SINE-AID IB, IBUPROFEN (OTC)
SINEMET, CARBIDOPA
SINEMET CR, CARBIDOPA
SINGULAIR, MONTELUKAST SODIUM
SINOGRAFIN, DIATRIZOATE MEGLUMINE
SINUVA, MOMETASONE FUROATE
SIROLIMUS, SIROLIMUS
SIRTURO, BEDAQUILINE FUMARATE
SITAVIG, ACYCLOVIR
SIVEXTRO, TEDIZOLID PHOSPHATE
SKELAXIN, METAXALONE
SKLICE, IVERMECTIN
SKYLA, LEVONORGESTREL
SMOFLIPID 20%, FISH OIL
SODIUM ACETATE, SODIUM ACETATE
SODIUM BICARBONATE, SODIUM BICARBONATE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% , SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE, SODIUM FERRIC GLUCONATE COMPLEX
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
SODIUM IODIDE I 123, SODIUM IODIDE I-123
SODIUM IODIDE I 131, SODIUM IODIDE I-131
SODIUM LACTATE IN PLASTIC CONTAINER, SODIUM LACTATE
SODIUM NITRITE, SODIUM NITRITE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SODIUM OXYBATE, SODIUM OXYBATE
SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE
SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE , MAGNESIUM SULFATE
SODIUM THIOSULFATE, SODIUM THIOSULFATE
SOJOURN, SEVOFLURANE
SOLARAZE, DICLOFENAC SODIUM
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
SOLIQUA 100/33, INSULIN GLARGINE
SOLODYN, MINOCYCLINE HYDROCHLORIDE
SOLOSEC, SECNIDAZOLE
SOLTAMOX, TAMOXIFEN CITRATE
SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE
SOMA, CARISOPRODOL
SOMATULINE DEPOT, LANREOTIDE ACETATE
SOMAVERT, PEGVISOMANT
SONATA, ZALEPLON
SOOLANTRA, IVERMECTIN
SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
SORIATANE, ACITRETIN
SORILUX, CALCIPOTRIENE
SORINE, SOTALOL HYDROCHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SOTRADECOL, SODIUM TETRADECYL SULFATE
SOTYLIZE, SOTALOL HYDROCHLORIDE

# APPENDIX A - PRODUCT NAME INDEX

**** S ****

SOVALDI, SOFOSBUVIR
SPECTAZOLE, ECONAZOLE NITRATE
SPINRAZA, NUSINERSEN SODIUM
SPIRIVA, TIOTROPIUM BROMIDE
SPIRIVA RESPIMAT, TIOTROPIUM BROMIDE
SPIRONOLACTONE, SPIRONOLACTONE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPORANOX, ITRACONAZOLE
SPRINTEC, ETHINYL ESTRADIOL
SPRITAM, LEVETIRACETAM
SPRIX, KETOROLAC TROMETHAMINE
SPRYCEL, DASATINIB
SPS, SODIUM POLYSTYRENE SULFONATE
SSD, SILVER SULFADIAZINE
SSD AF, SILVER SULFADIAZINE
STALEVO 100, CARBIDOPA
STALEVO 125, CARBIDOPA
STALEVO 150, CARBIDOPA
STALEVO 200, CARBIDOPA
STALEVO 50, CARBIDOPA
STALEVO 75, CARBIDOPA
STARLIX, NATEGLINIDE
STAVUDINE, STAVUDINE
STAXYN, VARDENAFIL HYDROCHLORIDE
STEGLATRO, ERTUGLIFLOZIN
STELUJAN, ERTUGLIFLOZIN
STENDRA, AVANAFIL
STERILE WATER, STERILE WATER FOR IRRIGATION
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
STERITALC, TALC
STIE-CORT, HYDROCORTISONE
STIMATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
STIOLTO RESPIMAT, OLODATEROL HYDROCHLORIDE
STIVARGA, REGORAFENIB
STRATTERA, ATOMOXETINE HYDROCHLORIDE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
STRIANT, TESTOSTERONE
STRIBILD, COBICISTAT
STRIVERDI RESPIMAT, OLODATEROL HYDROCHLORIDE
STROMECTOL, IVERMECTIN
STRONTIUM CHLORIDE SR-89, STRONTIUM CHLORIDE SR-89
SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE
SUBLOCADE, BUPRENORPHINE
SUBOXONE, BUPRENORPHINE HYDROCHLORIDE
SUBSYS, FENTANYL
SUCRAID, SACROSIDASE
SUCRALFATE, SUCRALFATE
SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
SUDAFED 24 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
SUFENTA PRESERVATIVE FREE, SUFENTANIL CITRATE
SUFENTANIL CITRATE, SUFENTANIL CITRATE
SULAR, NISOLDIPINE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
SULFADIAZINE, SULFADIAZINE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH, SULFAMETHOXAZOLE
SULFAMYLON, MAFENIDE ACETATE
SULFASALAZINE, SULFASALAZINE
SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
SULINDAC, SULINDAC
SUMATRIPTAN, SUMATRIPTAN

# APPENDIX A - PRODUCT NAME INDEX

**** S ****

SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
SUMAVEL DOSEPRO, SUMATRIPTAN SUCCINATE
SUPPRELIN LA, HISTRELIN ACETATE
SUPRANE, DESFLURANE
SUPRAX, CEFIXIME
SUPREP BOWEL PREP KIT, MAGNESIUM SULFATE
SURMONTIL, TRIMIPRAMINE MALEATE
SURVANTA, BERACTANT
SUSTIVA, EFAVIRENZ
SUSTOL, GRANISETRON
SUTENT, SUNITINIB MALATE
SYEDA, DROSPIRENONE
SYMBICORT, BUDESONIDE
SYMBYAX, FLUOXETINE HYDROCHLORIDE
SYMJEPI, EPINEPHRINE
SYMLIN, PRAMLINTIDE ACETATE
SYMPROIC, NALDEMEDINE TOSYLATE
SYNALAR, FLUOCINOLONE ACETONIDE
SYNALGOS-DC, ASPIRIN
SYNAREL, NAFARELIN ACETATE
SYNDROS, DRONABINOL
SYNERA, LIDOCAINE
SYNERCID, DALFOPRISTIN
SYNJARDY, EMPAGLIFLOZIN
SYNJARDY XR, EMPAGLIFLOZIN
SYNRIBO, OMACETAXINE MEPESUCCINATE
SYNTHROID, LEVOTHYROXINE SODIUM **
SYPRINE, TRIENTINE HYDROCHLORIDE

**** T ****

TAB-PROFEN, IBUPROFEN (OTC)
TACLONEX, BETAMETHASONE DIPROPIONATE
TACROLIMUS, TACROLIMUS
TAFINLAR, DABRAFENIB MESYLATE
TAGAMET HB, CIMETIDINE (OTC)
TAGITOL V, BARIUM SULFATE
TAGRISSO, OSIMERTINIB MESYLATE
TALC, TALC
TALWIN, PENTAZOCINE LACTATE
TAMBOCOR, FLECAINIDE ACETATE
TAMIFLU, OSELTAMIVIR PHOSPHATE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TAMSULOSIN HYDROCHLORIDE , TAMSULOSIN HYDROCHLORIDE
TAPAZOLE, METHIMAZOLE
TARCEVA, ERLOTINIB HYDROCHLORIDE
TARGRETIN, BEXAROTENE
TARKA, TRANDOLAPRIL
TASIGNA, NILOTINIB HYDROCHLORIDE MONOHYDRATE
TASMAR, TOLCAPONE
TAVIST-1, CLEMASTINE FUMARATE (OTC)
TAXOL, PACLITAXEL
TAXOTERE, DOCETAXEL
TAYTULLA, ETHINYL ESTRADIOL
TAZAROTENE, TAZAROTENE
TAZICEF, CEFTAZIDIME
TAZORAC, TAZAROTENE
TAZTIA XT, DILTIAZEM HYDROCHLORIDE
TECFIDERA, DIMETHYL FUMARATE
TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
TECHNESCAN, TECHNETIUM TC-99M OXIDRONATE KIT
TECHNESCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
TECHNESCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
TECHNETIUM TC 99M GENERATOR, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

# APPENDIX A - PRODUCT NAME INDEX

**** T ****

TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
TECHNETIUM TC-99M MEBROFENIN, TECHNETIUM TC-99M MEBROFENIN KIT
TECHNETIUM TC-99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
TECHNIVIE, OMBITASVIR
TEFLARO, CEFTAROLINE FOSAMIL
TEGRETOL, CARBAMAZEPINE
TEGRETOL-XR, CARBAMAZEPINE
TEKTURNA, ALISKIREN HEMIFUMARATE
TEKTURNA HCT, ALISKIREN HEMIFUMARATE
TELMISARTAN, TELMISARTAN
TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TEMAZEPAM, TEMAZEPAM
TEMODAR, TEMOZOLOMIDE
TEMOZOLOMIDE, TEMOZOLOMIDE
TENEX, GUANFACINE HYDROCHLORIDE
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TENORETIC 100, ATENOLOL
TENORETIC 50, ATENOLOL
TENORMIN, ATENOLOL
TENUATE, DIETHYLPROPION HYDROCHLORIDE
TENUATE DOSPAN, DIETHYLPROPION HYDROCHLORIDE
TEPADINA, THIOTEPA
TERAZOL 3, TERCONAZOLE
TERAZOL 7, TERCONAZOLE
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE (OTC)
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TERCONAZOLE, TERCONAZOLE
TERIL, CARBAMAZEPINE
TERRAMYCIN W/ POLYMYXIN B SULFATE, OXYTETRACYCLINE HYDROCHLORIDE
TESSALON, BENZONATATE
TESTIM, TESTOSTERONE
TESTOPEL, TESTOSTERONE
TESTOSTERONE, TESTOSTERONE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
TESTRED, METHYLTESTOSTERONE
TETRABENAZINE, TETRABENAZINE
TETRACAINE HYDROCHLORIDE, TETRACAINE HYDROCHLORIDE
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
TEVETEN, EPROSARTAN MESYLATE
TEXACORT, HYDROCORTISONE
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
THALOMID, THALIDOMIDE
THAM, TROMETHAMINE
THEO-24, THEOPHYLLINE
THEOCHRON, THEOPHYLLINE
THEOPHYLLINE, THEOPHYLLINE
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THERMAZENE, SILVER SULFADIAZINE
THEROXIDIL, MINOXIDIL (OTC)
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
THIOGUANINE, THIOGUANINE
THIOLA, TIOPRONIN
THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
THIOTEPA, THIOTEPA
THIOTHIXENE, THIOTHIXENE
THRIVE, NICOTINE POLACRILEX (OTC)
THYROGEN, THYROTROPIN ALFA

# APPENDIX A - PRODUCT NAME INDEX

**** T ****

# APPENDIX A - PRODUCT NAME INDEX

**** T ****

TRANYLCYPROMINE SULFATE, TRANYLCYPROMINE SULFATE
TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVATAN Z, TRAVOPROST
TRAVOPROST, TRAVOPROST
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TREANDA, BENDAMUSTINE HYDROCHLORIDE
TRECATOR, ETHIONAMIDE
TRELEGY ELLIPTA, FLUTICASONE FUROATE
TRELSTAR, TRIPTORELIN PAMOATE
TREPROSTINIL, TREPROSTINIL
TRESIBA, INSULIN DEGLUDEC
TRETINOIN, TRETINOIN
TREXALL, METHOTREXATE SODIUM
TREXIMET, NAPROXEN SODIUM
TREZIX, ACETAMINOPHEN
TRI LO SPRINTEC, ETHINYL ESTRADIOL
TRI-ESTARYLLA, ETHINYL ESTRADIOL
TRI-LEGEST 21, ETHINYL ESTRADIOL
TRI-LEGEST FE, ETHINYL ESTRADIOL
TRI-LINYAH, ETHINYL ESTRADIOL
TRI-LO-ESTARYLLA, ETHINYL ESTRADIOL
TRI-LO-MILI, ETHINYL ESTRADIOL
TRI-LUMA, FLUOCINOLONE ACETONIDE
TRI-MILI, ETHINYL ESTRADIOL
TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
TRI-PREVIFEM, ETHINYL ESTRADIOL
TRI-SPRINTEC, ETHINYL ESTRADIOL
TRIACIN-C, CODEINE PHOSPHATE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE (OTC)
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIAMCINOLONE ACETONIDE IN ABSORBASE, TRIAMCINOLONE ACETONIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIAZOLAM, TRIAZOLAM
TRIBENZOR, AMLODIPINE BESYLATE
TRICOR, FENOFIBRATE
TRIDERM, TRIAMCINOLONE ACETONIDE
TRIDIONE, TRIMETHADIONE
TRIESENCE, TRIAMCINOLONE ACETONIDE
TRIFERIC, FERRIC PYROPHOSPHATE CITRATE
TRIFERIC , FERRIC PYROPHOSPHATE CITRATE
TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
TRIFLURIDINE, TRIFLURIDINE
TRIGLIDE, FENOFIBRATE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
TRILEPTAL, OXCARBAZEPINE
TRILIPIX, CHOLINE FENOFIBRATE
TRILYTE, POLYETHYLENE GLYCOL 3350
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE, TRIMETHOBENZAMIDE HYDROCHLORIDE
TRIMETHOPRIM, TRIMETHOPRIM
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE
TRINTELLIX, VORTIOXETINE HYDROBROMIDE
TRIOSTAT, LIOTHYRONINE SODIUM
TRIPTODUR KIT, TRIPTORELIN PAMOATE
TRISENOX, ARSENIC TRIOXIDE
TRIUMEQ, ABACAVIR SULFATE
TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)
TRIVORA-28, ETHINYL ESTRADIOL
TRIZIVIR, ABACAVIR SULFATE
TROKENDI XR, TOPIRAMATE
TROPHAMINE, AMINO ACIDS
TROPHAMINE 10%, AMINO ACIDS

# APPENDIX A - PRODUCT NAME INDEX

**** T ****

TROPICACYL, TROPICAMIDE
TROPICAMIDE, TROPICAMIDE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
TRULANCE, PLECANATIDE
TRUSOPT, DORZOLAMIDE HYDROCHLORIDE
TRUVADA, EMTRICITABINE
TUDORZA PRESSAIR, ACLIDINIUM BROMIDE
TUSSICAPS, CHLORPHENIRAMINE POLISTIREX
TUSSIGON, HOMATROPINE METHYLBROMIDE
TUSSIONEX PENNKINETIC, CHLORPHENIRAMINE POLISTIREX
TUZISTRA XR, CHLORPHENIRAMINE POLISTIREX
TWYNSTA, AMLODIPINE BESYLATE
TYBOST, COBICISTAT
TYDEMY, DROSPIRENONE
TYGACIL, TIGECYCLINE
TYKERB, LAPATINIB DITOSYLATE
TYLENOL , ACETAMINOPHEN (OTC)
TYLENOL W/ CODEINE NO. 3, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 4, ACETAMINOPHEN
TYMLOS, ABALOPARATIDE
TYVASO, TREPROSTINIL
TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE

**** U ****

U-CORT, HYDROCORTISONE ACETATE
UCERIS, BUDESONIDE
ULESFIA, BENZYL ALCOHOL
ULORIC, FEBUXOSTAT
ULTACAN, ARTICAINE HYDROCHLORIDE
ULTACAN FORTE, ARTICAINE HYDROCHLORIDE
ULTANE, SEVOFLURANE
ULTIVA, REMIFENTANIL HYDROCHLORIDE
ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
ULTRACET, ACETAMINOPHEN
ULTRAM, TRAMADOL HYDROCHLORIDE
ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT
ULTRAVATE, HALOBETASOL PROPIONATE
ULTRAVIST (PHARMACY BULK), IOPROMIDE
ULTRAVIST 240, IOPROMIDE
ULTRAVIST 300, IOPROMIDE
ULTRAVIST 370, IOPROMIDE
ULTRESA, PANCRELIPASE (AMYLASE
UNASYN, AMPICILLIN SODIUM
UNISOM, DOXYLAMINE SUCCINATE (OTC)
UNITHROID, LEVOTHYROXINE SODIUM **
UPTRAVI, SELEXIPAG
URECHOLINE, BETHANECHOL CHLORIDE
UREX, METHENAMINE HIPPURATE
UROCIT-K, POTASSIUM CITRATE
UROXATRAL, ALFUZOSIN HYDROCHLORIDE
URSO 250, URSODIOL
URSO FORTE, URSODIOL
URSODIOL, URSODIOL
UTIBRON, GLYCOPYRROLATE
UVADEX, METHOXSALEN

**** V ****

VABOMERE, MEROPENEM
VAGIFEM, ESTRADIOL
VAGISTAT-1, TIOCONAZOLE (OTC)
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALCHLOR, MECHLORETHAMINE HYDROCHLORIDE
VALCYTE, VALGANCICLOVIR HYDROCHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VALIUM, DIAZEPAM

# APPENDIX A - PRODUCT NAME INDEX

**** V ****

VALNAC, BETAMETHASONE VALERATE
VALPROATE SODIUM, VALPROATE SODIUM
VALPROIC ACID, VALPROIC ACID
VALSARTAN, VALSARTAN
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSTAR PRESERVATIVE FREE, VALRUBICIN
VALTREX, VALACYCLOVIR HYDROCHLORIDE
VALTROPIN, SOMATROPIN RECOMBINANT
VANCOCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
VANDAZOLE, METRONIDAZOLE
VANIQA, EFLORNITHINE HYDROCHLORIDE
VANOS, FLUOCINONIDE
VANTAS, HISTRELIN ACETATE
VANTRELA ER, HYDROCODONE BITARTRATE
VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER, CONIVAPTAN HYDROCHLORIDE
VARIBAR, BARIUM SULFATE
VARIBAR NECTAR, BARIUM SULFATE
VARITHENA, POLIDOCANOL
VARUBI, ROLAPITANT HYDROCHLORIDE
VASCEPA, ICOSAPENT ETHYL
VASERETIC, ENALAPRIL MALEATE
VASOSTRICT, VASOPRESSIN
VASOTEC, ENALAPRIL MALEATE
VAZCULEP, PHENYLEPHRINE HYDROCHLORIDE
VECTICAL, CALCITRIOL
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VELCADE, BORTEZOMIB
VELETRI, EPOPROSTENOL SODIUM
VELIVET, DESOGESTREL
VELPHORO, SUCROFERRIC OXYHYDROXIDE
VELTASSA, PATIROMER SORBITEX CALCIUM
VELTIN, CLINDAMYCIN PHOSPHATE
VEMLIDY, TENOFOVIR ALAFENAMIDE FUMARATE
VENCLEXTA, VENETOCLAX
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VENOFER, IRON SUCROSE
VENTAVIS, ILOPROST
VENTOLIN HFA, ALBUTEROL SULFATE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VERDESO, DESONIDE
VEREGEN, SINECATECHINS
VERELAN, VERAPAMIL HYDROCHLORIDE
VERELAN PM, VERAPAMIL HYDROCHLORIDE
VERMOX, MEBENDAZOLE
VERSACLOZ, CLOZAPINE
VERZENIO, ABEMACICLIB
VESICARE, SOLIFENACIN SUCCINATE
VFEND, VORICONAZOLE
VIAGRA, SILDENAFIL CITRATE
VIBATIV, TELAVANCIN HYDROCHLORIDE
VIBERZI, ELUXADOLINE
VIBISONE, CYANOCOBALAMIN
VIBRAMYCIN, DOXYCYCLINE
VIBRAMYCIN, DOXYCYCLINE CALCIUM
VIBRAMYCIN, DOXYCYCLINE HYCLATE
VICTOZA, LIRAGLUTIDE RECOMBINANT
VIDAZA, AZACITIDINE
VIDEX, DIDANOSINE
VIDEX EC, DIDANOSINE
VIEKIRA PAK (COPACKAGED), DASABUVIR SODIUM
VIEKIRA XR, DASABUVIR SODIUM
VIENVA, ETHINYL ESTRADIOL

# APPENDIX A - PRODUCT NAME INDEX

** V **

VIGABATRIN, VIGABATRIN
VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE
VIIBRYD, VILAZODONE HYDROCHLORIDE
VIMOVO, ESOMEPRAZOLE MAGNESIUM
VIMPAT, LACOSAMIDE
VINBLASTINE SULFATE, VINBLASTINE SULFATE
VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE
VINORELBINE TARTRATE, VINORELBINE TARTRATE
VIOKACE, PANCRELIPASE (AMYLASE
VIORELE, DESOGESTREL
VIRACEPT, NELFINAVIR MESYLATE
VIRAMUNE, NEVIRAPINE
VIRAMUNE XR, NEVIRAPINE
VIRAZOLE, RIBAVIRIN
VIREAD, TENOFOVIR DISOPROXIL FUMARATE
VIROPTIC, TRIFLURIDINE
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)
VISINE-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
VISIONBLUE, TRYPAN BLUE
VISIPAQUE 270, IODIXANOL
VISIPAQUE 320, IODIXANOL
VISTARIL, HYDROXYZINE PAMOATE
VISTOGARD, URIDINE TRIACETATE
VISUDYNE, VERTEPORFIN
VITAMIN D, ERGOCALCIFEROL
VITAMIN K1, PHYTONADIONE
VITRASE, HYALURONIDASE
VITUZ, CHLORPHENIRAMINE MALEATE
VIVACTIL, PROTRIPTYLINE HYDROCHLORIDE
VIVELLE-DOT, ESTRADIOL
VIVITROL, NALTREXONE
VIVLODEX, MELOXICAM
VIZAMYL, FLUTEMETAMOL F-18
VOGELXO, TESTOSTERONE
VOLNEA, DESOGESTREL
VOLTAREN, DICLOFENAC SODIUM
VORICONAZOLE, VORICONAZOLE
VOSEVI, SOFOSBUVIR
VOSOL, ACETIC ACID, GLACIAL
VOSOL HC, ACETIC ACID, GLACIAL
VOSPIRE ER, ALBUTEROL SULFATE
VOTRIENT, PAZOPANIB HYDROCHLORIDE
VPRIV, VELAGLUCERASE ALFA
VRAYLAR, CARIPRAZINE HYDROCHLORIDE
VUSION, MICONAZOLE NITRATE
VYFEMLA, ETHINYL ESTRADIOL
VYTORIN, EZETIMIBE
VYVANSE, LISDEXAMFETAMINE DIMESYLATE
VYXEOS, CYTARABINE
VYZULTA, LATANOPROSTENE BUNOD

** W **

WARFARIN SODIUM, WARFARIN SODIUM
WELCHOL, COLESEVELAM HYDROCHLORIDE
WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
WELLBUTRIN XL, BUPROPION HYDROCHLORIDE
WERA, ETHINYL ESTRADIOL
WOMEN'S ROGAINE, MINOXIDIL (OTC)

** X **

XADAGO, SAFINAMIDE MESYLATE
XALATAN, LATANOPROST
XALKORI, CRIZOTINIB
XANAX, ALPRAZOLAM
XANAX XR, ALPRAZOLAM

# APPENDIX A - PRODUCT NAME INDEX

** X **

XARELTO, RIVAROXABAN
XATMEP, METHOTREXATE SODIUM
XELJANZ, TOFACITINIB CITRATE
XELJANZ XR, TOFACITINIB CITRATE
XELODA, CAPECITABINE
XENAZINE, TETRABENAZINE
XENICAL, ORLISTAT
XENON XE 133, XENON XE-133
XEPI, OZENOXACIN
XERESE, ACYCLOVIR
XERMELO, TELOTRISTAT ETIPRATE
XHANCE, FLUTICASONE PROPIONATE
XIFAXAN, RIFAXIMIN
XIGDUO XR, DAPAGLIFLOZIN PROPANEDIOL
XIIDRA, LIFITEGRAST
XIMINO, MINOCYCLINE HYDROCHLORIDE
XOFIGO, RADIUM RA-223 DICHLORIDE
XOLEGEL, KETOCONAZOLE
XOPENEX, LEVALBUTEROL HYDROCHLORIDE
XOPENEX HFA, LEVALBUTEROL TARTRATE
XTAMPZA ER, OXYCODONE
XTANDI, ENZALUTAMIDE
XTORO, FINAFLOXACIN
XULANE, ETHINYL ESTRADIOL
XULTOPHY 100/3.6, INSULIN DEGLUDEC
XURIDEN, URIDINE TRIACETATE
XYLOCAINE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE 4% PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
XYREM, SODIUM OXYBATE
XYZAL, LEVOCETIRIZINE DIHYDROCHLORIDE
XYZAL ALLERGY 24HR, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)

** Y **

YAELA, DROSPIRENONE
YASMIN, DROSPIRENONE
YAZ, DROSPIRENONE
YONDELIS, TRABECTEDIN
YOSPRALA, ASPIRIN

** Z **

ZAFIRLUKAST, ZAFIRLUKAST
ZALEPLON, ZALEPLON
ZANAFLEX, TIZANIDINE HYDROCHLORIDE
ZANOSAR, STREPTOZOCIN
ZANTAC, RANITIDINE HYDROCHLORIDE
ZANTAC 150, RANITIDINE HYDROCHLORIDE (OTC)
ZANTAC 150, RANITIDINE HYDROCHLORIDE
ZANTAC 300, RANITIDINE HYDROCHLORIDE
ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)
ZARONTIN, ETHOSUXIMIDE
ZAROXOLYN, METOLAZONE
ZAVESCA, MIGLUSTAT
ZEGERID, OMEPRAZOLE
ZEGERID OTC, OMEPRAZOLE (OTC)
ZEJULA, NIRAPARIB TOSYLATE
ZELAPAR, SELEGILINE HYDROCHLORIDE
ZELBORAF, VEMURAFENIB
ZEMBRACE SYMTOUCH, SUMATRIPTAN SUCCINATE
ZEMPLAR, PARICALCITOL
ZENATANE, ISOTRETINOIN
ZENPEP, PANCRELIPASE (AMYLASE
ZEPATIER, ELBASVIR
ZERBAXA, CEFTOLOZANE SULFATE

# APPENDIX A - PRODUCT NAME INDEX

**** z ****

ZERIT, STAVUDINE
ZERVIATE, CETIRIZINE HYDROCHLORIDE
ZESTORETIC, HYDROCHLOROTHIAZIDE
ZESTRIL, LISINOPRIL
ZETIA, EZETIMIBE
ZETONNA, CICLESONIDE
ZIAC, BISOPROLOL FUMARATE
ZIAGEN, ABACAVIR SULFATE
ZIANA, CLINDAMYCIN PHOSPHATE
ZIDOVUDINE, ZIDOVUDINE
ZILEUTON, ZILEUTON
ZILRETTA, TRIAMCINOLONE ACETONIDE
ZINACEF, CEFUROXIME SODIUM
ZINACEF IN PLASTIC CONTAINER, CEFUROXIME SODIUM
ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE
ZINECARD, DEXRAZOXANE HYDROCHLORIDE
ZINGO, LIDOCAINE HYDROCHLORIDE
ZIOPTAN, TAFLUPROST
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZIPSOR, DICLOFENAC POTASSIUM
ZIRGAN, GANCICLOVIR
ZITHROMAX, AZITHROMYCIN
ZMAX, AZITHROMYCIN
ZOCOR, SIMVASTATIN
ZOFRAN, ONDANSETRON HYDROCHLORIDE
ZOFRAN ODT, ONDANSETRON
ZOHYDRO ER, HYDROCODONE BITARTRATE
ZOLADEX, GOSERELIN ACETATE
ZOLEDRONIC ACID, ZOLEDRONIC ACID
ZOLINZA, VORINOSTAT
ZOLMITRIPTAN, ZOLMITRIPTAN
ZOLOFT, SERTRALINE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
ZOLPIMIST, ZOLPIDEM TARTRATE
ZOMACTON, SOMATROPIN RECOMBINANT
ZOMETA, ZOLEDRONIC ACID
ZOMIG, ZOLMITRIPTAN
ZOMIG-ZMT, ZOLMITRIPTAN
ZONALON, DOXEPIN HYDROCHLORIDE
ZONEGRAN, ZONISAMIDE
ZONISAMIDE, ZONISAMIDE
ZONTIVITY, VORAPAXAR SULFATE
ZORBTIVE, SOMATROPIN RECOMBINANT
ZORTRESS, EVEROLIMUS
ZORVOLEX, DICLOFENAC
ZOSYN, PIPERACILLIN SODIUM
ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM
ZOVIA 1/35E-28, ETHINYL ESTRADIOL
ZOVIA 1/50E-28, ETHINYL ESTRADIOL
ZOVIRAX, ACYCLOVIR
ZUBSOLV, BUPRENORPHINE HYDROCHLORIDE
ZUPLENZ, ONDANSETRON
ZURAMPIC, LESINURAD
ZUTRIPRO, CHLORPHENIRAMINE MALEATE
ZYBAN, BUPROPION HYDROCHLORIDE
ZYCLARA, IMIQUIMOD
ZYDELIG, IDELALISIB
ZYFLO, ZILEUTON
ZYFLO CR, ZILEUTON
ZYKADIA, CERITINIB
ZYLET, LOTEPREDNOL ETABONATE
ZYLOPRIM, ALLOPURINOL
ZYMAR, GATIFLOXACIN
ZYMAXID, GATIFLOXACIN
ZYPITAMAG, PITAVASTATIN MAGNESIUM

# APPENDIX A - PRODUCT NAME INDEX

**** Z ****

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** 3 ****

**3D IMAGING DRUG**
* 3D IMAGING DRUG DESIGN AND DEVELOPMENT LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**3M**
* 3M CO
PERIDEX, CHLORHEXIDINE GLUCONATE
* 3M HEALTH CARE INC
AVAGARD, ALCOHOL (OTC)
DURAPREP, IODINE POVACRYLEX (OTC)

**3M DRUG DELIVERY**
* 3M DRUG DELIVERY SYSTEMS
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL
PROVENTIL-HFA, ALBUTEROL SULFATE

**** A ****

**AAA USA INC**
* ADVANCED ACCELERATOR APPLICATIONS USA INC
NETSPOT, GALLIUM DOTATATE GA-68

**AAIPHARMA LLC**
* AAIPHARMA LLC
AZASAN, AZATHIOPRINE

**ABBVIE**
* ABBVIE INC
ANDROGEL, TESTOSTERONE
BIAXIN, CLARITHROMYCIN
CREON, PANCRELIPASE (AMYLASE
CYCLOSPORINE, CYCLOSPORINE
DEPACON, VALPROATE SODIUM
DEPAKENE, VALPROIC ACID
DEPAKOTE ER, DIVALPROEX SODIUM
DEPAKOTE, DIVALPROEX SODIUM
GENGRAF, CYCLOSPORINE
K-TAB, POTASSIUM CHLORIDE
KALETRA, LOPINAVIR
MARINOL, DRONABINOL
MAVIK, TRANDOLAPRIL
MIVACRON, MIVACURIUM CHLORIDE
NIASPAN, NIACIN
NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE
NIMBEX, CISATRACURIUM BESYLATE
NORVIR, RITONAVIR
SURVANTA, BERACTANT
SYNTHROID, LEVOTHYROXINE SODIUM **
TARKA, TRANDOLAPRIL
TEVETEN, EPROSARTAN MESYLATE
TRICOR, FENOFIBRATE
TRIDIONE, TRIMETHADIONE
TRILIPIX, CHOLINE FENOFIBRATE
ULTANE, SEVOFLURANE
ZEMPLAR, PARICALCITOL

**ABBVIE ENDOCRINE**
* ABBVIE ENDOCRINE INC
LUPANETA PACK, LEUPROLIDE ACETATE

**ABBVIE ENDOCRINE INC**
* ABBVIE ENDOCRINE INC
LUPRON DEPOT, LEUPROLIDE ACETATE
LUPRON DEPOT-PED, LEUPROLIDE ACETATE

**ABBVIE INC**
* ABBVIE INC

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ABBVIE INC
DUOPA, CARBIDOPA
MAVYRET, GLECAPREVIR
NORVIR, RITONAVIR
TECHNIVIE, OMBITASVIR
VENCLEXTA, VENETOCLAX
VIEKIRA PAK (COPACKAGED), DASABUVIR SODIUM
VIEKIRA XR, DASABUVIR SODIUM

**ABHAI INC**
* ABHAI INC
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

**ABHAI LLC**
* ABHAI LLC
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

**ABON PHARMS LLC**
* ABON PHARMACEUTICALS LLC
CLOFARABINE, CLOFARABINE

**ABRAXIS BIOSCIENCE**
* ABRAXIS BIOSCIENCE LLC
ABRAXANE, PACLITAXEL

**ABRAXIS PHARM**
* ABRAXIS PHARMACEUTICAL PRODUCTS
CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%, CLINDAMYCIN PHOSPHATE

**ACADIA PHARMS INC**
* ACADIA PHARMACEUTICALS INC
NUPLAZID, PIMAVANSERIN TARTRATE

**ACCELRX LABS**
* ACCELRX LABS LLC
CARISOPRODOL, CARISOPRODOL

**ACCORD HLTHCARE**
* ACCORD HEALTHCARE INC
ALLOPURINOL, ALLOPURINOL
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ANASTROZOLE, ANASTROZOLE
ARIPIPRAZOLE, ARIPIPRAZOLE
BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
BICALUTAMIDE, BICALUTAMIDE
BIVALIRUDIN, BIVALIRUDIN
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CAPECITABINE, CAPECITABINE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARBOPLATIN, CARBOPLATIN
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CISPLATIN, CISPLATIN
CLONAZEPAM, CLONAZEPAM
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLOZAPINE, CLOZAPINE
DECITABINE, DECITABINE
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
ENTECAVIR, ENTECAVIR
EPLERENONE, EPLERENONE
EPTIFIBATIDE, EPTIFIBATIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ACCORD HEALTHCARE INC
ETOPOSIDE, ETOPOSIDE
FINASTERIDE, FINASTERIDE
FLUOROURACIL, FLUOROURACIL
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLIMEPIRIDE, GLIMEPIRIDE
GLIPIZIDE, GLIPIZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
ITRACONAZOLE, ITRACONAZOLE
LETROZOLE, LETROZOLE
LEVETIRACETAM, LEVETIRACETAM
LISINOPRIL, LISINOPRIL
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHYLDOPA, METHYLDOPA
MITOMYCIN, MITOMYCIN
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE, NORETHINDRONE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PARICALCITOL, PARICALCITOL
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RAMIPRIL, RAMIPRIL
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
SPIRONOLACTONE, SPIRONOLACTONE
TACROLIMUS, TACROLIMUS
TEMOZOLOMIDE, TEMOZOLOMIDE
TOPIRAMATE, TOPIRAMATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

**ACELLA PHARMS LLC**
* ACELLA PHARMACEUTICALS LLC
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
GABAPENTIN, GABAPENTIN
HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE
PHENYTOIN SODIUM, PHENYTOIN SODIUM

**ACI HEALTHCARE LTD**
* ACI HEALTHCARE LTD
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
LEVETIRACETAM, LEVETIRACETAM
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

**ACIC FINE CHEMS**
* ACIC FINE CHEMICALS INC
TRANEXAMIC ACID, TRANEXAMIC ACID

**ACIC PHARMS**
* ACIC PHARMACEUTICALS INC
LEVETIRACETAM, LEVETIRACETAM
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

**ACLARIS THERAPS INC**

* ACLARIS THERAPEUTICS INC
ESKATA, HYDROGEN PEROXIDE

**ACORDA**

* ACORDA THERAPEUTICS INC
AMPYRA, DALFAMPRIDINE
QUTENZA, CAPSAICIN

**ACS DOBFAR**

* ACS DOBFAR SPA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFOXITIN, CEFOXITIN SODIUM
CEFTAZIDIME, CEFTAZIDIME
CEFTRIAXONE, CEFTRIAXONE SODIUM
IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
KEFZOL, CEFAZOLIN SODIUM
MEROPENEM, MEROPENEM

**ACS DOBFAR INFO SA**

* ACS DOBFAR INFO SA
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
ZOLEDRONIC ACID, ZOLEDRONIC ACID

**ACS DOBFAR SPA**

* ACS DOBFAR SPA
AMPICILLIN SODIUM, AMPICILLIN SODIUM
CEFUROXIME SODIUM, CEFUROXIME SODIUM

**ACTAVIS ELIZABETH**

* ACTAVIS ELIZABETH LLC
ALPRAZOLAM, ALPRAZOLAM
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CLONAZEPAM, CLONAZEPAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DEFERASIROX, DEFERASIROX
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE, DEXTROMETHORPHAN HYDROBROMIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GABAPENTIN, GABAPENTIN
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
INDAPAMIDE, INDAPAMIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LOVASTATIN, LOVASTATIN
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
NIFEDIPINE, NIFEDIPINE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
OXAZEPAM, OXAZEPAM
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ACTAVIS ELIZABETH LLC
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROPYLTHIOURACIL, PROPYLTHIOURACIL
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SPIRONOLACTONE, SPIRONOLACTONE
TEMAZEPAM, TEMAZEPAM
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

* ACTAVIS ELIZABETH LLC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
ALPRAZOLAM, ALPRAZOLAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
LAMOTRIGINE, LAMOTRIGINE
MORPHINE SULFATE, MORPHINE SULFATE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

**ACTAVIS INC**

* ACTAVIS INC
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
METHOXSALEN, METHOXSALEN
ZOLEDRONIC ACID, ZOLEDRONIC ACID

**ACTAVIS LABS**

* ACTAVIS LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
PERMETHRIN, PERMETHRIN

**ACTAVIS LABS FL**

* ACTAVIS LABORATORIES FL INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
GUAIFENESIN, GUAIFENESIN (OTC)

**ACTAVIS LABS FL INC**

* ACTAVIS LABORATORIES FL INC
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CABERGOLINE, CABERGOLINE
CARTIA XT, DILTIAZEM HYDROCHLORIDE
CLARITHROMYCIN, CLARITHROMYCIN
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DALFAMPRIDINE, DALFAMPRIDINE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
DUTASTERIDE, DUTASTERIDE
FENTANYL CITRATE, FENTANYL CITRATE
FLUTAMIDE, FLUTAMIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
KETOPROFEN, KETOPROFEN
LEVETIRACETAM, LEVETIRACETAM
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
LORATADINE, LORATADINE (OTC)
METAXALONE, METAXALONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MIRTAZAPINE, MIRTAZAPINE
NAPROXEN SODIUM, NAPROXEN SODIUM
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NITROGLYCERIN, NITROGLYCERIN
OMEPRAZOLE, OMEPRAZOLE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ACTAVIS LABORATORIES FL INC
OXYCODONE AND ASPIRIN, ASPIRIN
PALIPERIDONE, PALIPERIDONE
PAROXETINE MESYLATE, PAROXETINE MESYLATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PREDNISONE, PREDNISONE
RAMELTEON, RAMELTEON
RISPERIDONE, RISPERIDONE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TAZTIA XT, DILTIAZEM HYDROCHLORIDE
TETRABENAZINE, TETRABENAZINE
TRANEXAMIC ACID, TRANEXAMIC ACID
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**ACTAVIS LABS NY INC**

* ACTAVIS LABORATORIES NY INC
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)

**ACTAVIS LABS UT INC**

* ACTAVIS LABORATORIES UT INC
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLONIDINE, CLONIDINE
EMLA, LIDOCAINE
FIORICET W/ CODEINE, ACETAMINOPHEN
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
LIDOCAINE, LIDOCAINE
NORINYL 1+50 28-DAY, MESTRANOL
PROGESTERONE, PROGESTERONE
TENUATE DOSPAN, DIETHYLPROPION HYDROCHLORIDE
TENUATE, DIETHYLPROPION HYDROCHLORIDE
TESTOSTERONE, TESTOSTERONE
* ACTAVIS LABORATORIES UT INC INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
FENTANYL-100, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL
TESTOSTERONE, TESTOSTERONE

**ACTAVIS LLC**

* ACTAVIS LLC
AZACITIDINE, AZACITIDINE
DAPSONE, DAPSONE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
* ACTAVIS LLC AN INDIRECT WHOLLY-OWNED SUB OF TEVA PHARMACEUTICALS USA INC
BUSULFAN, BUSULFAN
DOCETAXEL, DOCETAXEL
HYDROXOCOBALAMIN, HYDROXOCOBALAMIN

**ACTAVIS MID ATLANTIC**

* ACTAVIS MID ATLANTIC LLC
ACETASOL HC, ACETIC ACID, GLACIAL
ACYCLOVIR, ACYCLOVIR
ADAPALENE AND BENZOYL PEROXIDE, ADAPALENE
ADAPALENE, ADAPALENE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE AND TRETINOIN, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
DESOXIMETASONE, DESOXIMETASONE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ACTAVIS MID ATLANTIC LLC
DICLOFENAC SODIUM, DICLOFENAC SODIUM
ENULOSE, LACTULOSE
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
HYDROCORTISONE, HYDROCORTISONE
IBUPROFEN, IBUPROFEN (OTC)
LEVETIRACETAM, LEVETIRACETAM
MICONAZOLE 7, MICONAZOLE NITRATE (OTC)
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
NITROFURANTOIN, NITROFURANTOIN
NYSTATIN, NYSTATIN
PROMETH VC W/ CODEINE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
VALNAC, BETAMETHASONE VALERATE

* ACTAVIS MID ATLANTIC LLC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
IBUPROFEN, IBUPROFEN
M-ZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
PERMETHRIN, PERMETHRIN (OTC)

**ACTAVIS PHARMA**

* ACTAVIS PHARMA INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
MICONAZOLE NITRATE, MICONAZOLE NITRATE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)

**ACTAVIS TOTOWA**

* ACTAVIS TOTOWA LLC
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
FINASTERIDE, FINASTERIDE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
PACLITAXEL, PACLITAXEL
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
REPAGLINIDE, REPAGLINIDE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VINORELBINE TARTRATE, VINORELBINE TARTRATE

**ACTAVIS TOTOWA TEVA**

* ACTAVIS TOTOWA LLC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
FINASTERIDE, FINASTERIDE

**ACTELION PHARMS**

* ACTELION PHARMACEUTICALS LTD
TRACLEER, BOSENTAN

**ACTELION PHARMS LTD**

* ACTELION PHARMACEUTICALS LTD
OPSUMIT, MACITENTAN
TRACLEER, BOSENTAN
UPTRAVI, SELEXIPAG
VALCHLOR, MECHLORETHAMINE HYDROCHLORIDE
VELETRI, EPOPROSTENOL SODIUM
VENTAVIS, ILOPROST
ZAVESCA, MIGLUSTAT

**ACTIENT PHARMS**

* ACTIENT PHARMACEUTICALS LLC
THEO-24, THEOPHYLLINE

**ADAMAS PHARMA**

* ADAMAS PHARMA LLC
GOCOVRI, AMANTADINE HYDROCHLORIDE

**ADAMIS PHARMS CORP**

* ADAMIS PHARMACEUTICALS CORP
SYMJEPI, EPINEPHRINE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

**ADAPT**
* ADAPT PHARMA OPERATIONS LTD
NARCAN, NALOXONE HYDROCHLORIDE

**ADARE PHARMS INC**
* ADARE PHARMACEUTICALS INC
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

**ADDMEDICA SAS**
* ADDMEDICA SAS
SIKLOS, HYDROXYUREA

**ADIENNE SA**
* ADIENNE SA
TEPADINA, THIOTEPA

**AEGERION**
* AEGERION PHARMACEUTICALS INC
JUXTAPID, LOMITAPIDE MESYLATE

**AERIE PHARMS INC**
* AERIE PHARMACEUTICALS INC
RHOPRESSA, NETARSUDIL DIMESYLATE

**AETERNA ZENTARIS**
* AETERNA ZENTARIS GMBH
MACRILEN, MACIMORELIN ACETATE

**AGOURON PHARMS**
* AGOURON PHARMACEUTICALS LLC
VIRACEPT, NELFINAVIR MESYLATE

**AILEX PHARMS LLC**
* AILEX PHARMACEUTICALS LLC
CROMOLYN SODIUM, CROMOLYN SODIUM
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

**AIPING PHARM INC**
* AIPING PHARMACEUTICAL INC
FOLIC ACID, FOLIC ACID
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)

**AJANTA PHARMA**
* AJANTA PHARMA LTD
LEVETIRACETAM, LEVETIRACETAM

**AJANTA PHARMA LTD**
* AJANTA PHARMA LTD
ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
ARIPIPRAZOLE, ARIPIPRAZOLE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
ENTACAPONE, ENTACAPONE
LANSOPRAZOLE, LANSOPRAZOLE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
OLANZAPINE, OLANZAPINE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
RISPERIDONE, RISPERIDONE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
VORICONAZOLE, VORICONAZOLE
ZOLMITRIPTAN, ZOLMITRIPTAN

**AKORN**
* AKORN INC
ADENOSINE, ADENOSINE
AK-FLUOR 10%, FLUORESCEIN SODIUM
AK-FLUOR 25%, FLUORESCEIN SODIUM
AKBETA, LEVOBUNOLOL HYDROCHLORIDE
AKPENTOLATE, CYCLOPENTOLATE HYDROCHLORIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AKORN INC

AKTEN, LIDOCAINE HYDROCHLORIDE
AKTOB, TOBRAMYCIN
ALFENTA, ALFENTANIL HYDROCHLORIDE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOCAPROIC, AMINOCAPROIC ACID
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ATROPINE SULFATE, ATROPINE SULFATE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN, BACITRACIN
BAL, DIMERCAPROL
BALANCED SALT, CALCIUM CHLORIDE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
CALCITRIOL, CALCITRIOL
CAPASTAT SULFATE, CAPREOMYCIN SULFATE
CARBOPLATIN, CARBOPLATIN
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CROMOLYN SODIUM, CROMOLYN SODIUM
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
DESOXIMETASONE, DESOXIMETASONE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
ENDOSOL EXTRA, CALCIUM CHLORIDE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
EPTIFIBATIDE, EPTIFIBATIDE
ERYTHROMYCIN, ERYTHROMYCIN
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
ETHOSUXIMIDE, ETHOSUXIMIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
GENTAK, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
IC-GREEN, INDOCYANINE GREEN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)
LATANOPROST, LATANOPROST
LEVOFLOXACIN, LEVOFLOXACIN
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NEDOCROMIL SODIUM, NEDOCROMIL SODIUM
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
OFLOXACIN, OFLOXACIN
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
PAREMYD, HYDROXYAMPHETAMINE HYDROBROMIDE
PARICALCITOL, PARICALCITOL
PYRAZINAMIDE, PYRAZINAMIDE
RIFAMPIN, RIFAMPIN
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
SUBLIMAZE PRESERVATIVE FREE, FENTANYL CITRATE
SUFENTA PRESERVATIVE FREE, SUFENTANIL CITRATE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TERBUTALINE SULFATE, TERBUTALINE SULFATE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AKORN INC
TIMOLOL MALEATE, TIMOLOL MALEATE
TIMOLOL, TIMOLOL
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TRANEXAMIC ACID, TRANEXAMIC ACID
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TROPICACYL, TROPICAMIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

**AKORN INC**

* AKORN INC
ACETYLCYSTEINE, ACETYLCYSTEINE
APRACLONIDINE HYDROCHLORIDE, APRACLONIDINE HYDROCHLORIDE
CEFTRIAXONE, CEFTRIAXONE SODIUM
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CYCLOPENTOLATE HYDROCHLORIDE, CYCLOPENTOLATE HYDROCHLORIDE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
DRONABINOL, DRONABINOL
EPHEDRINE SULFATE, EPHEDRINE SULFATE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
INAPSINE, DROPERIDOL
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
NAPHAZOLINE HYDROCHLORIDE, NAPHAZOLINE HYDROCHLORIDE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
TOBRAMYCIN, TOBRAMYCIN
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

**ALCON**

* ALCON LABORATORIES INC
BETOPTIC, BETAXOLOL HYDROCHLORIDE
BSS PLUS, CALCIUM CHLORIDE
BSS, CALCIUM CHLORIDE
CROMOLYN SODIUM, CROMOLYN SODIUM
MIOSTAT, CARBACHOL
NAPHCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)

**ALCON PHARMS LTD**

* ALCON PHARMACEUTICALS LTD
BETADINE, POVIDONE-IODINE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
KETOTIFEN FUMARATE, KETOTIFEN FUMARATE (OTC)

**ALEMBIC LTD**

* ALEMBIC LTD
LITHIUM CARBONATE, LITHIUM CARBONATE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE

**ALEMBIC PHARMS LTD**

* ALEMBIC PHARMACEUTICALS LTD
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
ARIPIPRAZOLE, ARIPIPRAZOLE
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ALEMBIC PHARMACEUTICALS LTD
CELECOXIB, CELECOXIB
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DESVENLAFAXINE, DESVENLAFAXINE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
FAMOTIDINE, FAMOTIDINE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
ITRACONAZOLE, ITRACONAZOLE
LAMOTRIGINE, LAMOTRIGINE
LEFLUNOMIDE, LEFLUNOMIDE
LINEZOLID, LINEZOLID
LITHIUM CARBONATE, LITHIUM CARBONATE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MEPROBAMATE, MEPROBAMATE
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE, METRONIDAZOLE
MODAFINIL, MODAFINIL
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TELMISARTAN, TELMISARTAN
THEOPHYLLINE, THEOPHYLLINE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN, VALSARTAN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZOLMITRIPTAN, ZOLMITRIPTAN

**ALIMERA SCIENCES INC**

* ALIMERA SCIENCES INC
ILUVIEN, FLUOCINOLONE ACETONIDE

**ALKEM**

* ALKEM LABORATORIES LTD
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
GABAPENTIN, GABAPENTIN
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

**ALKEM LABS LTD**

* ALKEM LABORATORIES LTD
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
CAPECITABINE, CAPECITABINE
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEPHALEXIN, CEPHALEXIN
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
EZETIMIBE AND SIMVASTATIN, EZETIMIBE
EZETIMIBE, EZETIMIBE
FINASTERIDE, FINASTERIDE
GABAPENTIN, GABAPENTIN
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
ITRACONAZOLE, ITRACONAZOLE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ALKEM LABORATORIES LTD
LAMOTRIGINE, LAMOTRIGINE
LIDOCAINE, LIDOCAINE
LINEZOLID, LINEZOLID
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RASAGILINE MESYLATE, RASAGILINE MESYLATE
RILUZOLE, RILUZOLE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
TAMSULOSIN HYDROCHLORIDE , TAMSULOSIN HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

**ALKERMES**

* ALKERMES INC
VIVITROL, NALTREXONE

**ALKERMES INC**

* ALKERMES INC
ARISTADA, ARIPIPRAZOLE LAUROXIL

**ALLEGIANCE HLTHCARE**

* ALLEGIANCE HEALTHCARE CORP
POVIDONE IODINE, POVIDONE-IODINE (OTC)

**ALLEGIS**

* ALLEGIS HOLDINGS LLC
PRIMSOL, TRIMETHOPRIM HYDROCHLORIDE

**ALLERGAN**

* ALLERGAN
ACULAR LS, KETOROLAC TROMETHAMINE
ALPHAGAN P, BRIMONIDINE TARTRATE
BLEPH-10, SULFACETAMIDE SODIUM
GENOPTIC, GENTAMICIN SULFATE
ZYMAXID, GATIFLOXACIN

* ALLERGAN INC
ACULAR, KETOROLAC TROMETHAMINE
ACUVAIL, KETOROLAC TROMETHAMINE
ACZONE, DAPSONE
ALOCRIL, NEDOCROMIL SODIUM
ALPHAGAN P, BRIMONIDINE TARTRATE
AVAGE, TAZAROTENE
AZELEX, AZELAIC ACID
COMBIGAN, BRIMONIDINE TARTRATE
ELESTAT, EPINASTINE HYDROCHLORIDE
LASTACAFT, ALCAFTADINE
LATISSE, BIMATOPROST
LUMIGAN, BIMATOPROST
OCUFLOX, OFLOXACIN
OZURDEX, DEXAMETHASONE
POLYTRIM, POLYMYXIN B SULFATE
RESTASIS MULTIDOSE, CYCLOSPORINE
RESTASIS, CYCLOSPORINE
TAZORAC, TAZAROTENE
ZYMAR, GATIFLOXACIN

* ALLERGAN PHARMACEUTICAL
BETAGAN, LEVOBUNOLOL HYDROCHLORIDE
BLEPHAMIDE S.O.P., PREDNISOLONE ACETATE
BLEPHAMIDE, PREDNISOLONE ACETATE
FML FORTE, FLUOROMETHOLONE
FML, FLUOROMETHOLONE
OCUFEN, FLURBIPROFEN SODIUM
PRED FORTE, PREDNISOLONE ACETATE
PRED MILD, PREDNISOLONE ACETATE
PRED-G, GENTAMICIN SULFATE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

**ALLERGAN HOLDINGS**
* ALLERGAN HOLDINGS UNLTD CO
VIBERZI, ELUXADOLINE

**ALLERGAN INC**
* ALLERGAN INC
ACZONE, DAPSONE
RHOFADE, OXYMETAZOLINE HYDROCHLORIDE

**ALLERGAN SALES LLC**
* ALLERGAN SALES LLC
ACTIGALL, URSODIOL
ALORA, ESTRADIOL
ANDRODERM, TESTOSTERONE
BREVICON 28-DAY, ETHINYL ESTRADIOL
CONDYLOX, PODOFILOX
CORDRAN, FLURANDRENOLIDE
CRINONE, PROGESTERONE
DALVANCE, DALBAVANCIN HYDROCHLORIDE
ESTRACE, ESTRADIOL
FIORINAL W/CODEINE, ASPIRIN
FIORINAL, ASPIRIN
GELNIQUE, OXYBUTYNIN CHLORIDE
INFED, IRON DEXTRAN
KADIAN, MORPHINE SULFATE
MICROZIDE, HYDROCHLOROTHIAZIDE
NORINYL 1+35 21-DAY, ETHINYL ESTRADIOL
NORINYL 1+35 28-DAY, ETHINYL ESTRADIOL
OXYTROL FOR WOMEN, OXYBUTYNIN (OTC)
OXYTROL, OXYBUTYNIN
RAPAFLO, SILODOSIN
SAVELLA, MILNACIPRAN HYDROCHLORIDE
TRELSTAR, TRIPTORELIN PAMOATE

**ALLERQUEST**
* ALLERQUEST LLC
PRE-PEN, BENZYLPENICILLOYL POLYLYSINE

**ALLIED PHARMA INC**
* ALLIED PHARMA INC
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CLARITHROMYCIN, CLARITHROMYCIN
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

**ALLOS**
* ALLOS THERAPEUTICS INC
FOLOTYN, PRALATREXATE

**ALPHARMA PHARMS**
* ALPHARMA PHARMACEUTICALS LLC
EMBEDA, MORPHINE SULFATE

**ALRA**
* ALRA LABORATORIES INC
CHOLAC, LACTULOSE
CONSTILAC, LACTULOSE
GEN-XENE, CLORAZEPATE DIPOTASSIUM
IBU-TAB 200, IBUPROFEN (OTC)
IBU-TAB, IBUPROFEN

**ALTAIRE PHARMS INC**
* ALTAIRE PHARMACEUTICALS INC
ALTAFLUOR BENOX, BENOXINATE HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE, NAPHAZOLINE HYDROCHLORIDE (OTC)
OFLOXACIN, OFLOXACIN

**ALTATHERA PHARMS LLC**
* ALTATHERA PHARMACEUTICALS LLC

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ALTATHERA PHARMACEUTICALS LLC
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

**ALVOGEN**

* ALVOGEN GROUP HOLDINGS 2 LLC
DAPSONE, DAPSONE
OFLOXACIN, OFLOXACIN
* ALVOGEN GROUP HOLDINGS 3 LLC
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FORFIVO XL, BUPROPION HYDROCHLORIDE
* ALVOGEN GROUP HOLDINGS LLC
ADALAT CC, NIFEDIPINE
* ALVOGEN INC
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

**ALVOGEN INC**

* ALVOGEN INC
ACETYLCYSTEINE, ACETYLCYSTEINE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE
VORICONAZOLE, VORICONAZOLE

**ALVOGEN MALTA**

* ALVOGEN MALTA OPERATIONS LTD
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
BUDESONIDE, BUDESONIDE
CARBIDOPA, CARBIDOPA
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DISULFIRAM , DISULFIRAM
EXEMESTANE, EXEMESTANE
FELBAMATE, FELBAMATE
MACROBID, NITROFURANTOIN
MACRODANTIN, NITROFURANTOIN, MACROCRYSTALLINE
MELPHALAN, MELPHALAN
NAPRELAN, NAPROXEN SODIUM
NATEGLINIDE, NATEGLINIDE
NEVIRAPINE, NEVIRAPINE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RIVASTIGMINE, RIVASTIGMINE
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE
SPECTAZOLE, ECONAZOLE NITRATE
TENORETIC 100, ATENOLOL
TENORETIC 50, ATENOLOL
TENORMIN, ATENOLOL
ZESTORETIC, HYDROCHLOROTHIAZIDE
ZESTRIL, LISINOPRIL

**ALVOGEN PINE BROOK**

* ALVOGEN PINE BROOK LLC
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE

**AM ANTIBIOTICS**

* AMERICAN ANTIBIOTICS INC
AMOXICILLIN, AMOXICILLIN

**AMAG PHARMA USA**

* AMAG PHARMA USA INC
MAKENA PRESERVATIVE FREE, HYDROXYPROGESTERONE CAPROATE
MAKENA, HYDROXYPROGESTERONE CAPROATE

**AMAG PHARMS INC**

* AMAG PHARMACEUTICALS INC
FERAHEME, FERUMOXYTOL
INTRAROSA, PRASTERONE

**AMARIN PHARMS**

* AMARIN PHARMACEUTICALS IRELAND LTD
VASCEPA, ICOSAPENT ETHYL

**AMERIGEN PHARMS LTD**

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AMERIGEN PHARMACEUTICALS LTD
CARBIDOPA, CARBIDOPA
INDAPAMIDE, INDAPAMIDE
TEMOZOLOMIDE, TEMOZOLOMIDE

**AMGEN**

* AMGEN INC
SENSIPAR, CINACALCET HYDROCHLORIDE

**AMGEN INC**

* AMGEN INC
CORLANOR, IVABRADINE HYDROCHLORIDE

**AMNEAL PHARM**

* AMNEAL PHARMACEUTICAL
ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FOLIC ACID, FOLIC ACID
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
PRIMIDONE, PRIMIDONE

**AMNEAL PHARMS**

* AMNEAL PHARMACEUTICALS
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ARIPIPRAZOLE, ARIPIPRAZOLE
ATOVAQUONE, ATOVAQUONE
CALCITRIOL, CALCITRIOL
CALCIUM ACETATE, CALCIUM ACETATE
CAPECITABINE, CAPECITABINE
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIVALPROEX SODIUM, DIVALPROEX SODIUM
ENTECAVIR, ENTECAVIR
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESTRADIOL, ESTRADIOL
FELBAMATE, FELBAMATE
GABAPENTIN, GABAPENTIN
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
INDOMETHACIN, INDOMETHACIN
ITRACONAZOLE, ITRACONAZOLE
LEVETIRACETAM, LEVETIRACETAM
LIDOCAINE, LIDOCAINE
LINEZOLID, LINEZOLID
LORAZEPAM, LORAZEPAM
MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
MEROPENEM, MEROPENEM
METAXALONE, METAXALONE
MILNACIPRAN HYDROCHLORIDE, MILNACIPRAN HYDROCHLORIDE
MOMETASONE FUROATE, MOMETASONE FUROATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NIACIN, NIACIN
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN
NIZATIDINE, NIZATIDINE
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXCARBAZEPINE, OXCARBAZEPINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AMNEAL PHARMACEUTICALS
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE AND PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
QUININE SULFATE, QUININE SULFATE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TELMISARTAN, TELMISARTAN
TEMAZEPAM, TEMAZEPAM
TEMOZOLOMIDE, TEMOZOLOMIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
WARFARIN SODIUM, WARFARIN SODIUM

* AMNEAL PHARMACEUTICALS HOLDINGS GMBH
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE

* AMNEAL PHARMACEUTICALS OF NEW YORK LLC
ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BUDESONIDE, BUDESONIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE , BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
DUTASTERIDE, DUTASTERIDE
EPTIFIBATIDE, EPTIFIBATIDE
IBUPROFEN, IBUPROFEN (OTC)
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE, NORETHINDRONE
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PARICALCITOL, PARICALCITOL
SPIRONOLACTONE, SPIRONOLACTONE
TOBRAMYCIN, TOBRAMYCIN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VALSARTAN, VALSARTAN

**AMNEAL PHARMS CO**

* AMNEAL PHARMACEUTICALS CO GMBH
BUMETANIDE, BUMETANIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
BUSULFAN, BUSULFAN
CLOFARABINE, CLOFARABINE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
EZETIMIBE AND SIMVASTATIN, EZETIMIBE
EZETIMIBE, EZETIMIBE
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FUROSEMIDE, FUROSEMIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AMNEAL PHARMACEUTICALS CO GMBH
NADOLOL, NADOLOL
OXAPROZIN, OXAPROZIN
PARICALCITOL, PARICALCITOL
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

**AMNEAL PHARMS LLC**

* AMNEAL PHARMACEUTICALS LLC
ACTIVELLA, ESTRADIOL
AZATHIOPRINE, AZATHIOPRINE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)

**AMNEAL PHARMS NY**

* AMNEAL PHARMACEUTICALS NY LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ALPRAZOLAM, ALPRAZOLAM
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
GABAPENTIN, GABAPENTIN
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN, NAPROXEN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
REPREXAIN, HYDROCODONE BITARTRATE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

* AMNEAL PHARMACEUTICALS OF NY LLC
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
ISOTRETINOIN, ISOTRETINOIN
PROGESTERONE, PROGESTERONE

**AMPHASTAR PHARM**

* AMPHASTAR PHARMACEUTICAL INC
AMPHADASE, HYALURONIDASE
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE

**AMPHASTAR PHARMS INC**

* AMPHASTAR PHARMACEUTICALS INC
CORTROSYN, COSYNTROPIN
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE

**AMRING PHARMS**

* AMRING PHARMACEUTICALS INC
BROMFENAC SODIUM, BROMFENAC SODIUM
LATANOPROST, LATANOPROST
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE

**ANACOR PHARMS INC**

* ANACOR PHARMACEUTICALS INC
EUCRISA, CRISABOROLE
KERYDIN, TAVABOROLE

**ANBEX**

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ANBEX INC
IOSAT, POTASSIUM IODIDE (OTC)

**ANBISON LAB CO LTD**

* ANBISON LABORATORY CO LTD
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM

**ANCHEN PHARMS**

* ANCHEN PHARMACEUTICALS INC
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CLONIDINE HYDROCHLORIDE , CLONIDINE HYDROCHLORIDE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE, DUTASTERIDE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRETINOIN, TRETINOIN
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

* ANCHEN PHARMACEUTICALS TAIWAN INC
DIVALPROEX SODIUM, DIVALPROEX SODIUM

* ANCHEN PHARMACEUTICALS, INC
ALPRAZOLAM, ALPRAZOLAM
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

**ANDA REPOSITORY**

* ANDA REPOSITORY LLC
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
PRIMIDONE, PRIMIDONE

**ANDRX LABS LLC**

* ANDRX LABS LLC
FORTAMET, METFORMIN HYDROCHLORIDE

**ANI PHARMS**

* ANI PHARMACEUTICALS INC
CORTENEMA, HYDROCORTISONE
LACTULOSE, LACTULOSE
LUVOX, FLUVOXAMINE MALEATE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
REGLAN, METOCLOPRAMIDE HYDROCHLORIDE

**ANI PHARMS INC**

* ANI PHARMACEUTICALS INC
ALPRAZOLAM, ALPRAZOLAM
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CHLORPROPAMIDE, CHLORPROPAMIDE
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
ETODOLAC, ETODOLAC
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GLIPIZIDE, GLIPIZIDE
GLUCAMIDE, CHLORPROPAMIDE
GUANABENZ ACETATE, GUANABENZ ACETATE
INDAPAMIDE, INDAPAMIDE
INDERAL LA, PROPRANOLOL HYDROCHLORIDE
INNOPRAN XL, PROPRANOLOL HYDROCHLORIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LITHOBID, LITHIUM CARBONATE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ANI PHARMACEUTICALS INC
LORAZEPAM, LORAZEPAM
METHAZOLAMIDE, METHAZOLAMIDE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NILUTAMIDE, NILUTAMIDE
NIZATIDINE, NIZATIDINE
OXCARBAZEPINE, OXCARBAZEPINE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
RISPERIDONE, RISPERIDONE
TESTOSTERONE, TESTOSTERONE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALPROIC ACID, VALPROIC ACID
VANCOCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

**ANTARES PHARMA INC**
* ANTARES PHARMA INC
OTREXUP, METHOTREXATE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

**ANTIBIOTICE**
* ANTIBIOTICE SA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
NAFCILLIN SODIUM, NAFCILLIN SODIUM

**ANTRIM PHARMS LLC**
* ANTRIM PHARMACEUTICALS LLC
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE

**APEX PHARMS INC**
* APEX PHARMACEUTICALS INC
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE

**APGDI**
* ASTELLAS PHARMA GLOBAL DEVELOPMENT INC
MYRBETRIQ, MIRABEGRON

**APICORE US**
* APICORE US LLC
TETRABENAZINE, TETRABENAZINE

**APIL**
* ALLERGAN PHARMACEUTICALS INTERNATIONAL LTD
ACTONEL, RISEDRONATE SODIUM
ASACOL HD, MESALAMINE
ATELVIA, RISEDRONATE SODIUM
DELZICOL, MESALAMINE
ENABLEX, DARIFENACIN HYDROBROMIDE
ESTROSTEP FE, ETHINYL ESTRADIOL
FEMCON FE, ETHINYL ESTRADIOL
FEMHRT, ETHINYL ESTRADIOL
FEMRING, ESTRADIOL ACETATE
LO LOESTRIN FE, ETHINYL ESTRADIOL
LO MINASTRIN FE, ETHINYL ESTRADIOL
LOESTRIN 21 1.5/30, ETHINYL ESTRADIOL
LOESTRIN 21 1/20, ETHINYL ESTRADIOL
LOESTRIN 24 FE, ETHINYL ESTRADIOL
LOESTRIN FE 1.5/30, ETHINYL ESTRADIOL
LOESTRIN FE 1/20, ETHINYL ESTRADIOL
MINASTRIN 24 FE, ETHINYL ESTRADIOL
NOR-QD, NORETHINDRONE
NORCO, ACETAMINOPHEN
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
SARAFEM, FLUOXETINE HYDROCHLORIDE
TAYTULLA, ETHINYL ESTRADIOL

**APOLLO PHARMS INC**
* APOLLO PHARMACEUTICALS INC
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

**APOPHARMA INC**

* APOPHARMA INC
FERRIPROX, DEFERIPRONE

**APOTEX**

* APOTEX CORP
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

* APOTEX INC
ALENDRONATE SODIUM, ALENDRONATE SODIUM
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CIMETIDINE, CIMETIDINE
CIMETIDINE, CIMETIDINE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CYCLOSPORINE, CYCLOSPORINE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
EPLERENONE, EPLERENONE
ETODOLAC, ETODOLAC
FAMCICLOVIR, FAMCICLOVIR
FAMOTIDINE, FAMOTIDINE
FLUCONAZOLE, FLUCONAZOLE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
GEMFIBROZIL, GEMFIBROZIL
GLIPIZIDE, GLIPIZIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LAMIVUDINE, LAMIVUDINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
OMEPRAZOLE, OMEPRAZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PENTOXIFYLLINE, PENTOXIFYLLINE
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
RAMIPRIL, RAMIPRIL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE

**APOTEX CORP**

* APOTEX CORP
AZITHROMYCIN, AZITHROMYCIN
CABERGOLINE, CABERGOLINE
CLARITHROMYCIN, CLARITHROMYCIN
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
RILUZOLE, RILUZOLE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

**APOTEX INC**

* APOTEX INC

ABACAVIR SULFATE, ABACAVIR SULFATE
ACYCLOVIR, ACYCLOVIR
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALKERAN, MELPHALAN
ALPRAZOLAM, ALPRAZOLAM
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
ANASTROZOLE, ANASTROZOLE
ARIPIPRAZOLE, ARIPIPRAZOLE
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
ATOVAQUONE, ATOVAQUONE
AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE, AZELASTINE HYDROCHLORIDE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BENZONATATE, BENZONATATE
BICALUTAMIDE, BICALUTAMIDE
BIMATOPROST, BIMATOPROST
BIVALIRUDIN, BIVALIRUDIN
BROMFENAC SODIUM, BROMFENAC SODIUM
BUDESONIDE, BUDESONIDE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CALCITONIN-SALMON, CALCITONIN SALMON
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CARBAMAZEPINE, CARBAMAZEPINE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CEFPROZIL, CEFPROZIL
CELECOXIB, CELECOXIB
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CICLOPIROX, CICLOPIROX
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DASATINIB, DASATINIB
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
DUTASTERIDE, DUTASTERIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
EZETIMIBE, EZETIMIBE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IMATINIB MESYLATE, IMATINIB MESYLATE
IMIQUIMOD, IMIQUIMOD
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LAMIVUDINE, LAMIVUDINE
LAMOTRIGINE, LAMOTRIGINE
LETROZOLE, LETROZOLE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
LOVASTATIN, LOVASTATIN
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MODAFINIL, MODAFINIL
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MOMETASONE FUROATE, MOMETASONE FUROATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* APOTEX INC
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
NABUMETONE, NABUMETONE
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
NEVIRAPINE, NEVIRAPINE
OFLOXACIN, OFLOXACIN
OLANZAPINE, OLANZAPINE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OXCARBAZEPINE, OXCARBAZEPINE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RAMIPRIL, RAMIPRIL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
RASAGILINE MESYLATE, RASAGILINE MESYLATE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RISPERIDONE, RISPERIDONE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TIMOLOL MALEATE, TIMOLOL MALEATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRANEXAMIC ACID, TRANEXAMIC ACID
TRAVOPROST, TRAVOPROST
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID
ZOLMITRIPTAN, ZOLMITRIPTAN
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

* APOTEX INC ETOBICOKE SITE
ACYCLOVIR, ACYCLOVIR
ALLOPURINOL, ALLOPURINOL
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARBAMAZEPINE, CARBAMAZEPINE
CARVEDILOL, CARVEDILOL
CILOSTAZOL, CILOSTAZOL
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DILTZAC, DILTIAZEM HYDROCHLORIDE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GABAPENTIN, GABAPENTIN
LEFLUNOMIDE, LEFLUNOMIDE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LORATADINE, LORATADINE (OTC)
MELOXICAM, MELOXICAM
MIRTAZAPINE, MIRTAZAPINE
OXAPROZIN, OXAPROZIN
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TORSEMIDE, TORSEMIDE
ZONISAMIDE, ZONISAMIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** A **

* APOTEX INC RICHMOND HILL
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BUDESONIDE, BUDESONIDE (OTC)
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
FLUNISOLIDE, FLUNISOLIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
RISPERIDONE, RISPERIDONE

* APOTEX INC.
DILTZAC, DILTIAZEM HYDROCHLORIDE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE

**APOTEX TECHNOLOGIES**

* APOTEX TECHNOLOGIES INC
PAXIL CR, PAROXETINE HYDROCHLORIDE
PAXIL, PAROXETINE HYDROCHLORIDE

**APOTHECON**

* APOTHECON INC DIV BRISTOL MYERS SQUIBB
KENALOG-10, TRIAMCINOLONE ACETONIDE
KENALOG-40, TRIAMCINOLONE ACETONIDE

**APP PHARMS**

* APP PHARMACEUTICALS LLC
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE

**APPCO PHARMA LLC**

* APPCO PHARMA LLC
BUDESONIDE, BUDESONIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
LAMIVUDINE, LAMIVUDINE
METRONIDAZOLE, METRONIDAZOLE
MODAFINIL, MODAFINIL
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
VORICONAZOLE, VORICONAZOLE
ZOLMITRIPTAN, ZOLMITRIPTAN

**APRECIA PHARMS**

* APRECIA PHARMACEUTICALS LLC
SPRITAM, LEVETIRACETAM

**AQUA PHARMS**

* AQUA PHARMACEUTICALS
ACTICLATE CAP, DOXYCYCLINE HYCLATE
CORDRAN SP, FLURANDRENOLIDE
CORDRAN, FLURANDRENOLIDE
MONODOX, DOXYCYCLINE
VERDESO, DESONIDE

* AQUA PHARMACEUTICALS LLC
FLUOROPLEX, FLUOROURACIL
XOLEGEL, KETOCONAZOLE

**AQUA PHARMS LLC**

* AQUA PHARMACEUTICALS LLC
ACTICLATE, DOXYCYCLINE HYCLATE
ALTABAX, RETAPAMULIN
VELTIN, CLINDAMYCIN PHOSPHATE

**ARALEZ PHARMS**

* ARALEZ PHARMACEUTICALS TRADING DAC
TOPROL-XL, METOPROLOL SUCCINATE
YOSPRALA, ASPIRIN
ZONTIVITY, VORAPAXAR SULFATE

**ARALEZ PHARMS INC**

* ARALEZ PHARMACEUTICALS INC
FIBRICOR, FENOFIBRIC ACID

**ARBOR PHARMS LLC**

* ARBOR PHARMACEUTICALS LLC
BIDIL, HYDRALAZINE HYDROCHLORIDE
CETYLEV, ACETYLCYSTEINE
E.E.S. 400, ERYTHROMYCIN ETHYLSUCCINATE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ARBOR PHARMACEUTICALS LLC
E.E.S., ERYTHROMYCIN ETHYLSUCCINATE
EDARBI, AZILSARTAN KAMEDOXOMIL
EDARBYCLOR, AZILSARTAN KAMEDOXOMIL
ERY-TAB, ERYTHROMYCIN
ERYPED, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROCIN STEARATE, ERYTHROMYCIN STEARATE
ERYTHROMYCIN ETHYLSUCCINATE, ERYTHROMYCIN ETHYLSUCCINATE
ERYTHROMYCIN, ERYTHROMYCIN
EVEKEO, AMPHETAMINE SULFATE
GLIADEL, CARMUSTINE
HORIZANT, GABAPENTIN ENACARBIL
NYMALIZE, NIMODIPINE
PCE, ERYTHROMYCIN
SKLICE, IVERMECTIN
SOTYLIZE, SOTALOL HYDROCHLORIDE
TRIPTODUR KIT, TRIPTORELIN PAMOATE

**ARCO PHARMS LLC**
* ARCO PHARMACEUTICALS LLC
THYROSHIELD, POTASSIUM IODIDE (OTC)

**AREVA PHARMS**
* AREVA PHARMACEUTICALS INC
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

**ARIAD**
* ARIAD PHARMACEUTICALS INC
ALUNBRIG, BRIGATINIB
ICLUSIG, PONATINIB HYDROCHLORIDE

**ARISE PHARMS**
* ARISE PHARMACEUTICALS LLC
IBUPROFEN, IBUPROFEN (OTC)

**ASCEND THERAPS US**
* ASCEND THERAPEUTICS US LLC
ESTROGEL, ESTRADIOL

**ASCENT PHARMS INC**
* ASCENT PHARMACEUTICALS INC
DUTASTERIDE, DUTASTERIDE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN (OTC)
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

**ASPEN GLOBAL**
* ASPEN GLOBAL INC
MYLERAN, BUSULFAN

**ASPEN GLOBAL INC**
* ASPEN GLOBAL INC
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CYCLESSA, DESOGESTREL
HYDROXYPROGESTERONE CAPROATE, HYDROXYPROGESTERONE CAPROATE
LEUKERAN, CHLORAMBUCIL
MYLERAN, BUSULFAN
THIOGUANINE, THIOGUANINE

**ASTELLAS**
* ASTELLAS PHARMA US INC
ADENOCARD, ADENOSINE
AMBISOME, AMPHOTERICIN B
ASTAGRAF XL, TACROLIMUS
CRESEMBA, ISAVUCONAZONIUM SULFATE
LEXISCAN, REGADENOSON
MYCAMINE, MICAFUNGIN SODIUM
PROGRAF, TACROLIMUS
VESICARE, SOLIFENACIN SUCCINATE
XTANDI, ENZALUTAMIDE

**ASTRAZENECA**

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ASTRAZENECA LP
PULMICORT FLEXHALER, BUDESONIDE
SYMBICORT, BUDESONIDE
* ASTRAZENECA PHARMACEUTICALS LP
ATACAND HCT, CANDESARTAN CILEXETIL
ATACAND, CANDESARTAN CILEXETIL
FASLODEX, FULVESTRANT
ZOMIG, ZOLMITRIPTAN
ZOMIG-ZMT, ZOLMITRIPTAN
* ASTRAZENECA UK LTD
CALQUENCE, ACALABRUTINIB
SEROQUEL XR, QUETIAPINE FUMARATE

**ASTRAZENECA AB**

* ASTRAZENECA AB
BYDUREON BCISE, EXENATIDE
BYDUREON PEN, EXENATIDE SYNTHETIC
BYDUREON, EXENATIDE SYNTHETIC
BYETTA, EXENATIDE SYNTHETIC
FARXIGA, DAPAGLIFLOZIN PROPANEDIOL
KOMBIGLYZE XR, METFORMIN HYDROCHLORIDE
ONGLYZA, SAXAGLIPTIN HYDROCHLORIDE
QTERN, DAPAGLIFLOZIN PROPANEDIOL
SYMLIN, PRAMLINTIDE ACETATE
XIGDUO XR, DAPAGLIFLOZIN PROPANEDIOL

**ASTRAZENECA LP**

* ASTRAZENECA LP
NEXIUM 24HR, ESOMEPRAZOLE MAGNESIUM (OTC)

**ASTRAZENECA PHARMS**

* ASTRAZENECA PHARMACEUTICALS LP
ALVESCO, CICLESONIDE
ARIMIDEX, ANASTROZOLE
BEVESPI AEROSPHERE, FORMOTEROL FUMARATE
BRILINTA, TICAGRELOR
CASODEX, BICALUTAMIDE
DALIRESP, ROFLUMILAST
EPANOVA, OMEGA-3-CARBOXYLIC ACIDS
IRESSA, GEFITINIB
LYNPARZA, OLAPARIB
MOVANTIK, NALOXEGOL OXALATE
NEXIUM IV, ESOMEPRAZOLE SODIUM
NEXIUM, ESOMEPRAZOLE MAGNESIUM
OMNARIS, CICLESONIDE
PRILOSEC OTC, OMEPRAZOLE MAGNESIUM (OTC)
PULMICORT RESPULES, BUDESONIDE
RHINOCORT ALLERGY, BUDESONIDE (OTC)
SEROQUEL, QUETIAPINE FUMARATE
TAGRISSO, OSIMERTINIB MESYLATE
TUDORZA PRESSAIR, ACLIDINIUM BROMIDE
ZETONNA, CICLESONIDE

**ATHENEX INC**

* ATHENEX INC
BUMETANIDE, BUMETANIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DOXAPRAM HYDROCHLORIDE, DOXAPRAM HYDROCHLORIDE
ENALAPRILAT, ENALAPRILAT
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
VALPROATE SODIUM, VALPROATE SODIUM

**ATLAS PHARMS LLC**

* ATLAS PHARMACEUTICALS LLC
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* ATLAS PHARMACEUTICALS LLC
METHOCARBAMOL, METHOCARBAMOL

**ATNAHS PHARMA US**

* ATNAHS PHARMA US LTD
ANAPROX DS, NAPROXEN SODIUM
ANAPROX, NAPROXEN SODIUM
EC-NAPROSYN, NAPROXEN
NAPROSYN, NAPROXEN

**ATON**

* ATON PHARMA INC
CUPRIMINE, PENICILLAMINE
EDECRIN, ETHACRYNATE SODIUM
EDECRIN, ETHACRYNIC ACID
LACRISERT, HYDROXYPROPYL CELLULOSE
LODOSYN, CARBIDOPA
SYPRINE, TRIENTINE HYDROCHLORIDE
TIMOPTIC IN OCUDOSE, TIMOLOL MALEATE

**ATON PHARMA VPNA**

* ATON PHARMA DIV VALEANT PHARMACEUTICALS NORTH AMERICA LLC
DEMSER, METYROSINE

**AUROBINDO**

* AUROBINDO PHARMA LTD
AMOXICILLIN, AMOXICILLIN
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLARITHROMYCIN, CLARITHROMYCIN
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
NEVIRAPINE, NEVIRAPINE
ZIDOVUDINE, ZIDOVUDINE

**AUROBINDO PHARMA**

* AUROBINDO PHARMA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM

* AUROBINDO PHARMA LTD
ALENDRONATE SODIUM, ALENDRONATE SODIUM
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMPICILLIN SODIUM, AMPICILLIN SODIUM
ATENOLOL, ATENOLOL
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
CARISOPRODOL, CARISOPRODOL
CARVEDILOL, CARVEDILOL
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFDINIR, CEFDINIR
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DIDANOSINE, DIDANOSINE
FINASTERIDE, FINASTERIDE
FLUCONAZOLE, FLUCONAZOLE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYBURIDE, GLYBURIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUROBINDO PHARMA LTD
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MELOXICAM, MELOXICAM
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
RIBAVARIN, RIBAVIRIN
RIBAVIRIN, RIBAVIRIN
RISPERIDONE, RISPERIDONE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
STAVUDINE, STAVUDINE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TORSEMIDE, TORSEMIDE
TRANDOLAPRIL, TRANDOLAPRIL
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZALEPLON, ZALEPLON
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**AUROBINDO PHARMA LTD**

* AUROBINDO PHARMA LIMITED
DIVALPROEX SODIUM, DIVALPROEX SODIUM
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
LEVOFLOXACIN, LEVOFLOXACIN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

* AUROBINDO PHARMA LTD
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ABACAVIR SULFATE, ABACAVIR SULFATE
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ADENOSINE, ADENOSINE
AFIRMELLE, ETHINYL ESTRADIOL
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALPRAZOLAM, ALPRAZOLAM
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
ARIPIPRAZOLE, ARIPIPRAZOLE
ATHENTIA NEXT, LEVONORGESTREL (OTC)
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
AUROVELA 1.5/30, ETHINYL ESTRADIOL
AUROVELA 1/20, ETHINYL ESTRADIOL
AUROVELA 24 FE, ETHINYL ESTRADIOL
AUROVELA FE 1.5/30, ETHINYL ESTRADIOL
AUROVELA FE 1/20, ETHINYL ESTRADIOL
AYUNA, ETHINYL ESTRADIOL
AZITHROMYCIN, AZITHROMYCIN
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUROBINDO PHARMA LTD
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
CAFFEINE CITRATE, CAFFEINE CITRATE
CEFIXIME, CEFIXIME
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CELECOXIB, CELECOXIB
CEPHALEXIN, CEPHALEXIN
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLOZAPINE, CLOZAPINE
CYONANZ, ETHINYL ESTRADIOL
DALFAMPRIDINE, DALFAMPRIDINE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
EFAVIRENZ, EFAVIRENZ
ENTACAPONE, ENTACAPONE
ENTECAVIR, ENTECAVIR
EPTIFIBATIDE, EPTIFIBATIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
ESZOPICLONE, ESZOPICLONE
ETOMIDATE, ETOMIDATE
EZETIMIBE, EZETIMIBE
FAMCICLOVIR, FAMCICLOVIR
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FELODIPINE, FELODIPINE
FENOFIBRATE, FENOFIBRATE
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
FINASTERIDE, FINASTERIDE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLUCONAZOLE, FLUCONAZOLE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
GABAPENTIN, GABAPENTIN
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GEMFIBROZIL, GEMFIBROZIL
GLIMEPIRIDE, GLIMEPIRIDE
GLIPIZIDE, GLIPIZIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN (OTC)
INCASSIA, NORETHINDRONE
INDOMETHACIN, INDOMETHACIN
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
ISOSULFAN BLUE, ISOSULFAN BLUE
KALLIGA, DESOGESTREL

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUROBINDO PHARMA LTD
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVOFLOXACIN, LEVOFLOXACIN
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LINEZOLID, LINEZOLID
LO SIMPESSE, ETHINYL ESTRADIOL
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MEROPENEM, MEROPENEM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
METHOCARBAMOL, METHOCARBAMOL
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METRONIDAZOLE, METRONIDAZOLE
MILI, ETHINYL ESTRADIOL
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
MODAFINIL, MODAFINIL
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NADOLOL, NADOLOL
NAFCILLIN SODIUM, NAFCILLIN SODIUM
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN, NAPROXEN
NEVIRAPINE, NEVIRAPINE
NEXESTA FE, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
NYLIA 1/35, ETHINYL ESTRADIOL
NYLIA 7/7/7, ETHINYL ESTRADIOL
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
OMEPRAZOLE, OMEPRAZOLE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXACILLIN SODIUM, OXACILLIN SODIUM
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PARICALCITOL, PARICALCITOL
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PRASUGREL, PRASUGREL HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
REPAGLINIDE, REPAGLINIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUROBINDO PHARMA LTD
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SIMPESSE, ETHINYL ESTRADIOL
SPIRONOLACTONE, SPIRONOLACTONE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TELMISARTAN, TELMISARTAN
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
TRI-LO-MILI, ETHINYL ESTRADIOL
TRI-MILI, ETHINYL ESTRADIOL
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN, VALSARTAN
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID
ZOLMITRIPTAN, ZOLMITRIPTAN
* AUROBINDO PHARMA LTD INC
ZIDOVUDINE, ZIDOVUDINE

**AUROLIFE PHARMA LLC**

* AUROLIFE PHARMA LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DUTASTERIDE, DUTASTERIDE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

**AUSTARPHARMA LLC**

* AUSTARPHARMA LLC
ALENDRONATE SODIUM, ALENDRONATE SODIUM
METHOCARBAMOL, METHOCARBAMOL
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE

**AUXILIUM PHARMS INC**

* AUXILIUM PHARMACEUTICALS INC
TESTOPEL, TESTOSTERONE
THEO-24, THEOPHYLLINE

**AUXILIUM PHARMS LLC**

* AUXILIUM PHARMACEUTICALS LLC
DILATRATE-SR, ISOSORBIDE DINITRATE
EDEX, ALPROSTADIL
ROBAXIN, METHOCARBAMOL

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AUXILIUM PHARMACEUTICALS LLC
ROBAXIN-750, METHOCARBAMOL
SEMPREX-D, ACRIVASTINE
STRIANT, TESTOSTERONE
TESTIM, TESTOSTERONE
THEO-24, THEOPHYLLINE

**AVACOR PRODS**
* AVACOR PRODUCTS LLC
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)

**AVADEL LEGACY**
* AVADEL LEGACY PHARMACEUTICALS LLC
VAZCULEP, PHENYLEPHRINE HYDROCHLORIDE

**AVADEL PHARMS**
* AVADEL PHARMACEUTICALS USA INC
ACIPHEX SPRINKLE, RABEPRAZOLE SODIUM

**AVADEL SPECLT**
* AVADEL SPECIALTY PHARMACEUTICALS LLC
NOCTIVA, DESMOPRESSIN ACETATE

**AVANIR PHARMS**
* AVANIR PHARMACEUTICALS
ONZETRA XSAIL, SUMATRIPTAN SUCCINATE
* AVANIR PHARMACEUTICALS INC
NUEDEXTA, DEXTROMETHORPHAN HYDROBROMIDE

**AVANTHI INC**
* AVANTHI INC
CHLORPHENIRAMINE MALEATE, CHLORPHENIRAMINE MALEATE (OTC)
DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE, DEXBROMPHENIRAMINE MALEATE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
INDOMETHACIN, INDOMETHACIN
LOMAIRA, PHENTERMINE HYDROCHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE

**AVEDRO INC**
* AVEDRO INC
PHOTREXA VISCOUS IN DEXTRAN 20%, RIBOFLAVIN 5'-PHOSPHATE SODIUM
PHOTREXA, RIBOFLAVIN 5'-PHOSPHATE SODIUM

**AVEMA PHARMA**
* AVEMA PHARMA SOLUTIONS
IBUPROFEN, IBUPROFEN (OTC)

**AVENT**
* AVENT INC
PYTEST KIT, UREA, C-14
PYTEST, UREA, C-14

**AVEVA**
* AVEVA DRUG DELIVERY SYSTEMS INC
CLONIDINE, CLONIDINE
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-37, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-62, FENTANYL
FENTANYL-75, FENTANYL
FENTANYL-87, FENTANYL
NICOTINE, NICOTINE (OTC)

**AVID RADIOPHARMS INC**
* AVID RADIOPHARMACEUTICALS INC
AMYVID, FLORBETAPIR F-18

**AVONDALE PHARMS**
* AVONDALE PHARMACEUTICALS LLC
NIACOR, NIACIN

**AYTU BIOSCIENCE INC**

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** A ****

* AYTU BIOSCIENCE INC
NATESTO, TESTOSTERONE

**** B ****

**B BRAUN**

* B BRAUN MEDICAL INC
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
AMINO ACIDS, AMINO ACIDS
BALANCED SALT, CALCIUM CHLORIDE
CEFAZOLIN AND DEXTROSE, CEFAZOLIN SODIUM
CEFEPIME AND DEXTROSE IN DUPLEX CONTAINER, CEFEPIME HYDROCHLORIDE
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER, CEFOTETAN DISODIUM
CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER, CEFOXITIN SODIUM
CEFTAZIDIME IN DEXTROSE CONTAINER, CEFTAZIDIME
CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINER, CEFTRIAXONE SODIUM
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER, CEFUROXIME SODIUM
DEXTROSE 10% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% IN HALF-STRENGTH LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM
DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE AND DEXTROSE 5%, DOPAMINE HYDROCHLORIDE
FREAMINE HBC 6.9%, AMINO ACIDS
FREAMINE III 10%, AMINO ACIDS
FREAMINE III 3% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5% W/ ELECTROLYTES, AMINO ACIDS
FREAMINE III 8.5%, AMINO ACIDS
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPATAMINE 8%, AMINO ACIDS
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
ISOLYTE S IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
ISOLYTE S PH 7.4 IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
METRO I.V. IN PLASTIC CONTAINER, METRONIDAZOLE
NEPHRAMINE 5.4%, AMINO ACIDS
NUTRILIPID 10%, SOYBEAN OIL
NUTRILIPID 20%, SOYBEAN OIL
PHYSIOLYTE IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* B BRAUN MEDICAL INC

POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.037% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.11% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.15% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.11% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROCALAMINE, AMINO ACIDS
RESECTISOL IN PLASTIC CONTAINER, MANNITOL
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* B BRAUN MEDICAL INC
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SORBITOL 3.3% IN PLASTIC CONTAINER, SORBITOL
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
THEOPHYLLINE 0.04% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.08% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.16% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
THEOPHYLLINE 0.32% AND DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
TROPHAMINE 10%, AMINO ACIDS
TROPHAMINE, AMINO ACIDS

**B BRAUN MEDICAL INC**

* B BRAUN MEDICAL INC
CLOROTEKAL, CHLOROPROCAINE HYDROCHLORIDE
MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER, MEROPENEM

**BAJAJ MEDICAL LLC**

* BAJAJ MECICAL LLC
DYNA-HEX, CHLORHEXIDINE GLUCONATE (OTC)

**BARR**

* BARR LABORATORIES INC
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
ARANELLE, ETHINYL ESTRADIOL
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
BALZIVA-28, ETHINYL ESTRADIOL
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CHLORDIAZEPOXIDE HYDROCHLORIDE, CHLORDIAZEPOXIDE HYDROCHLORIDE
CHLORZOXAZONE, CHLORZOXAZONE
CLONAZEPAM, CLONAZEPAM
DANAZOL, DANAZOL
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIAZEPAM, DIAZEPAM
DIDANOSINE, DIDANOSINE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
DUTASTERIDE, DUTASTERIDE
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
ESTRADIOL AND NORGESTIMATE, ESTRADIOL
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
HYDROXYUREA, HYDROXYUREA
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
ISONIAZID, ISONIAZID
JUNEL 1.5/30, ETHINYL ESTRADIOL
JUNEL 1/20, ETHINYL ESTRADIOL
JUNEL FE 1.5/30, ETHINYL ESTRADIOL
JUNEL FE 1/20, ETHINYL ESTRADIOL
KARIVA, DESOGESTREL
KELNOR, ETHINYL ESTRADIOL
LEFLUNOMIDE, LEFLUNOMIDE
LESSINA-28, ETHINYL ESTRADIOL
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
MEGESTROL ACETATE, MEGESTROL ACETATE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHOTREXATE SODIUM, METHOTREXATE SODIUM

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BARR LABORATORIES INC
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
NIACIN, NIACIN
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORTREL 0.5/35-28, ETHINYL ESTRADIOL
NORTREL 1/35-21, ETHINYL ESTRADIOL
NORTREL 1/35-28, ETHINYL ESTRADIOL
NORTREL 7/7/7, ETHINYL ESTRADIOL
ONDANSETRON, ONDANSETRON
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PORTIA-28, ETHINYL ESTRADIOL
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
SPRINTEC, ETHINYL ESTRADIOL
TEMOZOLOMIDE, TEMOZOLOMIDE
TREXALL, METHOTREXATE SODIUM
TRI-LEGEST 21, ETHINYL ESTRADIOL
TRI-LEGEST FE, ETHINYL ESTRADIOL
TRI-SPRINTEC, ETHINYL ESTRADIOL
WARFARIN SODIUM, WARFARIN SODIUM
* BARR PHARMACEUTICALS
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM

**BARR LABS DIV TEVA**

* BARR LABORATORIES INC SUB TEVA PHARMACEUTICALS USA
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
BUDESONIDE, BUDESONIDE
OXYBUTYNIN, OXYBUTYNIN

**BARR LABS INC**

* BARR LABORATORIES INC
ACITRETIN, ACITRETIN
CLOZAPINE, CLOZAPINE
DEXTROAMP SACCHARATE,AMP ASPARTATE,DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
ESTRADIOL, ESTRADIOL
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
OLANZAPINE, OLANZAPINE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
OXYCODONE HYDROCHLORIDE AND IBUPROFEN, IBUPROFEN
TRETINOIN, TRETINOIN
TRI LO SPRINTEC, ETHINYL ESTRADIOL

**BAUSCH AND LOMB**

* BAUSCH AND LOMB INC
ALAWAY, KETOTIFEN FUMARATE (OTC)
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALREX, LOTEPREDNOL ETABONATE
BESIVANCE, BESIFLOXACIN HYDROCHLORIDE
CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
FLURBIPROFEN SODIUM, FLURBIPROFEN SODIUM
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
ISTALOL, TIMOLOL MALEATE
LATANOPROST, LATANOPROST
LOTEMAX, LOTEPREDNOL ETABONATE
MIOCHOL-E, ACETYLCHOLINE CHLORIDE
OFLOXACIN, OFLOXACIN
OPCON-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
PROLENSA, BROMFENAC SODIUM
RETISERT, FLUOCINOLONE ACETONIDE
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
TIMOLOL MALEATE, TIMOLOL MALEATE
VITRASE, HYALURONIDASE
VYZULTA, LATANOPROSTENE BUNOD

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BAUSCH AND LOMB INC
ZIRGAN, GANCICLOVIR
ZYLET, LOTEPREDNOL ETABONATE
* BAUSCH AND LOMB PHARMACEUTICALS INC
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXASPORIN, DEXAMETHASONE
ERYTHROMYCIN, ERYTHROMYCIN
FLUNISOLIDE, FLUNISOLIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
NEOMYCIN AND POLYMYXIN B SULFATES AND GRAMICIDIN, GRAMICIDIN
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE, BACITRACIN ZINC
OFLOXACIN, OFLOXACIN
OPTIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
OTICAIR, HYDROCORTISONE
PENTOLAIR, CYCLOPENTOLATE HYDROCHLORIDE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PROPARACAINE HYDROCHLORIDE, PROPARACAINE HYDROCHLORIDE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TIMOLOL MALEATE, TIMOLOL MALEATE
TOBRAMYCIN AND DEXAMETHASONE, DEXAMETHASONE
TOBRAMYCIN, TOBRAMYCIN
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TROPICAMIDE, TROPICAMIDE

**BAUSCH AND LOMB INC**

* BAUSCH AND LOMB INC
BEPREVE, BEPOTASTINE BESILATE
LOTEMAX, LOTEPREDNOL ETABONATE
LUMIFY, BRIMONIDINE TARTRATE (OTC)

**BAXTER HLTHCARE**

* BAXTER HEALTHCARE CORP
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
AMINOACETIC ACID 1.5% IN PLASTIC CONTAINER, GLYCINE
ANCEF IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
BACTOCILL IN PLASTIC CONTAINER, OXACILLIN SODIUM
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVIBLOC IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
BREVIBLOC, ESMOLOL HYDROCHLORIDE
CARDIOPLEGIC IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CEFEPIME IN PLASTIC CONTAINER, CEFEPIME HYDROCHLORIDE
CEFTRIAXONE IN PLASTIC CONTAINER, CEFTRIAXONE SODIUM
CLINIMIX 2.75/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 2.75/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 4.25/5 SULFITE FREE IN DEXTROSE 5% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/10 SULFITE FREE IN DEXTROSE 10% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/15 SULFITE FREE IN DEXTROSE 15% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/20 SULFITE FREE IN DEXTROSE 20% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/25 SULFITE FREE IN DEXTROSE 25% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX 5/35 SULFITE FREE IN DEXTROSE 35% IN PLASTIC CONTAINER, AMINO ACIDS
CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC
CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC
CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BAXTER HEALTHCARE CORP

CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC
CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER,
CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER,
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.33% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 15MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 20MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 30MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 40MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ (K), DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 5MEQ, DEXTROSE
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 15MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.33% AND POTASSIUM CHLORIDE 5MEQ IN PLASTIC CONTAINER,
DEXTROSE 5%, SODIUM CHLORIDE 0.45% AND POTASSIUM CHLORIDE 20MEQ (K) IN PLASTIC
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 60% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
DIANEAL 137 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL 137 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL 137 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL LOW CALCIUM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DIANEAL PD-2 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
EXTRANEAL, ICODEXTRIN
FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER, FAMOTIDINE
FLAGYL I.V. RTU IN PLASTIC CONTAINER, METRONIDAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BAXTER HEALTHCARE CORP
FORANE, ISOFLURANE
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
HEPARIN SODIUM 1,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 2,000 UNITS AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
IFEX, IFOSFAMIDE
LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
LIDOCAINE HYDROCHLORIDE 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER, LIDOCAINE
MESNEX, MESNA
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
NALLPEN IN PLASTIC CONTAINER, NAFCILLIN SODIUM
NEXTERONE, AMIODARONE HYDROCHLORIDE
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
OSMITROL 10% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 10% IN WATER, MANNITOL
OSMITROL 15% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 15% IN WATER, MANNITOL
OSMITROL 20% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 20% IN WATER, MANNITOL
OSMITROL 5% IN WATER IN PLASTIC CONTAINER, MANNITOL
OSMITROL 5% IN WATER, MANNITOL
PENICILLIN G POTASSIUM IN PLASTIC CONTAINER, PENICILLIN G POTASSIUM
PLASMA-LYTE 148 IN WATER IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PLASMA-LYTE 56 AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
PLASMA-LYTE A IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 0.224% IN SODIUM CHLORIDE 0.9%, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
PREMASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
PREMASOL 6% IN PLASTIC CONTAINER, AMINO ACIDS
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
SEVOFLURANE, SEVOFLURANE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 3% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SORBITOL 3% IN PLASTIC CONTAINER, SORBITOL
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION
STERILE WATER, STERILE WATER FOR IRRIGATION

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BAXTER HEALTHCARE CORP
SUPRANE, DESFLURANE
TIS-U-SOL IN PLASTIC CONTAINER, MAGNESIUM SULFATE
TIS-U-SOL, MAGNESIUM SULFATE
TRAVASOL 10% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 5.5% IN PLASTIC CONTAINER, AMINO ACIDS
TRAVASOL 8.5% IN PLASTIC CONTAINER, AMINO ACIDS
VANCOCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE
* BAXTER HEALTHCARE INTERNATI0NAL SPECIALTY THERAPIES DIV
PROSOL 20% SULFITE FREE IN PLASTIC CONTAINER, AMINO ACIDS

**BAXTER HLTHCARE CORP**

* BAXTER HEALTHCARE CORP
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
CEFAZOLIN IN PLASTIC CONTAINER, CEFAZOLIN SODIUM
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPROFLOXACIN, CIPROFLOXACIN
CLINDAMYCIN PHOSPHATE IN 0.9% SODIUM CHLORIDE, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FUROSEMIDE, FUROSEMIDE
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVOFLOXACIN, LEVOFLOXACIN
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/0 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER, CALCIUM CHLORIDE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
* BAXTER HEALTHCARE CORP ANESTHESIA AND CRITICAL CARE
PROTOPAM CHLORIDE, PRALIDOXIME CHLORIDE
* BAXTER HEALTHCARE CORP ANESTHESIA CRITICAL CARE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

**BAYER**

* BAYER HEALTHCARE LLC
ALEVE, NAPROXEN SODIUM (OTC)
ALEVE-D SINUS & COLD, NAPROXEN SODIUM (OTC)

**BAYER HEALTHCARE**

* BAYER HEALTHCARE PHARMACEUTICALS INC
ALIQOPA, COPANLISIB DIHYDROCHLORIDE

**BAYER HEALTHCARE LLC**

* BAYER HEALTHCARE LLC
CHILDREN'S CLARITIN, LORATADINE (OTC)
CHLOR-TRIMETON, CHLORPHENIRAMINE MALEATE (OTC)
CLARITIN HIVES RELIEF REDITAB, LORATADINE (OTC)
CLARITIN HIVES RELIEF, LORATADINE (OTC)
CLARITIN REDITABS, LORATADINE (OTC)
CLARITIN, LORATADINE (OTC)
CLARITIN-D 24 HOUR, LORATADINE (OTC)
CLARITIN-D, LORATADINE (OTC)
LOTRIMIN ULTRA, BUTENAFINE HYDROCHLORIDE (OTC)
MIRALAX, POLYETHYLENE GLYCOL 3350 (OTC)
MYCELEX-7 COMBINATION PACK, CLOTRIMAZOLE (OTC)
MYCELEX-7, CLOTRIMAZOLE (OTC)

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BAYER HEALTHCARE LLC
ZEGERID OTC, OMEPRAZOLE (OTC)

**BAYER HLTHCARE**

* BAYER HEALTHCARE CONSUMER CARE
ALEVE PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
* BAYER HEALTHCARE PHARMACEUTICALS INC
ADEMPAS, RIOCIGUAT
ANGELIQ, DROSPIRENONE
AVELOX, MOXIFLOXACIN HYDROCHLORIDE
BEYAZ, DROSPIRENONE
BILTRICIDE, PRAZIQUANTEL
CIPRO, CIPROFLOXACIN
CIPRO, CIPROFLOXACIN HYDROCHLORIDE
CLIMARA PRO, ESTRADIOL
CLIMARA, ESTRADIOL
DESONATE, DESONIDE
EOVIST, GADOXETATE DISODIUM
FINACEA , AZELAIC ACID
FINACEA, AZELAIC ACID
GADAVIST, GADOBUTROL
KYLEENA, LEVONORGESTREL
LEVITRA, VARDENAFIL HYDROCHLORIDE
MAGNEVIST, GADOPENTETATE DIMEGLUMINE
MENOSTAR, ESTRADIOL
MIRENA, LEVONORGESTREL
NATAZIA, DIENOGEST
NEXAVAR, SORAFENIB TOSYLATE
PRECOSE, ACARBOSE
SAFYRAL, DROSPIRENONE
SKYLA, LEVONORGESTREL
STAXYN, VARDENAFIL HYDROCHLORIDE
STIVARGA, REGORAFENIB
ULTRAVIST (PHARMACY BULK), IOPROMIDE
ULTRAVIST 240, IOPROMIDE
ULTRAVIST 300, IOPROMIDE
ULTRAVIST 370, IOPROMIDE
XOFIGO, RADIUM RA-223 DICHLORIDE
YASMIN, DROSPIRENONE
YAZ, DROSPIRENONE

**BAYSHORE PHARMS LLC**

* BAYSHORE PHARMACEUTICALS LLC
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE

**BDSI**

* BIODELIVERY SCIENCES INTERNATIONAL INC
BELBUCA, BUPRENORPHINE HYDROCHLORIDE
BUNAVAIL, BUPRENORPHINE HYDROCHLORIDE

**BECTON DICKINSON**

* BECTON DICKINSON AND CO
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)
E-Z SCRUB 201, POVIDONE-IODINE (OTC)
E-Z SCRUB 241, POVIDONE-IODINE (OTC)

**BECTON DICKINSON CO**

* BECTON DICKINSON AND CO
CHLORAPREP ONE-STEP FREPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP SEPP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP ONE-STEP, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP SINGLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP TRIPLE SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
CHLORAPREP WITH TINT, CHLORHEXIDINE GLUCONATE (OTC)

**BEDFORD**

* BEDFORD LABORATORIES DIV BEN VENUE LABORATORIES INC
CEFTRIAXONE, CEFTRIAXONE SODIUM

**BEDFORD LABS**

* BEDFORD LABORATORIES

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BEDFORD LABORATORIES
LORAZEPAM PRESERVATIVE FREE, LORAZEPAM

**BELCHER PHARMS**
* BELCHER PHARMACEUTICALS LLC
CEPHALEXIN, CEPHALEXIN
DESLORATADINE, DESLORATADINE

**BELCHER PHARMS LLC**
* BELCHER PHARMACEUTICALS LLC
CEFIXIME, CEFIXIME
EPINEPHRINE, EPINEPHRINE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
TACROLIMUS, TACROLIMUS

**BEXIMCO PHARMS USA**
* BEXIMCO PHARMACEUTICALS USA INC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

**BEXIMCO USA**
* BEXIMCO PHARMACEUTICALS USA INC
CARVEDILOL, CARVEDILOL

**BI-COASTAL PHARMA**
* BI-COASTAL PHARMA INTERNATIONAL LLC
DUVOID, BETHANECHOL CHLORIDE

**BIO NUCLEONICS**
* BIO NUCLEONICS INC
STRONTIUM CHLORIDE SR-89, STRONTIUM CHLORIDE SR-89

**BIO PHARM INC**
* BIO PHARM INC
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE

**BIO-PHARM INC**
* BIO-PHARM INC
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,
LACTULOSE, LACTULOSE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE

**BIOCON LIMITED**
* BIOCON LIMITED
SIMVASTATIN, SIMVASTATIN

**BIOCON LTD**
* BIOCON LTD
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

**BIOCRYST**
* BIOCRYST PHARMACEUTICALS INC
RAPIVAB, PERAMIVIR

**BIOFRONTERA**
* BIOFRONTERA BIOSCIENCE GMBH
AMELUZ, AMINOLEVULINIC ACID HYDROCHLORIDE

**BIOGEN IDEC**
* BIOGEN IDEC INC
SPINRAZA, NUSINERSEN SODIUM

**BIOGEN IDEC INC**
* BIOGEN IDEC INC
TECFIDERA, DIMETHYL FUMARATE

**BIOMARIN PHARM**
* BIOMARIN PHARMACEUTICAL INC
KUVAN, SAPROPTERIN DIHYDROCHLORIDE

**BIOMEDCL RES FDN**
* BIOMEDICAL RESEARCH FOUNDATION NORTHWEST LOUISANA
AMMONIA N 13, AMMONIA N-13

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BIOMEDICAL RESEARCH FOUNDATION NORTHWEST LOUISANA
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**BIONPHARMA INC**

* BIONPHARMA INC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
BENZONATATE, BENZONATATE
BEXAROTENE, BEXAROTENE
CALCITRIOL, CALCITRIOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DUTASTERIDE, DUTASTERIDE
ETHOSUXIMIDE, ETHOSUXIMIDE
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
MIDOL LIQUID GELS, IBUPROFEN (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NIMODIPINE, NIMODIPINE
PARICALCITOL, PARICALCITOL
PROGESTERONE, PROGESTERONE
TETRABENAZINE, TETRABENAZINE
VALPROIC ACID, VALPROIC ACID
VITAMIN D, ERGOCALCIFEROL
ZONISAMIDE, ZONISAMIDE

**BLAIREX**

* BLAIREX LABORATORIES INC
BRONCHO SALINE, SODIUM CHLORIDE (OTC)

**BLUE EARTH**

* BLUE EARTH DIAGNOSTICS LTD
AXUMIN, FLUCICLOVINE F-18

**BOEHRINGER INGELHEIM**

* BOEHRINGER INGELHEIM
CATAPRES, CLONIDINE HYDROCHLORIDE
CATAPRES-TTS-1, CLONIDINE
CATAPRES-TTS-2, CLONIDINE
CATAPRES-TTS-3, CLONIDINE
GILOTRIF, AFATINIB DIMALEATE
GLYXAMBI, EMPAGLIFLOZIN
MICARDIS HCT, HYDROCHLOROTHIAZIDE
MICARDIS, TELMISARTAN
MIRAPEX, PRAMIPEXOLE DIHYDROCHLORIDE

* BOEHRINGER INGELHEIM PHARMACEUTICALS INC
AGGRENOX, ASPIRIN
APTIVUS, TIPRANAVIR
ATROVENT HFA, IPRATROPIUM BROMIDE
ATROVENT, IPRATROPIUM BROMIDE
COMBIVENT RESPIMAT, ALBUTEROL SULFATE
FLOMAX, TAMSULOSIN HYDROCHLORIDE
JARDIANCE, EMPAGLIFLOZIN
JENTADUETO XR, LINAGLIPTIN
JENTADUETO, LINAGLIPTIN
MIRAPEX ER, PRAMIPEXOLE DIHYDROCHLORIDE
MOBIC, MELOXICAM
OFEV, NINTEDANIB ESYLATE
PERSANTINE, DIPYRIDAMOLE
PRADAXA, DABIGATRAN ETEXILATE MESYLATE
SPIRIVA RESPIMAT, TIOTROPIUM BROMIDE
SPIRIVA, TIOTROPIUM BROMIDE
STIOLTO RESPIMAT, OLODATEROL HYDROCHLORIDE
STRIVERDI RESPIMAT, OLODATEROL HYDROCHLORIDE
SYNJARDY XR, EMPAGLIFLOZIN

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** B **

* BOEHRINGER INGELHEIM PHARMACEUTICALS INC
SYNJARDY, EMPAGLIFLOZIN
TRADJENTA, LINAGLIPTIN
TWYNSTA, AMLODIPINE BESYLATE
VIRAMUNE XR, NEVIRAPINE
VIRAMUNE, NEVIRAPINE

**BOSCOGEN**

* BOSCOGEN INC
ACYCLOVIR, ACYCLOVIR
REPAGLINIDE, REPAGLINIDE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE

**BPI LABS LLC**

* BPI LABS LLC
ZOLEDRONIC ACID, ZOLEDRONIC ACID

**BRACCO**

* BRACCO DIAGNOSTICS INC
CARDIOGEN-82, RUBIDIUM CHLORIDE RB-82
CHOLETEC, TECHNETIUM TC-99M MEBROFENIN KIT
CYSTOGRAFIN DILUTE, DIATRIZOATE MEGLUMINE
CYSTOGRAFIN, DIATRIZOATE MEGLUMINE
E-Z-HD, BARIUM SULFATE
E-Z-PAQUE, BARIUM SULFATE
GASTROGRAFIN, DIATRIZOATE MEGLUMINE
ISOVUE-200, IOPAMIDOL
ISOVUE-250, IOPAMIDOL
ISOVUE-300, IOPAMIDOL
ISOVUE-370, IOPAMIDOL
ISOVUE-M 200, IOPAMIDOL
ISOVUE-M 300, IOPAMIDOL
KINEVAC, SINCALIDE
LIQUID E-Z-PAQUE, BARIUM SULFATE
LUMASON, SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES
MULTIHANCE MULTIPACK, GADOBENATE DIMEGLUMINE
MULTIHANCE, GADOBENATE DIMEGLUMINE
PROHANCE MULTIPACK, GADOTERIDOL
PROHANCE, GADOTERIDOL
READI-CAT 2 SMOOTHIES, BARIUM SULFATE
READI-CAT 2, BARIUM SULFATE
RENOGRAFIN-76, DIATRIZOATE MEGLUMINE
SINOGRAFIN, DIATRIZOATE MEGLUMINE
TAGITOL V, BARIUM SULFATE
VARIBAR NECTAR, BARIUM SULFATE
VARIBAR, BARIUM SULFATE

**BRAEBURN PHARMS INC**

* BRAEBURN PHARMACEUTICALS INC
PROBUPHINE, BUPRENORPHINE HYDROCHLORIDE

**BRAINTREE**

* BRAINTREE LABORATORIES INC
GOLYTELY, POLYETHYLENE GLYCOL 3350
NULYTELY, POLYETHYLENE GLYCOL 3350
NULYTELY-FLAVORED, POLYETHYLENE GLYCOL 3350

**BRAINTREE LABS**

* BRAINTREE LABORATORIES INC
SUPREP BOWEL PREP KIT, MAGNESIUM SULFATE

**BRECKENRIDGE PHARM**

* BRECKENRIDGE PHARMACEUTICAL INC
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CILOSTAZOL, CILOSTAZOL
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
DUTASTERIDE, DUTASTERIDE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
LEVETIRACETAM, LEVETIRACETAM

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** B ****

* BRECKENRIDGE PHARMACEUTICAL INC
MEFENAMIC ACID, MEFENAMIC ACID
MEGESTROL ACETATE, MEGESTROL ACETATE
MELOXICAM, MELOXICAM
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
NEOMYCIN SULFATE, NEOMYCIN SULFATE
OMEPRAZOLE, OMEPRAZOLE
OXCARBAZEPINE, OXCARBAZEPINE
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE , POLYETHYLENE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

**BRIGHAM WOMENS**

* BRIGHAM AND WOMENS HOSP
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**BRIGHAM WOMENS HOSP**

* BRIGHAM AND WOMENS HOSP INC
AMMONIA N 13, AMMONIA N-13

**BRISTOL MYERS SQUIBB**

* BRISTOL MYERS SQUIBB
AZACTAM, AZTREONAM
BARACLUDE, ENTECAVIR
LYSODREN, MITOTANE
PRAVACHOL, PRAVASTATIN SODIUM
* BRISTOL MYERS SQUIBB CO
AZACTAM IN PLASTIC CONTAINER, AZTREONAM
DROXIA, HYDROXYUREA
GLUCOPHAGE XR, METFORMIN HYDROCHLORIDE
HYDREA, HYDROXYUREA
REYATAZ, ATAZANAVIR SULFATE
SPRYCEL, DASATINIB
SUSTIVA, EFAVIRENZ
VIDEX EC, DIDANOSINE
* BRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCH INSTITUTE
ELIQUIS, APIXABAN
ETOPOPHOS PRESERVATIVE FREE, ETOPOSIDE PHOSPHATE
GLUCOPHAGE, METFORMIN HYDROCHLORIDE
ZERIT, STAVUDINE
* BRISTOL MYERS SQUIBB PHARMA CO
COUMADIN, WARFARIN SODIUM

**BRISTOL-MYERS SQUIBB**

* BRISTOL-MYERS SQUIBB CO
DAKLINZA, DACLATASVIR DIHYDROCHLORIDE
EVOTAZ, ATAZANAVIR SULFATE
VIDEX, DIDANOSINE

**** C ****

**CADILA PHARMS LTD**

* CADILA PHARMACEUTICALS LTD
ACYCLOVIR, ACYCLOVIR
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
GEMFIBROZIL, GEMFIBROZIL
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
OFLOXACIN, OFLOXACIN
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
TELMISARTAN, TELMISARTAN

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CADILA PHARMACEUTICALS LTD
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

**CADISTA PHARMS**
* CADISTA PHARMACEUTICALS INC
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM

**CALL INC**
* CALL INC DBA ROCHESTER PHARMACEUTICALS
ADAPALENE, ADAPALENE

**CARDINAL HEALTH 414**
* CARDINAL HEALTH 414 LLC CARDINAL HEALTH NUCLEAR PHARMACY SERVICES
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
LYMPHOSEEK KIT, TECHNETIUM TC-99M TILMANOCEPT
MDP-BRACCO, TECHNETIUM TC-99M MEDRONATE KIT
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT

**CARDINAL HEALTH 418**
* CARDINAL HEALTH 418 INC
SODIUM IODIDE I 123, SODIUM IODIDE I-123

**CARIBE HOLDINGS**
* CARIBE HOLDINGS CAYMAN CO LTD DBA PURACAP CARIBE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
GEMFIBROZIL, GEMFIBROZIL

**CARLSBAD**
* CARLSBAD TECHNOLOGY INC
ACYCLOVIR, ACYCLOVIR
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
FAMOTIDINE, FAMOTIDINE
GLIMEPIRIDE, GLIMEPIRIDE
LOVASTATIN, LOVASTATIN

**CARLSBAD TECHNOLOGY**
* CARLSBAD TECHNOLOGY INC
ACYCLOVIR, ACYCLOVIR

**CARMEL BIOSCIENCES**
* CARMEL BIOSCIENCES INC
PREXXARTAN, VALSARTAN

**CASPER PHARMA LLC**
* CASPER PHARMA LLC
CASPORYN HC, HYDROCORTISONE
FURADANTIN, NITROFURANTOIN
NEOSPORIN, BACITRACIN ZINC
PERMAPEN, PENICILLIN G BENZATHINE
ROBINUL FORTE, GLYCOPYRROLATE
ROBINUL, GLYCOPYRROLATE
TERRAMYCIN W/ POLYMYXIN B SULFATE, OXYTETRACYCLINE HYDROCHLORIDE
ZYLOPRIM, ALLOPURINOL

**CATALENT**
* CATALENT PHARMA SOLUTIONS LLC
VALPROIC ACID, VALPROIC ACID

**CEDIPROF INC**
* CEDIPROF INC
LEVO-T, LEVOTHYROXINE SODIUM **

**CELATOR PHARMS**
* CELATOR PHARMACEUTICALS INC
VYXEOS, CYTARABINE

**CELERITY PHARMS**
* CELERITY PHARMACEUTICALS LLC
BIVALIRUDIN IN 0.9% SODIUM CHLORIDE, BIVALIRUDIN

**CELGENE**
* CELGENE CORP
ISTODAX, ROMIDEPSIN
POMALYST, POMALIDOMIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CELGENE CORP
REVLIMID, LENALIDOMIDE
THALOMID, THALIDOMIDE
VIDAZA, AZACITIDINE

**CELGENE CORP**
* CELGENE CORP
IDHIFA, ENASIDENIB MESYLATE
OTEZLA, APREMILAST

**CEPHALON**
* CEPHALON INC
ACTIQ, FENTANYL CITRATE
FENTORA, FENTANYL CITRATE
GABITRIL, TIAGABINE HYDROCHLORIDE
NUVIGIL, ARMODAFINIL
PROVIGIL, MODAFINIL
TREANDA, BENDAMUSTINE HYDROCHLORIDE
TRISENOX, ARSENIC TRIOXIDE

**CEREXA**
* CEREXA INC
TEFLARO, CEFTAROLINE FOSAMIL
* CEREXA INC A SUB OF FOREST LABORATORIES LLC
AVYCAZ, AVIBACTAM SODIUM

**CFT PHARMS LLC**
* CFT PHARMACEUTICALS LLC
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

**CHANGZHOU PHARM**
* CHANGZHOU PHARMACEUTICAL FACTORY
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

**CHARTWELL LIFE SCI**
* CHARTWELL LIFE SCIENCE LLC
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

**CHARTWELL MOLECULES**
* CHARTWELL MOLECULES LLC
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DISULFIRAM, DISULFIRAM
GEMFIBROZIL, GEMFIBROZIL
NABUMETONE, NABUMETONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

**CHARTWELL RX**
* CHARTWELL RX SCIENCES LLC
CALCIUM ACETATE, CALCIUM ACETATE
CILOSTAZOL, CILOSTAZOL
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
INDOMETHACIN, INDOMETHACIN
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE

**CHARTWELL TETRA**
* CHARTWELL TETRA LLC
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE

**CHATTEM**
* CHATTEM INC
SELSUN, SELENIUM SULFIDE
UNISOM, DOXYLAMINE SUCCINATE (OTC)

**CHEMI SPA**
* CHEMI SPA
DECITABINE, DECITABINE
TEMOZOLOMIDE, TEMOZOLOMIDE

**CHEMISCH FBRK KRSSLR**
* CHEMISCHE FABRIK KREUSSLER & CO. GMBH
ASCLERA, POLIDOCANOL

**CHEMO RESEARCH SL**
* CHEMO RESEARCH SL

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CHEMO RESEARCH SL
BENZNIDAZOLE, BENZNIDAZOLE
ECOZA, ECONAZOLE NITRATE
NUVESSA, METRONIDAZOLE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN

**CHEPLAPHARM**
* CHEPLAPHARM ARZNEIMITTEL GMBH
XENICAL, ORLISTAT

**CHIESI USA INC**
* CHIESI USA INC
BETHKIS, TOBRAMYCIN
CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER, NICARDIPINE HYDROCHLORIDE
CARDENE, NICARDIPINE HYDROCHLORIDE
CLEVIPREX, CLEVIDIPINE
CUROSURF, PORACTANT ALFA
KENGREAL, CANGRELOR
ZYFLO CR, ZILEUTON
ZYFLO, ZILEUTON

**CHILDRENS HOSP MI**
* CHILDRENS HOSP MICHIGAN
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**CHINA RESOURCES**
* CHINA RESOURCES SAIKE PHARMACEUTICAL CO LTD
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE

**CHIRHOCLIN**
* CHIRHOCLIN INC
CHIRHOSTIM, SECRETIN SYNTHETIC HUMAN

**CINTEX SVCS**
* CINTEX SERVICES LLC
FLURANDRENOLIDE, FLURANDRENOLIDE

**CIPHER PHARMS INC**
* CIPHER PHARMACEUTICALS INC
CONZIP, TRAMADOL HYDROCHLORIDE
LIPOFEN, FENOFIBRATE

**CIPLA**
* CIPLA LTD
NEVIRAPINE, NEVIRAPINE
RISPERIDONE, RISPERIDONE
ZIDOVUDINE, ZIDOVUDINE

**CIPLA LTD**
* CIPLA LTD
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ABACAVIR SULFATE, ABACAVIR SULFATE
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ANASTROZOLE, ANASTROZOLE
BUDESONIDE, BUDESONIDE
CARBOPLATIN, CARBOPLATIN
CARVEDILOL, CARVEDILOL
CELECOXIB, CELECOXIB
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CICLOPIROX, CICLOPIROX
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DECITABINE, DECITABINE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ENTECAVIR, ENTECAVIR
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
FAMCICLOVIR, FAMCICLOVIR
FENOFIBRATE, FENOFIBRATE
FINASTERIDE, FINASTERIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CIPLA LTD
FLUTAMIDE, FLUTAMIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
IRBESARTAN, IRBESARTAN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LAMIVUDINE, LAMIVUDINE
LAMOTRIGINE, LAMOTRIGINE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
MELOXICAM, MELOXICAM
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NEVIRAPINE, NEVIRAPINE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
STAVUDINE, STAVUDINE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
ZALEPLON, ZALEPLON
ZIDOVUDINE, ZIDOVUDINE
ZOLEDRONIC ACID, ZOLEDRONIC ACID
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**CLINIGEN HLTHCARE**
* CLINIGEN HEALTHCARE LTD
ETHYOL, AMIFOSTINE
FOSCAVIR, FOSCARNET SODIUM
TOTECT, DEXRAZOXANE HYDROCHLORIDE

**CLOVER PHARMS**
* CLOVER PHARMACEUTICALS CORP
AMICAR, AMINOCAPROIC ACID

**CLOVIS ONCOLOGY INC**
* CLOVIS ONCOLOGY INC
RUBRACA, RUCAPARIB CAMSYLATE

**CMP DEV LLC**
* CMP DEVELOPMENT LLC
CAROSPIR, SPIRONOLACTONE

**CMP PHARMA INC**
* CMP PHARMA INC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
HYDROCORTISONE IN ABSORBASE, HYDROCORTISONE
ISONIAZID, ISONIAZID
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SPS, SODIUM POLYSTYRENE SULFONATE
TRIAMCINOLONE ACETONIDE IN ABSORBASE, TRIAMCINOLONE ACETONIDE

**CNTY LINE PHARMS**
* COUNTY LINE PHARMACEUTICALS LLC
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CICLOPIROX, CICLOPIROX
DYNACIN, MINOCYCLINE HYDROCHLORIDE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRATE, FENOFIBRATE
FLUOCINONIDE, FLUOCINONIDE
LIDEX, FLUOCINONIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
TAMBOCOR, FLECAINIDE ACETATE
TRANDATE, LABETALOL HYDROCHLORIDE
UREX, METHENAMINE HIPPURATE

**COLGATE PALMOLIVE**

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* COLGATE PALMOLIVE
COLGATE TOTAL, SODIUM FLUORIDE (OTC)

**COLGATE PALMOLIVE CO**

* COLGATE PALMOLIVE CO
PERIOGARD, CHLORHEXIDINE GLUCONATE

**COLGATE-PALMOLIVE CO**

* COLGATE-PALMOLIVE CO
PERIOGARD, CHLORHEXIDINE GLUCONATE

**COLLEGIUM PHARM INC**

* COLLEGIUM PHARMACEUTICAL INC
XTAMPZA ER, OXYCODONE

**COMBE**

* COMBE INC
VAGISTAT-1, TIOCONAZOLE (OTC)

**CONCORDIA LABS INC**

* CONCORDIA LABORATORIES INC
PHOTOFRIN, PORFIMER SODIUM

**CONCORDIA PHARMS INC**

* CONCORDIA PHARMACEUTICALS INC
DIBENZYLINE, PHENOXYBENZAMINE HYDROCHLORIDE
DUTOPROL, HYDROCHLOROTHIAZIDE
DYRENIUM, TRIAMTERENE
KAPVAY, CLONIDINE HYDROCHLORIDE
LANOXIN, DIGOXIN
NILANDRON, NILUTAMIDE
ORAPRED ODT, PREDNISOLONE SODIUM PHOSPHATE
PARNATE, TRANYLCYPROMINE SULFATE
PLAQUENIL, HYDROXYCHLOROQUINE SULFATE
UROXATRAL, ALFUZOSIN HYDROCHLORIDE

**CONTRACT PHARMACAL**

* CONTRACT PHARMACAL CORP
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
PROFEN, IBUPROFEN (OTC)

**COOPERSURGICAL**

* COOPERSURGICAL INC
PARAGARD T 380A, COPPER

**CORCEPT THERAP**

* CORCEPT THERAPEUTICS INC
KORLYM, MIFEPRISTONE

**CORDEN PHARMA**

* CORDEN PHARMA LATINA SPA
GLEOSTINE, LOMUSTINE

**COREPHARMA**

* COREPHARMA LLC
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
GRISEOFULVIN, ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
METAXALONE, METAXALONE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE

**COVIS PHARMA BV**

* COVIS PHARMA BV
ALTOPREV, LOVASTATIN
BETAPACE AF, SOTALOL HYDROCHLORIDE
BETAPACE, SOTALOL HYDROCHLORIDE
LANOXIN PEDIATRIC, DIGOXIN
LANOXIN, DIGOXIN
PRILOSEC, OMEPRAZOLE MAGNESIUM
RILUTEK, RILUZOLE
SULAR, NISOLDIPINE
ZANAFLEX, TIZANIDINE HYDROCHLORIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

**CPDC**
* CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**CPPI CV**
* CP PHARMACEUTICALS INTERNATIONAL CV
SUTENT, SUNITINIB MALATE

**CRANE PHARMS LLC**
* CRANE PHARMACEUTICALS LLC
DAPTOMYCIN, DAPTOMYCIN

**CROSSMEDIKA SA**
* CROSSMEDIKA SA
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE

**CROWN LABS**
* CROWN LABORATORIES INC
ALA-CORT, HYDROCORTISONE
ALA-SCALP, HYDROCORTISONE
TRIDERM, TRIAMCINOLONE ACETONIDE

**CROWN LABS INC**
* CROWN LABORATORIES INC
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN

**CSPC NBP PHARM CO**
* CSPC NBP PHARMACEUTICAL CO LTD
BENZONATATE, BENZONATATE

**CSPC OUYI PHARM CO**
* CSPC OUYI PHARMACEUTICAL CO LTD
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

**CUBIST PHARMS**
* CUBIST PHARMACEUTICALS INC
ENTEREG, ALVIMOPAN

**CUBIST PHARMS LLC**
* CUBIST PHARMACEUTICALS LLC
CUBICIN RF, DAPTOMYCIN
CUBICIN, DAPTOMYCIN
DIFICID, FIDAXOMICIN
SIVEXTRO, TEDIZOLID PHOSPHATE
ZERBAXA, CEFTOLOZANE SULFATE

**CUMBERLAND PHARMS**
* CUMBERLAND PHARMACEUTICALS INC
ACETADOTE, ACETYLCYSTEINE
CALDOLOR, IBUPROFEN
LACTULOSE, LACTULOSE
VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER, CONIVAPTAN HYDROCHLORIDE

**CUSTOPHARM INC**
* CUSTOPHARM INC
ACETAMINOPHEN, ACETAMINOPHEN
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM

**CUTANEA**
* CUTANEA LIFE SCIENCES INC
AKTIPAK, BENZOYL PEROXIDE

**CUTIS HEALTH LLC**
* CUTIS HEALTH LLC
DORAL, QUAZEPAM

**CYCLE PHARMS LTD**
* CYCLE PHARMACEUTICALS LTD
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** C ****

* CYCLE PHARMACEUTICALS LTD
NITYR, NITISINONE

**CYNDEA PHARMA**
* CYNDEA PHARMA SL
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE

**CYPRESS PHARM**
* CYPRESS PHARMACEUTICAL INC
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
ELIPHOS, CALCIUM ACETATE
REZIRA, HYDROCODONE BITARTRATE
VITUZ, CHLORPHENIRAMINE MALEATE
ZUTRIPRO, CHLORPHENIRAMINE MALEATE

**** D ****

**DAEWOONG PHARM CO**
* DAEWOONG PHARMACEUTICAL CO LTD
MEROPENEM, MEROPENEM

**DAIICHI SANKYO**
* DAIICHI SANKYO INC
AZOR, AMLODIPINE BESYLATE
BENICAR HCT, HYDROCHLOROTHIAZIDE
BENICAR, OLMESARTAN MEDOXOMIL
TRIBENZOR, AMLODIPINE BESYLATE
WELCHOL, COLESEVELAM HYDROCHLORIDE

**DAIICHI SANKYO INC**
* DAIICHI SANKYO INC
EVOXAC, CEVIMELINE HYDROCHLORIDE
MORPHABOND ER, MORPHINE SULFATE
ROXYBOND, OXYCODONE HYDROCHLORIDE
SAVAYSA, EDOXABAN TOSYLATE

**DANCO LABS LLC**
* DANCO LABORATORIES LLC
MIFEPREX, MIFEPRISTONE

**DAVA INTL INC**
* DAVA INTERNATIONAL INC
ALPRAZOLAM, ALPRAZOLAM

**DAVA PHARMS INC**
* DAVA PHARMACEUTICALS INC
ACYCLOVIR, ACYCLOVIR
AMOXICILLIN, AMOXICILLIN
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
ATENOLOL, ATENOLOL
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
DIAZEPAM, DIAZEPAM
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
GLYBURIDE (MICRONIZED), GLYBURIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
MORPHINE SULFATE, MORPHINE SULFATE
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PROPYLTHIOURACIL, PROPYLTHIOURACIL
PYRAZINAMIDE, PYRAZINAMIDE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
VOSPIRE ER, ALBUTEROL SULFATE

**DAVIS AND GECK**
* DAVIS AND GECK DIV AMERICAN CYANAMID CO
PRE-OP II, HEXACHLOROPHENE
PRE-OP, HEXACHLOROPHENE

**DENTSPLY PHARM**
* DENTSPLY PHARMACEUTICAL INC
CITANEST FORTE DENTAL, EPINEPHRINE BITARTRATE
ORAQIX, LIDOCAINE

**DEPOMED INC**
* DEPOMED INC

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** D **

* DEPOMED INC
CAMBIA, DICLOFENAC POTASSIUM
GRALISE, GABAPENTIN
NUCYNTA ER, TAPENTADOL HYDROCHLORIDE
NUCYNTA, TAPENTADOL HYDROCHLORIDE
ZIPSOR, DICLOFENAC POTASSIUM

**DEPROCO**
* DEPROCO INC
LIGNOSPAN FORTE, EPINEPHRINE BITARTRATE
LIGNOSPAN STANDARD, EPINEPHRINE BITARTRATE
SCANDONEST L, LEVONORDEFRIN
SCANDONEST PLAIN, MEPIVACAINE HYDROCHLORIDE
SEPTOCAINE, ARTICAINE HYDROCHLORIDE

**DEVA HOLDING AS**
* DEVA HOLDING AS
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
TEMOZOLOMIDE, TEMOZOLOMIDE

**DEXCEL LTD**
* DEXCEL LTD
DICLOFENAC SODIUM, DICLOFENAC SODIUM
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE

**DEXCEL PHARMA**
* DEXCEL PHARMA TECHNOLOGIES LTD
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LEVETIRACETAM, LEVETIRACETAM
OMEPRAZOLE, OMEPRAZOLE (OTC)
PERIOCHIP, CHLORHEXIDINE GLUCONATE

**DFB ONCOLOGY LTD**
* DFB ONCOLOGY LTD
DOCETAXEL, DOCETAXEL

**DIAGNOSTIC GREEN**
* DIAGNOSTIC GREEN GMBH
INDOCYANINE GREEN, INDOCYANINE GREEN

**DIALYSIS SUPS**
* DIALYSIS SUPPLIES INC
NORMOCARB HF 25, MAGNESIUM CHLORIDE
NORMOCARB HF 35, MAGNESIUM CHLORIDE

**DIGESTIVE CARE INC**
* DIGESTIVE CARE INC
PERTZYE, PANCRELIPASE (AMYLASE

**DORC**
* DORC INTERNATIONAL BV
MEMBRANEBLUE, TRYPAN BLUE
VISIONBLUE, TRYPAN BLUE

**DOUGLAS PHARMS**
* DOUGLAS PHARMACEUTICALS AMERICA LTD
MYORISAN, ISOTRETINOIN

**DOW PHARM**
* DOW PHARMACEUTICAL SCIENCES
ACANYA, BENZOYL PEROXIDE
ATRALIN, TRETINOIN
JUBLIA, EFINACONAZOLE
ONEXTON, BENZOYL PEROXIDE
OXSORALEN-ULTRA, METHOXSALEN

**DR REDDYS LA**
* DR REDDYS LABORATORIES LOUISIANA LLC
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LOPURIN, ALLOPURINOL
SSD AF, SILVER SULFADIAZINE
SSD, SILVER SULFADIAZINE

**DR REDDYS LABS INC**
* DR REDDYS LABORATORIES INC

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** D ****

* DR REDDYS LABORATORIES INC
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMOXIL, AMOXICILLIN
AUGMENTIN '125', AMOXICILLIN
AUGMENTIN '250', AMOXICILLIN
AUGMENTIN '875', AMOXICILLIN
AUGMENTIN XR, AMOXICILLIN
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
FINASTERIDE, FINASTERIDE
FLUCONAZOLE, FLUCONAZOLE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LAROTID, AMOXICILLIN
LEVOFLOXACIN, LEVOFLOXACIN
MELOXICAM, MELOXICAM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NITROGLYCERIN, NITROGLYCERIN
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PROGESTERONE, PROGESTERONE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
SIMVASTATIN, SIMVASTATIN
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**DR REDDYS LABS INTL**

* DR REDDYS LABORATORIES INTERNATIONAL SA
RAMELTEON, RAMELTEON

**DR REDDYS LABS LTD**

* DR REDDYS LABORATORIES LIMITED
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE

* DR REDDYS LABORATORIES LTD
ALENDRONATE SODIUM, ALENDRONATE SODIUM
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ANASTROZOLE, ANASTROZOLE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AZACITIDINE, AZACITIDINE
BIVALIRUDIN, BIVALIRUDIN
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLOFARABINE, CLOFARABINE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DECITABINE, DECITABINE
DESLORATADINE AND PSEUDOEPHEDRINE SULFATE 24 HOUR, DESLORATADINE
DESLORATADINE, DESLORATADINE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOCETAXEL, DOCETAXEL
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** D ****

* DR REDDYS LABORATORIES LTD
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESZOPICLONE, ESZOPICLONE
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FINASTERIDE, FINASTERIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FONDAPARINUX SODIUM, FONDAPARINUX SODIUM
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLIMEPIRIDE, GLIMEPIRIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE, GUAIFENESIN (OTC)
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LAMOTRIGINE, LAMOTRIGINE
LANSOPRAZOLE, LANSOPRAZOLE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LATANOPROST, LATANOPROST
LETROZOLE, LETROZOLE
LEVETIRACETAM, LEVETIRACETAM
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MINOLIRA, MINOCYCLINE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
NAPROXEN SODIUM, NAPROXEN SODIUM
NATEGLINIDE, NATEGLINIDE
NIZATIDINE, NIZATIDINE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
OFLOXACIN, OFLOXACIN
OLANZAPINE, OLANZAPINE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
OMEPRAZOLE, OMEPRAZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXAPROZIN, OXAPROZIN
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PARICALCITOL, PARICALCITOL
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RAMIPRIL, RAMIPRIL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
RISPERIDONE, RISPERIDONE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SEVELAMER CARBONATE, SEVELAMER CARBONATE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SIROLIMUS, SIROLIMUS
TACROLIMUS, TACROLIMUS

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** D ****

* DR REDDYS LABORATORIES LTD
TETRABENAZINE, TETRABENAZINE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VINORELBINE TARTRATE, VINORELBINE TARTRATE
ZAFIRLUKAST, ZAFIRLUKAST
ZEMBRACE SYMTOUCH, SUMATRIPTAN SUCCINATE
ZENATANE, ISOTRETINOIN
ZOLEDRONIC ACID, ZOLEDRONIC ACID

**DR REDDYS LABS SA**

* DR REDDYS LABORATORIES SA
EZETIMIBE AND SIMVASTATIN, EZETIMIBE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
HABITROL, NICOTINE (OTC)
MERCAPTOPURINE, MERCAPTOPURINE

**DRAXIMAGE**

* DRAXIMAGE INC
DTPA, TECHNETIUM TC-99M PENTETATE KIT
TECHNETIUM TC 99M ALBUMIN AGGREGATED KIT, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

**DUCHESNAY**

* DUCHESNAY INC
BONJESTA, DOXYLAMINE SUCCINATE
DICLEGIS, DOXYLAMINE SUCCINATE
OSPHENA, OSPEMIFENE

**DURAMED PHARMS BARR**

* DURAMED PHARMACEUTICALS INC SUB BARR LABORATORIES INC
AVIANE-28, ETHINYL ESTRADIOL
CRYSELLE, ETHINYL ESTRADIOL
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
ENPRESSE-28, ETHINYL ESTRADIOL
METHYLPREDNISOLONE, METHYLPREDNISOLONE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VELIVET, DESOGESTREL

**DURAMED RES**

* DURAMED RESEARCH INC
AYGESTIN, NORETHINDRONE ACETATE

**DUSA**

* DUSA PHARMACEUTICALS INC
LEVULAN, AMINOLEVULINIC ACID HYDROCHLORIDE

**REDDYS**

* DOCTOR REDDYS LABORATORIES LTD
DESLORATADINE, DESLORATADINE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE

**** E ****

**EAGLE PHARMS**

* EAGLE PHARMACEUTICALS INC
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
BENDEKA, BENDAMUSTINE HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
RYANODEX, DANTROLENE SODIUM

**EASTMAN KODAK**

* EASTMAN KODAK CO
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE

**ECI PHARMS LLC**

* ECI PHARMACEUTICALS LLC
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
CALCIUM ACETATE, CALCIUM ACETATE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
LAMIVUDINE, LAMIVUDINE
LEVETIRACETAM, LEVETIRACETAM

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* ECI PHARMACEUTICALS LLC
METHIMAZOLE, METHIMAZOLE
PARICALCITOL, PARICALCITOL
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
VALPROIC ACID, VALPROIC ACID

**ECLAT PHARMS LLC**
* ECLAT PHARMACEUTICALS LLC
BLOXIVERZ, NEOSTIGMINE METHYLSULFATE

**ECOLAB**
* ECOLAB INC
CHG SCRUB, CHLORHEXIDINE GLUCONATE (OTC)
CIDA-STAT, CHLORHEXIDINE GLUCONATE (OTC)

**ECR**
* ECR PHARMACEUTICALS
DEXAMETHASONE, DEXAMETHASONE

**ECR PHARMA**
* ECR PHARMA
TUSSICAPS, CHLORPHENIRAMINE POLISTIREX

**EDENBRIDGE PHARMS**
* EDENBRIDGE PHARMACEUTICALS LLC
CARBIDOPA, CARBIDOPA
ETHACRYNIC ACID, ETHACRYNIC ACID
IVERMECTIN, IVERMECTIN
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
TINIDAZOLE, TINIDAZOLE

**EDISON THERAPS LLC**
* EDISON THERAPEUTICS LLC
METHERGINE, METHYLERGONOVINE MALEATE

**EGALET**
* EGALET CORP
ARYMO ER, MORPHINE SULFATE

**EGALET US INC**
* EGALET US INC
OXAYDO, OXYCODONE HYDROCHLORIDE
SPRIX, KETOROLAC TROMETHAMINE

**EI INC**
* EI INC
THEROXIDIL, MINOXIDIL (OTC)

**EISAI INC**
* EISAI INC
ACIPHEX, RABEPRAZOLE SODIUM
ARICEPT ODT, DONEPEZIL HYDROCHLORIDE
ARICEPT, DONEPEZIL HYDROCHLORIDE
BANZEL, RUFINAMIDE
BELVIQ XR, LORCASERIN HYDROCHLORIDE
BELVIQ, LORCASERIN HYDROCHLORIDE
FYCOMPA, PERAMPANEL
HALAVEN, ERIBULIN MESYLATE
HEXALEN, ALTRETAMINE
LENVIMA, LENVATINIB MESYLATE
PANRETIN, ALITRETINOIN
SALAGEN, PILOCARPINE HYDROCHLORIDE

**ELEFSEE PHARMS INTL**
* ELEFSEE PHARMACEUTICALS INTERNATIONAL LTD
LAZANDA, FENTANYL CITRATE

**ELI LILLY AND CO**
* ELI LILLY AND CO
BASAGLAR, INSULIN GLARGINE
EFFIENT, PRASUGREL HYDROCHLORIDE
HUMALOG KWIKPEN, INSULIN LISPRO RECOMBINANT
PROZAC, FLUOXETINE HYDROCHLORIDE
VERZENIO, ABEMACICLIB

**ELI LILLY CO**

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* ELI LILLY CO
ADCIRCA, TADALAFIL
ZYPREXA RELPREVV, OLANZAPINE PAMOATE

**ELITE LABS**

* ELITE LABORATORIES INC
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

**ELITE LABS INC**

* ELITE LABORATORIES INC
DANTROLENE SODIUM, DANTROLENE SODIUM
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
ISRADIPINE, ISRADIPINE
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
TRIMIPRAMINE MALEATE, TRIMIPRAMINE MALEATE

**EMCURE PHARMS**

* EMCURE PHARMACEUTICALS LTD
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE

**EMCURE PHARMS INDIA**

* EMCURE PHARMACEUTICALS LTD INDIA
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM

**EMCURE PHARMS LTD**

* EMCURE PHARMACEUTICALS LTD
ACARBOSE, ACARBOSE
ACETAZOLAMIDE SODIUM , ACETAZOLAMIDE SODIUM
ADENOSINE, ADENOSINE
AMIKACIN SULFATE, AMIKACIN SULFATE
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BICNU, CARMUSTINE
CIDOFOVIR, CIDOFOVIR
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
ETOMIDATE, ETOMIDATE
FUROSEMIDE, FUROSEMIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
RIFAMPIN, RIFAMPIN
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
TRANEXAMIC ACID, TRANEXAMIC ACID
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

**EMD SERONO**

* EMD SERONO INC
GONAL-F RFF REDI-JECT, FOLLITROPIN ALFA/BETA
GONAL-F RFF, FOLLITROPIN ALFA/BETA
GONAL-F, FOLLITROPIN ALFA/BETA
OVIDREL, CHORIOGONADOTROPIN ALFA
SAIZEN, SOMATROPIN RECOMBINANT
SEROSTIM, SOMATROPIN RECOMBINANT
ZORBTIVE, SOMATROPIN RECOMBINANT

**EMD SERONO INC**

* EMD SERONO INC
CETROTIDE, CETRORELIX

**EMERALD INTL LTD**

* EMERALD INTERNATIONAL LTD
BACLOFEN, BACLOFEN

**EMMAUS MEDCL**

* EMMAUS MEDICAL INC
ENDARI, L-GLUTAMINE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* EMMAUS MEDICAL INC
NUTRESTORE, L-GLUTAMINE

**ENDO PHARM**

* ENDO PHARMACEUTICAL SOLUTIONS INC
SUPPRELIN LA, HISTRELIN ACETATE
VALSTAR PRESERVATIVE FREE, VALRUBICIN
VANTAS, HISTRELIN ACETATE

**ENDO PHARMS**

* ENDO PHARMACEUTICALS INC
DELATESTRYL, TESTOSTERONE ENANTHATE
FORTESTA, TESTOSTERONE
FROVA, FROVATRIPTAN SUCCINATE
OPANA, OXYMORPHONE HYDROCHLORIDE
PERCODAN, ASPIRIN

**ENDO PHARMS INC**

* ENDO PHARMACEUTICALS INC
AVEED, TESTOSTERONE UNDECANOATE
COLY-MYCIN S, COLISTIN SULFATE
MEGACE ES, MEGESTROL ACETATE
NASCOBAL, CYANOCOBALAMIN
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE

**ENDO VENTURES LTD**

* ENDO VENTURES LTD IRELAND
SUMAVEL DOSEPRO, SUMATRIPTAN SUCCINATE

**EPI HLTH**

* EPI HEALTH LLC
SITAVIG, ACYCLOVIR

**EPIC PHARMA**

* EPIC PHARMA INC
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE

* EPIC PHARMA LLC
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
SULINDAC, SULINDAC
TRANDOLAPRIL, TRANDOLAPRIL
URSODIOL, URSODIOL

**EPIC PHARMA INC**

* EPIC PHARMA INC
ESTRADIOL, ESTRADIOL
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE

**EPIC PHARMA LLC**

* EPIC PHARMA LLC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
DEMECLOCYCLINE HYDROCHLORIDE, DEMECLOCYCLINE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
GABAPENTIN, GABAPENTIN
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLYBURIDE, GLYBURIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
MOLINDONE HYDROCHLORIDE, MOLINDONE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PHENYTOIN, PHENYTOIN
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
SULINDAC, SULINDAC
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** E **

**ESSENTIAL ISOTOPES**
* ESSENTIAL ISOTOPES LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**ETHYPHARM**
* ETHYPHARM
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE

**ETHYPHARM USA CORP**
* ETHYPHARM USA CORP
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE

**EUROHLTH INTL SARL**
* EUROHEALTH INTERNATIONAL SARL
DROPERIDOL, DROPERIDOL
MORPHINE SULFATE, MORPHINE SULFATE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE

**EXALENZ BIOSCIENCE**
* EXALENZ BIOSCIENCE LTD
IDKIT:HP, CITRIC ACID

**EXELA HOLDINGS**
* EXELA HOLDINGS INC
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM

**EXELA PHARMA SCIENCE**
* EXELA PHARMA SCIENCES
CAFFEINE CITRATE, CAFFEINE CITRATE
IBUPROFEN LYSINE, IBUPROFEN LYSINE
NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE, NICARDIPINE HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE

**EXELA PHARMA SCS LLC**
* EXELA PHARMA SCIENCES LLC
CAFFEINE CITRATE, CAFFEINE CITRATE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
GANCICLOVIR, GANCICLOVIR
MAGNESIUM SULFATE, MAGNESIUM SULFATE
NIPRIDE RTU IN SODIUM CHLORIDE 0.9%, SODIUM NITROPRUSSIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
POTASSIUM ACETATE, POTASSIUM ACETATE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

**EXELIXIS**
* EXELIXIS INC
COMETRIQ, CABOZANTINIB S-MALATE

**EXELIXIS INC**
* EXELIXIS INC
CABOMETYX, CABOZANTINIB S-MALATE

**EXELTIS USA INC**
* EXELTIS USA INC
ESTRASORB, ESTRADIOL HEMIHYDRATE

**EYEVANCE PHARMS**
* EYEVANCE PHARMACEUTICALS LLC
ZERVIATE, CETIRIZINE HYDROCHLORIDE

**LILLY**
* ELI LILLY AND CO
ALIMTA, PEMETREXED DISODIUM
CIALIS, TADALAFIL
CYMBALTA, DULOXETINE HYDROCHLORIDE
EVISTA, RALOXIFENE HYDROCHLORIDE
FORTEO, TERIPARATIDE RECOMBINANT HUMAN
GEMZAR, GEMCITABINE HYDROCHLORIDE
GLUCAGON, GLUCAGON RECOMBINANT
HUMALOG KWIKPEN, INSULIN LISPRO RECOMBINANT
HUMALOG MIX 50/50 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 50/50, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG MIX 75/25 KWIKPEN, INSULIN LISPRO PROTAMINE RECOMBINANT

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** E ****

* ELI LILLY AND CO
HUMALOG MIX 75/25, INSULIN LISPRO PROTAMINE RECOMBINANT
HUMALOG, INSULIN LISPRO RECOMBINANT
HUMATROPE, SOMATROPIN RECOMBINANT
HUMULIN 70/30 PEN, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
HUMULIN R KWIKPEN, INSULIN HUMAN
HUMULIN R PEN, INSULIN RECOMBINANT HUMAN (OTC)
HUMULIN R, INSULIN HUMAN
HUMULIN R, INSULIN RECOMBINANT HUMAN (OTC)
PROZAC WEEKLY, FLUOXETINE HYDROCHLORIDE
STRATTERA, ATOMOXETINE HYDROCHLORIDE
SYMBYAX, FLUOXETINE HYDROCHLORIDE
ZYPREXA ZYDIS, OLANZAPINE
ZYPREXA, OLANZAPINE

**** F ****

**FDC LTD**
* FDC LTD
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
LATANOPROST, LATANOPROST
OFLOXACIN, OFLOXACIN
TIMOLOL MALEATE, TIMOLOL MALEATE

**FDN CONSUMER**
* FOUNDATION CONSUMER HEALTHCARE LLC
LEVONORGESTREL, LEVONORGESTREL (OTC)
PLAN B ONE-STEP, LEVONORGESTREL (OTC)

**FEINSTEIN**
* FEINSTEIN INSTITUTE MEDICAL RESEARCH
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**FERA PHARMS**
* FERA PHARMACEUTICALS LLC
TOBRAMYCIN, TOBRAMYCIN

**FERA PHARMS LLC**
* FERA PHARMACEUTICALS LLC
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM

**FERRER INTERNACIONAL**
* FERRER INTERNACIONAL SA
XEPI, OZENOXACIN

**FERRING**
* FERRING PHARMACEUTICALS INC
ACTHREL, CORTICORELIN OVINE TRIFLUTATE
BRAVELLE, UROFOLLITROPIN
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
ENDOMETRIN, PROGESTERONE
FIRMAGON, DEGARELIX ACETATE
MENOPUR, MENOTROPINS (FSH
MINIRIN, DESMOPRESSIN ACETATE
ZOMACTON, SOMATROPIN RECOMBINANT

**FERRING PHARMS INC**
* FERRING PHARMACEUTICALS INC
CERVIDIL, DINOPROSTONE
CLENPIQ, CITRIC ACID
DDAVP (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DDAVP, DESMOPRESSIN ACETATE
LYSTEDA, TRANEXAMIC ACID
PREPOPIK, CITRIC ACID
STIMATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE

**FLAMEL IRELAND LTD**
* FLAMEL IRELAND LIMITED
AKOVAZ, EPHEDRINE SULFATE

**FLAMINGO PHARMS**

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** F ****

* FLAMINGO PHARMACEUTICALS LTD
METRONIDAZOLE, METRONIDAZOLE
PIROXICAM, PIROXICAM

**FLEXION THERAPS INC**

* FLEXION THERAPEUTICS INC
ZILRETTA, TRIAMCINOLONE ACETONIDE

**FOREST LABS**

* FOREST LABORATORIES INC
BYSTOLIC, NEBIVOLOL HYDROCHLORIDE
CELEXA, CITALOPRAM HYDROBROMIDE
LEXAPRO, ESCITALOPRAM OXALATE
THYROLAR-0.25, LIOTRIX (T4
THYROLAR-0.5, LIOTRIX (T4
THYROLAR-1, LIOTRIX (T4
THYROLAR-2, LIOTRIX (T4
THYROLAR-3, LIOTRIX (T4

**FOREST LABS INC**

* FOREST LABORATORIES INC
BENTYL PRESERVATIVE FREE, DICYCLOMINE HYDROCHLORIDE
BENTYL, DICYCLOMINE HYDROCHLORIDE
CARAFATE, SUCRALFATE
FETZIMA, LEVOMILNACIPRAN HYDROCHLORIDE
RECTIV, NITROGLYCERIN
ULTRESA, PANCRELIPASE (AMYLASE
URSO 250, URSODIOL
URSO FORTE, URSODIOL
VIOKACE, PANCRELIPASE (AMYLASE
ZENPEP, PANCRELIPASE (AMYLASE

**FOREST LABS LLC**

* FOREST LABORATORIES LLC
BYVALSON, NEBIVOLOL HYDROCHLORIDE
CANASA, MESALAMINE
LINZESS, LINACLOTIDE
NAMENDA XR, MEMANTINE HYDROCHLORIDE
NAMENDA, MEMANTINE HYDROCHLORIDE
NAMZARIC, DONEPEZIL HYDROCHLORIDE
PYLERA, BISMUTH SUBCITRATE POTASSIUM
SAPHRIS, ASENAPINE MALEATE
VIIBRYD, VILAZODONE HYDROCHLORIDE

**FOREST RES INST INC**

* FOREST RESEARCH INSTITUTE INC
VRAYLAR, CARIPRAZINE HYDROCHLORIDE

**FOUGERA PHARMS**

* FOUGERA PHARMACEUTICALS INC
ADAPALENE, ADAPALENE
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
AMCINONIDE, AMCINONIDE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE, CALCIPOTRIENE
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
CUTIVATE, FLUTICASONE PROPIONATE
DESONIDE, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** F **

* FOUGERA PHARMACEUTICALS INC
HYDROCORTISONE, HYDROCORTISONE
IMIQUIMOD, IMIQUIMOD
KETOCONAZOLE, KETOCONAZOLE
LIDOCAINE AND PRILOCAINE, LIDOCAINE
METRONIDAZOLE, METRONIDAZOLE
MOMETASONE FUROATE, MOMETASONE FUROATE
MUPIROCIN, MUPIROCIN
NYSTATIN, NYSTATIN
OXISTAT, OXICONAZOLE NITRATE
PANDEL, HYDROCORTISONE PROBUTATE
PREDNICARBATE, PREDNICARBATE
SOLARAZE, DICLOFENAC SODIUM
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TERCONAZOLE, TERCONAZOLE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TYZINE, TETRAHYDROZOLINE HYDROCHLORIDE

**FOUGERA PHARMS INC**

* FOUGERA PHARMACEUTICALS INC
ACYCLOVIR, ACYCLOVIR
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDROCORTISONE, HYDROCORTISONE
LIDOCAINE, LIDOCAINE
NITROGLYCERIN, NITROGLYCERIN
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
TACROLIMUS, TACROLIMUS

**FRESENIUS**

* FRESENIUS KABI DEUTSCHLAND GMBH
INTRALIPID 10%, SOYBEAN OIL
INTRALIPID 20%, SOYBEAN OIL
INTRALIPID 30%, SOYBEAN OIL

**FRESENIUS KABI**

* FRESENIUS KABI AUSTRIA GMBH
LACTULOSE, LACTULOSE

**FRESENIUS KABI ONCOL**

* FRESENIUS KABI ONCOLOGY PLC
ANASTROZOLE, ANASTROZOLE
BICALUTAMIDE, BICALUTAMIDE
CARBOPLATIN, CARBOPLATIN
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LETROZOLE, LETROZOLE
OXALIPLATIN, OXALIPLATIN
PACLITAXEL, PACLITAXEL

**FRESENIUS KABI USA**

* FRESENIUS KABI USA LLC
ACETAMINOPHEN, ACETAMINOPHEN
ACETYLCYSTEINE, ACETYLCYSTEINE
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ADENOSINE, ADENOSINE
AMIKACIN SULFATE, AMIKACIN SULFATE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ARGATROBAN, ARGATROBAN
ASTRAMORPH PF, MORPHINE SULFATE
AZITHROMYCIN, AZITHROMYCIN
AZTREONAM, AZTREONAM
BACITRACIN, BACITRACIN

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** F ****

* FRESENIUS KABI USA LLC
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BIVALIRUDIN, BIVALIRUDIN
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BORTEZOMIB, BORTEZOMIB
CAFFEINE CITRATE, CAFFEINE CITRATE
CALCIUM GLUCONATE, CALCIUM GLUCONATE
CARBOPLATIN, CARBOPLATIN
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
CEFOTETAN, CEFOTETAN DISODIUM
CHLORAMPHENICOL SODIUM SUCCINATE, CHLORAMPHENICOL SODIUM SUCCINATE
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CHORIONIC GONADOTROPIN, GONADOTROPIN, CHORIONIC
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CISPLATIN, CISPLATIN
CLADRIBINE, CLADRIBINE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DILAUDID, HYDROMORPHONE HYDROCHLORIDE
DILAUDID-HP, HYDROMORPHONE HYDROCHLORIDE
DIMENHYDRINATE, DIMENHYDRINATE
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPRIVAN, PROPOFOL
DIPYRIDAMOLE, DIPYRIDAMOLE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DOXY 100, DOXYCYCLINE HYCLATE
DOXY 200, DOXYCYCLINE HYCLATE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ETOPOSIDE, ETOPOSIDE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FLOXURIDINE, FLOXURIDINE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUMAZENIL, FLUMAZENIL
FLUOROURACIL, FLUOROURACIL
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
FOSAPREPITANT DIMEGLUMINE, FOSAPREPITANT DIMEGLUMINE
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FUROSEMIDE, FUROSEMIDE
GANCICLOVIR, GANCICLOVIR SODIUM
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GLUCAGON, GLUCAGON HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE, GRANISETRON HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN SODIUM IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** F ****

* FRESENIUS KABI USA LLC
HEPARIN SODIUM, HEPARIN SODIUM
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
IFOSFAMIDE, IFOSFAMIDE
INDOMETHACIN, INDOMETHACIN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
KABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
KANAMYCIN SULFATE, KANAMYCIN SULFATE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LINEZOLID, LINEZOLID
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MANNITOL 25%, MANNITOL
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MESNA, MESNA
METARAMINOL BITARTRATE, METARAMINOL BITARTRATE
METHOTREXATE PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NAROPIN, ROPIVACAINE HYDROCHLORIDE
NEBUPENT, PENTAMIDINE ISETHIONATE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
NESACAINE, CHLOROPROCAINE HYDROCHLORIDE
NESACAINE-MPF, CHLOROPROCAINE HYDROCHLORIDE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
OXYTOCIN, OXYTOCIN
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PENTAM, PENTAMIDINE ISETHIONATE
PERIKABIVEN IN PLASTIC CONTAINER, AMINO ACIDS
POLOCAINE, MEPIVACAINE HYDROCHLORIDE
POLOCAINE-MPF, MEPIVACAINE HYDROCHLORIDE
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
POTASSIUM CHLORIDE IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROGESTERONE, PROGESTERONE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROTAMINE SULFATE, PROTAMINE SULFATE
PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE
RIFAMPIN, RIFAMPIN
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE
SENSORCAINE, BUPIVACAINE HYDROCHLORIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** F ****

* FRESENIUS KABI USA LLC
SMOFLIPID 20%, FISH OIL
SODIUM ACETATE, SODIUM ACETATE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
TIGECYCLINE, TIGECYCLINE
TOBRAMYCIN SULFATE (PHARMACY BULK), TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
VALPROATE SODIUM, VALPROATE SODIUM
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VIBISONE, CYANOCOBALAMIN
VINBLASTINE SULFATE, VINBLASTINE SULFATE
VINORELBINE TARTRATE, VINORELBINE TARTRATE
XYLOCAINE 4% PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
XYLOCAINE W/ EPINEPHRINE, EPINEPHRINE
XYLOCAINE, LIDOCAINE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

**FRESENIUS MEDCL**

* FRESENIUS MEDICAL CARE NORTH AMERICA
DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 1.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER, CALCIUM
PHOSLO GELCAPS, CALCIUM ACETATE
PHOSLYRA, CALCIUM ACETATE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

**FRONTIDA BIOPHARM**

* FRONTIDA BIOPHARM INC
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE

**** G ****

**G AND W LABS**

* G AND W LABORATORIES INC
ACEPHEN, ACETAMINOPHEN (OTC)
CICLOPIROX, CICLOPIROX
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
INDOMETHACIN, INDOMETHACIN
METRONIDAZOLE, METRONIDAZOLE
MICONAZOLE 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MOMETASONE FUROATE, MOMETASONE FUROATE
PROCHLORPERAZINE, PROCHLORPERAZINE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROMETHEGAN, PROMETHAZINE HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

**G AND W LABS INC**

* G AND W LABORATORIES INC
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
BETA-VAL, BETAMETHASONE VALERATE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* G AND W LABORATORIES INC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE, CALCIPOTRIENE
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CICLOPIROX, CICLOPIROX
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DESONIDE, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DOXYCYCLINE, DOXYCYCLINE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
IMIQUIMOD, IMIQUIMOD
MESALAMINE, MESALAMINE
METRONIDAZOLE, METRONIDAZOLE
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MYKACET, NYSTATIN
NYSTATIN, NYSTATIN
PROMETH VC PLAIN, PHENYLEPHRINE HYDROCHLORIDE
PROMETH W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
QUINIDINE SULFATE, QUINIDINE SULFATE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
TAZAROTENE, TAZAROTENE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

**GALDERMA LABS**

* GALDERMA LABORATORIES INC
CLOBEX, CLOBETASOL PROPIONATE
EPIDUO FORTE, ADAPALENE

**GALDERMA LABS LP**

* GALDERMA LABORATORIES L P
CLOBEX, CLOBETASOL PROPIONATE
* GALDERMA LABORATORIES LP
CAPEX, FLUOCINOLONE ACETONIDE
CLOBEX, CLOBETASOL PROPIONATE
DESOWEN, DESONIDE
DIFFERIN, ADAPALENE
DIFFERIN, ADAPALENE (OTC)
EPIDUO, ADAPALENE
METROCREAM, METRONIDAZOLE
METROGEL, METRONIDAZOLE
METROLOTION, METRONIDAZOLE
MIRVASO, BRIMONIDINE TARTRATE
ORACEA, DOXYCYCLINE
SOOLANTRA, IVERMECTIN
TRI-LUMA, FLUOCINOLONE ACETONIDE
VECTICAL, CALCITRIOL

**GALEN SPECIALTY**

* GALEN SPECIALTY PHARMA US LLC
SYNERA, LIDOCAINE

**GALEN UK**

* GALEN LTD
ADASUVE, LOXAPINE

**GASTROENTERO**

* GASTROENTERO LOGIC LLC
OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN, AMOXICILLIN

**GATE PHARMS**

* GATE PHARMACEUTICALS
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
LINEZOLID, LINEZOLID

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

**GATOR PHARMS**
* GATOR PHARMACEUTICALS INC
COLPREP KIT, MAGNESIUM SULFATE

**GAVIS PHARMS**
* GAVIS PHARMACEUTICALS LLC
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NYSTATIN, NYSTATIN
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
QUINARETIC, HYDROCHLOROTHIAZIDE
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE

**GAVIS PHARMS LLC**
* GAVIS PHARMACEUTICALS LLC
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE

**GD SEARLE**
* GD SEARLE LLC
CELEBREX, CELECOXIB
DAYPRO, OXAPROZIN

**GD SEARLE LLC**
* GD SEARLE LLC
ALDACTAZIDE, HYDROCHLOROTHIAZIDE
ALDACTONE, SPIRONOLACTONE
ARTHROTEC, DICLOFENAC SODIUM
CALAN, VERAPAMIL HYDROCHLORIDE
CYTOTEC, MISOPROSTOL
FLAGYL ER, METRONIDAZOLE
FLAGYL, METRONIDAZOLE
INSPRA, EPLERENONE
LOMOTIL, ATROPINE SULFATE
NORPACE CR, DISOPYRAMIDE PHOSPHATE
NORPACE, DISOPYRAMIDE PHOSPHATE
SYNAREL, NAFARELIN ACETATE

**GE HEALTHCARE**
* GE HEALTHCARE
ADREVIEW, IOBENGUANE SULFATE I-123
CERETEC, TECHNETIUM TC-99M EXAMETAZIME KIT
INDICLOR, INDIUM IN-111 CHLORIDE
INDIUM IN 111 OXYQUINOLINE, INDIUM IN-111 OXYQUINOLINE
METASTRON, STRONTIUM CHLORIDE SR-89
MPI INDIUM DTPA IN 111, INDIUM IN-111 PENTETATE DISODIUM
MYOVIEW 30ML, TECHNETIUM TC-99M TETROFOSMIN KIT
OMNIPAQUE 140, IOHEXOL
OMNIPAQUE 180, IOHEXOL
OMNIPAQUE 240, IOHEXOL
OMNIPAQUE 300, IOHEXOL
OMNIPAQUE 350, IOHEXOL
OMNISCAN, GADODIAMIDE
OPTISON, ALBUMIN HUMAN
TECHNETIUM TC 99M GENERATOR, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
VISIPAQUE 270, IODIXANOL
VISIPAQUE 320, IODIXANOL
VIZAMYL, FLUTEMETAMOL F-18

**GE HLTHCARE INC**
* GE HEALTHCARE INC
DATSCAN, IOFLUPANE I-123

**GEDEON RICHTER USA**
* GEDEON RICHTER USA INC
FINASTERIDE, FINASTERIDE

**GEMINI LABS LLC**
* GEMINI LABORATORIES LLC
OXANDRIN, OXANDROLONE
PRANDIN, REPAGLINIDE

**GENENTECH**
* GENENTECH INC

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GENENTECH INC
ERIVEDGE, VISMODEGIB
NUTROPIN AQ NUSPIN, SOMATROPIN RECOMBINANT
NUTROPIN AQ PEN, SOMATROPIN RECOMBINANT

**GENENTECH INC**

* GENENTECH INC
COTELLIC, COBIMETINIB FUMARATE
ESBRIET, PIRFENIDONE

**GENUS LIFESCIENCES**

* GENUS LIFE SCIENCES INC
GOPRELTO, COCAINE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

**GENZYME**

* GENZYME CORP
CEREZYME, IMIGLUCERASE
CLOLAR, CLOFARABINE
MOZOBIL, PLERIXAFOR
RENAGEL, SEVELAMER HYDROCHLORIDE
RENVELA, SEVELAMER CARBONATE
THYROGEN, THYROTROPIN ALFA

**GENZYME CORP**

* GENZYME CORP
CAPRELSA, VANDETANIB
CERDELGA, ELIGLUSTAT TARTRATE
HECTOROL, DOXERCALCIFEROL

**GILEAD**

* GILEAD SCIENCES INC
ATRIPLA, EFAVIRENZ
CAYSTON, AZTREONAM
EMTRIVA, EMTRICITABINE
HEPSERA, ADEFOVIR DIPIVOXIL
LETAIRIS, AMBRISENTAN
RANEXA, RANOLAZINE
TRUVADA, EMTRICITABINE

**GILEAD SCIENCES INC**

* GILEAD SCIENCES INC
COMPLERA, EMTRICITABINE
DESCOVY, EMTRICITABINE
EPCLUSA, SOFOSBUVIR
GENVOYA, COBICISTAT
HARVONI, LEDIPASVIR
ODEFSEY, EMTRICITABINE
SOVALDI, SOFOSBUVIR
STRIBILD, COBICISTAT
TYBOST, COBICISTAT
VEMLIDY, TENOFOVIR ALAFENAMIDE FUMARATE
VIREAD, TENOFOVIR DISOPROXIL FUMARATE
VOSEVI, SOFOSBUVIR
ZYDELIG, IDELALISIB

**GLAND PHARMA LTD**

* GLAND PHARMA LTD
ADENOSINE, ADENOSINE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
AZITHROMYCIN, AZITHROMYCIN
CARBOPLATIN, CARBOPLATIN
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
CISPLATIN, CISPLATIN
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
ETOMIDATE, ETOMIDATE
FLUOROURACIL, FLUOROURACIL
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GLAND PHARMA LTD
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN SODIUM, HEPARIN SODIUM
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM
MEROPENEM, MEROPENEM
MESNA, MESNA
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE, MILRINONE LACTATE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
PACITAXEL, PACLITAXEL
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TRANEXAMIC ACID, TRANEXAMIC ACID
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

**GLASSHOUSE PHARMS**

* GLASSHOUSE PHARMACEUTICALS LTD CANADA
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE

**GLAXO GRP ENGLAND**

* GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE
INCRUSE ELLIPTA , UMECLIDINIUM BROMIDE

**GLAXO GRP LTD**

* GLAXO GROUP LTD DBA GLAXOSMITHKLINE
FLOVENT HFA, FLUTICASONE PROPIONATE
* GLAXO GROUP LTD ENGLAND DBA GLAXOSMITHKLINE
ADVAIR DISKUS 100/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 250/50, FLUTICASONE PROPIONATE
ADVAIR DISKUS 500/50, FLUTICASONE PROPIONATE
ADVAIR HFA, FLUTICASONE PROPIONATE
BREO ELLIPTA, FLUTICASONE FUROATE
FLOVENT DISKUS 100, FLUTICASONE PROPIONATE
FLOVENT DISKUS 250, FLUTICASONE PROPIONATE
FLOVENT DISKUS 50, FLUTICASONE PROPIONATE
ZANTAC 150, RANITIDINE HYDROCHLORIDE
ZANTAC 300, RANITIDINE HYDROCHLORIDE
ZANTAC, RANITIDINE HYDROCHLORIDE

**GLAXOSMITHKLINE**

* GLAXOSMITHKLINE
ABREVA, DOCOSANOL (OTC)
AVODART, DUTASTERIDE
BACTROBAN, MUPIROCIN CALCIUM
BECONASE AQ, BECLOMETHASONE DIPROPIONATE MONOHYDRATE
CEFTIN, CEFUROXIME AXETIL
EPIVIR-HBV, LAMIVUDINE
IMITREX STATDOSE, SUMATRIPTAN SUCCINATE
IMITREX, SUMATRIPTAN
IMITREX, SUMATRIPTAN SUCCINATE
JALYN, DUTASTERIDE
MALARONE PEDIATRIC, ATOVAQUONE
MALARONE, ATOVAQUONE
NICORETTE (MINT), NICOTINE POLACRILEX (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
RELENZA, ZANAMIVIR
VALTREX, VALACYCLOVIR HYDROCHLORIDE
WELLBUTRIN SR, BUPROPION HYDROCHLORIDE
ZYBAN, BUPROPION HYDROCHLORIDE
* GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC
LAMISIL, TERBINAFINE HYDROCHLORIDE (OTC)
* GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND
ANORO ELLIPTA, UMECLIDINIUM BROMIDE
ARNUITY ELLIPTA, FLUTICASONE FUROATE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LTD ENGLAND
TRELEGY ELLIPTA, FLUTICASONE FUROATE
* GLAXOSMITHKLINE INTELLECTUAL PROPERTY LTD ENGLAND
SEREVENT, SALMETEROL XINAFOATE
VENTOLIN HFA, ALBUTEROL SULFATE

**GLAXOSMITHKLINE CON**

* GLAXOSMITHKLINE CONSUMER HEALTH
TRANSDERM SCOP, SCOPOLAMINE

**GLAXOSMITHKLINE CONS**

* GLAXOSMITHKLINE CONSUMER HEALTHCARE
ALLI, ORLISTAT (OTC)
COMMIT, NICOTINE POLACRILEX (OTC)
EXCEDRIN (MIGRAINE), ACETAMINOPHEN (OTC)
FLONASE ALLERGY RELIEF, FLUTICASONE PROPIONATE (OTC)
FLONASE SENSIMIST ALLERGY RELIEF, FLUTICASONE FUROATE (OTC)
NICORETTE, NICOTINE POLACRILEX (OTC)
PREVACID 24 HR, LANSOPRAZOLE (OTC)
TAVIST-1, CLEMASTINE FUMARATE (OTC)
VOLTAREN, DICLOFENAC SODIUM

**GLAXOSMITHKLINE LLC**

* GLAXOSMITHKLINE LLC
AMERGE, NARATRIPTAN HYDROCHLORIDE
DYAZIDE, HYDROCHLOROTHIAZIDE
FLOLAN, EPOPROSTENOL SODIUM
LAMICTAL CD, LAMOTRIGINE
LAMICTAL ODT, LAMOTRIGINE
LAMICTAL XR, LAMOTRIGINE
LAMICTAL, LAMOTRIGINE
MEPRON, ATOVAQUONE
REQUIP XL, ROPINIROLE HYDROCHLORIDE
REQUIP, ROPINIROLE HYDROCHLORIDE
RYTHMOL SR, PROPAFENONE HYDROCHLORIDE
RYTHMOL, PROPAFENONE HYDROCHLORIDE

**GLENMARK GENERICS**

* GLENMARK GENERICS INC USA
ADAPALENE, ADAPALENE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
IMIQUIMOD, IMIQUIMOD
MOMETASONE FUROATE, MOMETASONE FUROATE
NIZATIDINE, NIZATIDINE
ZONISAMIDE, ZONISAMIDE
* GLENMARK GENERICS LIMITED
BRIELLYN, ETHINYL ESTRADIOL
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
* GLENMARK GENERICS LTD
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
ALYACEN 1/35, ETHINYL ESTRADIOL
ALYACEN 7/7/7, ETHINYL ESTRADIOL
ASHLYNA, ETHINYL ESTRADIOL
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
CARVEDILOL, CARVEDILOL
CICLOPIROX, CICLOPIROX
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DESOXIMETASONE, DESOXIMETASONE
ESZOPICLONE, ESZOPICLONE
FELODIPINE, FELODIPINE
FLUCONAZOLE, FLUCONAZOLE
FLUOCINONIDE, FLUOCINONIDE
HEATHER, NORETHINDRONE
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
LAMOTRIGINE, LAMOTRIGINE
LEVOFLOXACIN, LEVOFLOXACIN
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GLENMARK GENERICS LTD
LITHIUM CARBONATE, LITHIUM CARBONATE
MARLISSA, ETHINYL ESTRADIOL
MELOXICAM, MELOXICAM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MOMETASONE FUROATE, MOMETASONE FUROATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NAPROXEN, NAPROXEN
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE, NORETHINDRONE
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
OMEPRAZOLE, OMEPRAZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE
TOPIRAMATE, TOPIRAMATE
TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE, TRANDOLAPRIL
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
URSODIOL, URSODIOL
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VIORELE, DESOGESTREL
ZOLMITRIPTAN, ZOLMITRIPTAN

* GLENMARK GENERICS LTD INDIA
INDOMETHACIN, INDOMETHACIN
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE

**GLENMARK PHARMS**

* GLENMARK PHARMACEUTICALS INC USA
CICLOPIROX, CICLOPIROX
CLOTRIMAZOLE, CLOTRIMAZOLE
MUPIROCIN, MUPIROCIN

* GLENMARK PHARMACEUTICALS LTD
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

* GLENMARK PHARMACEUTICALS SA
CALCIPOTRIENE, CALCIPOTRIENE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
DESONIDE, DESONIDE
LINEZOLID, LINEZOLID
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

**GLENMARK PHARMS INC**

* GLENMARK PHARMACEUTICALS INC USA
CALCIPOTRIENE, CALCIPOTRIENE
LITHIUM CARBONATE, LITHIUM CARBONATE
MUPIROCIN, MUPIROCIN CALCIUM
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

**GLENMARK PHARMS LTD**

* GLENMARK PHARMACEUTICALS LTD
ACYCLOVIR, ACYCLOVIR
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
APREPITANT, APREPITANT
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DESONIDE, DESONIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** G ****

* GLENMARK PHARMACEUTICALS LTD
EZETIMIBE, EZETIMIBE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
GABAPENTIN, GABAPENTIN
HAILEY FE 1/20, ETHINYL ESTRADIOL
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
LAMOTRIGINE, LAMOTRIGINE
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL (OTC)
LIDOCAINE, LIDOCAINE
NAPROXEN SODIUM, NAPROXEN SODIUM
NITROGLYCERIN, NITROGLYCERIN
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OXCARBAZEPINE, OXCARBAZEPINE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RILUZOLE, RILUZOLE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
RUFINAMIDE, RUFINAMIDE
TELMISARTAN, TELMISARTAN
TRETINOIN, TRETINOIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VORICONAZOLE, VORICONAZOLE

**GLOBAL ISOTOPES LLC**
* GLOBAL ISOTOPES LLC DBA ZEVACOR MOLECULAR
AMMONIA N 13, AMMONIA N-13
CHOLINE C-11, CHOLINE C-11
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**GRANULES INDIA**
* GRANULES INDIA LTD
IBUPROFEN, IBUPROFEN (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

**GRANULES INDIA LTD**
* GRANULES INDIA LTD
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)

**GUARDIAN PHARMS**
* GUARDIAN PHARMACEUTICALS
GUAIFENESIN, GUAIFENESIN (OTC)

**GUERBET**
* GUERBET LLC
DOTAREM, GADOTERATE MEGLUMINE
LIPIODOL, ETHIODIZED OIL

**HANFORD GC**
* GC HANFORD MANUFACTURING CO
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM

**POHL BOSKAMP**
* G POHL BOSKAMP GMBH AND CO KG
GONITRO, NITROGLYCERIN

**** H ****

**HAEMONETICS**
* HAEMONETICS CORP
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

**HALOCARBON PRODS**
* HALOCARBON PRODUCTS CORP
ISOFLURANE, ISOFLURANE
SEVOFLURANE, SEVOFLURANE

**HALOZYME THERAP**
* HALOZYME THERAPEUTICS INC
HYLENEX RECOMBINANT, HYALURONIDASE RECOMBINANT HUMAN

**HAMELN PHARMA PLUS**
* HAMELN PHARMA PLUS GMBH
PENTETATE CALCIUM TRISODIUM, PENTETATE CALCIUM TRISODIUM
PENTETATE ZINC TRISODIUM, PENTETATE ZINC TRISODIUM

**HAMELN RDS GMBH**
* HAMELN RDS GMBH
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE

**HANDA PHARMS LLC**
* HANDA PHARMACEUTICALS LLC
LAMOTRIGINE, LAMOTRIGINE

**HANSAMED INC**
* HANSAMED INC
ULTACAN FORTE, ARTICAINE HYDROCHLORIDE
ULTACAN, ARTICAINE HYDROCHLORIDE

**HARRIS PHARM**
* HARRIS PHARMACEUTICAL INC
FLUCONAZOLE, FLUCONAZOLE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE

**HAUPT PHARMA**
* HAUPT PHARMA INC
DUTASTERIDE, DUTASTERIDE

**HEC PHARM USA INC**
* HEC PHARM USA INC
CLARITHROMYCIN, CLARITHROMYCIN

**HELSINN HLTHCARE**
* HELSINN HEALTHCARE SA
AKYNZEO, NETUPITANT
ALOXI, PALONOSETRON HYDROCHLORIDE

**HERCON PHARM**
* HERCON PHARMACEUTICAL LLC
NITROGLYCERIN, NITROGLYCERIN

**HERITAGE LIFE**
* HERITAGE LIFE SCIENCES BARBADOS INC
CLOZARIL, CLOZAPINE

**HERITAGE PHARMA**
* HERITAGE PHARMA LABS INC
ACETAZOLAMIDE, ACETAZOLAMIDE
ACHROMYCIN V, TETRACYCLINE HYDROCHLORIDE
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DIFLUNISAL, DIFLUNISAL
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
LITHIUM CARBONATE, LITHIUM CARBONATE
METHIMAZOLE, METHIMAZOLE
NIFEDIPINE, NIFEDIPINE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

**HERITAGE PHARMS INC**
* HERITAGE PHARMACEUTICALS INC
ACETAZOLAMIDE, ACETAZOLAMIDE
ACYCLOVIR, ACYCLOVIR
ALPRAZOLAM, ALPRAZOLAM
CALCIUM ACETATE, CALCIUM ACETATE
CARISOPRODOL AND ASPIRIN, ASPIRIN

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HERITAGE PHARMACEUTICALS INC
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
ETHOSUXIMIDE, ETHOSUXIMIDE
FELODIPINE, FELODIPINE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYBURIDE, GLYBURIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
INDOMETHACIN, INDOMETHACIN
KETOPROFEN, KETOPROFEN
LEFLUNOMIDE, LEFLUNOMIDE
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NIMODIPINE, NIMODIPINE
NYSTATIN, NYSTATIN
PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

**HERON THERAPS INC**

* HERON THERAPEUTICS INC
CINVANTI, APREPITANT
SUSTOL, GRANISETRON

**HETERO LABS LTD III**

* HETERO LABS LTD UNIT III
ABACAVIR SULFATE, ABACAVIR SULFATE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
FENOFIBRATE, FENOFIBRATE
FINASTERIDE, FINASTERIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
METHOCARBAMOL, METHOCARBAMOL
NEVIRAPINE, NEVIRAPINE
SIMVASTATIN, SIMVASTATIN
STAVUDINE, STAVUDINE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TORSEMIDE, TORSEMIDE
ZIDOVUDINE, ZIDOVUDINE

**HETERO LABS LTD V**

* HETERO LABS LTD UNIT V
ACYCLOVIR, ACYCLOVIR
ARIPIPRAZOLE, ARIPIPRAZOLE
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ENTECAVIR, ENTECAVIR
FAMCICLOVIR, FAMCICLOVIR
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
IRBESARTAN, IRBESARTAN
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LEVOFLOXACIN, LEVOFLOXACIN
LINEZOLID, LINEZOLID
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HETERO LABS LTD UNIT V
MONTELUKAST SODIUM, MONTELUKAST SODIUM
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TELMISARTAN, TELMISARTAN
TETRABENAZINE, TETRABENAZINE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR HYDROCHLORIDE
VALSARTAN, VALSARTAN

**HEYL CHEMISCH**

* HEYL CHEMISCH PHARMAZEUTISHE FABRIK
RADIOGARDASE (PRUSSIAN BLUE), FERRIC HEXACYANOFERRATE(II)

**HI TECH PHARMA**

* HI TECH PHARMACAL CO INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACYCLOVIR, ACYCLOVIR
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
CALCIPOTRIENE, CALCIPOTRIENE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CICLOPIROX, CICLOPIROX
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
CORMAX, CLOBETASOL PROPIONATE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
EMBELINE E, CLOBETASOL PROPIONATE
EMBELINE, CLOBETASOL PROPIONATE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
GABAPENTIN, GABAPENTIN
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
LACTULOSE, LACTULOSE
LEVOCARNITINE, LEVOCARNITINE
LEVOFLOXACIN, LEVOFLOXACIN
LIDOCAINE AND PRILOCAINE, LIDOCAINE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
NYSTATIN, NYSTATIN
OFLOXACIN, OFLOXACIN
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE, DEXTROMETHORPHAN
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TIMOLOL MALEATE, TIMOLOL MALEATE
VOSOL HC, ACETIC ACID, GLACIAL
VOSOL, ACETIC ACID, GLACIAL

**HI TECH PHARMA CO**

* HI TECH PHARMACAL CO INC
FLUNISOLIDE, FLUNISOLIDE
PREDNISOLONE, PREDNISOLONE

**HI-TECH PHARMA CO**

* HI-TECH PHARMACAL CO INC
FAMOTIDINE, FAMOTIDINE
GATIFLOXACIN, GATIFLOXACIN
LORAZEPAM, LORAZEPAM
PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE

**HI-TECH PHARMACAL**

* HI-TECH PHARMACAL CO INC
BROMFENAC SODIUM, BROMFENAC SODIUM

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HI-TECH PHARMACAL CO INC
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DESONIDE, DESONIDE
IBUPROFEN, IBUPROFEN
LEVETIRACETAM, LEVETIRACETAM
MEGESTROL ACETATE, MEGESTROL ACETATE
MORPHINE SULFATE, MORPHINE SULFATE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE
TRIFLURIDINE, TRIFLURIDINE

**HIGH TECH PHARMA**

* HIGH TECHNOLOGY PHARMACAL CO INC
VALPROIC ACID, VALPROIC ACID

**HIKMA**

* HIKMA FARMACEUTICA LDA
CEFOTAXIME, CEFOTAXIME SODIUM
* HIKMA PHARMACEUTICALS
AMOXICILLIN, AMOXICILLIN
CEFACLOR, CEFACLOR
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEPHALEXIN, CEPHALEXIN
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
GLYBURIDE (MICRONIZED), GLYBURIDE

**HIKMA FARMACEUTICA**

* HIKMA FARMACEUTICA (PORTUGAL) SA
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CEFOXITIN, CEFOXITIN SODIUM
CEFTRIAXONE, CEFTRIAXONE SODIUM
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPROFLOXACIN, CIPROFLOXACIN
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
ENALAPRILAT, ENALAPRILAT
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUMAZENIL, FLUMAZENIL
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MILRINONE LACTATE IN PLASTIC CONTAINER, MILRINONE LACTATE
MILRINONE LACTATE, MILRINONE LACTATE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PROGESTERONE, PROGESTERONE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
TERBUTALINE SULFATE, TERBUTALINE SULFATE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
VALPROATE SODIUM, VALPROATE SODIUM
* HIKMA FARMACEUTICA PORTUGAL LDA
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFUROXIME SODIUM, CEFUROXIME SODIUM
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
* HIKMA FARMACEUTICA PORTUGAL SA
CEFOTETAN, CEFOTETAN DISODIUM
CEFTRIAXONE SODIUM, CEFTRIAXONE SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
ETOMIDATE, ETOMIDATE
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
OXYTOCIN, OXYTOCIN
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HIKMA FARMACEUTICA PORTUGAL SA
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
* HIKMA FARMACEUTICA SA
ZOLEDRONIC ACID, ZOLEDRONIC ACID

**HIKMA INTL PHARMS**

* HIKMA INTERNATIONAL PHARMACEUTICALS LLC
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
CAPTOPRIL, CAPTOPRIL
CARISOPRODOL, CARISOPRODOL
CORTISONE ACETATE, CORTISONE ACETATE
DIGOXIN, DIGOXIN
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCORTISONE, HYDROCORTISONE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
METHOCARBAMOL, METHOCARBAMOL
MITIGARE, COLCHICINE
PRIMIDONE, PRIMIDONE

**HIKMA PHARM CO LTD**

* HIKMA PHARM CO LTD
ARGATROBAN, ARGATROBAN

**HIKMA PHARMS**

* HIKMA PHARMACEUTICALS
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
GEMFIBROZIL, GEMFIBROZIL
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LETROZOLE, LETROZOLE
MODAFINIL, MODAFINIL
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
RIFAMPIN, RIFAMPIN
* HIKMA PHARMACEUTICALS CO LTD
PARICALCITOL, PARICALCITOL
* HIKMA PHARMACEUTICALS LLC
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
DANTROLENE SODIUM, DANTROLENE SODIUM
DOXERCALCIFEROL, DOXERCALCIFEROL
FOLIC ACID, FOLIC ACID
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
OLANZAPINE, OLANZAPINE
PIROXICAM, PIROXICAM
PREDNISONE, PREDNISONE
ZALEPLON, ZALEPLON

**HILL DERMAC**

* HILL DERMACEUTICALS INC
DERMA-SMOOTHE/FS, FLUOCINOLONE ACETONIDE
DERMOTIC, FLUOCINOLONE ACETONIDE

**HILL DERMACEUTICALS**

* HILL DERMACEUTICALS INC
TOLAK, FLUOROURACIL

**HISAMITSU PHARM CO**

* HISAMITSU PHARMACEUTICAL CO INC
SALONPAS, MENTHOL (OTC)

**HISUN PHARM HANGZHOU**

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** H **

* HISUN PHARMACEUTICAL (HANGZHOU) CO LTD
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
* HISUN PHARMACEUTICAL HANGZHOU CO LTD
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
SIMVASTATIN, SIMVASTATIN

**HOFFMANN LA ROCHE**

* HOFFMANN LA ROCHE INC
BONIVA, IBANDRONATE SODIUM
INVIRASE, SAQUINAVIR MESYLATE
VALCYTE, VALGANCICLOVIR HYDROCHLORIDE
XELODA, CAPECITABINE
ZELBORAF, VEMURAFENIB

**HOFFMANN-LA ROCHE**

* HOFFMANN-LA ROCHE INC
ALECENSA, ALECTINIB HYDROCHLORIDE
INVIRASE, SAQUINAVIR MESYLATE

**HONG KONG**

* HONG KONG KING-FRIEND INDUSTRIAL CO LTD
CYTARABINE, CYTARABINE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

**HOPE PHARMS**

* HOPE PHARMACEUTICALS
NITHIODOTE, SODIUM NITRITE
SODIUM NITRITE, SODIUM NITRITE
SODIUM THIOSULFATE, SODIUM THIOSULFATE

**HORIZON PHARMA**

* HORIZON PHARMA INC
DUEXIS, FAMOTIDINE
RAYOS, PREDNISONE
* HORIZON PHARMA IRELAND LTD
PENNSAID, DICLOFENAC SODIUM
* HORIZON PHARMA RHEUMATOLOGY LLC
MIGERGOT, CAFFEINE

**HORIZON PHARMA INC**

* HORIZON PHARMA INC
BUPHENYL, SODIUM PHENYLBUTYRATE

**HORIZON PHARMA USA**

* HORIZON PHARMA USA INC
PROCYSBI, CYSTEAMINE BITARTRATE
VIMOVO, ESOMEPRAZOLE MAGNESIUM

**HORIZON THERAPS INC**

* HORIZON THERAPEUTICS INC
RAVICTI, GLYCEROL PHENYLBUTYRATE

**HOSPIRA**

* HOSPIRA INC
A-METHAPRED, METHYLPREDNISOLONE SODIUM SUCCINATE
ACETYLCYSTEINE, ACETYLCYSTEINE
ALFENTANIL, ALFENTANIL HYDROCHLORIDE
AMIDATE, ETOMIDATE
AMINOCAPROIC ACID IN PLASTIC CONTAINER, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMMONIUM CHLORIDE IN PLASTIC CONTAINER, AMMONIUM CHLORIDE
AQUASOL A, VITAMIN A PALMITATE
ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, ARTICAINE HYDROCHLORIDE
ATROPINE SULFATE ANSYR PLASTIC SYRINGE, ATROPINE SULFATE
ATROPINE SULFATE LIFESHIELD ABBOJECT SYRINGE, ATROPINE SULFATE
AZITHROMYCIN, AZITHROMYCIN
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
BACTERIOSTATIC WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BUMETANIDE, BUMETANIDE
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HOSPIRA INC

BUPIVACAINE HYDROCHLORIDE W/EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
CALCIUM CHLORIDE 10% IN PLASTIC CONTAINER, CALCIUM CHLORIDE
CARBOCAINE, MEPIVACAINE HYDROCHLORIDE
CARBOPLATIN, CARBOPLATIN
CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
CHROMIC CHLORIDE IN PLASTIC CONTAINER, CHROMIC CHLORIDE
CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, CIPROFLOXACIN
CIPROFLOXACIN, CIPROFLOXACIN
CORLOPAM, FENOLDOPAM MESYLATE
CUPRIC CHLORIDE IN PLASTIC CONTAINER, CUPRIC CHLORIDE
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DEMEROL, MEPERIDINE HYDROCHLORIDE
DEXTROSE 25%, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 50% , DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DIAZEPAM, DIAZEPAM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOBUTAMINE HYDROCHLORIDE
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER, DOPAMINE HYDROCHLORIDE
DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
DROPERIDOL, DROPERIDOL
ENALAPRILAT, ENALAPRILAT
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
ERYTHROCIN, ERYTHROMYCIN LACTOBIONATE
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FENTANYL CITRATE, FENTANYL CITRATE
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FUROSEMIDE, FUROSEMIDE
GENTAMICIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, GENTAMICIN SULFATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER, HEPARIN SODIUM
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, HEPARIN
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
ISOFLURANE, ISOFLURANE
ISUPREL, ISOPROTERENOL HYDROCHLORIDE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LEVOPHED, NOREPINEPHRINE BITARTRATE
LIDOCAINE HYDROCHLORIDE 5% AND DEXTROSE 7.5%, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE, EPINEPHRINE
LIDOCAINE HYDROCHLORIDE IN PLASTIC CONTAINER, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE IN PLASTIC CONTAINER, LIDOCAINE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM
LTA II KIT, LIDOCAINE HYDROCHLORIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HOSPIRA INC
M.V.I. ADULT (PHARMACY BULK PACKAGE), ASCORBIC ACID
M.V.I. ADULT, ASCORBIC ACID
M.V.I. PEDIATRIC, ASCORBIC ACID
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MANGANESE CHLORIDE IN PLASTIC CONTAINER, MANGANESE CHLORIDE
MANNITOL 25%, MANNITOL
MARCAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
MARCAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
MARCAINE, BUPIVACAINE HYDROCHLORIDE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
MORPHINE SULFATE, MORPHINE SULFATE
NALBUPHINE HYDROCHLORIDE, NALBUPHINE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NITROGLYCERIN IN DEXTROSE 5%, NITROGLYCERIN
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PACLITAXEL, PACLITAXEL
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PLEGISOL IN PLASTIC CONTAINER, CALCIUM CHLORIDE
POTASSIUM ACETATE, POTASSIUM ACETATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRECEDEX, DEXMEDETOMIDINE HYDROCHLORIDE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
PROPOFOL, PROPOFOL
QUELICIN PRESERVATIVE FREE, SUCCINYLCHOLINE CHLORIDE
QUELICIN, SUCCINYLCHOLINE CHLORIDE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SODIUM ACETATE, SODIUM ACETATE
SODIUM BICARBONATE, SODIUM BICARBONATE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM LACTATE IN PLASTIC CONTAINER, SODIUM LACTATE
SODIUM PHOSPHATES IN PLASTIC CONTAINER, SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
SUFENTANIL CITRATE, SUFENTANIL CITRATE
TALWIN, PENTAZOCINE LACTATE
TAZICEF, CEFTAZIDIME
THAM, TROMETHAMINE
TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, TOBRAMYCIN SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TPN ELECTROLYTES IN PLASTIC CONTAINER, CALCIUM CHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
VINORELBINE TARTRATE, VINORELBINE TARTRATE
VITAMIN K1, PHYTONADIONE
ZINC CHLORIDE IN PLASTIC CONTAINER, ZINC CHLORIDE

* HOSPIRA WORLDWIDE, INC
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HOSPIRA WORLDWIDE, INC
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
NITROPRESS, SODIUM NITROPRUSSIDE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE

**HOSPIRA INC**

* HOSPIRA INC
ADENOSINE, ADENOSINE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
ARGATROBAN, ARGATROBAN
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE
BIVALIRUDIN, BIVALIRUDIN
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
CEFOXITIN, CEFOXITIN SODIUM
CEFTRIAXONE, CEFTRIAXONE SODIUM
CEFUROXIME SODIUM, CEFUROXIME SODIUM
DAPTOMYCIN, DAPTOMYCIN
DOCETAXEL, DOCETAXEL
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
HEPARIN SODIUM, HEPARIN SODIUM
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
IMIPENEM AND CILASTATIN, CILASTATIN SODIUM
INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER, LEVOFLOXACIN
LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, LINEZOLID
LINEZOLID, LINEZOLID
MAGNESIUM SULFATE, MAGNESIUM SULFATE
MAXIPIME, CEFEPIME HYDROCHLORIDE
MEPIVACAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE
MEROPENEM, MEROPENEM
MILRINONE LACTATE, MILRINONE LACTATE
MORPHINE SULFATE, MORPHINE SULFATE
NIPENT, PENTOSTATIN
OXACILLIN SODIUM, OXACILLIN SODIUM
OXALIPLATIN, OXALIPLATIN
PARICALCITOL, PARICALCITOL
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
SODIUM BICARBONATE, SODIUM BICARBONATE
TACROLIMUS, TACROLIMUS
THEOPHYLLINE IN DEXTROSE 5% IN PLASTIC CONTAINER, THEOPHYLLINE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

**HOSPIRA WORLDWIDE**

* HOSPIRA WORLDWIDE PTY
OXALIPLATIN, OXALIPLATIN

**HOT SHOTS NM LLC**

* HOT SHOTS NUCLEAR MEDICINE LLC
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**HOUSTON CYCLOTRON**

* HOUSTON CYCLOTRON PARTNERS LP
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**HQ SPCLT PHARMA**

* HQ SPECIALTY PHARMA CORP

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** H ****

* HQ SPECIALTY PHARMA CORP
CISPLATIN, CISPLATIN
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER, ESMOLOL HYDROCHLORIDE
LINEZOLID, LINEZOLID
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MAGNESIUM SULFATE
MAGNESIUM SULFATE IN PLASTIC CONTAINER, MAGNESIUM SULFATE
TAXOL, PACLITAXEL

**HQ SPECIALITY PHARMA**

* HQ SPECIALITY PHARMA LLC
LEVETIRACETAM IN SODIUM CHLORIDE, LEVETIRACETAM

**HRA PHARMA**

* HRA PHARMA LLC
METOPIRONE, METYRAPONE

**HUMANWELL PURACAP**

* HUMANWELL PURACAP PHARMACEUTICAL WUHAN CO LTD
DUTASTERIDE, DUTASTERIDE
IBUPROFEN, IBUPROFEN (OTC)

**ROCHE**

* HOFFMANN LA ROCHE INC
BONIVA, IBANDRONATE SODIUM
COPEGUS, RIBAVIRIN
FUZEON, ENFUVIRTIDE
KLONOPIN, CLONAZEPAM
TAMIFLU, OSELTAMIVIR PHOSPHATE
VALIUM, DIAZEPAM

**** I ****

**IBA MOLECULAR N AM**

* IBA MOLECULAR NORTH AMERICA INC
AMMONIA N 13, AMMONIA N-13

**ICU MEDICAL INC**

* ICU MEDICAL INC
ACETIC ACID 0.25% IN PLASTIC CONTAINER, ACETIC ACID, GLACIAL
AMINOSYN 10% (PH6), AMINO ACIDS
AMINOSYN 10%, AMINO ACIDS
AMINOSYN 3.5% M, AMINO ACIDS
AMINOSYN 3.5%, AMINO ACIDS
AMINOSYN 5%, AMINO ACIDS
AMINOSYN 7% (PH6), AMINO ACIDS
AMINOSYN 7% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN 7%, AMINO ACIDS
AMINOSYN 8.5% (PH6), AMINO ACIDS
AMINOSYN 8.5% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN 8.5%, AMINO ACIDS
AMINOSYN II 10% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 10% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 10%, AMINO ACIDS
AMINOSYN II 15% IN PLASTIC CONTAINER, AMINO ACIDS
AMINOSYN II 7%, AMINO ACIDS
AMINOSYN II 8.5% W/ ELECTROLYTES, AMINO ACIDS
AMINOSYN II 8.5%, AMINO ACIDS
AMINOSYN-HBC 7%, AMINO ACIDS
AMINOSYN-HF 8%, AMINO ACIDS
AMINOSYN-PF 10%, AMINO ACIDS
AMINOSYN-PF 7%, AMINO ACIDS
AMINOSYN-RF 5.2%, AMINO ACIDS
DEXTROSE 10% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 20% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 30% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 40% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER, DEXTROSE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** I ****

* ICU MEDICAL INC
DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 50% IN PLASTIC CONTAINER, DEXTROSE
DEXTROSE 70% IN PLASTIC CONTAINER, DEXTROSE
GLYCINE 1.5% IN PLASTIC CONTAINER, GLYCINE
IONOSOL MB AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
LACTATED RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
MANNITOL 10% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 15% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 20% IN PLASTIC CONTAINER, MANNITOL
MANNITOL 5% IN PLASTIC CONTAINER, MANNITOL
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NORMOSOL-M AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R AND DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
NORMOSOL-R IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
PHYSIOSOL IN PLASTIC CONTAINER, MAGNESIUM CHLORIDE
POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 15MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% IN SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% IN PLASTIC CONTAINER, DEXTROSE
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER, POTASSIUM CHLORIDE
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, POTASSIUM
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER,
POTASSIUM CHLORIDE 5MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER,
RINGER'S IN PLASTIC CONTAINER, CALCIUM CHLORIDE
SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
SORBITOL-MANNITOL IN PLASTIC CONTAINER, MANNITOL
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
STERILE WATER IN PLASTIC CONTAINER, STERILE WATER FOR IRRIGATION

**IDENTI PHARMS INC**

* IDENTI PHARMACEUTICALS INC
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** I ****

**IDT AUSTRALIA LTD**

* IDT AUSTRALIA LTD
PINDOLOL, PINDOLOL
TEMOZOLOMIDE, TEMOZOLOMIDE

**IMPAX LABS**

* IMPAX LABORATORIES INC
ACARBOSE, ACARBOSE
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
BACLOFEN, BACLOFEN
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
COLESTIPOL HYDROCHLORIDE, COLESTIPOL HYDROCHLORIDE
DANTROLENE SODIUM, DANTROLENE SODIUM
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DIGOXIN, DIGOXIN
DIPYRIDAMOLE, DIPYRIDAMOLE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRATE, FENOFIBRATE
FLUDROCORTISONE ACETATE, FLUDROCORTISONE ACETATE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
NADOLOL AND BENDROFLUMETHIAZIDE, BENDROFLUMETHIAZIDE
OMEPRAZOLE, OMEPRAZOLE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RILUZOLE, RILUZOLE
RIMANTADINE HYDROCHLORIDE, RIMANTADINE HYDROCHLORIDE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TERBUTALINE SULFATE, TERBUTALINE SULFATE

**IMPAX LABS INC**

* IMPAX LABORATORIES INC
ACITRETIN, ACITRETIN
ADRENACLICK, EPINEPHRINE
ALBENZA, ALBENDAZOLE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
BUDESONIDE, BUDESONIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DEXEDRINE, DEXTROAMPHETAMINE SULFATE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE
EMVERM, MEBENDAZOLE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
EZETIMIBE AND SIMVASTATIN, EZETIMIBE
FELBAMATE, FELBAMATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYBURIDE, GLYBURIDE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
LAMOTRIGINE, LAMOTRIGINE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
METHENAMINE HIPPURATE, METHENAMINE HIPPURATE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METHYLTESTOSTERONE, METHYLTESTOSTERONE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
MORPHINE SULFATE, MORPHINE SULFATE
NABUMETONE, NABUMETONE
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** I **

* IMPAX LABORATORIES INC
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RYTARY, CARBIDOPA
SEVELAMER CARBONATE, SEVELAMER CARBONATE
URSODIOL, URSODIOL

**IMPAX PHARMS**
* IMPAX PHARMACEUTICALS
GEMFIBROZIL, GEMFIBROZIL
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

**INCYTE CORP**
* INCYTE CORP
JAKAFI, RUXOLITINIB PHOSPHATE

**INDICUS PHARMA**
* INDICUS PHARMA LLC
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
LETROZOLE, LETROZOLE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

**INDIVIOR INC**
* INDIVIOR INC
BUPRENEX, BUPRENORPHINE HYDROCHLORIDE
SUBLOCADE, BUPRENORPHINE
SUBOXONE, BUPRENORPHINE HYDROCHLORIDE

**INDOCO REMEDIES**
* INDOCO REMEDIES LTD
ALLOPURINOL, ALLOPURINOL
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
GLIMEPIRIDE, GLIMEPIRIDE

**INGENUS PHARMS LLC**
* INGENUS PHARMACEUTICALS LLC
CARBOPLATIN, CARBOPLATIN
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE

**INGENUS PHARMS NJ**
* INGENUS PHARMACEUTICALS NJ LLC
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
CARISOPRODOL, CARISOPRODOL
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PRIMAQUINE PHOSPHATE, PRIMAQUINE PHOSPHATE
PROBENECID AND COLCHICINE, COLCHICINE

**INJECTALIA**
* INJECTALIA SRL
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

**INNOGENIX**
* INNOGENIX LLC
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE

**INNOPHARMA LICENSING**
* INNOPHARMA LICENSING LLC
BENDAMUSTINE HYDROCHLORIDE, BENDAMUSTINE HYDROCHLORIDE

**INST BIOCHEM**
* INSTITUT BIOCHEMIQUE SA
FLECTOR, DICLOFENAC EPOLAMINE

**INSTITUT BIOCHIMIQUE**
* INSTITUT BIOCHIMIQUE SA (IBSA)
TIROSINT, LEVOTHYROXINE SODIUM

**INSYS DEV CO INC**
* INSYS DEVELOPMENT CO INC

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** I **

* INSYS DEVELOPMENT CO INC
SUBSYS, FENTANYL
SYNDROS, DRONABINOL

**INTAS PHARMS USA**

* INTAS PHARMACEUTICALS USA
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE

**INTELLIPHARMACEUTICS**

* INTELLIPHARMACEUTICS CORP
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE

**INTERCEPT PHARMS INC**

* INTERCEPT PHARMACEUTICALS INC
OCALIVA, OBETICHOLIC ACID

**INTERGEL PHARM**

* INTERGEL PHARMACEUTICAL INC
NIFEDIPINE, NIFEDIPINE

**INTERGEL PHARMS INC**

* INTERGEL PHARMACEUTICALS INC
DUTASTERIDE, DUTASTERIDE

**INTERPHARMA PRAHA AS**

* INTERPHARMA PRAHA AS
ORALTAG, IOHEXOL

**INTERSECT ENT INC**

* INTERSECT ENT INC
SINUVA, MOMETASONE FUROATE

**INTL MEDICATED**

* INTERNATIONAL MEDICATED SYSTEMS LTD
MILRINONE LACTATE, MILRINONE LACTATE

**INTL MEDICATION**

* INTERNATIONAL MEDICATION SYSTEM
LARYNG-O-JET KIT, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
MANNITOL 25%, MANNITOL
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
PHYTONADIONE, PHYTONADIONE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
* INTERNATIONAL MEDICATION SYSTEMS LTD
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE

**INTL MEDICATION SYS**

* INTERNATIONAL MEDICATION SYSTEMS LTD
LORAZEPAM, LORAZEPAM
SODIUM BICARBONATE, SODIUM BICARBONATE

**INVAGEN PHARMS**

* INVAGEN PHARMACEUTICALS INC
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CALCIUM ACETATE, CALCIUM ACETATE
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FOLIC ACID, FOLIC ACID
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GABAPENTIN, GABAPENTIN
GEMFIBROZIL, GEMFIBROZIL

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** I ****

* INVAGEN PHARMACEUTICALS INC
GLIMEPIRIDE, GLIMEPIRIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
MEPROBAMATE, MEPROBAMATE
NABUMETONE, NABUMETONE
NADOLOL, NADOLOL
NAPROXEN, NAPROXEN
OLANZAPINE, OLANZAPINE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SEVELAMER CARBONATE, SEVELAMER CARBONATE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM
ZOLMITRIPTAN, ZOLMITRIPTAN
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
ZONISAMIDE, ZONISAMIDE

**INVENTIA HLTHCARE**

* INVENTIA HEALTHCARE PRIVATE LTD
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
ILOPERIDONE, ILOPERIDONE
LANSOPRAZOLE, LANSOPRAZOLE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
TELMISARTAN, TELMISARTAN

**IPCA LABS LTD**

* IPCA LABORATORIES LTD
ALLOPURINOL, ALLOPURINOL
ATENOLOL, ATENOLOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
FUROSEMIDE, FUROSEMIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM

**IPR**

* IPR PHARMACEUTICALS INC
CRESTOR, ROSUVASTATIN CALCIUM
ZOMIG, ZOLMITRIPTAN

**IPSEN INC**

* IPSEN BIOPHARMACEUTICALS INC
INCRELEX, MECASERMIN RECOMBINANT
ONIVYDE, IRINOTECAN HYDROCHLORIDE

**IPSEN PHARMA**

* IPSEN PHARMA BIOTECH SAS
SOMATULINE DEPOT, LANREOTIDE ACETATE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** I ****

**IROKO PHARMS**
* IROKO PHARMACEUTICALS LLC
INDOCIN, INDOMETHACIN

**IROKO PHARMS LLC**
* IROKO PHARMACEUTICALS LLC
TIVORBEX, INDOMETHACIN
VIVLODEX, MELOXICAM
ZORVOLEX, DICLOFENAC

**IRONWOOD PHARMS INC**
* IRONWOOD PHARMACEUTICALS INC
DUZALLO, ALLOPURINOL
ZURAMPIC, LESINURAD

**ISO TEX**
* ISO TEX DIAGNOSTICS INC
JEANATOPE, ALBUMIN IODINATED I-125 SERUM
MEGATOPE, ALBUMIN IODINATED I-131 SERUM

**ISOTEX**
* ISOTEX DIAGNOSTICS
GLOFIL-125, IOTHALAMATE SODIUM I-125

**ISTITUTO BIO ITA SPA**
* ISTITUTO BIOCHIMICO ITALIANO SPA
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
NAFCILLIN SODIUM, NAFCILLIN SODIUM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PIPERACILLIN, PIPERACILLIN SODIUM

**IVAX PHARMS**
* IVAX PHARMACEUTICALS INC
VALSARTAN, VALSARTAN

**IVAX PHARMS INC**
* IVAX PHARMACEUTICALS INC
OLANZAPINE, OLANZAPINE

**IVAX SUB TEVA PHARMS**
* IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
BACLOFEN, BACLOFEN
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BUMETANIDE, BUMETANIDE
CABERGOLINE, CABERGOLINE
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CIMETIDINE, CIMETIDINE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLOZAPINE, CLOZAPINE
CYCLOSPORINE, CYCLOSPORINE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DIAZEPAM, DIAZEPAM
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FLUCONAZOLE, FLUCONAZOLE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FUROSEMIDE, FUROSEMIDE
GABAPENTIN, GABAPENTIN
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
INDOMETHACIN, INDOMETHACIN
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
METHYLDOPA, METHYLDOPA
MISOPROSTOL, MISOPROSTOL
NADOLOL, NADOLOL
OXAPROZIN, OXAPROZIN
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** I ****

* IVAX PHARMACEUTICALS INC SUB TEVA PHARMACEUTICALS USA
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
SIMVASTATIN, SIMVASTATIN
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

**** J ****

**J AND J CONSUMER INC**

* JOHNSON AND JOHNSON CONSUMER INC MCNEIL CONSUMER HEALTHCARE DIVISION
CHILDREN'S MOTRIN COLD, IBUPROFEN (OTC)
CHILDREN'S MOTRIN, IBUPROFEN (OTC)
CHILDREN'S ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
IMODIUM A-D, LOPERAMIDE HYDROCHLORIDE (OTC)
IMODIUM MULTI-SYMPTOM RELIEF, LOPERAMIDE HYDROCHLORIDE (OTC)
JUNIOR STRENGTH MOTRIN, IBUPROFEN (OTC)
MOTRIN IB, IBUPROFEN (OTC)
PEPCID AC , FAMOTIDINE (OTC)
PEPCID AC, FAMOTIDINE (OTC)
PEPCID COMPLETE, CALCIUM CARBONATE (OTC)
SINE-AID IB, IBUPROFEN (OTC)
SUDAFED 24 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
TYLENOL , ACETAMINOPHEN (OTC)
ZYRTEC ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
ZYRTEC HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
ZYRTEC-D 12 HOUR, CETIRIZINE HYDROCHLORIDE (OTC)

**JACOBUS**

* JACOBUS PHARMACEUTICAL CO
DAPSONE, DAPSONE
PASER, AMINOSALICYLIC ACID

**JANSSEN BIOTECH**

* JANSSEN BIOTECH INC
ZYTIGA, ABIRATERONE ACETATE

**JANSSEN PHARMS**

* JANSSEN PHARMACEUTICALS INC
AXERT, ALMOTRIPTAN MALATE
CONCERTA, METHYLPHENIDATE HYDROCHLORIDE
DITROPAN XL, OXYBUTYNIN CHLORIDE
DURAGESIC-100, FENTANYL
DURAGESIC-12, FENTANYL
DURAGESIC-25, FENTANYL
DURAGESIC-50, FENTANYL
DURAGESIC-75, FENTANYL
ELMIRON, PENTOSAN POLYSULFATE SODIUM
HALDOL, HALOPERIDOL DECANOATE
HALDOL, HALOPERIDOL LACTATE
INVEGA SUSTENNA, PALIPERIDONE PALMITATE
INVEGA TRINZA, PALIPERIDONE PALMITATE
INVEGA, PALIPERIDONE
INVOKAMET XR, CANAGLIFLOZIN
INVOKAMET, CANAGLIFLOZIN
INVOKANA, CANAGLIFLOZIN
LEVAQUIN, LEVOFLOXACIN
MICRONOR, NORETHINDRONE
MODICON 28, ETHINYL ESTRADIOL
NIZORAL, KETOCONAZOLE
ORTHO CYCLEN-28, ETHINYL ESTRADIOL
ORTHO TRI-CYCLEN LO, ETHINYL ESTRADIOL
ORTHO TRI-CYCLEN, ETHINYL ESTRADIOL
ORTHO-NOVUM 1/35-28, ETHINYL ESTRADIOL
ORTHO-NOVUM 7/7/7-28, ETHINYL ESTRADIOL
PANCREAZE, PANCRELIPASE (AMYLASE
RAZADYNE ER, GALANTAMINE HYDROBROMIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** J ****

* JANSSEN PHARMACEUTICALS INC
RAZADYNE, GALANTAMINE HYDROBROMIDE
RISPERDAL CONSTA, RISPERIDONE
RISPERDAL, RISPERIDONE
SPORANOX, ITRACONAZOLE
TERAZOL 3, TERCONAZOLE
TERAZOL 7, TERCONAZOLE
TOPAMAX, TOPIRAMATE
TYLENOL W/ CODEINE NO. 3, ACETAMINOPHEN
TYLENOL W/ CODEINE NO. 4, ACETAMINOPHEN
ULTRACET, ACETAMINOPHEN
ULTRAM, TRAMADOL HYDROCHLORIDE
VERMOX, MEBENDAZOLE
XARELTO, RIVAROXABAN

**JANSSEN PRODS**
* JANSSEN PRODUCTS LP
EDURANT, RILPIVIRINE HYDROCHLORIDE
OLYSIO, SIMEPREVIR SODIUM
PREZCOBIX, COBICISTAT
PREZISTA, DARUNAVIR ETHANOLATE
YONDELIS, TRABECTEDIN

**JANSSEN R AND D**
* JANSSEN RESEARCH AND DEVELOPMENT LLC
INTELENCE, ETRAVIRINE

**JANSSEN RES AND DEV**
* JANSSEN RESEARCH AND DEVELOPMENT LLC
DOXIL (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE

**JANSSEN THERAP**
* JANSSEN THERAPEUTICS DIV JANSSEN PRODUCTS LP
SIRTURO, BEDAQUILINE FUMARATE

**JAVELIN PHARMS INC**
* JAVELIN PHARMACEUTICALS INC A WHOLLY OWNED SUDSIDIARY OF HOSPIRA INC
DYLOJECT, DICLOFENAC SODIUM

**JAZZ PHARMS**
* JAZZ PHARMACEUTICALS INC
XYREM, SODIUM OXYBATE

**JAZZ PHARMS III**
* JAZZ PHARMACEUTICALS III INTERNATIONAL LTD
FAZACLO ODT, CLOZAPINE

**JAZZ PHARMS INC**
* JAZZ PHARMACEUTICALS INC
DEFITELIO, DEFIBROTIDE SODIUM

**JAZZ PHARMS INTL**
* JAZZ PHARMACEUTICALS INTERNATIONAL LTD
PRIALT, ZICONOTIDE ACETATE

**JIANGSU HANSOH PHARM**
* JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
VINORELBINE TARTRATE, VINORELBINE TARTRATE

**JIANGSU HENGRUI MED**
* JIANGSU HENGRUI MEDICINE CO LTD
CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
GABAPENTIN, GABAPENTIN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LETROZOLE, LETROZOLE
OXALIPLATIN, OXALIPLATIN

**JOHNS HOPKINS UNIV**
* JOHNS HOPKINS UNIV
AMMONIA N 13, AMMONIA N-13

**JOHNSON AND JOHNSON**

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** J ****

* JOHNSON AND JOHNSON CONSUMER INC
VISINE L.R., OXYMETAZOLINE HYDROCHLORIDE (OTC)
VISINE-A, NAPHAZOLINE HYDROCHLORIDE (OTC)
* JOHNSON AND JOHNSON GROUP CONSUMER COMPANIES
MEN'S ROGAINE, MINOXIDIL (OTC)
ROGAINE (FOR MEN), MINOXIDIL (OTC)
ROGAINE (FOR WOMEN), MINOXIDIL (OTC)
ROGAINE EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
WOMEN'S ROGAINE, MINOXIDIL (OTC)
* JOHNSON AND JOHNSON HEALTHCARE PRODUCTS DIV MCNEIL-PPC INC
NIZORAL A-D, KETOCONAZOLE (OTC)

**JUBILANT CADISTA**

* JUBILANT CADISTA PHARMACEUTICALS INC
ALENDRONATE SODIUM, ALENDRONATE SODIUM
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LAMOTRIGINE, LAMOTRIGINE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
PREDNISONE, PREDNISONE
PROCOMP, PROCHLORPERAZINE MALEATE
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE

**JUBILANT DRAXIMAGE**

* JUBILANT DRAXIMAGE INC
DRAX EXAMETAZIME, TECHNETIUM TC-99M EXAMETAZIME KIT
DRAXIMAGE MDP-25, TECHNETIUM TC-99M MEDRONATE
HICON, SODIUM IODIDE I-131
PULMOLITE, TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT
RUBY-FILL, RUBIDIUM CHLORIDE RB-82
SODIUM IODIDE I 131, SODIUM IODIDE I-131
* JUBILANT DRAXIMAGE RADIOPHARMACIES INC
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18
* JUBILANT DRAXIMAGE USA INC
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT

**JUBILANT GENERICS**

* JUBILANT GENERICS LTD
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CELECOXIB, CELECOXIB
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FELODIPINE, FELODIPINE
INDOMETHACIN, INDOMETHACIN
IRBESARTAN, IRBESARTAN
ITRACONAZOLE, ITRACONAZOLE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RISPERIDONE, RISPERIDONE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** J ****

* JUBILANT GENERICS LTD
SPIRONOLACTONE, SPIRONOLACTONE
TELMISARTAN, TELMISARTAN
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALSARTAN, VALSARTAN
ZOLMITRIPTAN, ZOLMITRIPTAN

**JUBILANT HOLLISTRSTR**

* JUBILANT HOLLISTERSTIER LLC
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

**STEVENS J**

* JEROME STEVENS PHARMACEUTICALS INC
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
DIGOXIN, DIGOXIN
METHOCARBAMOL AND ASPIRIN, ASPIRIN
UNITHROID, LEVOTHYROXINE SODIUM **

**** K ****

**GRIFFEN**

* KW GRIFFEN CO
BIOSCRUB, CHLORHEXIDINE GLUCONATE (OTC)

**KADMON PHARMS LLC**

* KADMON PHARMACEUTICALS LLC
RIBASPHERE, RIBAVIRIN
RIBAVIRIN, RIBAVIRIN

**KAI PHARMS INC**

* KAI PHARMACEUTICALS INC A WHOLLY OWNED SUBSIDIARY OF AMGEN INC
PARSABIV, ETELCALCETIDE

**KALEO INC**

* KALEO INC
AUVI-Q, EPINEPHRINE
EVZIO, NALOXONE HYDROCHLORIDE

**KASTLE THERAPS LLC**

* KASTLE THERAPEUTICS LLC
KYNAMRO, MIPOMERSEN SODIUM

**KEN LIFESCIENCE**

* KEN LIFESCIENCE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

**KERYX BIOPHARMS**

* KERYX BIOPHARMACEUTICALS INC
AURYXIA, FERRIC CITRATE

**KETTERING MEDCTR**

* KETTERING MEDCTR
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**KINEDEXE UK**

* KINEDEXE UK LTD
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE

**KING PHARMS**

* KING PHARMACEUTICALS INC
SYNERCID, DALFOPRISTIN
* KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT LLC
CYTOMEL, LIOTHYRONINE SODIUM
LEVOXYL, LEVOTHYROXINE SODIUM **
TUSSIGON, HOMATROPINE METHYLBROMIDE
* KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT LLC A SUB OF PFIZER INC
SKELAXIN, METAXALONE

**KING PHARMS LLC**

* KING PHARMACEUTICALS LLC
ALTACE, RAMIPRIL
BICILLIN C-R 900/300, PENICILLIN G BENZATHINE
BICILLIN C-R, PENICILLIN G BENZATHINE
BICILLIN L-A, PENICILLIN G BENZATHINE
CORZIDE, BENDROFLUMETHIAZIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** K **

* KING PHARMACEUTICALS LLC
PENICILLIN G PROCAINE, PENICILLIN G PROCAINE
SILVADENE, SILVER SULFADIAZINE
TAPAZOLE, METHIMAZOLE
TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE

**KNIGHT THERAPS**

* KNIGHT THERAPEUTICS USA INC
IMPAVIDO, MILTEFOSINE

**KOWA CO**

* KOWA CO LTD
LIVALO, PITAVASTATIN CALCIUM

**KREITCHMAN PET CTR**

* KREITCHMAN PET CENTER
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**KREMERS URBAN PHARMS**

* KREMERS URBAN PHARMACEUTICALS INC
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
GLYCOLAX, POLYETHYLENE GLYCOL 3350
GLYCOLAX, POLYETHYLENE GLYCOL 3350 (OTC)
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LANSOPRAZOLE, LANSOPRAZOLE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
OMEPRAZOLE, OMEPRAZOLE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
TEMOZOLOMIDE, TEMOZOLOMIDE

**KRKA TOVARNA ZDRAVIL**

* KRKA TOVARNA ZDRAVIL DD NOVO MESTO
LANSOPRAZOLE , LANSOPRAZOLE

**KVK TECH**

* KVK TECH INC
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
KALEXATE, SODIUM POLYSTYRENE SULFONATE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

**KVK TECH INC**

* KVK TECH INC
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

**KYOWA KIRIN**

* KYOWA KIRIN INC
FARESTON, TOREMIFENE CITRATE
SANCUSO, GRANISETRON

**KYTHERA BIOPHARMS**

* KYTHERA BIOPHARMACEUTICALS INC
KYBELLA, DEOXYCHOLIC ACID

** L **

**L PERRIGO CO**

* L PERRIGO CO
CIMETIDINE, CIMETIDINE (OTC)
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
IBUPROFEN, IBUPROFEN (OTC)

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** L ****

* L PERRIGO CO
JUNIOR STRENGTH IBUPROFEN, IBUPROFEN (OTC)
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)

**LA JOLLA PHARM CO**
* LA JOLLA PHARMACEUTICAL CO
GIAPREZA, ANGIOTENSIN II

**LAB HRA PHARMA**
* LABORATOIRE HRA PHARMA
ELLA, ULIPRISTAL ACETATE

**LABORATORIOS GRIFOLS**
* LABORATORIOS GRIFOLS SA
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

**LABORATORIOS SALVAT**
* LABORATORIOS SALVAT SA
OTOVEL, CIPROFLOXACIN HYDROCHLORIDE

**LABS LEON FARMA**
* LABORATORIOS LEON FARMA SA
ALTAVERA, ETHINYL ESTRADIOL
ELIFEMME, ETHINYL ESTRADIOL
ESTARYLLA, ETHINYL ESTRADIOL
INTROVALE, ETHINYL ESTRADIOL
ISIBLOOM, DESOGESTREL
JAIMIESS, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LORYNA, DROSPIRENONE
SYEDA, DROSPIRENONE
TRI-ESTARYLLA, ETHINYL ESTRADIOL
TRI-LO-ESTARYLLA, ETHINYL ESTRADIOL
VIENVA, ETHINYL ESTRADIOL
VOLNEA, DESOGESTREL

**LABS LICONSA**
* LABORATORIOUS LICONSA SA
LANSOPRAZOLE, LANSOPRAZOLE

**LANDELA PHARM**
* LANDELA PHARMACEUTICAL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE

**LANNETT**
* LANNETT CO INC
ACETAZOLAMIDE, ACETAZOLAMIDE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
LANIAZID, ISONIAZID
LANORINAL, ASPIRIN
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PRIMIDONE, PRIMIDONE
PROBALAN, PROBENECID
* LANNETT HOLDINGS INC
BACLOFEN, BACLOFEN
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLINDAMYCIN HYDROCLHORIDE, CLINDAMYCIN HYDROCHLORIDE
DANAZOL, DANAZOL
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
RIFAMPIN, RIFAMPIN
TERBUTALINE SULFATE, TERBUTALINE SULFATE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** L **

* LANNETT HOLDINGS INC
URSODIOL, URSODIOL

**LANNETT CO INC**

* LANNETT CO INC
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
MONOKET, ISOSORBIDE MONONITRATE
NIACIN, NIACIN
SUMATRIPTAN, SUMATRIPTAN

**LANNETT HOLDINGS INC**

* LANNETT HOLDINGS INC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CODEINE SULFATE, CODEINE SULFATE
DIAZEPAM, DIAZEPAM
DIETHYLPROPION HYDROCHLORIDE, DIETHYLPROPION HYDROCHLORIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
METAXALONE, METAXALONE
MORPHINE SULFATE, MORPHINE SULFATE
NEOMYCIN SULFATE, NEOMYCIN SULFATE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

**LANTHEUS MEDCL**

* LANTHEUS MEDICAL IMAGING INC
CARDIOLITE, TECHNETIUM TC-99M SESTAMIBI KIT
DEFINITY, PERFLUTREN
GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
NEUROLITE, TECHNETIUM TC-99M BICISATE KIT
TECHNELITE, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
XENON XE 133, XENON XE-133

**LANTHEUS MEDICAL**

* LANTHEUS MEDICAL IMAGING INC
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
QUADRAMET, SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

**LARKEN LABS**

* LARKEN LABORATORIES INC
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
OFLOXACIN, OFLOXACIN

**LARKEN LABS INC**

* LARKEN LABORATORIES INC
ACETAMINOPHEN, CAFFEINE AND DIHYDROCODEINE BITARTRATE, ACETAMINOPHEN
ALLZITAL, ACETAMINOPHEN
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
DEXAMETHASONE, DEXAMETHASONE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN

**LAVIPHARM LABS**

* LAVIPHARM LABORATORIES INC
FENTANYL-100, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL

**LEADIANT BIOSCI INC**

* LEADIANT BIOSCIENCES INC
ABELCET, AMPHOTERICIN B
CARNITOR SF, LEVOCARNITINE
CARNITOR, LEVOCARNITINE
CYSTARAN, CYSTEAMINE HYDROCHLORIDE
MATULANE, PROCARBAZINE HYDROCHLORIDE

**LEADING PHARMA LLC**

* LEADING PHARMA LLC
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** L ****

* LEADING PHARMA LLC
FOLIC ACID, FOLIC ACID
FUROSEMIDE, FUROSEMIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
LORAZEPAM, LORAZEPAM

**LEHIGH VALLEY**
* LEHIGH VALLEY TECHNOLOGIES INC
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

**LEO LABS**
* LEO LABORATORIES LTD
PICATO, INGENOL MEBUTATE

**LEO PHARMA AS**
* LEO PHARMA AS
DOVONEX, CALCIPOTRIENE
ENSTILAR, BETAMETHASONE DIPROPIONATE
PROTOPIC, TACROLIMUS
TACLONEX, BETAMETHASONE DIPROPIONATE

**LEXICON PHARMS INC**
* LEXICON PHARMACEUTICALS INC
XERMELO, TELOTRISTAT ETIPRATE

**LG CHEM LTD**
* LG CHEM LTD
FACTIVE, GEMIFLOXACIN MESYLATE
VALTROPIN, SOMATROPIN RECOMBINANT

**LIBERTY PHARMA INC**
* LIBERTY PHARMA INC
PRASUGREL, PRASUGREL HYDROCHLORIDE

**LIEBEL-FLARSHEIM**
* LIEBEL-FLARSHEIM CO LLC
CONRAY 30, IOTHALAMATE MEGLUMINE
CONRAY 43, IOTHALAMATE MEGLUMINE
CONRAY, IOTHALAMATE MEGLUMINE
CYSTO-CONRAY II, IOTHALAMATE MEGLUMINE
MD-GASTROVIEW, DIATRIZOATE MEGLUMINE
OPTIMARK IN PLASTIC CONTAINER, GADOVERSETAMIDE
OPTIMARK, GADOVERSETAMIDE
OPTIRAY 240, IOVERSOL
OPTIRAY 300, IOVERSOL
OPTIRAY 320, IOVERSOL
OPTIRAY 350, IOVERSOL
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE

**LIFESTAR PHARMA**
* LIFESTAR PHARMA LLC
RISPERIDONE, RISPERIDONE

**LNK**
* LNK INTERNATIONAL INC
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

**LNK INTL INC**
* LNK INTERNATIONAL INC
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)

**LOREAL USA**
* LOREAL USA PRODUCTS INC
ANTHELIOS 20, AVOBENZONE (OTC)
ANTHELIOS 40, AVOBENZONE (OTC)
ANTHELIOS SX, AVOBENZONE (OTC)
CAPITAL SOLEIL 15, AVOBENZONE (OTC)

**LOTUS PHARM CO LTD**
* LOTUS PHARMACEUTICAL CO LTD
LEVETIRACETAM, LEVETIRACETAM
LEVONORGESTREL, LEVONORGESTREL

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** L **

* LOTUS PHARMACEUTICAL CO LTD
LEVONORGESTREL, LEVONORGESTREL (OTC)
ROWEEPRA, LEVETIRACETAM

**LUITPOLD**

* LUITPOLD PHARMACEUTICALS INC
ACETYLCYSTEINE, ACETYLCYSTEINE
ADENOSINE, ADENOSINE
AMINOCAPROIC ACID, AMINOCAPROIC ACID
AMINOPHYLLINE, AMINOPHYLLINE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BETAMETHASONE ACETATE AND BETAMETHASONE SODIUM PHOSPHATE, BETAMETHASONE ACETATE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CAFFEINE CITRATE, CAFFEINE CITRATE
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYCLOSPORINE, CYCLOSPORINE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXFERRUM, IRON DEXTRAN
DOPAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DROPERIDOL, DROPERIDOL
ESTRADIOL VALERATE, ESTRADIOL VALERATE
ETOMIDATE, ETOMIDATE
FOMEPIZOLE, FOMEPIZOLE
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
GLYCOPYRROLATE, GLYCOPYRROLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
LEVETIRACETAM, LEVETIRACETAM
LEVOCARNITINE, LEVOCARNITINE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
MANNITOL 25%, MANNITOL
METHYLDOPATE HYDROCHLORIDE, METHYLDOPATE HYDROCHLORIDE
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
NITROGLYCERIN, NITROGLYCERIN
OLANZAPINE, OLANZAPINE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PHENYTOIN SODIUM, PHENYTOIN SODIUM
PROGESTERONE, PROGESTERONE
TRANEXAMIC ACID, TRANEXAMIC ACID
TRIMETHOBENZAMIDE HYDROCHLORIDE PRESERVATIVE FREE, TRIMETHOBENZAMIDE HYDROCHLORIDE
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
VENOFER, IRON SUCROSE
ZIDOVUDINE, ZIDOVUDINE

**LUITPOLD PHARMS INC**

* LUITPOLD PHARMACEUTICALS INC
BUSULFAN, BUSULFAN
CALCIUM CHLORIDE 10%, CALCIUM CHLORIDE
DACTINOMYCIN, DACTINOMYCIN
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
GANCICLOVIR, GANCICLOVIR SODIUM
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
INJECTAFER, FERRIC CARBOXYMALTOSE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
NANDROLONE DECANOATE, NANDROLONE DECANOATE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** L ****

* LUITPOLD PHARMACEUTICALS INC
OXALIPLATIN, OXALIPLATIN
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE

**LUKARE MEDICAL LLC**

* LUKARE MEDICAL LLC
ELLIOTTS B SOLUTION, CALCIUM CHLORIDE

**LUNDBECK NA LTD**

* LUNDBECK NA LTD
NORTHERA, DROXIDOPA

**LUNDBECK PHARMS LLC**

* LUNDBECK PHARMACEUTICALS LLC
CARNEXIV, CARBAMAZEPINE
ONFI, CLOBAZAM
SABRIL, VIGABATRIN

**LUPIN**

* LUPIN INC
SOLOSEC, SECNIDAZOLE
* LUPIN LTD
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
CARVEDILOL, CARVEDILOL
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFDINIR, CEFDINIR
CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
CEFPROZIL, CEFPROZIL
CEFTRIAXONE, CEFTRIAXONE SODIUM
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEPHALEXIN, CEPHALEXIN
DIVALPROEX SODIUM, DIVALPROEX SODIUM
ETHAMBUTOL HYDROCHLORIDE, ETHAMBUTOL HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LOVASTATIN, LOVASTATIN
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
TOPIRAMATE, TOPIRAMATE
TRANDOLAPRIL, TRANDOLAPRIL

**LUPIN ATLANTIS**

* LUPIN ATLANTIS HOLDINGS SA
ANTARA (MICRONIZED), FENOFIBRATE
DESOXIMETASONE, DESOXIMETASONE
MIBELAS 24 FE, ETHINYL ESTRADIOL
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
TOBRAMYCIN, TOBRAMYCIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

**LUPIN LTD**

* LUPIN LIMITED
LEVETIRACETAM, LEVETIRACETAM
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
* LUPIN LTD
ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE, ABACAVIR SULFATE
AMABELZ, ESTRADIOL
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
ARMODAFINIL, ARMODAFINIL
AZITHROMYCIN, AZITHROMYCIN
BEKYREE, DESOGESTREL
BIMATOPROST, BIMATOPROST
BLISOVI 24 FE, ETHINYL ESTRADIOL
BLISOVI FE 1.5/30, ETHINYL ESTRADIOL
BLISOVI FE 1/20, ETHINYL ESTRADIOL

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** L ****

* LUPIN LTD

BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CALCIUM ACETATE, CALCIUM ACETATE
CELECOXIB, CELECOXIB
CIPROFLOXACIN, CIPROFLOXACIN
CLARITHROMYCIN, CLARITHROMYCIN
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
DAYSEE, ETHINYL ESTRADIOL
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENSKYCE, DESOGESTREL
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESZOPICLONE, ESZOPICLONE
FALLBACK SOLO, LEVONORGESTREL (OTC)
FAMOTIDINE, FAMOTIDINE
FAYOSIM, ETHINYL ESTRADIOL
FENOFIBRATE, FENOFIBRATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FYAVOLV, ETHINYL ESTRADIOL
GATIFLOXACIN, GATIFLOXACIN
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
JENCYCLA, NORETHINDRONE
KAITLIB FE, ETHINYL ESTRADIOL
KURVELO, ETHINYL ESTRADIOL
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LORAZEPAM, LORAZEPAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEFENAMIC ACID, MEFENAMIC ACID
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NABUMETONE, NABUMETONE
NADOLOL, NADOLOL
NIACIN, NIACIN
NIKKI, DROSPIRENONE
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE, NORETHINDRONE
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OMEPRAZOLE, OMEPRAZOLE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PIRMELLA 1/35, ETHINYL ESTRADIOL
PIRMELLA 7/7/7, ETHINYL ESTRADIOL
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUININE SULFATE, QUININE SULFATE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
REPAGLINIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** L ****

* LUPIN LTD
RIFABUTIN, RIFABUTIN
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SUPRAX, CEFIXIME
TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TESTOSTERONE, TESTOSTERONE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TYDEMY, DROSPIRENONE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN, VALSARTAN
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VYFEMLA, ETHINYL ESTRADIOL
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**LUPIN PHARMS**
* LUPIN PHARMACEUTICALS INC
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
DESLORATADINE, DESLORATADINE
MELOXICAM, MELOXICAM
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
RIFAMPIN, RIFAMPIN
SUPRAX, CEFIXIME
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

**LYMOL MEDCL**
* LYMOL MEDICAL CORP
SCLEROSOL, TALC
TALC, TALC

**LYNE**
* LYNE LABORATORIES INC
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
LEVOCARNITINE, LEVOCARNITINE
NYSTATIN, NYSTATIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

**PERRIGO**
* L PERRIGO CO
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
ACETAMINOPHEN, ASPIRIN AND CAFFEINE, ACETAMINOPHEN (OTC)
CHILDREN'S IBUPROFEN, IBUPROFEN (OTC)
CROMOLYN SODIUM, CROMOLYN SODIUM (OTC)
DOXYLAMINE SUCCINATE, DOXYLAMINE SUCCINATE (OTC)
FAMOTIDINE, FAMOTIDINE (OTC)
IBUPROFEN AND PSEUDOEPHEDRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LORATADINE, LORATADINE (OTC)
MICONAZOLE 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE, NAPROXEN SODIUM (OTC)
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
TAB-PROFEN, IBUPROFEN (OTC)
TIOCONAZOLE, TIOCONAZOLE (OTC)

**** M ****

**MA GENERAL HOSP**
* MASSACHUSETTS GENERAL HOSP
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

**MACLEODS PHARMS LTD**

* MACLEODS PHARMACEUTICALS LTD

AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ARIPIPRAZOLE, ARIPIPRAZOLE
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CELECOXIB, CELECOXIB
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DARIFENACIN, DARIFENACIN HYDROBROMIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENTACAPONE, ENTACAPONE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESZOPICLONE, ESZOPICLONE
FAMCICLOVIR, FAMCICLOVIR
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NEVIRAPINE, NEVIRAPINE
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN, VALSARTAN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZOLMITRIPTAN, ZOLMITRIPTAN

**MAGNA PHARMS**

* MAGNA PHARMACEUTICALS INC

ZOLPIMIST, ZOLPIDEM TARTRATE

**MAIA PHARMS INC**

* MAIA PHARMACEUTICALS INC

SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE

**MALLINCKRODT ARD**

* MALLINCKRODT ARD INC

H.P. ACTHAR GEL, CORTICOTROPIN

**MALLINCKRODT HOSP**

* MALLINCKRODT HOSPITAL PRODUCTS IP LTD

INOMAX, NITRIC OXIDE
UVADEX, METHOXSALEN

**MALLINCKRODT IP**

* MALLINCKRODT IP

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MALLINCKRODT IP
OFIRMEV, ACETAMINOPHEN

**MALLINKRODT NUCLEAR**

* MALLINCKRODT NUCLEAR MEDICINE LLC
GALLIUM CITRATE GA 67, GALLIUM CITRATE GA-67
INDIUM IN 111 CHLORIDE, INDIUM IN-111 CHLORIDE
OCTREOSCAN, INDIUM IN-111 PENTETREOTIDE KIT
SODIUM IODIDE I 123, SODIUM IODIDE I-123
SODIUM IODIDE I 131, SODIUM IODIDE I-131
TECHNESCAN MAG3, TECHNETIUM TC-99M MERTIATIDE KIT
TECHNESCAN PYP KIT, TECHNETIUM TC-99M PYROPHOSPHATE KIT
TECHNESCAN, TECHNETIUM TC-99M OXIDRONATE KIT
TECHNETIUM TC-99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
THALLOUS CHLORIDE TL 201, THALLOUS CHLORIDE TL-201
ULTRA-TECHNEKOW FM, TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR
ULTRATAG, TECHNETIUM TC-99M RED BLOOD CELL KIT
XENON XE 133, XENON XE-133

**MANNKIND**

* MANNKIND CORP
AFREZZA, INSULIN RECOMBINANT HUMAN

**MARINA BIOTECH**

* MARINA BIOTECH INC
PRESTALIA, AMLODIPINE BESYLATE

**MARKSANS PHARMA**

* MARKSANS PHARMA LTD
DUTASTERIDE, DUTASTERIDE
GABAPENTIN, GABAPENTIN
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LORATADINE, LORATADINE (OTC)
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NAPROXEN, NAPROXEN
PARICALCITOL, PARICALCITOL

**MARNEL PHARMS**

* MARNEL PHARMACEUTICALS LLC
CROTAN, CROTAMITON

**MAYER LABS INC**

* MAYER LABORATORIES INC
TODAY, NONOXYNOL-9 (OTC)

**MAYNE PHARMA**

* MAYNE PHARMA INTERNATIONAL PTY LTD
DORYX MPC, DOXYCYCLINE HYCLATE
DORYX, DOXYCYCLINE HYCLATE
ERYC, ERYTHROMYCIN

* MAYNE PHARMA LLC
BUDESONIDE, BUDESONIDE
CAMILA, NORETHINDRONE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CLARITHROMYCIN, CLARITHROMYCIN
CLONIDINE, CLONIDINE
CLOZAPINE, CLOZAPINE
CYCLOSPORINE, CYCLOSPORINE
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DIAZEPAM, DIAZEPAM
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
ERRIN, NORETHINDRONE
ESTAZOLAM, ESTAZOLAM
ESTRADIOL, ESTRADIOL
FABIOR, TAZAROTENE
FENTANYL-100, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MAYNE PHARMA LLC
FENTANYL-75, FENTANYL
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVORA 0.15/30-28, ETHINYL ESTRADIOL
LOW-OGESTREL-28, ETHINYL ESTRADIOL
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MICROGESTIN 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN 1/20, ETHINYL ESTRADIOL
MICROGESTIN FE 1.5/30, ETHINYL ESTRADIOL
MICROGESTIN FE 1/20, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
SORILUX, CALCIPOTRIENE
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TRI-NORINYL 28-DAY, ETHINYL ESTRADIOL
TRIMETHOPRIM, TRIMETHOPRIM
TRIVORA-28, ETHINYL ESTRADIOL
ZOVIA 1/35E-28, ETHINYL ESTRADIOL

**MAYNE PHARMA INC**
* MAYNE PHARMA INC
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE, ASPIRIN
DOFETILIDE, DOFETILIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE, HYDROCODONE BITARTRATE
HYDROCODONE BITARTRATE,CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE,
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NYSTATIN, NYSTATIN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE AND ASPIRIN, ASPIRIN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

**MCGUFF**
* MCGUFF PHARMACEUTICALS INC
ASCOR, ASCORBIC ACID

**MCNEIL**
* MCNEIL CONSUMER PRODUCTS CO DIV MCNEILAB INC
IBUPROFEN, IBUPROFEN (OTC)

**MCNEIL CONS**
* MCNEIL CONSUMER HEALTHCARE
SUDAFED 12 HOUR, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)

**MCPRF**
* MAYO CLINIC PET RADIOCHEMISTRY FACILITY
AMMONIA N 13, AMMONIA N-13
CHOLINE C-11, CHOLINE C-11
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**MEDAC PHARMA INC**
* MEDAC PHARMA INC
RASUVO, METHOTREXATE

**MEDEFIL INC**
* MEDEFIL INC
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE

**MEDICINES360**
* MEDICINES360
LILETTA, LEVONORGESTREL

**MEDICIS**
* MEDICIS PHARMACEUTICAL CORP
ALDARA, IMIQUIMOD
AMMONUL, SODIUM BENZOATE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MEDICIS PHARMACEUTICAL CORP
CALCIUM DISODIUM VERSENATE, EDETATE CALCIUM DISODIUM
LOPROX, CICLOPIROX
LUZU, LULICONAZOLE
METROGEL-VAGINAL, METRONIDAZOLE
MINITRAN, NITROGLYCERIN
SOLODYN, MINOCYCLINE HYDROCHLORIDE
VANOS, FLUOCINONIDE
ZIANA, CLINDAMYCIN PHOSPHATE
ZYCLARA, IMIQUIMOD

**MEDICURE**
* MEDICURE INTERNATIONAL INC
AGGRASTAT, TIROFIBAN HYDROCHLORIDE

**MEDIGENE AG**
* MEDIGENE AG
VEREGEN, SINECATECHINS

**MEDIMETRIKS PHARMS**
* MEDIMETRIKS PHARMACEUTICALS INC
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
LOPROX, CICLOPIROX
NEO-SYNALAR, FLUOCINOLONE ACETONIDE
SYNALAR, FLUOCINOLONE ACETONIDE

**MEDTECH PRODUCTS**
* MEDTECH PRODUCTS INC
MONISTAT 1 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK (PREFILLED), MICONAZOLE NITRATE (OTC)
MONISTAT 3 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 3, MICONAZOLE NITRATE
MONISTAT 3, MICONAZOLE NITRATE (OTC)
MONISTAT 7 COMBINATION PACK, MICONAZOLE NITRATE (OTC)
MONISTAT 7, MICONAZOLE NITRATE (OTC)
NIX, PERMETHRIN (OTC)
TAGAMET HB, CIMETIDINE (OTC)

**MELINTA**
* MELINTA SUBSIDIARY CORP
BAXDELA, DELAFLOXACIN MEGLUMINE

**MEM SLOAN-KETTERING**
* MEMORIAL SLOAN-KETTERING CANCER CENTER
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**MERCK**
* MERCK AND CO INC
CANCIDAS, CASPOFUNGIN ACETATE
EMEND, APREPITANT
FOSAMAX PLUS D, ALENDRONATE SODIUM
MAXALT, RIZATRIPTAN BENZOATE
MAXALT-MLT, RIZATRIPTAN BENZOATE
PRIMAXIN, CILASTATIN SODIUM
PROSCAR, FINASTERIDE
ZOLINZA, VORINOSTAT
* MERCK RESEARCH LABORATORIES DIV MERCK CO INC
PRINIVIL, LISINOPRIL
PROPECIA, FINASTERIDE
SINGULAIR, MONTELUKAST SODIUM
TRUSOPT, DORZOLAMIDE HYDROCHLORIDE

**MERCK AND CO INC**
* MERCK AND CO INC
EMEND, FOSAPREPITANT DIMEGLUMINE
FOSAMAX, ALENDRONATE SODIUM

**MERCK SHARP DOHME**
* MERCK SHARP AND DOHME CORP
ASMANEX HFA, MOMETASONE FUROATE
ASMANEX TWISTHALER, MOMETASONE FUROATE
BELSOMRA, SUVOREXANT
CELESTONE SOLUSPAN, BETAMETHASONE ACETATE
CLARINEX D 24 HOUR, DESLORATADINE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MERCK SHARP AND DOHME CORP
CLARINEX, DESLORATADINE
CLARINEX-D 12 HOUR, DESLORATADINE
COZAAR, LOSARTAN POTASSIUM
CRIXIVAN, INDINAVIR SULFATE
DIPROLENE AF, BETAMETHASONE DIPROPIONATE
DIPROLENE, BETAMETHASONE DIPROPIONATE
DULERA, FORMOTEROL FUMARATE
ELOCON, MOMETASONE FUROATE
GUANIDINE HYDROCHLORIDE, GUANIDINE HYDROCHLORIDE
HYZAAR, HYDROCHLOROTHIAZIDE
INVANZ, ERTAPENEM SODIUM
ISENTRESS HD, RALTEGRAVIR POTASSIUM
ISENTRESS, RALTEGRAVIR POTASSIUM
JANUMET XR, METFORMIN HYDROCHLORIDE
JANUMET, METFORMIN HYDROCHLORIDE
JANUVIA, SITAGLIPTIN PHOSPHATE
LOTRISONE, BETAMETHASONE DIPROPIONATE
NASONEX, MOMETASONE FUROATE
NOXAFIL, POSACONAZOLE
PREVYMIS, LETERMOVIR
REBETOL, RIBAVIRIN
SEGLUROMET, ERTUGLIFLOZIN
SINEMET CR, CARBIDOPA
SINEMET, CARBIDOPA
STEGLATRO, ERTUGLIFLOZIN
STELUJAN, ERTUGLIFLOZIN
STROMECTOL, IVERMECTIN
TEMODAR, TEMOZOLOMIDE
ZEPATIER, ELBASVIR

**MERIDIAN MEDCL**
* MERIDIAN MEDICAL TECHNOLOGIES INC
DUODOTE, ATROPINE

**MERIDIAN MEDCL TECHN**
* MERIDIAN MEDICAL TECHNOLOGIES INC
ATROPEN, ATROPINE
MORPHINE SULFATE, MORPHINE SULFATE
PRALIDOXIME CHLORIDE, PRALIDOXIME CHLORIDE

**MERRO PHARM**
* MERRO PHARMACEUTICAL CO LTD
IBUPROFEN, IBUPROFEN (OTC)

**MERZ PHARMS**
* MERZ PHARMACEUTICALS LLC
CUVPOSA, GLYCOPYRROLATE

**METHAPHARM**
* METHAPHARM INC
PROVOCHOLINE, METHACHOLINE CHLORIDE

**METUCHEN PHARMS**
* METUCHEN PHARMACEUTICALS LLC
STENDRA, AVANAFIL

**MICRO LABS**
* MICRO LABS LTD
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
CAFFEINE CITRATE, CAFFEINE CITRATE
PIROXICAM, PIROXICAM
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE
TELMISARTAN, TELMISARTAN

**MICRO LABS LTD**
* MICRO LABS LTD
NEVIRAPINE, NEVIRAPINE

**MICRO LABS LTD INDIA**
* MICRO LABS LTD INDIA
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
CROMOLYN SODIUM, CROMOLYN SODIUM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MICRO LABS LTD INDIA
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN

**MIDATECH PHARMA US**

* MIDATECH PHARMA US INC
ORAVIG, MICONAZOLE
SOLTAMOX, TAMOXIFEN CITRATE
ZUPLENZ, ONDANSETRON

**MIDWEST MEDCL**

* MIDWEST MEDICAL ISOTOPES LLC CYCLOTRON DIV
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**MIKART**

* MIKART INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
BENZONATATE, BENZONATATE
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTAPAP, ACETAMINOPHEN
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CHLORZOXAZONE, CHLORZOXAZONE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
ERGOTAMINE TARTRATE AND CAFFEINE, CAFFEINE
ETHOSUXIMIDE, ETHOSUXIMIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
ISONIAZID, ISONIAZID
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

**MIKART INC**

* MIKART INC
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CHLORZOXAZONE, CHLORZOXAZONE

**MILLENNIUM PHARMS**

* MILLENNIUM PHARMACEUTICALS INC
NINLARO, IXAZOMIB CITRATE
VELCADE, BORTEZOMIB

**MIPS CRF**

* MIPS CYCLOTRON AND RADIOCHEMISTRY FACILITY
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**MISSION PHARMA**

* MISSION PHARMACAL CO
BINOSTO, ALENDRONATE SODIUM
LITHOSTAT, ACETOHYDROXAMIC ACID
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
TEXACORT, HYDROCORTISONE
THIOLA, TIOPRONIN
TINDAMAX, TINIDAZOLE
UROCIT-K, POTASSIUM CITRATE

**MISSION PHARMACAL CO**

* MISSION PHARMACAL CO
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
FLOWTUSS, GUAIFENESIN
HYCOFENIX, GUAIFENESIN
POTASSIUM IODIDE, POTASSIUM IODIDE (OTC)

**MIST PHARMS LLC**

* MIST PHARMACEUTICALS LLC
NITROMIST, NITROGLYCERIN

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

**MITSUBISHI TANABE**
* MITSUBISHI TANABE PHARMA CORP
RADICAVA, EDARAVONE

**MOBERG PHARMA NORTH**
* MOBERG PHARMA NORTH AMERICA LLC
CHILDREN'S ELIXSURE, IBUPROFEN (OTC)

**MOBIUS THERAP**
* MOBIUS THERAPEUTICS LLC
MITOSOL, MITOMYCIN

**MOLNLYCKE HLTH**
* MOLNLYCKE HEALTH CARE
HIBICLENS, CHLORHEXIDINE GLUCONATE (OTC)
HIBISTAT, CHLORHEXIDINE GLUCONATE (OTC)

**MONARCH PHARMS**
* MONARCH PHARMACEUTICALS LLC
CORTISPORIN, BACITRACIN ZINC
CORTISPORIN, HYDROCORTISONE ACETATE
CORTISPORIN, HYDROCORTISONE
MENEST, ESTROGENS, ESTERIFIED
NEOSPORIN G.U. IRRIGANT, NEOMYCIN SULFATE
NEOSPORIN, GRAMICIDIN
SEPTRA DS, SULFAMETHOXAZOLE
SEPTRA, SULFAMETHOXAZOLE
VIROPTIC, TRIFLURIDINE

**MONTEREY PHARMS LLC**
* MONTEREY PHARMACEUTICALS LLC
METHOCARBAMOL, METHOCARBAMOL

**MSD INTL**
* MSD INTERNATIONAL GMBH
VYTORIN, EZETIMIBE

**MSD INTL GMBH**
* MSD INTERNATIONAL GMBH
ZETIA, EZETIMIBE

**MSD MERCK CO**
* MERCK SHARP AND DOHME CORP A SUB OF MERCK AND CO INC
EMEND, APREPITANT
SINGULAIR, MONTELUKAST SODIUM
ZOCOR, SIMVASTATIN

**MSN LABS PVT LTD**
* MSN LABORATORIES PRIVATE LTD
CLOFARABINE, CLOFARABINE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM

**MURTY PHARMS**
* MURTY PHARMACEUTICALS INC
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE

**MUSTAFA NEVZAT ILAC**
* MUSTAFA NEVZAT ILAC SANAYII AS (MN PHARMACEUTICALS)
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

**MUTUAL PHARM**
* MUTUAL PHARMACEUTICAL CO INC
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
MINOXIDIL, MINOXIDIL
PREDNISONE, PREDNISONE

**MYLAN**
* MYLAN PHARMACEUTICALS
FENOFIBRATE, FENOFIBRATE
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
* MYLAN PHARMACEUTICALS INC

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MYLAN PHARMACEUTICALS INC
ACARBOSE, ACARBOSE
ACEBUTOLOL HYDROCHLORIDE, ACEBUTOLOL HYDROCHLORIDE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALLOPURINOL, ALLOPURINOL
ALPRAZOLAM, ALPRAZOLAM
AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, AMILORIDE HYDROCHLORIDE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
ANASTROZOLE, ANASTROZOLE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
AVITA, TRETINOIN
AZATHIOPRINE, AZATHIOPRINE
AZITHROMYCIN, AZITHROMYCIN
BACLOFEN, BACLOFEN
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BICALUTAMIDE, BICALUTAMIDE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BUDESONIDE, BUDESONIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CAPTOPRIL AND HYDROCHLOROTHIAZIDE, CAPTOPRIL
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CHLOROTHIAZIDE, CHLOROTHIAZIDE
CHLORPROPAMIDE, CHLORPROPAMIDE
CHLORTHALIDONE, CHLORTHALIDONE
CIMETIDINE, CIMETIDINE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
CLORPRES, CHLORTHALIDONE
CLOZAPINE, CLOZAPINE
CYSTAGON, CYSTEAMINE BITARTRATE
DIAZEPAM, DIAZEPAM
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ESTRADIOL, ESTRADIOL
ESTROPIPATE, ESTROPIPATE
ETIDRONATE DISODIUM, ETIDRONATE DISODIUM
ETOPOSIDE, ETOPOSIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MYLAN PHARMACEUTICALS INC
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
FAMCICLOVIR, FAMCICLOVIR
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FELODIPINE, FELODIPINE
FENOFIBRATE, FENOFIBRATE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FINASTERIDE, FINASTERIDE
FLUCONAZOLE, FLUCONAZOLE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FUROSEMIDE, FUROSEMIDE
GABAPENTIN, GABAPENTIN
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GLIMEPIRIDE, GLIMEPIRIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLIPIZIDE, GLIPIZIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
INDAPAMIDE, INDAPAMIDE
INDOMETHACIN, INDOMETHACIN
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LAMOTRIGINE, LAMOTRIGINE
LATANOPROST, LATANOPROST
LETROZOLE, LETROZOLE
LEVETIRACETAM, LEVETIRACETAM
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM **
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LORATADINE, LORATADINE (OTC)
LORAZEPAM, LORAZEPAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOVASTATIN, LOVASTATIN
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
MAPROTILINE HYDROCHLORIDE, MAPROTILINE HYDROCHLORIDE
MECLOFENAMATE SODIUM, MECLOFENAMATE SODIUM
MELOXICAM, MELOXICAM
MENTAX, BUTENAFINE HYDROCHLORIDE
MERCAPTOPURINE, MERCAPTOPURINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHIMAZOLE, METHIMAZOLE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METHYLDOPA AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
METHYLDOPA, METHYLDOPA
METOLAZONE, METOLAZONE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIRTAZAPINE, MIRTAZAPINE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NADOLOL, NADOLOL
NAPROXEN, NAPROXEN

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** M **

* MYLAN PHARMACEUTICALS INC
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NIFEDIPINE, NIFEDIPINE
NISOLDIPINE, NISOLDIPINE
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
OMEPRAZOLE, OMEPRAZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PENTOXIFYLLINE, PENTOXIFYLLINE
PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
PHENYTEK, PHENYTOIN SODIUM
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PROBENECID, PROBENECID
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
RISPERIDONE, RISPERIDONE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SELEGILINE HYDROCHLORIDE, SELEGILINE HYDROCHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
STAVUDINE, STAVUDINE
SULINDAC, SULINDAC
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TACROLIMUS, TACROLIMUS
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TEMAZEPAM, TEMAZEPAM
THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
THIOTHIXENE, THIOTHIXENE
TIMOLOL MALEATE, TIMOLOL MALEATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
URSODIOL, URSODIOL
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
ZONISAMIDE, ZONISAMIDE

**MYLAN ASI**

* MYLAN ASI LLC
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

**MYLAN INSTITUTIONAL**

* MYLAN INSTITUTIONAL INC
SULFAMYLON, MAFENIDE ACETATE
* MYLAN INSTITUTIONAL LLC
ACETYLCYSTEINE, ACETYLCYSTEINE
ALOPRIM, ALLOPURINOL SODIUM
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
ARGATROBAN, ARGATROBAN
AZACITIDINE, AZACITIDINE
CARBOPLATIN, CARBOPLATIN

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MYLAN INSTITUTIONAL LLC
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CIDOFOVIR, CIDOFOVIR
COSYNTROPIN, COSYNTROPIN
DANTROLENE SODIUM, DANTROLENE SODIUM
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
DIMETHYL SULFOXIDE, DIMETHYL SULFOXIDE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DURACLON, CLONIDINE HYDROCHLORIDE
ENLON, EDROPHONIUM CHLORIDE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
FOMEPIZOLE, FOMEPIZOLE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
IBUTILIDE FUMARATE, IBUTILIDE FUMARATE
ISOSULFAN BLUE, ISOSULFAN BLUE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
MEFOXIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MESNA, MESNA
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
PENTOSTATIN, PENTOSTATIN
PYRIDOXINE HYDROCHLORIDE, PYRIDOXINE HYDROCHLORIDE
RIMSO-50, DIMETHYL SULFOXIDE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SOTRADECOL, SODIUM TETRADECYL SULFATE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
ULTIVA, REMIFENTANIL HYDROCHLORIDE

**MYLAN IRELAND LTD**

* MYLAN IRELAND LTD
ARIXTRA, FONDAPARINUX SODIUM
CARBAMAZEPINE, CARBAMAZEPINE
MIACALCIN, CALCITONIN SALMON
PIROXICAM, PIROXICAM
SUCRALFATE, SUCRALFATE
THEOPHYLLINE, THEOPHYLLINE

**MYLAN LABS**

* MYLAN LABORATORIES LTD
NEVIRAPINE, NEVIRAPINE

**MYLAN LABS LTD**

* MYLAN LABORATORIES LTD
ADENOSINE, ADENOSINE
AMIFOSTINE, AMIFOSTINE
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
AZITHROMYCIN, AZITHROMYCIN
CAPREOMYCIN SULFATE, CAPREOMYCIN SULFATE
CARBOPLATIN, CARBOPLATIN
CASPOFUNGIN ACETATE, CASPOFUNGIN ACETATE
CISPLATIN, CISPLATIN
CLADRIBINE, CLADRIBINE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOFARABINE, CLOFARABINE
CYANOCOBALAMIN, CYANOCOBALAMIN

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MYLAN LABORATORIES LTD
CYTARABINE, CYTARABINE
DACTINOMYCIN, DACTINOMYCIN
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
ETOMIDATE, ETOMIDATE
ETOPOSIDE, ETOPOSIDE
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUMAZENIL, FLUMAZENIL
FLUOROURACIL, FLUOROURACIL
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
GANCICLOVIR, GANCICLOVIR SODIUM
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN SODIUM, HEPARIN SODIUM
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
IFOSFAMIDE, IFOSFAMIDE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
LEVONORGESTREL AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LEVONORGESTREL, LEVONORGESTREL
LEVONORGESTREL, LEVONORGESTREL (OTC)
LINEZOLID, LINEZOLID
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METRONIDAZOLE IN PLASTIC CONTAINER, METRONIDAZOLE
MITOMYCIN, MITOMYCIN
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MOXIFLOXACIN HYDROCHLORIDE IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER, MOXIFLOXACIN
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
NAFCILLIN SODIUM, NAFCILLIN SODIUM
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE,
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE ACETATE, NORETHINDRONE ACETATE
NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE, ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
NORETHINDRONE, NORETHINDRONE
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN
PACLITAXEL, PACLITAXEL
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PARICALCITOL, PARICALCITOL
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RIFAMPIN, RIFAMPIN
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MYLAN LABORATORIES LTD
VECURONIUM BROMIDE, VECURONIUM BROMIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

**MYLAN PHARMS INC**

* MYLAN PHARMACEUTICALS INC
ABACAVIR SULFATE, ABACAVIR SULFATE
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
ACITRETIN, ACITRETIN
ACYCLOVIR, ACYCLOVIR
ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMNESTEEM, ISOTRETINOIN
ARMODAFINIL, ARMODAFINIL
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
ATOVAQUONE AND PROGUANIL HYDROCHLORIDE, ATOVAQUONE
AVITA, TRETINOIN
BACLOFEN, BACLOFEN
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CABERGOLINE, CABERGOLINE
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CAPECITABINE, CAPECITABINE
CAPTOPRIL, CAPTOPRIL
CELECOXIB, CELECOXIB
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
CIPROFLOXACIN EXTENDED RELEASE, CIPROFLOXACIN
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLOZAPINE, CLOZAPINE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
CYTARABINE, CYTARABINE
DENAVIR, PENCICLOVIR
DESLORATADINE, DESLORATADINE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIGOXIN, DIGOXIN
DISULFIRAM, DISULFIRAM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DOXYCYCLINE, DOXYCYCLINE
DUTASTERIDE, DUTASTERIDE
EFAVIRENZ, EFAVIRENZ
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
ELIMITE, PERMETHRIN
EPLERENONE, EPLERENONE
EPROSARTAN MESYLATE, EPROSARTAN MESYLATE
ERYGEL, ERYTHROMYCIN
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
ESTRADIOL, ESTRADIOL
ESZOPICLONE, ESZOPICLONE
EVOCLIN, CLINDAMYCIN PHOSPHATE
EXEMESTANE, EXEMESTANE
EXTINA, KETOCONAZOLE
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRATE, FENOFIBRATE
FENOFIBRIC ACID, CHOLINE FENOFIBRATE
FINASTERIDE, FINASTERIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MYLAN PHARMACEUTICALS INC
FLUOROURACIL, FLUOROURACIL
FLURAZEPAM HYDROCHLORIDE, FLURAZEPAM HYDROCHLORIDE
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
FOSAMPRENAVIR CALCIUM, FOSAMPRENAVIR CALCIUM
FROVATRIPTAN SUCCINATE, FROVATRIPTAN SUCCINATE
GABAPENTIN, GABAPENTIN
GLATIRAMER ACETATE, GLATIRAMER ACETATE
GLIPIZIDE, GLIPIZIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IMATINIB MESYLATE, IMATINIB MESYLATE
INDOMETHACIN, INDOMETHACIN
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
ITRACONAZOLE, ITRACONAZOLE
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LAMIVUDINE, LAMIVUDINE
LANSOPRAZOLE, LANSOPRAZOLE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LINEZOLID, LINEZOLID
LITHIUM CARBONATE, LITHIUM CARBONATE
LUXIQ, BETAMETHASONE VALERATE
MAXZIDE, HYDROCHLOROTHIAZIDE
MAXZIDE-25, HYDROCHLOROTHIAZIDE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MESALAMINE, MESALAMINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHYCLOTHIAZIDE, METHYCLOTHIAZIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MODAFINIL, MODAFINIL
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MORPHINE SULFATE, MORPHINE SULFATE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
NABUMETONE, NABUMETONE
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NEVIRAPINE, NEVIRAPINE
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OLUX E, CLOBETASOL PROPIONATE
OLUX, CLOBETASOL PROPIONATE
PALIPERIDONE, PALIPERIDONE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PERPHENAZINE, PERPHENAZINE
PHENYTOIN, PHENYTOIN
PINDOLOL, PINDOLOL
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PRASUGREL, PRASUGREL HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISONE, PREDNISONE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
QUININE SULFATE, QUININE SULFATE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
RASAGILINE MESYLATE, RASAGILINE MESYLATE
REPAGLINIDE, REPAGLINIDE
RILUZOLE, RILUZOLE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MYLAN PHARMACEUTICALS INC
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
RUFINAMIDE, RUFINAMIDE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TELMISARTAN, TELMISARTAN
TEMOZOLOMIDE, TEMOZOLOMIDE
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOBRAMYCIN, TOBRAMYCIN
TOLAZAMIDE, TOLAZAMIDE
TOLBUTAMIDE, TOLBUTAMIDE
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAVOPROST, TRAVOPROST
TRETINOIN, TRETINOIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIAZOLAM, TRIAZOLAM
TRILYTE, POLYETHYLENE GLYCOL 3350
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN, VALSARTAN
VORICONAZOLE, VORICONAZOLE
VUSION, MICONAZOLE NITRATE
ZIDOVUDINE, ZIDOVUDINE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZOLMITRIPTAN, ZOLMITRIPTAN
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
ZONALON, DOXEPIN HYDROCHLORIDE
ZOVIRAX, ACYCLOVIR

* MYLAN PHARMACEUTICALS INC.
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
NIZATIDINE, NIZATIDINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

**MYLAN SPECIALITY LP**

* MYLAN SPECIALTY LP
ACCUNEB, ALBUTEROL SULFATE
AEROSPAN HFA, FLUNISOLIDE
ANADROL-50, OXYMETHOLONE
ASTELIN, AZELASTINE HYDROCHLORIDE
ASTEPRO, AZELASTINE HYDROCHLORIDE
AVC, SULFANILAMIDE
BUTISOL SODIUM, BUTABARBITAL SODIUM
CESAMET, NABILONE
COLYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
CORTIFOAM, HYDROCORTISONE ACETATE
CROMOLYN SODIUM, CROMOLYN SODIUM
DEMADEX, TORSEMIDE
DEPEN, PENICILLAMINE
DIPENTUM, OLSALAZINE SODIUM
DYMISTA, AZELASTINE HYDROCHLORIDE
EDLUAR, ZOLPIDEM TARTRATE
ELESTRIN, ESTRADIOL
EPIFOAM, HYDROCORTISONE ACETATE
EPIPEN JR., EPINEPHRINE
EPIPEN, EPINEPHRINE
FELBATOL, FELBAMATE
GASTROCROM, CROMOLYN SODIUM
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
MUSE, ALPROSTADIL
PROCTOFOAM HC, HYDROCORTISONE ACETATE
ROWASA, MESALAMINE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** M ****

* MYLAN SPECIALTY LP
SFROWASA, MESALAMINE
SOMA, CARISOPRODOL

**MYLAN SPECLT**

* MYLAN SPECIALTY LP
PERFOROMIST, FORMOTEROL FUMARATE

**MYLAN TECHNOLOGIES**

* MYLAN TECHNOLOGIES INC
CLONIDINE, CLONIDINE
ESTRADIOL, ESTRADIOL
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-37, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-62, FENTANYL
FENTANYL-75, FENTANYL
FENTANYL-87, FENTANYL
LIDOCAINE, LIDOCAINE
NITROGLYCERIN, NITROGLYCERIN
XULANE, ETHINYL ESTRADIOL

**MYLAN TEORANTA**

* MYLAN TEORANTA
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM

**** N ****

**NAMIGEN LLC**

* NAMIGEN LLC
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE

**NANG KUANG PHARM CO**

* NANG KUANG PHARMACEUTICAL CO LTD
LINEZOLID, LINEZOLID

**NANJING KING-FRIEND**

* NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO LTD
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
CARBOPLATIN, CARBOPLATIN

**NAPO PHARMS INC**

* NAPO PHARMACEUTICALS INC
FULYZAQ, CROFELEMER

**NATCO PHARMA**

* NATCO PHARMA LTD
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE

**NATCO PHARMA LTD**

* NATCO PHARMA LIMITED
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
* NATCO PHARMA LTD
ALPRAZOLAM, ALPRAZOLAM
ANASTROZOLE, ANASTROZOLE
ARMODAFINIL, ARMODAFINIL
AZACITIDINE, AZACITIDINE
CARISOPRODOL, CARISOPRODOL
CHLOROQUINE PHOSPHATE, CHLOROQUINE PHOSPHATE
GLYCOPYRROLATE, GLYCOPYRROLATE
LANSOPRAZOLE, LANSOPRAZOLE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LANTHANUM CARBONATE, LANTHANUM CARBONATE
LETROZOLE, LETROZOLE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

**NAVINTA LLC**

* NAVINTA LLC

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

* NAVINTA LLC
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
FAMOTIDINE, FAMOTIDINE
FOMEPIZOLE, FOMEPIZOLE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
METHOCARBAMOL, METHOCARBAMOL
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
RIBAVIRIN, RIBAVIRIN
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE
SODIUM PHENYLACETATE AND SODIUM BENZOATE, SODIUM BENZOATE

**NCM USA BRONX LLC**
* NCM USA BRONX LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**NEOS THERAP INC**
* NEOS THERAPEUTICS INC
HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX, CHLORPHENIRAMINE POLISTIREX

**NEOS THERAPS**
* NEOS THERAPEUTICS
ADZENYS XR-ODT, AMPHETAMINE

**NEOS THERAPS INC**
* NEOS THERAPEUTICS INC
ADZENYS ER, AMPHETAMINE
COTEMPLA XR-ODT, METHYLPHENIDATE

**NEPHRON**
* NEPHRON CORP
ALBUTEROL SULFATE, ALBUTEROL SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
* NEPHRON PHARMACEUTICALS CORP
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE

**NESHER PHARMS**
* NESHER PHARMACEUTICALS USA LLC
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
MICRO-K 10, POTASSIUM CHLORIDE
MICRO-K, POTASSIUM CHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NYSTATIN, NYSTATIN
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR PHOSPHATE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

**NEUROCRINE**
* NEUROCRINE BIOSCIENCES INC
INGREZZA, VALBENAZINE TOSYLATE

**NEW HAVEN PHARMS**
* NEW HAVEN PHARMACEUTICALS INC
DURLAZA, ASPIRIN

**NEW RIVER**
* NEW RIVER PHARMACEUTICALS INC
PROFERDEX, IRON DEXTRAN

**NEWGEN PHARMS LLC**
* NEWGEN PHARMACEUTICALS LLC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE

**NEXGEN PHARMA**
* NEXGEN PHARMA INC
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
CHENODIOL, CHENODIOL
GLYCOPYRROLATE, GLYCOPYRROLATE
MECAMYLAMINE HYDROCHLORIDE, MECAMYLAMINE HYDROCHLORIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

* NEXGEN PHARMA INC
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)

**NEXGEN PHARMA INC**

* NEXGEN PHARMA INC
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE, ASPIRIN
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350

**NEXTWAVE PHARMS**

* NEXTWAVE PHARMACEUTICALS INC
QUILLIVANT XR, METHYLPHENIDATE HYDROCHLORIDE

**NEXUS PHARMS**

* NEXUS PHARMACEUTICALS INC
ISOPROTERENOL HYDROCHLORIDE, ISOPROTERENOL HYDROCHLORIDE
PROCAINAMIDE HYDROCHLORIDE, PROCAINAMIDE HYDROCHLORIDE
SODIUM NITROPRUSSIDE, SODIUM NITROPRUSSIDE

**NIAGARA PHARMS**

* NIAGARA PHARMACEUTICALS INC
PUR-WASH, PURIFIED WATER (OTC)

**NODEN PHARMA**

* NODEN PHARMA DAC
TEKTURNA HCT, ALISKIREN HEMIFUMARATE
TEKTURNA, ALISKIREN HEMIFUMARATE

**NORTEC DEV ASSOC**

* NORTEC DEVELOPMENT ASSOC INC
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

**NORTHSTAR HLTHCARE**

* NORTHSTAR HEALTHCARE HOLDINGS LTD
ALLOPURINOL, ALLOPURINOL
BACLOFEN, BACLOFEN
GEMFIBROZIL, GEMFIBROZIL
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

**NORTON WATERFORD**

* NORTON WATERFORD LTD
QVAR REDIHALER, BECLOMETHASONE DIPROPIONATE

**NOSTRUM LABS INC**

* NOSTRUM LABORATORIES INC
ACETAZOLAMIDE, ACETAZOLAMIDE
CALCIUM ACETATE, CALCIUM ACETATE
CARISOPRODOL, CARISOPRODOL
DAPSONE, DAPSONE
ELIXOPHYLLIN, THEOPHYLLINE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NITROFURANTOIN, NITROFURANTOIN
PINDOLOL, PINDOLOL
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

**NOSTRUM PHARMS LLC**

* NOSTRUM PHARMACEUTICALS LLC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
THEOCHRON, THEOPHYLLINE

**NOVA LABS LTD**

* NOVA LABORATORIES LTD
PURIXAN, MERCAPTOPURINE

**NOVARTIS**

* NOVARTIS CONSUMER HEALTH INC
LAMISIL AT, TERBINAFINE (OTC)
LAMISIL AT, TERBINAFINE HYDROCHLORIDE (OTC)
THRIVE, NICOTINE POLACRILEX (OTC)
* NOVARTIS PHARMACEUTICALS CORP
AFINITOR, EVEROLIMUS

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

* NOVARTIS PHARMACEUTICALS CORP
COARTEM, ARTEMETHER
DESFERAL, DEFEROXAMINE MESYLATE
DIOVAN HCT, HYDROCHLOROTHIAZIDE
DIOVAN, VALSARTAN
EXELON, RIVASTIGMINE
EXELON, RIVASTIGMINE TARTRATE
EXFORGE HCT, AMLODIPINE BESYLATE
EXFORGE, AMLODIPINE BESYLATE
EXJADE, DEFERASIROX
FOCALIN XR, DEXMETHYLPHENIDATE HYDROCHLORIDE
FOCALIN, DEXMETHYLPHENIDATE HYDROCHLORIDE
GILENYA, FINGOLIMOD
GLEEVEC, IMATINIB MESYLATE
LAMISIL, TERBINAFINE HYDROCHLORIDE
LESCOL XL, FLUVASTATIN SODIUM
LOPRESSOR, METOPROLOL TARTRATE
LOTREL, AMLODIPINE BESYLATE
MYFORTIC, MYCOPHENOLIC ACID
NEORAL, CYCLOSPORINE
RECLAST, ZOLEDRONIC ACID
RITALIN LA, METHYLPHENIDATE HYDROCHLORIDE
RITALIN, METHYLPHENIDATE HYDROCHLORIDE
RITALIN-SR, METHYLPHENIDATE HYDROCHLORIDE
SANDIMMUNE, CYCLOSPORINE
SANDOSTATIN LAR, OCTREOTIDE ACETATE
SANDOSTATIN, OCTREOTIDE ACETATE
SIGNIFOR, PASIREOTIDE DIASPARTATE
STARLIX, NATEGLINIDE
TASIGNA, NILOTINIB HYDROCHLORIDE MONOHYDRATE
TEGRETOL, CARBAMAZEPINE
TEGRETOL-XR, CARBAMAZEPINE
TOBI PODHALER, TOBRAMYCIN
TRILEPTAL, OXCARBAZEPINE
VIVELLE-DOT, ESTRADIOL
VOLTAREN, DICLOFENAC SODIUM
ZOMETA, ZOLEDRONIC ACID
ZORTRESS, EVEROLIMUS

**NOVARTIS PHARM**
* NOVARTIS PHARMACEUTICAL CORP
AFINITOR DISPERZ, EVEROLIMUS

**NOVARTIS PHARMS**
* NOVARTIS PHARMACEUTICALS CORP
FEMARA, LETROZOLE
TOBI, TOBRAMYCIN

**NOVARTIS PHARMS CORP**
* NOVARTIS PHARMACEUTICALS CORP
ALCAINE, PROPARACAINE HYDROCHLORIDE
ALOMIDE, LODOXAMIDE TROMETHAMINE
ARGATROBAN, ARGATROBAN
ARRANON, NELARABINE
AZOPT, BRINZOLAMIDE
BETOPTIC S, BETAXOLOL HYDROCHLORIDE
CILOXAN, CIPROFLOXACIN HYDROCHLORIDE
CIPRO HC, CIPROFLOXACIN HYDROCHLORIDE
CIPRODEX, CIPROFLOXACIN
CYCLOGYL, CYCLOPENTOLATE HYDROCHLORIDE
CYCLOMYDRIL, CYCLOPENTOLATE HYDROCHLORIDE
DUREZOL, DIFLUPREDNATE
EMADINE, EMEDASTINE DIFUMARATE
ENTRESTO, SACUBITRIL
FARYDAK, PANOBINOSTAT LACTATE
FLAREX, FLUOROMETHOLONE ACETATE
FLUORESCITE, FLUORESCEIN SODIUM
HYCAMTIN, TOPOTECAN HYDROCHLORIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

* NOVARTIS PHARMACEUTICALS CORP
ILEVRO, NEPAFENAC
IOPIDINE, APRACLONIDINE HYDROCHLORIDE
ISOPTO ATROPINE, ATROPINE SULFATE
ISOPTO CARPINE, PILOCARPINE HYDROCHLORIDE
JADENU SPRINKLE, DEFERASIROX
JADENU, DEFERASIROX
KISQALI FEMARA CO-PACK (COPACKAGED), LETROZOLE
KISQALI, RIBOCICLIB SUCCINATE
MAXIDEX, DEXAMETHASONE
MAXITROL, DEXAMETHASONE
MEKINIST, TRAMETINIB DIMETHYL SULFOXIDE
MOXEZA, MOXIFLOXACIN HYDROCHLORIDE
MYDRIACYL, TROPICAMIDE
NATACYN, NATAMYCIN
NEVANAC, NEPAFENAC
OMNIPRED, PREDNISOLONE ACETATE
PATADAY, OLOPATADINE HYDROCHLORIDE
PATANASE, OLOPATADINE HYDROCHLORIDE
PATANOL, OLOPATADINE HYDROCHLORIDE
PAZEO, OLOPATADINE HYDROCHLORIDE
PROMACTA, ELTROMBOPAG OLAMINE
RYDAPT, MIDOSTAURIN
SIGNIFOR LAR, PASIREOTIDE PAMOATE
SIMBRINZA, BRIMONIDINE TARTRATE
TAFINLAR, DABRAFENIB MESYLATE
TETRACAINE HYDROCHLORIDE, TETRACAINE HYDROCHLORIDE
TOBRADEX ST, DEXAMETHASONE
TOBRADEX, DEXAMETHASONE
TOBREX, TOBRAMYCIN
TRAVATAN Z, TRAVOPROST
TRIESENCE, TRIAMCINOLONE ACETONIDE
TYKERB, LAPATINIB DITOSYLATE
VIGAMOX, MOXIFLOXACIN HYDROCHLORIDE
VOTRIENT, PAZOPANIB HYDROCHLORIDE
XTORO, FINAFLOXACIN
ZOFRAN ODT, ONDANSETRON
ZOFRAN, ONDANSETRON HYDROCHLORIDE
ZYKADIA, CERITINIB

**NOVAST LABS**

* NOVAST LABORATORIES CHINA LTD
NORETHINDRONE, NORETHINDRONE

**NOVAST LABS LTD**

* NOVAST LABORATORIES LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
CARISOPRODOL AND ASPIRIN, ASPIRIN
DASETTA 1/35, ETHINYL ESTRADIOL
DASETTA 7/7/7, ETHINYL ESTRADIOL
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
ELINEST, ETHINYL ESTRADIOL
FALMINA, ETHINYL ESTRADIOL
HER STYLE, LEVONORGESTREL (OTC)
INDOMETHACIN, INDOMETHACIN
LARIN 1.5/30, ETHINYL ESTRADIOL
LARIN 1/20, ETHINYL ESTRADIOL
LARIN 24 FE, ETHINYL ESTRADIOL
LARIN FE 1.5/30, ETHINYL ESTRADIOL
LARIN FE 1/20, ETHINYL ESTRADIOL
LERIBANE, ETHINYL ESTRADIOL
LEVONEST, ETHINYL ESTRADIOL
MAFENIDE ACETATE, MAFENIDE ACETATE
MELAMISA, DROSPIRENONE
MONO-LINYAH, ETHINYL ESTRADIOL
NIFEDIPINE, NIFEDIPINE
NORETHINDRONE, NORETHINDRONE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

* NOVAST LABORATORIES LTD
PHILITH, ETHINYL ESTRADIOL
PIMTREA, DESOGESTREL
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
SETLAKIN, ETHINYL ESTRADIOL
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
TRI-LINYAH, ETHINYL ESTRADIOL
WERA, ETHINYL ESTRADIOL
YAELA, DROSPIRENONE

**NOVATECH SA**

* NOVATECH SA
STERITALC, TALC

**NOVEL LABS INC**

* NOVEL LABORATORIES INC
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
CALCIPOTRIENE, CALCIPOTRIENE
CARBIDOPA, CARBIDOPA
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DESOXIMETASONE, DESOXIMETASONE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
FAMOTIDINE, FAMOTIDINE
FLUCYTOSINE, FLUCYTOSINE
FLUOCINONIDE, FLUOCINONIDE
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE, HOMATROPINE METHYLBROMIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
LEVONORGESTREL, LEVONORGESTREL (OTC)
LINEZOLID, LINEZOLID
METHYLERGONOVINE MALEATE, METHYLERGONOVINE MALEATE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MISOPROSTOL, MISOPROSTOL
MORPHINE SULFATE, MORPHINE SULFATE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NITROFURANTOIN, NITROFURANTOIN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PEG 3350 AND ELECTROLYTES, POLYETHYLENE GLYCOL 3350
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL
PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL,
PHENELZINE SULFATE, PHENELZINE SULFATE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
SODIUM SULFATE, POTASSIUM SULFATE AND MAGNESIUM SULFATE , MAGNESIUM SULFATE
TEMAZEPAM, TEMAZEPAM
TINIDAZOLE, TINIDAZOLE
TRIMETHOPRIM, TRIMETHOPRIM
VORICONAZOLE, VORICONAZOLE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**NOVEN**

* NOVEN PHARMACEUTICALS INC
MINIVELLE, ESTRADIOL

**NOVEN PHARMS INC**

* NOVEN PHARMACEUTICALS INC
COMBIPATCH, ESTRADIOL
DAYTRANA, METHYLPHENIDATE

**NOVITIUM PHARMA**

* NOVITIUM PHARMA LLC
DAPSONE, DAPSONE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** N ****

**NOVO NORDISK**
* NOVO NORDISK PHARMACEUTICALS INC
GLUCAGEN, GLUCAGON HYDROCHLORIDE RECOMBINANT

**NOVO NORDISK INC**
* NOVO NORDISK INC
FIASP FLEXTOUCH, INSULIN ASPART
FIASP, INSULIN ASPART
LEVEMIR FLEXTOUCH, INSULIN DETEMIR RECOMBINANT
LEVEMIR, INSULIN DETEMIR RECOMBINANT
NORDITROPIN FLEXPRO, SOMATROPIN RECOMBINANT
NOVOLIN 70/30, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLIN N, INSULIN SUSP ISOPHANE RECOMBINANT HUMAN (OTC)
NOVOLIN R, INSULIN RECOMBINANT HUMAN (OTC)
NOVOLOG FLEXPEN, INSULIN ASPART RECOMBINANT
NOVOLOG FLEXTOUCH, INSULIN ASPART RECOMBINANT
NOVOLOG MIX 70/30 FLEXPEN, INSULIN ASPART PROTAMINE RECOMBINANT
NOVOLOG MIX 70/30, INSULIN ASPART PROTAMINE RECOMBINANT
NOVOLOG PENFILL, INSULIN ASPART RECOMBINANT
NOVOLOG, INSULIN ASPART RECOMBINANT
OZEMPIC, SEMAGLUTIDE
RYZODEG 70/30, INSULIN ASPART
SAXENDA, LIRAGLUTIDE RECOMBINANT
TRESIBA, INSULIN DEGLUDEC
VAGIFEM, ESTRADIOL
VICTOZA, LIRAGLUTIDE RECOMBINANT
XULTOPHY 100/3.6, INSULIN DEGLUDEC

**NPS PHARMS INC**
* NPS PHARMACEUTICALS INC
GATTEX KIT, TEDUGLUTIDE RECOMBINANT

**NU PHARM**
* NU PHARM INC
DIVALPROEX SODIUM, DIVALPROEX SODIUM

**NUVO PHARM**
* NUVO PHARMACEUTICAL INC
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE

**NUVO PHARM INC**
* NUVO PHARMACEUTICAL INC
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
FOLIC ACID, FOLIC ACID
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE

**NXDC**
* NX DEVELOPMENT CORP
GLEOLAN, AMINOLEVULINIC ACID HYDROCHLORIDE

**NYCOMED US**
* NYCOMED US INC
TERCONAZOLE, TERCONAZOLE

**** O ****

**OAK PHARMS**
* OAK PHARMACEUTICALS INC
NEMBUTAL SODIUM, PENTOBARBITAL SODIUM
XYLOCAINE, LIDOCAINE HYDROCHLORIDE

**OAK PHARMS AKORN**
* OAK PHARMACEUTICALS INC SUB AKORN INC
COGENTIN, BENZTROPINE MESYLATE
DIURIL, CHLOROTHIAZIDE SODIUM

**OAK PHARMS INC**
* OAK PHARMACEUTICALS INC
ZIOPTAN, TAFLUPROST
* OAK PHARMACEUTICALS INC SUBSIDIARY OF AKORN INC
AZASITE, AZITHROMYCIN
BETIMOL, TIMOLOL

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** O ****

* OAK PHARMACEUTICALS INC SUBSIDIARY OF AKORN INC
COSOPT PF, DORZOLAMIDE HYDROCHLORIDE
COSOPT, DORZOLAMIDE HYDROCHLORIDE
XOPENEX, LEVALBUTEROL HYDROCHLORIDE

**OC PHARMA**
* OC PHARMA LLC
LEVONORGESTREL, LEVONORGESTREL (OTC)
NORGESTIMATE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL

**ODYSSEY PHARMS**
* ODYSSEY PHARMACEUTICALS INC
ANTABUSE, DISULFIRAM
NYSTATIN, NYSTATIN
SURMONTIL, TRIMIPRAMINE MALEATE
URECHOLINE, BETHANECHOL CHLORIDE
VIVACTIL, PROTRIPTYLINE HYDROCHLORIDE

**OHM**
* OHM CORP
IBUPROFEN, IBUPROFEN (OTC)

**OHM LABS**
* OHM LABORATORIES INC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
IBUPROHM COLD AND SINUS, IBUPROFEN (OTC)
IBUPROHM, IBUPROFEN (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)

**OHM LABS INC**
* OHM LABORATORIES INC
EZETIMIBE, EZETIMIBE
VALSARTAN, VALSARTAN

**OLTA PHARMS**
* OLTA PHARMACEUTICALS CORP
LINDANE, LINDANE

**OMEROS**
* OMEROS CORP
OMIDRIA, KETOROLAC TROMETHAMINE

**ONY**
* ONY INC
INFASURF PRESERVATIVE FREE, CALFACTANT

**ONYX THERAP**
* ONYX THERAPEUTICS INC A WHOLLY OWNED SUB OF AMGEN INC
KYPROLIS, CARFILZOMIB

**OPKO IRELAND GLOBAL**
* OPKO IRELAND GLOBAL HOLDINGS LTD
RAYALDEE, CALCIFEDIOL

**OPTNOSE US**
* OPTNOSE US INC
XHANCE, FLUTICASONE PROPIONATE

**ORAPHARMA**
* ORAPHARMA INC
ARESTIN, MINOCYCLINE HYDROCHLORIDE

**ORCHID HLTHCARE**
* ORCHID HEALTHCARE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ARIPIPRAZOLE, ARIPIPRAZOLE
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE
CEFDINIR, CEFDINIR
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CEPHALEXIN, CEPHALEXIN
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
DESLORATADINE, DESLORATADINE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
ESZOPICLONE, ESZOPICLONE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** O ****

* ORCHID HEALTHCARE
FELODIPINE, FELODIPINE
GEMIFLOXACIN MESYLATE, GEMIFLOXACIN MESYLATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
MODAFINIL, MODAFINIL
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
OLANZAPINE, OLANZAPINE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
RASAGILINE MESYLATE, RASAGILINE MESYLATE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZALEPLON, ZALEPLON

**OREXIGEN**
* OREXIGEN THERAPEUTICS INC
CONTRAVE, BUPROPION HYDROCHLORIDE

**OREXO US INC**
* OREXO US INC
ZUBSOLV, BUPRENORPHINE HYDROCHLORIDE

**ORGANON SUB MERCK**
* ORGANON USA INC A SUB OF MERCK AND CO INC
BRIDION, SUGAMMADEX SODIUM
NUVARING, ETHINYL ESTRADIOL

**ORGANON USA INC**
* ORGANON USA INC
DESOGEN, DESOGESTREL
FOLLISTIM AQ, FOLLITROPIN ALFA/BETA
GANIRELIX ACETATE, GANIRELIX ACETATE
NEXPLANON, ETONOGESTREL
PREGNYL, GONADOTROPIN, CHORIONIC
REMERON SOLTAB, MIRTAZAPINE
REMERON, MIRTAZAPINE

**ORIENT PHARMA CO LTD**
* ORIENT PHARMA CO LTD
CARISOPRODOL, CARISOPRODOL
MIGLITOL, MIGLITOL
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM

**ORION CORP ORION**
* ORION CORP ORION PHARMA
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE

**ORION PHARMA**
* ORION PHARMA
COMTAN, ENTACAPONE
STALEVO 100, CARBIDOPA
STALEVO 125, CARBIDOPA
STALEVO 150, CARBIDOPA
STALEVO 200, CARBIDOPA
STALEVO 50, CARBIDOPA
STALEVO 75, CARBIDOPA

**ORIT LABS LLC**
* ORIT LABORATORIES LLC
BENZONATATE, BENZONATATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
ERGOCALCIFEROL, ERGOCALCIFEROL
LEVETIRACETAM, LEVETIRACETAM
METRONIDAZOLE, METRONIDAZOLE

**ORPHAN EUROPE**
* ORPHAN EUROPE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** O ****

* ORPHAN EUROPE
CARBAGLU, CARGLUMIC ACID
* ORPHAN EUROPE SARL
CYSTADANE, BETAINE HYDROCHLORIDE

**OSI PHARMS**
* OSI PHARMACEUTICALS INC
TARCEVA, ERLOTINIB HYDROCHLORIDE

**OSMOTICA**
* OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE

**OSMOTICA PHARM**
* OSMOTICA PHARMACEUTICAL CORP
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

**OSMOTICA PHARM CORP**
* OSMOTICA PHARMACEUTICAL CORP
KHEDEZLA, DESVENLAFAXINE

**OSMOTICA PHARM US**
* OSMOTICA PHARMACEUTICAL US LLC
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
NIFEDIPINE, NIFEDIPINE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE

**OTONOMY INC**
* OTONOMY INC
OTIPRIO, CIPROFLOXACIN

**OTSUKA**
* OTSUKA PHARMACEUTICAL CO LTD
ABILIFY, ARIPIPRAZOLE

**OTSUKA AMERICA PHARM**
* OTSUKA AMERICA PHARMACEUTICAL INC
SAMSCA, TOLVAPTAN

**OTSUKA PHARM**
* OTSUKA PHARMACEUTICAL CO LTD
BUSULFEX, BUSULFAN

**OTSUKA PHARM CO LTD**
* OTSUKA PHARMACEUTICAL CO LTD
ABILIFY MAINTENA KIT, ARIPIPRAZOLE
ABILIFY MYCITE KIT, ARIPIPRAZOLE
DACOGEN, DECITABINE
REXULTI, BREXPIPRAZOLE

**OUTLOOK PHARMS**
* OUTLOOK PHARMACEUTICALS INC
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE

**OXFORD PHARMS**
* OXFORD PHARMACEUTICALS LLC
BACLOFEN, BACLOFEN
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CARISOPRODOL AND ASPIRIN, ASPIRIN
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
RIMACTANE, RIFAMPIN
RISPERIDONE, RISPERIDONE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE

**** P ****

**P AND L DEV LLC**
* P AND L DEVELOPMENT LLC DBA PLD DEVELOPMENTS LLC
IBUPROFEN, IBUPROFEN (OTC)

**PACIFIC PHARMA**
* PACIFIC PHARMA

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PACIFIC PHARMA
TIMOLOL MALEATE, TIMOLOL MALEATE
* PACIFIC PHARMA INC
TIMOLOL MALEATE, TIMOLOL MALEATE

**PACIRA PHARMS INC**

* PACIRA PHARMACEUTICALS INC
DEPOCYT, CYTARABINE
EXPAREL, BUPIVACAINE

**PADDOCK LLC**

* PADDOCK LABORATORIES LLC
ATOVAQUONE, ATOVAQUONE
BROMFENAC SODIUM, BROMFENAC SODIUM
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
CALCIUM ACETATE, CALCIUM ACETATE
CICLOPIROX, CICLOPIROX
CLINDA-DERM, CLINDAMYCIN PHOSPHATE
CLINDAMYCIN PALMITATE HYDROCHLORIDE, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
COLOCORT, HYDROCORTISONE
COMPRO, PROCHLORPERAZINE
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
FLAVOXATE HYDROCHLORIDE, FLAVOXATE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE, HYDROCODONE BITARTRATE
HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE ,
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
KIONEX, SODIUM POLYSTYRENE SULFONATE
LAX-LYTE WITH FLAVOR PACKS, POLYETHYLENE GLYCOL 3350
MIDAMOR, AMILORIDE HYDROCHLORIDE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NYSTOP, NYSTATIN
PODOFILOX, PODOFILOX
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
REPAGLINIDE, REPAGLINIDE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE
TROSPIUM CHLORIDE, TROSPIUM CHLORIDE

**PANACEA BIOTEC LTD**

* PANACEA BIOTEC LTD
PRASUGREL, PRASUGREL HYDROCHLORIDE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
TACROLIMUS, TACROLIMUS

**PAR FORM**

* PAR FORMULATIONS PRIVATE LTD
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
MAFENIDE ACETATE, MAFENIDE ACETATE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**PAR PHARM**

* PAR PHARMACEUTICAL
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
TESTOSTERONE, TESTOSTERONE
* PAR PHARMACEUTICAL INC
ALPRAZOLAM, ALPRAZOLAM
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PAR PHARMACEUTICAL INC
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
CABERGOLINE, CABERGOLINE
CALCITONIN-SALMON, CALCITONIN SALMON
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CLOMIPHENE CITRATE, CLOMIPHENE CITRATE
CLONAZEPAM, CLONAZEPAM
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DEXAMETHASONE, DEXAMETHASONE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE
ESTAZOLAM, ESTAZOLAM
FENTANYL CITRATE, FENTANYL CITRATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUTAMIDE, FLUTAMIDE
GLIPIZIDE, GLIPIZIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDRA-ZIDE, HYDRALAZINE HYDROCHLORIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROXYUREA, HYDROXYUREA
IBUPROFEN, IBUPROFEN (OTC)
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
LAMOTRIGINE, LAMOTRIGINE
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
MEGESTROL ACETATE, MEGESTROL ACETATE
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
METRONIDAZOLE, METRONIDAZOLE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL
NATEGLINIDE, NATEGLINIDE
NIFEDIPINE, NIFEDIPINE
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
OLANZAPINE, OLANZAPINE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
OXANDROLONE, OXANDROLONE
PIMOZIDE, PIMOZIDE
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TORSEMIDE, TORSEMIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRANYLCYPROMINE SULFATE, TRANYLCYPROMINE SULFATE
TRAVOPROST, TRAVOPROST
URSODIOL, URSODIOL
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE

**PAR PHARM INC**

* PAR PHARMACEUTICAL INC
ACCOLATE, ZAFIRLUKAST
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
ANTIZOL, FOMEPIZOLE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
DEXLANSOPRAZOLE, DEXLANSOPRAZOLE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE, DOXYLAMINE SUCCINATE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PAR PHARMACEUTICAL INC
ENTECAVIR, ENTECAVIR
ETHACRYNIC ACID, ETHACRYNIC ACID
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
ITRACONAZOLE, ITRACONAZOLE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
PRAZIQUANTEL, PRAZIQUANTEL
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOLCAPONE, TOLCAPONE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VIGABATRIN, VIGABATRIN
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**PAR STERILE PRODUCTS**

* PAR STERILE PRODUCTS LLC
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ADRENALIN, EPINEPHRINE
ARGATROBAN, ARGATROBAN
BREVITAL SODIUM, METHOHEXITAL SODIUM
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
COLY-MYCIN M, COLISTIMETHATE SODIUM
CORPHEDRA, EPHEDRINE SULFATE
DANTRIUM, DANTROLENE SODIUM
DELESTROGEN, ESTRADIOL VALERATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
ETOMIDATE, ETOMIDATE
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
GANCICLOVIR, GANCICLOVIR SODIUM
KETALAR, KETAMINE HYDROCHLORIDE
LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MEROPENEM, MEROPENEM
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE
PITOCIN, OXYTOCIN
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TIGAN, TRIMETHOBENZAMIDE HYDROCHLORIDE
TRIOSTAT, LIOTHYRONINE SODIUM
VASOSTRICT, VASOPRESSIN

**PARAGON BIOTECK**

* PARAGON BIOTECK INC
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE

**PARAPRO LLC**

* PARAPRO LLC
NATROBA, SPINOSAD

**PARKE DAVIS**

* PARKE DAVIS DIV WARNER LAMBERT CO
CELONTIN, METHSUXIMIDE
CEREBYX, FOSPHENYTOIN SODIUM
DILANTIN-125, PHENYTOIN
NARDIL, PHENELZINE SULFATE
NEURONTIN, GABAPENTIN
ZARONTIN, ETHOSUXIMIDE

**PARKE-DAVIS**

* PARKE-DAVIS DIVISION OF PFIZER INC
DILANTIN, PHENYTOIN SODIUM
ZARONTIN, ETHOSUXIMIDE

**PERNIX IRELAND LTD**

* PERNIX IRELAND LTD
TREXIMET, NAPROXEN SODIUM

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

**PERNIX IRELAND PAIN**
* PERNIX IRELAND PAIN LIMITED
ZOHYDRO ER, HYDROCODONE BITARTRATE

**PERNIX THERAPS LLC**
* PERNIX THERAPEUTICS LLC
SILENOR, DOXEPIN HYDROCHLORIDE

**PERRIGO**
* PERRIGO CO
MICONAZOLE NITRATE COMBINATION PACK, MICONAZOLE NITRATE (OTC)

**PERRIGO CO**
* PERRIGO CO OF TENESSEE INC
CICLOPIROX, CICLOPIROX
CLINDETS, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
ERYTHROMYCIN, ERYTHROMYCIN
STIE-CORT, HYDROCORTISONE

**PERRIGO CO TENNESSEE**
* PERRIGO CO TENNESSEE INC
BACITRACIN ZINC AND POLYMYXIN B SULFATE, BACITRACIN ZINC
BACITRACIN, BACITRACIN
BACITRACIN-NEOMYCIN-POLYMYXIN W/ HYDROCORTISONE ACETATE, BACITRACIN
ERYTHROMYCIN, ERYTHROMYCIN
GENTAMICIN SULFATE, GENTAMICIN SULFATE
NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC, BACITRACIN ZINC
NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE, DEXAMETHASONE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM

**PERRIGO ISRAEL**
* PERRIGO ISRAEL PHARMACEUTICALS LTD
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DESOXIMETASONE, DESOXIMETASONE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
GYNAZOLE-1, BUTOCONAZOLE NITRATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
IMIQUIMOD, IMIQUIMOD
KETOCONAZOLE, KETOCONAZOLE
MESALAMINE, MESALAMINE
MINOXIDIL, MINOXIDIL (OTC)
MOMETASONE FUROATE, MOMETASONE FUROATE
NITROGLYCERIN, NITROGLYCERIN
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
TESTOSTERONE, TESTOSTERONE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE (OTC)

**PERRIGO NEW YORK**
* PERRIGO NEW YORK INC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
AMMONIUM LACTATE, AMMONIUM LACTATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CENTANY, MUPIROCIN
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DESONIDE, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ERYTHROMYCIN, ERYTHROMYCIN
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
HYDROCORTISONE, HYDROCORTISONE
KETOCONAZOLE, KETOCONAZOLE
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PERRIGO NEW YORK INC
MOMETASONE FUROATE, MOMETASONE FUROATE
MUPIROCIN, MUPIROCIN
NYSTATIN, NYSTATIN
PERMETHRIN, PERMETHRIN
PERMETHRIN, PERMETHRIN (OTC)
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
SELENIUM SULFIDE, SELENIUM SULFIDE
TERCONAZOLE, TERCONAZOLE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

**PERRIGO PHARMA INTL**

* PERRIGO PHARMA INTERNATIONAL DAC
CLINDESSE, CLINDAMYCIN PHOSPHATE
ENTOCORT EC, BUDESONIDE
EVAMIST, ESTRADIOL
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)
LORATADINE, LORATADINE (OTC)
PILOCARPINE HYDROCHLORIDE, PILOCARPINE HYDROCHLORIDE
TRETINOIN, TRETINOIN

**PERRIGO PHARMS CO**

* PERRIGO PHARMACEUTICALS CO
SCOPOLAMINE, SCOPOLAMINE

**PERRIGO R AND D**

* PERRIGO R AND D CO
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
DESLORATADINE, DESLORATADINE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM (OTC)
FAMOTIDINE, CALCIUM CARBONATE, AND MAGNESIUM HYDROXIDE, CALCIUM CARBONATE (OTC)
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
GUAIFENESIN, GUAIFENESIN (OTC)
IBUPROFEN AND DIPHENHYDRAMINE CITRATE, DIPHENHYDRAMINE CITRATE (OTC)
IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE, IBUPROFEN (OTC)
IBUPROFEN SODIUM, IBUPROFEN SODIUM (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
LEVONORGESTREL, LEVONORGESTREL
LEVONORGESTREL, LEVONORGESTREL (OTC)
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MONTELUKAST SODIUM, MONTELUKAST SODIUM
NAPROXEN, NAPROXEN
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE (OTC)
OMEPRAZOLE MAGNESIUM, OMEPRAZOLE MAGNESIUM (OTC)
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)

**PERRIGO UK FINCO**

* PERRIGO UK FINCO LTD PARTNERSHIP
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
FLURANDRENOLIDE, FLURANDRENOLIDE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
TESTOSTERONE, TESTOSTERONE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

**PETNET**

* PETNET SOLUTIONS INC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PETNET SOLUTIONS INC
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**PF PRISM CV**

* PF PRISM CV
BOSULIF, BOSUTINIB MONOHYDRATE
INLYTA, AXITINIB
LYRICA, PREGABALIN
RAPAMUNE, SIROLIMUS
TORISEL, TEMSIROLIMUS
TYGACIL, TIGECYCLINE
VFEND, VORICONAZOLE
XALKORI, CRIZOTINIB
XELJANZ, TOFACITINIB CITRATE
ZMAX, AZITHROMYCIN

**PFIZER**

* PFIZER CENTRAL RESEARCH
DIFLUCAN, FLUCONAZOLE
ZITHROMAX, AZITHROMYCIN
* PFIZER CHEMICALS DIV PFIZER INC
DIFLUCAN, FLUCONAZOLE
ZITHROMAX, AZITHROMYCIN
* PFIZER INC
ADVIL ALLERGY AND CONGESTION RELIEF, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL COLD AND SINUS, IBUPROFEN (OTC)
ADVIL CONGESTION RELIEF, IBUPROFEN (OTC)
ADVIL LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MIGRAINE LIQUI-GELS, IBUPROFEN (OTC)
ADVIL MULTI-SYMPTOM COLD & FLU, CHLORPHENIRAMINE MALEATE (OTC)
ADVIL PM, DIPHENHYDRAMINE CITRATE (OTC)
ADVIL PM, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
ADVIL, IBUPROFEN (OTC)
ALAVERT, LORATADINE (OTC)
AXID AR, NIZATIDINE (OTC)
CADUET, AMLODIPINE BESYLATE
CALAN SR, VERAPAMIL HYDROCHLORIDE
CARDURA XL, DOXAZOSIN MESYLATE
CHILDREN'S ADVIL ALLERGY SINUS, CHLORPHENIRAMINE MALEATE (OTC)
CHILDREN'S ADVIL COLD, IBUPROFEN (OTC)
CHILDREN'S ADVIL, IBUPROFEN (OTC)
CHILDREN'S ADVIL-FLAVORED, IBUPROFEN (OTC)
ELELYSO, TALIGLUCERASE ALFA
GEODON, ZIPRASIDONE HYDROCHLORIDE
GEODON, ZIPRASIDONE MESYLATE
GLUCOTROL XL, GLIPIZIDE
GLUCOTROL, GLIPIZIDE
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
JUNIOR STRENGTH ADVIL, IBUPROFEN (OTC)
LIPITOR, ATORVASTATIN CALCIUM
LORATADINE, LORATADINE (OTC)
MERREM, MEROPENEM
NORVASC, AMLODIPINE BESYLATE
PEDIATRIC ADVIL, IBUPROFEN (OTC)
PROCARDIA, NIFEDIPINE
REVATIO, SILDENAFIL CITRATE
SONATA, ZALEPLON
TESSALON, BENZONATATE
TOVIAZ, FESOTERODINE FUMARATE
UNASYN, AMPICILLIN SODIUM
ZITHROMAX, AZITHROMYCIN
* PFIZER LABORATORIES DIV PFIZER INC
CARDURA, DOXAZOSIN MESYLATE
DIABINESE, CHLORPROPAMIDE
FELDENE, PIROXICAM

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PFIZER LABORATORIES DIV PFIZER INC
MINIPRESS, PRAZOSIN HYDROCHLORIDE
PFIZERPEN, PENICILLIN G POTASSIUM
PROCARDIA XL, NIFEDIPINE
UNASYN, AMPICILLIN SODIUM
VIBRAMYCIN, DOXYCYCLINE
VIBRAMYCIN, DOXYCYCLINE CALCIUM
VIBRAMYCIN, DOXYCYCLINE HYCLATE
VISTARIL, HYDROXYZINE PAMOATE
* PFIZER PHARMACEUTICALS INC
DILANTIN, PHENYTOIN
ZOLOFT, SERTRALINE HYDROCHLORIDE
* PFIZER PHARMACEUTICALS PRODUCTION CORP LTD
TIKOSYN, DOFETILIDE

**PFIZER CONS HLTHCARE**

* PFIZER CONSUMER HEALTHCARE
ADVIL, IBUPROFEN SODIUM (OTC)

**PFIZER INC**

* PFIZER INC
CAMPTOSAR, IRINOTECAN HYDROCHLORIDE
CHANTIX, VARENICLINE TARTRATE
ELLENCE, EPIRUBICIN HYDROCHLORIDE
FRAGMIN, DALTEPARIN SODIUM
IBRANCE, PALBOCICLIB
LYRICA CR, PREGABALIN
NICOTROL, NICOTINE
QUILLICHEW ER, METHYLPHENIDATE HYDROCHLORIDE
VIAGRA, SILDENAFIL CITRATE
XELJANZ XR, TOFACITINIB CITRATE

**PFIZER IRELAND**

* PFIZER IRELAND PHARMACEUTICALS
RELPAX, ELETRIPTAN HYDROBROMIDE

**PFIZER PHARMS**

* PFIZER PHARMACEUTICALS LTD
ACCUPRIL, QUINAPRIL HYDROCHLORIDE
ACCURETIC, HYDROCHLOROTHIAZIDE
LOPID, GEMFIBROZIL
NEURONTIN, GABAPENTIN
NITROSTAT, NITROGLYCERIN

**PHARM ASSOC**

* PHARMACEUTICAL ASSOC INC
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LORAZEPAM, LORAZEPAM
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
* PHARMACEUTICAL ASSOCIATES INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
ETHOSUXIMIDE, ETHOSUXIMIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LACTULOSE, LACTULOSE
LEVETIRACETAM, LEVETIRACETAM
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
NYSTATIN, NYSTATIN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PREDNISOLONE, PREDNISOLONE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PHARMACEUTICAL ASSOCIATES INC
THEOPHYLLINE, THEOPHYLLINE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
VALPROIC ACID, VALPROIC ACID

**PHARMA RES SOFTWARE**

* PHARMA RESEARCH SOFTWARE SOLUTION LLC
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

**PHARMACARE**

* PHARMACARE LTD
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE

**PHARMACHEMIE BV**

* PHARMACHEMIE BV
CARBOPLATIN, CARBOPLATIN
CISPLATIN, CISPLATIN
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM

**PHARMACIA AND UPJOHN**

* PHARMACIA AND UPJOHN
XANAX XR, ALPRAZOLAM

* PHARMACIA AND UPJOHN CO
AROMASIN, EXEMESTANE
AZULFIDINE EN-TABS, SULFASALAZINE
AZULFIDINE, SULFASALAZINE
BACITRACIN, BACITRACIN
CAVERJECT IMPULSE, ALPROSTADIL
CAVERJECT, ALPROSTADIL
CLEOCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
CLEOCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLEOCIN T, CLINDAMYCIN PHOSPHATE
CLEOCIN, CLINDAMYCIN PALMITATE HYDROCHLORIDE
CLEOCIN, CLINDAMYCIN PHOSPHATE
CORTEF, HYDROCORTISONE
CORVERT, IBUTILIDE FUMARATE
CYKLOKAPRON, TRANEXAMIC ACID
DEPO-ESTRADIOL, ESTRADIOL CYPIONATE
DEPO-MEDROL, METHYLPREDNISOLONE ACETATE
DEPO-PROVERA, MEDROXYPROGESTERONE ACETATE
DEPO-TESTOSTERONE, TESTOSTERONE CYPIONATE
DETROL LA, TOLTERODINE TARTRATE
DETROL, TOLTERODINE TARTRATE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
EMCYT, ESTRAMUSTINE PHOSPHATE SODIUM
ESTRING, ESTRADIOL
GENOTROPIN PRESERVATIVE FREE, SOMATROPIN RECOMBINANT
GENOTROPIN, SOMATROPIN RECOMBINANT
GLYNASE, GLYBURIDE
GLYSET, MIGLITOL
HALCION, TRIAZOLAM
HEMABATE, CARBOPROST TROMETHAMINE
IDAMYCIN PFS, IDARUBICIN HYDROCHLORIDE
LINCOCIN, LINCOMYCIN HYDROCHLORIDE
MEDROL, METHYLPREDNISOLONE
MYCOBUTIN, RIFABUTIN
NICOTROL, NICOTINE
OGEN 5, ESTROPIPATE
PREPIDIL, DINOPROSTONE
PROSTIN E2, DINOPROSTONE
PROSTIN VR PEDIATRIC, ALPROSTADIL
PROVERA, MEDROXYPROGESTERONE ACETATE
R-GENE 10, ARGININE HYDROCHLORIDE
SOLU-CORTEF, HYDROCORTISONE SODIUM SUCCINATE
SOLU-MEDROL, METHYLPREDNISOLONE SODIUM SUCCINATE
SOMAVERT, PEGVISOMANT
XALATAN, LATANOPROST

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** P **

* PHARMACIA AND UPJOHN CO
XANAX, ALPRAZOLAM
ZINECARD, DEXRAZOXANE HYDROCHLORIDE
ZYVOX, LINEZOLID
* PHARMACIA AND UPJOHN SUB PFIZER INC
DEPO-SUBQ PROVERA 104, MEDROXYPROGESTERONE ACETATE

**PHARMACIA UPJOHN**
* PHARMACIA AND UPJOHN CO A SUB OF PFIZER INC
COLESTID, COLESTIPOL HYDROCHLORIDE
FLAVORED COLESTID, COLESTIPOL HYDROCHLORIDE

**PHARMACYCLICS INC**
* PHARMACYCLICS INC
IMBRUVICA, IBRUTINIB

**PHARMADAX INC**
* PHARMADAX INC
GLYBURIDE, GLYBURIDE
LEVETIRACETAM, LEVETIRACETAM
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE

**PHARMAFORCE**
* PHARMAFORCE INC
FLOXURIDINE, FLOXURIDINE

**PHARMALUCENCE**
* PHARMALUCENCE INC
AN-SULFUR COLLOID, TECHNETIUM TC-99M SULFUR COLLOID KIT
CIS-MDP, TECHNETIUM TC-99M MEDRONATE KIT
CIS-PYRO, TECHNETIUM TC-99M PYROPHOSPHATE KIT
HEPATOLITE, TECHNETIUM TC-99M DISOFENIN KIT
TECHNETIUM TC 99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI KIT
TECHNETIUM TC-99M MEBROFENIN, TECHNETIUM TC-99M MEBROFENIN KIT

**PHARMASCIENCE INC**
* PHARMASCIENCE INC
BUSULFAN, BUSULFAN
DECITABINE, DECITABINE
GANCICLOVIR SODIUM, GANCICLOVIR SODIUM

**PHARMTAK INC**
* PHARMTAK INC
LEVETIRACETAM, LEVETIRACETAM

**PHOTOCURE ASA**
* PHOTOCURE ASA
CYSVIEW KIT, HEXAMINOLEVULINATE HYDROCHLORIDE

**PIERRE FABRE**
* PIERRE FABRE MEDICAMENT
NAVELBINE, VINORELBINE TARTRATE

**PIERRE FABRE DERMA**
* PIERRE FABRE DERMATOLOGIE
HEMANGEOL, PROPRANOLOL HYDROCHLORIDE

**PIERREL**
* PIERREL S.P.A.
ORABLOC, ARTICAINE HYDROCHLORIDE

**PII**
* PHARMACEUTICS INTERNATIONAL INC
BUTALBITAL, ASPIRIN AND CAFFEINE, ASPIRIN
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
HYDROCORTISONE, HYDROCORTISONE
PIROXICAM, PIROXICAM
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE

**PIRAMAL CRITICAL**
* PIRAMAL CRITICAL CARE INC
ISOFLURANE, ISOFLURANE
SOJOURN, SEVOFLURANE
* PIRAMAL CRITICAL CARE LTD
GABLOFEN, BACLOFEN

**PIRAMAL ENT**
* PIRAMAL ENTERPRISES LTD

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PIRAMAL ENTERPRISES LTD
ISOFLURANE, ISOFLURANE

**PIRAMAL IMAGING**

* PIRAMAL IMAGING SA
NEURACEQ, FLORBETABEN F-18

**PLD ACQUISITIONS LLC**

* PLD ACQUISITIONS LLC
ZOLMITRIPTAN, ZOLMITRIPTAN

**PLIVA**

* PLIVA INC
AZITHROMYCIN, AZITHROMYCIN
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CIMETIDINE, CIMETIDINE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
METRONIDAZOLE, METRONIDAZOLE
NAPROXEN, NAPROXEN
THEOPHYLLINE, THEOPHYLLINE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
WARFARIN SODIUM, WARFARIN SODIUM

**PLIVA HRVATSKA DOO**

* PLIVA HRVATSKA DOO
ADAPALENE, ADAPALENE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
RISPERIDONE, RISPERIDONE

**PLIVA LACHEMA**

* PLIVA LACHEMA AS
CARBOPLATIN, CARBOPLATIN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

**PLIVA PHARM IND**

* PLIVA PHARMACEUTICAL INDUSTRY INC
TORSEMIDE, TORSEMIDE

**PLX PHARMA**

* PLX PHARMA INC
ASPIRIN, ASPIRIN (OTC)

**POHL BOSKAMP**

* POHL BOSKAMP
NITROLINGUAL PUMPSPRAY, NITROGLYCERIN

**POLYGEN PHARMS**

* POLYGEN PHARMACEUTICALS INC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE

**POLYMEDICA**

* POLYMEDICA INDUSTRIES INC
NEOPAP, ACETAMINOPHEN (OTC)

**PORTOLA PHARMS INC**

* PORTOLA PHARMACEUTICALS INC
BEVYXXA, BETRIXABAN

**POWDER PHARMS**

* POWDER PHARMACEUTICALS INC
ZINGO, LIDOCAINE HYDROCHLORIDE

**PRAGMA PHARMS LLC**

* PRAGMA PHARMACEUTICALS LLC
KEFLEX, CEPHALEXIN

**PRECISION DERMAT**

* PRECISION DERMATOLOGY INC

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

* PRECISION DERMATOLOGY INC
CLINDAGEL, CLINDAMYCIN PHOSPHATE
LOCOID LIPOCREAM, HYDROCORTISONE BUTYRATE
LOCOID, HYDROCORTISONE BUTYRATE
MINOCIN, MINOCYCLINE HYDROCHLORIDE

**PRECISION DOSE**

* PRECISION DOSE INC
RISPERIDONE, RISPERIDONE

**PRECISION DOSE INC**

* PRECISION DOSE INC
PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE

**PRECISION NUCLEAR**

* PRECISION NUCLEAR LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**PRINSTON INC**

* PRINSTON PHARMACEUTICAL INC
ARIPIPRAZOLE, ARIPIPRAZOLE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CAPTOPRIL, CAPTOPRIL
CLONAZEPAM, CLONAZEPAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENTECAVIR, ENTECAVIR
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
FUROSEMIDE, FUROSEMIDE
GLIMEPIRIDE, GLIMEPIRIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LEVETIRACETAM, LEVETIRACETAM
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
METHOCARBAMOL, METHOCARBAMOL
NEVIRAPINE, NEVIRAPINE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
PAROXETINE MESYLATE, PAROXETINE MESYLATE
PAROXETINE, PAROXETINE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TELMISARTAN, TELMISARTAN
TEMAZEPAM, TEMAZEPAM
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
VALSARTAN, VALSARTAN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE

**PROF DSPLS**

* PROFESSIONAL DISPOSABLES INC
PREVANTICS MAXI SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)
PREVANTICS SWAB, CHLORHEXIDINE GLUCONATE (OTC)
PREVANTICS SWABSTICK, CHLORHEXIDINE GLUCONATE (OTC)

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** P ****

**PROMIUS PHARMA**
* PROMIUS PHARMA LLC
SECTRAL, ACEBUTOLOL HYDROCHLORIDE
TENEX, GUANFACINE HYDROCHLORIDE

**PROMIUS PHARMA LLC**
* PROMIUS PHARMA LLC
CLODERM, CLOCORTOLONE PIVALATE
IMPOYZ, CLOBETASOL PROPIONATE
SERNIVO, BETAMETHASONE DIPROPIONATE

**PROVENSIS**
* PROVENSIS LTD
VARITHENA, POLIDOCANOL

**PROVEPHARM SAS**
* PROVEPHARM SAS
PROVAYBLUE, METHYLENE BLUE

**PROVIDENT PHARM**
* PROVIDENT PHARMACEUTICAL INC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

**PTC THERAP**
* PTC THERAPEUTICS INC
EMFLAZA, DEFLAZACORT

**PULMOFLOW INC**
* PULMOFLOW INC
KITABIS PAK, TOBRAMYCIN

**PUMA BIOTECH**
* PUMA BIOTECHNOLOGY INC
NERLYNX, NERATINIB MALEATE

**PURACAP PHARM**
* PURACAP PHARMACEUTICAL LLC
MELOXICAM, MELOXICAM

**PURACAP PHARM LLC**
* PURACAP PHARMACEUTICAL LLC
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE

**PURDUE GMP**
* PURDUE GMP CENTER LLC DBA THE CHAO CENTER INDUSTRIAL PHARMACY
SEROMYCIN, CYCLOSERINE

**PURDUE PHARMA**
* PURDUE PHARMA PRODUCTS LP
INTERMEZZO, ZOLPIDEM TARTRATE

**PURDUE PHARMA LP**
* PURDUE PHARMA LP
BUTRANS, BUPRENORPHINE
HYSINGLA, HYDROCODONE BITARTRATE
MS CONTIN, MORPHINE SULFATE
OXYCONTIN, OXYCODONE HYDROCHLORIDE

**** Q ****

**QILU PHARM CO LTD**
* QILU PHARMACEUTICAL CO LTD
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFTRIAXONE, CEFTRIAXONE SODIUM
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
OLANZAPINE, OLANZAPINE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXALIPLATIN, OXALIPLATIN

**QOL MEDCL**
* QOL MEDICAL LLC
ETHAMOLIN, ETHANOLAMINE OLEATE
SUCRAID, SACROSIDASE

**QUEEN HAMAMATSU PET**
* QUEEN HAMAMATSU PET IMAGING CENTER
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** R **

**R-PHARM US LLC**
* R-PHARM US LLC
IXEMPRA KIT, IXABEPILONE

**R2 PHARMA LLC**
* R2 PHARMA LLC
ESOMEPRAZOLE STRONTIUM, ESOMEPRAZOLE STRONTIUM

**RADIUS HEALTH INC**
* RADIUS HEALTH INC
TYMLOS, ABALOPARATIDE

**RANBAXY**
* RANBAXY LABORATORIES INC
EURAX, CROTAMITON
HALOG, HALCINONIDE
ULTRAVATE, HALOBETASOL PROPIONATE

**RANBAXY LABS LTD**
* RANBAXY LABORATORIES LTD
KENALOG, TRIAMCINOLONE ACETONIDE

**RECIP**
* RECIP AB
THYROSAFE, POTASSIUM IODIDE (OTC)

**RECKITT BENCKISER**
* RECKITT BENCKISER LLC
DELSYM, DEXTROMETHORPHAN POLISTIREX (OTC)
LEVONORGESTREL, LEVONORGESTREL (OTC)
MUCINEX D, GUAIFENESIN (OTC)
MUCINEX DM, DEXTROMETHORPHAN HYDROBROMIDE (OTC)
MUCINEX, GUAIFENESIN (OTC)

**RECORDATI RARE**
* RECORDATI RARE DISEASES INC
CHEMET, SUCCIMER
COSMEGEN, DACTINOMYCIN
DESOXYN, METHAMPHETAMINE HYDROCHLORIDE
INDOCIN, INDOMETHACIN SODIUM
MUSTARGEN, MECHLORETHAMINE HYDROCHLORIDE
NEOPROFEN, IBUPROFEN LYSINE
PEGANONE, ETHOTOIN
TRANXENE, CLORAZEPATE DIPOTASSIUM

**RECRO GAINESVILLE**
* RECRO GAINESVILLE LLC
VERELAN PM, VERAPAMIL HYDROCHLORIDE
VERELAN, VERAPAMIL HYDROCHLORIDE

**RELYPSA INC**
* RELYPSA INC
VELTASSA, PATIROMER SORBITEX CALCIUM

**REMPEX PHARMS INC**
* REMPEX PHARMACEUTICALS INC
MINOCIN, MINOCYCLINE HYDROCHLORIDE

**REMPEX PHARMS MEDCNS**
* REMPEX PHARMACEUTICALS A WHOLLY OWNED SUB OF THE MEDICINES CO
VABOMERE, MEROPENEM

**RENAISSANCE SSA LLC**
* RENAISSANCE SSA LLC
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
METHOCARBAMOL, METHOCARBAMOL
MILRINONE LACTATE IN DEXTROSE 5%, MILRINONE LACTATE
OXACILLIN SODIUM, OXACILLIN SODIUM
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM

**RHODES PHARMS**
* RHODES PHARMACEUTICALS LP
APTENSIO XR, METHYLPHENIDATE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DILAUDID, HYDROMORPHONE HYDROCHLORIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** R **

* RHODES PHARMACEUTICALS LP
FENOFIBRATE (MICRONIZED), FENOFIBRATE
FENOFIBRATE, FENOFIBRATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
MORPHINE SULFATE, MORPHINE SULFATE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE

**RICONPHARMA LLC**

* RICONPHARMA LLC
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
CHLORTHALIDONE, CHLORTHALIDONE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
LIDOCAINE, LIDOCAINE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
QUININE SULFATE, QUININE SULFATE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

**RISING PHARMS INC**

* RISING PHARMACEUTICALS INC
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CROMOLYN SODIUM, CROMOLYN SODIUM
DESOXIMETASONE, DESOXIMETASONE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DOXERCALCIFEROL, DOXERCALCIFEROL
DUTASTERIDE, DUTASTERIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
HYDROCORTISONE, HYDROCORTISONE
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN
LEVOCARNITINE, LEVOCARNITINE
LEVOFLOXACIN, LEVOFLOXACIN
METHIMAZOLE, METHIMAZOLE
PARICALCITOL, PARICALCITOL
TEMOZOLOMIDE, TEMOZOLOMIDE
ZILEUTON, ZILEUTON

**ROCHE PALO**

* ROCHE PALO ALTO LLC
CELLCEPT, MYCOPHENOLATE MOFETIL
CELLCEPT, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
CYTOVENE, GANCICLOVIR SODIUM

**ROCKWELL MEDICAL INC**

* ROCKWELL MEDICAL INC
TRIFERIC , FERRIC PYROPHOSPHATE CITRATE
TRIFERIC, FERRIC PYROPHOSPHATE CITRATE

**ROMARK**

* ROMARK LABORATORIES
ALINIA, NITAZOXANIDE

**ROUSES POINT PHARMS**

* ROUSES POINT PHARMACEUTICALS LLC
LEVETIRACETAM, LEVETIRACETAM

**RP SCHERER**

* RP SCHERER TECHNOLOGIES LLC
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

**RTRX**

* RETROPHIN INC
CHOLBAM, CHOLIC ACID

**RUBICON RES PVT LTD**

* RUBICON RESEARCH PVT LTD
BACLOFEN, BACLOFEN
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
SILDENAFIL CITRATE, SILDENAFIL CITRATE

** S **

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

**SAGE PRODS**
* SAGE PRODUCTS INC
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE (OTC)

**SAGENT AGILA**
* SAGENT AGILA LLC
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE, BUPIVACAINE HYDROCHLORIDE
BUPIVACAINE HYDROCHLORIDE, BUPIVACAINE HYDROCHLORIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

**SAGENT AGILA LLC**
* SAGENT AGILA LLC
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LEVOFLOXACIN, LEVOFLOXACIN
MIDAZOLAM HYDROCHLORIDE PRESERVATIVE FREE, MIDAZOLAM HYDROCHLORIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE

**SAGENT PHARMS**
* SAGENT PHARMACEUTICALS INC
ACETYLCYSTEINE, ACETYLCYSTEINE
AMIKACIN SULFATE, AMIKACIN SULFATE
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
CAFFEINE CITRATE, CAFFEINE CITRATE
CEFEPIME HYDROCHLORIDE, CEFEPIME HYDROCHLORIDE
CEFTRIAXONE SODIUM, CEFTRIAXONE SODIUM
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
DAPTOMYCIN, DAPTOMYCIN
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUMAZENIL, FLUMAZENIL
FLUOROURACIL, FLUOROURACIL
GLYDO, LIDOCAINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM
IBANDRONATE SODIUM, IBANDRONATE SODIUM
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEVETIRACETAM, LEVETIRACETAM
LINEZOLID, LINEZOLID
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MESNA, MESNA
METHOCARBAMOL, METHOCARBAMOL
METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE
NAFCILLIN SODIUM, NAFCILLIN SODIUM
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXACILLIN SODIUM, OXACILLIN SODIUM
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PENTOBARBITAL SODIUM, PENTOBARBITAL SODIUM
PROPOFOL, PROPOFOL
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
THIAMINE HYDROCHLORIDE, THIAMINE HYDROCHLORIDE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

**SAGENT STRIDES**
* SAGENT STRIDES LLC
ADENOSINE, ADENOSINE
AZITHROMYCIN, AZITHROMYCIN
BACITRACIN, BACITRACIN

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SAGENT STRIDES LLC
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDOZALAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
POLYMYCIN B SULFATE, POLYMYXIN B SULFATE
ROPIVACAINE HYDROCHLORIDE, ROPIVACAINE HYDROCHLORIDE

**SALIX PHARMS**
* SALIX PHARMACEUTICALS INC
ANUSOL HC, HYDROCORTISONE
DIURIL, CHLOROTHIAZIDE
METOZOLV ODT, METOCLOPRAMIDE HYDROCHLORIDE
MOVIPREP, ASCORBIC ACID
OSMOPREP, SODIUM PHOSPHATE, DIBASIC, ANHYDROUS
PEPCID, FAMOTIDINE
RELISTOR, METHYLNALTREXONE BROMIDE
XIFAXAN, RIFAXIMIN

**SALIX PHARMS INC**
* SALIX PHARMACEUTICALS INC
RELISTOR, METHYLNALTREXONE BROMIDE

**SAMSON MEDCL**
* SAMSON MEDICAL TECHNOLOGIES LLC
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFOXITIN IN PLASTIC CONTAINER, CEFOXITIN SODIUM
CEFTRIAXONE, CEFTRIAXONE SODIUM
VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER, VANCOMYCIN HYDROCHLORIDE

**SANDOZ**
* SANDOZ
DOCETAXEL, DOCETAXEL
* SANDOZ INC
ALPRAZOLAM, ALPRAZOLAM
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMPICILLIN SODIUM, AMPICILLIN SODIUM
AMPICILLIN TRIHYDRATE, AMPICILLIN/AMPICILLIN TRIHYDRATE
APREPITANT, APREPITANT
ARGATROBAN IN SODIUM CHLORIDE, ARGATROBAN
ATENOLOL, ATENOLOL
AZITHROMYCIN, AZITHROMYCIN
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, BENAZEPRIL HYDROCHLORIDE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BICALUTAMIDE, BICALUTAMIDE
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BUMETANIDE, BUMETANIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CAFERGOT, CAFFEINE
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CARISOPRODOL AND ASPIRIN, ASPIRIN
CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE, ASPIRIN
CARVEDILOL, CARVEDILOL
CEFAZOLIN SODIUM, CEFAZOLIN SODIUM
CEFDINIR, CEFDINIR
CEFPODOXIME PROXETIL, CEFPODOXIME PROXETIL
CEFPROZIL, CEFPROZIL
CEFTRIAXONE, CEFTRIAXONE SODIUM
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CHOLESTYRAMINE, CHOLESTYRAMINE
CILOSTAZOL, CILOSTAZOL

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SANDOZ INC

CLARITHROMYCIN, CLARITHROMYCIN
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE (OTC)
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
COSYNTROPIN, COSYNTROPIN
CYCLOSPORINE, CYCLOSPORINE
DESIPRAMINE HYDROCHLORIDE, DESIPRAMINE HYDROCHLORIDE
DESLORATADINE, DESLORATADINE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOFENAC SODIUM AND MISOPROSTOL, DICLOFENAC SODIUM
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
EPLERENONE, EPLERENONE
ETODOLAC, ETODOLAC
FLUDARABINE PHOSPHATE, FLUDARABINE PHOSPHATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUPHENAZINE HYDROCHLORIDE, FLUPHENAZINE HYDROCHLORIDE
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE, FOSINOPRIL SODIUM
FUROSEMIDE, FUROSEMIDE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GLIPIZIDE, GLIPIZIDE
HALOPERIDOL, HALOPERIDOL
HEPARIN SODIUM, HEPARIN SODIUM
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
HYDROXYZINE PAMOATE, HYDROXYZINE PAMOATE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
INDOMETHACIN, INDOMETHACIN
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
ISONIAZID, ISONIAZID
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
ITRACONAZOLE, ITRACONAZOLE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LANSOPRAZOLE, LANSOPRAZOLE
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVOFLOXACIN, LEVOFLOXACIN
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LORATADINE, LORATADINE (OTC)
LORAZEPAM, LORAZEPAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOVASTATIN, LOVASTATIN
MECLIZINE HYDROCHLORIDE, MECLIZINE HYDROCHLORIDE
METAXALONE, METAXALONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHAZOLAMIDE, METHAZOLAMIDE
METHIMAZOLE, METHIMAZOLE
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METOLAZONE, METOLAZONE
MIDODRINE HYDROCHLORIDE, MIDODRINE HYDROCHLORIDE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NABUMETONE, NABUMETONE
NADOLOL, NADOLOL
NAFCILLIN SODIUM, NAFCILLIN SODIUM
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SANDOZ INC
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
NIZATIDINE, NIZATIDINE
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
OMEPRAZOLE, OMEPRAZOLE
OMNITROPE, SOMATROPIN RECOMBINANT
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE, ASPIRIN
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXACILLIN SODIUM, OXACILLIN SODIUM
OXALIPLATIN, OXALIPLATIN
OXAPROZIN, OXAPROZIN
OXAZEPAM, OXAZEPAM
PENICILLIN G POTASSIUM, PENICILLIN G POTASSIUM
PENICILLIN G SODIUM, PENICILLIN G SODIUM
PENICILLIN V POTASSIUM, PENICILLIN V POTASSIUM
PERPHENAZINE, PERPHENAZINE
PHENDIMETRAZINE TARTRATE, PHENDIMETRAZINE TARTRATE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE, GLIMEPIRIDE
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUINIDINE SULFATE, QUINIDINE SULFATE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RIBAVIRIN, RIBAVIRIN
RIFAMPIN, RIFAMPIN
RISPERIDONE, RISPERIDONE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
SPIRONOLACTONE, SPIRONOLACTONE
SULFADIAZINE, SULFADIAZINE
TACROLIMUS, TACROLIMUS
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TEMAZEPAM, TEMAZEPAM
TERAZOSIN HYDROCHLORIDE, TERAZOSIN HYDROCHLORIDE
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIFLUOPERAZINE HYDROCHLORIDE, TRIFLUOPERAZINE HYDROCHLORIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**SANDOZ INC**

* SANDOZ INC
ACETAMINOPHEN, ACETAMINOPHEN
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
ANECTINE, SUCCINYLCHOLINE CHLORIDE
ARISTOSPAN, TRIAMCINOLONE HEXACETONIDE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BIMATOPROST, BIMATOPROST
BRIMONIDINE TARTRATE, BRIMONIDINE TARTRATE
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BUDESONIDE, BUDESONIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSULFAN, BUSULFAN
CARBOPLATIN, CARBOPLATIN
CARTEOLOL HYDROCHLORIDE, CARTEOLOL HYDROCHLORIDE
CEFIXIME, CEFIXIME
CEFTRIAXONE, CEFTRIAXONE SODIUM

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SANDOZ INC

CISATRACURIUM BESYLATE PRESERVATIVE FREE, CISATRACURIUM BESYLATE
CISATRACURIUM BESYLATE, CISATRACURIUM BESYLATE
CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER, CLINDAMYCIN PHOSPHATE
DECITABINE, DECITABINE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIGOXIN, DIGOXIN
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ENOXAPARIN SODIUM, ENOXAPARIN SODIUM
ENTECAVIR, ENTECAVIR
EPHEDRINE SULFATE, EPHEDRINE SULFATE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
EZETIMIBE, EZETIMIBE
FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
FLUMAZENIL, FLUMAZENIL
GATIFLOXACIN, GATIFLOXACIN
GENTAMICIN SULFATE, GENTAMICIN SULFATE
GLATOPA, GLATIRAMER ACETATE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
INFUVITE ADULT, ALPHA-TOCOPHEROL ACETATE
INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE), ASCORBIC ACID
INFUVITE PEDIATRIC, ASCORBIC ACID
ISONIAZID, ISONIAZID
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN
LATANOPROST, LATANOPROST
LEVOBUNOLOL HYDROCHLORIDE, LEVOBUNOLOL HYDROCHLORIDE
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
LINEZOLID, LINEZOLID
MAXITROL, DEXAMETHASONE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METIPRANOLOL, METIPRANOLOL HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYDRIACYL, TROPICAMIDE
NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE, HYDROCORTISONE
NEVIRAPINE, NEVIRAPINE
OFLOXACIN, OFLOXACIN
OLANZAPINE, OLANZAPINE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PACLITAXEL, PACLITAXEL
PALONOSETRON HYDROCHLORIDE, PALONOSETRON HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PARICALCITOL, PARICALCITOL
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PROGESTERONE, PROGESTERONE
QOLIANA, BRIMONIDINE TARTRATE
REGONOL, PYRIDOSTIGMINE BROMIDE
REPAGLINIDE, REPAGLINIDE
RIBAVIRIN, RIBAVIRIN
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SILODOSIN, SILODOSIN

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SANDOZ INC
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TELMISARTAN, TELMISARTAN
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TIGECYCLINE, TIGECYCLINE
TIMOLOL MALEATE, TIMOLOL MALEATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOBREX, TOBRAMYCIN
TREPROSTINIL, TREPROSTINIL
TRIFLURIDINE, TRIFLURIDINE
TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**SANJA PHARMS CO**
* SANJA PHARMACEUTICALS CO
CARBOPLATIN, CARBOPLATIN
OXALIPLATIN, OXALIPLATIN

**SANOCHEMIA CORP USA**
* SANOCHEMIA CORP USA
SCANLUX-300, IOPAMIDOL
SCANLUX-370, IOPAMIDOL

**SANOFI AVENTIS US**
* SANOFI AVENTIS US INC
JEVTANA KIT, CABAZITAXEL
* SANOFI AVENTIS US LLC
ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA, FEXOFENADINE HYDROCHLORIDE
ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION, FEXOFENADINE HYDROCHLORIDE (OTC)
AMARYL, GLIMEPIRIDE
AMBIEN CR, ZOLPIDEM TARTRATE
AMBIEN, ZOLPIDEM TARTRATE
APIDRA SOLOSTAR, INSULIN GLULISINE RECOMBINANT
APIDRA, INSULIN GLULISINE RECOMBINANT
ARAVA, LEFLUNOMIDE
AUBAGIO, TERIFLUNOMIDE
AVALIDE, HYDROCHLOROTHIAZIDE
AVAPRO, IRBESARTAN
CHILDREN'S ALLEGRA ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S ALLEGRA HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CLOMID, CLOMIPHENE CITRATE
DIABETA, GLYBURIDE
ELOXATIN, OXALIPLATIN
FERRLECIT, SODIUM FERRIC GLUCONATE COMPLEX
GAVISCON, ALUMINUM HYDROXIDE (OTC)
LANTUS SOLOSTAR, INSULIN GLARGINE RECOMBINANT
LANTUS, INSULIN GLARGINE RECOMBINANT
LOVENOX (PRESERVATIVE FREE), ENOXAPARIN SODIUM
LOVENOX, ENOXAPARIN SODIUM
MULTAQ, DRONEDARONE HYDROCHLORIDE
NASACORT ALLERGY 24 HOUR, TRIAMCINOLONE ACETONIDE (OTC)
NICODERM CQ, NICOTINE (OTC)
PLAVIX, CLOPIDOGREL BISULFATE
PRIFTIN, RIFAPENTINE
PRIMAQUINE, PRIMAQUINE PHOSPHATE
RIFADIN, RIFAMPIN
RIFAMATE, ISONIAZID
RIFATER, ISONIAZID
TAXOTERE, DOCETAXEL

**SANOFI US**
* SANOFI US

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SANOFI US
ZANTAC 150, RANITIDINE HYDROCHLORIDE (OTC)
ZANTAC 75, RANITIDINE HYDROCHLORIDE (OTC)

**SANOFI US SERVICES**
* SANOFI US SERVICES INC
TOUJEO SOLOSTAR, INSULIN GLARGINE RECOMBINANT

**SANOFI-AVENTIS US**
* SANOFI-AVENTIS US LLC
ADLYXIN, LIXISENATIDE
ADMELOG SOLOSTAR, INSULIN LISPRO
ADMELOG, INSULIN LISPRO
SOLIQUA 100/33, INSULIN GLARGINE
XYZAL ALLERGY 24HR, LEVOCETIRIZINE DIHYDROCHLORIDE (OTC)
XYZAL, LEVOCETIRIZINE DIHYDROCHLORIDE

**SANTARUS INC**
* SANTARUS INC
FENOGLIDE, FENOFIBRATE
GLUMETZA, METFORMIN HYDROCHLORIDE
ZEGERID, OMEPRAZOLE

**SANTOS BIOTECH**
* SANTOS BIOTECH INDUSTRIES INC
ANASTROZOLE, ANASTROZOLE
ARIPIPRAZOLE, ARIPIPRAZOLE
BICALUTAMIDE, BICALUTAMIDE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE

**SAOL THERAPS RES LTD**
* SAOL THERAPEUTICS RESEARCH LTD
LIORESAL, BACLOFEN

**SAPTALIS PHARMS**
* SAPTALIS PHARMACEUTICALS LLC
LORAZEPAM, LORAZEPAM

**SAREPTA THERAPS INC**
* SAREPTA THERAPEUTICS INC
EXONDYS 51, ETEPLIRSEN

**SAVIOR LIFETEC CORP**
* SAVIOR LIFETEC CORP
MEROPENEM, MEROPENEM

**SAWAI USA**
* SAWAI USA INC
PITAVASTATIN CALCIUM, PITAVASTATIN CALCIUM

**SB PHARMCO**
* SB PHARMCO PUERTO RICO INC
AVANDIA, ROSIGLITAZONE MALEATE

**SCHERING**
* SCHERING CORP
INTEGRILIN, EPTIFIBATIDE
NOXAFIL, POSACONAZOLE
REBETOL, RIBAVIRIN

**SCHERING PLOUGH**
* SCHERING PLOUGH HEALTHCARE PRODUCTS INC
AFRINOL, PSEUDOEPHEDRINE SULFATE (OTC)

**SCIECURE PHARMA INC**
* SCIECURE PHARMA INC
BUDESONIDE, BUDESONIDE

**SCIEGEN PHARMS INC**
* SCIEGEN PHARMACEUTICALS INC
ARIPIPRAZOLE, ARIPIPRAZOLE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CARISOPRODOL, CARISOPRODOL
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SCIEGEN PHARMACEUTICALS INC
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
IRBESARTAN, IRBESARTAN
LAMOTRIGINE, LAMOTRIGINE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
METAXALONE, METAXALONE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
OMEPRAZOLE AND SODIUM BICARBONATE, OMEPRAZOLE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE

**SCIOS LLC**
* SCIOS LLC
NATRECOR, NESIRITIDE RECOMBINANT

**SEBELA IRELAND LTD**
* SEBELA IRELAND LTD
BRISDELLE, PAROXETINE MESYLATE
IMURAN, AZATHIOPRINE
LOTRONEX, ALOSETRON HYDROCHLORIDE
MICORT-HC, HYDROCORTISONE ACETATE
MOTOFEN, ATROPINE SULFATE
NAFTIN, NAFTIFINE HYDROCHLORIDE
ONMEL, ITRACONAZOLE
PEXEVA, PAROXETINE MESYLATE
PRAMOSONE, HYDROCORTISONE ACETATE
RIDAURA, AURANOFIN

**SECAN PHARMS**
* SECAN PHARMACEUTICALS INC
LEVETIRACETAM, LEVETIRACETAM

**SENTYNL THERAPS INC**
* SENTYNL THERAPEUTICS INC
ABSTRAL, FENTANYL CITRATE
LEVORPHANOL TARTRATE, LEVORPHANOL TARTRATE

**SEPTODONT**
* SEPTODONT INC
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE, BUPIVACAINE HYDROCHLORIDE
OCTOCAINE, EPINEPHRINE

**SEPTODONT HOLDING**
* SEPTODONT HOLDING SAS
ORAVERSE, PHENTOLAMINE MESYLATE

**SEPTODONT INC**
* SEPTODONT INC
ISOCAINE HYDROCHLORIDE, MEPIVACAINE HYDROCHLORIDE
LIDOCAINE, LIDOCAINE
PRILOCAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE, EPINEPHRINE BITARTRATE
PRILOCAINE HYDROCHLORIDE, PRILOCAINE HYDROCHLORIDE

**SERB SA**
* SERB SA
CYANOKIT, HYDROXOCOBALAMIN

**SETON PHARM**
* SETON PHARMACEUTICAL LLC
PEDIAPRED, PREDNISOLONE SODIUM PHOSPHATE

**SETON PHARMS**
* SETON PHARMACEUTICALS LLC
PENTAMIDINE ISETHIONATE, PENTAMIDINE ISETHIONATE

**SHANGHAI HENGRUI**
* SHANGHAI HENGRUI PHARMACEUTICAL CO LTD
SEVOFLURANE, SEVOFLURANE

**SHENZHEN TECHDOW**
* SHENZHEN TECHDOW PHARMACEUTICAL CO LTD
HEPARIN SODIUM PRESERVATIVE FREE, HEPARIN SODIUM
HEPARIN SODIUM, HEPARIN SODIUM

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

**SHERTECH LABS LLC**
* SHERTECH LABORATORIES LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**SHILPA MEDICARE**
* SHILPA MEDICARE LTD
AZACITIDINE, AZACITIDINE

**SHILPA MEDICARE LTD**
* SHILPA MEDICARE LTD
CAPECITABINE, CAPECITABINE

**SHIONOGI INC**
* SHIONOGI INC
PONSTEL, MEFENAMIC ACID
SYMPROIC, NALDEMEDINE TOSYLATE
ULESFIA, BENZYL ALCOHOL

**SHIRE**
* SHIRE DEVELOPMENT INC
ADDERALL XR 10, AMPHETAMINE ASPARTATE
ADDERALL XR 15, AMPHETAMINE ASPARTATE
ADDERALL XR 20, AMPHETAMINE ASPARTATE
ADDERALL XR 25, AMPHETAMINE ASPARTATE
ADDERALL XR 30, AMPHETAMINE ASPARTATE
ADDERALL XR 5, AMPHETAMINE ASPARTATE
CARBATROL, CARBAMAZEPINE
INTUNIV, GUANFACINE HYDROCHLORIDE
LIALDA, MESALAMINE
PENTASA, MESALAMINE

**SHIRE DEV LLC**
* SHIRE DEVELOPMENT LLC
FOSRENOL, LANTHANUM CARBONATE
MYDAYIS, AMPHETAMINE ASPARTATE
VYVANSE, LISDEXAMFETAMINE DIMESYLATE
XIIDRA, LIFITEGRAST

**SHIRE DEVELOPMENT**
* SHIRE DEVELOPMENT INC
VYVANSE, LISDEXAMFETAMINE DIMESYLATE

**SHIRE HUMAN GENETIC**
* SHIRE HUMAN GENETIC THERAPIES INC
VPRIV, VELAGLUCERASE ALFA

**SHIRE LLC**
* SHIRE DEVELOPMENT LLC
AGRYLIN, ANAGRELIDE HYDROCHLORIDE
FOSRENOL, LANTHANUM CARBONATE

**SHIRE ORPHAN THERAP**
* SHIRE ORPHAN THERAPIES INC
FIRAZYR, ICATIBANT ACETATE

**SIDMAK LABS INDIA**
* SIDMAK LABORATORIES INDIA PVT LTD
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE

**SIGMA TAU**
* SIGMA TAU PHARMACEUTICALS INC
ADAGEN, PEGADEMASE BOVINE

**SIGMAPHARM LABS LLC**
* SIGMAPHARM LABORATORIES LLC
ACITRETIN, ACITRETIN
ADEFOVIR DIPIVOXIL, ADEFOVIR DIPIVOXIL
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE
DISULFIRAM, DISULFIRAM
ERGOCALCIFEROL, ERGOCALCIFEROL
FLUCYTOSINE, FLUCYTOSINE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
GRISEOFULVIN,ULTRAMICROSIZE, GRISEOFULVIN, ULTRAMICROSIZE
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SIGMAPHARM LABORATORIES LLC
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
SODIUM PHENYLBUTYRATE, SODIUM PHENYLBUTYRATE

**SILARX**

* SILARX PHARMACEUTICALS INC
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL LACTATE
LEVETIRACETAM, LEVETIRACETAM
LORATADINE, LORATADINE (OTC)
METAPROTERENOL SULFATE, METAPROTERENOL SULFATE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
THEOPHYLLINE, THEOPHYLLINE

**SILARX PHARMS INC**

* SILARX PHARMACEUTICALS INC
ARIPIPRAZOLE, ARIPIPRAZOLE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
LAMIVUDINE, LAMIVUDINE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LOPINAVIR AND RITONAVIR, LOPINAVIR
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE

**SILVERGATE PHARMS**

* SILVERGATE PHARMACEUTICALS INC
EPANED KIT, ENALAPRIL MALEATE
EPANED, ENALAPRIL MALEATE
QBRELIS, LISINOPRIL
XATMEP, METHOTREXATE SODIUM

**SINOTHERAPEUTICS INC**

* SINOTHERAPEUTICS INC
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE

**SKINMEDICA**

* SKINMEDICA INC
VANIQA, EFLORNITHINE HYDROCHLORIDE

**SKYEPHARMA AG**

* SKYEPHARMA AG
TRIGLIDE, FENOFIBRATE

**SMITHKLINE BEECHAM**

* SMITHKLINE BEECHAM
LOVAZA, OMEGA-3-ACID ETHYL ESTERS
* SMITHKLINE BEECHAM (CORK) LTD IRELAND
COREG CR, CARVEDILOL PHOSPHATE
COREG, CARVEDILOL

**SOAPCO**

* SOAPCO INC
BRIAN CARE, CHLORHEXIDINE GLUCONATE (OTC)

**SOFGEN PHARMS**

* SOFGEN PHARMACEUTICALS
NIMODIPINE, NIMODIPINE
* SOFGEN PHARMACEUTICALS LLC
IBUPROFEN, IBUPROFEN (OTC)
PROGESTERONE, PROGESTERONE

**SOFIE**

* SOFIE CO DBA SOFIE (FKA ZEVACOR PHARMA INC)
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**SOMERSET**

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SOMERSET PHARMACEUTICALS INC
ELDEPRYL, SELEGILINE HYDROCHLORIDE
EMSAM, SELEGILINE

**SOMERSET THERAPS LLC**

* SOMERSET THERAPEUTICS LLC
CYANOCOBALAMIN, CYANOCOBALAMIN
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
GLYCOPYRROLATE, GLYCOPYRROLATE
METHOCARBAMOL, METHOCARBAMOL
NALOXONE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
TOBRAMYCIN, TOBRAMYCIN

**SPEAR PHARMS**

* SPEAR PHARMACEUTICALS INC
FLUOROURACIL, FLUOROURACIL

**SPECGX LLC**

* SPECGX LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ANAFRANIL, CLOMIPRAMINE HYDROCHLORIDE
ANEXSIA 5/325, ACETAMINOPHEN
ANEXSIA 7.5/325, ACETAMINOPHEN
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
EXALGO, HYDROMORPHONE HYDROCHLORIDE
FENTANYL CITRATE, FENTANYL CITRATE
FENTANYL-100, FENTANYL
FENTANYL-12, FENTANYL
FENTANYL-25, FENTANYL
FENTANYL-50, FENTANYL
FENTANYL-75, FENTANYL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHADOSE, METHADONE HYDROCHLORIDE
METHYLIN ER, METHYLPHENIDATE HYDROCHLORIDE
METHYLIN, METHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
OXYCET, ACETAMINOPHEN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PAMELOR, NORTRIPTYLINE HYDROCHLORIDE
RESTORIL, TEMAZEPAM
ROXICODONE, OXYCODONE HYDROCHLORIDE
TOFRANIL, IMIPRAMINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE

**SPECTRA MDCL DEVICES**

* SPECTRA MEDICAL DEVICES INC
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE

**SPECTRON MRC LLC**

* SPECTRON MRC LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**SPECTRUM PHARMS**

* SPECTRUM PHARMACEUTICALS INC
BELEODAQ, BELINOSTAT

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** S **

* SPECTRUM PHARMACEUTICALS INC
EVOMELA, MELPHALAN HYDROCHLORIDE
FUSILEV, LEVOLEUCOVORIN CALCIUM

**SPROUT PHARMS**
* SPROUT PHARMACEUTICALS INC
ADDYI, FLIBANSERIN

**ST RENATUS**
* ST RENATUS LLC
KOVANAZE, OXYMETAZOLINE HYDROCHLORIDE

**STAND HOMEOPATH**
* STANDARD HOMEOPATHIC CO
IVY BLOCK, BENTOQUATAM (OTC)

**STASON PHARMS**
* STASON PHARMACEUTICALS INC
PURINETHOL, MERCAPTOPURINE

**STI PHARMA LLC**
* STI PHARMA LLC
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
DEXAMETHASONE, DEXAMETHASONE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
MYAMBUTOL, ETHAMBUTOL HYDROCHLORIDE
SULFATRIM PEDIATRIC, SULFAMETHOXAZOLE
TRIACIN-C, CODEINE PHOSPHATE

**STIEFEL**
* STIEFEL LABORATORIES INC
DUAC, BENZOYL PEROXIDE

**STIEFEL LABS INC**
* STIEFEL LABORATORIES INC
SORIATANE, ACITRETIN

**STRIDES PHARMA**
* STRIDES PHARMA GLOBAL PTE LTD
ABACAVIR SULFATE, ABACAVIR SULFATE
ACARBOSE, ACARBOSE
ACETAZOLAMIDE, ACETAZOLAMIDE
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
BENZONATATE, BENZONATATE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CALCITRIOL, CALCITRIOL
CARISOPRODOL, CARISOPRODOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
DUTASTERIDE, DUTASTERIDE
ERGOCALCIFEROL, ERGOCALCIFEROL
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE (OTC)
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
IMIQUIMOD, IMIQUIMOD
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
MELOXICAM, MELOXICAM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METHOXSALEN, METHOXSALEN
METRONIDAZOLE, METRONIDAZOLE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NEVIRAPINE, NEVIRAPINE
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
PEG-3350, POTASSIUM CHLORIDE, SODIUM BICARBONATE, SODIUM CHLORIDE, POLYETHYLENE GLYCOL
POLYETHYLENE GLYCOL 3350, POLYETHYLENE GLYCOL 3350 (OTC)
POTASSIUM CITRATE, POTASSIUM CITRATE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
TACROLIMUS, TACROLIMUS
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE

**STRONGBRIDGE US**

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* STRONGBRIDGE US INC
KEVEYIS, DICHLORPHENAMIDE

**SUCAMPO PHARMA LLC**

* SUCAMPO PHARMA AMERICAS LLC
AMITIZA, LUBIPROSTONE

**SUN PHARM INDS**

* SUN PHARMACEUTICAL INDUSTRIES LTD
CARBIDOPA AND LEVODOPA, CARBIDOPA
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
DESLORATADINE, DESLORATADINE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
EPINASTINE HYDROCHLORIDE, EPINASTINE HYDROCHLORIDE
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
OLANZAPINE, OLANZAPINE
ONDANSETRON, ONDANSETRON
OXCARBAZEPINE, OXCARBAZEPINE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE

**SUN PHARM INDS (IN)**

* SUN PHARMACEUTICAL INDUSTRIES LTD
CEPHALEXIN, CEPHALEXIN
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ZONISAMIDE, ZONISAMIDE

**SUN PHARM INDS INC**

* SUN PHARMACEUTICAL INDUSTRIES INC
ABSORICA, ISOTRETINOIN
ALLOPURINOL, ALLOPURINOL
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATENOLOL, ATENOLOL
BACLOFEN, BACLOFEN
BENZONATATE, BENZONATATE
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLONAZEPAM, CLONAZEPAM
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLOZAPINE, CLOZAPINE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DIGOXIN, DIGOXIN
ERGOCALCIFEROL, ERGOCALCIFEROL
EXELDERM, SULCONAZOLE NITRATE
FLUMADINE, RIMANTADINE HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
GEMFIBROZIL, GEMFIBROZIL
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLIPIZIDE, GLIPIZIDE
HALOG, HALCINONIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
INDOMETHACIN, INDOMETHACIN
ISOSORBIDE DINITRATE, ISOSORBIDE DINITRATE
LITHIUM CARBONATE, LITHIUM CARBONATE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SUN PHARMACEUTICAL INDUSTRIES INC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHIMAZOLE, METHIMAZOLE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
NIMODIPINE, NIMODIPINE
OXAPROZIN, OXAPROZIN
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PAROMOMYCIN SULFATE, PAROMOMYCIN SULFATE
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
REPAGLINIDE, REPAGLINIDE
RISPERIDONE, RISPERIDONE
TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**SUN PHARM INDS LTD**

* SUN PHARMACEUTICAL INDUSTRIES LTD
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
AZITHROMYCIN, AZITHROMYCIN
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE , BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLARITHROMYCIN, CLARITHROMYCIN
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE HYDROCHLORIDE
DESMOPRESSIN ACETATE, DESMOPRESSIN ACETATE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE
FAMOTIDINE, FAMOTIDINE (OTC)
FELODIPINE, FELODIPINE
FENOFIBRATE, FENOFIBRATE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
GABAPENTIN, GABAPENTIN
GLYCOPYRROLATE, GLYCOPYRROLATE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
LANSOPRAZOLE, LANSOPRAZOLE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LISINOPRIL, LISINOPRIL
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE, LOPERAMIDE HYDROCHLORIDE (OTC)
LORATADINE AND PSEUDOEPHEDRINE SULFATE, LORATADINE (OTC)

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SUN PHARMACEUTICAL INDUSTRIES LTD
LORATADINE REDIDOSE, LORATADINE (OTC)
LORATADINE, LORATADINE (OTC)
LORAZEPAM, LORAZEPAM
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NAPROXEN SODIUM, NAPROXEN SODIUM (OTC)
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
OPCICON ONE-STEP, LEVONORGESTREL (OTC)
OXCARBAZEPINE, OXCARBAZEPINE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PSEUDOEPHEDRINE HYDROCHLORIDE, PSEUDOEPHEDRINE HYDROCHLORIDE (OTC)
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RILUZOLE, RILUZOLE
RIOMET, METFORMIN HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TOPIRAMATE, TOPIRAMATE
ULTRAVATE, HALOBETASOL PROPIONATE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALPROIC ACID, VALPROIC ACID
XIMINO, MINOCYCLINE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**SUN PHARM INDUSTRIES**

* SUN PHARMACEUTICAL INDUSTRIES INC
ACETAZOLAMIDE, ACETAZOLAMIDE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALLOPURINOL, ALLOPURINOL
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
ATENOLOL, ATENOLOL
BACTRIM DS, SULFAMETHOXAZOLE
BACTRIM, SULFAMETHOXAZOLE
CARISOPRODOL, CARISOPRODOL
CARVEDILOL PHOSPHATE, CARVEDILOL PHOSPHATE
CHLORTHALIDONE, CHLORTHALIDONE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE
ERGOLOID MESYLATES, ERGOLOID MESYLATES
FELODIPINE, FELODIPINE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
IMIPRAMINE HYDROCHLORIDE, IMIPRAMINE HYDROCHLORIDE
LEVETIRACETAM, LEVETIRACETAM
LOVASTATIN, LOVASTATIN
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL
MORPHINE SULFATE, MORPHINE SULFATE
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
NYSTATIN, NYSTATIN
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PINDOLOL, PINDOLOL
PIROXICAM, PIROXICAM
PREDNISONE, PREDNISONE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SUN PHARMACEUTICAL INDUSTRIES INC
QUALAQUIN, QUININE SULFATE
QUINIDINE GLUCONATE, QUINIDINE GLUCONATE
QUINIDINE SULFATE, QUINIDINE SULFATE
SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SULINDAC, SULINDAC
SYNALGOS-DC, ASPIRIN
TEMAZEPAM, TEMAZEPAM
THIORIDAZINE HYDROCHLORIDE, THIORIDAZINE HYDROCHLORIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIMETHOBENZAMIDE HYDROCHLORIDE, TRIMETHOBENZAMIDE HYDROCHLORIDE
ULTRAVATE, HALOBETASOL PROPIONATE

**SUN PHARMA GLOBAL**

* SUN PHARMA GLOBAL FZE
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
AMIFOSTINE, AMIFOSTINE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BROMSITE, BROMFENAC SODIUM
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CAFFEINE CITRATE, CAFFEINE CITRATE
CARBIDOPA AND LEVODOPA, CARBIDOPA
CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CHLOROTHIAZIDE SODIUM, CHLOROTHIAZIDE SODIUM
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DECITABINE, DECITABINE
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DESVENLAFAXINE, DESVENLAFAXINE FUMARATE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), DOXORUBICIN HYDROCHLORIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENTACAPONE, ENTACAPONE
ESOMEPRAZOLE SODIUM, ESOMEPRAZOLE SODIUM
ESZOPICLONE, ESZOPICLONE
FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE, FEXOFENADINE
FINASTERIDE, FINASTERIDE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
IMATINIB MESYLATE, IMATINIB MESYLATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
NALTREXONE HYDROCHLORIDE, NALTREXONE HYDROCHLORIDE
NIACIN, NIACIN
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
ODOMZO, SONIDEGIB PHOSPHATE
OXALIPLATIN, OXALIPLATIN
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TEMOZOLOMIDE, TEMOZOLOMIDE
TETRABENAZINE, TETRABENAZINE
TOPIRAMATE, TOPIRAMATE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** S ****

* SUN PHARMA GLOBAL FZE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

* SUN PHARMA GLOBAL INC
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
ALPRAZOLAM, ALPRAZOLAM
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BICALUTAMIDE, BICALUTAMIDE
CARBOPLATIN, CARBOPLATIN
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM

**SUNOVION**

* SUNOVION PHARMACEUTICALS INC
BROVANA, ARFORMOTEROL TARTRATE
XOPENEX HFA, LEVALBUTEROL TARTRATE

**SUNOVION PHARMS INC**

* SUNOVION PHARMACEUTICALS INC
APTIOM, ESLICARBAZEPINE ACETATE
ARCAPTA NEOHALER, INDACATEROL MALEATE
LATUDA, LURASIDONE HYDROCHLORIDE
LUNESTA, ESZOPICLONE
SEEBRI, GLYCOPYRROLATE
UTIBRON, GLYCOPYRROLATE
ZONEGRAN, ZONISAMIDE

**SUNOVION RESP**

* SUNOVION RESPIRATORY DEVELOPMENT INC
LONHALA MAGNAIR KIT, GLYCOPYRROLATE

**SUNRISE PHARM INC**

* SUNRISE PHARMACEUTICAL INC
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE

**SUNSTAR AMERICAS**

* SUNSTAR AMERICAS INC
PAROEX, CHLORHEXIDINE GLUCONATE

**SUPERNUS PHARMS**

* SUPERNUS PHARMACEUTICALS INC
OXTELLAR XR, OXCARBAZEPINE
TROKENDI XR, TOPIRAMATE

**SUVEN LIFE**

* SUVEN LIFE SCIENCES LTD
MALATHION, MALATHION

**SVC PHARMA**

* SVC PHARMA LP
DRONABINOL, DRONABINOL

**SWEDISH ORPHAN**

* SWEDISH ORPHAN BIOVITRUM AB PUBL
ORFADIN, NITISINONE

**SYNERGY PHARMS**

* SYNERGY PHARMACEUTICALS INC
TRULANCE, PLECANATIDE

**SYNTHON PHARMS**

* SYNTHON PHARMACEUTICALS INC
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE

**** T ****

**ACME LABS**

* THE ACME LABORATORIES LTD
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

**GEN HOSP**
* THE GENERAL HOSPITAL CORP
AMMONIA N 13, AMMONIA N-13

**METHODIST HOSP RES**
* THE METHODIST HOSP RESEARCH INSTITUTE
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**RITEDOSE CORP**
* THE RITEDOSE CORP
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE

**TAIHO ONCOLOGY**
* TAIHO ONCOLOGY INC
LONSURF, TIPIRACIL HYDROCHLORIDE

**TAKEDA PHARMS USA**
* TAKEDA PHARMACEUTICALS USA INC
ACTOPLUS MET XR, METFORMIN HYDROCHLORIDE
ACTOPLUS MET, METFORMIN HYDROCHLORIDE
ACTOS, PIOGLITAZONE HYDROCHLORIDE
COLCRYS, COLCHICINE
DEXILANT, DEXLANSOPRAZOLE
DUETACT, GLIMEPIRIDE
KAZANO, ALOGLIPTIN BENZOATE
NESINA, ALOGLIPTIN BENZOATE
OSENI, ALOGLIPTIN BENZOATE
PREVACID, LANSOPRAZOLE
PREVPAC, AMOXICILLIN
ROZEREM, RAMELTEON
TRINTELLIX, VORTIOXETINE HYDROBROMIDE
ULORIC, FEBUXOSTAT

**TALON THERAP**
* TALON THERAPEUTICS INC
MARQIBO KIT, VINCRISTINE SULFATE

**TAMARANG**
* TAMARANG SA
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE

**TARO**
* TARO PHARMACEUTICAL INDUSTRIES LTD
ACETAZOLAMIDE, ACETAZOLAMIDE
CARBAMAZEPINE, CARBAMAZEPINE
CARVEDILOL, CARVEDILOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
EXTENDED PHENYTOIN SODIUM, PHENYTOIN SODIUM
FLUCONAZOLE, FLUCONAZOLE
FLUOROURACIL, FLUOROURACIL
GABAPENTIN, GABAPENTIN
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
IMIQUIMOD, IMIQUIMOD
KETOCONAZOLE, KETOCONAZOLE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LORATADINE, LORATADINE (OTC)
MELOXICAM, MELOXICAM
METRONIDAZOLE, METRONIDAZOLE
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
OXCARBAZEPINE, OXCARBAZEPINE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** T **

* TARO PHARMACEUTICAL INDUSTRIES LTD
PHENYTOIN, PHENYTOIN
* TARO PHARMACEUTICALS USA INC
ACETIC ACID, ACETIC ACID, GLACIAL
ACYCLOVIR, ACYCLOVIR
ADAPALENE, ADAPALENE
ALCLOMETASONE DIPROPIONATE, ALCLOMETASONE DIPROPIONATE
AMMONIUM LACTATE, AMMONIUM LACTATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
BUTENAFINE HYDROCHLORIDE, BUTENAFINE HYDROCHLORIDE (OTC)
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLOTRIMAZOLE, CLOTRIMAZOLE
CLOTRIMAZOLE, CLOTRIMAZOLE (OTC)
DAPSONE, DAPSONE
DERMABET, BETAMETHASONE VALERATE
DESONIDE, DESONIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DIFLORASONE DIACETATE, DIFLORASONE DIACETATE
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
FLUOCINOLONE ACETONIDE, FLUOCINOLONE ACETONIDE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
GENTAMICIN SULFATE, GENTAMICIN SULFATE
HALOBETASOL PROPIONATE, HALOBETASOL PROPIONATE
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROCORTISONE VALERATE, HYDROCORTISONE VALERATE
HYDROCORTISONE, HYDROCORTISONE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
KETOZOLE, KETOCONAZOLE
LIDOCAINE, LIDOCAINE
LORATADINE, LORATADINE (OTC)
MICONAZOLE 3, MICONAZOLE NITRATE (OTC)
MICONAZOLE NITRATE, MICONAZOLE NITRATE (OTC)
MOMETASONE FUROATE, MOMETASONE FUROATE
MUPIROCIN, MUPIROCIN
NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
NYSTATIN, NYSTATIN
OXICONAZOLE NITRATE, OXICONAZOLE NITRATE
PHENYTOIN, PHENYTOIN
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, SODIUM CHLORIDE
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER, STERILE WATER FOR INJECTION
SULFACETAMIDE SODIUM, SULFACETAMIDE SODIUM
TAZAROTENE, TAZAROTENE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE (OTC)
TERCONAZOLE, TERCONAZOLE
TOPICORT, DESOXIMETASONE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
TRIVAGIZOLE 3, CLOTRIMAZOLE (OTC)
U-CORT, HYDROCORTISONE ACETATE

**TARO PHARM**

* TARO PHARMACEUTICAL INDUSTRIES LTD
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
BETAMETHASONE VALERATE, BETAMETHASONE VALERATE
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TARO PHARMACEUTICAL INDUSTRIES LTD
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLORAZEPATE DIPOTASSIUM, CLORAZEPATE DIPOTASSIUM
DESLORATADINE, DESLORATADINE
DESONIDE, DESONIDE
FELBAMATE, FELBAMATE
FLUOROURACIL, FLUOROURACIL
GABAPENTIN, GABAPENTIN
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
LORATADINE, LORATADINE (OTC)
METRONIDAZOLE, METRONIDAZOLE
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
NYSTATIN, NYSTATIN
OVIDE, MALATHION
TERIL, CARBAMAZEPINE
WARFARIN SODIUM, WARFARIN SODIUM

**TARO PHARM INDS**

* TARO PHARMACEUTICAL INDUSTRIES LTD
AMCINONIDE, AMCINONIDE
CARBAMAZEPINE, CARBAMAZEPINE
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
DESLORATADINE, DESLORATADINE
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE, ENALAPRIL MALEATE
ETODOLAC, ETODOLAC
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
LAMOTRIGINE, LAMOTRIGINE
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE

**TARO PHARMS**

* TARO PHARMACEUTICALS INC
PLIAGLIS, LIDOCAINE

**TARO PHARMS NORTH**

* TARO PHARMACEUTICALS NORTH AMERICA INC
ACETAMINOPHEN, ACETAMINOPHEN (OTC)
INFANTS' FEVERALL, ACETAMINOPHEN (OTC)

**TASMAN PHARMA**

* TASMAN PHARMA INC
VERSACLOZ, CLOZAPINE

**TCG FLUENT PHARMA**

* TCG FLUENT PHARMA INVESTORS LP
FLOLIPID, SIMVASTATIN

**TECH ORGANIZED**

* TECHNOLOGY ORGANIZED LLC
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
NEVIRAPINE, NEVIRAPINE

**TEDOR PHARM**

* TEDOR PHARMA INC
BENZPHETAMINE HYDROCHLORIDE, BENZPHETAMINE HYDROCHLORIDE

**TEDOR PHARMA INC**

* TEDOR PHARMA INC
BUTALBITAL AND ACETAMINOPHEN, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE

**TEIKOKU PHARMA USA**

* TEIKOKU PHARMA USA INC
LIDODERM, LIDOCAINE

**TELIGENT**

* TELIGENT OU
CEFOTAN, CEFOTETAN DISODIUM
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TELIGENT OU
FORTAZ IN PLASTIC CONTAINER, CEFTAZIDIME SODIUM
FORTAZ, CEFTAZIDIME
ZANTAC, RANITIDINE HYDROCHLORIDE
ZINACEF IN PLASTIC CONTAINER, CEFUROXIME SODIUM
ZINACEF, CEFUROXIME SODIUM

**TELIGENT PHARMA INC**

* TELIGENT PHARMA INC
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOBETASOL PROPIONATE (EMOLLIENT), CLOBETASOL PROPIONATE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DESONIDE, DESONIDE
DESOXIMETASONE, DESOXIMETASONE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
ECONAZOLE NITRATE, ECONAZOLE NITRATE
ERYTHROMYCIN, ERYTHROMYCIN
FLURANDRENOLIDE, FLURANDRENOLIDE
HYDROCORTISONE BUTYRATE, HYDROCORTISONE BUTYRATE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE, LIDOCAINE
NYSTATIN AND TRIAMCINOLONE ACETONIDE, NYSTATIN
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE

**TERSERA THERAPS LLC**

* TERSERA THERAPEUTICS LLC
ERGOMAR, ERGOTAMINE TARTRATE
ZOLADEX, GOSERELIN ACETATE

**TESARO INC**

* TESARO INC
VARUBI, ROLAPITANT HYDROCHLORIDE
ZEJULA, NIRAPARIB TOSYLATE

**TEVA**

* TEVA NEUROSCIENCE INC
AZILECT, RASAGILINE MESYLATE
* TEVA PHARMACEUTICALS USA INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACYCLOVIR, ACYCLOVIR
ADIPEX-P, PHENTERMINE HYDROCHLORIDE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN PEDIATRIC, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
ATENOLOL, ATENOLOL
AZITHROMYCIN, AZITHROMYCIN
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BICALUTAMIDE, BICALUTAMIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CALCITRIOL, CALCITRIOL
CAPTOPRIL, CAPTOPRIL
CARVEDILOL, CARVEDILOL
CEFACLOR, CEFACLOR
CEFPROZIL, CEFPROZIL
CELECOXIB, CELECOXIB
CEPHALEXIN, CEPHALEXIN
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CILOSTAZOL, CILOSTAZOL
CIMETIDINE, CIMETIDINE
CLARITHROMYCIN, CLARITHROMYCIN
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TEVA PHARMACEUTICALS USA INC
CLOTRIMAZOLE, CLOTRIMAZOLE
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE, AMPHETAMINE
DICLOFENAC POTASSIUM, DICLOFENAC POTASSIUM
DICLOXACILLIN SODIUM, DICLOXACILLIN SODIUM
DIFLUNISAL, DIFLUNISAL
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DISOPYRAMIDE PHOSPHATE, DISOPYRAMIDE PHOSPHATE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ENOXAPARIN SODIUM (PRESERVATIVE FREE), ENOXAPARIN SODIUM
EPITOL, CARBAMAZEPINE
ESZOPICLONE, ESZOPICLONE
ETODOLAC, ETODOLAC
FAMOTIDINE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE (OTC)
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE, FEXOFENADINE HYDROCHLORIDE
FINASTERIDE, FINASTERIDE
FLUCONAZOLE, FLUCONAZOLE
FLUOCINONIDE EMULSIFIED BASE, FLUOCINONIDE
FLUOCINONIDE, FLUOCINONIDE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLURBIPROFEN, FLURBIPROFEN
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
GALZIN, ZINC ACETATE
GEMFIBROZIL, GEMFIBROZIL
GLIMEPIRIDE, GLIMEPIRIDE
GLYBURIDE (MICRONIZED), GLYBURIDE
GLYBURIDE, GLYBURIDE
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
KETOCONAZOLE, KETOCONAZOLE
KETOPROFEN, KETOPROFEN
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LAMOTRIGINE, LAMOTRIGINE
LEVOFLOXACIN, LEVOFLOXACIN
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE
LORATADINE, LORATADINE (OTC)
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOVASTATIN, LOVASTATIN
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MEXILETINE HYDROCHLORIDE, MEXILETINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MOEXIPRIL HYDROCHLORIDE, MOEXIPRIL HYDROCHLORIDE
MUPIROCIN, MUPIROCIN
NAPROXEN SODIUM, NAPROXEN SODIUM
NAPROXEN, NAPROXEN
NEFAZODONE HYDROCHLORIDE, NEFAZODONE HYDROCHLORIDE
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NORTRIPTYLINE HYDROCHLORIDE, NORTRIPTYLINE HYDROCHLORIDE
NYSTATIN, NYSTATIN
OFLOXACIN, OFLOXACIN
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON, ONDANSETRON
ORAP, PIMOZIDE
OXAPROZIN, OXAPROZIN

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TEVA PHARMACEUTICALS USA INC
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PENICILLIN-VK, PENICILLIN V POTASSIUM
PIROXICAM, PIROXICAM
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PRELONE, PREDNISOLONE
QUINAPRIL HYDROCHLORIDE, QUINAPRIL HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RIBAVIRIN, RIBAVIRIN
RISPERIDONE, RISPERIDONE
ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
ROSIGLITAZONE MALEATE, ROSIGLITAZONE MALEATE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SUCRALFATE, SUCRALFATE
SULFAMETHOXAZOLE AND TRIMETHOPRIM DOUBLE STRENGTH, SULFAMETHOXAZOLE
TERBINAFINE HYDROCHLORIDE, TERBINAFINE HYDROCHLORIDE
TICLOPIDINE HYDROCHLORIDE, TICLOPIDINE HYDROCHLORIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOLMETIN SODIUM, TOLMETIN SODIUM
TOPIRAMATE, TOPIRAMATE
TORSEMIDE, TORSEMIDE
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**TEVA BRANDED PHARM**

* TEVA BRANDED PHARMACEUTICAL PRODUCTS R AND D INC
AUSTEDO, DEUTETRABENAZINE
DIAMOX, ACETAZOLAMIDE
LOSEASONIQUE, ETHINYL ESTRADIOL
PROAIR HFA, ALBUTEROL SULFATE
PROAIR RESPICLICK, ALBUTEROL SULFATE
PROGLYCEM, DIAZOXIDE
QNASL, BECLOMETHASONE DIPROPIONATE
QUARTETTE, ETHINYL ESTRADIOL
QVAR 40, BECLOMETHASONE DIPROPIONATE
QVAR 80, BECLOMETHASONE DIPROPIONATE
SEASONALE, ETHINYL ESTRADIOL
SEASONIQUE, ETHINYL ESTRADIOL
VANTRELA ER, HYDROCODONE BITARTRATE
ZIAC, BISOPROLOL FUMARATE

**TEVA PARENTERAL**

* TEVA PARENTERAL MEDICINES INC
DAPTOMYCIN, DAPTOMYCIN
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE

**TEVA PHARM**

* TEVA PHARMACEUTICAL INDUSTRIES LTD
AIRDUO RESPICLICK, FLUTICASONE PROPIONATE
ARMONAIR RESPICLICK, FLUTICASONE PROPIONATE

**TEVA PHARMS**

* TEVA PHARMACEUTICALS USA
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
ANASTROZOLE, ANASTROZOLE
AZITHROMYCIN, AZITHROMYCIN
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE
BUDESONIDE, BUDESONIDE
CARBAMAZEPINE, CARBAMAZEPINE
CEFADROXIL, CEFADROXIL/CEFADROXIL HEMIHYDRATE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TEVA PHARMACEUTICALS USA
CEFDINIR, CEFDINIR
CEFPROZIL, CEFPROZIL
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CROMOLYN SODIUM, CROMOLYN SODIUM
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
ETHOSUXIMIDE, ETHOSUXIMIDE
FAMCICLOVIR, FAMCICLOVIR
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
GABAPENTIN, GABAPENTIN
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GEMCITABINE HYDROCHLORIDE, GEMCITABINE HYDROCHLORIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL LACTATE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
IRBESARTAN, IRBESARTAN
LAMIVUDINE AND ZIDOVUDINE, LAMIVUDINE
LANSOPRAZOLE, LANSOPRAZOLE
LEFLUNOMIDE, LEFLUNOMIDE
LETROZOLE, LETROZOLE
LEVETIRACETAM, LEVETIRACETAM
LEVOCETIRIZINE DIHYDROCHLORIDE, LEVOCETIRIZINE DIHYDROCHLORIDE
LINEZOLID, LINEZOLID
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MEGESTROL ACETATE, MEGESTROL ACETATE
MELOXICAM, MELOXICAM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
OLANZAPINE AND FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
OLANZAPINE, OLANZAPINE
OXALIPLATIN, OXALIPLATIN
PACLITAXEL, PACLITAXEL
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PRAZOSIN HYDROCHLORIDE, PRAZOSIN HYDROCHLORIDE
PROCHLORPERAZINE MALEATE, PROCHLORPERAZINE MALEATE
PROGESTERONE, PROGESTERONE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
QUININE SULFATE, QUININE SULFATE
RAMIPRIL, RAMIPRIL
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE
SILDENAFIL CITRATE, SILDENAFIL CITRATE
SULFAMETHOXAZOLE AND TRIMETHOPRIM SINGLE STRENGTH, SULFAMETHOXAZOLE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TRANDOLAPRIL, TRANDOLAPRIL
URSODIOL, URSODIOL
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VANDAZOLE, METRONIDAZOLE
VORICONAZOLE, VORICONAZOLE
ZALEPLON, ZALEPLON

**TEVA PHARMS INTL**

* TEVA PHARMACEUTICALS INTERNATIONAL GMBH
AMRIX, CYCLOBENZAPRINE HYDROCHLORIDE
SYNRIBO, OMACETAXINE MEPESUCCINATE

**TEVA PHARMS USA**

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TEVA PHARMACEUTICALS USA

ABACAVIR SULFATE AND LAMIVUDINE, ABACAVIR SULFATE
ACITRETIN, ACITRETIN
ADENOSINE, ADENOSINE
ALMOTRIPTAN MALATE, ALMOTRIPTAN MALATE
ALPROSTADIL, ALPROSTADIL
AMIKACIN SULFATE, AMIKACIN SULFATE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE
ARGATROBAN IN 0.9% SODIUM CHLORIDE, ARGATROBAN
ARIPIPRAZOLE, ARIPIPRAZOLE
ATAZANAVIR SULFATE, ATAZANAVIR SULFATE
ATOMOXETINE HYDROCHLORIDE, ATOMOXETINE HYDROCHLORIDE
ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BUDESONIDE, BUDESONIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
CARBOPLATIN, CARBOPLATIN
CLARAVIS, ISOTRETINOIN
CLOZAPINE, CLOZAPINE
COPAXONE, GLATIRAMER ACETATE
DACARBAZINE, DACARBAZINE
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DOCETAXEL, DOCETAXEL
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ENALAPRILAT, ENALAPRILAT
ENTECAVIR, ENTECAVIR
EPOPROSTENOL SODIUM, EPOPROSTENOL SODIUM
EPTIFIBATIDE, EPTIFIBATIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESTRADIOL, ESTRADIOL
ETOPOSIDE, ETOPOSIDE
EZETIMIBE, EZETIMIBE
FLUOROURACIL, FLUOROURACIL
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUVASTATIN SODIUM, FLUVASTATIN SODIUM
GABAPENTIN, GABAPENTIN
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
IDARUBICIN HYDROCHLORIDE PFS, IDARUBICIN HYDROCHLORIDE
IFOSFAMIDE, IFOSFAMIDE
IMATINIB MESYLATE, IMATINIB MESYLATE
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN, AMOXICILLIN
LANSOPRAZOLE, LANSOPRAZOLE
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEUPROLIDE ACETATE, LEUPROLIDE ACETATE
LEVALBUTEROL HYDROCHLORIDE, LEVALBUTEROL HYDROCHLORIDE
LINEZOLID, LINEZOLID
LOGILIA, ULIPRISTAL ACETATE
MESNA, MESNA
METHYLPREDNISOLONE ACETATE, METHYLPREDNISOLONE ACETATE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
MYCOPHENOLIC ACID, MYCOPHENOLIC ACID
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TEVA PHARMACEUTICALS USA
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OMEGA-3-ACID ETHYL ESTERS, OMEGA-3-ACID ETHYL ESTERS
OMEPRAZOLE, OMEPRAZOLE
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PANCURONIUM BROMIDE, PANCURONIUM BROMIDE
PARICALCITOL, PARICALCITOL
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RISEDRONATE SODIUM, RISEDRONATE SODIUM
ROSIGLITAZONE MALEATE AND GLIMEPIRIDE, GLIMEPIRIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SOLIFENACIN SUCCINATE, SOLIFENACIN SUCCINATE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TENOFOVIR DISOPROXIL FUMARATE, TENOFOVIR DISOPROXIL FUMARATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TOBRAMYCIN, TOBRAMYCIN
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TOPOTECAN HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VINCRISTINE SULFATE PFS, VINCRISTINE SULFATE
VINORELBINE TARTRATE, VINORELBINE TARTRATE
ZANOSAR, STREPTOZOCIN
ZOLMITRIPTAN, ZOLMITRIPTAN

* TEVA PHARMACEUTICALS USA INC
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
CAPECITABINE, CAPECITABINE
DARUNAVIR ETHANOLATE, DARUNAVIR ETHANOLATE
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE, EMTRICITABINE
ESTRADIOL AND NORETHINDRONE ACETATE, ESTRADIOL
MEDROXYPROGESTERONE ACETATE, MEDROXYPROGESTERONE ACETATE
METRONIDAZOLE, METRONIDAZOLE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
SELFEMRA, FLUOXETINE HYDROCHLORIDE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE

**THE FEINSTEIN INST**

* THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**THE MEDICINES CO**

* THE MEDICINES CO
ANGIOMAX, BIVALIRUDIN
IONSYS, FENTANYL HYDROCHLORIDE
ORBACTIV, ORITAVANCIN DIPHOSPHATE

**THE PHARMA NETWORK**

* THE PHARMA NETWORK LLC
BENZONATATE, BENZONATATE

**THE PHARMANETWORK**

* THE PHARMANETWORK LLC
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE

**THEPHARMANETWORK LLC**

* THEPHARMANETWORK LLC
BENZONATATE, BENZONATATE
ISONIAZID, ISONIAZID
NIMODIPINE, NIMODIPINE
THERMAZENE, SILVER SULFADIAZINE

**THERATECHNOLOGIES**

* THERATECHNOLOGIES INC
EGRIFTA, TESAMORELIN ACETATE

**THERAVANCE BIOPHARMA**

* THERAVANCE BIOPHARMA R AND D INC

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* THERAVANCE BIOPHARMA R AND D INC
VIBATIV, TELAVANCIN HYDROCHLORIDE

**TOLMAR**

* TOLMAR INC
ACYCLOVIR, ACYCLOVIR
ADAPALENE, ADAPALENE
ATRIDOX, DOXYCYCLINE HYCLATE
BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE
CALCIPOTRIENE, CALCIPOTRIENE
CICLOPIROX, CICLOPIROX
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
DICLOFENAC SODIUM , DICLOFENAC SODIUM
ERYTHROMYCIN AND BENZOYL PEROXIDE, BENZOYL PEROXIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
IMIQUIMOD, IMIQUIMOD
KETOCONAZOLE, KETOCONAZOLE
LEVETIRACETAM, LEVETIRACETAM
LIDOCAINE AND PRILOCAINE, LIDOCAINE
METRONIDAZOLE, METRONIDAZOLE
MOMETASONE FUROATE, MOMETASONE FUROATE
NAFTIFINE HYDROCHLORIDE, NAFTIFINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE

**TOLMAR THERAP**

* TOLMAR THERAPEUTICS INC
ELIGARD, LEUPROLIDE ACETATE

**TORPHARM**

* TORPHARM INC
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE

**TORRENT PHARMA INC**

* TORRENT PHARMA INC
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE

**TORRENT PHARMS**

* TORRENT PHARMACEUTICALS LIMITED
LEVOFLOXACIN, LEVOFLOXACIN
* TORRENT PHARMACEUTICALS LTD
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
CARBAMAZEPINE, CARBAMAZEPINE
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
RISPERIDONE, RISPERIDONE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
* TORRENT PHARMACEUTICALS LTD.
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE

**TORRENT PHARMS LLC**

* TORRENT PHARMACEUTICALS LLC
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
OLANZAPINE, OLANZAPINE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

**TORRENT PHARMS LTD**

* TORRENT PHARMACEUTICALS LTD
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE AND VALSARTAN, AMLODIPINE BESYLATE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TORRENT PHARMACEUTICALS LTD
AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
ANAGRELIDE HYDROCHLORIDE, ANAGRELIDE HYDROCHLORIDE
ARIPIPRAZOLE, ARIPIPRAZOLE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CELECOXIB, CELECOXIB
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
DARIFENACIN HYDROBROMIDE, DARIFENACIN HYDROBROMIDE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE MAGNESIUM
FELODIPINE, FELODIPINE
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
OLANZAPINE, OLANZAPINE
OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, AMLODIPINE BESYLATE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RABEPRAZOLE SODIUM, RABEPRAZOLE SODIUM
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SILDENAFIL CITRATE, SILDENAFIL CITRATE
TELMISARTAN AND AMLODIPINE, AMLODIPINE BESYLATE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TELMISARTAN, TELMISARTAN
TOLTERODINE TARTRATE, TOLTERODINE TARTRATE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
VALSARTAN, VALSARTAN

**TRIS PHARMA INC**

* TRIS PHARMA INC
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF, CETIRIZINE HYDROCHLORIDE (OTC)
DEXMETHYLPHENIDATE HYDROCHLORIDE, DEXMETHYLPHENIDATE HYDROCHLORIDE
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
DEXTROMETHORPHAN POLISTIREX, DEXTROMETHORPHAN POLISTIREX (OTC)
DYANAVEL XR, AMPHETAMINE
GABAPENTIN, GABAPENTIN
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX, CHLORPHENIRAMINE POLISTIREX
IBUPROFEN, IBUPROFEN (OTC)
KARBINAL ER, CARBINOXAMINE MALEATE
LEVETIRACETAM, LEVETIRACETAM
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
THEOPHYLLINE, THEOPHYLLINE

**TRUSTEES UNIV PA**

* TRUSTEES OF THE UNIV OF PENNSYLVANIA
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**TWI PHARMS INC**

* TWI PHARMACEUTICALS INC
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** T ****

* TWI PHARMACEUTICALS INC
MEGESTROL ACETATE, MEGESTROL ACETATE
NIFEDIPINE, NIFEDIPINE

**** U ****

**UCB INC**
* UCB INC
BRIVIACT, BRIVARACETAM
KEPPRA XR, LEVETIRACETAM
KEPPRA, LEVETIRACETAM
METADATE CD, METHYLPHENIDATE HYDROCHLORIDE
METADATE ER, METHYLPHENIDATE HYDROCHLORIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
NEUPRO, ROTIGOTINE
TUSSIONEX PENNKINETIC, CHLORPHENIRAMINE POLISTIREX
VIMPAT, LACOSAMIDE
ZAROXOLYN, METOLAZONE

**UCLA BIOMEDICAL**
* UCLA BIOMEDICAL CYCLOTRON
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**UCSF RODIOPHARM**
* UCSF RADIOPHARMACEUTICAL FACILITY
AMMONIA N 13, AMMONIA N-13
CHOLINE C-11, CHOLINE C-11
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**UIHC PET IMAGING**
* UNIV IOWA HOSPS AND CLINICS PET IMAGING CENTER
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**UNICHEM**
* UNICHEM LABORATORIES LTD
BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE, BISOPROLOL FUMARATE
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
MELOXICAM, MELOXICAM
ZALEPLON, ZALEPLON

**UNICHEM LABS LTD**
* UNICHEM LABORATORIES LIMITED
DIVALPROEX SODIUM, DIVALPROEX SODIUM
* UNICHEM LABORATORIES LTD
ALFUZOSIN HYDROCHLORIDE, ALFUZOSIN HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
LAMOTRIGINE, LAMOTRIGINE
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
PIROXICAM, PIROXICAM
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RIZATRIPTAN BENZOATE, RIZATRIPTAN BENZOATE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE

**UNICHEM PHARMS (USA)**
* UNICHEM PHARMACEUTICALS (USA) INC
BISOPROLOL FUMARATE, BISOPROLOL FUMARATE

**UNIMARK REMEDIES LTD**
* UNIMARK REMEDIES LTD
MONTELUKAST SODIUM, MONTELUKAST SODIUM

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** U ****

**UNIQUE PHARM LABS**
* UNIQUE PHARMACEUTICAL LABORATORIES A DIVISION OF J.B. CHEMICALS AND PHARMACEUTICALS LTD
ATENOLOL, ATENOLOL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CETIRIZINE HYDROCHLORIDE HIVES, CETIRIZINE HYDROCHLORIDE (OTC)
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
FLUCONAZOLE, FLUCONAZOLE
GLIPIZIDE, GLIPIZIDE
LITHIUM CARBONATE, LITHIUM CARBONATE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
TINIDAZOLE, TINIDAZOLE

**UNITED BIOMEDCL**
* UNITED BIOMEDICAL INC
TERBUTALINE SULFATE, TERBUTALINE SULFATE

**UNITED GUARDIAN**
* UNITED GUARDIAN INC
RENACIDIN, CITRIC ACID

**UNITED THERAP**
* UNITED THERAPEUTICS CORP
ORENITRAM, TREPROSTINIL DIOLAMINE
REMODULIN, TREPROSTINIL
TYVASO, TREPROSTINIL

**UNIV MICHIGAN**
* UNIV MICHIGAN PET RADIOPHARMACEUTICAL PRODUCTION PROGRAM
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**UNIV NORTH DAKOTA**
* UNIV NORTH DAKOTA
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**UNIV TX MD ANDERSON**
* UNIV TEXAS MD ANDERSON CANCER CENTER
AMMONIA N 13, AMMONIA N-13
CHOLINE C-11, CHOLINE C-11
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**UNIV UTAH CYCLOTRON**
* UNIV UTAH CYCLOTRON RADIOCHEMISTRY LAB
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**UPSHER-SMITH LABS**
* UPSHER-SMITH LABORATORIES LLC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
EXEMESTANE, EXEMESTANE
FLUVOXAMINE MALEATE, FLUVOXAMINE MALEATE
FOSINOPRIL SODIUM, FOSINOPRIL SODIUM
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
KLOR-CON M10, POTASSIUM CHLORIDE
KLOR-CON M15, POTASSIUM CHLORIDE
KLOR-CON M20, POTASSIUM CHLORIDE
KLOR-CON, POTASSIUM CHLORIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
MORPHINE SULFATE, MORPHINE SULFATE
NYSTATIN, NYSTATIN
ORVATEN, MIDODRINE HYDROCHLORIDE
OXANDROLONE, OXANDROLONE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PACERONE, AMIODARONE HYDROCHLORIDE
PENTOXIL, PENTOXIFYLLINE
PREVALITE, CHOLESTYRAMINE
QUDEXY XR, TOPIRAMATE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** U ****

* UPSHER-SMITH LABORATORIES LLC
SORINE, SOTALOL HYDROCHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
VOGELXO, TESTOSTERONE

**US PHARM HOLDINGS**
* US PHARMACEUTICAL HOLDINGS II LLC
CLAFORAN, CEFOTAXIME SODIUM
DEMEROL, MEPERIDINE HYDROCHLORIDE
DRISDOL, ERGOCALCIFEROL
HIPREX, METHENAMINE HIPPURATE
LASIX, FUROSEMIDE
NORPRAMIN, DESIPRAMINE HYDROCHLORIDE

**US PHARMS HOLDINGS I**
* US PHARMACEUTICALS HOLDINGS I LLC
LOPRESSOR HCT, HYDROCHLOROTHIAZIDE
LOPRESSOR, METOPROLOL TARTRATE
LOTENSIN HCT, BENAZEPRIL HYDROCHLORIDE
LOTENSIN, BENAZEPRIL HYDROCHLORIDE
PARLODEL, BROMOCRIPTINE MESYLATE

**US WORLDMEDS**
* US WORLDMEDS LLC
APOKYN, APOMORPHINE HYDROCHLORIDE
REVONTO, DANTROLENE SODIUM

**US WORLDMEDS LLC**
* US WORLDMEDS LLC
CORGARD, NADOLOL
XADAGO, SAFINAMIDE MESYLATE

**USL PHARMA**
* USL PHARMA LLC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
BACLOFEN, BACLOFEN
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
FLUOXYMESTERONE, FLUOXYMESTERONE
JANTOVEN, WARFARIN SODIUM

**USPHARMA**
* USPHARMA LTD
NITRO-DUR, NITROGLYCERIN

**USV NORTH AMERICA**
* USV NORTH AMERICA INC
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
ZOLEDRONIC ACID, ZOLEDRONIC ACID

**** V ****

**VALEANT**
* VALEANT PHARMACEUTICALS INTERNATIONAL
ANCOBON, FLUCYTOSINE
BONTRIL PDM, PHENDIMETRAZINE TARTRATE
D.H.E. 45, DIHYDROERGOTAMINE MESYLATE
MIGRANAL, DIHYDROERGOTAMINE MESYLATE
MYSOLINE, PRIMIDONE

**VALEANT BERMUDA**
* VALEANT INTERNATIONAL BERMUDA
BENZACLIN, BENZOYL PEROXIDE
DERMATOP E EMOLLIENT, PREDNICARBATE
ELIDEL, PIMECROLIMUS
PENLAC, CICLOPIROX
RETIN-A, TRETINOIN
XERESE, ACYCLOVIR
ZOVIRAX, ACYCLOVIR

**VALEANT INTL**
* VALEANT INTERNATIONAL BARBADOS SRL
ATIVAN, LORAZEPAM

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** V **

* VALEANT INTERNATIONAL BARBADOS SRL
CARDIZEM CD, DILTIAZEM HYDROCHLORIDE
CARDIZEM LA, DILTIAZEM HYDROCHLORIDE
CARDIZEM, DILTIAZEM HYDROCHLORIDE
RETIN-A MICRO, TRETINOIN
RETIN-A, TRETINOIN
RETIN-A-MICRO, TRETINOIN
VASERETIC, ENALAPRIL MALEATE
WELLBUTRIN XL, BUPROPION HYDROCHLORIDE
* VALEANT INTERNATIONAL SRL
BENZAMYCIN, BENZOYL PEROXIDE

**VALEANT LUXEMBOURG**
* VALEANT PHARMACEUTICALS LUXEMBOURG SARL
ERTACZO, SERTACONAZOLE NITRATE
TARGRETIN, BEXAROTENE
VISUDYNE, VERTEPORFIN

**VALEANT PHARM INTL**
* VALEANT PHARMACEUTICALS INTERNATIONAL
ANDROID 25, METHYLTESTOSTERONE
EFUDEX, FLUOROURACIL
LIBRIUM, CHLORDIAZEPOXIDE HYDROCHLORIDE
MESTINON, PYRIDOSTIGMINE BROMIDE
TESTRED, METHYLTESTOSTERONE
VIRAZOLE, RIBAVIRIN
ZELAPAR, SELEGILINE HYDROCHLORIDE

**VALEANT PHARMS**
* VALEANT PHARMACEUTICALS NORTH AMERICA
MEPHYTON, PHYTONADIONE
* VALEANT PHARMACEUTICALS NORTH AMERICA LLC
LIBRAX, CHLORDIAZEPOXIDE HYDROCHLORIDE
MESTINON, PYRIDOSTIGMINE BROMIDE
MINITRAN, NITROGLYCERIN
PENTOXIFYLLINE, PENTOXIFYLLINE

**VALEANT PHARMS INC**
* VALEANT PHARMACEUTICALS INTERNATIONAL INC
GRIS-PEG, GRISEOFULVIN, ULTRAMICROSIZE

**VALEANT PHARMS INTL**
* VALEANT PHARMACEUTICALS INTERNATIONAL
APRISO, MESALAMINE
COLAZAL, BALSALAZIDE DISODIUM
GIAZO, BALSALAZIDE DISODIUM
UCERIS, BUDESONIDE

**VALEANT PHARMS LLC**
* VALEANT PHARMACEUTICALS NORTH AMERICA LLC
MACUGEN, PEGAPTANIB SODIUM
MESTINON, PYRIDOSTIGMINE BROMIDE
TASMAR, TOLCAPONE
TIMOPTIC-XE, TIMOLOL MALEATE

**VALEANT PHARMS NORTH**
* VALEANT PHARMACEUTICALS NORTH AMERICA LLC
APLENZIN, BUPROPION HYDROBROMIDE
CARAC, FLUOROURACIL
DERMATOP, PREDNICARBATE
DIASTAT ACUDIAL, DIAZEPAM
DIASTAT, DIAZEPAM
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
FENOFIBRATE, FENOFIBRATE
IPRIVASK, DESIRUDIN RECOMBINANT
ISORDIL, ISOSORBIDE DINITRATE
KLARON, SULFACETAMIDE SODIUM
MINITRAN, NITROGLYCERIN
NIFEDIPINE, NIFEDIPINE
NORITATE, METRONIDAZOLE
PEPCID, FAMOTIDINE
RENOVA, TRETINOIN

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** V **

* VALEANT PHARMACEUTICALS NORTH AMERICA LLC
RETIN-A, TRETINOIN
SECONAL SODIUM, SECOBARBITAL SODIUM
TIAZAC, DILTIAZEM HYDROCHLORIDE
VASOTEC, ENALAPRIL MALEATE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
XENAZINE, TETRABENAZINE

**VALIDUS PHARMS**

* VALIDUS PHARMACEUTICALS LLC
BUMEX, BUMETANIDE
EQUETRO, CARBAMAZEPINE
NIFEDIPINE, NIFEDIPINE
ROCALTROL, CALCITRIOL

**VALIDUS PHARMS INC**

* VALIDUS PHARMACEUTICALS INC
MARPLAN, ISOCARBOXAZID

**VANDA PHARMS INC**

* VANDA PHARMACEUTICALS INC
FANAPT, ILOPERIDONE
HETLIOZ, TASIMELTEON

**VELOXIS PHARMS INC**

* VELOXIS PHARMACEUTICALS INC
ENVARSUS XR, TACROLIMUS

**VERNALIS R AND D LTD**

* VERNALIS R AND D LTD
MOXATAG, AMOXICILLIN
TUZISTRA XR, CHLORPHENIRAMINE POLISTIREX

**VEROSCIENCE**

* VEROSCIENCE LLC
CYCLOSET, BROMOCRIPTINE MESYLATE

**VERTEX PHARMS**

* VERTEX PHARMACEUTICALS INC
KALYDECO, IVACAFTOR

**VERTEX PHARMS INC**

* VERTEX PHARMACEUTICALS INC
KALYDECO, IVACAFTOR
ORKAMBI, IVACAFTOR

**VERTICAL PHARMS LLC**

* VERTICAL PHARMACEUTICALS LLC
DIVIGEL, ESTRADIOL

**VIB**

* VALEANT INTERNATIONAL BERMUDA
ZOVIRAX, ACYCLOVIR

**VICURON**

* VICURON PHARMACEUTICALS INC
ERAXIS, ANIDULAFUNGIN

**VIFOR FRESENIUS**

* VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE
VELPHORO, SUCROFERRIC OXYHYDROXIDE

**VIIV HLTHCARE**

* VIIV HEALTHCARE CO
COMBIVIR, LAMIVUDINE
EPIVIR, LAMIVUDINE
EPZICOM, ABACAVIR SULFATE
JULUCA, DOLUTEGRAVIR SODIUM
LEXIVA, FOSAMPRENAVIR CALCIUM
RESCRIPTOR, DELAVIRDINE MESYLATE
RETROVIR, ZIDOVUDINE
SELZENTRY, MARAVIROC
TIVICAY, DOLUTEGRAVIR SODIUM
TRIUMEQ, ABACAVIR SULFATE
TRIZIVIR, ABACAVIR SULFATE
ZIAGEN, ABACAVIR SULFATE

**VINTAGE**

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** V ****

* VINTAGE PHARMACEUTICALS LLC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETIC ACID, ACETIC ACID, GLACIAL
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALPRAZOLAM, ALPRAZOLAM
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
BENZTROPINE MESYLATE, BENZTROPINE MESYLATE
CETIRIZINE HYDROCHLORIDE, CETIRIZINE HYDROCHLORIDE
FOLIC ACID, FOLIC ACID
HYDROCORTISONE AND ACETIC ACID, ACETIC ACID, GLACIAL
HYDROCORTISONE, HYDROCORTISONE
LIDOCAINE HYDROCHLORIDE VISCOUS, LIDOCAINE HYDROCHLORIDE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
NYSTATIN, NYSTATIN
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISOLONE, PREDNISOLONE
PROMETH HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE, CODEINE
PROMETHAZINE DM, DEXTROMETHORPHAN HYDROBROMIDE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE WITH CODEINE, CODEINE PHOSPHATE
RISPERIDONE, RISPERIDONE
SPIRONOLACTONE, SPIRONOLACTONE
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VALPROIC ACID, VALPROIC ACID
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

**VINTAGE PHARMS**

* VINTAGE PHARMACEUTICALS
ALPRAZOLAM, ALPRAZOLAM
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN
CARBINOXAMINE MALEATE, CARBINOXAMINE MALEATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CYCLAFEM 0.5/35, ETHINYL ESTRADIOL
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE
GILDAGIA, ETHINYL ESTRADIOL
GILDESS 24 FE, ETHINYL ESTRADIOL
GLYCOPYRROLATE, GLYCOPYRROLATE
GRISEOFULVIN, GRISEOFULVIN, MICROSIZE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
KIMIDESS, DESOGESTREL
LEVETIRACETAM, LEVETIRACETAM
METHSCOPOLAMINE BROMIDE, METHSCOPOLAMINE BROMIDE
METHYLPHENIDATE HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE
OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE

* VINTAGE PHARMACEUTICALS INC
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ALLOPURINOL, ALLOPURINOL
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
BACLOFEN, BACLOFEN
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE, ACETAMINOPHEN
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE, ACETAMINOPHEN
CARISOPRODOL, CARISOPRODOL
DEXAMETHASONE, DEXAMETHASONE
DIAZEPAM, DIAZEPAM
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
HYDROCODONE BITARTRATE AND IBUPROFEN, HYDROCODONE BITARTRATE
HYDROCORTISONE, HYDROCORTISONE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
IBUPROFEN, IBUPROFEN
IBUPROFEN, IBUPROFEN (OTC)
ISOSORBIDE MONONITRATE, ISOSORBIDE MONONITRATE
LACTULOSE, LACTULOSE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** V **

* VINTAGE PHARMACEUTICALS INC
LEVETIRACETAM, LEVETIRACETAM
LORAZEPAM, LORAZEPAM
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
METHOCARBAMOL, METHOCARBAMOL
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
NYSTATIN, NYSTATIN
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PERPHENAZINE, PERPHENAZINE
PREDNISONE, PREDNISONE
PRIMIDONE, PRIMIDONE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
SOTALOL HYDROCHLORIDE, SOTALOL HYDROCHLORIDE
SULFASALAZINE, SULFASALAZINE
TORSEMIDE, TORSEMIDE

**VINTAGE PHARMS LLC**

* VINTAGE PHARMACEUTICALS LLC
CYCLAFEM 1/35, ETHINYL ESTRADIOL
CYCLAFEM 7/7/7, ETHINYL ESTRADIOL
DUTASTERIDE, DUTASTERIDE
EMOQUETTE, DESOGESTREL
FELODIPINE, FELODIPINE
GILDESS 1.5/30, ETHINYL ESTRADIOL
GILDESS 1/20, ETHINYL ESTRADIOL
GILDESS FE 1.5/30, ETHINYL ESTRADIOL
GILDESS FE 1/20, ETHINYL ESTRADIOL
LETROZOLE, LETROZOLE
MEFENAMIC ACID, MEFENAMIC ACID
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MORPHINE SULFATE, MORPHINE SULFATE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
MYZILRA, ETHINYL ESTRADIOL
ORSYTHIA, ETHINYL ESTRADIOL
PERCOCET, ACETAMINOPHEN
PREVIFEM, ETHINYL ESTRADIOL
TRI-PREVIFEM, ETHINYL ESTRADIOL
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE

**VIRTUS PHARM**

* VIRTUS PHARMACEUTICAL INC
ACARBOSE, ACARBOSE

**VIRTUS PHARMS**

* VIRTUS PHARMACEUTICALS LLC
DAPSONE, DAPSONE
LEVETIRACETAM, LEVETIRACETAM
PROMETRIUM, PROGESTERONE
TRANEXAMIC ACID, TRANEXAMIC ACID

**VISTA PHARMS**

* VISTA PHARMACEUTICALS INC
SULFAMETHOXAZOLE AND TRIMETHOPRIM, SULFAMETHOXAZOLE

**VISTAPHARM**

* VISTAPHARM INC
ALBUTEROL SULFATE, ALBUTEROL SULFATE
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
LACTULOSE, LACTULOSE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MORPHINE SULFATE, MORPHINE SULFATE
NYSTATIN, NYSTATIN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PHENYTOIN, PHENYTOIN
PREDNISOLONE, PREDNISOLONE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** V ****

* VISTAPHARM INC
VALPROIC ACID, VALPROIC ACID

**VITRUVIAS THERAP**

* VITRUVIAS THERAPEUTICS LLC
LIDOCAINE, LIDOCAINE

**VIVA HLTHCARE**

* VIVA HEALTHCARE FZ LLC
GLIMEPIRIDE, GLIMEPIRIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEFENAMIC ACID, MEFENAMIC ACID
SIMVASTATIN, SIMVASTATIN
TRANEXAMIC ACID, TRANEXAMIC ACID

**VIVIMED GLOBAL**

* VIVIMED GLOBAL GENERICS PTE LTD
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
METRONIDAZOLE, METRONIDAZOLE

**VIVUS**

* VIVUS INC
QSYMIA, PHENTERMINE HYDROCHLORIDE

**VPNA**

* VALEANT PHARMACEUTICALS NORTH AMERICA
DICLOFENAC SODIUM, DICLOFENAC SODIUM

**VYERA PHARMS LLC**

* VYERA PHARMACEUTICALS LLC
DARAPRIM, PYRIMETHAMINE

**** W ****

**WA UNIV SCH MED**

* WASHINGTON UNIV SCHOOL MEDICINE
AMMONIA N 13, AMMONIA N-13
CHOLINE C-11, CHOLINE C-11

**WARNER CHILCOTT LLC**

* WARNER CHILCOTT CO LLC
CHOLEDYL SA, OXTRIPHYLLINE

**WATSON LABS**

* WATSON LABORATORIES
FOLIC ACID, FOLIC ACID
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE

* WATSON LABORATORIES INC
ACARBOSE, ACARBOSE
AFEDITAB CR, NIFEDIPINE
ALBUTEROL SULFATE, ALBUTEROL SULFATE
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALLOPURINOL, ALLOPURINOL
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMOXAPINE, AMOXAPINE
ATENOLOL AND CHLORTHALIDONE, ATENOLOL
CAPTOPRIL, CAPTOPRIL
CARISOPRODOL, CARISOPRODOL
CHLORZOXAZONE, CHLORZOXAZONE
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
CLONAZEPAM, CLONAZEPAM
COL-PROBENECID, COLCHICINE
DESOGESTREL AND ETHINYL ESTRADIOL, DESOGESTREL
DICYCLOMINE HYDROCHLORIDE, DICYCLOMINE HYDROCHLORIDE
DROSPIRENONE AND ETHINYL ESTRADIOL, DROSPIRENONE
ESTAZOLAM, ESTAZOLAM
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GLIPIZIDE, GLIPIZIDE
GUANFACINE HYDROCHLORIDE, GUANFACINE HYDROCHLORIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** W ****

* WATSON LABORATORIES INC
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LAMOTRIGINE, LAMOTRIGINE
LEVONORGESTREL AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
LISINOPRIL, LISINOPRIL
LORAZEPAM, LORAZEPAM
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
LOXAPINE SUCCINATE, LOXAPINE SUCCINATE
MEPROBAMATE, MEPROBAMATE
METHOCARBAMOL, METHOCARBAMOL
METHYLDOPA, METHYLDOPA
METHYLPREDNISOLONE, METHYLPREDNISOLONE
METOPROLOL TARTRATE, METOPROLOL TARTRATE
METRONIDAZOLE, METRONIDAZOLE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MINOXIDIL, MINOXIDIL
MIRTAZAPINE, MIRTAZAPINE
NABUMETONE, NABUMETONE
NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE
NATEGLINIDE, NATEGLINIDE
NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
NICOTINE POLACRILEX, NICOTINE POLACRILEX (OTC)
NIZATIDINE, NIZATIDINE
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
OGESTREL 0.5/50-28, ETHINYL ESTRADIOL
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXYCODONE AND ACETAMINOPHEN, ACETAMINOPHEN
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PREDNISOLONE, PREDNISOLONE
PREDNISONE, PREDNISONE
PRIMIDONE, PRIMIDONE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
QUASENSE, ETHINYL ESTRADIOL
QUINIDINE SULFATE, QUINIDINE SULFATE
RAMIPRIL, RAMIPRIL
RIVASTIGMINE TARTRATE, RIVASTIGMINE TARTRATE
SULFASALAZINE, SULFASALAZINE
SULINDAC, SULINDAC
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TELMISARTAN, TELMISARTAN
TETRACYCLINE HYDROCHLORIDE, TETRACYCLINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE
TRANDOLAPRIL, TRANDOLAPRIL
TRIAMTERENE AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TRIHEXYPHENIDYL HYDROCHLORIDE, TRIHEXYPHENIDYL HYDROCHLORIDE
TRIMETHOPRIM, TRIMETHOPRIM
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VERAPAMIL HYDROCHLORIDE, VERAPAMIL HYDROCHLORIDE
ZOVIA 1/50E-28, ETHINYL ESTRADIOL
* WATSON LABS INC
LISINOPRIL AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

**WATSON LABS INC**

* WATSON LABORATORIES INC
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE, AMLODIPINE BESYLATE
AMMONIUM LACTATE, AMMONIUM LACTATE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CELECOXIB, CELECOXIB
CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN HYDROCHLORIDE
DICLOFENAC SODIUM, DICLOFENAC SODIUM
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
DORZOLAMIDE HYDROCHLORIDE, DORZOLAMIDE HYDROCHLORIDE
DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM, DROSPIRENONE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

* WATSON LABORATORIES INC
EZETIMIBE AND SIMVASTATIN, EZETIMIBE
EZETIMIBE, EZETIMIBE
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
METRONIDAZOLE, METRONIDAZOLE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL (FOR WOMEN), MINOXIDIL (OTC)
MODAFINIL, MODAFINIL
MOXIFLOXACIN HYDROCHLORIDE, MOXIFLOXACIN HYDROCHLORIDE
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS), NITROFURANTOIN
PERPHENAZINE, PERPHENAZINE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROPAFENONE HYDROCHLORIDE, PROPAFENONE HYDROCHLORIDE
PROPOFOL, PROPOFOL
RALOXIFENE HYDROCHLORIDE, RALOXIFENE HYDROCHLORIDE
RASAGILINE MESYLATE, RASAGILINE MESYLATE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM
SILDENAFIL CITRATE, SILDENAFIL CITRATE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VALSARTAN, VALSARTAN

**WATSON LABS TEVA**

* WATSON LABORATORIES INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
AFEDITAB CR, NIFEDIPINE
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE, ALBUTEROL SULFATE
BICALUTAMIDE, BICALUTAMIDE
EZETIMIBE AND ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM
GLIPIZIDE, GLIPIZIDE
IBANDRONATE SODIUM, IBANDRONATE SODIUM
ISRADIPINE, ISRADIPINE
LEVOFLOXACIN, LEVOFLOXACIN
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
NORETHINDRONE AND ETHINYL ESTRADIOL (10/11), ETHINYL ESTRADIOL
NORETHINDRONE AND ETHINYL ESTRADIOL, ETHINYL ESTRADIOL
PROBENECID, PROBENECID
SIMVASTATIN, SIMVASTATIN
TEMOZOLOMIDE, TEMOZOLOMIDE
VALSARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE

**WATSON PHARMS INC**

* WATSON PHARMACEUTICALS INC
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
TESTOSTERONE ENANTHATE, TESTOSTERONE ENANTHATE

**WATSON PHARMS TEVA**

* WATSON PHARMACEUTICALS INC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
RIFAMPIN, RIFAMPIN

**WELLSTAT THERAP**

* WELLSTAT THERAPEUTICS CORP
VISTOGARD, URIDINE TRIACETATE
XURIDEN, URIDINE TRIACETATE

**WES PHARMA INC**

* WES PHARMA INC
HYDROCODONE BITARTRATE AND ACETAMINOPHEN, ACETAMINOPHEN
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE

**WEST WARD PHARM CORP**

* WEST WARD PHARMACEUTICAL CORP
PHENYLEPHRINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE
ROCURONIUM BROMIDE, ROCURONIUM BROMIDE

**WEST-WARD PHARM CORP**

* WEST-WARD PHARMACEUTICAL CORP
CEFOTETAN, CEFOTETAN DISODIUM

**WEST-WARD PHARMS INT**

* WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD
ACARBOSE, ACARBOSE
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
ADENOSINE, ADENOSINE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** W ****

* WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD
ALENDRONATE SODIUM, ALENDRONATE SODIUM
ALLOPURINOL SODIUM, ALLOPURINOL SODIUM
ALOSETRON HYDROCHLORIDE, ALOSETRON HYDROCHLORIDE
ALPRAZOLAM, ALPRAZOLAM
ALPROSTADIL, ALPROSTADIL
AMIKACIN SULFATE, AMIKACIN SULFATE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AMPICILLIN AND SULBACTAM, AMPICILLIN SODIUM
AMRINONE LACTATE, INAMRINONE LACTATE
ANASTROZOLE, ANASTROZOLE
ATIVAN, LORAZEPAM
ATRACURIUM BESYLATE PRESERVATIVE FREE, ATRACURIUM BESYLATE
ATRACURIUM BESYLATE, ATRACURIUM BESYLATE
AZATHIOPRINE SODIUM, AZATHIOPRINE SODIUM
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BALSALAZIDE DISODIUM, BALSALAZIDE DISODIUM
BLEOMYCIN SULFATE, BLEOMYCIN SULFATE
BUMETANIDE, BUMETANIDE
BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUPRENORPHINE HYDROCHLORIDE, BUPRENORPHINE HYDROCHLORIDE
BUTORPHANOL TARTRATE PRESERVATIVE FREE, BUTORPHANOL TARTRATE
BUTORPHANOL TARTRATE, BUTORPHANOL TARTRATE
CAFCIT, CAFFEINE CITRATE
CALCITRIOL, CALCITRIOL
CALCIUM ACETATE, CALCIUM ACETATE
CAPECITABINE, CAPECITABINE
CARBOPLATIN, CARBOPLATIN
CEFOXITIN, CEFOXITIN SODIUM
CERUBIDINE, DAUNORUBICIN HYDROCHLORIDE
CEVIMELINE HYDROCHLORIDE, CEVIMELINE HYDROCHLORIDE
CHLOROPROCAINE HYDROCHLORIDE, CHLOROPROCAINE HYDROCHLORIDE
CHLORPROMAZINE HYDROCHLORIDE, CHLORPROMAZINE HYDROCHLORIDE
CILOSTAZOL, CILOSTAZOL
CISPLATIN, CISPLATIN
CITALOPRAM HYDROBROMIDE, CITALOPRAM HYDROBROMIDE
CLADRIBINE, CLADRIBINE
CLARITHROMYCIN, CLARITHROMYCIN
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
CLOTRIMAZOLE, CLOTRIMAZOLE
CODEINE SULFATE, CODEINE SULFATE
CYANOCOBALAMIN, CYANOCOBALAMIN
CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE
CYCLOSPORINE, CYCLOSPORINE
CYTARABINE, CYTARABINE
DACARBAZINE, DACARBAZINE
DAUNORUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE
DEFEROXAMINE MESYLATE, DEFEROXAMINE MESYLATE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DEXAMETHASONE INTENSOL, DEXAMETHASONE
DEXAMETHASONE SODIUM PHOSPHATE, DEXAMETHASONE SODIUM PHOSPHATE
DEXAMETHASONE, DEXAMETHASONE
DEXMEDETOMIDINE HYDROCHLORIDE, DEXMEDETOMIDINE HYDROCHLORIDE
DEXRAZOXANE HYDROCHLORIDE, DEXRAZOXANE HYDROCHLORIDE
DIAZEPAM INTENSOL, DIAZEPAM
DIAZEPAM, DIAZEPAM
DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE), DICYCLOMINE HYDROCHLORIDE
DIGOXIN, DIGOXIN
DIHYDROERGOTAMINE MESYLATE, DIHYDROERGOTAMINE MESYLATE
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIPHENHYDRAMINE HYDROCHLORIDE, DIPHENHYDRAMINE HYDROCHLORIDE
DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE, ATROPINE SULFATE
DIPYRIDAMOLE, DIPYRIDAMOLE
DISULFIRAM, DISULFIRAM
DOBUTAMINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

* WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD
DOLOPHINE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
DOPRAM, DOXAPRAM HYDROCHLORIDE
DOXERCALCIFEROL, DOXERCALCIFEROL
DOXORUBICIN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
DURAMORPH PF, MORPHINE SULFATE
DUTASTERIDE, DUTASTERIDE
EPIRUBICIN HYDROCHLORIDE, EPIRUBICIN HYDROCHLORIDE
ESMOLOL HYDROCHLORIDE, ESMOLOL HYDROCHLORIDE
ESZOPICLONE, ESZOPICLONE
ETHACRYNIC ACID, ETHACRYNIC ACID
ETOMIDATE, ETOMIDATE
ETOPOSIDE, ETOPOSIDE
EXEMESTANE, EXEMESTANE
FAMCICLOVIR, FAMCICLOVIR
FAMOTIDINE PRESERVATIVE FREE, FAMOTIDINE
FAMOTIDINE, FAMOTIDINE
FENOLDOPAM MESYLATE, FENOLDOPAM MESYLATE
FENTANYL CITRATE PRESERVATIVE FREE, FENTANYL CITRATE
FLECAINIDE ACETATE, FLECAINIDE ACETATE
FLOXURIDINE, FLOXURIDINE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, FLUCONAZOLE
FLUCONAZOLE IN SODIUM CHLORIDE 0.9%, FLUCONAZOLE
FLUCONAZOLE, FLUCONAZOLE
FLUCYTOSINE, FLUCYTOSINE
FLUMAZENIL, FLUMAZENIL
FLUPHENAZINE DECANOATE, FLUPHENAZINE DECANOATE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE (OTC)
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FUROSEMIDE, FUROSEMIDE
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
HALOPERIDOL DECANOATE, HALOPERIDOL DECANOATE
HALOPERIDOL, HALOPERIDOL LACTATE
HEPARIN SODIUM, HEPARIN SODIUM
HYDROMORPHONE HYDROCHLORIDE, HYDROMORPHONE HYDROCHLORIDE
IDARUBICIN HYDROCHLORIDE, IDARUBICIN HYDROCHLORIDE
IFOSFAMIDE, IFOSFAMIDE
IMIPRAMINE PAMOATE, IMIPRAMINE PAMOATE
INDOMETHACIN SODIUM, INDOMETHACIN SODIUM
INFUMORPH, MORPHINE SULFATE
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE
IRBESARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
IRBESARTAN, IRBESARTAN
IRINOTECAN HYDROCHLORIDE, IRINOTECAN HYDROCHLORIDE
KETAMINE HYDROCHLORIDE, KETAMINE HYDROCHLORIDE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LACTULOSE, LACTULOSE
LETROZOLE, LETROZOLE
LEUCOVORIN CALCIUM PRESERVATIVE FREE, LEUCOVORIN CALCIUM
LEUCOVORIN CALCIUM, LEUCOVORIN CALCIUM
LEVOCARNITINE, LEVOCARNITINE
LEVOLEUCOVORIN CALCIUM, LEVOLEUCOVORIN CALCIUM
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LIDOCAINE VISCOUS, LIDOCAINE HYDROCHLORIDE
LINEZOLID, LINEZOLID
LITHIUM CARBONATE, LITHIUM CARBONATE
LITHIUM CITRATE, LITHIUM CITRATE
LORAZEPAM INTENSOL, LORAZEPAM
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEFLOQUINE HYDROCHLORIDE, MEFLOQUINE HYDROCHLORIDE
MEGESTROL ACETATE, MEGESTROL ACETATE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** W **

* WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD
MELPHALAN HYDROCHLORIDE, MELPHALAN HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE, MEPERIDINE HYDROCHLORIDE
MEPERIDINE HYDROCHLORIDE, MEPERIDINE HYDROCHLORIDE
MERCAPTOPURINE, MERCAPTOPURINE
MESNA, MESNA
METHADONE HYDROCHLORIDE INTENSOL, METHADONE HYDROCHLORIDE
METHADONE HYDROCHLORIDE, METHADONE HYDROCHLORIDE
METHAMPHETAMINE HYDROCHLORIDE, METHAMPHETAMINE HYDROCHLORIDE
METHOTREXATE SODIUM PRESERVATIVE FREE, METHOTREXATE SODIUM
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METOPROLOL TARTRATE, METOPROLOL TARTRATE
MIDAZOLAM HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE
MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER, MILRINONE LACTATE
MILRINONE LACTATE, MILRINONE LACTATE
MITOMYCIN, MITOMYCIN
MITOXANTRONE HYDROCHLORIDE, MITOXANTRONE HYDROCHLORIDE
MONTELUKAST SODIUM, MONTELUKAST SODIUM
MORPHINE SULFATE, MORPHINE SULFATE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL
NALOXONE, NALOXONE HYDROCHLORIDE
NAPROXEN, NAPROXEN
NARATRIPTAN, NARATRIPTAN HYDROCHLORIDE
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
NOREPINEPHRINE BITARTRATE, NOREPINEPHRINE BITARTRATE
OCTREOTIDE ACETATE (PRESERVATIVE FREE), OCTREOTIDE ACETATE
OCTREOTIDE ACETATE, OCTREOTIDE ACETATE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
ORPHENADRINE CITRATE, ORPHENADRINE CITRATE
OXCARBAZEPINE, OXCARBAZEPINE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
OXYMORPHONE HYDROCHLORIDE, OXYMORPHONE HYDROCHLORIDE
OXYTOCIN, OXYTOCIN
PACLITAXEL, PACLITAXEL
PAMIDRONATE DISODIUM, PAMIDRONATE DISODIUM
PENTOSTATIN, PENTOSTATIN
PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE
PHENOXYBENZAMINE HYDROCHLORIDE, PHENOXYBENZAMINE HYDROCHLORIDE
PHENTOLAMINE MESYLATE, PHENTOLAMINE MESYLATE
PHENYTOIN SODIUM, PHENYTOIN SODIUM
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
PREDNISONE INTENSOL, PREDNISONE
PREDNISONE, PREDNISONE
PROCHLORPERAZINE EDISYLATE, PROCHLORPERAZINE EDISYLATE
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
PROPANTHELINE BROMIDE, PROPANTHELINE BROMIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PROTRIPTYLINE HYDROCHLORIDE, PROTRIPTYLINE HYDROCHLORIDE
QUETIAPINE FUMARATE, QUETIAPINE FUMARATE
RAMIPRIL, RAMIPRIL
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RIFAMPIN, RIFAMPIN
RISPERIDONE, RISPERIDONE
RITONAVIR, RITONAVIR
ROBAXIN, METHOCARBAMOL
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ROXICET, ACETAMINOPHEN
RUFINAMIDE, RUFINAMIDE
SODIUM CHLORIDE 0.9% , SODIUM CHLORIDE
SODIUM CHLORIDE 0.9%, SODIUM CHLORIDE
SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE, SODIUM FERRIC GLUCONATE COMPLEX
SODIUM OXYBATE, SODIUM OXYBATE
SODIUM POLYSTYRENE SULFONATE, SODIUM POLYSTYRENE SULFONATE
STERILE WATER FOR INJECTION, STERILE WATER FOR INJECTION

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** W ****

* WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD
SUFENTANIL CITRATE, SUFENTANIL CITRATE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TESTOSTERONE CYPIONATE, TESTOSTERONE CYPIONATE
THIOTEPA, THIOTEPA
TINIDAZOLE, TINIDAZOLE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
TORSEMIDE, TORSEMIDE
TRIAZOLAM, TRIAZOLAM
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VECURONIUM BROMIDE, VECURONIUM BROMIDE
VINBLASTINE SULFATE, VINBLASTINE SULFATE
VINORELBINE TARTRATE, VINORELBINE TARTRATE
ZALEPLON, ZALEPLON
ZIDOVUDINE, ZIDOVUDINE

**WI MEDCL CYCLOTRON**

* WISCONSIN MEDICAL CYCLOTRON LLC
AMMONIA N 13, AMMONIA N-13
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**WILSHIRE PHARMS INC**

* WILSHIRE PHARMACEUTICALS INC
CARISOPRODOL, CARISOPRODOL
PERPHENAZINE, PERPHENAZINE
TIAGABINE HYDROCHLORIDE, TIAGABINE HYDROCHLORIDE

**WINDLAS HLTHCARE**

* WINDLAS HEALTHCARE PVT LTD
AMILORIDE HYDROCHLORIDE, AMILORIDE HYDROCHLORIDE

**WOCKHARDT**

* WOCKHARDT EU OPERATIONS (SWISS) AG
BROMFED-DM, BROMPHENIRAMINE MALEATE
CLEMASTINE FUMARATE, CLEMASTINE FUMARATE
CLINDAMYCIN PHOSPHATE, CLINDAMYCIN PHOSPHATE
LINDANE, LINDANE
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE

* WOCKHARDT LTD
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
AZITHROMYCIN, AZITHROMYCIN
BETAXOLOL HYDROCHLORIDE, BETAXOLOL HYDROCHLORIDE
BETHANECHOL CHLORIDE, BETHANECHOL CHLORIDE
CEFOTAXIME SODIUM, CEFOTAXIME SODIUM
CEFOTAXIME, CEFOTAXIME SODIUM
CEFPROZIL, CEFPROZIL
CEFTAZIDIME, CEFTAZIDIME
CEFTRIAXONE, CEFTRIAXONE SODIUM
CEFUROXIME AXETIL, CEFUROXIME AXETIL
CETIRIZINE HYDROCHLORIDE ALLERGY, CETIRIZINE HYDROCHLORIDE (OTC)
CLARITHROMYCIN, CLARITHROMYCIN
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
FAMOTIDINE, FAMOTIDINE (OTC)
FOSPHENYTOIN SODIUM, FOSPHENYTOIN SODIUM
FUROSEMIDE, FUROSEMIDE
KETOROLAC TROMETHAMINE, KETOROLAC TROMETHAMINE
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
LISINOPRIL, LISINOPRIL
METOPROLOL SUCCINATE, METOPROLOL SUCCINATE
NIACIN, NIACIN
NICARDIPINE HYDROCHLORIDE, NICARDIPINE HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE, ONDANSETRON HYDROCHLORIDE
ONDANSETRON HYDROCHLORIDE, ONDANSETRON HYDROCHLORIDE
PANTOPRAZOLE SODIUM, PANTOPRAZOLE SODIUM
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE (OTC)
RISPERIDONE, RISPERIDONE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** W ****

* WOCKHARDT LTD
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SUMATRIPTAN SUCCINATE, SUMATRIPTAN SUCCINATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TIMOLOL MALEATE, TIMOLOL MALEATE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE
ZONISAMIDE, ZONISAMIDE

**WOCKHARDT BIO AG**

* WOCKHARDT BIO AG
ACETAMINOPHEN AND CODEINE PHOSPHATE, ACETAMINOPHEN
ACETIC ACID, ACETIC ACID, GLACIAL
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMOXICILLIN AND CLAVULANATE POTASSIUM, AMOXICILLIN
AMOXICILLIN, AMOXICILLIN
CARBAMAZEPINE, CARBAMAZEPINE
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
CIMETIDINE HYDROCHLORIDE, CIMETIDINE HYDROCHLORIDE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CROMOLYN SODIUM, CROMOLYN SODIUM
CYCLOSPORINE, CYCLOSPORINE
DEXAMETHASONE, DEXAMETHASONE
DEXCHLORPHENIRAMINE MALEATE, DEXCHLORPHENIRAMINE MALEATE
DOXEPIN HYDROCHLORIDE, DOXEPIN HYDROCHLORIDE
ERYTHROMYCIN, ERYTHROMYCIN
FLUOXETINE HYDROCHLORIDE, FLUOXETINE HYDROCHLORIDE
FLUTICASONE PROPIONATE, FLUTICASONE PROPIONATE
FUROSEMIDE, FUROSEMIDE
GENERLAC, LACTULOSE
HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE, HOMATROPINE METHYLBROMIDE
HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE
LACTULOSE, LACTULOSE
LEVETIRACETAM, LEVETIRACETAM
LIDOCAINE HYDROCHLORIDE, LIDOCAINE HYDROCHLORIDE
LINDANE, LINDANE
LITHIUM CITRATE, LITHIUM CITRATE
LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE (OTC)
LORATADINE, LORATADINE (OTC)
MEGESTROL ACETATE, MEGESTROL ACETATE
METOCLOPRAMIDE HYDROCHLORIDE, METOCLOPRAMIDE HYDROCHLORIDE
MINOXIDIL (FOR MEN), MINOXIDIL (OTC)
MINOXIDIL EXTRA STRENGTH (FOR MEN), MINOXIDIL (OTC)
NYSTATIN, NYSTATIN
OXACILLIN SODIUM, OXACILLIN SODIUM
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
OXYCODONE HYDROCHLORIDE, OXYCODONE HYDROCHLORIDE
PIPERACILLIN AND TAZOBACTAM, PIPERACILLIN SODIUM
PREDNISOLONE SODIUM PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE
PREDNISOLONE, PREDNISOLONE
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE, CODEINE PHOSPHATE
PROMETHAZINE PLAIN, PROMETHAZINE HYDROCHLORIDE
PROMETHAZINE W/ DEXTROMETHORPHAN, DEXTROMETHORPHAN HYDROBROMIDE
SELENIUM SULFIDE, SELENIUM SULFIDE
TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE
VALPROIC ACID, VALPROIC ACID

**WOCKHARDT EU OPERATN**

* WOCKHARDT EU OPERATIONS SWISS AG
PHENYTOIN, PHENYTOIN

**WOCKHARDT LTD**

* WOCKHARDT LTD
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
CAPTOPRIL, CAPTOPRIL
CARBIDOPA, LEVODOPA AND ENTACAPONE, CARBIDOPA

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** W ****

* WOCKHARDT LTD
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
ENALAPRIL MALEATE, ENALAPRIL MALEATE
ENTACAPONE, ENTACAPONE
FAMOTIDINE, FAMOTIDINE
FEXOFENADINE HYDROCHLORIDE ALLERGY, FEXOFENADINE HYDROCHLORIDE (OTC)
FEXOFENADINE HYDROCHLORIDE HIVES, FEXOFENADINE HYDROCHLORIDE (OTC)
LAMOTRIGINE, LAMOTRIGINE
LANSOPRAZOLE, LANSOPRAZOLE (OTC)
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE

**WOCKHARDT USA**
* WOCKHARDT USA INC
GRANISETRON HYDROCHLORIDE, GRANISETRON HYDROCHLORIDE
* WOCKHARDT USA LLC
LANSOPRAZOLE, LANSOPRAZOLE

**WRASER PHARMS**
* WRASER PHARMACEUTICALS LLC
CETRAXAL, CIPROFLOXACIN HYDROCHLORIDE

**WRASER PHARMS LLC**
* WRASER PHARMACEUTICALS LLC
TREZIX, ACETAMINOPHEN

**WUSM CYCLOTRON**
* WASHINGTON UNIV SCH MEDICINE CYCLOTRON FACILITY
FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18

**WYETH PHARMS INC**
* WYETH PHARMACEUTICALS INC
EFFEXOR XR, VENLAFAXINE HYDROCHLORIDE
PHOSPHOLINE IODIDE, ECHOTHIOPHATE IODIDE
PREMARIN, ESTROGENS, CONJUGATED
PREMPHASE 14/14, ESTROGENS, CONJUGATED
PREMPRO, ESTROGENS, CONJUGATED
PRISTIQ, DESVENLAFAXINE SUCCINATE
PROTONIX IV, PANTOPRAZOLE SODIUM
PROTONIX, PANTOPRAZOLE SODIUM
TRECATOR, ETHIONAMIDE
ZOSYN IN PLASTIC CONTAINER, PIPERACILLIN SODIUM
ZOSYN, PIPERACILLIN SODIUM

**WYETH PHARMS PFIZER**
* WYETH PHARMACEUTICALS INC WHOLLY OWNED SUB PFIZER INC
DUAVEE, BAZEDOXIFENE ACETATE

**** X ****

**X GEN PHARMS**
* X GEN PHARMACEUTICALS INC
ACETAZOLAMIDE SODIUM, ACETAZOLAMIDE SODIUM
AMPHOTERICIN B, AMPHOTERICIN B
BACIIM, BACITRACIN
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
LEVETIRACETAM, LEVETIRACETAM
LIOTHYRONINE SODIUM, LIOTHYRONINE SODIUM
NEOMYCIN AND POLYMYXIN B SULFATE, NEOMYCIN SULFATE
NEOMYCIN SULFATE, NEOMYCIN SULFATE
NYSTATIN, NYSTATIN
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
STREPTOMYCIN SULFATE, STREPTOMYCIN SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE

**X-GEN PHARMS**
* X-GEN PHARMACEUTICALS INC
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

** X **

**X-GEN PHARMS INC**
* X-GEN PHARMACEUTICALS INC
HYDRALAZINE HYDROCHLORIDE, HYDRALAZINE HYDROCHLORIDE
LINCOMYCIN, LINCOMYCIN HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID

**XELLIA PHARMS APS**
* XELLIA PHARMACEUTICALS APS
BACITRACIN, BACITRACIN
COLISTIMETHATE SODIUM, COLISTIMETHATE SODIUM
DAPTOMYCIN, DAPTOMYCIN
POLYMYXIN B SULFATE, POLYMYXIN B SULFATE
TOBRAMYCIN SULFATE, TOBRAMYCIN SULFATE
VANCOMYCIN HYDROCHLORIDE, VANCOMYCIN HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE

**XIAMEN LP PHARM CO**
* XIAMEN LP PHARMACUETICAL CO LTD
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE

**XSPIRE PHARMA**
* XSPIRE PHARMA
NALFON, FENOPROFEN CALCIUM
* XSPIRE PHARMA LLC
DEXAMETHASONE, DEXAMETHASONE
FENOPROFEN CALCIUM, FENOPROFEN CALCIUM

**XTTRIUM**
* XTTRIUM LABORATORIES INC
CHLORHEXIDINE GLUCONATE, CHLORHEXIDINE GLUCONATE
EXIDINE, CHLORHEXIDINE GLUCONATE (OTC)

** Y **

**YABAO PHARM**
* YABAO PHARMACEUTICAL CO LTD BEIJING
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE

**YAOPHARMA CO LTD**
* YAOPHARMA CO LTD
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE

**YUNG SHIN PHARM**
* YUNG SHIN PHARMACEUTICAL INDUSTRIAL CO LTD
CEFACLOR, CEFACLOR
CEPHALEXIN, CEPHALEXIN
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
MELOXICAM, MELOXICAM
ZOLPIDEM TARTRATE, ZOLPIDEM TARTRATE

** Z **

**ZAMBON SPA**
* ZAMBON SPA
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE, DORZOLAMIDE HYDROCHLORIDE
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE
* ZAMBON SPA ITALY
MONUROL, FOSFOMYCIN TROMETHAMINE

**ZEVACOR PHARMA INC**
* ZEVACOR PHARMA INC
SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18

**ZHEJIANG HISUN PHARM**
* ZHEJIANG HISUN PHARMACEUTICAL CO LTD
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL

**ZO SKIN HEALTH**
* ZO SKIN HEALTH
TRETINOIN, TRETINOIN

**ZYDUS HLTHCARE**
* ZYDUS HEALTHCARE USA LLC
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
LANSOPRAZOLE, LANSOPRAZOLE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** Z ****

* ZYDUS HEALTHCARE USA LLC
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE

**ZYDUS PHARMS USA**

* ZYDUS PHARMACEUTICALS USA INC
AMLODIPINE BESYLATE, AMLODIPINE BESYLATE
ATENOLOL, ATENOLOL
AZATHIOPRINE, AZATHIOPRINE
BENAZEPRIL HYDROCHLORIDE, BENAZEPRIL HYDROCHLORIDE
BENZONATATE, BENZONATATE
CLINDAMYCIN HYDROCHLORIDE, CLINDAMYCIN HYDROCHLORIDE
HALOPERIDOL, HALOPERIDOL
LAMOTRIGINE, LAMOTRIGINE
MELOXICAM, MELOXICAM
METFORMIN HYDROCHLORIDE, METFORMIN HYDROCHLORIDE
NAPROXEN, NAPROXEN
PAROXETINE HYDROCHLORIDE, PAROXETINE HYDROCHLORIDE
PRAVASTATIN SODIUM, PRAVASTATIN SODIUM
PROMETHAZINE HYDROCHLORIDE, PROMETHAZINE HYDROCHLORIDE
RAMIPRIL, RAMIPRIL
RIBAVIRIN, RIBAVIRIN
RISPERIDONE, RISPERIDONE
SERTRALINE HYDROCHLORIDE, SERTRALINE HYDROCHLORIDE
SIMVASTATIN, SIMVASTATIN
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
WARFARIN SODIUM, WARFARIN SODIUM
ZONISAMIDE, ZONISAMIDE

**ZYDUS PHARMS USA INC**

* ZYDUS PHARMACEUTICALS USA INC
ACAMPROSATE CALCIUM, ACAMPROSATE CALCIUM
ACETAZOLAMIDE, ACETAZOLAMIDE
ACYCLOVIR SODIUM, ACYCLOVIR SODIUM
ACYCLOVIR, ACYCLOVIR
ALLOPURINOL, ALLOPURINOL
AMANTADINE HYDROCHLORIDE, AMANTADINE HYDROCHLORIDE
AMIODARONE HYDROCHLORIDE, AMIODARONE HYDROCHLORIDE
AMITRIPTYLINE HYDROCHLORIDE, AMITRIPTYLINE HYDROCHLORIDE
AMLODIPINE AND OLMESARTAN MEDOXOMIL, AMLODIPINE BESYLATE
ANASTROZOLE, ANASTROZOLE
ASPIRIN AND DIPYRIDAMOLE, ASPIRIN
AZELASTINE HYDROCHLORIDE, AZELASTINE HYDROCHLORIDE
BICALUTAMIDE, BICALUTAMIDE
BROMOCRIPTINE MESYLATE, BROMOCRIPTINE MESYLATE
BUDESONIDE, BUDESONIDE
BUPROPION HYDROCHLORIDE, BUPROPION HYDROCHLORIDE
BUSPIRONE HYDROCHLORIDE, BUSPIRONE HYDROCHLORIDE
CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE, CANDESARTAN CILEXETIL
CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL
CARVEDILOL, CARVEDILOL
CHOLESTYRAMINE LIGHT, CHOLESTYRAMINE
CLOBETASOL PROPIONATE, CLOBETASOL PROPIONATE
CLOMIPRAMINE HYDROCHLORIDE, CLOMIPRAMINE HYDROCHLORIDE
CLONIDINE HYDROCHLORIDE, CLONIDINE HYDROCHLORIDE
CLOPIDOGREL BISULFATE, CLOPIDOGREL BISULFATE
CLOZAPINE, CLOZAPINE
CYPROHEPTADINE HYDROCHLORIDE, CYPROHEPTADINE HYDROCHLORIDE
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION), DESMOPRESSIN ACETATE
DESOXIMETASONE, DESOXIMETASONE
DESVENLAFAXINE SUCCINATE, DESVENLAFAXINE SUCCINATE
DIFLUNISAL, DIFLUNISAL
DILTIAZEM HYDROCHLORIDE, DILTIAZEM HYDROCHLORIDE
DIPYRIDAMOLE, DIPYRIDAMOLE
DIVALPROEX SODIUM, DIVALPROEX SODIUM
DONEPEZIL HYDROCHLORIDE, DONEPEZIL HYDROCHLORIDE
DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE
DOXYCYCLINE HYCLATE, DOXYCYCLINE HYCLATE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** Z ****

* ZYDUS PHARMACEUTICALS USA INC
DOXYCYCLINE, DOXYCYCLINE
DOXYCYCLINE, DOXYCYCLINE HYCLATE
DULOXETINE HYDROCHLORIDE, DULOXETINE HYDROCHLORIDE
DUTASTERIDE, DUTASTERIDE
ELETRIPTAN HYDROBROMIDE, ELETRIPTAN HYDROBROMIDE
ENTECAVIR, ENTECAVIR
ESCITALOPRAM OXALATE, ESCITALOPRAM OXALATE
ETHACRYNATE SODIUM, ETHACRYNATE SODIUM
ETODOLAC, ETODOLAC
ETOMIDATE, ETOMIDATE
EZETIMIBE, EZETIMIBE
FELBAMATE, FELBAMATE
FESOTERODINE FUMARATE, FESOTERODINE FUMARATE
FINASTERIDE, FINASTERIDE
FLUCONAZOLE, FLUCONAZOLE
GABAPENTIN, GABAPENTIN
GALANTAMINE HYDROBROMIDE, GALANTAMINE HYDROBROMIDE
GLIPIZIDE AND METFORMIN HYDROCHLORIDE, GLIPIZIDE
GLYBURIDE AND METFORMIN HYDROCHLORIDE, GLYBURIDE
GLYBURIDE, GLYBURIDE
HYDROXYCHLOROQUINE SULFATE, HYDROXYCHLOROQUINE SULFATE
INDOMETHACIN, INDOMETHACIN
IRBESARTAN, IRBESARTAN
ITRACONAZOLE, ITRACONAZOLE
LABETALOL HYDROCHLORIDE, LABETALOL HYDROCHLORIDE
LAMOTRIGINE, LAMOTRIGINE
LEVETIRACETAM, LEVETIRACETAM
LEVOFLOXACIN, LEVOFLOXACIN
LINEZOLID, LINEZOLID
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
LOSARTAN POTASSIUM, LOSARTAN POTASSIUM
MEMANTINE HYDROCHLORIDE, MEMANTINE HYDROCHLORIDE
MESALAMINE, MESALAMINE
METHOTREXATE SODIUM, METHOTREXATE SODIUM
METRONIDAZOLE, METRONIDAZOLE
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE
MIRTAZAPINE, MIRTAZAPINE
MODAFINIL, MODAFINIL
MYCOPHENOLATE MOFETIL HYDROCHLORIDE, MYCOPHENOLATE MOFETIL HYDROCHLORIDE
NADOLOL, NADOLOL
NATEGLINIDE, NATEGLINIDE
NIFEDIPINE, NIFEDIPINE
NITROFURANTOIN, NITROFURANTOIN, MACROCRYSTALLINE
OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL
OMEPRAZOLE, OMEPRAZOLE
OXYBUTYNIN CHLORIDE, OXYBUTYNIN CHLORIDE
PHENTERMINE HYDROCHLORIDE, PHENTERMINE HYDROCHLORIDE
PINDOLOL, PINDOLOL
PIOGLITAZONE HYDROCHLORIDE, PIOGLITAZONE HYDROCHLORIDE
POTASSIUM CITRATE, POTASSIUM CITRATE
PRAMIPEXOLE DIHYDROCHLORIDE, PRAMIPEXOLE DIHYDROCHLORIDE
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE
PYRIDOSTIGMINE BROMIDE, PYRIDOSTIGMINE BROMIDE
RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE
RISPERIDONE, RISPERIDONE
ROPINIROLE HYDROCHLORIDE, ROPINIROLE HYDROCHLORIDE
SIROLIMUS, SIROLIMUS
TAMOXIFEN CITRATE, TAMOXIFEN CITRATE
TAMSULOSIN HYDROCHLORIDE, TAMSULOSIN HYDROCHLORIDE
TELMISARTAN AND HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE
TELMISARTAN, TELMISARTAN
TEMOZOLOMIDE, TEMOZOLOMIDE
TIZANIDINE HYDROCHLORIDE, TIZANIDINE HYDROCHLORIDE
TOPIRAMATE, TOPIRAMATE

# APPENDIX B - PRODUCT NAME SORTED BY APPLICANT

**** Z ****

* ZYDUS PHARMACEUTICALS USA INC
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN, ACETAMINOPHEN
TRAMADOL HYDROCHLORIDE, TRAMADOL HYDROCHLORIDE
TRANEXAMIC ACID, TRANEXAMIC ACID
TRAZODONE HYDROCHLORIDE, TRAZODONE HYDROCHLORIDE
VALACYCLOVIR HYDROCHLORIDE, VALACYCLOVIR HYDROCHLORIDE
VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE HYDROCHLORIDE
VORICONAZOLE, VORICONAZOLE
ZIPRASIDONE HYDROCHLORIDE, ZIPRASIDONE HYDROCHLORIDE
ZOLMITRIPTAN, ZOLMITRIPTAN
ZYPITAMAG, PITAVASTATIN MAGNESIUM

**ZYDUS WORLDWIDE**

* ZYDUS WORLDWIDE DMCC
MINOCYCLINE HYDROCHLORIDE, MINOCYCLINE HYDROCHLORIDE

# APPENDIX C

# UNIFORM TERMS

## *DOSAGE FORMS*

AEROSOL, FOAM
AEROSOL, METERED
CAPSULE
CAPSULE, DELAYED REL PELLETS
CAPSULE, DELAYED RELEASE
CAPSULE, EXTENDED RELEASE
CAPSULE, PELLET
CLOTH
CONCENTRATE
CREAM
CREAM, AUGMENTED
ELIXIR
EMULSION
ENEMA
FILM
FILM, EXTENDED RELEASE
FOR SOLUTION
FOR SUSPENSION
FOR SUSPENSION, DELAYED RELEASE
FOR SUSPENSION, EXTENDED RELEASE
GAS
GEL
GEL, AUGMENTED
GEL, METERED
GRANULE
GRANULE, DELAYED RELEASE
GUM, CHEWING
IMPLANT
INHALANT
INJECTABLE
INJECTABLE, LIPID COMPLEX
INJECTABLE, LIPOSOMAL
INJECTION, EXTENDED RELEASE
INSERT
INSERT, EXTENDED RELEASE
INTRAUTERINE DEVICE
JELLY
LIQUID
LOTION
LOTION, AUGMENTED
LOTION/SHAMPOO
OIL
OIL/DROPS
OINTMENT
OINTMENT, AUGMENTED
PASTE
PATCH
PELLET
POWDER
POWDER, EXTENDED RELEASE
POWDER, METERED
RING
SHAMPOO
SOLUTION
SOLUTION FOR SLUSH
SOLUTION, EXTENDED RELEASE
SOLUTION, GEL FORMING/DROPS
SOLUTION, METERED
SOLUTION/DROPS
SPONGE
SPRAY
SPRAY, METERED
SUPPOSITORY
SUSPENSION
SUSPENSION, EXTENDED RELEASE
SUSPENSION/DROPS
SWAB
SYRUP
SYSTEM
SYSTEM, EXTENDED RELEASE
TABLET
TABLET, CHEWABLE
TABLET, COATED PARTICLES
TABLET, DELAYED RELEASE
TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING
TABLET, EFFERVESCENT
TABLET, EXTENDED RELEASE
TABLET, EXTENDED RELEASE, CHEWABLE
TABLET, FOR SUSPENSION
TABLET, ORALLY DISINTEGRATING
TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE
TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE
TAPE
TROCHE/LOZENGE

Note: Terms comprise currently marketed products

# APPENDIX C

## UNIFORM TERMS

### *ROUTES OF ADMINISTRATION*

BUCCAL
DENTAL
ENDOCERVICAL
ENDOTRACHEL
FOR RX COMPOUNDING
IMPLANTATION
INHALATION
INJECTION
INTRA-ANAL
INTRACRANIAL
INTRAMUSCULAR
INTRAOCULAR
INTRAPERITONEAL
INTRAPLEURAL
INTRATHECAL
INTRATRACHEAL
INTRAUTERINE
INTRAVENOUS
INTRAVESICAL
INTRAVITREAL
IONTOPHORESIS
IRRIGATION
IV (INFUSION)
N/A
NASAL
OPHTHALMIC
ORAL
ORAL-21
ORAL-28
OTIC
PERFUSION, CARDIAC
PERIODONTAL
RECTAL
SPINAL
SUBCUTANEOUS
SUBLINGUAL
TOPICAL
TRANSDERMAL
TRANSMUCOSAL
URETHRAL
VAGINAL

Note: Terms comprise currently marketed products

# APPENDIX C

# UNIFORM TERMS

## *ABBREVIATIONS*

| | |
|---|---|
| AMP | AMPULE |
| AMPICIL | AMPICILLIN |
| APPROX | APPROXIMATELY |
| BOT | BOTTLE |
| CI | CURIE |
| CSR | CAROTID SINUS REFLEX |
| CU | CLINICAL UNITS |
| DIPROP | DIPROPIONATE |
| ELECT | ELECTROLYTE |
| EQ | EQUIVALENT TO |
| ER | EXTENDED RELEASE |
| GM | GRAM |
| HBR | HYDROBROMIDE |
| HCL | HYDROCHLORIDE |
| HR | HOUR |
| IM | INTRAMUSCULAR |
| INH | INHALATION |
| IU | INTERNATIONAL UNITS |
| IV | INTRAVENOUS |
| KIU | KALLIKREIN INHIBITOR UNITS |
| MCG | MICROGRAM |
| mCi | MILLICURIE |
| MEQ | MILLIEQUIVALENT |
| MG | MILLIGRAM |
| ML | MILLILITER |
| N/A | NOT APPLICABLE |
| PPM | PARTS PER MILLION |
| REL | RELEASE |
| SQ CM | SQUARE CENTIMETER |
| U | UNITS |
| uCi | MICROCURIE |
| UMOLAR | MICROMOLAR |
| USP | UNITED STATES PHARMACOPEIA |

# PATENT AND EXCLUSIVITY INFORMATION ADDENDUM

This *Addendum* identifies drugs that qualify under the Federal Food, Drug, and Cosmetic Act (FD&C Act) for periods of exclusivity and provides patent information concerning the listed drug products.

**Exclusivity**

During relevant exclusivity periods, certain abbreviated new drug applications (ANDAs) and applications described in Section 505(b)(2) of the FD&C Act (505(b)(2) applications) may not be submitted or approved as described below. This *Addendum* identifies drugs that qualify under the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman Amendments) for periods of exclusivity. This *Addendum* also identifies those drugs that have qualified for Orphan Drug Exclusivity pursuant to Section 527 of the FD&C Act, those drugs that have qualified for Pediatric Exclusivity pursuant to Section 505A of the FD&C Act, those drugs that have qualified for Generating Antibiotics Incentives Now (GAIN) exclusivity pursuant to Section 505E of the FD&C Act, and those drugs that have qualified for Competitive Generic Therapy (CGT) exclusivity pursuant to Section 505(j)(5)(B)(v) of the FD&C Act. This section is arranged in alphabetical order by active ingredient name followed by the trade name. Active ingredient headings for multiple ingredient fixed-combination drug products are arranged alphabetically.

For an explanation of the codes used in the *Addendum*, see the *Patent and Exclusivity Terms* Section. The exclusivity codes are general shorthand descriptions and do not necessarily identify, with specificity, the actual scope of exclusivity. Please note that beginning with the publication of the 38th edition of the Orange Book, individual descriptions of the protected use have been added to each Orphan Drug Exclusivity entry listed in the Orange Book. In previous editions of the Orange Book, Orphan Drug Exclusivity was not described with any specificity.

The exclusivities identified in the *Addendum* do not prevent the submission or approval of an application submitted pursuant to Section 505(b)(1) of the FD&C Act that would otherwise be blocked if it had been submitted pursuant to Section 505(b)(2) or 505(j), except in the case of Orphan Drug Exclusivity. Drugs that may qualify for periods of exclusivity include:

(1) A new chemical entity, submitted in a new drug application under Section 505(b) of the FD&C Act and approved after September 24, 1984. A new chemical entity is an active ingredient that contains “no active ingredient (including any ester or salt of the active ingredient)” that has been approved by FDA in any other application submitted under Section 505(b) of the FD&C Act. No subsequent ANDA or 505(b)(2) application for a drug that contains the same active moiety may be *submitted* for a period of *five years* from the date of approval of the original application, except that such an application may be *submitted* after *four years* if it contains a certification that a patent claiming the drug is invalid or will not be infringed by the product for which approval is sought. See Sections 505(j)(5)(F)(ii) and 505(c)(3)(E)(ii) of the FD&C Act.

(2) A new drug application approved after September 24, 1984, for a drug product containing ”an active ingredient (including any ester or salt of

the active ingredient)" that has been approved in an earlier new drug application and that includes reports of new clinical investigations (other than bioavailability studies). Such investigations must have been conducted or sponsored by the applicant and must have been essential to approval of the application. If these requirements are met, a subsequent ANDA or a 505(b)(2) application may not be approved for the exclusivity-protected "conditions of approval of such drug" before the expiration of *three years* from the date of approval of the original application. If an NDA has exclusivity only for a new indication or use, this exclusivity generally does not preclude the approval of an ANDA or 505(b)(2) application for indications and uses not covered by the exclusivity, assuming the proposed drug product will be safe and effective as labeled. See Sections 505(j)(5)(F)(iii) and 505(c)(3)(E)(iii) of the FD&C Act.

(3) A supplement to a new drug application for a drug containing a previously approved "active ingredient (including any ester or salt of the active ingredient)" approved after September 24, 1984, that contains reports of new clinical investigations (other than bioavailability studies) essential to the approval of the supplement and conducted or sponsored by the applicant. A subsequent ANDA or 505(b)(2) application may not be approved for an exclusivity-protected change approved in the supplement for *three years* from the date of approval of the supplement. See Sections 505(j)(5)(F)(iv) and 505(c)(3)(E)(iv) of the FD&C Act.

**Patent Information**

The FD&C Act requires that patent information be filed with all newly submitted Section 505(b) drug applications. No NDA may be approved after September 24, 1984, without the submission of patent information to the Agency. Effective August 18, 2003, this information must be filed using Form FDA 3542a "Patent Information Submitted with the Filing of an NDA, Amendment or Supplement".

Effective August 18, 2003, upon approval of an application, patent information for purposes of listing in the Orange Book must be submitted to the Agency within 30 days of the date of approval on Form FDA 3542 "Patent Information Submitted Upon and After Approval of an NDA or Supplement."[1] In November 2017, the Agency began including in the Orange Book the patent submission date (i.e., the date on which the FDA receives patent information from the NDA holder) for each newly listed patent. Patent information on unapproved applications or on patents beyond the scope of the FD&C Act (i.e., process or manufacturing patents) will not be published. Form FDA 3542 will be the only form used for the purposes of this publication.

The patents that FDA regards as covered by the statutory provisions for submission of patent information are: patents that claim the active ingredient(s); drug product patents, which include formulation/composition patents; method-of-use patents that claim one or more approved methods of using the approved drug product; and certain other patents as detailed on

[1] Please note that the date of approval for an NDA for a drug for which FDA intends to recommend controls under the Controlled Substances Act is the later of the date on the approval letter for the NDA or the date of issuance of the interim final rule controlling the drug (see section Section 505(x)(1) and (2) of the FD&C Act).

Form FDA 3542.[2] This information, as provided by the sponsor on Form FDA 3542, will be published as described above. As of December 5, 2016, an NDA holder submitting information on a patent that claims both the drug substance and the drug product (and is eligible for listing on either basis) is required only to specify that the patent claims either the drug substance or the drug product.

A requirement for submission of patent information to FDA for certain old antibiotics became effective October 7, 2008 under Section 4(b)(1) of the QI Program Supplemental Funding Act (Public Law 110-379) (QI Act).

Upon approval of an NDA, patent numbers and expiration dates for patent information submitted to FDA on Form FDA 3542 will be published daily in the Orange Book. The Addendum lists patent and exclusivity information up to January of the Edition year. The monthly Cumulative Supplements to the annual edition list patent and exclusivity information changes since the Annual Edition Addendum. Since all parts of this publication are subject to changes, additions, or deletions, the Orange Book, updated daily, should be consulted for the most recent patent and exclusivity information.

2 See 21 CFR 314.53(c)(2)(ii)(M), (N)(*2*) and (N)(*3*).

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| ABACAVIR SULFATE - ABACAVIR SULFATE | | | | | | |
| A 201107 001 | | | | | PC | Mar 14, 2018 |
| ABACAVIR SULFATE - ZIAGEN | | | | | | |
| N 020977 001 | 6294540 | May 14, 2018 | DS DP U-65 | | | |
| ABACAVIR SULFATE - ZIAGEN | | | | | | |
| N 020978 001 | 6294540 | May 14, 2018 | DS DP U-65 | | | |
| | 6641843 | Feb 04, 2019 | DP | | | |
| ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ | | | | | | |
| N 205551 001 | 6294540 | May 14, 2018 | DS DP U-1572 | | NCE | Aug 12, 2018 |
| | 6294540*PED | Nov 14, 2018 | | | | |
| | 8129385 | Oct 05, 2027 | DS DP | | | |
| | 9242986 | Dec 08, 2029 | DS DP | | | |
| ABACAVIR SULFATE; LAMIVUDINE - EPZICOM | | | | | | |
| N 021652 001 | 6294540 | May 14, 2018 | DS DP U-257 | | | |
| ABACAVIR SULFATE; LAMIVUDINE; ZIDOVUDINE - TRIZIVIR | | | | | | |
| N 021205 001 | 6294540 | May 14, 2018 | DS DP U-65 | | | |
| ABALOPARATIDE - TYMLOS | | | | | | |
| N 208743 001 | 7803770 | Mar 26, 2028 | U-2009 | | NCE | Apr 28, 2022 |
| | 8148333 | Nov 08, 2027 | DP | | | |
| | 8748382 | Oct 03, 2027 | U-2009 | | | |
| ABEMACICLIB - VERZENIO | | | | | | |
| N 208716 001 | 7855211 | Dec 15, 2029 | DS DP U-2132 | | NCE | Sep 28, 2022 |
| | 7855211 | Dec 15, 2029 | DS DP U-2135 | | | |
| ABEMACICLIB - VERZENIO | | | | | | |
| N 208716 002 | 7855211 | Dec 15, 2029 | DS DP U-2132 | | NCE | Sep 28, 2022 |
| | 7855211 | Dec 15, 2029 | DS DP U-2135 | | | |
| ABEMACICLIB - VERZENIO | | | | | | |
| N 208716 003 | 7855211 | Dec 15, 2029 | DS DP U-2132 | | NCE | Sep 28, 2022 |
| | 7855211 | Dec 15, 2029 | DS DP U-2135 | | | |
| ABEMACICLIB - VERZENIO | | | | | | |
| N 208716 004 | 7855211 | Dec 15, 2029 | DS DP U-2132 | | NCE | Sep 28, 2022 |
| | 7855211 | Dec 15, 2029 | DS DP U-2135 | | | |
| ABIRATERONE ACETATE - ZYTIGA | | | | | | |
| N 202379 001 | 8822438 | Aug 24, 2027 | U-1579 | | | |
| | 8822438 | Aug 24, 2027 | U-1580 | | | |
| ABIRATERONE ACETATE - ZYTIGA | | | | | | |
| N 202379 002 | 8822438 | Aug 24, 2027 | U-1579 | | | |
| | 8822438 | Aug 24, 2027 | U-1580 | | | |
| ACALABRUTINIB - CALQUENCE | | | | | | |
| N 210259 001 | 9290504 | Jul 11, 2032 | DS DP | | NCE | Oct 31, 2022 |
| | 9758524 | Jul 11, 2032 | U-2145 | | | |
| | 9796721 | Jul 01, 2036 | DS DP U-2145 | | | |
| ACETAMINOPHEN - OFIRMEV | | | | | | |
| N 022450 001 | 6028222 | Aug 05, 2017 | DP | | M-196 | Jan 27, 2020 |
| | 6028222*PED | Feb 05, 2018 | | | PED | Jul 27, 2020 |
| | 6992218 | Jun 06, 2021 | DP | | | |
| | 6992218*PED | Dec 06, 2021 | | | | |
| | 9399012 | Sep 11, 2031 | U-1882 | | | |
| | 9399012*PED | Mar 11, 2032 | | | | |
| | 9610265 | Nov 13, 2028 | U-2000 | | | |
| ACETAMINOPHEN; ASPIRIN; CAFFEINE - EXCEDRIN (MIGRAINE) | | | | | | |
| N 020802 001 | 5972916 | Jul 14, 2017 | U-296 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR | | | | | | | |
| N 204031 | 001 | 6488962 | Jun 20, 2020 | DP | | | |
| | | 7976870 | Jun 01, 2027 | U-1498 | | | |
| | | 8372432 | Mar 11, 2029 | DP U-1499 | | | |
| | | 8377453 | Nov 19, 2029 | DP U-1499 | | | |
| | | 8394408 | Mar 11, 2029 | DP | | | |
| | | 8597681 | Dec 21, 2030 | DP | | | |
| | | 8658631 | May 16, 2032 | DP | | | |
| | | 8668929 | Mar 11, 2029 | U-1499 | | | |
| | | 8741885 | May 16, 2032 | DP U-1499 | | | |
| | | 8980319 | Dec 21, 2030 | DP | | | |
| | | 8992975 | May 16, 2032 | DP | | | |
| | | 9050335 | May 16, 2032 | DP | | | |
| | | 9468636 | May 16, 2032 | U-1499 | | | |
| ACETYLCYSTEINE - ACETADOTE | | | | | | | |
| N 021539 | 001 | 8148356 | May 21, 2026 | DP | | | |
| | | 8399445 | Aug 24, 2025 | U-1373 | | | |
| | | 8653061 | Aug 24, 2025 | U-1373 | | | |
| | | 8722738 | Apr 06, 2032 | U-1373 | | | |
| | | 9327028 | Jul 21, 2031 | U-1839 | | | |
| ACETYLCYSTEINE - CETYLEV | | | | | | | |
| N 207916 | 001 | 8747894 | May 08, 2032 | DP U-1373 | | | |
| | | 9427421 | May 08, 2032 | DP | | | |
| | | 9561204 | May 08, 2032 | U-1373 | | | |
| ACETYLCYSTEINE - CETYLEV | | | | | | | |
| N 207916 | 002 | 8747894 | May 08, 2032 | DP U-1373 | | | |
| | | 9427421 | May 08, 2032 | DP | | | |
| | | 9561204 | May 08, 2032 | U-1373 | | | |
| ACLIDINIUM BROMIDE - TUDORZA PRESSAIR | | | | | | | |
| N 202450 | 001 | 6681768 | Aug 07, 2022 | DP | | NCE | Jul 23, 2017 |
| | | 7078412 | Jul 16, 2020 | DS DP U-1263 | | | |
| | | 8051851 | Apr 22, 2027 | DP | | | |
| | | 9056100 | Jul 07, 2020 | DP U-1263 | | | |
| | | 9333195 | Jul 07, 2020 | DP U-1263 | | | |
| | | RE46417 | Sep 05, 2020 | DS DP U-1263 | | | |
| ACYCLOVIR - SITAVIG | | | | | | | |
| N 203791 | 001 | 8592434 | Jun 16, 2030 | DP U-1460 | | | |
| | | 8747896 | Jun 03, 2027 | DP U-1460 | | | |
| | | 8791127 | Mar 23, 2027 | DP U-1460 | | | |
| ACYCLOVIR; HYDROCORTISONE - XERESE | | | | | | | |
| N 022436 | 001 | 6514980 | Jul 24, 2018 | DP U-1006 | | | |
| | | 6514980 | Jul 24, 2018 | DP U-1484 | | | |
| | | 7223387 | Nov 13, 2022 | DP U-1006 | | | |
| | | 7223387 | Nov 13, 2022 | DP U-1484 | | | |
| ADAPALENE - DIFFERIN | | | | | | | |
| N 020380 | 002 | | | | | RTO | Jul 08, 2019 |
| ADAPALENE - DIFFERIN | | | | | | | |
| N 021753 | 001 | 7579377 | Feb 23, 2025 | U-818 | | | |
| | | 7737181 | Aug 29, 2024 | DP | | | |
| | | 7834060 | Mar 12, 2023 | U-1078 | | | |
| | | 7838558 | Mar 12, 2023 | DP | | | |
| | | 7868044 | Mar 12, 2023 | U-1078 | | | |
| | | 8703820 | Mar 12, 2023 | U-1078 | | | |
| ADAPALENE - DIFFERIN | | | | | | | |
| N 022502 | 001 | 7998467 | May 31, 2028 | DP U-1078 | | | |
| | | 8435502 | Sep 15, 2026 | DP U-1078 | | | |
| | | 8709392 | Sep 15, 2026 | DP U-1078 | | | |
| ADAPALENE; BENZOYL PEROXIDE - ADAPALENE AND BENZOYL PEROXIDE | | | | | | | |
| A 203790 | 001 | | | | | PC | Jan 23, 2018 |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| ADAPALENE; BENZOYL PEROXIDE - EPIDUO | | | | | | | |
| N 022320 | 001 | 7820186 | Nov 23, 2025 | DP | | | |
| | | 7964202 | Sep 01, 2024 | DP U-1078 | | | |
| | | 8071644 | Jul 18, 2027 | DP U-1078 | | | |
| | | 8080537 | Jul 18, 2027 | U-1078 | | | |
| | | 8105618 | Dec 23, 2022 | U-1078 | | | |
| | | 8129362 | Jul 18, 2027 | U-1078 | | | |
| | | 8241649 | Dec 23, 2022 | DP | | | |
| | | 8445543 | Jul 12, 2027 | U-1078 | | | |
| | | 8809305 | Dec 23, 2022 | U-1078 | | | |
| | | 8936800 | Dec 23, 2022 | DP U-1078 | | | |
| ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE | | | | | | | |
| N 207917 | 001 | 8445543 | Dec 23, 2022 | U-1078 | | NP | Jul 15, 2018 |
| | | 8703820 | Mar 12, 2023 | U-1078 | | | |
| | | 8729127 | Mar 12, 2023 | U-1078 | | | |
| | | 8785420 | Dec 23, 2022 | U-1078 | | | |
| | | 8809305 | Dec 23, 2022 | U-1078 | | | |
| | | 8936800 | Dec 23, 2022 | DP U-1078 | | | |
| | | 9381179 | Mar 12, 2023 | U-1078 | | | |
| | | 9387187 | Mar 12, 2023 | U-1078 | | | |
| | | 9814690 | Dec 23, 2022 | DP U-1078 | | | |
| ADEFOVIR DIPIVOXIL - HEPSERA | | | | | | | |
| N 021449 | 001 | 6451340 | Jul 23, 2018 | DS DP U-470 | | | |
| AFATINIB DIMALEATE - GILOTRIF | | | | | | | |
| N 201292 | 001 | 6251912 | Jul 29, 2018 | DS DP U-1067 | | NCE | Jul 12, 2018 |
| | | 8426586 | Oct 10, 2029 | DS | | ODE-115 | Apr 15, 2023 |
| | | 8545884 | Dec 19, 2029 | DP | | ODE-50 | Jul 12, 2020 |
| | | 9539258 | Nov 09, 2026 | U-1950 | | | |
| | | RE43431 | Jan 22, 2022 | DS | | | |
| AFATINIB DIMALEATE - GILOTRIF | | | | | | | |
| N 201292 | 002 | 6251912 | Jul 29, 2018 | DS DP U-1067 | | NCE | Jul 12, 2018 |
| | | 8426586 | Oct 10, 2029 | DS | | ODE-115 | Apr 15, 2023 |
| | | 8545884 | Dec 19, 2029 | DP | | ODE-50 | Jul 12, 2020 |
| | | 9539258 | Nov 09, 2026 | U-1950 | | | |
| | | RE43431 | Jan 22, 2022 | DS | | | |
| AFATINIB DIMALEATE - GILOTRIF | | | | | | | |
| N 201292 | 003 | 6251912 | Jul 29, 2018 | DS DP U-1067 | | I-730 | Apr 15, 2019 |
| | | 8426586 | Oct 10, 2029 | DS | | NCE | Jul 12, 2018 |
| | | 8545884 | Dec 19, 2029 | DP | | ODE-115 | Apr 15, 2023 |
| | | 9539258 | Nov 09, 2026 | U-1950 | | ODE-50 | Jul 12, 2020 |
| | | RE43431 | Jan 22, 2022 | DS | | | |
| ALBUMIN HUMAN - OPTISON | | | | | | | |
| N 020899 | 001 | 6723303 | Apr 20, 2021 | DP | | | |
| ALBUTEROL SULFATE - ACCUNEB | | | | | | | |
| N 020949 | 001 | 6702997 | Dec 28, 2021 | U-558 | | | |
| ALBUTEROL SULFATE - ACCUNEB | | | | | | | |
| N 020949 | 002 | 6702997 | Dec 28, 2021 | U-558 | | | |
| ALBUTEROL SULFATE - VENTOLIN HFA | | | | | | | |
| N 020983 | 001 | 6161724 | Jan 16, 2018 | DP | | | |
| | | 6170717 | Dec 23, 2017 | DP | | | |
| | | 6315173 | Dec 23, 2017 | DP | | | |
| | | 6431168 | Jun 08, 2018 | DP | | | |
| | | 6435372 | Jan 16, 2018 | DP | | | |
| | | 6510969 | Dec 23, 2017 | DP | | | |
| | | 6938796 | Jan 16, 2018 | DP | | | |
| | | 6966467 | Dec 23, 2017 | DP | | | |
| | | 6997349 | Jan 16, 2018 | DP | | | |
| | | 7107986 | Jun 08, 2018 | DP | | | |
| | | 7143908 | Jan 16, 2018 | DP | | | |
| | | 7350676 | Aug 24, 2018 | DP | | | |
| | | 7500444 | Feb 26, 2026 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| ALBUTEROL SULFATE - VENTOLIN HFA | | | | | | | |
| N 020983 | 001 | 7500444*PED | Aug 26, 2026 | | | | |
| | | 7832351 | Jun 19, 2023 | DP | | | |
| ALBUTEROL SULFATE - PROAIR HFA | | | | | | | |
| N 021457 | 001 | 6446627 | Dec 18, 2017 | DP | | | |
| | | 7105152 | Sep 12, 2023 | DP | | | |
| | | 8132712 | Sep 07, 2028 | DP | | | |
| | | 9463289 | May 18, 2031 | DP | | | |
| | | 9808587 | May 18, 2031 | DP | | | |
| ALBUTEROL SULFATE - PROAIR RESPICLICK | | | | | | | |
| N 205636 | 001 | 6446627 | Dec 18, 2017 | DP | | NP | Mar 12, 2018 |
| | | 6701917 | Jun 23, 2021 | DP | | NPP | Apr 28, 2019 |
| | | 6718972 | Jun 23, 2021 | DP | | | |
| | | 6748947 | Jun 23, 2021 | DP | | | |
| | | 6871646 | Jun 23, 2021 | DP | | | |
| | | 7540282 | May 06, 2023 | DP | | | |
| | | 8006690 | Jun 23, 2021 | DP | | | |
| | | 8651103 | Mar 26, 2028 | DP | | | |
| | | 8978966 | Jan 13, 2032 | DP | | | |
| | | 9216260 | Jun 28, 2031 | DP | | | |
| | | 9463288 | May 19, 2025 | DP | | | |
| | | 9731087 | May 18, 2031 | DP | | | |
| ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - DUONEB | | | | | | | |
| N 020950 | 001 | 6632842 | Dec 28, 2021 | U-532 | | | |
| ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT | | | | | | | |
| N 021747 | 001 | 6846413 | Aug 28, 2018 | DP | | | |
| | | 6977042 | Aug 28, 2018 | DP | | | |
| | | 6988496 | Feb 23, 2020 | DP | | | |
| | | 7284474 | Aug 26, 2024 | DP | | | |
| | | 7396341 | Oct 10, 2026 | DP | | | |
| | | 7802568 | Feb 26, 2019 | DP | | | |
| | | 7837235 | Mar 13, 2028 | DP | | | |
| | | 7896264 | May 26, 2025 | DP | | | |
| | | 7988001 | Aug 04, 2021 | DP | | | |
| | | 8733341 | Oct 16, 2030 | DP | | | |
| | | 9027967 | Mar 31, 2027 | DP | | | |
| ALCAFTADINE - LASTACAFT | | | | | | | |
| N 022134 | 001 | 8664215 | Dec 23, 2027 | U-1493 | | | |
| ALECTINIB HYDROCHLORIDE - ALECENSA | | | | | | | |
| N 208434 | 001 | 9126931 | May 29, 2031 | DS | | I-756 | Nov 06, 2020 |
| | | 9365514 | Mar 04, 2032 | DP | | NCE | Dec 11, 2020 |
| | | 9440922 | Jun 09, 2030 | DP | | ODE | Nov 06, 2024 |
| | | | | | | ODE-105 | Dec 11, 2022 |
| ALENDRONATE SODIUM - FOSAMAX | | | | | | | |
| N 021575 | 001 | 5994329 | Jul 17, 2018 | | Y | | |
| | | 6015801 | Jul 17, 2018 | | Y | | |
| | | 6225294 | Jul 17, 2018 | | Y | | |
| ALENDRONATE SODIUM - BINOSTO | | | | | | | |
| N 202344 | 001 | 7488496 | Aug 11, 2023 | DS DP | | | |
| | | 7964212 | Mar 06, 2023 | DS DP | | | |
| ALENDRONATE SODIUM; CHOLECALCIFEROL - FOSAMAX PLUS D | | | | | | | |
| N 021762 | 001 | 5994329 | Jul 17, 2018 | U-647 | Y | | |
| ALFUZOSIN HYDROCHLORIDE - UROXATRAL | | | | | | | |
| N 021287 | 001 | 6149940 | Aug 22, 2017 | | | | |
| ALISKIREN HEMIFUMARATE - TEKTURNA | | | | | | | |
| N 021985 | 001 | 5559111 | Jul 21, 2018 | DS DP U-3 | | | |
| | | 5559111*PED | Jan 21, 2019 | | | | |
| | | 8617595 | Feb 19, 2026 | DP | | | |
| | | 8617595*PED | Aug 19, 2026 | | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| ALISKIREN HEMIFUMARATE - TEKTURNA | | | | | | | |
| N 021985 | 002 | 5559111 | Jul 21, 2018 | DS DP U-3 | | | |
| | | 5559111*PED | Jan 21, 2019 | | | | |
| | | 8617595 | Feb 19, 2026 | DP | | | |
| | | 8617595*PED | Aug 19, 2026 | | | | |
| ALISKIREN HEMIFUMARATE - TEKTURNA | | | | | | | |
| N 210709 | 001 | | | | | NP | Nov 14, 2020 |
| | | | | | | PED | May 14, 2021 |
| ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO | | | | | | | |
| N 022545 | 001 | 5559111 | Jul 21, 2018 | DS DP U-3 | | | |
| | | 8613949 | Dec 21, 2029 | DP | | | |
| ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO | | | | | | | |
| N 022545 | 002 | 5559111 | Jul 21, 2018 | DS DP U-3 | | | |
| | | 8613949 | Dec 21, 2029 | DP | | | |
| ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO | | | | | | | |
| N 022545 | 003 | 5559111 | Jul 21, 2018 | DS DP U-3 | | | |
| | | 8613949 | Dec 21, 2029 | DP | | | |
| ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO | | | | | | | |
| N 022545 | 004 | 5559111 | Jul 21, 2018 | DS DP U-3 | | | |
| | | 8613949 | Dec 21, 2029 | DP | | | |
| ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE | | | | | | | |
| N 200045 | 001 | 5559111 | Jul 21, 2018 | DS DP U-3 | | | |
| | | 8183295 | May 16, 2023 | DP | | | |
| | | 8618174 | Nov 15, 2021 | DP | | | |
| ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE | | | | | | | |
| N 200045 | 002 | 5559111 | Jul 21, 2018 | DS DP U-3 | | | |
| | | 8183295 | May 16, 2023 | DP | | | |
| | | 8618174 | Nov 15, 2021 | DP | | | |
| ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE | | | | | | | |
| N 200045 | 003 | 5559111 | Jul 21, 2018 | DS DP U-3 | | | |
| | | 8183295 | May 16, 2023 | DP | | | |
| | | 8618174 | Nov 15, 2021 | DP | | | |
| ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE | | | | | | | |
| N 200045 | 004 | 5559111 | Jul 21, 2018 | DS DP U-3 | | | |
| | | 8183295 | May 16, 2023 | DP | | | |
| | | 8618174 | Nov 15, 2021 | DP | | | |
| ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE | | | | | | | |
| N 200045 | 005 | 5559111 | Jul 21, 2018 | DS DP U-3 | | | |
| | | 8183295 | May 16, 2023 | DP | | | |
| | | 8618174 | Nov 15, 2021 | DP | | | |
| ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT | | | | | | | |
| N 022107 | 001 | 5559111 | Jul 21, 2018 | DS DP U-3 | | | |
| | | 5559111*PED | Jan 21, 2019 | | | | |
| | | 8618172 | Jul 13, 2028 | DP | | | |
| | | 9023893 | Mar 03, 2022 | DP | | | |
| ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT | | | | | | | |
| N 022107 | 002 | 5559111 | Jul 21, 2018 | DS DP U-3 | | | |
| | | 5559111*PED | Jan 21, 2019 | | | | |
| | | 8618172 | Jul 13, 2028 | DP | | | |
| | | 9023893 | Mar 03, 2022 | DP | | | |
| ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT | | | | | | | |
| N 022107 | 003 | 5559111 | Jul 21, 2018 | DS DP U-3 | | | |
| | | 5559111*PED | Jan 21, 2019 | | | | |
| | | 8618172 | Jul 13, 2028 | DP | | | |
| | | 9023893 | Mar 03, 2022 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTURNA HCT | | | | | | | |
| N 022107 | 004 | 5559111 | Jul 21, 2018 | DS DP U-3 | | | |
| | | 5559111*PED | Jan 21, 2019 | | | | |
| | | 8618172 | Jul 13, 2028 | DP | | | |
| | | 9023893 | Mar 03, 2022 | DP | | | |
| ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA | | | | | | | |
| N 022217 | 001 | 5559111 | Jul 21, 2018 | DS DP U-3 | | | |
| | | 8168616 | Jul 03, 2026 | DP | | | |
| ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA | | | | | | | |
| N 022217 | 002 | 5559111 | Jul 21, 2018 | DS DP U-3 | | | |
| | | 8168616 | Jul 03, 2026 | DP | | | |
| ALLOPURINOL; LESINURAD - DUZALLO | | | | | | | |
| N 209203 | 001 | 8003681 | Aug 25, 2025 | DS | | | |
| | | 8084483 | Aug 17, 2029 | U-2104 | | | |
| | | 8283369 | Nov 26, 2028 | U-2104 | | | |
| | | 8357713 | Nov 26, 2028 | DP U-2104 | | | |
| | | 8546436 | Feb 29, 2032 | DS | | | |
| | | 8546437 | Apr 29, 2029 | U-2104 | | | |
| | | 9216179 | Aug 01, 2031 | U-2104 | | | |
| ALLOPURINOL; LESINURAD - DUZALLO | | | | | | | |
| N 209203 | 002 | 8003681 | Aug 25, 2025 | DS | | | |
| | | 8084483 | Aug 17, 2029 | U-2104 | | | |
| | | 8283369 | Nov 26, 2028 | U-2104 | | | |
| | | 8357713 | Nov 26, 2028 | DP U-2104 | | | |
| | | 8546436 | Feb 29, 2032 | DS | | | |
| | | 8546437 | Apr 29, 2029 | U-2104 | | | |
| | | 9216179 | Aug 01, 2031 | U-2104 | | | |
| ALOGLIPTIN BENZOATE - NESINA | | | | | | | |
| N 022271 | 001 | 6890898 | Feb 02, 2019 | U-1335 | | M-177 | Apr 05, 2019 |
| | | 7078381 | Feb 02, 2019 | U-1335 | | NCE | Jan 25, 2018 |
| | | 7459428 | Feb 02, 2019 | U-1336 | | | |
| | | 7807689 | Jun 27, 2028 | DS DP U-1337 | | | |
| | | 8173663 | Dec 02, 2025 | U-1338 | | | |
| | | 8288539 | Mar 15, 2025 | DS | | | |
| | | 8697125 | Jun 16, 2029 | DP | | | |
| ALOGLIPTIN BENZOATE - NESINA | | | | | | | |
| N 022271 | 002 | 6890898 | Feb 02, 2019 | U-1335 | | M-177 | Apr 05, 2019 |
| | | 7078381 | Feb 02, 2019 | U-1335 | | NCE | Jan 25, 2018 |
| | | 7459428 | Feb 02, 2019 | U-1336 | | | |
| | | 7807689 | Jun 27, 2028 | DS DP U-1337 | | | |
| | | 8173663 | Dec 02, 2025 | U-1338 | | | |
| | | 8288539 | Mar 15, 2025 | DS | | | |
| | | 8697125 | Jun 16, 2029 | DP | | | |
| ALOGLIPTIN BENZOATE - NESINA | | | | | | | |
| N 022271 | 003 | 6890898 | Feb 02, 2019 | U-1335 | | M-177 | Apr 05, 2019 |
| | | 7078381 | Feb 02, 2019 | U-1335 | | NCE | Jan 25, 2018 |
| | | 7459428 | Feb 02, 2019 | U-1336 | | | |
| | | 7807689 | Jun 27, 2028 | DS DP U-1337 | | | |
| | | 8173663 | Dec 02, 2025 | U-1338 | | | |
| | | 8288539 | Mar 15, 2025 | DS | | | |
| | | 8697125 | Jun 16, 2029 | DP | | | |
| ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO | | | | | | | |
| N 203414 | 001 | 6890898 | Feb 02, 2019 | U-1335 | | M-177 | Apr 05, 2019 |
| | | 7078381 | Feb 02, 2019 | U-1335 | | NCE | Jan 25, 2018 |
| | | 7459428 | Feb 02, 2019 | U-1336 | | | |
| | | 7807689 | Jun 27, 2028 | DS DP U-1337 | | | |
| | | 8173663 | Mar 15, 2025 | U-1338 | | | |
| | | 8288539 | Jun 24, 2025 | DS | | | |
| | | 8900638 | May 24, 2029 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO | | | | | | | |
| N 203414 | 002 | 6890898 | Feb 02, 2019 | U-1335 | | M-177 | Apr 05, 2019 |
| | | 7078381 | Feb 02, 2019 | U-1335 | | NCE | Jan 25, 2018 |
| | | 7459428 | Feb 02, 2019 | U-1336 | | | |
| | | 7807689 | Jun 27, 2028 | DS DP U-1337 | | | |
| | | 8173663 | Mar 15, 2025 | U-1338 | | | |
| | | 8288539 | Jun 24, 2025 | DS | | | |
| | | 8900638 | May 24, 2029 | DP | | | |
| ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI | | | | | | | |
| N 022426 | 001 | 6329404 | Jun 19, 2021 | DP U-1334 | | M-177 | Apr 05, 2019 |
| | | 6890898 | Feb 02, 2019 | U-1335 | | NCE | Jan 25, 2018 |
| | | 7078381 | Feb 02, 2019 | U-1335 | | | |
| | | 7459428 | Feb 02, 2019 | U-1336 | | | |
| | | 7807689 | Jun 27, 2028 | DS DP U-1337 | | | |
| | | 8173663 | Mar 15, 2025 | U-1338 | | | |
| | | 8288539 | Mar 15, 2025 | DS | | | |
| | | 8637079 | Jun 04, 2029 | DP | | | |
| ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI | | | | | | | |
| N 022426 | 002 | 6329404 | Jun 19, 2021 | DP U-1334 | | M-177 | Apr 05, 2019 |
| | | 6890898 | Feb 02, 2019 | U-1335 | | NCE | Jan 25, 2018 |
| | | 7078381 | Feb 02, 2019 | U-1335 | | | |
| | | 7459428 | Feb 02, 2019 | U-1336 | | | |
| | | 7807689 | Jun 27, 2028 | DS DP U-1337 | | | |
| | | 8173663 | Mar 15, 2025 | U-1338 | | | |
| | | 8288539 | Mar 15, 2025 | DS | | | |
| | | 8637079 | Jun 04, 2029 | DP | | | |
| ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI | | | | | | | |
| N 022426 | 003 | 6329404 | Jun 19, 2021 | DP U-1334 | | M-177 | Apr 05, 2019 |
| | | 6890898 | Feb 02, 2019 | U-1335 | | NCE | Jan 25, 2018 |
| | | 7078381 | Feb 02, 2019 | U-1335 | | | |
| | | 7459428 | Feb 02, 2019 | U-1336 | | | |
| | | 7807689 | Jun 27, 2028 | DS DP U-1337 | | | |
| | | 8173663 | Mar 15, 2025 | U-1338 | | | |
| | | 8288539 | Mar 15, 2025 | DS | | | |
| | | 8637079 | Jun 04, 2029 | DP | | | |
| ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI | | | | | | | |
| N 022426 | 004 | 6329404 | Jun 19, 2021 | DP U-1334 | | M-177 | Apr 05, 2019 |
| | | 6890898 | Feb 02, 2019 | U-1335 | | NCE | Jan 25, 2018 |
| | | 7078381 | Feb 02, 2019 | U-1335 | | | |
| | | 7459428 | Feb 02, 2019 | U-1336 | | | |
| | | 7807689 | Jun 27, 2028 | DS DP U-1337 | | | |
| | | 8173663 | Mar 15, 2025 | U-1338 | | | |
| | | 8288539 | Mar 15, 2025 | DS | | | |
| | | 8637079 | Jun 04, 2029 | DP | | | |
| ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI | | | | | | | |
| N 022426 | 005 | 6329404 | Jun 19, 2021 | DP U-1334 | | M-177 | Apr 05, 2019 |
| | | 6890898 | Feb 02, 2019 | U-1335 | | NCE | Jan 25, 2018 |
| | | 7078381 | Feb 02, 2019 | U-1335 | | | |
| | | 7459428 | Feb 02, 2019 | U-1336 | | | |
| | | 7807689 | Jun 27, 2028 | DS DP U-1337 | | | |
| | | 8173663 | Mar 15, 2025 | U-1338 | | | |
| | | 8288539 | Mar 15, 2025 | DS | | | |
| | | 8637079 | Jun 04, 2029 | DP | | | |
| ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI | | | | | | | |
| N 022426 | 006 | 6890898 | Feb 02, 2019 | U-1335 | | M-177 | Apr 05, 2019 |
| | | 7078381 | Feb 02, 2019 | U-1335 | | NCE | Jan 25, 2018 |
| | | 7459428 | Feb 02, 2019 | U-1336 | | | |
| | | 7807689 | Jun 27, 2028 | DS DP U-1337 | | | |
| | | 8173663 | Mar 15, 2025 | U-1338 | | | |
| | | 8288539 | Mar 15, 2025 | DS | | | |
| | | 8637079 | Jun 04, 2029 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| ALPRAZOLAM - NIRAVAM | | | | | | | |
| N 021726 | 001 | 6024981 | Apr 09, 2018 | DP | | | |
| | | 6221392 | Apr 09, 2018 | DP | | | |
| ALPRAZOLAM - NIRAVAM | | | | | | | |
| N 021726 | 002 | 6024981 | Apr 09, 2018 | DP | | | |
| | | 6221392 | Apr 09, 2018 | DP | | | |
| ALPRAZOLAM - NIRAVAM | | | | | | | |
| N 021726 | 003 | 6024981 | Apr 09, 2018 | DP | | | |
| | | 6221392 | Apr 09, 2018 | DP | | | |
| ALPRAZOLAM - NIRAVAM | | | | | | | |
| N 021726 | 004 | 6024981 | Apr 09, 2018 | DP | | | |
| | | 6221392 | Apr 09, 2018 | DP | | | |
| ALVIMOPAN - ENTEREG | | | | | | | |
| N 021775 | 001 | 6469030 | Nov 29, 2020 | U-879 | | | |
| | | 8112290 | Jul 31, 2030 | U-1443 | Y | | |
| | | 8645160 | Jun 18, 2029 | U-1485 | Y | | |
| | | 8946262 | Feb 12, 2030 | U-1655 | | | |
| AMANTADINE HYDROCHLORIDE - GOCOVRI | | | | | | | |
| N 208944 | 001 | 8389578 | Jan 22, 2028 | U-2105 | | NP | Aug 24, 2020 |
| | | 8741343 | Dec 02, 2030 | U-2106 | | ODE-153 | Aug 24, 2024 |
| | | 8796337 | Nov 23, 2025 | U-2106 | | | |
| | | 8889740 | Nov 23, 2025 | DP | | | |
| | | 8895614 | Nov 23, 2025 | DP | | | |
| | | 8895615 | Nov 23, 2025 | U-2106 | | | |
| | | 8895616 | Nov 23, 2025 | U-2106 | | | |
| | | 8895617 | Nov 23, 2025 | U-2106 | | | |
| | | 8895618 | Nov 23, 2025 | DP | | | |
| AMANTADINE HYDROCHLORIDE - GOCOVRI | | | | | | | |
| N 208944 | 002 | 8389578 | Jan 22, 2028 | U-2105 | | NP | Aug 24, 2020 |
| | | 8741343 | Dec 02, 2030 | U-2106 | | ODE | Aug 24, 2024 |
| | | 8796337 | Nov 23, 2025 | U-2106 | | | |
| | | 8889740 | Nov 23, 2025 | DP | | | |
| | | 8895614 | Nov 23, 2025 | DP | | | |
| | | 8895615 | Nov 23, 2025 | U-2106 | | | |
| | | 8895616 | Nov 23, 2025 | U-2106 | | | |
| | | 8895617 | Nov 23, 2025 | U-2106 | | | |
| | | 8895618 | Nov 23, 2025 | DP | | | |
| AMBRISENTAN - LETAIRIS | | | | | | | |
| N 022081 | 001 | 8377933 | Dec 11, 2027 | U-1754 | | I-716 | Oct 02, 2018 |
| | | 9474752 | Dec 11, 2027 | U-1754 | | | |
| | | 9549926 | Oct 14, 2031 | U-1965 | | | |
| | | RE42462 | Jul 29, 2018 | DS | | | |
| AMBRISENTAN - LETAIRIS | | | | | | | |
| N 022081 | 002 | 8377933 | Dec 11, 2027 | U-1754 | | I-716 | Oct 02, 2018 |
| | | 9474752 | Dec 11, 2027 | U-1754 | | | |
| | | 9549926 | Oct 14, 2031 | U-1965 | | | |
| | | RE42462 | Jul 29, 2018 | DS | | | |
| AMIFOSTINE - ETHYOL | | | | | | | |
| N 020221 | 001 | 5994409 | Dec 08, 2017 | U-305 | | | |
| AMIFOSTINE - ETHYOL | | | | | | | |
| N 020221 | 002 | 5994409 | Dec 08, 2017 | U-305 | | | |
| AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN | | | | | | | |
| N 020965 | 001 | 5954703 | Oct 31, 2017 | U-289 | | | |
| | | 6709446 | May 01, 2018 | U-289 | | | |
| | | 7723910 | Jun 17, 2019 | U-289 | | | |
| | | 8216289 | May 01, 2018 | U-289 | | | |
| | | 8758418 | May 01, 2018 | U-289 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|
| AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ | | | | | | | | |
| N 208081 | 001 | | 6559183 | Nov 12, 2019 | DP U-804 | | NP | May 10, 2019 |
| AMINOLEVULINIC ACID HYDROCHLORIDE - GLEOLAN | | | | | | | | |
| N 208630 | 001 | | | | | | ODE-146 | Jun 06, 2024 |
| AMIODARONE HYDROCHLORIDE - NEXTERONE | | | | | | | | |
| N 022325 | 001 | | 6869939 | May 04, 2022 | DP | | | |
| | | | 7635773 | Mar 13, 2029 | DP | | | |
| AMIODARONE HYDROCHLORIDE - NEXTERONE | | | | | | | | |
| N 022325 | 002 | | 6869939 | May 04, 2022 | DP | | | |
| | | | 7635773 | Mar 13, 2029 | DP | | | |
| AMIODARONE HYDROCHLORIDE - NEXTERONE | | | | | | | | |
| N 022325 | 003 | | 6869939 | May 04, 2022 | DP | | | |
| | | | 7635773 | Mar 13, 2029 | DP | | | |
| AMLODIPINE BESYLATE - AMLODIPINE BESYLATE | | | | | | | | |
| N 022026 | 001 | | 6828339 | Nov 20, 2022 | DS | | | |
| AMLODIPINE BESYLATE - AMLODIPINE BESYLATE | | | | | | | | |
| N 022026 | 002 | | 6828339 | Nov 20, 2022 | DS | | | |
| AMLODIPINE BESYLATE - AMLODIPINE BESYLATE | | | | | | | | |
| N 022026 | 003 | | 6828339 | Nov 20, 2022 | DS | | | |
| AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET | | | | | | | | |
| N 021540 | 001 | | 6455574 | Aug 11, 2018 | U-552 | | | |
| AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET | | | | | | | | |
| N 021540 | 002 | | 6455574 | Aug 11, 2018 | U-552 | | | |
| AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET | | | | | | | | |
| N 021540 | 003 | | 6455574 | Aug 11, 2018 | U-552 | | | |
| AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET | | | | | | | | |
| N 021540 | 004 | | 6455574 | Aug 11, 2018 | U-552 | | | |
| AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET | | | | | | | | |
| N 021540 | 005 | | 6455574 | Aug 11, 2018 | U-552 | | | |
| AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET | | | | | | | | |
| N 021540 | 006 | | 6455574 | Aug 11, 2018 | U-552 | | | |
| AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET | | | | | | | | |
| N 021540 | 007 | | 6455574 | Aug 11, 2018 | U-552 | | | |
| AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET | | | | | | | | |
| N 021540 | 008 | | 6455574 | Aug 11, 2018 | U-552 | | | |
| AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET | | | | | | | | |
| N 021540 | 009 | | 6455574 | Aug 11, 2018 | U-552 | | | |
| AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET | | | | | | | | |
| N 021540 | 010 | | 6455574 | Aug 11, 2018 | U-552 | | | |
| AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM - CADUET | | | | | | | | |
| N 021540 | 011 | | 6455574 | Aug 11, 2018 | U-552 | | | |
| AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL | | | | | | | | |
| N 020364 | 002 | | 6162802 | Dec 19, 2017 | U-367 | | | |
| AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL | | | | | | | | |
| N 020364 | 003 | | 6162802 | Dec 19, 2017 | U-367 | | | |
| AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL | | | | | | | | |
| N 020364 | 004 | | 6162802 | Dec 19, 2017 | U-367 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL | | | | | | | |
| N 020364 | 005 | 6162802 | Dec 19, 2017 | U-367 | | | |
| AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL | | | | | | | |
| N 020364 | 006 | 6162802 | Dec 19, 2017 | DS DP U-185 | | | |
| AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE - LOTREL | | | | | | | |
| N 020364 | 007 | 6162802 | Dec 19, 2017 | DS DP U-185 | | | |
| AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT | | | | | | | |
| N 022314 | 001 | 8101599 | May 16, 2023 | DP | | | |
| | | 8475839 | May 16, 2023 | DP | | | |
| | | 8475839*PED | Nov 16, 2023 | | | | |
| AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT | | | | | | | |
| N 022314 | 002 | 8101599 | May 16, 2023 | DP | | | |
| | | 8475839 | May 16, 2023 | DP | | | |
| | | 8475839*PED | Nov 16, 2023 | | | | |
| AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT | | | | | | | |
| N 022314 | 003 | 8101599 | May 16, 2023 | DP | | | |
| | | 8475839 | May 16, 2023 | DP | | | |
| | | 8475839*PED | Nov 16, 2023 | | | | |
| AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT | | | | | | | |
| N 022314 | 004 | 8101599 | May 16, 2023 | DP | | | |
| | | 8475839 | May 16, 2023 | DP | | | |
| | | 8475839*PED | Nov 16, 2023 | | | | |
| AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT | | | | | | | |
| N 022314 | 005 | 8101599 | May 16, 2023 | DP | | | |
| | | 8475839 | May 16, 2023 | DP | | | |
| | | 8475839*PED | Nov 16, 2023 | | | | |
| AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA | | | | | | | |
| N 205003 | 001 | 6696481 | Apr 15, 2023 | DS DP U-3 | | NP | Jan 21, 2018 |
| | | 7846961 | Oct 05, 2029 | DS DP U-3 | | | |
| AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA | | | | | | | |
| N 205003 | 002 | 6696481 | Apr 15, 2023 | DS DP U-3 | | NP | Jan 21, 2018 |
| | | 7846961 | Oct 05, 2029 | DS DP U-3 | | | |
| AMLODIPINE BESYLATE; PERINDOPRIL ARGININE - PRESTALIA | | | | | | | |
| N 205003 | 003 | 6696481 | Apr 15, 2023 | DS DP U-3 | | NP | Jan 21, 2018 |
| | | 7846961 | Oct 05, 2029 | DS DP U-3 | | | |
| AMLODIPINE BESYLATE; VALSARTAN - EXFORGE | | | | | | | |
| N 021990 | 002 | 6395728 | Jul 08, 2019 | DP | | | |
| AMLODIPINE BESYLATE; VALSARTAN - EXFORGE | | | | | | | |
| N 021990 | 003 | 6395728 | Jul 08, 2019 | DP | | | |
| AMLODIPINE BESYLATE; VALSARTAN - EXFORGE | | | | | | | |
| N 021990 | 004 | 6395728 | Jul 08, 2019 | DP | | | |
| AMLODIPINE BESYLATE; VALSARTAN - EXFORGE | | | | | | | |
| N 021990 | 005 | 6395728 | Jul 08, 2019 | DP | | | |
| AMOXICILLIN - MOXATAG | | | | | | | |
| N 050813 | 001 | 6544555 | Oct 13, 2020 | DS DP U-897 | | | |
| | | 6669948 | Oct 13, 2020 | DS DP U-897 | | | |
| | | 6723341 | Oct 13, 2020 | DS DP U-897 | | | |
| | | 8299052 | May 07, 2027 | U-1304 | | | |
| | | 8357394 | Dec 08, 2026 | DP | | | |
| | | 8778924 | Dec 08, 2026 | DS DP U-897 | | | |
| AMOXICILLIN; CLAVULANATE POTASSIUM - AUGMENTIN XR | | | | | | | |
| N 050785 | 001 | 6746692 | Apr 04, 2020 | DP | | | |
| | | 6783773 | Apr 04, 2020 | DP | | | |
| | | 6878386 | Apr 04, 2020 | U-926 | | | |
| | | 7217430 | Apr 04, 2020 | DP U-926 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|
| AMOXICILLIN; CLAVULANATE POTASSIUM - AUGMENTIN XR | | | | | | | | |
| N | 050785 | 001 | 7250176 | Apr 04, 2020 | U-926 | | | |
| AMPHETAMINE - ADZENYS ER | | | | | | | | |
| N | 204325 | 001 | 8709491 | Jun 28, 2032 | DP | | | |
| | | | 9017731 | Jun 28, 2032 | DP | | | |
| | | | 9265737 | Jun 28, 2032 | DP | | | |
| AMPHETAMINE - ADZENYS XR-ODT | | | | | | | | |
| N | 204326 | 001 | 8709491 | Jun 28, 2032 | DP | | | |
| | | | 8840924 | Apr 09, 2026 | DP | | | |
| | | | 9017731 | Jun 28, 2032 | DP | | | |
| | | | 9265737 | Jun 28, 2032 | DP | | | |
| AMPHETAMINE - ADZENYS XR-ODT | | | | | | | | |
| N | 204326 | 002 | 8709491 | Jun 28, 2032 | DP | | | |
| | | | 8840924 | Apr 09, 2026 | DP | | | |
| | | | 9017731 | Jun 28, 2032 | DP | | | |
| | | | 9265737 | Jun 28, 2032 | DP | | | |
| AMPHETAMINE - ADZENYS XR-ODT | | | | | | | | |
| N | 204326 | 003 | 8709491 | Jun 28, 2032 | DP | | | |
| | | | 8840924 | Apr 09, 2026 | DP | | | |
| | | | 9017731 | Jun 28, 2032 | DP | | | |
| | | | 9265737 | Jun 28, 2032 | DP | | | |
| AMPHETAMINE - ADZENYS XR-ODT | | | | | | | | |
| N | 204326 | 004 | 8709491 | Jun 28, 2032 | DP | | | |
| | | | 8840924 | Apr 09, 2026 | DP | | | |
| | | | 9017731 | Jun 28, 2032 | DP | | | |
| | | | 9265737 | Jun 28, 2032 | DP | | | |
| AMPHETAMINE - ADZENYS XR-ODT | | | | | | | | |
| N | 204326 | 005 | 8709491 | Jun 28, 2032 | DP | | | |
| | | | 8840924 | Apr 09, 2026 | DP | | | |
| | | | 9017731 | Jun 28, 2032 | DP | | | |
| | | | 9265737 | Jun 28, 2032 | DP | | | |
| AMPHETAMINE - ADZENYS XR-ODT | | | | | | | | |
| N | 204326 | 006 | 8709491 | Jun 28, 2032 | DP | | | |
| | | | 8840924 | Apr 09, 2026 | DP | | | |
| | | | 9017731 | Jun 28, 2032 | DP | | | |
| | | | 9265737 | Jun 28, 2032 | DP | | | |
| AMPHETAMINE - DYANAVEL XR | | | | | | | | |
| N | 208147 | 001 | 8062667 | Mar 29, 2029 | DP | | NP | Oct 19, 2018 |
| | | | 8597684 | Mar 15, 2027 | DP | | | |
| | | | 8747902 | Mar 15, 2027 | DP | | | |
| | | | 8883217 | Mar 15, 2027 | DP | | | |
| | | | 9675703 | Mar 15, 2027 | DP | | | |
| AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 10 | | | | | | | | |
| N | 011522 | 007 | 6384020 | Jul 06, 2020 | | | | |
| AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 20 | | | | | | | | |
| N | 011522 | 008 | 6384020 | Jul 06, 2020 | | | | |
| AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 5 | | | | | | | | |
| N | 011522 | 009 | 6384020 | Jul 06, 2020 | | | | |
| AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 30 | | | | | | | | |
| N | 011522 | 010 | 6384020 | Jul 06, 2020 | | | | |
| AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 7.5 | | | | | | | | |
| N | 011522 | 011 | 6384020 | Jul 06, 2020 | | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|
| AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 12.5 | | | | | | | | |
| N | 011522 | 012 | 6384020 | Jul 06, 2020 | | | | |
| AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL 15 | | | | | | | | |
| N | 011522 | 013 | 6384020 | Jul 06, 2020 | | | | |
| AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 10 | | | | | | | | |
| N | 021303 | 001 | 6322819 | Oct 21, 2018 | | | | |
| | | | 6605300 | Oct 21, 2018 | | | | |
| | | | RE41148 | Oct 21, 2018 | DP | | | |
| | | | RE42096 | Oct 21, 2018 | DP | | | |
| AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 20 | | | | | | | | |
| N | 021303 | 002 | 6322819 | Oct 21, 2018 | | | | |
| | | | 6605300 | Oct 21, 2018 | | | | |
| | | | RE41148 | Oct 21, 2018 | DP | | | |
| | | | RE42096 | Oct 21, 2018 | DP | | | |
| AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 30 | | | | | | | | |
| N | 021303 | 003 | 6322819 | Oct 21, 2018 | | | | |
| | | | 6605300 | Oct 21, 2018 | | | | |
| | | | RE41148 | Oct 21, 2018 | DP | | | |
| | | | RE42096 | Oct 21, 2018 | DP | | | |
| AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 25 | | | | | | | | |
| N | 021303 | 004 | 6322819 | Oct 21, 2018 | | | | |
| | | | 6605300 | Oct 21, 2018 | | | | |
| | | | RE41148 | Oct 21, 2018 | DP | | | |
| | | | RE42096 | Oct 21, 2018 | DP | | | |
| AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 5 | | | | | | | | |
| N | 021303 | 005 | 6322819 | Oct 21, 2018 | | | | |
| | | | 6605300 | Oct 21, 2018 | | | | |
| | | | RE41148 | Oct 21, 2018 | DP | | | |
| | | | RE42096 | Oct 21, 2018 | DP | | | |
| AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - ADDERALL XR 15 | | | | | | | | |
| N | 021303 | 006 | 6322819 | Oct 21, 2018 | | | | |
| | | | 6605300 | Oct 21, 2018 | | | | |
| | | | RE41148 | Oct 21, 2018 | DP | | | |
| | | | RE42096 | Oct 21, 2018 | DP | | | |
| AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS | | | | | | | | |
| N | 022063 | 001 | 6913768 | May 24, 2023 | DP | U-2025 | NP | Jun 20, 2020 |
| | | | 8846100 | Aug 24, 2029 | DP | | | |
| | | | 9173857 | May 12, 2026 | | U-2025 | | |
| | | | RE41148 | Oct 21, 2018 | DP | | | |
| | | | RE42096 | Oct 21, 2018 | DP | | | |
| AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS | | | | | | | | |
| N | 022063 | 002 | 6913768 | May 24, 2023 | DP | U-2025 | NP | Jun 20, 2020 |
| | | | 8846100 | Aug 24, 2029 | DP | | | |
| | | | 9173857 | May 12, 2026 | | U-2025 | | |
| | | | RE41148 | Oct 21, 2018 | DP | | | |
| | | | RE42096 | Oct 21, 2018 | DP | | | |
| AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS | | | | | | | | |
| N | 022063 | 003 | 6913768 | May 24, 2023 | DP | U-2025 | NP | Jun 20, 2020 |
| | | | 8846100 | Aug 24, 2029 | DP | | | |
| | | | 9173857 | May 12, 2026 | | U-2025 | | |
| | | | RE41148 | Oct 21, 2018 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS | | | | | | | |
| N 022063 | 003 | RE42096 | Oct 21, 2018 | DP | | | |
| AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE - MYDAYIS | | | | | | | |
| N 022063 | 004 | 6913768 | May 24, 2023 | DP U-2025 | | NP | Jun 20, 2020 |
| | | 8846100 | Aug 24, 2029 | DP | | | |
| | | 9173857 | May 12, 2026 | U-2025 | | | |
| | | RE41148 | Oct 21, 2018 | DP | | | |
| | | RE42096 | Oct 21, 2018 | DP | | | |
| AMPHOTERICIN B - ABELCET | | | | | | | |
| N 050724 | 001 | 6406713 | Jun 18, 2019 | DS | | | |
| AMPRENAVIR - AGENERASE | | | | | | | |
| N 021007 | 001 | 6730679 | Nov 11, 2017 | DP | | | |
| AMPRENAVIR - AGENERASE | | | | | | | |
| N 021007 | 002 | 6730679 | Nov 11, 2017 | DP | | | |
| ANIDULAFUNGIN - ERAXIS | | | | | | | |
| N 021632 | 001 | 5965525 | Feb 17, 2020 | DS DP U-540 | | | |
| | | 6960564 | Apr 12, 2021 | DP U-540 | | | |
| | | 7709444 | Apr 12, 2021 | DP U-540 | | | |
| ANIDULAFUNGIN - ERAXIS | | | | | | | |
| N 021632 | 002 | 5965525 | Feb 17, 2020 | DS DP U-540 | | | |
| | | 6960564 | Apr 12, 2021 | DP U-540 | | | |
| | | 7709444 | Apr 12, 2021 | DP U-540 | | | |
| APIXABAN - ELIQUIS | | | | | | | |
| N 202155 | 001 | 6413980 | Dec 22, 2019 | DS DP U-1200 | | I-661 | Aug 21, 2017 |
| | | 6413980 | Dec 22, 2019 | DS DP U-1301 | | I-690 | Aug 21, 2017 |
| | | 6413980 | Dec 22, 2019 | DS DP U-1302 | | I-691 | Aug 21, 2017 |
| | | 6413980 | Dec 22, 2019 | DS DP U-1501 | | NCE | Dec 28, 2017 |
| | | 6967208 | Nov 21, 2026 | DS DP U-1167 | | | |
| | | 6967208 | Nov 21, 2026 | DS DP U-1200 | | | |
| | | 6967208 | Nov 21, 2026 | DS DP U-1301 | | | |
| | | 6967208 | Nov 21, 2026 | DS DP U-1302 | | | |
| | | 6967208 | Nov 21, 2026 | DS DP U-1323 | | | |
| | | 6967208 | Nov 21, 2026 | DS DP U-1501 | | | |
| | | 6967208 | Nov 21, 2026 | DS DP U-1502 | | | |
| | | 6967208 | Nov 21, 2026 | DS DP U-1729 | | | |
| | | 6967208 | Nov 21, 2026 | DS DP U-1730 | | | |
| | | 9326945 | Feb 24, 2031 | DP | | | |
| APIXABAN - ELIQUIS | | | | | | | |
| N 202155 | 002 | 6413980 | Dec 22, 2019 | DS DP U-1200 | | I-661 | Aug 21, 2017 |
| | | 6413980 | Dec 22, 2019 | DS DP U-1301 | | I-690 | Aug 21, 2017 |
| | | 6413980 | Dec 22, 2019 | DS DP U-1302 | | I-691 | Aug 21, 2017 |
| | | 6967208 | Nov 21, 2026 | DS DP U-1200 | | NCE | Dec 28, 2017 |
| | | 6967208 | Nov 21, 2026 | DS DP U-1301 | | | |
| | | 6967208 | Nov 21, 2026 | DS DP U-1302 | | | |
| | | 6967208 | Nov 21, 2026 | DS DP U-1323 | | | |
| | | 9326945 | Feb 24, 2031 | DP | | | |
| APREMILAST - OTEZLA | | | | | | | |
| N 205437 | 001 | 6020358 | Oct 30, 2018 | DS DP U-1504 | | I-694 | Sep 23, 2017 |
| | | 6962940 | Mar 19, 2023 | U-1504 | | NCE | Mar 21, 2019 |
| | | 7208516 | Mar 19, 2023 | U-1505 | | | |
| | | 7427638 | Nov 17, 2024 | DS DP | | | |
| | | 7659302 | Mar 19, 2023 | U-1505 | | | |
| | | 7659302 | Mar 19, 2023 | U-1595 | | | |
| | | 7893101 | Dec 09, 2023 | DS DP | | | |
| | | 8455536 | Mar 19, 2023 | U-1505 | | | |
| | | 8455536 | Mar 19, 2023 | U-1595 | | | |
| | | 8802717 | Mar 19, 2023 | U-1561 | | | |
| | | 9018243 | Mar 19, 2023 | U-1505 | | | |
| | | 9018243 | Mar 19, 2023 | U-1595 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| APREMILAST - OTEZLA | | | | | | | |
| N 205437 | 002 | 6020358 | Oct 30, 2018 | DS DP U-1504 | | I-694 | Sep 23, 2017 |
| | | 6962940 | Mar 19, 2023 | U-1504 | | NCE | Mar 21, 2019 |
| | | 7208516 | Mar 19, 2023 | U-1505 | | | |
| | | 7427638 | Nov 17, 2024 | DS DP | | | |
| | | 7659302 | Mar 19, 2023 | U-1505 | | | |
| | | 7659302 | Mar 19, 2023 | U-1595 | | | |
| | | 7893101 | Dec 09, 2023 | DS DP | | | |
| | | 8455536 | Mar 19, 2023 | U-1505 | | | |
| | | 8455536 | Mar 19, 2023 | U-1595 | | | |
| | | 8802717 | Mar 19, 2023 | U-1561 | | | |
| | | 9018243 | Mar 19, 2023 | U-1505 | | | |
| | | 9018243 | Mar 19, 2023 | U-1595 | | | |
| APREMILAST - OTEZLA | | | | | | | |
| N 205437 | 003 | 6020358 | Oct 30, 2018 | DS DP U-1504 | | I-694 | Sep 23, 2017 |
| | | 6962940 | Mar 19, 2023 | U-1504 | | NCE | Mar 21, 2019 |
| | | 7208516 | Mar 19, 2023 | U-1505 | | | |
| | | 7427638 | Nov 17, 2024 | DS DP | | | |
| | | 7659302 | Mar 19, 2023 | U-1505 | | | |
| | | 7659302 | Mar 19, 2023 | U-1595 | | | |
| | | 7893101 | Dec 09, 2023 | DS DP | | | |
| | | 8455536 | Mar 19, 2023 | U-1505 | | | |
| | | 8455536 | Mar 19, 2023 | U-1595 | | | |
| | | 8802717 | Mar 19, 2023 | U-1561 | | | |
| | | 9018243 | Mar 19, 2023 | U-1505 | | | |
| | | 9018243 | Mar 19, 2023 | U-1595 | | | |
| APREPITANT - EMEND | | | | | | | |
| N 021549 | 001 | 6096742 | Jul 01, 2018 | DS DP U-1743 | | NPP | Aug 28, 2018 |
| | | 6096742 | Jul 01, 2018 | DS DP U-1744 | | | |
| | | 6096742 | Jul 01, 2018 | DS DP U-745 | | | |
| | | 8258132 | Sep 26, 2027 | DP U-1743 | | | |
| | | 8258132 | Sep 26, 2027 | DP U-901 | | | |
| APREPITANT - EMEND | | | | | | | |
| N 021549 | 002 | 6096742 | Jul 01, 2018 | DS DP U-1743 | | NPP | Aug 28, 2018 |
| | | 6096742 | Jul 01, 2018 | DS DP U-1744 | | | |
| | | 6096742 | Jul 01, 2018 | DS DP U-745 | | | |
| | | 8258132 | Sep 26, 2027 | DP U-1743 | | | |
| | | 8258132 | Sep 26, 2027 | DP U-901 | | | |
| APREPITANT - EMEND | | | | | | | |
| N 021549 | 003 | 6096742 | Jul 01, 2018 | DS DP U-1743 | | NPP | Aug 28, 2018 |
| | | 6096742 | Jul 01, 2018 | DS DP U-1744 | | | |
| | | 6096742 | Jul 01, 2018 | DS DP U-745 | | | |
| | | 8258132 | Sep 26, 2027 | DP U-1743 | | | |
| | | 8258132 | Sep 26, 2027 | DP U-901 | | | |
| APREPITANT - EMEND | | | | | | | |
| N 207865 | 001 | 6096742 | Jul 01, 2018 | DS DP U-1916 | | NPP | Aug 28, 2018 |
| | | 8258132 | Sep 26, 2027 | DP U-1916 | | | |
| APREPITANT - CINVANTI | | | | | | | |
| N 209296 | 001 | 9561229 | Sep 18, 2035 | DP U-2161 | | | |
| | | 9808465 | Sep 18, 2035 | U-2161 | | | |
| ARFORMOTEROL TARTRATE - BROVANA | | | | | | | |
| N 021912 | 001 | 6472563 | Nov 09, 2021 | DS | | | |
| | | 6667344 | Jun 22, 2021 | DP | | | |
| | | 6720453 | Nov 09, 2021 | DS | | | |
| | | 6814953 | Jun 22, 2021 | U-793 | | | |
| | | 7145036 | Nov 09, 2021 | DS | | | |
| | | 7348362 | Jun 22, 2021 | DP U-793 | | | |
| | | 7462645 | Jun 22, 2021 | U-793 | | | |
| | | 7465756 | Jun 22, 2021 | DP | | | |
| | | 7473710 | Jun 22, 2021 | U-793 | | | |
| | | 7541385 | Jun 22, 2021 | U-793 | | | |
| | | 8110706 | Nov 09, 2021 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| ARGATROBAN - ARGATROBAN IN SODIUM CHLORIDE | | | | | | |
| N 022434 001 | 7589106 | Sep 26, 2027 | DP U-1163 | | | |
| | 7687516 | Sep 26, 2027 | DP U-1164 | | | |
| ARIPIPRAZOLE - ABILIFY | | | | | | |
| N 021436 001 | 7053092 | Jan 28, 2022 | U-839 | | I-700 | Dec 12, 2017 |
| | 8017615 | Jun 16, 2024 | DP | | ODE-80 | Dec 12, 2021 |
| | 8017615*PED | Dec 16, 2024 | | | | |
| | 8580796 | Sep 25, 2022 | DS | | | |
| | 8580796*PED | Mar 25, 2023 | | | | |
| | 8642600 | Jan 28, 2022 | U-1492 | | | |
| | 8642600*PED | Jul 28, 2022 | | | | |
| | 8642760 | Sep 25, 2022 | DS | | | |
| | 8642760*PED | Mar 25, 2023 | | | | |
| | 8759350 | Mar 02, 2027 | U-1529 | | | |
| | 9089567 | Jan 28, 2022 | U-543 | | | |
| | 9125939 | Jul 28, 2026 | U-1749 | | | |
| | 9359302 | Sep 25, 2022 | DS DP U-1859 | | | |
| | 9387182 | Dec 25, 2023 | U-1529 | | | |
| ARIPIPRAZOLE - ABILIFY | | | | | | |
| N 021436 002 | 7053092 | Jan 28, 2022 | U-839 | | I-700 | Dec 12, 2017 |
| | 8017615 | Jun 16, 2024 | DP | | ODE-80 | Dec 12, 2021 |
| | 8017615*PED | Dec 16, 2024 | | | | |
| | 8580796 | Sep 25, 2022 | DS | | | |
| | 8580796*PED | Mar 25, 2023 | | | | |
| | 8642600 | Jan 28, 2022 | U-1492 | | | |
| | 8642600*PED | Jul 28, 2022 | | | | |
| | 8642760 | Sep 25, 2022 | DS | | | |
| | 8642760*PED | Mar 25, 2023 | | | | |
| | 8759350 | Mar 02, 2027 | U-1529 | | | |
| | 9089567 | Jan 28, 2022 | U-543 | | | |
| | 9125939 | Jul 28, 2026 | U-1749 | | | |
| | 9359302 | Sep 25, 2022 | DS DP U-1859 | | | |
| | 9387182 | Dec 25, 2023 | U-1529 | | | |
| ARIPIPRAZOLE - ABILIFY | | | | | | |
| N 021436 003 | 7053092 | Jan 28, 2022 | U-839 | | I-700 | Dec 12, 2017 |
| | 8017615 | Jun 16, 2024 | DP | | ODE-80 | Dec 12, 2021 |
| | 8017615*PED | Dec 16, 2024 | | | | |
| | 8580796 | Sep 25, 2022 | DS | | | |
| | 8580796*PED | Mar 25, 2023 | | | | |
| | 8642600 | Jan 28, 2022 | U-1492 | | | |
| | 8642600*PED | Jul 28, 2022 | | | | |
| | 8642760 | Sep 25, 2022 | DS | | | |
| | 8642760*PED | Mar 25, 2023 | | | | |
| | 8759350 | Mar 02, 2027 | U-1529 | | | |
| | 9089567 | Jan 28, 2022 | U-543 | | | |
| | 9125939 | Jul 28, 2026 | U-1749 | | | |
| | 9359302 | Sep 25, 2022 | DS DP U-1859 | | | |
| | 9387182 | Dec 25, 2023 | U-1529 | | | |
| ARIPIPRAZOLE - ABILIFY | | | | | | |
| N 021436 004 | 7053092 | Jan 28, 2022 | U-839 | | I-700 | Dec 12, 2017 |
| | 8017615 | Jun 16, 2024 | DP | | ODE-80 | Dec 12, 2021 |
| | 8017615*PED | Dec 16, 2024 | | | | |
| | 8580796 | Sep 25, 2022 | DS | | | |
| | 8580796*PED | Mar 25, 2023 | | | | |
| | 8642600 | Jan 28, 2022 | U-1492 | | | |
| | 8642600*PED | Jul 28, 2022 | | | | |
| | 8642760 | Sep 25, 2022 | DS | | | |
| | 8642760*PED | Mar 25, 2023 | | | | |
| | 8759350 | Mar 02, 2027 | U-1529 | | | |
| | 9089567 | Jan 28, 2022 | U-543 | | | |
| | 9125939 | Jul 28, 2026 | U-1749 | | | |
| | 9359302 | Sep 25, 2022 | DS DP U-1859 | | | |
| | 9387182 | Dec 25, 2023 | U-1529 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| ARIPIPRAZOLE - ABILIFY | | | | | | |
| N 021436 005 | 7053092 | Jan 28, 2022 | U-839 | | I-700 | Dec 12, 2017 |
| | 8017615 | Jun 16, 2024 | DP | | ODE-80 | Dec 12, 2021 |
| | 8017615*PED | Dec 16, 2024 | | | | |
| | 8580796 | Sep 25, 2022 | DS | | | |
| | 8580796*PED | Mar 25, 2023 | | | | |
| | 8642600 | Jan 28, 2022 | U-1492 | | | |
| | 8642600*PED | Jul 28, 2022 | | | | |
| | 8642760 | Sep 25, 2022 | DS | | | |
| | 8642760*PED | Mar 25, 2023 | | | | |
| | 8759350 | Mar 02, 2027 | U-1529 | | | |
| | 9089567 | Jan 28, 2022 | U-543 | | | |
| | 9125939 | Jul 28, 2026 | U-1749 | | | |
| | 9359302 | Sep 25, 2022 | DS DP U-1859 | | | |
| | 9387182 | Dec 25, 2023 | U-1529 | | | |
| ARIPIPRAZOLE - ABILIFY | | | | | | |
| N 021436 006 | 7053092 | Jan 28, 2022 | U-839 | | I-700 | Dec 12, 2017 |
| | 8017615 | Jun 16, 2024 | DP | | ODE-80 | Dec 12, 2021 |
| | 8017615*PED | Dec 16, 2024 | | | | |
| | 8580796 | Sep 25, 2022 | DS | | | |
| | 8580796*PED | Mar 25, 2023 | | | | |
| | 8642600 | Jan 28, 2022 | U-1492 | | | |
| | 8642600*PED | Jul 28, 2022 | | | | |
| | 8642760 | Sep 25, 2022 | DS | | | |
| | 8642760*PED | Mar 25, 2023 | | | | |
| | 8759350 | Mar 02, 2027 | U-1529 | | | |
| | 9089567 | Jan 28, 2022 | U-543 | | | |
| | 9125939 | Jul 28, 2026 | U-1749 | | | |
| | 9359302 | Sep 25, 2022 | DS DP U-1859 | | | |
| | 9387182 | Dec 25, 2023 | U-1529 | | | |
| ARIPIPRAZOLE - ABILIFY | | | | | | |
| N 021713 001 | 6977257 | Apr 24, 2022 | DP | | I-700 | Dec 12, 2017 |
| | 6977257*PED | Oct 24, 2022 | | | ODE-80 | Dec 12, 2021 |
| | 7053092 | Jan 28, 2022 | U-839 | | | |
| | 8642600 | Jan 28, 2022 | U-1492 | | | |
| | 8642600*PED | Jul 28, 2022 | | | | |
| | 8759350 | Mar 02, 2027 | U-1529 | | | |
| | 9387182 | Dec 25, 2023 | U-1529 | | | |
| ARIPIPRAZOLE - ABILIFY | | | | | | |
| N 021729 002 | 7053092 | Jan 28, 2022 | U-839 | | I-700 | Dec 12, 2017 |
| | 8017615 | Jun 16, 2024 | DP | | ODE-80 | Dec 12, 2021 |
| | 8017615*PED | Dec 16, 2024 | | | | |
| | 8518421 | Jan 24, 2021 | DP | | | |
| | 8518421*PED | Jul 24, 2021 | | | | |
| | 8580796 | Sep 25, 2022 | DS | | | |
| | 8580796*PED | Mar 25, 2023 | | | | |
| | 8642600 | Jan 28, 2022 | U-1492 | | | |
| | 8642600*PED | Jul 28, 2022 | | | | |
| | 8642760 | Sep 25, 2022 | DS | | | |
| | 8642760*PED | Mar 25, 2023 | | | | |
| | 8759350 | Mar 02, 2027 | U-1529 | | | |
| | 9089567 | Jan 28, 2022 | U-543 | | | |
| | 9125939 | Jul 28, 2026 | U-1749 | | | |
| | 9358207 | Apr 12, 2020 | DP | | | |
| | 9359302 | Sep 25, 2022 | DS DP U-1859 | | | |
| | 9387182 | Dec 25, 2023 | U-1529 | | | |
| ARIPIPRAZOLE - ABILIFY | | | | | | |
| N 021729 003 | 7053092 | Jan 28, 2022 | U-839 | | I-700 | Dec 12, 2017 |
| | 8017615 | Jun 16, 2024 | DP | | ODE-80 | Dec 12, 2021 |
| | 8017615*PED | Dec 16, 2024 | | | | |
| | 8518421 | Jan 24, 2021 | DP | | | |
| | 8518421*PED | Jul 24, 2021 | | | | |
| | 8580796 | Sep 25, 2022 | DS | | | |
| | 8580796*PED | Mar 25, 2023 | | | | |
| | 8642600 | Jan 28, 2022 | U-1492 | | | |
| | 8642600*PED | Jul 28, 2022 | | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| ARIPIPRAZOLE - ABILIFY | | | | | | |
| N 021729 003 | 8642760 | Sep 25, 2022 | DS | | | |
| | 8642760*PED | Mar 25, 2023 | | | | |
| | 8759350 | Mar 02, 2027 | U-1529 | | | |
| | 9089567 | Jan 28, 2022 | U-543 | | | |
| | 9125939 | Jul 28, 2026 | U-1749 | | | |
| | 9358207 | Apr 12, 2020 | DP | | | |
| | 9359302 | Sep 25, 2022 | DS DP U-1859 | | | |
| | 9387182 | Dec 25, 2023 | U-1529 | | | |
| ARIPIPRAZOLE - ABILIFY | | | | | | |
| N 021729 004 | 7053092 | Jan 28, 2022 | U-839 | | I-700 | Dec 12, 2017 |
| | 8017615 | Jun 16, 2024 | DP | | ODE-80 | Dec 12, 2021 |
| | 8017615*PED | Dec 16, 2024 | | | | |
| | 8518421 | Jan 24, 2021 | DP | | | |
| | 8518421*PED | Jul 24, 2021 | | | | |
| | 8580796 | Sep 25, 2022 | DS | | | |
| | 8580796*PED | Mar 25, 2023 | | | | |
| | 8642600 | Jan 28, 2022 | U-1492 | | | |
| | 8642600*PED | Jul 28, 2022 | | | | |
| | 8642760 | Sep 25, 2022 | DS | | | |
| | 8642760*PED | Mar 25, 2023 | | | | |
| | 9358207 | Apr 12, 2020 | DP | | | |
| | 9359302 | Sep 25, 2022 | DS DP U-1859 | | | |
| | 9387182 | Dec 25, 2023 | U-1529 | | | |
| ARIPIPRAZOLE - ABILIFY | | | | | | |
| N 021729 005 | 7053092 | Jan 28, 2022 | U-839 | | I-700 | Dec 12, 2017 |
| | 8017615 | Jun 16, 2024 | DP | | ODE-80 | Dec 12, 2021 |
| | 8017615*PED | Dec 16, 2024 | | | | |
| | 8518421 | Jan 24, 2021 | DP | | | |
| | 8518421*PED | Jul 24, 2021 | | | | |
| | 8580796 | Sep 25, 2022 | DS | | | |
| | 8580796*PED | Mar 25, 2023 | | | | |
| | 8642600 | Jan 28, 2022 | U-1492 | | | |
| | 8642600*PED | Jul 28, 2022 | | | | |
| | 8642760 | Sep 25, 2022 | DS | | | |
| | 8642760*PED | Mar 25, 2023 | | | | |
| | 9358207 | Apr 12, 2020 | DP | | | |
| | 9359302 | Sep 25, 2022 | DS DP U-1859 | | | |
| | 9387182 | Dec 25, 2023 | U-1529 | | | |
| ARIPIPRAZOLE - ABILIFY | | | | | | |
| N 021866 001 | 7115587 | Jul 21, 2024 | DP U-764 | | I-700 | Dec 12, 2017 |
| | 7115587*PED | Jan 21, 2025 | | | ODE-80 | Dec 12, 2021 |
| | 7550445 | Jul 21, 2024 | DP | | | |
| ARIPIPRAZOLE - ABILIFY MAINTENA KIT | | | | | | |
| N 202971 001 | 7807680 | Oct 19, 2024 | DP | | I-746 | Jul 27, 2020 |
| | 8030313 | Oct 19, 2024 | U-1632 | | M-150 | Dec 05, 2017 |
| | 8030313 | Oct 19, 2024 | U-543 | | | |
| | 8338427 | Mar 15, 2025 | DP U-1633 | | | |
| | 8338427 | Mar 15, 2025 | DP U-543 | | | |
| | 8338428 | Aug 06, 2023 | DP U-1633 | | | |
| | 8338428 | Aug 06, 2023 | DP U-543 | | | |
| | 8399469 | Jun 29, 2025 | DS | | | |
| | 8722679 | Oct 19, 2024 | DP | | | |
| | 8759351 | Aug 06, 2023 | DP U-1530 | | | |
| | 8759351 | Aug 06, 2023 | DP U-1633 | | | |
| | 8993761 | Sep 25, 2022 | DS | | | |
| | 9089567 | Jan 28, 2022 | U-543 | | | |
| ARIPIPRAZOLE - ABILIFY MAINTENA KIT | | | | | | |
| N 202971 002 | 7807680 | Oct 19, 2024 | DP | | I-746 | Jul 27, 2020 |
| | 8030313 | Oct 19, 2024 | U-1632 | | M-150 | Dec 05, 2017 |
| | 8030313 | Oct 19, 2024 | U-543 | | | |
| | 8338427 | Mar 15, 2025 | DP U-1633 | | | |
| | 8338427 | Mar 15, 2025 | DP U-543 | | | |
| | 8338428 | Aug 06, 2023 | DP U-1633 | | | |
| | 8338428 | Aug 06, 2023 | DP U-543 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| ARIPIPRAZOLE - ABILIFY MAINTENA KIT | | | | | | |
| N 202971 002 | 8399469 | Jun 29, 2025 | DS | | | |
| | 8722679 | Oct 19, 2024 | DP | | | |
| | 8759351 | Aug 06, 2023 | DP U-1530 | | | |
| | 8759351 | Aug 06, 2023 | DP U-1633 | | | |
| | 8993761 | Sep 25, 2022 | DS | | | |
| | 9089567 | Jan 28, 2022 | U-543 | | | |
| ARIPIPRAZOLE - ABILIFY MAINTENA KIT | | | | | | |
| N 202971 003 | 7807680 | Oct 19, 2024 | DP | | I-746 | Jul 27, 2020 |
| | 8030313 | Oct 19, 2024 | U-1632 | | M-150 | Dec 05, 2017 |
| | 8030313 | Oct 19, 2024 | U-543 | | | |
| | 8338427 | Mar 15, 2025 | DP U-1633 | | | |
| | 8338427 | Mar 15, 2025 | DP U-543 | | | |
| | 8338428 | Aug 06, 2023 | DP U-1633 | | | |
| | 8338428 | Aug 06, 2023 | DP U-543 | | | |
| | 8399469 | Jun 29, 2025 | DS | | | |
| | 8722679 | Oct 19, 2024 | DP | | | |
| | 8759351 | Aug 06, 2023 | DP U-1530 | | | |
| | 8759351 | Aug 06, 2023 | DP U-1633 | | | |
| | 8993761 | Sep 25, 2022 | DS | | | |
| | 9089567 | Jan 28, 2022 | U-543 | | | |
| ARIPIPRAZOLE - ABILIFY MAINTENA KIT | | | | | | |
| N 202971 004 | 7807680 | Oct 19, 2024 | DP | | I-746 | Jul 27, 2020 |
| | 8030313 | Oct 19, 2024 | U-1632 | | M-150 | Dec 05, 2017 |
| | 8030313 | Oct 19, 2024 | U-543 | | | |
| | 8338427 | Mar 15, 2025 | DP U-1633 | | | |
| | 8338427 | Mar 15, 2025 | DP U-543 | | | |
| | 8338428 | Aug 06, 2023 | DP U-1633 | | | |
| | 8338428 | Aug 06, 2023 | DP U-543 | | | |
| | 8399469 | Jun 29, 2025 | DS | | | |
| | 8722679 | Oct 19, 2024 | DP | | | |
| | 8759351 | Aug 06, 2023 | DP U-1530 | | | |
| | 8759351 | Aug 06, 2023 | DP U-1633 | | | |
| | 8993761 | Sep 25, 2022 | DS | | | |
| | 9089567 | Jan 28, 2022 | U-543 | | | |
| ARIPIPRAZOLE - ABILIFY MYCITE KIT | | | | | | |
| N 207202 001 | 7053092 | Jan 28, 2022 | U-1529 | | I-746 | Jul 27, 2020 |
| | 7978064 | Sep 14, 2026 | DP | | M-150 | Dec 05, 2017 |
| | 8017615 | Jun 16, 2024 | DP | | | |
| | 8114021 | Nov 02, 2026 | DP | | | |
| | 8258962 | Nov 25, 2030 | DP | | | |
| | 8545402 | Apr 27, 2030 | DP | | | |
| | 8547248 | Dec 18, 2030 | DP U-2167 | | | |
| | 8580796 | Sep 25, 2022 | DS | | | |
| | 8642760 | Sep 25, 2022 | DS | | | |
| | 8674825 | Apr 09, 2029 | DP U-2170 | | | |
| | 8718193 | Dec 05, 2029 | DP | | | |
| | 8759350 | Mar 02, 2027 | U-1529 | | | |
| | 8847766 | Mar 29, 2030 | DP U-2167 | | | |
| | 8945005 | Aug 19, 2029 | DP U-2167 | | | |
| | 8956288 | Jul 06, 2029 | DP U-2167 | | | |
| | 8961412 | Nov 17, 2030 | DP | | | |
| | 9060708 | Mar 05, 2029 | DP | | | |
| | 9089567 | Jan 28, 2022 | U-543 | | | |
| | 9119554 | Dec 16, 2028 | DP | | | |
| | 9125939 | Jul 28, 2026 | U-1749 | | | |
| | 9149577 | Dec 15, 2029 | DP | | | |
| | 9258035 | Mar 05, 2029 | DP | | | |
| | 9268909 | Oct 15, 2033 | DP U-2168 | | | |
| | 9270503 | Sep 19, 2034 | DP U-2169 | | | |
| | 9320455 | Dec 15, 2031 | DP | | | |
| | 9359302 | Sep 25, 2022 | DS DP U-1529 | | | |
| | 9359302 | Sep 25, 2022 | DS DP U-1749 | | | |
| | 9359302 | Sep 25, 2022 | DS DP U-543 | | | |
| | 9387182 | Dec 25, 2023 | U-1529 | | | |
| | 9433371 | Sep 15, 2029 | DP | | | |
| | 9444503 | Nov 19, 2027 | DP U-2169 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| ARIPIPRAZOLE - ABILIFY MYCITE KIT | | | | | | |
| N 207202 001 | 9577864 | Oct 03, 2033 | DP U-2169 | | | |
| | 9787511 | Sep 19, 2034 | DP U-2169 | | | |
| ARIPIPRAZOLE - ABILIFY MYCITE KIT | | | | | | |
| N 207202 002 | 7053092 | Jan 28, 2022 | U-1529 | | I-746 | Jul 27, 2020 |
| | 7978064 | Sep 14, 2026 | DP | | M-150 | Dec 05, 2017 |
| | 8017615 | Jun 16, 2024 | DP | | | |
| | 8114021 | Nov 02, 2026 | DP | | | |
| | 8258962 | Nov 25, 2030 | DP | | | |
| | 8545402 | Apr 27, 2030 | DP | | | |
| | 8547248 | Dec 18, 2030 | DP U-2167 | | | |
| | 8580796 | Sep 25, 2022 | DS | | | |
| | 8642760 | Sep 25, 2022 | DS | | | |
| | 8674825 | Apr 09, 2029 | DP U-2170 | | | |
| | 8718193 | Dec 05, 2029 | DP | | | |
| | 8759350 | Mar 02, 2027 | U-1529 | | | |
| | 8847766 | Mar 29, 2030 | DP U-2167 | | | |
| | 8945005 | Aug 19, 2029 | DP U-2167 | | | |
| | 8956288 | Jul 06, 2029 | DP U-2167 | | | |
| | 8961412 | Nov 17, 2030 | DP | | | |
| | 9060708 | Mar 05, 2029 | DP | | | |
| | 9089567 | Jan 28, 2022 | U-543 | | | |
| | 9119554 | Dec 16, 2028 | DP | | | |
| | 9125939 | Jul 28, 2026 | U-1749 | | | |
| | 9149577 | Dec 15, 2029 | DP | | | |
| | 9258035 | Mar 05, 2029 | DP | | | |
| | 9268909 | Oct 15, 2033 | DP U-2168 | | | |
| | 9270503 | Sep 19, 2034 | DP U-2169 | | | |
| | 9320455 | Dec 15, 2031 | DP | | | |
| | 9359302 | Sep 25, 2022 | DS DP U-1529 | | | |
| | 9359302 | Sep 25, 2022 | DS DP U-1749 | | | |
| | 9359302 | Sep 25, 2022 | DS DP U-543 | | | |
| | 9387182 | Dec 25, 2023 | U-1529 | | | |
| | 9433371 | Sep 15, 2029 | DP | | | |
| | 9444503 | Nov 19, 2027 | DP U-2169 | | | |
| | 9577864 | Oct 03, 2033 | DP U-2169 | | | |
| | 9787511 | Sep 19, 2034 | DP U-2169 | | | |
| ARIPIPRAZOLE - ABILIFY MYCITE KIT | | | | | | |
| N 207202 003 | 7053092 | Jan 28, 2022 | U-1529 | | I-746 | Jul 27, 2020 |
| | 7978064 | Sep 14, 2026 | DP | | M-150 | Dec 05, 2017 |
| | 8017615 | Jun 16, 2024 | DP | | | |
| | 8114021 | Nov 02, 2026 | DP | | | |
| | 8258962 | Nov 25, 2030 | DP | | | |
| | 8545402 | Apr 27, 2030 | DP | | | |
| | 8547248 | Dec 18, 2030 | DP U-2167 | | | |
| | 8580796 | Sep 25, 2022 | DS | | | |
| | 8642760 | Sep 25, 2022 | DS | | | |
| | 8674825 | Apr 09, 2029 | DP U-2170 | | | |
| | 8718193 | Dec 05, 2029 | DP | | | |
| | 8759350 | Mar 02, 2027 | U-1529 | | | |
| | 8847766 | Mar 29, 2030 | DP U-2167 | | | |
| | 8945005 | Aug 19, 2029 | DP U-2167 | | | |
| | 8956288 | Jul 06, 2029 | DP U-2167 | | | |
| | 8961412 | Nov 17, 2030 | DP | | | |
| | 9060708 | Mar 05, 2029 | DP | | | |
| | 9089567 | Jan 28, 2022 | U-543 | | | |
| | 9119554 | Dec 16, 2028 | DP | | | |
| | 9125939 | Jul 28, 2026 | U-1749 | | | |
| | 9149577 | Dec 15, 2029 | DP | | | |
| | 9258035 | Mar 05, 2029 | DP | | | |
| | 9268909 | Oct 15, 2033 | DP U-2168 | | | |
| | 9270503 | Sep 19, 2034 | DP U-2169 | | | |
| | 9320455 | Dec 15, 2031 | DP | | | |
| | 9359302 | Sep 25, 2022 | DS DP U-1529 | | | |
| | 9359302 | Sep 25, 2022 | DS DP U-1749 | | | |
| | 9359302 | Sep 25, 2022 | DS DP U-543 | | | |
| | 9387182 | Dec 25, 2023 | U-1529 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| ARIPIPRAZOLE - ABILIFY MYCITE KIT | | | | | | |
| N 207202 003 | 9433371 | Sep 15, 2029 | DP | | | |
| | 9444503 | Nov 19, 2027 | DP U-2169 | | | |
| | 9577864 | Oct 03, 2033 | DP U-2169 | | | |
| | 9787511 | Sep 19, 2034 | DP U-2169 | | | |
| ARIPIPRAZOLE - ABILIFY MYCITE KIT | | | | | | |
| N 207202 004 | 7053092 | Jan 28, 2022 | U-1529 | | I-746 | Jul 27, 2020 |
| | 7978064 | Sep 14, 2026 | DP | | M-150 | Dec 05, 2017 |
| | 8017615 | Jun 16, 2024 | DP | | | |
| | 8114021 | Nov 02, 2026 | DP | | | |
| | 8258962 | Nov 25, 2030 | DP | | | |
| | 8545402 | Apr 27, 2030 | DP | | | |
| | 8547248 | Dec 18, 2030 | DP U-2167 | | | |
| | 8580796 | Sep 25, 2022 | DS | | | |
| | 8642760 | Sep 25, 2022 | DS | | | |
| | 8674825 | Apr 09, 2029 | DP U-2170 | | | |
| | 8718193 | Dec 05, 2029 | DP | | | |
| | 8759350 | Mar 02, 2027 | U-1529 | | | |
| | 8847766 | Mar 29, 2030 | DP U-2167 | | | |
| | 8945005 | Aug 19, 2029 | DP U-2167 | | | |
| | 8956288 | Jul 06, 2029 | DP U-2167 | | | |
| | 8961412 | Nov 17, 2030 | DP | | | |
| | 9060708 | Mar 05, 2029 | DP | | | |
| | 9089567 | Jan 28, 2022 | U-543 | | | |
| | 9119554 | Dec 16, 2028 | DP | | | |
| | 9125939 | Jul 28, 2026 | U-1749 | | | |
| | 9149577 | Dec 15, 2029 | DP | | | |
| | 9258035 | Mar 05, 2029 | DP | | | |
| | 9268909 | Oct 15, 2033 | DP U-2168 | | | |
| | 9270503 | Sep 19, 2034 | DP U-2169 | | | |
| | 9320455 | Dec 15, 2031 | DP | | | |
| | 9359302 | Sep 25, 2022 | DS DP U-1529 | | | |
| | 9359302 | Sep 25, 2022 | DS DP U-1749 | | | |
| | 9359302 | Sep 25, 2022 | DS DP U-543 | | | |
| | 9387182 | Dec 25, 2023 | U-1529 | | | |
| | 9433371 | Sep 15, 2029 | DP | | | |
| | 9444503 | Nov 19, 2027 | DP U-2169 | | | |
| | 9577864 | Oct 03, 2033 | DP U-2169 | | | |
| | 9787511 | Sep 19, 2034 | DP U-2169 | | | |
| ARIPIPRAZOLE - ABILIFY MYCITE KIT | | | | | | |
| N 207202 005 | 7053092 | Jan 28, 2022 | U-1529 | | I-746 | Jul 27, 2020 |
| | 7978064 | Sep 14, 2026 | DP | | M-150 | Dec 05, 2017 |
| | 8017615 | Jun 16, 2024 | DP | | | |
| | 8114021 | Nov 02, 2026 | DP | | | |
| | 8258962 | Nov 25, 2030 | DP | | | |
| | 8545402 | Apr 27, 2030 | DP | | | |
| | 8547248 | Dec 18, 2030 | DP U-2167 | | | |
| | 8580796 | Sep 25, 2022 | DS | | | |
| | 8642760 | Sep 25, 2022 | DS | | | |
| | 8674825 | Apr 09, 2029 | DP U-2170 | | | |
| | 8718193 | Dec 05, 2029 | DP | | | |
| | 8759350 | Mar 02, 2027 | U-1529 | | | |
| | 8847766 | Mar 29, 2030 | DP U-2167 | | | |
| | 8945005 | Aug 19, 2029 | DP U-2167 | | | |
| | 8956288 | Jul 06, 2029 | DP U-2167 | | | |
| | 8961412 | Nov 17, 2030 | DP | | | |
| | 9060708 | Mar 05, 2029 | DP | | | |
| | 9089567 | Jan 28, 2022 | U-543 | | | |
| | 9119554 | Dec 16, 2028 | DP | | | |
| | 9125939 | Jul 28, 2026 | U-1749 | | | |
| | 9149577 | Dec 15, 2029 | DP | | | |
| | 9258035 | Mar 05, 2029 | DP | | | |
| | 9268909 | Oct 15, 2033 | DP U-2168 | | | |
| | 9270503 | Sep 19, 2034 | DP U-2169 | | | |
| | 9320455 | Dec 15, 2031 | DP | | | |
| | 9359302 | Sep 25, 2022 | DS DP U-1529 | | | |
| | 9359302 | Sep 25, 2022 | DS DP U-1749 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| ARIPIPRAZOLE - ABILIFY MYCITE KIT | | | | | | |
| N 207202 005 | 9359302 | Sep 25, 2022 | DS DP U-543 | | | |
| | 9387182 | Dec 25, 2023 | U-1529 | | | |
| | 9433371 | Sep 15, 2029 | DP | | | |
| | 9444503 | Nov 19, 2027 | DP U-2169 | | | |
| | 9577864 | Oct 03, 2033 | DP U-2169 | | | |
| | 9787511 | Sep 19, 2034 | DP U-2169 | | | |
| ARIPIPRAZOLE - ABILIFY MYCITE KIT | | | | | | |
| N 207202 006 | 7053092 | Jan 28, 2022 | U-1529 | | I-746 | Jul 27, 2020 |
| | 7978064 | Sep 14, 2026 | DP | | M-150 | Dec 05, 2017 |
| | 8017615 | Jun 16, 2024 | DP | | | |
| | 8114021 | Nov 02, 2026 | DP | | | |
| | 8258962 | Nov 25, 2030 | DP | | | |
| | 8545402 | Apr 27, 2030 | DP | | | |
| | 8547248 | Dec 18, 2030 | DP U-2167 | | | |
| | 8580796 | Sep 25, 2022 | DS | | | |
| | 8642760 | Sep 25, 2022 | DS | | | |
| | 8674825 | Apr 09, 2029 | DP U-2170 | | | |
| | 8718193 | Dec 05, 2029 | DP | | | |
| | 8759350 | Mar 02, 2027 | U-1529 | | | |
| | 8847766 | Mar 29, 2030 | DP U-2167 | | | |
| | 8945005 | Aug 19, 2029 | DP U-2167 | | | |
| | 8956288 | Jul 06, 2029 | DP U-2167 | | | |
| | 8961412 | Nov 17, 2030 | DP | | | |
| | 9060708 | Mar 05, 2029 | DP | | | |
| | 9089567 | Jan 28, 2022 | U-543 | | | |
| | 9119554 | Dec 16, 2028 | DP | | | |
| | 9125939 | Jul 28, 2026 | U-1749 | | | |
| | 9149577 | Dec 15, 2029 | DP | | | |
| | 9258035 | Mar 05, 2029 | DP | | | |
| | 9268909 | Oct 15, 2033 | DP U-2168 | | | |
| | 9270503 | Sep 19, 2034 | DP U-2169 | | | |
| | 9320455 | Dec 15, 2031 | DP | | | |
| | 9359302 | Sep 25, 2022 | DS DP U-1529 | | | |
| | 9359302 | Sep 25, 2022 | DS DP U-1749 | | | |
| | 9359302 | Sep 25, 2022 | DS DP U-543 | | | |
| | 9387182 | Dec 25, 2023 | U-1529 | | | |
| | 9433371 | Sep 15, 2029 | DP | | | |
| | 9444503 | Nov 19, 2027 | DP U-2169 | | | |
| | 9577864 | Oct 03, 2033 | DP U-2169 | | | |
| | 9787511 | Sep 19, 2034 | DP U-2169 | | | |
| ARIPIPRAZOLE LAUROXIL - ARISTADA | | | | | | |
| N 207533 001 | 8431576 | Oct 26, 2030 | DS | | NCE | Oct 05, 2020 |
| | 8796276 | Jun 24, 2030 | U-543 | | | |
| | 9034867 | Nov 07, 2032 | DP U-543 | | | |
| | 9193685 | Oct 24, 2033 | DP U-543 | | | |
| | 9452131 | Mar 19, 2035 | U-543 | | | |
| | 9526726 | Mar 19, 2035 | DP | | | |
| ARIPIPRAZOLE LAUROXIL - ARISTADA | | | | | | |
| N 207533 002 | 8431576 | Oct 26, 2030 | DS | | NCE | Oct 05, 2020 |
| | 8796276 | Jun 24, 2030 | U-543 | | | |
| | 9034867 | Nov 07, 2032 | DP U-543 | | | |
| | 9193685 | Oct 24, 2033 | DP U-543 | | | |
| | 9452131 | Mar 19, 2035 | U-543 | | | |
| | 9526726 | Mar 19, 2035 | DP | | | |
| ARIPIPRAZOLE LAUROXIL - ARISTADA | | | | | | |
| N 207533 003 | 8431576 | Oct 26, 2030 | DS | | NCE | Oct 05, 2020 |
| | 8796276 | Jun 24, 2030 | U-543 | | | |
| | 9034867 | Nov 07, 2032 | DP U-543 | | | |
| | 9193685 | Oct 24, 2033 | DP U-543 | | | |
| | 9452131 | Mar 19, 2035 | U-543 | | | |
| | 9526726 | Mar 19, 2035 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| ARIPIPRAZOLE LAUROXIL - ARISTADA | | | | | | | |
| N 207533 | 004 | 8431576 | Oct 26, 2030 | DS | | NCE | Oct 05, 2020 |
| | | 8796276 | Jun 24, 2030 | U-543 | | | |
| | | 9034867 | Nov 07, 2032 | DP U-543 | | | |
| | | 9193685 | Oct 24, 2033 | DP U-543 | | | |
| | | 9452131 | Mar 19, 2035 | U-543 | | | |
| ARMODAFINIL - NUVIGIL | | | | | | | |
| N 021875 | 001 | 7132570 | Dec 18, 2023 | DS DP | | | |
| | | 7297346 | Nov 29, 2023 | DP | | | |
| ARMODAFINIL - NUVIGIL | | | | | | | |
| N 021875 | 002 | 7132570 | Dec 18, 2023 | DS DP | | | |
| | | 7297346 | Nov 29, 2023 | DP | | | |
| ARMODAFINIL - NUVIGIL | | | | | | | |
| N 021875 | 003 | 7132570 | Dec 18, 2023 | DS DP | | | |
| | | 7297346 | Nov 29, 2023 | DP | | | |
| ARMODAFINIL - NUVIGIL | | | | | | | |
| N 021875 | 004 | 7132570 | Dec 18, 2023 | DS DP | | | |
| | | 7297346 | Nov 29, 2023 | DP | | | |
| ARMODAFINIL - NUVIGIL | | | | | | | |
| N 021875 | 005 | 7132570 | Dec 18, 2023 | DS DP | | | |
| | | 7297346 | Nov 29, 2023 | DP | | | |
| ARSENIC TRIOXIDE - TRISENOX | | | | | | | |
| N 021248 | 001 | 6723351 | Nov 10, 2018 | U-573 | | | |
| | | 6855339 | Nov 10, 2018 | U-617 | | | |
| | | 6861076 | Nov 10, 2018 | U-617 | | | |
| | | 6884439 | Nov 10, 2018 | U-651 | | | |
| | | 6982096 | Nov 10, 2018 | U-651 | | | |
| | | 8273379 | Nov 10, 2018 | U-1291 | | | |
| ARSENIC TRIOXIDE - TRISENOX | | | | | | | |
| N 021248 | 002 | 6723351 | Nov 10, 2018 | U-2204 | | | |
| | | 6855339 | Nov 10, 2018 | U-2204 | | | |
| | | 6861076 | Nov 10, 2018 | U-2204 | | | |
| | | 6884439 | Nov 10, 2018 | U-2204 | | | |
| | | 6982096 | Nov 10, 2018 | U-2204 | | | |
| | | 8273379 | Nov 10, 2018 | U-2204 | | | |
| ASCORBIC ACID - ASCOR | | | | | | | |
| N 209112 | 001 | | | | | ODE | Oct 02, 2024 |
| ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - MOVIPREP | | | | | | | |
| N 021881 | 001 | 7169381 | Sep 01, 2024 | DS DP | | | |
| | | 7658914 | Sep 01, 2024 | DS DP | | | |
| ASENAPINE MALEATE - SAPHRIS | | | | | | | |
| N 022117 | 001 | 5763476 | Jun 09, 2020 | DP U-1960 | | D-166 | Jan 13, 2020 |
| | | 5763476 | Jun 09, 2020 | DP U-1961 | | I-597 | Jan 13, 2020 |
| | | 5763476 | Jun 09, 2020 | DP U-1962 | | M-158 | Mar 17, 2018 |
| | | 5763476 | Jun 09, 2020 | DP U-1963 | | NPP | Mar 17, 2018 |
| | | 5763476 | Jun 09, 2020 | DP U-326 | | PED | Sep 17, 2018 |
| | | 5763476*PED | Dec 09, 2020 | | | PED | Sep 17, 2018 |
| | | 7741358 | Apr 06, 2026 | DS DP U-1064 | | | |
| | | 7741358 | Apr 06, 2026 | DS DP U-1960 | | | |
| | | 7741358 | Apr 06, 2026 | DS DP U-1961 | | | |
| | | 7741358 | Apr 06, 2026 | DS DP U-1962 | | | |
| | | 7741358 | Apr 06, 2026 | DS DP U-1963 | | | |
| | | 7741358*PED | Oct 06, 2026 | | | | |
| | | 8022228 | Apr 06, 2026 | DS DP | | | |
| | | 8022228*PED | Oct 06, 2026 | | | | |
| ASENAPINE MALEATE - SAPHRIS | | | | | | | |
| N 022117 | 002 | 5763476 | Jun 09, 2020 | DP U-1960 | | D-166 | Jan 13, 2020 |
| | | 5763476 | Jun 09, 2020 | DP U-1961 | | I-597 | Jan 13, 2020 |
| | | 5763476 | Jun 09, 2020 | DP U-1962 | | M-158 | Mar 17, 2018 |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| ASENAPINE MALEATE - SAPHRIS | | | | | | | |
| N 022117 | 002 | 5763476 | Jun 09, 2020 | DP U-1963 | | NPP | Mar 17, 2018 |
| | | 5763476 | Jun 09, 2020 | DP U-326 | | PED | Sep 17, 2018 |
| | | 5763476*PED | Dec 09, 2020 | | | PED | Sep 17, 2018 |
| | | 7741358 | Apr 06, 2026 | DS DP U-1064 | | | |
| | | 7741358 | Apr 06, 2026 | DS DP U-1960 | | | |
| | | 7741358 | Apr 06, 2026 | DS DP U-1961 | | | |
| | | 7741358 | Apr 06, 2026 | DS DP U-1962 | | | |
| | | 7741358 | Apr 06, 2026 | DS DP U-1963 | | | |
| | | 7741358*PED | Oct 06, 2026 | | | | |
| | | 8022228 | Apr 06, 2026 | DS DP | | | |
| | | 8022228*PED | Oct 06, 2026 | | | | |
| ASENAPINE MALEATE - SAPHRIS | | | | | | | |
| N 022117 | 003 | 5763476 | Jun 09, 2020 | DP U-1893 | | D-166 | Jan 13, 2020 |
| | | 5763476 | Jun 09, 2020 | DP U-1966 | | I-597 | Jan 13, 2020 |
| | | 5763476*PED | Dec 09, 2020 | | | | |
| | | 7741358 | Apr 06, 2026 | DS DP U-1893 | | | |
| | | 7741358 | Apr 06, 2026 | DS DP U-1966 | | | |
| | | 7741358*PED | Oct 06, 2026 | | | | |
| | | 8022228 | Apr 06, 2026 | DS DP | | | |
| | | 8022228*PED | Oct 06, 2026 | | | | |
| ASPIRIN - ASPIRIN | | | | | | | |
| N 203697 | 001 | 8865187 | Mar 23, 2022 | DP | | | |
| | | 9101637 | Mar 23, 2022 | U-1731 | | | |
| | | 9101637 | Mar 23, 2022 | U-1732 | | | |
| | | 9101637 | Mar 23, 2022 | U-1733 | | | |
| | | 9216150 | Sep 29, 2032 | DP | | | |
| | | 9226892 | Sep 29, 2032 | U-1731 | | | |
| | | 9226892 | Sep 29, 2032 | U-1732 | | | |
| | | 9226892 | Sep 29, 2032 | U-1733 | | | |
| | | 9351984 | Dec 19, 2021 | DP | | | |
| ASPIRIN; OMEPRAZOLE - YOSPRALA | | | | | | | |
| N 205103 | 001 | 6926907 | Feb 28, 2023 | DP U-1902 | | NC | Sep 14, 2019 |
| | | 8206741 | Feb 28, 2023 | DP U-1902 | | | |
| | | 9364439 | May 31, 2022 | DP U-1902 | | | |
| | | 9539214 | Mar 13, 2033 | U-1902 | | | |
| ASPIRIN; OMEPRAZOLE - YOSPRALA | | | | | | | |
| N 205103 | 002 | 6926907 | Feb 28, 2023 | DP U-1902 | | NC | Sep 14, 2019 |
| | | 8206741 | Feb 28, 2023 | DP U-1902 | | | |
| | | 9364439 | May 31, 2022 | DP U-1902 | | | |
| | | 9539214 | Mar 13, 2033 | U-1902 | | | |
| ATAZANAVIR SULFATE - ATAZANAVIR SULFATE | | | | | | | |
| A 091673 | 001 | | | | | PC | Jun 25, 2018 |
| ATAZANAVIR SULFATE - ATAZANAVIR SULFATE | | | | | | | |
| A 091673 | 002 | | | | | PC | Jun 25, 2018 |
| ATAZANAVIR SULFATE - ATAZANAVIR SULFATE | | | | | | | |
| A 091673 | 003 | | | | | PC | Jun 25, 2018 |
| ATAZANAVIR SULFATE - ATAZANAVIR SULFATE | | | | | | | |
| A 091673 | 004 | | | | | PC | Jun 25, 2018 |
| ATAZANAVIR SULFATE - REYATAZ | | | | | | | |
| N 021567 | 001 | 5849911*PED | Dec 20, 2017 | | | | |
| | | 6087383 | Dec 21, 2018 | DS DP | | | |
| | | 6087383*PED | Jun 21, 2019 | | | | |
| ATAZANAVIR SULFATE - REYATAZ | | | | | | | |
| N 021567 | 002 | 5849911*PED | Dec 20, 2017 | | | | |
| | | 6087383 | Dec 21, 2018 | DS DP | | | |
| | | 6087383*PED | Jun 21, 2019 | | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| ATAZANAVIR SULFATE - REYATAZ | | | | | | | |
| N 021567 | 003 | 5849911*PED | Dec 20, 2017 | | | | |
| | | 6087383 | Dec 21, 2018 | DS DP | | | |
| | | 6087383*PED | Jun 21, 2019 | | | | |
| ATAZANAVIR SULFATE - REYATAZ | | | | | | | |
| N 021567 | 004 | 5849911*PED | Dec 20, 2017 | | | | |
| | | 6087383 | Dec 21, 2018 | DS DP | | | |
| | | 6087383*PED | Jun 21, 2019 | | | | |
| ATAZANAVIR SULFATE - REYATAZ | | | | | | | |
| N 206352 | 001 | 5849911*PED | Dec 20, 2017 | | | NPP | Sep 24, 2018 |
| | | 6087383 | Dec 21, 2018 | DS DP | | PED | Mar 24, 2019 |
| | | 6087383*PED | Jun 21, 2019 | | | | |
| ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ | | | | | | | |
| N 206353 | 001 | 5849911*PED | Dec 20, 2017 | | | NCE | Aug 27, 2017 |
| | | 6087383 | Dec 21, 2018 | DS DP | | | |
| | | 6087383*PED | Jun 21, 2019 | | | | |
| | | 8148374 | Sep 03, 2029 | DS DP U-1279 | | | |
| ATORVASTATIN CALCIUM - LIPITOR | | | | | | | |
| N 020702 | 001 | | | | | M-204 | Jun 23, 2020 |
| ATORVASTATIN CALCIUM - LIPITOR | | | | | | | |
| N 020702 | 002 | | | | | M-204 | Jun 23, 2020 |
| AVANAFIL - STENDRA | | | | | | | |
| N 202276 | 001 | 6656935 | Apr 27, 2025 | DS DP U-155 | | D-140 | Sep 17, 2017 |
| | | 7501409 | May 05, 2023 | DP | | | |
| AVANAFIL - STENDRA | | | | | | | |
| N 202276 | 002 | 6656935 | Apr 27, 2025 | DS DP U-155 | | D-140 | Sep 17, 2017 |
| | | 7501409 | May 05, 2023 | DP | | | |
| AVANAFIL - STENDRA | | | | | | | |
| N 202276 | 003 | 6656935 | Apr 27, 2025 | DS DP U-155 | | D-140 | Sep 17, 2017 |
| | | 7501409 | May 05, 2023 | DP | | | |
| AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ | | | | | | | |
| N 206494 | 001 | 7112592 | Feb 24, 2022 | DS DP U-282 | | | |
| | | 7612087 | Nov 12, 2026 | DP | | | |
| | | 8178554 | Jul 24, 2021 | DS DP U-282 | | | |
| | | 8471025 | Aug 12, 2031 | DS | | | |
| | | 8835455 | Oct 08, 2030 | DP | | | |
| | | 8969566 | Jun 15, 2032 | DS | | | |
| | | 9284314 | Jun 15, 2032 | DS | | | |
| | | 9695122 | Jun 15, 2032 | DS | | | |
| AXITINIB - INLYTA | | | | | | | |
| N 202324 | 001 | 6534524 | Apr 29, 2025 | DS DP | | | |
| | | 7141581 | Jun 30, 2020 | U-1220 | | | |
| | | 8791140 | Dec 14, 2030 | DS | | | |
| AXITINIB - INLYTA | | | | | | | |
| N 202324 | 002 | 6534524 | Apr 29, 2025 | DS DP | | | |
| | | 7141581 | Jun 30, 2020 | U-1220 | | | |
| | | 8791140 | Dec 14, 2030 | DS | | | |
| AZELAIC ACID - FINACEA | | | | | | | |
| N 021470 | 001 | 6534070 | Nov 18, 2018 | | | | |
| AZELAIC ACID - FINACEA | | | | | | | |
| N 207071 | 001 | 6730288 | Sep 08, 2019 | DP | | NP | Jul 29, 2018 |
| | | 7700076 | Sep 18, 2027 | DP | | | |
| | | 8435498 | Mar 01, 2024 | U-1727 | | | |
| | | 8722021 | Oct 24, 2023 | DP | | | |
| | | 8900554 | Oct 24, 2023 | DP | | | |
| | | 9211259 | Jan 26, 2029 | U-1796 | | | |
| | | 9265725 | Dec 08, 2027 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|
| AZELASTINE HYDROCHLORIDE - ASTEPRO | | | | | | | | |
| N | 022203 | 001 | 8071073 | Jun 04, 2028 | DP | | NPP | Feb 20, 2018 |
| | | | 8518919 | Nov 22, 2025 | U-1430 | | NPP | Feb 20, 2018 |
| AZELASTINE HYDROCHLORIDE - ASTEPRO | | | | | | | | |
| N | 022203 | 002 | 8071073 | Jun 04, 2028 | DP | | | |
| | | | 8518919 | Nov 22, 2025 | U-1430 | | | |
| AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA | | | | | | | | |
| N | 202236 | 001 | 8163723 | Aug 29, 2023 | U-1667 | | NPP | Feb 20, 2018 |
| | | | 8163723 | Aug 29, 2023 | U-644 | | PED | Aug 20, 2018 |
| | | | 8163723 | Aug 29, 2023 | U-707 | | | |
| | | | 8163723 | Aug 29, 2023 | U-77 | | | |
| | | | 8163723 | Aug 29, 2023 | U-81 | | | |
| | | | 8163723*PED | Feb 29, 2024 | | | | |
| | | | 8168620 | Feb 24, 2026 | DP | | | |
| | | | 9259428 | Jun 13, 2023 | U-644 | | | |
| | | | 9259428*PED | Dec 13, 2023 | | | | |
| AZILSARTAN KAMEDOXOMIL - EDARBI | | | | | | | | |
| N | 200796 | 001 | 7157584 | May 22, 2025 | DS | | | |
| | | | 7572920 | Jan 07, 2025 | DP U-3 | | | |
| | | | 9066936 | Mar 26, 2028 | DP | | | |
| AZILSARTAN KAMEDOXOMIL - EDARBI | | | | | | | | |
| N | 200796 | 002 | 7157584 | May 22, 2025 | DS | | | |
| | | | 7572920 | Jan 07, 2025 | DP U-3 | | | |
| | | | 9066936 | Mar 26, 2028 | DP | | | |
| AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR | | | | | | | | |
| N | 202331 | 001 | 7157584 | May 22, 2025 | DS | | | |
| | | | 7572920 | Jan 07, 2025 | DP U-3 | | | |
| | | | 9066936 | Mar 26, 2028 | DP | | | |
| | | | 9169238 | Feb 04, 2030 | DP | | | |
| AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR | | | | | | | | |
| N | 202331 | 002 | 7157584 | May 22, 2025 | DS | | | |
| | | | 7572920 | Jan 07, 2025 | DP U-3 | | | |
| | | | 9066936 | Mar 26, 2028 | DP | | | |
| | | | 9169238 | Feb 04, 2030 | DP | | | |
| AZITHROMYCIN - AZITHROMYCIN | | | | | | | | |
| A | 065488 | 001 | | | | | PC | Mar 26, 2018 |
| AZITHROMYCIN - AZITHROMYCIN | | | | | | | | |
| A | 065488 | 002 | | | | | PC | Mar 26, 2018 |
| AZITHROMYCIN - ZITHROMAX | | | | | | | | |
| N | 050693 | 001 | 6268489 | Jul 31, 2018 | DS | | | |
| AZITHROMYCIN - ZITHROMAX | | | | | | | | |
| N | 050710 | 001 | 6268489 | Jul 31, 2018 | DS | | | |
| AZITHROMYCIN - ZITHROMAX | | | | | | | | |
| N | 050710 | 002 | 6268489 | Jul 31, 2018 | DS | | | |
| AZITHROMYCIN - ZITHROMAX | | | | | | | | |
| N | 050711 | 001 | 6268489 | Jul 31, 2018 | DS | | | |
| AZITHROMYCIN - ZITHROMAX | | | | | | | | |
| N | 050730 | 001 | 6268489 | Jul 31, 2018 | DS | | | |
| AZITHROMYCIN - ZITHROMAX | | | | | | | | |
| N | 050733 | 001 | 6268489 | Jul 31, 2018 | DS | | | |
| AZITHROMYCIN - ZITHROMAX | | | | | | | | |
| N | 050784 | 001 | 6268489 | Jul 31, 2018 | DS | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|
| AZITHROMYCIN - ZMAX | | | | | | | | |
| N 050797 | 001 | 6268489 | Jul 31, 2018 | DS | | | | |
| | | 6984403 | Feb 14, 2024 | | DP U-282 | | | |
| | | 7887844 | Feb 14, 2024 | | DP | | | |
| AZITHROMYCIN - AZASITE | | | | | | | | |
| N 050810 | 001 | 6159458 | Nov 04, 2017 | | DP U-709 | | | |
| | | 6239113 | Mar 31, 2019 | | U-709 | | | |
| | | 6569443 | Mar 31, 2019 | | DP U-709 | | | |
| | | 6861411 | Nov 25, 2018 | | U-709 | | | |
| | | 7056893 | Mar 31, 2019 | | DP U-709 | | | |
| AZTREONAM - CAYSTON | | | | | | | | |
| N 050814 | 001 | 7208141 | Dec 20, 2021 | | DP U-1031 | | | |
| | | 7214364 | Dec 20, 2021 | | DP | | | |
| | | 7427633 | Dec 20, 2021 | | DP U-1031 | | | |
| | | 8399496 | Dec 20, 2021 | | DP U-1377 | | | |
| BACLOFEN - KEMSTRO | | | | | | | | |
| N 021589 | 001 | 6024981 | Apr 09, 2018 | | DP | | | |
| | | 6221392 | Apr 09, 2018 | | DP | | | |
| BACLOFEN - KEMSTRO | | | | | | | | |
| N 021589 | 002 | 6024981 | Apr 09, 2018 | | DP | | | |
| | | 6221392 | Apr 09, 2018 | | DP | | | |
| BALSALAZIDE DISODIUM - COLAZAL | | | | | | | | |
| N 020610 | 001 | 7452872 | Aug 24, 2026 | | U-141 | | | |
| | | 7625884 | Aug 24, 2026 | | U-141 | | | |
| BALSALAZIDE DISODIUM - GIAZO | | | | | | | | |
| N 022205 | 001 | 6197341 | Mar 13, 2018 | | DP U-1229 | | | |
| | | 7452872 | Aug 24, 2026 | | U-1229 | | | |
| | | 7625884 | Aug 24, 2026 | | U-1229 | | | |
| | | 8497256 | Jun 23, 2031 | | U-1229 | | | |
| | | 9192616 | Aug 02, 2026 | | U-1229 | | | |
| BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE | | | | | | | | |
| N 022247 | 001 | 5998402 | Apr 04, 2018 | DS | DP U-594 | | NCE | Oct 13, 2018 |
| | | 6479535 | May 06, 2019 | | DP U-594 | | | |
| | | 6479535 | May 06, 2019 | | DP U-904 | | | |
| | | 7683051 | Mar 10, 2027 | DS | DP U-594 | | | |
| | | 7683051 | Mar 10, 2027 | DS | DP U-904 | | | |
| | | 8815934 | May 06, 2019 | | DP | | | |
| BECLOMETHASONE DIPROPIONATE - QVAR 80 | | | | | | | | |
| N 020911 | 001 | 6446627 | Dec 18, 2017 | | DP | | | |
| | | 9463289 | May 18, 2031 | | DP | | | |
| | | 9808587 | May 18, 2031 | | DP | | | |
| BECLOMETHASONE DIPROPIONATE - QVAR 40 | | | | | | | | |
| N 020911 | 002 | 6446627 | Dec 18, 2017 | | DP | | | |
| | | 9463289 | May 18, 2031 | | DP | | | |
| | | 9808587 | May 18, 2031 | | DP | | | |
| BECLOMETHASONE DIPROPIONATE - QNASL | | | | | | | | |
| N 202813 | 001 | 7780038 | Jan 24, 2027 | | DP | | | |
| BECLOMETHASONE DIPROPIONATE - QNASL | | | | | | | | |
| N 202813 | 002 | 7780038 | Jan 24, 2027 | | DP | | NS | Dec 17, 2017 |
| BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER | | | | | | | | |
| N 207921 | 001 | 6446627 | Dec 18, 2017 | | DP | | | |
| | | 7637260 | Aug 25, 2020 | | DP | | | |
| | | 8132712 | Sep 07, 2028 | | DP | | | |
| | | 8931476 | Jul 17, 2031 | | DP | | | |
| BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER | | | | | | | | |
| N 207921 | 002 | 6446627 | Dec 18, 2017 | | DP | | | |
| | | 7637260 | Aug 25, 2020 | | DP | | | |
| | | 8132712 | Sep 07, 2028 | | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| BECLOMETHASONE DIPROPIONATE - QVAR REDIHALER | | | | | | | |
| N 207921 | 002 | 8931476 | Jul 17, 2031 | DP | | | |
| BEDAQUILINE FUMARATE - SIRTURO | | | | | | | |
| N 204384 | 001 | 7498343 | Dec 01, 2026 | DS DP U-1321 | | NCE | Dec 28, 2017 |
| | | 8546428 | Mar 19, 2029 | DS DP U-1321 | | ODE-38 | Dec 28, 2019 |
| BELINOSTAT - BELEODAQ | | | | | | | |
| N 206256 | 001 | 6888027 | Sep 27, 2021 | DS DP U-1544 | | NCE | Jul 03, 2019 |
| | | 8835501 | Oct 27, 2027 | DP | | ODE-68 | Jul 03, 2021 |
| BENDAMUSTINE HYDROCHLORIDE - TREANDA | | | | | | | |
| N 022249 | 001 | 8436190 | Oct 26, 2030 | DP | | | |
| | | 8436190*PED | Apr 26, 2031 | | | | |
| | | 8445524 | Mar 26, 2029 | DS DP U-1402 | | | |
| | | 8445524*PED | Sep 26, 2029 | | | | |
| | | 8609863 | Jan 12, 2026 | DP | | | |
| | | 8609863*PED | Jul 12, 2026 | | | | |
| | | 8669279 | Mar 26, 2029 | DP U-1402 | | | |
| | | 8669279*PED | Sep 26, 2029 | | | | |
| | | 8791270 | Jan 12, 2026 | DP U-1542 | | | |
| | | 8791270*PED | Jul 12, 2026 | | | | |
| | | 8883836 | Mar 26, 2029 | DP U-1402 | | | |
| | | 8883836*PED | Sep 26, 2029 | | | | |
| | | 8895756 | Jan 12, 2026 | DP | | | |
| | | 8895756*PED | Jul 12, 2026 | | | | |
| | | 9533955 | Mar 26, 2029 | DP U-1949 | | | |
| | | 9533955 | Mar 26, 2029 | DP U-1952 | | | |
| BENDAMUSTINE HYDROCHLORIDE - TREANDA | | | | | | | |
| N 022249 | 002 | 8436190 | Oct 26, 2030 | DP | | | |
| | | 8436190*PED | Apr 26, 2031 | | | | |
| | | 8445524 | Mar 26, 2029 | DS DP U-1402 | | | |
| | | 8445524*PED | Sep 26, 2029 | | | | |
| | | 8609863 | Jan 12, 2026 | DP | | | |
| | | 8609863*PED | Jul 12, 2026 | | | | |
| | | 8669279 | Mar 26, 2029 | DP U-1402 | | | |
| | | 8669279*PED | Sep 26, 2029 | | | | |
| | | 8791270 | Jan 12, 2026 | DP U-1542 | | | |
| | | 8791270*PED | Jul 12, 2026 | | | | |
| | | 8883836 | Mar 26, 2029 | DP U-1402 | | | |
| | | 8883836*PED | Sep 26, 2029 | | | | |
| | | 8895756 | Jan 12, 2026 | DP | | | |
| | | 8895756*PED | Jul 12, 2026 | | | | |
| | | 9533955 | Mar 26, 2029 | DP U-1949 | | | |
| | | 9533955 | Mar 26, 2029 | DP U-1952 | | | |
| BENDAMUSTINE HYDROCHLORIDE - TREANDA | | | | | | | |
| N 022249 | 003 | 8344006 | Sep 23, 2029 | DP U-1402 | | | |
| | | 8344006*PED | Mar 23, 2030 | | | | |
| | | 8445524 | Mar 26, 2029 | DS | | | |
| | | 8445524*PED | Sep 26, 2029 | | | | |
| | | 8791270 | Jan 12, 2026 | DP U-1542 | | | |
| | | 8791270*PED | Jul 12, 2026 | | | | |
| BENDAMUSTINE HYDROCHLORIDE - TREANDA | | | | | | | |
| N 022249 | 004 | 8344006 | Sep 23, 2029 | DP U-1402 | | | |
| | | 8344006*PED | Mar 23, 2030 | | | | |
| | | 8445524 | Mar 26, 2029 | DS | | | |
| | | 8445524*PED | Sep 26, 2029 | | | | |
| | | 8791270 | Jan 12, 2026 | DP U-1542 | | | |
| | | 8791270*PED | Jul 12, 2026 | | | | |
| BENDAMUSTINE HYDROCHLORIDE - BENDEKA | | | | | | | |
| N 208194 | 001 | 8609707 | Aug 11, 2031 | DP U-1542 | | | |
| | | 8791270 | Jan 12, 2026 | DP U-1790 | | | |
| | | 8791270*PED | Jul 12, 2026 | | | | |
| | | 9000021 | Mar 15, 2033 | U-1542 | | | |
| | | 9034908 | Mar 15, 2033 | U-1542 | | | |
| | | 9144568 | Mar 15, 2033 | U-1542 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|
| BENDAMUSTINE HYDROCHLORIDE - BENDEKA | | | | | | | | |
| N 208194 | 001 | 9265831 | Jan 28, 2031 | | DP | | | |
| | | 9572796 | Jan 28, 2031 | | DP U-1971 | | | |
| | | 9572796 | Jan 28, 2031 | | DP U-1972 | | | |
| | | 9572797 | Jan 28, 2031 | | U-1971 | | | |
| | | 9572797 | Jan 28, 2031 | | U-1972 | | | |
| | | 9572887 | Mar 15, 2033 | | U-1971 | | | |
| | | 9572887 | Mar 15, 2033 | | U-1972 | | | |
| | | 9579384 | Mar 15, 2033 | | U-1971 | | | |
| | | 9579384 | Mar 15, 2033 | | U-1972 | | | |
| | | 9597397 | Mar 15, 2033 | | U-1971 | | | |
| | | 9597397 | Mar 15, 2033 | | U-1972 | | | |
| | | 9597398 | Mar 15, 2033 | | U-1971 | | | |
| | | 9597399 | Mar 15, 2033 | | U-1971 | | | |
| | | 9597399 | Mar 15, 2033 | | U-1972 | | | |
| BENZNIDAZOLE - BENZNIDAZOLE | | | | | | | | |
| N 209570 | 001 | | | | | | NCE | Aug 29, 2022 |
| | | | | | | | ODE-154 | Aug 29, 2024 |
| BENZNIDAZOLE - BENZNIDAZOLE | | | | | | | | |
| N 209570 | 002 | | | | | | NCE | Aug 29, 2022 |
| | | | | | | | ODE-154 | Aug 29, 2024 |
| BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA | | | | | | | | |
| N 050819 | 001 | 8288434 | Aug 05, 2029 | | DP U-124 | | | |
| | | 8663699 | Jun 03, 2029 | | U-124 | | | |
| | | 8895070 | Jun 03, 2029 | | U-124 | | | |
| | | 9078870 | Jun 03, 2029 | | DP | | | |
| BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON | | | | | | | | |
| N 050819 | 002 | 8288434 | Aug 05, 2029 | | DP U-1033 | | | |
| | | 8288434 | Aug 05, 2029 | | DP U-124 | | | |
| | | 8288434 | Aug 05, 2029 | | DP U-134 | | | |
| | | 8288434 | Aug 05, 2029 | | DP U-818 | | | |
| | | 8288434 | Aug 05, 2029 | | DP U-916 | | | |
| | | 8288434 | Aug 05, 2029 | | DP U-921 | | | |
| | | 9504704 | Jun 03, 2029 | | DP U-124 | | | |
| | | 9504704 | Jun 03, 2029 | | DP U-134 | | | |
| | | 9504704 | Jun 03, 2029 | | DP U-818 | | | |
| | | 9504704 | Jun 03, 2029 | | DP U-916 | | | |
| | | 9561208 | Jun 03, 2029 | | DP U-916 | | | |
| BENZYL ALCOHOL - ULESFIA | | | | | | | | |
| N 022129 | 001 | 5858383 | Aug 11, 2017 | | U-970 | | | |
| | | 6139859 | Aug 11, 2017 | | U-970 | | | |
| | | 6793931 | Jul 11, 2022 | | DP U-970 | | | |
| | | 7294342 | May 19, 2024 | | U-970 | | | |
| BEPOTASTINE BESILATE - BEPREVE | | | | | | | | |
| N 022288 | 001 | 6780877 | Sep 19, 2019 | DS | DP | | | |
| | | 8784789 | Sep 05, 2024 | | DP | | | |
| | | 8877168 | Jul 30, 2023 | | DP | | | |
| BESIFLOXACIN HYDROCHLORIDE - BESIVANCE | | | | | | | | |
| N 022308 | 001 | 6685958 | Jun 29, 2021 | | DP U-80 | | | |
| | | 6699492 | Mar 31, 2019 | | DP U-80 | | | |
| | | 8415342 | Nov 07, 2030 | | U-80 | | | |
| | | 8481526 | Jan 09, 2031 | DS | | | | |
| | | 8604020 | Mar 12, 2030 | | DP | | | |
| | | 8937062 | Nov 13, 2029 | | U-80 | | | |
| BETAMETHASONE DIPROPIONATE - SERNIVO | | | | | | | | |
| N 208079 | 001 | 9364485 | Aug 31, 2030 | | DP U-1858 | | NDF | Feb 05, 2019 |
| | | 9433630 | Aug 31, 2030 | | DP U-1858 | | | |
| | | 9439911 | Aug 31, 2030 | | DP U-1858 | | | |
| | | 9655907 | Aug 31, 2030 | | DP U-1858 | | | |
| | | 9775851 | Aug 31, 2030 | | DP U-1858 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE - ENSTILAR | | | | | | | |
| N 207589 | 001 | 6753013 | Jan 27, 2020 | DP U-1761 | | NP | Oct 16, 2018 |
| | | 9119781 | Jun 10, 2031 | DP U-1761 | | | |
| BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX | | | | | | | |
| N 021852 | 001 | 6753013 | Jan 27, 2020 | DP U-193 | | NPP | Dec 23, 2017 |
| | | 6753013 | Jan 27, 2020 | DP U-88 | | | |
| BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX | | | | | | | |
| N 022185 | 001 | 6753013 | Jan 27, 2020 | DP U-1761 | | NPP | Aug 29, 2017 |
| | | 6753013 | Jan 27, 2020 | DP U-193 | | | |
| | | 6753013 | Jan 27, 2020 | DP U-88 | | | |
| | | 6787529 | Jan 27, 2020 | DP U-1761 | | | |
| | | 6787529 | Jan 27, 2020 | DP U-193 | | | |
| | | 6787529 | Jan 27, 2020 | DP U-88 | | | |
| BETRIXABAN - BEVYXXA | | | | | | | |
| N 208383 | 001 | 6376515 | Sep 15, 2020 | DS DP U-1167 | | NCE | Jun 23, 2022 |
| | | 6376515 | Sep 15, 2020 | DS DP U-1502 | | | |
| | | 6376515 | Sep 15, 2020 | DS DP U-2029 | | | |
| | | 6376515 | Sep 15, 2020 | DS DP U-2030 | | | |
| | | 6835739 | Sep 15, 2020 | DS DP | | | |
| | | 7598276 | Nov 08, 2026 | DS | | | |
| | | 8404724 | Mar 29, 2031 | DP U-2034 | | | |
| | | 8518977 | Sep 15, 2020 | DS | | | |
| | | 8557852 | Sep 08, 2028 | U-1167 | | | |
| | | 8557852 | Sep 08, 2028 | U-2030 | | | |
| | | 8691847 | Sep 15, 2020 | DS DP U-2029 | | | |
| | | 8691847 | Sep 15, 2020 | DS DP U-2035 | | | |
| | | 8987463 | Dec 28, 2030 | DP | | | |
| | | 9555023 | Nov 07, 2026 | U-1502 | | | |
| | | 9629831 | Sep 15, 2020 | U-1167 | | | |
| | | 9629831 | Sep 15, 2020 | U-1502 | | | |
| | | 9629831 | Sep 15, 2020 | U-2030 | | | |
| | | 9629831 | Sep 15, 2020 | U-2035 | | | |
| BETRIXABAN - BEVYXXA | | | | | | | |
| N 208383 | 002 | 6376515 | Sep 15, 2020 | DS DP U-1167 | | NCE | Jun 23, 2022 |
| | | 6376515 | Sep 15, 2020 | DS DP U-1502 | | | |
| | | 6376515 | Sep 15, 2020 | DS DP U-2029 | | | |
| | | 6376515 | Sep 15, 2020 | DS DP U-2030 | | | |
| | | 6835739 | Sep 15, 2020 | DS DP | | | |
| | | 7598276 | Nov 08, 2026 | DS | | | |
| | | 8404724 | Mar 29, 2031 | DP U-2034 | | | |
| | | 8518977 | Sep 15, 2020 | DS | | | |
| | | 8557852 | Sep 08, 2028 | U-1167 | | | |
| | | 8557852 | Sep 08, 2028 | U-2030 | | | |
| | | 8691847 | Sep 15, 2020 | DS DP U-2029 | | | |
| | | 8691847 | Sep 15, 2020 | DS DP U-2035 | | | |
| | | 8987463 | Dec 28, 2030 | DP | | | |
| | | 9555023 | Nov 07, 2026 | U-1502 | | | |
| | | 9629831 | Sep 15, 2020 | U-1167 | | | |
| | | 9629831 | Sep 15, 2020 | U-1502 | | | |
| | | 9629831 | Sep 15, 2020 | U-2030 | | | |
| | | 9629831 | Sep 15, 2020 | U-2035 | | | |
| BEXAROTENE - TARGRETIN | | | | | | | |
| N 021055 | 001 | | | | | M-164 | Jul 29, 2018 |
| BIMATOPROST - LUMIGAN | | | | | | | |
| N 022184 | 001 | 7851504 | Jun 13, 2027 | DS DP | | | |
| | | 8278353 | Mar 16, 2025 | DP | | | |
| | | 8299118 | Mar 16, 2025 | U-1295 | | | |
| | | 8309605 | Mar 16, 2025 | U-1293 | | | |
| | | 8309605 | Mar 16, 2025 | U-1294 | | | |
| | | 8338479 | Mar 16, 2025 | DP U-1295 | | | |
| | | 8524777 | Mar 16, 2025 | U-1235 | | | |
| | | 8586630 | Mar 16, 2025 | U-1458 | | | |
| | | 8772338 | Mar 16, 2025 | DP U-1528 | | | |
| | | 8933120 | Mar 16, 2025 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| BIMATOPROST - LUMIGAN | | | | | | | |
| N 022184 | 001 | 8933127 | Mar 16, 2025 | DP | | | |
| | | 9155716 | Mar 16, 2025 | DP U-1528 | | | |
| | | 9241918 | Mar 16, 2025 | DP U-1814 | | | |
| BIMATOPROST - LATISSE | | | | | | | |
| N 022369 | 001 | 8038988 | Aug 25, 2023 | DS DP U-1208 | | M-140 | Sep 04, 2017 |
| | | 8101161 | May 25, 2024 | U-1217 | | | |
| | | 8101161 | May 25, 2024 | U-1218 | | | |
| | | 8263054 | Jan 15, 2023 | U-1277 | | | |
| | | 8541466 | Jan 31, 2021 | U-1217 | | | |
| | | 8632760 | Jan 15, 2023 | U-1487 | | | |
| | | 8758733 | Jan 15, 2023 | U-1487 | | | |
| | | 8906962 | Jan 31, 2021 | U-1217 | | | |
| | | 8986715 | Jan 15, 2023 | U-1217 | | | |
| | | 9216183 | Jan 15, 2023 | U-1487 | | | |
| | | 9226931 | Jan 15, 2023 | U-1799 | | | |
| | | 9579270 | Jan 31, 2021 | U-1975 | | | |
| BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - HALFLYTELY | | | | | | | |
| N 021551 | 003 | 7291324 | Oct 22, 2022 | U-837 | | | |
| BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE - PYLERA | | | | | | | |
| N 050786 | 001 | 6350468 | Dec 14, 2018 | U-932 | | | |
| | | 6350468 | Dec 14, 2018 | U-956 | | | |
| BIVALIRUDIN - ANGIOMAX | | | | | | | |
| N 020873 | 001 | 7582727 | Jul 27, 2028 | DP | | | |
| | | 7598343 | Jul 27, 2028 | DP | | | |
| BOCEPREVIR - VICTRELIS | | | | | | | |
| N 202258 | 001 | 7772178 | Nov 11, 2027 | DP U-1128 | | | |
| | | 8119602 | Mar 17, 2027 | U-1233 | | | |
| | | RE43298 | Dec 22, 2024 | DS DP U-1128 | | | |
| BORTEZOMIB - VELCADE | | | | | | | |
| N 021602 | 001 | 5780454*PED | Nov 03, 2017 | | | D-141 | Oct 08, 2017 |
| | | 6713446 | Jan 25, 2022 | DS DP | | D-142 | Oct 08, 2017 |
| | | 6713446*PED | Jul 25, 2022 | | | I-695 | Oct 08, 2017 |
| | | 6958319 | Jan 25, 2022 | DS DP | | M-139 | Aug 08, 2017 |
| | | 6958319*PED | Jul 25, 2022 | | | M-165 | Sep 14, 2018 |
| | | | | | | ODE-76 | Oct 08, 2021 |
| | | | | | | PED | Feb 08, 2018 |
| | | | | | | PED | Apr 08, 2018 |
| | | | | | | PED | Apr 08, 2018 |
| | | | | | | PED | Apr 08, 2018 |
| | | | | | | PED | Mar 14, 2019 |
| | | | | | | PED | Apr 08, 2022 |
| BORTEZOMIB - BORTEZOMIB | | | | | | | |
| N 205004 | 001 | 8962572 | Nov 03, 2032 | DP | | | |
| BOSENTAN - TRACLEER | | | | | | | |
| N 021290 | 001 | | | | | NPP | Sep 05, 2020 |
| BOSENTAN - TRACLEER | | | | | | | |
| N 021290 | 002 | | | | | NPP | Sep 05, 2020 |
| BOSENTAN - TRACLEER | | | | | | | |
| N 209279 | 001 | 7959945 | Dec 28, 2027 | DP | | NP | Sep 05, 2020 |
| | | 8309126 | May 15, 2026 | DP | | ODE | Sep 05, 2024 |
| BOSUTINIB MONOHYDRATE - BOSULIF | | | | | | | |
| N 203341 | 001 | 6002008 | Mar 27, 2018 | DS DP U-1284 | | I-759 | Dec 19, 2020 |
| | | 7417148 | Jan 23, 2026 | U-1283 | | NCE | Sep 04, 2017 |
| | | 7767678 | Nov 23, 2026 | DS DP | | ODE-30 | Sep 04, 2019 |
| | | 7919625 | Dec 11, 2025 | DP | | | |
| | | RE42376 | Apr 13, 2024 | DS | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| BOSUTINIB MONOHYDRATE - BOSULIF | | | | | | | |
| N 203341 | 002 | 6002008 | Mar 27, 2018 | DS DP U-1284 | | I-759 | Dec 19, 2020 |
| | | 7417148 | Jan 23, 2026 | U-1283 | | NCE | Sep 04, 2017 |
| | | 7767678 | Nov 23, 2026 | DS DP | | ODE-30 | Sep 04, 2019 |
| | | 7919625 | Dec 11, 2025 | DP | | | |
| | | RE42376 | Apr 13, 2024 | DS | | | |
| BOSUTINIB MONOHYDRATE - BOSULIF | | | | | | | |
| N 203341 | 003 | 6002008 | Mar 27, 2018 | DS DP U-1284 | | I-759 | Dec 19, 2020 |
| | | 7417148 | Jan 23, 2026 | U-1283 | | ODE-30 | Sep 04, 2019 |
| | | 7767678 | Nov 23, 2026 | DS DP | | | |
| | | 7919625 | Dec 11, 2025 | DP | | | |
| | | RE42376 | Apr 13, 2024 | DS | | | |
| BREXPIPRAZOLE - REXULTI | | | | | | | |
| N 205422 | 001 | 7888362 | Feb 23, 2027 | DS | | M-186 | Sep 23, 2019 |
| | | 8349840 | Apr 12, 2026 | DP U-1529 | | NCE | Jul 10, 2020 |
| | | 8618109 | Apr 12, 2026 | U-543 | | | |
| | | 9839637 | Apr 12, 2026 | DP U-1529 | | | |
| | | 9839637 | Apr 12, 2026 | DP U-543 | | | |
| BREXPIPRAZOLE - REXULTI | | | | | | | |
| N 205422 | 002 | 7888362 | Feb 23, 2027 | DS | | M-186 | Sep 23, 2019 |
| | | 8349840 | Apr 12, 2026 | DP U-1529 | | NCE | Jul 10, 2020 |
| | | 8618109 | Apr 12, 2026 | U-543 | | | |
| | | 9839637 | Apr 12, 2026 | DP U-1529 | | | |
| | | 9839637 | Apr 12, 2026 | DP U-543 | | | |
| BREXPIPRAZOLE - REXULTI | | | | | | | |
| N 205422 | 003 | 7888362 | Feb 23, 2027 | DS | | M-186 | Sep 23, 2019 |
| | | 8349840 | Apr 12, 2026 | DP U-1529 | | NCE | Jul 10, 2020 |
| | | 8618109 | Apr 12, 2026 | U-543 | | | |
| | | 9839637 | Apr 12, 2026 | DP U-1529 | | | |
| | | 9839637 | Apr 12, 2026 | DP U-543 | | | |
| BREXPIPRAZOLE - REXULTI | | | | | | | |
| N 205422 | 004 | 7888362 | Feb 23, 2027 | DS | | M-186 | Sep 23, 2019 |
| | | 8349840 | Apr 12, 2026 | DP U-1529 | | NCE | Jul 10, 2020 |
| | | 8618109 | Apr 12, 2026 | U-543 | | | |
| | | 9839637 | Apr 12, 2026 | DP U-1529 | | | |
| | | 9839637 | Apr 12, 2026 | DP U-543 | | | |
| BREXPIPRAZOLE - REXULTI | | | | | | | |
| N 205422 | 005 | 7888362 | Feb 23, 2027 | DS | | M-186 | Sep 23, 2019 |
| | | 8349840 | Apr 12, 2026 | DP U-1529 | | NCE | Jul 10, 2020 |
| | | 8618109 | Apr 12, 2026 | U-543 | | | |
| | | 9839637 | Apr 12, 2026 | DP U-1529 | | | |
| | | 9839637 | Apr 12, 2026 | DP U-543 | | | |
| BREXPIPRAZOLE - REXULTI | | | | | | | |
| N 205422 | 006 | 7888362 | Feb 23, 2027 | DS | | M-186 | Sep 23, 2019 |
| | | 8349840 | Apr 12, 2026 | DP U-1529 | | NCE | Jul 10, 2020 |
| | | 8618109 | Apr 12, 2026 | U-543 | | | |
| | | 9839637 | Apr 12, 2026 | DP U-1529 | | | |
| | | 9839637 | Apr 12, 2026 | DP U-543 | | | |
| BRIGATINIB - ALUNBRIG | | | | | | | |
| N 208772 | 001 | 9012462 | Feb 06, 2031 | DS | | NCE | Apr 28, 2022 |
| | | 9273077 | May 21, 2029 | U-1927 | | ODE-142 | Apr 28, 2024 |
| | | 9611283 | Apr 10, 2034 | U-1927 | | | |
| BRIGATINIB - ALUNBRIG | | | | | | | |
| N 208772 | 002 | 9012462 | Feb 06, 2031 | DS | | NCE | Apr 28, 2022 |
| | | 9273077 | May 21, 2029 | U-1927 | | ODE-142 | Apr 28, 2024 |
| | | 9611283 | Apr 10, 2034 | U-1927 | | | |
| BRIGATINIB - ALUNBRIG | | | | | | | |
| N 208772 | 003 | 9012462 | Feb 06, 2031 | DS | | NCE | Apr 28, 2022 |
| | | 9273077 | May 21, 2029 | U-1927 | | ODE-142 | Apr 28, 2024 |
| | | 9611283 | Apr 10, 2034 | U-1927 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| BRIGATINIB - ALUNBRIG | | | | | | | |
| N 208772 | 003 | 9012462 | Feb 06, 2031 | DS | | NCE | Apr 28, 2022 |
| | | 9273077 | May 21, 2029 | U-1927 | | ODE-142 | Apr 28, 2024 |
| | | 9611283 | Apr 10, 2034 | U-1927 | | | |
| BRIMONIDINE TARTRATE - ALPHAGAN P | | | | | | | |
| N 021262 | 001 | 6562873 | Jul 10, 2021 | | | | |
| | | 6627210 | Jul 18, 2021 | DP | | | |
| | | 6641834 | Jul 28, 2021 | DP | | | |
| | | 6673337 | Jul 26, 2021 | DP | | | |
| | | 9295641 | Jul 10, 2021 | U-1833 | | | |
| | | 9295641*PED | Jan 10, 2022 | | | | |
| BRIMONIDINE TARTRATE - QOLIANA | | | | | | | |
| N 021764 | 001 | 7265117 | Aug 19, 2025 | DP | | | |
| BRIMONIDINE TARTRATE - ALPHAGAN P | | | | | | | |
| N 021770 | 001 | 6562873 | Jul 10, 2021 | DP | | | |
| | | 6627210 | Jul 18, 2021 | DP | | | |
| | | 6641834 | Jul 28, 2021 | DP | | | |
| | | 6673337 | Jul 26, 2021 | DP | | | |
| | | 8858961 | Sep 02, 2023 | DP | | | |
| | | 8858961*PED | Mar 02, 2024 | | | | |
| | | 9295641 | Jul 10, 2021 | U-1833 | | | |
| | | 9295641*PED | Jan 10, 2022 | | | | |
| | | 9687443 | Jul 10, 2021 | DP | | | |
| BRIMONIDINE TARTRATE - MIRVASO | | | | | | | |
| N 204708 | 001 | 7439241 | Aug 25, 2025 | U-1428 | | | |
| | | 8053427 | Jun 13, 2031 | DP U-1428 | | | |
| | | 8163725 | Jun 13, 2031 | DP | | | |
| | | 8231885 | May 24, 2025 | DP | | | |
| | | 8410102 | May 24, 2025 | U-1428 | | | |
| | | 8426410 | May 24, 2025 | U-1428 | | | |
| | | 8513247 | Mar 25, 2031 | DP U-1428 | | | |
| | | 8513249 | Mar 25, 2031 | DP U-1428 | | | |
| | | 8859551 | May 25, 2024 | U-1428 | | | |
| BRIMONIDINE TARTRATE - LUMIFY | | | | | | | |
| N 208144 | 001 | | | | | NP | Dec 22, 2020 |
| BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA | | | | | | | |
| N 204251 | 001 | 6316441 | Dec 07, 2019 | U-778 | | | |
| | | 9044484 | Oct 30, 2030 | DP | | | |
| | | 9421265 | Jun 17, 2030 | DP | | | |
| BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN | | | | | | | |
| N 021398 | 001 | 7030149 | Apr 19, 2022 | U-849 | | | |
| | | 7320976 | Apr 19, 2022 | U-849 | | | |
| | | 7323463 | Jan 19, 2023 | DP | Y | | |
| | | 7642258 | Apr 19, 2022 | DS DP U-1024 | | | |
| | | 8133890 | Apr 19, 2022 | U-1235 | | | |
| | | 8354409 | Apr 19, 2022 | DP U-1371 | | | |
| | | 8748425 | Apr 19, 2022 | DP U-1524 | | | |
| | | 9474751 | Apr 19, 2022 | DP U-1524 | | | |
| | | 9770453 | Apr 19, 2022 | DP U-2131 | | | |
| BRIVARACETAM - BRIVIACT | | | | | | | |
| N 205836 | 001 | 6784197 | Feb 21, 2021 | DS DP U-1815 | | NCE | May 12, 2021 |
| | | 6784197 | Feb 21, 2021 | DS DP U-2130 | | | |
| | | 6911461 | Feb 21, 2021 | DS DP U-1815 | | | |
| | | 6911461 | Feb 21, 2021 | DS DP U-2130 | | | |
| | | 8492416 | Feb 21, 2021 | U-1815 | | | |
| | | 8492416 | Feb 21, 2021 | U-2130 | | | |
| BRIVARACETAM - BRIVIACT | | | | | | | |
| N 205836 | 002 | 6784197 | Feb 21, 2021 | DS DP U-1815 | | NCE | May 12, 2021 |
| | | 6784197 | Feb 21, 2021 | DS DP U-2130 | | | |
| | | 6911461 | Feb 21, 2021 | DS DP U-1815 | | | |
| | | 6911461 | Feb 21, 2021 | DS DP U-2130 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| BRIVARACETAM - BRIVIACT | | | | | | |
| N 205836 002 | 8492416 | Feb 21, 2021 | U-1815 | | | |
| | 8492416 | Feb 21, 2021 | U-2130 | | | |
| BRIVARACETAM - BRIVIACT | | | | | | |
| N 205836 003 | 6784197 | Feb 21, 2021 | DS DP U-1815 | | NCE | May 12, 2021 |
| | 6784197 | Feb 21, 2021 | DS DP U-2130 | | | |
| | 6911461 | Feb 21, 2021 | DS DP U-1815 | | | |
| | 6911461 | Feb 21, 2021 | DS DP U-2130 | | | |
| | 8492416 | Feb 21, 2021 | U-1815 | | | |
| | 8492416 | Feb 21, 2021 | U-2130 | | | |
| BRIVARACETAM - BRIVIACT | | | | | | |
| N 205836 004 | 6784197 | Feb 21, 2021 | DS DP U-1815 | | NCE | May 12, 2021 |
| | 6784197 | Feb 21, 2021 | DS DP U-2130 | | | |
| | 6911461 | Feb 21, 2021 | DS DP U-1815 | | | |
| | 6911461 | Feb 21, 2021 | DS DP U-2130 | | | |
| | 8492416 | Feb 21, 2021 | U-1815 | | | |
| | 8492416 | Feb 21, 2021 | U-2130 | | | |
| BRIVARACETAM - BRIVIACT | | | | | | |
| N 205836 005 | 6784197 | Feb 21, 2021 | DS DP U-1815 | | NCE | May 12, 2021 |
| | 6784197 | Feb 21, 2021 | DS DP U-2130 | | | |
| | 6911461 | Feb 21, 2021 | DS DP U-1815 | | | |
| | 6911461 | Feb 21, 2021 | DS DP U-2130 | | | |
| | 8492416 | Feb 21, 2021 | U-1815 | | | |
| | 8492416 | Feb 21, 2021 | U-2130 | | | |
| BRIVARACETAM - BRIVIACT | | | | | | |
| N 205837 001 | 6784197 | Feb 21, 2021 | DS DP U-1815 | | NCE | May 12, 2021 |
| | 6784197 | Feb 21, 2021 | DS DP U-2130 | | | |
| | 6911461 | Feb 21, 2021 | DS DP U-1815 | | | |
| | 6911461 | Feb 21, 2021 | DS DP U-2130 | | | |
| | 8492416 | Feb 21, 2021 | U-1815 | | | |
| | 8492416 | Feb 21, 2021 | U-2130 | | | |
| BRIVARACETAM - BRIVIACT | | | | | | |
| N 205838 001 | 6784197 | Feb 21, 2021 | DS DP U-1815 | | NCE | May 12, 2021 |
| | 6784197 | Feb 21, 2021 | DS DP U-2130 | | | |
| | 6911461 | Feb 21, 2021 | DS DP U-1815 | | | |
| | 6911461 | Feb 21, 2021 | DS DP U-2130 | | | |
| | 8492416 | Feb 21, 2021 | U-1815 | | | |
| | 8492416 | Feb 21, 2021 | U-2130 | | | |
| BROMFENAC SODIUM - PROLENSA | | | | | | |
| N 203168 001 | 8129431 | Sep 11, 2025 | DS DP | | | |
| | 8669290 | Jan 16, 2024 | DP | | | |
| | 8754131 | Jan 16, 2024 | DP | | | |
| | 8871813 | Jan 16, 2024 | DP | | | |
| | 8927606 | Jan 16, 2024 | U-100 | | | |
| | 8927606 | Jan 16, 2024 | U-1095 | | | |
| | 8927606 | Jan 16, 2024 | U-810 | | | |
| | 9144609 | Jan 16, 2024 | DP | | | |
| | 9517220 | Nov 11, 2033 | U-1933 | | | |
| | 9561277 | Jan 16, 2024 | U-1933 | | | |
| BROMFENAC SODIUM - BROMSITE | | | | | | |
| N 206911 001 | 8778999 | Sep 03, 2029 | DP U-1834 | | NP | Apr 08, 2019 |
| BROMOCRIPTINE MESYLATE - CYCLOSET | | | | | | |
| N 020866 001 | 7888310 | Jul 25, 2023 | U-1433 | | | |
| | 8137992 | Jul 25, 2023 | U-1433 | | | |
| | 8137993 | Jul 25, 2023 | U-1433 | | | |
| | 8137994 | Jul 25, 2023 | U-1433 | | | |
| | 8431155 | Apr 30, 2032 | DP U-976 | | | |
| | 8613947 | Apr 30, 2032 | DP U-976 | | | |
| | 8877708 | Jun 07, 2030 | DP U-1706 | | | |
| | 9192576 | Apr 30, 2032 | DP U-976 | | | |
| | 9352025 | Jun 07, 2030 | U-2111 | | | |
| | 9352025 | Jun 07, 2030 | U-2112 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| BROMOCRIPTINE MESYLATE - CYCLOSET | | | | | | | |
| N 020866 | 001 | 9352025 | Jun 07, 2030 | U-2113 | | | |
| | | 9352025 | Jun 07, 2030 | U-2114 | | | |
| | | 9352025 | Jun 07, 2030 | U-2115 | | | |
| | | 9352025 | Jun 07, 2030 | U-2116 | | | |
| | | 9352025 | Jun 07, 2030 | U-2117 | | | |
| | | 9352025 | Jun 07, 2030 | U-2118 | | | |
| | | 9352025 | Jun 07, 2030 | U-2119 | | | |
| | | 9522117 | Apr 30, 2032 | DP U-1939 | | | |
| | | 9522117 | Apr 30, 2032 | DP U-976 | | | |
| | | 9700555 | Apr 30, 2032 | DP U-2183 | | | |
| | | 9700555 | Apr 30, 2032 | DP U-2184 | | | |
| | | 9700555 | Apr 30, 2032 | DP U-2185 | | | |
| | | 9700555 | Apr 30, 2032 | DP U-2186 | | | |
| | | 9700555 | Apr 30, 2032 | DP U-2187 | | | |
| | | 9700555 | Apr 30, 2032 | DP U-2188 | | | |
| | | 9700555 | Apr 30, 2032 | DP U-2189 | | | |
| | | 9700555 | Apr 30, 2032 | DP U-2190 | | | |
| | | 9700555 | Apr 30, 2032 | DP U-2191 | | | |
| | | 9700555 | Apr 30, 2032 | DP U-2192 | | | |
| | | 9700555 | Apr 30, 2032 | DP U-2193 | | | |
| | | 9700555 | Apr 30, 2032 | DP U-2194 | | | |
| | | 9700555 | Apr 30, 2032 | DP U-2195 | | | |
| | | 9700555 | Apr 30, 2032 | DP U-2196 | | | |
| | | 9700555 | Apr 30, 2032 | DP U-2197 | | | |
| | | 9700555 | Apr 30, 2032 | DP U-2198 | | | |
| BUDESONIDE - PULMICORT RESPULES | | | | | | | |
| N 020929 | 001 | 6598603 | Dec 23, 2018 | U-529 | | | |
| | | 6899099 | Dec 23, 2018 | U-529 | | | |
| | | 7524834 | Nov 11, 2018 | DP U-966 | | | |
| BUDESONIDE - PULMICORT RESPULES | | | | | | | |
| N 020929 | 002 | 6598603 | Dec 23, 2018 | U-529 | | | |
| | | 6899099 | Dec 23, 2018 | U-529 | | | |
| | | 7524834 | Nov 11, 2018 | DP U-966 | | | |
| BUDESONIDE - PULMICORT RESPULES | | | | | | | |
| N 020929 | 003 | 6598603 | Dec 23, 2018 | U-529 | | | |
| | | 6899099 | Dec 23, 2018 | U-529 | | | |
| | | 7524834 | Nov 11, 2018 | DP U-966 | | | |
| BUDESONIDE - ENTOCORT EC | | | | | | | |
| N 021324 | 001 | | | | | M-178 | Apr 29, 2019 |
| | | | | | | NPP | Apr 29, 2019 |
| BUDESONIDE - PULMICORT FLEXHALER | | | | | | | |
| N 021949 | 001 | 6027714 | Jan 09, 2018 | DP U-787 | | | |
| | | 6142145 | May 08, 2018 | DP | | | |
| | | 6287540 | Jan 09, 2018 | DP | | | |
| | | 7143764 | Mar 13, 2018 | DP | | | |
| BUDESONIDE - PULMICORT FLEXHALER | | | | | | | |
| N 021949 | 002 | 6027714 | Jan 09, 2018 | DP U-787 | | | |
| | | 6142145 | May 08, 2018 | DP | | | |
| | | 6287540 | Jan 09, 2018 | DP | | | |
| | | 7143764 | Mar 13, 2018 | DP | | | |
| BUDESONIDE - UCERIS | | | | | | | |
| N 203634 | 001 | 7410651 | Jun 09, 2020 | DP U-1325 | | | |
| | | 7431943 | Jun 09, 2020 | DP | | | |
| | | 8293273 | Jun 09, 2020 | DP | | | |
| | | 8784888 | Jun 09, 2020 | DP | | | |
| | | 8895064 | Sep 07, 2031 | DP | | | |
| | | 9132093 | Sep 07, 2031 | DP | | | |
| | | 9192581 | Sep 07, 2031 | DP U-1325 | | | |
| | | 9320716 | Jun 09, 2020 | DP U-1325 | | | |
| | | 9532954 | Jun 09, 2020 | DP U-1325 | | | |
| | | RE43799 | Jun 09, 2020 | DP U-1325 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| BUDESONIDE - UCERIS | | | | | | |
| N 205613 001 | | | | | NP | Oct 07, 2017 |
| BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT | | | | | | |
| N 021929 001 | 6123924 | Sep 26, 2017 | DP | | M-210 | Sep 11, 2020 |
| | 7367333 | Nov 11, 2018 | DP | | M-214 | Dec 20, 2020 |
| | 7367333*PED | May 11, 2019 | | | NPP | Jan 27, 2020 |
| | 7587988 | Apr 10, 2026 | DP | | PED | Jul 27, 2020 |
| | 7587988*PED | Oct 10, 2026 | | | | |
| | 7759328 | Jan 29, 2023 | DP U-2001 | | | |
| | 7759328 | Jan 29, 2023 | DP U-2002 | | | |
| | 7759328 | Jan 29, 2023 | DP U-2122 | | | |
| | 7759328*PED | Jul 29, 2023 | | | | |
| | 7967011 | Aug 11, 2021 | DP | | | |
| | 7967011*PED | Feb 11, 2022 | | | | |
| | 8143239 | Jan 29, 2023 | DP U-2001 | | | |
| | 8143239 | Jan 29, 2023 | DP U-2002 | | | |
| | 8143239 | Jan 29, 2023 | DP U-2122 | | | |
| | 8143239*PED | Jul 29, 2023 | | | | |
| | 8387615 | Nov 10, 2024 | DP | | | |
| | 8387615*PED | May 10, 2025 | | | | |
| | 8528545 | Oct 16, 2028 | DP | | | |
| | 8528545*PED | Apr 16, 2029 | | | | |
| | 8575137 | Jan 29, 2023 | DP U-2001 | | | |
| | 8575137 | Jan 29, 2023 | DP U-2002 | | | |
| | 8575137 | Jan 29, 2023 | DP U-2122 | | | |
| | 8575137*PED | Jul 29, 2023 | | | | |
| | 8616196 | Apr 07, 2029 | DP | | | |
| | 8616196*PED | Oct 07, 2029 | | | | |
| | 8875699 | Nov 10, 2024 | DP | | | |
| | 8875699*PED | May 10, 2025 | | | | |
| BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT | | | | | | |
| N 021929 002 | 6123924 | Sep 26, 2017 | DP | | M-210 | Sep 11, 2020 |
| | 7367333 | Nov 11, 2018 | DP | | M-214 | Dec 20, 2020 |
| | 7367333*PED | May 11, 2019 | | | | |
| | 7587988 | Apr 10, 2026 | DP | | | |
| | 7587988*PED | Oct 10, 2026 | | | | |
| | 7759328 | Jan 29, 2023 | DP U-2001 | | | |
| | 7759328 | Jan 29, 2023 | DP U-2002 | | | |
| | 7759328 | Jan 29, 2023 | DP U-2122 | | | |
| | 7759328*PED | Jul 29, 2023 | | | | |
| | 7897646 | Sep 09, 2018 | U-2002 | | | |
| | 7897646 | Sep 09, 2018 | U-2122 | | | |
| | 7897646*PED | Mar 09, 2019 | | | | |
| | 7967011 | Aug 11, 2021 | DP | | | |
| | 7967011*PED | Feb 11, 2022 | | | | |
| | 8143239 | Jan 29, 2023 | DP U-2001 | | | |
| | 8143239 | Jan 29, 2023 | DP U-2002 | | | |
| | 8143239 | Jan 29, 2023 | DP U-2122 | | | |
| | 8143239*PED | Jul 29, 2023 | | | | |
| | 8387615 | Nov 10, 2024 | DP | | | |
| | 8387615*PED | May 10, 2025 | | | | |
| | 8461211 | Sep 09, 2018 | U-2002 | | | |
| | 8461211 | Sep 09, 2018 | U-2122 | | | |
| | 8461211*PED | Mar 09, 2019 | | | | |
| | 8528545 | Oct 16, 2028 | DP | | | |
| | 8528545*PED | Apr 16, 2029 | | | | |
| | 8575137 | Jan 29, 2023 | DP U-2001 | | | |
| | 8575137 | Jan 29, 2023 | DP U-2002 | | | |
| | 8575137 | Jan 29, 2023 | DP U-2122 | | | |
| | 8575137*PED | Jul 29, 2023 | | | | |
| | 8616196 | Apr 07, 2029 | DP | | | |
| | 8616196*PED | Oct 07, 2029 | | | | |
| | 8875699 | Nov 10, 2024 | DP | | | |
| | 8875699*PED | May 10, 2025 | | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| BUPIVACAINE - EXPAREL | | | | | | |
| N 022496 001 | 8182835 | Sep 18, 2018 | DP U-1246 | | | |
| | 8834921 | Sep 18, 2018 | DP U-1587 | | | |
| | 9585838 | Dec 24, 2021 | DP | | | |
| BUPIVACAINE - EXPAREL | | | | | | |
| N 022496 002 | 8182835 | Sep 18, 2018 | DP U-1246 | | | |
| | 8834921 | Sep 18, 2018 | DP U-1587 | | | |
| | 9205052 | Sep 18, 2018 | U-1246 | | | |
| | 9585838 | Dec 24, 2021 | DP | | | |
| BUPRENORPHINE - BUTRANS | | | | | | |
| N 021306 001 | 9642850 | Sep 29, 2017 | U-1556 | | | |
| | RE41408 | Sep 29, 2017 | U-1072 | | | |
| | RE41408 | Sep 29, 2017 | U-1556 | | | |
| | RE41489 | Sep 29, 2017 | U-1072 | | | |
| | RE41489 | Sep 29, 2017 | U-1556 | | | |
| | RE41571 | Sep 29, 2017 | U-1072 | | | |
| | RE41571 | Sep 29, 2017 | U-1556 | | | |
| BUPRENORPHINE - BUTRANS | | | | | | |
| N 021306 002 | 9642850 | Sep 29, 2017 | U-1556 | | | |
| | RE41408 | Sep 29, 2017 | U-1072 | | | |
| | RE41408 | Sep 29, 2017 | U-1556 | | | |
| | RE41489 | Sep 29, 2017 | U-1072 | | | |
| | RE41489 | Sep 29, 2017 | U-1556 | | | |
| | RE41571 | Sep 29, 2017 | U-1072 | | | |
| | RE41571 | Sep 29, 2017 | U-1556 | | | |
| BUPRENORPHINE - BUTRANS | | | | | | |
| N 021306 003 | 9642850 | Sep 29, 2017 | U-1556 | | | |
| | RE41408 | Sep 29, 2017 | U-1072 | | | |
| | RE41408 | Sep 29, 2017 | U-1556 | | | |
| | RE41489 | Sep 29, 2017 | U-1072 | | | |
| | RE41489 | Sep 29, 2017 | U-1556 | | | |
| | RE41571 | Sep 29, 2017 | U-1072 | | | |
| | RE41571 | Sep 29, 2017 | U-1556 | | | |
| BUPRENORPHINE - BUTRANS | | | | | | |
| N 021306 004 | 9642850 | Sep 29, 2017 | U-1556 | | | |
| | RE41408 | Sep 29, 2017 | U-1072 | | | |
| | RE41408 | Sep 29, 2017 | U-1556 | | | |
| | RE41489 | Sep 29, 2017 | U-1072 | | | |
| | RE41489 | Sep 29, 2017 | U-1556 | | | |
| | RE41571 | Sep 29, 2017 | U-1072 | | | |
| | RE41571 | Sep 29, 2017 | U-1556 | | | |
| BUPRENORPHINE - BUTRANS | | | | | | |
| N 021306 005 | 9642850 | Sep 29, 2017 | U-1556 | | | |
| | RE41408 | Sep 29, 2017 | U-1072 | | | |
| | RE41408 | Sep 29, 2017 | U-1556 | | | |
| | RE41489 | Sep 29, 2017 | U-1072 | | | |
| | RE41489 | Sep 29, 2017 | U-1556 | | | |
| | RE41571 | Sep 29, 2017 | U-1072 | | | |
| | RE41571 | Sep 29, 2017 | U-1556 | | | |
| BUPRENORPHINE - SUBLOCADE | | | | | | |
| N 209819 001 | 8921387 | Jan 06, 2032 | DP U-2173 | | | |
| | 8921387 | Jan 06, 2032 | DP U-2174 | | | |
| | 8975270 | Sep 05, 2031 | DP U-2175 | | | |
| | 8975270 | Sep 05, 2031 | DP U-2206 | | | |
| | 9272044 | Jun 06, 2031 | U-2176 | | | |
| | 9272044 | Jun 06, 2031 | U-2177 | | | |
| | 9272044 | Jun 06, 2031 | U-2178 | | | |
| | 9272044 | Jun 06, 2031 | U-2209 | | | |
| | 9498432 | Jun 06, 2031 | DP U-2179 | | | |
| | 9782402 | Jun 06, 2031 | DP U-2176 | | | |
| | 9782402 | Jun 06, 2031 | DP U-2180 | | | |
| | 9782402 | Jun 06, 2031 | DP U-2207 | | | |
| | 9782402 | Jun 06, 2031 | DP U-2208 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|
| BUPRENORPHINE - SUBLOCADE | | | | | | | | |
| N | 209819 | 001 | 9827241 | Jun 06, 2031 | DP U-2174 | | | |
| | | | 9827241 | Jun 06, 2031 | DP U-2181 | | | |
| | | | 9827241 | Jun 06, 2031 | DP U-2206 | | | |
| | | | 9827241 | Jun 06, 2031 | DP U-2210 | | | |
| | | | 9827241 | Jun 06, 2031 | DP U-2211 | | | |
| BUPRENORPHINE - SUBLOCADE | | | | | | | | |
| N | 209819 | 002 | 8921387 | Jan 06, 2032 | DP U-2173 | | | |
| | | | 8921387 | Jan 06, 2032 | DP U-2174 | | | |
| | | | 8975270 | Sep 05, 2031 | DP U-2175 | | | |
| | | | 8975270 | Sep 05, 2031 | DP U-2206 | | | |
| | | | 9272044 | Jun 06, 2031 | U-2176 | | | |
| | | | 9272044 | Jun 06, 2031 | U-2177 | | | |
| | | | 9272044 | Jun 06, 2031 | U-2178 | | | |
| | | | 9272044 | Jun 06, 2031 | U-2209 | | | |
| | | | 9498432 | Jun 06, 2031 | DP U-2179 | | | |
| | | | 9782402 | Jun 06, 2031 | DP U-2176 | | | |
| | | | 9782402 | Jun 06, 2031 | DP U-2180 | | | |
| | | | 9782402 | Jun 06, 2031 | DP U-2207 | | | |
| | | | 9782402 | Jun 06, 2031 | DP U-2208 | | | |
| | | | 9827241 | Jun 06, 2031 | DP U-2174 | | | |
| | | | 9827241 | Jun 06, 2031 | DP U-2181 | | | |
| | | | 9827241 | Jun 06, 2031 | DP U-2206 | | | |
| | | | 9827241 | Jun 06, 2031 | DP U-2210 | | | |
| | | | 9827241 | Jun 06, 2031 | DP U-2211 | | | |
| BUPRENORPHINE HYDROCHLORIDE - PROBUPHINE | | | | | | | | |
| N | 204442 | 001 | 7736665 | Apr 25, 2024 | U-1878 | | NP | May 26, 2019 |
| BUPRENORPHINE HYDROCHLORIDE - BELBUCA | | | | | | | | |
| N | 207932 | 001 | 7579019 | Jan 22, 2020 | U-1769 | | NP | Oct 23, 2018 |
| | | | 8147866 | Jul 23, 2027 | DP U-1769 | | | |
| | | | 9655843 | Jul 23, 2027 | DP U-1556 | | | |
| BUPRENORPHINE HYDROCHLORIDE - BELBUCA | | | | | | | | |
| N | 207932 | 002 | 7579019 | Jan 22, 2020 | U-1769 | | NP | Oct 23, 2018 |
| | | | 8147866 | Jul 23, 2027 | DP U-1769 | | | |
| | | | 9655843 | Jul 23, 2027 | DP U-1556 | | | |
| BUPRENORPHINE HYDROCHLORIDE - BELBUCA | | | | | | | | |
| N | 207932 | 003 | 7579019 | Jan 22, 2020 | U-1769 | | NP | Oct 23, 2018 |
| | | | 8147866 | Jul 23, 2027 | DP U-1769 | | | |
| | | | 9655843 | Jul 23, 2027 | DP U-1556 | | | |
| BUPRENORPHINE HYDROCHLORIDE - BELBUCA | | | | | | | | |
| N | 207932 | 004 | 7579019 | Jan 22, 2020 | U-1769 | | NP | Oct 23, 2018 |
| | | | 8147866 | Jul 23, 2027 | DP U-1769 | | | |
| | | | 9655843 | Jul 23, 2027 | DP U-1556 | | | |
| BUPRENORPHINE HYDROCHLORIDE - BELBUCA | | | | | | | | |
| N | 207932 | 005 | 7579019 | Jan 22, 2020 | U-1769 | | NP | Oct 23, 2018 |
| | | | 8147866 | Jul 23, 2027 | DP U-1769 | | | |
| | | | 9655843 | Jul 23, 2027 | DP U-1556 | | | |
| BUPRENORPHINE HYDROCHLORIDE - BELBUCA | | | | | | | | |
| N | 207932 | 006 | 7579019 | Jan 22, 2020 | U-1769 | | NP | Oct 23, 2018 |
| | | | 8147866 | Jul 23, 2027 | DP U-1769 | | | |
| | | | 9655843 | Jul 23, 2027 | DP U-1556 | | | |
| BUPRENORPHINE HYDROCHLORIDE - BELBUCA | | | | | | | | |
| N | 207932 | 007 | 7579019 | Jan 22, 2020 | U-1769 | | NP | Oct 23, 2018 |
| | | | 8147866 | Jul 23, 2027 | DP U-1769 | | | |
| | | | 9655843 | Jul 23, 2027 | DP U-1556 | | | |
| BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE | | | | | | | | |
| N | 022410 | 001 | 8017150 | Feb 13, 2023 | DP | | | |
| | | | 8475832 | Mar 26, 2030 | DP U-1411 | | | |
| | | | 8603514 | Apr 03, 2024 | DP U-1464 | | | |
| | | | 9687454 | Aug 07, 2029 | DP U-1464 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE | | | | | | | |
| N 022410 | 001 | 9855221 | Feb 14, 2022 | DP | | | |
| BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE | | | | | | | |
| N 022410 | 002 | 8017150 | Feb 13, 2023 | DP | | | |
| | | 8475832 | Mar 26, 2030 | DP U-1411 | | | |
| | | 8603514 | Apr 03, 2024 | DP U-1464 | | | |
| | | 9687454 | Aug 07, 2029 | DP U-1464 | | | |
| | | 9855221 | Feb 14, 2022 | DP | | | |
| BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE | | | | | | | |
| N 022410 | 003 | 8017150 | Feb 13, 2023 | DP | | | |
| | | 8475832 | Mar 26, 2030 | DP U-1411 | | | |
| | | 8603514 | Apr 03, 2024 | DP U-1464 | | | |
| | | 9687454 | Aug 07, 2029 | DP U-1464 | | | |
| | | 9855221 | Feb 14, 2022 | DP | | | |
| BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE | | | | | | | |
| N 022410 | 004 | 8017150 | Feb 13, 2023 | DP | | | |
| | | 8475832 | Mar 26, 2030 | DP U-1411 | | | |
| | | 8603514 | Apr 03, 2024 | DP U-1464 | | | |
| | | 9687454 | Aug 07, 2029 | DP U-1464 | | | |
| | | 9855221 | Feb 14, 2022 | DP | | | |
| BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV | | | | | | | |
| N 204242 | 001 | 8454996 | Sep 24, 2019 | U-1421 | | I-713 | Aug 10, 2018 |
| | | 8470361 | May 22, 2030 | DP U-1425 | | | |
| | | 8658198 | Dec 03, 2027 | DP U-1494 | | | |
| | | 8940330 | Sep 18, 2032 | DP | | | |
| | | 9259421 | Sep 18, 2032 | DP | | | |
| | | 9439900 | Sep 18, 2032 | DP | | | |
| BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV | | | | | | | |
| N 204242 | 002 | 8454996 | Sep 24, 2019 | U-1421 | | I-713 | Aug 10, 2018 |
| | | 8470361 | May 22, 2030 | DP U-1425 | | | |
| | | 8658198 | Dec 03, 2027 | DP U-1494 | | | |
| | | 8940330 | Sep 18, 2032 | DP | | | |
| | | 9259421 | Sep 18, 2032 | DP | | | |
| | | 9439900 | Sep 18, 2032 | DP | | | |
| BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV | | | | | | | |
| N 204242 | 003 | 8454996 | Sep 24, 2019 | U-1421 | | I-713 | Aug 10, 2018 |
| | | 8470361 | May 22, 2030 | DP U-1425 | | | |
| | | 8658198 | Dec 03, 2027 | DP U-1494 | | | |
| | | 8940330 | Sep 18, 2032 | DP | | | |
| | | 9259421 | Sep 18, 2032 | DP | | | |
| | | 9439900 | Sep 18, 2032 | DP | | | |
| BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV | | | | | | | |
| N 204242 | 004 | 8454996 | Sep 24, 2019 | U-1421 | | I-713 | Aug 10, 2018 |
| | | 8470361 | May 22, 2030 | DP U-1425 | | | |
| | | 8658198 | Dec 03, 2027 | DP U-1494 | | | |
| | | 8940330 | Sep 18, 2032 | DP | | | |
| | | 9259421 | Sep 18, 2032 | DP | | | |
| | | 9439900 | Sep 18, 2032 | DP | | | |
| BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV | | | | | | | |
| N 204242 | 005 | 8454996 | Sep 24, 2019 | U-1421 | | I-713 | Aug 10, 2018 |
| | | 8470361 | May 22, 2030 | DP U-1425 | | | |
| | | 8658198 | Dec 03, 2027 | DP U-1494 | | | |
| | | 8940330 | Sep 18, 2032 | DP | | | |
| | | 9259421 | Sep 18, 2032 | DP | | | |
| | | 9439900 | Sep 18, 2032 | DP | | | |
| BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV | | | | | | | |
| N 204242 | 006 | 8454996 | Sep 24, 2019 | U-1421 | | I-713 | Aug 10, 2018 |
| | | 8470361 | May 22, 2030 | DP U-1425 | | | |
| | | 8658198 | Dec 03, 2027 | DP U-1494 | | | |
| | | 8940330 | Sep 18, 2032 | DP | | | |
| | | 9259421 | Sep 18, 2032 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV | | | | | | | |
| N 204242 | 006 | 9439900 | Sep 18, 2032 | DP | Y | | |
| BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL | | | | | | | |
| N 205637 | 001 | 7579019 | Jan 22, 2020 | U-1521 | | | |
| | | 8147866 | Jul 23, 2027 | DP U-1521 | | | |
| | | 8703177 | Aug 20, 2032 | DP | | | |
| | | 9522188 | Apr 24, 2035 | DP | | | |
| | | 9655843 | Jul 23, 2027 | DP U-2017 | | | |
| BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL | | | | | | | |
| N 205637 | 002 | 7579019 | Jan 22, 2020 | U-1521 | | | |
| | | 8147866 | Jul 23, 2027 | DP U-1521 | | | |
| | | 8703177 | Aug 20, 2032 | DP | | | |
| | | 9522188 | Apr 24, 2035 | DP | | | |
| | | 9655843 | Jul 23, 2027 | DP U-2017 | | | |
| BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL | | | | | | | |
| N 205637 | 003 | 7579019 | Jan 22, 2020 | U-1521 | | | |
| | | 8147866 | Jul 23, 2027 | DP U-1521 | | | |
| | | 8703177 | Aug 20, 2032 | DP | | | |
| | | 9522188 | Apr 24, 2035 | DP | | | |
| | | 9655843 | Jul 23, 2027 | DP U-2017 | | | |
| BUPROPION HYDROBROMIDE - APLENZIN | | | | | | | |
| N 022108 | 001 | 7241805 | Jun 27, 2026 | DP | | | |
| | | 7569610 | Jun 27, 2026 | U-997 | | | |
| | | 7572935 | Jun 27, 2026 | DP | | | |
| | | 7585897 | Jun 27, 2026 | DP | | | |
| | | 7645802 | Jun 27, 2026 | DP | | | |
| | | 7649019 | Jun 27, 2026 | DP | | | |
| | | 7662407 | Jun 27, 2026 | DP | | | |
| | | 7671094 | Jun 27, 2026 | DP | | | |
| BUPROPION HYDROBROMIDE - APLENZIN | | | | | | | |
| N 022108 | 002 | 7241805 | Jun 27, 2026 | DP | | | |
| | | 7569610 | Jun 27, 2026 | U-997 | | | |
| | | 7572935 | Jun 27, 2026 | DP | | | |
| | | 7585897 | Jun 27, 2026 | DP | | | |
| | | 7645802 | Jun 27, 2026 | DP | | | |
| | | 7649019 | Jun 27, 2026 | DP | | | |
| | | 7662407 | Jun 27, 2026 | DP | | | |
| | | 7671094 | Jun 27, 2026 | DP | | | |
| BUPROPION HYDROBROMIDE - APLENZIN | | | | | | | |
| N 022108 | 003 | 7241805 | Jun 27, 2026 | DP | | | |
| | | 7569610 | Jun 27, 2026 | U-997 | | | |
| | | 7572935 | Jun 27, 2026 | DP | | | |
| | | 7585897 | Jun 27, 2026 | DP | | | |
| | | 7645802 | Jun 27, 2026 | DP | | | |
| | | 7649019 | Jun 27, 2026 | DP | | | |
| | | 7662407 | Jun 27, 2026 | DP | | | |
| | | 7671094 | Jun 27, 2026 | DP | | | |
| BUPROPION HYDROCHLORIDE - WELLBUTRIN XL | | | | | | | |
| N 021515 | 001 | 6096341 | Oct 30, 2018 | | | | |
| BUPROPION HYDROCHLORIDE - WELLBUTRIN XL | | | | | | | |
| N 021515 | 002 | 6096341 | Oct 30, 2018 | | | | |
| BUPROPION HYDROCHLORIDE - FORFIVO XL | | | | | | | |
| N 022497 | 001 | 7674479 | Jun 25, 2027 | DP | | | |
| BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE | | | | | | | |
| N 200063 | 001 | 7375111 | Mar 26, 2025 | DP | | NC | Sep 10, 2017 |
| | | 7462626 | Jul 20, 2024 | U-1583 | | | |
| | | 8088786 | Feb 03, 2029 | DP | | | |
| | | 8318788 | Nov 08, 2027 | U-1584 | | | |
| | | 8722085 | Nov 08, 2027 | U-1585 | | | |
| | | 8815889 | Jul 20, 2024 | U-1586 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE | | | | | | | |
| N 200063 | 001 | 8916195 | Feb 02, 2030 | U-1639 | | | |
| | | 9107837 | Jun 04, 2027 | U-1639 | | | |
| | | 9125868 | Nov 08, 2027 | U-1585 | | | |
| | | 9248123 | Jan 13, 2032 | U-1808 | | | |
| BUTOCONAZOLE NITRATE - BUTOCONAZOLE NITRATE | | | | | | | |
| N 019881 | 001 | 5993856 | Nov 17, 2017 | DP U-457 | | | |
| CABAZITAXEL - JEVTANA KIT | | | | | | | |
| N 201023 | 001 | 5847170 | Mar 26, 2021 | DS DP | | M-201 | May 17, 2020 |
| | | 5847170*PED | Sep 26, 2021 | | | M-209 | Sep 14, 2020 |
| | | 7241907 | Dec 10, 2025 | DS | | PED | Nov 17, 2020 |
| | | 7241907*PED | Jun 10, 2026 | | | | |
| | | 8927592 | Oct 27, 2030 | U-1630 | | | |
| | | 8927592*PED | Apr 27, 2031 | | | | |
| CABOZANTINIB S-MALATE - COMETRIQ | | | | | | | |
| N 203756 | 001 | 7579473 | Aug 14, 2026 | DS DP | | NCE | Nov 29, 2017 |
| | | 8877776 | Oct 08, 2030 | DS DP U-1617 | | ODE-33 | Nov 29, 2019 |
| | | 9717720 | Feb 10, 2032 | DP | | | |
| CABOZANTINIB S-MALATE - COMETRIQ | | | | | | | |
| N 203756 | 002 | 7579473 | Aug 14, 2026 | DS DP | | NCE | Nov 29, 2017 |
| | | 8877776 | Oct 08, 2030 | DS DP U-1617 | | ODE-33 | Nov 29, 2019 |
| | | 9717720 | Feb 10, 2032 | DP | | | |
| CABOZANTINIB S-MALATE - CABOMETYX | | | | | | | |
| N 208692 | 001 | 7579473 | Aug 14, 2026 | DS DP | | I-760 | Dec 19, 2020 |
| | | 8497284 | Sep 24, 2024 | U-1220 | | NCE | Nov 29, 2017 |
| | | 8877776 | Oct 08, 2030 | DS DP | | NP | Apr 25, 2019 |
| | | 9724342 | Jul 09, 2033 | DP | | | |
| CABOZANTINIB S-MALATE - CABOMETYX | | | | | | | |
| N 208692 | 002 | 7579473 | Aug 14, 2026 | DS DP | | I-760 | Dec 19, 2020 |
| | | 8497284 | Sep 24, 2024 | U-1220 | | NCE | Nov 29, 2017 |
| | | 8877776 | Oct 08, 2030 | DS DP | | NP | Apr 25, 2019 |
| | | 9724342 | Jul 09, 2033 | DP | | | |
| CABOZANTINIB S-MALATE - CABOMETYX | | | | | | | |
| N 208692 | 003 | 7579473 | Aug 14, 2026 | DS DP | | I-760 | Dec 19, 2020 |
| | | 8497284 | Sep 24, 2024 | U-1220 | | NCE | Nov 29, 2017 |
| | | 8877776 | Oct 08, 2030 | DS DP | | NP | Apr 25, 2019 |
| | | 9724342 | Jul 09, 2033 | DP | | | |
| CALCIFEDIOL - RAYALDEE | | | | | | | |
| N 208010 | 001 | 6582727 | Aug 22, 2020 | DP | | NP | Jun 17, 2019 |
| | | 8207149 | Apr 25, 2028 | U-1871 | | | |
| | | 8361488 | Jul 19, 2028 | DP | | | |
| | | 8426391 | Aug 27, 2028 | DP U-1872 | | | |
| | | 8778373 | Apr 25, 2028 | U-1873 | | | |
| | | 8906410 | Feb 02, 2027 | DP | | | |
| | | 9408858 | Apr 25, 2028 | U-1888 | | | |
| | | 9498486 | Apr 25, 2028 | U-1920 | | | |
| CALCIPOTRIENE - SORILUX | | | | | | | |
| N 022563 | 001 | 8263580 | Sep 27, 2028 | DP U-1280 | | | |
| | | 8629128 | May 26, 2026 | DP U-1280 | | | |
| | | 8629128 | May 26, 2026 | DP U-1767 | | | |
| CALCITONIN SALMON RECOMBINANT - FORTICAL | | | | | | | |
| N 021406 | 001 | 6440392 | Feb 02, 2021 | DP U-227 | | | |
| | | RE40812 | Feb 02, 2021 | DP | | | |
| | | RE43580 | Feb 02, 2021 | DP U-227 | | | |
| CALCITRIOL - CALCIJEX | | | | | | | |
| N 018874 | 001 | 6051567 | Aug 02, 2019 | | | | |
| | | 6265392 | Aug 02, 2019 | | | | |
| | | 6274169 | Aug 02, 2019 | | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| CALCITRIOL - CALCIJEX | | | | | | | |
| N 018874 | 002 | 6051567 | Aug 02, 2019 | | | | |
| | | 6265392 | Aug 02, 2019 | | | | |
| | | 6274169 | Aug 02, 2019 | | | | |
| CALCIUM ACETATE - PHOSLO | | | | | | | |
| N 021160 | 002 | 6576665 | Apr 03, 2021 | | | | |
| CALCIUM ACETATE - PHOSLO GELCAPS | | | | | | | |
| N 021160 | 003 | 6576665 | Apr 03, 2021 | | | | |
| | | 6875445 | Jul 30, 2021 | DP | | | |
| CALCIUM ACETATE - PHOSLYRA | | | | | | | |
| N 022581 | 001 | 8591938 | Feb 23, 2030 | DP | U-1469 | | |
| | | 8592480 | Jul 20, 2027 | | U-1469 | | |
| | | 9089528 | Jul 20, 2027 | | U-1469 | | |
| CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE - PEPCID COMPLETE | | | | | | | |
| N 020958 | 001 | 5989588 | Sep 30, 2017 | DP | U-349 | | |
| | | 5989588*PED | Mar 30, 2018 | | | | |
| | | 6814978 | Aug 26, 2021 | DP | | | |
| CALCIUM CARBONATE; RISEDRONATE SODIUM - ACTONEL WITH CALCIUM (COPACKAGED) | | | | | | | |
| N 021823 | 001 | 5994329 | Jul 17, 2018 | | U-353 | | |
| | | 6015801 | Jul 17, 2018 | | U-353 | | |
| | | 6165513 | Jun 10, 2018 | DP | | | |
| | | 6432932 | Jul 17, 2018 | | U-595 | | |
| | | 6465443 | Aug 14, 2018 | DP | | | |
| CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATIONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - NAVSTEL | | | | | | | |
| N 022193 | 001 | 7084130 | Nov 29, 2021 | DP | U-891 | | |
| CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER | | | | | | | |
| N 207026 | 001 | | | | | ODE-85 | Jan 13, 2022 |
| CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER | | | | | | | |
| N 207026 | 002 | | | | | ODE-85 | Jan 13, 2022 |
| CANAGLIFLOZIN - INVOKANA | | | | | | | |
| N 204042 | 001 | 7943582 | Feb 26, 2029 | DS DP | U-493 | I-733 | May 20, 2019 |
| | | 7943788 | Jul 14, 2027 | DS DP | | M-197 | Feb 01, 2020 |
| | | 8222219 | Jul 30, 2024 | | U-493 | NCE | Mar 29, 2018 |
| | | 8513202 | Dec 03, 2027 | DS DP | U-493 | | |
| CANAGLIFLOZIN - INVOKANA | | | | | | | |
| N 204042 | 002 | 7943582 | Feb 26, 2029 | DS DP | U-493 | I-733 | May 20, 2019 |
| | | 7943788 | Jul 14, 2027 | DS DP | | M-197 | Feb 01, 2020 |
| | | 8222219 | Jul 30, 2024 | | U-493 | NCE | Mar 29, 2018 |
| | | 8513202 | Dec 03, 2027 | DS DP | U-493 | | |
| CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET | | | | | | | |
| N 204353 | 001 | 7943582 | Feb 26, 2029 | DS DP | U-493 | I-735 | May 20, 2019 |
| | | 7943788 | Jul 14, 2027 | DS DP | | M-197 | Feb 01, 2020 |
| | | 8222219 | Jul 30, 2024 | | U-493 | NC | Aug 08, 2017 |
| | | 8513202 | Dec 03, 2027 | DS DP | U-493 | NCE | Mar 29, 2018 |
| | | 8785403 | Jul 30, 2024 | DP | | | |
| CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET | | | | | | | |
| N 204353 | 002 | 7943582 | Feb 26, 2029 | DS DP | U-493 | I-735 | May 20, 2019 |
| | | 7943788 | Jul 14, 2027 | DS DP | | M-197 | Feb 01, 2020 |
| | | 8222219 | Jul 30, 2024 | | U-493 | NC | Aug 08, 2017 |
| | | 8513202 | Dec 03, 2027 | DS DP | U-493 | NCE | Mar 29, 2018 |
| | | 8785403 | Jul 30, 2024 | DP | | | |
| CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET | | | | | | | |
| N 204353 | 003 | 7943582 | Feb 26, 2029 | DS DP | U-493 | I-735 | May 20, 2019 |
| | | 7943788 | Jul 14, 2027 | DS DP | | M-197 | Feb 01, 2020 |
| | | 8222219 | Jul 30, 2024 | | U-493 | NC | Aug 08, 2017 |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET | | | | | | | |
| N 204353 | 003 | 8513202 | Dec 03, 2027 | DS DP U-493 | | NCE | Mar 29, 2018 |
| | | 8785403 | Jul 30, 2024 | DP | | | |
| CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET | | | | | | | |
| N 204353 | 004 | 7943582 | Feb 26, 2029 | DS DP U-493 | | I-735 | May 20, 2019 |
| | | 7943788 | Jul 14, 2027 | DS DP | | M-197 | Feb 01, 2020 |
| | | 8222219 | Jul 30, 2024 | U-493 | | NC | Aug 08, 2017 |
| | | 8513202 | Dec 03, 2027 | DS DP U-493 | | NCE | Mar 29, 2018 |
| | | 8785403 | Jul 30, 2024 | DP | | | |
| CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR | | | | | | | |
| N 205879 | 001 | 6723340 | Oct 25, 2021 | DP | | I-735 | May 20, 2019 |
| | | 7943582 | Feb 26, 2029 | DS DP U-493 | | NC | Aug 08, 2017 |
| | | 7943788 | Jul 14, 2027 | DS DP | | NCE | Mar 29, 2018 |
| | | 8222219 | Jul 30, 2024 | U-493 | | | |
| | | 8513202 | Dec 03, 2027 | DS DP U-493 | | | |
| | | 8785403 | Jul 30, 2024 | DP | | | |
| CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR | | | | | | | |
| N 205879 | 002 | 7943582 | Feb 26, 2029 | DS DP U-493 | | I-735 | May 20, 2019 |
| | | 7943788 | Jul 14, 2027 | DS DP | | NC | Aug 08, 2017 |
| | | 8222219 | Jul 30, 2024 | U-493 | | NCE | Mar 29, 2018 |
| | | 8513202 | Dec 03, 2027 | DS DP U-493 | | | |
| | | 8785403 | Jul 30, 2024 | DP | | | |
| CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR | | | | | | | |
| N 205879 | 003 | 6723340 | Oct 25, 2021 | DP | | I-735 | May 20, 2019 |
| | | 7943582 | Feb 26, 2029 | DS DP U-493 | | NC | Aug 08, 2017 |
| | | 7943788 | Jul 14, 2027 | DS DP | | NCE | Mar 29, 2018 |
| | | 8222219 | Jul 30, 2024 | U-493 | | | |
| | | 8513202 | Dec 03, 2027 | DS DP U-493 | | | |
| | | 8785403 | Jul 30, 2024 | DP | | | |
| CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET XR | | | | | | | |
| N 205879 | 004 | 7943582 | Feb 26, 2029 | DS DP U-493 | | I-735 | May 20, 2019 |
| | | 7943788 | Jul 14, 2027 | DS DP | | NC | Aug 08, 2017 |
| | | 8222219 | Jul 30, 2024 | U-493 | | NCE | Mar 29, 2018 |
| | | 8513202 | Dec 03, 2027 | DS DP U-493 | | | |
| | | 8785403 | Jul 30, 2024 | DP | | | |
| CANGRELOR - KENGREAL | | | | | | | |
| N 204958 | 001 | 6114313 | Dec 11, 2017 | DP U-1715 | | NCE | Jun 22, 2020 |
| | | 6130208 | Jun 29, 2018 | DP U-1715 | | | |
| | | 8680052 | Mar 09, 2033 | U-1715 | | | |
| | | 8759316 | May 13, 2029 | U-1715 | | | |
| | | 9295687 | Jul 10, 2035 | DP | | | |
| | | 9427448 | Nov 10, 2030 | U-1926 | | | |
| | | 9439921 | Jul 10, 2035 | DP | | | |
| | | 9700575 | Jul 10, 2035 | DP | | | |
| CAPSAICIN - QUTENZA | | | | | | | |
| N 022395 | 001 | 6239180 | Jun 04, 2021 | DP | | | |
| CARBAMAZEPINE - EQUETRO | | | | | | | |
| N 021710 | 001 | 6977253 | May 19, 2024 | U-693 | | | |
| CARBAMAZEPINE - EQUETRO | | | | | | | |
| N 021710 | 002 | 6977253 | May 19, 2024 | U-693 | | | |
| CARBAMAZEPINE - EQUETRO | | | | | | | |
| N 021710 | 003 | 6977253 | May 19, 2024 | U-693 | | | |
| CARBAMAZEPINE - CARNEXIV | | | | | | | |
| N 206030 | 001 | 7635773 | Mar 13, 2029 | DP | | ODE-124 | Oct 07, 2023 |
| | | 8410077 | Mar 13, 2029 | DP | | | |
| | | 9493582 | Feb 27, 2033 | DP | | | |
| | | 9629797 | Nov 10, 2028 | U-2004 | | | |
| | | 9629797 | Nov 10, 2028 | U-2005 | | | |
| | | 9629797 | Nov 10, 2028 | U-2006 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| CARBAMAZEPINE - CARNEXIV | | | | | | | |
| N 206030 | 001 | 9750822 | Mar 13, 2029 | DP | | | |
| | | 9770407 | Nov 10, 2028 | DP | | | |
| CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 50 | | | | | | | |
| N 021485 | 001 | 6500867 | Jun 29, 2020 | DP U-219 | | | |
| | | 6797732 | Jun 29, 2020 | DP | | | |
| CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 100 | | | | | | | |
| N 021485 | 002 | 6500867 | Jun 29, 2020 | DP U-219 | | | |
| | | 6797732 | Jun 29, 2020 | DP | | | |
| CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 150 | | | | | | | |
| N 021485 | 003 | 6500867 | Jun 29, 2020 | DP U-219 | | | |
| | | 6797732 | Jun 29, 2020 | DP | | | |
| CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 200 | | | | | | | |
| N 021485 | 004 | 6500867 | Jun 29, 2020 | DP U-219 | | | |
| | | 6797732 | Jun 29, 2020 | DP | | | |
| CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 75 | | | | | | | |
| N 021485 | 005 | 6500867 | Jun 29, 2020 | DP U-219 | | | |
| | | 6797732 | Jun 29, 2020 | DP | | | |
| CARBIDOPA; ENTACAPONE; LEVODOPA - STALEVO 125 | | | | | | | |
| N 021485 | 006 | 6500867 | Jun 29, 2020 | DP U-219 | | | |
| | | 6797732 | Jun 29, 2020 | DP | | | |
| CARBIDOPA; LEVODOPA - RYTARY | | | | | | | |
| N 203312 | 001 | 7094427 | May 29, 2022 | DP U-1645 | | NDF | Jan 07, 2018 |
| | | 8377474 | Dec 26, 2028 | DP U-1645 | | | |
| | | 8377474 | Dec 26, 2028 | DP U-219 | | | |
| | | 8454998 | Dec 26, 2028 | DP U-1645 | | | |
| | | 8454998 | Dec 26, 2028 | DP U-1646 | | | |
| | | 8454998 | Dec 26, 2028 | DP U-1647 | | | |
| | | 8454998 | Dec 26, 2028 | DP U-1649 | | | |
| | | 8454998 | Dec 26, 2028 | DP U-219 | | | |
| | | 8557283 | Dec 26, 2028 | DP U-1645 | | | |
| | | 8557283 | Dec 26, 2028 | DP U-219 | | | |
| | | 9089607 | Dec 26, 2028 | DP U-1645 | | | |
| | | 9089607 | Dec 26, 2028 | DP U-1720 | | | |
| | | 9089608 | Dec 26, 2028 | DP | | | |
| | | 9463246 | Dec 26, 2028 | DP U-219 | | | |
| | | 9533046 | Dec 26, 2028 | DP U-219 | | | |
| CARBIDOPA; LEVODOPA - RYTARY | | | | | | | |
| N 203312 | 002 | 7094427 | May 29, 2022 | DP U-1645 | | NDF | Jan 07, 2018 |
| | | 8377474 | Dec 26, 2028 | DP U-1645 | | | |
| | | 8377474 | Dec 26, 2028 | DP U-219 | | | |
| | | 8454998 | Dec 26, 2028 | DP U-1645 | | | |
| | | 8454998 | Dec 26, 2028 | DP U-1646 | | | |
| | | 8454998 | Dec 26, 2028 | DP U-1647 | | | |
| | | 8454998 | Dec 26, 2028 | DP U-1649 | | | |
| | | 8454998 | Dec 26, 2028 | DP U-219 | | | |
| | | 8557283 | Dec 26, 2028 | DP U-1645 | | | |
| | | 8557283 | Dec 26, 2028 | DP U-219 | | | |
| | | 9089607 | Dec 26, 2028 | DP U-1645 | | | |
| | | 9089607 | Dec 26, 2028 | DP U-1720 | | | |
| | | 9089608 | Dec 26, 2028 | DP | | | |
| | | 9463246 | Dec 26, 2028 | DP U-219 | | | |
| | | 9533046 | Dec 26, 2028 | DP U-219 | | | |
| CARBIDOPA; LEVODOPA - RYTARY | | | | | | | |
| N 203312 | 003 | 7094427 | May 29, 2022 | DP U-1645 | | NDF | Jan 07, 2018 |
| | | 8377474 | Dec 26, 2028 | DP U-1645 | | | |
| | | 8377474 | Dec 26, 2028 | DP U-219 | | | |
| | | 8454998 | Dec 26, 2028 | DP U-1645 | | | |
| | | 8454998 | Dec 26, 2028 | DP U-1646 | | | |
| | | 8454998 | Dec 26, 2028 | DP U-1647 | | | |
| | | 8454998 | Dec 26, 2028 | DP U-1649 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|
| CARBIDOPA; LEVODOPA - RYTARY | | | | | | | | |
| N 203312 | 003 | 8454998 | Dec 26, 2028 | | DP U-219 | | | |
| | | 8557283 | Dec 26, 2028 | | DP U-1645 | | | |
| | | 8557283 | Dec 26, 2028 | | DP U-219 | | | |
| | | 9089607 | Dec 26, 2028 | | DP U-1645 | | | |
| | | 9089607 | Dec 26, 2028 | | DP U-1720 | | | |
| | | 9089608 | Dec 26, 2028 | | DP | | | |
| | | 9463246 | Dec 26, 2028 | | DP U-219 | | | |
| | | 9533046 | Dec 26, 2028 | | DP U-219 | | | |
| CARBIDOPA; LEVODOPA - RYTARY | | | | | | | | |
| N 203312 | 004 | 7094427 | May 29, 2022 | | DP U-1645 | | NDF | Jan 07, 2018 |
| | | 8377474 | Dec 26, 2028 | | DP U-1645 | | | |
| | | 8377474 | Dec 26, 2028 | | DP U-219 | | | |
| | | 8454998 | Dec 26, 2028 | | DP U-1645 | | | |
| | | 8454998 | Dec 26, 2028 | | DP U-1646 | | | |
| | | 8454998 | Dec 26, 2028 | | DP U-1647 | | | |
| | | 8454998 | Dec 26, 2028 | | DP U-1649 | | | |
| | | 8454998 | Dec 26, 2028 | | DP U-219 | | | |
| | | 8557283 | Dec 26, 2028 | | DP U-1645 | | | |
| | | 8557283 | Dec 26, 2028 | | DP U-219 | | | |
| | | 9089607 | Dec 26, 2028 | | DP U-1645 | | | |
| | | 9089607 | Dec 26, 2028 | | DP U-1720 | | | |
| | | 9089608 | Dec 26, 2028 | | DP | | | |
| | | 9463246 | Dec 26, 2028 | | DP U-219 | | | |
| | | 9533046 | Dec 26, 2028 | | DP U-219 | | | |
| CARBIDOPA; LEVODOPA - DUOPA | | | | | | | | |
| N 203952 | 001 | | | | | | NP | Jan 09, 2018 |
| | | | | | | | ODE-84 | Jan 09, 2022 |
| CARBINOXAMINE MALEATE - KARBINAL ER | | | | | | | | |
| N 022556 | 001 | 8062667 | Mar 29, 2029 | | DP | | | |
| | | 9522191 | Jun 15, 2027 | | DP | | | |
| CARFILZOMIB - KYPROLIS | | | | | | | | |
| N 202714 | 001 | 7232818 | Apr 14, 2025 | DS | DP | | I-712 | Jul 24, 2018 |
| | | 7417042 | Jul 20, 2026 | DS | DP | | I-722 | Jan 21, 2019 |
| | | 7491704 | Apr 14, 2025 | | U-1260 | | I-723 | Jan 21, 2019 |
| | | 7737112 | Dec 07, 2027 | | DP | | NCE | Jul 20, 2017 |
| | | 8129346 | Apr 14, 2025 | | U-1260 | | ODE-27 | Jul 20, 2019 |
| | | 8207125 | Apr 14, 2025 | DS | DP | | | |
| | | 8207126 | Apr 14, 2025 | | DP | | | |
| | | 8207127 | Apr 14, 2025 | | U-1260 | | | |
| | | 8207297 | Apr 14, 2025 | DS | DP | | | |
| | | 9493582 | Feb 27, 2033 | | DP | | | |
| | | 9511109 | Oct 21, 2029 | | U-1924 | | | |
| CARFILZOMIB - KYPROLIS | | | | | | | | |
| N 202714 | 002 | 7232818 | Apr 14, 2025 | DS | DP | | I-712 | Jul 24, 2018 |
| | | 7417042 | Jul 20, 2026 | DS | DP | | I-722 | Jan 21, 2019 |
| | | 7491704 | Apr 14, 2025 | | U-1260 | | I-723 | Jan 21, 2019 |
| | | 7737112 | Dec 07, 2027 | | DP | | NCE | Jul 20, 2017 |
| | | 8129346 | Apr 14, 2025 | | U-1260 | | ODE-27 | Jul 20, 2019 |
| | | 8207125 | Apr 14, 2025 | DS | DP | | | |
| | | 8207126 | Apr 14, 2025 | | DP | | | |
| | | 8207127 | Apr 14, 2025 | | U-1260 | | | |
| | | 8207297 | Apr 14, 2025 | DS | DP | | | |
| | | 9493582 | Feb 27, 2033 | | DP | | | |
| | | 9511109 | Oct 21, 2029 | | U-1924 | | | |
| CARIPRAZINE HYDROCHLORIDE - VRAYLAR | | | | | | | | |
| N 204370 | 001 | 7737142 | Mar 27, 2027 | DS | DP U-1750 | | M-213 | Nov 09, 2020 |
| | | 7943621 | Dec 16, 2028 | DS | DP | | NCE | Sep 17, 2020 |
| CARIPRAZINE HYDROCHLORIDE - VRAYLAR | | | | | | | | |
| N 204370 | 002 | 7737142 | Mar 27, 2027 | DS | DP U-1750 | | M-213 | Nov 09, 2020 |
| | | 7943621 | Dec 16, 2028 | DS | DP | | NCE | Sep 17, 2020 |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| CARIPRAZINE HYDROCHLORIDE - VRAYLAR | | | | | | | |
| N 204370 | 003 | 7737142 | Mar 27, 2027 | DS DP U-1750 | | M-213 | Nov 09, 2020 |
| | | 7943621 | Dec 16, 2028 | DS DP | | NCE | Sep 17, 2020 |
| CARIPRAZINE HYDROCHLORIDE - VRAYLAR | | | | | | | |
| N 204370 | 004 | 7737142 | Mar 27, 2027 | DS DP U-1750 | | M-213 | Nov 09, 2020 |
| | | 7943621 | Dec 16, 2028 | DS DP | | NCE | Sep 17, 2020 |
| CARVEDILOL PHOSPHATE - CARVEDILOL PHOSPHATE | | | | | | | |
| A 090132 | 001 | | | | | PC | May 07, 2018 |
| CARVEDILOL PHOSPHATE - CARVEDILOL PHOSPHATE | | | | | | | |
| A 090132 | 002 | | | | | PC | May 07, 2018 |
| CARVEDILOL PHOSPHATE - CARVEDILOL PHOSPHATE | | | | | | | |
| A 090132 | 003 | | | | | PC | May 07, 2018 |
| CARVEDILOL PHOSPHATE - CARVEDILOL PHOSPHATE | | | | | | | |
| A 090132 | 004 | | | | | PC | May 07, 2018 |
| CARVEDILOL PHOSPHATE - COREG CR | | | | | | | |
| N 022012 | 001 | 7268156 | Jun 27, 2023 | DS DP U-3 | | | |
| | | 7268156 | Jun 27, 2023 | DS DP U-313 | | | |
| | | 8101209 | Sep 11, 2025 | DP | | | |
| CARVEDILOL PHOSPHATE - COREG CR | | | | | | | |
| N 022012 | 002 | 7268156 | Jun 27, 2023 | DS DP U-3 | | | |
| | | 7268156 | Jun 27, 2023 | DS DP U-313 | | | |
| | | 8101209 | Sep 11, 2025 | DP | | | |
| CARVEDILOL PHOSPHATE - COREG CR | | | | | | | |
| N 022012 | 003 | 7268156 | Jun 27, 2023 | DS DP U-3 | | | |
| | | 7268156 | Jun 27, 2023 | DS DP U-313 | | | |
| | | 8101209 | Sep 11, 2025 | DP | | | |
| CARVEDILOL PHOSPHATE - COREG CR | | | | | | | |
| N 022012 | 004 | 7268156 | Jun 27, 2023 | DS DP U-3 | | | |
| | | 7268156 | Jun 27, 2023 | DS DP U-313 | | | |
| | | 8101209 | Sep 11, 2025 | DP | | | |
| CASPOFUNGIN ACETATE - CASPOFUNGIN ACETATE | | | | | | | |
| N 206110 | 001 | 9636407 | Dec 21, 2032 | DP | | | |
| CASPOFUNGIN ACETATE - CASPOFUNGIN ACETATE | | | | | | | |
| N 206110 | 002 | 9636407 | Dec 21, 2032 | DP | | | |
| CEFIXIME - SUPRAX | | | | | | | |
| N 202091 | 001 | 9233112 | Dec 14, 2028 | DP U-1676 | | | |
| CEFTAROLINE FOSAMIL - TEFLARO | | | | | | | |
| N 200327 | 001 | 6417175 | Apr 11, 2022 | DS DP U-1676 | | NPP | May 27, 2019 |
| | | 6906055 | Dec 15, 2021 | DS DP | | NPP | May 27, 2019 |
| | | 7419973 | Dec 15, 2021 | DP | | | |
| | | 8247400 | Feb 10, 2031 | DP U-282 | | | |
| | | 9629861 | Sep 21, 2030 | DP | | | |
| CEFTAROLINE FOSAMIL - TEFLARO | | | | | | | |
| N 200327 | 002 | 6417175 | Apr 11, 2022 | DS DP U-1676 | | NPP | May 27, 2019 |
| | | 6906055 | Dec 15, 2021 | DS DP | | NPP | May 27, 2019 |
| | | 7419973 | Dec 15, 2021 | DP | | | |
| | | 8247400 | Feb 10, 2031 | DP U-282 | | | |
| | | 9629861 | Sep 21, 2030 | DP | | | |
| CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA | | | | | | | |
| N 206829 | 001 | 7129232 | Oct 21, 2024 | DS DP U-36 | | NCE | Dec 19, 2019 |
| | | 8476425 | Sep 27, 2032 | DS | | GAIN | Dec 19, 2024 |
| | | 8685957 | Sep 27, 2032 | DS U-36 | | | |
| | | 8906898 | May 28, 2034 | DS DP | | | |
| | | 8968753 | Mar 14, 2034 | U-1672 | | | |
| | | 8968753 | Mar 14, 2034 | U-1673 | | | |
| | | 9320740 | Mar 14, 2034 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA | | | | | | | |
| N 206829 | 001 | 7129232 | Oct 21, 2024 | DS DP U-36 | | NCE | Dec 19, 2019 |
| | | 8476425 | Sep 27, 2032 | DS | | GAIN | Dec 19, 2024 |
| | | 8685957 | Sep 27, 2032 | DS U-36 | | | |
| | | 8906898 | May 28, 2034 | DS DP | | | |
| | | 8968753 | Mar 14, 2034 | U-1672 | | | |
| | | 8968753 | Mar 14, 2034 | U-1673 | | | |
| | | 9320740 | Mar 14, 2034 | DP | | | |
| CERITINIB - ZYKADIA | | | | | | | |
| N 205755 | 001 | 7153964 | Feb 26, 2021 | DS DP | | M-199 | May 26, 2020 |
| | | 7893074 | Apr 25, 2026 | DS DP | | NCE | Apr 29, 2019 |
| | | 7964592 | Jan 13, 2027 | DS DP | | ODE-145 | May 26, 2024 |
| | | 8039479 | Jun 29, 2030 | DS DP | | ODE-66 | Apr 29, 2021 |
| | | 8188276 | Jan 31, 2023 | DS DP | | | |
| | | 8377921 | Nov 20, 2027 | U-1179 | | | |
| | | 8399450 | Nov 20, 2027 | DS DP | | | |
| | | 8703787 | Feb 02, 2032 | U-1179 | | | |
| | | 8835430 | Jan 31, 2023 | DS DP | | | |
| | | 9018204 | Jan 31, 2023 | DS DP | | | |
| | | 9309229 | Jan 18, 2032 | DS DP | | | |
| | | 9416112 | Jan 31, 2023 | DS DP | | | |
| CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC ALLERGY | | | | | | | |
| N 021621 | 003 | 6455533 | Jul 02, 2018 | DP U-295 | | | |
| CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC ALLERGY | | | | | | | |
| N 021621 | 004 | 6455533 | Jul 02, 2018 | DP U-295 | | | |
| CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC HIVES RELIEF | | | | | | | |
| N 021621 | 005 | 6455533 | Jul 02, 2018 | DP U-295 | | | |
| CETIRIZINE HYDROCHLORIDE - CHILDREN'S ZYRTEC HIVES RELIEF | | | | | | | |
| N 021621 | 006 | 6455533 | Jul 02, 2018 | DP U-295 | | | |
| CETIRIZINE HYDROCHLORIDE - ZERVIATE | | | | | | | |
| N 208694 | 001 | 8829005 | Mar 15, 2030 | U-1680 | | NDF | May 30, 2020 |
| | | 8829005*PED | Sep 15, 2030 | | | PED | Nov 30, 2020 |
| | | 9254286 | Jul 09, 2032 | DP | | | |
| | | 9254286*PED | Jan 09, 2033 | | | | |
| | | 9750684 | Mar 15, 2030 | DP | | | |
| CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ZYRTEC-D 12 HOUR | | | | | | | |
| N 021150 | 002 | 6469009 | Jul 13, 2019 | DP U-295 | | | |
| | | 7014867 | Jun 10, 2022 | DP | | | |
| | | 7226614 | Jun 10, 2022 | U-295 | | | |
| CETRORELIX - CETROTIDE | | | | | | | |
| N 021197 | 001 | 6319192 | Apr 23, 2019 | U-426 | | | |
| CETRORELIX - CETROTIDE | | | | | | | |
| N 021197 | 002 | 6319192 | Apr 23, 2019 | U-426 | | | |
| CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE | | | | | | | |
| N 021669 | 001 | 7066916 | Feb 17, 2024 | U-737 | | | |
| | | 7427574 | Apr 25, 2026 | DP | | | |
| | | 7595021 | May 12, 2023 | DP U-1022 | | | |
| | | 7717889 | Feb 27, 2025 | DP U-1022 | | | |
| | | 7935093 | Oct 02, 2027 | DP U-1022 | | | |
| CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP | | | | | | | |
| N 020832 | 001 | 6536975 | Nov 10, 2020 | DP | | | |
| CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT | | | | | | | |
| N 020832 | 002 | 6729786 | Mar 14, 2023 | DP | | | |
| | | 6991394 | Jan 31, 2024 | DP | | | |
| | | 7182536 | Dec 30, 2023 | DP | | | |
| | | 7241065 | Mar 14, 2023 | DP | | | |
| | | 7422388 | Apr 25, 2027 | DP U-1397 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP | | | | | | | |
| N 020832 | 004 | 6536975 | Nov 10, 2020 | DP | | | |
| CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT | | | | | | | |
| N 020832 | 005 | 6536975 | Nov 10, 2020 | DP | | | |
| | | 6729786 | Mar 14, 2023 | DP | | | |
| | | 7241065 | Mar 14, 2023 | DP | | | |
| | | 7422388 | Apr 25, 2027 | DP U-1397 | | | |
| CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP ONE-STEP | | | | | | | |
| N 020832 | 006 | 6991394 | Jan 31, 2024 | DP | | | |
| | | 7182536 | Dec 30, 2023 | DP | | | |
| CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL - CHLORAPREP WITH TINT | | | | | | | |
| N 020832 | 007 | 6536975 | Nov 10, 2020 | DP | | | |
| | | 6729786 | Mar 14, 2023 | DP | | | |
| | | 7241065 | Mar 14, 2023 | DP | | | |
| | | 7422388 | Apr 25, 2027 | DP U-1397 | | | |
| CHLOROPROCAINE HYDROCHLORIDE - CLOROTEKAL | | | | | | | |
| N 208791 | 001 | | | | | NP | Sep 26, 2020 |
| CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE - CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE | | | | | | | |
| N 206323 | 001 | 6248363 | Nov 23, 2019 | DP U-1716 | | | |
| | | 6383471 | Apr 06, 2019 | DP U-1716 | | | |
| | | 9066942 | Jan 03, 2032 | U-1716 | | | |
| | | 9107921 | Jan 03, 2032 | DP | | | |
| CHLORPHENIRAMINE MALEATE; IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - ADVIL ALLERGY SINUS | | | | | | | |
| N 021441 | 001 | 7863287 | Feb 28, 2027 | DP | | | |
| CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX - TUZISTRA XR | | | | | | | |
| N 207768 | 001 | 8062667 | Mar 29, 2029 | DP | | | |
| | | 8790700 | Mar 15, 2027 | DP | | | |
| CHOLIC ACID - CHOLBAM | | | | | | | |
| N 205750 | 001 | | | | | NCE | Mar 17, 2020 |
| | | | | | | ODE-91 | Mar 17, 2022 |
| CHOLIC ACID - CHOLBAM | | | | | | | |
| N 205750 | 002 | | | | | NCE | Mar 17, 2020 |
| | | | | | | ODE-91 | Mar 17, 2022 |
| CHOLINE C-11 - CHOLINE C-11 | | | | | | | |
| N 203155 | 001 | | | | | NCE | Sep 12, 2017 |
| | | | | | | W | Sep 12, 2017 |
| CHOLINE FENOFIBRATE - TRILIPIX | | | | | | | |
| N 022224 | 001 | 7259186 | Jan 07, 2025 | DS | | | |
| CHOLINE FENOFIBRATE - TRILIPIX | | | | | | | |
| N 022224 | 002 | 7259186 | Jan 07, 2025 | DS | | | |
| CHORIOGONADOTROPIN ALFA - OVIDREL | | | | | | | |
| N 021149 | 002 | 6706681 | Mar 16, 2021 | DP | | | |
| CICLESONIDE - ALVESCO | | | | | | | |
| N 021658 | 002 | 5482934 | Oct 24, 2017 | DS DP U-1002 | | | |
| | | 6120752 | May 13, 2018 | DP | | | |
| | | 6264923 | May 13, 2018 | DP | | | |
| | | 8371292 | Feb 01, 2028 | U-1355 | | | |
| CICLESONIDE - ALVESCO | | | | | | | |
| N 021658 | 003 | 5482934 | Oct 24, 2017 | DS DP U-1002 | | | |
| | | 6120752 | May 13, 2018 | DP | | | |
| | | 6264923 | May 13, 2018 | DP | | | |
| | | 8371292 | Feb 01, 2028 | U-1355 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | | PATENT NO | PATENT EXPIRATION DATE | | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|---|
| CICLESONIDE - OMNARIS | | | | | | | | | |
| N 022004 | 001 | | 5482934 | Oct 24, 2017 | DS | DP U-557 | | | |
| | | | 6767901 | Oct 21, 2020 | | DP | | | |
| | | | 6939559 | Apr 21, 2019 | | DP | | | |
| | | | 7235247 | Apr 21, 2019 | | DP | | | |
| | | | 8371292 | Feb 01, 2028 | | U-1356 | | | |
| | | | 8383611 | Oct 20, 2020 | | DP | | | |
| CICLESONIDE - ZETONNA | | | | | | | | | |
| N 202129 | 001 | | 5482934 | Oct 24, 2017 | DS | DP U-1002 | | | |
| | | | 6120752 | May 13, 2018 | | DP | | | |
| | | | 6264923 | May 13, 2018 | | DP | | | |
| | | | 8371292 | Feb 01, 2028 | | U-1357 | | | |
| CICLOPIROX - CICLOPIROX | | | | | | | | | |
| N 020519 | 001 | | 7018656 | Sep 05, 2018 | | DP | | | |
| CICLOPIROX - LOPROX | | | | | | | | | |
| N 021159 | 001 | | 7981909 | Sep 16, 2017 | | U-1162 | | | |
| | | | 8227490 | Sep 16, 2017 | | U-1256 | | | |
| CINACALCET HYDROCHLORIDE - SENSIPAR | | | | | | | | | |
| N 021688 | 001 | | 6011068 | Mar 08, 2018 | DS | DP | | M-200 | May 23, 2020 |
| | | | 7829595 | Sep 22, 2026 | | DP U-1098 | | ODE-78 | Nov 21, 2021 |
| | | | 9375405 | Sep 22, 2026 | | DP | | ODE-8 | Feb 25, 2018 |
| CINACALCET HYDROCHLORIDE - SENSIPAR | | | | | | | | | |
| N 021688 | 002 | | 6011068 | Mar 08, 2018 | DS | DP | | M-200 | May 23, 2020 |
| | | | 7829595 | Sep 22, 2026 | | DP U-1098 | | ODE-78 | Nov 21, 2021 |
| | | | 9375405 | Sep 22, 2026 | | DP | | ODE-8 | Feb 25, 2018 |
| CINACALCET HYDROCHLORIDE - SENSIPAR | | | | | | | | | |
| N 021688 | 003 | | 6011068 | Mar 08, 2018 | DS | DP | | M-200 | May 23, 2020 |
| | | | 7829595 | Sep 22, 2026 | | DP U-1098 | | ODE-78 | Nov 21, 2021 |
| | | | 9375405 | Sep 22, 2026 | | DP | | ODE-8 | Feb 25, 2018 |
| CIPROFLOXACIN - OTIPRIO | | | | | | | | | |
| N 207986 | 001 | | 8318817 | Apr 27, 2030 | | U-1792 | | NP | Dec 10, 2018 |
| | | | 9205048 | Apr 21, 2029 | | U-1793 | | | |
| | | | 9220796 | Jul 01, 2035 | | DP | | | |
| | | | 9233068 | Dec 11, 2029 | | DP | | | |
| CIPROFLOXACIN HYDROCHLORIDE - PROQUIN XR | | | | | | | | | |
| N 021744 | 001 | | 6488962 | Jun 20, 2020 | | DP | | | |
| CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE - OTOVEL | | | | | | | | | |
| N 208251 | 001 | | 8932610 | Mar 24, 2030 | | DP U-1578 | | NC | Apr 29, 2019 |
| CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR | | | | | | | | | |
| N 021473 | 001 | | 7709022 | Jun 23, 2021 | | DP | | | |
| | | | 8187632 | Jun 23, 2021 | | DP | | | |
| | | | 8187632*PED | Dec 23, 2021 | | | | | |
| CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE - CIPRO XR | | | | | | | | | |
| N 021473 | 002 | | 7709022 | Jun 23, 2021 | | DP | | | |
| | | | 8187632 | Jun 23, 2021 | | DP | | | |
| | | | 8187632*PED | Dec 23, 2021 | | | | | |
| CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX | | | | | | | | | |
| N 021537 | 001 | | 6284804 | Aug 10, 2020 | | | | | |
| | | | 6359016 | Aug 10, 2020 | | | | | |
| | | | 8846650 | Jun 04, 2025 | | DP U-1578 | | | |
| | | | 9149486 | Sep 13, 2022 | | DP U-1578 | | | |
| | | | 9345714 | Sep 13, 2022 | | DP U-1578 | | | |
| | | | 9402805 | Sep 13, 2022 | | DP U-1578 | | | |
| | | | 9402805 | Sep 13, 2022 | | DP U-1679 | | | |
| CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - PREPOPIK | | | | | | | | | |
| N 202535 | 001 | | 8450338 | Oct 10, 2028 | | DP | | | |
| | | | 8481083 | Oct 10, 2028 | | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | | PATENT NO | PATENT EXPIRATION DATE | | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|---|
| CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIQ | | | | | | | | | |
| N 209589 | 001 | | 9827231 | Jun 23, 2034 | | DP U-2162 | | | |
| CLEVIDIPINE - CLEVIPREX | | | | | | | | | |
| N 022156 | 001 | | 5856346 | Jan 05, 2021 | DS | DP U-893 | | | |
| | | | 8658676 | Oct 10, 2031 | | DP | | | |
| CLEVIDIPINE - CLEVIPREX | | | | | | | | | |
| N 022156 | 002 | | 5856346 | Jan 05, 2021 | DS | DP U-893 | | | |
| | | | 8658676 | Oct 10, 2031 | | DP | | | |
| CLEVIDIPINE - CLEVIPREX | | | | | | | | | |
| N 022156 | 003 | | 5856346 | Jan 05, 2021 | DS | DP U-893 | | | |
| | | | 8658676 | Oct 10, 2031 | | DP | | | |
| CLINDAMYCIN PHOSPHATE - CLEOCIN | | | | | | | | | |
| N 050767 | 001 | | 6495157 | Jul 20, 2020 | | DP | | | |
| CLINDAMYCIN PHOSPHATE - CLINDAGEL | | | | | | | | | |
| N 050782 | 001 | | 6387383 | Aug 03, 2020 | | DP U-818 | | | |
| CLINDAMYCIN PHOSPHATE - CLINDESSE | | | | | | | | | |
| N 050793 | 001 | | 5993856 | Nov 17, 2017 | | DP U-137 | | | |
| | | | 6899890 | Apr 27, 2023 | | DP U-137 | | | |
| | | | 9789057 | Dec 02, 2026 | | DP U-137 | | | |
| CLINDAMYCIN PHOSPHATE - EVOCLIN | | | | | | | | | |
| N 050801 | 001 | | 7141237 | Jan 23, 2024 | DS | DP | | | |
| | | | 7374747 | Aug 09, 2026 | DS | DP U-921 | | | |
| CLINDAMYCIN PHOSPHATE; TRETINOIN - ZIANA | | | | | | | | | |
| N 050802 | 001 | | 6387383 | Aug 03, 2020 | | DP U-916 | | | |
| CLOBAZAM - ONFI | | | | | | | | | |
| N 202067 | 001 | | | | | | | ODE-17 | Oct 21, 2018 |
| CLOBAZAM - ONFI | | | | | | | | | |
| N 202067 | 002 | | | | | | | ODE-17 | Oct 21, 2018 |
| CLOBAZAM - ONFI | | | | | | | | | |
| N 202067 | 003 | | | | | | | ODE-17 | Oct 21, 2018 |
| CLOBAZAM - ONFI | | | | | | | | | |
| N 203993 | 001 | | | | | | | ODE-18 | Oct 21, 2018 |
| CLOBETASOL PROPIONATE - CLOBEX | | | | | | | | | |
| N 021535 | 001 | | 6106848 | Sep 22, 2017 | | | | | |
| CLOBETASOL PROPIONATE - CLOBEX | | | | | | | | | |
| N 021644 | 001 | | 7316810 | Jun 17, 2019 | | DP | | | |
| | | | 7700081 | Jan 03, 2022 | | U-1044 | | | |
| | | | 8066975 | Jun 17, 2019 | | DP | | | |
| | | | 8066976 | Jun 17, 2019 | | DP | | | |
| CLOBETASOL PROPIONATE - CLOBEX | | | | | | | | | |
| N 021835 | 001 | | 5972920 | Feb 12, 2018 | | DP | | | |
| | | | 5990100 | Mar 24, 2018 | | DP U-742 | | | |
| CLOBETASOL PROPIONATE - OLUX E | | | | | | | | | |
| N 022013 | 001 | | 6730288 | Sep 08, 2019 | | DP | | | |
| | | | 7029659 | Sep 08, 2019 | | DP | | | |
| | | | 8460641 | Nov 05, 2028 | | DP U-1410 | | | |
| | | | 8962000 | Aug 31, 2025 | | DP U-1410 | | | |
| CLOBETASOL PROPIONATE - IMPOYZ | | | | | | | | | |
| N 209483 | 001 | | 9855334 | Mar 11, 2035 | | DP | | NP | Nov 28, 2020 |
| CLOFARABINE - CLOFARABINE | | | | | | | | | |
| A 204029 | 001 | | | | | | | PC | Nov 05, 2017 |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| CLOFARABINE - CLOLAR | | | | | | | |
| N 021673 | 001 | 5661136 | Jan 14, 2018 | U-626 | | | |
| CLONIDINE HYDROCHLORIDE - KAPVAY | | | | | | | |
| N 022331 | 003 | | | | | M-149 | Nov 20, 2017 |
| CLONIDINE HYDROCHLORIDE - KAPVAY | | | | | | | |
| N 022331 | 004 | | | | | M-149 | Nov 20, 2017 |
| CLOPIDOGREL BISULFATE - PLAVIX | | | | | | | |
| N 020839 | 001 | 6429210 | Jun 10, 2019 | DS DP | | | |
| | | 6504030 | Jun 10, 2019 | DS | | | |
| CLOPIDOGREL BISULFATE - PLAVIX | | | | | | | |
| N 020839 | 002 | 6429210 | Jun 10, 2019 | DS DP | | | |
| | | 6504030 | Jun 10, 2019 | DS | | | |
| CLOZAPINE - FAZACLO ODT | | | | | | | |
| N 021590 | 001 | 6024981 | Apr 09, 2018 | DP | | | |
| | | 6106861 | Dec 05, 2017 | DP | | | |
| | | 6221392 | Apr 09, 2018 | DP | | | |
| CLOZAPINE - FAZACLO ODT | | | | | | | |
| N 021590 | 002 | 6024981 | Apr 09, 2018 | DP | | | |
| | | 6106861 | Dec 05, 2017 | DP | | | |
| | | 6221392 | Apr 09, 2018 | DP | | | |
| CLOZAPINE - FAZACLO ODT | | | | | | | |
| N 021590 | 003 | 6024981 | Apr 09, 2018 | DP | | | |
| | | 6106861 | Dec 05, 2017 | DP | | | |
| | | 6221392 | Apr 09, 2018 | DP | | | |
| CLOZAPINE - FAZACLO ODT | | | | | | | |
| N 021590 | 004 | 6024981 | Apr 09, 2018 | DP | | | |
| | | 6106861 | Dec 05, 2017 | DP | | | |
| | | 6221392 | Apr 09, 2018 | DP | | | |
| CLOZAPINE - FAZACLO ODT | | | | | | | |
| N 021590 | 005 | 6024981 | Apr 09, 2018 | DP | | | |
| | | 6106861 | Dec 05, 2017 | DP | | | |
| | | 6221392 | Apr 09, 2018 | DP | | | |
| CLOZAPINE - FAZACLO ODT | | | | | | | |
| N 021590 | 006 | 6024981 | Apr 09, 2018 | DP | | | |
| | | 6106861 | Dec 05, 2017 | DP | | | |
| | | 6221392 | Apr 09, 2018 | DP | | | |
| COBICISTAT - TYBOST | | | | | | | |
| N 203094 | 001 | 8148374 | Sep 03, 2029 | DS DP U-1279 | | NCE | Aug 27, 2017 |
| | | | | | | NP | Sep 24, 2017 |
| COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX | | | | | | | |
| N 205395 | 001 | 7470506 | Jun 23, 2019 | U-1660 | | NCE | Aug 27, 2017 |
| | | 7470506*PED | Dec 23, 2019 | | | | |
| | | 7700645 | Dec 26, 2026 | DS DP | | | |
| | | 7700645*PED | Jun 26, 2027 | | | | |
| | | 8148374 | Sep 03, 2029 | DS DP U-1660 | | | |
| | | 8518987 | Feb 16, 2024 | DS DP | | | |
| | | 8518987*PED | Aug 16, 2024 | | | | |
| | | 8597876 | Jun 23, 2019 | U-1660 | | | |
| | | 8597876*PED | Dec 23, 2019 | | | | |
| | | RE43596*PED | Nov 09, 2017 | | | | |
| COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA | | | | | | | |
| N 207561 | 001 | 5914331 | Jul 02, 2017 | DS | | NCE | Aug 27, 2017 |
| | | 5914331*PED | Jan 02, 2018 | | | NCE | Nov 05, 2020 |
| | | 6642245 | Nov 04, 2020 | U-257 | | NPP | Sep 25, 2020 |
| | | 6642245*PED | May 04, 2021 | | | | |
| | | 6703396 | Mar 09, 2021 | DS DP | | | |
| | | 6703396*PED | Sep 09, 2021 | | | | |
| | | 7176220 | Aug 27, 2026 | DS DP U-257 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA | | | | | | | |
| N 207561 | 001 | 7390791 | May 07, 2022 | DS DP | | | |
| | | 7635704 | Oct 26, 2026 | DS DP | U-257 | | |
| | | 7803788 | Feb 02, 2022 | | U-257 | | |
| | | 8148374 | Sep 03, 2029 | DS DP | U-1279 | | |
| | | 8633219 | Apr 24, 2030 | DP | U-257 | | |
| | | 8754065 | Aug 15, 2032 | DS DP | U-257 | | |
| | | 8981103 | Oct 26, 2026 | DS DP | | | |
| | | 9296769 | Aug 15, 2032 | DS DP | U-257 | | |
| COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD | | | | | | | |
| N 203100 | 001 | 5914331 | Jul 02, 2017 | DS | | I-704 | Dec 17, 2017 |
| | | 5922695 | Jul 25, 2017 | DS | U-257 | NCE | Aug 27, 2017 |
| | | 5935946 | Jul 25, 2017 | DS DP | U-257 | NPP | Jan 27, 2020 |
| | | 5977089 | Jul 25, 2017 | DS DP | U-257 | | |
| | | 6043230 | Jul 25, 2017 | | U-257 | | |
| | | 6642245 | Nov 04, 2020 | | U-257 | | |
| | | 6703396 | Mar 09, 2021 | DS DP | | | |
| | | 7176220 | Aug 27, 2026 | DS DP | U-257 | | |
| | | 7635704 | Oct 26, 2026 | DS DP | U-257 | | |
| | | 8148374 | Sep 03, 2029 | DS DP | U-1279 | | |
| | | 8592397 | Jan 13, 2024 | DP | U-257 | | |
| | | 8633219 | Apr 24, 2030 | DP | U-257 | | |
| | | 8716264 | Jan 13, 2024 | DP | U-257 | | |
| | | 8981103 | Oct 26, 2026 | DS DP | | | |
| | | 9457036 | Jan 13, 2024 | DP | U-257 | | |
| | | 9744181 | Jan 13, 2024 | DP | U-257 | | |
| COBIMETINIB FUMARATE - COTELLIC | | | | | | | |
| N 206192 | 001 | 7803839 | Feb 01, 2027 | DS DP | | NCE | Nov 10, 2020 |
| | | 8362002 | Oct 05, 2026 | | U-1776 | ODE-101 | Nov 10, 2022 |
| COLCHICINE - COLCRYS | | | | | | | |
| N 022352 | 001 | 7601758 | Feb 10, 2029 | | U-1007 | | |
| | | 7619004 | Dec 03, 2028 | | U-1020 | | |
| | | 7820681 | Feb 17, 2029 | | U-1020 | | |
| | | 7906519 | Feb 17, 2029 | | U-1116 | | |
| | | 7915269 | Feb 17, 2029 | | U-1007 | | |
| | | 7935731 | Dec 03, 2028 | | U-1116 | | |
| | | 7964647 | Oct 06, 2028 | | U-1007 | | |
| | | 7964648 | Oct 06, 2028 | | U-1161 | | |
| | | 7981938 | Oct 06, 2028 | | U-1166 | | |
| | | 8093296 | Oct 06, 2028 | | U-1007 | | |
| | | 8093297 | Oct 06, 2028 | | U-1161 | | |
| | | 8093298 | Oct 06, 2028 | | U-1116 | | |
| | | 8097655 | Oct 06, 2028 | | U-1020 | | |
| | | 8415395 | Oct 06, 2028 | | U-1007 | | |
| | | 8415396 | Oct 06, 2028 | | U-1007 | | |
| | | 8440721 | Feb 17, 2029 | | U-1007 | | |
| | | 8440722 | Feb 17, 2029 | | U-1020 | | |
| COLCHICINE - MITIGARE | | | | | | | |
| N 204820 | 001 | 8927607 | Aug 22, 2033 | | U-1020 | | |
| | | 9399036 | Aug 22, 2033 | | U-1020 | | |
| | | 9555029 | Aug 22, 2033 | | U-1020 | | |
| | | 9675613 | Aug 22, 2033 | | U-1020 | | |
| | | 9789108 | Aug 22, 2033 | | U-1020 | | |
| COLESEVELAM HYDROCHLORIDE - WELCHOL | | | | | | | |
| N 021176 | 001 | 7229613 | Apr 17, 2022 | | U-851 | | |
| COLESEVELAM HYDROCHLORIDE - WELCHOL | | | | | | | |
| N 022362 | 001 | 7229613 | Apr 17, 2022 | | U-493 | | |
| COLESEVELAM HYDROCHLORIDE - WELCHOL | | | | | | | |
| N 022362 | 002 | 7229613 | Apr 17, 2022 | | U-493 | | |
| CONIVAPTAN HYDROCHLORIDE - VAPRISOL | | | | | | | |
| N 021697 | 001 | 5723606 | Dec 15, 2019 | DS DP | U-698 | | |
| | | 5723606 | Dec 15, 2019 | DS DP | U-868 | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| CONIVAPTAN HYDROCHLORIDE - VAPRISOL | | | | | | | |
| N 021697 | 001 | 5723606 | Dec 15, 2019 | DS DP U-698 | | | |
| | | 5723606 | Dec 15, 2019 | DS DP U-868 | | | |
| CONIVAPTAN HYDROCHLORIDE - VAPRISOL IN 5% DEXTROSE IN PLASTIC CONTAINER | | | | | | | |
| N 021697 | 002 | 5723606 | Dec 15, 2019 | DS DP U-698 | | | |
| | | 5723606 | Dec 15, 2019 | DS DP U-868 | | | |
| COPANLISIB DIHYDROCHLORIDE - ALIQOPA | | | | | | | |
| N 209936 | 001 | 7511041 | May 13, 2024 | DS DP | | NCE | Sep 14, 2022 |
| | | 8466283 | Oct 22, 2029 | DS DP U-2124 | | ODE-155 | Sep 14, 2024 |
| | | 9636344 | Mar 29, 2032 | U-2124 | | | |
| CORTICOTROPIN - H.P. ACTHAR GEL | | | | | | | |
| N 008372 | 008 | | | | | ODE-3 | Oct 15, 2017 |
| CRISABOROLE - EUCRISA | | | | | | | |
| N 207695 | 001 | 8039451 | Jun 11, 2026 | DS DP | | NCE | Dec 14, 2021 |
| | | 8168614 | Jan 20, 2030 | U-1932 | | | |
| | | 8501712 | Feb 16, 2027 | U-1932 | | | |
| | | 9682092 | Feb 16, 2027 | U-1932 | | | |
| CRIZOTINIB - XALKORI | | | | | | | |
| N 202570 | 001 | 7230098 | Aug 26, 2025 | DS | | M-163 | Sep 14, 2018 |
| | | 7825137 | May 12, 2027 | U-1179 | | ODE-111 | Mar 11, 2023 |
| | | 7858643 | Oct 08, 2029 | DS DP | | ODE-15 | Aug 26, 2018 |
| | | 8217057 | Nov 06, 2029 | DS DP | | | |
| | | 8785632 | Mar 01, 2025 | DS | | | |
| CRIZOTINIB - XALKORI | | | | | | | |
| N 202570 | 002 | 7230098 | Aug 26, 2025 | DS | | M-163 | Sep 14, 2018 |
| | | 7825137 | May 12, 2027 | U-1179 | | ODE-111 | Mar 11, 2023 |
| | | 7858643 | Oct 08, 2029 | DS DP | | ODE-15 | Aug 26, 2018 |
| | | 8217057 | Nov 06, 2029 | DS DP | | | |
| | | 8785632 | Mar 01, 2025 | DS | | | |
| CROFELEMER - FULYZAQ | | | | | | | |
| N 202292 | 001 | 7323195 | Jun 07, 2018 | DP | | NCE | Dec 31, 2017 |
| | | 7341744 | Jun 16, 2018 | U-1319 | | | |
| | | 8574634 | Jan 11, 2018 | U-1319 | | | |
| | | 8962680 | Oct 31, 2031 | U-1319 | | | |
| | | 9585868 | Oct 31, 2031 | DS U-1319 | | | |
| CYANOCOBALAMIN - NASCOBAL | | | | | | | |
| N 021642 | 001 | 7229636 | Aug 01, 2024 | DP U-817 | | | |
| | | 7404489 | Mar 12, 2024 | DP | | | |
| | | 7879349 | Aug 01, 2024 | DP U-1152 | | | |
| | | 8003353 | Aug 01, 2024 | U-817 | | | |
| | | 8940714 | Feb 26, 2024 | U-1152 | | | |
| | | 9415007 | Jul 28, 2024 | U-1896 | | | |
| CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX | | | | | | | |
| N 021777 | 001 | 7387793 | Feb 26, 2025 | DP | | | |
| | | 7544372 | Nov 14, 2023 | U-979 | | | |
| | | 7790199 | Nov 14, 2023 | DP | | | |
| | | 7820203 | Nov 14, 2023 | DP | | | |
| | | 7829121 | Nov 14, 2023 | U-1088 | | | |
| | | 9375410 | Nov 14, 2023 | U-1088 | | | |
| | | 9399025 | Nov 14, 2023 | DP U-979 | | | |
| CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX | | | | | | | |
| N 021777 | 002 | 7387793 | Feb 26, 2025 | DP | | | |
| | | 7544372 | Nov 14, 2023 | U-979 | | | |
| | | 7790199 | Nov 14, 2023 | DP | | | |
| | | 7820203 | Nov 14, 2023 | DP | | | |
| | | 7829121 | Nov 14, 2023 | U-1088 | | | |
| | | 9375410 | Nov 14, 2023 | U-1088 | | | |
| | | 9399025 | Nov 14, 2023 | DP U-979 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| CYCLOSPORINE - RESTASIS | | | | | | | |
| N 050790 | 001 | 8629111 | Aug 27, 2024 | DP | | | |
| | | 8633162 | Aug 27, 2024 | U-1479 | | | |
| | | 8642556 | Aug 27, 2024 | DP | | | |
| | | 8648048 | Aug 27, 2024 | U-1483 | | | |
| | | 8685930 | Aug 27, 2024 | DP | | | |
| | | 9248191 | Aug 27, 2024 | U-1479 | | | |
| CYCLOSPORINE - RESTASIS MULTIDOSE | | | | | | | |
| N 050790 | 002 | 8292129 | Feb 25, 2031 | DP | | | |
| | | 8561859 | Apr 16, 2032 | DP | | | |
| | | 8629111 | Aug 27, 2024 | DP | | | |
| | | 8633162 | Aug 27, 2024 | U-1479 | | | |
| | | 8642556 | Aug 27, 2024 | DP | | | |
| | | 8648048 | Aug 27, 2024 | U-1483 | | | |
| | | 8685930 | Aug 27, 2024 | DP | | | |
| | | 9248191 | Aug 27, 2024 | U-1479 | | | |
| | | 9669974 | May 11, 2034 | DP | | | |
| | | 9676525 | Feb 07, 2034 | DP | | | |
| CYSTEAMINE BITARTRATE - PROCYSBI | | | | | | | |
| N 203389 | 001 | 8026284 | Sep 22, 2027 | U-1399 | | M-216 | Dec 22, 2020 |
| | | 8026284*PED | Mar 22, 2028 | | | NPP | Aug 14, 2018 |
| | | 9173851 | Jun 17, 2034 | DP | | ODE-45 | Apr 30, 2020 |
| | | 9173851*PED | Dec 17, 2034 | | | ODE-97 | Aug 14, 2022 |
| | | 9192590 | Jan 26, 2027 | U-1399 | | PED | Oct 30, 2020 |
| | | 9192590*PED | Jul 26, 2027 | | | PED | Jun 22, 2021 |
| | | 9198882 | Jan 26, 2027 | U-1399 | | PED | Feb 14, 2023 |
| | | 9198882*PED | Jul 26, 2027 | | | | |
| | | 9233077 | Jun 17, 2034 | DP | | | |
| | | 9233077*PED | Dec 17, 2034 | | | | |
| CYSTEAMINE BITARTRATE - PROCYSBI | | | | | | | |
| N 203389 | 002 | 8026284 | Sep 22, 2027 | U-1399 | | M-216 | Dec 22, 2020 |
| | | 8026284*PED | Mar 22, 2028 | | | NPP | Aug 14, 2018 |
| | | 9173851 | Jun 17, 2034 | DP | | ODE-45 | Apr 30, 2020 |
| | | 9173851*PED | Dec 17, 2034 | | | ODE-97 | Aug 14, 2022 |
| | | 9192590 | Jan 26, 2027 | U-1399 | | PED | Oct 30, 2020 |
| | | 9192590*PED | Jul 26, 2027 | | | PED | Jun 22, 2021 |
| | | 9198882 | Jan 26, 2027 | U-1399 | | PED | Feb 14, 2023 |
| | | 9198882*PED | Jul 26, 2027 | | | | |
| | | 9233077 | Jun 17, 2034 | DP | | | |
| | | 9233077*PED | Dec 17, 2034 | | | | |
| CYSTEAMINE HYDROCHLORIDE - CYSTARAN | | | | | | | |
| N 200740 | 001 | | | | | ODE-31 | Oct 02, 2019 |
| CYTARABINE; DAUNORUBICIN - VYXEOS | | | | | | | |
| N 209401 | 001 | 7850990 | Jan 23, 2027 | DP U-2090 | | NP | Aug 03, 2020 |
| | | 8022279 | Sep 14, 2027 | DP U-2090 | | | |
| | | 8092828 | Apr 01, 2029 | U-2090 | | | |
| | | 8431806 | Apr 22, 2025 | DP U-2090 | | | |
| | | 8518437 | Jun 07, 2026 | DP | | | |
| | | 9271931 | Jan 23, 2027 | DP | | | |
| DABIGATRAN ETEXILATE MESYLATE - PRADAXA | | | | | | | |
| N 022512 | 001 | 6087380 | Dec 28, 2021 | DS DP U-1931 | | M-168 | Nov 20, 2018 |
| | | 7866474 | Aug 31, 2027 | DP | Y | | |
| | | 7932273 | Sep 07, 2025 | DS DP | | | |
| | | 9034822 | Jan 20, 2031 | U-1759 | | | |
| DABIGATRAN ETEXILATE MESYLATE - PRADAXA | | | | | | | |
| N 022512 | 002 | 6087380 | Dec 28, 2021 | DS DP U-1931 | | M-168 | Nov 20, 2018 |
| | | 7866474 | Aug 31, 2027 | DP | Y | | |
| | | 7932273 | Sep 07, 2025 | DS DP | | | |
| | | 9034822 | Jan 20, 2031 | U-1759 | | | |
| DABIGATRAN ETEXILATE MESYLATE - PRADAXA | | | | | | | |
| N 022512 | 003 | 6087380 | Dec 28, 2021 | DS DP U-1931 | | NS | Nov 20, 2018 |
| | | 7866474 | Aug 31, 2027 | DP | Y | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| DABIGATRAN ETEXILATE MESYLATE - PRADAXA | | | | | | | |
| N 022512 | 003 | 7932273 | Sep 07, 2025 | DS DP | | | |
| | | 9034822 | Jan 20, 2031 | U-1759 | | | |
| DABRAFENIB MESYLATE - TAFINLAR | | | | | | | |
| N 202806 | 001 | 7994185 | Jan 20, 2030 | DS DP U-1406 | | I-745 | Jun 22, 2020 |
| | | 7994185 | Jan 20, 2030 | DS DP U-2031 | | M-170 | Nov 20, 2018 |
| | | 7994185 | Jan 20, 2030 | DS DP U-2032 | | NCE | May 29, 2018 |
| | | 8415345 | Jan 20, 2030 | DS DP U-1406 | | ODE-147 | Jun 22, 2024 |
| | | 8415345 | Jan 20, 2030 | DS DP U-2031 | | ODE-47 | May 29, 2020 |
| | | 8415345 | Jan 20, 2030 | DS DP U-2032 | | ODE-58 | Jan 09, 2021 |
| | | 8703781 | Oct 15, 2030 | DS DP U-1713 | | | |
| | | 8835443 | Sep 13, 2025 | U-2026 | | | |
| | | 8835443 | Sep 13, 2025 | U-2027 | | | |
| | | 8952018 | Oct 15, 2030 | U-2027 | | | |
| | | 9233956 | May 04, 2029 | U-1811 | | | |
| DABRAFENIB MESYLATE - TAFINLAR | | | | | | | |
| N 202806 | 002 | 7994185 | Jan 20, 2030 | DS DP U-1406 | | I-745 | Jun 22, 2020 |
| | | 7994185 | Jan 20, 2030 | DS DP U-2031 | | M-170 | Nov 20, 2018 |
| | | 7994185 | Jan 20, 2030 | DS DP U-2032 | | NCE | May 29, 2018 |
| | | 8415345 | Jan 20, 2030 | DS DP U-1406 | | ODE-147 | Jun 22, 2024 |
| | | 8415345 | Jan 20, 2030 | DS DP U-2031 | | ODE-47 | May 29, 2020 |
| | | 8415345 | Jan 20, 2030 | DS DP U-2032 | | ODE-58 | Jan 09, 2021 |
| | | 8703781 | Oct 15, 2030 | DS DP U-1713 | | | |
| | | 8835443 | Sep 13, 2025 | U-2026 | | | |
| | | 8835443 | Sep 13, 2025 | U-2027 | | | |
| | | 8952018 | Oct 15, 2030 | U-2027 | | | |
| | | 9233956 | May 04, 2029 | U-1811 | | | |
| DACLATASVIR DIHYDROCHLORIDE - DAKLINZA | | | | | | | |
| N 206843 | 001 | 8329159 | Apr 13, 2028 | DS | | D-161 | Feb 05, 2019 |
| | | 8629171 | Jun 13, 2031 | DS DP U-1724 | | D-162 | Feb 05, 2019 |
| | | 8642025 | Aug 11, 2027 | DS DP U-1724 | | I-726 | Feb 05, 2019 |
| | | 8642025 | Aug 11, 2027 | DS DP U-1725 | | I-727 | Feb 05, 2019 |
| | | 8900566 | Aug 08, 2027 | U-1724 | | NCE | Jul 24, 2020 |
| | | 8900566 | Aug 08, 2027 | U-1725 | | | |
| | | 9421192 | Aug 08, 2027 | DS U-1724 | | | |
| | | 9421192 | Aug 08, 2027 | DS U-1725 | | | |
| DACLATASVIR DIHYDROCHLORIDE - DAKLINZA | | | | | | | |
| N 206843 | 002 | 8329159 | Apr 13, 2028 | DS | | D-161 | Feb 05, 2019 |
| | | 8629171 | Jun 13, 2031 | DS DP U-1724 | | D-162 | Feb 05, 2019 |
| | | 8642025 | Aug 11, 2027 | DS DP U-1724 | | I-726 | Feb 05, 2019 |
| | | 8642025 | Aug 11, 2027 | DS DP U-1725 | | I-727 | Feb 05, 2019 |
| | | 8900566 | Aug 08, 2027 | U-1724 | | NCE | Jul 24, 2020 |
| | | 8900566 | Aug 08, 2027 | U-1725 | | | |
| | | 9421192 | Aug 08, 2027 | DS U-1724 | | | |
| | | 9421192 | Aug 08, 2027 | DS U-1725 | | | |
| DACLATASVIR DIHYDROCHLORIDE - DAKLINZA | | | | | | | |
| N 206843 | 003 | 9421192 | Aug 08, 2027 | DS U-1724 | | | |
| | | 9421192 | Aug 08, 2027 | DS U-1725 | | | |
| DALBAVANCIN HYDROCHLORIDE - DALVANCE | | | | | | | |
| N 021883 | 001 | 6900175 | Dec 25, 2023 | U-1517 | | D-154 | Jan 20, 2019 |
| | | 7115564 | Nov 14, 2023 | DP | | NCE | May 23, 2019 |
| | | 7119061 | Nov 14, 2023 | DP | | GAIN | May 23, 2024 |
| | | 8143212 | Nov 14, 2023 | U-1517 | | | |
| DALFAMPRIDINE - AMPYRA | | | | | | | |
| N 022250 | 001 | 5540938 | Jul 30, 2018 | U-1030 | | | |
| | | 8007826 | May 26, 2027 | U-1030 | | | |
| | | 8354437 | Dec 22, 2026 | U-1030 | | | |
| | | 8440703 | Apr 08, 2025 | U-1030 | | | |
| | | 8663685 | Jan 18, 2025 | U-1030 | | | |
| DANTROLENE SODIUM - RYANODEX | | | | | | | |
| N 205579 | 001 | 7758890 | Jul 01, 2025 | DP | | ODE-69 | Jul 22, 2021 |
| | | 8110225 | Dec 24, 2022 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| DANTROLENE SODIUM - RYANODEX | | | | | | |
| N 205579 001 | 8604072 | Dec 24, 2022 | DP | | | |
| | 8685460 | Feb 15, 2023 | U-1546 | | | |
| DAPAGLIFLOZIN PROPANEDIOL - FARXIGA | | | | | | |
| N 202293 001 | 6414126 | Oct 04, 2020 | DS DP U-2139 | | M-157 | Mar 11, 2018 |
| | 6414126 | Oct 04, 2020 | DS DP U-493 | | M-212 | Oct 20, 2020 |
| | 6479065 | Aug 10, 2020 | DP | Y | NCE | Jan 08, 2019 |
| | 6495164 | May 25, 2020 | DP | Y | | |
| | 6515117 | Oct 04, 2020 | DS DP U-2139 | | | |
| | 6515117 | Oct 04, 2020 | DS DP U-493 | | | |
| | 6667061 | May 25, 2020 | DP | Y | | |
| | 6824822 | Oct 09, 2022 | DP | Y | | |
| | 6872700 | Jan 14, 2020 | U-654 | Y | | |
| | 6936590 | Oct 04, 2020 | U-493 | | | |
| | 6956026 | Jan 07, 2018 | U-687 | Y | | |
| | 7223440 | Aug 31, 2021 | DP | Y | | |
| | 7456254 | Jun 30, 2025 | DP U-1223 | | | |
| | 7456254 | Jun 30, 2025 | DP U-2139 | | | |
| | 7563871 | Apr 15, 2024 | DP | Y | | |
| | 7612176 | Apr 13, 2025 | DP U-1223 | Y | | |
| | 7741269 | Jan 07, 2018 | U-1224 | Y | | |
| | 7851502 | Aug 19, 2028 | DP | | | |
| | 7919598 | Dec 16, 2029 | DS | | | |
| | 8216180 | Jan 11, 2028 | DP | Y | | |
| | 8221786 | Mar 21, 2028 | DP | | | |
| | 8329648 | Aug 18, 2026 | U-1313 | | | |
| | 8329648 | Aug 18, 2026 | U-2139 | | | |
| | 8329648 | Aug 18, 2026 | U-2153 | | | |
| | 8329648 | Aug 18, 2026 | U-2155 | | | |
| | 8329648 | Aug 18, 2026 | U-2156 | | | |
| | 8329648 | Aug 18, 2026 | U-2212 | | | |
| | 8329648 | Aug 18, 2026 | U-2213 | | | |
| | 8361972 | Mar 21, 2028 | U-2139 | | | |
| | 8361972 | Mar 21, 2028 | U-493 | | | |
| | 8431685 | Apr 13, 2025 | DP U-2139 | | | |
| | 8431685 | Apr 13, 2025 | DP U-412 | | | |
| | 8439864 | Mar 25, 2028 | DP | Y | | |
| | 8461105 | Apr 13, 2025 | DP U-2139 | | | |
| | 8461105 | Apr 13, 2025 | DP U-412 | | | |
| | 8501698 | Jun 20, 2027 | DP U-493 | | | |
| | 8685934 | May 26, 2030 | U-1522 | | | |
| | 8690837 | May 19, 2029 | DP | Y | | |
| | 8716251 | Mar 21, 2028 | DP | | | |
| | 8721615 | Jan 18, 2030 | DP | | | |
| | 8758292 | Nov 12, 2027 | DP | Y | | |
| | 8827963 | Feb 04, 2029 | DP | Y | | |
| | 8906851 | Aug 18, 2026 | U-1313 | | | |
| | 8906851 | Aug 18, 2026 | U-2139 | | | |
| | 8998876 | Jan 07, 2030 | DP | Y | | |
| | 9198925 | Oct 04, 2020 | U-2139 | | | |
| | 9198925 | Oct 04, 2020 | U-493 | | | |
| | 9238076 | Apr 15, 2024 | DP U-2139 | | | |
| | 9238076 | Apr 15, 2024 | DP U-412 | | | |
| | 9320853 | Mar 25, 2028 | DP | Y | | |
| DAPAGLIFLOZIN PROPANEDIOL - FARXIGA | | | | | | |
| N 202293 002 | 6414126 | Oct 04, 2020 | DS DP U-2139 | | M-157 | Mar 11, 2018 |
| | 6414126 | Oct 04, 2020 | DS DP U-493 | | M-212 | Oct 20, 2020 |
| | 6479065 | Aug 10, 2020 | DP | Y | NCE | Jan 08, 2019 |
| | 6495164 | May 25, 2020 | DP | Y | | |
| | 6515117 | Oct 04, 2020 | DS DP U-2139 | | | |
| | 6515117 | Oct 04, 2020 | DS DP U-493 | | | |
| | 6667061 | May 25, 2020 | DP | Y | | |
| | 6824822 | Oct 09, 2022 | DP | Y | | |
| | 6872700 | Jan 14, 2020 | U-654 | Y | | |
| | 6936590 | Oct 04, 2020 | U-493 | | | |
| | 6956026 | Jan 07, 2018 | U-687 | Y | | |
| | 7223440 | Aug 31, 2021 | DP | Y | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| DAPAGLIFLOZIN PROPANEDIOL - FARXIGA | | | | | | | |
| N 202293 | 002 | 7456254 | Jun 30, 2025 | DP U-1223 | | | |
| | | 7456254 | Jun 30, 2025 | DP U-2139 | | | |
| | | 7563871 | Apr 15, 2024 | DP | Y | | |
| | | 7612176 | Apr 13, 2025 | DP U-1223 | Y | | |
| | | 7741269 | Jan 07, 2018 | U-1224 | Y | | |
| | | 7851502 | Aug 19, 2028 | DP | | | |
| | | 7919598 | Dec 16, 2029 | DS | | | |
| | | 8216180 | Jan 11, 2028 | DP | Y | | |
| | | 8221786 | Mar 21, 2028 | DP | | | |
| | | 8329648 | Aug 18, 2026 | U-1313 | | | |
| | | 8329648 | Aug 18, 2026 | U-2139 | | | |
| | | 8329648 | Aug 18, 2026 | U-2153 | | | |
| | | 8329648 | Aug 18, 2026 | U-2155 | | | |
| | | 8329648 | Aug 18, 2026 | U-2156 | | | |
| | | 8329648 | Aug 18, 2026 | U-2212 | | | |
| | | 8329648 | Aug 18, 2026 | U-2213 | | | |
| | | 8361972 | Mar 21, 2028 | U-2139 | | | |
| | | 8361972 | Mar 21, 2028 | U-493 | | | |
| | | 8431685 | Apr 13, 2025 | DP U-2139 | | | |
| | | 8431685 | Apr 13, 2025 | DP U-412 | | | |
| | | 8439864 | Mar 25, 2028 | DP | Y | | |
| | | 8461105 | Apr 13, 2025 | DP U-2139 | | | |
| | | 8461105 | Apr 13, 2025 | DP U-412 | | | |
| | | 8501698 | Jun 20, 2027 | DP U-493 | | | |
| | | 8685934 | May 26, 2030 | U-1522 | | | |
| | | 8690837 | May 19, 2029 | DP | Y | | |
| | | 8716251 | Mar 21, 2028 | DP | | | |
| | | 8721615 | Jan 18, 2030 | DP | | | |
| | | 8758292 | Nov 12, 2027 | DP | Y | | |
| | | 8827963 | Feb 04, 2029 | DP | Y | | |
| | | 8906851 | Aug 18, 2026 | U-1313 | | | |
| | | 8906851 | Aug 18, 2026 | U-2139 | | | |
| | | 8998876 | Jan 07, 2030 | DP | Y | | |
| | | 9198925 | Oct 04, 2020 | U-2139 | | | |
| | | 9198925 | Oct 04, 2020 | U-493 | | | |
| | | 9238076 | Apr 15, 2024 | DP U-2139 | | | |
| | | 9238076 | Apr 15, 2024 | DP U-412 | | | |
| | | 9320853 | Mar 25, 2028 | DP | Y | | |
| DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR | | | | | | | |
| N 205649 | 001 | 6414126 | Oct 04, 2020 | DS DP U-493 | | NCE | Jan 08, 2019 |
| | | 6515117 | Oct 04, 2020 | DS DP U-493 | | | |
| | | 6936590 | Oct 04, 2020 | U-493 | | | |
| | | 7919598 | Dec 16, 2029 | DS | | | |
| | | 8501698 | Jun 20, 2027 | DP U-493 | | | |
| | | 8685934 | May 26, 2030 | U-1522 | | | |
| | | 9198925 | Oct 04, 2020 | U-493 | | | |
| | | 9616028 | Nov 12, 2030 | DP | | | |
| DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR | | | | | | | |
| N 205649 | 002 | 6414126 | Oct 04, 2020 | DS DP U-493 | | NCE | Jan 08, 2019 |
| | | 6515117 | Oct 04, 2020 | DS DP U-493 | | | |
| | | 6936590 | Oct 04, 2020 | U-493 | | | |
| | | 7919598 | Dec 16, 2029 | DS | | | |
| | | 8501698 | Jun 20, 2027 | DP U-493 | | | |
| | | 8685934 | May 26, 2030 | U-1522 | | | |
| | | 9198925 | Oct 04, 2020 | U-493 | | | |
| | | 9616028 | Nov 12, 2030 | DP | | | |
| DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR | | | | | | | |
| N 205649 | 003 | 6414126 | Oct 04, 2020 | DS DP U-493 | | NCE | Jan 08, 2019 |
| | | 6515117 | Oct 04, 2020 | DS DP U-493 | | | |
| | | 6936590 | Oct 04, 2020 | U-493 | | | |
| | | 7919598 | Dec 16, 2029 | DS | | | |
| | | 8501698 | Jun 20, 2027 | DP U-493 | | | |
| | | 8685934 | May 26, 2030 | U-1522 | | | |
| | | 9198925 | Oct 04, 2020 | U-493 | | | |
| | | 9616028 | Nov 12, 2030 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR | | | | | | | |
| N 205649 | 004 | 6414126 | Oct 04, 2020 | DS DP U-493 | | NCE | Jan 08, 2019 |
| | | 6515117 | Oct 04, 2020 | DS DP U-493 | | | |
| | | 6936590 | Oct 04, 2020 | U-493 | | | |
| | | 7919598 | Dec 16, 2029 | DS | | | |
| | | 8501698 | Jun 20, 2027 | DP U-493 | | | |
| | | 8685934 | May 26, 2030 | U-1522 | | | |
| | | 9198925 | Oct 04, 2020 | U-493 | | | |
| | | 9616028 | Nov 12, 2030 | DP | | | |
| DAPAGLIFLOZIN PROPANEDIOL; METFORMIN HYDROCHLORIDE - XIGDUO XR | | | | | | | |
| N 205649 | 005 | 6414126 | Oct 04, 2020 | DS DP U-493 | | NCE | Jan 08, 2019 |
| | | 6515117 | Oct 04, 2020 | DS DP U-493 | | | |
| | | 6936590 | Oct 04, 2020 | U-493 | | | |
| | | 7919598 | Dec 16, 2029 | DS | | | |
| | | 8501698 | Jun 20, 2027 | DP U-493 | | | |
| | | 8685934 | May 26, 2030 | U-1522 | | | |
| | | 9198925 | Oct 04, 2020 | U-493 | | | |
| | | 9616028 | Nov 12, 2030 | DP | | | |
| DAPAGLIFLOZIN PROPANEDIOL; SAXAGLIPTIN HYDROCHLORIDE - QTERN | | | | | | | |
| N 209091 | 001 | 6414126 | Oct 04, 2020 | DS DP U-1976 | | M-175 | Apr 05, 2019 |
| | | 6414126 | Oct 04, 2020 | DS DP U-1977 | | NC | Feb 27, 2020 |
| | | 6515117 | Oct 04, 2020 | DS DP U-1976 | | NCE | Jan 08, 2019 |
| | | 6515117 | Oct 04, 2020 | DS DP U-1977 | | | |
| | | 6936590 | Oct 04, 2020 | U-1976 | | | |
| | | 6936590 | Oct 04, 2020 | U-1977 | | | |
| | | 7919598 | Dec 16, 2029 | DS | | | |
| | | 8221786 | Mar 21, 2028 | DP | | | |
| | | 8361972 | Mar 21, 2028 | U-1976 | | | |
| | | 8361972 | Mar 21, 2028 | U-1977 | | | |
| | | 8501698 | Jun 20, 2027 | DP U-1976 | | | |
| | | 8501698 | Jun 20, 2027 | DP U-1977 | | | |
| | | 8628799 | Jul 13, 2025 | DP | | | |
| | | 8716251 | Mar 21, 2028 | DP | | | |
| | | 9198925 | Oct 04, 2020 | U-1976 | | | |
| | | 9198925 | Oct 04, 2020 | U-1977 | | | |
| | | RE44186 | Jul 31, 2023 | DS DP U-1976 | | | |
| | | RE44186 | Jul 31, 2023 | DS DP U-1977 | | | |
| DAPSONE - ACZONE | | | | | | | |
| N 207154 | 001 | 9161926 | Nov 18, 2033 | DP | | NS | Feb 24, 2019 |
| | | 9517219 | Nov 18, 2033 | U-1033 | | | |
| DAPTOMYCIN - CUBICIN | | | | | | | |
| N 021572 | 002 | 8003673 | Sep 04, 2028 | U-1180 | | M-211 | Sep 01, 2020 |
| | | | | | | NPP | Mar 29, 2020 |
| DAPTOMYCIN - CUBICIN RF | | | | | | | |
| N 021572 | 003 | 9138456 | Nov 23, 2030 | DP | | M-211 | Sep 01, 2020 |
| | | | | | | NPP | Mar 29, 2020 |
| DARUNAVIR ETHANOLATE - PREZISTA | | | | | | | |
| N 021976 | 001 | 7470506 | Jun 23, 2019 | U-1209 | | | |
| | | 7470506 | Jun 23, 2019 | U-1305 | | | |
| | | 7470506 | Jun 23, 2019 | U-935 | | | |
| | | 7700645 | Dec 26, 2026 | DS DP | | | |
| | | 8518987 | Feb 16, 2024 | DS DP | | | |
| | | 8518987*PED | Aug 16, 2024 | | | | |
| | | 8597876 | Jun 23, 2019 | U-1305 | | | |
| | | 8597876*PED | Dec 23, 2019 | | | | |
| DARUNAVIR ETHANOLATE - PREZISTA | | | | | | | |
| N 021976 | 002 | 7470506 | Jun 23, 2019 | U-1209 | | | |
| | | 7470506 | Jun 23, 2019 | U-1305 | | | |
| | | 7470506 | Jun 23, 2019 | U-935 | | | |
| | | 7700645 | Dec 26, 2026 | DS DP | | | |
| | | 8518987 | Feb 16, 2024 | DS DP | | | |
| | | 8518987*PED | Aug 16, 2024 | | | | |
| | | 8597876 | Jun 23, 2019 | U-1305 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| DARUNAVIR ETHANOLATE - PREZISTA | | | | | | |
| N 021976 002 | 8597876*PED | Dec 23, 2019 | | | | |
| DARUNAVIR ETHANOLATE - PREZISTA | | | | | | |
| N 021976 003 | 7470506 | Jun 23, 2019 | U-1209 | | | |
| | 7470506 | Jun 23, 2019 | U-1305 | | | |
| | 7470506 | Jun 23, 2019 | U-935 | | | |
| | 7700645 | Dec 26, 2026 | DS DP | | | |
| | 8518987 | Feb 16, 2024 | DS DP | | | |
| | 8518987*PED | Aug 16, 2024 | | | | |
| | 8597876 | Jun 23, 2019 | U-1305 | | | |
| | 8597876*PED | Dec 23, 2019 | | | | |
| DARUNAVIR ETHANOLATE - PREZISTA | | | | | | |
| N 021976 004 | 7470506 | Jun 23, 2019 | U-1209 | | | |
| | 7470506 | Jun 23, 2019 | U-1305 | | | |
| | 7470506 | Jun 23, 2019 | U-935 | | | |
| | 7700645 | Dec 26, 2026 | DS DP | | | |
| | 8518987 | Feb 16, 2024 | DS DP | | | |
| | 8518987*PED | Aug 16, 2024 | | | | |
| | 8597876 | Jun 23, 2019 | U-1305 | | | |
| | 8597876*PED | Dec 23, 2019 | | | | |
| DARUNAVIR ETHANOLATE - PREZISTA | | | | | | |
| N 021976 005 | 7470506 | Jun 23, 2019 | U-1209 | | | |
| | 7470506 | Jun 23, 2019 | U-1305 | | | |
| | 7470506 | Jun 23, 2019 | U-935 | | | |
| | 7700645 | Dec 26, 2026 | DS DP | | | |
| | 8518987 | Feb 16, 2024 | DS DP | | | |
| | 8518987*PED | Aug 16, 2024 | | | | |
| | 8597876 | Jun 23, 2019 | U-1305 | | | |
| | 8597876*PED | Dec 23, 2019 | | | | |
| DARUNAVIR ETHANOLATE - PREZISTA | | | | | | |
| N 021976 006 | 7470506 | Jun 23, 2019 | U-1209 | | | |
| | 7470506 | Jun 23, 2019 | U-1305 | | | |
| | 7470506 | Jun 23, 2019 | U-935 | | | |
| | 7700645 | Dec 26, 2026 | DS DP | | | |
| | 8518987 | Feb 16, 2024 | DS DP | | | |
| | 8518987*PED | Aug 16, 2024 | | | | |
| | 8597876 | Jun 23, 2019 | U-1305 | | | |
| | 8597876*PED | Dec 23, 2019 | | | | |
| DARUNAVIR ETHANOLATE - PREZISTA | | | | | | |
| N 202895 001 | 7470506 | Jun 23, 2019 | U-1209 | | | |
| | 7470506 | Jun 23, 2019 | U-1305 | | | |
| | 7700645 | Dec 26, 2026 | DS DP | | | |
| | 8518987 | Feb 16, 2024 | DS DP | | | |
| | 8518987*PED | Aug 16, 2024 | | | | |
| | 8597876 | Jun 23, 2019 | U-1305 | | | |
| | 8597876*PED | Dec 23, 2019 | | | | |
| DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED) | | | | | | |
| N 206619 001 | 7148359 | Jul 19, 2019 | DP | | D-163 | Apr 22, 2019 |
| | 7364752 | Nov 10, 2020 | DP | | NCE | Dec 19, 2019 |
| | 8188104 | May 17, 2029 | DS DP U-1636 | | | |
| | 8268349 | Aug 25, 2024 | DP | | | |
| | 8399015 | Aug 25, 2024 | DP | | | |
| | 8420596 | Apr 10, 2031 | DS DP | | | |
| | 8466159 | Sep 04, 2032 | U-1637 | | | |
| | 8492386 | Sep 04, 2032 | U-1840 | | | |
| | 8501238 | Sep 17, 2028 | DS DP U-1636 | | | |
| | 8642538 | Sep 10, 2029 | DS DP U-1638 | | | |
| | 8680106 | Sep 04, 2032 | U-1637 | | | |
| | 8685984 | Sep 04, 2032 | U-1840 | | | |
| | 8686026 | Jun 09, 2031 | DP | | | |
| | 8691938 | Apr 13, 2032 | DS DP | | | |
| | 9006387 | Jun 10, 2030 | U-1687 | | | |
| | 9044480 | Apr 10, 2031 | U-1638 | | | |
| | 9139536 | Nov 09, 2028 | U-1753 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED) | | | | | | | |
| N 206619 | 001 | 9629841 | Oct 18, 2033 | DP U-1753 | | | |
| DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA XR | | | | | | | |
| N 208624 | 001 | 7148359 | Jul 19, 2019 | DP | | NCE | Dec 19, 2019 |
| | | 7364752 | Nov 10, 2020 | DP | | | |
| | | 8188104 | May 17, 2029 | DS DP U-1636 | | | |
| | | 8268349 | Aug 25, 2024 | DP | | | |
| | | 8399015 | Aug 25, 2024 | DP | | | |
| | | 8420596 | Apr 10, 2031 | DS DP | | | |
| | | 8466159 | Sep 04, 2032 | U-1637 | | | |
| | | 8492386 | Sep 04, 2032 | U-1840 | | | |
| | | 8501238 | Sep 17, 2028 | DS DP U-1636 | | | |
| | | 8642538 | Sep 10, 2029 | DS DP U-1638 | | | |
| | | 8680106 | Sep 04, 2032 | U-1637 | | | |
| | | 8685984 | Sep 04, 2032 | U-1840 | | | |
| | | 8686026 | Jun 09, 2031 | DP | | | |
| | | 8691938 | Apr 13, 2032 | DS DP | | | |
| | | 9006387 | Jun 10, 2030 | U-1687 | | | |
| | | 9044480 | Apr 10, 2031 | U-1638 | | | |
| | | 9139536 | Nov 09, 2028 | U-1753 | | | |
| | | 9333204 | Jan 02, 2035 | DP U-1889 | | | |
| | | 9744170 | Jan 02, 2035 | DP U-1889 | | | |
| DASATINIB - SPRYCEL | | | | | | | |
| N 021986 | 001 | 6596746 | Jun 28, 2020 | DS DP U-748 | | NPP | Nov 09, 2020 |
| | | 6596746 | Jun 28, 2020 | DS DP U-780 | | | |
| | | 7125875 | Apr 13, 2020 | U-779 | | | |
| | | 7125875 | Apr 13, 2020 | U-780 | | | |
| | | 7153856 | Apr 28, 2020 | U-780 | | | |
| | | 7491725 | Mar 28, 2026 | DS DP | | | |
| | | 8680103 | Feb 04, 2025 | DP | | | |
| DASATINIB - SPRYCEL | | | | | | | |
| N 021986 | 002 | 6596746 | Jun 28, 2020 | DS DP U-748 | | NPP | Nov 09, 2020 |
| | | 6596746 | Jun 28, 2020 | DS DP U-780 | | | |
| | | 7125875 | Apr 13, 2020 | U-779 | | | |
| | | 7125875 | Apr 13, 2020 | U-780 | | | |
| | | 7153856 | Apr 28, 2020 | U-780 | | | |
| | | 7491725 | Mar 28, 2026 | DS DP | | | |
| | | 8680103 | Feb 04, 2025 | DP | | | |
| DASATINIB - SPRYCEL | | | | | | | |
| N 021986 | 003 | 6596746 | Jun 28, 2020 | DS DP U-748 | | NPP | Nov 09, 2020 |
| | | 6596746 | Jun 28, 2020 | DS DP U-780 | | | |
| | | 7125875 | Apr 13, 2020 | U-779 | | | |
| | | 7125875 | Apr 13, 2020 | U-780 | | | |
| | | 7153856 | Apr 28, 2020 | U-780 | | | |
| | | 7491725 | Mar 28, 2026 | DS DP | | | |
| | | 8680103 | Feb 04, 2025 | DP | | | |
| DASATINIB - SPRYCEL | | | | | | | |
| N 021986 | 004 | 6596746 | Jun 28, 2020 | DS DP U-748 | | NPP | Nov 09, 2020 |
| | | 6596746 | Jun 28, 2020 | DS DP U-780 | | | |
| | | 7125875 | Apr 13, 2020 | U-779 | | | |
| | | 7125875 | Apr 13, 2020 | U-780 | | | |
| | | 7153856 | Apr 28, 2020 | U-780 | | | |
| | | 7491725 | Mar 28, 2026 | DS DP | | | |
| | | 8680103 | Feb 04, 2025 | DP | | | |
| DASATINIB - SPRYCEL | | | | | | | |
| N 021986 | 005 | 6596746 | Jun 28, 2020 | DS DP U-748 | | NPP | Nov 09, 2020 |
| | | 6596746 | Jun 28, 2020 | DS DP U-780 | | | |
| | | 7125875 | Apr 13, 2020 | U-779 | | | |
| | | 7125875 | Apr 13, 2020 | U-780 | | | |
| | | 7153856 | Apr 28, 2020 | U-780 | | | |
| | | 7491725 | Mar 28, 2026 | DS DP | | | |
| | | 8680103 | Feb 04, 2025 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| DASATINIB - SPRYCEL | | | | | | |
| N 021986 006 | 6596746 | Jun 28, 2020 | DS DP U-748 | | NPP | Nov 09, 2020 |
| | 6596746 | Jun 28, 2020 | DS DP U-780 | | | |
| | 7125875 | Apr 13, 2020 | U-779 | | | |
| | 7125875 | Apr 13, 2020 | U-780 | | | |
| | 7153856 | Apr 28, 2020 | U-780 | | | |
| | 7491725 | Mar 28, 2026 | DS DP | | | |
| | 8680103 | Feb 04, 2025 | DP | | | |
| DEFERASIROX - EXJADE | | | | | | |
| N 021882 001 | 6465504 | Apr 05, 2019 | DS DP | | ODE-39 | Jan 23, 2020 |
| DEFERASIROX - EXJADE | | | | | | |
| N 021882 002 | 6465504 | Apr 05, 2019 | DS DP | | ODE-39 | Jan 23, 2020 |
| DEFERASIROX - EXJADE | | | | | | |
| N 021882 003 | 6465504 | Apr 05, 2019 | DS DP | | ODE-39 | Jan 23, 2020 |
| DEFERASIROX - JADENU | | | | | | |
| N 206910 001 | 6465504 | Apr 05, 2019 | DS DP | | ODE-39 | Jan 23, 2020 |
| | 9283209 | Nov 21, 2034 | DS DP | | | |
| DEFERASIROX - JADENU | | | | | | |
| N 206910 002 | 6465504 | Apr 05, 2019 | DS DP | | ODE-39 | Jan 23, 2020 |
| | 9283209 | Nov 21, 2034 | DS DP | | | |
| DEFERASIROX - JADENU | | | | | | |
| N 206910 003 | 6465504 | Apr 05, 2019 | DS DP | | ODE-39 | Jan 23, 2020 |
| | 9283209 | Nov 21, 2034 | DS DP | | | |
| DEFERASIROX - JADENU SPRINKLE | | | | | | |
| N 207968 001 | 6465504 | Apr 05, 2019 | DS DP | | | |
| DEFERASIROX - JADENU SPRINKLE | | | | | | |
| N 207968 002 | 6465504 | Apr 05, 2019 | DS DP | | | |
| DEFERASIROX - JADENU SPRINKLE | | | | | | |
| N 207968 003 | 6465504 | Apr 05, 2019 | DS DP | | | |
| DEFERIPRONE - FERRIPROX | | | | | | |
| N 021825 001 | 7049328 | Jun 28, 2021 | U-735 | | ODE-16 | Oct 14, 2018 |
| DEFERIPRONE - FERRIPROX | | | | | | |
| N 208030 001 | 7049328 | Jun 28, 2021 | U-735 | | ODE-16 | Oct 14, 2018 |
| | 8703156 | Oct 29, 2029 | DP U-735 | | | |
| DEFIBROTIDE SODIUM - DEFITELIO | | | | | | |
| N 208114 001 | | | | | NCE | Mar 30, 2021 |
| | | | | | ODE-112 | Mar 30, 2023 |
| DEFLAZACORT - EMFLAZA | | | | | | |
| N 208684 001 | | | | | NCE | Feb 09, 2022 |
| | | | | | ODE-130 | Feb 09, 2024 |
| DEFLAZACORT - EMFLAZA | | | | | | |
| N 208684 002 | | | | | NCE | Feb 09, 2022 |
| | | | | | ODE-130 | Feb 09, 2024 |
| DEFLAZACORT - EMFLAZA | | | | | | |
| N 208684 003 | | | | | NCE | Feb 09, 2022 |
| | | | | | ODE-130 | Feb 09, 2024 |
| DEFLAZACORT - EMFLAZA | | | | | | |
| N 208684 004 | | | | | NCE | Feb 09, 2022 |
| | | | | | ODE-130 | Feb 09, 2024 |
| DEFLAZACORT - EMFLAZA | | | | | | |
| N 208685 001 | | | | | NCE | Feb 09, 2022 |
| | | | | | ODE-130 | Feb 09, 2024 |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| DEGARELIX ACETATE - FIRMAGON | | | | | | | |
| N 022201 | 001 | 5925730 | May 18, 2021 | DS DP U-943 | | | |
| | | 9415085 | Apr 27, 2032 | U-1895 | | | |
| | | 9579359 | Feb 10, 2029 | U-1978 | | | |
| DEGARELIX ACETATE - FIRMAGON | | | | | | | |
| N 022201 | 002 | 5925730 | May 18, 2021 | DS DP U-943 | | | |
| | | 9415085 | Apr 27, 2032 | U-1895 | | | |
| | | 9579359 | Feb 10, 2029 | U-1978 | | | |
| DELAFLOXACIN MEGLUMINE - BAXDELA | | | | | | | |
| N 208610 | 001 | 7728143 | Nov 20, 2027 | DS | | NCE | Jun 19, 2022 |
| | | 8252813 | Oct 02, 2026 | DP U-2028 | | GAIN | Jun 19, 2027 |
| | | 8273892 | Aug 06, 2026 | DS | | | |
| | | 8497378 | Dec 28, 2029 | DS | | | |
| | | 8648093 | Oct 07, 2025 | DP U-2028 | | | |
| | | 8871938 | Sep 23, 2029 | DS | | | |
| | | 8969569 | Oct 07, 2025 | DP U-2028 | | | |
| | | 9539250 | Oct 07, 2025 | DS DP U-2028 | | | |
| | | RE46617 | Dec 28, 2029 | DS | | | |
| DELAFLOXACIN MEGLUMINE - BAXDELA | | | | | | | |
| N 208611 | 001 | 7635773 | Mar 13, 2029 | DP | | NCE | Jun 19, 2022 |
| | | 7728143 | Nov 20, 2027 | DS | | GAIN | Jun 19, 2027 |
| | | 8252813 | Oct 02, 2026 | DP U-2028 | | | |
| | | 8273892 | Aug 06, 2026 | DS | | | |
| | | 8410077 | Mar 13, 2029 | DP | | | |
| | | 8497378 | Dec 28, 2029 | DS | | | |
| | | 8648093 | Oct 07, 2025 | DP U-2028 | | | |
| | | 8871938 | Sep 23, 2029 | DS | | | |
| | | 9200088 | Mar 13, 2029 | DP | | | |
| | | 9493582 | Feb 27, 2033 | DP | | | |
| | | 9539250 | Oct 07, 2025 | DS DP U-2028 | | | |
| | | 9750822 | Mar 13, 2029 | DP | | | |
| | | RE46617 | Dec 28, 2029 | DS | | | |
| DELAVIRDINE MESYLATE - RESCRIPTOR | | | | | | | |
| N 020705 | 002 | 6177101 | Jun 07, 2019 | | | | |
| DEOXYCHOLIC ACID - KYBELLA | | | | | | | |
| N 206333 | 001 | 7622130 | Dec 10, 2027 | U-1690 | | | |
| | | 7754230 | Dec 10, 2027 | U-1690 | | | |
| | | 8101593 | Mar 02, 2030 | DP | | | |
| | | 8242294 | May 16, 2028 | DS | | | |
| | | 8298556 | Aug 03, 2025 | U-1690 | | | |
| | | 8367649 | Mar 02, 2030 | DP | | | |
| | | 8461140 | Feb 21, 2028 | DP | | | |
| | | 8546367 | Feb 21, 2028 | DP U-1690 | | | |
| | | 8653058 | Mar 02, 2030 | DP | | | |
| | | 8846066 | Feb 08, 2025 | U-1690 | | | |
| | | 8883770 | Feb 21, 2028 | DP | | | |
| | | 9522155 | Feb 21, 2028 | DP U-1940 | | | |
| | | 9636349 | Feb 21, 2028 | U-1940 | | | |
| DESLORATADINE - CLARINEX | | | | | | | |
| N 021165 | 001 | 6100274 | Jul 07, 2019 | | | | |
| | | 7405223 | Jul 07, 2019 | U-886 | | | |
| DESLORATADINE - CLARINEX | | | | | | | |
| N 021300 | 001 | 6514520 | Jun 01, 2018 | DP | | | |
| DESLORATADINE - CLARINEX | | | | | | | |
| N 021312 | 001 | 6100274 | Jul 07, 2019 | DP | | | |
| | | 7618649 | Dec 19, 2020 | DP U-1017 | | | |
| DESLORATADINE - CLARINEX | | | | | | | |
| N 021312 | 002 | 6100274 | Jul 07, 2019 | DP | | | |
| | | 7618649 | Dec 19, 2020 | DP U-1017 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|
| DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX-D 12 HOUR | | | | | | | | |
| N 021313 | 001 | 6100274 | Jul 07, 2019 | | DP | | | |
| | | 6709676 | Feb 18, 2021 | | DP U-707 | | | |
| | | 7618649 | Dec 19, 2020 | | DP U-1017 | | | |
| | | 8187630 | Dec 19, 2020 | | DP U-1017 | | | |
| DESLORATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX D 24 HOUR | | | | | | | | |
| N 021605 | 001 | 6100274 | Jul 07, 2019 | | DP | | | |
| | | 6979463 | Mar 28, 2022 | | DP | | | |
| | | 7618649 | Dec 19, 2020 | | DP U-1017 | | | |
| | | 7820199 | Mar 28, 2022 | | DP | | | |
| DESMOPRESSIN ACETATE - NOCTIVA | | | | | | | | |
| N 201656 | 001 | 7405203 | May 06, 2023 | | U-1980 | | NP | Mar 03, 2020 |
| | | 7579321 | May 06, 2023 | | U-1980 | | | |
| | | 7799761 | Sep 26, 2024 | | DP | | | |
| | | 9539302 | Jun 15, 2030 | | DP | | | |
| DESMOPRESSIN ACETATE - NOCTIVA | | | | | | | | |
| N 201656 | 002 | 7405203 | May 06, 2023 | | U-1980 | | NP | Mar 03, 2020 |
| | | 7579321 | May 06, 2023 | | U-1980 | | | |
| | | 9539302 | Jun 15, 2030 | | DP | | | |
| DESONIDE - DESONATE | | | | | | | | |
| N 021844 | 001 | 6387383 | Aug 03, 2020 | DS | DP U-783 | | | |
| DESONIDE - VERDESO | | | | | | | | |
| N 021978 | 001 | 6730288 | Sep 08, 2019 | | DP | | | |
| | | 7029659 | Sep 08, 2019 | | DP | | | |
| | | 8460641 | Nov 05, 2028 | | DP U-1412 | | | |
| | | 8962000 | Aug 31, 2025 | | DP U-1412 | | | |
| | | 9492384 | Aug 31, 2025 | | DP U-1412 | | | |
| DESOXIMETASONE - TOPICORT | | | | | | | | |
| N 204141 | 001 | 5990100 | Mar 24, 2018 | | DP U-1408 | | | |
| | | 8277780 | Sep 01, 2028 | | DP U-1408 | | | |
| | | 8715624 | May 26, 2026 | | DP U-1408 | | | |
| DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE | | | | | | | | |
| A 204003 | 001 | | | | | | PC | Aug 28, 2017 |
| DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE | | | | | | | | |
| A 204003 | 002 | | | | | | PC | Aug 28, 2017 |
| DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE | | | | | | | | |
| A 204028 | 001 | | | | | | PC | Aug 28, 2017 |
| DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE | | | | | | | | |
| A 204028 | 002 | | | | | | PC | Aug 28, 2017 |
| DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE | | | | | | | | |
| A 204065 | 002 | | | | | | PC | Aug 28, 2017 |
| DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE | | | | | | | | |
| A 204065 | 003 | | | | | | PC | Aug 28, 2017 |
| DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE | | | | | | | | |
| A 204082 | 001 | | | | | | PC | Aug 28, 2017 |
| DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE | | | | | | | | |
| A 204083 | 001 | | | | | | PC | Aug 28, 2017 |
| DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE | | | | | | | | |
| A 204095 | 001 | | | | | | PC | Aug 28, 2017 |
| DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE | | | | | | | | |
| A 204095 | 002 | | | | | | PC | Aug 28, 2017 |
| DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE | | | | | | | | |
| A 204172 | 001 | | | | | | PC | Aug 28, 2017 |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| DESVENLAFAXINE SUCCINATE - DESVENLAFAXINE SUCCINATE | | | | | | |
| A 204172 002 | | | | | PC | Aug 28, 2017 |
| DESVENLAFAXINE SUCCINATE - PRISTIQ | | | | | | |
| N 021992 001 | 6673838 | Mar 01, 2022 | DS U-1364 | | | |
| | 6673838 | Mar 01, 2022 | DS U-860 | | | |
| | 8269040 | Jul 05, 2027 | DS | | | |
| DESVENLAFAXINE SUCCINATE - PRISTIQ | | | | | | |
| N 021992 002 | 6673838 | Mar 01, 2022 | DS U-1364 | | | |
| | 6673838 | Mar 01, 2022 | DS U-860 | | | |
| | 8269040 | Jul 05, 2027 | DS | | | |
| DESVENLAFAXINE SUCCINATE - PRISTIQ | | | | | | |
| N 021992 003 | 6673838 | Mar 01, 2022 | DS U-1364 | | | |
| | 6673838 | Mar 01, 2022 | DS U-860 | | | |
| | 8269040 | Jul 05, 2027 | DS | | | |
| DEUTETRABENAZINE - AUSTEDO | | | | | | |
| N 208082 001 | 8524733 | Mar 27, 2031 | DS DP | | I-751 | Aug 30, 2020 |
| | 9233959 | Sep 18, 2033 | DP | | NCE | Apr 03, 2022 |
| | 9296739 | Sep 18, 2033 | DP | | ODE-134 | Apr 03, 2024 |
| | 9550780 | Sep 18, 2033 | DS DP U-1846 | | | |
| | 9550780 | Sep 18, 2033 | DS DP U-1995 | | | |
| | 9814708 | Sep 18, 2033 | DP | | | |
| DEUTETRABENAZINE - AUSTEDO | | | | | | |
| N 208082 002 | 8524733 | Mar 27, 2031 | DS DP | | I-751 | Aug 30, 2020 |
| | 9233959 | Sep 18, 2033 | DP | | NCE | Apr 03, 2022 |
| | 9296739 | Sep 18, 2033 | DP | | ODE-134 | Apr 03, 2024 |
| | 9550780 | Sep 18, 2033 | DS DP U-1846 | | | |
| | 9550780 | Sep 18, 2033 | DS DP U-1995 | | | |
| | 9814708 | Sep 18, 2033 | DP | | | |
| DEUTETRABENAZINE - AUSTEDO | | | | | | |
| N 208082 003 | 8524733 | Mar 27, 2031 | DS DP | | I-751 | Aug 30, 2020 |
| | 9233959 | Sep 18, 2033 | DP | | NCE | Apr 03, 2022 |
| | 9296739 | Sep 18, 2033 | DP | | ODE-134 | Apr 03, 2024 |
| | 9550780 | Sep 18, 2033 | DS DP U-1846 | | | |
| | 9550780 | Sep 18, 2033 | DS DP U-1995 | | | |
| | 9814708 | Sep 18, 2033 | DP | | | |
| DEXAMETHASONE - OZURDEX | | | | | | |
| N 022315 001 | 6726918 | Oct 20, 2020 | DP U-1204 | | ODE-2 | Sep 24, 2017 |
| | 6726918 | Oct 20, 2020 | DP U-1205 | | | |
| | 6899717 | Nov 01, 2023 | U-1206 | | | |
| | 7033605 | Oct 20, 2020 | DP | | | |
| | 7767223 | Nov 28, 2021 | DP | | | |
| | 8034366 | Jan 09, 2023 | DP U-1204 | | | |
| | 8034366 | Jan 09, 2023 | DP U-1205 | | | |
| | 8034370 | Jan 09, 2023 | DP | | | |
| | 8043628 | Oct 20, 2020 | U-1205 | | | |
| | 8063031 | Oct 20, 2020 | DP | | | |
| | 8088407 | Oct 20, 2020 | U-1205 | | | |
| | 8506987 | Jan 09, 2023 | U-1204 | | | |
| | 8506987 | Jan 09, 2023 | U-1205 | | | |
| | 9012437 | Oct 20, 2020 | U-1205 | | | |
| | 9192511 | Jan 09, 2023 | DP | | | |
| | 9283178 | Oct 20, 2020 | U-1205 | | | |
| | 9592242 | Oct 20, 2020 | U-1989 | | | |
| | 9592242 | Oct 20, 2020 | U-1990 | | | |
| | 9775849 | Oct 20, 2020 | U-1989 | | | |
| | 9775849 | Oct 20, 2020 | U-1990 | | | |
| DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST | | | | | | |
| N 050818 001 | 7795316 | Aug 03, 2028 | DP U-1082 | | | |
| | 8101582 | Dec 19, 2027 | DP U-1082 | | | |
| | 8450287 | Dec 19, 2027 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| DEXLANSOPRAZOLE - DEXILANT | | | | | | |
| N 022287 001 | 6462058 | Jun 15, 2020 | DS DP U-949 | | NPP | Jul 08, 2019 |
| | 6462058 | Jun 15, 2020 | DS DP U-950 | | NPP | Jul 08, 2019 |
| | 6462058 | Jun 15, 2020 | DS DP U-951 | | NPP | Jul 08, 2019 |
| | 6664276 | Jan 30, 2023 | DS DP U-1507 | | | |
| | 6664276 | Jan 30, 2023 | DS DP U-949 | | | |
| | 6664276 | Jan 30, 2023 | DS DP U-950 | | | |
| | 6664276 | Jan 30, 2023 | DS DP U-951 | | | |
| | 6664276*PED | Jul 30, 2023 | | | | |
| | 6939971 | Jun 15, 2020 | U-949 | | | |
| | 6939971 | Jun 15, 2020 | U-950 | | | |
| | 6939971 | Jun 15, 2020 | U-951 | | | |
| | 7285668 | Jun 15, 2020 | DS | | | |
| | 7790755 | Aug 02, 2026 | DP | | | |
| | 8105626 | Sep 27, 2026 | DP | | | |
| | 8173158 | Mar 17, 2030 | U-949 | | | |
| | 8173158 | Mar 17, 2030 | U-950 | | | |
| | 8173158 | Mar 17, 2030 | U-951 | | | |
| | 8461187 | Jan 17, 2026 | DP | | | |
| | 8461187*PED | Jul 17, 2026 | | | | |
| | 8722084 | Oct 15, 2023 | DP | | | |
| | 8722084*PED | Apr 15, 2024 | | | | |
| | 8784885 | Oct 15, 2023 | DP U-1552 | | | |
| | 8784885 | Oct 15, 2023 | DP U-1553 | | | |
| | 8784885 | Oct 15, 2023 | DP U-1554 | | | |
| | 8784885*PED | Apr 15, 2024 | | | | |
| | 8871273 | Jan 11, 2028 | DP | | | |
| | 9011926 | Feb 24, 2026 | DP | | | |
| | 9145389 | Jun 15, 2020 | DS DP | | | |
| | 9233103 | Mar 05, 2032 | U-1805 | | | |
| | 9238029 | Jan 17, 2026 | DP | | | |
| DEXLANSOPRAZOLE - DEXILANT | | | | | | |
| N 022287 002 | 6462058 | Jun 15, 2020 | DS DP U-949 | | NPP | Jul 08, 2019 |
| | 6462058 | Jun 15, 2020 | DS DP U-950 | | NPP | Jul 08, 2019 |
| | 6462058 | Jun 15, 2020 | DS DP U-951 | | NPP | Jul 08, 2019 |
| | 6664276 | Jan 30, 2023 | DS DP U-1507 | | | |
| | 6664276 | Jan 30, 2023 | DS DP U-949 | | | |
| | 6664276 | Jan 30, 2023 | DS DP U-950 | | | |
| | 6664276 | Jan 30, 2023 | DS DP U-951 | | | |
| | 6664276*PED | Jul 30, 2023 | | | | |
| | 6939971 | Jun 15, 2020 | U-949 | | | |
| | 6939971 | Jun 15, 2020 | U-950 | | | |
| | 6939971 | Jun 15, 2020 | U-951 | | | |
| | 7285668 | Jun 15, 2020 | DS | | | |
| | 7790755 | Aug 02, 2026 | DP | | | |
| | 8105626 | Sep 27, 2026 | DP | | | |
| | 8173158 | Mar 17, 2030 | U-949 | | | |
| | 8173158 | Mar 17, 2030 | U-950 | | | |
| | 8173158 | Mar 17, 2030 | U-951 | | | |
| | 8461187 | Jan 17, 2026 | DP | | | |
| | 8461187*PED | Jul 17, 2026 | | | | |
| | 8722084 | Oct 15, 2023 | DP | | | |
| | 8722084*PED | Apr 15, 2024 | | | | |
| | 8784885 | Oct 15, 2023 | DP U-1552 | | | |
| | 8784885 | Oct 15, 2023 | DP U-1553 | | | |
| | 8784885 | Oct 15, 2023 | DP U-1554 | | | |
| | 8784885*PED | Apr 15, 2024 | | | | |
| | 8871273 | Jan 11, 2028 | DP | | | |
| | 9011926 | Feb 24, 2026 | DP | | | |
| | 9145389 | Jun 15, 2020 | DS DP | | | |
| | 9233103 | Mar 05, 2032 | U-1805 | | | |
| | 9238029 | Jan 17, 2026 | DP | | | |
| DEXLANSOPRAZOLE - DEXILANT SOLUTAB | | | | | | |
| N 208056 001 | 6328994 | May 17, 2019 | DP | | | |
| | 6328994*PED | Nov 17, 2019 | | | | |
| | 6462058 | Jun 15, 2020 | DS DP U-950 | | | |
| | 6462058 | Jun 15, 2020 | DS DP U-951 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|
| DEXLANSOPRAZOLE - DEXILANT SOLUTAB | | | | | | | | |
| N 208056 | 001 | | 6462058*PED | Dec 15, 2020 | | | | |
| | | | 6664276 | Jan 30, 2023 | DS DP | | U-950 | |
| | | | 6664276 | Jan 30, 2023 | DS DP | | U-951 | |
| | | | 6664276*PED | Jul 30, 2023 | | | | |
| | | | 6939971 | Jun 15, 2020 | | | U-950 | |
| | | | 6939971 | Jun 15, 2020 | | | U-951 | |
| | | | 6939971*PED | Dec 15, 2020 | | | | |
| | | | 7285668 | Jun 15, 2020 | DS | | | |
| | | | 7285668*PED | Dec 15, 2020 | | | | |
| | | | 7399485 | May 26, 2018 | DP | | | |
| | | | 7399485*PED | Nov 26, 2018 | | | | |
| | | | 7431942 | May 17, 2019 | DP | | | |
| | | | 7431942*PED | Nov 17, 2019 | | | | |
| | | | 7875292 | May 17, 2019 | DP | | | |
| | | | 7875292*PED | Nov 17, 2019 | | | | |
| | | | 8461187 | Jan 17, 2026 | DP | | | |
| | | | 8461187*PED | Jul 17, 2026 | | | | |
| | | | 8784885 | Oct 15, 2023 | DP | | | |
| | | | 8784885*PED | Apr 15, 2024 | | | | |
| | | | 8871273 | Jan 11, 2028 | DP | | | |
| | | | 8871273*PED | Jul 11, 2028 | | | | |
| | | | 9011926 | Feb 24, 2026 | DP | | | |
| | | | 9145389 | Jun 15, 2020 | DS DP | | | |
| | | | 9238029 | Jan 17, 2026 | DP | | | |
| | | | 9241910 | Mar 10, 2029 | DP | | | |
| DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX | | | | | | | | |
| N 021038 | 001 | | 6716867 | Mar 31, 2019 | | | U-1472 | |
| | | | 6716867*PED | Oct 01, 2019 | | | | |
| DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX | | | | | | | | |
| N 021038 | 002 | | 6716867 | Mar 31, 2019 | | | U-1472 | |
| | | | 6716867*PED | Oct 01, 2019 | | | | |
| | | | 8242158 | Jan 04, 2032 | DP | | | |
| | | | 8242158*PED | Jul 04, 2032 | | | | |
| | | | 8338470 | Jan 04, 2032 | DP | | | |
| | | | 8338470*PED | Jul 04, 2032 | | | | |
| | | | 8455527 | Jan 04, 2032 | | | U-421 | |
| | | | 8455527*PED | Jul 04, 2032 | | | | |
| | | | 8648106 | Jan 04, 2032 | DP | | | |
| | | | 8648106*PED | Jul 04, 2032 | | | | |
| | | | 9320712 | Jan 04, 2032 | DP | | | |
| | | | 9320712*PED | Jul 04, 2032 | | | | |
| | | | 9616049 | Jan 04, 2032 | DP | | | |
| | | | 9616049*PED | Jul 04, 2032 | | | | |
| DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX | | | | | | | | |
| N 021038 | 003 | | 6716867 | Mar 31, 2019 | | | U-1472 | |
| | | | 6716867*PED | Oct 01, 2019 | | | | |
| | | | 8242158 | Jan 04, 2032 | DP | | | |
| | | | 8242158*PED | Jul 04, 2032 | | | | |
| | | | 8338470 | Jan 04, 2032 | DP | | | |
| | | | 8338470*PED | Jul 04, 2032 | | | | |
| | | | 8455527 | Jan 04, 2032 | | | U-421 | |
| | | | 8455527*PED | Jul 04, 2032 | | | | |
| | | | 8648106 | Jan 04, 2032 | DP | | | |
| | | | 8648106*PED | Jul 04, 2032 | | | | |
| | | | 9320712 | Jan 04, 2032 | DP | | | |
| | | | 9320712*PED | Jul 04, 2032 | | | | |
| | | | 9616049 | Jan 04, 2032 | DP | | | |
| | | | 9616049*PED | Jul 04, 2032 | | | | |
| DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX | | | | | | | | |
| N 021038 | 004 | | 6716867 | Mar 31, 2019 | | | U-1472 | |
| | | | 6716867*PED | Oct 01, 2019 | | | | |
| | | | 8242158 | Jan 04, 2032 | DP | | | |
| | | | 8242158*PED | Jul 04, 2032 | | | | |
| | | | 8338470 | Jan 04, 2032 | DP | | | |
| | | | 8338470*PED | Jul 04, 2032 | | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX | | | | | | | |
| N 021038 | 004 | 8455527 | Jan 04, 2032 | U-421 | | | |
| | | 8455527*PED | Jul 04, 2032 | | | | |
| | | 8648106 | Jan 04, 2032 | DP | | | |
| | | 8648106*PED | Jul 04, 2032 | | | | |
| | | 9320712 | Jan 04, 2032 | DP | | | |
| | | 9320712*PED | Jul 04, 2032 | | | | |
| | | 9616049 | Jan 04, 2032 | DP | | | |
| | | 9616049*PED | Jul 04, 2032 | | | | |
| DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE | | | | | | | |
| A 202842 | 005 | | | | | PC | Jul 04, 2017 |
| DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE | | | | | | | |
| A 202842 | 007 | | | | | PC | Jul 04, 2017 |
| DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR | | | | | | | |
| N 021802 | 001 | 6228398 | Nov 01, 2019 | DP U-676 | | | |
| | | 6730325 | Nov 01, 2019 | DP U-676 | | | |
| DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR | | | | | | | |
| N 021802 | 002 | 6228398 | Nov 01, 2019 | DP U-676 | | | |
| | | 6730325 | Nov 01, 2019 | DP U-676 | | | |
| DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR | | | | | | | |
| N 021802 | 003 | 6228398 | Nov 01, 2019 | DP U-676 | | | |
| | | 6730325 | Nov 01, 2019 | DP U-676 | | | |
| DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR | | | | | | | |
| N 021802 | 004 | 6228398 | Nov 01, 2019 | DP U-676 | | | |
| | | 6730325 | Nov 01, 2019 | DP U-676 | | | |
| DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR | | | | | | | |
| N 021802 | 005 | 6228398 | Nov 01, 2019 | DP U-676 | | | |
| | | 6730325 | Nov 01, 2019 | DP U-676 | | | |
| DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR | | | | | | | |
| N 021802 | 006 | 6228398 | Nov 01, 2019 | DP U-676 | | | |
| | | 6730325 | Nov 01, 2019 | DP U-676 | | | |
| DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR | | | | | | | |
| N 021802 | 007 | 6228398 | Nov 01, 2019 | DP U-676 | | | |
| | | 6730325 | Nov 01, 2019 | DP U-676 | | | |
| DEXMETHYLPHENIDATE HYDROCHLORIDE - FOCALIN XR | | | | | | | |
| N 021802 | 008 | 6228398 | Nov 01, 2019 | DP U-676 | | | |
| | | 6730325 | Nov 01, 2019 | DP U-676 | | | |
| DEXRAZOXANE HYDROCHLORIDE - TOTECT | | | | | | | |
| N 022025 | 001 | 6727253 | Mar 13, 2020 | U-829 | | | |
| DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN - MUCINEX DM | | | | | | | |
| N 021620 | 001 | 6372252 | Apr 28, 2020 | DP | | | |
| | | 6955821 | Apr 28, 2020 | DP U-685 | | | |
| | | 7838032 | Apr 28, 2020 | DP | | | |
| DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN - MUCINEX DM | | | | | | | |
| N 021620 | 002 | 6372252 | Apr 28, 2020 | DP | | | |
| | | 6955821 | Apr 28, 2020 | DP U-685 | | | |
| | | 7838032 | Apr 28, 2020 | DP | | | |
| DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE - NUEDEXTA | | | | | | | |
| N 021879 | 001 | 7659282 | Aug 13, 2026 | U-1093 | | | |
| | | 8227484 | Jul 17, 2023 | U-1093 | | | |
| DICHLORPHENAMIDE - KEVEYIS | | | | | | | |
| N 011366 | 002 | | | | | ODE-96 | Aug 07, 2022 |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| DICLOFENAC - ZORVOLEX | | | | | | | |
| N 204592 | 001 | 8679544 | Apr 23, 2030 | DP | | I-692 | Aug 22, 2017 |
| | | 8999387 | Apr 23, 2030 | U-55 | | | |
| | | 9017721 | Apr 23, 2030 | DP | | | |
| | | 9173854 | Apr 23, 2030 | DP | | | |
| | | 9180095 | Apr 23, 2030 | U-55 | | | |
| | | 9180096 | Apr 23, 2030 | DP | | | |
| | | 9186328 | Apr 23, 2030 | U-55 | | | |
| DICLOFENAC - ZORVOLEX | | | | | | | |
| N 204592 | 002 | 8679544 | Apr 23, 2030 | DP | | I-692 | Aug 22, 2017 |
| | | 8999387 | Apr 23, 2030 | U-55 | | | |
| | | 9017721 | Apr 23, 2030 | DP | | | |
| | | 9173854 | Apr 23, 2030 | DP | | | |
| | | 9180095 | Apr 23, 2030 | U-55 | | | |
| | | 9180096 | Apr 23, 2030 | DP | | | |
| | | 9186328 | Apr 23, 2030 | U-55 | | | |
| DICLOFENAC EPOLAMINE - FLECTOR | | | | | | | |
| N 021234 | 001 | 5607690 | Apr 13, 2019 | DP | | | |
| DICLOFENAC POTASSIUM - CAMBIA | | | | | | | |
| N 022165 | 001 | 7759394 | Jun 16, 2026 | DS DP U-436 | | | |
| | | 8097651 | Jun 16, 2026 | DS DP U-436 | | | |
| | | 8927604 | Jun 16, 2026 | U-436 | | | |
| | | 9827197 | Jun 16, 2026 | DP | | | |
| DICLOFENAC POTASSIUM - ZIPSOR | | | | | | | |
| N 022202 | 001 | 6287594 | Jan 15, 2019 | DP | | | |
| | | 6365180 | Jul 15, 2019 | DP U-980 | | | |
| | | 7662858 | Feb 24, 2029 | U-1035 | | | |
| | | 7884095 | Feb 24, 2029 | U-1111 | | | |
| | | 7939518 | Feb 24, 2029 | U-980 | | | |
| | | 8110606 | Feb 24, 2029 | U-980 | | | |
| | | 8623920 | Feb 24, 2029 | U-1482 | | | |
| | | 9561200 | Feb 24, 2029 | U-1482 | | | |
| DICLOFENAC SODIUM - PENNSAID | | | | | | | |
| N 020947 | 001 | 8217078 | Jul 10, 2029 | U-1248 | | | |
| | | 8546450 | Aug 09, 2030 | U-1435 | | | |
| | | 8546450 | Aug 09, 2030 | U-1436 | | | |
| | | 8618164 | Jul 10, 2029 | U-1477 | | | |
| | | 8741956 | Jul 10, 2029 | U-1435 | | | |
| DICLOFENAC SODIUM - DYLOJECT | | | | | | | |
| N 022396 | 001 | 6407079 | Jun 18, 2019 | DP | | NP | Dec 23, 2017 |
| | | 8946292 | Mar 22, 2027 | U-1659 | | | |
| DICLOFENAC SODIUM - PENNSAID | | | | | | | |
| N 204623 | 001 | 8217078 | Jul 10, 2029 | U-1477 | | | |
| | | 8252838 | Apr 21, 2028 | DP U-1489 | | | |
| | | 8546450 | Aug 09, 2030 | U-1435 | | | |
| | | 8546450 | Aug 09, 2030 | U-1436 | | | |
| | | 8563613 | Oct 17, 2027 | DP U-1488 | | | |
| | | 8618164 | Jul 10, 2029 | U-1477 | | | |
| | | 8741956 | Jul 10, 2029 | U-1435 | | | |
| | | 8871809 | Oct 17, 2027 | U-1614 | | | |
| | | 9066913 | Oct 17, 2027 | DP U-1488 | | | |
| | | 9101591 | Oct 17, 2027 | DP U-1488 | | | |
| | | 9132110 | Oct 17, 2027 | U-1488 | | | |
| | | 9168304 | Oct 17, 2027 | DP | | | |
| | | 9168305 | Oct 17, 2027 | U-1488 | | | |
| | | 9220784 | Oct 17, 2027 | U-1488 | | | |
| | | 9339551 | Oct 17, 2027 | U-1488 | | | |
| | | 9339552 | Oct 17, 2027 | DP U-1488 | | | |
| | | 9370501 | Jul 10, 2029 | U-1614 | | | |
| | | 9375412 | Jul 10, 2029 | U-1614 | | | |
| | | 9415029 | Jul 10, 2029 | U-1614 | | | |
| | | 9539335 | Oct 17, 2027 | U-1614 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| DIENOGEST; DIENOGEST; DIENOGEST; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE - NATAZIA | | | | | | | |
| N 022252 | 001 | 8071577 | May 13, 2026 | DP U-1 | | | |
| | | 8153616 | Jan 30, 2028 | U-1240 | | | |
| DIFLUPREDNATE - DUREZOL | | | | | | | |
| N 022212 | 001 | 6114319 | May 18, 2019 | DP | | ODE-26 | Jun 13, 2019 |
| | | 6114319*PED | Nov 18, 2019 | | | PED | Dec 13, 2019 |
| DILTIAZEM HYDROCHLORIDE - CARDIZEM LA | | | | | | | |
| N 021392 | 001 | 6923984 | Feb 25, 2021 | DP | | | |
| | | 7108866 | Dec 17, 2019 | DP U-107 | | | |
| DILTIAZEM HYDROCHLORIDE - CARDIZEM LA | | | | | | | |
| N 021392 | 002 | 6923984 | Feb 25, 2021 | DP | | | |
| | | 7108866 | Dec 17, 2019 | DP U-107 | | | |
| DILTIAZEM HYDROCHLORIDE - CARDIZEM LA | | | | | | | |
| N 021392 | 003 | 6923984 | Feb 25, 2021 | DP | | | |
| | | 7108866 | Dec 17, 2019 | DP U-107 | | | |
| DILTIAZEM HYDROCHLORIDE - CARDIZEM LA | | | | | | | |
| N 021392 | 004 | 6923984 | Feb 25, 2021 | DP | | | |
| | | 7108866 | Dec 17, 2019 | DP U-107 | | | |
| DILTIAZEM HYDROCHLORIDE - CARDIZEM LA | | | | | | | |
| N 021392 | 005 | 6923984 | Feb 25, 2021 | DP | | | |
| | | 7108866 | Dec 17, 2019 | DP U-107 | | | |
| DILTIAZEM HYDROCHLORIDE - CARDIZEM LA | | | | | | | |
| N 021392 | 006 | 6923984 | Feb 25, 2021 | DP | | | |
| | | 7108866 | Dec 17, 2019 | DP U-107 | | | |
| DIMETHYL FUMARATE - TECFIDERA | | | | | | | |
| N 204063 | 001 | 6509376 | Oct 29, 2019 | DP | | NCE | Mar 27, 2018 |
| | | 7320999 | May 18, 2020 | U-1384 | | | |
| | | 7619001 | Apr 01, 2018 | U-1384 | | | |
| | | 7803840 | Apr 01, 2018 | U-1385 | | | |
| | | 8399514 | Feb 07, 2028 | U-1384 | | | |
| | | 8524773 | Apr 01, 2018 | U-1384 | | | |
| | | 8759393 | Oct 29, 2019 | DP | | | |
| DIMETHYL FUMARATE - TECFIDERA | | | | | | | |
| N 204063 | 002 | 6509376 | Oct 29, 2019 | DP | | NCE | Mar 27, 2018 |
| | | 7320999 | May 18, 2020 | U-1384 | | | |
| | | 7619001 | Apr 01, 2018 | U-1384 | | | |
| | | 7803840 | Apr 01, 2018 | U-1385 | | | |
| | | 8399514 | Feb 07, 2028 | U-1384 | | | |
| | | 8524773 | Apr 01, 2018 | U-1384 | | | |
| | | 8759393 | Oct 29, 2019 | DP | | | |
| DIPHENHYDRAMINE CITRATE; IBUPROFEN - ADVIL PM | | | | | | | |
| N 021394 | 001 | 8263647 | May 30, 2022 | DP | | | |
| DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN - ADVIL PM | | | | | | | |
| N 021393 | 001 | 8883849 | Jan 17, 2022 | U-1618 | | | |
| | | 9155718 | Jan 17, 2022 | DP | | | |
| DIVALPROEX SODIUM - DEPAKOTE ER | | | | | | | |
| N 021168 | 001 | 6419953 | Dec 18, 2018 | | | | |
| | | 6511678 | Dec 18, 2018 | | | | |
| | | 6528090 | Dec 18, 2018 | DP | | | |
| | | 6528091 | Dec 18, 2018 | U-106 | | | |
| | | 6713086 | Dec 18, 2018 | DP U-579 | | | |
| | | 6720004 | Dec 18, 2018 | DP | | | |
| DIVALPROEX SODIUM - DEPAKOTE ER | | | | | | | |
| N 021168 | 002 | 6511678 | Dec 18, 2018 | | | | |
| | | 6528090 | Dec 18, 2018 | DP | | | |
| | | 6713086 | Dec 18, 2018 | DP U-579 | | | |
| | | 6720004 | Dec 18, 2018 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| DIVALPROEX SODIUM - DEPAKOTE ER | | | | | | | |
| N 021168 | 002 | 6511678 | Dec 18, 2018 | | | | |
| | | 6528090 | Dec 18, 2018 | DP | | | |
| | | 6713086 | Dec 18, 2018 | DP U-579 | | | |
| | | 6720004 | Dec 18, 2018 | DP | | | |
| DOCETAXEL - DOCETAXEL | | | | | | | |
| N 205934 | 001 | 8940786 | Sep 30, 2033 | DP U-1789 | | | |
| | | 9308195 | Sep 30, 2033 | DP | | | |
| DOCETAXEL - DOCETAXEL | | | | | | | |
| N 205934 | 002 | 8940786 | Sep 30, 2033 | DP U-1789 | | | |
| | | 9308195 | Sep 30, 2033 | DP | | | |
| DOCETAXEL - DOCETAXEL | | | | | | | |
| N 205934 | 003 | 8940786 | Sep 30, 2033 | DP U-1789 | | | |
| | | 9308195 | Sep 30, 2033 | DP | | | |
| DOFETILIDE - TIKOSYN | | | | | | | |
| N 020931 | 001 | 6124363 | Oct 09, 2018 | | | | |
| DOFETILIDE - TIKOSYN | | | | | | | |
| N 020931 | 002 | 6124363 | Oct 09, 2018 | | | | |
| DOFETILIDE - TIKOSYN | | | | | | | |
| N 020931 | 003 | 6124363 | Oct 09, 2018 | | | | |
| DOLUTEGRAVIR SODIUM - TIVICAY | | | | | | | |
| N 204790 | 001 | 8129385 | Oct 05, 2027 | DS DP | | I-758 | Nov 21, 2020 |
| | | 9242986 | Dec 08, 2029 | DS DP | | M-166 | Jul 30, 2018 |
| | | | | | | NCE | Aug 12, 2018 |
| DOLUTEGRAVIR SODIUM - TIVICAY | | | | | | | |
| N 204790 | 002 | 8129385 | Oct 05, 2027 | DS DP | | I-758 | Nov 21, 2020 |
| | | 9242986 | Dec 08, 2029 | DS DP | | NCE | Aug 12, 2018 |
| DOLUTEGRAVIR SODIUM - TIVICAY | | | | | | | |
| N 204790 | 003 | 8129385 | Oct 05, 2027 | DS DP | | I-758 | Nov 21, 2020 |
| | | 9242986 | Dec 08, 2029 | DS DP | | NCE | Aug 12, 2018 |
| DOLUTEGRAVIR SODIUM; RILPIVIRINE HYDROCHLORIDE - JULUCA | | | | | | | |
| N 210192 | 001 | 6838464 | Feb 26, 2021 | DS DP | | NC | Nov 21, 2020 |
| | | 7067522 | Dec 20, 2019 | DS DP | | NCE | Aug 12, 2018 |
| | | 7125879 | Apr 21, 2025 | DS DP U-257 | | | |
| | | 8080551 | Apr 11, 2023 | DS DP | | | |
| | | 8101629 | Aug 09, 2022 | DP | | | |
| | | 8129385 | Oct 05, 2027 | DS DP | | | |
| | | 9242986 | Dec 08, 2029 | DS DP | | | |
| DONEPEZIL HYDROCHLORIDE - ARICEPT | | | | | | | |
| N 022568 | 001 | 8481565 | Oct 04, 2026 | DP | | | |
| DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC | | | | | | | |
| N 206439 | 001 | 8039009 | Mar 24, 2029 | U-1641 | | | |
| | | 8039009*PED | Sep 24, 2029 | | | | |
| | | 8058291 | Dec 05, 2029 | U-1641 | | | |
| | | 8168209 | Nov 22, 2025 | DP | | | |
| | | 8168209*PED | May 22, 2026 | | | | |
| | | 8173708 | Nov 22, 2025 | U-1641 | | | |
| | | 8173708*PED | May 22, 2026 | | | | |
| | | 8283379 | Nov 22, 2025 | U-1641 | | | |
| | | 8283379*PED | May 22, 2026 | | | | |
| | | 8293794 | Nov 22, 2025 | DP | | | |
| | | 8329752 | Nov 22, 2025 | DP | | | |
| | | 8329752*PED | May 22, 2026 | | | | |
| | | 8338485 | Nov 22, 2025 | DP | | | |
| | | 8338486 | Nov 22, 2025 | U-1641 | | | |
| | | 8362085 | Nov 22, 2025 | U-1641 | | | |
| | | 8362085*PED | May 22, 2026 | | | | |
| | | 8580858 | Nov 22, 2025 | U-1641 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC | | | | | | | |
| N 206439 | 001 | 8598233 | Nov 22, 2025 | DP | | | |
| | | 8598233*PED | May 22, 2026 | | | | |
| DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC | | | | | | | |
| N 206439 | 002 | 8039009 | Mar 24, 2029 | U-1641 | | | |
| | | 8039009*PED | Sep 24, 2029 | | | | |
| | | 8058291 | Dec 05, 2029 | U-1641 | | | |
| | | 8168209 | Nov 22, 2025 | DP | | | |
| | | 8168209*PED | May 22, 2026 | | | | |
| | | 8173708 | Nov 22, 2025 | U-1641 | | | |
| | | 8173708*PED | May 22, 2026 | | | | |
| | | 8283379 | Nov 22, 2025 | U-1641 | | | |
| | | 8283379*PED | May 22, 2026 | | | | |
| | | 8293794 | Nov 22, 2025 | DP | | | |
| | | 8329752 | Nov 22, 2025 | DP | | | |
| | | 8329752*PED | May 22, 2026 | | | | |
| | | 8338485 | Nov 22, 2025 | DP | | | |
| | | 8338486 | Nov 22, 2025 | U-1641 | | | |
| | | 8362085 | Nov 22, 2025 | U-1641 | | | |
| | | 8362085*PED | May 22, 2026 | | | | |
| | | 8580858 | Nov 22, 2025 | U-1641 | | | |
| | | 8598233 | Nov 22, 2025 | DP | | | |
| | | 8598233*PED | May 22, 2026 | | | | |
| DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC | | | | | | | |
| N 206439 | 003 | 8039009 | Mar 24, 2029 | U-1641 | | | |
| | | 8039009*PED | Sep 24, 2029 | | | | |
| | | 8058291 | Dec 05, 2029 | U-1641 | | | |
| | | 8168209 | Nov 22, 2025 | DP | | | |
| | | 8168209*PED | May 22, 2026 | | | | |
| | | 8173708 | Nov 22, 2025 | U-1641 | | | |
| | | 8173708*PED | May 22, 2026 | | | | |
| | | 8283379 | Nov 22, 2025 | U-1641 | | | |
| | | 8283379*PED | May 22, 2026 | | | | |
| | | 8293794 | Nov 22, 2025 | DP | | | |
| | | 8329752 | Nov 22, 2025 | DP | | | |
| | | 8329752*PED | May 22, 2026 | | | | |
| | | 8338485 | Nov 22, 2025 | DP | | | |
| | | 8338486 | Nov 22, 2025 | U-1641 | | | |
| | | 8362085 | Nov 22, 2025 | U-1641 | | | |
| | | 8362085*PED | May 22, 2026 | | | | |
| | | 8580858 | Nov 22, 2025 | U-1641 | | | |
| | | 8598233 | Nov 22, 2025 | DP | | | |
| | | 8598233*PED | May 22, 2026 | | | | |
| DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC | | | | | | | |
| N 206439 | 004 | 8039009 | Mar 24, 2029 | U-1641 | | | |
| | | 8039009*PED | Sep 24, 2029 | | | | |
| | | 8058291 | Dec 05, 2029 | U-1641 | | | |
| | | 8168209 | Nov 22, 2025 | DP | | | |
| | | 8168209*PED | May 22, 2026 | | | | |
| | | 8173708 | Nov 22, 2025 | U-1641 | | | |
| | | 8173708*PED | May 22, 2026 | | | | |
| | | 8283379 | Nov 22, 2025 | U-1641 | | | |
| | | 8283379*PED | May 22, 2026 | | | | |
| | | 8293794 | Nov 22, 2025 | DP | | | |
| | | 8329752 | Nov 22, 2025 | DP | | | |
| | | 8329752*PED | May 22, 2026 | | | | |
| | | 8338485 | Nov 22, 2025 | DP | | | |
| | | 8338486 | Nov 22, 2025 | U-1641 | | | |
| | | 8362085 | Nov 22, 2025 | U-1641 | | | |
| | | 8362085*PED | May 22, 2026 | | | | |
| | | 8580858 | Nov 22, 2025 | U-1641 | | | |
| | | 8598233 | Nov 22, 2025 | DP | | | |
| | | 8598233*PED | May 22, 2026 | | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|
| DORIPENEM - DORIBAX | | | | | | | | |
| N | 022106 | 001 | 8247402 | Mar 30, 2021 | DS DP | | | |
| DORIPENEM - DORIBAX | | | | | | | | |
| N | 022106 | 002 | 8247402 | Mar 30, 2021 | DS DP | | | |
| DOXEPIN HYDROCHLORIDE - SILENOR | | | | | | | | |
| N | 022036 | 001 | 6211229 | Feb 17, 2020 | | | U-620 | |
| | | | 7915307 | Aug 24, 2027 | | | U-620 | |
| | | | 8513299 | Sep 07, 2030 | | | U-620 | |
| | | | 9107898 | May 01, 2028 | | | U-620 | |
| | | | 9486437 | May 18, 2027 | | | U-620 | |
| | | | 9532971 | Jun 01, 2029 | DP | | | |
| | | | 9572814 | Jul 20, 2027 | | | U-620 | |
| DOXEPIN HYDROCHLORIDE - SILENOR | | | | | | | | |
| N | 022036 | 002 | 6211229 | Feb 17, 2020 | | | U-620 | |
| | | | 7915307 | Aug 24, 2027 | | | U-620 | |
| | | | 8513299 | Sep 07, 2030 | | | U-620 | |
| | | | 9107898 | May 01, 2028 | | | U-620 | |
| | | | 9486437 | May 18, 2027 | | | U-620 | |
| | | | 9532971 | Jun 01, 2029 | DP | | | |
| | | | 9572814 | Jul 20, 2027 | | | U-620 | |
| DOXYCYCLINE - ORACEA | | | | | | | | |
| N | 050805 | 001 | 7211267 | Apr 05, 2022 | | | U-925 | |
| | | | 7232572 | Apr 05, 2022 | | | U-925 | |
| | | | 7749532 | Dec 19, 2027 | DP | | U-1063 | |
| | | | 8206740 | Dec 24, 2025 | DP | | U-925 | |
| | | | 8394405 | Apr 07, 2024 | DP | | U-925 | |
| | | | 8394406 | Apr 07, 2024 | DP | | U-925 | |
| | | | 8470364 | Apr 07, 2024 | DP | | U-925 | |
| | | | 8603506 | Apr 05, 2022 | | | U-1063 | |
| | | | 8709478 | Apr 07, 2024 | | | U-1063 | |
| | | | 9241946 | Apr 05, 2022 | | | U-1063 | |
| DOXYCYCLINE HYCLATE - DORYX | | | | | | | | |
| N | 050795 | 001 | 6958161 | Dec 15, 2022 | DP | | U-918 | |
| | | | 8715724 | Feb 03, 2028 | DP | | | |
| DOXYCYCLINE HYCLATE - DORYX | | | | | | | | |
| N | 050795 | 002 | 6958161 | Dec 15, 2022 | DP | | U-918 | |
| | | | 8715724 | Feb 03, 2028 | DP | | | |
| DOXYCYCLINE HYCLATE - DORYX | | | | | | | | |
| N | 050795 | 003 | 6958161 | Dec 15, 2022 | DP | | U-918 | |
| | | | 8715724 | Feb 03, 2028 | DP | | | |
| DOXYCYCLINE HYCLATE - DORYX | | | | | | | | |
| N | 050795 | 004 | 6958161 | Dec 15, 2022 | DP | | U-918 | |
| | | | 8715724 | Feb 03, 2028 | DP | | | |
| DOXYCYCLINE HYCLATE - DORYX | | | | | | | | |
| N | 050795 | 005 | 6958161 | Dec 15, 2022 | DP | | U-918 | |
| | | | 8715724 | Feb 03, 2028 | DP | | | |
| DOXYCYCLINE HYCLATE - DORYX | | | | | | | | |
| N | 050795 | 006 | 6958161 | Dec 15, 2022 | DP | | U-918 | |
| | | | 8715724 | Feb 03, 2028 | DP | | | |
| DOXYCYCLINE HYCLATE - DORYX MPC | | | | | | | | |
| N | 050795 | 007 | 6958161 | Dec 15, 2022 | DP | | U-918 | |
| | | | 8715724 | Feb 03, 2028 | DP | | | |
| | | | 9295652 | Oct 23, 2034 | DP | | U-918 | |
| | | | 9446057 | Dec 23, 2034 | DP | | U-918 | |
| | | | 9511031 | Oct 23, 2034 | DP | | | |
| DOXYCYCLINE HYCLATE - DORYX MPC | | | | | | | | |
| N | 050795 | 008 | 6958161 | Dec 15, 2022 | DP | | U-918 | |
| | | | 8715724 | Feb 03, 2028 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| DOXYCYCLINE HYCLATE - DORYX MPC | | | | | | | |
| N 050795 | 008 | 9295652 | Oct 23, 2034 | DP U-918 | | | |
| | | 9446057 | Dec 23, 2034 | DP U-918 | | | |
| | | 9511031 | Oct 23, 2034 | DP | | | |
| DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - DICLEGIS | | | | | | | |
| N 021876 | 001 | 6340695 | Jun 21, 2021 | DP U-1382 | | | |
| | | 7560122 | Jan 25, 2019 | DP | | | |
| DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE - BONJESTA | | | | | | | |
| N 209661 | 001 | 7560122 | Jan 25, 2019 | DP | | | |
| | | 9089489 | Feb 18, 2033 | DP U-1382 | | | |
| | | 9375404 | Feb 18, 2033 | DP U-1382 | | | |
| | | 9526703 | Feb 18, 2033 | DP U-1382 | | | |
| DRONABINOL - SYNDROS | | | | | | | |
| N 205525 | 001 | 8222292 | Aug 06, 2028 | DS DP | | | |
| | | 9345771 | Aug 06, 2028 | DS DP | | | |
| DRONEDARONE HYDROCHLORIDE - MULTAQ | | | | | | | |
| N 022425 | 001 | 7323493 | Jun 19, 2018 | DP | | | |
| | | 8318800 | Jun 19, 2018 | DP | | | |
| | | 8410167 | Apr 16, 2029 | U-1387 | | | |
| | | 8410167 | Apr 16, 2029 | U-1388 | | | |
| | | 8602215 | Jun 30, 2031 | U-1473 | | | |
| | | 9107900 | Apr 16, 2029 | U-1726 | | | |
| | | 9107900 | Apr 16, 2029 | U-1728 | | | |
| DROSPIRENONE; ESTRADIOL - ANGELIQ | | | | | | | |
| N 021355 | 001 | 8906890 | Oct 22, 2031 | DP | | | |
| DROSPIRENONE; ESTRADIOL - ANGELIQ | | | | | | | |
| N 021355 | 002 | 6933395 | Aug 11, 2017 | DS | | | |
| DROSPIRENONE; ETHINYL ESTRADIOL - YASMIN | | | | | | | |
| N 021098 | 001 | 6787531 | Aug 31, 2020 | DP | | | |
| | | 6933395 | Aug 11, 2017 | DS | | | |
| DROSPIRENONE; ETHINYL ESTRADIOL - YAZ | | | | | | | |
| N 021676 | 001 | 6787531 | Aug 31, 2020 | DP | | | |
| | | 6933395 | Aug 11, 2017 | DP | | | |
| | | 6958326 | Dec 20, 2021 | DP | | | |
| | | 6987101 | Dec 22, 2017 | U-758 | | | |
| | | 7163931 | Dec 20, 2021 | U-1 | | | |
| DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ | | | | | | | |
| N 022532 | 001 | 6441168 | Jul 30, 2022 | DS | | | |
| | | 6958326 | Dec 20, 2021 | DP | | | |
| | | 7163931 | Mar 03, 2022 | U-1 | | | |
| | | 8617597 | Feb 08, 2030 | DP | | | |
| DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL | | | | | | | |
| N 022574 | 001 | 6441168 | Apr 17, 2020 | DS | | | |
| | | 6958326 | Dec 20, 2021 | DP | | | |
| | | 7163931 | Mar 03, 2022 | U-1 | | | |
| | | 8617597 | Feb 08, 2030 | DP | | | |
| DROXIDOPA - NORTHERA | | | | | | | |
| N 203202 | 001 | | | | | NCE | Feb 18, 2019 |
| | | | | | | ODE-61 | Feb 18, 2021 |
| DROXIDOPA - NORTHERA | | | | | | | |
| N 203202 | 002 | | | | | NCE | Feb 18, 2019 |
| | | | | | | ODE-61 | Feb 18, 2021 |
| DROXIDOPA - NORTHERA | | | | | | | |
| N 203202 | 003 | | | | | NCE | Feb 18, 2019 |
| | | | | | | ODE-61 | Feb 18, 2021 |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| DULOXETINE HYDROCHLORIDE - CYMBALTA | | | | | | | |
| N 021427 | 001 | 6596756 | Sep 10, 2019 | U-882 | | NPP | Oct 16, 2017 |
| | | | | | | NPP | Oct 16, 2017 |
| DULOXETINE HYDROCHLORIDE - CYMBALTA | | | | | | | |
| N 021427 | 002 | 6596756 | Sep 10, 2019 | U-882 | | NPP | Oct 16, 2017 |
| | | | | | | NPP | Oct 16, 2017 |
| DULOXETINE HYDROCHLORIDE - CYMBALTA | | | | | | | |
| N 021427 | 004 | 6596756 | Sep 10, 2019 | U-882 | | NPP | Oct 16, 2017 |
| | | | | | | NPP | Oct 16, 2017 |
| ECONAZOLE NITRATE - ECOZA | | | | | | | |
| N 205175 | 001 | 5993830 | Jan 16, 2018 | DP U-1449 | | | |
| EDARAVONE - RADICAVA | | | | | | | |
| N 209176 | 001 | 6933310 | Nov 13, 2020 | U-2013 | | NCE | May 05, 2022 |
| | | | | | | ODE-144 | May 05, 2024 |
| EDOXABAN TOSYLATE - SAVAYSA | | | | | | | |
| N 206316 | 001 | 7365205 | Jun 12, 2023 | DS | | NCE | Jan 08, 2020 |
| | | 9149532 | Mar 28, 2028 | DP | | | |
| EDOXABAN TOSYLATE - SAVAYSA | | | | | | | |
| N 206316 | 002 | 7365205 | Jun 12, 2023 | DS | | NCE | Jan 08, 2020 |
| | | 9149532 | Mar 28, 2028 | DP | | | |
| EDOXABAN TOSYLATE - SAVAYSA | | | | | | | |
| N 206316 | 003 | 7365205 | Jun 12, 2023 | DS | | NCE | Jan 08, 2020 |
| | | 9149532 | Mar 28, 2028 | DP | | | |
| EFAVIRENZ - SUSTIVA | | | | | | | |
| N 020972 | 001 | 6238695 | Apr 06, 2019 | DP | | | |
| | | 6238695*PED | Oct 06, 2019 | | | | |
| | | 6555133 | Apr 06, 2019 | U-248 | | | |
| | | 6555133*PED | Oct 06, 2019 | | | | |
| | | 6639071 | Feb 14, 2018 | DS | | | |
| | | 6639071*PED | Aug 14, 2018 | | | | |
| | | 6939964 | Jan 20, 2018 | DS | | | |
| | | 6939964*PED | Jul 20, 2018 | | | | |
| EFAVIRENZ - SUSTIVA | | | | | | | |
| N 020972 | 002 | 6238695 | Apr 06, 2019 | DP | | | |
| | | 6238695*PED | Oct 06, 2019 | | | | |
| | | 6555133 | Apr 06, 2019 | U-248 | | | |
| | | 6555133*PED | Oct 06, 2019 | | | | |
| | | 6639071 | Feb 14, 2018 | DS | | | |
| | | 6639071*PED | Aug 14, 2018 | | | | |
| | | 6939964 | Jan 20, 2018 | DS | | | |
| | | 6939964*PED | Jul 20, 2018 | | | | |
| EFAVIRENZ - SUSTIVA | | | | | | | |
| N 020972 | 003 | 6238695 | Apr 06, 2019 | DP | | | |
| | | 6238695*PED | Oct 06, 2019 | | | | |
| | | 6555133 | Apr 06, 2019 | U-248 | | | |
| | | 6555133*PED | Oct 06, 2019 | | | | |
| | | 6639071 | Feb 14, 2018 | DS | | | |
| | | 6639071*PED | Aug 14, 2018 | | | | |
| | | 6939964 | Jan 20, 2018 | DS | | | |
| | | 6939964*PED | Jul 20, 2018 | | | | |
| EFAVIRENZ - SUSTIVA | | | | | | | |
| N 021360 | 001 | 6639071 | Feb 14, 2018 | DS | | | |
| | | 6639071*PED | Aug 14, 2018 | | | | |
| | | 6939964 | Jan 20, 2018 | DS | | | |
| | | 6939964*PED | Jul 20, 2018 | | | | |
| EFAVIRENZ - SUSTIVA | | | | | | | |
| N 021360 | 002 | 6639071 | Feb 14, 2018 | DS | | | |
| | | 6639071*PED | Aug 14, 2018 | | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| EFAVIRENZ - SUSTIVA | | | | | | | |
| N 021360 | 002 | 6939964 | Jan 20, 2018 | DS | | | |
| | | 6939964*PED | Jul 20, 2018 | | | | |
| EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA | | | | | | | |
| N 021937 | 001 | 5914331 | Jul 02, 2017 | DS | | | |
| | | 5922695 | Jul 25, 2017 | DS U-1170 | | | |
| | | 5922695 | Jul 25, 2017 | DS U-750 | | | |
| | | 5935946 | Jul 25, 2017 | DS DP U-1170 | | | |
| | | 5935946 | Jul 25, 2017 | DS DP U-750 | | | |
| | | 5977089 | Jul 25, 2017 | DS DP U-1170 | | | |
| | | 5977089 | Jul 25, 2017 | DS DP U-750 | | | |
| | | 6043230 | Jul 25, 2017 | U-1170 | | | |
| | | 6043230 | Jul 25, 2017 | U-750 | | | |
| | | 6639071 | Feb 14, 2018 | DS | | | |
| | | 6639071*PED | Aug 14, 2018 | | | | |
| | | 6642245 | Nov 04, 2020 | U-1170 | | | |
| | | 6642245 | Nov 04, 2020 | U-750 | | | |
| | | 6703396 | Mar 09, 2021 | DS DP | | | |
| | | 6939964 | Jan 20, 2018 | DS | | | |
| | | 6939964*PED | Jul 20, 2018 | | | | |
| | | 8592397 | Jan 13, 2024 | DP U-1170 | | | |
| | | 8592397 | Jan 13, 2024 | DP U-750 | | | |
| | | 8598185 | Apr 28, 2029 | DP | | | |
| | | 8716264 | Jan 13, 2024 | DP U-257 | | | |
| | | 9018192 | Jun 13, 2026 | U-1170 | | | |
| | | 9018192 | Jun 13, 2026 | U-750 | | | |
| | | 9457036 | Jan 13, 2024 | DP U-257 | | | |
| | | 9545414 | Jun 13, 2026 | DP U-1170 | | | |
| | | 9545414 | Jun 13, 2026 | DP U-750 | | | |
| | | 9744181 | Jan 13, 2024 | DP U-257 | | | |
| EFINACONAZOLE - JUBLIA | | | | | | | |
| N 203567 | 001 | 7214506 | Oct 05, 2021 | U-281 | | NCE | Jun 06, 2019 |
| | | 8039494 | Jul 08, 2030 | U-281 | | | |
| | | 8486978 | Oct 24, 2030 | DP | | | |
| | | 9302009 | Oct 24, 2030 | DP | | | |
| | | 9566272 | Jan 03, 2028 | U-1969 | | | |
| | | 9662394 | Oct 02, 2034 | DP | | | |
| | | 9861698 | Jul 08, 2030 | DP | | | |
| ELBASVIR; GRAZOPREVIR - ZEPATIER | | | | | | | |
| N 208261 | 001 | 7973040 | Jul 24, 2029 | DS DP U-1813 | | NCE | Jan 28, 2021 |
| | | 8871759 | May 04, 2031 | DS DP U-1813 | | | |
| ELETRIPTAN HYDROBROMIDE - RELPAX | | | | | | | |
| N 021016 | 001 | 6110940 | Aug 29, 2017 | | | | |
| ELETRIPTAN HYDROBROMIDE - RELPAX | | | | | | | |
| N 021016 | 002 | 6110940 | Aug 29, 2017 | | | | |
| ELIGLUSTAT TARTRATE - CERDELGA | | | | | | | |
| N 205494 | 001 | 6916802 | Apr 29, 2022 | U-1571 | | NCE | Aug 19, 2019 |
| | | 7196205 | Apr 29, 2022 | DS | | ODE-73 | Aug 19, 2021 |
| | | 7615573 | Apr 29, 2022 | U-1571 | | | |
| ELTROMBOPAG OLAMINE - PROMACTA | | | | | | | |
| N 022291 | 001 | 6280959 | Oct 30, 2018 | DS DP U-1306 | | D-149 | Jun 11, 2018 |
| | | 6280959 | Oct 30, 2018 | DS DP U-1575 | | I-711 | Jun 11, 2018 |
| | | 6280959 | Oct 30, 2018 | DS DP U-1714 | | ODE-75 | Aug 26, 2021 |
| | | 6280959 | Oct 30, 2018 | DS DP U-930 | | PED | Dec 11, 2018 |
| | | 6280959*PED | Apr 30, 2019 | | | PED | Dec 11, 2018 |
| | | 7160870 | Nov 20, 2022 | DS DP U-1306 | | PED | Feb 26, 2022 |
| | | 7160870 | Nov 20, 2022 | DS DP U-1575 | | | |
| | | 7160870 | Nov 20, 2022 | DS DP U-1714 | | | |
| | | 7160870 | Nov 20, 2022 | DS DP U-930 | | | |
| | | 7160870*PED | May 20, 2023 | | | | |
| | | 7332481 | May 24, 2021 | U-1306 | | | |
| | | 7332481 | May 24, 2021 | U-1575 | | | |
| | | 7332481 | May 24, 2021 | U-1714 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| ELTROMBOPAG OLAMINE - PROMACTA | | | | | | |
| N 022291 001 | 7332481 | May 24, 2021 | U-930 | | | |
| | 7332481*PED | Nov 24, 2021 | | | | |
| | 7452874 | May 24, 2021 | DS DP U-1714 | | | |
| | 7452874*PED | Nov 24, 2021 | | | | |
| | 7473686 | May 24, 2021 | DS DP U-1306 | | | |
| | 7473686 | May 24, 2021 | DS DP U-1575 | | | |
| | 7473686 | May 24, 2021 | DS DP U-1714 | | | |
| | 7473686 | May 24, 2021 | DS DP U-930 | | | |
| | 7473686*PED | Nov 24, 2021 | | | | |
| | 7547719 | Jul 13, 2025 | DS DP U-1306 | | | |
| | 7547719 | Jul 13, 2025 | DS DP U-1575 | | | |
| | 7547719 | Jul 13, 2025 | DS DP U-1714 | | | |
| | 7547719 | Jul 13, 2025 | DS DP U-930 | | | |
| | 7547719*PED | Jan 13, 2026 | | | | |
| | 7790704 | May 24, 2021 | U-1306 | | | |
| | 7790704 | May 24, 2021 | U-1575 | | | |
| | 7790704 | May 24, 2021 | U-1714 | | | |
| | 7790704 | May 24, 2021 | U-930 | | | |
| | 7790704*PED | Nov 24, 2021 | | | | |
| | 7795293 | May 21, 2023 | U-1306 | | | |
| | 7795293 | May 21, 2023 | U-1575 | | | |
| | 7795293 | May 21, 2023 | U-1714 | | | |
| | 7795293 | May 21, 2023 | U-930 | | | |
| | 7795293*PED | Nov 21, 2023 | | | | |
| | 8052993 | Aug 01, 2027 | DP U-1306 | | | |
| | 8052993 | Aug 01, 2027 | DP U-1575 | | | |
| | 8052993 | Aug 01, 2027 | DP U-1714 | | | |
| | 8052993 | Aug 01, 2027 | DP U-930 | | | |
| | 8052993*PED | Feb 01, 2028 | | | | |
| | 8052994 | Aug 01, 2027 | DP U-1714 | | | |
| | 8052994*PED | Feb 01, 2028 | | | | |
| | 8062665 | Aug 01, 2027 | DP U-1714 | | | |
| | 8062665*PED | Feb 01, 2028 | | | | |
| | 8071129 | Aug 01, 2027 | DP U-1714 | | | |
| | 8071129*PED | Feb 01, 2028 | | | | |
| | 8828430 | Aug 01, 2027 | DP U-1306 | | | |
| | 8828430 | Aug 01, 2027 | DP U-1619 | | | |
| | 8828430 | Aug 01, 2027 | DP U-1714 | | | |
| | 8828430*PED | Feb 01, 2028 | | | | |
| ELTROMBOPAG OLAMINE - PROMACTA | | | | | | |
| N 022291 002 | 6280959 | Oct 30, 2018 | DS DP U-1306 | | D-149 | Jun 11, 2018 |
| | 6280959 | Oct 30, 2018 | DS DP U-1575 | | I-711 | Jun 11, 2018 |
| | 6280959 | Oct 30, 2018 | DS DP U-1714 | | ODE-75 | Aug 26, 2021 |
| | 6280959 | Oct 30, 2018 | DS DP U-930 | | PED | Dec 11, 2018 |
| | 6280959*PED | Apr 30, 2019 | | | PED | Dec 11, 2018 |
| | 7160870 | Nov 20, 2022 | DS DP U-1306 | | PED | Feb 26, 2022 |
| | 7160870 | Nov 20, 2022 | DS DP U-1575 | | | |
| | 7160870 | Nov 20, 2022 | DS DP U-1714 | | | |
| | 7160870 | Nov 20, 2022 | DS DP U-930 | | | |
| | 7160870*PED | May 20, 2023 | | | | |
| | 7332481 | May 24, 2021 | U-1306 | | | |
| | 7332481 | May 24, 2021 | U-1575 | | | |
| | 7332481 | May 24, 2021 | U-1714 | | | |
| | 7332481 | May 24, 2021 | U-930 | | | |
| | 7332481*PED | Nov 24, 2021 | | | | |
| | 7452874 | May 24, 2021 | DS DP U-1714 | | | |
| | 7452874*PED | Nov 24, 2021 | | | | |
| | 7473686 | May 24, 2021 | DS DP U-1306 | | | |
| | 7473686 | May 24, 2021 | DS DP U-1575 | | | |
| | 7473686 | May 24, 2021 | DS DP U-1714 | | | |
| | 7473686 | May 24, 2021 | DS DP U-930 | | | |
| | 7473686*PED | Nov 24, 2021 | | | | |
| | 7547719 | Jul 13, 2025 | DS DP U-1306 | | | |
| | 7547719 | Jul 13, 2025 | DS DP U-1575 | | | |
| | 7547719 | Jul 13, 2025 | DS DP U-1714 | | | |
| | 7547719 | Jul 13, 2025 | DS DP U-930 | | | |
| | 7547719*PED | Jan 13, 2026 | | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| ELTROMBOPAG OLAMINE - PROMACTA | | | | | | |
| N 022291 002 | 7790704 | May 24, 2021 | U-1306 | | | |
| | 7790704 | May 24, 2021 | U-1575 | | | |
| | 7790704 | May 24, 2021 | U-1714 | | | |
| | 7790704 | May 24, 2021 | U-930 | | | |
| | 7790704*PED | Nov 24, 2021 | | | | |
| | 7795293 | May 21, 2023 | U-1306 | | | |
| | 7795293 | May 21, 2023 | U-1575 | | | |
| | 7795293 | May 21, 2023 | U-1714 | | | |
| | 7795293 | May 21, 2023 | U-930 | | | |
| | 7795293*PED | Nov 21, 2023 | | | | |
| | 8052993 | Aug 01, 2027 | DP U-1714 | | | |
| | 8052993*PED | Feb 01, 2028 | | | | |
| | 8052994 | Aug 01, 2027 | DP U-1306 | | | |
| | 8052994 | Aug 01, 2027 | DP U-1575 | | | |
| | 8052994 | Aug 01, 2027 | DP U-1714 | | | |
| | 8052994 | Aug 01, 2027 | DP U-930 | | | |
| | 8052994*PED | Feb 01, 2028 | | | | |
| | 8062665 | Aug 01, 2027 | DP U-1714 | | | |
| | 8062665*PED | Feb 01, 2028 | | | | |
| | 8071129 | Aug 01, 2027 | DP U-1714 | | | |
| | 8071129*PED | Feb 01, 2028 | | | | |
| | 8828430 | Aug 01, 2027 | DP U-1306 | | | |
| | 8828430 | Aug 01, 2027 | DP U-1619 | | | |
| | 8828430 | Aug 01, 2027 | DP U-1714 | | | |
| | 8828430*PED | Feb 01, 2028 | | | | |
| ELTROMBOPAG OLAMINE - PROMACTA | | | | | | |
| N 022291 003 | 6280959 | Oct 30, 2018 | DS DP U-1306 | | D-149 | Jun 11, 2018 |
| | 6280959 | Oct 30, 2018 | DS DP U-1575 | | I-711 | Jun 11, 2018 |
| | 6280959 | Oct 30, 2018 | DS DP U-1714 | | ODE-75 | Aug 26, 2021 |
| | 6280959 | Oct 30, 2018 | DS DP U-930 | | PED | Dec 11, 2018 |
| | 6280959*PED | Apr 30, 2019 | | | PED | Dec 11, 2018 |
| | 7160870 | Nov 20, 2022 | DS DP U-1306 | | PED | Feb 26, 2022 |
| | 7160870 | Nov 20, 2022 | DS DP U-1575 | | | |
| | 7160870 | Nov 20, 2022 | DS DP U-1714 | | | |
| | 7160870 | Nov 20, 2022 | DS DP U-930 | | | |
| | 7160870*PED | May 20, 2023 | | | | |
| | 7332481 | May 24, 2021 | U-1306 | | | |
| | 7332481 | May 24, 2021 | U-1575 | | | |
| | 7332481 | May 24, 2021 | U-1714 | | | |
| | 7332481 | May 24, 2021 | U-930 | | | |
| | 7332481*PED | Nov 24, 2021 | | | | |
| | 7452874 | May 24, 2021 | DS DP U-1714 | | | |
| | 7452874*PED | Nov 24, 2021 | | | | |
| | 7473686 | May 24, 2021 | DS DP U-1306 | | | |
| | 7473686 | May 24, 2021 | DS DP U-1575 | | | |
| | 7473686 | May 24, 2021 | DS DP U-1714 | | | |
| | 7473686 | May 24, 2021 | DS DP U-930 | | | |
| | 7473686*PED | Nov 24, 2021 | | | | |
| | 7547719 | Jul 13, 2025 | DS DP U-1306 | | | |
| | 7547719 | Jul 13, 2025 | DS DP U-1575 | | | |
| | 7547719 | Jul 13, 2025 | DS DP U-1714 | | | |
| | 7547719 | Jul 13, 2025 | DS DP U-930 | | | |
| | 7547719*PED | Jan 13, 2026 | | | | |
| | 7790704 | May 24, 2021 | U-1306 | | | |
| | 7790704 | May 24, 2021 | U-1575 | | | |
| | 7790704 | May 24, 2021 | U-1714 | | | |
| | 7790704 | May 24, 2021 | U-930 | | | |
| | 7790704*PED | Nov 24, 2021 | | | | |
| | 7795293 | May 21, 2023 | U-1306 | | | |
| | 7795293 | May 21, 2023 | U-1575 | | | |
| | 7795293 | May 21, 2023 | U-1714 | | | |
| | 7795293 | May 21, 2023 | U-930 | | | |
| | 7795293*PED | Nov 21, 2023 | | | | |
| | 8052993 | Aug 01, 2027 | DP U-1714 | | | |
| | 8052993*PED | Feb 01, 2028 | | | | |
| | 8052994 | Aug 01, 2027 | DP U-1714 | | | |
| | 8052994*PED | Feb 01, 2028 | | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| ELTROMBOPAG OLAMINE - PROMACTA | | | | | | |
| N 022291 003 | 8062665 | Aug 01, 2027 | DP U-1306 | | | |
| | 8062665 | Aug 01, 2027 | DP U-1575 | | | |
| | 8062665 | Aug 01, 2027 | DP U-1714 | | | |
| | 8062665 | Aug 01, 2027 | DP U-930 | | | |
| | 8062665*PED | Feb 01, 2028 | | | | |
| | 8071129 | Aug 01, 2027 | DP U-1714 | | | |
| | 8071129*PED | Feb 01, 2028 | | | | |
| | 8828430 | Aug 01, 2027 | DP U-1306 | | | |
| | 8828430 | Aug 01, 2027 | DP U-1619 | | | |
| | 8828430 | Aug 01, 2027 | DP U-1714 | | | |
| | 8828430*PED | Feb 01, 2028 | | | | |
| ELTROMBOPAG OLAMINE - PROMACTA | | | | | | |
| N 022291 004 | 6280959 | Oct 30, 2018 | DS DP U-1306 | | D-149 | Jun 11, 2018 |
| | 6280959 | Oct 30, 2018 | DS DP U-1575 | | I-711 | Jun 11, 2018 |
| | 6280959 | Oct 30, 2018 | DS DP U-1714 | | ODE-75 | Aug 26, 2021 |
| | 6280959 | Oct 30, 2018 | DS DP U-930 | | PED | Dec 11, 2018 |
| | 6280959*PED | Apr 30, 2019 | | | PED | Dec 11, 2018 |
| | 7160870 | Nov 20, 2022 | DS DP U-1306 | | PED | Feb 26, 2022 |
| | 7160870 | Nov 20, 2022 | DS DP U-1575 | | | |
| | 7160870 | Nov 20, 2022 | DS DP U-1714 | | | |
| | 7160870 | Nov 20, 2022 | DS DP U-930 | | | |
| | 7160870*PED | May 20, 2023 | | | | |
| | 7332481 | May 24, 2021 | U-1306 | | | |
| | 7332481 | May 24, 2021 | U-1575 | | | |
| | 7332481 | May 24, 2021 | U-1714 | | | |
| | 7332481 | May 24, 2021 | U-930 | | | |
| | 7332481*PED | Nov 24, 2021 | | | | |
| | 7452874 | May 24, 2021 | DS DP U-1714 | | | |
| | 7452874*PED | Nov 24, 2021 | | | | |
| | 7473686 | May 24, 2021 | DS DP U-1306 | | | |
| | 7473686 | May 24, 2021 | DS DP U-1575 | | | |
| | 7473686 | May 24, 2021 | DS DP U-1714 | | | |
| | 7473686 | May 24, 2021 | DS DP U-930 | | | |
| | 7473686*PED | Nov 24, 2021 | | | | |
| | 7547719 | Jul 13, 2025 | DS DP U-1306 | | | |
| | 7547719 | Jul 13, 2025 | DS DP U-1575 | | | |
| | 7547719 | Jul 13, 2025 | DS DP U-1714 | | | |
| | 7547719 | Jul 13, 2025 | DS DP U-930 | | | |
| | 7547719*PED | Jan 13, 2026 | | | | |
| | 7790704 | May 24, 2021 | U-1306 | | | |
| | 7790704 | May 24, 2021 | U-1575 | | | |
| | 7790704 | May 24, 2021 | U-1714 | | | |
| | 7790704 | May 24, 2021 | U-930 | | | |
| | 7790704*PED | Nov 24, 2021 | | | | |
| | 7795293 | May 21, 2023 | U-1306 | | | |
| | 7795293 | May 21, 2023 | U-1575 | | | |
| | 7795293 | May 21, 2023 | U-1714 | | | |
| | 7795293 | May 21, 2023 | U-930 | | | |
| | 7795293*PED | Nov 21, 2023 | | | | |
| | 8052993 | Aug 01, 2027 | DP U-1714 | | | |
| | 8052993*PED | Feb 01, 2028 | | | | |
| | 8052994 | Aug 01, 2027 | DP U-1714 | | | |
| | 8052994*PED | Feb 01, 2028 | | | | |
| | 8062665 | Aug 01, 2027 | DP U-1714 | | | |
| | 8062665*PED | Feb 01, 2028 | | | | |
| | 8071129 | Aug 01, 2027 | DP U-1306 | | | |
| | 8071129 | Aug 01, 2027 | DP U-1575 | | | |
| | 8071129 | Aug 01, 2027 | DP U-1714 | | | |
| | 8071129 | Aug 01, 2027 | DP U-930 | | | |
| | 8071129*PED | Feb 01, 2028 | | | | |
| | 8828430 | Aug 01, 2027 | DP U-1306 | | | |
| | 8828430 | Aug 01, 2027 | DP U-1619 | | | |
| | 8828430 | Aug 01, 2027 | DP U-1714 | | | |
| | 8828430*PED | Feb 01, 2028 | | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| ELTROMBOPAG OLAMINE - PROMACTA | | | | | | |
| N 022291 005 | 6280959 | Oct 30, 2018 | DS DP U-1306 | | D-149 | Jun 11, 2018 |
| | 6280959 | Oct 30, 2018 | DS DP U-1575 | | I-711 | Jun 11, 2018 |
| | 6280959 | Oct 30, 2018 | DS DP U-1714 | | ODE-75 | Aug 26, 2021 |
| | 6280959 | Oct 30, 2018 | DS DP U-930 | | PED | Dec 11, 2018 |
| | 6280959*PED | Apr 30, 2019 | | | PED | Dec 11, 2018 |
| | 7160870 | Nov 20, 2022 | DS DP U-1306 | | PED | Feb 26, 2022 |
| | 7160870 | Nov 20, 2022 | DS DP U-1575 | | | |
| | 7160870 | Nov 20, 2022 | DS DP U-1714 | | | |
| | 7160870 | Nov 20, 2022 | DS DP U-930 | | | |
| | 7160870*PED | May 20, 2023 | | | | |
| | 7332481 | May 24, 2021 | U-1306 | | | |
| | 7332481 | May 24, 2021 | U-1575 | | | |
| | 7332481 | May 24, 2021 | U-1714 | | | |
| | 7332481 | May 24, 2021 | U-930 | | | |
| | 7332481*PED | Nov 24, 2021 | | | | |
| | 7452874 | May 24, 2021 | DS DP U-1714 | | | |
| | 7452874*PED | Nov 24, 2021 | | | | |
| | 7473686 | May 24, 2021 | DS DP U-1306 | | | |
| | 7473686 | May 24, 2021 | DS DP U-1575 | | | |
| | 7473686 | May 24, 2021 | DS DP U-1714 | | | |
| | 7473686 | May 24, 2021 | DS DP U-930 | | | |
| | 7473686*PED | Nov 24, 2021 | | | | |
| | 7547719 | Jul 13, 2025 | DS DP U-1306 | | | |
| | 7547719 | Jul 13, 2025 | DS DP U-1575 | | | |
| | 7547719 | Jul 13, 2025 | DS DP U-930 | | | |
| | 7547719*PED | Jan 13, 2026 | | | | |
| | 7790704 | May 24, 2021 | U-1306 | | | |
| | 7790704 | May 24, 2021 | U-1575 | | | |
| | 7790704 | May 24, 2021 | U-930 | | | |
| | 7790704*PED | Nov 24, 2021 | | | | |
| | 7795293 | May 21, 2023 | U-1306 | | | |
| | 7795293 | May 21, 2023 | U-1575 | | | |
| | 7795293 | May 21, 2023 | U-930 | | | |
| | 7795293*PED | Nov 21, 2023 | | | | |
| | 8052995 | Aug 01, 2027 | DP U-1306 | | | |
| | 8052995 | Aug 01, 2027 | DP U-1575 | | | |
| | 8052995*PED | Feb 01, 2028 | | | | |
| ELTROMBOPAG OLAMINE - PROMACTA | | | | | | |
| N 207027 001 | 6280959 | Oct 30, 2018 | DS DP U-1736 | | D-149 | Jun 11, 2018 |
| | 6280959*PED | Apr 30, 2019 | | | I-711 | Jun 11, 2018 |
| | 7160870 | Nov 20, 2022 | DS DP U-1736 | | ODE-74 | Aug 26, 2021 |
| | 7160870*PED | May 20, 2023 | | | PED | Dec 11, 2018 |
| | 7332481 | May 24, 2021 | U-1736 | | PED | Dec 11, 2018 |
| | 7332481*PED | Nov 24, 2021 | | | PED | Feb 26, 2022 |
| | 7452874 | May 24, 2021 | DS DP | | | |
| | 7452874*PED | Nov 24, 2021 | | | | |
| | 7473686 | May 24, 2021 | DS DP U-1736 | | | |
| | 7473686*PED | Nov 24, 2021 | | | | |
| | 7547719 | Jul 13, 2025 | DS DP U-1736 | | | |
| | 7547719*PED | Jan 13, 2026 | | | | |
| | 7790704 | May 24, 2021 | U-1736 | | | |
| | 7790704*PED | Nov 24, 2021 | | | | |
| | 7795293 | May 24, 2023 | U-1736 | | | |
| | 7795293*PED | Nov 24, 2023 | | | | |
| ELUXADOLINE - VIBERZI | | | | | | |
| N 206940 001 | 7741356 | Mar 25, 2028 | DS DP | | NCE | May 27, 2020 |
| | 7786158 | Mar 14, 2025 | DS | | | |
| | 8344011 | Mar 14, 2025 | U-1709 | | | |
| | 8609709 | Mar 14, 2025 | DS | | | |
| | 8691860 | Jul 07, 2028 | DS U-1709 | | | |
| | 8772325 | Mar 14, 2025 | U-1709 | | | |
| | 9115091 | Jul 07, 2028 | DS DP U-1738 | | | |
| | 9205076 | Mar 14, 2025 | U-1709 | | | |
| | 9364489 | Jul 07, 2028 | U-1709 | | | |
| | 9675587 | Mar 14, 2033 | DP | | | |
| | 9700542 | Mar 14, 2025 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| ELUXADOLINE - VIBERZI | | | | | | |
| N 206940 001 | 9789125 | Jul 07, 2028 | DP U-1709 | | | |
| | 9789125 | Jul 07, 2028 | DP U-2152 | | | |
| ELUXADOLINE - VIBERZI | | | | | | |
| N 206940 002 | 7741356 | Mar 25, 2028 | DS DP | | NCE | May 27, 2020 |
| | 7786158 | Mar 14, 2025 | DS | | | |
| | 8344011 | Mar 14, 2025 | U-1709 | | | |
| | 8609709 | Mar 14, 2025 | DS | | | |
| | 8691860 | Jul 07, 2028 | DS U-1709 | | | |
| | 8772325 | Mar 14, 2025 | U-1709 | | | |
| | 9115091 | Jul 07, 2028 | DS DP U-1738 | | | |
| | 9205076 | Mar 14, 2025 | U-1709 | | | |
| | 9364489 | Jul 07, 2028 | U-1709 | | | |
| | 9675587 | Mar 14, 2033 | DP | | | |
| | 9700542 | Mar 14, 2025 | DP | | | |
| | 9789125 | Jul 07, 2028 | DP U-1709 | | | |
| | 9789125 | Jul 07, 2028 | DP U-2152 | | | |
| ELVITEGRAVIR - VITEKTA | | | | | | |
| N 203093 001 | 7176220 | Aug 27, 2026 | DS DP U-257 | | NCE | Aug 27, 2017 |
| | 7635704 | Oct 26, 2026 | DS DP U-257 | | NP | Sep 24, 2017 |
| | 8981103 | Oct 26, 2026 | DS DP | | | |
| ELVITEGRAVIR - VITEKTA | | | | | | |
| N 203093 002 | 7176220 | Aug 27, 2026 | DS DP U-257 | | NCE | Aug 27, 2017 |
| | 7635704 | Oct 26, 2026 | DS DP U-257 | | NP | Sep 24, 2017 |
| | 8981103 | Oct 26, 2026 | DS DP | | | |
| EMPAGLIFLOZIN - JARDIANCE | | | | | | |
| N 204629 001 | 7579449 | Nov 05, 2025 | DS | | I-739 | Dec 02, 2019 |
| | 7713938 | Apr 15, 2027 | DS DP | | M-160 | Jun 26, 2018 |
| | 8551957 | Oct 14, 2029 | U-1651 | | M-161 | Jun 26, 2018 |
| | | | | | M-174 | Mar 18, 2019 |
| | | | | | NCE | Aug 01, 2019 |
| EMPAGLIFLOZIN - JARDIANCE | | | | | | |
| N 204629 002 | 7579449 | Nov 05, 2025 | DS | | I-739 | Dec 02, 2019 |
| | 7713938 | Apr 15, 2027 | DS DP | | M-160 | Jun 26, 2018 |
| | 8551957 | Oct 14, 2029 | U-1651 | | M-161 | Jun 26, 2018 |
| | | | | | M-174 | Mar 18, 2019 |
| | | | | | NCE | Aug 01, 2019 |
| EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI | | | | | | |
| N 206073 001 | 6890898 | Feb 02, 2019 | U-1652 | | I-739 | Dec 02, 2019 |
| | 7078381 | Feb 02, 2019 | U-1651 | | NC | Jan 30, 2018 |
| | 7407955 | May 02, 2025 | DS DP | | NCE | Aug 01, 2019 |
| | 7459428 | Feb 02, 2019 | U-1651 | | | |
| | 7579449 | Nov 05, 2025 | DS | | | |
| | 7713938 | Apr 15, 2027 | DS DP | | | |
| | 8119648 | Aug 12, 2023 | U-1651 | | | |
| | 8178541 | Aug 12, 2023 | DP U-1653 | | | |
| | 8178541 | Aug 12, 2023 | DP U-1654 | | | |
| | 8551957 | Oct 14, 2029 | DP U-1651 | | | |
| | 8673927 | May 04, 2027 | U-1652 | | | |
| | 8883805 | Nov 26, 2025 | DP | | | |
| | 9173859 | May 04, 2027 | DP U-1772 | | | |
| EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI | | | | | | |
| N 206073 002 | 6890898 | Feb 02, 2019 | U-1652 | | I-739 | Dec 02, 2019 |
| | 7078381 | Feb 02, 2019 | U-1651 | | NC | Jan 30, 2018 |
| | 7407955 | May 02, 2025 | DS DP | | NCE | Aug 01, 2019 |
| | 7459428 | Feb 02, 2019 | U-1651 | | | |
| | 7579449 | Nov 05, 2025 | DS | | | |
| | 7713938 | Apr 15, 2027 | DS DP | | | |
| | 8119648 | Aug 12, 2023 | U-1651 | | | |
| | 8178541 | Aug 12, 2023 | DP U-1653 | | | |
| | 8178541 | Aug 12, 2023 | DP U-1654 | | | |
| | 8551957 | Oct 14, 2029 | DP U-1651 | | | |
| | 8673927 | May 04, 2027 | U-1652 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI | | | | | | | |
| N 206073 | 002 | 8883805 | Nov 26, 2025 | DP | | | |
| | | 9173859 | May 04, 2027 | DP U-1772 | | | |
| EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY | | | | | | | |
| N 206111 | 001 | 7579449 | Nov 05, 2025 | DS | | I-739 | Dec 02, 2019 |
| | | 7713938 | Apr 15, 2027 | DS DP | | M-174 | Mar 18, 2019 |
| | | | | | | NCE | Aug 01, 2019 |
| | | | | | | NP | Aug 26, 2018 |
| EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY | | | | | | | |
| N 206111 | 002 | 7579449 | Nov 05, 2025 | DS | | I-739 | Dec 02, 2019 |
| | | 7713938 | Apr 15, 2027 | DS DP | | M-174 | Mar 18, 2019 |
| | | | | | | NCE | Aug 01, 2019 |
| | | | | | | NP | Aug 26, 2018 |
| EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY | | | | | | | |
| N 206111 | 003 | 7579449 | Nov 05, 2025 | DS | | I-739 | Dec 02, 2019 |
| | | 7713938 | Apr 15, 2027 | DS DP | | M-174 | Mar 18, 2019 |
| | | | | | | NCE | Aug 01, 2019 |
| | | | | | | NP | Aug 26, 2018 |
| EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY | | | | | | | |
| N 206111 | 004 | 7579449 | Nov 05, 2025 | DS | | I-739 | Dec 02, 2019 |
| | | 7713938 | Apr 15, 2027 | DS DP | | M-174 | Mar 18, 2019 |
| | | | | | | NCE | Aug 01, 2019 |
| | | | | | | NP | Aug 26, 2018 |
| EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR | | | | | | | |
| N 208658 | 001 | 6488962 | Jun 20, 2020 | DP | | I-739 | Dec 02, 2019 |
| | | 7579449 | Nov 05, 2025 | DS | | NCE | Aug 01, 2019 |
| | | 7713938 | Apr 15, 2027 | DS DP | | | |
| EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR | | | | | | | |
| N 208658 | 002 | 6488962 | Jun 20, 2020 | DP | | I-739 | Dec 02, 2019 |
| | | 7579449 | Nov 05, 2025 | DS | | NCE | Aug 01, 2019 |
| | | 7713938 | Apr 15, 2027 | DS DP | | | |
| EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR | | | | | | | |
| N 208658 | 003 | 6488962 | Jun 20, 2020 | DP | | I-739 | Dec 02, 2019 |
| | | 7579449 | Nov 05, 2025 | DS | | NCE | Aug 01, 2019 |
| | | 7713938 | Apr 15, 2027 | DS DP | | | |
| EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR | | | | | | | |
| N 208658 | 004 | 6488962 | Jun 20, 2020 | DP | | I-739 | Dec 02, 2019 |
| | | 7579449 | Nov 05, 2025 | DS | | NCE | Aug 01, 2019 |
| | | 7713938 | Apr 15, 2027 | DS DP | | | |
| EMTRICITABINE - EMTRIVA | | | | | | | |
| N 021500 | 001 | 5914331 | Jul 02, 2017 | DS | | | |
| | | 6642245 | Nov 04, 2020 | U-257 | | | |
| | | 6642245 | Nov 04, 2020 | U-541 | | | |
| | | 6703396 | Mar 09, 2021 | DS DP | | | |
| EMTRICITABINE - EMTRIVA | | | | | | | |
| N 021896 | 001 | 5914331 | Jul 02, 2017 | DS | | | |
| | | 6642245 | Nov 04, 2020 | U-257 | | | |
| | | 6703396 | Mar 09, 2021 | DS DP | | | |
| EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY | | | | | | | |
| N 208351 | 001 | 5914331 | Jul 02, 2017 | DS | | M-206 | Aug 21, 2020 |
| | | 5914331*PED | Jan 02, 2018 | | | M-207 | Aug 21, 2020 |
| | | 6642245 | Nov 04, 2020 | U-257 | | NCE | Nov 05, 2020 |
| | | 6642245*PED | May 04, 2021 | | | | |
| | | 6703396 | Mar 09, 2021 | DS DP | | | |
| | | 6703396*PED | Sep 09, 2021 | | | | |
| | | 6838464 | Feb 26, 2021 | DS DP | | | |
| | | 7067522 | Dec 20, 2019 | DS DP | | | |
| | | 7125879 | Apr 21, 2025 | DS DP U-257 | | | |
| | | 7390791 | May 07, 2022 | DS DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY | | | | | | | |
| N 208351 | 001 | 7803788 | Feb 02, 2022 | U-257 | | | |
| | | 8080551 | Apr 11, 2023 | DS DP | | | |
| | | 8101629 | Aug 09, 2022 | DP | | | |
| | | 8754065 | Aug 15, 2032 | DS DP U-257 | | | |
| | | 9296769 | Aug 15, 2032 | DS DP U-257 | | | |
| EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA | | | | | | | |
| N 202123 | 001 | 5914331 | Jul 02, 2017 | DS | | | |
| | | 5922695 | Jul 25, 2017 | DS U-257 | | | |
| | | 5935946 | Jul 25, 2017 | DS DP U-257 | | | |
| | | 5977089 | Jul 25, 2017 | DS DP U-257 | | | |
| | | 6043230 | Jul 25, 2017 | U-257 | | | |
| | | 6642245 | Nov 04, 2020 | U-257 | | | |
| | | 6703396 | Mar 09, 2021 | DS DP | | | |
| | | 6838464 | Feb 26, 2021 | DS DP | | | |
| | | 7067522 | Dec 20, 2019 | DS DP | | | |
| | | 7125879 | Apr 21, 2025 | DS DP U-257 | | | |
| | | 8080551 | Apr 11, 2023 | DS DP | | | |
| | | 8101629 | Aug 09, 2022 | DP | | | |
| | | 8592397 | Jan 13, 2024 | DP U-257 | | | |
| | | 8716264 | Jan 13, 2024 | DP U-257 | | | |
| | | 8841310 | Dec 09, 2025 | DP U-257 | | | |
| | | 9457036 | Jan 13, 2024 | DP U-257 | | | |
| | | 9744181 | Jan 13, 2024 | DP U-257 | | | |
| EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY | | | | | | | |
| N 208215 | 001 | 5914331 | Jul 02, 2017 | DS | | NCE | Nov 05, 2020 |
| | | 5914331*PED | Jan 02, 2018 | | | NPP | Sep 25, 2020 |
| | | 6642245 | Nov 04, 2020 | U-257 | | | |
| | | 6642245*PED | May 04, 2021 | | | | |
| | | 6703396 | Mar 09, 2021 | DS DP | | | |
| | | 6703396*PED | Sep 09, 2021 | | | | |
| | | 7390791 | May 07, 2022 | DS DP | | | |
| | | 7803788 | Feb 02, 2022 | U-257 | | | |
| | | 8754065 | Aug 15, 2032 | DS DP U-257 | | | |
| | | 9296769 | Aug 15, 2032 | DS DP U-257 | | | |
| EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA | | | | | | | |
| N 021752 | 001 | 5914331 | Jul 02, 2017 | DS | | | |
| | | 5914331*PED | Jan 02, 2018 | | | | |
| | | 5922695 | Jul 25, 2017 | DS U-1170 | | | |
| | | 5922695 | Jul 25, 2017 | DS U-1259 | | | |
| | | 5922695 | Jul 25, 2017 | DS U-248 | | | |
| | | 5922695 | Jul 25, 2017 | DS U-541 | | | |
| | | 5935946 | Jul 25, 2017 | DS DP U-1170 | | | |
| | | 5935946 | Jul 25, 2017 | DS DP U-1259 | | | |
| | | 5935946 | Jul 25, 2017 | DS DP U-248 | | | |
| | | 5935946 | Jul 25, 2017 | DS DP U-541 | | | |
| | | 5977089 | Jul 25, 2017 | DS DP U-1170 | | | |
| | | 5977089 | Jul 25, 2017 | DS DP U-1259 | | | |
| | | 5977089 | Jul 25, 2017 | DS DP U-248 | | | |
| | | 5977089 | Jul 25, 2017 | DS DP U-541 | | | |
| | | 6043230 | Jul 25, 2017 | U-1170 | | | |
| | | 6043230 | Jul 25, 2017 | U-1259 | | | |
| | | 6043230 | Jul 25, 2017 | U-248 | | | |
| | | 6043230 | Jul 25, 2017 | U-541 | | | |
| | | 6043230*PED | Jan 25, 2018 | | | | |
| | | 6642245 | Nov 04, 2020 | U-1170 | | | |
| | | 6642245 | Nov 04, 2020 | U-248 | | | |
| | | 6642245 | Nov 04, 2020 | U-541 | | | |
| | | 6703396 | Mar 09, 2021 | DS DP | | | |
| | | 8592397 | Jan 13, 2024 | DP U-1170 | | | |
| | | 8592397 | Jan 13, 2024 | DP U-248 | | | |
| | | 8592397 | Jan 13, 2024 | DP U-541 | | | |
| | | 8716264 | Jan 13, 2024 | DP U-257 | | | |
| | | 9457036 | Jan 13, 2024 | DP U-257 | | | |
| | | 9744181 | Jan 13, 2024 | DP U-257 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA | | | | | | |
| N 021752 002 | 5914331 | Jul 02, 2017 | DS | | | |
| | 5914331*PED | Jan 02, 2018 | | | | |
| | 5922695 | Jul 25, 2017 | DS | | U-1170 | |
| | 5922695 | Jul 25, 2017 | DS | | U-1259 | |
| | 5922695 | Jul 25, 2017 | DS | | U-248 | |
| | 5922695 | Jul 25, 2017 | DS | | U-541 | |
| | 5935946 | Jul 25, 2017 | DS DP | | U-1170 | |
| | 5935946 | Jul 25, 2017 | DS DP | | U-1259 | |
| | 5935946 | Jul 25, 2017 | DS DP | | U-248 | |
| | 5935946 | Jul 25, 2017 | DS DP | | U-541 | |
| | 5935946*PED | Jan 25, 2018 | | | | |
| | 5977089 | Jul 25, 2017 | DS DP | | U-1170 | |
| | 5977089 | Jul 25, 2017 | DS DP | | U-1259 | |
| | 5977089 | Jul 25, 2017 | DS DP | | U-248 | |
| | 5977089 | Jul 25, 2017 | DS DP | | U-541 | |
| | 5977089*PED | Jan 25, 2018 | | | | |
| | 6043230 | Jul 25, 2017 | | | U-1170 | |
| | 6043230 | Jul 25, 2017 | | | U-1259 | |
| | 6043230 | Jul 25, 2017 | | | U-248 | |
| | 6043230 | Jul 25, 2017 | | | U-541 | |
| | 6043230*PED | Jan 25, 2018 | | | | |
| | 6642245 | Nov 04, 2020 | | | U-1170 | |
| | 6642245 | Nov 04, 2020 | | | U-248 | |
| | 6642245 | Nov 04, 2020 | | | U-541 | |
| | 6642245*PED | May 04, 2021 | | | | |
| | 6703396 | Mar 09, 2021 | DS DP | | | |
| | 6703396*PED | Sep 09, 2021 | | | | |
| EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA | | | | | | |
| N 021752 003 | 5914331 | Jul 02, 2017 | DS | | | |
| | 5914331*PED | Jan 02, 2018 | | | | |
| | 5922695 | Jul 25, 2017 | DS | | U-1170 | |
| | 5922695 | Jul 25, 2017 | DS | | U-1259 | |
| | 5922695 | Jul 25, 2017 | DS | | U-248 | |
| | 5922695 | Jul 25, 2017 | DS | | U-541 | |
| | 5922695*PED | Jan 25, 2018 | | | | |
| | 5935946 | Jul 25, 2017 | DS DP | | U-1170 | |
| | 5935946 | Jul 25, 2017 | DS DP | | U-1259 | |
| | 5935946 | Jul 25, 2017 | DS DP | | U-248 | |
| | 5935946 | Jul 25, 2017 | DS DP | | U-541 | |
| | 5935946*PED | Jan 25, 2018 | | | | |
| | 5977089 | Jul 25, 2017 | DS DP | | U-1170 | |
| | 5977089 | Jul 25, 2017 | DS DP | | U-1259 | |
| | 5977089 | Jul 25, 2017 | DS DP | | U-248 | |
| | 5977089 | Jul 25, 2017 | DS DP | | U-541 | |
| | 5977089*PED | Jan 25, 2018 | | | | |
| | 6043230 | Jul 25, 2017 | | | U-1170 | |
| | 6043230 | Jul 25, 2017 | | | U-1259 | |
| | 6043230 | Jul 25, 2017 | | | U-248 | |
| | 6043230 | Jul 25, 2017 | | | U-541 | |
| | 6043230*PED | Jan 25, 2018 | | | | |
| | 6642245 | Nov 04, 2020 | | | U-1170 | |
| | 6642245 | Nov 04, 2020 | | | U-248 | |
| | 6642245 | Nov 04, 2020 | | | U-541 | |
| | 6642245*PED | May 04, 2021 | | | | |
| | 6703396 | Mar 09, 2021 | DS DP | | | |
| | 6703396*PED | Sep 09, 2021 | | | | |
| EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA | | | | | | |
| N 021752 004 | 5914331 | Jul 02, 2017 | DS | | | |
| | 5914331*PED | Jan 02, 2018 | | | | |
| | 5922695 | Jul 25, 2017 | DS | | U-1170 | |
| | 5922695 | Jul 25, 2017 | DS | | U-1259 | |
| | 5922695 | Jul 25, 2017 | DS | | U-248 | |
| | 5922695 | Jul 25, 2017 | DS | | U-541 | |
| | 5922695*PED | Jan 25, 2018 | | | | |
| | 5935946 | Jul 25, 2017 | DS DP | | U-1170 | |
| | 5935946 | Jul 25, 2017 | DS DP | | U-1259 | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA | | | | | | | |
| N 021752 | 004 | 5935946 | Jul 25, 2017 | DS DP U-248 | | | |
| | | 5935946 | Jul 25, 2017 | DS DP U-541 | | | |
| | | 5935946*PED | Jan 25, 2018 | | | | |
| | | 5977089 | Jul 25, 2017 | DS DP U-1170 | | | |
| | | 5977089 | Jul 25, 2017 | DS DP U-1259 | | | |
| | | 5977089 | Jul 25, 2017 | DS DP U-248 | | | |
| | | 5977089 | Jul 25, 2017 | DS DP U-541 | | | |
| | | 5977089*PED | Jan 25, 2018 | | | | |
| | | 6043230 | Jul 25, 2017 | U-1170 | | | |
| | | 6043230 | Jul 25, 2017 | U-1259 | | | |
| | | 6043230 | Jul 25, 2017 | U-248 | | | |
| | | 6043230 | Jul 25, 2017 | U-541 | | | |
| | | 6043230*PED | Jan 25, 2018 | | | | |
| | | 6642245 | Nov 04, 2020 | U-1170 | | | |
| | | 6642245 | Nov 04, 2020 | U-248 | | | |
| | | 6642245 | Nov 04, 2020 | U-541 | | | |
| | | 6642245*PED | May 04, 2021 | | | | |
| | | 6703396 | Mar 09, 2021 | DS DP | | | |
| | | 6703396*PED | Sep 09, 2021 | | | | |
| ENALAPRIL MALEATE - EPANED KIT | | | | | | | |
| N 204308 | 001 | 8568747 | Nov 06, 2032 | DP | | | |
| | | 8778366 | Nov 06, 2032 | U-1723 | | | |
| | | 8778366 | Nov 06, 2032 | U-185 | | | |
| | | 8778366 | Nov 06, 2032 | U-1892 | | | |
| | | 8778366 | Nov 06, 2032 | U-3 | | | |
| | | 8778366 | Nov 06, 2032 | U-71 | | | |
| | | 9855214 | Nov 06, 2032 | DP | | | |
| ENALAPRIL MALEATE - EPANED | | | | | | | |
| N 208686 | 001 | 9669008 | Mar 25, 2036 | DP | | | |
| | | 9808442 | Mar 25, 2036 | U-1723 | | | |
| | | 9808442 | Mar 25, 2036 | U-185 | | | |
| | | 9808442 | Mar 25, 2036 | U-1892 | | | |
| | | 9808442 | Mar 25, 2036 | U-3 | | | |
| | | 9808442 | Mar 25, 2036 | U-71 | | | |
| ENASIDENIB MESYLATE - IDHIFA | | | | | | | |
| N 209606 | 001 | 9512107 | Jan 07, 2033 | DS DP U-2087 | | NCE | Aug 01, 2022 |
| | | 9732062 | Sep 16, 2034 | DS | | ODE-151 | Aug 01, 2024 |
| | | 9738625 | Aug 01, 2034 | DS | | | |
| ENASIDENIB MESYLATE - IDHIFA | | | | | | | |
| N 209606 | 002 | 9512107 | Jan 07, 2033 | DS DP U-2087 | | NCE | Aug 01, 2022 |
| | | 9732062 | Sep 16, 2034 | DS | | ODE-151 | Aug 01, 2024 |
| | | 9738625 | Aug 01, 2034 | DS | | | |
| ENTACAPONE - COMTAN | | | | | | | |
| N 020796 | 001 | 6599530 | Sep 14, 2018 | DP U-219 | | | |
| ENZALUTAMIDE - XTANDI | | | | | | | |
| N 203415 | 001 | 7709517 | Aug 13, 2027 | DS DP | | I-693 | Sep 10, 2017 |
| | | 8183274 | Aug 24, 2026 | U-1281 | | NCE | Aug 31, 2017 |
| | | 8183274 | Aug 24, 2026 | U-1588 | | | |
| | | 9126941 | May 15, 2026 | U-1588 | | | |
| EPINEPHRINE - EPIPEN | | | | | | | |
| N 019430 | 001 | 7449012 | Sep 11, 2025 | DP | | | |
| | | 7794432 | Sep 11, 2025 | DP | | | |
| | | 8048035 | Sep 11, 2025 | DP | | | |
| | | 8870827 | Sep 11, 2025 | DP | | | |
| | | 9586010 | Sep 11, 2025 | DP | | | |
| EPINEPHRINE - EPIPEN JR. | | | | | | | |
| N 019430 | 002 | 7449012 | Sep 11, 2025 | DP | | | |
| | | 7794432 | Sep 11, 2025 | DP | | | |
| | | 8048035 | Sep 11, 2025 | DP | | | |
| | | 8870827 | Sep 11, 2025 | DP | | | |
| | | 9586010 | Sep 11, 2025 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| EPINEPHRINE - EPIPEN JR. | | | | | | | |
| N 019430 | 002 | 7449012 | Sep 11, 2025 | DP | | | |
| | | 7794432 | Sep 11, 2025 | DP | | | |
| | | 8048035 | Sep 11, 2025 | DP | | | |
| | | 8870827 | Sep 11, 2025 | DP | | | |
| | | 9586010 | Sep 11, 2025 | DP | | | |
| EPINEPHRINE - TWINJECT 0.3 | | | | | | | |
| N 020800 | 001 | 7297136 | Jan 18, 2025 | DP | | | |
| | | 7621891 | Feb 04, 2025 | DP | | | |
| EPINEPHRINE - TWINJECT 0.15 | | | | | | | |
| N 020800 | 002 | 7297136 | Jan 18, 2025 | DP | | | |
| | | 7621891 | Feb 04, 2025 | DP | | | |
| EPINEPHRINE - ADRENACLICK | | | | | | | |
| N 020800 | 003 | 7905352 | Apr 12, 2027 | DP | | | |
| EPINEPHRINE - ADRENACLICK | | | | | | | |
| N 020800 | 004 | 7905352 | Apr 12, 2027 | DP | | | |
| EPINEPHRINE - AUVI-Q | | | | | | | |
| N 201739 | 001 | 7731686 | Jun 01, 2026 | DP | | | |
| | | 7731690 | Jan 15, 2025 | DP | | | |
| | | 7749194 | Oct 30, 2028 | DP | | | |
| | | 7918823 | Nov 23, 2024 | DP | | | |
| | | 7947017 | Mar 12, 2028 | DP | | | |
| | | 8016788 | Mar 21, 2025 | DP | | | |
| | | 8021344 | Nov 02, 2029 | DP | | | |
| | | 8206360 | Feb 27, 2027 | DP | | | |
| | | 8226610 | Apr 10, 2029 | DP | | | |
| | | 8231573 | Nov 25, 2028 | DP | | | |
| | | 8313466 | Nov 23, 2024 | DP | | | |
| | | 8361029 | Nov 23, 2024 | DP | | | |
| | | 8425462 | Nov 23, 2024 | DP | | | |
| | | 8608698 | Nov 23, 2024 | DP | | | |
| | | 8920377 | Nov 23, 2024 | DP | | | |
| | | 8926594 | Mar 31, 2026 | DP | | | |
| | | 9056170 | Nov 23, 2024 | DP | | | |
| | | 9149579 | Jul 19, 2025 | | | U-1758 | |
| | | 9238108 | Feb 20, 2027 | DP | | | |
| | | 9259539 | Feb 01, 2026 | DP | | | |
| | | 9278182 | Feb 01, 2026 | DP | | | |
| | | 9724471 | May 23, 2027 | DP | | U-2092 | |
| | | 9737669 | Nov 23, 2024 | DP | | | |
| EPINEPHRINE - AUVI-Q | | | | | | | |
| N 201739 | 002 | 7731686 | Jun 01, 2026 | DP | | | |
| | | 7731690 | Jan 15, 2025 | DP | | | |
| | | 7749194 | Oct 30, 2028 | DP | | | |
| | | 7918823 | Nov 23, 2024 | DP | | | |
| | | 7947017 | Mar 12, 2028 | DP | | | |
| | | 8016788 | Mar 21, 2025 | DP | | | |
| | | 8021344 | Nov 02, 2029 | DP | | | |
| | | 8206360 | Feb 27, 2027 | DP | | | |
| | | 8226610 | Apr 10, 2029 | DP | | | |
| | | 8231573 | Nov 25, 2028 | DP | | | |
| | | 8313466 | Nov 23, 2024 | DP | | | |
| | | 8361029 | Nov 23, 2024 | DP | | | |
| | | 8425462 | Nov 23, 2024 | DP | | | |
| | | 8608698 | Nov 23, 2024 | DP | | | |
| | | 8920377 | Nov 23, 2024 | DP | | | |
| | | 8926594 | Mar 31, 2026 | DP | | | |
| | | 9056170 | Nov 23, 2024 | DP | | | |
| | | 9149579 | Jul 19, 2025 | | | U-1758 | |
| | | 9238108 | Feb 20, 2027 | DP | | | |
| | | 9259539 | Feb 01, 2026 | DP | | | |
| | | 9278182 | Feb 01, 2026 | DP | | | |
| | | 9724471 | May 23, 2027 | DP | | U-2092 | |
| | | 9737669 | Nov 23, 2024 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| EPINEPHRINE - AUVI-Q | | | | | | |
| N 201739 002 | 7731686 | Jun 01, 2026 | DP | | | |
| | 7731690 | Jan 15, 2025 | DP | | | |
| | 7749194 | Oct 30, 2028 | DP | | | |
| | 7918823 | Nov 23, 2024 | DP | | | |
| | 7947017 | Mar 12, 2028 | DP | | | |
| | 8016788 | Mar 21, 2025 | DP | | | |
| | 8021344 | Nov 02, 2029 | DP | | | |
| | 8206360 | Feb 27, 2027 | DP | | | |
| | 8226610 | Apr 10, 2029 | DP | | | |
| | 8231573 | Nov 25, 2028 | DP | | | |
| | 8313466 | Nov 23, 2024 | DP | | | |
| | 8361029 | Nov 23, 2024 | DP | | | |
| | 8425462 | Nov 23, 2024 | DP | | | |
| | 8608698 | Nov 23, 2024 | DP | | | |
| | 8920377 | Nov 23, 2024 | DP | | | |
| | 8926594 | Mar 31, 2026 | DP | | | |
| | 9056170 | Nov 23, 2024 | DP | | | |
| | 9149579 | Jul 19, 2025 | | | U-1758 | |
| | 9238108 | Feb 20, 2027 | DP | | | |
| | 9259539 | Feb 01, 2026 | DP | | | |
| | 9278182 | Feb 01, 2026 | DP | | | |
| | 9724471 | May 23, 2027 | DP | | U-2092 | |
| | 9737669 | Nov 23, 2024 | DP | | | |
| EPINEPHRINE - AUVI-Q | | | | | | |
| N 201739 003 | 7731686 | Jun 01, 2026 | DP | | | |
| | 7731690 | Jan 15, 2025 | DP | | | |
| | 7749194 | Oct 30, 2028 | DP | | | |
| | 7918823 | Nov 23, 2024 | DP | | | |
| | 7947017 | Mar 12, 2028 | DP | | | |
| | 8016788 | Mar 21, 2025 | DP | | | |
| | 8021344 | Nov 02, 2029 | DP | | | |
| | 8206360 | Feb 27, 2027 | DP | | | |
| | 8226610 | Apr 10, 2029 | DP | | | |
| | 8231573 | Nov 25, 2028 | DP | | | |
| | 8313466 | Nov 23, 2024 | DP | | | |
| | 8361029 | Nov 23, 2024 | DP | | | |
| | 8425462 | Nov 23, 2024 | DP | | | |
| | 8608698 | Nov 23, 2024 | DP | | | |
| | 8920377 | Nov 23, 2024 | DP | | | |
| | 8926594 | Mar 31, 2026 | DP | | | |
| | 9056170 | Nov 23, 2024 | DP | | | |
| | 9149579 | Jul 19, 2025 | | | U-1758 | |
| | 9238108 | Feb 20, 2027 | DP | | | |
| | 9259539 | Feb 01, 2026 | DP | | | |
| | 9278182 | Feb 01, 2026 | DP | | | |
| | 9724471 | May 23, 2027 | DP | | U-2092 | |
| | 9737669 | Nov 23, 2024 | DP | | | |
| | 9833573 | Nov 23, 2024 | | | U-2172 | |
| EPINEPHRINE - ADRENALIN | | | | | | |
| N 204200 001 | 9119876 | Mar 13, 2035 | DP | | | |
| | 9295657 | Mar 13, 2035 | | | U-1829 | |
| EPINEPHRINE - ADRENALIN | | | | | | |
| N 204640 001 | 9119876 | Mar 13, 2035 | DP | | | |
| | 9295657 | Mar 13, 2035 | | | U-1829 | |
| EPINEPHRINE - EPINEPHRINE | | | | | | |
| N 205029 001 | 9283197 | Aug 15, 2034 | DP | | U-1828 | |
| | 9283197 | Aug 15, 2034 | DP | | U-1829 | |
| | 9283197 | Aug 15, 2034 | DP | | U-1830 | |
| EPINEPHRINE; LIDOCAINE HYDROCHLORIDE - LIDOSITE TOPICAL SYSTEM KIT | | | | | | |
| N 021504 001 | 6629968 | Jun 30, 2020 | DS DP | | | |
| | 6635045 | Jun 29, 2021 | DS DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| EPLERENONE - INSPRA | | | | | | |
| N 021437 001 | 6410054 | Dec 08, 2019 | U-3 | | | |
| | 6410054 | Dec 08, 2019 | U-537 | | | |
| | 6410524 | Nov 05, 2019 | U-467 | | | |
| | 6495165 | Dec 08, 2019 | U-3 | | | |
| | 6495165 | Dec 08, 2019 | U-537 | | | |
| | 6534093 | Dec 08, 2019 | U-3 | | | |
| | 6534093 | Dec 08, 2019 | U-537 | | | |
| | 6558707 | Dec 08, 2019 | DP U-537 | | | |
| | 6747020 | Nov 05, 2019 | U-587 | | | |
| | 7157101 | Dec 08, 2019 | DP U-664 | | | |
| EPLERENONE - INSPRA | | | | | | |
| N 021437 002 | 6410054 | Dec 08, 2019 | U-3 | | | |
| | 6410054 | Dec 08, 2019 | U-537 | | | |
| | 6410524 | Nov 05, 2019 | U-467 | | | |
| | 6495165 | Dec 08, 2019 | U-3 | | | |
| | 6495165 | Dec 08, 2019 | U-537 | | | |
| | 6534093 | Dec 08, 2019 | U-3 | | | |
| | 6534093 | Dec 08, 2019 | U-537 | | | |
| | 6558707 | Dec 08, 2019 | DP U-537 | | | |
| | 6747020 | Nov 05, 2019 | U-587 | | | |
| | 7157101 | Dec 08, 2019 | DP U-664 | | | |
| EPLERENONE - INSPRA | | | | | | |
| N 021437 003 | 6410054 | Dec 08, 2019 | U-3 | | | |
| | 6410054 | Dec 08, 2019 | U-537 | | | |
| | 6410524 | Nov 05, 2019 | U-467 | | | |
| | 6495165 | Dec 08, 2019 | U-3 | | | |
| | 6495165 | Dec 08, 2019 | U-537 | | | |
| | 6534093 | Dec 08, 2019 | U-3 | | | |
| | 6534093 | Dec 08, 2019 | U-537 | | | |
| | 6558707 | Dec 08, 2019 | DP U-537 | | | |
| | 6747020 | Nov 05, 2019 | U-587 | | | |
| | 7157101 | Dec 08, 2019 | DP U-664 | | | |
| EPOPROSTENOL SODIUM - VELETRI | | | | | | |
| N 022260 001 | 8318802 | Mar 15, 2027 | DP | | | |
| | 8598227 | Feb 02, 2027 | | | | |
| EPOPROSTENOL SODIUM - VELETRI | | | | | | |
| N 022260 002 | 8318802 | Mar 15, 2027 | DP | | | |
| | 8598227 | Feb 02, 2027 | | | | |
| ERIBULIN MESYLATE - HALAVEN | | | | | | |
| N 201532 001 | 6214865 | Jul 20, 2023 | DS | | I-721 | Jan 28, 2019 |
| | 6469182 | Jun 16, 2019 | U-1096 | | ODE-107 | Jan 28, 2023 |
| | 6469182 | Jun 16, 2019 | U-1812 | | | |
| | 7470720 | Jun 16, 2019 | DP | | | |
| | 8097648 | Jan 22, 2021 | U-1096 | | | |
| ERLOTINIB HYDROCHLORIDE - TARCEVA | | | | | | |
| N 021743 001 | 5747498 | Nov 08, 2018 | DS DP U-659 | | D-164 | May 20, 2019 |
| | 5747498*PED | May 08, 2019 | | | M-181 | Jun 01, 2019 |
| | 6900221 | Nov 09, 2020 | DS DP U-1046 | | M-190 | Oct 18, 2019 |
| | 6900221 | Nov 09, 2020 | DS DP U-1403 | | | |
| | 6900221 | Nov 09, 2020 | DS DP U-659 | | | |
| | 6900221 | Nov 09, 2020 | DS DP U-875 | | | |
| | 6900221*PED | May 09, 2021 | | | | |
| | 7087613 | Nov 09, 2020 | U-1045 | | | |
| | 7087613 | Nov 09, 2020 | U-1403 | | | |
| | 7087613 | Nov 09, 2020 | U-659 | | | |
| | 7087613*PED | May 09, 2021 | | | | |
| | RE41065 | Nov 08, 2018 | DS DP | | | |
| | RE41065*PED | May 08, 2019 | | | | |
| ERLOTINIB HYDROCHLORIDE - TARCEVA | | | | | | |
| N 021743 002 | 5747498 | Nov 08, 2018 | DS DP U-659 | | D-164 | May 20, 2019 |
| | 5747498*PED | May 08, 2019 | | | M-181 | Jun 01, 2019 |
| | 6900221 | Nov 09, 2020 | DS DP U-1046 | | M-190 | Oct 18, 2019 |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| ERLOTINIB HYDROCHLORIDE - TARCEVA | | | | | | | |
| N 021743 | 002 | 6900221 | Nov 09, 2020 | DS DP U-1403 | | | |
| | | 6900221 | Nov 09, 2020 | DS DP U-659 | | | |
| | | 6900221 | Nov 09, 2020 | DS DP U-875 | | | |
| | | 6900221*PED | May 09, 2021 | | | | |
| | | 7087613 | Nov 09, 2020 | U-1045 | | | |
| | | 7087613 | Nov 09, 2020 | U-1403 | | | |
| | | 7087613 | Nov 09, 2020 | U-659 | | | |
| | | 7087613*PED | May 09, 2021 | | | | |
| | | RE41065 | Nov 08, 2018 | DS DP | | | |
| | | RE41065*PED | May 08, 2019 | | | | |
| ERLOTINIB HYDROCHLORIDE - TARCEVA | | | | | | | |
| N 021743 | 003 | 5747498 | Nov 08, 2018 | DS DP U-659 | | D-164 | May 20, 2019 |
| | | 5747498*PED | May 08, 2019 | | | M-181 | Jun 01, 2019 |
| | | 6900221 | Nov 09, 2020 | DS DP U-1046 | | M-190 | Oct 18, 2019 |
| | | 6900221 | Nov 09, 2020 | DS DP U-1403 | | | |
| | | 6900221 | Nov 09, 2020 | DS DP U-659 | | | |
| | | 6900221 | Nov 09, 2020 | DS DP U-875 | | | |
| | | 6900221*PED | May 09, 2021 | | | | |
| | | 7087613 | Nov 09, 2020 | U-1045 | | | |
| | | 7087613 | Nov 09, 2020 | U-1403 | | | |
| | | 7087613 | Nov 09, 2020 | U-659 | | | |
| | | 7087613*PED | May 09, 2021 | | | | |
| | | RE41065 | Nov 08, 2018 | DS DP | | | |
| | | RE41065*PED | May 08, 2019 | | | | |
| ERTUGLIFLOZIN - STEGLATRO | | | | | | | |
| N 209803 | 001 | | | | | NCE | Dec 19, 2022 |
| ERTUGLIFLOZIN - STEGLATRO | | | | | | | |
| N 209803 | 002 | | | | | NCE | Dec 19, 2022 |
| ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET | | | | | | | |
| N 209806 | 001 | | | | | NCE | Dec 19, 2022 |
| ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET | | | | | | | |
| N 209806 | 002 | | | | | NCE | Dec 19, 2022 |
| ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET | | | | | | | |
| N 209806 | 003 | | | | | NCE | Dec 19, 2022 |
| ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE - SEGLUROMET | | | | | | | |
| N 209806 | 004 | | | | | NCE | Dec 19, 2022 |
| ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN | | | | | | | |
| N 209805 | 001 | | | | | NCE | Dec 19, 2022 |
| ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE - STEGLUJAN | | | | | | | |
| N 209805 | 002 | | | | | NCE | Dec 19, 2022 |
| ESCITALOPRAM OXALATE - LEXAPRO | | | | | | | |
| N 021323 | 001 | 6916941 | Aug 12, 2022 | DS DP | | | |
| | | 7420069 | Aug 12, 2022 | DP | | | |
| ESCITALOPRAM OXALATE - LEXAPRO | | | | | | | |
| N 021323 | 002 | 6916941 | Aug 12, 2022 | DS DP | | | |
| | | 7420069 | Aug 12, 2022 | DP | | | |
| ESCITALOPRAM OXALATE - LEXAPRO | | | | | | | |
| N 021323 | 003 | 6916941 | Aug 12, 2022 | DS DP | | | |
| | | 7420069 | Aug 12, 2022 | DP | | | |
| ESLICARBAZEPINE ACETATE - APTIOM | | | | | | | |
| N 022416 | 001 | 5753646 | Jun 27, 2021 | DS DP U-2041 | | D-150 | Aug 27, 2018 |
| | | 8372431 | Apr 17, 2030 | DP | | I-715 | Aug 27, 2018 |
| | | 9206135 | Apr 21, 2026 | DS | | NCE | Nov 08, 2018 |
| | | 9566244 | Oct 23, 2028 | DP | | | |
| | | 9643929 | Apr 21, 2026 | DP | | | |
| | | 9750747 | Aug 24, 2032 | U-2041 | | | |
| | | 9750747 | Aug 24, 2032 | U-2121 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| ESLICARBAZEPINE ACETATE - APTIOM | | | | | | |
| N 022416 001 | 9763954 | Sep 13, 2028 | U-2123 | | | |
| ESLICARBAZEPINE ACETATE - APTIOM | | | | | | |
| N 022416 002 | 5753646 | Jun 27, 2021 | DS DP U-2041 | | D-150 | Aug 27, 2018 |
| | 8372431 | Apr 17, 2030 | DP | | I-715 | Aug 27, 2018 |
| | 9206135 | Apr 21, 2026 | DS | | NCE | Nov 08, 2018 |
| | 9566244 | Oct 23, 2028 | DP | | | |
| | 9643929 | Apr 21, 2026 | DP | | | |
| | 9750747 | Aug 24, 2032 | U-2041 | | | |
| | 9750747 | Aug 24, 2032 | U-2121 | | | |
| | 9763954 | Sep 13, 2028 | U-2123 | | | |
| ESLICARBAZEPINE ACETATE - APTIOM | | | | | | |
| N 022416 003 | 5753646 | Jun 27, 2021 | DS DP U-2041 | | D-150 | Aug 27, 2018 |
| | 8372431 | Apr 17, 2030 | DP | | I-715 | Aug 27, 2018 |
| | 9206135 | Apr 21, 2026 | DS | | NCE | Nov 08, 2018 |
| | 9566244 | Oct 23, 2028 | DP | | | |
| | 9643929 | Apr 21, 2026 | DP | | | |
| | 9750747 | Aug 24, 2032 | U-2041 | | | |
| | 9750747 | Aug 24, 2032 | U-2121 | | | |
| | 9763954 | Sep 13, 2028 | U-2123 | | | |
| ESLICARBAZEPINE ACETATE - APTIOM | | | | | | |
| N 022416 004 | 5753646 | Jun 27, 2021 | DS DP U-2041 | | D-150 | Aug 27, 2018 |
| | 8372431 | Apr 17, 2030 | DP | | I-715 | Aug 27, 2018 |
| | 9206135 | Apr 21, 2026 | DS | | NCE | Nov 08, 2018 |
| | 9566244 | Oct 23, 2028 | DP | | | |
| | 9643929 | Apr 21, 2026 | DP | | | |
| | 9750747 | Aug 24, 2032 | U-2041 | | | |
| | 9750747 | Aug 24, 2032 | U-2121 | | | |
| | 9763954 | Sep 13, 2028 | U-2123 | | | |
| ESMOLOL HYDROCHLORIDE - BREVIBLOC IN PLASTIC CONTAINER | | | | | | |
| N 019386 004 | 6310094 | Jan 12, 2021 | | | | |
| | 6528540 | Jan 12, 2021 | | | | |
| ESMOLOL HYDROCHLORIDE - BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER | | | | | | |
| N 019386 005 | 6310094 | Jan 12, 2021 | | | | |
| | 6528540 | Jan 12, 2021 | | | | |
| ESMOLOL HYDROCHLORIDE - BREVIBLOC | | | | | | |
| N 019386 006 | 6310094 | Jan 12, 2021 | | | | |
| | 6528540 | Jan 12, 2021 | | | | |
| ESMOLOL HYDROCHLORIDE - BREVIBLOC | | | | | | |
| N 019386 007 | 6310094 | Jan 12, 2021 | | | | |
| | 6528540 | Jan 12, 2021 | | | | |
| ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER | | | | | | |
| N 205703 001 | 6310094 | Jan 12, 2021 | DP | | | |
| | 6528540 | Jan 12, 2021 | DP | | | |
| | 8829054 | Mar 15, 2033 | DP | | | |
| | 8835505 | Mar 15, 2033 | DP | | | |
| ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER | | | | | | |
| N 205703 002 | 6310094 | Jan 12, 2021 | DP | | | |
| | 6528540 | Jan 12, 2021 | DP | | | |
| | 8829054 | Mar 15, 2033 | DP | | | |
| | 8835505 | Mar 15, 2033 | DP | | | |
| ESOMEPRAZOLE MAGNESIUM - NEXIUM | | | | | | |
| N 021153 001 | 6147103 | Oct 09, 2018 | | | | |
| | 6166213 | Oct 09, 2018 | | | | |
| | 6191148 | Oct 09, 2018 | | | | |
| | 6369085 | May 25, 2018 | DS DP U-729 | | | |
| | 6369085 | May 25, 2018 | DS DP U-770 | | | |
| | 6428810 | Nov 03, 2019 | DP U-469 | | | |
| | 6428810 | Nov 03, 2019 | DP U-729 | | | |
| | 6428810 | Nov 03, 2019 | DP U-770 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| ESOMEPRAZOLE MAGNESIUM - NEXIUM | | | | | | | |
| N 021153 | 001 | 7411070 | May 25, 2018 | DS | | | |
| | | 8466175 | May 25, 2018 | U-1417 | | | |
| | | 8466175*PED | Nov 25, 2018 | | | | |
| ESOMEPRAZOLE MAGNESIUM - NEXIUM | | | | | | | |
| N 021153 | 002 | 6147103 | Oct 09, 2018 | | | | |
| | | 6166213 | Oct 09, 2018 | | | | |
| | | 6191148 | Oct 09, 2018 | | | | |
| | | 6369085 | May 25, 2018 | DS DP U-729 | | | |
| | | 6369085 | May 25, 2018 | DS DP U-770 | | | |
| | | 6428810 | Nov 03, 2019 | DP U-469 | | | |
| | | 6428810 | Nov 03, 2019 | DP U-729 | | | |
| | | 6428810 | Nov 03, 2019 | DP U-770 | | | |
| | | 7411070 | May 25, 2018 | DS | | | |
| | | 8466175 | May 25, 2018 | U-1417 | | | |
| | | 8466175*PED | Nov 25, 2018 | | | | |
| ESOMEPRAZOLE MAGNESIUM - NEXIUM | | | | | | | |
| N 021957 | 001 | 6369085 | May 25, 2018 | DS DP U-1207 | | | |
| | | 6369085 | May 25, 2018 | DS DP U-729 | | | |
| | | 6369085 | May 25, 2018 | DS DP U-773 | | | |
| | | 6428810 | Nov 03, 2019 | DP U-1207 | | | |
| | | 6428810 | Nov 03, 2019 | DP U-729 | | | |
| | | 6428810 | Nov 03, 2019 | DP U-773 | | | |
| | | 7411070 | May 25, 2018 | DS | | | |
| | | 8466175 | May 25, 2018 | U-1417 | | | |
| | | 8466175*PED | Nov 25, 2018 | | | | |
| ESOMEPRAZOLE MAGNESIUM - NEXIUM | | | | | | | |
| N 021957 | 002 | 6369085 | May 25, 2018 | DS DP U-1207 | | | |
| | | 6369085 | May 25, 2018 | DS DP U-729 | | | |
| | | 6369085 | May 25, 2018 | DS DP U-773 | | | |
| | | 6428810 | Nov 03, 2019 | DP U-1207 | | | |
| | | 6428810 | Nov 03, 2019 | DP U-729 | | | |
| | | 6428810 | Nov 03, 2019 | DP U-773 | | | |
| | | 7411070 | May 25, 2018 | DS | | | |
| | | 8466175 | May 25, 2018 | U-1417 | | | |
| | | 8466175*PED | Nov 25, 2018 | | | | |
| ESOMEPRAZOLE MAGNESIUM - NEXIUM | | | | | | | |
| N 021957 | 003 | 6369085 | May 25, 2018 | DS DP U-1207 | | | |
| | | 6428810 | Nov 03, 2019 | DP U-1207 | | | |
| | | 7411070 | May 25, 2018 | DS | | | |
| ESOMEPRAZOLE MAGNESIUM - NEXIUM | | | | | | | |
| N 021957 | 004 | 6369085 | May 25, 2018 | DS DP U-1207 | | | |
| | | 6428810 | Nov 03, 2019 | DP U-1207 | | | |
| | | 7411070 | May 25, 2018 | DS | | | |
| ESOMEPRAZOLE MAGNESIUM - NEXIUM | | | | | | | |
| N 022101 | 001 | 6369085 | May 25, 2018 | DS DP U-858 | | | |
| | | 6428810 | Nov 03, 2019 | DP U-858 | | | |
| | | 7411070 | May 25, 2018 | DS | | | |
| ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR | | | | | | | |
| N 204655 | 001 | 6369085 | May 25, 2018 | DS DP U-1509 | | | |
| | | 6369085 | May 25, 2018 | DS DP U-1875 | | | |
| | | 6369085*PED | Nov 25, 2018 | | | | |
| | | 6428810 | Nov 03, 2019 | DP U-1509 | | | |
| | | 6428810 | Nov 03, 2019 | DP U-1874 | | | |
| | | 6428810*PED | May 03, 2020 | | | | |
| | | 7411070 | May 25, 2018 | DS | | | |
| | | 7411070*PED | Nov 25, 2018 | | | | |
| ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR | | | | | | | |
| N 207920 | 001 | 6369085 | May 25, 2018 | DS DP U-1784 | | | |
| | | 6369085*PED | Nov 25, 2018 | | | | |
| | | 6428810 | Nov 03, 2019 | DP U-1785 | | | |
| | | 6428810*PED | May 03, 2020 | | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR | | | | | | | |
| N 207920 | 001 | 7411070 | May 18, 2018 | DS | | | |
| | | 7411070*PED | Nov 18, 2018 | | | | |
| ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO | | | | | | | |
| N 022511 | 001 | 6369085 | May 25, 2018 | DS DP U-1053 | | NPP | Jul 06, 2020 |
| | | 6926907 | Feb 28, 2023 | DP U-1052 | | | |
| | | 7411070 | May 25, 2018 | DS U-1053 | | | |
| | | 7745466 | Oct 13, 2018 | DP U-1053 | | | |
| | | 8557285 | May 31, 2022 | DP | | | |
| | | 8852636 | May 31, 2022 | DP U-1052 | | | |
| | | 8858996 | May 31, 2022 | DP U-1052 | | | |
| | | 8945621 | Oct 17, 2031 | U-1661 | | | |
| | | 9161920 | May 31, 2022 | U-1760 | | | |
| | | 9198888 | May 31, 2022 | U-1781 | | | |
| | | 9220698 | Mar 10, 2031 | U-1781 | | | |
| | | 9345695 | May 31, 2022 | DP | | | |
| | | 9393208 | Sep 03, 2029 | U-1781 | | | |
| | | 9707181 | May 31, 2022 | DP | | | |
| ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO | | | | | | | |
| N 022511 | 002 | 6369085 | May 25, 2018 | DS DP U-1053 | | NPP | Jul 06, 2020 |
| | | 6926907 | Feb 28, 2023 | DP U-1052 | | | |
| | | 7411070 | May 25, 2018 | DS U-1053 | | | |
| | | 7745466 | Oct 13, 2018 | DP U-1053 | | | |
| | | 8557285 | May 31, 2022 | DP | | | |
| | | 8852636 | May 31, 2022 | DP U-1052 | | | |
| | | 8858996 | May 31, 2022 | DP U-1052 | | | |
| | | 8945621 | Oct 17, 2031 | U-1661 | | | |
| | | 9161920 | May 31, 2022 | U-1760 | | | |
| | | 9198888 | May 31, 2022 | U-1781 | | | |
| | | 9345695 | May 31, 2022 | DP | | | |
| | | 9393208 | Sep 03, 2029 | U-1781 | | | |
| | | 9707181 | May 31, 2022 | DP | | | |
| ESTRADIOL - VAGIFEM | | | | | | | |
| N 020908 | 002 | 5860946 | Jul 01, 2017 | DP | | | |
| | | 7018992 | Sep 17, 2022 | U-1023 | | | |
| ESTRADIOL - MENOSTAR | | | | | | | |
| N 021674 | 001 | 5891868 | Nov 21, 2017 | DP U-594 | | | |
| | | 6692763 | Nov 21, 2017 | DP U-594 | | | |
| ESTRADIOL - ELESTRIN | | | | | | | |
| N 021813 | 001 | 7198801 | Jun 25, 2022 | DP | | | |
| | | 7470433 | Aug 03, 2021 | DP | | | |
| ESTRADIOL - EVAMIST | | | | | | | |
| N 022014 | 001 | 6978945 | Jul 31, 2022 | DP | | | |
| ESTRADIOL - MINIVELLE | | | | | | | |
| N 203752 | 001 | 6841716 | Apr 27, 2020 | DP | | | |
| | | 8231906 | Jul 04, 2030 | DS DP | | | |
| | | 9730900 | Jul 10, 2028 | U-2086 | | | |
| | | 9833419 | Jul 10, 2028 | DP | | | |
| ESTRADIOL - MINIVELLE | | | | | | | |
| N 203752 | 002 | 6841716 | Apr 27, 2020 | DP | | | |
| | | 8231906 | Jul 04, 2030 | DS DP | | | |
| | | 9730900 | Jul 10, 2028 | U-2086 | | | |
| | | 9833419 | Jul 10, 2028 | DP | | | |
| ESTRADIOL - MINIVELLE | | | | | | | |
| N 203752 | 003 | 6841716 | Apr 27, 2020 | DP | | | |
| | | 8231906 | Jul 04, 2030 | DS DP | | | |
| | | 9730900 | Jul 10, 2028 | U-2086 | | | |
| | | 9833419 | Jul 10, 2028 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| ESTRADIOL - MINIVELLE | | | | | | | |
| N 203752 | 004 | 6841716 | Apr 27, 2020 | DP | | | |
| | | 8231906 | Jul 04, 2030 | DS DP | | | |
| | | 9730900 | Jul 10, 2028 | U-2086 | | | |
| | | 9833419 | Jul 10, 2028 | DP | | | |
| ESTRADIOL - MINIVELLE | | | | | | | |
| N 203752 | 005 | 6841716 | Apr 27, 2020 | DP | | | |
| | | 8231906 | Jul 04, 2030 | DS DP | | | |
| | | 9724310 | Jul 10, 2028 | DS DP | | | |
| | | 9730900 | Jul 10, 2028 | DP U-2086 | | | |
| | | 9833419 | Jul 10, 2028 | DP | | | |
| ESTRADIOL ACETATE - FEMTRACE | | | | | | | |
| N 021633 | 001 | 6962908 | Dec 21, 2021 | DP | | | |
| | | 7572779 | Oct 02, 2025 | U-904 | | | |
| | | 7799771 | Dec 21, 2021 | DP | | | |
| ESTRADIOL ACETATE - FEMTRACE | | | | | | | |
| N 021633 | 002 | 6962908 | Dec 21, 2021 | DP | | | |
| | | 7572779 | Oct 02, 2025 | U-904 | | | |
| | | 7799771 | Dec 21, 2021 | DP | | | |
| ESTRADIOL ACETATE - FEMTRACE | | | | | | | |
| N 021633 | 003 | 6962908 | Dec 21, 2021 | DP | | | |
| | | 7572779 | Oct 02, 2025 | U-904 | | | |
| | | 7799771 | Dec 21, 2021 | DP | | | |
| ESTRADIOL; ESTRADIOL; NORGESTIMATE - PREFEST | | | | | | | |
| N 021040 | 001 | 6747019 | Mar 20, 2020 | U-311 | | | |
| | | 7320970 | Mar 30, 2020 | DP U-844 | | | |
| ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA | | | | | | | |
| N 021443 | 001 | 6660726 | Mar 08, 2021 | DS DP U-904 | | | |
| | | 6660726 | Mar 08, 2021 | DS DP U-905 | | | |
| | | 6855703 | Feb 12, 2021 | DS DP U-904 | | | |
| | | 6855703 | Feb 12, 2021 | DS DP U-905 | | | |
| ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA | | | | | | | |
| N 021443 | 002 | 6660726 | Mar 08, 2021 | DS DP U-904 | | | |
| | | 6660726 | Mar 08, 2021 | DS DP U-905 | | | |
| | | 6855703 | Feb 12, 2021 | DS DP U-904 | | | |
| | | 6855703 | Feb 12, 2021 | DS DP U-905 | | | |
| ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA | | | | | | | |
| N 021443 | 003 | 6660726 | Mar 08, 2021 | DS DP U-904 | | | |
| | | 6660726 | Mar 08, 2021 | DS DP U-905 | | | |
| | | 6855703 | Feb 12, 2021 | DS DP U-904 | | | |
| | | 6855703 | Feb 12, 2021 | DS DP U-905 | | | |
| ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA | | | | | | | |
| N 021443 | 004 | 6660726 | Mar 08, 2021 | DS DP U-904 | | | |
| | | 6660726 | Mar 08, 2021 | DS DP U-905 | | | |
| | | 6855703 | Feb 12, 2021 | DS DP U-904 | | | |
| | | 6855703 | Feb 12, 2021 | DS DP U-905 | | | |
| ESTROGENS, CONJUGATED SYNTHETIC B - ENJUVIA | | | | | | | |
| N 021443 | 005 | 6660726 | Mar 08, 2021 | DS DP U-904 | | | |
| | | 6660726 | Mar 08, 2021 | DS DP U-905 | | | |
| | | 6855703 | Feb 12, 2021 | DS DP U-904 | | | |
| | | 6855703 | Feb 12, 2021 | DS DP U-905 | | | |
| ETELCALCETIDE - PARSABIV | | | | | | | |
| N 208325 | 001 | 8377880 | Jul 29, 2030 | DS DP | | NCE | Feb 07, 2022 |
| | | 8999932 | Jul 29, 2030 | DS DP U-2014 | | | |
| | | 9278995 | Jul 29, 2030 | DS | | | |
| | | 9701712 | Jul 29, 2030 | DS DP U-2014 | | | |
| | | 9820938 | Jun 27, 2034 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| ETELCALCETIDE - PARSABIV | | | | | | | |
| N 208325 | 002 | 8377880 | Jul 29, 2030 | DS DP | | NCE | Feb 07, 2022 |
| | | 8999932 | Jul 29, 2030 | DS DP U-2014 | | | |
| | | 9278995 | Jul 29, 2030 | DS | | | |
| | | 9701712 | Jul 29, 2030 | DS DP U-2014 | | | |
| | | 9820938 | Jun 27, 2034 | DP | | | |
| ETELCALCETIDE - PARSABIV | | | | | | | |
| N 208325 | 003 | 8377880 | Jul 29, 2030 | DS DP | | NCE | Feb 07, 2022 |
| | | 8999932 | Jul 29, 2030 | DS DP U-2014 | | | |
| | | 9278995 | Jul 29, 2030 | DS | | | |
| | | 9701712 | Jul 29, 2030 | DS DP U-2014 | | | |
| | | 9820938 | Jun 27, 2034 | DP | | | |
| ETEPLIRSEN - EXONDYS 51 | | | | | | | |
| N 206488 | 001 | 8486907 | Jun 28, 2025 | U-1904 | Y | NCE | Sep 19, 2021 |
| | | 9018368 | Jun 28, 2025 | DS DP | | ODE-122 | Sep 19, 2023 |
| | | 9243245 | Oct 27, 2028 | DS U-2097 | | | |
| | | 9243245 | Oct 27, 2028 | DS U-2098 | | | |
| | | 9416361 | May 04, 2021 | DS | | | |
| | | 9506058 | Mar 14, 2034 | U-1918 | | | |
| | | 9506058 | Mar 14, 2034 | U-1919 | | | |
| ETEPLIRSEN - EXONDYS 51 | | | | | | | |
| N 206488 | 002 | 8486907 | Jun 28, 2025 | U-1904 | Y | NCE | Sep 19, 2021 |
| | | 9018368 | Jun 28, 2025 | DS DP | | ODE-122 | Sep 19, 2023 |
| | | 9243245 | Oct 27, 2028 | DS U-2097 | | | |
| | | 9243245 | Oct 27, 2028 | DS U-2098 | | | |
| | | 9416361 | May 04, 2021 | DS | | | |
| | | 9506058 | Mar 14, 2034 | U-1918 | | | |
| | | 9506058 | Mar 14, 2034 | U-1919 | | | |
| ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; NORGESTIMATE; NORGESTIMATE; NORGESTIMATE - ORTHO TRI-CYCLEN LO | | | | | | | |
| N 021241 | 001 | 6214815 | Jun 09, 2019 | U-112 | | | |
| ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; LEVONORGESTREL - SEASONIQUE | | | | | | | |
| N 021840 | 001 | 7320969 | Jan 30, 2024 | U-828 | | | |
| | | 7615545 | Jun 15, 2023 | U-1 | | | |
| | | 7855190 | Dec 05, 2028 | U-1 | | | |
| | | 7858605 | Jun 23, 2023 | DP | | | |
| ETHINYL ESTRADIOL; ETHINYL ESTRADIOL; LEVONORGESTREL - LOSEASONIQUE | | | | | | | |
| N 022262 | 001 | 7615545 | Jun 15, 2023 | U-1 | | | |
| | | 7855190 | Dec 05, 2028 | U-1 | | | |
| | | 7858605 | Jun 23, 2023 | DP | | | |
| ETHINYL ESTRADIOL; ETONOGESTREL - NUVARING | | | | | | | |
| N 021187 | 001 | 5989581 | Apr 08, 2018 | | | | |
| ETHINYL ESTRADIOL; LEVONORGESTREL - FAYOSIM | | | | | | | |
| A 205943 | 001 | | | | | PC | Sep 30, 2017 |
| ETHINYL ESTRADIOL; LEVONORGESTREL - PREVEN EMERGENCY CONTRACEPTIVE KIT | | | | | | | |
| N 020946 | 001 | 6156742 | Dec 05, 2020 | U-374 | | | |
| ETHINYL ESTRADIOL; LEVONORGESTREL - LYBREL | | | | | | | |
| N 021864 | 001 | 6500814 | Sep 03, 2018 | U-1 | | | |
| ETHINYL ESTRADIOL; LEVONORGESTREL - QUARTETTE | | | | | | | |
| N 204061 | 001 | 8415332 | Mar 11, 2029 | DP | | | |
| | | 8450299 | Oct 07, 2025 | U-1 | | | |
| ETHINYL ESTRADIOL; NORETHINDRONE - FEMCON FE | | | | | | | |
| N 021490 | 001 | 6667050 | Apr 06, 2019 | DP U-1 | | | |
| ETHINYL ESTRADIOL; NORETHINDRONE - NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE | | | | | | | |
| N 022573 | 001 | 6667050 | Apr 06, 2019 | DP U-828 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MIBELAS 24 FE | | | | | | | |
| A 206287 | 001 | | | | | PC | Sep 11, 2017 |
| ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO LOESTRIN FE | | | | | | | |
| N 022501 | 001 | 7704984 | Feb 02, 2029 | U-1090 | | | |
| ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MINASTRIN 24 FE | | | | | | | |
| N 203667 | 001 | 6667050 | Apr 06, 2019 | DP U-1 | | | |
| ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - TAYTULLA | | | | | | | |
| N 204426 | 001 | 6652880 | Mar 29, 2020 | DP | | | |
| ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - LO MINASTRIN FE | | | | | | | |
| N 204654 | 001 | 6667050 | Apr 06, 2019 | DP U-1 | | | |
| | | 7704984 | Feb 02, 2029 | U-1 | | | |
| ETHIODIZED OIL - LIPIODOL | | | | | | | |
| N 009190 | 001 | | | | | ODE-64 | Apr 04, 2021 |
| ETONOGESTREL - IMPLANON | | | | | | | |
| N 021529 | 001 | 9757552 | Jul 28, 2030 | DP U-1 | | | |
| ETONOGESTREL - NEXPLANON | | | | | | | |
| N 021529 | 002 | 8722037 | Sep 28, 2027 | DP | | | |
| | | 8888745 | Aug 28, 2026 | DP | | | |
| | | 9757552 | Jul 28, 2030 | DP U-1 | | | |
| ETRAVIRINE - INTELENCE | | | | | | | |
| N 022187 | 001 | 6878717 | Nov 05, 2019 | U-1016 | | | |
| | | 6878717 | Nov 05, 2019 | U-1237 | | | |
| | | 6878717 | Nov 05, 2019 | U-256 | | | |
| | | 7037917 | Dec 13, 2020 | DS DP U-1016 | | | |
| | | 7037917 | Dec 13, 2020 | DS DP U-1237 | | | |
| | | 7037917 | Dec 13, 2020 | DS DP U-256 | | | |
| | | 7887845 | Mar 25, 2019 | DP | | | |
| | | 8003789 | Nov 01, 2019 | DS DP | | | |
| ETRAVIRINE - INTELENCE | | | | | | | |
| N 022187 | 002 | 6878717 | Nov 05, 2019 | U-1016 | | | |
| | | 6878717 | Nov 05, 2019 | U-1237 | | | |
| | | 6878717 | Nov 05, 2019 | U-256 | | | |
| | | 7037917 | Dec 13, 2020 | DS DP U-1016 | | | |
| | | 7037917 | Dec 13, 2020 | DS DP U-1237 | | | |
| | | 7037917 | Dec 13, 2020 | DS DP U-256 | | | |
| | | 7887845 | Mar 25, 2019 | DP | | | |
| | | 8003789 | Nov 01, 2019 | DS DP | | | |
| ETRAVIRINE - INTELENCE | | | | | | | |
| N 022187 | 003 | 6878717 | Nov 05, 2019 | U-1016 | | | |
| | | 6878717 | Nov 05, 2019 | U-1237 | | | |
| | | 6878717 | Nov 05, 2019 | U-256 | | | |
| | | 7037917 | Dec 13, 2020 | DS DP U-1237 | | | |
| | | 7887845 | Mar 25, 2019 | DP | | | |
| | | 8003789 | Nov 01, 2019 | DS DP | | | |
| EVEROLIMUS - ZORTRESS | | | | | | | |
| N 021560 | 001 | 5665772 | Sep 09, 2019 | DS DP U-1049 | | | |
| | | 5665772 | Sep 09, 2019 | DS DP U-1365 | | | |
| | | 5665772*PED | Mar 09, 2020 | | | | |
| | | 6239124 | Jul 29, 2017 | U-1049 | | | |
| | | 6239124*PED | Jan 29, 2018 | | | | |
| | | 6455518 | Jul 29, 2017 | U-1049 | | | |
| | | 6455518 | Jul 29, 2017 | U-1365 | | | |
| | | 6455518*PED | Jan 29, 2018 | | | | |
| EVEROLIMUS - ZORTRESS | | | | | | | |
| N 021560 | 002 | 5665772 | Sep 09, 2019 | DS DP U-1049 | | | |
| | | 5665772 | Sep 09, 2019 | DS DP U-1365 | | | |
| | | 5665772*PED | Mar 09, 2020 | | | | |
| | | 6239124 | Jul 29, 2017 | U-1049 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| EVEROLIMUS - ZORTRESS | | | | | | | |
| N 021560 | 002 | 6239124*PED | Jan 29, 2018 | | | | |
| | | 6455518 | Jul 29, 2017 | U-1049 | | | |
| | | 6455518 | Jul 29, 2017 | U-1365 | | | |
| | | 6455518*PED | Jan 29, 2018 | | | | |
| EVEROLIMUS - ZORTRESS | | | | | | | |
| N 021560 | 003 | 5665772 | Sep 09, 2019 | DS DP U-1049 | | | |
| | | 5665772 | Sep 09, 2019 | DS DP U-1365 | | | |
| | | 5665772*PED | Mar 09, 2020 | | | | |
| | | 6239124 | Jul 29, 2017 | U-1049 | | | |
| | | 6239124*PED | Jan 29, 2018 | | | | |
| | | 6455518 | Jul 29, 2017 | U-1049 | | | |
| | | 6455518 | Jul 29, 2017 | U-1365 | | | |
| | | 6455518*PED | Jan 29, 2018 | | | | |
| EVEROLIMUS - AFINITOR | | | | | | | |
| N 022334 | 001 | 5665772 | Sep 09, 2019 | DS DP | | I-724 | Feb 26, 2019 |
| | | 7297703 | Dec 06, 2019 | DP | | ODE-108 | Feb 26, 2023 |
| | | 7741338 | Dec 06, 2019 | DP | | ODE-11 | May 05, 2018 |
| | | 8410131 | Nov 01, 2025 | U-1368 | | ODE-24 | Apr 26, 2019 |
| | | 8410131*PED | May 01, 2026 | | | ODE-4 | Oct 29, 2017 |
| | | 8436010 | Feb 22, 2022 | U-1396 | | PED | Apr 29, 2018 |
| | | 8436010*PED | Aug 22, 2022 | | | PED | Nov 05, 2018 |
| | | 8778962 | Feb 18, 2022 | U-1541 | | PED | Oct 26, 2019 |
| | | 8778962*PED | Aug 18, 2022 | | | | |
| | | 9006224 | Jul 01, 2028 | U-1681 | | | |
| EVEROLIMUS - AFINITOR | | | | | | | |
| N 022334 | 002 | 5665772 | Sep 09, 2019 | DS DP | | I-724 | Feb 26, 2019 |
| | | 7297703 | Dec 06, 2019 | DP | | ODE-108 | Feb 26, 2023 |
| | | 7741338 | Dec 06, 2019 | DP | | ODE-11 | May 05, 2018 |
| | | 8410131 | Nov 01, 2025 | U-1368 | | ODE-24 | Apr 26, 2019 |
| | | 8410131*PED | May 01, 2026 | | | ODE-4 | Oct 29, 2017 |
| | | 8436010 | Feb 22, 2022 | U-1396 | | PED | Apr 29, 2018 |
| | | 8436010*PED | Aug 22, 2022 | | | PED | Nov 05, 2018 |
| | | 8778962 | Feb 18, 2022 | U-1541 | | PED | Oct 26, 2019 |
| | | 8778962*PED | Aug 18, 2022 | | | | |
| | | 9006224 | Jul 01, 2028 | U-1681 | | | |
| EVEROLIMUS - AFINITOR | | | | | | | |
| N 022334 | 003 | 5665772 | Sep 09, 2019 | DS DP | | I-724 | Feb 26, 2019 |
| | | 7297703 | Dec 06, 2019 | DP | | ODE-108 | Feb 26, 2023 |
| | | 7741338 | Dec 06, 2019 | DP | | ODE-11 | May 05, 2018 |
| | | 8410131 | Nov 01, 2025 | U-1368 | | ODE-24 | Apr 26, 2019 |
| | | 8410131*PED | May 01, 2026 | | | ODE-4 | Oct 29, 2017 |
| | | 8436010 | Feb 22, 2022 | U-1396 | | PED | Apr 29, 2018 |
| | | 8436010*PED | Aug 22, 2022 | | | PED | Nov 05, 2018 |
| | | 8778962 | Feb 18, 2022 | U-1541 | | PED | Oct 26, 2019 |
| | | 8778962*PED | Aug 18, 2022 | | | | |
| | | 9006224 | Jul 01, 2028 | U-1681 | | | |
| EVEROLIMUS - AFINITOR | | | | | | | |
| N 022334 | 004 | 5665772 | Sep 09, 2019 | DS DP | | I-724 | Feb 26, 2019 |
| | | 7297703 | Dec 06, 2019 | DP | | ODE-108 | Feb 26, 2023 |
| | | 7741338 | Dec 06, 2019 | DP | | ODE-11 | May 05, 2018 |
| | | 8410131 | Nov 01, 2025 | U-1368 | | ODE-24 | Apr 26, 2019 |
| | | 8410131*PED | May 01, 2026 | | | ODE-4 | Oct 29, 2017 |
| | | 8436010 | Feb 22, 2022 | U-1396 | | PED | Apr 29, 2018 |
| | | 8436010*PED | Aug 22, 2022 | | | PED | Nov 05, 2018 |
| | | 8778962 | Feb 18, 2022 | U-1541 | | PED | Oct 26, 2019 |
| | | 8778962*PED | Aug 18, 2022 | | | | |
| | | 9006224 | Jul 01, 2028 | U-1681 | | | |
| EVEROLIMUS - AFINITOR DISPERZ | | | | | | | |
| N 203985 | 001 | 5665772 | Sep 09, 2019 | DS DP | | ODE-4 | Oct 29, 2017 |
| | | 7297703 | Dec 06, 2019 | DP | | PED | Apr 29, 2018 |
| | | 8617598 | Sep 27, 2022 | DP | | | |
| | | 8617598*PED | Mar 27, 2023 | | | | |
| | | 8778962 | Feb 18, 2022 | U-1541 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| EVEROLIMUS - AFINITOR DISPERZ | | | | | | | |
| N 203985 | 001 | 8778962*PED | Aug 18, 2022 | | | | |
| EVEROLIMUS - AFINITOR DISPERZ | | | | | | | |
| N 203985 | 002 | 5665772 | Sep 09, 2019 | DS DP | | ODE-4 | Oct 29, 2017 |
| | | 7297703 | Dec 06, 2019 | DP | | PED | Apr 29, 2018 |
| | | 8617598 | Sep 27, 2022 | DP | | | |
| | | 8617598*PED | Mar 27, 2023 | | | | |
| | | 8778962 | Feb 18, 2022 | U-1541 | | | |
| | | 8778962*PED | Aug 18, 2022 | | | | |
| EVEROLIMUS - AFINITOR DISPERZ | | | | | | | |
| N 203985 | 003 | 5665772 | Sep 09, 2019 | DS DP | | ODE-4 | Oct 29, 2017 |
| | | 7297703 | Dec 06, 2019 | DP | | PED | Apr 29, 2018 |
| | | 8617598 | Sep 27, 2022 | DP | | | |
| | | 8617598*PED | Mar 27, 2023 | | | | |
| | | 8778962 | Feb 18, 2022 | U-1541 | | | |
| | | 8778962*PED | Aug 18, 2022 | | | | |
| EXENATIDE - BYDUREON BCISE | | | | | | | |
| N 209210 | 001 | 6479065 | Aug 10, 2020 | DP | | NP | Oct 20, 2020 |
| | | 6667061 | May 25, 2020 | DP | | | |
| | | 6824822 | Oct 09, 2022 | DP | | | |
| | | 6872700 | Jan 14, 2020 | U-654 | | | |
| | | 6956026 | Jan 07, 2018 | U-687 | | | |
| | | 7223440 | Aug 31, 2021 | DP | | | |
| | | 7456254 | Jun 30, 2025 | DP U-1223 | | | |
| | | 7563871 | Apr 15, 2024 | DP | | | |
| | | 7612176 | Apr 13, 2025 | DP U-1223 | | | |
| | | 7741269 | Jan 07, 2018 | U-1224 | | | |
| | | 8329648 | Aug 18, 2026 | U-1313 | | | |
| | | 8329648 | Aug 18, 2026 | U-2154 | | | |
| | | 8329648 | Aug 18, 2026 | U-2155 | | | |
| | | 8329648 | Aug 18, 2026 | U-2156 | | | |
| | | 8431685 | Apr 13, 2025 | DP U-412 | | | |
| | | 8461105 | Apr 13, 2025 | DP U-412 | | | |
| | | 8895033 | Oct 04, 2030 | DP U-1313 | | | |
| | | 8895033 | Oct 04, 2030 | DP U-2157 | | | |
| | | 8895033 | Oct 04, 2030 | DP U-2158 | | | |
| | | 8906851 | Aug 18, 2026 | U-1313 | | | |
| | | 9238076 | Apr 15, 2024 | DP U-412 | | | |
| EXENATIDE SYNTHETIC - BYETTA | | | | | | | |
| N 021773 | 001 | 6872700 | Jan 14, 2020 | U-654 | | M-148 | Nov 24, 2017 |
| | | 6902744 | Jan 14, 2020 | DP | | | |
| | | 6956026 | Jan 07, 2018 | U-1074 | | | |
| | | 6956026 | Jan 07, 2018 | U-1623 | | | |
| | | 6956026 | Jan 07, 2018 | U-687 | | | |
| | | 7297761 | Oct 15, 2017 | DP | | | |
| | | 7521423 | Oct 15, 2017 | DP | | | |
| | | 7741269 | Jan 07, 2018 | U-1074 | | | |
| | | 7741269 | Jan 07, 2018 | U-1108 | | | |
| | | 7741269 | Jan 07, 2018 | U-653 | | | |
| EXENATIDE SYNTHETIC - BYETTA | | | | | | | |
| N 021773 | 002 | 6872700 | Jan 14, 2020 | U-654 | | M-148 | Nov 24, 2017 |
| | | 6902744 | Jan 14, 2020 | DP | | | |
| | | 6956026 | Jan 07, 2018 | U-1074 | | | |
| | | 6956026 | Jan 07, 2018 | U-1623 | | | |
| | | 6956026 | Jan 07, 2018 | U-687 | | | |
| | | 7297761 | Oct 15, 2017 | DP | | | |
| | | 7521423 | Oct 15, 2017 | DP | | | |
| | | 7741269 | Jan 07, 2018 | U-1074 | | | |
| | | 7741269 | Jan 07, 2018 | U-1108 | | | |
| | | 7741269 | Jan 07, 2018 | U-653 | | | |
| EXENATIDE SYNTHETIC - BYDUREON | | | | | | | |
| N 022200 | 001 | 6414126 | Oct 04, 2020 | DS DP U-2139 | | M-162 | Sep 24, 2018 |
| | | 6414126 | Oct 04, 2020 | DS DP U-493 | | M-212 | Oct 20, 2020 |
| | | 6479065 | Aug 10, 2020 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| EXENATIDE SYNTHETIC - BYDUREON | | | | | | |
| N 022200 001 | 6495164 | May 25, 2020 | DP | | | |
| | 6515117 | Oct 04, 2020 | DS DP U-2139 | | | |
| | 6515117 | Oct 04, 2020 | DS DP U-493 | | | |
| | 6667061 | May 25, 2020 | DP | | | |
| | 6824822 | Oct 09, 2022 | DP | | | |
| | 6872700 | Jan 14, 2020 | U-654 | | | |
| | 6936590 | Oct 04, 2020 | U-493 | | | |
| | 6956026 | Jan 07, 2018 | U-687 | | | |
| | 7223440 | Aug 31, 2021 | DP | | | |
| | 7456254 | Jun 30, 2025 | DP U-1223 | | | |
| | 7563871 | Apr 15, 2024 | DP | | | |
| | 7612176 | Apr 13, 2025 | DP U-1223 | | | |
| | 7741269 | Jan 07, 2018 | U-1224 | | | |
| | 7851502 | Aug 19, 2028 | DP | | | |
| | 7919598 | Dec 16, 2029 | DS | | | |
| | 8221786 | Mar 21, 2028 | DP | | | |
| | 8329648 | Aug 18, 2026 | U-1313 | | | |
| | 8361972 | Mar 21, 2028 | U-2139 | | | |
| | 8361972 | Mar 21, 2028 | U-493 | | | |
| | 8431685 | Apr 13, 2025 | DP U-412 | | | |
| | 8461105 | Apr 13, 2025 | DP U-412 | | | |
| | 8501698 | Jun 20, 2027 | DP U-493 | | | |
| | 8685934 | May 26, 2030 | U-1522 | | | |
| | 8716251 | Mar 21, 2028 | DP | | | |
| | 8906851 | Aug 18, 2026 | U-1313 | | | |
| | 9198925 | Oct 04, 2020 | U-2139 | | | |
| | 9198925 | Oct 04, 2020 | U-493 | | | |
| | 9238076 | Apr 15, 2024 | DP U-412 | | | |
| EXENATIDE SYNTHETIC - BYDUREON PEN | | | | | | |
| N 022200 002 | 6414126 | Oct 04, 2020 | DS DP U-2139 | | | |
| | 6414126 | Oct 04, 2020 | DS DP U-493 | | | |
| | 6479065 | Aug 10, 2020 | DP | | | |
| | 6495164 | May 25, 2020 | DP | | | |
| | 6515117 | Oct 04, 2020 | DS DP U-2139 | | | |
| | 6515117 | Oct 04, 2020 | DS DP U-493 | | | |
| | 6667061 | May 25, 2020 | DP | | | |
| | 6824822 | Oct 09, 2022 | DP | | | |
| | 6872700 | Jan 14, 2020 | U-654 | | | |
| | 6936590 | Oct 04, 2020 | U-493 | | | |
| | 6956026 | Jan 07, 2018 | U-687 | | | |
| | 7223440 | Aug 31, 2021 | DP | | | |
| | 7456254 | Jun 30, 2025 | DP U-1223 | | | |
| | 7563871 | Apr 15, 2024 | DP | | | |
| | 7612176 | Apr 13, 2025 | DP U-1223 | | | |
| | 7741269 | Jan 07, 2018 | U-1224 | | | |
| | 7851502 | Aug 19, 2028 | DP | | | |
| | 7919598 | Dec 16, 2029 | DS | | | |
| | 8216180 | Jan 12, 2028 | DP | | | |
| | 8221786 | Mar 21, 2028 | DP | | | |
| | 8329648 | Aug 18, 2026 | U-1313 | | | |
| | 8361972 | Mar 21, 2028 | U-2139 | | | |
| | 8361972 | Mar 21, 2028 | U-493 | | | |
| | 8431685 | Apr 13, 2025 | DP U-412 | | | |
| | 8439864 | Mar 25, 2028 | DP | | | |
| | 8461105 | Apr 13, 2025 | DP U-412 | | | |
| | 8501698 | Jun 20, 2027 | DP U-493 | | | |
| | 8685934 | May 26, 2030 | U-1522 | | | |
| | 8690837 | May 19, 2029 | DP | | | |
| | 8716251 | Mar 21, 2028 | DP | | | |
| | 8721615 | Jan 18, 2030 | DP | | | |
| | 8758292 | Nov 12, 2027 | DP | | | |
| | 8827963 | Feb 04, 2029 | DP | | | |
| | 8906851 | Aug 18, 2026 | U-1313 | | | |
| | 8998876 | Jan 07, 2030 | DP | | | |
| | 9198925 | Oct 04, 2020 | U-2139 | | | |
| | 9198925 | Oct 04, 2020 | U-493 | | | |
| | 9238076 | Apr 15, 2024 | DP U-412 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| EXENATIDE SYNTHETIC - BYDUREON PEN | | | | | | | |
| N 022200 | 002 | 9320853 | Mar 25, 2028 | DP | | | |
| EZETIMIBE - ZETIA | | | | | | | |
| N 021445 | 001 | 7030106 | Jan 25, 2022 | DP | | | |
| | | 7612058 | Oct 30, 2025 | U-1027 | | | |
| | | 7612058 | Oct 30, 2025 | U-1173 | | | |
| | | 7612058*PED | Apr 30, 2026 | | | | |
| FAMOTIDINE - PEPCID AC | | | | | | | |
| N 020801 | 002 | 6814978 | Aug 26, 2021 | DP | | | |
| FAMOTIDINE - FLUXID | | | | | | | |
| N 021712 | 001 | 6024981 | Apr 09, 2018 | DP | | | |
| | | 6221392 | Apr 09, 2018 | DP | | | |
| FAMOTIDINE - FLUXID | | | | | | | |
| N 021712 | 002 | 6024981 | Apr 09, 2018 | DP | | | |
| | | 6221392 | Apr 09, 2018 | DP | | | |
| FAMOTIDINE; IBUPROFEN - DUEXIS | | | | | | | |
| N 022519 | 001 | 8067033 | Jul 18, 2026 | DP | | | |
| | | 8067451 | Jul 18, 2026 | DP U-1196 | | | |
| | | 8309127 | Jul 18, 2026 | DP | | | |
| | | 8318202 | Jul 18, 2026 | DP | | | |
| | | 8449910 | Jul 18, 2026 | DP | | | |
| | | 8501228 | Jul 18, 2026 | U-1196 | | | |
| FEBUXOSTAT - ULORIC | | | | | | | |
| N 021856 | 001 | 5614520 | Mar 25, 2019 | DS DP U-954 | | M-205 | Aug 15, 2020 |
| | | 6225474 | Jun 18, 2019 | DS | | | |
| | | 7361676 | Mar 08, 2024 | DP | | | |
| | | 8372872 | Sep 08, 2031 | U-1346 | | | |
| | | 9107912 | Sep 08, 2031 | U-1346 | | | |
| FEBUXOSTAT - ULORIC | | | | | | | |
| N 021856 | 002 | 5614520 | Mar 25, 2019 | DS DP U-954 | | M-205 | Aug 15, 2020 |
| | | 6225474 | Jun 18, 2019 | DS | | | |
| | | 7361676 | Mar 08, 2024 | DP | | | |
| | | 8372872 | Sep 08, 2031 | U-1346 | | | |
| | | 9107912 | Sep 08, 2031 | U-1346 | | | |
| FENOFIBRATE - TRICOR | | | | | | | |
| N 021203 | 001 | 6074670 | Jan 09, 2018 | | | | |
| | | 6277405 | Jan 09, 2018 | | | | |
| | | 6589552 | Jan 09, 2018 | | | | |
| | | 6652881 | Jan 09, 2018 | DP | | | |
| | | 7037529 | Jan 09, 2018 | DP | | | |
| | | 7041319 | Jan 09, 2018 | DP | | | |
| FENOFIBRATE - TRICOR | | | | | | | |
| N 021203 | 003 | 6074670 | Jan 09, 2018 | | | | |
| | | 6277405 | Jan 09, 2018 | | | | |
| | | 6589552 | Jan 09, 2018 | | | | |
| | | 6652881 | Jan 09, 2018 | DP | | | |
| | | 7037529 | Jan 09, 2018 | DP | | | |
| | | 7041319 | Jan 09, 2018 | DP | | | |
| FENOFIBRATE - TRIGLIDE | | | | | | | |
| N 021350 | 001 | 6696084 | Sep 11, 2021 | DS DP U-680 | | | |
| FENOFIBRATE - TRIGLIDE | | | | | | | |
| N 021350 | 002 | 6696084 | Sep 11, 2021 | DS DP U-680 | | | |
| FENOFIBRATE - TRICOR | | | | | | | |
| N 021656 | 001 | 6277405 | Jan 09, 2018 | DS | | | |
| | | 6375986 | Sep 21, 2020 | DP U-615 | | | |
| | | 6652881 | Jan 09, 2018 | DS | | | |
| | | 7037529 | Jan 09, 2018 | DP | | | |
| | | 7041319 | Jan 09, 2018 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| FENOFIBRATE - TRICOR | | | | | | |
| N 021656 001 | 7276249 | Feb 21, 2023 | DP | | | |
| | 7320802 | Feb 21, 2023 | U-847 | | | |
| FENOFIBRATE - TRICOR | | | | | | |
| N 021656 002 | 6277405 | Jan 09, 2018 | DS | | | |
| | 6375986 | Sep 21, 2020 | DP U-615 | | | |
| | 6652881 | Jan 09, 2018 | DS | | | |
| | 7037529 | Jan 09, 2018 | DP | | | |
| | 7041319 | Jan 09, 2018 | DP | | | |
| | 7276249 | Feb 21, 2023 | DP | | | |
| | 7320802 | Feb 21, 2023 | U-847 | | | |
| FENOFIBRATE - ANTARA (MICRONIZED) | | | | | | |
| N 021695 001 | 7101574 | Aug 20, 2020 | DS DP | | | |
| | 7863331 | Aug 08, 2020 | U-1106 | | | |
| | 7863331 | Aug 08, 2020 | U-1107 | | | |
| FENOFIBRATE - ANTARA (MICRONIZED) | | | | | | |
| N 021695 003 | 7101574 | Aug 20, 2020 | DS DP | | | |
| | 7863331 | Aug 08, 2020 | U-1106 | | | |
| | 7863331 | Aug 08, 2020 | U-1107 | | | |
| FENOFIBRATE - ANTARA (MICRONIZED) | | | | | | |
| N 021695 004 | 8026281 | Apr 22, 2025 | U-1447 | | | |
| | 8026281 | Apr 22, 2025 | U-1448 | | | |
| FENOFIBRATE - ANTARA (MICRONIZED) | | | | | | |
| N 021695 005 | 8026281 | Apr 22, 2025 | U-1447 | | | |
| | 8026281 | Apr 22, 2025 | U-1448 | | | |
| | 9314447 | May 31, 2033 | DP U-1447 | | | |
| | 9314447 | May 31, 2033 | DP U-1448 | | | |
| FENOFIBRATE - FENOGLIDE | | | | | | |
| N 022118 001 | 7658944 | Dec 09, 2024 | DP | | | |
| | 8124125 | Oct 01, 2024 | DP U-1234 | | | |
| | 8481078 | Oct 01, 2024 | DP U-1416 | | | |
| | 9173847 | Oct 01, 2024 | DP | | | |
| FENOFIBRATE - FENOGLIDE | | | | | | |
| N 022118 002 | 7658944 | Dec 09, 2024 | DP | | | |
| | 8124125 | Oct 01, 2024 | DP U-1234 | | | |
| | 8481078 | Oct 01, 2024 | DP U-1416 | | | |
| | 9173847 | Oct 01, 2024 | DP | | | |
| FENOFIBRIC ACID - FIBRICOR | | | | | | |
| N 022418 001 | 7569612 | Aug 20, 2027 | U-1000 | | | |
| | 7741373 | Aug 20, 2027 | U-1059 | | | |
| | 7741374 | Aug 20, 2027 | U-1060 | | | |
| | 7741374 | Aug 20, 2027 | U-1061 | | | |
| | 7915247 | Aug 20, 2027 | U-1000 | | | |
| | 7915247 | Aug 20, 2027 | U-1059 | | | |
| | 7915247 | Aug 20, 2027 | U-1061 | | | |
| FENOFIBRIC ACID - FIBRICOR | | | | | | |
| N 022418 002 | 7569612 | Aug 20, 2027 | U-1000 | | | |
| | 7741373 | Aug 20, 2027 | U-1059 | | | |
| | 7741374 | Aug 20, 2027 | U-1060 | | | |
| | 7741374 | Aug 20, 2027 | U-1061 | | | |
| | 7915247 | Aug 20, 2027 | U-1000 | | | |
| | 7915247 | Aug 20, 2027 | U-1059 | | | |
| | 7915247 | Aug 20, 2027 | U-1061 | | | |
| FENTANYL - SUBSYS | | | | | | |
| N 202788 001 | 8486972 | Apr 27, 2030 | DP | | | |
| | 8486973 | Apr 27, 2030 | U-55 | | | |
| | 8835459 | Jan 25, 2027 | DP | | | |
| | 8835460 | Jan 25, 2027 | DP U-55 | | | |
| | 9241935 | Jan 25, 2027 | DP | | | |
| | 9289387 | Jan 25, 2027 | DP U-55 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| FENTANYL - SUBSYS | | | | | | | |
| N 202788 | 001 | 9642797 | Jan 25, 2027 | DP U-55 | | | |
| | | 9642844 | Jan 25, 2027 | DP | | | |
| FENTANYL - SUBSYS | | | | | | | |
| N 202788 | 002 | 8486972 | Apr 27, 2030 | DP | | | |
| | | 8486973 | Apr 27, 2030 | U-55 | | | |
| | | 8835460 | Jan 25, 2027 | DP U-55 | | | |
| | | 9241935 | Jan 25, 2027 | DP | | | |
| | | 9289387 | Jan 25, 2027 | DP U-55 | | | |
| | | 9642797 | Jan 25, 2027 | DP U-55 | | | |
| | | 9642844 | Jan 25, 2027 | DP | | | |
| FENTANYL - SUBSYS | | | | | | | |
| N 202788 | 003 | 8486972 | Apr 27, 2030 | DP | | | |
| | | 8486973 | Apr 27, 2030 | U-55 | | | |
| | | 8835459 | Jan 25, 2027 | DP | | | |
| | | 8835460 | Jan 25, 2027 | DP U-55 | | | |
| | | 9241935 | Jan 25, 2027 | DP | | | |
| | | 9289387 | Jan 25, 2027 | DP U-55 | | | |
| | | 9642797 | Jan 25, 2027 | DP U-55 | | | |
| | | 9642844 | Jan 25, 2027 | DP | | | |
| FENTANYL - SUBSYS | | | | | | | |
| N 202788 | 004 | 8486972 | Apr 27, 2030 | DP | | | |
| | | 8486973 | Apr 27, 2030 | U-55 | | | |
| | | 8835459 | Jan 25, 2027 | DP | | | |
| | | 8835460 | Jan 25, 2027 | DP U-55 | | | |
| | | 9241935 | Jan 25, 2027 | DP | | | |
| | | 9289387 | Jan 25, 2027 | DP U-55 | | | |
| | | 9642797 | Jan 25, 2027 | DP U-55 | | | |
| | | 9642844 | Jan 25, 2027 | DP | | | |
| FENTANYL - SUBSYS | | | | | | | |
| N 202788 | 005 | 8486972 | Apr 27, 2030 | DP | | | |
| | | 8486973 | Apr 27, 2030 | U-55 | | | |
| | | 8835460 | Jan 25, 2027 | DP U-55 | | | |
| | | 9241935 | Jan 25, 2027 | DP | | | |
| | | 9289387 | Jan 25, 2027 | DP U-55 | | | |
| | | 9642797 | Jan 25, 2027 | DP U-55 | | | |
| | | 9642844 | Jan 25, 2027 | DP | | | |
| FENTANYL - SUBSYS | | | | | | | |
| N 202788 | 006 | 8486972 | Apr 27, 2030 | DP | | | |
| | | 8486973 | Apr 27, 2030 | U-55 | | | |
| | | 8835459 | Jan 25, 2027 | DP | | | |
| | | 8835460 | Jan 25, 2027 | DP U-55 | | | |
| | | 9241935 | Jan 25, 2027 | DP | | | |
| | | 9289387 | Jan 25, 2027 | DP U-55 | | | |
| | | 9642797 | Jan 25, 2027 | DP U-55 | | | |
| | | 9642844 | Jan 25, 2027 | DP | | | |
| FENTANYL - SUBSYS | | | | | | | |
| N 202788 | 007 | 8486972 | Apr 27, 2030 | DP | | | |
| | | 8486973 | Apr 27, 2030 | U-55 | | | |
| | | 8835459 | Jan 25, 2027 | DP | | | |
| | | 8835460 | Jan 25, 2027 | DP U-55 | | | |
| | | 9241935 | Jan 25, 2027 | DP | | | |
| | | 9289387 | Jan 25, 2027 | DP U-55 | | | |
| | | 9642797 | Jan 25, 2027 | DP U-55 | | | |
| | | 9642844 | Jan 25, 2027 | DP | | | |
| FENTANYL CITRATE - FENTORA | | | | | | | |
| N 021947 | 001 | 6200604 | Mar 26, 2019 | U-767 | | | |
| | | 6974590 | Mar 26, 2019 | U-767 | | | |
| | | 7862832 | Jun 15, 2028 | DP | | | |
| | | 7862833 | Jun 15, 2028 | DP | | | |
| | | 8092832 | Dec 30, 2024 | DP | | | |
| | | 8728441 | Mar 26, 2019 | U-1514 | | | |
| | | 8753611 | Mar 26, 2019 | U-1514 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| FENTANYL CITRATE - FENTORA | | | | | | |
| N 021947 001 | 8765100 | Mar 26, 2019 | DP | | | |
| FENTANYL CITRATE - FENTORA | | | | | | |
| N 021947 002 | 6200604 | Mar 26, 2019 | U-767 | | | |
| | 6974590 | Mar 26, 2019 | U-767 | | | |
| | 7862832 | Jun 15, 2028 | DP | | | |
| | 7862833 | Jun 15, 2028 | DP | | | |
| | 8092832 | Dec 30, 2024 | DP | | | |
| | 8119158 | Dec 30, 2024 | DP | | | |
| | 8728441 | Mar 26, 2019 | U-1514 | | | |
| | 8753611 | Mar 26, 2019 | U-1514 | | | |
| | 8765100 | Mar 26, 2019 | DP | | | |
| FENTANYL CITRATE - FENTORA | | | | | | |
| N 021947 003 | 6200604 | Mar 26, 2019 | U-767 | | | |
| | 6974590 | Mar 26, 2019 | U-767 | | | |
| | 7862832 | Jun 15, 2028 | DP | | | |
| | 7862833 | Jun 15, 2028 | DP | | | |
| | 8092832 | Dec 30, 2024 | DP | | | |
| | 8119158 | Dec 30, 2024 | DP | | | |
| | 8728441 | Mar 26, 2019 | U-1514 | | | |
| | 8753611 | Mar 26, 2019 | U-1514 | | | |
| | 8765100 | Mar 26, 2019 | DP | | | |
| FENTANYL CITRATE - FENTORA | | | | | | |
| N 021947 004 | 6200604 | Mar 26, 2019 | U-767 | | | |
| | 6974590 | Mar 26, 2019 | U-767 | | | |
| | 7862832 | Jun 15, 2028 | DP | | | |
| | 7862833 | Jun 15, 2028 | DP | | | |
| | 8092832 | Dec 30, 2024 | DP | | | |
| | 8119158 | Dec 30, 2024 | DP | | | |
| | 8728441 | Mar 26, 2019 | U-1514 | | | |
| | 8753611 | Mar 26, 2019 | U-1514 | | | |
| | 8765100 | Mar 26, 2019 | DP | | | |
| FENTANYL CITRATE - FENTORA | | | | | | |
| N 021947 005 | 6200604 | Mar 26, 2019 | U-767 | | | |
| | 6974590 | Mar 26, 2019 | U-767 | | | |
| | 7862832 | Jun 15, 2028 | DP | | | |
| | 7862833 | Jun 15, 2028 | DP | | | |
| | 8092832 | Dec 30, 2024 | DP | | | |
| | 8119158 | Dec 30, 2024 | DP | | | |
| | 8728441 | Mar 26, 2019 | U-1514 | | | |
| | 8753611 | Mar 26, 2019 | U-1514 | | | |
| | 8765100 | Mar 26, 2019 | DP | | | |
| FENTANYL CITRATE - FENTORA | | | | | | |
| N 021947 006 | 6200604 | Mar 26, 2019 | U-767 | | | |
| | 6974590 | Mar 26, 2019 | U-767 | | | |
| FENTANYL CITRATE - ONSOLIS | | | | | | |
| N 022266 001 | 7579019 | Jan 22, 2020 | U-767 | | | |
| | 9597288 | Jul 23, 2027 | DP U-767 | | | |
| FENTANYL CITRATE - ONSOLIS | | | | | | |
| N 022266 002 | 7579019 | Jan 22, 2020 | U-767 | | | |
| | 9597288 | Jul 23, 2027 | DP U-767 | | | |
| FENTANYL CITRATE - ONSOLIS | | | | | | |
| N 022266 003 | 7579019 | Jan 22, 2020 | U-767 | | | |
| | 9597288 | Jul 23, 2027 | DP U-767 | | | |
| FENTANYL CITRATE - ONSOLIS | | | | | | |
| N 022266 004 | 7579019 | Jan 22, 2020 | U-767 | | | |
| | 9597288 | Jul 23, 2027 | DP U-767 | | | |
| FENTANYL CITRATE - ONSOLIS | | | | | | |
| N 022266 005 | 7579019 | Jan 22, 2020 | U-767 | | | |
| | 9597288 | Jul 23, 2027 | DP U-767 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| FENTANYL CITRATE - ONSOLIS | | | | | | | |
| N 022266 | 005 | 7579019 | Jan 22, 2020 | U-767 | | | |
| | | 9597288 | Jul 23, 2027 | DP U-767 | | | |
| FENTANYL CITRATE - ABSTRAL | | | | | | | |
| N 022510 | 001 | 6759059 | Sep 24, 2019 | DP U-767 | | | |
| | | 6761910 | Sep 24, 2019 | DP U-767 | | | |
| | | 7910132 | Sep 24, 2019 | DP U-767 | | | |
| FENTANYL CITRATE - ABSTRAL | | | | | | | |
| N 022510 | 002 | 6759059 | Sep 24, 2019 | DP U-767 | | | |
| | | 6761910 | Sep 24, 2019 | DP U-767 | | | |
| | | 7910132 | Sep 24, 2019 | DP U-767 | | | |
| FENTANYL CITRATE - ABSTRAL | | | | | | | |
| N 022510 | 003 | 6759059 | Sep 24, 2019 | DP U-767 | | | |
| | | 6761910 | Sep 24, 2019 | DP U-767 | | | |
| | | 7910132 | Sep 24, 2019 | DP U-767 | | | |
| FENTANYL CITRATE - ABSTRAL | | | | | | | |
| N 022510 | 004 | 6759059 | Sep 24, 2019 | DP U-767 | | | |
| | | 6761910 | Sep 24, 2019 | DP U-767 | | | |
| | | 7910132 | Sep 24, 2019 | DP U-767 | | | |
| FENTANYL CITRATE - ABSTRAL | | | | | | | |
| N 022510 | 005 | 6759059 | Sep 24, 2019 | DP U-767 | | | |
| | | 6761910 | Sep 24, 2019 | DP U-767 | | | |
| | | 7910132 | Sep 24, 2019 | DP U-767 | | | |
| FENTANYL CITRATE - ABSTRAL | | | | | | | |
| N 022510 | 006 | 6759059 | Sep 24, 2019 | DP U-767 | | | |
| | | 6761910 | Sep 24, 2019 | DP U-767 | | | |
| | | 7910132 | Sep 24, 2019 | DP U-767 | | | |
| FENTANYL CITRATE - LAZANDA | | | | | | | |
| N 022569 | 001 | 6432440 | Apr 20, 2018 | DP U-1169 | | | |
| | | 8216604 | Oct 03, 2024 | U-767 | | | |
| | | 8889176 | Jan 16, 2024 | U-767 | | | |
| | | 9078814 | Jan 08, 2024 | DP | | | |
| | | 9731869 | Jan 26, 2032 | DP | | | |
| FENTANYL CITRATE - LAZANDA | | | | | | | |
| N 022569 | 002 | 6432440 | Apr 20, 2018 | DP U-1169 | | | |
| | | 8216604 | Oct 03, 2024 | U-767 | | | |
| | | 8889176 | Jan 16, 2024 | U-767 | | | |
| | | 9078814 | Jan 08, 2024 | DP | | | |
| | | 9731869 | Jan 26, 2032 | DP | | | |
| FENTANYL CITRATE - LAZANDA | | | | | | | |
| N 022569 | 003 | 9731869 | Jan 26, 2032 | DP | | | |
| FENTANYL HYDROCHLORIDE - IONSYS | | | | | | | |
| N 021338 | 001 | 6169920 | Jan 02, 2018 | DP U-736 | | | |
| | | 6181963 | Nov 02, 2019 | DP | | | |
| | | 6195582 | Jan 28, 2019 | DP U-736 | | | |
| | | 6881208 | Apr 19, 2022 | U-736 | | | |
| | | 6975902 | Apr 01, 2024 | DP | | | |
| | | 8301238 | Sep 30, 2031 | DP | | | |
| | | 8428708 | May 21, 2032 | U-736 | | | |
| | | 8428709 | Jun 11, 2032 | DP U-736 | | | |
| | | 8781571 | Mar 31, 2032 | DP U-736 | | | |
| | | 9095706 | Feb 03, 2033 | DP | | | |
| | | 9364656 | Sep 30, 2031 | U-736 | | | |
| | | 9731121 | Oct 17, 2031 | DP | | | |
| FERRIC CARBOXYMALTOSE - INJECTAFER | | | | | | | |
| N 203565 | 001 | 7612109 | Feb 05, 2024 | DS DP | | | |
| | | 7754702 | Feb 13, 2027 | DP U-1432 | | | |
| | | 8895612 | Jan 08, 2027 | DP U-1620 | | | |
| | | 9376505 | Oct 20, 2023 | DS DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| FERRIC CITRATE - AURYXIA | | | | | | | |
| N 205874 | 001 | 7767851 | Feb 18, 2024 | DS DP | | | |
| | | 8093423 | Apr 21, 2026 | | | U-1577 | |
| | | 8299298 | Feb 18, 2024 | DP | | | |
| | | 8338642 | Feb 18, 2024 | DS DP | | U-1577 | |
| | | 8609896 | Feb 18, 2024 | DP | | | |
| | | 8754257 | Feb 18, 2024 | DP | | | |
| | | 8754258 | Feb 18, 2024 | DP | | | |
| | | 8846976 | Feb 18, 2024 | | | U-1577 | |
| | | 8901349 | Feb 18, 2024 | | | U-1577 | |
| | | 9050316 | Feb 18, 2024 | | | U-1577 | |
| | | 9328133 | Feb 18, 2024 | DS DP | | U-1577 | |
| | | 9387191 | Jul 21, 2030 | DP | | | |
| | | 9757416 | Feb 18, 2024 | DS DP | | U-1577 | |
| FERRIC PYROPHOSPHATE CITRATE - TRIFERIC | | | | | | | |
| N 206317 | 001 | 7816404 | Apr 17, 2029 | DP | | U-1656 | |
| FERUMOXYTOL - FERAHEME | | | | | | | |
| N 022180 | 001 | 6599498 | Jun 30, 2023 | DS DP | | | |
| | | 7553479 | Mar 08, 2020 | DS DP | | | |
| | | 7871597 | Mar 08, 2020 | DS DP | | | |
| | | 8501158 | Mar 08, 2020 | | | U-1422 | |
| | | 8591864 | Mar 08, 2020 | DP | | | |
| | | 8926947 | Mar 08, 2020 | DS DP | | | |
| FESOTERODINE FUMARATE - TOVIAZ | | | | | | | |
| N 022030 | 001 | 6858650 | Jul 03, 2022 | DS | | U-913 | |
| | | 7384980 | May 11, 2019 | DS DP | | U-913 | |
| | | 7807715 | Jun 07, 2027 | DP | | U-913 | |
| | | 7855230 | May 11, 2019 | | | U-913 | |
| | | 7985772 | May 11, 2019 | DS DP | | U-913 | |
| | | 8088398 | Jun 07, 2027 | DP | | U-913 | |
| | | 8338478 | May 11, 2019 | DS DP | | U-913 | |
| | | 8501723 | Jun 07, 2027 | DP | | | |
| FESOTERODINE FUMARATE - TOVIAZ | | | | | | | |
| N 022030 | 002 | 6858650 | Jul 03, 2022 | DS | | U-913 | |
| | | 7384980 | May 11, 2019 | DS DP | | U-913 | |
| | | 7807715 | Jun 07, 2027 | DP | | U-913 | |
| | | 7855230 | May 11, 2019 | | | U-913 | |
| | | 7985772 | May 11, 2019 | DS DP | | U-913 | |
| | | 8088398 | Jun 07, 2027 | DP | | U-913 | |
| | | 8338478 | May 11, 2019 | DS DP | | U-913 | |
| | | 8501723 | Jun 07, 2027 | DP | | | |
| FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY | | | | | | | |
| N 021909 | 002 | 6723348 | Nov 26, 2021 | DP | | U-1466 | |
| FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES | | | | | | | |
| N 021909 | 003 | 6723348 | Nov 26, 2021 | DP | | | |
| FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY | | | | | | | |
| N 201373 | 001 | 8933097 | Aug 16, 2032 | DP | | | |
| FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES | | | | | | | |
| N 201373 | 002 | 8933097 | Aug 16, 2032 | DP | | | |
| FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION | | | | | | | |
| N 020786 | 002 | 6039974 | Jul 31, 2018 | DP | | | |
| FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE - ALLEGRA-D 24 HOUR ALLERGY AND CONGESTION | | | | | | | |
| N 021704 | 002 | 6613357 | Dec 25, 2020 | DP | | U-1159 | |
| | | RE39069 | May 29, 2018 | DP | | | |
| FIDAXOMICIN - DIFICID | | | | | | | |
| N 201699 | 001 | 7378508 | Jul 31, 2027 | DS DP | | | |
| | | 7863249 | Jul 31, 2027 | DS DP | | | |
| | | 7906489 | Mar 04, 2027 | | | U-319 | |
| | | 8586551 | Jul 15, 2023 | DS DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| FIDAXOMICIN - DIFICID | | | | | | | |
| N 201699 | 001 | 8859510 | Jul 31, 2027 | U-319 | | | |
| FINAFLOXACIN - XTORO | | | | | | | |
| N 206307 | 001 | 8536167 | Aug 08, 2031 | U-1679 | | NCE | Dec 17, 2019 |
| | | 9119859 | Jul 02, 2030 | U-1679 | | PED | Jun 17, 2020 |
| | | 9504691 | Nov 21, 2033 | DP U-1679 | | | |
| FINASTERIDE - PROSCAR | | | | | | | |
| N 020180 | 001 | 5942519 | Oct 23, 2018 | U-280 | | | |
| FINGOLIMOD - GILENYA | | | | | | | |
| N 022527 | 001 | 5604229 | Feb 18, 2019 | DS U-1086 | | | |
| | | 6004565 | Sep 23, 2017 | U-1086 | | | |
| | | 8324283 | Mar 29, 2026 | | | | |
| | | 9187405 | Jun 25, 2027 | U-1086 | | | |
| FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20% | | | | | | | |
| N 207648 | 001 | | | | | NCE | Jul 13, 2021 |
| FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20% | | | | | | | |
| N 207648 | 002 | | | | | NCE | Jul 13, 2021 |
| FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - SMOFLIPID 20% | | | | | | | |
| N 207648 | 003 | | | | | NCE | Jul 13, 2021 |
| FLIBANSERIN - ADDYI | | | | | | | |
| N 022526 | 001 | 7151103 | May 09, 2023 | U-1734 | | NCE | Aug 18, 2020 |
| | | 7420057 | Aug 01, 2022 | DS DP | | | |
| | | 8227471 | May 09, 2023 | U-1734 | | | |
| | | 9468639 | Oct 16, 2022 | U-1734 | | | |
| FLORBETABEN F-18 - NEURACEQ | | | | | | | |
| N 204677 | 001 | 7807135 | Mar 18, 2029 | DS DP U-1497 | | NCE | Mar 21, 2019 |
| FLORBETAPIR F-18 - AMYVID | | | | | | | |
| N 202008 | 001 | 7687052 | Apr 30, 2027 | DS DP | | | |
| | | 8506929 | Apr 30, 2027 | DS DP U-1423 | | | |
| FLORBETAPIR F-18 - AMYVID | | | | | | | |
| N 202008 | 002 | 7687052 | Apr 30, 2027 | DS DP | | | |
| | | 8506929 | Apr 30, 2027 | DS DP U-1423 | | | |
| FLORBETAPIR F-18 - AMYVID | | | | | | | |
| N 202008 | 003 | 7687052 | Apr 30, 2027 | DS DP | | | |
| | | 8506929 | Apr 30, 2027 | DS DP U-1423 | | | |
| FLUCICLOVINE F-18 - AXUMIN | | | | | | | |
| N 208054 | 001 | 5808146 | Nov 09, 2018 | DS | | NCE | May 27, 2021 |
| | | 9387266 | Nov 28, 2026 | U-1879 | | | |
| FLUDARABINE PHOSPHATE - OFORTA | | | | | | | |
| N 022273 | 001 | 7148207 | Dec 20, 2022 | DP U-944 | | | |
| | | 7547776 | Dec 10, 2018 | DS | | | |
| FLUOCINOLONE ACETONIDE - RETISERT | | | | | | | |
| N 021737 | 001 | 6217895 | Mar 22, 2019 | DP U-708 | | | |
| | | 6548078 | Mar 22, 2019 | DP U-708 | | | |
| FLUOCINOLONE ACETONIDE - ILUVIEN | | | | | | | |
| N 201923 | 001 | 6217895 | Mar 22, 2019 | DP U-1597 | | NP | Sep 26, 2017 |
| | | 6375972 | Apr 26, 2020 | DP U-1597 | | | |
| | | 6548078 | Mar 22, 2019 | DP U-1597 | | | |
| | | 8252307 | Jun 27, 2019 | DP | | | |
| | | 8871241 | Aug 12, 2027 | DP | | | |
| FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA | | | | | | | |
| N 021112 | 001 | 7915243 | Mar 22, 2026 | DP | | | |
| | | 7939516 | May 04, 2025 | DP | | | |
| | | 8247395 | Oct 22, 2022 | DP | | | |
| | | 8653053 | Oct 25, 2022 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA | | | | | | | |
| N 021112 | 001 | 7915243 | Mar 22, 2026 | DP | | | |
| | | 7939516 | May 04, 2025 | DP | | | |
| | | 8247395 | Oct 22, 2022 | DP | | | |
| | | 8653053 | Oct 25, 2022 | DP | | | |
| FLUOCINONIDE - VANOS | | | | | | | |
| N 021758 | 001 | 6765001 | Dec 21, 2021 | DP | | | |
| | | 7220424 | Jan 07, 2023 | U-861 | | | |
| | | 7794738 | Sep 11, 2022 | U-1084 | | | |
| | | 8232264 | Mar 09, 2023 | DP | | | |
| FLUOROURACIL - CARAC | | | | | | | |
| N 020985 | 001 | 6670335 | Jun 02, 2021 | DP U-68 | | | |
| FLUOROURACIL - TOLAK | | | | | | | |
| N 022259 | 001 | 7169401 | Jul 18, 2023 | DP | | NP | Sep 18, 2018 |
| FLUOXETINE HYDROCHLORIDE - PROZAC | | | | | | | |
| N 018936 | 001 | 6960577 | Nov 01, 2017 | U-963 | | | |
| FLUOXETINE HYDROCHLORIDE - PROZAC | | | | | | | |
| N 018936 | 003 | 6960577 | Nov 01, 2017 | U-963 | | | |
| FLUOXETINE HYDROCHLORIDE - PROZAC | | | | | | | |
| N 018936 | 006 | 6960577 | Nov 01, 2017 | U-963 | | | |
| FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX | | | | | | | |
| N 021520 | 001 | 6960577 | Nov 01, 2017 | U-962 | | M-142 | Oct 10, 2017 |
| FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX | | | | | | | |
| N 021520 | 002 | 6960577 | Nov 01, 2017 | U-962 | | M-142 | Oct 10, 2017 |
| FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX | | | | | | | |
| N 021520 | 003 | 6960577 | Nov 01, 2017 | U-962 | | M-142 | Oct 10, 2017 |
| FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX | | | | | | | |
| N 021520 | 004 | 6960577 | Nov 01, 2017 | U-962 | | M-142 | Oct 10, 2017 |
| FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX | | | | | | | |
| N 021520 | 005 | 6960577 | Nov 01, 2017 | U-962 | | M-142 | Oct 10, 2017 |
| FLUTEMETAMOL F-18 - VIZAMYL | | | | | | | |
| N 203137 | 001 | 7270800 | Sep 03, 2025 | DS DP U-336 | | NCE | Oct 25, 2018 |
| | | 7351401 | Jan 24, 2023 | DS DP U-336 | | | |
| | | 8236282 | May 21, 2024 | DS DP | | | |
| | | 8691185 | Jan 24, 2023 | U-336 | | | |
| | | 8916131 | Sep 16, 2028 | DP | | | |
| FLUTEMETAMOL F-18 - VIZAMYL | | | | | | | |
| N 203137 | 002 | 7270800 | Sep 03, 2025 | DS DP U-336 | | NCE | Oct 25, 2018 |
| | | 7351401 | Jan 24, 2023 | DS DP U-336 | | | |
| | | 8236282 | May 21, 2024 | DS DP | | | |
| | | 8691185 | Jan 24, 2023 | U-336 | | | |
| | | 8916131 | Sep 16, 2028 | DP | | | |
| FLUTICASONE FUROATE - FLONASE SENSIMIST ALLERGY RELIEF | | | | | | | |
| N 022051 | 002 | 6858596 | Aug 03, 2021 | DP U-1890 | | | |
| | | 7101866 | Aug 03, 2021 | DS DP U-1890 | | | |
| | | 7541350 | Aug 03, 2021 | DP U-1890 | | | |
| | | 8062264 | Apr 05, 2026 | DP | | | |
| | | 8147461 | Oct 15, 2028 | DP | | | |
| | | 8347879 | Jul 15, 2028 | DP | | | |
| | | 8752543 | Apr 05, 2026 | DP | | | |
| | | 9320862 | Nov 06, 2024 | DP | | | |
| FLUTICASONE FUROATE - ARNUITY ELLIPTA | | | | | | | |
| N 205625 | 001 | 7101866 | Aug 03, 2021 | DS DP U-1559 | | NP | Aug 20, 2017 |
| | | 7629335 | Aug 03, 2021 | DP | | | |
| | | 8113199 | Oct 23, 2027 | DP | | | |
| | | 8161968 | Feb 05, 2028 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| FLUTICASONE FUROATE - ARNUITY ELLIPTA | | | | | | | |
| N 205625 | 001 | 8201556 | Feb 05, 2029 | DP | | | |
| | | 8534281 | Aug 10, 2029 | DP | | | |
| | | 8746242 | Oct 11, 2030 | DP | | | |
| | | 9333310 | Oct 02, 2027 | DP | | | |
| FLUTICASONE FUROATE - ARNUITY ELLIPTA | | | | | | | |
| N 205625 | 002 | 7101866 | Aug 03, 2021 | DS DP U-1559 | | NP | Aug 20, 2017 |
| | | 7629335 | Aug 03, 2021 | DP | | | |
| | | 8113199 | Oct 23, 2027 | DP | | | |
| | | 8161968 | Feb 05, 2028 | DP | | | |
| | | 8201556 | Feb 05, 2029 | DP | | | |
| | | 8534281 | Aug 10, 2029 | DP | | | |
| | | 8746242 | Oct 11, 2030 | DP | | | |
| | | 9333310 | Oct 02, 2027 | DP | | | |
| FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA | | | | | | | |
| N 209482 | 001 | 6537983 | Aug 03, 2021 | DP U-2125 | | NCE | May 10, 2018 |
| | | 6759398 | Aug 03, 2021 | DP U-2125 | | NCE | Dec 18, 2018 |
| | | 6878698 | Aug 03, 2021 | U-2134 | | | |
| | | 7101866 | Aug 03, 2021 | DS DP U-2126 | | | |
| | | 7439393 | May 21, 2025 | DS DP U-2127 | | | |
| | | 7488827 | Dec 18, 2027 | DS DP | | | |
| | | 7498440 | Apr 27, 2025 | DS DP | | | |
| | | 7629335 | Aug 03, 2021 | DP | | | |
| | | 7776895 | Sep 11, 2022 | DP | | | |
| | | 8113199 | Oct 23, 2027 | DP | | | |
| | | 8161968 | Feb 05, 2028 | DP | | | |
| | | 8183257 | Jul 27, 2025 | U-2128 | | | |
| | | 8309572 | Apr 27, 2025 | U-2129 | | | |
| | | 8511304 | Jun 14, 2027 | DP | | | |
| | | 8534281 | Aug 10, 2029 | DP | | | |
| | | 8746242 | Oct 11, 2030 | DP | | | |
| | | 9333310 | Oct 02, 2027 | DP | | | |
| | | 9750762 | Nov 29, 2030 | DP | | | |
| | | RE44874 | Mar 23, 2023 | DS DP U-2127 | | | |
| FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA | | | | | | | |
| N 204275 | 001 | 6537983 | Aug 03, 2021 | DP U-1401 | | I-708 | Apr 30, 2018 |
| | | 6537983 | Aug 03, 2021 | DP U-1691 | | M-202 | May 15, 2020 |
| | | 6759398 | Aug 03, 2021 | DP U-1401 | | NCE | May 10, 2018 |
| | | 6759398 | Aug 03, 2021 | DP U-1691 | | | |
| | | 6878698 | Aug 03, 2021 | U-1401 | | | |
| | | 7101866 | Aug 03, 2021 | DS DP U-1401 | | | |
| | | 7101866 | Aug 03, 2021 | DS DP U-1691 | | | |
| | | 7439393 | May 21, 2025 | DS DP U-1401 | | | |
| | | 7439393 | May 21, 2025 | DS DP U-1691 | | | |
| | | 7439393 | May 21, 2025 | DS DP U-2099 | | | |
| | | 7439393 | May 21, 2025 | DS DP U-2100 | | | |
| | | 7629335 | Aug 03, 2021 | DP | | | |
| | | 7776895 | Sep 11, 2022 | DP | | | |
| | | 8113199 | Oct 23, 2027 | DP | | | |
| | | 8161968 | Feb 05, 2028 | DP | | | |
| | | 8511304 | Jun 14, 2027 | DP U-1424 | | | |
| | | 8511304 | Jun 14, 2027 | DP U-1691 | | | |
| | | 8534281 | Aug 10, 2029 | DP | | | |
| | | 8746242 | Oct 11, 2030 | DP | | | |
| | | 9333310 | Oct 02, 2027 | DP | | | |
| | | RE44874 | Mar 23, 2023 | DS DP U-1548 | | | |
| | | RE44874 | Mar 23, 2023 | DS DP U-1691 | | | |
| FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA | | | | | | | |
| N 204275 | 002 | 6537983 | Aug 03, 2021 | DP U-1691 | | M-202 | May 15, 2020 |
| | | 6759398 | Aug 03, 2021 | DP U-1691 | | NCE | May 10, 2018 |
| | | 7101866 | Aug 03, 2021 | DS DP U-1691 | | NP | Apr 30, 2018 |
| | | 7439393 | May 21, 2025 | DS DP U-1691 | | | |
| | | 7439393 | May 21, 2025 | DS DP U-2099 | | | |
| | | 7439393 | May 21, 2025 | DS DP U-2100 | | | |
| | | 7629335 | Aug 03, 2021 | DP | | | |
| | | 7776895 | Sep 11, 2022 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|
| FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA | | | | | | | | |
| N 204275 | 002 | | 8113199 | Oct 23, 2027 | DP | | | |
| | | | 8161968 | Feb 05, 2028 | DP | | | |
| | | | 8511304 | Jun 14, 2027 | DP U-1691 | | | |
| | | | 8534281 | Aug 10, 2029 | DP | | | |
| | | | 8746242 | Oct 11, 2030 | DP | | | |
| | | | 9333310 | Oct 02, 2027 | DP | | | |
| | | | RE44874 | Mar 23, 2023 | DS DP U-1691 | | | |
| FLUTICASONE PROPIONATE - CUTIVATE | | | | | | | | |
| N 021152 | 001 | | 7300669 | Oct 20, 2019 | DP U-835 | | NPP | Jan 16, 2018 |
| FLUTICASONE PROPIONATE - FLOVENT HFA | | | | | | | | |
| N 021433 | 001 | | 6161724 | Jan 16, 2018 | DP | | | |
| | | | 6170717 | Dec 23, 2017 | DP | | | |
| | | | 6315173 | Dec 23, 2017 | DP | | | |
| | | | 6431168 | Jun 08, 2018 | DP | | | |
| | | | 6435372 | Jan 16, 2018 | DP | | | |
| | | | 6510969 | Dec 23, 2017 | DP | | | |
| | | | 6938796 | Jan 16, 2018 | DP | | | |
| | | | 6966467 | Dec 23, 2017 | DP | | | |
| | | | 6997349 | Jan 16, 2018 | DP | | | |
| | | | 7107986 | Jun 08, 2018 | DP | | | |
| | | | 7107986*PED | Dec 08, 2018 | | | | |
| | | | 7143908 | Jan 16, 2018 | DP | | | |
| | | | 7350676 | Aug 24, 2018 | DP | | | |
| | | | 7500444 | Feb 26, 2026 | DP | | | |
| | | | 7500444*PED | Aug 26, 2026 | | | | |
| | | | 7832351 | Jun 19, 2023 | DP | | | |
| FLUTICASONE PROPIONATE - FLOVENT HFA | | | | | | | | |
| N 021433 | 002 | | 6161724 | Jan 16, 2018 | DP | | | |
| | | | 6170717 | Dec 23, 2017 | DP | | | |
| | | | 6315173 | Dec 23, 2017 | DP | | | |
| | | | 6431168 | Jun 08, 2018 | DP | | | |
| | | | 6435372 | Jan 16, 2018 | DP | | | |
| | | | 6510969 | Dec 23, 2017 | DP | | | |
| | | | 6743413 | Jun 01, 2021 | U-581 | Y | | |
| | | | 6938796 | Jan 16, 2018 | DP | | | |
| | | | 6966467 | Dec 23, 2017 | DP | | | |
| | | | 6997349 | Jan 16, 2018 | DP | | | |
| | | | 7107986 | Jun 08, 2018 | DP | | | |
| | | | 7107986*PED | Dec 08, 2018 | | | | |
| | | | 7143908 | Jan 16, 2018 | DP | | | |
| | | | 7350676 | Aug 24, 2018 | DP | | | |
| | | | 7500444 | Feb 26, 2026 | DP | | | |
| | | | 7500444*PED | Aug 26, 2026 | | | | |
| | | | 7832351 | Jun 19, 2023 | DP | | | |
| FLUTICASONE PROPIONATE - FLOVENT HFA | | | | | | | | |
| N 021433 | 003 | | 6161724 | Jan 16, 2018 | DP | | | |
| | | | 6170717 | Dec 23, 2017 | DP | | | |
| | | | 6315173 | Dec 23, 2017 | DP | | | |
| | | | 6431168 | Jun 08, 2018 | DP | | | |
| | | | 6435372 | Jan 16, 2018 | DP | | | |
| | | | 6510969 | Dec 23, 2017 | DP | | | |
| | | | 6938796 | Jan 16, 2018 | DP | | | |
| | | | 6966467 | Dec 23, 2017 | DP | | | |
| | | | 6997349 | Jan 16, 2018 | DP | | | |
| | | | 7107986 | Jun 08, 2018 | DP | | | |
| | | | 7107986*PED | Dec 08, 2018 | | | | |
| | | | 7143908 | Jan 16, 2018 | DP | | | |
| | | | 7350676 | Aug 24, 2018 | DP | | | |
| | | | 7500444 | Feb 26, 2026 | DP | | | |
| | | | 7500444*PED | Aug 26, 2026 | | | | |
| | | | 7832351 | Jun 19, 2023 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| FLUTICASONE PROPIONATE - FLONASE ALLERGY RELIEF | | | | | | | |
| N 205434 | 001 | | | | | M-147 | Jul 23, 2017 |
| FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK | | | | | | | |
| N 208798 | 001 | 6446627 | Dec 18, 2017 | DP | | NP | Jan 27, 2020 |
| | | 6701917 | Jun 23, 2021 | DP | | | |
| | | 6718972 | Jun 23, 2021 | DP | | | |
| | | 6748947 | Jun 23, 2021 | DP | | | |
| | | 6871646 | Jun 23, 2021 | DP | | | |
| | | 7540282 | May 06, 2023 | DP | | | |
| | | 8006690 | Jun 23, 2021 | DP | | | |
| | | 8651103 | Mar 26, 2028 | DP | | | |
| | | 8714149 | Feb 25, 2032 | DP | | | |
| | | 8978966 | Jan 13, 2032 | DP | | | |
| | | 9216260 | Jun 28, 2031 | DP | | | |
| | | 9463288 | May 19, 2025 | DP | | | |
| | | 9616024 | Sep 01, 2024 | DP | | | |
| | | 9731087 | May 18, 2031 | DP | | | |
| FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK | | | | | | | |
| N 208798 | 002 | 6446627 | Dec 18, 2017 | DP | | NP | Jan 27, 2020 |
| | | 6701917 | Jun 23, 2021 | DP | | | |
| | | 6718972 | Jun 23, 2021 | DP | | | |
| | | 6748947 | Jun 23, 2021 | DP | | | |
| | | 6871646 | Jun 23, 2021 | DP | | | |
| | | 7540282 | May 06, 2023 | DP | | | |
| | | 8006690 | Jun 23, 2021 | DP | | | |
| | | 8651103 | Mar 26, 2028 | DP | | | |
| | | 8714149 | Feb 25, 2032 | DP | | | |
| | | 8978966 | Jan 13, 2032 | DP | | | |
| | | 9216260 | Jun 28, 2031 | DP | | | |
| | | 9463288 | May 19, 2025 | DP | | | |
| | | 9616024 | Sep 01, 2024 | DP | | | |
| | | 9731087 | May 18, 2031 | DP | | | |
| FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK | | | | | | | |
| N 208798 | 003 | 6446627 | Dec 18, 2017 | DP | | NP | Jan 27, 2020 |
| | | 6701917 | Jun 23, 2021 | DP | | | |
| | | 6718972 | Jun 23, 2021 | DP | | | |
| | | 6748947 | Jun 23, 2021 | DP | | | |
| | | 6871646 | Jun 23, 2021 | DP | | | |
| | | 7540282 | May 06, 2023 | DP | | | |
| | | 8006690 | Jun 23, 2021 | DP | | | |
| | | 8651103 | Mar 26, 2028 | DP | | | |
| | | 8714149 | Feb 25, 2032 | DP | | | |
| | | 8978966 | Jan 13, 2032 | DP | | | |
| | | 9216260 | Jun 28, 2031 | DP | | | |
| | | 9463288 | May 19, 2025 | DP | | | |
| | | 9616024 | Sep 01, 2024 | DP | | | |
| | | 9731087 | May 18, 2031 | DP | | | |
| FLUTICASONE PROPIONATE - XHANCE | | | | | | | |
| N 209022 | 001 | 6715485 | Mar 03, 2020 | DP | | NP | Sep 18, 2020 |
| | | 7975690 | Dec 29, 2025 | U-2133 | | | |
| | | 8327844 | Oct 08, 2023 | U-2133 | | | |
| | | 8522778 | May 11, 2022 | DP | | | |
| | | 8550073 | Oct 22, 2029 | DP | | | |
| | | 8555878 | Mar 20, 2020 | DP | | | |
| | | 8978647 | Aug 06, 2030 | DP | | | |
| | | 9072857 | Apr 10, 2021 | DP | | | |
| | | 9468727 | Jul 30, 2020 | DP | | | |
| FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 100/50 | | | | | | | |
| N 021077 | 001 | | | | | M-214 | Dec 20, 2020 |
| FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 250/50 | | | | | | | |
| N 021077 | 002 | | | | | M-214 | Dec 20, 2020 |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR DISKUS 500/50 | | | | | | | |
| N 021077 | 003 | | | | | M-214 | Dec 20, 2020 |
| FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA | | | | | | | |
| N 021254 | 001 | 6161724 | Jan 16, 2018 | DP | | | |
| | | 6170717 | Dec 23, 2017 | DP | | | |
| | | 6315173 | Dec 23, 2017 | DP | | | |
| | | 6431168 | Jun 08, 2018 | DP | | | |
| | | 6435372 | Jan 16, 2018 | DP | | | |
| | | 6510969 | Dec 23, 2017 | | | | |
| | | 6938796 | Jan 16, 2018 | DP | | | |
| | | 6966467 | Dec 23, 2017 | DP | | | |
| | | 6997349 | Jan 16, 2018 | DP | | | |
| | | 7107986 | Jun 08, 2018 | DP | | | |
| | | 7143908 | Jan 16, 2018 | DP | | | |
| | | 7350676 | Aug 24, 2018 | DP | | | |
| | | 7500444 | Feb 26, 2026 | DP | | | |
| | | 7500444*PED | Aug 26, 2026 | | | | |
| | | 7832351 | Jun 19, 2023 | DP | | | |
| FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA | | | | | | | |
| N 021254 | 002 | 6161724 | Jan 16, 2018 | DP | | | |
| | | 6170717 | Dec 23, 2017 | DP | | | |
| | | 6315173 | Dec 23, 2017 | DP | | | |
| | | 6431168 | Jun 08, 2018 | DP | | | |
| | | 6435372 | Jan 16, 2018 | DP | | | |
| | | 6510969 | Dec 23, 2017 | DP | | | |
| | | 6938796 | Jan 16, 2018 | DP | | | |
| | | 6966467 | Dec 23, 2017 | DP | | | |
| | | 6997349 | Jan 16, 2018 | DP | | | |
| | | 7107986 | Jun 08, 2018 | DP | | | |
| | | 7143908 | Jan 16, 2018 | DP | | | |
| | | 7350676 | Aug 24, 2018 | DP | | | |
| | | 7500444 | Feb 26, 2026 | DP | | | |
| | | 7500444*PED | Aug 26, 2026 | | | | |
| | | 7832351 | Jun 19, 2023 | DP | | | |
| FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA | | | | | | | |
| N 021254 | 003 | 6161724 | Jan 16, 2018 | DP | | | |
| | | 6170717 | Dec 23, 2017 | DP | | | |
| | | 6315173 | Dec 23, 2017 | DP | | | |
| | | 6431168 | Jun 08, 2018 | DP | | | |
| | | 6435372 | Jan 16, 2018 | DP | | | |
| | | 6510969 | Dec 23, 2017 | DP | | | |
| | | 6938796 | Jan 16, 2018 | DP | | | |
| | | 6966467 | Dec 23, 2017 | DP | | | |
| | | 6997349 | Jan 16, 2018 | DP | | | |
| | | 7107986 | Jun 08, 2018 | DP | | | |
| | | 7143908 | Jan 16, 2018 | DP | | | |
| | | 7350676 | Aug 24, 2018 | DP | | | |
| | | 7500444 | Feb 26, 2026 | DP | | | |
| | | 7500444*PED | Aug 26, 2026 | | | | |
| | | 7832351 | Jun 19, 2023 | DP | | | |
| FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK | | | | | | | |
| N 208799 | 001 | 6446627 | Dec 18, 2017 | DP | | NP | Jan 27, 2020 |
| | | 6701917 | Jun 23, 2021 | DP | | | |
| | | 6718972 | Jun 23, 2021 | DP | | | |
| | | 6748947 | Jun 23, 2021 | DP | | | |
| | | 6871646 | Jun 23, 2021 | DP | | | |
| | | 7540282 | May 06, 2023 | DP | | | |
| | | 8006690 | Jun 23, 2021 | DP | | | |
| | | 8651103 | Mar 26, 2028 | DP | | | |
| | | 8714149 | Feb 25, 2032 | DP | | | |
| | | 8978966 | Jan 13, 2032 | DP | | | |
| | | 9066957 | Oct 06, 2034 | DP U-645 | | | |
| | | 9216260 | Jun 28, 2031 | DP | | | |
| | | 9415008 | Oct 06, 2034 | DP U-645 | | | |
| | | 9463288 | May 19, 2025 | DP | | | |
| | | 9616024 | Sep 01, 2024 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|
| FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK | | | | | | | | |
| N | 208799 | 001 | 9731087 | May 18, 2031 | DP | | | |
| FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK | | | | | | | | |
| N | 208799 | 002 | 6446627 | Dec 18, 2017 | DP | | NP | Jan 27, 2020 |
| | | | 6701917 | Jun 23, 2021 | DP | | | |
| | | | 6718972 | Jun 23, 2021 | DP | | | |
| | | | 6748947 | Jun 23, 2021 | DP | | | |
| | | | 6871646 | Jun 23, 2021 | DP | | | |
| | | | 7540282 | May 06, 2023 | DP | | | |
| | | | 8006690 | Jun 23, 2021 | DP | | | |
| | | | 8651103 | Mar 26, 2028 | DP | | | |
| | | | 8714149 | Feb 25, 2032 | DP | | | |
| | | | 8978966 | Jan 13, 2032 | DP | | | |
| | | | 9066957 | Oct 06, 2034 | DP U-645 | | | |
| | | | 9216260 | Jun 28, 2031 | DP | | | |
| | | | 9463288 | May 19, 2025 | DP | | | |
| | | | 9616024 | Sep 01, 2024 | DP | | | |
| | | | 9731087 | May 18, 2031 | DP | | | |
| FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK | | | | | | | | |
| N | 208799 | 003 | 6446627 | Dec 18, 2017 | DP | | NP | Jan 27, 2020 |
| | | | 6701917 | Jun 23, 2021 | DP | | | |
| | | | 6718972 | Jun 23, 2021 | DP | | | |
| | | | 6748947 | Jun 23, 2021 | DP | | | |
| | | | 6871646 | Jun 23, 2021 | DP | | | |
| | | | 7540282 | May 06, 2023 | DP | | | |
| | | | 8006690 | Jun 23, 2021 | DP | | | |
| | | | 8651103 | Mar 26, 2028 | DP | | | |
| | | | 8714149 | Feb 25, 2032 | DP | | | |
| | | | 8978966 | Jan 13, 2032 | DP | | | |
| | | | 9066957 | Oct 06, 2034 | DP U-645 | | | |
| | | | 9216260 | Jun 28, 2031 | DP | | | |
| | | | 9463288 | May 19, 2025 | DP | | | |
| | | | 9616024 | Sep 01, 2024 | DP | | | |
| | | | 9731087 | May 18, 2031 | DP | | | |
| FLUVASTATIN SODIUM - LESCOL XL | | | | | | | | |
| N | 021192 | 001 | 6242003 | Apr 13, 2020 | | | | |
| FLUVOXAMINE MALEATE - LUVOX CR | | | | | | | | |
| N | 022033 | 001 | 7465462 | May 10, 2020 | DP U-929 | | | |
| FLUVOXAMINE MALEATE - LUVOX CR | | | | | | | | |
| N | 022033 | 002 | 7465462 | May 10, 2020 | DP U-929 | | | |
| FOLLITROPIN ALFA/BETA - GONAL-F | | | | | | | | |
| N | 020378 | 004 | 7563763 | Aug 23, 2019 | DP | | | |
| FOLLITROPIN ALFA/BETA - GONAL-F | | | | | | | | |
| N | 020378 | 005 | 7563763 | Aug 23, 2019 | DP | | | |
| FOLLITROPIN ALFA/BETA - FOLLISTIM AQ | | | | | | | | |
| N | 021211 | 001 | 5929028 | Jan 14, 2018 | DP U-1366 | | | |
| | | | 5929028 | Jan 14, 2018 | DP U-567 | | | |
| | | | 7446090 | Aug 23, 2019 | DP | | | |
| | | | 7563763 | Aug 23, 2019 | U-1183 | | | |
| | | | 7563763 | Aug 23, 2019 | U-1367 | | | |
| | | | 7563763 | Aug 23, 2019 | U-993 | | | |
| FOLLITROPIN ALFA/BETA - FOLLISTIM AQ | | | | | | | | |
| N | 021211 | 002 | 5929028 | Jan 14, 2018 | DP U-1366 | | | |
| | | | 5929028 | Jan 14, 2018 | DP U-567 | | | |
| | | | 7446090 | Aug 23, 2019 | DP | | | |
| | | | 7563763 | Aug 23, 2019 | U-1183 | | | |
| | | | 7563763 | Aug 23, 2019 | U-1367 | | | |
| | | | 7563763 | Aug 23, 2019 | U-993 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| FOLLITROPIN ALFA/BETA - FOLLISTIM AQ | | | | | | | |
| N 021211 | 003 | 5929028 | Jan 14, 2018 | DP U-1366 | | | |
| | | 5929028 | Jan 14, 2018 | DP U-567 | | | |
| | | 7446090 | Aug 23, 2019 | DP | | | |
| | | 7563763 | Aug 23, 2019 | U-1183 | | | |
| | | 7563763 | Aug 23, 2019 | U-1367 | | | |
| | | 7563763 | Aug 23, 2019 | U-993 | | | |
| FOLLITROPIN ALFA/BETA - FOLLISTIM AQ | | | | | | | |
| N 021211 | 004 | 5929028 | Jan 14, 2018 | DP U-1366 | | | |
| | | 5929028 | Jan 14, 2018 | DP U-567 | | | |
| | | 7446090 | Aug 23, 2019 | DP | | | |
| | | 7563763 | Aug 23, 2019 | U-1183 | | | |
| | | 7563763 | Aug 23, 2019 | U-1367 | | | |
| | | 7563763 | Aug 23, 2019 | U-993 | | | |
| FOLLITROPIN ALFA/BETA - FOLLISTIM AQ | | | | | | | |
| N 021273 | 001 | 5929028 | Jan 14, 2018 | DP U-1366 | | | |
| FOLLITROPIN ALFA/BETA - FOLLISTIM AQ | | | | | | | |
| N 021273 | 002 | 5929028 | Jan 14, 2018 | DP U-1366 | | | |
| FOLLITROPIN ALFA/BETA - GONAL-F RFF REDI-JECT | | | | | | | |
| N 021684 | 001 | 7446090 | Aug 23, 2019 | DP | | | |
| | | 7741268 | Apr 02, 2024 | DP | | | |
| FOLLITROPIN ALFA/BETA - GONAL-F RFF REDI-JECT | | | | | | | |
| N 021684 | 002 | 7446090 | Aug 23, 2019 | DP | | | |
| | | 7741268 | Apr 02, 2024 | DP | | | |
| FOLLITROPIN ALFA/BETA - GONAL-F RFF REDI-JECT | | | | | | | |
| N 021684 | 003 | 7446090 | Aug 23, 2019 | DP | | | |
| | | 7741268 | Apr 02, 2024 | DP | | | |
| FOMEPIZOLE - ANTIZOL | | | | | | | |
| N 020696 | 001 | 7553863 | Jun 30, 2027 | DS DP | | | |
| FORMOTEROL FUMARATE - FORADIL | | | | | | | |
| N 020831 | 001 | 6488027 | Mar 08, 2019 | | | | |
| | | 6887459 | Nov 28, 2020 | U-762 | | | |
| FORMOTEROL FUMARATE - PERFOROMIST | | | | | | | |
| N 022007 | 001 | 6667344 | Jun 22, 2021 | DP | | | |
| | | 6814953 | Jun 22, 2021 | DP U-813 | | | |
| | | 7348362 | Jun 22, 2021 | DP | | | |
| | | 7462645 | Jun 22, 2021 | DP U-813 | | | |
| | | 8623922 | Jun 22, 2021 | DP | | | |
| FORMOTEROL FUMARATE; GLYCOPYRROLATE - BEVESPI AEROSPHERE | | | | | | | |
| N 208294 | 001 | 8324266 | May 28, 2030 | U-1841 | | NP | Apr 25, 2019 |
| | | 8703806 | May 28, 2030 | U-1841 | | | |
| | | 8808713 | May 28, 2030 | DP U-1841 | | | |
| | | 8815258 | Mar 17, 2031 | U-1841 | | | |
| | | 9415009 | May 28, 2030 | U-1841 | | | |
| | | 9463161 | May 28, 2030 | DP U-1841 | | | |
| FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA | | | | | | | |
| N 022518 | 001 | 6068832 | Aug 27, 2017 | DP U-1068 | | M-214 | Dec 20, 2020 |
| | | 7067502 | May 21, 2020 | DP U-1068 | | | |
| | | 7566705 | May 21, 2020 | DP U-1068 | | | |
| FORMOTEROL FUMARATE; MOMETASONE FUROATE - DULERA | | | | | | | |
| N 022518 | 002 | 6068832 | Aug 27, 2017 | DP U-1068 | | M-214 | Dec 20, 2020 |
| | | 7067502 | May 21, 2020 | DP U-1068 | | | |
| | | 7566705 | May 21, 2020 | DP U-1068 | | | |
| FOSAMPRENAVIR CALCIUM - LEXIVA | | | | | | | |
| N 021548 | 001 | 6436989 | Dec 24, 2017 | DS DP U-257 | | | |
| | | 6514953 | Jul 15, 2019 | DS DP U-257 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| FOSAMPRENAVIR CALCIUM - LEXIVA | | | | | | | |
| N 022116 | 001 | 6436989 | Dec 24, 2017 | DS DP U-257 | | | |
| FOSAPREPITANT DIMEGLUMINE - EMEND | | | | | | | |
| N 022023 | 001 | 5691336 | Mar 04, 2019 | DS DP | | | |
| FOSAPREPITANT DIMEGLUMINE - EMEND | | | | | | | |
| N 022023 | 002 | 5691336 | Mar 04, 2019 | DS DP | | D-155 | Feb 01, 2019 |
| FOSPROPOFOL DISODIUM - LUSEDRA | | | | | | | |
| N 022244 | 001 | 6204257 | Jul 01, 2022 | DS DP U-945 | | | |
| | | 6872838 | Aug 07, 2018 | DS | | | |
| FULVESTRANT - FASLODEX | | | | | | | |
| N 021344 | 001 | 6774122 | Jan 09, 2021 | U-1826 | | I-725 | Feb 19, 2019 |
| | | 6774122 | Jan 09, 2021 | U-2108 | | I-749 | Aug 25, 2020 |
| | | 6774122 | Jan 09, 2021 | U-2163 | | | |
| | | 6774122 | Jan 09, 2021 | U-596 | | | |
| | | 6774122*PED | Jul 09, 2021 | | | | |
| | | 7456160 | Jan 09, 2021 | U-1826 | | | |
| | | 7456160 | Jan 09, 2021 | U-2108 | | | |
| | | 7456160 | Jan 09, 2021 | U-2163 | | | |
| | | 7456160 | Jan 09, 2021 | U-596 | | | |
| | | 7456160*PED | Jul 09, 2021 | | | | |
| | | 8329680 | Jan 09, 2021 | U-1826 | | | |
| | | 8329680 | Jan 09, 2021 | U-2108 | | | |
| | | 8329680 | Jan 09, 2021 | U-2163 | | | |
| | | 8329680 | Jan 09, 2021 | U-596 | | | |
| | | 8329680*PED | Jul 09, 2021 | | | | |
| | | 8466139 | Jan 09, 2021 | U-1826 | | | |
| | | 8466139 | Jan 09, 2021 | U-2108 | | | |
| | | 8466139 | Jan 09, 2021 | U-2163 | | | |
| | | 8466139 | Jan 09, 2021 | U-596 | | | |
| | | 8466139*PED | Jul 09, 2021 | | | | |
| GABAPENTIN - NEURONTIN | | | | | | | |
| N 021129 | 001 | 7256216 | May 28, 2022 | DP | | | |
| GABAPENTIN - GRALISE | | | | | | | |
| N 022544 | 001 | 6488962 | Jun 20, 2020 | DP | | ODE-6 | Jan 28, 2018 |
| | | 6723340 | Oct 25, 2021 | DP | | | |
| | | 7438927 | Feb 26, 2024 | U-1114 | | | |
| | | 7731989 | Oct 25, 2022 | DP | | | |
| | | 8192756 | Oct 25, 2022 | DP U-1114 | | | |
| | | 8252332 | Oct 25, 2022 | DP U-1114 | | | |
| | | 8333992 | Oct 25, 2022 | DP U-1114 | | | |
| GABAPENTIN - GRALISE | | | | | | | |
| N 022544 | 002 | 6488962 | Jun 20, 2020 | DP | | ODE-6 | Jan 28, 2018 |
| | | 6723340 | Oct 25, 2021 | DP | | | |
| | | 7438927 | Feb 26, 2024 | U-1114 | | | |
| | | 7731989 | Oct 25, 2022 | DP | | | |
| | | 8192756 | Oct 25, 2022 | DP U-1114 | | | |
| | | 8252332 | Oct 25, 2022 | DP U-1114 | | | |
| | | 8333992 | Oct 25, 2022 | DP U-1114 | | | |
| GABAPENTIN ENACARBIL - HORIZANT | | | | | | | |
| N 022399 | 001 | 6818787 | Nov 06, 2022 | DS DP | | ODE-25 | Jun 06, 2019 |
| | | 8026279 | Nov 10, 2026 | DS DP | | | |
| | | 8048917 | Nov 06, 2022 | DS DP U-1247 | | | |
| | | 8114909 | Apr 11, 2026 | U-1231 | | | |
| | | 8686034 | Jan 24, 2025 | U-1231 | | | |
| | | 8686034 | Jan 24, 2025 | U-1247 | | | |
| | | 8795725 | Jun 10, 2029 | DP U-1231 | | | |
| | | 8795725 | Jun 10, 2029 | DP U-1247 | | | |
| GABAPENTIN ENACARBIL - HORIZANT | | | | | | | |
| N 022399 | 002 | 6818787 | Nov 06, 2022 | DS DP | | ODE-25 | Jun 06, 2019 |
| | | 8026279 | Nov 10, 2026 | DS DP | | | |
| | | 8048917 | Nov 06, 2022 | DS DP U-1247 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| GABAPENTIN ENACARBIL - HORIZANT | | | | | | | |
| N 022399 | 002 | 8114909 | Apr 11, 2026 | U-1231 | | | |
| | | 8686034 | Jan 24, 2025 | U-1231 | | | |
| | | 8686034 | Jan 24, 2025 | U-1247 | | | |
| | | 8795725 | Jun 10, 2029 | DP U-1231 | | | |
| | | 8795725 | Jun 10, 2029 | DP U-1247 | | | |
| GADOBUTROL - GADAVIST | | | | | | | |
| N 201277 | 002 | | | | | I-731 | Apr 27, 2019 |
| GADOBUTROL - GADAVIST | | | | | | | |
| N 201277 | 006 | 5980864 | Nov 09, 2021 | DS DP U-1119 | | | |
| GADOFOSVESET TRISODIUM - ABLAVAR | | | | | | | |
| N 021711 | 001 | 6676929 | May 04, 2020 | DP | | | |
| GADOFOSVESET TRISODIUM - ABLAVAR | | | | | | | |
| N 021711 | 002 | 6676929 | May 04, 2020 | DP | | | |
| GADOTERATE MEGLUMINE - DOTAREM | | | | | | | |
| N 204781 | 001 | | | | | NCE | Mar 20, 2018 |
| | | | | | | NPP | Aug 25, 2020 |
| GADOTERATE MEGLUMINE - DOTAREM | | | | | | | |
| N 204781 | 002 | | | | | NCE | Mar 20, 2018 |
| | | | | | | NPP | Aug 25, 2020 |
| GADOTERATE MEGLUMINE - DOTAREM | | | | | | | |
| N 204781 | 003 | | | | | NCE | Mar 20, 2018 |
| | | | | | | NPP | Aug 25, 2020 |
| GADOTERATE MEGLUMINE - DOTAREM | | | | | | | |
| N 204781 | 004 | | | | | NCE | Mar 20, 2018 |
| | | | | | | NPP | Aug 25, 2020 |
| GADOTERATE MEGLUMINE - DOTAREM | | | | | | | |
| N 204781 | 005 | | | | | NCE | Mar 20, 2018 |
| | | | | | | NPP | Aug 25, 2020 |
| GADOXETATE DISODIUM - EOVIST | | | | | | | |
| N 022090 | 001 | 6039931 | Nov 13, 2021 | U-1239 | | M-155 | Mar 27, 2018 |
| GADOXETATE DISODIUM - EOVIST | | | | | | | |
| N 022090 | 002 | | | | | M-155 | Mar 27, 2018 |
| GALANTAMINE HYDROBROMIDE - RAZADYNE ER | | | | | | | |
| N 021615 | 001 | 7160559 | Dec 20, 2019 | DP | | | |
| GALANTAMINE HYDROBROMIDE - RAZADYNE ER | | | | | | | |
| N 021615 | 002 | 7160559 | Dec 20, 2019 | DP | | | |
| GALANTAMINE HYDROBROMIDE - RAZADYNE ER | | | | | | | |
| N 021615 | 003 | 7160559 | Dec 20, 2019 | DP | | | |
| GALLIUM DOTATATE GA-68 - NETSPOT | | | | | | | |
| N 208547 | 001 | | | | | NCE | Jun 01, 2021 |
| | | | | | | ODE-120 | Jun 01, 2023 |
| GANCICLOVIR - GANCICLOVIR | | | | | | | |
| N 209347 | 001 | 9486530 | Sep 02, 2034 | DP | | | |
| GANIRELIX ACETATE - GANIRELIX ACETATE | | | | | | | |
| N 021057 | 001 | 6653286 | Jun 16, 2018 | U-1354 | | | |
| GATIFLOXACIN - ZYMAR | | | | | | | |
| N 021493 | 001 | 6333045 | Aug 20, 2019 | DP | Y | | |
| | | 6333045*PED | Feb 20, 2020 | | | | |
| GEFITINIB - IRESSA | | | | | | | |
| N 206995 | 001 | | | | | NP | Jul 13, 2018 |
| | | | | | | ODE-95 | Jul 13, 2022 |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| GEFITINIB - IRESSA | | | | | | | |
| N 206995 | 001 | | | | | NP | Jul 13, 2018 |
| | | | | | | ODE-95 | Jul 13, 2022 |
| GEMIFLOXACIN MESYLATE - FACTIVE | | | | | | | |
| N 021158 | 001 | 6262071 | Sep 21, 2019 | U-513 | | | |
| | | 6331550 | Sep 21, 2019 | U-511 | | | |
| | | 6340689 | Sep 14, 2019 | U-512 | | | |
| | | 6455540 | Sep 21, 2019 | U-511 | | | |
| | | 6723734 | Mar 20, 2018 | DS DP | | | |
| | | 6803376 | Sep 21, 2019 | DS DP U-608 | | | |
| | | 6803376 | Sep 21, 2019 | DS DP U-609 | | | |
| GLATIRAMER ACETATE - COPAXONE | | | | | | | |
| N 020622 | 003 | 8232250 | Aug 19, 2030 | U-441 | | | |
| | | 8399413 | Aug 19, 2030 | U-441 | | | |
| | | 8969302 | Aug 19, 2030 | U-441 | | | |
| | | 9155776 | Aug 19, 2030 | U-441 | | | |
| | | 9402874 | Aug 19, 2030 | U-441 | | | |
| GLECAPREVIR; PIBRENTASVIR - MAVYRET | | | | | | | |
| N 209394 | 001 | 8648037 | Jan 19, 2032 | DS DP U-2141 | | NCE | Aug 03, 2022 |
| | | 8937150 | May 18, 2032 | DS DP | | | |
| | | 9321807 | Jun 05, 2035 | DS | | | |
| | | 9586978 | Jun 10, 2030 | U-2141 | | | |
| GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT | | | | | | | |
| N 021925 | 001 | 7700128 | Jan 30, 2027 | DP | | | |
| | | 8071130 | Jun 08, 2028 | DP | | | |
| GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE - DUETACT | | | | | | | |
| N 021925 | 002 | 7700128 | Jan 30, 2027 | DP | | | |
| | | 8071130 | Jun 08, 2028 | DP | | | |
| GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL | | | | | | | |
| N 021700 | 001 | 7358366 | Apr 19, 2020 | DS | | | |
| GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL | | | | | | | |
| N 021700 | 002 | 7358366 | Apr 19, 2020 | DS | | | |
| GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL | | | | | | | |
| N 021700 | 003 | 7358366 | Apr 19, 2020 | DS | | | |
| GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL | | | | | | | |
| N 021700 | 004 | 7358366 | Apr 19, 2020 | DS | | | |
| GLIMEPIRIDE; ROSIGLITAZONE MALEATE - AVANDARYL | | | | | | | |
| N 021700 | 005 | 7358366 | Apr 19, 2020 | DS | | | |
| GLIPIZIDE - GLUCOTROL XL | | | | | | | |
| N 020329 | 001 | RE44459 | Mar 26, 2019 | U-1431 | | | |
| GLIPIZIDE - GLUCOTROL XL | | | | | | | |
| N 020329 | 002 | RE44459 | Mar 26, 2019 | U-1431 | | | |
| GLIPIZIDE - GLUCOTROL XL | | | | | | | |
| N 020329 | 003 | RE44459 | Mar 26, 2019 | U-1431 | | | |
| GLYBURIDE; METFORMIN HYDROCHLORIDE - GLUCOVANCE | | | | | | | |
| N 021178 | 001 | 6303146 | Jul 14, 2019 | U-412 | | | |
| GLYBURIDE; METFORMIN HYDROCHLORIDE - GLUCOVANCE | | | | | | | |
| N 021178 | 002 | 6303146 | Jul 14, 2019 | U-412 | | | |
| GLYBURIDE; METFORMIN HYDROCHLORIDE - GLUCOVANCE | | | | | | | |
| N 021178 | 003 | 6303146 | Jul 14, 2019 | U-412 | | | |
| GLYCEROL PHENYLBUTYRATE - RAVICTI | | | | | | | |
| N 203284 | 001 | 5968979 | Jul 28, 2018 | DS DP U-1378 | | NPP | Apr 28, 2020 |
| | | 8404215 | Mar 09, 2032 | U-1383 | | ODE | Apr 28, 2024 |
| | | 8642012 | Sep 22, 2030 | U-1383 | | ODE-42 | Feb 01, 2020 |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| GLYCEROL PHENYLBUTYRATE - RAVICTI | | | | | | | |
| N 203284 | 001 | 9095559 | Mar 09, 2032 | U-1383 | | | |
| | | 9254278 | Mar 09, 2032 | U-1816 | | | |
| | | 9326966 | Mar 09, 2032 | U-1816 | | | |
| | | 9561197 | Sep 22, 2030 | U-1383 | | | |
| GLYCOPYRROLATE - CUVPOSA | | | | | | | |
| N 022571 | 001 | 7638552 | Aug 20, 2023 | U-1076 | | ODE-1 | Jul 28, 2017 |
| | | 7816396 | Aug 20, 2023 | U-1076 | | | |
| GLYCOPYRROLATE - SEEBRI | | | | | | | |
| N 207923 | 001 | 7229607 | Apr 09, 2021 | U-1773 | | NP | Oct 29, 2018 |
| | | 7736670 | Jun 27, 2021 | DP | | | |
| | | 8029768 | Apr 09, 2021 | U-1773 | | | |
| | | 8048451 | Jun 27, 2021 | DP | | | |
| | | 8182838 | Oct 20, 2028 | DP | | | |
| | | 8303991 | Jun 27, 2021 | DP | | | |
| | | 8435567 | Jun 27, 2021 | DP | | | |
| | | 8479730 | Oct 11, 2028 | DP | | | |
| | | 8580306 | Jun 27, 2021 | DP | | | |
| | | 8956661 | Jun 27, 2021 | DP | | | |
| GLYCOPYRROLATE - LONHALA MAGNAIR KIT | | | | | | | |
| N 208437 | 001 | 6962151 | Oct 27, 2020 | DP | | NP | Dec 05, 2020 |
| | | 7316067 | Sep 06, 2022 | DP | | | |
| | | 7458372 | Nov 18, 2024 | DP | | | |
| | | 7931212 | Nov 25, 2025 | DP | | | |
| | | 8511581 | Nov 08, 2023 | DP | | | |
| | | 9168556 | Sep 01, 2032 | DP | | | |
| | | 9265900 | Dec 07, 2028 | DP | | | |
| | | 9604018 | May 16, 2033 | DP | | | |
| | | 9789270 | Oct 30, 2030 | DP | | | |
| GLYCOPYRROLATE ; INDACATEROL MALEATE - UTIBRON | | | | | | | |
| N 207930 | 001 | 6878721 | Feb 25, 2025 | DS DP U-1773 | | NP | Oct 29, 2018 |
| | | 7229607 | Apr 09, 2021 | U-1773 | | | |
| | | 7736670 | Jun 27, 2021 | DP | | | |
| | | 7820694 | Jun 02, 2020 | DP U-1773 | | | |
| | | 8029768 | Apr 09, 2021 | U-1773 | | | |
| | | 8048451 | Jun 27, 2021 | DP | | | |
| | | 8067437 | Jun 02, 2020 | U-1773 | | | |
| | | 8182838 | Oct 20, 2028 | DP | | | |
| | | 8283362 | Jun 02, 2020 | DP U-1773 | | | |
| | | 8303991 | Jun 27, 2021 | DP | | | |
| | | 8435567 | Jun 27, 2021 | DP | | | |
| | | 8479730 | Oct 11, 2028 | DP | | | |
| | | 8580306 | Jun 27, 2021 | DP | | | |
| | | 8658673 | Jun 02, 2020 | DP U-1773 | | | |
| | | 8796307 | Jun 02, 2020 | DP | | | |
| | | 8956661 | Jun 27, 2021 | DP | | | |
| GOSERELIN ACETATE - ZOLADEX | | | | | | | |
| N 019726 | 001 | 7118552 | Apr 13, 2022 | DP | | | |
| | | 7220247 | Apr 09, 2022 | DP | | | |
| | | 7500964 | Feb 26, 2021 | DP | | | |
| GOSERELIN ACETATE - ZOLADEX | | | | | | | |
| N 020578 | 001 | 7118552 | Apr 13, 2022 | DP | | | |
| | | 7220247 | Apr 09, 2022 | DP | | | |
| | | 7500964 | Feb 26, 2021 | DP | | | |
| GRANISETRON - SANCUSO | | | | | | | |
| N 022198 | 001 | 7608282 | Jan 22, 2025 | DP U-1011 | | | |
| GRANISETRON - SUSTOL | | | | | | | |
| N 022445 | 001 | 6613355 | Jun 28, 2021 | DP | | NDF | Aug 09, 2019 |
| | | 6790458 | May 11, 2021 | DP | | | |
| | | 8252304 | Sep 28, 2024 | DP | | | |
| | | 8252305 | Sep 28, 2024 | U-1891 | | | |
| | | 8715710 | Sep 28, 2024 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| GRANISETRON - SUSTOL | | | | | | | |
| N 022445 | 001 | 6613355 | Jun 28, 2021 | DP | | NDF | Aug 09, 2019 |
| | | 6790458 | May 11, 2021 | DP | | | |
| | | 8252304 | Sep 28, 2024 | DP | | | |
| | | 8252305 | Sep 28, 2024 | U-1891 | | | |
| | | 8715710 | Sep 28, 2024 | DP | | | |
| GUAIFENESIN - MUCINEX | | | | | | | |
| N 021282 | 001 | 6372252 | Apr 28, 2020 | U-489 | | | |
| | | 6955821 | Apr 28, 2020 | DP U-489 | | | |
| | | 7838032 | Apr 28, 2020 | DP | | | |
| GUAIFENESIN - MUCINEX | | | | | | | |
| N 021282 | 002 | 6372252 | Apr 28, 2020 | U-489 | | | |
| | | 6955821 | Apr 28, 2020 | DP U-489 | | | |
| | | 7838032 | Apr 28, 2020 | DP | | | |
| GUAIFENESIN; HYDROCODONE BITARTRATE - OBREDON | | | | | | | |
| N 205474 | 001 | 9549907 | Nov 13, 2035 | DS DP U-2023 | | | |
| GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE - MUCINEX D | | | | | | | |
| N 021585 | 001 | 6372252 | Apr 28, 2020 | DP | | | |
| | | 6955821 | Apr 28, 2020 | DP U-686 | | | |
| | | 7838032 | Apr 28, 2020 | DP | | | |
| GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE - MUCINEX D | | | | | | | |
| N 021585 | 002 | 6372252 | Apr 28, 2020 | DP | | | |
| | | 6955821 | Apr 28, 2020 | DP U-686 | | | |
| | | 7838032 | Apr 28, 2020 | DP | | | |
| GUANFACINE HYDROCHLORIDE - INTUNIV | | | | | | | |
| N 022037 | 001 | 6287599 | Dec 20, 2020 | DP | | D-145 | Nov 19, 2017 |
| | | 6287599*PED | Jun 20, 2021 | | | M-154 | Mar 18, 2018 |
| | | 6811794 | Jul 04, 2022 | DP U-494 | | PED | May 19, 2018 |
| | | 6811794*PED | Jan 04, 2023 | | | | |
| GUANFACINE HYDROCHLORIDE - INTUNIV | | | | | | | |
| N 022037 | 002 | 6287599 | Dec 20, 2020 | DP | | D-145 | Nov 19, 2017 |
| | | 6287599*PED | Jun 20, 2021 | | | M-154 | Mar 18, 2018 |
| | | 6811794 | Jul 04, 2022 | DP U-494 | | PED | May 19, 2018 |
| | | 6811794*PED | Jan 04, 2023 | | | | |
| GUANFACINE HYDROCHLORIDE - INTUNIV | | | | | | | |
| N 022037 | 003 | 6287599 | Dec 20, 2020 | DP | | D-145 | Nov 19, 2017 |
| | | 6287599*PED | Jun 20, 2021 | | | M-154 | Mar 18, 2018 |
| | | 6811794 | Jul 04, 2022 | DP U-494 | | PED | May 19, 2018 |
| | | 6811794*PED | Jan 04, 2023 | | | | |
| GUANFACINE HYDROCHLORIDE - INTUNIV | | | | | | | |
| N 022037 | 004 | 6287599 | Dec 20, 2020 | DP | | D-145 | Nov 19, 2017 |
| | | 6287599*PED | Jun 20, 2021 | | | M-154 | Mar 18, 2018 |
| | | 6811794 | Jul 04, 2022 | DP U-494 | | PED | May 19, 2018 |
| | | 6811794*PED | Jan 04, 2023 | | | | |
| HALOBETASOL PROPIONATE - ULTRAVATE | | | | | | | |
| N 208183 | 001 | 8962028 | Jun 19, 2033 | DP U-1775 | | NP | Nov 06, 2018 |
| HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT | | | | | | | |
| N 022555 | 001 | 7348361 | Nov 06, 2020 | DP U-1087 | | | |
| HISTRELIN ACETATE - SUPPRELIN LA | | | | | | | |
| N 022058 | 001 | 8062652 | Jun 16, 2026 | U-1197 | | | |
| HYALURONIDASE RECOMBINANT HUMAN - HYLENEX RECOMBINANT | | | | | | | |
| N 021859 | 001 | 7767429 | Sep 23, 2027 | DS DP | | | |
| HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE - BIDIL | | | | | | | |
| N 020727 | 001 | 6465463 | Sep 08, 2020 | U-71 | | | |
| | | 6784177 | Sep 08, 2020 | U-71 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|
| HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT | | | | | | | | |
| N | 021162 | 001 | 6358986 | Jan 10, 2020 | | | | |
| HYDROCHLOROTHIAZIDE; TELMISARTAN - MICARDIS HCT | | | | | | | | |
| N | 021162 | 002 | 6358986 | Jan 10, 2020 | | | | |
| HYDROCODONE BITARTRATE - ZOHYDRO ER | | | | | | | | |
| N | 202880 | 001 | 6228398 | Nov 01, 2019 | DP | | | |
| | | | 6902742 | Nov 01, 2019 | DP | | | |
| | | | 9132096 | Sep 12, 2034 | DP | | | |
| | | | 9265760 | Jul 25, 2033 | | | U-1810 | |
| | | | 9326982 | Jul 25, 2033 | | | U-1810 | |
| | | | 9333201 | Jul 25, 2033 | | | U-1810 | |
| | | | 9339499 | Jul 25, 2033 | | | U-1810 | |
| | | | 9421200 | Jul 25, 2033 | | | U-1810 | |
| | | | 9433619 | Jul 25, 2033 | | | U-1810 | |
| | | | 9452163 | Sep 12, 2034 | | | U-55 | |
| | | | 9486451 | Sep 12, 2034 | | | U-55 | |
| | | | 9610286 | Jul 25, 2033 | | | U-1810 | |
| | | | 9713611 | Sep 12, 2034 | DP | | U-55 | |
| HYDROCODONE BITARTRATE - ZOHYDRO ER | | | | | | | | |
| N | 202880 | 002 | 6228398 | Nov 01, 2019 | DP | | | |
| | | | 6902742 | Nov 01, 2019 | DP | | | |
| | | | 9132096 | Sep 12, 2034 | DP | | | |
| | | | 9265760 | Jul 25, 2033 | | | U-1810 | |
| | | | 9326982 | Jul 25, 2033 | | | U-1810 | |
| | | | 9333201 | Jul 25, 2033 | | | U-1810 | |
| | | | 9339499 | Jul 25, 2033 | | | U-1810 | |
| | | | 9421200 | Jul 25, 2033 | | | U-1810 | |
| | | | 9433619 | Jul 25, 2033 | | | U-1810 | |
| | | | 9452163 | Sep 12, 2034 | | | U-55 | |
| | | | 9486451 | Sep 12, 2034 | | | U-55 | |
| | | | 9610286 | Jul 25, 2033 | | | U-1810 | |
| | | | 9713611 | Sep 12, 2034 | DP | | U-55 | |
| HYDROCODONE BITARTRATE - ZOHYDRO ER | | | | | | | | |
| N | 202880 | 003 | 6228398 | Nov 01, 2019 | DP | | | |
| | | | 6902742 | Nov 01, 2019 | DP | | | |
| | | | 9132096 | Sep 12, 2034 | DP | | | |
| | | | 9265760 | Jul 25, 2033 | | | U-1810 | |
| | | | 9326982 | Jul 25, 2033 | | | U-1810 | |
| | | | 9333201 | Jul 25, 2033 | | | U-1810 | |
| | | | 9339499 | Jul 25, 2033 | | | U-1810 | |
| | | | 9421200 | Jul 25, 2033 | | | U-1810 | |
| | | | 9433619 | Jul 25, 2033 | | | U-1810 | |
| | | | 9452163 | Sep 12, 2034 | | | U-55 | |
| | | | 9486451 | Sep 12, 2034 | | | U-55 | |
| | | | 9610286 | Jul 25, 2033 | | | U-1810 | |
| | | | 9713611 | Sep 12, 2034 | DP | | U-55 | |
| HYDROCODONE BITARTRATE - ZOHYDRO ER | | | | | | | | |
| N | 202880 | 004 | 6228398 | Nov 01, 2019 | DP | | | |
| | | | 6902742 | Nov 01, 2019 | DP | | | |
| | | | 9132096 | Sep 12, 2034 | DP | | | |
| | | | 9265760 | Jul 25, 2033 | | | U-1810 | |
| | | | 9326982 | Jul 25, 2033 | | | U-1810 | |
| | | | 9333201 | Jul 25, 2033 | | | U-1810 | |
| | | | 9339499 | Jul 25, 2033 | | | U-1810 | |
| | | | 9421200 | Jul 25, 2033 | | | U-1810 | |
| | | | 9433619 | Jul 25, 2033 | | | U-1810 | |
| | | | 9452163 | Sep 12, 2034 | | | U-55 | |
| | | | 9486451 | Sep 12, 2034 | | | U-55 | |
| | | | 9610286 | Jul 25, 2033 | | | U-1810 | |
| | | | 9713611 | Sep 12, 2034 | DP | | U-55 | |
| HYDROCODONE BITARTRATE - ZOHYDRO ER | | | | | | | | |
| N | 202880 | 005 | 6228398 | Nov 01, 2019 | DP | | | |
| | | | 6902742 | Nov 01, 2019 | DP | | | |
| | | | 9132096 | Sep 12, 2034 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| HYDROCODONE BITARTRATE - ZOHYDRO ER | | | | | | |
| N 202880 005 | 9265760 | Jul 25, 2033 | U-1810 | | | |
| | 9326982 | Jul 25, 2033 | U-1810 | | | |
| | 9333201 | Jul 25, 2033 | U-1810 | | | |
| | 9339499 | Jul 25, 2033 | U-1810 | | | |
| | 9421200 | Jul 25, 2033 | U-1810 | | | |
| | 9433619 | Jul 25, 2033 | U-1810 | | | |
| | 9452163 | Sep 12, 2034 | U-55 | | | |
| | 9486451 | Sep 12, 2034 | U-55 | | | |
| | 9610286 | Jul 25, 2033 | U-1810 | | | |
| | 9713611 | Sep 12, 2034 | DP U-55 | | | |
| HYDROCODONE BITARTRATE - ZOHYDRO ER | | | | | | |
| N 202880 006 | 6228398 | Nov 01, 2019 | DP | | | |
| | 6902742 | Nov 01, 2019 | DP | | | |
| | 9132096 | Sep 12, 2034 | DP | | | |
| | 9265760 | Jul 25, 2033 | U-1810 | | | |
| | 9326982 | Jul 25, 2033 | U-1810 | | | |
| | 9333201 | Jul 25, 2033 | U-1810 | | | |
| | 9339499 | Jul 25, 2033 | U-1810 | | | |
| | 9421200 | Jul 25, 2033 | U-1810 | | | |
| | 9433619 | Jul 25, 2033 | U-1810 | | | |
| | 9452163 | Sep 12, 2034 | U-55 | | | |
| | 9486451 | Sep 12, 2034 | U-55 | | | |
| | 9610286 | Jul 25, 2033 | U-1810 | | | |
| | 9713611 | Sep 12, 2034 | DP U-55 | | | |
| HYDROCODONE BITARTRATE - HYSINGLA | | | | | | |
| N 206627 001 | 6733783 | Oct 30, 2021 | DP U-1556 | | | |
| | 8309060 | Nov 20, 2023 | DP U-1556 | | | |
| | 8361499 | Oct 30, 2021 | DP | | | |
| | 8529948 | Aug 06, 2022 | DP | | | |
| | 8551520 | Oct 30, 2021 | DP | | | |
| | 8647667 | Oct 30, 2021 | DP | | | |
| | 8808740 | Dec 21, 2031 | DP U-1556 | | | |
| | 9023401 | Oct 30, 2020 | DP | | | |
| | 9056052 | Oct 30, 2020 | DP | | | |
| | 9060940 | Oct 30, 2020 | U-1556 | | | |
| | 9084816 | Aug 24, 2027 | DP | | | |
| | 9095614 | Aug 24, 2027 | U-1556 | | | |
| | 9095615 | Aug 24, 2027 | DP | | | |
| | 9198863 | Oct 30, 2020 | DP | | | |
| | 9205056 | Oct 30, 2020 | DP | | | |
| | 9289391 | Oct 30, 2020 | DP | | | |
| | 9486412 | Aug 24, 2027 | DP | | | |
| | 9486413 | Aug 24, 2027 | DP | | | |
| | 9492389 | Aug 24, 2027 | DP | | | |
| | 9492390 | Aug 24, 2027 | U-1556 | | | |
| | 9492391 | Aug 24, 2027 | U-1556 | | | |
| | 9517236 | Oct 30, 2020 | DP | | | |
| | 9545380 | Aug 24, 2027 | U-1556 | | | |
| | 9572779 | Dec 21, 2031 | DP | | | |
| | 9572804 | Oct 30, 2020 | DP | | | |
| | 9669023 | Oct 30, 2020 | DP | | | |
| | 9669024 | Oct 30, 2020 | DP | | | |
| | 9675610 | Jun 16, 2023 | DP | | | |
| | 9675611 | Oct 30, 2020 | U-1556 | | | |
| | 9682077 | Oct 30, 2020 | U-1556 | | | |
| | 9750703 | Dec 21, 2031 | DP | | | |
| | 9763933 | Aug 24, 2027 | DP | | | |
| | 9770416 | Aug 24, 2027 | DP | | | |
| | 9775809 | Aug 24, 2027 | DP | | | |
| | 9861584 | Dec 21, 2031 | DP | | | |
| HYDROCODONE BITARTRATE - HYSINGLA | | | | | | |
| N 206627 002 | 6733783 | Oct 30, 2021 | DP U-1556 | | | |
| | 8309060 | Nov 20, 2023 | DP U-1556 | | | |
| | 8361499 | Oct 30, 2021 | DP | | | |
| | 8529948 | Aug 06, 2022 | DP | | | |
| | 8551520 | Oct 30, 2021 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| HYDROCODONE BITARTRATE - HYSINGLA | | | | | | |
| N 206627 002 | 8647667 | Oct 30, 2021 | DP | | | |
| | 8808740 | Dec 21, 2031 | DP | | U-1556 | |
| | 9023401 | Oct 30, 2020 | DP | | | |
| | 9056052 | Oct 30, 2020 | DP | | | |
| | 9060940 | Oct 30, 2020 | | | U-1556 | |
| | 9084816 | Aug 24, 2027 | DP | | | |
| | 9095614 | Aug 24, 2027 | | | U-1556 | |
| | 9095615 | Aug 24, 2027 | DP | | | |
| | 9198863 | Oct 30, 2020 | DP | | | |
| | 9205056 | Oct 30, 2020 | DP | | | |
| | 9289391 | Oct 30, 2020 | DP | | | |
| | 9486412 | Aug 24, 2027 | DP | | | |
| | 9486413 | Aug 24, 2027 | DP | | | |
| | 9492389 | Aug 24, 2027 | DP | | | |
| | 9492390 | Aug 24, 2027 | | | U-1556 | |
| | 9492391 | Aug 24, 2027 | | | U-1556 | |
| | 9517236 | Oct 30, 2020 | DP | | | |
| | 9545380 | Aug 24, 2027 | | | U-1556 | |
| | 9572779 | Dec 21, 2031 | DP | | | |
| | 9572804 | Oct 30, 2020 | DP | | | |
| | 9669023 | Oct 30, 2020 | DP | | | |
| | 9669024 | Oct 30, 2020 | DP | | | |
| | 9675610 | Jun 16, 2023 | DP | | | |
| | 9675611 | Oct 30, 2020 | | | U-1556 | |
| | 9682077 | Oct 30, 2020 | | | U-1556 | |
| | 9750703 | Dec 21, 2031 | DP | | | |
| | 9763933 | Aug 24, 2027 | DP | | | |
| | 9770416 | Aug 24, 2027 | DP | | | |
| | 9775809 | Aug 24, 2027 | DP | | | |
| | 9861584 | Dec 21, 2031 | DP | | | |
| HYDROCODONE BITARTRATE - HYSINGLA | | | | | | |
| N 206627 003 | 6733783 | Oct 30, 2021 | DP | | U-1556 | |
| | 8309060 | Nov 20, 2023 | DP | | U-1556 | |
| | 8361499 | Oct 30, 2021 | DP | | | |
| | 8529948 | Aug 06, 2022 | DP | | | |
| | 8551520 | Oct 30, 2021 | DP | | | |
| | 8647667 | Oct 30, 2021 | DP | | | |
| | 8808740 | Dec 21, 2031 | DP | | U-1556 | |
| | 9023401 | Oct 30, 2020 | DP | | | |
| | 9056052 | Oct 30, 2020 | DP | | | |
| | 9060940 | Oct 30, 2020 | | | U-1556 | |
| | 9084816 | Aug 24, 2027 | DP | | | |
| | 9095614 | Aug 24, 2027 | | | U-1556 | |
| | 9095615 | Aug 24, 2027 | DP | | | |
| | 9198863 | Oct 30, 2020 | DP | | | |
| | 9205056 | Oct 30, 2020 | DP | | | |
| | 9289391 | Oct 30, 2020 | DP | | | |
| | 9486412 | Aug 24, 2027 | DP | | | |
| | 9486413 | Aug 24, 2027 | DP | | | |
| | 9492389 | Aug 24, 2027 | DP | | | |
| | 9492390 | Aug 24, 2027 | | | U-1556 | |
| | 9492391 | Aug 24, 2027 | | | U-1556 | |
| | 9517236 | Oct 30, 2020 | DP | | | |
| | 9545380 | Aug 24, 2027 | | | U-1556 | |
| | 9572779 | Dec 21, 2031 | DP | | | |
| | 9572804 | Oct 30, 2020 | DP | | | |
| | 9669023 | Oct 30, 2020 | DP | | | |
| | 9669024 | Oct 30, 2020 | DP | | | |
| | 9675610 | Jun 16, 2023 | DP | | | |
| | 9675611 | Oct 30, 2020 | | | U-1556 | |
| | 9682077 | Oct 30, 2020 | | | U-1556 | |
| | 9750703 | Dec 21, 2031 | DP | | | |
| | 9763933 | Aug 24, 2027 | DP | | | |
| | 9770416 | Aug 24, 2027 | DP | | | |
| | 9775809 | Aug 24, 2027 | DP | | | |
| | 9861584 | Dec 21, 2031 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| HYDROCODONE BITARTRATE - HYSINGLA | | | | | | |
| N 206627 004 | 6733783 | Oct 30, 2021 | DP U-1556 | | | |
| | 8309060 | Nov 20, 2023 | DP U-1556 | | | |
| | 8361499 | Oct 30, 2021 | DP | | | |
| | 8529948 | Aug 06, 2022 | DP | | | |
| | 8551520 | Oct 30, 2021 | DP | | | |
| | 8647667 | Oct 30, 2021 | DP | | | |
| | 8808740 | Dec 21, 2031 | DP U-1556 | | | |
| | 9023401 | Oct 30, 2020 | DP | | | |
| | 9056052 | Oct 30, 2020 | DP | | | |
| | 9060940 | Oct 30, 2020 | U-1556 | | | |
| | 9084816 | Aug 24, 2027 | DP | | | |
| | 9095614 | Aug 24, 2027 | U-1556 | | | |
| | 9095615 | Aug 24, 2027 | DP | | | |
| | 9198863 | Oct 30, 2020 | DP | | | |
| | 9205056 | Oct 30, 2020 | DP | | | |
| | 9289391 | Oct 30, 2020 | DP | | | |
| | 9486412 | Aug 24, 2027 | DP | | | |
| | 9486413 | Aug 24, 2027 | DP | | | |
| | 9492389 | Aug 24, 2027 | DP | | | |
| | 9492390 | Aug 24, 2027 | U-1556 | | | |
| | 9492391 | Aug 24, 2027 | U-1556 | | | |
| | 9517236 | Oct 30, 2020 | DP | | | |
| | 9545380 | Aug 24, 2027 | U-1556 | | | |
| | 9572779 | Dec 21, 2031 | DP | | | |
| | 9572804 | Oct 30, 2020 | DP | | | |
| | 9669023 | Oct 30, 2020 | DP | | | |
| | 9669024 | Oct 30, 2020 | DP | | | |
| | 9675610 | Jun 16, 2023 | DP | | | |
| | 9675611 | Oct 30, 2020 | U-1556 | | | |
| | 9682077 | Oct 30, 2020 | U-1556 | | | |
| | 9750703 | Dec 21, 2031 | DP | | | |
| | 9763933 | Aug 24, 2027 | DP | | | |
| | 9770416 | Aug 24, 2027 | DP | | | |
| | 9775809 | Aug 24, 2027 | DP | | | |
| | 9861584 | Dec 21, 2031 | DP | | | |
| HYDROCODONE BITARTRATE - HYSINGLA | | | | | | |
| N 206627 005 | 6733783 | Oct 30, 2021 | DP U-1556 | | | |
| | 8309060 | Nov 20, 2023 | DP U-1556 | | | |
| | 8361499 | Oct 30, 2021 | DP | | | |
| | 8529948 | Aug 06, 2022 | DP | | | |
| | 8551520 | Oct 30, 2021 | DP | | | |
| | 8647667 | Oct 30, 2021 | DP | | | |
| | 8808740 | Dec 21, 2031 | DP U-1556 | | | |
| | 9056052 | Oct 30, 2020 | DP | | | |
| | 9060940 | Oct 30, 2020 | U-1556 | | | |
| | 9084816 | Aug 24, 2027 | DP | | | |
| | 9095614 | Aug 24, 2027 | U-1556 | | | |
| | 9095615 | Aug 24, 2027 | DP | | | |
| | 9198863 | Oct 30, 2020 | DP | | | |
| | 9205056 | Oct 30, 2020 | DP | | | |
| | 9289391 | Oct 30, 2020 | DP | | | |
| | 9486412 | Aug 24, 2027 | DP | | | |
| | 9486413 | Aug 24, 2027 | DP | | | |
| | 9492389 | Aug 24, 2027 | DP | | | |
| | 9492390 | Aug 24, 2027 | U-1556 | | | |
| | 9492391 | Aug 24, 2027 | U-1556 | | | |
| | 9517236 | Oct 30, 2020 | DP | | | |
| | 9545380 | Aug 24, 2027 | U-1556 | | | |
| | 9572779 | Dec 21, 2031 | DP | | | |
| | 9572804 | Oct 30, 2020 | DP | | | |
| | 9669023 | Oct 30, 2020 | DP | | | |
| | 9669024 | Oct 30, 2020 | DP | | | |
| | 9675610 | Jun 16, 2023 | DP | | | |
| | 9675611 | Oct 30, 2020 | U-1556 | | | |
| | 9682077 | Oct 30, 2020 | U-1556 | | | |
| | 9750703 | Dec 21, 2031 | DP | | | |
| | 9763933 | Aug 24, 2027 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| HYDROCODONE BITARTRATE - HYSINGLA | | | | | | |
| N 206627 005 | 9770416 | Aug 24, 2027 | DP | | | |
| | 9775809 | Aug 24, 2027 | DP | | | |
| | 9861584 | Dec 21, 2031 | DP | | | |
| HYDROCODONE BITARTRATE - HYSINGLA | | | | | | |
| N 206627 006 | 6733783 | Oct 30, 2021 | DP | | U-1556 | |
| | 8309060 | Nov 20, 2023 | DP | | U-1556 | |
| | 8361499 | Oct 30, 2021 | DP | | | |
| | 8529948 | Aug 06, 2022 | DP | | | |
| | 8551520 | Oct 30, 2021 | DP | | | |
| | 8647667 | Oct 30, 2021 | DP | | | |
| | 8808740 | Dec 21, 2031 | DP | | U-1556 | |
| | 9056052 | Oct 30, 2020 | DP | | | |
| | 9060940 | Oct 30, 2020 | | | U-1556 | |
| | 9084816 | Aug 24, 2027 | DP | | | |
| | 9095614 | Aug 24, 2027 | | | U-1556 | |
| | 9095615 | Aug 24, 2027 | DP | | | |
| | 9198863 | Oct 30, 2020 | DP | | | |
| | 9205056 | Oct 30, 2020 | DP | | | |
| | 9289391 | Oct 30, 2020 | DP | | | |
| | 9486412 | Aug 24, 2027 | DP | | | |
| | 9486413 | Aug 24, 2027 | DP | | | |
| | 9492389 | Aug 24, 2027 | DP | | | |
| | 9492390 | Aug 24, 2027 | | | U-1556 | |
| | 9492391 | Aug 24, 2027 | | | U-1556 | |
| | 9517236 | Oct 30, 2020 | DP | | | |
| | 9545380 | Aug 24, 2027 | | | U-1556 | |
| | 9572779 | Dec 21, 2031 | DP | | | |
| | 9572804 | Oct 30, 2020 | DP | | | |
| | 9669023 | Oct 30, 2020 | DP | | | |
| | 9669024 | Oct 30, 2020 | DP | | | |
| | 9675610 | Jun 16, 2023 | DP | | | |
| | 9675611 | Oct 30, 2020 | | | U-1556 | |
| | 9682077 | Oct 30, 2020 | | | U-1556 | |
| | 9750703 | Dec 21, 2031 | DP | | | |
| | 9763933 | Aug 24, 2027 | DP | | | |
| | 9770416 | Aug 24, 2027 | DP | | | |
| | 9775809 | Aug 24, 2027 | DP | | | |
| | 9861584 | Dec 21, 2031 | DP | | | |
| HYDROCODONE BITARTRATE - HYSINGLA | | | | | | |
| N 206627 007 | 6733783 | Oct 30, 2021 | DP | | U-1556 | |
| | 8309060 | Nov 20, 2023 | DP | | U-1556 | |
| | 8361499 | Oct 30, 2021 | DP | | | |
| | 8529948 | Aug 06, 2022 | DP | | | |
| | 8551520 | Oct 30, 2021 | DP | | | |
| | 8647667 | Oct 30, 2021 | DP | | | |
| | 8808740 | Dec 21, 2031 | DP | | U-1556 | |
| | 9056052 | Oct 30, 2020 | DP | | | |
| | 9060940 | Oct 30, 2020 | | | U-1556 | |
| | 9084816 | Aug 24, 2027 | DP | | | |
| | 9095614 | Aug 24, 2027 | | | U-1556 | |
| | 9095615 | Aug 24, 2027 | DP | | | |
| | 9198863 | Oct 30, 2020 | DP | | | |
| | 9205056 | Oct 30, 2020 | DP | | | |
| | 9289391 | Oct 30, 2020 | DP | | | |
| | 9486412 | Aug 24, 2027 | DP | | | |
| | 9486413 | Aug 24, 2027 | DP | | | |
| | 9492389 | Aug 24, 2027 | DP | | | |
| | 9492390 | Aug 24, 2027 | | | U-1556 | |
| | 9492391 | Aug 24, 2027 | | | U-1556 | |
| | 9517236 | Oct 30, 2020 | DP | | | |
| | 9545380 | Aug 24, 2027 | | | U-1556 | |
| | 9572779 | Dec 21, 2031 | DP | | | |
| | 9572804 | Oct 30, 2021 | DP | | | |
| | 9669023 | Oct 30, 2020 | DP | | | |
| | 9669024 | Oct 30, 2020 | DP | | | |
| | 9675610 | Jun 16, 2023 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|
| HYDROCODONE BITARTRATE - HYSINGLA | | | | | | | | |
| N 206627 | 007 | | 9675611 | Oct 30, 2020 | U-1556 | | | |
| | | | 9682077 | Oct 30, 2020 | U-1556 | | | |
| | | | 9750703 | Dec 21, 2031 | DP | | | |
| | | | 9763933 | Aug 24, 2027 | DP | | | |
| | | | 9770416 | Aug 24, 2027 | DP | | | |
| | | | 9775809 | Aug 24, 2027 | DP | | | |
| | | | 9861584 | Dec 21, 2031 | DP | | | |
| HYDROCODONE BITARTRATE - VANTRELA ER | | | | | | | | |
| N 207975 | 001 | | 8445018 | Jul 31, 2029 | DP | | | |
| | | | 9216176 | Sep 13, 2027 | DP | | | |
| | | | 9572803 | Sep 13, 2027 | DP | | | |
| HYDROCODONE BITARTRATE - VANTRELA ER | | | | | | | | |
| N 207975 | 002 | | 8445018 | Jul 31, 2029 | DP | | | |
| | | | 9216176 | Sep 13, 2027 | DP | | | |
| | | | 9572803 | Sep 13, 2027 | DP | | | |
| HYDROCODONE BITARTRATE - VANTRELA ER | | | | | | | | |
| N 207975 | 003 | | 8445018 | Jul 31, 2029 | DP | | | |
| | | | 9216176 | Sep 13, 2027 | DP | | | |
| | | | 9572803 | Sep 13, 2027 | DP | | | |
| HYDROCODONE BITARTRATE - VANTRELA ER | | | | | | | | |
| N 207975 | 004 | | 8445018 | Jul 31, 2029 | DP | | | |
| | | | 9216176 | Sep 13, 2027 | DP | | | |
| | | | 9572803 | Sep 13, 2027 | DP | | | |
| HYDROCODONE BITARTRATE - VANTRELA ER | | | | | | | | |
| N 207975 | 005 | | 8445018 | Jul 31, 2029 | DP | | | |
| | | | 9216176 | Sep 13, 2027 | DP | | | |
| | | | 9572803 | Sep 13, 2027 | DP | | | |
| HYDROCORTISONE BUTYRATE - LOCOID | | | | | | | | |
| N 022076 | 001 | | 7378405 | Dec 19, 2026 | DP | | | |
| | | | 7981877 | Jan 23, 2025 | DP | | | |
| HYDROGEN PEROXIDE - ESKATA | | | | | | | | |
| N 209305 | 001 | | 7381427 | Jun 08, 2022 | U-2205 | | NP | Dec 14, 2020 |
| | | | 9675639 | Jul 04, 2035 | DP U-2205 | | | |
| HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP | | | | | | | | |
| N 019034 | 001 | | 6589960 | Nov 09, 2020 | DP | | | |
| HYDROMORPHONE HYDROCHLORIDE - DILAUDID-HP | | | | | | | | |
| N 019034 | 002 | | 6589960 | Nov 09, 2020 | DP | | | |
| HYDROMORPHONE HYDROCHLORIDE - DILAUDID | | | | | | | | |
| N 019034 | 003 | | 6589960 | Nov 09, 2020 | DS DP | | | |
| HYDROMORPHONE HYDROCHLORIDE - DILAUDID | | | | | | | | |
| N 019034 | 004 | | 6589960 | Nov 09, 2020 | DS DP | | | |
| HYDROMORPHONE HYDROCHLORIDE - DILAUDID | | | | | | | | |
| N 019034 | 005 | | 6589960 | Nov 09, 2020 | DS DP | | | |
| HYDROMORPHONE HYDROCHLORIDE - DILAUDID | | | | | | | | |
| N 019891 | 001 | | 6589960 | Nov 09, 2020 | DS DP | | | |
| HYDROMORPHONE HYDROCHLORIDE - DILAUDID | | | | | | | | |
| N 019892 | 001 | | 6589960 | Nov 09, 2020 | DS DP | | | |
| HYDROMORPHONE HYDROCHLORIDE - DILAUDID | | | | | | | | |
| N 019892 | 002 | | 6589960 | Nov 09, 2020 | DS DP | | | |
| HYDROMORPHONE HYDROCHLORIDE - DILAUDID | | | | | | | | |
| N 019892 | 003 | | 6589960 | Nov 09, 2020 | DS DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|
| HYDROMORPHONE HYDROCHLORIDE - PALLADONE | | | | | | | | |
| N | 021044 | 001 | 6589960 | Nov 09, 2020 | DP | | | |
| HYDROMORPHONE HYDROCHLORIDE - PALLADONE | | | | | | | | |
| N | 021044 | 002 | 6589960 | Nov 09, 2020 | DP | | | |
| HYDROMORPHONE HYDROCHLORIDE - PALLADONE | | | | | | | | |
| N | 021044 | 003 | 6589960 | Nov 09, 2020 | DP | | | |
| HYDROMORPHONE HYDROCHLORIDE - PALLADONE | | | | | | | | |
| N | 021044 | 004 | 6589960 | Nov 09, 2020 | DP | | | |
| HYDROXYPROGESTERONE CAPROATE - MAKENA | | | | | | | | |
| N | 021945 | 001 | | | | | ODE-7 | Feb 03, 2018 |
| HYDROXYPROGESTERONE CAPROATE - MAKENA PRESERVATIVE FREE | | | | | | | | |
| N | 021945 | 002 | | | | | ODE-7 | Feb 03, 2018 |
| HYDROXYUREA - SIKLOS | | | | | | | | |
| N | 208843 | 001 | | | | | NP | Dec 21, 2020 |
| HYDROXYUREA - SIKLOS | | | | | | | | |
| N | 208843 | 002 | | | | | NP | Dec 21, 2020 |
| IBANDRONATE SODIUM - BONIVA | | | | | | | | |
| N | 021455 | 001 | 6294196 | Oct 07, 2019 | DP | | | |
| IBANDRONATE SODIUM - BONIVA | | | | | | | | |
| N | 021455 | 002 | 6294196 | Oct 07, 2019 | DP | | | |
| | | | 7192938 | May 06, 2023 | U-798 | | | |
| | | | 7410957 | May 06, 2023 | U-887 | | | |
| | | | 7718634 | May 06, 2023 | U-642 | | | |
| IBRUTINIB - IMBRUVICA | | | | | | | | |
| N | 205552 | 001 | 7514444 | Dec 28, 2026 | DS DP | | D-165 | May 06, 2019 |
| | | | 8008309 | Dec 28, 2026 | DS DP | | I-689 | Jul 28, 2017 |
| | | | 8476284 | Dec 28, 2026 | U-1456 | | I-702 | Jan 29, 2018 |
| | | | 8476284 | Dec 28, 2026 | U-1650 | | I-729 | Mar 04, 2019 |
| | | | 8476284 | Dec 28, 2026 | U-1946 | | I-736 | May 06, 2019 |
| | | | 8476284 | Dec 28, 2026 | U-1947 | | I-737 | May 06, 2019 |
| | | | 8497277 | Dec 28, 2026 | U-1456 | | I-741 | Jan 18, 2020 |
| | | | 8497277 | Dec 28, 2026 | U-1491 | | I-753 | Aug 02, 2020 |
| | | | 8497277 | Dec 28, 2026 | U-1650 | | NCE | Nov 13, 2018 |
| | | | 8497277 | Dec 28, 2026 | U-1946 | | ODE-109 | Mar 04, 2023 |
| | | | 8497277 | Dec 28, 2026 | U-1947 | | ODE-117 | May 06, 2023 |
| | | | 8697711 | Dec 28, 2026 | DS DP | | ODE-128 | Jan 18, 2024 |
| | | | 8703780 | Dec 28, 2026 | U-1491 | | ODE-152 | Aug 02, 2024 |
| | | | 8735403 | Dec 28, 2026 | DS DP | | ODE-55 | Nov 13, 2020 |
| | | | 8754090 | Jun 03, 2031 | U-1456 | | ODE-60 | Feb 12, 2021 |
| | | | 8754091 | Dec 28, 2026 | DP | | ODE-72 | Jul 28, 2021 |
| | | | 8952015 | Dec 28, 2026 | U-1456 | | ODE-86 | Jan 29, 2022 |
| | | | 8952015 | Dec 28, 2026 | U-1491 | | | |
| | | | 8952015 | Dec 28, 2026 | U-1650 | | | |
| | | | 8952015 | Dec 28, 2026 | U-1946 | | | |
| | | | 8952015 | Dec 28, 2026 | U-1947 | | | |
| | | | 8957079 | Dec 28, 2026 | DS DP | | | |
| | | | 8999999 | Jun 03, 2031 | U-1683 | | | |
| | | | 8999999 | Jun 03, 2031 | U-1684 | | | |
| | | | 9125889 | Jun 03, 2031 | U-1745 | | | |
| | | | 9181257 | Dec 28, 2026 | DS DP | | | |
| | | | 9296753 | Oct 30, 2033 | DS DP | | | |
| | | | 9540382 | Aug 18, 2033 | U-1456 | | | |
| | | | 9540382 | Aug 18, 2033 | U-1650 | | | |
| | | | 9540382 | Aug 18, 2033 | U-1684 | | | |
| | | | 9540382 | Aug 18, 2033 | U-1946 | | | |
| | | | 9540382 | Aug 18, 2033 | U-1947 | | | |
| | | | 9713617 | Jun 03, 2033 | DP | | | |
| | | | 9725455 | Jun 03, 2033 | DS | | | |
| | | | 9795604 | Oct 24, 2034 | U-2150 | | | |
| | | | 9801881 | Jun 03, 2031 | U-1491 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| IBRUTINIB - IMBRUVICA | | | | | | | |
| N 205552 | 001 | 9801883 | Jun 03, 2031 | U-2159 | | | |
| | | 9814721 | Jun 03, 2031 | U-1947 | | | |
| IBUPROFEN - MIDOL LIQUID GELS | | | | | | | |
| N 021472 | 001 | 6251426 | Jun 25, 2018 | | | | |
| IBUPROFEN - CALDOLOR | | | | | | | |
| N 022348 | 001 | 6727286 | Nov 27, 2021 | DP U-981 | | | |
| IBUPROFEN - CALDOLOR | | | | | | | |
| N 022348 | 002 | 6727286 | Nov 27, 2021 | DP U-981 | | D-152 | Nov 20, 2018 |
| | | 8735452 | Sep 30, 2029 | U-981 | | NPP | Nov 20, 2018 |
| | | 8871810 | Sep 30, 2029 | U-1599 | | | |
| | | 9012508 | Sep 14, 2030 | U-981 | | | |
| | | 9114068 | Sep 30, 2029 | U-1735 | | | |
| | | 9138404 | Sep 30, 2029 | U-1756 | | | |
| | | 9295639 | Sep 30, 2029 | U-1756 | | | |
| | | 9649284 | Sep 30, 2029 | U-2018 | | | |
| IBUPROFEN LYSINE - NEOPROFEN | | | | | | | |
| N 021903 | 001 | 6342530 | Nov 14, 2020 | DP U-1127 | | | |
| | | 6342530 | Nov 14, 2020 | DP U-794 | | | |
| | | 6344479 | Mar 20, 2021 | DS DP U-794 | Y | | |
| | | 8415337 | Mar 02, 2032 | DS DP | | | |
| IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE - CHILDREN'S MOTRIN COLD | | | | | | | |
| N 021128 | 001 | 6211246 | Jun 10, 2019 | | | | |
| ICATIBANT ACETATE - FIRAZYR | | | | | | | |
| N 022150 | 001 | 5648333 | Jul 15, 2019 | DS DP U-1187 | | ODE-14 | Aug 25, 2018 |
| ICODEXTRIN - EXTRANEAL | | | | | | | |
| N 021321 | 001 | 6248726 | Jun 19, 2018 | U-495 | | | |
| ICOSAPENT ETHYL - VASCEPA | | | | | | | |
| N 202057 | 001 | 8188146 | Jan 27, 2020 | DS DP | | NCE | Jul 26, 2017 |
| | | 8293727 | Feb 09, 2030 | U-1287 | | | |
| | | 8293728 | Feb 09, 2030 | U-1287 | | | |
| | | 8298554 | Apr 29, 2030 | DP | | | |
| | | 8314086 | Feb 09, 2030 | U-1287 | | | |
| | | 8318715 | Feb 09, 2030 | U-1287 | | | |
| | | 8357677 | Feb 09, 2030 | U-1287 | | | |
| | | 8367652 | Feb 09, 2030 | U-1287 | | | |
| | | 8377920 | Feb 09, 2030 | U-1287 | | | |
| | | 8399446 | Feb 09, 2030 | U-1287 | | | |
| | | 8415335 | Feb 09, 2030 | U-1287 | | | |
| | | 8426399 | Feb 09, 2030 | U-1287 | | | |
| | | 8431560 | Feb 09, 2030 | U-1287 | | | |
| | | 8440650 | Feb 09, 2030 | U-1287 | | | |
| | | 8445003 | Apr 29, 2030 | U-1287 | | | |
| | | 8445013 | Apr 29, 2030 | U-1287 | | | |
| | | 8501225 | Apr 29, 2030 | U-1287 | | | |
| | | 8518929 | Apr 29, 2030 | U-1287 | | | |
| | | 8524698 | Apr 29, 2030 | U-1287 | | | |
| | | 8546372 | Apr 29, 2030 | U-1287 | | | |
| | | 8551521 | Apr 29, 2030 | U-1287 | | | |
| | | 8563608 | Apr 29, 2030 | U-1287 | | | |
| | | 8617593 | Apr 29, 2030 | U-1478 | | | |
| | | 8617594 | Apr 29, 2030 | U-1287 | | | |
| | | 8623406 | Apr 29, 2030 | U-1478 | | | |
| ICOSAPENT ETHYL - VASCEPA | | | | | | | |
| N 202057 | 002 | 8188146 | Jan 27, 2020 | DS DP | | NCE | Jul 26, 2017 |
| | | 8293727 | Feb 09, 2030 | U-1287 | | | |
| | | 8293728 | Feb 09, 2030 | U-1287 | | | |
| | | 8298554 | Apr 29, 2030 | DP | | | |
| | | 8314086 | Feb 09, 2030 | U-1287 | | | |
| | | 8318715 | Feb 09, 2030 | U-1287 | | | |
| | | 8357677 | Feb 09, 2030 | U-1287 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| ICOSAPENT ETHYL - VASCEPA | | | | | | |
| N 202057 002 | 8367652 | Feb 09, 2030 | U-1287 | | | |
| | 8377920 | Feb 09, 2030 | U-1287 | | | |
| | 8399446 | Feb 09, 2030 | U-1287 | | | |
| | 8415335 | Feb 09, 2030 | U-1287 | | | |
| | 8426399 | Feb 09, 2030 | U-1287 | | | |
| | 8440650 | Feb 09, 2030 | U-1287 | | | |
| | 8445003 | Apr 29, 2030 | U-1287 | | | |
| | 8445013 | Apr 29, 2030 | U-1287 | | | |
| | 8501225 | Apr 29, 2030 | U-1287 | | | |
| | 8518929 | Apr 29, 2030 | U-1287 | | | |
| | 8524698 | Apr 29, 2030 | U-1287 | | | |
| | 8546372 | Apr 29, 2030 | U-1287 | | | |
| | 8551521 | Apr 29, 2030 | U-1287 | | | |
| | 8563608 | Apr 29, 2030 | U-1287 | | | |
| | 8617593 | Apr 29, 2030 | U-1287 | | | |
| | 8617594 | Apr 29, 2030 | U-1287 | | | |
| | 8623406 | Apr 29, 2030 | U-1287 | | | |
| IDELALISIB - ZYDELIG | | | | | | |
| N 205858 001 | 6800620 | Apr 24, 2021 | DS U-1560 | | NCE | Jul 23, 2019 |
| | 6949535 | Apr 24, 2021 | DS U-1560 | | ODE-70 | Jul 23, 2021 |
| | 8138195 | Apr 24, 2021 | DS DP U-1549 | | ODE-71 | Jul 23, 2021 |
| | 8492389 | Apr 24, 2021 | DS DP | | | |
| | 8637533 | Apr 24, 2021 | DS DP | | | |
| | 8865730 | Mar 05, 2033 | DS DP U-1615 | | | |
| | 8980901 | May 12, 2025 | U-1678 | | | |
| | 9149477 | May 12, 2025 | U-1757 | | | |
| | 9469643 | Sep 02, 2033 | DS | | | |
| | 9492449 | Mar 11, 2030 | U-1914 | | | |
| | RE44599 | Jul 21, 2025 | U-1558 | | | |
| | RE44599 | Jul 21, 2025 | U-1615 | | | |
| | RE44638 | Aug 05, 2025 | DS DP | | | |
| IDELALISIB - ZYDELIG | | | | | | |
| N 205858 002 | 6800620 | Apr 24, 2021 | DS U-1560 | | NCE | Jul 23, 2019 |
| | 6949535 | Apr 24, 2021 | DS U-1560 | | ODE-70 | Jul 23, 2021 |
| | 8138195 | Apr 24, 2021 | DS DP U-1549 | | ODE-71 | Jul 23, 2021 |
| | 8492389 | Apr 24, 2021 | DS DP | | | |
| | 8637533 | Apr 24, 2021 | DS DP | | | |
| | 8865730 | Mar 05, 2033 | DS DP U-1615 | | | |
| | 8980901 | May 12, 2025 | U-1678 | | | |
| | 9149477 | May 12, 2025 | U-1757 | | | |
| | 9469643 | Sep 02, 2033 | DS | | | |
| | 9492449 | Mar 11, 2030 | U-1914 | | | |
| | RE44599 | Jul 21, 2025 | U-1558 | | | |
| | RE44599 | Jul 21, 2025 | U-1615 | | | |
| | RE44638 | Aug 05, 2025 | DS DP | | | |
| ILOPERIDONE - FANAPT | | | | | | |
| N 022192 001 | 8586610 | Nov 02, 2027 | U-1625 | | M-180 | May 26, 2019 |
| | 8652776 | Aug 31, 2030 | U-1685 | | | |
| | 8999638 | Oct 28, 2030 | U-1674 | | | |
| | 9072742 | Jan 16, 2031 | U-1674 | | | |
| | 9074254 | Dec 28, 2031 | U-1674 | | | |
| | 9074255 | Dec 17, 2030 | U-1674 | | | |
| | 9074256 | Feb 10, 2031 | U-1674 | | | |
| | 9138432 | Sep 30, 2025 | U-1737 | | | |
| | 9157121 | Apr 05, 2030 | U-1674 | | | |
| ILOPERIDONE - FANAPT | | | | | | |
| N 022192 002 | 8586610 | Nov 02, 2027 | U-1625 | | M-180 | May 26, 2019 |
| | 8652776 | Aug 31, 2030 | U-1685 | | | |
| | 8999638 | Oct 28, 2030 | U-1674 | | | |
| | 9072742 | Jan 16, 2031 | U-1674 | | | |
| | 9074254 | Dec 28, 2031 | U-1674 | | | |
| | 9074255 | Dec 17, 2030 | U-1674 | | | |
| | 9074256 | Feb 10, 2031 | U-1674 | | | |
| | 9138432 | Sep 30, 2025 | U-1737 | | | |
| | 9157121 | Apr 05, 2030 | U-1674 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| ILOPERIDONE - FANAPT | | | | | | |
| N 022192 002 | 8586610 | Nov 02, 2027 | U-1625 | | M-180 | May 26, 2019 |
| | 8652776 | Aug 31, 2030 | U-1685 | | | |
| | 8999638 | Oct 28, 2030 | U-1674 | | | |
| | 9072742 | Jan 16, 2031 | U-1674 | | | |
| | 9074254 | Dec 28, 2031 | U-1674 | | | |
| | 9074255 | Dec 17, 2030 | U-1674 | | | |
| | 9074256 | Feb 10, 2031 | U-1674 | | | |
| | 9138432 | Sep 30, 2025 | U-1737 | | | |
| | 9157121 | Apr 05, 2030 | U-1674 | | | |
| ILOPERIDONE - FANAPT | | | | | | |
| N 022192 003 | 8586610 | Nov 02, 2027 | U-1625 | | M-180 | May 26, 2019 |
| | 8652776 | Aug 31, 2030 | U-1685 | | | |
| | 8999638 | Oct 28, 2030 | U-1674 | | | |
| | 9072742 | Jan 16, 2031 | U-1674 | | | |
| | 9074254 | Dec 28, 2031 | U-1674 | | | |
| | 9074255 | Dec 17, 2030 | U-1674 | | | |
| | 9074256 | Feb 10, 2031 | U-1674 | | | |
| | 9138432 | Sep 30, 2025 | U-1737 | | | |
| | 9157121 | Apr 05, 2030 | U-1674 | | | |
| ILOPERIDONE - FANAPT | | | | | | |
| N 022192 004 | 8586610 | Nov 02, 2027 | U-1625 | | M-180 | May 26, 2019 |
| | 8652776 | Aug 31, 2030 | U-1685 | | | |
| | 8999638 | Oct 28, 2030 | U-1674 | | | |
| | 9072742 | Jan 16, 2031 | U-1674 | | | |
| | 9074254 | Dec 28, 2031 | U-1674 | | | |
| | 9074255 | Dec 17, 2030 | U-1674 | | | |
| | 9074256 | Feb 10, 2031 | U-1674 | | | |
| | 9138432 | Sep 30, 2025 | U-1737 | | | |
| | 9157121 | Apr 05, 2030 | U-1674 | | | |
| ILOPERIDONE - FANAPT | | | | | | |
| N 022192 005 | 8586610 | Nov 02, 2027 | U-1625 | | M-180 | May 26, 2019 |
| | 8652776 | Aug 31, 2030 | U-1685 | | | |
| | 8999638 | Oct 28, 2030 | U-1674 | | | |
| | 9072742 | Jan 16, 2031 | U-1674 | | | |
| | 9074254 | Dec 28, 2031 | U-1674 | | | |
| | 9074255 | Dec 17, 2030 | U-1674 | | | |
| | 9074256 | Feb 10, 2031 | U-1674 | | | |
| | 9138432 | Sep 30, 2025 | U-1737 | | | |
| | 9157121 | Apr 05, 2030 | U-1674 | | | |
| ILOPERIDONE - FANAPT | | | | | | |
| N 022192 006 | 8586610 | Nov 02, 2027 | U-1625 | | M-180 | May 26, 2019 |
| | 8652776 | Aug 31, 2030 | U-1685 | | | |
| | 8999638 | Oct 28, 2030 | U-1674 | | | |
| | 9072742 | Jan 16, 2031 | U-1674 | | | |
| | 9074254 | Dec 28, 2031 | U-1674 | | | |
| | 9074255 | Dec 17, 2030 | U-1674 | | | |
| | 9074256 | Feb 10, 2031 | U-1674 | | | |
| | 9138432 | Sep 30, 2025 | U-1737 | | | |
| | 9157121 | Apr 05, 2030 | U-1674 | | | |
| ILOPERIDONE - FANAPT | | | | | | |
| N 022192 007 | 8586610 | Nov 02, 2027 | U-1625 | | M-180 | May 26, 2019 |
| | 8652776 | Aug 31, 2030 | U-1685 | | | |
| | 8999638 | Oct 28, 2030 | U-1674 | | | |
| | 9072742 | Jan 16, 2031 | U-1674 | | | |
| | 9074254 | Dec 28, 2031 | U-1674 | | | |
| | 9074255 | Dec 17, 2030 | U-1674 | | | |
| | 9074256 | Feb 10, 2031 | U-1674 | | | |
| | 9138432 | Sep 30, 2025 | U-1737 | | | |
| | 9157121 | Apr 05, 2030 | U-1674 | | | |
| IMATINIB MESYLATE - GLEEVEC | | | | | | |
| N 021335 001 | 6894051 | May 23, 2019 | DS DP U-649 | | | |
| | 6958335 | Dec 19, 2021 | U-791 | | | |
| | RE43932 | Jul 16, 2018 | DS DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| IMATINIB MESYLATE - GLEEVEC | | | | | | | |
| N 021335 | 001 | RE43932*PED | Jan 16, 2019 | | | | |
| IMATINIB MESYLATE - GLEEVEC | | | | | | | |
| N 021335 | 002 | 6894051 | May 23, 2019 | DS DP U-649 | | | |
| | | 6958335 | Dec 19, 2021 | U-791 | | | |
| | | RE43932 | Jul 16, 2018 | DS DP | | | |
| | | RE43932*PED | Jan 16, 2019 | | | | |
| IMATINIB MESYLATE - GLEEVEC | | | | | | | |
| N 021588 | 001 | 6894051 | May 23, 2019 | DS DP U-649 | | ODE-40 | Jan 25, 2020 |
| | | 6958335 | Dec 19, 2021 | U-1883 | | | |
| | | 6958335 | Dec 19, 2021 | U-791 | | | |
| | | 6958335*PED | Jun 19, 2022 | | | | |
| | | 7544799 | Jul 16, 2018 | DS DP | Y | | |
| | | 7544799*PED | Jan 16, 2019 | | | | |
| | | RE43932 | Jul 16, 2018 | DS DP | | | |
| | | RE43932*PED | Jan 16, 2019 | | | | |
| IMATINIB MESYLATE - GLEEVEC | | | | | | | |
| N 021588 | 002 | 6894051 | May 23, 2019 | DS DP U-649 | | ODE-40 | Jan 25, 2020 |
| | | 6958335 | Dec 19, 2021 | U-1883 | | | |
| | | 6958335 | Dec 19, 2021 | U-791 | | | |
| | | 6958335*PED | Jun 19, 2022 | | | | |
| | | 7544799 | Jul 16, 2018 | DS DP | Y | | |
| | | 7544799*PED | Jan 16, 2019 | | | | |
| | | RE43932 | Jul 16, 2018 | DS DP | | | |
| | | RE43932*PED | Jan 16, 2019 | | | | |
| IMIQUIMOD - ALDARA | | | | | | | |
| N 020723 | 001 | 7696159 | Apr 01, 2024 | DS U-1047 | | | |
| | | 7696159 | Apr 01, 2024 | DS U-1048 | | | |
| IMIQUIMOD - ZYCLARA | | | | | | | |
| N 022483 | 001 | 8236816 | Dec 11, 2029 | U-68 | | | |
| | | 8299109 | Dec 11, 2029 | U-68 | | | |
| | | 8598196 | Aug 18, 2029 | U-1455 | | | |
| | | 8598196 | Aug 18, 2029 | U-172 | | | |
| IMIQUIMOD - ZYCLARA | | | | | | | |
| N 022483 | 002 | 8222270 | Dec 11, 2029 | U-68 | | | |
| INDACATEROL MALEATE - ARCAPTA NEOHALER | | | | | | | |
| N 022383 | 001 | 6878721 | Feb 25, 2025 | DS DP U-1168 | | | |
| | | 8067437 | Jun 02, 2020 | U-1168 | | | |
| | | 8479730 | Oct 11, 2028 | DP | | | |
| | | 8658673 | Jun 02, 2020 | DS DP U-1168 | | | |
| | | 8796307 | Jun 02, 2020 | DS DP | | | |
| INDINAVIR SULFATE - CRIXIVAN | | | | | | | |
| N 020685 | 001 | 6645961 | Mar 04, 2018 | DP | | | |
| | | 6689761 | Feb 10, 2021 | U-554 | | | |
| INDINAVIR SULFATE - CRIXIVAN | | | | | | | |
| N 020685 | 003 | 6645961 | Mar 04, 2018 | DP | | | |
| | | 6689761 | Feb 10, 2021 | U-554 | | | |
| INDINAVIR SULFATE - CRIXIVAN | | | | | | | |
| N 020685 | 005 | 6645961 | Mar 04, 2018 | DP | | | |
| | | 6689761 | Feb 10, 2021 | U-554 | | | |
| INDINAVIR SULFATE - CRIXIVAN | | | | | | | |
| N 020685 | 006 | 6645961 | Mar 04, 2018 | DP | | | |
| | | 6689761 | Feb 10, 2021 | U-554 | | | |
| INDIUM IN-111 PENTETREOTIDE KIT - OCTREOSCAN | | | | | | | |
| N 020314 | 001 | 6123916 | Sep 26, 2017 | U-1125 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| INDOMETHACIN - TIVORBEX | | | | | | | |
| N 204768 | 001 | 8734847 | Apr 23, 2030 | DP | | | |
| | | 8992982 | Apr 23, 2030 | DP | | | |
| | | 9089471 | Apr 23, 2030 | U-55 | | | |
| INDOMETHACIN - TIVORBEX | | | | | | | |
| N 204768 | 002 | 8734847 | Apr 23, 2030 | DP | | | |
| | | 8992982 | Apr 23, 2030 | DP | | | |
| | | 9089471 | Apr 23, 2030 | U-55 | | | |
| INGENOL MEBUTATE - PICATO | | | | | | | |
| N 202833 | 001 | 6432452 | Aug 19, 2018 | U-68 | | M-169 | Nov 19, 2018 |
| | | 6787161 | Aug 19, 2018 | U-68 | | | |
| | | 6844013 | Dec 13, 2018 | U-1221 | | | |
| | | 7410656 | Oct 10, 2020 | U-1222 | | | |
| | | 8278292 | Jul 06, 2027 | DP | | | |
| | | 8372827 | Dec 18, 2026 | DP | | | |
| | | 8372828 | Dec 18, 2026 | DP | | | |
| | | 8377919 | Dec 18, 2026 | DP | | | |
| | | 8536163 | Dec 18, 2026 | U-1440 | | | |
| | | 8716271 | Dec 18, 2026 | U-1440 | | | |
| | | 8735375 | Dec 18, 2026 | U-1440 | | | |
| | | 9789078 | May 15, 2033 | U-2138 | | | |
| | | 9820959 | Dec 18, 2026 | DP U-1440 | | | |
| | | 9833428 | Dec 18, 2026 | DP | | | |
| | | 9833429 | Dec 18, 2026 | DP | | | |
| INGENOL MEBUTATE - PICATO | | | | | | | |
| N 202833 | 002 | 6432452 | Aug 19, 2018 | U-68 | | | |
| | | 6787161 | Aug 19, 2018 | U-68 | | | |
| | | 6844013 | Dec 13, 2018 | U-1221 | | | |
| | | 7410656 | Oct 10, 2020 | U-1222 | | | |
| | | 8278292 | Jul 06, 2027 | DP | | | |
| | | 8372827 | Dec 18, 2026 | DP | | | |
| | | 8372828 | Dec 18, 2026 | DP | | | |
| | | 8377919 | Dec 18, 2026 | DP | | | |
| | | 8536163 | Dec 18, 2026 | U-1440 | | | |
| | | 8716271 | Dec 18, 2026 | U-1440 | | | |
| | | 8735375 | Dec 18, 2026 | U-1440 | | | |
| | | 9820959 | Dec 18, 2026 | DP U-1440 | | | |
| | | 9833428 | Dec 18, 2026 | DP | | | |
| | | 9833429 | Dec 18, 2026 | DP | | | |
| INSULIN ASPART - FIASP | | | | | | | |
| N 208751 | 001 | 8324157 | Jun 25, 2030 | DP | | NP | Sep 29, 2020 |
| INSULIN ASPART - FIASP FLEXTOUCH | | | | | | | |
| N 208751 | 002 | 6899699 | Jan 02, 2022 | DP | | NP | Sep 29, 2020 |
| | | 7686786 | Aug 03, 2026 | DP | | | |
| | | 8324157 | Jun 25, 2030 | DP | | | |
| | | 8672898 | Jan 02, 2022 | DP | | | |
| | | 8684969 | Oct 20, 2025 | DP | | | |
| | | 8920383 | Jul 17, 2026 | DP | | | |
| | | 9108002 | Jan 20, 2026 | DP | | | |
| | | 9132239 | Feb 01, 2032 | DP | | | |
| | | 9457154 | Jan 20, 2026 | DP | | | |
| | | 9486588 | Jan 02, 2022 | DP | | | |
| | | 9687611 | Feb 27, 2027 | DP | | | |
| | | 9775953 | Jul 17, 2026 | DP | | | |
| INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN | | | | | | | |
| N 021172 | 004 | 6004297 | Jan 28, 2019 | DP | | | |
| | | 9265893 | Sep 23, 2032 | DP | | | |
| | | RE41956 | Jan 21, 2021 | DP | | | |
| | | RE43834 | Jan 28, 2019 | DP | | | |
| INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN | | | | | | | |
| N 020986 | 003 | 6004297 | Jan 28, 2019 | DP | | | |
| | | 9265893 | Sep 23, 2032 | DP | | | |
| | | RE41956 | Jan 21, 2021 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN | | | | | | |
| N 020986 003 | RE43834 | Jan 28, 2019 | DP | | | |
| INSULIN ASPART RECOMBINANT - NOVOLOG INNOLET | | | | | | |
| N 020986 004 | RE41956 | Jan 21, 2021 | DP | | | |
| INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH | | | | | | |
| N 020986 005 | 5866538*PED | Dec 20, 2017 | | | | |
| | 6899699 | Jan 02, 2022 | DP | | | |
| | 8672898 | Jan 02, 2022 | DP | | | |
| | 8684969 | Oct 20, 2025 | DP | | | |
| | 8920383 | Jul 17, 2026 | DP | | | |
| | 9108002 | Jan 20, 2026 | DP | | | |
| | 9132239 | Feb 01, 2032 | DP | | | |
| | 9457154 | Sep 27, 2027 | DP | | | |
| | 9486588 | Jan 02, 2022 | DP | | | |
| | 9687611 | Feb 27, 2027 | DP | | | |
| | 9775953 | Jul 17, 2026 | DP | | | |
| | RE46363 | Aug 03, 2026 | DP | | | |
| INSULIN ASPART; INSULIN DEGLUDEC - RYZODEG 70/30 | | | | | | |
| N 203313 001 | 6899699 | Jan 02, 2022 | DP | | NCE | Sep 25, 2020 |
| | 7615532 | May 25, 2025 | DS DP | | NPP | Dec 16, 2019 |
| | 8672898 | Jan 02, 2022 | DP | | | |
| | 8684969 | Oct 20, 2025 | DP | | | |
| | 8920383 | Jul 17, 2026 | DP | | | |
| | 9108002 | Jan 20, 2026 | DP | | | |
| | 9132239 | Feb 01, 2032 | DP | | | |
| | 9457154 | Sep 27, 2027 | DP | | | |
| | 9486588 | Jan 02, 2022 | DP | | | |
| | 9687611 | Feb 27, 2027 | DP | | | |
| | 9775953 | Jul 17, 2026 | DP | | | |
| | RE46363 | Aug 03, 2026 | DP | | | |
| INSULIN DEGLUDEC - TRESIBA | | | | | | |
| N 203314 001 | 6899699 | Jan 02, 2022 | DP | | NCE | Sep 25, 2020 |
| | 7615532 | May 25, 2025 | DS DP | | NPP | Dec 16, 2019 |
| | 8672898 | Jan 02, 2022 | DP | | | |
| | 8684969 | Oct 20, 2025 | DP | | | |
| | 8920383 | Jul 17, 2026 | DP | | | |
| | 9108002 | Jan 20, 2026 | DP | | | |
| | 9132239 | Feb 01, 2032 | DP | | | |
| | 9457154 | Sep 27, 2027 | DP | | | |
| | 9486588 | Jan 02, 2022 | DP | | | |
| | 9687611 | Feb 27, 2027 | DP | | | |
| | 9775953 | Jul 17, 2026 | DP | | | |
| | RE46363 | Aug 03, 2026 | DP | | | |
| INSULIN DEGLUDEC - TRESIBA | | | | | | |
| N 203314 002 | 6899699 | Jan 02, 2022 | DP | | NCE | Sep 25, 2020 |
| | 7615532 | May 25, 2025 | DS DP | | NPP | Dec 16, 2019 |
| | 8672898 | Jan 02, 2022 | DP | | | |
| | 8684969 | Oct 20, 2025 | DP | | | |
| | 8920383 | Jul 17, 2026 | DP | | | |
| | 9108002 | Jan 20, 2026 | DP | | | |
| | 9132239 | Feb 01, 2032 | DP | | | |
| | 9457154 | Sep 27, 2027 | DP | | | |
| | 9486588 | Jan 02, 2022 | DP | | | |
| | 9687611 | Feb 27, 2027 | DP | | | |
| | 9775953 | Jul 17, 2026 | DP | | | |
| | RE46363 | Aug 03, 2026 | DP | | | |
| INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6 | | | | | | |
| N 208583 001 | 6268343 | Aug 22, 2022 | DS DP | | NC | Nov 21, 2019 |
| | 6458924 | Aug 22, 2017 | DS DP | | NCE | Sep 25, 2020 |
| | 6899699 | Jan 02, 2022 | DP | | | |
| | 7235627 | Aug 22, 2017 | DS | | | |
| | 7615532 | May 25, 2025 | DS DP | | | |
| | 8672898 | Jan 02, 2022 | DP | | | |
| | 8684969 | Oct 20, 2025 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| INSULIN DEGLUDEC; LIRAGLUTIDE - XULTOPHY 100/3.6 | | | | | | | |
| N 208583 | 001 | 8846618 | Jun 27, 2022 | DS DP | | | |
| | | 8920383 | Jul 17, 2026 | DP | | | |
| | | 8937042 | May 05, 2029 | DP | | | |
| | | 9108002 | Jan 20, 2026 | DP | | | |
| | | 9132239 | Feb 01, 2032 | DP | | | |
| | | 9457154 | Sep 27, 2027 | DP | | | |
| | | 9486588 | Jan 02, 2022 | DP | | | |
| | | 9687611 | Feb 27, 2027 | DP | | | |
| | | 9775953 | Jul 17, 2026 | DP | | | |
| | | RE46363 | Aug 03, 2026 | DP | | | |
| INSULIN DETEMIR RECOMBINANT - LEVEMIR | | | | | | | |
| N 021536 | 001 | 5750497 | Jun 16, 2019 | DS DP U-668 | | | |
| INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXPEN | | | | | | | |
| N 021536 | 002 | 5750497 | Jun 16, 2019 | DS DP U-668 | | | |
| | | 6004297 | Jan 28, 2019 | DP | | | |
| | | 9265893 | Sep 23, 2032 | DP | | | |
| | | RE41956 | Jan 21, 2021 | DP | | | |
| | | RE43834 | Jan 28, 2019 | DP | | | |
| INSULIN DETEMIR RECOMBINANT - LEVEMIR INNOLET | | | | | | | |
| N 021536 | 003 | 5750497 | Jun 16, 2019 | DS DP U-668 | | | |
| INSULIN DETEMIR RECOMBINANT - LEVEMIR PENFILL | | | | | | | |
| N 021536 | 004 | 5750497 | Jun 16, 2019 | DS DP U-668 | | | |
| INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH | | | | | | | |
| N 021536 | 005 | 5750497 | Jun 16, 2019 | DS DP U-668 | | | |
| | | 6899699 | Jan 02, 2022 | DP | | | |
| | | 7686786 | Aug 03, 2026 | DP | | | |
| | | 8672898 | Jan 02, 2022 | DP | | | |
| | | 8684969 | Oct 20, 2025 | DP | | | |
| | | 8920383 | Jul 17, 2026 | DP | | | |
| | | 9108002 | Jan 20, 2026 | DP | | | |
| | | 9132239 | Feb 01, 2032 | DP | | | |
| | | 9457154 | Sep 27, 2027 | DP | | | |
| | | 9486588 | Jan 02, 2022 | DP | | | |
| | | 9687611 | Feb 27, 2027 | DP | | | |
| | | 9775953 | Jul 17, 2026 | DP | | | |
| | | RE46363 | Aug 03, 2026 | DP | | | |
| INSULIN GLARGINE - BASAGLAR | | | | | | | |
| N 205692 | 001 | | | | | NP | Dec 16, 2018 |
| INSULIN GLARGINE RECOMBINANT - LANTUS | | | | | | | |
| N 021081 | 001 | 7476652 | Jul 23, 2023 | DP | | | |
| | | 7713930 | Jun 13, 2023 | DP | | | |
| | | 7918833 | Sep 23, 2027 | DP | | | |
| INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR | | | | | | | |
| N 021081 | 002 | 8512297 | Sep 15, 2024 | DP | | | |
| | | 8556864 | Mar 03, 2024 | DP | | | |
| | | 8603044 | Mar 02, 2024 | DP | | | |
| | | 8679069 | Apr 12, 2025 | DP | | | |
| | | 8992486 | Jun 05, 2024 | DP | | | |
| | | 9011391 | Mar 26, 2024 | U-1832 | | | |
| | | 9233211 | Mar 02, 2024 | DP | | | |
| | | 9408979 | Mar 02, 2024 | DP | | | |
| | | 9526844 | Mar 02, 2024 | DP | | | |
| | | 9533105 | Aug 17, 2024 | DP | | | |
| | | 9561331 | Aug 28, 2024 | DP | | | |
| | | 9604008 | Mar 02, 2024 | DP | | | |
| | | 9604009 | Aug 16, 2024 | DP | | | |
| | | 9610409 | Mar 02, 2024 | DP | | | |
| | | 9623189 | Aug 19, 2024 | DP | | | |
| | | 9775954 | Mar 02, 2024 | DP | | | |
| | | 9827379 | Mar 02, 2024 | DP U-2146 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR | | | | | | |
| N 206538 001 | 7918833 | Sep 23, 2027 | DP | | NP | Feb 25, 2018 |
| | 7918833*PED | Mar 23, 2028 | | | | |
| | 8512297 | Sep 15, 2024 | DP | | | |
| | 8556864 | Mar 03, 2024 | DP | | | |
| | 8603044 | Mar 02, 2024 | DP | | | |
| | 8679069 | Apr 12, 2025 | DP | | | |
| | 8992486 | Jun 05, 2024 | DP | | | |
| | 9011391 | Mar 26, 2024 | U-1832 | | | |
| | 9233211 | Mar 02, 2024 | DP | | | |
| | 9345750 | May 18, 2031 | DP U-1855 | | | |
| | 9408979 | Mar 02, 2024 | DP | | | |
| | 9526844 | Mar 02, 2024 | DP | | | |
| | 9533105 | Aug 17, 2024 | DP | | | |
| | 9561331 | Aug 28, 2024 | DP | | | |
| | 9604008 | Mar 02, 2024 | DP | | | |
| | 9604009 | Aug 16, 2024 | DP | | | |
| | 9610409 | Mar 02, 2024 | DP | | | |
| | 9623189 | Aug 19, 2024 | DP | | | |
| | 9775954 | Mar 02, 2024 | DP | | | |
| | 9827379 | Mar 02, 2024 | DP U-2146 | | | |
| INSULIN GLARGINE; LIXISENATIDE - SOLIQUA 100/33 | | | | | | |
| N 208673 001 | 7918833 | Sep 23, 2027 | DP | | NC | Nov 21, 2019 |
| | 8512297 | Sep 15, 2024 | DP | | NCE | Jul 27, 2021 |
| | 8556864 | Mar 03, 2024 | DP | | | |
| | 8603044 | Mar 02, 2024 | DP | | | |
| | 8679069 | Apr 12, 2025 | DP | | | |
| | 8992486 | Jun 05, 2024 | DP | | | |
| | 9011391 | Mar 26, 2024 | U-1923 | | | |
| | 9233211 | Mar 02, 2024 | DP | | | |
| | 9408979 | Mar 02, 2024 | DP | | | |
| | 9526764 | Oct 09, 2029 | DP | | | |
| | 9526844 | Mar 02, 2024 | DP | | | |
| | 9533105 | Aug 17, 2024 | DP | | | |
| | 9561331 | Aug 28, 2024 | DP | | | |
| | 9604008 | Mar 02, 2024 | DP | | | |
| | 9604009 | Aug 16, 2024 | DP | | | |
| | 9610409 | Mar 02, 2024 | DP | | | |
| | 9623189 | Aug 19, 2024 | DP | | | |
| | 9707176 | Nov 11, 2030 | DP | | | |
| | 9775954 | Mar 02, 2024 | DP | | | |
| | 9821032 | May 09, 2032 | U-2182 | | | |
| | 9827379 | Mar 02, 2024 | DP U-2146 | | | |
| | RE45313 | Jul 12, 2020 | DS DP | | | |
| INSULIN GLULISINE RECOMBINANT - APIDRA | | | | | | |
| N 021629 001 | 6221633 | Jun 18, 2018 | DS DP U-471 | | | |
| | 6960561 | Jan 25, 2023 | DP U-471 | | | |
| | 7452860 | Mar 22, 2022 | DP | | | |
| | 7696162 | Mar 22, 2022 | DP U-471 | | | |
| INSULIN GLULISINE RECOMBINANT - APIDRA | | | | | | |
| N 021629 002 | 6221633 | Jun 18, 2018 | DS DP U-471 | | | |
| | 6960561 | Jan 25, 2023 | DP U-471 | | | |
| | 7452860 | Mar 22, 2022 | DP | | | |
| | 7696162 | Mar 22, 2022 | DP U-471 | | | |
| INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR | | | | | | |
| N 021629 003 | 6221633 | Jun 18, 2018 | DS DP U-471 | | | |
| | 6960561 | Jan 25, 2023 | DP U-471 | | | |
| | 7452860 | Mar 22, 2022 | DP | | | |
| | 7696162 | Mar 22, 2022 | DP U-471 | | | |
| | 7918833 | Sep 23, 2027 | DP | | | |
| | 8512297 | Sep 15, 2024 | DP | | | |
| | 8556864 | Mar 03, 2024 | DP | | | |
| | 8603044 | Mar 02, 2024 | DP | | | |
| | 8679069 | Apr 12, 2025 | DP | | | |
| | 8992486 | Jun 05, 2024 | DP | | | |
| | 9011391 | Mar 26, 2024 | U-1832 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR | | | | | | |
| N 021629 003 | 9233211 | Mar 02, 2024 | DP | | | |
| | 9408979 | Mar 02, 2024 | DP | | | |
| | 9526844 | Mar 02, 2024 | DP | | | |
| | 9533105 | Aug 17, 2024 | DP | | | |
| | 9561331 | Aug 28, 2024 | DP | | | |
| | 9604008 | Mar 02, 2024 | DP | | | |
| | 9604009 | Aug 16, 2024 | DP | | | |
| | 9610409 | Mar 02, 2024 | DP | | | |
| | 9623189 | Aug 19, 2024 | DP | | | |
| | 9775954 | Mar 02, 2024 | DP | | | |
| | 9827379 | Mar 02, 2024 | DP U-2146 | | | |
| INSULIN HUMAN - HUMULIN R | | | | | | |
| N 018780 004 | 7291132 | Aug 09, 2024 | DP | | | |
| INSULIN LISPRO - ADMELOG | | | | | | |
| N 209196 001 | | | | | NP | Dec 11, 2020 |
| INSULIN LISPRO - ADMELOG SOLOSTAR | | | | | | |
| N 209196 002 | | | | | NP | Dec 11, 2020 |
| INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 75/25 KWIKPEN | | | | | | |
| N 021017 002 | 7291132 | Aug 09, 2024 | DP | | | |
| INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT - HUMALOG MIX 50/50 KWIKPEN | | | | | | |
| N 021018 002 | 7291132 | Aug 09, 2024 | DP | | | |
| INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN | | | | | | |
| N 020563 003 | 7291132 | Aug 09, 2024 | DP | | | |
| INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN | | | | | | |
| N 205747 001 | 6034054 | Jun 11, 2018 | DP U-1707 | | | |
| | 6034054 | Jun 11, 2018 | DP U-1708 | | | |
| | 6551992 | Jun 11, 2018 | DP U-1707 | | | |
| | 6551992 | Jun 11, 2018 | DP U-1708 | | | |
| | 7291132 | Aug 09, 2024 | DP | | | |
| INSULIN RECOMBINANT HUMAN - EXUBERA | | | | | | |
| N 021868 001 | 6257233 | May 14, 2019 | U-704 | | | |
| | 6546929 | May 14, 2019 | U-704 | | | |
| | 6582728 | Jun 24, 2020 | DP | | | |
| | 6685967 | Sep 11, 2018 | DP | | | |
| INSULIN RECOMBINANT HUMAN - EXUBERA | | | | | | |
| N 021868 002 | 6257233 | May 14, 2019 | U-704 | | | |
| | 6546929 | May 14, 2019 | U-704 | | | |
| | 6582728 | Jun 24, 2020 | DP | | | |
| | 6685967 | Sep 11, 2018 | DP | | | |
| INSULIN RECOMBINANT HUMAN - AFREZZA | | | | | | |
| N 022472 001 | 6444226 | Jun 29, 2020 | DP U-1534 | | | |
| | 6652885 | Jun 29, 2020 | U-1535 | | | |
| | 7305986 | Jan 16, 2023 | DP | | | |
| | 7464706 | Mar 02, 2023 | DP | | | |
| | 7648960 | Jun 29, 2020 | U-1535 | | | |
| | 7943178 | Jun 29, 2020 | DP U-1535 | | | |
| | 7943572 | Aug 10, 2026 | U-1539 | | | |
| | 8119593 | Aug 11, 2029 | U-1537 | | | |
| | 8146588 | Apr 24, 2023 | DP | | | |
| | 8156936 | Jan 16, 2023 | DP | | | |
| | 8215300 | Nov 24, 2022 | DP | | | |
| | 8258095 | Aug 11, 2029 | U-1537 | | | |
| | 8389470 | Jun 29, 2020 | DP U-1621 | | | |
| | 8424518 | Oct 17, 2031 | DP | | | |
| | 8485180 | Mar 25, 2030 | DP | | | |
| | 8499757 | Feb 19, 2032 | DP | | | |
| | 8551528 | Jun 11, 2030 | DP | | | |
| | 8623817 | Sep 18, 2029 | U-1537 | | | |
| | 8636001 | Jul 12, 2032 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| INSULIN RECOMBINANT HUMAN - AFREZZA | | | | | | |
| N 022472 001 | 8729019 | Dec 26, 2028 | DP | | | |
| | 8734845 | Jun 11, 2030 | DP | | | |
| | 8778403 | Jun 11, 2030 | DP | | U-1538 | |
| | 8889099 | Jun 29, 2020 | DP | | U-1621 | |
| | 8912193 | Jun 12, 2029 | DP | | U-1538 | |
| | 8950397 | Jul 20, 2021 | DP | | | |
| | 9192675 | Jun 12, 2029 | DP | | U-1788 | |
| | 9283193 | Sep 14, 2026 | DP | | | |
| | 9339615 | Oct 20, 2029 | DP | | | |
| | 9358352 | Feb 15, 2031 | DP | | U-1861 | |
| | 9393372 | Jul 04, 2029 | DP | | | |
| | 9446133 | Jun 12, 2029 | DP | | U-1861 | |
| | 9511198 | Feb 16, 2030 | | | U-1929 | |
| | 9511198 | Feb 16, 2030 | | | U-1930 | |
| | 9597374 | Oct 08, 2031 | | | U-1987 | |
| | 9662461 | Jun 12, 2029 | DP | | U-2019 | |
| | 9717689 | Sep 14, 2026 | DP | | | |
| INSULIN RECOMBINANT HUMAN - AFREZZA | | | | | | |
| N 022472 002 | 6444226 | Jun 29, 2020 | DP | | U-1534 | |
| | 6652885 | Jun 29, 2020 | | | U-1535 | |
| | 7305986 | Jan 16, 2023 | DP | | | |
| | 7464706 | Mar 02, 2023 | DP | | | |
| | 7648960 | Jun 29, 2020 | | | U-1535 | |
| | 7943178 | Jun 29, 2020 | DP | | U-1535 | |
| | 7943572 | Aug 10, 2026 | | | U-1539 | |
| | 8119593 | Aug 11, 2029 | | | U-1537 | |
| | 8146588 | Apr 24, 2023 | DP | | | |
| | 8156936 | Jan 16, 2023 | DP | | | |
| | 8215300 | Nov 24, 2022 | DP | | | |
| | 8258095 | Aug 11, 2029 | | | U-1537 | |
| | 8389470 | Jun 29, 2020 | DP | | U-1621 | |
| | 8424518 | Oct 17, 2031 | DP | | | |
| | 8485180 | Mar 25, 2030 | DP | | | |
| | 8499757 | Feb 19, 2032 | DP | | | |
| | 8551528 | Jun 11, 2030 | DP | | | |
| | 8623817 | Sep 18, 2029 | | | U-1537 | |
| | 8636001 | Jul 12, 2032 | DP | | | |
| | 8729019 | Dec 26, 2028 | DP | | | |
| | 8734845 | Jun 11, 2030 | DP | | | |
| | 8778403 | Jun 11, 2030 | DP | | U-1538 | |
| | 8889099 | Jun 29, 2020 | DP | | U-1621 | |
| | 8912193 | Jun 12, 2029 | DP | | U-1538 | |
| | 8950397 | Jul 20, 2021 | DP | | | |
| | 9192675 | Jun 12, 2029 | DP | | U-1788 | |
| | 9283193 | Sep 14, 2026 | DP | | | |
| | 9339615 | Oct 20, 2029 | DP | | | |
| | 9358352 | Feb 15, 2031 | DP | | U-1861 | |
| | 9393372 | Jul 04, 2029 | DP | | | |
| | 9446133 | Jun 12, 2029 | DP | | U-1861 | |
| | 9511198 | Feb 16, 2030 | | | U-1929 | |
| | 9511198 | Feb 16, 2030 | | | U-1930 | |
| | 9597374 | Oct 08, 2031 | | | U-1987 | |
| | 9662461 | Jun 12, 2029 | DP | | U-2019 | |
| | 9717689 | Sep 14, 2026 | DP | | | |
| INSULIN RECOMBINANT HUMAN - AFREZZA | | | | | | |
| N 022472 003 | 6444226 | Jun 29, 2020 | DP | | U-1534 | |
| | 6652885 | Jun 29, 2020 | | | U-1535 | |
| | 7305986 | Jan 16, 2023 | DP | | | |
| | 7464706 | Mar 02, 2023 | DP | | | |
| | 7648960 | Jun 29, 2020 | | | U-1535 | |
| | 7943178 | Jun 29, 2020 | DP | | U-1535 | |
| | 7943572 | Aug 10, 2026 | | | U-1539 | |
| | 8119593 | Aug 11, 2029 | | | U-1537 | |
| | 8146588 | Apr 24, 2023 | DP | | | |
| | 8156936 | Jan 16, 2023 | DP | | | |
| | 8215300 | Nov 24, 2022 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| INSULIN RECOMBINANT HUMAN - AFREZZA | | | | | | | |
| N 022472 | 003 | 8258095 | Aug 11, 2029 | U-1537 | | | |
| | | 8389470 | Jun 29, 2020 | DP U-1621 | | | |
| | | 8424518 | Oct 17, 2031 | DP | | | |
| | | 8485180 | Mar 25, 2030 | DP | | | |
| | | 8499757 | Feb 19, 2032 | DP | | | |
| | | 8551528 | Jun 11, 2030 | DP | | | |
| | | 8623817 | Sep 18, 2029 | U-1537 | | | |
| | | 8636001 | Jul 12, 2032 | DP | | | |
| | | 8729019 | Dec 26, 2028 | DP | | | |
| | | 8734845 | Jun 11, 2030 | DP | | | |
| | | 8778403 | Jun 11, 2030 | DP U-1538 | | | |
| | | 8889099 | Jun 29, 2020 | DP U-1621 | | | |
| | | 8912193 | Jun 12, 2029 | DP U-1538 | | | |
| | | 8950397 | Jul 20, 2021 | DP | | | |
| | | 9192675 | Jun 12, 2029 | DP U-1788 | | | |
| | | 9283193 | Sep 14, 2026 | DP | | | |
| | | 9339615 | Oct 20, 2029 | DP | | | |
| | | 9358352 | Feb 15, 2031 | DP U-1861 | | | |
| | | 9393372 | Jul 04, 2029 | DP | | | |
| | | 9446133 | Jun 12, 2029 | DP U-1861 | | | |
| | | 9511198 | Feb 16, 2030 | U-1929 | | | |
| | | 9511198 | Feb 16, 2030 | U-1930 | | | |
| | | 9597374 | Oct 08, 2031 | U-1987 | | | |
| | | 9662461 | Jun 12, 2029 | DP U-2019 | | | |
| | | 9717689 | Sep 14, 2026 | DP | | | |
| INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN 70/30 | | | | | | | |
| N 019717 | 001 | 7291132 | Aug 09, 2024 | DP | | | |
| INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN 70/30 PEN | | | | | | | |
| N 019717 | 002 | 7291132 | Aug 09, 2024 | DP | | | |
| INSULIN SUSP ISOPHANE RECOMBINANT HUMAN - HUMULIN N | | | | | | | |
| N 018781 | 001 | 7291132 | Aug 09, 2024 | DP | | | |
| IODIXANOL - VISIPAQUE 320 | | | | | | | |
| N 020351 | 002 | | | | | I-752 | Apr 05, 2020 |
| IODIXANOL - VISIPAQUE 320 | | | | | | | |
| N 020808 | 002 | | | | | I-752 | Apr 05, 2020 |
| IPRATROPIUM BROMIDE - ATROVENT HFA | | | | | | | |
| N 021527 | 001 | 6739333 | May 26, 2020 | DP | | | |
| | | 6983743 | May 26, 2020 | DP | | | |
| | | 8474447 | Jan 17, 2030 | DP | | | |
| IRINOTECAN HYDROCHLORIDE - CAMPTOSAR | | | | | | | |
| N 020571 | 001 | 6403569 | Apr 28, 2020 | U-449 | | | |
| | | 6794370 | May 01, 2020 | U-606 | | | |
| IRINOTECAN HYDROCHLORIDE - CAMPTOSAR | | | | | | | |
| N 020571 | 002 | 6403569 | Apr 28, 2020 | U-449 | | | |
| | | 6794370 | May 01, 2020 | U-606 | | | |
| IRINOTECAN HYDROCHLORIDE - ONIVYDE | | | | | | | |
| N 207793 | 001 | 8147867 | Aug 29, 2028 | DS DP | | NP | Oct 22, 2018 |
| | | 8329213 | May 02, 2025 | DS DP | | ODE-99 | Oct 22, 2022 |
| | | 8703181 | May 02, 2025 | U-1434 | | | |
| | | 8992970 | May 02, 2025 | DS DP | | | |
| | | 9339497 | Jun 12, 2033 | U-1848 | | | |
| | | 9364473 | Jun 12, 2033 | U-1856 | | | |
| | | 9452162 | Jun 12, 2033 | U-1899 | | | |
| | | 9492442 | Jun 12, 2033 | U-1848 | | | |
| | | 9492442 | Jun 12, 2033 | U-1899 | | | |
| | | 9492442 | Jun 12, 2033 | U-1917 | | | |
| | | 9717724 | Jun 12, 2033 | U-1848 | | | |
| | | 9717724 | Jun 12, 2033 | U-2091 | | | |
| | | 9724303 | May 02, 2025 | DS DP | | | |
| | | 9730891 | May 02, 2025 | U-1848 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| IRINOTECAN HYDROCHLORIDE - ONIVYDE | | | | | | | |
| N 207793 | 001 | 9782349 | May 02, 2025 | DS DP | | | |
| ISAVUCONAZONIUM SULFATE - CRESEMBA | | | | | | | |
| N 207500 | 001 | 6812238 | Oct 31, 2020 | DS | | NCE | Mar 06, 2020 |
| | | 7459561 | Oct 31, 2020 | DS | | ODE-90 | Mar 06, 2022 |
| | | | | | | GAIN | Mar 06, 2025 |
| | | | | | | GAIN | Mar 06, 2027 |
| ISAVUCONAZONIUM SULFATE - CRESEMBA | | | | | | | |
| N 207501 | 001 | 6812238 | Oct 31, 2020 | DS | | NCE | Mar 06, 2020 |
| | | 7459561 | Oct 31, 2020 | DS | | ODE-90 | Mar 06, 2022 |
| | | | | | | GAIN | Mar 06, 2025 |
| | | | | | | GAIN | Mar 06, 2027 |
| ISOTRETINOIN - ABSORICA | | | | | | | |
| N 021951 | 001 | 7435427 | Sep 21, 2021 | DP | | | |
| | | 8367102 | Sep 21, 2021 | U-1347 | | | |
| | | 8952064 | Sep 21, 2021 | DP | | | |
| | | 9078925 | Sep 21, 2021 | DP | | | |
| | | 9089534 | Sep 21, 2021 | DP | | | |
| ISOTRETINOIN - ABSORICA | | | | | | | |
| N 021951 | 002 | 7435427 | Sep 21, 2021 | DP | | | |
| | | 8367102 | Sep 21, 2021 | U-1347 | | | |
| | | 8952064 | Sep 21, 2021 | DP | | | |
| | | 9078925 | Sep 21, 2021 | DP | | | |
| | | 9089534 | Sep 21, 2021 | DP | | | |
| ISOTRETINOIN - ABSORICA | | | | | | | |
| N 021951 | 003 | 7435427 | Sep 21, 2021 | DP | | | |
| | | 8367102 | Sep 21, 2021 | U-1347 | | | |
| | | 8952064 | Sep 21, 2021 | DP | | | |
| | | 9078925 | Sep 21, 2021 | DP | | | |
| | | 9089534 | Sep 21, 2021 | DP | | | |
| ISOTRETINOIN - ABSORICA | | | | | | | |
| N 021951 | 004 | 7435427 | Sep 21, 2021 | DP | | | |
| | | 8367102 | Sep 21, 2021 | U-1347 | | | |
| | | 8952064 | Sep 21, 2021 | DP | | | |
| | | 9078925 | Sep 21, 2021 | DP | | | |
| | | 9089534 | Sep 21, 2021 | DP | | | |
| ISOTRETINOIN - ABSORICA | | | | | | | |
| N 021951 | 005 | 7435427 | Sep 21, 2021 | DP | | | |
| | | 8367102 | Sep 21, 2021 | U-1347 | | | |
| | | 8952064 | Sep 21, 2021 | DP | | | |
| | | 9078925 | Sep 21, 2021 | DP | | | |
| | | 9089534 | Sep 21, 2021 | DP | | | |
| ISOTRETINOIN - ABSORICA | | | | | | | |
| N 021951 | 006 | 7435427 | Sep 21, 2021 | DP | | | |
| | | 8367102 | Sep 21, 2021 | U-1347 | | | |
| | | 8952064 | Sep 21, 2021 | DP | | | |
| | | 9078925 | Sep 21, 2021 | DP | | | |
| | | 9089534 | Sep 21, 2021 | DP | | | |
| ITRACONAZOLE - SPORANOX | | | | | | | |
| N 020657 | 001 | 6407079 | Jun 18, 2019 | | | | |
| ITRACONAZOLE - SPORANOX | | | | | | | |
| N 020966 | 001 | 6407079 | Jun 18, 2019 | | | | |
| ITRACONAZOLE - ONMEL | | | | | | | |
| N 022484 | 001 | 8486456 | Oct 03, 2028 | DP U-1054 | | | |
| IVABRADINE HYDROCHLORIDE - CORLANOR | | | | | | | |
| N 206143 | 001 | 7361649 | Apr 17, 2026 | DS DP U-1694 | | NCE | Apr 15, 2020 |
| | | 7361650 | Apr 14, 2026 | DS DP U-1694 | | | |
| | | 7867996 | Feb 22, 2026 | DS DP U-1694 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| IVABRADINE HYDROCHLORIDE - CORLANOR | | | | | | | |
| N 206143 | 001 | 7879842 | Feb 22, 2026 | DS DP U-1694 | | | |
| IVABRADINE HYDROCHLORIDE - CORLANOR | | | | | | | |
| N 206143 | 002 | 7361649 | Apr 17, 2026 | DS DP U-1694 | | NCE | Apr 15, 2020 |
| | | 7361650 | Apr 14, 2026 | DS DP U-1694 | | | |
| | | 7867996 | Feb 22, 2026 | DS DP U-1694 | | | |
| | | 7879842 | Feb 22, 2026 | DS DP U-1694 | | | |
| IVACAFTOR - KALYDECO | | | | | | | |
| N 203188 | 001 | 7495103 | May 20, 2027 | DS DP | | I-705 | Dec 30, 2017 |
| | | 8324242 | Aug 05, 2027 | U-1311 | | NPP | Jul 31, 2020 |
| | | 8324242 | Aug 05, 2027 | U-1906 | | ODE-20 | Jan 31, 2019 |
| | | 8354427 | Jul 06, 2026 | U-1311 | | | |
| | | 8354427 | Jul 06, 2026 | U-1905 | | | |
| | | 8410274 | Dec 28, 2026 | DP | | | |
| | | 8754224 | Dec 28, 2026 | DS DP | | | |
| | | 9670163 | Dec 28, 2026 | DP U-1311 | | | |
| IVACAFTOR - KALYDECO | | | | | | | |
| N 207925 | 001 | 7495103 | May 20, 2027 | DS DP | | NPP | Jul 31, 2020 |
| | | 8324242 | Aug 05, 2027 | U-1311 | | ODE-20 | Jan 31, 2019 |
| | | 8324242 | Aug 05, 2027 | U-1906 | | | |
| | | 8354427 | Jul 06, 2026 | U-1311 | | | |
| | | 8354427 | Jul 06, 2026 | U-1905 | | | |
| | | 8410274 | Dec 28, 2026 | DP | | | |
| | | 8754224 | Dec 28, 2026 | DS DP | | | |
| | | 8883206 | Feb 27, 2033 | DP | | | |
| | | 9670163 | Dec 28, 2026 | DP U-1311 | | | |
| IVACAFTOR - KALYDECO | | | | | | | |
| N 207925 | 002 | 7495103 | May 20, 2027 | DS DP | | NPP | Jul 31, 2020 |
| | | 8324242 | Aug 05, 2027 | U-1311 | | ODE-20 | Jan 31, 2019 |
| | | 8324242 | Aug 05, 2027 | U-1906 | | | |
| | | 8354427 | Jul 06, 2026 | U-1311 | | | |
| | | 8354427 | Jul 06, 2026 | U-1905 | | | |
| | | 8410274 | Dec 28, 2026 | DP | | | |
| | | 8754224 | Dec 28, 2026 | DS DP | | | |
| | | 8883206 | Feb 27, 2033 | DP | | | |
| | | 9670163 | Dec 28, 2026 | DP U-1311 | | | |
| IVACAFTOR; LUMACAFTOR - ORKAMBI | | | | | | | |
| N 206038 | 001 | 7495103 | May 20, 2027 | DS DP | | NCE | Jul 02, 2020 |
| | | 7973038 | Nov 08, 2026 | U-1973 | | ODE-123 | Sep 28, 2023 |
| | | 8324242 | Aug 05, 2027 | U-1311 | | ODE-93 | Jul 02, 2022 |
| | | 8324242 | Aug 05, 2027 | U-1911 | | | |
| | | 8410274 | Dec 28, 2026 | DP | | | |
| | | 8507534 | Sep 20, 2030 | DS DP | | | |
| | | 8653103 | Dec 04, 2028 | DP | | | |
| | | 8716338 | Sep 20, 2030 | DP U-1718 | | | |
| | | 8716338 | Sep 20, 2030 | DP U-1910 | | | |
| | | 8741933 | Nov 08, 2026 | U-1717 | | | |
| | | 8741933 | Nov 08, 2026 | U-1909 | | | |
| | | 8754224 | Dec 28, 2026 | DS DP | | | |
| | | 8846718 | Dec 04, 2028 | U-1717 | | | |
| | | 8846718 | Dec 04, 2028 | U-1908 | | | |
| | | 8993600 | Dec 11, 2030 | DP | | | |
| | | 9150552 | Dec 04, 2028 | U-1908 | | | |
| | | 9192606 | Sep 29, 2029 | DP U-1912 | | | |
| | | 9216969 | Nov 08, 2026 | DS DP | | | |
| | | 9670163 | Dec 28, 2026 | DP U-1911 | | | |
| IVACAFTOR; LUMACAFTOR - ORKAMBI | | | | | | | |
| N 206038 | 002 | 7495103 | May 20, 2027 | DS DP | | NCE | Jul 02, 2020 |
| | | 7973038 | Nov 08, 2026 | U-1973 | | NPP | Sep 28, 2019 |
| | | 8324242 | Aug 05, 2027 | U-1911 | | ODE-123 | Sep 28, 2023 |
| | | 8410274 | Dec 28, 2026 | DP | | ODE-93 | Jul 02, 2022 |
| | | 8507534 | Sep 20, 2030 | DS DP | | | |
| | | 8653103 | Dec 04, 2028 | DP | | | |
| | | 8716338 | Sep 20, 2030 | DP U-1910 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| IVACAFTOR; LUMACAFTOR - ORKAMBI | | | | | | |
| N 206038 002 | 8741933 | Nov 08, 2026 | U-1909 | | | |
| | 8754224 | Dec 28, 2026 | DS DP | | | |
| | 8846718 | Dec 04, 2028 | U-1908 | | | |
| | 8993600 | Dec 11, 2030 | DP | | | |
| | 9150552 | Dec 04, 2028 | U-1908 | | | |
| | 9192606 | Sep 29, 2029 | DP U-1912 | | | |
| | 9216969 | Nov 08, 2026 | DP | | | |
| | 9670163 | Dec 28, 2026 | DP U-1911 | | | |
| IVERMECTIN - SKLICE | | | | | | |
| N 202736 001 | 6103248 | May 22, 2018 | DP | | | |
| | 8791153 | Oct 12, 2027 | DP | | | |
| | 8927595 | Oct 12, 2027 | U-1782 | | | |
| IVERMECTIN - SOOLANTRA | | | | | | |
| N 206255 001 | 5952372 | Sep 18, 2018 | U-1631 | | NP | Dec 19, 2017 |
| | 6133310 | Apr 26, 2019 | U-1631 | | | |
| | 7550440 | Apr 22, 2024 | DP U-1631 | | | |
| | 8080530 | Apr 22, 2024 | DP U-1631 | | | |
| | 8093219 | Apr 22, 2024 | DP U-1631 | | | |
| | 8415311 | Apr 22, 2024 | DP U-1631 | | | |
| | 8470788 | Apr 22, 2024 | DP U-1631 | | | |
| | 8815816 | Apr 22, 2024 | DP U-1631 | | | |
| | 9089587 | Mar 13, 2034 | U-1631 | | | |
| | 9233117 | Mar 13, 2034 | U-1631 | | | |
| | 9233118 | Mar 13, 2034 | U-1631 | | | |
| | 9782425 | Mar 13, 2034 | U-1631 | | | |
| IXABEPILONE - IXEMPRA KIT | | | | | | |
| N 022065 001 | 6670384 | Jan 23, 2022 | DP U-959 | | | |
| | 6670384 | Jan 23, 2022 | DP U-960 | | | |
| | 7022330 | Jan 23, 2022 | DP U-958 | | | |
| | 7125899 | May 26, 2018 | DS DP U-957 | | | |
| | 7312237 | Aug 21, 2024 | U-965 | | | |
| | RE41393 | Feb 08, 2022 | U-961 | | | |
| | RE41911 | Sep 28, 2020 | DS DP U-961 | | | |
| IXABEPILONE - IXEMPRA KIT | | | | | | |
| N 022065 002 | 6670384 | Jan 23, 2022 | DP U-959 | | | |
| | 6670384 | Jan 23, 2022 | DP U-960 | | | |
| | 7022330 | Jan 23, 2022 | DP U-958 | | | |
| | 7125899 | May 26, 2018 | DS DP U-957 | | | |
| | 7312237 | Aug 21, 2024 | U-965 | | | |
| | RE41393 | Feb 08, 2022 | U-961 | | | |
| | RE41911 | Sep 28, 2020 | DS DP U-961 | | | |
| IXAZOMIB CITRATE - NINLARO | | | | | | |
| N 208462 001 | 7442830 | Aug 06, 2027 | DS DP U-1780 | | NCE | Nov 20, 2020 |
| | 7687662 | Aug 06, 2027 | DS DP | | ODE-103 | Nov 20, 2022 |
| | 8003819 | Aug 06, 2027 | DS DP U-1780 | | | |
| | 8530694 | Aug 06, 2027 | DS DP U-1780 | | | |
| | 8546608 | Aug 12, 2024 | DS | | | |
| | 8859504 | Jun 16, 2029 | DS DP | | | |
| | 8871745 | Aug 06, 2027 | U-1779 | | | |
| | 9175017 | Jun 16, 2029 | U-1778 | | | |
| | 9233115 | Aug 12, 2024 | U-1778 | | | |
| IXAZOMIB CITRATE - NINLARO | | | | | | |
| N 208462 002 | 7442830 | Aug 06, 2027 | DS DP U-1780 | | NCE | Nov 20, 2020 |
| | 7687662 | Aug 06, 2027 | DS DP | | ODE-103 | Nov 20, 2022 |
| | 8003819 | Aug 06, 2027 | DS DP U-1780 | | | |
| | 8530694 | Aug 06, 2027 | DS DP U-1780 | | | |
| | 8546608 | Aug 12, 2024 | DS | | | |
| | 8859504 | Jun 16, 2029 | DS DP | | | |
| | 8871745 | Aug 06, 2027 | U-1779 | | | |
| | 9175017 | Jun 16, 2029 | U-1778 | | | |
| | 9233115 | Aug 12, 2024 | U-1778 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| IXAZOMIB CITRATE - NINLARO | | | | | | | |
| N 208462 | 003 | 7442830 | Aug 06, 2027 | DS DP U-1780 | | NCE | Nov 20, 2020 |
| | | 7687662 | Aug 06, 2027 | DS DP | | ODE-103 | Nov 20, 2022 |
| | | 8003819 | Aug 06, 2027 | DS DP U-1780 | | | |
| | | 8530694 | Aug 06, 2027 | DS DP U-1780 | | | |
| | | 8546608 | Aug 12, 2024 | DS | | | |
| | | 8859504 | Jun 16, 2029 | DS DP | | | |
| | | 8871745 | Aug 06, 2027 | U-1779 | | | |
| | | 9175017 | Jun 16, 2029 | U-1778 | | | |
| | | 9233115 | Aug 12, 2024 | U-1778 | | | |
| KETOCONAZOLE - EXTINA | | | | | | | |
| N 021738 | 001 | 7553835 | Oct 19, 2018 | DP U-245 | | | |
| | | 8026238 | Oct 19, 2018 | DP U-1213 | | | |
| KETOCONAZOLE - XOLEGEL | | | | | | | |
| N 021946 | 001 | 7179475 | Dec 04, 2018 | DP U-792 | | | |
| | | 8232276 | Nov 24, 2020 | DP | | | |
| | | 8735393 | Dec 04, 2018 | DP | | | |
| KETOROLAC TROMETHAMINE - ACULAR LS | | | | | | | |
| N 021528 | 001 | 8008338 | May 24, 2027 | DS DP U-1181 | | | |
| | | 8207215 | May 28, 2024 | U-1251 | | | |
| | | 8377982 | May 28, 2024 | U-1363 | | | |
| | | 8377982*PED | Nov 28, 2024 | | | | |
| | | 8541463 | May 28, 2024 | U-1441 | | | |
| | | 8541463*PED | Nov 28, 2024 | | | | |
| | | 8648107 | May 28, 2024 | DP | | | |
| | | 8906950 | May 28, 2024 | U-1626 | | | |
| | | 8946281 | May 28, 2024 | U-1662 | | | |
| | | 9216167 | May 28, 2024 | U-1800 | | | |
| KETOROLAC TROMETHAMINE - SPRIX | | | | | | | |
| N 022382 | 001 | 6333044 | Dec 25, 2018 | DP U-1057 | | | |
| KETOROLAC TROMETHAMINE - ACUVAIL | | | | | | | |
| N 022427 | 001 | 7842714 | Aug 15, 2029 | DS DP | | | |
| | | 8512717 | Mar 07, 2028 | DP | | | |
| | | 8992952 | Aug 05, 2024 | DP | | | |
| | | 9192571 | Mar 07, 2028 | DP | | | |
| KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - OMIDRIA | | | | | | | |
| N 205388 | 001 | 8173707 | Jul 30, 2023 | U-1518 | | NPP | Dec 08, 2020 |
| | | 8173707*PED | Jan 30, 2024 | | | PED | Jun 08, 2021 |
| | | 8586633 | Jul 30, 2023 | DP | | | |
| | | 8586633*PED | Jan 30, 2024 | | | | |
| | | 9066856 | Oct 23, 2033 | DP | | | |
| | | 9066856*PED | Apr 23, 2034 | | | | |
| | | 9278101 | Jul 30, 2023 | U-1518 | | | |
| | | 9278101*PED | Jan 30, 2024 | | | | |
| | | 9399040 | Jul 30, 2023 | DP | | | |
| | | 9399040*PED | Jan 30, 2024 | | | | |
| | | 9486406 | Oct 23, 2033 | DP | | | |
| | | 9486406*PED | Apr 23, 2034 | | | | |
| | | 9855246 | Oct 23, 2033 | DP | | | |
| L-GLUTAMINE - ENDARI | | | | | | | |
| N 208587 | 001 | | | | | I-748 | Jul 07, 2020 |
| | | | | | | ODE-150 | Jul 07, 2024 |
| LACOSAMIDE - VIMPAT | | | | | | | |
| N 022253 | 001 | RE38551 | Mar 17, 2022 | DS U-1567 | | D-143 | Aug 29, 2017 |
| | | RE38551 | Mar 17, 2022 | DS U-2140 | | D-144 | Aug 29, 2017 |
| | | | | | | I-696 | Aug 29, 2017 |
| | | | | | | NPP | Nov 03, 2020 |
| LACOSAMIDE - VIMPAT | | | | | | | |
| N 022253 | 002 | RE38551 | Mar 17, 2022 | DS U-1567 | | D-143 | Aug 29, 2017 |
| | | RE38551 | Mar 17, 2022 | DS U-2140 | | D-144 | Aug 29, 2017 |
| | | | | | | I-696 | Aug 29, 2017 |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| LACOSAMIDE - VIMPAT | | | | | | |
| N 022253 002 | | | | | NPP | Nov 03, 2020 |
| LACOSAMIDE - VIMPAT | | | | | | |
| N 022253 003 | RE38551 | Mar 17, 2022 | DS U-1567 | | D-143 | Aug 29, 2017 |
| | RE38551 | Mar 17, 2022 | DS U-2140 | | D-144 | Aug 29, 2017 |
| | | | | | I-696 | Aug 29, 2017 |
| | | | | | NPP | Nov 03, 2020 |
| LACOSAMIDE - VIMPAT | | | | | | |
| N 022253 004 | RE38551 | Mar 17, 2022 | DS U-1567 | | D-143 | Aug 29, 2017 |
| | RE38551 | Mar 17, 2022 | DS U-2140 | | D-144 | Aug 29, 2017 |
| | | | | | I-696 | Aug 29, 2017 |
| | | | | | NPP | Nov 03, 2020 |
| LACOSAMIDE - VIMPAT | | | | | | |
| N 022254 001 | RE38551 | Mar 17, 2022 | DS DP U-1565 | | D-143 | Aug 29, 2017 |
| | RE38551 | Mar 17, 2022 | DS DP U-1568 | | D-144 | Aug 29, 2017 |
| | | | | | I-696 | Aug 29, 2017 |
| | | | | | M-217 | Nov 03, 2020 |
| LACOSAMIDE - VIMPAT | | | | | | |
| N 022255 001 | RE38551 | Mar 17, 2022 | DS U-1567 | | D-143 | Aug 29, 2017 |
| | RE38551 | Mar 17, 2022 | DS U-2140 | | D-144 | Aug 29, 2017 |
| | | | | | I-696 | Aug 29, 2017 |
| | | | | | NPP | Nov 03, 2020 |
| LAMIVUDINE - EPIVIR | | | | | | |
| N 020596 001 | 6004968 | Mar 20, 2018 | DP U-248 | | | |
| | 6004968*PED | Sep 20, 2018 | | | | |
| LAMIVUDINE - EPIVIR-HBV | | | | | | |
| N 021004 001 | 6004968 | Mar 20, 2018 | | | | |
| LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS | | | | | | |
| N 206510 001 | 7169780 | Oct 03, 2023 | DS DP | | | |
| | 7169780*PED | Apr 03, 2024 | | | | |
| | 7217713 | Oct 21, 2022 | U-1663 | | | |
| | 7217713*PED | Apr 21, 2023 | | | | |
| | 7435734 | Oct 21, 2022 | U-1663 | | | |
| | 7435734*PED | Apr 21, 2023 | | | | |
| | 7754731 | Mar 11, 2029 | DS DP U-1663 | | | |
| | 7754731*PED | Sep 11, 2029 | | | | |
| | 7820660 | Apr 25, 2023 | DS | | | |
| LAMOTRIGINE - LAMICTAL | | | | | | |
| N 020241 001 | | | | | M-159 | May 18, 2018 |
| LAMOTRIGINE - LAMICTAL | | | | | | |
| N 020241 002 | | | | | M-159 | May 18, 2018 |
| LAMOTRIGINE - LAMICTAL | | | | | | |
| N 020241 003 | | | | | M-159 | May 18, 2018 |
| LAMOTRIGINE - LAMICTAL | | | | | | |
| N 020241 004 | | | | | M-159 | May 18, 2018 |
| LAMOTRIGINE - LAMICTAL | | | | | | |
| N 020241 005 | | | | | M-159 | May 18, 2018 |
| LAMOTRIGINE - LAMICTAL | | | | | | |
| N 020241 006 | | | | | M-159 | May 18, 2018 |
| LAMOTRIGINE - LAMICTAL CD | | | | | | |
| N 020764 001 | | | | | M-159 | May 18, 2018 |
| LAMOTRIGINE - LAMICTAL CD | | | | | | |
| N 020764 002 | | | | | M-159 | May 18, 2018 |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| LAMOTRIGINE - LAMICTAL CD | | | | | | | |
| N 020764 003 | | | | | | M-159 | May 18, 2018 |
| LAMOTRIGINE - LAMICTAL CD | | | | | | | |
| N 020764 004 | | | | | | M-159 | May 18, 2018 |
| LAMOTRIGINE - LAMICTAL XR | | | | | | | |
| N 022115 001 | 8637512 | Jun 14, 2028 | | DP | | | |
| | 9144547 | Sep 22, 2023 | | DP | | | |
| LAMOTRIGINE - LAMICTAL XR | | | | | | | |
| N 022115 002 | 8637512 | Jun 14, 2028 | | DP | | | |
| | 9144547 | Sep 22, 2023 | | DP | | | |
| LAMOTRIGINE - LAMICTAL XR | | | | | | | |
| N 022115 003 | 8637512 | Jun 14, 2028 | | DP | | | |
| | 9144547 | Sep 22, 2023 | | DP | | | |
| LAMOTRIGINE - LAMICTAL XR | | | | | | | |
| N 022115 004 | 8637512 | Jun 14, 2028 | | DP | | | |
| | 9144547 | Sep 22, 2023 | | DP | | | |
| LAMOTRIGINE - LAMICTAL XR | | | | | | | |
| N 022115 005 | 8637512 | Jun 14, 2028 | | DP | | | |
| | 9144547 | Sep 22, 2023 | | DP | | | |
| LAMOTRIGINE - LAMICTAL XR | | | | | | | |
| N 022115 006 | 8637512 | Jun 14, 2028 | | DP | | | |
| | 9144547 | Sep 22, 2023 | | DP | | | |
| LAMOTRIGINE - LAMICTAL ODT | | | | | | | |
| N 022251 001 | 7919115 | Jan 04, 2029 | DS | DP | | M-159 | May 18, 2018 |
| | 8840925 | Jul 02, 2028 | | DP U-1596 | | | |
| | 9339504 | Jul 02, 2028 | | DP U-1596 | | | |
| LAMOTRIGINE - LAMICTAL ODT | | | | | | | |
| N 022251 002 | 7919115 | Jan 04, 2029 | DS | DP | | M-159 | May 18, 2018 |
| | 8840925 | Jul 02, 2028 | | DP U-1596 | | | |
| | 9339504 | Jul 02, 2028 | | DP U-1596 | | | |
| LAMOTRIGINE - LAMICTAL ODT | | | | | | | |
| N 022251 003 | 7919115 | Jan 04, 2029 | DS | DP | | M-159 | May 18, 2018 |
| | 8840925 | Jul 02, 2028 | | DP U-1596 | | | |
| | 9339504 | Jul 02, 2028 | | DP U-1596 | | | |
| LAMOTRIGINE - LAMICTAL ODT | | | | | | | |
| N 022251 004 | 7919115 | Jan 04, 2029 | DS | DP | | M-159 | May 18, 2018 |
| | 8840925 | Jul 02, 2028 | | DP U-1596 | | | |
| | 9339504 | Jul 02, 2028 | | DP U-1596 | | | |
| LANREOTIDE ACETATE - SOMATULINE DEPOT | | | | | | | |
| N 022074 001 | 5595760 | Mar 08, 2020 | | DP U-831 | | I-701 | Dec 19, 2017 |
| | | | | | | I-754 | Sep 15, 2020 |
| | | | | | | ODE-156 | Sep 15, 2024 |
| | | | | | | ODE-82 | Dec 16, 2021 |
| LANREOTIDE ACETATE - SOMATULINE DEPOT | | | | | | | |
| N 022074 002 | 5595760 | Mar 08, 2020 | | DP U-831 | | I-701 | Dec 19, 2017 |
| | | | | | | I-754 | Sep 15, 2020 |
| | | | | | | ODE-156 | Sep 15, 2024 |
| | | | | | | ODE-82 | Dec 16, 2021 |
| LANREOTIDE ACETATE - SOMATULINE DEPOT | | | | | | | |
| N 022074 003 | 5595760 | Mar 08, 2020 | | DP U-831 | | I-701 | Dec 19, 2017 |
| | | | | | | I-754 | Sep 15, 2020 |
| | | | | | | ODE-156 | Sep 15, 2024 |
| | | | | | | ODE-82 | Dec 16, 2021 |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| LANSOPRAZOLE - PREVACID | | | | | | | |
| N 021428 | 001 | 6328994 | May 17, 2019 | | | | |
| | | 7399485 | May 26, 2018 | DP | | | |
| | | 7431942 | May 17, 2019 | DP | | | |
| | | 7875292 | May 17, 2019 | DP | | | |
| LANSOPRAZOLE - PREVACID | | | | | | | |
| N 021428 | 002 | 6328994 | May 17, 2019 | | | | |
| | | 7399485 | May 26, 2018 | DP | | | |
| | | 7431942 | May 17, 2019 | DP | | | |
| | | 7875292 | May 17, 2019 | DP | | | |
| LANSOPRAZOLE - PREVACID IV | | | | | | | |
| N 021566 | 001 | 7396841 | Aug 17, 2021 | DP U-947 | | | |
| LANTHANUM CARBONATE - FOSRENOL | | | | | | | |
| N 021468 | 001 | 5968976 | Oct 26, 2018 | DP U-613 | | | |
| | | 7381428 | Aug 26, 2024 | U-890 | | | |
| | | 7465465 | Aug 26, 2024 | DP | | | |
| LANTHANUM CARBONATE - FOSRENOL | | | | | | | |
| N 021468 | 002 | 5968976 | Oct 26, 2018 | DP U-613 | | | |
| | | 7381428 | Aug 26, 2024 | U-890 | | | |
| | | 7465465 | Aug 26, 2024 | DP | | | |
| LANTHANUM CARBONATE - FOSRENOL | | | | | | | |
| N 021468 | 003 | 5968976 | Oct 26, 2018 | DP U-613 | | | |
| | | 7381428 | Aug 26, 2024 | U-890 | | | |
| | | 7465465 | Aug 26, 2024 | DP | | | |
| LANTHANUM CARBONATE - FOSRENOL | | | | | | | |
| N 021468 | 004 | 5968976 | Oct 26, 2018 | DP U-613 | | | |
| | | 7381428 | Aug 26, 2024 | U-890 | | | |
| | | 7465465 | Aug 26, 2024 | DP | | | |
| LANTHANUM CARBONATE - FOSRENOL | | | | | | | |
| N 204734 | 001 | 5968976 | Oct 26, 2018 | DP U-1592 | | | |
| | | 7465465 | Aug 26, 2024 | DP | | | |
| | | 8980327 | Dec 01, 2030 | DP | | | |
| | | 9023397 | Dec 01, 2030 | DP | | | |
| LANTHANUM CARBONATE - FOSRENOL | | | | | | | |
| N 204734 | 002 | 5968976 | Oct 26, 2018 | DP U-1592 | | | |
| | | 7465465 | Aug 26, 2024 | DP | | | |
| | | 8980327 | Dec 01, 2030 | DP | | | |
| | | 9023397 | Dec 01, 2030 | DP | | | |
| LAPATINIB DITOSYLATE - TYKERB | | | | | | | |
| N 022059 | 001 | 6391874 | Jul 11, 2017 | DS DP U-1429 | | | |
| | | 6391874 | Jul 11, 2017 | DS DP U-800 | | | |
| | | 6713485 | Sep 29, 2020 | DS DP U-1429 | | | |
| | | 6713485 | Sep 29, 2020 | DS DP U-800 | | | |
| | | 6727256 | Jan 08, 2019 | DS DP U-1429 | | | |
| | | 6727256 | Jan 08, 2019 | DS DP U-800 | | | |
| | | 6828320 | Jul 11, 2017 | U-1429 | | | |
| | | 6828320 | Jul 11, 2017 | U-800 | | | |
| | | 7157466 | Nov 19, 2021 | DS DP | | | |
| | | 8513262 | Jan 08, 2019 | DS DP | | | |
| | | 8821927 | Sep 18, 2029 | DS DP | | | |
| LATANOPROSTENE BUNOD - VYZULTA | | | | | | | |
| N 207795 | 001 | 6211233 | Jun 17, 2018 | DS DP | | | |
| | | 7273946 | Oct 03, 2025 | DS DP U-2144 | | | |
| | | 7629345 | Jan 05, 2025 | DP U-2144 | | | |
| | | 7910767 | Jan 05, 2025 | DS DP U-2144 | | | |
| | | 8058467 | Jan 05, 2025 | DS U-2144 | | | |
| LEDIPASVIR; SOFOSBUVIR - HARVONI | | | | | | | |
| N 205834 | 001 | 7964580 | Mar 26, 2029 | DS DP U-1470 | | D-153 | Nov 12, 2018 |
| | | 8088368 | May 12, 2030 | DS DP | | D-158 | Feb 12, 2019 |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| LEDIPASVIR; SOFOSBUVIR - HARVONI | | | | | | |
| N 205834 001 | 8273341 | May 12, 2030 | U-1470 | | D-159 | Feb 12, 2019 |
| | 8334270 | Mar 21, 2028 | DS DP U-1470 | | D-160 | Feb 12, 2019 |
| | 8580765 | Mar 21, 2028 | DS DP U-1470 | | I-718 | Nov 12, 2018 |
| | 8618076 | Dec 11, 2030 | DS DP U-1470 | | I-719 | Nov 12, 2018 |
| | 8633309 | Mar 26, 2029 | DS DP U-1470 | | I-720 | Nov 12, 2018 |
| | 8735372 | Mar 21, 2028 | U-1470 | | NCE | Oct 10, 2019 |
| | 8822430 | May 12, 2030 | DS DP U-1470 | | NPP | Nov 12, 2018 |
| | 8841278 | May 12, 2030 | DP U-1470 | | NPP | Apr 07, 2020 |
| | 8889159 | Mar 26, 2029 | DP U-1470 | | ODE-136 | Apr 07, 2024 |
| | 9085573 | Mar 21, 2028 | DS DP U-1470 | | | |
| | 9284342 | Sep 13, 2030 | DS DP U-1470 | | | |
| | 9393256 | Sep 14, 2032 | U-1470 | | | |
| | 9511056 | May 12, 2030 | DP U-1470 | | | |
| LENALIDOMIDE - REVLIMID | | | | | | |
| N 021880 001 | 5635517 | Oct 04, 2019 | DS | | I-706 | Feb 17, 2018 |
| | 6045501 | Aug 28, 2018 | U-1210 | | ODE-131 | Feb 22, 2024 |
| | 6315720 | Oct 23, 2020 | U-1210 | | ODE-49 | Jun 05, 2020 |
| | 6561976 | Aug 28, 2018 | U-1210 | | ODE-88 | Feb 17, 2022 |
| | 6561977 | Oct 23, 2020 | U-1210 | | | |
| | 6755784 | Oct 23, 2020 | U-1210 | | | |
| | 6908432 | Aug 28, 2018 | U-1210 | | | |
| | 7189740 | Apr 11, 2023 | U-1215 | | | |
| | 7465800 | Apr 27, 2027 | DS DP | | | |
| | 7468363 | Oct 07, 2023 | U-1414 | | | |
| | 7855217 | Nov 24, 2024 | DS DP | | | |
| | 7968569 | Oct 07, 2023 | U-1216 | | | |
| | 8204763 | Aug 28, 2018 | U-1249 | | | |
| | 8315886 | Oct 23, 2020 | U-1249 | | | |
| | 8404717 | Apr 11, 2023 | U-1215 | | | |
| | 8530498 | May 15, 2023 | U-1216 | | | |
| | 8589188 | Aug 28, 2018 | U-1210 | | | |
| | 8626531 | Oct 23, 2020 | U-1210 | | | |
| | 8648095 | May 15, 2023 | U-1216 | | | |
| | 8741929 | Mar 08, 2028 | U-1414 | | | |
| | 9056120 | Apr 11, 2023 | U-1215 | | | |
| | 9101621 | May 15, 2023 | U-1216 | | | |
| | 9101622 | May 15, 2023 | U-1216 | | | |
| LENALIDOMIDE - REVLIMID | | | | | | |
| N 021880 002 | 5635517 | Oct 04, 2019 | DS | | I-706 | Feb 17, 2018 |
| | 6045501 | Aug 28, 2018 | U-1210 | | ODE-131 | Feb 22, 2024 |
| | 6315720 | Oct 23, 2020 | U-1210 | | ODE-49 | Jun 05, 2020 |
| | 6561976 | Aug 28, 2018 | U-1210 | | ODE-88 | Feb 17, 2022 |
| | 6561977 | Oct 23, 2020 | U-1210 | | | |
| | 6755784 | Oct 23, 2020 | U-1210 | | | |
| | 6908432 | Aug 28, 2018 | U-1210 | | | |
| | 7189740 | Apr 11, 2023 | U-1215 | | | |
| | 7465800 | Apr 27, 2027 | DS DP | | | |
| | 7468363 | Oct 07, 2023 | U-1414 | | | |
| | 7855217 | Nov 24, 2024 | DS DP | | | |
| | 7968569 | Oct 07, 2023 | U-1216 | | | |
| | 8204763 | Aug 28, 2018 | U-1249 | | | |
| | 8315886 | Oct 23, 2020 | U-1249 | | | |
| | 8404717 | Apr 11, 2023 | U-1215 | | | |
| | 8530498 | May 15, 2023 | U-1216 | | | |
| | 8589188 | Aug 28, 2018 | U-1210 | | | |
| | 8626531 | Oct 23, 2020 | U-1210 | | | |
| | 8648095 | May 15, 2023 | U-1216 | | | |
| | 8741929 | Mar 08, 2028 | U-1414 | | | |
| | 9056120 | Apr 11, 2023 | U-1215 | | | |
| | 9101621 | May 15, 2023 | U-1216 | | | |
| | 9101622 | May 15, 2023 | U-1216 | | | |
| LENALIDOMIDE - REVLIMID | | | | | | |
| N 021880 003 | 5635517 | Oct 04, 2019 | DS | | I-706 | Feb 17, 2018 |
| | 6045501 | Aug 28, 2018 | U-1210 | | ODE-131 | Feb 22, 2024 |
| | 6315720 | Oct 23, 2020 | U-1210 | | ODE-49 | Jun 05, 2020 |
| | 6561976 | Aug 28, 2018 | U-1210 | | ODE-88 | Feb 17, 2022 |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| LENALIDOMIDE - REVLIMID | | | | | | |
| N 021880 003 | 6561977 | Oct 23, 2020 | U-1210 | | | |
| | 6755784 | Oct 23, 2020 | U-1210 | | | |
| | 6908432 | Aug 28, 2018 | U-1210 | | | |
| | 7189740 | Apr 11, 2023 | U-1215 | | | |
| | 7465800 | Apr 27, 2027 | DS DP | | | |
| | 7468363 | Oct 07, 2023 | U-1414 | | | |
| | 7855217 | Nov 24, 2024 | DS DP | | | |
| | 7968569 | Oct 07, 2023 | U-1216 | | | |
| | 8204763 | Aug 28, 2018 | U-1249 | | | |
| | 8315886 | Oct 23, 2020 | U-1249 | | | |
| | 8404717 | Apr 11, 2023 | U-1215 | | | |
| | 8530498 | May 15, 2023 | U-1216 | | | |
| | 8589188 | Aug 28, 2018 | U-1210 | | | |
| | 8626531 | Oct 23, 2020 | U-1210 | | | |
| | 8648095 | May 15, 2023 | U-1216 | | | |
| | 8741929 | Mar 08, 2028 | U-1414 | | | |
| | 9056120 | Apr 11, 2023 | U-1215 | | | |
| | 9101621 | May 15, 2023 | U-1216 | | | |
| | 9101622 | May 15, 2023 | U-1216 | | | |
| LENALIDOMIDE - REVLIMID | | | | | | |
| N 021880 004 | 5635517 | Oct 04, 2019 | DS | | I-706 | Feb 17, 2018 |
| | 6045501 | Aug 28, 2018 | U-1210 | | ODE-131 | Feb 22, 2024 |
| | 6315720 | Oct 23, 2020 | U-1210 | | ODE-49 | Jun 05, 2020 |
| | 6561976 | Aug 28, 2018 | U-1210 | | ODE-88 | Feb 17, 2022 |
| | 6561977 | Oct 23, 2020 | U-1210 | | | |
| | 6755784 | Oct 23, 2020 | U-1210 | | | |
| | 6908432 | Aug 28, 2018 | U-1210 | | | |
| | 7189740 | Apr 11, 2023 | U-1215 | | | |
| | 7465800 | Apr 27, 2027 | DS DP | | | |
| | 7468363 | Oct 07, 2023 | U-1414 | | | |
| | 7855217 | Nov 24, 2024 | DS DP | | | |
| | 7968569 | Oct 07, 2023 | U-1216 | | | |
| | 8204763 | Aug 28, 2018 | U-1249 | | | |
| | 8315886 | Oct 23, 2020 | U-1249 | | | |
| | 8404717 | Apr 11, 2023 | U-1215 | | | |
| | 8530498 | May 15, 2023 | U-1216 | | | |
| | 8589188 | Aug 28, 2018 | U-1210 | | | |
| | 8626531 | Oct 23, 2020 | U-1210 | | | |
| | 8648095 | May 15, 2023 | U-1216 | | | |
| | 8741929 | Mar 08, 2028 | U-1414 | | | |
| | 9056120 | Apr 11, 2023 | U-1215 | | | |
| | 9101621 | May 15, 2023 | U-1216 | | | |
| | 9101622 | May 15, 2023 | U-1216 | | | |
| LENALIDOMIDE - REVLIMID | | | | | | |
| N 021880 005 | 5635517 | Oct 04, 2019 | DS | | I-706 | Feb 17, 2018 |
| | 6045501 | Aug 28, 2018 | U-1210 | | ODE-131 | Feb 22, 2024 |
| | 6315720 | Oct 23, 2020 | U-1210 | | ODE-49 | Jun 05, 2020 |
| | 6561976 | Aug 28, 2018 | U-1210 | | ODE-88 | Feb 17, 2022 |
| | 6561977 | Oct 23, 2020 | U-1210 | | | |
| | 6755784 | Oct 23, 2020 | U-1210 | | | |
| | 6908432 | Aug 28, 2018 | U-1210 | | | |
| | 7189740 | Apr 11, 2023 | U-1215 | | | |
| | 7465800 | Apr 27, 2027 | DS DP | | | |
| | 7468363 | Oct 07, 2023 | U-1414 | | | |
| | 7855217 | Nov 24, 2024 | DS DP | | | |
| | 7968569 | Oct 07, 2023 | U-1216 | | | |
| | 8204763 | Aug 28, 2018 | U-1249 | | | |
| | 8315886 | Oct 23, 2020 | U-1249 | | | |
| | 8404717 | Apr 11, 2023 | U-1215 | | | |
| | 8530498 | May 15, 2023 | U-1216 | | | |
| | 8589188 | Aug 28, 2018 | U-1210 | | | |
| | 8626531 | Oct 23, 2020 | U-1210 | | | |
| | 8648095 | May 15, 2023 | U-1216 | | | |
| | 8741929 | Mar 08, 2028 | U-1414 | | | |
| | 9056120 | Apr 11, 2023 | U-1215 | | | |
| | 9101621 | May 15, 2023 | U-1216 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| LENALIDOMIDE - REVLIMID | | | | | | | |
| N 021880 | 005 | 9101622 | May 15, 2023 | U-1216 | | | |
| LENALIDOMIDE - REVLIMID | | | | | | | |
| N 021880 | 006 | 5635517 | Oct 04, 2019 | DS | | I-706 | Feb 17, 2018 |
| | | 6045501 | Aug 28, 2018 | U-1210 | | ODE-131 | Feb 22, 2024 |
| | | 6315720 | Oct 23, 2020 | U-1210 | | ODE-49 | Jun 05, 2020 |
| | | 6561976 | Aug 28, 2018 | U-1210 | | ODE-88 | Feb 17, 2022 |
| | | 6561977 | Oct 23, 2020 | U-1210 | | | |
| | | 6755784 | Oct 23, 2020 | U-1210 | | | |
| | | 6908432 | Aug 28, 2018 | U-1210 | | | |
| | | 7189740 | Apr 11, 2023 | U-1215 | | | |
| | | 7465800 | Apr 27, 2027 | DS DP | | | |
| | | 7468363 | Oct 07, 2023 | U-1414 | | | |
| | | 7855217 | Nov 24, 2024 | DS DP | | | |
| | | 7968569 | Oct 07, 2023 | U-1216 | | | |
| | | 8204763 | Aug 28, 2018 | U-1249 | | | |
| | | 8315886 | Oct 23, 2020 | U-1249 | | | |
| | | 8404717 | Apr 11, 2023 | U-1215 | | | |
| | | 8530498 | May 15, 2023 | U-1216 | | | |
| | | 8589188 | Aug 28, 2018 | U-1210 | | | |
| | | 8626531 | Oct 23, 2020 | U-1210 | | | |
| | | 8648095 | May 15, 2023 | U-1216 | | | |
| | | 8741929 | Mar 08, 2028 | U-1414 | | | |
| | | 9056120 | Apr 11, 2023 | U-1215 | | | |
| | | 9101621 | May 15, 2023 | U-1216 | | | |
| | | 9101622 | May 15, 2023 | U-1216 | | | |
| LENVATINIB MESYLATE - LENVIMA | | | | | | | |
| N 206947 | 001 | 7253286 | Oct 19, 2021 | DS DP | | I-734 | May 13, 2019 |
| | | 7612208 | Sep 19, 2026 | DS DP | | NCE | Feb 13, 2020 |
| | | 9006256 | Jul 27, 2027 | U-1695 | | ODE-87 | Feb 13, 2022 |
| LENVATINIB MESYLATE - LENVIMA | | | | | | | |
| N 206947 | 002 | 7253286 | Oct 19, 2021 | DS DP | | I-734 | May 13, 2019 |
| | | 7612208 | Sep 19, 2026 | DS DP | | NCE | Feb 13, 2020 |
| | | 9006256 | Jul 27, 2027 | U-1695 | | ODE-87 | Feb 13, 2022 |
| LESINURAD - ZURAMPIC | | | | | | | |
| N 207988 | 001 | 8003681 | Aug 25, 2025 | DS | | NCE | Dec 22, 2020 |
| | | 8084483 | Aug 17, 2029 | U-1801 | | | |
| | | 8283369 | Nov 26, 2028 | U-1802 | | | |
| | | 8283369 | Nov 26, 2028 | U-1804 | | | |
| | | 8357713 | Nov 26, 2028 | DP U-1801 | | | |
| | | 8357713 | Nov 26, 2028 | DP U-1802 | | | |
| | | 8357713 | Nov 26, 2028 | DP U-1803 | | | |
| | | 8546436 | Feb 29, 2032 | DS DP | | | |
| | | 8546437 | Apr 29, 2029 | U-1803 | | | |
| | | 9216179 | Aug 01, 2031 | U-1806 | | | |
| LETERMOVIR - PREVYMIS | | | | | | | |
| N 209939 | 001 | 7196086 | May 22, 2024 | DS DP | | NCE | Nov 08, 2022 |
| | | 8513255 | May 22, 2024 | DS DP | | | |
| LETERMOVIR - PREVYMIS | | | | | | | |
| N 209939 | 002 | 7196086 | May 22, 2024 | DS DP | | NCE | Nov 08, 2022 |
| | | 8513255 | May 22, 2024 | DS DP | | | |
| LETERMOVIR - PREVYMIS | | | | | | | |
| N 209940 | 001 | 7196086 | May 22, 2024 | DS DP | | NCE | Nov 08, 2022 |
| | | 8513255 | May 22, 2024 | DS DP | | | |
| LETERMOVIR - PREVYMIS | | | | | | | |
| N 209940 | 002 | 7196086 | May 22, 2024 | DS DP | | NCE | Nov 08, 2022 |
| | | 8513255 | May 22, 2024 | DS DP | | | |
| LETROZOLE; RIBOCICLIB SUCCINATE - KISQALI FEMARA CO-PACK (COPACKAGED) | | | | | | | |
| N 209935 | 001 | 8324225 | Jun 17, 2028 | DS DP | | NCE | Mar 13, 2022 |
| | | 8415355 | Feb 19, 2031 | DS DP | | | |
| | | 8685980 | May 25, 2030 | DS DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| LETROZOLE; RIBOCICLIB SUCCINATE - KISQALI FEMARA CO-PACK (COPACKAGED) | | | | | | | |
| N 209935 | 001 | 8962630 | Dec 09, 2029 | U-1981 | | | |
| | | 9193732 | Nov 09, 2031 | DS DP | | | |
| | | 9416136 | Aug 20, 2029 | U-1981 | | | |
| LEUPROLIDE ACETATE - LUPRON DEPOT | | | | | | | |
| N 020517 | 003 | 7429559 | Jan 13, 2019 | DP | | | |
| | | 8815801 | Jun 28, 2022 | DP | | | |
| | | 8921326 | Feb 05, 2031 | DP U-1666 | | | |
| LEUPROLIDE ACETATE - VIADUR | | | | | | | |
| N 021088 | 001 | 6113938 | Jul 24, 2018 | | | | |
| | | 6375978 | Dec 17, 2018 | | | | |
| LEUPROLIDE ACETATE - ELIGARD | | | | | | | |
| N 021343 | 001 | 6565874 | Oct 28, 2018 | DP U-801 | | | |
| | | 6626870 | Mar 27, 2020 | DP | | | |
| | | 6773714 | Oct 28, 2018 | DP U-801 | | | |
| | | 9254307 | Oct 28, 2018 | DS DP | | | |
| LEUPROLIDE ACETATE - ELIGARD | | | | | | | |
| N 021379 | 001 | 6565874 | Oct 28, 2018 | DP U-801 | | | |
| | | 6626870 | Mar 27, 2020 | DP | | | |
| | | 6773714 | Oct 28, 2018 | DP U-801 | | | |
| | | 8470359 | Oct 15, 2023 | DS DP U-621 | | | |
| | | 8486455 | Oct 28, 2018 | DS DP | | | |
| | | 8840916 | Nov 13, 2020 | DP | | | |
| | | 9283282 | Oct 28, 2018 | DS DP | | | |
| | | 9539333 | Nov 13, 2020 | DS DP U-621 | | | |
| LEUPROLIDE ACETATE - ELIGARD | | | | | | | |
| N 021488 | 001 | 6565874 | Oct 28, 2018 | DP U-801 | | | |
| | | 6626870 | Mar 27, 2020 | DP | | | |
| | | 6773714 | Oct 28, 2018 | DP U-801 | | | |
| | | 8470359 | Oct 15, 2023 | DS DP U-621 | | | |
| | | 8486455 | Oct 28, 2018 | DS DP | | | |
| | | 8840916 | Nov 13, 2020 | DP | | | |
| | | 9283282 | Oct 28, 2018 | DS DP | | | |
| | | 9539333 | Nov 13, 2020 | DS DP U-621 | | | |
| LEUPROLIDE ACETATE - ELIGARD | | | | | | | |
| N 021731 | 001 | 6565874 | Oct 28, 2018 | DP U-621 | | | |
| | | 6626870 | Mar 27, 2020 | DP | | | |
| | | 6773714 | Oct 28, 2018 | U-621 | | | |
| | | 8470359 | Oct 15, 2023 | DS DP U-621 | | | |
| | | 8486455 | Oct 28, 2018 | DS DP | | | |
| | | 8840916 | Nov 13, 2020 | DP | | | |
| | | 9283282 | Oct 28, 2018 | DS DP | | | |
| | | 9539333 | Nov 13, 2020 | DS DP U-621 | | | |
| LEVALBUTEROL HYDROCHLORIDE - XOPENEX | | | | | | | |
| N 020837 | 001 | 6451289 | Mar 21, 2021 | | | M-151 | Jan 22, 2018 |
| LEVALBUTEROL HYDROCHLORIDE - XOPENEX | | | | | | | |
| N 020837 | 002 | 6451289 | Mar 21, 2021 | | | M-151 | Jan 22, 2018 |
| LEVALBUTEROL HYDROCHLORIDE - XOPENEX | | | | | | | |
| N 020837 | 003 | 6451289 | Mar 21, 2021 | | | M-151 | Jan 22, 2018 |
| LEVALBUTEROL HYDROCHLORIDE - XOPENEX | | | | | | | |
| N 020837 | 004 | 6451289 | Mar 21, 2021 | DP | | M-151 | Jan 22, 2018 |
| LEVALBUTEROL TARTRATE - XOPENEX HFA | | | | | | | |
| N 021730 | 001 | 7256310 | Oct 08, 2024 | DS DP U-636 | | M-156 | Mar 12, 2018 |
| | | 8765153 | Dec 08, 2023 | DP | | | |
| LEVETIRACETAM - ROWEEPRA | | | | | | | |
| A 090906 | 003 | | | | | PC | Sep 13, 2017 |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| LEVETIRACETAM - KEPPRA | | | | | | |
| N 021035 001 | 8802142 | Jun 07, 2031 | DP | | | |
| | 8802142*PED | Dec 07, 2031 | | | | |
| LEVETIRACETAM - KEPPRA | | | | | | |
| N 021035 002 | 8802142 | Jun 07, 2031 | DP | | | |
| | 8802142*PED | Dec 07, 2031 | | | | |
| LEVETIRACETAM - KEPPRA | | | | | | |
| N 021035 003 | 8802142 | Jun 07, 2031 | DP | | | |
| | 8802142*PED | Dec 07, 2031 | | | | |
| LEVETIRACETAM - KEPPRA | | | | | | |
| N 021035 004 | 8802142 | Jun 07, 2031 | DP | | | |
| | 8802142*PED | Dec 07, 2031 | | | | |
| LEVETIRACETAM - KEPPRA XR | | | | | | |
| N 022285 001 | 7858122 | Sep 17, 2028 | DP | | | |
| LEVETIRACETAM - KEPPRA XR | | | | | | |
| N 022285 002 | 7858122 | Sep 17, 2028 | DP | | | |
| LEVETIRACETAM - SPRITAM | | | | | | |
| N 207958 001 | 6471992 | Feb 20, 2018 | DP | | | |
| | 9339489 | Mar 14, 2034 | DP | | U-1850 | |
| | 9463160 | Feb 20, 2018 | DP | | | |
| | 9669009 | Mar 14, 2034 | | | U-1850 | |
| | 9669009 | Mar 14, 2034 | | | U-2021 | |
| | 9669009 | Mar 14, 2034 | | | U-2022 | |
| LEVETIRACETAM - SPRITAM | | | | | | |
| N 207958 002 | 6471992 | Feb 20, 2018 | DP | | | |
| | 9339489 | Mar 14, 2034 | DP | | U-1850 | |
| | 9463160 | Feb 20, 2018 | DP | | | |
| | 9669009 | Mar 14, 2034 | | | U-1850 | |
| | 9669009 | Mar 14, 2034 | | | U-2021 | |
| | 9669009 | Mar 14, 2034 | | | U-2022 | |
| LEVETIRACETAM - SPRITAM | | | | | | |
| N 207958 003 | 6471992 | Feb 20, 2018 | DP | | | |
| | 9339489 | Mar 14, 2034 | DP | | U-1850 | |
| | 9463160 | Feb 20, 2018 | DP | | | |
| | 9669009 | Mar 14, 2034 | | | U-1850 | |
| | 9669009 | Mar 14, 2034 | | | U-2021 | |
| | 9669009 | Mar 14, 2034 | | | U-2022 | |
| LEVETIRACETAM - SPRITAM | | | | | | |
| N 207958 004 | 6471992 | Feb 20, 2018 | DP | | | |
| | 9339489 | Mar 14, 2034 | DP | | U-1850 | |
| | 9463160 | Feb 20, 2018 | DP | | | |
| | 9669009 | Mar 14, 2034 | | | U-1850 | |
| | 9669009 | Mar 14, 2034 | | | U-2021 | |
| | 9669009 | Mar 14, 2034 | | | U-2022 | |
| LEVOCARNITINE - CARNITOR | | | | | | |
| N 020182 001 | 6335369 | Jan 18, 2021 | | | U-433 | |
| | 6429230 | Jan 18, 2021 | | | U-433 | |
| | 6696493 | Jan 18, 2021 | | | U-433 | |
| LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL ALLERGY 24HR | | | | | | |
| N 209090 001 | 8633194 | Oct 16, 2027 | DP | | | |
| LEVOFLOXACIN - LEVAQUIN | | | | | | |
| N 021721 001 | 6806256 | Feb 26, 2022 | DP | | | |
| LEVOLEUCOVORIN CALCIUM - FUSILEV | | | | | | |
| N 020140 001 | 6500829 | Mar 07, 2022 | DS DP | | ODE-10 | Apr 29, 2018 |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|
| LEVOLEUCOVORIN CALCIUM - FUSILEV | | | | | | | | |
| N | 020140 | 002 | 6500829 | Mar 07, 2022 | DS DP | | ODE-10 | Apr 29, 2018 |
| LEVOLEUCOVORIN CALCIUM - FUSILEV | | | | | | | | |
| N | 020140 | 003 | 6500829 | Mar 07, 2022 | DS DP | | ODE-10 | Apr 29, 2018 |
| LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA | | | | | | | | |
| N | 204168 | 001 | 8481598 | Mar 02, 2031 | U-839 | | NCE* | Jul 25, 2018 |
| | | | 8865937 | May 23, 2032 | DS DP | | | |
| | | | RE43879 | Jun 03, 2023 | U-839 | | | |
| LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA | | | | | | | | |
| N | 204168 | 002 | 8481598 | Mar 02, 2031 | U-839 | | NCE* | Jul 25, 2018 |
| | | | 8865937 | May 23, 2032 | DS DP | | | |
| | | | RE43879 | Jun 03, 2023 | U-839 | | | |
| LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA | | | | | | | | |
| N | 204168 | 003 | 8481598 | Mar 02, 2031 | U-839 | | NCE* | Jul 25, 2018 |
| | | | 8865937 | May 23, 2032 | DS DP | | | |
| | | | RE43879 | Jun 03, 2023 | U-839 | | | |
| LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA | | | | | | | | |
| N | 204168 | 004 | 8481598 | Mar 02, 2031 | U-839 | | NCE* | Jul 25, 2018 |
| | | | 8865937 | May 23, 2032 | DS DP | | | |
| | | | RE43879 | Jun 03, 2023 | U-839 | | | |
| LEVONORGESTREL - MIRENA | | | | | | | | |
| N | 021225 | 001 | 9615965 | Sep 16, 2029 | DP U-2003 | | | |
| | | | 9668912 | Apr 01, 2031 | DP | | | |
| LEVONORGESTREL - SKYLA | | | | | | | | |
| N | 203159 | 001 | 7252839 | Nov 13, 2023 | DP | | | |
| | | | 9615965 | Sep 16, 2029 | DP U-2003 | | | |
| | | | 9668912 | Apr 01, 2031 | DP | | | |
| LEVONORGESTREL - LILETTA | | | | | | | | |
| N | 206229 | 001 | | | | | NP | Feb 26, 2018 |
| LEVONORGESTREL - KYLEENA | | | | | | | | |
| N | 208224 | 001 | 7252839 | Nov 13, 2023 | DP | | NP | Sep 16, 2019 |
| | | | 9615965 | Sep 16, 2029 | DP U-2003 | | | |
| | | | 9668912 | Apr 01, 2031 | DP | | | |
| LEVOTHYROXINE SODIUM - LEVOXYL | | | | | | | | |
| N | 021301 | 001 | 6555581 | Feb 15, 2022 | | | | |
| | | | 7067148 | Feb 15, 2022 | DP | | | |
| | | | 7101569 | Oct 02, 2023 | U-759 | | | |
| LEVOTHYROXINE SODIUM - LEVOXYL | | | | | | | | |
| N | 021301 | 002 | 6555581 | Feb 15, 2022 | | | | |
| | | | 7067148 | Feb 15, 2022 | DP | | | |
| | | | 7101569 | Oct 02, 2023 | U-759 | | | |
| LEVOTHYROXINE SODIUM - LEVOXYL | | | | | | | | |
| N | 021301 | 003 | 6555581 | Feb 15, 2022 | | | | |
| | | | 7067148 | Feb 15, 2022 | DP | | | |
| | | | 7101569 | Oct 02, 2023 | U-759 | | | |
| LEVOTHYROXINE SODIUM - LEVOXYL | | | | | | | | |
| N | 021301 | 004 | 6555581 | Feb 15, 2022 | | | | |
| | | | 7067148 | Feb 15, 2022 | DP | | | |
| | | | 7101569 | Oct 02, 2023 | U-759 | | | |
| LEVOTHYROXINE SODIUM - LEVOXYL | | | | | | | | |
| N | 021301 | 005 | 6555581 | Feb 15, 2022 | | | | |
| | | | 7067148 | Feb 15, 2022 | DP | | | |
| | | | 7101569 | Oct 02, 2023 | U-759 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| LEVOTHYROXINE SODIUM - LEVOXYL | | | | | | |
| N 021301 006 | 6555581 | Feb 15, 2022 | | | | |
| | 7067148 | Feb 15, 2022 | DP | | | |
| | 7101569 | Oct 02, 2023 | U-759 | | | |
| LEVOTHYROXINE SODIUM - LEVOXYL | | | | | | |
| N 021301 007 | 6555581 | Feb 15, 2022 | | | | |
| | 7067148 | Feb 15, 2022 | DP | | | |
| | 7101569 | Oct 02, 2023 | U-759 | | | |
| LEVOTHYROXINE SODIUM - LEVOXYL | | | | | | |
| N 021301 008 | 6555581 | Feb 15, 2022 | | | | |
| | 7067148 | Feb 15, 2022 | DP | | | |
| | 7101569 | Oct 02, 2023 | U-759 | | | |
| LEVOTHYROXINE SODIUM - LEVOXYL | | | | | | |
| N 021301 009 | 6555581 | Feb 15, 2022 | | | | |
| | 7067148 | Feb 15, 2022 | DP | | | |
| | 7101569 | Oct 02, 2023 | U-759 | | | |
| LEVOTHYROXINE SODIUM - LEVOXYL | | | | | | |
| N 021301 010 | 6555581 | Feb 15, 2022 | | | | |
| | 7067148 | Feb 15, 2022 | DP | | | |
| | 7101569 | Oct 02, 2023 | U-759 | | | |
| LEVOTHYROXINE SODIUM - LEVOXYL | | | | | | |
| N 021301 011 | 6555581 | Feb 15, 2022 | | | | |
| | 7067148 | Feb 15, 2022 | DP | | | |
| | 7101569 | Oct 02, 2023 | U-759 | | | |
| LEVOTHYROXINE SODIUM - LEVOXYL | | | | | | |
| N 021301 012 | 6555581 | Feb 15, 2022 | | | | |
| | 7067148 | Feb 15, 2022 | DP | | | |
| | 7101569 | Oct 02, 2023 | U-759 | | | |
| LEVOTHYROXINE SODIUM - LEVO-T | | | | | | |
| N 021342 001 | 6399101 | Mar 30, 2020 | | | | |
| LEVOTHYROXINE SODIUM - LEVO-T | | | | | | |
| N 021342 002 | 6399101 | Mar 30, 2020 | | | | |
| LEVOTHYROXINE SODIUM - LEVO-T | | | | | | |
| N 021342 003 | 6399101 | Mar 30, 2020 | | | | |
| LEVOTHYROXINE SODIUM - LEVO-T | | | | | | |
| N 021342 004 | 6399101 | Mar 30, 2020 | | | | |
| LEVOTHYROXINE SODIUM - LEVO-T | | | | | | |
| N 021342 005 | 6399101 | Mar 30, 2020 | | | | |
| LEVOTHYROXINE SODIUM - LEVO-T | | | | | | |
| N 021342 006 | 6399101 | Mar 30, 2020 | | | | |
| LEVOTHYROXINE SODIUM - LEVO-T | | | | | | |
| N 021342 007 | 6399101 | Mar 30, 2020 | | | | |
| LEVOTHYROXINE SODIUM - LEVO-T | | | | | | |
| N 021342 008 | 6399101 | Mar 30, 2020 | | | | |
| LEVOTHYROXINE SODIUM - LEVO-T | | | | | | |
| N 021342 009 | 6399101 | Mar 30, 2020 | | | | |
| LEVOTHYROXINE SODIUM - LEVO-T | | | | | | |
| N 021342 010 | 6399101 | Mar 30, 2020 | | | | |
| LEVOTHYROXINE SODIUM - LEVO-T | | | | | | |
| N 021342 011 | 6399101 | Mar 30, 2020 | | | | |
| LEVOTHYROXINE SODIUM - TIROSINT | | | | | | |
| N 021924 002 | 7691411 | Mar 14, 2024 | DP | | | |
| | 7723390 | Mar 14, 2024 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| LEVOTHYROXINE SODIUM - TIROSINT | | | | | | | |
| N 021924 | 002 | 7691411 | Mar 14, 2024 | DP | | | |
| | | 7723390 | Mar 14, 2024 | DP | | | |
| LEVOTHYROXINE SODIUM - TIROSINT | | | | | | | |
| N 021924 | 003 | 7691411 | Mar 14, 2024 | DP | | | |
| | | 7723390 | Mar 14, 2024 | DP | | | |
| LEVOTHYROXINE SODIUM - TIROSINT | | | | | | | |
| N 021924 | 004 | 7691411 | Mar 14, 2024 | DP | | | |
| | | 7723390 | Mar 14, 2024 | DP | | | |
| LEVOTHYROXINE SODIUM - TIROSINT | | | | | | | |
| N 021924 | 005 | 7691411 | Mar 14, 2024 | DP | | | |
| | | 7723390 | Mar 14, 2024 | DP | | | |
| LEVOTHYROXINE SODIUM - TIROSINT | | | | | | | |
| N 021924 | 006 | 7691411 | Mar 14, 2024 | DP | | | |
| | | 7723390 | Mar 14, 2024 | DP | | | |
| LEVOTHYROXINE SODIUM - TIROSINT | | | | | | | |
| N 021924 | 007 | 7691411 | Mar 14, 2024 | DP | | | |
| | | 7723390 | Mar 14, 2024 | DP | | | |
| LEVOTHYROXINE SODIUM - TIROSINT | | | | | | | |
| N 021924 | 008 | 7691411 | Mar 14, 2024 | DP | | | |
| | | 7723390 | Mar 14, 2024 | DP | | | |
| LEVOTHYROXINE SODIUM - TIROSINT | | | | | | | |
| N 021924 | 009 | 7691411 | Mar 14, 2024 | DP | | | |
| | | 7723390 | Mar 14, 2024 | DP | | | |
| LEVOTHYROXINE SODIUM - TIROSINT | | | | | | | |
| N 021924 | 010 | 7691411 | Mar 14, 2024 | DP | | | |
| | | 7723390 | Mar 14, 2024 | DP | | | |
| LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM | | | | | | | |
| N 202231 | 001 | 9006289 | Oct 03, 2032 | DP | | | |
| | | 9168238 | Aug 29, 2032 | DP | | | |
| | | 9168239 | Aug 29, 2032 | DP | | | |
| LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM | | | | | | | |
| N 202231 | 002 | 9006289 | Oct 03, 2032 | DP | | | |
| | | 9168238 | Aug 29, 2032 | DP | | | |
| | | 9168239 | Aug 29, 2032 | DP | | | |
| LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM | | | | | | | |
| N 202231 | 003 | 9006289 | Oct 03, 2032 | DP | | | |
| | | 9168238 | Aug 29, 2032 | DP | | | |
| | | 9168239 | Aug 29, 2032 | DP | | | |
| LIDOCAINE HYDROCHLORIDE - ZINGO | | | | | | | |
| N 022114 | 001 | 8540665 | Oct 22, 2029 | | | U-1438 | |
| | | 9358338 | Apr 27, 2035 | | | U-1870 | |
| | | 9370622 | Sep 28, 2035 | | | U-1870 | |
| LIDOCAINE HYDROCHLORIDE - AKTEN | | | | | | | |
| N 022221 | 001 | 8759401 | Jul 24, 2026 | DP | | U-1523 | |
| LIDOCAINE; TETRACAINE - SYNERA | | | | | | | |
| N 021623 | 001 | 6465709 | Jul 07, 2020 | DP | | | |
| LIDOCAINE; TETRACAINE - PLIAGLIS | | | | | | | |
| N 021717 | 001 | 6528086 | Sep 28, 2019 | DP | | | |
| LIFITEGRAST - XIIDRA | | | | | | | |
| N 208073 | 001 | 7314938 | Mar 10, 2025 | DS DP | | NCE | Jul 11, 2021 |
| | | 7745460 | Nov 05, 2024 | DS DP | | U-1880 | |
| | | 7790743 | Nov 05, 2024 | | | U-1880 | |
| | | 7928122 | Nov 05, 2024 | DS DP | | | |
| | | 8084047 | May 17, 2026 | DS DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| LIFITEGRAST - XIIDRA | | | | | | |
| N 208073 001 | 8168655 | May 09, 2029 | U-1880 | | | |
| | 8367701 | Apr 15, 2029 | DP U-1880 | | | |
| | 8592450 | May 17, 2026 | U-1880 | | | |
| | 8927574 | Nov 12, 2030 | DP | | | |
| | 9085553 | Jul 25, 2033 | DP | | | |
| | 9216174 | Nov 05, 2024 | DP | | | |
| | 9353088 | Oct 21, 2030 | DP | | | |
| | 9447077 | Apr 15, 2029 | U-1900 | | | |
| LINACLOTIDE - LINZESS | | | | | | |
| N 202811 001 | 7304036 | Aug 30, 2026 | DS DP U-1278 | | NCE | Aug 30, 2017 |
| | 7304036 | Aug 30, 2026 | DS DP U-1516 | | | |
| | 7371727 | Jan 28, 2024 | DS | | | |
| | 7704947 | Jan 28, 2024 | DS DP | | | |
| | 7745409 | Jan 28, 2024 | DS DP | | | |
| | 8080526 | Jan 28, 2024 | DS DP | | | |
| | 8110553 | Jan 28, 2024 | U-1278 | | | |
| | 8748573 | Oct 30, 2031 | U-1515 | | | |
| | 8748573 | Oct 30, 2031 | U-1516 | | | |
| | 8802628 | Nov 17, 2031 | DP | | | |
| | 8933030 | Feb 17, 2031 | DP | | | |
| | 9708371 | Aug 16, 2033 | DP U-1515 | | | |
| | 9708371 | Aug 16, 2033 | DP U-1516 | | | |
| LINACLOTIDE - LINZESS | | | | | | |
| N 202811 002 | 7304036 | Aug 30, 2026 | DS DP U-1278 | | NCE | Aug 30, 2017 |
| | 7304036 | Aug 30, 2026 | DS DP U-1516 | | | |
| | 7371727 | Jan 28, 2024 | DS | | | |
| | 7704947 | Jan 28, 2024 | DS DP | | | |
| | 7745409 | Jan 28, 2024 | DS DP | | | |
| | 8080526 | Jan 28, 2024 | DS DP | | | |
| | 8110553 | Jan 28, 2024 | U-1278 | | | |
| | 8748573 | Oct 30, 2031 | U-1515 | | | |
| | 8748573 | Oct 30, 2031 | U-1516 | | | |
| | 8802628 | Nov 17, 2031 | DP | | | |
| | 8933030 | Feb 17, 2031 | DP | | | |
| | 9708371 | Aug 16, 2033 | DP U-1515 | | | |
| LINACLOTIDE - LINZESS | | | | | | |
| N 202811 003 | 7304036 | Aug 30, 2026 | DS DP U-1516 | | NCE | Aug 30, 2017 |
| | 7371727 | Jan 28, 2024 | DS | | NS | Jan 25, 2020 |
| | 7704947 | Jan 28, 2024 | DS DP | | | |
| | 7745409 | Jan 28, 2024 | DS DP | | | |
| | 8080526 | Jan 28, 2024 | DS DP | | | |
| | 8110553 | Jan 28, 2024 | U-1516 | | | |
| | 8933030 | Feb 17, 2031 | DP U-1516 | | | |
| | 9708371 | Aug 16, 2033 | DP U-1516 | | | |
| LINAGLIPTIN - TRADJENTA | | | | | | |
| N 201280 001 | 6890898 | Feb 02, 2019 | U-1270 | | | |
| | 6890898 | Feb 02, 2019 | U-493 | | | |
| | 7078381 | Feb 02, 2019 | U-1270 | | | |
| | 7078381 | Feb 02, 2019 | U-493 | | | |
| | 7407955 | May 02, 2025 | DS DP | | | |
| | 7459428 | Feb 02, 2019 | U-1270 | | | |
| | 7459428 | Feb 02, 2019 | U-493 | | | |
| | 8119648 | Aug 12, 2023 | U-1270 | | | |
| | 8119648 | Aug 12, 2023 | U-774 | | | |
| | 8178541 | Aug 12, 2023 | U-1244 | | | |
| | 8178541 | Aug 12, 2023 | U-1245 | | | |
| | 8178541 | Aug 12, 2023 | U-1270 | | | |
| | 8178541 | Aug 12, 2023 | U-775 | | | |
| | 8673927 | May 04, 2027 | U-1503 | | | |
| | 8846695 | Jun 04, 2030 | U-1503 | Y | | |
| | 8853156 | Mar 05, 2031 | U-1642 | | | |
| | 8883805 | Nov 26, 2025 | DP | | | |
| | 9173859 | May 04, 2027 | DP U-1503 | | | |
| | 9173859 | May 04, 2027 | DP U-1768 | | | |
| | 9486526 | Aug 05, 2029 | U-1915 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| LINAGLIPTIN - TRADJENTA | | | | | | | |
| N 201280 | 001 | 6890898 | Feb 02, 2019 | U-1270 | | | |
| | | 6890898 | Feb 02, 2019 | U-493 | | | |
| | | 7078381 | Feb 02, 2019 | U-1270 | | | |
| | | 7078381 | Feb 02, 2019 | U-493 | | | |
| | | 7407955 | May 02, 2025 | DS DP | | | |
| | | 7459428 | Feb 02, 2019 | U-1270 | | | |
| | | 7459428 | Feb 02, 2019 | U-493 | | | |
| | | 8119648 | Aug 12, 2023 | U-1270 | | | |
| | | 8119648 | Aug 12, 2023 | U-774 | | | |
| | | 8178541 | Aug 12, 2023 | U-1244 | | | |
| | | 8178541 | Aug 12, 2023 | U-1245 | | | |
| | | 8178541 | Aug 12, 2023 | U-1270 | | | |
| | | 8178541 | Aug 12, 2023 | U-775 | | | |
| | | 8673927 | May 04, 2027 | U-1503 | | | |
| | | 8846695 | Jun 04, 2030 | U-1503 | Y | | |
| | | 8853156 | Mar 05, 2031 | U-1642 | | | |
| | | 8883805 | Nov 26, 2025 | DP | | | |
| | | 9173859 | May 04, 2027 | DP U-1503 | | | |
| | | 9173859 | May 04, 2027 | DP U-1768 | | | |
| | | 9486526 | Aug 05, 2029 | U-1915 | | | |
| LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO | | | | | | | |
| N 201281 | 001 | 6890898 | Feb 02, 2019 | U-1039 | | M-146 | Jul 30, 2017 |
| | | 7078381 | Feb 02, 2019 | U-1039 | | | |
| | | 7407955 | May 02, 2025 | DS DP | | | |
| | | 7459428 | Feb 02, 2019 | U-1039 | | | |
| | | 8119648 | Aug 12, 2023 | U-802 | | | |
| | | 8178541 | Aug 12, 2023 | DP U-775 | | | |
| | | 8673927 | May 04, 2027 | U-1503 | | | |
| | | 8846695 | Jun 04, 2030 | U-1503 | | | |
| | | 8883805 | Nov 26, 2025 | DP | | | |
| | | 9155705 | May 21, 2030 | DP | | | |
| | | 9173859 | May 04, 2027 | DP U-1503 | | | |
| | | 9415016 | Apr 02, 2029 | DP | | | |
| LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO | | | | | | | |
| N 201281 | 002 | 6890898 | Feb 02, 2019 | U-1039 | | M-146 | Jul 30, 2017 |
| | | 7078381 | Feb 02, 2019 | U-1039 | | | |
| | | 7407955 | May 02, 2025 | DS DP | | | |
| | | 7459428 | Feb 02, 2019 | U-1039 | | | |
| | | 8119648 | Aug 12, 2023 | U-802 | | | |
| | | 8178541 | Aug 12, 2023 | DP U-775 | | | |
| | | 8673927 | May 04, 2027 | U-1503 | | | |
| | | 8846695 | Jun 04, 2030 | U-1503 | | | |
| | | 8883805 | Nov 26, 2025 | DP | | | |
| | | 9155705 | May 21, 2030 | DP | | | |
| | | 9173859 | May 04, 2027 | DP U-1503 | | | |
| | | 9415016 | Apr 02, 2029 | DP | | | |
| LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO | | | | | | | |
| N 201281 | 003 | 6890898 | Feb 02, 2019 | U-1039 | | M-146 | Jul 30, 2017 |
| | | 7078381 | Feb 02, 2019 | U-1039 | | | |
| | | 7407955 | May 02, 2025 | DS DP | | | |
| | | 7459428 | Feb 02, 2019 | U-1039 | | | |
| | | 8119648 | Aug 12, 2023 | U-802 | | | |
| | | 8178541 | Aug 12, 2023 | DP U-775 | | | |
| | | 8673927 | May 04, 2027 | U-1503 | | | |
| | | 8846695 | Jun 04, 2030 | U-1503 | Y | | |
| | | 8883805 | Nov 26, 2025 | DP | | | |
| | | 9155705 | May 21, 2030 | DP | | | |
| | | 9173859 | May 04, 2027 | DP U-1503 | | | |
| | | 9415016 | Apr 02, 2029 | DP | | | |
| LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR | | | | | | | |
| N 208026 | 001 | 6488962 | Jun 20, 2020 | DP | | | |
| | | 6890898 | Feb 02, 2019 | U-803 | | | |
| | | 7078381 | Feb 02, 2019 | U-803 | | | |
| | | 7407955 | May 02, 2025 | DS DP | | | |
| | | 7459428 | Feb 02, 2019 | U-803 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR | | | | | | | |
| N 208026 | 001 | 8119648 | Aug 12, 2023 | U-802 | | | |
| | | 8178541 | Aug 12, 2023 | DP U-1853 | | | |
| | | 8673927 | May 04, 2027 | U-1503 | | | |
| | | 8883805 | Nov 26, 2025 | DP | | | |
| | | 9155705 | May 21, 2030 | DP | | | |
| | | 9173859 | May 04, 2027 | DP U-1503 | | | |
| | | 9415016 | Apr 02, 2029 | DP | | | |
| | | 9555001 | Mar 06, 2033 | DP U-1967 | | | |
| | | 9555001 | Mar 06, 2033 | DP U-1968 | | | |
| LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR | | | | | | | |
| N 208026 | 002 | 6488962 | Jun 20, 2020 | DP | | | |
| | | 6890898 | Feb 02, 2019 | U-803 | | | |
| | | 7078381 | Feb 02, 2019 | U-803 | | | |
| | | 7407955 | May 02, 2025 | DS DP | | | |
| | | 7459428 | Feb 02, 2019 | U-803 | | | |
| | | 8119648 | Aug 12, 2023 | U-802 | | | |
| | | 8178541 | Aug 12, 2023 | DP U-1853 | | | |
| | | 8673927 | May 04, 2027 | U-1503 | | | |
| | | 8883805 | Nov 26, 2025 | DP | | | |
| | | 9155705 | May 21, 2030 | DP | | | |
| | | 9173859 | May 04, 2027 | DP U-1503 | | | |
| | | 9415016 | Apr 02, 2029 | DP | | | |
| | | 9555001 | Mar 06, 2033 | DP U-1967 | | | |
| | | 9555001 | Mar 06, 2033 | DP U-1968 | | | |
| LINEZOLID - ZYVOX | | | | | | | |
| N 021130 | 001 | 6514529 | Mar 15, 2021 | DP | | | |
| | | 6559305 | Jan 29, 2021 | DS | | | |
| LINEZOLID - ZYVOX | | | | | | | |
| N 021130 | 002 | 6514529 | Mar 15, 2021 | DP | | | |
| | | 6559305 | Jan 29, 2021 | DS | | | |
| LINEZOLID - ZYVOX | | | | | | | |
| N 021131 | 001 | 6559305 | Jan 29, 2021 | DS | | | |
| LINEZOLID - ZYVOX | | | | | | | |
| N 021131 | 002 | 6559305 | Jan 29, 2021 | DS | | | |
| | | 6559305*PED | Jul 29, 2021 | | | | |
| LINEZOLID - ZYVOX | | | | | | | |
| N 021131 | 003 | 6559305 | Jan 29, 2021 | DS | | | |
| | | 6559305*PED | Jul 29, 2021 | | | | |
| LINEZOLID - ZYVOX | | | | | | | |
| N 021132 | 001 | 6559305 | Jan 29, 2021 | DS | | | |
| LIRAGLUTIDE RECOMBINANT - VICTOZA | | | | | | | |
| N 022341 | 001 | 6004297 | Jan 28, 2019 | DP | | I-750 | Aug 25, 2020 |
| | | 6268343 | Aug 22, 2022 | DS DP U-968 | | M-176 | Apr 22, 2019 |
| | | 6458924 | Aug 22, 2017 | DS DP U-968 | | | |
| | | 7235627 | Aug 22, 2017 | DS DP | | | |
| | | 8114833 | Aug 13, 2025 | DP | | | |
| | | 8846618 | Jun 27, 2022 | DP | | | |
| | | 9265893 | Sep 23, 2032 | DP | | | |
| | | RE41956 | Jan 21, 2021 | DP | | | |
| | | RE43834 | Jan 28, 2019 | DP | | | |
| LIRAGLUTIDE RECOMBINANT - SAXENDA | | | | | | | |
| N 206321 | 001 | 6268343 | Aug 22, 2022 | DS DP U-1255 | | | |
| | | 6458924 | Aug 22, 2017 | DS DP U-1255 | | | |
| | | 6899699 | Jan 01, 2022 | DP | | | |
| | | 7235627 | Aug 22, 2017 | DS DP | | | |
| | | 8114833 | Aug 13, 2025 | DP | | | |
| | | 8672898 | Jan 02, 2022 | DP | | | |
| | | 8684969 | Oct 20, 2025 | DP | | | |
| | | 8846618 | Jun 27, 2022 | DP | | | |
| | | 8920383 | Jul 17, 2026 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| LIRAGLUTIDE RECOMBINANT - SAXENDA | | | | | | | |
| N 206321 | 001 | 9108002 | Jan 26, 2026 | DP | | | |
| | | 9132239 | Feb 01, 2032 | DP | | | |
| | | 9457154 | Sep 27, 2027 | DP | | | |
| | | 9486588 | Jan 02, 2022 | DP | | | |
| | | 9687611 | Feb 27, 2027 | DP | | | |
| | | 9775953 | Jul 17, 2026 | DP | | | |
| | | RE46363 | Aug 03, 2026 | DP | | | |
| LISDEXAMFETAMINE DIMESYLATE - VYVANSE | | | | | | | |
| N 021977 | 001 | 7105486 | Feb 24, 2023 | U-727 | | I-703 | Jan 30, 2018 |
| | | 7223735 | Feb 24, 2023 | DP | | M-188 | Oct 14, 2019 |
| | | 7655630 | Feb 24, 2023 | DS | | | |
| | | 7659253 | Feb 24, 2023 | DS DP U-727 | | | |
| | | 7659254 | Feb 24, 2023 | U-1034 | | | |
| | | 7662787 | Feb 24, 2023 | DS | | | |
| | | 7662788 | Feb 24, 2023 | U-727 | | | |
| | | 7671030 | Feb 24, 2023 | DP U-727 | | | |
| | | 7671031 | Feb 24, 2023 | U-727 | | | |
| | | 7674774 | Feb 24, 2023 | DP U-842 | | | |
| | | 7678770 | Feb 24, 2023 | U-842 | | | |
| | | 7678771 | Feb 24, 2023 | DP U-842 | | | |
| | | 7687466 | Feb 24, 2023 | DP | | | |
| | | 7687467 | Feb 24, 2023 | DP U-842 | | | |
| | | 7700561 | Feb 24, 2023 | DP | | | |
| | | 7713936 | Feb 24, 2023 | U-727 | | | |
| | | 7718619 | Feb 24, 2023 | DP U-842 | | | |
| | | 7723305 | Feb 24, 2023 | DP U-842 | | | |
| LISDEXAMFETAMINE DIMESYLATE - VYVANSE | | | | | | | |
| N 021977 | 002 | 7105486 | Feb 24, 2023 | U-727 | | I-703 | Jan 30, 2018 |
| | | 7223735 | Feb 24, 2023 | DP | | M-188 | Oct 14, 2019 |
| | | 7655630 | Feb 24, 2023 | DS | | | |
| | | 7659253 | Feb 24, 2023 | DS DP U-727 | | | |
| | | 7659254 | Feb 24, 2023 | U-1034 | | | |
| | | 7662787 | Feb 24, 2023 | DS | | | |
| | | 7662788 | Feb 24, 2023 | U-727 | | | |
| | | 7671030 | Feb 24, 2023 | DP U-727 | | | |
| | | 7671031 | Feb 24, 2023 | U-727 | | | |
| | | 7674774 | Feb 24, 2023 | DP U-842 | | | |
| | | 7678770 | Feb 24, 2023 | U-842 | | | |
| | | 7678771 | Feb 24, 2023 | DP U-842 | | | |
| | | 7687466 | Feb 24, 2023 | DP | | | |
| | | 7687467 | Feb 24, 2023 | DP U-842 | | | |
| | | 7700561 | Feb 24, 2023 | DP | | | |
| | | 7713936 | Feb 24, 2023 | U-727 | | | |
| | | 7718619 | Feb 24, 2023 | DP U-842 | | | |
| | | 7723305 | Feb 24, 2023 | DP U-842 | | | |
| LISDEXAMFETAMINE DIMESYLATE - VYVANSE | | | | | | | |
| N 021977 | 003 | 7105486 | Feb 24, 2023 | U-727 | | I-703 | Jan 30, 2018 |
| | | 7223735 | Feb 24, 2023 | DP | | M-188 | Oct 14, 2019 |
| | | 7655630 | Feb 24, 2023 | DS | | | |
| | | 7659253 | Feb 24, 2023 | DS DP U-727 | | | |
| | | 7659254 | Feb 24, 2023 | U-1034 | | | |
| | | 7662787 | Feb 24, 2023 | DS | | | |
| | | 7662788 | Feb 24, 2023 | U-727 | | | |
| | | 7671030 | Feb 24, 2023 | DP U-727 | | | |
| | | 7671031 | Feb 24, 2023 | U-727 | | | |
| | | 7674774 | Feb 24, 2023 | DP U-842 | | | |
| | | 7678770 | Feb 24, 2023 | U-842 | | | |
| | | 7678771 | Feb 24, 2023 | DP U-842 | | | |
| | | 7687466 | Feb 24, 2023 | DP | | | |
| | | 7687467 | Feb 24, 2023 | DP U-842 | | | |
| | | 7700561 | Feb 24, 2023 | DP | | | |
| | | 7713936 | Feb 24, 2023 | U-727 | | | |
| | | 7718619 | Feb 24, 2023 | DP U-842 | | | |
| | | 7723305 | Feb 24, 2023 | DP U-842 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| LISDEXAMFETAMINE DIMESYLATE - VYVANSE | | | | | | |
| N 021977 004 | 7105486 | Feb 24, 2023 | U-727 | | I-703 | Jan 30, 2018 |
| | 7105486 | Feb 24, 2023 | U-842 | | M-188 | Oct 14, 2019 |
| | 7223735 | Feb 24, 2023 | DP | | | |
| | 7655630 | Feb 24, 2023 | DS | | | |
| | 7659253 | Feb 24, 2023 | DS DP U-727 | | | |
| | 7659254 | Feb 24, 2023 | U-1034 | | | |
| | 7662787 | Feb 24, 2023 | DS | | | |
| | 7662788 | Feb 24, 2023 | U-727 | | | |
| | 7671030 | Feb 24, 2023 | DP U-727 | | | |
| | 7671031 | Feb 24, 2023 | U-727 | | | |
| | 7674774 | Feb 24, 2023 | DP U-842 | | | |
| | 7678770 | Feb 24, 2023 | U-842 | | | |
| | 7678771 | Feb 24, 2023 | DP U-842 | | | |
| | 7687466 | Feb 24, 2023 | DP | | | |
| | 7687467 | Feb 24, 2023 | DP U-842 | | | |
| | 7700561 | Feb 24, 2023 | DP | | | |
| | 7713936 | Feb 24, 2023 | U-727 | | | |
| | 7718619 | Feb 24, 2023 | DP U-842 | | | |
| | 7723305 | Feb 24, 2023 | DP U-842 | | | |
| LISDEXAMFETAMINE DIMESYLATE - VYVANSE | | | | | | |
| N 021977 005 | 7105486 | Feb 24, 2023 | U-842 | | I-703 | Jan 30, 2018 |
| | 7223735 | Feb 24, 2023 | DP | | M-188 | Oct 14, 2019 |
| | 7655630 | Feb 24, 2023 | DS | | | |
| | 7659253 | Feb 24, 2023 | DS DP U-727 | | | |
| | 7659254 | Feb 24, 2023 | U-1034 | | | |
| | 7662787 | Feb 24, 2023 | DS | | | |
| | 7662788 | Feb 24, 2023 | U-727 | | | |
| | 7671030 | Feb 24, 2023 | DP U-727 | | | |
| | 7671031 | Feb 24, 2023 | U-727 | | | |
| | 7674774 | Feb 24, 2023 | DP U-842 | | | |
| | 7678770 | Feb 24, 2023 | U-842 | | | |
| | 7678771 | Feb 24, 2023 | DP U-842 | | | |
| | 7687466 | Feb 24, 2023 | DP | | | |
| | 7687467 | Feb 24, 2023 | DP U-842 | | | |
| | 7700561 | Feb 24, 2023 | DP | | | |
| | 7713936 | Feb 24, 2023 | U-727 | | | |
| | 7718619 | Feb 24, 2023 | DP U-842 | | | |
| | 7723305 | Feb 24, 2023 | DP U-842 | | | |
| LISDEXAMFETAMINE DIMESYLATE - VYVANSE | | | | | | |
| N 021977 006 | 7105486 | Feb 24, 2023 | U-727 | | I-703 | Jan 30, 2018 |
| | 7105486 | Feb 24, 2023 | U-842 | | M-188 | Oct 14, 2019 |
| | 7223735 | Feb 24, 2023 | DP | | | |
| | 7655630 | Feb 24, 2023 | DS | | | |
| | 7659253 | Feb 24, 2023 | DS DP U-727 | | | |
| | 7659254 | Feb 24, 2023 | U-1034 | | | |
| | 7662787 | Feb 24, 2023 | DS | | | |
| | 7662788 | Feb 24, 2023 | U-727 | | | |
| | 7671030 | Feb 24, 2023 | DP U-727 | | | |
| | 7671031 | Feb 24, 2023 | U-727 | | | |
| | 7674774 | Feb 24, 2023 | DP U-842 | | | |
| | 7678770 | Feb 24, 2023 | U-842 | | | |
| | 7678771 | Feb 24, 2023 | DP U-842 | | | |
| | 7687466 | Feb 24, 2023 | DP | | | |
| | 7687467 | Feb 24, 2023 | DP U-842 | | | |
| | 7700561 | Feb 24, 2023 | DP | | | |
| | 7713936 | Feb 24, 2023 | U-727 | | | |
| | 7718619 | Feb 24, 2023 | DP U-842 | | | |
| | 7723305 | Feb 24, 2023 | DP U-842 | | | |
| LISDEXAMFETAMINE DIMESYLATE - VYVANSE | | | | | | |
| N 021977 007 | 7223735 | Feb 24, 2023 | DP | | I-703 | Jan 30, 2018 |
| | 7655630 | Feb 24, 2023 | DS | | M-188 | Oct 14, 2019 |
| | 7659253 | Feb 24, 2023 | DS DP U-727 | | | |
| | 7659254 | Feb 24, 2023 | U-1034 | | | |
| | 7662787 | Feb 24, 2023 | DS | | | |
| | 7662788 | Feb 24, 2023 | U-727 | | | |
| | 7671030 | Feb 24, 2023 | DP U-727 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| LISDEXAMFETAMINE DIMESYLATE - VYVANSE | | | | | | |
| N 021977 007 | 7671031 | Feb 24, 2023 | U-727 | | | |
| | 7674774 | Feb 24, 2023 | DP U-842 | | | |
| | 7678770 | Feb 24, 2023 | U-842 | | | |
| | 7678771 | Feb 24, 2023 | DP | | | |
| | 7687466 | Feb 24, 2023 | DP | | | |
| | 7687467 | Feb 24, 2023 | DP U-842 | | | |
| | 7700561 | Feb 24, 2023 | DP | | | |
| | 7713936 | Feb 24, 2023 | U-727 | | | |
| | 7718619 | Feb 24, 2023 | DP U-842 | | | |
| LISDEXAMFETAMINE DIMESYLATE - VYVANSE | | | | | | |
| N 208510 001 | 7105486 | Feb 24, 2023 | U-727 | | I-703 | Jan 30, 2018 |
| | 7223735 | Feb 24, 2023 | DP | | M-188 | Oct 14, 2019 |
| | 7655630 | Feb 24, 2023 | DS DP | | | |
| | 7659253 | Feb 24, 2023 | DS DP U-727 | | | |
| | 7659254 | Feb 24, 2023 | U-727 | | | |
| | 7662787 | Feb 24, 2023 | DS | | | |
| | 7662788 | Feb 24, 2023 | U-727 | | | |
| | 7671030 | Feb 24, 2023 | DP U-727 | | | |
| | 7671031 | Feb 24, 2023 | U-727 | | | |
| | 7674774 | Feb 24, 2023 | DP U-727 | | | |
| | 7678770 | Feb 24, 2023 | U-727 | | | |
| | 7678771 | Feb 24, 2023 | DP U-727 | | | |
| | 7687466 | Feb 24, 2023 | DP | | | |
| | 7687467 | Feb 24, 2023 | DP U-727 | | | |
| | 7713936 | Feb 24, 2023 | U-727 | | | |
| | 7718619 | Feb 24, 2023 | DP U-727 | | | |
| | 7723305 | Feb 24, 2023 | DP U-727 | | | |
| LISDEXAMFETAMINE DIMESYLATE - VYVANSE | | | | | | |
| N 208510 002 | 7105486 | Feb 24, 2023 | U-727 | | I-703 | Jan 30, 2018 |
| | 7223735 | Feb 24, 2023 | DP | | M-188 | Oct 14, 2019 |
| | 7655630 | Feb 24, 2023 | DS DP | | | |
| | 7659253 | Feb 24, 2023 | DS DP U-727 | | | |
| | 7659254 | Feb 24, 2023 | U-727 | | | |
| | 7662787 | Feb 24, 2023 | DS | | | |
| | 7662788 | Feb 24, 2023 | U-727 | | | |
| | 7671030 | Feb 24, 2023 | DP U-727 | | | |
| | 7671031 | Feb 24, 2023 | U-727 | | | |
| | 7674774 | Feb 24, 2023 | DP U-727 | | | |
| | 7678770 | Feb 24, 2023 | U-727 | | | |
| | 7678771 | Feb 24, 2023 | DP U-727 | | | |
| | 7687466 | Feb 24, 2023 | DP | | | |
| | 7687467 | Feb 24, 2023 | DP U-727 | | | |
| | 7713936 | Feb 24, 2023 | U-727 | | | |
| | 7718619 | Feb 24, 2023 | DP U-727 | | | |
| | 7723305 | Feb 24, 2023 | DP U-727 | | | |
| LISDEXAMFETAMINE DIMESYLATE - VYVANSE | | | | | | |
| N 208510 003 | 7105486 | Feb 24, 2023 | U-727 | | I-703 | Jan 30, 2018 |
| | 7223735 | Feb 24, 2023 | DP | | M-188 | Oct 14, 2019 |
| | 7655630 | Feb 24, 2023 | DS DP | | | |
| | 7659253 | Feb 24, 2023 | DS DP U-727 | | | |
| | 7659254 | Feb 24, 2023 | U-727 | | | |
| | 7662787 | Feb 24, 2023 | DS | | | |
| | 7662788 | Feb 24, 2023 | U-727 | | | |
| | 7671030 | Feb 24, 2023 | DP U-727 | | | |
| | 7671031 | Feb 24, 2023 | U-727 | | | |
| | 7674774 | Feb 24, 2023 | DP U-727 | | | |
| | 7678770 | Feb 24, 2023 | U-727 | | | |
| | 7678771 | Feb 24, 2023 | DP U-727 | | | |
| | 7687466 | Feb 24, 2023 | DP | | | |
| | 7687467 | Feb 24, 2023 | DP U-727 | | | |
| | 7713936 | Feb 24, 2023 | U-727 | | | |
| | 7718619 | Feb 24, 2023 | DP U-727 | | | |
| | 7723305 | Feb 24, 2023 | DP U-727 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| LISDEXAMFETAMINE DIMESYLATE - VYVANSE | | | | | | |
| N 208510 004 | 7105486 | Feb 24, 2023 | U-727 | | I-703 | Jan 30, 2018 |
| | 7223735 | Feb 24, 2023 | DP | | M-188 | Oct 14, 2019 |
| | 7655630 | Feb 24, 2023 | DS DP | | | |
| | 7659253 | Feb 24, 2023 | DS DP U-727 | | | |
| | 7659254 | Feb 24, 2023 | U-727 | | | |
| | 7662787 | Feb 24, 2023 | DS | | | |
| | 7662788 | Feb 24, 2023 | U-727 | | | |
| | 7671030 | Feb 24, 2023 | DP U-727 | | | |
| | 7671031 | Feb 24, 2023 | U-727 | | | |
| | 7674774 | Feb 24, 2023 | DP U-727 | | | |
| | 7678770 | Feb 24, 2023 | U-727 | | | |
| | 7678771 | Feb 24, 2023 | DP U-727 | | | |
| | 7687466 | Feb 24, 2023 | DP | | | |
| | 7687467 | Feb 24, 2023 | DP U-727 | | | |
| | 7713936 | Feb 24, 2023 | U-727 | | | |
| | 7718619 | Feb 24, 2023 | DP U-727 | | | |
| | 7723305 | Feb 24, 2023 | DP U-727 | | | |
| LISDEXAMFETAMINE DIMESYLATE - VYVANSE | | | | | | |
| N 208510 005 | 7105486 | Feb 24, 2023 | U-727 | | I-703 | Jan 30, 2018 |
| | 7223735 | Feb 24, 2023 | DP | | M-188 | Oct 14, 2019 |
| | 7655630 | Feb 24, 2023 | DS DP | | | |
| | 7659253 | Feb 24, 2023 | DS DP U-727 | | | |
| | 7659254 | Feb 24, 2023 | U-727 | | | |
| | 7662787 | Feb 24, 2023 | DS | | | |
| | 7662788 | Feb 24, 2023 | U-727 | | | |
| | 7671030 | Feb 24, 2023 | DP U-727 | | | |
| | 7671031 | Feb 24, 2023 | U-727 | | | |
| | 7674774 | Feb 24, 2023 | DP U-727 | | | |
| | 7678770 | Feb 24, 2023 | U-727 | | | |
| | 7678771 | Feb 24, 2023 | DP U-727 | | | |
| | 7687466 | Feb 24, 2023 | DP | | | |
| | 7687467 | Feb 24, 2023 | DP U-727 | | | |
| | 7713936 | Feb 24, 2023 | U-727 | | | |
| | 7718619 | Feb 24, 2023 | DP U-727 | | | |
| | 7723305 | Feb 24, 2023 | DP U-727 | | | |
| LISDEXAMFETAMINE DIMESYLATE - VYVANSE | | | | | | |
| N 208510 006 | 7105486 | Feb 24, 2023 | U-727 | | I-703 | Jan 30, 2018 |
| | 7223735 | Feb 24, 2023 | DP | | M-188 | Oct 14, 2019 |
| | 7655630 | Feb 24, 2023 | DS DP | | | |
| | 7659253 | Feb 24, 2023 | DS DP U-727 | | | |
| | 7659254 | Feb 24, 2023 | U-727 | | | |
| | 7662787 | Feb 24, 2023 | DS | | | |
| | 7662788 | Feb 24, 2023 | U-727 | | | |
| | 7671030 | Feb 24, 2023 | DP U-727 | | | |
| | 7671031 | Feb 24, 2023 | U-727 | | | |
| | 7674774 | Feb 24, 2023 | DP U-727 | | | |
| | 7678770 | Feb 24, 2023 | U-727 | | | |
| | 7678771 | Feb 24, 2023 | DP U-727 | | | |
| | 7687466 | Feb 24, 2023 | DP | | | |
| | 7687467 | Feb 24, 2023 | DP U-727 | | | |
| | 7713936 | Feb 24, 2023 | U-727 | | | |
| | 7718619 | Feb 24, 2023 | DP U-727 | | | |
| | 7723305 | Feb 24, 2023 | DP U-727 | | | |
| LISINOPRIL - QBRELIS | | | | | | |
| N 208401 001 | 9463183 | Nov 06, 2035 | DP | | | |
| | 9616096 | Nov 06, 2035 | U-1723 | | | |
| | 9616096 | Nov 06, 2035 | U-185 | | | |
| | 9616096 | Nov 06, 2035 | U-1864 | | | |
| | 9616096 | Nov 06, 2035 | U-1991 | | | |
| | 9616096 | Nov 06, 2035 | U-3 | | | |
| | 9616096 | Nov 06, 2035 | U-71 | | | |
| | 9616096 | Nov 06, 2035 | U-8 | | | |
| | 9814751 | Nov 06, 2035 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| LIXISENATIDE - ADLYXIN | | | | | | | |
| N 208471 | 001 | 8475414 | Dec 28, 2030 | DP U-1881 | | NCE | Jul 27, 2021 |
| | | 8882721 | Jun 28, 2031 | DP | | | |
| | | 8915888 | Jun 08, 2030 | DP U-1881 | | | |
| | | 9072836 | Mar 15, 2032 | DP | | | |
| | | 9084853 | Oct 05, 2031 | DP | | | |
| | | 9308329 | Dec 28, 2030 | DP U-1881 | | | |
| | | 9408893 | Aug 27, 2032 | U-1894 | | | |
| | | 9511193 | Jan 19, 2032 | DP | | | |
| | | 9707176 | Nov 11, 2030 | DP | | | |
| | | 9821032 | May 09, 2032 | U-2200 | | | |
| | | RE45313 | Jul 12, 2020 | DS DP | | | |
| LIXISENATIDE - ADLYXIN | | | | | | | |
| N 208471 | 002 | 8475414 | Dec 28, 2030 | DP U-1881 | | NCE | Jul 27, 2021 |
| | | 8882721 | Jun 28, 2031 | DP | | | |
| | | 8915888 | Jun 08, 2030 | DP U-1881 | | | |
| | | 9072836 | Mar 15, 2032 | DP | | | |
| | | 9084853 | Oct 05, 2031 | DP | | | |
| | | 9308329 | Dec 28, 2030 | DP U-1881 | | | |
| | | 9408893 | Aug 27, 2032 | U-1894 | | | |
| | | 9511193 | Jan 19, 2032 | DP | | | |
| | | 9707176 | Nov 11, 2030 | DP | | | |
| | | 9821032 | May 09, 2032 | U-2200 | | | |
| | | RE45313 | Jul 12, 2020 | DS DP | | | |
| LOMITAPIDE MESYLATE - JUXTAPID | | | | | | | |
| N 203858 | 001 | 5712279 | Feb 21, 2020 | DS DP U-1317 | | NCE | Dec 21, 2017 |
| | | 6492365 | Dec 10, 2019 | U-1318 | | ODE-36 | Dec 21, 2019 |
| | | 7932268 | Aug 19, 2027 | U-1316 | | | |
| | | 8618135 | Mar 07, 2025 | U-1316 | | | |
| | | 9265758 | Mar 07, 2025 | U-1316 | | | |
| | | 9364470 | Mar 07, 2025 | U-1851 | | | |
| | | 9433617 | Mar 07, 2025 | U-1316 | | | |
| LOMITAPIDE MESYLATE - JUXTAPID | | | | | | | |
| N 203858 | 002 | 5712279 | Feb 21, 2020 | DS DP U-1317 | | NCE | Dec 21, 2017 |
| | | 6492365 | Dec 10, 2019 | U-1318 | | ODE-36 | Dec 21, 2019 |
| | | 7932268 | Aug 19, 2027 | U-1316 | | | |
| | | 8618135 | Mar 07, 2025 | U-1316 | | | |
| | | 9265758 | Mar 07, 2025 | U-1316 | | | |
| | | 9364470 | Mar 07, 2025 | U-1851 | | | |
| | | 9433617 | Mar 07, 2025 | U-1316 | | | |
| LOMITAPIDE MESYLATE - JUXTAPID | | | | | | | |
| N 203858 | 003 | 5712279 | Feb 21, 2020 | DS DP U-1317 | | NCE | Dec 21, 2017 |
| | | 6492365 | Dec 10, 2019 | U-1318 | | ODE-36 | Dec 21, 2019 |
| | | 7932268 | Aug 19, 2027 | U-1316 | | | |
| | | 8618135 | Mar 07, 2025 | U-1316 | | | |
| | | 9265758 | Mar 07, 2025 | U-1316 | | | |
| | | 9364470 | Mar 07, 2025 | U-1851 | | | |
| | | 9433617 | Mar 07, 2025 | U-1316 | | | |
| LOMITAPIDE MESYLATE - JUXTAPID | | | | | | | |
| N 203858 | 004 | 5712279 | Feb 21, 2020 | DS DP U-1317 | | NCE | Dec 21, 2017 |
| | | 6492365 | Dec 10, 2019 | U-1318 | | ODE-36 | Dec 21, 2019 |
| | | 7932268 | Aug 19, 2027 | U-1316 | | | |
| | | 8618135 | Mar 07, 2025 | U-1316 | | | |
| | | 9265758 | Mar 07, 2025 | U-1316 | | | |
| | | 9364470 | Mar 07, 2025 | U-1851 | | | |
| | | 9433617 | Mar 07, 2025 | U-1316 | | | |
| LOMITAPIDE MESYLATE - JUXTAPID | | | | | | | |
| N 203858 | 005 | 5712279 | Feb 21, 2020 | DS DP U-1317 | | NCE | Dec 21, 2017 |
| | | 6492365 | Dec 10, 2019 | U-1318 | | ODE-36 | Dec 21, 2019 |
| | | 7932268 | Aug 19, 2027 | U-1316 | | | |
| | | 8618135 | Mar 07, 2025 | U-1316 | | | |
| | | 9265758 | Mar 07, 2025 | U-1316 | | | |
| | | 9364470 | Mar 07, 2025 | U-1851 | | | |
| | | 9433617 | Mar 07, 2025 | U-1316 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| LOMITAPIDE MESYLATE - JUXTAPID | | | | | | | |
| N 203858 | 005 | 5712279 | Feb 21, 2020 | DS DP U-1317 | | NCE | Dec 21, 2017 |
| | | 6492365 | Dec 10, 2019 | U-1318 | | ODE-36 | Dec 21, 2019 |
| | | 7932268 | Aug 19, 2027 | U-1316 | | | |
| | | 8618135 | Mar 07, 2025 | U-1316 | | | |
| | | 9265758 | Mar 07, 2025 | U-1316 | | | |
| | | 9364470 | Mar 07, 2025 | U-1851 | | | |
| | | 9433617 | Mar 07, 2025 | U-1316 | | | |
| LOMITAPIDE MESYLATE - JUXTAPID | | | | | | | |
| N 203858 | 006 | 5712279 | Feb 21, 2020 | DS DP U-1317 | | NCE | Dec 21, 2017 |
| | | 6492365 | Dec 10, 2019 | U-1318 | | ODE-36 | Dec 21, 2019 |
| | | 7932268 | Aug 19, 2027 | U-1316 | | | |
| | | 8618135 | Mar 07, 2025 | U-1316 | | | |
| | | 9265758 | Mar 07, 2025 | U-1316 | | | |
| | | 9364470 | Mar 07, 2025 | U-1851 | | | |
| | | 9433617 | Mar 07, 2025 | U-1316 | | | |
| LOPERAMIDE HYDROCHLORIDE - IMODIUM A-D EZ CHEWS | | | | | | | |
| N 020448 | 001 | 6814978 | Aug 26, 2021 | DP | | | |
| LOPERAMIDE HYDROCHLORIDE; SIMETHICONE - IMODIUM MULTI-SYMPTOM RELIEF | | | | | | | |
| N 021140 | 001 | 6103260 | Jul 17, 2017 | DP | | | |
| LOPINAVIR; RITONAVIR - KALETRA | | | | | | | |
| N 021226 | 001 | 6232333 | Nov 07, 2017 | | | | |
| | | 6458818 | Nov 07, 2017 | | | | |
| | | 6521651 | Nov 07, 2017 | DP | | | |
| | | 7141593 | May 22, 2020 | DP | | | |
| | | 7432294 | May 22, 2020 | DP | | | |
| LOPINAVIR; RITONAVIR - KALETRA | | | | | | | |
| N 021251 | 001 | 6911214 | Nov 28, 2021 | DP U-895 | | | |
| | | 8501219 | Nov 28, 2021 | DP | | | |
| LOPINAVIR; RITONAVIR - KALETRA | | | | | | | |
| N 021906 | 001 | 7148359 | Jul 19, 2019 | DP | | | |
| | | 7364752 | Nov 10, 2020 | DP U-688 | | | |
| | | 8025899 | Dec 14, 2027 | DP | | | |
| | | 8025899*PED | Jun 14, 2028 | | | | |
| | | 8268349 | Aug 25, 2024 | DP | | | |
| | | 8309613 | Dec 24, 2024 | U-688 | | | |
| | | 8377952 | Oct 22, 2027 | U-1372 | | | |
| | | 8377952*PED | Apr 22, 2028 | | | | |
| | | 8399015 | Aug 25, 2024 | DP | | | |
| | | 8399015*PED | Feb 25, 2025 | | | | |
| | | 8470347 | Sep 17, 2026 | DP | | | |
| | | 8470347*PED | Mar 17, 2027 | | | | |
| | | 8691878 | Aug 25, 2024 | U-1513 | | | |
| | | 8691878*PED | Feb 25, 2025 | | | | |
| LOPINAVIR; RITONAVIR - KALETRA | | | | | | | |
| N 021906 | 002 | 7148359 | Jul 19, 2019 | DP | | | |
| | | 7364752 | Nov 10, 2020 | DP U-688 | | | |
| | | 8025899 | Dec 14, 2027 | DP | | | |
| | | 8025899*PED | Jun 14, 2028 | | | | |
| | | 8268349 | Aug 25, 2024 | DP | | | |
| | | 8309613 | Dec 24, 2024 | U-688 | | | |
| | | 8377952 | Oct 22, 2027 | U-1372 | | | |
| | | 8377952*PED | Apr 22, 2028 | | | | |
| | | 8399015 | Aug 25, 2024 | DP | | | |
| | | 8399015*PED | Feb 25, 2025 | | | | |
| | | 8470347 | Sep 17, 2026 | DP | | | |
| | | 8470347*PED | Mar 17, 2027 | | | | |
| | | 8691878 | Aug 25, 2024 | U-1513 | | | |
| | | 8691878*PED | Feb 25, 2025 | | | | |
| LORATADINE - CLARITIN | | | | | | | |
| N 020641 | 002 | 6132758 | Jun 01, 2018 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| LORCASERIN HYDROCHLORIDE - BELVIQ | | | | | | |
| N 022529 001 | 6953787 | Apr 10, 2023 | DS DP U-1252 | | | |
| | 6953787 | Apr 10, 2023 | DS DP U-1253 | | | |
| | 6953787 | Apr 10, 2023 | DS DP U-1254 | | | |
| | 6953787 | Apr 10, 2023 | DS DP U-1255 | | | |
| | 7514422 | Apr 10, 2023 | U-1252 | | | |
| | 7514422 | Apr 10, 2023 | U-1253 | | | |
| | 7514422 | Apr 10, 2023 | U-1254 | | | |
| | 7514422 | Apr 10, 2023 | U-1255 | | | |
| | 7977329 | Apr 10, 2023 | DS DP U-1252 | | | |
| | 7977329 | Apr 10, 2023 | DS DP U-1253 | | | |
| | 7977329 | Apr 10, 2023 | DS DP U-1254 | | | |
| | 7977329 | Apr 10, 2023 | DS DP U-1255 | | | |
| | 8168624 | Apr 18, 2029 | DS DP | | | |
| | 8207158 | Apr 10, 2023 | U-1252 | | | |
| | 8207158 | Apr 10, 2023 | U-1253 | | | |
| | 8207158 | Apr 10, 2023 | U-1254 | | | |
| | 8207158 | Apr 10, 2023 | U-1255 | | | |
| | 8273734 | Apr 10, 2023 | U-1254 | | | |
| | 8273734 | Apr 10, 2023 | U-1255 | | | |
| | 8367657 | Apr 10, 2023 | DS DP U-1252 | | | |
| | 8367657 | Apr 10, 2023 | DS DP U-1253 | | | |
| | 8367657 | Apr 10, 2023 | DS DP U-1254 | | | |
| | 8367657 | Apr 10, 2023 | DS DP U-1255 | | | |
| | 8546379 | Apr 10, 2023 | DS DP U-1252 | | | |
| | 8546379 | Apr 10, 2023 | DS DP U-1253 | | | |
| | 8546379 | Apr 10, 2023 | DS DP U-1254 | | | |
| | 8546379 | Apr 10, 2023 | DS DP U-1255 | | | |
| | 8575149 | Apr 10, 2023 | U-1452 | | | |
| | 8697686 | Dec 20, 2025 | DS DP | | | |
| | 8946207 | Jun 16, 2024 | DP | | | |
| | 8980881 | Dec 20, 2025 | U-1252 | | | |
| | 8980881 | Dec 20, 2025 | U-1253 | | | |
| | 8980881 | Dec 20, 2025 | U-1254 | | | |
| | 8980881 | Dec 20, 2025 | U-1255 | | | |
| | 8999970 | Feb 07, 2033 | U-1688 | | | |
| | 8999970 | Feb 07, 2033 | U-1689 | | | |
| | 8999970 | Feb 07, 2033 | U-1692 | | | |
| | 9169213 | Dec 06, 2032 | U-1762 | | | |
| | 9169213 | Dec 06, 2032 | U-1763 | | | |
| | 9169213 | Dec 06, 2032 | U-1764 | | | |
| | 9169213 | Dec 06, 2032 | U-1765 | | | |
| | 9770455 | Aug 31, 2031 | U-2110 | | | |
| LORCASERIN HYDROCHLORIDE - BELVIQ XR | | | | | | |
| N 208524 001 | 6953787 | Apr 10, 2023 | DS DP U-1252 | | | |
| | 6953787 | Apr 10, 2023 | DS DP U-1253 | | | |
| | 6953787 | Apr 10, 2023 | DS DP U-1254 | | | |
| | 6953787 | Apr 10, 2023 | DS DP U-1255 | | | |
| | 7514422 | Apr 10, 2023 | U-1252 | | | |
| | 7514422 | Apr 10, 2023 | U-1253 | | | |
| | 7514422 | Apr 10, 2023 | U-1254 | | | |
| | 7514422 | Apr 10, 2023 | U-1255 | | | |
| | 7977329 | Apr 10, 2023 | DS DP U-1252 | | | |
| | 7977329 | Apr 10, 2023 | DS DP U-1253 | | | |
| | 7977329 | Apr 10, 2023 | DS DP U-1254 | | | |
| | 7977329 | Apr 10, 2023 | DS DP U-1255 | | | |
| | 8168624 | Apr 18, 2029 | DS DP | | | |
| | 8207158 | Apr 10, 2023 | U-1252 | | | |
| | 8207158 | Apr 10, 2023 | U-1253 | | | |
| | 8207158 | Apr 10, 2023 | U-1254 | | | |
| | 8207158 | Apr 10, 2023 | U-1255 | | | |
| | 8273734 | Apr 10, 2023 | U-1254 | | | |
| | 8273734 | Apr 10, 2023 | U-1255 | | | |
| | 8367657 | Apr 10, 2023 | DS DP U-1252 | | | |
| | 8367657 | Apr 10, 2023 | DS DP U-1253 | | | |
| | 8367657 | Apr 10, 2023 | DS DP U-1254 | | | |
| | 8367657 | Apr 10, 2023 | DS DP U-1255 | | | |
| | 8546379 | Apr 10, 2023 | DS DP U-1252 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| LORCASERIN HYDROCHLORIDE - BELVIQ XR | | | | | | | |
| N 208524 | 001 | 8546379 | Apr 10, 2023 | DS DP | | U-1253 | |
| | | 8546379 | Apr 10, 2023 | DS DP | | U-1254 | |
| | | 8546379 | Apr 10, 2023 | DS DP | | U-1255 | |
| | | 8575149 | Apr 10, 2023 | | | U-1452 | |
| | | 8697686 | Dec 20, 2025 | DS DP | | | |
| | | 8946207 | Jun 16, 2024 | DP | | | |
| | | 8980881 | Dec 20, 2025 | | | U-1252 | |
| | | 8980881 | Dec 20, 2025 | | | U-1253 | |
| | | 8980881 | Dec 20, 2025 | | | U-1254 | |
| | | 8980881 | Dec 20, 2025 | | | U-1255 | |
| | | 8999970 | Feb 07, 2033 | | | U-1688 | |
| | | 8999970 | Feb 07, 2033 | | | U-1689 | |
| | | 8999970 | Feb 07, 2033 | | | U-1692 | |
| | | 9169213 | Dec 06, 2032 | | | U-1884 | |
| | | 9169213 | Dec 06, 2032 | | | U-1885 | |
| | | 9169213 | Dec 06, 2032 | | | U-1886 | |
| | | 9169213 | Dec 06, 2032 | | | U-1887 | |
| | | 9770455 | Aug 31, 2031 | | | U-2110 | |
| LOVASTATIN - ALTOPREV | | | | | | | |
| N 021316 | 001 | 5916595 | Dec 12, 2017 | | | | |
| | | 6080778 | Mar 23, 2018 | | | U-456 | |
| | | 6485748 | Dec 12, 2017 | DP | | | |
| LOVASTATIN - ALTOPREV | | | | | | | |
| N 021316 | 002 | 5916595 | Dec 12, 2017 | | | | |
| | | 6080778 | Mar 23, 2018 | | | U-456 | |
| | | 6485748 | Dec 12, 2017 | DP | | | |
| LOVASTATIN - ALTOPREV | | | | | | | |
| N 021316 | 003 | 5916595 | Dec 12, 2017 | | | | |
| | | 6080778 | Mar 23, 2018 | | | U-456 | |
| | | 6485748 | Dec 12, 2017 | DP | | | |
| LOVASTATIN - ALTOPREV | | | | | | | |
| N 021316 | 004 | 5916595 | Dec 12, 2017 | | | | |
| | | 6080778 | Mar 23, 2018 | | | U-456 | |
| | | 6485748 | Dec 12, 2017 | DP | | | |
| LOXAPINE - ADASUVE | | | | | | | |
| N 022549 | 001 | 6716416 | May 20, 2022 | DP | | | |
| | | 7052679 | Oct 26, 2021 | DP | | | |
| | | 7078020 | Oct 26, 2021 | DP | | U-1375 | |
| | | 7090830 | Oct 26, 2021 | DP | | | |
| | | 7458374 | Aug 18, 2024 | DP | | | |
| | | 7537009 | Oct 28, 2024 | DP | | | |
| | | 7585493 | Oct 26, 2021 | DP | | | |
| | | 7601337 | Oct 26, 2021 | DP | | | |
| | | 8074644 | Jul 25, 2022 | DP | | | |
| | | 8173107 | Oct 26, 2021 | DP | | | |
| | | 8235037 | Oct 26, 2021 | DP | | | |
| | | 8387612 | Oct 23, 2026 | DP | | | |
| | | 8955512 | Oct 26, 2021 | DP | | | |
| | | 8991387 | May 21, 2024 | DP | | | |
| | | 9370629 | May 20, 2024 | DP | | | |
| | | 9439907 | Oct 26, 2021 | DP | | | |
| | | 9440034 | Oct 26, 2021 | DP | | | |
| | | 9687487 | Oct 26, 2021 | DS DP | | | |
| LUBIPROSTONE - AMITIZA | | | | | | | |
| N 021908 | 001 | 6414016 | Sep 05, 2020 | | | U-1392 | |
| | | 6414016 | Sep 05, 2020 | | | U-717 | |
| | | 6583174 | Oct 16, 2020 | DP | | | |
| | | 6982283 | Dec 04, 2022 | | | U-1391 | |
| | | 7064148 | Aug 30, 2022 | | | U-1404 | |
| | | 7064148 | Aug 30, 2022 | | | U-739 | |
| | | 7417067 | Oct 16, 2020 | DP | | | |
| | | 8026393 | Oct 25, 2027 | DP | | | |
| | | 8071613 | Sep 05, 2020 | | | U-1203 | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| LUBIPROSTONE - AMITIZA | | | | | | |
| N 021908 001 | 8071613 | Sep 05, 2020 | U-1393 | | | |
| | 8088934 | May 18, 2021 | DS | | | |
| | 8097649 | Oct 16, 2020 | DP | | | |
| | 8097653 | Nov 14, 2022 | U-1214 | | | |
| | 8097653 | Nov 14, 2022 | U-1394 | | | |
| | 8114890 | Sep 05, 2020 | DP | | | |
| | 8338639 | Jan 23, 2027 | DP | | | |
| | 8389542 | Nov 14, 2022 | DP U-1345 | | | |
| | 8389542 | Nov 14, 2022 | DP U-1395 | | | |
| | 8748481 | Sep 01, 2025 | U-1520 | | | |
| | 8779187 | Jul 23, 2027 | DP | | | |
| LUBIPROSTONE - AMITIZA | | | | | | |
| N 021908 002 | 6414016 | Sep 05, 2020 | U-874 | | | |
| | 6583174 | Oct 16, 2020 | DP | | | |
| | 7064148 | Aug 30, 2022 | U-739 | | | |
| | 7064148 | Aug 30, 2022 | U-873 | | | |
| | 7417067 | Oct 16, 2020 | DP | | | |
| | 7795312 | Sep 17, 2024 | U-1085 | | | |
| | 8026393 | Oct 25, 2027 | DP | | | |
| | 8071613 | Sep 05, 2020 | U-1202 | | | |
| | 8088934 | May 18, 2021 | DS | | | |
| | 8097649 | Oct 16, 2020 | DP | | | |
| | 8114890 | Sep 05, 2020 | DP | | | |
| | 8338639 | Jan 23, 2027 | DP | | | |
| | 8748481 | Sep 01, 2025 | U-1519 | | | |
| | 8779187 | Jan 23, 2027 | DP | | | |
| LULICONAZOLE - LUZU | | | | | | |
| N 204153 001 | 5900488 | Jan 18, 2020 | DS DP | | NCE | Nov 14, 2018 |
| | 8980931 | Apr 28, 2034 | DP | | | |
| | 9012484 | Sep 06, 2033 | DS DP U-540 | | | |
| | 9199977 | Sep 06, 2033 | DS DP | | | |
| | 9453006 | Sep 06, 2033 | DS | | | |
| LURASIDONE HYDROCHLORIDE - LATUDA | | | | | | |
| N 200603 001 | 5532372 | Jul 02, 2018 | DS | | M-195 | Jan 27, 2020 |
| | 5532372*PED | Jan 02, 2019 | | | NPP | Jan 27, 2020 |
| | 8729085 | May 26, 2026 | DP | | PED | Jul 27, 2020 |
| | 8729085*PED | Nov 26, 2026 | | | PED | Jul 27, 2020 |
| | 8883794 | May 26, 2026 | DP | | | |
| | 8883794*PED | Nov 26, 2026 | | | | |
| | 9174975 | Jun 25, 2026 | U-1770 | | | |
| | 9174975*PED | Dec 25, 2026 | | | | |
| | 9259423 | May 23, 2031 | U-1822 | | | |
| | 9259423*PED | Nov 23, 2031 | | | | |
| | 9555027 | May 26, 2026 | DP U-543 | | | |
| | 9815827 | Feb 20, 2024 | U-2166 | | | |
| | 9815827 | Feb 20, 2024 | U-543 | | | |
| | 9827242 | May 23, 2031 | U-2199 | | | |
| | 9827242 | May 23, 2031 | U-2201 | | | |
| | RE45573 | Jun 23, 2025 | DS | | | |
| | RE45573*PED | Dec 23, 2025 | | | | |
| LURASIDONE HYDROCHLORIDE - LATUDA | | | | | | |
| N 200603 002 | 5532372 | Jul 02, 2018 | DS | | NPP | Jan 27, 2020 |
| | 5532372*PED | Jan 02, 2019 | | | PED | Jul 27, 2020 |
| | 8729085 | May 26, 2026 | DP | | | |
| | 8729085*PED | Nov 26, 2026 | | | | |
| | 8883794 | May 26, 2026 | DP | | | |
| | 8883794*PED | Nov 26, 2026 | | | | |
| | 9174975 | Jun 25, 2026 | U-1770 | | | |
| | 9174975*PED | Dec 25, 2026 | | | | |
| | 9259423 | May 23, 2031 | U-1822 | | | |
| | 9259423*PED | Nov 23, 2031 | | | | |
| | 9555027 | May 26, 2026 | DP U-543 | | | |
| | 9815827 | Feb 20, 2024 | U-2166 | | | |
| | 9815827 | Feb 20, 2024 | U-543 | | | |
| | 9827242 | May 23, 2031 | U-2199 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| LURASIDONE HYDROCHLORIDE - LATUDA | | | | | | | |
| N 200603 | 002 | 9827242 | May 23, 2031 | U-2201 | | | |
| | | RE45573 | Jun 23, 2025 | DS | | | |
| | | RE45573*PED | Dec 23, 2025 | | | | |
| LURASIDONE HYDROCHLORIDE - LATUDA | | | | | | | |
| N 200603 | 003 | 5532372 | Jul 02, 2018 | DS | | M-195 | Jan 27, 2020 |
| | | 5532372*PED | Jan 02, 2019 | | | NPP | Jan 27, 2020 |
| | | 8729085 | May 26, 2026 | DP | | PED | Jul 27, 2020 |
| | | 8729085*PED | Nov 26, 2026 | | | PED | Jul 27, 2020 |
| | | 8883794 | May 26, 2026 | DP | | | |
| | | 8883794*PED | Nov 26, 2026 | | | | |
| | | 9174975 | Jun 25, 2026 | U-1770 | | | |
| | | 9174975*PED | Dec 25, 2026 | | | | |
| | | 9259423 | May 23, 2031 | U-1822 | | | |
| | | 9259423*PED | Nov 23, 2031 | | | | |
| | | 9555027 | May 26, 2026 | DP U-543 | | | |
| | | 9815827 | Feb 20, 2024 | U-2166 | | | |
| | | 9815827 | Feb 20, 2024 | U-543 | | | |
| | | 9827242 | May 23, 2031 | U-2199 | | | |
| | | 9827242 | May 23, 2031 | U-2201 | | | |
| | | RE45573 | Jun 23, 2025 | DS | | | |
| | | RE45573*PED | Dec 23, 2025 | | | | |
| LURASIDONE HYDROCHLORIDE - LATUDA | | | | | | | |
| N 200603 | 004 | 5532372 | Jul 02, 2018 | DS | | | |
| | | 5532372*PED | Jan 02, 2019 | | | | |
| | | 8729085 | May 26, 2026 | DP | | | |
| | | 8729085*PED | Nov 26, 2026 | | | | |
| | | 8883794 | May 26, 2026 | DP | | | |
| | | 8883794*PED | Nov 26, 2026 | | | | |
| | | 9174975 | Jun 25, 2026 | U-1770 | | | |
| | | 9174975*PED | Dec 25, 2026 | | | | |
| | | 9259423 | May 23, 2031 | U-1822 | | | |
| | | 9259423*PED | Nov 23, 2031 | | | | |
| | | 9555027 | May 26, 2026 | DP U-543 | | | |
| | | 9815827 | Feb 20, 2024 | U-2166 | | | |
| | | 9815827 | Feb 20, 2024 | U-543 | | | |
| | | 9827242 | May 23, 2031 | U-2199 | | | |
| | | 9827242 | May 23, 2031 | U-2201 | | | |
| | | RE45573 | Jun 23, 2025 | DS | | | |
| | | RE45573*PED | Dec 23, 2025 | | | | |
| LURASIDONE HYDROCHLORIDE - LATUDA | | | | | | | |
| N 200603 | 005 | 5532372 | Jul 02, 2018 | DS | | M-195 | Jan 27, 2020 |
| | | 5532372*PED | Jan 02, 2019 | | | NPP | Jan 27, 2020 |
| | | 8729085 | May 26, 2026 | DP | | PED | Jul 27, 2020 |
| | | 8729085*PED | Nov 26, 2026 | | | PED | Jul 27, 2020 |
| | | 8883794 | May 26, 2026 | DP | | | |
| | | 8883794*PED | Nov 26, 2026 | | | | |
| | | 9174975 | Jun 25, 2026 | U-1770 | | | |
| | | 9174975*PED | Dec 25, 2026 | | | | |
| | | 9259423 | May 23, 2031 | U-1822 | | | |
| | | 9259423*PED | Nov 23, 2031 | | | | |
| | | 9555027 | May 26, 2026 | DP U-543 | | | |
| | | 9815827 | Feb 20, 2024 | U-2166 | | | |
| | | 9815827 | Feb 20, 2024 | U-543 | | | |
| | | 9827242 | May 23, 2031 | U-2199 | | | |
| | | 9827242 | May 23, 2031 | U-2201 | | | |
| | | RE45573 | Jun 23, 2025 | DS | | | |
| | | RE45573*PED | Dec 23, 2025 | | | | |
| MACIMORELIN ACETATE - MACRILEN | | | | | | | |
| N 205598 | 001 | | | | | NCE | Dec 20, 2022 |
| MACITENTAN - OPSUMIT | | | | | | | |
| N 204410 | 001 | 7094781 | Oct 12, 2022 | DS DP | | NCE | Oct 18, 2018 |
| | | 8268847 | Apr 18, 2029 | U-1446 | | ODE-54 | Oct 18, 2020 |
| | | 8367685 | Oct 04, 2028 | DP U-1445 | | | |
| | | 9265762 | May 29, 2027 | DP U-1820 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| MACITENTAN - OPSUMIT | | | | | | | |
| N 204410 | 001 | 7094781 | Oct 12, 2022 | DS DP | | NCE | Oct 18, 2018 |
| | | 8268847 | Apr 18, 2029 | U-1446 | | ODE-54 | Oct 18, 2020 |
| | | 8367685 | Oct 04, 2028 | DP U-1445 | | | |
| | | 9265762 | May 29, 2027 | DP U-1820 | | | |
| MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - NORMOCARB HF 25 | | | | | | | |
| N 021910 | 001 | 5945449 | Oct 31, 2017 | DP U-785 | | | |
| | | 7300674 | Mar 04, 2023 | DP U-785 | | | |
| MAGNESIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE - NORMOCARB HF 35 | | | | | | | |
| N 021910 | 002 | 5945449 | Oct 31, 2017 | DP U-785 | | | |
| MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE - SUPREP BOWEL PREP KIT | | | | | | | |
| N 022372 | 001 | 6946149 | Mar 07, 2023 | DP U-837 | | | |
| MALATHION - OVIDE | | | | | | | |
| N 018613 | 001 | 7560445 | Feb 01, 2027 | DS DP U-986 | | | |
| | | 7977324 | Aug 14, 2026 | DP | | | |
| MARAVIROC - SELZENTRY | | | | | | | |
| N 022128 | 001 | 6586430 | Dec 01, 2019 | DS DP U-824 | | NPP | Nov 04, 2019 |
| | | 6667314 | Aug 06, 2021 | DS DP U-824 | | NS | Nov 04, 2019 |
| | | 7368460 | Nov 25, 2022 | U-824 | | | |
| | | 7576097 | May 25, 2021 | DS | | | |
| MARAVIROC - SELZENTRY | | | | | | | |
| N 022128 | 002 | 6586430 | Dec 01, 2019 | DS DP U-824 | | NPP | Nov 04, 2019 |
| | | 6667314 | Aug 06, 2021 | DS DP U-824 | | NS | Nov 04, 2019 |
| | | 7368460 | Nov 25, 2022 | U-824 | | | |
| | | 7576097 | May 25, 2021 | DS | | | |
| MARAVIROC - SELZENTRY | | | | | | | |
| N 022128 | 003 | 6586430 | Dec 01, 2019 | DS DP U-824 | | NPP | Nov 04, 2019 |
| | | 6667314 | Aug 06, 2021 | DS DP U-824 | | NS | Nov 04, 2019 |
| | | 7368460 | Nov 25, 2022 | U-824 | | | |
| | | 7576097 | May 25, 2021 | DS | | | |
| MARAVIROC - SELZENTRY | | | | | | | |
| N 022128 | 004 | 6586430 | Dec 01, 2019 | DS DP U-824 | | NPP | Nov 04, 2019 |
| | | 6667314 | Aug 06, 2021 | DS DP U-824 | | NS | Nov 04, 2019 |
| | | 7368460 | Nov 25, 2022 | U-824 | | | |
| | | 7576097 | May 25, 2021 | DS | | | |
| MARAVIROC - SELZENTRY | | | | | | | |
| N 208984 | 001 | 6586430 | Dec 01, 2019 | DS DP U-824 | | NP | Nov 04, 2019 |
| | | 6667314 | Aug 06, 2021 | DS DP U-824 | | | |
| | | 7368460 | Nov 25, 2022 | U-824 | | | |
| | | 7576097 | May 25, 2021 | DS | | | |
| MEBENDAZOLE - VERMOX | | | | | | | |
| N 208398 | 001 | | | | | NS | Oct 19, 2019 |
| MECASERMIN RECOMBINANT - INCRELEX | | | | | | | |
| N 021839 | 001 | 5681814 | Sep 18, 2017 | DP | | | |
| MECHLORETHAMINE HYDROCHLORIDE - VALCHLOR | | | | | | | |
| N 202317 | 001 | 7838564 | Mar 07, 2026 | DP | | ODE-51 | Aug 23, 2020 |
| | | 7872050 | Jul 08, 2029 | U-1427 | | | |
| | | 8450375 | Mar 07, 2026 | DP | | | |
| | | 8501818 | Mar 07, 2026 | DP | | | |
| | | 8501819 | Mar 07, 2026 | U-1427 | | | |
| | | 9382191 | Mar 07, 2026 | DP | | | |
| MEDROXYPROGESTERONE ACETATE - DEPO-SUBQ PROVERA 104 | | | | | | | |
| N 021583 | 001 | 6495534 | May 15, 2020 | DP | | | |
| MEGESTROL ACETATE - MEGACE ES | | | | | | | |
| N 021778 | 001 | 6592903 | Sep 21, 2020 | DP | | | |
| | | 7101576 | Apr 22, 2024 | U-755 | | | |
| | | 9040088 | Apr 22, 2024 | U-755 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| MEGESTROL ACETATE - MEGACE ES | | | | | | | |
| N 021778 | 001 | 9101540 | Apr 22, 2024 | DP U-755 | | | |
| | | 9101549 | Apr 22, 2024 | U-755 | | | |
| | | 9107827 | Apr 22, 2024 | U-755 | | | |
| MELOXICAM - MOBIC | | | | | | | |
| N 021530 | 001 | 6184220 | Mar 25, 2019 | DP | | | |
| MELOXICAM - VIVLODEX | | | | | | | |
| N 207233 | 001 | 9526734 | Mar 31, 2033 | DP | | NP | Oct 22, 2018 |
| | | 9649318 | Mar 31, 2035 | DP | | | |
| | | 9808468 | Mar 31, 2035 | U-2160 | | | |
| | | 9808468 | Mar 31, 2035 | U-2165 | | | |
| MELOXICAM - VIVLODEX | | | | | | | |
| N 207233 | 002 | 9526734 | Mar 31, 2033 | DP | | NP | Oct 22, 2018 |
| | | 9649318 | Mar 31, 2035 | DP | | | |
| | | 9808468 | Mar 31, 2035 | U-2160 | | | |
| | | 9808468 | Mar 31, 2035 | U-2165 | | | |
| MELPHALAN HYDROCHLORIDE - EVOMELA | | | | | | | |
| N 207155 | 001 | 8410077 | Mar 13, 2029 | DP | | ODE-110 | Mar 10, 2023 |
| | | 9200088 | Mar 13, 2029 | DP | | | |
| | | 9493582 | Feb 27, 2033 | DP | | | |
| MEMANTINE HYDROCHLORIDE - NAMENDA XR | | | | | | | |
| N 022525 | 001 | 8039009 | Mar 24, 2029 | U-539 | | M-138 | Jul 03, 2017 |
| | | 8039009*PED | Sep 24, 2029 | | | PED | Jan 03, 2018 |
| | | 8168209 | Nov 22, 2025 | DP | | | |
| | | 8168209*PED | May 22, 2026 | | | | |
| | | 8173708 | Nov 22, 2025 | U-539 | | | |
| | | 8173708*PED | May 22, 2026 | | | | |
| | | 8283379 | Nov 22, 2025 | U-539 | | | |
| | | 8283379*PED | May 22, 2026 | | | | |
| | | 8329752 | Nov 22, 2025 | DP | | | |
| | | 8329752*PED | May 22, 2026 | | | | |
| | | 8362085 | Nov 22, 2025 | U-539 | | | |
| | | 8362085*PED | May 22, 2026 | | | | |
| MEMANTINE HYDROCHLORIDE - NAMENDA XR | | | | | | | |
| N 022525 | 002 | 8039009 | Mar 24, 2029 | U-539 | | M-138 | Jul 03, 2017 |
| | | 8039009*PED | Sep 24, 2029 | | | PED | Jan 03, 2018 |
| | | 8168209 | Nov 22, 2025 | DP | | | |
| | | 8168209*PED | May 22, 2026 | | | | |
| | | 8173708 | Nov 22, 2025 | U-539 | | | |
| | | 8173708*PED | May 22, 2026 | | | | |
| | | 8283379 | Nov 22, 2025 | U-539 | | | |
| | | 8283379*PED | May 22, 2026 | | | | |
| | | 8329752 | Nov 22, 2025 | DP | | | |
| | | 8329752*PED | May 22, 2026 | | | | |
| | | 8362085 | Nov 22, 2025 | U-539 | | | |
| | | 8362085*PED | May 22, 2026 | | | | |
| MEMANTINE HYDROCHLORIDE - NAMENDA XR | | | | | | | |
| N 022525 | 003 | 8039009 | Mar 24, 2029 | U-539 | | M-138 | Jul 03, 2017 |
| | | 8039009*PED | Sep 24, 2029 | | | PED | Jan 03, 2018 |
| | | 8168209 | Nov 22, 2025 | DP | | | |
| | | 8168209*PED | May 22, 2026 | | | | |
| | | 8173708 | Nov 22, 2025 | U-539 | | | |
| | | 8173708*PED | May 22, 2026 | | | | |
| | | 8283379 | Nov 22, 2025 | U-539 | | | |
| | | 8283379*PED | May 22, 2026 | | | | |
| | | 8329752 | Nov 22, 2025 | DP | | | |
| | | 8329752*PED | May 22, 2026 | | | | |
| | | 8362085 | Nov 22, 2025 | U-539 | | | |
| | | 8362085*PED | May 22, 2026 | | | | |
| MEMANTINE HYDROCHLORIDE - NAMENDA XR | | | | | | | |
| N 022525 | 004 | 8039009 | Mar 24, 2029 | U-539 | | M-138 | Jul 03, 2017 |
| | | 8039009*PED | Sep 24, 2029 | | | PED | Jan 03, 2018 |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| MEMANTINE HYDROCHLORIDE - NAMENDA XR | | | | | | | |
| N 022525 | 004 | 8168209 | Nov 22, 2025 | DP | | | |
| | | 8168209*PED | May 22, 2026 | | | | |
| | | 8173708 | Nov 22, 2025 | U-539 | | | |
| | | 8173708*PED | May 22, 2026 | | | | |
| | | 8283379 | Nov 22, 2025 | U-539 | | | |
| | | 8283379*PED | May 22, 2026 | | | | |
| | | 8329752 | Nov 22, 2025 | DP | | | |
| | | 8329752*PED | May 22, 2026 | | | | |
| | | 8362085 | Nov 22, 2025 | U-539 | | | |
| | | 8362085*PED | May 22, 2026 | | | | |
| | | 8598233 | Nov 22, 2025 | DP | | | |
| | | 8598233*PED | May 22, 2026 | | | | |
| MENTHOL; METHYL SALICYLATE - SALONPAS | | | | | | | |
| N 022029 | 001 | 8809615 | Jan 03, 2030 | DP | | | |
| | | 9233184 | Aug 01, 2027 | DP | | | |
| MENTHOL; METHYL SALICYLATE - SALONPAS | | | | | | | |
| N 022029 | 002 | 8809615 | Jan 03, 2030 | DP | | | |
| | | 9233184 | Aug 01, 2027 | DP | | | |
| MEQUINOL; TRETINOIN - SOLAGE | | | | | | | |
| N 020922 | 001 | 6353029 | Aug 24, 2020 | | | | |
| MERCAPTOPURINE - PURIXAN | | | | | | | |
| N 205919 | 001 | | | | | ODE-65 | Apr 28, 2021 |
| MEROPENEM; VABORBACTAM - VABOMERE | | | | | | | |
| N 209776 | 001 | 8680136 | Aug 17, 2031 | DS DP | | | |
| | | 9694025 | Aug 08, 2031 | U-2120 | | | |
| MESALAMINE - MESALAMINE | | | | | | | |
| A 091640 | 001 | | | | | PC | Jan 14, 2018 |
| MESALAMINE - SFROWASA | | | | | | | |
| N 019618 | 002 | 7645801 | Jul 24, 2027 | DS DP | | | |
| MESALAMINE - CANASA | | | | | | | |
| N 021252 | 001 | | | | | M-187 | Sep 02, 2019 |
| MESALAMINE - CANASA | | | | | | | |
| N 021252 | 002 | 8217083 | Jun 06, 2028 | DP | | | |
| | | 8436051 | Jun 06, 2028 | DP | | | |
| MESALAMINE - ASACOL HD | | | | | | | |
| N 021830 | 001 | 6893662 | Nov 15, 2021 | DP U-141 | | | |
| | | 8580302 | Nov 15, 2021 | DP | | | |
| | | 9089492 | Nov 15, 2021 | DP | | | |
| MESALAMINE - LIALDA | | | | | | | |
| N 022000 | 001 | 6773720 | Jun 08, 2020 | DP | | | |
| MESALAMINE - APRISO | | | | | | | |
| N 022301 | 001 | 6551620 | Apr 20, 2018 | DS DP U-907 | | | |
| | | 8337886 | Apr 20, 2018 | DP U-1310 | | | |
| | | 8496965 | Apr 20, 2018 | DP | | | |
| | | 8865688 | May 01, 2030 | U-1310 | | | |
| | | 8911778 | Apr 20, 2018 | DP U-1310 | | | |
| | | 8940328 | Apr 20, 2018 | DP | | | |
| | | 8956647 | Apr 20, 2018 | DP | | | |
| MESALAMINE - DELZICOL | | | | | | | |
| N 204412 | 001 | 6649180 | Apr 13, 2020 | DP | | | |
| METAXALONE - SKELAXIN | | | | | | | |
| N 013217 | 003 | 7122566 | Feb 06, 2026 | U-915 | | | |
| | | 7714006 | Dec 03, 2021 | U-1050 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|
| METFORMIN HYDROCHLORIDE - GLUCOPHAGE XR | | | | | | | | |
| N 021202 | 001 | 6475521 | Mar 19, 2018 | | | | | |
| | | 6660300 | Mar 19, 2018 | | U-542 | | | |
| METFORMIN HYDROCHLORIDE - GLUCOPHAGE XR | | | | | | | | |
| N 021202 | 004 | 6475521 | Mar 19, 2018 | | | | | |
| | | 6660300 | Mar 19, 2018 | | U-542 | | | |
| METFORMIN HYDROCHLORIDE - FORTAMET | | | | | | | | |
| N 021574 | 001 | 6099859 | Mar 20, 2018 | | DP | | | |
| | | 6495162 | Mar 20, 2018 | | DP | | | |
| | | 6790459 | Mar 17, 2021 | | U-604 | | | |
| | | 6866866 | Mar 17, 2021 | | DP | | | |
| | | 7919116 | Mar 20, 2018 | | DP | | | |
| | | 8475841 | Mar 20, 2018 | | U-604 | | | |
| METFORMIN HYDROCHLORIDE - FORTAMET | | | | | | | | |
| N 021574 | 002 | 6099859 | Mar 20, 2018 | | DP | | | |
| | | 6495162 | Mar 20, 2018 | | DP | | | |
| | | 6790459 | Mar 17, 2021 | | U-604 | | | |
| | | 6866866 | Mar 17, 2021 | | DP | | | |
| | | 7919116 | Mar 20, 2018 | | DP | | | |
| | | 8475841 | Mar 20, 2018 | | U-604 | | | |
| METFORMIN HYDROCHLORIDE - RIOMET | | | | | | | | |
| N 021591 | 001 | 6890957 | Sep 14, 2023 | | DP | | | |
| METFORMIN HYDROCHLORIDE - GLUMETZA | | | | | | | | |
| N 021748 | 001 | 6488962 | Jun 20, 2020 | DS | DP | | | |
| | | 6723340 | Oct 25, 2021 | DS | DP | | | |
| METFORMIN HYDROCHLORIDE - GLUMETZA | | | | | | | | |
| N 021748 | 002 | 6488962 | Jun 20, 2020 | DS | DP | | | |
| | | 7780987 | Mar 23, 2025 | DS | DP | | | |
| | | 8323692 | Mar 23, 2025 | | DP | | | |
| METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET | | | | | | | | |
| N 021842 | 001 | 9101660 | Jan 22, 2027 | | DP | | | |
| | | 9320714 | Feb 03, 2029 | | DP | | | |
| METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET | | | | | | | | |
| N 021842 | 002 | 9101660 | Jan 22, 2027 | | DP | | | |
| | | 9320714 | Feb 03, 2029 | | DP | | | |
| METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR | | | | | | | | |
| N 022024 | 001 | 6099859 | Mar 20, 2018 | | DP | | | |
| | | 6495162 | Mar 20, 2018 | | DP | | | |
| | | 6790459 | Mar 17, 2021 | | U-974 | | | |
| | | 6866866 | Mar 17, 2021 | | DP | | | |
| | | 7785627 | Jul 31, 2026 | | DP | | | |
| | | 7919116 | Mar 20, 2018 | | U-1120 | | | |
| | | 7919116 | Mar 20, 2018 | | U-973 | | | |
| | | 7959946 | Jul 31, 2026 | | DP | | | |
| | | 8470368 | Sep 19, 2023 | | DP | | | |
| | | 8475841 | Mar 20, 2018 | | U-973 | | | |
| | | 8668931 | Sep 19, 2023 | | DP | | | |
| | | 9060941 | Sep 19, 2023 | | DP | | | |
| METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR | | | | | | | | |
| N 022024 | 002 | 6099859 | Mar 20, 2018 | | DP | | | |
| | | 6495162 | Mar 20, 2018 | | DP | | | |
| | | 6790459 | Mar 17, 2021 | | U-974 | | | |
| | | 6866866 | Mar 17, 2021 | | DP | | | |
| | | 7785627 | Jul 31, 2026 | | DP | | | |
| | | 7919116 | Mar 20, 2018 | | U-1120 | | | |
| | | 7919116 | Mar 20, 2018 | | U-973 | | | |
| | | 7959946 | Jul 31, 2026 | | DP | | | |
| | | 8470368 | Sep 19, 2023 | | DP | | | |
| | | 8475841 | Mar 20, 2018 | | U-973 | | | |
| | | 8668931 | Sep 19, 2023 | | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR | | | | | | | |
| N 022024 | 002 | 9060941 | Sep 19, 2023 | DP | | | |
| METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET | | | | | | | |
| N 021410 | 001 | 7358366 | Apr 19, 2020 | DS | | | |
| | | 8236345 | Oct 07, 2022 | DP | | | |
| METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET | | | | | | | |
| N 021410 | 002 | 7358366 | Apr 19, 2020 | DS | | | |
| | | 8236345 | Oct 07, 2022 | DP | | | |
| METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET | | | | | | | |
| N 021410 | 003 | 7358366 | Apr 19, 2020 | DS | | | |
| | | 8236345 | Oct 07, 2022 | DP | | | |
| METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET | | | | | | | |
| N 021410 | 004 | 7358366 | Apr 19, 2020 | DS | | | |
| | | 8236345 | Oct 07, 2022 | DP | | | |
| METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET | | | | | | | |
| N 021410 | 005 | 7358366 | Apr 19, 2020 | DS | | | |
| | | 8236345 | Oct 07, 2022 | DP | | | |
| METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR | | | | | | | |
| N 200678 | 001 | 8628799 | Jul 13, 2025 | DP | | M-175 | Apr 05, 2019 |
| | | 9339472 | Jul 13, 2025 | DP | | M-198 | Feb 27, 2020 |
| | | RE44186 | Jul 31, 2023 | DS DP U-1097 | | | |
| | | RE44186 | Jul 31, 2023 | DS DP U-1838 | | | |
| METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR | | | | | | | |
| N 200678 | 002 | 9339472 | Jul 13, 2025 | DP | | M-175 | Apr 05, 2019 |
| | | RE44186 | Jul 31, 2023 | DS DP U-1097 | | M-198 | Feb 27, 2020 |
| | | RE44186 | Jul 31, 2023 | DS DP U-1838 | | | |
| METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR | | | | | | | |
| N 200678 | 003 | 9339472 | Jul 13, 2025 | DP | | M-175 | Apr 05, 2019 |
| | | RE44186 | Jul 31, 2023 | DS DP U-1097 | | M-198 | Feb 27, 2020 |
| | | RE44186 | Jul 31, 2023 | DS DP U-1838 | | | |
| METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET | | | | | | | |
| N 022044 | 001 | 6699871 | Jul 26, 2022 | DS DP U-802 | | | |
| | | 6890898 | Feb 02, 2019 | U-1996 | | | |
| | | 7078381 | Feb 02, 2019 | U-1996 | | | |
| | | 7125873 | Jul 26, 2022 | DP U-1036 | | | |
| | | 7125873 | Jul 26, 2022 | DP U-1038 | | | |
| | | 7125873 | Jul 26, 2022 | DP U-803 | | | |
| | | 7326708 | Nov 24, 2026 | DS DP U-802 | | | |
| | | 7459428 | Feb 02, 2019 | U-1996 | | | |
| | | 8414921 | Jul 21, 2028 | DP U-1036 | | | |
| METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET | | | | | | | |
| N 022044 | 002 | 6699871 | Jul 26, 2022 | DS DP U-802 | | | |
| | | 6890898 | Feb 02, 2019 | U-1996 | | | |
| | | 7078381 | Feb 02, 2019 | U-1996 | | | |
| | | 7125873 | Jul 26, 2022 | DP U-1036 | | | |
| | | 7125873 | Jul 26, 2022 | DP U-1038 | | | |
| | | 7125873 | Jul 26, 2022 | DP U-803 | | | |
| | | 7326708 | Nov 24, 2026 | DS DP U-802 | | | |
| | | 7459428 | Feb 02, 2019 | U-1996 | | | |
| | | 8414921 | Jul 21, 2028 | DP U-1036 | | | |
| METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR | | | | | | | |
| N 202270 | 001 | 6699871 | Jul 26, 2022 | DS DP U-1227 | | | |
| | | 6890898 | Feb 02, 2019 | U-1996 | | | |
| | | 7078381 | Feb 02, 2019 | U-1996 | | | |
| | | 7125873 | Jul 26, 2022 | DP U-1227 | | | |
| | | 7326708 | Nov 24, 2026 | DS DP U-1227 | | | |
| | | 7459428 | Feb 02, 2019 | U-1996 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR | | | | | | | |
| N 202270 | 002 | 6699871 | Jul 26, 2022 | DS DP U-1227 | | | |
| | | 6890898 | Feb 02, 2019 | U-1996 | | | |
| | | 7078381 | Feb 02, 2019 | U-1996 | | | |
| | | 7125873 | Jul 26, 2022 | DP U-1227 | | | |
| | | 7326708 | Nov 24, 2026 | DS DP U-1227 | | | |
| | | 7459428 | Feb 02, 2019 | U-1996 | | | |
| METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR | | | | | | | |
| N 202270 | 003 | 6699871 | Jul 26, 2022 | DS DP U-1227 | | | |
| | | 6890898 | Feb 02, 2019 | U-1996 | | | |
| | | 7078381 | Feb 02, 2019 | U-1996 | | | |
| | | 7125873 | Jul 26, 2022 | DP U-1227 | | | |
| | | 7326708 | Nov 24, 2026 | DS DP U-1227 | | | |
| | | 7459428 | Feb 02, 2019 | U-1996 | | | |
| METHOTREXATE - OTREXUP | | | | | | | |
| N 204824 | 001 | 6746429 | Apr 12, 2020 | DP | | | |
| | | 7744582 | Aug 10, 2019 | DP U-1442 | | | |
| | | 7776015 | Aug 10, 2019 | DP | | | |
| | | 8021335 | Oct 04, 2026 | DP | | | |
| | | 8480631 | Mar 19, 2030 | DP U-1442 | | | |
| | | 8562564 | Jan 24, 2026 | DP | | | |
| | | 8579865 | Mar 19, 2030 | DP U-1442 | | | |
| | | 8945063 | Mar 19, 2030 | DP U-1442 | | | |
| | | 9421333 | Mar 19, 2030 | DP U-1442 | | | |
| | | 9533102 | Jan 24, 2026 | DP | | | |
| | | 9629959 | Jan 24, 2026 | DP | | | |
| | | RE44846 | Aug 10, 2019 | DP | | | |
| | | RE44847 | Aug 10, 2019 | DP U-1442 | | | |
| METHOTREXATE - OTREXUP | | | | | | | |
| N 204824 | 002 | 6746429 | Apr 12, 2020 | DP | | | |
| | | 7744582 | Aug 10, 2019 | DP U-1442 | | | |
| | | 7776015 | Aug 10, 2019 | DP | | | |
| | | 8021335 | Oct 04, 2026 | DP | | | |
| | | 8480631 | Mar 19, 2030 | DP U-1442 | | | |
| | | 8562564 | Jan 24, 2026 | DP | | | |
| | | 8579865 | Mar 19, 2030 | DP U-1442 | | | |
| | | 8945063 | Mar 19, 2030 | DP U-1442 | | | |
| | | 9421333 | Mar 19, 2030 | DP U-1442 | | | |
| | | 9533102 | Jan 24, 2026 | DP | | | |
| | | 9629959 | Jan 24, 2026 | DP | | | |
| | | RE44846 | Aug 10, 2019 | DP | | | |
| | | RE44847 | Aug 10, 2019 | DP U-1442 | | | |
| METHOTREXATE - OTREXUP | | | | | | | |
| N 204824 | 003 | 6746429 | Apr 12, 2020 | DP | | | |
| | | 7744582 | Aug 10, 2019 | DP U-1442 | | | |
| | | 7776015 | Aug 10, 2019 | DP | | | |
| | | 8021335 | Oct 04, 2026 | DP | | | |
| | | 8480631 | Mar 19, 2030 | DP U-1442 | | | |
| | | 8562564 | Jan 24, 2026 | DP | | | |
| | | 8579865 | Mar 19, 2030 | DP U-1442 | | | |
| | | 8945063 | Mar 19, 2030 | DP U-1442 | | | |
| | | 9421333 | Mar 19, 2030 | DP U-1442 | | | |
| | | 9533102 | Jan 24, 2026 | DP | | | |
| | | 9629959 | Jan 24, 2026 | DP | | | |
| | | RE44846 | Aug 10, 2019 | DP | | | |
| | | RE44847 | Aug 10, 2019 | DP U-1442 | | | |
| METHOTREXATE - OTREXUP | | | | | | | |
| N 204824 | 004 | 6746429 | Apr 12, 2020 | DP | | | |
| | | 7744582 | Aug 10, 2019 | DP U-1442 | | | |
| | | 7776015 | Aug 10, 2019 | DP | | | |
| | | 8021335 | Oct 04, 2026 | DP | | | |
| | | 8480631 | Mar 19, 2030 | DP U-1442 | | | |
| | | 8562564 | Jan 24, 2026 | DP | | | |
| | | 8579865 | Mar 19, 2030 | DP U-1442 | | | |
| | | 8945063 | Mar 19, 2030 | DP U-1442 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| METHOTREXATE - OTREXUP | | | | | | |
| N 204824 004 | 9421333 | Mar 19, 2030 | DP U-1442 | | | |
| | 9533102 | Jan 24, 2026 | DP | | | |
| | 9629959 | Jan 24, 2026 | DP | | | |
| | RE44846 | Aug 10, 2019 | DP | | | |
| | RE44847 | Aug 10, 2019 | DP U-1442 | | | |
| METHOTREXATE - OTREXUP | | | | | | |
| N 204824 005 | 6746429 | Apr 12, 2020 | DP | | | |
| | 8021335 | Oct 04, 2026 | DP | | | |
| | 8480631 | Mar 19, 2030 | DP U-1442 | | | |
| | 8562564 | Jan 24, 2026 | DP | | | |
| | 8579865 | Mar 19, 2030 | DP U-1442 | | | |
| | 8945063 | Mar 19, 2030 | DP U-1442 | | | |
| | 9421333 | Mar 19, 2030 | DP U-1442 | | | |
| | 9533102 | Jan 24, 2026 | DP | | | |
| | 9629959 | Jan 24, 2026 | DP | | | |
| | RE44846 | Aug 10, 2019 | DP | | | |
| | RE44847 | Aug 10, 2019 | DP U-1442 | | | |
| METHOTREXATE - OTREXUP | | | | | | |
| N 204824 006 | 6746429 | Apr 12, 2020 | DP | | | |
| | 8021335 | Oct 04, 2026 | DP | | | |
| | 8480631 | Mar 19, 2030 | DP U-1442 | | | |
| | 8562564 | Jan 24, 2026 | DP | | | |
| | 8579865 | Mar 19, 2030 | DP U-1442 | | | |
| | 8945063 | Mar 19, 2030 | DP U-1442 | | | |
| | 9421333 | Mar 19, 2030 | DP U-1442 | | | |
| | 9533102 | Jan 24, 2026 | DP | | | |
| | 9629959 | Jan 24, 2026 | DP | | | |
| | RE44846 | Aug 10, 2019 | DP | | | |
| | RE44847 | Aug 10, 2019 | DP U-1442 | | | |
| METHOTREXATE - OTREXUP | | | | | | |
| N 204824 007 | 6746429 | Apr 12, 2020 | DP | | | |
| | 8021335 | Oct 04, 2026 | DP | | | |
| | 8480631 | Mar 19, 2030 | DP U-1442 | | | |
| | 8562564 | Jan 24, 2026 | DP | | | |
| | 8579865 | Mar 19, 2030 | DP U-1442 | | | |
| | 8945063 | Mar 19, 2030 | DP U-1442 | | | |
| | 9421333 | Mar 19, 2030 | DP U-1442 | | | |
| | 9533102 | Jan 24, 2026 | DP | | | |
| | 9629959 | Jan 24, 2026 | DP | | | |
| | RE44846 | Aug 10, 2019 | DP | | | |
| | RE44847 | Aug 10, 2019 | DP U-1442 | | | |
| METHOTREXATE - OTREXUP | | | | | | |
| N 204824 008 | 6746429 | Apr 12, 2020 | DP | | | |
| | 8021335 | Oct 04, 2026 | DP | | | |
| | 8480631 | Mar 19, 2030 | DP U-1442 | | | |
| | 8562564 | Jan 24, 2026 | DP | | | |
| | 8579865 | Mar 19, 2030 | DP U-1442 | | | |
| | 8945063 | Mar 19, 2030 | DP U-1442 | | | |
| | 9421333 | Mar 19, 2030 | DP U-1442 | | | |
| | 9533102 | Jan 24, 2026 | DP | | | |
| | 9629959 | Jan 24, 2026 | DP | | | |
| | RE44846 | Aug 10, 2019 | DP | | | |
| | RE44847 | Aug 10, 2019 | DP U-1442 | | | |
| METHOTREXATE - RASUVO | | | | | | |
| N 205776 001 | 8664231 | Jun 01, 2029 | U-1442 | | | |
| METHOTREXATE - RASUVO | | | | | | |
| N 205776 002 | 8664231 | Jun 01, 2029 | U-1442 | | | |
| METHOTREXATE - RASUVO | | | | | | |
| N 205776 003 | 8664231 | Jun 01, 2029 | U-1442 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| METHOTREXATE - RASUVO | | | | | | | |
| N 205776 | 004 | 8664231 | Jun 01, 2029 | U-1442 | | | |
| METHOTREXATE - RASUVO | | | | | | | |
| N 205776 | 005 | 8664231 | Jun 01, 2029 | U-1442 | | | |
| METHOTREXATE - RASUVO | | | | | | | |
| N 205776 | 006 | 8664231 | Jun 01, 2029 | U-1442 | | | |
| METHOTREXATE - RASUVO | | | | | | | |
| N 205776 | 007 | 8664231 | Jun 01, 2029 | U-1442 | | | |
| METHOTREXATE - RASUVO | | | | | | | |
| N 205776 | 008 | 8664231 | Jun 01, 2029 | U-1442 | | | |
| METHOTREXATE - RASUVO | | | | | | | |
| N 205776 | 009 | 8664231 | Jun 01, 2029 | U-1442 | | | |
| METHOTREXATE - RASUVO | | | | | | | |
| N 205776 | 010 | 8664231 | Jun 01, 2029 | U-1442 | | | |
| METHOTREXATE SODIUM - XATMEP | | | | | | | |
| N 208400 | 001 | 9259427 | Jan 02, 2033 | DP | | ODE-137 | Apr 25, 2024 |
| | | | | | | ODE-138 | Apr 25, 2024 |
| METHYLENE BLUE - PROVAYBLUE | | | | | | | |
| N 204630 | 001 | | | | | ODE-113 | Apr 08, 2023 |
| METHYLNALTREXONE BROMIDE - RELISTOR | | | | | | | |
| N 021964 | 001 | 6559158 | Nov 03, 2017 | U-1185 | | | |
| | | 8247425 | Dec 31, 2030 | U-1185 | | | |
| | | 8420663 | Sep 30, 2029 | U-1185 | | | |
| | | 8552025 | Apr 08, 2024 | DP | | | |
| | | 8822490 | Sep 30, 2029 | DP U-1185 | | | |
| | | 9180125 | Sep 30, 2029 | DP U-1185 | | | |
| | | 9492445 | Sep 30, 2029 | DP U-1185 | | | |
| | | 9669096 | Apr 08, 2024 | DP | | | |
| METHYLNALTREXONE BROMIDE - RELISTOR | | | | | | | |
| N 021964 | 002 | 6559158 | Nov 03, 2017 | U-1185 | | | |
| | | 8247425 | Dec 31, 2030 | U-1185 | | | |
| | | 8420663 | Sep 30, 2029 | U-1185 | | | |
| | | 8552025 | Apr 08, 2024 | DP | | | |
| | | 8822490 | Sep 30, 2029 | DP U-1185 | | | |
| | | 9180125 | Sep 30, 2029 | DP U-1185 | | | |
| | | 9492445 | Sep 30, 2029 | DP U-1185 | | | |
| | | 9669096 | Apr 08, 2024 | DP | | | |
| METHYLNALTREXONE BROMIDE - RELISTOR | | | | | | | |
| N 021964 | 003 | 8247425 | Dec 31, 2030 | U-1185 | | | |
| | | 8420663 | Sep 30, 2029 | U-1185 | | | |
| | | 8552025 | Apr 08, 2024 | DP | | | |
| | | 8822490 | Sep 30, 2029 | DP U-1185 | | | |
| | | 9180125 | Sep 30, 2029 | DP U-1185 | | | |
| | | 9492445 | Sep 30, 2029 | DP U-1185 | | | |
| | | 9669096 | Apr 08, 2024 | DP | | | |
| METHYLNALTREXONE BROMIDE - RELISTOR | | | | | | | |
| N 208271 | 001 | 6559158 | Nov 03, 2017 | U-1185 | | NP | Jul 19, 2019 |
| | | 8420663 | Sep 30, 2029 | U-1185 | | | |
| | | 8524276 | Mar 10, 2031 | DP | | | |
| | | 8956651 | Mar 10, 2031 | DP | | | |
| | | 9180125 | Sep 30, 2029 | DP U-1185 | | | |
| | | 9314461 | Mar 10, 2031 | DP | | | |
| | | 9492445 | Sep 30, 2029 | DP U-1185 | | | |
| | | 9724343 | Sep 30, 2029 | DP U-1185 | | | |
| METHYLPHENIDATE - DAYTRANA | | | | | | | |
| N 021514 | 001 | 6210705 | Sep 30, 2018 | DP U-727 | | | |
| | | 6348211 | Sep 30, 2018 | DP U-727 | | | |
| | | 8632802 | Oct 07, 2025 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|
| METHYLPHENIDATE - DAYTRANA | | | | | | | | |
| N | 021514 | 001 | 9034370 | Oct 07, 2025 | DP | | | |
| | | | 9668981 | Oct 07, 2025 | U-2024 | | | |
| METHYLPHENIDATE - DAYTRANA | | | | | | | | |
| N | 021514 | 002 | 6210705 | Sep 30, 2018 | DP U-727 | | | |
| | | | 6348211 | Sep 30, 2018 | DP U-727 | | | |
| | | | 8632802 | Oct 07, 2025 | DP | | | |
| | | | 9034370 | Oct 07, 2025 | DP | | | |
| | | | 9668981 | Oct 07, 2025 | U-2024 | | | |
| METHYLPHENIDATE - DAYTRANA | | | | | | | | |
| N | 021514 | 003 | 6210705 | Sep 30, 2018 | DP U-727 | | | |
| | | | 6348211 | Sep 30, 2018 | DP U-727 | | | |
| | | | 8632802 | Oct 07, 2025 | DP | | | |
| | | | 9034370 | Oct 07, 2025 | DP | | | |
| | | | 9668981 | Oct 07, 2025 | U-2024 | | | |
| METHYLPHENIDATE - DAYTRANA | | | | | | | | |
| N | 021514 | 004 | 6210705 | Sep 30, 2018 | DP U-727 | | | |
| | | | 6348211 | Sep 30, 2018 | DP U-727 | | | |
| | | | 8632802 | Oct 07, 2025 | DP | | | |
| | | | 9034370 | Oct 07, 2025 | DP | | | |
| | | | 9668981 | Oct 07, 2025 | U-2024 | | | |
| METHYLPHENIDATE - COTEMPLA XR-ODT | | | | | | | | |
| N | 205489 | 001 | 8840924 | Jun 05, 2026 | DP | | NP | Jun 19, 2020 |
| | | | 9072680 | Jun 28, 2032 | DP | | | |
| | | | 9089496 | Jun 28, 2032 | DP | | | |
| METHYLPHENIDATE - COTEMPLA XR-ODT | | | | | | | | |
| N | 205489 | 002 | 8840924 | Jun 05, 2026 | DP | | NP | Jun 19, 2020 |
| | | | 9072680 | Jun 28, 2032 | DP | | | |
| | | | 9089496 | Jun 28, 2032 | DP | | | |
| METHYLPHENIDATE - COTEMPLA XR-ODT | | | | | | | | |
| N | 205489 | 003 | 8840924 | Jun 05, 2026 | DP | | NP | Jun 19, 2020 |
| | | | 9072680 | Jun 28, 2032 | DP | | | |
| | | | 9089496 | Jun 28, 2032 | DP | | | |
| METHYLPHENIDATE HYDROCHLORIDE - CONCERTA | | | | | | | | |
| N | 021121 | 001 | 6919373 | Jul 31, 2017 | U-666 | | | |
| | | | 6930129 | Jul 31, 2017 | U-666 | | | |
| | | | 8163798 | Jul 31, 2017 | DP | | | |
| | | | 8629179 | Jul 31, 2017 | DP | | | |
| | | | 8629179*PED | Jan 31, 2018 | | | | |
| | | | 9000038 | Jul 31, 2017 | U-1693 | | | |
| | | | 9000038 | Jul 31, 2017 | U-666 | | | |
| | | | 9000038*PED | Jan 31, 2018 | | | | |
| | | | 9029416 | Jul 31, 2017 | DP U-666 | | | |
| | | | 9144549 | Jul 31, 2017 | U-1747 | | | |
| | | | 9144549 | Jul 31, 2017 | U-1748 | | | |
| METHYLPHENIDATE HYDROCHLORIDE - CONCERTA | | | | | | | | |
| N | 021121 | 002 | 6919373 | Jul 31, 2017 | U-666 | | | |
| | | | 6930129 | Jul 31, 2017 | U-666 | | | |
| | | | 8163798 | Jul 31, 2017 | DP | | | |
| | | | 8629179 | Jul 31, 2017 | DP | | | |
| | | | 8629179*PED | Jan 31, 2018 | | | | |
| | | | 9000038 | Jul 31, 2017 | U-1693 | | | |
| | | | 9000038 | Jul 31, 2017 | U-666 | | | |
| | | | 9000038*PED | Jan 31, 2018 | | | | |
| | | | 9029416 | Jul 31, 2017 | DP U-666 | | | |
| | | | 9144549 | Jul 31, 2017 | U-1747 | | | |
| | | | 9144549 | Jul 31, 2017 | U-1748 | | | |
| METHYLPHENIDATE HYDROCHLORIDE - CONCERTA | | | | | | | | |
| N | 021121 | 003 | 6919373 | Jul 31, 2017 | U-666 | | | |
| | | | 6930129 | Jul 31, 2017 | U-666 | | | |
| | | | 8163798 | Jul 31, 2017 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| METHYLPHENIDATE HYDROCHLORIDE - CONCERTA | | | | | | | |
| N 021121 | 003 | 8629179 | Jul 31, 2017 | DP | | | |
| | | 8629179*PED | Jan 31, 2018 | | | | |
| | | 9000038 | Jul 31, 2017 | U-1693 | | | |
| | | 9000038 | Jul 31, 2017 | U-666 | | | |
| | | 9000038*PED | Jan 31, 2018 | | | | |
| | | 9029416 | Jul 31, 2017 | DP U-666 | | | |
| | | 9144549 | Jul 31, 2017 | U-1747 | | | |
| | | 9144549 | Jul 31, 2017 | U-1748 | | | |
| METHYLPHENIDATE HYDROCHLORIDE - CONCERTA | | | | | | | |
| N 021121 | 004 | 6919373 | Jul 31, 2017 | U-666 | | | |
| | | 6930129 | Jul 31, 2017 | U-666 | | | |
| | | 8163798 | Jul 31, 2017 | DP | | | |
| | | 8629179 | Jul 31, 2017 | DP | | | |
| | | 8629179*PED | Jan 31, 2018 | | | | |
| | | 9000038 | Jul 31, 2017 | U-1693 | | | |
| | | 9000038 | Jul 31, 2017 | U-666 | | | |
| | | 9000038*PED | Jan 31, 2018 | | | | |
| | | 9029416 | Jul 31, 2017 | DP U-666 | | | |
| | | 9144549 | Jul 31, 2017 | U-1747 | | | |
| | | 9144549 | Jul 31, 2017 | U-1748 | | | |
| METHYLPHENIDATE HYDROCHLORIDE - METADATE CD | | | | | | | |
| N 021259 | 001 | 6344215 | Oct 27, 2020 | DP | | | |
| METHYLPHENIDATE HYDROCHLORIDE - METADATE CD | | | | | | | |
| N 021259 | 002 | 6344215 | Oct 27, 2020 | DP | | | |
| METHYLPHENIDATE HYDROCHLORIDE - METADATE CD | | | | | | | |
| N 021259 | 003 | 6344215 | Oct 27, 2020 | DP | | | |
| METHYLPHENIDATE HYDROCHLORIDE - METADATE CD | | | | | | | |
| N 021259 | 004 | 6344215 | Oct 27, 2020 | DP | | | |
| METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA | | | | | | | |
| N 021284 | 001 | 6228398 | Nov 01, 2019 | DP U-472 | | | |
| METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA | | | | | | | |
| N 021284 | 002 | 6228398 | Nov 01, 2019 | DP U-472 | | | |
| METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA | | | | | | | |
| N 021284 | 003 | 6228398 | Nov 01, 2019 | DP U-472 | | | |
| METHYLPHENIDATE HYDROCHLORIDE - RITALIN LA | | | | | | | |
| N 021284 | 004 | 6228398 | Nov 01, 2019 | DP U-472 | | | |
| METHYLPHENIDATE HYDROCHLORIDE - METHYLIN | | | | | | | |
| N 021419 | 001 | 7691880 | Oct 07, 2024 | DP | | | |
| METHYLPHENIDATE HYDROCHLORIDE - METHYLIN | | | | | | | |
| N 021419 | 002 | 7691880 | Oct 07, 2024 | DP | | | |
| METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR | | | | | | | |
| N 202100 | 001 | 8062667 | Mar 29, 2029 | DP | | | |
| | | 8287903 | Feb 15, 2031 | DP | | | |
| | | 8465765 | Feb 15, 2031 | DP U-1415 | | | |
| | | 8563033 | Feb 15, 2031 | DP U-1415 | | | |
| | | 8778390 | Feb 15, 2031 | DP U-1543 | | | |
| | | 8956649 | Feb 15, 2031 | DP U-1665 | | | |
| | | 9040083 | Feb 15, 2031 | DP | | | |
| METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR | | | | | | | |
| N 205831 | 001 | 6419960 | Dec 16, 2019 | DP | | NP | Apr 17, 2018 |
| | | 7083808 | Dec 16, 2019 | DP | | | |
| | | 7247318 | Dec 16, 2019 | DP | | | |
| | | 7438930 | Dec 16, 2019 | DP | Y | | |
| | | 8580310 | Dec 16, 2019 | DP | | | |
| | | 9066869 | Dec 16, 2019 | DP | | | |
| | | 9801823 | Dec 16, 2019 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR | | | | | | | |
| N 205831 | 002 | 6419960 | Dec 16, 2019 | DP | | NP | Apr 17, 2018 |
| | | 7083808 | Dec 16, 2019 | DP | | | |
| | | 7247318 | Dec 16, 2019 | DP | | | |
| | | 7438930 | Dec 16, 2019 | DP | Y | | |
| | | 8580310 | Dec 16, 2019 | DP | | | |
| | | 9066869 | Dec 16, 2019 | DP | | | |
| | | 9801823 | Dec 16, 2019 | DP | | | |
| METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR | | | | | | | |
| N 205831 | 003 | 6419960 | Dec 16, 2019 | DP | | NP | Apr 17, 2018 |
| | | 7083808 | Dec 16, 2019 | DP | | | |
| | | 7247318 | Dec 16, 2019 | DP | | | |
| | | 7438930 | Dec 16, 2019 | DP | Y | | |
| | | 8580310 | Dec 16, 2019 | DP | | | |
| | | 9066869 | Dec 16, 2019 | DP | | | |
| | | 9801823 | Dec 16, 2019 | DP | | | |
| METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR | | | | | | | |
| N 205831 | 004 | 6419960 | Dec 16, 2019 | DP | | NP | Apr 17, 2018 |
| | | 7083808 | Dec 16, 2019 | DP | | | |
| | | 7247318 | Dec 16, 2019 | DP | | | |
| | | 7438930 | Dec 16, 2019 | DP | Y | | |
| | | 8580310 | Dec 16, 2019 | DP | | | |
| | | 9066869 | Dec 16, 2019 | DP | | | |
| | | 9801823 | Dec 16, 2019 | DP | | | |
| METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR | | | | | | | |
| N 205831 | 005 | 6419960 | Dec 16, 2019 | DP | | NP | Apr 17, 2018 |
| | | 7083808 | Dec 16, 2019 | DP | | | |
| | | 7247318 | Dec 16, 2019 | DP | | | |
| | | 7438930 | Dec 16, 2019 | DP | Y | | |
| | | 8580310 | Dec 16, 2019 | DP | | | |
| | | 9066869 | Dec 16, 2019 | DP | | | |
| | | 9801823 | Dec 16, 2019 | DP | | | |
| METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR | | | | | | | |
| N 205831 | 006 | 6419960 | Dec 16, 2019 | DP | | NP | Apr 17, 2018 |
| | | 7083808 | Dec 16, 2019 | DP | | | |
| | | 7247318 | Dec 16, 2019 | DP | | | |
| | | 7438930 | Dec 16, 2019 | DP | Y | | |
| | | 8580310 | Dec 16, 2019 | DP | | | |
| | | 9066869 | Dec 16, 2019 | DP | | | |
| | | 9801823 | Dec 16, 2019 | DP | | | |
| METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR | | | | | | | |
| N 205831 | 007 | 6419960 | Dec 16, 2019 | DP | | NP | Apr 17, 2018 |
| | | 7083808 | Dec 16, 2019 | DP | | | |
| | | 7247318 | Dec 16, 2019 | DP | | | |
| | | 7438930 | Dec 16, 2019 | DP | Y | | |
| | | 8580310 | Dec 16, 2019 | DP | | | |
| | | 9066869 | Dec 16, 2019 | DP | | | |
| | | 9801823 | Dec 16, 2019 | DP | | | |
| METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER | | | | | | | |
| N 207960 | 001 | 8202537 | Mar 15, 2027 | DP | | NP | Dec 04, 2018 |
| | | 8287903 | Feb 15, 2031 | DP | | | |
| | | 8999386 | Aug 14, 2033 | DP | | | |
| | | 9295642 | Aug 14, 2033 | DP U-1827 | | | |
| | | 9545399 | Aug 14, 2033 | DP U-1827 | | | |
| | | 9844544 | Aug 14, 2033 | DP U-2203 | | | |
| METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER | | | | | | | |
| N 207960 | 002 | 8202537 | Mar 15, 2027 | DP | | NP | Dec 04, 2018 |
| | | 8287903 | Feb 15, 2031 | DP | | | |
| | | 8999386 | Aug 14, 2033 | DP | | | |
| | | 9295642 | Aug 14, 2033 | DP U-1827 | | | |
| | | 9545399 | Aug 14, 2033 | DP U-1827 | | | |
| | | 9844544 | Aug 14, 2033 | DP U-2203 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|
| METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER | | | | | | | | |
| N 207960 | 003 | 8202537 | Mar 15, 2027 | | DP | | NP | Dec 04, 2018 |
| | | 8287903 | Feb 15, 2031 | | DP | | | |
| | | 8999386 | Aug 14, 2033 | | DP | | | |
| | | 9295642 | Aug 14, 2033 | | DP U-1827 | | | |
| | | 9545399 | Aug 14, 2033 | | DP U-1827 | | | |
| | | 9844544 | Aug 14, 2033 | | DP U-2203 | | | |
| METOCLOPRAMIDE HYDROCHLORIDE - REGLAN ODT | | | | | | | | |
| N 021793 | 001 | 6024981 | Apr 09, 2018 | | DP | | | |
| | | 6221392 | Apr 09, 2018 | | DP | | | |
| METOCLOPRAMIDE HYDROCHLORIDE - REGLAN ODT | | | | | | | | |
| N 021793 | 002 | 6024981 | Apr 09, 2018 | | DP | | | |
| | | 6221392 | Apr 09, 2018 | | DP | | | |
| METOCLOPRAMIDE HYDROCHLORIDE - METOZOLV ODT | | | | | | | | |
| N 022246 | 001 | 6413549 | Jul 11, 2017 | | DP | | | |
| METOCLOPRAMIDE HYDROCHLORIDE - METOZOLV ODT | | | | | | | | |
| N 022246 | 002 | 6413549 | Jul 11, 2017 | | DP | | | |
| METRONIDAZOLE - METROGEL | | | | | | | | |
| N 021789 | 001 | 6881726 | Feb 21, 2022 | | DP U-743 | | | |
| | | 7348317 | Feb 21, 2022 | | DP U-743 | | | |
| METRONIDAZOLE - VANDAZOLE | | | | | | | | |
| N 021806 | 001 | 7456207 | Sep 22, 2024 | | DP | | | |
| METRONIDAZOLE - NUVESSA | | | | | | | | |
| N 205223 | 001 | 7893097 | Feb 19, 2028 | | DP | | | |
| | | 8658678 | Jun 27, 2028 | | U-1682 | | | |
| | | 8877792 | Feb 02, 2028 | | DP | | | |
| | | 8946276 | Jun 28, 2032 | | U-1664 | | | |
| | | 9198858 | Jun 28, 2032 | | U-1664 | | | |
| MICAFUNGIN SODIUM - MYCAMINE | | | | | | | | |
| N 021506 | 002 | 6107458 | Mar 16, 2019 | DS | DP U-650 | | | |
| | | 6107458 | Mar 16, 2019 | DS | DP U-845 | | | |
| | | 6774104 | Jan 08, 2021 | | DP U-650 | | | |
| | | 6774104 | Jan 08, 2021 | | DP U-845 | | | |
| MICAFUNGIN SODIUM - MYCAMINE | | | | | | | | |
| N 021506 | 003 | 6107458 | Mar 16, 2019 | DS | DP U-650 | | | |
| | | 6107458 | Mar 16, 2019 | DS | DP U-845 | | | |
| | | 6774104 | Jan 08, 2021 | | DP U-650 | | | |
| | | 6774104 | Jan 08, 2021 | | DP U-845 | | | |
| MICONAZOLE - ORAVIG | | | | | | | | |
| N 022404 | 001 | 6916485 | Sep 11, 2022 | | DP U-1051 | | | |
| | | 7651698 | Sep 11, 2022 | | U-1051 | | | |
| | | 8518442 | Sep 11, 2022 | | DP | | | |
| MICONAZOLE NITRATE; MICONAZOLE NITRATE - MONISTAT 1 COMBINATION PACK | | | | | | | | |
| N 021308 | 001 | 6153635 | Nov 28, 2020 | | | Y | | |
| MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE - VUSION | | | | | | | | |
| N 021026 | 001 | 8147852 | Mar 30, 2028 | | U-1426 | | | |
| MIDOSTAURIN - RYDAPT | | | | | | | | |
| N 207997 | 001 | 7973031 | Oct 17, 2024 | | U-2007 | | NCE | Apr 28, 2022 |
| | | 8222244 | Oct 29, 2022 | | U-2007 | | ODE-140 | Apr 28, 2024 |
| | | 8575146 | Dec 02, 2030 | | U-2008 | | ODE-141 | Apr 28, 2024 |
| MIFEPRISTONE - KORLYM | | | | | | | | |
| N 202107 | 001 | 8921348 | Aug 27, 2028 | | U-1643 | | ODE-22 | Feb 17, 2019 |
| | | 9829495 | Aug 15, 2036 | | U-1643 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|
| MILNACIPRAN HYDROCHLORIDE - SAVELLA | | | | | | | | |
| N 022256 | 001 | | 6602911 | Jan 14, 2023 | U-882 | | | |
| | | | 6992110 | Nov 05, 2021 | U-882 | | | |
| | | | 7888342 | Nov 05, 2021 | U-882 | | | |
| | | | 7994220 | Sep 19, 2029 | U-819 | | | |
| MILNACIPRAN HYDROCHLORIDE - SAVELLA | | | | | | | | |
| N 022256 | 002 | | 6602911 | Jan 14, 2023 | U-882 | | | |
| | | | 6992110 | Nov 05, 2021 | U-882 | | | |
| | | | 7888342 | Nov 05, 2021 | U-882 | | | |
| | | | 7994220 | Sep 19, 2029 | U-819 | | | |
| MILNACIPRAN HYDROCHLORIDE - SAVELLA | | | | | | | | |
| N 022256 | 003 | | 6602911 | Jan 14, 2023 | U-882 | | | |
| | | | 6992110 | Nov 05, 2021 | U-882 | | | |
| | | | 7888342 | Nov 05, 2021 | U-882 | | | |
| | | | 7994220 | Sep 19, 2029 | U-819 | | | |
| MILNACIPRAN HYDROCHLORIDE - SAVELLA | | | | | | | | |
| N 022256 | 004 | | 6602911 | Jan 14, 2023 | U-882 | | | |
| | | | 6992110 | Nov 05, 2021 | U-882 | | | |
| | | | 7888342 | Nov 05, 2021 | U-882 | | | |
| | | | 7994220 | Sep 19, 2029 | U-819 | | | |
| MILTEFOSINE - IMPAVIDO | | | | | | | | |
| N 204684 | 001 | | | | | | NCE | Mar 19, 2019 |
| | | | | | | | ODE-63 | Mar 19, 2021 |
| MINOCYCLINE HYDROCHLORIDE - MINOCIN | | | | | | | | |
| N 050444 | 001 | | 9084802 | May 12, 2031 | U-282 | | | |
| | | | 9278105 | May 12, 2031 | U-282 | | | |
| MINOCYCLINE HYDROCHLORIDE - ARESTIN | | | | | | | | |
| N 050781 | 001 | | 6682348 | Mar 29, 2022 | DP | | | |
| | | | 7699609 | Mar 29, 2022 | DP | | | |
| MINOCYCLINE HYDROCHLORIDE - SOLODYN | | | | | | | | |
| N 050808 | 001 | | 5908838 | Feb 19, 2018 | U-917 | | | |
| | | | 7790705 | Jun 24, 2025 | U-1078 | | | |
| | | | 7919483 | Mar 07, 2027 | U-1078 | | | |
| | | | 8252776 | Jun 24, 2025 | U-124 | | | |
| | | | 8268804 | Jun 24, 2025 | U-1078 | | | |
| MINOCYCLINE HYDROCHLORIDE - SOLODYN | | | | | | | | |
| N 050808 | 002 | | 5908838 | Feb 19, 2018 | U-917 | | | |
| | | | 7541347 | Apr 02, 2027 | U-917 | | | |
| | | | 7544373 | Apr 02, 2027 | DP | | | |
| | | | 7790705 | Jun 24, 2025 | U-1078 | | | |
| | | | 7919483 | Mar 07, 2027 | U-1078 | | | |
| | | | 8252776 | Jun 24, 2025 | U-124 | | | |
| | | | 8268804 | Jun 24, 2025 | U-1078 | | | |
| MINOCYCLINE HYDROCHLORIDE - SOLODYN | | | | | | | | |
| N 050808 | 003 | | 5908838 | Feb 19, 2018 | U-917 | | | |
| | | | 7790705 | Jun 24, 2025 | U-1078 | | | |
| | | | 7919483 | Mar 07, 2027 | U-1078 | | | |
| | | | 8252776 | Jun 24, 2025 | U-124 | | | |
| | | | 8268804 | Jun 24, 2025 | U-1078 | | | |
| MINOCYCLINE HYDROCHLORIDE - SOLODYN | | | | | | | | |
| N 050808 | 004 | | 5908838 | Feb 19, 2018 | U-917 | | | |
| | | | 7790705 | Jun 24, 2025 | U-1078 | | | |
| | | | 7919483 | Mar 07, 2027 | U-1078 | | | |
| | | | 8252776 | Jun 24, 2025 | U-124 | | | |
| | | | 8268804 | Jun 24, 2025 | U-1078 | | | |
| | | | 9192615 | Nov 17, 2031 | DP | | | |
| MINOCYCLINE HYDROCHLORIDE - SOLODYN | | | | | | | | |
| N 050808 | 005 | | 5908838 | Feb 19, 2018 | U-917 | | | |
| | | | 7790705 | Jun 24, 2025 | U-1078 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| MINOCYCLINE HYDROCHLORIDE - SOLODYN | | | | | | | |
| N 050808 | 005 | 7919483 | Mar 07, 2027 | U-1078 | | | |
| | | 8252776 | Jun 24, 2025 | U-124 | | | |
| | | 8268804 | Jun 24, 2025 | U-1078 | | | |
| | | 9192615 | Nov 17, 2031 | DP | | | |
| MINOCYCLINE HYDROCHLORIDE - SOLODYN | | | | | | | |
| N 050808 | 006 | 5908838 | Feb 19, 2018 | U-917 | | | |
| | | 7790705 | Jun 24, 2025 | U-1078 | | | |
| | | 7919483 | Mar 07, 2027 | U-1078 | | | |
| | | 8252776 | Jun 24, 2025 | U-124 | | | |
| | | 8268804 | Jun 24, 2025 | U-1078 | | | |
| | | 8722650 | Jun 24, 2025 | U-1078 | | | |
| MINOCYCLINE HYDROCHLORIDE - SOLODYN | | | | | | | |
| N 050808 | 007 | 5908838 | Feb 19, 2018 | U-917 | | | |
| | | 7790705 | Jun 24, 2025 | U-1078 | | | |
| | | 7919483 | Mar 07, 2027 | U-1078 | | | |
| | | 8252776 | Jun 24, 2025 | U-124 | | | |
| | | 8268804 | Jun 24, 2025 | U-1078 | | | |
| | | 8722650 | Jun 24, 2025 | U-1078 | | | |
| MINOCYCLINE HYDROCHLORIDE - SOLODYN | | | | | | | |
| N 050808 | 008 | 5908838 | Feb 19, 2018 | U-917 | | | |
| | | 7790705 | Jun 24, 2025 | U-1078 | | | |
| | | 7919483 | Mar 07, 2027 | U-1078 | | | |
| | | 8252776 | Jun 24, 2025 | U-124 | | | |
| | | 8268804 | Jun 24, 2025 | U-1078 | | | |
| | | 8722650 | Jun 24, 2025 | U-1078 | | | |
| MINOCYCLINE HYDROCHLORIDE - XIMINO | | | | | | | |
| N 201922 | 001 | 5908838 | Feb 19, 2018 | U-1376 | | | |
| | | 7541347 | Apr 02, 2027 | U-917 | | | |
| | | 7544373 | Apr 02, 2027 | DP | | | |
| | | 7790705 | Jun 24, 2025 | U-124 | | | |
| | | 7919483 | Mar 07, 2027 | U-124 | | | |
| | | 8252776 | Jun 24, 2025 | U-124 | | | |
| | | 8268804 | Jun 24, 2025 | U-124 | | | |
| MINOCYCLINE HYDROCHLORIDE - XIMINO | | | | | | | |
| N 201922 | 003 | 5908838 | Feb 19, 2018 | U-1376 | | | |
| | | 7541347 | Apr 02, 2027 | U-917 | | | |
| | | 7544373 | Apr 02, 2027 | DP | | | |
| | | 7790705 | Jun 24, 2025 | U-124 | | | |
| | | 7919483 | Mar 07, 2027 | U-124 | | | |
| | | 8252776 | Jun 24, 2025 | U-124 | | | |
| | | 8268804 | Jun 24, 2025 | U-124 | | | |
| MINOCYCLINE HYDROCHLORIDE - XIMINO | | | | | | | |
| N 201922 | 005 | 5908838 | Feb 19, 2018 | U-1376 | | | |
| | | 7541347 | Apr 02, 2027 | U-917 | | | |
| | | 7544373 | Apr 02, 2027 | DP | | | |
| | | 7790705 | Jun 24, 2025 | U-124 | | | |
| | | 7919483 | Mar 07, 2027 | U-124 | | | |
| | | 8252776 | Jun 24, 2025 | U-124 | | | |
| | | 8268804 | Jun 24, 2025 | U-124 | | | |
| MINOXIDIL - MEN'S ROGAINE | | | | | | | |
| N 021812 | 001 | 6946120 | Apr 20, 2019 | DP U-702 | | | |
| MINOXIDIL - WOMEN'S ROGAINE | | | | | | | |
| N 021812 | 002 | 6946120 | Apr 20, 2019 | DP U-702 | | | |
| MIPOMERSEN SODIUM - KYNAMRO | | | | | | | |
| N 203568 | 001 | 6166197 | Dec 26, 2017 | DS | | NCE | Jan 29, 2018 |
| | | 7015315 | Mar 21, 2023 | DS | | ODE-41 | Jan 29, 2020 |
| | | 7101993 | Sep 05, 2023 | DS | | | |
| | | 7407943 | Aug 01, 2021 | U-1353 | | | |
| | | 7511131 | Jan 29, 2027 | DS | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| MIRABEGRON - MYRBETRIQ | | | | | | | |
| N 202611 | 001 | 6346532 | Mar 27, 2022 | DS DP | | | |
| | | 6562375 | Aug 01, 2020 | DP | | | |
| | | 7342117 | Nov 04, 2023 | DS | | | |
| | | 7982049 | Nov 04, 2023 | DP | | | |
| | | 8835474 | Nov 04, 2023 | U-1527 | | | |
| | | RE44872 | Nov 04, 2023 | U-1527 | | | |
| MIRABEGRON - MYRBETRIQ | | | | | | | |
| N 202611 | 002 | 6346532 | Mar 27, 2022 | DS DP | | | |
| | | 6562375 | Aug 01, 2020 | DP | | | |
| | | 7342117 | Nov 04, 2023 | DS | | | |
| | | 7982049 | Nov 04, 2023 | DP | | | |
| | | 8835474 | Nov 04, 2023 | U-1527 | | | |
| | | RE44872 | Nov 04, 2023 | U-1527 | | | |
| MITOMYCIN - MITOSOL | | | | | | | |
| N 022572 | 001 | 7806265 | Feb 01, 2029 | DP | | ODE-21 | Feb 07, 2019 |
| | | 8186511 | Jul 19, 2026 | DP | | | |
| | | 9205075 | Jul 19, 2026 | DP | | | |
| | | 9539241 | Jan 02, 2028 | DS DP U-2095 | | | |
| | | 9649428 | May 21, 2029 | U-2095 | | | |
| MODAFINIL - PROVIGIL | | | | | | | |
| N 020717 | 001 | 7297346 | Nov 29, 2023 | DP | | | |
| MODAFINIL - PROVIGIL | | | | | | | |
| N 020717 | 002 | 7297346 | Nov 29, 2023 | DP | | | |
| MOMETASONE FUROATE - NASONEX | | | | | | | |
| N 020762 | 001 | 6127353 | Oct 03, 2017 | DS DP | | | |
| MOMETASONE FUROATE - ASMANEX TWISTHALER | | | | | | | |
| N 021067 | 001 | 6503537 | Mar 17, 2018 | DP | | | |
| | | 8173172 | Mar 17, 2018 | DP | | | |
| MOMETASONE FUROATE - ASMANEX TWISTHALER | | | | | | | |
| N 021067 | 002 | 6503537 | Mar 17, 2018 | DP | | | |
| | | 8173172 | Mar 17, 2018 | DP | | | |
| MOMETASONE FUROATE - ASMANEX HFA | | | | | | | |
| N 205641 | 001 | 6068832 | Aug 27, 2017 | DP U-645 | | | |
| MOMETASONE FUROATE - ASMANEX HFA | | | | | | | |
| N 205641 | 002 | 6068832 | Aug 27, 2017 | DP U-645 | | | |
| MOMETASONE FUROATE - SINUVA | | | | | | | |
| N 209310 | 001 | | | | | NP | Dec 08, 2020 |
| MONTELUKAST SODIUM - SINGULAIR | | | | | | | |
| N 021409 | 001 | 8007830 | Oct 24, 2022 | DP | | | |
| MORPHINE SULFATE - AVINZA | | | | | | | |
| N 021260 | 001 | 6066339 | Nov 25, 2017 | DP | | | |
| MORPHINE SULFATE - AVINZA | | | | | | | |
| N 021260 | 002 | 6066339 | Nov 25, 2017 | DP | | | |
| MORPHINE SULFATE - AVINZA | | | | | | | |
| N 021260 | 003 | 6066339 | Nov 25, 2017 | DP | | | |
| MORPHINE SULFATE - AVINZA | | | | | | | |
| N 021260 | 004 | 6066339 | Nov 25, 2017 | DP | | | |
| MORPHINE SULFATE - AVINZA | | | | | | | |
| N 021260 | 005 | 6066339 | Nov 25, 2017 | DP | | | |
| MORPHINE SULFATE - AVINZA | | | | | | | |
| N 021260 | 006 | 6066339 | Nov 25, 2017 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|
| MORPHINE SULFATE - MORPHINE SULFATE | | | | | | | | |
| N | 204223 | 001 | 9072781 | Mar 12, 2034 | DP | | | |
| | | | 9192608 | Mar 12, 2034 | U-43 | | | |
| | | | 9192608 | Mar 12, 2034 | U-55 | | | |
| | | | 9248229 | Mar 12, 2034 | DP | | | |
| MORPHINE SULFATE - MORPHINE SULFATE | | | | | | | | |
| N | 204223 | 002 | 9072781 | Mar 12, 2034 | DP | | | |
| | | | 9192608 | Mar 12, 2034 | U-43 | | | |
| | | | 9192608 | Mar 12, 2034 | U-55 | | | |
| | | | 9248229 | Mar 12, 2034 | DP | | | |
| MORPHINE SULFATE - MORPHINE SULFATE | | | | | | | | |
| N | 204223 | 003 | 9072781 | Mar 12, 2034 | DP | | | |
| | | | 9192608 | Mar 12, 2034 | U-43 | | | |
| | | | 9192608 | Mar 12, 2034 | U-55 | | | |
| | | | 9248229 | Mar 12, 2034 | DP | | | |
| MORPHINE SULFATE - MORPHINE SULFATE | | | | | | | | |
| N | 204223 | 004 | 9072781 | Mar 12, 2034 | DP | | | |
| | | | 9192608 | Mar 12, 2034 | U-43 | | | |
| | | | 9192608 | Mar 12, 2034 | U-55 | | | |
| | | | 9248229 | Mar 12, 2034 | DP | | | |
| MORPHINE SULFATE - MORPHINE SULFATE | | | | | | | | |
| N | 204223 | 005 | 9072781 | Mar 12, 2034 | DP | | | |
| | | | 9192608 | Mar 12, 2034 | U-43 | | | |
| | | | 9192608 | Mar 12, 2034 | U-55 | | | |
| | | | 9248229 | Mar 12, 2034 | DP | | | |
| MORPHINE SULFATE - MORPHABOND ER | | | | | | | | |
| N | 206544 | 001 | 7955619 | Aug 12, 2028 | DP | | M-189 | Oct 02, 2018 |
| MORPHINE SULFATE - MORPHABOND ER | | | | | | | | |
| N | 206544 | 002 | 7955619 | Aug 12, 2028 | DP | | M-189 | Oct 02, 2018 |
| MORPHINE SULFATE - MORPHABOND ER | | | | | | | | |
| N | 206544 | 003 | 7955619 | Aug 12, 2028 | DP | | M-189 | Oct 02, 2018 |
| MORPHINE SULFATE - MORPHABOND ER | | | | | | | | |
| N | 206544 | 004 | 7955619 | Aug 12, 2028 | DP | | M-189 | Oct 02, 2018 |
| MORPHINE SULFATE - ARYMO ER | | | | | | | | |
| N | 208603 | 001 | 9044402 | Jul 01, 2033 | DP U-1556 | | | |
| | | | 9549899 | Jul 01, 2033 | DP U-1556 | | | |
| MORPHINE SULFATE - ARYMO ER | | | | | | | | |
| N | 208603 | 002 | 9044402 | Jul 01, 2033 | DP U-1556 | | | |
| | | | 9549899 | Jul 01, 2033 | DP U-1556 | | | |
| MORPHINE SULFATE - ARYMO ER | | | | | | | | |
| N | 208603 | 003 | 9044402 | Jul 01, 2033 | DP U-1556 | | | |
| | | | 9549899 | Jul 01, 2033 | DP U-1556 | | | |
| MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA | | | | | | | | |
| N | 022321 | 001 | 7682633 | Jun 19, 2027 | U-1510 | | | |
| | | | 7682634 | Jun 19, 2027 | DP | | | |
| | | | 7815934 | Dec 12, 2027 | DP | | | |
| | | | 8158156 | Jun 19, 2027 | U-1510 | | | |
| | | | 8623418 | Nov 07, 2029 | U-1640 | | | |
| | | | 8685443 | Jul 03, 2025 | U-1508 | | | |
| | | | 8685444 | Jul 03, 2025 | DP | | | |
| | | | 8846104 | Jun 19, 2027 | DP | | | |
| | | | 8877247 | Jun 19, 2027 | DP | | | |
| MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA | | | | | | | | |
| N | 022321 | 002 | 7682633 | Jun 19, 2027 | U-1510 | | | |
| | | | 7682634 | Jun 19, 2027 | DP | | | |
| | | | 7815934 | Dec 12, 2027 | DP | | | |
| | | | 8158156 | Jun 19, 2027 | U-1510 | | | |
| | | | 8623418 | Nov 07, 2029 | U-1640 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|
| MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA | | | | | | | | |
| N | 022321 | 002 | 8685443 | Jul 03, 2025 | U-1508 | | | |
| | | | 8685444 | Jul 03, 2025 | DP | | | |
| | | | 8846104 | Jun 19, 2027 | DP | | | |
| | | | 8877247 | Jun 19, 2027 | DP | | | |
| MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA | | | | | | | | |
| N | 022321 | 003 | 7682633 | Jun 19, 2027 | U-1510 | | | |
| | | | 7682634 | Jun 19, 2027 | DP | | | |
| | | | 7815934 | Dec 12, 2027 | DP | | | |
| | | | 8158156 | Jun 19, 2027 | U-1510 | | | |
| | | | 8623418 | Nov 07, 2029 | U-1640 | | | |
| | | | 8685443 | Jul 03, 2025 | U-1508 | | | |
| | | | 8685444 | Jul 03, 2025 | DP | | | |
| | | | 8846104 | Jun 19, 2027 | DP | | | |
| | | | 8877247 | Jun 19, 2027 | DP | | | |
| MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA | | | | | | | | |
| N | 022321 | 004 | 7682633 | Jun 19, 2027 | U-1510 | | | |
| | | | 7682634 | Jun 19, 2027 | DP | | | |
| | | | 7815934 | Dec 12, 2027 | DP | | | |
| | | | 8158156 | Jun 19, 2027 | U-1510 | | | |
| | | | 8623418 | Nov 07, 2029 | U-1640 | | | |
| | | | 8685443 | Jul 03, 2025 | U-1508 | | | |
| | | | 8685444 | Jul 03, 2025 | DP | | | |
| | | | 8846104 | Jun 19, 2027 | DP | | | |
| | | | 8877247 | Jun 19, 2027 | DP | | | |
| MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA | | | | | | | | |
| N | 022321 | 005 | 7682633 | Jun 19, 2027 | U-1510 | | | |
| | | | 7682634 | Jun 19, 2027 | DP | | | |
| | | | 7815934 | Dec 12, 2027 | DP | | | |
| | | | 8158156 | Jun 19, 2027 | U-1510 | | | |
| | | | 8623418 | Nov 07, 2029 | U-1640 | | | |
| | | | 8685443 | Jul 03, 2025 | U-1508 | | | |
| | | | 8685444 | Jul 03, 2025 | DP | | | |
| | | | 8846104 | Jun 19, 2027 | DP | | | |
| | | | 8877247 | Jun 19, 2027 | DP | | | |
| MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA | | | | | | | | |
| N | 022321 | 006 | 7682633 | Jun 19, 2027 | U-1510 | | | |
| | | | 7682634 | Jun 19, 2027 | DP | | | |
| | | | 7815934 | Dec 12, 2027 | DP | | | |
| | | | 8158156 | Jun 19, 2027 | U-1510 | | | |
| | | | 8623418 | Nov 07, 2029 | U-1640 | | | |
| | | | 8685443 | Jul 03, 2025 | U-1508 | | | |
| | | | 8685444 | Jul 03, 2025 | DP | | | |
| | | | 8846104 | Jun 19, 2027 | DP | | | |
| | | | 8877247 | Jun 19, 2027 | DP | | | |
| MOXIFLOXACIN HYDROCHLORIDE - AVELOX | | | | | | | | |
| N | 021085 | 001 | 6610327 | Oct 29, 2019 | DP U-298 | | M-185 | Sep 27, 2019 |
| MOXIFLOXACIN HYDROCHLORIDE - AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER | | | | | | | | |
| N | 021277 | 001 | 6548079 | Jul 25, 2020 | DP U-298 | | M-185 | Sep 27, 2019 |
| MOXIFLOXACIN HYDROCHLORIDE - VIGAMOX | | | | | | | | |
| N | 021598 | 001 | 6716830 | Sep 29, 2019 | DP | | | |
| | | | 7671070 | Sep 29, 2019 | U-709 | | | |
| MOXIFLOXACIN HYDROCHLORIDE - MOXEZA | | | | | | | | |
| N | 022428 | 001 | 6716830 | Sep 29, 2019 | DP | | | |
| | | | 7671070 | Sep 29, 2019 | DP U-709 | | | |
| | | | 8450311 | May 29, 2029 | DP | | | |
| | | | 9114168 | May 29, 2029 | DP | | | |
| MUPIROCIN - CENTANY | | | | | | | | |
| N | 050788 | 001 | 6013657 | Jul 08, 2018 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| MYCOPHENOLIC ACID - MYFORTIC | | | | | | | |
| N 050791 | 001 | 6306900 | Feb 27, 2018 | DP | | | |
| MYCOPHENOLIC ACID - MYFORTIC | | | | | | | |
| N 050791 | 002 | 6306900 | Feb 27, 2018 | DP | | | |
| NAFTIFINE HYDROCHLORIDE - NAFTIN | | | | | | | |
| N 019599 | 002 | | | | | M-191 | Nov 10, 2019 |
| NAFTIFINE HYDROCHLORIDE - NAFTIN | | | | | | | |
| N 204286 | 001 | 8778365 | Jan 31, 2033 | DP | | | |
| | | 9161914 | Jan 31, 2033 | U-540 | | | |
| NALDEMEDINE TOSYLATE - SYMPROIC | | | | | | | |
| N 208854 | 001 | 9108975 | Nov 11, 2031 | DS DP | | NCE | Mar 23, 2022 |
| | | RE46365 | Jan 11, 2028 | DS DP | | | |
| | | RE46375 | Oct 05, 2026 | DS DP U-1185 | | | |
| NALOXEGOL OXALATE - MOVANTIK | | | | | | | |
| N 204760 | 001 | 7056500 | Jun 29, 2024 | DP U-1185 | | NCE | Sep 16, 2019 |
| | | 7662365 | Oct 18, 2022 | DS DP | | | |
| | | 7786133 | Dec 19, 2027 | DS DP | | | |
| | | 8067431 | Dec 16, 2024 | U-1185 | | | |
| | | 8617530 | Oct 18, 2022 | U-1185 | | | |
| | | 9012469 | Apr 02, 2032 | DS DP | | | |
| NALOXEGOL OXALATE - MOVANTIK | | | | | | | |
| N 204760 | 002 | 7056500 | Jun 29, 2024 | DP U-1185 | | NCE | Sep 16, 2019 |
| | | 7662365 | Oct 18, 2022 | DS DP | | | |
| | | 7786133 | Dec 19, 2027 | DS DP | | | |
| | | 8067431 | Dec 16, 2024 | U-1185 | | | |
| | | 8617530 | Oct 18, 2022 | U-1185 | | | |
| | | 9012469 | Apr 02, 2032 | DS DP | | | |
| NALOXONE HYDROCHLORIDE - EVZIO | | | | | | | |
| N 205787 | 001 | 7731686 | Jun 10, 2026 | DP | | | |
| | | 7731690 | Jan 15, 2025 | DP | | | |
| | | 7749194 | Oct 30, 2028 | DP | | | |
| | | 7918823 | Nov 23, 2024 | DP | | | |
| | | 7947017 | Mar 12, 2028 | DP | | | |
| | | 8016788 | Mar 21, 2025 | DP | | | |
| | | 8021344 | Nov 02, 2029 | DP | | | |
| | | 8206360 | Feb 27, 2027 | DP | | | |
| | | 8226610 | Apr 10, 2029 | DP | | | |
| | | 8231573 | Nov 25, 2028 | DP | | | |
| | | 8313466 | Nov 23, 2024 | DP | | | |
| | | 8361029 | Nov 23, 2024 | DP | | | |
| | | 8425462 | Nov 23, 2024 | DP | | | |
| | | 8608698 | Nov 23, 2024 | DP | | | |
| | | 8627816 | Feb 04, 2032 | DP | | | |
| | | 8926594 | Mar 31, 2026 | DP | | | |
| | | 8939943 | Feb 28, 2031 | DP | | | |
| | | 9022022 | Feb 28, 2031 | DP | | | |
| | | 9056170 | Nov 23, 2024 | DP | | | |
| | | 9238108 | Feb 20, 2027 | DP | | | |
| | | 9278182 | Feb 01, 2026 | DP | | | |
| | | 9474869 | Feb 28, 2031 | DP U-1907 | | | |
| | | 9517307 | Jul 18, 2034 | DP U-1925 | | | |
| | | 9724471 | May 23, 2027 | DP U-2092 | | | |
| | | 9737669 | Nov 23, 2024 | DP | | | |
| NALOXONE HYDROCHLORIDE - NARCAN | | | | | | | |
| N 208411 | 001 | 9211253 | Mar 16, 2035 | DP | | | |
| | | 9468747 | Mar 16, 2035 | DP U-1903 | | | |
| | | 9561177 | Mar 16, 2035 | DP U-1903 | | | |
| | | 9629965 | Mar 16, 2035 | DP U-1903 | | | |
| | | 9775838 | Mar 16, 2035 | U-1903 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| NALOXONE HYDROCHLORIDE - NARCAN | | | | | | | |
| N 208411 | 002 | 9480644 | Mar 16, 2035 | DP U-1903 | | | |
| | | 9707226 | Mar 16, 2035 | DP U-1903 | | | |
| NALOXONE HYDROCHLORIDE - EVZIO | | | | | | | |
| N 209862 | 001 | 7731686 | Jun 01, 2026 | DP | | | |
| | | 7731690 | Jan 15, 2025 | DP | | | |
| | | 7749194 | Oct 30, 2028 | DP | | | |
| | | 7918823 | Nov 23, 2024 | DP | | | |
| | | 7947017 | Mar 12, 2028 | DP | | | |
| | | 8016788 | Mar 21, 2025 | DP | | | |
| | | 8021344 | Nov 02, 2029 | DP | | | |
| | | 8206360 | Feb 27, 2027 | DP | | | |
| | | 8226610 | Apr 10, 2029 | DP | | | |
| | | 8231573 | Nov 25, 2028 | DP | | | |
| | | 8313466 | Nov 23, 2024 | DP | | | |
| | | 8361029 | Nov 23, 2024 | DP | | | |
| | | 8425462 | Nov 23, 2024 | DP | | | |
| | | 8608698 | Nov 23, 2024 | DP | | | |
| | | 8627816 | Feb 04, 2032 | DP | | | |
| | | 8926594 | Mar 31, 2026 | DP | | | |
| | | 8939943 | Feb 28, 2031 | DP | | | |
| | | 9022022 | Feb 28, 2031 | DP | | | |
| | | 9056170 | Nov 23, 2024 | DP | | | |
| | | 9238108 | Feb 20, 2027 | DP | | | |
| | | 9278182 | Feb 01, 2026 | DP | | | |
| | | 9474869 | Feb 28, 2031 | DP U-1907 | | | |
| | | 9517307 | Jul 18, 2034 | DP U-1925 | | | |
| | | 9724471 | May 23, 2027 | DP U-2092 | | | |
| | | 9737669 | Nov 23, 2024 | DP | | | |
| NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ | | | | | | | |
| N 205777 | 001 | 6277384 | Dec 22, 2018 | DP | | NC | Jul 23, 2017 |
| | | 6696066 | Dec 22, 2018 | DP | | | |
| | | 8673355 | Dec 22, 2018 | DP | | | |
| | | 8822487 | Dec 22, 2018 | DP | | | |
| | | 8846090 | Apr 04, 2023 | DP | | | |
| | | 8846091 | Apr 04, 2023 | DP | | | |
| | | 8969369 | May 10, 2022 | DP U-1556 | | | |
| | | 9056051 | May 10, 2022 | DP U-1556 | | | |
| | | 9073933 | Mar 30, 2025 | DS | | | |
| | | 9084729 | May 10, 2022 | DP U-1556 | | | |
| | | 9161937 | May 10, 2022 | DP U-1556 | | | |
| | | 9168252 | May 10, 2022 | DP U-1556 | | | |
| | | 9205082 | Dec 22, 2018 | DP U-1556 | | | |
| | | 9283216 | May 10, 2022 | DP U-1819 | | | |
| | | 9283221 | May 10, 2022 | DP U-1819 | | | |
| | | 9345701 | May 10, 2022 | DP U-1819 | | | |
| | | 9474750 | Dec 22, 2018 | DP U-1556 | | | |
| | | 9511066 | May 10, 2022 | U-1921 | | | |
| | | 9522919 | Mar 30, 2025 | DS DP | | | |
| | | 9555000 | Apr 04, 2023 | DP U-1556 | | | |
| NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ | | | | | | | |
| N 205777 | 002 | 6277384 | Dec 22, 2018 | DP | | NC | Jul 23, 2017 |
| | | 6696066 | Dec 22, 2018 | DP | | | |
| | | 8673355 | Dec 22, 2018 | DP | | | |
| | | 8822487 | Dec 22, 2018 | DP | | | |
| | | 8846090 | Apr 04, 2023 | DP | | | |
| | | 8846091 | Apr 04, 2023 | DP | | | |
| | | 8969369 | May 10, 2022 | DP U-1556 | | | |
| | | 9056051 | May 10, 2022 | DP U-1556 | | | |
| | | 9073933 | Mar 30, 2025 | DS | | | |
| | | 9084729 | May 10, 2022 | DP U-1556 | | | |
| | | 9161937 | May 10, 2022 | DP U-1556 | | | |
| | | 9168252 | May 10, 2022 | DP U-1556 | | | |
| | | 9205082 | Dec 22, 2018 | DP U-1556 | | | |
| | | 9283216 | May 10, 2022 | DP U-1819 | | | |
| | | 9283221 | May 10, 2022 | DP U-1819 | | | |
| | | 9345701 | May 10, 2022 | DP U-1819 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|
| NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ | | | | | | | | |
| N 205777 | 002 | 9474750 | Dec 22, 2018 | | DP U-1556 | | | |
| | | 9511066 | May 10, 2022 | | U-1921 | | | |
| | | 9522919 | Mar 30, 2025 | DS | DP | | | |
| | | 9555000 | Apr 04, 2023 | | DP U-1556 | | | |
| NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ | | | | | | | | |
| N 205777 | 003 | 6277384 | Dec 22, 2018 | | DP | | NC | Jul 23, 2017 |
| | | 6696066 | Dec 22, 2018 | | DP | | | |
| | | 8673355 | Dec 22, 2018 | | DP | | | |
| | | 8822487 | Dec 22, 2018 | | DP | | | |
| | | 8846090 | Apr 04, 2023 | | DP | | | |
| | | 8846091 | Apr 04, 2023 | | DP | | | |
| | | 8969369 | May 10, 2022 | | DP U-1556 | | | |
| | | 9056051 | May 10, 2022 | | DP U-1556 | | | |
| | | 9073933 | Mar 30, 2025 | DS | | | | |
| | | 9084729 | May 10, 2022 | | DP U-1556 | | | |
| | | 9161937 | May 10, 2022 | | DP U-1556 | | | |
| | | 9168252 | May 10, 2022 | | DP U-1556 | | | |
| | | 9205082 | Dec 22, 2018 | | DP U-1556 | | | |
| | | 9283216 | May 10, 2022 | | DP U-1819 | | | |
| | | 9283221 | May 10, 2022 | | DP U-1819 | | | |
| | | 9345701 | May 10, 2022 | | DP U-1819 | | | |
| | | 9474750 | Dec 22, 2018 | | DP U-1556 | | | |
| | | 9511066 | May 10, 2022 | | U-1921 | | | |
| | | 9522919 | Mar 30, 2025 | DS | DP | | | |
| NALTREXONE - VIVITROL | | | | | | | | |
| N 021897 | 001 | 6194006 | Dec 30, 2018 | | DP | | | |
| | | 6264987 | May 19, 2020 | | DP | | | |
| | | 6331317 | Nov 12, 2019 | | DP | | | |
| | | 6379703 | Dec 30, 2018 | | DP | | | |
| | | 6379704 | May 19, 2020 | | DP | | | |
| | | 6395304 | Nov 12, 2019 | | DP | | | |
| | | 6495164 | May 25, 2020 | | DP | | | |
| | | 6495166 | Nov 12, 2019 | | DP | | | |
| | | 6534092 | May 19, 2020 | | DP | | | |
| | | 6537586 | Nov 12, 2019 | | DP | | | |
| | | 6596316 | Dec 30, 2018 | | DP | | | |
| | | 6667061 | May 25, 2020 | | DP | | | |
| | | 6713090 | Nov 12, 2019 | | DP | | | |
| | | 6939033 | Nov 12, 2019 | | DP | | | |
| | | 7799345 | May 25, 2020 | | DP | | | |
| | | 7919499 | Oct 15, 2029 | | U-1123 | | | |
| | | 7919499 | Oct 15, 2029 | | U-1124 | | | |
| NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER | | | | | | | | |
| N 207621 | 001 | 7815934 | Dec 12, 2027 | | DP | | NC | Aug 19, 2019 |
| | | 8685443 | Jul 03, 2025 | | U-1508 | | | |
| NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER | | | | | | | | |
| N 207621 | 002 | 7815934 | Dec 12, 2027 | | DP | | NC | Aug 19, 2019 |
| | | 8685443 | Jul 03, 2025 | | U-1508 | | | |
| NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER | | | | | | | | |
| N 207621 | 003 | 7815934 | Dec 12, 2027 | | DP | | NC | Aug 19, 2019 |
| | | 8685443 | Jul 03, 2025 | | U-1508 | | | |
| NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER | | | | | | | | |
| N 207621 | 004 | 7815934 | Dec 12, 2027 | | DP | | NC | Aug 19, 2019 |
| | | 8685443 | Jul 03, 2025 | | U-1508 | | | |
| NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER | | | | | | | | |
| N 207621 | 005 | 7815934 | Dec 12, 2027 | | DP | | NC | Aug 19, 2019 |
| | | 8685443 | Jul 03, 2025 | | U-1508 | | | |
| NALTREXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TROXYCA ER | | | | | | | | |
| N 207621 | 006 | 7815934 | Dec 12, 2027 | | DP | | NC | Aug 19, 2019 |
| | | 8685443 | Jul 03, 2025 | | U-1508 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| NAPROXEN SODIUM - NAPROXEN SODIUM | | | | | | | |
| N 021920 | 001 | 9693978 | Mar 03, 2026 | DP | | | |
| | | 9693979 | Mar 03, 2026 | DP | | | |
| NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET | | | | | | | |
| N 021926 | 001 | 6060499 | Aug 14, 2017 | DP U-867 | | | |
| | | 6060499*PED | Feb 14, 2018 | | | | |
| | | 6586458 | Aug 14, 2017 | DP U-867 | | | |
| | | 6586458*PED | Feb 14, 2018 | | | | |
| | | 7332183 | Oct 02, 2025 | DP U-867 | | | |
| | | 7332183*PED | Apr 02, 2026 | | | | |
| | | 8022095 | Aug 14, 2017 | DP U-867 | | | |
| | | 8022095*PED | Feb 14, 2018 | | | | |
| NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET | | | | | | | |
| N 021926 | 002 | 5872145 | Aug 14, 2017 | DP U-1719 | | NP | May 14, 2018 |
| | | 5872145*PED | Feb 14, 2018 | | | PED | Nov 14, 2018 |
| | | 6060499 | Aug 14, 2017 | DP U-1719 | | | |
| | | 6060499*PED | Feb 14, 2018 | | | | |
| | | 6586458 | Aug 14, 2017 | DP U-1719 | | | |
| | | 6586458*PED | Feb 14, 2018 | | | | |
| | | 7332183 | Oct 02, 2025 | DP U-1719 | | | |
| | | 7332183*PED | Apr 02, 2026 | | | | |
| NATEGLINIDE - STARLIX | | | | | | | |
| N 021204 | 001 | 6559188 | Sep 15, 2020 | DP U-827 | | | |
| | | 6641841 | Nov 14, 2017 | DP U-214 | | | |
| | | 6844008 | Nov 14, 2017 | DP U-214 | | | |
| | | 6878749 | Sep 15, 2020 | DP | | | |
| NATEGLINIDE - STARLIX | | | | | | | |
| N 021204 | 002 | 6559188 | Sep 15, 2020 | DP U-827 | | | |
| | | 6641841 | Nov 14, 2017 | DP U-214 | | | |
| | | 6844008 | Nov 14, 2017 | DP U-214 | | | |
| | | 6878749 | Sep 15, 2020 | DP | | | |
| NEBIVOLOL HYDROCHLORIDE - BYSTOLIC | | | | | | | |
| N 021742 | 002 | 6545040 | Dec 17, 2021 | DP U-3 | | | |
| NEBIVOLOL HYDROCHLORIDE - BYSTOLIC | | | | | | | |
| N 021742 | 003 | 6545040 | Dec 17, 2021 | DP U-3 | | | |
| NEBIVOLOL HYDROCHLORIDE - BYSTOLIC | | | | | | | |
| N 021742 | 004 | 6545040 | Dec 17, 2021 | DP U-3 | | | |
| NEBIVOLOL HYDROCHLORIDE - BYSTOLIC | | | | | | | |
| N 021742 | 005 | 6545040 | Dec 17, 2021 | DP U-3 | | | |
| NEBIVOLOL HYDROCHLORIDE; VALSARTAN - BYVALSON | | | | | | | |
| N 206302 | 001 | 7803838 | Aug 29, 2026 | DP | | NC | Jun 03, 2019 |
| | | 7838552 | Oct 04, 2027 | U-185 | | | |
| NEPAFENAC - NEVANAC | | | | | | | |
| N 021862 | 001 | 7834059 | Jan 31, 2027 | U-1095 | | | |
| | | 8071648 | Dec 02, 2025 | DP | | | |
| | | 8324281 | Dec 02, 2025 | DP | | | |
| NEPAFENAC - ILEVRO | | | | | | | |
| N 203491 | 001 | 6403609 | Jul 17, 2018 | DP | | | |
| | | 7947295 | Jun 08, 2024 | DP | | | |
| | | 8921337 | Mar 31, 2032 | DP | | | |
| | | 9662398 | Dec 01, 2030 | DP | | | |
| NERATINIB MALEATE - NERLYNX | | | | | | | |
| N 208051 | 001 | 6288082 | Sep 24, 2019 | DS DP U-2043 | | NCE | Jul 17, 2022 |
| | | 7399865 | Dec 29, 2025 | DS DP | | | |
| | | 7982043 | Oct 08, 2025 | U-2043 | | | |
| | | 8518446 | Nov 20, 2030 | DP U-2043 | | | |
| | | 8790708 | Nov 05, 2030 | DP U-2043 | | | |
| | | 9139558 | Oct 15, 2028 | U-2043 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| NERATINIB MALEATE - NERLYNX | | | | | | | |
| N 208051 | 001 | 9211291 | Mar 24, 2030 | U-2043 | | | |
| | | 9630946 | Oct 15, 2028 | U-2043 | | | |
| NETARSUDIL DIMESYLATE - RHOPRESSA | | | | | | | |
| N 208254 | 001 | 8394826 | Nov 10, 2030 | DS DP U-1524 | | NCE | Dec 18, 2022 |
| | | 8450344 | Jul 11, 2026 | DS DP U-1524 | | | |
| | | 9096569 | Jul 11, 2026 | DS DP U-1524 | | | |
| | | 9415043 | Mar 14, 2034 | DS | | | |
| NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO | | | | | | | |
| N 205718 | 001 | 6297375 | Feb 22, 2020 | DS | | NCE | Oct 10, 2019 |
| | | 8623826 | Nov 18, 2030 | U-528 | | | |
| | | 8951969 | Nov 18, 2030 | DP | | | |
| | | 9186357 | Nov 18, 2030 | U-528 | | | |
| | | 9271975 | Sep 09, 2031 | U-528 | | | |
| NEVIRAPINE - VIRAMUNE XR | | | | | | | |
| N 201152 | 001 | 8460704 | Mar 12, 2029 | U-1409 | | | |
| NIACIN - NIASPAN | | | | | | | |
| N 020381 | 002 | 6469035 | Mar 15, 2018 | U-1142 | | | |
| | | 6469035 | Mar 15, 2018 | U-1143 | | | |
| | | 6469035 | Mar 15, 2018 | U-1144 | | | |
| | | 6469035 | Mar 15, 2018 | U-1145 | | | |
| | | 6469035 | Mar 15, 2018 | U-768 | | | |
| NIACIN - NIASPAN | | | | | | | |
| N 020381 | 003 | 6469035 | Mar 15, 2018 | U-1142 | | | |
| | | 6469035 | Mar 15, 2018 | U-1143 | | | |
| | | 6469035 | Mar 15, 2018 | U-1144 | | | |
| | | 6469035 | Mar 15, 2018 | U-1145 | | | |
| | | 6469035 | Mar 15, 2018 | U-768 | | | |
| NIACIN - NIASPAN | | | | | | | |
| N 020381 | 004 | 6469035 | Mar 15, 2018 | U-1142 | | | |
| | | 6469035 | Mar 15, 2018 | U-1143 | | | |
| | | 6469035 | Mar 15, 2018 | U-1144 | | | |
| | | 6469035 | Mar 15, 2018 | U-1145 | | | |
| | | 6469035 | Mar 15, 2018 | U-768 | | | |
| NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER | | | | | | | |
| N 019734 | 002 | 7612102 | Dec 26, 2027 | DP | | | |
| | | 7659291 | Apr 18, 2027 | U-1029 | | | |
| | | 8455524 | Apr 18, 2027 | U-1029 | | | |
| | | 9364564 | Dec 26, 2027 | DP | | | |
| NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER | | | | | | | |
| N 019734 | 003 | 7612102 | Dec 26, 2027 | DP | | | |
| | | 7659291 | Apr 18, 2027 | U-1029 | | | |
| | | 8455524 | Apr 18, 2027 | U-1029 | | | |
| | | 9364564 | Dec 26, 2027 | DP | | | |
| NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER | | | | | | | |
| N 019734 | 004 | 7612102 | Dec 26, 2027 | DP | | | |
| | | 7659291 | Apr 18, 2027 | U-1029 | | | |
| | | 8455524 | Apr 18, 2027 | U-1029 | | | |
| | | 9364564 | Dec 26, 2027 | DP | | | |
| NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER | | | | | | | |
| N 019734 | 005 | 7612102 | Dec 26, 2027 | DP | | | |
| | | 7659291 | Apr 18, 2027 | U-1029 | | | |
| | | 8455524 | Apr 18, 2027 | U-1029 | | | |
| | | 9364564 | Dec 26, 2027 | DP | | | |
| NICOTINE - NICODERM CQ | | | | | | | |
| N 020165 | 004 | 8075911 | May 22, 2021 | DP | | | |
| | | 8663680 | Feb 13, 2020 | DP | | | |
| | | 8999379 | Feb 13, 2020 | U-1686 | | | |
| | | 9205059 | Dec 15, 2019 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| NICOTINE - NICODERM CQ | | | | | | | |
| N 020165 | 005 | 8075911 | May 22, 2021 | DP | | | |
| | | 8663680 | Feb 13, 2020 | DP | | | |
| | | 8999379 | Feb 13, 2020 | U-1686 | | | |
| | | 9205059 | Dec 15, 2019 | DP | | | |
| NICOTINE - NICODERM CQ | | | | | | | |
| N 020165 | 006 | 8075911 | May 22, 2021 | DP | | | |
| | | 8663680 | Feb 13, 2020 | DP | | | |
| | | 8999379 | Feb 13, 2020 | U-1686 | | | |
| | | 9205059 | Dec 15, 2019 | DP | | | |
| NICOTINE POLACRILEX - NICORETTE | | | | | | | |
| N 018612 | 002 | 8323683 | Apr 30, 2028 | | | | |
| NICOTINE POLACRILEX - NICORETTE | | | | | | | |
| N 020066 | 002 | 8323683 | Apr 30, 2028 | DP | | | |
| NICOTINE POLACRILEX - NICORETTE | | | | | | | |
| N 022360 | 001 | 8501164 | Jun 14, 2029 | DP | | | |
| | | 8940772 | Apr 30, 2029 | DP | | | |
| NICOTINE POLACRILEX - NICORETTE | | | | | | | |
| N 022360 | 002 | 8501164 | Jun 14, 2029 | DP | | | |
| | | 8940772 | Apr 30, 2029 | DP | | | |
| NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA | | | | | | | |
| N 022068 | 001 | 7169791 | Jul 04, 2023 | DS DP U-836 | | | |
| | | 8163904 | Aug 23, 2028 | DS DP | | | |
| | | 8293756 | Sep 25, 2027 | DP | | | |
| | | 8389537 | Jul 18, 2026 | DS DP U-1374 | | | |
| | | 8415363 | Jul 18, 2026 | DS DP U-1407 | | | |
| | | 8501760 | Jul 18, 2026 | DS DP | | | |
| | | 9061029 | Apr 07, 2032 | DP U-1374 | | | |
| NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA | | | | | | | |
| N 022068 | 002 | 7169791 | Jul 04, 2023 | DS DP U-836 | | | |
| | | 8163904 | Aug 23, 2028 | DS DP | | | |
| | | 8293756 | Sep 25, 2027 | DP | | | |
| | | 8389537 | Jul 18, 2026 | DS DP U-1374 | | | |
| | | 8415363 | Jul 18, 2026 | DS DP U-1407 | | | |
| | | 8501760 | Jul 18, 2026 | DS DP | | | |
| | | 9061029 | Apr 07, 2032 | DP U-1374 | | | |
| NIMODIPINE - NYMALIZE | | | | | | | |
| N 203340 | 001 | | | | | ODE-46 | May 10, 2020 |
| NINTEDANIB ESYLATE - OFEV | | | | | | | |
| N 205832 | 001 | 6762180 | Dec 10, 2020 | DS DP | | NCE | Oct 15, 2019 |
| | | 7119093 | Feb 21, 2024 | DS DP | | ODE-77 | Oct 15, 2021 |
| | | 7989474 | Apr 06, 2024 | U-1677 | | | |
| NINTEDANIB ESYLATE - OFEV | | | | | | | |
| N 205832 | 002 | 6762180 | Dec 10, 2020 | DS DP | | NCE | Oct 15, 2019 |
| | | 7119093 | Feb 21, 2024 | DS DP | | ODE-77 | Oct 15, 2021 |
| | | 7989474 | Apr 06, 2024 | U-1677 | | | |
| NIRAPARIB TOSYLATE - ZEJULA | | | | | | | |
| N 208447 | 001 | 8071623 | Mar 22, 2030 | DS DP | | NCE | Mar 27, 2022 |
| | | 8436185 | Apr 24, 2029 | DS | | ODE-133 | Mar 27, 2024 |
| NITAZOXANIDE - ALINIA | | | | | | | |
| N 021498 | 001 | 5965590 | Jul 03, 2017 | U-523 | | | |
| NITISINONE - ORFADIN | | | | | | | |
| N 021232 | 001 | | | | | D-169 | Sep 01, 2020 |
| NITISINONE - ORFADIN | | | | | | | |
| N 021232 | 002 | | | | | D-169 | Sep 01, 2020 |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| NITISINONE - ORFADIN | | | | | | |
| N 021232 003 | | | | | D-169 | Sep 01, 2020 |
| NITISINONE - ORFADIN | | | | | | |
| N 021232 004 | | | | | D-169 | Sep 01, 2020 |
| NITISINONE - ORFADIN | | | | | | |
| N 206356 001 | 9301932 | Feb 28, 2033 | DP U-1836 | | D-169 | Sep 01, 2020 |
| NITRIC OXIDE - INOMAX | | | | | | |
| N 020845 002 | 6125846*PED | Nov 16, 2017 | | | | |
| | 8282966 | Jun 30, 2029 | U-1286 | | | |
| | 8291904 | Jan 06, 2031 | DP U-1226 | | | |
| | 8293284 | Jun 30, 2029 | U-1286 | | | |
| | 8431163 | Jun 30, 2029 | U-1286 | | | |
| | 8431163*PED | Dec 30, 2029 | | | | |
| | 8573209 | Jan 06, 2031 | DP | | | |
| | 8573209*PED | Jul 06, 2031 | | | | |
| | 8573210 | Jan 06, 2031 | DP U-1453 | | | |
| | 8573210*PED | Jul 06, 2031 | | | | |
| | 8776794 | Jan 06, 2031 | DP U-1226 | | | |
| | 8776794*PED | Jul 06, 2031 | | | | |
| | 8776795 | Jan 06, 2031 | DP U-1226 | | | |
| | 8776795*PED | Jul 06, 2031 | | | | |
| | 8795741 | Jun 30, 2029 | U-1286 | | | |
| | 8795741*PED | Dec 30, 2029 | | | | |
| | 8846112 | Jun 30, 2029 | U-1286 | | | |
| | 8846112*PED | Dec 30, 2029 | | | | |
| NITRIC OXIDE - INOMAX | | | | | | |
| N 020845 003 | 6125846*PED | Nov 16, 2017 | | | M-167 | Oct 09, 2018 |
| | 8282966 | Jun 30, 2029 | U-1286 | | | |
| | 8291904 | Jan 06, 2031 | DP U-1226 | | | |
| | 8293284 | Jun 30, 2029 | U-1286 | | | |
| | 8431163 | Jun 30, 2029 | U-1286 | | | |
| | 8431163*PED | Dec 30, 2029 | | | | |
| | 8573209 | Jan 06, 2031 | DP | | | |
| | 8573209*PED | Jul 06, 2031 | | | | |
| | 8573210 | Jan 06, 2031 | DP U-1453 | | | |
| | 8573210*PED | Jul 06, 2031 | | | | |
| | 8776794 | Jan 06, 2031 | DP U-1226 | | | |
| | 8776794*PED | Jul 06, 2031 | | | | |
| | 8776795 | Jan 06, 2031 | DP U-1226 | | | |
| | 8776795*PED | Jul 06, 2031 | | | | |
| | 8795741 | Jun 30, 2029 | U-1286 | | | |
| | 8795741*PED | Dec 30, 2029 | | | | |
| | 8846112 | Jun 30, 2029 | U-1286 | | | |
| | 8846112*PED | Dec 30, 2029 | | | | |
| | 9265911 | Jan 06, 2031 | DP U-1824 | | | |
| | 9265911*PED | Jul 06, 2031 | | | | |
| | 9279794 | Feb 19, 2034 | DP U-1823 | | | |
| | 9279794*PED | Aug 19, 2034 | | | | |
| | 9295802 | Jan 06, 2031 | DP U-1226 | | | |
| | 9295802*PED | Jul 06, 2031 | | | | |
| | 9408993 | Jan 06, 2031 | DP U-1824 | | | |
| | 9408993*PED | Jul 06, 2031 | | | | |
| | 9770570 | May 03, 2036 | U-2148 | | | |
| | 9770570*PED | Nov 03, 2036 | | | | |
| NITROGLYCERIN - NITROLINGUAL PUMPSPRAY | | | | | | |
| N 018705 002 | 7872049 | Mar 14, 2028 | DP U-39 | | | |
| NITROGLYCERIN - NITROSTAT | | | | | | |
| N 021134 001 | 6500456 | Sep 16, 2018 | | | | |
| NITROGLYCERIN - NITROSTAT | | | | | | |
| N 021134 002 | 6500456 | Sep 16, 2018 | | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| NITROGLYCERIN - NITROSTAT | | | | | | | |
| N 021134 | 003 | 6500456 | Sep 16, 2018 | | | | |
| NITROGLYCERIN - GONITRO | | | | | | | |
| N 208424 | 001 | 9101592 | Mar 11, 2032 | DP | | | |
| NIZATIDINE - AXID | | | | | | | |
| N 021494 | 001 | 6930119 | Jul 17, 2022 | DP | | | |
| NUSINERSEN SODIUM - SPINRAZA | | | | | | | |
| N 209531 | 001 | 6166197 | Dec 26, 2017 | DS | | NCE | Dec 23, 2021 |
| | | 6210892 | Oct 07, 2018 | U-1942 | | ODE-127 | Dec 23, 2023 |
| | | 7101993 | Sep 05, 2023 | DS | | | |
| | | 7838657 | Jul 11, 2027 | DS | | | |
| | | 8110560 | Dec 05, 2025 | U-1942 | | | |
| | | 8110560 | Dec 05, 2025 | U-1943 | | | |
| | | 8110560 | Dec 05, 2025 | U-1944 | | | |
| | | 8361977 | May 27, 2030 | DS DP | | | |
| | | 8980853 | Nov 24, 2030 | U-1941 | | | |
| | | 9717750 | Jun 17, 2030 | U-1942 | | | |
| | | 9717750 | Jun 17, 2030 | U-1943 | | | |
| | | 9717750 | Jun 17, 2030 | U-2093 | | | |
| | | 9717750 | Jun 17, 2030 | U-2094 | | | |
| OBETICHOLIC ACID - OCALIVA | | | | | | | |
| N 207999 | 001 | 7138390 | Nov 16, 2022 | DS DP | | NCE | May 27, 2021 |
| | | 8058267 | Feb 21, 2022 | U-1854 | | ODE-119 | May 27, 2023 |
| | | 8377916 | Feb 21, 2022 | U-1854 | | | |
| | | 9238673 | Jun 17, 2033 | DP | | | |
| OBETICHOLIC ACID - OCALIVA | | | | | | | |
| N 207999 | 002 | 7138390 | Nov 16, 2022 | DS DP | | NCE | May 27, 2021 |
| | | 8058267 | Feb 21, 2022 | U-1854 | | ODE-119 | May 27, 2023 |
| | | 8377916 | Feb 21, 2022 | U-1854 | | | |
| | | 9238673 | Jun 17, 2033 | DP | | | |
| OLANZAPINE - ZYPREXA | | | | | | | |
| N 020592 | 001 | 6960577 | Nov 01, 2017 | U-963 | | | |
| OLANZAPINE - ZYPREXA | | | | | | | |
| N 020592 | 002 | 6960577 | Nov 01, 2017 | U-963 | | | |
| OLANZAPINE - ZYPREXA | | | | | | | |
| N 020592 | 003 | 6960577 | Nov 01, 2017 | U-963 | | | |
| OLANZAPINE - ZYPREXA | | | | | | | |
| N 020592 | 004 | 6960577 | Nov 01, 2017 | U-963 | | | |
| OLANZAPINE - ZYPREXA | | | | | | | |
| N 020592 | 005 | 6960577 | Nov 01, 2017 | U-963 | | | |
| OLANZAPINE - ZYPREXA | | | | | | | |
| N 020592 | 006 | 6960577 | Nov 01, 2017 | U-963 | | | |
| OLANZAPINE - ZYPREXA ZYDIS | | | | | | | |
| N 021086 | 001 | 6960577 | Nov 01, 2017 | U-964 | | | |
| OLANZAPINE - ZYPREXA ZYDIS | | | | | | | |
| N 021086 | 002 | 6960577 | Nov 01, 2017 | U-964 | | | |
| OLANZAPINE - ZYPREXA ZYDIS | | | | | | | |
| N 021086 | 003 | 6960577 | Nov 01, 2017 | U-964 | | | |
| OLANZAPINE - ZYPREXA ZYDIS | | | | | | | |
| N 021086 | 004 | 6960577 | Nov 01, 2017 | U-964 | | | |
| OLANZAPINE PAMOATE - ZYPREXA RELPREVV | | | | | | | |
| N 022173 | 001 | 6169084 | Sep 30, 2018 | DS DP U-1026 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| OLANZAPINE PAMOATE - ZYPREXA RELPREVV | | | | | | | |
| N 022173 | 002 | 6169084 | Sep 30, 2018 | DS DP U-1026 | | | |
| OLANZAPINE PAMOATE - ZYPREXA RELPREVV | | | | | | | |
| N 022173 | 003 | 6169084 | Sep 30, 2018 | DS DP U-1026 | | | |
| OLAPARIB - LYNPARZA | | | | | | | |
| N 206162 | 001 | 7151102 | Apr 29, 2022 | DS DP | | NCE | Dec 19, 2019 |
| | | 7449464 | Oct 11, 2024 | DS DP | | ODE-83 | Dec 19, 2021 |
| | | 7981889 | Oct 11, 2024 | DS DP | | | |
| | | 8143241 | Aug 12, 2027 | U-1634 | | | |
| | | 8247416 | Sep 24, 2028 | DS | | | |
| | | 8859562 | Aug 04, 2031 | U-1634 | | | |
| | | 8912187 | Mar 12, 2024 | U-1634 | | | |
| OLAPARIB - LYNPARZA | | | | | | | |
| N 208558 | 001 | 7151102 | Apr 29, 2022 | DS DP | | NCE | Dec 19, 2019 |
| | | 7449464 | Oct 11, 2024 | DS DP | | NP | Aug 17, 2020 |
| | | 7981889 | Oct 11, 2024 | DS DP | | ODE-83 | Dec 19, 2021 |
| | | 8143241 | Aug 12, 2027 | U-2101 | | | |
| | | 8143241 | Aug 12, 2027 | U-2102 | | | |
| | | 8143241 | Aug 12, 2027 | U-2103 | | | |
| | | 8475842 | Dec 31, 2029 | DP | | | |
| | | 8859562 | Aug 04, 2031 | U-2101 | | | |
| | | 8859562 | Aug 04, 2031 | U-2102 | | | |
| | | 8912187 | Mar 12, 2024 | U-2101 | | | |
| | | 8912187 | Mar 12, 2024 | U-2102 | | | |
| OLAPARIB - LYNPARZA | | | | | | | |
| N 208558 | 002 | 7151102 | Apr 29, 2022 | DS DP | | NCE | Dec 19, 2019 |
| | | 7449464 | Oct 11, 2024 | DS DP | | NP | Aug 17, 2020 |
| | | 7981889 | Oct 11, 2024 | DS DP | | ODE-83 | Dec 19, 2021 |
| | | 8143241 | Aug 12, 2027 | U-2101 | | | |
| | | 8143241 | Aug 12, 2027 | U-2102 | | | |
| | | 8143241 | Aug 12, 2027 | U-2103 | | | |
| | | 8475842 | Dec 31, 2029 | DP | | | |
| | | 8859562 | Aug 04, 2031 | U-2101 | | | |
| | | 8859562 | Aug 04, 2031 | U-2102 | | | |
| | | 8912187 | Mar 12, 2024 | U-2101 | | | |
| | | 8912187 | Mar 12, 2024 | U-2102 | | | |
| OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT | | | | | | | |
| N 203108 | 001 | 6846413 | Aug 28, 2018 | DP | | NCE | Jul 31, 2019 |
| | | 6977042 | Aug 28, 2018 | DP | | | |
| | | 6988496 | Feb 23, 2020 | DP U-1547 | | | |
| | | 7056916 | Dec 07, 2023 | DS DP | | | |
| | | 7220742 | May 12, 2025 | DS DP U-1547 | | | |
| | | 7284474 | Aug 26, 2024 | DP | | | |
| | | 7396341 | Oct 10, 2026 | DP U-1547 | | | |
| | | 7491719 | Nov 10, 2023 | DS DP | | | |
| | | 7727984 | Nov 10, 2023 | DS | | | |
| | | 7786111 | Nov 10, 2023 | DP | | | |
| | | 7802568 | Feb 26, 2019 | DP | | | |
| | | 7837235 | Mar 13, 2028 | DP | | | |
| | | 7896264 | May 26, 2025 | DP | | | |
| | | 7988001 | Aug 04, 2021 | DP | | | |
| | | 8034809 | May 12, 2025 | U-1547 | | | |
| | | 8044046 | Nov 10, 2023 | U-1547 | | | |
| | | 8733341 | Oct 16, 2030 | DP | | | |
| | | 9027967 | Mar 31, 2027 | DP | | | |
| OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT | | | | | | | |
| N 206756 | 001 | 6846413 | Aug 28, 2018 | DP | | M-173 | Mar 18, 2019 |
| | | 6846413*PED | Feb 28, 2019 | | | NC | May 21, 2018 |
| | | 6977042 | Aug 28, 2018 | DP | | NCE | Jul 31, 2019 |
| | | 6977042*PED | Feb 28, 2019 | | | | |
| | | 6988496 | Feb 23, 2020 | DP | | | |
| | | 6988496*PED | Aug 23, 2020 | | | | |
| | | 7056916 | Dec 07, 2023 | DS DP | | | |
| | | 7220742 | May 12, 2025 | DS DP U-1703 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT | | | | | | | |
| N 206756 | 001 | 7284474 | Aug 26, 2024 | DP | | | |
| | | 7284474*PED | Feb 26, 2025 | | | | |
| | | 7396341 | Oct 10, 2026 | DP | | | |
| | | 7396341*PED | Apr 10, 2027 | | | | |
| | | 7491719 | Nov 10, 2023 | DS DP | | | |
| | | 7727984 | Nov 10, 2023 | DS | | | |
| | | 7786111 | Nov 10, 2023 | DP | | | |
| | | 7802568 | Feb 26, 2019 | DP | | | |
| | | 7802568*PED | Aug 26, 2019 | | | | |
| | | 7837235 | Mar 13, 2028 | DP | | | |
| | | 7837235*PED | Sep 13, 2028 | | | | |
| | | 7896264 | May 26, 2025 | DP | | | |
| | | 7988001 | Aug 04, 2021 | DP | | | |
| | | 8034809 | May 12, 2025 | U-1702 | | | |
| | | 8044046 | Nov 10, 2023 | U-1702 | | | |
| | | 8733341 | Oct 16, 2030 | DP | | | |
| | | 9027967 | Mar 31, 2027 | DP | | | |
| | | RE39820 | Jan 30, 2018 | DS DP U-1702 | | | |
| OLOPATADINE HYDROCHLORIDE - OLOPATADINE HYDROCHLORIDE | | | | | | | |
| A 090848 | 001 | | | | | PC | Dec 05, 2017 |
| OLOPATADINE HYDROCHLORIDE - PATADAY | | | | | | | |
| N 021545 | 001 | 6995186 | Nov 12, 2023 | DP U-765 | | | |
| | | 7402609 | Jun 19, 2022 | DP | | | |
| OLOPATADINE HYDROCHLORIDE - PATANASE | | | | | | | |
| N 021861 | 001 | 7977376 | Feb 02, 2023 | DP | | | |
| | | 8399508 | Sep 17, 2022 | U-726 | | | |
| | | 8399508*PED | Mar 17, 2023 | | | | |
| OLOPATADINE HYDROCHLORIDE - PAZEO | | | | | | | |
| N 206276 | 001 | 8791154 | May 19, 2032 | DP U-1680 | | NP | Jan 30, 2018 |
| | | 9533053 | May 19, 2032 | DP | | PED | Jul 30, 2018 |
| OMACETAXINE MEPESUCCINATE - SYNRIBO | | | | | | | |
| N 203585 | 001 | 6987103 | Oct 26, 2026 | U-1300 | | NCE | Oct 26, 2017 |
| | | RE45128 | Mar 16, 2019 | DS DP U-1576 | | ODE-32 | Oct 26, 2019 |
| OMBITASVIR; PARITAPREVIR; RITONAVIR - TECHNIVIE | | | | | | | |
| N 207931 | 001 | 7148359 | Jul 19, 2019 | DP | | I-743 | Jul 24, 2018 |
| | | 7148359*PED | Jan 19, 2020 | | | NCE | Dec 19, 2019 |
| | | 7364752 | Nov 10, 2020 | DP | | NP | Jul 24, 2018 |
| | | 7364752*PED | May 10, 2021 | | | | |
| | | 8268349 | Aug 25, 2024 | DP | | | |
| | | 8268349*PED | Feb 25, 2025 | | | | |
| | | 8399015 | Aug 25, 2024 | DP | | | |
| | | 8399015*PED | Feb 25, 2025 | | | | |
| | | 8420596 | Apr 10, 2031 | DS DP | | | |
| | | 8420596*PED | Oct 10, 2031 | | | | |
| | | 8642538 | Sep 10, 2029 | DS DP U-1638 | | | |
| | | 8686026 | Jun 09, 2031 | DP | | | |
| | | 8691938 | Apr 13, 2032 | DS DP | | | |
| | | 9006387 | Jun 10, 2030 | U-1687 | | | |
| | | 9044480 | Apr 10, 2031 | U-1638 | | | |
| OMEGA-3-ACID ETHYL ESTERS TYPE A - OMTRYG | | | | | | | |
| N 204977 | 001 | | | | | NCE | Apr 23, 2019 |
| OMEGA-3-CARBOXYLIC ACIDS - EPANOVA | | | | | | | |
| N 205060 | 001 | 5792795 | May 13, 2018 | DP | | NCE | May 05, 2019 |
| | | 5948818 | May 13, 2018 | DP | | | |
| | | 7960370 | Feb 07, 2025 | DP | | | |
| | | 8383678 | Feb 07, 2025 | DP U-1511 | | | |
| | | 9012501 | Feb 07, 2025 | DP U-1511 | | | |
| | | 9050308 | Jan 04, 2033 | U-1511 | | | |
| | | 9050309 | Jan 04, 2033 | DS | | | |
| | | 9132112 | Feb 07, 2025 | DP U-1511 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|
| OMEPRAZOLE - PRILOSEC | | | | | | | | |
| N 019810 | 001 | | 6147103 | Oct 09, 2018 | | | | |
| | | | 6150380 | Nov 10, 2018 | | | | |
| | | | 6166213 | Oct 09, 2018 | | | | |
| | | | 6191148 | Oct 09, 2018 | | | | |
| OMEPRAZOLE - PRILOSEC | | | | | | | | |
| N 019810 | 002 | | 6147103 | Oct 09, 2018 | | | | |
| | | | 6150380 | Nov 10, 2018 | | | | |
| | | | 6166213 | Oct 09, 2018 | | | | |
| | | | 6191148 | Oct 09, 2018 | | | | |
| OMEPRAZOLE - PRILOSEC | | | | | | | | |
| N 019810 | 003 | | 6147103 | Oct 09, 2018 | | | | |
| | | | 6150380 | Nov 10, 2018 | | | | |
| | | | 6166213 | Oct 09, 2018 | | | | |
| | | | 6191148 | Oct 09, 2018 | | | | |
| OMEPRAZOLE - OMEPRAZOLE | | | | | | | | |
| N 022032 | 001 | | 9023391 | Aug 16, 2025 | DP | | | |
| OMEPRAZOLE MAGNESIUM - OMEPRAZOLE MAGNESIUM | | | | | | | | |
| A 204152 | 001 | | | | | | PC | May 30, 2018 |
| OMEPRAZOLE MAGNESIUM - PRILOSEC OTC | | | | | | | | |
| N 021229 | 001 | | 6403616 | Nov 15, 2019 | | | | |
| | | | 6428810 | Nov 03, 2019 | | | | |
| OMEPRAZOLE MAGNESIUM - PRILOSEC | | | | | | | | |
| N 022056 | 001 | | 6428810 | Nov 03, 2019 | DP U-1817 | | | |
| | | | 6428810 | Nov 03, 2019 | DP U-864 | | | |
| OMEPRAZOLE MAGNESIUM - PRILOSEC | | | | | | | | |
| N 022056 | 002 | | 6428810 | Nov 03, 2019 | DP U-864 | | | |
| ONDANSETRON - ZUPLENZ | | | | | | | | |
| N 022524 | 001 | | 8580830 | Nov 23, 2029 | DP | | | |
| | | | 9095577 | Jul 13, 2030 | DP | | | |
| ONDANSETRON - ZUPLENZ | | | | | | | | |
| N 022524 | 002 | | 8580830 | Nov 23, 2029 | DP | | | |
| | | | 9095577 | Jul 13, 2030 | DP | | | |
| ORITAVANCIN DIPHOSPHATE - ORBACTIV | | | | | | | | |
| N 206334 | 001 | | 5840684 | Nov 24, 2017 | DS DP U-1569 | | NCE | Aug 06, 2019 |
| | | | 5998581 | Nov 12, 2017 | DS | | GAIN | Aug 06, 2024 |
| | | | 8420592 | Aug 29, 2029 | U-1570 | | | |
| | | | 9649352 | Jul 16, 2035 | DP | | | |
| | | | 9682061 | Apr 26, 2030 | U-1569 | | | |
| ORLISTAT - XENICAL | | | | | | | | |
| N 020766 | 001 | | 6004996 | Jan 06, 2018 | | | | |
| ORLISTAT - ALLI | | | | | | | | |
| N 021887 | 001 | | 6004996 | Jan 06, 2018 | DP | | | |
| OSIMERTINIB MESYLATE - TAGRISSO | | | | | | | | |
| N 208065 | 001 | | 8946235 | Aug 08, 2032 | DS DP U-1777 | | NCE | Nov 13, 2020 |
| | | | 9732058 | Jul 25, 2032 | DS DP U-1777 | | ODE-102 | Nov 13, 2022 |
| OSIMERTINIB MESYLATE - TAGRISSO | | | | | | | | |
| N 208065 | 002 | | 8946235 | Aug 08, 2032 | DS DP U-1777 | | NCE | Nov 13, 2020 |
| | | | 9732058 | Jul 25, 2032 | DS DP U-1777 | | ODE-102 | Nov 13, 2022 |
| OSPEMIFENE - OSPHENA | | | | | | | | |
| N 203505 | 001 | | 6245819 | Jul 21, 2025 | U-1370 | | NCE | Feb 26, 2018 |
| | | | 8236861 | Aug 11, 2026 | U-1369 | | | |
| | | | 8236861 | Aug 11, 2026 | U-1370 | | | |
| | | | 8470890 | Feb 13, 2024 | U-1369 | | | |
| | | | 8470890 | Feb 13, 2024 | U-1370 | | | |
| | | | 8642079 | Jul 09, 2028 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| OSPEMIFENE - OSPHENA | | | | | | | |
| N 203505 | 001 | 8772353 | Feb 13, 2024 | U-1369 | | | |
| | | 8772353 | Feb 13, 2024 | U-1370 | | | |
| | | 9241915 | Feb 13, 2024 | U-1369 | | | |
| | | 9241915 | Feb 13, 2024 | U-1370 | | | |
| | | 9566252 | Jul 21, 2020 | U-1370 | | | |
| OXANDROLONE - OXANDRIN | | | | | | | |
| N 013718 | 001 | 5872147 | Dec 05, 2017 | U-585 | | | |
| | | 6090799 | Jul 18, 2017 | U-585 | | | |
| | | 6576659 | Dec 05, 2017 | U-585 | | | |
| | | 6828313 | Dec 05, 2017 | U-585 | | | |
| OXANDROLONE - OXANDRIN | | | | | | | |
| N 013718 | 002 | 5872147 | Dec 05, 2017 | U-585 | | | |
| | | 6090799 | Jul 18, 2017 | U-585 | | | |
| | | 6576659 | Dec 05, 2017 | U-585 | | | |
| | | 6828313 | Dec 05, 2017 | U-585 | | | |
| OXCARBAZEPINE - TRILEPTAL | | | | | | | |
| N 021014 | 001 | 7037525 | Feb 12, 2018 | U-724 | | | |
| OXCARBAZEPINE - TRILEPTAL | | | | | | | |
| N 021014 | 002 | 7037525 | Feb 12, 2018 | U-724 | | | |
| OXCARBAZEPINE - TRILEPTAL | | | | | | | |
| N 021014 | 003 | 7037525 | Feb 12, 2018 | U-724 | | | |
| OXCARBAZEPINE - TRILEPTAL | | | | | | | |
| N 021285 | 001 | 7037525 | Feb 12, 2018 | U-724 | | | |
| | | 8119148 | Dec 19, 2020 | DP U-724 | | | |
| OXCARBAZEPINE - OXTELLAR XR | | | | | | | |
| N 202810 | 001 | 7722898 | Apr 13, 2027 | DP | | | |
| | | 7910131 | Apr 13, 2027 | U-1298 | | | |
| | | 8617600 | Apr 13, 2027 | DP | | | |
| | | 8821930 | Apr 13, 2027 | DP | | | |
| | | 9119791 | Apr 13, 2027 | U-1298 | | | |
| | | 9351975 | Apr 13, 2027 | DP | | | |
| | | 9370525 | Apr 13, 2027 | DP | | | |
| | | 9855278 | Apr 13, 2027 | DP | | | |
| OXCARBAZEPINE - OXTELLAR XR | | | | | | | |
| N 202810 | 002 | 7722898 | Apr 13, 2027 | DP | | | |
| | | 7910131 | Apr 13, 2027 | U-1298 | | | |
| | | 8617600 | Apr 13, 2027 | DP | | | |
| | | 8821930 | Apr 13, 2027 | DP | | | |
| | | 9119791 | Apr 13, 2027 | U-1298 | | | |
| | | 9351975 | Apr 13, 2027 | DP | | | |
| | | 9370525 | Apr 13, 2027 | DP | | | |
| | | 9855278 | Apr 13, 2027 | DP | | | |
| OXCARBAZEPINE - OXTELLAR XR | | | | | | | |
| N 202810 | 003 | 7722898 | Apr 13, 2027 | DP | | | |
| | | 7910131 | Apr 13, 2027 | U-1298 | | | |
| | | 8617600 | Apr 13, 2027 | DP | | | |
| | | 8821930 | Apr 13, 2027 | DP | | | |
| | | 9119791 | Apr 13, 2027 | U-1298 | | | |
| | | 9351975 | Apr 13, 2027 | DP | | | |
| | | 9370525 | Apr 13, 2027 | DP | | | |
| | | 9855278 | Apr 13, 2027 | DP | | | |
| OXYBUTYNIN - OXYTROL | | | | | | | |
| N 021351 | 002 | 6743441 | Apr 26, 2020 | DP U-318 | | | |
| | | 7081249 | Apr 26, 2020 | DP U-318 | | | |
| | | 7081250 | Apr 26, 2020 | DP U-318 | | | |
| | | 7081251 | Apr 26, 2020 | DP U-318 | | | |
| | | 7081252 | Apr 26, 2020 | DP U-318 | | | |
| | | 7179483 | Apr 26, 2020 | DS DP U-318 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| OXYBUTYNIN - OXYTROL FOR WOMEN | | | | | | | |
| N 202211 | 001 | 6743441 | Apr 26, 2020 | DP U-1329 | | | |
| | | 7081249 | Apr 26, 2020 | DP U-1329 | | | |
| | | 7081250 | Apr 26, 2020 | DP U-1329 | | | |
| | | 7081251 | Apr 26, 2020 | DP U-1329 | | | |
| | | 7081252 | Apr 26, 2020 | DP U-1329 | | | |
| | | 7179483 | Apr 26, 2020 | U-1329 | | | |
| OXYBUTYNIN - GELNIQUE 3% | | | | | | | |
| N 202513 | 001 | 7029694 | Apr 26, 2020 | DP U-318 | | | |
| | | 7179483 | Apr 26, 2020 | U-318 | | | |
| | | 7198801 | Jun 25, 2022 | DP | | | |
| | | 8241662 | Apr 26, 2020 | U-318 | | | |
| OXYBUTYNIN CHLORIDE - GELNIQUE | | | | | | | |
| N 022204 | 001 | 7029694 | Apr 26, 2020 | DP U-318 | | | |
| | | 7179483 | Apr 26, 2020 | U-318 | | | |
| | | 8241662 | Apr 26, 2020 | U-318 | | | |
| | | 8920392 | Mar 26, 2031 | U-1644 | | | |
| | | 9259388 | Nov 06, 2029 | U-1644 | | | |
| OXYCODONE - XTAMPZA ER | | | | | | | |
| N 208090 | 001 | 7399488 | Mar 24, 2025 | DP | | NP | Apr 26, 2019 |
| | | 7771707 | Mar 24, 2025 | DP | | | |
| | | 8449909 | Mar 24, 2025 | DP | | | |
| | | 8557291 | Mar 21, 2025 | DP | | | |
| | | 8758813 | Jun 10, 2025 | U-1556 | | | |
| | | 8840928 | Jul 07, 2023 | DP U-1556 | | | |
| | | 9044398 | Jul 07, 2023 | DP | | | |
| | | 9248195 | Jul 07, 2023 | U-1556 | | | |
| | | 9592200 | Jul 07, 2023 | DP | | | |
| | | 9682075 | Dec 10, 2030 | DP U-1556 | | | |
| | | 9737530 | Sep 02, 2036 | DP U-1556 | | | |
| | | 9763883 | Jul 07, 2023 | DP | | | |
| OXYCODONE - XTAMPZA ER | | | | | | | |
| N 208090 | 002 | 7399488 | Mar 24, 2025 | DP | | NP | Apr 26, 2019 |
| | | 7771707 | Mar 24, 2025 | DP | | | |
| | | 8449909 | Mar 24, 2025 | DP | | | |
| | | 8557291 | Mar 21, 2025 | DP | | | |
| | | 8758813 | Jun 10, 2025 | U-1556 | | | |
| | | 8840928 | Jul 07, 2023 | DP U-1556 | | | |
| | | 9044398 | Jul 07, 2023 | DP | | | |
| | | 9248195 | Jul 07, 2023 | U-1556 | | | |
| | | 9592200 | Jul 07, 2023 | DP | | | |
| | | 9682075 | Dec 10, 2030 | DP U-1556 | | | |
| | | 9737530 | Sep 02, 2036 | DP U-1556 | | | |
| | | 9763883 | Jul 07, 2023 | DP | | | |
| OXYCODONE - XTAMPZA ER | | | | | | | |
| N 208090 | 003 | 7399488 | Mar 24, 2025 | DP | | NP | Apr 26, 2019 |
| | | 7771707 | Mar 24, 2025 | DP | | | |
| | | 8449909 | Mar 24, 2025 | DP | | | |
| | | 8557291 | Mar 21, 2025 | DP | | | |
| | | 8758813 | Jun 10, 2025 | U-1556 | | | |
| | | 8840928 | Jul 07, 2023 | DP U-1556 | | | |
| | | 9044398 | Jul 07, 2023 | DP | | | |
| | | 9248195 | Jul 07, 2023 | U-1556 | | | |
| | | 9592200 | Jul 07, 2023 | DP | | | |
| | | 9682075 | Dec 10, 2030 | DP U-1556 | | | |
| | | 9737530 | Sep 02, 2036 | DP U-1556 | | | |
| | | 9763883 | Jul 07, 2023 | DP | | | |
| OXYCODONE - XTAMPZA ER | | | | | | | |
| N 208090 | 004 | 7399488 | Mar 24, 2025 | DP | | NP | Apr 26, 2019 |
| | | 7771707 | Mar 24, 2025 | DP | | | |
| | | 8449909 | Mar 24, 2025 | DP | | | |
| | | 8557291 | Mar 21, 2025 | DP | | | |
| | | 8758813 | Jun 10, 2025 | U-1556 | | | |
| | | 8840928 | Jul 07, 2023 | DP U-1556 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| OXYCODONE - XTAMPZA ER | | | | | | | |
| N 208090 | 004 | 9044398 | Jul 07, 2023 | DP | | | |
| | | 9248195 | Jul 07, 2023 | U-1556 | | | |
| | | 9592200 | Jul 07, 2023 | DP | | | |
| | | 9682075 | Dec 10, 2030 | DP U-1556 | | | |
| | | 9737530 | Sep 02, 2036 | DP U-1556 | | | |
| | | 9763883 | Jul 07, 2023 | DP | | | |
| OXYCODONE - XTAMPZA ER | | | | | | | |
| N 208090 | 005 | 7399488 | Mar 24, 2025 | DP | | NP | Apr 26, 2019 |
| | | 7771707 | Mar 24, 2025 | DP | | | |
| | | 8449909 | Mar 24, 2025 | DP | | | |
| | | 8557291 | Mar 21, 2025 | DP | | | |
| | | 8758813 | Jun 10, 2025 | U-1556 | | | |
| | | 8840928 | Jul 07, 2023 | DP U-1556 | | | |
| | | 9044398 | Jul 07, 2023 | DP | | | |
| | | 9248195 | Jul 07, 2023 | U-1556 | | | |
| | | 9592200 | Jul 07, 2023 | DP | | | |
| | | 9682075 | Dec 10, 2030 | DP U-1556 | | | |
| | | 9737530 | Sep 02, 2036 | DP U-1556 | | | |
| | | 9763883 | Jul 07, 2023 | DP | | | |
| OXYCODONE HYDROCHLORIDE - OXYCONTIN | | | | | | | |
| N 022272 | 001 | 7674799 | Mar 30, 2025 | DP | Y | NPP | Aug 13, 2018 |
| | | 7674800 | Mar 30, 2025 | DS | Y | | |
| | | 7683072 | Mar 30, 2025 | DS | Y | | |
| | | 7776314 | Apr 19, 2025 | DP | Y | | |
| | | 8309060 | Nov 20, 2023 | DP U-1556 | | | |
| | | 8808741 | Aug 24, 2027 | U-1556 | | | |
| | | 8894987 | Mar 29, 2030 | DP | | | |
| | | 8894988 | Aug 24, 2027 | DP | | | |
| | | 9060976 | Aug 06, 2022 | DP | | | |
| | | 9073933 | Mar 30, 2025 | DS | | | |
| | | 9492389 | Aug 24, 2027 | DP | | | |
| | | 9492391 | Aug 24, 2027 | U-1556 | | | |
| | | 9492392 | Aug 24, 2027 | DP | | | |
| | | 9492393 | Aug 24, 2027 | U-1556 | | | |
| | | 9522919 | Mar 30, 2025 | DS DP | | | |
| | | 9675610 | Jun 16, 2023 | DP | | | |
| | | 9763933 | Aug 24, 2027 | DP | | | |
| | | 9770416 | Aug 24, 2027 | DP | | | |
| | | 9775808 | Aug 24, 2027 | DP | | | |
| OXYCODONE HYDROCHLORIDE - OXYCONTIN | | | | | | | |
| N 022272 | 002 | 7674799 | Mar 30, 2025 | DP | Y | NPP | Aug 13, 2018 |
| | | 7674800 | Mar 30, 2025 | DS | Y | | |
| | | 7683072 | Mar 30, 2025 | DS | Y | | |
| | | 7776314 | Apr 19, 2025 | DP | Y | | |
| | | 8309060 | Nov 20, 2023 | DP U-1556 | | | |
| | | 8808741 | Aug 24, 2027 | U-1556 | | | |
| | | 8894987 | Mar 29, 2030 | DP | | | |
| | | 8894988 | Aug 24, 2027 | DP | | | |
| | | 9060976 | Aug 06, 2022 | DP | | | |
| | | 9073933 | Mar 30, 2025 | DS | | | |
| | | 9492389 | Aug 24, 2027 | DP | | | |
| | | 9492391 | Aug 24, 2027 | U-1556 | | | |
| | | 9492392 | Aug 24, 2027 | DP | | | |
| | | 9492393 | Aug 24, 2027 | U-1556 | | | |
| | | 9522919 | Mar 30, 2025 | DS DP | | | |
| | | 9675610 | Jun 16, 2023 | DP | | | |
| | | 9763933 | Aug 24, 2027 | DP | | | |
| | | 9770416 | Aug 24, 2027 | DP | | | |
| | | 9775808 | Aug 24, 2027 | DP | | | |
| OXYCODONE HYDROCHLORIDE - OXYCONTIN | | | | | | | |
| N 022272 | 003 | 7674799 | Mar 30, 2025 | DP | Y | NPP | Aug 13, 2018 |
| | | 7674800 | Mar 30, 2025 | DS | Y | | |
| | | 7683072 | Mar 30, 2025 | DS | Y | | |
| | | 7776314 | Apr 19, 2025 | DP | Y | | |
| | | 8309060 | Nov 20, 2023 | DP U-1556 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| OXYCODONE HYDROCHLORIDE - OXYCONTIN | | | | | | | |
| N 022272 | 003 | 8808741 | Aug 24, 2027 | U-1556 | | | |
| | | 8894987 | Mar 29, 2030 | DP | | | |
| | | 8894988 | Aug 24, 2027 | DP | | | |
| | | 9060976 | Aug 06, 2022 | DP | | | |
| | | 9073933 | Mar 30, 2025 | DS | | | |
| | | 9492389 | Aug 24, 2027 | DP | | | |
| | | 9492391 | Aug 24, 2027 | U-1556 | | | |
| | | 9492392 | Aug 24, 2027 | DP | | | |
| | | 9492393 | Aug 24, 2027 | U-1556 | | | |
| | | 9522919 | Mar 30, 2025 | DS DP | | | |
| | | 9675610 | Jun 16, 2023 | DP | | | |
| | | 9763933 | Aug 24, 2027 | DP | | | |
| | | 9770416 | Aug 24, 2027 | DP | | | |
| | | 9775808 | Aug 24, 2027 | DP | | | |
| OXYCODONE HYDROCHLORIDE - OXYCONTIN | | | | | | | |
| N 022272 | 004 | 8309060 | Nov 20, 2023 | DP U-1556 | | NPP | Aug 13, 2018 |
| | | 8808741 | Aug 24, 2027 | U-1556 | | | |
| | | 8894987 | Mar 29, 2030 | DP | | | |
| | | 8894988 | Aug 24, 2027 | DP | | | |
| | | 9060976 | Aug 06, 2022 | DP | | | |
| | | 9073933 | Mar 30, 2025 | DS | | | |
| | | 9492389 | Aug 24, 2027 | DP | | | |
| | | 9492391 | Aug 24, 2027 | U-1556 | | | |
| | | 9492392 | Aug 24, 2027 | DP | | | |
| | | 9492393 | Aug 24, 2027 | U-1556 | | | |
| | | 9522919 | Mar 30, 2025 | DS DP | | | |
| | | 9675610 | Jun 16, 2023 | DP | | | |
| | | 9763933 | Aug 24, 2027 | DP | | | |
| | | 9770416 | Aug 24, 2027 | DP | | | |
| | | 9775808 | Aug 24, 2027 | DP | | | |
| OXYCODONE HYDROCHLORIDE - OXYCONTIN | | | | | | | |
| N 022272 | 005 | 7674799 | Mar 30, 2025 | DP | Y | NPP | Aug 13, 2018 |
| | | 7674800 | Mar 30, 2025 | DS | Y | | |
| | | 7683072 | Mar 30, 2025 | DS | Y | | |
| | | 7776314 | Apr 19, 2025 | DP | Y | | |
| | | 8309060 | Nov 20, 2023 | DP U-1556 | | | |
| | | 8808741 | Aug 24, 2027 | U-1556 | | | |
| | | 8894988 | Aug 24, 2027 | DP | | | |
| | | 9060976 | Aug 06, 2022 | DP | | | |
| | | 9073933 | Mar 30, 2025 | DS | | | |
| | | 9492389 | Aug 24, 2027 | DP | | | |
| | | 9492391 | Aug 24, 2027 | U-1556 | | | |
| | | 9492392 | Aug 24, 2027 | DP | | | |
| | | 9492393 | Aug 24, 2027 | U-1556 | | | |
| | | 9522919 | Mar 30, 2025 | DS DP | | | |
| | | 9675610 | Jun 16, 2023 | DP | | | |
| | | 9763933 | Aug 24, 2027 | DP | | | |
| | | 9770416 | Aug 24, 2027 | DP | | | |
| | | 9775808 | Aug 24, 2027 | DP | | | |
| OXYCODONE HYDROCHLORIDE - OXYCONTIN | | | | | | | |
| N 022272 | 006 | 8309060 | Nov 20, 2023 | DP U-1556 | | NPP | Aug 13, 2018 |
| | | 8808741 | Aug 24, 2027 | U-1556 | | | |
| | | 8894988 | Aug 24, 2027 | DP | | | |
| | | 9060976 | Aug 06, 2022 | DP | | | |
| | | 9073933 | Mar 30, 2025 | DS | | | |
| | | 9492389 | Aug 24, 2027 | DP | | | |
| | | 9492391 | Aug 24, 2027 | U-1556 | | | |
| | | 9492392 | Aug 24, 2027 | DP | | | |
| | | 9492393 | Aug 24, 2027 | U-1556 | | | |
| | | 9522919 | Mar 30, 2025 | DS DP | | | |
| | | 9675610 | Jun 16, 2023 | DP | | | |
| | | 9763933 | Aug 24, 2027 | DP | | | |
| | | 9770416 | Aug 24, 2027 | DP | | | |
| | | 9775808 | Aug 24, 2027 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| OXYCODONE HYDROCHLORIDE - OXYCONTIN | | | | | | | |
| N 022272 | 007 | 8309060 | Nov 20, 2023 | DP U-1556 | | NPP | Aug 13, 2018 |
| | | 8808741 | Aug 24, 2027 | U-1556 | | | |
| | | 8894988 | Aug 24, 2027 | DP | | | |
| | | 9060976 | Aug 06, 2022 | DP | | | |
| | | 9073933 | Mar 30, 2025 | DS | | | |
| | | 9492389 | Aug 24, 2027 | DP | | | |
| | | 9492391 | Aug 24, 2027 | U-1556 | | | |
| | | 9492392 | Aug 24, 2027 | DP | | | |
| | | 9492393 | Aug 24, 2027 | U-1556 | | | |
| | | 9522919 | Mar 30, 2025 | DS DP | | | |
| | | 9675610 | Jun 16, 2023 | DP | | | |
| | | 9763933 | Aug 24, 2027 | DP | | | |
| | | 9770416 | Aug 24, 2027 | DP | | | |
| | | 9775808 | Aug 24, 2027 | DP | | | |
| OXYCODONE HYDROCHLORIDE - OXAYDO | | | | | | | |
| N 202080 | 001 | 7201920 | Mar 16, 2025 | DP | | | |
| | | 7510726 | Nov 26, 2023 | DP | | | |
| | | 7981439 | Nov 26, 2023 | DP | | | |
| | | 8409616 | Nov 26, 2023 | DP | | | |
| | | 8637540 | Nov 26, 2023 | DP | | | |
| | | 9492443 | May 26, 2024 | DP | | | |
| OXYCODONE HYDROCHLORIDE - OXAYDO | | | | | | | |
| N 202080 | 002 | 7201920 | Mar 16, 2025 | DP | | | |
| | | 7510726 | Nov 26, 2023 | DP | | | |
| | | 7981439 | Nov 26, 2023 | DP | | | |
| | | 8409616 | Nov 26, 2023 | DP | | | |
| | | 8637540 | Nov 26, 2023 | DP | | | |
| | | 9492443 | May 26, 2024 | DP | | | |
| OXYCODONE HYDROCHLORIDE - ROXYBOND | | | | | | | |
| N 209777 | 001 | 7955619 | Aug 12, 2028 | DP | | | |
| OXYCODONE HYDROCHLORIDE - ROXYBOND | | | | | | | |
| N 209777 | 002 | 7955619 | Aug 12, 2028 | DP | | | |
| OXYCODONE HYDROCHLORIDE - ROXYBOND | | | | | | | |
| N 209777 | 003 | 7955619 | Aug 12, 2028 | DP | | | |
| OXYMETAZOLINE HYDROCHLORIDE - RHOFADE | | | | | | | |
| N 208552 | 001 | 7812049 | May 02, 2028 | U-1959 | | NP | Jan 18, 2020 |
| | | 8420688 | Aug 02, 2024 | U-1959 | | | |
| | | 8883838 | Dec 01, 2031 | DP | | | |
| OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE - KOVANAZE | | | | | | | |
| N 208032 | 001 | 6413499 | Mar 20, 2020 | U-1876 | | NC | Jun 29, 2019 |
| | | 8580282 | Apr 02, 2030 | DP U-1876 | | | |
| | | 9308191 | Apr 02, 2030 | DP U-1876 | | | |
| OXYMORPHONE HYDROCHLORIDE - OPANA ER | | | | | | | |
| N 021610 | 001 | 7276250 | Feb 04, 2023 | DP U-826 | | | |
| OXYMORPHONE HYDROCHLORIDE - OPANA ER | | | | | | | |
| N 021610 | 002 | 7276250 | Feb 04, 2023 | DP U-826 | | | |
| OXYMORPHONE HYDROCHLORIDE - OPANA ER | | | | | | | |
| N 021610 | 003 | 7276250 | Feb 04, 2023 | DP U-826 | | | |
| OXYMORPHONE HYDROCHLORIDE - OPANA ER | | | | | | | |
| N 021610 | 004 | 7276250 | Feb 04, 2023 | DP U-826 | | | |
| OXYMORPHONE HYDROCHLORIDE - OPANA ER | | | | | | | |
| N 021610 | 005 | 7276250 | Feb 04, 2023 | DP U-826 | | | |
| OXYMORPHONE HYDROCHLORIDE - OPANA ER | | | | | | | |
| N 021610 | 006 | 7276250 | Feb 04, 2023 | DP U-826 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|
| OXYMORPHONE HYDROCHLORIDE - OPANA ER | | | | | | | | |
| N | 021610 | 007 | 7276250 | Feb 04, 2023 | DP | | U-826 | |
| OXYMORPHONE HYDROCHLORIDE - OPANA ER | | | | | | | | |
| N | 201655 | 001 | 7851482 | Jul 10, 2029 | DS | | | |
| | | | 8075872 | Nov 20, 2023 | DP | | | |
| | | | 8114383 | Aug 08, 2024 | DP | | | |
| | | | 8192722 | Sep 15, 2025 | DP | | | |
| | | | 8309060 | Nov 20, 2023 | DP | | | |
| | | | 8309122 | Feb 04, 2023 | DP | | | |
| | | | 8329216 | Feb 04, 2023 | DP | | | |
| | | | 8808737 | Jun 21, 2027 | | | U-1598 | |
| | | | 8871779 | Nov 22, 2029 | DS | | | |
| OXYMORPHONE HYDROCHLORIDE - OPANA ER | | | | | | | | |
| N | 201655 | 002 | 7851482 | Jul 10, 2029 | DS | | | |
| | | | 8075872 | Nov 20, 2023 | DP | | | |
| | | | 8114383 | Aug 08, 2024 | DP | | | |
| | | | 8192722 | Sep 15, 2025 | DP | | | |
| | | | 8309060 | Nov 20, 2023 | DP | | | |
| | | | 8309122 | Feb 04, 2023 | DP | | | |
| | | | 8329216 | Feb 04, 2023 | DP | | | |
| | | | 8808737 | Jun 21, 2027 | | | U-1598 | |
| | | | 8871779 | Nov 22, 2029 | DS | | | |
| OXYMORPHONE HYDROCHLORIDE - OPANA ER | | | | | | | | |
| N | 201655 | 003 | 7851482 | Jul 10, 2029 | DS | | | |
| | | | 8075872 | Nov 20, 2023 | DP | | | |
| | | | 8114383 | Aug 08, 2024 | DP | | | |
| | | | 8192722 | Sep 15, 2025 | DP | | | |
| | | | 8309060 | Nov 20, 2023 | DP | | | |
| | | | 8309122 | Feb 04, 2023 | DP | | | |
| | | | 8329216 | Feb 04, 2023 | DP | | | |
| | | | 8808737 | Jun 21, 2027 | | | U-1598 | |
| | | | 8871779 | Nov 22, 2029 | DS | | | |
| OXYMORPHONE HYDROCHLORIDE - OPANA ER | | | | | | | | |
| N | 201655 | 004 | 7851482 | Jul 10, 2029 | DS | | | |
| | | | 8075872 | Nov 20, 2023 | DP | | | |
| | | | 8114383 | Aug 08, 2024 | DP | | | |
| | | | 8192722 | Sep 15, 2025 | DP | | | |
| | | | 8309060 | Nov 20, 2023 | DP | | | |
| | | | 8309122 | Feb 04, 2023 | DP | | | |
| | | | 8329216 | Feb 04, 2023 | DP | | | |
| | | | 8808737 | Jun 21, 2027 | | | U-1598 | |
| | | | 8871779 | Nov 22, 2029 | DS | | | |
| OXYMORPHONE HYDROCHLORIDE - OPANA ER | | | | | | | | |
| N | 201655 | 005 | 7851482 | Jul 10, 2029 | DS | | | |
| | | | 8075872 | Nov 20, 2023 | DP | | | |
| | | | 8114383 | Aug 08, 2024 | DP | | | |
| | | | 8192722 | Sep 15, 2025 | DP | | | |
| | | | 8309060 | Nov 20, 2023 | DP | | | |
| | | | 8309122 | Feb 04, 2023 | DP | | | |
| | | | 8329216 | Feb 04, 2023 | DP | | | |
| | | | 8808737 | Jun 21, 2027 | | | U-1598 | |
| | | | 8871779 | Nov 22, 2029 | DS | | | |
| OXYMORPHONE HYDROCHLORIDE - OPANA ER | | | | | | | | |
| N | 201655 | 006 | 7851482 | Jul 10, 2029 | DS | | | |
| | | | 8075872 | Nov 20, 2023 | DP | | | |
| | | | 8114383 | Aug 08, 2024 | DP | | | |
| | | | 8192722 | Sep 15, 2025 | DP | | | |
| | | | 8309060 | Nov 20, 2023 | DP | | | |
| | | | 8309122 | Feb 04, 2023 | DP | | | |
| | | | 8329216 | Feb 04, 2023 | DP | | | |
| | | | 8808737 | Jun 21, 2027 | | | U-1598 | |
| | | | 8871779 | Nov 22, 2029 | DS | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| OXYMORPHONE HYDROCHLORIDE - OPANA ER | | | | | | | |
| N 201655 | 007 | 7851482 | Jul 10, 2029 | DS | | | |
| | | 8075872 | Nov 20, 2023 | DP | | | |
| | | 8114383 | Aug 08, 2024 | DP | | | |
| | | 8192722 | Sep 15, 2025 | DP | | | |
| | | 8309060 | Nov 20, 2023 | DP | | | |
| | | 8309122 | Feb 04, 2023 | DP | | | |
| | | 8329216 | Feb 04, 2023 | DP | | | |
| | | 8808737 | Jun 21, 2027 | U-1598 | | | |
| | | 8871779 | Nov 22, 2029 | DS | | | |
| OZENOXACIN - XEPI | | | | | | | |
| N 208945 | 001 | | | | | NCE | Dec 11, 2022 |
| PACLITAXEL - ABRAXANE | | | | | | | |
| N 021660 | 001 | 7758891 | Feb 21, 2026 | U-1434 | | ODE-52 | Sep 06, 2020 |
| | | 7820788 | Oct 27, 2024 | DP U-1092 | | | |
| | | 7820788 | Oct 27, 2024 | DP U-1290 | | | |
| | | 7820788 | Oct 27, 2024 | DP U-1434 | | | |
| | | 7923536 | Dec 09, 2023 | U-1117 | | | |
| | | 7923536 | Dec 09, 2023 | U-1290 | | | |
| | | 7923536 | Dec 09, 2023 | U-1434 | | | |
| | | 8034375 | Aug 13, 2026 | U-1290 | | | |
| | | 8138229 | Dec 09, 2023 | DP U-1092 | | | |
| | | 8138229 | Dec 09, 2023 | DP U-1290 | | | |
| | | 8138229 | Dec 09, 2023 | DP U-1434 | | | |
| | | 8268348 | Feb 21, 2026 | U-1290 | | | |
| | | 8314156 | Dec 09, 2023 | U-1290 | | | |
| | | 8314156 | Dec 09, 2023 | U-1434 | | | |
| | | 8853260 | Oct 10, 2020 | DP U-1092 | | | |
| | | 8853260 | Oct 10, 2020 | DP U-1290 | | | |
| | | 8853260 | Oct 10, 2020 | DP U-1434 | | | |
| | | 9101543 | Feb 21, 2026 | U-1434 | | | |
| | | 9393318 | Mar 04, 2032 | U-1290 | | | |
| | | 9511046 | Jan 12, 2034 | U-1434 | | | |
| | | 9597409 | Mar 04, 2032 | U-1290 | | | |
| PALBOCICLIB - IBRANCE | | | | | | | |
| N 207103 | 001 | 6936612 | Jan 22, 2023 | DS DP | | I-725 | Feb 19, 2019 |
| | | 7208489 | Jan 16, 2023 | DS DP | | NCE | Feb 03, 2020 |
| | | 7456168 | Jan 16, 2023 | U-1998 | | | |
| PALBOCICLIB - IBRANCE | | | | | | | |
| N 207103 | 002 | 6936612 | Jan 22, 2023 | DS DP | | I-725 | Feb 19, 2019 |
| | | 7208489 | Jan 16, 2023 | DS DP | | NCE | Feb 03, 2020 |
| | | 7456168 | Jan 16, 2023 | U-1998 | | | |
| PALBOCICLIB - IBRANCE | | | | | | | |
| N 207103 | 003 | 6936612 | Jan 22, 2023 | DS DP | | I-725 | Feb 19, 2019 |
| | | 7208489 | Jan 16, 2023 | DS DP | | NCE | Feb 03, 2020 |
| | | 7456168 | Jan 16, 2023 | U-1998 | | | |
| PALIPERIDONE PALMITATE - INVEGA SUSTENNA | | | | | | | |
| N 022264 | 001 | 6555544 | Nov 10, 2018 | DP U-543 | | I-698 | Nov 12, 2017 |
| | | 9439906 | Jan 26, 2031 | U-1901 | | M-215 | Dec 20, 2020 |
| | | 9439906 | Jan 26, 2031 | U-543 | | | |
| PALIPERIDONE PALMITATE - INVEGA SUSTENNA | | | | | | | |
| N 022264 | 002 | 6555544 | Nov 10, 2018 | DP U-543 | | I-698 | Nov 12, 2017 |
| | | 9439906 | Jan 26, 2031 | U-1901 | | M-215 | Dec 20, 2020 |
| | | 9439906 | Jan 26, 2031 | U-543 | | | |
| PALIPERIDONE PALMITATE - INVEGA SUSTENNA | | | | | | | |
| N 022264 | 003 | 6555544 | Nov 10, 2018 | DP U-543 | | I-698 | Nov 12, 2017 |
| | | 9439906 | Jan 26, 2031 | U-1901 | | M-215 | Dec 20, 2020 |
| | | 9439906 | Jan 26, 2031 | U-543 | | | |
| PALIPERIDONE PALMITATE - INVEGA SUSTENNA | | | | | | | |
| N 022264 | 004 | 6555544 | Nov 10, 2018 | DP U-543 | | I-698 | Nov 12, 2017 |
| | | 9439906 | Jan 26, 2031 | U-1901 | | M-215 | Dec 20, 2020 |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| PALIPERIDONE PALMITATE - INVEGA SUSTENNA | | | | | | | |
| N 022264 | 004 | 9439906 | Jan 26, 2031 | U-543 | | | |
| PALIPERIDONE PALMITATE - INVEGA SUSTENNA | | | | | | | |
| N 022264 | 005 | 6555544 | Nov 10, 2018 | DP U-543 | | I-698 | Nov 12, 2017 |
| | | 9439906 | Jan 26, 2031 | U-1901 | | M-215 | Dec 20, 2020 |
| | | 9439906 | Jan 26, 2031 | U-543 | | | |
| PALIPERIDONE PALMITATE - INVEGA TRINZA | | | | | | | |
| N 207946 | 001 | 6077843*PED | Nov 12, 2017 | | | NP | May 18, 2018 |
| PALIPERIDONE PALMITATE - INVEGA TRINZA | | | | | | | |
| N 207946 | 002 | 6077843*PED | Nov 12, 2017 | | | NP | May 18, 2018 |
| PALIPERIDONE PALMITATE - INVEGA TRINZA | | | | | | | |
| N 207946 | 003 | 6077843*PED | Nov 12, 2017 | | | NP | May 18, 2018 |
| PALIPERIDONE PALMITATE - INVEGA TRINZA | | | | | | | |
| N 207946 | 004 | 6077843*PED | Nov 12, 2017 | | | NP | May 18, 2018 |
| PALONOSETRON HYDROCHLORIDE - ALOXI | | | | | | | |
| N 021372 | 001 | 7947724 | Jan 30, 2024 | DP | | | |
| | | 7947724*PED | Jul 30, 2024 | | | | |
| | | 7947725 | Jan 30, 2024 | DP | | | |
| | | 7947725*PED | Jul 30, 2024 | | | | |
| | | 7960424 | Jan 30, 2024 | DP | | | |
| | | 7960424*PED | Jul 30, 2024 | | | | |
| | | 8518981 | Jan 30, 2024 | DP | | | |
| | | 8518981*PED | Jul 30, 2024 | | | | |
| | | 8598218 | Jan 30, 2024 | DP | | | |
| | | 8598218*PED | Jul 30, 2024 | | | | |
| | | 8598219 | Jan 30, 2024 | DP | | | |
| | | 8598219*PED | Jul 30, 2024 | | | | |
| | | 8729094 | Jan 30, 2024 | DP U-528 | | | |
| | | 8729094*PED | Jul 30, 2024 | | | | |
| | | 9066980 | Jan 30, 2024 | DP U-528 | | | |
| | | 9066980*PED | Jul 30, 2024 | | | | |
| | | 9125905 | Jan 30, 2024 | DP | | | |
| | | 9125905*PED | Jul 30, 2024 | | | | |
| | | 9173942 | Jan 30, 2024 | DP | | | |
| | | 9173942*PED | Jul 30, 2024 | | | | |
| | | 9439854 | Jan 30, 2024 | DP | | | |
| | | 9439854*PED | Jul 30, 2024 | | | | |
| | | 9457020 | Jan 30, 2024 | DP | | | |
| | | 9457020*PED | Jul 30, 2024 | | | | |
| | | 9457021 | Jan 30, 2024 | DP | | | |
| | | 9457021*PED | Jul 30, 2024 | | | | |
| PALONOSETRON HYDROCHLORIDE - ALOXI | | | | | | | |
| N 021372 | 002 | 7947724 | Jan 30, 2024 | DP | | | |
| | | 7947724*PED | Jul 30, 2024 | | | | |
| | | 7947725 | Jan 30, 2024 | DP | | | |
| | | 7947725*PED | Jul 30, 2024 | | | | |
| | | 7960424 | Jan 30, 2024 | DP | | | |
| | | 7960424*PED | Jul 30, 2024 | | | | |
| | | 8518981 | Jan 30, 2024 | DP | | | |
| | | 8518981*PED | Jul 30, 2024 | | | | |
| | | 8598218 | Jan 30, 2024 | DP | | | |
| | | 8598218*PED | Jul 30, 2024 | | | | |
| | | 9173942 | Jan 30, 2024 | DP | | | |
| | | 9173942*PED | Jul 30, 2024 | | | | |
| | | 9439854 | Jan 30, 2024 | DP | | | |
| | | 9439854*PED | Jul 30, 2024 | | | | |
| | | 9457020 | Jan 30, 2024 | DP | | | |
| | | 9457020*PED | Jul 30, 2024 | | | | |
| PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP | | | | | | | |
| N 022210 | 001 | 7658918 | Feb 20, 2028 | DP | | | |
| | | 8221747 | Feb 20, 2028 | DP | | | |
| | | 8246950 | Feb 20, 2028 | U-1274 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP | | | | | | | |
| N 022210 | 001 | 8562978 | Feb 20, 2028 | DP | | | |
| | | 8562979 | Feb 20, 2028 | DP U-1274 | | | |
| | | 8562980 | Feb 20, 2028 | DP U-1274 | | | |
| | | 8562981 | Feb 20, 2028 | U-1274 | | | |
| PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP | | | | | | | |
| N 022210 | 002 | 7658918 | Feb 20, 2028 | DP | | | |
| | | 8221747 | Feb 20, 2028 | DP | | | |
| | | 8246950 | Feb 20, 2028 | U-1274 | | | |
| | | 8562978 | Feb 20, 2028 | DP | | | |
| | | 8562979 | Feb 20, 2028 | DP U-1274 | | | |
| | | 8562980 | Feb 20, 2028 | DP U-1274 | | | |
| | | 8562981 | Feb 20, 2028 | U-1274 | | | |
| PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP | | | | | | | |
| N 022210 | 003 | 7658918 | Feb 20, 2028 | DP | | | |
| | | 8221747 | Feb 20, 2028 | DP | | | |
| | | 8246950 | Feb 20, 2028 | U-1274 | | | |
| | | 8562978 | Feb 20, 2028 | DP | | | |
| | | 8562979 | Feb 20, 2028 | DP U-1274 | | | |
| | | 8562980 | Feb 20, 2028 | DP U-1274 | | | |
| | | 8562981 | Feb 20, 2028 | | | | |
| PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP | | | | | | | |
| N 022210 | 004 | 7658918 | Feb 20, 2028 | DP | | | |
| | | 8221747 | Feb 20, 2028 | DP | | | |
| | | 8246950 | Feb 20, 2028 | U-1274 | | | |
| | | 8562978 | Feb 20, 2028 | DP | | | |
| | | 8562979 | Feb 20, 2028 | DP U-1274 | | | |
| | | 8562980 | Feb 20, 2028 | DP U-1274 | | | |
| | | 8562981 | Feb 20, 2028 | U-1274 | | | |
| PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP | | | | | | | |
| N 022210 | 005 | 8221747 | Feb 20, 2028 | DP | | | |
| | | 8562978 | Feb 20, 2028 | DP | | | |
| | | 8562979 | Feb 20, 2028 | DP U-1274 | | | |
| | | 8562980 | Feb 20, 2028 | DP U-1274 | | | |
| | | 8562981 | Feb 20, 2028 | U-1274 | | | |
| PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP | | | | | | | |
| N 022210 | 006 | 8221747 | Feb 20, 2028 | DP | | | |
| | | 8562978 | Feb 20, 2028 | DP | | | |
| | | 8562979 | Feb 20, 2028 | DP U-1274 | | | |
| | | 8562980 | Feb 20, 2028 | DP U-1274 | | | |
| | | 8562981 | Feb 20, 2028 | U-1274 | | | |
| PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP | | | | | | | |
| N 022210 | 007 | 8221747 | Feb 20, 2028 | DP | | | |
| | | 8562978 | Feb 20, 2028 | DP | | | |
| | | 8562979 | Feb 20, 2028 | DP U-1274 | | | |
| | | 8562980 | Feb 20, 2028 | DP U-1274 | | | |
| | | 8562981 | Feb 20, 2028 | U-1274 | | | |
| PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PANCREAZE | | | | | | | |
| N 022523 | 005 | 8221747 | Feb 20, 2028 | DP | | | |
| | | 8562978 | Feb 20, 2028 | DP | | | |
| | | 8562979 | Feb 20, 2028 | DP U-1274 | | | |
| | | 8562980 | Feb 20, 2028 | DP U-1274 | | | |
| | | 8562981 | Feb 20, 2028 | DP U-1274 | | | |
| PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON | | | | | | | |
| N 020725 | 001 | 9198871 | Feb 07, 2030 | DP U-1787 | | | |
| PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON | | | | | | | |
| N 020725 | 002 | 9198871 | Feb 07, 2030 | DP U-1787 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON | | | | | | | |
| N 020725 | 003 | 9198871 | Feb 07, 2030 | DP U-1787 | | | |
| PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON | | | | | | | |
| N 020725 | 004 | 9198871 | Feb 07, 2030 | DP U-1787 | | M-93 | Jul 29, 2019 |
| PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE); PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON | | | | | | | |
| N 020725 | 005 | 9198871 | Feb 07, 2030 | DP U-1787 | | M-93 | Jul 29, 2019 |
| PANOBINOSTAT LACTATE - FARYDAK | | | | | | | |
| N 205353 | 001 | 6552065 | Aug 31, 2021 | DS DP | | NCE | Feb 23, 2020 |
| | | 6833384 | Sep 30, 2021 | DS DP U-1669 | | ODE-89 | Feb 23, 2022 |
| | | 7067551 | Aug 31, 2021 | U-1669 | | | |
| | | 7989494 | Jan 17, 2028 | DS DP | | | |
| | | 8883842 | Jun 13, 2028 | U-1669 | | | |
| PANOBINOSTAT LACTATE - FARYDAK | | | | | | | |
| N 205353 | 002 | 6552065 | Aug 31, 2021 | DS DP | | NCE | Feb 23, 2020 |
| | | 6833384 | Sep 30, 2021 | DS DP U-1669 | | ODE-89 | Feb 23, 2022 |
| | | 7067551 | Aug 31, 2021 | U-1669 | | | |
| | | 7989494 | Jan 17, 2028 | DS DP | | | |
| | | 8883842 | Jun 13, 2028 | U-1669 | | | |
| PANOBINOSTAT LACTATE - FARYDAK | | | | | | | |
| N 205353 | 003 | 6552065 | Aug 31, 2021 | DS DP | | NCE | Feb 23, 2020 |
| | | 6833384 | Sep 30, 2021 | DS DP U-1669 | | ODE-89 | Feb 23, 2022 |
| | | 7067551 | Aug 31, 2021 | U-1669 | | | |
| | | 7989494 | Jan 17, 2028 | DS DP | | | |
| | | 8883842 | Jun 13, 2028 | U-1669 | | | |
| PANTOPRAZOLE SODIUM - PROTONIX IV | | | | | | | |
| N 020988 | 001 | 6780881 | Nov 17, 2021 | DP | | | |
| | | 7351723 | Nov 17, 2021 | DP | | | |
| | | 8754108 | Nov 17, 2021 | DP | | | |
| | | 8754108*PED | May 17, 2022 | | | | |
| PANTOPRAZOLE SODIUM - PROTONIX | | | | | | | |
| N 022020 | 001 | 7544370 | Jun 07, 2026 | DP | | | |
| | | 7550153 | Sep 30, 2024 | U-859 | | | |
| | | 7553498 | Sep 30, 2024 | U-859 | | | |
| | | 7838027 | Sep 30, 2024 | DP U-859 | | | |
| PARICALCITOL - ZEMPLAR | | | | | | | |
| N 020819 | 001 | 6136799 | Apr 08, 2018 | | | | |
| | | 6361758 | Apr 08, 2018 | DP | | | |
| PARICALCITOL - ZEMPLAR | | | | | | | |
| N 020819 | 002 | 6136799 | Apr 08, 2018 | | | | |
| | | 6361758 | Apr 08, 2018 | DP | | | |
| PARICALCITOL - ZEMPLAR | | | | | | | |
| N 020819 | 003 | 6136799 | Apr 08, 2018 | | | | |
| | | 6136799*PED | Oct 08, 2018 | | | | |
| | | 6361758 | Apr 08, 2018 | DP | | | |
| | | 6361758*PED | Oct 08, 2018 | | | | |
| PARICALCITOL - ZEMPLAR | | | | | | | |
| N 021606 | 001 | | | | | NPP | Oct 18, 2019 |
| | | | | | | NPP | Oct 18, 2019 |
| | | | | | | ODE-125 | Oct 18, 2023 |
| PARICALCITOL - ZEMPLAR | | | | | | | |
| N 021606 | 002 | | | | | NPP | Oct 18, 2019 |
| | | | | | | NPP | Oct 18, 2019 |
| | | | | | | ODE-125 | Oct 18, 2023 |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| PARICALCITOL - ZEMPLAR | | | | | | | |
| N 021606 | 003 | | | | | NPP | Oct 18, 2019 |
| | | | | | | NPP | Oct 18, 2019 |
| | | | | | | ODE-125 | Oct 18, 2023 |
| PAROXETINE HYDROCHLORIDE - PAXIL | | | | | | | |
| N 020885 | 001 | 6063927 | Apr 23, 2019 | | | | |
| | | 6172233 | Jan 15, 2018 | | | | |
| PAROXETINE HYDROCHLORIDE - PAXIL | | | | | | | |
| N 020885 | 002 | 6063927 | Apr 23, 2019 | | | | |
| | | 6172233 | Jan 15, 2018 | | | | |
| PAROXETINE HYDROCHLORIDE - PAXIL | | | | | | | |
| N 020885 | 003 | 6063927 | Apr 23, 2019 | | | | |
| | | 6172233 | Jan 15, 2018 | | | | |
| PAROXETINE HYDROCHLORIDE - PAXIL | | | | | | | |
| N 020885 | 004 | 6063927 | Apr 23, 2019 | | | | |
| | | 6172233 | Jan 15, 2018 | | | | |
| PAROXETINE MESYLATE - PEXEVA | | | | | | | |
| N 021299 | 001 | 7598271 | May 04, 2025 | DS | | | |
| PAROXETINE MESYLATE - PEXEVA | | | | | | | |
| N 021299 | 002 | 7598271 | May 04, 2025 | DS | | | |
| PAROXETINE MESYLATE - PEXEVA | | | | | | | |
| N 021299 | 003 | 7598271 | May 04, 2025 | DS | | | |
| PAROXETINE MESYLATE - PEXEVA | | | | | | | |
| N 021299 | 004 | 7598271 | May 04, 2025 | DS | | | |
| PAROXETINE MESYLATE - BRISDELLE | | | | | | | |
| N 204516 | 001 | 7598271 | May 04, 2025 | DS | | | |
| | | 8658663 | Apr 06, 2029 | DS DP U-904 | | | |
| | | 8946251 | Aug 04, 2026 | DS DP U-904 | | | |
| | | 9393237 | Aug 04, 2026 | U-904 | | | |
| PASIREOTIDE DIASPARTATE - SIGNIFOR | | | | | | | |
| N 200677 | 001 | 7473761 | Dec 14, 2026 | DS DP | | NCE | Dec 14, 2017 |
| | | 8299209 | Dec 27, 2025 | DS DP | | ODE-34 | Dec 14, 2019 |
| PASIREOTIDE DIASPARTATE - SIGNIFOR | | | | | | | |
| N 200677 | 002 | 7473761 | Dec 14, 2026 | DS DP | | NCE | Dec 14, 2017 |
| | | 8299209 | Dec 27, 2025 | DS DP | | ODE-34 | Dec 14, 2019 |
| PASIREOTIDE DIASPARTATE - SIGNIFOR | | | | | | | |
| N 200677 | 003 | 7473761 | Dec 14, 2026 | DS DP | | NCE | Dec 14, 2017 |
| | | 8299209 | Dec 27, 2025 | DS DP | | ODE-34 | Dec 14, 2019 |
| PASIREOTIDE PAMOATE - SIGNIFOR LAR | | | | | | | |
| N 203255 | 001 | 7473761 | Dec 14, 2026 | DS DP | | NCE | Dec 14, 2017 |
| | | 7759308 | Oct 25, 2026 | DP | | NP | Dec 15, 2017 |
| | | 8822637 | Aug 06, 2023 | U-1629 | | ODE-81 | Dec 15, 2021 |
| | | 9351923 | May 23, 2028 | DP | | | |
| PASIREOTIDE PAMOATE - SIGNIFOR LAR | | | | | | | |
| N 203255 | 002 | 7473761 | Dec 14, 2026 | DS DP | | NCE | Dec 14, 2017 |
| | | 7759308 | Oct 25, 2026 | DP | | NP | Dec 15, 2017 |
| | | 8822637 | Aug 06, 2023 | U-1629 | | ODE-81 | Dec 15, 2021 |
| | | 9351923 | May 23, 2028 | DP | | | |
| PASIREOTIDE PAMOATE - SIGNIFOR LAR | | | | | | | |
| N 203255 | 003 | 7473761 | Dec 14, 2026 | DS DP | | NCE | Dec 14, 2017 |
| | | 7759308 | Oct 25, 2026 | DP | | NP | Dec 15, 2017 |
| | | 8822637 | Aug 06, 2023 | U-1629 | | ODE-81 | Dec 15, 2021 |
| | | 9351923 | May 23, 2028 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| PATIROMER SORBITEX CALCIUM - VELTASSA | | | | | | | |
| N 205739 | 001 | 7556799 | Feb 27, 2025 | U-1766 | | NCE | Oct 21, 2020 |
| | | 8147873 | Mar 11, 2026 | DP | | | |
| | | 8216560 | Mar 14, 2027 | U-1766 | | | |
| | | 8282913 | Mar 11, 2026 | DP | | | |
| | | 8287847 | Mar 30, 2024 | U-1766 | | | |
| | | 8337824 | May 29, 2030 | DS U-1766 | | | |
| | | 8475780 | Mar 30, 2024 | U-1766 | | | |
| | | 8778324 | Mar 30, 2024 | U-1766 | | | |
| | | 8889115 | Mar 30, 2024 | U-1766 | | | |
| | | 9492476 | Oct 08, 2033 | U-1766 | | | |
| PATIROMER SORBITEX CALCIUM - VELTASSA | | | | | | | |
| N 205739 | 002 | 7556799 | Feb 27, 2025 | U-1766 | | NCE | Oct 21, 2020 |
| | | 8147873 | Mar 11, 2026 | DP | | | |
| | | 8216560 | Mar 14, 2027 | U-1766 | | | |
| | | 8282913 | Mar 11, 2026 | DP | | | |
| | | 8287847 | Mar 30, 2024 | U-1766 | | | |
| | | 8337824 | May 29, 2030 | DS U-1766 | | | |
| | | 8475780 | Mar 30, 2024 | U-1766 | | | |
| | | 8778324 | Mar 30, 2024 | U-1766 | | | |
| | | 8889115 | Mar 30, 2024 | U-1766 | | | |
| | | 9492476 | Oct 08, 2033 | U-1766 | | | |
| PATIROMER SORBITEX CALCIUM - VELTASSA | | | | | | | |
| N 205739 | 003 | 7556799 | Feb 27, 2025 | U-1766 | | NCE | Oct 21, 2020 |
| | | 8147873 | Mar 11, 2026 | DP | | | |
| | | 8216560 | Mar 14, 2027 | U-1766 | | | |
| | | 8282913 | Mar 11, 2026 | DP | | | |
| | | 8287847 | Mar 30, 2024 | U-1766 | | | |
| | | 8337824 | May 29, 2030 | DS U-1766 | | | |
| | | 8475780 | Mar 30, 2024 | U-1766 | | | |
| | | 8778324 | Mar 30, 2024 | U-1766 | | | |
| | | 8889115 | Mar 30, 2024 | U-1766 | | | |
| | | 9492476 | Oct 08, 2033 | U-1766 | | | |
| PAZOPANIB HYDROCHLORIDE - VOTRIENT | | | | | | | |
| N 022465 | 001 | 7105530 | Oct 19, 2023 | DS DP | | ODE-23 | Apr 26, 2019 |
| | | 7262203 | Dec 19, 2021 | DS DP | | | |
| | | 8114885 | Dec 19, 2021 | DS DP | | | |
| PAZOPANIB HYDROCHLORIDE - VOTRIENT | | | | | | | |
| N 022465 | 002 | 7105530 | Oct 19, 2023 | DS DP | | ODE-23 | Apr 26, 2019 |
| | | 7262203 | Dec 19, 2021 | DS DP | | | |
| | | 8114885 | Dec 19, 2021 | DS DP | | | |
| PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE | | | | | | | |
| N 202799 | 001 | 7084245 | May 12, 2024 | DS DP U-1238 | | | |
| | | 7414105 | May 12, 2024 | DS DP U-1238 | | | |
| | | 7528104 | May 12, 2024 | DS DP | | | |
| | | 7550433 | Jun 02, 2026 | U-1238 | | | |
| | | 7919118 | May 12, 2024 | DS DP | | | |
| | | 7919461 | Jun 02, 2026 | U-1238 | | | |
| PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE | | | | | | | |
| N 202799 | 002 | 7084245 | May 12, 2024 | DS DP U-1238 | | | |
| | | 7414105 | May 12, 2024 | DS DP U-1238 | | | |
| | | 7528104 | May 12, 2024 | DS DP | | | |
| | | 7550433 | Jun 02, 2026 | U-1238 | | | |
| | | 7919118 | May 12, 2024 | DS DP | | | |
| | | 7919461 | Jun 02, 2026 | U-1238 | | | |
| PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE | | | | | | | |
| N 202799 | 003 | 7084245 | May 12, 2024 | DS DP U-1238 | | | |
| | | 7414105 | May 12, 2024 | DS DP U-1238 | | | |
| | | 7528104 | May 12, 2024 | DS DP | | | |
| | | 7550433 | Jun 02, 2026 | U-1238 | | | |
| | | 7919118 | May 12, 2024 | DS DP | | | |
| | | 7919461 | Jun 02, 2026 | U-1238 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|
| PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE | | | | | | | | |
| N | 202799 | 004 | 7084245 | May 12, 2024 | DS DP U-1238 | | | |
| | | | 7414105 | May 12, 2024 | DS DP U-1238 | | | |
| | | | 7528104 | May 12, 2024 | DS DP | | | |
| | | | 7550433 | Jun 02, 2026 | U-1238 | | | |
| | | | 7919118 | May 12, 2024 | DS DP | | | |
| | | | 7919461 | Jun 02, 2026 | U-1238 | | | |
| PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE | | | | | | | | |
| N | 202799 | 005 | 7084245 | May 12, 2024 | DS DP U-1238 | | | |
| | | | 7414105 | May 12, 2024 | DS DP U-1238 | | | |
| | | | 7528104 | May 12, 2024 | DS DP | | | |
| | | | 7550433 | Jun 02, 2026 | U-1238 | | | |
| | | | 7919118 | May 12, 2024 | DS DP | | | |
| | | | 7919461 | Jun 02, 2026 | U-1238 | | | |
| PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE | | | | | | | | |
| N | 202799 | 006 | 7084245 | May 12, 2024 | DS DP U-1238 | | | |
| | | | 7414105 | May 12, 2024 | DS DP U-1238 | | | |
| | | | 7528104 | May 12, 2024 | DS DP | | | |
| | | | 7550433 | Jun 02, 2026 | U-1238 | | | |
| | | | 7919118 | May 12, 2024 | DS DP | | | |
| | | | 7919461 | Jun 02, 2026 | U-1238 | | | |
| PEGINESATIDE ACETATE - OMONTYS | | | | | | | | |
| N | 202799 | 007 | 7084245 | May 12, 2024 | DS DP U-1238 | | | |
| | | | 7414105 | May 12, 2024 | DS DP U-1238 | | | |
| | | | 7528104 | May 12, 2024 | DS DP | | | |
| | | | 7550433 | Jun 02, 2026 | U-1238 | | | |
| | | | 7919118 | May 12, 2024 | DS DP | | | |
| | | | 7919461 | Jun 02, 2026 | U-1238 | | | |
| PEGINESATIDE ACETATE - OMONTYS | | | | | | | | |
| N | 202799 | 008 | 7084245 | May 12, 2024 | DS DP U-1238 | | | |
| | | | 7414105 | May 12, 2024 | DS DP U-1238 | | | |
| | | | 7528104 | May 12, 2024 | DS DP | | | |
| | | | 7550433 | Jun 02, 2026 | U-1238 | | | |
| | | | 7919118 | May 12, 2024 | DS DP | | | |
| | | | 7919461 | Jun 02, 2026 | U-1238 | | | |
| PEMETREXED DISODIUM - ALIMTA | | | | | | | | |
| N | 021462 | 001 | 7772209 | Nov 24, 2021 | U-1077 | | | |
| | | | 7772209 | Nov 24, 2021 | U-1296 | | | |
| PEMETREXED DISODIUM - ALIMTA | | | | | | | | |
| N | 021462 | 002 | 7772209 | Nov 24, 2021 | U-1296 | | | |
| PENCICLOVIR - DENAVIR | | | | | | | | |
| N | 020629 | 001 | 6469015 | Oct 22, 2019 | U-501 | | | |
| | | | 6579981 | Jun 17, 2020 | U-501 | | | |
| PERAMIVIR - RAPIVAB | | | | | | | | |
| N | 206426 | 001 | 6503745 | Nov 05, 2019 | DS | | NCE | Dec 19, 2019 |
| | | | 6562861 | Dec 17, 2018 | DS | | NPP | Sep 20, 2020 |
| | | | 8778997 | May 07, 2027 | U-1627 | | | |
| PERAMPANEL - FYCOMPA | | | | | | | | |
| N | 202834 | 001 | 6949571 | Jun 08, 2021 | DS DP U-106 | | I-710 | Jun 19, 2018 |
| | | | 6949571 | Jun 08, 2021 | DS DP U-2088 | | NCE | Oct 22, 2017 |
| | | | 6949571 | Jun 08, 2021 | DS DP U-2089 | | | |
| | | | 8772497 | May 16, 2026 | DS | | | |
| PERAMPANEL - FYCOMPA | | | | | | | | |
| N | 202834 | 002 | 6949571 | Jun 08, 2021 | DS DP U-106 | | I-710 | Jun 19, 2018 |
| | | | 6949571 | Jun 08, 2021 | DS DP U-2088 | | NCE | Oct 22, 2017 |
| | | | 6949571 | Jun 08, 2021 | DS DP U-2089 | | | |
| | | | 8772497 | May 16, 2026 | DS | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| PERAMPANEL - FYCOMPA | | | | | | | |
| N 202834 | 003 | 6949571 | Jun 08, 2021 | DS DP U-106 | | I-710 | Jun 19, 2018 |
| | | 6949571 | Jun 08, 2021 | DS DP U-2088 | | NCE | Oct 22, 2017 |
| | | 6949571 | Jun 08, 2021 | DS DP U-2089 | | | |
| | | 8772497 | May 16, 2026 | DS | | | |
| PERAMPANEL - FYCOMPA | | | | | | | |
| N 202834 | 004 | 6949571 | Jun 08, 2021 | DS DP U-106 | | I-710 | Jun 19, 2018 |
| | | 6949571 | Jun 08, 2021 | DS DP U-2088 | | NCE | Oct 22, 2017 |
| | | 6949571 | Jun 08, 2021 | DS DP U-2089 | | | |
| | | 8772497 | May 16, 2026 | DS | | | |
| PERAMPANEL - FYCOMPA | | | | | | | |
| N 202834 | 005 | 6949571 | Jun 08, 2021 | DS DP U-106 | | I-710 | Jun 19, 2018 |
| | | 6949571 | Jun 08, 2021 | DS DP U-2088 | | NCE | Oct 22, 2017 |
| | | 6949571 | Jun 08, 2021 | DS DP U-2089 | | | |
| | | 8772497 | May 16, 2026 | DS | | | |
| PERAMPANEL - FYCOMPA | | | | | | | |
| N 202834 | 006 | 6949571 | Jun 08, 2021 | DS DP U-106 | | I-710 | Jun 19, 2018 |
| | | 6949571 | Jun 08, 2021 | DS DP U-2088 | | NCE | Oct 22, 2017 |
| | | 6949571 | Jun 08, 2021 | DS DP U-2089 | | | |
| | | 8772497 | May 16, 2026 | DS | | | |
| PERAMPANEL - FYCOMPA | | | | | | | |
| N 208277 | 001 | 6949571 | Jun 08, 2021 | DS DP U-106 | | NCE | Oct 22, 2017 |
| | | 6949571 | Jun 08, 2021 | DS DP U-2088 | | | |
| | | 6949571 | Jun 08, 2021 | DS DP U-2089 | | | |
| | | 8772497 | May 16, 2026 | DS | | | |
| PERFLUTREN - DEFINITY | | | | | | | |
| N 021064 | 001 | 8658205 | Jun 18, 2019 | DP | | | |
| | | 8685441 | Jan 13, 2019 | U-665 | | | |
| | | 9545457 | Jan 13, 2019 | U-665 | | | |
| | | 9789210 | Mar 16, 2037 | U-665 | | | |
| PHENTERMINE HYDROCHLORIDE - SUPRENZA | | | | | | | |
| N 202088 | 001 | 6149938 | Jul 23, 2018 | DP | | | |
| | | 8440170 | Mar 14, 2029 | DP | | | |
| PHENTERMINE HYDROCHLORIDE - SUPRENZA | | | | | | | |
| N 202088 | 002 | 6149938 | Jul 23, 2018 | DP | | | |
| | | 8440170 | Mar 14, 2029 | DP | | | |
| PHENTERMINE HYDROCHLORIDE - SUPRENZA | | | | | | | |
| N 202088 | 003 | 6149938 | Jul 23, 2018 | DP U-1243 | | | |
| | | 8440170 | Mar 14, 2029 | DP | | | |
| PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA | | | | | | | |
| N 022580 | 001 | 7056890 | Jun 14, 2020 | DP U-1262 | | | |
| | | 7553818 | Jun 14, 2020 | U-1262 | | | |
| | | 7659256 | Jun 14, 2020 | DP U-1262 | | | |
| | | 7674776 | Jun 14, 2020 | DP U-1262 | | | |
| | | 8580298 | May 15, 2029 | DP | | | |
| | | 8580299 | Jun 14, 2029 | U-1262 | | | |
| | | 8895057 | Jun 09, 2028 | U-1262 | | | |
| | | 8895058 | Jun 09, 2028 | DP | | | |
| | | 9011905 | Jun 09, 2028 | DP | | | |
| | | 9011906 | Jun 09, 2028 | U-1262 | | | |
| PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA | | | | | | | |
| N 022580 | 002 | 7056890 | Jun 14, 2020 | DP U-1262 | | | |
| | | 7553818 | Jun 14, 2020 | U-1262 | | | |
| | | 7659256 | Jun 14, 2020 | DP U-1262 | | | |
| | | 7674776 | Jun 14, 2020 | DP U-1262 | | | |
| | | 8580298 | May 15, 2029 | DP | | | |
| | | 8580299 | Jun 14, 2029 | U-1262 | | | |
| | | 8895057 | Jun 09, 2028 | U-1262 | | | |
| | | 8895058 | Jun 09, 2028 | DP | | | |
| | | 9011905 | Jun 09, 2028 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | | PATENT NO | PATENT EXPIRATION DATE | | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|---|
| PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA | | | | | | | | | |
| N | 022580 | 002 | 9011906 | Jun 09, 2028 | | U-1262 | | | |
| PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA | | | | | | | | | |
| N | 022580 | 003 | 7056890 | Jun 14, 2020 | | DP U-1262 | | | |
| | | | 7553818 | Jun 14, 2020 | | U-1262 | | | |
| | | | 7659256 | Jun 14, 2020 | | DP U-1262 | | | |
| | | | 7674776 | Jun 14, 2020 | | DP U-1262 | | | |
| | | | 8580298 | May 15, 2029 | | DP | | | |
| | | | 8580299 | Jun 14, 2029 | | U-1262 | | | |
| | | | 8895057 | Jun 09, 2028 | | U-1262 | | | |
| | | | 8895058 | Jun 09, 2028 | | DP | | | |
| | | | 9011905 | Jun 09, 2028 | | DP | | | |
| | | | 9011906 | Jun 09, 2028 | | U-1262 | | | |
| PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA | | | | | | | | | |
| N | 022580 | 004 | 7056890 | Jun 14, 2020 | | DP U-1262 | | | |
| | | | 7553818 | Jun 14, 2020 | | U-1262 | | | |
| | | | 7659256 | Jun 14, 2020 | | DP U-1262 | | | |
| | | | 7674776 | Jun 14, 2020 | | DP U-1262 | | | |
| | | | 8580298 | May 15, 2029 | | DP | | | |
| | | | 8580299 | Jun 14, 2029 | | U-1262 | | | |
| | | | 8895057 | Jun 09, 2028 | | U-1262 | | | |
| | | | 8895058 | Jun 09, 2028 | | DP | | | |
| | | | 9011905 | Jun 09, 2028 | | DP | | | |
| | | | 9011906 | Jun 09, 2028 | | U-1262 | | | |
| PHENTOLAMINE MESYLATE - ORAVERSE | | | | | | | | | |
| N | 022159 | 001 | 6764678 | May 11, 2021 | | U-967 | | NPP | Mar 18, 2019 |
| | | | 6872390 | May 11, 2021 | | DP | | | |
| | | | 7229630 | Jun 20, 2023 | | DP | | | |
| | | | 7569230 | Oct 17, 2023 | | U-967 | | | |
| | | | 7575757 | Apr 21, 2025 | | DP | | | |
| PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE | | | | | | | | | |
| N | 203510 | 001 | 8859623 | Nov 14, 2033 | | U-1594 | | | |
| PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE | | | | | | | | | |
| N | 203510 | 002 | 8859623 | Nov 14, 2033 | | U-1594 | | | |
| PIMAVANSERIN TARTRATE - NUPLAZID | | | | | | | | | |
| N | 207318 | 001 | 6756393 | Mar 06, 2021 | DS | DP | | NCE | Apr 29, 2021 |
| | | | 6815458 | Mar 06, 2021 | DS | DP U-1843 | | | |
| | | | 7115634 | Oct 06, 2021 | DS | DP | | | |
| | | | 7601740 | Jun 17, 2027 | DS | DP | | | |
| | | | 7659285 | Aug 24, 2026 | | U-1844 | | | |
| | | | 7732615 | Jun 03, 2028 | DS | DP | | | |
| | | | 7858789 | Dec 13, 2020 | DS | DP | | | |
| | | | 7923564 | Sep 26, 2025 | DS | DP | | | |
| | | | 8110574 | Dec 13, 2020 | DS | DP | | | |
| | | | 8618130 | Jan 15, 2024 | | U-1845 | | | |
| | | | 8921393 | Jan 15, 2024 | | U-1846 | | | |
| | | | 9296694 | Mar 06, 2021 | DS | DP | | | |
| | | | 9566271 | Jan 15, 2024 | | U-1974 | | | |
| | | | 9765053 | Jul 27, 2022 | | U-1974 | | | |
| PIMECROLIMUS - ELIDEL | | | | | | | | | |
| N | 021302 | 001 | 6423722 | Jun 26, 2018 | | | | | |
| PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN | | | | | | | | | |
| N | 050684 | 001 | 6900184 | Apr 14, 2023 | | DP U-282 | | | |
| | | | 7915229 | Apr 14, 2023 | | DP | | | |
| | | | 8133883 | Apr 14, 2023 | | DP U-282 | | | |
| PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN | | | | | | | | | |
| N | 050684 | 002 | 6900184 | Apr 14, 2023 | | DP U-282 | | | |
| | | | 7915229 | Apr 14, 2023 | | DP | | | |
| | | | 8133883 | Apr 14, 2023 | | DP U-282 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN | | | | | | | |
| N 050684 | 003 | 6900184 | Apr 14, 2023 | DP U-282 | | | |
| | | 7915229 | Apr 14, 2023 | DP | | | |
| | | 8133883 | Apr 14, 2023 | DP U-282 | | | |
| PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN | | | | | | | |
| N 050684 | 004 | 6900184 | Apr 14, 2023 | DP U-282 | | | |
| | | 7915229 | Apr 14, 2023 | DP | | | |
| | | 8133883 | Apr 14, 2023 | DP U-282 | | | |
| PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER | | | | | | | |
| N 050750 | 001 | 6207661 | Feb 22, 2019 | DP | | | |
| | | 6900184 | Apr 14, 2023 | DP U-282 | | | |
| | | 7915229 | Apr 14, 2023 | DP | | | |
| | | 8133883 | Apr 14, 2023 | DP U-282 | | | |
| PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER | | | | | | | |
| N 050750 | 002 | 6207661 | Feb 22, 2019 | DP | | | |
| | | 6900184 | Apr 14, 2023 | DP U-282 | | | |
| | | 7915229 | Apr 14, 2023 | DP | | | |
| | | 8133883 | Apr 14, 2023 | DP U-282 | | | |
| PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER | | | | | | | |
| N 050750 | 003 | 6207661 | Feb 22, 2019 | DP | | | |
| | | 6900184 | Apr 14, 2023 | DP U-282 | | | |
| | | 7915229 | Apr 14, 2023 | DP | | | |
| | | 8133883 | Apr 14, 2023 | DP U-282 | | | |
| PIRFENIDONE - ESBRIET | | | | | | | |
| N 022535 | 001 | 7566729 | Apr 22, 2029 | U-1600 | | NCE | Oct 15, 2019 |
| | | 7635707 | Apr 22, 2029 | U-1609 | | ODE-77 | Oct 15, 2021 |
| | | 7696236 | Dec 18, 2027 | U-1601 | | | |
| | | 7767225 | Sep 22, 2026 | DP U-1602 | | | |
| | | 7767700 | Dec 18, 2027 | U-1601 | | | |
| | | 7816383 | Jan 08, 2030 | U-1603 | | | |
| | | 7910610 | Jan 08, 2030 | U-1604 | | | |
| | | 7988994 | Sep 22, 2026 | DP U-1602 | | | |
| | | 8013002 | Jan 08, 2030 | U-1603 | | | |
| | | 8084475 | Jan 08, 2030 | U-1605 | | | |
| | | 8318780 | Jan 08, 2030 | U-1606 | | | |
| | | 8383150 | Sep 22, 2026 | DP U-1607 | | | |
| | | 8420674 | Dec 18, 2027 | DP U-1608 | | | |
| | | 8592462 | Apr 22, 2029 | U-1609 | | | |
| | | 8609701 | Apr 22, 2029 | U-1610 | | | |
| | | 8648098 | Jan 08, 2030 | U-1611 | | | |
| | | 8753679 | Sep 22, 2026 | DP U-1602 | | | |
| | | 8754109 | Jan 08, 2030 | U-1612 | | | |
| | | 8778947 | Aug 30, 2033 | U-1613 | | | |
| PIRFENIDONE - ESBRIET | | | | | | | |
| N 208780 | 001 | 7566729 | Apr 22, 2029 | U-2077 | | NCE | Oct 15, 2019 |
| | | 7566729 | Apr 22, 2029 | U-2078 | | ODE-77 | Oct 15, 2021 |
| | | 7635707 | Apr 22, 2029 | U-2072 | | | |
| | | 7635707 | Apr 22, 2029 | U-2073 | | | |
| | | 7635707 | Apr 22, 2029 | U-2074 | | | |
| | | 7635707 | Apr 22, 2029 | U-2075 | | | |
| | | 7635707 | Apr 22, 2029 | U-2076 | | | |
| | | 7635707 | Apr 22, 2029 | U-2083 | | | |
| | | 7767700 | Dec 18, 2027 | U-2080 | | | |
| | | 7816383 | Jan 08, 2030 | U-2042 | | | |
| | | 7816383 | Jan 08, 2030 | U-2050 | | | |
| | | 7910610 | Jan 08, 2030 | U-2048 | | | |
| | | 7910610 | Jan 08, 2030 | U-2049 | | | |
| | | 8013002 | Jan 08, 2030 | U-2047 | | | |
| | | 8013002 | Jan 08, 2030 | U-2082 | | | |
| | | 8084475 | Jan 08, 2030 | U-2052 | | | |
| | | 8084475 | Jan 08, 2030 | U-2054 | | | |
| | | 8318780 | Jan 08, 2030 | U-2046 | | | |
| | | 8318780 | Jan 08, 2030 | U-2081 | | | |
| | | 8383150 | Sep 22, 2026 | DP U-1607 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| PIRFENIDONE - ESBRIET | | | | | | |
| N 208780 001 | 8420674 | Dec 18, 2017 | U-2079 | | | |
| | 8592462 | Apr 22, 2029 | U-2055 | | | |
| | 8592462 | Apr 22, 2029 | U-2056 | | | |
| | 8592462 | Apr 22, 2029 | U-2057 | | | |
| | 8592462 | Apr 22, 2029 | U-2058 | | | |
| | 8592462 | Apr 22, 2029 | U-2059 | | | |
| | 8592462 | Apr 22, 2029 | U-2060 | | | |
| | 8592462 | Apr 22, 2029 | U-2061 | | | |
| | 8592462 | Apr 22, 2029 | U-2062 | | | |
| | 8592462 | Apr 22, 2029 | U-2063 | | | |
| | 8609701 | Apr 22, 2029 | U-2064 | | | |
| | 8609701 | Apr 22, 2029 | U-2065 | | | |
| | 8609701 | Apr 22, 2029 | U-2066 | | | |
| | 8609701 | Apr 22, 2029 | U-2067 | | | |
| | 8609701 | Apr 22, 2029 | U-2068 | | | |
| | 8609701 | Apr 22, 2029 | U-2069 | | | |
| | 8609701 | Apr 22, 2029 | U-2070 | | | |
| | 8648098 | Jan 08, 2030 | U-2051 | | | |
| | 8648098 | Jan 08, 2030 | U-2052 | | | |
| | 8754109 | Jan 08, 2030 | U-2053 | | | |
| | 8778947 | Aug 30, 2033 | U-2044 | | | |
| | 8778947 | Aug 30, 2033 | U-2045 | | | |
| | 9561217 | Jan 25, 2022 | DP | | | |
| PIRFENIDONE - ESBRIET | | | | | | |
| N 208780 002 | | | | | NCE | Oct 15, 2019 |
| | | | | | ODE-77 | Oct 15, 2021 |
| PIRFENIDONE - ESBRIET | | | | | | |
| N 208780 003 | 7566729 | Apr 22, 2029 | U-2077 | | NCE | Oct 15, 2019 |
| | 7566729 | Apr 22, 2029 | U-2078 | | ODE-77 | Oct 15, 2021 |
| | 7635707 | Apr 22, 2029 | U-2072 | | | |
| | 7635707 | Apr 22, 2029 | U-2073 | | | |
| | 7635707 | Apr 22, 2029 | U-2074 | | | |
| | 7635707 | Apr 22, 2029 | U-2075 | | | |
| | 7635707 | Apr 22, 2029 | U-2076 | | | |
| | 7635707 | Apr 22, 2029 | U-2083 | | | |
| | 7767700 | Dec 18, 2027 | U-2080 | | | |
| | 7816383 | Jan 08, 2030 | U-2042 | | | |
| | 7816383 | Jan 08, 2030 | U-2050 | | | |
| | 7910610 | Jan 08, 2030 | U-2048 | | | |
| | 7910610 | Jan 08, 2030 | U-2049 | | | |
| | 8013002 | Jan 08, 2030 | U-2047 | | | |
| | 8013002 | Jan 08, 2030 | U-2082 | | | |
| | 8084475 | Jan 08, 2030 | U-2052 | | | |
| | 8084475 | Jan 08, 2030 | U-2054 | | | |
| | 8318780 | Jan 08, 2030 | U-2046 | | | |
| | 8318780 | Jan 08, 2030 | U-2081 | | | |
| | 8383150 | Sep 22, 2026 | DP U-1607 | | | |
| | 8420674 | Dec 18, 2017 | U-2079 | | | |
| | 8592462 | Apr 22, 2029 | U-2055 | | | |
| | 8592462 | Apr 22, 2029 | U-2056 | | | |
| | 8592462 | Apr 22, 2029 | U-2057 | | | |
| | 8592462 | Apr 22, 2029 | U-2058 | | | |
| | 8592462 | Apr 22, 2029 | U-2059 | | | |
| | 8592462 | Apr 22, 2029 | U-2060 | | | |
| | 8592462 | Apr 22, 2029 | U-2061 | | | |
| | 8592462 | Apr 22, 2029 | U-2062 | | | |
| | 8592462 | Apr 22, 2029 | U-2063 | | | |
| | 8609701 | Apr 22, 2029 | U-2064 | | | |
| | 8609701 | Apr 22, 2029 | U-2065 | | | |
| | 8609701 | Apr 22, 2029 | U-2066 | | | |
| | 8609701 | Apr 22, 2029 | U-2067 | | | |
| | 8609701 | Apr 22, 2029 | U-2068 | | | |
| | 8609701 | Apr 22, 2029 | U-2069 | | | |
| | 8609701 | Apr 22, 2029 | U-2070 | | | |
| | 8648098 | Jan 08, 2030 | U-2051 | | | |
| | 8648098 | Jan 08, 2030 | U-2052 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| PIRFENIDONE - ESBRIET | | | | | | | |
| N 208780 | 003 | 8754109 | Jan 08, 2030 | U-2053 | | | |
| | | 8778947 | Aug 30, 2033 | U-2044 | | | |
| | | 8778947 | Aug 30, 2033 | U-2045 | | | |
| | | 9561217 | Jan 25, 2022 | DP | | | |
| PITAVASTATIN CALCIUM - LIVALO | | | | | | | |
| N 022363 | 001 | 5856336 | Dec 25, 2020 | DS U-998 | | | |
| | | 7022713 | Feb 19, 2024 | U-998 | | | |
| | | 8557993 | Feb 02, 2024 | DP | | | |
| PITAVASTATIN CALCIUM - LIVALO | | | | | | | |
| N 022363 | 002 | 5856336 | Dec 25, 2020 | DS U-998 | | | |
| | | 7022713 | Feb 19, 2024 | U-998 | | | |
| | | 8557993 | Feb 02, 2024 | DP | | | |
| PITAVASTATIN CALCIUM - LIVALO | | | | | | | |
| N 022363 | 003 | 5856336 | Dec 25, 2020 | DS U-998 | | | |
| | | 7022713 | Feb 19, 2024 | U-998 | | | |
| | | 8557993 | Feb 02, 2024 | DS DP | | | |
| PITAVASTATIN MAGNESIUM - ZYPITAMAG | | | | | | | |
| N 208379 | 001 | 8829186 | Jan 19, 2031 | DS DP | | | |
| PITAVASTATIN MAGNESIUM - ZYPITAMAG | | | | | | | |
| N 208379 | 002 | 8829186 | Jan 19, 2031 | DS DP | | | |
| PITAVASTATIN MAGNESIUM - ZYPITAMAG | | | | | | | |
| N 208379 | 003 | 8829186 | Jan 19, 2031 | DS DP | | | |
| PLECANATIDE - TRULANCE | | | | | | | |
| N 208745 | 001 | 7041786 | Mar 25, 2023 | DS | | NCE | Jan 19, 2022 |
| | | 7799897 | Jun 09, 2022 | DS | | | |
| | | 8637451 | Mar 28, 2022 | U-1964 | | | |
| | | 9610321 | Sep 11, 2031 | U-1999 | | | |
| | | 9616097 | Jul 02, 2032 | DP | | | |
| PLERIXAFOR - MOZOBIL | | | | | | | |
| N 022311 | 001 | 6987102 | Jul 22, 2023 | U-936 | | | |
| | | 7897590 | Jul 22, 2023 | U-936 | | | |
| | | RE42152 | Dec 10, 2018 | DP | | | |
| POLIDOCANOL - VARITHENA | | | | | | | |
| N 205098 | 001 | 6572873 | May 26, 2020 | U-1461 | | | |
| | | 6846412 | Jul 19, 2022 | DP | | | |
| | | 6942165 | May 26, 2020 | DP | | | |
| | | 7025290 | May 26, 2020 | DP U-1461 | | | |
| | | 7357336 | May 26, 2020 | U-1461 | | | |
| | | 7604185 | May 26, 2020 | DS DP U-1462 | | | |
| | | 7731986 | Nov 17, 2024 | DS DP U-1463 | | | |
| | | 7814943 | Nov 19, 2027 | DP U-1461 | | | |
| | | 7842282 | May 26, 2020 | U-1461 | | | |
| | | 7842283 | May 26, 2020 | DP | | | |
| | | 8122917 | Sep 09, 2024 | DP | | | |
| | | 8323677 | May 26, 2020 | DS | | | |
| | | 8734833 | May 26, 2020 | DS DP | | | |
| | | 9480652 | May 12, 2032 | DP | | | |
| POMALIDOMIDE - POMALYST | | | | | | | |
| N 204026 | 001 | 6045501 | Aug 28, 2018 | U-1361 | | I-707 | Apr 23, 2018 |
| | | 6315720 | Oct 23, 2020 | U-1361 | | NCE | Feb 08, 2018 |
| | | 6561976 | Aug 28, 2018 | U-1361 | | ODE-43 | Feb 08, 2020 |
| | | 6561977 | Oct 23, 2020 | U-1361 | | | |
| | | 6755784 | Oct 23, 2020 | U-1361 | | | |
| | | 6908432 | Aug 28, 2018 | U-1361 | | | |
| | | 8198262 | Oct 19, 2024 | U-1360 | | | |
| | | 8204763 | Aug 28, 2018 | U-1361 | | | |
| | | 8315886 | Oct 23, 2020 | U-1361 | | | |
| | | 8589188 | Aug 28, 2018 | U-1361 | | | |
| | | 8626531 | Oct 23, 2020 | U-1361 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| POMALIDOMIDE - POMALYST | | | | | | |
| N 204026 001 | 8673939 | May 15, 2023 | U-1360 | | | |
| | 8735428 | May 15, 2023 | U-1360 | | | |
| | 8828427 | Jun 21, 2031 | DS DP | | | |
| POMALIDOMIDE - POMALYST | | | | | | |
| N 204026 002 | 6045501 | Aug 28, 2018 | U-1361 | | I-707 | Apr 23, 2018 |
| | 6315720 | Oct 23, 2020 | U-1361 | | NCE | Feb 08, 2018 |
| | 6561976 | Aug 28, 2018 | U-1361 | | ODE-43 | Feb 08, 2020 |
| | 6561977 | Oct 23, 2020 | U-1361 | | | |
| | 6755784 | Oct 23, 2020 | U-1361 | | | |
| | 6908432 | Aug 28, 2018 | U-1361 | | | |
| | 8198262 | Oct 19, 2024 | U-1360 | | | |
| | 8204763 | Aug 28, 2018 | U-1361 | | | |
| | 8315886 | Oct 23, 2020 | U-1361 | | | |
| | 8589188 | Aug 28, 2018 | U-1361 | | | |
| | 8626531 | Oct 23, 2020 | U-1361 | | | |
| | 8673939 | May 15, 2023 | U-1360 | | | |
| | 8735428 | May 15, 2023 | U-1360 | | | |
| | 8828427 | Jun 21, 2031 | DS DP | | | |
| POMALIDOMIDE - POMALYST | | | | | | |
| N 204026 003 | 6045501 | Aug 28, 2018 | U-1361 | | I-707 | Apr 23, 2018 |
| | 6315720 | Oct 23, 2020 | U-1361 | | NCE | Feb 08, 2018 |
| | 6561976 | Aug 28, 2018 | U-1361 | | ODE-43 | Feb 08, 2020 |
| | 6561977 | Oct 23, 2020 | U-1361 | | | |
| | 6755784 | Oct 23, 2020 | U-1361 | | | |
| | 6908432 | Aug 28, 2018 | U-1361 | | | |
| | 8198262 | Oct 19, 2024 | U-1360 | | | |
| | 8204763 | Aug 28, 2018 | U-1361 | | | |
| | 8315886 | Oct 23, 2020 | U-1361 | | | |
| | 8589188 | Aug 28, 2018 | U-1361 | | | |
| | 8626531 | Oct 23, 2020 | U-1361 | | | |
| | 8673939 | May 15, 2023 | U-1360 | | | |
| | 8735428 | May 15, 2023 | U-1360 | | | |
| | 8828427 | Jun 21, 2031 | DS DP | | | |
| POMALIDOMIDE - POMALYST | | | | | | |
| N 204026 004 | 6045501 | Aug 28, 2018 | U-1361 | | I-707 | Apr 23, 2018 |
| | 6315720 | Oct 23, 2020 | U-1361 | | NCE | Feb 08, 2018 |
| | 6561976 | Aug 28, 2018 | U-1361 | | ODE-43 | Feb 08, 2020 |
| | 6561977 | Oct 23, 2020 | U-1361 | | | |
| | 6755784 | Oct 23, 2020 | U-1361 | | | |
| | 6908432 | Aug 28, 2018 | U-1361 | | | |
| | 8198262 | Oct 19, 2024 | U-1360 | | | |
| | 8204763 | Aug 28, 2018 | U-1361 | | | |
| | 8315886 | Oct 23, 2020 | U-1361 | | | |
| | 8589188 | Aug 28, 2018 | U-1361 | | | |
| | 8626531 | Oct 23, 2020 | U-1361 | | | |
| | 8673939 | May 15, 2023 | U-1360 | | | |
| | 8735428 | May 15, 2023 | U-1360 | | | |
| | 8828427 | Jun 21, 2031 | DS DP | | | |
| PONATINIB HYDROCHLORIDE - ICLUSIG | | | | | | |
| N 203469 001 | 8114874 | Dec 22, 2026 | DS DP | | NCE | Dec 14, 2017 |
| | 9029533 | Dec 22, 2026 | U-1283 | | ODE-35 | Dec 14, 2019 |
| | 9029533 | Dec 22, 2026 | U-1699 | | | |
| | 9029533 | Dec 22, 2026 | U-1700 | | | |
| | 9029533 | Dec 22, 2026 | U-1701 | | | |
| | 9029533 | Dec 22, 2026 | U-836 | | | |
| | 9493470 | Dec 12, 2033 | DS DP U-1700 | | | |
| | 9493470 | Dec 12, 2033 | DS DP U-1948 | | | |
| PONATINIB HYDROCHLORIDE - ICLUSIG | | | | | | |
| N 203469 002 | 8114874 | Dec 22, 2026 | DS DP | | NCE | Dec 14, 2017 |
| | 9029533 | Dec 22, 2026 | U-1283 | | ODE-35 | Dec 14, 2019 |
| | 9029533 | Dec 22, 2026 | U-1699 | | | |
| | 9029533 | Dec 22, 2026 | U-1700 | | | |
| | 9029533 | Dec 22, 2026 | U-1701 | | | |
| | 9029533 | Dec 22, 2026 | U-836 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| PONATINIB HYDROCHLORIDE - ICLUSIG | | | | | | | |
| N 203469 | 002 | 9493470 | Dec 12, 2033 | DS DP U-1700 | | | |
| | | 9493470 | Dec 12, 2033 | DS DP U-1948 | | | |
| PONATINIB HYDROCHLORIDE - ICLUSIG | | | | | | | |
| N 203469 | 003 | 8114874 | Dec 22, 2026 | DS DP | | NCE | Dec 14, 2017 |
| | | 9029533 | Dec 22, 2026 | U-1283 | | ODE-35 | Dec 14, 2019 |
| | | 9029533 | Dec 22, 2026 | U-1699 | | | |
| | | 9029533 | Dec 22, 2026 | U-1700 | | | |
| | | 9029533 | Dec 22, 2026 | U-1701 | | | |
| | | 9029533 | Dec 22, 2026 | U-836 | | | |
| | | 9493470 | Dec 12, 2033 | DS DP U-1700 | | | |
| | | 9493470 | Dec 12, 2033 | DS DP U-1948 | | | |
| POSACONAZOLE - NOXAFIL | | | | | | | |
| N 022003 | 001 | 5661151 | Jul 19, 2019 | DS DP U-760 | | | |
| | | 6958337 | Oct 05, 2018 | DS DP U-760 | | | |
| | | 8263600 | Apr 01, 2022 | DP | | | |
| POSACONAZOLE - NOXAFIL | | | | | | | |
| N 205053 | 001 | 5661151 | Jul 19, 2019 | DS DP U-1454 | | | |
| POSACONAZOLE - NOXAFIL | | | | | | | |
| N 205596 | 001 | 5661151 | Jul 19, 2019 | DS DP U-1454 | | | |
| | | 8410077 | Mar 13, 2029 | DP | | | |
| | | 9023790 | Jul 04, 2031 | DP U-1698 | | | |
| | | 9358297 | Jun 24, 2031 | DP U-1454 | | | |
| | | 9493582 | Feb 27, 2033 | DP | | | |
| | | 9750822 | Mar 13, 2029 | DP | | | |
| PRALATREXATE - FOLOTYN | | | | | | | |
| N 022468 | 001 | 6028071 | Jul 16, 2022 | DS DP U-1004 | | | |
| | | 7622470 | May 31, 2025 | U-1015 | | | |
| | | 8299078 | May 31, 2025 | U-1004 | | | |
| PRALATREXATE - FOLOTYN | | | | | | | |
| N 022468 | 002 | 6028071 | Jul 16, 2022 | DS DP U-1004 | | | |
| | | 7622470 | May 31, 2025 | U-1015 | | | |
| | | 8299078 | May 31, 2025 | U-1004 | | | |
| PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX | | | | | | | |
| N 020667 | 001 | 6001861 | Jan 16, 2018 | U-784 | | | |
| | | 6194445 | Jan 16, 2018 | U-784 | | | |
| PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX | | | | | | | |
| N 020667 | 002 | 6001861 | Jan 16, 2018 | U-784 | | | |
| | | 6194445 | Jan 16, 2018 | U-784 | | | |
| PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX | | | | | | | |
| N 020667 | 003 | 6001861 | Jan 16, 2018 | U-784 | | | |
| | | 6194445 | Jan 16, 2018 | U-784 | | | |
| PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX | | | | | | | |
| N 020667 | 005 | 6001861 | Jan 16, 2018 | U-784 | | | |
| | | 6194445 | Jan 16, 2018 | U-784 | | | |
| PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX | | | | | | | |
| N 020667 | 006 | 6001861 | Jan 16, 2018 | U-784 | | | |
| | | 6194445 | Jan 16, 2018 | U-784 | | | |
| PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX | | | | | | | |
| N 020667 | 007 | 6001861 | Jan 16, 2018 | U-784 | | | |
| | | 6194445 | Jan 16, 2018 | U-784 | | | |
| PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER | | | | | | | |
| N 022421 | 001 | 7695734 | Apr 26, 2028 | DP | | | |
| | | 8679533 | Sep 08, 2029 | DP U-219 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER | | | | | | |
| N 022421 002 | 7695734 | Apr 26, 2028 | DP | | | |
| | 8679533 | Sep 08, 2029 | DP U-219 | | | |
| PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER | | | | | | |
| N 022421 003 | 7695734 | Apr 26, 2028 | DP | | | |
| | 8679533 | Sep 08, 2029 | DP U-219 | | | |
| PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER | | | | | | |
| N 022421 004 | 7695734 | Apr 26, 2028 | DP | | | |
| | 8679533 | Sep 08, 2029 | DP U-219 | | | |
| PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER | | | | | | |
| N 022421 005 | 7695734 | Apr 26, 2028 | DP | | | |
| | 8679533 | Sep 08, 2029 | DP U-219 | | | |
| PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER | | | | | | |
| N 022421 006 | 7695734 | Apr 26, 2028 | DP | | | |
| | 8679533 | Sep 08, 2029 | DP U-219 | | | |
| PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER | | | | | | |
| N 022421 007 | 7695734 | Apr 26, 2028 | DP | | | |
| | 8679533 | Sep 08, 2029 | DP U-219 | | | |
| PRAMLINTIDE ACETATE - SYMLIN | | | | | | |
| N 021332 001 | 5686411 | Mar 16, 2019 | DS DP U-638 | | | |
| | 6114304 | Sep 05, 2017 | U-640 | | | |
| PRAMLINTIDE ACETATE - SYMLIN | | | | | | |
| N 021332 002 | 5686411 | Mar 16, 2019 | DS DP U-638 | | | |
| | 6114304 | Sep 05, 2017 | U-637 | | | |
| | 6114304 | Sep 05, 2017 | U-640 | | | |
| PRAMLINTIDE ACETATE - SYMLIN | | | | | | |
| N 021332 003 | 5686411 | Mar 16, 2019 | DS DP U-638 | | | |
| | 6114304 | Sep 05, 2017 | U-637 | | | |
| | 6114304 | Sep 05, 2017 | U-640 | | | |
| PRASTERONE - INTRAROSA | | | | | | |
| N 208470 001 | 8268806 | Mar 19, 2031 | DP | | NCE | Nov 16, 2021 |
| | 8629129 | Aug 07, 2028 | DP | | | |
| | 8957054 | Aug 07, 2028 | U-1922 | | | |
| PRASUGREL HYDROCHLORIDE - PRASUGREL | | | | | | |
| A 205927 001 | | | | | PC | Feb 11, 2018 |
| PRASUGREL HYDROCHLORIDE - PRASUGREL | | | | | | |
| A 205927 002 | | | | | PC | Feb 11, 2018 |
| PRASUGREL HYDROCHLORIDE - EFFIENT | | | | | | |
| N 022307 001 | 5288726*PED | Oct 14, 2017 | | | M-182 | Jul 12, 2019 |
| | 8404703 | Jan 02, 2023 | U-1381 | | PED | Jan 12, 2020 |
| | 8404703*PED | Jul 02, 2023 | | | | |
| | 8569325 | Jan 02, 2023 | U-1381 | | | |
| | 8569325*PED | Jul 02, 2023 | | | | |
| PRASUGREL HYDROCHLORIDE - EFFIENT | | | | | | |
| N 022307 002 | 5288726*PED | Oct 14, 2017 | | | M-182 | Jul 12, 2019 |
| | 8404703 | Jan 02, 2023 | U-1381 | | PED | Jan 12, 2020 |
| | 8404703*PED | Jul 02, 2023 | | | | |
| | 8569325 | Jan 02, 2023 | U-1381 | | | |
| | 8569325*PED | Jul 02, 2023 | | | | |
| PREDNISOLONE ACETATE - FLO-PRED | | | | | | |
| N 022067 001 | 6071523 | Jun 03, 2018 | DP | | | |
| | 6399079 | Jun 03, 2018 | DP | | | |
| | 6656482 | Jun 03, 2018 | DP | | | |
| | 7799331 | Oct 11, 2028 | DP U-1068 | | | |
| | 7799331 | Oct 11, 2028 | DP U-139 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| PREDNISOLONE ACETATE - FLO-PRED | | | | | | | |
| N 022067 | 002 | 6071523 | Jun 03, 2018 | DP | | | |
| | | 6399079 | Jun 03, 2018 | DP | | | |
| | | 6656482 | Jun 03, 2018 | DP | | | |
| | | 7799331 | Oct 11, 2028 | DP U-1068 | | | |
| | | 7799331 | Oct 11, 2028 | DP U-139 | | | |
| PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT | | | | | | | |
| N 021959 | 001 | 6740341 | Nov 24, 2019 | DP | | | |
| PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT | | | | | | | |
| N 021959 | 002 | 6740341 | Nov 24, 2019 | DP | | | |
| PREDNISOLONE SODIUM PHOSPHATE - ORAPRED ODT | | | | | | | |
| N 021959 | 003 | 6740341 | Nov 24, 2019 | DP | | | |
| PREDNISONE - RAYOS | | | | | | | |
| N 202020 | 001 | 6488960 | Mar 14, 2020 | DP U-1267 | | | |
| | | 6677326 | Mar 14, 2020 | DP U-1268 | | | |
| | | 8309124 | Apr 23, 2024 | U-1292 | | | |
| | | 8394407 | Apr 23, 2024 | DP U-1362 | | | |
| | | 9040085 | Apr 23, 2024 | U-1362 | | | |
| | | 9186332 | Apr 23, 2024 | U-1362 | | | |
| | | 9504699 | Aug 03, 2027 | U-1362 | | | |
| PREDNISONE - RAYOS | | | | | | | |
| N 202020 | 002 | 6488960 | Mar 14, 2020 | DP U-1267 | | | |
| | | 6677326 | Mar 14, 2020 | DP U-1268 | | | |
| | | 8309124 | Apr 23, 2024 | | | | |
| | | 8394407 | Apr 23, 2024 | DP U-1362 | | | |
| | | 9040085 | Apr 23, 2024 | U-1362 | | | |
| | | 9186332 | Apr 23, 2024 | U-1362 | | | |
| | | 9504699 | Aug 03, 2027 | U-1362 | | | |
| PREDNISONE - RAYOS | | | | | | | |
| N 202020 | 003 | 8168218 | Jan 07, 2028 | DP U-1269 | | | |
| | | 8309124 | Apr 23, 2024 | U-1292 | | | |
| | | 8394407 | Apr 23, 2024 | DP U-1362 | | | |
| | | 9040085 | Apr 23, 2024 | U-1362 | | | |
| | | 9186332 | Apr 23, 2024 | U-1362 | | | |
| | | 9504699 | Aug 03, 2027 | U-1362 | | | |
| PREGABALIN - LYRICA | | | | | | | |
| N 021446 | 001 | 6001876 | Dec 30, 2018 | U-55 | Y | M-193 | Dec 22, 2019 |
| | | 6001876 | Dec 30, 2018 | U-819 | Y | | |
| | | 6197819 | Dec 30, 2018 | DS DP | | | |
| | | RE41920 | Dec 30, 2018 | U-1250 | | | |
| PREGABALIN - LYRICA | | | | | | | |
| N 021446 | 002 | 6001876 | Dec 30, 2018 | U-55 | Y | M-193 | Dec 22, 2019 |
| | | 6001876 | Dec 30, 2018 | U-819 | Y | | |
| | | 6197819 | Dec 30, 2018 | DS DP | | | |
| | | RE41920 | Dec 30, 2018 | U-1250 | | | |
| PREGABALIN - LYRICA | | | | | | | |
| N 021446 | 003 | 6001876 | Dec 30, 2018 | U-55 | Y | M-193 | Dec 22, 2019 |
| | | 6001876 | Dec 30, 2018 | U-819 | Y | | |
| | | 6197819 | Dec 30, 2018 | DS DP | | | |
| | | RE41920 | Dec 30, 2018 | U-1250 | | | |
| PREGABALIN - LYRICA | | | | | | | |
| N 021446 | 004 | 6001876 | Dec 30, 2018 | U-55 | Y | M-193 | Dec 22, 2019 |
| | | 6001876 | Dec 30, 2018 | U-819 | Y | | |
| | | 6197819 | Dec 30, 2018 | DS DP | | | |
| | | RE41920 | Dec 30, 2018 | U-1250 | | | |
| PREGABALIN - LYRICA | | | | | | | |
| N 021446 | 005 | 6001876 | Dec 30, 2018 | U-55 | Y | M-193 | Dec 22, 2019 |
| | | 6001876 | Dec 30, 2018 | U-819 | Y | | |
| | | 6197819 | Dec 30, 2018 | DS DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| PREGABALIN - LYRICA | | | | | | | |
| N 021446 | 005 | RE41920 | Dec 30, 2018 | U-1250 | | | |
| PREGABALIN - LYRICA | | | | | | | |
| N 021446 | 006 | 6001876 | Dec 30, 2018 | U-55 | Y | M-193 | Dec 22, 2019 |
| | | 6001876 | Dec 30, 2018 | U-819 | Y | | |
| | | 6197819 | Dec 30, 2018 | DS DP | | | |
| | | RE41920 | Dec 30, 2018 | U-1250 | | | |
| PREGABALIN - LYRICA | | | | | | | |
| N 021446 | 007 | 6001876 | Dec 30, 2018 | U-55 | Y | M-193 | Dec 22, 2019 |
| | | 6001876 | Dec 30, 2018 | U-819 | Y | | |
| | | 6197819 | Dec 30, 2018 | DS DP | | | |
| | | RE41920 | Dec 30, 2018 | U-1250 | | | |
| PREGABALIN - LYRICA | | | | | | | |
| N 021446 | 008 | 6001876 | Dec 30, 2018 | U-55 | Y | M-193 | Dec 22, 2019 |
| | | 6001876 | Dec 30, 2018 | U-819 | Y | | |
| | | 6197819 | Dec 30, 2018 | DS DP | | | |
| | | RE41920 | Dec 30, 2018 | U-1250 | | | |
| PREGABALIN - LYRICA | | | | | | | |
| N 022488 | 001 | 6001876 | Dec 30, 2018 | U-55 | Y | M-193 | Dec 22, 2019 |
| | | 6001876 | Dec 30, 2018 | U-819 | Y | | |
| | | 6197819 | Dec 30, 2018 | DS DP | | | |
| | | RE41920 | Dec 30, 2018 | U-1250 | | | |
| PREGABALIN - LYRICA CR | | | | | | | |
| N 209501 | 001 | 6197819 | Dec 30, 2018 | DS DP | | NP | Oct 11, 2020 |
| | | 8945620 | Nov 02, 2026 | DP U-2136 | | | |
| | | 8945620 | Nov 02, 2026 | DP U-2137 | | | |
| | | 9144559 | Nov 02, 2026 | DP | | | |
| | | RE41920 | Dec 30, 2018 | U-2136 | | | |
| | | RE41920 | Dec 30, 2018 | U-2137 | | | |
| PREGABALIN - LYRICA CR | | | | | | | |
| N 209501 | 002 | 6197819 | Dec 30, 2018 | DS DP | | NP | Oct 11, 2020 |
| | | 8945620 | Nov 02, 2026 | DP U-2136 | | | |
| | | 8945620 | Nov 02, 2026 | DP U-2137 | | | |
| | | 9144559 | Nov 02, 2026 | DP | | | |
| | | RE41920 | Dec 30, 2018 | U-2136 | | | |
| | | RE41920 | Dec 30, 2018 | U-2137 | | | |
| PREGABALIN - LYRICA CR | | | | | | | |
| N 209501 | 003 | 6197819 | Dec 30, 2018 | DS DP | | NP | Oct 11, 2020 |
| | | 8945620 | Nov 02, 2026 | DP U-2136 | | | |
| | | 8945620 | Nov 02, 2026 | DP U-2137 | | | |
| | | 9144559 | Nov 02, 2026 | DP | | | |
| | | RE41920 | Dec 30, 2018 | U-2136 | | | |
| | | RE41920 | Dec 30, 2018 | U-2137 | | | |
| PROGESTERONE - ENDOMETRIN | | | | | | | |
| N 022057 | 001 | 7300664 | Nov 17, 2019 | U-856 | | | |
| | | 7320800 | Nov 17, 2019 | U-856 | | | |
| | | 7393543 | Nov 17, 2019 | DP U-880 | | | |
| PROPOFOL - DIPRIVAN | | | | | | | |
| N 019627 | 002 | 8476010 | Dec 01, 2024 | DS DP | | | |
| | | 8476010*PED | Jun 01, 2025 | | | | |
| PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL | | | | | | | |
| N 021438 | 001 | 6500454 | Oct 04, 2021 | DP | | | |
| PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL | | | | | | | |
| N 021438 | 002 | 6500454 | Oct 04, 2021 | DP | | | |
| PROPRANOLOL HYDROCHLORIDE - HEMANGEOL | | | | | | | |
| N 205410 | 001 | 8338489 | Oct 16, 2028 | U-1496 | | ODE-62 | Mar 14, 2021 |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| QUAZEPAM - DORAL | | | | | | | |
| N 018708 | 001 | 7608616 | Jun 03, 2028 | U-1012 | | | |
| QUAZEPAM - DORAL | | | | | | | |
| N 018708 | 003 | 7608616 | Jun 03, 2028 | U-1012 | | | |
| RADIUM RA-223 DICHLORIDE - XOFIGO | | | | | | | |
| N 203971 | 001 | 6635234 | Jan 03, 2020 | U-1405 | | NCE | May 15, 2018 |
| RALTEGRAVIR POTASSIUM - ISENTRESS | | | | | | | |
| N 022145 | 001 | 7169780 | Oct 03, 2023 | DS DP | | D-167 | May 26, 2020 |
| | | 7169780*PED | Apr 03, 2024 | | | NPP | Nov 22, 2020 |
| | | 7217713 | Oct 21, 2022 | U-257 | | PED | Nov 26, 2020 |
| | | 7217713*PED | Apr 21, 2023 | | | PED | May 22, 2021 |
| | | 7435734 | Oct 21, 2022 | U-257 | | | |
| | | 7435734 | Oct 21, 2022 | U-900 | | | |
| | | 7435734*PED | Apr 21, 2023 | | | | |
| | | 7754731 | Mar 11, 2029 | DS DP U-257 | | | |
| | | 7754731*PED | Sep 11, 2029 | | | | |
| RALTEGRAVIR POTASSIUM - ISENTRESS HD | | | | | | | |
| N 022145 | 002 | 7169780 | Oct 03, 2023 | DS DP | | NPP | Nov 22, 2020 |
| | | 7169780*PED | Apr 03, 2024 | | | NS | May 26, 2020 |
| | | 7217713 | Oct 21, 2022 | U-257 | | PED | Nov 26, 2020 |
| | | 7217713*PED | Apr 21, 2023 | | | PED | May 22, 2021 |
| | | 7435734 | Oct 21, 2022 | U-257 | | | |
| | | 7435734 | Oct 21, 2022 | U-900 | | | |
| | | 7435734*PED | Apr 21, 2023 | | | | |
| | | 7754731 | Mar 11, 2029 | DS DP U-257 | | | |
| | | 7754731*PED | Sep 11, 2029 | | | | |
| | | 9649311 | Oct 21, 2030 | DP | | | |
| | | 9649311*PED | Apr 21, 2031 | | | | |
| RALTEGRAVIR POTASSIUM - ISENTRESS | | | | | | | |
| N 203045 | 001 | 7169780 | Oct 03, 2023 | DS DP | | NPP | Nov 22, 2020 |
| | | 7169780*PED | Apr 03, 2024 | | | PED | May 22, 2021 |
| | | 7217713 | Oct 21, 2022 | U-257 | | | |
| | | 7217713*PED | Apr 21, 2023 | | | | |
| | | 7435734 | Oct 21, 2022 | U-257 | | | |
| | | 7435734*PED | Apr 21, 2023 | | | | |
| | | 7754731 | Mar 11, 2029 | DS DP U-257 | | | |
| | | 7754731*PED | Sep 11, 2029 | | | | |
| RALTEGRAVIR POTASSIUM - ISENTRESS | | | | | | | |
| N 203045 | 002 | 7169780 | Oct 03, 2023 | DS DP | | NPP | Nov 22, 2020 |
| | | 7169780*PED | Apr 03, 2024 | | | PED | May 22, 2021 |
| | | 7217713 | Oct 21, 2022 | U-257 | | | |
| | | 7217713*PED | Apr 21, 2023 | | | | |
| | | 7435734 | Oct 21, 2022 | U-257 | | | |
| | | 7435734*PED | Apr 21, 2023 | | | | |
| | | 7754731 | Mar 11, 2029 | DS DP U-257 | | | |
| | | 7754731*PED | Sep 11, 2029 | | | | |
| RALTEGRAVIR POTASSIUM - ISENTRESS | | | | | | | |
| N 205786 | 001 | 7169780 | Oct 03, 2023 | DS DP | | NPP | Nov 22, 2020 |
| | | 7169780*PED | Apr 03, 2024 | | | PED | May 22, 2021 |
| | | 7217713 | Oct 21, 2022 | U-257 | | | |
| | | 7217713*PED | Apr 21, 2023 | | | | |
| | | 7435734 | Oct 21, 2022 | U-257 | | | |
| | | 7435734*PED | Apr 21, 2023 | | | | |
| | | 7754731 | Mar 11, 2029 | DS DP U-257 | | | |
| | | 7754731*PED | Sep 11, 2029 | | | | |
| RAMELTEON - ROZEREM | | | | | | | |
| N 021782 | 001 | 6034239 | Jul 22, 2019 | DS DP U-674 | | | |
| RAMIPRIL - ALTACE | | | | | | | |
| N 019901 | 001 | 7368469 | Aug 30, 2020 | U-871 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| RAMIPRIL - ALTACE | | | | | | | |
| N 019901 | 002 | 7368469 | Aug 30, 2020 | U-871 | | | |
| RAMIPRIL - ALTACE | | | | | | | |
| N 019901 | 003 | 7368469 | Aug 30, 2020 | U-871 | | | |
| RAMIPRIL - ALTACE | | | | | | | |
| N 019901 | 004 | 7368469 | Aug 30, 2020 | U-871 | | | |
| RAMIPRIL - ALTACE | | | | | | | |
| N 022021 | 001 | 7368469 | Aug 30, 2020 | U-871 | | | |
| RAMIPRIL - ALTACE | | | | | | | |
| N 022021 | 002 | 7368469 | Aug 30, 2020 | U-871 | | | |
| RAMIPRIL - ALTACE | | | | | | | |
| N 022021 | 003 | 7368469 | Aug 30, 2020 | U-871 | | | |
| RAMIPRIL - ALTACE | | | | | | | |
| N 022021 | 004 | 7368469 | Aug 30, 2020 | U-871 | | | |
| RANOLAZINE - RANEXA | | | | | | | |
| N 021526 | 001 | 6303607 | May 27, 2019 | U-705 | | | |
| | | 6369062 | May 27, 2019 | DP | Y | | |
| | | 6479496 | May 27, 2019 | U-705 | | | |
| | | 6503911 | May 27, 2019 | DP | | | |
| | | 6525057 | May 27, 2019 | U-705 | | | |
| | | 6562826 | May 27, 2019 | U-705 | | | |
| | | 6617328 | May 27, 2019 | DP | | | |
| | | 6620814 | May 27, 2019 | U-705 | | | |
| | | 6852724 | May 27, 2019 | U-705 | | | |
| | | 6864258 | May 27, 2019 | U-705 | | | |
| RANOLAZINE - RANEXA | | | | | | | |
| N 021526 | 002 | 6303607 | May 27, 2019 | U-705 | | | |
| | | 6369062 | May 27, 2019 | DP | | | |
| | | 6479496 | May 27, 2019 | U-705 | | | |
| | | 6503911 | May 27, 2019 | DP | | | |
| | | 6525057 | May 27, 2019 | U-705 | | | |
| | | 6562826 | May 27, 2019 | U-705 | | | |
| | | 6617328 | May 27, 2019 | DP | | | |
| | | 6620814 | May 27, 2019 | U-705 | | | |
| | | 6852724 | May 27, 2019 | U-705 | | | |
| | | 6864258 | May 27, 2019 | U-705 | | | |
| RASAGILINE MESYLATE - RASAGILINE MESYLATE | | | | | | | |
| A 201823 | 001 | | | | | PC | Jul 01, 2017 |
| RASAGILINE MESYLATE - RASAGILINE MESYLATE | | | | | | | |
| A 201823 | 002 | | | | | PC | Jul 01, 2017 |
| RASAGILINE MESYLATE - RASAGILINE MESYLATE | | | | | | | |
| A 201950 | 001 | | | | | PC | Jul 01, 2017 |
| RASAGILINE MESYLATE - RASAGILINE MESYLATE | | | | | | | |
| A 201950 | 002 | | | | | PC | Jul 01, 2017 |
| RASAGILINE MESYLATE - AZILECT | | | | | | | |
| N 021641 | 001 | 7572834 | Dec 05, 2026 | DP | | | |
| | | 7815942 | Aug 27, 2027 | DS DP U-219 | | | |
| RASAGILINE MESYLATE - AZILECT | | | | | | | |
| N 021641 | 002 | 7572834 | Dec 05, 2026 | DP | | | |
| | | 7815942 | Aug 27, 2027 | DS DP U-219 | | | |
| REGADENOSON - LEXISCAN | | | | | | | |
| N 022161 | 001 | 6403567 | Apr 10, 2022 | DS DP U-869 | | M-194 | Jan 17, 2020 |
| | | 6642210 | Jun 22, 2019 | DS DP U-869 | | | |
| | | 7144872 | Jun 22, 2019 | DS DP U-116 | | | |
| | | 7144872 | Jun 22, 2019 | DS DP U-869 | | | |
| | | 7144872 | Jun 22, 2019 | DS DP U-870 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| REGADENOSON - LEXISCAN | | | | | | | |
| N 022161 | 001 | 7183264 | Jun 22, 2019 | DP U-116 | | | |
| | | 7183264 | Jun 22, 2019 | DP U-869 | | | |
| | | 7183264 | Jun 22, 2019 | DP U-870 | | | |
| | | 7582617 | Jun 22, 2019 | U-1003 | | | |
| | | 7655636 | Jun 22, 2019 | U-869 | | | |
| | | 7655637 | Jun 22, 2019 | DS DP U-869 | | | |
| | | 7683037 | Jun 22, 2019 | U-1042 | | | |
| | | 8106029 | Jun 22, 2019 | U-1042 | | | |
| | | 8106183 | Feb 02, 2027 | DS | | | |
| | | 8133879 | Jun 22, 2019 | DP | | | |
| | | 8183226 | Jun 22, 2019 | U-116 | | | |
| | | 8470801 | Jun 22, 2019 | U-116 | | | |
| | | 8536150 | Jun 22, 2019 | U-116 | | | |
| | | 9045519 | Jun 22, 2019 | DP | | | |
| | | 9085601 | Feb 02, 2027 | DP | | | |
| | | 9289446 | Jun 22, 2019 | DP U-116 | | | |
| REGORAFENIB - STIVARGA | | | | | | | |
| N 203085 | 001 | 7351834 | Jun 28, 2022 | DS | | I-744 | Apr 27, 2020 |
| | | 8637553 | Feb 16, 2031 | DS DP | | NCE | Sep 27, 2017 |
| | | 8680124 | Jun 02, 2030 | U-1506 | | ODE-139 | Apr 27, 2024 |
| | | 9458107 | Apr 08, 2031 | DP | | ODE-44 | Feb 25, 2020 |
| REMIFENTANIL HYDROCHLORIDE - ULTIVA | | | | | | | |
| N 020630 | 001 | 5866591 | Sep 10, 2017 | DP | | | |
| REMIFENTANIL HYDROCHLORIDE - ULTIVA | | | | | | | |
| N 020630 | 002 | 5866591 | Sep 10, 2017 | DP | | | |
| REMIFENTANIL HYDROCHLORIDE - ULTIVA | | | | | | | |
| N 020630 | 003 | 5866591 | Sep 10, 2017 | DP | | | |
| RETAPAMULIN - ALTABAX | | | | | | | |
| N 022055 | 001 | 7875630 | Feb 14, 2027 | DS | | | |
| | | 8207191 | Aug 30, 2024 | U-805 | | | |
| | | RE43390 | Apr 12, 2021 | DS DP U-805 | | | |
| RIBAVIRIN - VIRAZOLE | | | | | | | |
| N 018859 | 001 | 6150337 | Nov 21, 2017 | U-400 | | | |
| RIBAVIRIN - REBETOL | | | | | | | |
| N 020903 | 001 | 6172046 | Sep 21, 2017 | U-1014 | | | |
| | | 6172046 | Sep 21, 2017 | U-377 | | | |
| | | 6472373 | Sep 21, 2017 | U-1014 | | | |
| | | 6472373 | Sep 21, 2017 | U-479 | | | |
| RIBAVIRIN - REBETOL | | | | | | | |
| N 020903 | 002 | 6172046 | Sep 21, 2017 | U-1014 | | | |
| | | 6172046 | Sep 21, 2017 | U-377 | | | |
| | | 6472373 | Sep 21, 2017 | U-1014 | | | |
| | | 6472373 | Sep 21, 2017 | U-479 | | | |
| RIBAVIRIN - REBETOL | | | | | | | |
| N 021546 | 001 | 6172046 | Sep 21, 2017 | U-1014 | | | |
| | | 6172046 | Sep 21, 2017 | U-521 | | | |
| | | 6472373 | Sep 21, 2017 | U-521 | | | |
| | | 6790837 | Apr 05, 2023 | DP | | | |
| RIBOCICLIB SUCCINATE - KISQALI | | | | | | | |
| N 209092 | 001 | 8324225 | Jun 17, 2028 | DS DP | | NCE | Mar 13, 2022 |
| | | 8415355 | Feb 19, 2031 | DS DP | | | |
| | | 8685980 | May 25, 2030 | DS DP | | | |
| | | 8962630 | Dec 09, 2029 | U-1981 | | | |
| | | 9193732 | Nov 09, 2031 | DS DP | | | |
| | | 9416136 | Aug 20, 2029 | U-1981 | | | |
| RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA | | | | | | | |
| N 203324 | 001 | | | | | NP | Apr 15, 2019 |
| | | | | | | ODE-116 | Apr 15, 2023 |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA | | | | | | |
| N 203324 001 | | | | | ODE-121 | Jul 15, 2023 |
| RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA VISCOUS IN DEXTRAN 20% | | | | | | |
| N 203324 002 | | | | | NP | Apr 15, 2019 |
| | | | | | ODE-116 | Apr 15, 2023 |
| | | | | | ODE-121 | Jul 15, 2023 |
| RIFAXIMIN - XIFAXAN | | | | | | |
| N 021361 001 | 7045620 | Jun 19, 2024 | DS DP | | | |
| | 7612199 | Jun 19, 2024 | DS DP | | | |
| | 7902206 | Jun 19, 2024 | DS DP | | | |
| | 7906542 | Jun 01, 2025 | DS DP | | | |
| | 7928115 | Jul 24, 2029 | U-1121 | | | |
| | 8158644 | Jun 19, 2024 | DP | | | |
| | 8158781 | Jun 19, 2024 | DS | | | |
| | 8193196 | Sep 02, 2027 | DS DP | | | |
| | 8518949 | Feb 27, 2026 | DP | | | |
| | 8741904 | Feb 27, 2026 | DS U-1526 | | | |
| | 8835452 | Jun 19, 2024 | DS DP | | | |
| | 8853231 | Jun 19, 2024 | DP | | | |
| | 9271968 | Feb 27, 2026 | DP | | | |
| RIFAXIMIN - XIFAXAN | | | | | | |
| N 022554 001 | 6861053 | Aug 11, 2019 | U-1707 | | I-709 | May 27, 2018 |
| | 6861053 | Aug 11, 2019 | U-1708 | | | |
| | 7045620 | Jun 19, 2024 | DS | | | |
| | 7452857 | Aug 11, 2019 | U-1707 | | | |
| | 7452857 | Aug 11, 2019 | U-1708 | | | |
| | 7605240 | Aug 11, 2019 | U-1707 | | | |
| | 7605240 | Aug 11, 2019 | U-1708 | | | |
| | 7612199 | Jun 19, 2024 | DS DP | | | |
| | 7718608 | Aug 11, 2019 | U-1707 | | | |
| | 7718608 | Aug 11, 2019 | U-1708 | | | |
| | 7902206 | Jun 19, 2024 | DS DP | | | |
| | 7906542 | Jun 01, 2025 | DS DP | | | |
| | 7915275 | Feb 23, 2025 | U-1707 | | | |
| | 7915275 | Feb 23, 2025 | U-1708 | | | |
| | 7935799 | Aug 11, 2019 | U-1707 | | | |
| | 7935799 | Aug 11, 2019 | U-1708 | | | |
| | 8158644 | Jun 19, 2024 | DP | | | |
| | 8158781 | Jun 19, 2024 | DS | | | |
| | 8193196 | Sep 02, 2027 | DS DP U-1707 | | | |
| | 8193196 | Sep 02, 2027 | DS DP U-1708 | | | |
| | 8309569 | Jul 18, 2029 | U-1707 | | | |
| | 8309569 | Jul 18, 2029 | U-1708 | | | |
| | 8518949 | Feb 27, 2026 | DP | | | |
| | 8642573 | Oct 02, 2029 | U-1481 | | | |
| | 8741904 | Feb 27, 2026 | DS U-1526 | | | |
| | 8741904 | Feb 27, 2026 | DS U-1707 | | | |
| | 8741904 | Feb 27, 2026 | DS U-1708 | | | |
| | 8829017 | Jul 24, 2029 | U-1562 | | | |
| | 8835452 | Jun 19, 2024 | DS DP | | | |
| | 8853231 | Jun 19, 2024 | DP | | | |
| | 8946252 | Jul 24, 2029 | U-1481 | | | |
| | 8969398 | Oct 02, 2029 | U-1481 | | | |
| | 9271968 | Feb 27, 2026 | DP | | | |
| | 9421195 | Mar 10, 2030 | U-1481 | | | |
| | 9629828 | Jul 24, 2029 | U-1994 | | | |
| RILPIVIRINE HYDROCHLORIDE - EDURANT | | | | | | |
| N 202022 001 | 6838464 | Feb 26, 2021 | DS DP | | NPP | Aug 26, 2018 |
| | 7067522 | Dec 20, 2019 | DS DP | | | |
| | 7125879 | Apr 21, 2025 | DS DP U-1153 | | | |
| | 7125879 | Apr 21, 2025 | DS DP U-1307 | | | |
| | 7125879 | Apr 21, 2025 | DS DP U-1740 | | | |
| | 7638522 | Apr 14, 2023 | DP | | | |
| | 8080551 | Apr 11, 2023 | DS DP | | | |
| | 8101629 | Aug 09, 2022 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| RIOCIGUAT - ADEMPAS | | | | | | | |
| N 204819 | 001 | 6743798 | Jul 16, 2019 | DS DP | | NCE | Oct 08, 2018 |
| | | 7173037 | Apr 25, 2023 | DS DP | | ODE-53 | Oct 08, 2020 |
| RIOCIGUAT - ADEMPAS | | | | | | | |
| N 204819 | 002 | 6743798 | Jul 16, 2019 | DS DP | | NCE | Oct 08, 2018 |
| | | 7173037 | Apr 25, 2023 | DS DP | | ODE-53 | Oct 08, 2020 |
| RIOCIGUAT - ADEMPAS | | | | | | | |
| N 204819 | 003 | 6743798 | Jul 16, 2019 | DS DP | | NCE | Oct 08, 2018 |
| | | 7173037 | Apr 25, 2023 | DS DP | | ODE-53 | Oct 08, 2020 |
| RIOCIGUAT - ADEMPAS | | | | | | | |
| N 204819 | 004 | 6743798 | Jul 16, 2019 | DS DP | | NCE | Oct 08, 2018 |
| | | 7173037 | Apr 25, 2023 | DS DP | | ODE-53 | Oct 08, 2020 |
| RIOCIGUAT - ADEMPAS | | | | | | | |
| N 204819 | 005 | 6743798 | Jul 16, 2019 | DS DP | | NCE | Oct 08, 2018 |
| | | 7173037 | Apr 25, 2023 | DS DP | | ODE-53 | Oct 08, 2020 |
| RISEDRONATE SODIUM - ACTONEL | | | | | | | |
| N 020835 | 001 | 6165513 | Jun 10, 2018 | | | | |
| RISEDRONATE SODIUM - ACTONEL | | | | | | | |
| N 020835 | 002 | 6165513 | Jun 10, 2018 | | | | |
| RISEDRONATE SODIUM - ACTONEL | | | | | | | |
| N 020835 | 003 | 5994329 | Jul 17, 2018 | U-353 | | | |
| | | 6015801 | Jul 17, 2018 | U-353 | | | |
| | | 6165513 | Jun 10, 2018 | DP | | | |
| | | 6432932 | Jul 17, 2018 | U-595 | | | |
| | | 6465443 | Aug 14, 2018 | DP | | | |
| RISEDRONATE SODIUM - ACTONEL | | | | | | | |
| N 020835 | 004 | 6165513 | Jun 10, 2018 | DP | | | |
| RISEDRONATE SODIUM - ACTONEL | | | | | | | |
| N 020835 | 005 | 6165513 | Jun 10, 2018 | DP | | | |
| | | 7192938 | May 06, 2023 | U-353 | | | |
| | | 7718634 | May 06, 2023 | U-662 | | | |
| RISEDRONATE SODIUM - ATELVIA | | | | | | | |
| N 022560 | 001 | 7645459 | Jan 09, 2028 | DP U-662 | | | |
| | | 7645460 | Jan 09, 2028 | DP U-662 | | | |
| | | 8246989 | Jan 16, 2026 | DP | | | |
| RISPERIDONE - RISPERDAL CONSTA | | | | | | | |
| N 021346 | 001 | 6194006 | Dec 30, 2018 | DP | | | |
| | | 6379703 | Dec 30, 2018 | DP | | | |
| | | 6596316 | Dec 30, 2018 | DP | | | |
| | | 6667061 | May 25, 2020 | DP | | | |
| RISPERIDONE - RISPERDAL CONSTA | | | | | | | |
| N 021346 | 002 | 6194006 | Dec 30, 2018 | DP | | | |
| | | 6379703 | Dec 30, 2018 | DP | | | |
| | | 6596316 | Dec 30, 2018 | DP | | | |
| | | 6667061 | May 25, 2020 | DP | | | |
| RISPERIDONE - RISPERDAL CONSTA | | | | | | | |
| N 021346 | 003 | 6194006 | Dec 30, 2018 | DP | | | |
| | | 6379703 | Dec 30, 2018 | DP | | | |
| | | 6596316 | Dec 30, 2018 | DP | | | |
| | | 6667061 | May 25, 2020 | DP | | | |
| RISPERIDONE - RISPERDAL CONSTA | | | | | | | |
| N 021346 | 004 | 6194006 | Dec 30, 2018 | DP | | | |
| | | 6379703 | Dec 30, 2018 | DP | | | |
| | | 6596316 | Dec 30, 2018 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| RITONAVIR - NORVIR | | | | | | |
| N 020945 001 | 6232333 | Nov 07, 2017 | | | | |
| | 7141593 | May 22, 2020 | DP | | | |
| | 7432294 | May 22, 2020 | DP | | | |
| RITONAVIR - NORVIR | | | | | | |
| N 022417 001 | 7148359 | Jul 19, 2019 | DP | | | |
| | 7364752 | Nov 10, 2020 | DP U-688 | | | |
| | 8268349 | Aug 25, 2024 | DP | | | |
| | 8399015 | Aug 25, 2024 | DP | | | |
| | 8399015*PED | Feb 25, 2025 | | | | |
| | 8470347 | Sep 17, 2026 | DP | | | |
| | 8470347*PED | Mar 17, 2027 | | | | |
| | 8691878 | Aug 25, 2024 | U-688 | | | |
| | 8691878*PED | Feb 25, 2025 | | | | |
| RIVAROXABAN - XARELTO | | | | | | |
| N 022406 001 | 7157456 | Aug 28, 2024 | DS DP U-1301 | | D-168 | Oct 27, 2020 |
| | 7157456 | Aug 28, 2024 | DS DP U-1302 | | | |
| | 7585860 | Dec 11, 2020 | DS | | | |
| | 7592339 | Dec 11, 2020 | U-1167 | | | |
| | 7592339 | Dec 11, 2020 | U-1200 | | | |
| | 7592339 | Dec 11, 2020 | U-1301 | | | |
| | 7592339 | Dec 11, 2020 | U-1302 | | | |
| | 7592339 | Dec 11, 2020 | U-1303 | | | |
| | 7592339 | Dec 11, 2020 | U-2142 | | | |
| | 9415053 | Nov 13, 2024 | DP U-1167 | | | |
| | 9415053 | Nov 13, 2024 | DP U-1200 | | | |
| | 9415053 | Nov 13, 2024 | DP U-1301 | | | |
| | 9415053 | Nov 13, 2024 | DP U-1302 | | | |
| | 9415053 | Nov 13, 2024 | DP U-1303 | | | |
| | 9415053 | Nov 13, 2024 | DP U-2142 | | | |
| | 9539218 | Feb 17, 2034 | U-1953 | | | |
| | 9539218 | Feb 17, 2034 | U-1954 | | | |
| | 9539218 | Feb 17, 2034 | U-1955 | | | |
| | 9539218 | Feb 17, 2034 | U-1956 | | | |
| | 9539218 | Feb 17, 2034 | U-1957 | | | |
| | 9539218 | Feb 17, 2034 | U-2143 | | | |
| RIVAROXABAN - XARELTO | | | | | | |
| N 022406 002 | 7157456 | Aug 28, 2024 | DS DP U-1301 | | | |
| | 7157456 | Aug 28, 2024 | DS DP U-1302 | | | |
| | 7585860 | Dec 11, 2020 | DS | | | |
| | 7592339 | Dec 11, 2020 | U-1167 | | | |
| | 7592339 | Dec 11, 2020 | U-1200 | | | |
| | 7592339 | Dec 11, 2020 | U-1301 | | | |
| | 7592339 | Dec 11, 2020 | U-1302 | | | |
| | 7592339 | Dec 11, 2020 | U-1303 | | | |
| | 9415053 | Nov 13, 2024 | DP U-1167 | | | |
| | 9415053 | Nov 13, 2024 | DP U-1200 | | | |
| | 9415053 | Nov 13, 2024 | DP U-1301 | | | |
| | 9415053 | Nov 13, 2024 | DP U-1302 | | | |
| | 9415053 | Nov 13, 2024 | DP U-1303 | | | |
| | 9539218 | Feb 17, 2034 | U-1953 | | | |
| | 9539218 | Feb 17, 2034 | U-1954 | | | |
| | 9539218 | Feb 17, 2034 | U-1955 | | | |
| | 9539218 | Feb 17, 2034 | U-1956 | | | |
| | 9539218 | Feb 17, 2034 | U-1957 | | | |
| RIVAROXABAN - XARELTO | | | | | | |
| N 022406 003 | 7157456 | Aug 28, 2024 | DS DP U-1301 | | | |
| | 7157456 | Aug 28, 2024 | DS DP U-1302 | | | |
| | 7585860 | Dec 11, 2020 | DS | | | |
| | 7592339 | Dec 11, 2020 | U-1167 | Y | | |
| | 7592339 | Dec 11, 2020 | U-1200 | Y | | |
| | 7592339 | Dec 11, 2020 | U-1301 | Y | | |
| | 7592339 | Dec 11, 2020 | U-1302 | Y | | |
| | 9415053 | Nov 13, 2024 | DP U-1167 | | | |
| | 9415053 | Nov 13, 2024 | DP U-1200 | | | |
| | 9415053 | Nov 13, 2024 | DP U-1301 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| RIVAROXABAN - XARELTO | | | | | | | |
| N 022406 | 003 | 9415053 | Nov 13, 2024 | DP U-1302 | | | |
| | | 9415053 | Nov 13, 2024 | DP U-1303 | | | |
| | | 9539218 | Feb 17, 2034 | U-1953 | | | |
| | | 9539218 | Feb 17, 2034 | U-1954 | | | |
| | | 9539218 | Feb 17, 2034 | U-1955 | | | |
| | | 9539218 | Feb 17, 2034 | U-1957 | | | |
| RIVASTIGMINE - EXELON | | | | | | | |
| N 022083 | 001 | 6316023 | Jan 08, 2019 | DP | | | |
| | | 6335031 | Jan 08, 2019 | DP | | | |
| RIVASTIGMINE - EXELON | | | | | | | |
| N 022083 | 002 | 6316023 | Jan 08, 2019 | DP | | | |
| | | 6335031 | Jan 08, 2019 | DP | | | |
| RIVASTIGMINE - EXELON | | | | | | | |
| N 022083 | 005 | 6316023 | Jan 08, 2019 | DP | | | |
| | | 6335031 | Jan 08, 2019 | DP | | | |
| ROFLUMILAST - DALIRESP | | | | | | | |
| N 022522 | 001 | 5712298 | Jan 27, 2020 | DS DP U-1115 | | M-208 | Aug 31, 2020 |
| | | 8431154 | Feb 19, 2023 | DP | | | |
| | | 8536206 | Mar 08, 2024 | U-1115 | | | |
| | | 8604064 | Mar 08, 2024 | U-1115 | | | |
| | | 8618142 | Mar 08, 2024 | DP | | | |
| | | 9468598 | Feb 19, 2023 | DP | | | |
| ROLAPITANT HYDROCHLORIDE - VARUBI | | | | | | | |
| N 206500 | 001 | 7049320 | Dec 08, 2023 | DS DP U-1741 | | NCE | Sep 01, 2020 |
| | | 7563801 | Apr 04, 2027 | DP | | | |
| | | 7981905 | Apr 04, 2027 | U-1741 | | | |
| | | 8178550 | Apr 04, 2027 | DS DP | | | |
| | | 8361500 | Oct 09, 2029 | DP | | | |
| | | 8404702 | Apr 04, 2027 | U-1741 | | | |
| | | 8470842 | Jan 18, 2029 | U-1741 | | | |
| | | 8796299 | Dec 17, 2022 | U-1741 | | | |
| ROLAPITANT HYDROCHLORIDE - VARUBI | | | | | | | |
| N 208399 | 001 | 7049320 | Dec 08, 2023 | DS DP U-1741 | | NCE | Sep 01, 2020 |
| | | 7981905 | Apr 04, 2027 | U-1741 | | | |
| | | 8178550 | Apr 04, 2027 | DS DP | | | |
| | | 8404702 | Apr 04, 2027 | U-1741 | | | |
| | | 8470842 | Jan 18, 2029 | U-1741 | | | |
| | | 8796299 | Dec 17, 2022 | U-1741 | | | |
| | | 9101615 | Jul 14, 2032 | U-1741 | | | |
| ROMIDEPSIN - ISTODAX | | | | | | | |
| N 022393 | 001 | 7608280 | Aug 22, 2021 | DS | | ODE-12 | Jun 16, 2018 |
| | | 7611724 | Aug 22, 2021 | DS | | | |
| ROPINIROLE HYDROCHLORIDE - REQUIP XL | | | | | | | |
| N 022008 | 001 | 7927624 | Dec 02, 2021 | DP U-20 | | M-203 | Mar 23, 2020 |
| | | 8303986 | Apr 12, 2021 | DP | | | |
| ROPINIROLE HYDROCHLORIDE - REQUIP XL | | | | | | | |
| N 022008 | 002 | 7927624 | Dec 02, 2021 | DP U-20 | | M-203 | Mar 23, 2020 |
| | | 8303986 | Apr 12, 2021 | DP | | | |
| ROPINIROLE HYDROCHLORIDE - REQUIP XL | | | | | | | |
| N 022008 | 003 | 7927624 | Dec 02, 2021 | DP U-20 | | M-203 | Mar 23, 2020 |
| | | 8303986 | Apr 12, 2021 | DP | | | |
| ROPINIROLE HYDROCHLORIDE - REQUIP XL | | | | | | | |
| N 022008 | 004 | 7927624 | Dec 02, 2021 | DP U-20 | | M-203 | Mar 23, 2020 |
| | | 8303986 | Apr 12, 2021 | DP | | | |
| ROPINIROLE HYDROCHLORIDE - REQUIP XL | | | | | | | |
| N 022008 | 005 | 7927624 | Dec 02, 2021 | DP U-20 | | M-203 | Mar 23, 2020 |
| | | 8303986 | Apr 12, 2021 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| ROPINIROLE HYDROCHLORIDE - REQUIP XL | | | | | | | |
| N 022008 | 006 | 7927624 | Dec 02, 2021 | DP U-20 | | M-203 | Mar 23, 2020 |
| | | 8303986 | Apr 12, 2021 | DP | | | |
| ROPIVACAINE HYDROCHLORIDE - NAROPIN | | | | | | | |
| N 020533 | 006 | 7828787 | Oct 18, 2025 | DP | | | |
| | | 7857802 | Nov 28, 2026 | DP | | | |
| | | 8118802 | May 18, 2023 | DP | | | |
| | | 8162915 | May 23, 2024 | DP | | | |
| ROPIVACAINE HYDROCHLORIDE - NAROPIN | | | | | | | |
| N 020533 | 007 | 7828787 | Oct 18, 2025 | DP | | | |
| | | 7857802 | Nov 28, 2026 | DP | | | |
| | | 8118802 | May 18, 2023 | DP | | | |
| | | 8162915 | May 23, 2024 | DP | | | |
| ROSIGLITAZONE MALEATE - AVANDIA | | | | | | | |
| N 021071 | 002 | 7358366 | Apr 19, 2020 | DS | | | |
| ROSIGLITAZONE MALEATE - AVANDIA | | | | | | | |
| N 021071 | 003 | 7358366 | Apr 19, 2020 | DS | | | |
| ROSIGLITAZONE MALEATE - AVANDIA | | | | | | | |
| N 021071 | 004 | 7358366 | Apr 19, 2020 | DS | | | |
| ROSUVASTATIN CALCIUM - CRESTOR | | | | | | | |
| N 021366 | 002 | 6316460 | Aug 04, 2020 | DP | | NPP | Nov 20, 2018 |
| | | 6858618 | Dec 17, 2021 | U-1032 | | ODE-118 | May 27, 2023 |
| | | 6858618 | Dec 17, 2021 | U-1807 | | | |
| | | 6858618 | Dec 17, 2021 | U-618 | | | |
| | | 6858618*PED | Jun 17, 2022 | | | | |
| | | 7030152 | Apr 02, 2018 | U-1032 | | | |
| | | 7964614 | Apr 02, 2018 | U-1032 | | | |
| ROSUVASTATIN CALCIUM - CRESTOR | | | | | | | |
| N 021366 | 003 | 6316460 | Aug 04, 2020 | DP | | NPP | Nov 20, 2018 |
| | | 6858618 | Dec 17, 2021 | U-1032 | | ODE-118 | May 27, 2023 |
| | | 6858618 | Dec 17, 2021 | U-1807 | | | |
| | | 6858618 | Dec 17, 2021 | U-618 | | | |
| | | 6858618*PED | Jun 17, 2022 | | | | |
| | | 7030152 | Apr 02, 2018 | U-1032 | | | |
| | | 7964614 | Apr 02, 2018 | U-1032 | | | |
| ROSUVASTATIN CALCIUM - CRESTOR | | | | | | | |
| N 021366 | 004 | 6316460 | Aug 04, 2020 | DP | | I-732 | May 27, 2019 |
| | | 6858618 | Dec 17, 2021 | U-1032 | | NPP | Nov 20, 2018 |
| | | 6858618 | Dec 17, 2021 | U-1807 | | ODE-118 | May 27, 2023 |
| | | 6858618 | Dec 17, 2021 | U-618 | | | |
| | | 6858618*PED | Jun 17, 2022 | | | | |
| | | 7030152 | Apr 02, 2018 | U-1032 | | | |
| | | 7964614 | Apr 02, 2018 | U-1032 | | | |
| ROSUVASTATIN CALCIUM - CRESTOR | | | | | | | |
| N 021366 | 005 | 6316460 | Aug 04, 2020 | DP | | ODE-118 | May 27, 2023 |
| | | 6858618 | Dec 17, 2021 | U-618 | | | |
| | | 7030152 | Apr 02, 2018 | U-1032 | | | |
| | | 7964614 | Apr 02, 2018 | U-1032 | | | |
| ROTIGOTINE - NEUPRO | | | | | | | |
| N 021829 | 001 | 6699498 | Nov 27, 2020 | DP | | | |
| | | 6884434 | Mar 30, 2021 | DP | | | |
| | | 7413747 | Mar 18, 2019 | DP | | | |
| | | 8246979 | Sep 01, 2027 | DP U-1272 | | | |
| | | 8246979 | Sep 01, 2027 | DP U-1273 | | | |
| | | 8246980 | Nov 27, 2025 | DP | | | |
| | | 8617591 | Jul 22, 2023 | DP U-1474 | | | |
| ROTIGOTINE - NEUPRO | | | | | | | |
| N 021829 | 002 | 6699498 | Nov 27, 2020 | DP | | | |
| | | 6884434 | Mar 30, 2021 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| ROTIGOTINE - NEUPRO | | | | | | |
| N 021829 002 | 7413747 | Mar 18, 2019 | DP | | | |
| | 8246979 | Sep 01, 2027 | DP U-1272 | | | |
| | 8246979 | Sep 01, 2027 | DP U-1273 | | | |
| | 8246980 | Nov 27, 2025 | DP | | | |
| | 8617591 | Jul 22, 2023 | DP U-1474 | | | |
| ROTIGOTINE - NEUPRO | | | | | | |
| N 021829 003 | 6699498 | Nov 27, 2020 | DP | | | |
| | 6884434 | Mar 30, 2021 | DP | | | |
| | 7413747 | Mar 18, 2019 | DP | | | |
| | 8246979 | Sep 01, 2027 | DP U-1272 | | | |
| | 8246979 | Sep 01, 2027 | DP U-1273 | | | |
| | 8246980 | Nov 27, 2025 | DP | | | |
| | 8617591 | Jul 22, 2023 | DP U-1474 | | | |
| ROTIGOTINE - NEUPRO | | | | | | |
| N 021829 004 | 6699498 | Nov 27, 2020 | DP | | | |
| | 6884434 | Mar 30, 2021 | DP | | | |
| | 7413747 | Mar 18, 2019 | DP | | | |
| | 8246979 | Sep 01, 2027 | DP U-1272 | | | |
| | 8246979 | Sep 01, 2027 | DP U-1273 | | | |
| | 8246980 | Nov 27, 2025 | DP | | | |
| | 8617591 | Jul 22, 2023 | DP U-1474 | | | |
| ROTIGOTINE - NEUPRO | | | | | | |
| N 021829 005 | 6699498 | Nov 27, 2020 | DP | | | |
| | 6884434 | Mar 30, 2021 | DP | | | |
| | 7413747 | Mar 18, 2019 | DP | | | |
| | 8246979 | Sep 01, 2027 | DP U-1272 | | | |
| | 8246979 | Sep 01, 2027 | DP U-1273 | | | |
| | 8246980 | Nov 27, 2025 | DP | | | |
| | 8617591 | Jul 22, 2023 | DP U-1474 | | | |
| ROTIGOTINE - NEUPRO | | | | | | |
| N 021829 006 | 6699498 | Nov 27, 2020 | DP | | | |
| | 6884434 | Mar 30, 2021 | DP | | | |
| | 7413747 | Mar 18, 2019 | DP | | | |
| | 8246979 | Sep 01, 2027 | DP U-1272 | | | |
| | 8246979 | Sep 01, 2027 | DP U-1273 | | | |
| | 8246980 | Nov 27, 2025 | DP | | | |
| | 8617591 | Jul 22, 2023 | DP U-1474 | | | |
| RUCAPARIB CAMSYLATE - RUBRACA | | | | | | |
| N 209115 001 | 6495541 | Jan 10, 2020 | DS DP | | NCE | Dec 19, 2021 |
| | 7351701 | Jul 23, 2024 | U-2012 | | ODE-126 | Dec 19, 2023 |
| | 7531530 | Jul 23, 2024 | U-2012 | | | |
| | 8071579 | Aug 12, 2027 | U-2012 | | | |
| | 8143241 | Aug 12, 2027 | U-2012 | | | |
| | 8754072 | Feb 10, 2031 | DS DP | | | |
| | 8859562 | Aug 04, 2031 | U-2012 | | | |
| | 9045487 | Feb 10, 2031 | DS DP | | | |
| RUCAPARIB CAMSYLATE - RUBRACA | | | | | | |
| N 209115 002 | 6495541 | Jan 10, 2020 | DS DP | | NCE | Dec 19, 2021 |
| | 7351701 | Jul 23, 2024 | U-2012 | | ODE-126 | Dec 19, 2023 |
| | 7531530 | Jul 23, 2024 | U-2012 | | | |
| | 8071579 | Aug 12, 2027 | U-2012 | | | |
| | 8143241 | Aug 12, 2027 | U-2012 | | | |
| | 8754072 | Feb 10, 2031 | DS DP | | | |
| | 8859562 | Aug 04, 2031 | U-2012 | | | |
| | 9045487 | Feb 10, 2031 | DS DP | | | |
| RUCAPARIB CAMSYLATE - RUBRACA | | | | | | |
| N 209115 003 | 6495541 | Jan 10, 2020 | DS DP | | NCE | Dec 19, 2021 |
| | 7351701 | Jul 23, 2024 | U-2012 | | ODE-126 | Dec 19, 2023 |
| | 7531530 | Jul 23, 2024 | U-2012 | | | |
| | 8071579 | Aug 12, 2027 | U-2012 | | | |
| | 8143241 | Aug 12, 2027 | U-2012 | | | |
| | 8754072 | Feb 10, 2031 | DS DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| RUCAPARIB CAMSYLATE - RUBRACA | | | | | | | |
| N 209115 | 003 | 8859562 | Aug 04, 2031 | U-2012 | | | |
| | | 9045487 | Feb 10, 2031 | DS DP | | | |
| RUFINAMIDE - BANZEL | | | | | | | |
| N 021911 | 001 | 6740669 | Nov 14, 2022 | DS DP | | | |
| | | 6740669*PED | May 14, 2023 | | | | |
| | | 7750028 | Oct 19, 2018 | U-106 | | | |
| | | 7750028*PED | Apr 19, 2019 | | | | |
| | | 8076362 | Jun 08, 2018 | DP | | | |
| | | 8076362*PED | Dec 08, 2018 | | | | |
| RUFINAMIDE - BANZEL | | | | | | | |
| N 021911 | 002 | 6740669 | Nov 14, 2022 | DS DP | | | |
| | | 6740669*PED | May 14, 2023 | | | | |
| | | 7750028 | Oct 19, 2018 | U-106 | | | |
| | | 7750028*PED | Apr 19, 2019 | | | | |
| | | 8076362 | Jun 08, 2018 | DP | | | |
| | | 8076362*PED | Dec 08, 2018 | | | | |
| RUFINAMIDE - BANZEL | | | | | | | |
| N 021911 | 003 | 6740669 | Nov 14, 2022 | DS DP | | | |
| | | 6740669*PED | May 14, 2023 | | | | |
| | | 7750028 | Oct 19, 2018 | U-106 | | | |
| | | 7750028*PED | Apr 19, 2019 | | | | |
| | | 8076362 | Jun 08, 2018 | DP | | | |
| | | 8076362*PED | Dec 08, 2018 | | | | |
| RUFINAMIDE - BANZEL | | | | | | | |
| N 201367 | 001 | 6740669 | Nov 14, 2022 | DS DP | | | |
| | | 6740669*PED | May 14, 2023 | | | | |
| | | 7750028 | Oct 19, 2018 | U-106 | | | |
| | | 7750028*PED | Apr 19, 2019 | | | | |
| RUXOLITINIB PHOSPHATE - JAKAFI | | | | | | | |
| N 202192 | 001 | 7598257 | Dec 24, 2027 | DS DP U-1201 | | I-699 | Dec 04, 2017 |
| | | 7598257 | Dec 24, 2027 | DS DP U-1622 | | ODE-19 | Nov 16, 2018 |
| | | 8415362 | Dec 24, 2027 | DS DP | | ODE-79 | Dec 04, 2021 |
| | | 8722693 | Jun 12, 2028 | DS DP | | | |
| | | 8822481 | Jun 12, 2028 | U-1573 | | | |
| | | 8829013 | Jun 12, 2028 | U-1201 | | | |
| | | 8829013 | Jun 12, 2028 | U-1622 | | | |
| | | 9079912 | Dec 12, 2026 | U-1573 | | | |
| | | 9079912 | Dec 12, 2026 | U-1721 | | | |
| | | 9662335 | Dec 12, 2026 | DS | | | |
| RUXOLITINIB PHOSPHATE - JAKAFI | | | | | | | |
| N 202192 | 002 | 7598257 | Dec 24, 2027 | DS DP U-1201 | | I-699 | Dec 04, 2017 |
| | | 7598257 | Dec 24, 2027 | DS DP U-1622 | | ODE-19 | Nov 16, 2018 |
| | | 8415362 | Dec 24, 2027 | DS DP | | ODE-79 | Dec 04, 2021 |
| | | 8722693 | Jun 12, 2028 | DS DP | | | |
| | | 8822481 | Jun 12, 2028 | U-1573 | | | |
| | | 8829013 | Jun 12, 2028 | U-1201 | | | |
| | | 8829013 | Jun 12, 2028 | U-1622 | | | |
| | | 9079912 | Dec 12, 2026 | U-1573 | | | |
| | | 9079912 | Dec 12, 2026 | U-1721 | | | |
| | | 9662335 | Dec 12, 2026 | DS | | | |
| RUXOLITINIB PHOSPHATE - JAKAFI | | | | | | | |
| N 202192 | 003 | 7598257 | Dec 24, 2027 | DS DP U-1201 | | I-699 | Dec 04, 2017 |
| | | 7598257 | Dec 24, 2027 | DS DP U-1622 | | ODE-19 | Nov 16, 2018 |
| | | 8415362 | Dec 24, 2027 | DS DP | | ODE-79 | Dec 04, 2021 |
| | | 8722693 | Jun 12, 2028 | DS DP | | | |
| | | 8822481 | Jun 12, 2028 | U-1573 | | | |
| | | 8829013 | Jun 12, 2028 | U-1201 | | | |
| | | 8829013 | Jun 12, 2028 | U-1622 | | | |
| | | 9079912 | Dec 12, 2026 | U-1573 | | | |
| | | 9079912 | Dec 12, 2026 | U-1721 | | | |
| | | 9662335 | Dec 12, 2026 | DS | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| RUXOLITINIB PHOSPHATE - JAKAFI | | | | | | | |
| N 202192 | 004 | 7598257 | Dec 24, 2027 | DS DP U-1201 | | I-699 | Dec 04, 2017 |
| | | 7598257 | Dec 24, 2027 | DS DP U-1622 | | ODE-19 | Nov 16, 2018 |
| | | 8415362 | Dec 24, 2027 | DS DP | | ODE-79 | Dec 04, 2021 |
| | | 8722693 | Jun 12, 2028 | DS DP | | | |
| | | 8822481 | Jun 12, 2028 | U-1573 | | | |
| | | 8829013 | Jun 12, 2028 | U-1201 | | | |
| | | 8829013 | Jun 12, 2028 | U-1622 | | | |
| | | 9079912 | Dec 12, 2026 | U-1573 | | | |
| | | 9079912 | Dec 12, 2026 | U-1721 | | | |
| | | 9662335 | Dec 12, 2026 | DS | | | |
| RUXOLITINIB PHOSPHATE - JAKAFI | | | | | | | |
| N 202192 | 005 | 7598257 | Dec 24, 2027 | DS DP U-1201 | | I-699 | Dec 04, 2017 |
| | | 7598257 | Dec 24, 2027 | DS DP U-1622 | | ODE-19 | Nov 16, 2018 |
| | | 8415362 | Dec 24, 2027 | DS DP | | ODE-79 | Dec 04, 2021 |
| | | 8722693 | Jun 12, 2028 | DS DP | | | |
| | | 8822481 | Jun 12, 2028 | U-1573 | | | |
| | | 8829013 | Jun 12, 2028 | U-1201 | | | |
| | | 8829013 | Jun 12, 2028 | U-1622 | | | |
| | | 9079912 | Dec 12, 2026 | U-1573 | | | |
| | | 9079912 | Dec 12, 2026 | U-1721 | | | |
| | | 9662335 | Dec 12, 2026 | DS | | | |
| SACROSIDASE - SUCRAID | | | | | | | |
| N 020772 | 001 | 9469847 | Feb 07, 2034 | DS DP | | | |
| SACUBITRIL; VALSARTAN - ENTRESTO | | | | | | | |
| N 207620 | 001 | 7468390 | Nov 27, 2023 | DP | | NCE | Jul 07, 2020 |
| | | 8101659 | Jan 14, 2023 | DP | | | |
| | | 8404744 | Jan 14, 2023 | DP | | | |
| | | 8796331 | Jan 14, 2023 | U-1723 | | | |
| | | 8877938 | May 27, 2027 | DS DP | | | |
| | | 9388134 | Nov 08, 2026 | U-1723 | | | |
| SACUBITRIL; VALSARTAN - ENTRESTO | | | | | | | |
| N 207620 | 002 | 7468390 | Nov 27, 2023 | DP | | NCE | Jul 07, 2020 |
| | | 8101659 | Jan 14, 2023 | DP | | | |
| | | 8404744 | Jan 14, 2023 | DP | | | |
| | | 8796331 | Jan 14, 2023 | U-1723 | | | |
| | | 8877938 | May 27, 2027 | DS DP | | | |
| | | 9388134 | Nov 08, 2026 | U-1723 | | | |
| SACUBITRIL; VALSARTAN - ENTRESTO | | | | | | | |
| N 207620 | 003 | 7468390 | Nov 27, 2023 | DP | | NCE | Jul 07, 2020 |
| | | 8101659 | Jan 14, 2023 | DP | | | |
| | | 8404744 | Jan 14, 2023 | DP | | | |
| | | 8796331 | Jan 14, 2023 | U-1723 | | | |
| | | 8877938 | May 27, 2027 | DS DP | | | |
| | | 9388134 | Nov 08, 2026 | U-1723 | | | |
| SAFINAMIDE MESYLATE - XADAGO | | | | | | | |
| N 207145 | 001 | 8076515 | Dec 10, 2028 | DS DP U-1993 | | NCE | Mar 21, 2022 |
| | | 8278485 | Jun 08, 2027 | DS U-1993 | | | |
| | | 8283380 | Sep 01, 2027 | U-1993 | | | |
| SAFINAMIDE MESYLATE - XADAGO | | | | | | | |
| N 207145 | 002 | 8076515 | Dec 10, 2028 | DS DP U-1993 | | NCE | Mar 21, 2022 |
| | | 8278485 | Jun 08, 2027 | DS U-1993 | | | |
| | | 8283380 | Sep 01, 2027 | U-1993 | | | |
| SAPROPTERIN DIHYDROCHLORIDE - KUVAN | | | | | | | |
| N 022181 | 001 | 7566462 | Nov 16, 2025 | DP | | | |
| | | 7566462*PED | May 16, 2026 | | | | |
| | | 7566714 | Nov 17, 2024 | U-989 | | | |
| | | 7566714*PED | May 17, 2025 | | | | |
| | | 7612073 | Nov 17, 2024 | U-1010 | | | |
| | | 7612073*PED | May 17, 2025 | | | | |
| | | 7727987 | Nov 17, 2024 | DP | | | |
| | | 7727987*PED | May 17, 2025 | | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| SAPROPTERIN DIHYDROCHLORIDE - KUVAN | | | | | | | |
| N 022181 | 001 | 7947681 | Nov 17, 2024 | U-1156 | Y | | |
| | | 7947681*PED | May 17, 2025 | | | | |
| | | 8003126 | Nov 16, 2025 | | | | |
| | | 8003126*PED | May 16, 2026 | | | | |
| | | 8067416 | Nov 17, 2024 | U-989 | | | |
| | | 8067416*PED | May 17, 2025 | | | | |
| | | 8318745 | Nov 17, 2024 | DP | | | |
| | | 8318745*PED | May 17, 2025 | | | | |
| | | 9433624 | Nov 17, 2024 | U-1589 | | | |
| | | RE43797 | Nov 17, 2024 | U-1156 | | | |
| | | RE43797*PED | May 17, 2025 | | | | |
| SAPROPTERIN DIHYDROCHLORIDE - KUVAN | | | | | | | |
| N 205065 | 001 | 7566714 | Nov 17, 2024 | U-1589 | | | |
| | | 7566714*PED | May 17, 2025 | | | | |
| | | 7612073 | Nov 17, 2024 | U-1010 | | | |
| | | 7612073*PED | May 17, 2025 | | | | |
| | | 8067416 | Nov 17, 2024 | U-1589 | | | |
| | | 8067416*PED | May 17, 2025 | | | | |
| | | 9216178 | Nov 01, 2032 | DP | | | |
| | | 9433624 | Nov 17, 2024 | U-1589 | | | |
| | | RE43797 | Nov 17, 2024 | U-1590 | | | |
| | | RE43797*PED | May 17, 2025 | | | | |
| SAPROPTERIN DIHYDROCHLORIDE - KUVAN | | | | | | | |
| N 205065 | 002 | 7566714 | Nov 17, 2024 | U-1589 | | | |
| | | 7566714*PED | May 17, 2025 | | | | |
| | | 7612073 | Nov 17, 2024 | U-1010 | | | |
| | | 7612073*PED | May 17, 2025 | | | | |
| | | 8067416 | Nov 17, 2024 | U-1589 | | | |
| | | 8067416*PED | May 17, 2025 | | | | |
| | | 9216178 | Nov 01, 2032 | DP | | | |
| | | 9433624 | Nov 17, 2024 | U-1589 | | | |
| | | RE43797 | Nov 17, 2024 | U-1590 | | | |
| | | RE43797*PED | May 17, 2025 | | | | |
| SAQUINAVIR - FORTOVASE | | | | | | | |
| N 020828 | 001 | 6352717 | Nov 16, 2019 | | | | |
| SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA | | | | | | | |
| N 022350 | 001 | 7951400 | Nov 30, 2028 | DP | | M-175 | Apr 05, 2019 |
| | | RE44186 | Jul 31, 2023 | DS DP U-1837 | | M-198 | Feb 27, 2020 |
| | | RE44186 | Jul 31, 2023 | DS DP U-995 | | | |
| SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA | | | | | | | |
| N 022350 | 002 | 7951400 | Nov 30, 2028 | DP | | M-175 | Apr 05, 2019 |
| | | RE44186 | Jul 31, 2023 | DS DP U-1837 | | M-198 | Feb 27, 2020 |
| | | RE44186 | Jul 31, 2023 | DS DP U-995 | | | |
| SECNIDAZOLE - SOLOSEC | | | | | | | |
| N 209363 | 001 | | | | | NCE | Sep 15, 2022 |
| | | | | | | GAIN | Sep 15, 2027 |
| SELEGILINE - EMSAM | | | | | | | |
| N 021336 | 001 | 7070808 | May 10, 2018 | DS DP | | | |
| | | 7150881 | Jun 12, 2018 | DS DP | | | |
| | | 7638140 | May 10, 2018 | DP | | | |
| SELEGILINE - EMSAM | | | | | | | |
| N 021336 | 002 | 7070808 | May 10, 2018 | DS DP | | | |
| | | 7150881 | Jun 12, 2018 | DS DP | | | |
| | | 7638140 | May 10, 2018 | DP | | | |
| SELEGILINE - EMSAM | | | | | | | |
| N 021336 | 003 | 7070808 | May 10, 2018 | DS DP | | | |
| | | 7150881 | Jun 12, 2018 | DS DP | | | |
| | | 7638140 | May 10, 2018 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| SELEXIPAG - UPTRAVI | | | | | | |
| N 207947 001 | 7205302 | Apr 04, 2023 | DS DP U-1797 | | NCE | Dec 21, 2020 |
| | 8791122 | Aug 01, 2030 | DS DP | | ODE-106 | Dec 21, 2022 |
| | 9173881 | Aug 12, 2029 | U-1798 | | | |
| | 9284280 | Jun 25, 2030 | U-1831 | | | |
| SELEXIPAG - UPTRAVI | | | | | | |
| N 207947 002 | 7205302 | Apr 04, 2023 | DS DP U-1797 | | NCE | Dec 21, 2020 |
| | 8791122 | Aug 01, 2030 | DS DP | | ODE-106 | Dec 21, 2022 |
| | 9173881 | Aug 12, 2029 | U-1798 | | | |
| | 9284280 | Jun 25, 2030 | U-1831 | | | |
| SELEXIPAG - UPTRAVI | | | | | | |
| N 207947 003 | 7205302 | Apr 04, 2023 | DS DP U-1797 | | NCE | Dec 21, 2020 |
| | 8791122 | Aug 01, 2030 | DS DP | | ODE-106 | Dec 21, 2022 |
| | 9173881 | Aug 12, 2029 | U-1798 | | | |
| | 9284280 | Jun 25, 2030 | U-1831 | | | |
| SELEXIPAG - UPTRAVI | | | | | | |
| N 207947 004 | 7205302 | Apr 04, 2023 | DS DP U-1797 | | NCE | Dec 21, 2020 |
| | 8791122 | Aug 01, 2030 | DS DP | | ODE-106 | Dec 21, 2022 |
| | 9173881 | Aug 12, 2029 | U-1798 | | | |
| | 9284280 | Jun 25, 2030 | U-1831 | | | |
| SELEXIPAG - UPTRAVI | | | | | | |
| N 207947 005 | 7205302 | Apr 04, 2023 | DS DP U-1797 | | NCE | Dec 21, 2020 |
| | 8791122 | Aug 01, 2030 | DS DP | | ODE-106 | Dec 21, 2022 |
| | 9173881 | Aug 12, 2029 | U-1798 | | | |
| | 9284280 | Jun 25, 2030 | U-1831 | | | |
| SELEXIPAG - UPTRAVI | | | | | | |
| N 207947 006 | 7205302 | Apr 04, 2023 | DS DP U-1797 | | NCE | Dec 21, 2020 |
| | 8791122 | Aug 01, 2030 | DS DP | | ODE-106 | Dec 21, 2022 |
| | 9173881 | Aug 12, 2029 | U-1798 | | | |
| | 9284280 | Jun 25, 2030 | U-1831 | | | |
| SELEXIPAG - UPTRAVI | | | | | | |
| N 207947 007 | 7205302 | Apr 04, 2023 | DS DP U-1797 | | NCE | Dec 21, 2020 |
| | 8791122 | Aug 01, 2030 | DS DP | | ODE-106 | Dec 21, 2022 |
| | 9173881 | Aug 12, 2029 | U-1798 | | | |
| | 9284280 | Jun 25, 2030 | U-1831 | | | |
| SELEXIPAG - UPTRAVI | | | | | | |
| N 207947 008 | 7205302 | Apr 04, 2023 | DS DP U-1797 | | NCE | Dec 21, 2020 |
| | 8791122 | Aug 01, 2030 | DS DP | | ODE-106 | Dec 21, 2022 |
| | 9173881 | Aug 12, 2029 | U-1798 | | | |
| | 9284280 | Jun 25, 2030 | U-1831 | | | |
| SEMAGLUTIDE - OZEMPIC | | | | | | |
| N 209637 001 | 6899699 | Jan 02, 2022 | DP | | NCE | Dec 05, 2022 |
| | 7762994 | May 23, 2024 | DP | | | |
| | 8114833 | Aug 13, 2025 | DP | | | |
| | 8129343 | Jan 29, 2029 | DS DP U-2202 | | | |
| | 8536122 | Mar 20, 2026 | DS DP U-2202 | | | |
| | 8579869 | Jun 30, 2023 | DP | | | |
| | 8672898 | Jan 02, 2022 | DP | | | |
| | 8684969 | Oct 20, 2025 | DP | | | |
| | 8920383 | Jul 17, 2026 | DP | | | |
| | 9108002 | Jan 20, 2026 | DP | | | |
| | 9132239 | Feb 01, 2032 | DP | | | |
| | 9457154 | Sep 27, 2027 | DP | | | |
| | 9486588 | Jan 02, 2022 | DP | | | |
| | 9687611 | Feb 27, 2027 | DP | | | |
| | 9775953 | Jul 17, 2026 | DP | | | |
| | RE46363 | Aug 03, 2026 | DP | | | |
| SERTRALINE HYDROCHLORIDE - ZOLOFT | | | | | | |
| N 020990 001 | 6727283 | Oct 11, 2019 | DP U-580 | | | |
| | 7067555 | Oct 11, 2019 | DP | | | |
| | 7067555*PED | Apr 11, 2020 | | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|
| SERTRALINE HYDROCHLORIDE - ZOLOFT | | | | | | | | |
| N 020990 | 001 | | 6727283 | Oct 11, 2019 | DP U-580 | | | |
| | | | 7067555 | Oct 11, 2019 | DP | | | |
| | | | 7067555*PED | Apr 11, 2020 | | | | |
| SEVELAMER CARBONATE - RENVELA | | | | | | | | |
| N 022127 | 001 | | 7985418 | Oct 27, 2025 | DP | | NPP | Nov 25, 2019 |
| SEVELAMER CARBONATE - RENVELA | | | | | | | | |
| N 022318 | 001 | | 9095509 | Dec 06, 2030 | DP | | NPP | Nov 25, 2019 |
| SEVELAMER CARBONATE - RENVELA | | | | | | | | |
| N 022318 | 002 | | 9095509 | Dec 06, 2030 | DP | | NPP | Nov 25, 2019 |
| SEVELAMER HYDROCHLORIDE - RENAGEL | | | | | | | | |
| N 021179 | 001 | | 6733780 | Oct 18, 2020 | DP | | | |
| SEVELAMER HYDROCHLORIDE - RENAGEL | | | | | | | | |
| N 021179 | 002 | | 6733780 | Oct 18, 2020 | DP | | | |
| SEVOFLURANE - ULTANE | | | | | | | | |
| N 020478 | 001 | | 6074668 | Jan 09, 2018 | | | | |
| SILDENAFIL CITRATE - SILDENAFIL CITRATE | | | | | | | | |
| A 077342 | 001 | | | | | | PC | Jun 09, 2018 |
| SILDENAFIL CITRATE - SILDENAFIL CITRATE | | | | | | | | |
| A 077342 | 002 | | | | | | PC | Jun 09, 2018 |
| SILDENAFIL CITRATE - SILDENAFIL CITRATE | | | | | | | | |
| A 077342 | 003 | | | | | | PC | Jun 09, 2018 |
| SILDENAFIL CITRATE - VIAGRA | | | | | | | | |
| N 020895 | 001 | | 6469012 | Oct 22, 2019 | U-155 | | | |
| SILDENAFIL CITRATE - VIAGRA | | | | | | | | |
| N 020895 | 002 | | 6469012 | Oct 22, 2019 | U-155 | | | |
| SILDENAFIL CITRATE - VIAGRA | | | | | | | | |
| N 020895 | 003 | | 6469012 | Oct 22, 2019 | U-155 | | | |
| SILODOSIN - RAPAFLO | | | | | | | | |
| N 022206 | 001 | | 5387603 | Dec 01, 2018 | DS DP | | | |
| SILODOSIN - RAPAFLO | | | | | | | | |
| N 022206 | 002 | | 5387603 | Dec 01, 2018 | DS DP | | | |
| SIMEPREVIR SODIUM - OLYSIO | | | | | | | | |
| N 205123 | 001 | | 7671032 | May 19, 2025 | DS DP | | D-151 | Oct 05, 2018 |
| | | | 8148399 | Sep 05, 2029 | DS DP U-1467 | | I-697 | Nov 05, 2017 |
| | | | 8349869 | Jul 28, 2026 | DS DP U-1467 | | I-717 | Oct 05, 2018 |
| | | | 8741926 | Jul 28, 2026 | DS U-1467 | | M-171 | Feb 26, 2019 |
| | | | 8754106 | Jul 28, 2026 | DS U-1467 | | M-179 | May 20, 2019 |
| | | | 9040562 | Jul 28, 2026 | DS DP U-1467 | | NCE | Nov 22, 2018 |
| | | | 9353103 | Jul 28, 2026 | U-1467 | | | |
| | | | 9623022 | Jul 28, 2026 | U-1467 | | | |
| SIMVASTATIN - FLOLIPID | | | | | | | | |
| N 206679 | 001 | | 9597289 | Feb 23, 2030 | DP | | | |
| SIMVASTATIN - FLOLIPID | | | | | | | | |
| N 206679 | 002 | | 9597289 | Feb 23, 2030 | DP | | | |
| SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC | | | | | | | | |
| N 202343 | 001 | | 6699871 | Jul 26, 2022 | DS DP U-1188 | | | |
| | | | 6890898 | Feb 02, 2019 | U-1189 | | | |
| | | | 6890898 | Feb 02, 2019 | U-1190 | | | |
| | | | 6890898 | Feb 02, 2019 | U-1191 | | | |
| | | | 7078381 | Feb 02, 2019 | U-1188 | | | |
| | | | 7125873 | Jul 26, 2022 | DP U-1189 | | | |
| | | | 7125873 | Jul 26, 2022 | DP U-1190 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | | PATENT NO | PATENT EXPIRATION DATE | | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|---|
| SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC | | | | | | | | | |
| N 202343 | 001 | | 7125873 | Jul 26, 2022 | | DP U-1192 | | | |
| | | | 7125873 | Jul 26, 2022 | | DP U-1193 | | | |
| | | | 7326708 | Apr 11, 2026 | DS | DP U-1188 | | | |
| | | | 7459428 | Feb 02, 2019 | | U-1189 | | | |
| | | | 8168637 | Jun 26, 2022 | | DP U-1188 | | | |
| SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC | | | | | | | | | |
| N 202343 | 002 | | 6699871 | Jul 26, 2022 | DS | DP U-1188 | | | |
| | | | 6890898 | Feb 02, 2019 | | U-1189 | | | |
| | | | 6890898 | Feb 02, 2019 | | U-1190 | | | |
| | | | 6890898 | Feb 02, 2019 | | U-1191 | | | |
| | | | 7078381 | Feb 02, 2019 | | U-1188 | | | |
| | | | 7125873 | Jul 26, 2022 | | DP U-1189 | | | |
| | | | 7125873 | Jul 26, 2022 | | DP U-1190 | | | |
| | | | 7125873 | Jul 26, 2022 | | DP U-1192 | | | |
| | | | 7125873 | Jul 26, 2022 | | DP U-1193 | | | |
| | | | 7326708 | Apr 11, 2026 | DS | DP U-1188 | | | |
| | | | 7459428 | Feb 02, 2019 | | U-1189 | | | |
| | | | 8168637 | Jun 26, 2022 | | DP U-1188 | | | |
| SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC | | | | | | | | | |
| N 202343 | 003 | | 6699871 | Jul 26, 2022 | DS | DP U-1188 | | | |
| | | | 6890898 | Feb 02, 2019 | | U-1189 | | | |
| | | | 6890898 | Feb 02, 2019 | | U-1190 | | | |
| | | | 6890898 | Feb 02, 2019 | | U-1191 | | | |
| | | | 7078381 | Feb 02, 2019 | | U-1188 | | | |
| | | | 7125873 | Jul 26, 2022 | | DP U-1189 | | | |
| | | | 7125873 | Jul 26, 2022 | | DP U-1190 | | | |
| | | | 7125873 | Jul 26, 2022 | | DP U-1192 | | | |
| | | | 7125873 | Jul 26, 2022 | | DP U-1193 | | | |
| | | | 7326708 | Apr 11, 2026 | DS | DP U-1188 | | | |
| | | | 7459428 | Feb 02, 2019 | | U-1189 | | | |
| | | | 8168637 | Jun 26, 2022 | | DP U-1188 | | | |
| SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC | | | | | | | | | |
| N 202343 | 004 | | 6699871 | Jul 26, 2022 | DS | DP U-1188 | | | |
| | | | 6890898 | Feb 02, 2019 | | U-1189 | | | |
| | | | 6890898 | Feb 02, 2019 | | U-1190 | | | |
| | | | 6890898 | Feb 02, 2019 | | U-1191 | | | |
| | | | 7078381 | Feb 02, 2019 | | U-1188 | | | |
| | | | 7125873 | Jul 26, 2022 | | DP U-1189 | | | |
| | | | 7125873 | Jul 26, 2022 | | DP U-1190 | | | |
| | | | 7125873 | Jul 26, 2022 | | DP U-1192 | | | |
| | | | 7125873 | Jul 26, 2022 | | DP U-1193 | | | |
| | | | 7326708 | Apr 11, 2026 | DS | DP U-1188 | | | |
| | | | 7459428 | Feb 02, 2019 | | U-1189 | | | |
| | | | 8168637 | Jun 26, 2022 | | DP U-1188 | | | |
| SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC | | | | | | | | | |
| N 202343 | 005 | | 6699871 | Jul 26, 2022 | DS | DP U-1188 | | | |
| | | | 6890898 | Feb 02, 2019 | | U-1189 | | | |
| | | | 6890898 | Feb 02, 2019 | | U-1190 | | | |
| | | | 6890898 | Feb 02, 2019 | | U-1191 | | | |
| | | | 7078381 | Feb 02, 2019 | | U-1188 | | | |
| | | | 7125873 | Jul 26, 2022 | | DP U-1189 | | | |
| | | | 7125873 | Jul 26, 2022 | | DP U-1190 | | | |
| | | | 7125873 | Jul 26, 2022 | | DP U-1192 | | | |
| | | | 7125873 | Jul 26, 2022 | | DP U-1193 | | | |
| | | | 7326708 | Apr 11, 2026 | DS | DP U-1188 | | | |
| | | | 7459428 | Feb 02, 2019 | | U-1189 | | | |
| | | | 8168637 | Jun 26, 2022 | | DP U-1188 | | | |
| SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC | | | | | | | | | |
| N 202343 | 006 | | 6699871 | Jul 26, 2022 | DS | DP U-1188 | | | |
| | | | 6890898 | Feb 02, 2019 | | U-1189 | | | |
| | | | 6890898 | Feb 02, 2019 | | U-1190 | | | |
| | | | 6890898 | Feb 02, 2019 | | U-1191 | | | |
| | | | 7078381 | Feb 02, 2019 | | U-1188 | | | |
| | | | 7125873 | Jul 26, 2022 | | DP U-1189 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|
| SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC | | | | | | | | |
| N 202343 | 006 | | 7125873 | Jul 26, 2022 | DP U-1190 | | | |
| | | | 7125873 | Jul 26, 2022 | DP U-1192 | | | |
| | | | 7125873 | Jul 26, 2022 | DP U-1193 | | | |
| | | | 7326708 | Apr 11, 2026 | DS DP U-1188 | | | |
| | | | 7459428 | Feb 02, 2019 | U-1189 | | | |
| | | | 8168637 | Jun 26, 2022 | DP U-1188 | | | |
| SINCALIDE - KINEVAC | | | | | | | | |
| N 017697 | 001 | | 6803046 | Aug 16, 2022 | DP | | | |
| SINECATECHINS - VEREGEN | | | | | | | | |
| N 021902 | 001 | | 5795911 | Oct 31, 2020 | U-172 | | | |
| | | | 7858662 | Oct 02, 2026 | DP U-172 | | | |
| | | | 9770406 | Jul 12, 2025 | DP U-172 | | | |
| SIROLIMUS - RAPAMUNE | | | | | | | | |
| N 021083 | 001 | | | | | | ODE-92 | May 28, 2022 |
| SIROLIMUS - RAPAMUNE | | | | | | | | |
| N 021110 | 001 | | 5989591 | Mar 11, 2018 | DP | | ODE-92 | May 28, 2022 |
| SIROLIMUS - RAPAMUNE | | | | | | | | |
| N 021110 | 002 | | 5989591 | Mar 11, 2018 | DP | | ODE-92 | May 28, 2022 |
| SIROLIMUS - RAPAMUNE | | | | | | | | |
| N 021110 | 003 | | 5989591 | Mar 11, 2018 | DP | | ODE-92 | May 28, 2022 |
| SIROLIMUS - RAPAMUNE | | | | | | | | |
| N 021110 | 004 | | 5989591 | Mar 11, 2018 | DP | | ODE-92 | May 28, 2022 |
| SITAGLIPTIN PHOSPHATE - JANUVIA | | | | | | | | |
| N 021995 | 001 | | 6699871 | Jul 26, 2022 | DS DP U-774 | | | |
| | | | 6890898 | Feb 02, 2019 | U-1997 | | | |
| | | | 7078381 | Feb 02, 2019 | U-1997 | | | |
| | | | 7125873 | Jul 26, 2022 | U-1036 | | | |
| | | | 7125873 | Jul 26, 2022 | U-1037 | | | |
| | | | 7125873 | Jul 26, 2022 | U-1038 | | | |
| | | | 7125873 | Jul 26, 2022 | U-775 | | | |
| | | | 7326708 | Nov 24, 2026 | DS DP U-802 | | | |
| | | | 7459428 | Feb 02, 2019 | U-1945 | | | |
| SITAGLIPTIN PHOSPHATE - JANUVIA | | | | | | | | |
| N 021995 | 002 | | 6699871 | Jul 26, 2022 | DS DP U-774 | | | |
| | | | 6890898 | Feb 02, 2019 | U-1997 | | | |
| | | | 7078381 | Feb 02, 2019 | U-1997 | | | |
| | | | 7125873 | Jul 26, 2022 | U-1036 | | | |
| | | | 7125873 | Jul 26, 2022 | U-1037 | | | |
| | | | 7125873 | Jul 26, 2022 | U-1038 | | | |
| | | | 7125873 | Jul 26, 2022 | U-775 | | | |
| | | | 7326708 | Nov 24, 2026 | DS DP U-802 | | | |
| | | | 7459428 | Feb 02, 2019 | U-1945 | | | |
| SITAGLIPTIN PHOSPHATE - JANUVIA | | | | | | | | |
| N 021995 | 003 | | 6699871 | Jul 26, 2022 | DS DP U-774 | | | |
| | | | 6890898 | Feb 02, 2019 | U-1997 | | | |
| | | | 7078381 | Feb 02, 2019 | U-1997 | | | |
| | | | 7125873 | Jul 26, 2022 | U-1036 | | | |
| | | | 7125873 | Jul 26, 2022 | U-1037 | | | |
| | | | 7125873 | Jul 26, 2022 | U-1038 | | | |
| | | | 7125873 | Jul 26, 2022 | U-775 | | | |
| | | | 7326708 | Nov 24, 2026 | DS DP U-802 | | | |
| | | | 7459428 | Feb 02, 2019 | U-1945 | | | |
| SODIUM NITRITE - SODIUM NITRITE | | | | | | | | |
| N 203922 | 001 | | 8568793 | Dec 24, 2031 | DS DP | | ODE-5 | Jan 14, 2018 |
| SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE | | | | | | | | |
| N 201444 | 001 | | 8496973 | Mar 29, 2031 | DS DP U-1419 | | ODE-5 | Jan 14, 2018 |
| | | | 8568793 | Dec 24, 2031 | DS DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| SODIUM NITRITE; SODIUM THIOSULFATE - NITHIODOTE | | | | | | | |
| N 201444 | 001 | 9345724 | Mar 29, 2031 | DS DP U-2015 | | | |
| | | 9585912 | Mar 29, 2031 | DS DP | | | |
| SODIUM OXYBATE - XYREM | | | | | | | |
| N 021196 | 001 | 6780889 | Jul 04, 2020 | DP | | | |
| | | 7262219 | Jul 04, 2020 | DP | | | |
| | | 7668730 | Jun 16, 2024 | U-1110 | | | |
| | | 7765106 | Jun 16, 2024 | U-1069 | | | |
| | | 7765107 | Jun 16, 2024 | U-1070 | | | |
| | | 7851506 | Dec 22, 2019 | U-1101 | | | |
| | | 7851506 | Dec 22, 2019 | U-1102 | | | |
| | | 7895059 | Dec 17, 2022 | U-1110 | | | |
| | | 8263650 | Dec 22, 2019 | DP U-1101 | | | |
| | | 8263650 | Dec 22, 2019 | DP U-1102 | | | |
| | | 8324275 | Dec 22, 2019 | U-1101 | | | |
| | | 8324275 | Dec 22, 2019 | U-1102 | | | |
| | | 8457988 | Dec 17, 2022 | U-1110 | | | |
| | | 8589182 | Dec 17, 2022 | U-1110 | | | |
| | | 8731963 | Dec 17, 2022 | U-1110 | | | |
| | | 8772306 | Mar 15, 2033 | U-1532 | | | |
| | | 8859619 | Dec 22, 2019 | DP | | | |
| | | 8952062 | Dec 22, 2019 | U-1101 | | | |
| | | 8952062 | Dec 22, 2019 | U-1102 | | | |
| | | 9050302 | Mar 15, 2033 | U-1532 | | | |
| | | 9486426 | Mar 15, 2033 | U-1532 | | | |
| | | 9539330 | Dec 22, 2019 | DP | | | |
| SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE - OSMOPREP | | | | | | | |
| N 021892 | 001 | 7687075 | Jun 22, 2028 | DS DP | | | |
| SODIUM THIOSULFATE - SODIUM THIOSULFATE | | | | | | | |
| N 203923 | 001 | 8496973 | Mar 29, 2031 | DS DP U-1419 | | ODE-5 | Jan 14, 2018 |
| | | 9345724 | Mar 29, 2031 | DS DP U-2015 | | | |
| | | 9585912 | Mar 29, 2031 | DS DP | | | |
| SOFOSBUVIR - SOVALDI | | | | | | | |
| N 204671 | 001 | 7964580 | Mar 26, 2029 | DS DP U-1470 | | NCE | Dec 06, 2018 |
| | | 8334270 | Mar 21, 2028 | DS DP U-1470 | | NPP | Apr 07, 2020 |
| | | 8580765 | Mar 21, 2028 | DS DP U-1470 | | ODE-135 | Apr 07, 2024 |
| | | 8618076 | Dec 11, 2030 | DS DP U-1470 | | | |
| | | 8633309 | Mar 26, 2029 | DS DP U-1470 | | | |
| | | 8889159 | Mar 26, 2029 | DP U-1470 | | | |
| | | 9085573 | Mar 21, 2028 | DS DP U-1470 | | | |
| | | 9284342 | Sep 13, 2030 | DS DP U-1470 | | | |
| | | 9549941 | Mar 26, 2029 | U-1958 | | | |
| SOFOSBUVIR; VELPATASVIR - EPCLUSA | | | | | | | |
| N 208341 | 001 | 7964580 | Mar 26, 2029 | DS DP U-1470 | | NCE | Dec 06, 2018 |
| | | 8334270 | Mar 21, 2028 | DS DP U-1470 | | NCE | Jun 28, 2021 |
| | | 8575135 | Nov 16, 2032 | DS DP U-1470 | | NPP | Aug 01, 2020 |
| | | 8580765 | Mar 21, 2028 | DS DP U-1470 | | | |
| | | 8618076 | Dec 11, 2030 | DS DP U-1470 | | | |
| | | 8633309 | Mar 26, 2029 | DS DP U-1470 | | | |
| | | 8735372 | Mar 21, 2028 | U-1470 | | | |
| | | 8889159 | Mar 26, 2029 | DP U-1470 | | | |
| | | 8921341 | Nov 16, 2032 | DS DP U-1470 | | | |
| | | 8940718 | Nov 16, 2032 | DS DP U-1470 | | | |
| | | 9085573 | Mar 21, 2028 | DS DP U-1470 | | | |
| | | 9284342 | Sep 13, 2030 | DS DP U-1470 | | | |
| | | 9757406 | Jan 30, 2034 | DP | | | |
| SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI | | | | | | | |
| N 209195 | 001 | 7964580 | Mar 26, 2029 | DS DP U-2039 | | NCE | Jul 18, 2022 |
| | | 7964580 | Mar 26, 2029 | DS DP U-2040 | | | |
| | | 8334270 | Mar 21, 2028 | DS DP U-2039 | | | |
| | | 8334270 | Mar 21, 2028 | DS DP U-2040 | | | |
| | | 8575135 | Nov 05, 2033 | DS DP U-2039 | | | |
| | | 8575135 | Nov 05, 2033 | DS DP U-2040 | | | |
| | | 8580765 | Mar 21, 2028 | DS DP U-2039 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|
| SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI | | | | | | | | |
| N 209195 | 001 | | 8580765 | Mar 21, 2028 | DS DP U-2040 | | | |
| | | | 8618076 | Dec 11, 2030 | DS DP U-2039 | | | |
| | | | 8618076 | Dec 11, 2030 | DS DP U-2040 | | | |
| | | | 8633309 | Mar 26, 2029 | DS DP U-2039 | | | |
| | | | 8633309 | Mar 26, 2029 | DS DP U-2040 | | | |
| | | | 8735372 | Mar 21, 2028 | DS DP U-2039 | | | |
| | | | 8735372 | Mar 21, 2028 | DS DP U-2040 | | | |
| | | | 8889159 | Mar 26, 2029 | DS DP U-2039 | | | |
| | | | 8889159 | Mar 26, 2029 | DS DP U-2040 | | | |
| | | | 8921341 | Nov 16, 2032 | DS DP U-2039 | | | |
| | | | 8921341 | Nov 16, 2032 | DS DP U-2040 | | | |
| | | | 8940718 | Nov 16, 2032 | DS DP U-2039 | | | |
| | | | 8940718 | Nov 16, 2032 | DS DP U-2040 | | | |
| | | | 9085573 | Mar 21, 2028 | DS DP U-2039 | | | |
| | | | 9085573 | Mar 21, 2028 | DS DP U-2040 | | | |
| | | | 9284342 | Sep 13, 2030 | DS DP U-2039 | | | |
| | | | 9284342 | Sep 13, 2030 | DS DP U-2040 | | | |
| | | | 9296782 | Jul 17, 2034 | DS DP | | | |
| | | | 9585906 | Mar 21, 2028 | DS DP U-2039 | | | |
| | | | 9585906 | Mar 21, 2028 | DS DP U-2040 | | | |
| SOLIFENACIN SUCCINATE - VESICARE | | | | | | | | |
| N 021518 | 001 | | 6017927 | Nov 19, 2018 | DS DP | | | |
| | | | 6017927*PED | May 19, 2019 | | | | |
| SOLIFENACIN SUCCINATE - VESICARE | | | | | | | | |
| N 021518 | 002 | | 6017927 | Nov 19, 2018 | DS DP | | | |
| | | | 6017927*PED | May 19, 2019 | | | | |
| SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE | | | | | | | | |
| N 020280 | 001 | | 6152897 | Nov 20, 2018 | DP | | | |
| SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE | | | | | | | | |
| N 020280 | 002 | | 6152897 | Nov 20, 2018 | DP | | | |
| SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE | | | | | | | | |
| N 020280 | 003 | | 6152897 | Nov 20, 2018 | DP | | | |
| SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE | | | | | | | | |
| N 020280 | 005 | | 6152897 | Nov 20, 2018 | DP | | | |
| SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE | | | | | | | | |
| N 020280 | 008 | | 6152897 | Nov 20, 2018 | DP | | | |
| SOMATROPIN RECOMBINANT - GENOTROPIN PRESERVATIVE FREE | | | | | | | | |
| N 020280 | 009 | | 6152897 | Nov 20, 2018 | DP | | | |
| SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX | | | | | | | | |
| N 021148 | 004 | | 6004297 | Jan 28, 2019 | DP | | | |
| | | | 6235004 | Jan 28, 2019 | DP | | | |
| | | | RE41956 | Jan 21, 2021 | DP | | | |
| SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX | | | | | | | | |
| N 021148 | 005 | | 6004297 | Jan 28, 2019 | DP | | | |
| | | | 6235004 | Jan 28, 2019 | DP | | | |
| | | | RE41956 | Jan 21, 2021 | DP | | | |
| SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX | | | | | | | | |
| N 021148 | 006 | | 6004297 | Jan 28, 2019 | DP | | | |
| | | | 6235004 | Jan 28, 2019 | DP | | | |
| | | | RE41956 | Jan 21, 2021 | DP | | | |
| SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX | | | | | | | | |
| N 021148 | 007 | | 6004297 | Jan 28, 2019 | DP | | | |
| | | | 8841252 | Dec 26, 2017 | DP | | | |
| | | | RE41956 | Jan 21, 2021 | DP | | | |
| | | | RE43834 | Jan 28, 2019 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO | | | | | | | |
| N 021148 | 008 | 6899699 | Jan 02, 2022 | DP | | | |
| | | 8672898 | Jan 02, 2022 | DP | | | |
| | | 8684969 | Oct 20, 2025 | DP | | | |
| | | 8841252 | Dec 26, 2017 | DP | | | |
| | | 8920383 | Jul 17, 2026 | DP | | | |
| | | 9108002 | Jan 20, 2026 | DP | | | |
| | | 9132239 | Feb 01, 2032 | DP | | | |
| | | 9457154 | Sep 27, 2027 | DP | | | |
| | | 9486588 | Jan 02, 2022 | DP | | | |
| | | 9687611 | Feb 27, 2027 | DP | | | |
| | | 9775953 | Jul 17, 2026 | DP | | | |
| | | RE46363 | Aug 03, 2026 | DP | | | |
| SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO | | | | | | | |
| N 021148 | 009 | 6899699 | Jan 02, 2022 | DP | | | |
| | | 8672898 | Jan 02, 2022 | DP | | | |
| | | 8684969 | Oct 20, 2025 | DP | | | |
| | | 8841252 | Dec 26, 2017 | DP | | | |
| | | 8920383 | Jul 17, 2026 | DP | | | |
| | | 9108002 | Jan 20, 2026 | DP | | | |
| | | 9132239 | Feb 01, 2032 | DP | | | |
| | | 9457154 | Sep 27, 2027 | DP | | | |
| | | 9486588 | Jan 02, 2022 | DP | | | |
| | | 9687611 | Feb 27, 2027 | DP | | | |
| | | 9775953 | Jul 17, 2026 | DP | | | |
| | | RE46363 | Aug 03, 2026 | DP | | | |
| SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO | | | | | | | |
| N 021148 | 010 | 6899699 | Jan 02, 2022 | DP | | | |
| | | 8672898 | Jan 02, 2022 | DP | | | |
| | | 8684969 | Oct 20, 2025 | DP | | | |
| | | 8841252 | Dec 26, 2017 | DP | | | |
| | | 8920383 | Jul 17, 2026 | DP | | | |
| | | 9108002 | Jan 20, 2026 | DP | | | |
| | | 9132239 | Feb 01, 2032 | DP | | | |
| | | 9457154 | Sep 27, 2027 | DP | | | |
| | | 9486588 | Jan 02, 2022 | DP | | | |
| | | 9687611 | Feb 27, 2027 | DP | | | |
| | | 9775953 | Jul 17, 2026 | DP | | | |
| | | RE46363 | Aug 03, 2026 | DP | | | |
| SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO | | | | | | | |
| N 021148 | 011 | 6899699 | Jan 02, 2022 | DP | | | |
| | | 8672898 | Jan 02, 2022 | DP | | | |
| | | 8684969 | Oct 20, 2025 | DP | | | |
| | | 8841252 | Dec 26, 2017 | DP | | | |
| | | 8920383 | Jul 17, 2026 | DP | | | |
| | | 9108002 | Jan 20, 2026 | DP | | | |
| | | 9132239 | Feb 01, 2032 | DP | | | |
| | | 9457154 | Sep 27, 2027 | DP | | | |
| | | 9486588 | Jan 02, 2022 | DP | | | |
| | | 9687611 | Feb 27, 2027 | DP | | | |
| | | 9775953 | Jul 17, 2026 | DP | | | |
| | | RE46363 | Aug 03, 2026 | DP | | | |
| SONIDEGIB PHOSPHATE - ODOMZO | | | | | | | |
| N 205266 | 001 | 8063043 | Sep 15, 2029 | DS DP | | NCE | Jul 24, 2020 |
| | | 8178563 | Feb 06, 2029 | DS U-1722 | | | |
| SORAFENIB TOSYLATE - NEXAVAR | | | | | | | |
| N 021923 | 001 | 7235576 | Jan 12, 2020 | DS DP | | ODE-56 | Nov 22, 2020 |
| | | 7351834 | Jan 12, 2020 | DS | | | |
| | | 7897623 | Jan 12, 2020 | DP | | | |
| | | 8124630 | Jan 12, 2020 | U-1459 | | | |
| | | 8618141 | Feb 11, 2023 | U-1480 | | | |
| | | 8841330 | Jan 12, 2020 | U-1696 | | | |
| | | 8877933 | Dec 24, 2027 | DS DP U-1624 | | | |
| | | 9737488 | Sep 10, 2028 | DP U-1480 | | | |
| | | 9737488 | Sep 10, 2028 | DP U-1696 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|
| SORAFENIB TOSYLATE - NEXAVAR | | | | | | | | |
| N 021923 | 001 | 9737488 | Sep 10, 2028 | | DP U-2107 | | | |
| SOTALOL HYDROCHLORIDE - SOTYLIZE | | | | | | | | |
| N 205108 | 001 | 9724297 | Aug 31, 2035 | | DP U-2096 | | | |
| SPINOSAD - NATROBA | | | | | | | | |
| N 022408 | 001 | 6063771 | Jul 25, 2023 | | DP U-1670 | | M-152 | Nov 30, 2017 |
| | | 6342482 | Jun 22, 2019 | | DP U-1105 | | | |
| | | 7030095 | Jul 02, 2021 | | DP U-1105 | | | |
| SPIRONOLACTONE - CAROSPIR | | | | | | | | |
| N 209478 | 001 | 9757394 | Oct 28, 2036 | | DP U-2109 | | | |
| STAVUDINE - ZERIT XR | | | | | | | | |
| N 021453 | 001 | 7135465 | Feb 18, 2023 | | DP U-167 | | | |
| STAVUDINE - ZERIT XR | | | | | | | | |
| N 021453 | 002 | 7135465 | Feb 18, 2023 | | DP U-167 | | | |
| STAVUDINE - ZERIT XR | | | | | | | | |
| N 021453 | 003 | 7135465 | Feb 18, 2023 | | DP U-167 | | | |
| STAVUDINE - ZERIT XR | | | | | | | | |
| N 021453 | 004 | 7135465 | Feb 18, 2023 | | DP U-167 | | | |
| SUCROFERRIC OXYHYDROXIDE - VELPHORO | | | | | | | | |
| N 205109 | 001 | 6174442 | Dec 19, 2018 | DS | U-1468 | | | |
| | | 9561251 | Jan 23, 2030 | | DP U-1468 | | | |
| SUGAMMADEX SODIUM - BRIDION | | | | | | | | |
| N 022225 | 001 | 6949527 | Jan 27, 2021 | | U-1795 | | NCE | Dec 15, 2020 |
| | | 7265099 | Aug 07, 2020 | | U-1795 | | | |
| | | RE44733 | Jan 27, 2021 | DS | DP U-1794 | | | |
| SUGAMMADEX SODIUM - BRIDION | | | | | | | | |
| N 022225 | 002 | 6949527 | Jan 27, 2021 | | U-1795 | | NCE | Dec 15, 2020 |
| | | 7265099 | Aug 07, 2020 | | U-1795 | | | |
| | | RE44733 | Jan 27, 2021 | DS | DP U-1794 | | | |
| SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON | | | | | | | | |
| N 203684 | 001 | 5686060 | Nov 11, 2019 | DS | DP | | I-728 | Mar 31, 2019 |
| | | | | | | | NCE | Oct 10, 2019 |
| SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO | | | | | | | | |
| N 022239 | 001 | 7776007 | Nov 22, 2026 | | DP | | | |
| | | 7901385 | Jul 31, 2026 | | DP | | | |
| | | 8118771 | Aug 10, 2023 | | DP | | | |
| | | 8241243 | Aug 10, 2023 | | DP | | | |
| | | 8241244 | Nov 21, 2022 | | DP | | | |
| | | 8267903 | Mar 18, 2023 | | DP | | | |
| | | 8287489 | Dec 06, 2024 | | DP | | | |
| | | 8343130 | Oct 18, 2022 | | DP | | | |
| | | 8491524 | Nov 21, 2022 | | DP | | | |
| SUMATRIPTAN SUCCINATE - ALSUMA | | | | | | | | |
| N 022377 | 001 | 7811254 | Aug 26, 2027 | | DP U-1083 | | | |
| SUMATRIPTAN SUCCINATE - ZECUITY | | | | | | | | |
| N 202278 | 001 | 6745071 | Feb 21, 2023 | | DP | | | |
| | | 7973058 | Apr 12, 2027 | | U-1328 | | | |
| | | 8155737 | Apr 12, 2027 | | U-1328 | | | |
| | | 8366600 | Apr 21, 2029 | | U-1327 | | | |
| | | 8470853 | Apr 12, 2027 | | U-1328 | | | |
| | | 8597272 | Apr 12, 2027 | | DP | | | |
| | | 8983594 | Nov 19, 2030 | | DP U-1328 | | | |
| | | 9272137 | Sep 07, 2027 | | DP | | | |
| | | 9327114 | Oct 08, 2032 | | DP U-1328 | | | |
| | | 9427578 | Apr 12, 2027 | | DP U-1328 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| SUMATRIPTAN SUCCINATE - ONZETRA XSAIL | | | | | | | |
| N 206099 | 001 | 6715485 | Mar 03, 2020 | DP | | | |
| | | 7975690 | Aug 18, 2025 | DP U-1809 | | | |
| | | 8047202 | Jul 02, 2023 | DP | | | |
| | | 8327844 | Oct 03, 2023 | U-1809 | | | |
| | | 8550073 | Oct 22, 2029 | DP | | | |
| | | 8555877 | Mar 03, 2020 | DP | | | |
| | | 8590530 | Sep 15, 2025 | DP U-1809 | | | |
| | | 8875704 | Apr 07, 2028 | DP U-1809 | | | |
| | | 8899229 | Aug 18, 2030 | DP | | | |
| | | 8978647 | Dec 06, 2030 | DP | | | |
| | | 9108015 | Sep 15, 2025 | DP | | | |
| | | 9119932 | Apr 23, 2024 | DP | | | |
| | | 9649456 | Oct 21, 2030 | DP U-1719 | | | |
| | | 9649456 | Oct 21, 2030 | DP U-2010 | | | |
| | | 9649456 | Oct 21, 2030 | DP U-2011 | | | |
| SUNITINIB MALATE - SUTENT | | | | | | | |
| N 021938 | 001 | 6573293 | Feb 15, 2021 | DS DP U-1154 | | I-755 | Nov 16, 2020 |
| | | 6573293 | Feb 15, 2021 | DS DP U-2171 | | | |
| | | 7125905 | Feb 15, 2021 | DS DP | | | |
| | | 7211600 | Dec 22, 2020 | U-883 | | | |
| SUNITINIB MALATE - SUTENT | | | | | | | |
| N 021938 | 002 | 6573293 | Feb 15, 2021 | DS DP U-1154 | | I-755 | Nov 16, 2020 |
| | | 6573293 | Feb 15, 2021 | DS DP U-2171 | | | |
| | | 7125905 | Feb 15, 2021 | DS DP | | | |
| | | 7211600 | Dec 22, 2020 | U-883 | | | |
| SUNITINIB MALATE - SUTENT | | | | | | | |
| N 021938 | 003 | 6573293 | Feb 15, 2021 | DS DP U-1154 | | I-755 | Nov 16, 2020 |
| | | 6573293 | Feb 15, 2021 | DS DP U-2171 | | | |
| | | 7125905 | Feb 15, 2021 | DS DP | | | |
| | | 7211600 | Dec 22, 2020 | U-883 | | | |
| SUNITINIB MALATE - SUTENT | | | | | | | |
| N 021938 | 004 | 6573293 | Feb 15, 2021 | DS DP U-1154 | | I-755 | Nov 16, 2020 |
| | | 6573293 | Feb 15, 2021 | DS DP U-2171 | | | |
| | | 7125905 | Feb 15, 2021 | DS DP | | | |
| | | 7211600 | Dec 22, 2020 | U-883 | | | |
| SUVOREXANT - BELSOMRA | | | | | | | |
| N 204569 | 001 | 7951797 | Nov 20, 2029 | DS DP U-620 | | NCE | Aug 13, 2019 |
| SUVOREXANT - BELSOMRA | | | | | | | |
| N 204569 | 002 | 7951797 | Nov 20, 2029 | DS DP U-620 | | NCE | Aug 13, 2019 |
| SUVOREXANT - BELSOMRA | | | | | | | |
| N 204569 | 003 | 7951797 | Nov 20, 2029 | DS DP U-620 | | NCE | Aug 13, 2019 |
| SUVOREXANT - BELSOMRA | | | | | | | |
| N 204569 | 004 | 7951797 | Nov 20, 2029 | DS DP U-620 | | NCE | Aug 13, 2019 |
| TACROLIMUS - ASTAGRAF XL | | | | | | | |
| N 204096 | 001 | 6440458 | Mar 25, 2019 | DP | | | |
| | | 6576259 | Mar 25, 2019 | DP U-1420 | | | |
| | | 6884433 | Mar 25, 2019 | DP U-1420 | | | |
| | | 8551522 | Mar 25, 2019 | DP | | | |
| TACROLIMUS - ASTAGRAF XL | | | | | | | |
| N 204096 | 002 | 6440458 | Mar 25, 2019 | DP | | | |
| | | 6576259 | Mar 25, 2019 | DP U-1420 | | | |
| | | 6884433 | Mar 25, 2019 | DP U-1420 | | | |
| | | 8551522 | Mar 25, 2019 | DP | | | |
| TACROLIMUS - ASTAGRAF XL | | | | | | | |
| N 204096 | 003 | 6440458 | Mar 25, 2019 | DP | | | |
| | | 6576259 | Mar 25, 2019 | DP U-1420 | | | |
| | | 6884433 | Mar 25, 2019 | DP U-1420 | | | |
| | | 8551522 | Mar 25, 2019 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| TACROLIMUS - ENVARSUS XR | | | | | | | |
| N 206406 | 001 | 7994214 | Aug 30, 2024 | DP | | ODE-94 | Jul 10, 2022 |
| | | 8486993 | Aug 30, 2024 | DP U-1752 | | | |
| | | 8586084 | Aug 30, 2024 | U-1752 | | | |
| | | 8591946 | Aug 30, 2024 | DP | | | |
| | | 8617599 | Aug 30, 2024 | DP | | | |
| | | 8623410 | Aug 30, 2024 | DP | | | |
| | | 8623411 | Aug 30, 2024 | U-1752 | | | |
| | | 8664239 | May 30, 2028 | U-1752 | | | |
| | | 8685998 | May 30, 2028 | DP U-1752 | | | |
| | | 8889185 | Aug 30, 2024 | U-1752 | | | |
| | | 8889186 | Aug 30, 2024 | U-1752 | | | |
| | | 9161907 | Aug 30, 2024 | DP U-1752 | | | |
| | | 9549918 | May 30, 2028 | DP | | | |
| | | 9757362 | Aug 30, 2024 | DP | | | |
| | | 9763920 | Aug 30, 2024 | DP | | | |
| TACROLIMUS - ENVARSUS XR | | | | | | | |
| N 206406 | 002 | 7994214 | Aug 30, 2024 | DP | | ODE-94 | Jul 10, 2022 |
| | | 8486993 | Aug 30, 2024 | DP U-1752 | | | |
| | | 8586084 | Aug 30, 2024 | U-1752 | | | |
| | | 8591946 | Aug 30, 2024 | DP | | | |
| | | 8617599 | Aug 30, 2024 | DP | | | |
| | | 8623410 | Aug 30, 2024 | DP | | | |
| | | 8623411 | Aug 30, 2024 | U-1752 | | | |
| | | 8664239 | May 30, 2028 | U-1752 | | | |
| | | 8685998 | May 30, 2028 | DP U-1752 | | | |
| | | 8889185 | Aug 30, 2024 | U-1752 | | | |
| | | 8889186 | Aug 30, 2024 | U-1752 | | | |
| | | 9161907 | Aug 30, 2024 | DP U-1752 | | | |
| | | 9549918 | May 30, 2028 | DP | | | |
| | | 9757362 | Aug 30, 2024 | DP | | | |
| | | 9763920 | Aug 30, 2024 | DP | | | |
| TACROLIMUS - ENVARSUS XR | | | | | | | |
| N 206406 | 003 | 7994214 | Aug 30, 2024 | DP | | ODE-94 | Jul 10, 2022 |
| | | 8486993 | Aug 30, 2024 | DP U-1752 | | | |
| | | 8586084 | Aug 30, 2024 | U-1752 | | | |
| | | 8591946 | Aug 30, 2024 | DP | | | |
| | | 8617599 | Aug 30, 2024 | DP | | | |
| | | 8623410 | Aug 30, 2024 | DP | | | |
| | | 8623411 | Aug 30, 2024 | U-1752 | | | |
| | | 8664239 | May 30, 2028 | U-1752 | | | |
| | | 8685998 | May 30, 2028 | DP U-1752 | | | |
| | | 8889185 | Aug 30, 2024 | U-1752 | | | |
| | | 8889186 | Aug 30, 2024 | U-1752 | | | |
| | | 9161907 | Aug 30, 2024 | DP U-1752 | | | |
| | | 9549918 | May 30, 2028 | DP | | | |
| | | 9757362 | Aug 30, 2024 | DP | | | |
| | | 9763920 | Aug 30, 2024 | DP | | | |
| TADALAFIL - CIALIS | | | | | | | |
| N 021368 | 001 | 5859006 | Nov 21, 2017 | DS DP | Y | | |
| | | 5859006*PED | May 21, 2018 | | | | |
| | | 6821975 | Nov 19, 2020 | DS DP U-1184 | | | |
| | | 6821975 | Nov 19, 2020 | DS DP U-533 | | | |
| | | 6821975 | Nov 19, 2020 | DS DP U-614 | | | |
| | | 6821975*PED | May 19, 2021 | | | | |
| | | 6943166 | Apr 26, 2020 | U-1184 | | | |
| | | 6943166 | Apr 26, 2020 | U-155 | | | |
| | | 6943166 | Apr 26, 2020 | U-614 | | | |
| | | 6943166*PED | Oct 26, 2020 | | | | |
| | | 7182958 | Apr 26, 2020 | DP U-1184 | | | |
| | | 7182958 | Apr 26, 2020 | DP U-155 | | | |
| | | 7182958*PED | Oct 26, 2020 | | | | |
| TADALAFIL - CIALIS | | | | | | | |
| N 021368 | 002 | 5859006 | Nov 21, 2017 | DS DP | | | |
| | | 5859006*PED | May 21, 2018 | | | | |
| | | 6821975 | Nov 19, 2020 | DS DP U-533 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| TADALAFIL - CIALIS | | | | | | | |
| N 021368 | 002 | 6821975 | Nov 19, 2020 | DS DP U-614 | | | |
| | | 6821975*PED | May 19, 2021 | | | | |
| | | 6943166 | Apr 26, 2020 | U-155 | | | |
| | | 6943166 | Apr 26, 2020 | U-614 | | | |
| | | 6943166*PED | Oct 26, 2020 | | | | |
| | | 7182958 | Apr 26, 2020 | DP U-155 | | | |
| | | 7182958*PED | Oct 26, 2020 | | | | |
| TADALAFIL - CIALIS | | | | | | | |
| N 021368 | 003 | 5859006 | Nov 21, 2017 | DS DP | | | |
| | | 5859006*PED | May 21, 2018 | | | | |
| | | 6821975 | Nov 19, 2020 | DS DP U-533 | | | |
| | | 6821975 | Nov 19, 2020 | DS DP U-614 | | | |
| | | 6821975*PED | May 19, 2021 | | | | |
| | | 6943166 | Apr 26, 2020 | U-614 | | | |
| | | 6943166*PED | Oct 26, 2020 | | | | |
| | | 7182958 | Apr 26, 2020 | DP U-155 | | | |
| | | 7182958*PED | Oct 26, 2020 | | | | |
| TADALAFIL - CIALIS | | | | | | | |
| N 021368 | 004 | 5859006 | Nov 21, 2017 | DS DP | | | |
| | | 5859006*PED | May 21, 2018 | | | | |
| | | 6821975 | Nov 19, 2020 | DS DP U-533 | | | |
| | | 6821975 | Nov 19, 2020 | DS DP U-614 | | | |
| | | 6821975*PED | May 19, 2021 | | | | |
| | | 6943166 | Apr 26, 2020 | U-155 | | | |
| | | 6943166*PED | Oct 26, 2020 | | | | |
| | | 7182958 | Apr 26, 2020 | DP U-155 | | | |
| | | 7182958*PED | Oct 26, 2020 | | | | |
| TADALAFIL - ADCIRCA | | | | | | | |
| N 022332 | 001 | 5859006 | Nov 21, 2017 | DS DP U-975 | | | |
| | | 5859006*PED | May 21, 2018 | | | | |
| | | 6821975 | Nov 19, 2020 | DS DP | | | |
| | | 6821975*PED | May 19, 2021 | | | | |
| | | 7182958 | Apr 26, 2020 | DP | | | |
| | | 7182958*PED | Oct 26, 2020 | | | | |
| TAFLUPROST - ZIOPTAN | | | | | | | |
| N 202514 | 001 | 5886035 | Dec 18, 2022 | DS DP U-778 | | | |
| TALC - STERITALC | | | | | | | |
| N 205555 | 001 | | | | | ODE-143 | May 01, 2024 |
| TALC - STERITALC | | | | | | | |
| N 205555 | 002 | | | | | ODE-143 | May 01, 2024 |
| TALC - STERITALC | | | | | | | |
| N 205555 | 003 | | | | | ODE-143 | May 01, 2024 |
| TALIGLUCERASE ALFA - ELELYSO | | | | | | | |
| N 022458 | 001 | 8227230 | Feb 24, 2024 | DS DP | | NPP | Aug 27, 2017 |
| | | 8741620 | Feb 24, 2024 | DS DP | | | |
| | | 8790641 | Oct 18, 2025 | U-1564 | | | |
| | | 8790641 | Oct 18, 2025 | U-1574 | | | |
| TAMOXIFEN CITRATE - SOLTAMOX | | | | | | | |
| N 021807 | 001 | 6127425 | Jun 26, 2018 | DP | | | |
| TAPENTADOL HYDROCHLORIDE - NUCYNTA | | | | | | | |
| N 022304 | 001 | 7994364 | Jun 27, 2025 | DS DP U-931 | | | |
| | | RE39593 | Aug 05, 2022 | DS DP U-931 | | | |
| TAPENTADOL HYDROCHLORIDE - NUCYNTA | | | | | | | |
| N 022304 | 002 | 7994364 | Jun 27, 2025 | DS DP U-931 | | | |
| | | RE39593 | Aug 05, 2022 | DS DP U-931 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| TAPENTADOL HYDROCHLORIDE - NUCYNTA | | | | | | | |
| N 022304 | 003 | 7994364 | Jun 27, 2025 | DS DP U-931 | | | |
| | | RE39593 | Aug 05, 2022 | DS DP U-931 | | | |
| TAPENTADOL HYDROCHLORIDE - NUCYNTA ER | | | | | | | |
| N 200533 | 001 | 7994364 | Jun 27, 2025 | DS DP U-1178 | | | |
| | | 7994364 | Jun 27, 2025 | DS DP U-1276 | | | |
| | | 8075872 | Nov 20, 2023 | DP | | | |
| | | 8114383 | Oct 10, 2024 | DP | Y | | |
| | | 8309060 | Nov 20, 2023 | DP U-1178 | | | |
| | | 8309060 | Nov 20, 2023 | DP U-1276 | | | |
| | | 8420056 | Nov 20, 2023 | DP | | | |
| | | 8536130 | Sep 22, 2028 | U-1276 | | | |
| | | RE39593 | Aug 05, 2022 | DS DP U-1178 | | | |
| | | RE39593 | Aug 05, 2022 | DS DP U-1276 | | | |
| TAPENTADOL HYDROCHLORIDE - NUCYNTA ER | | | | | | | |
| N 200533 | 002 | 7994364 | Jun 27, 2025 | DS DP U-1178 | | | |
| | | 7994364 | Jun 27, 2025 | DS DP U-1276 | | | |
| | | 8075872 | Nov 20, 2023 | DP | | | |
| | | 8114383 | Oct 10, 2024 | DP | Y | | |
| | | 8309060 | Nov 20, 2023 | DP U-1178 | | | |
| | | 8309060 | Nov 20, 2023 | DP U-1276 | | | |
| | | 8420056 | Nov 20, 2023 | DP | | | |
| | | 8536130 | Sep 22, 2028 | U-1276 | | | |
| | | RE39593 | Aug 05, 2022 | DS DP U-1178 | | | |
| | | RE39593 | Aug 05, 2022 | DS DP U-1276 | | | |
| TAPENTADOL HYDROCHLORIDE - NUCYNTA ER | | | | | | | |
| N 200533 | 003 | 7994364 | Jun 27, 2025 | DS DP U-1178 | | | |
| | | 7994364 | Jun 27, 2025 | DS DP U-1276 | | | |
| | | 8075872 | Nov 20, 2023 | DP | | | |
| | | 8114383 | Oct 10, 2024 | DP | Y | | |
| | | 8309060 | Nov 20, 2023 | DP U-1178 | | | |
| | | 8309060 | Nov 20, 2023 | DP U-1276 | | | |
| | | 8420056 | Nov 20, 2023 | DP | | | |
| | | 8536130 | Sep 22, 2028 | U-1276 | | | |
| | | RE39593 | Aug 05, 2022 | DS DP U-1178 | | | |
| | | RE39593 | Aug 05, 2022 | DS DP U-1276 | | | |
| TAPENTADOL HYDROCHLORIDE - NUCYNTA ER | | | | | | | |
| N 200533 | 004 | 7994364 | Jun 27, 2025 | DS DP U-1178 | | | |
| | | 7994364 | Jun 27, 2025 | DS DP U-1276 | | | |
| | | 8075872 | Nov 20, 2023 | DP | | | |
| | | 8114383 | Oct 10, 2024 | DP | Y | | |
| | | 8309060 | Nov 20, 2023 | DP U-1178 | | | |
| | | 8309060 | Nov 20, 2023 | DP U-1276 | | | |
| | | 8420056 | Nov 20, 2023 | DP | | | |
| | | 8536130 | Sep 22, 2028 | U-1276 | | | |
| | | RE39593 | Aug 05, 2022 | DS DP U-1178 | | | |
| | | RE39593 | Aug 05, 2022 | DS DP U-1276 | | | |
| TAPENTADOL HYDROCHLORIDE - NUCYNTA ER | | | | | | | |
| N 200533 | 005 | 7994364 | Jun 27, 2025 | DS DP U-1178 | | | |
| | | 7994364 | Jun 27, 2025 | DS DP U-1276 | | | |
| | | 8075872 | Nov 20, 2023 | DP | | | |
| | | 8114383 | Oct 10, 2024 | DP | Y | | |
| | | 8309060 | Nov 20, 2023 | DP U-1178 | | | |
| | | 8309060 | Nov 20, 2023 | DP U-1276 | | | |
| | | 8420056 | Nov 20, 2023 | DP | | | |
| | | 8536130 | Sep 22, 2028 | U-1276 | | | |
| | | RE39593 | Aug 05, 2022 | DS DP U-1178 | | | |
| | | RE39593 | Aug 05, 2022 | DS DP U-1276 | | | |
| TAPENTADOL HYDROCHLORIDE - NUCYNTA | | | | | | | |
| N 203794 | 001 | 7994364 | Jun 27, 2025 | DS DP U-1289 | | | |
| | | RE39593 | Aug 05, 2022 | DS DP U-1289 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| TASIMELTEON - HETLIOZ | | | | | | | |
| N 205677 | 001 | 5856529 | Dec 09, 2018 | DS DP U-2149 | | NCE | Jan 31, 2019 |
| | | 9060995 | Jan 25, 2033 | U-1710 | | ODE-59 | Jan 31, 2021 |
| | | 9539234 | Jan 25, 2033 | U-1934 | | | |
| | | 9549913 | Jan 25, 2033 | U-1486 | | | |
| | | 9730910 | May 17, 2034 | U-2085 | | | |
| | | RE46604 | Jan 25, 2033 | U-2147 | | | |
| TAVABOROLE - KERYDIN | | | | | | | |
| N 204427 | 001 | 7582621 | May 26, 2027 | U-2016 | | NCE | Jul 07, 2019 |
| | | 9549938 | Feb 16, 2026 | U-1951 | | | |
| | | 9566289 | Feb 16, 2026 | DP | | | |
| | | 9566290 | Feb 16, 2026 | U-1970 | | | |
| | | 9572823 | Feb 16, 2026 | U-1970 | | | |
| TAZAROTENE - FABIOR | | | | | | | |
| N 202428 | 001 | 8808716 | Feb 24, 2030 | DP | | | |
| TECHNETIUM TC-99M SULFUR COLLOID KIT - AN-SULFUR COLLOID | | | | | | | |
| N 017858 | 001 | | | | | ODE-29 | Aug 13, 2019 |
| TECHNETIUM TC-99M TEBOROXIME KIT - CARDIOTEC | | | | | | | |
| N 019928 | 001 | 6056941 | Jul 28, 2019 | DP | | | |
| TECHNETIUM TC-99M TETROFOSMIN KIT - MYOVIEW 30ML | | | | | | | |
| N 020372 | 002 | 9549999 | Mar 10, 2030 | DP | | | |
| TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT | | | | | | | |
| N 202207 | 001 | 6409990 | May 12, 2020 | DS | | NCE | Mar 13, 2018 |
| | | 9439985 | Sep 27, 2033 | DS DP | | ODE-67 | Jun 13, 2021 |
| TEDIZOLID PHOSPHATE - SIVEXTRO | | | | | | | |
| N 205435 | 001 | 7816379 | Feb 23, 2028 | DS DP U-282 | | NCE | Jun 20, 2019 |
| | | 8420676 | Feb 23, 2028 | DS DP U-282 | | GAIN | Jun 20, 2024 |
| | | 8426389 | Dec 31, 2030 | DS DP U-282 | | | |
| TEDIZOLID PHOSPHATE - SIVEXTRO | | | | | | | |
| N 205436 | 001 | 7816379 | Feb 23, 2028 | DS DP U-282 | | NCE | Jun 20, 2019 |
| | | 8420676 | Feb 23, 2028 | DS DP U-282 | | GAIN | Jun 20, 2024 |
| | | 8426389 | Dec 31, 2030 | DS DP U-282 | | | |
| TEDUGLUTIDE RECOMBINANT - GATTEX KIT | | | | | | | |
| N 203441 | 001 | 5789379 | Apr 14, 2020 | DS DP U-1320 | | NCE | Dec 21, 2017 |
| | | 7056886 | Sep 18, 2022 | DP U-1320 | | ODE-37 | Dec 21, 2019 |
| | | 7847061 | Nov 01, 2025 | U-1320 | | | |
| | | 9060992 | Nov 01, 2025 | U-1320 | | | |
| | | 9539310 | Nov 01, 2025 | U-1320 | | | |
| | | 9545434 | Nov 01, 2025 | U-1320 | | | |
| | | 9545435 | Nov 01, 2025 | U-1320 | | | |
| | | 9555079 | Nov 01, 2025 | U-1320 | | | |
| | | 9572867 | Nov 01, 2025 | U-1320 | | | |
| | | 9592273 | Nov 01, 2025 | U-1320 | | | |
| | | 9592274 | Nov 01, 2025 | U-1320 | | | |
| TELAPREVIR - INCIVEK | | | | | | | |
| N 201917 | 001 | 7820671 | Feb 25, 2025 | DS DP | | | |
| | | 8431615 | May 30, 2028 | U-1398 | | | |
| | | 8529882 | Aug 31, 2021 | U-1398 | | | |
| TELAVANCIN HYDROCHLORIDE - VIBATIV | | | | | | | |
| N 022110 | 001 | 6635618 | Sep 11, 2023 | DS DP U-728 | | | |
| | | 6858584 | Aug 24, 2022 | DP | | | |
| | | 6872701 | Jun 05, 2021 | DP | | | |
| | | 7008923 | May 06, 2021 | U-1005 | | | |
| | | 7208471 | May 01, 2021 | DS DP | | | |
| | | 7351691 | May 01, 2021 | DS DP U-728 | | | |
| | | 7531623 | Jan 01, 2027 | DS | | | |
| | | 7544364 | May 01, 2021 | DP | | | |
| | | 7700550 | May 01, 2021 | U-282 | | | |
| | | 8101575 | May 01, 2021 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| TELAVANCIN HYDROCHLORIDE - VIBATIV | | | | | | | |
| N 022110 | 001 | 8158580 | May 01, 2021 | DP | | | |
| TELAVANCIN HYDROCHLORIDE - VIBATIV | | | | | | | |
| N 022110 | 002 | 6635618 | Sep 11, 2023 | DS DP U-728 | | | |
| | | 6858584 | Aug 24, 2022 | DP | | | |
| | | 6872701 | Jun 05, 2021 | DP | | | |
| | | 7008923 | May 06, 2021 | U-1005 | | | |
| | | 7208471 | May 01, 2021 | DS DP | | | |
| | | 7351691 | May 01, 2021 | DS DP U-728 | | | |
| | | 7531623 | Jan 01, 2027 | DS | | | |
| | | 7544364 | May 01, 2021 | DP | | | |
| | | 7700550 | May 01, 2021 | U-282 | | | |
| | | 8101575 | May 01, 2021 | DP | | | |
| | | 8158580 | May 01, 2021 | DP | | | |
| TELBIVUDINE - TYZEKA | | | | | | | |
| N 022011 | 001 | 6395716 | Aug 10, 2019 | U-782 | | | |
| | | 6444652 | Aug 10, 2019 | U-782 | | | |
| | | 6566344 | Aug 10, 2019 | U-782 | | | |
| | | 6569837 | Oct 25, 2020 | U-782 | | | |
| | | 6569837 | Oct 25, 2020 | U-999 | | | |
| | | 7589079 | Sep 11, 2023 | DS DP U-999 | | | |
| | | 7795238 | Aug 10, 2019 | U-999 | | | |
| | | 7858594 | Sep 11, 2023 | DS DP U-999 | | | |
| TELBIVUDINE - TYZEKA | | | | | | | |
| N 022154 | 001 | 6395716 | Aug 10, 2019 | U-999 | | | |
| | | 6444652 | Aug 10, 2019 | U-999 | | | |
| | | 6566344 | Aug 10, 2019 | U-999 | | | |
| | | 6569837 | Oct 25, 2020 | U-999 | | | |
| | | 7795238 | Aug 10, 2019 | U-999 | | | |
| | | 7858594 | Sep 11, 2023 | DS DP U-999 | | | |
| TELITHROMYCIN - KETEK | | | | | | | |
| N 021144 | 001 | 5635485 | Apr 01, 2018 | DS DP U-578 | | | |
| TELITHROMYCIN - KETEK | | | | | | | |
| N 021144 | 002 | 5635485 | Apr 01, 2018 | DS DP U-578 | | | |
| TELMISARTAN - MICARDIS | | | | | | | |
| N 020850 | 001 | 6358986 | Jan 10, 2020 | | | | |
| TELMISARTAN - MICARDIS | | | | | | | |
| N 020850 | 002 | 6358986 | Jan 10, 2020 | | | | |
| | | 7998953 | Jun 06, 2020 | U-1177 | | | |
| | | 8003679 | Oct 06, 2022 | U-1176 | | | |
| TELMISARTAN - MICARDIS | | | | | | | |
| N 020850 | 003 | 6358986 | Jan 10, 2020 | | | | |
| TELOTRISTAT ETIPRATE - XERMELO | | | | | | | |
| N 208794 | 001 | 7553840 | Dec 11, 2027 | DS | | NCE | Feb 28, 2022 |
| | | 7709493 | Dec 11, 2027 | DS U-1979 | | ODE-132 | Feb 28, 2024 |
| | | 7968559 | Dec 11, 2027 | U-1979 | | | |
| | | 8193204 | Feb 27, 2031 | DS | | | |
| | | 8653094 | Dec 19, 2028 | U-1979 | | | |
| TEMOZOLOMIDE - TEMODAR | | | | | | | |
| N 022277 | 001 | 6987108 | Sep 08, 2023 | DP | | | |
| | | 7786118 | Feb 21, 2023 | DP | | | |
| | | 8623868 | Feb 21, 2023 | DP | | | |
| TEMSIROLIMUS - TORISEL | | | | | | | |
| N 022088 | 001 | 5362718 | Feb 15, 2019 | DS DP | Y | | |
| | | 5362718*PED | Aug 15, 2019 | | | | |
| | | 8026276 | Jan 20, 2026 | DP | | | |
| | | 8299116 | Jul 25, 2023 | DP | | | |
| | | 8455539 | Jul 25, 2023 | DP | | | |
| | | 8455539*PED | Jan 25, 2024 | | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| TEMSIROLIMUS - TORISEL | | | | | | | |
| N 022088 | 001 | 8722700 | Jul 25, 2023 | DP | | | |
| | | 8722700*PED | Jan 25, 2024 | | | | |
| | | 8791097 | May 10, 2032 | U-1550 | | | |
| | | 8791097 | May 10, 2032 | U-1551 | | | |
| | | 8791097*PED | Nov 10, 2032 | | | | |
| | | RE44768 | Feb 15, 2019 | DS DP | | | |
| | | RE44768*PED | Aug 15, 2019 | | | | |
| TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY | | | | | | | |
| N 208464 | 001 | 7390791 | May 07, 2022 | DS DP | | NCE | Nov 05, 2020 |
| | | 7803788 | Feb 02, 2022 | U-999 | | NP | Nov 11, 2019 |
| | | 8754065 | Aug 15, 2032 | DS DP U-999 | | | |
| | | 9296769 | Aug 15, 2032 | DS DP U-999 | | | |
| TENOFOVIR DISOPROXIL FUMARATE - VIREAD | | | | | | | |
| N 021356 | 001 | 5922695 | Jul 25, 2017 | DS U-1275 | | PED | Sep 24, 2017 |
| | | 5922695 | Jul 25, 2017 | DS U-248 | | | |
| | | 5922695 | Jul 25, 2017 | DS U-250 | | | |
| | | 5922695 | Jul 25, 2017 | DS U-256 | | | |
| | | 5922695 | Jul 25, 2017 | DS U-999 | | | |
| | | 5935946 | Jul 25, 2017 | DS DP U-1275 | | | |
| | | 5935946 | Jul 25, 2017 | DS DP U-248 | | | |
| | | 5935946 | Jul 25, 2017 | DS DP U-250 | | | |
| | | 5935946 | Jul 25, 2017 | DS DP U-256 | | | |
| | | 5935946 | Jul 25, 2017 | DS DP U-999 | | | |
| | | 5977089 | Jul 25, 2017 | DS DP U-1275 | | | |
| | | 5977089 | Jul 25, 2017 | DS DP U-248 | | | |
| | | 5977089 | Jul 25, 2017 | DS DP U-250 | | | |
| | | 5977089 | Jul 25, 2017 | DS DP U-256 | | | |
| | | 5977089 | Jul 25, 2017 | DS DP U-999 | | | |
| | | 6043230 | Jul 25, 2017 | U-1275 | | | |
| | | 6043230 | Jul 25, 2017 | U-248 | | | |
| | | 6043230 | Jul 25, 2017 | U-250 | | | |
| | | 6043230 | Jul 25, 2017 | U-256 | | | |
| | | 6043230 | Jul 25, 2017 | U-999 | | | |
| TENOFOVIR DISOPROXIL FUMARATE - VIREAD | | | | | | | |
| N 021356 | 002 | 5922695 | Jul 25, 2017 | DS U-1275 | | PED | Sep 24, 2017 |
| | | 5922695 | Jul 25, 2017 | DS U-248 | | | |
| | | 5922695 | Jul 25, 2017 | DS U-250 | | | |
| | | 5922695 | Jul 25, 2017 | DS U-256 | | | |
| | | 5922695 | Jul 25, 2017 | DS U-999 | | | |
| | | 5935946 | Jul 25, 2017 | DS DP U-1275 | | | |
| | | 5935946 | Jul 25, 2017 | DS DP U-248 | | | |
| | | 5935946 | Jul 25, 2017 | DS DP U-250 | | | |
| | | 5935946 | Jul 25, 2017 | DS DP U-256 | | | |
| | | 5935946 | Jul 25, 2017 | DS DP U-999 | | | |
| | | 5977089 | Jul 25, 2017 | DS DP U-1275 | | | |
| | | 5977089 | Jul 25, 2017 | DS DP U-248 | | | |
| | | 5977089 | Jul 25, 2017 | DS DP U-250 | | | |
| | | 5977089 | Jul 25, 2017 | DS DP U-256 | | | |
| | | 5977089 | Jul 25, 2017 | DS DP U-999 | | | |
| | | 6043230 | Jul 25, 2017 | U-1275 | | | |
| | | 6043230 | Jul 25, 2017 | U-248 | | | |
| | | 6043230 | Jul 25, 2017 | U-250 | | | |
| | | 6043230 | Jul 25, 2017 | U-256 | | | |
| | | 6043230 | Jul 25, 2017 | U-999 | | | |
| TENOFOVIR DISOPROXIL FUMARATE - VIREAD | | | | | | | |
| N 021356 | 003 | 5922695 | Jul 25, 2017 | DS U-1275 | | PED | Sep 24, 2017 |
| | | 5922695 | Jul 25, 2017 | DS U-248 | | | |
| | | 5922695 | Jul 25, 2017 | DS U-250 | | | |
| | | 5922695 | Jul 25, 2017 | DS U-256 | | | |
| | | 5922695 | Jul 25, 2017 | DS U-999 | | | |
| | | 5935946 | Jul 25, 2017 | DS DP U-1275 | | | |
| | | 5935946 | Jul 25, 2017 | DS DP U-248 | | | |
| | | 5935946 | Jul 25, 2017 | DS DP U-250 | | | |
| | | 5935946 | Jul 25, 2017 | DS DP U-256 | | | |
| | | 5935946 | Jul 25, 2017 | DS DP U-999 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| TENOFOVIR DISOPROXIL FUMARATE - VIREAD | | | | | | |
| N 021356 003 | 5977089 | Jul 25, 2017 | DS DP U-1275 | | | |
| | 5977089 | Jul 25, 2017 | DS DP U-248 | | | |
| | 5977089 | Jul 25, 2017 | DS DP U-250 | | | |
| | 5977089 | Jul 25, 2017 | DS DP U-256 | | | |
| | 5977089 | Jul 25, 2017 | DS DP U-999 | | | |
| | 6043230 | Jul 25, 2017 | U-1275 | | | |
| | 6043230 | Jul 25, 2017 | U-248 | | | |
| | 6043230 | Jul 25, 2017 | U-250 | | | |
| | 6043230 | Jul 25, 2017 | U-256 | | | |
| | 6043230 | Jul 25, 2017 | U-999 | | | |
| TENOFOVIR DISOPROXIL FUMARATE - VIREAD | | | | | | |
| N 021356 004 | 5922695 | Jul 25, 2017 | DS U-1275 | | PED | Sep 24, 2017 |
| | 5922695 | Jul 25, 2017 | DS U-248 | | | |
| | 5922695 | Jul 25, 2017 | DS U-250 | | | |
| | 5922695 | Jul 25, 2017 | DS U-256 | | | |
| | 5922695 | Jul 25, 2017 | DS U-999 | | | |
| | 5935946 | Jul 25, 2017 | DS DP U-1275 | | | |
| | 5935946 | Jul 25, 2017 | DS DP U-248 | | | |
| | 5935946 | Jul 25, 2017 | DS DP U-250 | | | |
| | 5935946 | Jul 25, 2017 | DS DP U-256 | | | |
| | 5935946 | Jul 25, 2017 | DS DP U-999 | | | |
| | 5977089 | Jul 25, 2017 | DS DP U-1275 | | | |
| | 5977089 | Jul 25, 2017 | DS DP U-248 | | | |
| | 5977089 | Jul 25, 2017 | DS DP U-250 | | | |
| | 5977089 | Jul 25, 2017 | DS DP U-256 | | | |
| | 5977089 | Jul 25, 2017 | DS DP U-999 | | | |
| | 6043230 | Jul 25, 2017 | U-1275 | | | |
| | 6043230 | Jul 25, 2017 | U-248 | | | |
| | 6043230 | Jul 25, 2017 | U-250 | | | |
| | 6043230 | Jul 25, 2017 | U-256 | | | |
| | 6043230 | Jul 25, 2017 | U-999 | | | |
| TENOFOVIR DISOPROXIL FUMARATE - VIREAD | | | | | | |
| N 022577 001 | 5922695 | Jul 25, 2017 | DS U-1275 | | PED | Sep 24, 2017 |
| | 5922695 | Jul 25, 2017 | DS U-248 | | | |
| | 5922695 | Jul 25, 2017 | DS U-250 | | | |
| | 5922695 | Jul 25, 2017 | DS U-256 | | | |
| | 5922695 | Jul 25, 2017 | DS U-999 | | | |
| | 5935946 | Jul 25, 2017 | DS DP U-1275 | | | |
| | 5935946 | Jul 25, 2017 | DS DP U-248 | | | |
| | 5935946 | Jul 25, 2017 | DS DP U-250 | | | |
| | 5935946 | Jul 25, 2017 | DS DP U-256 | | | |
| | 5935946 | Jul 25, 2017 | DS DP U-999 | | | |
| | 5977089 | Jul 25, 2017 | DS DP U-1275 | | | |
| | 5977089 | Jul 25, 2017 | DS DP U-248 | | | |
| | 5977089 | Jul 25, 2017 | DS DP U-250 | | | |
| | 5977089 | Jul 25, 2017 | DS DP U-256 | | | |
| | 5977089 | Jul 25, 2017 | DS DP U-999 | | | |
| | 6043230 | Jul 25, 2017 | U-1275 | | | |
| | 6043230 | Jul 25, 2017 | U-248 | | | |
| | 6043230 | Jul 25, 2017 | U-250 | | | |
| | 6043230 | Jul 25, 2017 | U-256 | | | |
| | 6043230 | Jul 25, 2017 | U-999 | | | |
| TERIFLUNOMIDE - AUBAGIO | | | | | | |
| N 202992 001 | 6794410 | Sep 12, 2026 | U-1285 | | NCE | Sep 12, 2017 |
| | 8802735 | Sep 14, 2030 | DP | | | |
| | 9186346 | Feb 04, 2034 | U-1786 | | | |
| TERIFLUNOMIDE - AUBAGIO | | | | | | |
| N 202992 002 | 6794410 | Sep 12, 2026 | U-1285 | | NCE | Sep 12, 2017 |
| | 8802735 | Sep 14, 2030 | DP | | | |
| | 9186346 | Feb 04, 2034 | U-1786 | | | |
| TERIPARATIDE RECOMBINANT HUMAN - FORTEO | | | | | | |
| N 021318 001 | 6770623 | Dec 08, 2018 | DP U-597 | | | |
| | 6977077 | Aug 19, 2019 | U-597 | | | |
| | 7144861 | Dec 08, 2018 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| TERIPARATIDE RECOMBINANT HUMAN - FORTEO | | | | | | | |
| N 021318 | 001 | 7163684 | Aug 19, 2019 | U-790 | | | |
| | | 7351414 | Aug 19, 2019 | U-865 | | | |
| | | 7517334 | Mar 25, 2025 | DP | | | |
| | | 7550434 | Dec 08, 2018 | DP U-982 | | | |
| TERIPARATIDE RECOMBINANT HUMAN - FORTEO | | | | | | | |
| N 021318 | 002 | 6770623 | Dec 08, 2018 | DP U-982 | | | |
| | | 6977077 | Aug 19, 2019 | U-982 | | | |
| | | 6977077 | Aug 19, 2019 | U-994 | | | |
| | | 7144861 | Dec 08, 2018 | DP | | | |
| | | 7163684 | Aug 19, 2019 | U-983 | | | |
| | | 7163684 | Aug 19, 2019 | U-994 | | | |
| | | 7351414 | Aug 19, 2019 | U-984 | | | |
| | | 7351414 | Aug 19, 2019 | U-994 | | | |
| | | 7517334 | Mar 25, 2025 | DP | | | |
| | | 7550434 | Dec 08, 2018 | DP U-982 | | | |
| TESAMORELIN ACETATE - EGRIFTA | | | | | | | |
| N 022505 | 001 | 5861379 | May 26, 2020 | DS DP U-1100 | | | |
| | | 7144577 | Jul 14, 2020 | U-1100 | | | |
| | | 7316997 | Aug 14, 2023 | U-1100 | | | |
| TESAMORELIN ACETATE - EGRIFTA | | | | | | | |
| N 022505 | 002 | 7144577 | Jul 14, 2020 | U-1100 | | | |
| | | 7316997 | Aug 14, 2023 | U-1100 | | | |
| TESTOSTERONE - TESTODERM TTS | | | | | | | |
| N 020791 | 001 | 6348210 | Nov 10, 2019 | U-440 | | | |
| TESTOSTERONE - ANDROGEL | | | | | | | |
| N 021015 | 001 | 6503894 | Aug 30, 2020 | U-490 | | | |
| | | 9125816 | Aug 30, 2020 | U-490 | | | |
| | | 9125816*PED | Mar 02, 2021 | | | | |
| | | 9132089 | Aug 30, 2020 | U-490 | | | |
| | | 9132089*PED | Mar 02, 2021 | | | | |
| TESTOSTERONE - ANDROGEL | | | | | | | |
| N 021015 | 002 | 6503894 | Aug 30, 2020 | U-490 | | | |
| | | 9125816 | Aug 30, 2020 | U-490 | | | |
| | | 9125816*PED | Mar 02, 2021 | | | | |
| | | 9132089 | Aug 30, 2020 | U-490 | | | |
| | | 9132089*PED | Mar 02, 2021 | | | | |
| TESTOSTERONE - ANDROGEL | | | | | | | |
| N 021015 | 003 | 6503894 | Aug 30, 2020 | U-490 | | | |
| | | 9125816 | Aug 30, 2020 | U-490 | | | |
| | | 9125816*PED | Mar 02, 2021 | | | | |
| | | 9132089 | Aug 30, 2020 | U-490 | | | |
| | | 9132089*PED | Mar 02, 2021 | | | | |
| TESTOSTERONE - TESTIM | | | | | | | |
| N 021454 | 001 | 7320968 | Jan 18, 2025 | U-843 | | | |
| | | 7608605 | Apr 21, 2023 | U-1009 | | | |
| | | 7608606 | Apr 21, 2023 | U-1009 | | | |
| | | 7608607 | Apr 21, 2023 | U-1009 | | | |
| | | 7608608 | Apr 21, 2023 | U-1009 | | | |
| | | 7608609 | Apr 21, 2023 | U-1009 | | | |
| | | 7608610 | Apr 21, 2023 | U-1009 | | | |
| | | 7935690 | Apr 21, 2023 | U-1009 | | | |
| | | 8063029 | Apr 21, 2023 | U-843 | | | |
| | | 8178518 | Apr 21, 2023 | DP | | | |
| TESTOSTERONE - FORTESTA | | | | | | | |
| N 021463 | 001 | 6319913 | Nov 09, 2018 | U-490 | | | |
| | | 6579865 | Nov 09, 2018 | DP | | | |
| TESTOSTERONE - STRIANT | | | | | | | |
| N 021543 | 001 | 6248358 | Aug 23, 2019 | U-527 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| TESTOSTERONE - ANDROGEL | | | | | | |
| N 022309 001 | 6503894 | Aug 30, 2020 | U-1103 | | | |
| | 6503894*PED | Mar 02, 2021 | | | | |
| | 8466136 | Oct 12, 2026 | DP | | | |
| | 8466137 | Oct 12, 2026 | U-1103 | | | |
| | 8466138 | Oct 12, 2026 | U-1103 | | | |
| | 8486925 | Oct 12, 2026 | DP | | | |
| | 8729057 | Oct 12, 2026 | DP | | | |
| | 8741881 | Oct 12, 2026 | U-1103 | | | |
| | 8754070 | Oct 12, 2026 | DP | | | |
| | 8759329 | Oct 12, 2026 | DP | | | |
| | 9125816 | Aug 30, 2020 | U-1103 | | | |
| | 9125816*PED | Mar 02, 2021 | | | | |
| | 9132089 | Aug 30, 2020 | U-1103 | | | |
| | 9132089*PED | Mar 02, 2021 | | | | |
| TESTOSTERONE - ANDROGEL | | | | | | |
| N 022309 002 | 6503894 | Aug 30, 2020 | U-1103 | | | |
| | 6503894*PED | Mar 02, 2021 | | | | |
| | 8466136 | Oct 12, 2026 | DP | | | |
| | 8466137 | Oct 12, 2026 | U-1103 | | | |
| | 8466138 | Oct 12, 2026 | U-1103 | | | |
| | 8486925 | Oct 12, 2026 | DP | | | |
| | 8729057 | Oct 12, 2026 | DP | | | |
| | 8741881 | Oct 12, 2026 | U-1103 | | | |
| | 8754070 | Oct 12, 2026 | DP | | | |
| | 8759329 | Oct 12, 2026 | DP | | | |
| | 9125816 | Aug 30, 2020 | U-1103 | | | |
| | 9125816*PED | Mar 02, 2021 | | | | |
| | 9132089 | Aug 30, 2020 | U-1103 | | | |
| | 9132089*PED | Mar 02, 2021 | | | | |
| TESTOSTERONE - ANDROGEL | | | | | | |
| N 022309 003 | 6503894 | Aug 30, 2020 | U-1103 | | | |
| | 6503894*PED | Mar 02, 2021 | | | | |
| | 8466136 | Oct 12, 2026 | DP | | | |
| | 8466137 | Oct 12, 2026 | U-1103 | | | |
| | 8466138 | Oct 12, 2026 | U-1103 | | | |
| | 8486925 | Oct 12, 2026 | DP | | | |
| | 8729057 | Oct 12, 2026 | DP | | | |
| | 8741881 | Oct 12, 2026 | U-1103 | | | |
| | 8754070 | Oct 12, 2026 | DP | | | |
| | 8759329 | Oct 12, 2026 | DP | | | |
| | 9125816 | Aug 30, 2020 | U-1103 | | | |
| | 9125816*PED | Mar 02, 2021 | | | | |
| | 9132089 | Aug 30, 2020 | U-1103 | | | |
| | 9132089*PED | Mar 02, 2021 | | | | |
| TESTOSTERONE - AXIRON | | | | | | |
| N 022504 001 | 8419307 | Feb 26, 2027 | U-1386 | | | |
| | 8435944 | Sep 27, 2027 | U-1390 | | | |
| | 8784878 | Jul 13, 2023 | DP U-1545 | | | |
| | 8807861 | Feb 26, 2027 | DP U-1563 | | | |
| | 8993520 | Jun 02, 2026 | U-1390 | | | |
| | 9180194 | Jun 02, 2026 | U-1390 | | | |
| | 9289586 | Feb 26, 2027 | U-1390 | | | |
| TESTOSTERONE - VOGELXO | | | | | | |
| N 204399 002 | 8785426 | Feb 11, 2034 | DP U-1531 | | | |
| | 9295675 | Feb 11, 2034 | DP U-1531 | | | |
| | 9662340 | Feb 11, 2034 | DP U-1531 | | | |
| TESTOSTERONE - VOGELXO | | | | | | |
| N 204399 003 | 8785426 | Feb 11, 2034 | DP U-1531 | | | |
| | 9295675 | Feb 11, 2034 | DP U-1531 | | | |
| | 9662340 | Feb 11, 2034 | DP U-1531 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| TESTOSTERONE - NATESTO | | | | | | |
| N 205488 001 | 8574622 | Feb 04, 2024 | DP | | | |
| | 8784869 | Feb 04, 2024 | DP | | | |
| | 8784882 | Feb 04, 2024 | DP U-1557 | | | |
| | 8877230 | Feb 04, 2024 | U-1616 | | | |
| TESTOSTERONE UNDECANOATE - AVEED | | | | | | |
| N 022219 001 | 7718640 | Mar 14, 2027 | DP | | | |
| | 8338395 | Feb 27, 2026 | U-1500 | | | |
| THALIDOMIDE - THALOMID | | | | | | |
| N 020785 001 | 6045501 | Aug 28, 2018 | U-371 | | | |
| | 6045501 | Aug 28, 2018 | U-731 | | | |
| | 6315720 | Oct 23, 2020 | U-442 | | | |
| | 6315720 | Oct 23, 2020 | U-731 | | | |
| | 6561976 | Aug 28, 2018 | U-371 | | | |
| | 6561976 | Aug 28, 2018 | U-731 | | | |
| | 6561977 | Oct 23, 2020 | U-371 | | | |
| | 6561977 | Oct 23, 2020 | U-731 | | | |
| | 6755784 | Oct 23, 2020 | U-371 | | | |
| | 6755784 | Oct 23, 2020 | U-731 | | | |
| | 6869399 | Oct 23, 2020 | U-371 | | | |
| | 6869399 | Oct 23, 2020 | U-731 | | | |
| | 6869399 | Oct 23, 2020 | U-732 | | | |
| | 6869399 | Oct 23, 2020 | U-733 | | | |
| | 6908432 | Aug 28, 2018 | U-371 | | | |
| | 6908432 | Aug 28, 2018 | U-731 | | | |
| | 7141018 | Oct 23, 2020 | U-371 | | | |
| | 7141018 | Oct 23, 2020 | U-731 | | | |
| | 7141018 | Oct 23, 2020 | U-732 | | | |
| | 7141018 | Oct 23, 2020 | U-733 | | | |
| | 7230012 | Dec 09, 2023 | DP | | | |
| | 7435745 | Nov 03, 2017 | U-899 | | | |
| | 7874984 | Aug 28, 2018 | U-1109 | | | |
| | 7874984 | Aug 28, 2018 | U-371 | | | |
| | 7874984 | Aug 28, 2018 | U-442 | | | |
| | 7874984 | Aug 28, 2018 | U-732 | | | |
| | 7874984 | Aug 28, 2018 | U-733 | | | |
| | 7959566 | Oct 23, 2020 | U-1155 | | | |
| | 8204763 | Aug 28, 2018 | U-1249 | | | |
| | 8315886 | Oct 23, 2020 | U-1249 | | | |
| | 8589188 | Aug 28, 2018 | U-1465 | | | |
| | 8626531 | Oct 23, 2020 | U-1465 | | | |
| THALIDOMIDE - THALOMID | | | | | | |
| N 020785 002 | 6045501 | Aug 28, 2018 | U-371 | | | |
| | 6045501 | Aug 28, 2018 | U-731 | | | |
| | 6315720 | Oct 23, 2020 | U-442 | | | |
| | 6315720 | Oct 23, 2020 | U-731 | | | |
| | 6561976 | Aug 28, 2018 | U-371 | | | |
| | 6561976 | Aug 28, 2018 | U-731 | | | |
| | 6561977 | Oct 23, 2020 | U-371 | | | |
| | 6561977 | Oct 23, 2020 | U-731 | | | |
| | 6755784 | Oct 23, 2020 | U-371 | | | |
| | 6755784 | Oct 23, 2020 | U-731 | | | |
| | 6869399 | Oct 23, 2020 | U-371 | | | |
| | 6869399 | Oct 23, 2020 | U-731 | | | |
| | 6869399 | Oct 23, 2020 | U-732 | | | |
| | 6869399 | Oct 23, 2020 | U-733 | | | |
| | 6908432 | Aug 28, 2018 | U-371 | | | |
| | 6908432 | Aug 28, 2018 | U-731 | | | |
| | 7141018 | Oct 23, 2020 | U-371 | | | |
| | 7141018 | Oct 23, 2020 | U-731 | | | |
| | 7141018 | Oct 23, 2020 | U-732 | | | |
| | 7141018 | Oct 23, 2020 | U-733 | | | |
| | 7230012 | Dec 09, 2023 | DP | | | |
| | 7435745 | Nov 03, 2017 | U-899 | | | |
| | 7874984 | Aug 28, 2018 | U-1109 | | | |
| | 7874984 | Aug 28, 2018 | U-371 | | | |
| | 7874984 | Aug 28, 2018 | U-442 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| THALIDOMIDE - THALOMID | | | | | | |
| N 020785 002 | 7874984 | Aug 28, 2018 | U-732 | | | |
| | 7874984 | Aug 28, 2018 | U-733 | | | |
| | 7959566 | Oct 23, 2020 | U-1155 | | | |
| | 8204763 | Aug 28, 2018 | U-1249 | | | |
| | 8315886 | Oct 23, 2020 | U-1249 | | | |
| | 8589188 | Aug 28, 2018 | U-1465 | | | |
| | 8626531 | Oct 23, 2020 | U-1465 | | | |
| THALIDOMIDE - THALOMID | | | | | | |
| N 020785 003 | 6045501 | Aug 28, 2018 | U-371 | | | |
| | 6045501 | Aug 28, 2018 | U-731 | | | |
| | 6315720 | Oct 23, 2020 | U-442 | | | |
| | 6315720 | Oct 23, 2020 | U-731 | | | |
| | 6561976 | Aug 28, 2018 | U-371 | | | |
| | 6561976 | Aug 28, 2018 | U-731 | | | |
| | 6561977 | Oct 23, 2020 | U-371 | | | |
| | 6561977 | Oct 23, 2020 | U-731 | | | |
| | 6755784 | Oct 23, 2020 | U-371 | | | |
| | 6755784 | Oct 23, 2020 | U-731 | | | |
| | 6869399 | Oct 23, 2020 | U-371 | | | |
| | 6869399 | Oct 23, 2020 | U-731 | | | |
| | 6869399 | Oct 23, 2020 | U-732 | | | |
| | 6869399 | Oct 23, 2020 | U-733 | | | |
| | 6908432 | Aug 28, 2018 | U-371 | | | |
| | 6908432 | Aug 28, 2018 | U-731 | | | |
| | 7141018 | Oct 23, 2020 | U-371 | | | |
| | 7141018 | Oct 23, 2020 | U-731 | | | |
| | 7141018 | Oct 23, 2020 | U-732 | | | |
| | 7141018 | Oct 23, 2020 | U-733 | | | |
| | 7230012 | Dec 09, 2023 | DP | | | |
| | 7435745 | Nov 03, 2017 | U-899 | | | |
| | 7874984 | Aug 28, 2018 | U-1109 | | | |
| | 7874984 | Aug 28, 2018 | U-371 | | | |
| | 7874984 | Aug 28, 2018 | U-442 | | | |
| | 7874984 | Aug 28, 2018 | U-732 | | | |
| | 7874984 | Aug 28, 2018 | U-733 | | | |
| | 7959566 | Oct 23, 2020 | U-1155 | | | |
| | 8204763 | Aug 28, 2018 | U-1249 | | | |
| | 8315886 | Oct 23, 2020 | U-1249 | | | |
| | 8589188 | Aug 28, 2018 | U-1465 | | | |
| | 8626531 | Oct 23, 2020 | U-1465 | | | |
| THALIDOMIDE - THALOMID | | | | | | |
| N 020785 004 | 6045501 | Aug 28, 2018 | U-731 | | | |
| | 6315720 | Oct 23, 2020 | U-731 | | | |
| | 6561976 | Aug 28, 2018 | U-731 | | | |
| | 6561977 | Oct 23, 2020 | U-731 | | | |
| | 6755784 | Oct 23, 2020 | U-731 | | | |
| | 6869399 | Oct 23, 2020 | U-731 | | | |
| | 6908432 | Aug 28, 2018 | U-731 | | | |
| | 7141018 | Oct 23, 2020 | U-731 | | | |
| | 7435745 | Nov 03, 2017 | U-899 | | | |
| | 7874984 | Aug 28, 2018 | U-1109 | | | |
| | 7874984 | Aug 28, 2018 | U-371 | | | |
| | 7874984 | Aug 28, 2018 | U-442 | | | |
| | 7874984 | Aug 28, 2018 | U-732 | | | |
| | 7874984 | Aug 28, 2018 | U-733 | | | |
| | 7959566 | Oct 23, 2020 | U-1155 | | | |
| | 8204763 | Aug 28, 2018 | U-1249 | | | |
| | 8315886 | Oct 23, 2020 | U-1249 | | | |
| | 8589188 | Aug 28, 2018 | U-1465 | | | |
| | 8626531 | Oct 23, 2020 | U-1465 | | | |
| THIOTEPA - TEPADINA | | | | | | |
| N 208264 001 | | | | | I-747 | Jan 26, 2020 |
| | | | | | ODE-129 | Jan 26, 2024 |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| THIOTEPA - TEPADINA | | | | | | | |
| N 208264 | 002 | | | | | I-747 | Jan 26, 2020 |
| | | | | | | ODE-129 | Jan 26, 2024 |
| TICAGRELOR - BRILINTA | | | | | | | |
| N 022433 | 001 | 6251910 | Jul 15, 2018 | DS | | I-714 | Sep 03, 2018 |
| | | 6525060 | Dec 02, 2019 | DS DP U-1171 | Y | | |
| | | 6525060 | Dec 02, 2019 | DS DP U-1860 | Y | | |
| | | 6525060 | Dec 02, 2019 | DS DP U-1862 | Y | | |
| | | 6525060 | Dec 02, 2019 | DS DP U-1863 | Y | | |
| | | 7250419 | Dec 02, 2019 | DS DP U-1171 | | | |
| | | 7250419 | Dec 02, 2019 | DS DP U-1860 | | | |
| | | 7250419 | Dec 02, 2019 | DS DP U-1864 | | | |
| | | 7250419 | Dec 02, 2019 | DS DP U-1865 | | | |
| | | 7250419 | Dec 02, 2019 | DS DP U-1866 | | | |
| | | 7250419 | Dec 02, 2019 | DS DP U-1867 | | | |
| | | 7265124 | Jul 09, 2021 | DS DP U-1171 | | | |
| | | 7265124 | Jul 09, 2021 | DS DP U-1860 | | | |
| | | 7265124 | Jul 09, 2021 | DS DP U-1868 | | | |
| | | 7265124 | Jul 09, 2021 | DS DP U-1869 | | | |
| | | 8425934 | Apr 17, 2030 | DP | | | |
| | | RE46276 | Oct 30, 2024 | DS DP U-1935 | | | |
| | | RE46276 | Oct 30, 2024 | DS DP U-1936 | | | |
| | | RE46276 | Oct 30, 2024 | DS DP U-1937 | | | |
| | | RE46276 | Oct 30, 2024 | DS DP U-1938 | | | |
| TICAGRELOR - BRILINTA | | | | | | | |
| N 022433 | 002 | 6251910 | Jul 15, 2018 | DS | | NS | Sep 03, 2018 |
| | | 6525060 | Dec 02, 2019 | DS DP U-1171 | Y | | |
| | | 6525060 | Dec 02, 2019 | DS DP U-1860 | Y | | |
| | | 6525060 | Dec 02, 2019 | DS DP U-1862 | Y | | |
| | | 6525060 | Dec 02, 2019 | DS DP U-1863 | Y | | |
| | | 7250419 | Dec 02, 2019 | DS DP U-1171 | | | |
| | | 7250419 | Dec 02, 2019 | DS DP U-1860 | | | |
| | | 7250419 | Dec 02, 2019 | DS DP U-1864 | | | |
| | | 7250419 | Dec 02, 2019 | DS DP U-1865 | | | |
| | | 7250419 | Dec 02, 2019 | DS DP U-1866 | | | |
| | | 7250419 | Dec 02, 2019 | DS DP U-1867 | | | |
| | | 7265124 | Jul 09, 2021 | DS DP U-1171 | | | |
| | | 7265124 | Jul 09, 2021 | DS DP U-1860 | | | |
| | | 7265124 | Jul 09, 2021 | DS DP U-1868 | | | |
| | | 7265124 | Jul 09, 2021 | DS DP U-1869 | | | |
| | | 8425934 | Apr 17, 2030 | DP | | | |
| | | RE46276 | Oct 30, 2024 | DS DP U-1935 | | | |
| | | RE46276 | Oct 30, 2024 | DS DP U-1936 | | | |
| | | RE46276 | Oct 30, 2024 | DS DP U-1937 | | | |
| | | RE46276 | Oct 30, 2024 | DS DP U-1938 | | | |
| TIGECYCLINE - TYGACIL | | | | | | | |
| N 021821 | 001 | 7879828 | Feb 05, 2029 | DP | | | |
| | | 8372995 | Oct 08, 2030 | DP | | | |
| | | 8975242 | Oct 24, 2028 | DP | | | |
| | | 9254328 | Mar 13, 2026 | DP | | | |
| | | 9694078 | Mar 13, 2026 | DP | | | |
| TIMOLOL MALEATE - TIMOLOL MALEATE | | | | | | | |
| N 020963 | 001 | 6174524 | Mar 26, 2019 | DP | | | |
| TIMOLOL MALEATE - TIMOLOL MALEATE | | | | | | | |
| N 020963 | 002 | 6174524 | Mar 26, 2019 | DP | | | |
| TIMOLOL MALEATE - ISTALOL | | | | | | | |
| N 021516 | 001 | 6335335 | Nov 02, 2018 | DP | | | |
| | | 6645963 | Nov 16, 2018 | DP | | | |
| TIOTROPIUM BROMIDE - SPIRIVA | | | | | | | |
| N 021395 | 001 | 6777423 | Sep 24, 2021 | DS DP | | | |
| | | 6777423*PED | Mar 24, 2022 | | | | |
| | | 6908928 | Sep 24, 2021 | DS DP U-566 | | | |
| | | 6908928 | Sep 24, 2021 | DS DP U-762 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| TIOTROPIUM BROMIDE - SPIRIVA | | | | | | | |
| N 021395 | 001 | 6908928*PED | Mar 24, 2022 | | | | |
| | | 7070800 | Jan 22, 2022 | DP U-566 | | | |
| | | 7070800*PED | Jul 22, 2022 | | | | |
| | | 7309707 | Sep 24, 2021 | DS DP | | | |
| | | 7309707*PED | Mar 24, 2022 | | | | |
| | | 7642268 | Sep 24, 2021 | DS DP | | | |
| | | 7642268*PED | Mar 24, 2022 | | | | |
| | | 7694676 | Mar 12, 2027 | DP | | | |
| | | 7694676*PED | Sep 12, 2027 | | | | |
| | | 8022082 | Jan 19, 2026 | DP U-1186 | | | |
| | | 8022082*PED | Jul 19, 2026 | | | | |
| | | 9010323 | Apr 19, 2030 | DP | | | |
| | | RE38912 | Oct 11, 2021 | DP | | | |
| | | RE38912*PED | Apr 11, 2022 | | | | |
| | | RE39820 | Jan 30, 2018 | DS DP U-566 | | | |
| | | RE39820*PED | Jul 30, 2018 | | | | |
| TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT | | | | | | | |
| N 021936 | 001 | 6846413 | Aug 28, 2018 | DP | | NP | Sep 24, 2017 |
| | | 6846413*PED | Feb 28, 2019 | | | NPP | Feb 15, 2020 |
| | | 6977042 | Aug 28, 2018 | DP | | PED | Mar 24, 2018 |
| | | 6977042*PED | Feb 28, 2019 | | | PED | Aug 15, 2020 |
| | | 6988496 | Feb 23, 2020 | DP | | | |
| | | 6988496*PED | Aug 23, 2020 | | | | |
| | | 7284474 | Aug 26, 2024 | DP | | | |
| | | 7284474*PED | Feb 26, 2025 | | | | |
| | | 7396341 | Oct 10, 2026 | DP | | | |
| | | 7396341*PED | Apr 10, 2027 | | | | |
| | | 7802568 | Feb 26, 2019 | DP | | | |
| | | 7802568*PED | Aug 26, 2019 | | | | |
| | | 7837235 | Mar 13, 2028 | DP | | | |
| | | 7837235*PED | Sep 13, 2028 | | | | |
| | | 7896264 | May 26, 2025 | DP | | | |
| | | 7896264*PED | Nov 26, 2025 | | | | |
| | | 7988001 | Aug 04, 2021 | DP | | | |
| | | 7988001*PED | Feb 04, 2022 | | | | |
| | | 8733341 | Oct 16, 2030 | DP | | | |
| | | 8733341*PED | Apr 16, 2031 | | | | |
| | | 9027967 | Mar 31, 2027 | DP | | | |
| | | 9027967*PED | Oct 01, 2027 | | | | |
| | | RE39820 | Jan 30, 2018 | DS DP U-1593 | | | |
| | | RE39820*PED | Jul 30, 2018 | | | | |
| TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT | | | | | | | |
| N 021936 | 002 | 6846413 | Aug 28, 2018 | DP | | NP | Sep 15, 2018 |
| | | 6846413*PED | Feb 28, 2019 | | | NPP | Feb 15, 2020 |
| | | 6977042 | Aug 28, 2018 | DP | | PED | Mar 15, 2019 |
| | | 6977042*PED | Feb 28, 2019 | | | PED | Aug 15, 2020 |
| | | 6988496 | Feb 23, 2020 | DP | | | |
| | | 6988496*PED | Aug 23, 2020 | | | | |
| | | 7284474 | Aug 26, 2024 | DP | | | |
| | | 7284474*PED | Feb 26, 2025 | | | | |
| | | 7396341 | Oct 10, 2026 | DP | | | |
| | | 7396341*PED | Apr 10, 2027 | | | | |
| | | 7802568 | Feb 26, 2019 | DP | | | |
| | | 7802568*PED | Aug 26, 2019 | | | | |
| | | 7837235 | Mar 13, 2028 | DP | | | |
| | | 7837235*PED | Sep 13, 2028 | | | | |
| | | 7896264 | May 26, 2025 | DP | | | |
| | | 7896264*PED | Nov 26, 2025 | | | | |
| | | 7988001 | Aug 04, 2021 | DP | | | |
| | | 7988001*PED | Feb 04, 2022 | | | | |
| | | 8733341 | Oct 16, 2030 | DP | | | |
| | | 8733341*PED | Apr 16, 2031 | | | | |
| | | 9027967 | Mar 31, 2027 | DP | | | |
| | | 9027967*PED | Oct 01, 2027 | | | | |
| | | RE39820 | Jan 30, 2018 | DS DP | | | |
| | | RE39820*PED | Jul 30, 2018 | | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF | | | | | | | |
| N 207981 | 001 | 6479500 | Mar 16, 2020 | U-1751 | | NCE | Sep 22, 2020 |
| | | 9527833 | Jun 17, 2034 | DS DP | | | |
| | | RE46284 | Dec 16, 2026 | U-1751 | | | |
| TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF | | | | | | | |
| N 207981 | 002 | 6479500 | Mar 16, 2020 | U-1751 | | NCE | Sep 22, 2020 |
| | | 9527833 | Jun 17, 2034 | DS DP | | | |
| | | RE46284 | Dec 16, 2026 | U-1751 | | | |
| TIPRANAVIR - APTIVUS | | | | | | | |
| N 021814 | 001 | 5852195 | Jun 22, 2019 | DS | | | |
| | | 6147095 | Oct 29, 2019 | U-670 | | | |
| | | 6231887 | Jul 27, 2018 | DP | | | |
| TIPRANAVIR - APTIVUS | | | | | | | |
| N 022292 | 001 | 5852195 | Jun 22, 2019 | DS | | | |
| | | 6147095 | Oct 29, 2019 | U-670 | | | |
| TIROFIBAN HYDROCHLORIDE - AGGRASTAT | | | | | | | |
| N 020912 | 001 | 5978698 | Oct 08, 2017 | | | | |
| | | 6136794 | Jan 29, 2019 | | | | |
| | | 6770660 | May 01, 2023 | U-1444 | | | |
| TIROFIBAN HYDROCHLORIDE - AGGRASTAT | | | | | | | |
| N 020912 | 002 | 5978698 | Oct 08, 2017 | U-1897 | | | |
| | | 6136794 | Jan 29, 2019 | U-1898 | | | |
| | | 6770660 | May 01, 2023 | U-1444 | | | |
| TIROFIBAN HYDROCHLORIDE - AGGRASTAT | | | | | | | |
| N 020913 | 001 | 5978698 | Oct 08, 2017 | | | | |
| | | 6136794 | Jan 29, 2019 | | | | |
| | | 6770660 | May 01, 2023 | U-1444 | | | |
| TIROFIBAN HYDROCHLORIDE - AGGRASTAT | | | | | | | |
| N 020913 | 002 | 5978698 | Oct 08, 2017 | | | | |
| | | 6136794 | Jan 29, 2019 | | | | |
| | | 6770660 | May 01, 2023 | U-1444 | | | |
| TIROFIBAN HYDROCHLORIDE - AGGRASTAT | | | | | | | |
| N 020913 | 003 | 5978698 | Oct 08, 2017 | | | | |
| | | 6136794 | Jan 29, 2019 | | | | |
| | | 6770660 | May 01, 2023 | U-1444 | | | |
| TOBRAMYCIN - TOBI PODHALER | | | | | | | |
| N 201688 | 001 | 7368102 | Dec 19, 2022 | DP U-909 | | | |
| | | 7442388 | May 10, 2020 | DP | | | |
| | | 7516741 | Jan 11, 2024 | DP | | | |
| | | 7559325 | Oct 27, 2025 | DP | | | |
| | | 8069851 | Sep 24, 2024 | DP | | | |
| | | 8349294 | May 10, 2020 | DP | | | |
| | | 8715623 | Dec 19, 2022 | DP U-909 | | | |
| TOBRAMYCIN - BETHKIS | | | | | | | |
| N 201820 | 001 | 6987094 | Sep 22, 2022 | DP | | | |
| | | 7696178 | Mar 17, 2023 | DP | | | |
| | | 7939502 | Jun 14, 2022 | U-1324 | | | |
| TOFACITINIB CITRATE - XELJANZ | | | | | | | |
| N 203214 | 001 | 6956041 | Dec 08, 2020 | DP | | I-761 | Dec 14, 2020 |
| | | 6965027 | Mar 25, 2023 | DS | | NCE | Nov 06, 2017 |
| | | 7091208 | Dec 08, 2020 | U-247 | | | |
| | | 7265221 | Dec 08, 2020 | DS | | | |
| | | 7301023 | May 23, 2022 | DS | | | |
| | | RE41783 | Dec 08, 2025 | DS | | | |
| TOFACITINIB CITRATE - XELJANZ XR | | | | | | | |
| N 208246 | 001 | 6956041 | Dec 08, 2020 | DP | | I-761 | Dec 14, 2020 |
| | | 6965027 | Mar 25, 2023 | DS | | NCE | Nov 06, 2017 |
| | | 7091208 | Dec 08, 2020 | U-247 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| TOFACITINIB CITRATE - XELJANZ XR | | | | | | | |
| N 208246 | 001 | 7265221 | Dec 08, 2020 | DS | | | |
| | | 7301023 | May 23, 2022 | DS | | | |
| | | RE41783 | Dec 08, 2025 | DS | | | |
| TOLTERODINE TARTRATE - DETROL LA | | | | | | | |
| N 021228 | 001 | 6630162 | Nov 11, 2019 | DP | | U-544 | |
| | | 6770295 | Aug 26, 2019 | DP | | U-544 | |
| | | 6911217 | Nov 11, 2019 | DP | | U-544 | |
| | | 6911217*PED | May 11, 2020 | | | | |
| TOLTERODINE TARTRATE - DETROL LA | | | | | | | |
| N 021228 | 002 | 6630162 | Nov 11, 2019 | DP | | U-544 | |
| | | 6770295 | Aug 26, 2019 | DP | | U-544 | |
| | | 6911217 | Nov 11, 2019 | DP | | U-544 | |
| | | 6911217*PED | May 11, 2020 | | | | |
| TOLVAPTAN - SAMSCA | | | | | | | |
| N 022275 | 001 | 5753677 | May 19, 2020 | | | U-978 | |
| | | 8501730 | Sep 01, 2026 | DS | | | |
| TOLVAPTAN - SAMSCA | | | | | | | |
| N 022275 | 002 | 5753677 | May 19, 2020 | | | U-978 | |
| | | 8501730 | Sep 01, 2026 | DS | | | |
| TOLVAPTAN - SAMSCA | | | | | | | |
| N 022275 | 003 | 5753677 | May 19, 2020 | | | U-978 | |
| | | 8501730 | Sep 01, 2026 | DS | | | |
| TOPIRAMATE - TOPAMAX | | | | | | | |
| N 020844 | 001 | 7125560 | Mar 01, 2019 | | | U-766 | |
| TOPIRAMATE - TOPAMAX | | | | | | | |
| N 020844 | 002 | 7125560 | Mar 01, 2019 | | | U-766 | |
| TOPIRAMATE - TOPAMAX SPRINKLE | | | | | | | |
| N 020844 | 003 | 7125560 | Mar 01, 2019 | | | U-766 | |
| TOPIRAMATE - TROKENDI XR | | | | | | | |
| N 201635 | 001 | 8298576 | Apr 04, 2028 | DP | | U-106 | |
| | | 8298576 | Apr 04, 2028 | DP | | U-1992 | |
| | | 8298580 | Nov 16, 2027 | DP | | U-106 | |
| | | 8298580 | Nov 16, 2027 | DP | | U-1992 | |
| | | 8663683 | Nov 16, 2027 | DP | | U-106 | |
| | | 8663683 | Nov 16, 2027 | DP | | U-1992 | |
| | | 8877248 | Nov 16, 2027 | DP | | U-106 | |
| | | 8877248 | Nov 16, 2027 | DP | | U-1992 | |
| | | 8889191 | Nov 16, 2027 | | | U-106 | |
| | | 8889191 | Nov 16, 2027 | | | U-1992 | |
| | | 8992989 | Nov 16, 2027 | DP | | U-1675 | |
| | | 8992989 | Nov 16, 2027 | DP | | U-1992 | |
| | | 9549940 | Nov 16, 2027 | DP | | U-1675 | |
| | | 9549940 | Nov 16, 2027 | DP | | U-1992 | |
| | | 9555004 | Nov 16, 2027 | DP | | U-1675 | |
| | | 9555004 | Nov 16, 2027 | DP | | U-1992 | |
| | | 9622983 | Nov 16, 2027 | DP | | U-1675 | |
| | | 9622983 | Nov 16, 2027 | DP | | U-1992 | |
| TOPIRAMATE - TROKENDI XR | | | | | | | |
| N 201635 | 002 | 8298576 | Apr 04, 2028 | DP | | U-106 | |
| | | 8298576 | Apr 04, 2028 | DP | | U-1992 | |
| | | 8298580 | Nov 16, 2027 | DP | | U-106 | |
| | | 8298580 | Nov 16, 2027 | DP | | U-1992 | |
| | | 8663683 | Nov 16, 2027 | DP | | U-106 | |
| | | 8663683 | Nov 16, 2027 | DP | | U-1992 | |
| | | 8877248 | Nov 16, 2027 | DP | | U-106 | |
| | | 8877248 | Nov 16, 2027 | DP | | U-1992 | |
| | | 8889191 | Nov 16, 2027 | | | U-106 | |
| | | 8889191 | Nov 16, 2027 | | | U-1992 | |
| | | 8992989 | Nov 16, 2027 | DP | | U-1675 | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| TOPIRAMATE - TROKENDI XR | | | | | | | |
| N 201635 | 002 | 8992989 | Nov 16, 2027 | DP U-1992 | | | |
| | | 9549940 | Nov 16, 2027 | DP U-1675 | | | |
| | | 9549940 | Nov 16, 2027 | DP U-1992 | | | |
| | | 9555004 | Nov 16, 2027 | DP U-1675 | | | |
| | | 9555004 | Nov 16, 2027 | DP U-1992 | | | |
| | | 9622983 | Nov 16, 2027 | DP U-1675 | | | |
| | | 9622983 | Nov 16, 2027 | DP U-1992 | | | |
| TOPIRAMATE - TROKENDI XR | | | | | | | |
| N 201635 | 003 | 8298576 | Apr 04, 2028 | DP U-106 | | | |
| | | 8298576 | Apr 04, 2028 | DP U-1992 | | | |
| | | 8298580 | Nov 16, 2027 | DP U-106 | | | |
| | | 8298580 | Nov 16, 2027 | DP U-1992 | | | |
| | | 8663683 | Nov 16, 2027 | DP U-106 | | | |
| | | 8663683 | Nov 16, 2027 | DP U-1992 | | | |
| | | 8877248 | Nov 16, 2027 | DP U-106 | | | |
| | | 8877248 | Nov 16, 2027 | DP U-1992 | | | |
| | | 8889191 | Nov 16, 2027 | U-106 | | | |
| | | 8889191 | Nov 16, 2027 | U-1992 | | | |
| | | 8992989 | Nov 16, 2027 | DP U-1675 | | | |
| | | 8992989 | Nov 16, 2027 | DP U-1992 | | | |
| | | 9549940 | Nov 16, 2027 | DP U-1675 | | | |
| | | 9549940 | Nov 16, 2027 | DP U-1992 | | | |
| | | 9555004 | Nov 16, 2027 | DP U-1675 | | | |
| | | 9555004 | Nov 16, 2027 | DP U-1992 | | | |
| | | 9622983 | Nov 16, 2027 | DP U-1675 | | | |
| | | 9622983 | Nov 16, 2027 | DP U-1992 | | | |
| TOPIRAMATE - TROKENDI XR | | | | | | | |
| N 201635 | 004 | 8298576 | Apr 04, 2028 | DP U-106 | | | |
| | | 8298576 | Apr 04, 2028 | DP U-1992 | | | |
| | | 8298580 | Nov 16, 2027 | DP U-106 | | | |
| | | 8298580 | Nov 16, 2027 | DP U-1992 | | | |
| | | 8663683 | Nov 16, 2027 | DP U-106 | | | |
| | | 8663683 | Nov 16, 2027 | DP U-1992 | | | |
| | | 8877248 | Nov 16, 2027 | DP U-106 | | | |
| | | 8877248 | Nov 16, 2027 | DP U-1992 | | | |
| | | 8889191 | Nov 16, 2027 | U-106 | | | |
| | | 8889191 | Nov 16, 2027 | U-1992 | | | |
| | | 8992989 | Nov 16, 2027 | DP U-1675 | | | |
| | | 8992989 | Nov 16, 2027 | DP U-1992 | | | |
| | | 9549940 | Nov 16, 2027 | DP U-1675 | | | |
| | | 9549940 | Nov 16, 2027 | DP U-1992 | | | |
| | | 9555004 | Nov 16, 2027 | DP U-1675 | | | |
| | | 9555004 | Nov 16, 2027 | DP U-1992 | | | |
| | | 9622983 | Nov 16, 2027 | DP U-1675 | | | |
| | | 9622983 | Nov 16, 2027 | DP U-1992 | | | |
| TOPIRAMATE - QUDEXY XR | | | | | | | |
| N 205122 | 001 | 8652527 | Mar 19, 2033 | DP | | | |
| | | 8889190 | Mar 19, 2033 | DP | | | |
| | | 9101545 | Mar 19, 2033 | DP | | | |
| | | 9555005 | Mar 19, 2033 | DP | | | |
| TOPIRAMATE - QUDEXY XR | | | | | | | |
| N 205122 | 002 | 8652527 | Mar 19, 2033 | DP | | | |
| | | 8889190 | Mar 19, 2033 | DP | | | |
| | | 9101545 | Mar 19, 2033 | DP | | | |
| | | 9555005 | Mar 19, 2033 | DP | | | |
| TOPIRAMATE - QUDEXY XR | | | | | | | |
| N 205122 | 003 | 8652527 | Mar 19, 2033 | DP | | | |
| | | 8889190 | Mar 19, 2033 | DP | | | |
| | | 9101545 | Mar 19, 2033 | DP | | | |
| | | 9555005 | Mar 19, 2033 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|---|
| TOPIRAMATE - QUDEXY XR | | | | | | | | |
| N 205122 | 004 | 8652527 | Mar 19, 2033 | | DP | | | |
| | | 8889190 | Mar 19, 2033 | | DP | | | |
| | | 9101545 | Mar 19, 2033 | | DP | | | |
| | | 9555005 | Mar 19, 2033 | | DP | | | |
| TOPIRAMATE - QUDEXY XR | | | | | | | | |
| N 205122 | 005 | 8652527 | Mar 19, 2033 | | DP | | | |
| | | 8889190 | Mar 19, 2033 | | DP | | | |
| | | 9101545 | Mar 19, 2033 | | DP | | | |
| | | 9555005 | Mar 19, 2033 | | DP | | | |
| TOPOTECAN HYDROCHLORIDE - HYCAMTIN | | | | | | | | |
| N 020981 | 001 | 8158645 | Dec 10, 2024 | | DP | | | |
| TOPOTECAN HYDROCHLORIDE - HYCAMTIN | | | | | | | | |
| N 020981 | 002 | 8158645 | Dec 10, 2024 | | DP | | | |
| TRABECTEDIN - YONDELIS | | | | | | | | |
| N 207953 | 001 | 8895557 | Jan 07, 2028 | | DP | | NCE | Oct 23, 2020 |
| | | | | | | | ODE-100 | Oct 23, 2022 |
| TRAMADOL HYDROCHLORIDE - ULTRAM | | | | | | | | |
| N 020281 | 001 | 6339105 | Oct 12, 2019 | | U-435 | | | |
| TRAMADOL HYDROCHLORIDE - ULTRAM | | | | | | | | |
| N 020281 | 002 | 6339105 | Oct 12, 2019 | | U-435 | | | |
| TRAMADOL HYDROCHLORIDE - RYBIX ODT | | | | | | | | |
| N 021693 | 001 | 6106861 | Dec 05, 2017 | | DP | | | |
| TRAMADOL HYDROCHLORIDE - RYZOLT | | | | | | | | |
| N 021745 | 001 | 6607748 | Jun 29, 2020 | | DP | | | |
| | | 7988998 | Oct 27, 2023 | | DP | | | |
| TRAMADOL HYDROCHLORIDE - RYZOLT | | | | | | | | |
| N 021745 | 002 | 6607748 | Jun 29, 2020 | | DP | | | |
| | | 7988998 | Oct 27, 2023 | | DP | | | |
| TRAMADOL HYDROCHLORIDE - RYZOLT | | | | | | | | |
| N 021745 | 003 | 6607748 | Jun 29, 2020 | | DP | | | |
| | | 7988998 | Oct 27, 2023 | | DP | | | |
| TRAMADOL HYDROCHLORIDE - CONZIP | | | | | | | | |
| N 022370 | 001 | 7858118 | Apr 11, 2022 | | DP U-1104 | | | |
| TRAMADOL HYDROCHLORIDE - CONZIP | | | | | | | | |
| N 022370 | 002 | 7858118 | Apr 11, 2022 | | DP U-1104 | | | |
| TRAMADOL HYDROCHLORIDE - CONZIP | | | | | | | | |
| N 022370 | 003 | 7858118 | Apr 11, 2022 | | DP U-1104 | | | |
| TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST | | | | | | | | |
| N 204114 | 001 | 7378423 | Sep 13, 2025 | DS | DP | | I-745 | Jun 22, 2020 |
| | | 8580304 | Jan 28, 2032 | | DP | | M-170 | Nov 20, 2018 |
| | | 8703781 | Oct 15, 2030 | DS | DP U-1712 | | NCE | May 29, 2018 |
| | | 8703781 | Oct 15, 2030 | DS | DP U-2033 | | ODE-148 | Jun 22, 2024 |
| | | 8835443 | Sep 13, 2025 | | U-1581 | | ODE-48 | May 29, 2020 |
| | | 8835443 | Sep 13, 2025 | | U-1582 | | ODE-57 | Jan 08, 2021 |
| | | 8835443 | Sep 13, 2025 | | U-2020 | | | |
| | | 8835443 | Sep 13, 2025 | | U-2037 | | | |
| | | 8952018 | Oct 15, 2030 | | U-2020 | | | |
| | | 9155706 | Jan 28, 2032 | | DP | | | |
| | | 9271941 | Jan 28, 2032 | | DP | | | |
| TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST | | | | | | | | |
| N 204114 | 002 | 7378423 | Sep 13, 2025 | DS | DP | | I-745 | Jun 22, 2020 |
| | | 8580304 | Jan 28, 2032 | | DP | | NCE | May 29, 2018 |
| | | 8703781 | Oct 15, 2030 | DS | DP U-1712 | | ODE-148 | Jun 22, 2024 |
| | | 8703781 | Oct 15, 2030 | DS | DP U-2033 | | ODE-48 | May 29, 2020 |
| | | 8835443 | Sep 13, 2025 | | U-1581 | | ODE-57 | Jan 08, 2021 |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST | | | | | | | |
| N 204114 | 002 | 8835443 | Sep 13, 2025 | U-1582 | | | |
| | | 8835443 | Sep 13, 2025 | U-2020 | | | |
| | | 8835443 | Sep 13, 2025 | U-2037 | | | |
| | | 8952018 | Oct 15, 2030 | U-2020 | | | |
| | | 9155706 | Jan 28, 2032 | DP | | | |
| | | 9271941 | Jan 28, 2032 | DP | | | |
| TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST | | | | | | | |
| N 204114 | 003 | 7378423 | Sep 13, 2025 | DS DP | | I-745 | Jun 22, 2020 |
| | | 8580304 | Jan 28, 2032 | DP | | M-170 | Nov 20, 2018 |
| | | 8703781 | Oct 15, 2030 | DS DP U-1712 | | NCE | May 29, 2018 |
| | | 8703781 | Oct 15, 2030 | DS DP U-2033 | | ODE-148 | Jun 22, 2024 |
| | | 8835443 | Sep 13, 2025 | U-1581 | | ODE-48 | May 29, 2020 |
| | | 8835443 | Sep 13, 2025 | U-1582 | | ODE-57 | Jan 08, 2021 |
| | | 8835443 | Sep 13, 2025 | U-2020 | | | |
| | | 8835443 | Sep 13, 2025 | U-2037 | | | |
| | | 8952018 | Oct 15, 2030 | U-2020 | | | |
| | | 9155706 | Jan 28, 2032 | DP | | | |
| | | 9271941 | Jan 28, 2032 | DP | | | |
| TRANEXAMIC ACID - LYSTEDA | | | | | | | |
| N 022430 | 001 | 7947739 | Mar 04, 2025 | DP | | | |
| | | 8022106 | Mar 04, 2025 | U-1182 | | | |
| | | 8273795 | Mar 04, 2025 | U-1182 | | | |
| | | 8487005 | Mar 04, 2025 | DP U-1182 | | | |
| | | 8791160 | Mar 04, 2025 | DP U-1182 | | | |
| | | 8809394 | Mar 04, 2025 | DP U-1182 | | | |
| | | 8957113 | Mar 04, 2025 | DP U-1182 | | | |
| | | 9060939 | Mar 04, 2025 | DP | | | |
| TRAVOPROST - TRAVATAN Z | | | | | | | |
| N 021994 | 001 | 8268299 | Oct 13, 2029 | DP | | | |
| | | 8323630 | Sep 20, 2027 | DP | | | |
| | | 8388941 | Sep 20, 2027 | DP | | | |
| TRAVOPROST - IZBA | | | | | | | |
| N 204822 | 001 | 8178582 | Oct 10, 2029 | DP | | | |
| | | 8722735 | Oct 10, 2029 | DP | | | |
| | | 8754123 | May 19, 2029 | DP | | | |
| | | 9144561 | Mar 13, 2029 | DP | | | |
| TRAZODONE HYDROCHLORIDE - DESYREL | | | | | | | |
| N 018207 | 001 | 8133893 | Mar 13, 2029 | DS DP | | | |
| TRAZODONE HYDROCHLORIDE - DESYREL | | | | | | | |
| N 018207 | 002 | 8133893 | Mar 13, 2029 | DS DP | | | |
| TRAZODONE HYDROCHLORIDE - DESYREL | | | | | | | |
| N 018207 | 003 | 8133893 | Mar 13, 2029 | DS DP | | | |
| TRAZODONE HYDROCHLORIDE - DESYREL | | | | | | | |
| N 018207 | 004 | 8133893 | Mar 13, 2029 | DS DP | | | |
| TRAZODONE HYDROCHLORIDE - OLEPTRO | | | | | | | |
| N 022411 | 001 | 6607748 | Jun 29, 2020 | DP | | | |
| | | 7829120 | Mar 27, 2027 | DP U-796 | | | |
| | | 8133893 | Mar 13, 2029 | DS DP | | | |
| TRAZODONE HYDROCHLORIDE - OLEPTRO | | | | | | | |
| N 022411 | 002 | 6607748 | Jun 29, 2020 | DP | | | |
| | | 7829120 | Mar 27, 2027 | DP U-796 | | | |
| | | 8133893 | Mar 13, 2029 | DS DP | | | |
| TREPROSTINIL - REMODULIN | | | | | | | |
| N 021272 | 001 | 6765117 | Oct 24, 2017 | DS | | | |
| | | 7999007 | Mar 29, 2029 | DP U-1437 | | | |
| | | 8497393 | Dec 15, 2028 | DS | | | |
| | | 8653137 | Sep 05, 2028 | U-1437 | | | |
| | | 8658694 | Sep 05, 2028 | U-1437 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| TREPROSTINIL - REMODULIN | | | | | | |
| N 021272 001 | 9199908 | May 24, 2024 | U-1771 | | | |
| | 9593066 | Dec 15, 2028 | DS | | | |
| | 9604901 | Dec 15, 2028 | DS | | | |
| | 9713599 | Dec 16, 2024 | U-2036 | | | |
| TREPROSTINIL - REMODULIN | | | | | | |
| N 021272 002 | 6765117 | Oct 24, 2017 | DS | | | |
| | 7999007 | Mar 29, 2029 | DP U-1437 | | | |
| | 8497393 | Dec 15, 2028 | DS | | | |
| | 8653137 | Sep 05, 2028 | U-1437 | | | |
| | 8658694 | Sep 05, 2028 | U-1437 | | | |
| | 9199908 | May 24, 2024 | U-1771 | | | |
| | 9593066 | Dec 15, 2028 | DS | | | |
| | 9604901 | Dec 15, 2028 | DS | | | |
| | 9713599 | Dec 16, 2024 | U-2036 | | | |
| TREPROSTINIL - REMODULIN | | | | | | |
| N 021272 003 | 6765117 | Oct 24, 2017 | DS | | | |
| | 7999007 | Mar 29, 2029 | DP U-1437 | | | |
| | 8497393 | Dec 15, 2028 | DS | | | |
| | 8653137 | Sep 05, 2028 | U-1437 | | | |
| | 8658694 | Sep 05, 2028 | U-1437 | | | |
| | 9199908 | May 24, 2024 | U-1771 | | | |
| | 9593066 | Dec 15, 2028 | DS | | | |
| | 9604901 | Dec 15, 2028 | DS | | | |
| | 9713599 | Dec 16, 2024 | U-2036 | | | |
| TREPROSTINIL - REMODULIN | | | | | | |
| N 021272 004 | 6765117 | Oct 24, 2017 | DS | | | |
| | 7999007 | Mar 29, 2029 | DP U-1437 | | | |
| | 8497393 | Dec 15, 2028 | DS | | | |
| | 8653137 | Sep 05, 2028 | U-1437 | | | |
| | 8658694 | Sep 05, 2028 | U-1437 | | | |
| | 9199908 | May 24, 2024 | U-1771 | | | |
| | 9593066 | Dec 15, 2028 | DS | | | |
| | 9604901 | Dec 15, 2028 | DS | | | |
| | 9713599 | Dec 16, 2024 | U-2036 | | | |
| TREPROSTINIL - TYVASO | | | | | | |
| N 022387 001 | 6521212 | Nov 13, 2018 | U-1018 | | | |
| | 6756033 | Nov 13, 2018 | U-1018 | | | |
| | 6765117 | Oct 24, 2017 | DS | | | |
| | 8497393 | Dec 15, 2028 | DS | | | |
| | 9339507 | Mar 10, 2028 | DP | | | |
| | 9358240 | May 05, 2028 | U-1849 | | | |
| | 9593066 | Dec 15, 2028 | DS | | | |
| | 9604901 | Dec 15, 2028 | DS | | | |
| TREPROSTINIL DIOLAMINE - ORENITRAM | | | | | | |
| N 203496 001 | 6765117 | Oct 24, 2017 | DS | | D-156 | Jan 28, 2019 |
| | 7417070 | Jul 30, 2026 | DS | | D-157 | Jan 28, 2019 |
| | 7544713 | Jul 14, 2024 | U-1475 | | | |
| | 8252839 | May 24, 2024 | DP | | | |
| | 8349892 | Jan 22, 2031 | DP | | | |
| | 8410169 | Feb 13, 2030 | DP | | | |
| | 8497393 | Dec 15, 2028 | DS | | | |
| | 8747897 | Oct 08, 2029 | DP | | | |
| | 9050311 | May 24, 2024 | DS DP | | | |
| | 9278901 | May 24, 2024 | U-1475 | | | |
| | 9393203 | Apr 27, 2026 | DP U-1877 | | | |
| | 9422223 | May 24, 2024 | DP | | | |
| | 9593066 | Dec 15, 2028 | DS | | | |
| | 9604901 | Dec 15, 2028 | DS | | | |
| TREPROSTINIL DIOLAMINE - ORENITRAM | | | | | | |
| N 203496 002 | 6765117 | Oct 24, 2017 | DS | | D-156 | Jan 28, 2019 |
| | 7417070 | Jul 30, 2026 | DS | | D-157 | Jan 28, 2019 |
| | 7544713 | Jul 14, 2024 | U-1475 | | | |
| | 8252839 | May 24, 2024 | DP | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| TREPROSTINIL DIOLAMINE - ORENITRAM | | | | | | | |
| N 203496 | 002 | 8349892 | Jan 22, 2031 | DP | | | |
| | | 8410169 | Feb 13, 2030 | DP | | | |
| | | 8497393 | Dec 15, 2028 | DS | | | |
| | | 8747897 | Oct 08, 2029 | DP | | | |
| | | 9050311 | May 24, 2024 | DS DP | | | |
| | | 9278901 | May 24, 2024 | U-1475 | | | |
| | | 9393203 | Apr 27, 2026 | DP U-1877 | | | |
| | | 9422223 | May 24, 2024 | DP | | | |
| | | 9593066 | Dec 15, 2028 | DS | | | |
| | | 9604901 | Dec 15, 2028 | DS | | | |
| TREPROSTINIL DIOLAMINE - ORENITRAM | | | | | | | |
| N 203496 | 003 | 6765117 | Oct 24, 2017 | DS | | D-156 | Jan 28, 2019 |
| | | 7417070 | Jul 30, 2026 | DS | | D-157 | Jan 28, 2019 |
| | | 7544713 | Jul 14, 2024 | U-1475 | | | |
| | | 8252839 | May 24, 2024 | DP | | | |
| | | 8349892 | Jan 22, 2031 | DP | | | |
| | | 8410169 | Feb 13, 2030 | DP | | | |
| | | 8497393 | Dec 15, 2028 | DS | | | |
| | | 8747897 | Oct 08, 2029 | DP | | | |
| | | 9050311 | May 24, 2024 | DS DP | | | |
| | | 9278901 | May 24, 2024 | U-1475 | | | |
| | | 9393203 | Apr 27, 2026 | DP U-1877 | | | |
| | | 9422223 | May 24, 2024 | DP | | | |
| | | 9593066 | Dec 15, 2028 | DS | | | |
| | | 9604901 | Dec 15, 2028 | DS | | | |
| TREPROSTINIL DIOLAMINE - ORENITRAM | | | | | | | |
| N 203496 | 004 | 6765117 | Oct 24, 2017 | DS | | D-156 | Jan 28, 2019 |
| | | 7417070 | Jul 30, 2026 | DS | | D-157 | Jan 28, 2019 |
| | | 7544713 | Jul 14, 2024 | U-1475 | | | |
| | | 8252839 | May 24, 2024 | DP | | | |
| | | 8349892 | Jan 22, 2031 | DP | | | |
| | | 8410169 | Feb 13, 2030 | DP | | | |
| | | 8497393 | Dec 15, 2028 | DS | | | |
| | | 8747897 | Oct 08, 2029 | DP | | | |
| | | 9050311 | May 24, 2024 | DS DP | | | |
| | | 9278901 | May 24, 2024 | U-1475 | | | |
| | | 9393203 | Apr 27, 2026 | DP U-1877 | | | |
| | | 9422223 | May 24, 2024 | DP | | | |
| | | 9593066 | Dec 15, 2028 | DS | | | |
| | | 9604901 | Dec 15, 2028 | DS | | | |
| TREPROSTINIL DIOLAMINE - ORENITRAM | | | | | | | |
| N 203496 | 005 | 6765117 | Oct 24, 2017 | DS | | D-156 | Jan 28, 2019 |
| | | 7417070 | Jul 30, 2026 | DS | | D-157 | Jan 28, 2019 |
| | | 7544713 | Jul 14, 2024 | U-1475 | | | |
| | | 8252839 | May 24, 2024 | DP | | | |
| | | 8349892 | Jan 22, 2031 | DP | | | |
| | | 8410169 | Feb 13, 2030 | DP | | | |
| | | 8497393 | Dec 15, 2028 | DS | | | |
| | | 8747897 | Oct 08, 2029 | DP | | | |
| | | 9050311 | May 24, 2024 | DS DP | | | |
| | | 9278901 | May 24, 2024 | U-1475 | | | |
| | | 9393203 | Apr 27, 2026 | DP U-1877 | | | |
| | | 9422223 | May 24, 2024 | DP | | | |
| | | 9593066 | Dec 15, 2028 | DS | | | |
| | | 9604901 | Dec 15, 2028 | DS | | | |
| TRETINOIN - RENOVA | | | | | | | |
| N 021108 | 001 | 6531141 | Mar 07, 2020 | | | | |
| TRIAMCINOLONE ACETONIDE - TRIESENCE | | | | | | | |
| N 022048 | 001 | 6395294 | Jan 13, 2020 | DP U-846 | | | |
| | | 8128960 | Dec 17, 2029 | DP | | | |
| | | 8211880 | Mar 10, 2029 | U-1257 | | | |
| | | 8211880 | Mar 10, 2029 | U-1258 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| TRIAMCINOLONE ACETONIDE - ZILRETTA | | | | | | | |
| N 208845 | 001 | 8828440 | Aug 04, 2031 | DP | | NP | Oct 06, 2020 |
| | | 9555048 | Aug 04, 2031 | U-2151 | | | |
| TRIMETREXATE GLUCURONATE - NEUTREXIN | | | | | | | |
| N 020326 | 001 | 6017922 | May 18, 2018 | | | | |
| TRIMETREXATE GLUCURONATE - NEUTREXIN | | | | | | | |
| N 020326 | 002 | 6017922 | May 18, 2018 | | | | |
| TRIPTORELIN PAMOATE - TRIPTODUR KIT | | | | | | | |
| N 208956 | 001 | | | | | NP | Jun 29, 2020 |
| | | | | | | ODE-149 | Jun 29, 2024 |
| TROGLITAZONE - PRELAY | | | | | | | |
| N 020719 | 001 | 5859037 | Nov 13, 2017 | U-251 | | | |
| | | 6011049 | Nov 13, 2017 | U-301 | | | |
| TROGLITAZONE - PRELAY | | | | | | | |
| N 020719 | 002 | 5859037 | Nov 13, 2017 | U-251 | | | |
| | | 6011049 | Nov 13, 2017 | U-301 | | | |
| TROGLITAZONE - PRELAY | | | | | | | |
| N 020719 | 003 | 5859037 | Nov 13, 2017 | U-251 | | | |
| | | 6011049 | Nov 13, 2017 | U-301 | | | |
| TROSPIUM CHLORIDE - SANCTURA XR | | | | | | | |
| N 022103 | 001 | 7410978 | Feb 01, 2025 | DP | | | |
| | | 7759359 | Nov 04, 2024 | U-1071 | | | |
| | | 7763635 | Nov 04, 2024 | U-1071 | | | |
| | | 7781448 | Nov 04, 2024 | U-1071 | | | |
| | | 7781449 | Nov 04, 2024 | U-1071 | | | |
| ULIPRISTAL ACETATE - ELLA | | | | | | | |
| N 022474 | 001 | 8426392 | Jun 12, 2030 | U-1389 | | | |
| | | 8512745 | Jun 02, 2030 | DP | | | |
| | | 8735380 | Feb 20, 2029 | DP | | | |
| | | 8962603 | Jun 12, 2030 | U-1657 | | | |
| | | 9283233 | Apr 13, 2030 | U-1821 | | | |
| UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA | | | | | | | |
| N 205382 | 001 | 7488827 | Dec 18, 2027 | DS DP | | M-172 | Feb 24, 2019 |
| | | 7498440 | Apr 27, 2025 | DS DP | | NCE | Dec 18, 2018 |
| | | 8113199 | Oct 23, 2027 | DP | | | |
| | | 8161968 | Feb 05, 2028 | DP | | | |
| | | 8183257 | Jul 27, 2025 | U-1476 | | | |
| | | 8201556 | Feb 05, 2029 | DP | | | |
| | | 8309572 | Apr 27, 2025 | U-1476 | | | |
| | | 8534281 | Aug 10, 2029 | DP | | | |
| | | 8746242 | Oct 11, 2030 | DP | | | |
| | | 9333310 | Oct 02, 2027 | DP | | | |
| UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA | | | | | | | |
| N 203975 | 001 | 7439393 | May 21, 2025 | DS DP U-1476 | | NCE | May 10, 2018 |
| | | 7488827 | Dec 18, 2027 | DS DP | | NCE | Dec 18, 2018 |
| | | 7498440 | Apr 27, 2025 | DS DP | | | |
| | | 7776895 | Sep 11, 2022 | DP | | | |
| | | 8113199 | Oct 23, 2027 | DP | | | |
| | | 8161968 | Feb 05, 2028 | DP | | | |
| | | 8183257 | Jul 27, 2025 | U-1476 | | | |
| | | 8309572 | Apr 27, 2025 | U-1476 | | | |
| | | 8511304 | Jun 14, 2027 | DP U-1476 | | | |
| | | 8534281 | Aug 10, 2029 | DP | | | |
| | | 8746242 | Oct 11, 2030 | DP | | | |
| | | 9333310 | Oct 02, 2027 | DP | | | |
| | | 9750726 | Nov 29, 2030 | DP | | | |
| | | RE44874 | Mar 23, 2023 | DS DP U-1476 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| UNOPROSTONE ISOPROPYL - RESCULA | | | | | | | |
| N 021214 | 001 | 6458836 | Jul 09, 2021 | U-1315 | | | |
| | | 6458836 | Jul 09, 2021 | U-333 | | | |
| | | 6770675 | Nov 24, 2018 | DP U-1322 | | | |
| URIDINE TRIACETATE - VISTOGARD | | | | | | | |
| N 208159 | 001 | 6258795 | Jul 10, 2018 | DP | | NCE | Sep 04, 2020 |
| | | 7776838 | Aug 17, 2027 | U-1791 | | NP | Dec 11, 2018 |
| | | | | | | ODE-104 | Dec 11, 2022 |
| URIDINE TRIACETATE - XURIDEN | | | | | | | |
| N 208169 | 001 | 6258795 | Jul 10, 2018 | DP | | NCE | Sep 04, 2020 |
| | | | | | | ODE-98 | Sep 04, 2022 |
| VALBENAZINE TOSYLATE - INGREZZA | | | | | | | |
| N 209241 | 001 | 8039627 | Oct 06, 2029 | DS DP | | NCE | Apr 11, 2022 |
| | | 8357697 | Nov 08, 2027 | U-1995 | | | |
| VALBENAZINE TOSYLATE - INGREZZA | | | | | | | |
| N 209241 | 002 | 8039627 | Oct 06, 2029 | DS DP | | NCE | Apr 11, 2022 |
| | | 8357697 | Nov 08, 2027 | U-1995 | | | |
| VALGANCICLOVIR HYDROCHLORIDE - VALCYTE | | | | | | | |
| N 021304 | 001 | | | | | D-148 | Apr 23, 2018 |
| | | | | | | NPP | Apr 23, 2018 |
| VALGANCICLOVIR HYDROCHLORIDE - VALCYTE | | | | | | | |
| N 022257 | 001 | 8889109 | Dec 11, 2027 | DP | | D-148 | Apr 23, 2018 |
| | | 9642911 | Dec 11, 2027 | DP | | NPP | Apr 23, 2018 |
| VANDETANIB - CAPRELSA | | | | | | | |
| N 022405 | 001 | 8067427 | Aug 08, 2028 | DP | | ODE-9 | Apr 06, 2018 |
| | | RE42353 | Jun 27, 2022 | DS DP | | | |
| VANDETANIB - CAPRELSA | | | | | | | |
| N 022405 | 002 | 8067427 | Aug 08, 2028 | DP | | ODE-9 | Apr 06, 2018 |
| | | RE42353 | Jun 27, 2022 | DS DP | | | |
| VARDENAFIL HYDROCHLORIDE - LEVITRA | | | | | | | |
| N 021400 | 001 | 6362178 | Oct 31, 2018 | DS DP U-533 | | | |
| | | 7696206 | Oct 31, 2018 | DS DP U-533 | | | |
| | | 8273876 | Jul 23, 2027 | U-1288 | | | |
| | | 8841446 | Jul 03, 2023 | DP | | | |
| VARDENAFIL HYDROCHLORIDE - LEVITRA | | | | | | | |
| N 021400 | 002 | 6362178 | Oct 31, 2018 | DS DP U-533 | | | |
| | | 7696206 | Oct 31, 2018 | DS DP U-533 | | | |
| | | 8273876 | Jul 23, 2027 | U-1288 | | | |
| | | 8841446 | Jul 03, 2023 | DP | | | |
| VARDENAFIL HYDROCHLORIDE - LEVITRA | | | | | | | |
| N 021400 | 003 | 6362178 | Oct 31, 2018 | DS DP U-533 | | | |
| | | 7696206 | Oct 31, 2018 | DS DP U-533 | | | |
| | | 8273876 | Jul 23, 2027 | U-1288 | | | |
| | | 8841446 | Jul 03, 2023 | DP | | | |
| VARDENAFIL HYDROCHLORIDE - LEVITRA | | | | | | | |
| N 021400 | 004 | 6362178 | Oct 31, 2018 | DS DP U-533 | | | |
| | | 7696206 | Oct 31, 2018 | DS DP U-533 | | | |
| | | 8273876 | Jul 23, 2027 | U-1288 | | | |
| | | 8841446 | Jul 03, 2023 | DP | | | |
| VARDENAFIL HYDROCHLORIDE - STAXYN | | | | | | | |
| N 200179 | 001 | 6362178 | Oct 31, 2018 | U-155 | | | |
| | | 7696206 | Oct 31, 2018 | U-155 | | | |
| | | 8613950 | Dec 23, 2028 | DP | | | |
| VARENICLINE TARTRATE - CHANTIX | | | | | | | |
| N 021928 | 001 | 6410550 | May 10, 2020 | DS DP U-56 | | M-143 | Oct 15, 2017 |
| | | 6890927 | May 06, 2022 | DS DP U-56 | | M-144 | Oct 15, 2017 |
| | | 7265119 | Aug 03, 2022 | DS DP U-56 | | M-183 | Aug 12, 2019 |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| VARENICLINE TARTRATE - CHANTIX | | | | | | |
| N 021928 001 | | | | | M-192 | Dec 16, 2019 |
| VARENICLINE TARTRATE - CHANTIX | | | | | | |
| N 021928 002 | 6410550 | May 10, 2020 | DS DP U-56 | | M-143 | Oct 15, 2017 |
| | 6890927 | May 06, 2022 | DS DP U-56 | | M-144 | Oct 15, 2017 |
| | 7265119 | Aug 03, 2022 | DS DP U-56 | | M-183 | Aug 12, 2019 |
| | | | | | M-192 | Dec 16, 2019 |
| VASOPRESSIN - VASOSTRICT | | | | | | |
| N 204485 001 | 9375478 | Jan 30, 2035 | U-1857 | | | |
| | 9687526 | Jan 30, 2035 | U-1857 | | | |
| | 9744209 | Jan 30, 2035 | U-1857 | | | |
| | 9744239 | Jan 30, 2035 | U-1857 | | | |
| | 9750785 | Jan 30, 2035 | DP | | | |
| VASOPRESSIN - VASOSTRICT | | | | | | |
| N 204485 002 | 9375478 | Jan 30, 2035 | U-1857 | | | |
| | 9687526 | Jan 30, 2035 | U-1857 | | | |
| | 9744209 | Jan 30, 2035 | U-1857 | | | |
| | 9744239 | Jan 30, 2035 | U-1857 | | | |
| | 9750785 | Jan 30, 2035 | DP | | | |
| VEMURAFENIB - ZELBORAF | | | | | | |
| N 202429 001 | 7504509 | Oct 22, 2026 | DS DP | | I-757 | Nov 06, 2020 |
| | 7863288 | Jun 20, 2029 | DS DP | | M-184 | Aug 31, 2019 |
| | 8143271 | Jun 21, 2026 | DS DP | | ODE | Nov 06, 2024 |
| | 8470818 | Aug 02, 2026 | U-1418 | | ODE-13 | Aug 17, 2018 |
| | 8470818 | Aug 02, 2026 | U-2164 | | | |
| | 8741920 | Jul 27, 2030 | DS DP | | | |
| | 9447089 | Jun 06, 2032 | DP | | | |
| VENETOCLAX - VENCLEXTA | | | | | | |
| N 208573 001 | 8546399 | Jun 27, 2031 | DS DP | | NCE | Apr 11, 2021 |
| | 9174982 | May 26, 2030 | U-1835 | | ODE-114 | Apr 11, 2023 |
| VENETOCLAX - VENCLEXTA | | | | | | |
| N 208573 002 | 8546399 | Jun 27, 2031 | DS DP | | NCE | Apr 11, 2021 |
| | 9174982 | May 26, 2030 | U-1835 | | ODE-114 | Apr 11, 2023 |
| VENETOCLAX - VENCLEXTA | | | | | | |
| N 208573 003 | 8546399 | Jun 27, 2031 | DS DP | | NCE | Apr 11, 2021 |
| | 9174982 | May 26, 2030 | U-1835 | | ODE-114 | Apr 11, 2023 |
| VILAZODONE HYDROCHLORIDE - VIIBRYD | | | | | | |
| N 022567 001 | 5532241 | Sep 29, 2019 | DS DP | | D-146 | Mar 16, 2018 |
| | 7834020 | Jun 05, 2022 | DS DP U-839 | | | |
| | 8193195 | Jun 05, 2022 | U-839 | | | |
| | 8236804 | Jun 05, 2022 | U-839 | | | |
| | 8673921 | Jun 05, 2022 | DS DP | | | |
| VILAZODONE HYDROCHLORIDE - VIIBRYD | | | | | | |
| N 022567 002 | 5532241 | Sep 29, 2019 | DS DP | | D-146 | Mar 16, 2018 |
| | 7834020 | Jun 05, 2022 | DS DP U-839 | | | |
| | 8193195 | Jun 05, 2022 | U-839 | | | |
| | 8236804 | Jun 05, 2022 | U-839 | | | |
| | 8673921 | Jun 05, 2022 | DS DP | | | |
| VILAZODONE HYDROCHLORIDE - VIIBRYD | | | | | | |
| N 022567 003 | 5532241 | Sep 29, 2019 | DS DP | | D-146 | Mar 16, 2018 |
| | 7834020 | Jun 05, 2022 | DS DP U-839 | | | |
| | 8193195 | Jun 05, 2022 | U-839 | | | |
| | 8236804 | Jun 05, 2022 | U-839 | | | |
| | 8673921 | Jun 05, 2022 | DS DP | | | |
| VINCRISTINE SULFATE - MARQIBO KIT | | | | | | |
| N 202497 001 | 6723338 | Mar 31, 2020 | U-1271 | | ODE-28 | Aug 09, 2019 |
| | 7247316 | Sep 25, 2020 | DP | | | |
| | 7887836 | Mar 31, 2020 | U-1271 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| VISMODEGIB - ERIVEDGE | | | | | | | |
| N 203388 | 001 | 7888364 | Nov 11, 2028 | DS DP | | | |
| | | 9278961 | Dec 15, 2028 | U-1825 | | | |
| VORAPAXAR SULFATE - ZONTIVITY | | | | | | | |
| N 204886 | 001 | 7235567 | Jun 13, 2021 | DS DP | | NCE | May 08, 2019 |
| | | 7304078 | Apr 06, 2024 | DS DP U-1512 | | | |
| VORICONAZOLE - VFEND | | | | | | | |
| N 021267 | 001 | 6632803 | Jun 02, 2018 | DP | | | |
| VORINOSTAT - ZOLINZA | | | | | | | |
| N 021991 | 001 | 7399787 | Feb 09, 2025 | U-892 | | | |
| | | 7456219 | Mar 11, 2027 | DS | | | |
| | | 7652069 | Mar 04, 2023 | DP | | | |
| | | 7732490 | Mar 04, 2023 | U-892 | | | |
| | | 7851509 | Feb 21, 2024 | DP U-892 | | | |
| | | 8067472 | Mar 04, 2023 | U-892 | | | |
| | | 8093295 | May 16, 2026 | DP | | | |
| | | 8101663 | Mar 04, 2023 | U-892 | | | |
| | | 8450372 | Mar 18, 2028 | U-892 | | | |
| VORTIOXETINE HYDROBROMIDE - TRINTELLIX | | | | | | | |
| N 204447 | 001 | 7144884 | Oct 02, 2022 | DS DP U-1439 | | NCE | Sep 30, 2018 |
| | | 8476279 | Oct 02, 2022 | DP U-1439 | | | |
| | | 8722684 | Jun 30, 2031 | DS DP | | | |
| | | 8969355 | Jun 15, 2027 | U-1668 | | | |
| | | 9227946 | Jun 15, 2027 | U-1668 | | | |
| VORTIOXETINE HYDROBROMIDE - TRINTELLIX | | | | | | | |
| N 204447 | 002 | 7144884 | Oct 02, 2022 | DS DP U-1439 | | NCE | Sep 30, 2018 |
| | | 8476279 | Oct 02, 2022 | DP U-1439 | | | |
| | | 8722684 | Jun 30, 2031 | DS DP | | | |
| | | 8969355 | Jun 15, 2027 | U-1668 | | | |
| | | 9227946 | Jun 15, 2027 | U-1668 | | | |
| VORTIOXETINE HYDROBROMIDE - TRINTELLIX | | | | | | | |
| N 204447 | 003 | 7144884 | Oct 02, 2022 | DS DP U-1439 | | NCE | Sep 30, 2018 |
| | | 8476279 | Oct 02, 2022 | DP U-1439 | | | |
| | | 8722684 | Jun 30, 2031 | DS DP | | | |
| | | 8969355 | Jun 15, 2027 | U-1668 | | | |
| | | 9227946 | Jun 15, 2027 | U-1668 | | | |
| VORTIOXETINE HYDROBROMIDE - TRINTELLIX | | | | | | | |
| N 204447 | 004 | 7144884 | Oct 02, 2022 | DS DP U-1439 | | NCE | Sep 30, 2018 |
| | | 8476279 | Oct 02, 2022 | DP U-1439 | | | |
| | | 8722684 | Jun 30, 2031 | DS DP | | | |
| | | 8969355 | Jun 15, 2027 | U-1668 | | | |
| | | 9227946 | Jun 15, 2027 | U-1668 | | | |
| ZICONOTIDE ACETATE - PRIALT | | | | | | | |
| N 021060 | 001 | 8653033 | Oct 01, 2024 | U-48 | | | |
| | | 8653033 | Oct 01, 2024 | U-55 | | | |
| | | 8765680 | Oct 01, 2024 | U-48 | | | |
| | | 8765680 | Oct 01, 2024 | U-55 | | | |
| | | 9707270 | Oct 01, 2024 | U-2084 | | | |
| ZICONOTIDE ACETATE - PRIALT | | | | | | | |
| N 021060 | 002 | 8653033 | Oct 01, 2024 | U-48 | | | |
| | | 8653033 | Oct 01, 2024 | U-55 | | | |
| | | 8765680 | Oct 01, 2024 | U-48 | | | |
| | | 8765680 | Oct 01, 2024 | U-55 | | | |
| | | 9707270 | Oct 01, 2024 | U-2084 | | | |
| ZICONOTIDE ACETATE - PRIALT | | | | | | | |
| N 021060 | 003 | 8653033 | Oct 01, 2024 | U-48 | | | |
| | | 8653033 | Oct 01, 2024 | U-55 | | | |
| | | 8765680 | Oct 01, 2024 | U-48 | | | |
| | | 8765680 | Oct 01, 2024 | U-55 | | | |
| | | 9707270 | Oct 01, 2024 | U-2084 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|---|
| ZICONOTIDE ACETATE - PRIALT | | | | | | | |
| N 021060 | 003 | 8653033 | Oct 01, 2024 | U-48 | | | |
| | | 8653033 | Oct 01, 2024 | U-55 | | | |
| | | 8765680 | Oct 01, 2024 | U-48 | | | |
| | | 8765680 | Oct 01, 2024 | U-55 | | | |
| | | 9707270 | Oct 01, 2024 | U-2084 | | | |
| ZICONOTIDE ACETATE - PRIALT | | | | | | | |
| N 021060 | 004 | 8653033 | Oct 01, 2024 | U-48 | | | |
| | | 8653033 | Oct 01, 2024 | U-55 | | | |
| | | 8765680 | Oct 01, 2024 | U-48 | | | |
| | | 8765680 | Oct 01, 2024 | U-55 | | | |
| | | 9707270 | Oct 01, 2024 | U-2084 | | | |
| ZIPRASIDONE HYDROCHLORIDE - GEODON | | | | | | | |
| N 020825 | 001 | 6150366 | May 27, 2019 | DP | | | |
| | | 6245766 | Dec 18, 2018 | U-601 | | | |
| ZIPRASIDONE HYDROCHLORIDE - GEODON | | | | | | | |
| N 020825 | 002 | 6150366 | May 27, 2019 | DP | | | |
| | | 6245766 | Dec 18, 2018 | U-601 | | | |
| ZIPRASIDONE HYDROCHLORIDE - GEODON | | | | | | | |
| N 020825 | 003 | 6150366 | May 27, 2019 | DP | | | |
| | | 6245766 | Dec 18, 2018 | U-601 | | | |
| ZIPRASIDONE HYDROCHLORIDE - GEODON | | | | | | | |
| N 020825 | 004 | 6150366 | May 27, 2019 | DP | | | |
| | | 6245766 | Dec 18, 2018 | U-601 | | | |
| ZIPRASIDONE HYDROCHLORIDE - GEODON | | | | | | | |
| N 021483 | 001 | 6150366 | May 27, 2019 | DP U-719 | | | |
| | | 6245766 | Dec 18, 2018 | U-601 | | | |
| | | 7175855 | May 18, 2020 | DP | | | |
| ZOLEDRONIC ACID - ZOMETA | | | | | | | |
| N 021223 | 002 | 8324189 | May 29, 2025 | U-1308 | | | |
| | | 8324189 | May 29, 2025 | U-1309 | | | |
| | | 8324189 | May 29, 2025 | U-53 | | | |
| ZOLEDRONIC ACID - ZOMETA | | | | | | | |
| N 021223 | 003 | 7932241 | Feb 05, 2028 | DP | | | |
| | | 8324189 | May 29, 2025 | U-1308 | | | |
| | | 8324189 | May 29, 2025 | U-1309 | | | |
| | | 8324189 | May 29, 2025 | U-53 | | | |
| ZOLEDRONIC ACID - RECLAST | | | | | | | |
| N 021817 | 001 | 7932241 | Feb 05, 2028 | DP | | | |
| | | 8052987 | Oct 27, 2023 | U-1199 | | | |
| ZOLMITRIPTAN - ZOMIG | | | | | | | |
| N 021450 | 003 | 6750237 | Nov 28, 2020 | DP | | NPP | Jun 12, 2018 |
| | | 6750237*PED | May 28, 2021 | | | | |
| | | 7220767 | Nov 28, 2020 | DP | | | |
| | | 7220767*PED | May 28, 2021 | | | | |
| ZOLMITRIPTAN - ZOMIG | | | | | | | |
| N 021450 | 004 | 6750237 | Nov 28, 2020 | DP | | NPP | Jun 12, 2018 |
| | | 7220767 | Nov 28, 2020 | DP | | | |
| ZOLPIDEM TARTRATE - AMBIEN CR | | | | | | | |
| N 021774 | 001 | 6514531 | Dec 01, 2019 | DP | | | |
| ZOLPIDEM TARTRATE - AMBIEN CR | | | | | | | |
| N 021774 | 002 | 6514531 | Dec 01, 2019 | DP | | | |
| ZOLPIDEM TARTRATE - EDLUAR | | | | | | | |
| N 021997 | 001 | 6761910 | Sep 24, 2019 | DP U-674 | | | |
| | | 8512747 | Sep 24, 2019 | U-674 | | | |
| | | 9265720 | Feb 25, 2031 | U-674 | | | |
| | | 9597281 | Apr 06, 2027 | U-674 | | | |

# PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST

See report footnote for information regarding report content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE(S) | EXCLUSIVITY EXPIRATION DATE |
|---|---|---|---|---|---|---|
| ZOLPIDEM TARTRATE - EDLUAR | | | | | | |
| N 021997 001 | 6761910 | Sep 24, 2019 | DP | | U-674 | |
| | 8512747 | Sep 24, 2019 | | | U-674 | |
| | 9265720 | Feb 25, 2031 | | | U-674 | |
| | 9597281 | Apr 06, 2027 | | | U-674 | |
| ZOLPIDEM TARTRATE - EDLUAR | | | | | | |
| N 021997 002 | 6761910 | Sep 24, 2019 | DP | | U-674 | |
| | 8512747 | Sep 24, 2019 | | | U-674 | |
| | 9265720 | Feb 25, 2031 | | | U-674 | |
| | 9597281 | Apr 06, 2027 | | | U-674 | |
| ZOLPIDEM TARTRATE - ZOLPIMIST | | | | | | |
| N 022196 001 | 7632517 | Oct 01, 2017 | | | U-70 | |
| | 8236285 | Aug 07, 2032 | DS DP | | U-70 | |
| ZOLPIDEM TARTRATE - INTERMEZZO | | | | | | |
| N 022328 001 | 7658945 | Apr 15, 2027 | DP | | U-1194 | |
| | 7682628 | Feb 16, 2025 | | | U-1194 | |
| | 8242131 | Aug 20, 2029 | | | U-1266 | |
| | 8252809 | Feb 16, 2025 | DP | | | |
| ZOLPIDEM TARTRATE - INTERMEZZO | | | | | | |
| N 022328 002 | 7658945 | Apr 15, 2027 | DP | | U-1194 | |
| | 7682628 | Feb 16, 2025 | | | U-1194 | |
| | 8242131 | Aug 20, 2029 | | | U-1266 | |
| | 8252809 | Feb 16, 2025 | DP | | | |

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

# PATENT AND EXCLUSIVITY TERMS



## PATENT & EXCLUSIVITY ABBREVIATIONS

| | |
|---|---|
| CGT | COMPETITIVE GENERIC THERAPY |
| D | NEW DOSING SCHEDULE (SEE INDIVIDUAL REFERENCES) |
| GAIN | GAIN EXCLUSIVITY |
| I | NEW INDICATION (SEE INDIVIDUAL REFERENCES) |
| M | MISCELLANEOUS EXCLUSIVITY CODES (SEE INDIVIDUAL REFERENCES) |
| NC | NEW COMBINATION |
| NCE | NEW CHEMICAL ENTITY |
| NCE* | NEW CHEMICAL ENTITY (AN ENANTIOMER OF PREVIOUSLY APPROVED RACEMIC MIXTURE. SEE SECTION 505(U) OF THE FEDERAL FOOD AND DRUG COSMETIC ACT). |
| NDF | NEW DOSAGE FORM |
| NE | NEW ESTER OR SALT OF AN ACTIVE INGREDIENT |
| NP | NEW PRODUCT |
| NP* | NEW PRODUCT (MINT FLAVORED) |
| NPP | NEW PATIENT POPULATION |
| NR | NEW ROUTE |
| NS | NEW STRENGTH |
| ODE | ORPHAN DRUG EXCLUSIVITY (SEE INDIVIDUAL REFERENCES) |
| PC | PATENT CHALLENGE |
| PED | PEDIATRIC EXCLUSIVITY |
| RTO | RX TO OTC SWITCH OR OTC USE |
| RTO* | OTC USE FOR WOMEN AGES 15 AND 16 |
| RTO** | OTC USE FOR WOMEN 14 AND BELOW |
| U | PATENT USE CODE (SEE INDIVIDUAL REFERENCES) |
| W | EXCLUSIVITY ON THIS APPLICATION EXPIRING ON THIS DATE HAS BEEN WAIVED BY SPONSOR - SEE SECTION 1.8 OF ORANGE BOOK PREFACE WAIVED EXCLUSIVITY |

## EXCLUSIVITY DOSING SCHEDULE

| | |
|---|---|
| D-1 | ONCE A DAY APPLICATION |
| D-2 | ONCE DAILY DOSING |
| D-3 | SEVEN DAYS/SEVEN DAYS/SEVEN DAYS DOSING SCHEDULE |
| D-4 | SEVEN DAYS/FOURTEEN DAYS DOSING SCHEDULE |
| D-5 | TEN DAYS/ELEVEN DAYS DOSING SCHEDULE |
| D-6 | SEVEN DAYS/NINE DAYS/FIVE DAYS DOSING SCHEDULE |
| D-7 | BID DOSING |
| D-8 | INTRAVENOUS, EPIDURAL AND INTRATHECAL DOSING |
| D-9 | NARCOTIC OVERDOSE IN ADULTS |
| D-10 | NARCOTIC OVERDOSE IN CHILDREN |
| D-11 | POSTOPERATIVE NARCOTIC DEPRESSION IN CHILDREN |
| D-12 | BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE DUODENAL ULCER |
| D-13 | INCREASED MAXIMUM DAILY DOSAGE RECOMMENDATION |
| D-14 | BEDTIME DOSING OF 800MG FOR TREATMENT OF ACTIVE BENIGN GASTRIC ULCER |
| D-15 | SINGLE DAILY DOSE OF 25MG/37.5MG |
| D-16 | CONTINUOUS INTRAVENOUS INFUSION |
| D-17 | 400MG EVERY 12 HOURS FOR THREE DAYS FOR UNCOMPLICATED URINARY TRACT INFECTIONS |
| D-18 | LOWER RECOMMENDED STARTING DOSE GUIDELINES |
| D-19 | BOLUS DOSING GUIDELINES |
| D-20 | SINGLE 32MG DOSE |
| D-21 | ALTERNATIVE DOSAGE OF 300MG ONCE DAILY AFTER THE EVENING MEAL |
| D-22 | REDUCTION IN INFUSION TIME FROM 24 TO 4 HOURS FOR THE 60MG DOSE |
| D-23 | INCREASE MAXIMUM DOSE AND VARIATIONS IN THE DOSING REGIMEN |
| D-24 | FOR OVARIAN CANCER THE RECOMMENDED REGIMEN IS 135MG/M2 OR 175MG/M2 INTRAVENOUSLY OVER THREE HOURS EVERY THREE WEEKS |
| D-25 | ADDITIONAL DOSAGE REGIMEN EQUAL TO HALF THE ORIGINAL DOSING REGIMEN |

**EXCLUSIVITY DOSING SCHEDULE**

| | |
|---|---|
| D-26 | ONCE WEEKLY APPLICATION |
| D-27 | BID DOSING IN PATIENTS 12 YEARS OF AGE AND OLDER FOR PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH MODERATE EMETOGENIC CANCER CHEMOTHERAPY |
| D-28 | USE OF ISOVUE-370 IN EXCRETORY UROGRAPHY AT EQUIVALENT GRAMS OF IODINE TO THE CURRENTLY APPROVED ISOVUE-250 AND ISOVUE-300 |
| D-29 | INCREASE OF CUMULATIVE DOSE TO 0.3MMOL/KG FOR MRI OF CNS IN ADULTS |
| D-30 | 5000 IU DOSE FOR PROPHYLAXIS AGAINST DEEP VEIN THROMBOSIS |
| D-31 | CHANGE IN RECOMMENDED TOTAL DAILY DOSE TO 80MG (40MG BID) |
| D-32 | REMOVAL OF THE RESTRICTIONS LIMITING TREATMENT TO TWO CONSECUTIVE WEEKS AND TO SMALL AREAS |
| D-33 | ONCE DAILY DOSING FOR PLAQUE PSORIASIS |
| D-34 | EVERY FOUR MONTHS DOSAGE REGIMEN |
| D-35 | FOR A ONE WEEK DOSING OF INTERDIGITAL TINEA PEDIS |
| D-36 | FOR A SINGLE 2MG DOSE AS AN ALTERNATIVE TO THE 1MG DOSE GIVEN TWICE DAILY |
| D-37 | DOSING REGIMEN FOR ADMINISTRATION EITHER ONCE DAILY (QD) OR TWICE DAILY (BID) |
| D-38 | CONTINUOUS INFUSION AS AN ALTERNATE METHOD OF ADMINISTRATION |
| D-39 | CHANGE IN TIME TO TAKE THE DRUG PRIOR TO A MEAL TO PREVENT MEAL-INDUCED HEARTBURN SYMPTOMS FROM "..1/2 TO 1 HOUR BEFORE EATING" TO ".. RIGHT BEFORE EATING OR UP TO 60MIN BEFORE CONSUMING..." |
| D-40 | ONCE-A-DAY DOSING REGIMEN |
| D-41 | DRUG MAY BE DOSED RIGHT BEFORE A MEAL OR ANY TIME UP TO 30MIN BEFORE EATING OR DRINKING FOOD AND BEVERAGES THAT WOULD BE EXPECTED TO CAUSE SYMPTOMS |
| D-42 | TEN DAY DOSING REGIMEN FOR TRIPLE THERAPY, PREVACID IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN, FOR THE ERADICATION OF H.PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE |
| D-43 | INITIATION OF TREATMENT WITH 900MG/DAY BY DELETION OF THE REQUIREMENT TO TITRATE TO 900MG/DAY OVER A 3-DAY PERIOD |
| D-44 | IN A CLINICAL TRIAL, FEWER DISCONTINUATIONS DUE TO ADVERSE EVENTS, ESPECIALLY DIZZINESS AND VERTIGO, WERE OBSERVED WHEN TITRATING THE DOSE IN INCREMENTS OF 50MG/DAY EVERY 3 DAYS UNTIL AN EFFECTIVE DOSE (NOT EXCEEDING 400MG/DAY) WAS REACHED |
| D-45 | ONCE DAILY DOSING FOR MAINTENANCE ONLY |
| D-46 | NEW DOSING REGIMEN OF 80MG DAILY |
| D-47 | PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL |
| D-48 | ADMINISTRATION OF CISATRACURIUM A NEUROMUSCULAR BLOCKING AGENT AT DOSES OF 3 AND 4X THE ED95 OF CISATRICURIUM FOLLOWING INDUCTION WITH THIOPENTAL |
| D-49 | PEDIATRIC DOSING GUIDELINES |
| D-50 | INFORMATION FOR USE OF CORVERT IN POST-CARDIAC SURGERY PATIENTS |
| D-51 | OPTIONAL STARTING DOSE OF 40MG/DAY |
| D-52 | ALTERNATE DOSING REGIMEN OF 1250MG TWICE DAILY |
| D-53 | USE IN PEDIATRIC PATIENTS FROM 1 MONTH TO 16 YEARS OF AGE |
| D-54 | USE OF ZYBAN FOR MAINTENANCE THERAPY. TREATMENT UP TO 6 MONTHS WAS SHOWN EFFICACIOUS |
| D-55 | ADDITION OF A HIGHER DOSE OF NUTROPIN FOR PUBERTAL PATIENTS (PUBERTAL DOSE LESS THAN OR EQUAL TO 0.7MG/KG/WEEK) |
| D-56 | ADDITION OF POSTPRANDIAL DOSING |
| D-57 | 3-HOUR INFUSION OF TAXOL GIVEN EVERY THREE WEEKS AT A DOSE OF 175MG/M2 FOLLOWED BY CISPLATIN AT A DOSE OF 75MG/M2 FOR THE FIRST-LINE TREATMENT OF ADVANCED OVARIAN CANCER |
| D-58 | CHANGE IN DOSING INTERVAL TO ONCE-DAILY ADMINISTRATION |
| D-59 | REDUCTION OF ELEVATED LDL-C IN A NEW, HIGHER STRENGTH TABLET, 0.8MG, AND FOR EXTENSION OF THE DOSAGE RANGE TO 0.8MG DAILY |

**EXCLUSIVITY DOSING SCHEDULE**

| | |
|---|---|
| D-60 | ADDITION OF A POST-OPERATIVE DOSING REGIMEN |
| D-61 | ONCE WEEKLY DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS |
| D-62 | ONCE WEEKLY DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS |
| D-63 | TO ALLOW A TITRATION DOSING REGIMEN USING A 25MG DOSE |
| D-64 | INCREASING DOSAGE FOR NERVE BLOCK ANESTHESIA USING NAROPIN 7.5MG/ML AND FOR EXTENDING THE DURATION OF TREATMENT FOR POSTOPERATIVE ANALGESIA USING NAROPIN 2MG/ML |
| D-65 | CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS |
| D-66 | DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI |
| D-67 | SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES |
| D-68 | CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS |
| D-69 | SHORTENED DOSING REGIMEN TO 5 DAYS FOR THE TREATMENT OF ACUTE EXACERBATION OF CHRONIC BRONCHITIS |
| D-70 | 80MG ONCE DAILY DOSING REGIMEN |
| D-71 | EIGHT WEEK DOSING REGIMEN |
| D-72 | INFORMATION REGARDING INCREASED RATE OF INFUSION FOR DEPACON |
| D-73 | ONCE A WEEK DOSING FOR THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS |
| D-74 | ONCE A WEEK DOSING FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS |
| D-75 | INTERMITTENT DOSING REGIMEN, STARTING DAILY DOSE 14 DAYS PRIOR TO THE ANTICIPATED ONSET OF MENSTRUATION THROUGH THE FIRST FULL DAY OF MENSES AND REPEATING WITH EACH NEW CYCLE |
| D-76 | FOR USE ON AN "AS NEEDED" OR PRN BASIS FOR THE MANAGEMENT OF NASAL SYMPTOMS IN PATIENTS FOR WHOM THE DRUG IS INDICATED |
| D-77 | ADDITION OF 20MG AND 40MG DAILY AS OPTIONAL STARTING DOSES WITH 40MG INTENDED FOR PATIENTS WHO REQUIRE A LARGE REDUCTION IN LDL-C (MORE THAN 45%) |
| D-78 | USE OF FLEXERIL 5MG FOR THE RELIEF OF MUSCLE SPASM ASSOCIATED WITH ACUTE, PAINFUL, MUSCULOSKELETAL CONDITIONS |
| D-79 | NEW LOWER STARTING DOSE FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS AND/OR MODERATE TO SEVERE SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED W/ THE MENOPAUSE |
| D-80 | CHANGE OF DOSING SCHEDULE FOR LANTUS FROM ONCE DAILY AT BEDTIME TO FLEXIBLE DAILY DOSING |
| D-81 | NEW LOWER STARTING DOSE FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPORSIS |
| D-82 | USE OF PREMARIN 0.3 MG AND 0.45 MG FOR THE PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS |
| D-83 | 750 MG, ONCE DAILY FOR 5 DAYS FOR COMMUNITY ACQUIRED PNEUMONIA (CAP) |
| D-84 | ONCE-A-DAY DOSING OF FLOXACIN OTIC FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS(AGES 6 MO & OLDER) W/ OTITIS EXTERNA CAUSED BY SUSCEPTIBLE STRAINS OF E.COLI, P.AERUGINOSA AND S.AUREUS |
| D-85 | LOWER RECOMMENDED STARTING DOSE GUIDELINES FOR TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE |
| D-86 | FOR USE IN SELECT EXTERNAL INSULIN PUMPS |
| D-87 | ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS |
| D-88 | NEW DOSING RANGE OF 200-400MG PER DAY IN TWO DIVIDED DOSES FOR ADULTS WITH PARTIAL SEIZURES |
| D-89 | USE OF REYATAZ 300 MG/RITONAVIR 100 MG ONCE DAILY FOR TREATMENT IN HIV-INFECTED ANTIRETROVIRAL-EXPERIENCED PATIENTS |
| D-90 | ADDITION OF DAYTIME ADMINISTRATION TO TREAT VULVOVAGINAL CANDIDIASIS |
| D-91 | ALTERNATE INTERMITTENT DOSING REGIMEN |

**EXCLUSIVITY DOSING SCHEDULE**

| | |
|---|---|
| D-92 | ALTERNATIVE DOSAGE OF 1000MG ONCE DAILY AT BEDTIME |
| D-93 | ALTERNATE TWO OR THREE TIMES DAILY DOSING REGIMENS |
| D-94 | NEW MAXIMUM DOSAGE OF 72 MG/DAY IN ADOLESCENTS 13-17 YEARS OF AGE WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
| D-95 | BROADENED INITIAL STARTING DOSE FOR HYPERTENSION FROM 50 MG TO 100 MG TO 25 MG TO 100 MG DOSE RANGE |
| D-96 | ONCE-MONTHLY TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS WITH BONIVA (IBANDRONATE SODIUM) 150 MG TABLETS |
| D-97 | PED CANCER PT POPULATION EXPANDED TO INCLUDE PTS 6 MOS UP TO BUT NOT INCLUDING 4 YRS AND DOSING INSTRUCTIONS TO ADMIN 30 MIN BEFORE CHEMO WITH SECOND AND THIRD DOSES 4 & 8 HOURS AFTER FIRST DOSE |
| D-98 | DOSING FOR PED SURGICAL PTS EXPANDED TO INCLUDE PTS 1 MONTH UP TO BUT NOT INCLUDING 2 YEARS OF AGE |
| D-99 | ONCE DAILY ADMINISTRATION FOR THE TREATMENT OF HIV INFECTION IN THERAPY NAIVE ADULT PATIENTS |
| D-100 | 750 MG ONCE DAILY FOR FIVE DAYS FOR THE TREATMENT OF ACUTE BACTERIAL SINUSITIS |
| D-101 | ONCE DAILY IN CHRONIC IDIOPATHIC URTICARIA FOR ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER |
| D-102 | NEW DOSING REGIMEN OF ONE SPRAY TWICE DAILY FOR SEASONAL ALLERIC RHINITIS IN PATIENTS 12 YRS OF AGE AND OLDER |
| D-103 | NEW DOSING RECOMMENDATION FOR THE TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT PATIENTS, SPECIFICALLY A REDUCTION IN COURSE OF THERAPY FROM FAMCICLOVIR 125 MG TWICE-A-DAY FOR 5 DAYS TO 1000 MG TWICE-A-DAY FOR 1 DAY. |
| D-104 | 0.5MG/0.1MG FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE IN WOMEN WHO HAVE A UTERUS |
| D-105 | USE OF ACTONEL 75MG TWO CONSECUTIVE DAYS PER MONTH FOR THE PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS |
| D-106 | FIVE DAY TREATMENT OF SELECTED SUSCEPTIBLE STRAINS OF STREPTOCOCCUS PNEUMONIAE, HAEMOPHILUS INFLUENZA, MYCOPLASMA PNEUMONIAE, AND CHLAMYDIA PNEUMONIAE FOR COMMUNITY-ACQUIRED PNEUMONIA |
| D-107 | PROVIDES FOR THE COMBINATION TABLET OF 70MG ALENDRONATE AND 5600 IU OF VITAMIN D3 FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS |
| D-108 | TREATMENT OF COMPLICATED URINARY TRACT INFECTION AND ACUTE PYELONEPHRITIS WITH LEVAQUIN 750MG ONCE DAILY FOR FIVE DAYS |
| D-109 | PROVIDE FOR THE USE OF A LOWER DOSE FOR THE TREATMENT OF ADULTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB MESYLATE |
| D-110 | TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGED 13-17 |
| D-111 | PROVIDES FOR ONCE DAILY USE OF CIALIS, 2.5 MG AND 5 MG, FOR THE TREATMENT OF ERECTILE DYSFUNCTION |
| D-112 | PROVIDES FOR PEDIATRIC PUMP USE |
| D-113 | ONCE DAILY DOSING REGIMEN FOR PATIENTS WHO BECOME CONSTIPATED ON TWICE DAILY REGIMEN |
| D-114 | NEW DOSING RECOMMENDATIONS FOR USE OF SIROLIMUS IN COMBINATION WITH CYCLOSPORINE FOR THE PROPHYLAXIS OF REJECTION IN HIGH-RISK RENAL TRANSPLANT RECIPIENTS |
| D-115 | STARTING DOSE OF 15MG/DAY FOR MONOTHERAPY IN ACUTE TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED |
| D-116 | ALTERNATIVE DOSING REGIMEN ATAZANAVIR SULATE CO-ADMINISTERED WITH RITONAVIR FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT NAIVE PATIENTS |
| D-117 | 50 MG TABLET FOR INITIATION OF DOSE TITRATION FOR BIPOLAR DISORDER |
| D-118 | TWO 400MG TABLETS ONCE DAILY, CO-ADMINISTERED WITH 100MG RITONAVIR |
| D-119 | DOSING RECOMMENDATIONS FOR HIV INFECTED PEDIATRIC PATIENTS 6 TO LESS THAN 18 YEARS OF AGE |
| D-120 | DOSING REGIMEN ADJUSTMENTS |
| D-121 | CHANGE TO REMOVE 20 MG MAXIMUM DOSAGE RESTRICTION |

**EXCLUSIVITY DOSING SCHEDULE**

| | |
|---|---|
| D-122 | USE OF VAGIFEM 10 MCG FOR THE TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE |
| D-123 | ALTERNATIVE DOSING REGIMEN DOSE OF 20 MG/METER SQUARE BY CONTINUOUS INTRAVENOUS INFUSION OVER 1 HOUR REPEATED DAILY FOR 5 DAYS |
| D-124 | ONCE DAILY DOSING REGIMEN IN ADULT PATIENTS WITH LESS THAN THREE LOPINAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS |
| D-125 | EXTEND CURRENT DOSING REGIMEN TO 900MG (2-450MG TABLETS) ONCE A DAY WITHIN 10 DAYS OF TRANSPLANTATION UNTIL 200 DAYS POST-TRANSPLANTATION FOR THE PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN ADULT KIDNEY TRANSPLANT PATIENTS AT HIGH RISK. |
| D-126 | CHANGE DOSAGE REGIMEN FROM 250MG TO 500MG |
| D-127 | DOSING REGIMEN FOR ADULT PATIENTS WITH CHRONIC HEPATITIS B (CHB) AND DECOMPENSATED LIVER DESEASE |
| D-128 | SINGLE IV DOSE OF FOSAPREPITANT 150MG, DOSED CONCOMITANTLY WITH 5HT3 RECEPTOR ANTAGONIST & CORTICOSTEROID, FOR PREVENTION OF ACUTE & DELAYED NAUSEA & VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMO |
| D-129 | 800/100 MG DARUNAVIR/RITONAVIR, ONCE DAILY, IN TREATMENT-EXPERIENCED HIV-1 INFECTED PATIENTS WITH NO DARUNAVIR RESISTANCE ASSOCIATED SUBSTITUTIONS |
| D-130 | DOSING RECOMMENDATIONS FOR TREATMENT OF HIV-1 INFECTION DURING PREGNANCY BASED ON DATA FROM STUDY AI424-182, A STUDY OF ATAZANAVIR/RITONAVIR IN COMBINATION WITH ZIDOVUDINE/LAMIVUDINE IN HIV INFECTED PREGNANT WOMEN |
| D-131 | EVERY 6 TO 8 WEEKS FOR THE 120MG STRENGTH FOR PATIENTS WHO ARE CONTROLLED ON SOMATULINE DEPOT 60MG OR 90MG |
| D-132 | 45MG FOR 6 MONTH ADMINISTRATION |
| D-133 | NEW EFFICACY DATA AND DOSING REGIMEN FOR PREGNANCY IN NORMAL OVULATORY WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION AS PART OF AN IVF OR INTRACYTOPLASMIC SPERM INJECTION (ICSI) CYCLE |
| D-134 | INCREASING MAXIMUM DOSING OF PATIENTS WITH SCHIZOPHRENIA TO 160 MG/DAY |
| D-135 | UPDATE LABELING WITH ONCE DAILY DOSING IN HIV-1 INFECTED, TREATMENT-NAIVE PEDIATRIC PATIENTS 12 TO LESS THAN 18 YEARS OF AGE |
| D-136 | ALTERNATE DOSING REGIMEN FOR UNCOMPLICATED URETHRAL OR ENDOCERVICAL INFECTION CAUSED BY CHLAMYDIA TRACHOMATIS, ADMINISTER 200 MG BY MOUTH ONCE-A-DAY FOR 7 DAYS |
| D-137 | NEW LOWER DOSING REGIMEN FOR REVATIO IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP 1) IN ADULTS |
| D-138 | 80 MG DOSING REGIMEN FOR THE RISK REDUCTION OF REBLEEDING OF GASTRIC AND DUODENAL ULCERS IN THE FIRST 72 HOURS FOLLOWING THERAPEUTIC ENDOSCOPY IN ADULTS |
| D-139 | ADDITIONAL INFORMATION ADDED TO THE DOSING AND ADMINISTRATION SECTION OF THE LABELING REGARDING THE ADMINISTRATION OF BRAVELLE AND MENOPUR IN THE SAME SYRINGE TO OVULATORY WOMEN AS PART OF AN ART CYCLE |
| D-140 | REVISED DOSING SCHEDULE TO ADMINISTER AVANAFIL 15 MINUTES PRIOR TO SEXUAL ACTIVITY |
| D-141 | DOSING INFORMATION IN PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA |
| D-142 | DOSE MODIFICATION GUIDELINES FOR BORTEZOMIB WHEN GIVEN IN COMBINATION WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE |
| D-143 | INITIATION OF VIMPAT THERAPY WITH A LOADING DOSE OF 200MG |
| D-144 | LOWER LIMIT OF 15 MINUTES FOR THE INFUSION DURATION |
| D-145 | UPDATES TO THE DOSAGE AND ADMINISTRATION SECTION OF THE LABELING TO REFLECT THE RESULTS OF TWO SHORT TERM STUDIES EVALUATING THE SAFETY AND EFFICACY OF INTUNIV IN CHILDREN AND ADOLESCENTS AGES 6 TO 17 WITH ADHD. |
| D-146 | CHANGE IN TARGET DOSING TO 20MG TO 40MG ORALLY ONCE DAILY |
| D-147 | ONCE DAILY DOSING IN PEDIATRIC PATIENTS 3 MONTHS OF AGE AND OLDER IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION |
| D-148 | EXTENDED THE DURATION OF THE DOSING REGIMEN FROM 100 DAYS TO 200 DAYS POST-TRANSPLANTATION FOR THE PREVENTION OF CMV DISEASE IN PEDIATRIC KIDNEY TRANSPLANT |
| D-149 | DOSING INFORMATION ADDED TO THE LABELING REGARDING PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH ITP |

**EXCLUSIVITY DOSING SCHEDULE**

| | |
|---|---|
| D-150 | 1600MG DAILY FOR PATIENTS ON ADJUNCTIVE THERAPY WHO DID NOT ACHIEVE A SATISFACTORY RESPONSE ON 1200MG DAILY DOSE |
| D-151 | DOSING RECOMMENDATIONS FOR THE TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS CO-INFECTED WITH HIV-1 |
| D-152 | DOSING RECOMMENDATIONS AS NECESSARY FOR FEVER AND PAIN FOR AGES 6MO TO LESS THAN 12 YEARS AND 12 TO 17 YEARS. |
| D-153 | IN COMBINATION WITH RIBAVIRIN FOR 12 WEEKS, FOR THE TREATMENT OF GENOTYPE 1, CHRONIC HEPATITIS C TREATMENT EXPERIENCED PATIENTS WITH COMPENSATED CIRRHOSIS BASED UPON THE RESULTS OF THE SIRIUS STUDY |
| D-154 | ADDITION OF A 1500MG-SINGLE-DOSE REGIMEN FOR THE TREATMENT OF ADULT PATIENTS WITH ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSI) |
| D-155 | SINGLE IV DOSE OF FOSAPREPITANT 150MG DOSED CONCOMITANTLY WITH 5HT3 RECEPTOR ANTAGONIST & CORTICOSTEROID FOR PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY |
| D-156 | DOSING INFORMATION ADDED TO THE LABELING PROVIDING INFORMATION ON TRANSITIONING FROM SUBCUTANEOUS OR INTRAVENOUS ROUTES OF ADMINISTRATION OF TREPROSTINIL |
| D-157 | UPDATED INFORMATION ADDED TO THE DOSAGE AND ADMINISTRATION SECTION OF THE LABELING PROVIDING DOSAGE RECOMMENDATIONS FOR INTERRUPTIONS AND DISCONTINUATION OF THERAPY |
| D-158 | REVISED DOSING TO EXPAND PATIENT POPULATION TO INCLUDE LIVER TRANSPLANT RECIPIENTS WITH GENOTYPE 1 HCV INFECTION |
| D-159 | REVISED DOSING TO EXPAND PATIENT POPULATION TO INCLUDE LIVER TRANSPLANT RECIPIENTS WITH GENOTYPE 4 HCV INFECTION |
| D-160 | REVISED DOSING TO EXPAND PATIENT POPULATION TO INCLUDE PATIENTS WITH DECOMPENSATED CIRRHOSIS WITH GENOTYPE 1 HCV INFECTION |
| D-161 | DOSAGE RECOMMENDATIONS ADDED TO INCLUDE TREATMENT OF HCV GENOTYPE 3 SUBJECTS CO-INFECTED WITH HIV-1 |
| D-162 | DOSING TO INCLUDE PATIENTS WITH CHRONIC HCV GENOTYPE 1 INFECTION WITH COMPENSATED (CHILD-PUGH A) OR DECOMPENSATED (CHILD-PUGH B OR C) CIRRHOSIS AND TREATMENT OF CHRONIC HCV GENOTYPE 3 INFECTION IN SUBJECTS WITH DECOMPENSATED (CHILD-PUGH B OR C) CIRRHOSIS |
| D-163 | DOSING TO INCLUDE PATIENTS WITH CHRONIC HCV GENOTYPE 1A INFECTION WITH COMPENSATED (CHILD-PUGH A) CIRRHOSIS AND GENOTYPE 1B WITH OR WITHOUT COMPENSATED (CHILD-PUGH A) CIRRHOSIS |
| D-164 | UPDATES TO THE DOSAGE AND ADMINISTRATION, DOSE MODIFICATIONS SECTION OF THE LABELING |
| D-165 | DOSING RECOMMENDATION ADDED TO THE LABELING FOR IMBRUVICA USE IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LEUKEMIA (SLL) |
| D-166 | BROADEN INITIAL STARTING DOSE FOR BIPOLAR I DISORDER TO 5-10MG TWICE DAILY |
| D-167 | ADDITION OF 1200 MG ONCE DAILY DOSING FOR TREATMENT-NAÏVE PATIENTS OR PATIENTS WHO ARE VIROLOGICALLY SUPPRESSED ON AN INITIAL REGIMEN OF RALTEGRAVIR FILM-COATED TABLETS 400 MG TWICE DAILY |
| D-168 | NEW DOSING REGIMEN OF 10 MG ONCE DAILY FOR THE REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE) IN PATIENTS AT CONTINUED RISK FOR DVT AND/OR PE AFTER COMPLETION OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS |
| D-169 | ONCE-DAILY DOSING FOR PATIENTS 5 YEARS OF AGE AND OLDER WHO HAVE UNDETECTABLE SERUM AND URINE SUCCINYLACETONE CONCENTRATIONS AFTER A MINIMUM OF 4 WEEKS ON A STABLE DOSAGE OF NITISINONE |

**EXCLUSIVITY INDICATION**

| | |
|---|---|
| I-1 | DYSMENORRHEA |
| I-2 | CHOLANGIOPANCREATOGRAPHY |
| I-3 | INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY |
| I-4 | PERIPHERAL VENOGRAPHY (PHLEBOGRAPHY) |

**EXCLUSIVITY INDICATION**

| | |
|---|---|
| I-5 | HYSTEROSALPINGOGRAPHY |
| I-6 | TREATMENT OF JUVENILE ARTHRITIS |
| I-7 | BIOPSY PROVEN MINIMAL CHANGE NEPHROTIC SYNDROME IN CHILDREN |
| I-8 | ADULT INTRAVENOUS CONTRAST-ENHANCED COMPUTED TOMOGRAPHY OF THE HEAD AND BODY |
| I-9 | PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING |
| I-10 | PREVENTION OF POSTOPERATIVE DEEP VENOUS THROMBOSIS AND PULMONARY EMBOLISM IN TOTAL HIP REPLACEMENT SURGERY |
| I-11 | RELIEF OF MILD TO MODERATE PAIN |
| I-12 | TREATMENT OF CUTANEOUS CANDIDIASIS |
| I-13 | URINARY TRACT INFECTION (UTI) PREVENTION FOR PERIODS UP TO FIVE MONTHS IN WOMEN WITH A HISTORY OF RECURRENT UTI |
| I-14 | SEBORRHEIC DERMATITIS |
| I-15 | PHOTOPHERESIS IN THE PALLIATIVE TREATMENT OF SKIN MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PERSONS NOT RESPONSIVE TO OTHER TREATMENT |
| I-16 | STIMULATE THE DEVELOPMENT OF MULTIPLE FOLLICLES/OOCYTES IN OVULATORY PATIENTS PARTICIPATING IN AN IN VITRO FERTILIZATION PROGRAM |
| I-17 | MANAGEMENT OF CONGESTIVE HEART FAILURE |
| I-18 | ENDOSCOPIC RETROGRADE PANCREATOGRAPHY |
| I-19 | HERNIOGRAPHY |
| I-20 | KNEE ARTHROGRAPHY |
| I-21 | HIGH DOSE METHOTREXATE WITH LEUCOVORIN RESCUE IN COMBINATION WITH OTHER CHEMOTHERAPEUTIC AGENTS TO DELAY RECURRENCE IN PATIENTS WITH NONMETASTATIC OSTEOSARCOMA WHO HAVE UNDERGONE SURGICAL RESECTION OR AMPUTATION FOR THE PRIMARY TUMOR |
| I-22 | RESCUE AFTER HIGH-DOSE METHOTREXATE THERAPY IN OSTEOSARCOMA |
| I-23 | SHORT-TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER |
| I-24 | TREATMENT OF RHEUMATOID ARTHRITIS |
| I-25 | ADULT INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY OF THE HEAD, NECK, ABDOMINAL, RENAL AND PERIPHERAL VESSELS |
| I-26 | TREATMENT OF LIVER FLUKES |
| I-27 | ADJUNCTIVE THERAPY TO DIET TO REDUCE THE RISK OF CORONARY ARTERY DISEASE |
| I-28 | SELECTIVE ADULT VISCERAL ARTERIOGRAPHY |
| I-29 | METASTATIC BREAST CANCER IN PREMENOPAUSAL WOMEN AS AN ALTERNATIVE TO OOPHORECTOMY OR OVARIAN IRRADIATION |
| I-30 | TREATMENT OF TINEA PEDIS |
| I-31 | CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS IN THE SPINE AND ASSOCIATED TISSUES |
| I-32 | PEDIATRIC MYELOGRAPHY |
| I-33 | ORAL USE OF DILUTED OMNIPAQUE INJECTION IN ADULTS FOR CONTRAST ENHANCED COMPUTED TOMOGRAPHY OF THE ABDOMEN |
| I-34 | ORAL USE IN ADULTS FOR PASS-THROUGH EXAMINATION OF THE GASTROINTESTINAL TRACT |
| I-35 | PEDIATRIC CONTRAST ENHANCEMENT OF COMPUTED TOMOGRAPHIC HEAD IMAGING |
| I-36 | ARTHROGRAPHY OF THE SHOULDER JOINTS IN ADULTS |
| I-37 | RADIOGRAPHY OF THE TEMPOROMANDIBULAR JOINT IN ADULTS |
| I-38 | CONTRAST ENHANCEMENT AGENT TO FACILITATE VISUALIZATION OF LESIONS OF THE CENTRAL NERVOUS SYSTEM IN CHILDREN (2 YEARS OF AGE AND OLDER) |
| I-39 | TREATMENT OF ACUTE MYOCARDIAL INFARCTION |
| I-40 | PRIMARY NOCTURNAL ENURESIS |
| I-41 | MIGRAINE HEADACHE PROPHYLAXIS |
| I-42 | HERPES ZOSTER |

| | **EXCLUSIVITY INDICATION** |
|---|---|
| I-43 | HERPES SIMPLEX ENCEPHALITIS |
| I-44 | MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY |
| I-45 | ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS |
| I-46 | USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING |
| I-47 | TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE |
| I-48 | PEDIATRIC ANGIOCARDIOGRAPHY |
| I-49 | TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI |
| I-50 | FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER |
| I-51 | TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS |
| I-52 | PEDIATRIC EXCRETORY UROGRAPHY |
| I-53 | TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA |
| I-54 | RENAL CONCENTRATION CAPACITY TEST |
| I-55 | HYPERTENSION |
| I-56 | EROSIVE GASTROESOPHAGEAL REFLUX DISEASE |
| I-57 | SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER |
| I-58 | INITIAL TREATMENT OF ADVANCED OVARIAN CARCINOMA IN COMBINATION WITH OTHER APPROVED CHEMOTHERAPEUTIC AGENTS |
| I-59 | ENDOSCOPICALLY DIAGNOSED ESOPHAGITIS, INCLUDING EROSIVE AND ULCERATIVE ESOPHAGITIS, AND ASSOCIATED HEARTBURN DUE TO GASTROESOPHAGEAL REFLUX DISEASE |
| I-60 | SINGLE APPLICATION TREATMENT OF HEAD LICE IN CHILDREN TWO MONTHS TO TWO YEARS IN AGE |
| I-61 | FEMALE ANDROGENETIC ALOPECIA |
| I-62 | PREVENTION AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS |
| I-63 | ONCE DAILY TREATMENT AS INITIAL THERAPY IN THE TREATMENT OF HYPERTENSION |
| I-64 | PREVENTION OF SUPRAVENTRICULAR TACHYCARDIAS |
| I-65 | PREVENTION OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS |
| I-66 | UNCOMPLICATED GONORRHEA |
| I-67 | TREATMENT OF ACUTE ASTHMATIC ATTACKS IN CHILDREN SIX YEARS OF AGE AND OLDER |
| I-68 | CENTRAL PRECOCIOUS PUBERTY |
| I-69 | SHORT TERM TREATMENT OF PATIENTS WITH SYMPTOMS OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), AND FOR THE SHORT TERM TREATMENT OF ESOPHAGITIS DUE TO GERD INCLUDING ULCERATIVE DISEASE DIAGNOSED BY ENDOSCOPY |
| I-70 | USE IN COMBINATION WITH 5-FLUOROURACIL TO PROLONG SURVIVAL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER |
| I-71 | VARICELLA INFECTIONS (CHICKENPOX) |
| I-72 | PREVENTION OF CMV DISEASE IN TRANSPLANT PATIENTS AT RISK FOR CMV DISEASE |
| I-73 | INITIATE AND MAINTAIN MONITORED ANESTHESIA CARE (MAC) SEDATION DURING DIAGNOSTIC PROCEDURES |
| I-74 | INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY |
| I-75 | TREATMENT OF ENDOSCOPICALLY DIAGNOSED EROSIVE ESOPHAGITIS |
| I-76 | PREVENTION OF OSTEOPOROSIS |
| I-77 | DERMAL INFECTIONS-TINEA PEDIS, TINEA CORPORIS, TINEA CRURIS DUE TO EPIDERMOPHYTON FLOCCOSUM |
| I-78 | CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY AND INTRAVENOUS EXCRETORY UROGRAPHY |
| I-79 | MANAGEMENT OF CHRONIC STABLE ANGINA AND ANGINA DUE TO CORONARY ARTERY SPASM |
| I-80 | DIAGNOSIS AND LOCALIZATION OF ISCHEMIA AND CORONARY HEART DISEASE |

**EXCLUSIVITY INDICATION**

| | |
|---|---|
| I-81 | PROPHYLAXIS IN DESIGNATED IMMUNOCOMPROMISED CONDITIONS TO REDUCE THE INCIDENCE OF OROPHARYNGEAL CANDIDIASIS |
| I-82 | TREATMENT OF TRAVELERS' DIARRHEA |
| I-83 | ANGIOCARDIOGRAPHY, CONTRAST ENHANCED COMPUTED TOMOGRAPHIC IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY IN CHILDREN |
| I-84 | INTRAOPERATIVE AND POSTOPERATIVE TACHYCARDIA AND/OR HYPERTENSION |
| I-85 | TREATMENT OF ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS |
| I-86 | TREATMENT OF SECONDARY CARNITINE DEFICIENCY |
| I-87 | RENAL IMAGING AGENT FOR USE IN CHILDREN |
| I-88 | MANAGEMENT OF ENDOMETRIOSIS |
| I-89 | EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE |
| I-90 | INTENSIVE CARE UNIT SEDATION |
| I-91 | MONOTHERAPY USE FOR HYPERTENSION |
| I-92 | ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE |
| I-93 | PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS |
| I-94 | USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART] |
| I-95 | TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION |
| I-96 | TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA |
| I-97 | ORAL OR RECTAL USE IN CHILDREN FOR THE EXAMINATION OF THE GASTROINTESTINAL TRACT |
| I-98 | TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE ASSOCIATED WITH CHRONIC RENAL INSUFFICIENCY |
| I-99 | PEDIATRIC ANESTHESIA IN CHILDREN 3 YEARS AND OLDER |
| I-100 | TO DECREASE THE INCIDENCE OF CANDIDIASIS IN PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION WHO RECEIVE CYTOTOXIC CHEMOTHERAPY AND/OR RADIATION THERAPY |
| I-101 | TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN-DEPENDENT DIABETES MELLITUS AND RETINOPATHY |
| I-102 | TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER |
| I-103 | PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN INDIVIDUALS WHO ARE IMMUNOCOMPROMISED AND CONSIDERED TO BE AT RISK OF DEVELOPING PNEUMOCYSTIS CARINII PNEUMONIA |
| I-104 | TREATMENT OF PULMONARY AND EXTRAPULMONARY ASPERGILLOSIS IN PATENTS WHO ARE INTOLERANT OF OR WHO ARE REFRACTORY TO AMPHOTERICIN B THERAPY |
| I-105 | TREATMENT OF METASTATIC CARCINOMA OF THE BREAST AFTER FAILURE OF FIRST-LINE OR SUBSEQUENT CHEMOTHERAPY |
| I-106 | TREATMENT OF ACROMEGALY |
| I-107 | VAGINAL CANDIDIASIS |
| I-108 | EXPANDED USE-FOR ICU PATIENTS UNDERGOING LONG-TERM INFUSION DURING MECHANICAL VENTILATION |
| I-109 | TYPHOID FEVER |
| I-110 | PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIOTHERAPY |
| I-111 | TREATMENT OF PAGET'S DISEASE OF BONE |
| I-112 | MANAGEMENT OF MODERATE TO SEVERE PAIN |
| I-113 | TREATMENT OF PROSTATITIS |
| I-114 | USE IN CHILDREN TO VISUALIZE LESIONS WITH ABNORMAL VASCULARITY IN THE BRAIN (INTRACRANIAL LESIONS), SPINE, AND ASSOCIATED TISSUE |
| I-115 | USE IN MRI IN ADULTS TO VISUALIZE LESIONS IN THE HEAD AND NECK |
| I-116 | MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS |
| I-117 | TO SLOW THE PROGRESSION FO CORONANY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE |
| I-118 | PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM |

| | **EXCLUSIVITY INDICATION** |
|---|---|
| | FOLLOWING KNEE REPLACEMENT SURGERY |
| I-119 | TREATMENT OF ANEMIA CAUSED BY UTERINE LEIOMYOMATA IN WOMEN WHO FAIL IRON THERAPY |
| I-120 | MAINTENANCE THERAPY FOR GASTRIC ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING ACUTE ULCERS |
| I-121 | EXPANDED PATIENT POPULATION -- USE IN ICU PATIENTS |
| I-122 | PSORIASIS OF THE SCALP |
| I-123 | RELIEF OF MILD TO MODERATE PAIN IN PATIENTS AGED 6 MONTHS AND OLDER |
| I-124 | LEUCOCYTE LABELED SCINTIGRAPHY AS AN ADJUNCT IN THE LOCALIZATION OF INTRA-ABDOMINAL INFECTION AND INFLAMMATORY BOWEL DISEASE |
| I-125 | EXPANSION OF CONSCIOUS SEDATION INDICATION TO INCLUDE SHORT THERAPEUTIC PROCEDURES |
| I-126 | ADJUNCT TO THALLIUM- 201 MYOCARDIAL PERFUSION IN PATIENTS UNABLE TO EXERCISE ADEQUATELY |
| I-127 | TREATMENT OF ACYCLOVIR-RESISTANT HERPES IN IMMUNOCOMPROMISED PATIENTS |
| I-128 | IN PT W/ CH DISEASE AND HYPERCHOLESTEROLEMIA: REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH; REDUCE RISK NON-FATAL MI; REDUCE RISK UNDERGOING MYOCARDIAL REVASCULARIZATION PROCEDURES; REDUCTION ELEVATED TOTAL AND LDL CHOL LEVELS... |
| I-129 | TREATMENT OF ALCOHOL DEPENDENCE |
| I-130 | MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS |
| I-131 | PERIPHERAL ARTERIOGRAPHY |
| I-132 | TREATMENT OF MANIC PHASE OF BIPOLAR DISORDER |
| I-133 | MANAGEMENT OF CHRONIC STABLE ANGINA |
| I-134 | HEART FAILURE POST MYOCARDIAL INFARCTION |
| I-135 | BONE METASTASES ASSOCIATED WITH MULTIPLE MYELOMA |
| I-136 | IDIOPATHIC CHRONIC URTICARIA |
| I-137 | PREVENTION OF METAL-INDUCED HEART BURN, ACID INDIGESTION, AND SOUR STOMACH WHEN TAKEN 30 MINUTES PRIOR TO CONSUMING FOOD OR BEVERAGES |
| I-138 | TREATMENT OF ACUTE RECURRENT GENITAL HERPES |
| I-139 | PALLIATIVE TREATMENT OF ADVANCED BREAST CANCER IN PRE- AND PERIMENOPAUSAL WOMEN |
| I-140 | PREVENTION OF CYTOMEGALOVIRUS (CMV) DISEASE IN INDIVIDUALS WITH HIV INFECTION AT RISK FOR DEVELOPING CMV DISEASE |
| I-141 | TREATMENT OF HEMODYNAMICALLY STABLE PATIENTS WITHIN 24 HOURS OF ACUTE MYOCARDIAL INFARCTION TO IMPROVE SURVIVAL |
| I-142 | LOCALIZE MYOCARDIAL ISCHEMIA(REVERSIBLE DEFECT) AND INFARCTION (NON-REVERSIBLE DEFECTS) IN EVALUATING MYOCARDIAL FUNCTION |
| I-143 | EPISODIC TREATMENT OF RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT ADULTS |
| I-144 | ENHANCEMENT OF MRI OF THE ADULT BODY INTERNAL ORGANS |
| I-145 | 0.1MMOL/KG AS A SINGLE INTRAVEOUS BOLUS FOR MRI OF THE CNS IN CHILDREN |
| I-146 | CONTRAST ENHANCEMENT AND FACILITATION OF VISUALIZATION OF EXTRACRANIAL HEAD AND NECK LESIONS |
| I-147 | PREVENTION OF GALLSTONE FORMATION IN OBESE PATIENTS EXPERIENCING RAPID WEIGHT LOSS |
| I-148 | TREATMENT OF ACUTE PNEUMOCYSTIC CARINI PNEUMONIA (PCP) IN HIV-INFECTED PATIENTS WHOSE ALVEOLAR-ARTERIAL OXYGEN DIFFERENCE (AaDO2) IS LESS THAN OR EQUAL TO 55 TORR |
| I-149 | TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER |
| I-150 | TREATMENT OF OBSESSIVE COMPULSIVE DISORDER AND PANIC DISORDER |
| I-151 | PREVENTION OF AND PREVENTION OF FURTHER POSTOPERATIVE NAUSEA AND VOMITING IN PEDIATRIC PATIENTS RECEIVING GENERAL ANESTHESIA |
| I-152 | SLOWING THE PROGRESSION OF CORONARY ATHEROSCLEROSIS AND REDUCING THE RISK OF ACUTE CORONARY EVENTS |

**EXCLUSIVITY INDICATION**

| | |
|---|---|
| I-153 | MANAGEMENT OF SEVERE SPASTICITY [ENCOMPASSES SPINAL AND CEREBRAL ORIGIN] |
| I-154 | PATIENT POPULATION ALTERED TO INCLUDE PEDIATRIC USE |
| I-155 | TREATMENT OF ONCHOMYCOSIS DUE TO DERMATOPHYTES (TINEA UNGUIUM) OF THE TOENAIL WITH OR WITHOUT FINGERNAIL INVOLVEMENT |
| I-156 | ADDITIONAL DATA REGARDING THE SAFE USE OF NORVASC IN PATIENTS WITH HEART FAILURE |
| I-157 | TREATMENT OF ACUTE UNCOMPLICATED CYSTITIS IN FEMALES |
| I-158 | TREATMENT OF OSTEOLYTIC BONE METASTASES OF BREAST CANCER |
| I-159 | FOR HYPERCHOLESTEROLEMIC PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE REDUCE THE RISK OF MYOCARDIAL INFARCTION, REVASCULARIZATION, AND DEATH DUE TO CARDIOVASCULAR CAUSES WITH NO INCREASE IN DEATH FROM NON-CARDIOVASCULAR CAUSES |
| I-160 | TREATMENT OF BACTERIAL CORNEAL ULCERS |
| I-161 | TREATMENT OF ADULT-ONSET OR CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENCY |
| I-162 | FOR USE IN PATIENTS 6-11 YEARS OF AGE |
| I-163 | TREATMENT OF PHOTOPHOBIA |
| I-164 | CHRONIC BACTERIAL PROSTATITIS |
| I-165 | MANAGEMENT OF ADULTS WITH ACTIVE, CLASSIC AND DEFINITIVE RHEUMATOID ARTHRITIS WHO HAVE HAD INSUFFICIENT THERAPEUTIC RESPONSE TO OR ARE INTOLERANT OF AN ADEQUATE TRIAL OF FULL DOSES OF ONE OR MORE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS |
| I-166 | TREATMENT OF BULIMIA |
| I-167 | COMPLICATED INTRA-ABDOMINAL INFECTIONS (USED IN COMBINATION WITH METRONIDAZOLE) CAUSED BY MIXED AEROBIC/ANAEROBIC PATHOGENS |
| I-168 | MANAGEMENT OF LOCALLY CONFINED STAGE B2-C METASTATIC CARCINOMA OF THE PROSTATE (IN COMBINATION WITH LHRH AGONISTS) |
| I-169 | USE IN COMBINATION WITH CORTICOSTEROIDS AS INITIAL CHEMOTHERAPY FOR THE TREATMENT OF PATIENTS WITH PAIN RELATED TO ADVANCED HORMONE-REFRACTORY PROSTATE CANCER |
| I-170 | PROPHYLACTIC USE DURING HEAD LICE EPIDEMICS |
| I-171 | RELIEF OF SYMPTOMS OF THE COMMON COLD |
| I-172 | TREATMENT OF INITIAL EPISODE OF GENITAL HERPES |
| I-173 | PREOPERATIVELY FOR THE PREVENTION OF INFECTION IN TRANSRECTAL PROSTATE BIOPSY |
| I-174 | PELVIC INFLAMMATORY DISEASE |
| I-175 | TREATMENT OF TINEA CORPORIS AND TINEA CRURIS |
| I-176 | TREATMENT OF POSTOPERATIVE INFLAMMATION IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION |
| I-177 | TX OF MODERATE ACNE VULGARIS IN FEMALES,GREATER OR EQUAL TO 15YRS OF AGE,WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY,DESIRE CONTRACEPTION,HAVE ACHIEVED MENARCHE AND ARE UNRESPONSIVE TO TOPICAL ANTI-ACNE MEDICATIONS |
| I-178 | TREATMENT OF ONCHOMYCOSIS OF THE FINGERNAIL WITHOUT CONCOMITANT ONCHOMYCOSIS OF THE TOENAIL WITH A PULSE DOSING REGIMEN |
| I-179 | NOSOCOMIAL PNEUMONIA-MILD TO MODERATE AND SEVERE CAUSED BY HAEMOPHILUS INFLUENZAE OR KLEBSIELLA PNEUMONIAE |
| I-180 | TREATMENT OF PLANTAR TINEA PEDIS (MOCCASIN TYPE) |
| I-181 | TREATMENT OF PATIENTS WITH COMPLEX PARTIAL SEIZURES WITH AND WITHOUT SECONDARY GENERALIZATION |
| I-182 | TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME |
| I-183 | MAINTENANCE THERAPY IN THE MANAGEMENT OF MILD TO MODERATE ASTHMA IN PEDIATRIC PATIENTS AGES 6-11 |
| I-184 | TREATMENT OF PANIC DISORDER AT A RECOMMENDED DOSE RANGE OF 1 TO 2MG/DAY (MAXIMUM OF 4MG) |
| I-185 | PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN |
| I-186 | TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR CAUSED BY OR PRESUMED TO BE CAUSED BY |

| | EXCLUSIVITY INDICATION |
|---|---|
| | PITYROSPORUM ORBICULARE (ALSO KNOWN AS MALASSEZIA FURFUR OR M. ORBICULARE) |
| I-187 | PREVENTION OF FRACTURES IN THE TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS |
| I-188 | TREATMENT OF ACUTE SINUSITIS AND ACUTE EXACERBATION OF CHRONIC SINUSITIS |
| I-189 | TREATMENT OF ACUTE OTITIS MEDIA IN PEDIATRIC PATIENTS |
| I-190 | PLANAR IMAGING AS A SECOND LINE DIAGNOSTIC DRUG AFTER MAMMOGRAPHY TO ASSIST IN THE EVALUATION OF BREAST LESIONS IN PATIENTS WITH AN ABNORMAL MAMMOGRAM OR A PALPABLE BREAST MASS |
| I-191 | ENDOMETRIAL THINNING AGENT PRIOR TO ENDOMETRIAL ABLATION FOR DYSFUNCTIONAL UTERINE BLEEDING |
| I-192 | THE PREVENTION OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS AND A NEW DOSAGE REGIMEN, 40MG ONCE DAILY, FOR THIS INDICATION |
| I-193 | TREATMENT OF PANIC DISORDER IN A RECOMMENDED DOSE RANGE OF 50 TO 200MG/DAY |
| I-194 | CONGESTIVE HEART FAILURE |
| I-195 | FOR USE OF LANSOPRAZOLE IN COMBINATION WITH CLARITHROMYCIN AND AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF DUODENAL ULCER |
| I-196 | ACUTE TREATMENT OF ACTIVE BENIGN GASTRIC ULCER |
| I-197 | MAINTENANCE OF HEALING OF DUODENAL ULCER |
| I-198 | FOR THE USE OF LANSOPRAZOLE IN COMBINATION WITH AMOXICILLIN FOR THE ERADICATION OF HELICOBACTER PYLORI IN PATIENTS WITH ACTIVE DUODENAL ULCER DISEASE OR A ONE-YEAR HISTORY OF A DUODENAL ULCER |
| I-199 | MONOTHERAPY AND COMBINATION THERAPY WITH SULFONYLUREA IN THE TREATMENT OF TYPE II DIABETES |
| I-200 | TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR |
| I-201 | EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIC PATIENTS |
| I-202 | SECOND-LINE TREAMENT OF AIDS-RELATED KAPOSI'S SARCOMA |
| I-203 | MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS |
| I-204 | USE IN PEDIATRIC PATIENTS BETWEEN THE AGES OF 6 AND 11 FOR THE TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS |
| I-205 | INITIAL ANTICONVULSANT TREATMENT OF STATUS EPILEPTICUS |
| I-206 | TREATMENT OF EDEMA ASSOCIATED WITH CHRONIC RENAL FAILURE |
| I-207 | FOR THE SUPPRESSION OF RECURRENT EPISODES OF GENITAL HERPES IN IMMUNOCOMPETENT ADULTS |
| I-208 | TREATMENT OF OBSESSIVE COMPULSIVE DISORDER IN THE PEDIATRIC POPULATION |
| I-209 | PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA (PSVT) |
| I-210 | TO SLOW THE PROGRESSION OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL AND LDL CHOLESTEROL TO TARGET LEVELS |
| I-211 | FOR USE IN PEDIATRIC POPULATION |
| I-212 | TREATMENT OF SYMPTOMS OF DRY MOUTH IN PATIENTS WITH SJOGREN'S SYNDROME |
| I-213 | TEMPORARY RELIEF OF PAIN AND PHOTOPHOBIA IN PATIENTS UNDERGOING CORNEAL REFRACTIVE SURGERY |
| I-214 | TREATMENT OF OSTEOPOROSIS |
| I-215 | PRE-PROCEDURAL APPLICATION TO ADULT MALE GENITAL SKIN PRIOR TO SITE-SPECIFIC SUBCUTANEOUS INFILTRATION WITH LIDOCAINE FOR THE REMOVAL OF GENITAL WARTS |
| I-216 | FOR THE LONG-TERM TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA |
| I-217 | PREVENTION (DURING AND FOLLOWING HOSPITALIZATION) OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY |
| I-218 | USE OF LIPITOR AS AN ADJUNCTIVE THERAPY TO DIET FOR THE TREATMENT OF PATIENTS WITH ELEVATED SERUM TRIGLYCERIDE LEVELS (FREDERICKSON TYPE IV) |

**EXCLUSIVITY INDICATION**

| | |
|---|---|
| I-219 | USE OF LIPITOR BY PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDERICKSON TYPE III) WHO DO NOT RESPOND ADEQUATELY TO DIET |
| I-220 | TREATMENT OF EPISODIC- HEARTBURN, ACID INDIGESTION AND SOUR STOMACH |
| I-221 | TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH) IN MEN WITH AN ENLARGED PROSTATE TO IMPROVE SYMPTOMS, REDUCE THE RISK OF ACUTE URINARY RETENTION AND REDUCE THE RISK OF THE NEED OF SURGERY |
| I-222 | PREVENTION OF ISCHEMIC COMPLICATIONS OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION, WHEN CONCURRENTLY ADMINISTERED WITH ASPIRIN |
| I-223 | USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH ALLERGIC AND NONALLERGIC-PERENNIAL RHINITIS IN CHILDREN AGE 6-11 YEARS |
| I-224 | FOR THE USE IN PEDIATRIC PATIENTS 4 TO 11 YEARS OF AGE FOR THE MANAGEMENT OF THE NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS |
| I-225 | USE IN PATIENTS WITH PREVIOUS MI AND NORMAL CHOLESTEROL LEVELS, TO REDUCE RISK OF RECURRENT MI, MYOCARDIAL REVASCULARIZATION, AND CEREBROVASCULAR DISEASE EVENTS |
| I-226 | FIRST-LINE THERAPY FOR THE TREATMENT OF ADVANCED CARCINOMA OF THE OVARY IN COMBINATION WITH CISPLATIN |
| I-227 | SHORT-TERM TREATMENT OF SYMPTOMATIC GASTROESPHAGEAL REFLUX DISEASE (GERD) |
| I-228 | PREVENTION OF MEAL INDUCED HEARTBURN AT A DOSE OF 75MG TAKEN 30-60MIN PRIOR TO A MEAL |
| I-229 | PRILOSEC (OMEPRAZOLE), AMOXICILLIN, AND CLARITHROMYCIN FOR THE ERADICATION OF H. PYLORI IN PATIENTS WITH DUODENAL ULCER DISEASE |
| I-230 | IN COMBINATION WITH CIS-PLATIN, FOR THE FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN PATIENTS WHO ARE NOT CANDIDATES FOR POTENTIALLY CURATIVE SURGERY AND/OR RADIATION |
| I-231 | TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY |
| I-232 | TREATMENT OF RECURRENT MUCOCUTANEOUS HERPES SIMPLEX INFECTIONS IN HIV-AFFECTED PATIENTS AT A DOSE OF 500MG TWICE DAILY |
| I-233 | PROPHYLACTIC USE TO REDUCE PERIOPERATIVE BLOOD LOSS AND THE NEED FOR BLOOD TRANSUFSION IN PATIENTS UNDERGOING CARDIOPULMONARY BYPASS IN THE COURSE OF CORONARY ARTERY BYPASS GRAFT SURGERY |
| I-234 | FOR USE IN COMBINATION WITH CISPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED (STAGE IIIA OR IIIB) OR METASTATIC (STAGE IV) NON-SMALL CELL LUNG CANCER |
| I-235 | PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 12 YEARS OF AGE AND OLDER |
| I-236 | PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER |
| I-237 | MAINTENANCE TREATMENT OF ASTHMA AND PREVENTION OF BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER |
| I-238 | ADJUNCTIVE TREATMENT OF LENNOX-GASTAUT SYNDROME IN PEDIATRIC AND ADULT PATIENTS |
| I-239 | TREATMENT OF PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA |
| I-240 | MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM AND RESULTANT METABOLIC BONE DISEASE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL FAILURE (CCR 15 TO 55ML/MIN) NOT YET ON DIALYSIS |
| I-241 | USE IN PHOTODYNAMIC THERAPY (PDT) FOR REDUCTION OF OBSTRUCTION AND PALLIATION OF SYMPTOMS IN PATIENTS WITH COMPLETELY OR PARTIALLY OBSTRUCTING ENDOBRONCHIAL NONSMALL CELL LUNG CANCER |
| I-242 | TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH THE MENOPAUSE AND IN THE TREATMENT OF VULVAR AND VAGINAL ATROPHY IN WOMEN WITH AN INTACT UTERUS |
| I-243 | USE IN THE SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH THE COMMON COLD IN CHILDREN AGE 5 TO 11 YEARS |
| I-244 | REDUCE THE INCIDENCE OF BREAST CANCER IN WOMEN AT HIGH RISK FOR BREAST CANCER |
| I-245 | TREATMENT OF ACUTE SINUSITIS |
| I-246 | TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS |

**EXCLUSIVITY INDICATION**

I-247 USE IN CONVERSION TO MONOTHERAPY IN ADULTS WITH PARTIAL SEIZURES WHO ARE RECEIVING TREATMENT WITH A SINGLE ENZYME-INDUCING ANTIEPILEPTIC DRUG

I-248 INPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITH/WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIM AND OUTPATIENT TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMIN WITH WARFARIN SODIUM

I-249 TREATMENT OF CHRONIC HEPATITIS C IN PATIENTS WITH COMPENSATED LIVER DISEASE PREVIOUSLY UNTREATED WITH ALPHA INTERFERON THERAPY

I-250 PRIMARY PREVENTION OF CORONARY HEART DISEASE IN PATIENTS WITHOUT SYMPATOMATIC CARDIOVASCULAR DISEASE WHO HAVE AVERAGE TO MODERATELY ELEVATED TOTAL-C AND LDL-C AND BELOW AVERAGE HDL-C

I-251 TREATMENT OF GENERALIZED ANXIETY DISORDER

I-252 NEW COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS METFORMIN

I-253 COMBINATION USE OF PRECOSE FOR PATIENTS WITH TYPE 2 DIABETES TREATED WITH DIET PLUS INSULIN

I-254 PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS (LOSS OF BONE MASS)

I-255 PREVENTION OF PNEUMOCYSTIS CARINII PNEUMONIA (PCP)

I-256 USE IN TREATMENT OF SMALL CELL LUNG CANCER SENSITIVE DISEASE AFTER FAILURE OF FIRST-LINE CHEMOTHERAPY

I-257 TREATMENT OF CHRONIC HEPATITIS B ASSOCIATED WITH EVIDENCE OF HEPATITIS B VIRAL REPLICATION AND ACTIVE LIVER INFLAMATION

I-258 FOR PERENNIAL NONALLERGIC RHINITIS FOR AGES 4 AND ABOVE

I-259 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM, IN PATIENTS UNDERGOING HIP REPLACEMENT SURGERY

I-260 EXPANDED PEDIATRIC USE IN CHILDREN YOUNGER THAN ONE MONTH OF AGE TO BIRTH (WITH A GESTATIONAL AGE OF 37 WEEKS OR GREATER)

I-261 TREATMENT OF SOCIAL ANXIETY DISORDER

I-262 TREATMENT OR PREVENTION OF BRONCHOSPASM WITH REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE AND FOR THE PREVENTION OF EXERCISE INDUCED BRONCHOSPASM IN CHILDREN AGES 4-12

I-263 TREATMENT OF UNSTABLE ANGINA AND NON-Q-WAVE MYOCARDIAL INFARCTION FOR THE PREVENTION OF ISCHEMIC COMPLICATIONS IN PATIENTS ON CONCURRENT ASPIRIN THERAPY

I-264 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH RADIATION, INCLUDING TOTAL BODY IRRADIATION (TBI) AND FRACTIONATED ABDOMINAL RADIATION

I-265 TREATMENT OF ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 6 YEARS AND OLDER

I-266 USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS AGES 2-16 YEARS WITH PARTIAL ONSET SEIZURES

I-267 USE IN PEDIATRIC PATIENTS 3 MONTHS OLD AND OLDER - FOR CORTICOSTEROID-RESPONSIVE DERMATOSES

I-268 PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 7-11 YEARS OF AGE

I-269 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING CISPLATIN

I-270 ADJUVANT TREATMENT OF NODE-POSITIVE BREAST CANCER ADMINISTRERED SEQUENTIALLY TO STANDARD DOXORUBICIN-CONTAINING COMBINATION CHEMOTHERAPY

I-271 TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN

I-272 TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN MEN AND WOMEN RECEIVING GLUCOCORTICOIDS IN A DAILY DOSE EQUIVALENT TO 7.5MG OR GREATER OF PREDNISONE AND WHO HAVE LOW BONE MINERAL DENSITY

I-273 ADJUNCT TO DIET TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NON FAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB)

I-274 USE OF TOPAMAX AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES

I-275 USE IN COMBINATION WITH METFORMIN AND SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES

I-276 USE OF REZULIN IN COMBINATION WITH METFORMIN AND SULFONYLUREAS IN PATIENTS WITH

| | **EXCLUSIVITY INDICATION** |
|---|---|
| | TYPE 2 DIABETES |
| I-277 | TREATMENT OF TYPE III HYPERLIPOPROTEINEMIA |
| I-278 | TREATMENT OF PATIENTS WITH ISOLATED HYPERTRIGLYCERIDEMIA (FREDERICKSON TYPE IV) |
| I-279 | TREATMENT OF POST-TRAUMATIC STRESS DISORDER |
| I-280 | USE OF CARNITOR INJECTION FOR THE PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS |
| I-281 | INCREASING HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (HETEROZYGOUS FAMILIAL AND NONFAMILIAL) AND MIXED DYSLIPIDEMIA (FREDERICKSON TYPES IIA AND IIB) |
| I-282 | TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY |
| I-283 | TO REDUCE THE INCIDENCE OF MODERATE TO SEVERE XEROSTOMIA IN PATIENTS UNDERGOING POST-OPERATIVE RADIATION TREATMENT FOR HEAD AND NECK CANCER, WHERE THE RADIATION PORT INCLUDES A SUBSTANTIAL PORTION OF THE PAROTID GLANDS |
| I-284 | TO REDUCE THE NUMBER OF ADENOMATOUS COLORECTAL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS PATIENTS AS AN ADJUNCT TO USUAL CARE |
| I-285 | TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN ADULTS AND CHILDREN 3 YEARS OF AGE AND OLDER |
| I-286 | TREATMENT OF PATIENTS WITH FREDERICKSON TYPE III |
| I-287 | USE OF PRAVASTATIN IN PATIENTS WITH EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF TOTAL MORTALITY BY REDUCING CORONARY DEATH |
| I-288 | CHANGES IN SEVERAL SECTIONS OF THE INSERT TO INCORPORATE STATEMENTS CONCERNING THE USE OF HIGH DOSES OF LISINOPRIL TO REDUCE THE RISK OF THE COMBINED OUTCOMES OF MORTALITY AND HOSPITALIZATION IN PATIENTS WITH CONGESTIVE HEART FAILURE |
| I-289 | USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLLITUS WHEN DIET AND EXERCISE WITH EITHER SINGLE AGENT DOES NOT ACHIEVE ADEQUATE GLYCEMIC CONTROL |
| I-290 | PREVENTION OF CORTICOSTEROID-INDUCED OSTEOPOROSIS |
| I-291 | PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS |
| I-292 | TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS |
| I-293 | TREATMENT OF CORTICOSTEROID-INDUCED OSTEOPOROSIS |
| I-294 | TREATMENT OF UNCOMPLICATED ACUTE ILLNESS DUE TO INFLUENZA A AND B IN PEDIATRIC PATIENTS 7 YEARS AND OLDER WHO HAVE BEEN SYMPTOMATIC FOR NO MORE THAN 2 DAYS |
| I-295 | PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR WOMEN WITH AN INTACT UTERUS |
| I-296 | LONG-TERM INTRAVENOUS TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH THE SCLERODERMA SPECTRUM OF DISEASE IN NYHA CLASS III AND CLASS IV PATIENTS WHO DO NOT RESPOND TO CONVENTIONAL THERAPY |
| I-297 | SHORT-TERM TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER |
| I-298 | TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IIA AND IIB HYPERLIPOPROTEINEMIA |
| I-299 | USE OF CAMPTOSAR AS A COMPONENT OF FIRST-LINE THERAPY IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVARIN FOR PATIENTS WITH METASTATIC CARCINOMA OF THE COLON OR RECTUM |
| I-300 | PROPHYLAXIS FOR ASTHMA IN CHILDREN 2-5 YEARS OF AGE |
| I-301 | TREATMENT OF SIGNS AND SYMPTOMS OF ALLERGIC CONJUNCTIVITIS |
| I-302 | TREATMENT OF PEDIATRIC PATIENTS WITH PRADER-WILLI SYNDROME |
| I-303 | INCREASING HDL-CHOLESTEROL IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIAS |
| I-304 | TREATMENT OF PATIENTS WITH FREDERICKSON TYPE IV |
| I-305 | TREATMENT OF LEVOFLOXACIN SUSCEPTIBLE STRAINS OF PENICILLIN-RESISTANT STREPTOCOCCUS PNEUMONIAE IN PATIENTS WITH COMMUNITY ACQUIRED PNEUMONIA |
| I-306 | INDUCTION OF SPERMATOGENESIS IN MEN WITH PRIMARY AND SECONDARY HYPOGONADOTROPIC HYPOGONADISM IN WHOM THE CAUSE OF INFERTILITY IS NOT DUE TO PRIMARY TESTICULAR FAILURE |
| I-307 | NEW COMBINATION USE OF METFORMIN AND INSULIN IN TYPE 2 DIABETES |

**EXCLUSIVITY INDICATION**

| | |
|---|---|
| I-308 | TREATMENT OF PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS WHO RESPONDED INADEQUATELY TO SALICYLATES OR OTHER NSAIDS |
| I-309 | USE OF ACTONEL 35MG ONCE A WEEK TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS |
| I-310 | REDUCTION IN RISK OF MYOCARDIAL INFARCTION, STROKE, AND DEATH FROM CARDIOVASCULAR CAUSES |
| I-311 | ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS AGE 3 TO 12 YEARS |
| I-312 | FIRST LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER |
| I-313 | EXTENSION OF INDICATION TO PROVIDE FOR MAINTENANCE OF RESPONSE |
| I-314 | TOPICAL ANESTHETIC FOR SUPERFICIAL MINOR SURGERY OF GENITAL MUCOUS MEMBRANES AND AS AN ADJUNCT FOR LOCAL INFILTRATION ANESTHESIA IN GENITAL MUCOUS MEMBRANES |
| I-315 | THROMBOPROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM,IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS |
| I-316 | TREATMENT OF NSAID-ASSOCIATED GASTRIC ULCER PATIENTS WHO CONTINUE NSAID USE AND REDUCING RISK OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS WITH HISTORY OF DOCUMENTED GASTRIC ULCER WHO REQUIRE USE OF AN NSAID |
| I-317 | PROPHYLAXIS OF INFLUENZA IN ADULTS AND ADOLESCENTS 13 YEARS AND OLDER |
| I-318 | FIRSTLINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE OR HORMONE RECEPTOR UNKNOWN LOCALLY ADVANCED OR METASTATIC BREAST CANCER |
| I-319 | USE FOR SUSPECTED OR CONFIRMED METHANOL POISONING, EITHER ALONE OR IN COMBINATION WITH HEMODIALYSIS |
| I-320 | TREATMENT OF TYPE 2 DIABETES IN PEDIATRIC PATIENTS (AGES 10-16 YEARS) |
| I-321 | JUVENILE RHEUMATOID ARTHRITIS |
| I-322 | USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS |
| I-323 | COLORECTAL CANCER |
| I-324 | REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS |
| I-325 | PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION |
| I-326 | GENERALIZED ANXIETY DISORDER |
| I-327 | SYMPTOMATIC RELIEF OF RHINORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER |
| I-328 | PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE |
| I-329 | UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS |
| I-330 | MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYMPTOMS IN PATIENTS WITH GERD |
| I-331 | TREATMENT OF MODERATE ACNE VULGARIS |
| I-332 | EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (EFTN) |
| I-333 | TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE) |
| I-334 | LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE |
| I-335 | ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME |
| I-336 | EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS |
| I-337 | PATHOLOGICAL HYPERSECRETION ASSOCIATED WITH ZOLLINGER-ELLISON SNYDROME |
| I-338 | MANAGEMENT OF ACUTE PAIN IN ADULTS AND TREATMENT OF PRIMARY DYSMENORRHEA |
| I-339 | TREATMENT OF HEPATITIS B IN PEDIATRIC PATIENTS AGES 2-17 YEARS |
| I-340 | ATOPIC DERMATITIS IN PEDIATRIC PATIENTS AGES 2-5 |

**EXCLUSIVITY INDICATION**

| | |
|---|---|
| I-341 | BREAST CANCER COMBINATION THERAPY |
| I-342 | USE OF FORADIL FOR LONG-TERM, TWICE DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHO-CONSTRICTION IN PATIENTS WITH COPD INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA |
| I-343 | USE OF COREG FOR SEVERE HEART FAILURE |
| I-344 | ACNE VULGARIS |
| I-345 | TREATMENT OF POSTTRAUMATIC STRESS DISORDER |
| I-346 | TREATMENT OF SYMPTOMATIC GASTRO ESOPHAGEAL REFLUX DISEASE (GERD) |
| I-347 | TREATMENT OR PREVENTION OF BRONCHOSPASM IN CHILDREN 6 YEARS OF AGE AND OLDER WITH OBSTRUCTIVE AIRWAY DISEASE |
| I-348 | LONG-TERM, TWICE-DAILY (MORNING AND EVENING) ADMINISTRATION IN THE MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD (INCLUDING EMPHYSEMA AND CHRONIC BRONCHITIS) |
| I-349 | ACUTE CORONARY SYNDROME |
| I-350 | TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND GIRLS AT LEAST ONE YEAR POSTMENARCHAL, AGES 10 TO 17 YEARS, WITH A RECOMMENDED DOSING RANGE OF 10 TO 40MG ONCE DAILY |
| I-351 | PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS FOR ALL STRENGTHS |
| I-352 | ANTICOAGULANT IN PATIENTS WITH OR AT RISK FOR HEPARIN-INDUCED THROMBOCYTOPENIA UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI) |
| I-353 | TREATMENT OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS |
| I-354 | MANAGEMENT OF POST HERPETIC NEURALGIA |
| I-355 | PREMENSTRUAL DYSPHORIC DISORDER |
| I-356 | TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS, INCLUDING ZOLLINGER-ELLISON SYNDROME |
| I-357 | TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS |
| I-358 | TREATMENT OF PANIC DISORDER |
| I-359 | TREATMENT OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE |
| I-360 | TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL RHINITIS IN CHILDREN AGES TWO UP TO AGE THREE |
| I-361 | TREATMENT OF MULTIPLE MYELOMA AND DOCUMENTED BONE METASTASES FROM SOLID TUMORS, IN CONJUNCTION WITH STANDARD ANTINEOPLASTIC THERAPY. PROSTATE CANCER SHOULD HAVE PROGRESSED AFTER TREATMENT WITH AT LEAST ONE HORMONAL THERAPY |
| I-362 | TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA |
| I-363 | ADJUVANT TREATMENT OF POST MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER |
| I-364 | TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA IN ADULTS |
| I-365 | TREATMENT OF HEART FAILURE (NYHA CLASS II-IV) IN PATIENTS WHO ARE INTOLERANT TO AN ACE INHIBITOR |
| I-366 | PREVENTION OF RELAPSE FOLLOWING LONG-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER |
| I-367 | COMBINATION THERAPY WITH THIAZOLIDINEDIONE TO LOWER BLOOD GLUCOSE IN PTS WHOSE HYPERGLYCEMIA CANNOT BE CONTROLLED BY DIET/EXERCISE PLUS MONOTHERAPY WITH ANY OF THE FOLLOWING AGENTS: METFORMIN, SULFONYLUREAS, REPAGLINIDE, OR THIAZOLIDINEDIONES |
| I-368 | USE OF GLUCOVANCE WITH A THIAZOLIDINEDIONE WHEN GLYCEMIC CONTROL IS NOT OBTAINED WITH GLUCOVANCE ALONE |
| I-369 | PREVENTION AND TREATMENT OF POSTOPERATIVE NAUSEA AND VOMITING |
| I-370 | TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN CHILDREN, AGES 8-13 YEARS, WITH RECOMMENDED DOSE OF 20MG ONCE DAILY AND IN ADOLESCENTS, AGES 14-18 WITH A RECOMMENDED DOSE OF 40MG ONCE DAILY |
| I-371 | HELICOBACTER PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE |
| I-372 | NOSOCOMIAL PNEUMONIA |
| I-373 | TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY |

**EXCLUSIVITY INDICATION**

I-374 SHORT TERM TOPICAL TREATMENT OF MILD TO MODERATE PLAQUE-TYPE PSORIASIS OF NON SCALP REGIONS

I-375 FIRST LINE THERAPY FOR THE REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION

I-376 TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (CML)

I-377 USE OF BRAVELLE FOR MULTIPLE FOLLICULAR DEVELOPMENT (CONTROLLED OVARIAN STIMULATION) DURING ASSISTED REPRODUCTIVE TECHNOLOGY CYCLES IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED PITUITARY SUPPRESSION

I-378 RELIEF OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER

I-379 USE TAXOTERE IN COMBINATION WITH CISPLATIN FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHO HAVE NOT PREVIOUSLY RECEIVED CHEMOTHERAPY FOR THIS CONDITION

I-380 TO TREAT PATIENTS WITH SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDER AT RISK FOR EMERGENT SUICIDAL BEHAVIOR

I-381 TREATMENT OF COLD SORES (HERPES LABIALIS) IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER

I-382 FOR NEWLY-DIAGNOSED HIGH GRADE MALIGNANT GLIOMA PATIENTS AS AN ADJUNCT TO SURGERY AND RADIATION

I-383 TREATMENT OF TYPE 2 DIABETIC NEPHROPATHY

I-384 USE IN COMBINATION WITH INSULIN FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS

I-385 MODIFICATION OF THE INDICATION FOR COMMUNITY ACQUIRED PNEUMONIA TO ADD"INCLUDING PENICILLIN-RESISTANT STRAINS, MIC PENICILLIN>=2MCG/ML TO STREPTOCOCCUS PNEUMONIAE

I-386 RAPAMUNE (SIROLIMUS) WITHIN AN IMMUNOSUPPRESSIVE REGIMEN THAT WOULD ALLOW FOR THE WITHDRAWAL OF CYCLOSPORINE 2 TO 4 MONTHS AFTER RENAL TRANSPLANTATION IN PATIENTS CONSIDERED AT LOW TO MODERATE IMMUNOLOGIC RISK FOR RENAL TRANSPLANT REJECTION

I-387 ADJUNCTIVE THERAPY OF PARTIAL SEIZURES IN PEDIATRIC PATIENTS GREATER THAT OR EQUAL TO 2 YEARS OF AGE

I-388 TREATMENT OF PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION

I-389 SUPRESSION OF RECURRENT GENITAL HERPES IN HIV-INFECTED INDIVIDUALS

I-390 USE IN PTS AT HIGH RISK CORONARY EVENTS DUE TO EXISTING CORONARY HEART DISEASE, DIABETES, PERIPHERAL VESSEL DISEASE, STROKE HISTORY, OTHER CV DISEASE TO REDUCE RISK TOTAL MORTALITY BY REDUCING CORONARY DEATH, REDUCE NONFATAL MI & STROKE.....

I-391 ABLATION OF HIGH-GRADE DYSPLASIA IN BARRETT'S ESOPHAGUS PATIENTS WHO DO NOT UNDERGO ESOPHAGECTOMY

I-392 TX OF PED PATIENTS W/PH+ CHRONIC PHASE CML DISEASE RECURRANCE AFTER STEM CELL TRANSPLANT OR RESISTANCE TO INTERFERON ALPHA THERAPY. NO CONTROLLED TRIALS DEMONSTRATING A CLINICAL BENEFIT SUCH AS IMPROVEMENT IN DISEASE RELATED SX OR INCREASED SURVIVAL

I-393 CHRONIC BACTERIAL PROSTATITIS

I-394 USE IN PATIENTS WITH CORONARY HEART DISEASE TO REDUCE THE RISK OF UNDERGOING CORONARY REVASCULARIZATION PROCEDURES

I-395 TO IMPROVE PHYSICAL FUNCTION

I-396 EXPANDED INDICATION TO INCLUDE THE ASSESSMENT OF VENTRICULAR FUNCTION IN SUBJECTS BEING EVALUATED FOR HEART DISEASE AND/OR VENTRICULAR FUNCTION

I-397 EXTENDED PROPHYLAXIS IN PATIENTS UNDERGOING HIP FRACTURE SURGERY

I-398 IDIOPATHIC SHORT STATURE

I-399 TREATMENT OF CANDIDEMIA AND THE FOLLOWING CANDIDA INFECTIONS: INTRA-ABDOMINAL ABSCESSES, PERITONITIS AND PLEURAL SPACE INFECTIONS

I-400 USE OF OLANZAPINE IN COMBINATION WITH LITHIUM OR VALPROATE FOR THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR DISORDER

**EXCLUSIVITY INDICATION**

| | |
|---|---|
| I-401 | LONGER-TERM EFFICACY OF ARIPIPRAZOLE IN THE TREATMENT OF SCHIZOPHRENIA |
| I-402 | DIABETIC FOOT INFECTIONS WITHOUT CONCOMITANT OSTEOMYELITIS |
| I-403 | USE OF VALTREX IN COMBINATION WITH SAFER SEX PRACTICES FOR THE REDUCTION OF THE RISK OF TRANSMISSION OF GENITAL HERPES DURING SUPPRESIVE THERAPY OF THE SOURCE PARTNER IN A HETEROSEXUAL COUPLE |
| I-404 | MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES (DEPRESSION, MANIA, HYPOMANIA, MIXED EPISODES) IN PATIENTS TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY |
| I-405 | TREATMENT OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) USING AN INTERMITTENT DOSING REGIMEN |
| I-406 | PREVENTION OF CYTOMEGALOVIRUS DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE) |
| I-407 | IMPROVE SURVIVAL OF STABLE PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (EJECTION FRACTION<=40%) AND CLINICAL EVIDENCE OF CONGESTIVE HEART FAILURE AFTER AN ACUTE MYOCARDIAL INFARCTION |
| I-408 | STIMULATION OF PANCREATIC SECRETIONS TO FACILITATE THE INDENTIFICATION OF THE AMPULLA OF VATER AND ACCESSORY PAPILLA DURING ENDOSCOPIC RETROGRADE CHOLANGIO-PANCREATOGRAPHY (ERCP) |
| I-409 | ESOPHAGEAL CANDIDIASIS |
| I-410 | USE OF ADVAIR DISKUS 250/50 FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) ASSOCIATED WITH CHRONIC BRONCHITIS |
| I-411 | EXPANDED INDICATION FOR USE IN COMBINATION WITH ANTIDIABETIC DRUGS IN THE THIAZOLIDINEDIONE CLASS |
| I-412 | MONOTHERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER |
| I-413 | ADJUNCTIVE THERAPY FOR THE SHORT TERM TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER |
| I-414 | PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT), WHICH MAY LEAD TO PULMONARY EMBOLISM (PE) IN MEDICAL PATIENTS WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS DUE TO SEVERELY RESTRICTED MOBILITY DURING ACUTE ILLNESS |
| I-415 | SEVERE HYPERTENSION WHEN THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY |
| I-416 | THE USE OF CIPRO XR FOR COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS |
| I-417 | USE IN THE LONG TERM TREATMENT OF BIPOLAR I DISORDER |
| I-418 | ADJUNCTIVE THERAPY W/ MOOD STABILIZERS (LITHIUM OR DIVALPROEX) IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDERS |
| I-419 | MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC EPISODES ASSOCIATED WITH BIPOLAR I DISORDER |
| I-420 | TOPICAL TREATMENT OF CLINICALLY TYPICAL, NONHYPERKERATOTIC, NONHYPERTROPHIC ACTINIC KERATOSES ON THE FACE OR SCALP IN IMMUNOCOMPETENT ADULTS |
| I-421 | TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND PYELONEPHRITIS DUE TO E.COLI FOR PED PATIENTS (1-17) NOT AS FIRST CHOICE |
| I-422 | INDICATED FOR THE IN-HOSPITAL SHORT-TERM (UP TO 4 HOURS) REDUCTION IN BLOOD PRESSURE IN PEDIATRIC PATIENTS |
| I-423 | ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS |
| I-424 | MANAGEMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH MODERATE TO SEVERE CHRONIC RENAL INSUFFICIENCY NOT YET ON DIALYSIS |
| I-425 | ELOXATIN IN COMBINATION WITH INFUSIONAL 5-FLUOROURACIL (5-FU) AND LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS PREVIOUSLY UNTREATED FOR ADVANCED COLORECTAL CANCER |
| I-426 | TREATMENT OF ACUTE PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM |
| I-427 | TREATMENT OF ACUTE DEEP VEIN THROMBOSIS WITHOUT PULMONARY EMBOLISM WHEN ADMINISTERED IN CONJUNCTION WITH WARFARIN SODIUM |
| I-428 | FOR USE IN COMBINATION WITH PACLITAXEL FOR THE FIRST-LINE TREATMENT OF PATIENTS |

**EXCLUSIVITY INDICATION**

WITH METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR ANTHRACYCLINE CONTAINING ADJUVANT CHEMOTHERAPY UNLESS ANTHRACYCLINES WERE CLINICALLY CONTRAINDICATED

I-429 FOR USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER

I-430 FOR USE IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS

I-431 NOSOCOMIAL PNEUMONIA AND COMMUNITY-ACQUIRED PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE INDICATION EXPANDED TO INCLUDE MULTI-DRUG RESISTANT STRAINS

I-432 TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA CAUSED BY MULTI-DRUG RESISTANT STREPTOCOCCUS PNEUMONIAE

I-433 TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA IN IMMUNOCOMPETENT ADULTS, WITH A MAXIMUM TUMOR DIAMETER OF 2.0CM, LOCATED ON THE TRUNK (EXCLUDING ANOGENITAL SKIN), NECK, OR EXTREMITIES (EXCLUDING HANDS AND FEET)

I-434 PREVENTION OF CARDIOVASCULAR DISEASE IN ADULT PATIENTS WITHOUT CLINICALLY EVIDENT HEART DISEASE, BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE TO REDUCE RISK OF MI AND RISK FOR REVASCULARIZATION PROCEDURES AND ANGINA

I-435 CHRONIC IDIOPATHIC CONSTIPATION

I-436 FOR USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER

I-437 TREATMENT OF ACUTE MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER

I-438 EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS

I-439 USED TO TREAT ADULTS WITH GROWTH HORMONE DEFICIENCY

I-440 FOR THE REPLACEMENT OF ENDOGENOUS GROWTH HORMONE IN ADULTS WITH GROWTH HORMONE DEFICIENCY

I-441 USE COMBINATION WITH INFUSIONAL 5-FU/LV FOR ADJUVANT TREATMENT STAGE III COLON CANCER PTS WHO HAVE UNDERGONE COMPLETE RESECTION PRIMARY TUMOR-BASED ON IMPROVEMENT IN DISEASE FREE SURVIVAL, NO DEMONSTRATED BENEFIT OVERALL SURVIVAL AFTER 4YRS

I-442 USED FOR CANDIDEMIA IN NONNEUTROPENIC PATIENTS AND THE FOLLOWING CANDIDA INFECTIONS: DISSEMINATED INFECTIONS IN SKIN & INFECTIONS IN ABDOMEN, KIDNEY, BLADDER WALL, AND WOUNDS

I-443 TREATMENT OF NASAL POLYPS IN PATIENTS 18 YEARS OF AGE AND OLDER

I-444 USE OF PROTONIX IV FOR INJECTION AS STAND ALONE THERAPY FOR THE SHORT-TERM TREATMENT OF PATIENTS HAVING GASTROESOPHAGEAL REFLUX (GERD) WITH A HISTORY OF EROSIVE ESOPHAGITIS

I-445 TO IMPROVE (COMPARED TO 4.25% DEXTROSE) LONG-DWELL ULTRAFILTRATION AND CLEARANCE OF CREATININE AND UREA NITROGEN IN PATIENTS WITH HIGH AVERAGE OR GREATER TRANSPORT CHARACTERISTICS, AS DEFINED USING THE PERITONEAL EQUILIBRATION TEST (PET)

I-446 EXTENDED ADJUVANT TREATMENT OF EARLY BREAST CANCER IN POSTMENOPAUSAL WOMEN WHO HAVE RECEIVED 5 YRS ADJUVANT TAMOXIFEN THERAPY-EFFECTIVENESS BASED ON AN ANALYSIS OF DISEASE FREE SURVIVAL IN PATIENTS TREATED FOR A MEDIAN 24 MONTHS

I-447 USE OF COPEGUS (RIBAVIRIN) FOR TREATMENT OF CHRONIC HEPATITIS C IN ADULT PATIENTS COINFECTED WITH HIV IN COMBINATION WITH PEGASYS (PEGINTERFERON ALFA-2A)

I-448 TREATMENT OF HEART FAILURE (NYHA CLASS II-IV AND EJECTION FRACTION <=40%) TO REDUCE THE RISK OF DEATH FROM CARDIOVASCULAR CAUSES AND TO REDUCE HOSPITALIZATIONS FOR HEART FAILURE

I-449 TO IMPROVE WAKEFULNESS IN TWO NEW PATIENT POPULATIONS WITH EXCESSIVE SLEEPINESS: THOSE WITH OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME AND THOSE WITH SHIFT WORK SLEEP DISORDER

I-450 TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED HIGH GRADE GLIOMAS CONCOMITANTLY WITH RADIOTHERAPY AND THEN AS ADJUVANT TREATMENT

I-451 MANAGEMENT OF ENDOMETRIOSIS ASSOCIATED PAIN

I-452 EXPANDED INDICATION TO INCLUDE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY

I-453 USE IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN WHEN DIET, EXERCISE AND

**EXCLUSIVITY INDICATION**

| | |
|---|---|
| | BOTH AGENTS DO NOT RESULT IN ADEQUATE GLYCEMIC CONTROL (TRIPLE THERAPY) |
| I-454 | MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON FOR UP TO 3 MONTHS |
| I-455 | MODIFIED HEART FAILURE INDICATION TO INCLUDE TREATMENT OF HEART FAILURE IN PATIENTS WITH LEFT VENTRICULAR SYSTOLIC DYSFUNCTION (NYHA CLASS II-IV; EJECTION FRACTION LESS THAN OR EQUAL TO 40% |
| I-456 | TO REDUCE CARDIOVASCULAR DEATH AND TO REDUCE HEART FAILURE HOSPITALIZATIONS. INCLUDES ADDITIONAL INFORMATION ON THE ADDED EFFECT ON THESE OUTCOMES WHEN USED WITH AN ACE INHIBITOR |
| I-457 | TREATMENT OF PATIENTS UNDERGOING ABDOMINAL SURGERY WHO ARE AT RISK FOR THROMBOEMBOLIC COMPLICATIONS |
| I-458 | USE OF BIVALIRUDIN FOR INJECTION WITH PROVISIONAL USE OF GLYCOPROTEIN IIB/IIA INHIBITOR (GPI) AS LISTED IN THE CLINICAL TRIALS REPLACE-2 SECTION FOR USE AS AN ANTICOAGULANT IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI) |
| I-459 | NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE (NDD-CKD) PATIENTS RECEIVING OR NOT RECEIVING AN ERYTHROPOIETIN |
| I-460 | TREATMENT OF DIARRHEA CAUSED BY CRYPTOSPORIDIUM PARVUM IN NON-HIV INFECTED PATIENTS 12 YEARS OF AGE AND OLDER |
| I-461 | USE AS A SINGLE AGENT FOR ADJUVANT TREATMENT IN PATIENTS WITH DUKES' C COLON CANCER WHO HAVE UNDERGONE COMPLETE RESECTION OF THE PRIMARY TUMOR WHEN TREATMENT WITH FLUOROPYRIMIDINE THERAPY ALONE IS PREFERRED |
| I-462 | LONG TERM TREATMENT OF IDIOPATHIC SHORT STATURE |
| I-463 | TREATMENT OF PATIENTS POST MYOCARDIAL INFARCTION |
| I-464 | TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME |
| I-465 | PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 6 MONTHS OF AGE AND OLDER |
| I-466 | FOR RELIEF OF THE SIGNS AND SYMPTOMS OF ANKYLOSING SPONDYLITIS |
| I-467 | USE OF TOPIRAMATE AS INITIAL MONOTHERAPY IN PATIENTS 10 YEARS OF AGE AND OLDER WITH PARTIAL ONSET OR PRIMARY GENERALIZED TONIC CLONIC SEIZURES |
| I-468 | USE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE TO REDUSE THE RISK OF CARDIOVASCULAR MORTALITY OR NON-FATAL MYOCARDIAL INFECTION |
| I-469 | RELIEF OF THE SIGNS AND SYMPTOMS OF PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS IN PATIENTS 2 YEARS OF AGE AND OLDER |
| I-470 | DIABETIC PERIPHERAL NEUROPATHIC PAIN |
| I-471 | INDICATED TO REDUCE THE RISK OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH TYPE 2 DIABETES AND WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH MULTIPLE RISK FACTORS FOR CORONARY HEART DISEASE |
| I-472 | USE IN PATIENTS WITH ANGIOGRAPHICALLY DOCUMENTED CORONARY ARTERY DISEASE |
| I-473 | USE IN COMBINATION WITH GEMCITABINE FOR THE FIRST LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER |
| I-474 | TREATMENT OF IRON DEFICIENCY ANEMIA IN PERITONEAL DIALYSIS DEPENDANT CHRONIC KIDNEY DISEASE IN PATIENTS RECIEVING AN ERYTHROPOIETIN |
| I-475 | PREVENTION OF NAUSEA AND VOMITTING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF MODERATELY EMETOGENIC CANCER CHEMOTHERAPY |
| I-476 | TREATMENT OF DIABETIC FOOT INFECTIONS WITHOUT OSTEOMYELITIS |
| I-477 | TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS, ESCHERICHIA COLI, KLEBSIELLA PNEUMONIAE, OR ENTEROBACTER CLOACAE |
| I-478 | FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES IN CHILDREN WITH EPILEPSY AGED 2-4 YEARS |
| I-479 | TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS CAUSED BY E.COLI, B. FRAGILIS, S.ANGINOSUS, S.CONSTELLATUS, E. FAECALIS, P. MIRABILIS, C. PERFRINGENS, B. THETAIOTAOMICRON OR PEPTOSTREPTOCOCCUS SPECIES |
| I-480 | PROPHYLAXIS OF INFLUENZA FOR PATIENTS BETWEEN 1-12 YEARS OF AGE |
| I-481 | INDICATED FOR THE ADJUVANT TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE EARLY BREAST CANCER |

**EXCLUSIVITY INDICATION**

| | |
|---|---|
| I-482 | TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH OR WITHOUT PSYCHOTIC FEATURES |
| I-483 | PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS |
| I-484 | FOR THE RISK REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS |
| I-485 | TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT EXTRACTION |
| I-486 | ANGIOMAX IS INDICATED FOR PATIENTS WITH, OR AT RISK OF, HIT/HITTS UNDERGOING PCI |
| I-487 | INDICATED FOR THE RELIEF OF THE INFAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YRS OF AGE OR OLDER |
| I-488 | MAINTENANCE THERAPY IN BIPOLAR I DISORDER |
| I-489 | FOR USE IN PEDIATRIC PATIENTS WITH TYPE I DIABETES |
| I-490 | FOR USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE TREATMENT OF PATIENTS WITH ADVANCED GASTRIC ADENOCARCINOMA, INCLUDING ADENOCARCINOMA OF GASTROESOPHAGEAL JUNCTION, WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR ADVANCED DISEASE |
| I-491 | INFLUENZA PROPHYLAXIS |
| I-492 | MONOTHERAPY IN THE TREATMENT OF ACUTE MANIC OR MIXED EPISODES IN BIPOLAR I DISORDER, WITH OR WITHOUT PSYCHOTIC FEATURES |
| I-493 | ADMINISTERED IN COMBINATION WITH FENOFIBRATE, AS ADJUNCTIVE THERAPY TO DIET FOR THE REDUCTION OF ELEVATED TOTAL-C, LDL-C, APO B, AND NON-HDL-C IN PATIENTS WITH MIXED HYPERLIPIDEMIA |
| I-494 | CLINICAL DATA IN SUPPORT OF AVANDAMET AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH DUAL ROSIGLITAZONE AND METFORMIN THERAPY IS APPROPRIATE |
| I-495 | ADJUVANT TX OF POSTMENOPAUSAL WOMEN WITH ESTROGEN-RECEPTOR POSITIVE EARLY BREAST CANCER WHO HAVE RECEIVED 2 TO 3 YRS OF TAMOXIFEN AND ARE SWITCHED TO AROMASIN FOR COMPLETION OF A TOTAL OF 5 CONSECUTIVE YRS OF ADJUVANT HORMONAL THERAPY |
| I-496 | LONG TERM TREATMENT OF GROWTH FAILURE ASSOCIATED WITH TURNER SYNDROME IN PATIENTS WHO HAVE OPEN EPIPHYSES |
| I-497 | PREVENTION OF SEASONAL MAJOR DEPRESSIVE EPISODES IN PATIENTS WITH SEASONAL AFFECTIVE DISORDER |
| I-498 | PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING |
| I-499 | USE OF GEMZAR IN COMBINATION WITH CARBOPLATIN FOR THE TREATMENT OF PATIENTS WITH ADVANCED OVARIAN CANCER THAT HAS RELAPSED AT LEAST 6 MONTHS AFTER COMPLETION OF PLATINUM-BASED THERAPY |
| I-500 | FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
| I-501 | TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN IMMUNOCOMPETANT PATIENTS WITH A SINGLE DOSE OF FAMCICLOVIR 1500 MG. |
| I-502 | FOR PTS WITH ST-SEGMENT ELEVATION ACUTE MYOCARDIAL INFARCTION, PLAVIX TO REDUCE RATE OF DEATH FROM ANY CAUSE AND THE RATE OF A COMBINED ENDPOINT OF DEATH, REINFARCTION OR STROKE. NOT KNOWN TO PERTAIN TO PTS WHO RECEIVE PRIMARY ANGIOPLASTY |
| I-503 | TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER |
| I-504 | TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME |
| I-505 | TREATMENT OF STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA), INCLUDING THOSE WITH RIGHT SIDED INFECTIVE ENDOCARDITIS, CAUSED BY METHICILLIN-SUSCEPTIBLE AND METHICILLIN-RESISTANT ISOLATES |
| I-506 | ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 12 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY |
| I-507 | ADJUNCT TO DIET TO REDUCE TOTAL-C, LDL-C AND APO B LEVELS IN ADOLESCENT BOYS AND GIRLS WHO ARE AT LEAST ONE YEAR POST-MENARCHE, 10-16 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA |
| I-508 | PREMENSTRUAL DYSPHONIC DISORDER |
| I-509 | TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER |

**EXCLUSIVITY INDICATION**

| | |
|---|---|
| I-510 | ADULT DERMAFIBROSARCOMA PROTUBERANS (DFSP) |
| I-511 | ADULT MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE DISEASES (MDS/MDP) |
| I-512 | ADULT PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MONOTHERAPY |
| I-513 | ADULT AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM) |
| I-514 | ADULT HYPEREOSINOPHILIC SYNDROME/CHRONIC EOSINOPHILIC LEUKEMIA (HES/CEL) |
| I-515 | PROPHYLAXIS OF SURGICAL SITE INFECTION FOLLOWING ELECTIVE COLORECTAL SURGERY |
| I-516 | PRIMARY GENERALIZED TONIC CLONIC SEIZURES IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER |
| I-517 | TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEG SYNDROME (RLS) |
| I-518 | TREATMENT OF SHORT STATURE OR GROWTH FAILURE IN CHILDREN WITH SHOX (SHORT STATURE HOMEOBOX CONTAINING GENE) DEFICIENCY WHOSE EPIPHYSES ARE NOT CLOSED |
| I-519 | USE OF TAXOTERE (DOCETAXEL) INJECTION CONCENTRATE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION OF PATIENTS WITH INOPERABLE LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) |
| I-520 | USE OF EXENATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE USING A THIAZOLIDINEDIONE ALONE OR IN COMBINATION WITH METFORMIN BUT HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL |
| I-521 | TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 YEAR PRIOR THERAPY |
| I-522 | TREATMENT OF MODERATE ACNE VULGARIS IN WOMEN AT LEAST 14 YRS OF AGE, WHO HAVE NO KNOWN CONTRAINDICATIONS TO ORAL CONTRACEPTIVE THERAPY, AND HAVE ACHIEVED MENARCHE, IF THE PATIENT DESIRES AN ORAL CONTRACEPTIVE FOR BIRTH CONTROL. |
| I-523 | USE IN ADULT PATIENTS WITH CLINICALLY EVIDENT CORONARY HEART DISEASE TO REDUCE THE RISK OF NONFATAL MYOCARDIAL INFARCTION, FATAL AND NONFATAL STROKE, ANGINA, REVASCULARIZATION PROCEDURES AND HOSPITALIZATION FOR CONGESTIVE HEART FAILURE |
| I-524 | GENERALIZED ANXIETY DISORDER (GAD) |
| I-525 | USE OF 0.5MG/0.1MG FOR PREVENTION OF POST-MENOPAUSAL OSTEOPOROSIS |
| I-526 | TREATMENT OF HYPONATREMIA IN HOSPITALIZED PATIENTS |
| I-527 | ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY |
| I-528 | TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY ASSOCIATED WITH MENOPAUSE |
| I-529 | TREATMENT OF DEMENTIA OF THE ALZHEIMER'S TYPE IN PATIENTS WITH SEVERE ALZHEIMER'S DISEASE |
| I-530 | PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION IN PATIENTS 15 YEARS OF AGE AND OLDER |
| I-531 | MAINTENANCE TREATMENT OF SCHIZOPHRENIA |
| I-532 | TREATMENT OF BACTERIAL VAGINOSIS IN NON-PREGNANT FEMALES |
| I-533 | ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI) |
| I-534 | EXTENDED TREATMENT OF SYMPTOMATIC VENOUS THROMBOEMBOLISM (VTE) AND/OR PULMONARY EMBOLISM TO REDUCE THE RECURRENCE OF VTE IN PATIENTS WITH CANCER |
| I-535 | MANAGEMENT OF FIBROMYALGIA |
| I-536 | FOR THE TREATMENT OF SHORT STATURE IN CHILDREN WITH NOONAN SYNDROME |
| I-537 | LONG TERM TREATMENT OF PANIC DISORDER |
| I-538 | SHORT TERM TREATMENT OF PANIC DISORDER |
| I-539 | REDUCTION IN RISK OF INVASIVE BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS OR AT HIGH RISK FOR INVASIVE BREAST CANCER |
| I-540 | TREATMENT OF SCHIZOPHRENIA IN ADOLESCENTS AGES 13-17 |
| I-541 | TREATMENT OF BIPOLAR I DISORDER IN CHILDREN AGES 10-12 AND ADOLESCENTS AGES 13-17 |
| I-542 | EXPANSION OF PATIENT POPULATION FOR HEAD AND NECK CANCER FROM "INOPERABLE" PATIENTS TO ALL PATIENTS |

**EXCLUSIVITY INDICATION**

| | |
|---|---|
| I-543 | USE IN COMBINATION WITH CISPLATIN AND FLUOROURACIL FOR THE INDUCTION TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) |
| I-544 | ADJUNCTIVE THERAPY OF MYOCLONIC SEIZURES IN ADULTS AND ADOLESCENTS AGE 16 AND OVER WITH JUVENILE MYOCLONIC EPILEPSY |
| I-545 | ADJUNCTIVE TREATMENT TO TREAT PATIENTS WITH MAJOR DEPRESSIVE DISORDER |
| I-546 | TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA |
| I-547 | ADJUNCTIVE THERAPY TO DIET TO SLOW THE PROGRESSION OF ARTHEROSCLEROSIS IN ADULT PATIENTS AS PART OF A TREATMENT STRATEGY TO LOWER TOTAL-C AND LDL-C TO TARGET LEVELS |
| I-548 | SEASONAL ALLERGIC RHINITIS IN PATIENTS 6 THROUGH LESS THAN 12 YEARS OF AGE |
| I-549 | USE OF AVALIDE TABLETS AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS |
| I-550 | TREATMENT OF HYPERTENSION IN PEDIATRIC PATIENTS 6-16 YEARS OF AGE |
| I-551 | TREATMENT OF SHORT STATURE IN CHILDREN WITH TURNER'S SYNDROME |
| I-552 | ADJUNCTIVE TREATMENT FOR RADIOIODINE ABLATION OF THYROID TISSUE REMNANTS IN PATIENTS WHO HAVE UNDERGONE THYROIDECTOMY FOR WELL-DIFFERENTIATED THYROID CANCER AND WHO DO NOT HAVE EVIDENCE OF METASTATIC THYROID CANCER |
| I-553 | FOR USE AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS |
| I-554 | TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES |
| I-555 | TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER IN PEDIATRIC PATIENTS AGED 10-17 YEARS |
| I-556 | PREVENTION OF POST OPERATIVE NAUSEA AND VOMITING FOR UP TO 24 HOURS FOLLOWING SURGERY |
| I-557 | USE OF AMITIZA (LUBIPROSTONE) 8 MCG TWICE DAILY FOR TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN WOMEN GREATER THAN OR EQUAL TO 18 YEARS OLD |
| I-558 | MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION AND REDUCING EXACERATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA |
| I-559 | ADJUNCTIVE THERAPY ADDED TO LITHIUM OR VALPROATE IN SHORT TERM TREATMENT OF BIPOLAR DISORDER, MANIC OR MIXED |
| I-560 | MAINTENANCE TREATMENT FOR BIPOLAR I DISORDER, AS ADJUNCTIVE THERAPY TO LITHIUM OR DIVALPROEX |
| I-561 | LONG-TERM TREATMENT OF SOCIAL ANXIETY DISORDER |
| I-562 | MAINTENANCE TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS |
| I-563 | ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SIEZURES IN ADULTS AND CHILDREN 16 YEARS OF AGE AND OLDER WITH IDIOPATHIC GENERALIZED EPILEPSY |
| I-564 | TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA |
| I-565 | USE OF DUTASTERIDE IN COMBINATION WITH TAMSULOSIN FOR THE TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH) |
| I-566 | MANAGEMENT OF FIBROMYALGIA |
| I-567 | INITIAL THERAPY IN PATIENTS LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS |
| I-568 | USE OF APTIVUS, CO-ADMINISTERED W/RITONAVIR, FOR COMBINATION ANTIRETROVIRAL TREATMENT OF HIV-1 INFECTED PED (AGE 2-18 YRS) PATIENTS WHO ARE TREATMENT-EXPERIENCED AND INFECTED W/HIV-1 STRAINS RESISTANT TO MORE THAN ONE PROTEASE INHIBITOR |
| I-569 | TREATMENT OF CHRONIC HEPATITIS B |
| I-570 | TREATMENT OF CHICKEN POX IN IMMUNOCOMPETENT PEDIATRIC PATIENTS 2 TO <18 YEARS OF AGE |
| I-571 | NON-SMALL CELL LUNG CANCER IN COMBINATION WITH CISPLATIN AND AS SINGLE AGENT FOR NONSQAUMOUS NON-SMALL CELL LUNG CANCER |

**EXCLUSIVITY INDICATION**

| | |
|---|---|
| I-572 | TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE (SGA) WITH NO CATCH-UP BY AGE 2-4 YRS. |
| I-573 | TO TREAT PATIENTS WITH PRIMARY DYSBETALIPOPROTEINEMIA (FREDRICKSON TYPE III HYPERLIPOPROTEINEMIA) AS AN ADJUNCT TO DIET |
| I-574 | MONOTHERAPY IN THE TREATMENT OF BIPOLAR DEPRESSION |
| I-575 | MONOTHERAPY IN THE TREATMENT OF BIPOLAR MANIA |
| I-576 | ADJUNCTIVE THERAPY IN THE TREATMENT OF BIPOLAR MANIA |
| I-577 | SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES |
| I-578 | EXPANSION OF INDICATION TO INCLUDE TREATMENT OF HIV IN TREATMENT NAIVE ADULTS |
| I-579 | TREATMENT OF MODERATE TO SEVERE DYSPAREUNIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE AND NEW TWICE WEEKLY DOSING REGIMEN FOR THIS INDICATION |
| I-580 | INDOLENT B-CELL NON-HODGKINS LYMPHOMA (NHL) THAT HAS PROGRESSED DURING OR WITHIN SIX MONTHS OF TREATMENT WITH RITUXIMAB OR A RITUXIMAB CONTAINING REGIMEN |
| I-581 | TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS |
| I-582 | TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
| I-583 | ADJUVANT TREATMENT OF ADULT PATIENTS FOLLOWING COMPLETE GROSS RESECTION OF KIT (CD117) POSITIVE GASTOINTESTINAL STROMAL TUMORS (GIST) |
| I-584 | TREATMENT AND PREVENTION OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS IN PATIENTS EXPECTED TO BE ON GLUCOCORTICOIDS FOR AT LEAST 12 MONTHS |
| I-585 | TREATMENT OF SHORT STATURE IN PEDIATRIC PATIENTS SMALL FOR GESTATIONAL AGE WHO DO NOT MANIFEST CATCH UP GROWTH BY AGE 2 TO 4 YEARS |
| I-586 | COMMUNITY ACQUIRED BACTERIAL PNEUMONIA |
| I-587 | ADDITIONAL PATHOGENS TO COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS INDICATION |
| I-588 | ADDITIONAL PATHOGENS TO COMPLICATED INTRA-ABDOMINAL INFECTIONS INDICATION |
| I-589 | TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH OLANZAPINE |
| I-590 | ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH OLANZAPINE) |
| I-591 | TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) IN COMBINATION WITH FLUOXETINE |
| I-592 | ACUTE TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER (IN COMBINATION WITH FLUOXETINE) |
| I-593 | TREATMENT OF TREATMENT RESISTANT DEPRESSION (TRD) |
| I-594 | INDICATION EXPANDED TO INCLUDE PATIENTS WHO HAVE EXPERIENCED A FIRST CLINICAL EPISODE AND HAVE MRI FEATURES CONSISTENT WITH MULTIPLE SCLEROSIS |
| I-595 | PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN |
| I-596 | USE AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER |
| I-597 | MONOTHERAPY FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER |
| I-598 | TREATMENT OF PULMONARY ARTERIAL HYPERTENSION INDICATION EXPANDED TO INCLUDE DELAY IN CLINICAL WORSENING |
| I-599 | PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS |
| I-600 | FOR USE AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS |
| I-601 | MAINTENANCE TREATMENT IN PATIENTS WITH ADVANCED OR METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST LINE CHEMOTHERAPY |
| I-602 | TREATMENT OF MEN AND WOMEN WITH OSTEOPOROSIS ASSOCIATED WITH SUSTAINED SYSTEMIC GLUCOCORTICOID THERAPY AT HIGH RISK FOR FRACTURE |
| I-603 | GOUT FLARES |
| I-604 | PREVENTION OF CMV DISEASE IN KIDNEY AND HEART TRANSPLANT PATIENTS 4 MONTHS TO 16 |

**EXCLUSIVITY INDICATION**

| | |
|---|---|
| | YEARS AT HIGH RISK |
| I-605 | ADJUNCT TO MOOD STABILIZERS AND/OR ANTIDEPRESSANTS FOR SCHIZOAFFECTIVE DISORDER |
| I-606 | TREATMENT OF SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY |
| I-607 | INDICATION EXPANDED TO INCLUDE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP I) IN PATIENTS WITH CLASS II SYMPTOMS |
| I-608 | REDUCE LDL-C LEVELS IN BOYS AND POSTMENARCHAL GIRLS, 10 TO 17 YEARS OF AGE, WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AS MONOTHERAPY OR IN COMBINATION WITH A STATIN AFTER FAILING AN ADEQUATE TRIAL OF DIET THERAPY |
| I-610 | TREATMENT OF HEAVY MENSTRUAL BLEEDING FOR WOMEN WHO CHOOSE TO USE INTRAUTERINE CONTRACEPTION AS THEIR METHOD OF CONTRACEPTION |
| I-611 | TREATMENT OF HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA IN ADOLESCENT BOYS AND POSTMENARCHAL GIRLS, AGES 10 TO 17 YEARS, WITH A RECOMMENDATION DOSING RANGE OF 5 TO 20 MG ONCE DAILY |
| I-612 | MICARDIS 80 MG FOR REDUCTION OF THE RISK OF MYOCARDIAL INFARCTION, STROKE, OR DEATH FROM CARDIOVASCULAR CAUSES IN PATIENTS 55 YEARS OF AGE OR OLDER AT HIGH RISK OF DEVELOPING MAJOR CARDIOVASCULAR EVENTS WHO ARE UNABLE TO TAKE ACE INHIBITORS |
| I-613 | MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE TO LESS THAN 18 YEARS OF AGE |
| I-614 | SHORT TERM TREATMENT OF EROSIVE ESOPHAGITIS ASSOCIATED WITH GERD IN PEDIATRIC PATIENTS AGES FIVE YEARS AND OLDER |
| I-615 | MAINTENANCE TREATMENT OF BIPOLAR DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE |
| I-616 | TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17 YEARS OF AGE |
| I-617 | MAINTENANCE OF GENERALIZED ANXIETY DISORDER (GAD) |
| I-618 | ADJUNCTIVE THERAPY IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) |
| I-619 | INTRAVENOUS CONTRAST ENHANCED COMPUTER TOMOGRAPHY OF THE HEAD AND BODY |
| I-620 | FOR USE IN COMBINATION WITH LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER THAT OVEREXPRESSES THE HER2 RECEPTOR FOR WHOM HORMONAL THERAPY IS INDICATED |
| I-621 | PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE, BASED ON THE RESULTS OF JUSTIFICATION FOR THE USE OF STATINS IN PRIMARY PREVENTION; AN INTERVENTION TRIAL EVALUATING ROSUVASTATIN (JUPITER) |
| I-622 | ADJUNCTIVE THERAPY FOR PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS THIRTEEN YEARS OF AGE AND OLDER |
| I-623 | TREATMENT OF SIGNS AND SYMPTOMS OF ADVANCED IDIOPATHIC PARKINSON'S DISEASE |
| I-624 | MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST-LINE CHEMOTHERAPY |
| I-625 | PANCREATIC INSUFFICIENCY DUE TO CHRONIC PANCREATITIS AND PANCREATECTOMY |
| I-626 | RELIEF OF NASAL CONGESTION ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATENTS 2 YEARS OF AGE AND OLDER |
| I-627 | TREATMENT OF NEWLY DIAGNOSED ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH & CML) IN CHRONIC PHASE. |
| I-628 | MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN ADULTS |
| I-629 | ADJUNCTIVE THERAPY WITH EITHER LITHIUM OR VALPROATE FOR THE ACUTE TREATMENT OF MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER |
| I-630 | TREATMENT OF PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBEROUS SCLEROSIS (TS) WHO REQUIRE THERAPEUTIC INTERVENTION BUT ARE NOT CANDIDATES FOR CURATIVE SURGICAL RESECTION. |
| I-631 | PREVENTION OF RELAPSE TO OPIOID DEPENDENCE FOLLOWING OPIOID DETOXIFICATION |
| I-632 | MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN |
| I-633 | MAINTENANCE TREATMENT OF BIPOLAR I DISORDER AS AN ADJUNCT TO LITHIUM OR VALPROATE |
| I-634 | TREATMENT OF SEVERE HYPERCALCEMIA IN PATIENTS WITH PRIMARY HYPERPARATHYROIDISM WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY |

**EXCLUSIVITY INDICATION**

| | |
|---|---|
| I-635 | ADJUNCTIVE TREATMENT WITH LONG-ACTING ORAL PSYCHOSTIMULANTS FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
| I-636 | TREATMENT OF EXTERNAL GENITAL AND PERIANAL WARTS/CONDYLOMA ACUMINATA IN PATIENTS 12 YEARS OR OLDER |
| I-637 | USE IN COMBINATION CHEMOTHERAPY WITH 5-FLUOROURACIL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED METASTATIC COLORECTAL CANCER |
| I-638 | FOR PATIENTS WITH PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC. |
| I-639 | TREATMENT OF PROGRESSIVE, WELL-DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMORS IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED, OR METASTATIC DISEASE |
| I-640 | MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS |
| I-641 | TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH) |
| I-642 | TREATMENT OF ERECTILE DYSFUNCTION (ED) AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH) |
| I-643 | REDUCE THE RISK OF STROKE AND SYSTEMIC EMBOLISM IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION. |
| I-644 | MONOTHERAPY IN PATIENTS 13 YEARS OF AGE AND OLDER WITH PARTIAL SEIZURES WHO ARE RECEIVING THERAPY WITH A SINGLE ANTIEPILEPTIC DRUG (AED) |
| I-645 | MAINTENANCE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS |
| I-646 | SIGNS AND SYMPTOMS OF ADVANCED PARKINSON'S DISEASE (APD) |
| I-647 | SIGNS AND SYMPTOMS OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS) |
| I-648 | TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION |
| I-649 | TREATMENT OF PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (STS) WHO HAVE RECEIVED PRIOR CHEMOTHERAPY |
| I-650 | TREATMENT OF ADULTS WITH RENAL ANGIOMYOLIPOMA AND TUBEROUS SCLEROSIS COMPLEX (TSC), NOT REQUIRING IMMEDIATE SURGERY |
| I-651 | MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH SPINAL CORD INJURY |
| I-652 | MANAGEMENT OF POSTHERPETIC NEURALGIA |
| I-653 | TREATMENT OF ENDOGENOUS ANTERIOR UVEITIS |
| I-654 | MAGNETIC RESONANCE ANGIOGRAPHY (MRA) TO EVALUATE ADULTS WITH KNOWN OR SUSPECTED RENAL OR AORTO-ILIO-FEMORAL OCCLUSIVE VASCULAR DISEASE |
| I-655 | TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED HORMONE RECEPTOR-POSITIVE,HER2-NEGATIVE BREAST CANCER (ADVANCED HR+BC) IN COMBINATION WITH EXEMESTANE, AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE |
| I-656 | MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY (DPN) IN ADULTS WHEN A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME |
| I-657 | PLAQUE PSORIASIS OF THE SCALP |
| I-658 | FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER, IN COMBINATION WITH CARBOPLATIN, IN PATIENTS WHO ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION THERAPY |
| I-659 | PLAQUE PSORIASIS OF THE BODY |
| I-660 | TREATMENT OF DEEP VEIN THROMBOSIS |
| I-661 | TREATMENT OF PULMONARY EMBOLISM |
| I-662 | REDUCTION IN RISK FOR DEEP VEIN THROMBOSIS AND THE REDUCTION IN RISK FOR PULMONARY EMBOLISM |
| I-663 | IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER |
| I-664 | TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY |
| I-665 | TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS 10 YRS OF AGE AND OLDER WITH (NTDT)SYNDROMES AND WITH A (LIC) OF AT LEAST 5 MG OF IRON PER GRAM OF LIVER DRY WEIGHT (MG FE/G DW) AND SERUM FERRITIN GREATER THAN 300MCG/L |

**EXCLUSIVITY INDICATION**

I-666 TREATMENT OF PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL) IN COMBINATION WITH CHEMOTHERAPY

I-667 TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE BEEN PREVIOUSLY TREATED WITH IMATINIB MESYLATE AND SUNITINIB MALATE

I-668 PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT

I-669 SCINTIGRAPHIC ASSESSMENT OF SYMPATHETIC INNERVATION OF THE MYOCARDIUM BY MEASUREMENT OF THE HEART TO MEDIASTINUM (H/M) RATIO OF RADIOACTIVITY UPTAKE IN PATIENTS WITH NYHA CLASS II OR CLASS III HEART FAILURE AND LVEF LESS THAN 35%

I-670 TREATMENT OF OPIOID-INDUCED CONSTIPATION (OIC) IN ADULTS WITH CHRONIC, NON-CANCER PAIN

I-671 FIRSTLINE TREATMENT OF PATIENTS WITH METASTATIC NON- SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21(L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST

I-672 USE IN PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB

I-673 TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA/VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP/VABP) CAUSED BY SUSCEPTIBLE ISOLATES OF S. AUREUS (INCLUDING METHICILLIN-SUSCEPTIBLE AND RESISTANT ISOLATES) WHEN ALTERNATIVE TREATMENTS ARE NOT SUITABLE

I-674 TREATMENT OF PATIENTS WITH DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION) AS MONOTHERAPY AND AS ADJUNCTIVE THERAPY WITH LITHIUM OR VALPROATE

I-675 MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER

I-676 FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC ADENOCARACINOMA OF THE PANCREAS, IN COMBINATION WITH GEMCITABINE

I-677 TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA (DTC) THAT IS REFRACTORY TO RADIOACTIVE IODINE TREATMENT

I-678 TRAMETINIB, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST

I-679 RISK REDUCTION OF REBLEEDING OF GASTRIC OR DUODENAL ULCERS FOLLOWING THERAPEUTIC ENDOSCOPY IN ADULTS

I-680 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY

I-681 PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT) WHICH MAY LEAD TO PULMONARY EMBOLISM (PE), IN ADULT PATIENTS WHO HAVE UNDERGONE HIP OR KNEE REPLACEMENT

I-682 TREATMENT OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) IN PATIENTS WHO HAVE BEEN TREATED WITH A PARENTERAL ANTICOAGULANT FOR 5-10 DAYS

I-683 TO REDUCE THE RISK OF RECURRENCE OF DVT AND PE IN PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED

I-684 PREVENTION OF ACUTE NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF EMETOGENIC CANCER CHEMOTHERAPY, INCLUDING HIGHLY EMETOGENIC CANCER CHEMOTHERAPY IN PEDIATRIC PATIENTS AGED 1 MONTH TO LESS THAN 17 YEARS

I-685 EXPANDED INDICATION OF RASAGILINE AS AN ADD-ON THERAPY TO STABLE DOSES OF DOPAMINE AGONISTS IN THE TREATMENT OF EARLY PARKINSON'S DISEASE

I-686 INDICATED FOR THE TREATMENT OF DIABETIC MACULAR EDEMA IN PATIENTS WHO ARE PSEUDOPHAKIC OR ARE PHAKIC AND SCHEDULED FOR CATARACT SURGERY

I-687 GUIDING SENTINEL LYMPH NODE BIOPSY, USING A HAND-HELD GAMMA COUNTER IN PATIENTS WITH CLINICALLY NODE NEGATIVE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY

I-688 GADAVIST IS INDICATED WITH MRI TO DETECT THE PRESENCE AND EXTENT OF MALIGNANT BREAST DISEASE

I-689 TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION

I-690 INDICATED FOR THE TREATMENT OF DEEP VEIN THROMBOSIS (DVT)

I-691 INDICATED TO REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT) AND

**EXCLUSIVITY INDICATION**

PULMONARY EMBOLISM (PE) FOLLOWING INITIAL THERAPY

I-692 INDICATED FOR MANAGEMENT OF OSTEOARTHRITIS PAIN.

I-693 TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC)

I-694 TREATMENT OF PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WHO ARE CANDIDATES FOR PHOTOTHERAPY OR SYSTEMIC THERAPY

I-695 REVISED INDICATION FOR BORTEZOMIB IN THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA

I-696 USE AS MONOTHERAPY IN THE TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGE 17 YEARS AND OLDER

I-697 FOR USE IN COMBINATION WITH SOFOSBUVIR FOR THE TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1 INFECTION

I-698 SCHIZOAFFECTIVE DISORDER AS MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS

I-699 FOR TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA

I-700 TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S DISORDER (6-18 YEARS)

I-701 FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE, WELL-OR MODERATELY-DIFFERENTIATED, LOCALLY ADVANCED OR METASTATIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETS) TO IMPROVE PROGRESSION FREE SURVIVAL

I-702 FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA

I-703 MODERATE TO SEVERE BINGE EATING DISORDER (BED)

I-704 EXPANDED INDICATION TO INCLUDE PATIENTS WHO ARE VIROLOGICALLY-SUPPRESSED (HIV-1 RNA <50 COPIES/ML) ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS WITH NO HISTORY OF TREATMENT FAILURE IN ORDER TO REPLACE THEIR CURRENT REGIMEN

I-705 TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 6 YEARS AND OLDER WHO HAVE AN R117H MUTATION IN THE CFTR GENE

I-706 EXPANDED INDICATION FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA

I-707 POMALYST, IN COMBINATION WITH DEXAMETHASONE, IS INDICATED FOR PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 2 PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY

I-708 DAILY TREATMENT OF ASTHMA IN PATIENTS AGED 18 YEARS AND OLDER

I-709 TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS

I-710 ADJUNCTIVE THERAPY FOR THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC (PG TC) SEIZURES IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE OR OLDER.

I-711 INCLUSION OF PEDIATRIC PATIENTS AGES 6 YRS AND OLDER FOR THE TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC ITP WHO HAVE HAD AN INSUFFICIENT RESPONSE TO CORTICOSTEROIDS, IMMUNOGLOBULINS, OR SPLENECTOMY.

I-712 EXPANDED INDICATION FOR USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE PRIOR LINES OF THERAPY

I-713 REVISIONS TO THE LABELING TO PERMIT THE USE OF ZUBSOLV AS INITIAL ("INDUCTION") TREATMENT OF OPIOID DEPENDENCE

I-714 EXTENDS THE 2011 APPROVAL OF BRILINTA FOR USE BEGINNING WITH ACS TO USE BEGINNING MORE REMOTE FROM MYOCARDIAL INFRACTION

I-715 FOR THE ADDITION OF THE INDICATION FOR MONOTHERAPY TREATMENT IN PARTIAL-ONSET SEIZURES IN ADULTS.

I-716 REVISED INDICATION TO INCLUDE LANGUAGE ABOUT THE BENEFITS OF USING LETAIRIS IN COMBINATION WITH TADALAFIL TO REDUCE THE RISK OF DISEASE PROGRESSION AND HOSPITALIZATION FOR WORSENING PAH AND TO IMPROVE EXERCISE ABILITY, BASED ON THE AMBITION STUDY

I-717 EXPANDED INDICATION TO INCLUDE THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 4

I-718 EXPANDED INDICATION TO INCLUDE SUBJECTS INFECTED WITH CHRONIC HEPATITIS C, GENOTYPE 6 VIRUS INFECTION BASED UPON THE RESULTS OF THE ELECTRON- 2 STUDY

I-719 EXPANDED INDICATION TO INCLUDE THE TREATMENT OF SUBJECTS WITH GENOTYPE 5 CHRONIC HEPATITIS C VIRUS INFECTION BASED ON THE RESULTS FROM STUDY GS-US-337-119.

**EXCLUSIVITY INDICATION**

I-720 EXPANDED INDICATION TO INCLUDE TREATMENT OF GENOTYPE 4, CHRONIC HEPATITIS C VIRUS INFECTION BASED UPON THE RESULTS FROM STUDIES ION-4 AND GS-US-337-119.

I-721 TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA WHO HAVE RECEIVED A PRIOR ANTHRACYCLINE-CONTAINING REGIMEN.

I-722 REVISED INDICATION FOR USE IN COMBINATION WITH DEXAMETHASONE OR WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY.

I-723 AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE OR MORE LINES OF THERAPY

I-724 TREATMENT OF ADULT PATIENTS WITH PROGRESSIVE, WELL DIFFERENTIATED, NON-FUNCTIONAL NEUROENDOCRINE TUMORS (NET) OF GI OR LUNG ORIGIN WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE

I-725 TREATMENT OF HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION THERAPY WITH PALBOCICLIB AND FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY.

I-726 EXPANSION OF THE PATIENT POPULATION TO INCLUDE PATIENTS WITH RECURRENCE OF HEPATITIS C VIRUS (HCV) GENOTYPE 1 OR 3 AFTER LIVER TRANSPLANTATION

I-727 EXPANSION OF THE INDICATION TO INCLUDE TREATMENT OF SUBJECTS WITH GENOTYPE-1 CHRONIC HEPATITIS C VIRUS INFECTION, INCLUDING SUBJECTS WHO ARE CO-INFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS (HIV-1) BASED ON THE RESULTS FROM THE ALLY-2 CLINICAL TRIAL

I-728 EXPANDED INDICATION FOR USE IN ULTRASONOGRAPHY OF THE LIVER FOR CHARACTERIZATION OF FOCAL LIVER LESIONS IN ADULT AND PEDIATRIC PATIENTS

I-729 PROVIDES FOR THE FRONTLINE INDICATION FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

I-730 NEW INDICATION FOR THE TREATMENT OF PATIENTS WITH METASTATIC, SQUAMOUS, NON-SMALL CELL LUNG CANCER PROGRESSING AFTER PLATINUM-BASED CHEMOTHERAPY

I-731 FOR USE IN MAGNETIC RESONANCE ANGIOGRAPHY IN ADULT AND PEDIATRIC PATIENTS (INCLUDING TERM NEONATES) TO EVALUATE KNOWN OR SUSPECTED SUPRA-AORTIC OR RENAL ARTERY DISEASE

I-732 TREATMENT OF PEDIATRIC PATIENTS 7 TO 17 YEARS OF AGE WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA TO REDUCE LDL-C, TOTAL C, NONHDL-C AND APOB AS AN ADJUNCT TO DIET, EITHER ALONE OR WITH OTHER LIPID-LOWERING TREATMENTS

I-733 USE OF CANAGLIFLOZIN FOR INITIAL THERAPY IN COMBINATION WITH METFORMIN

I-734 EXPANDED INDICATION FOR THE USE OF LENVIMA IN COMBINATION WITH EVEROLIMUS FOR THE TREATMENT OF PATIENTS WITH ADVANCED RCC FOLLOWING ONE PRIOR ANTI-ANGIOGENIC THERAPY.

I-735 AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH CANAGLIFLOZIN AND METFORMIN IS APPROPRIATE

I-736 REVISED INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA (SLL)

I-737 REVISED INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA (SLL) WITH 17P DELETION

I-738 REVISIONS TO THE INDICATIONS AND USAGE SECTION WITH RESPECT TO COMPLICATED INTRA-ABDOMINAL INFECTIONS

I-739 TO REDUCE THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE

I-740 EXPANDED INDICATION FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 6 YEARS AND OLDER TO INCLUDE THE G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, OR S549R MUTATION IN THE CFTR GENE

I-741 TREATMENT OF PATIENTS WITH MARGINAL ZONE LYMPHOMA (MZL) WHO REQUIRE SYSTEMIC THERAPY AND HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED THERAPY

I-742 TREATMENT OF NODAL MARGINAL ZONE LYMPHOMA

I-743 INFORMATION ADDED TO THE LABELING FOR THE ADDITION OF THE TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 4 (GT4) INFECTED PATIENTS WITH COMPENSATED CIRRHOSIS BASED ON RESULTS FROM STUDY M11-665

I-744 TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB

**EXCLUSIVITY INDICATION**

| | |
|---|---|
| I-745 | MEKINIST, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST. |
| I-746 | NEW INDICATION OF MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER IN ADULTS |
| I-747 | FOR REDUCING THE RISK OF GRAFT REJECTION WHEN USED WITH HIGH-DOSE BUSULFAN AND CYCLOPHOSPHAMIDE AS A PREPARATIVE REGIMEN FOR ALLOGENEIC HEMATOPOIETIC PROGENITOR (STEM) CELL TRANSPLANTATION FOR PEDIATRIC PATIENTS WITH CLASS 3 BETA-THALASSEMIA |
| I-748 | TO REDUCE THE ACUTE COMPLICATIONS OF SICKLE CELL DISEASE IN ADULT AND PEDIATRIC PATIENTS FIVE YEARS OF AGE AND OLDER |
| I-749 | MONOTHERAPY FOR THE TREATMENT OF HORMONE RECEPTOR (HR) POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE, ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN NOT PREVIOUSLY TREATED WITH ENDOCRINE THERAPY |
| I-750 | REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE |
| I-751 | TREATMENT OF TARDIVE DYSKINESIA |
| I-752 | CORONARY COMPUTED TOMOGRAPHY ANGIOGRAPHY (CCTA) TO ASSIST DIAGNOSTIC EVALUATION OF PATIENTS WITH SUSPECTED CORONARY ARTERY DISEASE |
| I-753 | TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY |
| I-754 | TO REDUCE THE FREQUENCY OF SHORT-ACTING SOMATOSTATIN ANALOG RESCUE THERAPY WHEN USED FOR THE TREATMENT OF ADULTS WITH CARCINOID SYNDROME |
| I-755 | ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RENAL CELL CARCINOMA (RCC) FOLLOWING NEPHRECTOMY |
| I-756 | EXPANDED THE APPROVED INDICATION BY REMOVING THE RESTRICTION FOR USE ONLY IN PATIENTS WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB |
| I-757 | TREATMENT OF PATIENTS WITH ERDHEIM-CHESTER DISEASE WITH BRAF V600 MUTATION |
| I-758 | FOR USE WITH RILPIVIRINE AS A COMPLETE REGIMEN TO REPLACE THE CURRENT ARV REGIMEN IN VIROLOGICALLY SUPPRESSED PATIENTS ON A STABLE ARV REGIMEN FOR AT LEAST 6 MONTHS WITH NO HISTORY OF TX FAILURE OR KNOWN SUBSTITUTIONS ASSOC. WITH RESISTANCE TO EITHER ARV |
| I-759 | TREATMENT OF ADULT PATIENTS WITH NEWLY-DIAGNOSED CHRONIC PHASE (CP) PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (PH+CML) |
| I-760 | FOR THE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA |
| I-761 | TREATMENT OF ADULT PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO METHOTREXATE OR OTHER NON-BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS |

**EXCLUSIVITY MISCELLANEOUS**

| | |
|---|---|
| M-1 | INFORMATION REGARDING SUPERIORITY CLAIM OVER RANITIDINE FOR DAY AND NIGHT HEARTBURN ADDED TO CLINICAL STUDIES SECTION |
| M-2 | APPROVAL FOR ADDITION TO CLINICAL PHARMACOLOGY SECTION OF THE LABEL REGARDING (1) IMPROVEMENT IN BONE MINERAL DENSITY IN CHILDHOOD-ONSET ADULT GROWTH HORMONE DEFICIENT PATIENTS AND (2) INCREASES IN SERUM ALKALINE PHOSPHATASE |
| M-3 | ADDITION OF EFFICACY AND SAFETY INFORMATION IN WHICH FOSAMAX WAS USED CONCOMITANTLY WITH ESTROGEN ALONE OR WITH ESTROGEN PLUS PROGESTIN |
| M-4 | CHANGES TO PEDIATRIC USE SECTION TO PROVIDE INFORMATION REGARDING SAFETY AND EFFICACY IN PEDIATRIC PATIENTS AS YOUNG AS 2 YEARS OLD |
| M-5 | INFORMATION REGARDING EFFECTS IN PATIENTS WITH ASTHMA ON CONCOMITANT INHALED CORTICOSTEROIDS IN CLINICAL PHARMACOLOGY SECTION |
| M-6 | ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUCOPHAGE/GLYBURIDE COMBINATION ADDED TO CLINICAL PHARMACOLOGY AND DOSING AND ADMINISTRATION |
| M-7 | CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION |
| M-8 | ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING |

**EXCLUSIVITY MISCELLANEOUS**

| | |
|---|---|
| M-9 | ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY |
| M-10 | INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING |
| M-11 | USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER |
| M-12 | NEW LANGUAGE FOR PEDIATRIC USE |
| M-13 | INFORMATION FROM PEDIATRIC STUDIES ADDED TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION |
| M-14 | ADDITIONAL CLINICAL TRIAL INFORMATION ADDED TO PEDIATRIC USE SUBSECTION |
| M-15 | LONGER TERM EFFICACY INFORMATION FOR RISPERIDONE IN THE TREATMENT OF SCHIZOPHRENIA |
| M-16 | CHANGE IN WORDING OF THE PEDIATRIC SECTION OF THE PACKAGE INSERT |
| M-17 | INFORMATION REGARDING USE OF ULTANE IN PEDIATRIC PATIENTS WITH CONGENITAL HEART DISEASE |
| M-18 | INFORMATION DENOTING THE EFFICACY OF REMERON IN MAINTAINING A RESPONSE IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD) |
| M-19 | INFORMATION REGARDING USE IN PEDIATRIC PATIENTS TWO YEARS OF AGE AND OLDER |
| M-20 | LABELING REVISIONS RELATED TO MCCUNE ALBRIGHT SYNDROME |
| M-21 | COMPARISON DATA ON THE ANTIHYPERTENSIVE EFFECTS OF ATACAND AND COZAAR |
| M-22 | CHANGE IN TIME TO ONSET OF ACTION |
| M-23 | INFORMATION REGARDING ELIMINATION ADDED TO CLINICAL PHARMACOLOGY, STUDY RESULTS IN PATIENTS WITH HEPATIC AND RENAL IMPAIRMENT |
| M-24 | INFORMATION ON RESULTS OF A LONG TERM LONGITUDINAL GROWTH STUDY AND PEDIATRIC SAFETY INFORMATION |
| M-25 | ADDITIONAL SAFETY AND PHARMACOKINETICS INFORMATION IN CHILDREN 6 MONTHS TO LESS THAN 6 YEARS OF AGE ADDED TO PACKAGE INSERT |
| M-26 | INCORPORATION OF INFORMATION CONTAINED IN THE PEG-INTRON PACKAGE INSERT INTO THE REBETOL PACKAGE INSERT AND MEDGUIDE-PEG-INTRON WAS APPROVED FOR USE IN COMBINATION WITH REBETOL FOR TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION ON 8/7/01 |
| M-27 | INFORMATION DESCRIBING ASPIRIN ENDOSCOPY STUDY AND THE MAXIMUM RECOMMENDED DOSE FOR PATIENTS WITH MODERATE HEPATIC INSUFFICIENCY |
| M-28 | INFORMATION FROM A STUDY IN PEDIATRIC PATIENTS IN ASSOCIATION WITH A NEUROLOGICAL CONDITION |
| M-29 | LABELING CHANGES TO PROVIDE INFORMATION IN THE MANAGEMENT OF OBESITY IN ADOLESCENTS AGED 12 TO 16 YEARS |
| M-30 | CHANGES TO CLINICAL PHARMACOLOGY, PRECAUTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS OF LABELING CONCERNING USE OF LOTENSIN IN PEDIATRIC PATIENTS WITH HYPERTENSION |
| M-31 | INFORMATION FOR USE IN PEDIATRIC PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE 5 (END-STAGE RENAL DISEASE) |
| M-32 | ADDITIONAL LANGUAGE TO CLINICAL PHARMACOLOGY AND CLINICAL STUDIES |
| M-33 | INFORMATION FOR USE OF ADVAIR DISKUS 100/50 IN CHILDREN 4 TO 11 YEARS OF AGE WITH ASTHMA |
| M-34 | EXPANDED INFORMATION TO PEDIATRIC USE SUBSECTION OF LABELING IN RESPONSE TO PEDIATRIC WRITTEN REQUEST |
| M-35 | ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH ACTOS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, OR INSULIN ADDED TO CLINICAL PHARMACOLOGY |
| M-36 | ADDITION OF INFORMATION TO CLINICAL STUDIES REGARDING PREVENTION OF CARDIOVASCULAR DISEASE |
| M-37 | INFORMATION ADDED TO THE LABELING THAT DETAILS INFORMATION RELATIVE TO STUDIES DONE IN PEDIATRIC POPULATIONS IN THE CLINICAL PHARMACOLOGY AND PEDIATRIC USE SUBSECTIONS |
| M-38 | SAFETY AND IOP-LOWERING EFFECTS OF TRUSOPT HAVE BEEN DEMONSTRATED IN PEDIATRIC PATIENTS IN A 3 MONTH, MULTI-CENTER DOUBLE MASKED ACTIVE-TREATMENT-CONTROLLED |

**EXCLUSIVITY MISCELLANEOUS**

| | |
|---|---|
| | TRIAL |
| M-39 | FOR LABELING CHANGES BASED ON RESULTS OF THE SPD422-202 CLINICAL STUDY REPORT (CSR) SUBMITTED IN RESPONSE TO THE WRITTEN REQUEST |
| M-40 | ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED IN PEDIATRIC PATIENTS WITH LEUKEMIA ADDED TO PRECAUTIONS |
| M-41 | REVISION TO THE PEDIATRIC USE PRECAUTIONS OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM THE CAPPS-169 STUDY ENTITLED "THE EFFECT OF ORTHO TRICYCLEN ON BONE MINERAL DENSITY IN PEDIATRIC SUBJECTS WITH ANOREXIA NERVOSA" |
| M-42 | ADDITION OF A GERIATRIC USE SUBSECTION TO THE PRECAUTIONS SECTION OF THE PACKAGE INSERT AND GERIATRIC DOSING INFORMATION |
| M-43 | INCLUSION OF RESULTS OF STUDY "PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY AND PILOT EFFICACY OF ILOPROST AS ADD ON THERAPY WITH BOSENTAN IN SUBJECTS WITH PULMONARY ARTERIAL HYPERTENSION" |
| M-44 | CLINICAL INFORMATION ADDED TO THE PEDIATRIC USE SUBSECTION OF PRECAUTIONS REGARDING THE USE OF NOVOLOG IN ADOLESCENTS WITH TYPE I DIABETES AGE 6 TO 18 |
| M-45 | INFORMATION ADDED TO CLINICAL TRIALS SECTION OF LABELING, "EFFECTS OF HUMATROPE TREATMENT IN ADULTS WITH GROWTH HORMONE DEFICIENCY" |
| M-46 | PROVISION OF RESULTS OF STUDY AND PROPOSED REVISIONS TO PACKAGE INSERT SEE SECTION ON CARDIAC ELECTROPHYSIOLOGY |
| M-47 | PROVIDES FOR USE OF ANTARA WITHOUT REGARD TO MEALS |
| M-48 | CHANGES TO THE LABELING DESCRIBING THE RESULTS OF A STUDY OF THE USE OF NOVOLOG MIX 70/30 WITH ORAL ANTIDIABETIC AGENTS IN PATIENTS WITH TYPE 2 DIABETES |
| M-49 | CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING EFFECT OF SINGULAIR ON GROWTH RATES IN PREPUBERTAL CHILDREN |
| M-50 | NEW INFO TO THE CLINICAL STUDIES, ADULT GROWTH HORMONE DEFICIENCY (GHD) SUBSECTION OF THE NUTROPIN AQ PACKAGE INSERT DESCRIBING THE EFFECTS OF SOMATROPIN ON VISCERAL ADIPOSE TISSUE IN THE ADULT GROWTH HORMONE DEFICIENT PATIENT POPULATION |
| M-51 | INFORMATION ADDED TO LABELING REGARDING OSTEOGENESIS IMPERFECTA STUDY |
| M-52 | INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY/CLINICAL STUDIES SECTION REGARDING THE USE OF RISEDRONATE ADMINISTERED ONCE A WEEK IN THE PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN |
| M-53 | FOR LABELING CHANGES TO THE QUALITY OF LIFE (QOL) STATEMENT IN THE APPROVED PACKAGE INSERT |
| M-54 | INFORMATION FROM PEDIATRIC STUDIES ADDED TO LABEL |
| M-55 | INFORMATION ON RESULTS OF A STUDY OF THE USE OF SANDOSTATIN LAR DEPOT IN PEDIATRIC PATIENTS WITH HYPOTHALAMIC OBESITY. |
| M-56 | INFORMATION ADDED TO CLINICAL TRIAL SECTION WITH INFORMATION ON "GEMINI" TRIAL |
| M-57 | CLINICAL DATA ADDED TO THE CLINICAL PHARMACOLOGY SECTION REGARDING THE PHARMACOKINETICS OF EZETIMIBE IN ASIAN SUBJECTS |
| M-58 | CHANGES TO THE CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, VYTORIN SUBSECTION OF THE PACKAGE INSERT TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR AN ATORVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PRMTRS |
| M-59 | RESULTS OF THE T20-310 STUDY WHICH EVALUATED THE PHARMACOKINETICS, SAFETY, AND ANTIVIRAL ACTIVITY OF FUZEON IN TREATMENT EXPERIENCED PEDIATRIC SUBJECTS AND ADOLESCENTS WAS ADDED TO THE PEDIATRIC SUBSECTION OF PRECAUTIONS |
| M-60 | CHANGES TO CLINICAL STUDIES, PRIMARY HYPERCHOLESTEROLEMIA, TO ADD EFFICACY DATA FOR THE EZETIMIBE/SIMVASTATIN COMBINATION PRODUCT AND FOR A ROSUVASTATIN PRODUCT ON LDL-C AND OTHER LIPID PARAMETERS IN PATIENTS WTH HYPERCHOLESTEROLEMIA |
| M-61 | REVISIONS TO LABELING BASED ON DATA SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST |
| M-62 | CLINICAL INFORMATION FROM ONE CLINICAL STUDY INVESTIGATING THE USE OF AVANDAMET PLUS INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE NOT ACHIEVED ADEQUATE GLYCEMIC CONTROL WITH PREVIOUS ANTI-DIABETIC THERAPIES |
| M-63 | DETAILED INFORMATION ON AN INCONCLUSIVE PEDIATRIC STUDY |
| M-64 | CHANGES TO CLINICAL PHARMACOLOGY DETAILING STUDY RESULTS |

**EXCLUSIVITY MISCELLANEOUS**

M-65 ADDITION OF INFORMATION TO LABEL TO INCLUDE INFORMATION REGARDING USE IN PATIENTS WITH HIV-ASSOCIATED ADIPOSE REDISTRIBUTION SYNDROME (HARS)

M-66 USE IN SPECIFIC POPULATIONS - PATIENTS WITH CONCOMITANT ILLNESS SUBSECTION OF THE LABELING REGARDING USE OF STRATTERA IN PATIENTS WITH ADHD WHO HAVE COMORBID TIC DISORDER

M-67 INDICATION EXPANDED TO INCLUDE PATIENTS ON PERITONEAL DIALYSIS

M-68 DESCRIPTION OF RESULTS OF STUDY OF INITIAL THERAPY IN COMBINATION WITH METFORMIN WHEN DIET AND EXERCISE DO NOT PROVIDE GLYCEMIC CONTROL

M-69 RESULTS OF STUDY OF COMBINATION THERAPY AND NON-INFERIORITY STUDY

M-70 PROVISION OF INFORMATION OF THE RESULTS OF A PHASE 2 RANDOMIZED TRIAL OF SPRYCEL 70MG TWICE DAILY OR IMATINIB 800MG DAILY

M-71 REVISIONS TO PROVIDE FOR RESULTS OF MAINTENANCE DATA IN ADULT PATIENTS WITH MAJOR DEPRESSIVE DISORDER

M-72 INFORMATION ABOUT USE OF INSPRA (EPLERENONE) FOR HYPERTENSION IN PEDIATRIC PATIENTS

M-73 NEW INFORMATION ADDED REGARDING THE TUMOR SHRINKING POTENTIAL OF SANDOSTATIN LAR DEPOT INJECTION ON GH - SECRETING PITUITARY ADENOMAS

M-74 REVISIONS TO CLINICAL STUDIES - CHILDREN AND ADOLESCENTS BASED ON CLINICAL TRIAL DATA TO SUPPORT A DURATION OF ACTION CLAIM UP TO 12 HOURS

M-75 PROVISION FOR USE OF ARGATROBAN IN CERTAIN PEDIATRIC PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) OR HEPARIN-INDUCED THROMBOCYTOPENIA WITH THROMBOSIS (HITTS)

M-76 REMOVAL OF SCREEN REQUIREMENT IN PTS WITH G6PD DEFICIENCY PRIOR TO INITIATING ACZONE TREATMENT; REMOVAL OF BLOOD COUNT & RETICULOCYTE MONITORING DURING TREATMENT IN G6PD DEFICIENT PTS AND IN PATIENTS WITH HISTORY OF ANEMIA

M-77 USE IN COMBINATION WITH THE NEW AKTILITE CL128 LAMP FOR THE TREATMENT OF THIN AND MODERATELY THICK, NON-HYPERKERATOTIC, NON-PIGMENTED ACTINIC KERATOSES OF THE FACE AND SCALP IN IMMUNOCOMPETENT PATIENTS

M-78 CLINICAL TRIAL INFO ON USE OF STRATTERA IN PATIENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) AND COMORBID ANXIETY DISORDER WITHOUT CAUSING WORSENING OF ANXIETY

M-79 LABELING REVISIONS RELATED TO SMOKING AND ERLOTINIB EXPOSURE

M-80 ADDITIONAL TIME POINT OF 30 MINUTES (0.5 HOUR) IN CHILDREN AGED 6-12 YEARS WITH A DIAGNOSIS OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)

M-81 ADDITIONAL INFO FOR PEDIATRIC USE FOR CASODEX (STUDIED IN COMBINATION WITH ARIMIDEX) IN THE PEDIATRIC POPULATION, SPECIFICALLY BOYS WITH FAMILIAL MALE-LIMITED PRECOCIOUS PUBERTY (TESTOXICOSIS)

M-82 LABELING REVISIONS RELATED TO CLINICAL STUDIES

M-83 ADDITIONAL INFORMATION ADDED TO LABELING REGARDING ESTABLISHMENT OF EFFICACY IN ADDITIONAL CLINICAL TRIALS AND ONE MAINTENANCE TRIAL

M-84 STUDY INFORMATION ADDED TO LABEL REGARDING BONE MINERAL DENSITY

M-85 INFORMATION ADDED TO LABELING REGARDING USE OF PREVACID IN PATIENTS LESS THAN 1 YEAR WITH SYMPTOMATIC GERD

M-86 LABELING CHANGES SUBMITTED IN RESPONSE TO PEDIATRIC WRITTEN REQUEST FOR INFANTS AGES BIRTH TO 11 MONTH INCLUSIVE REFLECTING LACK OF EFFICACY FOR GERD INDICATION FOR THIS PATIENT POPULATION

M-87 INCLUSION OF RESULTS FROM TWO DRUG INTERACTION STUDIES WITH LIPITOR AND CRESTOR IN CLINICAL PHARMACOLOGY SECTION

M-88 ADDITION OF INFORMATION REGARDING ABUSE POTENTIAL OF CONCERTA VERSUS IMMEDIATE-RELEASE METHYLPHENIDATE

M-89 PROVIDES FOR REVISIONS TO MULTIPLE SECTIONS OF THE PACKAGE INSERT TO REFLECT RESULTS OF CLINICAL TRIALS 205.235 (UPLIFT) AND 205.266 (VA STUDY) IN SUPPORT OF EXACERBATION CLAIM

M-90 LABELING CHANGES BASED ON DATA FROM CLINICAL STUDIES NV20235 AND NV20236 STUDIES OF SEASONAL PROPHYLAXIS OF INFLUENZA IN IMMUNOCOMPROMISED PATIENTS AND CHILDREN AGES 1-12

M-91 UPDATED LABELING BASED UPON STUDY: A SINGLE-DOSE, SINGLE-BLIND, PLACEBO-AND MOXIFLOXACIN-CONTROLLED 2-PERIOD, RANDOMIZED, CROSSOVER, 3RD PERIOD SEQUENTIAL

**EXCLUSIVITY MISCELLANEOUS**

| | |
|---|---|
| | STUDY OF SIDE EFFECTS OF TEMSIROLIMUS ON CARDIAC REPOLARIZATION IN HEALTHY SUBJECTS |
| M-92 | UPDATES TO THE PACKAGE INSERT BASED UPON THE TRIAL ENTITLED "A PHASE I PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF TEMSIROLIMUS IN PATIENTS WITH ADVANCED MALIGNANCIES AND NORMAL AND IMPAIRED LIVER FUNCTION" |
| M-93 | EXPANSION OF LABELING TO INCLUDE INFORMATION ON SAFETY AND EFFICACY OF CREON IN PATIENTS AGES 7 YEARS THROUGH 11 YEARS WITH PANCREATIC EXOCRINE INSUFFICIENCY DUE TO CYSTIC FIBROSIS |
| M-94 | INFO ADDED TO LABEL RELATED TO NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE (PH+) CHRONIC MYELOID LEUKEMIA IC CHRONIC PHASE |
| M-95 | INFORMATION FOR TREATMENT OF CHRONIC HEPATITIS B (CHB) IN ADULT PATIENTS WITH DECOMPENSATED LIVER DISEASE BASED ON DATA FROM CLINICAL TRIAL GS-US-174-0108 |
| M-96 | UPDATED INFORMATION IN THE CLINICAL STUDIES SECTION RELATED TO THE LOSS AND RECOVERY OF BONE MINERAL DENSITY IN ADOLESCENT GIRLS DURING AND FOLLOWING THE USE OF DEPO-PROVERA CONTRACEPTIVE INJECTION |
| M-97 | LABELING CHANGES IN RESPONSE TO PEDIATRIC STUDIES - NOT INDICATED FOR USE IN PEDIATRIC POPULATION |
| M-98 | NEW INFORMATION FROM A STUDY WHICH EVALUATED THE SAFETY AND EFFICACY OF FAMVIR IN TREATING RECURRENT GENITAL HERPES IN IMMUNOCOMPETENT BLACK/AFRICAN AMERICAN SUBJECTS. |
| M-99 | ADDITION OF FINDINGS FROM A SINGLE PEDIATRIC CLINICAL TRIAL (P04292) OF NASONEX NASAL SPRAY IN THE TREATMENT OF NASAL POLYPS IN PATENTS 6 TO <18 YEARS OF AGE TO THE PACKAGE INSERT. |
| M-100 | INFORMATION ADDED TO LABEL BASED UPON COMPLETED CLINICAL TRIAL REPORTS |
| M-101 | INCLUSION OF DATA FROM AN ADDITIONAL 19 SUBJECTS WITH HYPERCALCEMIA FROM PARATHYROID CARCINOMA TO THE INFORMATION CURRENTLY PRESENTED IN THE LABEL |
| M-102 | INFORMATION FROM PEDIATRIC STUDY REPORT ML16633, "INTRAVENOUS GRANISETRON (KYTRIL) IN THE PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING (PONV) IN PEDIATRIC SUBJECTS UNDERGOING TONSILLECTOMY OR ADENOTONSILLECTOMY." |
| M-103 | SAFETY, EFFICACY AND PHARMACOKINETIC INFO FOR FASLODEX IN THE PEDIATRIC POPULATION, SPECIFICALLY FOR GIRLS WITH PROGRESSIVE PRECOCIOUS PUBERTY ASSOCIATED WITH MCCUNE-ALBRIGHT SYNDROME ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING |
| M-104 | INFORMATION ADDED TO DOSING AND ADMINISTRATION REGARDING A 26 WEEK STUDY |
| M-105 | NEW LANGUAGE ADDED TO CLINICAL STUDIES REGARDING USE IN SMOKERS WITH CARDIOVASCULAR DISEASE, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND USE ACCORDING TO AN ALTERNATIVE SET OF DIRECTIONS FOR SETTING A QUIT DATE |
| M-106 | ADDITION OF THE T1-WEIGHTED GD-ENHANCED LESION EFFICACY VARIABLE IN THE CLINICAL STUDIES SECTION 14 OF THE PACKAGE INSERT |
| M-107 | INFORMATION TO THE CLINICAL STUDIES SECTION OF THE LUPRON DEPOT-PED 1-MONTH BASED UPON THE PHASE 3/4 COMPLETED CLINICAL STUDY REPORT FOR STUDY M90-516 ENTITLED "STUDY OF LUPRON DEPOT IN THE TREATMENT OF CENTRAL PRECOCIOUS PUBERTY". |
| M-108 | CHANGES ARE BASED ON RESULTS FROM STUDY CV181057 |
| M-109 | CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL |
| M-110 | CHANGES TO THE PACKAGE INSERT TO REFLECT THE RESULTS OF THE STUDY OF HEART AND RENAL PROTECTION (SHARP) TRIAL |
| M-111 | LABELING CHANGES BASED ON STUDY HW80-EW-GWCI ENTITLED A PLACEBO AND POSITIVE CONTROLLED STUDY OF THE ELECTROPHYSIOLOGICAL EFFECTS OF A SINGLE 10 MCG DOSE OF EXENATIDE ON THE 12 LEAD ELECTROCARDIOGRAM QT INTERVAL IN HEALTHY SUBJECTS |
| M-112 | REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO ADD INFORMATION FROM A PEDIATRIC STUDY IN PATIENTS AGED 12 YEARS TO LESS THAN 18 YEARS OF AGE WITH RECURRENT HERPES LABIALIS |
| M-113 | LABELING CHANGES BASED ON STUDY H80-US-GWCO ENTITLED A RANDOMIZED TRIAL COMPARING EXENATIDE WITH PLACEBO IN SUBJECTS WITH TYPE 2 DIABETES ON INSULIN GLARGINE WITH OR WITHOUT ORAL ANTIHYPERGLYCEMIC MEDICATIONS |
| M-114 | CHANGES IN SECTION 14 OF THE PACKAGE INSERT TO INCLUDE DATA FROM THE SWITCHMRK STUDIES (SWITCH OF SUPPRESSED SUBJECTS FROM LOPINAVIR/RITONAVIR TO RALTEGRAVIR) |

**EXCLUSIVITY MISCELLANEOUS**

M-115 REVISIONS TO THE PI BASED ON RESULTS FROM STUDY NN2211-1842, ENTITLED THE EFFECT OF INSULIN DETEMIR IN COMBINATION WITH LIRAGLUTIDE AND METFORMIN COMPARED TO LIRAGLUTIDE AND METFORMIN IN SUBJECTS WITH TYPE 2 DIABETES

M-116 LABELING CHANGES BASED ON RESULTS FROM CLINICAL STUDY 01-06-TL-OPIMET-008

M-117 ADDITION OF RESULTS OF PEDIATRIC TRIAL TO LABEL

M-118 LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.36

M-119 LABELING CHANGES REGARDING MISSED DOSES

M-120 CHANGES TO CLINICAL TRIALS DETAILING STUDY RESULTS

M-121 LABELING CHANGES BASED UPON SAFETY AND EFFICACY RESULTS FROM TRIAL 1218.43

M-122 LABELING CHANGES TO INCLUDE THE RESULTS OF THE PARAMOUNT TRIAL

M-123 UPDATED RESULTS OF OVERALL SURVIVAL FROM 'CONFIRM' STUDY

M-124 LONG TERM SAFETY AND EFFICACY DATA FROM STUDY CLDT600A2303 FOR SUBJECTS PREVIOUSLY ENROLLED IN THE ORIGINAL TWO YEAR GLOBE (NV-02B-007/CLDT600A2302) AND NV02B-015 STUDIES WHO CONTINUED TELBIVUDINE TREATMENT FOR UP TO 208 WEEKS

M-125 LABELING CHANGES TO INCLUDE LACK OF EFFICACY IN CHILDREN 6 MONTHS TO 4 YEARS OF AGE

M-126 UPDATES TO THE CLINICAL STUDIES SECTION 14, OF THE PACKAGE INSERT (PI), WITH THE RESULTS OF CLINICAL TRIAL P06086

M-127 REVISIONS TO THE PEDIATRIC USE SECTION OF THE PACKAGE INSERT TO REFLECT THE RESULTS FROM CLINICAL STUDY C-10-004

M-128 CLINICAL TRIAL STUDY RESULTS

M-129 RESULTS OF A CLINICAL STUDY REPORT WHICH ASSESSES THE SAFETY AND EFFICACY IN CHILDREN AGES 6 TO 12 YEARS OF AGE

M-130 ADDITION OF INFORMATION ON LONG-TERM TREATMENT WITH VPRIV IN THE CLINICAL TRIALS SECTION OF THE PACKAGE INSERT

M-131 INFORMATION FROM STUDIES CONDUCTED IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED NON-DISSEMINATED DIFFUSED INTRINSIC BRAINSTEM GLIOMAS

M-132 REVISIONS TO THE CLINICAL TRIALS SECTION IN THE INOMAX LABEL TO REFLECT RESULTS FROM THE PEDIATRIC STUDY REPORTS

M-133 INFORMATION ADDED TO THE LABELING REGARDING THE ADDITION OF SILDENAFIL TO BOSENTAN THERAPY

M-134 ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES PERFORMED WITH SAXAGLIPTIN IN COMBINATION WITH METFORMIN AND A SULFONYLUREA ADDED TO THE LABELING

M-135 ADDITION OF INFORMATION TO THE CLINICAL STUDIES - RADIOGRAPHIC RESPONSE SECTION OF THE PACKAGE INSERT

M-136 ADDITIONAL INFORMATION ADDED TO THE USE IN SPECIFIC POPULATIONS SECTION OF THE LABELING REGARDING POST-OPERATIVE NAUSEA AND VOMITING STUDIES IN PEDIATRIC PATIENTS

M-137 LABELING REVISIONS RESULTING FROM A MAINTENANCE TRIAL IN PEDIATRIC PATIENTS WITH IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER

M-138 INFORMATION ADDED TO THE 8.4 PEDIATRIC USE SECTION ON THE USE OF MEMANTINE IN CHILDREN AGES 6-12 YEARS WITH AUTISM SPECTRUM DISORDER

M-139 INFORMATION ADDED TO THE DOSING AND ADMINISTRATION SECTION OF THE PACKAGE INSERT REGARDING RETREATMENT WITH VELCADE FOR PATIENTS WITH MULTIPLE MYELOMA

M-140 INFORMATION ADDED TO THE PEDIATRIC USE SECTION OF THE LABELING REGARDING USE OF LATISSE IN PATIENTS WHO WERE POST-CHEMOTHERAPY OR HAD ALOPECIA AREATA, AND ADOLESCENTS WHO HAD HYPERTRICHOSIS WITH NO ASSOCIATED MEDICAL CONDITION

M-141 REVISIONS TO THE PEDIATRIC USE SECTION OF THE LABELING TO INCORPORATE STUDY RESULTS FOR TREATMENT OF MAJOR DEPRESSIVE DISORDER IN ADOLESCENTS (AGES 12-17)

M-142 ADDITIONS TO THE LABELING DESCRIBING RESULTS FROM STUDY H6P-MC-HDAY

M-143 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN PATIENTS WITH CURRENT OR PAST HISTORY OF MAJOR DEPRESSIVE DISORDER

M-144 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN PATIENTS WHO HAD BEEN PREVIOUSLY TREATED WITH VARENICLINE

**EXCLUSIVITY MISCELLANEOUS**

M-145 ADDITION OF INFORMATION ABOUT LONG-TERM TREATMENT OF PULMONARY ARTERIAL HYPERTENSION TO THE CLINICAL STUDIES SECTION OF THE LABELING

M-146 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION ON INITIAL COMBINATION THERAPY WITH LINAGLIPTIN AND METFORMIN VS. LINAGLIPTIN MONOTHERAPY IN TREATMENT NAIVE PATIENTS

M-147 OTC USE FOR TEMPORARY RELIEF OF OCULAR SYMPTOMS DUE TO HAY FEVER OR OTHER UPPER RESPIRATORY ALLERGIES

M-148 LABELING CHANGES BASED ON STUDY H80-EW-GWDM

M-149 INFORMATION ADDED TO THE LABELING REGARDING MAINTENANCE MONOTHERAPY FOR ADHD

M-150 ADDITION OF THE RESULTS OF A CONTROLLED CLINICAL STUDY TREATING ADULT PATIENTS WITH SCHIZOPHRENIA EXPERIENCING AN ACUTE RELAPSE

M-151 REVISIONS TO THE LABELING BASED ON THE OUTCOMES OF PEDIATRIC STUDIES CONDUCTED TO ASSESS THE SAFETY AND EFFICACY OF XOPENEX IN SUBJECTS LESS THAN 6 YEARS OF AGE

M-152 INFORMATION ADDED TO THE CLINICAL PHARMACOLOGY SECTION OF THE LABELING REGARDING A SAFETY STUDY IN PEDIATRIC SUBJECTS AGES 6 MONTHS TO 4 YEARS OF AGE WITH AN ACTIVE HEAD LICE INFESTATION

M-153 ADDITION OF INFORMATION REGARDING THE INTRANASAL ABUSE POTENTIAL OF OXYCONTIN

M-154 UPDATE TO THE LABELING TO REFLECT THE RESULTS OF A LONG-TERM MAINTENANCE TREATMENT STUDY OF ADHD IN CHILDREN AND ADOLESCENTS AGES 6-17.

M-155 ADDITION OF CLINICAL FINDINGS FROM AN OBSERVATIONAL STUDY IN A PEDIATRIC AGE GROUP GREATER THAN 2 MONTHS TO 18 YEARS IN SECTION 8.4 PEDIATRIC USE OF THE PACKAGE INSERT

M-156 UPDATE TO THE LABELING WITH INFORMATION REGARDING A CLINICAL TRIAL IN CHILDREN LESS THAN 4 YEARS OF AGE.

M-157 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF DAPAGLIFLOZIN 10MG ONCE DAILY IN PATIENTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A BACKGROUND COMBINATION OF METFORMIN AND SULFONYLUREA

M-158 UPDATES TO THE LABELING TO REFLECT SAFETY RESULTS FROM CLINICAL TRIALS IN SCHIZOPHRENIA ADOLESCENT PATIENTS AGED 12 TO 17 YEARS

M-159 ADDITION OF PED SAFETY INFORMATION DERIVED FROM A MAINTENANCE TREATMENT STUDY OF BIPOLAR 1 DISORDER TO DELAY THE TIME TO OCCURRENCE OF MOOD EPISODES IN PATIENTS (> THAN OR = TO 13 YRS OF AGE) TREATED FOR ACUTE MOOD EPISODES WITH STANDARD THERAPY

M-160 UPDATED LABELING WITH DATA FROM A RANDOMIZED, DOUBLE-BLIND ACTIVE-CONTROLLED STUDY COMPARING EMPAGLIFLOZIN TO GLIMEPIRIDE IN PATIENTS WITH TYPE 2 DIABETES AND INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN TREATMENT

M-161 UPDATED LABELING WITH DATA FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND INSUFFICIENT GLYCEMIC CONTROL ON A MULTIPLE DAILY INJECTION INSULIN REGIMEN ALONE OR WITH METFORMIN

M-162 INCLUSION OF EFFICACY AND SAFETY DATA TO THE PRESCRIBING INFORMATION OF BYDUREON BASED ON STUDY GWDE

M-163 INFORMATION ADDED TO THE LABELING REGARDING PREVIOUSLY UNTREATED ALK-POSITIVE METASTATIC NON SMALL CELL LUNG CANCER (NSCLC)

M-164 REVISES THE CLINICAL TRIALS SECTION OF THE PRESCRIBING INFORMATION TO INCORPORATE THE RESULTS FROM STUDY E7273-G000-401 ENTITLED "PHASE IV RANDOMIZED STUDY OF TWO DOSE LEVELS OF TARGRETIN CAPSULES IN SUBJECTS WITH REFRACTORY CUTANEOUS T-CELL LYMPHOMA"

M-165 PROVIDES FOR UPDATES TO THE PEDIATRIC USE SECTION BASED ON THE PEDIATRIC STUDY REPORT ENTITLED, "A PHASE II PILOT TRIAL OF BORTEZOMIB IN COMBINATION WITH INTENSIVE RE-INDUCTION THERAPY IN CHILDREN WITH RELAPSED ACUTE LYMPHOBLASTIC LYMPHOMA (LL)"

M-166 UPDATE TO LABELING WITH WEEK 48 RESULTS FROM VIKING-4 IN ANTIRETROVIRAL THERAPY (ART) - EXPERIENCED INTEGRASE STRAND TRANSFER INHIBITOR (INSTI) - RESISTANT SUBJECTS

M-167 APPROVED FOR REVISIONS TO THE LABELING BASED ON THE CLINICAL STUDY ENTITLED "BRONCHOPULMONARY DYSPLASIA (BPD) IN PRETERM INFANTS REQUIRING MECHANICAL VENTILATION OR POSITIVE PRESSURE SUPPORT ON DAYS 5 TO 14 AFTER BIRTH".

**EXCLUSIVITY MISCELLANEOUS**

M-168 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING REGARDING THE RE-NOVATE AND RE-NOVATE LL STUDIES (PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM FOLLOWING HIP REPLACEMENT SURGERY)

M-169 UPDATES TO LABELING DESCRIBING RESPONSE TO A REPEAT COURSE OF PICATO GEL 0.015% ON THE FACE OR SCALP IF AN INCOMPLETE RESPONSE IS OBSERVED AT A FOLLOW-UP EXAMINATION.

M-170 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION REGARDING USE FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST

M-171 UPDATES TO LABELING WITH RESULTS TO THE TIGER CLINICAL TRIAL

M-172 UPDATES TO THE CLINICAL TRIALS SECTION OF THE LABELING TO INCLUDE RESULTS OF STUDIES PERFORMED TO EVALUATE THE BENEFIT OF ADDING INCRUSE ELLIPTA TO PATIENTS WHO ARE ON BACKGROUND THERAPY WITH BREO ELLIPTA AND ADVAIR DISKUS

M-173 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING DESCRIBING THE EFFECTS OF STIOLTO RESPIMAT ON COPD PATIENTS

M-174 INFORMATION ADDED TO CLINICAL STUDIES SECTION OF THE LABELING REGARDING INITIAL COMBINATION THERAPY OF EMPAGLIFLOZIN WITH METFORMIN

M-175 INFORMATION ADDED TO THE LABELING DESCRIBING SAVOR, A PHASE IV TRIAL EVALUATING THE EFFECT OF SAXAGLIPTIN ON THE INCIDENCE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION OR ISCHAEMIC STROKE IN PATIENTS WITH TYPE 2 DIABETES

M-176 INFORMATION ADDED TO THE LABELING DESCRIBING TRIAL NN2211-3916, A TRIAL EVALUATING THE SAFETY AND EFFICACY OF LIRAGLUTIDE IN SUBJECTS WITH TYPE 2 DIABETES AND MODERATE RENAL IMPAIRMENT

M-177 INFORMATION ADDED TO THE LABELING DESCRIBING EXAMINE, A TRIAL EVALUATING CARDIOVASCULAR ISCHEMIC RISKS ASSOCIATED WITH ALOGLIPTIN USE IN PATIENTS WITH TYPE 2 DIABETES AT HIGH RISK OF ISCHEMIC CARDIOVASCULAR DISEASE

M-178 INFORMATION ADDED TO THE LABELING REGARDING MAINTENANCE OF REMISSION IN CROHN'S DISEASE IN PEDIATRIC PATIENTS

M-179 UPDATES TO THE PRODUCT LABELING WITH STUDY REPORTS FROM THE OPTIMIST-1 AND OPTIMIST-2 CLINICAL TRIALS

M-180 INFORMATION ADDED TO THE LABELING REGARDING THE ADDITION OF MAINTENANCE TREATMENT IN PATIENTS WITH SCHIZOPHRENIA

M-181 UPDATE TO THE DOSAGE AND ADMINISTRATION, PATIENT SELECTION (2.1), SECTION OF THE PACKAGE INSERT TO INCLUDE THE USE OF AN FDA-APPROVED PLASMA TEST FOR THE IDENTIFICATION OF EGFR EXON 19 DELETION OR EXON 21 (L858R) SUBSTITUTION MUTATIONS

M-182 UPDATES TO THE PRODUCT LABELING BASED ON THE RESULTS OF STUDY H7T-MC-TADO TITLED, "A PHASE 3 DOUBLE-BLIND, RANDOMIZED, MULTICENTER, EFFICACY AND SAFETY STUDY OF PRASUGREL COMPARED TO PLACEBO IN PEDIATRIC PATIENTS WITH SICKLE CELL DISEASE"

M-183 CHANGES TO THE DOSAGE AND ADMINISTRATION AND CLINICAL STUDIES SECTIONS OF THE LABELING TO SUPPORT THE REDUCE-TO-QUIT PARADIGM

M-184 UPDATES MADE TO THE LABELING TO INCLUDE INFORMATION FROM STUDY MO25743 ON THE ANTI-TUMOR ACTIVITY OF VEMURAFENIB IN THE TREATMENT OF PATIENTS WITH BRAF V600E MUTATION-POSITIVE MELANOMA WITH BRAIN METASTASES

M-185 UPDATES TO THE LABELING TO INCLUDE RESULTS OF A TRIAL TO EVALUATE THE SAFETY OF MOXIFLOXACIN IN PEDIATRIC PATIENTS WITH COMPLICATED INTRA-ABDOMINAL INFECTIONS

M-186 UPDATES TO THE PRODUCT INFORMATION REGARDING MAINTENANCE TREATMENT OF SCHIZOPHRENIA IN ADULTS BASED UPON THE RESULTS FROM STUDY 331-10-232

M-187 ADDITION OF CLINICAL INFORMATION OBTAINED FROM A PEDIATRIC TRIAL TO SECTION 8.4 OF THE LABELING

M-188 PROVIDES FOR DATA SUPPORTING THE SAFETY AND EFFECTIVENESS FOR THE MAINTENANCE TREATMENT OF MODERATE TO SEVERE BINGE EATING DISORDER (BED)

M-189 LABELING DESCRIBING THE EXPECTED REDUCTION OF ABUSE OF SINGLE-ENTITY MORPHINE BY THE INTRANASAL ROUTE OF ADMINISTRATION DUE TO PHYSICOCHEMICAL PROPERTIES

M-190 INFORMATION ADDED TO THE CLINICAL STUDIES SECTION OF THE LABELING REGARDING THE LACK OF EFFICACY OF TARCEVA IN MAINTENANCE TREATMENT OF PATIENTS WITHOUT EGFR MUTATIONS

M-191 ADDITION OF DATA BASED ON PEDIATRIC STUDIES TO FULFILL THE POSTMARKETING

**EXCLUSIVITY MISCELLANEOUS**

REQUIREMENT 1857-2

M-192 PROVIDES FOR DATA EVALUATING THE NEUROPSYCHIATRIC SAFETY AND EFFICACY OF VARENICLINE FOR SMOKING CESSATION IN SUBJECTS WITH AND WITHOUT A HISTORY OF PSYCHIATRIC DISORDERS

M-193 INFORMATION ADDED TO THE LABELING REGARDING A 15-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED FLEXIBLE-DOSE SAFETY AND EFFICACY STUDY OF PREGABALIN IN ADOLESCENTS (12 THROUGH 17 YEARS OLD) WITH FIBROMYALGIA

M-194 INFORMATION ADDED TO THE LABELING REGARDING USE OF REGADENOSON ADMINISTRATION FOLLOWING AN INADEQUATE EXERCISE STRESS TEST AS COMPARED TO REGADENOSON ALONE

M-195 REVISIONS TO THE PEDIATRIC USE SECTION OF THE LABELING REFLECTING LACK OF EFFICACY FOR IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER IN PEDIATRIC PATIENTS AGES 6-17

M-196 REVISIONS TO THE PACKAGE INSERT BASED ON DATA FROM A RANDOMIZED, PLACEBO CONTROLLED, MULTICENTER STUDY OF INTRAVENOUS ACETAMINOPHEN FOR THE TREATMENT OF ACUTE PAIN IN PEDIATRIC PATIENTS TO FULFILL THE POST-MARKETING REQUIREMENT 1704-1

M-197 NEW CLINICAL DATA ADDED TO THE PRESCRIBING INFORMATION REGARDING CANAGLIFLOZIN ADD-ON COMBINATION THERAPY WITH METFORMIN AND A DIPEPTIDYL-PEPTIDASE-4 INHIBITOR

M-198 PACKAGE INSERT UPDATED WITH RESULTS FROM STUDY CV181168, A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, PHASE 3 TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF SAXAGLIPTIN ADDED TO DAPAGLIFLOZIN AND METFORMIN

M-199 INFORMATION ADDED TO LABELING REGARDING THE TREATMENT OF PATIENTS WITH ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAD NOT RECEIVED PRIOR SYSTEMIC THERAPY FOR METASTATIC DISEASE.

M-200 CLINICAL INFORMATION ADDED TO THE USE IN SPECIFIC POPULATIONS SECTION OF THE LABELING.

M-201 REVISIONS TO THE PACKAGE INSERT BASED ON DATA FROM AN OPEN LABEL, MULTI-CENTER STUDY OF CABAZITAXEL IN PEDIATRIC PATIENTS WITH REFRACTORY SOLID TUMORS INCLUDING TUMORS OF THE CENTRAL NERVOUS SYSTEM.

M-202 INCLUSION OF DATA FROM THE SUMMIT STUDY FOR BREO ELLIPTA (FLUTICASONE FUROATE/VILANTEROL TRIFENATATE) INHALATION POWDER IN THE PACKAGE INSERT.

M-203 PROVIDES FOR REVISIONS TO THE PACKAGE INSERT TO REFLECT RESULTS OF TWO POSTMARKETING REQUIREMENT STUDIES ROP111662 AND ROP111569

M-204 CLINICAL INFORMATION ADDED TO THE PACKAGE INSERT REGARDING USE OF ATORVASTATIN IN CHILDREN AND ADOLESCENTS AGES 10-17 WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)

M-205 INFORMATION ADDED TO THE LABELING REGARDING RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES ON PATIENTS WITH SEVERE RENAL IMPAIRMENT

M-206 INFORMATION ADDED TO LABELING REGARDING 48 WEEK EFFICACY, RESISTANCE AND SAFETY DATA ON VIROLOGICALLY SUPPRESSED HIV-1 INFECTED ADULTS SWITCHING FROM COMPLERA TO ODEFSEY

M-207 INFORMATION ADDED TO LABELING REGARDING 48 WEEK EFFICACY, RESISTANCE AND SAFETY DATA ON VIROLOGICALLY SUPPRESSED HIV-1 INFECTED ADULTS SWITCHING FROM ATRIPLA TO ODEFSEY

M-208 INFORMATION ADDED TO THE LABELING TO INCLUDE RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS

M-209 INFORMATION ADDED TO THE LABELING REGARDING CABAZITAXEL AT 20 MG/M2 BASED ON THE RESULTS OF THE PROSELICA STUDY

M-210 INFORMATION ADDED TO LABELING TO SUPPORT THE USE OF SYMBICORT TO REDUCE EXACERBATIONS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)

M-211 PROVIDES FOR LABELING CHANGES REGARDING THE USE OF DAPTOMYCIN IN THE PEDIATRIC POPULATION FOR STAPHYLOCOCCUS AUREUS BACTEREMIA (SAB) BASED ON RESULTS OF A TRIAL IN PEDIATRIC PATIENTS 1 TO 17 YEARS OF AGE

M-212 INFORMATION ADDED TO THE LABELING REGARDING THE SAFETY AND EFFICACY OF DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A BACKGROUND COMBINATION OF METFORMIN AND EXENATIDE EXTENDED RELEASE

M-213 INFORMATION ADDED TO THE LABELING TO INCLUDE THE EFFICACY AND SAFETY OF CARIPRAZINE RELATIVE TO PLACEBO IN THE PREVENTION OF RELAPSE OF SYMPTOMS IN

**EXCLUSIVITY MISCELLANEOUS**

| | |
|---|---|
| | PATIENTS WITH SCHIZOPHRENIA |
| M-214 | INFORMATION ADDED TO THE CLINICAL TRIALS SECTION OF THE LABELING REGARDING A POSTMARKETING SAFETY AND EFFICACY STUDY EVALUATING THE RISK OF SERIOUS ASTHMA-RELATED EVENTS |
| M-215 | INFORMATION ADDED TO THE LABELING REGARDING THE COMPARISON OF PALIPERIDONE PALMITATE COMPARED WITH ORAL ANTIPSYCHOTIC TREATMENT IN DELAYING TIME TO TREATMENT FAILURE IN ADULTS WITH SCHIZOPHRENIA WHO HAVE BEEN INCARCERATED |
| M-216 | UPDATE THE PRESCRIBING INFORMATION AND PATIENT LABELING WITH FINDINGS FROM STUDY RP103-08 CONDUCTED IN TREATMENT-NAIVE NEPHROPATHIC CYSTINOSIS PATIENTS TO EXPAND THE INDCIATED POPULATION TO PATIENTS 1 YEAR AND OLDER |
| M-217 | INCORPORATION OF THE LABELING REVISIONS PROVIDED FOR IN NDA 022253/S-039 AND NDA 022255/S-022 INTO THE LACOSAMIDE INJECTION LABELING |

**ORPHAN DRUG EXCLUSIVITY**

| | |
|---|---|
| ODE-1 | TO REDUCE CHRONIC DROOLING IN PATIENTS AGED 3 - 16 WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING (E.G. CEREBRAL PALSY) |
| ODE-2 | FOR TREATMENT OF NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE |
| ODE-3 | TO TREAT INFANTILE SPASMS |
| ODE-4 | TREATMENT OF PATIENTS WITH SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBEROUS SCLEROSIS WHO REQUIRE THERAPEUTIC INTERVENTION BUT ARE NOT CANDIDATES FOR CURATIVE SURGICAL RESECTION |
| ODE-5 | FOR SEQUENTIAL USE FOR THE TREATMENT OF CYANIDE POISONING THAT IS JUDGED TO BE LIFE-THREATENING |
| ODE-6 | FOR THE MANAGEMENT OF POSTHERPETIC NEURALGIA |
| ODE-7 | TO REDUCE THE RISK OF PRETERM BIRTH IN WOMEN WITH SINGLETON PREGNANCY WHO HAVE A HISTORY OF SINGLETON SPONTANEOUS PRETERM BIRTH |
| ODE-8 | TREATMENT OF SEVERE HYPERCALCEMIA IN PATIENTS WITH PRIMARYHYPERPARATHYROIDISM WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY |
| ODE-9 | TREATMENT OF ASYMPTOMATIC OR PROGRESSIVE MEDULLARY THYROID CANCER IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC DISEASE |
| ODE-10 | FOR USE IN COMBINATION CHEMOTHERAPY WITH 5-FLUOROURACIL IN THE PALLIATIVE TREATMENT OF PATIENTS WITH ADVANCED METASTATIC COLORECTAL CANCER |
| ODE-11 | TREATMENT OF PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) IN PATIENTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE |
| ODE-12 | TREATMENT OF PERIPHERAL T-CELL LYMPHOMA (PTCL) IN PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
| ODE-13 | TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA WITH THE BRAFV600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST |
| ODE-14 | TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA IN ADULTS 18 YEARS OF AGE AND OLDER |
| ODE-15 | TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNGCANCER (NSCLC) THAT IS ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE AS DETECTED BY AN FDAAPPROVEDTEST |
| ODE-16 | TREATMENT OF PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD DUE TO THALASSEMIA SYNDROMES WHEN CURRENT CHELATION THERAPY IS INADEQUATE |
| ODE-17 | ADJUNCTIVE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME IN PATIENTS 2 YEARS OF AGE OR OLDER |
| ODE-18 | ADJUNCTIVE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME INPATIENTS 2 YEARS OF AGE OR OLDER |
| ODE-19 | TREATMENT OF PATIENTS WITH INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS, INCLUDING PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS |
| ODE-20 | TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6 YEARS AND OLDER WHO HAVE A G551D MUTATION IN THE CFTR GENE. |
| ODE-21 | AN ADJUNCT TO AB EXTERNO GLAUCOMA SURGERY |

**ORPHAN DRUG EXCLUSIVITY**

| | |
|---|---|
| ODE-22 | FOR THE CONTROL OF HYPERGLYCEMIA SECONDARY TO HYPERCORTISOLISM IN ADULT PATIENTS WITH ENDOGENOUS CUSHING'S SYNDROME WHO HAVE TYPE 2 DIABETES MELLITUS OR GLUCOSE INTOLERANCE AND HAVE FAILED SURGERY OR ARE NOT CANDIDATES FOR SURGERY |
| ODE-23 | ADVANCED SOFT TISSUE SARCOMA (STS) WHO HAVE RECEIVED PRIOR CHEMOTHERAPY |
| ODE-24 | TREATMENT OF ADULTS WITH RENAL ANGIOMYOLIPOMA AND TUBEROUS SCLEROSIS COMPLEX (TSC) NOT REQUIRING IMMEDIATE SURGERY |
| ODE-25 | MANAGEMENT OF POSTHERPETIC NEURALGIA IN ADULTS. |
| ODE-26 | TREATMENT OF ENDOGENOUS ANTERIOR UVEITIS |
| ODE-27 | TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY |
| ODE-28 | TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE (PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MORE ANTI-LEUKEMIA THERAPIES |
| ODE-29 | LOCALIZATION OF LYMPH NODES DRAINING A PRIMARY TUMOR IN PATIENTS WITH MELANOMA WHEN USED WITH A HAND-HELD GAMMA COUNTER |
| ODE-30 | TREATMENT OF ADULT PATIENTS WITH CHRONIC, ACCELERATED OR BLAST PHASE PHILADELPHIA CHROMOSOME-POSITIVE (PH+) CHRONIC MYELOGENOUS LEUKEMIA (CML) WITH RESISTANCE, OR INTOLERANCE TO PRIOR THERAPY |
| ODE-31 | TREATMENT OF CORNEAL CYSTINE CRYSTAL ACCUMULATION IN PATIENTS WITH CYSTINOSIS |
| ODE-32 | TREATMENT OF ADULT PATIENTS WITH CHRONIC OR ACCELERATED PHASE CHRONIC MYELOID LEUKEMIA (CML) WITH RESISTANCE AND/OR INTOLERANCE TO TWO OR MORE TYROSINE KINASE INHIBITORS (TKI) |
| ODE-33 | TREATMENT OF PROGRESSIVE, METASTATIC MEDULLARY THYROID CANCER (MTC) |
| ODE-34 | TREATMENT OF ADULT PATIENTS WITH CUSHING'S DISEASE FOR WHOM PITUITARY SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE |
| ODE-35 | TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ALL) THAT IS RESISTANT OR INTOLERANT TO PRIOR TYROSINE KINASE INHIBITOR THERAPY. |
| ODE-36 | ADJUNCT TO A LOW-FAT DIET AND OTHER LIPID-LOWERING TREATMENTS, INCLUDING LDL APHERESIS WHERE AVAILABLE, TO REDUCE LDL-C, TC, APOLIPOPROTEIN B, & NON-HDL-C IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA |
| ODE-37 | TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME (SBS) WHO ARE DEPENDENT ON PARENTERAL SUPPORT |
| ODE-38 | PART OF COMBINATION THERAPY IN ADULTS (GREATER THAN OR EQUAL TO 18 YEARS) WITH PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS (MDR-TB) |
| ODE-39 | TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS 10 YRS. & OLDER WITH NON-TRANSFUSION DEPENDENT THALASSEMIA (NTDT) SYNDROMES AND WITH A LIVER IRON CONCENTRATION OF AT LEAST 5 MG OF IRON PER GRAM OF LIVER DRY WEIGHT & SERUM FERRITIN GREATER THAN 300 MCG/L. |
| ODE-40 | TREATMENT OF PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) IN COMBINATION WITH CHEMOTHERAPY, APPROVED UNDER NDA #21588/S-037 |
| ODE-41 | ADJUNCT TO LIPID-LOWERING MEDICATIONS AND DIET TO REDUCE LDL-C, APOLIPOPROTEIN B (APO B), TOTAL CHOLESTEROL (TC), AND NON-HIGH DENSITY LIPOPROTEIN-CHOLESTEROL (NON-HDL-C) IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH) |
| ODE-42 | USE AS A NITROGEN-BINDING ADJUNCTIVE THERAPY FOR CHRONIC MGMT OF ADULT AND PEDIATRIC PATIENTS AT LEAST 2 YRS WITH UREA CYCLE DISORDERS THAT CANNOT BE MANAGED BY DIETARY PROTEIN RESTRICTION AND/OR AMINO ACID SUPPLEMENTATION ALONE |
| ODE-43 | TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING LENALIDOMIDE AND BORTEZOMIB AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY. |
| ODE-44 | TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) WHO HAVE BEEN PREVIOUSLY TREATED WITH IMATINIB MESYLATE AND SUNITINIB MALATE. |
| ODE-45 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS IN ADULTS AND CHILDREN AGES 6 YEARS AND OLDER. |

**ORPHAN DRUG EXCLUSIVITY**

| | |
|---|---|
| ODE-46 | IMPROVEMENT OF NEUROLOGICAL OUTCOME BY REDUCING THE INCIDENCE AND SEVERITY OF ISCHEMIC DEFICITS IN ADULT PATIENTS WITH SUBARACHNOID HEMORRHAGE FROM RUPTURED INTRACRANIAL BERRY ANEURYSMS REGARDLESS OF THEIR POST-ICTUS NEUROLOGICAL CONDITION |
| ODE-47 | TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATION AS DETECTED BY AN FDA APPROVED TEST. |
| ODE-48 | TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA APPROVED TEST |
| ODE-49 | TREATMENT OF MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB |
| ODE-50 | FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLS) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST. |
| ODE-51 | TOPICAL TREATMENT OF STAGE 1A AND 1B MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN-DIRECTED THERAPY |
| ODE-52 | TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS AS FIRST-LINE TREATMENT, IN COMBINATION WITH GEMCITABINE. |
| ODE-53 | TREATMENT OF ADULTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) WHO GROUP 1, TO IMPROVE EXERCISE CAPACITY, WHO FUNCTIONAL CLASS AND TO DELAY CLINICAL WORSENING. |
| ODE-54 | TX OF PAH TO DELAY DISEASE PROGRESSION. DISEASE PROGRESSION INCLUDED: DEATH, INITIATION OF IV OR SC PROSTANOIDS, OR CLINICAL WORSENING OF PAH (DECREASED 6-MINUTE WALK DISTANCE, WORSENED PAH SYMPTOMS AND NEED FOR ADDITIONAL PAH TREATMENT). |
| ODE-55 | TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
| ODE-56 | TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA (DCT) THAT IS REFRACTORY TO RADIOACTIVE IODINE TREATMENT. |
| ODE-57 | TRAMETINIB IN COMBO WITH DABRAFENIB FOR TX. OF PTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST. THIS INDICATION IS BASED ON THE DEMONSTRATION OF DURABLE RESPONSE RATE |
| ODE-58 | DABRAFENIB IN COMBO WITH TRAMETINIB FOR TX. OF PTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST. THIS INDICATION IS BASED ON THE DEMONSTRATION OF DURABLE RESPONSE RATE |
| ODE-59 | TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER |
| ODE-60 | TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
| ODE-61 | TREATMENT OF NEUROGENIC SYMPTOMATIC ORTHOSTATIC HYPOTENSION IN PATIENTS WITH PRIMARY AUTONOMIC FAILURE, DOPAMINE-BETA-HYDROXYLASE DEFICIENCY, AND NONDIABETIC AUTONOMIC NEUROPATHY |
| ODE-62 | TREATMENT OF PROLIFERATING INFANTILE HEMANGIOMA REQUIRING SYSTEMIC THERAPY. |
| ODE-63 | TREATMENT OF VISCERAL LEISHMANIASIS DUE TO LEISHMANIA DONOVANI; CUTANEOUS LEISHMANIASIS DUE TO LEISHMANIA BRAZILIENSIS, LEISHMANIA GUYANENSIS, AND LEISHMANIA PANAMENSIS; AND MUCOSAL LEISHMANIASIS DUE TO LEISHMANIA BRAZILIENSIS. |
| ODE-64 | SELECTIVE HEPATIC INTRA-ARTERIAL USE FOR IMAGING TUMORS IN ADULTS WITH KNOWN HEPATOCELLULAR CARCINOMA (HCC) |
| ODE-65 | TREATMENT OF PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AS PART OF A COMBINATION REGIMEN. |
| ODE-66 | TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB. |
| ODE-67 | GUIDING SENTINEL LYMPH NODE BIOPSY, USING A HAND-HELD GAMMA COUNTER IN PATIENTS WITH CLINICALLY NODE NEGATIVE SQUAMOUS CELL CARCINOMA OF THE ORAL CAVITY |
| ODE-68 | TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA |
| ODE-69 | TREATMENT OF MALIGNANT HYPERTHERMIA IN CONJUNCTION WITH APPROPRIATE SUPPORTIVE MEASURES AND FOR THE PREVENTION OF MALIGNANT HYPERTHERMIA IN PATIENTS AT HIGH |

**ORPHAN DRUG EXCLUSIVITY**

| | |
|---|---|
| | RISK |
| ODE-70 | RELAPSED CLL, IN COMBO. WITH RITUXIMAB, IN PATIENTS FOR WHOM RITUXIMAB ALONE WOULD BE CONSIDERED APPROPRIATE THERAPY DUE TO OTHER CO-MORBIDITIES; AND RELAPSED SLL IN PATIENTS WHO HAVE RECEIVED AT LEAST 2 PRIOR SYSTEMIC THERAPIES |
| ODE-71 | RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA (FL) IN PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES |
| ODE-72 | TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY |
| ODE-73 | LONG-TERM TREATMENT OF ADULT PATIENTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 EXTENSIVE METABOLIZERS (EMS), INTERMEDIATE METABOLIZERS (IMS), OR POOR METABOLIZERS (PMS) AS DETECTED BY AN FDA-CLEARED TEST. |
| ODE-74 | TREATMENT OF PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY |
| ODE-75 | TREATMENT OF PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY. |
| ODE-76 | TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE NOT RECEIVED AT LEAST 1 PRIOR THERAPY |
| ODE-77 | TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS |
| ODE-78 | TREATMENT OF HYPERCALCEMIA IN ADULT PATIENTS WITH PRIMARY HYPERPARATHYROIDISM FOR WHOM PARATHYROIDECTOMY WOULD BE INDICATED ON THE BASIS OF SERUM CALCIUM LEVELS, BUT WHO ARE UNABLE TO UNDERGO PARATHYROIDECTOMY. |
| ODE-79 | TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA |
| ODE-80 | TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S |
| ODE-81 | TREATMENT OF PATIENTS WITH ACROMEGALY WHO HAVE HAD AN INADEQUATE RESPONSE TO SURGERY AND/OR FOR WHOM SURGERY IS NOT AN OPTION |
| ODE-82 | TREATMENT OF PATIENTS WITH UNRESECTABLE,WELL- OR MODERATELY-DIFFERENTIATED LOCALLY ADVANCED OR METASTATIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS TO IMPROVE PROGRESSION-FREE SURVIVAL |
| ODE-83 | USE OF AS MONOTHERAPY FOR PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA MUTATED (AS DETECTED BY AN FDA-APPROVED TEST) ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY |
| ODE-84 | TREATMENT OF MOTOR FLUCUATIONS IN PATIENTS WITH ADVANCED PARKINSON'S DISEASE |
| ODE-85 | AS A REPLACEMENT SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) AND IN CASE OF DRUG POISONING WHEN CRRT IS USED TO REMOVE DIALZABLE SUBSTANCES |
| ODE-86 | TREATMENT OF PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA |
| ODE-87 | TREATMENT OF PATIENTS WITH LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, RADIOACTIVE IODINE REFRACTORY DIFFERENTIATED THYROID CANCER |
| ODE-88 | FOR USE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY (FIRST LINE TREATMENT) |
| ODE-89 | TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 2 PRIOR REGIMENS, INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT |
| ODE-90 | TREATMENT OF INVASIVE MUCORMYCOSIS IN PATIENTS 18 YEARS OF AGE AND OLDER |
| ODE-91 | TREATMENT OF BILE ACID SYNTHESIS DISORDERS DUE TO SINGLE ENZYME DEFECTS |
| ODE-92 | TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS (LAM) |
| ODE-93 | TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 12 YEARS AND OLDER WHO ARE HOMOZYGOUS FOR F508DEL MUTATION IN THE CFTR GENE |
| ODE-94 | PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY TRANSPLANT PATIENTS CONVERTED FROM TACROLIMUS IMMEDIATE-RELEASE FORMULATIONS IN COMBINATION WITH OTHER IMMUNOSUPPRESSANTS |
| ODE-95 | FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST |
| ODE-96 | TREATMENT OF PRIMARY HYPERKALEMIC PERIODIC PARALYSIS, PRIMARY HYPOKALEMIC PERIOD PARALYSIS, AND RELATED VARIANTS |

**ORPHAN DRUG EXCLUSIVITY**

| | |
|---|---|
| ODE-97 | TO EXPAND THE INDICATION TO PEDIATRIC PATIENTS 2-6 YEARS OF AGE WITH NEPHROPATHIC CYSTINOSIS |
| ODE-98 | TREATMENT OF HEREDITARY OROTIC ACIDURIA |
| ODE-99 | FOR USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN, FOR THE TREATMENT OF PATIENTS WITH METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED FOLLOWING GEMCITABINE-BASED THERAPY |
| ODE-100 | FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA OR LEIOMYOSARCOMA WHO RECEIVED A PRIOR ANTHRACYCLINE-CONTAINING REGIMEN |
| ODE-101 | FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATION, IN COMBINATION WITH VEMURAFENIB. COTELLIC IS NOT INDICATED FOR TREATMENT OF PATIENTS WITH WILD-TYPE BRAF MELANOMA |
| ODE-102 | FOR TREATMENT OF PATIENTS WITH METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC), AS DETECTED BY AN FDA-APPROVED TEST, WHO HAVE PROGRESSED ON OR AFTER EGFR TKI THERAPY |
| ODE-103 | USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
| ODE-104 | EMERGENCY TX OF PTS FOLLOWING A FU OR CAPECITABINE OD, OR WHO EXHIBIT EARLY-ONSET, SEVERE OR LIFE-THREATENING TOXICITY AFFECTING THE CARDIAC SYSTEM OR CNS, AND/OR EARLY-ONSET, UNUSUALLY SEVERE AR W/IN 96 HRS FOLLOWING THE END OF FU OR CAPECITABINE ADMIN. |
| ODE-105 | TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB |
| ODE-106 | FOR USE OF UPTRAVI (SELEXIPAG) TABLETS, 200, 400, 600, 800, 1000, 1200, 1400, AND 1600 MCG FOR TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH, WHO GROUP I) TO REDUCE THE RISKS OF DISEASE PROGRESSION AND HOSPITALIZATION FOR PAH |
| ODE-107 | TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA WHO HAVE RECEIVED A PRIOR ANTHRACYCLNE-CONTAINING REGIMEN |
| ODE-108 | TREATMENT OF ADULT PATIENTS WITH PROGRESSIVE, WELL-DIFFERENTIATED, NON-FUNCTIONAL, NEUROENDOCRINE TUMORS (NET) OF GASTROINTESTINAL (GI) OR LUNG ORIGIN, (EXCLUDING PANCREATIC) WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC DISEASE |
| ODE-109 | INDICATED FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITHOUT 17P DELETION WHO HAVE NOT RECEIVED AT LEAST ONE PRIOR THERAPY (FIRST LINE THERAPY) |
| ODE-110 | FOR HIGH-DOSE CONDITIONING TREATMENT PRIOR TO HEMATOPOIETIC PROGENITOR (STEM) CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA |
| ODE-111 | TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS ARE ROS-1 POSITIVE. |
| ODE-112 | FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH HEPATIC VENO-OCCLUSIVE DISEASE (VOD), ALSO KNOWN AS SINUSOIDAL OBSTRUCTION SYNDROME (SOS), WITH RENAL OR PULMONARY DYSFUNCTION FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT). |
| ODE-113 | FOR TREATMENT OF PEDIATRIC AND ADULT PATIENTS WITH ACQUIRED METHEMOGLOBINEMIA. |
| ODE-114 | TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
| ODE-115 | TREATMENT OF PATIENTS WITH METASTATIC, SQUAMOUS, NON-SMALL CELL LUNG CANCER PROGRESSING AFTER PLATINUM-BASED CHEMOTHERAPY |
| ODE-116 | TREATMENT OF PROGRESSIVE KERATOCONUS |
| ODE-117 | FOR TREATMENT OF PATIENTS WITH SMALL LYMPHOCYTIC LYMPHOMA (SLL) |
| ODE-118 | AN ADJUNCT TO DIET TO REDUCE LDL-C, TOTAL-C, NONHDL-C AND APOB IN CHILDREN AND ADOLESCENTS 7 TO 17 YEARS OF AGE WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA, EITHER ALONE OR WITH OTHER LIPID-LOWERING TREATMENTS (E.G., LDL APHERESIS) |
| ODE-119 | TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN COMBINATION WITH URSODEOXYCHOLIC ACID (UDCA) IN ADULTS WITH AN INADEQUATE RESPONSE TO UDCA, OR AS MONOTHERAPY IN ADULTS UNABLE TO TOLERATE UDCA |
| ODE-120 | FOR USE AFTER RADIOLABELING WITH GA 68, WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT AND PEDIATRIC PATIENTS. |

**ORPHAN DRUG EXCLUSIVITY**

| | |
|---|---|
| ODE-121 | TREATMENT OF CORNEAL ECTASIA FOLLOWING REFRACTIVE SURGERY |
| ODE-122 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING |
| ODE-123 | TREATMENT OF CYSTIC FIBROSIS (CF) IN PATIENTS AGE 6-11 YEAR OLD WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE |
| ODE-124 | REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE FORMULATIONS, WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE, IN ADULTS WITH THE FOLLOWING SEIZURE TYPES: PARTIAL WITH COMPLEX SYMPTOMOLOGY, GENERALIZED CLONIC-TONIC, AND MIXED |
| ODE-125 | INDICATED IN PEDIATRIC PATIENTS 10 YEARS AND OLDER FOR THE PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGES 3 AND 4 AND CKD STAGE 5 IN PATIENTS ON HEMODIALYSIS OR PERITONEAL DIALYSIS |
| ODE-126 | AS MONOTHERAPY FOR THE TREATMENT OF PATIENTS WITH DELETERIOUS BRCA MUTATION (GERMLINE AND/OR SOMATIC) ASSOCIATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH TWO OR MORE CHEMOTHERAPIES |
| ODE-127 | TREATMENT OF SPINAL MUSCULAR ATROPHY IN PEDIATRIC AND ADULT PATIENTS |
| ODE-128 | TREATMENT OF PATIENTS WITH MARGINAL ZONE LYMPHOMA (MZL) WHO REQUIRE SYSTEMIC THERAPY AND HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED THERAPY |
| ODE-129 | INDICATED FOR REDUCING THE RISK OF GRAFT REJECTION WHEN USED IN CONJUNCTION WITH HIGH-DOSE BUSULFAN & CYCLOPHOSPHAMIDE AS A PREPARATIVE REGIMEN FOR ALLOGENIC HEMATOPOIETIC PROGENITOR CELL TRANSPLANTATION FOR PEDS. PATIENTS WITH CLASS 3 BETA-THALASSEMIA |
| ODE-130 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY IN PATIENTS 5 YEARS OF AGE AND OLDER |
| ODE-131 | TREATMENT OF MULTIPLE MYELOMA (MM), AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT) |
| ODE-132 | TREATMENT OF CARCINOID SYNDROME DIARRHEA IN COMBINATION WITH SOMATOSTATIN ANALOG (SSA) THERAPY IN ADULTS INADEQUATELY CONTROLLED BY SSA THERAPY |
| ODE-133 | INDICATED FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY |
| ODE-134 | TREATMENT OF CHOREA ASSOCIATED WITH HUNTINGTON'S DISEASE |
| ODE-135 | TREATMENT OF CHRONIC HCV GENOTYPE 2 OR 3 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER OR WEIGHING AT LEAST 35 KG WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS FOR USE IN COMBINATION WITH RIBAVIRIN |
| ODE-136 | TREATMENT OF PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER OR WEIGHING AT LEAST 35 KG WITH CHRONIC HEPATITIS C VIRUS GENOTYPE 1, 4, 5, OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS |
| ODE-137 | TREATMENT OF OLIGOARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PERSISTENT OLIGOARTHRITIS, PSORIATIC JUVENILE IDIOPATHIC ARTHRITIS, ENTHESITIS-RELATED ARTHRITIS, OR UNDIFFERENTIATED ARTHRITIS) & POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS IN CHILDREN 0-16 YRS |
| ODE-138 | TREATMENT OF PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA AS A COMPONENT OF A COMBINATION CHEOMOTHERAPY MAINTENANCE REGIMEN |
| ODE-139 | TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC OR LIVER CANCER) WHO HAVE BEEN PREVIOUSLY TREATED WITH THE DRUG SORAFENIB. |
| ODE-140 | TREATMENT OF ADULT PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN), OR MAST CELL LEUKEMIA (MCL) |
| ODE-141 | TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) THAT IS FLT3 MUTATION-POSITIVE AS DETECTED BY AN FDA APPROVED TEST, IN COMBINATION WITH STANDARD CYTARABINE AND DAUNORUBICIN INDUCTION AND CYTARABINE CONSOLIDATION |
| ODE-142 | TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB |
| ODE-143 | TO DECREASE THE RECURRENCE OF PNEUMOTHORAX IN ADULTS |
| ODE-144 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| ODE-145 | TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE |

**ORPHAN DRUG EXCLUSIVITY**

| | |
|---|---|
| | TUMORS ARE ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE AS DETECTED BY AN FDA-APPROVED TEST |
| ODE-146 | OPTICAL IMAGING AGENT INDICATED IN PATIENTS WITH GLIOMA (SUSPECTED WORLD HEALTH ORGANIZATION GRADES III OR IV ON PREOPERATIVE IMAGING) AS AN ADJUNCT FOR THE VISUALIZATION OF MALIGNANT TISSUE DURING SURGERY |
| ODE-147 | DABRAFENIB IN COMBINATION WITH TRAMETINIB, FOR THE TX. OF PTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST |
| ODE-148 | TRAMETINIB IN COMBINATION WITH DABRAFENIB, FOR THE TX. OF PTS WITH METASTATIC NON-SMALL CELL LUNG CANCER WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST |
| ODE-149 | TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH CENTRAL PRECOCIOUS PUBERTY |
| ODE-150 | TO REDUCE THE ACUTE COMPLICATIONS OF SICKLE CELL DISEASE IN ADULT AND PEDIATRIC PATIENTS 5 YEARS OF AGE AND OLDER. |
| ODE-151 | TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION AS DETECTED BY AN FDA-APPROVED TEST |
| ODE-152 | TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT VERSUS HOST DISEASE (CGVHD) |
| ODE-153 | TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY WITH OR WITHOUT CONCOMITANT DOPMINERGIC MEDICATIONS |
| ODE-154 | FOR USE IN CHILDREN AGES 2 TO 12 YEARS OLD WITH CHAGAS DISEASE |
| ODE-155 | TREATMENT OF ADULT PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES |
| ODE-156 | TREATMENT OF ADULTS WITH CARCINOID SYNDROME; WHEN USED, IT REDUCES THE FREQUENCY OF SHORT-ACTING SOMATOSTATIN ANALOG RESCUE THERAPY |

**PATENT USE**

| | |
|---|---|
| U-1 | PREVENTION OF PREGNANCY |
| U-2 | TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA |
| U-3 | TREATMENT OF HYPERTENSION |
| U-4 | PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS |
| U-5 | METHOD OF PRODUCING BRONCHODILATION |
| U-6 | METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS |
| U-7 | INCREASING CARDIAC CONTRACTILITY |
| U-8 | ACUTE MYOCARDIAL INFARCTION |
| U-9 | CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT |
| U-10 | DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALAMIC MALFUNCTIONS OR LESIONS IN HUMANS |
| U-11 | TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS |
| U-12 | METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION |
| U-13 | A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT |
| U-14 | ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES |
| U-15 | METHOD OF LOWERING INTRAOCULAR PRESSURE |
| U-16 | USE IN LUNG SCANNING PROCEDURES |
| U-17 | TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS |
| U-18 | METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS |
| U-19 | TREATMENT OF INFLAMMATION |
| U-20 | A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT |
| U-21 | TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY |

**PATENT USE**

| | |
|---|---|
| | CYTOSTATICALLY ACTIVE ALKYLATING AGENTS |
| U-22 | METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS |
| U-23 | METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE |
| U-24 | METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST |
| U-25 | REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS |
| U-26 | REDUCING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF |
| U-27 | DISSOLVING CHOLESTEROL GALLSTONES AND/OR FRAGMENTS THEREOF |
| U-28 | CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY |
| U-29 | CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY |
| U-30 | CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY |
| U-31 | INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY |
| U-32 | PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN |
| U-33 | TREATING VIRAL INFECTIONS IN A MAMMAL |
| U-34 | TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL |
| U-35 | TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION |
| U-36 | METHODS OF TREATING BACTERIAL ILLNESSES |
| U-37 | METHOD OF TREATING GASTROINTESTINAL DISEASE |
| U-38 | TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA |
| U-39 | ANGINA PECTORIS |
| U-40 | METHOD OF TREATMENT OF BURNS |
| U-41 | METHOD OF TREATING CARDIAC ARRHYTHMIAS |
| U-42 | ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER |
| U-43 | MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA |
| U-44 | RELIEF OF NAUSEA AND VOMITING |
| U-45 | TREATMENT OF INFLAMMATION AND ANALGESIA |
| U-46 | TREATMENT OF PANIC DISORDER |
| U-47 | STIMULATION OF THE RELEASE OF GROWTH HORMONE |
| U-48 | ANALGESIA |
| U-49 | SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA |
| U-50 | USE IN TREATING INFLAMMATORY DERMATOSES |
| U-51 | BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF GASTROINTESTINAL BLEEDING |
| U-52 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS(OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION |
| U-53 | HYPERCALCEMIA OF MALIGNANCY |
| U-54 | REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS |
| U-55 | TREATMENT OF PAIN |
| U-56 | AID TO SMOKING CESSATION |
| U-57 | OPHTHALMIC USE OF NORFLOXACIN |
| U-58 | METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES |
| U-59 | METHOD OF TREATING HYPERCHOLESTEROLEMIA |
| U-60 | NASAL ADMINISTRATION OF BUTORPHANOL |
| U-61 | CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD |

**PATENT USE**

| | |
|---|---|
| U-62 | CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY |
| U-63 | ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE |
| U-64 | TREATMENT OF VIRAL INFECTIONS |
| U-65 | METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV |
| U-66 | TRIPHASIC REGIMEN |
| U-67 | METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL |
| U-68 | TREATMENT OF ACTINIC KERATOSIS |
| U-69 | TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS |
| U-70 | TREATMENT OF TRANSIENT INSOMNIA |
| U-71 | METHOD OF TREATMENT OF HEART FAILURE |
| U-72 | TREATMENT OF MIGRAINE |
| U-73 | METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES |
| U-74 | METHOD OF PROVIDING HYPNOTIC EFFECT |
| U-75 | RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS |
| U-76 | USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM |
| U-77 | TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS |
| U-78 | ULCERATIVE COLITIS |
| U-79 | SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURN DUE TO GERD |
| U-80 | METHOD OF TREATING OCULAR BACTERIAL INFECTIONS |
| U-81 | RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS |
| U-82 | TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE |
| U-83 | TREATMENT OF SEIZURES |
| U-84 | A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS |
| U-85 | NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS |
| U-86 | METHOD OF TREATING CERTAIN FORMS OF EPILEPSY |
| U-87 | METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS |
| U-88 | TREATMENT OF MODERATE PLAQUE PSORIASIS |
| U-89 | TREATMENT OR PROPHYLAXIS OF EMESIS |
| U-90 | TREATMENT OF PSYCHOTIC DISORDERS |
| U-91 | ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS |
| U-92 | TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATY |
| U-93 | USE AS AN ANTIHISTAMINE/DECONGESTANT |
| U-94 | TREATMENT-ADULTS W/ ADVANCED HIV,INTOLERANT OF APPROVED THERAPIES,INTOLERANT OF APPROVED THERAPIES W/PROVEN BENEFIT OR HAVE EXPERIENCED CLINICAL/IMMUNOLOGICAL DETERIORATION WHILE RECEIVING..OR FOR WHOM SUCH THERAPIES-CONTRAINDICATED |
| U-95 | SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS |
| U-96 | METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS |
| U-97 | A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT |
| U-98 | A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL |
| U-99 | METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM |
| U-100 | METHOD OF TREATING OCULAR INFLAMMATION |
| U-101 | ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED |
| U-102 | METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN |

**PATENT USE**

| | |
|---|---|
| U-103 | TREATMENT OF OCULAR HYPERTENSION |
| U-104 | TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE |
| U-105 | EMESIS |
| U-106 | TREATMENT OF EPILEPSY |
| U-107 | TREATMENT OF HYPERTENSION AND ANGINA PECTORIS |
| U-108 | SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGIAL HYPERSECRETORY CONDITIONS AND MAINTENANCE HEALING OF EROSIVE ESOPHAGITIS |
| U-109 | ADJUNCT DIET IN THE TX OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PTS W/PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SAT FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE |
| U-110 | USE AS A RETRIEVABLE PESSARY |
| U-111 | DIABETES |
| U-112 | CONTRACEPTION |
| U-113 | METHOD OF CONDUCTING RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE |
| U-114 | USE FOR INHIBITING BONE RESORPTION |
| U-115 | USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS |
| U-116 | METHOD OF MYOCARDIAL IMAGING |
| U-117 | TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES |
| U-118 | METHOD OF LOWERING BLOOD SUGAR LEVEL |
| U-119 | TREATMENT OF NASAL HYPERSECRETION |
| U-120 | CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES |
| U-121 | METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS |
| U-122 | A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS |
| U-123 | METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS |
| U-124 | TREATMENT OF ACNE |
| U-125 | TREATMENT NEUROGENERATIVE DISEASES |
| U-126 | TREATMENT OF GASTRITIS |
| U-127 | METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE |
| U-128 | METHOD FOR TREATMENT OF TUMORS |
| U-129 | METHOD TO DESTROY OR IMPAIR TARGET CELLS |
| U-130 | MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS |
| U-131 | PHOTODAMAGED SKIN |
| U-132 | INHIBITING HIV PROTEASE |
| U-133 | MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET |
| U-134 | TREATMENT OF ACNE VULGARIS |
| U-135 | ANTITUMOR AGENT |
| U-136 | PROCESS FOR WASTE NITROGEN REMOVAL |
| U-137 | METHOD OF TREATING BACTERIAL VAGINOSIS |
| U-138 | TREATMENT OF ALLERGIC RHINITIS |
| U-139 | TREATMENT OF ALLERGIC REACTIONS |
| U-140 | USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION |
| U-141 | TREATMENT OF ULCERATIVE COLITIS |

**PATENT USE**

| | |
|---|---|
| U-142 | METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE |
| U-143 | BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING |
| U-144 | BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS |
| U-145 | BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS |
| U-146 | METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS |
| U-147 | DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF 13CO2 |
| U-148 | DEVICE FOR COLLECTING A BREATH SAMPLE |
| U-149 | METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES |
| U-150 | METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE |
| U-151 | RELIEF OF SYMPTOMS OF THE COMMON COLD |
| U-152 | METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER |
| U-153 | TREATMENT OF INITIAL EPISODE GENITAL HERPES |
| U-154 | METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER |
| U-155 | TREATMENT OF ERECTILE DYSFUNCTION |
| U-156 | METHOD OF PROVIDING ANESTHESIA |
| U-157 | TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY |
| U-158 | ANGINA |
| U-159 | TREATMENT OF INTERSTITIAL CYSTITIS |
| U-160 | TREATMENT OF BACTERIAL INFECTIOUS DISEASE |
| U-161 | METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT |
| U-162 | METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA |
| U-163 | METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS |
| U-164 | METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS |
| U-165 | TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA |
| U-166 | TREATMENT OF H.PYLORI-ASSOCIATED DUODENAL ULCER |
| U-167 | METHOD FOR TREATING HIV-1 INFECTION |
| U-168 | METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA |
| U-169 | METHODS OF USING THE COMPOUND/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING |
| U-170 | METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION/DRUG PRODUCT AS A CONTRAST AGENT |
| U-171 | METHODS OF USING THE COMPOUND/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT |
| U-172 | TREATMENT OF GENITAL WARTS |
| U-173 | ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES |
| U-174 | USE AS AN ANTIHISTAMINE AGENT |
| U-175 | METHOD OF TREATING MALIGNANT TUMORS |
| U-176 | METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES |
| U-177 | FUNGICIDE |
| U-178 | FACILITATED ADHERENCE OF AGENTS TO SKIN |

**PATENT USE**

| | |
|---|---|
| U-179 | ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT |
| U-180 | TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER 6 MONTHS OF AGE) WITH ADVANCED HIV INFECTION |
| U-181 | PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST |
| U-182 | USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION |
| U-183 | TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION |
| U-184 | TREATING ALLERGIC EYE DISEASES IN HUMANS |
| U-185 | METHOD OF TREATING HYPERTENSION |
| U-186 | METHOD FOR TREATING GI DISORDERS CAUSED BY H. PYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT |
| U-187 | THERAPEUTIC TREATMENT OF CALCIFIC TUMORS |
| U-188 | TREATMENT OF H.PYLORI ASSOCIATED DUODENAL ULCER |
| U-189 | ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE |
| U-190 | USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR |
| U-191 | METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN |
| U-192 | USE IN TREATING ALLERGIC REACTIONS |
| U-193 | PSORIASIS |
| U-194 | TREATING ANGINA PECTORIS AND HIGH BLOOD PRESSURE |
| U-195 | METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOPE OR NITROGEN LABELED CARBON |
| U-196 | TREATMENT OF METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS |
| U-197 | USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER |
| U-198 | TREATMENT METASTATIC CARCINOMA OF OVARY AFTER 1ST LINE FAILURE OR SUBSQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND 2ND LINE TREATMENT OF AIDS RELATED KAPOSI'S SARCOMA |
| U-199 | METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORIDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT |
| U-200 | METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT |
| U-201 | METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT |
| U-202 | METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS |
| U-203 | TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY |
| U-204 | USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA |
| U-205 | METHOD FOR TREATING HEARTBURN |
| U-206 | METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENEOUS LH, IN IN VITRO FERTILIZATION |
| U-207 | USE AS NASAL SPRAY |
| U-208 | VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION |
| U-209 | VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION |
| U-210 | METHOD OF TREATING CONGESTIVE HEART FAILURE |
| U-211 | USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION |
| U-212 | METHOD OF TREATMENT OF PARKINSON'S DISEASE |
| U-213 | METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA |

**PATENT USE**

| | |
|---|---|
| | AND METHOD FOR TREATING HYPERLIPIDEMIA |
| U-214 | USE AS A BLOOD GLUCOSE-LOWERING AGENT |
| U-215 | TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG/ML OVER 12 HOURS |
| U-216 | TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C BY ADMINISTERING AN AGONIST OF LH-RH AND FLUTAMIDE |
| U-217 | METHOD OF PRODUCING ANESTHESIA |
| U-218 | METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT |
| U-219 | TREATMENT OF PARKINSON'S DISEASE |
| U-220 | METHOD OF DIAGNOSIS |
| U-221 | SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION |
| U-222 | METHOD OF TREATING PAGET'S DISEASE USING ACTONEL |
| U-223 | TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS |
| U-224 | CONTROLLING INTRAOCULAR PRESSURE |
| U-225 | METHOD FOR DELIVERY |
| U-226 | METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE |
| U-227 | NASAL ADMINISTRATION |
| U-228 | ASTHMA |
| U-229 | CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE) |
| U-230 | PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS |
| U-231 | USE IN PARKINSON'S DISEASE |
| U-232 | METHOD OF TREATING MIGRAINE |
| U-233 | DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE |
| U-234 | METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS |
| U-235 | METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE |
| U-236 | TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG/DAY |
| U-237 | METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS |
| U-238 | IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IN ENHANCED.... |
| U-239 | TREATING OR CONTROLLING OCULAR INFLAMMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID |
| U-240 | TREATMENT OF ACUTE MIGRAINE ATTACKS |
| U-241 | FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS |
| U-242 | USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION |
| U-243 | TOPICAL ADMINISTRATION |
| U-244 | PLATELET AGGREGATION INHIBITORS |
| U-245 | TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS |
| U-246 | PHOSPHATE BINDING |
| U-247 | TREATMENT OF RHEUMATOID ARTHRITIS |
| U-248 | TREATMENT OF HIV |

**PATENT USE**

| | |
|---|---|
| U-249 | METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE |
| U-250 | TREATMENT OF HEPATITIS B INFECTION |
| U-251 | USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES |
| U-252 | METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE |
| U-253 | ORAL TRANSMUCOSAL USE |
| U-254 | USE OF AGGRASTAT IN COMBINATION WITH HEPARIN |
| U-255 | IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY |
| U-256 | TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS |
| U-257 | TREATMENT OF HIV INFECTION |
| U-258 | TREATMENT OF NEURODEGENERATIVE DISEASES |
| U-259 | TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE |
| U-260 | REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION |
| U-261 | TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE |
| U-262 | TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE |
| U-263 | METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN |
| U-264 | METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN |
| U-265 | USE AS LAXATIVE |
| U-266 | RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENORRHEA; ACUTE TREATMENT OF MIGRAINE ATTACKS IN ADULTS |
| U-267 | PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE |
| U-268 | ACROMEGALY |
| U-269 | EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS |
| U-270 | METHOD OF IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT |
| U-271 | METHOD OF TREATING TUMORS |
| U-272 | METHOD OF TREATING CARCINOMA |
| U-273 | CUTANEOUS T-CELL LYMPHOMA |
| U-274 | ZANAMIVIR FOR INHALATION |
| U-275 | METHOD OF USE OF THE DRUG SUBSTANCE |
| U-276 | METHOD OF USE OF LEVOBUPIVACAINE |
| U-277 | NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING) |
| U-278 | METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT |
| U-279 | METHOD OF USE OF THE APPROVED PRODUCT |
| U-280 | TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE |
| U-281 | ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS |
| U-282 | METHOD OF TREATING BACTERIAL INFECTIONS |
| U-283 | METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE |
| U-284 | MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED |

**PATENT USE**

| | |
|---|---|
| | WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS |
| U-285 | DEPRESSION AND SOCIAL ANXIETY DISORDER/SOCIAL PHOBIA |
| U-286 | DEPRESSION |
| U-287 | TREATMENT OR PREVENTION OF OSTEOPOROSIS |
| U-288 | THERAPY OF INFLUENZA |
| U-289 | TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP |
| U-290 | INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) |
| U-291 | INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN |
| U-292 | INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE |
| U-293 | INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID |
| U-294 | TREATMENT OF HYPERPIGMENTARY DISORDERS |
| U-295 | TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS |
| U-296 | TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA NAUSEA AND FUNCTIONAL DISABILITY |
| U-297 | PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS |
| U-298 | METHOD OF COMBATING BACTERIA IN A PATIENT |
| U-299 | TREATMENT OF ADENOMATOUS POLYPS |
| U-300 | INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA |
| U-301 | USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES |
| U-302 | TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS |
| U-303 | METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPOROSIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID INDUCED OSTEOPOROSIS |
| U-304 | A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION |
| U-305 | METHODS FOR USING THE DRUG PRODUCT |
| U-306 | TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY |
| U-307 | CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES,EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA |
| U-308 | CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOLES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA |
| U-309 | TREATING SJOEGREN SYNDROME |
| U-310 | TREATMENT OF XEROSTOMIA |
| U-311 | HORMONE REPLACEMENT |
| U-312 | PANIC DISORDER, OBSESSIVE-COMPULSIVE DISORDER, POSTTRAUMATIC STRESS DISORDER |
| U-313 | TREATMENT OF CONGESTIVE HEART FAILURE |
| U-314 | METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY |
| U-315 | METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT |
| U-316 | METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER |
| U-317 | METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE |
| U-318 | TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE |

**PATENT USE**

| | |
|---|---|
| U-319 | TREATMENT OF MICROBIAL INFECTIONS |
| U-320 | INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA |
| U-321 | REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS |
| U-322 | TREATMENT OF ALZHEIMER'S DEMENTIA |
| U-323 | USE AS A BILE ACID SEQUESTRANT |
| U-324 | METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE |
| U-325 | METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING "BIPOLAR DISORDER NOS" EMPLOYING OLANZAPINE |
| U-326 | METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER |
| U-327 | METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITONS EMPLOYING OLANZAPINE |
| U-328 | METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING "A PSYCHOTIC CONDITION" EMPLOYING AN OLANZAPINE POLYMORPH |
| U-329 | USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS |
| U-330 | TREATMENT OF NAUSEA AND VOMITING |
| U-331 | METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT |
| U-332 | TREATMENT OR PREVENTION OF BRONCHOSPASM |
| U-333 | METHOD OF TREATING OCULAR HYPERTENSION |
| U-334 | TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR |
| U-335 | USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS |
| U-336 | DIAGNOSTIC RADIOIMAGING |
| U-337 | USE OF CARDIOLITE/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI |
| U-338 | METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME |
| U-339 | PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN |
| U-340 | THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN |
| U-341 | METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER |
| U-342 | METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER |
| U-343 | REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION |
| U-344 | METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR |
| U-345 | RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION |
| U-346 | METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMCOKINETICS OF A DRUG THAT IS METABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR |
| U-347 | METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS |
| U-348 | METHOD OF USE FOR INHIBITING HIV INFECTION |
| U-349 | METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION |
| U-350 | PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR |
| U-351 | INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIIR |
| U-352 | INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR |
| U-353 | PREVENTION AND TREATMENT OF OSTEOPOROSIS |

**PATENT USE**

| | |
|---|---|
| U-354 | METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT |
| U-355 | METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING |
| U-356 | DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A. |
| U-357 | USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE |
| U-358 | DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER |
| U-359 | METHOD OF USE OF VISICOL |
| U-360 | METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011 |
| U-361 | MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY |
| U-362 | USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS |
| U-363 | METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION THE SUBJECT MATTER OF SUPPLEMENT 011 |
| U-364 | TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011 |
| U-365 | METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION |
| U-366 | METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION |
| U-367 | TREATMENT OF CARDIOVASCULAR DISORDERS |
| U-368 | HEARTBURN |
| U-369 | METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE |
| U-370 | INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS |
| U-371 | APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.) |
| U-372 | METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL... |
| U-373 | GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING "PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE |
| U-374 | KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX |
| U-375 | METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C |
| U-376 | TREATMENT OF INFLUENZA |
| U-377 | METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS |
| U-378 | METHOD FOR TREATING INCONTINENCE |
| U-379 | METHOD OF TREATING ONYCHROMYCOSIS |
| U-380 | COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS |
| U-381 | TREATMENT OF HYPERPHOSPHATEMIA |
| U-382 | METHOD OF STABLIZING PROSTAGLANDIN |
| U-383 | METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION |

**PATENT USE**

| | |
|---|---|
| U-384 | TREATMENT OF CMV RETINITIS |
| U-385 | TREATMENT OF PEPTIC ULCERS |
| U-386 | TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA |
| U-387 | TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS |
| U-388 | SMOKING CESSATION AID APPLIED TO THE SKIN |
| U-389 | SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS |
| U-390 | METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS) |
| U-391 | USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER |
| U-392 | TREATMENT OF PATIENTS FOR INFLAMMATION |
| U-393 | MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT |
| U-394 | METHOD OF USE OF ALPHAGAN |
| U-395 | METHOD OF USE OF ALPHAGAN P |
| U-396 | METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION |
| U-397 | METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA |
| U-398 | TREATMENT OF GENERALIZED ANXIETY DISORDER |
| U-399 | IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS |
| U-400 | USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESP0NSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS |
| U-401 | USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS |
| U-402 | TREATMENT OF ACTINIC KERATOSES |
| U-403 | ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES |
| U-404 | TREATMENT OF ALLERGIC CONJUNCTIVITIS |
| U-405 | FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS) |
| U-406 | METHOD OF USE OF ATOVAQUONE AND PROGUANIL |
| U-407 | METHOD OF TREATING OTOPATHY |
| U-408 | FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION |
| U-409 | METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE |
| U-410 | METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER |
| U-411 | METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION |
| U-412 | TREATMENT OF TYPE 2 DIABETES |
| U-413 | USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS |
| U-414 | A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE |
| U-415 | A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS |
| U-416 | A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING |

**PATENT USE**

| | |
|---|---|
| | PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS |
| U-417 | COMBINATION USE OF AD-4833 WITH A BIGUANIDE |
| U-418 | A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER |
| U-419 | A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE |
| U-420 | METHOD OF TREATMENT OF TYPE II DIABETES |
| U-421 | USE FOR SEDATION |
| U-422 | METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER |
| U-423 | METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA |
| U-424 | FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS |
| U-425 | METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER |
| U-426 | PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION |
| U-427 | METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS |
| U-428 | METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE |
| U-429 | METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS |
| U-430 | METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT COMPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER |
| U-431 | POSTTRAUMATIC STRESS DISORDER |
| U-432 | REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE |
| U-433 | USE OF LEVOCARNITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS |
| U-434 | CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS |
| U-435 | A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG |
| U-436 | ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS |
| U-437 | METHOD OF USE EQUAL TO PROCESS OF PREPARATION |
| U-438 | TREATMENT/PREVENTION OF NEURODEGENERATIVE DISEASE |
| U-439 | TREATMENT OF OBESITY |
| U-440 | METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE |
| U-441 | METHOD OF TREATING MS BY ADMINISTERING COPAXONE |
| U-442 | METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG |
| U-443 | MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME |
| U-444 | TREATMENT OF MIGRAINE |
| U-445 | USE AS AN ANTIMYCOTIC AGENT |
| U-446 | TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA |
| U-447 | METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT |

**PATENT USE**

| | |
|---|---|
| U-448 | METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT |
| U-449 | USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER |
| U-450 | INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS,SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING |
| U-451 | TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER |
| U-452 | USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI) |
| U-453 | TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS |
| U-454 | METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG/KG TO 2MCG/KG, ONCE WEEKLY, AND RIBAVIRIN |
| U-455 | TREATMENT OF PULMONARY HYPERTENSION WITH UT-15 |
| U-456 | METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE |
| U-457 | METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN |
| U-458 | METHOD OF USE OF IMAGENT |
| U-459 | TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER |
| U-460 | METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE |
| U-461 | METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE |
| U-462 | SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA |
| U-463 | VENOGRAPHY |
| U-464 | PERIPHERAL ARTERIOGRAPHY |
| U-465 | CT IMAGING OF THE HEAD |
| U-466 | TREATMENT OF IRRITABLE BOWEL SYNDROME |
| U-467 | USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION |
| U-468 | METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS |
| U-469 | TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE |
| U-470 | THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION |
| U-471 | METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS |
| U-472 | TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES |
| U-473 | TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL |
| U-474 | TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN |
| U-475 | TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY |
| U-476 | METHOD OF TREATING ANDROGEN RESPONSIVE/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY |
| U-477 | METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA |

**PATENT USE**

| | |
|---|---|
| U-478 | METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B |
| U-479 | METHOD OF USING PEG-INTRON/REBETOL COMBINATION THERAPY AND INTRON/REBETOL COMBINATION THERAPY |
| U-480 | CONTRAST AGENT FOR MRI |
| U-481 | DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY |
| U-482 | METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR INDUCING OVULATION.... |
| U-483 | METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND |
| U-484 | METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION |
| U-485 | METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA) |
| U-486 | EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE |
| U-487 | METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA) |
| U-488 | METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA |
| U-489 | EXPECTORANT |
| U-490 | TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE |
| U-491 | METHOD OF DELIVERING A DRUG TO THE LUNG |
| U-492 | METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP CONSISTING OF NONACNE INFLAMMATORY DERMATOSES... COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID |
| U-493 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
| U-494 | TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER |
| U-495 | PERITONEAL DIALYSIS SOLUTION |
| U-496 | METHOD FOR TREATING CHRONIC RENAL FAILURE |
| U-497 | RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS |
| U-498 | INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST |
| U-499 | METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION |
| U-500 | USE AS AN ANTIHYPERTENSIVE AGENT |
| U-501 | TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS |
| U-502 | PITYRIASIS VERSICOLOR |
| U-503 | GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR |
| U-504 | TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS |
| U-505 | ULTRASOUND CONTRAST AGENT |
| U-506 | PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE,BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE.. |
| U-507 | ACROMEGALY IN PATIENTS W/INADEQUATE RESPONSE TO SURGERY AND/OR RADIATION THERAPY AND/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE |
| U-508 | METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS |
| U-509 | TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY |

**PATENT USE**

| | |
|---|---|
| U-510 | TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES |
| U-511 | USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA |
| U-512 | USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA |
| U-513 | METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC AMYCOPLASMA BACTERIA |
| U-514 | PREVENTION OF OVULATION IN A WOMAN |
| U-515 | TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY |
| U-516 | METHOD OF TREATING A PSYCHOTIC DISEASE |
| U-517 | STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS |
| U-518 | OBSESSIVE COMPULSIVE DISORDER |
| U-519 | POST OPERATIVE NAUSEA AND VOMITING |
| U-520 | PREMENOPAUSAL OSTEOPOROSIS |
| U-521 | METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C |
| U-522 | TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA |
| U-523 | METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED MAMMAL |
| U-524 | METHOD OF TREATING DIARRHEA |
| U-525 | METHOD OF TREATING PARASITIC INFECTIONS |
| U-526 | METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION |
| U-527 | METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE |
| U-528 | PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING |
| U-529 | ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE |
| U-530 | TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES |
| U-531 | TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION. MAY BE USED ALONE OR GIVEN WITH OTHER CLASSES OF ANTIHYPERTENSIVES, ESPECIALLY THIAZIDE DERIVATIVES |
| U-532 | TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE BRONCHO DILATOR |
| U-533 | ERECTILE DYSFUNCTION |
| U-534 | HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA |
| U-535 | TREATMENT OF SOCIAL ANXIETY DISORDER |
| U-536 | CONTRAST AGENT FOR MAGNETIC RESONACE IMAGING |
| U-537 | TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE |
| U-538 | FIRST LINE TREATMENT OF SEVERE HYPERTENSION, IN PATIENTS WITH HYPERTENSION SEVERE ENOUGH THAT THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY IN THESE PATIENTS |
| U-539 | TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE |
| U-540 | TREATMENT OF FUNGAL INFECTIONS |
| U-541 | METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1 |
| U-542 | METHOD OF TREATING PATIENT WITH TYPE 2 DIABETES BY ONCE DAILY ADMINISTRATION |
| U-543 | TREATMENT OF SCHIZOPHRENIA |
| U-544 | TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE. |

**PATENT USE**

| | |
|---|---|
| U-545 | METHOD FOR THE PREVENTION AND/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT |
| U-546 | USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE |
| U-547 | MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER |
| U-548 | A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER |
| U-549 | USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER |
| U-550 | TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA |
| U-551 | METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID |
| U-552 | TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION |
| U-553 | MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIDONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIDONTAL POCKETS |
| U-554 | TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS |
| U-555 | TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS |
| U-556 | USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING |
| U-557 | NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS |
| U-558 | INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE) |
| U-559 | METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION;METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL |
| U-560 | METHOD OF DECREASING PARATHYROID HORMONE LEVEL;METHOD OF TREATING HYPERPARATHYROIDISM |
| U-561 | COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS |
| U-562 | TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA |
| U-563 | MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS |
| U-564 | TREATMENT OF HIV IN CONCOMITANT THERAPY |
| U-565 | TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA |
| U-566 | FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA |
| U-567 | METHOD OF TREATING INFERTILITY |
| U-568 | METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION |
| U-569 | METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED |
| U-570 | METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU/KG |
| U-571 | TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA |
| U-572 | INTENSIVE CARE UNIT SEDATION |
| U-573 | TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL) |
| U-574 | PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER |
| U-575 | LOTEMAX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TREATMENT OF STEROID RESPONSIVE CONDITIONS OF THE PALPEBRAL BULBAR CONJUNCTIVA, CORNEA AND ANTERIOR |

**PATENT USE**

| | |
|---|---|
| | SEGMENT OF THE GLOBE. |
| U-576 | ALREX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TEMPORARY RELIEF OF THE SIGNS AND SYMPTOMS OF SEASONAL ALLERGIC CONJUNCTIVITIS. |
| U-577 | TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN |
| U-578 | TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER. |
| U-579 | TREATMENT OF EPILEPSY AND/OR MIGRAINE. |
| U-580 | TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS |
| U-581 | METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413 |
| U-582 | METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762 |
| U-583 | METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928 |
| U-584 | SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY |
| U-585 | TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS |
| U-586 | AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE-A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH |
| U-587 | USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION |
| U-588 | SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS |
| U-589 | METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966 |
| U-590 | METHOD FOR TREATMENT OF A RESPIRATORY DISORDER,E.G.,BRONCHOSPASM,COMPRISING ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO.6532955 |
| U-591 | TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG |
| U-592 | TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH) |
| U-593 | TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH) |
| U-594 | PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS |
| U-595 | 35 MG ORALLY ONCE A WEEK FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN; 35 MG ORALLY ONCE A WEEK FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN |
| U-596 | TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY |
| U-597 | FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE |
| U-598 | PROPHYLACTIC TREATMENT OF MIGRAINE |
| U-599 | METHOD FOR TREATING ALLERGIC CONJUNCTIVITIS |
| U-600 | A METHOD OF TREATING A PATIENT IN NEED OF OPHTHALMIC ANTIMICROBIAL THERAPY WITH LEVOFLOXACIN |
| U-601 | TREATMENT OF BIPOLAR DISORDER |
| U-602 | SIGNS AND SYMPTOMS OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS IN ADULTS, AND/OR |

**PATENT USE**

| | |
|---|---|
| | PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS, ACUTE PAIN IN ADULTS; PRIMARY DYSMENORRHEA; AND/OR ACUTE MIGRAINE ATTACKS IN ADULTS |
| U-603 | METHOD OF TREATING INFECTIONS COMPRISING ORALLY ADMINISTERING AN EFFECTIVE AMOUNT OF THE FDA APPROVED ORAL SUSPENSION |
| U-604 | METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION |
| U-605 | TREATMENT OF MAJOR DEPRESSIVE DISORDER(MDD);ALTHOUGH THE MEHCHANISM OF THE ANTIDEPRESSANT ACTION OF DULOXETINE IN HUMANS IS UNKNOWN, IT IS BELIEVED TO BE RELATED TO ITS POTENTIATION OF SERATONERGIC AND NORADRENERGIC ACTIVITY IN THE CNS |
| U-606 | USE OF IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER |
| U-607 | CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS. |
| U-608 | USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA |
| U-609 | USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA |
| U-610 | ATROVENT HFA (IPRATROPIUM BROMIDE HFA) INHALATION AEROSOL IS INDICATED AS A BRONCHODILATOR FOR MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA. |
| U-611 | METHOD OF USING DESLORATADINE TO TREAT SEASONAL AND PERENNIAL ALLERGIC RHINITIS, PRURITIS, AND CHRONIC IDIOPATHIC URTICARIA IN PATIENTS 2 YEARS OF AGE AND OLDER |
| U-612 | TREATMENT OF SEASONAL ALLERGY SYMPTOMS WITH NASAL CONGESTION IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER |
| U-613 | REDUCTION OF SERUM PHOSPHATE |
| U-614 | TREATMENT OF SEXUAL DYSFUNCTION |
| U-615 | ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TOTAL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V) |
| U-616 | MANAGEMENT OF PERSISTENT, MODERATE TO SEVERE PAIN IN PATIENTS REQUIRING CONTINUOUS, AROUND-THE-CLOCK ANALGESIA WITH A HIGH POTENCY OPIOID FOR AN EXTENDED PERIOD OF TIME GENERALLY WEEKS TO MONTHS OR LONGER |
| U-617 | TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL) |
| U-618 | USE OF ROSUVASTATIN CALCIUM TO REDUCE ELEVATED TOTAL-C, LDL-C, APOB, NONHDL-C OR TG LEVELS; TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA; AND TO SLOW THE PROGRESSION OF ATHEROSCLEROSIS. |
| U-619 | TREATMENT OF MALIGNANT NEOPLASM |
| U-620 | TREATMENT OF INSOMNIA |
| U-621 | METHOD OF TREATING CANCER |
| U-622 | TREATMENT OF VEGF MEDIATED OCULAR DISEASE. |
| U-623 | SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER |
| U-624 | REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS |
| U-625 | ALLERGIC RHINITIS OR NASAL POLYPS |
| U-626 | CLOLAR IS INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 TO 21 YEARS OLD WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AFTER AT LEAST TWO PRIOR REGIMENS |
| U-627 | TREATMENT OF PATIENTS USING EXTENDED-RELEASE CARBAMAZEPINE |
| U-628 | USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA, AND IN COMBINATION WITH METFORMIN AND A SULFONYLUREA TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS |
| U-629 | METHOD OF INDUCING A HYPNOTIC OR SEDATIVE EFFECT IN A HUMAN BY ADMINISTERING ESZOPICLONE |
| U-630 | TREATING URINARY INCONTINENCE BY ADMINISTERING AN EXTENDED-RELEASE FORM OF DARIFENACIN |
| U-631 | TREATING A DISEASE OF ALTERED MOTILITY OR TONE OF SMOOTH MUSCLE BY ADMINISTERING A MUSCARINIC RECEPTOR ANTAGONIZING AMOUNT OF DARIFENACIN |

**PATENT USE**

| | |
|---|---|
| U-632 | METHOD OF TREATMENT OF CANCER BY ADMINISTERING PARTICLES OF PACLITAXEL THAT HAVE A PROTEIN COATING |
| U-633 | METHOD FOR TREATMENT OF TUMORS BY ADMINISTERING PACLITAXEL AT A DOSE IN THE RANGE OF ABOUT 30MG/METER SQUARE TO ABOUT 100MG/METER SQUARE IN A PHARMACEUTICALLY ACCEPTABLE FORMULATION THAT DOES NOT CONTAIN CREMOPHOR |
| U-634 | METHOD FOR DELIVERY OF A BIOLOGIC (INCLUDING ANTINEOPLASTIC AGENTS) BY ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF A BIOLOGIC AS A SOLID OR LIQUID WITH A POLYMERIC BIOCOMPATIBLE MATERIAL |
| U-635 | TREATMENT OF GERD, MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND RISK REDUCTION OF NSAID ASSOCIATED GASTRIC ULCERS |
| U-636 | TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS |
| U-637 | TREATMENT OF DIABETES WITH AN AMYLIN AGONIST |
| U-638 | TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN |
| U-639 | TREATMENT OF A MAMMAL HAVING A NEED OF OR REDUCED ABILITY TO PRODUCE INSULIN WITH AN INSULIN AND AN AMYLIN SUCH AS PRAMLINTIDE |
| U-640 | USE OF AN AMYLIN AGONIST TO REDUCE GASTRIC MOTILITY AND TREAT POST PRANDIAL HYPERGYLCEMIA |
| U-641 | USE OF AN AMYLIN AGONIST HAVING SPECIFIED BINDING ACTIVITY TO REDUCE GASTRIC MOTILITY, INCLUDING USE THROUGH PARENTERAL ADMINISTRATION |
| U-642 | TREATMENT AND PREVENTION OF OSTEOPOROSIS |
| U-643 | THE SHORT TERM TREATMENT (UP TO 10 DAYS) IN PTS HAVING GASTROESOPHAGEAL REFLUX DISEASE (GERD) AS AN ALTERNATIVE TO ORAL THERAPY IN PTS WHEN THERAPY WITH NEXIUM CAPSULES IS NOT POSSIBLE OR APPROPRIATE |
| U-644 | TREATMENT OF SEASONAL ALLERGIC RHINITIS |
| U-645 | TREATMENT OF ASTHMA |
| U-646 | METHOD OF TREATING OTITIS |
| U-647 | TREATMENT OF OSTEOPOROSIS IN POST MENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS |
| U-648 | THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND/OR THE TREATMENT TO INCREASE BONE MASS IN MEN |
| U-649 | A METHOD FOR TREATING A TUMOR DISEASE |
| U-650 | TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS |
| U-651 | TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL) |
| U-652 | TREATMENT OF CARDIAC ARRHYTHMIA |
| U-653 | STIMULATING INSULIN RELEASE BY ADMINISTERING EXENATIDE |
| U-654 | LOWERING PLASMA GLUCAGON IN A SUBJECT IN NEED THEREOF, INCLUDING ONE WITH TYPE 2 DIABETES, BY ADMINISTERING AN EXENDIN OR ANALOG, SUCH AS EXENDIN-4 |
| U-655 | TREATMENT OF MILD TO MODERATE ACTIVE CHROHN'S DISEASE INVOLVING THE ILEUM AND/OR THE ASCENDING COLON AND THE MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND/OR ASCENDING COLON FOR UP TO 3 MONTHS |
| U-656 | REDUCING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4 |
| U-657 | PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN |
| U-658 | TREATMENT OF ADVANCED HORMONE-DEPENDENT BREAST CANCER |
| U-659 | TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN |
| U-660 | TREATMENT OF HYPERTENSION AND TREATMENT OF HEART FAILURE |
| U-661 | TREATMENT OF SEIZURE DISORDER |
| U-662 | TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN |
| U-663 | THE TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS |
| U-664 | TREATMENT OF CONDITIONS FOR WHICH AN ALDOSTERONE RECEPTOR BLOCKER IS INDICATED, SUCH AS HYPERTENSION, HEART FAILURE, AND POST-MYOCARDIAL INFARCTION |

**PATENT USE**

| | |
|---|---|
| U-665 | METHOD OF USING THE DRUG SUBSTANCE/DRUG PRODUCT FOR ULTRASOUND IMAGING |
| U-666 | METHOD OF TREATING ADHD |
| U-667 | MANAGEMENT OF INCONTINENCE; METHOD FOR TREATING INCONTINENCE |
| U-668 | LEVEMIR IS A LONG-ACTING BASAL INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS |
| U-669 | INDICATION OF TYPE II DIABETES |
| U-670 | TREATMENT OF HIV-1 INFECTION BY THE CO-ADMINISTRATION OF TIPRANAVIR AND RITONAVIR. |
| U-671 | PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND 4 |
| U-672 | TREATMENT OF INFLAMMATION OR AN INFLAMMATION-ASSOCIATED DISORDER |
| U-673 | METHOD OF TREATMENT WITH ONCE-DAILY DOSES OF 625MG/5ML |
| U-674 | METHOD OF TREATING INSOMNIA CHARACTERIZED BY DIFFICULTY WITH SLEEP ONSET |
| U-675 | PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA; RELIEF OF SYMPTOMS OF ALLERGIC RHINITIS |
| U-676 | METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION |
| U-677 | A METHOD OF TREATING DISEASE AMENABLE TO TREATMENT WITH A PHENIDATE DRUG BY ONCE DAILY ORAL ADMINISTRATION OF AN EXTENDED RELEASE DOSAGE FORM |
| U-678 | METHOD OF TREATING ATTENTION DEFICIT DISORDER AND/OR ATTENTION DEFICIT HYPERACTIVITY DISORDER |
| U-679 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN |
| U-680 | A METHOD OF TREATING DYSLIPIDEMIA AND DYSLIPOPROTEINEMIA USING A DOSAGE FORM THAT CAN PROVIDE AN EFFECTIVE AMOUNT OF FENOFIBRATE TO A PATIENT IN A FASTED STATE WHICH IS AT LEAST 90% OF THE AUC AMOUNT PROVIDED BY THE DOSAGE FORM |
| U-681 | TREATMENT OF PRIMARY IGF-1 DEFICIENCY |
| U-682 | NON-BENZODIAZEPINE HYPNOTIC AGENT INDICATED FOR TREATMENT OF INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND/OR SLEEP MAINTENANCE |
| U-683 | PREVENTION OR TREATMENT OF ISCHEMIC HEART DISEASE |
| U-684 | TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER |
| U-685 | EXPECTORANT AND COUGH SUPPRESSANT |
| U-686 | EXPECTORANT AND NASAL DECONGESTANT |
| U-687 | REDUCING FOOD INTAKE IN A SUBJECT WITH TYPE 2 DIABETES BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4 |
| U-688 | TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS |
| U-689 | TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS |
| U-690 | TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS |
| U-691 | USE AS A MONOTHERAPY, IN COMBINATION WITH A SULFONYLUREA, METFORMIN OR INSULIN OR IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS |
| U-692 | USE OF VALSARTAN TO REDUCE CARDIOVASCULAR MORTALITY IN CLINICALLY STABLE PATIENTS WITH LEFT VENTRICULAR FAILURE OR LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION |
| U-693 | THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE. |
| U-694 | LENALIDOMIDE IS AN ANALOGUE OF THALIDOMIDE. THALIDOMIDE IS A KNOWN HUMAN TERATOGEN THAT CAUSES SEVERE LIFE-THREATENING HUMAN BIRTH DEFECTS. IF LENALIDOMIDE IS TAKEN DURING PREGNANCY, IT MAY CAUSE BIRTH DEFECTS OR DEATH TO AN UNBORN BABY. |
| U-695 | TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND T-CELL |

**PATENT USE**

| | |
|---|---|
| | LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS |
| U-696 | TREATMENT OF PATIENTS WITH T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS |
| U-697 | A METHOD OF USING RINFABATE RECOMBINANT (RHIGFBP-3) WITH MECASERMIN RECOMBINANT (RHIGF-1) TO PROMOTE LINEAR GROWTH IN THE TRATMENT OF PRIMARY IGF-1 DEFICIENCY |
| U-698 | METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH EUVOLEMIC HYPONATREMIA |
| U-699 | NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS |
| U-700 | TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN |
| U-701 | TREATMENT OF HYPERCHOLESTEROLEMIA AND/OR HYPERTRIGLYCERIDEMIA |
| U-702 | TOPICAL AEROSOL HAIR REGROWTH TREATMENT |
| U-703 | TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMOR AND RENAL CELL CARCINOMA WITH SUNITINIB |
| U-704 | METHOD OF ADMINISTERING INSULIN VIA INHALATION |
| U-705 | TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE |
| U-706 | TREATMENT OF BENIGN PROSTATIC HYPERPLASIA |
| U-707 | ALLERGIC RHINITIS |
| U-708 | TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE |
| U-709 | METHOD OF COMBATING BACTERIA IN A PATIENT |
| U-710 | A METHOD OF TREATING RESPIRATORY DISORDERS, E.G., ASTHMA, WHICH COMPRISES ADMINISTRATION BY INHALATION OF AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT NO. 5658549 |
| U-711 | ACUTE AND LONGER-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER |
| U-712 | A METHOD OF USING A NICOTINIC ACID FORMULATION TO REDUCE ELEVATED TC, LDL-C AND TG LEVELS, AND RAISE HDL-C LEVELS IN PATIENTS WITH HYPERLIPIDEMIA |
| U-713 | TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE |
| U-714 | TOPICAL TREATMENT OF INTERDIGITAL TINEA PEDIS AND TINEA CORPORIS DUE TO TRICHOPHYTON RUBRUM, TRICHOPHYTON MENTAGROPHYTES OR EPIDERMOPHYTON FLOCCOSUM |
| U-715 | FOR CLEANSING THE BOWEL IN PREPARATION FOR COLONOSCOPY, IN ADULTS 18 YEARS OF AGE OR OLDER |
| U-716 | THE TREATMENT OR PREVENTION OF BRONCHOSPASM IN ADULTS AND CHILDREN 4 YEARS OF AGE AND OLDER WITH REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE AND THE PREVENTION OF EXERCISED-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER |
| U-717 | METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT |
| U-718 | TREATMENT OF FUNGAL INFECTIONS |
| U-719 | TREATENT OF PSYCHOSIS |
| U-720 | TREATMENT OF NEUROLEPTIC DISEASES |
| U-721 | TREATMENT OF INFLUENZA |
| U-722 | PROPHYLAXIS OF INFLUENZA |
| U-723 | PROPHYLACTIC TREATMENT OF MIGRAINE |
| U-724 | METHOD OF TREATING SEIZURES |
| U-725 | ALLERGIC RHINITIS AND URTICARIA |
| U-726 | ALLERGIC RHINITIS |
| U-727 | FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) |
| U-728 | METHOD FOR TREATING BACTERIAL INFECTION |
| U-729 | TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER, H. PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE |
| U-730 | USE AS A NASAL SPRAY FOR TREATMENT OF THE SYMPTOMS OF SEASONAL ALLERGIC RHINITIS |

**PATENT USE**

| | |
|---|---|
| | AND VASOMOTOR RHINITIS |
| U-731 | USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA |
| U-732 | ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL) |
| U-733 | MAINTENANCE THERAPY FOR PREVENTION AND SUPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE |
| U-734 | FIRST LINE THERAPY FOR TYPE 2 DIABETES MELLITUS |
| U-735 | METHOD OF TREATING CHRONIC IRON OVERLOAD |
| U-736 | METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE |
| U-737 | DISINFECTION OF PATIENT SKIN PRIOR TO AN INVASIVE PROCEDURE |
| U-738 | INDICATED FOR THE LONG-TERM, TWICE-DAILY MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE OR OLDER |
| U-739 | METHOD FOR TREATING CONSTIPATION BY OPENING CIC CHANNELS IN A MAMMALIAN SUBJECT |
| U-740 | FOR THE TREATMENT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS |
| U-741 | COMBINATION THERAPY WITH CISPLATIN FOR THE TREATMENT OF LATE STAGE CERVICAL CANCER |
| U-742 | TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS. |
| U-743 | ONCE A DAY TOPICAL TREATMENT OF THE INFLAMMATORY LESIONS OF ROSACEA |
| U-744 | TREATMENT OF HIV INFECTION IN ANTIRETROVIRAL TREATMENT-EXPERIENCED ADULT PATIENTS |
| U-745 | TREATMENT OR PREVENTION OF EMESIS |
| U-746 | PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT |
| U-747 | PREVENTION OR TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING |
| U-748 | A METHOD FOR THE TREATMENT OF A PROTEIN TYROSINE KINASE-ASSOCIATED DISORDER |
| U-749 | METHOD OF CONTRACEPTION |
| U-750 | TREATMENT OF HIV-1 INFECTION IN ADULTS |
| U-751 | ONCE DAILY DOSING OF BUDESONIDE VIA NEBULIZER FOR THE TREATMENT OF ASTHMA |
| U-752 | SUNSCREEN |
| U-753 | AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES |
| U-754 | USE FOR THE LONG-TERM MAINTENANCE TREATMENT OF ASTHMA |
| U-755 | TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) |
| U-756 | ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS |
| U-757 | USE AS A BILE ACID SEQUESTRANT FOR LOWERING CHOLESTEROL |
| U-758 | TREATMENT OF SYMPTOMS OF PREMENSTRUAL DYSPHORIC DISORDER |
| U-759 | METHOD OF USE OF ADMINISTERING LEVOTHYROXINE |
| U-760 | PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS AND TREATMENT OF OROPHARYNGEAL CANDIDAIASIS |
| U-761 | TREATMENT OF SCHIZOPHRENIA INCLUDING MAINTAINING STABILITY IN PATIENTS WITH SCHIZOPHRENIA |
| U-762 | TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
| U-763 | ADMINISTRATION OF ARIPIPRAZOLE BY INJECTION |
| U-764 | TREATMENT OF SCHIZOPHRENIA |
| U-765 | METHOD OF TREATING ALLERGIC CONJUNCTIVITIS |
| U-766 | TREATMENT OF SEIZURES |
| U-767 | MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER |

**PATENT USE**

| | |
|---|---|
| U-768 | A METHOD OF REDUCING THE CAPACITY OF EXTENDED RELEASE NICOTINIC ACID TO PROVOKE A FLUSHING REACTION BY PRETREATING AN INDIVIDUAL WITH A FLUSH INHIBITING AGENT PRIOR TO THE ADMINISTRATION OF THE EXTENDED RELEASE NICOTINIC ACID |
| U-769 | REVLIMID (LENALIDOMIDE) IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
| U-770 | LONG-TERM TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS |
| U-771 | METHOD FOR THE TREATMENT OF DIABETES MELLITUS, SUCH AS TYPE 1 DIABETES MELLITUS OR TYPE 2 DIABETES MELITUS, IN A HUMAN PATIENT |
| U-772 | RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS |
| U-773 | PATHOLOGICAL HYPERSECRETORY CONDITIONS |
| U-774 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASTE-IV INHIBITOR |
| U-775 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA |
| U-776 | TREATMENT OF CUTANEOUS MANIFESTATION IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL) WHO HAVE PROGRESSIVE, PERSISTENT OR RECURRENT DISEASE ON OR FOLLOWING TWO SYSTEMIC THERAPIES. |
| U-777 | DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE |
| U-778 | REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION |
| U-779 | A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA |
| U-780 | A METHOD FOR THE TREATMENT OF CANCER |
| U-781 | FOR TREATMENT OF ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE NAIVE TO PHARMACOLOGIC THERAPY |
| U-782 | TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS WITH EVIDENCE OF VIRAL REPLICATION AND EITHER EVIDENCE OF PERSISTANT ELEVATIONS IN SERUM AMINOTRANSFERASES (ALT OR AST) OR HISTOLOGICALLY ACTIVE DISEASE |
| U-783 | DESONATE GEL IS INDICATED FOR THE TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE AND OLDER |
| U-784 | TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS) |
| U-785 | USE AS REPLACEMENT SOLUTION, HEMOFILTRATION SOLUTION OR HEMODIAFILTRATION SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY |
| U-786 | PRODUCT IS APPROVED FOR THE TOPICAL TREATMENT OF TINEA PEDIS |
| U-787 | MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND PEDIATRIC PATIENTS SIX YEARS OF AGE OR OLDER, INCLUDING PATIENTS REQUIRING ORAL CORTICOSTEROID THERAPY FOR ASTHMA |
| U-788 | METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING PAROXETINE |
| U-789 | TREATMENT OF KNOWN OR SUSPECTED CYANIDE POISONING |
| U-790 | FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT RISK FOR FRACTURE. FORTEO CAN BE USED BY PEOPLE WHO HAVE HAD A FRACTURE RELATED TO OSTEOPOROSIS |
| U-791 | GLEEVEC IS ALSO INDICATED FOR THE TREATMENT OF PATIENTS WITH KIT (CD117) POSITIVE UNRESECTABLE AND/OR METASTATIC MALIGNANT GASTROINTESTINAL STROMAL TUMORS (GIST) |
| U-792 | TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS |
| U-793 | FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA |
| U-794 | CLOSURE OF A CLNICALLY SIGNIFICANT PATENT DUCTUS ARTERIOSUS IN PREMATURE INFANTS WEIGHING BETWEEN 500 AND 1500G, WHO ARE NO MORE THAN 32 WEEKS GESTATIONAL AGE WHEN USUAL MEDICAL MANAGEMENT IS INEFFECTIVE |
| U-795 | METHOD FOR INHIBITING NOREPINEPHRINE UPTAKE |

**PATENT USE**

| | |
|---|---|
| U-796 | METHOD OF TREATING DEPRESSION |
| U-797 | METHOD OF TREATING ANXIETY |
| U-798 | TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN BY ONCE-MONTHLY ORAL ADMINISTRATION OF IBANDRONATE SODIUM MONOHYDRATE EQUIVALENT TO 150MG OF IBANDRONIC ACID |
| U-799 | METHOD FOR INHIBITING SEROTONIN UPTAKE |
| U-800 | TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER WHOSE TUMORS OVEREXPRESS HER2 AND WHO HAVE RECEIVED PRIOR THERAPY INCLUDING ANTHRACYCLINE, A TAXANE AND TRASTUZUMAB |
| U-801 | METHOD OF TREATING CANCER |
| U-802 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR |
| U-803 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN |
| U-804 | TREATMENT OF ACTINIC KERATOSES BY PHOTODYNAMIC THERAPY |
| U-805 | TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES |
| U-806 | INTRATHECAL TREATMENT OF LYMPHOMATOUS MENINGITIS |
| U-807 | PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION |
| U-808 | THE TREATMENT OF THE SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN PATIENTS 2 YEARS OF AGE AND OLDER |
| U-809 | TREATMENT OF CHRONIC IDIOPATHIC URTICARIA |
| U-810 | METHOD OF TREATMENT TO ALLEVIATE INFLAMMATION OF THE EYE |
| U-811 | RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS AND TREATMENT OF THE UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA |
| U-812 | RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS |
| U-813 | MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) |
| U-814 | TREATMENT OF SCHIZOPHRENIA |
| U-815 | TREATS COLD SORES/FEVER BLISTERS ON THE FACE OR LIPS. SHORTENS HEALING TIME AND DURATION OF SYMPTOMS: TINGLING, PAIN, BURNING AND/OR ITCHING |
| U-816 | DEPRESSION, PANIC DISORDER, PREMENSTRUAL DISORDERS AND SOCIAL ANXIETY DISORDER |
| U-817 | NASAL ADMINISTRATION OF CYANOCOBALAMIN |
| U-818 | TOPICAL TREATMENT OF ACNE VULGARIS |
| U-819 | MANAGEMENT OF FIBROMYALGIA |
| U-820 | IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY, OBSTRUCTIVE SLEEP APNEA/HYPOPNEA SYNDROME, AND SHIFT WORK SLEEP DISORDER |
| U-821 | METHOD OF INHIBITING ENTHOTHELIN RECEPTORS BY ADMINISTERING AMBRISENTAN TO A PATIENT TO TREAT PULMONARY ARTERIAL HYPERTENSION. |
| U-822 | USE IN LIPID MANAGEMENT |
| U-823 | RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS AND FOR THE TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 TO 11 YEARS OF AGE |
| U-824 | METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1 |
| U-825 | USE FOR PREVENTION OF BREAST CANCER |
| U-826 | RELIEF OF MODERATE TO SEVERE PAIN |
| U-827 | USE FOR TREATMENT OF DIABETES, PARTICULARLY TYPE 2 DIABETES |
| U-828 | PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION |
| U-829 | TREATMENT OF EXTRAVASATION RESULTING FROM IV ANTHRACYCLINE CHEMOTHERAPY |
| U-830 | TREATMENT OF RELAPSED SMALL CELL LUNG CANCER |

**PATENT USE**

| | |
|---|---|
| U-831 | METHOD OF ADMINISTERING LANREOTIDE ACETATE |
| U-832 | ZINGO IS INDICATED FOR THE USE ON INTACT SKIN TO PROVIDE LOCAL ANALGESIA PRIOR TO VENIPUNCTURE OR INTRAVENOUS CANNULATION. |
| U-833 | METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.25% BY WEIGHT OF ROPIVACAINE |
| U-834 | INVIRASE IN COMBINATION WITH RITONAVIR AND OTHER ANTIRETROVIRAL AGENTS IS INDICATED FOR THE TREATMENT OF HIV INFECTION |
| U-835 | RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF ATOPIC DERMATITIS IN PATIENTS ONE YEAR OF AGE OR OLDER |
| U-836 | A METHOD FOR THE TREATMENT OF LEUKEMIAS |
| U-837 | GASTROINTESTINAL LAVAGE INDICATED FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY IN ADULTS |
| U-838 | METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.5% BY WEIGHT OF ROPIVACAINE |
| U-839 | TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) |
| U-840 | TREATMENT FOR TYPE 2 DIABETES MELLITUS |
| U-841 | INDICATED FOR THE LONG-TERM, MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE AND OLDER |
| U-842 | INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) |
| U-843 | METHOD FOR ADMINISTRATION OF TESTOSTERONE |
| U-844 | PREFEST IS INDICATED IN WOMEN WHO HAVE A UTERUS FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE; TREATMENT OF VULVAR AND VAGINAL ATROPHY; PREVENTION OF OSTEOPOROSIS |
| U-845 | TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES |
| U-846 | USE FOR DELINEATION (VISUALIZATION) DURING A VITRECTOMY SURGICAL PROCEDURE |
| U-847 | ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V) |
| U-848 | ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA |
| U-849 | REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP. DOSE IS ONE DROP OF COMBIGAN IN THE AFFECTED EYE TWICE DAILY |
| U-850 | PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT |
| U-851 | TREATMENT OF TYPE 2 DIABETES MELLITUS |
| U-852 | RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS |
| U-853 | TREATMENT OR PREVENTION OF EMESIS |
| U-854 | PREVENTION OF CMV DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE/RECIPIENT CMV SERONEGATIVE) |
| U-855 | METHOD TO INDUCE NATRIURESIS, DIURESIS AND/OR VASODILATION |
| U-856 | SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN |
| U-857 | INHIBITION OF TRANSPLANT REJECTION |
| U-858 | PEDIATRIC USE AGED 1-11 YEARS, GERD AND EROSIVE ESOPHAGITIS |
| U-859 | EROSIVE ESOPHAGITIS, HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME, MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND REDUCTION OF SYMPTOMS IN PATIENTS WITH GERD |
| U-860 | FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION |
| U-861 | RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER |

**PATENT USE**

| | |
|---|---|
| U-862 | ADJUNCT TO DIET TO REDUCE ELEVATED TOTAL-C, LDL-C, NON-HDL-C, APO B, TG, AND LP(A) LEVELS AND TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, MIXED DYSLIPIDEMIA, AND HYPERTRIGLYCERIDEMIA |
| U-863 | TAKING ASPIRIN OR NON-STEROIDAL ANTI-INFLAMMATORY MEDICATIONS APPROXIMATELY 30 MINUTES BEFORE DOSING CAN MINIMIZE FLUSHING, A COMMON SIDE EFFECT OF NIACIN THERAPY |
| U-864 | PEDIATRIC USE AGES 1-2 YEARS, GERD AND EROSIVE ESOPHAGITIS |
| U-865 | TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND A HIGH RISK FOR BONE FRACTURE BY REDUCING THE RISK OF VERTEBRAL AND NONVERTEBRAL BONE FRACTURE |
| U-866 | THE LABEL REFERENCES THE EFFECTS OF THE ACTIVE INGREDIENT OF REVLIMID UPON CYTOKINES |
| U-867 | TREATMENT OF MIGRAINE |
| U-868 | METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH HYPERVOLEMIC HYPONATREMIA |
| U-869 | METHOD FOR STIMULATING CORONOARY VASODILATION FOR PURPOSES OF IMAGING THE HEART |
| U-870 | METHOD OF PRODUCING CORONARY VASODILATION WITHOUT PERIPHERAL VASODILATION |
| U-871 | METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH |
| U-872 | TWICE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA. TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS |
| U-873 | METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME BY OPENING CHLORIDE CHANNELS (CIC) |
| U-874 | METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME |
| U-875 | FIRST-LINE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER, IN COMBINATION WITH GEMCITABINE |
| U-876 | TREATMENT OF MIGRAINE WITH OR WITHOUT AURA |
| U-877 | FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PEPTIC ULCER |
| U-878 | A METHOD FOR BINDING A PERIPHERAL OPIOID RECEPTOR |
| U-879 | A METHOD OF TREATING OR PREVENTING ILEUS |
| U-880 | ENDOMETRIN IS A PROGESTERONE INDICATED TO SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN |
| U-881 | TREATMENT OF NON-SMALL CELL LUNG CANCER |
| U-882 | MANAGEMENT OF FIBROMYALGIA (FM) |
| U-883 | TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB |
| U-884 | TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA |
| U-885 | TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY |
| U-886 | ADMINISTERING DESLORATADINE TO TREAT THE SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS, SEASONAL ALLERGIC RHINITIS, OR CHRONIC IDIOPATHIC URTICARIA |
| U-887 | TREATMENT AND PREVENTION OF OSTEOPOROSIS |
| U-888 | FEMALE HORMONE REPLACEMENT THERAPY FOR POSTMENOPAUSAL WOMEN |
| U-889 | MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE) |
| U-890 | REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE |
| U-891 | USE AS AN INTRAOCULAR IRRIGATING SOLUTION DURING SURGICAL PROCEDURES INVOLVING PERFUSION OF THE EYE |
| U-892 | TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WTIH CUTANEOUS T-CELL LYMPHOMA (CTCL) |
| U-893 | CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE |
| U-894 | TREATMENT OF COLD SORES IN PEDIATRIC PATIENTS TWELVE YEARS OF AGE AND OLDER |

**PATENT USE**

| | |
|---|---|
| U-895 | TREATMENT OF HIV INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS |
| U-896 | TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN TWO YEARS OF AGE AND OLDER |
| U-897 | METHOD OF TREATING TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES IN A ONCE-A-DAY AMOXICILLIN PRODUCT |
| U-898 | USE OF GLUTAMINE TOGETHER WITH GROWTH HORMONE FOR THE TREATMENT OF PATIENTS WITH SHORT BOWEL SYNDROME |
| U-899 | USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA |
| U-900 | INTEGRASE INHIBITION FOR THE TREATMENT OF HIV INFECTION |
| U-901 | PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING |
| U-902 | USE IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH) |
| U-903 | TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ADULT PATIENTS |
| U-904 | TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE |
| U-905 | TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE |
| U-906 | PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY, LIVER AND HEART ALLOGENIC TRANSPLANTS; TREATMENT OF PATIENTS WITH SEVERE ACTIVE, RHEUMATOID ARTHRITIS; TREATMENT OF ADULT, NONIMMUNOCOMPROMISED PATIENTS WITH SEVERE, RECALCITRANT, PLAQUE PSORIASIS |
| U-907 | FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS IN SUBJECTS 18 YEARS OF AGE AND OLDER |
| U-908 | PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS RECEIVING ALLOGENEIC RENAL TRANSPLANTS |
| U-909 | TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA |
| U-910 | TREATMENT OF METASTATIC CARCINOMA OF THE OVARY AFTER FAILURE OF INITIAL OR SUBSEQUENT CHEMOTHERAPY |
| U-911 | METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL TREATMENT IS TEMPORARILY NOT FEASIBLE |
| U-912 | SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES |
| U-913 | TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY |
| U-914 | METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER |
| U-915 | TREATMENT OF MUSCULOSKELETAL CONDITIONS |
| U-916 | TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER |
| U-917 | TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS |
| U-918 | TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET |
| U-919 | FOR THE TREATMENT OF DERMATITIS |
| U-920 | STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS |
| U-921 | TREATMENT OF ACNE VULGARIS |
| U-922 | FOR THE TREATMENT OF FUNGAL INFECTIONS |
| U-923 | METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION |
| U-924 | TREATMENT OF MILD TO MODERATE INFECTION CAUSED BY SUSCEPTIBLE STRAINS |
| U-925 | TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTILES) OF ROSACEA |
| U-926 | MGT SPECIFIC BACTERIAL INFECTIONS. TREATMENT PTS W/ COMMUNITY ACQUIRED PNEUMONIA OR BACTERIAL SINUSITIS DUE TO CONFIRMED, OR SUSPECTED B-LACTAMASE PRODUCING PATHOGENS & S. PNEUMONIAE WITH REDUCED SUSCEPTIBILITY TO PENICILLIN (MIC=2MC/ML) |

**PATENT USE**

| | |
|---|---|
| U-927 | METHOD FOR INCREASING TEAR PRODUCTION |
| U-928 | TREATMENT OF BACTERIAL INFECTIOUS DISEASE |
| U-929 | TREATMENT OF OBSESSIVE COMPULSIVE DISORDER TREATABLE WITH AN SSRI |
| U-930 | TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP) |
| U-931 | RELIEF OF MODERATE TO SEVERE ACUTE PAIN |
| U-932 | PYLERA CAPSULES, IN COMBINATION WITH OMEPRAZOLE ARE INDICATED FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI |
| U-933 | FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI. THE ERADICATION OF HELICOBACTER PYLORI HAS BEEN SHOWN TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE |
| U-934 | IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELL TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT AUTOLOGOUS TRANSPLANTATION WITH NON-HODGKINS LYMPHOMA AND MULTIPLE MYELOMA |
| U-935 | TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER |
| U-936 | USE IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELLS TO PERIPHERAL BLOOD FOR COLLECTION & SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA & MULTIPLE MYELOMA |
| U-937 | TREATMENT OF PROSTATE CANCER |
| U-938 | TREATMENT OF HAIR LOSS AND HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS |
| U-939 | TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING AND STIMULATING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS |
| U-940 | METHOD TO TREAT AIDS-RELATED KAPOSI'S SARCOMA |
| U-941 | METHOD TO TREAT OVARIAN CANCER |
| U-942 | METHOD TO TREAT MULTIPLE MYELOMA |
| U-943 | GNRH ANTAGONIST INDICATED FOR TREATMENT OF PATIENTS WITH ADVANCED PROSTATE CANCER |
| U-944 | TREATMENT OF PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) |
| U-945 | SEDATIVE-HYPNOTIC AGENT INDICATED FOR MONITORED ANESTHESIA CARE (MAC) SEDATION |
| U-946 | TREATMENT OF BREAST CANCER |
| U-947 | WHEN PATIENTS ARE UNABLE TO TAKE THE ORAL FORMULATIONS, PREVACID IV, FOR INJECTION IS INDICATED AS AN ALTERNATIVE FOR THE SHORT-TERM TREATMENT (UP TO 7 DAYS) OF ALL GRADES OF EROSIVE ESOPHAGITIS |
| U-948 | TREATMENT OF DIABETES MELLITUS |
| U-949 | HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS |
| U-950 | MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS |
| U-951 | TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS |
| U-952 | USE AS AN ANALGESIC |
| U-953 | METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION |
| U-954 | CHRONIC MANAGEMENT OF HYPERURICEMIA IN PATIENTS WITH GOUT. NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA |
| U-955 | PROPHYLACTIC TREATMENT OF MIGRAINE |
| U-956 | TREATMENT OF PATIENTS WITH H. PYLORI INFECTION AND DUODENAL ULCER DISEASE |
| U-957 | A METHOD OF TREATING CANCER IN A PATIENT COMPRISING ADMINISTERING IXABEPILONE OR PHARMACEUTICAL COMPOSITIONS COMPRISING IXABEPILONE |
| U-958 | METHOD OF TREATING PATIENT COMPRISING MIXING FIRST AND SECOND VIALS OF PRODUCT COMPRISING LYOPHILIZED IXABEPILONE TO PROVIDE AN EPOTHILONE ANALOG SOLUTION, DILUTING SOLUTION WITH A SUITABLE DILUENT TO PREPARE INTRAVENOUS FORMULATION FOR PT |

**PATENT USE**

| | |
|---|---|
| U-959 | METHOD OF TREATING CANCER, IV ADMIN, LYOPHYLIZED IXABEPILONE DILUTED, EVERY WEEK OR 3 WEEKS; LYOPHILIZED IXABEPILONE WITH SOLVENT(DEHYDRATED ETHANOL) DILUTED TO CONCENTRATION OF 0.1MG/ML TO 0.9MG/ML |
| U-960 | METHOD OF TREATING CANCER IN A PATIENT COMPRISING INTRAVENOUSLY ADMINISTERING TO THE PATIENT IXABEPILONE DILUTED IN A PARENTERAL DILUENT |
| U-961 | METHOD OF TREATING BREAST CANCER BY ADMINISTERING IXABEPILONE; A METHOD OF TREATING A CANCER RESPONSIBLE TO MICROTUBULE STABILIZATION BY ADMINISTERING IXABEPILONE |
| U-962 | SYMBYAX IS INDICATED FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS |
| U-963 | PROZAC AND OLANZAPINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS |
| U-964 | ZYPREXA ZYDIS AND FLUOXETINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS |
| U-965 | USE OF IXABEPILONE IN COMBINATION WITH CAPECITABINE IN TREATMENT OF METASTASIS BREAST CANCER |
| U-966 | TREATMENT OF ASTHMA (MAINTENANCE AND PROPHYLACTIC THERAPY) |
| U-967 | A METHOD OF REVERSING SOFT-TISSUE ANESTHESIA I.E. ANESTHESIA OF THE LIP AND TONGUE, AND THE ASSOCIATED FUNCTIONAL DEFICITS RESULTING FROM AN INTRAORAL SUBMUCOSAL INJECTION OF A LOCAL ANESTHETIC |
| U-968 | A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS |
| U-969 | TREATMENT OF MIGRAINE |
| U-970 | TOPICAL TREATMENT OF LICE INFESTATIONS |
| U-971 | INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA |
| U-972 | MONOTHERAPY OR AS ADJUNCTIVE THERAPY TO LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER |
| U-973 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH PIOGLITAZONE AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON PIOGLITAZONE OR METFORMIN ALONE |
| U-974 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN |
| U-975 | TREATMENT OF PULMONARY HYPERTENSION |
| U-976 | IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES |
| U-977 | TREATMENT OF ACUTE, UNCOMPLICATED MALARIA INFECTION DUE TO PLASMODIUM FALCIPARUM IN PATIENTS OF 5KG BODYWEIGHT AND ABOVE |
| U-978 | METHOD OF TREATING HYPONATREMIA |
| U-979 | RELIEF OF MUSCLE SPASM |
| U-980 | NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN |
| U-981 | MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY |
| U-982 | A METHOD OF TREATING OSTEOPOROSIS |
| U-983 | METHOD OF TREATING OSTEOPOROSIS IN A POST-MENOPAUSAL WOMAN AT RISK FOR FRACTURE |
| U-984 | METHOD FOR THE TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND AT RISK FOR BONE FRACTURE |
| U-985 | TREATMENT OF MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (BRVO) OR CENTRAL RETINAL VEIN OCCLUSION (CRVO) |
| U-986 | TREATMENT OF PATIENTS INFECTED WITH PEDICULUS HUMANUS CAPITIS (HEAD LICE AND THEIR OVA) OF THE SCALP HAIR |
| U-987 | TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS |
| U-988 | TREATMENT OF RHINITIS COMPRISING THE NASAL APPLICATION OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT 7541350 |
| U-989 | FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA |

**PATENT USE**

| | |
|---|---|
| U-990 | TREATMENT OF PROTOZOAL INFECTION |
| U-991 | TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISMS |
| U-992 | REDUCTION OF THE RISK OF CARDIOVASCULAR HOSPITALIZATION |
| U-993 | METHOD OF TREATING INFERTILITY |
| U-994 | METHOD OF TREATMENT OF OSTEOPOROSIS WHEREIN THE OSTEOPOROSIS IS STEROID-INDUCED |
| U-995 | METHOD FOR TREATING TYPE II DIABETES BY ADMINISTERING SAXAGLIPTIN |
| U-996 | AN ADJUNCTIVE THERAPY TO DIET TO REDUCT ELEVATED TOTAL CHOLESTEROL (TC), LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES, AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIX DYSLIPIDEMIA |
| U-997 | TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS |
| U-998 | ADJUNCITVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPRTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA |
| U-999 | TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS |
| U-1000 | ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS |
| U-1001 | METHOD FOR DELIVERING DRUG TO LUNG OF MAMMAL, COMPRISING ADMINISTERING DRUG PRODUCT BY INHALATION. TREATING A MAMMAL HAVING A CONDITION CAPABLE OF TREATMENT BY INHALATION, COMPRISING ADMINISTERING TO THE LUNG THE DRUG PRODUCT BY INHALATION |
| U-1002 | METHOD OF TREATING INFLAMMATORY CONDITIONS |
| U-1003 | A METHOD OF MYOCARDIAL PERFUSION IMAGING AND INCREASING CORONARY BLOOD FLOW |
| U-1004 | TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA |
| U-1005 | METHOD OF TREATING A STAPHYLOCOCCAL INFECTION |
| U-1006 | NEW COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND ADOLESCENTS (12 YEARS OF AGE AND OLDER) |
| U-1007 | METHOD OF TREATING GOUT FLARES |
| U-1008 | APPLICATION OF ANTISEPTIC WITH MOISTURIZERS FOR SURGICAL AND HEALTHCARE PERSONNEL SKIN DISINFECTION |
| U-1009 | METHOD FOR ADMINISTRATION OF TESTOSTERONE |
| U-1010 | TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA DUE TO TETRA HYDROBIOPTERIN RESPONSIVE PHENYLKETONURIA. KUVAN SHOULD BE TAKEN ORALLY WITH FOOD TO INCREASE ABSORPTION |
| U-1011 | USE OF GRANISETRON TRANSDERMAL SYSTEM TO TREAT/PREVENT CHEMOTHERAPY INDUCED NAUSEA AND VOMITING |
| U-1012 | METHOD FOR TREATING INSOMNIA WHILE REDUCING THE RISK OF AN ADVERSE DRUG INTERACTION |
| U-1013 | METHOD OF USING RIBAVIRIN IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2B TO TREAT PATIENTS WITH CHRONIC HEPATITIS C |
| U-1014 | METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTERFERON ALPHA-2B(PEGYLATED AND NONPEGYLATED) TO TREAT PATIENTS WITH CHRONIC HEPATITIS C |
| U-1015 | TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA |
| U-1016 | IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-EXPERIENCED ADULT PATIENTS, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO AN NNRTI AND OTHER ANTIRETROVIRAL AGENTS |
| U-1017 | A METHOD OF TREATING NASAL AND NON-NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS |
| U-1018 | TREATMENT OF PULMONARY HYPERTENSION BY INHALATION |
| U-1019 | TREATMENT OF PULMONARY HYPERTENSION |
| U-1020 | METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES |
| U-1021 | SHORT-TERM TREATMENT (4-8 WEEKS) OF ACTIVE BENIGN GASTRIC ULCER |
| U-1022 | FOR THE PREPARATION OF SKIN PRIOR TO SURGERY; HELPS REDUCE BACTERIA THAT CAN POTENTIALLY CAUSE SKIN INFECTION |

**PATENT USE**

| | |
|---|---|
| U-1023 | TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE |
| U-1024 | REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP |
| U-1025 | TREATING FREQUENT HEARTBURN |
| U-1026 | A METHOD OF TREATING HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS. |
| U-1027 | REDUCTION OF ELEVATED PLASMA STEROL AND/OR STANOL LEVELS IN A MAMMAL |
| U-1028 | A METHOD OF DISTRIBUTING SODIUM OXYBATE UNDER CONTROL OF A CENTRAL PHARMACY |
| U-1029 | METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF |
| U-1030 | IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS) |
| U-1031 | IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA |
| U-1032 | USE OF ROSUVASTATIN CALCIUM FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN INDIVIDUALS WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH INCREASED RISK FACTORS |
| U-1033 | TOPICAL TREATMENT OF ACNE VULGARIS |
| U-1034 | TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS |
| U-1035 | NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN |
| U-1036 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN |
| U-1037 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH A PPAR-GAMMA AGONIST |
| U-1038 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN AND A PPAR-GAMMA AGONIST |
| U-1039 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN |
| U-1040 | INHIBITION OF THROMBIN IN A PATIENT |
| U-1041 | TREATMENT OF DISORDERS RESPONSIVE TO GROWTH HORMONE |
| U-1042 | METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART |
| U-1043 | MANAGEMENT OF MODERATE TO SEVERE PAIN |
| U-1044 | TOPICAL TREATMENT OF SCALP PSORIASIS |
| U-1045 | MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHO HAVE NOT PROGRESSED ON 1ST-LINE TREATMENT WTH PLATINUM-BASED CHEMOTHERAPY |
| U-1046 | MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES PLATINUM-BASED CHEMOTHERAPY |
| U-1047 | TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA (SBCC) |
| U-1048 | WORKS THROUGH THE INDUCTION OF INTERFERON AND OTHER CYTOKINES |
| U-1049 | PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A RENAL TRANSPLANT |
| U-1050 | USE OF METAXALONE FOR TREATMENT OF MUSCULOSKELETAL CONDITIONS |
| U-1051 | TREATMENT OF OROPHARYNGEAL CANDIDIASIS |
| U-1052 | RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER |
| U-1053 | RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER |
| U-1054 | ONYCHOMYCOSIS OF THE TOENAIL CAUSED BY TRICOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES, ONCE DAILY USE FOR 12 CONSECUTIVE WEEKS |
| U-1055 | AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH A THIAZOLIDINEDIONE (TZD) AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A TZD OR METFORMIN ALONE |
| U-1056 | TREATMENT OF PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE |
| U-1057 | TREATMENT OF INFLAMMATION AND PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE |

**PATENT USE**

| | |
|---|---|
| U-1058 | USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA |
| U-1059 | ADJUNCTIVE THERAPY TO DIET TO PATIENTS WITH HYPERTRIGLYCERIDEMIA |
| U-1060 | ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH ELEVATED CHOLESTEROL AND/OR LIPID LEVELS |
| U-1061 | ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA |
| U-1062 | ADMINISTRATION OF APPROVED PRODUCT FOR TREATMENT OF ALZHEIMER'S DISEASE |
| U-1063 | TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA |
| U-1064 | TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA |
| U-1065 | METHOD OF TREATING ANDROGEN RESPONSIVE OR MEDICATED CONDITION IN A MAMMAL BY ADMINISTERING A SAFE & EFFECTIVE AMOUNT OF DUTASTERIDE OR A PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF.. CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY |
| U-1066 | METHOD OF TREATING AN ANDROGEN RESPONSE OR MEDIATED DISEASE IN A MAMMAL BY ADMINISTERING AN EFFECTIVE ANDROGEN RESPONSIVE OR MEDICATED DISEASE AMOUNT OF DUTASTERIDE..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERPLASIA |
| U-1067 | TREATMENT OF CANCER |
| U-1068 | TREATMENT OF ASTHMA |
| U-1069 | A METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING AN EXCLUSIVE COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION |
| U-1070 | A METHOD TO CONTROL ABUSE OF A SENSITIVE DRUG BY CONTROLLING WITH A COMPUTER PROCESSOR THE DISTRIBUTION OF THE SENSITIVE DRUG VIA AN EXCLUSIVITY CENTRAL PHARMACY THAT MAINTAINS A CENTRAL DATABASE |
| U-1071 | METHOD OF TREATING BLADDER DSYFUNCTION WITH ONCE A DAY TROSPIUM SALT FORMULATION |
| U-1072 | THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN IN PATIENTS REQUIRING A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC FOR AN EXTENDED PERIOD OF TIME |
| U-1073 | USE FOR THE TREATMENT OF ASTHMA AND COPD |
| U-1074 | USE OF EXENATIDE MAY RESULT IN REDUCTION IN BODY WEIGHT |
| U-1075 | USE FOR THE TREATMENT OF ASTHMA |
| U-1076 | REDUCE CHRONIC SEVERE DROOLING (I.E., SIALORRHEA) IN PATIENTS WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING |
| U-1077 | PRETREATMENT OF PATIENTS WITH VITAMIN B12 AND FOLIC ACID PRIOR TO PEMETREXED DISODIUM ADMINISTRATION |
| U-1078 | TREATMENT OF ACNE |
| U-1079 | REVLIMID (LENALIDOMIDE) IS INDICATED FOR THE TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS) |
| U-1080 | METHOD TO TREAT PULMONARY HYPERTENSION BY ADMINISTERING AMBRISENTAN TO A PATIENT |
| U-1081 | LUMIGAN IS A PROSTAGLANDIN ANALOG INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION |
| U-1082 | USE OF A COMBINATION OF TOBRAMYCIN AND DEXAMETHASONE TO TREAT OCULAR INFLAMMATION WHERE AN INFECTION OR RISK OF INFECTION EXISTS |
| U-1083 | ACUTE TREATMENT OF MIGRAINE ATTACKS, WITH OR WITHOUT AURA, AND THE TREATMENT OF CLUSTER HEADACHE EPISODES |
| U-1084 | RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER |
| U-1085 | METHOD FOR TREATING IRRITABLE BOWEL SYNDROME AND METHOD FOR TREATING ABDOMINAL DISCOMFORT ASSOCIATED WITH IRRITABLE BOWEL SYNDROME |
| U-1086 | TREATMENT OF AUTOIMMUNE DISEASE |
| U-1087 | DETECTION OF NON-MUSCLE INVASIVE PAPILLARY CANCER OF THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY |
| U-1088 | RELIEF OF MUSCLE SPASM |
| U-1089 | INHIBITION OF THROMBIN |
| U-1090 | LO LOESTRIN FE IS INDICATED FOR THE PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOF OF CONTRACEPTION |

**PATENT USE**

| | |
|---|---|
| U-1091 | ASSESSMENT OF BRONCHIAL HYPERRESPONSIVENESS IN PATIENTS 6 YEARS OF AGE OR OLDER WHO DO NOT HAVE CLINICALLY APPARENT ASTHMA |
| U-1092 | TREATMENT OF BREAST CANCER |
| U-1093 | TREATMENT OF PSEUDOBULBAR AFFECT |
| U-1094 | MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN |
| U-1095 | METHOD OF TREATING OCULAR INFLAMMATION |
| U-1096 | TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER |
| U-1097 | ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT WITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE |
| U-1098 | METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA |
| U-1099 | TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA |
| U-1100 | REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY |
| U-1101 | METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY |
| U-1102 | METHOD OF TREATING CATAPLEXY IN PATIENTS WITH NARCOLEPSY |
| U-1103 | TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE |
| U-1104 | USE OF TRAMADOL FOR THE MANAGEMENT OF MODERATE TO MODERATELY SEVERE CHRONIC PAIN |
| U-1105 | TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS FOUR (4) YEARS OF AGE AND OLDER |
| U-1106 | TREATING HYPERTRIGLYCERIDEMIAS WITH REDUCTION OF FOOD EFFECT |
| U-1107 | TREATING HYPERCHOLESTEROLEMIAS WITH REDUCTION OF FOOD EFFECT |
| U-1108 | TREATING TYPE 2 DIABETES MELLITUS WITH EXENATIDE BY STIMULATING INSULIN RELEASE |
| U-1109 | TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL) IN CONNECTION WITH A SPECIAL PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.) |
| U-1110 | METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING A COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION |
| U-1111 | NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN |
| U-1112 | METHOD OF MR IMAGING OF A MAMMAL |
| U-1113 | TREATMENT AND PROPHYLAXIS OF INFLUENZA |
| U-1114 | TREATMENT WITH GABAPENTIN, INCLUDING TREATMENT OF NEUROPATHIC PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH POSTHERPETIC NEURALGIA |
| U-1115 | TREATMENT TO REDUCE THE RISK OF COPD EXACERBATIONS IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS |
| U-1116 | METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS |
| U-1117 | TREATMENT OF BREAST CANCER |
| U-1118 | USE FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA |
| U-1119 | CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING |
| U-1120 | TO REDUCE GASTROINTESTINAL SIDE EFFECTS ADMINISTER WITH A MEAL; AS STARTING DOSE ADMINISTER ONCE DAILY WITH EVENING MEAL |
| U-1121 | METHOD OF TREATING TRAVELERS' DIARRHEA |
| U-1122 | TREATMENT OF SECONDARILY INFECTED TRAUMATIC SKIN LESIONS DUE TO S. AUREUS AND S. PYOGENES |
| U-1123 | TREATMENT OF ALCOHOL DEPENDENCE |
| U-1124 | PREVENTION OF RELAPSE TO OPIOID DEPENDENCE, FOLLOWING OPIOID DETOXIFICATION |
| U-1125 | METHOD FOR THE DETECTION OF NEUROENDOCRINE TUMORS |
| U-1126 | USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE RECEIVED PRIOR CHEMOTHERAPY |

**PATENT USE**

| | |
|---|---|
| | CONTAINING DOCETAXEL |
| U-1127 | TREATMENT OF PATENT DUCTUS ARTERIOSUS |
| U-1128 | TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN IN ADULT PATIENTS (>=18 YEARS OF AGE) WITH COMPENSATED LIVER DISEASE |
| U-1129 | TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN |
| U-1130 | SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR A NIGHT WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN |
| U-1131 | TREATMENT OF HYPERTRIGLYDERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN |
| U-1132 | TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT |
| U-1133 | SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT |
| U-1134 | TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT |
| U-1135 | TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A) AND INCREASE OF HDL-C |
| U-1136 | SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C |
| U-1137 | TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C |
| U-1138 | TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT |
| U-1139 | REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT |
| U-1140 | REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT |
| U-1141 | REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT |
| U-1142 | TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN |
| U-1143 | REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR A T NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN |
| U-1144 | REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITIN AGENT SUCH AS ASPIRIN |
| U-1145 | REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN |
| U-1146 | REDUCTION IN TG WITH REDUCED FLUSHING BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT |
| U-1147 | TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C |
| U-1148 | REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C |
| U-1149 | TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN |
| U-1150 | TRETMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, TG, LP(A), AND INCREASE OF HDL-C |
| U-1151 | TREATMENT OF HYPERTRIGLYCDERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, LP(A), AND INCREASE OF HDL-C |
| U-1152 | CYANOCOBALAMIN ADMINISTRATION THROUGH NASAL INFUSION |

**PATENT USE**

| | |
|---|---|
| U-1153 | IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, IS INDICATED FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION IN ANTIRETROVIRAL TREATMENT-NAIVE ADULT PATIENTS, AS SET FORTH IN THE LABELING, INCLUDING I&U SECTION |
| U-1154 | TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMORS, RENAL CELL CARCINOMA AND ADVANCED PANCREATIC NEUROENDOCRINE TUMORS, WITH SUNITINIB |
| U-1155 | USE OF THALIDOMIDE IN TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL) |
| U-1156 | TO REDUCE BLOOD PHENYLALANINE (PHE) LEVELS IN PATINETS WITH HYPERPHENYLALANINEMIA (HPA) |
| U-1157 | RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES IN ADULTS AND CHILDREN 2 YEARS OF AGE AND OLDER AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER |
| U-1158 | RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER |
| U-1159 | RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES, SWELLING OF THE NASAL PASSAGES AND SINUS CONGESTION AND PRESSURE IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER |
| U-1160 | RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER AND 12 YEARS OF AGE AND OLDER |
| U-1161 | FOR THE TREATMENT AND PROPHYLAXIS OF GOUT FLARES & THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER |
| U-1162 | TREATMENT OF SEBORRHEIC DERMATITIS OF THE SCALP |
| U-1163 | METHOD OF TREATING THROMBOSIS |
| U-1164 | METHOD OF TREATING AN ARGATROBAN TREATABLE CONDITION |
| U-1165 | USE FOR THE TREATMENT OF MULTIPLE MYELOMA |
| U-1166 | A METHOD FOR TREATMENT OF GOUT FLARES DURING PROPHYLAXIS |
| U-1167 | PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT) |
| U-1168 | THE LONG TERM, ONCE-DAILY MAINTENANCE BRONCHODILATOR TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA |
| U-1169 | MANAGEMENT OF BREAKTHROUGH PAIN IN CANCER PATIENTS 18 YEARS OF AGE AND OLDER WHO ARE RECEIVING AND TOLERANT TO OPIOID THERAPY FOR THEIR UNDERLYING PERSISTENT CANCER PAIN |
| U-1170 | TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER |
| U-1171 | REDUCTION OF THE RATE OF THROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME |
| U-1172 | TO REDUCE ELEVATED TOTAL-C, APO B, AND NON-HDL-C IN PATIENTS WIHT PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE IN COMBINATION WITH A STATIN |
| U-1173 | TO REDUCE ELEVATED TOTAL-C, LDL-C, APO B AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE ALONE OR IN COMBINATION WITH A STATIN OR WITH FENOFIBRATE |
| U-1174 | ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION, 0.9% SODIUM CHLORIDE INJECTION, OR FLOLAN STERIILE DILUENT FOR INJECTION PRIOR TO ADMINISTRATION |
| U-1175 | REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION |
| U-1176 | TREATMENT OR PREVENTION OF STROKE |
| U-1177 | REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION |
| U-1178 | RELIEF OF MODERATE TO SEVERE CHRONIC PAIN |
| U-1179 | TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK) |
| U-1180 | TREATMENT OF THE FOLLOWING INFECTIONS: COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS |

**PATENT USE**

| | |
|---|---|
| U-1181 | A METHOD OF TREATING OR PREVENTING OCULAR PAIN IN A PATIENT |
| U-1182 | TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING |
| U-1183 | A METHOD FOR ADMINISTERING FOLLICLE STIMULATING HORMONE (FSH) FOR OVARIAN FOLLICLE OR TESTICULAR STIMULATION IN THE HUMAN |
| U-1184 | TREATMENT OF ERECTILE DYSFUNCTION AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA |
| U-1185 | TREATMENT OF OPIOID-INDUCED CONSTIPATION |
| U-1186 | ADMINISTRATION OF AN INHALABLE POWDER COMPRISING TIOTROPIUM VIA DEVICE |
| U-1187 | TREATMENT OF PATHOLOGICAL STATE BY ANTAGONIZING BRADYKININ RECEPTOR INCLUDING TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA (HAE) |
| U-1188 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE |
| U-1189 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH METFORMIN |
| U-1190 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH INSULIN |
| U-1191 | METHOD OF TX TYPE 2 DM IN PTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBO WITH AN AGENT ACTING ON AN ATP-DEPENDENT CHANNEL IN BETA CELLS SUCH AS A SULFYONYLUREA(INCL GLIPIZIDE, GLIMEPIRIIDE & GLYBURIDE) |
| U-1192 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A SULFONYLUREA (SUCH AS GLIPIZIDE, GLIMEPIRIDE AND GLYBURIDE) |
| U-1193 | METHOD OF TREATING TYPE 2 DIABETES MELITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A PPAR-GAMMA AGONIST (SUCH AS PIOGLITAZONE AND ROSIGLITAZONE) |
| U-1194 | METHOD FOR TREATING INSOMNIA |
| U-1195 | PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5, WHICH MAY RESULT IN RENAL OSTEODYSTROPHY, WHILE AVOIDING HYPERPHOSPHATEMIA |
| U-1196 | RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS |
| U-1197 | METHOD OF TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY |
| U-1198 | RECTIV IS A NITRATE VASODILATOR INDICATED FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH CHRONIC ANAL FISSURE |
| U-1199 | TREATMENT AND PREVENTION OF POSTMENOPAUSAL OR GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS |
| U-1200 | REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM |
| U-1201 | FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS |
| U-1202 | METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME |
| U-1203 | METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT |
| U-1204 | TREATMENT OF UVEITIS |
| U-1205 | TREATMENT OF MACULAR EDEMA |
| U-1206 | DELIVERING AN OCULAR IMPLANT AS DESCRIBED IN THE DOSAGE AND ADMINISTRATION SECTION OF THE APPROVED LABELING OF OZURDEX |
| U-1207 | INFANT USE AGED 1 MONTH TO LESS THAN ONE YEAR, GERD AND EROSIVE ESOPHAGITIS |
| U-1208 | TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS |
| U-1209 | TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER |
| U-1210 | USE OF REVLIMID (LENALIDOMIDE) WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO REVLIMID (LENALIDOMIDE) |

**PATENT USE**

| | |
|---|---|
| U-1211 | USE OF REVLIMID (LENALIDOMIDE) TO INHIBIT THE SECRETION OF PRO-INFLAMMATORY CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA |
| U-1212 | USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA AND TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS) |
| U-1213 | TOPICAL TREATMENT OF SEBORRHEIC DERMATITIS IN IMMUNOCOMPETENT PATIENTS 12 YEARS OF AGE AND OLDER |
| U-1214 | METHOD FOR RELIEVING CONSTIPATION IN A HUMAN PATIENT THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING (I) 24MCG+/- 10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT |
| U-1215 | USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS) |
| U-1216 | USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA |
| U-1217 | METHOD OF INCREASING HAIR GROWTH |
| U-1218 | METHOD OF STIMULATING HAIR GROWTH |
| U-1219 | METHOD OF INCREASING THE NUMBER OF HAIRS |
| U-1220 | TREATMENT OF RENAL CELL CARCINOMA |
| U-1221 | TO STIMULATE THE IMMUNE SYSTEM TO INDUCE T CELL PROLIFERATION |
| U-1222 | TO INHIBIT THE PROLIFERATIVE ACTIVITY OF NEOPLASTIC CELLS |
| U-1223 | METHOD FOR TREATING TYPE 2 DIABETES USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENATIDE |
| U-1224 | REDUCTIONS IN BODY WEIGHT ARE OBSERVED WITH EXENATIDE |
| U-1225 | ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING PARTIAL LARGE OR SMALL BOWEL RESECTION SURGERY WITH PRIMARY ANASTOMOSIS |
| U-1226 | A METHOD OF PROVIDING A PREDETERMINED CONCENTRATION OF NITRIC OXIDE TO A PATIENT |
| U-1227 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE |
| U-1228 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE ALONE OR IN COMBINATION WITH INSULIN |
| U-1229 | TREATMENT OF MILDLY TO MODERATELY ACTIVE ULCERATIVE COLITIS IN MALE PATIENTS |
| U-1230 | A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT |
| U-1231 | TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS |
| U-1232 | USE AS ANTICOAGULANT IN PTS W/ UNSTABLE ANGINA UNDERGOING PTCA; W/ PROVISIONAL USE OF GLYCOPROTEIN IIB/IIIA INHIBITOR, AS ANTICOAGULANT IN PTS UNDERGOING PCI AND FOR PTS W/, OR AT RISK OF, HIT/HITTS UNDERGOING PCI.INTENDED FOR USE W/ASPIRIN |
| U-1233 | TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION, ADMINISTERED WITH FOOD |
| U-1234 | FOR REDUCING TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES, AND TREATING HYPERTRIGLYCERIDEMIA |
| U-1235 | REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION |
| U-1236 | USE OF THALOMID (THALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA |
| U-1237 | COMBO W/ OTHER ANTIRETROVIRALS FOR TX OF HIV-1 IN ANTIRETROVIRAL TX-EXPERIENCED PT 6 YEARS UP, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR AND OTHER ANTIRETROVIRALS |
| U-1238 | TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE |
| U-1239 | MAGNETIC RESONANCE IMAGING OF THE LIVER |
| U-1240 | TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION |
| U-1241 | MANAGEMENT OF MODERATE TO SEVERE PAIN BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED |
| U-1242 | PREVENTION OF RESPIRATORY DISTRESS (RDS) IN PREMATURE INFANTS |

**PATENT USE**

| | |
|---|---|
| U-1243 | WITH DRY HANDS, GENTLY REMOVE THE SUPRENZA (PHENTERMINE HYDROCHLORIDE ODT) TABLET FROM THE BOTTLE. IMMEDIATELY PLACE THE SUPRENZA TABLET ON TOP OF THE TONGUE WHERE IT WILL DISSOLVE, THEN SWALLOW WITH OR WITHOUT WATER |
| U-1244 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH SULFONLYUREA |
| U-1245 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH PIOGLITAZONE |
| U-1246 | SINGLE DOSE ADMINISTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA |
| U-1247 | MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS |
| U-1248 | USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL MEDICATION ON THE SAME KNEE |
| U-1249 | TREATMENT OF MALE PATIENT HAVING A DISEASE OR CONDITION RESPONSIVE TO A TERATOGENIC DRUG |
| U-1250 | TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY OR SPINAL CORD INJURY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA |
| U-1251 | A METHOD OF CONTROLLING POSTOPERATIVE OCULAR PAIN AND BURNING/STINGING IN A PATIENT |
| U-1252 | METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE |
| U-1253 | METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY |
| U-1254 | METHOD FOR CHRONIC WIEGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN |
| U-1255 | METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY |
| U-1256 | TREATMENT OF SEBORRHEIC DERMATITIS |
| U-1257 | TREATMENT OF OPHTHALMIC DISORDERS |
| U-1258 | VISUALIZATION DURING VITRECTOMY PROCEDURES |
| U-1259 | PROPHYLAXIS OF HIV-1 INFECTION |
| U-1260 | TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY |
| U-1261 | REDUCTION OF THE RISK OF HOSPITALIZATION FOR ATRIAL FIBRILLATION |
| U-1262 | USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND/OR TREATING OVERWEIGHT |
| U-1263 | TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) OR CHRONIC BRONCHITIS |
| U-1264 | TREATMENT OF A RESPIRATORY DISEASE |
| U-1265 | PATENTED METHOD OF USING REPAGLINIDE IN COMBINATION WITH METFORMIN AS INDICATED FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS |
| U-1266 | METHOD OF TREATING MIDDLE-OF-THE-NIGHT INSOMNIA |
| U-1267 | TREATMENT OF RHEUMATOID ARTHRITIS BY DELAYED RELEASE FORMULATION OF 1MG OR 2MG OF PREDNISONE |
| U-1268 | TREATMENT OF PULMONARY, GASTROINTESTINAL AND/OR RHEUMATOLOGICAL DISEASES OR CONDITIONS BY USE OF DELAYED RELEASE FORMULATIONS OF 1MG OR 2MG PREDNISONE |
| U-1269 | TREATMENT OF RHEUMATOLOGIC, ALLERGIC, PULMONARY, GASTROINTESTINAL, DERMATOLOGIC DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 5MG PREDNISONE TABLET |
| U-1270 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH INSULIN (WITH OR WITHOUT METFORMIN AND/OR PIOGLITAZONE) |
| U-1271 | TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE(PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MORE ANTI-LEUKEMIA THERAPIES |
| U-1272 | TREATMENT OF SIGNS AND SYMPTOMS OF PARKINSON'S DISEASE BY APPLICATION OF CLAIMED TRANSDERMAL SYSTEM |
| U-1273 | TREATMENT OF RESTLESS LEGS SYNDROME BY APPLICATION OF CLAIMED TRANSDERMAL |

**PATENT USE**

| | |
|---|---|
| | DELIVERY SYSTEM |
| U-1274 | TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CYSTIC FIBROSIS OR OTHER CONDITIONS |
| U-1275 | TREATMENT OF CHRONIC HEPATITIS B IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER |
| U-1276 | MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY |
| U-1277 | METHOD OF INCREASING EYELASH GROWTH INCLUDING LENGTH, THICKNESS, DARKNESS AND/OR NUMBER OF EYELASHES BY ADMINISTERING BIMATOPROST TO AN EYELID MARGIN |
| U-1278 | METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULTS |
| U-1279 | TREATMENT OF HIV INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE |
| U-1280 | USE OF A CALCIPOTRIENE CONTAINING FOAM FOR THE TREATMENT OF PSORIASIS |
| U-1281 | THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE PREVIOUSLY RECEIVED DOCETAXEL |
| U-1282 | PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING |
| U-1283 | A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA |
| U-1284 | A METHOD OF TREATING A NEOPLASM |
| U-1285 | TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS |
| U-1286 | A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE |
| U-1287 | METHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA |
| U-1288 | TREATEMENT OF ERECTIILE DYSFUNCTION BY ADMINISTERING A FILM-COATED TABLET |
| U-1289 | MANAGEMENT OF MODERATE TO SEVERE ACUTE PAIN |
| U-1290 | TREATMENT OF LUNG CANCER |
| U-1291 | TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE (15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION |
| U-1292 | TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 1, 2, OR 5 MG PREDNISONE TABLET |
| U-1293 | A METHOD OF LOWERING INTRAOCULAR PRESSURE IN A PATIENT WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION |
| U-1294 | METHOD OF TREATING GLAUCOMA IN A PATIENT |
| U-1295 | A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION |
| U-1296 | USE OF PEMETREXED WITH PRIOR AND/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION |
| U-1297 | TREATMENT OF PULMONARY ARTERIAL HYPERTENSION BY INHIBITING ENDOTHELIN RECEPTORS |
| U-1298 | ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES |
| U-1299 | TREATMENT OF PATIENTS WITH LEUKEMIA INCLUDING CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML) |
| U-1300 | TREATMENT OF PATIENTS WITH TYROSINE KINASE INHIBITOR (TKI) RESISTANT OR INTOLERANT CHRONIC MYELOID/MYELOGENOUS LEUKEMIA (CML) |
| U-1301 | TREATMENT OF DEEP VEIN THROMBOSIS (DVT) |
| U-1302 | TREATMENT OF PULMONARY EMBOLISM (PE) |
| U-1303 | REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM |
| U-1304 | USE OF ONCE-A-DAY AMOXICILLIN PRODUCT TO TREAT TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES |
| U-1305 | TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS, AND TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER, CO-ADMINISTERED WITH RITONAVIR (PREZISTA/RITONAVIR) AND WITH OTHER ANTIRETROVIRAL AGENTS |
| U-1306 | TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY |

**PATENT USE**

| | |
|---|---|
| U-1307 | IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE ADULT PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THERAPY |
| U-1308 | MULTIPLE MYELOMA |
| U-1309 | BONE METASTASES |
| U-1310 | FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS |
| U-1311 | METHOD OF TREATING CYSTIC FIBROSIS |
| U-1312 | USE FOR THE TREATMENT OF HYPERGLYCEMIA |
| U-1313 | AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS |
| U-1314 | USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER |
| U-1315 | THE LONG TERM TREATMENT OF PROPHYLACTIC MANAGEMENT OF OCULAR HYPERTENSION AND GLAUCOMA |
| U-1316 | A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES |
| U-1317 | TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND HYPERLIPOPROTEINEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA |
| U-1318 | TREATMENT OF HYPERCHOLESTEROLEMIA BY DECREASING THE AMOUNT OR ACTIVITY OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA |
| U-1319 | SYMPTOMATIC RELIEF OF NON-INFECTIOUS DIARRHEA |
| U-1320 | TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT |
| U-1321 | TREATMENT OF PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS |
| U-1322 | METHOD OF REDUCING OCULAR HYPERTENSION |
| U-1323 | REDUCING THE RISK OF STROKE |
| U-1324 | MANAGEMENT OF CYSTIC FIBROSIS PATIENTS |
| U-1325 | INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS |
| U-1326 | METHOD OF INDUCING CONTRACEPTION IN A FEMALE OF REPRODUCTIVE AGE WHO HAS NOT YET REACHED PREMENOPAUSE |
| U-1327 | METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF, USING A FLOWABLE HYDROGEL FORMULATION |
| U-1328 | METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF |
| U-1329 | TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER |
| U-1330 | METHODS OF TREATING LIPID METABOLISM AND GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER |
| U-1331 | METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER |
| U-1332 | METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER |
| U-1333 | METHODS OF LOWERING ELEVATED POST PRANDIAL BLOOD GLUCOSE LEVELS COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR |
| U-1334 | METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER |
| U-1335 | METHODS OF MODIFYING GLUCOSE METABOLISM AND TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR AND ONE OR MORE OTHER THERAPEUTIC AGENTS SUCH AS METFORMIN |
| U-1336 | METHODS OF TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE |

**PATENT USE**

| | |
|---|---|
| | INHIBITOR AND METFORMIN |
| U-1337 | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN |
| U-1338 | METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN |
| U-1339 | METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN |
| U-1340 | METHODS OF TREATING LIPID METABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN |
| U-1341 | METHODS OF TREATING GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN |
| U-1342 | METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN |
| U-1343 | METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN |
| U-1344 | METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN PREPARATION |
| U-1345 | USE IN RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH A DOSAGE UNIT COMPRISING 24MICROG+/- 10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT |
| U-1346 | USE OF FEBUXOSTAT FOR THE MANAGEMENT OF HYPERURICEMIA IN PATIENTS SUFFERING FROM GOUT AND, WHEN USED WITH THEOPHYLLINE WITHOUT THE NEED FOR DOSE ADJUSTMENT OF THEOPHYLLINE |
| U-1347 | TREATMENT OF A SKIN DISORDER |
| U-1348 | TREATMENT OF OSTEOARTHRITIS |
| U-1349 | TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS |
| U-1350 | TREATMENT OF ANKYLOSING SPONDYLITIS |
| U-1351 | TREATMENT OF ACUTE PAIN |
| U-1352 | TREATMENT OF PRIMARY DYSMENORRHEA |
| U-1353 | ADJUNCTIVE THERAPY TO LIPID-LOWERING MEDICATIONS AND DIET TO REDUCE LOW DENSITY LIPOPROTEIN-CHOLESTEROL, APOLIPOPROTEIN B, TOTAL CHOLESTEROL, AND NON-HIGH DENSITY LIPOPROTEIN CHOLESTEROL IN PTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA |
| U-1354 | INHIBITION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN HYPERSTIMULATION WITH FSH |
| U-1355 | MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHOD FOR TREATING A RESPIRATORY DISEASE IN A CHILD |
| U-1356 | TREATMENT OF NASAL SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER. TREATMENT OF NASAL SYMPTOMS ASSOCIATED W PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER |
| U-1357 | TREATMENT OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHODS FOR TREATING A RESPIRATORY DISEASE IN A CHILD |
| U-1358 | TREATMENT OF BACTERIAL INFECTIONS IN THE NASAL PASSAGE OF ADULT PATIENTS AND HEALTH CARE WORKERS WITH METHICILLIN RESISTANT S. AUREUS |
| U-1359 | USE OF POMALIDOMIDE TO INHIBIT THE SECRETION OF PRO-INFLAMMATION CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA |
| U-1360 | USE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA |
| U-1361 | USE OF POMALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO POMALIDOMIDE |
| U-1362 | TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET |

**PATENT USE**

| | |
|---|---|
| U-1363 | A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING/STINGING FOLLOWING CORNEAL SURGERY |
| U-1364 | MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) |
| U-1365 | PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT |
| U-1366 | TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY TO ANOVULATORY INFERTILE WOMEN |
| U-1367 | METHOD OF ADMINISTERING FSH FOR THE TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY IN ANOVULATORY INFERTILE WOMEN |
| U-1368 | TREATMENT OF SOLID EXCRETORY SYSTEM TUMORS; ADVANCED RENAL CELL CARCINOMA (RCC), AFTER FAILURE OF TREATMENT WITH SUNITINIB OR SORAFENIB |
| U-1369 | TREATMENT OF VAGINAL SYMPTOMS OF UROGENITAL ATROPHY BY ORALLY ADMINISTERING OSPEMIFENE WITH FOOD TO ENHANCE BIOAVAILABILITY OF OSPEMIFENE |
| U-1370 | TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE |
| U-1371 | REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH ELEVATED INTRAOCULAR PRESSURE OR GLAUCOMA |
| U-1372 | ADMINISTRATION WITHOUT FOOD FOR TREATMENT OF HIV-1 INFECTION |
| U-1373 | METHOD OF TREATING ACETAMINOPHEN OVERDOSE WITH ACETYLCYSTEINE SOLUTIONS |
| U-1374 | TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML) |
| U-1375 | ADASUVE IS A TYPICAL ANTIPSYCHOTIC INDICATED FOR THE ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I DISORDER IN ADULTS |
| U-1376 | TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS |
| U-1377 | IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA |
| U-1378 | TREATMENT OF A NITROGEN METABOLISM DISORDER |
| U-1379 | IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS |
| U-1380 | IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS WHEREIN THE PATIENT HAS CARDIOVASCULAR DISEASE |
| U-1381 | USE OF PRASUGREL AND ASPIRIN IN PATIENTS REQUIRING THE REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS |
| U-1382 | TREATMENT OF NAUSEA AND VOMITING OF PREGNANCY IN WOMEN WHO DO NOT RESPOND TO CONSERVATIVE MANAGEMENT |
| U-1383 | DOSAGE ADJUSTMENT OF A NITROGEN SCAVENGING DRUG IN THE TREATMENT OF A UREA CYCLE DISORDER |
| U-1384 | METHOD OF TREATING MULTIPLE SCLEROSIS |
| U-1385 | METHOD OF TREATING AN AUTOIMMUNE DISEASE SELECTED FROM AUTOIMMUNE POLYARTHRITIS AND MULTIPLE SCLEROSIS BUT NOT TREATING PSORIATIC ARTHRITIS |
| U-1386 | A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF A PERSON IN NEED THEREOF |
| U-1387 | REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAILY WITH MORNING AND EVENING MEALS |
| U-1388 | TREATMENT OF PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS |
| U-1389 | ELLA IS A PROGESTERONE AGONIST/ANTAGONIST EMERGENCY CONTRACEPTION INDICATED FOR THE PREVENTION OF PREGNANCY FOLLOWING UNPROTECTED INTERCOURSE OR A KNOWN OR SUSPECTED CONTRACEPTIVE FAILURE. ELLA CAN BE TAKEN WITH OR WITHOUT FOOD |
| U-1390 | A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF AN ADULT MALE SUBJECT IN NEED THEREOF |
| U-1391 | METHOD FOR TREATING OPIOID-INDUCED CONSTIPATION |
| U-1392 | METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH OPIOID-INDUCED CONSTIPATION |

**PATENT USE**

| | |
|---|---|
| U-1393 | METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION |
| U-1394 | METHOD FOR RELIEVING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING(I)24MICROG+/- 10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT |
| U-1395 | USE IN RELIEVING OR PREVENTING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION WITH A DOSAGE UNIT COMPRISING 24MICROG +/- 10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT |
| U-1396 | TREATMENT OF ADVANCED HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE BREAST CANCER IN COMBINATION WITH EXEMESTANE AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE |
| U-1397 | USE AS AN ANTISEPTIC FOR THE PREPARATION OF A PATIENT'S SKIN PRIOR TO SURGERY |
| U-1398 | METHOD OF TREATING CHRONIC HEPATITIS C |
| U-1399 | MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES |
| U-1400 | FOR THE TREATMENT OF PRIMARY HYPERLIPIDEMIA, MIXED HYPERLIPIDEMIA OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA |
| U-1401 | INDICATED FOR LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PTS WITH A HISTORY OF EXACERBATIONS |
| U-1402 | FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL) |
| U-1403 | FIRST-LINE TREATMENT OF METASTATIC NON SMAL-CELL LUNG CANCER (NSCLC) WITH EGFR EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST |
| U-1404 | METHOD FOR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION BY OPENING CIC CHANNELS |
| U-1405 | THERAPEUTIC TREATMENT OF BONE METASTASES |
| U-1406 | TREATMENT OF MELANOMA |
| U-1407 | TREATMENT OF NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH + CML) |
| U-1408 | TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER |
| U-1409 | TREATMENT OF HIV-1 BY ONCE DAILY ADMINISTRATION |
| U-1410 | TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES |
| U-1411 | THIS DRUG IS ADMINISTERED BY SUBLINGUAL ROUTE TO HUMANS FOR MAINTENANCE TREATMENT OF OPIOID DEPENDENCE |
| U-1412 | TREATMENT OF ATOPIC DERMATITIS |
| U-1413 | ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH FLOLAN STERILE DILUENT FOR INJECTION PRIOR TO INFUSION |
| U-1414 | USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL) |
| U-1415 | TREATING A PATIENT HAVING A CONDITION SUSCEPTIBLE TO TREATMENT WITH METHYLPHENIDATE, SUCH AS ADHD, BY ADMINISTERING THE FORMULATION RECITED IN CLAIMS 1 OR 2 |
| U-1416 | USE OF FENOFIBRATE FOR REDUCING ELEVATED TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES |
| U-1417 | USE FOR TREATMENT OF HELICOBACTER INFECTIONS |
| U-1418 | TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAFV600E MUTATION AS DETECTED BY AN FDA APPROVED TEST |
| U-1419 | TREATMENT OF ACUTE CYANIDE POISONING THAT IS JUDGED TO BE LIFE THREATENING |
| U-1420 | METHOD OF ONCE A DAY ADMINISTRATION |
| U-1421 | SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE |
| U-1422 | METHOD OF TREATING PATIENTS NEEDING AN IRON SUPPLEMENT |
| U-1423 | AMYVID IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) |

**PATENT USE**

| | |
|---|---|
| | IMAGING OF THE BRAIN TO ESTIMATE BETA-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT |
| U-1424 | LONG-TERM, ONCE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS |
| U-1425 | SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE |
| U-1426 | USE FOR TREATMENT OF DIAPER DERMATITIS COMPLICATED BY CANDIDIASIS |
| U-1427 | ALKYLATING DRUG INDICATED FOR THE TOPICAL TREATMENT OF STAGE IA AND IB MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN DIRECTED THERAPY |
| U-1428 | TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA |
| U-1429 | TREATMENT OF PATIENTS WITH BREAST CANCER WHOSE TUMORS OVEREXPRESS THE HER2 RECEPTOR |
| U-1430 | TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL AND PERENNIAL ALLERGIC RHINITIS |
| U-1431 | METHOD OF TREATING HYPERGLYCEMIA TO IMPROVE GLYCEMIC CONTROL IN A PATIENT BY ORAL ADMIN OF ONCE A DAY OSMOTIC DOSAGE FORM OF GLIPIZIDE WITH POLYETHYLENE OXIDE, HYDROXYPROPYLMETHYLCELLULOSE, CELLULOSE ACETATE, AND SODIUM CHLORIDE |
| U-1432 | METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX |
| U-1433 | IMPROVEMENTS OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS |
| U-1434 | TREATMENT OF PANCREATIC CANCER |
| U-1435 | COMBINATION USE OF TOPICAL DICLOFENAC ON THE KNEE AND ADMINISTRATION OF AN ORAL NSAID. |
| U-1436 | USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL AGENT SELECTED FROM SUNSCREEN AND INSECT REPELLANT |
| U-1437 | ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE DILUENT FOR FLOLAN OR STERILE DILUENT FOR EPOPROSTENOL SODIUM PRIOR TO ADMINISTRATION |
| U-1438 | ZINGO INTRADERMAL INJECTION SYSTEM IS A DRUG DELIVERY SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION |
| U-1439 | METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION |
| U-1440 | USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS |
| U-1441 | A METHOD OF TREATING OR REDUCING OCULAR PAIN AND BURNING/STINGING |
| U-1442 | SUBCUTANEOUS INJECTION OF METHOTREXATE |
| U-1443 | ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS |
| U-1444 | A DOSING REGIMEN OF AGGRASTAT (TIROFIBAN HYDROCHLORIDE)(25MCG/KG FOLLOWED BY 0.15MCG/KG/MIN INFUSION) TO REDUCE THE RATE OF THROMBOTIC CORONARY EVENTS ASSOCIATED WITH ACUTE CORONARY SYNDROME (ACS) IN PATIENTS WITH NON-ST ELEVATION ACS |
| U-1445 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN AND A POLYSORBATE, WHERIN THE POLYSORBATE REPRESENTS 0.1 TO 1% OF THE WEIGHT OF SAID PHARMACEUTICAL COMPOSITION |
| U-1446 | METHOD OF TREATING PULMONARY HYPERTENSION COMPRISING ADMINISTERING MACITENTAN IN COMBINATION WITH A COMPOUND HAVING PHOSPHODIESTERASE-5 INHIBITORY PROPERTIES |
| U-1447 | TREATING PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIA |
| U-1448 | TREATING SEVERE HYPERTRIGLYCERIDEMIA |
| U-1449 | METHOD OF ALLEVIATING A SKIN CONDITION |
| U-1450 | TREATMENT OF ALLERGIC RHINITIS SYMPTOMS |
| U-1451 | APPROVED INDICATIONS: APTIOM (ESLICARBAZEPINE ACETATE) IS INDICATED AS ADJUNCTIVE TREATMENT OF PARTIAL-ONSET SEIZURES AND APPROVED IN PATIENTS WITH |

**PATENT USE**

| | |
|---|---|
| | EPILEPSY. PATENT CLAIMS: IN A METHOD OF TREATING A SUBJECT AFFLICTED WITH EPILEPSY |
| U-1452 | METHOD FOR CHRONIC WEIGHT MANAGEMENT |
| U-1453 | A METHOD OF TREATING HYPOXIC RESPIRATORY FAILURE BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT |
| U-1454 | PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS |
| U-1455 | TREATMENT OF PERIANAL WARTS |
| U-1456 | TREATMENT OF MANTLE CELL LYMPHOMA |
| U-1457 | A METHOD OF PURGING A NITRIC OXIDE DELIVERY SYSTEM |
| U-1458 | A METHOD OF REDUCING INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION |
| U-1459 | TREATMENT OF CARCINOMA OF THE THYROID |
| U-1460 | TREATMENT OF HERPES LABIALIS |
| U-1461 | A METHOD OF GENERATING AN INJECTABLE FOAM OF CONTROLLED DENSITY AND BUBBLE SIZE |
| U-1462 | A METHOD OF USING A SCLEROSING AGENT FOR THE TREATMENT OF INCOMPETENT GREAT SAPHENOUS VEINS, ACCESSORY SAPHENOUS VEINS AND VISIBLE VARICOSITIES OF THE GREAT SAPHENOUS (GSV) SYSTEM ABOVE AND BELOW THE KNEE |
| U-1463 | A METHOD OF INTRAVENOUS INJECTION USING ULTRASOUND GUIDANCE, ADMINISTERED VIA A SINGLE CANNULA INTO THE LUMEN OF THE TARGET INCOMPETENT TRUNK VEINS OR BY DIRECT INJECTION INTO VARICOSITIES |
| U-1464 | TREATMENT OF OPIOID DEPENDENCE/SUBLINGUAL OR BUCCAL APPLICATION |
| U-1465 | USE OF THALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO THALIDOMIDE |
| U-1466 | RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER |
| U-1467 | METHOD OF TREATING HEPATITIS C |
| U-1468 | CONTROL OF PHOSPHOROUS LEVELS IN PATIENTS |
| U-1469 | USE OF PHOSYLRA FOR REDUCTION OF SERUM PHOSPHOROUS IN PATIENTS |
| U-1470 | FOR THE TREATMENT OF HEPATITIS C |
| U-1471 | A METHOD FOR TREATING CARDIOVASCULAR DISEASE COMPRISING ADMINISTERING A RECONSTITUTED LYOPHILIZED PHARMACEUTICAL COMPOSITION COMPRISING EPOPROSTENOL, ARGININE AND SODIUM HYDROXIDE. |
| U-1472 | INTENSIVE CARE UNIT SEDATION, INCLUDING SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND/OR DURING SURGICAL AND OTHER PROCEDURES |
| U-1473 | MANAGEMENT OF RISK OF DRONEDARONE/BETA-BLOCKER INTERACTION IN PATIENTS IN SINUS RYTHM WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF |
| U-1474 | A METHOD FOR THE TREATMENT OF A PATIENT SUFFERING FROM A DISEASE TREATABLE WITH ROTIGOTINE, COMPRISING APPLYING THE CLAIMED TRANSDERMAL DELIVERY SYSTEM (TDS) TO THE SKIN OF THE PATIENT |
| U-1475 | USE OF ORENITRAM FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1). |
| U-1476 | INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA. |
| U-1477 | USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL PRESCRIPTION MEDICATION ON THE SAME KNEE |
| U-1478 | METHOD OF REDUCING TG LEVELS IN PATIENT ON STATIN THERAPY SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA |
| U-1479 | INCREASE TEAR PRODUCTION TO TREAT PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE). |
| U-1480 | TREATMENT OF ADVANCED RENAL CELL CARCINOMA |
| U-1481 | REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE |
| U-1482 | DICLOFENAC POTASSIUM FOR RELIEF OF MILD TO MODERATE ACUTE PAIN |
| U-1483 | INCREASE TEAR PRODUCTION IN PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE). |

**PATENT USE**

| | |
|---|---|
| U-1484 | COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND CHILDREN (6 YEARS OF AGE AND OLDER) |
| U-1485 | TREATING A SUBJECT UNDERGOING ABDOMINAL SURGERY BY ADMINISTERING ALVIMOPAN TO ACCELERATE THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS |
| U-1486 | TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER |
| U-1487 | METHOD OF INCREASING EYELASH GROWTH |
| U-1488 | USE OF TOPICAL DICLOFENAC FOR TREATING PAIN |
| U-1489 | USE OF TOPICAL DICLOFENAC ON A JOINT FOR TREATING OSTEOARTHRITIS |
| U-1490 | FOR USE IN PATIENTS HAVING SYMPTOMATIC OR PROGRESSIVE MEDULLARY THYROID CANCER, WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC DISEASE |
| U-1491 | TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA |
| U-1492 | TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER |
| U-1493 | METHOD FOR PREVENTING ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS |
| U-1494 | SUBLINGUAL OR BUCCAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE |
| U-1495 | RISK REDUCTION OF REBLEEDING IN PTS FOLLOWING THERAPEUTIC ENDOSCOPY FOR ACUTE BLEEDING GASTRIC OR DUODENAL ULCERS IN ADULTS. |
| U-1496 | METHOD TO TREAT HEMANGIOMA. |
| U-1497 | NEURACEQ IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE P-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT |
| U-1498 | METHOD OF TREATING PATIENTS WITH GASTRIC RETENTIVE DOSAGE FORM |
| U-1499 | MANAGEMENT OF ACUTE PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA |
| U-1500 | TESTOSTERONE REPLACEMENT THERAPY IN ADULT MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE; PRIMARY HYPOGONADISM (CONGENITAL OR ACQUIRED); HYPOGONADOTROPIC HYPOGONADISM (CONGENITAL OR ACQUIRED). |
| U-1501 | PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM |
| U-1502 | PROPHYLAXIS OF PULMONARY EMBOLISM |
| U-1503 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
| U-1504 | USE OF OTEZLA (APREMILAST) FOR INHIBITING PDE4 |
| U-1505 | USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS |
| U-1506 | TREATMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR (GIST), INCLUDING BUT NOT LIMITED TO PATIENTS PREVIOUSLY TREATED WITH IMATINIB AND PATIENTS WITH GIST HAVING RESISTANCE TO A KIT TYROSINE KINASE INHIBITOR |
| U-1507 | TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN |
| U-1508 | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING A PLURALITY OF COMPOSITE SUBUNITS AS CLAIMED |
| U-1509 | TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING A GASTRIC ACID REDUCER |
| U-1510 | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATEMENT BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED. |
| U-1511 | TREATMENT OF HYPERTRIGLYCERIDEMIA |
| U-1512 | REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS |
| U-1513 | TREATMENT OF HIV-1 INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS |
| U-1514 | MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER BY BUCCAL OR SUBLINGUAL ADMINISTRATION OF FENTANYL |
| U-1515 | METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULT PATIENTS. |
| U-1516 | METHOD OF TREATING CHRONIC IDIOPATHIC CONSTIPATION IN ADULT PATIENTS. |
| U-1517 | TREATMENT OF BACTERIAL INFECTIONS USING A TWO-DOSE REGIMEN OF DALBAVANCIN. |

**PATENT USE**

| | |
|---|---|
| U-1518 | MAINTAINING PUPIL SIZE BY PREVENTING INTRAOPERATIVE MIOSIS AND REDUCING POSTOPERATIVE OCULAR PAIN |
| U-1519 | METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT WITH IRRITABLE BOWEL SYNDROME |
| U-1520 | METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT |
| U-1521 | MAINTENANCE TREATMENT OF OPIOID DEPENDENCE |
| U-1522 | TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE |
| U-1523 | METHOD OF INDUCING TOPICAL ANESTHESIA IN THE EYE |
| U-1524 | REDUCTION OF ELEVATED INTRAOCULAR PRESSURE |
| U-1525 | METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY |
| U-1526 | THE TREATMENT OF PATIENTS WITH TRAVELERS' DIARRHEA (TD) OR THE REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE |
| U-1527 | FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY |
| U-1528 | A METHOD OF LOWERING INTRAOCULAR PRESSURE |
| U-1529 | ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) |
| U-1530 | USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION |
| U-1531 | METHOD FOR TRANSDERMAL DELIVERY OF TESTOSTERONE |
| U-1532 | METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS AND/OR CATAPLEXY IN NARCOLEPSY PATIENTS WITH SODIUM OXYBATE WHEN DIVALPROEX SODIUM IS CONCOMITANTLY ADMINISTERED. |
| U-1533 | PULMONARY ADMINISTRATION OF PARTICLES COMPRISING A DIKETOPIPERAZINE AND INSULIN. |
| U-1534 | ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN COMPLEXED WITH A DIKETOPIPERAZINE. |
| U-1535 | ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN COMPLEXED WITH MICROPARTICLES OF A DIKETOPIPERAZINE. |
| U-1536 | ADMINISTRATION OF A COMPOSITION COMPRISING A DIKETOPIPERAZINE AND INSULIN. |
| U-1537 | TREATMENT OF A PATIENT HAVING DIABETES MELLITUS WITH A PRANDIAL RAPID ACTING INSULIN. |
| U-1538 | ADMINISTRATION OF FDKP MICROPARTICLES COMPRISING INSULIN. |
| U-1539 | PULMONARY ADMINISTRATION OF AN INSULIN COMPOSITION COMPRISING FDKP AT THE BEGINNING OF A MEAL TO A PATIENT ALSO BEING TREATED WITH A LONG-ACTING INSULIN. |
| U-1540 | BUTRANS IS A PARTIAL OPIOID AGONIST PRODUCT INDICATED FOR THE MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE. |
| U-1541 | TREATMENT OF PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX (TSC) WHO HAVE SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) THAT REQUIRES THERAPEUTIC INTERVENTION BUT CANNOT BE CURATIVELY RESECTED. |
| U-1542 | FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND/OR NON-HODGKINS LYMPHOMA |
| U-1543 | TREATMENT OF A PATIENT BY ADMINISTERING THE FORMULATION RECITED IN CLAIM 1 OR CLAIM 23 |
| U-1544 | TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA (PTCL). |
| U-1545 | A METHOD OF TRANSDERMALLY DELIVERING TESTOSTERONE |
| U-1546 | FOR USE IN THE TREATMENT OF MALIGNANT HYPERTHERMIA IN CONJUNCTION WITH APPROPRIATE SUPPORTIVE MEASURES AND FOR THE PREVENTION OF MALIGNANT HYPERTHERMIA IN PATIENTS AT HIGH RISK. |
| U-1547 | TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA |
| U-1548 | FOR THE LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS |

**PATENT USE**

| | |
|---|---|
| U-1549 | FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA |
| U-1550 | METHOD OF TREATING METASTATIC PAPILLARY RENAL CELL CARCINOMA WITH TEMSIROLIMUS. |
| U-1551 | METHOD OF TREATING PAPILLARY RENAL CELL CARCINOMA WITH TEMSIROLIMUS, IN THE ABSENCE OF INTERFERON ALPHA. |
| U-1552 | FOR HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) |
| U-1553 | TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN |
| U-1554 | FOR THE TREATMENT OF HEARTBURN ASSOCIATED WITH SYMPTOMATIC NON-EROSIVE GASTROESOPHAGEAL DISEASE (GERD) |
| U-1555 | MANAGEMENT OF MODERATE TO SEVERE PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE. |
| U-1556 | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE. |
| U-1557 | A METHOD OF TESTOSTERONE REPLACEMENT THERAPY COMPRISING THE STEP OF NASALLY ADMINISTERING TO A PATIENT IN NEED OF SUCH TREATMENT AN EFFECTIVE AMOUNT OF TESTOSTERONE GEL FORMULATION. |
| U-1558 | FOR THE TREATMENT OF PATIENTS WITH RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA OR [RELAPSED] SMALL LYMPHOCYTIC LYMPHOMA |
| U-1559 | INDICATED FOR THE ONCE-DAILY MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN PATIENTS AGED 12 YEARS OF AGE AND OLDER |
| U-1560 | A METHOD OF DISRUPTING LEUKOCYTE FUNCTION, INCLUDING AS AN INHIBITOR OF PI3KDELTA KINASE |
| U-1561 | USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS |
| U-1562 | TREATMENT OF PATIENTS WITH HEPATIC ENCEPHALOPATHY (HE) |
| U-1563 | A METHOD OF TRANSDERMAL ADMINISTRATION OF A PHYSIOLOGICALLY ACTIVE AGENT TO A SUBJECT. |
| U-1564 | A METHOD OF TREATING GAUCHER'S DISEASE |
| U-1565 | METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE |
| U-1566 | METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER |
| U-1567 | METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER |
| U-1568 | METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE |
| U-1569 | TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS |
| U-1570 | TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS USING A SINGLE DOSE |
| U-1571 | TREATMENT OF GAUCHER DISEASE TYPE 1 |
| U-1572 | TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION. |
| U-1573 | USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2. |
| U-1574 | A METHOD OF CATALYZING THE HYDROLYSIS OF GLUCOCEREBROSIDE TO GLUCOSE AND CERAMIDE. |
| U-1575 | PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY |
| U-1576 | TREATMENT OF LEUKEMIA |
| U-1577 | CONTROL OF SERUM PHOSPHOROUS LEVELS |
| U-1578 | TREATMENT OF ACUTE OTITIS MEDIA |
| U-1579 | USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER |
| U-1580 | USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAD RECEIVED PRIOR DOCETAXEL |

**PATENT USE**

| | |
|---|---|
| | CHEMOTHERAPY |
| U-1581 | IN COMBINATION WITH DABRAFENIB FOR THE TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA. |
| U-1582 | TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA |
| U-1583 | FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY |
| U-1584 | USE OF NALTREXONE AND BUPROPION IN A LAYERED FORMULATION FOR CHRONIC WEIGHT MANAGEMENT FOR AFFECTING WEIGHT LOSS |
| U-1585 | USE OF NALTREXONE AND BUPROPION BASED ON AN ESCALATING DOSE SCHEDULE |
| U-1586 | FOR EFFECT ON BLOOD GLUCOSE PARAMETERS IN PATIENTS WITH INSULIN RESISTANCE |
| U-1587 | SINGLE-DOSE INFILTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA. |
| U-1588 | THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC). |
| U-1589 | METHOD OF USE FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA |
| U-1590 | KUVAN IS INDICATED TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA |
| U-1591 | TREATMENT OF ASTHMA IN PATIENTS AGED 12 YEARS AND OLDER |
| U-1592 | TO REDUCE SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE |
| U-1593 | MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA, AND REDUCTION OF EXACERBATIONS IN COPD PATIENTS. |
| U-1594 | DILATION OF THE PUPIL |
| U-1595 | USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIASIS |
| U-1596 | LAMICTAL IS AN ANTIEPILEPTIC DRUG (AED) INDICATED FOR: EPILEPSY-ADJUNCTIVE THERAPY IN PATIENTS GREATER THAN OR EQUAL TO 2 YEARS OF AGE: (1.1) PARTIAL SEIZURES PRIMARY GENERALIZED TONIC-CLONIC SEIZURES |
| U-1597 | TREATMENT OF DIABETIC MACULAR EDEMA |
| U-1598 | METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE |
| U-1599 | MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADNUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY |
| U-1600 | DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS |
| U-1601 | DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS |
| U-1602 | METHOD OF ADMINISTERING PIRFENIDONE CAPSULES TO TREAT A FIBROTIC CONDITION |
| U-1603 | METHOD FOR ADMINISTERING PIRFENDONE TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE |
| U-1604 | METHOD FOR ADMINISTERING PIRFENDONE TO REDUCE DRUG INTERACTIONS WITH A STRONG INHIBITOR OF CYP1A2 |
| U-1605 | METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY DISCONTINUING SMOKING OR BY DISCONTINUING OR AVOIDING ANOTHER STRONG CYP1A2 INDUCER |
| U-1606 | METHOD FOR ADMINISTERING PIRFENIDONE WHILE AVOIDING OR DISCONTINUING CONCOMITANT USE OF A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME INVOLVED IN PIRFENIDONE METABOLISM |
| U-1607 | METHOD OF ADMINISTERING A DOSAGE FORM THAT INCLUDES A GRANULATE FORMULATION OF PIRFENIDONE TO TREAT A FIBROTIC CONDITION |
| U-1608 | DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF A FIBROSIS CONDITION |
| U-1609 | CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS |
| U-1610 | CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELVATED LIVER ENZYMES IN USE OF PIRFENIDONE |
| U-1611 | METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY DISCONTINUING SMOKING OR BY DISCONTINUING A STRONG CYP1A2 INDUCER |
| U-1612 | METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY AVOIDING SMOKING OR BY AVOIDING ANOTHER STRONG CYP1A2 INDUCER |

**PATENT USE**

| | |
|---|---|
| U-1613 | DOSAGE MODIFICATION IN TREATMENT WITH PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH CIPROFLOXACIN |
| U-1614 | USE OF TOPICAL DICLOFENAC SODIUM FOR TREATING PAIN |
| U-1615 | FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL |
| U-1616 | NASAL ADMINISTRATION OF A TESTOSTERONE GEL TO A PATIENT TO TREAT THE PATIENT FOR A CONDITION ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE |
| U-1617 | METHOD OF TREATING MEDULLARY THYROID CANCER |
| U-1618 | A METHOD OF TREATING A PATIENT SUFFERING FROM A PAIN ASSOCIATED SLEEP DISTURBANCE COMPRISING ADMINISTERING A LIQUID COMPOSITION FORMULATED INSIDE A SOFT GEL CAPSULE, AS CLAIMED, TO THE PATIENT |
| U-1619 | TREATMENT OF IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP) |
| U-1620 | METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX, WITH A SUBSTANTIALLY NON-IMMUNOGENIC CARBOHYDRATE COMPONENT, IN ABOUT 15 MINUTES OR LESS. |
| U-1621 | PULMONARY ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN BOUND TO A COMPLEXING AGENT. |
| U-1622 | FOR THE TREATMENT OF POLYCYTHEMIA VERA |
| U-1623 | USE OF EXENATIDE MAY RESULT IN REDUCTION IN APPETITE. |
| U-1624 | TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA, ADVANCED RENAL CELL CARCINOMA, OR DIFFERENTIATED THYROID CARCINOMA. |
| U-1625 | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE POOR METABOLIZERS OF CYP2D6 |
| U-1626 | A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING |
| U-1627 | TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN ADULTS |
| U-1628 | METHOD OF TREATING DISORDERS WITH AN ETIOLOGY COMPRISING OR ASSOCIATED WITH EXCESS GH-SECRETION |
| U-1629 | METHOD OF TREATING ACROMEGALY |
| U-1630 | TREATMENT IN COMBINATION WITH A CORTICOID SUCH AS PREDNISONE OF PROSTATE CANCER PREVIOUSLY TREATED IWTH DOCETAXEL |
| U-1631 | TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA. |
| U-1632 | TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA |
| U-1633 | USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA |
| U-1634 | TREATMENT OF BRCA MUTATED OVARIAN CANCER USING PARP INHIBITOR |
| U-1635 | USE OF RITONAVIR AS A POTENT CYP3A INHIBITOR TO INCREASE PLASMA DRUG CONCENTRATION OF PARITAPREVIR AND OVERALL DRUG EXPOSURE FOR TREATMENT OF HCV INFECTION |
| U-1636 | USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION. |
| U-1637 | TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN. |
| U-1638 | TREATMENT OF HCV INFECTION USING PARITAPREVIR |
| U-1639 | USE OF NALTREXONE AND BUPROPION IN EXTENDED-RELEASE FORM FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY |
| U-1640 | TREATMENT OF MODERATE TO SEVERE CHRONIC PAIN BY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED |
| U-1641 | MEMANTINE HCL/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE |
| U-1642 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN |
| U-1643 | TREATING CUSHING'S SYNDROME |
| U-1644 | TREATMENT OF OVERACTIVE BLADDER BY APPLICATION OF OXYBUTYNIN CHLORIDE GEL TO SKIN |

**PATENT USE**

| | |
|---|---|
| U-1645 | TREATMENT OF PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
| U-1646 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
| U-1647 | TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
| U-1648 | TREATMENT OF PATIENTS WITH PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION |
| U-1649 | TREATMENT OF POST-ENCEPHALITIC PARKINSONISM |
| U-1650 | TREATMENT OF WALDENSTROM'S MACROGLOBULINEMIA |
| U-1651 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN |
| U-1652 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
| U-1653 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT METFORMIN) |
| U-1654 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT INSULIN OR A SULFONYLUREA) |
| U-1655 | A METHOD TO ACCELERATE THE TIME TO GASTROINTESTINAL RECOVERY BY ADMINISTERING ABOUT 12 MG OF ALVIMOPAN TO THE PATIENT FROM ABOUT 30 TO 60 MINUTES PRIOR TO SURGERY |
| U-1656 | METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT |
| U-1657 | METHOD FOR PROVIDING POST COITAL CONTRACEPTION TO A WOMAN BY ADMINISTERING ABOUT 30 MG OF ULIPRISTAL ACETATE WITHIN ABOUT 120 HOURS AFTER INTERCOURSE, WHEREIN THE WOMAN IS OVERWEIGHT  HAVING A BMI OF 25 TO 29.99 |
| U-1658 | TREATMENT OF ER-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER IN COMBINATION WITH LETROZOLE AS INITIAL ENDOCRINE-BASED THERAPY FOR METASTATIC DISEASE IN POSTMENOPAUSAL WOMEN |
| U-1659 | MANAGEMENT OF PAIN |
| U-1660 | TREATMENT OF HIV-1 INFECTION IN ADULTS WITH NO DARUNAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS |
| U-1661 | RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS ALSO TAKING LOW DOSE ASPIRIN |
| U-1662 | A METHOD OF TREATING OCULAR PAIN |
| U-1663 | TREATMENT OF HIV-1 INFECTION |
| U-1664 | TREATMENT OF BACTERIAL VAGINOSIS WITH METRONIDAZOLE GEL |
| U-1665 | METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING THE COMPOSITION OF CLAIM 1 |
| U-1666 | PALLIATIVE TREATMENT OF PROSTATE CANCER |
| U-1667 | TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL ALLERGIC RHINITIS |
| U-1668 | METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER |
| U-1669 | TREATMENT OF MULTIPLE MYELOMA, IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE |
| U-1670 | NATROBA TOPICAL SUSPENSION IS A PEDICULICIDE INDICATED FOR THE TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS SIX (6) MONTHS OF AGE AND OLDER. |
| U-1671 | TREATMENT OF OCULAR ITCHING ASSOCIATED WITH CONJUNCTIVITIS |
| U-1672 | TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION |
| U-1673 | TREATMENT OF COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS |
| U-1674 | DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE |
| U-1675 | USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY |
| U-1676 | METHODS FOR TREATING BACTERIAL INFECTIONS |
| U-1677 | TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (IPF) |

**PATENT USE**

| | |
|---|---|
| U-1678 | FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL |
| U-1679 | TREATMENT OF ACUTE OTITIS EXTERNA |
| U-1680 | TREATMENT OF OCULAR ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS |
| U-1681 | TREATMENT OF PATIENTS WITH PROGESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC |
| U-1682 | TREATMENT OF BACTERIAL VAGINOSIS |
| U-1683 | TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION |
| U-1684 | TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA |
| U-1685 | DOSAGE MODIFICATION TO REDUCE THE RISK ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE |
| U-1686 | A METHOD TO REDUCE WITHDRAWAL SYMPTOMS, INCLUDING NICOTINE CRAVING, ASSOCIATED WITH SMOKING CESSATION |
| U-1687 | TREATMENT OF HCV INFECTION USING OMBITASVIR |
| U-1688 | METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD |
| U-1689 | METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD |
| U-1690 | METHOD FOR REDUCTION OF SUBMENTAL FAT |
| U-1691 | INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER |
| U-1692 | METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD |
| U-1693 | METHOD OF TREATING ADHD IN CHILDREN 6 YEARS OF AGE AND OLDER AND ADOLESCENTS |
| U-1694 | A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE |
| U-1695 | METHOD FOR TREATING THYROID CARCINOMA INCLUDING DIFFERENTIATED THYROID CANCER |
| U-1696 | TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA |
| U-1697 | PULMONARY ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN BOUND TO A DIKETOPIPERAZINE. |
| U-1698 | PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS |
| U-1699 | A METHOD FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA |
| U-1700 | A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA |
| U-1701 | A METHOD FOR TREATING LEUKEMIA RESULTING FROM A MUTATION IN THE BCR-ABL KINASE DOMAIN |
| U-1702 | TREATMENT OF COPD |
| U-1703 | TREATMENT OF RESPIRATORY COMPLAINTS |
| U-1704 | USE FOR TREATMENT IN PATIENTS WITH DIABETES |
| U-1705 | USE FOR TREATMENT IN PATIENTS WITH HYPERGLYCEMIA |
| U-1706 | TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE WHEREIN THE COMBINED THERAPEUTIC EFFECT IS GREATER THAN THE ADDITIVE EFFECT OF ADMINISTERING EACH AGENT ALONE |
| U-1707 | TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS AND SYMPTOMS THEREOF. |
| U-1708 | TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS. |
| U-1709 | TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE). |
| U-1710 | TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH FLUVOXAMINE |
| U-1711 | FOR THE TREATMENT OF PATIENTS WITH CLL, FL OR SLL |
| U-1712 | MEKENIST IN COMBINATION WITH DABRAFENIB FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA |

**PATENT USE**

| | |
|---|---|
| U-1713 | TAFINLAR IN COMBINATION WITH TRAMETINIB FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA |
| U-1714 | TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP) |
| U-1715 | P2Y12 PLATELET INHIBITOR FOR USE AS ADJUNCT TO PERCUTANEOUS CORONARY INTERVENTION TO REDUCE RISK OF VARIOUS DISEASES/CONDITIONS IN PATIENTS NOT TREATED WITH A P2Y12 PLATELET INHIBITOR AND NOT GIVEN A GLYCOPROTEIN IIB/IIIA INHIBITOR |
| U-1716 | TREATMENT OF COUGH AND SYMPTOMS ASSOCIATED WITH UPPER RESPIRATORY ALLERGIES OR A COMMON COLD WITH CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE ORALLY ADMINISTERED EXTENDED RELEASE TABLETS |
| U-1717 | METHOD OF TREATING CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE |
| U-1718 | METHOD OF TREATING CYSTIC FIBROSIS IN PATIENTS WHO HAVE THE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE. |
| U-1719 | ACUTE TREATMENT OF MIGRAINE |
| U-1720 | METHOD OF PROVIDING A THERAPEUTICALLY EFFECTIVE AND STABLE MEDIAN BLOOD PLASMA LEVEL OF LEVODOPA |
| U-1721 | USE OF RUXOLITINIB (JAKAFI) FOR BLOCKING SIGNAL TRANSDUCTION OF JANUS ASSOCIATED KINASES (JAKS) JAK1 AND/OR JAK2 |
| U-1722 | TREATMENT OF BASAL CELL CARCINOMA |
| U-1723 | TREATMENT OF HEART FAILURE |
| U-1724 | METHOD OF INHIBITING HEPATITIS C VIRUS |
| U-1725 | METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY |
| U-1726 | REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH CORONARY HEART DISEASE AND A HISTORY OF PAROXYSMAL OR PERSISTENT AF AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS |
| U-1727 | TOPICAL TREATMENT OF INFLAMMATORY PAPULES AND PUSTULES OF MILD TO MODERATE ROSACEA |
| U-1728 | REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH STABLE NYHA CLASS III HEART FAILURE AND A HISTORY OF PAROXYSMAL OR PERSISTENT AF AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS |
| U-1729 | REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT) |
| U-1730 | REDUCE THE RISK OF RECURRENT PULMONARY EMBOLISM |
| U-1731 | TEMPORARY RELIEF OF MINOR ACHES AND PAINS |
| U-1732 | TEMPORARY REDUCTION OF FEVER |
| U-1733 | TREATMENT/PREVENTION OF CARDIOVASCULAR DISEASE |
| U-1734 | USE OF FLIBANSERIN OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF TO TREAT HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) |
| U-1735 | METHODS OF TREATING PAIN, INFLAMMATION AND/OR FEVER WITH INTRAVENOUS IBUPROFEN SUCH THAT MEAN ARTERIAL BLOOD PRESSURE DOES NOT INCREASE THE DOSAGE INTERVAL |
| U-1736 | TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP) |
| U-1737 | METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE BEING TREATED WITH FLUOXETINE |
| U-1738 | TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE) |
| U-1739 | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND -THE-CLOCK, LONG-TERM OPIOID TREATMENT, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY |
| U-1740 | IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THEARPY |
| U-1741 | PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY |

**PATENT USE**

| | |
|---|---|
| U-1742 | ROLAPITANT IS APPROVED FOR THE PREVENTION OF DELAYED NAUSEA AND VOMITING (I.E., EMESIS) ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY |
| U-1743 | FOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY |
| U-1744 | PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING |
| U-1745 | FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA |
| U-1746 | MONOTHERAPY OR ADJUNCTIVE THERAPY FOR TREATMENT OF PARTIAL-ONSET SEIZURES AND APPROVED IN PATIENTS WITH EPILEPSY |
| U-1747 | FOR CLAIMS 1-3,6-13,16-24 AND 26-32: METHOD OF TREATING ADHD |
| U-1748 | FOR CLAIMS 1-4,6-14,16-24 AND 26-32: METHOD OF TREATING ADHD IN CHILDREN 6 YEARS OF AGE AND OLDER AND ADOLESCENTS |
| U-1749 | ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER |
| U-1750 | TREATMENT OF SCHIZOPHRENIA AND/OR ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE |
| U-1751 | TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER WHO HAVE BEEN PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN- AND IRINOTECAN-BASED CHEMOTHERAPY, AN ANTI-VEGF BIOLOGICAL THERAPY, AND IF RAS WILD-TYPE, AN ANTI-EGFR THERAPY |
| U-1752 | PROPHYLAXIS OF ORGAN REJECTION |
| U-1753 | TREATMENT OF HCV INFECTION USING DASABUVIR |
| U-1754 | FOR THE TREATMENT OF PULMONARY HYPERTENSION (PAH) IN COMBINATION WITH TADALAFIL |
| U-1755 | FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS |
| U-1756 | METHODS OF TREATING PAIN, INFLAMMATION AND/OR FEVER IN A CRITICALLY ILL PATIENT WITH INTRAVENOUS IBUPROFEN IN NEED THEREOF |
| U-1757 | INHIBITION ON PI3K KINASE |
| U-1758 | METHOD OF TREATING ALLERGIC REACTION VIA INJECTION |
| U-1759 | METHOD OF REVERSING THE ANTICOAGULANT EFFECT OF DABIGATRAN USING IDARUCIZUMAB |
| U-1760 | RISK-REDUCTION OF NSAID GASTRIC ULCER IN PATIENTS REQUIRING CHRONIC NSAID TREATMENT |
| U-1761 | PLAQUE PSORIASIS |
| U-1762 | USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT |
| U-1763 | USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT |
| U-1764 | USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT |
| U-1765 | USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT |
| U-1766 | TREATMENT OF HYPERKALEMIA |
| U-1767 | USE OF CALCIPOTRIENE FOAM FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS AGED 18 YEARS AND OLDER |
| U-1768 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN |
| U-1769 | TREATEMENT OF PAIN BY TRANSMUCOSAL DELIVERY OF BUPRENORPHINE |
| U-1770 | TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN NEGATIVE SYMPTOMS AND/OR COGNITIVE DYSFUNCTION OF SCHIZOPHRENIA |
| U-1771 | ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION OR 0.9% SODIUM CHLORIDE INJECTION PRIOR TO ADMINISTRATION |
| U-1772 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN |
| U-1773 | LONG - TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) |

**PATENT USE**

| | |
|---|---|
| U-1774 | USE OF A LOTION CONTAINING HALOBETASOL PROPIONATE FOR THE TREATMENT OF CORTICOSTEROID-RESPONSIVE |
| U-1775 | USE OF A LOTION CONTAINING HALOBETASOL PROPIONATE FOR THE TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES INCLUDING PSORIASIS |
| U-1776 | METHOD OF USING COBIMETINIB FOR THE TREATMENT OF MELANOMA |
| U-1777 | TREATMENT OF PATIENTS WITH METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC), WHO HAVE PROGRESSED ON OR AFTER EGFR TKI THERAPY |
| U-1778 | METHOD FOR TREATING MULTIPLE MYELOMA |
| U-1779 | METHOD FOR TREATING MULTIPLE MYELOMA WITH ONE OR MORE OTHER THERAPEUTIC AGENTS |
| U-1780 | METHOD FOR TREATING CANCER, INCLUDING MULTIPLE MYELOMA |
| U-1781 | RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER IN PATIENTS REQUIRING NSAID TREATMENT |
| U-1782 | FOR HEAD LICE INFESTATIONS |
| U-1783 | METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN ESOMEPRAZOLE MAGNESIUM AS CLAIMED |
| U-1784 | METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN ESOMEPRAZOLE MAGNESIUM TRIHYDRATE AS CLAIMED |
| U-1785 | METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN ESOMEPRAZOLE MAGNESIUM FORMULATION AS CLAIMED |
| U-1786 | TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS WHILE MANAGING THE RISK OF TERIFLUNOMIDE AND ROSUVASTATIN INTERACTION BY LIMITING THE ROSUVASTATIN DOSE TO NO MORE THAN 10MG AND/OR ADMINISTERING ABOUT HALF THE NORMAL DOSE |
| U-1787 | TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY |
| U-1788 | TREATMENT OF PATIENT HAVING DIABETES MELLITUS VIA ORAL INHALATION OF FDKP MICROPARTICLES COMPRISING INSULIN |
| U-1789 | METHOD OF ADMINISTERING AN ETHANOL-FREE TAXANE LIQUID NANODISPERSION FORMULATION TO A SUBJECT COMBINING THE FORMULATION WITH AN AQUEOUS MEDIUM TO PROVIDE AN ETHANOL-FREE TAXANE DILUTED SOLUTION |
| U-1790 | FOR USE IN TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR NON-HODGKIN'S LYMPHOMA |
| U-1791 | EMERGENCY TREATMENT OF ADULT & PEDIATRIC PATIENTS FOLLOWING FLUOROURACIL OR CAPECITABINE OVERDOSE,OR WHO EXHIBIT EARLY-ONSET,SEVERE OR LIFE-THREATENING CARDIAC OR CNS TOXICITY OR UNUSUALLY SEVERE ADVERSE REACTIONS WITHIN 96 HOURS |
| U-1792 | TREATMENT OF OTIC INFECTION OR INFLAMMATION |
| U-1793 | TREATMENT OF PEDIATRIC PATIENTS WITH OTITIS MEDIA WITH EFFUSION UNDERGOING TYMPANOSTOMY TUBE PLACEMENT |
| U-1794 | REVERSAL OF DRUG-INDUCED NEUROMUSCULAR BLOCK |
| U-1795 | REVERSAL OF NEUROMUSCULAR BLOCKAGE INDUCED BY ROCURONIUM BROMIDE OR VECURONIUM BROMIDE |
| U-1796 | TOPICAL TREATMENT OF INFLAMMATORY PAPULES AND PUSTULES OF MILD TO MODERATE ROSACEA |
| U-1797 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG |
| U-1798 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN |
| U-1799 | METHOD OF INCREASING GROWTH OF HAIR INCLUDING EYELASHES |
| U-1800 | A METHOD OF TREATING OCULAR PAIN AND/OR ENHANCING OCULAR COMFORT |
| U-1801 | REDUCTION OF SERUM URIC ACID LEVELS |
| U-1802 | TREATMENT OF GOUT |
| U-1803 | TREATMENT OF HYPERURICEMIA |
| U-1804 | ACHIEVING A THERAPEUTIC BENEFIT IN A SUBJECT WITH GOUT |
| U-1805 | USE OF DEXLANSOPRAZOLE IN PATIENTS TAKING CLOPIDOGREL WITHOUT MEANINGFUL CYP2C19 INTERACTIONS |

**PATENT USE**

| | |
|---|---|
| U-1806 | COADMINISTERING WITH ALLOPURINOL TO REDUCE SERUM URIC ACID (SUA) BELOW 4 MG/DL; BELOW 6MG/DL IN PATIENTS HAVING URIC ACID DEPOSITS; AND/OR BELOW 6MG/DL WITH SUA INTRADAY CHANGE MORE THAN 50% AND/OR ADVERSE EVENT RATE LESS THAN 15% |
| U-1807 | TREATMENT OF PEDIATRIC PATIENTS 8 TO 17 YEARS OF AGE WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH) |
| U-1808 | USE OF NALTREXONE AND BUPROPION FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER |
| U-1809 | METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY |
| U-1810 | TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT |
| U-1811 | TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATIONS AFTER CONFIRMING THE PRESENCE OF BRAF V600E MUTATION |
| U-1812 | TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA |
| U-1813 | TREATMENT OF PATIENTS INFECTED WITH HEPATITIS C VIRUS |
| U-1814 | METHOD OF TREATING GLAUCOMA OR ELEVATED INTRAOCULAR PRESSURE |
| U-1815 | TREATMENT OF PARTIAL-ONSET SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY |
| U-1816 | TREATMENT OF A UREA CYCLE DISORDER |
| U-1817 | PEDIATRIC USE AGES 1 MONTH TO 2 YEARS, GERD AND EROSIVE ESOPHAGITIS |
| U-1818 | TREATING HR-POS., HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER WITH PALBOCICLIB IN COMBO WITH LETROZOLE AS INITIAL ENDOCRINE BASED THERAPY IN POSTMENOPAUSAL WOMEN, OR FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY |
| U-1819 | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE |
| U-1820 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN AND A POLYSORBATE, WHEREIN THE POLYSORBATE REPRESENTS 0.1 TO 3% OF THE WEIGHT OF SAID PHARMACEUTICAL COMPOSITION |
| U-1821 | METHOD FOR CONTRACEPTION TO A WOMAN COMPRISING ADMINISTERING TO THE WOMAN 30MG OF ULIPRISTAL ACETATE MORE THAN 72 HOURS AND UP TO 120 HOURS AFTER AN UNPROTECTED INTERCOURSE |
| U-1822 | TREATMENT OF SCHIZOPHRENIA OR BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA AND/OR BIPOLAR DISORDER |
| U-1823 | A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY COMPENSATING LONG-TERM SENSITIVITY DRIFT OF ELECTROCHEMICAL GAS SENSORS USED IN SYSTEMS FOR DELIVERING THERAPEUTIC NITRIC OXIDE TO A PATIENT |
| U-1824 | A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT |
| U-1825 | METHOD OF USING VISMODEGIB TO TREAT CANCER IN A MAMMAL |
| U-1826 | TREATMENT OF HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION WITH PALBOCOCLIB IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY |
| U-1827 | A METHOD OF PROVIDING A SUBJECT WITH THERAPEUTICALLY EFFECTIVE AMOUNT OF RACEMIC METHYLPHENIDATE BY ORALLY ADMINISTERING TO SAID SUBJECT A SINGLE METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET ACCORDING TO CLAIM 1 |
| U-1828 | INCREASING MEAN ARTERIAL BLOOD PRESSURE IN ADULT PATIENTS WITH HYPOTENSION ASSOCIATED WITH SEPTIC SHOCK |
| U-1829 | EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE I), INCLUDING ANAPHYLAXIS |
| U-1830 | INDUCTION AND MAINTENANCE OF MYDRIASIS DURING INTRAOCULAR SURGERY |
| U-1831 | METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A CRYSTALLINE FORM OF SELEXIPAG |
| U-1832 | IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR WITH A THREADED DRIVE SLEEVE |
| U-1833 | REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION |
| U-1834 | TREATMENT OF POSTOPERATIVE INFLAMMATION AND PREVENTION OF OCULAR PAIN IN |

**PATENT USE**

| | |
|---|---|
| | PATIENTS UNDERGOING CATARACT SURGERY |
| U-1835 | TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
| U-1836 | TREATMENT OF HEREDITARY TYROSINEMIA TYPE 1 (HT-1) IN COMBINATION WITH DIETARY RESTRICTION OF TYROSINE AND PHENYLALANIE |
| U-1837 | METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN ALONE OR IN COMBINATION WITH INSULIN, METFORMIN, A THIAZOLIDINEDIONE, GLYBURIDE OR METFORMIN PLUS A SULFONYLUREA |
| U-1838 | METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN IN COMBINATION WITH METFORMIN |
| U-1839 | COMPOSITION AND METHOD FOR PROVIDING A REDUCTION IN SIDE EFFECTS FOR HUMAN PATIENTS IN NEED OF ACETYLCYSTEINE THERAPY |
| U-1840 | TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN |
| U-1841 | USE IN THE LONG-TERM, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) |
| U-1842 | METHOD OF TREATING EPILEPSY |
| U-1843 | TREATMENT OF PSYCHOSIS |
| U-1844 | TREATMENT OF PARKINSON'S DISEASE PSYCHOSIS |
| U-1845 | TREATMENT OF PSYCHOSIS OR A SYMPTOM THEREOF |
| U-1846 | TREATMENT OF A NEURODEGENERATIVE DISEASE OR A SYMPTOM THEREOF |
| U-1847 | METHOD OF TREATING A BACTERIAL INFECTION |
| U-1848 | TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN |
| U-1849 | METHOD OF TREATING PULMONARY HYPERTENSION BY ADMINISTERING TREPROSTINIL OR A SALT THEREOF BY INHALATION USING A DEVICE |
| U-1850 | METHOD OF ADMINISTERING LEVETIRACETAM |
| U-1851 | A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES |
| U-1852 | METHOD OF TREATING TYPE 2 DIABETES |
| U-1853 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND, OPTIONALLY, A SULFONYLUREA |
| U-1854 | TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) |
| U-1855 | IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS |
| U-1856 | TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN, IN A PATIENT HOMOZYGOUS FOR THE UGT1A1*28 ALLELE |
| U-1857 | TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES |
| U-1858 | TREATMENT OF PLAQUE PSORIASIS |
| U-1859 | TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER |
| U-1860 | REDUCTION OF THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION |
| U-1861 | USE OF AN INHALER TO ADMINISTER DRY POWDER MEDICAMENT |
| U-1862 | TREATMENT OF POST-MYOCARDIAL INFARCTION |
| U-1863 | TREATMENT OF STROKE |
| U-1864 | TREATMENT OF MYOCARDIAL INFARCTION |
| U-1865 | TREATMENT OF THROMBOTIC STROKE |
| U-1866 | TREATMENT OF STABLE AND UNSTABLE ANGINA |

**PATENT USE**

| | |
|---|---|
| U-1867 | METHOD OF INHIBITING PLATELET AGGREGATION |
| U-1868 | TREATMENT OF ARTERIAL THROMBOTIC COMPLICATIONS SELECTED FROM THE GROUP CONSISTING OF UNSTABLE ANGINA, THROMBOTIC OR EMBOLIC STROKE, TRANSIENT ISCHAEMIC ATTACKS, PERIPHERAL VASCULAR DISEASE AND MYOCARDIAL INFARCTION |
| U-1869 | TREATMENT OF AN ARTERIAL THROMBOTIC COMPLICATION IN A PATIENT WITH CORONARY ARTERY, CEREBROVASCULAR OR PERIPHERAL VASCULAR DISEASE |
| U-1870 | ZINGO IS A POWDER INTRADERMAL SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION |
| U-1871 | TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH STAGE 3 OR 4 CHRONIC KIDNEY DISEASE USING CONTROLLED RELEASE, ORAL 25-HYDROXYVITAMIN D |
| U-1872 | USE OF SUSTAINED RELEASE 25-HYDROXYVITAMIN D IN TREATING PATIENTS HAVING 25-HYDROXYVITAMIN D INSUFFICIENCY OR DEFICIENCY |
| U-1873 | ADMINISTRATION OF 25-HYDROXYVITAMIN D3 BY CONTROLLED RELEASE |
| U-1874 | TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING OMEPRAZOLE ACCORDING TO CLAIMS 1-8 |
| U-1875 | TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING S-OMEPRAZOLE TRIHYDRATE ACCORDING TO CLAIMS 1-3 |
| U-1876 | METHOD OF ANESTHETIZING AT LEAST A PORTION OF THE MAXILLARY DENTAL ARCH |
| U-1877 | METHOD OF TREATING PULMONARY HYPERTENSION BY ORALLY ADMINISTERING A FORMULATION OF A PHARMACEUTICALLY ACCEPTABLE SALT OF TREPROSTINIL |
| U-1878 | FOR OPIOID DEPENDENCE |
| U-1879 | METHOD OF DIAGNOSING TUMORS USING POSITRON EMISSION TOMOGRAPHY |
| U-1880 | TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED) |
| U-1881 | IMPROVEMENT IN GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR |
| U-1882 | MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANALGESIC AND ANTIPYRETIC ACTIVITY |
| U-1883 | TREATMENT OF GASTROINTESTINAL STROMAL TUMORS (GIST) |
| U-1884 | USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT |
| U-1885 | USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT |
| U-1886 | USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT |
| U-1887 | USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT |
| U-1888 | USE OF CONTROLLED RELEASE 25-HYDROXYVITAMIN D IN TREATING SECONDARY HYPERPARATHYROIDISM IN PATIENTS HAVING CHRONIC KIDNEY DISEASE |
| U-1889 | TREATMENT OF HCV INFECTION USING DASABUVIR/OMBITASVIR/PARITAPREVIR/RITONAVIR FIXED DOSE COMBINATION |
| U-1890 | OTC USE: ALLERGY SYMPTOM RELIEVER; TEMPORARILY RELIEVES THESE SYMPTOMS DUE TO HAY FEVER OR OTHER UPPER RESPIRATORY ALLERGIES; NASAL CONGESTION, RUNNY NOSE, SNEEZING, ITCHY NOSE, AND (ITCHY WATER EYES (AGES 12 AND UP)) |
| U-1891 | TREATMENT OR PREVENTION OF NAUSEA AND VOMITING |
| U-1892 | METHOD OF TREATING LEFT VENTRICULAR DYSFUNCTION |
| U-1893 | METHOD OF TREATING MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER IN PEDIATRIC PATIENTS |
| U-1894 | COMBINATION TREATMENT WITH A GLITAZONE FOR IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS |
| U-1895 | METHOD OF TREATING PROSTATE CANCER |
| U-1896 | SUPPLEMENT FOR VITAMIN B12 DEFICIENCIES |

**PATENT USE**

U-1897 METHOD OF TREATING ACS USING ANGIOPLASTY WITH AGGRASTAT (TIROFIBAN HYDROCHLORIDE)

U-1898 METHOD OF INHIBITING PLATELET AGGREGATION WITH AGGRASTAT (TIROFIBAN HYDROCHLORIDE)

U-1899 TREATMENT OF PANCREATIC CANCER THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN

U-1900 TREATMENT OF THE SIGNS SYMPTOMS OF DRY EYE DISEASE (DED)

U-1901 TREATMENT OF SCHIZOAFFECTIVE DISORDER AS A MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS

U-1902 TREATMENT OR SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE, CARDIOVASCULAR EVENTS, OR CEREBROVASCULAR EVENTS AND RISK-REDUCTION OF ASPIRIN-ASSOCIATED GASTRIC ULCERS

U-1903 USE OF NALOXONE HYDROCHLORIDE FOR EMERGENCY TREATMENT OF KNOWN OR SUSPECTED OPIOID OVERDOSE, AS MANIFESTED BY RESPIRATORY AND/OR CENTRAL NERVOUS SYSTEM DEPRESSION.

U-1904 (I)TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY; (II)RESTORING/INCREASING FUNCTIONAL DYSTROPHIN PROTEIN; OR (III) INDUCING SKIPPING; EACH OF (I)-(III) IN PATIENTS HAVING A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING

U-1905 METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS, THE PATIENT HAVING A R117H MUTATION IN CFTR, USING N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE

U-1906 METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS, SUCH AS A PATIENT HAVING A G551D MUTATION IN CFTR, USING N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE

U-1907 USE OF A DELIVERY DEVICE TO ADMINISTER A DOSE OF NALOXONE

U-1908 METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING IVACAFTOR AND FORM I LUMACAFTOR

U-1909 METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING IVACAFTOR AND LUMACAFTOR

U-1910 METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING THE DOSAGE UNIT OF CLAIM 1 OF U.S. PATENT NO. 8,716,338

U-1911 METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS USING IVACAFTOR AND LUMACAFTOR

U-1912 METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING A DOSAGE UNIT AS DEFINED IN CLAIM 1 OF U.S. PATENT NO. 9,192,606

U-1913 TREATMENT OF PEDIATRIC PATIENTS WITH BILATERAL OTITIS MEDIA WITH EFFUSION UNDERGOING TYMPANOSTOMY TUBE PLACEMENT

U-1914 IN COMBINATION WITH RITUXIMAB, FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

U-1915 METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND WHO ARE INELIGIBLE FOR METFORMIN THERAPY BY ADMINISTERING LINAGLIPTIN

U-1916 PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY (CINV)

U-1917 TREATMENT OF EXOCRINE PANCREATIC CANCER THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN

U-1918 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING

U-1919 RESTORING AN MRNA READING FRAME TO INDUCE DYSTROPHIN PROTEIN PRODUCTION IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING

U-1920 USE OF EXTENDED RELEASE ORAL 25-HYDROXYVITAMIN D3 IN TREATING SECONDARY HYPERPARATHYROIDISM IN ADULT PATIENTS HAVING CHRONIC KIDNEY DISEASE STAGE 3 OR STAGE 4

U-1921 MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE BY PROVIDING AN ABUSE-DETERRENT ORAL CONTROLLED RELEASE COMBINATION DRUG PRODUCT

U-1922 INTRAVAGINAL PRASTERONE (DEHYDROEPIANDROSTERONE) AT A DAILY DOSE OF 6.5MG FOR THE TREATMENT OF DYSPAREUNIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO

**PATENT USE**

| | |
|---|---|
| | MENOPAUSE |
| U-1923 | IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY BASAL INSULIN OR LIXISENATIDE BY USE OF A PEN INJECTOR WITH A THREADED DRIVE SLEEVE |
| U-1924 | KYPROLIS IS INDICATED IN COMBINATION WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY |
| U-1925 | USE OF AN AUTO INJECTOR TO ADMINISTER NALOXONE HCL |
| U-1926 | METHOD OF TREATING, REDUCING THE INCIDENCE OF, OR PREVENTING AN ISCHEMIC EVENT IN A PATIENT UNDERGOING PCI BY ADMINISTERING INTRAVENOUSLY 30 UG/KG BOLUS BEFORE PCI AND CONTINUOUS INFUSION OF 4 UG/KG/MIN FOR AT LEAST 2 HOURS OR THE DURATION OF THE PCI |
| U-1927 | TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB |
| U-1928 | RUBRACA IS INDICATED AS MONOTHERAPY FOR THE TREATMENT OF PATIENTS WITH DELETERIOUS BRCA MUTATION (GERMLINE AND/OR SOMATIC) ASSOCIATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH TWO OR MORE CHEMOTHERAPIES. |
| U-1929 | TREATMENT OF DIABETES MELLITUS WITH AN INHALED INSULIN TO IMPROVE GLYCEMIC CONTROL USING A DRY POWDER INHALATION SYSTEM COMPRISING AN INHALER, A CARTRIDGE AND A DRY POWDER MEDICAMENT COMPRISING INSULIN IN A SINGLE INHALATION |
| U-1930 | METHOD OF AEROSOLIZING/DEAGGLOMERATING AN INSULIN DRY POWDER FOR USE IN TREATING DIABETES MELLITUS VIA ORAL INHALATION USING AN INHALER WITH A CARTRIDGE CONTAINING THE INSULIN DRY POWDER. |
| U-1931 | PROPHYLAXIS OR TREATMENT OF VENOUS AND ARTERIAL THROMBOTIC DISEASE |
| U-1932 | METHOD OF TREATING MILD TO MODERATE ATOPIC DERMATITIS. |
| U-1933 | TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT SURGERY |
| U-1934 | TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH A STRONG CYP1A2 INHIBITOR |
| U-1935 | REDUCTION OF THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTION |
| U-1936 | TREATMENT OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION |
| U-1937 | TREATMENT OF MYOCARDIAL INFARCTION IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION |
| U-1938 | TREATMENT OF STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION |
| U-1939 | ADMINISTRATION ONCE DAILY WITHIN TWO HOURS AFTER WAKING IN THE MORNING FOR IMPROVEMENT OF GLYCEMIC CONTROL IN A TYPE 2 DIABETES PATIENT |
| U-1940 | IMPROVEMENT IN THE APPEARANCE OF MODERATE TO SEVERE CONVEXITY OR FULLNESS ASSOCIATED WITH SUBMENTAL FAT IN ADULTS BY MEANS OF REDUCING SUBMENTAL FAT VOLUME AS DESCRIBED IN THE APPROVED LABELING |
| U-1941 | TREATMENT OF INFANTILE-ONSET SPINAL MUSCULAR ATROPHY |
| U-1942 | TREATMENT OF SPINAL MUSCULAR ATROPHY BY INCREASING EXON-7 INCLUSION IN SMN2 MRNA |
| U-1943 | TREATMENT OF SPINAL MUSCULAR ATROPHY |
| U-1944 | TREATMENT OF SPINAL MUSCULAR ATROPHY BY INHIBITING AN SMN2 PRE-MRNA INTRONIC SPLICING SILENCER SITE |
| U-1945 | IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN. |
| U-1946 | TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA |
| U-1947 | TREATMENT OF MARGINAL ZONE LYMPHOMA |
| U-1948 | A METHOD FOR TREATING CHRONIC MYELOID LEUKEMIA |
| U-1949 | FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) |
| U-1950 | TREATMENT OF PATIENTS WITH ADVANCED (METASTATIC) NON-SMALL CELL LUNG CANCER WHOSE DISEASE PROGRESSED DURING OR AFTER PLATINUM-BASED CHEMOTHERAPY |

**PATENT USE**

| | |
|---|---|
| U-1951 | TREATMENT OF ONYCHOMYCOSIS OF A TOENAIL |
| U-1952 | FOR USE IN THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA |
| U-1953 | REDUCE THE RISK OF STROKE IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS |
| U-1954 | TREATMENT OF DEEP VEIN THROMBOSIS WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS |
| U-1955 | TREATMENT OF PULMONARY EMBOLISM WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS |
| U-1956 | FOLLOWING INITIAL 6 MONTHS TREATMENT FOR DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE), REDUCTION IN THE RISK OF RECURRENCE OF DVT AND OF PE WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS |
| U-1957 | PROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM IN PATIENTS UNDERGOING KNEE OR HIP REPLACEMENT SURGERY, WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS |
| U-1958 | FOR THE TREATMENT OF GENOTYPE 1, 2, 3 OR 4 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION AS A COMPONENT OF A COMBINATION ANTIVIRAL TREATMENT REGIMEN WITH RIBAVIRIN |
| U-1959 | TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM |
| U-1960 | USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS |
| U-1961 | USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: ACUTE MONOTHERAPY OF MANIC OR MIXED EPISODES (AGES 10 TO ADULT) |
| U-1962 | USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: MAINTENANCE MONOTHERAPY IN ADULTS |
| U-1963 | USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: AS ADJUNCTIVE TREATMENT TO LITHIUM OR VALPROATE IN ADULTS |
| U-1964 | ELEVATION OF INTRACELLULAR CGMP RESULTING IN INCREASED INTESTINAL FLUID AND ACCELERATED TRANSIT |
| U-1965 | FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) IN COMBINATION WITH TADALAFIL, WHEREIN THE WEIGHT RATIO OF AMBRISENTAN TO TADALAFIL IS ABOUT 1:2 TO ABOUT 1:3 |
| U-1966 | USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: ACUTE MONOTHERAPY OF MANIC OR MIXED EPISODES IN PEDIATRIC PATIENTS AGE 10-17 |
| U-1967 | METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH ONE OR MORE CONVENTIONAL ANTIHYPERGLYCEMIC AGENTS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
| U-1968 | METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WHO HAVE NOT BEEN PREVIOUSLY TREATED WITH AN ANTIHYPERGLYCEMIC AGENT BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
| U-1969 | TOPICAL TREATMENT OF ONYCHOMYCOSIS OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM AND TRICHOPHYTON MENTAGROPHYTES |
| U-1970 | TREATMENT OF ONYCHOMYCHOSIS OF A TOENAIL CAUSED BY TRICHOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES |
| U-1971 | FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA |
| U-1972 | FOR THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA |
| U-1973 | METHOD OF TREATING CYSTIC FIBROSIS USING N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE AND 3-(6-(1-2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID |
| U-1974 | TREATMENT OF HALLUCINATIONS AND DELUSIONS ASSOCIATED WITH PARKINSON'S DISEASE PSYCHOSIS |
| U-1975 | METHOD OF INCREASING EYELASH GROWTH WITH BIMATOPROST |
| U-1976 | METHOD FOR TREATING TYPE 2 DIABETES MELLITUS (T2DM) IN PATIENTS WHO HAVE INADEQUATE CONTROL WITH DAPAGLIFLOZIN |

**PATENT USE**

| | |
|---|---|
| U-1977 | METHOD FOR TREATING TYPE 2 DIABETES MELLITUS (T2DM) IN PATIENTS WHO ARE ALREADY TREATED WITH DAPAGLIFLOZIN AND SAXAGLIPTIN |
| U-1978 | TREATMENT OF ADVANCED PROSTATE CANCER WITH A REDUCED LIKELIHOOD OF CAUSING A GONADOTROPHIN RELEASING HORMONE AGONIST SIDE-EFFECT |
| U-1979 | THE TREATMENT OF CARCINOID SYNDROME DIARRHEA IN COMBINATION WITH SOMATOSTATIN ANALOG (SSA) THERAPY IN ADULTS INADEQUATELY CONTROLLED BY SSA THERAPY |
| U-1980 | A METHOD OF TREATING NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS |
| U-1981 | IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER-2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER |
| U-1982 | USE OF REVLIMID (LENALIDOMIDE) FOR TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA DUE TO LOW-OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES ASSOCIATED WITH A DELETION 5Q ABNORMALITY WITH OR WITHOUT ADDITIONAL CYTOGENETIC ABNORMALITIES |
| U-1983 | USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB |
| U-1984 | USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE |
| U-1985 | USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT) |
| U-1986 | USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE, WHEREIN THOSE PATIENTS HAVE NOT RECEIVED PREVIOUS TREATMENT FOR MULTIPLE MYELOMA |
| U-1987 | METHOD OF CONTROLLING GLYCEMIA IN DIABETICS BY ADMINISTERING AN INITIAL DOSE OF INSULIN-FDKP WITH A MEAL; DETERMINING BLOOD GLUCOSE LEVEL 1-2 HRS AFTER AND ADMINISTERING A SUPPLEMENTAL DOSE OF INSULIN-FDKP IF POSTPRANDIAL GLUCOSE LEVEL IS >140 MG/DL |
| U-1988 | METHOD TO TREAT INFANTILE HEMANGIOMA |
| U-1989 | INTRAVITREAL TREATMENT OF MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (BRVO) OR CENTRAL RETINAL VEIN OCCLUSION (CRVO) |
| U-1990 | INTRAVITREAL TREATMENT OF DIABETIC MACULAR EDEMA |
| U-1991 | REDUCTION OF MORTALITY IN ACUTE MYCARDIAL INFARCTION |
| U-1992 | USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE |
| U-1993 | ADJUNCTIVE TREATMENT TO LEVODOPA/CARBIDOPA IN PATIENTS WITH PARKINSON'S DISEASE EXPERIENCING "OFF" EPISODES |
| U-1994 | REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) IN ADULTS |
| U-1995 | TREATMENT OF TARDIVE DYSKINESIA |
| U-1996 | IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS |
| U-1997 | IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND/OR A PPAR-GAMMA AGONIST AND/OR SULFONYLUREA AND/OR INSULIN |
| U-1998 | TREATING HR-POS., HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER WITH PALBOCICLIB IN COMBO WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE BASED THERAPY IN POSTMENOPAUSAL WOMEN OR FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY |
| U-1999 | CHRONIC IDIOPATHIC CONSTIPATION |
| U-2000 | MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS |
| U-2001 | USE FOR THE TREATMENT OF ASTHMA IN PATIENTS 6 YEARS OF AGE AND OLDER |
| U-2002 | USE FOR MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
| U-2003 | A METHOD OF POSITIONING AN INTRAUTERINE SYSTEM BY HOLDING AN INSERTER HANDLE WITH ONE HAND, ADVANCING THE INSERTER THROUGH THE CERVIX AND INTO THE UTERUS, AND RETRACTING A SLIDER ON THE HANDLE TO RELEASE THE INTRAUTERINE SYSTEM |
| U-2004 | REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE IN ADULTS WITH PARTIAL SEIZURES WITH COMPLEX SYMPTOMATOLOGY |

**PATENT USE**

| | |
|---|---|
| U-2005 | REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE IN ADULTS WITH GENERALIZED TONIC-CLONIC SEIZURES |
| U-2006 | REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE IN ADULTS WITH MIXED SEIZURE PATTERNS THAT INCLUDE PARTIAL SEIZURES WITH COMPLEX SYMPTOMATOLOGY, GENERALIZED TONIC-CLONIC SEIZURES, OR OTHER PARTIAL OR GENERALIZED SEIZURES |
| U-2007 | TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WHO ARE FLT3 MUTATION-POSITIVE, IN COMBINATION WITH STANDARD CYTARABINE AND DAUNORUBICIN INDUCTION AND CYTARABINE CONSOLIDATION CHEMOTHERAPY |
| U-2008 | TREATMENT OF ADULT PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN), OR MAST CELL LEUKEMIA (MCL) |
| U-2009 | METHOD OF TREATING POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AT HIGH RISK FOR FRACTURE. |
| U-2010 | ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE |
| U-2011 | TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY |
| U-2012 | A METHOD FOR TREATING OVARIAN CANCER BY ADMINISTERING RUCAPARIB, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION |
| U-2013 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| U-2014 | A METHOD OF TREATING SECONDARY HYPERPARATHYROIDISM (SHPT) |
| U-2015 | SODIUM THIOSULFATE INJECTION IS INDICATED FOR SEQUENTIAL USE WITH SODIUM NITRITE FOR THE TREATMENT OF ACUTE CYANIDE POISONING |
| U-2016 | TREATMENT FOR ONYCHOMYCOSIS THAT IS TINEA UNGUIUM |
| U-2017 | TREATMENT OF OPIOID DEPENDENCE |
| U-2018 | MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS IN A CRITICALLY ILL PATIENT WITH INTRAVENOUS IBUPROFEN IN NEED THEREOF |
| U-2019 | METHOD OF DELIVERING TO A PATIENT WITH DIABETES MELLITUS IN A SINGLE INHALATION, GREATER THAN 75% OF A DRY POWDER DOSE COMPRISING INSULIN AND FUMARYL DIKETOPIPERAZINE USING A HIGH RESISTANCE TO FLOW DRY POWDER INHALER. |
| U-2020 | MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST |
| U-2021 | METHOD OF ADMINISTERING LEVETIRACETAM UNDER FASTED CONDITIONS |
| U-2022 | METHOD OF ADMINISTERING LEVETIRACETAM UNDER FED CONDITIONS |
| U-2023 | A METHOD OF INCREASING THE BIOAVAILABILITY OF GUAIFENESIN IN A SOLUTION CONTAINING 54% TO 66% BY WEIGHT OF PROPYLENE GLYCOL AND GLYCEROL, WHEREIN THE METHOD INCREASES THE CMAX BY AT LEAST 1.5 AND/OR INCREASES THE AUC (0-INF) BY AT LEAST 1.4 |
| U-2024 | METHOD FOR TRANSDERMALLY DELIVERING A DRUG TO A USER IN NEED THEREOF |
| U-2025 | TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER |
| U-2026 | TAFINLAR(R) IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST. |
| U-2027 | TAFINLAR(R) IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST. |
| U-2028 | TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY DESIGNATED SUSCEPTIBLE BACTERIA IN ADULTS |
| U-2029 | PREVENTING CONDITION CHARACTERIZED BY UNDESIRED THROMBOSIS |
| U-2030 | PROPHYLAXIS OF VENOUS THROMBOSIS |
| U-2031 | TAFINLAR IS INDICATED AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST |
| U-2032 | TAFINLAR IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST. |

**PATENT USE**

| | |
|---|---|
| U-2033 | MEKINIST IS INDICATED, AS A SINGLE AGENT OR IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS |
| U-2034 | INHIBITING COAGULATION |
| U-2035 | PROPHYLAXIS OF VENOUS THROMBOEMBOLISM |
| U-2036 | A METHOD OF TREATING PULMONARY HYPERTENSION COMPRISING PARENTERALLY ADMINISTERING A FORMULATION COMPRISING A) 0.1 TO 5% W/V OF TREPROSTINIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND B) A CITRATE BUFFER |
| U-2037 | MEKINIST IS INDICATED, AS A SINGLE AGENT OR IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST |
| U-2038 | MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST |
| U-2039 | TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR |
| U-2040 | TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR |
| U-2041 | TREATMENT OF PARTIAL-ONSET SEIZURES |
| U-2042 | DISCONTINUING ADMINISTRATION OF FLUVOXAMINE TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE AND THEN ADMINISTERING PIRFENIDONE |
| U-2043 | EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY STAGE HER2-OVEREXPRESSED/AMPLIFIED BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASE THERAPY |
| U-2044 | DOSE REDUCTION OF PIRFENIDONE BY ABOUT ONE HALF DURING CONCURRENT ADMINISTRATION OF CIPROFLOXACIN AT A DOSE OF 750 MG TWICE DAILY (1500 MG/DAY) TO REDUCE DRUG INTERACTIONS IN TREATMENT OF A FIBROTIC, INFLAMMATORY, OR AUTOIMMUNE DISORDER |
| U-2045 | ADMINISTRATION OF PIRFENIDONE AND AVOIDING CONCURRENT ADMINISTRATION OF CIPROFLOXACIN AT A DOSE OF 750 MG TO REDUCE DRUG INTERACTIONS IN TREATMENT OF A FIBROTIC, INFLAMMATORY, OR AUTOIMMUNE DISORDER |
| U-2046 | ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT USE OF A CYP1A2 INHIBITOR THAT IS A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME SELECTED FROM CYP2C9, CYP2C19, AND CYP2D6 |
| U-2047 | ADMINISTERING PIRFENIDONE CONCURRENTLY WITH FLUVOXAMINE, THE PIRFENIDONE AT A DOSE OF ABOUT 801 MG/DAY TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE |
| U-2048 | ADMINISTERING PIRFENIDONE WHILE AVOIDING CO-ADMINISTRATION OF A STRONG CYP1A2 INHIBITOR TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE |
| U-2049 | DISCONTINUING ADMINISTRATION OF A STRONG CYP1A2 INHIBITOR TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE AND THEN ADMINISTERING PIRFENIDONE |
| U-2050 | ADMINISTERING PIRFENIDONE WHILE AVOIDING CO-ADMINISTRATION OF FLUVOXAMINE TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE |
| U-2051 | DISCONTINUING SMOKING TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE |
| U-2052 | DISCONTINUING ADMINISTRATION OF A STRONG CYP1A2 INDUCER TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE |
| U-2053 | ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT ADMINISTRATION OF A STRONG INDUCER OF CYP1A2, INCLUDING CIGARETTE SMOKE, TO AVOID REDUCED PIRFENIDONE EFFICACY |
| U-2054 | ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT ADMINISTRATION OF A STRONG INDUCER OF CYP1A2 TO AVOID REDUCED PIRFENIDONE EFFICACY |
| U-2055 | DOSING OF AT LEAST 1600 MG/DAY FOLLOWING GRADE 2 LIVER ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF |
| U-2056 | DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-1600 MG/DAY, FOLLOWING BY ADMINISTERING AT LEAST 1600 MG/DAY IN TREATMENT OF IPF |
| U-2057 | DOSING 2403 MG/DAY PIRFENIDONE FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF |

**PATENT USE**

U-2058 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400MG/DAY DOSE, FOLLOWED BY ADMINISTERING 2403MG/DAY IN TREATMENT OF IPF

U-2059 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, FOLLOWED BY FULL DAILY DOSE IN TREATMENT OF IPF

U-2060 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, THEN AT LEAST 1600MG/DAY IN TREATMENT OF IPF

U-2061 DOSING OF AT LEAST 1600 MG/DAY FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF

U-2062 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-1600 MG/DAY DOSE, FOLLOWED BY ADMINISTERING AT LEAST 1600 MG/DAY DOSE IN TREATMENT OF IPF

U-2063 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, FOLLOWED BY ADMINISTERING AT LEAST 1600 MG/DAY IN TREATMENT OF IPF

U-2064 DOSING AT LEAST 1602 MG/DAY FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION

U-2065 FULL DAILY DOSING FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION

U-2066 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400 MG/DAY DOSE, FOLLOWED BY FULL DAILY DOSE

U-2067 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE, FOLLOWED BY ADMINISTERING AT LEAST 1602 MG/DAY

U-2068 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, FOLLOWED BY FULL DAILY DOSE

U-2069 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING A SUB-1600 MG/DAY DOSE, FOLLOWED BY ADMINISTERING AT LEAST 1602 MG/DAY

U-2070 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, THEN SUB-1600 MG/DAY, THEN AT LEAST 1602 MG/DAY

U-2071 FULL DAILY DOSING FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF

U-2072 FULL DAILY DOSING FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF

U-2073 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, FOLLOWED BY ADMINISTERING FULL DAILY DOSE IN TREATMENT OF IPF

U-2074 DOSING 1602 MG/DAY PIRFENIDONE FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF

U-2075 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS FOLLOWED BY ADMINISTERING 1602 MG/DAY IN TREATMENT OF IPF

U-2076 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING 801 MG/DAY FOLLOWED BY ADMINISTERING 1602 MG/DAY IN TREATMENT OF IPF

U-2077 DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400 MG/DAY DOSE THEN FULL DAY DAILY DOSE IN TREATMENT OF IPF

**PATENT USE**

| | |
|---|---|
| U-2078 | DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN LIMITS, THEN SUB-2400MG/DAY DOSE, THEN FULL DAILY DOSE IN TREATMENT OF IPF |
| U-2079 | PIRFENIDONE DOSE ESCALATION REGIMEN FOR TREATMENT OF FIBROSIS AS 801 MG/DAY FOR DAYS 1-7 OF THE REGIMEN, 1602 MG/DAY FOR DAYS 8-14 OF THE REGIMEN, AND 2403 MG/DAY FOR AT LEAST DAY 15 OF THE REGIMEN |
| U-2080 | PIRFENIDONE DOSE ESCALATION REGIMEN FOR TREATMENT OF IPF AS 801 MG/DAY FOR DAYS 1-7 OF THE REGIMEN, 1602 MG/DAY FOR DAYS 8-14 OF THE REGIMEN, AND 2403 MG/DAY FOR AT LEAST DAY 15 OF THE REGIMEN |
| U-2081 | DISCONTINUING USE OF A CYP1A2 INHIBITOR THAT IS A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME SELECTED FROM CYP2C9, CYP2C19, AND CYP2D6 AND THEN ADMINISTERING PIRFENIDONE |
| U-2082 | MODIFYING PIRFENIDONE ADMINISTRATION FROM A DOSE OF ABOUT 2400 MG/DAY DOWNWARD BY ABOUT 1600 MG/DAY WHILE CO-ADMINISTERING FLUVOXAMINE TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE |
| U-2083 | DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, FOLLOWED BY 801 MG/DAY, DOSE, THEN 1602 MG/DAY IN TREATMENT OF IPF |
| U-2084 | TREATMENT OF SEVERE CHRONIC PAIN VIA INTRATHECAL INFUSION OF ZICONOTIDE IN PATIENTS ALSO RECEIVING MORPHINE |
| U-2085 | TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH RIFAMPIN |
| U-2086 | A METHOD FOR ADMINISTERING ESTRADIOL COMPRISING A MONOLITHIC TRANSDERMAL DRUG DELIVERY SYSTEM CONSISTING OF (I) A BACKING LAYER AND (II) A SINGLE ADHESIVE POLYMER MATRIX LAYER AS CLAIMED IN US PATENT NO. 9730900 |
| U-2087 | TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION |
| U-2088 | TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY |
| U-2089 | TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY |
| U-2090 | FOR THE TREATMENT OF ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) |
| U-2091 | TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN, IN A PATIENT NOT HOMOZYGOUS FOR THE UGT1A1*28 ALLELE |
| U-2092 | METHOD FOR CONFIRMING DOSE DELIVERY |
| U-2093 | TREATMENT OF TYPE II SPINAL MUSCULAR ATROPHY |
| U-2094 | TREATMENT OF TYPE III SPINAL MUSCULAR ATROPHY |
| U-2095 | MITOSOL IS AN ANTIMETABOLITE INDICATED AS AN ADJUNCT TO AB EXTERNO GLAUCOMA SURGERY. IT IS INTENDED FOR TOPICAL APPLICATION TO THE SITE OF GLAUCOMA FILTRATION SURGERY |
| U-2096 | SOTYLIZE IS INDICATED FOR THE MAINTENANCE OF NORMAL SINUS RHYTHM [DELAY IN TIME TO RECURRANCE OF ATRIAL FIBRILLATION/ATRIAL FLUTTER (AFIB/AFL)] IN PATIENTS WITH SYMPTOMATIC AFIB/AFL WHO ARE CURRENTLY IN SINUS RHYTHM |
| U-2097 | TREATMENT OF DMD IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING |
| U-2098 | INCREASING PRODUCTION OF FUNCTIONAL DYSTROPHIN PROTEIN IN DMD PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING |
| U-2099 | INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING BRONCHITIS AND/OR EMPHYSEMA |
| U-2100 | INDICATED FOR THE ONCE-DAILY TREATMENT OF ASTHMA IN PATIENTS 18 YEARS AND OLDER |
| U-2101 | MAINTENANCE TREATMENT OF RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY |

**PATENT USE**

U-2102 TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY BASED ON AN FDA-APPROVED COMPANION DIAGNOSTIC FOR LYNPARZA

U-2103 MAINTENANCE TREATMENT OF BRCA-MUTATED RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY

U-2104 TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE

U-2105 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING IMMEDIATE RELEASE LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS

U-2106 TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS

U-2107 TREATMENT OF LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA REFRACTORY TO RADIOACTIVE IODINE TREATMENT

U-2108 TREATMENT OF HORMONE RECEPTOR POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN NOT PREVIOUSLY TREATED WITH ENDOCRINE THERAPY

U-2109 CAROSPIR IS INDICATED FOR TREATMENT OF NYHA CLASS III-IV HEART FAILURE AND REDUCED EJECTION FRACTION TO INCREASE SURVIVAL, MANAGE EDEMA, AND TO REDUCE THE NEED FOR HOSPITALIZATION FOR HEART FAILURE

U-2110 METHOD FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS WITH MODERATE RENAL IMPAIRMENT WHO ARE OBESE, OR OVERWEIGHT AND HAVE AT LEAST ONE WEIGHT RELATED COMORBID CONDITION

U-2111 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1-5 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1-5

U-2112 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 6 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 6

U-2113 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 7 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 7

U-2114 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 9 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 9

U-2115 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 10 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 10

U-2116 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 12 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 12

U-2117 ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 14-15 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 14-15

U-2118 ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 16-18 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 16-18

U-2119 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 19 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 19

U-2120 TREATMENT OF PATIENTS 18 YEARS OF AGE AND OLDER WITH COMPLICATED URINARY TRACT

**PATENT USE**

| | |
|---|---|
| | INFECTIONS CAUSED BY SUSCEPTIBLE MICROORGANISMS |
| U-2121 | TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ABSENCE SEIZURES |
| U-2122 | USE FOR REDUCING EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
| U-2123 | TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY WHO HAVE BEEN PREVIOUSLY TREATED WITH OXCARBAZEPINE |
| U-2124 | TREATMENT OF ADULT PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES |
| U-2125 | THE TREATMENT OF AN INFLAMMATORY DISORDER OF THE RESPIRATORY TRACT BY ONCE-PER-DAY ADMINISTRATION OF A PHARMACEUTICAL FORMULATION COMPRISING FLUTICASONE FUROATE AND A LONG-ACTING BETA2 ADRENORECEPTOR AGONIST |
| U-2126 | USE OF FLUTICASONE FUROATE FOR THE TREATMENT OF AN INFLAMMATORY OR ALLERGIC CONDITIONS, INCLUDING CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
| U-2127 | INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND/OR EMPHYSEMA |
| U-2128 | METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLININUM, VIA INHALATION |
| U-2129 | METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLININUM, VIA TOPICAL APPLICATION |
| U-2130 | TREATMENT OF PARTIAL ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY |
| U-2131 | REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION, WITH COMPARABLE EFFICACY, AND A REDUCTION IN SPECIFIED ADVERSE EVENTS, COMPARED TO BRIMONIDINE 0.2% TID |
| U-2132 | IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY |
| U-2133 | METHOD OF DELIVERING FLUTICASONE PROPIONATE TO A NASAL AIRWAY |
| U-2134 | THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY ONCE-PER-DAY ADMINISTRATION OF A PHARMACEUTICAL FORMULATION COMPRISING FLUTICASONE FUROATE AND A LONG-ACTING BETA2 ADRENORECEPTOR |
| U-2135 | AS MONOTHERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTIC BREAST CANCER WITH DIEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY AND PRIOR CHEMOTHERAPY IN THE METASTATIC SETTING |
| U-2136 | TREATMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY |
| U-2137 | TREATMENT OF POSTHERPETIC NEURALGIA |
| U-2138 | TOPICAL TREATMENT OF ACTINIC KERATOSIS OF THE FACE OR SCALP USING MORE THAN ONE TREATMENT COURSE OF INGENOL MEBUTATE |
| U-2139 | TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE |
| U-2140 | METHOD OF TREATING PARTIAL ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER |
| U-2141 | TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 |
| U-2142 | REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND/OR PULMONARY EMBOLISM (PE) IN PATIENTS AT CONTINUED RISK FOR RECURRENT DVT AND/OR AFTER COMPLETON OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS |
| U-2143 | AFTER COMPLETION OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS, TO REDUCE THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS AND/OR PULMONARY EMBOLISM IN CERTAIN PATIENTS WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST 5 CONSECUTIVE DAYS |
| U-2144 | REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION |
| U-2145 | TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY |
| U-2146 | IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR WITH A ROTATING DRIVE SLEEVE |

**PATENT USE**

| | |
|---|---|
| U-2147 | TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ORALLY ADMINISTERING 20MG OF TASIMELTEON ONCE DAILY BEFORE BEDTIME |
| U-2148 | A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY MEASURING AND DISPLAYING AN INDICATION OF THE CALCULATED DELIVERY CONCENTRATION OF NITIRIC OXIDE AS COMPARED TO THE DESIRED DELIVERY CONCENTRATION OF NITRIC OXIDE |
| U-2149 | TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON |
| U-2150 | TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE |
| U-2151 | METHOD OF TREATING PAIN OR INFLAMMATION WITH AN INJECTABLE CONTROLLED OR SUSTAINED RELEASE FORMULATION OF TRIAMCINOLONE ACETONIDE |
| U-2152 | TREATMENT OF PAIN ASSOCIATED WITH IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE) |
| U-2153 | REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4 |
| U-2154 | REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4 |
| U-2155 | REDUCING BODY WEIGHT IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4 |
| U-2156 | REDUCING HBA1C IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4 |
| U-2157 | TREATING TYPE 2 DIABETES MELLITUS BY STIMULATING INSULIN RELEASE |
| U-2158 | DECREASING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY USING A SUSTAINED-RELEASE COMPOSITION |
| U-2159 | TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA |
| U-2160 | MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 5 MG OF MELOXICAM |
| U-2161 | TREATMENT OF NAUSEA AND VOMITING, INCLUDING THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY OR MODERATELY EMETOGENIC CANCER CHEMOTHERAPY |
| U-2162 | FOR CLEANSING THE LARGE INTESTINE AS A PREPARATION FOR COLONOSCOPY |
| U-2163 | TREATMENT OF HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER-2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION WITH PALBOCOCLIB OR ABEMACICLIB IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY |
| U-2164 | ZELBORAF IS INDICATED FOR THE TREATMENT OF PATIENTS WITH ERDHEIM-CHESTER DISEASE WITH BRAF V600 MUTATION |
| U-2165 | MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 10 MG OF MELOXICAM |
| U-2166 | TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER |
| U-2167 | METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER |
| U-2168 | METHOD OF USING A LOGIC CIRCUIT TO STABILIZE BATTERY VOLTAGE SUPPLIED TO A SENSOR EMBEDDED WITH A TABLET AND THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER |
| U-2169 | METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT |
| U-2170 | METHOD OF USING A RECEIVER TO RECEIVE A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT |
| U-2171 | ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISH OF RECURRENT RCC FOLLOWING NEPHRECTOMY |
| U-2172 | METHOD TO TREAT SEVERE ALLERGIC EMERGENCIES IN PATIENTS WEIGHING 7.5 TO 15 KG (16.5 TO 33 LBS) |
| U-2173 | TREATING OPIOID DEPENDENCE BY ADMINISTERING BUPRENORPHINE |
| U-2174 | TREATING OPIOID DEPENDENCY BY ADMINISTERING BUPRENORPHINE ONCE PER MONTH |
| U-2175 | TREATING OPIOID DEPENDENCY BY ADMINISTERING BUPRENORPHINE ONCE MONTHLY |
| U-2176 | TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE |
| U-2177 | TREATING OPIOID ADDICTION BY SUBCUTANEOUS INJECTION OF BUPRENORPHINE |
| U-2178 | TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE COMPOSITION WITH 28 DAY DOSE DURATION |

**PATENT USE**

U-2179 IN SITU FORMATION OF SOLID BUPRENORPHINE COMPOSITION

U-2180 TREATING ADDICTION WITH 100 MG OR 300 MG DOSE OF BUPRENORPHINE

U-2181 TREATING OPIOID DEPENDENCY BY SUBCUTANEOUSLY ADMINISTERING BUPRENORPHINE

U-2182 IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS

U-2183 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 13

U-2184 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1, 13, AND 14

U-2185 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 15 AND 27

U-2186 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 15, 27, AND 28

U-2187 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 29 AND 39

U-2188 ADJUNCT TO DIET AND EXECRISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 29, 39, AND 40

U-2189 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 41 AND 52

U-2190 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 41, 52, AND 53

U-2191 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 54 AND 64

U-2192 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 54, 64, AND 65

U-2193 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 66 AND 75

U-2194 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 66, 75, AND 76

U-2195 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 77 AND 87

U-2196 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 77, 87, AND 88

U-2197 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 89 AND 99

U-2198 ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 89, 99, AND 100

U-2199 TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA

U-2200 COMBINATION TREATMENT WITH INSULIN GLARGINE WITH OR WITHOUT METFORMIN FOR IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS

U-2201 TREATMENT OF BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN BIPOLAR DISORDER

U-2202 OZEMPIC IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC

**PATENT USE**

| | |
|---|---|
| | CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS |
| U-2203 | A METHOD OF PROVIDING A SUBJECT WITH A THERAPEUTICALLY EFFECTIVE AMOUNT OF RACEMIC METHYLPHENIDATE BY ORALLY ADMINISTERING TO SAID SUBJECT A SINGLE METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET AS CLAIMED |
| U-2204 | TREATING PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA (APL) WHO ARE REFRACTORY TO, OR HAVE RELAPSED FROM, RETINOID AND ANTHRACYCLINE CHEMOTHERAPY, AND WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE T(15;17) TRANSLOCATION OR PML/RAR-ALPHA GENE EXPRESSION |
| U-2205 | TREATMENT OF SEBORRHEIC KERATOSES THAT ARE RAISED |
| U-2206 | TREATING OPIOID DEPENDENCY BY ADMINISTERING BUPRENORPHINE |
| U-2207 | TREATING ADDICTION BY SUBCUTANEOUS INJECTION OF BUPRENORPHINE |
| U-2208 | TREATING ADDICTION BY ONCE PER MONTH ADMINISTRATION OF BUPRENORPHINE |
| U-2209 | TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE ONCE PER MONTH |
| U-2210 | TREATING OPIOID ADDICTION BY 100 MG OR 300 MG DOSE BUPRENORPHINE |
| U-2211 | TREATING OPIOID ADDICTION BY ADMINISTRATION OF BUPRENORPHINE |
| U-2212 | REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF IN COMBINATION WITH A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4 |
| U-2213 | REDUCING HBA1C IN A HUMAN IN NEED THEREOF IN COMBINATION WITH A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4 |
| U-2214 | AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES |
| U-2215 | ERTUGLIFLOZIN IN COMBINATION WITH SITAGLIPTIN AND IN FURTHER COMBINATION WITH METFORMIN AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS |
| U-2216 | ERTUGLIFLOZIN AND SITAGLIPTIN IN COMBINATION AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS |
| U-2217 | TREATING HIGH OUTPUT SHOCK WITH ANGIOTENSIN II BY INCREASING MEAN ARTERIAL PRESSURE IN PATIENTS TREATED WITH CATECHOLAMINES AND REDUCING CATECHOLAMINE USE |
| U-2218 | MAINTAINING MEAN ARTERIAL PRESSURE OF ABOUT 65 MMHG OR HIGHER WITH ANGIOTENSIN II IN SHOCK PATIENTS TREATED WITH CATECHOLAMINES AND REDUCING CATECHOLAMINE USE |
| U-2219 | TREATMENT OF CHRONIC SMALL LYMPHOCYTIC LEUKEMIA |
| U-2220 | A METHOD FOR THE DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY BY MEASURING THE LEVEL OF GROWTH HORMONE AFTER ORAL ADMINISTRATION OF MACIIMORELIN |
| U-2221 | TREATING REFRACTORY HYPOTENSION WITH ABOUT 20 MG/KG/MIN ANGIOTENSIN II IN A PATIENT RECEIVING VASOPRESSOR |
| U-2222 | RELIEVES REDNESS OF THE EYE DUE TO MINOR EYE IRRITATIONS |
| U-2223 | METHOD OF TREATING ANGINA PECTORIS |